EMEA	O
/	O
H	O
/	O
C	O
/	O
551	O

PRIALT	B-CHEM

Qu	O
’	O
est	O
ce	O
que	O
Prialt	B-CHEM
?	O

Prialt	B-CHEM
est	O
une	O
solution	B-CHEM
pour	O
perfusion	B-PROC
contenant	O
le	O
principe	B-CHEM
actif	I-CHEM
ziconotide	B-CHEM
,	O
à	O
des	O
concentrations	O
de	O
100	O
ou	O
25	O
microgrammes	O
par	O
millilitre	O
.	O

Dans	O
quel	O
cas	O
Prialt	B-CHEM
est	O
-	O
il	O
utilisé	O
?	O

Prialt	B-CHEM
est	O
indiqué	B-DISO
pour	O
le	O
traitement	B-PROC
des	O
douleurs	B-DISO
intenses	I-DISO
,	I-DISO
chroniques	I-DISO
(	I-DISO
de	I-DISO
long	I-DISO
terme	I-DISO
)	O
chez	O
les	O
patients	B-LIVB
nécessitant	O
une	O
analgésie	B-PROC
intrarachidienne	I-PROC
(	O
injection	B-PROC
dans	O
l	O
’	O
espace	O
qui	O
entoure	O
la	O
moelle	B-ANAT
épinière	I-ANAT
et	O
le	O
cerveau	B-ANAT
)	O
.	O

Comme	O
le	O
nombre	O
de	O
patients	B-LIVB
souffrant	O
de	O
douleurs	B-DISO
chroniques	I-DISO
nécessitant	O
une	O
analgésie	B-PROC
intrarachidienne	I-PROC
(	O
analgésiques	B-CHEM
injectés	B-PROC
directement	O
dans	O
la	O
moelle	B-ANAT
)	O
est	O
limité	O
,	O
la	O
maladie	B-DISO
est	I-DISO
considérée	I-DISO
comme	I-DISO
«	I-DISO
rare	I-DISO
»	O
et	O
Prialt	B-CHEM
a	O
reçu	O
la	O
désignation	O
de	O
«	O
médicament	B-CHEM
orphelin	I-CHEM
»	O
(	O
médicament	B-CHEM
utilisé	O
pour	O
les	O
maladies	B-DISO
rares	I-DISO
)	O
le	O
9	O
juillet	O
2001	O
.	O

Comment	O
Prialt	B-CHEM
est	O
-	O
il	O
utilisé	O
?	O

Le	O
traitement	B-PROC
par	O
Prialt	B-CHEM
ne	O
doit	O
être	O
réalisé	O
que	O
par	O
un	O
médecin	B-LIVB
ayant	O
l	O
’	O
expérience	O
de	O
l	O
’	O
administration	B-PROC
de	I-PROC
médicaments	I-PROC
par	I-PROC
voie	I-PROC
intrarachidienne	I-PROC
.	O

Prialt	B-CHEM
doit	O
être	O
administré	B-PROC
en	O
perfusion	B-PROC
continue	O
très	O
lente	O
par	O
l	O
’	O
intermédiaire	O
d	O
’	O
un	O
cathéter	B-DEVI
intrarachidien	B-ANAT
(	O
tube	B-DEVI
inséré	O
dans	O
le	O
canal	B-ANAT
rachidien	I-ANAT
)	O
avec	O
une	O
pompe	B-DEVI
à	O
perfusion	B-PROC
pouvant	O
délivrer	B-PROC
un	O
volume	O
de	O
perfusion	B-PROC
précis	O
.	O

Lorsque	O
les	O
doses	O
nécessaires	O
de	O
Prialt	B-CHEM
sont	O
faibles	O
,	O
par	O
exemple	O
au	O
début	O
du	O
traitement	B-PROC
,	O
il	O
peut	O
s	O

La	O
dose	O
peut	O
être	O
augmentée	O
par	O
intervalles	O
de	O
1	O
à	O
2	O
jours	O
,	O
voire	O
plus	O
,	O
pour	O
obtenir	O
le	O
meilleur	O
équilibre	O
entre	O
le	O
soulagement	B-PROC
de	I-PROC
la	I-PROC
douleur	I-PROC
et	O
les	O
effets	B-DISO
indésirables	I-DISO
éventuels	O
.	O

La	O
plupart	O
des	O
patients	B-LIVB
nécessitent	O
des	O
doses	O
inférieures	O
à	O
9	O
,	O
6	O
microgrammes	O
par	O
jour	O
.	O

La	O
dose	O
quotidienne	O
maximale	O
est	O
de	O
21	O
,	O
6	O
microgrammes	O
par	O
jour	O
.	O

Prialt	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
chez	O
l	O
’	O
enfant	B-LIVB
.	O

Comment	O
Prialt	B-CHEM
fonctionne	O
-	O
t	O
-	O
il	O
?	O

Le	O
principe	B-CHEM
actif	I-CHEM
de	O
Prialt	B-CHEM
,	O
le	O
ziconotide	B-CHEM
,	O
est	O
une	O
copie	B-OBJC
d	O
’	O
une	O
substance	B-OBJC
naturelle	O
,	O
un	O
oméga	O
-	O
conopeptide	O
,	O
extraite	B-PROC
du	O
venin	B-CHEM
d	O
’	O
un	O
type	O
de	O
limace	B-LIVB
de	I-LIVB
mer	I-LIVB
.	O

Le	O
ziconotide	B-CHEM
agit	O
en	O
se	O
fixant	O
à	O
des	O
canaux	B-ANAT
spéciaux	O
(	O
les	O
canaux	B-CHEM
calciques	I-CHEM
)	O
à	O
la	O
surface	O
des	O
cellules	B-ANAT
nerveuses	I-ANAT
qui	O
transmettent	B-PHEN
les	O
signaux	B-PHEN
de	O
la	O
douleur	B-DISO
.	O

En	O
bloquant	O
le	O
flux	B-PHEN
de	O
calcium	B-CHEM
dans	O
les	O
cellules	B-ANAT
nerveuses	I-ANAT
,	O
le	O
ziconotide	B-CHEM
interfère	O
avec	O
la	O
transmission	B-PHEN
des	O
signaux	B-PHEN
de	O
douleur	B-DISO
dans	O
la	O
moelle	B-ANAT
et	O
permet	O
de	O
soulager	B-PROC
la	O
douleur	B-DISO
.	O

La	O
troisième	O
étude	B-PROC
portait	O
sur	O
l	O
’	O
utilisation	O
du	O
médicament	B-CHEM
pendant	O
3	O
semaines	O
chez	O
des	O
patients	B-LIVB
adultes	B-LIVB
atteints	O
de	O
douleurs	B-DISO
intenses	I-DISO
,	I-DISO
chroniques	I-DISO
.	O

Dans	O
les	O
trois	O
études	B-PROC
,	O
la	O
principale	O
mesure	O
d	O
’	O
efficacité	O
était	O
le	O
changement	O
du	O
score	O
d	O
’	O
intensité	B-PROC
de	I-PROC
la	I-PROC
douleur	I-PROC
sur	I-PROC
l	I-PROC
’	I-PROC
échelle	I-PROC
visuelle	I-PROC
analogique	I-PROC
(	O
EVA	B-PROC
)	O
.	O

Quels	O
ont	O
été	O
les	O
bénéfices	O
démontrés	O
par	O
Prialt	B-CHEM
au	O
cours	O
des	O
études	B-PROC
?	O

Prialt	B-CHEM
a	O
été	O
plus	O
efficace	O
que	O
le	O
placebo	B-CHEM
dans	O
les	O
deux	O
premières	O
études	B-PROC
.	O

Avant	O
le	O
traitement	B-PROC
,	O
les	O
patients	B-LIVB
avaient	O
des	O
scores	O
d	O
’	O
intensité	O
de	O
la	O
douleur	B-DISO
sur	O
l	O

Les	O
effets	B-DISO
indésirables	I-DISO
les	O
plus	O
courants	O
(	O
observés	O
chez	O
plus	O
d	O
’	O
un	O
patient	B-LIVB
sur	O
10	O
)	O
sont	O
un	O
état	B-DISO
confusionnel	I-DISO
,	O
des	O
sensations	B-DISO
vertigineuses	I-DISO
,	O
un	O
nystagmus	B-DISO
(	O
mouvement	B-DISO
oculaire	I-DISO
incontrôlé	I-DISO
)	O
,	O
des	O
troubles	B-DISO
mnésiques	I-DISO
(	O
perte	B-DISO
de	I-DISO
mémoire	I-DISO
)	O
,	O
des	O
céphalées	B-DISO
,	O
une	O
somnolence	B-DISO
(	O
endormissement	B-DISO
)	O
,	O
un	O
flou	B-DISO
visuel	I-DISO
,	O
des	O
nausées	B-DISO
(	O
mal	B-DISO
au	I-DISO
cœur	I-DISO
)	O
,	O
des	O
vomissements	B-DISO
,	O
des	O
troubles	B-DISO
de	I-DISO
la	I-DISO
démarche	I-DISO
(	O
difficulté	B-DISO
pour	I-DISO
marcher	I-DISO
)	O
et	O
une	O
asthénie	B-DISO
(	O
faiblesse	B-DISO
)	O
.	O

Pour	O
une	O
description	O
complète	O
des	O
effets	B-DISO
indésirables	I-DISO
observés	O
sous	O
Prialt	B-CHEM
,	O
veuillez	O
vous	O
reporter	O
à	O
la	O
notice	B-PROC
.	O

Prialt	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
chez	O
les	O
patients	B-LIVB
pouvant	O
présenter	O
une	O
hypersensibilité	B-DISO
(	O
allergie	B-DISO
)	O
au	O
ziconotide	B-CHEM
ou	O
à	O
l	O
’	O
un	O
des	O
autres	O
ingrédients	B-CHEM
.	O

Prialt	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
chez	O
des	O
patients	B-LIVB
sous	O
chimiothérapie	B-PROC
intrarachidienne	I-PROC
(	O
anti	B-CHEM
-	I-CHEM
cancéreux	I-CHEM
injectés	B-PROC
dans	O
le	O
canal	B-ANAT
rachidien	I-ANAT
)	O
.	O

Pourquoi	O
Prialt	B-CHEM
a	O
-	O
t	O
-	O
il	O
été	O
approuvé	O
?	O

Le	O
comité	O
des	O
médicaments	B-CHEM
à	O
usage	O
humain	B-LIVB
(	O
CHMP	O
)	O
a	O
estimé	O
que	O
Prialt	B-CHEM
était	O
une	O
alternative	O
aux	O
autres	O
analgésiques	B-CHEM
intrarachidiens	B-ANAT
,	O
comme	O
les	O
opioïdes	B-CHEM
.	O

Quelles	O
sont	O
les	O
informations	O
que	O
l	O
’	O
on	O
attend	O
encore	O
au	O
sujet	O
de	O
Prialt	B-CHEM
?	O

La	O
société	O
qui	O
fabrique	O
Prialt	B-CHEM
réalise	O
actuellement	O
une	O
étude	B-PROC
sur	O
l	O
’	O
utilisation	O
à	O
long	O
terme	O
du	O
médicament	B-CHEM
,	O
portant	O
en	O
particulier	O
sur	O
la	O
possibilité	O
d	O
’	O
un	O
développement	O
de	O
la	O
tolérance	B-DISO
au	O
traitement	B-PROC
(	O
lorsque	O
des	O
doses	O
d	O
’	O
un	O
médicament	B-CHEM
qui	O
étaient	O
efficaces	O
deviennent	O
au	O
fur	O
et	O
à	O
mesure	O
moins	O
efficaces	O
)	O
.	O

Autres	O
informations	O
relatives	O
à	O
Prialt	B-CHEM
:	O

Le	O
dossier	O
de	O
désignation	O
de	O
Prialt	B-CHEM
comme	O
médicament	B-CHEM
orphelin	I-CHEM
est	O
disponible	O
à	O
l	O
’	O
adresse	O
suivante	O
:	O
ici	O
.	O

L	O
’	O
EPAR	O
complet	O
est	O
disponible	O
à	O
l	O
’	O
adresse	O
suivante	O
:	O
ici	O
.	O

Prialt	B-CHEM

1	O
ml	O
(	O
100	O
μ	O
g	O
/	O
ml	O
)	O

2	O
ml	O
(	O
100	O
μ	O
g	O
/	O
ml	O
)	O

5	O
ml	O
(	O
100	O
μ	O
g	O
/	O
ml	O
)	O

25	O
μ	O
g	O
/	O
ml	O

20	O
ml	O
(	O
25	O
μ	O
g	O
/	O
ml	O
)	O

Prialt	B-CHEM
100	O
microgrammes	O
/	O
ml	O
,	O
solution	B-CHEM
pour	O
perfusion	B-PROC
.	O

Un	O
ml	O
de	O
solution	B-CHEM
contient	O
100	O
μ	O
g	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O

Solution	B-CHEM
transparente	O
et	O
incolore	O
,	O
exempte	O
de	O
particules	B-CHEM
visibles	O
.	O

Le	O
ziconotide	B-CHEM
est	O
indiqué	B-DISO
pour	O
le	O
traitement	B-PROC
des	O
douleurs	B-DISO
intenses	I-DISO
,	I-DISO
chroniques	I-DISO
chez	O
les	O
patients	B-LIVB
nécessitant	O
une	O
analgésie	B-PROC
intrarachidienne	I-PROC
.	O

Le	O
traitement	B-PROC
par	O
ziconotide	B-CHEM
ne	O
doit	O
être	O
réalisé	O
que	O
par	O
des	O
médecins	B-LIVB
ayant	O
l	O
’	O
expérience	O
de	O
l	O
’	O
administration	B-PROC
de	I-PROC
médicaments	I-PROC
par	I-PROC
voie	I-PROC
intrarachidienne	I-PROC
.	O

Prialt	B-CHEM
est	O
exclusivement	O
destiné	O
à	O
l	O

Adultes	B-LIVB
(	O
y	O
compris	O
sujets	B-LIVB
âgés	I-LIVB
≥	I-LIVB
65	I-LIVB
ans	I-LIVB
)	O

Le	O
traitement	B-PROC
par	O
ziconotide	B-CHEM
doit	O
être	O
instauré	O
à	O
la	O
dose	O
de	O
2	O
,	O
4	O
µg	O
/	O
jour	O
et	O
peut	O
ensuite	O
être	O
adapté	O
en	O
fonction	O
de	O
la	O
réponse	B-PHYS
analgésique	B-CHEM
du	O
patient	B-LIVB
et	O
de	O
la	O
survenue	O
d	O
’	O
événements	B-DISO
indésirables	I-DISO
.	O

Environ	O
75	O
%	O
des	O
patients	B-LIVB
répondant	O
de	O
façon	O
satisfaisante	O
au	O
traitement	B-PROC
nécessitent	O
une	O
posologie	O
≤	O
9	O
,	O
6	O
μ	O
g	O
/	O
jour	O
.	O

Le	O
risque	O
de	O
méningite	B-DISO
secondaire	O
étant	O
plus	O
élevé	O
lors	O
de	O
l	O
’	O
utilisation	O
prolongée	O
d	O
’	O
un	O
cathéter	B-DEVI
sous	B-ANAT
-	I-ANAT
arachnoïdien	I-ANAT
avec	O
système	O
de	O
perfusion	B-PROC
externe	O
,	O
les	O
systèmes	O
implantés	B-PROC
sont	O
préconisés	B-PROC
pour	O
l	O
’	O
administration	B-PROC
de	O
ziconotide	B-CHEM
pendant	O
des	O
périodes	O
prolongées	O
.	O

Un	O
système	O
de	O
cathéter	B-DEVI
externe	O
ne	O
sera	O
utilisé	O
que	O
lorsqu	O
’	O
un	O
système	O
interne	O
ne	O
peut	O
pas	O
être	O
implanté	B-PROC
.	O

Prialt	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
chez	O
l	O
’	O
enfant	B-LIVB
en	I-LIVB
dessous	I-LIVB
de	I-LIVB
18	I-LIVB
ans	I-LIVB
suite	O
à	O
un	O
manque	O
de	O
données	O
concernant	O
la	O
sécurité	B-PHEN
et	O
l	O
’	O
efficacité	O
.	O

Bien	O
que	O
l	O
’	O
efficacité	O
et	O
la	O
sécurité	B-PHEN
d	O
’	O
emploi	O
à	O
long	O
terme	O
du	O
ziconotide	B-CHEM
ait	O
été	O
étudié	B-PROC
au	O
cours	O
d	O
’	O
essais	B-PROC
cliniques	I-PROC
en	O
ouvert	O
,	O
aucun	O
essai	B-PROC
contrôlé	O
d	O
’	O
une	O
durée	O
supérieure	O
à	O
trois	O
semaines	O
n	O
’	O
a	O
été	O
réalisé	O
(	O
voir	O
rubrique	O
5	O
.	O
1	O
)	O
.	O

La	O
possibilité	O
d	O
’	O
effets	B-DISO
toxiques	I-DISO
locaux	O
à	O
long	O
terme	O
au	O
niveau	O
de	O
la	O
moelle	B-ANAT
épinière	I-ANAT
n	O
’	O
est	O
pas	O
exclue	O
et	O
les	O
données	O
précliniques	O
disponibles	O
sont	O
limitées	O
(	O
voir	O
rubrique	O
5	O
.	O
3	O
)	O
.	O

La	O
prudence	O
s	O
’	O
impose	O
donc	O
lors	O
d	O
’	O
un	O
traitement	B-PROC
au	O
long	O
cours	O
.	O

Les	O
patients	B-LIVB
et	O
les	O
médecins	B-LIVB
doivent	O
être	O
vigilants	O
concernant	O
l	O
’	O
apparition	O
de	O
symptômes	B-DISO
et	O
signes	B-DISO
typiques	O
de	O
méningite	B-DISO
.	O

Le	O
positionnement	O
intrathécal	B-ANAT
optimal	O
du	O
cathéter	B-DEVI
n	O
’	O
a	O
pas	O
été	O
établi	O
.	O

Le	O
positionnement	O
du	O
cathéter	B-DEVI
à	O
un	O
niveau	O
plus	O
bas	O
,	O
ex	O
.	O
au	O
niveau	O
lombaire	B-ANAT
,	O
pourrait	O
peut	O
-	O
être	O
diminuer	O
les	O
réactions	B-DISO
neurologiques	I-DISO
indésirables	O
liées	O
au	O
ziconotide	B-CHEM
.	O

Le	O
positionnement	O
du	O
cathéter	B-DEVI
doit	O
donc	O
être	O
évalué	B-PROC
soigneusement	O
pour	O
permettre	O
un	O
accès	O
adéquat	O
aux	O
segments	O
nociceptifs	B-ANAT
rachidiens	B-ANAT
tout	O
en	O
diminuant	O
les	O
concentrations	O
de	O
médicament	B-CHEM
au	O
niveau	O
cérébral	B-ANAT
.	O

Le	O
nombre	O
de	O
patients	B-LIVB
ayant	O
reçu	O
une	O
chimiothérapie	B-PROC
systémique	I-PROC
et	O
le	O
ziconotide	B-CHEM
par	O
voie	O
intrarachidienne	B-ANAT
étant	O
faible	O
,	O
la	O
prudence	O
s	O

Des	O
élévations	O
de	O
la	O
créatine	B-CHEM
phosphokinase	I-CHEM
(	O
CPK	B-CHEM
)	O
,	O
généralement	O
asymptomatiques	B-DISO
,	O
sont	O
fréquentes	O
chez	O
les	O
patients	B-LIVB
traités	B-PROC
par	O
ziconotide	B-CHEM
par	O
voie	O
intrarachidienne	B-ANAT
.	O

Une	O
élévation	O
progressive	O
de	O
la	O
créatine	B-CHEM
phosphokinase	I-CHEM
est	O
,	O
en	O
revanche	O
,	O
peu	O
fréquente	O
.	O

Une	O
surveillance	B-PROC
des	O
taux	O
de	O
créatine	B-CHEM
phosphokinase	I-CHEM
est	O
toutefois	O
recommandée	B-PROC
.	O

Des	O
réactions	B-DISO
indésirables	I-DISO
cognitives	O
et	O
neuropsychiatriques	O
,	O
en	O
particulier	O
une	O
confusion	B-DISO
,	O
ont	O
été	O
fréquemment	O
décrites	O
chez	O
les	O
patients	B-LIVB
sous	O
ziconotide	B-CHEM
.	O

Les	O
troubles	B-DISO
cognitifs	I-DISO
apparaissent	O
typiquement	O
après	O
plusieurs	O
semaines	O
de	O
traitement	B-PROC
.	O

Des	O
épisodes	O
de	O
troubles	B-DISO
psychiatriques	I-DISO
aigus	O
,	O
tels	O
que	O
hallucinations	B-DISO
,	O
réactions	B-DISO
paranoïdes	I-DISO
,	O
hostilité	B-PHYS
,	O
délire	B-DISO
,	O
psychose	B-DISO
et	O
réactions	B-DISO
maniaques	I-DISO
ont	O
été	O
rapportés	O
chez	O
des	O
patients	B-LIVB
traités	B-PROC
par	O
le	O
ziconotide	B-CHEM
.	O

Des	O
patients	B-LIVB
ont	O
présenté	O
des	O
troubles	B-DISO
de	I-DISO
la	I-DISO
conscience	I-DISO
sous	O
ziconotide	B-CHEM
.	O

La	O
réintroduction	O
du	O
ziconotide	B-CHEM
est	O
déconseillée	O
chez	O
ces	O
patients	B-LIVB
.	O

Chez	O
les	O
patients	B-LIVB
présentant	O
des	O
douleurs	B-DISO
chroniques	I-DISO
intenses	I-DISO
,	O
la	O
fréquence	O
des	O
suicides	B-DISO
et	O
des	O
tentatives	B-DISO
de	I-DISO
suicide	I-DISO
est	O
plus	O
élevée	O
que	O
dans	O
la	O
population	B-LIVB
générale	O
.	O

Le	O
ziconotide	B-CHEM
peut	O
provoquer	O
ou	O
aggraver	B-DISO
une	O
dépression	B-DISO
,	O
avec	O
un	O
risque	O
de	O
suicide	B-DISO
chez	O
certains	O
patients	B-LIVB
.	O

Aucune	O
étude	B-PROC
clinique	I-PROC
spécifique	O
sur	O
les	O
interactions	B-PHYS
médicamenteuses	I-PHYS
n	O

Toutefois	O
,	O
en	O
raison	O
des	O
faibles	O
concentrations	O
plasmatiques	B-ANAT
du	O
ziconotide	B-CHEM
,	O
de	O
son	O
métabolisme	B-PHYS
assuré	O
par	O
des	O
peptidases	B-CHEM
ubiquitaires	O
et	O
de	O
sa	O
fixation	O
relativement	O
faible	O
aux	O
protéines	B-CHEM
plasmatiques	I-CHEM
(	O
voir	O
rubrique	O
5	O
.	O
2	O
)	O
,	O
les	O
interactions	B-PHYS
médicamenteuses	I-PHYS
liées	O
au	O
métabolisme	B-PHYS
ou	O
au	O
déplacement	O
des	O
sites	B-CHEM
de	I-CHEM
fixation	I-CHEM
protéique	B-CHEM
sont	O
peu	O
probables	O
entre	O
le	O
ziconotide	B-CHEM
et	O
d	O
’	O
autres	O
médicaments	B-CHEM
.	O

Le	O
nombre	O
de	O
patients	B-LIVB
ayant	O
reçu	O
une	O
chimiothérapie	B-PROC
systémique	I-PROC
et	O
le	O
ziconotide	B-CHEM
par	O
voie	O
intrarachidienne	B-ANAT
étant	O
faible	O
,	O
la	O
prudence	O
s	O

Les	O
médicaments	B-CHEM
interférant	O
avec	O
des	O
peptidases	B-CHEM
/	O
protéases	B-CHEM
spécifiques	O
ne	O
devraient	O
pas	O
agir	O
sur	O
les	O
concentrations	O
plasmatiques	B-ANAT
du	O
ziconotide	B-CHEM
.	O

Le	O
ziconotide	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
pendant	O
la	O
grossesse	B-PHYS
sauf	O
en	O
cas	O
de	O
nécessité	O
absolue	O
.	O

La	O
sécurité	B-PHEN
d	O
’	O
emploi	O
du	O
ziconotide	B-CHEM
administré	B-PROC
en	O
perfusion	B-PROC
intrarachidienne	B-ANAT
continue	O
a	O
été	O
évaluée	B-PROC
chez	O
plus	O
de	O
1400	O
patients	B-LIVB
participant	O
à	O
des	O
études	B-PROC
cliniques	I-PROC
évaluant	B-PROC
la	O
douleur	B-DISO
aiguë	I-DISO
et	I-DISO
chronique	I-DISO
.	O

La	O
durée	O
du	O
traitement	B-PROC
est	O
allée	O
d	O
’	O
une	O
heure	O
de	O
perfusion	B-PROC
en	O
bolus	B-PHYS
à	O
une	O
utilisation	O
continue	O
de	O
plus	O
de	O
6	O
ans	O
.	O

Dans	O
les	O
études	B-PROC
cliniques	I-PROC
,	O
88	O
%	O
des	O
patients	B-LIVB
ont	O
présenté	O
des	O
effets	B-DISO
indésirables	I-DISO
.	O

Les	O
effets	B-DISO
indésirables	I-DISO
les	O
plus	O
fréquemment	O
rapportés	O
dans	O
les	O
études	B-PROC
cliniques	I-PROC
à	O
long	O
terme	O
ont	O
été	O
les	O
suivants	O
:	O
sensations	B-DISO
vertigineuses	I-DISO
(	O
42	O
%	O
)	O
,	O
nausées	B-DISO
(	O
30	O
%	O
)	O
,	O
nystagmus	B-DISO
(	O
23	O
%	O
)	O
,	O
état	B-DISO
confusionnel	I-DISO
(	O
25	O
%	O
)	O
,	O
troubles	B-DISO
de	I-DISO
la	I-DISO
démarche	I-DISO
(	O
16	O
%	O
)	O
,	O
troubles	B-DISO
mnésiques	I-DISO
(	I-DISO
13	I-DISO
%	O
)	O
,	O
flou	B-DISO
visuel	I-DISO
(	O
14	O
%	O
)	O
,	O
céphalées	B-DISO
(	O
12	O
%	O
)	O
,	O
asthénie	B-DISO
(	O
13	O
%	O
)	O
,	O
vomissements	B-DISO
(	O
11	O
%	O
)	O
et	O
somnolence	B-DISO
(	O
10	O
%	O
)	O
.	O

La	O
plupart	O
de	O
ces	O
effets	B-DISO
étaient	O
d	O
’	O
intensité	O
légère	O
à	O
modérée	O
et	O
ont	O
disparu	O
avec	O
le	O
temps	O
.	O

Tous	O
les	O
effets	B-DISO
indésirables	I-DISO
décrits	O
dans	O
les	O
études	B-PROC
cliniques	I-PROC
au	O
cours	O
desquelles	O
le	O
ziconotide	B-CHEM
a	O
été	O
administré	B-PROC
par	O
voie	O
intrarachidienne	B-ANAT
(	O
administration	B-PROC
à	O
court	O
et	O
long	O
termes	O
)	O
sont	O
présentés	O
ci	O
-	O
dessous	O
par	O
ordre	O
de	O
fréquence	O
.	O

Fréquents	O
:	O
anxiété	B-DISO
,	O
hallucinations	B-DISO
auditives	I-DISO
,	O
insomnie	B-DISO
,	O
agitation	B-DISO
,	O
désorientation	B-DISO
,	O
hallucination	B-DISO
,	O
hallucinations	B-DISO
visuelles	I-DISO
,	O
dépression	B-DISO
,	O
paranoïa	B-DISO
,	O
irritabilité	B-DISO
,	O
dépression	B-DISO
aggravée	I-DISO
,	O
nervosité	B-DISO
,	O
labilité	B-DISO
émotionnelle	I-DISO
,	O
modifications	O
de	O
l	O

Peu	O
fréquents	O
:	O
délire	B-DISO
,	O
troubles	B-DISO
psychotiques	I-DISO
,	O
idées	B-DISO
suicidaires	I-DISO
,	O
tentative	B-DISO
de	I-DISO
suicide	I-DISO
,	O
blocage	B-DISO
de	I-DISO
la	I-DISO
pensée	I-DISO
,	O
rêves	B-DISO
anormaux	I-DISO
,	O

Affections	B-DISO
du	I-DISO
système	I-DISO
nerveux	I-DISO

Très	O
fréquents	O
:	O
sensations	B-DISO
vertigineuses	I-DISO
,	O
nystagmus	B-DISO
,	O
troubles	B-DISO
mnésiques	I-DISO
,	O
céphalées	B-DISO
,	O
somnolence	B-DISO

Peu	O
fréquents	O
:	O
incohérence	B-DISO
,	O
perte	B-DISO
de	I-DISO
conscience	I-DISO
,	O
coma	B-DISO
,	O
stupeur	B-DISO
,	O
convulsions	B-DISO
,	O
accident	B-DISO
vasculaire	I-DISO
cérébral	I-DISO
,	O
encéphalopathie	B-DISO

Fréquents	O
:	O
diplopie	B-DISO
,	O
troubles	B-DISO
de	I-DISO
la	I-DISO
vision	I-DISO
,	O
photophobie	B-DISO

Fréquents	O
:	O
vertige	B-DISO
,	O
acouphènes	B-DISO

Fréquents	O
:	O
hypotension	B-DISO
orthostatique	I-DISO
,	O
hypotension	B-DISO

Fréquents	O
:	O
diarrhée	B-DISO
,	O
sécheresse	B-DISO
buccale	I-DISO
,	O
constipation	B-DISO
,	O
aggravation	B-DISO
des	O
nausées	B-DISO
,	O
douleurs	B-DISO
abdominales	I-DISO
hautes	O

Fréquents	O
:	O
prurit	B-DISO
,	O
hypersudation	B-DISO

Fréquents	O
:	O
douleurs	B-DISO
dans	I-DISO
les	I-DISO
membres	I-DISO
,	O
myalgie	B-DISO
,	O
spasmes	B-DISO
musculaires	B-ANAT
,	O
crampes	B-DISO
musculaires	I-DISO
,	O
faiblesse	B-DISO
musculaire	I-DISO
,	O
arthralgie	B-DISO
,	O
œdèmes	B-DISO
périphériques	I-DISO

Peu	O
fréquents	O
:	O
rhabdomyolyse	B-DISO
,	O
myosite	B-DISO
,	O
dorsalgies	B-DISO
,	O
clonies	O
,	O
cervicalgies	B-DISO

Affections	B-DISO
du	I-DISO
rein	I-DISO
et	O
des	O
voies	B-ANAT
urinaires	I-ANAT

Peu	O
fréquents	O
:	O
insuffisance	B-DISO
rénale	I-DISO
aiguë	I-DISO

Très	O
fréquents	O
:	O
anomalies	B-DISO
de	I-DISO
la	I-DISO
démarche	I-DISO
,	O
asthénie	B-DISO

Fréquents	O
:	O
fatigue	B-DISO
,	O
pyrexie	B-DISO
,	O
léthargie	B-DISO
,	O
œdèmes	B-DISO
périphériques	I-DISO
,	O
frissons	B-DISO
,	O
chutes	B-DISO
,	O
douleurs	B-DISO
thoraciques	I-DISO
,	O
sensation	B-PHYS
de	I-PHYS
froid	I-PHYS
,	O
sensation	O
d	O

Fréquents	O
:	O
augmentation	O
des	O
taux	O
sanguins	B-ANAT
de	O
créatine	B-CHEM
phosphokinase	I-CHEM
,	O
diminution	B-DISO
du	I-DISO
poids	I-DISO

Peu	O
fréquents	O
:	O
électrocardiogramme	B-DISO
anormal	I-DISO
,	O
aspartate	B-CHEM
aminotransférase	I-CHEM
,	O
créatine	B-CHEM
phosphokinase	I-CHEM
MM	O
,	O
augmentation	O
de	O
la	O
température	B-PHYS
corporelle	I-PHYS

Des	O
commentaires	O
spécifiques	O
et	O
des	O
recommandations	B-PROC
de	O
prudence	O
concernant	O
la	O
méningite	B-DISO
,	O
l	O
’	O
élévation	O
des	O
taux	O
de	O
créatine	B-CHEM
phosphokinase	I-CHEM
et	O
les	O
effets	B-DISO
indésirables	I-DISO
sur	O
le	O
SNC	B-ANAT
figurent	O
à	O
la	O
rubrique	O
4	O
.	O
4	O
.	O

Dans	O
les	O
études	B-PROC
de	O
perfusion	B-PROC
intraveineuse	O
,	O
des	O
volontaires	B-LIVB
sains	O
de	O
sexe	B-PHYS
masculin	I-PHYS
ont	O
reçu	O
le	O
ziconotide	B-CHEM
à	O
des	O
doses	O
atteignant	O
70	O
000	O
µg	O
/	O
jour	O
ou	O
3	O
,	O
200	O
fois	O
la	O
dose	O
journalière	O
maximale	O
recommandée	B-PROC
par	O
voie	O
intrarachidienne	B-ANAT
.	O

Une	O
hypotension	B-DISO
orthostatique	I-DISO
a	O
été	O
observée	O
chez	O
presque	O
tous	O
les	O
sujets	B-LIVB
ayant	O
reçu	O
de	O
fortes	O
doses	O
intraveineuses	O
de	O
ziconotide	B-CHEM
.	O

La	O
posologie	O
maximale	O
recommandée	B-PROC
par	O
voie	O
intrarachidienne	B-ANAT
est	O
de	O
21	O
,	O
6	O
µg	O
/	O
jour	O
.	O

Dans	O
les	O
études	B-PROC
cliniques	I-PROC
,	O
la	O
dose	O
maximale	O
prévue	O
de	O
ziconotide	B-CHEM
administré	B-PROC
par	O
voie	O
intrarachidienne	B-ANAT
était	O
de	O
912	O
µg	O
/	O
jour	O
après	O
une	O
augmentation	O
posologique	O
sur	O
7	O
jours	O
.	O

La	O
plupart	O
des	O
patients	B-LIVB
sous	O
observation	B-DISO
ont	O
récupéré	B-PHYS
dans	O
les	O
24	O
heures	O
suivant	O
l	O

L	O
’	O
Agence	O
européenne	O
du	O
médicament	B-CHEM
(	O
EMEA	O
)	O
réévaluera	B-PROC
chaque	O
année	O
toute	O
nouvelle	O
information	O
qui	O
pourrait	O
être	O
fournie	O
,	O
et	O
si	O
nécessaire	O
cet	O
RCP	O
sera	O
mis	O
à	O
jour	O
.	O

De	O
nombreux	O
patients	B-LIVB
répondant	O
au	O
traitement	B-PROC
obtiennent	O
une	O
analgésie	O
quasi	O
-	O
maximale	O
dans	O
les	O
heures	O
suivant	O
l	O

Si	O
nécessaire	O
,	O
la	O
posologie	O
peut	O
être	O
diminuée	O
sans	O
limitation	O
de	O
dose	O
(	O
avec	O
possibilité	O
éventuelle	O
d	O

Les	O
effets	B-DISO
indésirables	I-DISO
neurologiques	B-ANAT
,	O
notamment	O
les	O
sensations	B-DISO
vertigineuses	I-DISO
,	O
les	O
nausées	B-DISO
et	O
les	O
troubles	B-DISO
de	I-DISO
la	I-DISO
démarche	I-DISO
semblent	O
corrélées	O
avec	O
les	O
concentrations	O
céphalo	O
-	O
rachidiennes	O
mais	O
aucune	O
relation	O
définitive	O
n	O

Pour	O
limiter	O
la	O
survenue	O
d	O
’	O
effets	B-DISO
indésirables	I-DISO
graves	O
,	O
il	O
est	O
recommandé	B-PROC
de	O
ne	O
pas	O
dépasser	O
21	O
,	O
6	O
µg	O
/	O
jour	O
.	O

Cependant	O
,	O
dans	O
les	O
études	B-PROC
cliniques	I-PROC
,	O
on	O
a	O
observé	O
que	O
les	O
patients	B-LIVB
qui	O
tolèrent	B-PHYS
des	O
doses	O
de	O
21	O
,	O
6	O
µg	O
/	O
jour	O
après	O
une	O
augmentation	O
progressive	O
des	O

8	O
doses	O
pendant	O
une	O
période	O
de	O
3	O
à	O
4	O
semaines	O
,	O
tolèrent	B-PHYS
généralement	O
des	O
doses	O
plus	O
élevées	O
,	O
pouvant	O
atteindre	O
48	O
,	O
0	O
µg	O
/	O
jour	O
.	O

Toutefois	O
,	O
compte	O
tenu	O
des	O
données	O
limitées	O
disponibles	O
,	O
l	O
’	O
apparition	O
d	O
’	O
une	O
accoutumance	B-DISO
ne	O
peut	O
être	O
exclue	O
.	O

La	O
perméabilité	B-PHEN
du	O
cathéter	B-DEVI
intrarachidien	B-ANAT
doit	O
être	O
examinée	O
en	O
cas	O
de	O
nécessité	O
d	O
’	O
une	O
augmentation	O
continue	O
des	O
doses	O
de	O
ziconotide	B-CHEM
n	O

Trois	O
études	B-PROC
cliniques	I-PROC
du	O
ziconotide	B-CHEM
intrarachidien	B-ANAT
contrôlées	O
contre	O
placebo	B-CHEM
ont	O
été	O
réalisées	O
.	O

Score	O
EVA	B-PROC
moyen	O
à	O
la	O
fin	O
du	O
titrage	O
de	O
doses	O
initial	O
,	O
en	O
mm	O
(	O
ET	O
)	O

_	O

Répondeursa	O
n	O
(	O
%	O
)	O
Dose	O
en	O
fin	O
de	O
titrage	O
de	O
doses	O
(	O
μ	O
g	O
/	O
h	O
)	O

Placebo	B-CHEM
(	O
n	O
=	O
86	O
)	O

L	O
’	O
étiologie	O
de	O
la	O
douleur	B-DISO
dans	O
les	O
études	B-PROC
95	O
-	O
001	O
(	O
douleur	B-DISO
cancéreuse	I-DISO
)	O
et	O
96	O
-	O
002	O
(	O
douleur	B-DISO
non	O
cancéreuse	B-DISO
)	O
variait	O
,	O
incluant	O
des	O
douleurs	B-DISO
osseuses	I-DISO
(	O
n	O
=	O
380	O
)	O
,	O
due	O
principalement	O
à	O
des	O
métastases	B-DISO
osseuses	I-DISO
(	O
n	O
=	O
34	O
)	O
,	O
une	O
myélopathie	B-DISO
(	O
n	O
=	O
38	O
)	O
,	O
dont	O
la	O
moitié	O
présentait	O
un	O
traumatisme	B-DISO
médullaire	B-ANAT
avec	O
paralysie	B-DISO
(	O
n	O
=	O
19	O
)	O
,	O
neuropathie	B-DISO
(	O
n	O
=	O
79	O
)	O
,	O
radiculopathie	B-DISO
(	O
n	O
=	O
24	O
)	O
,	O
douleur	B-DISO
médullaire	B-ANAT
(	O
n	O
=	O
91	O
)	O
due	O
principalement	O
à	O
l	O
’	O
échec	O
d	O
’	O
une	O
intervention	B-DISO
chirurgicale	I-DISO
au	O
niveau	O
dorsal	B-ANAT
(	O
n	O
=	O
82	O
)	O
et	O
autres	O
étiologies	O
(	O
n	O
=	O
82	O
)	O
.	O

Certains	O
patients	B-LIVB
présentaient	O
plusieurs	O
causes	O
de	O
douleur	B-DISO
.	O

Le	O
critère	O
de	O
jugement	O
principal	O
était	O
le	O
pourcentage	O
de	O
changement	O
sur	O
l	O
’	O
EVA	B-PROC
.	O

L	O
’	O
efficacité	O
de	O
l	O
’	O
administration	B-PROC
intrarachidienne	B-ANAT
de	O
ziconotide	B-CHEM
dans	O
l	O
’	O
étude	B-PROC
301	O
était	O
plus	O
faible	O
que	O
dans	O
les	O
deux	O
études	B-PROC
précédentes	O
à	O
court	O
terme	O
.	O

La	O
fréquence	O
et	O
la	O
sévérité	O
des	O
effets	B-DISO
indésirables	I-DISO
étaient	O
également	O
plus	O
faibles	O
.	O

Ziconotide	B-CHEM
(	O
n	O
=	O
112	O
)	O

Placebo	B-CHEM
(	O
n	O
=	O
108	O
)	O

Les	O
paramètres	O
pharmacocinétiques	B-PHYS
plasmatiques	B-ANAT
ont	O
également	O
été	O
étudiés	B-PROC
après	O
administration	B-PROC
intraveineuse	O
(	O
0	O
,	O
3	O
–	O
10	O
μ	O
g	O
/	O
kg	O
/	O
24	O
h	O
)	O
.	O

Paramètres	O
pharmacocinétiques	B-PHYS
du	O
ziconotide	B-CHEM
dans	O
le	O
plasma	B-ANAT
et	O
le	O
LCR	B-ANAT
[	O
moyenne	O
±	O
ET	O
(	O
médiane	O
)	O
]	O

Matrice	O

Vd	O
(	O
ml	O
)	O

t½	O
(	O
h	O
)	O

liquide	B-OBJC

Intraveineuse	O

Plasma	B-ANAT

CL	O
=	O
clairance	B-PHYS
;	O
Vd	O
=	O
volume	O
de	O
distribution	B-PHYS
;	O
t½	O
=	O
demi	O
-	O
vie	O

Après	O
administration	B-PROC
intrarachidienne	B-ANAT
pendant	O
une	O
heure	O
(	O
1	O
–	O
10	O
µg	O
)	O
,	O
les	O
concentrations	O
cumulées	O
(	O
SSC	O
;	O
extrêmes	O
:	O

83	O
,	O
6	O
–	O
608	O
ng	O
/	O
h	O
/	O
ml	O
)	O
et	O
les	O
concentrations	O
maximales	O
(	O
Cmax	O
;	O
extrêmes	O
:	O

Aucune	O
accumulation	B-DISO
plasmatique	B-ANAT
du	O
ziconotide	B-CHEM
après	O
administration	B-PROC
intrarachidienne	B-ANAT
à	O
long	O
terme	O
(	O
jusqu	O

Le	O
ziconotide	B-CHEM
est	O
un	O
peptide	B-CHEM
constitué	O
de	O
25	O
acides	B-CHEM
aminés	I-CHEM
naturels	O
en	O
configuration	O
L	O
et	O
il	O
ne	O
semble	O
pas	O
être	O
métabolisé	B-PHYS
de	O
façon	O
quantifiable	O
dans	O
le	O
LCR	B-ANAT
.	O

Les	O
acides	B-CHEM
aminés	I-CHEM
libres	O
générés	O
sont	O
probablement	O
captés	O
par	O
des	O
systèmes	O
de	O
transport	B-PHYS
cellulaires	I-PHYS
et	O
soumis	O
ultérieurement	O
au	O
métabolisme	B-PHYS
intermédiaire	O
habituel	O
ou	O
utilisés	O
comme	O
substrats	O
pour	O
des	O
processus	O
de	O
biosynthèse	B-PHYS
constitutive	O
.	O

La	O
CL	O
moyenne	O
du	O
ziconotide	B-CHEM
(	O
0	O
,	O
38	O
ml	O
/	O
min	O
)	O
est	O
proche	O
du	O
débit	O
de	O
renouvellement	O
du	O
LCR	B-ANAT
chez	O
l	O

Populations	B-LIVB
particulières	O
:	O

Bien	O
que	O
les	O
données	O
disponibles	O
soient	O
en	O
nombre	O
limité	O
,	O
aucun	O
effet	B-DISO
en	O
fonction	O
de	O
la	O
race	B-LIVB
,	I-LIVB
l	I-LIVB
de	O
la	O
taille	B-PHYS
,	O
du	O
poids	B-PHYS
,	O
du	O
sexe	B-PHYS
ou	O
de	O
l	O

Ces	O
effets	B-DISO
ont	O
été	O
définis	O
par	O
des	O
actions	B-PHEN
pharmacologiques	I-PHEN
amplifiées	O
du	O
ziconotide	B-CHEM
et	O
non	O
par	O
des	O
lésions	B-DISO
neurotoxiques	B-DISO
ou	O
une	O
toxicité	B-DISO
dirigée	O
contre	O
des	O
organes	B-ANAT
cibles	O
.	O

Les	O
observations	B-PROC
ont	O
inclus	O
des	O
effets	B-PHYS
neurologiques	I-PHYS
transitoires	O
et	O
réversibles	O
,	O
à	O
type	O
de	O
tremblements	B-DISO
,	O
incoordination	B-DISO
des	O
mouvements	B-PHYS
et	O
hyper	B-DISO
-	O
ou	O
hypoactivité	B-DISO
.	O

Les	O
modifications	O
éventuelles	O
de	O
la	O
transmission	B-PHEN
des	O
signaux	B-PHEN
neurologiques	B-ANAT
chez	O
l	O

Méthionine	B-CHEM
Chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
Eau	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
Acide	B-CHEM
chlorhydrique	I-CHEM
(	O
ajustement	O
du	O
pH	B-PHEN
)	O
Hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
(	O
ajustement	O
du	O
pH	B-PHEN
)	O

La	O
stabilité	O
physico	O
-	O
chimique	O
du	O
produit	B-OBJC
après	O
première	O
ouverture	O
a	O
été	O
démontrée	O
pendant	O
60	O
jours	O
à	O
37	O
C	O
.	O

Du	O
point	O
de	O
vue	O
microbiologique	O
,	O
si	O
le	O
produit	B-OBJC
est	O
dilué	B-PROC
,	O
il	O
doit	O
être	O
transféré	O
immédiatement	O
dans	O
la	O
pompe	B-DEVI
de	O
perfusion	B-PROC
.	O

Flacons	B-DEVI
en	O
verre	B-OBJC
de	O
type	O
I	O
à	O
usage	O
unique	O
,	O
avec	O
bouchon	B-OBJC
en	O
caoutchouc	B-CHEM
butylique	I-CHEM
recouverts	O
de	O
polymère	B-CHEM
fluoré	I-CHEM
.	O

Chaque	O
flacon	B-DEVI
contient	O
1	O
,	O
2	O
ou	O
5	O
ml	O
de	O
solution	B-CHEM
pour	O
perfusion	B-PROC
.	O

Si	O
une	O
dilution	B-PROC
est	O
nécessaire	O
,	O
elle	O
doit	O
être	O
effectuée	O
de	O
façon	O
aseptique	O
avec	O
une	O
solution	B-CHEM
de	O
chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
à	O
9	O
mg	O
/	O
ml	O
(	O
0	O
,	O
9	O
%	O
)	O
pour	O
solution	B-CHEM
injectable	I-CHEM
sans	O
conservateurs	B-CHEM
,	O
avant	O
utilisation	O
.	O

La	O
concentration	O
de	O
la	O
solution	B-CHEM
utilisée	O
dans	O
la	O
pompe	B-DEVI
à	O
perfusion	B-PROC
ne	O
doit	O
pas	O
être	O
inférieure	O
à	O
5	O
µg	O
/	O
ml	O
de	O
ziconotide	B-CHEM
dans	O
une	O
pompe	B-DEVI
externe	O
et	O
à	O
25	O
μ	O
g	O
/	O
ml	O
dans	O
une	O
pompe	B-DEVI
interne	O
.	O

Des	O
conditions	O
aseptiques	O
strictes	O
doivent	O
être	O
respectées	O
pendant	O
la	O
préparation	O
et	O
la	O
manipulation	O
de	O
la	O
solution	B-CHEM
pour	O
perfusion	B-PROC
et	O
le	O
remplissage	O
de	O
la	O
pompe	B-DEVI
.	O

Le	O
patient	B-LIVB
et	O
le	O
personnel	B-LIVB
soignant	I-LIVB
doivent	O
être	O
familiarisés	O
avec	O
la	O
manipulation	O
du	O
système	O
de	O
pompe	B-DEVI
externe	O
ou	O
interne	O
et	O
être	O
conscients	O
de	O
la	O
nécessité	O
absolue	O
d	O

Aux	O
concentrations	O
indiquées	O
ci	O
-	O
dessus	O
,	O
Prialt	B-CHEM
est	O
compatible	O
chimiquement	O
et	O
physiquement	O
avec	O
la	O
pompe	B-DEVI
implantable	B-PROC
Synchromed	O
et	O
la	O
pompe	B-DEVI
externe	O
micro	O
-	O
CADD	O
.	O

Le	O
produit	B-OBJC
doit	O
donc	O
être	O
remplacé	O
au	O
bout	O
de	O
14	O
jours	O
après	O
remplissage	O
initial	O
de	O
la	O
pompe	B-DEVI
.	O

Prialt	B-CHEM
s	O
’	O
est	O
avéré	O
stable	O
pendant	O
60	O
jours	O
à	O
37	O
C	O
dans	O
une	O
pompe	B-DEVI
Synchromed	O
déjà	O
exposée	O
au	O
médicament	B-CHEM
.	O

Dans	O
la	O
pompe	B-DEVI
CADD	O
-	O
Micro	O
,	O
le	O
produit	B-OBJC
reste	O
stable	O
pendant	O
21	O
jours	O
à	O
température	O
ambiante	O
.	O

Par	O
conséquent	O
,	O
après	O
une	O
première	O
utilisation	O
de	O
Prialt	B-CHEM
,	O
le	O
réservoir	B-OBJC
doit	O
être	O
vidé	O
et	O
rempli	O
à	O
nouveau	O
au	O
bout	O
de	O
14	O
jours	O
.	O

Par	O
la	O
suite	O
,	O
la	O
pompe	B-DEVI
peut	O
être	O
remplie	O
et	O
vidée	O
tous	O
les	O
60	O
jours	O
.	O

14	O
Prialt	B-CHEM
est	O
une	O
solution	B-CHEM
limpide	O
et	O
incolore	O
.	O

La	O
solution	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisée	O
si	O
elle	O
est	O
colorée	O
ou	O
trouble	O
ou	O
en	O
cas	O
de	O
présence	O
de	O
particules	B-CHEM
.	O

Tout	O
produit	B-OBJC
inutilisé	O
doit	O
être	O
éliminé	O
conformément	O
aux	O
réglementations	O
locales	O
.	O

Eisai	O
Ltd	O
.	O
,	O
3	O
Shortlands	O
London	O
W6	O
8EE	O
Royaume	B-GEOG
-	I-GEOG
Uni	I-GEOG

Des	O
informations	O
détaillées	O
sur	O
ce	O
médicament	B-CHEM
sont	O
disponibles	O
sur	O
le	O
site	O
internet	O
de	O
l	O
’	O
Agence	O
européenne	O
du	O
médicament	B-CHEM
(	O
EMEA	O
)	O
www	O
.	O
emea	O
.	O
europa	O
.	O
eu	O

Prialt	B-CHEM
25	O
microgrammes	O
/	O
ml	O
,	O
solution	B-CHEM
pour	O
perfusion	B-PROC
.	O

Un	O
ml	O
de	O
solution	B-CHEM
contient	O
25	O
μ	O
g	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O

Des	O
réactions	B-DISO
indésirables	I-DISO
cognitives	O
et	O
neuropsychiatriques	O
,	O
en	O
particulier	O
une	O
confusion	B-DISO
,	O
ont	O
été	O
fréquemment	O
décrites	O
chez	O
les	O
patients	B-LIVB
sous	O
ziconotide	B-CHEM
.	O

Des	O
épisodes	O
de	O
troubles	B-DISO
psychiatriques	I-DISO
aigus	O
,	O
tels	O
que	O
hallucinations	B-DISO
,	O
réactions	B-DISO
paranoïdes	I-DISO
,	O
hostilité	B-PHYS
,	O
délire	B-DISO
,	O
psychose	B-DISO
et	O
réactions	B-DISO
maniaques	I-DISO
ont	O
été	O
rapportés	O
chez	O
des	O
patients	B-LIVB
traités	B-PROC
par	O
le	O
ziconotide	B-CHEM
.	O

4	O
.	O
6	O
Grossesse	B-PHYS
et	O
allaitement	B-PHYS

Affections	B-DISO
du	I-DISO
rein	I-DISO
et	I-DISO
des	I-DISO
voies	I-DISO
urinaires	I-DISO

6	O
.	O
5	O
Nature	O
et	O
contenu	O
de	O
l	O
’	O
emballage	B-DEVI
extérieur	O

Chaque	O
flacon	B-DEVI
contient	O
20	O
ml	O
de	O
solution	B-CHEM
pour	O
perfusion	B-PROC
.	O

Eisai	O
Manufacturing	O
Limited	O
European	O
Knowledge	O
Centre	O
Mosquito	O
Way	O
Hatfield	O
Herts	O
AL10	O
9SN	O
Royaume	B-GEOG
-	I-GEOG
Uni	I-GEOG

Un	O
registre	O
patients	B-LIVB
sera	O
mis	O
en	O
place	O
chez	O
les	O
patients	B-LIVB
traités	B-PROC
après	O
commercialisation	O
de	O
PRIALT	B-CHEM
(	O
PRIME	O
)	O
.	O

Ce	O
registre	O
permettra	O
de	O
recueillir	O
des	O
données	O
sur	O
l	O
’	O
efficacité	O
et	O
la	O
sécurité	B-PHEN
d	O
’	O
emploi	O
du	O
ziconotide	B-CHEM
en	O
administration	B-PROC
intrathécale	B-ANAT
au	O
long	O
cours	O
,	O
chez	O
des	O
patients	B-LIVB
présentant	O
des	O
douleurs	B-DISO
intenses	I-DISO
chroniques	I-DISO
cancéreuses	I-DISO
ou	O
non	O
.	O

L	O
’	O
analyse	O
de	O
l	O
’	O
évolution	O
de	O
l	O
’	O
état	O
des	O
patients	B-LIVB
sera	O
effectuée	O
en	O
fonction	O
de	O
l	O
’	O
étiologie	O
(	O
cancéreuse	B-DISO
ou	O
non	O
)	O
,	O
du	O
mécanisme	O
(	O
neuropathique	B-DISO
ou	O
non	O
)	O
et	O
de	O
l	O
’	O
intensité	O
de	O
la	O
douleur	B-DISO
(	O
score	O
EVA	B-PROC
initial	O
supérieur	O
ou	O
inférieur	O
à	O
50	O
mm	O
)	O
.	O

Ce	O
registre	O
permettra	O
d	O
’	O
obtenir	O
des	O
données	O
d	O
’	O
utilisation	O
du	O
ziconotide	B-CHEM
,	O
notamment	O
pour	O
ce	O
qui	O
concerne	O
le	O
schéma	O
posologique	O
optimal	O
et	O
le	O
délai	O
d	O
’	O
apparition	O
d	O
’	O
une	O
accoutumance	B-DISO
éventuelle	O
.	O

L	O
’	O
utilisation	O
du	O
ziconotide	B-CHEM
en	O
association	B-PHYS
avec	O
la	O
morphine	B-CHEM
ou	O
le	O
baclofène	B-CHEM
,	O
ou	O
d	O
’	O
autres	O
médicaments	B-CHEM
,	O
la	O
qualité	O
de	O
vie	O
et	O
les	O
effets	B-DISO
indésirables	I-DISO
observés	O
seront	O
également	O
analysés	B-PROC
.	O

Les	O
inclusions	O
se	O
poursuivront	O
jusqu	O
’	O
à	O
un	O
total	O
d	O
’	O
au	O
moins	O
150	O
patients	B-LIVB
.	O

Au	O
moment	O
de	O
la	O
réévaluation	B-PROC
annuelle	O
,	O
le	O
titulaire	O
de	O
l	O
’	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
devra	O
fournir	O
,	O
la	O
mise	O
à	O
jour	O
de	O
l	O
’	O
état	O
d	O
’	O
avancement	O
des	O
inclusions	O
au	O
registre	O
PRIME	O
,	O
ainsi	O
que	O
les	O
analyses	B-PROC
intermédiaires	O
.	O

Cette	O
étude	B-PROC
a	O
débuté	O
en	O
mars	O
2008	O
.	O

Le	O
titulaire	O
de	O
l	O
’	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
devra	O
soumettre	O
un	O
rapport	O
d	O
’	O
étude	B-PROC
final	O
au	O
CHMP	O
et	O
à	O
la	O
lumière	O
des	O
résultats	O
obtenus	O
,	O
envisager	O
la	O
nécessité	O
de	O
modifier	O
le	O
RCP	O
de	O
médicament	B-CHEM
.	O

Prialt	B-CHEM
100	O
microgrammes	O
/	O
ml	O
,	O
solution	B-CHEM
pour	O
perfusion	B-PROC
,	O
ziconotide	B-CHEM

1	O
ml	O
:	O

Chaque	O
ml	O
de	O
solution	B-CHEM
contient	O
100	O
microgrammes	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O

2	O
ml	O
:	O

Chaque	O
ml	O
de	O
solution	B-CHEM
contient	O
100	O
microgrammes	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O

5	O
ml	O
:	O

Chaque	O
ml	O
de	O
solution	B-CHEM
contient	O
100	O
microgrammes	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O

méthionine	B-CHEM
,	O
chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
eau	B-CHEM
pour	O
préparation	B-CHEM
injectable	I-CHEM
,	O
acide	B-CHEM
chlorhydrique	I-CHEM
et	O
hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
.	O

1	O
ml	O
(	O
1	O
x	O
1	O
ml	O
flacon	B-DEVI
)	O

2	O
ml	O
(	O
1	O
x	O
2	O
ml	O
flacon	B-DEVI
)	O

5	O
ml	O
(	O
1	O
x	O
5	O
ml	O
flacon	B-DEVI
)	O

Uniquement	O
par	O
voie	O
intrarachidienne	B-ANAT

3	O
Shortlands	O
London	O
W6	O
8EE	O
Royaume	B-GEOG
-	I-GEOG
Uni	I-GEOG

Prialt	B-CHEM
100	O
μ	O
g	O
/	O
ml	O

Perfusion	B-PROC
intrarachidienne	B-ANAT

Prialt	B-CHEM
25	O
microgrammes	O
/	O
ml	O
,	O
solution	B-CHEM
pour	O
perfusion	B-PROC
,	O
ziconotide	B-CHEM

Chaque	O
ml	O
de	O
solution	B-CHEM
contient	O
25	O
microgrammes	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O
’	O
acétate	B-CHEM
)	O
,	O
(	O
500	O
microgrammes	O
par	O
flacon	B-DEVI
)	O
,	O

20	O
ml	O
(	O
1	O
x	O
20	O
ml	O
flacon	B-DEVI
)	O

Prialt	B-CHEM
25	O
μ	O
g	O
/	O
ml	O

-	O
Si	O
vous	O
avez	O
toute	O
autre	O
question	O
,	O
si	O
vous	O
avez	O
un	O
doute	O
,	O
demandez	O
plus	O
d	O

Prialt	B-CHEM
contient	O
une	O
substance	B-OBJC
appelée	O
ziconotide	B-CHEM
,	O
qui	O
appartient	O
à	O
un	O
groupe	O
de	O
médicaments	B-CHEM
dénommés	O
antalgiques	B-CHEM
ou	O

Prialt	B-CHEM
est	O
utilisé	O
pour	O
le	O
traitement	B-PROC
des	O
douleurs	B-DISO
chroniques	I-DISO
lorsque	O
le	O
traitement	B-PROC
en	O
cours	O
n	O

douleur	B-DISO
ou	O
écoulement	B-PHEN
,	O
vous	O
devez	O
le	O
signaler	O
immédiatement	O
à	O
votre	O
médecin	B-LIVB
qui	O
vous	O
prescrira	B-PROC
un	O
traitement	B-PROC
contre	O
l	O

conseil	O
à	O
votre	O
médecin	B-LIVB
aussi	O
rapidement	O
que	O
possible	O
car	O
cette	O
augmentation	B-PHEN
de	I-PHEN
sensibilité	I-PHEN
peut	O
être	O
un	O
premier	O
signe	B-DISO
d	O

fatigue	B-DISO
,	O
confusion	B-DISO
,	O
sensation	B-DISO
de	I-DISO
malaise	I-DISO
,	O
vomissements	B-DISO
ou	O
évanouissements	B-DISO
,	O
vous	O
avez	O
peut	O
-	O
être	O

Prialt	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
pendant	O
la	O
grossesse	B-PHYS
à	O
moins	O
d	O

Demandez	O
conseil	O
à	O
votre	O
médecin	B-LIVB
si	O
vous	O
devez	O
conduire	O
un	O
véhicule	B-OBJC
ou	O
utiliser	O
une	O
machine	B-OBJC
.	O

COMMENT	O
UTILISER	O
PRIALT	B-CHEM

Votre	O
médecin	B-LIVB
discutera	O
avec	O
vous	O
du	O
type	O
de	O
pompe	B-DEVI
le	O
mieux	O
adapté	O
pour	O
vous	O
et	O
du	O
rythme	O
de	O
remplissage	O
de	O
la	O
pompe	B-DEVI
.	O

La	O
dose	O
maximale	O
est	O
de	O
21	O
,	O
6	O
microgrammes	O
/	O
jour	O
.	O

Au	O
début	O
du	O
traitement	B-PROC
,	O
le	O
médecin	B-LIVB
pourra	O
augmenter	O
la	O
dose	O
tous	O
les	O
1	O
à	O
2	O
jours	O
ou	O
plus	O
.	O

Si	O
nécessaire	O
,	O
le	O
traitement	B-PROC
pourra	O
être	O
diminué	O
ou	O
interrompu	O
si	O
les	O
effets	B-DISO
indésirables	I-DISO
sont	O
trop	O
importants	O
.	O

Il	O
est	O
possible	O
que	O
votre	O
médecin	B-LIVB
,	O
avant	O
d	O
’	O
administrer	B-PROC
Prialt	B-CHEM
,	O
décide	O
d	O
’	O
arrêter	O
de	O
vous	O
administrer	B-PROC
des	O
opiacés	B-CHEM
dans	O
l	O
’	O
espace	B-ANAT
entourant	I-ANAT
votre	I-ANAT
moelle	I-ANAT
épinière	I-ANAT
et	O
qu	O
’	O
il	O
les	O
remplace	O
par	O
d	O
’	O
autres	O
médicaments	B-CHEM
contre	I-CHEM
la	I-CHEM
douleur	I-CHEM
.	O

COMMENT	O
CONSERVER	B-PROC
PRIALT	B-CHEM

Conserver	B-PROC
au	O
réfrigérateur	B-OBJC
dans	O
un	O
flacon	B-DEVI
non	O
ouvert	O
(	O
2	O
°	O
C	O
–	O
8	O
°	O
C	O
)	O
.	O

Que	O
contient	O
Prialt	B-CHEM

La	O
substance	B-CHEM
active	I-CHEM
est	O
le	O
ziconotide	B-CHEM
.	O

Un	O
ml	O
de	O
solution	B-CHEM
contient	O
100	O
microgrammes	O
de	O
ziconotide	B-CHEM
(	O
sous	O
forme	O
d	O

Un	O
flacon	B-DEVI
de	O
1	O
ml	O
contient	O
100	O
microgrammes	O
;	O
un	O
flacon	B-DEVI
de	O
2	O
ml	O
contient	O
200	O
microgrammes	O
;	O

Les	O
autres	O
composants	O
sont	O
les	O
suivants	O
:	O
méthionine	B-CHEM
,	O
chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
eau	B-CHEM
pour	O
préparations	B-CHEM
injectables	I-CHEM
,	O
acide	B-CHEM
chlorhydrique	I-CHEM
et	O
hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
.	O

Prialt	B-CHEM
est	O
fourni	O
en	O
conditionnements	O
contenant	O
un	O
seul	O
flacon	B-DEVI
de	O
1	O
ml	O
,	O
2	O
ml	O
ou	O
5	O
ml	O
.	O

Č	O
eská	O
republika	O
Eisai	O
GmbH	O
Tel	O
:	O
+	O
420	O
602	O
311	O
962	O

Malta	O
Associated	O
Drug	O
Company	O
Ltd	O
Tel	O
:	O
+	O
356	O
(	O
0	O
)	O
227	O
780	O
00	O

Ελλάδα	O
Arriani	O
Pharmaceuticals	O
Τηλ	O
:	O
+	O
30	O
(	O
0	O
)	O
210	O
668	O
3000	O

Portugal	B-GEOG
EF	O
-	O
Eisai	O
Farmacêutica	O
,	O
Unipessoal	O
Lda	O
Tel	O
:	O
+	O
351	O
214	O
875	O
540	O

Slovenská	O
republika	O
Eisai	O
GmbH	O
Tel	O
:	O
+	O
420	O
602	O
311	O
962	O

La	O
dernière	O
date	O
à	O
laquelle	O
cette	O
notice	B-PROC
a	O
été	O
approuvée	O
est	O
{	O
MM	O
/	O
AAAA	O
}	O
.	O

Cela	O
signifie	O
que	O
à	O
cause	O
de	O
la	O
rareté	O
de	O
cette	O
maladie	B-DISO
il	O
est	O
impossible	O
d	O
’	O
obtenir	O
des	O
informations	O
complètes	O
sur	O
ce	O
médicament	B-CHEM
.	O

Prialt	B-CHEM
est	O
fourni	O
sous	O
forme	O
de	O
solution	B-CHEM
limpide	O
et	O
incolore	O
dans	O
des	O
flacons	B-DEVI
à	O
usage	O
unique	O
.	O

Un	O
flacon	B-DEVI
de	O
20	O
ml	O
contient	O
500	O
microgrammes	O
.	O

Prialt	B-CHEM
est	O
fourni	O
en	O
conditionnements	O
contenant	O
un	O
seul	O
flacon	B-DEVI
de	O
20	O
ml	O
.	O

EMEA	O
/	O
H	O
/	O
C	O
/	O
122	O

REFLUDAN	B-CHEM

Qu	O
’	O
est	O
-	O
ce	O
que	O
Refludan	B-CHEM
?	O

Refludan	B-CHEM
se	O
présente	O
sous	O
forme	O
de	O
poudre	B-CHEM
,	O
conditionnée	O
en	O
flacon	B-OBJC
,	O
à	O
faire	O
dissoudre	B-PROC
pour	O
obtenir	O
une	O
solution	B-CHEM
injectable	I-CHEM
ou	O
perfusable	B-PROC
(	O
goutte	B-PROC
-	I-PROC
à	I-PROC
-	I-PROC
goutte	I-PROC
dans	I-PROC
une	I-PROC
veine	I-PROC
)	O
.	O

Son	O
principe	B-CHEM
actif	I-CHEM
est	O
la	O
lépirudine	B-CHEM
.	O

Dans	O
quels	O
cas	O
Refludan	B-CHEM
est	O
-	O
il	O
utilisé	O
?	O

Refludan	B-CHEM
est	O
utilisé	O
pour	O
prévenir	O
la	O
coagulation	B-PHYS
chez	O
les	O
patients	B-LIVB
atteints	O
de	O
thrombocytopénie	B-DISO
induite	I-DISO
par	I-DISO
l	I-DISO
’	I-DISO
héparine	I-DISO
(	O
dite	O
TIH	B-DISO
–	O
il	O
s	O
’	O
agit	O
d	O
’	O
une	O
certaine	O
forme	O
d	O
’	O
allergie	B-DISO
vis	O
-	O
à	O
-	O
vis	O
de	O
l	O
’	O
héparine	B-CHEM
,	O
qui	O
se	O
traduit	O
par	O
une	O
carence	B-DISO
de	I-DISO
plaquettes	I-DISO
sanguines	I-DISO
ou	O
une	O
formation	O
de	O
caillots	B-DISO
dans	O
les	O
vaisseaux	B-ANAT
sanguins	I-ANAT
)	O
et	O
de	O
maladie	B-DISO
thromboembolique	I-DISO
(	O
développement	O
anormal	O
de	O
caillots	B-DISO
de	O
sang	B-ANAT
)	O
nécessitant	O
un	O
traitement	B-PROC
antithrombotique	B-CHEM
par	O
injection	B-CHEM
,	O
généralement	O
de	O
l	O
’	O
héparine	B-CHEM
.	O

Le	O
diagnostic	B-DISO
doit	O
être	O
confirmé	O
par	O
des	O
tests	B-PROC
spécifiques	O
,	O
tels	O
que	O
le	O
test	B-PROC
HIPAA	I-PROC
(	O
heparin	B-PROC
induced	I-PROC
platelet	I-PROC
aggregation	I-PROC
assay	I-PROC
)	O
d	O
’	O
activation	B-PHYS
plaquettaire	I-PHYS
induite	O
par	O
l	O
’	O
héparine	B-CHEM
.	O

Comment	O
Refludan	B-CHEM
est	O
-	O
il	O
utilisé	O
?	O

Refludan	B-CHEM
est	O
administré	B-PROC
par	O
injection	B-CHEM
et	O
par	O
perfusion	B-PROC
intraveineuse	I-PROC
(	O
goutte	B-PROC
-	I-PROC
à	I-PROC
-	I-PROC
goutte	I-PROC
dans	I-PROC
une	I-PROC
veine	I-PROC
)	O
.	O

Le	O
traitement	B-PROC
par	O
Refludan	B-CHEM
doit	O
être	O
initié	O
sous	O
le	O
contrôle	O
d	O
’	O
un	O
médecin	B-LIVB
ayant	O
une	O
expérience	O
dans	O
le	O
traitement	B-PROC
de	O
la	O
coagulation	B-PHYS
(	O
formation	O
de	O
caillots	B-DISO
sanguins	B-ANAT
)	O
.	O

La	O
dose	O
recommandée	O
est	O
de	O
0	O
,	O
4	O
mg	O
/	O
kg	O
de	O
poids	B-PHYS
corporel	I-PHYS
administrée	O
en	O
une	O
seule	O
injection	B-DISO
intraveineuse	I-DISO
,	O
suivie	O
de	O
0	O
,	O
15	O
mg	O
/	O
kg	O
de	O
poids	B-PHYS
corporel	I-PHYS
par	O
heure	O
en	O
perfusion	B-PROC
intraveineuse	I-PROC
continue	I-PROC
pendant	O
2	O
à	O
10	O
jours	O
,	O
voire	O
davantage	O
si	O
nécessaire	O
.	O

Les	O
doses	O
doivent	O
être	O
réduites	O
chez	O
les	O
patients	B-LIVB
souffrant	O
de	O
troubles	B-DISO
rénaux	I-DISO
.	O

Comment	O
Refludan	B-CHEM
fonctionne	O
-	O
t	O
-	O
il	O
?	O

La	O
lépirudine	B-CHEM
,	O
principe	B-CHEM
actif	I-CHEM
de	O
Refludan	B-CHEM
,	O
est	O
quasiment	O
identique	O
à	O
l	O
’	O
hirudine	B-CHEM
,	O
substance	B-CHEM
anticoagulante	I-CHEM
produite	O
par	O
les	O
sangsues	B-LIVB
.	O

La	O
lépirudine	B-CHEM
est	O
fabriquée	O
par	O
une	O
levure	B-LIVB
ayant	O
reçu	O
un	O
gène	O
(	O
ADN	B-CHEM
)	O
qui	O
la	O
rend	O
apte	O
à	O
produire	O
cette	O
substance	O
.	O

La	O
lépirudine	B-CHEM
bloque	O
spécifiquement	O
l	O
’	O
une	O
des	O
substances	O
impliquées	O
dans	O
le	O
processus	O
de	O
coagulation	B-PHYS
,	O
la	O
thrombine	B-CHEM
.	O

Celle	O
-	O
ci	O
se	O
trouve	O
au	O
centre	O
du	O
processus	O
complexe	O
de	O
la	O
coagulation	B-PHYS
sanguine	I-PHYS
.	O

Refludan	B-CHEM
réduit	O
fortement	O
le	O
risque	O
de	O
coagulation	B-PHYS
,	O
prévenant	O
ainsi	O
les	O
dommages	O
subséquents	O
.	O

Refludan	B-CHEM
a	O
été	O
étudié	B-PROC
au	O
cours	O
de	O
deux	O
essais	B-PROC
regroupant	O
198	O
patients	B-LIVB
.	O

Les	O
études	B-PROC
se	O
sont	O
penchées	O
sur	O
les	O
décès	B-PHYS
,	O
les	O
amputations	B-PROC
et	O
les	O
nouvelles	O
complications	B-DISO
thromboemboliques	I-DISO
(	O
coagulation	B-PHYS
)	O
.	O

Quels	O
bénéfices	O
ont	O
été	O
démontrés	O
par	O
Refludan	B-CHEM
au	O
cours	O
des	O
études	B-PROC
?	O

Dans	O
la	O
comparaison	O
avec	O
les	O
témoins	O
historiques	O
,	O
les	O
deux	O
essais	B-PROC
pris	O
dans	O
leur	O
ensemble	O
ont	O
révélé	O
les	O
effets	O
significativement	O
bénéfiques	O
de	O
Refludan	B-CHEM
sur	O
le	O
taux	O
des	O
nouvelles	O
complications	B-DISO
thromboemboliques	I-DISO
et	O
en	O
termes	O
d	O
’	O
amélioration	O
des	O
conditions	O
de	O
survie	O
.	O

Quels	O
sont	O
les	O
risques	B-DISO
associés	O
à	O
Refludan	B-CHEM
?	O

À	O
l	O
’	O
instar	O
d	O
’	O
autres	O
médicaments	B-CHEM
antithrombotiques	I-CHEM
,	O
l	O
’	O
effet	B-DISO
secondaire	I-DISO
le	O
plus	O
fréquemment	O
rapporté	O
de	O
Refludan	B-CHEM
(	O
constaté	O
chez	O
plus	O
d	O
’	O
un	O
patient	B-LIVB
sur	O
dix	O
)	O
est	O
le	O
saignement	B-DISO
.	O

Un	O
tel	O
saignement	B-DISO
conduisant	O
au	O
décès	B-PHYS
est	O
rapporté	O
chez	O
approximativement	O
un	O
patient	B-LIVB
sur	O
100	O
.	O

Pour	O
une	O
description	O
complète	O
des	O
effets	B-DISO
indésirables	I-DISO
observés	B-PROC
sous	O
Refludan	B-CHEM
,	O
veuillez	O
vous	O
reporter	O
à	O
la	O
notice	B-PROC
.	O

Pourquoi	O
Refludan	B-CHEM
a	O
-	O
t	O
-	O
il	O
été	O
approuvé	O
?	O

Du	O
fait	O
qu	O
’	O
il	O
s	O
’	O
agit	O
d	O
’	O
une	O
maladie	B-DISO
très	I-DISO
grave	I-DISO
et	O
qu	O
’	O
il	O
n	O
’	O
existe	O
pas	O
d	O
’	O
autre	O
traitement	B-PROC
efficace	O
,	O
le	O
comité	O
des	O
médicaments	B-CHEM
à	O
usage	O
humain	O
(	O
CHMP	O
)	O
a	O
considéré	O
que	O
les	O
bénéfices	O
du	O
Refludan	B-CHEM
sont	O
supérieurs	O
à	O
ses	O
risques	B-DISO
pour	O
le	O
traitement	B-PROC
des	O
patients	B-LIVB
souffrant	O
de	O
thrombocytopénie	B-DISO
induite	I-DISO
par	I-DISO
l	I-DISO
’	I-DISO
héparine	I-DISO
et	O
de	O
maladie	B-DISO
thromboembolique	I-DISO
.	O

Il	O
a	O
,	O
dès	O
lors	O
,	O
recommandé	O
l	O
’	O
octroi	O
d	O
’	O
une	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
pour	O
Refludan	B-CHEM
.	O

Autres	O
informations	O
relatives	O
à	O
Refludan	B-CHEM
:	O

Le	O
13	O
mars	O
1997	O
,	O
la	O
Commission	O
européenne	B-GEOG
a	O
délivré	O
une	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
valable	O
dans	O
toute	O
l	O
’	O
Union	B-GEOG
européenne	I-GEOG
pour	O
Refludan	B-CHEM
.	O

Pour	O
consulter	O
l	O
’	O
EPAR	O
complet	O
relatif	O
à	O
Refludan	B-CHEM
,	O
veuillez	O
cliquer	O
ici	O
.	O

Refludan	B-CHEM
,	O
20	O
mg	O
,	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC

Chaque	O
flacon	B-OBJC
contient	O
20	O
mg	O
de	O
lépirudine	B-CHEM
.	O

(	O
La	O
lépirudine	B-CHEM
est	O
un	O
produit	O
ADN	B-CHEM
recombinant	O
dérivé	O
de	O
cellules	B-CHEM
de	I-CHEM
levure	I-CHEM
)	O

Poudre	O
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
.	O

Poudre	B-CHEM
lyophilisée	O
blanche	O
à	O
presque	O
blanche	O
.	O

Posologie	O
initiale	O

Inhibition	B-PHYS
de	O
la	O
coagulation	B-PHYS
chez	O
des	O
patients	B-LIVB
adultes	B-LIVB
atteints	O
d	O

La	O
posologie	O
dépend	O
du	O
poids	B-PHYS
corporel	I-PHYS
du	O
patient	B-LIVB
jusqu	O

Chez	O
les	O
patients	B-LIVB
pesant	O
plus	O
de	O
110	O
kg	O
,	O
la	O
posologie	O
ne	O
doit	O
pas	O
dépasser	O
celle	O
calculée	O
pour	O
les	O
patients	B-LIVB
pesant	O
110	O
kg	O
(	O
voir	O
aussi	O
tableaux	O
2	O
et	O
3	O
ci	O
-	O
après	O
)	O
.	O

Surveillance	O
du	O
traitement	B-PROC
par	O
Refludan	B-CHEM
et	O
modification	O
du	O
schéma	O
posologique	O

EMEA	O
/	O
H	O
/	O
C	O
/	O
122	O

Recommandations	O
standard	O

Comme	O
la	O
lépirudine	B-CHEM
est	O
excrétée	B-PHYS
et	O
métabolisée	B-PHYS
en	O
quasi	O
-	O
totalité	O
par	O
le	O
rein	B-ANAT
(	O
voir	O
également	O
la	O
rubrique	O
5	O
.	O
2	O
)	O
,	O
il	O
est	O
nécessaire	O
de	O
connaître	O
l	O

Les	O
recommandations	O
posologiques	O
suivantes	O
sont	O
basées	O
sur	O
les	O
résultats	O
d	O

Dans	O
tous	O
les	O
autres	O
cas	O
,	O
les	O
ajustements	O
posologiques	O
seront	O
basés	O
sur	O
la	O
créatininémie	B-PROC
.	O

La	O
vitesse	O
de	O
perfusion	B-PROC
doit	O
être	O
réduite	O
selon	O
les	O
indications	O
données	O
dans	O
le	O
tableau	O
1	O
.	O

Une	O
surveillance	O
plus	O
fréquente	O
du	O
TCA	B-PROC
est	O
obligatoire	O
.	O

Reconstituer	O
la	O
solution	B-OBJC
comme	O
il	O
est	O
indiqué	O
en	O
rubrique	O
6	O
.	O
6	O
.	O

Bolus	B-PROC
intraveineux	I-PROC
initial	O
:	O

Le	O
bolus	B-PROC
intraveineux	I-PROC
est	O
préparé	O
avec	O
une	O
solution	B-OBJC
dosée	O
à	O
5	O
mg	O
/	O
ml	O
.	O

pour	O
une	O
posologie	O
de	O
0	O
,	O
2	O
mg	O
/	O
kg	O
de	O
poids	B-PHYS
corporel	I-PHYS

4	O
La	O
perfusion	B-PROC
intraveineuse	I-PROC
est	O
préparée	O
avec	O
une	O
solution	B-OBJC
dosée	O
à	O
2	O
mg	O
/	O
ml	O
.	O

La	O
vitesse	O
(	O
ml	O
/	O
h	O
)	O
de	O
la	O
seringue	B-DEVI
électrique	O
doit	O
être	O
réglée	O
en	O
fonction	O
du	O
poids	B-PHYS
corporel	I-PHYS
.	O

Débit	O
de	O
perfusion	B-PROC
(	O
ml	O
/	O
h	O
)	O
pour	O
une	O
posologie	O
de	O

Des	O
réactions	B-DISO
anaphylactiques	I-DISO
d	O
’	O
évolution	O
fatale	O
ont	O
été	O
rapportées	O
lors	O
d	O
’	O
une	O
ré	O
-	O
exposition	O
au	O
Refludan	B-CHEM
.	O

Aussi	O
,	O
avant	O
toute	O
ré	O
-	O
exposition	O
au	O
Refludan	B-CHEM
,	O
une	O
autre	O
alternative	O
thérapeutique	B-PROC
devra	O
avoir	O
été	O
envisagée	O
et	O
discutée	O
.	O

Ces	O
réactions	O
étant	O
de	O
type	O
immunologique	B-PHYS
,	O
les	O
patients	B-LIVB
précédemment	O
traités	B-PROC
par	O
l	O
’	O
hirudine	B-CHEM
ou	O
un	O
analogue	O
de	O
l	O
’	O
hirudine	B-CHEM
devront	O
être	O
considérés	O
comme	O
des	O
patients	B-LIVB
à	O
risque	O
.	O

Il	O
peut	O
s	O
’	O
avérer	O
nécessaire	O
d	O
’	O
exclure	O
les	O
insuffisants	B-DISO
rénaux	I-DISO
du	O
traitement	B-PROC
par	O
lépirudine	B-CHEM
.	O

Une	O
cirrhose	B-DISO
du	I-DISO
foie	I-DISO
peut	O
également	O
affecter	O
l	O
’	O
excrétion	B-PHYS
rénale	I-PHYS
de	O
la	O
lépirudine	B-CHEM
.	O

La	O
tolérance	B-PHYS
et	O
l	O
’	O
efficacité	O
chez	O
l	O
’	O
enfant	B-LIVB
n	O
’	O
ont	O
pas	O
été	O
démontrées	O
.	O
•	O
Patient	B-LIVB
âgé	I-LIVB
:	O

Les	O
patients	B-LIVB
d	O
’	O
un	O
âge	B-PHYS
avancé	O
présentent	O
un	O
risque	B-DISO
accru	O
de	O
complications	B-DISO
hémorragiques	B-DISO
avec	O
les	O
anticoagulants	B-CHEM
.	O

Aucun	O
ajustement	O
spécifique	O
de	O
la	O
posologie	O
n	O
’	O
est	O
fait	O
chez	O
le	O
sujet	B-LIVB
âgé	I-LIVB
.	O

Ces	O
ajustements	O
sont	O
basés	O
sur	O
la	O
fonction	B-PHYS
rénale	I-PHYS
,	O
le	O
poids	B-PHYS
et	O
le	O
TCA	B-PROC
(	O
voirrubrique	O
4	O
.	O
2	O
)	O
.	O

Un	O
traitement	B-PROC
concomittant	O
par	O
des	O
dérivés	O
coumariniques	O
(	O
antivitamines	B-CHEM
K	I-CHEM
)	O
ainsi	O
que	O
par	O
des	O
médicaments	B-CHEM
qui	O
affectent	O
la	O
fonction	B-PHYS
plaquettaire	I-PHYS
peuvent	O
également	O
accroître	O
le	O
risque	B-DISO
de	I-DISO
saignement	I-DISO
.	O

Par	O
conséquent	O
,	O
Refludan	B-CHEM
ne	O
doit	O
pas	O
être	O
administré	O
à	O
la	O
femme	B-LIVB
enceinte	I-LIVB
ou	O
qui	O
allaite	B-PHYS
.	O

Les	O
cas	O
de	O
saignements	B-DISO
menaçant	O
le	O
pronostic	O
vital	O
(	O
incluant	O
les	O
saignements	B-DISO
intracrâniens	B-ANAT
)	O
ont	O
été	O
peu	O
fréquents	O
(	O

Un	O
surdosage	B-DISO
est	O
susceptible	O
de	O
majorer	O
le	O
risque	B-DISO
hémorragique	I-DISO
.	O

Agent	B-CHEM
antithrombotique	I-CHEM
–	O
inhibiteur	B-CHEM
direct	I-CHEM
de	I-CHEM
la	I-CHEM
thrombine	I-CHEM
,	O
code	O
ATC	O
:	O

La	O
lépirudine	B-CHEM
(	O
[	O
Leu1	O
,	O
Thr2	O
]	O
-	O
63	O
-	O
désulfohirudine	O
)	O
est	O
une	O
hirudine	B-CHEM
recombinante	O
dérivée	O
de	O
cellules	B-CHEM
de	I-CHEM
levure	I-CHEM
)	O
.	O

Ce	O
polypeptide	B-CHEM
,	O
composé	O
de	O
65	O
acides	B-CHEM
aminés	I-CHEM
,	O
a	O
un	O
poids	O
moléculaire	O
de	O
6	O
979	O
,	O
5	O
Daltons	O
.	O

La	O
lépirudine	B-CHEM
est	O
un	O
inhibiteur	O
direct	O
et	O
hautement	O
spécifique	O
de	O
la	O
thrombine	B-CHEM
.	O

Son	O
activité	O
se	O
mesure	O
par	O
une	O
méthode	B-PROC
chromogénique	I-PROC
.	O

De	O
ce	O
fait	O
,	O
tous	O
les	O
tests	O
de	O
coagulation	B-PHYS
thrombine	O
-	O
dépendants	O
sont	O
modifiés	O
;	O
par	O
exemple	O
,	O
le	O
TCA	B-PROC
s	O

Les	O
informations	O
cliniques	O
à	O
propos	O
des	O
TIH	B-DISO
de	I-DISO
type	I-DISO
II	I-DISO
présentées	O
dans	O
ce	O
RCP	O
reposent	O
sur	O
les	O
données	O
de	O
deux	O
essais	B-PROC
cliniques	I-PROC
prospectifs	O
qui	O
ont	O
inclus	O
un	O
total	O
de	O
198	O
patients	B-LIVB
atteints	O
de	O
TIH	B-DISO
de	I-DISO
type	I-DISO
II	I-DISO
traités	B-PROC
par	O
Refludan	B-CHEM
.	O

Les	O
propriétés	O
pharmacocinétiques	O
de	O
la	O
lépirudine	B-CHEM
administrée	B-PROC
par	I-PROC
voie	I-PROC
intraveineuse	I-PROC
sont	O
bien	O
décrites	O
par	O
un	O
modèle	O
bicompartimental	O
.	O

Environ	O
35	O
%	O
de	O
la	O
dose	O
administrée	B-PROC
sont	O
excrétés	B-PHYS
sous	O
forme	O
inchangée	O
.	O

Les	O
études	B-PROC
réalisées	O
en	O
administration	B-PROC
unique	O
ou	O
réitérée	O
chez	O
la	O
souris	B-LIVB
,	O
le	O
rat	B-LIVB
et	O
le	O
singe	B-LIVB
ont	O
mis	O
en	O
évidence	O
les	O
effets	B-DISO
secondaires	I-DISO
attendus	O
d	O
’	O
un	O
effet	O
pharmacodynamique	O
trop	O
intense	O
de	O
la	O
lépirudine	B-CHEM
.	O

Chez	O
le	O
singe	B-LIVB
sont	O
survenues	O
des	O
hémorragies	B-DISO
rétiniennes	I-DISO
.	O

Mannitol	B-CHEM
,	O
hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
pour	O
ajustement	O
du	O
pH	O
à	O
7	O
.	O

Après	O
reconstitution	O
:	O
utiliser	O
immédiatement	O
.	O

Celgene	O
Europe	B-GEOG
Ltd	O
.	O
,	O
Riverside	O
House	O
,	O
Riverside	O
Walk	O
,	O
Windsor	O
,	O
SL4	O
1NA	O
,	O
Royaume	B-GEOG
Uni	I-GEOG

Refludan	B-CHEM
,	O
50	O
mg	O
,	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC

Chaque	O
flacon	B-OBJC
contient	O
50	O
mg	O
de	O
lépirudine	B-CHEM
.	O

Clairance	B-PHYS

EMEA	O
/	O
H	O
/	O
C	O
/	O
122	O

4	O
.	O
3	O
Contre	O
-	O
indications	O

CSL	O
Behring	O
GmbH	O
Emil	O
-	O
von	O
-	O
Behring	O
-	O
Straße	O
76	O
35041	O
Marburg	O
Allemagne	B-GEOG

25	O
MENTIONS	O
DEVANT	O
FIGURER	O
SUR	O
L	O
’	O
EMBALLAGE	B-DEVI
EXTERIEUR	O
ET	O
SUR	O
LE	O
CONDITIONNEMENT	O
PRIMAIRE	O

1	O
flacon	B-OBJC
contient	O
20	O
mg	O
de	O
lépirudine	B-CHEM
.	O

Contient	O
également	O
:	O
mannitol	B-CHEM
,	O
hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
.	O

1	O
flacon	B-OBJC
de	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
.	O

Reconstituer	O
le	O
flacon	B-OBJC
(	O
20	O
mg	O
de	O
lépirudine	B-CHEM
)	O
avec	O
0	O
,	O
4	O
ml	O
d	O
’	O
eau	B-CHEM
pour	O
préparations	B-CHEM
injectables	I-CHEM
ou	O
d	O
’	O
une	O
solution	B-OBJC
de	I-OBJC
chlorure	I-OBJC
de	I-OBJC
sodium	I-OBJC
à	O
9	O
mg	O
/	O
ml	O
(	O
0	O
,	O
9	O
%	O
)	O
.	O

Une	O
dilution	B-PROC
ultérieure	O
est	O
nécessaire	O
avant	O
utilisation	O
.	O

La	O
solution	B-CHEM
reconstituée	I-CHEM
doit	O
être	O
utilisée	O
immédiatement	O
.	O

Ne	O
pas	O
utiliser	O
de	O
solutions	B-CHEM
troubles	O
ou	O
qui	O
contiennent	O
des	O
particules	B-CHEM
.	O

27	O
MENTIONS	O
DEVANT	O
FIGURER	O
SUR	O
L	O
’	O
EMBALLAGE	B-DEVI
EXTERIEUR	O
ET	O
SUR	O
LE	O
CONDITIONNEMENT	O
PRIMAIRE	O

10	O
x	O
1	O
flacon	B-OBJC
de	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
.	O

Refludan	B-CHEM
20	O
mg	O
en	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
.	O
lépirudine	B-CHEM
Voie	O
intraveineuse	O

Refludan	B-CHEM
50	O
mg	O
en	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
lépirudine	B-CHEM

1	O
flacon	B-OBJC
contient	O
50	O
mg	O
de	O
lépirudine	B-CHEM
.	O

Reconstituer	O
le	O
flacon	B-OBJC
(	O
50	O
mg	O
de	O
lépirudine	B-CHEM
)	O
avec	O
1	O
ml	O
d	O
’	O
eau	B-CHEM
pour	O
préparations	B-CHEM
injectables	I-CHEM
ou	O
d	O
’	O
une	O
solution	O
de	O
chlorure	O
de	O
á	O
sodium	B-CHEM
9	O
mg	O
/	O
ml	O
(	O
0	O
,	O
9	O
%	O
)	O
.	O

Refludan	B-CHEM
50	O
mg	O
en	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
lépirudine	B-CHEM
Voie	O
intraveineuse	O

Refludan	B-CHEM
20	O
mg	O
en	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
Lepirudine	B-CHEM

QU	O
’	O
EST	O
-	O
CE	O
QUE	O
REFLUDAN	B-CHEM
ET	O
DANS	O
QUEL	O
CAS	O
EST	O
-	O
IL	O
UTILISE	O

Refludan	B-CHEM
est	O
un	O
antithrombotique	B-CHEM
.	O

Les	O
antithrombotiques	B-CHEM
sont	O
des	O
médicaments	B-CHEM
destinés	O
à	O
prévenir	O
la	O
formation	O
de	O
caillots	B-DISO
sanguins	I-DISO
(	O
thrombose	B-DISO
)	O
.	O

Refludan	B-CHEM
est	O
utilisé	O
pour	O
inhiber	O
la	O
coagulation	B-PHYS
chez	O
des	O
patients	B-LIVB
adultes	I-LIVB
atteints	O
d	O
’	O
une	O
thrombopénie	B-DISO
induite	I-DISO
par	I-DISO
l	I-DISO
’	I-DISO
héparine	I-DISO
(	I-DISO
TIH	I-DISO
)	I-DISO
de	I-DISO
type	I-DISO
II	I-DISO
et	O
de	O
maladie	B-DISO
thrombo	I-DISO
-	I-DISO
embolique	I-DISO
nécessitant	O
un	O
traitement	B-PROC
antithrombotique	B-CHEM
injectable	B-PROC
.	O

La	O
thrombopénie	B-DISO
induite	I-DISO
par	I-DISO
l	I-DISO
’	I-DISO
héparine	I-DISO
(	I-DISO
TIH	I-DISO
)	I-DISO
de	I-DISO
type	I-DISO
II	I-DISO
est	O
une	O
maladie	B-DISO
qui	O
peut	O
survenir	O
après	O
que	O
vous	O
ayez	O
pris	O
des	O
médicaments	B-CHEM
contenant	O
de	O
l	O
’	O
héparine	B-CHEM
.	O

Cela	O
peut	O
conduire	O
ensuite	O
à	O
un	O
dépôt	O
de	O
ces	O
caillots	B-DISO
dans	O
certains	O
organes	B-ANAT
.	O

De	O
même	O
,	O
veuillez	O
prévenir	O
votre	O
médecin	B-LIVB
si	O
vous	O
souffrez	O
d	O
’	O
insuffisance	B-DISO
rénale	I-DISO
ou	O
d	O
’	O
une	O
cirrhose	B-DISO
du	I-DISO
foie	I-DISO
(	O
maladie	B-DISO
du	I-DISO
foie	I-DISO
à	O
un	O
stade	O
avancé	O
)	O
,	O
car	O
il	O
faudra	O
dans	O
ce	O
cas	O
réduire	O
la	O
posologie	O
de	O
Refludan	B-CHEM
.	O

Vous	O
devez	O
également	O
prévenir	O
votre	O
médecin	B-LIVB
si	O
jamais	O
vous	O
avez	O
déjà	O
pris	O
du	O
Refludan	B-CHEM
,	O
une	O
autre	O
hirudine	B-CHEM
ou	O
un	O
analogue	O
de	O
l	O
’	O
hirudine	B-CHEM
.	O

Les	O
médicaments	B-CHEM
destinés	O
à	O
détruire	O
les	O
caillots	B-DISO
sanguins	I-DISO
ou	O
les	O
comprimés	B-CHEM
destinés	O
à	O
prévenir	O
leur	O
formation	O
(	O
coumariniques	B-CHEM
)	O
peuvent	O
accroître	O
le	O
risque	B-DISO
de	I-DISO
saignement	I-DISO
lorsqu	O
’	O
ils	O
sont	O
administrés	B-PROC
en	O
même	O
temps	O
que	O
Refludan	B-CHEM
.	O

Refludan	B-CHEM
ne	O
doit	O
pas	O
être	O
administré	B-PROC
aux	O
femmes	B-LIVB
enceintes	I-LIVB
ou	O
qui	O
allaitent	B-PHYS

COMMENT	O
UTILISER	O
REFLUDAN	B-CHEM

Votre	O
médecin	B-LIVB
déterminera	O
et	O
contrôlera	O
la	O
posologie	O
et	O
la	O
durée	O
de	O
votre	O
traitement	B-PROC
par	O
Refludan	B-CHEM
en	O
fonction	O
de	O
votre	O
état	O
clinique	O
,	O
de	O
votre	O
poids	B-PHYS
corporel	I-PHYS
et	O
de	O
certains	O
paramètres	O
biologiques	O
.	O

Si	O
vous	O
avez	O
l	O
’	O
impression	O
que	O
l	O
’	O
effet	O
de	O
Refludan	B-CHEM
est	O
trop	O
fort	O
ou	O
trop	O
faible	B-DISO
,	O
consultez	O
votre	O
médecin	B-LIVB
ou	O
votre	O
pharmacien	B-LIVB
.	O

Refludan	B-CHEM
,	O
une	O
fois	O
reconstitué	O
avec	O
le	O
solvant	B-CHEM
approprié	O
,	O
sera	O
administré	B-PROC
dans	O
une	O
veine	B-ANAT
,	O
par	O
injection	B-CHEM
et	O
ensuite	O
par	O
perfusion	B-PROC
.	O

Très	O
fréquent	O
(	O
au	O
moins	O
1	O
personne	O
sur	O
10	O
)	O

38	O
Anémie	B-DISO
ou	O
baisse	O
du	O
taux	O
d	O
’	O
hémoglobine	B-CHEM
sans	O
source	O
de	O
saignement	B-DISO
manifeste	O
,	O
contusion	B-DISO
,	O
saignement	B-DISO
au	O
niveau	O
des	O
sites	O
de	O
ponction	B-PROC
,	O
saignement	B-DISO
nasal	I-DISO
,	O
sang	B-DISO
dans	I-DISO
les	I-DISO
urines	I-DISO
,	O
saignement	B-DISO
gastrointestinal	I-DISO
,	O
saignement	B-DISO
vaginal	I-DISO
,	O
saignement	B-DISO
rectal	I-DISO
,	O
hémorragie	B-DISO
pulmonaire	I-DISO
,	O
saignement	B-DISO
au	I-DISO
niveau	I-DISO
de	I-DISO
la	I-DISO
poitrine	I-DISO
et	I-DISO
autour	I-DISO
du	I-DISO
cœur	I-DISO
suite	O
à	O
une	O
intervention	B-DISO
chirurgicale	I-DISO
,	O
saignement	B-DISO
au	I-DISO
niveau	I-DISO
du	I-DISO
cerveau	I-DISO
.	O

Une	O
hémorragie	B-DISO
sévère	O
et	O
,	O
en	O
particulier	O
,	O
une	O
hémorragie	B-DISO
intracrânienne	I-DISO
peut	O
être	O
fatale	O
.	O

Lors	O
de	O
la	O
surveillance	O
post	O
-	O
marketing	O
intensive	O
,	O
dans	O
la	O
TIH	B-DISO
de	I-DISO
type	I-DISO
II	I-DISO
,	O
ont	O
été	O
rapportées	O
des	O
hémorragies	B-DISO
fatales	O
chez	O
1	O
%	O
des	O
patients	B-LIVB
et	O
des	O
hémorragies	B-DISO
intracrâniennes	I-DISO
chez	O
0	O
,	O
2	O
%	O
des	O
patients	B-LIVB
.	O

Une	O
hémorragie	B-DISO
sévère	O
peut	O
provoquer	O
une	O
diminution	O
du	O
volume	O
de	O
sang	B-ANAT
circulant	O
,	O
une	O
pression	B-DISO
artérielle	I-DISO
basse	I-DISO
,	O
un	O
état	B-DISO
de	I-DISO
choc	I-DISO
,	O
et	O
les	O
séquelles	O
cliniques	O
qui	O
en	O
résultent	O
.	O

COMMENT	O
CONSERVER	O
REFLUDAN	B-CHEM

Conserver	O
le	O
flacon	B-OBJC
dans	O
l	O
’	O
emballage	B-DEVI
extérieur	O
.	O

Ne	O
pas	O
utiliser	O
Refludan	B-CHEM
si	O
la	O
solution	B-OBJC
reconstituée	O
est	O
trouble	O
ou	O
contient	O
des	O
particules	B-CHEM
.	O

Une	O
fois	O
reconstitué	O
,	O
Refludan	B-CHEM
doit	O
être	O
utilisé	O
immédiatement	O
.	O

Toute	O
solution	B-OBJC
non	O
utilisée	O
doit	O
être	O
jetée	O
de	O
manière	O
appropriée	O
.	O

La	O
substance	O
active	O
est	O
la	O
lépirudine	B-CHEM
,	O
idem	O
RCPun	O
composé	O
produit	O
par	O
la	O
technique	O
d	O
’	O
ADN	B-CHEM
recombinant	I-CHEM
à	O
partir	O
de	O
cellules	B-CHEM
de	I-CHEM
levure	I-CHEM
.	O

Les	O
autres	O
composants	O
sont	O
le	O
mannitol	B-CHEM
(	O
E	B-CHEM
421	I-CHEM
)	O
et	O
l	O
’	O
hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
pour	O
l	O
’	O
ajustement	O
du	O
pH	O
.	O

Qu	O
’	O
est	O
-	O
ce	O
que	O
REFLUDAN	B-CHEM
et	O
contenu	O
de	O
l	O
’	O
emballage	B-DEVI
extérieur	O
Refludan	B-CHEM
est	O
une	O
poudre	B-CHEM
blanche	O
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
perfusion	B-PROC
fournie	O
dans	O
un	O
flacon	B-OBJC
contenant	O
20	O
mg	O
de	O
lépirudine	B-CHEM
.	O

Refludan	B-CHEM
est	O
disponible	O
en	O
boîtes	B-OBJC
de	O
1	O
ou	O
10	O
flacons	B-OBJC
.	O

Fabricant	O
CSL	O
Behring	O
GmbH	O
,	O
Emil	O
-	O
von	O
-	O
Behring	O
-	O
Straße	O
76	O
,	O
35041	O
Marburg	O
,	O
Germany	O
.	O

Refludan	B-CHEM
50	O
mg	O
en	O
poudre	B-CHEM
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
pour	O
perfusion	B-PROC
Lepirudine	B-CHEM

Les	O
autres	O
composants	O
sont	O
le	O
mannitol	B-CHEM
(	O
E	B-CHEM
421	I-CHEM
)	O
et	O
l	O
’	O
hydroxyde	B-CHEM
de	I-CHEM
sodium	I-CHEM
pour	O
l	O
’	O
ajustement	O
du	O
pH	O
.	O

Qu	O
’	O
est	O
-	O
ce	O
que	O
REFLUDAN	B-CHEM
et	O
contenu	O
de	O
l	O
’	O
emballage	B-DEVI
extérieur	O
Refludan	B-CHEM
est	O
une	O
poudre	B-CHEM
blanche	O
pour	O
solution	B-CHEM
injectable	I-CHEM
ou	O
perfusion	B-PROC
fournie	O
dans	O
un	O
flacon	B-OBJC
contenant	O
50	O
mg	O
de	O
lépirudine	B-CHEM
.	O

EMEA	O
/	O
H	O
/	O
C	O
/	O
603	O

TYSABRI	B-CHEM

Qu	O
’	O
est	O
-	O
ce	O
que	O
Tysabri	B-CHEM
?	O

Tysabri	B-CHEM
est	O
une	O
solution	B-OBJC
à	O
diluer	O
pour	O
perfusion	B-PROC
(	O
goutte	B-PROC
-	I-PROC
à	I-PROC
-	I-PROC
goutte	I-PROC
dans	I-PROC
une	I-PROC
veine	I-PROC
)	O
.	O

Il	O
contient	O
le	O
principe	B-CHEM
actif	I-CHEM
natalizumab	B-CHEM
.	O

Dans	O
quel	O
cas	O
Tysabri	B-CHEM
est	O
-	O
il	O
utilisé	O
?	O

Tysabri	B-CHEM
est	O
utilisé	O
dans	O
le	O
traitement	B-PROC
des	O
adultes	B-LIVB
atteints	O
de	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
(	O
SEP	B-DISO
)	O
.	O

Comment	O
Tysabri	B-CHEM
est	O
-	O
il	O
utilisé	O
?	O

Le	O
traitement	B-PROC
par	O
Tysabri	B-CHEM
doit	O
être	O
mis	O
en	O
place	O
et	O
surveillé	O
par	O
un	O
médecin	B-LIVB
expérimenté	O
dans	O
le	O
traitement	B-PROC
des	O
maladies	B-DISO
du	I-DISO
système	I-DISO
nerveux	I-DISO
,	O
et	O
qui	O
a	O
accès	O
à	O
un	O
certain	O
type	O
de	O
scanner	B-OBJC
,	O
appelé	O
appareil	O
d	O
’	O
imagerie	B-PROC
par	I-PROC
résonance	I-PROC
magnétique	I-PROC
(	O
IRM	B-PROC
)	O
.	O

Cette	O
machine	O
permettra	O
au	O
médecin	B-LIVB
de	O
surveiller	O
tout	O
changement	O
dans	O
le	O
cerveau	B-ANAT
lié	O
à	O
la	O
SEP	B-DISO
ou	O
à	O
une	O
infection	B-DISO
rare	O
du	O
cerveau	B-ANAT
,	O
appelée	O
leucoencéphalite	B-DISO
multifocale	I-DISO
progressive	I-DISO
(	O
LEMP	B-DISO
)	O
.	O

Tysabri	B-CHEM
est	O
administré	O
en	O
perfusion	B-PROC
d	O
’	O
une	O
durée	O
d	O
’	O
une	O
heure	O
toutes	O
les	O
quatre	O
semaines	O
.	O

La	O
perfusion	B-PROC
étant	O
susceptible	O
de	O
provoquer	O
une	O
réaction	B-DISO
allergique	I-DISO
,	O
le	O
patient	B-LIVB
doit	O
être	O
surveillé	O
pendant	O
toute	O
la	O
durée	O
de	O
la	O
perfusion	B-PROC
et	O
pendant	O
l	O
’	O
heure	O
qui	O
suit	O
.	O

Si	O
le	O
patient	B-LIVB
ne	O
présente	O
aucun	O
signe	B-DISO
de	O
bénéfice	O
évident	O
après	O
six	O
mois	O
,	O
le	O
médecin	B-LIVB
devra	O
réévaluer	O
le	O
traitement	B-PROC
.	O

Les	O
patients	B-LIVB
traités	B-PROC
par	O
Tysabri	B-CHEM
doivent	O
recevoir	O
une	O
carte	O
d	O
’	O
alerte	O
spéciale	O
qui	O
résume	O
les	O
principales	O
informations	O
sur	O
la	O
sécurité	O
du	O
médicament	B-CHEM
.	O

Le	O
patient	B-LIVB
doit	O
montrer	O
cette	O
carte	O
à	O
son	O
partenaire	B-LIVB
ou	O
à	O
son	O
aide	B-LIVB
-	I-LIVB
soignant	I-LIVB
,	O
ainsi	O
qu	O
’	O
à	O
ses	O
autres	B-LIVB
médecins	I-LIVB
,	O
car	O
ceux	O
-	O
ci	O
sont	O
susceptibles	O
de	O
remarquer	O
des	O
symptômes	B-DISO
de	I-DISO
LEMP	I-DISO
dont	O
le	O
patient	B-LIVB
n	O
’	O
est	O
pas	O
conscient	O
,	O
tels	O
que	O
des	O
variations	B-DISO
d	I-DISO
’	I-DISO
humeur	I-DISO
,	O
de	O
comportement	B-DISO
ou	O
de	O
langage	B-DISO
.	O

Les	O
effets	O
de	O
Tysabri	B-CHEM
ont	O
d	O
’	O
abord	O
été	O
testés	O
sur	O
des	O
modèles	B-LIVB
expérimentaux	I-LIVB
avant	O
d	O
’	O
être	O
étudiés	O
chez	O
l	O
’	O
homme	B-LIVB
.	O

Deux	O
études	B-PROC
,	O
toutes	O
deux	O
d	O
’	O
une	O
durée	O
de	O
deux	O
ans	O
,	O
ont	O
permis	O
d	O
’	O
évaluer	O
Tysabri	B-CHEM
dans	O
la	O
SEP	B-DISO
.	O

L	O
’	O
une	O
de	O
ces	O
études	B-PROC
a	O
comparé	O
Tysabri	B-CHEM
administré	B-PROC
seul	O
(	O
monothérapie	O
)	O
à	O
un	O
placebo	B-CHEM
(	O
un	O
traitement	B-PROC
fictif	I-PROC
)	O
chez	O
942	O
patients	B-LIVB
.	O

Les	O
principaux	O
critères	O
d	O
’	O
évaluation	O
de	O
l	O
’	O
efficacité	O
étaient	O
le	O
nombre	O
de	O
rechutes	B-PHEN
et	O
l	O
’	O
évolution	O
du	O
degré	O
d	O
’	O
handicap	B-DISO
des	O
patients	B-LIVB
,	O
mesuré	O
à	O
l	O
’	O
aide	O
de	O
l	O
’	O
échelle	O
d	O
’	O
évaluation	O
du	O
handicap	B-DISO
(	O
Expanded	O
Disability	O
Status	O
Scale	O
)	O
.	O

Quel	O
est	O
le	O
bénéfice	O
démontré	O
par	O
Tysabri	B-CHEM
au	O
cours	O
des	O
études	B-PROC
?	O

Tysabri	B-CHEM
s	O
’	O
est	O
également	O
révélé	O
plus	O
efficace	O
qu	O
’	O
un	O
placebo	B-CHEM
sur	O
les	O
effets	O
handicapants	B-DISO
de	O
la	O
SEP	B-DISO
:	O
en	O
deux	O
ans	O
,	O
le	O
risque	O
d	O
’	O
aggravation	O
du	O
handicap	B-DISO
a	O
été	O
réduit	O
de	O
42	O
%	O
par	O
rapport	O
à	O
un	O
placebo	B-CHEM
.	O

Les	O
patients	B-LIVB
,	O
leurs	O
aides	B-LIVB
-	I-LIVB
soignants	I-LIVB
et	O
les	O
médecins	B-LIVB
doivent	O
être	O
conscients	O
que	O
Tysabri	B-CHEM
peut	O
être	O
lié	O
à	O
des	O
infections	B-DISO
,	O
notamment	O
une	O
LEMP	B-DISO
.	O

La	O
LEMP	B-DISO
présente	O
des	O
symptômes	B-DISO
similaires	O
à	O
ceux	O
ressentis	O
lors	O
d	O
’	O
une	O
poussée	O
de	O
SEP	B-DISO
et	O
entraîne	O
généralement	O
un	O
handicap	B-DISO
grave	O
ou	O
le	O
décès	B-PHYS
.	O

En	O
cas	O
de	O
suspicion	O
de	O
LEMP	B-DISO
,	O
le	O
médecin	B-LIVB
doit	O
arrêter	O
le	O
traitement	B-PROC
jusqu	O
’	O
à	O
ce	O
qu	O
’	O
il	O
soit	O
établi	O
avec	O
certitude	O
que	O
le	O
patient	B-LIVB
ne	O
souffre	O
pas	O
de	O
cette	O
infection	B-DISO
.	O

Au	O
cours	O
des	O
études	B-PROC
,	O
les	O
effets	B-DISO
indésirables	I-DISO
les	O
plus	O
couramment	O
observés	O
sous	O
Tysabri	B-CHEM
(	O
chez	O
un	O
à	O
dix	O
patients	B-LIVB
sur	O
100	O
)	O
étaient	O
les	O
suivants	O
:	O
infections	B-DISO
des	I-DISO
voies	I-DISO
urinaires	I-DISO
(	O
infection	B-DISO
des	I-DISO
structures	I-DISO
véhiculant	I-DISO
l	I-DISO
’	I-DISO
urine	I-DISO
)	O
,	O
rhinopharyngite	B-DISO
(	O
inflammation	B-DISO
du	I-DISO
nez	I-DISO
et	I-DISO
de	I-DISO
la	I-DISO
gorge	I-DISO
)	O
,	O
urticaire	B-DISO
(	O
éruption	B-DISO
cutanée	I-DISO
)	O
,	O
maux	B-DISO
de	I-DISO
tête	I-DISO
,	O
vertiges	B-DISO
,	O
vomissements	B-DISO
,	O
nausée	B-DISO
,	O
arthralgie	B-DISO
(	O
douleurs	B-ANAT
articulaires	I-ANAT
)	O
,	O
frissons	B-DISO
,	O
pyrexie	B-DISO
(	O
fièvre	B-DISO
)	O
et	O
fatigue	B-DISO
.	O

Pour	O
une	O
description	O
complète	O
des	O
effets	B-DISO
indésirables	I-DISO
observés	O
sous	O
Tysabri	B-CHEM
,	O
voir	O
la	O
notice	B-PROC
.	O

Tysabri	B-CHEM
ne	O
doit	O
pas	O
être	O
utilisé	O
chez	O
les	O
personnes	B-LIVB
pouvant	O
présenter	O
une	O
hypersensibilité	B-DISO
(	O
allergie	B-DISO
)	O
au	O
natalizumab	B-CHEM
ou	O
à	O
l	O
’	O
un	O
des	O
autres	O
composants	O
.	O

Il	O
ne	O
doit	O
pas	O
être	O
administré	O
à	O
des	O
patients	B-LIVB
souffrant	O
de	O
LEMP	B-DISO
ou	O
à	O
des	O
patients	B-LIVB
présentant	O
un	O
risque	O
d	O
’	O
infection	B-DISO
,	O
y	O
compris	O
les	O
patients	B-LIVB
immunodéprimés	O
par	O
leur	O
maladie	B-DISO
ou	O
un	O
autre	O
traitement	B-PROC
actuel	O
ou	O
antérieur	O
.	O

Tysabri	B-CHEM
ne	O
doit	O
pas	O
être	O
associé	O
à	O
l	O
’	O
interféron	B-CHEM
bêta	I-CHEM
ou	O
à	O
l	O
’	O
acétate	B-CHEM
de	I-CHEM
glatiramère	I-CHEM
(	O
d	O
’	O
autres	O
médicaments	B-CHEM
utilisés	O
dans	O
le	O
traitement	B-PROC
de	O
longue	O
durée	O
de	O
la	O
SEP	B-DISO
)	O
.	O

Il	O
ne	O
doit	O
pas	O
non	O
plus	O
être	O
prescrit	O
à	O
des	O
patients	B-LIVB
atteints	O
de	O
cancer	B-DISO
(	O
sauf	O
dans	O
le	O
cas	O
d	O
’	O
un	O
type	O
de	O
cancer	B-DISO
de	I-DISO
la	I-DISO
peau	I-DISO
appelé	O
carcinome	B-DISO
baso	I-DISO
-	I-DISO
cellulaire	I-DISO
)	O
,	O
ni	O
à	O
des	O
sujets	B-LIVB
de	I-LIVB
moins	I-LIVB
de	I-LIVB
18	I-LIVB
ans	I-LIVB
.	O

2	O
/	O
3	O
Pourquoi	O
Tysabri	B-CHEM
a	O
-	O
t	O
-	O
il	O
été	O
approuvé	O
?	O

Le	O
comité	O
a	O
recommandé	O
l	O
’	O
octroi	O
d	O
’	O
une	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
pour	O
Tysabri	B-CHEM
.	O

Quelles	O
sont	O
les	O
mesures	O
prises	O
pour	O
assurer	O
la	O
sécurité	O
de	O
Tysabri	B-CHEM
?	O

La	O
société	O
fabricant	O
Tysabri	B-CHEM
s	O
’	O
assurera	O
que	O
tous	O
les	O
médecins	B-LIVB
prescrivant	O
Tysabri	B-CHEM
ont	O
reçu	O
un	O
kit	O
d	O
’	O
informations	O
comportant	O
toutes	O
les	O
données	O
dont	O
ils	O
ont	O
besoin	O
pour	O
être	O
sûrs	O
que	O
ce	O
médicament	B-CHEM
est	O
utilisé	O
correctement	O
et	O
que	O
les	O
patients	B-LIVB
sont	O
étroitement	O
surveillés	O
.	O

Autres	O
informations	O
relatives	O
à	O
Tysabri	B-CHEM
:	O

La	O
Commission	O
européenne	B-GEOG
a	O
délivré	O
une	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
valide	O
dans	O
toute	O
l	O
’	O
Union	B-GEOG
européenne	I-GEOG
pour	O
Tysabri	B-CHEM
à	O
Elan	O
Pharma	O
International	O
Ltd	O
,	O
le	O
27	O
juin	O
2006	O
.	O

L	O
’	O
EPAR	O
complet	O
relatif	O
à	O
Tysabri	B-CHEM
est	O
disponible	O
:	O
ici	O
.	O

Tysabri	B-CHEM

TYSABRI	B-CHEM
300	O
mg	O
solution	B-OBJC
à	O
diluer	O
pour	O
perfusion	B-PROC
.	O

Chaque	O
ml	O
de	O
solution	B-OBJC
à	O
diluer	O
contient	O
20	O
mg	O
de	O
natalizumab	B-CHEM
.	O

Le	O
natalizumab	B-CHEM
est	O
un	O
anticorps	B-CHEM
anti	O
-	O
α	O
4	O
-	O
intégrine	O
humanisé	O
recombinant	O
,	O
produit	O
dans	O
une	O
lignée	B-ANAT
cellulaire	I-ANAT
murine	B-LIVB
par	O
génie	O
génétique	O
.	O

Après	O
dilution	O
(	O
voir	O
rubrique	O
6	O
.	O
6	O
)	O
,	O
la	O
solution	B-OBJC
pour	O
perfusion	B-PROC
contient	O
environ	O
2	O
,	O
6	O
mg	O
/	O
ml	O
de	O
natalizumab	B-CHEM
.	O

TYSABRI	B-CHEM
est	O
indiqué	O
en	O
monothérapie	O
comme	O
traitement	B-PROC
de	O
fond	O
des	O
formes	O
très	O
actives	O
de	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
(	O
SEP	B-DISO
)	O
rémittente	O
-	O
récurrente	O
pour	O
les	O
groupes	B-LIVB
de	O
patients	B-LIVB
suivants	O
:	O

•	O
Patients	B-LIVB
présentant	O
une	O
forme	O
très	O
active	O
de	O
la	O
maladie	B-DISO
malgré	O
un	O
traitement	B-PROC
par	O
interféron	B-CHEM
bêta	I-CHEM
(	O
voir	O
rubrique	O
5	O
.	O
1	O
)	O
;	O

•	O
Patients	B-LIVB
présentant	O
une	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
rémittente	O
-	O
récurrente	O
sévère	O
d	O
’	O
évolution	O
rapide	O
(	O
voir	O
rubrique	O
5	O
.	O
1	O
)	O
.	O

Le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
doit	O
être	O
instauré	O
et	O
surveillé	O
par	O
des	O
médecins	B-LIVB
spécialistes	B-LIVB
,	O
ayant	O
l	O
’	O
expérience	O
du	O
diagnostic	B-DISO
et	O
du	O
traitement	B-PROC
des	O
affections	B-DISO
neurologiques	I-DISO
,	O
dans	O
des	O
centres	O
bénéficiant	O
d	O
’	O
un	O
accès	O
rapide	O
à	O
l	O

Les	O
patients	B-LIVB
traités	B-PROC
par	O
TYSABRI	B-CHEM
doivent	O
recevoir	O
une	O
carte	O
patient	B-LIVB
spéciale	O
.	O

Le	O
matériel	O
nécessaire	O
à	O
la	O
prise	O
en	O
charge	O
d	O
’	O
éventuelles	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
ainsi	O
qu	O
’	O
un	O
accès	O
à	O
l	O
’	O
IRM	B-PROC
devront	O
être	O
disponibles	O
.	O

Par	O
conséquent	O
,	O
le	O
médecin	B-LIVB
devra	O
vérifier	O
l	O
’	O
absence	O
d	O
’	O
immunosuppression	B-PHYS
avant	O
l	O
’	O
instauration	O
du	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
.	O

La	O
poursuite	O
du	O
traitement	B-PROC
devra	O
être	O
reconsidérée	O
soigneusement	O
chez	O
les	O
patients	B-LIVB
ne	O
présentant	O
aucun	O
signe	O
de	O
bénéfice	O
thérapeutique	O
au	O
-	O
delà	O
de	O
6	O
mois	O
.	O

On	O
ne	O
dispose	O
pas	O
de	O
données	O
sur	O
la	O
sécurité	O
et	O
l	O
’	O
efficacité	O
du	O
natalizumab	B-CHEM
au	O
-	O
delà	O
de	O
2	O
ans	O
.	O

La	O
prolongation	O
du	O
traitement	B-PROC
après	O
ce	O
délai	O
ne	O
devra	O
être	O
envisagée	O
qu	O
’	O
après	O
une	O
ré	O
-	O
évaluation	O
du	O
rapport	O
bénéfice	O
-	O
risque	O
.	O

TYSABRI	B-CHEM
300	O
mg	O
est	O
administré	B-PROC
en	O
perfusion	B-PROC
intraveineuse	I-PROC
une	O
fois	O
toutes	O
les	O
4	O
semaines	O
.	O

TYSABRI	B-CHEM
n	O
’	O
est	O
pas	O
recommandé	O
chez	O
les	O
sujets	B-LIVB
âgés	I-LIVB
de	I-LIVB
plus	I-LIVB
de	I-LIVB
65	I-LIVB
ans	I-LIVB
en	O
raison	O
de	O
l	O
’	O
absence	O
de	O
données	O
dans	O
cette	O
population	B-LIVB
.	O

TYSABRI	B-CHEM
est	O
contre	O
indiqué	O
chez	O
les	O
enfants	B-LIVB
et	O
les	O
adolescents	B-LIVB
(	O
voir	O
rubrique	O
4	O
.	O
3	O
)	O
.	O

Aucune	O
étude	B-PROC
n	O
’	O
a	O
été	O
effectuée	O
pour	O
examiner	O
les	O
effets	O
d	O
’	O
une	O
insuffisance	B-DISO
rénale	I-DISO
ou	O
hépatique	B-ANAT
.	O

Le	O
mécanisme	O
d	O
’	O
élimination	O
et	O
les	O
résultats	O
des	O
études	B-PROC
de	O
pharmacocinétique	O
de	O
populations	O
suggèrent	O
qu	O
’	O
il	O
n	O
’	O
est	O
pas	O
nécessaire	O
d	O
’	O
ajuster	O
la	O
posologie	O
en	O
cas	O
d	O
’	O
insuffisance	B-DISO
rénale	I-DISO
ou	O
hépatique	B-ANAT
.	O

L	O
’	O
efficacité	O
d	O
’	O
une	O
réadministration	O
n	O
’	O
a	O
pas	O
été	O
établie	O
;	O
pour	O
la	O
sécurité	O
d	O
’	O
emploi	B-PHEN
,	O
voir	O
rubrique	O
4	O
.	O
4	O

Hypersensibilité	B-DISO
au	O
natalizumab	B-CHEM
ou	O
à	O
l	O
’	O
un	O
des	O
excipients	B-CHEM
.	O

Leucoencéphalopathie	B-DISO
multifocale	I-DISO
progressive	I-DISO
(	O
LEMP	B-DISO
)	O
.	O

Patients	B-LIVB
présentant	O
un	O
risque	O
accru	O
d	O
’	O
infections	B-DISO
opportunistes	I-DISO
,	O
y	O
compris	O
patients	B-LIVB
immunodéprimés	O
(	O
patients	B-LIVB
sous	O
traitement	B-PROC
immunosuppresseur	O
ou	O
patients	B-LIVB
immunodéprimés	O
par	O
des	O
traitement	B-PROC
s	O
antérieurs	O
,	O
par	O
exemple	O
mitoxantrone	B-CHEM
ou	O
cyclophosphamide	B-CHEM
,	O
voir	O
également	O
les	O
rubriques	O
4	O
.	O
4	O
et	O
4	O
.	O
8	O
)	O
.	O

Association	B-PHYS
avec	O
les	O
interférons	B-CHEM
bêta	I-CHEM
ou	O
l	O
’	O
acétate	B-CHEM
de	I-CHEM
glatiramère	I-CHEM
.	O

Cancers	B-DISO
diagnostiqués	O
en	O
évolution	O
,	O
à	O
l	O
’	O
exception	O
des	O
carcinomes	B-DISO
cutanés	I-DISO
baso	I-DISO
-	I-DISO
cellulaires	I-DISO
.	O

Leucoencéphalopathie	B-DISO
multifocale	I-DISO
progressive	I-DISO
(	O
LEMP	B-DISO
)	O

Un	O
examen	O
d	O
’	O
imagerie	B-PROC
par	I-PROC
résonance	I-PROC
magnétique	I-PROC
(	O
IRM	B-PROC
)	O
récent	O
(	O
effectué	O
généralement	O
dans	O
les	O
3	O
mois	O
précédents	O
)	O
doit	O
être	O
disponible	O
préalablement	O
à	O
l	O
’	O
instauration	O
du	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
.	O

Les	O
patients	B-LIVB
doivent	O
être	O
surveillés	O
à	O
intervalles	O
réguliers	O
,	O
afin	O
de	O
détecter	O
l	O
’	O
apparition	O
ou	O
l	O
’	O
aggravation	O
de	O
symptômes	B-DISO
ou	O
de	O
signes	B-DISO
neurologiques	I-DISO
pouvant	O
évoquer	O
une	O
LEMP	B-DISO
.	O

Le	O
médecin	B-LIVB
devra	O
examiner	O
soigneusement	O
le	O
patient	B-LIVB
pour	O
déterminer	O
si	O
les	O
symptômes	B-DISO
indiquent	O
un	O
dysfonctionnement	B-DISO
neurologique	I-DISO
,	O
et	O
si	O
c	O
’	O
est	O
le	O
cas	O
il	O
devra	O
établir	O
si	O
ces	O
symptômes	B-DISO
sont	O
typiques	O
d	O
’	O
une	O
SEP	B-DISO
ou	O
évocateurs	O
d	O
’	O
une	O
LEMP	B-DISO
.	O

En	O
cas	O
de	O
doute	O
,	O
des	O
examens	B-PROC
complémentaires	I-PROC
,	O
notamment	O
une	O
IRM	B-PROC
,	O
de	O
préférence	O
avec	O
produit	B-CHEM
de	I-CHEM
contraste	I-CHEM
(	O
à	O
comparer	O
avec	O
l	O
’	O
IRM	B-PROC
réalisée	O
avant	O
traitement	B-PROC
)	O
et	O
un	O
dosage	O
de	O
l	O
’	O
ADN	B-ANAT
du	O
virus	B-LIVB
JC	I-LIVB
dans	O
le	O
LCR	B-ANAT
ainsi	O
que	O
des	O
examens	B-PROC
neurologiques	I-PROC
répétés	O
devront	O
être	O
envisagés	O
,	O
tels	O
que	O
décrits	O
dans	O
le	O
Guide	O
de	O
Prescription	O
pour	O
la	O
prise	B-PROC
en	I-PROC
charge	I-PROC
des	O
patients	B-LIVB
présentant	O
une	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
et	O
traités	B-PROC
par	O
TYSABRI	B-CHEM
(	O
voir	O
conduite	O
éducative	O
)	O
.	O

Le	O
traitement	B-PROC
par	O
natalizumab	B-CHEM
ne	O
pourra	O
redémarrer	O
qu	O
’	O
après	O
exclusion	O
du	O
diagnostic	O
de	O
LEMP	B-DISO
(	O
si	O
nécessaire	O
après	O
avoir	O
réitéré	O
les	O
examens	B-DISO
cliniques	I-DISO
,	O
d	O
’	O
imagerie	B-PROC
et	O
/	O
ou	O
biologiques	B-PROC
si	O
un	O
doute	O
clinique	O
subsiste	O
)	O
.	O

Le	O
médecin	B-LIVB
devra	O
être	O
particulièrement	O
attentif	O
à	O
l	O
’	O
apparition	O
de	O
symptômes	B-DISO
évocateurs	O
d	O
’	O
une	O
LEMP	B-DISO
que	O
le	O
patient	B-LIVB
pourrait	O
ne	O
pas	O
remarquer	O
(	O
par	O
exemple	O
,	O
symptômes	B-DISO
cognitifs	I-DISO
ou	I-DISO
psychiatriques	I-DISO
)	O
.	O

En	O
cas	O
d	O
’	O
apparition	O
d	O
’	O
une	O
LEMP	B-DISO
,	O
le	O
traitement	B-DISO
par	I-DISO
TYSABRI	I-DISO
devra	I-DISO
être	I-DISO
arrêté	I-DISO
définitivement	I-DISO
.	O

Après	O
reconstitution	O
du	O
système	B-ANAT
immunitaire	I-ANAT
chez	O
les	O
patients	B-LIVB
immunodéprimés	B-DISO
ayant	O
une	O
LEMP	B-DISO
,	O
on	O
a	O
observé	O
une	O
stabilisation	O
ou	O
une	O
amélioration	O
de	O
l	O
’	O
évolution	O
(	O
voir	O
rubrique	O
5	O
.	O
2	O
)	O
.	O

Actuellement	O
on	O
ne	O
sait	O
pas	O
si	O
la	O
détection	O
précoce	O
d	O
’	O
une	O
LEMP	B-DISO
et	O
l	O
’	O
arrêt	B-DISO
du	I-DISO
traitement	I-DISO
par	O
TYSABRI	B-CHEM
peuvent	O
conduire	O
à	O
une	O
telle	O
stabilisation	O
ou	O
amélioration	O
de	O
l	O
’	O
évolution	O
.	O

Autres	O
infections	B-DISO
opportunistes	I-DISO

Des	O
infections	B-DISO
opportunistes	I-DISO
ont	O
également	O
été	O
décrites	O
chez	O
des	O
patients	B-LIVB
souffrant	B-DISO
de	O
SEP	B-DISO
et	O
traités	B-PROC
par	O
TYSABRI	B-CHEM
en	O
monothérapie	O
(	O
voir	O
rubrique	O
4	O
.	O
8	O
)	O
.	O

En	O
cas	O
de	O
suspicion	O
d	O
’	O
infection	B-DISO
opportuniste	I-DISO
,	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
devra	O
être	O
suspendu	O
jusqu	O
’	O
à	O
ce	O
que	O
la	O
présence	O
d	O
’	O
une	O
telle	O
infection	B-DISO
soit	O
exclue	O
à	O
la	O
suite	O
d	O
’	O
examens	B-PROC
complémentaires	O
.	O

La	O
survenue	O
d	O
’	O
une	O
infection	B-DISO
opportuniste	I-DISO
sous	O
TYSABRI	B-CHEM
doit	O
conduire	O
à	O
l	O
’	O
arrêt	B-DISO
définitif	I-DISO
du	I-DISO
traitement	I-DISO
.	O

4	O
Tous	O
les	O
médecins	B-LIVB
ayant	O
l	O
’	O
intention	O
de	O
prescrire	O
TYSABRI	B-CHEM
doivent	O
avoir	O
pris	O
connaissance	O
du	O
Guide	O
de	O
Prescription	O
pour	O
la	O
prise	B-PROC
en	I-PROC
charge	I-PROC
des	O
patients	B-LIVB
présentant	O
une	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
et	O
traités	B-PROC
par	O
TYSABRI	B-CHEM
.	O

Les	O
patients	B-LIVB
devront	O
être	O
informés	O
qu	O
’	O
en	O
cas	O
d	O
’	O
apparition	O
d	O
’	O
une	O
quelconque	O
infection	B-DISO
,	O
ils	O
devront	O
prévenir	O
leur	O
médecin	B-LIVB
qu	O
’	O
ils	O
sont	O
traités	B-PROC
par	O
TYSABRI	B-CHEM
.	O

Les	O
médecins	B-LIVB
doivent	O
informer	O
les	O
patients	B-LIVB
de	O
l	O
’	O
importance	O
de	O
ne	O
pas	O
interrompre	B-DISO
le	I-DISO
traitement	I-DISO
,	O
particulièrement	O
lors	O
des	O
premiers	O
mois	O
de	O
traitement	B-PROC
(	O
voir	O
rubrique	O
Hypersensibilité	B-DISO
)	O
.	O

Des	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
ont	O
été	O
associées	O
à	O
l	O
’	O
utilisation	O
de	O
TYSABRI	B-CHEM
,	O
elles	O
peuvent	O
être	O
des	O
réactions	B-PHYS
systémiques	I-PHYS
graves	O
(	O
voir	O
rubrique	O
4	O
.	O
8	O
)	O
.	O

Ces	O
réactions	O
surviennent	O
généralement	O
pendant	O
la	O
perfusion	B-PROC
ou	O
dans	O
l	O
’	O
heure	O
qui	O
suit	O
la	O
fin	O
de	O
la	O
perfusion	B-PROC
.	O

Le	O
risque	O
de	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
a	O
été	O
plus	O
important	O
au	O
cours	O
des	O
premières	O
perfusions	B-PROC
ainsi	O
que	O
chez	O
les	O
patients	B-LIVB
recevant	O
de	O
nouveau	O
TYSABRI	B-CHEM
après	O
une	O
exposition	B-DISO
initiale	O
courte	O
(	O
une	O
ou	O
deux	O
perfusions	B-PROC
)	O
suivie	O
d	O
’	O
une	O
période	O
prolongée	O
sans	O
traitement	B-PROC
(	O
trois	O
mois	O
ou	O
plus	O
)	O
.	O

Néanmoins	O
ce	O
risque	O
de	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
doit	O
être	O
envisagé	O
à	O
chaque	O
perfusion	B-PROC
.	O

Le	O
matériel	O
nécessaire	O
à	O
la	O
prise	B-PROC
en	I-PROC
charge	I-PROC
d	O
’	O
éventuelles	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
devra	O
être	O
disponible	O
.	O

Le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
devra	O
être	O
interrompu	O
et	O
un	O
traitement	B-PROC
approprié	O
devra	O
être	O
instauré	O
dès	O
les	O
premiers	O
signes	B-DISO
ou	O
symptômes	B-DISO
d	O
’	O
hypersensibilité	B-DISO
.	O

Les	O
patients	B-LIVB
ayant	O
présenté	O
une	O
réaction	O
d	O
’	O
hypersensibilité	B-DISO
doivent	O
arrêter	B-DISO
définitivement	I-DISO
le	I-DISO
traitement	I-DISO
par	O
TYSABRI	B-CHEM
.	O

Traitement	B-PROC
associé	O
ou	O
traitement	B-PROC
antérieur	O
par	O
immunosuppresseurs	B-CHEM

L	O
’	O
efficacité	O
et	O
la	O
tolérance	O
de	O
TYSABRI	B-CHEM
en	O
association	O
à	O
d	O
’	O
autres	O
traitements	B-PROC
immunosuppresseurs	B-CHEM
ou	O
anticancéreux	B-CHEM
n	O
’	O
ont	O
pas	O
été	O
totalement	O
établies	O
.	O

L	O
’	O
utilisation	O
concomitante	O
de	O
ces	O
médicaments	B-CHEM
avec	O
TYSABRI	B-CHEM
est	O
susceptible	O
de	O
majorer	O
le	O
risque	O
d	O
’	O
infections	B-DISO
,	O
y	O
compris	O
les	O
infections	B-DISO
opportunistes	I-DISO
,	O
et	O
est	O
par	O
conséquent	O
contre	O
-	O
indiquée	O
(	O
voir	O
rubrique	O
4	O
.	O
3	O
)	O
.	O

Les	O
patients	B-LIVB
ayant	O
reçu	O
un	O
traitement	B-PROC
antérieur	O
par	O
immunosuppresseurs	B-CHEM
,	O
(	O
dont	O
cyclophosphamide	B-CHEM
et	O
mitoxantrone	B-CHEM
)	O
,	O
peuvent	O
présenter	O
une	O
immunosuppression	B-PHYS
prolongée	O
et	O
donc	O
un	O
risque	O
accru	O
de	O
LEMP	B-DISO
.	O

Chez	O
les	O
patients	B-LIVB
ayant	O
reçu	O
un	O
traitement	B-PROC
antérieur	O
par	O
immunosuppresseur	B-CHEM
,	O
il	O
faudra	O
veiller	O
à	O
laisser	O
un	O
délai	O
suffisant	O
pour	O
permettre	O
la	O
reconstitution	O
du	O
système	B-ANAT
immunitaire	I-ANAT
.	O

Avant	O
de	O
débuter	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
,	O
les	O
médecins	B-LIVB
devront	O
évaluer	O
chaque	O
cas	O
individuellement	O
pour	O
mettre	O
en	O
évidence	O
une	O
éventuelle	O
immunosuppression	B-PHYS
(	O
voir	O
rubrique	O
4	O
.	O
3	O
)	O
.	O

Au	O
cours	O
des	O
études	B-PROC
cliniques	O
de	O
Phase	O
3	O
réalisées	O
dans	O
la	O
SEP	B-DISO
,	O
le	O
traitement	B-PROC
concomitant	O
des	O
poussées	O
par	O
des	O
corticoïdes	B-CHEM
sur	O
une	O
courte	O
période	O
n	O
’	O
a	O
pas	O
été	O
associé	O
à	O
une	O
augmentation	O
du	O
taux	O
des	O
infections	B-DISO
.	O

Des	O
cures	O
courtes	O
de	O
corticoïdes	B-CHEM
peuvent	O
être	O
administrées	B-PROC
en	O
association	O
avec	O
TYSABRI	B-CHEM
.	O

Une	O
aggravation	B-DISO
de	I-DISO
la	I-DISO
maladie	I-DISO
ou	O
la	O
survenue	O
d	O
’	O
évènements	O
liés	O
à	O
la	O
perfusion	B-PROC
peuvent	O
faire	O
suspecter	O
le	O
développement	O
d	O
’	O
anticorps	B-CHEM
anti	I-CHEM
-	I-CHEM
natalizumab	I-CHEM
.	O

Il	O
conviendra	O
chez	O
ces	O
patients	B-LIVB
de	O
détecter	O
la	O
présence	O
d	O
’	O
anticorps	B-CHEM
avant	O
la	O
reprise	O
du	O
traitement	B-PROC
;	O
en	O
cas	O
de	O
résultat	O
positif	O
confirmé	O
par	O
un	O
second	O
test	O
effectué	O
6	O
semaines	O
plus	O
tard	O
,	O
le	O
traitement	B-PROC
ne	O
devra	O
pas	O
être	O
réintroduit	O
.	O

Des	O
troubles	B-DISO
hépatiques	I-DISO
graves	O
ont	O
été	O
rapportés	O
spontanément	O
depuis	O
la	O
mise	O
sur	O
le	O
marché	O
de	O
Tysabri	B-CHEM
.	O

Ces	O
troubles	B-DISO
hépatiques	I-DISO
peuvent	O
survenir	O
à	O
tout	O
moment	O
au	O
cours	O
du	O
traitement	B-PROC
,	O
même	O
après	O
la	O
première	O
perfusion	B-PROC
.	O

La	O
fonction	B-PHYS
biologique	I-PHYS
hépatique	I-PHYS
des	O
patients	B-LIVB
traités	B-PROC
doit	O
être	O
surveillée	O
de	O
façon	O
appropriée	O
;	O
les	O
patients	B-LIVB
doivent	O
être	O
avertis	O
de	O
la	O
nécessité	O
de	O
contacter	O
leur	O
médecin	B-LIVB
en	O
cas	O
de	O
survenue	O
de	O
signes	B-DISO
ou	O
symptômes	B-DISO
évocateurs	O
de	O
troubles	B-DISO
hépatiques	I-DISO
tels	O
qu	O

En	O
cas	O
de	O
troubles	B-DISO
hépatiques	I-DISO
significatifs	O
,	O
le	O
traitement	B-DISO
par	I-DISO
TYSABRI	I-DISO
devra	I-DISO
être	I-DISO
arrêté	I-DISO
.	O

Arrêt	B-DISO
du	I-DISO
traitement	I-DISO
par	O
TYSABRI	B-CHEM

En	O
cas	O
de	O
décision	O
d	O
’	O
arrêt	B-DISO
du	I-DISO
traitement	I-DISO
,	O
le	O
médecin	B-LIVB
doit	O
être	O
averti	O
que	O
le	O
natalizumab	B-CHEM
reste	O
présent	O
dans	O
le	O
sang	B-ANAT
et	O
a	O
des	O
effets	O
pharmacodynamiques	O
(	O
par	O
exemple	O
,	O
augmentation	O
des	O
lymphocytes	B-ANAT
)	O
pendant	O
environ	O
12	O
semaines	O
après	O
la	O
dernière	O
administration	B-PROC
.	O

L	O
’	O
instauration	O
d	O
’	O
autres	O
traitements	B-PROC
au	O
cours	O
de	O
cette	O
période	O
conduira	O
donc	O
à	O
une	O
exposition	B-DISO
concomitante	O
au	O
natalizumab	B-CHEM
.	O

Au	O
cours	O
des	O
essais	B-PROC
cliniques	I-PROC
,	O
une	O
exposition	B-DISO
concomitante	O
de	O
cette	O
durée	O
à	O
l	O
’	O
interféron	B-CHEM
ou	O
à	O
l	O
’	O
acétate	B-CHEM
de	I-CHEM
glatiramère	I-CHEM
n	O
’	O
a	O
pas	O
été	O
associée	O
à	O
des	O
problèmes	O
de	O
sécurité	O
.	O

Il	O
n	O
’	O
existe	O
actuellement	O
aucune	O
donnée	O
sur	O
l	O
’	O
exposition	B-DISO
concomitante	O
aux	O
immunosuppresseurs	B-CHEM
chez	O
les	O
patients	B-LIVB
souffrant	O
de	O
SEP	B-DISO
.	O

L	O
’	O
utilisation	O
de	O
ces	O
médicaments	B-CHEM
peu	O
après	O
l	O
’	O
arrêt	O
du	O
natalizumab	B-CHEM
peut	O
conduire	O
à	O
un	O
effet	O
immunosuppresseur	O
additif	O
.	O

Ceci	O
devra	O
être	O
considéré	O
avec	O
attention	O
,	O
au	O
cas	O
par	O
cas	O
et	O
l	O
’	O
instauration	O
d	O
’	O
une	O
fenêtre	O
thérapeutique	O
pourrait	O
être	O
appropriée	O
.	O

Au	O
cours	O
des	O
essais	B-PROC
cliniques	I-PROC
,	O
le	O
traitement	B-PROC
des	O
poussées	O
par	O
des	O
corticoïdes	B-CHEM
sur	O
une	O
courte	O
période	O
n	O
’	O
a	O
pas	O
été	O
associé	O
à	O
une	O
augmentation	O
du	O
taux	O
des	O
infections	B-DISO
.	O

Le	O
natalizumab	B-CHEM
ne	O
doit	O
pas	O
être	O
administré	O
au	O
cours	O
de	O
la	O
grossesse	B-PHYS
sauf	O
en	O
cas	O
de	O
nécessité	O
absolue	O
.	O

En	O
cas	O
de	O
grossesse	B-PHYS
débutant	O
sous	O
TYSABRI	B-CHEM
,	O
l	O
’	O
arrêt	O
de	O
TYSABRI	B-CHEM
devra	O
être	O
envisagé	O
.	O

Le	O
passage	O
de	O
TYSABRI	B-CHEM
dans	O
le	O
lait	B-ANAT
maternel	I-ANAT
n	O
’	O
est	O
pas	O
connu	O
,	O
cependant	O
il	O
a	O
été	O
observé	O
chez	O
l	O
’	O
animal	B-LIVB
(	O
voir	O
rubrique	O
5	O
.	O
3	O
)	O
.	O

Par	O
conséquent	O
,	O
les	O
femmes	B-LIVB
traitées	B-PROC
par	O
TYSABRI	B-CHEM
ne	O
doivent	O
pas	O
allaiter	B-PHYS
.	O

Compte	O
tenu	O
du	O
mécanisme	O
d	O
’	O
action	O
pharmacologique	O
du	O
natalizumab	B-CHEM
,	O
l	O
’	O
utilisation	O
de	O
TYSABRI	B-CHEM
ne	O
devrait	O
pas	O
modifier	O
l	O
’	O
aptitude	O
du	O
patient	B-LIVB
à	O
conduire	O
des	O
véhicules	B-OBJC
ou	O
à	O
utiliser	O
des	O
machines	B-OBJC
.	O

Dans	O
les	O
études	B-PROC
contrôlées	O
contre	O
placebo	B-CHEM
réalisées	O
chez	O
1	O
617	O
patients	B-LIVB
souffrant	O
de	O
SEP	B-DISO
et	O
traités	B-PROC
par	O
natalizumab	B-CHEM
pendant	O
un	O
maximum	O
de	O
2	O
ans	O
(	O
placebo	B-CHEM
:	O

6	O
à	O
l	O
’	O
arrêt	B-DISO
du	I-DISO
traitement	I-DISO
se	O
sont	O
produits	O
chez	O
5	O
,	O
8	O
%	O
des	O
patients	B-LIVB
sous	O
natalizumab	B-CHEM
(	O
placebo	B-CHEM
:	O

Pendant	O
les	O
deux	O
années	O
de	O
ces	O
études	B-PROC
,	O
43	O
,	O
5	O
%	O
des	O
patients	B-LIVB
traités	B-PROC
par	O
le	O
natalizumab	B-CHEM
ont	O
présenté	O
des	O
effets	B-DISO
indésirables	I-DISO
liés	O
au	O
médicament	B-CHEM
(	O
placebo	B-CHEM
:	O

Les	O
effets	B-DISO
indésirables	I-DISO
liés	O
au	O
médicament	B-CHEM
,	O
rapportés	O
sous	O
natalizumab	B-CHEM
avec	O
une	O
incidence	O
supérieure	O
de	O
0	O
,	O
5	O
%	O
par	O
rapport	O
au	O
placebo	B-CHEM
,	O
sont	O
présentés	O
ci	O
-	O
dessous	O
.	O

Les	O
fréquences	O
ont	O
été	O
définies	O
comme	O
suit	O
:	O

Fréquent	O
(	O
≥	O
1	O
/	O
100	O
,	O
à	O

Affections	B-DISO
musculo	I-DISO
-	I-DISO
squelettiques	I-DISO
et	I-DISO
systémiques	I-DISO
Fréquent	O

Dans	O
les	O
études	B-PROC
cliniques	I-PROC
contrôlées	O
réalisées	O
sur	O
2	O
ans	O
chez	O
des	O
patients	B-LIVB
atteints	O
de	O
SEP	B-DISO
,	O
un	O
événement	O
lié	O
à	O
la	O
perfusion	B-PROC
a	O
été	O
défini	O
comme	O
un	O
événement	B-DISO
indésirable	I-DISO
survenant	O
pendant	O
la	O
perfusion	B-PROC
ou	O
dans	O
l	O
’	O
heure	O
suivant	O
l	O
’	O
arrêt	O
de	O
celle	O
-	O
ci	O
.	O

Ce	O
type	O
d	O
’	O
événement	O
s	O
’	O
est	O
produit	O
chez	O
23	O
,	O
1	O
%	O
des	O
patients	B-LIVB
souffrant	B-DISO
de	O
SEP	B-DISO
traités	B-PROC
par	O
natalizumab	B-CHEM
(	O
placebo	B-CHEM
:	O

Les	O
événements	O
qui	O
ont	O
été	O
rapportés	O
plus	O
souvent	O
sous	O
natalizumab	B-CHEM
que	O
sous	O
placebo	B-CHEM
comportaient	O
:	O
sensations	B-DISO
vertigineuses	I-DISO
,	O
nausées	B-DISO
,	O
urticaire	B-DISO
et	O
frissons	B-DISO
.	O

Au	O
cours	O
des	O
études	B-PROC
cliniques	I-PROC
contrôlées	O
réalisées	O
sur	O
2	O
ans	O
chez	O
des	O
patients	B-LIVB
atteints	O
de	O
SEP	B-DISO
,	O
des	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
sont	O
survenues	O
chez	O
4	O
%	O
des	O
patients	B-LIVB
.	O

Des	O
anticorps	B-CHEM
anti	O
-	O
natalizumab	B-CHEM
ont	O
été	O
décelés	O
chez	O
10	O
%	O
des	O
patients	B-LIVB
au	O
cours	O
des	O
études	B-PROC
contrôlées	O
réalisées	O
sur	O
2	O
ans	O
chez	O
des	O
patients	B-LIVB
atteints	O
de	O
SEP	B-DISO
.	O

Des	O
anticorps	B-CHEM
ont	O
été	O
détectés	O
à	O
une	O
seule	O
reprise	O
chez	O
4	O
%	O
des	O
patients	B-LIVB
.	O

La	O
présence	O
des	O
anticorps	B-CHEM
persistants	O
a	O
été	O
associée	O
à	O
une	O
diminution	O
importante	O
de	O
l	O
’	O
efficacité	O
de	O
TYSABRI	B-CHEM
et	O
à	O
une	O
augmentation	O
de	O
la	O
fréquence	O
des	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
.	O

Les	O
autres	O
réactions	B-DISO
liées	O
à	O
la	O
perfusion	B-PROC
et	O
associées	O
à	O
la	O
présence	O
d	O
’	O
anticorps	B-CHEM
persistants	O
ont	O
comporté	O
:	O
frissons	B-DISO
,	O
nausées	B-DISO
,	O
vomissements	B-DISO
et	O
bouffées	B-DISO
vasomotrices	I-DISO
(	O
voir	O
rubrique	O
4	O
.	O
4	O
)	O
.	O

Lorsqu	O
’	O
après	O
environ	O
6	O
mois	O
de	O
traitement	B-PROC
,	O
la	O
présence	O
d	O
’	O
anticorps	B-CHEM
persistants	O
est	O
suspectée	O
,	O
du	O
fait	O
d	O
’	O
une	O
diminution	O
de	O
l	O
’	O
efficacité	O
,	O
ou	O
de	O
la	O
survenue	O
d	O
’	O
évènements	O
liés	O
à	O
la	O
perfusion	B-PROC
,	O
une	O
recherche	O
des	O
anticorps	B-CHEM
sera	O
effectuée	O
et	O
le	O
résultat	O
positif	O
devra	O
être	O
confirmé	O
par	O
un	O
second	O
test	O
effectué	O
6	O
semaines	O
plus	O
tard	O
.	O

Etant	O
donné	O
que	O
la	O
présence	O
de	O
ces	O
anticorps	B-CHEM
peut	O
être	O
associée	O
à	O
une	O
diminution	O
de	O
l	O
’	O
efficacité	O
du	O
traitement	B-PROC
et	O
à	O
une	O
augmentation	O
des	O
réactions	O
d	O
’	O
hypersensibilité	B-DISO
ou	O
des	O
réactions	B-DISO
liées	O
à	O
la	O
perfusion	B-PROC
,	O
il	O
conviendra	O
d	O
’	O
interrompre	O
le	O
traitement	B-PROC
chez	O
les	O
patients	B-LIVB
porteurs	O
d	O
’	O
anticorps	B-CHEM
persistants	O
.	O

Infections	B-DISO
,	O
y	O
compris	O
LEMP	B-DISO
et	O
infections	B-DISO
opportunistes	I-DISO

Dans	O
d	O
’	O
autres	O
études	B-PROC
cliniques	I-PROC
,	O
d	O
’	O
autres	O
cas	O
d	O
’	O
infections	B-DISO
opportunistes	I-DISO
ont	O
été	O
rapportés	O
,	O
certains	O
ont	O
été	O
fatals	O
.	O

Dans	O
les	O
études	B-PROC
cliniques	I-PROC
,	O
la	O
survenue	O
d	O
’	O
infections	B-DISO
herpétiques	B-DISO
(	O
virus	B-LIVB
Varicelle	I-LIVB
-	I-LIVB
Zona	I-LIVB
,	O
virus	B-LIVB
Herpès	I-LIVB
-	I-LIVB
Simplex	I-LIVB
)	O
a	O
été	O
un	O
peu	O
plus	O
fréquente	O
chez	O
les	O
patients	B-LIVB
traités	B-PROC
par	O
natalizumab	B-CHEM
que	O
chez	O
les	O
patients	B-LIVB
sous	O
placebo	B-CHEM
.	O

Après	O
commercialisation	O
,	O
des	O
cas	O
graves	O
ont	O
été	O
rapportés	O
,	O
dont	O
un	O
cas	O
fatal	O
d	O
’	O
encéphalite	B-DISO
herpétique	I-DISO
.	O

La	O
majorité	O
des	O
patients	B-LIVB
n	O
’	O
a	O
pas	O
interrompu	O
le	O
traitement	B-PROC
par	O
natalizumab	B-CHEM
au	O
cours	O
des	O
infections	B-DISO
et	O
leur	O
guérison	O
a	O
été	O
obtenue	O
par	O
un	O
traitement	B-PROC
approprié	O
.	O

Des	O
cas	O
de	O
LEMP	B-DISO
ont	O
été	O
rapportés	O
au	O
cours	O
des	O
études	B-PROC
cliniques	I-PROC
.	O

Cette	O
leucoencéphalopathie	B-DISO
entraîne	O
généralement	O
un	O
handicap	B-DISO
sévère	O
ou	O
le	O
décès	B-PHYS
(	O
voir	O
rubrique	O
4	O
.	O
4	O
)	O
.	O

Deux	O
cas	O
,	O
dont	O
un	O
mortel	O
,	O
sont	O
survenus	O
au	O
cours	O
des	O
études	B-PROC
pivots	O
chez	O
les	O
patients	B-LIVB
souffrant	O
de	O
SEP	B-DISO
et	O
ayant	O
reçu	O
un	O
traitement	B-PROC
concomitant	O
par	O
interféron	B-CHEM
bêta	I-CHEM
-	I-CHEM
1a	I-CHEM
pendant	O
plus	O
de	O
2	O
ans	O
.	O

Par	O
ailleurs	O
,	O
au	O
cours	O
d	O
’	O
un	O
autre	O
essai	B-PROC
,	O
une	O
LEMP	B-DISO
ayant	O
entraîné	O
le	O
décès	B-PHYS
est	O
survenue	O
chez	O
un	O
patient	B-LIVB
atteint	O
de	O
la	O
maladie	B-DISO
de	I-DISO
Crohn	I-DISO
,	O
qui	O
avait	O
reçu	O
antérieurement	O
de	O
manière	O
prolongée	O
des	O
traitements	B-PROC
immunosuppresseurs	B-CHEM
et	O
qui	O
présentait	O
une	O
lymphopénie	B-DISO
associée	O
.	O

Des	O
cas	O
de	O
LEMP	B-DISO
chez	O
des	O
patients	B-LIVB
ayant	O
reçu	O
TYSABRI	B-CHEM
en	O
monothérapie	O
ont	O
été	O
rapportés	O
après	O
commercialisation	O
.	O

Des	O
cas	O
de	O
troubles	B-DISO
hépatiques	I-DISO
graves	O
,	O
des	O
cas	O
d	O
’	O
augmentation	O
des	O
enzymes	B-CHEM
hépatiques	I-CHEM
,	O
et	O
d	O
’	O
hyperbilirubinémie	B-DISO
,	O
ont	O
été	O
rapportés	O
spontanément	O
depuis	O
la	O
mise	O
sur	O
le	O
marché	O
de	O
Tysabri	B-CHEM
(	O
voir	O
rubrique	O
4	O
.	O
4	O
)	O
.	O

Effets	O
sur	O
les	O
paramètres	O
biologiques	O

Ces	O
augmentations	O
étaient	O
comprises	O
entre	O
35	O
%	O
et	O
140	O
%	O
pour	O
les	O
types	O
cellulaires	O
individuels	O
(	O
lymphocytes	B-ANAT
,	O
monocytes	B-ANAT
,	O
éosinophiles	B-ANAT
et	O
basophiles	B-ANAT
)	O
,	O
mais	O
les	O
numérations	B-PROC
moyennes	O
sont	O
restées	O
comprises	O
dans	O
les	O
limites	O
de	O
la	O
normale	O
.	O

Le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
a	O
également	O
été	O
associé	O
à	O
de	O
faibles	O
diminutions	O
de	O
l	O
’	O
hémoglobine	B-CHEM
(	O
diminution	O
moyenne	O
de	O
0	O
,	O
6	O
g	O
/	O
dl	O
)	O
,	O
de	O
l	O
’	O
hématocrite	B-PROC
(	O
diminution	O
moyenne	O
de	O
2	O
%	O
)	O
et	O
des	O
érythrocytes	B-ANAT
(	O
diminution	O
moyenne	O
de	O
0	O
,	O
1	O
x	O
106	O
/	O
l	O
)	O
.	O

Ces	O
anomalies	O
n	O
’	O
ont	O
pas	O
été	O
associées	O
à	O
des	O
symptômes	B-DISO
cliniques	I-DISO
et	O
les	O
paramètres	O
hématologiques	O
se	O
sont	O
normalisés	O
généralement	O
dans	O
les	O
16	O
semaines	O
après	O
la	O
dernière	O
administration	B-PROC
de	O
TYSABRI	B-CHEM
.	O

Agent	B-CHEM
immunosuppresseur	I-CHEM
sélectif	O
,	O
code	O
ATC	O
:	O

Il	O
se	O
fixe	O
sur	O
la	O
sous	O
-	O
unité	O
α	O
4	O
des	O
intégrines	B-CHEM
humaines	B-LIVB
,	O
fortement	O
exprimée	O
à	O
la	O
surface	O
de	O
tous	O
les	O
leucocytes	B-ANAT
,	O
à	O
l	O
’	O
exception	O
des	O
neutrophiles	B-ANAT
.	O

Plus	O
spécifiquement	O
,	O
le	O
natalizumab	B-CHEM
se	O
lie	O
à	O
l	O
’	O
intégrine	B-CHEM
α	O
4β	O
1	O
en	O
bloquant	O
l	O
’	O
interaction	B-PHYS
de	O
cette	O
molécule	O
avec	O
son	O
récepteur	B-CHEM
,	O
la	O
molécule	B-OBJC
VCAM	B-CHEM
-	I-CHEM
1	I-CHEM
(	O
vascular	B-CHEM
cell	I-CHEM
adhesion	I-CHEM
molecule	I-CHEM
-	I-CHEM
1	I-CHEM
)	O
et	O
les	O
ligands	B-CHEM
ostéopontine	B-CHEM
,	O
ainsi	O
qu	O
’	O
un	O
variant	O
d	O
’	O
épissage	O
de	O
la	O
fibronectine	B-CHEM
,	O
le	O
CS	B-CHEM
-	I-CHEM
1	I-CHEM
(	O
connecting	B-CHEM
segment	I-CHEM
-	I-CHEM
1	I-CHEM
)	O
.	O

Le	O
natalizumab	B-CHEM
bloque	O
l	O
’	O
interaction	B-PHYS
de	O
l	O
’	O
intégrine	B-CHEM
α	I-CHEM
4β	I-CHEM
7	I-CHEM
avec	O
la	O
molécule	O
MadCAM	B-CHEM
-	I-CHEM
1	I-CHEM
(	O
mucosal	B-CHEM
addressin	I-CHEM
cell	I-CHEM
adhesion	I-CHEM
molecule	I-CHEM
-	I-CHEM
1	I-CHEM
)	O
.	O

L	O
’	O
inhibition	O
de	O
ces	O
interactions	B-PHYS
moléculaires	O
empêche	O
la	O
transmigration	O
des	O
leucocytes	B-ANAT
mononucléés	I-ANAT
à	O
travers	O
l	O
’	O
endothélium	B-ANAT
vers	O
les	O
tissus	B-ANAT
parenchymateux	I-ANAT
inflammatoires	O
.	O

Un	O
autre	O
mécanisme	O
d	O
’	O
action	O
du	O
natalizumab	B-CHEM
pourrait	O
être	O
de	O
supprimer	O
les	O
réactions	B-PHYS
inflammatoires	I-PHYS
en	O
cours	O
dans	O
les	O
tissus	B-ANAT
pathologiques	O
en	O
inhibant	O
les	O
interactions	B-PHYS
des	O
leucocytes	B-ANAT
exprimant	O
la	O
sous	O
-	O
unité	O
α	O
4	O
avec	O
leurs	O
ligands	B-CHEM
dans	O
la	O
matrice	B-ANAT
extracellulaire	I-ANAT
et	O
sur	O
les	O
cellules	B-ANAT
parenchymateuses	I-ANAT
.	O

Par	O
conséquent	O
,	O
le	O
natalizumab	B-CHEM
pourrait	O
agir	O
en	O
supprimant	O
l	O
’	O
activité	B-PHYS
inflammatoire	I-PHYS
au	O
site	O
de	O
la	O
maladie	B-DISO
et	O
en	O
inhibant	O
le	O
recrutement	O
ultérieur	O
de	O
cellules	B-ANAT
immunitaires	I-ANAT
dans	O
les	O
tissus	B-DISO
inflammatoires	I-DISO
.	O

Il	O
semble	O
que	O
,	O
dans	O
la	O
SEP	B-DISO
,	O
les	O
lésions	B-DISO
apparaissent	O
lorsque	O
les	O
lymphocytes	B-ANAT
T	I-ANAT
activés	O
traversent	O
la	O
barrière	B-PHYS
hémato	I-PHYS
-	I-PHYS
encéphalique	I-PHYS
(	O
BHE	B-PHYS
)	O
.	O

L	O
’	O
interaction	B-PHYS
entre	O
l	O
’	O
intégrine	B-CHEM
α	I-CHEM
4β	I-CHEM
1	I-CHEM
et	O
ses	O
cibles	O
est	O
une	O
composante	O
importante	O
de	O
l	O
’	O
inflammation	B-DISO
pathologique	I-DISO
cérébrale	I-DISO
,	O
qui	O
diminue	O
avec	O
l	O
’	O
inhibition	O
de	O
ces	O
interactions	B-PHYS
.	O

Dans	O
le	O
contexte	O
de	O
l	O
’	O
inflammation	B-DISO
du	I-DISO
système	I-DISO
nerveux	I-DISO
central	I-DISO
(	O
SNC	B-ANAT
)	O
associée	O
à	O
la	O
SEP	B-DISO
,	O
c	O
’	O
est	O
l	O
’	O
interaction	B-PHYS
de	O
l	O
’	O
intégrine	B-CHEM
α	I-CHEM
4β	I-CHEM
1	I-CHEM
avec	O
les	O
VCAM	B-CHEM
-	I-CHEM
1	I-CHEM
,	O
CS	B-CHEM
-	I-CHEM
1	I-CHEM
et	O
ostéopontine	B-CHEM
qui	O
sert	O
de	O
médiateur	O
à	O
l	O
’	O
adhésion	O
ferme	O
et	O
la	O
transmigration	O
des	O
leucocytes	B-ANAT
dans	O
le	O
parenchyme	B-ANAT
cérébral	B-ANAT
,	O
pouvant	O
perpétuer	O
la	O
cascade	O
inflammatoire	O
dans	O
le	O
tissu	B-ANAT
du	O
SNC	B-ANAT
.	O

TYSABRI	B-CHEM
est	O
indiqué	O
en	O
monothérapie	O
comme	O
traitement	B-PROC
de	O
fond	O
de	O
la	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
rémittente	O
-	O
récurrente	O
afin	O
de	O
prévenir	O
les	O
poussées	O
et	O
retarder	O
la	O
progression	O
du	O
handicap	B-DISO
.	O

Compte	O
tenu	O
des	O
problèmes	O
de	O
sécurité	O
(	O
voir	O
rubriques	O
4	O
.	O
4	O
et	O
4	O
.	O
8	O
)	O
,	O
le	O
traitement	B-PROC
est	O
limité	O
aux	O
groupes	B-LIVB
de	O
patients	B-LIVB
suivants	O
:	O

•	O
Patients	B-LIVB
n	O
’	O
ayant	O
pas	O
répondu	O
à	O
un	O
traitement	B-PROC
complet	O
et	O
bien	O
conduit	O
par	O
interféron	B-CHEM
bêta	I-CHEM
.	O

Les	O
patients	B-LIVB
doivent	O
avoir	O
présenté	O
au	O
moins	O
1	O
poussée	O
au	O
cours	O
de	O
l	O
’	O
année	O
précédente	O
alors	O
qu	O
’	O
ils	O
étaient	O
sous	O
traitement	B-PROC
et	O
doivent	O
présenter	O
au	O
moins	O
9	O
lésions	B-DISO
hyperintenses	O
en	O
T2	B-ANAT
à	O
l	O
’	O
IRM	B-PROC
cérébrale	I-PROC
ou	O
au	O
moins	O
1	O
lésion	B-DISO
rehaussée	O
après	O
injection	B-PROC
de	O
Gadolinium	B-CHEM
.	O

•	O
Patients	B-LIVB
présentant	O
une	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
rémittente	O
-	O
récurrente	O
sévère	O
et	O
d	O
’	O
évolution	O
rapide	O
,	O
définie	O
par	O
2	O
poussées	O
invalidantes	O
ou	O
plus	O
au	O
cours	O
d	O
’	O
une	O
année	O
associées	O
à	O
1	O
ou	O
plusieurs	O
lésion	B-DISO
(	I-DISO
s	I-DISO
)	O
rehaussée	O
(	O
s	O
)	O
après	O
injection	B-PROC
de	O
Gadolinium	B-CHEM
sur	O
l	O
’	O
IRM	B-PROC
cérébrale	I-PROC
ou	O
une	O
augmentation	O
significative	O
de	O
la	O
charge	B-DISO
lésionnelle	I-DISO
en	O
T2	B-ANAT
par	O
rapport	O
à	O
une	O
IRM	B-PROC
antérieure	O
récente	O
.	O

L	O
’	O
efficacité	O
en	O
monothérapie	O
a	O
été	O
évaluée	O
au	O
cours	O
d	O
’	O
une	O
étude	B-PROC
de	I-PROC
2	I-PROC
ans	I-PROC
(	I-PROC
étude	I-PROC
AFFIRM	I-PROC
)	I-PROC
randomisée	I-PROC
,	I-PROC
en	I-PROC
double	I-PROC
insu	I-PROC
,	I-PROC
contrôlée	I-PROC
versus	O
placebo	B-CHEM
,	O
réalisée	O
chez	O
des	O
patients	B-LIVB
atteints	O
de	O
SEP	B-DISO
rémittente	O
-	O
récurrente	O
ayant	O
présenté	O
au	O
moins	O
1	O
poussée	O
clinique	O
au	O
cours	O
de	O
l	O
’	O
année	O
précédant	O
l	O
’	O
inclusion	O
dans	O
l	O
’	O
étude	B-PROC
,	O
et	O
dont	O
le	O
score	O
EDSS	O
(	O
Kurtzke	O
Expanded	O
Disability	O
Status	O
Scale	O
,	O
échelle	O
d	O
’	O
évaluation	O
du	O
handicap	B-DISO
)	O
était	O
compris	O
entre	O
0	O
et	O
5	O
.	O

L	O
’	O
âge	O
médian	O
était	O
de	O
37	O
ans	O
et	O
la	O
durée	O
médiane	O
de	O
la	O
maladie	B-DISO
de	O
5	O
ans	O
.	O

Des	O
examens	B-PROC
neurologiques	I-PROC
ont	O
été	O
effectués	O
toutes	O
les	O
12	O
semaines	O
et	O
en	O
cas	O
de	O
suspicion	O
de	O
poussées	O
.	O

Les	O
examens	O
IRM	B-PROC
(	O
recherche	O
de	O
lésions	B-DISO
rehaussées	O
par	O
gadolinium	B-CHEM
avec	O
pondération	O
en	O
T1	B-ANAT
et	O
recherche	O
de	O
lésions	B-DISO
hyperintenses	O
en	O
T2	B-ANAT
)	O
ont	O
été	O
effectués	O
tous	O
les	O
ans	O
.	O

Les	O
caractéristiques	O
et	O
les	O
résultats	O
de	O
l	O
’	O
étude	B-PROC
sont	O
présentés	O
dans	O
le	O
tableau	O
ci	O
-	O
dessous	O
.	O

SEP	B-DISO
RR	I-DISO
(	O
critères	O
de	O
McDonald	O
)	O

Deux	O
ans	O

Handicap	B-DISO

12	O
semaines	O
,	O
critère	O
d	O
’	O
évaluation	O
principal	O
)	O

(	O
p	O

11	O
Nombre	O
moyen	O
de	O
lésions	B-DISO
rehaussées	O

Ces	O
résultats	O
ont	O
été	O
obtenus	O
à	O
partir	O
d	O
’	O
une	O
analyse	O
post	O
-	O
hoc	O
et	O
doivent	O
donc	O
être	O

Il	O
n	O
’	O
y	O
a	O
pas	O
de	O
données	O
disponibles	O
sur	O
la	O
sévérité	O
des	O
poussées	O
avant	O
l	O
’	O
inclusion	O
des	O
patients	B-LIVB
dans	O
l	O
’	O
étude	B-PROC
.	O

Après	O
administration	O
intraveineuse	O
répétée	O
d	O
’	O
une	O
dose	O
de	O
300	O
mg	O
de	O
natalizumab	B-CHEM
chez	O
des	O
patients	B-LIVB
souffrant	B-DISO
de	O
SEP	B-DISO
,	O
les	O
concentrations	O
sériques	B-ANAT
maximales	O
moyennes	O
ont	O
été	O
de	O
110	O
±	O
52	O
μ	O
g	O
/	O
ml	O
.	O

Les	O
concentrations	O
minimales	O
moyennes	O
à	O
l	O
’	O
équilibre	O
au	O
cours	O
de	O
la	O
période	O
de	O
traitement	B-PROC
étaient	O
comprises	O
entre	O
23	O
μ	O
g	O
/	O
ml	O
et	O
29	O
μ	O
g	O
/	O
ml	O
.	O

Le	O
délai	O
prévu	O
pour	O
atteindre	O
l	O
’	O
équilibre	O
était	O
d	O
’	O
environ	O
36	O
semaines	O
.	O

Une	O
analyse	O
de	O
pharmacocinétique	O
de	O
population	O
a	O
été	O
effectuée	O
sur	O
des	O
groupes	B-LIVB
de	O
plus	O
de	O
1	O
100	O
patients	B-LIVB
souffrant	O
de	O
SEP	B-DISO
recevant	O
des	O
doses	O
comprises	O
entre	O
3	O
et	O
6	O
mg	O
/	O
kg	O
de	O
natalizumab	B-CHEM
.	O

Parmi	O
ces	O
patients	B-LIVB
,	O
581	O
ont	O
reçu	O
une	O
dose	O
fixe	O
de	O
300	O
mg	O
en	O
monothérapie	O
.	O

La	O
clairance	B-PHYS
moyenne	O
±	O
ET	O
à	O
l	O
’	O
équilibre	O
était	O
de	O
13	O
,	O
1	O
±	O
5	O
,	O
0	O
ml	O
/	O
h	O
,	O
avec	O
une	O
demi	O
-	O
vie	O
moyenne	O
±	O
ET	O
de	O
16	O
±	O
4	O
jours	O
.	O

L	O
’	O
analyse	O
a	O
exploré	O
les	O
effets	O
de	O
covariables	O
sélectionnées	O
sur	O
les	O
paramètres	O
pharmacocinétiques	O
,	O
notamment	O
le	O
poids	O
,	O
l	O
’	O
âge	B-PHYS
,	O
le	O
sexe	O
,	O
la	O
fonction	B-PHYS
hépatique	I-PHYS
et	O
rénale	B-ANAT
ainsi	O
que	O
la	O
présence	O
d	O
’	O
anticorps	B-CHEM
anti	O
-	O
natalizumab	B-CHEM
.	O

Seuls	O
le	O
poids	O
et	O
la	O
présence	O
d	O
’	O
anticorps	B-CHEM
anti	O
-	O
natalizumab	B-CHEM
ont	O
modifié	O
l	O
’	O
élimination	O
du	O
natalizumab	B-CHEM
.	O

L	O
’	O
effet	O
du	O
poids	B-PHYS
n	O
’	O
a	O
pas	O
été	O
totalement	O
proportionnel	O
,	O
puisqu	O
’	O
une	O
variation	O
de	O
43	O
%	O
du	O
poids	O
a	O
conduit	O
à	O
une	O
variation	O
de	O
31	O
%	O
à	O
34	O
%	O
de	O
la	O
clairance	B-PHYS
.	O

Cette	O
modification	O
de	O
la	O
clairance	B-PHYS
n	O
’	O
a	O
pas	O
été	O
cliniquement	O
significative	O
.	O

La	O
présence	O
d	O
’	O
anticorps	B-CHEM
anti	O
-	O
natalizumab	B-CHEM
persistants	O
a	O
approximativement	O
triplé	O
la	O
clairance	B-PHYS
du	O
natalizumab	B-CHEM
,	O
ce	O
qui	O
est	O
cohérent	O
avec	O
la	O
diminution	O
des	O
concentrations	O
sériques	B-ANAT
de	O
natalizumab	B-CHEM
observée	O
chez	O
les	O
patients	B-LIVB
porteurs	O
de	O
ce	O
type	O
d	O
’	O
anticorps	B-CHEM
(	O
voir	O
rubrique	O
4	O
.	O
8	O
)	O
.	O

Les	O
paramètres	O
pharmacocinétiques	O
du	O
natalizumab	B-CHEM
n	O
’	O
ont	O
pas	O
été	O
étudiés	O
chez	O
l	O
’	O
enfant	B-LIVB
et	O
chez	O
l	O
’	O
insuffisant	O
rénal	B-ANAT
ou	O
hépatique	B-ANAT
.	O

L	O
’	O
effet	O
des	O
échanges	B-PROC
plasmatiques	I-PROC
sur	O
la	O
clairance	B-PHYS
et	O
les	O
paramètres	O
pharmacodynamiques	O
du	O
natalizumab	B-CHEM
a	O
été	O
évalué	O
lors	O
d	O
’	O
une	O
étude	B-PROC
chez	O
12	O
patients	B-LIVB
atteints	O
de	O
SEP	B-DISO
.	O

L	O
’	O
élimination	O
du	O
médicament	B-CHEM
après	O
3	O
échanges	B-PROC
plasmatiques	I-PROC
(	O
sur	O
une	O
période	O
de	O
5	O
à	O
8	O
jours	O
)	O
est	O
estimée	O
à	O
environ	O
70	O
-	O
80	O
%	O
.	O

Ceci	O
est	O
à	O
comparer	O
au	O
taux	O
d	O
’	O
environ	O
40	O
%	O
mesuré	O
lors	O
d	O
’	O
études	B-PROC
antérieures	O
dans	O
lesquelles	O
les	O
dosages	O
avaient	O
été	O
effectués	O
après	O
arrêt	B-DISO
du	I-DISO
traitement	I-DISO
,	O
sur	O
une	O
période	O
d	O
’	O
observation	B-DISO
identique	O
.	O

L	O
’	O
impact	O
des	O
échanges	B-PROC
plasmatiques	I-PROC
sur	O
la	O
reprise	O
de	O
la	O
migration	B-PHYS
lymphocytaire	I-PHYS
et	O
par	O
conséquent	O
leur	O
utilité	O
clinique	O
ne	O
sont	O
pas	O
connus	O
.	O

Du	O
fait	O
de	O
l	O
’	O
activité	O
pharmacologique	O
du	O
natalizumab	B-CHEM
,	O
une	O
modification	O
de	O
la	O
circulation	O
des	O
lymphocytes	B-ANAT
,	O
une	O
augmentation	O
des	O
globules	B-ANAT
blancs	I-ANAT
ainsi	O
qu	O
’	O
une	O
hypersplénie	B-DISO
ont	O
été	O
observées	O
dans	O
la	O
plupart	O
des	O
études	B-PROC
in	I-PROC
vivo	I-PROC
.	O

Ces	O
modifications	O
ont	O
été	O
réversibles	O
et	O
n	O
’	O
ont	O
pas	O
semblé	O
provoquer	O
d	O
’	O
effets	O
toxiques	B-CHEM
.	O

12	O
Dans	O
les	O
études	B-PROC
réalisées	O
chez	O
la	O
souris	B-LIVB
,	O
l	O
’	O
administration	O
de	O
natalizumab	B-CHEM
n	O
’	O
a	O
pas	O
provoqué	O
de	O
croissance	B-PHYS
ni	O
d	O
’	O
apparition	O
de	O
métastases	B-DISO
de	O
tumeurs	B-DISO
de	O
type	O
mélanome	B-DISO
ou	O
leucémie	B-DISO
lymphoblastique	I-DISO
.	O

Le	O
natalizumab	B-CHEM
n	O
’	O
a	O
exercé	O
aucun	O
effet	O
clastogène	B-CHEM
ou	O
mutagène	B-CHEM
dans	O
les	O
tests	B-PROC
d	I-PROC
’	I-PROC
Ames	I-PROC
ou	O
dans	O
les	O
tests	O
d	O
’	O
aberrations	B-DISO
chromosomiques	I-DISO
de	O
cellules	B-ANAT
humaines	I-ANAT
.	O

Il	O
n	O
’	O
a	O
,	O
par	O
ailleurs	O
,	O
présenté	O
aucun	O
effet	O
dans	O
les	O
essais	B-PROC
in	I-PROC
vitro	I-PROC
de	O
prolifération	B-DISO
de	O
lignées	B-ANAT
tumorales	I-ANAT
intégrine	B-CHEM
α	I-CHEM
4	I-CHEM
-	O
positives	O
et	O
aucune	O
cytotoxicité	B-DISO
.	O

Aucun	O
effet	O
sur	O
les	O
taux	O
d	O
’	O
avortements	B-PROC
n	O
’	O
a	O
été	O
observé	O
dans	O
aucune	O
autre	O
étude	B-PROC
.	O

Une	O
étude	B-PROC
chez	O
la	O
femelle	B-LIVB
singe	B-ANAT
cynomolgus	I-ANAT
gravide	B-DISO
a	O
mis	O
en	O
évidence	O
des	O
modifications	O
fœtales	O
attribuées	O
au	O
natalizumab	B-CHEM
,	O
notamment	O
une	O
faible	O
anémie	B-DISO
,	O
une	O
diminution	B-DISO
des	I-DISO
plaquettes	I-DISO
,	O
une	O
augmentation	O
du	O
poids	O
de	O
la	O
rate	B-ANAT
ainsi	O
qu	O
’	O
une	O
diminution	O
du	O
poids	O
du	O
foie	B-ANAT
et	O
du	O
thymus	B-ANAT
.	O

Ces	O
modifications	O
ont	O
été	O
associées	O
à	O
une	O
augmentation	O
de	O
l	O
’	O
hématopoïèse	B-PHYS
extramédullaire	I-PHYS
splénique	B-ANAT
,	O
ainsi	O
qu	O
’	O
à	O
une	O
atrophie	B-DISO
du	I-DISO
thymus	I-DISO
et	O
à	O
une	O
diminution	O
de	O
l	O
’	O
hématopoïèse	B-PHYS
hépatique	O
.	O

Le	O
taux	O
des	O
plaquettes	B-ANAT
était	O
également	O
diminué	O
chez	O
les	O
nouveau	B-LIVB
-	I-LIVB
nés	I-LIVB
de	O
mères	O
traitées	B-PROC
par	O
le	O
natalizumab	B-CHEM
jusqu	O
’	O
à	O
la	O
mise	B-PHYS
-	I-PHYS
bas	I-PHYS
,	O
cependant	O
il	O
n	O
’	O
a	O
pas	O
été	O
observé	O
d	O
’	O
anémie	B-DISO
chez	O
ces	O
nouveau	B-LIVB
-	I-LIVB
nés	I-LIVB
.	O

Toutes	O
ces	O
modifications	O
observées	O
à	O
des	O
doses	O
supérieures	O
à	O
celles	O
utilisées	O
chez	O
l	O
’	O
homme	B-LIVB
ont	O
disparu	O
après	O
élimination	O
du	O
natalizumab	B-CHEM
.	O

Phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
monobasique	O
,	O
monohydraté	O
Phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
dibasique	O
,	O
heptahydraté	O
Chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
Polysorbate	B-CHEM
80	I-CHEM
(	O
E433	B-CHEM
)	O
Eau	B-CHEM
pour	O
préparation	B-CHEM
injectable	I-CHEM
.	O

TYSABRI	B-CHEM
ne	O
doit	O
pas	O
être	O
mélangé	O
avec	O
d	O
’	O
autres	O
médicaments	B-CHEM
à	O
l	O
’	O
exception	O
de	O
ceux	O
mentionnés	O
dans	O
la	O
rubrique	O
6	O
.	O
6	O
.	O

Solution	O
diluée	O

À	O
conserver	O
au	O
réfrigérateur	O
(	O
entre	O
2	O
°	O
C	O
et	O
8	O
°	O
C	O
)	O
.	O

15	O
ml	O
de	O
TYSABRI	B-CHEM
dans	O
un	O
flacon	B-OBJC
(	O
verre	O
type	O
I	O
)	O
muni	O
d	O
’	O
un	O
bouchon	O
de	O
caoutchouc	B-CHEM
(	O
bromobutyle	B-CHEM
)	O
serti	O
avec	O
une	O
bague	O
(	O
aluminium	B-CHEM
)	O
surmonté	O
d	O
’	O
une	O
capsule	B-CHEM
protectrice	O
plastique	O
.	O

Avant	O
de	O
diluer	O
et	O
d	O
’	O
administrer	O
TYSABRI	B-CHEM
,	O
inspectez	O
le	O
flacon	B-OBJC
pour	O
vérifier	O
l	O
’	O
absence	O
de	O
particules	O
.	O

Le	O
flacon	B-OBJC
ne	O
doit	O
pas	O
être	O
utilisé	O
s	O
’	O
il	O
contient	O
des	O
particules	B-CHEM
et	O
/	O
ou	O
si	O
le	O
liquide	B-OBJC
n	O
’	O
est	O
pas	O
incolore	O
,	O
limpide	O
à	O
légèrement	O
opalescent	O
.	O

Respectez	O
les	O
conditions	O
d	O
’	O
asepsie	B-PROC
pour	O
préparer	O
la	O
solution	B-OBJC
de	O
TYSABRI	B-CHEM
pour	O
perfusion	B-PROC
intraveineuse	I-PROC
(	O
IV	B-PROC
)	O
.	O

Retirez	O
la	O
capsule	B-CHEM
du	O
flacon	B-OBJC
.	O

Introduisez	O
l	O
’	O
aiguille	B-DEVI
de	O
la	O
seringue	B-DEVI
dans	O
le	O
flacon	B-OBJC
en	O
perçant	O
le	O
centre	O
du	O
bouchon	O
de	O
caoutchouc	B-CHEM
et	O
aspirez	O
15	O
ml	O
de	O
solution	B-OBJC
à	O
diluer	B-PROC
pour	O
perfusion	B-PROC
.	O

Ajoutez	O
les	O
15	O
ml	O
de	O
solution	B-OBJC
à	O
diluer	B-PROC
pour	O
perfusion	B-PROC
à	O
100	O
ml	O
d	O
’	O
une	O
solution	B-CHEM
injectable	I-CHEM
de	O
chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
à	O
9	O
mg	O
/	O
ml	O
(	O
0	O
,	O
9	O
%	O
)	O
.	O

TYSABRI	B-CHEM
ne	O
doit	O
pas	O
être	O
mélangé	O
avec	O
d	O
’	O
autres	O
médicaments	B-CHEM
ou	O
diluants	B-CHEM
.	O

Inspectez	O
visuellement	O
le	O
produit	O
dilué	B-PROC
pour	O
vérifier	O
l	O
’	O
absence	O
de	O
particules	B-CHEM
ou	O
de	O
coloration	O
avant	O
l	O
’	O
administration	B-PROC
.	O

Ne	O
pas	O
utiliser	O
en	O
cas	O
de	O
présence	O
de	O
particules	B-CHEM
ou	O
de	O
coloration	O
.	O

Le	O
produit	O
dilué	B-PROC
doit	O
être	O
utilisé	O
dès	O
que	O
possible	O
et	O
dans	O
un	O
délai	O
maximum	O
de	O
8	O
heures	O
après	O
la	O
dilution	B-PROC
.	O

Si	O
le	O
produit	O
dilué	B-PROC
est	O
conservé	O
à	O
une	O
température	O
de	O
2	O
à	O
8	O
°	O
C	O
(	O
ne	O
pas	O
congeler	O
)	O
,	O
laissez	O
la	O
solution	B-OBJC
se	O
réchauffer	O
à	O
température	O
ambiante	O
avant	O
la	O
perfusion	B-PROC
.	O

La	O
solution	B-OBJC
diluée	O
doit	O
être	O
perfusée	B-PROC
par	I-PROC
voie	I-PROC
intraveineuse	I-PROC
pendant	O
1	O
heure	O
à	O
un	O
débit	O
d	O
’	O
environ	O
2	O
ml	O
/	O
minute	O
.	O

Dès	O
que	O
la	O
perfusion	B-PROC
est	O
terminée	O
,	O
rincez	O
la	O
voie	B-DEVI
intraveineuse	I-DEVI
avec	O
une	O
solution	B-CHEM
injectable	I-CHEM
de	O
chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
à	O
9	O
mg	O
/	O
ml	O
(	O
0	O
,	O
9	O
%	O
)	O
.	O

Tout	O
produit	O
restant	O
ou	O
inutilisé	O
doit	O
être	O
traité	B-PROC
conformément	O
aux	O
dispositions	O
réglementaires	O
nationales	O
.	O

Elan	O
Pharma	O
International	O
Ltd	O
.	O
,	O
Monksland	O
,	O
Athlone	O
,	O
County	O
Westmeath	O
,	O
Irlande	B-GEOG

Des	O
informations	O
détaillées	O
sur	O
ce	O
médicament	B-CHEM
sont	O
disponibles	O
sur	O
le	O
site	O
internet	O
de	O
l	O
’	O
Agence	O
européenne	B-GEOG
du	O
médicament	O
(	O
EMEA	O
)	O
http	O
:	O
/	O
/	O
www	O
.	O
emea	O
.	O
europa	O
.	O
eu	O
/	O

Biogen	O
Idec	O
Inc	O
5000	O
Davis	O
Drive	O
Research	O
Triangle	O
Park	O
NC	O
27709	O
-	O
4627	O
USA	B-GEOG

Biogen	O
Idec	O
B	O
.	O
V	O
.	O

Robijnlaan	O
8	O
NL	O
-	O
2132	O
Hoofddorp	O
Pays	B-GEOG
-	I-GEOG
Bas	I-GEOG

Biogen	O
Idec	O
Denmark	O
Manufacturing	O
ApS	O
Biogen	O
Idec	O
Allé	O
1	O
DK	O
-	O
3400	O
Hillerød	O
Danemark	B-GEOG

Le	O
titulaire	O
de	O
l	O
’	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
devra	O
s	O
’	O
assurer	O
sur	O
un	O
plan	O
national	O
,	O
préalablement	O
à	O
la	O
commercialisation	O
et	O
comme	O
convenu	O
avec	O
les	O
autorités	O
compétentes	O
des	O
états	O
membres	O
que	O
tous	O
les	O
médecins	B-LIVB
ayant	O
l	O
’	O
intention	O
de	O
prescire	O
TYSABRI	B-CHEM
,	O
aient	O
bien	O
à	O
leur	O
disposition	O
un	O
dossier	O
médical	O
contenant	O
les	O
éléments	O
suivants	O
:	O
•	O
Monographie	O
du	O
médicament	B-CHEM
•	O
Information	O
médicale	O
sur	O
TYSABRI	B-CHEM
•	O
Carte	O
patient	B-LIVB
.	O

L	O
’	O
information	O
médicale	O
sur	O
TYSABRI	B-CHEM
devra	O
comporter	O
les	O
éléments	O
clés	O
suivants	O
:	O
•	O
Indication	O
restreinte	O
•	O
Infections	B-DISO
atypiques	I-DISO
/	I-DISO
opportunistes	I-DISO
,	O
notamment	O
la	O
LEMP	B-DISO
et	O
incluant	O
:	O

Diagnostic	B-DISO
de	O
LEMP	B-DISO
avec	O
différenciation	O
entre	O
la	O
LEMP	B-DISO
et	O
les	O
poussées	O
de	O
SEP	B-DISO
Arbre	O
de	O
décision	O
de	O
prise	O
en	O
charge	O
de	O
la	O
LEMP	B-DISO
Possibilité	O
d	O
’	O
autres	O
infections	B-DISO
opportunistes	I-DISO

Le	O
titulaire	O
de	O
l	O
’	O
AMM	O
devra	O
s	O
’	O
assurer	O
que	O
le	O
système	O
de	O
pharmacovigilance	B-PROC
est	O
en	O
place	O
et	O
qu	O
’	O
il	O
fonctionne	O
avant	O
de	O
mettre	O
le	O
médicament	B-CHEM
sur	O
le	O
marché	O
et	O
cela	O
aussi	O
longtemps	O
que	O
le	O
produit	O
commercialisé	O
sera	O
utilisé	O
.	O

Le	O
titulaire	O
de	O
l	O
’	O
AMM	O
s	O
’	O
engage	O
à	O
effectuer	O
les	O
études	O
et	O
autres	O
actions	O
de	O
pharmacovigilance	B-PROC
détaillées	O
dans	O
le	O
plan	O
de	O
pharmacovigilance	B-PROC
.	O

Un	O
plan	O
de	O
gestion	O
des	O
risques	O
actualisé	O
devrait	O
être	O
fourni	O
conformément	O
au	O
Guideline	O
CHMP	O
relatif	O
aux	O
systèmes	O
de	O
gestion	O
des	O
risques	B-DISO
des	I-DISO
médicaments	I-DISO
à	O
usage	O
humain	B-LIVB
.	O

TYSABRI	B-CHEM
300	O
mg	O
solution	B-OBJC
à	O
diluer	O
pour	O
perfusion	B-PROC
natalizumab	B-CHEM

Chaque	O
flacon	B-OBJC
de	O
15	O
ml	O
de	O
concentré	O
contient	O
300	O
mg	O
de	O
natalizumab	B-CHEM
(	O
20	O
mg	O
/	O
ml	O
)	O
;	O

phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
monobasique	O
,	O
monohydraté	O
;	O
phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
dibasique	O
,	O
heptahydraté	O
;	O
chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
;	O
polysorbate	B-CHEM
80	I-CHEM
(	O
E433	B-CHEM
)	O
et	O
eau	B-CHEM
pour	O
préparation	B-CHEM
injectable	I-CHEM
.	O

Diluer	O
avant	O
perfusion	B-PROC
.	O

Elan	O
Pharma	O
International	O
Ltd	O
.	O

Monksland	O
Athlone	O
County	O
Westmeath	O
Irlande	B-GEOG

-	O
Il	O
est	O
important	O
que	O
vous	O
conserviez	O
cette	O
carte	O
avec	O
vous	O
pendant	O
le	O
traitement	B-PROC
et	O
pendant	O
les	O
6	O

mois	O
suivant	O
l	O
’	O
administration	O
de	O
la	O
dernière	O
dose	O
de	O
TYSABRI	B-CHEM
car	O
des	O
effets	O
secondaires	O
peuvent	O
se	O
produire	O
même	O
après	O
l	O
’	O
arrêt	B-DISO
du	I-DISO
traitement	I-DISO
.	O

Qu	O
’	O
est	O
ce	O
que	O
TYSABRI	B-CHEM
et	O
dans	O
quel	O
cas	O
est	O
-	O
il	O
utilisé	O
2	O
.	O

Comment	O
utiliser	O
TYSABRI	B-CHEM
4	O
.	O

QU	O
’	O
EST	O
-	O
CE	O
QUE	O
TYSABRI	B-CHEM
ET	O
DANS	O
QUEL	O
CAS	O
EST	O
-	O
IL	O
UTILISE	O

TYSABRI	B-CHEM
est	O
utilisé	O
pour	O
traiter	B-PROC
la	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
(	O
SEP	B-DISO
)	O
.	O

Les	O
symptômes	B-DISO
de	O
SEP	B-DISO
peuvent	O
varier	O
d	O
’	O
un	O
patient	B-LIVB
à	O
l	O
’	O
autre	O
et	O
il	O
est	O
possible	O
que	O
vous	O
ne	O
présentiez	O
aucun	O
des	O
symptômes	B-DISO
décrits	O
ici	O
,	O
notamment	O
:	O
troubles	B-DISO
de	I-DISO
la	I-DISO
marche	I-DISO
,	O
engourdissement	B-DISO
du	I-DISO
visage	I-DISO
,	I-DISO
des	I-DISO
bras	I-DISO
ou	I-DISO
des	I-DISO
jambes	I-DISO
,	O
problèmes	B-DISO
de	I-DISO
vue	I-DISO
,	O
fatigue	B-DISO
,	O
sensation	B-DISO
de	I-DISO
déséquilibre	I-DISO
ou	O
d	O
’	O
étourdissement	B-DISO
,	O
problèmes	B-DISO
urinaires	I-DISO
et	O
intestinaux	B-ANAT
,	O
difficultés	B-DISO
à	I-DISO
penser	I-DISO
et	I-DISO
à	I-DISO
se	I-DISO
concentrer	I-DISO
,	O
dépression	B-DISO
,	O
douleur	B-DISO
aiguë	I-DISO
ou	I-DISO
chronique	I-DISO
,	O
problèmes	B-DISO
sexuels	I-DISO
,	O
ainsi	O
que	O
raideurs	B-DISO
et	I-DISO
spasmes	I-DISO
musculaires	I-DISO
.	O

L	O
’	O
aggravation	O
de	O
ces	O
symptômes	B-DISO
est	O
une	O
récidive	B-DISO
(	O
ou	O
poussée	O
de	O
SEP	B-DISO
)	O
.	O

Elle	O
peut	O
être	O
brutale	O
,	O
avec	O
apparition	O
des	O
symptômes	B-DISO
en	O
quelques	O
heures	O
,	O
ou	O
progressive	O
,	O
évoluant	O
sur	O
plusieurs	O
jours	O
.	O

Les	O
symptômes	B-DISO
s	O
’	O
améliorent	O
ensuite	O
progressivement	O
(	O
phénomène	O
qualifié	O
de	O
rémission	B-DISO
)	O
.	O

La	O
SEP	B-DISO
provoque	O
une	O
inflammation	B-DISO
du	O
cerveau	B-ANAT
,	O
susceptible	O
d	O
’	O
endommager	O
les	O
cellules	B-ANAT
nerveuses	I-ANAT
.	O

La	O
substance	B-CHEM
active	I-CHEM
de	O
TYSABRI	B-CHEM
est	O
le	O
natalizumab	B-CHEM
,	O
une	O
protéine	B-CHEM
comparable	O
à	O
vos	O
propres	O
anticorps	B-CHEM
.	O

Au	O
cours	O
des	O
études	B-PROC
cliniques	I-PROC
,	O
TYSABRI	B-CHEM
a	O
réduit	O
de	O
moitié	O
la	O
progression	O
des	O
effets	O
invalidants	O
de	O
la	O
SEP	B-DISO
et	O
a	O
également	O
diminué	O
de	O
deux	O
-	O
tiers	O
environ	O
le	O
nombre	O
de	O
poussées	O
de	O
SEP	B-DISO
.	O

Cependant	O
,	O
TYSABRI	B-CHEM
ne	O
peut	O
pas	O
réparer	O
les	O
dommages	O
qui	O
ont	O
été	O
provoqués	O
par	O
la	O
maladie	B-DISO
.	O

Par	O
conséquent	O
,	O
lorsque	O
vous	O
serez	O
traité	B-PROC
par	O
TYSABRI	B-CHEM
,	O
vous	O
ne	O
constaterez	O
peut	O
-	O
être	O
pas	O
d	O
’	O
amélioration	O
mais	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
pourra	O
empêcher	O
l	O
’	O
aggravation	O
de	O
votre	O
maladie	B-DISO
.	O

25	O
Il	O
est	O
essentiel	O
de	O
continuer	O
votre	O
traitement	B-PROC
aussi	O
longtemps	O
que	O
vous	O
et	O
votre	O
médecin	B-LIVB
pensez	O
qu	O
’	O
il	O
est	O
utile	O
.	O

Avant	O
de	O
débuter	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
,	O
il	O
est	O
primordial	O
de	O
discuter	O
avec	O
votre	O
médecin	B-LIVB
des	O
bénéfices	O
que	O
vous	O
pouvez	O
attendre	O
de	O
ce	O
traitement	B-PROC
ainsi	O
que	O
des	O
risque	B-DISO
éventuels	O
qui	O
lui	O
sont	O
associés	O
.	O

N	O
’	O
utilisez	O
jamais	O
TYSABRI	B-CHEM
•	O
Si	O
vous	O
êtes	O
allergique	B-DISO
(	O
hydpersensible	B-DISO
)	O
au	O
natalizumab	B-CHEM
ou	O
à	O
l	O
’	O
un	O
des	O
autres	O
composants	B-CHEM
contenus	O
dans	O
TYSABRI	B-CHEM
(	O
voir	O
les	O
composants	O
en	O
rubrique	O
6	O
)	O
.	O

•	O
Si	O
vous	O
avez	O
des	O
perturbations	O
graves	O
du	O
système	B-ANAT
immunitaire	I-ANAT
(	O
dues	O
à	O
une	O
maladie	B-DISO
,	O
telle	O
que	O
leucémie	B-DISO
ou	O
infection	B-DISO
à	I-DISO
VIH	I-DISO
,	O
ou	O
dues	O
à	O
un	O
médicament	B-CHEM
que	O
vous	O
prenez	O
ou	O
avez	O
pris	O
)	O
.	O

•	O
Si	O
vous	O
avez	O
un	O
cancer	B-DISO
(	O
sauf	O
s	O
’	O
il	O
s	O
’	O
agit	O
d	O
’	O
un	O
cancer	B-DISO
de	I-DISO
la	I-DISO
peau	I-DISO
de	I-DISO
type	I-DISO
baso	I-DISO
-	I-DISO
cellulaire	I-DISO
)	O
.	O

•	O
Si	O
vous	O
êtes	O
âgé	B-LIVB
(	I-LIVB
e	I-LIVB
)	I-LIVB
de	I-LIVB
moins	I-LIVB
de	I-LIVB
18	I-LIVB
ans	I-LIVB
.	O

Faites	O
attention	O
avec	O
TYSABRI	B-CHEM
Des	O
cas	O
d	O
’	O
infection	B-DISO
cérébrale	I-DISO
rare	O
appelée	O
LEMP	B-DISO
(	O
leucoencéphalopathie	B-DISO
multifocale	I-DISO
progressive	I-DISO
)	O
ont	O
été	O
rapportés	O
chez	O
des	O
patients	B-LIVB
traités	B-PROC
par	O
TYSABRI	B-CHEM
.	O

Cette	O
leucoencéphalopathie	B-DISO
entraîne	O
généralement	O
un	O
handicap	B-DISO
sévère	O
ou	O
le	O
décès	B-PHYS
.	O

Par	O
conséquent	O
,	O
si	O
vous	O
pensez	O
que	O
votre	O
SEP	B-DISO
s	O
’	O
aggrave	O
ou	O
si	O
vous	O
remarquez	O
de	O
nouveaux	O
symptômes	B-DISO
,	O
il	O
est	O
très	O
important	O
d	O
’	O
en	O
parler	O
à	O
votre	O
médecin	B-LIVB
dès	O
que	O
possible	O
.	O

Discutez	O
de	O
votre	O
traitement	B-PROC
avec	O
votre	O
conjoint	B-LIVB
ou	O
avec	O
le	O
personnel	B-LIVB
soignant	I-LIVB
.	O

Ils	O
pourraient	O
voir	O
de	O
nouveaux	O
symptômes	B-DISO
que	O
vous	O
n	O
’	O
avez	O
pas	O
remarqués	O
vous	O
-	O
même	O
,	O
tels	O
que	O
des	O
changements	B-DISO
d	I-DISO
’	I-DISO
humeur	I-DISO
ou	I-DISO
de	I-DISO
comportement	I-DISO
,	O
des	O
trous	B-DISO
de	I-DISO
mémoire	I-DISO
,	O
des	O
difficultés	B-DISO
d	I-DISO
’	I-DISO
élocution	I-DISO
ou	I-DISO
de	I-DISO
communication	I-DISO
,	O
que	O
votre	O
médecin	B-LIVB
devra	O
évaluer	O
afin	O
d	O
’	O
éliminer	O
une	O
LEMP	B-DISO
éventuelle	O
.	O

Vous	O
trouverez	O
également	O
ces	O
informations	O
sur	O
la	O
carte	O
patient	B-LIVB
qui	O
vous	O
a	O
été	O
remise	O
par	O
votre	O
médecin	B-LIVB
.	O

Il	O
est	O
important	O
de	O
conserver	O
cette	O
carte	O
et	O
de	O
la	O
montrer	O
à	O
votre	O
conjoint	B-LIVB
ou	O
au	O
personnel	B-LIVB
soignant	I-LIVB
.	O

Des	O
infections	B-DISO
graves	O
peuvent	O
survenir	O
sous	O
TYSABRI	B-CHEM
.	O

En	O
cas	O
d	O
’	O
infection	B-DISO
ou	O
si	O
vous	O
développez	O
des	O
symptômes	B-DISO
tels	O
qu	O
’	O
une	O
fièvre	B-DISO
inexpliquée	O
,	O
une	O
diarrhée	B-DISO
sévère	I-DISO
,	O
des	O
vertiges	B-DISO
/	O
céphalées	B-DISO
/	O
raideur	B-DISO
de	I-DISO
la	I-DISO
nuque	I-DISO
prolongés	O
,	O
une	O
perte	B-DISO
de	I-DISO
poids	I-DISO
ou	O
une	O
lassitude	B-DISO
,	O
ou	O
d	O
’	O
autres	O
symptômes	B-DISO
potentiellement	O
associés	O
à	O
une	O
infection	B-DISO
pendant	O
votre	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
,	O
vous	O
devez	O
en	O
parler	O
à	O
votre	O
médecin	B-LIVB
dès	O
que	O
possible	O
et	O
lui	O
montrer	O
la	O
carte	O
patient	B-LIVB
,	O
ainsi	O
que	O
cette	O
notice	B-PROC
.	O

Il	O
est	O
important	O
que	O
vous	O
conserviez	O
cette	O
carte	O
.	O

Grossesse	B-PHYS
et	O
allaitement	B-PHYS
Vous	O
ne	O
devez	O
pas	O
utiliser	O
TYSABRI	B-CHEM
si	O
vous	O
êtes	O
enceinte	B-LIVB
,	O
sauf	O
si	O
vous	O
en	O
avez	O
discuté	O
au	O
préalable	O
avec	O
votre	O
médecin	B-LIVB
.	O

Veillez	O
à	O
informer	O
immédiatement	O
votre	O
médecin	B-LIVB
de	O
toute	O
grossesse	B-DISO
en	I-DISO
cours	I-DISO
,	I-DISO
suspectée	I-DISO
ou	I-DISO
envisagée	I-DISO
.	O

Vous	O
ne	O
devez	O
pas	O
allaiter	B-PHYS
pendant	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
.	O

Vous	O
devrez	O
discuter	O
avec	O
votre	O
médecin	B-LIVB
du	O
choix	O
d	O
’	O
allaiter	B-PHYS
ou	O
d	O
’	O
être	O
traitée	B-PROC
par	O
TYSABRI	B-CHEM
.	O

Demandez	O
conseil	O
à	O
votre	O
médecin	B-LIVB
ou	O
à	O
votre	O
pharmacien	B-LIVB
avant	O
de	O
prendre	O
tout	O
autre	O
médicament	B-CHEM
.	O

Conduite	O
de	O
véhicules	B-OBJC
et	O
utilisation	O
de	O
machines	B-OBJC
TYSABRI	B-CHEM
ne	O
devrait	O
pas	O
avoir	O
d	O
’	O
effet	O
sur	O
l	O
’	O
aptitude	O
à	O
conduire	O
des	O
véhicules	B-OBJC
et	O
à	O
utiliser	O
des	O
machines	B-OBJC
.	O

Si	O
vous	O
êtes	O
concerné	O
(	O
e	O
)	O
,	O
discutez	O
-	O
en	O
avec	O
votre	O
médecin	B-LIVB
.	O

COMMENT	O
UTILISER	O
TYSABRI	B-CHEM

TYSABRI	B-CHEM
sera	O
préparé	O
et	O
administré	O
par	O
un	O
médecin	B-LIVB
.	O

Les	O
instructions	O
relatives	O
à	O
la	O
préparation	O
et	O
l	O
’	O
administration	O
de	O
TYSABRI	B-CHEM
sont	O
fournies	O
à	O
la	O
fin	O
de	O
cette	O
notice	B-PROC
à	O
l	O
’	O
attention	O
des	O
professionnels	B-LIVB
de	I-LIVB
santé	I-LIVB
.	O

TYSABRI	B-CHEM
doit	O
être	O
dilué	O
avant	O
son	O
administration	O
.	O

Quelques	O
patients	B-LIVB
ont	O
présenté	O
une	O
réaction	B-DISO
allergique	I-DISO
à	O
TYSABRI	B-CHEM
.	O

Votre	O
médecin	B-LIVB
vérifiera	O
l	O
’	O
absence	O
de	O
réactions	B-DISO
allergiques	I-DISO
pendant	O
la	O
perfusion	B-PROC
et	O
dans	O
l	O
’	O
heure	O
qui	O
suit	O
la	O
fin	O
de	O
la	O
perfusion	B-PROC
.	O

Il	O
est	O
très	O
important	O
de	O
ne	O
pas	O
interrompre	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
,	O
en	O
particulier	O
dans	O
les	O
tout	O
premiers	O
mois	O
du	O
traitement	B-PROC
.	O

En	O
effet	O
,	O
les	O
patients	B-LIVB
ayant	O
reçu	O
une	O
ou	O
deux	O
perfusions	B-PROC
de	O
TYSABRI	B-CHEM
suivies	O
d	O
’	O
une	O
période	O
d	O
’	O
arrêt	O
de	O
traitement	B-PROC
de	O
trois	O
mois	O
ou	O
plus	O
sont	O
plus	O
à	O
risque	O
de	O
présenter	O
une	O
réaction	B-DISO
allergique	I-DISO
lors	O
de	O
la	O
reprise	O
du	O
traitement	B-PROC
.	O

27	O
Signes	B-DISO
d	O
’	O
allergie	O
à	O
TYSABRI	B-CHEM
,	O
pendant	O
ou	O
peu	O
après	O
la	O
perfusion	B-PROC
:	O
•	O
Éruption	B-DISO
et	O
démangeaisons	B-DISO
(	O
urticaire	B-DISO
)	O
•	O
œdème	B-DISO
du	I-DISO
visage	I-DISO
,	I-DISO
des	I-DISO
lèvres	I-DISO
ou	I-DISO
de	I-DISO
la	I-DISO
langue	I-DISO
•	O
Difficultés	B-DISO
respiratoires	I-DISO
•	O
Douleur	B-DISO
ou	O
gêne	B-DISO
thoracique	I-DISO
•	O
Augmentation	O
ou	O
diminution	O
de	O
la	O
tension	B-PHYS
artérielle	I-PHYS
(	O
constatée	O
par	O
votre	O
médecin	B-LIVB
ou	O
votre	O
infirmière	B-LIVB
lors	O
de	O
la	O
mesure	O
de	O
votre	O
tension	B-PHYS
artérielle	I-PHYS
)	O
.	O

Signes	B-DISO
évocateurs	O
d	O
’	O
éventuels	O
troubles	B-DISO
hépatiques	I-DISO
:	O
•	O
Jaunisse	B-DISO
(	O
coloration	O
jaune	O
de	O
la	O
peau	B-ANAT
ou	O
du	O
blanc	O
des	O
yeux	B-ANAT
)	O
•	O
Urines	B-DISO
anormalement	I-DISO
foncées	I-DISO
.	O

TYSABRI	B-CHEM
peut	O
également	O
avoir	O
d	O
’	O
autres	O
effets	B-DISO
indésirables	I-DISO
.	O

Ces	O
effets	B-DISO
indésirables	I-DISO
sont	O
listés	O
ci	O
-	O
dessous	O
par	O
ordre	O
de	O
fréquence	O
d	O
’	O
apparition	O
au	O
cours	O
des	O
études	B-PROC
cliniques	I-PROC
:	O

Effets	B-DISO
indésirables	I-DISO
fréquents	O
pouvant	O
survenir	O
chez	O
moins	O
de	O
10	O
patients	B-LIVB
sur	O
100	O
:	O
•	O
Infection	B-DISO
urinaire	I-DISO
•	O
Mal	B-DISO
de	I-DISO
gorge	I-DISO
et	O
écoulement	B-DISO
nasal	I-DISO
ou	O
nez	B-DISO
bouché	I-DISO
•	O
Frissons	B-DISO
•	O
Éruption	B-DISO
et	O
démangeaisons	B-DISO
(	O
urticaire	B-DISO
)	O
•	O
Maux	B-DISO
de	I-DISO
tête	I-DISO
•	O
Sensations	O
vertigineuses	O
•	O
Nausées	B-DISO
•	O
Vomissements	B-DISO
•	O
Douleurs	B-DISO
articulaires	B-ANAT
•	O
Fièvre	B-DISO
•	O
Fatigue	B-DISO
.	O

Effets	B-DISO
indésirables	I-DISO
peu	O
fréquents	O
pouvant	O
survenir	O
chez	O
moins	O
de	O
1	O
patient	B-LIVB
sur	O
100	O
:	O
•	O
Allergie	B-DISO
sévère	O
(	O
hypersensibilité	B-DISO
)	O
.	O

Les	O
symptômes	B-DISO
de	O
LEMP	B-DISO
peuvent	O
être	O
comparables	O
à	O
une	O
poussée	O
de	O
SEP	B-DISO
.	O
•	O
Par	O
conséquent	O
,	O
si	O
vous	O
pensez	O
que	O
votre	O
SEP	B-DISO
s	O
’	O
aggrave	O
ou	O
si	O
vous	O
remarquez	O
de	O
nouveaux	O
symptômes	B-DISO
,	O
vous	O
devez	O
en	O
parler	O
à	O
votre	O
médecin	B-LIVB
dès	O
que	O
possible	O
.	O
•	O
Discutez	O
de	O
votre	O
traitement	B-PROC
avec	O
votre	O
conjoint	B-LIVB
ou	O
le	O
personnel	B-LIVB
soignant	I-LIVB
.	O

Ils	O
pourraient	O
voir	O
de	O
nouveaux	O
symptômes	B-DISO
que	O
vous	O
-	O
même	O
n	O
’	O
avez	O
pas	O
remarqués	O
,	O
tels	O
que	O
des	O
changements	B-DISO
d	I-DISO
’	I-DISO
humeur	I-DISO
ou	I-DISO
de	I-DISO
comportement	I-DISO
,	O
des	O
trous	B-DISO
de	I-DISO
mémoire	I-DISO
,	O
des	O
difficultés	B-DISO
d	I-DISO
’	I-DISO
élocution	I-DISO
ou	I-DISO
de	I-DISO
communication	I-DISO
,	O
que	O
votre	O
médecin	B-LIVB
devra	O
évaluer	O
afin	O
d	O
’	O
éliminer	O
une	O
LEMP	B-DISO
éventuelle	O
.	O
•	O
Montrez	O
la	O
carte	O
d	O
’	O
alerte	O
patient	B-LIVB
ainsi	O
que	O
cette	O
notice	B-PROC
à	O
tout	O
médecin	B-LIVB
que	O
vous	O
pourriez	O
consulter	O
,	O
et	O
non	O
pas	O
seulement	O
à	O
votre	O
neurologue	B-LIVB
.	O

•	O
Parlez	O
à	O
votre	O
médecin	B-LIVB
dès	O
que	O
possible	O
si	O
vous	O
pensez	O
avoir	O
une	O
infection	B-DISO
.	O
•	O
Montrez	O
la	O
carte	O
patient	B-LIVB
ainsi	O
que	O
cette	O
notice	B-PROC
à	O
tout	O
médecin	B-LIVB
impliqué	O
dans	O
votre	O
traitement	B-PROC
et	O
pas	O
uniquement	O
à	O
votre	O
neurologue	B-LIVB
.	O

TYSABRI	B-CHEM
sera	O
-	O
t	O
-	O
il	O
toujours	O
efficace	O
?	O

Chez	O
certains	O
patients	B-LIVB
recevant	O
TYSABRI	B-CHEM
,	O
les	O
défenses	O
naturelles	O
de	O
l	O
’	O
organisme	O
finissent	O
par	O
empêcher	O
TYSABRI	B-CHEM
d	O
’	O
agir	O
correctement	O
(	O
car	O
l	O
’	O
organisme	B-ANAT
produit	O
des	O
anticorps	B-CHEM
dirigés	O
contre	O
TYSABRI	B-CHEM
)	O
.	O

Votre	O
médecin	B-LIVB
pourra	O
vérifier	O
si	O
c	O
’	O
est	O
le	O
cas	O
en	O
dosant	O
ces	O
anticorps	B-CHEM
dans	O
votre	O
sang	B-ANAT
et	O
arrêtera	O
le	O
traitement	B-PROC
par	O
TYSABRI	B-CHEM
,	O
si	O
nécessaire	O
.	O

COMMENT	O
CONSERVER	O
TYSABRI	B-CHEM

Ne	O
pas	O
utiliser	O
TYSABRI	B-CHEM
après	O
la	O
date	O
de	O
péremption	O
mentionnée	O
sur	O
l	O
’	O
étiquette	B-OBJC
et	O
la	O
boîte	B-OBJC
.	O

Ne	O
pas	O
utiliser	O
TYSABRI	B-CHEM
si	O
vous	O
remarquez	O
la	O
présence	O
de	O
particules	B-CHEM
dans	O
le	O
liquide	B-OBJC
et	O
/	O
ou	O
une	O
coloration	O
du	O
liquide	B-OBJC
dans	O
le	O
flacon	B-OBJC
.	O

Que	O
contient	O
TYSABRI	B-CHEM
Chaque	O
flacon	B-OBJC
de	O
15	O
ml	O
de	O
solution	B-OBJC
à	O
diluer	O
pour	O
perfusion	B-PROC
contient	O
300	O
mg	O
de	O
natalizumab	B-CHEM
(	O
20	O
mg	O
/	O
ml	O
)	O
.	O

Phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
monobasique	O
,	O
monohydraté	O
Phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
,	O
dibasique	O
,	O
heptahydraté	O
Chlorure	B-CHEM
de	I-CHEM
sodium	I-CHEM
Polysorbate	B-CHEM
80	I-CHEM
(	O
E433	O
)	O
Eau	B-CHEM
pour	O
préparation	B-CHEM
injectable	I-CHEM
.	O

Chaque	O
boîte	B-OBJC
contient	O
un	O
flacon	B-OBJC
en	O
verre	O
.	O

Titulaire	O
de	O
l	O
’	O
autorisation	O
de	O
mise	O
sur	O
le	O
marché	O
Elan	O
Pharma	O
International	O
Ltd	O
.	O

Fabricant	O
Biogen	O
Idec	O
B	O
.	O
V	O
.	O

Ces	O
informations	O
sont	O
fournies	O
à	O
la	O
fin	O
de	O
la	O
notice	B-PROC

België	O
/	O
Belgique	B-GEOG
/	O
Belgien	O
Biogen	O
Idec	O
Belgium	O
N	O
.	O
V	O
.	O
/	O
S	O
.	O
A	O
.	O

Luxembourg	B-GEOG
/	O
Luxemburg	O
Biogen	O
Idec	O
Belgium	O
N	O
.	O
V	O
.	O
/	O
SA	O
.	O

Magyarország	O
Gedeon	O
Richter	B-DISO
Plc	O
.	O

Č	O
eská	O
republika	O
Biogen	O
Idec	O
(	O
Czech	O
Republic	O
)	O
s	O
.	O
r	O
.	O
o	O
.	O

Malta	O
Interpharma	O
Co	O
.	O

Danmark	O
Biogen	O
Idec	O
Denmark	O
A	O
/	O
S	O
Tlf	O
:	O
+	O
45	O
77	O
41	O
57	O
88	O

Nederland	O
Biogen	O
Idec	O
International	O
B	O
.	O
V	O
.	O

Deutschland	O
Biogen	O
Idec	O
GmbH	O
Tel	O
:	O
+	O
49	O
(	O
0	O
)	O
89	O
99	O
6170	O

Norge	O
Biogen	O
Idec	O
Norway	O
AS	O
Tlf	O
:	O
+	O
47	O
23	O
00	O
52	O
50	O

Eesti	O
Richter	B-DISO
Gedeon	O
Eesti	O
filiaal	O
Tel	O
:	O
+	O
372	O
742	O
0200	O

Österreich	O
Biogen	O
Idec	O
Austria	O
GmbH	O
Tel	O
:	O
+	O
43	O
1	O
484	O
46	O
13	O

Polska	O
Gedeon	O
Richter	B-DISO
Plc	O
.	O

Przedstawicielstwo	O
w	O
Polsce	O
Tel	O
.	O
:	O
+	O
48	O
22	O
642	O
67	O
39	O

30	O
España	O
Biogen	O
Idec	O
Iberia	O
SL	O
Tel	O
:	O
+	O
34	O
91	O
310	O
7110	O

Portugal	B-GEOG
Biogen	O
Idec	O
Portugal	B-GEOG
Sociedade	O
Farmacêutica	O
Unipessoal	O
,	O
Lda	O
Tel	O
:	O
+	O
351	O
21	O
318	O
8450	O

România	O
MEDISON	O
PHARMA	O
SRL	O
Tel	O
:	O
+	O
40	O
31	O
7104035	O

Ireland	O
Biogen	O
Idec	O
(	O
Ireland	O
)	O
Ltd	O
.	O

Slovenija	O
Biogen	O
Idec	O
d	O
.	O
o	O
.	O
o	O
.	O

Slovenská	O
republika	O
Biogen	O
Idec	O
(	O
Slovak	O
Republic	O
)	O
s	O
.	O
r	O
.	O
o	O
Tel	O
:	O
+	O
421	O
2	O
324	O
101	O
88	O

Italia	O
Biogen	O
-	O
Dompé	O
s	O
.	O
r	O
.	O
l	O
.	O

Suomi	O
/	O
Finland	O
Biogen	O
Idec	O
Finland	O
Oy	O
Puh	O
/	O
Tel	O
:	O
+	O
358	O
207	O
401	O
200	O

Κύπρος	O
Genesis	O
Pharma	O
Cyprus	O
Ltd	O
Τηλ	O
:	O
+	O
3572	O
2	O
769946	O

Sverige	O
Biogen	O
Idec	O
Sweden	O
AB	O
Tel	O
:	O
+	O
46	O
8	O
594	O
113	O
60	O

Latvija	O
Gedeon	O
Richter	B-DISO
Plc	O
.	O

United	O
Kingdom	O
Biogen	O
Idec	O
Limited	O
Tel	O
:	O
+	O
44	O
(	O
0	O
)	O
1628	O
50	O
1000	O

Lietuva	O
Gedeon	O
Richter	B-DISO
Plc	O
.	O

Inspectez	O
visuellement	O
le	O
produit	O
dilué	O
pour	O
vérifier	O
l	O
’	O
absence	O
de	O
particules	B-CHEM
ou	O
de	O
coloration	O
avant	O
l	O
’	O
administration	O
.	O

Si	O
le	O
produit	O
dilué	O
est	O
conservé	O
à	O
une	O
température	O
de	O
2	O
à	O
8	O
°	O
C	O
(	O
ne	O
pas	O
congeler	O
)	O
,	O
laissez	O
la	O
solution	B-OBJC
se	O
réchauffer	O
à	O
température	O
ambiante	O
avant	O
la	O
perfusion	B-PROC
.	O








DCTN4	B-CHEM
as	O
a	O
modifier	O
of	O
chronic	B-DISO
Pseudomonas	I-DISO
aeruginosa	I-DISO
infection	I-DISO
in	O
cystic	B-DISO
fibrosis	I-DISO
Pseudomonas	B-DISO
aeruginosa	I-DISO
(	I-DISO
Pa	I-DISO
)	I-DISO
infection	I-DISO
in	O
cystic	B-DISO
fibrosis	I-DISO
(	O
CF	B-DISO
)	O
patients	B-LIVB
is	O
associated	O
with	O
worse	O
long	O
-	O
term	O
pulmonary	B-DISO
disease	I-DISO
and	O
shorter	O
survival	O
,	O
and	O
chronic	B-DISO
Pa	I-DISO
infection	I-DISO
(	O
CPA	B-DISO
)	O
is	O
associated	O
with	O
reduced	B-DISO
lung	I-DISO
function	I-DISO
,	O
faster	B-DISO
rate	I-DISO
of	I-DISO
lung	I-DISO
decline	I-DISO
,	O
increased	O
rates	O
of	O
exacerbations	B-DISO
and	O
shorter	O
survival	O
.	O

By	O
using	O
exome	B-PROC
sequencing	I-PROC
and	O
extreme	O
phenotype	O
design	O
,	O
it	O
was	O
recently	O
shown	O
that	O
isoforms	B-CHEM
of	O
dynactin	B-CHEM
4	I-CHEM
(	O
DCTN4	B-CHEM
)	O
may	O
influence	O
Pa	B-DISO
infection	I-DISO
in	O
CF	B-DISO
,	O
leading	O
to	O
worse	O
respiratory	B-DISO
disease	I-DISO
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
investigate	O
the	O
role	O
of	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
on	O
Pa	B-DISO
infection	I-DISO
incidence	O
,	O
age	B-PHYS
at	O
first	O
Pa	B-DISO
infection	I-DISO
and	O
chronic	B-DISO
Pa	I-DISO
infection	I-DISO
incidence	O
in	O
a	O
cohort	B-LIVB
of	O
adult	B-LIVB
CF	B-DISO
patients	B-LIVB
from	O
a	O
single	O
centre	B-OBJC
.	O

Polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
and	O
direct	B-PROC
sequencing	I-PROC
were	O
used	O
to	O
screen	O
DNA	B-ANAT
samples	I-ANAT
for	O
DCTN4	B-CHEM
variants	B-CHEM
.	O

A	O
total	O
of	O
121	O
adult	B-LIVB
CF	B-DISO
patients	B-LIVB
from	O
the	O
Cochin	B-OBJC
Hospital	I-OBJC
CF	I-OBJC
centre	I-OBJC
have	O
been	O
included	O
,	O
all	O
of	O
them	O
carrying	O
two	O
CFTR	O
defects	O
:	O
103	O
developed	O
at	O
least	O
1	O
pulmonary	B-DISO
infection	I-DISO
with	O
Pa	B-LIVB
,	O
and	O
68	O
patients	B-LIVB
of	O
them	O
had	O
CPA	B-DISO
.	O

DCTN4	B-CHEM
variants	B-CHEM
were	O
identified	O
in	O
24	O
%	O
(	O
29	O
/	O
121	O
)	O
CF	B-DISO
patients	B-LIVB
with	O
Pa	B-DISO
infection	I-DISO
and	O
in	O
only	O
17	O
%	O
(	O
3	O
/	O
18	O
)	O
CF	B-DISO
patients	B-LIVB
with	O
no	O
Pa	B-DISO
infection	I-DISO
.	O

Of	O
the	O
patients	B-LIVB
with	O
CPA	B-DISO
,	O
29	O
%	O
(	O
20	O
/	O
68	O
)	O
had	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
vs	O
23	O
%	O
(	O
8	O
/	O
35	O
)	O
in	O
patients	B-LIVB
without	O
CPA	B-DISO
.	O

Interestingly	O
,	O
p	B-CHEM
.	I-CHEM
Tyr263Cys	I-CHEM
tend	O
to	O
be	O
more	O
frequently	O
observed	O
in	O
CF	B-DISO
patients	B-LIVB
with	O
CPA	B-DISO
than	O
in	O
patients	B-LIVB
without	O
CPA	B-DISO
(	O
4	O
/	O
68	O
vs	O
0	O
/	O
35	O
)	O
,	O
and	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
tend	O
to	O
be	O
more	O
frequent	O
in	O
male	B-PHYS
CF	B-DISO
patients	B-LIVB
with	O
CPA	B-DISO
bearing	O
two	O
class	B-PHYS
II	I-PHYS
mutations	I-PHYS
than	O
in	O
male	B-PHYS
CF	B-DISO
patients	B-LIVB
without	O
CPA	B-DISO
bearing	O
two	O
class	B-PHYS
II	I-PHYS
mutations	I-PHYS
(	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

Our	O
observations	O
reinforce	O
that	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
,	O
especially	O
p	B-CHEM
.	I-CHEM

Tyr263Cys	I-CHEM
,	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
CPA	B-DISO
in	O
male	B-PHYS
CF	B-DISO
.	O

Nonylphenol	B-CHEM
diethoxylate	I-CHEM
inhibits	O
apoptosis	B-PHYS
induced	O
in	O
PC12	B-ANAT
cells	I-ANAT
Nonylphenol	B-CHEM
and	O
short	B-CHEM
-	I-CHEM
chain	I-CHEM
nonylphenol	I-CHEM
ethoxylates	I-CHEM
such	O
as	O
NP2	B-CHEM
EO	I-CHEM
are	O
present	B-DISO
in	O
aquatic	B-PHEN
environment	I-PHEN
as	O
wastewater	B-PHEN
contaminants	B-OBJC
,	O
and	O
their	O
toxic	B-DISO
effects	I-DISO
on	O
aquatic	B-LIVB
species	I-LIVB
have	O
been	O
reported	O
.	O

Apoptosis	B-PHYS
has	O
been	O
shown	O
to	O
be	O
induced	O
by	O
serum	B-ANAT
deprivation	O
or	O
copper	B-CHEM
treatment	O
.	O

To	O
understand	O
the	O
toxicity	O
of	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
,	O
we	O
investigated	O
the	O
effects	O
of	O
NP2	B-CHEM
EO	I-CHEM
on	O
apoptosis	B-PHYS
induced	O
by	O
serum	B-ANAT
deprivation	O
and	O
copper	B-CHEM
by	O
using	O
PC12	B-ANAT
cell	I-ANAT
system	I-ANAT
.	O

Nonylphenol	B-CHEM
diethoxylate	I-CHEM
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	B-PHYS
viability	I-PHYS
from	O
apoptosis	B-PHYS
.	O

In	O
addition	O
,	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
decreased	O
DNA	B-PHYS
fragmentation	I-PHYS
caused	O
by	O
apoptosis	B-PHYS
in	O
PC12	B-ANAT
cells	I-ANAT
.	O

This	O
phenomenon	B-PHEN
was	O
confirmed	O
after	O
treating	O
apoptotic	O
PC12	B-ANAT
cells	I-ANAT
with	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
,	O
whereas	O
the	O
cytochrome	B-CHEM
c	I-CHEM
release	O
into	O
the	O
cytosol	B-ANAT
decreased	O
as	O
compared	O
to	O
that	O
in	O
apoptotic	B-ANAT
cells	I-ANAT
not	O
treated	O
with	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
s	O
.	O

Furthermore	O
,	O
Bax	B-CHEM
contents	O
in	O
apoptotic	B-ANAT
cells	I-ANAT
were	O
reduced	O
after	O
exposure	O
to	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
.	O

Thus	O
,	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
has	O
the	O
opposite	O
effect	O
on	O
apoptosis	B-PHYS
in	O
PC12	B-ANAT
cells	I-ANAT
compared	O
to	O
nonylphenol	B-CHEM
,	O
which	O
enhances	O
apoptosis	B-PHYS
induced	O
by	O
serum	B-ANAT
deprivation	O
.	O

The	O
difference	O
in	O
structure	O
of	O
the	O
two	O
compounds	B-CHEM
is	O
hypothesized	O
to	O
be	O
responsible	O
for	O
this	O
phenomenon	B-PHEN
.	O

These	O
results	B-DISO
indicated	O
that	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
has	O
capability	O
to	O
affect	O
cell	B-PHYS
differentiation	I-PHYS
and	O
development	B-PHYS
and	O
has	O
potentially	O
harmful	B-DISO
effect	I-DISO
on	O
organisms	B-LIVB
because	O
of	O
its	O
unexpected	O
impact	O
on	O
apoptosis	B-PHYS
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O
Environ	O
Toxicol	O
31	O
:	O
1389	O
-	O
1398	O
,	O
2016	O
.	O

Prevascularized	O
silicon	B-CHEM
membranes	B-OBJC
for	O
the	O
enhancement	O
of	O
transport	O
to	O
implanted	B-DISO
medical	I-DISO
devices	I-DISO
Recent	O
advances	O
in	O
drug	B-DEVI
delivery	I-DEVI
and	O
sensing	B-OBJC
devices	I-OBJC
for	O
in	O
situ	O
applications	B-PROC
are	O
limited	O
by	O
the	O
diffusion	B-PHEN
-limiting	O
foreign	B-DISO
body	I-DISO
response	I-DISO
of	O
fibrous	O
encapsulation	B-PHEN
.	O

In	O
this	O
study	O
,	O
we	O
fabricated	O
prevascularized	O
synthetic	B-OBJC
device	I-OBJC
ports	I-OBJC
to	O
help	O
mitigate	B-PHEN
this	O
limitation	O
.	O

Membranes	B-OBJC
with	O
rectilinear	O
arrays	O
of	O
square	O
pores	O
with	O
widths	O
ranging	O
from	O
40	O
to	O
200	O
μm	O
were	O
created	O
using	O
materials	B-OBJC
(	O
50	O
μm	O
thick	O
double	O
-	O
sided	O
polished	B-CHEM
silicon	I-CHEM
)	O
and	O
processes	B-PHEN
(	O
photolithography	O
and	O
directed	B-PHEN
reactive	I-PHEN
ion	I-PHEN
etching	I-PHEN
)	O
common	O
in	O
the	O
manufacturing	O
of	O
microfabricated	B-OBJC
sensors	I-OBJC
.	O

Vascular	B-ANAT
endothelial	I-ANAT
cells	I-ANAT
responded	O
to	O
membrane	B-OBJC
geometry	I-OBJC
by	O
either	O
forming	O
vascular	B-ANAT
tubes	I-ANAT
that	O
extended	O
through	O
the	O
pore	O
or	O
completely	O
filling	O
membrane	B-OBJC
pores	O
after	O
4	O
days	O
in	O
culture	B-PROC
.	O

Although	O
tube	O
formation	O
began	O
to	O
predominate	O
overgrowth	B-DISO
around	O
75	O
μm	O
and	O
continued	O
to	O
increase	O
at	O
even	O
larger	O
pore	O
sizes	O
,	O
tubes	O
formed	O
at	O
these	O
large	O
pore	O
sizes	O
were	O
not	O
completely	O
round	O
and	O
had	O
relatively	O
thin	O
walls	O
.	O

Thus	O
,	O
the	O
optimum	O
range	O
of	O
pore	O
size	O
for	O
prevascularization	O
of	O
these	O
membranes	B-OBJC
was	O
estimated	O
to	O
be	O
75	O
-	O
100	O
μm	O
.	O

This	O
study	B-PROC
lays	O
the	O
foundation	O
for	O
creating	O
a	O
prevascularized	O
port	B-OBJC
that	O
can	O
be	O
used	O
to	O
reduce	O
fibrous	O
encapsulation	B-PHEN
and	O
thus	O
enhance	O
diffusion	B-PHEN
to	O
implanted	B-DISO
medical	I-DISO
devices	I-DISO
and	O
sensors	B-OBJC
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
104B	O
:	O
1602	O
-	O
1609	O
,	O
2016	O
.	O

Seated	B-DISO
maximum	O
flexion	B-PHYS
:	O
An	O
alternative	O
to	O
standing	O
maximum	O
flexion	B-PHYS
for	O
determining	O
presence	O
of	O
flexion	B-PHYS
-	O
relaxation	O
?	O

The	O
flexion	B-PHYS
-	O
relaxation	O
phenomenon	B-PHEN
(	O
FRP	B-PHEN
)	O
in	O
standing	O
is	O
a	O
specific	O
and	O
sensitive	O
diagnostic	B-PROC
tool	I-PROC
for	O
low	B-DISO
back	I-DISO
pain	I-DISO
.	O

Seated	B-PHYS
flexion	I-PHYS
as	O
an	O
alternative	O
could	O
be	O
beneficial	O
for	O
certain	O
populations	B-LIVB
,	O
yet	O
the	O
behavior	O
of	O
the	O
trunk	O
extensors	O
during	O
seated	B-DISO
maximum	O
flexion	B-PHYS
compared	O
to	O
standing	O
flexion	B-PHYS
remains	O
unclear	O
.	O

Compare	O
FRP	B-PHEN
occurrences	O
and	O
spine	B-ANAT
angles	O
between	O
seated	B-DISO
and	O
standing	O
flexion	B-PHYS
postures	B-PHYS
in	O
three	O
levels	O
of	O
the	O
erector	B-ANAT
spinae	I-ANAT
muscles	I-ANAT
.	O

Thirty	O
-	O
one	O
participants	B-LIVB
free	O
of	O
back	B-DISO
pain	I-DISO
performed	O
seated	B-DISO
and	O
standing	O
maximum	O
trunk	B-ANAT
flexion	B-PHYS
.	O

Electromyographical	B-PHEN
signals	I-PHEN
were	O
recorded	O
from	O
the	O
bilateral	B-ANAT
lumbar	I-ANAT
(	I-ANAT
L3	I-ANAT
)	I-ANAT
,	O
lower	B-ANAT
-	I-ANAT
thoracic	I-ANAT
(	I-ANAT
T9	I-ANAT
)	I-ANAT
,	O
and	O
upper	B-ANAT
-	I-ANAT
thoracic	I-ANAT
(	I-ANAT
T4	I-ANAT
)	I-ANAT
erector	B-ANAT
spinae	I-ANAT
and	O
assessed	O
for	O
the	O
occurrence	O
of	O
FRP	B-PHEN
.	O

Spine	O
angles	O
corresponding	O
to	O
FRP	B-PHEN
onset	O
and	O
cessation	O
were	O
determined	O
,	O
and	O
FRP	B-PHEN
occurrences	O
and	O
angles	O
were	O
compared	O
between	O
posture	B-PHYS
and	O
muscle	O
.	O

FRP	B-PHEN
occurrence	O
was	O
similar	O
in	O
standing	O
and	O
seated	B-DISO
maximum	O
flexion	B-PHYS
across	O
all	O
muscles	O
,	O
with	O
the	O
lumbar	O
muscles	O
showing	O
the	O
greatest	O
consistency	O
.	O

Standing	O
FRP	B-PHEN
onset	O
and	O
cessation	O
angles	O
were	O
consistently	O
greater	O
than	O
the	O
corresponding	O
seated	B-DISO
FRP	B-PHEN
angles	O
.	O

Considering	O
the	O
similar	O
number	O
of	O
FRP	B-PHEN
occurrences	O
,	O
seated	B-DISO
maximum	O
flexion	B-PHYS
may	O
constitute	O
an	O
objective	O
criterion	O
for	O
low	B-DISO
back	I-DISO
pain	I-DISO
diagnosis	B-DISO
.	O

Future	O
work	O
should	O
seek	O
to	O
confirm	O
the	O
utility	O
of	O
this	O
test	O
in	O
individuals	B-LIVB
with	O
low	B-DISO
back	I-DISO
pain	I-DISO
.	O

The	O
Relationship	O
Between	O
Distance	O
and	O
Post	B-DISO
-	I-DISO
operative	I-DISO
Visit	O
Attendance	O
Following	O
Medical	O
Male	B-PROC
Circumcision	I-PROC
in	O
Nyanza	B-GEOG
Province	I-GEOG
,	O
Kenya	B-GEOG
To	O
date	O
,	O
there	O
is	O
no	O
research	B-PROC
on	O
voluntary	O
medical	O
male	B-PROC
circumcision	I-PROC
(	O
VMMC	B-PROC
)	O
catchment	B-GEOG
areas	I-GEOG
or	O
the	O
relationship	O
between	O
distance	O
to	O
a	O
VMMC	B-PROC
facility	B-OBJC
and	O
attendance	O
at	O
a	O
post	B-DISO
-	I-DISO
operative	I-DISO
follow	B-PROC
-	I-PROC
up	I-PROC
visit	I-PROC
.	O

We	O
analyzed	B-PROC
data	O
from	O
a	O
randomly	O
selected	O
subset	O
of	O
males	B-LIVB
self	B-PROC
-	I-PROC
seeking	I-PROC
circumcision	I-PROC
at	O
one	O
of	O
16	O
participating	O
facilities	B-OBJC
in	O
Nyanza	B-GEOG
Province	I-GEOG
,	O
Kenya	B-GEOG
between	O
2008	O
and	O
2010	O
.	O

Among	O
1437	O
participants	B-LIVB
,	O
46	O
.	O
7	O
%	O
attended	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

The	O
median	O
distance	O
from	O
residence	O
to	O
utilized	O
facility	B-OBJC
was	O
2	O
.	O
98	O
km	O
(	O
IQR	O
1	O
.	O
31	O
-	O
5	O
.	O
38	O
)	O
.	O

Nearly	O
all	O
participants	B-LIVB
(	O
98	O
.	O
8	O
%	O
)	O
lived	O
within	O
5	O
km	O
from	O
a	O
facility	B-OBJC
,	O
however	O
,	O
26	O
.	O

3	O
%	O
visited	O
a	O
facility	B-OBJC
more	O
than	O
5	O
km	O
away	O
.	O

Stratified	O
results	O
demonstrated	O
that	O
among	O
those	O
utilizing	O
fixed	O
facilities	B-OBJC
,	O
greater	O
distance	O
was	O
associated	O
with	O
higher	O
odds	O
of	O
follow	B-PROC
-	I-PROC
up	I-PROC
non	O
-	O
attendance	O
(	O
OR	O
5	O
.	O
01	O
-	O
10	O
km	O
vs	O
.	O

0	O
-	O
1	O
km	O
=	O
1	O
.	O
71	O
,	O
95	O
%	O
CI	O
1	O
.	O
08	O
,	O
2	O
.	O
70	O
,	O
p	O
=	O
0	O
.	O

02	O
;	O
OR	O
>	O
10	O
km	O
vs	O
.	O

0	O
-	O
1	O
km	O
=	O
2	O
.	O
80	O
,	O
95	O
%	O
CI	O
1	O
.	O
26	O
,	O
6	O
.	O
21	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
adjusting	O
for	O
age	B-PHYS
and	O
district	O
of	O
residence	O
.	O

We	O
found	O
5	O
km	O
marked	O
the	O
threshold	O
distance	O
beyond	O
which	O
follow	B-PROC
-	I-PROC
up	I-PROC
attendance	O
significantly	O
dropped	O
.	O

These	O
results	O
demonstrate	O
distance	O
is	O
an	O
important	O
predictor	O
of	O
attending	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
and	O
this	O
relationship	O
appears	O
to	O
be	O
modified	O
by	O
facility	B-OBJC
type	O
.	O

Promoting	O
lifestyle	O
behaviour	O
change	O
and	O
well	B-DISO
-	I-DISO
being	I-DISO
in	O
hospital	B-LIVB
patients	I-LIVB
:	O
a	O
pilot	B-PROC
study	I-PROC
of	O
an	O
evidence	O
-	O
based	O
psychological	O
intervention	B-PROC
Lifestyle	O
risk	O
behaviours	O
show	O
an	O
inverse	O
social	O
gradient	O
,	O
clustering	O
in	O
vulnerable	B-LIVB
groups	I-LIVB
.	O

We	O
designed	O
and	O
piloted	O
an	O
intervention	B-PROC
to	O
address	O
barriers	O
to	O
lifestyle	O
behaviour	O
change	O
among	O
hospital	B-LIVB
patients	I-LIVB
.	O

We	O
designed	O
our	O
intervention	B-PROC
using	O
effective	O
components	O
of	O
behaviour	O
change	O
interventions	B-PROC
informed	O
by	O
psychological	O
theory	O
.	O

Delivered	O
by	O
a	O
health	B-LIVB
psychologist	I-LIVB
based	O
at	O
the	O
Royal	O
Free	O
London	O
NHS	O
Foundation	O
Trust	O
,	O
the	O
4	O
-	O
week	O
intervention	B-PROC
included	O
detailed	O
baseline	B-PROC
assessment	I-PROC
,	O
personalized	O
goal	B-PROC
setting	I-PROC
,	O
psychological	B-PHYS
skills	I-PHYS
development	I-PHYS
,	O
motivation	B-PROC
support	I-PROC
and	O
referral	B-PROC
to	I-PROC
community	O
services	O
.	O

Primary	O
outcomes	O
were	O
feasibility	O
and	O
patient	B-LIVB
acceptability	O
.	O

We	O
also	O
evaluated	O
changes	O
to	O
health	O
and	O
well	B-DISO
-	I-DISO
being	I-DISO
.	O

From	O
1	O
July	O
2013	O
to	O
31	O
September	O
2014	O
,	O
686	O
patients	B-LIVB
were	O
referred	O
,	O
338	O
(	O
49	O
.	O

3	O
%	O
)	O
attended	O
a	O
first	O
appointment	O
and	O
172	O
(	O
25	O
.	O

1	O
%	O
)	O
completed	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Furthermore	O
,	O
72	O
.	O
1	O
%	O
of	O
attenders	B-LIVB
were	O
female	B-PHYS
with	O
the	O
median	O
age	B-PHYS
55	O
years	O
and	O
poor	O
self	O
-	O
reported	O
baseline	O
health	O
.	O

After	O
4	O
weeks	O
,	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O
health	O
and	O
well	O
-	O
being	O
scores	O
significantly	B-DISO
improved	I-DISO
:	O
63	O
%	O
of	O
lifestyle	B-DISO
goals	I-DISO
and	O
89	O
%	O
of	O
health	B-PROC
management	I-PROC
goals	O
were	O
fully	O
achieved	B-DISO
;	O
58	O
%	O
of	O
referrals	B-PROC
to	I-PROC
community	O
lifestyle	O
behaviour	O
change	O
services	O
and	O
79	O
%	O
of	O
referrals	O
to	O
other	O
services	B-PROC
(	O
e	O
.	O

g	O
.	O

Citizen	B-LIVB
's	I-LIVB
Advice	I-LIVB
Bureau	I-LIVB
)	O
were	O
accepted	O
;	O
99	O
%	O
were	O
satisfied	O
/	O
very	B-DISO
satisfied	I-DISO
with	O
the	O
service	B-PROC
.	O

Our	O
hospital	B-PROC
-	I-PROC
based	I-PROC
intervention	I-PROC
was	O
feasible	O
,	O
acceptable	O
and	O
showed	O
preliminary	B-DISO
health	I-DISO
and	I-DISO
well	I-DISO
-	I-DISO
being	I-DISO
gains	I-DISO
.	O

The	O
Impact	O
of	O
Deployment	O
on	O
Parental	B-LIVB
,	O
Family	B-LIVB
and	O
Child	B-LIVB
Adjustment	O
in	O
Military	B-LIVB
Families	I-LIVB
Since	O
9	O
/	O
11	O
,	O
military	B-LIVB
service	I-LIVB
in	O
the	O
United	B-GEOG
States	I-GEOG
has	O
been	O
characterized	O
by	O
wartime	O
deployments	O
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-DISO
for	O
military	B-LIVB
families	I-LIVB
.	O

Research	B-PROC
indicates	O
the	O
negative	B-DISO
impact	I-DISO
of	O
wartime	O
deployment	O
on	O
the	O
well	O
being	O
of	O
service	B-LIVB
members	B-LIVB
,	O
military	B-LIVB
spouses	B-LIVB
,	O
and	O
children	B-LIVB
.	O

Yet	O
,	O
few	O
studies	O
have	O
considered	O
how	O
parental	B-LIVB
deployments	O
may	O
affect	O
adjustment	O
in	O
young	B-LIVB
children	I-LIVB
and	O
their	O
families	B-LIVB
.	O

Using	O
deployment	O
records	O
and	O
parent	B-LIVB
-	O
reported	O
measures	O
from	O
primary	O
caregiving	O
(	O
N	O
=	O
680	O
)	O
and	O
military	B-LIVB
(	O
n	O
=	O
310	O
)	O
parents	B-LIVB
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	O
on	O
adjustment	O
in	O
military	B-LIVB
families	I-LIVB
with	O
children	B-LIVB
ages	O
0	O
-	O
10	O
years	O
.	O

Greater	O
deployment	O
exposure	O
was	O
related	O
to	O
impaired	O
family	O
functioning	O
and	O
marital	B-DISO
instability	B-DISO
.	O

Parental	B-LIVB
depressive	B-DISO
and	O
posttraumatic	B-DISO
stress	I-DISO
symptoms	I-DISO
were	O
associated	O
with	O
impairments	O
in	O
social	O
emotional	B-DISO
adjustment	O
in	O
young	B-LIVB
children	I-LIVB
,	O
increased	O
anxiety	B-DISO
in	O
early	O
childhood	O
,	O
and	O
adjustment	O
problems	O
in	O
school	B-LIVB
-	I-LIVB
age	I-LIVB
children	I-LIVB
.	O

Conversely	O
,	O
parental	B-LIVB
sensitivity	B-PHYS
was	O
associated	O
with	O
improved	O
social	O
and	O
emotional	B-DISO
outcomes	I-DISO
across	O
childhood	O
.	O

These	O
findings	B-DISO
provide	O
guidance	O
to	O
developing	O
preventive	O
approaches	O
for	O
military	B-LIVB
families	I-LIVB
with	O
young	O
children	B-LIVB
.	O

Combining	O
electrostatic	B-OBJC
powder	I-OBJC
with	O
an	O
insecticide	B-CHEM
:	O
effect	O
on	O
stored	O
-	O
product	B-OBJC
beetles	O
and	O
on	O
the	O
commodity	B-OBJC
The	O
opportunity	O
to	O
reduce	O
the	O
amount	O
of	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
applied	O
to	O
grain	B-OBJC
by	O
formulating	O
it	O
in	O
an	O
electrostatic	B-OBJC
powder	I-OBJC
was	O
investigated	O
.	O

The	O
insecticidal	B-CHEM
efficacy	O
of	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
in	O
EC	B-CHEM
formulation	I-CHEM
or	O
formulated	O
using	O
electrostatic	B-OBJC
powder	I-OBJC
(	O
EP	B-OBJC
)	O
as	O
an	O
inert	B-OBJC
carrier	I-OBJC
was	O
investigated	O
against	O
Sitophilus	O
oryzae	O
(	O
L	O
.	O
)	O
,	O
Oryzaephilus	O
surinamensis	O
(	O
L	O
.	O
)	O
,	O
Rhyzopertha	O
dominica	O
(	O
F	O
.	O
)	O
and	O
Tribolium	O
confusum	O
Jacquelin	O
du	O
Val	O
.	O

Furthermore	O
,	O
the	O
adhesive	B-PHEN
properties	O
of	O
EP	B-OBJC
to	O
rice	B-OBJC
,	O
corn	B-OBJC
and	O
wheat	B-OBJC
,	O
together	O
with	O
the	O
effect	O
on	O
bulk	O
density	O
and	O
bread	B-OBJC
-	O
and	O
pasta	B-OBJC
-	O
making	O
properties	O
,	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
formulated	O
with	O
EP	B-OBJC
provided	O
better	O
efficacy	O
against	O
adults	O
when	O
compared	O
with	O
EC	B-CHEM
formulation	I-CHEM
for	O
O	O
.	O

surinamensis	O
and	O
T	O
.	O

confusum	O
,	O
but	O
there	O
was	O
no	O
difference	O
for	O
R	O
.	O

dominica	O
.	O

Progeny	B-LIVB
production	O
was	O
consistently	O
lower	O
in	O
grain	B-OBJC
treated	B-PROC
with	I-PROC
the	O
EP	B-OBJC
formulation	O
than	O
in	O
grain	B-OBJC
treated	B-PROC
with	I-PROC
the	O
EC	B-CHEM
.	O

Tests	O
showed	O
that	O
EP	B-OBJC
adhered	B-PHEN
to	O
the	O
kernels	B-OBJC
for	O
longer	O
on	O
hard	O
wheat	B-OBJC
than	O
on	O
maize	B-OBJC
or	O
rice	B-OBJC
.	O

In	O
most	O
commodities	B-OBJC
,	O
EP	B-OBJC
did	O
not	O
alter	O
the	O
bulk	O
density	O
.	O

Finally	O
,	O
the	O
addition	O
of	O
EP	B-OBJC
did	O
not	O
affect	O
flour	B-OBJC
-	O
and	O
bread	B-OBJC
-	O
making	O
properties	O
,	O
nor	O
the	O
pasta	B-OBJC
-making	O
properties	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
an	O
EP	B-OBJC
could	O
be	O
used	O
to	O
reduce	O
the	O
amount	O
of	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
applied	O
to	O
grain	B-OBJC
for	O
effective	O
pest	O
control	O
,	O
with	O
no	O
detrimental	O
effects	O
on	O
grain	B-OBJC
quality	O
.	O

©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Radiofrequency	B-PROC
ablation	I-PROC
of	O
posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
associated	O
with	O
coronary	B-DISO
sinus	I-DISO
diverticula	I-DISO
Posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
may	O
be	O
associated	O
with	O
a	O
coronary	B-DISO
sinus	I-DISO
(	I-DISO
CS	I-DISO
)	I-DISO
diverticulum	I-DISO
.	O

Our	O
purpose	O
was	O
to	O
describe	O
the	O
clinical	B-PHYS
characteristics	I-PHYS
,	O
mapping	O
and	O
ablation	B-PROC
of	I-PROC
these	I-PROC
pathways	I-PROC
.	O

This	O
was	O
a	O
retrospective	B-PROC
study	I-PROC
of	O
all	O
patients	B-LIVB
who	O
underwent	O
ablation	B-PROC
of	O
posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
in	O
a	O
single	O
centre	O
.	O

Patients	B-LIVB
with	O
a	O
diverticulum	B-DISO
of	I-DISO
the	I-DISO
CS	I-DISO
or	O
one	O
of	O
its	O
tributaries	B-ANAT
were	O
included	O
in	O
group	O
I	O
,	O
while	O
the	O
other	O
patients	B-LIVB
formed	O
group	O
II	O
.	O

Clinical	O
presentation	O
,	O
ablation	B-PROC
procedure	I-PROC
and	O
outcome	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

A	O
total	O
of	O
51	O
patients	B-LIVB
were	O
included	O
,	O
16	O
in	O
group	O
I	O
and	O
35	O
in	O
group	O
II	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
age	O
or	O
sex	O
distribution	O
.	O

Atrial	B-DISO
fibrillation	I-DISO
(	O
AF	B-DISO
)	O
and	O
previous	O
unsuccessful	O
ablation	B-PROC
were	O
more	O
common	O
in	O
group	O
I	O
.	O

A	O
negative	B-DISO
delta	B-DISO
wave	I-DISO
in	O
lead	O
II	O
was	O
the	O
ECG	B-PROC
finding	B-DISO
with	O
best	O
sensitivity	O
and	O
specificity	O
for	O
the	O
presence	O
of	O
a	O
diverticulum	B-DISO
.	O

A	O
pathway	B-ANAT
potential	O
was	O
common	O
at	O
the	O
successful	O
site	O
in	O
group	O
I	O
,	O
and	O
the	O
interval	O
between	O
local	B-PROC
ventricular	I-PROC
electrogram	I-PROC
and	O
delta	B-DISO
wave	I-DISO
onset	O
was	O
shorter	O
(	O
19	O
.	O
5	O
±	O
8	O
vs	O
33	O
.	O
1	O
±	O
7	O
.	O

6	O
ms	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
lower	O
procedural	O
success	O
rate	O
and	O
higher	O
recurrence	B-PHEN
rate	O
in	O
group	O
I	O
,	O
although	O
this	O
was	O
not	O
significant	O
.	O

CS	B-DISO
diverticula	I-DISO
should	O
be	O
suspected	O
in	O
patients	B-LIVB
with	O
manifest	O
posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
who	O
have	O
a	O
previous	O
failed	O
ablation	B-PROC
,	O
documented	O
AF	B-DISO
or	O
typical	O
electrocardiographic	B-DISO
signs	I-DISO
.	O

A	O
discrete	O
potential	O
is	O
frequently	O
seen	O
at	O
the	O
successful	O
site	O
,	O
but	O
the	O
local	B-PROC
ventricular	I-PROC
electrogram	I-PROC
is	O
not	O
as	O
early	O
as	O
in	O
other	O
accessory	B-ANAT
pathways	I-ANAT
.	O

Association	O
of	O
RBP4	B-CHEM
levels	O
with	O
increased	O
arterial	B-PHYS
stiffness	I-PHYS
in	O
adolescents	B-LIVB
with	O
family	B-DISO
history	I-DISO
of	I-DISO
type	I-DISO
2	I-DISO
diabetes	I-DISO
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
explore	O
the	O
impact	O
of	O
family	B-DISO
history	I-DISO
of	I-DISO
type	I-DISO
2	I-DISO
diabetes	I-DISO
(	O
FH2D	B-DISO
)	O
on	O
arterial	B-PHYS
stiffness	I-PHYS
in	O
young	O
people	B-LIVB
and	O
its	O
relationship	O
to	O
adipocytokines	B-CHEM
.	O

This	O
case	B-PROC
-	I-PROC
control	I-PROC
study	I-PROC
included	O
52	O
adolescents	B-LIVB
(	O
male	B-PHYS
/	O
female	B-PHYS
28	O
/	O
24	O
)	O
with	O
FH2D	B-DISO
(	O
FH2D	B-DISO
+	I-DISO
)	O
and	O
40	O
adolescents	B-LIVB
(	O
male	B-PHYS
/	O
female	B-PHYS
21	O
/	O
19	O
)	O
without	O
FH2D	B-DISO
(	O
FH2D	B-DISO
-	I-DISO
)	O
.	O

Anthropometric	O
measurements	O
,	O
including	O
height	B-PHYS
,	O
weight	B-PHYS
,	O
waist	B-PHYS
circumference	I-PHYS
(	O
WC	B-PHYS
)	O
,	O
and	O
blood	B-PHYS
pressure	I-PHYS
,	O
were	O
obtained	O
.	O

Blood	B-ANAT
samples	I-ANAT
were	O
collected	O
,	O
fasting	B-PROC
plasma	I-PROC
glucose	I-PROC
(	O
FPG	B-PROC
)	O
,	O
serum	B-PROC
lipids	I-PROC
,	O
Retinol	B-CHEM
Binding	I-CHEM
Protein	I-CHEM
4	I-CHEM
(	O
RBP4	B-CHEM
)	O
,	O
C	B-PROC
reactive	I-PROC
protein	I-PROC
(	O
CRP	B-PROC
)	O
,	O
adiponectin	B-PROC
and	O
visfatin	B-CHEM
were	O
examined	O
.	O

Brachial	O
-	O
ankle	O
pulse	O
wave	O
velocity	O
(	O
baPWV	O
)	O
was	O
used	O
to	O
evaluate	O
arterial	B-PHYS
stiffness	I-PHYS
.	O

Visceral	B-PHYS
fat	I-PHYS
area	I-PHYS
(	O
VFA	B-PHYS
)	O
was	O
measured	O
by	O
computerized	B-PROC
tomography	I-PROC
.	O

Compared	O
with	O
FH2D	B-DISO
-	I-DISO
group	B-LIVB
,	O
FH2D	B-DISO
+	I-DISO
group	B-LIVB
had	O
a	O
significantly	O
higher	O
oral	B-PROC
glucose	I-PROC
tolerance	I-PROC
test	I-PROC
(	I-PROC
OGTT	I-PROC
)	I-PROC
2	I-PROC
-	I-PROC
hour	I-PROC
insulin	I-PROC
,	O
RBP4	B-CHEM
and	O
baPWV	O
levels	O
,	O
a	O
lower	O
adiponectin	B-PROC
and	O
glucose	O
infusing	O
rate	O
(	O
GIR	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

BaPWV	O
was	O
positively	O
correlated	O
with	O
age	B-PHYS
,	O
systolic	B-PHYS
blood	I-PHYS
pressure	I-PHYS
(	O
SBP	B-PHYS
)	O
,	O
diastolic	B-PHYS
blood	I-PHYS
pressure	I-PHYS
(	O
DBP	B-PHYS
)	O
,	O
2	B-PROC
-	I-PROC
hour	I-PROC
(	I-PROC
OGTT	I-PROC
)	I-PROC
insulin	I-PROC
,	O
RBP4	B-CHEM
,	O
and	O
VFA	B-PHYS
,	O
and	O
negatively	O
correlated	O
with	O
GIR	O
in	O
FH2D	B-DISO
+	I-DISO
group	B-LIVB
.	O

After	O
multivariate	O
analysis	O
,	O
age	B-PHYS
,	O
SBP	B-PHYS
,	O
RBP4	B-CHEM
and	O
VFA	B-PHYS
maintained	O
an	O
independent	O
association	O
with	O
baPWV	O
in	O
FH2D	B-DISO
+	I-DISO
group	B-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
only	O
age	B-PHYS
,	O
SBP	B-PHYS
,	O
and	O
VFA	B-PHYS
were	O
independent	O
predictors	O
of	O
baPWV	O
in	O
FH2D	B-DISO
-	I-DISO
group	B-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
findings	B-DISO
led	O
to	O
the	O
conclusion	O
that	O
RBP4	B-CHEM
level	O
was	O
associated	O
with	O
increased	O
arterial	B-PHYS
stiffness	I-PHYS
in	O
young	O
subjects	B-LIVB
with	O
family	B-DISO
history	I-DISO
of	I-DISO
type	I-DISO
2	I-DISO
diabetes	I-DISO
.	O

EZH2	O
and	O
ZFX	O
oncogenes	O
in	O
malignant	O
behaviour	O
of	O
parathyroid	B-DISO
neoplasms	I-DISO
Several	O
studies	B-PROC
reported	O
somatic	B-DISO
mutations	I-DISO
of	O
many	O
genes	O
(	O
MEN1	O
,	O
CTNNB1	O
,	O
CDKIs	O
and	O
others	O
)	O
in	O
parathyroid	B-DISO
adenoma	I-DISO
,	O
although	O
with	O
different	O
prevalence	O
.	O

Recently	O
,	O
activating	O
mutations	B-PHYS
of	O
the	O
EZH2	O
and	O
ZFX	O
oncogenes	O
were	O
identified	O
in	O
benign	O
parathyroid	B-DISO
adenoma	I-DISO
by	O
whole	B-PROC
exome	I-PROC
sequencing	I-PROC
.	O

The	O
same	O
mutations	B-PHYS
had	O
been	O
found	O
in	O
blood	B-ANAT
and	O
ovary	B-ANAT
malignant	B-DISO
tumours	I-DISO
.	O

On	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	O
that	O
these	O
oncogenes	O
may	O
play	O
a	O
role	O
in	O
the	O
onset	O
of	O
parathyroid	B-DISO
tumour	I-DISO
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	O
,	O
rather	O
benign	O
,	O
parathyroid	B-DISO
neoplasm	I-DISO
.	O

Our	O
aim	O
was	O
to	O
verify	O
the	O
occurrence	O
of	O
selected	O
mutations	B-PHYS
of	O
the	O
EZH2	O
and	O
ZFX	O
genes	O
in	O
an	O
Italian	B-LIVB
cohort	B-LIVB
of	O
23	O
sporadic	O
parathyroid	B-DISO
carcinomas	I-DISO
,	O
12	O
atypical	O
and	O
45	O
typical	O
adenomas	B-DISO
.	O

DNA	B-CHEM
was	O
extracted	B-PROC
from	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
PCR	B-PROC
amplified	B-PHEN
and	O
directly	O
sequenced	O
.	O

No	B-DISO
mutations	B-PHYS
were	O
detected	B-DISO
in	O
the	O
coding	B-CHEM
sequence	I-CHEM
and	O
boundaries	B-CHEM
of	O
both	O
genes	O
in	O
any	O
of	O
the	O
samples	B-OBJC
.	O

Two	O
polymorphisms	B-PHYS
of	O
the	O
EZH2	O
gene	O
were	O
identified	O
with	O
different	O
prevalence	O
:	O
the	O
rs2072407	O
variant	O
was	O
present	B-DISO
in	O
the	O
30	O
%	O
of	O
the	O
samples	B-OBJC
,	O
in	O
keeping	O
with	O
the	O
overall	O
frequency	O
in	O
larger	O
populations	O
,	O
while	O
the	O
rs78589034	O
variant	O
,	O
located	O
close	O
to	O
the	O
5	B-CHEM
'	I-CHEM
end	I-CHEM
of	O
the	O
exon	B-CHEM
16	I-CHEM
,	O
was	O
detected	B-DISO
in	O
only	O
one	O
proband	B-LIVB
with	O
familial	O
isolated	O
hyperparathyroidism	B-DISO
;	O
we	O
investigated	O
the	O
possible	O
outcome	O
on	O
the	O
splicing	B-PHYS
process	I-PHYS
.	O

EZH2	O
and	O
ZFX	O
genes	O
do	O
not	O
seem	O
to	O
have	O
an	O
impact	O
on	O
the	O
onset	O
of	O
most	O
parathyroid	B-DISO
tumours	I-DISO
,	O
both	O
benign	O
and	O
malignant	O
,	O
though	O
further	O
studies	O
on	O
larger	O
cohorts	B-LIVB
of	O
different	O
ethnicity	O
are	O
needed	O
.	O

The	O
effect	O
of	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
on	O
sagittal	B-ANAT
spinal	O
-	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
and	O
low	B-DISO
back	I-DISO
pain	I-DISO
in	O
patients	B-LIVB
with	O
severe	O
hip	B-DISO
osteoarthritis	I-DISO
Sagittal	B-ANAT
spinopelvic	B-ANAT
malalignment	B-DISO
has	O
been	O
reported	O
in	O
spinal	B-DISO
disorders	I-DISO
such	O
as	O
low	B-DISO
back	I-DISO
pain	I-DISO
(	O
LBP	B-DISO
)	O
,	O
and	O
restoration	O
of	O
normal	O
alignment	B-DISO
is	O
targeted	O
when	O
treating	B-PROC
these	O
disorders	B-DISO
.	O

Abnormal	B-DISO
sagittal	B-ANAT
spinal	O
-	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
has	O
been	O
reported	O
in	O
patients	B-LIVB
with	O
severe	O
hip	B-DISO
osteoarthritis	I-DISO
(	O
OA	B-DISO
)	O
,	O
who	O
have	O
a	O
high	O
prevalence	O
of	O
associated	O
LBP	B-DISO
.	O

This	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
aimed	O
to	O
investigate	O
changes	O
in	O
sagittal	B-ANAT
spinal	O
-	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
after	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
(	O
THA	B-PROC
)	O
in	O
patients	B-LIVB
with	O
severe	O
hip	B-DISO
OA	I-DISO
,	O
and	O
whether	O
these	O
changes	O
contribute	O
to	O
LBP	B-DISO
relief	B-DISO
.	O

Patients	B-LIVB
undergoing	O
primary	O
THA	B-PROC
due	O
to	O
severe	O
unilateral	O
hip	B-DISO
OA	I-DISO
were	O
recruited	O
.	O

Physical	B-PROC
examination	I-PROC
and	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
films	I-DEVI
were	O
taken	O
to	O
rule	O
out	O
any	O
spinal	B-DISO
disorder	I-DISO
.	O

Sagittal	B-ANAT
alignment	B-DISO
of	O
pelvis	B-ANAT
,	O
hip	B-ANAT
,	O
and	O
spine	B-ANAT
was	O
analyzed	O
on	O
lateral	B-PROC
radiographs	I-PROC
taken	O
before	O
(	O
baseline	O
)	O
and	O
1	O
year	O
after	O
(	O
follow	B-PROC
-	I-PROC
up	I-PROC
)	O
THA	B-PROC
.	O

Functional	B-DEVI
instruments	I-DEVI
were	O
completed	O
by	O
patients	B-LIVB
including	O
:	O
visual	B-PROC
analog	I-PROC
scale	I-PROC
(	O
VAS	B-PROC
)	O
for	O
LBP	B-DISO
,	O
Roland	O
-	O
Morris	O
Disability	O
Questionnaire	O
(	O
RMDQ	O
)	O
,	O
and	O
Harris	B-DISO
Hip	I-DISO
Score	I-DISO
(	O
HHS	B-DISO
)	O
.	O

Comparisons	O
were	O
carried	O
out	O
at	O
baseline	O
and	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
and	O
between	O
patients	B-LIVB
with	O
and	O
without	O
LBP	B-DISO
.	O

The	O
recruited	O
69	O
patients	B-LIVB
showed	O
significantly	O
reduced	O
hip	B-DISO
flexion	I-DISO
and	O
improved	O
global	B-DISO
spinal	I-DISO
balance	I-DISO
at	O
follow	B-PROC
-	I-PROC
up	I-PROC
compared	O
with	O
baseline	O
.	O

LBP	B-DISO
was	O
reported	O
by	O
39	O
patients	B-LIVB
(	O
56	O
.	O
5	O
%	O
)	O
before	O
surgery	O
;	O
at	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
17	O
reported	O
complete	O
resolution	O
,	O
while	O
22	O
reported	O
significant	O
relief	B-DISO
.	O

Significant	O
decreases	O
in	O
VAS	B-PHYS
and	O
RMDQ	O
scores	O
in	O
lumbar	B-ANAT
spine	I-ANAT
and	O
increase	O
in	O
hip	B-ANAT
HHS	B-DISO
were	O
observed	O
.	O

THA	B-PROC
in	O
patients	B-LIVB
with	O
severe	O
hip	B-DISO
OA	I-DISO
could	O
help	O
correct	O
abnormal	O
sagittal	B-ANAT
spinal	O
-	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
and	O
relieve	O
comorbid	B-DISO
LBP	B-DISO
.	O

Improvements	O
in	O
hip	B-DISO
flexion	I-DISO
and	O
global	O
spinal	O
balance	B-PHYS
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
LBP	B-DISO
relief	B-DISO
.	O

Beyond	O
neutral	O
and	O
forbidden	O
links	O
:	O
morphological	O
matches	O
and	O
the	O
assembly	O
of	O
mutualistic	B-PHEN
hawkmoth	O
-	O
plant	B-LIVB
networks	O
A	O
major	O
challenge	O
in	O
evolutionary	O
ecology	O
is	O
to	O
understand	O
how	O
co	B-PHEN
-	I-PHEN
evolutionary	I-PHEN
processes	I-PHEN
shape	O
patterns	O
of	O
interactions	O
between	O
species	O
at	O
community	B-LIVB
level	O
.	O

Pollination	B-PHYS
of	O
flowers	B-LIVB
with	O
long	B-LIVB
corolla	I-LIVB
tubes	I-LIVB
by	O
long	O
-	O
tongued	O
hawkmoths	O
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	B-DEVI
of	O
co	B-PHYS
-	I-PHYS
evolution	I-PHYS
.	O

Recently	O
,	O
optimal	O
foraging	O
models	B-DEVI
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	O
between	O
mouthparts	O
'	O
length	O
and	O
the	O
corolla	B-LIVB
depth	O
of	O
the	O
visited	O
flowers	B-LIVB
,	O
thus	O
favouring	O
trait	B-PHYS
convergence	O
and	O
specialization	O
at	O
community	B-LIVB
level	O
.	O

Here	O
,	O
we	O
assessed	O
whether	O
hawkmoths	O
more	O
frequently	O
pollinate	B-LIVB
plants	I-LIVB
with	O
floral	O
tube	O
lengths	O
similar	O
to	O
their	O
proboscis	O
lengths	O
(	O
morphological	O
match	O
hypothesis	O
)	O
against	O
abundance	O
-based	O
processes	B-PHEN
(	O
neutral	O
hypothesis	O
)	O
and	O
ecological	B-PHYS
trait	I-PHYS
mismatches	O
constraints	O
(	O
forbidden	O
links	O
hypothesis	O
)	O
,	O
and	O
how	O
these	O
processes	B-PHEN
structure	O
hawkmoth	O
-	O
plant	B-LIVB
mutualistic	O
networks	O
from	O
five	O
communities	B-LIVB
in	O
four	O
biogeographical	B-GEOG
regions	I-GEOG
of	O
South	B-GEOG
America	I-GEOG
.	O

We	O
found	O
convergence	O
in	O
morphological	O
traits	B-PHYS
across	O
the	O
five	O
communities	B-LIVB
and	O
that	O
the	O
distribution	O
of	O
morphological	O
differences	O
between	O
hawkmoths	O
and	O
plants	B-LIVB
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	O
match	O
hypothesis	O
in	O
three	O
of	O
the	O
five	O
communities	B-LIVB
.	O

In	O
the	O
two	O
remaining	O
communities	B-LIVB
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical	B-GEOG
areas	I-GEOG
,	O
interactions	O
are	O
better	O
predicted	O
by	O
the	O
neutral	O
hypothesis	O
.	O

Our	O
findings	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co	B-PHYS
-	I-PHYS
evolution	I-PHYS
drives	O
the	O
evolution	B-PHYS
of	O
extremely	O
long	O
proboscises	O
and	O
flower	B-LIVB
tubes	I-LIVB
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	O
traits	B-PHYS
,	O
beyond	O
the	O
forbidden	O
links	O
hypothesis	O
,	O
in	O
structuring	O
interactions	O
between	O
mutualistic	O
partners	O
,	O
revealing	O
that	O
the	O
role	O
of	O
niche	B-PHEN
-	I-PHEN
based	I-PHEN
processes	I-PHEN
can	O
be	O
much	O
more	O
complex	O
than	O
previously	O
known	O
.	O

Impact	O
of	O
totally	O
laparoscopic	B-PROC
combined	O
management	O
of	O
colorectal	B-DISO
cancer	I-DISO
with	O
synchronous	O
hepatic	B-DISO
metastases	I-DISO
on	O
severity	O
of	O
complications	O
:	O
a	O
propensity	O
-	O
score	O
-based	O
analysis	B-PROC
Thanks	O
to	O
widespread	O
diffusion	O
of	O
minimally	B-PROC
invasive	I-PROC
approach	I-PROC
in	O
the	O
setting	O
of	O
both	O
colorectal	B-PROC
and	O
hepatic	B-PROC
surgeries	I-PROC
,	O
the	O
interest	O
in	O
combined	O
resections	O
for	O
colorectal	B-DISO
cancer	I-DISO
and	O
synchronous	O
liver	B-DISO
metastases	I-DISO
(	O
SCLM	B-DISO
)	O
by	O
totally	B-PROC
laparoscopic	I-PROC
approach	I-PROC
(	O
TLA	B-PROC
)	O
has	O
increased	O
.	O

Aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
outcome	O
of	O
combined	O
resections	O
for	O
SCLM	B-DISO
performed	O
by	O
TLA	B-PROC
or	O
by	O
open	O
approach	O
,	O
in	O
a	O
propensity	B-PROC
-	I-PROC
score	I-PROC
-	I-PROC
based	I-PROC
study	I-PROC
.	O

All	O
25	O
patients	B-LIVB
undergoing	O
combined	O
TLA	B-PROC
for	O
SCLM	B-DISO
at	O
San	B-OBJC
Raffaele	I-OBJC
Hospital	I-OBJC
in	O
Milano	O
were	O
compared	O
in	O
a	O
case	B-PROC
-	I-PROC
matched	I-PROC
analysis	I-PROC
with	O
25	O
out	O
of	O
91	O
patients	B-LIVB
undergoing	O
totally	B-PROC
open	I-PROC
approach	I-PROC
(	O
TOA	B-LIVB
group	I-LIVB
)	O
.	O

Groups	B-LIVB
were	O
matched	O
with	O
1	O
:	O
2	O
ratio	O
using	O
propensity	O
scores	O
based	O
on	O
covariates	O
representing	O
disease	O
severity	O
.	O

Main	O
endpoints	O
were	O
postoperative	O
morbidity	O
and	O
long	O
-	O
term	O
outcome	O
.	O

The	O
Modified	B-PROC
Accordion	I-PROC
Severity	I-PROC
Grading	I-PROC
System	I-PROC
was	O
used	O
to	O
quantify	O
complications	O
.	O

The	O
groups	O
resulted	O
comparable	O
in	O
terms	O
of	O
patients	B-LIVB
and	O
disease	B-DISO
characteristics	I-DISO
.	O

The	O
TLA	B-LIVB
group	I-LIVB
,	O
as	O
compared	O
to	O
the	O
TOA	B-LIVB
group	I-LIVB
,	O
had	O
lower	O
blood	B-DISO
loss	I-DISO
(	O
350	O
vs	O
600	O
mL	O
)	O
,	O
shorter	O
postoperative	O
stay	O
(	O
9	O
vs	O
12	O
days	O
)	O
,	O
lower	O
postoperative	O
morbidity	O
index	O
(	O
0	O
.	O
14	O
vs	O
0	O
.	O

20	O
)	O
and	O
severity	O
score	O
for	O
complicated	O
patients	B-LIVB
(	O
0	O
.	O
60	O
vs	O
0	O
.	O
85	O
)	O
.	O

Colonic	B-PROC
anastomosis	I-PROC
leakage	B-DISO
had	O
the	O
highest	O
fractional	O
complication	O
burden	O
in	O
both	O
groups	B-LIVB
.	O

In	O
spite	O
of	O
comparable	O
long	O
-	O
term	O
overall	O
survival	O
,	O
the	O
TLA	B-LIVB
group	I-LIVB
had	O
better	O
recurrence	B-DISO
-	I-DISO
free	I-DISO
survival	I-DISO
.	O

TLA	B-PROC
for	O
combined	O
resections	O
is	O
feasible	O
,	O
and	O
its	O
indications	O
can	O
be	O
widened	O
to	O
encompass	O
a	O
larger	O
population	O
of	O
patients	B-LIVB
,	O
provided	O
its	O
benefits	O
in	O
terms	O
of	O
reduced	O
overall	O
risk	O
and	O
severity	O
of	O
complications	O
,	O
rapid	O
functional	B-DISO
recovery	I-DISO
and	O
favorable	O
long	O
-	O
term	O
outcomes	O
.	O

Application	O
of	O
an	O
Analytical	O
Solution	O
as	O
a	O
Screening	B-PROC
Tool	O
for	O
Sea	B-OBJC
Water	I-OBJC
Intrusion	B-PHEN
Sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
into	O
aquifers	B-PHEN
is	O
problematic	B-DISO
in	O
many	O
coastal	O
areas	O
.	O

The	O
physics	O
and	O
chemistry	O
of	O
this	O
issue	O
are	O
complex	O
,	O
and	O
sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
remains	O
challenging	O
to	O
quantify	O
.	O

Simple	O
assessment	O
tools	O
like	O
analytical	O
models	O
offer	O
advantages	O
of	O
rapid	O
application	O
,	O
but	O
their	O
applicability	O
to	O
field	O
situations	O
is	O
unclear	O
.	O

This	O
study	B-PROC
examines	O
the	O
reliability	O
of	O
a	O
popular	O
sharp	O
-	O
interface	O
analytical	O
approach	O
for	O
estimating	O
the	O
extent	O
of	O
sea	B-OBJC
water	I-OBJC
in	O
a	O
homogeneous	O
coastal	O
aquifer	B-PHEN
subjected	O
to	O
pumping	O
and	O
regional	B-PHEN
flow	I-PHEN
effects	O
and	O
under	O
steady	B-PHEN
-	I-PHEN
state	I-PHEN
conditions	I-PHEN
.	O

The	O
analytical	O
model	O
is	O
tested	O
against	O
observations	O
from	O
Canada	B-GEOG
,	O
the	O
United	B-GEOG
States	I-GEOG
,	O
and	O
Australia	B-GEOG
to	O
assess	B-PROC
its	O
utility	O
as	O
an	O
initial	O
approximation	B-PROC
of	O
sea	B-OBJC
water	I-OBJC
extent	O
for	O
the	O
purposes	O
of	O
rapid	O
groundwater	O
management	O
decision	B-PHYS
making	I-PHYS
.	O

The	O
occurrence	O
of	O
sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
resulting	O
in	O
increased	O
salinity	B-PHEN
at	O
pumping	B-OBJC
wells	I-OBJC
was	O
correctly	O
predicted	O
in	O
approximately	O
60	O
%	O
of	O
cases	O
.	O

Application	O
of	O
a	O
correction	O
to	O
account	O
for	O
dispersion	O
did	O
not	O
markedly	O
improve	B-DISO
the	O
results	O
.	O

Failure	O
of	O
the	O
analytical	O
model	O
to	O
provide	O
correct	O
predictions	O
can	O
be	O
attributed	O
to	O
mismatches	O
between	O
its	O
simplifying	O
assumptions	O
and	O
more	O
complex	O
field	O
settings	O
.	O

The	O
best	O
results	O
occurred	O
where	O
the	O
toe	O
of	O
the	O
salt	B-CHEM
water	I-CHEM
wedge	O
is	O
expected	O
to	O
be	O
the	O
closest	O
to	O
the	O
coast	B-GEOG
under	O
predevelopment	O
conditions	O
.	O

Predictions	O
were	O
the	O
poorest	O
for	O
aquifers	B-PHEN
where	O
the	O
salt	B-CHEM
water	I-CHEM
wedge	O
was	O
expected	O
to	O
extend	O
further	O
inland	B-GEOG
under	O
predevelopment	O
conditions	O
and	O
was	O
therefore	O
more	O
dispersive	O
prior	O
to	O
pumping	O
.	O

Sharp	O
-	O
interface	O
solutions	O
remain	O
useful	O
tools	O
to	O
screen	B-PROC
for	O
the	O
vulnerability	B-DISO
of	O
coastal	O
aquifers	B-PHEN
to	O
sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
,	O
although	O
the	O
significant	O
sources	O
of	O
uncertainty	O
identified	O
in	O
this	O
study	B-PROC
require	O
careful	O
consideration	O
to	O
avoid	O
misinterpreting	O
sharp	O
-	O
interface	O
results	O
.	O

Patient	B-LIVB
-	O
Physician	B-LIVB
Discordance	O
in	O
Global	B-PROC
Assessment	I-PROC
in	O
Rheumatoid	B-DISO
Arthritis	I-DISO
:	O
A	O
Systematic	O
Literature	O
Review	O
With	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
The	O
integration	O
of	O
the	O
patient	B-LIVB
in	O
therapeutic	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
is	O
important	O
in	O
the	O
management	B-PROC
of	O
rheumatoid	B-DISO
arthritis	I-DISO
(	O
RA	B-DISO
)	O
,	O
but	O
the	O
patient	B-LIVB
opinion	B-PHYS
regarding	O
disease	B-DISO
status	O
may	O
differ	O
from	O
the	O
physician	B-LIVB
's	I-LIVB
opinion	B-PHYS
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
assess	O
in	O
the	O
published	O
literature	O
the	O
frequency	O
and	O
drivers	O
of	O
patient	B-LIVB
-	O
physician	B-LIVB
discordance	O
in	O
global	B-PROC
assessment	I-PROC
in	O
RA	B-DISO
.	O

A	O
systematic	O
literature	O
review	O
of	O
all	O
articles	O
published	O
up	O
to	O
January	O
2015	O
in	O
Medline	O
or	O
Embase	O
,	O
reporting	O
discordance	O
in	O
RA	B-DISO
,	O
was	O
conducted	O
by	O
2	O
investigators	B-LIVB
.	O

Discordance	O
was	O
defined	O
based	O
on	O
the	O
absolute	O
difference	O
of	O
patient	O
global	O
(	O
PGA	O
)	O
and	O
physician	B-PROC
global	I-PROC
assessments	I-PROC
(	O
PhGA	B-PROC
)	O
on	O
0	O
-	O
10	O
-	O
cm	O
scales	O
.	O

The	O
frequency	O
of	O
discordance	O
and	O
its	O
predictors	B-DISO
were	O
collected	O
in	O
each	O
study	B-PROC
.	O

Frequencies	O
of	O
discordance	O
were	O
pooled	O
by	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
using	O
random	O
effect	O
.	O

In	O
all	O
,	O
12	O
studies	B-PROC
were	O
selected	O
(	O
i	O
.	O
e	O
.	O
,	O
11	O
,	O
879	O
patients	B-LIVB
)	O
:	O
weighted	O
mean	O
±	O
SD	O
age	B-PHYS
was	O
55	O
.	O
1	O
±	O
13	O
.	O
9	O
years	O
,	O
weighted	O
mean	O
±	O
SD	O
disease	O
duration	O
was	O
10	O
.	O
4	O
±	O
9	O
.	O

3	O
years	O
,	O
and	O
80	O
.	O

7	O
%	O
were	O
women	B-LIVB
.	O

The	O
value	O
of	O
the	O
difference	O
|	O
PGA	O
-	O
PhGA	B-PROC
|	O
defining	O
discordance	O
varied	O
between	O
≥0	O
.	O

5	O
cm	O
(	O
n	O
=	O
2	O
studies	O
)	O
to	O
≥3	O
cm	O
(	O
n	O
=	O
5	O
studies	O
)	O
;	O
the	O
weighted	O
mean	O
value	O
was	O
2	O
.	O
7	O
cm	O
.	O

The	O
pooled	O
percentage	O
of	O
patients	B-LIVB
with	O
discordance	O
was	O
43	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
36	O
%	O
-	O
51	O
%	O
;	O
range	O
25	O
%	O
-	O
76	O
%	O
)	O
.	O

PGA	O
was	O
usually	O
higher	O
than	O
PhGA	B-PROC
.	O

The	O
drivers	O
of	O
PGA	O
were	O
pain	B-DISO
and	O
functional	O
incapacity	B-PHYS
,	O
whereas	O
drivers	O
of	O
PhGA	B-PROC
were	O
joint	O
counts	O
and	O
acute	B-CHEM
-	I-CHEM
phase	I-CHEM
reactants	I-CHEM
.	O

Discordance	O
in	O
global	B-PROC
assessment	I-PROC
was	O
most	O
frequently	O
defined	O
as	O
a	O
difference	O
of	O
3	O
points	O
or	O
more	O
;	O
even	O
with	O
such	O
a	O
stringent	O
definition	O
,	O
up	O
to	O
half	O
the	O
patients	B-LIVB
were	O
found	O
to	O
be	O
discordant	O
.	O

The	O
long	O
-	O
term	O
consequences	O
of	O
this	O
discordance	O
remain	O
to	O
be	O
determined	O
.	O

Nosocomial	B-DISO
pneumonia	I-DISO
caused	O
by	O
methicillin	B-LIVB
-	I-LIVB
resistant	I-LIVB
Staphylococcus	I-LIVB
aureus	I-LIVB
treated	B-PROC
with	I-PROC
linezolid	B-CHEM
or	O
vancomycin	B-CHEM
:	O
A	O
secondary	O
economic	O
analysis	O
of	O
resource	O
use	O
from	O
a	O
Spanish	B-GEOG
perspective	O
Adopting	O
a	O
unique	O
Spanish	B-GEOG
perspective	O
,	O
this	O
study	B-PROC
aims	O
to	O
assess	O
healthcare	O
resource	O
utilization	O
(	O
HCRU	O
)	O
and	O
the	O
costs	O
of	O
treating	O
nosocomial	B-DISO
pneumonia	I-DISO
(	O
NP	B-DISO
)	O
produced	O
by	O
methicillin	B-LIVB
-	I-LIVB
resistant	I-LIVB
Staphylococcus	I-LIVB
aureus	I-LIVB
(	O
MRSA	B-LIVB
)	O
in	O
hospitalized	B-DISO
adults	I-DISO
using	O
linezolid	B-CHEM
or	O
vancomycin	B-CHEM
.	O

An	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal	B-DISO
failure	I-DISO
rate	O
and	O
related	O
economic	O
outcomes	O
between	O
study	O
groups	O
.	O

An	O
economic	O
post	B-PROC
hoc	I-PROC
evaluation	I-PROC
of	O
a	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
multicenter	B-PROC
phase	I-PROC
4	I-PROC
study	I-PROC
was	O
carried	O
out	O
.	O

Nosocomial	B-DISO
pneumonia	I-DISO
due	O
to	O
MRSA	B-LIVB
in	O
hospitalized	B-DISO
adults	I-DISO
.	O

The	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
population	B-LIVB
comprised	O
224	O
linezolid	B-CHEM
-	O
and	O
224	O
vancomycin	B-CHEM
-	O
treated	B-PROC
patients	B-LIVB
.	O

Costs	O
and	O
HCRU	O
were	O
evaluated	O
between	O
patients	B-LIVB
administered	O
either	O
linezolid	B-CHEM
or	O
vancomycin	B-CHEM
,	O
and	O
between	O
patients	B-LIVB
who	O
developed	O
renal	B-DISO
failure	I-DISO
and	O
those	O
who	O
did	O
not	O
.	O

Analysis	O
of	O
HCRU	O
outcomes	O
and	O
costs	O
.	O

Total	O
costs	O
were	O
similar	O
between	O
the	O
linezolid	B-CHEM
-	O
(	O
€	O
17	O
,	O
782±€9	O
,	O
615	O
)	O
and	O
vancomycin	B-CHEM
-	O
treated	B-PROC
patients	B-LIVB
(	O
€	O
17	O
,	O
423±€9	O
,	O
460	O
)	O
(	O
P	O
=	O
.	O

69	O
)	O
.	O

The	O
renal	B-DISO
failure	I-DISO
rate	O
was	O
significantly	O
lower	O
in	O
the	O
linezolid	B-CHEM
-	O
treated	B-PROC
patients	B-LIVB
(	O
4	O
%	O
vs	O
.	O

15	O
%	O
;	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
total	O
costs	O
tended	O
to	O
be	O
higher	O
in	O
patients	B-LIVB
who	O
developed	O
renal	B-DISO
failure	I-DISO
(	O
€	O
19	O
,	O
626±€10	O
,	O
840	O
vs	O
.	O

€	O
17	O
,	O
388±€9	O
,	O
369	O
;	O
P	O
=	O
.	O

14	O
)	O
.	O

Among	O
the	O
patients	B-LIVB
who	O
developed	O
renal	B-DISO
failure	I-DISO
,	O
HCRU	O
(	O
days	O
on	O
mechanical	B-PROC
ventilation	I-PROC
:	O
13	O
.	O

2±10	O
.	O

7	O
vs	O
.	O

7	O
.	O

6±3	O
.	O

6	O
days	O
;	O
P	O
=	O
.	O

21	O
;	O
ICU	O
stay	O
:	O
14	O
.	O

4±10	O
.	O

5	O
vs	O
.	O
9	O
.	O

9±6	O
.	O

6	O
days	O
;	O
P	O
=	O
.	O

30	O
;	O
hospital	O
stay	O
:	O
19	O
.	O

5±9	O
.	O

5	O
vs	O
.	O
16	O
.	O

1±11	O
.	O
0	O
days	O
;	O
P	O
=	O
.	O

26	O
)	O
and	O
cost	O
(	O
€	O
17	O
,	O
219±€8	O
,	O
792	O
vs	O
.	O

€	O
20	O
,	O
263±€11	O
,	O
350	O
;	O
P	O
=	O
.	O

51	O
)	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	B-CHEM
-	O
vs	O
.	O

vancomycin	B-CHEM
-	O
treated	B-PROC
patients	B-LIVB
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	O
per	O
patient	B-LIVB
-	O
day	O
between	O
cohorts	B-LIVB
after	O
correcting	O
for	O
mortality	O
(	O
€	O
1000	O
vs	O
.	O

€	O
1	O
,	O
010	O
;	O
P	O
=	O
.	O

98	O
)	O
.	O

From	O
a	O
Spanish	B-GEOG
perspective	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	O
between	O
the	O
linezolid	B-CHEM
and	O
vancomycin	B-CHEM
pneumonia	B-DISO
cohorts	B-LIVB
.	O

The	O
drug	O
cost	O
corresponding	O
to	O
linezolid	B-CHEM
was	O
partially	O
offset	O
by	O
fewer	O
renal	B-DISO
failure	I-DISO
adverse	B-DISO
events	I-DISO
.	O

The	O
Role	O
of	O
TRAF4	O
and	O
B3GAT1	O
Gene	B-PHYS
Expression	I-PHYS
in	O
the	O
Food	B-DISO
Hypersensitivity	I-DISO
and	O
Insect	B-DISO
Venom	I-DISO
Allergy	I-DISO
in	O
Mastocytosis	B-DISO
Mastocytosis	B-DISO
is	O
an	O
uncommon	O
disease	B-DISO
classified	O
as	O
a	O
myeloproliferative	B-DISO
neoplasm	I-DISO
,	O
however	O
,	O
its	O
symptoms	B-DISO
are	O
broad	O
and	O
place	O
patients	B-LIVB
at	O
crossroads	O
between	O
dermatology	O
,	O
hematology	O
and	O
allergology	O
.	O

Patients	B-LIVB
with	O
mastocytosis	B-DISO
often	O
suffer	O
from	O
symptoms	B-DISO
resulting	O
from	O
the	O
activation	O
and	O
release	O
of	O
mediators	O
from	O
the	O
mast	B-ANAT
cells	I-ANAT
,	O
such	O
as	O
generalized	O
itching	B-DISO
,	O
redness	B-DISO
,	O
headache	B-DISO
,	O
abdominal	B-DISO
cramps	I-DISO
,	O
diarrhea	B-DISO
,	O
bone	B-DISO
pain	I-DISO
or	O
arthritis	B-DISO
,	O
hypotension	B-DISO
and	O
shock	B-DISO
.	O

The	O
possible	O
severe	O
,	O
fatal	O
or	O
near	O
fatal	O
reactions	O
caused	O
by	O
food	B-DISO
hypersensitivity	I-DISO
are	O
reasons	O
for	O
the	O
research	O
focused	O
on	O
marker	B-PHYS
identification	O
.	O

The	O
aim	O
of	O
the	O
study	B-PROC
was	O
to	O
analyse	O
the	O
gene	B-PHYS
expression	I-PHYS
differences	O
in	O
mastocytosis	B-DISO
patients	B-LIVB
with	O
and	O
without	O
food	B-DISO
and	O
drug	B-DISO
hypersensitivity	I-DISO
and	O
insect	B-DISO
venom	I-DISO
allergy	I-DISO
(	O
IVA	B-DISO
)	O
.	O

A	O
total	O
of	O
57	O
Caucasian	B-LIVB
patients	B-LIVB
with	O
mastocytosis	B-DISO
were	O
studied	O
[	O
median	O
age	B-PHYS
41	O
.	O
8	O
;	O
range	O
18	O
-	O
77	O
years	O
;	O
15	O
(	O
26	O
.	O
3	O
%	O
)	O
males	B-PHYS
and	O
42	O
(	O
73	O
.	O
7	O
%	O
)	O
females	B-PHYS
]	O
.	O

Quantitative	B-PROC
RT	I-PROC
-	I-PROC
PCRs	I-PROC
of	O
11	O
genes	O
plus	O
ribosomal	B-CHEM
18S	I-CHEM
RNA	I-CHEM
were	O
run	O
.	O

Symptoms	B-DISO
of	O
food	B-DISO
hypersensitivity	I-DISO
were	O
found	O
in	O
12	O
patients	B-LIVB
(	O
21	O
%	O
)	O
,	O
including	O
3	O
patients	B-LIVB
(	O
13	O
%	O
)	O
with	O
cutaneous	B-DISO
mastocytosis	I-DISO
(	O
CM	B-DISO
)	O
,	O
and	O
9	O
(	O
28	O
%	O
)	O
with	O
indolent	B-DISO
systemic	I-DISO
mastocytosis	I-DISO
(	O
ISM	B-DISO
)	O
.	O

IVA	B-DISO
was	O
confirmed	O
in	O
13	O
patients	B-LIVB
(	O
22	O
.	O
8	O
%	O
)	O
including	O
6	O
patients	B-LIVB
(	O
10	O
.	O
5	O
%	O
)	O
with	O
CM	B-DISO
,	O
and	O
7	O
patients	B-LIVB
(	O
12	O
.	O

3	O
%	O
)	O
with	O
ISM	B-DISO
.	O

Drug	B-DISO
hypersensitivity	I-DISO
was	O
diagnosed	B-DISO
in	O
10	O
patients	B-LIVB
(	O
17	O
.	O
5	O
%	O
)	O
.	O

Significant	O
differences	O
in	O
the	O
gene	B-PHYS
expression	I-PHYS
were	O
found	O
for	O
TRAF4	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
in	O
the	O
comparison	O
of	O
the	O
mastocytosis	B-DISO
patients	B-LIVB
with	O
and	O
without	O
concomitant	O
food	B-DISO
hypersensitivity	I-DISO
.	O

Furthermore	O
significant	O
differences	O
were	O
found	O
in	O
gene	B-PHYS
expression	I-PHYS
for	O
B3GAT1	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
in	O
patients	B-LIVB
with	O
IVA	B-DISO
compared	O
to	O
patients	B-LIVB
without	O
insect	B-DISO
sting	I-DISO
anaphylaxis	B-DISO
in	O
the	O
medical	O
history	O
.	O

The	O
expression	B-PHYS
of	O
studied	O
genes	O
did	O
not	O
differ	O
according	O
to	O
the	O
presence	O
of	O
drug	B-DISO
hypersensitivity	I-DISO
.	O

The	O
TRAF4	O
expression	B-PHYS
was	O
higher	O
in	O
mastocytosis	B-DISO
patients	B-LIVB
with	O
food	B-DISO
hypersensitivity	I-DISO
in	O
their	O
medical	B-DISO
history	I-DISO
,	O
the	O
B3GAT1	O
expression	B-PHYS
was	O
lower	O
in	O
mastocytosis	B-DISO
patients	B-LIVB
with	O
IVA	B-DISO
in	O
history	O
.	O

Generalized	B-DISO
Weakness	I-DISO
in	O
a	O
Transplant	B-DISO
Patient	B-LIVB
:	O
A	O
Case	O
Presentation	O
Generalized	B-DISO
weakness	I-DISO
in	O
transplant	B-DISO
patients	B-LIVB
is	O
a	O
major	O
complaint	O
in	O
tertiary	O
rehabilitation	B-OBJC
hospitals	I-OBJC
.	O

The	O
diagnosis	B-DISO
and	O
management	B-PROC
of	O
generalized	B-DISO
weakness	I-DISO
in	O
this	O
population	B-LIVB
pose	O
challenges	O
for	O
physicians	B-LIVB
.	O

We	O
present	O
the	O
case	O
of	O
a	O
transplant	B-DISO
patient	B-LIVB
with	O
generalized	B-DISO
weakness	I-DISO
who	O
was	O
eventually	O
diagnosed	B-DISO
with	O
calciphylaxis	B-DISO
using	O
a	O
multidisciplinary	B-PROC
diagnostic	I-PROC
approach	I-PROC
of	O
electrodiagnostics	B-PROC
,	O
vascular	B-ANAT
study	B-PROC
,	O
and	O
skin	B-PROC
biopsy	I-PROC
.	O

Calciphylaxis	B-DISO
is	O
a	O
rare	O
cutaneous	B-DISO
disorder	I-DISO
that	O
mimics	O
other	O
collagen	B-DISO
vascular	I-DISO
diseases	I-DISO
in	O
its	O
presentation	O
and	O
fulminant	O
course	O
.	O

Physiatrists	B-LIVB
should	O
be	O
cognizant	O
of	O
calciphylaxis	B-DISO
,	O
as	O
it	O
signals	O
a	O
poor	B-DISO
prognosis	I-DISO
if	O
not	O
correctly	O
diagnosed	O
and	O
treated	O
in	O
a	O
timely	O
manner	O
,	O
with	O
high	O
incidence	O
of	O
sepsis	B-DISO
,	O
wound	B-DISO
pain	I-DISO
,	O
and	O
disability	B-DISO
.	O

V	O
.	O

Use	O
of	O
ecoacoustics	O
to	O
determine	O
biodiversity	O
patterns	O
across	O
ecological	O
gradients	O
The	O
variety	O
of	O
local	O
animal	B-LIVB
sounds	B-PHEN
characterizes	O
a	O
landscape	O
.	O

We	O
used	O
ecoacoustics	O
to	O
noninvasively	O
assess	O
the	O
species	O
richness	O
of	O
various	O
biotopes	B-GEOG
typical	O
of	O
an	O
ecofriendly	B-PHEN
forest	I-PHEN
plantation	I-PHEN
with	O
diverse	O
ecological	O
gradients	O
and	O
both	O
nonnative	B-DISO
and	O
indigenous	O
vegetation	B-LIVB
.	O

The	O
reference	O
area	B-GEOG
was	O
an	O
adjacent	O
large	O
World	B-GEOG
Heritage	I-GEOG
Site	I-GEOG
protected	I-GEOG
area	I-GEOG
(	O
PA	B-GEOG
)	O
.	O

All	O
sites	O
were	O
in	O
a	O
global	B-GEOG
biodiversity	I-GEOG
hotspot	I-GEOG
.	O

Our	O
results	O
showed	O
how	O
taxa	O
segregated	O
into	O
various	O
biotopes	B-GEOG
.	O

We	O
identified	O
65	O
singing	O
species	O
,	O
including	O
birds	B-LIVB
,	O
frogs	B-LIVB
,	O
crickets	O
,	O
and	O
katydids	O
.	O

Large	O
,	O
natural	O
,	O
protected	O
grassland	O
sites	O
in	O
the	O
PA	B-GEOG
had	O
the	O
highest	O
mean	O
acoustic	O
diversity	O
(	O
14	O
.	O
1	O
species	O
/	O
site	O
)	O
.	O

Areas	O
covered	O
in	O
nonnative	B-LIVB
timber	I-LIVB
or	O
grass	B-LIVB
species	O
were	O
devoid	O
of	O
acoustic	O
species	O
.	O

Sites	O
grazed	O
by	O
native	O
and	O
domestic	O
megaherbivores	B-LIVB
were	O
fairly	O
rich	O
(	O
5	O
.	O
1	O
)	O
in	O
acoustic	O
species	O
but	O
none	O
were	O
unique	O
to	O
this	O
habitat	O
type	O
,	O
where	O
acoustic	O
diversity	O
was	O
greater	O
than	O
in	O
intensively	O
managed	O
grassland	O
sites	O
(	O
0	O
.	O
04	O
)	O
.	O

Natural	B-PHEN
vegetation	I-PHEN
patches	O
inside	O
the	O
plantation	O
mosaic	O
supported	O
high	O
mean	O
acoustic	O
diversity	O
(	O
indigenous	O
forests	B-PHEN
7	O
.	O
6	O
,	O
grasslands	O
8	O
.	O
0	O
,	O
wetlands	B-PHEN
9	O
.	O
1	O
)	O
,	O
which	O
increased	O
as	O
plant	B-LIVB
heterogeneity	O
and	O
patch	O
size	O
increased	O
.	O

Indigenous	O
forest	B-PHEN
patches	I-PHEN
within	O
the	O
plantation	O
mosaic	O
contained	O
a	O
highly	O
characteristic	O
acoustic	O
species	O
assemblage	O
,	O
emphasizing	O
their	O
complementary	O
contribution	O
to	O
local	O
biodiversity	O
.	O

Overall	O
,	O
acoustic	B-PHEN
signals	I-PHEN
determined	O
spatial	O
biodiversity	O
patterns	O
and	O
can	O
be	O
a	O
useful	O
tool	O
for	O
guiding	O
conservation	O
.	O

A	O
Randomized	B-PROC
Controlled	I-PROC
Noninferiority	I-PROC
Trial	I-PROC
of	O
Single	O
Dose	O
of	O
Oral	B-CHEM
Dexamethasone	I-CHEM
Versus	O
5	O
Days	O
of	O
Oral	B-CHEM
Prednisone	I-CHEM
in	O
Acute	O
Adult	B-LIVB
Asthma	B-DISO
Oral	B-CHEM
dexamethasone	I-CHEM
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	B-CHEM
prednisone	I-CHEM
but	O
has	O
a	O
longer	O
half	O
-	O
life	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	B-CHEM
dexamethasone	I-CHEM
plus	O
4	O
days	O
of	O
placebo	B-CHEM
is	O
not	O
inferior	O
to	O
5	O
days	O
of	O
oral	B-CHEM
prednisone	I-CHEM
in	O
treatment	O
of	O
adults	B-LIVB
with	O
mild	B-DISO
to	O
moderate	B-DISO
asthma	B-DISO
exacerbations	I-DISO
to	O
prevent	O
relapse	B-PHEN
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	B-DISO
treatment	I-DISO
for	O
persistent	B-DISO
or	O
worsening	O
asthma	B-DISO
within	O
14	O
days	O
.	O

Adult	B-LIVB
emergency	B-OBJC
department	I-OBJC
patients	B-LIVB
(	O
aged	B-PHYS
18	O
to	O
55	O
years	O
)	O
were	O
randomized	B-PROC
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	B-CHEM
dexamethasone	I-CHEM
with	O
4	O
days	O
of	O
placebo	B-CHEM
or	O
a	O
5	O
-	O
day	O
course	O
of	O
oral	B-CHEM
prednisone	I-CHEM
60	O
mg	O
a	O
day	O
.	O

Outcomes	O
including	O
relapse	B-PHEN
were	O
assessed	O
by	O
a	O
follow	B-PROC
-	I-PROC
up	I-PROC
telephone	I-PROC
interview	I-PROC
at	O
2	O
weeks	O
.	O

One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	B-CHEM
and	O
203	O
prednisone	B-CHEM
subjects	B-LIVB
completed	O
the	O
study	O
regimen	O
and	O
telephone	B-PROC
follow	I-PROC
-	I-PROC
up	I-PROC
.	O

The	O
dexamethasone	B-CHEM
group	O
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8	O
%	O
difference	O
between	O
groups	O
for	O
noninferiority	O
in	O
relapse	B-PHEN
rates	O
within	O
14	O
days	O
(	O
12	O
.	O

1	O
%	O
versus	O
9	O
.	O

8	O
%	O
;	O
difference	O
2	O
.	O

3	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-4	O
.	O
1	O
%	O
to	O
8	O
.	O
6	O
%	O
)	O
.	O

Subjects	B-LIVB
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	B-PROC
for	O
their	O
relapse	B-PHEN
visit	B-PROC
(	O
dexamethasone	B-CHEM
3	O
.	O
4	O
%	O
versus	O
prednisone	B-CHEM
2	O
.	O
9	O
%	O
;	O
difference	O
0	O
.	O
5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-4	O
.	O

1	O
%	O
to	O
3	O
.	O
1	O
%	O
)	O
.	O

Adverse	O
effect	O
rates	O
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	O
.	O

A	O
single	O
dose	O
of	O
oral	B-CHEM
dexamethasone	I-CHEM
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	B-CHEM
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	B-LIVB
with	O
mild	B-DISO
to	O
moderate	B-DISO
asthma	B-DISO
exacerbations	I-DISO
.	O

Enhanced	O
compliance	B-DISO
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	B-CHEM
regardless	O
.	O

Relationship	O
between	O
XspI	B-CHEM
Site	B-DISO
Polymorphisms	I-DISO
of	O
LDL	O
-	O
R	O
Gene	O
and	O
Serum	B-CHEM
IL	I-CHEM
-	I-CHEM
2	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
in	O
Patients	B-LIVB
with	O
Hypercholesterolemia	B-DISO
Relationship	O
has	O
been	O
identified	O
in	O
sporadic	B-DISO
reports	I-DISO
between	O
polymorphisms	B-PHYS
and	O
hypercholesterolemia	B-DISO
.	O

However	O
,	O
the	O
relationship	O
between	O
inflammatory	O
cytokines	B-CHEM
and	O
polymorphism	B-PHYS
of	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDL	O
-	O
R	O
)	O
gene	O
in	O
hypercholesterolemia	B-DISO
is	O
unclear	B-DISO
.	O

This	O
study	B-PROC
aimed	O
to	O
explore	O
the	O
relationship	O
and	O
significance	O
between	O
polymorphisms	B-PHYS
of	O
LDL	O
-	O
R	O
gene	O
and	O
serum	B-CHEM
Interleukin	I-CHEM
-	I-CHEM
2	I-CHEM
(	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
)	O
,	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
in	O
patients	B-LIVB
with	O
hypercholesterolemia	B-DISO
.	O

PCR	B-PROC
-	I-PROC
RFLP	I-PROC
and	O
direct	B-PROC
DNA	I-PROC
sequencing	I-PROC
assay	I-PROC
were	O
employed	B-DISO
to	O
determine	O
polymorphism	B-PHYS
of	O
LDL	O
-	O
R	O
gene	O
in	O
900	O
patients	B-LIVB
with	O
hypercholesterolemia	B-DISO
and	O
400	O
healthy	O
cases	O
.	O

ELISA	B-PROC
was	O
applied	O
to	O
assay	O
serum	O
concentration	O
of	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
.	O

Blood	B-CHEM
lipid	I-CHEM
indexes	O
were	O
tested	O
in	O
all	O
cases	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
level	O
of	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
increased	O
significantly	O
,	O
while	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
decreased	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Correlation	B-PROC
analysis	I-PROC
showed	O
that	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
was	O
positively	B-DISO
correlated	O
with	O
total	B-CHEM
cholesterol	I-CHEM
(	O
TC	B-CHEM
)	O
,	O
LDL	B-CHEM
-	I-CHEM
c	I-CHEM
,	O
and	O
genotype	B-PHYS
(	O
r	O
=	O
0	O
.	O

542	O
,	O
0	O
.	O
410	O
,	O
0	O
.	O
598	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
negatively	B-DISO
correlated	O
with	O
HDL	B-CHEM
-	I-CHEM
c	I-CHEM
(	O
r	O
=	O
-0	O
.	O

352	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Negative	B-DISO
relationship	O
also	O
was	O
found	O
between	O
TC	B-CHEM
,	O
LDL	B-CHEM
-	I-CHEM
c	I-CHEM
,	O
genotype	B-PHYS
,	O
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
(	O
r	O
=	O
-0	O
.	O

452	O
,	O
-0	O
.	O
390	O
,	O
-0	O
.	O

613	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
positive	B-DISO
correlation	O
between	O
HDL	B-CHEM
-	I-CHEM
c	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
(	O
r	O
=	O
0	O
.	O

398	O

,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Multiple	O
linear	O
regression	O
showed	O
that	O
genotypes	B-PHYS
and	O
TC	B-CHEM
were	O
independent	O
factors	O
affecting	O
the	O
levels	B-PROC
of	I-PROC
IL	I-PROC
-	I-PROC
2	I-PROC
and	O
IL	B-PROC
-	I-PROC
10	I-PROC
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

IL	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
were	O
related	O
to	O
gene	B-PHYS
polymorphisms	I-PHYS
of	O
LDL	O
-	O
R	O
,	O
which	O
might	O
be	O
involved	O
in	O
the	O
development	O
and	O
progress	O
of	O
hypercholesterolemia	B-DISO
.	O

HERG1	B-CHEM
potassium	B-CHEM
channel	I-CHEM
expression	B-PHYS
in	O
potentially	O
malignant	B-DISO
disorders	I-DISO
of	O
the	O
oral	B-ANAT
mucosa	I-ANAT
and	O
prognostic	O
relevance	O
in	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
HERG1	B-CHEM
potassium	B-CHEM
channel	I-CHEM
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	B-PHYS
proliferation	I-PHYS
.	O

HERG1	B-CHEM
protein	I-CHEM
expression	B-PHYS
was	O
analyzed	B-PROC
by	O
immunohistochemistry	B-PROC
(	O
IHC	B-PROC
)	O
in	O
62	O
patients	B-LIVB
with	O
oral	B-DISO
leukoplakias	I-DISO
and	O
100	O
patients	B-LIVB
with	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinomas	I-DISO
(	O
OSCC	B-DISO
)	O
.	O

HERG1	O
mRNA	B-CHEM
levels	O
were	O
assessed	O
by	O
real	B-PROC
-	I-PROC
time	I-PROC
reverse	I-PROC
transcriptase	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
(	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
)	O
in	O
22	O
patients	B-LIVB
with	O
primary	O
head	B-DISO
and	I-DISO
neck	I-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
HNSCC	B-DISO
)	O
.	O

Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	B-CHEM
expression	B-PHYS
and	O
tobacco	O
consumption	O
,	O
disease	B-PROC
stage	I-PROC
,	O
tumor	B-DISO
differentiation	B-PHYS
,	O
tumor	B-DISO
recurrence	I-DISO
,	O
and	O
reduced	O
survival	O
.	O

There	O
was	O
no	O
association	O
between	O
HERG1	B-CHEM
expression	B-PHYS
and	O
the	O
risk	O
of	O
progression	B-DISO
from	O
oral	B-DISO
leukoplakia	I-DISO
to	O
OSCC	B-DISO
.	O

In	O
addition	O
,	O
a	O
high	O
proportion	O
of	O
tumors	B-DISO
(	O
80	O
%	O
)	O
showed	O
increased	O
HERG1	O
mRNA	B-CHEM
levels	O
compared	O
to	O
normal	O
mucosa	O
from	O
nononcologic	B-LIVB
patients	I-LIVB
.	O

Aberrant	O
HERG1	B-CHEM
expression	B-PHYS
increases	O
as	O
oral	O
tumorigenesis	B-DISO
progresses	I-DISO
from	O
oral	B-DISO
hyperplasia	I-DISO
to	O
OSCC	B-DISO
.	O

Increased	O
HERG1	O
mRNA	B-CHEM
levels	O
were	O
also	O
frequently	O
detected	B-DISO
in	O
OSCC	B-DISO
and	O
other	O
HNSCC	B-DISO
subsites	O
.	O

HERG1	B-CHEM
expression	B-PHYS
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	B-DISO
progression	I-DISO
and	O
a	O
potential	O
poor	O
prognostic	O
biomarker	B-PHYS
for	O
OSCC	B-DISO
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Head	O
Neck	O
38	O
:	O
1708	O
-	O
1716	O
,	O
2016	O
.	O

Malignancy	B-DISO
is	O
associated	O
with	O
microcalcification	B-DISO
and	O
higher	O
AP	O
/	O
T	O
ratio	O
in	O
ultrasonography	B-PROC
,	O
but	O
not	O
with	O
Hashimoto	B-DISO
's	I-DISO
thyroiditis	I-DISO
in	O
histopathology	B-PROC
in	O
patients	B-LIVB
with	O
thyroid	B-DISO
nodules	I-DISO
evaluated	O
as	O
Bethesda	B-DISO
Category	I-DISO
III	I-DISO
(	O
AUS	B-DISO
/	O
FLUS	B-DISO
)	O
in	O
cytology	B-PROC
The	O
predictors	O
of	O
malignancy	B-DISO
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-PROC
in	O
nodules	B-DISO
with	O
atypia	B-DISO
of	I-DISO
undetermined	I-DISO
significance	I-DISO
/	O
follicular	B-DISO
lesion	I-DISO
of	I-DISO
undetermined	I-DISO
significance	I-DISO
(	O
AUS	B-DISO
/	O
FLUS	B-DISO
)	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	O
,	O
clinical	O
,	O
and	O
biochemical	O
predictors	O
of	O
malignancy	B-DISO
in	O
these	O
patients	B-LIVB
.	O

A	O
total	O
of	O
427	O
patients	B-LIVB
with	O
cytologically	B-DISO
Bethesda	I-DISO
Category	I-DISO
III	I-DISO
(	O
AUS	B-DISO
/	O
FLUS	B-DISO
)	O
thyroid	B-DISO
nodules	I-DISO
were	O
included	O
in	O
this	O
retrospective	B-PROC
study	I-PROC
.	O

We	O
divided	O
the	O
nodules	B-DISO
into	O
two	O
subgroups	B-LIVB
according	O
to	O
the	O
histopathology	B-PROC
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	B-PHYS
,	O
clinical	B-PHYS
,	O
and	O
biochemical	B-DISO
findings	I-DISO
.	O

In	O
overall	O
,	O
427	O
patients	B-LIVB
with	O
449	O
AUS	B-DISO
/	O
FLUS	B-DISO
nodules	B-DISO
who	O
had	O
undergone	O
surgery	B-PROC
,	O
the	O
rate	O
of	O
malignancy	B-DISO
was	O
23	O
.	O

4	O
%	O
(	O
105	O
/	O
449	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B-DISO
was	O
25	O
.	O

8	O
%	O
in	O
nodules	B-DISO
with	O
AUS	B-DISO
(	O
82	O
/	O
318	O
)	O
and	O
17	O
.	O

6	O
%	O
in	O
nodules	B-DISO
with	O
FLUS	B-DISO
(	O
23	O
/	O
131	O
)	O
(	O
p	O
=	O
0	O
.	O
061	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B-PROC
consisted	O
of	O
papillary	B-DISO
thyroid	I-DISO
carcinoma	I-DISO
(	O
PTC	B-DISO
)	O
(	O
n	O
=	O
91	O
,	O
86	O
.	O
7	O
%	O
)	O
.	O

Preoperative	O
ultrasonographic	B-PHYS
features	I-PHYS
of	O
105	O
malignant	B-DISO
nodules	I-DISO
in	O
histopathology	B-PROC
were	O
compared	O
with	O
the	O
344	O
benign	B-DISO
nodules	I-DISO
in	O
histopathology	B-PROC
.	O

Anteroposterior	O
/	O
Transverse	O
(	O
AP	O
/	O
T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	B-LIVB
group	I-LIVB
compared	O
to	O
benign	B-LIVB
group	I-LIVB
(	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O

In	O
multiple	B-PROC
logistic	I-PROC
analysis	I-PROC
,	O
we	O
found	O
that	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	B-DISO
were	O
independently	O
associated	O
with	O
malignancy	B-DISO
(	O
p	O
<	O
0	O
.	O

05	O
)	O
.	O

The	O
malignancy	B-DISO
-associated	O
cut	O
-	O
off	O
value	O
of	O
AP	O
/	O
T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0	O
.	O
81	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	B-DISO
and	O
Hashimoto	B-DISO
's	I-DISO
thyroiditis	I-DISO
in	O
histopathology	B-PROC
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

In	O
Bethesda	B-DISO
Category	I-DISO
III	I-DISO
nodules	I-DISO
with	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	B-DISO
,	O
surgery	B-PROC
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	B-PROC
-	I-PROC
needle	I-PROC
aspiration	I-PROC
biopsy	I-PROC
or	O
observation	B-PROC
.	O

Low	O
serum	B-ANAT
vitamin	B-CHEM
D	I-CHEM
is	O
associated	O
with	O
higher	O
cortical	B-ANAT
porosity	O
in	O
elderly	B-LIVB
men	B-LIVB
Bone	B-DISO
loss	I-DISO
at	O
peripheral	O
sites	B-ANAT
in	O
the	O
elderly	B-LIVB
is	O
mainly	O
cortical	B-ANAT
and	O
involves	O
increased	O
cortical	B-ANAT
porosity	O
.	O

However	O
,	O
an	O
association	O
between	O
bone	B-DISO
loss	I-DISO
at	O
these	O
sites	B-ANAT
and	O
25	B-CHEM
-	I-CHEM
hydroxyvitamin	I-CHEM
D	I-CHEM
has	O
not	O
been	O
reported	O
.	O

To	O
investigate	O
the	O
association	O
between	O
serum	B-ANAT
levels	B-PROC
of	I-PROC
25	I-PROC
-	I-PROC
hydroxyvitamin	I-PROC
D	I-PROC
,	O
bone	B-ANAT
microstructure	I-ANAT
and	O
areal	B-PHYS
bone	I-PHYS
mineral	I-PHYS
density	I-PHYS
(	O
BMD	B-PHYS
)	O
in	O
elderly	B-LIVB
men	B-LIVB
.	O

A	O
population	B-LIVB
-based	O
cohort	B-LIVB
of	O
444	O
elderly	B-LIVB
men	B-LIVB
(	O
mean	O
±	O
SD	O
age	B-PHYS
80	O
.	O

2	O
±	O
3	O
.	O

5	O
years	O
)	O
was	O
investigated	O
.	O

Bone	B-ANAT
microstructure	I-ANAT
was	O
measured	O
by	O
high	B-PROC
-	I-PROC
resolution	I-PROC
peripheral	I-PROC
quantitative	I-PROC
computed	I-PROC
tomography	I-PROC
,	O
areal	B-PHYS
BMD	I-PHYS
by	O
dual	B-PROC
-	I-PROC
energy	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
absorptiometry	I-PROC
and	O
serum	B-ANAT
25	B-PROC
-	I-PROC
hydroxyvitamin	I-PROC
D	I-PROC
and	O
parathyroid	B-PROC
hormone	I-PROC
levels	I-PROC
by	O
immunoassay	B-PROC
.	O

Mean	O
cortical	B-ANAT
porosity	O
at	O
the	O
distal	B-ANAT
tibia	I-ANAT
was	O
14	O
.	O

7	O
%	O
higher	O
(	O
12	O
.	O
5	O
±	O
4	O
.	O

3	O
%	O
vs	O
.	O

10	O
.	O
9	O
±	O
4	O
.	O
1	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
whilst	O
cortical	B-ANAT
volumetric	B-PHYS
BMD	I-PHYS
,	O
area	O
,	O
trabecular	O
bone	O
volume	O
fraction	O
and	O
femoral	B-ANAT
neck	I-ANAT
areal	B-PHYS
BMD	I-PHYS
were	O
lower	O
in	O
men	B-LIVB
in	O
the	O
lowest	O
quartile	O
of	O
vitamin	B-PROC
D	I-PROC
levels	I-PROC
compared	O
to	O
the	O
highest	O
.	O

In	O
men	B-LIVB
with	O
vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
(	O
<	O
25	O
nmol	O
L	O
(	O
-	O
1	O
)	O
)	O
or	O
insufficiency	O
[	O
25	O
-	O
49	O
nmol	O
L	O
(	O
-	O
1	O
)	O
,	O
in	O
combination	O
with	O
an	O
elevated	O
serum	B-ANAT
level	B-PROC
of	I-PROC
parathyroid	I-PROC
hormone	I-PROC
(	O
>	O
6	O
.	O
8	O
pmol	O
L	O
(	O
-	O
1	O
)	O
)	O
]	O
,	O
cortical	B-ANAT
porosity	O
was	O
17	O
.	O

2	O
%	O
higher	O
than	O
in	O
vitamin	B-CHEM
D	I-CHEM
-	O
sufficient	O
men	B-LIVB
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

A	O
linear	O
regression	O
model	O
including	O
age	B-PHYS
,	O
weight	B-PHYS
,	O
height	B-PHYS
,	O
daily	B-PROC
calcium	I-PROC
intake	I-PROC
,	O
physical	O
activity	O
,	O
smoking	O
vitamin	B-CHEM
D	I-CHEM
supplementation	B-CHEM
and	O
parathyroid	B-CHEM
hormone	I-CHEM
showed	O
that	O
25	B-CHEM
-	I-CHEM
hydroxyvitamin	I-CHEM
D	I-CHEM
independently	O
predicted	O
cortical	B-ANAT
porosity	O
(	O
standardized	O
β	O
=	O
-0	O
.	O
110	O
,	O
R	O
(	O
2	O
)	O
=	O
1	O
.	O
1	O
%	O
,	O
P	O
=	O
0	O
.	O
024	O
)	O
,	O
area	O
(	O
β	O
=	O
0	O
.	O
123	O
,	O
R	O
(	O
2	O
)	O
=	O
1	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
cortical	B-ANAT
volumetric	B-PHYS
BMD	I-PHYS
(	O
β	O
=	O
0	O
.	O
125	O
,	O
R	O
(	O
2	O
)	O
=	O
1	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
of	O
the	O
tibia	B-ANAT
as	O
well	O
as	O
areal	B-PHYS
BMD	I-PHYS
of	O
the	O
femoral	B-ANAT
neck	I-ANAT
(	O
β	O
=	O
0	O
.	O
102	O
,	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
9	O
%	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

Serum	B-ANAT
vitamin	B-CHEM
D	I-CHEM
is	O
associated	O
with	O
cortical	B-ANAT
porosity	O
,	O
area	O
and	O
density	B-PHYS
,	O
indicating	O
that	O
bone	B-ANAT
fragility	B-DISO
as	O
a	O
result	O
of	O
low	O
vitamin	B-CHEM
D	I-CHEM
could	O
be	O
due	O
to	O
changes	O
in	O
cortical	B-ANAT
bone	B-ANAT
microstructure	I-ANAT
and	O
geometry	O
.	O

Nationwide	O
reduction	O
in	O
the	O
number	O
of	O
corneal	B-PROC
transplantations	I-PROC
for	O
keratoconus	B-DISO
following	O
the	O
implementation	O
of	O
cross	B-PROC
-	I-PROC
linking	I-PROC
Keratoconus	B-DISO
is	O
characterized	O
by	O
corneal	B-DISO
ectasia	I-DISO
and	O
irregular	B-DISO
astigmatism	I-DISO
,	O
which	O
can	O
lead	O
to	O
diminished	B-DISO
vision	I-DISO
and	O
corneal	B-DISO
scarring	I-DISO
.	O

Approximately	O
10	O
-	O
20	O
%	O
of	O
patients	B-LIVB
with	O
keratoconus	B-DISO
eventually	O
require	O
a	O
corneal	B-PROC
transplant	I-PROC
.	O

Corneal	B-PROC
cross	I-PROC
-	I-PROC
linking	I-PROC
(	O
CXL	B-PROC
)	O
is	O
a	O
relatively	O
new	O
treatment	B-PROC
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-PROC
transplantation	I-PROC
.	O

Here	O
,	O
we	O
investigated	O
whether	O
the	O
introduction	O
of	O
CXL	B-PROC
has	O
reduced	O
the	O
number	O
of	O
corneal	B-PROC
transplants	I-PROC
performed	O
annually	O
.	O

Data	O
regarding	O
the	O
transplantation	B-PROC
procedures	I-PROC
performed	O
in	O
patients	B-LIVB
under	O
the	O
age	B-PHYS
of	O
50	O
years	O
were	O
extracted	O
from	O
the	O
Dutch	O
National	O
Organ	O
Transplant	O
Registry	O
.	O

The	O
number	O
of	O
corneal	B-PROC
transplants	I-PROC
performed	O
prior	O
to	O
(	O
i	O
.	O

e	O
.	O

in	O
2005	O
through	O
2007	O
)	O
and	O
following	O
the	O
introduction	O
of	O
CXL	B-PROC
(	O
i	O
.	O

e	O
.	O

in	O
2012	O
through	O
2014	O
)	O
were	O
compared	O
.	O

Furthermore	O
,	O
a	O
trend	O
analysis	O
on	O
annual	O
keratoplasties	B-PROC
over	O
time	O
was	O
performed	O
.	O

Approximately	O
25	O
%	O
fewer	O
corneal	B-PROC
transplants	I-PROC
were	O
performed	O
in	O
the	O
3	O
-	O
year	O
period	O
following	O
the	O
introduction	O
of	O
CXL	B-PROC
compared	O
to	O
the	O
3	O
-	O
year	O
period	O
prior	O
to	O
the	O
introduction	O
of	O
CXL	B-PROC
(	O
201	O
versus	O
269	O
transplants	B-PROC
,	O
respectively	O
;	O
p	O
=	O
0	O
.	O

005	O
)	O
.	O

Age	B-PHYS
,	O
gender	B-PHYS
and	O
visual	B-PHYS
acuity	I-PHYS
were	O
similar	O
between	O
the	O
patient	B-LIVB
groups	O
in	O
the	O
two	O
time	O
periods	O
.	O

Trend	O
analysis	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
amount	O
of	O
corneal	B-PROC
transplants	I-PROC
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Significantly	O
fewer	O
corneal	B-PROC
transplants	I-PROC
were	O
performed	O
for	O
treating	O
keratoconus	B-DISO
following	O
the	O
nationwide	O
introduction	O
of	O
CXL	B-PROC
.	O

This	O
reduction	O
suggests	O
that	O
corneal	B-PROC
cross	I-PROC
-	I-PROC
linking	I-PROC
can	O
significantly	O
reduce	O
the	O
need	O
for	O
corneal	B-PROC
transplantation	I-PROC
.	O

Rapid	O
Fabrication	O
of	O
a	O
Cell	B-ANAT
-	O
Seeded	B-PROC
Collagen	B-CHEM
Gel	B-CHEM
-Based	O
Tubular	B-DEVI
Construct	I-DEVI
that	O
Withstands	O
Arterial	B-PHYS
Pressure	I-PHYS
:	O
Rapid	O
Fabrication	O
of	O
a	O
Gel	B-CHEM
-Based	O
Media	B-OBJC
Equivalent	O
Based	O
on	O
plastically	B-PHEN
compressed	I-PHEN
cell	B-ANAT
-	O
seeded	B-PROC
collagen	B-CHEM
gels	B-CHEM
,	O
we	O
fabricated	O
a	O
small	O
-	O
diameter	O
tubular	B-DEVI
construct	I-DEVI
that	O
withstands	O
arterial	B-PHYS
pressure	I-PHYS
without	O
prolonged	O
culture	B-PROC
in	O
vitro	O
.	O

Specifically	O
,	O
to	O
mimic	O
the	O
microstructure	O
of	O
vascular	O
media	O
,	O
the	O
cell	B-ANAT
-	O
seeded	B-PROC
collagen	B-CHEM
gel	B-CHEM
was	O
uniaxially	O
stretched	O
prior	O
to	O
plastic	B-OBJC
compression	B-PHEN
to	O
align	O
collagen	O
fibers	O
and	O
hence	O
cells	B-ANAT
in	O
the	O
gel	B-CHEM
.	O

The	O
resulting	O
gel	B-CHEM
sheet	B-CHEM
was	O
then	O
wrapped	O
around	O
a	O
custom	O
-	O
made	O
multi	B-DEVI
-	I-DEVI
layered	I-DEVI
braided	I-DEVI
tube	I-DEVI
to	O
form	O
aligned	O
tubular	B-DEVI
constructs	I-DEVI
whereas	O
the	O
gel	B-CHEM
sheet	B-CHEM
prepared	O
similarly	O
but	O
without	O
uniaxial	O
stretching	O
formed	O
control	O
constructs	B-DEVI
.	O

With	O
the	O
braided	B-DEVI
tube	I-DEVI
,	O
fluid	B-OBJC
in	O
the	O
gel	B-CHEM
construct	B-DEVI
was	O
further	O
removed	O
by	O
vacuum	B-DEVI
suction	I-DEVI
aiming	O
to	O
consolidate	O
the	O
concentric	O
layers	O
of	O
the	O
construct	B-DEVI
.	O

The	O
construct	B-DEVI
was	O
finally	O
treated	O
with	O
transglutaminase	B-CHEM
.	O

Both	O
SEM	B-PROC
and	O
histology	B-PROC
confirmed	O
the	O
absence	O
of	O
gaps	O
in	O
the	O
wall	O
of	O
the	O
construct	B-DEVI
.	O

Particularly	O
,	O
cells	B-ANAT
in	O
the	O
wall	O
of	O
the	O
aligned	O
tubular	B-DEVI
construct	I-DEVI
were	O
circumferentially	O
aligned	O
.	O

The	O
enzyme	B-CHEM
-mediated	O
crosslinking	B-PHEN
increased	O
burst	B-PHEN
pressure	I-PHEN
of	O
both	O
the	O
constructs	B-DEVI
significantly	O
;	O
the	O
extent	O
of	O
the	O
increase	O
of	O
burst	B-PHEN
pressure	I-PHEN
for	O
the	O
aligned	O
tubular	B-DEVI
construct	I-DEVI
was	O
greater	O
than	O
that	O
for	O
the	O
control	O
counterpart	O
.	O

Increasing	O
crosslinking	B-PHEN
left	O
the	O
compliance	O
of	O
the	O
aligned	O
tubular	B-DEVI
construct	I-DEVI
unchanged	O
but	O
reduced	O
that	O
of	O
the	O
control	O
construct	B-DEVI
.	O

Cells	B-ANAT
remained	O
viable	O
in	O
transglutaminase	B-CHEM
-treated	O
plastically	B-PHEN
compressed	I-PHEN
gels	B-CHEM
after	O
6	O
days	O
in	O
culture	O
.	O

This	O
study	B-PROC
demonstrated	O
that	O
by	O
combining	O
stretch	O
-	O
induced	O
fiber	O
alignment	O
,	O
plastic	B-OBJC
compression	B-PHEN
,	O
and	O
enzyme	B-CHEM
-mediated	O
crosslinking	B-PHEN
,	O
a	O
cell	B-ANAT
-	O
seeded	B-PROC
collagen	B-CHEM
gel	B-CHEM
-based	O
tubular	B-DEVI
construct	I-DEVI
with	O
potential	O
to	O
be	O
used	O
as	O
vascular	O
media	O
can	O
be	O
made	O
within	O
3	O
days	O
.	O

Impact	O
of	O
cofactor	B-CHEM
-	O
binding	O
loop	O
mutations	B-PHYS
on	O
thermotolerance	B-PHYS
and	O
activity	B-PHYS
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
transketolase	B-CHEM
Improvement	O
of	O
thermostability	B-PHEN
in	O
engineered	B-CHEM
enzymes	I-CHEM
can	O
allow	O
biocatalysis	B-PHEN
on	O
substrates	B-OBJC
with	O
poor	O
aqueous	O
solubility	O
.	O

Denaturation	B-PHYS
of	O
the	O
cofactor	B-CHEM
-	O
binding	O
loops	O
of	O
Escherichia	B-LIVB
coli	I-LIVB
transketolase	B-CHEM
(	O
TK	B-CHEM
)	O
was	O
previously	O
linked	O
to	O
the	O
loss	O
of	O
enzyme	B-PHYS
activity	I-PHYS
under	O
conditions	O
of	O
high	O
pH	O
or	O
urea	B-CHEM
.	O

Incubation	B-PROC
at	O
temperatures	O
just	O
below	O
the	O
thermal	B-PHEN
melting	I-PHEN
transition	I-PHEN
,	O
above	O
which	O
the	O
protein	B-CHEM
aggregates	O
,	O
was	O
also	O
found	O
to	O
anneal	O
the	O
enzyme	B-CHEM
to	O
give	O
an	O
increased	O
specific	O
activity	B-PHYS
.	O

The	O
potential	O
role	O
of	O
cofactor	B-CHEM
-	O
binding	O
loop	O
instability	B-DISO
in	O
this	O
process	O
remained	O
unclear	O
.	O

In	O
this	O
work	O
,	O
the	O
two	O
cofactor	B-CHEM
-	O
binding	O
loops	O
(	O
residues	O
185	O
-	O
192	O
and	O
382	O
-	O
392	O
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	O
from	O
the	O
thermostable	O
Thermus	B-LIVB
thermophilus	I-LIVB
TK	B-CHEM
and	O
variants	O
assessed	O
for	O
their	O
impact	O
on	O
both	O
thermostability	B-PHEN
and	O
activity	O
.	O

Cofactor	O
-	O
binding	O
loop	O
2	O
variants	O
had	O
detrimental	O
effects	O
on	O
specific	O
activity	O
at	O
elevated	O
temperatures	O
,	O
whereas	O
the	O
H192P	B-PHYS
mutation	I-PHYS
in	O
cofactor	O
-	O
binding	O
loop	O
1	O
resulted	O
in	O
a	O
two	O
-	O
fold	O
improved	O
stability	B-PHEN
to	O
inactivation	O
at	O
elevated	O
temperatures	O
,	O
and	O
increased	O
the	O
critical	O
onset	O
temperature	O
for	O
aggregation	O
.	O

The	O
specific	O
activity	O
of	O
H192P	B-PHYS
was	O
3	O
-	O
fold	O
and	O
19	O
-	O
fold	O
higher	O
than	O
that	O
for	O
wild	O
-	O
type	O
at	O
60°C	O
and	O
65°C	O
respectively	O
,	O
and	O
also	O
remained	O
2	O
.	O
7	O
-	O
4	O
fold	O
higher	O
after	O
re	B-PHEN
-	I-PHEN
cooling	I-PHEN
from	O
pre	B-PROC
-	I-PROC
incubations	I-PROC
at	O
either	O
55°C	O
or	O
60°C	O
for	O
1h	O
.	O

Interestingly	O
,	O
H192P	B-PHYS
was	O
also	O
2	O
-	O
times	O
more	O
active	O
than	O
wild	O
-	O
type	O
TK	B-CHEM
at	O
25°C	O
.	O

Optimal	O
activity	O
was	O
achieved	O
at	O
60°C	O
for	O
H192P	B-PHYS
compared	O
to	O
55°C	O
for	O
wild	O
type	O
.	O

These	O
results	O
show	O
that	O
cofactor	O
-	O
binding	O
loop	O
1	O
,	O
plays	O
a	O
pivotal	O
role	O
in	O
partial	O
denaturation	B-PHYS
and	O
aggregation	O
at	O
elevated	O
temperatures	O
.	O

Furthermore	O
,	O
a	O
single	B-PHYS
rigidifying	I-PHYS
mutation	I-PHYS
within	O
this	O
loop	O
can	O
significantly	O
improve	O
the	O
enzyme	B-PHYS
specific	I-PHYS
activity	I-PHYS
,	O
as	O
well	O
as	O
the	O
stability	B-PHEN
to	O
thermal	B-PHEN
denaturation	B-PHYS
and	O
aggregation	O
,	O
to	O
give	O
an	O
increased	O
temperature	O
optimum	O
for	O
activity	B-PHYS
.	O

Expression	B-PHYS
and	O
Purification	B-PROC
of	O
E2	B-CHEM
Glycoprotein	I-CHEM
from	O
Insect	O
Cells	B-ANAT
(	O
Sf9	B-ANAT
)	O
for	O
Use	O
in	O
Serology	B-PROC
Chikungunya	B-LIVB
virus	I-LIVB
(	O
CHIKV	B-LIVB
)	O
is	O
a	O
mosquito	O
-	O
borne	B-DISO
arbovirus	B-LIVB
which	O
poses	O
a	O
major	O
threat	O
to	O
global	O
public	B-PROC
health	I-PROC
.	O

Definitive	O
CHIKV	B-LIVB
diagnosis	B-DISO
is	O
crucial	O
,	O
especially	O
in	O
distinguishing	O
the	O
disease	B-DISO
from	O
dengue	B-LIVB
virus	I-LIVB
,	O
which	O
co	O
-	O
circulates	O
in	O
endemic	O
areas	O
and	O
shares	O
the	O
same	O
mosquito	O
vectors	O
.	O

Laboratory	B-PROC
diagnosis	I-PROC
is	O
mainly	O
based	O
on	O
serological	O
or	O
molecular	O
approaches	O
.	O

The	O
E2	B-CHEM
glycoprotein	I-CHEM
is	O
a	O
good	O
candidate	O
for	O
serological	B-PROC
diagnosis	I-PROC
since	O
it	O
is	O
the	O
immunodominant	B-CHEM
antigen	I-CHEM
during	O
the	O
course	O
of	O
infection	B-DISO
,	O
and	O
reacts	O
with	O
seropositive	O
CHIKV	B-LIVB
sera	B-ANAT
.	O

In	O
this	O
chapter	O
,	O
we	O
describe	O
the	O
generation	O
of	O
stable	O
clone	B-ANAT
Sf9	B-ANAT
(	O
Spodoptera	O
frugiperda	O
)	O
cells	B-ANAT
expressing	B-PHYS
secreted	B-PHYS
,	O
soluble	B-ANAT
,	O
and	O
native	O
recombinant	B-LIVB
CHIKV	B-LIVB
E2	B-CHEM
glycoprotein	I-CHEM
.	O

We	O
use	O
direct	O
plasmid	B-CHEM
expression	B-PROC
in	O
insect	O
cells	B-ANAT
,	O
rather	O
than	O
the	O
traditional	O
technique	O
of	O
generating	O
recombinant	B-LIVB
baculovirus	I-LIVB
.	O

This	O
recombinant	B-CHEM
protein	I-CHEM
is	O
useful	O
for	O
serological	B-PROC
diagnosis	I-PROC
of	O
CHIKV	B-LIVB
infection	B-DISO
.	O

Acute	O
risk	B-DISO
factors	I-DISO
for	O
suicide	B-DISO
attempts	I-DISO
and	O
death	B-DISO
:	O
prospective	B-PROC
findings	I-PROC
from	O
the	O
STEP	B-PROC
-	O
BD	B-DISO
study	B-PROC
Suicide	B-DISO
is	O
unfortunately	O
common	O
in	O
psychiatric	O
practice	B-PHYS
,	O
but	O
difficult	O
to	O
predict	O
.	O

The	O
present	O
study	B-PROC
sought	O
to	O
assess	B-PROC
which	O
clinical	O
symptoms	B-DISO
increase	O
in	O
the	O
months	O
before	O
suicidal	B-DISO
behavior	I-DISO
in	O
a	O
sample	B-OBJC
of	O
psychiatric	O
outpatients	B-LIVB
with	O
bipolar	B-DISO
disorder	I-DISO
.	O

Data	O
from	O
the	O
Systematic	B-PROC
Treatment	I-PROC
Enhancement	I-PROC
Program	I-PROC
for	O
Bipolar	B-DISO
Disorder	I-DISO
(	O
STEP	B-PROC
-	O
BD	B-DISO
)	O
trial	B-PROC
were	O
used	O
.	O

A	O
total	O
of	O
103	O
participants	B-LIVB
who	O
attempted	B-DISO
suicide	I-DISO
or	O
died	B-DISO
by	O
suicide	B-DISO
during	O
the	O
trial	B-PROC
were	O
included	O
;	O
a	O
15	O
%	O
random	O
sample	B-OBJC
of	O
the	O
remaining	O
participants	B-LIVB
(	O
n	O
=	O
427	O
)	O
was	O
used	O
as	O
a	O
comparison	O
sample	B-OBJC
.	O

Linear	O
mixed	O
models	O
in	O
the	O
six	O
months	O
before	O
suicidal	B-DISO
behavior	I-DISO
were	O
conducted	O
for	O
each	O
of	O
five	O
proposed	O
acute	O
risk	B-DISO
factors	I-DISO
for	O
suicidal	B-DISO
behavior	I-DISO
.	O

Participants	B-LIVB
were	O
assessed	O
using	O
the	O
Clinical	B-PROC
Monitoring	I-PROC
Form	I-PROC
(	O
CMF	B-PROC
)	O
at	O
each	O
visit	B-PROC
for	O
the	O
following	O
potential	O
acute	O
risk	B-DISO
factors	I-DISO
for	O
suicidal	B-DISO
behavior	I-DISO
:	O
suicidal	B-DISO
ideation	I-DISO
,	O
loss	B-DISO
of	I-DISO
interest	I-DISO
,	O
anxiety	B-DISO
,	O
psychomotor	B-DISO
agitation	I-DISO
,	O
and	O
high	O
-	O
risk	O
behavior	O
.	O

Each	O
of	O
the	O
five	O
symptoms	B-DISO
was	O
elevated	O
overall	O
in	O
individuals	B-LIVB
who	O
engaged	O
in	O
suicidal	B-DISO
behavior	I-DISO
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
severity	O
of	O
both	O
suicidal	B-DISO
ideation	I-DISO
and	O
loss	B-DISO
of	I-DISO
interest	I-DISO
significantly	O
increased	O
in	O
the	O
months	O
before	O
suicidal	B-DISO
behavior	I-DISO
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Anxiety	B-DISO
demonstrated	O
comparable	O
effect	O
sizes	O
across	O
multiple	O
models	O
.	O

Psychomotor	B-DISO
agitation	I-DISO
and	O
high	O
-	O
risk	O
behavior	O
were	O
not	O
significantly	O
elevated	O
before	O
suicidal	B-DISO
behavior	I-DISO
.	O

Suicidal	B-DISO
ideation	I-DISO
,	O
loss	B-DISO
of	I-DISO
interest	I-DISO
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
anxiety	B-DISO
may	O
represent	O
acute	O
suicide	B-DISO
risk	B-DISO
factors	I-DISO
up	O
to	O
four	O
months	O
before	O
suicidal	B-DISO
behavior	I-DISO
in	O
outpatients	B-LIVB
with	O
bipolar	B-DISO
disorder	I-DISO
.	O

Further	O
investigation	B-PROC
of	O
these	O
potential	O
acute	O
risk	B-DISO
factors	I-DISO
in	O
prospective	B-PROC
analyses	I-PROC
is	O
warranted	O
.	O

Measurement	O
of	O
Outcomes	O
of	O
Upper	B-DISO
Limb	I-DISO
Reconstructive	I-DISO
Surgery	I-DISO
for	O
Tetraplegia	B-DISO
Reconstructive	B-DISO
arm	I-DISO
/	I-DISO
hand	I-DISO
surgery	I-DISO
for	O
tetraplegia	B-DISO
is	O
performed	O
to	O
improve	B-DISO
arm	B-PHYS
/	I-PHYS
hand	I-PHYS
function	I-PHYS
and	O
therefore	O
personal	B-DISO
well	I-DISO
-	I-DISO
being	I-DISO
for	O
individuals	B-LIVB
who	O
accept	O
such	O
elective	B-PROC
surgeries	I-PROC
.	O

However	O
,	O
changes	O
at	O
an	O
impairment	O
level	O
do	O
not	O
always	O
translate	O
into	O
functional	O
or	O
quality	O
of	O
life	O
changes	O
.	O

Therefore	O
,	O
multiple	B-OBJC
outcome	I-OBJC
tools	I-OBJC
should	O
be	O
used	O
that	O
incorporate	O
sufficient	B-DISO
responsiveness	I-DISO
to	O
detect	B-DISO
changes	O
in	O
arm	B-PHYS
/	I-PHYS
hand	I-PHYS
function	I-PHYS
,	O
activity	O
and	O
participation	O
,	O
and	O
quality	O
of	O
life	O
of	O
the	O
individuals	B-LIVB
involved	O
.	O

This	O
narrative	O
review	O
aims	O
to	O
assist	B-PROC
clinicians	B-LIVB
to	O
choose	O
the	O
most	O
appropriate	O
tools	B-OBJC
to	O
assess	O
the	O
need	O
for	O
reconstructive	B-DISO
surgery	I-DISO
and	O
to	O
evaluate	B-PROC
its	O
outcomes	O
.	O

Our	O
specific	O
objectives	O
are	O
(	O
1	O
)	O
to	O
describe	O
aspects	O
to	O
consider	O
when	O
choosing	O
a	O
measure	O
and	O
(	O
2	O
)	O
to	O
describe	O
the	O
measures	O
advised	O
by	O
an	O
international	O
therapist	B-LIVB
consensus	O
group	O
established	O
in	O
2007	O
.	O

All	O
advised	O
measures	O
are	O
appraised	O
in	O
terms	O
of	O
the	O
underlying	O
construct	O
,	O
administration	B-PROC
,	O
and	O
clinical	O
relevance	O
to	O
arm	B-PROC
/	I-PROC
hand	I-PROC
reconstructions	I-PROC
.	O

Essentially	O
there	O
are	O
currently	O
no	O
criterion	O
standard	O
measures	O
to	O
evaluate	B-PROC
the	O
consequences	O
of	O
reconstructive	B-DISO
arm	I-DISO
/	I-DISO
hand	I-DISO
surgery	I-DISO
.	O

However	O
,	O
with	O
judicious	O
use	O
of	O
available	O
measures	O
it	O
is	O
possible	O
to	O
ensure	O
the	O
questions	B-DISO
asked	I-DISO
or	O
tasks	O
completed	O
are	O
relevant	O
to	O
the	O
surgical	B-PROC
reconstruction	I-PROC
(	O
s	O
)	O
undertaken	O
.	O

Further	O
work	O
in	O
this	O
field	O
is	O
required	O
.	O

This	O
would	O
be	O
best	O
met	O
by	O
immediate	O
collaboration	O
between	O
2	O
outcome	O
's	O
tool	O
developers	O
and	O
by	O
analysis	O
of	O
pre	O
-	O
and	O
postoperative	O
data	O
already	O
held	O
in	O
various	O
international	O
sites	O
,	O
which	O
would	O
allow	O
further	O
evaluation	B-PROC
of	O
the	O
measures	O
already	O
in	O
use	O
,	O
or	O
components	B-OBJC
thereof	O
.	O

Basal	B-PHYS
and	O
maximal	O
metabolic	B-PHYS
rates	I-PHYS
differ	O
in	O
their	O
response	B-PHYS
to	O
rapid	O
temperature	O
change	O
among	O
avian	B-LIVB
species	O
In	O
birds	B-LIVB
,	O
acclimation	B-PHYS
and	O
acclimatization	B-PHYS
to	O
temperature	O
are	O
associated	O
with	O
changes	O
in	O
basal	B-PHYS
(	O
BMR	B-PHYS
)	O
,	O
summit	B-PHYS
(	O
Msum	B-PHYS
)	O
and	O
maximal	O
(	O
MMR	B-PHYS
)	O
metabolic	B-PHYS
rates	I-PHYS
but	O
little	O
is	O
known	O
about	O
the	O
rate	B-PHYS
at	O
which	O
species	O
adjust	O
their	O
phenotype	B-PHYS
to	O
short	O
-	O
term	O
temperature	O
variations	O
.	O

Our	O
aims	O
were	O
(	O
1	O
)	O
to	O
determine	O
the	O
pattern	O
of	O
metabolic	O
adjustments	O
following	O
a	O
rapid	O
temperature	O
change	O
,	O
(	O
2	O
)	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	B-PHYS
during	O
exposure	O
to	O
warm	B-PHEN
or	O
cold	B-PHEN
environments	I-PHEN
,	O
and	O
(	O
3	O
)	O
to	O
determine	O
if	O
BMR	B-PHYS
,	O
Msum	B-PHYS
and	O
MMR	B-PHYS
change	O
at	O
comparable	O
rates	B-PHYS
during	O
thermal	B-PHEN
acclimation	B-PHYS
.	O

We	O
measured	O
these	O
parameters	O
in	O
white	B-LIVB
-	I-LIVB
throated	I-LIVB
sparrows	I-LIVB
(	O
Zonotrichia	B-LIVB
albicollis	I-LIVB
)	O
,	O
black	B-LIVB
-	I-LIVB
capped	I-LIVB
chickadees	I-LIVB
(	O
Poecile	B-LIVB
atricapillus	I-LIVB
)	O
,	O
and	O
snow	B-LIVB
buntings	I-LIVB
(	O
Plectrophenax	B-LIVB
nivalis	I-LIVB
)	O
after	O
acclimation	B-PHYS
to	O
10	O
°	O
C	O
(	O
day	O
0	O
)	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	O
of	O
acclimation	B-PHYS
to	O
either	O
-5	O
or	O
28	O
°	O
C	O
.	O

Birds	B-LIVB
changed	O
their	O
metabolic	O
phenotype	B-PHYS
within	O
8	O
days	O
with	O
patterns	O
differing	O
among	O
species	O
.	O

Sparrows	B-LIVB
expressed	O
the	O
expected	O
metabolic	O
increases	O
in	O
the	O
cold	B-PHEN
and	O
decreases	O
at	O
thermoneutrality	O
while	O
performance	O
in	O
chickadees	B-LIVB
and	O
buntings	B-LIVB
was	O
not	O
influenced	O
by	O
temperature	O
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	O
.	O

Our	O
results	B-DISO
suggest	O
that	O
BMR	B-PHYS
varies	O
at	O
comparable	O
rates	B-PHYS
in	O
warm	B-PHEN
and	O
cold	B-PHEN
environments	I-PHEN
but	O
changes	O
faster	O
than	O
Msum	B-PHYS
and	O
MMR	B-PHYS
,	O
likely	O
due	O
to	O
limitations	O
in	O
the	O
rate	B-PHYS
of	O
change	O
in	O
organ	B-PHYS
size	I-PHYS
and	O
function	O
.	O

They	O
also	O
suggest	O
that	O
maximal	O
metabolic	O
capacity	O
is	O
lost	O
faster	O
in	O
a	O
warm	B-PHEN
environment	I-PHEN
than	O
it	O
is	O
gained	O
in	O
a	O
cold	B-PHEN
environment	I-PHEN
.	O

With	O
the	O
expected	O
increase	O
in	O
temperature	O
stochasticity	O
at	O
northern	B-GEOG
latitudes	I-GEOG
,	O
a	O
loss	O
of	O
thermogenic	B-PHEN
capacity	O
during	O
warm	B-PHEN
winter	O
days	O
could	O
,	O
therefore	O
,	O
be	O
detrimental	O
if	O
birds	B-LIVB
are	O
slow	O
to	O
readjust	O
their	O
phenotype	B-PHYS
with	O
the	O
return	O
of	O
cold	B-PHEN
days	O
.	O

Factors	O
preventing	O
kneeling	B-PHYS
in	O
a	O
group	O
of	O
pre	B-PROC
-	I-PROC
educated	I-PROC
patients	B-LIVB
post	O
total	B-PROC
knee	I-PROC
arthroplasty	I-PROC
Difficulties	B-DISO
in	I-DISO
kneeling	I-DISO
,	O
one	O
of	O
the	O
poorest	B-DISO
scoring	I-DISO
functional	I-DISO
outcomes	I-DISO
post	O
total	B-PROC
knee	I-PROC
arthroplasty	I-PROC
(	O
TKA	B-PROC
)	O
,	O
have	O
been	O
attributed	O
to	O
a	O
lack	O
of	O
patient	B-LIVB
education	B-PROC
.	O

This	O
is	O
the	O
first	O
study	O
to	O
investigate	O
specific	O
factors	O
affecting	O
a	O
patient	B-LIVB
's	I-LIVB
perceived	B-PHYS
ability	B-PHYS
to	I-PHYS
kneel	I-PHYS
post	O
TKA	B-PROC
,	O
following	O
exposure	O
to	O
a	O
preoperative	O
kneeling	B-PHYS
education	B-PROC
session	I-PROC
.	O

A	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
was	O
conducted	O
following	O
TKA	B-PROC
with	O
patients	B-LIVB
who	O
had	O
been	O
educated	B-PROC
about	O
kneeling	B-PHYS
prior	O
to	O
the	O
operation	B-PROC
.	O

Patients	B-LIVB
completed	O
kneeling	B-PHYS
questionnaires	O
at	O
6	O
(	O
n	O
=	O
115	O
)	O
and	O
12	O
(	O
n	O
=	O
82	O
)	O
months	O
post	O
TKA	B-PROC
.	O

In	O
addition	O
to	O
the	O
12	O
-	O
month	O
kneeling	B-PHYS
questionnaire	O
,	O
patients	B-LIVB
also	O
completed	O
the	O
Oxford	B-PHYS
knee	I-PHYS
score	I-PHYS
(	O
OKS	B-PHYS
)	O
survey	O
.	O

Seventy	O
-	O
two	O
percent	O
of	O
patients	B-LIVB
perceived	B-PHYS
they	O
could	O
kneel	B-PHYS
at	O
12	O
months	O
post	O
TKA	B-PROC
.	O

Overall	O
,	O
pain	B-DISO
and	O
discomfort	B-DISO
were	O
the	O
most	O
common	O
factors	O
deterring	O
patients	B-LIVB
from	O
kneeling	B-PHYS
.	O

Perceived	B-PHYS
kneeling	B-PHYS
ability	B-PHYS
was	O
the	O
poorest	O
scored	O
outcome	O
on	O
the	O
OKS	B-PHYS
with	O
patients	B-LIVB
reporting	O
mild	O
to	O
moderate	O
difficulty	B-DISO
with	O
this	O
task	O
.	O

Kneeling	B-PHYS
scores	O
were	O
strongly	O
correlated	O
with	O
overall	O
knee	B-DISO
function	I-DISO
scores	I-DISO
(	O
R	O
=	O
0	O
.	O
70	O
)	O
,	O
strongly	O
correlated	O
with	O
pain	B-DISO
scores	I-DISO
(	O
R	O
=	O
0	O
.	O
45	O
)	O
and	O
weakly	O
correlated	O
with	O
knee	B-DISO
stability	I-DISO
scores	I-DISO
(	O
R	O
=	O
0	O
.	O
29	O
)	O
.	O

When	O
asked	O
about	O
other	O
factors	O
preventing	O
kneeling	B-PHYS
other	O
than	O
pain	B-DISO
or	O
discomfor	B-DISO
t	O
,	O
75	O
%	O
had	O
reasons	O
unrelated	B-DISO
to	O
the	O
knee	B-ANAT
or	O
TKA	B-PROC
.	O

The	O
most	O
common	O
reason	O
was	O
'	O
problems	O
with	O
the	O
other	O
knee	B-ANAT
'	O
(	O
n	O
=	O
19	O
)	O
.	O

Patients	B-LIVB
in	O
this	O
study	O
were	O
provided	O
with	O
education	B-PROC
regarding	O
their	O
kneeling	B-PHYS
ability	B-PHYS
post	O
TKA	B-PROC
,	O
yet	O
still	O
experienced	O
limitations	O
in	O
perceived	B-PHYS
kneeling	B-PHYS
ability	O
post	O
operatively	O
.	O

Contrary	O
to	O
previous	O
research	O
,	O
our	O
study	O
suggests	O
that	O
factors	O
other	O
than	O
patient	B-LIVB
education	B-PROC
affect	B-PROC
a	O
patient	B-LIVB
's	I-LIVB
perceived	B-PHYS
kneeling	B-PHYS
ability	B-PHYS
post	O
TKA	B-PROC
.	O

Improved	B-DISO
diagnostic	O
yield	O
of	O
neuromuscular	B-DISO
disorders	I-DISO
applying	O
clinical	O
exome	B-PROC
sequencing	I-PROC
in	O
patients	B-LIVB
arising	O
from	O
a	O
consanguineous	O
population	B-LIVB
Neuromuscular	B-DISO
diseases	I-DISO
(	O
NMDs	B-DISO
)	O
include	O
a	O
broad	O
range	O
of	O
disorders	B-DISO
affecting	O
muscles	O
,	O
nerves	O
and	O
neuromuscular	B-ANAT
junctions	I-ANAT
.	O

Their	O
overlapping	O
phenotypes	B-PHYS
and	O
heterogeneous	B-PHYS
genetic	I-PHYS
nature	I-PHYS
have	O
created	O
challenges	O
in	O
diagnosis	B-DISO
which	O
calls	O
for	O
the	O
implementation	O
of	O
massive	B-PROC
parallel	I-PROC
sequencing	I-PROC
as	O
a	O
candidate	O
strategy	O
to	O
increase	O
the	O
diagnostic	O
yield	O
.	O

In	O
this	O
study	B-PROC
,	O
total	O
of	O
45	O
patients	B-LIVB
,	O
mostly	O
offspring	B-LIVB
of	O
consanguineous	O
marriages	O
were	O
examined	O
using	O
whole	B-PROC
exome	I-PROC
sequencing	I-PROC
.	O

Data	O
analysis	O
was	O
performed	O
to	O
identify	O
the	O
most	O
probable	O
pathogenic	B-DISO
rare	O
variants	O
in	O
known	O
NMD	B-DISO
genes	O
which	O
led	O
to	O
identification	O
of	O
causal	O
variants	O
for	O
33	O
out	O
of	O
45	O
patients	B-LIVB
(	O
73	O
.	O

3	O
%	O
)	O
in	O
the	O
following	O
known	O
genes	O
:	O
CAPN3	O
,	O
Col6A1	O
,	O
Col6A3	O
,	O
DMD	O
,	O
DYSF	O
,	O
FHL1	O
,	O
GJB1	O
,	O
ISPD	O
,	O
LAMA2	O
,	O
LMNA	O
,	O
PLEC1	O
,	O
RYR1	O
,	O
SGCA	O
,	O
SGCB	O
,	O
SYNE1	O
,	O
TNNT1	O
and	O
22	O
novel	O
pathogenic	B-DISO
variants	O
were	O
detected	B-DISO
.	O

Today	O
,	O
the	O
advantage	O
of	O
whole	B-PROC
exome	I-PROC
sequencing	I-PROC
in	O
clinical	B-PROC
diagnostic	I-PROC
strategies	O
of	O
heterogeneous	B-DISO
disorders	I-DISO
is	O
clear	O
.	O

In	O
this	O
cohort	B-LIVB
,	O
a	O
diagnostic	O
yield	O
of	O
73	O
.	O

3	O
%	O
was	O
achieved	O
which	O
is	O
quite	O
high	O
compared	O
to	O
the	O
overall	O
reported	O
diagnostic	O
yield	O
of	O
25	O
%	O
to	O
50	O
%	O
.	O

This	O
could	O
be	O
explained	O
by	O
the	O
consanguineous	O
background	O
of	O
these	O
patients	B-LIVB
and	O
is	O
another	O
strong	O
advantage	O
of	O
offering	O
clinical	O
exome	B-PROC
sequencing	I-PROC
in	O
diagnostic	O
laboratories	B-OBJC
,	O
especially	O
in	O
populations	B-LIVB
with	O
high	O
rate	O
of	O
consanguinity	B-DISO
.	O

Safety	B-PROC
of	O
transradial	B-PROC
diagnostic	I-PROC
cardiac	I-PROC
catheterization	I-PROC
in	O
patients	B-LIVB
under	O
oral	O
anticoagulant	B-PROC
therapy	I-PROC
Cardiac	B-PROC
catheterization	I-PROC
in	O
anticoagulated	O
patients	B-LIVB
is	O
usually	O
performed	O
after	O
the	O
anticoagulation	B-PROC
has	O
been	O
withdrawn	B-PROC
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	B-PROC
therapy	I-PROC
with	I-PROC
heparin	I-PROC
is	O
used	O
.	O

A	O
prospective	O
observational	B-PROC
study	I-PROC
including	O
489	O
patients	B-LIVB
undergoing	O
transradial	B-PROC
catheterization	I-PROC
was	O
conducted	O
.	O

A	O
total	O
of	O
140	O
patients	B-LIVB
were	O
under	O
acenocoumarol	B-CHEM
(	O
group	O
A	O
)	O
and	O
they	O
were	O
compared	O
with	O
the	O
remainder	O
(	O
group	O
B	O
)	O
for	O
complications	B-DISO
after	O
the	O
procedure	B-PROC
(	O
bleeding	B-DISO
and	O
vascular	B-DISO
access	I-DISO
complications	I-DISO
)	O
.	O

Patients	B-LIVB
in	O
group	O
A	O
were	O
older	B-LIVB
(	O
74±12	O
years	O
vs	O
.	O

68±17	O
years	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
the	O
main	O
indication	O
for	O
anticoagulation	B-PROC
was	O
atrial	B-DISO
fibrillation	I-DISO
(	O
58	O
.	O
6	O
%	O
)	O
.	O

No	B-DISO
complications	B-DISO
occurred	O
during	O
the	O
procedures	B-PROC
.	O

There	O
were	O
no	B-DISO
acute	B-DISO
bleedings	I-DISO
just	O
after	O
the	O
bandage	B-DEVI
removal	O
.	O

During	O
the	O
first	O
24h	O
,	O
only	O
3	O
(	O
2	O
.	O
1	O
%	O
)	O
radial	B-DISO
occlusions	I-DISO
in	O
group	O
A	O
and	O
2	O
(	O
0	O
.	O
6	O
%	O
)	O
in	O
group	O
B	O
(	O
p	O
=	O
0	O
.	O

14	O
)	O
were	O
recorded	O
.	O

Hematomas	B-DISO
between	O
5	O
and	O
10	O
cm	O
appeared	O
in	O
5	O
%	O
of	O
the	O
group	O
A	O
vs	O
.	O

4	O
.	O
6	O
%	O
in	O
group	O
B	O
.	O

During	O
the	O
1	O
-	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
,	O
one	O
more	O
radial	B-DISO
occlusion	I-DISO
in	O
each	O
group	O
was	O
recorded	O
and	O
there	O
were	O
4	O
(	O
1	O
.	O
1	O
%	O
)	O
additional	O
mild	O
hematomas	B-DISO
in	O
group	O
B	O
and	O
none	O
in	O
group	O
A	O
(	O
p	O
=	O
0	O
.	O
48	O
)	O
.	O

Performing	O
a	O
transradial	B-PROC
diagnostic	I-PROC
cardiac	I-PROC
catheterization	I-PROC
without	O
removal	O
of	O
the	O
oral	O
chronic	O
anticoagulation	O
appears	O
safe	B-DISO
in	O
patients	B-LIVB
under	O
acenocumarol	B-CHEM
therapy	B-PROC
.	O

Does	O
infrared	B-DEVI
visualization	O
improve	O
selection	O
of	O
venipuncture	B-PROC
sites	O
for	O
indwelling	O
needle	B-DEVI
at	O
the	O
forearm	B-ANAT
in	O
second	O
-	O
year	O
nursing	B-LIVB
students	I-LIVB
?	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
vein	B-DEVI
visualization	I-DEVI
display	I-DEVI
system	I-DEVI
using	O
near	B-PHEN
-	I-PHEN
infrared	I-PHEN
light	I-PHEN
(	O
""""	O
Vein	B-DEVI
Display	I-DEVI
""""	O
)	O
for	O
the	O
safe	O
and	O
proper	O
selection	O
of	O
venipuncture	B-PROC
sites	O
for	O
indwelling	O
needle	B-DEVI
placement	O
in	O
the	O
forearm	B-ANAT
.	O

Ten	O
second	O
year	O
nursing	B-LIVB
students	I-LIVB
were	O
recruited	O
to	O
apply	O
an	O
indwelling	O
needle	B-DEVI
line	O
with	O
and	O
without	O
Vein	B-ANAT
Display	O
.	O

Another	O
ten	O
participants	B-LIVB
were	O
recruited	O
from	O
various	O
faculty	B-LIVB
to	O
serve	O
as	O
patients	B-LIVB
.	O

The	O
quality	O
of	O
the	O
venipuncture	B-PROC
procedure	I-PROC
at	O
various	O
selected	O
sites	O
was	O
evaluated	O
according	O
to	O
a	O
scale	O
developed	O
by	O
the	O
authors	B-LIVB
.	O

Time	O
,	O
scores	O
and	O
patterns	O
of	O
puncture	B-PROC
-	O
site	O
selection	O
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
:	O
[	O
1	O
]	O
attempt	O
1	O
(	O
tourniquet	B-DEVI
only	O
)	O
,	O
[	O
2	O
]	O
attempt	O
2	O
(	O
Vein	B-DEVI
Display	I-DEVI
only	O
)	O
and	O
[	O
3	O
]	O
attempt	O
3	O
(	O
both	O
)	O
.	O

To	O
validate	O
the	O
effectiveness	O
of	O
Vein	B-ANAT
Display	O
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O

We	O
found	O
that	O
venipuncture	B-PROC
site	O
selection	O
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein	B-DEVI
Display	I-DEVI
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	O
venipuncture	B-PROC
sites	O
.	O

Overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-PROC
quality	O
,	O
as	O
determined	O
by	O
our	O
scale	O
.	O

These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein	B-DEVI
Display	I-DEVI
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	O
skills	O
,	O
such	O
as	O
venipuncture	B-PROC
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	B-LIVB
patients	B-LIVB
.	O

Elective	B-PROC
Nephron	B-PROC
Sparing	I-PROC
Surgery	I-PROC
Decreases	O
Other	B-DISO
Cause	I-DISO
Mortality	I-DISO
Relative	O
to	O
Radical	B-PROC
Nephrectomy	I-PROC
Only	O
in	O
Specific	O
Subgroups	O
of	O
Patients	B-LIVB
with	O
Renal	B-DISO
Cell	I-DISO
Carcinoma	I-DISO
There	O
is	O
no	O
consensus	O
regarding	O
a	O
protective	B-DISO
effect	I-DISO
on	O
mortality	O
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-DISO
in	O
patients	B-LIVB
treated	B-PROC
with	I-PROC
elective	B-PROC
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
relative	O
to	O
their	O
radical	B-PROC
nephrectomy	I-PROC
counterparts	O
.	O

We	O
test	O
whether	O
the	O
protective	B-DISO
effect	I-DISO
of	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
relative	O
to	O
radical	B-PROC
nephrectomy	I-PROC
is	O
universal	O
or	O
present	O
in	O
specific	O
subgroups	O
of	O
patients	B-LIVB
.	O

A	O
collaborative	O
database	O
of	O
5	O
institutions	O
was	O
queried	O
to	O
evaluate	B-PROC
1	O
,	O
783	O
patients	B-LIVB
without	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
diagnosed	B-DISO
with	O
a	O
clinical	O
T1	B-DISO
renal	I-DISO
mass	I-DISO
that	O
was	O
treated	B-PROC
with	I-PROC
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
or	O
radical	B-PROC
nephrectomy	I-PROC
.	O

Multivariable	O
Cox	O
regression	O
analysis	O
was	O
done	O
to	O
assess	B-PROC
the	O
impact	O
of	O
surgery	B-PROC
type	O
(	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
vs	O
radical	B-PROC
nephrectomy	I-PROC
)	O
on	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
after	O
adjustment	O
for	O
patient	B-LIVB
and	O
cancer	B-DISO
characteristics	O
.	O

Interaction	O
terms	O
were	O
used	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
impact	O
of	O
surgery	B-PROC
type	O
varies	O
according	O
to	O
specific	O
subcohorts	B-LIVB
of	O
patients	B-LIVB
.	O

Ten	O
-	O
year	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
-free	O
survival	O
rates	O
were	O
90	O
%	O
and	O
88	O
%	O
after	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
and	O
radical	B-PROC
nephrectomy	I-PROC
,	O
respectively	O
.	O

In	O
the	O
overall	O
population	B-LIVB
radical	B-PROC
nephrectomy	I-PROC
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
on	O
multivariable	O
analysis	O
compared	O
to	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
(	O
HR	O
0	O
.	O
91	O
,	O
95	O
%	O
CI	O
0	O
.	O
6	O
-	O
1	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
6	O
)	O
.	O

However	O
,	O
radical	B-PROC
nephrectomy	I-PROC
increased	O
the	O
risk	O
of	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
according	O
to	O
the	O
increasing	O
baseline	O
Charlson	O
comorbidity	O
index	O
(	O
interaction	O
test	O
p	O
=	O
0	O
.	O
0008	O
)	O
.	O

For	O
example	O
,	O
in	O
a	O
patient	B-LIVB
with	O
a	O
Charlson	O
comorbidity	O
index	O
of	O
4	O
the	O
probability	O
of	O
10	O
-	O
year	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
-free	O
survival	O
was	O
86	O
%	O
after	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
and	O
60	O
%	O
after	O
radical	B-PROC
nephrectomy	I-PROC
.	O

Elective	B-PROC
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
does	O
not	O
improve	B-DISO
other	O
cause	O
survival	O
relative	O
to	O
radical	B-PROC
nephrectomy	I-PROC
consistently	O
in	O
all	O
patients	B-LIVB
with	O
kidney	B-DISO
cancer	I-DISO
.	O

Patients	B-LIVB
who	O
are	O
more	O
ill	B-DISO
with	O
relevant	O
comorbidities	O
are	O
those	O
who	O
benefit	O
the	O
most	O
from	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
in	O
terms	O
of	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
.	O

A	O
prime	B-PHYS
a	O
day	O
keeps	O
calories	O
away	O
:	O
The	O
effects	O
of	O
supraliminal	B-PHYS
priming	I-PHYS
on	O
food	O
consumption	O
and	O
the	O
moderating	O
role	O
of	O
gender	B-PHYS
and	O
eating	O
restraint	O
The	O
link	O
between	O
intentions	B-PHYS
and	O
action	O
in	O
weight	B-PROC
control	I-PROC
is	O
weaker	O
than	O
previously	O
thought	O
,	O
so	O
recent	O
research	B-PROC
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-PROC
control	I-PROC
that	O
bypass	O
conscious	B-PHYS
intentions	B-PHYS
.	O

Priming	B-PHYS
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	B-PHYS
cognition	B-PHYS
.	O

This	O
paper	O
investigates	O
the	O
effects	O
of	O
semantic	O
priming	O
using	O
healthy	O
body	B-PHYS
image	I-PHYS
,	O
goal	O
-	O
oriented	O
words	O
on	O
food	O
consumption	O
.	O

The	O
moderating	O
role	O
of	O
both	O
restrained	O
eating	O
and	O
gender	B-PHYS
is	O
investigated	O
.	O

161	O
participants	B-LIVB
were	O
involved	O
in	O
an	O
experiment	B-PROC
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	O
priming	B-PHYS
game	O
.	O

The	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	O
consumed	B-PROC
,	O
examined	O
using	O
a	O
between	O
subjects	O
ANCOVA	O
with	O
priming	B-PHYS
,	O
gender	B-PHYS
,	O
restrained	O
eating	O
index	O
,	O
self	B-PROC
-	I-PROC
reported	I-PROC
BMI	B-PHYS
,	O
and	O
two	O
interaction	O
terms	O
(	O
priming	B-PHYS
x	O
gender	B-PHYS
,	O
and	O
priming	B-PHYS
x	O
restrained	O
eating	O
index	O
)	O
.	O

There	O
was	O
no	O
main	O
effect	O
of	O
priming	B-PHYS
but	O
there	O
was	O
an	O
interaction	O
of	O
priming	B-PHYS
with	O
gender	B-PHYS
.	O

Females	B-PHYS
consumed	O
significantly	O
fewer	O
kilocalories	O
after	O
being	O
exposed	O
to	O
priming	B-PHYS
words	O
related	O
to	O
a	O
healthy	O
body	B-PHYS
image	I-PHYS
(	O
i	O
.	O
e	O
.	O
""""	O
slim	O
""""	O
,	O
""""	O
fit	O
,	O
""""	O
)	O
compared	O
to	O
females	B-PHYS
receiving	O
the	O
neutral	O
prime	B-PHYS
,	O
with	O
a	O
medium	O
effect	O
size	O
(	O
d	O
=	O
0	O
.	O
58	O
)	O
.	O

The	O
body	B-PHYS
image	I-PHYS
prime	B-PHYS
did	O
not	O
significantly	O
affect	O
food	B-PHYS
intake	I-PHYS
for	O
males	B-PHYS
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained	B-LIVB
eaters	I-LIVB
.	O

This	O
study	O
shows	O
that	O
priming	B-PHYS
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	B-PHYS
to	O
reduce	O
food	B-PHYS
intake	I-PHYS
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	B-LIVB
or	O
unrestrained	B-LIVB
eaters	I-LIVB
.	O

Future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	B-PHYS
words	O
related	O
to	O
a	O
male	B-PHYS
's	I-PHYS
healthy	O
body	B-PHYS
image	I-PHYS
goal	O
(	O
i	O
.	O
e	O
.	O
""""	O
buff	O
,	O
""""	O
""""	O
muscles	O
,	O
""""	O
etc	O
.	O
)	O
would	O
similarly	O
reduce	O
food	B-PHYS
intake	I-PHYS
for	O
males	B-PHYS
.	O

Neurotrophins	B-CHEM
and	O
specific	B-CHEM
receptors	I-CHEM
in	O
the	O
oviduct	B-ANAT
tracts	I-ANAT
of	O
Japanese	B-LIVB
quail	I-LIVB
(	O
Coturnix	B-LIVB
coturnix	I-LIVB
japonica	I-LIVB
)	O
Neurotrophins	B-CHEM
(	O
NGF	B-CHEM
,	O
BDNF	B-CHEM
and	O
NT	B-CHEM
-	I-CHEM
3	I-CHEM
)	O
and	O
their	O
specific	B-CHEM
receptors	I-CHEM
(	O
TrkA	B-CHEM
,	O
TrkB	B-CHEM
and	O
TrkC	B-CHEM
)	O
were	O
studied	B-PROC
in	O
the	O
oviduct	B-ANAT
of	O
egg	B-PHYS
laying	I-PHYS
quails	B-LIVB
.	O

Neurotrophins	B-CHEM
(	O
NTs	B-CHEM
)	O
are	O
mainly	O
involved	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
neuronal	B-ANAT
populations	I-ANAT
in	O
the	O
central	B-ANAT
and	O
peripheral	B-ANAT
nervous	I-ANAT
system	I-ANAT
,	O
but	O
also	O
in	O
reproductive	B-ANAT
system	I-ANAT
.	O

In	O
this	O
survey	O
,	O
we	O
first	O
studied	B-PROC
the	O
morphological	O
organization	B-PHYS
of	O
the	O
quail	B-LIVB
oviduct	B-ANAT
,	O
distinguished	O
in	O
infundibulum	B-ANAT
,	O
magnum	B-ANAT
,	O
isthmus	B-ANAT
,	O
uterus	B-ANAT
and	O
vagina	B-ANAT
,	O
and	O
then	O
we	O
analyzed	B-PROC
the	O
expression	B-PHYS
and	O
localization	B-PHYS
of	O
NTs	B-CHEM
and	O
Trks	B-CHEM
receptors	I-CHEM
in	O
the	O
whole	O
tracts	B-ANAT
.	O

By	O
western	B-PROC
blotting	I-PROC
we	O
detected	O
that	O
the	O
investigated	O
NTs	B-CHEM
and	O
Trks	B-CHEM
receptors	I-CHEM
are	O
expressed	B-PHYS
in	O
all	O
oviductal	B-ANAT
tracts	I-ANAT
.	O

By	O
immunohistochemistry	B-PROC
we	O
were	O
able	O
to	O
define	O
the	O
distribution	B-PHYS
of	O
NTs	B-CHEM
and	O
Trks	B-CHEM
.	O

Specifically	O
,	O
NGF	B-CHEM
,	O
BDNF	B-CHEM
and	O
NT3	B-CHEM
were	O
localized	O
in	O
lining	O
and	O
ductal	B-ANAT
epithelial	I-ANAT
cells	I-ANAT
,	O
and	O
NGF	B-CHEM
was	O
also	O
detected	O
in	O
secretory	B-ANAT
cells	I-ANAT
of	O
tubular	B-ANAT
glands	I-ANAT
and	O
in	O
nervous	B-ANAT
fibers	I-ANAT
of	O
vessel	B-ANAT
wall	I-ANAT
.	O

TrkA	B-CHEM
and	O
TrkB	B-CHEM
were	O
present	O
in	O
the	O
lining	O
and	O
ductal	O
epithelium	O
;	O
TrkA	B-CHEM
and	O
TrkC	B-CHEM
were	O
present	O
in	O
nervous	B-ANAT
fibers	I-ANAT
of	O
vessel	B-ANAT
wall	I-ANAT
in	O
all	O
oviductal	B-ANAT
tracts	I-ANAT
.	O

Furthermore	O
,	O
we	O
also	O
observed	O
NGF	B-CHEM
and	O
BDNF	B-CHEM
co	O
-	O
localized	O
with	O
TrkA	B-CHEM
and	O
TrkB	B-CHEM
in	O
cells	B-ANAT
of	O
the	O
lining	O
and	O
ductal	O
epithelium	O
,	O
suggesting	O
an	O
autocrine	B-PHYS
mechanism	I-PHYS
of	O
action	O
.	O

Laser	B-OBJC
-facilitated	O
epicutaneous	B-PROC
immunotherapy	B-PROC
to	O
IgE	B-DISO
-	I-DISO
mediated	I-DISO
allergy	I-DISO
Allergen	B-PROC
specific	I-PROC
immunotherapy	I-PROC
has	O
been	O
shown	O
to	O
be	O
the	O
only	O
effective	O
treatment	B-PROC
for	O
long	O
-	O
lasting	O
clinical	O
benefit	O
to	O
IgE	B-DISO
-	I-DISO
mediated	I-DISO
allergic	I-DISO
diseases	I-DISO
,	O
but	O
a	O
fewer	O
than	O
5	O
%	O
of	O
patients	B-LIVB
choose	O
the	O
treatment	B-PROC
because	O
of	O
inconvenience	O
and	O
a	O
high	B-DISO
risk	I-DISO
of	I-DISO
anaphylaxis	B-DISO
.	O

Recently	O
,	O
epicutaneous	B-PROC
allergen	I-PROC
-	I-PROC
specific	I-PROC
immunotherapy	I-PROC
(	O
EPIT	B-PROC
)	O
has	O
proven	O
effective	O
,	O
yet	O
with	O
limitations	O
owing	O
to	O
strong	B-PHYS
skin	I-PHYS
reactions	I-PHYS
.	O

We	O
demonstrate	O
here	O
safer	O
and	O
faster	O
EPIT	B-PROC
,	O
named	O
μEPIT	B-PROC
,	O
by	O
delivering	O
powdered	B-CHEM
allergen	I-CHEM
and	O
adjuvants	B-CHEM
into	O
many	O
micropores	B-ANAT
in	O
the	O
epidermis	O
.	O

We	O
fabricated	O
a	O
microarray	B-OBJC
patch	B-DEVI
fractionally	O
coated	O
with	O
a	O
powder	B-CHEM
mixture	I-CHEM
of	I-CHEM
ovalbumin	I-CHEM
(	O
OVA	B-CHEM
)	O
model	O
allergen	B-CHEM
,	O
CpG	B-CHEM
,	O
and	O
1	B-CHEM
,	I-CHEM
25	I-CHEM
-	I-CHEM
dihydroxyvitamin	I-CHEM
D3	I-CHEM
(	O
VD3	B-CHEM
)	O
.	O

Topical	B-PROC
application	I-PROC
of	O
the	O
patch	B-DEVI
onto	O
laser	B-DISO
-	I-DISO
microperforated	I-DISO
skin	B-ANAT
resulted	O
in	O
a	O
high	O
level	O
of	O
epidermal	O
delivery	O
while	O
greatly	O
minimizing	O
allergen	B-CHEM
leakage	B-DISO
into	O
circulation	B-ANAT
system	I-ANAT
as	O
compared	O
to	O
current	O
subcutaneous	B-PROC
immunotherapy	I-PROC
(	O
SCIT	B-PROC
)	O
.	O

Moreover	O
,	O
only	O
three	O
times	O
of	O
μEPIT	B-PROC
over	O
two	O
weeks	O
could	O
sufficiently	O
inhibit	O
allergen	B-CHEM
-	I-CHEM
specific	I-CHEM
IgE	I-CHEM
responses	B-PHYS
in	O
mice	B-LIVB
suffering	O
OVA	B-CHEM
-induced	O
airway	B-DISO
hyperresponsivness	I-DISO
(	O
AHR	B-DISO
)	O
,	O
which	O
was	O
unattainable	O
by	O
eight	O
times	O
of	O
SCIT	B-PROC
over	O
three	O
weeks	O
.	O

Mechanistically	O
,	O
μEPIT	B-PROC
preferably	O
enhanced	O
IgG2a	B-CHEM
production	B-PHEN
suggesting	O
TH1	B-ANAT
-	I-ANAT
biased	I-ANAT
immune	B-PHYS
responses	I-PHYS
and	O
induced	O
a	O
high	O
level	O
of	O
T	B-ANAT
-	I-ANAT
regulatory	I-ANAT
(	O
Treg	B-ANAT
)	O
cells	B-ANAT
against	O
repeated	O
allergen	B-DISO
sensitization	I-DISO
.	O

The	O
immune	B-DISO
tolerance	I-DISO
was	O
confirmed	O
by	O
marked	O
reduction	B-PROC
in	O
airway	B-ANAT
wall	I-ANAT
thickness	B-DISO
as	O
well	O
as	O
eosinophil	B-ANAT
and	O
neutrophil	B-PHYS
infiltration	I-PHYS
into	O
the	O
respiratory	B-ANAT
airway	I-ANAT
.	O

The	O
μEPIT	B-PROC
represents	O
a	O
novel	O
and	O
painless	O
technology	O
to	O
treat	B-PROC
IgE	B-DISO
-	I-DISO
mediated	I-DISO
allergic	I-DISO
diseases	I-DISO
with	O
little	O
local	B-PHYS
skin	I-PHYS
reaction	I-PHYS
and	O
a	O
minimal	O
risk	O
of	O
anaphylaxis	B-DISO
.	O

Predicting	O
real	O
-	O
world	B-LIVB
functional	O
milestones	O
in	O
schizophrenia	B-DISO
Schizophrenia	B-DISO
is	O
a	O
severe	B-DISO
disorder	I-DISO
that	O
often	O
causes	O
impairments	O
in	O
major	O
areas	O
of	O
functioning	O
,	O
and	O
most	O
patients	B-LIVB
do	O
not	O
achieve	O
expected	O
real	O
-	O
world	B-LIVB
functional	O
milestones	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
identify	O
which	O
variables	O
of	O
demography	O
,	O
illness	B-DISO
activity	O
,	O
and	O
functional	B-DISO
capacity	I-DISO
predict	O
patients	B-LIVB
'	O
ability	O
to	O
attain	O
real	O
-	O
world	B-LIVB
functional	O
milestones	O
.	O

Participants	B-LIVB
were	O
235	O
outpatients	B-LIVB
,	O
149	O
men	B-LIVB
and	O
86	O
women	B-LIVB
,	O
diagnosed	B-DISO
with	O
schizophrenia	B-DISO
spectrum	B-DISO
disorder	I-DISO
.	O

Our	O
results	O
showed	O
that	O
younger	O
patients	B-LIVB
managed	O
to	O
achieve	O
a	O
higher	O
level	O
of	O
functioning	O
in	O
educational	B-DISO
level	I-DISO
,	O
marital	O
status	O
,	O
and	O
social	B-DISO
contacts	I-DISO
.	O

Patients	B-LIVB
'	O
functional	B-DISO
capacity	I-DISO
was	O
primarily	O
associated	O
with	O
educational	B-DISO
level	I-DISO
and	O
housing	B-OBJC
situation	O
.	O

We	O
also	O
found	O
that	O
women	B-LIVB
needed	O
less	O
support	O
regarding	O
housing	B-OBJC
and	O
obtained	O
a	O
higher	O
level	O
of	O
marital	O
status	O
as	O
compared	O
with	O
men	B-LIVB
.	O

Our	O
findings	B-DISO
demonstrate	O
the	O
importance	O
of	O
considering	O
current	O
symptoms	B-DISO
,	O
especially	O
negative	B-DISO
symptoms	B-DISO
,	O
and	O
remission	B-DISO
stability	O
over	O
time	O
,	O
together	O
with	O
age	B-PHYS
,	O
duration	O
of	O
illness	O
,	O
gender	B-PHYS
,	O
educational	B-DISO
level	I-DISO
,	O
and	O
current	O
functional	B-DISO
capacity	I-DISO
,	O
when	O
predicting	O
patients	B-LIVB
'	O
future	O
real	O
-	O
world	B-LIVB
functioning	O
.	O

We	O
also	O
conclude	O
that	O
there	O
is	O
an	O
advantage	O
in	O
exploring	O
symptoms	B-DISO
divided	O
into	O
positive	B-DISO
,	O
negative	B-DISO
,	O
and	O
general	O
domains	O
considering	O
their	O
probable	O
impact	O
on	O
functional	O
achievements	O
.	O

LDLR	O
,	O
ApoB	O
and	O
ApoE	O
genes	O
polymorphisms	B-PHYS
and	O
classical	O
risk	B-DISO
factors	I-DISO
in	O
premature	B-DISO
coronary	I-DISO
artery	I-DISO
disease	I-DISO
Lipoproteins	B-CHEM
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	B-DISO
disease	I-DISO
.	O

So	O
,	O
with	O
their	O
ability	O
to	O
affect	O
lipid	B-PHEN
levels	I-PHEN
,	O
the	O
LDLR	O
,	O
ApoB	O
and	O
ApoE	O
polymorphisms	B-PHYS
could	O
be	O
one	O
of	O
the	O
factors	O
influencing	O
development	O
of	O
atherosclerosis	B-DISO
.	O

This	O
hypothesis	O
has	O
been	O
tested	O
in	O
different	O
populations	O
with	O
conflicting	O
results	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
the	O
LDLR	O
,	O
ApoB	O
and	O
ApoE	O
genes	O
polymorphisms	B-PHYS
with	O
premature	B-DISO
CAD	I-DISO
(	O
PCAD	B-DISO
)	O
in	O
Egyptians	B-LIVB
.	O

One	O
hundred	O
thirty	O
-	O
five	O
patients	B-LIVB
of	O
PCAD	B-DISO
and	O
one	O
hundred	O
thirty	O
-	O
two	O
ages	B-PHYS
and	O
sex	B-PHYS
matched	O
control	O
subjects	O
were	O
included	O
in	O
the	O
study	O
.	O

LDLR	O
and	O
ApoB	O
genes	O
polymorphisms	B-PHYS
were	O
analyzed	B-PROC
by	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
(	O
PCR	B-PROC
)	O
.	O

The	O
ApoE	O
genotypes	B-PHYS
were	O
identified	O
by	O
multiplex	B-PROC
amplification	I-PROC
refractory	I-PROC
mutation	I-PROC
system	I-PROC
(	O
multi	B-PROC
-	I-PROC
AMRS	I-PROC
)	O
.	O

We	O
found	O
that	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	B-PHYS
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
increased	O
the	O
risk	O
of	O
PCAD	B-DISO
by	O
1	O
.	O

8	O
,	O
2	O
.	O
1	O
and	O
12	O
.	O
1	O
respectively	O
.	O

The	O
present	O
study	O
proved	O
that	O
smoking	O
,	O
metabolic	B-DISO
syndrome	I-DISO
,	O
ApoB	O
X	O
(	O
+	O
)	O
X	O
(	O
+	O
)	O
genotype	B-PHYS
and	O
ApoE	O
E4	O
allele	O
were	O
independent	O
risk	B-DISO
factors	I-DISO
for	O
the	O
development	O
of	O
PCAD	B-DISO
.	O

This	O
is	O
the	O
first	O
study	O
investigate	O
the	O
association	O
between	O
low	O
density	O
lipoprotein	O
receptor	O
,	O
apolipoprotein	O
B	O
and	O
apolipoprotein	O
E	O
genes	O
polymorphisms	B-PHYS
with	O
PCAD	B-DISO
and	O
lipid	B-PHEN
levels	I-PHEN
in	O
Egyptians	B-LIVB
and	O
we	O
concluded	O
that	O
the	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	B-PHYS
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
development	O
of	O
PCAD	B-DISO
by	O
elevated	O
levels	B-PROC
of	I-PROC
total	I-PROC
cholesterol	I-PROC
(	I-PROC
TC	I-PROC
)	I-PROC
and	O
low	B-PROC
density	I-PROC
lipoprotein	I-PROC
(	O
LDLc	B-PROC
)	O
.	O

The	O
coexistence	O
of	O
CAD	B-DISO
risk	B-DISO
factors	I-DISO
with	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	B-PHYS
,	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O
ApoE	O
E4	O
allele	O
may	O
increase	O
the	O
risk	O
of	O
the	O
development	O
of	O
PCAD	B-DISO
in	O
Egyptian	B-LIVB
patients	B-LIVB
.	O

The	O
influence	O
of	O
liposomal	B-CHEM
formulation	O
on	O
the	O
incorporation	O
and	O
retention	O
of	O
PNA	B-CHEM
oligomers	I-CHEM
Liposomal	B-CHEM
formulations	O
composed	O
of	O
phospholipids	B-CHEM
with	O
different	O
unsaturation	O
degrees	O
,	O
head	O
groups	O
and	O
at	O
different	O
cholesterol	B-PROC
content	I-PROC
have	I-PROC
been	I-PROC
tested	I-PROC
for	O
the	O
encapsulation	B-PHEN
of	O
Peptide	B-CHEM
Nucleic	I-CHEM
Acid	I-CHEM
(	I-CHEM
PNA	I-CHEM
)	I-CHEM
oligomers	I-CHEM
.	O

The	O
best	O
loading	O
capability	O
(	O
177μg	O
,	O
ER	O
%	O
=	O
87	O
.	O

2	O
)	O
was	O
obtained	O
for	O
pure	O
liposomes	B-CHEM
of	O
phosphatidylglycerol	B-CHEM
(	O
DOPG	B-CHEM
)	O
with	O
negatively	B-CHEM
charged	I-CHEM
head	O
group	O
.	O

The	O
insertion	B-PROC
of	O
a	O
10	O
-	O
20	O
%	O
of	O
cholesterol	B-CHEM
in	O
DOPG	B-CHEM
based	O
liposomes	B-CHEM
provides	O
a	O
slight	O
decrease	O
(	O
∼160μg	O
)	O
of	O
the	O
PNA	B-CHEM
loading	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
cholesterol	B-CHEM
addition	O
(	O
20	O
-	O
30	O
%	O
)	O
slows	O
down	O
the	O
PNA	B-CHEM
's	I-CHEM
release	B-PHEN
(	O
∼27	O
%	O
)	O
in	O
fetal	B-CHEM
bovine	I-CHEM
serum	I-CHEM
from	O
the	O
liposomal	B-CHEM
formulation	O
.	O

Based	O
on	O
the	O
encapsulation	B-PHEN
and	O
the	O
release	B-PHEN
properties	I-PHEN
,	O
PEGylated	B-CHEM
DOPG	B-CHEM
liposomes	B-CHEM
with	O
a	O
percentage	O
of	O
cholesterol	B-CHEM
of	O
10	O
-	O
20	O
%	O
are	O
the	O
optimal	B-PROC
formulation	I-PROC
for	O
the	O
loading	O
of	O
PNA	B-CHEM
-	I-CHEM
a210	I-CHEM
.	O

Mandibular	B-ANAT
kinesiographic	O
pattern	O
of	O
women	B-LIVB
with	O
chronic	O
TMD	B-DISO
after	O
management	B-PROC
with	O
educational	O
and	O
self	B-PROC
-	I-PROC
care	I-PROC
therapies	I-PROC
:	O
A	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
Limited	B-DISO
mandibular	I-DISO
movements	I-DISO
are	O
one	O
of	O
the	O
most	O
important	O
signs	B-DISO
of	O
temporomandibular	B-DISO
disorders	I-DISO
(	O
TMDs	B-DISO
)	O
and	O
may	O
cause	O
functional	O
difficulties	O
.	O

The	O
purpose	O
of	O
this	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
was	O
to	O
evaluate	B-PROC
the	O
effect	O
of	O
treatment	B-PROC
with	O
only	O
educational	O
or	O
education	O
associated	O
with	O
self	B-PROC
-	I-PROC
care	I-PROC
therapies	I-PROC
on	O
the	O
pattern	O
of	O
mandibular	B-ANAT
movements	B-PHYS
of	O
women	B-LIVB
with	O
chronic	B-DISO
painful	I-DISO
TMDs	B-DISO
.	O

Forty	O
-	O
two	O
women	B-LIVB
were	O
selected	O
and	O
randomly	O
divided	O
into	O
3	O
groups	O
,	O
control	B-LIVB
group	I-LIVB
(	O
CG	B-LIVB
,	O
n	O
=	O
13	O
)	O
,	O
education	O
group	O
(	O
EG	O
,	O
n	O
=	O
16	O
)	O
,	O
and	O
education	O
and	O
self	O
-	O
care	O
group	O
(	O
ESG	O
,	O
n	O
=	O
13	O
)	O
,	O
according	O
to	O
the	O
sequence	O
of	O
treatment	B-PROC
they	O
received	O
.	O

A	O
kinesiograph	B-DEVI
device	I-DEVI
recorded	O
mandibular	B-ANAT
movements	B-PHYS
during	O
maximum	O
mouth	B-ANAT
opening	B-PHYS
and	O
mastication	B-PHYS
at	O
baseline	O
(	O
T0	O
)	O
and	O
at	O
30	O
-	O
day	O
(	O
T1	O
)	O
and	O
60	O
-	O
day	O
(	O
T2	O
)	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Kinesiographic	O
data	O
were	O
statistically	B-PROC
analyzed	I-PROC
using	O
1	O
-	O
way	O
ANOVA	O
,	O
followed	O
by	O
the	O
Bonferroni	O
test	O
for	O
multiple	O
comparisons	O
of	O
means	O
(	O
α	O
=	O
.	O
05	O
)	O
.	O

The	O
ESG	O
group	O
demonstrated	O
an	O
improvement	O
in	O
the	O
maximum	B-PHYS
vertical	I-PHYS
opening	I-PHYS
(	O
MVO	B-PHYS
=	O
5	O
.	O
1	O
±3	O
.	O
4	O
mm	O
;	O
P	O
=	O
.	O

012	O
)	O
and	O
anteroposterior	B-PHYS
mandibular	I-PHYS
movement	I-PHYS
(	O
MAM	B-PHYS
)	O
during	O
maximum	O
opening	B-PHYS
(	O
7	O
.	O
4	O
±9	O
.	O
5	O
;	O
P	O
=	O
.	O

019	O
)	O
,	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
EG	O
(	O
MVO	B-PHYS
=	O
1	O
.	O
8	O
±3	O
.	O
5	O
mm	O
;	O
MAM	B-PHYS
=	O
0	O
.	O
8	O
±5	O
.	O
0	O
mm	O
)	O
and	O
the	O
CG	B-LIVB
(	O
MVO	B-PHYS
=	O
0	O
.	O
9	O
±3	O
.	O
8	O
mm	O
;	O
MAM	B-PHYS
=	O
0	O
.	O
8	O
±4	O
.	O
4	O
mm	O
)	O
after	O
30	O
days	O
of	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Moreover	O
,	O
at	O
T1	O
,	O
vertical	O
mandibular	B-ANAT
movement	B-PHYS
during	O
mastication	B-PHYS
was	O
significantly	O
higher	O
in	O
the	O
ESG	O
group	O
(	O
17	O
.	O
4	O
±1	O
.	O
7	O
mm	O
)	O
than	O
in	O
the	O
EG	O
group	O
(	O
15	O
.	O
0	O
±2	O
.	O
8	O
,	O
P	O
=	O
.	O

027	O
)	O
.	O

No	B-DISO
significant	I-DISO
differences	O
were	O
found	B-DISO
between	O
the	O
women	B-LIVB
who	O
received	O
treatment	B-PROC
with	O
educational	O
and	O
self	B-PROC
-	I-PROC
care	I-PROC
therapies	I-PROC
for	O
60	O
days	O
and	O
the	O
women	B-LIVB
who	O
received	O
this	O
treatment	B-PROC
for	O
30	O
days	O
.	O

In	O
the	O
short	O
-	O
term	O
,	O
education	O
and	O
self	B-PROC
-	I-PROC
care	I-PROC
treatment	I-PROC
positively	B-DISO
influenced	O
the	O
mandibular	B-ANAT
movement	B-PHYS
pattern	O
of	O
women	B-LIVB
with	O
chronic	B-DISO
painful	I-DISO
TMDs	B-DISO
.	O

Histopathology	O
of	O
the	O
filum	B-ANAT
terminale	I-ANAT
in	O
children	B-LIVB
with	O
and	O
without	O
tethered	B-DISO
cord	I-DISO
syndrome	I-DISO
with	O
attention	O
to	O
the	O
elastic	O
tissue	O
within	O
the	O
filum	B-ANAT
To	O
compare	O
histologically	O
transected	O
fila	B-ANAT
from	O
pediatric	O
patients	B-LIVB
with	O
tethered	B-DISO
cord	I-DISO
syndrome	I-DISO
(	O
TCS	B-DISO
)	O
,	O
with	O
and	O
without	O
a	O
low	B-ANAT
conus	B-ANAT
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	O
and	O
elastic	O
tissue	O
.	O

Thirty	O
fila	B-ANAT
from	O
patients	B-LIVB
with	O
TCS	B-DISO
,	O
including	O
5	O
where	O
minimal	O
cautery	B-PROC
was	O
used	O
prior	O
to	O
filum	B-ANAT
section	B-PROC
,	O
were	O
compared	O
with	O
fila	B-ANAT
from	O
27	O
pediatric	O
cadavers	B-ANAT
without	O
TCS	B-DISO
(	O
controls	B-LIVB
)	O
.	O

Sections	B-OBJC
of	O
fila	B-ANAT
were	O
stained	B-PROC
with	O
H	B-PROC
&	I-PROC
E	I-PROC
,	O
Masson	B-PROC
trichrome	I-PROC
and	O
Verhoeff	B-PROC
von	I-PROC
Gieson	I-PROC
elastic	I-PROC
stains	I-PROC
,	O
and	O
7	O
with	O
Gordon	B-PROC
and	I-PROC
Sweet	I-PROC
's	I-PROC
reticulin	I-PROC
stain	I-PROC
.	O

Fila	B-ANAT
from	O
controls	B-LIVB
showed	O
loose	O
fibrous	O
connective	O
tissue	O
(	O
FCT	O
)	O
with	O
thin	O
and	O
evenly	O
dispersed	O
elastic	O
fibers	O
(	O
EFs	O
)	O
.	O

Reticulin	B-CHEM
fibers	I-CHEM
(	O
RFs	B-CHEM
)	O
were	O
seen	O
in	O
blood	B-ANAT
vessel	I-ANAT
walls	I-ANAT
and	O
nerve	O
twigs	O
.	O

Fat	B-CHEM
was	O
identified	O
microscopically	O
in	O
2	O
fila	B-ANAT
.	O

All	O
fila	B-ANAT
from	O
patients	B-LIVB
with	O
TCS	B-DISO
had	O
dense	O
FCT	O
.	O

The	O
EFs	O
were	O
in	O
normal	O
numbers	O
in	O
17	O
,	O
and	O
focally	O
or	O
diffusely	O
decreased	O
in	O
13	O
.	O

All	O
25	O
patients	B-LIVB
where	O
the	O
fila	B-ANAT
were	O
cauterized	B-PROC
during	O
resection	B-PROC
had	O
thick	O
and	O
coiled	O
EFs	O
.	O

Coiling	O
was	O
not	O
seen	O
when	O
minimal	O
cautery	B-PROC
was	O
applied	O
.	O

RFs	B-CHEM
were	O
seen	O
in	O
blood	B-ANAT
vessel	I-ANAT
walls	I-ANAT
and	O
nerve	O
twigs	O
.	O

Fat	B-CHEM
was	O
identified	O
in	O
19	O
patients	B-LIVB
.	O

Findings	B-DISO
were	O
similar	O
,	O
whether	O
the	O
conus	B-ANAT
termination	O
was	O
normal	O
or	O
low	O
.	O

The	O
fila	B-ANAT
of	O
all	O
patients	B-LIVB
with	O
TCS	B-DISO
,	O
whether	O
or	O
not	O
the	O
conus	B-ANAT
was	O
low	O
,	O
showed	O
abnormal	B-DISO
FCT	O
.	O

EFs	O
were	O
decreased	O
in	O
48	O
%	O
of	O
patients	B-LIVB
;	O
however	O
,	O
there	O
were	O
thick	O
and	O
coiled	O
EFs	O
in	O
all	O
patients	B-LIVB
.	O

Coiling	O
of	O
EFs	O
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	B-DISO
in	O
patients	B-LIVB
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	B-DISO
of	O
cautery	B-PROC
(	O
i	O
.	O
e	O
.	O
,	O
artifactual	B-PHEN
/	O
iatrogenic	O
coiling	O
)	O
.	O

Clinical	B-DISO
value	I-DISO
of	O
pathologic	B-PROC
examination	I-PROC
of	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
in	O
patients	B-LIVB
with	O
upper	B-ANAT
urinary	I-ANAT
tract	I-ANAT
malignancies	B-DISO
While	O
surgical	B-PROC
resection	I-PROC
remains	O
the	O
standard	O
of	O
care	O
in	O
the	O
treatment	B-PROC
of	O
upper	B-ANAT
urinary	I-ANAT
tract	I-ANAT
malignancies	B-DISO
,	O
nephrectomy	B-PROC
is	O
a	O
risk	B-DISO
factor	I-DISO
for	O
the	O
development	O
of	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
(	O
CKD	B-DISO
)	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	O
whether	O
histologic	O
evaluation	B-PROC
of	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
could	O
enable	O
early	B-PROC
identification	I-PROC
of	O
unrecognized	O
kidney	B-DISO
disease	I-DISO
and	O
could	O
be	O
of	O
prognostic	O
value	O
in	O
predicting	O
postoperative	O
renal	B-ANAT
outcomes	O
.	O

We	O
retrospectively	B-PROC
analyzed	I-PROC
51	O
patients	B-LIVB
with	O
upper	B-ANAT
urinary	I-ANAT
tract	I-ANAT
malignancies	B-DISO
who	O
received	O
uninephrectomy	B-PROC
or	O
uninephroureterectomy	B-PROC
.	O

A	O
thorough	O
pathologic	O
evaluation	B-PROC
of	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
including	O
special	B-PROC
stains	I-PROC
,	O
immunofluorescence	B-PROC
,	O
and	O
electron	B-PROC
microscopic	I-PROC
studies	I-PROC
was	O
performed	O
.	O

The	O
degree	O
of	O
parenchymal	B-ANAT
changes	O
was	O
graded	O
from	O
0	O
to	O
15	O
.	O

Of	O
51	O
patients	B-LIVB
,	O
only	O
13	O
showed	O
normal	O
kidney	B-ANAT
pathology	O
.	O

Fifteen	O
patients	B-LIVB
showed	O
glomerular	B-DISO
abnormalities	I-DISO
,	O
14	O
showed	O
diabetic	B-DISO
nephropathy	I-DISO
,	O
and	O
11	O
showed	O
vascular	B-ANAT
nephropathy	B-PROC
.	O

There	O
was	O
one	O
case	O
each	O
of	O
reflux	B-DISO
nephropathy	I-DISO
and	O
chronic	B-DISO
pyelonephritis	I-DISO
.	O

The	O
median	O
histologic	O
score	O
was	O
5	O
points	O
.	O

Only	O
25	O
.	O
4	O
%	O
of	O
patients	B-LIVB
had	O
≤	O
3	O
points	O
.	O

Score	O
more	O
than	O
5	O
was	O
observed	O
in	O
47	O
.	O

1	O
%	O
of	O
patients	B-LIVB
.	O

Postoperative	O
estimated	B-PROC
glomerular	I-PROC
filtration	I-PROC
rate	I-PROC
(	O
eGFR	B-PROC
)	O
at	O
3	O
to	O
36	O
months	O
were	O
obtained	O
from	O
90	O
.	O

2	O
%	O
of	O
patients	B-LIVB
,	O
and	O
of	O
those	O
,	O
34	O
.	O

8	O
%	O
had	O
de	O
novo	O
CKD	B-DISO
.	O

Since	O
no	O
one	O
had	O
CKD	B-DISO
in	O
partial	O
nephrectomized	B-LIVB
patients	I-LIVB
,	O
we	O
determined	O
risk	B-DISO
factors	I-DISO
for	O
CKD	B-DISO
in	O
radical	O
nephrectomized	B-LIVB
patients	I-LIVB
.	O

Cox	O
regression	O
analysis	O
revealed	O
that	O
postoperative	O
AKI	B-DISO
,	O
preoperative	O
eGFR	B-PROC
,	O
and	O
histologic	O
score	O
of	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
were	O
the	O
independent	O
predictors	O
for	O
CKD	B-DISO
.	O

We	O
conclude	O
that	O
routine	O
pathologic	O
evaluation	B-PROC
of	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
provides	O
valuable	O
diagnostic	O
and	O
prognostic	O
information	O
.	O

Prospective	O
study	O
of	O
dietary	B-OBJC
Non	B-PROC
Enzymatic	I-PROC
Antioxidant	I-PROC
Capacity	I-PROC
on	O
the	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
in	O
the	O
elderly	B-LIVB
Dietary	B-OBJC
antioxidants	I-OBJC
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	B-DISO
loss	I-DISO
and	O
associated	O
fractures	B-DISO
by	O
reducing	O
levels	O
of	O
oxidative	B-DISO
stress	I-DISO
.	O

We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	B-OBJC
Non	B-PROC
Enzymatic	I-PROC
Antioxidant	I-PROC
Capacity	I-PROC
(	O
NEAC	B-PROC
)	O
and	O
the	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	O
.	O

In	O
the	O
Swedish	B-LIVB
National	I-LIVB
March	I-LIVB
Cohort	I-LIVB
13	O
,	O
409	O
men	B-LIVB
and	O
women	B-LIVB
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-DISO
,	O
cardiovascular	B-DISO
disease	I-DISO
or	O
hip	B-DISO
fracture	I-DISO
,	O
were	O
followed	O
through	O
record	B-PROC
-	I-PROC
linkages	I-PROC
from	O
1997	O
through	O
2010	O
.	O

NEAC	B-PROC
was	O
assessed	O
by	O
a	O
validated	O
food	O
frequency	O
questionnaire	O
collected	O
at	O
baseline	O
.	O

We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-PROC
into	O
sex	B-PHYS
-	O
specific	O
quartiles	O
and	O
used	O
multivariable	O
adjusted	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
to	O
estimate	O
hazard	O
ratios	O
(	O
HRs	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

During	O
a	O
mean	O
follow	B-PROC
-	I-PROC
up	I-PROC
time	O
of	O
12	O
.	O

4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	B-DISO
fracture	I-DISO
.	O

Subjects	O
in	O
the	O
highest	O
quartile	O
of	O
dietary	B-OBJC
NEAC	B-PROC
had	O
a	O
39	O
%	O
lower	B-DISO
risk	I-DISO
of	O
incident	O
hip	B-DISO
fracture	I-DISO
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
HR	O
:	O
0	O
.	O
61	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
44	O
-	O
0	O
.	O
85	O
)	O
.	O

The	O
association	O
was	O
non	O
-	O
linear	O
(	O
p	O
for	O
non	O
-	O
linearity	O
:	O
0	O
.	O
004	O
)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	O
and	O
no	O
further	O
risk	O
reduction	O
at	O
higher	O
levels	O
of	O
dietary	B-OBJC
NEAC	B-PROC
.	O

Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	B-OBJC
NEAC	B-PROC
and	O
smoking	O
on	O
a	O
multiplicative	O
or	O
additive	O
scale	O
.	O

Higher	O
dietary	O
NEAC	B-PROC
intake	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
in	O
the	O
elderly	O
.	O

MiR	O
-	O
211	O
is	O
epigenetically	B-PHYS
regulated	I-PHYS
by	O
DNMT1	O
mediated	O
methylation	B-PHYS
and	O
inhibits	O
EMT	B-PHYS
of	O
melanoma	B-ANAT
cells	I-ANAT
by	O
targeting	B-PROC
RAB22A	O
MiR	O
-	O
211	O
has	O
strong	O
inhibitive	O
effects	O
on	O
melanoma	B-DISO
cell	B-PHYS
growth	I-PHYS
,	O
invasion	B-DISO
and	O
metastasis	B-DISO
.	O

However	O
,	O
how	O
it	O
is	O
downregulated	B-PHYS
and	O
whether	O
other	O
genes	O
are	O
involved	O
its	O
downstream	O
regulation	B-PHYS
in	O
melanoma	B-DISO
are	O
not	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
firstly	O
verified	O
the	O
expression	B-PHYS
of	O
miR	O
-	O
211	O
in	O
melanoma	B-ANAT
cell	I-ANAT
lines	I-ANAT
and	O
observed	O
that	O
its	O
downregulation	B-PHYS
is	O
associated	O
with	O
increased	O
DNMT1	O
expression	B-PHYS
.	O

By	O
performing	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
and	O
MSP	B-PROC
analysis	I-PROC
,	O
we	O
confirmed	O
that	O
DNMT1	O
is	O
negatively	B-DISO
correlated	O
with	O
miR	O
-	O
211	O
expression	B-PHYS
and	O
can	O
modulate	O
DNA	B-PHYS
methylation	I-PHYS
in	O
the	O
promoter	B-CHEM
region	I-CHEM
of	O
miR	O
-	O
211	O
.	O

By	O
performing	O
bioinformatics	O
analysis	O
,	O
we	O
found	O
that	O
RAB22A	O
is	O
a	O
possible	O
target	O
of	O
miR	O
-	O
211	O
,	O
which	O
has	O
two	O
broadly	O
conversed	O
binding	B-CHEM
sites	I-CHEM
with	O
miR	O
-	O
211	O
in	O
the	O
3	O
'	O
UTR	O
.	O

Following	O
dual	O
luciferase	B-CHEM
assay	B-PROC
,	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
and	O
western	B-PROC
blot	I-PROC
analysis	I-PROC
confirmed	O
the	O
direct	O
binding	B-PHYS
between	O
miR	O
-	O
211	O
and	O
RAB22A	O
and	O
the	O
suppressive	B-PHYS
effect	I-PHYS
of	O
miR	O
-	O
211	O
on	O
RAB22A	O
expression	B-PHYS
.	O

Knockdown	B-PROC
of	O
RAB22A	O
increased	O
epithelial	O
properties	O
and	O
impaired	O
mesenchymal	O
properties	O
of	O
the	O
melanoma	B-ANAT
cells	I-ANAT
,	O
suggesting	O
that	O
miR	O
-	O
211	O
modulates	O
epithelial	B-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O
EMT	B-PHYS
)	O
of	O
melanoma	B-ANAT
cells	I-ANAT
via	O
downregulating	B-PHYS
RAB22A	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
firstly	O
demonstrated	O
that	O
DNMT1	O
mediated	O
promoter	B-CHEM
methylation	B-PHYS
is	O
a	O
mechanism	O
of	O
miRNA	B-CHEM
suppression	B-PHYS
in	O
melanoma	B-DISO
and	O
revealed	O
a	O
new	O
tumor	O
suppressor	O
role	O
of	O
the	O
miR	O
-	O
211	O
by	O
targeting	B-PROC
RAB22A	O
in	O
melanoma	B-DISO
.	O

The	O
DNMT1	O
/	O
miR	O
-	O
211	O
/	O
RAB22A	O
axis	O
provides	O
a	O
novel	O
insight	O
into	O
the	O
pathogenesis	B-DISO
of	O
melanoma	B-DISO
,	O
particularly	O
in	O
the	O
EMT	B-PHYS
process	I-PHYS
.	O

Concordant	O
but	O
Varied	O
Phenotypes	B-PHYS
among	O
Duchenne	B-DISO
Muscular	I-DISO
Dystrophy	I-DISO
Patient	B-LIVB
-Specific	O
Myoblasts	B-ANAT
Derived	O
using	O
a	O
Human	B-LIVB
iPSC	B-ANAT
-Based	O
Model	B-DISO
Duchenne	B-DISO
muscular	I-DISO
dystrophy	I-DISO
(	O
DMD	B-DISO
)	O
remains	O
an	O
intractable	O
genetic	B-DISO
disease	I-DISO
.	O

Althogh	O
there	O
are	O
several	O
animal	B-DISO
models	I-DISO
of	O
DMD	B-DISO
,	O
there	O
is	O
no	O
human	B-ANAT
cell	I-ANAT
model	O
that	O
carries	O
patient	B-LIVB
-specific	O
DYSTROPHIN	O
mutations	B-PHYS
.	O

Here	O
,	O
we	O
present	O
a	O
human	B-LIVB
DMD	B-DISO
model	B-DISO
using	O
human	B-ANAT
induced	I-ANAT
pluripotent	I-ANAT
stem	I-ANAT
cells	I-ANAT
(	O
hiPSCs	B-ANAT
)	O
.	O

Our	O
model	O
reveals	O
concordant	O
disease	B-DISO
-	O
related	O
phenotypes	B-PHYS
with	O
patient	B-LIVB
-	O
dependent	O
variation	O
,	O
which	O
are	O
partially	O
reversed	O
by	O
genetic	O
and	O
pharmacological	O
approaches	O
.	O

Our	O
""""	O
chemical	B-CHEM
-	I-CHEM
compound	I-CHEM
-based	O
""""	O
strategy	B-PROC
successfully	O
directs	O
hiPSCs	B-ANAT
into	O
expandable	O
myoblasts	B-ANAT
,	O
which	O
exhibit	O
a	O
myogenic	B-PHYS
transcriptional	I-PHYS
program	O
,	O
forming	O
striated	O
contractile	B-ANAT
myofibers	B-ANAT
and	O
participating	O
in	O
muscle	B-DISO
regeneration	I-DISO
in	O
vivo	O
.	O

DMD	B-DISO
-	O
hiPSC	B-ANAT
-derived	O
myoblasts	B-ANAT
show	O
disease	B-DISO
-	O
related	O
phenotypes	B-PHYS
with	O
patient	B-LIVB
-to	O
-	O
patient	B-LIVB
variability	O
,	O
including	O
aberrant	O
expression	O
of	O
inflammation	B-DISO
or	O
immune	O
-	O
response	O
genes	O
and	O
collagens	B-CHEM
,	O
increased	O
BMP	B-PHYS
/	O
TGFβ	B-PHYS
signaling	I-PHYS
,	O
and	O
reduced	O
fusion	O
competence	O
.	O

Furthermore	O
,	O
by	O
genetic	O
correction	O
and	O
pharmacological	O
""""	O
dual	O
-	O
SMAD	B-CHEM
""""	O
inhibition	B-PHYS
,	O
the	O
DMD	B-DISO
-	O
hiPSC	B-ANAT
-derived	O
myoblasts	B-ANAT
and	O
genetically	O
corrected	O
isogenic	O
myoblasts	B-ANAT
form	O
""""	O
rescued	O
""""	O
multi	O
-	O
nucleated	O
myotubes	B-ANAT
.	O

In	O
conclusion	O
,	O
our	O
findings	O
demonstrate	O
the	O
feasibility	O
of	O
establishing	O
a	O
human	B-LIVB
""""	O
DMD	B-DISO
-in	O
-	O
a	O
-	O
dish	O
""""	O
model	B-DISO
using	O
hiPSC	B-ANAT
-based	O
disease	B-DISO
modeling	I-DISO
.	O

SNAI1	B-CHEM
promotes	O
the	O
development	O
of	O
HCC	B-DISO
through	O
the	O
enhancement	O
of	O
proliferation	O
and	O
inhibition	B-PHYS
of	I-PHYS
apoptosis	I-PHYS
SNAI1	B-CHEM
,	O
a	O
zinc	B-CHEM
-	I-CHEM
finger	I-CHEM
transcription	I-CHEM
factor	I-CHEM
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
epithelial	B-PHYS
-	I-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O
EMT	B-PHYS
)	O
in	O
various	O
cancers	B-DISO
.	O

However	O
,	O
the	O
possible	O
functions	O
of	O
SNAI1	B-CHEM
in	O
the	O
proliferation	O
and	O
apoptosis	B-PHYS
of	O
hepatocellular	B-DISO
carcinoma	I-DISO
have	O
not	O
been	O
clearly	O
identified	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
investigated	O
the	O
effects	O
and	O
mechanisms	O
of	O
SNAI1	B-CHEM
in	O
the	O
proliferation	O
and	O
apoptosis	B-PHYS
of	O
hepatocellular	B-DISO
carcinoma	I-DISO
using	O
clinical	O
samples	B-OBJC
and	O
cell	B-ANAT
lines	I-ANAT
.	O

We	O
found	O
that	O
SNAI1	B-CHEM
is	O
highly	O
expressed	B-PHYS
in	O
the	O
tissues	O
of	O
liver	B-DISO
cancer	I-DISO
compared	O
with	O
adjacent	O
nontumor	O
tissues	O
.	O

SNAI1	B-CHEM
is	O
also	O
highly	O
expressed	B-PHYS
in	O
the	O
hepatoma	B-ANAT
cell	I-ANAT
lines	I-ANAT
HepG2	I-ANAT
,	O
SMMC	B-ANAT
-	I-ANAT
7721	I-ANAT
,	O
and	O
BEL	B-ANAT
-	I-ANAT
7402	I-ANAT
compared	O
with	O
the	O
human	B-ANAT
normal	I-ANAT
liver	I-ANAT
cell	I-ANAT
line	I-ANAT
L02	I-ANAT
.	O

We	O
also	O
observed	O
that	O
SNAI1	B-CHEM
expression	B-PHYS
was	O
correlated	O
with	O
distal	B-DISO
metastasis	I-DISO
,	O
incomplete	O
tumor	B-DISO
capsule	I-DISO
formation	I-DISO
,	O
and	O
histological	B-PHYS
differentiation	I-PHYS
in	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O
HCC	B-DISO
)	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
knockdown	B-PROC
of	O
SNAI1	O
via	O
lentiviral	B-LIVB
vectors	B-CHEM
of	O
RNAi	B-PHYS
against	O
SNAI	B-CHEM
inhibited	O
cell	O
proliferation	O
by	O
inducing	O
G1	B-PHYS
arrest	I-PHYS
,	O
which	O
was	O
accompanied	O
by	O
the	O
downregulation	B-PHYS
of	O
cyclin	B-CHEM
D1	I-CHEM
but	O
not	O
that	O
of	O
cyclin	B-CHEM
A	I-CHEM
.	O

In	O
addition	O
,	O
knockdown	B-PROC
of	O
SNAI1	O
promoted	O
apoptosis	B-PHYS
by	O
decreasing	O
the	O
expression	B-PHYS
of	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
.	O

In	O
conclusion	O
,	O
our	O
findings	O
revealed	O
that	O
SNAI1	B-CHEM
is	O
involved	O
in	O
the	O
development	O
of	O
hepatocellular	B-DISO
carcinoma	I-DISO
via	O
regulating	B-PHYS
the	I-PHYS
growth	I-PHYS
and	O
apoptosis	B-PHYS
of	O
tumor	B-ANAT
cells	I-ANAT
.	O

Function	B-PHYS
and	O
clinical	O
meaningfulness	O
of	O
treatments	B-PROC
for	O
mild	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
Effectiveness	O
of	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O
AD	B-DISO
)	O
treatments	B-PROC
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	B-PHYS
with	O
function	B-PHYS
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	B-PHYS
effect	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	B-PHYS
outcomes	O
in	O
mild	O
AD	B-DISO
or	O
mild	B-DISO
cognitive	I-DISO
impairment	I-DISO
(	O
MCI	B-DISO
)	O
patients	B-LIVB
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
AD	B-DISO
)	O
treated	B-PROC
with	I-PROC
approved	O
AD	B-DISO
drugs	B-CHEM
.	O

Cognitive	B-PROC
and	O
functional	B-PHYS
treatment	B-PROC
differences	O
in	O
mild	O
AD	B-DISO
patients	B-LIVB
in	O
solanezumab	B-CHEM
EXPEDITION	O
/	O
EXPEDITION2	O
studies	B-PROC
were	O
compared	O
across	O
time	O
.	O

Seven	O
publications	B-OBJC
provided	O
MCI	B-DISO
/	O
mild	O
AD	B-DISO
functional	B-PHYS
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B-PHYS
treatment	B-DISO
effect	I-DISO
.	O

Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	B-PROC
suggested	O
a	O
smaller	O
functional	B-PHYS
effect	O
of	O
solanezumab	B-CHEM
relative	O
to	O
cognition	B-PHYS
.	O

An	O
increasing	O
effect	O
of	O
solanezumab	B-CHEM
over	O
18	O
months	O
was	O
shown	O
for	O
cognition	B-PHYS
and	O
function	B-PHYS
.	O

Function	B-PHYS
as	O
the	O
sole	O
measure	O
to	O
demonstrate	O
clinical	O
meaningfulness	O
of	O
cognitive	B-PHYS
effects	O
in	O
mild	O
AD	B-DISO
may	O
have	O
limitations	O
.	O

For	O
disease	B-DISO
-	O
modifying	O
treatments	B-PROC
,	O
point	O
differences	O
on	O
cognitive	B-PHYS
and	O
functional	B-PHYS
scales	O
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

Body	B-PHYS
mass	I-PHYS
index	I-PHYS
and	O
suicide	B-DISO
methods	O
Overweight	B-DISO
and	O
obesity	B-DISO
is	O
associated	O
with	O
lower	O
rates	O
of	O
suicide	B-DISO
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
with	O
different	O
suicide	B-DISO
methods	O
.	O

We	O
studied	O
the	O
association	O
between	O
groups	O
of	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
and	O
suicide	B-DISO
methods	O
.	O

We	O
identified	O
all	O
medicolegal	O
autopsy	B-PROC
cases	O
with	O
a	O
cause	B-DISO
of	I-DISO
death	I-DISO
due	O
to	O
external	B-DISO
causes	I-DISO
in	O
Sweden	B-GEOG
during	O
1999	O
-	O
2013	O
(	O
N	O
=	O
39	O
,	O
368	O
)	O
and	O
included	O
11	O
,	O
715	O
suicides	B-DISO
and	O
13	O
,	O
316	O
accidents	B-PHEN
or	O
homicides	O
as	O
controls	B-LIVB
.	O

We	O
applied	O
multinomial	O
regression	O
models	O
adjusted	O
for	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
year	O
and	O
season	O
of	O
death	B-DISO
.	O

Obesity	B-DISO
was	O
associated	O
with	O
suicidal	B-DISO
intoxication	B-DISO
,	O
OR	O
1	O
.	O

15	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
02	O
,	O
1	O
.	O
30	O
]	O
and	O
negatively	B-DISO
associated	O
with	O
all	O
other	O
suicide	B-DISO
methods	O
studied	O
.	O

Underweight	B-DISO
showed	O
a	O
negative	B-DISO
association	O
with	O
suicidal	B-DISO
drowning	B-DISO
and	O
there	O
was	O
an	O
indication	O
towards	O
a	O
negative	B-DISO
association	O
with	O
hanging	B-DISO
in	O
men	B-LIVB
OR	O
0	O
.	O
81	O
(	O
95	O
%	O
CI	O
0	O
.	O
65	O
,	O
1	O
.	O
01	O
)	O
.	O

We	O
conclude	O
that	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O
BMI	B-PHYS
)	O
is	O
associated	O
with	O
the	O
choice	O
of	O
suicide	B-DISO
method	O
.	O

This	O
may	O
be	O
of	O
importance	O
in	O
a	O
public	B-PROC
health	I-PROC
perspective	I-PROC
,	O
e	O
.	O

g	O
.	O

potential	O
for	O
prevention	B-PROC
of	O
intoxications	B-DISO
.	O

In	O
the	O
practice	O
of	O
forensic	O
medicine	O
,	O
the	O
physician	B-LIVB
's	I-LIVB
level	O
of	O
suspicion	B-PHYS
may	O
rise	O
if	O
the	O
apparent	O
suicidal	B-DISO
method	O
is	O
less	O
common	O
for	O
the	O
individual	O
characteristics	O
of	O
the	O
deceased	B-PHYS
,	O
such	O
as	O
BMI	B-PHYS
.	O

Quantitative	O
assessment	O
of	O
fluorescent	B-CHEM
proteins	I-CHEM
The	O
advent	O
of	O
fluorescent	B-CHEM
proteins	I-CHEM
(	O
FPs	B-CHEM
)	O
for	O
genetic	B-PROC
labeling	I-PROC
of	O
molecules	B-OBJC
and	O
cells	B-ANAT
has	O
revolutionized	O
fluorescence	B-PROC
microscopy	I-PROC
.	O

Genetic	B-PROC
manipulations	I-PROC
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
FPs	B-CHEM
spanning	O
blue	O
to	O
red	O
spectral	O
regions	O
.	O

Common	O
to	O
autofluorescent	B-PROC
FPs	B-CHEM
is	O
their	O
tight	O
β	O
-	O
barrel	O
structure	O
,	O
which	O
provides	O
the	O
rigidity	O
and	O
chemical	B-CHEM
environment	O
needed	O
for	O
effectual	O
fluorescence	B-PHEN
.	O

Despite	O
the	O
common	O
structure	O
,	O
each	O
FP	B-CHEM
has	O
unique	O
properties	O
.	O

Thus	O
,	O
there	O
is	O
no	O
single	O
'	O
best	O
'	O
FP	B-CHEM
for	O
every	O
circumstance	O
,	O
and	O
each	O
FP	B-CHEM
has	O
advantages	O
and	O
disadvantages	O
.	O

To	O
guide	O
decisions	O
about	O
which	O
FP	B-CHEM
is	O
right	O
for	O
a	O
given	O
application	O
,	O
we	O
have	O
quantitatively	O
characterized	O
the	O
brightness	B-PHEN
,	O
photostability	B-DISO
,	O
pH	O
stability	O
and	O
monomeric	B-CHEM
properties	O
of	O
more	O
than	O
40	O
FPs	B-CHEM
to	O
enable	O
straightforward	O
and	O
direct	O
comparison	O
between	O
them	O
.	O

We	O
focus	O
on	O
popular	O
and	O
/	O
or	O
top	O
-	O
performing	O
FPs	B-CHEM
in	O
each	O
spectral	O
region	O
.	O

Cognitive	B-DISO
impairment	I-DISO
in	O
HIV	B-LIVB
and	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
:	O
a	O
systematic	O
review	O
and	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
Cognitive	B-DISO
impairment	I-DISO
has	O
been	O
well	O
documented	O
in	O
human	B-LIVB
immunodeficiency	I-LIVB
virus	I-LIVB
(	O
HIV	B-LIVB
)	O
and	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
(	O
HCV	B-LIVB
)	O
mono	B-DISO
-	I-DISO
infections	I-DISO
.	O

However	O
,	O
in	O
the	O
context	O
of	O
HIV	B-LIVB
/	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infection	I-DISO
the	O
research	O
is	O
more	O
limited	O
.	O

The	O
aim	O
of	O
this	O
systematic	O
review	O
was	O
to	O
describe	O
the	O
characteristics	O
of	O
cognitive	B-DISO
impairment	I-DISO
in	O
HIV	B-LIVB
/	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infection	I-DISO
and	O
to	O
examine	B-DISO
the	O
differences	O
in	O
cognitive	B-PHYS
performance	I-PHYS
between	O
HIV	B-LIVB
/	O
HCV	B-LIVB
and	O
HIV	B-LIVB
and	O
HCV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O

Of	O
the	O
437	O
records	O
initially	O
screened	B-PROC
,	O
24	O
papers	O
met	O
the	O
inclusion	O
criteria	O
and	O
were	O
included	O
in	O
the	O
systematic	O
review	O
.	O

Four	O
studies	B-PROC
were	O
included	O
in	O
the	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O

Most	O
studies	B-PROC
indicated	O
that	O
HIV	B-LIVB
/	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
had	O
a	O
higher	O
level	O
of	O
cognitive	B-DISO
impairment	I-DISO
than	O
HIV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O

Meta	B-PROC
-	I-PROC
analysis	I-PROC
also	O
indicated	O
that	O
HIV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
had	O
a	O
significantly	O
lower	O
global	O
deficit	O
score	O
than	O
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O

The	O
results	O
also	O
indicated	O
that	O
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
were	O
more	O
likely	O
to	O
be	O
impaired	B-DISO
in	O
information	B-PHYS
processing	I-PHYS
speed	I-PHYS
than	O
HIV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O

These	O
findings	B-DISO
can	O
be	O
challenged	O
by	O
biasing	O
factors	O
such	O
as	O
the	O
small	O
number	O
of	O
included	O
studies	B-PROC
,	O
heterogeneity	O
of	O
the	O
samples	O
and	O
a	O
large	O
diversity	O
of	O
methodological	O
procedures	O
.	O

Future	O
research	O
with	O
consistent	O
and	O
comprehensive	O
neuropsychological	O
batteries	O
and	O
covering	O
a	O
greater	O
diversity	O
of	O
risk	B-DISO
factors	I-DISO
is	O
needed	O
,	O
in	O
order	O
to	O
clarify	O
the	O
effects	O
of	O
both	O
viruses	B-LIVB
on	O
cognitive	B-PHYS
function	I-PHYS
and	O
the	O
mechanisms	O
that	O
underlie	O
these	O
effects	O
.	O

Because	O
cognitive	B-DISO
impairments	I-DISO
may	O
pose	O
significant	O
challenges	B-PROC
to	O
medication	B-DISO
adherence	I-DISO
,	O
quality	O
of	O
life	O
and	O
overall	O
functioning	O
,	O
such	O
knowledge	O
may	O
have	O
important	O
implications	O
to	O
the	O
planning	B-PROC
and	O
implementation	B-PROC
of	O
effective	O
interventions	O
aimed	O
at	O
optimising	O
the	O
clinical	B-PROC
management	I-PROC
of	O
these	O
infections	B-DISO
.	O

Consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
associated	O
with	O
other	O
risk	O
behaviors	O
among	O
adolescents	B-LIVB
in	O
Northeast	B-GEOG
Brazil	I-GEOG
To	O
determine	O
the	O
prevalence	O
of	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
and	O
identify	O
the	O
association	O
with	O
low	O
level	O
of	O
physical	O
activity	O
,	O
exposure	O
to	O
sedentary	B-DISO
behavior	I-DISO
,	O
consumption	O
of	O
soft	B-OBJC
drinks	I-OBJC
and	O
overweight	B-DISO
/	O
obesity	B-DISO
in	O
adolescents	B-LIVB
.	O

This	O
is	O
a	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
school	I-PROC
-	I-PROC
based	I-PROC
study	I-PROC
with	O
a	O
representative	O
sample	B-OBJC
of	O
3992	O
students	B-LIVB
aged	O
14	O
-	O
19	O
years	O
from	O
the	O
state	B-GEOG
of	I-GEOG
Sergipe	I-GEOG
,	O
Brazil	B-GEOG
.	O

The	O
outcome	O
was	O
low	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
(	O
<	O
5	O
servings	O
/	O
day	O
)	O
.	O

Independent	O
variables	O
were	O
:	O
level	O
of	O
physical	O
activity	O
,	O
sedentary	B-DISO
behavior	I-DISO
,	O
consumption	O
of	O
soft	B-OBJC
drinks	I-OBJC
,	O
and	O
overweight	B-DISO
/	O
obesity	B-DISO
.	O

Global	O
Student	O
Health	O
Survey	O
questionnaire	O
and	O
body	B-PROC
mass	I-PROC
and	O
height	B-PHYS
measurements	B-PROC
were	O
used	O
,	O
as	O
well	O
as	O
chi	O
-	O
square	O
test	O
and	O
crude	B-PROC
and	I-PROC
adjusted	I-PROC
binary	I-PROC
logistic	I-PROC
regression	I-PROC
.	O

The	O
significance	B-PROC
level	I-PROC
adopted	O
was	O
5	O
%	O
.	O

The	O
prevalence	O
of	O
inadequate	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
was	O
high	O
-	O
88	O
.	O

6	O
%	O
(	O
95	O
%	O
CI	O
=	O
87	O
.	O
6	O
-	O
89	O
.	O
5	O
)	O
.	O

Higher	O
likelihood	O
of	O
low	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
was	O
verified	O
among	O
boys	B-LIVB
who	O
were	O
exposed	O
to	O
sedentary	B-DISO
behavior	I-DISO
(	O
OR	O
=	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
18	O
-	O
2	O
.	O
24	O
)	O
,	O
who	O
consumed	O
soft	B-OBJC
drinks	I-OBJC
(	O
OR	O
=	O
3	O
.	O
04	O
;	O
95	O
%	O
CI	O
=	O
2	O
.	O
10	O
-	O
4	O
.	O
40	O
)	O
,	O
with	O
insufficiently	O
physical	O
activity	O
(	O
OR	O
=	O
1	O
.	O
98	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
43	O
-	O
2	O
.	O
73	O
)	O
and	O
girls	B-LIVB
who	O
consumed	O
soft	B-OBJC
drinks	I-OBJC
(	O
OR	O
=	O
1	O
.	O
88	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
43	O
-	O
2	O
.	O
47	O
)	O
and	O
those	O
with	O
overweight	B-DISO
/	O
obesity	B-DISO
(	O
OR	O
=	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
19	O
-	O
2	O
.	O
23	O
)	O
.	O

There	O
is	O
a	O
need	O
of	O
public	O
policies	O
aimed	O
at	O
encouraging	O
the	O
consumption	O
of	O
healthy	O
foods	O
among	O
adolescents	B-LIVB
.	O

Usefulness	O
of	O
Embolization	B-PROC
for	O
Iatrogenic	B-DISO
Dural	B-DISO
Arteriovenous	I-DISO
Fistula	I-DISO
Associated	O
with	O
Recurrent	O
Chronic	B-DISO
Subdural	I-DISO
Hematoma	I-DISO
:	O
A	O
Case	O
Report	O
and	O
Literature	O
Review	O
Refractory	O
chronic	B-DISO
subdural	I-DISO
hematomas	I-DISO
due	O
to	O
iatrogenic	B-DISO
dural	B-DISO
arteriovenous	I-DISO
fistulas	I-DISO
(	O
dAVFs	B-DISO
)	O
are	O
difficult	O
to	O
treat	O
.	O

We	O
report	O
our	O
experience	O
and	O
propose	O
a	O
guideline	B-PROC
on	O
basis	O
of	O
a	O
literature	O
review	O
for	O
the	O
usefulness	O
of	O
embolization	B-PROC
of	O
middle	B-ANAT
meningeal	I-ANAT
artery	I-ANAT
(	O
MMA	B-ANAT
)	O
for	O
the	O
treatment	B-PROC
of	O
the	O
same	O
.	O

We	O
report	O
a	O
case	O
with	O
right	B-DISO
hemiparesis	I-DISO
and	O
aphasia	B-DISO
1	O
month	O
after	O
a	O
fall	B-DISO
from	O
a	O
bicycle	B-OBJC
.	O

Computed	B-PROC
tomography	I-PROC
scan	I-PROC
of	O
the	O
head	B-ANAT
showed	O
left	O
chronic	B-DISO
subdural	I-DISO
hematoma	I-DISO
,	O
which	O
was	O
evacuated	B-PROC
by	I-PROC
burr	I-PROC
-	I-PROC
hole	I-PROC
drainage	I-PROC
.	O

The	O
postoperative	O
course	O
was	O
complicated	O
by	O
reaccumulation	B-DISO
within	O
short	O
period	O
of	O
time	O
.	O

On	O
superselective	B-PROC
digital	I-PROC
subtraction	I-PROC
angiography	I-PROC
of	O
MMA	B-ANAT
,	O
iatrogenic	B-DISO
dAVF	B-DISO
was	O
found	O
on	O
left	O
side	O
.	O

We	O
embolized	B-PROC
successfully	O
it	O
using	O
n	B-CHEM
-	I-CHEM
butyl	I-CHEM
cyanoacrylate	I-CHEM
after	O
a	O
third	O
irrigation	B-PROC
.	O

No	O
reaccumulation	B-DISO
found	O
in	O
the	O
postoperative	O
period	O
or	O
at	O
last	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

We	O
propose	O
treatment	B-PROC
protocol	I-PROC
based	O
on	O
our	O
experience	O
and	O
literature	O
review	O
.	O

Refractory	O
chronic	B-DISO
subdural	I-DISO
hematoma	I-DISO
with	O
reaccumulation	B-DISO
within	O
a	O
short	O
interval	O
should	O
be	O
subjected	O
to	O
digital	B-PROC
subtraction	I-PROC
angiography	I-PROC
of	O
the	O
MMA	B-ANAT
.	O

Embolization	B-PROC
of	O
ipsilateral	O
MMA	B-ANAT
is	O
safe	O
,	O
effective	O
,	O
and	O
a	O
useful	O
option	O
for	O
the	O
treatment	B-PROC
of	O
iatrogenic	B-DISO
dAVF	B-DISO
and	O
resolution	O
of	O
hematoma	B-DISO
.	O

In	O
Search	O
of	O
the	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
Compounds	B-CHEM
that	O
Change	O
the	O
Antibiotic	B-CHEM
Production	O
Pattern	O
of	O
Streptomyces	B-LIVB
coelicolor	I-LIVB
During	O
Inter	O
-	O
species	O
Interaction	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
interaction	O
between	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
and	O
Streptomyces	B-LIVB
coelicolor	I-LIVB
A3	I-LIVB
(	I-LIVB
2	I-LIVB
)	I-LIVB
for	O
the	O
increased	O
production	O
of	O
undecylprodigiosin	B-CHEM
and	O
identify	O
the	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
actives	O
mediating	O
this	O
inter	O
-	O
species	O
interaction	O
.	O

The	O
antibiotics	B-CHEM
of	O
interest	O
were	O
the	O
red	B-CHEM
-	I-CHEM
pigmented	I-CHEM
undecylprodigiosin	I-CHEM
and	O
blue	O
-	O
pigmented	O
actinorhodin	B-CHEM
.	O

Pure	O
cultures	B-PROC
of	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
in	O
a	O
defined	O
medium	B-CHEM
produced	O
higher	O
concentrations	O
of	O
actinorhodin	B-CHEM
compared	O
to	O
those	O
of	O
undecylprodigiosin	B-CHEM
.	O

The	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	B-PHYS
and	O
antitumor	B-PHYS
properties	I-PHYS
.	O

As	O
a	O
strategy	O
to	O
increase	O
undecylprodigiosin	B-CHEM
production	O
,	O
we	O
added	O
separately	O
,	O
live	B-ANAT
cells	I-ANAT
and	O
heat	B-PHEN
-	I-PHEN
killed	I-PHEN
cells	B-ANAT
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
C600	I-LIVB
,	O
and	O
the	O
cell	B-ANAT
-	I-ANAT
free	I-ANAT
supernatant	I-ANAT
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
culture	B-PROC
to	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
cultures	B-PROC
in	I-PROC
shake	I-PROC
flasks	I-PROC
.	O

The	O
interaction	O
with	O
live	B-ANAT
cells	I-ANAT
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
altered	O
the	O
antibiotic	B-CHEM
production	O
pattern	O
and	O
undecylprodigiosin	B-CHEM
production	O
was	O
enhanced	O
by	O
3	O
.	O
5	O
-	O
fold	O
compared	O
to	O
the	O
pure	B-PROC
cultures	I-PROC
of	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
and	O
actinorhodin	B-CHEM
decreased	O
by	O
15	O
-	O
fold	O
.	O

The	O
heat	B-PHEN
-	I-PHEN
killed	I-PHEN
cells	B-ANAT
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
however	O
,	O
had	O
no	O
effect	O
on	O
antibiotic	B-CHEM
production	O
.	O

In	O
all	O
cases	O
,	O
growth	B-PHYS
and	O
glucose	B-DISO
consumption	I-DISO
of	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
remained	O
almost	O
the	O
same	O
as	O
those	O
observed	O
in	O
the	O
pure	B-PROC
culture	I-PROC
indicating	O
that	O
the	O
changes	O
in	O
antibiotic	B-CHEM
production	O
were	O
not	O
due	O
to	O
nutritional	B-PHYS
stress	B-DISO
.	O

Results	O
with	O
cell	B-ANAT
-	I-ANAT
free	I-ANAT
supernatant	I-ANAT
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
culture	B-PROC
indicated	O
that	O
the	O
interaction	O
between	O
S	B-LIVB
.	I-LIVB
coelicolor	I-LIVB
and	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
was	O
mediated	O
via	O
diffusible	B-CHEM
molecule	I-CHEM
(	I-CHEM
s	I-CHEM
)	I-CHEM
.	O

Using	O
a	O
set	O
of	O
extraction	B-PROC
procedures	I-PROC
and	O
agar	B-PROC
-	I-PROC
well	I-PROC
diffusion	I-PROC
bioassays	I-PROC
,	O
we	O
isolated	O
and	O
preliminarily	O
identified	O
a	O
class	B-CHEM
of	I-CHEM
compounds	I-CHEM
.	O

For	O
the	O
preliminary	O
verification	O
,	O
we	O
added	O
the	O
compound	B-CHEM
which	O
was	O
the	O
common	O
chemical	B-CHEM
structural	I-CHEM
moiety	I-CHEM
in	O
this	O
class	B-CHEM
of	I-CHEM
compounds	I-CHEM
to	O
the	O
pure	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
cultures	B-PROC
.	O

We	O
observed	O
similar	O
effects	O
on	O
antibiotic	B-CHEM
production	O
as	O
with	O
the	O
live	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
cells	B-ANAT
and	O
their	O
supernatant	B-ANAT
indicating	O
that	O
this	O
class	B-CHEM
of	I-CHEM
compounds	I-CHEM
secreted	B-PHYS
by	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
indeed	O
could	O
act	O
as	O
actives	O
during	O
interspecies	O
interaction	O
and	O
increase	O
the	O
production	O
of	O
undecylprodigiosin	B-CHEM
.	O

Group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
limit	O
the	O
intramuscular	O
metabolic	O
perturbation	O
during	O
whole	B-ANAT
body	I-ANAT
exercise	O
in	O
humans	B-LIVB
The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	B-PROC
the	O
role	O
of	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
in	O
limiting	O
the	O
endurance	B-DISO
exercise	O
-	O
induced	O
metabolic	O
perturbation	O
assayed	B-PROC
in	O
muscle	O
biopsy	O
samples	O
taken	O
from	O
locomotor	B-PHYS
muscle	O
.	O

Lumbar	B-ANAT
intrathecal	B-ANAT
fentanyl	B-CHEM
was	O
used	O
to	O
attenuate	O
the	O
central	O
projection	O
of	O
μ	B-CHEM
-	I-CHEM
opioid	I-CHEM
receptor	I-CHEM
-	O
sensitive	O
locomotor	B-PHYS
muscle	O
afferents	B-ANAT
during	O
a	O
5	O
km	O
cycling	O
time	O
trial	B-PROC
.	O

The	O
findings	B-DISO
suggest	O
that	O
the	O
central	O
projection	O
of	O
group	O
III	O
/	O
IV	O
muscle	O
afferent	B-ANAT
feedback	B-PHYS
constrains	O
voluntary	O
neural	O
'	O
drive	B-PHYS
'	O
to	O
working	O
locomotor	B-PHYS
muscle	O
and	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
.	O

Therefore	O
,	O
the	O
CNS	B-ANAT
might	O
regulate	B-PHEN
the	O
degree	O
of	O
metabolic	O
perturbation	O
within	O
locomotor	B-PHYS
muscle	O
and	O
thereby	O
limit	O
peripheral	O
fatigue	B-DISO
.	O

It	O
appears	O
that	O
the	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
are	O
an	O
important	O
neural	O
link	B-ANAT
in	O
this	O
regulatory	B-PHEN
mechanism	O
,	O
which	O
probably	O
serves	O
to	O
protect	B-DISO
locomotor	B-PHYS
muscle	O
from	O
the	O
potentially	O
severe	O
functional	B-DISO
impairment	I-DISO
as	O
a	O
consequence	O
of	O
severe	O
intramuscular	O
metabolic	O
disturbance	O
.	O

To	O
investigate	O
the	O
role	O
of	O
metabo	B-PHYS
-	O
and	O
mechanosensitive	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
in	O
limiting	O
the	O
intramuscular	O
metabolic	O
perturbation	O
during	O
whole	B-ANAT
body	I-ANAT
endurance	B-DISO
exercise	O
,	O
eight	O
subjects	B-LIVB
performed	O
5	O
km	O
cycling	O
time	O
trials	B-PROC
under	B-DISO
control	I-DISO
conditions	I-DISO
(	O
CTRL	B-DISO
)	O
and	O
with	O
lumbar	B-ANAT
intrathecal	B-ANAT
fentanyl	B-CHEM
impairing	O
lower	B-ANAT
limb	I-ANAT
muscle	O
afferent	B-ANAT
feedback	B-PHYS
(	O
FENT	B-PHYS
)	O
.	O

Vastus	B-ANAT
lateralis	I-ANAT
muscle	O
biopsies	O
were	O
obtained	O
before	O
and	O
immediately	O
after	O
exercise	O
.	O

Motoneuronal	B-ANAT
output	B-PROC
was	I-PROC
estimated	I-PROC
through	O
vastus	B-ANAT
lateralis	I-ANAT
surface	I-ANAT
electromyography	B-PROC
(	O
EMG	B-PROC
)	O
.	O

Exercise	O
-	O
induced	O
changes	O
in	O
intramuscular	O
metabolites	B-CHEM
were	O
determine	B-PROC
d	O
using	O
liquid	B-OBJC
and	O
gas	B-PROC
chromatography	I-PROC
-	I-PROC
mass	I-PROC
spectrometry	I-PROC
.	O

Quadriceps	B-ANAT
fatigue	B-DISO
was	O
quantified	O
by	O
pre	O
-	O
to	O
post	O
-	O
exercise	O
changes	O
in	O
potentiated	B-PHEN
quadriceps	I-PHEN
twitch	I-PHEN
torque	I-PHEN
(	O
ΔQTsingle	B-PHEN
)	O
evoked	O
by	O
electrical	O
femoral	B-ANAT
nerve	I-ANAT
stimulation	B-PROC
.	O

Although	O
motoneuronal	B-ANAT
output	O
was	O
21	O
±	O
12	O
%	O
higher	O
during	O
FENT	B-PHYS
compared	O
to	O
CTRL	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
time	O
to	O
complete	O
the	O
time	O
trial	B-PROC
was	O
similar	O
(	O
∼8	O
.	O
8	O
min	O
)	O
.	O

Compared	O
to	O
CTRL	B-DISO
,	O
power	B-PHEN
output	I-PHEN
during	O
FENT	B-PHYS
was	O
10	O
±	O
4	O
%	O
higher	O
in	O
the	O
first	B-DISO
half	I-DISO
of	O
the	O
time	O
trial	B-PROC
,	O
but	O
11	O
±	O
5	O
%	O
lower	O
in	O
the	O
second	B-DISO
half	I-DISO
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
exercise	O
-	O
induced	O
increase	O
in	O
intramuscular	O
inorganic	B-CHEM
phosphate	I-CHEM
,	O
H	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
adenosine	B-CHEM
diphosphate	I-CHEM
,	O
lactate	B-CHEM
and	O
phosphocreatine	B-CHEM
depletion	O
was	O
55	O
±	O
30	O
,	O
62	O
±	O
18	O
,	O
129	O
±	O
63	O
,	O
47	O
±	O
14	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
27	O
±	O
14	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
greater	O
in	O
FENT	B-PHYS
than	O
CTRL	B-DISO
.	O

ΔQTsingle	B-PHEN
was	O
greater	O
following	O
FENT	B-PHYS
than	O
CTRL	B-DISO
(	O
-52	O
±	O
2	O
vs	O
-31	O
±	O
1	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
this	O
difference	O
was	O
positively	B-DISO
correlated	O
with	O
the	O
difference	O
in	O
inorganic	B-CHEM
phosphate	I-CHEM
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
H	O
(	O
+	O
)	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
92	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
conclusion	O
,	O
during	O
whole	B-ANAT
body	I-ANAT
exercise	O
,	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
provide	O
feedback	B-PHYS
to	O
the	O
CNS	B-ANAT
which	O
,	O
in	O
turn	O
,	O
constrains	O
motoneuronal	B-ANAT
output	O
to	O
the	O
active	O
skeletal	O
muscle	O
.	O

This	O
regulatory	B-PHEN
mechanism	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
,	O
preventing	O
an	O
abnormal	B-DISO
homeostatic	I-DISO
challenge	B-PROC
and	O
excessive	O
peripheral	O
fatigue	B-DISO
.	O

Incidence	O
of	O
crown	B-DISO
fracture	I-DISO
and	O
risk	B-DISO
factors	I-DISO
in	O
the	O
primary	B-ANAT
dentition	I-ANAT
:	O
a	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
Few	O
studies	O
have	O
assessed	O
the	O
incidence	O
and	O
risk	B-DISO
factors	I-DISO
to	O
crown	B-DISO
fractures	I-DISO
in	O
preschool	B-LIVB
children	I-LIVB
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
incidence	O
of	O
crown	B-DISO
fracture	I-DISO
in	O
the	O
primary	B-ANAT
dentition	I-ANAT
over	O
a	O
1	O
-	O
year	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
,	O
identify	O
risk	B-DISO
factors	I-DISO
,	O
and	O
test	O
the	O
hypothesis	O
that	O
children	B-LIVB
with	O
previous	O
crown	B-DISO
fracture	I-DISO
are	O
more	O
prone	O
to	O
experience	O
further	O
cases	O
of	O
crown	B-DISO
fracture	I-DISO
independently	O
of	O
other	O
risk	B-DISO
factors	I-DISO
.	O

This	O
study	O
was	O
developed	O
in	O
two	O
phases	O
:	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
and	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
.	O

The	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
was	O
carried	O
out	O
261	O
preschool	B-LIVB
children	I-LIVB
.	O

The	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
was	O
carried	O
out	O
194	O
children	B-LIVB
allocated	O
to	O
two	O
groups	O
:	O
exposed	B-LIVB
group	I-LIVB
(	O
children	B-LIVB
with	O
prior	O
exposure	O
to	O
crown	B-DISO
fracture	I-DISO
)	O
and	O
non	B-DISO
-	O
exposed	B-LIVB
group	I-LIVB
(	O
children	B-LIVB
without	O
prior	O
exposure	O
)	O
.	O

On	O
both	O
occasions	O
,	O
children	B-LIVB
were	O
examined	O
for	O
the	O
diagnosis	B-DISO
of	O
crown	B-DISO
fracture	I-DISO
and	O
evaluation	O
of	O
lip	B-ANAT
coverage	O
and	O
overjet	B-DISO
.	O

The	O
parents	O
were	O
interviewed	O
with	O
regard	O
to	O
the	O
socioeconomic	O
indicators	O
.	O

New	O
cases	O
of	O
crown	B-DISO
fracture	I-DISO
were	O
identified	O
based	O
on	O
the	O
comparison	O
of	O
the	O
two	O
examinations	O
.	O

Data	O
analysis	O
involved	O
Pearson	O
's	O
chi	O
-	O
square	O
test	O
,	O
McNemar	O
's	O
test	O
,	O
and	O
Poisson	O
regression	O
with	O
robust	O
variance	O
.	O

Among	O
the	O
261	O
children	B-LIVB
who	O
participated	O
in	O
the	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
,	O
194	O
were	O
re	O
-	O
examined	O
(	O
65	O
in	O
the	O
exposed	B-LIVB
group	I-LIVB
and	O
129	O
in	O
the	O
non	B-DISO
-	O
exposed	B-LIVB
group	I-LIVB
)	O
.	O

The	O
overall	O
incidence	O
of	O
crown	B-DISO
fracture	I-DISO
was	O
55	O
.	O

7	O
%	O
(	O
n	O
=	O
108	O
)	O
.	O

The	O
difference	O
in	O
percentage	O
of	O
increased	B-DISO
risk	I-DISO
of	I-DISO
crown	B-DISO
fracture	I-DISO
in	O
exposed	O
and	O
non	B-DISO
-	O
exposed	B-LIVB
groups	I-LIVB
was	O
13	O
.	O

4	O
%	O
.	O

A	O
greater	O
incidence	O
of	O
crown	B-DISO
fracture	I-DISO
was	O
found	O
in	O
the	O
exposed	O
group	O
(	O
64	O
.	O
6	O
%	O
;	O
P	O
<	O
0	O
,	O
001	O
)	O
.	O

The	O
children	B-LIVB
exposed	O
(	O
RR	O
:	O
1	O
.	O
30	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
01	O
-	O
1	O
.	O
67	O
)	O
had	O
a	O
greater	B-DISO
risk	I-DISO
of	I-DISO
developing	O
new	O
cases	O
of	O
crown	B-DISO
fracture	I-DISO
in	O
comparison	O
with	O
the	O
non	B-DISO
-	O
exposed	B-LIVB
group	I-LIVB
.	O

The	O
incidence	O
of	O
crown	B-DISO
fracture	I-DISO
was	O
high	O
and	O
children	B-LIVB
with	O
previous	O
crown	B-DISO
fracture	I-DISO
had	O
a	O
greater	B-DISO
risk	I-DISO
of	I-DISO
suffering	O
new	O
cases	O
of	O
crown	B-DISO
fracture	I-DISO
during	O
the	O
1	O
-	O
year	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
.	O

An	O
Efficient	O
and	O
Reliable	O
Statistical	B-PROC
Method	I-PROC
for	O
Estimating	O
Functional	O
Connectivity	O
in	O
Large	O
Scale	O
Brain	B-ANAT
Networks	B-PHYS
Using	O
Partial	O
Correlation	O
Currently	O
,	O
network	B-PHYS
-	I-PHYS
oriented	I-PHYS
analysis	B-PROC
of	O
fMRI	B-PROC
data	O
has	O
become	O
an	O
important	B-OBJC
tool	I-OBJC
for	O
understanding	O
brain	B-ANAT
organization	B-PHYS
and	O
brain	B-ANAT
networks	B-PHYS
.	O

Among	O
the	O
range	O
of	O
network	B-PHYS
modeling	O
methods	O
,	O
partial	O
correlation	O
has	O
shown	O
great	O
promises	O
in	O
accurately	O
detecting	B-DISO
true	O
brain	B-ANAT
network	B-PHYS
connections	O
.	O

However	O
,	O
the	O
application	O
of	O
partial	O
correlation	O
in	O
investigating	O
brain	B-ANAT
connectivity	O
,	O
especially	O
in	O
large	O
-	O
scale	O
brain	B-ANAT
networks	B-PHYS
,	O
has	O
been	O
limited	O
so	O
far	O
due	O
to	O
the	O
technical	B-PHEN
challenges	I-PHEN
in	O
its	O
estimation	O
.	O

In	O
this	O
paper	O
,	O
we	O
propose	O
an	O
efficient	O
and	O
reliable	O
statistical	B-PROC
method	I-PROC
for	O
estimating	O
partial	O
correlation	O
in	O
large	O
-	O
scale	O
brain	B-ANAT
network	B-PHYS
modeling	B-PROC
.	O

Our	O
method	O
derives	O
partial	O
correlation	O
based	O
on	O
the	O
precision	O
matrix	O
estimated	O
via	O
Constrained	B-PROC
L1	I-PROC
-	I-PROC
minimization	I-PROC
Approach	I-PROC
(	O
CLIME	B-PROC
)	O
,	O
which	O
is	O
a	O
recently	O
developed	O
statistical	B-PROC
method	I-PROC
that	O
is	O
more	O
efficient	O
and	O
demonstrates	O
better	O
performance	O
than	O
the	O
existing	O
methods	O
.	O

To	O
help	O
select	O
an	O
appropriate	O
tuning	O
parameter	O
for	O
sparsity	O
control	O
in	O
the	O
network	B-PHYS
estimation	O
,	O
we	O
propose	O
a	O
new	O
Dens	B-PROC
-	I-PROC
based	I-PROC
selection	I-PROC
method	I-PROC
that	O
provides	O
a	O
more	O
informative	O
and	O
flexible	O
tool	O
to	O
allow	O
the	O
users	O
to	O
select	O
the	O
tuning	O
parameter	O
based	O
on	O
the	O
desired	O
sparsity	O
level	O
.	O

Another	O
appealing	O
feature	O
of	O
the	O
Dens	B-PROC
-	I-PROC
based	I-PROC
method	I-PROC
is	O
that	O
it	O
is	O
much	O
faster	O
than	O
the	O
existing	O
methods	O
,	O
which	O
provides	O
an	O
important	O
advantage	O
in	O
neuroimaging	B-PROC
applications	I-PROC
.	O

Simulation	B-PROC
studies	I-PROC
show	O
that	O
the	O
Dens	B-PROC
-	I-PROC
based	I-PROC
method	I-PROC
demonstrates	O
comparable	O
or	O
better	O
performance	O
with	O
respect	O
to	O
the	O
existing	O
methods	O
in	O
network	B-PHYS
estimation	O
.	O

We	O
applied	O
the	O
proposed	O
partial	O
correlation	O
method	O
to	O
investigate	O
resting	B-PROC
state	I-PROC
functional	I-PROC
connectivity	I-PROC
using	I-PROC
rs	I-PROC
-	I-PROC
fMRI	I-PROC
data	I-PROC
from	O
the	O
Philadelphia	O
Neurodevelopmental	O
Cohort	O
(	O
PNC	O
)	O
study	O
.	O

Our	O
results	O
show	O
that	O
partial	O
correlation	O
analysis	B-PROC
removed	O
considerable	O
between	O
-	O
module	O
marginal	O
connections	O
identified	O
by	O
full	O
correlation	B-PROC
analysis	I-PROC
,	O
suggesting	O
these	O
connections	O
were	O
likely	O
caused	O
by	O
global	O
effects	O
or	O
common	O
connection	O
to	O
other	O
nodes	B-ANAT
.	O

Based	O
on	O
partial	O
correlation	O
,	O
we	O
find	O
that	O
the	O
most	O
significant	O
direct	O
connections	O
are	O
between	O
homologous	O
brain	B-ANAT
locations	B-ANAT
in	O
the	O
left	B-ANAT
and	O
right	B-ANAT
hemisphere	I-ANAT
.	O

When	O
comparing	O
partial	O
correlation	O
derived	O
under	O
different	O
sparse	O
tuning	O
parameters	O
,	O
an	O
important	O
finding	O
is	O
that	O
the	O
sparse	O
regularization	O
has	O
more	O
shrinkage	O
effects	O
on	O
negative	B-DISO
functional	O
connections	O
than	O
on	O
positive	B-DISO
connections	O
,	O
which	O
supports	O
previous	O
findings	O
that	O
many	O
of	O
the	O
negative	B-DISO
brain	B-ANAT
connections	O
are	O
due	O
to	O
non	B-PHYS
-	I-PHYS
neurophysiological	I-PHYS
effects	I-PHYS
.	O

An	O
R	O
package	O
""""	O
DensParcorr	O
""""	O
can	O
be	O
downloaded	O
from	O
CRAN	O
for	O
implementing	O
the	O
proposed	O
statistical	B-PROC
methods	I-PROC
.	O

Mitochondrial	B-ANAT
Ultrastructure	B-ANAT
and	O
Glucose	B-PHYS
Signaling	I-PHYS
Pathways	I-PHYS
Attributed	O
to	O
the	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
Ion	I-CHEM
Channel	I-CHEM
Gene	B-PROC
-	I-PROC
targeted	I-PROC
deletion	B-PHYS
of	O
the	O
potassium	B-CHEM
channel	I-CHEM
Kv1	I-CHEM
.	I-CHEM

3	I-CHEM
(	O
Kv1	B-PHEN
.	I-PHEN

3	I-PHEN
(	I-PHEN
-	I-PHEN
∕	I-PHEN
-	I-PHEN
)	I-PHEN
)	I-PHEN
results	I-PHEN
i	I-PHEN
n	O
""""	O
S	O
uper	B-LIVB
-	I-LIVB
smeller	I-LIVB
""""	I-LIVB
mice	I-LIVB
with	O
a	O
se	O
nsory	O
p	O
h	O
enotype	B-PHYS
t	I-PHYS
hat	O
includes	O
an	O
increased	O
olfactory	B-PHYS
ability	B-PHYS
linked	O
to	O
changes	O
in	O
olfactory	B-PHYS
circuitry	O
,	O
increased	O
abundance	O
of	O
olfactory	B-ANAT
cilia	I-ANAT
,	O
and	O
increased	O
expression	B-PHYS
of	O
odorant	B-CHEM
receptors	I-CHEM
and	O
the	O
G	B-CHEM
-	I-CHEM
protein	I-CHEM
,	I-CHEM
Golf	I-CHEM
.	O

Kv1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
mice	I-LIVB
a	I-LIVB
lso	O
have	O
a	O
metabolic	O
p	O
h	O
enotype	B-PHYS
i	I-PHYS
ncluding	O
lo	O
wer	O
b	O
o	O
dy	B-PHYS
weight	I-PHYS
a	I-PHYS
nd	O
de	O
creased	O
a	O
d	O
iposity	B-PHYS
,	I-PHYS
in	O
creased	B-DISO
total	I-DISO
energy	I-DISO
expenditure	I-DISO
(	O
TEE	B-DISO
)	O
,	O
increased	O
locomotor	B-PHYS
activity	I-PHYS
,	O
and	O
resistance	B-PHYS
to	O
both	O
diet	B-OBJC
-	O
and	O
genetic	B-PHYS
-	I-PHYS
induced	I-PHYS
obesity	B-DISO
.	O

We	O
explored	O
two	O
cellular	O
aspects	O
to	O
elucidate	O
the	O
mechanism	O
by	O
which	O
loss	O
of	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
channel	I-CHEM
in	O
the	O
olfactory	B-ANAT
bulb	I-ANAT
(	O
OB	B-ANAT
)	O
may	O
enhance	O
glucose	B-PHYS
utilization	I-PHYS
and	O
metabolic	B-PHYS
rate	I-PHYS
.	O

First	O
,	O
using	O
in	B-PROC
situ	I-PROC
hybridization	I-PROC
we	O
find	O
that	O
Kv1	B-CHEM
.	I-CHEM
3	I-CHEM
and	O
the	O
insulin	B-CHEM
-	O
dependent	O
glucose	B-CHEM
transporter	I-CHEM
type	I-CHEM
4	I-CHEM
(	O
GLUT4	B-CHEM
)	O
are	O
co	O
-	O
localized	O
to	O
the	O
mitral	B-ANAT
cell	B-ANAT
layer	I-ANAT
of	O
the	O
OB	B-ANAT
.	O

Disruption	O
of	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
conduction	B-PHEN
via	O
construction	O
of	O
a	O
pore	B-PHYS
mutation	I-PHYS
(	O
W386F	B-PHYS
Kv1	I-PHYS
.	I-PHYS

3	I-PHYS
)	O
was	O
sufficient	O
to	O
independently	O
translocate	B-PHYS
GLUT4	B-CHEM
to	O
the	O
plasma	B-ANAT
membrane	I-ANAT
in	O
HEK	B-ANAT
293	I-ANAT
cells	I-ANAT
.	O

Because	O
olfactory	B-PHYS
sensory	I-PHYS
perception	I-PHYS
and	O
the	O
maintenance	O
of	O
action	B-PHYS
potential	I-PHYS
(	I-PHYS
AP	I-PHYS
)	I-PHYS
firing	O
frequency	O
by	O
mitral	B-ANAT
cells	B-ANAT
of	O
the	O
OB	B-ANAT
is	O
highly	O
energy	O
demanding	O
and	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
is	O
also	O
expressed	O
in	O
mitochondria	B-ANAT
,	O
we	O
next	O
explored	O
the	O
structure	O
of	O
this	O
organelle	B-ANAT
in	O
mitral	B-ANAT
cells	B-ANAT
.	O

We	O
challenged	O
wildtype	B-LIVB
(	O
WT	B-LIVB
)	O
and	O
Kv1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
male	I-LIVB
mice	I-LIVB
with	O
a	O
m	O
oderately	B-PROC
high	I-PROC
-	I-PROC
fat	I-PROC
diet	I-PROC
(	I-PROC
M	O
HF	B-PROC
,	I-PROC
31	O
.	O
8	O
%	O
kcal	O
fat	O
)	O
for	O
4	O
months	O
and	O
then	O
examined	O
OB	B-ANAT
ultrastructure	B-ANAT
using	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
.	O

In	O
WT	B-LIVB
mice	I-LIVB
,	O
mitochondria	B-ANAT
were	O
significantly	O
enlarged	O
following	O
diet	B-DISO
-	I-DISO
induced	I-DISO
obesity	I-DISO
(	O
DIO	B-DISO
)	O
and	O
there	O
were	O
fewer	O
mitochondria	B-ANAT
,	O
likely	O
due	O
to	O
mitophagy	B-PHYS
.	O

Interestingly	O
,	O
mitochondria	B-ANAT
were	O
significantly	O
smaller	O
in	O
Kv1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
mice	I-LIVB
c	I-LIVB
ompared	O
with	O
that	O
of	O
W	O
T	B-LIVB
mice	I-LIVB
.	I-LIVB

Similar	O
to	O
their	O
m	O
etabolic	O
r	O
esistance	O
to	O
D	O
IO	B-DISO
,	I-DISO
the	O
K	O
v1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
mice	I-LIVB
ha	I-LIVB
d	O
unchanged	O
mit	O
ochondria	B-ANAT
in	I-ANAT
terms	O
of	O
cros	O
s	O
sectional	O
area	O
and	O
abundance	O
following	O
a	O
challenge	O
with	O
modified	B-PROC
diet	I-PROC
.	O

We	O
are	O
very	O
interested	O
to	O
understand	O
how	O
targeted	O
disruption	O
of	O
the	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
channel	I-CHEM
in	O
the	O
OB	B-ANAT
can	O
modify	O
TEE	B-DISO
.	O

Our	O
study	O
demonstrates	O
that	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
regulates	O
mitochondrial	B-ANAT
structure	I-ANAT
and	O
alters	O
glucose	B-PHYS
utilization	I-PHYS
;	O
two	O
important	O
metabolic	O
changes	O
that	O
could	O
drive	O
whole	O
system	O
changes	O
in	O
metabolism	B-PHYS
initiated	O
at	O
the	O
OB	B-ANAT
.	O

Cobalamin	B-CHEM
Protection	B-DISO
against	O
Oxidative	B-DISO
Stress	I-DISO
in	O
the	O
Acidophilic	O
Iron	B-LIVB
-	I-LIVB
oxidizing	I-LIVB
Bacterium	I-LIVB
Leptospirillum	B-LIVB
Group	I-LIVB
II	I-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
Members	O
of	O
the	O
genus	O
Leptospirillum	B-LIVB
are	O
aerobic	O
iron	B-LIVB
-	I-LIVB
oxidizing	I-LIVB
bacteria	I-LIVB
belonging	O
to	O
the	O
phylum	B-LIVB
Nitrospira	I-LIVB
.	O

They	O
are	O
important	O
members	O
of	O
microbial	B-LIVB
communities	B-PHEN
that	O
catalyze	B-PHEN
the	O
biomining	O
of	O
sulfidic	B-CHEM
ores	I-CHEM
,	O
thereby	O
solubilizing	O
metal	B-CHEM
ions	I-CHEM
.	O

These	O
microorganisms	B-LIVB
live	O
under	O
extremely	O
acidic	O
and	O
metal	B-CHEM
-loaded	O
environments	O
and	O
thus	O
must	O
tolerate	O
high	O
concentrations	O
of	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O
ROS	B-CHEM
)	O
.	O

Cobalamin	B-CHEM
(	O
vitamin	B-CHEM
B12	I-CHEM
)	O
is	O
a	O
cobalt	B-CHEM
-containing	O
tetrapyrrole	B-CHEM
cofactor	B-CHEM
involved	O
in	O
intramolecular	B-PHEN
rearrangement	I-PHEN
reactions	I-PHEN
and	O
has	O
recently	O
been	O
suggested	O
to	O
be	O
an	O
intracellular	O
antioxidant	B-CHEM
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
exogenous	O
addition	O
of	O
cobalamin	B-CHEM
on	O
oxidative	B-DISO
stress	I-DISO
parameters	O
in	O
Leptospirillum	B-LIVB
group	I-LIVB
II	I-LIVB
strain	I-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
.	O

Our	O
results	O
revealed	O
that	O
the	O
external	B-OBJC
supplementation	I-OBJC
of	O
cobalamin	B-CHEM
reduces	O
the	O
levels	O
of	O
intracellular	O
ROSs	B-CHEM
and	O
the	O
damage	O
to	O
biomolecules	B-CHEM
,	O
and	O
also	O
stimulates	B-PHEN
the	O
growth	B-PHYS
and	O
survival	B-PHYS
of	I-PHYS
cells	I-PHYS
exposed	O
to	O
oxidative	B-DISO
stress	I-DISO
exerted	O
by	O
ferric	B-CHEM
ion	I-CHEM
,	O
hydrogen	B-CHEM
peroxide	I-CHEM
,	O
chromate	B-CHEM
and	O
diamide	B-CHEM
.	O

Furthermore	O
,	O
exposure	O
of	O
strain	B-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
to	O
oxidative	B-DISO
stress	I-DISO
elicitors	O
resulted	O
in	O
the	O
transcriptional	B-PHYS
activation	I-PHYS
of	O
the	O
cbiA	O
gene	O
encoding	O
CbiA	B-CHEM
of	O
the	O
cobalamin	B-CHEM
biosynthetic	B-PHYS
pathway	I-PHYS
.	O

Altogether	O
,	O
these	O
data	O
suggest	O
that	O
cobalamin	B-CHEM
plays	O
an	O
important	O
role	O
in	O
redox	B-PHYS
protection	B-DISO
of	O
Leptospirillum	B-LIVB
strain	I-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
,	O
supporting	O
survival	O
of	O
this	O
microorganism	B-LIVB
under	O
extremely	O
oxidative	O
environmental	O
conditions	O
.	O

Understanding	O
the	O
mechanisms	O
underlying	O
the	O
protective	B-DISO
effect	O
of	O
cobalamin	B-CHEM
against	O
oxidative	B-DISO
stress	I-DISO
may	O
help	O
to	O
develop	O
strategies	O
to	O
make	O
biomining	O
processes	B-PHEN
more	O
effective	O
.	O

Metabolite	B-CHEM
Profiling	O
of	O
Italian	B-GEOG
Tomato	B-OBJC
Landraces	O
with	O
Different	O
Fruit	B-OBJC
Types	O
Increased	O
interest	O
toward	O
traditional	O
tomato	B-OBJC
varieties	O
is	O
fueled	O
by	O
the	O
need	O
to	O
rescue	O
desirable	O
organoleptic	O
traits	O
and	O
to	O
improve	B-DISO
the	O
quality	O
of	O
fresh	O
and	O
processed	O
tomatoes	B-OBJC
in	O
the	O
market	B-GEOG
.	O

In	O
addition	O
,	O
the	O
phenotypic	B-PHYS
and	O
genetic	B-PHEN
variation	I-PHEN
preserved	O
in	O
tomato	B-OBJC
landraces	O
represents	O
a	O
means	O
to	O
understand	O
the	O
genetic	O
basis	O
of	O
traits	B-PHYS
related	O
to	O
health	O
and	O
organoleptic	O
aspects	O
and	O
improve	O
them	O
in	O
modern	O
varieties	O
.	O

To	O
establish	O
a	O
framework	O
for	O
this	O
approach	O
,	O
we	O
studied	B-PROC
the	O
content	O
of	O
several	O
metabolites	B-CHEM
in	O
a	O
panel	O
of	O
Italian	B-GEOG
tomato	B-OBJC
landraces	O
categorized	O
into	O
three	O
broad	O
fruit	B-OBJC
type	O
classes	O
(	O
flattened	O
/	O
ribbed	O
,	O
pear	B-OBJC
/	O
oxheart	B-OBJC
,	O
round	O
/	O
elongate	O
)	O
.	O

Three	O
modern	B-LIVB
hybrids	I-LIVB
,	O
corresponding	O
to	O
the	O
three	O
fruit	B-OBJC
shape	O
typologies	O
,	O
were	O
included	O
as	O
reference	O
.	O

Red	B-OBJC
ripe	I-OBJC
fruits	I-OBJC
were	O
morphologically	O
characterized	O
and	O
biochemically	B-PROC
analyzed	I-PROC
for	O
their	O
content	O
in	O
glycoalkaloids	B-CHEM
,	O
phenols	B-CHEM
,	O
amino	B-CHEM
acids	I-CHEM
,	O
and	O
Amadori	B-CHEM
products	I-CHEM
.	O

The	O
round	O
/	O
elongate	O
types	O
showed	O
a	O
higher	O
content	O
in	O
glycoalkaloids	B-CHEM
,	O
whereas	O
flattened	O
types	O
had	O
higher	O
levels	O
of	O
phenolic	B-CHEM
compounds	I-CHEM
.	O

Flattened	O
tomatoes	B-OBJC
were	O
also	O
rich	O
in	O
total	O
amino	B-CHEM
acids	I-CHEM
and	O
in	O
particular	O
in	O
glutamic	B-CHEM
acid	I-CHEM
.	O

Multivariate	O
analysis	O
of	O
amino	B-PROC
acid	I-PROC
content	I-PROC
clearly	O
separated	O
the	O
three	O
classes	O
of	O
fruit	B-OBJC
types	O
.	O

Making	O
allowance	O
of	O
the	O
very	O
low	O
number	O
of	O
genotypes	B-PHYS
,	O
phenotype	B-PHYS
-	I-PHYS
marker	I-PHYS
relationships	O
were	O
analyzed	B-PROC
after	O
retrieving	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
among	O
the	O
landraces	O
available	O
in	O
the	O
literature	O
.	O

Sixty	O
-	O
six	O
markers	O
were	O
significantly	O
associated	O
with	O
the	O
studied	B-PROC
traits	B-PHYS
.	O

The	O
positions	O
of	O
several	O
of	O
these	O
SNPs	O
showed	O
correspondence	O
with	O
already	O
described	O
genomic	O
regions	O
and	O
QTLs	O
supporting	O
the	O
reliability	O
of	O
the	O
association	O
.	O

Overall	O
the	O
data	O
indicated	O
that	O
significant	O
changes	O
in	O
quality	O
-related	O
metabolites	B-CHEM
occur	O
depending	O
on	O
the	O
genetic	B-PHYS
background	I-PHYS
in	O
traditional	O
tomato	B-OBJC
germplasm	B-ANAT
,	O
frequently	O
according	O
to	O
specific	O
fruit	B-OBJC
shape	O
categories	O
.	O

Such	O
a	O
variability	O
is	O
suitable	O
to	O
harness	O
association	O
mapping	O
for	O
metabolic	O
quality	O
traits	B-PHYS
using	O
this	O
germplasm	B-ANAT
as	O
an	O
experimental	O
population	O
,	O
paving	O
the	O
way	O
for	O
investigating	O
their	O
genetic	O
/	O
molecular	O
basis	O
,	O
and	O
facilitating	O
breeding	B-PHYS
for	O
quality	O
-	O
related	O
compounds	B-CHEM
in	O
tomato	B-OBJC
fruits	B-OBJC
.	O

Cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
features	O
of	O
deoxynivalenol	B-CHEM
(	O
DON	B-CHEM
)	O
-	O
targeted	O
immunoaffinity	B-PROC
columns	B-DEVI
aiming	O
to	O
achieve	O
simultaneous	O
analysis	B-PROC
of	O
DON	B-CHEM
and	O
major	O
conjugates	B-CHEM
in	O
cereal	B-OBJC
samples	B-OBJC
Immunoafﬁnity	B-PROC
columns	B-DEVI
(	O
IACs	B-DEVI
)	O
are	O
a	O
well	O
-	O
established	O
tool	O
in	O
the	O
determination	O
of	O
regulated	O
mycotoxins	B-CHEM
in	O
food	B-OBJC
and	O
feed	B-OBJC
commodities	I-OBJC
.	O

However	O
,	O
they	O
also	O
have	O
the	O
potential	O
to	O
become	O
attractive	O
pre	O
-	O
concentration	O
and	O
clean	B-OBJC
-	I-OBJC
up	I-OBJC
materials	I-OBJC
for	O
the	O
determination	O
of	O
masked	O
(	O
also	O
called	O
modified	O
)	O
mycotoxins	B-CHEM
,	O
which	O
have	O
been	O
recognised	O
as	O
important	O
contributors	O
to	O
the	O
toxicological	B-PHEN
hazard	O
deriving	O
from	O
fungal	O
spoilage	B-PHEN
of	O
goods	B-OBJC
.	O

However	O
,	O
the	O
information	O
available	O
in	O
the	O
literature	O
concerning	O
the	O
cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
of	O
DON	B-CHEM
-	O
IACs	B-DEVI
against	O
the	O
major	O
conjugates	B-CHEM
(	O
DON	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
G	I-CHEM
,	O
15	B-CHEM
-	I-CHEM
AcDON	I-CHEM
and	O
3	B-CHEM
-	I-CHEM
AcDON	I-CHEM
)	O
is	O
incomplete	O
and	O
often	O
contradictory	O
.	O

We	O
have	O
carried	O
out	O
a	O
detailed	O
characterisation	O
of	O
the	O
cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
of	O
the	O
four	O
main	O
IACs	B-DEVI
brands	O
against	O
DON	B-CHEM
and	O
its	O
conjugates	B-CHEM
as	O
well	O
as	O
an	O
assessment	O
of	O
the	O
competition	O
among	O
the	O
analytes	B-CHEM
.	O

Only	O
one	O
IAC	B-DEVI
enabled	O
the	O
simultaneous	O
analysis	B-PROC
of	O
all	O
relevant	O
DON	B-CHEM
forms	O
while	O
two	O
missed	O
15	B-CHEM
-	I-CHEM
AcDON	I-CHEM
and	O
the	O
fourth	O
one	O
missed	O
DON	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
G	I-CHEM
and	O
3	B-CHEM
-	I-CHEM
AcDON	I-CHEM
.	O

In	O
the	O
case	O
of	O
the	O
multivalent	O
IAC	B-DEVI
,	O
the	O
analytes	B-CHEM
modified	O
at	O
the	O
C	O
-	O
3	O
position	O
compete	O
for	O
the	O
antibody	B-CHEM
binding	I-CHEM
with	O
preference	O
for	O
3	B-CHEM
-	I-CHEM
AcDON	I-CHEM
(	O
less	O
spatially	O
hindered	O
)	O
while	O
DON	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
G	I-CHEM
has	O
the	O
more	O
-	O
hindered	O
access	O
to	O
the	O
active	B-CHEM
sites	I-CHEM
.	O

Taking	O
into	O
consideration	O
the	O
levels	O
of	O
DON	B-CHEM
conjugates	B-CHEM
existing	O
in	O
real	B-OBJC
samples	I-OBJC
,	O
the	O
cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
of	O
one	O
DON	B-CHEM
-	O
IAC	B-DEVI
allows	O
a	O
quantitative	O
analysis	O
of	O
all	O
of	O
these	O
analytes	B-CHEM
.	O

Important	O
but	O
rather	O
neglected	O
aspects	O
such	O
as	O
the	O
continuous	O
supply	O
of	O
IACs	B-DEVI
with	O
identical	O
characteristics	O
,	O
and	O
of	O
columns	B-DEVI
which	O
are	O
strictly	O
blank	O
,	O
are	O
also	O
addressed	O
in	O
this	O
paper	O
.	O

A	O
longitudinal	B-PROC
study	I-PROC
assessing	O
childcare	O
services	O
'	O
adoption	O
of	O
obesity	B-DISO
prevention	B-PROC
policies	I-PROC
and	I-PROC
practices	I-PROC
Despite	O
ongoing	O
investments	O
to	O
improve	O
the	O
obesogenic	B-DISO
environments	O
of	O
childcare	O
settings	O
,	O
little	O
is	O
known	O
regarding	O
how	O
these	O
services	O
have	O
changed	O
their	O
physical	O
activity	O
and	O
nutrition	B-PROC
-	I-PROC
promoting	I-PROC
practices	I-PROC
.	O

This	O
study	O
aims	O
to	O
describe	O
changes	O
in	O
the	O
proportion	O
of	O
Australian	B-LIVB
childcare	O
services	O
that	O
have	O
adopted	O
best	B-PROC
-	I-PROC
practice	I-PROC
healthy	B-PROC
eating	I-PROC
and	O
physical	O
activity	O
practices	B-PROC
between	O
2006	O
and	O
2013	O
and	O
to	O
assess	O
whether	O
adoption	O
varied	O
by	O
socio	O
-	O
economic	O
status	O
and	O
locality	O
.	O

A	O
randomly	B-PROC
selected	I-PROC
sample	I-PROC
of	O
nominated	O
supervisors	B-LIVB
(	O
n	O
=	O
358	O
)	O
from	O
childcare	O
services	O
located	O
in	O
New	B-GEOG
South	I-GEOG
Wales	I-GEOG
,	O
Australia	B-GEOG
,	O
participated	O
in	O
a	O
telephone	B-PROC
survey	I-PROC
in	O
2006	O
,	O
2009	O
,	O
2010	O
and	O
2013	O
.	O

Supervisors	B-LIVB
reported	O
on	O
their	O
service	O
's	O
adoption	O
of	O
six	O
practices	B-PROC
:	O
(	O
i	O
)	O
having	O
written	O
nutrition	B-PROC
and	O
physical	O
activity	O
policies	O
;	O
(	O
ii	O
)	O
staff	B-LIVB
trained	O
in	O
physical	O
activity	O
and	O
nutrition	B-PROC
in	O
the	O
past	O
year	O
;	O
(	O
iii	O
)	O
scheduled	O
time	O
for	O
fundamental	O
movement	B-PHYS
skills	O
and	O
(	O
iv	O
)	O
outdoor	O
play	O
;	O
(	O
v	O
)	O
weekly	O
or	O
less	O
screen	B-DISO
time	I-DISO
opportunitie	I-DISO
s	O
;	O
and	O
(	O
vi	O
)	O
serving	O
only	O
non	B-OBJC
-	I-OBJC
sweetened	I-OBJC
beverages	I-OBJC
.	O

A	O
significant	O
increase	O
in	O
the	O
prevalence	O
of	O
services	O
adopting	O
all	O
but	O
one	O
practice	B-PROC
,	O
between	O
2006	O
and	O
2013	O
was	O
identified	O
.	O

Ninety	O
one	O
percent	O
of	O
services	O
adopted	O
four	O
or	O
more	O
practices	B-PROC
,	O
a	O
significant	O
increase	O
from	O
38	O
%	O
in	O
2006	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
services	O
adopting	O
each	O
practice	B-PROC
by	O
locality	O
and	O
socio	O
-	O
economic	O
status	O
.	O

Government	O
investment	O
in	O
obesity	B-DISO
prevention	B-PROC
programmes	I-PROC
can	O
equitably	O
improve	O
childcare	O
service	O
's	O
adoption	O
of	O
healthy	B-PROC
eating	I-PROC
and	O
physical	O
activity	O
promoting	O
practices	B-PROC
on	O
a	O
jurisdiction	O
-wide	O
basis	O
.	O

The	O
establishment	O
of	O
a	O
routine	O
system	O
to	O
monitor	O
adoption	O
of	O
a	O
broader	O
range	O
of	O
practices	B-PROC
by	O
childcare	O
services	O
is	O
warranted	O
.	O

Improving	O
Early	B-PROC
Identification	I-PROC
and	O
Ongoing	O
Care	O
of	O
Children	B-LIVB
With	O
Autism	B-DISO
Spectrum	I-DISO
Disorder	I-DISO
Poor	O
adherence	O
to	O
recommended	O
screening	B-PROC
for	O
autism	B-DISO
spectrum	I-DISO
disorder	I-DISO
(	O
ASD	B-DISO
)	O
and	O
pediatricians	B-LIVB
'	O
lack	B-DISO
of	I-DISO
confidence	I-DISO
in	O
providing	O
care	O
for	O
children	B-LIVB
with	O
ASD	B-DISO
reflect	O
quality	O
gaps	O
in	O
primary	B-PROC
care	I-PROC
.	O

This	O
study	B-PROC
aimed	O
to	O
increase	O
the	O
proportion	O
of	O
toddlers	B-LIVB
screened	O
for	O
ASD	B-DISO
and	O
improve	B-DISO
physicians	B-LIVB
'	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
in	O
providing	O
care	O
to	O
children	B-LIVB
with	O
ASD	B-DISO
.	O

Twenty	O
-	O
six	O
Utah	O
primary	B-PROC
care	I-PROC
practices	I-PROC
participated	O
in	O
a	O
3	O
to	O
6	O
month	O
learning	O
collaborative	O
(	O
LC	O
)	O
to	O
improve	B-DISO
identification	B-PHYS
and	O
ongoing	O
care	O
of	O
children	B-LIVB
with	O
ASD	B-DISO
.	O

Monthly	O
chart	O
audits	O
assessed	O
whether	O
an	O
ASD	B-DISO
screening	B-PROC
tool	I-PROC
was	O
administered	O
at	O
18	O
-	O
and	O
24	O
-	O
month	O
visits	B-PROC
.	O

Physicians	B-LIVB
completed	O
pre	O
-	O
LC	O
and	O
post	O
-	O
LC	O
surveys	O
to	O
assess	O
changes	O
in	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
in	O
providing	O
care	O
and	O
changes	O
in	O
perceived	B-PHYS
barriers	O
to	O
implementation	O
of	O
screening	B-PROC
and	O
caring	O
for	O
children	B-LIVB
with	O
ASD	B-DISO
.	O

Before	O
the	O
LC	O
,	O
15	O
%	O
of	O
18	O
-	O
and	O
24	O
-	O
month	O
visits	B-PROC
had	O
documented	B-PROC
ASD	B-DISO
screening	B-PROC
,	O
compared	O
with	O
91	O
%	O
during	O
the	O
last	O
month	O
of	O
the	O
LC	O
(	O
P	O
<	O
.001	O
)	O
.	O

This	O
rate	O
of	O
ASD	B-DISO
screening	B-PROC
was	O
sustained	O
4	O
years	O
after	O
the	O
LC	O
by	O
most	O
practices	O
.	O

Compared	O
with	O
survey	B-PROC
responses	O
before	O
the	O
LC	O
,	O
physicians	B-LIVB
reported	O
significant	O
improvement	O
in	O
their	O
ability	O
to	O
care	O
for	O
children	B-LIVB
with	O
ASD	B-DISO
and	O
decreases	O
in	O
their	O
perceived	B-PHYS
barriers	O
to	O
screening	B-PROC
and	O
caring	O
for	O
children	B-LIVB
with	O
ASD	B-DISO
.	O

The	O
LC	O
was	O
effective	O
in	O
increasing	O
and	O
sustaining	O
recommended	O
ASD	B-DISO
screening	B-PROC
of	O
toddlers	B-LIVB
and	O
improving	O
physicians	B-LIVB
'	O
perceived	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
in	O
caring	O
for	O
children	B-LIVB
with	O
ASD	B-DISO
.	O

Improving	O
primary	B-PROC
care	I-PROC
screening	B-PROC
,	O
skills	O
,	O
and	O
knowledge	B-DISO
may	O
improve	B-DISO
the	O
timing	O
of	O
diagnosis	B-PROC
,	O
initiation	O
of	O
treatment	B-PROC
,	O
quality	B-PROC
of	I-PROC
care	I-PROC
,	O
and	O
outcomes	O
for	O
children	B-LIVB
with	O
ASD	B-DISO
.	O

Describing	O
Self	O
-	O
Care	O
Self	B-PHYS
-	I-PHYS
Efficacy	I-PHYS
:	O
Definition	O
,	O
Measurement	O
,	O
Outcomes	O
,	O
and	O
Implications	O
The	O
pragmatic	B-PROC
utility	I-PROC
method	I-PROC
of	O
concept	O
analysis	B-PROC
was	O
used	O
to	O
explore	O
the	O
usefulness	O
of	O
the	O
concept	O
self	O
-	O
care	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
.	O

Empirical	B-PROC
studies	I-PROC
across	O
disciplines	O
published	O
between	O
1996	O
and	O
2015	O
were	O
used	O
as	O
data	O
.	O

A	O
data	O
matrix	O
was	O
developed	O
.	O

Analytical	O
questions	O
and	O
responses	O
were	O
derived	O
from	O
the	O
data	O
to	O
understand	O
patterns	O
,	O
develop	O
new	O
knowledge	O
and	O
achieve	O
synthesis	O
.	O

Usefulness	O
of	O
the	O
concept	O
is	O
contingent	O
on	O
how	O
it	O
is	O
defined	O
and	O
measured	O
.	O

Self	O
-	O
care	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
is	O
associated	O
with	O
performance	O
of	O
self	O
-	O
care	O
activities	O
and	O
positive	B-DISO
health	O
outcomes	O
in	O
diverse	O
populations	B-LIVB
.	O

Research	B-PROC
can	O
guide	O
development	O
of	O
targeted	O
interventions	B-PROC
to	O
increase	O
patients	B-LIVB
'	O
self	O
-	O
care	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O
thus	O
reducing	O
costs	O
,	O
and	O
assisting	B-PROC
people	B-LIVB
to	O
achieve	O
optimal	O
health	O
.	O

Dynamics	B-PHEN
of	O
intestinal	B-ANAT
metabolites	B-CHEM
and	O
morphology	O
in	O
response	B-PHYS
to	O
necrotic	B-DISO
enteritis	I-DISO
challenge	B-PROC
in	O
broiler	B-LIVB
chickens	I-LIVB
Despite	O
the	O
relatively	O
small	O
contribution	O
to	O
metabolizable	O
energy	O
that	O
volatile	B-CHEM
fatty	I-CHEM
acids	I-CHEM
(	O
VFAs	B-CHEM
)	O
provide	O
in	O
chickens	B-LIVB
,	O
these	O
organic	B-CHEM
acids	I-CHEM
have	O
been	O
reported	B-PROC
to	O
play	O
beneficial	O
roles	O
in	O
the	O
gastrointestinal	B-ANAT
tract	I-ANAT
(	O
GIT	B-ANAT
)	O
of	O
birds	B-LIVB
,	O
for	O
example	O
,	O
inhibition	B-PHYS
of	I-PHYS
the	I-PHYS
growth	I-PHYS
of	O
some	O
pathogenic	B-LIVB
bacteria	B-LIVB
.	O

However	O
,	O
information	O
regarding	O
the	O
dynamics	B-PHEN
of	O
these	O
metabolites	B-CHEM
in	O
the	O
GIT	B-ANAT
of	O
chickens	B-LIVB
is	O
still	O
scarce	O
,	O
especially	O
under	O
disease	B-DISO
conditions	I-DISO
such	O
as	O
necrotic	B-DISO
enteritis	I-DISO
(	O
NE	B-DISO
)	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
dynamics	B-PHEN
of	O
VFAs	B-CHEM
and	O
lactic	B-CHEM
acid	I-CHEM
,	O
and	O
intestinal	B-ANAT
morphology	O
in	O
response	B-PHYS
to	O
NE	B-DISO
predisposing	O
factors	O
,	O
that	O
is	O
,	O
excessive	O
dietary	B-OBJC
fishmeal	B-OBJC
and	O
Eimeria	O
inoculation	B-PROC
,	O
and	O
causative	B-DISO
agent	I-DISO
Clostridium	B-LIVB
perfringens	I-LIVB
producing	O
NetB	B-CHEM
toxin	I-CHEM
.	O

The	O
experiment	B-PROC
was	O
designed	B-PROC
in	O
a	O
2	O
×	O
2	O
×	O
2	O
factorial	O
arrangement	B-PROC
of	O
treatments	B-PROC
with	O
or	O
without	O
:	O
fishmeal	B-OBJC
feeding	O
,	O
Eimeria	O
inoculation	B-PROC
and	O
C	B-LIVB
.	I-LIVB

perfringens	I-LIVB
challenge	B-PROC
.	O

The	O
results	B-DISO
showed	O
that	O
these	O
factors	O
significantly	O
influenced	O
composition	B-PHYS
and	O
concentration	O
of	O
VFAs	B-CHEM
and	O
lactic	B-CHEM
acids	I-CHEM
,	O
pH	O
and	O
histomorphometry	O
in	O
one	O
way	O
or	O
another	O
.	O

These	O
changes	O
may	O
be	O
important	O
for	O
the	O
onset	O
of	O
NE	B-DISO
or	O
only	O
the	O
synergetic	B-PHYS
responses	I-PHYS
to	O
micro	O
environmental	O
stress	B-DISO
.	O

Eimeria	O
appeared	O
to	O
be	O
more	O
important	O
than	O
fishmeal	B-OBJC
in	O
predisposing	O
birds	B-LIVB
to	O
NE	B-DISO
,	O
thus	O
the	O
application	O
of	O
Eimeria	O
in	O
NE	B-DISO
challenge	B-PROC
provides	O
more	O
consistent	O
success	O
in	O
inducing	O
the	O
disease	B-DISO
.	O

The	O
metabolic	O
responses	B-PHYS
to	O
various	O
adverse	B-DISO
factors	O
such	O
as	O
excessive	O
dietary	B-OBJC
fishmeal	B-OBJC
and	O
Eimeria	O
infection	B-DISO
are	O
complex	O
.	O

Thus	O
,	O
intensive	O
efforts	B-PHYS
are	O
required	O
to	O
better	O
understand	B-PHYS
NE	B-DISO
so	O
as	O
to	O
achieve	O
the	O
control	B-PROC
of	I-PROC
the	I-PROC
disease	I-PROC
in	O
the	O
absence	O
of	O
antibiotics	B-CHEM
.	O

The	O
effects	O
of	O
paternal	O
high	B-OBJC
-	I-OBJC
fat	I-OBJC
diet	I-OBJC
exposure	O
on	O
offspring	B-LIVB
metabolism	B-PHYS
with	O
epigenetic	B-PHYS
changes	I-PHYS
in	O
the	O
mouse	O
adiponectin	O
and	O
leptin	O
gene	O
promoters	O
Recent	O
studies	B-PROC
have	O
demonstrated	O
that	O
epigenetic	B-PHYS
changes	I-PHYS
resulting	O
from	O
malnutrition	B-DISO
might	O
play	O
important	O
roles	O
in	O
transgenerational	O
links	O
with	O
metabolic	B-DISO
diseases	I-DISO
.	O

Previously	O
,	O
we	O
observed	O
that	O
exposure	O
to	O
a	O
high	B-OBJC
-	I-OBJC
fat	I-OBJC
diet	I-OBJC
(	O
HFD	B-OBJC
)	O
in	B-LIVB
utero	I-LIVB
caused	O
a	O
metabolic	O
syndrome	B-DISO
-like	O
phenomenon	B-PHEN
through	O
epigenetic	B-PHYS
modifications	I-PHYS
of	O
the	O
adiponectin	O
and	O
leptin	O
genes	O
that	O
persisted	O
for	O
multiple	O
generations	O
.	O

Recent	O
etiological	O
studies	B-PROC
indicated	B-DISO
that	O
paternal	O
BMI	B-PHYS
had	O
effects	O
on	O
offspring	B-LIVB
BMI	B-PHYS
that	O
were	O
independent	O
of	O
but	O
additive	O
to	O
maternal	B-DISO
BMI	B-PHYS
effects	O
.	O

Thus	O
,	O
we	O
examined	O
whether	O
paternal	O
HFD	B-OBJC
-	O
induced	O
obesity	B-DISO
affected	O
the	O
metabolic	O
status	O
of	O
offspring	B-LIVB
through	O
epigenetic	B-PHYS
changes	I-PHYS
in	O
the	O
adiponectin	O
and	O
leptin	O
genes	O
.	O

Additionally	O
,	O
we	O
investigated	O
whether	O
a	O
normal	O
diet	O
during	O
subsequent	O
generations	O
abolished	O
the	O
epigenetic	B-PHYS
changes	I-PHYS
associated	O
with	O
paternal	O
HFD	B-OBJC
exposure	O
before	O
conception	B-PHYS
.	O

We	O
observed	O
the	O
effects	O
of	O
paternal	O
HFD	B-OBJC
exposure	O
before	O
conception	B-PHYS
over	O
multiple	O
generations	O
on	O
offspring	B-LIVB
metabolic	O
traits	B-PHYS
,	O
including	O
weight	B-DISO
and	O
fat	B-CHEM
gain	O
,	O
glucose	B-DISO
intolerance	I-DISO
,	O
hypertriglyceridemia	B-DISO
,	O
abnormal	B-CHEM
adipocytokine	I-CHEM
levels	O
,	O
hypertension	B-DISO
,	O
and	O
adiponectin	O
and	O
leptin	O
gene	O
expression	B-PHYS
and	O
epigenetic	B-PHYS
changes	I-PHYS
.	O

Normal	O
diet	O
consumption	O
by	O
male	O
offspring	B-LIVB
during	O
the	O
subsequent	O
generation	O
following	O
paternal	O
HFD	B-OBJC
exposure	O
diminished	O
whereas	O
consumption	O
for	O
two	O
generations	O
completely	O
abolished	O
the	O
effect	O
of	O
paternal	O
HFD	B-OBJC
exposure	O
on	O
metabolic	O
traits	B-PHYS
and	O
adipocytokine	B-CHEM
promoter	O
epigenetic	B-PHYS
changes	I-PHYS
in	O
the	O
offspring	B-LIVB
.	O

The	O
effects	O
of	O
paternal	O
HFD	B-OBJC
exposure	O
on	O
offspring	B-LIVB
were	O
relatively	O
weaker	O
than	O
those	O
following	O
HFD	B-OBJC
exposure	O
in	B-LIVB
utero	I-LIVB
.	O

However	O
,	O
paternal	O
HFD	B-OBJC
exposure	O
had	O
an	O
additive	O
metabolic	O
effect	O
for	O
two	O
generations	O
,	O
suggesting	O
that	O
both	O
paternal	O
and	O
maternal	B-DISO
nutrition	B-PHYS
might	O
affect	O
offspring	B-LIVB
metabolism	B-PHYS
through	O
epigenetic	B-PHYS
modifications	I-PHYS
of	O
adipocytokine	O
genes	O
for	O
multiple	O
generations	O
.	O

Ehlers	B-DISO
-	I-DISO
Danlos	I-DISO
syndrome	I-DISO
The	O
Ehlers	B-DISO
-	I-DISO
Danlos	I-DISO
syndromes	I-DISO
(	O
EDSs	B-DISO
)	O
were	O
originally	O
described	O
by	O
Ehlers	B-LIVB
in	O
Denmark	B-GEOG
and	O
Danlos	B-LIVB
in	O
Paris	B-GEOG
in	O
1898	O
and	O
1908	O
,	O
respectively	O
.	O

They	O
had	O
both	O
published	O
individual	O
case	O
studies	O
in	O
which	O
the	O
common	O
factor	O
was	O
laxity	B-DISO
of	I-DISO
ligaments	I-DISO
leading	O
to	O
joint	B-DISO
hypermobility	I-DISO
and	O
hyperextensibility	B-DISO
of	I-DISO
the	I-DISO
skin	I-DISO
.	O

The	O
choice	O
of	O
the	O
name	O
of	O
this	O
eponymous	O
disease	O
had	O
been	O
made	O
by	O
Dr	B-LIVB
Parkes	I-LIVB
Weber	I-LIVB
,	O
an	O
eminent	O
London	B-GEOG
physician	B-LIVB
in	O
the	O
1930s	O
,	O
who	O
had	O
a	O
penchant	O
for	O
eponymous	O
diseases	O
,	O
having	O
had	O
no	O
less	O
than	O
seven	O
attributed	O
to	O
himself	O
,	O
at	O
least	O
in	O
part	O
.	O

Unfortunately	O
,	O
this	O
was	O
before	O
the	O
age	O
of	O
a	O
computerised	O
literature	O
search	O
,	O
and	O
Parkes	B-LIVB
Weber	I-LIVB
had	O
inadvertently	O
overlooked	O
the	O
very	O
first	O
description	O
of	O
EDS	B-DISO
which	O
had	O
been	O
made	O
by	O
Tchernabogov	B-LIVB
,	O
a	O
Russian	B-LIVB
dermatologist	B-LIVB
,	O
whose	O
description	O
was	O
published	O
in	O
1891	O
and	O
remains	O
one	O
of	O
the	O
best	O
descriptions	O
of	O
EDS	B-DISO
in	O
the	O
literature	O
.	O

Assessment	B-PROC
of	O
laparoscopic	B-PROC
stomach	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O
sentinel	B-PROC
basin	I-PROC
dissection	I-PROC
versus	O
standard	O
gastrectomy	B-PROC
with	O
lymphadenectomy	B-PROC
in	O
early	B-DISO
gastric	I-DISO
cancer	I-DISO
-A	O
multicenter	B-PROC
randomized	I-PROC
phase	I-PROC
III	I-PROC
clinical	I-PROC
trial	I-PROC
(	I-PROC
SENORITA	I-PROC
trial	I-PROC
)	I-PROC
protocol	I-PROC
Along	O
with	O
the	O
marked	O
increase	O
in	O
early	B-DISO
gastric	I-DISO
cancer	I-DISO
(	O
EGC	B-DISO
)	O
in	O
the	O
Eastern	B-GEOG
countries	I-GEOG
,	O
there	O
has	O
been	O
an	O
effort	O
to	O
adopt	O
the	O
sentinel	B-ANAT
node	I-ANAT
concept	O
in	O
EGC	B-DISO
to	O
preserve	O
gastric	B-PHYS
function	I-PHYS
and	O
reduce	O
the	O
occurrence	O
of	O
postoperative	B-DISO
complications	I-DISO
.	O

Based	O
on	O
promising	O
results	O
from	O
a	O
previous	B-PROC
quality	I-PROC
control	I-PROC
study	I-PROC
,	O
this	O
prospective	B-PROC
multicenter	I-PROC
randomized	I-PROC
controlled	I-PROC
phase	I-PROC
III	I-PROC
clinical	I-PROC
trial	I-PROC
aims	O
to	O
elucidate	O
the	O
oncologic	O
safety	B-PROC
of	O
laparoscopic	B-PROC
stomach	I-PROC
-	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O
sentinel	B-PROC
basin	I-PROC
dissection	I-PROC
(	O
SBD	B-PROC
)	O
compared	O
to	O
a	O
standard	O
laparoscopic	O
gastrectomy	B-PROC
.	O

This	O
trial	O
is	O
an	O
investigator	O
-	O
initiated	O
,	O
open	O
-	O
label	O
,	O
multicenter	B-PROC
randomized	I-PROC
controlled	I-PROC
phase	I-PROC
III	I-PROC
trial	I-PROC
with	O
a	O
non	B-PROC
-	I-PROC
inferiority	I-PROC
design	I-PROC
.	O

Patients	O
diagnosed	O
with	O
a	O
single	B-DISO
lesion	I-DISO
of	O
clinical	O
stage	O
T1N0M0	O
gastric	B-DISO
adenocarcinoma	I-DISO
,	O
with	O
a	O
diameter	O
of	O
3	O
cm	O
or	O
less	O
are	O
eligible	O
for	O
the	O
present	O
study	O
.	O

A	O
total	O
of	O
580	O
patients	B-LIVB
(	O
290	O
per	O
group	O
)	O
will	O
be	O
randomized	B-DISO
to	O
either	O
laparoscopic	B-PROC
stomach	I-PROC
-	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O
SBD	B-PROC
or	O
standard	B-PROC
surgery	I-PROC
.	O

The	O
primary	O
end	O
-	O
point	O
is	O
3	O
-	O
year	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
the	O
secondary	O
endpoints	O
include	O
postoperative	B-DISO
morbidity	I-DISO
and	O
mortality	O
,	O
quality	O
of	O
life	O
,	O
5	O
-	O
year	O
DFS	O
,	O
and	O
overall	O
survival	O
.	O

Qualified	B-LIVB
investigators	I-LIVB
who	O
completed	O
the	O
prior	O
quality	O
control	O
study	O
are	O
exclusively	O
allowed	O
to	O
participate	O
in	O
this	O
phase	B-PROC
III	I-PROC
clinical	I-PROC
trial	I-PROC
.	O

The	O
proposed	O
trial	O
is	O
expected	O
to	O
verify	O
whether	O
laparoscopic	B-PROC
stomach	I-PROC
-	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O
SBD	B-PROC
achieves	O
similar	O
oncologic	B-DISO
outcomes	I-DISO
and	O
improved	O
quality	O
of	O
life	O
compared	O
to	O
a	O
standard	B-PROC
gastrectomy	I-PROC
in	O
EGC	B-DISO
patients	B-LIVB
.	O

This	O
study	O
was	O
registered	O
at	O
the	O
NIH	O
ClinicalTrial	O
.	O

gov	O
database	O
(	O
NCT01804998	O
)	O
on	O
March	O
4th	O
,	O
2013	O
.	O

Isolation	O
and	O
characterization	O
of	O
Burkholderia	B-LIVB
sp	I-LIVB
.	I-LIVB

strain	I-LIVB
CCA53	I-LIVB
exhibiting	O
ligninolytic	B-PHYS
potential	O
Microbial	B-LIVB
degradation	B-PHYS
of	O
lignin	B-CHEM
releases	O
fermentable	B-CHEM
sugars	I-CHEM
,	O
effective	O
utilization	O
of	O
which	O
could	O
support	O
biofuel	B-CHEM
production	O
from	O
lignocellulosic	B-CHEM
biomass	O
.	O

In	O
the	O
present	O
study	B-PROC
,	O
a	O
lignin	B-PHYS
-	I-PHYS
degrading	I-PHYS
bacterium	B-LIVB
was	O
isolated	O
from	O
leaf	B-LIVB
soil	B-OBJC
and	O
identified	O
as	O
Burkholderia	B-LIVB
sp	I-LIVB
.	I-LIVB

based	O
on	O
16S	B-CHEM
rRNA	I-CHEM
gene	B-PROC
sequencing	I-PROC
.	O

This	O
strain	O
was	O
named	O
CCA53	B-LIVB
,	O
and	O
its	O
lignin	B-PHYS
-	I-PHYS
degrading	I-PHYS
capability	O
was	O
assessed	O
by	O
observing	O
its	O
growth	B-PHYS
on	O
medium	B-CHEM
containing	O
alkali	B-CHEM
lignin	I-CHEM
or	O
lignin	B-CHEM
-associated	O
aromatic	B-CHEM
monomers	I-CHEM
as	O
the	O
sole	O
carbon	B-CHEM
source	B-DISO
.	O

Alkali	B-CHEM
lignin	I-CHEM
and	O
at	O
least	O
eight	O
lignin	B-CHEM
-associated	O
aromatic	B-CHEM
monomers	I-CHEM
supported	O
growth	B-PHYS
of	O
this	O
strain	O
,	O
and	O
the	O
most	O
effective	O
utilization	O
was	O
observed	O
for	O
p	B-CHEM
-	I-CHEM
hydroxybenzene	I-CHEM
monomers	I-CHEM
.	O

These	O
findings	B-DISO
indicate	O
that	O
Burkholderia	B-LIVB
sp	I-LIVB
.	I-LIVB

strain	I-LIVB
CCA53	I-LIVB
has	O
fragmentary	O
activity	O
for	O
lignin	B-PHYS
degradation	I-PHYS
.	O

Association	O
of	O
Metabolites	B-CHEM
with	O
Obesity	B-DISO
and	O
Type	B-DISO
2	I-DISO
Diabetes	I-DISO
Based	O
on	O
FTO	O
Genotype	B-PHYS
The	O
single	O
nucleotide	O
polymorphism	O
rs9939609	O
of	O
the	O
gene	O
FTO	O
,	O
which	O
encodes	O
fat	B-PHYS
mass	I-PHYS
and	O
obesity	B-DISO
-associated	O
protein	B-CHEM
,	O
is	O
strongly	O
associated	O
with	O
obesity	B-DISO
and	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
(	O
T2D	B-DISO
)	O
in	O
multiple	O
populations	B-LIVB
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
of	O
this	O
association	O
is	O
unclear	O
.	O

The	O
present	O
study	B-PROC
aimed	O
to	O
investigate	O
FTO	O
genotype	B-PHYS
-dependent	O
metabolic	B-PHYS
changes	O
in	O
obesity	B-DISO
and	O
T2D	B-DISO
.	O

To	O
elucidate	O
metabolic	B-DISO
dysregulation	I-DISO
associated	O
with	O
disease	B-PHYS
risk	I-PHYS
genotype	B-PHYS
,	O
genomic	O
and	O
metabolomic	O
datasets	O
were	O
recruited	O
from	O
2	O
,	O
577	O
participants	B-LIVB
of	O
the	O
Korean	B-LIVB
Association	I-LIVB
REsource	I-LIVB
(	I-LIVB
KARE	I-LIVB
)	I-LIVB
cohort	I-LIVB
,	O
including	O
40	O
homozygous	B-PHYS
carriers	B-DISO
of	O
the	O
FTO	O
risk	O
allele	O
(	O
AA	O
)	O
,	O
570	O
heterozygous	B-PHYS
carriers	B-DISO
(	O
AT	O
)	O
,	O
and	O
1	O
,	O
967	O
participants	B-LIVB
carrying	O
no	O
risk	O
allele	O
(	O
TT	O
)	O
.	O

A	O
total	O
of	O
134	O
serum	B-ANAT
metabolites	B-CHEM
were	O
quantified	O
using	O
a	O
targeted	O
metabolomics	O
approach	O
.	O

Through	O
comparison	O
of	O
various	O
statistical	B-PROC
methods	I-PROC
,	O
seven	O
metabolites	B-CHEM
were	O
identified	O
that	O
are	O
significantly	O
altered	O
in	O
obesity	B-DISO
and	O
T2D	B-DISO
based	O
on	O
the	O
FTO	O
risk	O
allele	O
(	O
adjusted	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
identified	O
metabolites	B-CHEM
are	O
relevant	O
to	O
phosphatidylcholine	B-CHEM
metabolic	O
pathway	O
,	O
and	O
previously	O
reported	O
to	O
be	O
metabolic	B-CHEM
markers	I-CHEM
of	O
obesity	B-DISO
and	O
T2D	B-DISO
.	O

In	O
conclusion	O
,	O
using	O
metabolomics	O
with	O
the	O
information	O
from	O
genome	B-PROC
-	I-PROC
wide	I-PROC
association	I-PROC
studies	I-PROC
revealed	O
significantly	O
altered	O
metabolites	B-CHEM
depending	O
on	O
the	O
FTO	O
genotype	B-PHYS
in	O
complex	O
disorders	O
.	O

This	O
study	B-PROC
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
biological	O
mechanisms	O
linking	O
obesity	B-DISO
and	O
T2D	B-DISO
.	O

Anthology	O
of	O
Venezuelan	B-LIVB
psychiatry	O
Reception	O
of	O
Psychiatry	O
in	O
Venezuela	B-GEOG
since	O
the	O
19th	O
Century	O
to	O
the	O
late	O
20th	O
Century	O
merits	O
a	O
historical	O
approach	O
.	O

The	O
following	O
work	O
proposes	O
to	O
research	B-PROC
some	O
of	O
the	O
very	O
origins	O
of	O
Venezuelan	B-LIVB
psychiatry	O
and	O
its	O
possible	O
influence	O
on	O
contemporary	O
mental	B-PROC
health	I-PROC
practice	I-PROC
.	O

Through	O
documental	O
research	O
,	O
the	O
early	O
works	O
of	O
local	B-LIVB
authors	I-LIVB
from	O
the	O
19th	O
Century	O
through	O
20th	O
Century	O
finals	O
:	O
Carlos	B-LIVB
Arvelo	I-LIVB
,	O
Lisandro	B-LIVB
Alvarado	I-LIVB
,	O
Francisco	B-LIVB
Herrera	I-LIVB
Luque	I-LIVB
,	O
Jose	B-LIVB
Luis	I-LIVB
Vethencourt	I-LIVB
and	O
Jose	B-LIVB
Solanes	I-LIVB
,	O
are	O
subjected	O
to	O
study	O
.	O

This	O
journey	O
illustrates	O
a	O
descriptive	O
panoramic	O
view	O
which	O
allows	O
to	O
better	O
comprenhend	O
the	O
current	O
state	O
of	O
our	O
psychiatry	O
.	O

In	O
a	O
brief	O
introduction	O
the	O
most	O
important	O
events	O
are	O
described	O
,	O
since	O
the	O
arrival	O
of	O
Pinel	B-LIVB
's	I-LIVB
ideas	O
,	O
followed	O
by	O
the	O
early	O
research	O
paperworks	O
published	O
and	O
the	O
beginnings	O
of	O
the	O
academic	O
teachings	O
of	O
this	O
specialty	O
in	O
Venezuela	B-GEOG
and	O
displaying	O
the	O
main	O
contemporary	O
research	O
groups	O
thorough	B-GEOG
the	I-GEOG
country	I-GEOG
.	O

Study	B-PROC
of	O
the	O
Microfocus	O
X	B-DEVI
-	I-DEVI
Ray	I-DEVI
Tube	I-DEVI
Based	O
on	O
a	O
Point	O
-	O
Like	O
Target	O
Used	O
for	O
Micro	B-PROC
-	I-PROC
Computed	I-PROC
Tomography	I-PROC
For	O
a	O
micro	B-PROC
-	I-PROC
Computed	I-PROC
Tomography	I-PROC
(	I-PROC
Micro	I-PROC
-	I-PROC
CT	I-PROC
)	I-PROC
system	I-PROC
,	O
the	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
is	O
an	O
essential	O
component	O
because	O
the	O
spatial	O
resolution	O
of	O
CT	B-PROC
images	O
,	O
in	O
theory	O
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	O
and	O
stability	O
of	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
of	O
the	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
.	O

However	O
,	O
many	O
factors	O
,	O
including	O
voltage	O
fluctuations	O
,	O
mechanical	B-PHEN
vibrations	B-PHEN
,	O
and	O
temperature	O
changes	O
,	O
can	O
cause	O
the	O
size	O
and	O
the	O
stability	O
of	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
to	O
degrade	B-PHEN
.	O

A	O
new	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
based	O
on	O
a	O
point	O
-	O
like	O
micro	O
-	O
target	O
in	O
which	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
target	O
is	O
irradiated	B-PHEN
with	O
an	O
unfocused	O
electron	B-OBJC
beam	I-OBJC
was	O
investigated	O
.	O

EGS4	O
Monte	O
Carlo	O
simulation	O
code	O
was	O
employed	O
for	O
the	O
calculation	O
of	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
intensity	B-PHEN
produced	O
from	O
the	O
point	O
-	O
like	O
micro	O
-	O
target	O
and	O
the	O
substrate	B-OBJC
.	O

The	O
effects	O
of	O
several	O
arrangements	O
of	O
the	O
target	O
material	B-OBJC
,	O
target	O
and	O
beam	B-OBJC
size	O
were	O
studied	B-PROC
.	O

The	O
simulation	B-PROC
results	O
demonstrated	O
that	O
if	O
the	O
intensity	B-PHEN
of	O
X	B-PROC
-	I-PROC
rays	I-PROC
generated	O
at	O
the	O
point	O
-	O
like	O
target	O
is	O
greater	O
than	O
half	O
of	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
intensity	B-PHEN
produced	O
on	O
the	O
substrate	B-OBJC
,	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
is	O
determined	O
in	O
part	O
by	O
the	O
point	O
-	O
like	O
target	O
rather	O
than	O
by	O
the	O
electron	B-OBJC
beam	I-OBJC
in	O
the	O
conventional	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
.	O

In	O
theory	O
,	O
since	O
it	O
is	O
able	O
to	O
reduce	O
those	O
unfavorable	O
effects	O
such	O
as	O
the	O
electron	B-DISO
beam	I-DISO
trajectory	I-DISO
swinging	I-DISO
and	O
the	O
beam	B-OBJC
size	O
changing	O
for	O
the	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
,	O
it	O
could	O
alleviate	O
CT	B-PROC
image	O
artifacts	B-PHEN
caused	O
by	O
the	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
shift	B-DISO
and	O
size	O
change	O
.	O

How	O
variation	O
between	O
individuals	B-LIVB
affects	O
species	O
coexistence	O
Although	O
the	O
effects	O
of	O
variation	O
between	O
individuals	B-LIVB
within	O
species	O
are	O
traditionally	O
ignored	O
in	O
studies	B-PROC
of	O
species	O
coexistence	O
,	O
the	O
magnitude	O
of	O
intraspecific	O
variation	O
in	O
nature	O
is	O
forcing	O
ecologists	B-LIVB
to	O
reconsider	O
.	O

Compelling	O
intuitive	O
arguments	O
suggest	O
that	O
individual	B-LIVB
variation	O
may	O
provide	O
a	O
previously	O
unrecognised	O
route	O
to	O
diversity	O
maintenance	O
by	O
blurring	O
species	O
-	O
level	O
competitive	O
differences	O
or	O
substituting	O
for	O
species	O
-	O
level	O
niche	O
differences	O
.	O

These	O
arguments	O
,	O
which	O
are	O
motivating	B-PHYS
a	O
large	O
body	O
of	O
empirical	O
work	O
,	O
have	O
rarely	O
been	O
evaluated	O
with	O
quantitative	O
theory	O
.	O

Here	O
we	O
incorporate	O
intraspecific	O
variation	O
into	O
a	O
common	O
model	O
of	O
competition	O
and	O
identify	O
three	O
pathways	O
by	O
which	O
this	O
variation	O
affects	O
coexistence	O
:	O
(	O
1	O
)	O
changes	O
in	O
competitive	O
dynamics	O
because	O
of	O
nonlinear	O
averaging	O
,	O
(	O
2	O
)	O
changes	O
in	O
species	O
'	O
mean	O
interaction	O
strengths	O
because	O
of	O
variation	O
in	O
underlying	O
traits	B-PHYS
(	O
also	O
via	O
nonlinear	O
averaging	O
)	O
and	O
(	O
3	O
)	O
effects	O
on	O
stochastic	B-PROC
demography	I-PROC
.	O

As	O
a	O
consequence	O
of	O
the	O
first	O
two	O
mechanisms	O
,	O
we	O
find	B-DISO
that	O
intraspecific	O
variation	O
in	O
competitive	O
ability	B-PHYS
increases	O
the	O
dominance	O
of	O
superior	O
competitors	B-LIVB
,	O
and	O
intraspecific	O
niche	O
variation	O
reduces	O
species	O
-	O
level	O
niche	O
differentiation	O
,	O
both	O
of	O
which	O
make	O
coexistence	O
more	O
difficult	O
.	O

In	O
addition	O
,	O
individual	B-LIVB
variation	O
can	O
exacerbate	O
the	O
effects	O
of	O
demographic	B-PROC
stochasticity	I-PROC
,	O
and	O
this	O
further	O
destabilises	O
coexistence	O
.	O

Our	O
work	O
provides	O
a	O
theoretical	B-PROC
foundation	I-PROC
for	O
emerging	O
empirical	O
interests	B-PHYS
in	O
the	O
effects	O
of	O
intraspecific	O
variation	O
on	O
species	O
diversity	O
.	O

Intracellular	B-PHYS
Metabolism	I-PHYS
of	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
Unsaturated	I-CHEM
Carbonyl	I-CHEM
Compounds	I-CHEM
,	O
Acrolein	B-CHEM
,	O
Crotonaldehyde	B-CHEM
and	O
Methyl	B-CHEM
Vinyl	I-CHEM
Ketone	I-CHEM
,	O
Active	O
Toxicants	B-CHEM
in	O
Cigarette	B-CHEM
Smoke	I-CHEM
:	O
Participation	O
of	O
Glutathione	B-CHEM
Conjugation	B-PHYS
Ability	O
and	O
Aldehyde	B-PHYS
-	I-PHYS
Ketone	I-PHYS
Sensitive	I-PHYS
Reductase	I-PHYS
Activity	I-PHYS
The	O
major	O
toxicants	B-CHEM
in	O
cigarette	B-CHEM
smoke	I-CHEM
,	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
aldehydes	I-CHEM
,	O
such	O
as	O
acrolein	B-CHEM
(	O
ACR	B-CHEM
)	O
and	O
crotonaldehyde	B-CHEM
(	O
CA	B-CHEM
)	O
,	O
and	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
ketone	I-CHEM
,	O
methyl	B-CHEM
vinyl	I-CHEM
ketone	I-CHEM
(	O
MVK	B-CHEM
)	O
,	O
are	O
known	O
to	O
form	O
Michael	B-CHEM
-	I-CHEM
type	I-CHEM
adducts	I-CHEM
with	O
glutathione	B-CHEM
(	O
GSH	B-CHEM
)	O
and	O
consequently	O
cause	O
intracellular	O
GSH	B-CHEM
depletion	O
,	O
which	O
is	O
involved	O
in	O
cigarette	B-CHEM
smoke	I-CHEM
-	O
induced	O
cytotoxicity	B-DISO
.	O

We	O
have	O
previously	O
clarified	O
that	O
exposure	O
to	O
cigarette	B-CHEM
smoke	I-CHEM
extract	I-CHEM
(	O
CSE	B-CHEM
)	O
of	O
a	O
mouse	B-LIVB
melanoma	B-ANAT
cell	I-ANAT
culture	B-CHEM
medium	I-CHEM
causes	O
rapid	O
reduction	O
of	O
intracellular	O
GSH	B-CHEM
levels	O
,	O
and	O
that	O
the	O
GSH	B-CHEM
-	O
MVK	B-CHEM
adduct	B-CHEM
can	O
be	O
detected	B-DISO
by	O
LC	B-PROC
/	I-PROC
MS	I-PROC
analysis	I-PROC
while	O
the	O
GSH	B-CHEM
-	O
CA	B-CHEM
adduct	B-CHEM
is	O
hardly	O
detected	B-DISO
.	O

In	O
the	O
present	O
study	B-PROC
,	O
to	O
clarify	O
why	O
the	O
GSH	B-CHEM
-	O
CA	B-CHEM
adduct	B-CHEM
is	O
difficult	O
to	O
detect	B-DISO
in	O
the	O
cell	B-ANAT
medium	B-CHEM
,	O
we	O
conducted	O
detailed	O
investigation	O
of	O
the	O
structures	O
of	O
the	O
reaction	B-CHEM
products	I-CHEM
of	O
ACR	B-CHEM
,	O
CA	B-CHEM
,	O
MVK	B-CHEM
and	O
CSE	B-CHEM
in	O
the	O
GSH	B-CHEM
solution	B-OBJC
or	O
the	O
cell	B-ANAT
culture	B-CHEM
medium	I-CHEM
.	O

The	O
mass	B-PROC
spectra	I-PROC
indicated	O
that	O
in	O
the	O
presence	O
of	O
the	O
cells	B-ANAT
,	O
the	O
GSH	B-CHEM
-	O
CA	B-CHEM
and	O
GSH	B-CHEM
-	O
ACR	B-CHEM
adducts	B-CHEM
were	O
almost	O
not	O
detected	B-DISO
while	O
their	O
corresponding	B-CHEM
alcohols	I-CHEM
were	O
detected	B-DISO
.	O

On	O
the	O
other	O
hand	O
,	O
both	O
the	O
GSH	B-CHEM
-	O
MVK	B-CHEM
adducts	B-CHEM
and	O
their	O
reduced	B-OBJC
products	I-OBJC
were	O
detected	B-DISO
.	O

In	O
the	O
absence	O
of	O
the	O
cells	B-ANAT
,	O
the	O
reaction	O
of	O
GSH	B-CHEM
with	O
all	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
carbonyls	I-CHEM
produced	O
only	O
their	O
corresponding	O
adducts	B-CHEM
.	O

These	O
results	O
show	O
that	O
the	O
GSH	B-CHEM
adducts	B-CHEM
of	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
aldehydes	I-CHEM
,	O
CA	B-CHEM
and	O
ACR	B-CHEM
,	O
are	O
quickly	O
reduced	B-PHEN
by	O
certain	O
intracellular	O
carbonyl	B-CHEM
reductase	I-CHEM
(	I-CHEM
s	I-CHEM
)	I-CHEM
and	O
excreted	O
from	O
the	O
cells	B-ANAT
,	O
unlike	O
the	O
GSH	B-CHEM
adduct	B-CHEM
of	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
ketone	I-CHEM
,	O
MVK	B-CHEM
.	O

Such	O
a	O
difference	O
in	O
reactivity	O
to	O
the	O
carbonyl	B-PHYS
reductase	I-PHYS
might	O
be	O
related	O
to	O
differences	O
in	O
the	O
cytotoxicity	B-DISO
of	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
aldehydes	I-CHEM
and	O
ketones	B-CHEM
.	O

Diagnostic	O
utility	O
of	O
additional	O
conventional	O
techniques	B-PROC
after	O
endobronchial	B-PROC
ultrasonography	I-PROC
guidance	B-PROC
during	O
transbronchial	B-PROC
biopsy	I-PROC
Endobronchial	B-PROC
ultrasonography	I-PROC
with	O
a	O
guide	B-DEVI
sheath	I-DEVI
transbronchial	B-PROC
biopsy	I-PROC
(	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
)	O
has	O
been	O
used	O
to	O
diagnose	B-DISO
peripheral	B-DISO
pulmonary	I-DISO
lesions	I-DISO
(	O
PPLs	B-DISO
)	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
conventional	O
TBB	B-PROC
after	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
.	O

A	O
retrospective	B-PROC
analysis	I-PROC
of	O
patients	B-LIVB
who	O
underwent	O
conventional	O
TBB	B-PROC
after	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
for	O
PPL	B-DISO
between	O
August	O
1	O
,	O
2012	O
and	O
December	O
31	O
,	O
2014	O
.	O

We	O
performed	O
multivariate	O
analysis	O
to	O
examine	O
the	O
association	O
of	O
various	O
clinical	O
factors	O
,	O
including	O
EBUS	B-PROC
probe	B-DEVI
distance	O
and	O
sample	O
size	O
area	O
,	O
with	O
diagnostic	O
yield	O
.	O

Of	O
88	O
eligible	O
patients	B-LIVB
,	O
57	O
(	O
65	O
%	O
)	O
were	O
successfully	O
diagnosed	B-DISO
by	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
.	O

In	O
31	O
patients	B-LIVB
not	O
diagnosed	B-DISO
by	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
,	O
15	O
(	O
48	O
%	O
)	O
were	O
successfully	O
diagnosed	B-DISO
by	O
additional	O
conventional	O
TBB	B-PROC
.	O

Ground	B-DISO
glass	I-DISO
opacity	I-DISO
(	O
GGO	B-DISO
)	O
was	O
a	O
significant	O
factor	O
associated	O
with	O
the	O
diagnostic	O
yield	O
of	O
additional	O
conventional	O
TBB	B-PROC
following	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
.	O

Multivariate	O
analysis	O
and	O
receiver	O
operator	O
curves	O
revealed	O
that	O
distance	O
between	O
the	O
PPL	B-DISO
and	O
the	O
EBUS	B-PROC
probe	B-DEVI
of	O
less	O
than	O
2	O
.	O
55	O
mm	O
favored	O
the	O
utility	O
of	O
conventional	O
TBB	B-PROC
.	O

Additional	O
conventional	O
TBB	B-PROC
after	O
EBUS	B-PROC
-	O
GS	B-DEVI
TBB	B-PROC
could	O
be	O
a	O
useful	O
procedure	B-PROC
for	O
the	O
diagnosis	B-DISO
of	O
ground	B-DISO
glass	I-DISO
opacity	I-DISO
PPLs	B-DISO
and	O
in	O
cases	O
of	O
a	O
distance	O
of	O
less	O
than	O
2	O
.	O

55	O
mm	O
between	O
the	O
EBUS	B-PROC
probe	B-DEVI
and	O
the	O
lesion	B-DISO
.	O

Strategies	B-PROC
for	O
Assaying	B-PROC
Lysosomal	B-ANAT
Membrane	I-ANAT
Permeabilization	B-PHYS
Late	B-ANAT
endosomal	I-ANAT
organelles	B-ANAT
have	O
an	O
acidic	O
pH	O
and	O
contain	O
hydrolytic	B-CHEM
enzymes	I-CHEM
to	O
degrade	O
cargo	O
delivered	O
either	O
from	O
the	O
extracellular	B-ANAT
environment	O
by	O
endocytosis	B-PHYS
or	O
from	O
within	O
the	O
cell	B-ANAT
itself	O
by	O
autophagy	B-PHYS
.	O

In	O
the	O
event	O
of	O
lysosomal	B-ANAT
membrane	I-ANAT
permeabilization	B-PHYS
(	O
LMP	B-PHYS
)	O
,	O
the	O
contents	O
of	O
late	B-ANAT
endosomes	I-ANAT
and	O
lysosomes	B-ANAT
can	O
be	O
released	O
into	O
the	O
cytosol	B-ANAT
and	O
then	O
initiate	O
apoptosis	B-PHYS
.	O

Compounds	O
that	O
can	O
trigger	O
LMP	B-PHYS
are	O
therefore	O
candidates	O
for	O
the	O
induction	O
of	O
apoptosis	B-PHYS
,	O
in	O
particular	O
in	O
anticancer	B-PROC
therapy	I-PROC
.	O

Alternatively	O
,	O
drug	B-DEVI
-	I-DEVI
delivery	I-DEVI
systems	I-DEVI
,	O
such	O
as	O
nanoparticles	B-OBJC
,	O
can	O
have	O
side	O
effects	O
that	O
can	O
include	O
LMP	B-PHYS
,	O
which	O
has	O
toxic	B-DISO
consequences	I-DISO
for	O
the	O
cells	B-ANAT
.	O

To	O
determine	O
when	O
,	O
to	O
what	O
extent	O
,	O
and	O
with	O
what	O
consequences	O
LMP	B-PHYS
occurs	O
is	O
therefore	O
of	O
paramount	O
importance	O
for	O
the	O
evaluation	B-PROC
of	O
new	O
potentially	O
LMP	B-PHYS
-	O
inducing	O
compounds	O
.	O

In	O
this	O
introduction	O
,	O
we	O
provide	O
an	O
overview	O
of	O
some	O
basic	B-PROC
assays	I-PROC
for	O
assessing	B-PROC
LMP	B-PHYS
,	O
such	O
as	O
staining	O
with	O
lysosomotropic	B-CHEM
dyes	I-CHEM
and	O
measurement	O
of	O
cysteine	B-CHEM
cathepsin	B-CHEM
activity	B-PHYS
,	O
and	O
discuss	O
additional	O
strategies	B-PROC
for	O
the	O
detection	B-PROC
of	O
the	O
release	O
of	O
endogenous	O
lysosomal	B-ANAT
molecules	B-OBJC
or	O
preloaded	O
exogenous	O
tracers	B-CHEM
into	O
the	O
cytosol	B-ANAT
.	O

Active	O
diffusion	B-PHEN
and	O
microtubule	B-PHYS
-	I-PHYS
based	I-PHYS
transport	I-PHYS
oppose	O
myosin	B-CHEM
forces	B-PHEN
to	O
position	O
organelles	B-ANAT
in	O
cells	B-ANAT
Even	O
distribution	O
of	O
peroxisomes	B-ANAT
(	O
POs	B-ANAT
)	O
and	O
lipid	B-ANAT
droplets	I-ANAT
(	O
LDs	B-ANAT
)	O
is	O
critical	O
to	O
their	O
role	O
in	O
lipid	B-CHEM
and	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
homeostasis	B-PHEN
.	O

How	O
even	O
distribution	O
is	O
achieved	O
remains	O
elusive	O
,	O
but	O
diffusive	B-PHEN
motion	I-PHEN
and	O
directed	O
motility	B-PHYS
may	O
play	O
a	O
role	O
.	O

Here	O
we	O
show	O
that	O
in	O
the	O
fungus	B-LIVB
Ustilago	B-LIVB
maydis	I-LIVB
~95	O
%	O
of	O
POs	B-ANAT
and	O
LDs	B-ANAT
undergo	O
diffusive	B-PHEN
motions	I-PHEN
.	O

These	O
movements	B-PHYS
require	O
ATP	B-CHEM
and	O
involve	O
bidirectional	O
early	O
endosome	B-ANAT
motility	B-PHYS
,	O
indicating	O
that	O
microtubule	B-ANAT
-	O
associated	O
membrane	B-ANAT
trafficking	B-PHYS
enhances	O
diffusion	B-PHEN
of	O
organelles	B-ANAT
.	O

When	O
early	O
endosome	B-PHYS
transport	I-PHYS
is	O
abolished	O
,	O
POs	B-ANAT
and	O
LDs	B-ANAT
drift	O
slowly	O
towards	O
the	O
growing	B-ANAT
cell	I-ANAT
end	I-ANAT
.	O

This	O
pole	B-PHYS
-	I-PHYS
ward	I-PHYS
drift	I-PHYS
is	O
facilitated	O
by	O
anterograde	B-PHYS
delivery	I-PHYS
of	O
secretory	B-CHEM
cargo	I-CHEM
to	O
the	O
cell	B-ANAT
tip	I-ANAT
by	O
myosin	B-CHEM
-	I-CHEM
5	I-CHEM
.	O

Modelling	B-PROC
reveals	O
that	O
microtubule	B-PHYS
-	I-PHYS
based	I-PHYS
directed	I-PHYS
transport	I-PHYS
and	O
active	O
diffusion	B-PHEN
support	O
distribution	O
,	O
mobility	B-PHYS
and	O
mixing	O
of	O
POs	B-ANAT
.	O

In	O
mammalian	B-LIVB
COS	B-ANAT
-	I-ANAT
7	I-ANAT
cells	I-ANAT
,	O
microtubules	B-ANAT
and	O
F	B-CHEM
-	I-CHEM
actin	I-CHEM
also	O
counteract	O
each	O
other	O
to	O
distribute	O
POs	B-ANAT
.	O

This	O
highlights	O
the	O
importance	O
of	O
opposing	O
cytoskeletal	B-ANAT
forces	B-PHEN
in	O
organelle	B-ANAT
positioning	O
in	O
eukaryotes	O
.	O

Stimulation	O
of	O
cell	B-PHYS
proliferation	I-PHYS
by	O
glutathione	B-CHEM
monoethyl	I-CHEM
ester	I-CHEM
in	O
aged	B-ANAT
bone	I-ANAT
marrow	I-ANAT
stromal	I-ANAT
cells	I-ANAT
is	O
associated	O
with	O
the	O
assistance	O
of	O
TERT	O
gene	B-PHYS
expression	I-PHYS
and	O
telomerase	B-PHYS
activity	I-PHYS
The	O
proliferation	B-PHYS
and	O
differentiation	B-PHYS
potential	O
of	O
aged	B-ANAT
bone	I-ANAT
marrow	I-ANAT
stromal	I-ANAT
cells	I-ANAT
(	O
BMSCs	B-ANAT
)	O
are	O
significantly	O
reduced	O
.	O

In	O
order	O
to	O
improve	B-DISO
the	O
performance	O
of	O
the	O
aged	B-PHYS
BMSCs	B-ANAT
,	O
these	O
cells	B-ANAT
were	O
treated	O
with	O
2	O
mM	O
glutathione	B-CHEM
monoethyl	I-CHEM
ester	I-CHEM
(	O
GSH	B-CHEM
-	I-CHEM
MEE	I-CHEM
)	O
for	O
24	O
h	O
.	O

Proliferation	B-PHYS
rate	O
,	O
telomerase	B-PHYS
activity	I-PHYS
,	O
telomere	B-ANAT
length	O
,	O
and	O
differentiation	B-PHYS
to	O
cholinergic	B-ANAT
neuron	I-ANAT
-	I-ANAT
like	I-ANAT
cells	I-ANAT
(	O
CNLCs	B-ANAT
)	O
were	O
observed	O
to	O
increase	O
.	O

Though	O
,	O
the	O
expression	O
level	O
of	O
telomerase	O
reverse	O
transcriptase	O
gene	O
increased	O
,	O
but	O
CTC1	O
and	O
TEN1	O
genes	O
from	O
Ctc1	B-ANAT
-	I-ANAT
Stn1	I-ANAT
-	I-ANAT
Ten1	I-ANAT
complex	I-ANAT
encoding	O
proteins	B-CHEM
with	O
regulatory	B-PHYS
function	I-PHYS
significantly	O
decreased	O
.	O

Trypan	B-PROC
blue	I-PROC
exclusion	I-PROC
assay	I-PROC
was	O
used	O
to	O
analyze	O
the	O
proliferation	B-PHYS
and	O
,	O
while	O
telomere	B-ANAT
length	O
,	O
its	O
several	O
related	O
gene	B-PHYS
expressions	I-PHYS
,	O
and	O
telomerase	B-PHYS
activity	I-PHYS
were	O
measured	O
using	O
the	O
real	B-PROC
time	I-PROC
reverse	I-PROC
transcription	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
and	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
enzyme	B-PROC
-	I-PROC
linked	I-PROC
immunosorbent	I-PROC
assay	I-PROC
techniques	I-PROC
,	O
respectively	O
.	O

CNLCs	B-ANAT
differentiation	B-PHYS
potential	O
was	O
evaluated	O
by	O
estimating	O
the	O
percentage	O
of	O
choline	O
acetyltransferase	O
immunereactive	B-ANAT
cells	I-ANAT
.The	O

results	O
suggested	O
that	O
GSH	B-CHEM
-	I-CHEM
MEE	I-CHEM
could	O
improve	B-DISO
aged	O
rat	B-LIVB
BMSC	B-ANAT
properties	O
and	O
would	O
be	O
of	O
potential	O
benefit	O
for	O
enhancing	O
the	O
performance	O
of	O
aged	B-LIVB
people	I-LIVB
's	I-LIVB
BMSCs	B-ANAT
.	O

Wild	B-OBJC
food	I-OBJC
plants	I-OBJC
and	O
fungi	B-LIVB
used	O
in	O
the	O
mycophilous	B-OBJC
Tibetan	B-GEOG
community	B-LIVB
of	O
Zhagana	B-GEOG
(	O
Tewo	B-GEOG
County	I-GEOG
,	O
Gansu	B-GEOG
,	O
China	B-GEOG
)	O
The	O
aim	O
of	O
the	O
study	B-PROC
was	O
to	O
investigate	O
knowledge	O
and	O
use	O
of	O
wild	B-OBJC
food	I-OBJC
plants	I-OBJC
and	O
fungi	B-LIVB
in	O
a	O
highland	O
valley	O
in	O
the	O
Gannan	B-GEOG
Tibetan	I-GEOG
Autonomous	I-GEOG
Region	I-GEOG
on	O
the	O
north	O
-	O
eastern	O
edges	O
of	O
the	O
Tibetan	B-GEOG
Plateau	I-GEOG
.	O

Field	O
research	O
was	O
carried	O
out	O
in	O
four	O
neighbouring	O
villages	B-GEOG
in	O
a	O
mountain	B-GEOG
valley	O
of	O
the	O
Diebu	B-GEOG
(	I-GEOG
Tewo	I-GEOG
)	I-GEOG
county	I-GEOG
,	O
surrounded	O
by	O
spruce	B-PHEN
forests	I-PHEN
.	O

The	O
study	B-PROC
consisted	O
of	O
30	O
interviews	O
with	O
single	O
informants	O
,	O
or	O
group	B-PROC
interviews	I-PROC
(	O
altogether	O
63	O
informants	O
)	O
.	O

Apart	O
from	O
collecting	O
voucher	O
specimens	B-OBJC
,	O
we	O
also	O
identified	O
fungi	B-LIVB
using	O
DNA	B-PROC
barcoding	I-PROC
.	O

We	O
recorded	O
the	O
use	O
of	O
54	O
species	O
of	O
vascular	B-LIVB
plants	I-LIVB
.	O

We	O
also	O
recorded	O
the	O
use	O
of	O
22	O
mushroom	B-OBJC
taxa	I-OBJC
,	O
which	O
made	O
up	O
the	O
largest	O
category	O
of	O
wild	B-OBJC
foods	I-OBJC
.	O

Fruits	B-OBJC
formed	O
the	O
largest	O
category	O
of	O
food	B-OBJC
plants	I-OBJC
,	O
with	O
21	O
species	O
,	O
larger	O
than	O
the	O
wild	B-LIVB
greens	I-LIVB
category	O
,	O
which	O
consisted	O
of	O
20	O
species	O
eaten	B-PHYS
after	O
boiling	O
or	O
frying	O
and	O
7	O
as	O
raw	O
snacks	B-OBJC
.	O

We	O
also	O
recorded	O
the	O
alimentary	O
use	O
of	O
10	O
species	O
of	O
edible	B-LIVB
flowers	I-LIVB
and	O
3	O
species	O
with	O
underground	O
edible	B-OBJC
organs	I-OBJC
.	O

On	O
average	O
,	O
20	O
.	O
8	O
edible	B-OBJC
taxa	I-OBJC
were	O
listed	O
per	O
interview	O
(	O
median	O
-	O
21	O
)	O
.	O

The	O
most	O
listed	O
category	O
of	O
wild	B-OBJC
foods	I-OBJC
was	O
green	B-OBJC
vegetables	I-OBJC
(	O
mean	O
-	O
7	O
.	O
5	O
species	O
,	O
median	O
-	O
8	O
species	O
)	O
,	O
but	O
fruits	B-OBJC
and	O
mushrooms	B-OBJC
were	O
listed	O
nearly	O
as	O
frequently	O
(	O
mean	O
-	O
6	O
.	O
3	O
,	O
median	O
-	O
6	O
and	O
mean	O
-	O
5	O
.	O
8	O
,	O
-	O
median	O
6	O
respectively	O
)	O
.	O

Other	O
category	O
lists	O
were	O
very	O
short	O
,	O
e	O
.	O

g	O
.	O
,	O
flowers	B-LIVB
(	O
mean	O
-	O
1	O
.	O
3	O
,	O
median	O
-	O
1	O
)	O
and	O
underground	O
edible	B-OBJC
parts	I-OBJC
(	O
mean	O
-	O
0	O
.	O

7	O
,	O
median	O
-	O
1	O
)	O
.	O

Wild	B-OBJC
vegetables	I-OBJC
are	O
usually	O
boiled	O
and	O
/	O
or	O
fried	O
and	O
served	O
as	O
side	O
-	O
dishes	O
,	O
or	O
their	O
green	B-LIVB
parts	I-LIVB
are	O
eaten	B-PHYS
as	O
snacks	B-OBJC
during	O
mountain	B-GEOG
treks	O
(	O
e	O
.	O
g	O
.	O
,	O
peeled	B-LIVB
rhubarb	I-LIVB
shoots	I-LIVB
)	O
.	O

Wild	B-OBJC
fruits	I-OBJC
are	O
mainly	O
collected	O
by	O
children	B-LIVB
and	O
eaten	B-PHYS
raw	O
,	O
they	O
are	O
not	O
stored	O
for	O
further	O
use	O
.	O

The	O
most	O
widely	O
used	O
wild	B-OBJC
staple	I-OBJC
foods	I-OBJC
are	O
Potetilla	B-LIVB
anserina	I-LIVB
roots	B-LIVB
,	O
an	O
important	O
ceremonial	B-OBJC
food	I-OBJC
served	O
on	O
such	O
occasions	O
as	O
New	O
Year	O
or	O
at	O
funerals	O
.	O

They	O
are	O
boiled	O
and	O
served	O
with	O
sugar	B-CHEM
and	O
butter	B-OBJC
.	O

The	O
most	O
important	O
famine	B-PHEN
plants	B-LIVB
remembered	O
by	O
people	B-LIVB
are	O
the	O
aerial	B-LIVB
bulbils	I-LIVB
of	O
Persicaria	B-LIVB
vivipara	I-LIVB
.	O

Flowers	B-LIVB
are	O
used	O
as	O
children	B-LIVB
's	I-LIVB
snacks	B-OBJC
-	O
their	O
nectar	B-CHEM
is	O
sucked	O
.	O

The	O
number	O
of	O
wild	B-LIVB
taxa	I-LIVB
eaten	B-PHYS
in	O
the	O
studied	O
valley	O
is	O
similar	O
to	O
that	O
of	O
other	O
Tibetan	B-GEOG
areas	I-GEOG
.	O

The	O
structure	O
of	O
wild	B-OBJC
food	I-OBJC
plant	I-OBJC
taxa	O
is	O
also	O
very	O
typical	O
for	O
Tibetan	O
speaking	O
areas	B-GEOG
(	O
e	O
.	O

g	O
.	O
,	O
the	O
use	O
of	O
rhubarb	B-LIVB
shoots	I-LIVB
,	O
Potentilla	B-LIVB
anserina	I-LIVB
,	O
Persicaria	B-LIVB
vivipara	I-LIVB
)	O
.	O

The	O
studied	O
community	B-LIVB
show	O
a	O
high	O
level	O
of	O
mycophilia	B-OBJC
.	O

Early	O
assessment	B-PROC
of	O
bilateral	B-PROC
inguinal	I-PROC
hernia	I-PROC
repair	I-PROC
:	O
A	O
comparison	O
between	O
the	O
laparoscopic	B-PROC
total	I-PROC
extraperitoneal	I-PROC
and	O
Stoppa	B-PROC
approaches	I-PROC
The	O
present	O
clinical	B-PROC
trial	I-PROC
was	O
designed	O
to	O
compare	O
the	O
results	O
of	O
bilateral	B-PROC
inguinal	I-PROC
hernia	I-PROC
repair	I-PROC
between	O
patients	B-LIVB
who	O
underwent	O
the	O
conventional	O
Stoppa	B-PROC
technique	I-PROC
and	O
laparoscopic	B-PROC
total	I-PROC
extraperitoneal	I-PROC
repair	I-PROC
(	O
LTE	B-PROC
)	O
with	O
a	O
single	O
mesh	B-DEVI
and	O
without	O
staple	B-PROC
fixation	I-PROC
.	O

This	O
controlled	O
,	O
randomised	B-PROC
clinical	B-PROC
trial	I-PROC
was	O
conducted	O
at	O
General	O
Surgery	O
and	O
Trauma	O
of	O
the	O
Clinics	O
Hospital	O
,	O
Medical	O
School	O
,	O
the	O
University	O
of	O
Sγo	O
Paulo	O
between	O
September	O
2010	O
and	O
February	O
2011	O
.	O

Totally	O
,	O
50	O
male	B-PHYS
patients	B-LIVB
,	O
with	O
a	O
bilateral	B-DISO
inguinal	I-DISO
hernia	I-DISO
,	O
older	O
than	O
25	O
years	O
were	O
considered	O
eligible	O
for	O
the	O
study	B-PROC
.	O

The	O
following	O
parameters	O
were	O
analysed	B-PROC
during	O
the	O
early	O
post	O
-	O
operative	O
period	O
:	O
(	O
1	O
)	O
The	O
intensity	O
of	O
surgical	B-DISO
trauma	I-DISO
,	O
operation	O
time	O
,	O
C	B-CHEM
-	I-CHEM
reactive	I-CHEM
protein	I-CHEM
(	O
CRP	B-CHEM
)	O
levels	O
,	O
white	B-PROC
blood	I-PROC
cell	I-PROC
count	I-PROC
,	O
bleeding	B-DISO
and	O
pain	B-PHYS
intensity	I-PHYS
;	O
(	O
2	O
)	O
quality	O
of	O
life	O
assessment	B-PROC
;	O
and	O
(	O
3	O
)	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
.	O

LTE	B-PROC
procedure	I-PROC
was	O
longer	O
than	O
the	O
Stoppa	B-PROC
procedure	I-PROC
(	O
134	O
.	O

6	O
min	O
΁	O
38	O
.	O

3	O
vs	O
.	O

90	O
.	O
6	O
min	O
΁	O
41	O
.	O

3	O

;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
levels	O
of	O
CRP	B-CHEM
were	O
higher	O
in	O
the	O
Stoppa	B-PROC
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
the	O
number	O
of	O
leucocytes	B-ANAT
,	O
haematocrit	B-DISO
,	O
and	O
haemoglobin	B-CHEM
were	O
similar	O
between	O
the	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	B-DISO
difference	I-DISO
in	O
pain	B-DISO
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post	B-DISO
-	I-DISO
operative	I-DISO
,	O
physical	B-DISO
functioning	I-DISO
,	O
physical	O
limitation	O
,	O
the	O
impact	O
of	O
pain	B-DISO
on	O
daily	O
activities	O
,	O
and	O
the	O
Carolinas	O
Comfort	O
Scale	O
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post	B-DISO
-	I-DISO
operative	I-DISO
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Complications	B-DISO
occurred	O
in	O
88	O
%	O
of	O
Stoppa	B-PROC
group	O
(	O
22	O
patients	B-LIVB
)	O
and	O
64	O
%	O
in	O
LTE	B-PROC
group	O
(	O
16	O
patients	B-LIVB
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
comparative	B-PROC
study	I-PROC
between	O
the	O
Stoppa	B-PROC
and	O
LTE	B-PROC
approaches	O
for	O
the	O
bilateral	B-PROC
inguinal	I-PROC
hernia	I-PROC
repair	I-PROC
demonstrated	O
that	O
:	O
(	O
1	O
)	O
The	O
LTE	B-PROC
approach	O
showed	O
less	O
surgical	B-DISO
trauma	I-DISO
despite	O
the	O
longer	O
operation	O
time	O
;	O
(	O
2	O
)	O
Quality	O
of	O
life	O
during	O
the	O
early	O
post	O
-	O
operative	O
period	O
were	O
similar	O
;	O
and	O
(	O
3	O
)	O
Complication	B-DISO
rates	O
were	O
higher	O
in	O
the	O
Stoppa	B-PROC
group	O
.	O

The	O
role	O
of	O
catheter	B-PROC
ablation	I-PROC
in	O
the	O
management	B-PROC
of	O
atrial	B-DISO
fibrillation	I-DISO
Atrial	B-DISO
fibrillation	I-DISO
is	O
driven	O
by	O
spontaneous	O
electrical	B-PHYS
activation	I-PHYS
emerging	O
from	O
the	O
pulmonary	B-ANAT
veins	I-ANAT
.	O

Catheter	B-PROC
ablation	I-PROC
using	O
either	O
radiofrequency	B-PROC
or	O
cryothermal	B-PROC
energy	I-PROC
electrically	O
isolates	O
these	O
veins	B-ANAT
from	O
the	O
left	B-ANAT
atrium	I-ANAT
,	O
both	O
reducing	O
the	O
burden	O
of	O
atrial	B-DISO
fibrillation	I-DISO
episodes	O
and	O
improving	O
the	O
patient	B-LIVB
's	I-LIVB
symptoms	B-DISO
.	O

Catheter	B-PROC
ablation	I-PROC
is	O
superior	O
to	O
antiarryhthmic	B-CHEM
drugs	I-CHEM
when	O
patients	B-LIVB
are	O
carefully	O
selected	O
.	O

Underlying	O
medical	B-PHYS
problems	I-PHYS
-	O
including	O
obesity	B-DISO
,	O
hypertension	B-DISO
and	O
obstructive	B-DISO
sleep	I-DISO
apnoea	I-DISO
-	O
should	O
be	O
optimally	O
treated	O
before	O
considering	O
ablation	B-PROC
.	O

Although	O
this	O
treatment	B-PROC
has	O
the	O
potential	O
to	O
cure	O
patients	B-LIVB
of	O
their	O
symptoms	B-DISO
,	O
they	O
should	O
be	O
aware	O
of	O
the	O
important	O
associated	O
procedural	B-DISO
complications	I-DISO
.	O

The	O
Chinese	O
Herbal	O
Mixture	B-OBJC
Tien	B-CHEM
-	I-CHEM
Hsien	I-CHEM
Liquid	I-CHEM
Augments	O
the	O
Anticancer	O
Immunity	B-PHYS
in	O
Tumor	B-ANAT
Cell	I-ANAT
-	O
Vaccinated	B-DISO
Mice	B-LIVB
Background	O
The	O
Chinese	O
herbal	O
mixture	B-OBJC
,	O
Tien	B-CHEM
-	I-CHEM
Hsien	I-CHEM
liquid	I-CHEM
(	O
THL	B-CHEM
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	O
dietary	B-OBJC
supplement	I-OBJC
for	O
more	O
than	O
20	O
years	O
.	O

Our	O
previous	O
studies	B-PROC
have	O
shown	O
that	O
THL	B-CHEM
can	O
modulate	O
immune	B-PHYS
response	I-PHYS
and	O
inhibit	O
tumor	B-DISO
growth	I-DISO
.	O

In	O
this	O
study	B-PROC
,	O
we	O
further	O
evaluated	B-PROC
the	O
effect	O
of	O
THL	B-CHEM
on	O
anticancer	O
immune	B-PHYS
response	I-PHYS
in	O
mice	B-LIVB
vaccinated	B-DISO
with	O
γ	B-PHEN
-	I-PHEN
ray	I-PHEN
-	O
irradiated	B-PHEN
tumor	B-ANAT
cells	I-ANAT
.	O

Methods	O
The	O
antitumor	O
effect	O
of	O
THL	B-CHEM
was	O
determined	O
in	O
mice	B-LIVB
vaccinated	B-DISO
with	O
low	B-ANAT
-	I-ANAT
tumorigenic	I-ANAT
CT	I-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
low	I-ANAT
colon	I-ANAT
cancer	I-ANAT
cells	I-ANAT
or	O
γ	B-PROC
-	I-PROC
ray	I-PROC
-	I-PROC
irradiated	I-PROC
high	B-ANAT
-	I-ANAT
tumorigenic	I-ANAT
CT	I-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
colon	I-ANAT
cancer	I-ANAT
cells	I-ANAT
.	O

The	O
number	O
of	O
natural	B-ANAT
killer	I-ANAT
(	I-ANAT
NK	I-ANAT
)	I-ANAT
cells	I-ANAT
and	O
T	B-ANAT
lymphocytes	I-ANAT
in	O
the	O
spleen	B-ANAT
was	O
analyzed	B-PROC
by	O
flow	B-PROC
cytometry	I-PROC
.	O

The	O
tumor	B-DISO
-	O
killing	B-PHYS
activities	O
of	O
NK	B-ANAT
cells	I-ANAT
and	O
cytotoxic	B-ANAT
T	I-ANAT
lymphocytes	I-ANAT
(	O
CTLs	B-ANAT
)	O
were	O
analyzed	B-PROC
by	O
flow	B-PROC
cytometry	I-PROC
using	O
YAC	B-ANAT
-	I-ANAT
1	I-ANAT
and	O
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
,	O
respectively	O
,	O
as	O
target	O
cells	B-ANAT
.	O

The	O
levels	O
of	O
IFN	B-CHEM
-	I-CHEM
γ	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
and	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
were	O
determined	O
by	O
ELISA	B-PROC
.	O

Results	O
THL	B-CHEM
suppressed	O
the	O
growth	B-PHYS
of	O
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
tumor	I-ANAT
in	O
mice	B-LIVB
previously	O
vaccinated	B-DISO
with	O
low	B-ANAT
-	I-ANAT
tumorigenic	I-ANAT
CT	I-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
low	I-ANAT
cells	I-ANAT
or	O
γ	B-PROC
-	I-PROC
irradiated	I-PROC
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
.	O

THL	B-CHEM
increased	O
the	O
populations	O
of	O
NK	B-ANAT
cells	I-ANAT
and	O
CD4	B-ANAT
+	I-ANAT
T	I-ANAT
lymphocytes	I-ANAT
in	O
the	O
spleen	B-ANAT
and	O
enhanced	O
the	O
tumor	B-DISO
-	O
killing	B-PHYS
activities	O
of	O
NK	B-ANAT
cells	I-ANAT
and	O
CTL	B-ANAT
in	O
mice	B-LIVB
vaccinated	B-DISO
with	O
γ	B-PROC
-	I-PROC
irradiated	I-PROC
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
.	O

THL	B-CHEM
increased	O
the	O
production	O
of	O
IFN	B-CHEM
-	I-CHEM
γ	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
and	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
in	O
mice	B-LIVB
vaccinated	B-DISO
with	O
γ	B-PROC
-	I-PROC
irradiated	I-PROC
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
.	O

Conclusion	O
THL	B-CHEM
can	O
enhance	O
the	O
antitumor	O
immune	B-PHYS
responses	I-PHYS
in	O
mice	B-LIVB
vaccinated	B-DISO
with	O
killed	O
tumor	B-ANAT
cells	I-ANAT
.	O

These	O
results	O
suggest	O
that	O
THL	B-CHEM
may	O
be	O
used	O
as	O
a	O
complementary	O
medicine	O
for	O
cancer	B-DISO
patients	B-LIVB
previously	O
treated	O
with	O
killed	B-CHEM
tumor	I-CHEM
cell	I-CHEM
vaccines	I-CHEM
,	O
radiotherapy	B-PROC
,	O
or	O
chemotherapy	B-PROC
.	O

Comparison	O
of	O
Head	B-ANAT
Elevation	B-PROC
Protocols	I-PROC
Following	O
Femoral	B-ANAT
Artery	I-ANAT
Sheath	I-ANAT
Removal	B-PROC
After	O
Coronary	B-PROC
Angiography	I-PROC
To	O
compare	O
2	O
standard	O
protocols	B-PROC
for	O
head	B-ANAT
elevation	B-PROC
following	O
removal	O
of	O
a	O
femoral	B-ANAT
artery	I-ANAT
sheath	I-ANAT
after	O
coronary	B-PROC
angiography	I-PROC
and	O
their	O
effects	O
on	O
bleeding	B-DISO
complications	B-DISO
and	O
reported	O
levels	O
of	O
back	B-DISO
pain	I-DISO
.	O

One	O
protocol	B-PROC
involved	O
flat	O
supine	O
bed	B-PROC
rest	I-PROC
;	O
the	O
other	O
allowed	O
progressive	O
head	B-ANAT
elevation	B-PROC
.	O

A	O
prospective	O
comparative	B-PROC
study	I-PROC
of	O
80	O
adult	B-LIVB
patients	B-LIVB
undergoing	O
coronary	B-PROC
angiography	I-PROC
via	O
the	O
femoral	B-ANAT
approach	O
.	O

The	O
Numeric	O
Rating	O
Scale	O
was	O
used	O
as	O
the	O
measure	O
of	O
reported	O
pain	B-DISO
.	O

No	O
bleeding	B-DISO
complications	B-DISO
occurred	O
in	O
either	O
group	O
.	O

Both	O
groups	O
had	O
very	O
low	O
mean	O
pain	B-DISO
scores	I-DISO
.	O

Repeated	O
-	O
measures	O
analysis	B-PROC
demonstrated	O
that	O
the	O
experience	O
of	O
pain	B-DISO
differed	O
significantly	O
over	O
time	O
by	O
location	B-ANAT
(	O
F5	O
,	O
70	O
=	O
3	O
.	O
864	O
,	O
P	O
=	O
.004	O
)	O
,	O
with	O
a	O
notable	O
decrease	O
in	O
pain	B-DISO
scores	I-DISO
more	O
than	O
1	O
hour	O
after	O
sheath	B-ANAT
removal	B-PROC
at	O
the	O
location	B-ANAT
that	O
used	O
the	O
progressive	O
head	B-ANAT
elevation	B-PROC
protocol	I-PROC
.	O

Patients	B-LIVB
'	O
satisfaction	O
scores	O
after	O
discharge	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

Patients	B-LIVB
with	O
a	O
history	B-DISO
of	O
chronic	O
back	B-DISO
pain	I-DISO
had	O
consistently	O
higher	O
pain	B-DISO
scores	I-DISO
,	O
but	O
those	O
pain	B-DISO
scores	I-DISO
did	O
not	O
differ	O
significantly	O
by	O
location	B-ANAT
(	O
or	O
protocol	B-PROC
)	O
.	O

It	O
appears	O
that	O
using	O
a	O
progressive	O
head	B-ANAT
-	O
elevation	B-PROC
protocol	I-PROC
within	O
the	O
first	O
3	O
hours	O
after	O
diagnostic	O
angiography	B-PROC
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
bleeding	B-DISO
complications	B-DISO
at	O
the	O
access	O
site	O
and	O
warrants	O
further	O
exploration	O
in	O
the	O
mitigation	O
of	O
back	B-DISO
pain	I-DISO
associated	O
with	O
prolonged	O
supine	O
bed	B-PROC
rest	I-PROC
.	O

Morphological	O
characteristics	O
regulating	O
phallic	B-ANAT
glans	I-ANAT
engorgement	B-DISO
in	O
the	O
American	B-LIVB
alligator	I-LIVB
The	O
distal	O
part	O
of	O
the	O
crocodilian	B-LIVB
phallus	B-ANAT
consists	O
of	O
a	O
bulbous	B-ANAT
glans	I-ANAT
containing	O
well	O
-	O
developed	O
vascular	O
tissues	O
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	O
activity	O
,	O
enlarging	O
and	O
elaborating	O
the	O
glans	B-ANAT
into	O
a	O
complex	O
,	O
though	O
still	O
functionally	O
undefined	O
,	O
copulatory	O
structure	O
.	O

An	O
enlarged	O
glans	B-ANAT
putatively	O
interacts	O
with	O
the	O
female	B-PHYS
cloaca	B-ANAT
and	O
may	O
change	O
the	O
shape	O
of	O
her	B-ANAT
reproductive	I-ANAT
tract	I-ANAT
to	O
facilitate	O
insemination	B-PHYS
and	O
increase	O
the	O
probability	O
of	O
fertilization	B-PHYS
.	O

Here	O
,	O
we	O
investigated	O
the	O
cellular	B-PHYS
-	I-PHYS
level	I-PHYS
properties	I-PHYS
of	O
the	O
glans	B-ANAT
and	O
other	O
inflatable	O
phallic	O
tissues	O
associated	O
with	O
the	O
sperm	B-ANAT
-conducting	O
sulcus	B-ANAT
spermaticus	B-ANAT
in	O
the	O
American	B-LIVB
alligator	I-LIVB
(	O
Alligator	B-LIVB
mississippiensis	I-LIVB
)	O
.	O

Using	O
histochemical	B-PROC
staining	I-PROC
,	O
we	O
visualized	O
and	O
defined	O
collagen	B-CHEM
and	O
elastin	O
fiber	O
densities	O
and	O
orientations	O
in	O
these	O
tissues	O
.	O

Extracellular	O
matrix	O
architectures	O
provided	O
insights	O
about	O
phallic	B-ANAT
glans	I-ANAT
material	O
properties	O
and	O
how	O
they	O
may	O
affect	O
tissue	O
strength	O
and	O
flexibility	O
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	O
forces	B-PHEN
.	O

We	O
also	O
investigated	O
the	O
potential	O
sources	O
of	O
fluids	B-OBJC
that	O
induce	O
inflation	O
in	O
alligator	B-LIVB
phalli	B-ANAT
.	O

Combining	O
serial	B-PROC
sectioning	I-PROC
and	O
three	B-PROC
-	I-PROC
dimensional	I-PROC
reconstruction	I-PROC
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	B-ANAT
plexus	I-ANAT
vascular	I-ANAT
bodies	B-ANAT
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	B-LIVB
phallus	B-ANAT
that	O
extend	O
distally	O
adjacent	O
to	O
ventro	O
-	O
medial	O
sulcus	O
tissues	O
.	O

Together	O
,	O
our	O
gross	O
and	O
histological	B-DISO
examination	I-DISO
of	O
the	O
American	B-LIVB
alligator	I-LIVB
phallic	B-ANAT
glans	I-ANAT
suggests	O
that	O
its	O
tissues	O
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-ANAT
inflation	O
to	O
expand	O
the	O
glans	B-ANAT
to	O
a	O
specific	O
and	O
repeatable	O
shape	O
,	O
and	O
potentially	O
release	O
secretory	B-ANAT
products	I-ANAT
into	O
the	O
female	B-ANAT
reproductive	I-ANAT
tract	I-ANAT
.	O

Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	O
sexual	O
selection	O
,	O
by	O
mechanically	O
and	O
/	O
or	O
chemically	O
affecting	B-PHYS
female	I-PHYS
reproductive	I-PHYS
physiology	I-PHYS
.	O

Heterogeneous	O
Mechanisms	O
of	O
Primary	B-PHEN
and	I-PHEN
Acquired	I-PHEN
Resistance	I-PHEN
to	O
Third	B-CHEM
-	I-CHEM
Generation	I-CHEM
EGFR	I-CHEM
Inhibitors	I-CHEM
To	O
identify	O
novel	O
mechanisms	O
of	O
resistance	O
to	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
EGFR	I-CHEM
inhibitors	I-CHEM
in	O
patients	B-LIVB
with	O
lung	B-DISO
adenocarcinoma	I-DISO
that	O
progressed	O
under	O
therapy	B-PROC
with	O
either	O
AZD9291	B-CHEM
or	O
rociletinib	B-CHEM
(	O
CO	B-CHEM
-	I-CHEM
1686	I-CHEM
)	O
.	O

We	O
analyzed	B-PROC
tumor	B-PROC
biopsies	I-PROC
from	O
seven	O
patients	B-LIVB
obtained	O
before	O
,	O
during	O
,	O
and	O
/	O
or	O
after	O
treatment	B-PROC
with	O
AZD9291	B-CHEM
or	O
rociletinib	B-CHEM
(	O
CO	B-CHEM
-	I-CHEM
1686	I-CHEM
)	O
.	O

Targeted	B-PROC
sequencing	I-PROC
and	O
FISH	B-PROC
analyses	I-PROC
were	O
performed	O
,	O
and	O
the	O
relevance	O
of	O
candidate	O
genes	O
was	O
functionally	O
assessed	O
in	O
in	B-PROC
vitro	I-PROC
models	I-PROC
.	O

We	O
found	O
recurrent	B-PHYS
amplification	I-PHYS
of	O
either	O
MET	O
or	O
ERBB2	O
in	O
tumors	B-DISO
that	O
were	O
resistant	B-PHEN
or	O
developed	B-PHEN
resistance	I-PHEN
to	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
EGFR	I-CHEM
inhibitors	I-CHEM
and	O
show	O
that	O
ERBB2	B-PHYS
and	O
MET	B-PHYS
activation	I-PHYS
can	O
confer	O
resistance	B-PHEN
to	O
these	B-CHEM
compounds	I-CHEM
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
KRAS	B-DISO
(	I-DISO
G12S	I-DISO
)	I-DISO
mutation	I-DISO
in	O
a	O
patient	B-LIVB
with	O
acquired	B-PHEN
resistance	I-PHEN
to	O
AZD9291	B-CHEM
as	O
a	O
potential	O
driver	O
of	O
acquired	B-PHEN
resistance	I-PHEN
.	O

Finally	O
,	O
we	O
show	O
that	O
dual	O
inhibition	O
of	O
EGFR	B-CHEM
/MEK	I-CHEM
might	O
be	O
a	O
viable	B-PHYS
strategy	I-PHYS
to	O
overcome	O
resistance	B-PHEN
in	O
EGFR	B-ANAT
-	I-ANAT
mutant	I-ANAT
cells	I-ANAT
expressing	O
mutant	B-DISO
KRAS	I-DISO
CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
heterogeneous	O
mechanisms	O
of	O
resistance	O
can	O
drive	O
primary	B-PHEN
and	I-PHEN
acquired	I-PHEN
resistance	I-PHEN
to	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
EGFR	I-CHEM
inhibitors	I-CHEM
and	O
provide	O
a	O
rationale	O
for	O
potential	O
combination	B-PROC
strategies	I-PROC
.	O

Clin	O
Cancer	O
Res	O
;	O
1	O
-	O
11	O
.	O

©	O
2016	O
AACR	O
.	O

Nax	B-CHEM
signaling	B-PHYS
evoked	O
by	O
an	O
increase	O
in	O
[	O
Na	B-CHEM
+	I-CHEM
]	O
in	O
CSF	B-ANAT
induces	O
water	B-PHYS
intake	I-PHYS
via	O
EET	B-CHEM
-mediated	O
TRPV4	B-CHEM
activation	B-PHYS
Water	B-PHYS
-	I-PHYS
intake	I-PHYS
behavior	O
is	O
under	O
the	O
control	O
of	O
brain	B-ANAT
systems	I-ANAT
that	O
sense	O
body	B-ANAT
-	I-ANAT
fluid	I-ANAT
conditions	O
at	O
sensory	B-ANAT
circumventricular	I-ANAT
organs	I-ANAT
(	O
sCVOs	B-ANAT
)	O
;	O
however	O
,	O
the	O
underlying	O
mechanisms	O
have	O
not	O
yet	O
been	O
elucidated	O
in	O
detail	O
.	O

Nax	B-CHEM
is	O
a	O
sodium	B-CHEM
(	O
Na	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
)	O
level	O
sensor	B-PHYS
in	O
the	O
brain	B-ANAT
,	O
and	O
the	O
transient	B-CHEM
receptor	I-CHEM
potential	I-CHEM
vanilloid	I-CHEM
(	I-CHEM
TRPV	I-CHEM
)	I-CHEM
channels	I-CHEM
,	O
TRPV1	B-CHEM
and	O
TRPV4	B-CHEM
,	O
have	O
been	O
proposed	O
to	O
function	O
as	O
osmosensors	B-PHYS
.	O

We	O
herein	O
investigated	O
voluntary	O
water	B-PHYS
intake	I-PHYS
immediately	O
induced	O
after	O
an	O
intracerebroventricular	O
(	O
icv	O
)	O
administration	B-PROC
of	O
a	O
hypertonic	B-CHEM
NaCl	I-CHEM
solution	I-CHEM
in	O
TRPV1	O
-	O
,	O
TRPV4	O
-	O
,	O
Nax	O
-	O
,	O
and	O
their	O
double	B-LIVB
-	I-LIVB
gene	I-LIVB
knockout	I-LIVB
(	I-LIVB
KO	I-LIVB
)	I-LIVB
mice	I-LIVB
.	O

The	O
induction	O
of	O
water	B-PHYS
intake	I-PHYS
by	O
TRPV1	O
-	O
KO	B-LIVB
mice	I-LIVB
was	O
normal	O
,	O
whereas	O
that	O
by	O
TRPV4	O
-	O
KO	B-LIVB
and	O
Nax	O
-	O
KO	B-LIVB
mice	I-LIVB
was	O
significantly	O
less	O
than	O
that	O
by	O
WT	B-LIVB
mice	I-LIVB
.	O

Water	B-PHYS
intake	I-PHYS
by	O
Nax	O
/	O
TRPV4	O
-	O
double	B-LIVB
KO	I-LIVB
mice	I-LIVB
was	O
similar	O
to	O
that	O
by	O
the	O
respective	O
single	O
KO	B-LIVB
mice	I-LIVB
.	O

When	O
TRPV4	B-CHEM
activity	B-PHYS
was	O
blocked	O
with	O
a	O
specific	B-CHEM
antagonist	I-CHEM
HC	B-CHEM
-	I-CHEM
067047	I-CHEM
,	O
water	B-PHYS
intake	I-PHYS
by	O
WT	B-LIVB
mice	I-LIVB
was	O
significantly	O
reduced	O
,	O
whereas	O
that	O
by	O
TRPV4	O
-	O
KO	B-LIVB
and	O
Nax	O
-	O
KO	B-LIVB
mice	I-LIVB
was	O
not	O
.	O

Similar	O
results	B-DISO
were	O
obtained	O
with	O
the	O
administration	B-PROC
of	O
miconazole	B-CHEM
,	O
which	O
inhibits	O
the	O
biosynthesis	O
of	O
epoxyeicosatrienoic	B-CHEM
acids	I-CHEM
(	O
EETs	B-CHEM
)	O
,	O
endogenous	O
agonists	B-CHEM
for	O
TRPV4	B-CHEM
,	O
from	O
arachidonic	B-CHEM
acid	I-CHEM
(	O
AA	B-CHEM
)	O
.	O

Icv	O
injection	B-PROC
of	O
hypertonic	B-CHEM
NaCl	I-CHEM
with	O
AA	B-CHEM
or	O
5	B-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
EET	I-CHEM
restored	O
water	B-PHYS
intake	I-PHYS
by	O
Nax	O
-	O
KO	B-LIVB
mice	I-LIVB
to	O
the	O
WT	O
level	O
,	O
but	O
not	O
that	O
by	O
TRPV4	O
-	O
KO	B-LIVB
mice	I-LIVB
.	O

These	O
results	B-DISO
suggest	O
that	O
the	O
Na	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
signal	B-PHEN
generated	O
in	O
Nax	B-CHEM
-	O
positive	B-DISO
glial	B-ANAT
cells	I-ANAT
leads	O
to	O
the	O
activation	B-PHYS
of	O
TRPV4	B-CHEM
-	O
positive	B-DISO
neurons	B-ANAT
in	O
sCVOs	B-ANAT
in	O
order	O
to	O
stimulate	B-PROC
water	B-PHYS
intake	I-PHYS
by	O
using	O
EETs	B-CHEM
as	O
gliotransmitters	B-CHEM
.	O

Timing	O
of	O
False	O
Ring	B-PHYS
Formation	I-PHYS
in	O
Pinus	B-LIVB
halepensis	I-LIVB
and	O
Arbutus	B-LIVB
unedo	I-LIVB
in	O
Southern	O
Italy	B-GEOG
:	O
Outlook	B-PHYS
from	O
an	O
Analysis	B-PROC
of	O
Xylogenesis	B-PHYS
and	O
Tree	B-LIVB
-	I-LIVB
Ring	I-LIVB
Chronologies	O
Mediterranean	B-GEOG
tree	B-LIVB
rings	I-LIVB
are	O
characterized	O
by	O
intra	O
-	O
annual	O
density	O
fluctuations	O
(	O
IADFs	O
)	O
due	O
to	O
partly	O
climate	B-PHEN
-	I-PHEN
driven	I-PHEN
cambial	B-PHYS
activity	I-PHYS
.	O

IADFs	O
are	O
used	O
as	O
structural	O
signals	O
to	O
gain	O
information	O
on	O
relations	O
between	O
environmental	O
conditions	O
and	O
eco	B-PHYS
-	I-PHYS
physiological	I-PHYS
processes	B-PHEN
during	O
xylogenesis	B-PHYS
,	O
with	O
intra	O
-	O
annual	O
resolution	O
.	O

To	O
reach	O
an	O
unbiased	B-PROC
synchronization	O
of	O
the	O
IADF	O
position	O
within	O
tree	B-LIVB
rings	O
and	O
seasonal	O
fluctuations	B-DISO
in	O
environmental	O
conditions	O
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
timing	O
of	O
cambial	B-PHYS
activity	I-PHYS
and	O
wood	B-OBJC
formation	O
,	O
which	O
are	O
species	O
-	O
and	O
site	O
-	O
specific	O
processes	B-PHEN
.	O

We	O
applied	O
the	O
microcoring	O
technique	O
to	O
analyze	B-PROC
xylogenesis	B-PHYS
in	O
Pinus	B-LIVB
halepensis	I-LIVB
and	O
Arbutus	B-LIVB
unedo	I-LIVB
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
attempt	O
to	O
study	B-PROC
xylogenesis	B-PHYS
in	O
a	O
hardwood	B-OBJC
species	O
forming	O
frequent	O
IADFs	O
.	O

Both	O
species	O
co	O
-	O
occur	O
at	O
a	O
site	O
in	O
southern	O
Italy	B-GEOG
characterized	O
by	O
a	O
Mediterranean	B-GEOG
climate	B-PHEN
.	O

To	O
facilitate	O
tree	B-PROC
-	I-PROC
ring	I-PROC
dating	I-PROC
and	O
identification	O
of	O
IADFs	O
,	O
we	O
performed	O
traditional	O
dendroecological	O
analysis	B-PROC
.	O

We	O
analyzed	B-PROC
xylogenesis	B-PHYS
during	O
summer	O
,	O
which	O
is	O
considered	O
a	O
constraint	O
for	O
xylogenesis	B-PHYS
and	O
a	O
trigger	O
for	O
IADF	O
formation	O
.	O

We	O
followed	O
the	O
different	O
phases	O
of	O
cell	B-PHYS
development	I-PHYS
in	O
the	O
current	O
wood	B-OBJC
increment	O
with	O
the	O
aim	O
of	O
evaluating	O
whether	O
and	O
which	O
type	O
of	O
IADFs	O
were	O
formed	O
.	O

We	O
additionally	O
analyzed	B-PROC
the	O
same	O
phases	O
again	O
in	O
September	O
and	O
in	O
winter	O
to	O
verify	O
the	O
possible	B-DISO
formation	O
of	O
IADFs	O
in	O
fall	O
and	O
whether	O
cell	B-ANAT
production	B-PHYS
and	O
differentiation	B-PHYS
was	O
completed	O
by	O
the	O
end	O
of	O
the	O
calendar	O
year	O
.	O

Both	O
species	O
formed	O
the	O
same	O
type	O
of	O
IADFs	O
(	O
earlywood	B-OBJC
-like	O
cells	B-ANAT
within	O
latewood	B-OBJC
)	O
,	O
due	O
to	O
temporary	O
growth	B-PHEN
restoration	B-DISO
triggered	O
by	O
rain	B-PHEN
events	O
during	O
the	O
period	O
of	O
summer	O
drought	B-PHEN
.	O

At	O
the	O
end	O
of	O
the	O
calendar	O
year	O
,	O
no	O
cells	B-ANAT
in	O
the	O
phases	O
of	O
enlargement	O
and	O
secondary	B-ANAT
cell	I-ANAT
wall	I-ANAT
deposition	O
occurred	O
.	O

A	B-LIVB
.	I-LIVB

unedo	I-LIVB
was	O
more	O
sensitive	O
than	O
P	B-LIVB
.	I-LIVB

halepensis	I-LIVB
because	O
IADF	O
s	O
were	O
formed	O
earlier	O
in	O
the	O
season	O
and	O
were	O
more	O
frequent	O
in	O
the	O
tree	B-LIVB
-	I-LIVB
ring	I-LIVB
series	O
.	O

The	O
dendro	O
-	O
anatomical	O
approach	O
,	O
combining	O
analysis	B-PROC
of	O
tree	B-LIVB
-	I-LIVB
ring	I-LIVB
series	O
and	O
of	O
xylogenesis	B-PHYS
,	O
helped	O
to	O
detect	B-DISO
the	O
period	O
of	O
IADF	O
formation	O
in	O
the	O
two	O
species	O
.	O

Results	O
are	O
discussed	O
in	O
functional	O
terms	O
,	O
highlighting	O
the	O
environmental	O
conditions	O
triggering	O
IADFs	O
,	O
and	O
also	O
in	O
methodological	O
terms	O
,	O
evaluating	O
the	O
applicability	O
of	O
xylogenesis	B-PHYS
analysis	B-PROC
in	O
Mediterranean	B-GEOG
woods	B-OBJC
,	O
especially	O
when	O
the	O
formation	O
of	O
IADFs	O
is	O
not	O
uniform	O
around	O
the	O
stem	B-LIVB
.	O

An	O
Accessible	O
and	O
Pragmatic	B-LIVB
Experimental	I-LIVB
Model	I-LIVB
of	O
Nonalcoholic	B-DISO
Fatty	I-DISO
Liver	I-DISO
Disease	I-DISO
BACKGROUND	O
There	O
is	O
no	O
convenient	O
cheap	O
pragmatic	B-LIVB
experimental	I-LIVB
model	I-LIVB
for	O
Nonalcoholic	B-DISO
Fatty	I-DISO
Liver	I-DISO
Disease	I-DISO
(	O
NAFLD	B-DISO
)	O
/	O
Nonalcoholic	B-DISO
Steatohepatitis	I-DISO
(	O
NASH	B-DISO
)	O
.	O

Our	O
objective	O
was	O
to	O
create	O
a	O
pragmatic	B-LIVB
model	I-LIVB
of	O
NAFLD	B-DISO
/	O
NASH	B-DISO
.	O

METHODS	O
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
were	O
fed	O
a	O
high	B-PROC
-	I-PROC
fat	I-PROC
,	O
high	B-PROC
sugar	I-PROC
homemade	I-PROC
diet	I-PROC
ad	O
libitum	O
for	O
seven	O
weeks	O
.	O

The	O
high	B-PROC
-	I-PROC
fat	I-PROC
,	O
high	B-PROC
sugar	I-PROC
diet	I-PROC
included	O
59	O
%	O
of	O
energy	O
derived	O
from	O
fat	B-CHEM
,	O
30	O
%	O
from	O
carbohydrates	B-OBJC
,	O
and	O
11	O
%	O
from	O
protein	B-OBJC
.	O

Serum	B-PROC
levels	I-PROC
of	I-PROC
fasting	I-PROC
glucose	I-PROC
,	O
triglyceride	B-PROC
,	O
cholesterol	B-PROC
,	O
liver	B-PROC
enzymes	I-PROC
,	O
insulin	B-PROC
,	O
and	O
hepatic	B-ANAT
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
-	I-CHEM
alpha	I-CHEM
(	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
)	O
gene	B-PHYS
expression	I-PHYS
were	O
determined	O
.	O

Hepatic	B-ANAT
histology	B-PROC
was	O
examined	O
by	O
H	B-PROC
&	I-PROC
E	I-PROC
stain	I-PROC
.	O

RESULTS	O
Rats	B-LIVB
fed	O
the	O
high	B-PROC
-	I-PROC
fat	I-PROC
,	O
high	B-PROC
sugar	I-PROC
diet	I-PROC
developed	O
hepatic	B-DISO
steatosis	I-DISO
,	O
and	O
a	O
moderate	B-DISO
inflammation	I-DISO
,	O
which	O
was	O
associated	O
with	O
increased	B-DISO
serum	I-DISO
levels	I-DISO
of	I-DISO
liver	I-DISO
enzymes	I-DISO
,	O
glucose	B-PHEN
,	O
insulin	B-PHEN
,	O
triglyceride	B-PHEN
,	O
cholesterol	B-PHEN
,	O
and	O
hepatic	B-ANAT
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
gene	B-PHYS
expression	I-PHYS
.	O

CONCLUSION	O
This	O
rat	B-LIVB
model	B-LIVB
resembles	O
the	O
key	O
features	O
of	O
human	B-LIVB
NAFLD	B-DISO
/	O
NASH	B-DISO
and	O
provides	O
a	O
simple	O
pragmatic	B-LIVB
experimental	I-LIVB
model	I-LIVB
for	O
elucidating	O
the	O
disease	B-PROC
prevention	I-PROC
and	O
treatment	B-PROC
.	O

Comparison	O
of	O
the	O
Effects	O
of	O
Subcutaneous	B-PROC
Versus	O
Continuous	B-PROC
Infusion	I-PROC
of	O
Heparin	B-CHEM
on	O
Key	O
Inflammatory	O
Parameters	O
Following	O
Sepsis	B-DISO
Sepsis	B-DISO
is	O
the	O
result	O
of	O
the	O
interaction	O
between	O
inflammatory	B-CHEM
mediators	I-CHEM
and	O
coagulation	B-PHYS
pathway	I-PHYS
.	O

Unfractionated	B-CHEM
heparin	I-CHEM
may	O
play	O
a	O
role	O
as	O
an	O
anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
agent	I-CHEM
beyond	O
its	O
anticoagulatory	O
effect	O
in	O
sepsis	B-DISO
.	O

As	O
a	O
result	O
,	O
it	O
may	O
cause	O
reduction	O
in	O
organ	B-DISO
failure	I-DISO
rate	O
in	O
patients	B-LIVB
with	O
sepsis	B-DISO
due	O
to	O
its	O
impact	O
on	O
both	O
inflammatory	O
and	O
coagulation	B-PHYS
process	I-PHYS
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
heparin	B-CHEM
in	O
sepsis	B-DISO
.	O

Plasma	B-ANAT
plasminogen	B-CHEM
activator	I-CHEM
inhibitor	I-CHEM
-	I-CHEM
1	I-CHEM
(	O
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
as	O
an	O
inflammatory	B-CHEM
mediator	I-CHEM
and	O
urinary	O
necoutrophil	B-CHEM
gelatinase	I-CHEM
-	I-CHEM
associated	I-CHEM
lipocalin	I-CHEM
(	O
NGAL	B-CHEM
)	O
as	O
a	O
marker	B-PHYS
of	O
kidney	B-DISO
injury	I-DISO
were	O
investigated	O
.	O

This	O
prospective	B-PROC
,	O
randomized	B-PROC
controlled	I-PROC
trial	I-PROC
was	O
conducted	O
in	O
a	O
32	O
-	O
bed	O
intensive	B-OBJC
care	I-OBJC
unit	I-OBJC
.	O

Thirty	O
patients	B-LIVB
with	O
sepsis	B-DISO
were	O
randomized	B-PROC
to	O
receive	O
heparin	B-CHEM
infusion	O
of	O
500	O
units	O
/	O
hour	O
or	O
5000	O
units	O
of	O
heparin	B-CHEM
three	O
times	O
a	O
day	O
,	O
subcutaneously	B-DISO
.	O

The	O
plasma	B-ANAT
level	O
of	O
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
urinary	O
level	O
of	O
NGAL	B-CHEM
were	O
determined	O
at	O
day	B-DISO
0	I-DISO
,	O
2	B-DISO
and	O
7	B-DISO
.	O

The	O
infusion	O
group	O
had	O
a	O
lower	O
plasma	B-ANAT
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
level	O
compared	O
to	O
the	O
subcutaneous	O
group	O
at	O
day	B-DISO
7	I-DISO
(	O
11	O
.	O

3	O
±	O
1	O
.	O
6	O
vs	O
.	O

16	O
.	O
5	O
±	O
4	O
.	O
2	O
;	O
P	O
=	O
0	O
.	O

003	O
)	O
.	O

The	O
urinary	O
NGAL	B-CHEM
level	O
was	O
lower	O
in	O
the	O
infusion	O
group	O
at	O
day	B-DISO
2	I-DISO
(	O
131	O
.	O

3	O
±	O
11	O
.	O
9	O
vs	O
.	O

151	O
.	O
2	O
±	O
20	O
.	O
6	O
;	O
P	O
=	O
0	O
.	O
014	O
)	O
;	O
however	O
,	O
at	O
day	B-DISO
7	I-DISO
the	O
NGAL	B-CHEM
level	O
was	O
decreased	O
in	O
the	O
subcutaneous	O
group	O
as	O
much	O
as	O
the	O
infusion	O
group	O
and	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
acute	B-PROC
physiology	I-PROC
and	I-PROC
chronic	I-PROC
health	I-PROC
evaluation	I-PROC
(	I-PROC
APACHE	I-PROC
)	I-PROC
II	I-PROC
and	O
sequential	B-DISO
organ	I-DISO
failure	I-DISO
assessment	I-DISO
(	I-DISO
SOFA	I-DISO
)	I-DISO
scores	I-DISO
between	O
the	O
two	O
groups	O
at	O
day	B-DISO
0	I-DISO
,	O
2	B-DISO
and	O
7	B-DISO
.	O

Low	O
-	O
dose	O
heparin	B-CHEM
infusion	O
compared	O
to	O
subcutaneous	O
heparin	B-CHEM
can	O
decrease	O
the	O
plasma	B-ANAT
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
urinary	O
NGAL	B-CHEM
levels	O
more	O
rapidly	O
.	O

It	O
can	O
be	O
related	O
to	O
anti	O
-	O
inflammatory	O
effects	O
of	O
heparin	B-CHEM
,	O
which	O
may	O
be	O
more	O
prominent	O
in	O
infusion	O
route	O
.	O

The	O
Spreading	O
of	O
Social	O
Energy	O
:	O
How	O
Exposure	O
to	O
Positive	B-DISO
and	O
Negative	B-DISO
Social	O
News	O
Affects	O
Behavior	O
Social	O
news	O
,	O
unlike	O
video	B-OBJC
games	I-OBJC
or	O
TV	O
programs	O
,	O
conveys	O
real	O
-	O
life	O
interactions	B-DISO
.	O

Theoretically	O
,	O
social	O
news	O
in	O
which	O
people	B-LIVB
help	O
or	O
harm	O
each	O
other	O
and	O
violate	O
rules	O
should	O
influence	O
both	O
prosocial	O
and	O
violation	O
behaviors	O
.	O

In	O
two	O
experiments	O
,	O
we	O
demonstrated	O
the	O
spreading	O
effects	O
of	O
social	O
news	O
in	O
a	O
social	B-DISO
interaction	I-DISO
context	O
emphasizing	O
social	O
conventions	B-PHEN
and	O
a	O
nonsocial	B-DISO
interaction	I-DISO
context	O
emphasizing	O
moral	O
norms	O
.	O

Across	O
the	O
two	O
studies	B-PROC
,	O
the	O
results	O
showed	O
that	O
positive	B-DISO
social	O
news	O
increased	O
cooperation	O
(	O
decreased	O
defection	O
)	O
but	O
had	O
no	B-DISO
effect	O
on	O
cheating	O
,	O
whereas	O
negative	B-DISO
social	O
news	O
increased	O
cheating	O
but	O
with	O
no	B-DISO
change	O
in	O
cooperation	O
(	O
or	O
defection	O
)	O
.	O

We	O
conclude	O
that	O
there	O
is	O
a	O
spreading	O
impact	O
of	O
positive	B-DISO
social	O
news	O
in	O
the	O
conventional	O
norm	O
domain	O
and	O
of	O
negative	B-DISO
social	O
news	O
in	O
the	O
moral	O
norm	O
domain	O
.	O

Using	O
Evolutionary	O
Theory	O
to	O
Guide	O
Mental	B-PHYS
Health	I-PHYS
Research	B-PROC
Evolutionary	O
approaches	O
to	O
medicine	O
can	O
shed	O
light	O
on	O
the	O
origins	O
and	O
etiology	O
of	O
disease	O
.	O

Such	O
an	O
approach	O
may	O
be	O
especially	O
useful	O
in	O
psychiatry	B-PROC
,	O
which	O
frequently	O
addresses	O
conditions	O
with	O
heterogeneous	O
presentation	O
and	O
unknown	B-DISO
causes	I-DISO
.	O

We	O
review	O
several	O
previous	O
applications	O
of	O
evolutionary	O
theory	O
that	O
highlight	O
the	O
ways	O
in	O
which	O
psychiatric	B-DISO
conditions	I-DISO
may	O
persist	O
despite	O
and	O
because	O
of	O
natural	B-PHEN
selection	I-PHEN
.	O

One	O
lesson	O
from	O
the	O
evolutionary	O
approach	O
is	O
that	O
some	O
conditions	O
currently	O
classified	O
as	O
disorders	B-DISO
(	O
because	O
they	O
cause	O
distress	B-DISO
and	O
impairment	B-DISO
)	O
may	O
actually	O
be	O
caused	O
by	O
functioning	O
adaptations	B-PHEN
operating	O
""""	O
normally	O
""""	O
(	O
as	O
designed	O
by	O
natural	B-PHEN
selection	I-PHEN
)	O
.	O

Such	O
conditions	O
suggest	O
an	O
alternative	O
illness	B-DISO
model	I-DISO
that	O
may	O
generate	O
alternative	O
intervention	B-PROC
strategies	I-PROC
.	O

Thus	O
,	O
the	O
evolutionary	O
approach	O
suggests	O
that	O
psychiatry	B-PROC
should	O
sometimes	O
think	O
differently	O
about	O
distress	B-DISO
and	O
impairment	B-DISO
.	O

The	O
complexity	O
of	O
the	O
human	B-LIVB
brain	B-ANAT
,	O
including	O
normal	O
functioning	B-PHYS
and	O
potential	O
for	O
dysfunctions	B-DISO
,	O
has	O
developed	O
over	O
evolutionary	O
time	O
and	O
has	O
been	O
shaped	O
by	O
natural	B-PHEN
selection	I-PHEN
.	O

Understanding	O
the	O
evolutionary	O
origins	O
of	O
psychiatric	B-DISO
conditions	I-DISO
is	O
therefore	O
a	O
crucial	O
component	O
to	O
a	O
complete	O
understanding	O
of	O
etiology	O
.	O

Transcriptomic	B-PHYS
and	O
Physiological	B-PHYS
Responses	I-PHYS
of	O
the	O
Green	O
Microalga	O
Chlamydomonas	O
reinhardtii	O
during	O
Short	O
-	O
Term	O
Exposure	O
to	O
Subnanomolar	O
Methylmercury	B-CHEM
Concentrations	O
The	O
effects	O
of	O
short	O
-	O
term	O
exposure	O
to	O
subnanomolar	O
methyl	B-CHEM
-	I-CHEM
mercury	I-CHEM
(	O
MeHg	B-CHEM
)	O
concentrations	O
,	O
representative	O
of	O
contaminated	O
environments	O
,	O
on	O
the	O
microalga	O
Chlamydomonas	O
reinhardtii	O
were	O
assessed	O
using	O
both	O
physiological	B-PHYS
end	I-PHYS
points	I-PHYS
and	O
gene	B-PROC
expression	I-PROC
analysis	I-PROC
.	O

MeHg	B-CHEM
bioaccumulated	B-PHYS
and	O
induced	O
significant	O
increase	O
of	O
the	O
photosynthesis	B-PHEN
efficiency	O
,	O
while	O
the	O
algal	B-PHEN
growth	I-PHEN
,	O
oxidative	B-DISO
stress	I-DISO
,	O
and	O
chlorophyll	B-PHYS
fluorescence	I-PHYS
were	O
unaffected	O
.	O

At	O
the	O
molecular	O
level	O
,	O
MeHg	B-CHEM
significantly	O
dysregulated	B-PHYS
the	O
expression	B-PHYS
of	I-PHYS
genes	I-PHYS
involved	O
in	O
motility	B-PHYS
,	O
energy	B-PHYS
metabolism	I-PHYS
,	O
lipid	B-PHYS
metabolism	I-PHYS
,	O
metal	B-PHYS
transport	I-PHYS
,	O
and	O
antioxidant	B-CHEM
enzymes	B-CHEM
.	O

Data	O
suggest	O
that	O
the	O
cells	B-ANAT
were	O
able	B-DISO
to	I-DISO
cope	I-DISO
with	O
subnanomolar	O
MeHg	B-CHEM
exposure	O
,	O
but	O
this	O
tolerance	O
resulted	O
in	O
a	O
significant	O
cost	O
to	O
the	O
cell	B-PHYS
energy	I-PHYS
and	I-PHYS
reserve	I-PHYS
metabolism	I-PHYS
as	O
well	O
as	O
ample	O
changes	O
in	O
the	O
nutrition	B-PHYS
and	O
motility	B-PHYS
of	O
C	O
.	O

reinhardtii	O
.	O

The	O
present	O
results	O
allowed	O
gaining	O
new	O
insights	O
on	O
the	O
effects	O
and	O
uptake	B-PHYS
mechanisms	I-PHYS
of	O
MeHg	B-CHEM
at	O
subnanomolar	O
concentrations	O
in	O
aquatic	O
primary	O
producers	O
.	O

Emergence	O
of	O
family	O
medicine	O
in	O
Ethiopia	B-GEOG
[	O
corrected	O
]	O
:	O
an	O
international	O
collaborative	O
education	O
model	O
Family	O
Medicine	O
(	O
FM	O
)	O
is	O
a	O
new	O
specialty	O
in	O
Ethiopia	B-GEOG
.	O

The	O
first	B-LIVB
seven	I-LIVB
family	I-LIVB
physicians	I-LIVB
graduated	B-LIVB
in	O
February	O
2016	O
from	O
the	O
inaugural	O
residency	B-PROC
programme	O
at	O
Addis	B-OBJC
Ababa	I-OBJC
University	I-OBJC
.	O

Cooperation	O
amongst	O
Ethiopian	B-LIVB
and	O
expatriate	B-DISO
decision	B-LIVB
-	I-LIVB
makers	I-LIVB
and	O
physicians	B-LIVB
was	O
needed	O
to	O
begin	O
the	O
programme	O
.	O

Intentional	O
replacement	O
of	O
expatriates	B-DISO
with	O
Ethiopian	B-LIVB
family	B-LIVB
physicians	I-LIVB
has	O
begun	O
.	O

Barriers	O
include	O
lack	O
of	O
understanding	B-PHYS
of	O
FM	O
and	O
the	O
human	O
and	O
financial	B-DISO
resources	I-DISO
needed	O
for	O
scaling	O
up	O
the	O
programme	O
.	O

Regular	O
programme	O
review	O
with	O
resident	B-LIVB
physician	I-LIVB
involvement	O
has	O
allowed	O
the	O
FM	O
training	B-PROC
programme	I-PROC
to	O
adapt	O
and	O
fit	O
the	O
Ethiopian	B-LIVB
context	O
.	O

Further	O
successes	O
will	O
result	O
from	O
ongoing	O
support	O
and	O
advocacy	O
from	O
the	O
Federal	O
Ministry	O
of	O
Health	O
and	O
other	O
Ethiopian	B-LIVB
,	O
African	B-LIVB
,	O
and	O
international	O
primary	O
care	O
organisations	O
.	O

Hierarchical	O
Targeting	O
Strategy	B-PROC
for	O
Enhanced	O
Tumor	O
Tissue	O
Accumulation	O
/	O
Retention	B-PHYS
and	O
Cellular	B-PHYS
Internalization	I-PHYS
Targeted	O
delivery	B-PHEN
of	O
therapeutic	B-CHEM
agents	I-CHEM
is	O
an	O
important	O
way	B-PHEN
to	O
improve	O
the	O
therapeutic	O
index	O
and	O
reduce	O
side	B-DISO
effects	I-DISO
.	O

To	O
design	O
nanoparticles	B-OBJC
for	O
targeted	O
delivery	B-PHEN
,	O
both	O
enhanced	O
tumor	O
tissue	O
accumulation	O
/	O
retention	B-PHYS
and	O
enhanced	O
cellular	B-PHYS
internalization	I-PHYS
should	O
be	O
considered	O
simultaneously	O
.	O

So	O
far	O
,	O
there	O
have	O
been	O
very	O
few	O
nanoparticles	B-OBJC
with	O
immutable	O
structures	O
that	O
can	O
achieve	O
this	O
goal	O
efficiently	O
.	O

Hierarchical	O
targeting	O
,	O
a	O
novel	O
targeting	O
strategy	B-PROC
based	O
on	O
stimuli	B-PHEN
responsiveness	B-PHYS
,	O
shows	O
good	O
potential	O
to	O
enhance	O
both	O
tumor	O
tissue	O
accumulation	O
/	O
retention	B-PHYS
and	O
cellular	B-PHYS
internalization	I-PHYS
.	O

Here	O
,	O
the	O
recent	O
design	O
and	O
development	O
of	O
hierarchical	O
targeting	O
nanoplatforms	O
,	O
based	O
on	O
changeable	O
particle	O
sizes	O
,	O
switchable	O
surface	O
charges	O
and	O
activatable	O
surface	O
ligands	B-CHEM
,	O
will	O
be	O
introduced	O
.	O

In	O
general	O
,	O
the	O
targeting	O
moieties	O
in	O
these	O
nanoplatforms	O
are	O
not	O
activated	O
during	O
blood	B-PHYS
circulation	I-PHYS
for	O
efficient	O
tumor	O
tissue	O
accumulation	O
,	O
but	O
re	O
-	O
activated	O
by	O
certain	O
internal	O
or	O
external	O
stimuli	B-PHEN
in	O
the	O
tumor	B-PHEN
microenvironment	I-PHEN
for	O
enhanced	O
cellular	B-PHYS
internalization	I-PHYS
.	O

Subsolid	B-DISO
pulmonary	I-DISO
nodule	I-DISO
morphology	O
and	O
associated	O
patient	B-PHYS
characteristics	I-PHYS
in	O
a	O
routine	O
clinical	O
population	B-LIVB
To	O
determine	O
the	O
presence	O
and	O
morphology	O
of	O
subsolid	B-DISO
pulmonary	I-DISO
nodules	I-DISO
(	O
SSNs	B-DISO
)	O
in	O
a	O
non	O
-	O
screening	O
setting	O
and	O
relate	O
them	O
to	O
clinical	B-PHYS
and	O
patient	B-PHYS
characteristics	I-PHYS
.	O

A	O
total	O
of	O
16	O
,	O
890	O
reports	O
of	O
clinically	O
obtained	O
chest	B-PROC
CT	I-PROC
(	O
06	O
/	O
2011	O
to	O
11	O
/	O
2014	O
,	O
single	O
-	O
centre	O
)	O
were	O
searched	O
describing	O
an	O
SSN	B-DISO
.	O

Subjects	B-LIVB
with	O
a	O
visually	O
confirmed	O
SSN	B-DISO
and	O
at	O
least	O
two	O
thin	B-PROC
-	I-PROC
slice	I-PROC
CTs	I-PROC
were	O
included	O
.	O

Nodule	B-DISO
volumes	O
were	O
measured	O
.	O

Progression	O
was	O
defined	O
as	O
volume	O
increase	O
exceeding	O
the	O
software	B-PROC
interscan	I-PROC
variation	O
.	O

Nodule	B-DISO
morphology	O
,	O
location	B-ANAT
,	O
and	O
patient	B-PHYS
characteristics	I-PHYS
were	O
evaluated	B-PROC
.	O

Fifteen	O
transient	O
and	O
74	O
persistent	O
SSNs	B-DISO
were	O
included	O
(	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
19	O
.	O

6	O
[	O
8	O
.	O
3	O
-	O
36	O
.	O
8	O
]	O
months	O
)	O
.	O

Subjects	B-LIVB
with	O
an	O
SSN	B-DISO
were	O
slightly	O
older	O
than	O
those	O
without	O
(	O
62	O
vs	O
.	O

58	O
years	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
but	O
no	O
gender	B-PHYS
predilection	O
was	O
found	O
.	O

SSNs	B-DISO
were	O
mostly	O
located	O
in	O
the	O
upper	B-ANAT
lobes	I-ANAT
.	O

Women	B-LIVB
showed	O
significantly	O
more	O
often	O
persistent	O
lesions	B-DISO
than	O
men	B-LIVB
(	O
94	O
%	O
vs	O
.	O

69	O
%	O
;	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

Part	B-DISO
-	I-DISO
solid	I-DISO
lesions	I-DISO
were	O
larger	O
(	O
1638	O
vs	O
.	O

383	O
mm	O
(	O
3	O
)	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
more	O
often	O
progressive	O
(	O
68	O
%	O
vs	O
.	O

38	O
%	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
compared	O
to	O
pure	O
ground	B-DISO
-	I-DISO
glass	I-DISO
nodules	I-DISO
.	O

Progressive	O
SSNs	B-DISO
were	O
rare	O
under	O
the	O
age	B-PHYS
of	O
50	O
years	O
.	O

Logistic	O
regression	O
analysis	O
did	O
not	O
identify	O
additional	O
nodule	B-DISO
parameters	B-DISO
of	O
future	O
progression	O
,	O
apart	O
from	O
part	O
-	O
solid	O
nature	O
.	O

This	O
study	B-PROC
confirms	O
previously	O
reported	O
characteristics	O
of	O
SSNs	B-DISO
and	O
associated	O
factors	O
in	O
a	O
European	B-LIVB
,	O
routine	O
clinical	O
population	B-LIVB
.	O

•	O
SSNs	B-DISO
in	O
women	B-LIVB
are	O
significantly	O
more	O
often	O
persistent	O
compared	O
to	O
men	B-LIVB
.	O

•	O
SSN	B-DISO
persistence	O
is	O
not	O
associated	O
with	O
age	B-PHYS
or	O
prior	O
malignancy	B-DISO
.	O

•	O
The	O
majority	O
of	O
(	O
persistent	O
)	O
SSNs	B-DISO
are	O
located	O
in	O
the	O
upper	B-ANAT
lung	I-ANAT
lobes	I-ANAT
.	O

•	O
A	O
part	O
-	O
solid	O
nature	O
is	O
associated	O
with	O
future	O
nodule	B-DISO
growth	B-PHYS
.	O

•	O
Progressive	O
solitary	B-DISO
SSNs	I-DISO
are	O
rare	O
under	O
the	O
age	B-PHYS
of	O
50	O
years	O
.	O

Dynamic	B-PROC
CT	I-PROC
myocardial	I-PROC
perfusion	I-PROC
imaging	I-PROC
identifies	O
early	O
perfusion	B-PHYS
abnormalities	B-DISO
in	O
diabetes	B-DISO
and	O
hypertension	B-DISO
:	O
Insights	O
from	O
a	O
multicenter	B-PROC
registry	O
To	O
identify	O
patients	B-LIVB
with	O
early	B-DISO
signs	I-DISO
of	O
myocardial	B-PHYS
perfusion	I-PHYS
reduction	O
,	O
a	O
reference	O
base	O
for	O
perfusion	B-PHYS
measures	O
is	O
needed	O
.	O

To	O
analyze	O
perfusion	B-PHYS
parameters	B-DISO
derived	O
from	O
dynamic	B-PROC
computed	I-PROC
tomography	I-PROC
perfusion	I-PROC
imaging	I-PROC
(	O
CTPI	B-PROC
)	O
in	O
patients	B-LIVB
with	O
suspected	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O
CAD	B-DISO
)	O
,	O
and	O
relationship	O
with	O
risk	B-DISO
factors	I-DISO
.	O

In	O
this	O
multicenter	B-PROC
study	I-PROC
,	O
coronary	B-PROC
CT	I-PROC
angiography	I-PROC
(	O
cCTA	B-PROC
)	O
and	O
dynamic	B-PROC
CTPI	I-PROC
were	O
performed	O
by	O
second	B-PROC
-	I-PROC
generation	I-PROC
dual	I-PROC
-	I-PROC
source	I-PROC
CT	I-PROC
in	O
patients	B-LIVB
suspected	O
of	O
CAD	B-DISO
.	O

Risk	B-DISO
factors	I-DISO
were	O
collected	O
from	O
hospital	B-OBJC
records	I-OBJC
.	O

Patients	B-LIVB
with	O
visual	O
perfusion	B-PHYS
defects	O
on	O
CTPI	B-PROC
,	O
previous	O
coronary	B-PROC
intervention	I-PROC
,	O
or	O
missing	O
risk	B-DISO
factor	I-DISO
details	O
were	O
excluded	O
.	O

This	O
analysis	B-PROC
included	O
98	O
patients	B-LIVB
(	O
mean	O
age	O
±	O
standard	O
deviation	O
[	O
SD	O
]	O
,	O
59	O
.	O
0	O
±	O
8	O
.	O

6yrs	O
;	O
73	O
male	B-LIVB
)	O
.	O

Global	O
measures	O
of	O
left	B-ANAT
ventricular	I-ANAT
myocardial	B-PHYS
blood	I-PHYS
flow	I-PHYS
(	O
MBF	B-PHYS
)	O
,	O
myocardial	B-PHYS
blood	I-PHYS
volume	I-PHYS
(	O
MBV	B-PHYS
)	O
and	O
volume	O
transfer	O
constant	O
(	O
K	O
(	O
trans	O
)	O
)	O
were	O
calculated	O
.	O

Mean	O
MBF	B-PHYS
was	O
139	O
.	O

3	O
±	O
31	O
.	O

4	O
mL	O
/	O
100	O
mL	O
/	O
min	O
,	O
MBV	B-PHYS
19	O
.	O
1	O
±	O
2	O
.	O

7	O
mL	O
/	O
100	O
mL	O
,	O
and	O
Ktrans	O
85	O
.	O
0	O
±	O
17	O
.	O

5	O
mL	O
/	O
100	O
mL	O
/	O
min	O
.	O

No	O
significant	O
differences	O
in	O
perfusion	B-PHYS
parameters	B-DISO
were	O
found	O
by	O
gender	B-PHYS
or	O
age	B-PHYS
category	O
.	O

Hypertension	B-DISO
and	O
diabetes	B-DISO
mellitus	I-DISO
resulted	O
in	O
lower	O
perfusion	B-PHYS
parameters	B-DISO
(	O
hypertension	B-DISO
vs	O
normotension	B-DISO
:	O
MBV	B-PHYS
18	O
.	O

5	O
±	O
3	O
.	O
0	O
vs	O
19	O
.	O

7	O
±	O
2	O
.	O

3	O
mL	O
/	O
100	O
mL	O
and	O
K	O
(	O
trans	O
)	O
82	O
.	O
0	O
±	O
18	O
.	O
0	O
vs	O
89	O
.	O

0	O
±	O
16	O
.	O
0	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
diabetes	B-DISO
vs	O
no	B-DISO
diabetes	I-DISO
:	O
MBF	B-PHYS
128	O
.	O

5	O
±	O
31	O
.	O
5	O
vs	O
144	O
.	O

0	O
±	O
30	O
.	O

5	O
mL	O
/	O
100	O
mL	O
/	O
min	O
and	O
MBV	B-PHYS
17	O
.	O
9	O
±	O
2	O
.	O
4	O
vs	O
19	O
.	O
4	O
±	O
2	O
.	O
8	O
mL	O
/	O
100	O
mL	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	B-LIVB
with	O
hyperlipidemia	B-DISO
,	O
MBF	B-PHYS
was	O
higher	O
(	O
146	O
.	O
8	O
±	O
34	O
.	O

4	O
vs	O
130	O
.	O

7	O
±	O
24	O
.	O

3	O
mL	O
/	O
100	O
mL	O
/	O
min	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Smoking	O
and	O
family	B-DISO
history	I-DISO
did	O
not	O
show	O
perfusion	B-PHYS
parameter	B-DISO
differences	O
.	O

Dynamic	B-PROC
CTPI	I-PROC
identifies	O
early	O
perfusion	B-PHYS
disturbances	O
in	O
conditions	O
like	O
diabetes	B-DISO
and	O
hypertension	B-DISO
.	O

With	O
further	O
standardization	B-PROC
,	O
absolute	O
perfusion	B-PHYS
measures	O
may	O
improve	O
CAD	B-DISO
risk	O
stratification	B-PROC
in	O
patients	B-LIVB
without	O
visual	O
perfusion	B-PHYS
defects	O
.	O

Cognition	B-PHYS
Enhancing	O
Activity	O
of	O
Sulforaphane	B-CHEM
Against	O
Scopolamine	B-CHEM
Induced	O
Cognitive	B-DISO
Impairment	I-DISO
in	O
Zebra	B-LIVB
Fish	I-LIVB
(	O
Danio	B-LIVB
rerio	I-LIVB
)	O
Several	O
epidemiological	B-PROC
studies	I-PROC
have	O
shown	O
that	O
consumption	O
of	O
large	O
quantities	O
of	O
vegetables	B-OBJC
especially	O
cruciferous	B-OBJC
vegetables	I-OBJC
(	O
Broccoli	B-OBJC
and	O
Brussels	B-OBJC
sprouts	I-OBJC
)	O
can	O
protect	O
against	O
chronic	B-DISO
diseases	I-DISO
.	O

Sulforaphane	B-CHEM
,	O
an	O
isothiocynate	B-CHEM
found	B-DISO
in	O
cruciferous	B-OBJC
vegetables	I-OBJC
has	O
been	O
demonstrated	O
to	O
have	O
neuroprotective	O
effects	O
in	O
several	O
experimental	B-PROC
paradigms	I-PROC
.	O

This	O
study	B-PROC
was	O
undertaken	O
to	O
examine	O
the	O
effect	O
of	O
sulforaphane	B-CHEM
on	O
cognitive	B-DISO
impairment	I-DISO
in	O
zebra	B-LIVB
fish	I-LIVB
model	B-DISO
using	O
a	O
novel	O
method	O
of	O
fear	B-PHYS
conditioning	I-PHYS
.	O

Initially	O
,	O
the	O
normal	O
behaviour	O
of	O
zebra	B-LIVB
fishes	I-LIVB
was	O
studied	B-PROC
in	O
light	B-OBJC
-	I-OBJC
dark	I-OBJC
tank	I-OBJC
for	O
10	O
min	O
daily	O
for	O
10	O
days	O
.	O

Fishes	B-LIVB
were	O
then	O
divided	O
into	O
seven	O
groups	O
of	O
twelve	O
in	O
each	O
.	O

Group	O
I	O
served	O
as	O
normal	O
,	O
group	O
II	O
served	O
as	O
fear	B-PHYS
conditioned	I-PHYS
control	I-PHYS
,	O
group	O
III	O
and	O
group	O
IV	O
were	O
sulforaphane	B-CHEM
(	O
25	O
µM	O
/	O
L	O
)	O
and	O
piracetam	B-CHEM
(	O
200	O
mg	O
/	O
L	O
)	O
treated	O
respectively	O
.	O

Group	O
V	O
served	O
as	O
scopolamine	B-CHEM
(	O
400	O
µM	O
/	O
L	O
)	O
induced	O
memory	B-DISO
impairment	I-DISO
fishes	B-LIVB
.	O

Group	O
VI	O
and	O
VII	O
were	O
sulforaphane	B-CHEM
(	O
25	O
µM	O
/	O
L	O
)	O
and	O
piracetam	B-CHEM
(	O
200	O
mg	O
/	O
L	O
)	O
treated	O
scopolamine	B-CHEM
induced	O
memory	B-DISO
impairment	I-DISO
groups	O
respectively	O
.	O

In	O
normal	O
behavioural	B-PROC
analysis	I-PROC
,	O
fishes	B-LIVB
preferred	O
to	O
stay	O
in	O
dark	O
compartment	O
.	O

The	O
average	O
number	O
of	O
entries	B-OBJC
into	O
the	O
dark	O
and	O
time	O
spent	O
in	O
dark	O
were	O
significantly	O
more	O
.	O

Fishes	B-LIVB
in	O
group	O
II	O
to	O
VII	O
were	O
individually	O
subjected	O
to	O
fear	B-PHYS
conditioning	I-PHYS
passive	B-PROC
avoidance	I-PROC
task	I-PROC
and	O
evaluated	B-PROC
for	O
learned	B-PHYS
task	I-PHYS
memory	I-PHYS
.	O

It	O
was	O
observed	O
that	O
the	O
average	O
number	O
of	O
entries	B-OBJC
into	O
dark	O
and	O
time	O
spent	O
in	O
dark	O
were	O
significantly	O
decreased	O
.	O

After	O
exposure	O
to	O
respective	O
treatment	O
fishes	B-LIVB
in	O
group	O
III	O
to	O
VII	O
were	O
subjected	O
to	O
cognitive	B-PHYS
evaluation	B-PROC
.	O

There	O
was	O
no	B-DISO
significant	I-DISO
difference	O
in	O
cognition	B-PHYS
of	O
group	O
III	O
and	O
IV	O
fishes	B-LIVB
exposed	O
to	O
sulforaphane	B-CHEM
and	O
piracetam	B-CHEM
alone	O
respectively	O
.	O

Fishes	B-LIVB
exposed	O
to	O
scopolamine	B-CHEM
showed	O
a	O
significant	O
cognitive	B-DISO
impairment	I-DISO
.	O

Sulforaphane	B-CHEM
exposure	O
prior	O
to	O
scopolamine	B-CHEM
significantly	O
retained	O
the	O
memory	B-PHYS
of	O
learned	B-PHYS
task	O
.	O

These	O
findings	B-DISO
suggest	O
that	O
sulforaphane	B-CHEM
might	O
be	O
a	O
promising	O
therapeutic	B-CHEM
agent	I-CHEM
for	O
cognitive	B-PHYS
enhancement	O
in	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
.	O

Value	O
of	O
MDM2	B-CHEM
,	O
CDK4	B-CHEM
and	O
SATB2	B-CHEM
immunohistochemistry	B-PROC
in	O
histologic	B-PHYS
diagnosis	B-DISO
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
To	O
investigate	O
the	O
value	O
of	O
combined	O
application	O
of	O
MDM2	B-CHEM
,	O
CDK4	B-CHEM
and	O
SATB2	B-CHEM
immunohistochemistry	B-PROC
in	O
pathological	O
diagnosis	B-DISO
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
.	O

Forty	O
-	O
seven	O
cases	O
of	O
low	B-DISO
grade	I-DISO
osteosarcoma	B-DISO
,	O
including	O
low	B-DISO
grade	I-DISO
central	I-DISO
osteosarcoma	I-DISO
(	O
n	O
=	O
20	O
)	O
and	O
parosteal	B-DISO
osteosarcoma	I-DISO
(	O
n	O
=	O
27	O
)	O
,	O
were	O
selected	O
from	O
Shanghai	B-OBJC
Jiaotong	I-OBJC
University	I-OBJC
Affiliated	O
the	O
Sixth	B-OBJC
People	I-OBJC
's	I-OBJC
Hospital	I-OBJC
.	O

The	O
clinical	O
,	O
radiography	B-PROC
and	O
histopathology	B-PHEN
were	O
reviewed	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MDM2	B-CHEM
,	O
CDK4	B-CHEM
and	O
SATB2	B-CHEM
immunohistochemistry	B-PROC
in	O
the	O
diagnosis	B-DISO
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
were	O
assessed	B-PROC
along	O
with	O
an	O
evaluation	B-PROC
of	O
their	O
expressions	B-PHYS
in	O
fibrous	B-DISO
dysplasia	I-DISO
,	O
desmoplastic	B-DISO
fibroma	I-DISO
,	O
low	B-DISO
-	I-DISO
grade	I-DISO
fibrosarcoma	B-DISO
and	O
other	O
fibrous	B-DISO
tumors	I-DISO
.	O

Low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
had	O
protracted	B-DISO
clinical	I-DISO
course	I-DISO
,	O
occurring	O
mostly	O
in	O
elder	B-LIVB
adults	I-LIVB
and	O
mainly	O
involving	O
long	O
bones	B-ANAT
.	O

Radiographic	O
studies	O
showed	O
that	O
low	B-DISO
-	I-DISO
grade	I-DISO
central	I-DISO
osteosarcoma	I-DISO
had	O
a	O
mainly	O
malignant	O
lytic	O
presentation	O
,	O
however	O
about	O
5	O
/	O
18	O
of	O
t	O
umors	O
overlapping	O
with	O
intermediate	O
and	O
benign	O
bone	B-DISO
diseases	I-DISO
,	O
while	O
parosteal	B-DISO
osteosarcoma	I-DISO
was	O
characterized	O
by	O
a	O
densely	O
sclerotic	O
malignant	O
appearance	O
.	O

Histologically	B-PHYS
,	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
s	O
were	O
characterized	O
by	O
well	O
-	O
differentiated	O
spindle	B-ANAT
tumor	B-ANAT
cells	I-ANAT
,	O
various	O
mature	O
tumor	B-DISO
bones	I-DISO
and	O
an	O
aggressive	O
growth	B-DISO
pattern	I-DISO
.	O

The	O
positive	B-PHYS
expression	I-PHYS
rates	O
of	O
MDM2	B-CHEM
and	O
CDK4	B-CHEM
in	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
were	O
74	O
.	O

5	O
%	O
and	O
55	O
.	O

3	O
%	O
,	O
respectively	O
.	O

Eighty	O
-	O
three	O
percent	O
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
expressed	O
one	O
or	O
both	O
markers	O
.	O

Low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
and	O
fibrous	B-DISO
dysplasia	I-DISO
were	O
both	O
positive	B-DISO
for	O
SATB2	B-CHEM
,	O
while	O
desmoplastic	B-DISO
fibroma	I-DISO
,	O
low	B-DISO
-	I-DISO
grade	I-DISO
fibrosacoma	B-DISO
and	O
other	O
fibrous	B-DISO
tumors	I-DISO
were	O
negative	B-DISO
for	O
SATB2	B-CHEM
.	O

Accurate	O
diagnosis	B-DISO
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
should	O
be	O
based	O
on	O
combination	O
of	O
clinical	O
presentation	O
,	O
imaging	B-PROC
and	O
histopathology	B-PHEN
,	O
with	O
immunohistochemistry	B-PROC
as	O
a	O
diagnostic	O
adjunct	O
.	O

Positive	B-PROC
immunostaining	I-PROC
for	O
CDK4	B-CHEM
and	O
/	O
or	O
MDM2	B-CHEM
supports	O
the	O
diagnosis	B-DISO
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
,	O
but	O
the	O
negative	O
one	O
does	O
not	O
rule	O
out	O
such	O
lesion	B-DISO
.	O

The	O
negative	O
expression	B-PHYS
of	O
SATB2	B-CHEM
is	O
helpful	O
to	O
exclude	O
fibrous	B-DISO
tumors	I-DISO
originating	O
from	O
bone	B-ANAT
with	O
the	O
exception	O
of	O
fibrous	B-DISO
dysplasia	I-DISO
.	O

Biobank	B-OBJC
and	O
Genomic	O
Research	B-PROC
in	O
Uganda	B-GEOG
:	O
Are	O
Extant	O
Privacy	O
and	O
Confidentiality	O
Regimes	O
Adequate	O
?	O
Not	O
many	O
African	B-GEOG
countries	I-GEOG
have	O
been	O
able	O
to	O
develop	O
a	O
robust	O
system	O
for	O
regulating	O
health	B-PROC
research	I-PROC
within	O
their	O
respective	O
jurisdictions	O
,	O
particularly	O
in	O
the	O
realm	O
of	O
biobanking	B-OBJC
and	O
genomics	O
.	O

This	O
is	O
not	O
without	O
reason	O
.	O

Aside	O
from	O
underdevelopment	O
and	O
all	O
that	O
it	O
entails	O
or	O
perhaps	O
in	O
consequence	O
thereof	O
,	O
countries	B-GEOG
in	O
the	O
region	B-GEOG
have	O
been	O
unable	O
to	O
make	O
significant	O
strides	O
in	O
medical	B-PROC
research	I-PROC
.	O

But	O
there	O
are	O
exceptions	O
.	O

Amongst	O
the	O
few	O
seeming	O
success	O
stories	O
is	O
Uganda	B-GEOG
.	O

Nonetheless	O
,	O
although	O
the	O
country	O
has	O
developed	O
what	O
appears	O
to	O
be	O
a	O
functional	O
framework	O
to	O
govern	O
genomic	O
research	B-PROC
and	O
biobanking	B-OBJC
,	O
the	O
consistency	O
of	O
key	O
provisions	O
with	O
international	O
standards	O
,	O
especially	O
those	O
pertaining	O
to	O
privacy	O
of	O
research	B-PROC
participants	B-LIVB
and	O
confidentiality	O
of	O
their	O
health	B-PROC
information	I-PROC
,	O
is	O
not	O
at	O
all	O
clear	O
.	O

Yet	O
,	O
making	O
this	O
determination	O
-	O
the	O
main	O
objective	O
of	O
this	O
article	O
-	O
is	O
critical	O
in	O
determining	O
the	O
adequacy	O
of	O
protection	B-DISO
available	O
to	O
human	B-LIVB
research	B-LIVB
subjects	I-LIVB
in	O
the	O
country	B-GEOG
.	O

Impact	O
of	O
a	O
Casino	B-OBJC
Opening	O
on	O
Gambling	O
Behaviors	O
of	O
People	B-LIVB
Engaged	O
in	O
Methadone	B-CHEM
Maintenance	O
This	O
study	O
examined	O
gambling	O
behavior	O
in	O
the	O
context	O
of	O
a	O
newly	O
opening	O
casino	B-OBJC
,	O
comparing	O
disordered	O
gamblers	O
to	O
non	O
-	O
disordered	O
gamblers	O
,	O
in	O
a	O
population	B-LIVB
of	O
individuals	B-LIVB
involved	O
in	O
methadone	B-PROC
maintenance	I-PROC
treatment	I-PROC
.	O

Disordered	O
gamblers	O
(	O
N	O
=	O
50	O
)	O
and	O
non	O
-	O
disordered	O
gamblers	O
(	O
N	O
=	O
50	O
)	O
were	O
surveyed	B-PROC
before	O
and	O
after	O
the	O
opening	O
of	O
a	O
new	O
casino	B-OBJC
on	O
gambling	O
behaviors	O
,	O
substance	B-DISO
use	I-DISO
,	O
and	O
psychological	B-DISO
symptoms	I-DISO
.	O

No	B-DISO
statistically	I-DISO
significant	I-DISO
changes	I-DISO
in	O
gambling	O
behaviors	O
were	O
observed	O
for	O
disordered	O
gamblers	O
or	O
non	O
-	O
disordered	O
gamblers	O
across	O
time	O
points	O
;	O
however	O
,	O
non	O
-	O
disordered	O
gamblers	O
demonstrated	O
non	B-DISO
-	I-DISO
significant	I-DISO
increases	I-DISO
in	O
horse	O
and	O
dog	O
race	O
betting	O
,	O
electronic	B-OBJC
games	I-OBJC
,	O
and	O
casino	B-OBJC
table	O
games	O
.	O

As	O
expected	O
,	O
disordered	O
gamblers	O
were	O
found	O
to	O
spend	B-DISO
significantly	I-DISO
more	I-DISO
money	I-DISO
on	O
electronic	B-OBJC
games	I-OBJC
and	O
casino	B-OBJC
table	O
games	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
demonstrated	O
higher	O
rates	O
of	O
drug	B-DISO
use	I-DISO
and	O
impulsivity	O
than	O
non	O
-	O
disordered	O
gamblers	O
.	O

The	O
introduction	O
of	O
a	O
new	O
casino	B-OBJC
did	O
not	O
appear	O
to	O
have	O
a	O
major	O
impact	O
on	O
gambling	O
behaviors	O
of	O
individuals	B-LIVB
attending	O
methadone	B-PROC
maintenance	I-PROC
treatment	I-PROC
,	O
though	O
the	O
non	B-DISO
-	I-DISO
significant	I-DISO
increases	I-DISO
in	O
gambling	O
among	O
non	O
-	O
disordered	O
gamblers	O
may	O
indicate	O
that	O
this	O
population	B-LIVB
is	O
preferentially	O
impacted	O
by	O
the	O
opening	O
of	O
a	O
new	O
casino	B-OBJC
.	O

Future	O
investigation	O
into	O
the	O
longer	B-PHEN
term	I-PHEN
effects	I-PHEN
of	O
opening	O
a	O
new	O
casino	B-OBJC
on	O
this	O
population	B-LIVB
may	O
be	O
warranted	O
.	O

Association	O
between	O
Leukoaraiosis	B-DISO
and	O
Poor	B-DISO
Outcome	I-DISO
is	O
not	O
due	O
to	O
Reperfusion	B-PHEN
Inefficiency	B-DISO
after	O
Intravenous	B-PROC
Thrombolysis	I-PROC
Leukoaraiosis	B-DISO
(	O
LA	B-DISO
)	O
is	O
associated	O
with	O
structural	B-DISO
and	O
functional	B-DISO
cerebrovascular	I-DISO
impairment	I-DISO
,	O
which	O
may	O
compromise	O
the	O
capacity	O
of	O
ischemic	O
tissue	O
to	O
maximize	O
reperfusion	B-PHEN
after	O
intravenous	B-PROC
thrombolysis	I-PROC
(	O
IVT	B-PROC
)	O
.	O

We	O
aimed	O
to	O
determine	O
whether	O
severe	O
LA	B-DISO
is	O
correlated	O
with	O
reperfusion	B-PHEN
inefficiency	B-DISO
,	O
which	O
contributes	O
to	O
infarct	B-PHEN
growth	I-PHEN
and	O
poor	B-DISO
functional	I-DISO
outcome	I-DISO
.	O

We	O
analyzed	O
data	O
from	O
our	O
consecutive	O
acute	B-DISO
ischemic	I-DISO
stroke	I-DISO
(	O
AIS	B-DISO
)	O
patients	B-LIVB
who	O
had	O
acquired	O
baseline	O
and	O
24	O
-	O
h	O
follow	B-PROC
-	I-PROC
up	I-PROC
diffusion	B-PROC
-	I-PROC
and	O
perfusion	B-PROC
-	I-PROC
weighted	I-PROC
imaging	I-PROC
.	O

Reperfusion	B-PHEN
was	O
defined	O
as	O
reduction	B-PROC
of	O
≥70	O
%	O
of	O
hypoperfusion	B-DISO
lesion	B-DISO
at	O
24	O
h	O
from	O
baseline	O
.	O

Severe	O
LA	B-DISO
was	O
defined	O
as	O
Fazekas	O
score	O
2	O
or	O
3	O
on	O
FLAIR	B-PROC
images	I-PROC
.	O

We	O
investigated	O
the	O
relationship	O
between	O
severity	O
of	O
LA	B-DISO
and	O
reperfusion	B-PHEN
status	O
.	O

Multivariate	O
statistical	B-PROC
analysis	I-PROC
was	O
carried	O
out	O
for	O
modeling	B-PROC
the	O
independent	O
predictors	O
of	O
reperfusion	B-PHEN
,	O
infarct	B-PHEN
growth	I-PHEN
,	O
and	O
functional	O
outcome	O
.	O

Finally	O
,	O
79	O
patients	B-LIVB
were	O
included	O
,	O
among	O
them	O
30	O
(	O
37	O
.	O
97	O
%	O
)	O
had	O
severe	O
LA	B-DISO
.	O

Reperfusion	B-PHEN
was	O
observed	O
in	O
41	O
(	O
51	O
.	O
89	O
%	O
)	O
patients	B-LIVB
,	O
the	O
proportion	O
of	O
reperfusion	B-PHEN
was	O
very	O
similar	O
in	O
patients	B-LIVB
with	O
and	O
without	O
severe	O
LA	B-DISO
(	O
53	O
.	O
33	O
vs	O
51	O
.	O

02	O
%	O
,	O
p	O
=	O
1	O
.	O
000	O
)	O
.	O

Large	O
artery	B-DISO
occlusion	I-DISO
was	O
the	O
only	O
independent	O
unfavorable	O
predictor	O
for	O
reperfusion	B-PHEN
(	O
OR	O
=	O
0	O
.	O
202	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
060	O
-	O
0	O
.	O
673	O
;	O
p	O
=	O
0	O
.	O

014	O
)	O
.	O

Multiple	O
linear	O
regression	O
analysis	O
revealed	O
that	O
severe	O
LA	B-DISO
was	O
independently	O
associated	O
with	O
infarct	B-PHEN
growth	I-PHEN
(	O
standardized	O
coefficients	O
=	O
0	O
.	O
191	O
,	O
p	O
=	O
0	O
.	O
040	O
)	O
.	O

Severe	O
LA	B-DISO
was	O
also	O
an	O
independent	O
predictor	O
of	O
poor	B-DISO
outcome	I-DISO
(	O
mRS	O
≥	O
3	O
)	O
(	O
OR	O
=	O
4	O
.	O

004	O
,	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
267	O
-	O
12	O
.	O

656	O
,	O
p	O
=	O
0	O
.	O

018	O
)	O
after	O
adjusting	O
for	O
reperfusion	B-PHEN
and	O
baseline	O
severity	O
of	O
stroke	B-DISO
.	O

Severe	O
LA	B-DISO
was	O
associated	O
with	O
infarct	B-PHEN
growth	I-PHEN
and	O
poor	B-DISO
outcome	I-DISO
independent	O
of	O
reperfusion	B-PHEN
status	O
,	O
which	O
may	O
expand	O
the	O
notion	O
that	O
LA	B-DISO
contributes	O
the	O
intrinsic	B-DISO
vulnerability	I-DISO
of	O
brain	B-ANAT
tissue	I-ANAT
to	O
acute	B-DISO
ischemic	I-DISO
insults	I-DISO
.	O

The	O
burden	O
of	O
LA	B-DISO
may	O
not	O
serve	O
as	O
an	O
imaging	O
indicator	O
of	O
reperfusion	B-PHEN
inefficiency	B-DISO
after	O
IVT	B-PROC
for	O
AIS	B-DISO
patients	B-LIVB
.	O

The	O
Experience	B-PHYS
of	O
Women	B-LIVB
Veterans	B-LIVB
Coming	O
Back	O
from	O
War	O
Issues	B-DISO
surrounding	I-DISO
mental	I-DISO
health	I-DISO
are	O
common	O
for	O
women	B-LIVB
veterans	B-LIVB
who	O
have	O
served	O
in	O
Iraq	B-GEOG
and	O
Afghanistan	B-GEOG
wars	O
.	O

The	O
goal	O
of	O
this	O
phenomenological	O
study	B-PROC
was	O
to	O
document	O
themes	O
in	O
the	O
stories	O
gathered	O
from	O
eight	O
women	B-LIVB
veterans	B-LIVB
who	O
had	O
come	O
back	O
from	O
war	O
.	O

Themes	O
in	O
the	O
stories	O
were	O
:	O
arriving	O
with	O
mixed	O
sentiments	O
;	O
evolving	O
to	O
a	O
changed	O
view	B-PHYS
of	I-PHYS
self	I-PHYS
;	O
permeating	B-DISO
aggravation	I-DISO
;	O
confounding	O
broken	O
relationships	O
,	O
frequent	B-DISO
deployments	I-DISO
,	O
and	O
change	B-DISO
in	I-DISO
military	I-DISO
status	I-DISO
;	O
remembering	B-PHYS
war	O
experiences	B-PHYS
;	O
and	O
seeking	B-DISO
opportunity	I-DISO
for	I-DISO
what	I-DISO
is	I-DISO
possible	I-DISO
.	O

Mental	B-DISO
health	I-DISO
issues	I-DISO
can	O
be	O
observed	O
in	O
the	O
themes	O
.	O

Including	O
story	O
as	O
part	O
of	O
the	O
mental	B-PHYS
health	I-PHYS
visit	O
with	O
veterans	B-LIVB
may	O
be	O
beneficial	O
to	O
veterans	B-LIVB
as	O
they	O
deal	O
with	O
the	O
transition	O
of	O
coming	O
back	O
.	O

A	O
novel	O
role	O
for	O
poly	B-CHEM
(	I-CHEM
C	I-CHEM
)	I-CHEM
binding	I-CHEM
proteins	I-CHEM
in	O
programmed	B-PHYS
ribosomal	I-PHYS
frameshifting	I-PHYS
Translational	B-PHYS
control	O
through	O
programmed	B-PHYS
ribosomal	I-PHYS
frameshifting	I-PHYS
(	O
PRF	B-PHYS
)	O
is	O
exploited	O
widely	O
by	O
viruses	B-LIVB
and	O
increasingly	O
documented	O
in	O
cellular	B-ANAT
genes	O
.	O

Frameshifting	B-PHYS
is	O
induced	O
by	O
mRNA	B-CHEM
secondary	I-CHEM
structures	I-CHEM
that	O
compromise	O
ribosome	B-ANAT
fidelity	B-PHYS
during	O
decoding	O
of	O
a	O
heptanucleotide	O
'	O
slippery	O
'	O
sequence	O
.	O

The	O
nsp2	B-CHEM
PRF	B-PHYS
signal	B-PHYS
of	O
porcine	B-LIVB
reproductive	I-LIVB
and	I-LIVB
respiratory	I-LIVB
syndrome	I-LIVB
virus	I-LIVB
is	O
distinctive	O
in	O
directing	O
both	O
-2	B-PHYS
and	O
-1	B-PHYS
PRF	I-PHYS
and	O
in	O
its	O
requirement	O
for	O
a	O
trans	B-CHEM
-	I-CHEM
acting	I-CHEM
protein	I-CHEM
factor	I-CHEM
,	O
the	O
viral	B-LIVB
replicase	B-CHEM
subunit	I-CHEM
nsp1β	I-CHEM
.	O

Here	O
we	O
show	O
that	O
the	O
the	O
trans	B-PHYS
-	I-PHYS
activation	I-PHYS
of	O
frameshifting	B-PHYS
is	O
carried	O
out	O
by	O
a	O
protein	B-CHEM
complex	I-CHEM
composed	O
of	O
nsp1β	B-CHEM
and	O
a	O
cellular	B-ANAT
poly	B-CHEM
(	I-CHEM
C	I-CHEM
)	I-CHEM
binding	I-CHEM
protein	I-CHEM
(	O
PCBP	B-CHEM
)	O
.	O

From	O
the	O
results	O
of	O
in	O
vitro	O
translation	B-PHYS
and	O
electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	B-CHEM
/	O
nsp1β	B-CHEM
complex	B-CHEM
binds	O
to	O
a	O
C	O
-	O
rich	O
sequence	O
downstream	O
of	O
the	O
slippery	O
sequence	O
and	O
here	O
mimics	O
the	O
activity	O
of	O
a	O
structured	O
mRNA	B-CHEM
stimulator	B-CHEM
of	O
PRF	B-PHYS
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	O
for	O
a	O
trans	B-CHEM
-	I-CHEM
acting	I-CHEM
cellular	I-CHEM
protein	I-CHEM
in	O
PRF	B-PHYS
.	O

The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	O
associated	O
with	O
poly	B-CHEM
(	I-CHEM
C	I-CHEM
)	I-CHEM
binding	I-CHEM
proteins	I-CHEM
and	O
prototypes	O
a	O
new	O
class	O
of	O
virus	B-LIVB
-	O
host	B-LIVB
interactions	O
.	O

RNA	B-CHEM
topoisomerase	I-CHEM
is	O
prevalent	O
in	O
all	O
domains	O
of	O
life	O
and	O
associates	O
with	O
polyribosomes	B-ANAT
in	O
animals	B-LIVB
DNA	B-CHEM
Topoisomerases	I-CHEM
are	O
essential	O
to	O
resolve	O
topological	O
problems	O
during	O
DNA	B-PHYS
metabolism	I-PHYS
in	O
all	O
species	O
.	O

However	O
,	O
the	O
prevalence	O
and	O
function	O
of	O
RNA	B-CHEM
topoisomerases	I-CHEM
remain	O
uncertain	O
.	O

Here	O
,	O
we	O
show	O
that	O
RNA	B-PHYS
topoisomerase	I-PHYS
activity	I-PHYS
is	O
prevalent	O
in	O
Type	B-CHEM
IA	I-CHEM
topoisomerases	I-CHEM
from	O
bacteria	B-LIVB
,	O
archaea	B-LIVB
,	O
and	O
eukarya	O
.	O

Moreover	O
,	O
this	O
activity	B-PHYS
always	O
requires	O
the	O
conserved	O
Type	O
IA	O
core	O
domains	O
and	O
the	O
same	O
catalytic	O
residue	O
used	O
in	O
DNA	B-PHYS
topoisomerase	I-PHYS
reaction	I-PHYS
;	O
however	O
,	O
it	O
does	O
not	O
absolutely	O
require	O
the	O
non	O
-	O
conserved	O
carboxyl	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
,	O
which	O
is	O
necessary	O
for	O
relaxation	B-PHYS
reactions	I-PHYS
of	O
supercoiled	B-CHEM
DNA	I-CHEM
.	O

The	O
RNA	B-PHYS
topoisomerase	I-PHYS
activity	I-PHYS
of	O
human	B-CHEM
Top3β	I-CHEM
differs	O
from	O
that	O
of	O
Escherichia	B-LIVB
coli	I-LIVB
topoisomerase	B-CHEM
I	I-CHEM
in	O
that	O
the	O
former	O
but	O
not	O
the	O
latter	O
requires	O
the	O
CTD	O
,	O
indicating	O
that	O
topoisomerases	B-CHEM
have	O
developed	O
distinct	O
mechanisms	O
during	O
evolution	O
to	O
catalyze	B-PHEN
RNA	B-CHEM
topoisomerase	I-CHEM
reactions	B-PHEN
.	O

Notably	O
,	O
Top3β	B-CHEM
proteins	I-CHEM
from	O
several	O
animals	B-LIVB
associate	O
with	O
polyribosomes	B-ANAT
,	O
which	O
are	O
units	O
of	O
mRNA	B-CHEM
translation	B-PHYS
,	O
whereas	O
the	O
Top3	O
homologs	O
from	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
and	O
yeast	B-LIVB
lack	O
the	O
association	O
.	O

The	O
Top3β	B-CHEM
-	O
polyribosome	B-ANAT
association	B-PHEN
requires	O
TDRD3	B-CHEM
,	O
which	O
directly	O
interacts	O
with	O
Top3β	B-CHEM
and	O
is	O
present	O
in	O
animals	B-LIVB
but	O
not	O
bacteria	B-LIVB
or	O
yeast	B-LIVB
.	O

We	O
propose	O
that	O
RNA	B-CHEM
topoisomerases	I-CHEM
arose	O
in	O
the	O
early	O
RNA	B-CHEM
world	O
,	O
and	O
that	O
they	O
are	O
retained	O
through	O
all	O
domains	O
of	O
DNA	B-CHEM
-based	O
life	O
,	O
where	O
they	O
mediate	O
mRNA	B-CHEM
translation	B-PHYS
as	O
part	O
of	O
polyribosomes	B-ANAT
in	O
animals	B-LIVB
.	O

First	O
Draft	O
Genome	O
Sequence	O
of	O
Staphylococcus	B-LIVB
condimenti	I-LIVB
F	I-LIVB
-	I-LIVB
2	I-LIVB
T	I-LIVB
This	O
report	O
describes	O
the	O
draft	O
genome	O
sequence	O
of	O
S	B-LIVB
.	I-LIVB

condimenti	I-LIVB
strain	I-LIVB
F	I-LIVB
-	I-LIVB
2	I-LIVB
(	I-LIVB
T	I-LIVB
)	I-LIVB
(	I-LIVB
DSM	I-LIVB
11674	I-LIVB
)	I-LIVB
,	O
a	O
potential	O
starter	B-PROC
culture	I-PROC
.	O

The	O
genome	O
assembly	O
comprised	O
2	O
,	O
616	O
,	O
174	O
bp	B-PHYS
with	O
34	O
.	O

6	O
%	O
GC	O
content	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
documentation	O
that	O
reports	O
the	O
whole	O
-	O
genome	O
sequence	O
of	O
S	B-LIVB
.	I-LIVB

condimenti	I-LIVB
.	O

Trajectories	O
of	O
Health	O
and	O
Behavioral	B-PROC
Health	I-PROC
Services	I-PROC
Use	O
among	O
Community	B-LIVB
Corrections	O
-Involved	O
Rural	B-DISO
Adults	B-LIVB
This	O
article	O
seeks	O
to	O
establish	O
time	O
-	O
based	O
trajectories	O
of	O
health	O
and	O
behavioral	B-PROC
health	I-PROC
services	I-PROC
utilization	O
for	O
community	O
corrections	O
-	O
involved	O
(	O
CCI	O
)	O
adults	B-LIVB
and	O
to	O
examine	O
demographic	O
and	O
clinical	O
correlates	O
associated	O
with	O
these	O
trajectories	O
.	O

To	O
accomplish	O
this	O
aim	O
,	O
the	O
authors	O
applied	O
a	O
latent	B-PROC
class	I-PROC
growth	I-PROC
analysis	I-PROC
(	O
LCGA	B-PROC
)	O
to	O
services	B-PROC
use	O
data	O
from	O
a	O
sample	O
of	O
rural	B-DISO
CCI	O
adults	B-LIVB
who	O
reported	O
their	O
medical	O
,	O
mental	B-PHYS
health	I-PHYS
,	O
and	O
substance	O
use	O
treatment	O
utilization	O
behavior	O
every	O
60	O
days	O
for	O
1	O
.	O

5	O
years	O
.	O

LCGA	B-PROC
established	O
1	O
.	O
5	O
-	O
year	O
trajectories	O
and	O
demographic	O
correlates	O
of	O
health	B-PROC
services	I-PROC
among	O
rural	B-DISO
CCI	O
adults	B-LIVB
.	O

For	O
medical	B-PROC
services	I-PROC
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
users	B-LIVB
,	O
13	O
%	O
;	O
stable	O
-	O
intermediate	O
users	B-LIVB
,	O
40	O
%	O
;	O
and	O
stable	O
-	O
high	O
users	B-LIVB
,	O
47	O
%	O
)	O
.	O

For	O
mental	B-PHYS
health	I-PHYS
and	O
substance	O
use	O
services	B-PROC
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
,	O
69	O
%	O
and	O
61	O
%	O
,	O
respectively	O
;	O
low	O
-	O
baseline	O
-	O
increase	O
,	O
10	O
%	O
and	O
12	O
%	O
,	O
respectively	O
;	O
high	O
-	O
baseline	O
decline	O
,	O
21	O
%	O
and	O
28	O
%	O
,	O
respectively	O
)	O
.	O

Employment	O
,	O
gender	B-PHYS
,	O
medication	B-DISO
usage	I-DISO
,	O
and	O
depression	B-DISO
severity	O
predicted	O
membership	O
across	O
all	O
services	B-PROC
.	O

Results	O
underscore	O
the	O
importance	O
of	O
social	B-LIVB
workers	I-LIVB
and	O
other	O
community	B-PROC
services	I-PROC
providers	B-LIVB
aligning	O
health	B-PROC
services	I-PROC
access	O
with	O
the	O
needs	O
of	O
the	O
CCI	O
population	O
,	O
and	O
highlight	O
CCI	O
adults	B-LIVB
as	O
being	O
at	O
risk	O
of	O
underservice	O
in	O
critical	O
prevention	B-PROC
and	O
intervention	B-PROC
domains	I-PROC
.	O

Data	O
set	O
of	O
interactomes	B-PHYS
and	O
metabolic	O
pathways	O
of	O
proteins	B-CHEM
differentially	O
expressed	B-PHYS
in	O
brains	B-ANAT
with	O
Alzheimer׳s	B-DISO
disease	I-DISO
Alzheimer׳s	B-DISO
disease	I-DISO
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	B-DISO
in	O
the	O
elderly	B-LIVB
and	O
its	O
frequency	O
is	O
on	O
the	O
rise	O
worldwide	B-LIVB
.	O

It	O
is	O
considered	O
the	O
result	O
of	O
complex	O
interactions	O
between	O
genetic	O
and	O
environmental	O
factors	O
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	B-CHEM
players	I-CHEM
for	O
the	O
understanding	O
of	O
this	O
disease	B-DISO
.	O

In	O
this	O
data	O
article	O
we	O
determined	O
the	O
protein	B-PHYS
expression	I-PHYS
profiles	O
of	O
whole	O
protein	B-CHEM
extracts	B-OBJC
from	O
cortex	B-ANAT
regions	I-ANAT
of	I-ANAT
brains	I-ANAT
from	O
patients	B-LIVB
with	O
Alzheimer׳s	B-DISO
disease	I-DISO
in	O
comparison	O
to	O
a	O
normal	B-ANAT
brain	I-ANAT
.	O

We	O
identified	O
721	O
iTRAQ	B-CHEM
-	I-CHEM
labeled	I-CHEM
polypeptides	B-CHEM
with	O
more	O
than	O
95	O
%	O
in	O
confidence	O
.	O

We	O
analyzed	B-PROC
all	O
proteins	B-CHEM
that	O
changed	O
in	O
their	O
expression	O
level	O
and	O
located	O
them	O
in	O
the	O
KEGG	O
metabolic	O
pathways	O
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	B-ANAT
complexes	I-ANAT
of	I-ANAT
the	I-ANAT
electron	I-ANAT
transport	I-ANAT
chain	I-ANAT
and	O
ATP	B-CHEM
synthase	I-CHEM
.	O

In	O
addition	O
,	O
we	O
analyzed	B-PROC
the	O
over	B-CHEM
-	I-CHEM
and	I-CHEM
sub	I-CHEM
-	I-CHEM
expressed	I-CHEM
polypeptides	I-CHEM
through	O
IPA	B-OBJC
software	I-OBJC
,	O
specifically	O
Core	O
I	O
and	O
Biomarkers	O
I	O
modules	O
.	O

Data	O
in	O
this	O
article	O
is	O
related	O
to	O
the	O
research	B-PROC
article	O
""""	O
Identification	O
of	O
proteins	B-CHEM
that	O
are	O
differentially	O
expressed	B-PHYS
in	O
brains	B-ANAT
with	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
using	O
iTRAQ	B-PROC
labeling	I-PROC
and	O
tandem	B-PROC
mass	I-PROC
spectrometry	I-PROC
""""	O
(	O
Minjarez	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O

Emergency	B-PROC
general	I-PROC
surgery	I-PROC
specific	O
frailty	O
index	O
:	O
A	O
validation	B-PROC
study	I-PROC
Assessment	B-PROC
of	O
operative	O
risk	O
in	O
geriatric	B-LIVB
patients	I-LIVB
undergoing	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
(	O
EGS	B-PROC
)	O
is	O
challenging	O
.	O

Frailty	B-DISO
is	O
an	O
established	O
measure	O
for	O
risk	B-PROC
assessment	I-PROC
in	O
surgical	O
cases	O
.	O

The	O
aim	O
of	O
our	O
study	B-PROC
was	O
to	O
validate	B-PROC
a	O
modified	O
15	O
variable	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
specific	I-PROC
frailty	I-PROC
index	I-PROC
(	O
EGSFI	B-PROC
)	O
.	O

We	O
prospectively	O
collected	O
geriatric	O
(	O
age	B-LIVB
>	I-LIVB
65	I-LIVB
)	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
patients	B-LIVB
for	O
1	O
-	O
year	O
.	O

Post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
were	O
collected	O
.	O

Frailty	O
Index	O
was	O
calculated	B-PROC
for	O
200	O
patients	B-LIVB
based	O
on	O
their	O
pre	O
-	O
admission	O
condition	O
using	O
50	O
-	O
variable	O
modified	O
Rockwood	O
Frailty	O
Index	O
(	O
FI	O
)	O
.	O

EGSFI	B-PROC
was	O
developed	O
based	O
on	O
the	O
regression	O
model	O
for	O
complications	B-DISO
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	O
.	O

ROC	O
curve	O
analysis	O
was	O
performed	O
to	O
determine	O
cutoff	O
for	O
frail	B-DISO
status	O
.	O

We	O
validated	B-PROC
our	O
results	O
using	O
60	O
patients	B-LIVB
for	O
predicting	O
complications	B-DISO
.	O

A	O
total	O
of	O
260	O
patients	B-LIVB
(	O
200	O
developing	O
,	O
60	O
Validation	B-PROC
)	O
were	O
enrolled	B-PROC
in	O
this	O
study	B-PROC
.	O

Mean	B-PHYS
age	I-PHYS
was	O
71	O
±	O
11	O
years	O
,	O
and	O
33	O
%	O
developed	O
complications	B-DISO
.	O

Most	O
common	O
complications	B-DISO
were	O
pneumonia	B-DISO
(	O
12	O
%	O
)	O
,	O
UTI	B-DISO
(	O
9	O
%	O
)	O
,	O
and	O
wound	B-DISO
infection	I-DISO
(	O
7	O
%	O
)	O
.	O

Univariate	B-PROC
analysis	I-PROC
identified	O
15	O
variables	O
significantly	O
associated	O
with	O
complications	B-DISO
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	B-PROC
.	O

A	O
cutoff	O
frailty	B-DISO
score	I-DISO
of	O
0	O
.	O

325	O
was	O
identified	O
using	O
ROC	O
curve	O
analysis	O
for	O
frail	B-DISO
status	O
.Sixty	O
-	O
patients	B-LIVB
(	O
frail	B-DISO
:	O
18	O
,	O
non	B-DISO
-	I-DISO
frail	I-DISO
:	O
42	O
)	O
were	O
enrolled	B-PROC
in	O
the	O
validation	B-PROC
cohort	B-LIVB
.	O

Frail	B-DISO
patients	B-LIVB
were	O
more	O
likely	O
to	O
have	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
(	O
47	O
%	O
vs	O
.	O

20	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
compared	O
to	O
nonfrail	B-LIVB
patients	I-LIVB
.	O

Frail	B-DISO
status	O
based	O
on	O
EGSFI	B-PROC
was	O
a	O
significant	O
predictor	O
of	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
(	O
OR	O
=	O
7	O
.	O

3	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
7	O
-	O
19	O
.	O
8	O
;	O
p	O
=	O
0	O
.	O

006	O
)	O
.	O

Age	B-PHYS
was	O
not	O
associated	O
with	O
postoperative	B-DISO
complications	I-DISO
(	O
OR	O
=	O
0	O
.	O

99	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
92	O
-1	O
.	O
06	O
;	O
p	O
=	O
0	O
.	O
86	O
)	O
.	O

The	O
15	O
-	O
variable	O
validated	B-PROC
EGSFI	B-PROC
is	O
a	O
simple	O
and	O
reliable	O
bedside	B-OBJC
tool	I-OBJC
to	O
determine	O
the	O
frailty	B-DISO
status	I-DISO
of	O
patients	B-LIVB
undergoing	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
.	O

Frail	B-DISO
status	O
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	B-PROC
is	O
an	O
independent	O
predictor	O
of	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
and	O
mortality	O
in	O
geriatric	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
patients	B-LIVB
.	O

Level	O
II	O
,	O
Prognostic	B-PROC
Studies	I-PROC
-	O
Investigating	O
the	O
Effect	O
of	O
a	O
Patient	B-PHYS
Characteristic	I-PHYS
on	O
the	O
Outcome	B-DISO
of	I-DISO
Disease	I-DISO
.	O

Comparative	O
Epidemiologic	O
Characteristics	O
of	O
Pertussis	B-DISO
in	O
10	O
Central	B-GEOG
and	O
Eastern	B-GEOG
European	I-GEOG
Countries	I-GEOG
,	O
2000	O
-	O
2013	O
We	O
undertook	O
an	O
epidemiological	B-PROC
survey	I-PROC
of	O
the	O
annual	O
incidence	O
of	O
pertussis	B-DISO
reported	B-PROC
from	O
2000	O
to	O
2013	O
in	O
ten	O
Central	B-GEOG
and	O
Eastern	B-GEOG
European	I-GEOG
countries	I-GEOG
to	O
ascertain	O
whether	O
increased	O
pertussis	B-DISO
reports	O
in	O
some	O
countries	B-GEOG
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	O
in	O
each	O
country	B-GEOG
.	O

The	O
annual	O
incidence	O
of	O
pertussis	B-DISO
in	O
the	O
participating	O
countries	B-GEOG
was	O
obtained	O
from	O
relevant	O
government	O
institutions	O
and	O
/	O
or	O
national	O
surveillance	O
systems	O
.	O

We	O
reviewed	O
the	O
changes	O
in	O
the	O
pertussis	B-DISO
incidence	O
rates	O
in	O
each	O
country	B-GEOG
to	O
explore	O
differences	O
and	O
/	O
or	O
similarities	O
between	O
countries	B-GEOG
in	O
relation	O
to	O
pertussis	B-DISO
surveillance	O
;	O
case	O
definitions	O
for	O
detection	B-DISO
and	O
confirmation	O
of	O
pertussis	B-DISO
;	O
incidence	O
and	O
number	O
of	O
cases	O
of	O
pertussis	B-DISO
by	O
year	O
,	O
overall	O
and	O
by	O
age	B-LIVB
group	I-LIVB
;	O
population	B-LIVB
by	O
year	O
,	O
overall	O
and	O
by	O
age	B-LIVB
group	I-LIVB
;	O
pertussis	B-DISO
immunization	B-PROC
schedule	I-PROC
and	O
coverage	O
,	O
and	O
switch	O
from	O
whole	B-CHEM
-	I-CHEM
cell	I-CHEM
pertussis	I-CHEM
vaccines	I-CHEM
(	O
wP	B-CHEM
)	O
to	O
acellular	B-CHEM
pertussis	I-CHEM
vaccines	I-CHEM
(	O
aP	B-CHEM
)	O
.	O

There	O
was	O
heterogeneity	O
in	O
the	O
reported	B-PROC
annual	O
incidence	O
rates	O
and	O
trends	O
observed	O
across	O
countries	B-GEOG
.	O

Reported	B-PROC
pertussis	B-DISO
incidence	O
rates	O
varied	O
considerably	O
,	O
ranging	O
from	O
0	O
.	O

01	O
to	O
96	O
per	O
100	O
,	O
000	O
population	B-LIVB
,	O
with	O
the	O
highest	O
rates	O
generally	O
reported	B-PROC
in	O
Estonia	B-GEOG
and	O
the	O
lowest	O
in	O
Hungary	B-GEOG
and	O
Serbia	B-GEOG
.	O

The	O
greatest	O
burden	O
appears	O
for	O
the	O
most	O
part	O
in	O
infants	B-LIVB
(	O
<	O
1	O
year	O
)	O
in	O
Bulgaria	B-GEOG
,	O
Hungary	B-GEOG
,	O
Latvia	B-GEOG
,	O
Romania	B-GEOG
,	O
and	O
Serbia	B-GEOG
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	B-GEOG
where	O
the	O
burden	O
may	O
have	O
shifted	O
to	O
older	B-LIVB
children	I-LIVB
,	O
though	O
surveillance	O
of	O
adults	B-LIVB
may	O
be	O
inappropriate	O
.	O

There	O
was	O
no	O
consistent	O
pattern	O
associated	O
with	O
the	O
switch	O
from	O
wP	B-CHEM
to	O
aP	B-CHEM
vaccines	I-CHEM
on	O
reported	B-PROC
pertussis	B-DISO
incidence	O
rates	O
.	O

The	O
heterogeneity	O
in	O
reported	B-PROC
data	O
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	O
including	O
surveillance	O
system	O
characteristics	O
or	O
capabilities	O
,	O
different	O
case	O
definitions	O
,	O
type	O
of	O
pertussis	B-DISO
confirmation	B-PROC
tests	I-PROC
used	O
,	O
public	O
awareness	B-DISO
of	O
the	O
disease	B-DISO
,	O
as	O
well	O
as	O
real	O
differences	O
in	O
the	O
magnitude	O
of	O
the	O
disease	B-DISO
,	O
or	O
a	O
combination	O
of	O
these	O
factors	O
.	O

Our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	B-DISO
detection	B-DISO
and	O
confirmation	O
in	O
surveillance	B-PROC
programs	I-PROC
across	O
Europe	B-GEOG
,	O
complemented	O
with	O
carefully	O
-	O
designed	O
seroprevalence	B-PROC
studies	I-PROC
using	O
the	O
same	O
protocols	O
and	O
methodologies	B-PROC
.	O

Efficacy	O
of	O
a	O
coaxial	O
system	O
with	O
a	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
for	O
navigation	O
of	O
the	O
Penumbra	B-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
in	O
tortuous	B-DISO
arteries	I-DISO
:	O
technique	O
and	O
case	O
experience	B-PHYS
OBJECTIVE	O
The	O
authors	B-LIVB
describe	O
a	O
method	O
by	O
which	O
they	O
easily	B-DISO
and	O
atraumatically	O
navigate	O
a	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
of	O
the	O
Penumbra	B-DEVI
system	I-DEVI
to	O
an	O
embolus	B-DISO
by	O
using	O
a	O
coaxial	O
system	O
with	O
a	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
in	O
patients	B-LIVB
with	O
tortuous	B-DISO
arteries	I-DISO
.	O

METHODS	O
A	O
retrospective	B-PROC
review	I-PROC
of	O
the	O
prospective	O
endovascular	B-ANAT
database	O
was	O
performed	O
to	O
identify	O
cases	O
in	O
which	O
a	O
coaxial	O
system	O
with	O
a	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
(	O
Scepter	B-DEVI
C	I-DEVI
,	O
MicroVention	B-DEVI
/	O
Terumo	B-DEVI
;	O
or	O
TransForm	B-DEVI
C	I-DEVI
,	O
Stryker	B-DEVI
Neurovascular	B-ANAT
)	O
and	O
a	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
of	O
the	O
Penumbra	B-DEVI
system	I-DEVI
(	O
Penumbra	O
,	O
Inc	O
.	O
)	O
was	O
used	O
.	O

The	O
authors	B-LIVB
achieved	O
a	O
stable	O
guiding	B-DEVI
sheath	O
position	O
and	O
delivered	O
the	O
coaxial	O
system	O
with	O
a	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
and	O
a	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
.	O

Then	O
,	O
the	O
balloon	B-DEVI
was	O
inflated	O
somewhat	O
when	O
the	O
distal	O
tip	O
of	O
the	O
balloon	B-DEVI
was	O
slightly	O
advanced	O
from	O
the	O
tip	O
of	O
the	O
reperfusion	B-PHEN
catheter	B-DEVI
,	O
and	O
together	O
the	O
coaxial	O
system	O
was	O
advanced	O
to	O
an	O
embolus	B-DISO
over	O
a	O
0	O
.	O
014	O
-	O
in	O
guidewire	B-OBJC
,	O
even	O
around	O
the	O
corner	O
.	O

When	O
the	O
distal	O
tip	O
of	O
the	O
balloon	B-DEVI
catheter	I-DEVI
reached	O
the	O
embolus	B-DISO
,	O
the	O
authors	B-LIVB
deflated	O
the	O
balloon	B-DEVI
and	O
navigated	O
the	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
to	O
the	O
embolus	B-DISO
.	O

Finally	O
,	O
the	O
aspiration	B-PROC
of	O
the	O
embolus	B-DISO
with	O
the	O
Penumbra	B-DEVI
MAX	B-DEVI
pump	I-DEVI
was	O
begun	O
.	O

RESULTS	O
Between	O
May	O
2014	O
and	O
September	O
2015	O
,	O
the	O
authors	B-LIVB
used	O
this	O
technique	O
in	O
17	O
cases	O
:	O
16	O
cases	O
of	O
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
(	O
including	O
5	O
cases	O
of	O
internal	B-DISO
carotid	I-DISO
artery	I-DISO
occlusion	I-DISO
)	O
and	O
1	O
case	O
of	O
basilar	B-DISO
artery	I-DISO
occlusion	I-DISO
(	O
age	B-PHYS
range	O
36	O
-	O
88	O
years	O
,	O
mean	O
age	B-PHYS
74	O
.	O

7	O
years	O
,	O
13	O
men	B-LIVB
)	O
.	O

For	O
the	O
reperfusion	B-PHEN
catheter	B-DEVI
of	O
the	O
Penumbra	B-DEVI
system	I-DEVI
,	O
the	O
5MAX	B-DEVI
ACE	I-DEVI
was	O
used	O
in	O
15	O
cases	O
,	O
and	O
the	O
5MAX	B-DEVI
was	O
used	O
in	O
2	O
cases	O
.	O

As	O
a	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
,	O
the	O
Scepter	B-DEVI
C	I-DEVI
was	O
used	O
in	O
16	O
cases	O
,	O
and	O
the	O
TransForm	B-DEVI
C	I-DEVI
was	O
used	O
in	O
1	O
case	O
.	O

The	O
technique	O
was	O
successful	O
in	O
16	O
cases	O
(	O
94	O
.	O
1	O
%	O
)	O
.	O

No	O
parent	B-LIVB
artery	B-DISO
dissections	I-DISO
were	O
noted	O
in	O
any	O
cases	O
.	O

Catheter	B-DEVI
-induced	O
vasospasm	B-DISO
was	O
noted	O
in	O
1	O
case	O
,	O
but	O
the	O
vasospasm	B-DISO
was	O
transient	O
.	O

CONCLUSIONS	O
A	O
coaxial	O
system	O
with	O
a	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
can	O
help	O
safely	O
and	O
easily	B-DISO
to	O
navigate	O
the	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
of	O
the	O
Penumbra	B-DEVI
system	I-DEVI
to	O
an	O
embolus	B-DISO
in	O
patients	B-LIVB
with	O
tortuous	B-DISO
arteries	I-DISO
.	O

Hepatic	B-ANAT
and	O
renal	B-ANAT
toxicological	O
evaluations	B-PROC
of	O
an	O
industrial	O
ovotoxic	B-CHEM
chemical	I-CHEM
,	O
4	B-CHEM
-	I-CHEM
vinylcyclohexene	I-CHEM
diepoxide	I-CHEM
,	O
in	O
both	O
sexes	B-PHYS
of	O
Wistar	B-LIVB
rats	I-LIVB
4	B-CHEM
-	I-CHEM
Vinylcyclohexene	I-CHEM
diepoxide	I-CHEM
(	O
VCD	B-CHEM
)	O
is	O
an	O
industrial	O
occupational	O
health	B-CHEM
hazard	I-CHEM
chemical	I-CHEM
because	O
it	O
induces	O
ovotoxicity	B-DISO
in	O
rodents	B-LIVB
.	O

The	O
current	O
study	B-PROC
investigated	O
the	O
impacts	O
of	O
VCD	B-CHEM
on	O
selected	O
hepatic	B-ANAT
and	O
renal	B-ANAT
markers	B-PHYS
of	O
oxidative	B-DISO
stress	I-DISO
and	O
inflammation	B-DISO
in	O
both	O
sexes	B-PHYS
of	O
Wistar	B-LIVB
rats	I-LIVB
.	O

Thus	O
,	O
male	B-PHYS
and	O
female	B-PHYS
rats	B-LIVB
were	O
randomly	O
distributed	O
into	O
four	O
groups	O
of	O
ten	O
rats	B-LIVB
per	O
group	O
,	O
and	O
dosed	O
orally	O
with	O
VCD	B-CHEM
for	O
28	O
days	O
.	O

The	O
control	B-LIVB
male	B-PHYS
and	O
female	B-PHYS
groups	O
of	O
rats	B-LIVB
received	O
corn	B-CHEM
oil	I-CHEM
only	O
,	O
while	O
each	O
of	O
the	O
three	O
remaining	O
groups	O
of	O
both	O
sexes	B-PHYS
of	O
rats	B-LIVB
received	O
VCD	B-CHEM
(	O
100	O
,	O
250	O
and	O
500	O
mg	O
/	O
kg	O
BW	O
)	O
respectively	O
.	O

Thereafter	O
,	O
biomarkers	B-PHYS
of	O
hepatic	B-DISO
and	O
renal	B-DISO
oxidative	I-DISO
damage	I-DISO
,	O
inflammation	B-DISO
and	O
immunohistochemical	B-PROC
expressions	I-PROC
of	O
iNOS	B-CHEM
,	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
caspase	B-CHEM
-	I-CHEM
9	I-CHEM
and	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
were	O
evaluated	B-PROC
.	O

The	O
results	O
revealed	O
that	O
VCD	B-CHEM
increased	O
markers	B-PHYS
of	O
liver	B-PHYS
and	O
kidney	B-PHYS
functions	I-PHYS
,	O
oxidative	B-DISO
damage	I-DISO
and	O
inflammation	B-DISO
,	O
and	O
disrupted	O
the	O
antioxidant	B-PHEN
homeostasis	I-PHEN
of	O
the	O
rats	B-LIVB
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Lastly	O
,	O
VCD	B-CHEM
enhanced	O
the	O
immunohistochemical	B-PROC
expressions	I-PROC
of	O
iNOS	B-CHEM
,	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
caspase	B-CHEM
-	I-CHEM
9	I-CHEM
and	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
in	O
the	O
liver	B-ANAT
of	O
the	O
rats	B-LIVB
.	O

Thus	O
,	O
our	O
data	O
imply	O
that	O
VCD	B-CHEM
induced	O
toxicity	B-DISO
in	O
the	O
liver	B-ANAT
and	O
kidney	B-ANAT
of	O
rats	B-LIVB
via	O
the	O
combined	O
impacts	O
of	O
oxidative	B-DISO
damage	I-DISO
and	O
inflammation	B-DISO
.	O

Combinatorial	B-CHEM
Library	I-CHEM
Screening	O
Coupled	O
to	O
Mass	B-PROC
Spectrometry	I-PROC
to	O
Identify	O
Valuable	O
Cyclic	B-CHEM
Peptides	I-CHEM
Combinatorial	B-CHEM
library	I-CHEM
screening	O
coupled	O
to	O
mass	B-PROC
spectrometry	I-PROC
(	I-PROC
MS	I-PROC
)	I-PROC
analysis	I-PROC
is	O
a	O
practical	O
approach	O
to	O
identify	O
useful	O
peptides	B-CHEM
.	O

Cyclic	B-CHEM
peptides	I-CHEM
can	O
have	O
high	O
biological	B-PHEN
activity	I-PHEN
,	O
selectivity	O
,	O
and	O
affinity	B-PHEN
for	O
target	O
proteins	B-CHEM
,	O
and	O
high	O
stability	O
against	O
proteolytic	B-PHYS
degradation	I-PHYS
.	O

Here	O
we	O
describe	O
two	O
strategies	O
to	O
prepare	O
combinatorial	B-CHEM
libraries	I-CHEM
suitable	O
for	O
MS	B-PROC
analysis	I-PROC
to	O
accelerate	O
the	O
discovery	B-PROC
of	O
cyclic	B-CHEM
peptide	I-CHEM
structures	O
.	O

Both	O
approaches	O
use	O
ChemMatrix	B-CHEM
resin	I-CHEM
and	O
the	O
linker	O
4	B-CHEM
-	I-CHEM
hydroxymethylbenzoic	I-CHEM
acid	I-CHEM
.	O

One	O
strategy	O
involves	O
the	O
synthesis	O
of	O
a	O
one	B-CHEM
-	I-CHEM
bead	I-CHEM
-	I-CHEM
two	I-CHEM
-	I-CHEM
peptides	I-CHEM
library	I-CHEM
in	O
which	O
each	O
bead	O
contains	O
both	O
the	O
cyclic	B-CHEM
peptide	I-CHEM
and	O
its	O
linear	O
counterpart	O
to	O
facilitate	O
MS	B-PROC
analysis	I-PROC
.	O

The	O
other	O
protocol	O
is	O
based	O
on	O
the	O
synthesis	O
of	O
a	O
cyclic	B-CHEM
depsipeptide	I-CHEM
library	I-CHEM
in	O
which	O
a	O
glycolamidic	B-CHEM
ester	I-CHEM
group	I-CHEM
is	O
incorporated	O
by	O
adding	O
glycolic	B-CHEM
acid	I-CHEM
.	O

After	O
library	B-CHEM
screening	O
,	O
the	O
ring	O
is	O
opened	O
and	O
the	O
peptide	B-CHEM
is	O
released	O
simultaneously	O
for	O
subsequent	O
MS	B-PROC
analysis	I-PROC
.	O

©	O
2016	O
by	O
John	O
Wiley	O
&	O
Sons	O
,	O
Inc	O
.	O

Women	B-LIVB
's	I-LIVB
Sexual	O
Issues	O
After	O
Myocardial	B-DISO
Infarction	I-DISO
:	O
A	O
Literature	O
Review	O
Sexual	O
activity	O
after	O
myocardial	B-DISO
infarction	I-DISO
(	O
MI	B-DISO
)	O
is	O
a	O
concern	O
for	O
patients	B-LIVB
and	O
often	O
a	O
challenge	O
for	O
health	B-LIVB
care	I-LIVB
professionals	I-LIVB
to	O
address	O
.	O

It	O
is	O
widely	O
recognized	O
that	O
most	O
patients	B-LIVB
,	O
of	O
both	O
sexes	B-PHYS
,	O
report	O
sexual	B-DISO
problems	I-DISO
or	O
concerns	O
after	O
MI	B-DISO
.	O

However	O
,	O
there	O
are	O
reported	O
differences	O
between	O
men	B-LIVB
and	O
women	B-LIVB
.	O

Women	B-LIVB
with	O
sexual	O
concerns	O
may	O
seek	O
less	O
help	O
from	O
health	B-LIVB
care	I-LIVB
providers	I-LIVB
and	O
are	O
more	O
inclined	O
to	O
conceal	O
them	O
because	O
of	O
cultural	B-DISO
barriers	I-DISO
.	O

The	O
aim	O
of	O
the	O
current	B-PROC
study	I-PROC
is	O
to	O
present	O
a	O
comprehensive	O
review	O
of	O
the	O
literature	O
describing	O
women	B-LIVB
's	I-LIVB
sexual	O
issues	O
after	O
MI	B-DISO
.	O

A	O
systematic	O
search	O
of	O
the	O
relevant	O
literature	O
was	O
performed	O
within	O
international	O
databases	O
,	O
including	O
PubMed	O
/	O
Medline	O
,	O
Scopus	O
,	O
ScienceDirect	O
,	O
and	O
ProQuest	O
,	O
as	O
well	O
as	O
Google	O
Scholar	O
using	O
relevant	O
keywords	O
.	O

Also	O
,	O
Persian	O
electronic	O
databases	O
such	O
as	O
Magiran	O
,	O
Scientific	O
Information	O
Databases	O
,	O
and	O
Iran	O
Medex	O
were	O
searched	O
from	O
the	O
inception	O
to	O
October	O
2014	O
.	O

Articles	O
focusing	O
on	O
the	O
sexual	O
issues	O
after	O
MI	B-DISO
only	O
in	O
women	B-LIVB
,	O
as	O
well	O
as	O
articles	O
on	O
both	O
sexes	B-PHYS
where	O
women	B-LIVB
's	I-LIVB
results	O
could	O
be	O
separated	O
,	O
were	O
included	O
in	O
this	O
review	B-PROC
.	O

A	O
total	O
of	O
8	O
articles	O
were	O
included	O
in	O
the	O
final	O
dataset	O
.	O

The	O
main	O
themes	O
of	O
women	B-LIVB
's	I-LIVB
sexual	O
concerns	O
after	O
MI	B-DISO
were	O
""""	O
loss	O
or	O
decrease	O
of	O
sexual	O
activity	O
,	O
""""	O
""""	O
dissatisfaction	B-DISO
of	I-DISO
sexual	I-DISO
relationship	I-DISO
,	O
""""	O
""""	O
doubt	B-PHYS
about	O
resumption	B-DISO
time	I-DISO
of	O
sexual	O
activity	O
,	O
""""	O
""""	O
fear	B-PHYS
of	O
reinfarction	B-DISO
or	O
sudden	B-DISO
death	I-DISO
during	O
sexual	O
activity	O
after	O
MI	B-DISO
,	O
""""	O
""""	O
knowledge	B-DISO
deficit	I-DISO
regarding	O
sexual	O
activity	O
after	O
MI	B-DISO
,	O
""""	O
and	O
""""	O
poor	O
performance	O
of	O
health	B-LIVB
care	I-LIVB
providers	I-LIVB
in	O
sexual	B-PROC
counseling	I-PROC
.	O
""""	O
The	O
results	O
of	O
this	O
review	B-PROC
demonstrate	O
that	O
women	B-LIVB
's	I-LIVB
post	O
-	O
MI	B-DISO
sexual	O
activity	O
is	O
affected	O
by	O
many	O
concerns	O
.	O

The	O
concerns	O
may	O
be	O
a	O
knowledge	B-DISO
deficit	I-DISO
related	O
to	O
not	O
receiving	O
necessary	O
consultation	B-PROC
on	O
this	O
topic	O
.	O

Nurses	B-LIVB
,	O
as	O
first	B-LIVB
-	I-LIVB
line	I-LIVB
care	I-LIVB
givers	I-LIVB
,	O
can	O
provide	O
appropriate	O
consultation	B-PROC
and	O
education	O
for	O
patients	B-LIVB
post	O
-	O
MI	B-DISO
.	O

As	O
a	O
result	O
,	O
breaking	O
taboo	O
imposed	O
by	O
cultural	B-DISO
barriers	I-DISO
,	O
personal	O
assumptions	O
,	O
or	O
lack	B-DISO
of	I-DISO
confidence	I-DISO
on	O
giving	O
sexual	B-PROC
consultation	I-PROC
may	O
ultimately	O
help	O
patients	B-LIVB
to	O
improve	O
their	O
quality	O
of	O
life	O
.	O

Effect	O
of	O
autohydrolysis	B-PHEN
on	O
the	O
wettability	O
,	O
absorbility	B-PHEN
and	O
further	O
alkali	B-CHEM
impregnation	B-PHEN
of	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
Autohydrolysis	B-PHEN
with	O
different	O
severity	O
factors	O
was	O
performed	O
on	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
prior	O
to	O
pulping	B-PHEN
,	O
and	O
the	O
wettability	O
,	O
absorbility	B-PHEN
and	O
the	O
following	O
impregnation	B-PHEN
of	O
NaOH	B-CHEM
solution	B-OBJC
for	O
the	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
were	O
then	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
after	O
autohydrolysis	B-PHEN
pretreatment	O
the	O
porosity	O
,	O
shrinkage	O
and	O
fiber	B-DISO
saturation	I-DISO
point	I-DISO
(	O
FSP	B-DISO
)	O
of	O
the	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
were	O
increased	O
,	O
while	O
the	O
surface	O
contact	O
angle	O
decreased	O
as	O
the	O
severity	O
factor	O
was	O
increased	O
.	O

The	O
autohydrolyzed	B-PHEN
chips	B-OBJC
absorbed	B-PHEN
more	O
NaOH	B-CHEM
in	O
impregnation	B-PHEN
that	O
resulted	O
in	O
a	O
low	O
NaOH	B-CHEM
concentration	O
in	O
the	O
bulk	O
impregnation	B-PHEN
liquor	B-OBJC
(	O
i	O
.	O

e	O
.	O
,	O
the	O
impregnation	B-PHEN
liquor	B-OBJC
outside	O
wood	B-OBJC
chips	I-OBJC
)	O
,	O
while	O
the	O
concentration	O
in	O
the	O
entrapped	B-DISO
liquor	B-OBJC
(	O
i	O
.	O

e	O
.	O
,	O
the	O
impregnation	B-PHEN
liquor	B-OBJC
inside	O
wood	B-OBJC
chips	I-OBJC
)	O
was	O
increased	O
.	O

Autohydrolysis	B-PHEN
substantially	O
improved	B-DISO
the	O
effectiveness	O
of	O
alkali	B-CHEM
impregnation	B-PHEN
.	O

Effect	O
of	O
Transcatheter	B-PROC
Arterial	I-PROC
Chemoembolization	I-PROC
Combined	O
with	O
Argon	B-PROC
-	I-PROC
Helium	I-PROC
Cryosurgery	I-PROC
System	I-PROC
on	O
the	O
Changes	O
of	O
NK	B-ANAT
Cells	I-ANAT
and	O
T	B-ANAT
Cell	I-ANAT
Subsets	I-ANAT
in	O
Peripheral	B-ANAT
Blood	I-ANAT
of	O
Hepatocellular	B-DISO
Carcinoma	I-DISO
Patients	B-LIVB
Hepatocellular	B-DISO
carcinoma	I-DISO
(	O
HCC	B-DISO
)	O
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	B-DISO
in	O
humans	B-LIVB
.	O

T	B-ANAT
lymphocytes	I-ANAT
and	O
natural	B-ANAT
killer	I-ANAT
(	O
NK	B-ANAT
)	O
cells	B-ANAT
are	O
the	O
body	B-LIVB
's	I-LIVB
first	O
line	O
of	O
defense	B-PHYS
to	O
prevent	O
tumor	B-ANAT
cell	I-ANAT
growth	B-PHYS
.	O

Previous	B-PROC
studies	I-PROC
have	O
demonstrated	O
that	O
transcatheter	B-PROC
arterial	I-PROC
chemoembolization	I-PROC
(	O
TACE	B-PROC
)	O
combined	O
with	O
argon	B-PROC
-	I-PROC
helium	I-PROC
cryosurgery	I-PROC
system	I-PROC
(	O
AHCS	B-PROC
)	O
can	O
effectively	O
treat	B-PROC
liver	B-DISO
cancer	I-DISO
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
treatment	B-PROC
is	O
unclear	B-DISO
yet	O
.	O

In	O
the	O
current	O
study	B-PROC
,	O
we	O
investigated	O
the	O
effects	O
of	O
TACE	B-PROC
combined	O
with	O
AHCS	B-PROC
on	O
the	O
changes	O
of	O
T	B-ANAT
cell	I-ANAT
subsets	I-ANAT
and	O
NK	B-ANAT
cells	I-ANAT
in	O
peripheral	B-ANAT
blood	I-ANAT
of	O
HCC	B-DISO
.	O

Our	O
data	O
show	O
that	O
alpha	B-CHEM
-	I-CHEM
fetoprotein	I-CHEM
(	O
AFP	B-CHEM
)	O
levels	O
in	O
peripheral	B-ANAT
blood	I-ANAT
were	O
significantly	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
in	O
HCC	B-DISO
patients	B-LIVB
before	O
treatment	B-PROC
when	O
compared	O
with	O
healthy	O
people	B-LIVB
and	O
reduced	O
after	O
TACE	B-PROC
combined	O
with	O
AHCS	B-PROC
treatment	B-PROC
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
CD4	B-ANAT
+	I-ANAT
cells	I-ANAT
and	O
NK	B-ANAT
cells	I-ANAT
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
CD8	B-ANAT
+	I-ANAT
cells	I-ANAT
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
HCC	B-DISO
patients	B-LIVB
when	O
compared	O
with	O
healthy	O
people	B-LIVB
.	O

After	O
treatment	B-PROC
,	O
the	O
CD4	B-ANAT
+	I-ANAT
cells	I-ANAT
,	O
CD4	B-ANAT
+	I-ANAT
/	O
CD8	B-ANAT
+	I-ANAT
ratio	O
,	O
and	O
NK	B-ANAT
cells	I-ANAT
were	O
dramatically	O
increased	O
in	O
HCC	B-DISO
patients	B-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
contrast	O
,	O
CD8	B-ANAT
+	I-ANAT
cells	I-ANAT
were	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

TACE	B-PROC
combined	O
with	O
AHCS	B-PROC
treatment	B-PROC
significantly	O
prolonged	O
1	O
-	O
year	O
survival	O
rate	O
of	O
HCC	B-DISO
patients	B-LIVB
and	O
did	O
not	O
show	O
significant	O
side	B-DISO
effects	I-DISO
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
TACE	B-PROC
combined	O
with	O
AHCS	B-PROC
treatment	B-PROC
improves	B-DISO
patients	B-LIVB
'	O
immune	B-ANAT
system	I-ANAT
.	O

It	O
is	O
a	O
feasible	O
and	O
effective	O
therapeutic	B-PROC
method	I-PROC
for	O
HCC	B-DISO
patients	B-LIVB
.	O

Identification	O
and	O
characterization	O
of	O
Dichelobacter	B-LIVB
nodosus	I-LIVB
serogroup	O
H	O
from	O
ovine	B-LIVB
footrot	B-DISO
in	O
India	B-GEOG
A	O
total	O
of	O
56	O
foot	B-OBJC
swabs	I-OBJC
were	O
collected	O
from	O
inter	B-ANAT
digital	I-ANAT
spaces	I-ANAT
of	O
sheep	B-LIVB
with	O
footrot	B-DISO
lesions	B-DISO
were	O
screened	B-PROC
for	O
16	O
rRNA	B-CHEM
of	O
Dichelobacter	B-LIVB
nodosus	I-LIVB
by	O
PCR	B-PROC
.	O

Out	O
of	O
the	O
56	O
samples	O
,	O
38	O
(	O
67	O
.	O

85	O
%	O
)	O
were	O
found	O
to	O
be	O
positive	B-DISO
.	O

All	O
the	O
positive	B-DISO
samples	O
were	O
subjected	O
to	O
multiplex	B-PROC
PCR	I-PROC
targeting	B-PROC
fimA	I-PROC
gene	I-PROC
for	O
identification	O
of	O
serogroups	O
of	O
D	B-LIVB
.	I-LIVB

nodosus	I-LIVB
.	O

Serogroup	O
H	O
was	O
found	O
along	O
with	O
serogroup	O
B	O
in	O
12	O
(	O
55	O
.	O
26	O
%	O
)	O
samples	O
and	O
with	O
serogroup	O
I	O
in	O
8	O
(	O
22	O
.	O

2	O
%	O
)	O
samples	O
.	O

The	O
serogroup	O
H	O
was	O
identified	O
for	O
the	O
first	O
time	O
from	O
the	O
Indian	B-GEOG
subcontinent	I-GEOG
.	O

The	O
phylogenetic	B-PROC
analysis	I-PROC
of	O
the	O
present	O
sequence	O
with	O
the	O
available	O
serogroup	O
H	O
sequences	O
of	O
GenBank	O
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	O
H1	O
.	O

Production	O
of	O
bioactive	B-OBJC
conjugated	B-CHEM
linoleic	I-CHEM
acid	I-CHEM
by	O
the	O
multifunctional	B-CHEM
enolase	B-CHEM
from	O
Lactobacillus	B-LIVB
plantarum	I-LIVB
Lactobacillus	B-LIVB
plantarum	I-LIVB
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
,	O
a	O
multifunctional	B-CHEM
-anchorless	O
-	O
surface	B-CHEM
protein	I-CHEM
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	B-CHEM
with	O
a	O
central	O
role	O
in	O
glycolytic	B-PHYS
metabolism	B-PHYS
,	O
was	O
characterized	O
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	B-PHYS
metabolism	I-PHYS
of	O
biohydrogenation	B-PHEN
of	O
linoleic	B-CHEM
acid	I-CHEM
,	O
catalyzing	B-PHEN
the	O
formation	O
of	O
bioactive	B-OBJC
9	B-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
11	I-CHEM
-	I-CHEM
trans	I-CHEM
-	I-CHEM
CLA	I-CHEM
through	O
dehydration	B-PHEN
and	O
isomerization	B-PHYS
of	O
10	B-CHEM
-	I-CHEM
hydroxy	I-CHEM
-	I-CHEM
12	I-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
octadecenoic	I-CHEM
acid	I-CHEM
.	O

The	O
identity	O
of	O
the	O
enolase	B-CHEM
was	O
confirmed	O
through	O
mass	B-PROC
spectrometric	I-PROC
analysis	I-PROC
that	O
showed	O
the	O
characteristic	O
442	O
amino	O
acid	O
sequence	O
with	O
a	O
molecular	O
mass	O
of	O
48	O
.	O

03	O
kDa	O
.	O

The	O
enolase	B-CHEM
was	O
not	O
capable	O
of	O
using	O
linoleic	B-CHEM
acid	I-CHEM
directly	O
as	O
a	O
substrate	B-OBJC
but	O
instead	O
uses	O
its	O
hydroxyl	B-CHEM
derivative	O
10	B-CHEM
-	I-CHEM
hydroxi	I-CHEM
-	I-CHEM
12	I-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
octadecenoic	I-CHEM
acid	I-CHEM
to	O
finally	O
form	O
bioactive	B-OBJC
conjugated	B-CHEM
linoleic	I-CHEM
acid	I-CHEM
.	O

Biochemical	O
optimization	O
studies	B-PROC
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9	B-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
11	I-CHEM
-	I-CHEM
trans	I-CHEM
-	I-CHEM
CLA	I-CHEM
and	O
maximum	O
stability	B-PHYS
of	O
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
when	O
catalyzing	B-PHEN
this	O
reaction	B-PHEN
.	O

Furthermore	O
,	O
through	O
structural	B-PROC
analysis	I-PROC
of	O
the	O
protein	B-CHEM
,	O
we	O
propose	O
the	O
binding	B-CHEM
sites	I-CHEM
of	O
substrate	B-OBJC
and	O
product	B-OBJC
molecules	B-OBJC
that	O
were	O
characterized	O
as	O
two	O
hydrophobic	O
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	B-CHEM
connected	O
through	O
a	O
channel	B-CHEM
where	O
the	O
catalysis	B-PHEN
of	O
dehydration	B-PHEN
and	O
isomerization	B-PHYS
might	O
occur	O
.	O

These	O
results	O
prove	O
that	O
multifunctional	B-CHEM
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
also	O
plays	O
a	O
role	O
in	O
cell	B-PHYS
detoxification	I-PHYS
from	O
polyunsaturated	B-CHEM
fatty	I-CHEM
acids	I-CHEM
such	O
as	O
linoleic	B-CHEM
acid	I-CHEM
,	O
along	O
with	O
the	O
linoleate	B-CHEM
isomerase	I-CHEM
complex	B-CHEM
.	O

The	O
""""	O
tight	O
orbit	O
""""	O
:	O
Incidence	O
and	O
management	B-PROC
of	O
the	O
orbital	B-DISO
compartment	I-DISO
syndrome	I-DISO
The	O
orbital	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O
OCS	B-DISO
)	O
constitutes	O
a	O
severe	O
emergency	B-PHEN
,	O
requiring	O
immediate	O
clinical	B-PROC
diagnosis	I-PROC
and	O
surgical	B-PROC
decompression	I-PROC
.	O

The	O
key	O
symptom	B-DISO
is	O
progressive	B-DISO
visual	I-DISO
impairment	I-DISO
caused	O
by	O
an	O
increase	O
in	O
intraorbital	B-PHYS
pressure	I-PHYS
,	O
impairing	O
the	O
perfusion	B-PROC
of	O
relevant	O
neurovascular	B-ANAT
and	O
neurosensory	B-ANAT
structures	I-ANAT
.	O

Intraorbital	B-DISO
bleeding	I-DISO
due	O
to	O
trauma	B-DISO
and	O
surgical	B-DISO
intervention	I-DISO
is	O
known	O
to	O
be	O
the	O
main	O
etiological	O
factor	O
.	O

A	O
retrospective	O
analysis	B-PROC
of	O
all	O
patients	B-LIVB
affected	O
by	O
an	O
OCS	B-DISO
between	O
January	O
1	O
,	O
2012	O
,	O
and	O
May	O
31	O
,	O
2015	O
,	O
was	O
performed	O
.	O

Patients	B-LIVB
'	I-LIVB
records	O
were	O
reviewed	O
with	O
regard	O
to	O
etiology	O
,	O
initial	O
ophthalmologic	O
status	O
,	O
fracture	B-DISO
pattern	I-DISO
,	O
concomitant	O
medication	O
,	O
surgical	B-PROC
management	I-PROC
,	O
and	O
postoperative	O
outcome	O
.	O

The	O
incidence	O
of	O
OCS	B-DISO
was	O
calculated	O
based	O
on	O
the	O
total	O
number	O
of	O
craniomaxillofacial	B-ANAT
(	O
CMF	B-ANAT
)	O
emergencies	B-DISO
.	O

Within	O
3	O
.	O
5	O
years	O
,	O
a	O
total	O
of	O
18	O
,	O
093	O
CMF	B-ANAT
emergencies	B-DISO
were	O
registered	B-PROC
.	O

In	O
16	O
patients	B-LIVB
,	O
an	O
OCS	B-DISO
was	O
documented	B-PROC
,	O
corresponding	O
to	O
an	O
incidence	O
of	O
0	O
.	O

088	O
%	O
.	O

The	O
mean	O
patient	B-LIVB
age	B-PHYS
was	O
67	O
.	O

31	O
±	O
23	O
.	O

86	O
years	O
,	O
ranging	O
from	O
22	O
to	O
102	O
years	O
.	O

The	O
etiology	O
varied	O
,	O
but	O
trauma	B-DISO
with	O
subsequent	O
intraorbital	B-DISO
bleeding	I-DISO
was	O
the	O
main	O
cause	B-DISO
.	O

The	O
use	O
of	O
anticoagulative	B-PROC
medication	I-PROC
was	O
documented	B-PROC
in	O
50	O
%	O
of	O
the	O
cases	O
.	O

In	O
14	O
patients	B-LIVB
,	O
immediate	O
surgical	B-PROC
orbital	I-PROC
decompression	I-PROC
was	O
performed	O
:	O
in	O
10	O
patients	B-LIVB
,	O
vision	B-PHYS
could	O
be	O
preserved	B-PROC
;	O
in	O
three	O
patients	B-LIVB
,	O
blindness	B-DISO
resulted	O
;	O
and	O
one	O
patient	B-LIVB
was	O
lost	O
to	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Two	O
patients	B-LIVB
were	O
managed	O
without	O
surgery	B-PROC
.	O

With	O
regard	O
to	O
the	O
total	O
number	O
of	O
CMF	B-ANAT
emergencies	B-DISO
,	O
OCS	B-DISO
is	O
a	O
rare	O
condition	O
.	O

Early	O
clinical	B-PROC
diagnosis	I-PROC
and	O
surgical	B-PROC
decompression	I-PROC
are	O
required	O
to	O
prevent	O
permanent	O
vision	B-DISO
impairment	I-DISO
.	O

Anticoagulative	B-PROC
medication	I-PROC
must	O
be	O
considered	O
as	O
a	O
predisposing	O
factor	O
for	O
an	O
orbital	B-DISO
compartment	I-DISO
syndrome	I-DISO
in	O
patients	B-LIVB
affected	O
by	O
periorbital	O
trauma	O
.	O

Ammonia	B-CHEM
as	O
an	O
In	O
Situ	O
Sanitizer	B-DEVI
:	O
Influence	O
of	O
Virus	B-LIVB
Genome	O
Type	O
on	O
Inactivation	O
Treatment	O
of	O
human	B-LIVB
excreta	B-ANAT
and	O
animal	B-LIVB
manure	B-OBJC
(	O
HEAM	B-ANAT
)	O
is	O
key	O
in	O
controlling	B-PHEN
the	O
spread	O
of	O
persistent	O
enteric	O
pathogens	B-LIVB
,	O
such	O
as	O
viruses	B-LIVB
.	O

The	O
extent	O
of	O
virus	B-PROC
inactivation	I-PROC
during	O
HEAM	B-ANAT
storage	O
and	O
treatment	O
appears	O
to	O
vary	O
with	O
virus	B-LIVB
genome	O
type	O
,	O
although	O
the	O
reasons	O
for	O
this	O
variability	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
inactivation	O
of	O
viruses	B-LIVB
of	O
different	O
genome	O
types	O
under	O
conditions	O
representative	O
of	O
HEAM	B-ANAT
storage	O
or	O
mesophilic	O
digestion	B-PHYS
.	O

The	O
goals	O
were	O
to	O
characterize	O
the	O
influence	O
of	O
HEAM	B-ANAT
solution	O
conditions	O
on	O
inactivation	O
and	O
to	O
determine	O
the	O
potential	O
mechanisms	O
involved	O
.	O

Specifically	O
,	O
eight	O
viruses	B-LIVB
representing	O
the	O
four	O
viral	O
genome	O
types	O
(	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
[	O
ssRNA	B-CHEM
]	O
,	O
double	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
[	O
dsRNA	B-CHEM
]	O
,	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
DNA	I-CHEM
[	O
ssDNA	B-CHEM
]	O
,	O
and	O
double	B-CHEM
-	I-CHEM
stranded	I-CHEM
DNA	I-CHEM
[	O
dsDNA	B-CHEM
]	O
)	O
were	O
exposed	O
to	O
synthetic	B-OBJC
solutions	I-OBJC
with	O
well	O
-	O
controlled	O
temperature	O
(	O
20	O
to	O
35°C	O
)	O
,	O
pH	O
(	O
8	O
to	O
9	O
)	O
,	O
and	O
ammonia	B-CHEM
(	O
NH3	B-CHEM
)	O
concentrations	O
(	O
0	O
to	O
40	O
mmol	O
liter	O
(	O
-	O
1	O
)	O
)	O
.	O

DNA	B-CHEM
and	O
dsRNA	B-CHEM
viruses	B-LIVB
were	O
considerably	O
more	O
resistant	O
than	O
ssRNA	B-LIVB
viruses	I-LIVB
,	O
resulting	O
in	O
up	O
to	O
1	O
,	O
000	O
-	O
fold	O
-	O
longer	O
treatment	O
times	O
to	O
reach	O
a	O
4	O
-	O
log	O
inactivation	O
.	O

The	O
apparently	O
slower	O
inactivation	O
of	O
DNA	B-LIVB
viruses	I-LIVB
was	O
rationalized	O
by	O
the	O
higher	O
stability	B-PROC
of	O
DNA	B-CHEM
than	O
that	O
of	O
ssRNA	B-CHEM
in	O
HEAM	B-ANAT
.	O

Pushing	O
the	O
system	O
toward	O
harsher	B-DISO
pH	O
(	O
>	O
9	O
)	O
and	O
temperature	O
(	O
>	O
35°C	O
)	O
conditions	O
,	O
such	O
as	O
those	O
encountered	O
in	O
thermophilic	B-PHEN
digestion	B-PHYS
and	O
alkaline	O
treatments	O
,	O
led	O
to	O
more	O
consistent	O
inactivation	O
kinetics	B-PHEN
among	O
ssRNA	B-CHEM
and	O
other	O
viruses	B-LIVB
.	O

This	O
suggests	O
that	O
the	O
dependence	O
of	O
inactivation	O
on	O
genome	O
type	O
disappeared	O
in	O
favor	O
of	O
protein	B-CHEM
-mediated	O
inactivation	O
mechanisms	O
common	O
to	O
all	O
viruses	B-LIVB
.	O

Finally	O
,	O
we	O
recommend	O
the	O
use	O
of	O
MS2	B-LIVB
as	O
a	O
conservative	O
indicator	O
to	O
assess	O
the	O
inactivation	O
of	O
ssRNA	B-LIVB
viruses	I-LIVB
and	O
the	O
stable	O
ΦX174	B-LIVB
or	O
dsDNA	B-CHEM
phages	B-LIVB
as	O
indicators	O
for	O
persistent	O
viruses	B-LIVB
.	O

Viruses	B-LIVB
are	O
among	O
the	O
most	O
environmentally	O
persistent	O
pathogens	B-LIVB
.	O

They	O
can	O
be	O
present	B-DISO
in	O
high	O
concentrations	O
in	O
human	B-LIVB
excreta	B-ANAT
and	O
animal	B-LIVB
manure	B-OBJC
(	O
HEAM	B-ANAT
)	O
.	O

Therefore	O
,	O
appropriate	O
treatment	O
of	O
HEAM	B-ANAT
is	O
important	O
prior	O
to	O
its	O
reuse	O
or	O
discharge	B-ANAT
into	O
the	O
environment	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
factors	O
that	O
determine	O
the	O
persistence	O
of	O
viruses	B-LIVB
in	O
HEAM	B-ANAT
,	O
and	O
we	O
determined	O
the	O
main	O
mechanisms	O
that	O
lead	O
to	O
their	O
inactivation	O
.	O

Unlike	O
other	O
organisms	B-LIVB
,	O
viruses	B-LIVB
can	O
have	O
four	O
different	O
genome	O
types	O
(	O
double	O
-	O
or	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
or	O
DNA	B-CHEM
)	O
,	O
and	O
the	O
viruses	B-LIVB
studied	O
herein	O
represent	O
all	O
four	O
types	O
.	O

Genome	O
type	O
appeared	O
to	O
be	O
the	O
major	O
determinant	O
for	O
persistence	O
.	O

Single	B-LIVB
-	I-LIVB
stranded	I-LIVB
RNA	I-LIVB
viruses	I-LIVB
are	O
the	O
most	O
labile	O
,	O
because	O
this	O
genome	O
type	O
is	O
susceptible	O
to	O
degradation	O
in	O
HEAM	B-ANAT
.	O

In	O
contrast	O
,	O
the	O
other	O
genome	O
types	O
are	O
more	O
stable	O
;	O
therefore	O
,	O
inactivation	O
is	O
slower	O
and	O
mainly	O
driven	O
by	O
the	O
degradation	O
of	O
viral	B-CHEM
proteins	I-CHEM
.	O

Overall	O
,	O
this	O
study	O
allows	O
us	O
to	O
better	O
understand	O
the	O
behavior	O
of	O
viruses	B-LIVB
in	O
HEAM	B-ANAT
.	O

An	O
electrochemical	B-PROC
genosensor	B-DEVI
for	O
Leishmania	O
major	O
detection	B-PROC
based	O
on	O
dual	O
effect	O
of	O
immobilization	B-PROC
and	O
electrocatalysis	B-PHEN
of	O
cobalt	B-CHEM
-	I-CHEM
zinc	I-CHEM
ferrite	I-CHEM
quantum	B-OBJC
dots	I-OBJC
Identification	O
of	O
Leishmania	O
parasites	O
is	O
important	O
in	O
diagnosis	B-DISO
and	O
clinical	B-PROC
studies	I-PROC
of	O
leishmaniasis	B-DISO
.	O

Although	O
epidemiological	B-PROC
and	O
clinical	O
methods	O
are	O
available	O
,	O
they	O
are	O
not	O
sufficient	O
for	O
identification	O
of	O
causative	B-DISO
agents	I-DISO
of	O
leishmaniasis	B-DISO
.	O

In	O
the	O
present	O
study	B-PROC
,	O
quantum	B-OBJC
dots	I-OBJC
of	O
magnetic	B-PHEN
cobalt	B-CHEM
-	I-CHEM
zinc	I-CHEM
ferrite	I-CHEM
(	O
Co0	B-CHEM
.	I-CHEM

5Zn0	I-CHEM
.	I-CHEM

5Fe2O4	I-CHEM
)	O
were	O
synthesized	O
and	O
characterized	O
by	O
physicochemical	B-PHEN
methods	I-PHEN
.	O

The	O
quantum	B-OBJC
dots	I-OBJC
were	O
then	O
employed	O
as	O
an	O
electrode	B-DEVI
modifier	B-DEVI
to	O
immobilize	O
a	O
24	O
-	O
mer	O
specific	O
single	B-CHEM
stranded	I-CHEM
DNA	B-CHEM
probe	I-CHEM
,	O
and	O
fabrication	O
of	O
a	O
label	O
-	O
free	O
,	O
PCR	O
-	O
free	O
and	O
signal	O
-	O
on	O
electrochemical	B-PROC
genosensor	B-DEVI
for	O
the	O
detection	B-PROC
of	O
Leishmania	O
major	O
.	O

Hybridization	B-PROC
of	O
the	O
complementary	B-CHEM
single	B-CHEM
stranded	I-CHEM
DNA	O
sequence	O
with	O
the	O
probe	B-CHEM
under	O
the	O
selected	O
conditions	O
was	O
explored	O
using	O
methylene	B-CHEM
blue	I-CHEM
as	O
a	O
redox	B-PHYS
marker	I-PHYS
,	O
utilizing	O
the	O
electrocatalytic	B-PHEN
effect	O
of	O
the	O
quantum	B-OBJC
dots	I-OBJC
on	O
the	O
methylene	B-CHEM
blue	I-CHEM
electroreduction	B-PHEN
process	B-PHEN
.	O

The	O
genosensor	B-DEVI
could	O
detect	B-PROC
a	O
synthetic	B-CHEM
single	I-CHEM
stranded	I-CHEM
DNA	I-CHEM
target	I-CHEM
in	O
a	O
range	O
of	O
1	O
.	O

0×10	O
(	O
-	O
11	O
)	O
to	O
1	O
.	O

0×10	O
(	O
-	O
18	O
)	O
molL	O
(	O
-	O
1	O
)	O
with	O
a	O
limit	O
of	O
detection	O
of	O
2	O
.	O

0×10	O
(	O
-	O
19	O
)	O
molL	O
(	O
-	O
1	O
)	O
,	O
and	O
genomic	B-CHEM
DNA	I-CHEM
in	O
a	O
range	O
of	O
7	O
.	O

31×10	O
(	O
-	O
14	O
)	O
to	O
7	O
.	O

31×10	O
(	O
-	O
6	O
)	O
ngμL	O
(	O
-	O
1	O
)	O
with	O
a	O
limit	O
of	O
detection	O
of	O
1	O
.	O

80×10	O
(	O
-	O
14	O
)	O
ngμL	O
(	O
-	O
1	O
)	O
with	O
a	O
high	O
selectivity	O
and	O
sensitivity	O
.	O

Associations	O
of	O
Body	B-PHYS
Mass	I-PHYS
Index	I-PHYS
and	O
Physical	O
Activity	O
With	O
Sexual	B-DISO
Dysfunction	I-DISO
in	O
Breast	B-DISO
Cancer	I-DISO
Survivors	B-LIVB
Sexual	B-DISO
dysfunction	I-DISO
is	O
a	O
common	O
and	O
distressing	B-DISO
consequence	O
of	O
breast	B-DISO
cancer	I-DISO
(	O
BC	B-DISO
)	O
treatment	B-PROC
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
investigated	O
the	O
sexual	B-PHYS
functioning	I-PHYS
of	O
BC	B-DISO
patients	B-LIVB
and	O
its	O
association	B-PHYS
with	O
women	B-LIVB
's	I-LIVB
personal	B-PHYS
characteristics	O
and	O
cancer	B-PROC
treatments	I-PROC
.	O

In	O
this	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
,	O
sexual	B-PHYS
function	I-PHYS
was	O
assessed	O
using	O
the	O
Female	O
Sexual	O
Function	O
Index	O
(	O
FSFI	O
)	O
.	O

The	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
was	O
measured	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
QLQ	O
-	O
C30	O
and	O
its	O
breast	O
module	O
BR	O
-	O
23	O
.	O

Of	O
the	O
235	O
participants	B-LIVB
approached	O
,	O
216	O
participants	B-LIVB
were	O
included	O
in	O
the	O
study	O
.	O

Of	O
these	O
,	O
63	O
patients	B-LIVB
reported	O
no	B-DISO
sexual	I-DISO
activity	I-DISO
in	O
the	O
last	O
month	O
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual	B-PHYS
desire	I-PHYS
domain	O
of	O
FSFI	O
.	O

A	O
total	O
of	O
154	O
(	O
71	O
.	O
3	O
%	O
)	O
patients	B-LIVB
were	O
classified	O
with	O
hypoactive	B-DISO
sexual	I-DISO
desire	I-DISO
disorder	I-DISO
(	O
HSDD	B-DISO
)	O
.	O

From	O
those	O
patients	B-LIVB
reporting	O
sexual	O
activity	O
in	O
the	O
last	O
month	O
,	O
63	O
.	O
3	O
%	O
(	O
97	O
out	O
of	O
153	O
)	O
were	O
classified	O
with	O
sexual	B-DISO
dysfunction	I-DISO
.	O

Using	O
hierarchical	B-PROC
logistic	I-PROC
regression	I-PROC
,	O
the	O
variance	O
explained	O
(	O
change	O
in	O
R	O
(	O
2	O
)	O
)	O
by	O
the	O
addition	O
of	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O
BMI	B-PHYS
)	O
and	O
mild	O
to	O
moderate	O
physical	O
activity	O
in	O
the	O
prediction	O
models	O
of	O
sexual	B-DISO
dysfunction	I-DISO
and	O
HSDD	B-DISO
were	O
6	O
.	O
8	O
and	O
7	O
.	O
2	O
%	O
,	O
respectively	O
.	O

Age	B-PHYS
,	O
BMI	B-PHYS
,	O
and	O
physical	O
activity	O
were	O
independently	O
associated	O
with	O
sexual	B-DISO
dysfunction	I-DISO
and	O
HSDD	B-DISO
.	O

Additionally	O
,	O
BC	B-DISO
patients	B-LIVB
with	O
sexual	B-DISO
dysfunction	I-DISO
reported	O
lower	O
scores	O
on	O
global	O
HRQOL	O
,	O
role	O
functioning	O
,	O
and	O
fatigue	B-DISO
.	O

Based	O
on	O
our	O
findings	B-DISO
,	O
BC	B-DISO
survivors	B-LIVB
should	O
be	O
encouraged	O
to	O
practice	B-PHYS
regular	O
physical	O
activity	O
and	O
to	O
lose	O
weight	O
in	O
order	O
to	O
avoid	O
sexual	B-DISO
dysfunction	I-DISO
.	O

However	O
,	O
future	O
clinical	B-PROC
trials	I-PROC
are	O
needed	O
to	O
confirm	O
these	O
findings	B-DISO
.	O

The	O
N	B-CHEM
-	I-CHEM
Methyl	I-CHEM
d	I-CHEM
-	I-CHEM
Aspartate	I-CHEM
Glutamate	I-CHEM
Receptor	I-CHEM
Antagonist	I-CHEM
Ketamine	B-CHEM
Disrupts	O
the	O
Functional	O
State	O
of	O
the	O
Corticothalamic	B-ANAT
Pathway	O
The	O
non	O
-	O
competitive	O
N	B-CHEM
-	I-CHEM
methyl	I-CHEM
d	I-CHEM
-	I-CHEM
aspartate	I-CHEM
glutamate	I-CHEM
receptor	I-CHEM
(	I-CHEM
NMDAR	I-CHEM
)	I-CHEM
antagonist	I-CHEM
ketamine	B-CHEM
elicits	O
a	O
brain	B-ANAT
state	O
resembling	O
high	B-DISO
-	I-DISO
risk	I-DISO
states	O
for	O
developing	O
psychosis	B-DISO
and	O
early	O
stages	O
of	O
schizophrenia	B-DISO
characterized	O
by	O
sensory	B-DISO
and	O
cognitive	B-DISO
deficits	I-DISO
and	O
aberrant	O
ongoing	O
gamma	B-PHYS
oscillations	I-PHYS
(	O
30	O
-	O
80	O
Hz	O
)	O
in	O
cortical	B-ANAT
and	O
subcortical	B-ANAT
structures	O
,	O
including	O
the	O
thalamus	B-ANAT
.	O

The	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	B-PROC
was	O
to	O
determine	O
whether	O
a	O
ketamine	B-CHEM
-	O
induced	O
psychotic	B-DISO
-	O
relevant	O
state	O
disturbs	O
the	O
functional	O
state	O
of	O
the	O
corticothalamic	B-ANAT
(	O
CT	B-ANAT
)	O
pathway	O
.	O

Multisite	B-PROC
field	I-PROC
recordings	I-PROC
were	O
performed	O
in	O
the	O
somatosensory	B-ANAT
CT	I-ANAT
system	I-ANAT
of	O
the	O
sedated	B-DISO
rat	B-LIVB
.	O

Baseline	O
activity	O
was	O
challenged	O
by	O
activation	O
of	O
vibrissa	B-ANAT
-	O
related	O
prethalamic	B-ANAT
inputs	O
.	O

The	O
sensory	O
-	O
evoked	B-PHYS
thalamic	I-PHYS
response	I-PHYS
was	O
characterized	O
by	O
a	O
short	O
-	O
latency	O
(	O
∼4	O
ms	O
)	O
prethalamic	B-ANAT
-mediated	O
negative	O
sharp	O
potential	B-PHYS
and	O
a	O
longer	O
latency	O
(	O
∼10	O
ms	O
)	O
CT	B-ANAT
-mediated	O
negative	O
potential	B-PHYS
.	O

Following	O
a	O
single	O
subcutaneous	O
injection	O
of	O
ketamine	B-CHEM
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
,	O
spontaneously	O
occurring	O
and	O
sensory	O
-	O
evoked	B-PHYS
thalamic	I-PHYS
gamma	I-PHYS
oscillations	I-PHYS
increased	O
and	O
decreased	O
in	O
power	O
,	O
respectively	O
.	O

The	O
power	O
of	O
the	O
sensory	O
-related	O
gamma	B-PHYS
oscillations	I-PHYS
was	O
positively	B-DISO
correlated	O
with	O
both	O
the	O
amplitude	O
and	O
the	O
area	O
under	O
the	O
curve	O
of	O
the	O
corresponding	O
CT	B-ANAT
potential	B-PHYS
but	O
not	O
with	O
the	O
prethalamic	B-ANAT
potential	B-PHYS
.	O

The	O
present	O
results	O
show	O
that	O
the	O
layer	B-ANAT
VI	I-ANAT
CT	B-ANAT
pathway	O
significantly	O
contributes	O
in	O
thalamic	B-ANAT
gamma	B-PHYS
oscillations	I-PHYS
,	O
and	O
they	O
support	O
the	O
hypothesis	O
that	O
reduced	O
NMDAR	B-CHEM
activation	B-PHYS
disturbs	O
the	O
functional	O
state	O
of	O
CT	B-ANAT
and	O
corticocortical	B-ANAT
networks	B-PHYS
.	O

Combination	B-CHEM
of	O
telmisartan	B-CHEM
with	O
sildenafil	B-CHEM
ameliorate	O
progression	B-DISO
of	O
diabetic	B-DISO
nephropathy	I-DISO
in	O
streptozotocin	B-CHEM
-	O
induced	O
diabetic	B-DISO
model	O
Diabetic	B-DISO
nephropathy	I-DISO
(	O
DN	B-DISO
)	O
is	O
a	O
leading	O
cause	O
of	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
in	O
the	O
world	O
.	O

Several	O
signaling	B-PHYS
pathways	I-PHYS
are	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
DN	B-DISO
including	O
elevation	O
in	O
level	O
of	O
angiotensin	B-CHEM
II	I-CHEM
,	O
formation	O
of	O
advanced	B-CHEM
glycation	I-CHEM
end	I-CHEM
products	I-CHEM
(	O
AGE	B-CHEM
)	O
,	O
activation	B-PHYS
of	O
protein	B-CHEM
kinase	I-CHEM
c	I-CHEM
(	O
PKC	B-CHEM
)	O
,	O
and	O
lipid	B-DISO
accumulation	I-DISO
.	O

These	O
pathways	B-PHYS
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	B-DISO
stress	I-DISO
,	O
increasing	O
expression	B-PHYS
of	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
beta	I-CHEM
-	I-CHEM
1	I-CHEM
(	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
1	I-CHEM
)	O
and	O
release	O
of	O
interleukins	B-CHEM
and	O
adhesion	B-CHEM
molecules	I-CHEM
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-DISO
pathway	O
to	O
ameliorate	O
the	O
progression	B-DISO
of	O
DN	B-DISO
.	O

In	O
the	O
present	O
study	B-PROC
,	O
white	B-LIVB
male	I-LIVB
rats	I-LIVB
(	O
N	O
=	O
48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	B-LIVB
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	B-LIVB
control	I-LIVB
and	O
a	O
control	B-LIVB
vehicle	I-LIVB
group	I-LIVB
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-DISO
by	O
a	O
single	O
intraperitoneal	B-PROC
injection	I-PROC
of	O
Streptozotocin	B-CHEM
(	O
STZ	B-CHEM
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	B-DISO
.	O

Thereafter	O
,	O
the	O
rats	B-LIVB
were	O
divided	O
into	O
DN	B-DISO
group	O
,	O
DN	B-DISO
group	O
receiving	O
Telmisartan	B-CHEM
or	O
Sildenafil	B-CHEM
or	O
Telmisartan	B-CHEM
Sildenafil	B-CHEM
combination	B-CHEM
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	B-ANAT
samples	I-ANAT
were	O
collected	O
(	O
using	O
metabolic	B-OBJC
cages	I-OBJC
)	O
to	O
measure	O
proteinuria	B-DISO
,	O
animals	B-LIVB
were	O
then	O
euthanized	O
,	O
blood	B-ANAT
and	O
tissue	O
samples	O
were	O
collected	O
for	O
measurement	B-PROC
of	I-PROC
Blood	I-PROC
glucose	I-PROC
,	O
BUN	B-PROC
,	O
S	B-PROC
.	I-PROC

Cr	I-PROC
,	O
LDL	B-PROC
,	O
NO	B-PROC
,	O
TGF	B-PROC
-	I-PROC
β1	I-PROC
,	O
IL	B-PROC
-	I-PROC
1β	I-PROC
,	O
AGEPs	B-PROC
,	O
and	O
SOD	B-PROC
.	O

The	O
combination	B-PROC
therapy	I-PROC
showed	O
significant	O
decrease	O
in	O
BUN	B-CHEM
,	O
S	B-CHEM
.	I-CHEM

Cr	I-CHEM
,	O
LDL	B-CHEM
,	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
,	O
Proteinuria	B-DISO
and	O
AGEPs	B-CHEM
and	O
significant	O
increase	O
in	O
SOD	B-CHEM
and	O
NO	B-CHEM
.	O

The	O
findings	O
showed	O
that	O
combination	B-PROC
therapy	I-PROC
was	O
able	O
to	O
ameliorate	O
DN	B-DISO
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	B-CHEM
alone	O
.	O

Analysis	B-PROC
of	O
Low	O
-	O
Biomass	O
Microbial	B-LIVB
Communities	I-LIVB
in	O
the	O
Deep	O
Biosphere	O
Over	O
the	O
past	O
few	O
decades	O
,	O
the	O
subseafloor	O
biosphere	O
has	O
been	O
explored	O
by	O
scientific	O
ocean	O
drilling	O
to	O
depths	O
of	O
about	O
2	O
.	O
5	O
km	O
below	O
the	O
seafloor	O
.	O

Although	O
organic	O
-	O
rich	O
anaerobic	O
sedimentary	O
habitats	O
in	O
the	O
ocean	O
margins	O
harbor	O
large	O
numbers	O
of	O
microbial	B-LIVB
cells	I-LIVB
,	O
microbial	B-LIVB
populations	I-LIVB
in	O
ultraoligotrophic	O
aerobic	O
sedimentary	O
habitats	O
in	O
the	O
open	O
ocean	O
gyres	O
are	O
several	O
orders	O
of	O
magnitude	O
less	O
abundant	O
.	O

Despite	O
advances	O
in	O
cultivation	O
-	O
independent	O
molecular	O
ecological	O
techniques	O
,	O
exploring	O
the	O
low	O
-	O
biomass	O
environment	O
remains	O
technologically	O
challenging	O
,	O
especially	O
in	O
the	O
deep	O
subseafloor	O
biosphere	O
.	O

Reviewing	O
the	O
historical	O
background	O
of	O
deep	O
-	O
biosphere	O
analytical	O
methods	O
,	O
the	O
importance	O
of	O
obtaining	O
clean	B-OBJC
samples	I-OBJC
and	O
tracing	B-DISO
contamination	O
,	O
as	O
well	O
as	O
methods	O
for	O
detecting	B-DISO
microbial	B-LIVB
life	O
,	O
technological	O
aspects	O
of	O
molecular	O
microbiology	O
,	O
and	O
detecting	B-DISO
subseafloor	O
metabolic	B-PHYS
activity	I-PHYS
will	O
be	O
discussed	O
.	O

Novel	O
immunotherapeutic	B-PROC
strategies	I-PROC
to	O
target	O
alloantibody	B-CHEM
-producing	O
B	B-ANAT
and	O
plasma	B-ANAT
cells	I-ANAT
in	O
transplantation	B-PROC
There	O
is	O
an	O
unmet	O
need	O
for	O
immunotherapeutic	B-CHEM
agents	I-CHEM
that	O
target	O
humoral	B-PHYS
alloimmunity	I-PHYS
in	O
solid	B-PROC
organ	I-PROC
transplantation	I-PROC
.	O

This	O
includes	O
sensitized	B-LIVB
patients	I-LIVB
with	O
preformed	O
donor	B-LIVB
-specific	O
human	B-CHEM
leucocyte	I-CHEM
antigen	I-CHEM
antibodies	B-CHEM
and	O
patients	B-LIVB
who	O
develop	O
de	O
-	O
novo	O
donor	B-LIVB
-specific	O
antibodies	B-CHEM
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
antibody	B-DISO
-	I-DISO
mediated	I-DISO
rejection	I-DISO
and	O
allograft	B-PROC
loss	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
recent	O
progress	O
in	O
the	O
generation	O
of	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
and	O
plasma	B-ANAT
cell	I-ANAT
-targeted	O
therapeutics	B-PROC
,	O
with	O
an	O
emphasis	O
on	O
novel	O
agents	B-CHEM
.	O

To	O
deplete	O
or	O
inhibit	O
B	B-ANAT
cells	I-ANAT
,	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
-specific	O
mAbs	B-CHEM
have	O
been	O
developed	O
,	O
including	O
CD20	B-CHEM
,	O
CD22	B-CHEM
,	O
CD19	B-CHEM
and	O
bi	O
-	O
specific	O
antibodies	B-CHEM
that	O
target	O
two	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
antigens	B-CHEM
.	O

In	O
addition	O
,	O
inhibition	O
of	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
-	O
activating	B-PHYS
cytokines	B-CHEM
,	O
such	O
as	O
B	B-CHEM
cell	I-CHEM
-	I-CHEM
activating	I-CHEM
factor	I-CHEM
,	O
may	O
also	O
reduce	O
allo	B-PHYS
-	I-PHYS
B	I-PHYS
-	I-PHYS
cell	I-PHYS
activation	I-PHYS
.	O

Plasma	B-ANAT
cells	I-ANAT
remain	O
a	O
difficult	O
therapeutic	B-PROC
target	O
,	O
but	O
inhibition	O
of	O
germinal	O
centre	O
responses	B-PHYS
via	O
costimulatory	O
blockade	O
or	O
IL21	B-CHEM
neutralization	O
,	O
induction	O
of	O
plasma	B-ANAT
cell	I-ANAT
apoptosis	B-PHYS
using	O
proteasome	B-CHEM
inhibitors	I-CHEM
or	O
disruption	O
of	O
the	O
plasma	B-ANAT
cell	I-ANAT
niche	O
are	O
potential	O
avenues	O
being	O
explored	O
.	O

The	O
ultimate	O
aim	O
of	O
these	O
animal	B-LIVB
and	O
human	B-PROC
studies	I-PROC
is	O
to	O
develop	O
agents	O
that	O
efficiently	O
target	O
humoral	B-ANAT
effectors	I-ANAT
,	O
whilst	O
sparing	O
B	B-ANAT
and	O
plasma	B-ANAT
cells	I-ANAT
with	O
a	O
regulatory	O
capacity	B-DISO
to	O
promote	O
long	O
-	O
term	O
allograft	B-PROC
survival	B-PHYS
,	O
but	O
we	O
remain	O
some	O
distance	O
away	O
from	O
this	O
goal	O
.	O

Survival	B-DISO
status	I-DISO
and	O
functional	O
outcome	O
of	O
children	B-LIVB
who	O
required	O
prolonged	O
intensive	B-PROC
care	I-PROC
after	O
cardiac	B-PROC
surgery	I-PROC
Children	B-LIVB
who	O
require	O
prolonged	O
intensive	B-PROC
care	I-PROC
after	O
cardiac	B-PROC
surgery	I-PROC
are	O
at	O
risk	O
of	O
high	O
mortality	O
.	O

The	O
long	O
-	O
term	O
survival	B-DISO
and	O
functional	O
outcome	O
of	O
these	O
children	B-LIVB
have	O
not	O
been	O
studied	O
in	O
detail	O
.	O

Children	B-LIVB
who	O
stayed	B-DISO
in	O
intensive	B-PROC
care	I-PROC
for	O
>	O
28	O
days	O
after	O
cardiac	B-PROC
surgery	I-PROC
from	O
1997	O
to	O
2012	O
were	O
studied	O
in	O
a	O
single	O
institution	O
.	O

A	O
total	O
of	O
116	O
patients	B-LIVB
were	O
identified	O
;	O
107	O
(	O
92	O
%	O
)	O
were	O
<	O
1	O
year	O
of	O
age	O
and	O
63	O
(	O
54	O
%	O
)	O
had	O
univentricular	B-DISO
physiology	I-DISO
.	O

The	O
incidence	O
of	O
children	B-LIVB
requiring	O
prolonged	O
intensive	B-PROC
care	I-PROC
increased	O
from	O
1	O
.	O
01	O
/	O
100	O
undergoing	O
cardiac	B-PROC
surgery	I-PROC
in	O
1997	O
to	O
2000	O
to	O
2	O
.	O
66	O
/	O
100	O
in	O
2009	O
to	O
2012	O
(	O
P	O
trend	O
=	O
.002	O
)	O
.	O

This	O
increase	O
coincided	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
children	B-LIVB
with	O
hypoplastic	B-DISO
left	I-DISO
heart	I-DISO
syndrome	I-DISO
having	O
prolonged	O
intensive	B-PROC
care	I-PROC
during	O
the	O
same	O
period	O
(	O
0	O
.	O
13	O
/	O
100	O
in	O
1997	O
-	O
2000	O
to	O
1	O
.	O
0	O
/	O
100	O
in	O
2009	O
-	O
2012	O
;	O
P	O
trend	O
=	O
.001	O
)	O
.	O

Survival	B-DISO
to	O
pediatric	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
(	O
PICU	B-OBJC
)	O
discharge	B-PROC
was	O
74	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
65	O
-	O
82	O
)	O
and	O
51	O
%	O
(	O
95	O
%	O
CI	O
,	O
41	O
-	O
59	O
)	O
at	O
3	O
years	O
.	O

Factors	O
associated	O
with	O
mortality	O
were	O
univentricular	B-PROC
repair	I-PROC
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
2	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
21	O
-	O
3	O
.	O
70	O
;	O
P	O
=	O
.008	O
)	O
and	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O
HR	O
,	O
3	O
.	O
01	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
77	O
-	O
5	O
.	O
12	O
;	O
P	O
<	O
.001	O
)	O
,	O
but	O
era	O
did	O
not	O
influence	O
mortality	O
(	O
1997	O
-	O
2005	O
vs	O
2006	O
-	O
2012	O
;	O
log	O
-	O
rank	O
P	O
=	O
.66	O
)	O
.	O

Among	O
PICU	B-OBJC
survivors	B-LIVB
,	O
3	O
-	O
year	O
survival	B-DISO
in	O
those	O
who	O
did	O
not	O
need	O
early	O
reoperation	B-PROC
was	O
81	O
%	O
(	O
95	O
%	O
CI	O
,	O
66	O
-	O
90	O
)	O
,	O
compared	O
with	O
58	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
-	O
71	O
)	O
in	O
those	O
who	O
required	O
early	O
reoperation	B-PROC
(	O
log	O
-	O
rank	O
P	O
=	O
.01	O
)	O
.	O

Among	O
survivors	B-LIVB
,	O
36	O
%	O
had	O
either	O
moderate	B-DISO
or	O
severe	B-DISO
disability	I-DISO
and	O
13	O
%	O
had	O
poor	B-DISO
quality	I-DISO
of	I-DISO
life	I-DISO
.	O

The	O
incidence	O
of	O
children	B-LIVB
requiring	O
prolonged	O
intensive	B-PROC
care	I-PROC
after	O
cardiac	B-PROC
surgery	I-PROC
has	O
increase	O
d	O
in	O
our	O
institution	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
long	O
-	O
term	O
outcome	O
for	O
most	O
of	O
these	O
children	B-LIVB
is	O
poor	O
,	O
especially	O
after	O
univentricular	B-PROC
repair	I-PROC
.	O

Haptic	B-PHYS
feedback	B-PHYS
helps	O
bipedal	B-ANAT
coordination	B-PHYS
The	O
present	O
study	B-PROC
investigated	O
whether	O
special	O
haptic	B-PHYS
or	O
visual	B-PHYS
feedback	I-PHYS
would	O
facilitate	O
the	O
coordination	B-PHYS
of	O
in	O
-	O
phase	O
,	O
cyclical	O
feet	B-ANAT
movements	B-PHYS
of	O
different	O
amplitudes	O
.	O

Seventeen	O
healthy	B-LIVB
participants	I-LIVB
sat	O
with	O
their	O
feet	B-ANAT
on	O
sliding	O
panels	B-OBJC
that	O
were	O
moved	O
externally	O
over	O
the	O
same	O
or	O
different	O
amplitudes	O
.	O

The	O
participants	B-LIVB
were	O
asked	O
to	O
generate	O
simultaneous	O
knee	B-ANAT
flexion	O
-	O
extension	O
movements	B-PHYS
,	O
or	O
to	O
let	O
their	O
feet	B-ANAT
be	O
dragged	B-DISO
,	O
resulting	O
in	O
reference	O
foot	B-ANAT
displacements	B-PROC
of	O
150	O
mm	O
and	O
experimental	O
foot	B-ANAT
displacements	B-PROC
of	O
150	O
,	O
120	O
,	O
or	O
90	O
mm	O
.	O

Four	O
types	O
of	O
feedback	B-PHYS
were	O
given	O
:	O
(	O
1	O
)	O
special	O
haptic	B-PHYS
feedback	B-PHYS
,	O
involving	O
actively	O
following	O
the	O
motions	O
of	O
the	O
sliders	B-DEVI
manipulated	B-PROC
by	O
two	O
confederates	B-LIVB
,	O
(	O
2	O
)	O
haptic	B-PHYS
feedback	B-PHYS
resulting	O
from	O
passive	B-PHYS
motion	I-PHYS
,	O
(	O
3	O
)	O
veridical	O
visual	B-PHYS
feedback	I-PHYS
,	O
and	O
(	O
4	O
)	O
enhanced	O
visual	B-PHYS
feedback	I-PHYS
.	O

Both	O
with	O
respect	O
to	O
amplitude	O
assimilation	B-PHYS
effects	O
,	O
correlations	O
and	O
standard	O
deviation	O
of	O
relative	O
phase	O
,	O
the	O
results	B-PHEN
showed	O
that	O
enhanced	O
visual	B-PHYS
feedback	I-PHYS
did	O
not	O
facilitate	O
bipedal	B-ANAT
independence	O
,	O
but	O
haptic	B-PHYS
feedback	B-PHYS
with	O
active	B-PHYS
movement	I-PHYS
did	O
.	O

Implications	O
of	O
the	O
findings	B-DISO
for	O
movement	B-PHYS
rehabilitation	B-DISO
contexts	O
are	O
discussed	O
.	O

Synthesis	O
and	O
in	O
vitro	O
bone	B-ANAT
cell	I-ANAT
activity	O
of	O
analogues	B-CHEM
of	O
the	O
cyclohexapeptide	B-CHEM
dianthin	I-CHEM
G	I-CHEM
The	O
cyclohexapeptide	B-CHEM
natural	I-CHEM
product	I-CHEM
dianthin	I-CHEM
G	I-CHEM
promotes	O
osteoblast	B-PHYS
(	I-PHYS
bone	I-PHYS
-	I-PHYS
forming	I-PHYS
cell	I-PHYS
)	I-PHYS
proliferation	I-PHYS
in	O
vitro	O
at	O
nanomolar	O
concentrations	O
,	O
and	O
is	O
therefore	O
considered	O
a	O
promising	O
candidate	O
for	O
the	O
treatment	O
of	O
osteoporosis	B-DISO
.	O

An	O
N	B-CHEM
(	I-CHEM
α	I-CHEM
)	I-CHEM
-	I-CHEM
methyl	I-CHEM
amide	I-CHEM
bond	I-CHEM
scan	O
of	O
dianthin	B-CHEM
G	I-CHEM
was	O
performed	O
to	O
probe	O
the	O
effect	O
of	O
modifying	O
amide	B-CHEM
bonds	I-CHEM
on	O
osteoblast	B-PHYS
proliferation	I-PHYS
.	O

In	O
addition	O
,	O
to	O
provide	O
greater	O
structural	O
diversity	O
,	O
a	O
series	O
of	O
dicarba	B-CHEM
dianthin	I-CHEM
G	I-CHEM
analogues	I-CHEM
was	O
synthesised	O
using	O
ring	B-PHEN
closing	I-PHEN
metathesis	I-PHEN
.	O

Dianthin	B-CHEM
G	I-CHEM
and	O
one	O
novel	O
dicarba	B-CHEM
analogue	I-CHEM
increased	O
the	O
number	O
of	O
human	B-LIVB
osteoblasts	B-ANAT
and	O
importantly	O
they	O
did	O
not	O
increase	O
osteoclast	B-PHYS
(	I-PHYS
bone	I-PHYS
-	I-PHYS
resorbing	I-PHYS
cell	I-PHYS
)	I-PHYS
differentiation	I-PHYS
in	O
bone	B-ANAT
marrow	I-ANAT
cells	I-ANAT
.	O

Effects	O
of	O
grazing	B-PHYS
cow	I-PHYS
diet	B-OBJC
on	O
volatile	B-CHEM
compounds	I-CHEM
as	O
well	O
as	O
physicochemical	B-PHEN
and	O
sensory	O
characteristics	O
of	O
12	O
-	O
month	O
-	O
ripened	B-OBJC
Montasio	I-OBJC
cheese	I-OBJC
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
the	O
effects	O
of	O
pasture	O
type	O
and	O
cow	B-LIVB
feeding	O
supplementation	B-OBJC
level	O
on	O
a	O
12	O
-	O
mo	O
-	O
ripened	B-OBJC
Montasio	I-OBJC
protected	O
designation	O
of	O
origin	O
(	O
PDO	O
)	O
cheese	B-OBJC
,	O
which	O
is	O
one	O
of	O
the	O
most	O
important	O
PDO	O
cheeses	B-OBJC
produced	O
in	O
northeast	B-GEOG
Italy	I-GEOG
.	O

Cheeses	B-OBJC
were	O
characterized	O
for	O
volatile	B-CHEM
compounds	I-CHEM
,	O
color	O
,	O
mechanical	O
variables	O
,	O
and	O
sensory	O
descriptors	O
.	O

Pasture	O
type	O
significantly	O
affected	O
most	O
of	O
the	O
instrumental	O
variables	O
considered	O
and	O
,	O
as	O
a	O
consequence	O
,	O
sensory	O
properties	O
were	O
affected	O
as	O
well	O
.	O

Cheeses	B-OBJC
from	O
the	O
pasture	O
characterized	O
by	O
a	O
nutrient	B-OBJC
-	I-OBJC
rich	I-OBJC
vegetation	B-OBJC
type	O
were	O
higher	O
in	O
protein	B-CHEM
and	O
lower	O
in	O
fat	B-CHEM
content	O
.	O

Furthermore	O
,	O
such	O
cheeses	B-OBJC
,	O
evaluated	B-PROC
by	O
a	O
sensory	B-LIVB
panel	I-LIVB
,	O
were	O
more	O
intense	O
in	O
color	O
with	O
a	O
more	O
pungent	B-PHEN
and	O
less	O
cow	B-PHEN
-	I-PHEN
like	I-PHEN
odor	I-PHEN
,	O
in	O
agreement	O
with	O
what	O
found	O
through	O
instrumental	O
analyses	B-PROC
.	O

Supplementation	B-OBJC
level	O
resulted	O
in	O
less	O
pronounced	O
effects	O
,	O
limited	O
to	O
volatile	B-CHEM
compounds	I-CHEM
and	O
texture	O
properties	O
,	O
which	O
were	O
not	O
detected	O
by	O
sensory	O
analysis	B-PROC
.	O

The	O
characterization	O
of	O
the	O
12	O
-	O
mo	O
ripened	B-OBJC
Montasio	I-OBJC
cheese	I-OBJC
reported	O
here	O
is	O
an	O
important	O
step	O
for	O
the	O
valorization	O
of	O
this	O
PDO	O
product	B-OBJC
.	O

Conservation	B-PROC
education	I-PROC
and	O
habitat	O
restoration	O
for	O
the	O
endangered	B-LIVB
Sagalla	B-LIVB
caecilian	I-LIVB
(	O
Boulengerula	B-LIVB
niedeni	I-LIVB
)	O
in	O
Sagalla	B-GEOG
Hill	I-GEOG
,	O
Kenya	B-GEOG
The	O
Sagalla	B-LIVB
caecilian	I-LIVB
(	O
Boulengerula	B-LIVB
niedeni	I-LIVB
)	O
is	O
an	O
endangered	B-LIVB
amphibian	B-LIVB
endemic	O
to	O
Sagalla	B-GEOG
Hill	I-GEOG
in	O
the	O
Taita	B-GEOG
Hills	I-GEOG
.	O

This	O
burrowing	O
worm	O
-like	O
species	O
prefers	O
soft	O
soil	B-OBJC
with	O
high	O
moisture	B-OBJC
and	O
organic	B-OBJC
matter	I-OBJC
.	O

The	O
major	O
threats	O
to	O
the	O
Sagalla	B-LIVB
caecilian	I-LIVB
are	O
soil	B-PHEN
erosion	I-PHEN
caused	O
by	O
steep	O
slopes	O
,	O
bare	O
ground	B-GEOG
and	O
water	B-PHEN
siphoning	I-PHEN
/	O
soil	B-PHEN
hardening	I-PHEN
from	O
exotic	B-LIVB
eucalyptus	I-LIVB
trees	I-LIVB
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
get	O
a	O
better	O
understanding	B-PHYS
of	O
the	O
local	O
people	B-LIVB
's	I-LIVB
attitude	B-PHYS
towards	O
this	O
species	O
and	O
how	O
they	O
can	O
contribute	O
to	O
its	O
continued	O
conservation	O
through	O
restoration	O
of	O
its	O
remaining	O
habitat	O
.	O

In	O
this	O
study	B-PROC
,	O
it	O
was	O
found	B-DISO
that	O
96	O
%	O
of	O
Sagalla	B-GEOG
people	B-LIVB
are	O
aware	B-PHYS
of	O
the	O
species	O
,	O
its	O
habits	O
and	O
its	O
association	O
with	O
soils	B-OBJC
high	O
in	O
organic	B-OBJC
matter	I-OBJC
.	O

It	O
was	O
also	O
found	B-DISO
that	O
96	O
%	O
of	O
Sagalla	B-GEOG
people	B-LIVB
use	O
organic	O
manure	B-OBJC
from	O
cow	B-LIVB
dung	B-ANAT
in	O
their	O
farms	O
.	O

Habitat	O
restoration	O
through	O
planting	O
of	O
indigenous	O
plants	B-LIVB
was	O
found	B-DISO
to	O
be	O
ongoing	O
,	O
especially	O
on	O
compounds	B-CHEM
of	O
public	O
institutions	O
as	O
well	O
as	O
on	O
private	O
lands	O
.	O

Although	O
drought	B-PHEN
was	O
found	B-DISO
to	O
be	O
a	O
challenge	O
for	O
seedlings	B-LIVB
development	O
especially	O
on	O
the	O
low	O
elevation	O
sites	O
,	O
destruction	O
by	O
livestock	B-LIVB
especially	O
during	O
the	O
dry	O
season	O
is	O
also	O
a	O
major	O
threat	O
.	O

In	O
this	O
study	B-PROC
,	O
it	O
was	O
recommended	O
that	O
any	O
future	O
habitat	O
restoration	O
initiative	B-PHYS
should	O
include	O
strong	O
chain	B-OBJC
-	I-OBJC
link	I-OBJC
fencing	O
to	O
protect	O
the	O
seedlings	B-LIVB
from	O
livestock	B-LIVB
activity	O
.	O

Recognizing	O
that	O
the	O
preferred	O
habitats	O
for	O
the	O
species	O
are	O
in	O
the	O
valleys	O
,	O
systematic	O
planting	O
of	O
keystone	B-LIVB
plant	I-LIVB
species	O
such	O
as	O
fig	B-LIVB
trees	I-LIVB
(	O
Ficus	B-LIVB
)	O
creates	O
the	O
best	O
microhabitats	O
.	O

These	O
are	O
better	O
than	O
general	O
woodlots	O
of	O
indigenous	O
trees	B-LIVB
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR	B-CHEM
-	I-CHEM
70	I-CHEM
immunoassay	B-PROC
as	O
a	O
tumor	B-CHEM
marker	I-CHEM
for	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
Lung	B-DISO
cancer	I-DISO
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	B-LIVB
with	O
lung	B-DISO
cancer	I-DISO
are	O
usually	O
diagnosed	B-PROC
at	O
advanced	B-ANAT
or	O
locally	B-ANAT
advanced	I-ANAT
stage	I-ANAT
,	O
for	O
this	O
reason	O
early	B-PROC
diagnosis	I-PROC
of	O
lung	B-DISO
cancer	I-DISO
is	O
very	O
important	O
.	O

For	O
early	B-PROC
detection	I-PROC
of	O
lung	B-DISO
cancer	I-DISO
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	B-PROC
-	I-PROC
dose	I-PROC
computed	I-PROC
tomography	I-PROC
or	O
tumor	B-CHEM
biomarkers	I-CHEM
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-PROC
DR	B-CHEM
-	I-CHEM
70	I-CHEM
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	B-CHEM
marker	I-CHEM
in	O
detection	B-PROC
of	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancers	I-DISO
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	B-ANAT
samples	I-ANAT
from	O
88	O
non	B-DISO
lung	I-DISO
cancer	I-DISO
patients	B-LIVB
,	O
86	O
patients	B-LIVB
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disesase	I-DISO
were	O
obtained	O
.	O

Blood	B-ANAT
samples	I-ANAT
from	O
each	O
participant	B-LIVB
were	O
analyzed	B-PROC
for	O
DR	B-CHEM
-	I-CHEM
70	I-CHEM
level	O
.	O

Totally	O
174	O
patients	B-LIVB
were	O
enrolled	O
to	O
the	O
study	B-PROC
(	O
152	O
male	B-LIVB
,	O
22	O
female	B-LIVB
)	O
.	O

Histopathologically	O
47	O
(	O
53	O
.	O

4	O
%	O
)	O
patients	B-LIVB
were	O
diagnosed	B-PROC
with	O
squamous	B-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
,	O
34	O
(	O
38	O
.	O
6	O
%	O
)	O
with	O
adenocarcinoma	B-DISO
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
.	O

The	O
mean	B-CHEM
serum	I-CHEM
DR	I-CHEM
-	I-CHEM
70	I-CHEM
levels	O
in	O
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
(	O
2	O
.	O
43	O
±	O
1	O
.	O
82	O
µg	O
/	O
mL	O
)	O
was	O
significantly	B-DISO
higher	I-DISO
compared	O
to	O
the	O
86	O
non	B-DISO
-	I-DISO
cancerous	I-DISO
subjects	B-LIVB
(	O
1	O
.	O
15	O
±	O
0	O
.	O

70	O
µg	O
/	O
mL	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

DR	B-CHEM
-	I-CHEM
70	I-CHEM
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54	O
.	O

5	O
and	O
83	O
.	O

7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1	O
.	O
98	O
µg	O
/	O
mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-DISO
is	O
6	O
.	O
171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR	B-CHEM
-	I-CHEM
70	I-CHEM
level	O
is	O
1	O
.	O
98	O
µg	O
/	O
mL	O
and	O
higher	O
.	O

DR	B-CHEM
-	I-CHEM
70	I-CHEM
,	O
a	O
marker	B-CHEM
used	O
to	O
measure	O
fibrin	B-CHEM
degradation	I-CHEM
products	I-CHEM
,	O
generated	O
by	O
all	O
major	O
cancers	B-DISO
,	O
may	O
helps	O
to	O
find	O
high	B-DISO
risk	I-DISO
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O

The	O
biological	O
effect	O
of	O
metal	B-CHEM
ions	B-CHEM
on	O
the	O
granulation	B-PROC
of	O
aerobic	O
granular	O
activated	O
sludge	B-PHEN
As	O
a	O
special	O
biofilm	B-LIVB
structure	O
,	O
microbial	B-LIVB
attachment	O
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
granulation	B-PROC
of	O
aerobic	O
granular	O
activated	O
sludge	B-PHEN
(	O
AGAS	B-PHEN
)	O
.	O

This	O
experiment	O
was	O
to	O
investigate	O
the	O
biological	O
effect	O
of	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	I-CHEM
Mg	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
Fe	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
Zn	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
and	O
K	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
which	O
are	O
the	O
most	O
common	O
ions	B-CHEM
present	O
in	O
biological	O
wastewater	B-PHEN
treatment	O
systems	O
,	O
on	O
the	O
microbial	B-LIVB
attachment	O
of	O
AGAS	B-PHEN
and	O
flocculent	B-PHYS
activated	O
sludge	B-PHEN
(	O
FAS	B-PHEN
)	O
,	O
from	O
which	O
AGAS	B-PHEN
is	O
always	O
derived	O
,	O
in	O
order	O
to	O
provide	O
a	O
new	O
strategy	O
for	O
the	O
rapid	O
cultivation	O
and	O
stability	O
control	O
of	O
AGAS	B-PHEN
.	O

The	O
result	O
showed	O
that	O
attachment	O
biomass	O
of	O
AGAS	B-PHEN
was	O
about	O
300	O
%	O
higher	O
than	O
that	O
of	O
FAS	B-PHEN
without	O
the	O
addition	O
of	O
metal	B-CHEM
ions	B-CHEM
.	O

Different	O
metal	B-CHEM
ions	B-CHEM
had	O
different	O
effects	O
on	O
the	O
process	B-PHEN
of	O
microbial	B-LIVB
attachment	O
.	O

FAS	B-PHEN
and	O
AGAS	B-PHEN
reacted	O
differently	O
to	O
the	O
metal	B-CHEM
ions	B-CHEM
as	O
well	O
,	O
and	O
in	O
fact	O
,	O
AGAS	B-PHEN
was	O
more	O
sensitive	O
to	O
the	O
metal	B-CHEM
ions	B-CHEM
.	O

Specifically	O
,	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
Mg	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
and	O
K	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
could	O
increase	O
the	O
microbial	B-LIVB
attachment	O
ability	O
of	O
both	O
AGAS	B-PHEN
and	O
FAS	B-PHEN
under	O
appropriate	O
concentrations	O
,	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
Fe	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
and	O
Zn	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
were	O
also	O
beneficial	O
to	O
the	O
microbial	B-LIVB
attachment	O
of	O
FAS	B-PHEN
at	O
low	O
concentrations	O
,	O
but	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
Fe	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
and	O
Zn	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
greatly	O
inhibited	O
the	O
attachment	O
process	O
of	O
AGAS	B-PHEN
even	O
at	O
extremely	O
low	O
concentrations	O
.	O

In	O
addition	O
,	O
the	O
acylated	B-CHEM
homoserine	I-CHEM
lactone	I-CHEM
(	O
AHL	B-CHEM
)	O
-	O
based	O
quorum	B-PHYS
sensing	I-PHYS
system	I-PHYS
,	O
the	O
content	O
of	O
extracellular	B-ANAT
polymeric	B-CHEM
substances	I-CHEM
and	O
the	O
relative	O
hydrophobicity	O
of	O
the	O
sludges	B-PHEN
were	O
greatly	O
influenced	O
by	O
metal	B-CHEM
ions	B-CHEM
.	O

As	O
all	O
these	O
parameters	O
had	O
close	O
relationships	O
with	O
the	O
microbial	B-LIVB
attachment	O
process	O
,	O
the	O
microbial	B-LIVB
attachment	O
may	O
be	O
affected	O
by	O
changes	O
of	O
these	O
parameters	O
.	O

The	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	B-DISO
during	O
lung	B-PROC
resection	I-PROC
surgery	I-PROC
:	O
A	O
retrospective	B-PROC
matched	I-PROC
cohort	I-PROC
analysis	I-PROC
of	O
real	O
-	O
world	B-LIVB
data	O
The	O
objective	O
of	O
this	O
retrospective	B-PROC
study	I-PROC
was	O
to	O
quantify	O
the	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	B-DISO
in	O
lung	B-PROC
resection	I-PROC
surgery	I-PROC
in	O
the	O
US	B-GEOG
.	O

This	O
study	B-PROC
utilized	O
2009	O
-	O
2012	O
data	O
from	O
the	O
Premier	O
Perspective	O
Database	O
(	O
TM	O
)	O
.	O

Adult	B-LIVB
patients	B-LIVB
with	O
primary	B-PROC
pulmonary	I-PROC
lobectomy	I-PROC
or	O
segmentectomy	B-PROC
procedures	I-PROC
were	O
categorized	O
by	O
the	O
surgical	O
approach	O
(	O
VATS	B-PROC
vs	O
open	B-PROC
)	O
and	O
primary	O
diagnosis	O
(	O
primary	B-PROC
or	O
metastatic	B-PROC
lung	I-PROC
cancer	I-PROC
vs	O
non	B-PROC
-	I-PROC
lung	I-PROC
cancer	I-PROC
)	O
.	O

Patients	B-LIVB
requiring	O
≥3	O
units	O
of	O
blood	B-CHEM
products	I-CHEM
with	O
at	O
least	O
1	O
unit	O
of	O
PRBCs	B-CHEM
:	O
""""	O
significant	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
;	O
those	O
requiring	O
<	O
3	O
units	O
:	O
""""	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O
cohort	B-LIVB
;	O
and	O
those	O
not	O
requiring	O
blood	B-CHEM
products	I-CHEM
:	O
""""	O
no	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
.	O

A	O
matched	O
cohort	B-PROC
analysis	I-PROC
was	O
performed	O
between	O
the	O
""""	O
significant	O
bleeding	B-DISO
""""	O
and	O
the	O
""""	O
no	O
bleeding	B-DISO
cohort	B-LIVB
""""	O
using	O
matching	O
variables	O
:	O
hospital	B-OBJC
,	O
lung	B-PROC
cancer	I-PROC
diagnosis	I-PROC
,	O
year	O
of	O
surgery	O
,	O
APR	O
-	O
DRG	O
severity	O
score	O
,	O
procedure	B-PHYS
type	I-PHYS
and	O
approach	O
,	O
age	B-PHYS
,	O
and	O
gender	B-PHYS
.	O

The	O
""""	O
All	O
-	O
patient	B-LIVB
""""	O
cohort	B-LIVB
comprised	O
21	O
,	O
429	O
patients	B-LIVB
:	O
213	O
""""	O
significant	O
bleeding	B-DISO
""""	O
;	O
2	O
,	O
780	O
""""	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O
;	O
and	O
18	O
,	O
436	O
""""	O
no	O
bleeding	B-DISO
""""	O
.	O

Overall	O
incidence	O
of	O
significant	O
chest	B-ANAT
bleeding	B-DISO
was	O
0	O
.	O

99	O
%	O
.	O

Patients	B-LIVB
from	O
""""	O
significant	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
and	O
""""	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O
cohort	B-LIVB
had	O
2	O
.	O

5	O
days	O
and	O
2	O
days	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
longer	O
length	O
of	O
stay	O
in	O
the	O
hospital	B-OBJC
compared	O
to	O
those	O
in	O
the	O
""""	O
no	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
,	O
respectively	O
.	O

Overall	O
,	O
hospital	O
costs	O
for	O
""""	O
significant	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
were	O
higher	O
than	O
""""	O
no	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
for	O
those	O
who	O
were	O
covered	O
under	O
Medicare	O
(	O
$	O
59	O
,	O
871	O
vs	O
$	O
23	O
,	O
641	O
)	O
,	O
were	O
≥76	O
years	O
of	O
age	O
(	O
$	O
64	O
,	O
010	O
vs	O
$	O
24	O
,	O
243	O
)	O
,	O
had	O
greater	O
severity	O
of	O
illness	O
(	O
$	O
97	O
,	O
813	O
vs	O
$	O
51	O
,	O
871	O
)	O
and	O
underwent	O
open	O
segmentectomy	B-PROC
(	O
$	O
74	O
,	O
220	O
vs	O
$	O
21	O
,	O
903	O
)	O
.	O

Hospital	O
costs	O
for	O
""""	O
significant	O
bleeding	B-DISO
""""	O
cohort	B-LIVB
and	O
""""	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O
were	O
significantly	O
higher	O
(	O
$	O
11	O
,	O
589	O
and	O
$	O
5	O
,	O
280	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
than	O
no	O
bleeding	B-DISO
cohort	B-LIVB
.	O

Although	O
significant	O
bleeding	B-DISO
during	O
lung	B-PROC
resection	I-PROC
surgery	I-PROC
is	O
rare	O
,	O
patients	B-LIVB
with	O
such	O
complication	B-DISO
could	O
stay	O
longer	O
at	O
the	O
hospital	B-OBJC
and	O
cost	O
an	O
average	O
of	O
$	O
13	O
,	O
103	O
more	O
than	O
those	O
without	O
.	O

Laceration	B-DISO
of	O
a	O
branch	O
of	O
the	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
caused	O
by	O
a	O
spike	B-DISO
of	O
the	O
displaced	O
lesser	B-ANAT
trochanter	I-ANAT
in	O
an	O
inter	B-ANAT
-	I-ANAT
trochanteric	I-ANAT
femoral	B-DISO
fracture	I-DISO
.	O

A	O
case	O
report	O
Injury	B-DISO
of	O
femoral	B-ANAT
vessels	I-ANAT
is	O
an	O
extremely	O
rare	O
complication	B-DISO
in	O
intertrochanteric	B-ANAT
femoral	B-DISO
fractures	I-DISO
.	O

In	O
most	O
cases	O
reported	B-PROC
,	O
the	O
vascular	B-DISO
lesion	I-DISO
involves	O
the	O
superficial	B-ANAT
femoral	I-ANAT
artery	I-ANAT
,	O
whereas	O
in	O
very	O
few	O
cases	O
does	O
it	O
involve	O
the	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
.	O

We	O
report	O
a	O
case	O
of	O
acute	B-DISO
bleeding	I-DISO
due	O
to	O
laceration	B-DISO
of	O
a	O
perforating	B-DISO
branch	O
of	O
the	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
caused	O
by	O
a	O
sharp	B-DISO
fragment	O
of	O
the	O
displaced	O
lesser	B-ANAT
trochanter	I-ANAT
in	O
an	O
intertrochanteric	B-ANAT
femoral	B-DISO
fracture	I-DISO
;	O
the	O
lesion	B-DISO
was	O
treated	O
by	O
transcatheter	B-PROC
embolization	I-PROC
.	O

The	O
arterial	B-DISO
injury	I-DISO
may	O
be	O
iatrogenic	O
,	O
occurring	O
during	O
intramedullary	O
internal	B-PROC
fixation	I-PROC
,	O
or	O
less	O
frequently	O
,	O
the	O
injury	B-DISO
may	O
be	O
due	O
to	O
the	O
fracture	B-DISO
itself	O
,	O
caused	O
by	O
a	O
sharp	B-DISO
bone	B-DISO
fragment	I-DISO
that	O
damages	O
the	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
or	O
one	O
of	O
its	O
perforating	B-DISO
branches	O
.	O

We	O
believe	O
that	O
intertrochanteric	B-ANAT
femoral	B-DISO
fractures	I-DISO
with	O
avulsed	B-DISO
lesser	B-ANAT
trochanter	I-ANAT
are	O
at	O
risk	O
for	O
femoral	B-ANAT
vessel	I-ANAT
injuries	B-DISO
caused	O
by	O
the	O
displaced	O
bone	B-ANAT
spike	B-DISO
,	O
and	O
we	O
advise	O
meticulous	O
clinical	O
and	O
laboratory	B-PROC
monitoring	I-PROC
pre	O
-	O
and	O
post	O
-	O
operatively	O
to	O
prevent	B-PROC
serious	I-PROC
complications	I-PROC
.	O

Catastrophic	O
expenditure	O
and	O
impoverishment	O
of	O
patients	B-LIVB
affected	O
by	O
7	O
rare	B-DISO
diseases	I-DISO
in	O
China	B-GEOG
China	B-GEOG
is	O
actively	O
promoting	O
regulation	O
of	O
rare	B-DISO
diseases	I-DISO
,	O
rare	B-DISO
disease	I-DISO
and	O
orphan	B-CHEM
drugs	I-CHEM
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national	O
planning	O
.	O

However	O
,	O
few	O
studies	B-PROC
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	O
of	O
rare	B-DISO
disease	I-DISO
patients	B-LIVB
in	O
China	B-GEOG
.	O

This	O
study	O
aims	O
to	O
provide	O
policy	O
recommendations	O
for	O
the	O
establishment	O
of	O
social	O
security	O
mechanism	O
for	O
rare	B-DISO
diseases	I-DISO
in	O
China	B-GEOG
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	O
caused	O
by	O
these	O
diseases	B-DISO
.	O

A	O
total	O
of	O
7	O
rare	B-DISO
diseases	I-DISO
were	O
selected	O
by	O
Delphi	B-PROC
method	I-PROC
.	O

Affordability	O
of	O
treatment	B-PROC
for	O
the	O
7	O
rare	B-DISO
diseases	I-DISO
was	O
assessed	O
through	O
annual	O
per	O
capital	O
income	O
,	O
catastrophic	O
expenditure	O
and	O
impoverishment	O
expenditure	O
among	O
urban	B-LIVB
and	O
rural	B-LIVB
residents	I-LIVB
in	O
China	B-GEOG
.	O

Assessed	O
through	O
annual	O
per	O
capital	O
income	O
,	O
health	O
expenditure	O
for	O
the	O
7	O
rare	B-DISO
diseases	I-DISO
are	O
all	O
rather	O
high	O
.	O

The	O
highest	O
health	O
expenditure	O
is	O
equivalent	O
to	O
income	O
of	O
69	O
.	O

34	O
years	O
of	O
one	O
urban	B-LIVB
resident	I-LIVB
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural	B-LIVB
residents	I-LIVB
.	O

Through	O
catastrophic	O
expenditure	O
assessment	O
,	O
proportions	O
of	O
the	O
population	B-LIVB
experiencing	O
catastrophic	O
expenditure	O
caused	O
by	O
the	O
7	O
rare	B-DISO
diseases	I-DISO
are	O
all	O
under	O
0	O
.	O

167	O
‰	O
.	O

However	O
,	O
once	O
one	O
is	O
ill	B-DISO
and	O
taking	O
medications	O
,	O
he	O
will	O
suffer	O
from	O
catastrophic	O
health	O
expenditure	O
.	O

Through	O
impoverishment	O
expenditure	O
assessment	O
,	O
the	O
proportions	O
of	O
impoverishment	O
payment	O
are	O
low	O
among	O
both	O
urban	B-LIVB
and	O
rural	B-LIVB
residents	I-LIVB
,	O
but	O
the	O
7	O
rare	B-DISO
diseases	I-DISO
could	O
lead	O
nearly	O
4	O
.	O
6	O
million	O
people	B-LIVB
into	O
poverty	O
on	O
a	O
national	O
scale	O
.	O

The	O
affordability	O
of	O
treatment	B-PROC
for	O
rare	B-DISO
disease	I-DISO
as	O
well	O
as	O
orphan	B-CHEM
drugs	I-CHEM
is	O
rather	O
poor	O
.	O

Residents	B-LIVB
of	O
different	O
income	O
levels	O
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-PROC
for	O
rare	B-DISO
diseases	I-DISO
,	O
so	O
poverty	O
caused	O
by	O
rare	B-DISO
diseases	I-DISO
is	O
quite	O
widespread	O
.	O

Therefore	O
,	O
social	O
security	O
mechanism	O
for	O
rare	B-DISO
disease	I-DISO
patients	B-LIVB
should	O
be	O
established	O
and	O
specific	O
payment	O
pattern	O
for	O
orphan	B-CHEM
drugs	I-CHEM
should	O
be	O
set	O
up	O
.	O

Rh	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
-	O
Catalyzed	B-PHEN
Oxidative	B-PHEN
Annulation	I-PHEN
Leading	O
to	O
Substituted	B-CHEM
Indolizines	I-CHEM
by	O
Cleavage	B-PHEN
of	O
C	B-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
2	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
/	I-PHEN
C	I-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
3	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
Bonds	I-PHEN
Rhodium	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
-	O
catalyzed	B-PHEN
oxidative	B-PHEN
annulation	I-PHEN
reactions	I-PHEN
of	O
pyridinium	B-CHEM
trifluoromethanesulfonate	I-CHEM
salts	I-CHEM
with	O
alkynes	B-CHEM
leading	O
to	O
substituted	B-CHEM
indolizines	I-CHEM
by	O
cleavage	B-PHEN
of	O
C	B-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
2	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
/	I-PHEN
C	I-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
3	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
bonds	I-PHEN
are	O
developed	O
.	O

The	O
starting	B-OBJC
materials	I-OBJC
are	O
readily	O
available	O
,	O
and	O
the	O
reactions	B-PHEN
have	O
a	O
broad	O
substrate	B-OBJC
scope	O
.	O

This	O
reaction	B-PHEN
overcomes	O
some	O
drawbacks	O
of	O
the	O
previous	O
indolizine	B-CHEM
synthetic	B-PHEN
methods	I-PHEN
and	O
provides	O
a	O
new	O
efficient	O
route	O
to	O
indolizine	B-CHEM
derivatives	I-CHEM
.	O

Pyomyositis	B-DISO
in	O
childhood	O
-	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
Pyomyositis	B-DISO
is	O
a	O
pyogenic	B-DISO
infection	I-DISO
of	O
skeletal	O
muscle	O
that	O
arises	O
from	O
hematogenous	B-DISO
spread	I-DISO
and	O
usually	O
presents	O
with	O
localized	O
abscess	B-DISO
.	O

This	O
muscle	B-DISO
infection	I-DISO
has	O
been	O
rarely	O
reported	O
in	O
adult	B-DISO
-	I-DISO
onset	I-DISO
systemic	B-DISO
lupus	I-DISO
erythematous	I-DISO
and	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
has	B-DISO
not	I-DISO
been	I-DISO
diagnosed	I-DISO
in	O
pediatric	O
lupus	B-LIVB
population	I-LIVB
.	O

Among	O
our	O
childhood	B-DISO
-	I-DISO
onset	I-DISO
systemic	B-DISO
lupus	I-DISO
erythematous	I-DISO
population	B-LIVB
,	O
including	O
289	O
patients	B-LIVB
,	O
one	O
presented	O
pyomyositis	B-DISO
.	O

This	O
patient	B-LIVB
was	O
diagnosed	B-DISO
with	O
childhood	B-DISO
-	I-DISO
onset	I-DISO
systemic	B-DISO
lupus	I-DISO
erythematous	I-DISO
at	O
the	O
age	B-PHYS
of	O
10	O
years	O
-	O
old	O
.	O

After	O
six	O
years	O
,	O
while	O
being	O
treated	O
with	O
prednisone	B-CHEM
,	O
azathioprine	B-CHEM
and	O
hydroxychloroquine	B-CHEM
,	O
she	O
was	O
hospitalized	B-DISO
due	O
to	O
a	O
30	O
-	O
day	O
history	O
of	O
insidious	O
pain	O
in	O
the	O
left	B-ANAT
thigh	I-ANAT
and	O
no	O
apparent	O
trauma	B-DISO
or	O
fever	B-DISO
were	O
reported	O
.	O

Her	O
physical	B-PROC
examination	I-PROC
showed	O
muscle	B-DISO
tenderness	I-DISO
and	O
woody	B-DISO
induration	I-DISO
.	O

Laboratory	B-PROC
tests	I-PROC
revealed	O
anemia	B-DISO
,	O
increased	O
acute	B-CHEM
phase	I-CHEM
reactants	I-CHEM
and	O
normal	B-DISO
muscle	I-DISO
enzymes	I-DISO
.	O

Computer	B-ANAT
tomography	I-ANAT
of	I-ANAT
the	I-ANAT
left	I-ANAT
thigh	I-ANAT
showed	O
collection	O
on	O
the	O
middle	O
third	O
of	O
the	O
vastus	B-ANAT
intermedius	I-ANAT
,	O
suggesting	O
purulent	O
stage	O
of	O
pyomyositis	B-DISO
.	O

Treatment	B-PROC
with	O
broad	B-CHEM
-	I-CHEM
spectrum	I-CHEM
antibiotic	I-CHEM
was	O
initiated	O
,	O
leading	O
to	O
a	O
complete	O
clinical	O
resolution	O
.	O

In	O
conclusion	O
,	O
we	O
described	O
the	O
first	O
case	O
of	O
pyomyositis	B-DISO
during	O
childhood	O
in	O
pediatric	O
lupus	B-LIVB
population	I-LIVB
.	O

This	O
report	O
reinforces	O
that	O
the	O
presence	O
of	O
localized	B-DISO
muscle	I-DISO
pain	I-DISO
in	O
immunocompromised	B-DISO
patients	I-DISO
,	O
even	O
without	O
elevation	O
of	O
muscle	B-PROC
enzymes	I-PROC
,	O
should	O
raise	O
the	O
suspicion	B-PHYS
of	O
pyomyositis	B-DISO
.	O

A	O
prompt	O
antibiotic	B-PROC
therapy	I-PROC
is	O
strongly	O
recommended	O
.	O

Quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
and	O
cervical	B-PROC
length	I-PROC
to	O
predict	O
preterm	B-DISO
birth	I-DISO
in	O
asymptomatic	B-DISO
women	B-LIVB
with	O
previous	O
cervical	B-PROC
surgery	I-PROC
Quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
testing	I-PROC
has	O
demonstrated	B-PROC
accuracy	O
for	O
prediction	O
of	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
in	O
asymptomatic	B-DISO
women	B-LIVB
with	O
a	O
history	B-DISO
of	O
preterm	B-DISO
birth	I-DISO
.	O

Predictive	O
accuracy	O
in	O
women	B-LIVB
with	O
previous	O
cervical	B-PROC
surgery	I-PROC
(	O
a	O
potentially	O
different	O
risk	O
mechanism	O
)	O
is	O
not	O
known	O
.	O

We	O
sought	O
to	O
compare	O
the	O
predictive	O
accuracy	O
of	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
and	O
cervical	B-PROC
length	I-PROC
testing	I-PROC
in	O
asymptomatic	B-DISO
women	B-LIVB
with	O
previous	O
cervical	B-PROC
surgery	I-PROC
to	O
that	O
in	O
women	B-LIVB
with	O
1	O
previous	O
preterm	B-DISO
birth	I-DISO
.	O

We	O
conducted	O
a	O
prospective	B-PROC
blinded	B-PROC
secondary	O
analysis	B-PROC
of	O
a	O
larger	O
observational	B-PROC
study	I-PROC
of	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
concentration	O
in	O
asymptomatic	B-DISO
women	B-LIVB
measured	O
with	O
a	O
Hologic	O
10Q	O
system	O
(	O
Hologic	O
,	O
Marlborough	B-GEOG
,	O
MA	B-GEOG
)	O
.	O

Prediction	O
of	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
(	O
<	O
30	O
,	O
<	O
34	O
,	O
and	O
<	O
37	O
weeks	O
)	O
with	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
concentration	O
in	O
primiparous	B-DISO
women	B-LIVB
who	O
had	O
undergone	O
at	O
least	O
1	O
invasive	O
cervical	B-PROC
procedure	I-PROC
(	O
n	O
=	O
473	O
)	O
was	O
compared	O
with	O
prediction	O
in	O
women	B-LIVB
who	O
had	O
previous	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
,	O
preterm	B-DISO
prelabor	I-DISO
rupture	I-DISO
of	I-DISO
membranes	I-DISO
,	O
or	O
late	B-DISO
miscarriage	I-DISO
(	O
n	O
=	O
821	O
)	O
.	O

Relationship	O
with	O
cervical	O
length	O
was	O
explored	O
.	O

The	O
rate	O
of	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
<	O
34	O
weeks	O
in	O
the	O
cervical	B-PROC
surgery	I-PROC
group	O
was	O
3	O
%	O
compared	O
with	O
9	O
%	O
in	O
previous	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
group	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
comparing	O
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
for	O
prediction	O
at	O
all	O
3	O
gestational	O
end	O
points	O
were	O
comparable	O
between	O
the	O
cervical	B-PROC
surgery	I-PROC
and	O
previous	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
groups	O
(	O
34	O
weeks	O
:	O
area	O
under	O
the	O
curve	O
,	O
0	O
.	O
78	O
[	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
64	O
-	O
0	O
.	O
93	O
]	O
vs	O
0	O
.	O
71	O
[	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
64	O
-	O
0	O
.	O
78	O
]	O
;	O
P	O
=	O
.39	O
)	O
.	O

Prediction	O
of	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
using	O
cervical	B-PROC
length	I-PROC
compared	O
with	O
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
for	O
prediction	O
of	O
preterm	B-DISO
birth	I-DISO
<	O
34	O
weeks	O
of	O
gestation	B-PHYS
offered	O
similar	O
prediction	O
(	O
area	O
under	O
the	O
curve	O
,	O
0	O
.	O
88	O
[	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
79	O
-	O
0	O
.	O
96	O
]	O
vs	O
0	O
.	O

77	O
[	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
62	O
-	O
0	O
.	O
92	O
]	O
,	O
P	O
=	O
.12	O
in	O
the	O
cervical	B-PROC
surgery	I-PROC
group	O
;	O
and	O
0	O
.	O
77	O
[	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
70	O
-	O
0	O
.	O
84	O
]	O
vs	O
0	O
.	O
74	O
[	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
67	O
-	O
0	O
.	O
81	O
]	O
,	O
P	O
=	O
.32	O
in	O
the	O
previous	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
group	O
)	O
.	O

Prediction	O
of	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
using	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
in	O
asymptomatic	B-DISO
women	B-LIVB
with	O
cervical	B-PROC
surgery	I-PROC
is	O
valid	O
,	O
and	O
has	O
comparative	O
accuracy	O
to	O
that	O
in	O
women	B-LIVB
with	O
a	O
history	B-DISO
of	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
.	O

Proteome	B-CHEM
changes	O
in	O
rat	B-LIVB
serum	B-ANAT
after	O
a	O
chronic	B-PHEN
ingestion	I-PHEN
of	O
enriched	O
uranium	B-CHEM
:	O
Toward	O
a	O
biological	B-PHYS
signature	I-PHYS
of	O
internal	O
contamination	O
and	O
radiological	O
effect	O
The	O
civilian	B-LIVB
and	O
military	B-LIVB
use	O
of	O
uranium	B-CHEM
results	O
in	O
an	O
increased	O
risk	O
of	O
human	B-LIVB
exposure	O
.	O

The	O
toxicity	B-DISO
of	O
uranium	B-CHEM
results	O
from	O
both	O
its	O
chemical	B-PHEN
and	O
radiological	O
properties	O
that	O
vary	O
with	O
isotopic	O
composition	B-PHYS
.	O

Validated	O
biomarkers	B-PHYS
of	O
health	O
effects	O
associated	O
with	O
exposure	O
to	O
uranium	B-CHEM
are	O
neither	O
sensitive	O
nor	O
specific	O
to	O
uranium	B-CHEM
radiotoxicity	B-DISO
and	O
/	O
or	O
radiological	O
effect	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
if	O
serum	B-CHEM
proteins	I-CHEM
could	O
be	O
useful	O
as	O
biomarkers	B-PHYS
of	O
both	O
uranium	O
exposure	O
and	O
radiological	O
effect	O
.	O

Male	O
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
were	O
chronically	O
exposed	O
through	O
drinking	B-OBJC
water	I-OBJC
to	O
low	O
levels	O
(	O
40mg	O
/	O
L	O
,	O
corresponding	O
to	O
1	O
mg	O
of	O
uranium	B-CHEM
per	O
animal	B-LIVB
per	O
day	O
)	O
of	O
either	O
4	O
%	O
(	O
235	O
)	O
U	B-CHEM
-	I-CHEM
enriched	I-CHEM
uranium	I-CHEM
(	O
EU	B-CHEM
)	O
or	O
12	O
%	O
EU	B-CHEM
during	O
6	O
weeks	O
.	O

A	O
proteomics	O
approach	O
based	O
on	O
two	O
-	O
dimensional	O
electrophoresis	O
(	O
2D	B-PROC
-	I-PROC
DIGE	I-PROC
)	O
and	O
mass	B-PROC
spectrometry	I-PROC
(	O
MS	B-PROC
)	O
was	O
used	O
to	O
establish	O
protein	B-PHYS
expression	I-PHYS
profiles	B-PROC
that	O
could	O
be	O
relevant	O
for	O
discriminating	O
between	O
groups	O
,	O
and	O
to	O
identify	O
some	O
differentially	O
expressed	B-PHYS
proteins	I-PHYS
following	O
uranium	B-CHEM
ingestion	B-PHEN
.	O

It	O
demonstrated	O
that	O
the	O
expressions	B-PHYS
of	O
174	O
protein	B-CHEM
spots	I-CHEM
over	O
1045	O
quantified	O
spots	B-CHEM
were	O
altered	O
after	O
uranium	O
exposure	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Using	O
both	O
inferential	O
and	O
non	B-PROC
-	I-PROC
supervised	I-PROC
multivariate	I-PROC
statistics	I-PROC
,	O
we	O
show	O
sets	O
of	O
spots	B-CHEM
features	O
that	O
lead	O
to	O
a	O
clear	O
discrimination	O
between	O
controls	B-LIVB
and	O
EU	O
exposed	O
groups	O
on	O
the	O
one	O
hand	O
(	O
21	O
spots	B-CHEM
)	O
,	O
and	O
between	O
4	O
%	O
EU	B-CHEM
and	O
12	O
%	O
EU	B-CHEM
on	O
the	O
other	O
hand	O
(	O
7	O
spots	B-CHEM
)	O
,	O
showing	O
that	O
investigation	O
of	O
the	O
serum	B-ANAT
proteome	B-CHEM
may	O
possibly	O
be	O
of	O
relevance	O
to	O
address	O
both	O
uranium	B-CHEM
contamination	O
and	O
radiological	O
effect	O
.	O

Finally	O
,	O
using	O
bioinformatics	O
tools	O
,	O
pathway	O
analyses	O
of	O
differentially	O
expressed	B-PHYS
MS	B-PROC
-	O
identified	O
proteins	B-CHEM
find	O
that	O
acute	O
phase	O
,	O
inflammatory	O
and	O
immune	B-PHYS
responses	I-PHYS
as	O
well	O
as	O
oxidative	B-DISO
stress	I-DISO
are	O
likely	O
involved	O
in	O
the	O
response	O
to	O
contamination	O
,	O
suggesting	O
a	O
physiological	O
perturbation	O
,	O
but	O
that	O
does	O
not	O
necessarily	O
lead	O
to	O
a	O
toxic	B-DISO
effect	I-DISO
.	O

Prediction	O
of	O
extravasation	B-DISO
in	O
pelvic	B-DISO
fracture	I-DISO
using	O
coagulation	B-PHYS
biomarkers	B-PHYS
To	O
evaluate	O
the	O
usefulness	O
of	O
coagulation	B-PHYS
biomarkers	B-PHYS
,	O
which	O
are	O
easy	O
and	O
quick	O
to	O
analyze	O
in	O
emergency	B-PHEN
settings	I-PHEN
,	O
for	O
prediction	O
of	O
arterial	B-ANAT
extravasation	B-DISO
due	O
to	O
pelvic	B-DISO
fracture	I-DISO
.	O

The	O
medical	O
records	O
of	O
pelvic	B-DISO
fracture	I-DISO
patients	B-LIVB
transferred	O
to	O
the	O
emergency	O
department	O
of	O
Gunma	O
University	O
Hospital	O
between	O
December	O
2009	O
and	O
May	O
2015	O
were	O
reviewed	O
.	O

Patients	B-LIVB
were	O
divided	O
into	O
two	O
groups	O
,	O
those	O
with	O
(	O
Extra	B-DISO
(	I-DISO
+	I-DISO
)	I-DISO
)	O
and	O
without	O
(	O
Extra	B-DISO
(	I-DISO
-	I-DISO
)	I-DISO
)	O
arterial	B-ANAT
extravasation	B-DISO
on	O
enhanced	O
CT	B-PROC
or	O
angiography	B-PROC
.	O

Levels	O
of	O
fibrin	B-PROC
degradation	I-PROC
products	I-PROC
(	O
FDP	B-PROC
)	O
,	O
D	B-PROC
-	I-PROC
dimer	I-PROC
,	O
fibrinogen	B-PROC
,	O
the	O
ratio	B-PROC
of	I-PROC
FDP	I-PROC
to	I-PROC
fibrinogen	I-PROC
,	O
the	O
ratio	B-PROC
of	I-PROC
D	I-PROC
-	I-PROC
dimer	I-PROC
to	I-PROC
fibrinogen	I-PROC
,	O
systolic	B-PHYS
blood	I-PHYS
pressure	I-PHYS
,	O
heart	B-PHYS
rate	I-PHYS
,	O
the	O
Glasgow	O
Coma	O
Scale	O
,	O
pH	O
,	O
base	B-PROC
excess	I-PROC
,	O
hemoglobin	B-PROC
and	O
lactate	B-PROC
levels	O
,	O
the	O
pattern	O
of	O
pelvic	B-DISO
injury	I-DISO
,	O
and	O
injury	O
severity	O
score	O
were	O
measured	O
at	O
hospital	B-PROC
admission	I-PROC
,	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

Parameters	O
with	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
were	O
used	O
to	O
construct	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
.	O

The	O
study	O
included	O
29	O
patients	B-LIVB
with	O
pelvic	B-DISO
fracture	I-DISO
.	O

FDP	B-CHEM
,	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O
the	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
were	O
the	O
most	O
useful	O
parameters	O
for	O
predicting	O
arterial	B-ANAT
extravasation	B-DISO
due	O
to	O
pelvic	B-DISO
fracture	I-DISO
.	O

FDP	B-CHEM
,	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
the	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
,	O
and	O
hemoglobin	B-PHEN
and	O
lactate	B-PHEN
levels	I-PHEN
were	O
significantly	O
higher	O
in	O
the	O
Extra	B-DISO
(	I-DISO
+	I-DISO
)	I-DISO
group	O
than	O
in	O
the	O
Extra	B-DISO
(	I-DISO
-	I-DISO
)	I-DISO
group	O
(	O
FDP	B-CHEM
,	O
354	O
.	O

8μg	O
/	O
mL	O
[	O
median	O
]	O
versus	O
96	O
.	O

6μg	O
/	O
mL	O
;	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O
122	O
.	O

3μg	O
/	O
mL	O
versus	O
42	O
.	O

1μg	O
/	O
mL	O
;	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
3	O
.	O
39	O
versus	O
0	O
.	O
42	O
;	O
the	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
,	O
1	O
.	O
14	O
versus	O
0	O
.	O
18	O
;	O
hemoglobin	B-PHEN
,	O
10	O
.	O

5g	O
/	O
dL	O
versus	O
13	O
.	O

5g	O
/	O
dL	O
;	O
lactate	B-PHEN
,	O
3	O
.	O

5mmol	O
/	O
L	O
versus	O
1	O
.	O

7mmol	O
/	O
L	O
)	O
.	O

The	O
area	O
under	O
the	O
ROC	O
curves	O
for	O
FDP	B-CHEM
,	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O
the	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O
the	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
,	O
hemoglobin	B-PHEN
and	O
lactate	B-PHEN
levels	I-PHEN
were	O
0	O
.	O
900	O
,	O
0	O
.	O
882	O
,	O
0	O
.	O
918	O
,	O
0	O
.	O
900	O
,	O
0	O
.	O
815	O
and	O
0	O
.	O
765	O
,	O
respectively	O
.	O

Coagulation	B-PHYS
biomarkers	B-PHYS
,	O
and	O
hemoglobin	B-PHEN
and	O
lactate	B-PHEN
levels	I-PHEN
could	O
be	O
useful	O
to	O
predict	O
the	O
existence	B-DISO
of	O
arterial	B-ANAT
extravasation	B-DISO
due	O
to	O
pelvic	B-DISO
fracture	I-DISO
.	O

The	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O
the	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
were	O
the	O
most	O
accurate	B-DEVI
markers	I-DEVI
.	O

Coagulation	B-PHYS
biomarkers	B-PHYS
may	O
enable	O
more	O
rapid	O
and	O
specific	O
treatment	O
for	O
pelvic	B-DISO
fracture	I-DISO
.	O

Social	O
security	O
status	O
and	O
mortality	B-DISO
in	O
Belgian	B-LIVB
and	O
Spanish	B-LIVB
male	B-LIVB
workers	B-LIVB
To	O
assess	B-PROC
differences	O
in	O
mortality	O
rates	O
between	O
social	O
security	O
statuses	O
in	O
two	O
independent	O
samples	B-LIVB
of	O
Belgian	B-LIVB
and	O
Spanish	B-LIVB
male	B-LIVB
workers	B-LIVB
.	O

Study	B-PROC
of	I-PROC
two	I-PROC
retrospective	I-PROC
cohorts	I-PROC
(	O
Belgium	B-GEOG
,	O
n	O
=	O
23	O
,	O
607	O
;	O
Spain	B-GEOG
,	O
n	O
=	O
44	O
,	O
385	O
)	O
of	O
50	O
-	O
60	O
year	O
old	O
male	B-LIVB
employees	B-LIVB
with	O
4	O
years	O
of	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Mortality	O
rate	O
ratios	O
(	O
MRR	O
)	O
were	O
estimated	O
using	O
Poisson	O
regression	O
models	O
.	O

Mortality	B-DISO
for	O
subjects	B-LIVB
with	O
permanent	O
disability	B-DISO
was	O
higher	O
than	O
for	O
the	O
employed	B-DISO
,	O
for	O
both	O
Belgium	B-GEOG
[	O
MRR	O
=	O
4	O
.	O
56	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
88	O
-	O
7	O
.	O
21	O
)	O
]	O
and	O
Spain	B-GEOG
[	O
MRR	O
=	O
7	O
.	O
15	O
(	O
95	O
%	O
CI	O
:	O
5	O
.	O
37	O
-	O
9	O
.	O
51	O
)	O
]	O
.	O

For	O
the	O
unemployed	B-DISO
/	O
early	O
retirees	B-LIVB
,	O
mortality	B-DISO
was	O
higher	O
in	O
Spain	B-GEOG
[	O
MRR	O
=	O
1	O
.	O

64	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
24	O
-	O
2	O
.	O
17	O
)	O
]	O
than	O
in	O
Belgium	B-GEOG
[	O
MRR	O
=	O
0	O
.	O
88	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
46	O
-	O
1	O
.	O
71	O
)	O
]	O
.	O

MRR	O
differences	O
between	O
Belgium	B-GEOG
and	O
Spain	B-GEOG
for	O
unemployed	B-DISO
workers	B-LIVB
could	O
be	O
partly	O
explained	O
because	O
of	O
differences	O
between	O
the	O
two	O
social	O
security	O
systems	O
.	O

Future	O
studies	B-PROC
should	O
further	O
explore	O
mortality	B-DISO
differences	O
between	O
countries	B-GEOG
with	O
different	O
social	O
security	O
systems	O
.	O

Direct	O
contact	O
with	O
perivascular	B-ANAT
tumor	B-ANAT
cells	I-ANAT
enhances	O
integrin	B-CHEM
αvβ3	I-CHEM
signaling	B-PHYS
and	O
migration	B-PHYS
of	O
endothelial	B-ANAT
cells	I-ANAT
The	O
secretion	B-PHYS
of	O
soluble	O
pro	B-CHEM
-	I-CHEM
angiogenic	I-CHEM
factors	I-CHEM
by	O
tumor	B-ANAT
cells	I-ANAT
and	O
stromal	B-ANAT
cells	I-ANAT
in	O
the	O
perivascular	B-ANAT
niche	O
promotes	O
the	O
aggressive	B-DISO
angiogenesis	I-DISO
that	O
is	O
typical	O
of	O
glioblastoma	B-DISO
(	O
GBM	B-DISO
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
angiogenesis	B-DISO
also	O
can	O
be	O
promoted	O
by	O
a	O
direct	O
interaction	O
between	O
brain	B-ANAT
tumor	B-ANAT
cells	I-ANAT
,	O
including	O
tumor	B-ANAT
cells	I-ANAT
with	O
cancer	B-ANAT
stem	I-ANAT
-like	O
properties	O
(	O
CSCs	B-ANAT
)	O
,	O
and	O
endothelial	B-ANAT
cells	I-ANAT
(	O
ECs	B-ANAT
)	O
.	O

As	O
shown	O
in	O
vitro	O
,	O
this	O
direct	O
interaction	O
is	O
mediated	O
by	O
binding	B-PHYS
of	O
integrin	B-CHEM
αvβ3	I-CHEM
expressed	B-PHYS
on	O
ECs	B-ANAT
to	O
the	O
RGD	B-CHEM
-	I-CHEM
peptide	I-CHEM
in	O
L1CAM	B-CHEM
expressed	B-PHYS
on	O
CSCs	B-ANAT
.	O

It	O
promotes	O
both	O
EC	B-ANAT
network	B-PHYS
formation	I-PHYS
and	O
enhances	O
directed	O
migration	B-PHYS
toward	O
basic	O
fibroblast	B-CHEM
growth	I-CHEM
factor	I-CHEM
.	O

Activation	O
of	O
αvβ3	B-CHEM
and	O
bone	B-CHEM
marrow	I-CHEM
tyrosine	I-CHEM
kinase	I-CHEM
on	I-CHEM
chromosome	I-CHEM
X	I-CHEM
(	O
BMX	B-CHEM
)	O
is	O
required	O
for	O
migration	B-PHYS
stimulated	O
by	O
direct	O
binding	B-PHYS
but	O
not	O
for	O
migration	B-PHYS
stimulated	O
by	O
soluble	O
factors	O
.	O

RGD	B-CHEM
-	I-CHEM
peptide	I-CHEM
treatment	O
of	O
mice	B-LIVB
with	O
established	O
intracerebral	O
GBM	B-DISO
xenografts	B-CHEM
significantly	O
reduced	O
the	O
percentage	O
of	O
Sox2	B-CHEM
-positive	O
tumor	B-ANAT
cells	I-ANAT
and	O
CSCs	B-ANAT
in	O
close	O
proximity	O
to	O
ECs	B-ANAT
,	O
decreased	O
integrin	B-CHEM
αvβ3	I-CHEM
and	O
BMX	B-CHEM
activation	O
and	O
p130CAS	B-CHEM
phosphorylation	B-PHYS
in	O
the	O
ECs	B-ANAT
,	O
and	O
reduced	O
the	O
vessel	B-ANAT
surface	O
area	O
.	O

These	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
aspect	O
of	O
the	O
regulation	B-PHEN
of	O
angiogenesis	B-DISO
in	O
GBM	B-DISO
that	O
can	O
impact	O
therapeutic	O
anti	B-CHEM
-	I-CHEM
angiogenic	I-CHEM
targeting	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
for	O
Magnetic	B-PROC
Resonance	I-PROC
Imaging	I-PROC
Diagnosis	B-PROC
of	O
Prostate	B-DISO
Cancer	I-DISO
in	O
Patients	B-LIVB
with	O
Prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
Antigen	I-CHEM
<	O
20	O
ng	O
/	O
ml	O
The	O
European	O
Society	O
of	O
Urogenital	O
Radiology	O
has	O
built	O
the	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
(	O
PI	O
-	O
RADS	O
)	O
for	O
standardizing	O
the	O
diagnosis	B-PROC
of	O
prostate	B-DISO
cancer	I-DISO
(	O
PCa	B-DISO
)	O
.	O

This	O
study	B-PROC
evaluated	O
the	O
PI	O
-	O
RADS	O
diagnosis	B-PROC
method	I-PROC
in	O
patients	B-LIVB
with	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
antigen	I-CHEM
(	O
PSA	B-CHEM
)	O
<	O
20	O
ng	O
/	O
ml	O
.	O

A	O
total	O
of	O
133	O
patients	B-LIVB
with	O
PSA	B-CHEM
<	O
20	O
ng	O
/	O
ml	O
were	O
prospectively	O
recruited	O
.	O

T2	B-PROC
-	I-PROC
weighted	I-PROC
(	O
T2WI	B-PROC
)	O
and	O
diffusion	B-PROC
-	I-PROC
weighted	I-PROC
(	I-PROC
DWI	I-PROC
)	I-PROC
magnetic	I-PROC
resonance	I-PROC
images	I-PROC
of	O
the	O
prostate	B-ANAT
were	O
acquired	O
before	O
a	O
12	B-PROC
-	I-PROC
core	I-PROC
transrectal	I-PROC
prostate	I-PROC
biopsy	I-PROC
.	O

Each	O
patient	B-LIVB
's	I-LIVB
peripheral	B-ANAT
zone	I-ANAT
was	O
divided	O
into	O
six	O
regions	O
on	O
the	O
images	O
;	O
each	O
region	O
corresponded	O
to	O
two	O
of	O
the	O
12	O
biopsy	B-PROC
cores	I-PROC
.	O

T2WI	B-PROC
,	O
DWI	B-PROC
,	O
and	O
T2WI	B-PROC
+	O
DWI	B-PROC
scores	O
were	O
computed	O
according	O
to	O
PI	O
-	O
RADS	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
PI	O
-	O
RADS	O
score	O
was	O
evaluated	O
using	O
histopathology	O
of	O
prostate	B-PROC
biopsies	I-PROC
as	O
the	O
reference	O
standard	O
.	O

PCa	B-DISO
was	O
histologically	O
diagnosed	O
in	O
169	O
(	O
21	O
.	O
2	O
%	O
)	O
regions	O
.	O

Increased	O
PI	O
-	O
RADS	O
score	O
correlated	O
positively	O
with	O
increased	O
cancer	B-PROC
detection	I-PROC
rate	O
.	O

The	O
cancer	B-PROC
detection	I-PROC
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2	O
.	O

8	O
%	O
,	O
15	O
.	O
0	O
%	O
,	O
34	O
.	O

6	O
%	O
,	O
52	O
.	O

6	O
%	O
,	O
and	O
88	O
.	O

9	O
%	O
,	O
respectively	O
,	O
using	O
T2WI	B-PROC
and	O
12	O
.	O
0	O
%	O
,	O
20	O
.	O
2	O
%	O
,	O
48	O
.	O
0	O
%	O
,	O
85	O
.	O
7	O
%	O
,	O
and	O
93	O
.	O
3	O
%	O
,	O
respectively	O
,	O
using	O
DWI	B-PROC
.	O

For	O
T2WI	B-PROC
+	O
DWI	B-PROC
,	O
the	O
cancer	B-PROC
detection	I-PROC
rate	O
was	O
1	O
.	O

5	O
%	O
(	O
score	O
2	O
)	O
,	O
13	O
.	O
5	O
%	O
(	O
scores	O
3	O
-	O
4	O
)	O
,	O
41	O
.	O
3	O
%	O
(	O
scores	O
5	O
-	O
6	O
)	O
,	O
75	O
.	O
9	O
%	O
(	O
scores	O
7	O
-	O
8	O
)	O
,	O
and	O
92	O
.	O
3	O
%	O
(	O
scores	O
9	O
-	O
10	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	B-PROC
detection	I-PROC
was	O
0	O
.	O
700	O
(	O
T2WI	B-PROC
)	O
,	O
0	O
.	O
735	O
(	O
DWI	B-PROC
)	O
and	O
0	O
.	O
749	O
(	O
T2WI	B-PROC
+	O
DWI	B-PROC
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
were	O
53	O
.	O

8	O
%	O
and	O
89	O
.	O

2	O
%	O
,	O
respectively	O
,	O
when	O
using	O
scores	O
5	O
-	O
6	O
as	O
the	O
cutoff	O
value	O
for	O
T2WI	B-PROC
+	O
DWI	B-PROC
.	O

The	O
PI	O
-	O
RADS	O
score	O
correlates	O
with	O
the	O
PCa	B-PROC
detection	I-PROC
rate	O
in	O
patients	B-LIVB
with	O
PSA	B-CHEM
<	O
20	O
ng	O
/	O
ml	O
.	O

The	O
summed	O
score	O
of	O
T2WI	B-PROC
+	O
DWI	B-PROC
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
PCa	B-DISO
.	O

However	O
,	O
the	O
sensitivity	O
should	O
be	O
further	O
improved	O
.	O

The	O
use	O
of	O
Ocimum	B-LIVB
americanum	I-LIVB
essential	B-CHEM
oil	I-CHEM
against	O
the	O
pathogens	B-LIVB
Aeromonas	B-LIVB
hydrophila	I-LIVB
and	O
Gyrodactylus	O
sp	O
.	O

in	O
silver	B-LIVB
catfish	I-LIVB
(	O
Rhamdia	B-LIVB
quelen	I-LIVB
)	O
The	O
bactericidal	B-PHEN
activity	I-PHEN
(	O
MIC	B-PROC
-	I-PROC
test	I-PROC
)	O
of	O
Ocimum	B-LIVB
americanum	I-LIVB
(	O
inflorescences	B-LIVB
)	O
essential	B-CHEM
oil	I-CHEM
(	O
OAEO	B-CHEM
)	O
against	O
Aeromonas	B-LIVB
hydrophila	I-LIVB
was	O
determined	O
in	O
this	O
study	O
.	O

It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	B-CHEM
and	O
the	O
main	O
compound	O
found	O
in	O
the	O
oil	B-CHEM
(	O
linalool	B-CHEM
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	B-CHEM
of	O
hemolysis	B-DISO
caused	O
by	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
in	O
fish	B-LIVB
erythrocytes	B-ANAT
.	O

An	O
in	B-PROC
vivo	I-PROC
experiment	I-PROC
was	O
conducted	O
to	O
evaluate	O
survival	O
of	O
fish	B-LIVB
(	O
Rhamdia	B-LIVB
quelen	I-LIVB
)	O
experimentally	B-PROC
infected	B-DISO
with	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
and	O
exposed	O
to	O
OAEO	B-CHEM
.	O

A	O
second	O
experiment	B-PROC
was	O
conducted	O
to	O
evaluate	O
the	O
in	B-PROC
vitro	I-PROC
and	O
in	B-PROC
vivo	I-PROC
activity	O
of	O
OAEO	B-CHEM
(	O
mix	O
from	O
inflorescences	B-LIVB
and	O
leaves	B-LIVB
)	O
against	O
the	O
parasite	O
Gyrodactylus	O
sp	O
.	O

The	O
OAEO	B-CHEM
showed	O
weak	O
in	B-PROC
vitro	I-PROC
activity	O
against	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
(	O
6400	O
μg	O
ml	O
(	O
-	O
1	O
)	O
)	O
.	O

At	O
subinhibitory	O
concentrations	O
OAEO	B-CHEM
(	O
100	O
μg	O
ml	O
(	O
-	O
1	O
)	O
)	O
inhibited	O
hemolysis	B-DISO
(	O
90	O
%	O
)	O
caused	O
by	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
in	O
fish	B-LIVB
erythrocytes	B-ANAT
,	O
however	O
,	O
linalool	B-CHEM
did	O
not	O
present	O
hemolysis	B-DISO
inhibition	O
activity	O
.	O

At	O
low	O
concentrations	O
(	O
10	O
and	O
20	O
mg	O
l	O
(	O
-	O
1	O
)	O
)	O
added	O
to	O
the	O
water	B-CHEM
OAEO	B-CHEM
promoted	O
survival	O
of	O
experimentally	O
infected	B-DISO
fish	B-LIVB
with	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
.	O

Lastly	O
,	O
OAEO	B-CHEM
-mix	O
(	O
50	O
mg	O
l	O
(	O
-	O
1	O
)	O
)	O
was	O
effective	O
against	O
Gyrodactylus	O
sp	O
.	O

significantly	O
reducing	O
(	O
60	O
%	O
)	O
the	O
number	O
of	O
parasites	O
in	O
the	O
fish	B-LIVB
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Efficacy	O
and	O
safety	O
of	O
asenapine	B-CHEM
in	O
Asian	B-LIVB
patients	B-LIVB
with	O
an	O
acute	B-DISO
exacerbation	I-DISO
of	O
schizophrenia	B-DISO
:	O
a	O
multicentre	B-PROC
,	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
6	O
-	O
week	O
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
study	I-PROC
Asenapine	B-CHEM
is	O
a	O
second	O
generation	O
anti	B-CHEM
-	I-CHEM
psychotic	I-CHEM
approved	O
in	O
the	O
USA	B-GEOG
in	O
2009	O
for	O
the	O
treatment	B-PROC
of	O
schizophrenia	B-DISO
,	O
but	O
its	O
efficacy	O
has	O
not	O
been	O
proven	O
in	O
Asian	B-LIVB
patients	B-LIVB
.	O

The	O
objectives	O
of	O
this	O
study	B-PROC
are	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
asenapine	B-CHEM
in	O
Asian	B-LIVB
patients	B-LIVB
experiencing	O
an	O
acute	B-DISO
exacerbation	I-DISO
of	O
schizophrenia	B-DISO
.	O

In	O
this	O
prospective	O
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
study	I-PROC
,	O
patients	B-LIVB
in	O
Japan	B-GEOG
,	O
Korea	B-GEOG
,	O
and	O
Taiwan	B-GEOG
were	O
randomized	B-PROC
(	O
1	O
:	O
1	O
:	O
1	O
)	O
to	O
asenapine	B-CHEM
5	O
mg	O
twice	O
daily	O
(	O
bid	O
)	O
,	O
10	O
mg	O
bid	O
or	O
placebo	B-PROC
for	O
6	O
weeks	O
after	O
a	O
3	O
-	O
to	O
7	O
-	O
day	O
washout	O
/	O
screening	O
period	O
.	O

The	O
primary	B-CHEM
endpoint	I-CHEM
was	O
the	O
mean	O
change	O
in	O
the	O
positive	O
and	O
negative	O
syndrome	O
scale	O
(	O
PANSS	O
)	O
total	O
score	O
from	O
baseline	O
to	O
day	O
42	O
/	O
treatment	B-PROC
end	O
.	O

Of	O
the	O
532	O
participants	B-LIVB
randomized	B-PROC
,	O
530	O
received	O
treatment	B-PROC
.	O

The	O
primary	B-CHEM
endpoint	I-CHEM
was	O
significantly	O
greater	O
with	O
asenapine	B-CHEM
5	O
and	O
10	O
mg	O
bid	O
than	O
with	O
placebo	B-PROC
(	O
-12	O
.	O
24	O
and	O
-14	O
.	O
17	O
vs	O
.	O

-0	O
.	O
95	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
results	O
of	O
secondary	O
endpoints	O
including	O
PANSS	O
negative	O
subscale	O
scores	O
and	O
PANSS	O
responders	O
at	O
the	O
end	O
of	O
treatment	B-PROC
supported	O
the	O
results	O
of	O
the	O
primary	B-CHEM
endpoint	I-CHEM
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
incidence	O
of	O
treatment	O
-emergent	O
adverse	B-DISO
events	I-DISO
reported	O
with	O
asenapine	B-CHEM
5	O
and	O
10	O
mg	O
bid	O
and	O
placebo	B-PROC
(	O
84	O
.	O
6	O
,	O
80	O
.	O
7	O
,	O
and	O
81	O
.	O
6	O
%	O
)	O
.	O

There	O
was	O
a	O
mean	O
(	O
±	O
standard	O
deviation	O
)	O
change	O
in	O
weight	O
of	O
-1	O
.	O

76	O
±	O
2	O
.	O

45	O
kg	O
for	O
placebo	B-PROC
,	O
+0	O
.	O

42	O
±	O
2	O
.	O
65	O
kg	O
for	O
asenapine	B-CHEM
5	O
mg	O
bid	O
,	O
and	O
+0	O
.	O

81	O
±	O
2	O
.	O
89	O
kg	O
for	O
asenapine	B-CHEM
10	O
mg	O
bid	O
group	O
.	O

Asenapine	B-CHEM
was	O
effective	O
and	O
generally	O
well	O
tolerated	O
when	O
used	O
for	O
the	O
treatment	B-PROC
of	O
acute	B-DISO
exacerbations	I-DISO
of	O
schizophrenia	B-DISO
in	O
Asian	B-LIVB
patients	B-LIVB
.	O

Interleukin	B-CHEM
-	I-CHEM
1β	I-CHEM
induced	O
Stress	B-ANAT
Granules	I-ANAT
Sequester	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
mRNA	B-CHEM
and	O
Regulates	B-PHEN
its	O
Stability	O
and	O
Translation	O
in	O
Human	B-LIVB
OA	B-DISO
Chondrocytes	B-ANAT
Enhanced	O
and	O
immediate	O
expression	B-PHYS
of	O
cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
mRNA	B-CHEM
is	O
observed	O
in	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-	O
stimulated	B-PROC
OA	B-DISO
chondrocytes	B-ANAT
but	O
the	O
synthesis	B-PHYS
of	I-PHYS
protein	I-PHYS
found	O
significantly	O
delayed	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
stress	B-ANAT
granules	I-ANAT
(	O
SGs	B-ANAT
)	O
,	O
ribonucleoprotein	B-ANAT
complexes	I-ANAT
that	O
regulate	B-PHEN
mRNA	O
translation	O
,	O
in	O
the	O
delayed	O
translation	O
of	O
COX	O
-	O
2	O
mRNAs	B-CHEM
in	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-	O
stimulated	B-PROC
OA	B-DISO
chondrocytes	B-ANAT
.	O

Stimulation	B-PROC
of	O
human	B-LIVB
chondrocytes	B-ANAT
with	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
activated	O
the	O
stress	B-PHYS
response	I-PHYS
genes	O
and	O
the	O
phosphorylation	B-PHYS
of	O
eIF2α	B-CHEM
that	O
triggered	O
the	O
assembly	B-PHYS
of	I-PHYS
SGs	I-PHYS
.	O

Using	O
combined	O
immunofluorescence	B-PROC
staining	I-PROC
of	O
SGs	B-ANAT
markers	B-PHYS
and	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
protein	I-CHEM
,	O
RNA	B-CHEM
fluorescence	B-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
and	O
RNA	B-CHEM
immunoprecipitation	B-PROC
,	O
the	O
COX	O
-	O
2	O
mRNAs	B-CHEM
were	O
found	O
sequestered	O
in	O
SGs	B-ANAT
in	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-	O
stimulated	B-PROC
OA	B-DISO
chondrocytes	B-ANAT
.	O

No	B-DISO
increase	O
in	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
protein	B-PHYS
expression	I-PHYS
was	O
observed	O
during	O
the	O
persistence	O
of	O
SGs	B-ANAT
but	O
enhanced	O
expression	B-PHYS
of	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
protein	I-CHEM
was	O
noted	O
upon	O
clearance	O
of	O
the	O
SGs	B-ANAT
.	O

Inhibition	O
of	O
SGs	B-ANAT
clearance	O
blocked	O
COX	O
-	O
2	O
mRNA	B-CHEM
translation	O
whereas	O
blocking	O
the	O
assembly	B-PHYS
of	I-PHYS
SGs	I-PHYS
by	O
TIA	B-CHEM
-	I-CHEM
1	I-CHEM
depletion	O
resulted	O
in	O
rapid	O
and	O
increased	O
production	O
of	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
PGE2	B-CHEM
.	O

Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	B-PHYS
of	I-PHYS
SGs	I-PHYS
and	O
sequestration	O
of	O
COX	O
-	O
2	O
mRNAs	B-CHEM
in	O
human	B-LIVB
OA	B-DISO
chondrocytes	B-ANAT
under	O
pathological	B-DISO
conditions	I-DISO
.	O

Post	B-PHYS
-	I-PHYS
transcriptional	I-PHYS
regulation	I-PHYS
of	O
COX	O
-	O
2	O
mRNAs	O
translation	O
by	O
SGs	B-ANAT
indicates	O
a	O
role	O
in	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-mediated	O
catabolic	O
response	B-PHYS
that	O
could	O
be	O
therapeutically	B-PROC
targeted	O
in	O
OA	B-DISO
.	O

Effect	O
of	O
target	O
animacy	O
on	O
hand	B-DISO
preference	I-DISO
in	O
Sichuan	B-LIVB
snub	I-LIVB
-	I-LIVB
nosed	I-LIVB
monkeys	I-LIVB
(	O
Rhinopithecus	B-LIVB
roxellana	I-LIVB
)	O
Twenty	O
-	O
eight	O
captive	O
Sichuan	B-LIVB
snub	I-LIVB
-	I-LIVB
nosed	I-LIVB
monkeys	I-LIVB
(	O
Rhinopithecus	B-LIVB
roxellana	I-LIVB
)	O
were	O
involved	O
in	O
the	O
current	O
study	B-PROC
.	O

Many	O
individuals	O
showed	O
handedness	B-PHYS
,	O
with	O
a	O
modest	O
tendency	O
toward	O
left	B-DISO
-	I-DISO
hand	I-DISO
use	I-DISO
especially	O
for	O
animate	O
targets	O
,	O
although	O
no	O
group	O
-	O
level	O
handedness	B-PHYS
was	O
found	B-DISO
.	O

There	O
was	O
no	B-DISO
significant	I-DISO
gender	B-PHYS
difference	I-PHYS
in	O
the	O
direction	O
and	O
strength	O
of	O
hand	B-DISO
preference	I-DISO
for	O
both	O
targets	O
.	O

Females	B-PHYS
showed	O
a	O
significantly	O
higher	O
overall	O
rate	O
of	O
actions	O
toward	O
animate	O
targets	O
than	O
inanimate	O
targets	O
for	O
both	O
hands	B-ANAT
,	O
whereas	O
males	B-PHYS
displayed	O
almost	O
the	O
reversed	O
pattern	O
.	O

There	O
were	O
no	B-DISO
significant	I-DISO
interactions	O
between	O
lateral	O
hand	B-PHYS
use	I-PHYS
and	O
target	O
animacy	O
for	O
either	B-DISO
males	B-PHYS
or	O
females	B-PHYS
.	O

Most	O
individuals	O
showed	O
rightward	O
or	O
leftward	O
laterality	O
shift	O
trends	O
between	O
inanimate	O
and	O
animate	O
targets	O
.	O

These	O
findings	B-DISO
to	O
some	O
extent	O
support	O
the	O
existence	O
of	O
a	O
potential	O
trend	O
concerning	O
a	O
categorical	O
neural	O
distinction	O
between	O
targets	O
demanding	O
functional	O
manipulation	B-DISO
(	O
inanimate	B-OBJC
objects	I-OBJC
)	O
and	O
those	O
demanding	O
social	O
manipulation	B-DISO
(	O
animate	B-OBJC
objects	I-OBJC
)	O
,	O
even	O
though	O
specialized	O
hand	B-DISO
preference	I-DISO
based	O
on	O
target	O
animacy	O
has	O
not	O
been	O
fully	O
established	O
in	O
this	O
arboreal	B-LIVB
Old	I-LIVB
World	I-LIVB
monkey	I-LIVB
species	I-LIVB
.	O

Association	O
of	O
Autoimmune	B-DISO
Encephalitis	I-DISO
With	O
Combined	O
Immune	B-CHEM
Checkpoint	I-CHEM
Inhibitor	I-CHEM
Treatment	O
for	O
Metastatic	B-DISO
Cancer	I-DISO
Paraneoplastic	B-DISO
encephalitides	I-DISO
usually	O
precede	O
a	O
diagnosis	B-PROC
of	I-PROC
cancer	I-PROC
and	O
are	O
often	O
refractory	O
to	O
immunosuppressive	B-PROC
therapy	I-PROC
.	O

Conversely	O
,	O
autoimmune	B-DISO
encephalitides	I-DISO
are	O
reversible	O
conditions	O
that	O
can	O
occur	O
in	O
the	O
presence	B-DISO
or	O
absence	O
of	O
cancer	B-DISO
.	O

To	O
report	O
the	O
induction	O
of	O
autoimmune	B-DISO
encephalitis	I-DISO
in	O
2	O
patients	B-LIVB
after	O
treatment	O
of	O
metastatic	B-DISO
cancer	I-DISO
with	O
a	O
combination	O
of	O
the	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitors	I-CHEM
nivolumab	B-CHEM
and	O
ipilimumab	B-CHEM
.	O

A	O
retrospective	B-PROC
case	I-PROC
study	I-PROC
was	O
conducted	O
of	O
the	O
clinical	B-PROC
and	I-PROC
management	I-PROC
course	O
of	O
2	O
patients	B-LIVB
with	O
progressive	O
,	O
treatment	O
-	O
refractory	B-DISO
metastatic	I-DISO
cancer	I-DISO
who	O
were	O
treated	B-PROC
with	I-PROC
a	O
single	O
dose	O
each	O
(	O
concomitantly	O
)	O
of	O
the	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitors	I-CHEM
nivolumab	B-CHEM
,	O
1	O
mg	O
/	O
kg	O
,	O
and	O
ipilimumab	B-CHEM
,	O
3	O
mg	O
/	O
kg	O
.	O

Nivolumab	B-CHEM
and	O
ipilimumab	B-CHEM
.	O

The	O
clinical	B-DISO
response	I-DISO
to	O
immunosuppressive	B-PROC
therapy	I-PROC
in	O
suspected	O
autoimmune	B-DISO
encephalitis	I-DISO
in	O
the	O
setting	O
of	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitor	I-CHEM
use	O
.	O

Autoantibody	B-PROC
testing	I-PROC
confirmed	B-DISO
identification	O
of	O
anti	B-CHEM
-	I-CHEM
N	I-CHEM
-	I-CHEM
methyl	I-CHEM
-	I-CHEM
D	I-CHEM
-	I-CHEM
aspartate	I-CHEM
receptor	I-CHEM
antibodies	I-CHEM
in	O
the	O
cerebrospinal	B-ANAT
fluid	I-ANAT
of	O
1	O
patient	B-LIVB
.	O

Withdrawal	O
of	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitors	I-CHEM
and	O
initiation	O
of	O
immunosuppressive	B-PROC
therapy	I-PROC
,	O
consisting	O
of	O
intravenous	O
methylprednisolone	B-CHEM
sodium	I-CHEM
succinate	I-CHEM
equivalent	I-CHEM
to	I-CHEM
1000	I-CHEM
mg	I-CHEM
of	I-CHEM
methylprednisolone	I-CHEM
for	O
5	O
days	O
,	O
0	O
.	O
4	O
mg	O
/	O
kg	O
/	O
d	O
of	O
intravenous	B-CHEM
immunoglobulin	I-CHEM
for	O
5	O
days	O
,	O
and	O
2	O
doses	O
of	O
rituximab	B-CHEM
,	O
1000	O
mg	O
,	O
in	O
1	O
patient	B-LIVB
and	O
oral	B-CHEM
prednisone	I-CHEM
,	O
60	O
mg	O
/	O
d	O
,	O
in	O
the	O
other	O
patient	B-LIVB
,	O
resulted	O
in	O
improved	B-DISO
neurologic	B-DISO
symptoms	I-DISO
.	O

Immune	B-PHYS
checkpoint	I-PHYS
inhibition	I-PHYS
may	O
favor	O
the	O
development	O
of	O
immune	B-PHYS
responses	I-PHYS
against	O
neuronal	B-CHEM
antigens	I-CHEM
,	O
leading	O
to	O
autoimmune	B-DISO
encephalitis	I-DISO
.	O

Early	B-PROC
recognition	I-PROC
and	O
treatment	O
of	O
autoimmune	B-DISO
encephalitis	I-DISO
in	O
patients	B-LIVB
receiving	O
immune	B-PROC
checkpoint	I-PROC
blockade	I-PROC
therapy	I-PROC
will	O
likely	O
be	O
essential	O
for	O
maximizing	O
clinical	O
recovery	O
and	O
minimizing	O
the	O
effect	O
of	O
drug	B-DISO
-	I-DISO
related	I-DISO
toxic	I-DISO
effects	I-DISO
.	O

The	O
mechanisms	O
by	O
which	O
immune	B-PHYS
checkpoint	I-PHYS
inhibition	I-PHYS
may	O
contribute	O
to	O
autoimmune	B-DISO
encephalitis	I-DISO
require	O
further	O
study	O
.	O

Spatio	O
-	O
Temporal	O
Distribution	O
of	O
Bark	B-LIVB
and	O
Ambrosia	B-LIVB
Beetles	O
in	O
a	O
Brazilian	B-GEOG
Tropical	B-PHEN
Dry	I-PHEN
Forest	I-PHEN
Bark	B-LIVB
and	O
the	O
ambrosia	B-LIVB
beetles	O
dig	O
into	O
host	O
plants	O
and	O
live	O
most	O
of	O
their	O
lives	O
in	O
concealed	O
tunnels	O
.	O

We	O
assessed	O
beetle	O
community	B-LIVB
dynamics	O
in	O
tropical	B-PHEN
dry	I-PHEN
forest	I-PHEN
sites	O
in	O
early	O
,	O
intermediate	O
,	O
and	O
late	O
successional	O
stages	O
,	O
evaluating	O
the	O
influence	O
of	O
resource	O
availability	O
and	O
seasonal	O
variations	O
in	O
guild	O
structure	O
.	O

We	O
collected	O
a	O
total	O
of	O
763	O
beetles	O
from	O
23	O
species	O
,	O
including	O
14	O
bark	B-LIVB
beetle	O
species	O
,	O
and	O
9	O
ambrosia	B-LIVB
beetle	O
species	O
.	O

Local	O
richness	O
of	O
bark	B-LIVB
and	O
ambrosia	B-LIVB
beetles	O
was	O
estimated	O
at	O
31	O
species	O
.	O

Bark	B-LIVB
and	O
ambrosia	B-LIVB
composition	O
was	O
similar	O
over	O
the	O
successional	O
stages	O
gradient	O
,	O
and	O
beta	O
diversity	O
among	O
sites	O
was	O
primarily	O
determined	O
by	O
species	O
turnover	O
,	O
mainly	O
in	O
the	O
bark	B-LIVB
beetle	O
community	B-LIVB
.	O

Bark	B-LIVB
beetle	O
richness	O
and	O
abundance	O
were	O
higher	O
at	O
intermediate	O
stages	O
;	O
availability	O
of	O
wood	B-OBJC
was	O
the	O
main	O
spatial	O
mechanism	O
.	O

Climate	B-PHEN
factors	O
were	O
effectively	O
non	O
-	O
seasonal	O
.	O

Ambrosia	B-LIVB
beetles	O
were	O
not	O
influenced	O
by	O
successional	O
stages	O
,	O
however	O
the	O
increase	O
in	O
wood	B-OBJC
resulted	O
in	O
increased	O
abundance	O
.	O

We	O
found	O
higher	O
richness	O
at	O
the	O
end	O
of	O
the	O
dry	O
and	O
wet	O
seasons	O
,	O
and	O
abundance	O
increased	O
with	O
air	B-OBJC
moisture	B-OBJC
and	O
decreased	O
with	O
higher	O
temperatures	O
and	O
greater	O
rainfall	B-PHEN
.	O

In	O
summary	O
,	O
bark	B-LIVB
beetle	O
species	O
accumulation	O
was	O
higher	O
at	O
sites	O
with	O
better	O
wood	B-OBJC
production	O
,	O
while	O
the	O
needs	O
of	O
fungi	B-LIVB
(	O
host	O
and	O
air	B-OBJC
moisture	B-OBJC
)	O
,	O
resulted	O
in	O
a	O
favorable	O
conditions	O
for	O
species	O
accumulation	O
of	O
ambrosia	B-LIVB
.	O

The	O
overall	O
biological	O
pattern	O
among	O
guilds	O
differed	O
from	O
tropical	B-PHEN
rain	I-PHEN
forests	I-PHEN
,	O
showing	O
patterns	O
similar	O
to	O
dry	B-PHEN
forest	I-PHEN
areas	I-PHEN
.	O

Intron	B-CHEM
Derived	O
Size	O
Polymorphism	B-PHYS
in	O
the	O
Mitochondrial	O
Genomes	O
of	O
Closely	O
Related	O
Chrysoporthe	B-LIVB
Species	I-LIVB
In	O
this	O
study	O
,	O
the	O
complete	O
mitochondrial	O
(	O
mt	O
)	O
genomes	O
of	O
Chrysoporthe	B-LIVB
austroafricana	I-LIVB
(	O
190	O
,	O
834	O
bp	O
)	O
,	O
C	B-LIVB
.	I-LIVB

cubensis	I-LIVB
(	O
89	O
,	O
084	O
bp	O
)	O
and	O
C	B-LIVB
.	I-LIVB

deuterocubensis	I-LIVB
(	O
124	O
,	O
412	O
bp	O
)	O
were	O
determined	O
.	O

Additionally	O
,	O
the	O
mitochondrial	O
genome	O
of	O
another	O
member	O
of	O
the	O
Cryphonectriaceae	B-LIVB
,	O
namely	O
Cryphonectria	B-LIVB
parasitica	I-LIVB
(	O
158	O
,	O
902	O
bp	O
)	O
,	O
was	O
retrieved	O
and	O
annotated	O
for	O
comparative	B-PROC
purposes	I-PROC
.	O

These	O
genomes	O
showed	O
high	O
levels	O
of	O
synteny	B-PHYS
,	O
especially	O
in	O
regions	O
including	O
genes	O
involved	O
in	O
oxidative	B-PHYS
phosphorylation	I-PHYS
and	O
electron	B-PHYS
transfer	I-PHYS
,	O
unique	O
open	O
reading	O
frames	O
(	O
uORFs	O
)	O
,	O
ribosomal	B-CHEM
RNAs	I-CHEM
(	B-CHEM
rRNAs	I-CHEM
)	I-CHEM
and	O
transfer	B-CHEM
RNAs	I-CHEM
(	B-CHEM
tRNAs	I-CHEM
)	I-CHEM
,	O
as	O
well	O
as	O
intron	B-CHEM
positions	O
.	O

Comparative	B-PROC
analyses	I-PROC
revealed	O
signatures	O
of	O
duplication	B-PHYS
events	O
,	O
intron	B-CHEM
number	B-PHEN
and	I-PHEN
length	I-PHEN
variation	I-PHEN
,	O
and	O
varying	B-PHEN
intronic	B-CHEM
ORFs	O
which	O
highlighted	O
the	O
genetic	B-PHEN
diversity	I-PHEN
of	O
mt	O
genomes	O
among	O
the	O
Cryphonectriaceae	B-LIVB
.	O

These	O
mt	O
genomes	O
showed	O
remarkable	O
size	O
polymorphism	B-PHYS
.	O

The	O
size	O
polymorphism	B-PHYS
in	O
the	O
mt	O
genomes	O
of	O
these	O
closely	O
related	O
Chrysoporthe	B-LIVB
species	I-LIVB
was	O
attributed	O
to	O
the	O
varying	B-PHEN
number	I-PHEN
and	I-PHEN
length	I-PHEN
of	O
introns	B-CHEM
,	O
coding	O
sequences	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
intergenic	B-CHEM
sequences	I-CHEM
.	O

Compared	O
to	O
publicly	O
available	O
fungal	O
mt	O
genomes	O
,	O
the	O
C	B-LIVB
.	I-LIVB

austroafricana	I-LIVB
mt	O
genome	O
is	O
the	O
second	O
largest	O
in	O
the	O
Ascomycetes	B-LIVB
thus	O
far	O
.	O

Detection	B-PROC
and	O
Characterization	O
of	O
Flat	B-DISO
Aberrant	I-DISO
Crypt	I-DISO
Foci	I-DISO
(	I-DISO
Flat	I-DISO
ACF	I-DISO
)	I-DISO
in	O
the	O
Novel	O
A	B-DISO
/	I-DISO
J	I-DISO
Min	I-DISO
/	I-DISO
+	I-DISO
Mouse	I-DISO
Flat	B-DISO
aberrant	I-DISO
crypt	I-DISO
foci	I-DISO
(	O
flat	B-DISO
ACF	I-DISO
)	O
and	O
mucin	B-DISO
-	I-DISO
depleted	I-DISO
foci	I-DISO
(	O
MDF	B-DISO
)	O
have	O
previously	O
been	O
described	O
as	O
preneoplastic	B-DISO
colonic	I-DISO
lesions	I-DISO
.	O

We	O
used	O
the	O
novel	O
A	B-DISO
/	I-DISO
J	I-DISO
Min	I-DISO
/	I-DISO
+	I-DISO
mouse	I-DISO
model	I-DISO
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon	B-DISO
carcinogenesis	I-DISO
to	O
refine	O
the	O
method	O
of	O
detection	B-PROC
of	O
flat	B-DISO
ACF	I-DISO
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	B-DISO
by	O
histological	B-PROC
examination	I-PROC
and	O
comparison	O
with	O
MDF	B-DISO
.	O

Colons	B-ANAT
were	O
stained	B-PROC
with	I-PROC
methylene	I-PROC
blue	I-PROC
(	O
MB	B-CHEM
)	O
for	O
flat	B-DISO
ACF	I-DISO
detection	B-PROC
and	O
restained	B-PROC
with	O
high	B-CHEM
-	I-CHEM
iron	I-CHEM
diamine	I-CHEM
-	I-CHEM
alcian	I-CHEM
blue	I-CHEM
(	O
HID	B-CHEM
-	I-CHEM
AB	I-CHEM
)	O
for	O
MDF	B-DISO
detection	B-PROC
.	O

Optimal	O
flat	B-DISO
ACF	I-DISO
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post	O
-	O
MB	B-PROC
staining	I-PROC
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics	O
.	O

The	O
fraction	O
of	O
flat	B-DISO
ACF	I-DISO
corresponding	O
with	O
MDF	B-DISO
was	O
93	O
%	O
.	O

Flat	B-DISO
ACF	I-DISO
/	O
MDF	B-DISO
displayed	O
the	O
same	O
picture	O
of	O
severe	B-DISO
dysplasia	I-DISO
,	O
lack	O
of	O
mucus	B-ANAT
and	O
goblet	B-ANAT
cells	I-ANAT
and	O
accumulation	B-DISO
of	O
cytoplasmic	B-ANAT
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
.	O

The	O
easily	O
detectable	O
flat	B-DISO
ACF	I-DISO
are	O
reliable	O
surface	B-ANAT
biomarkers	B-PHYS
of	O
Apc	O
-driven	O
colon	B-DISO
carcinogenesis	I-DISO
.	O

The	O
flavivirus	B-LIVB
dengue	B-LIVB
induces	O
hypertrophy	B-DISO
of	O
white	O
matter	O
astrocytes	B-ANAT
Flaviviruses	B-LIVB
,	O
including	O
Zika	B-LIVB
and	O
dengue	B-LIVB
(	O
DENV	B-LIVB
)	O
,	O
pose	O
a	O
serious	O
global	O
threat	O
to	O
human	B-LIVB
health	O
.	O

Of	O
the	O
50	O
+	O
million	O
humans	B-LIVB
infected	B-DISO
with	O
DENV	B-LIVB
annually	O
,	O
approximately	O
1	O
-	O
3	O
%	O
progress	O
to	O
severe	B-PHEN
disease	I-PHEN
manifestations	I-PHEN
,	O
dengue	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
(	O
DHF	B-DISO
)	O
or	O
dengue	B-DISO
shock	I-DISO
syndrome	I-DISO
(	O
DSS	B-DISO
)	O
.	O

Several	O
factors	O
are	O
suspected	O
to	O
mediate	O
the	O
course	O
of	O
infection	B-DISO
and	O
pathogenesis	B-DISO
of	O
DENV	B-LIVB
infection	B-DISO
.	O

DHF	B-DISO
and	O
DSS	B-DISO
are	O
associated	O
with	O
vascular	B-DISO
leakage	I-DISO
and	O
neurological	B-DISO
sequelae	I-DISO
.	O

Our	O
hypothesis	O
was	O
that	O
altered	O
astrocyte	B-PHYS
activation	I-PHYS
and	O
morphology	O
would	O
alter	O
the	O
dynamics	B-PHEN
of	O
the	O
extracellular	B-ANAT
space	I-ANAT
and	O
hence	O
,	O
neuronal	B-PHYS
and	O
vascular	B-PHYS
function	I-PHYS
.	O

We	O
investigated	O
the	O
mechanisms	O
of	O
neuropathogenesis	B-DISO
DENV	B-LIVB
infection	B-DISO
in	O
rhesus	B-LIVB
macaques	I-LIVB
.	O

There	O
were	O
decreased	B-DISO
numbers	I-DISO
of	O
GFAP	B-CHEM
immunopositive	B-ANAT
astrocytes	I-ANAT
per	O
unit	O
area	O
,	O
although	O
those	O
that	O
remained	O
had	O
increased	O
arbor	O
length	O
and	O
complexity	B-DISO
.	O

This	O
was	O
combined	O
with	O
structural	O
hypertrophy	B-DISO
of	O
white	O
matter	O
astrocytes	B-ANAT
in	O
the	O
absence	O
of	O
increased	O
vascular	B-DISO
leakage	I-DISO
.	O

Combined	O
,	O
these	O
studies	O
show	O
how	O
even	O
low	O
-	O
grade	O
infection	B-DISO
with	O
DENV	B-LIVB
induces	O
measurable	O
changes	O
within	O
the	O
parenchyma	B-ANAT
of	O
infected	B-DISO
individuals	B-LIVB
.	O

Transcriptional	B-PHYS
enhancement	I-PHYS
of	O
Smn	O
levels	B-PHEN
in	O
motoneurons	B-ANAT
is	O
crucial	O
for	O
proper	O
axon	B-ANAT
morphology	O
in	O
zebrafish	B-LIVB
An	O
unresolved	O
mystery	O
in	O
the	O
field	O
of	O
spinal	B-DISO
muscular	I-DISO
atrophy	I-DISO
(	O
SMA	B-DISO
)	O
is	O
why	O
a	O
reduction	O
of	O
the	O
ubiquitously	O
expressed	O
Smn	B-CHEM
protein	I-CHEM
causes	O
defects	B-DISO
mostly	O
in	O
motoneurons	B-ANAT
.	O

We	O
addressed	O
the	O
possibility	O
that	O
this	O
restricted	O
vulnerability	O
stems	O
from	O
elevated	O
Smn	B-PHYS
expression	I-PHYS
in	O
motoneurons	B-ANAT
.	O

To	O
explore	O
this	O
,	O
we	O
established	O
an	O
ex	B-DEVI
vivo	I-DEVI
zebrafish	I-DEVI
culture	I-DEVI
system	I-DEVI
of	O
GFP	B-CHEM
-	O
marked	O
motoneurons	B-ANAT
to	O
quantitatively	O
measure	O
Smn	B-PHEN
protein	I-PHEN
and	O
smn	B-CHEM
mRNA	I-CHEM
levels	O
as	O
well	O
as	O
promoter	O
activity	O
in	O
motoneurons	B-ANAT
versus	O
other	O
cell	B-ANAT
types	O
.	O

Importantly	O
,	O
we	O
uncovered	O
that	O
Smn	B-PHEN
levels	I-PHEN
are	O
elevated	O
in	O
motoneurons	B-ANAT
by	O
means	O
of	O
transcriptional	B-PHYS
activation	I-PHYS
.	O

In	O
addition	O
,	O
we	O
identified	O
the	O
ETS	B-CHEM
family	I-CHEM
transcription	I-CHEM
factor	I-CHEM
Etv5b	I-CHEM
to	O
be	O
responsible	O
for	O
increased	O
smn	B-PHYS
transcription	I-PHYS
in	O
motoneurons	B-ANAT
.	O

Moreover	O
,	O
we	O
established	O
that	O
the	O
additional	O
supply	O
of	O
Smn	B-CHEM
protein	I-CHEM
in	O
motoneurons	B-ANAT
is	O
necessary	O
for	O
proper	O
axonogenesis	B-PHYS
in	O
a	O
cell	B-PHYS
-	I-PHYS
autonomous	I-PHYS
manner	I-PHYS
.	O

These	O
findings	B-PHEN
demonstrate	O
the	O
reliance	O
of	O
motoneurons	B-ANAT
on	O
more	O
Smn	B-CHEM
,	O
thereby	O
adding	O
a	O
novel	O
piece	O
of	O
evidence	O
for	O
their	O
increased	O
vulnerability	B-PHYS
under	O
SMA	B-DISO
conditions	I-DISO
.	O

Experimental	B-PROC
study	I-PROC
in	O
pulmonary	B-ANAT
artery	I-ANAT
sealing	B-PROC
with	O
a	O
vessel	B-DEVI
-	I-DEVI
sealing	I-DEVI
device	I-DEVI
The	O
development	O
of	O
vessel	B-DEVI
-	I-DEVI
sealing	I-DEVI
devices	I-DEVI
will	O
facilitate	O
safety	B-PHEN
in	O
video	B-PROC
-	I-PROC
assisted	I-PROC
thoracoscopic	I-PROC
surgery	I-PROC
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	O
and	O
safety	B-PHEN
of	O
sealing	B-PROC
pulmonary	B-ANAT
arteries	I-ANAT
with	O
the	O
Enseal	B-DEVI
tissue	I-DEVI
-	I-DEVI
sealing	I-DEVI
device	I-DEVI
.	O

Pulmonary	B-ANAT
arteries	I-ANAT
from	O
beagle	B-LIVB
dogs	I-LIVB
(	O
mean	O
body	O
weight	O
13	O
.	O
1	O
kg	O
,	O
range	O
10	O
.	O
5	O
-	O
15	O
.	O
4	O
kg	O
)	O
were	O
divided	O
into	O
3	O
groups	B-LIVB
according	O
to	O
the	O
in	O
-	O
vivo	O
sealing	O
method	O
used	O
(	O
Enseal	B-DEVI
,	O
ligation	B-PROC
,	O
and	O
proximal	O
ligation	B-PROC
plus	O
distal	O
Enseal	B-DEVI
)	O
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	B-PHEN
tolerance	O
up	O
to	O
75	O
mm	O
Hg	O
at	O
the	O
sealed	O
end	O
.	O

A	O
left	O
lower	O
lobectomy	B-PROC
was	O
performed	O
to	O
evaluate	O
chronic	O
-	O
phase	O
durability	O
of	O
the	O
sealed	B-DEVI
stumps	I-DEVI
in	O
a	O
survival	B-LIVB
model	I-LIVB
.	O

Two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary	B-ANAT
arteries	I-ANAT
in	O
each	O
dog	B-LIVB
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	B-LIVB
.	O

After	O
the	O
scheduled	O
survival	O
period	O
,	O
the	O
pulmonary	B-ANAT
arteries	I-ANAT
were	O
sampled	O
.	O

Pressure	B-PHEN
tolerance	O
at	O
the	O
sealed	O
end	O
was	O
evaluated	O
in	O
91	O
pulmonary	B-ANAT
artery	I-ANAT
sections	O
.	O

All	O
sealed	O
ends	O
showed	O
pressure	B-PHEN
tolerance	O
>	O
75	O
mm	O
Hg	O
.	O

A	O
left	O
lower	O
lobectomy	B-PROC
was	O
performed	O
in	O
13	O
dogs	B-LIVB
in	O
which	O
35	O
pulmonary	B-ANAT
artery	I-ANAT
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	B-LIVB
.	O

No	B-DISO
sealing	B-PROC
failure	O
was	O
found	O
,	O
and	O
pathological	O
findings	B-DISO
showed	O
healing	B-PHYS
and	O
persistent	O
hemostasis	B-PHYS
at	O
all	O
sealed	O
ends	O
of	O
the	O
pulmonary	B-ANAT
arteries	I-ANAT
after	O
2	O
and	O
4	O
weeks	O
of	O
the	O
survival	O
period	O
.	O

Pulmonary	B-ANAT
arteries	I-ANAT
sealed	O
in	O
vivo	O
with	O
the	O
Enseal	B-DEVI
device	I-DEVI
showed	O
pressure	B-PHEN
tolerance	O
>	O
75	O
mm	O
Hg	O
in	O
the	O
acute	O
phase	O
,	O
and	O
persistent	O
hemostasis	B-PHYS
after	O
2	O
or	O
4	O
weeks	O
.	O

Pulmonary	B-ANAT
artery	I-ANAT
sealing	B-PROC
with	O
the	O
Enseal	B-DEVI
device	I-DEVI
is	O
feasible	O
and	O
safe	B-PHEN
in	O
thoracic	B-PROC
surgery	I-PROC
settings	O
.	O

Pathophysiology	O
,	O
treatment	B-PROC
and	O
prevention	B-PROC
of	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
Severe	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
(	O
OHSS	B-DISO
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	B-LIVB
that	O
undergo	O
treatment	B-PROC
with	O
assisted	B-PROC
reproductive	I-PROC
technology	I-PROC
.	O

The	O
review	O
aims	O
to	O
summarize	O
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	B-PROC
,	O
and	O
prevention	B-PROC
of	O
OHSS	B-DISO
.	O

The	O
pathophysiology	O
is	O
still	O
not	O
completely	O
understood	B-PHYS
;	O
however	O
,	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
is	O
likely	O
to	O
be	O
an	O
important	O
mediator	O
.	O

Human	B-CHEM
chorionic	I-CHEM
gonadotropin	I-CHEM
was	O
previously	O
thought	B-PHYS
to	O
be	O
necessary	O
for	O
OHSS	B-DISO
to	O
occur	O
;	O
however	O
,	O
recent	O
case	O
reports	O
have	O
proven	O
otherwise	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti	B-CHEM
-	I-CHEM
Mullerian	I-CHEM
hormone	I-CHEM
signalling	B-PHYS
pathway	I-PHYS
and	O
CD11c	B-CHEM
+	O
HLA	B-CHEM
-	I-CHEM
DR	I-CHEM
+	O
dendritic	B-ANAT
cells	I-ANAT
and	O
associated	O
interleukins	B-CHEM
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	B-DISO
.	O

Treatment	B-PROC
is	O
largely	O
supportive	B-PROC
and	O
is	O
based	O
mainly	O
on	O
consensus	O
statements	O
rather	O
than	O
evidence	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	B-PROC
women	B-LIVB
at	O
risk	O
,	O
allowing	O
the	O
clinician	B-LIVB
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	B-CHEM
antagonist	I-CHEM
cycles	O
with	O
agonist	B-CHEM
triggers	O
.	O

More	O
research	B-PROC
is	O
required	O
to	O
elucidate	O
the	O
pathophysiology	O
behind	O
the	O
condition	O
.	O

Clinicians	B-LIVB
should	O
employ	O
strategies	B-PHYS
to	O
prevent	B-PROC
OHSS	B-DISO
.	O

A	O
DANGEROUS	O
MUDDYING	O
OF	O
THE	O
WATERS	O
?	O
THE	O
'	O
SIGNIFICANT	O
HARM	O
'	O
OF	O
RE	B-LIVB
B	I-LIVB
AND	I-LIVB
G	I-LIVB
(	I-LIVB
CHILDREN	I-LIVB
)	O
(	O
CARE	O
PROCEEDINGS	O
)	O
[	O
2015	O
]	O
EWFC	O
3	O
The	O
academic	O
debate	O
rages	B-PHYS
on	O
as	O
to	O
whether	O
male	B-PROC
circumcision	I-PROC
really	O
is	O
in	O
the	O
best	O
interests	B-PHYS
of	O
the	O
child	B-LIVB
or	O
if	O
it	O
constitutes	O
an	O
abusive	O
practice	O
.	O

This	O
commentary	O
discusses	O
the	O
recent	O
case	O
of	O
Re	B-LIVB
B	I-LIVB
and	I-LIVB
G	I-LIVB
(	I-LIVB
children	I-LIVB
)	I-LIVB
(	O
care	O
proceedings	O
)	O
[	O
2015	O
]	O
EWFC	O
3	O
,	O
delivered	O
by	O
the	O
current	O
President	B-LIVB
of	O
the	O
Family	O
Division	O
of	O
the	O
High	O
court	O
,	O
Sir	O
James	O
Munby	O
.	O

Two	O
key	O
issues	B-DISO
are	O
raised	O
by	O
this	O
judgment	B-DISO
.	O

First	O
,	O
that	O
President	B-LIVB
Munby	O
's	O
obiter	O
comments	O
constitute	O
an	O
attack	O
on	O
the	O
legally	O
accepted	O
act	O
of	O
male	B-PROC
circumcision	I-PROC
by	O
suggesting	O
a	O
similar	O
nature	O
between	O
the	O
illegal	O
act	O
of	O
female	O
genital	O
mutilation	O
(	O
FGM	O
)	O
and	O
that	O
of	O
male	B-PROC
circumcision	I-PROC
as	O
well	O
as	O
the	O
suggestion	O
that	O
male	B-PROC
circumcision	I-PROC
can	O
be	O
classed	O
as	O
a	O
significant	O
harm	O
.	O

Second	O
,	O
that	O
this	O
case	O
reflects	B-PHYS
the	O
woefully	O
unprepared	O
condition	O
of	O
the	O
UK	B-GEOG
medical	O
profession	O
in	O
dealing	O
with	O
FGM	O
.	O

Zinc	B-CHEM
transporter	I-CHEM
ZIP10	B-CHEM
forms	O
a	O
heteromer	O
with	O
ZIP6	B-CHEM
which	O
regulates	B-PHEN
embryonic	B-PHYS
development	I-PHYS
and	O
cell	B-PHYS
migration	I-PHYS
There	O
is	O
growing	O
evidence	O
that	O
zinc	B-CHEM
and	O
its	O
transporters	B-CHEM
are	O
involved	O
in	O
cell	B-PHYS
migration	I-PHYS
during	O
development	B-PHYS
and	O
in	O
cancer	B-DISO
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
show	O
that	O
zinc	B-CHEM
transporter	I-CHEM
ZIP10	B-CHEM
(	O
SLC39A10	B-CHEM
)	O
stimulates	B-PHEN
cell	B-PHYS
motility	I-PHYS
and	O
proliferation	B-PHYS
,	O
both	O
in	O
mammalian	B-ANAT
cells	I-ANAT
and	O
in	O
the	O
zebrafish	B-LIVB
embryo	B-ANAT
.	O

This	O
is	O
associated	O
with	O
inactivation	B-PHYS
of	O
GSK	B-CHEM
-	I-CHEM
3α	I-CHEM
and	O
-3ß	B-CHEM
and	O
downregulation	B-PHYS
of	O
E	B-CHEM
-	I-CHEM
cadherin	I-CHEM
(	O
CDH1	B-CHEM
)	O
.	O

Morpholino	B-CHEM
-mediated	O
knock	B-PROC
-	I-PROC
down	I-PROC
of	O
zip10	O
causes	O
delayed	O
epiboly	B-PHYS
and	O
deformities	O
of	O
the	O
head	B-ANAT
,	O
eye	B-ANAT
,	O
heart	B-ANAT
and	O
tail	B-ANAT
.	O

Furthermore	O
,	O
zip10	B-CHEM
deficiency	O
results	O
in	O
overexpression	B-PHYS
of	O
cdh1	B-CHEM
,	O
zip6	B-CHEM
and	O
stat3	B-CHEM
,	O
the	O
latter	O
gene	B-CHEM
product	I-CHEM
driving	O
transcription	B-PHYS
of	O
both	O
zip6	B-CHEM
and	O
zip10	B-CHEM
The	O
non	O
-	O
reduntant	O
requirement	O
of	O
Zip6	B-CHEM
and	O
Zip10	B-CHEM
for	O
epithelial	B-PHYS
to	I-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O
EMT	B-PHYS
)	O
is	O
consistent	O
with	O
our	O
finding	B-DISO
that	O
they	O
exist	O
as	O
a	O
heteromer	O
.	O

We	O
postulate	O
that	O
a	O
subset	O
of	O
ZIPs	B-CHEM
carrying	O
PrP	O
-	O
like	O
ectodomains	O
,	O
including	O
ZIP6	B-CHEM
and	O
ZIP10	B-CHEM
,	O
are	O
integral	O
to	O
cellular	B-PROC
pathways	B-PHYS
and	O
plasticity	B-PHYS
programs	O
,	O
such	O
as	O
EMT	B-PHYS
.	O

Evaluation	B-PROC
of	O
response	O
from	O
axitinib	B-CHEM
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
versus	O
Choi	O
criteria	O
in	O
previously	O
treated	B-DISO
patients	B-LIVB
with	O
metastatic	B-DISO
renal	I-DISO
cell	I-DISO
carcinoma	I-DISO
Axitinib	B-CHEM
,	O
a	O
selective	O
and	O
potent	O
tyrosine	B-CHEM
kinase	I-CHEM
inhibitor	I-CHEM
of	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
receptors	I-CHEM
,	O
was	O
available	O
to	O
patients	B-LIVB
from	O
Canada	B-GEOG
and	O
Australia	B-GEOG
,	O
prior	O
to	O
regulatory	O
approval	O
of	O
axitinib	B-CHEM
in	O
these	O
countries	B-GEOG
,	O
for	O
treatment	B-PROC
of	O
clear	B-DISO
-	I-DISO
cell	I-DISO
metastatic	I-DISO
renal	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
mRCC	B-DISO
)	O
after	O
failure	O
of	O
one	O
prior	O
systemic	O
regimen	B-PROC
.	O

This	O
single	B-PROC
-	I-PROC
arm	I-PROC
,	O
open	B-PROC
-	I-PROC
label	I-PROC
study	I-PROC
of	O
axitinib	B-CHEM
evaluated	O
the	O
efficacy	B-PROC
,	O
safety	B-PROC
,	O
and	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
in	O
patients	B-LIVB
with	O
mRCC	B-DISO
whose	O
disease	B-DISO
progressed	B-DISO
after	O
one	O
prior	O
systemic	O
first	B-PROC
-	I-PROC
line	I-PROC
regimen	I-PROC
.	O

Primary	O
objective	O
was	O
objective	O
response	O
rate	O
evaluated	B-PROC
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
and	O
Choi	O
criteria	O
.	O

Progression	O
-	O
free	O
survival	O
,	O
overall	O
survival	O
,	O
safety	B-PROC
,	O
and	O
QoL	O
were	O
secondary	O
end	O
points	O
.	O

Due	O
to	O
the	O
small	O
study	B-PROC
size	O
,	O
analyses	O
comprised	O
of	O
descriptive	O
statistics	B-PROC
.	O

Fifteen	O
patients	B-LIVB
were	O
recruited	O
,	O
five	O
from	O
Canada	B-GEOG
and	O
ten	O
from	O
Australia	B-GEOG
,	O
over	O
a	O
limited	O
recruitment	O
period	O
.	O

Thirteen	O
patients	B-LIVB
received	O
sunitinib	B-CHEM
as	O
prior	O
therapy	B-PROC
.	O

All	O
patients	B-LIVB
had	O
clear	B-DISO
-	I-DISO
cell	I-DISO
carcinoma	I-DISO
,	O
eleven	O
had	O
prior	O
nephrectomy	B-PROC
.	O

Liver	B-ANAT
,	O
lung	B-ANAT
,	O
and	O
lymph	B-ANAT
nodes	I-ANAT
were	O
the	O
most	O
frequent	O
sites	O
of	O
metastases	B-DISO
;	O
one	O
patient	B-LIVB
had	O
brain	B-DISO
metastasis	I-DISO
.	O

Median	O
time	O
on	O
axitinib	B-CHEM
was	O
118	O
.	O

0	O
days	O
(	O
range	O
:	O
3	O
.	O
5	O
-	O
645	O
.	O
0	O
days	O
)	O
;	O
estimated	O
survival	O
probability	O
at	O
12	O
months	O
was	O
57	O
.	O
8	O
%	O
.	O

Two	O
(	O
13	O
.	O
3	O
%	O
)	O
patients	B-LIVB
had	O
objective	O
responses	B-PHYS
per	O
RECIST	O
versus	O
nine	O
(	O
60	O
.	O
0	O
%	O
)	O
per	O
Choi	O
criteria	O
.	O

Six	O
patients	B-LIVB
had	O
progressive	B-DISO
disease	B-DISO
based	O
on	O
RECIST	O
versus	O
three	O
per	O
Choi	O
criteria	O
.	O

Nine	O
(	O
60	O
.	O

0	O
%	O
)	O
events	O
of	O
progression	B-DISO
or	O
death	B-PHYS
occurred	O
by	O
the	O
end	O
of	O
study	B-PROC
,	O
and	O
three	O
patients	B-LIVB
continued	O
to	O
receive	O
the	O
study	B-PROC
drug	B-CHEM
.	O

Fatigue	B-DISO
(	O
33	O
%	O
)	O
and	O
diarrhea	B-DISO
(	O
20	O
%	O
)	O
were	O
the	O
most	O
common	O
grade	O
≥3	O
all	O
-	O
causality	O
,	O
treatment	B-PROC
-emergent	O
adverse	B-DISO
events	I-DISO
.	O

The	O
mean	O
change	O
in	O
European	B-GEOG
Quality	O
of	O
Life	O
-	O
5	O
Dimensions	O
score	O
from	O
baseline	O
to	O
end	O
of	O
treatment	B-PROC
was	O
-0	O
.	O
0837	O
.	O

The	O
small	O
number	O
of	O
patients	B-LIVB
and	O
lack	O
of	O
a	O
comparator	O
arm	O
limit	O
the	O
ability	O
to	O
draw	O
definitive	O
conclusions	O
;	O
however	O
,	O
safety	B-PROC
and	O
efficacy	B-PROC
profiles	O
of	O
axitinib	B-CHEM
were	O
consistent	O
with	O
reports	O
from	O
previous	O
studies	B-PROC
in	O
patients	B-LIVB
with	O
mRCC	B-DISO
,	O
and	O
patients	B-LIVB
generally	O
maintained	O
QoL	O
.	O

The	O
sizeable	O
difference	O
observed	O
in	O
objective	O
response	O
rate	O
by	O
RECIST	O
versus	O
Choi	O
criteria	O
merits	O
further	O
research	B-PROC
.	O

Demographics	O
,	O
Health	O
,	O
and	O
Risk	O
Behaviors	O
of	O
Young	B-LIVB
Adults	I-LIVB
Who	O
Drink	B-OBJC
Energy	B-OBJC
Drinks	I-OBJC
and	O
Coffee	B-OBJC
Beverages	B-OBJC
Objective	O
:	O
The	O
present	B-DISO
study	B-PROC
investigates	O
risk	O
behaviors	O
,	O
sleep	B-DISO
habits	I-DISO
,	O
and	O
mental	B-DISO
health	I-DISO
factors	I-DISO
associated	O
with	O
caffeinated	B-OBJC
beverage	I-OBJC
use	O
in	O
young	B-LIVB
adults	I-LIVB
.	O

Materials	B-OBJC
and	O
Methods	O
:	O
Students	B-LIVB
from	O
a	O
midsize	B-OBJC
private	I-OBJC
university	I-OBJC
(	O
n	O
=	O
159	O
)	O
completed	O
a	O
15	O
-	O
minute	O
anonymous	O
questionnaire	O
,	O
including	O
questions	O
on	O
risk	O
behaviors	O
,	O
sleep	B-DISO
habits	I-DISO
,	O
alcohol	O
,	O
and	O
caffeine	O
consumption	O
.	O

We	O
compared	O
behaviors	O
between	O
the	O
top	O
∼15	O
%	O
(	O
""""	O
high	O
end	O
""""	O
)	O
of	O
energy	B-OBJC
drink	I-OBJC
users	B-LIVB
(	O
≥3	O
/	O
month	O
)	O
and	O
coffee	B-OBJC
users	B-LIVB
(	O
≥16	O
/	O
month	O
)	O
to	O
those	O
with	O
less	O
frequent	O
or	O
no	O
caffeine	O
consumption	O
.	O

Results	B-DISO
:	O
Caffeine	O
consumption	O
was	O
frequent	O
among	O
young	B-LIVB
adults	I-LIVB
.	O

In	O
the	O
last	O
month	O
,	O
36	O
%	O
of	O
students	B-LIVB
had	O
an	O
energy	B-OBJC
drink	I-OBJC
,	O
69	O
%	O
had	O
coffee	B-OBJC
or	O
espresso	B-OBJC
,	O
and	O
86	O
%	O
reported	O
having	O
any	O
caffeine	B-CHEM
;	O
however	O
,	O
the	O
majority	O
of	O
students	B-LIVB
were	O
unaware	B-PROC
of	O
the	O
caffeine	B-CHEM
content	O
in	O
these	O
beverages	B-OBJC
.	O

High	O
-	O
end	O
energy	B-OBJC
drink	I-OBJC
consumers	B-LIVB
reported	O
more	O
risk	O
-	O
taking	O
behaviors	O
(	O
increased	B-DISO
drug	I-DISO
and	O
alcohol	O
use	O
and	O
less	O
frequent	O
seat	B-DISO
belt	I-DISO
use	I-DISO
)	O
,	O
sleep	B-DISO
disturbances	I-DISO
(	O
later	O
bedtimes	O
,	O
harder	B-DISO
time	I-DISO
falling	I-DISO
asleep	I-DISO
,	O
and	O
more	O
all	O
-	O
nighters	O
)	O
,	O
and	O
higher	O
frequency	O
of	O
mental	B-DISO
illness	I-DISO
diagnoses	B-DISO
than	O
those	O
who	O
consumed	B-DISO
fewer	O
energy	B-OBJC
drinks	I-OBJC
.	O

In	O
contrast	O
,	O
the	O
frequency	O
of	O
most	O
risk	O
behaviors	O
,	O
sleep	B-DISO
disturbances	I-DISO
,	O
and	O
mental	B-DISO
illness	I-DISO
diagnoses	B-DISO
was	O
not	O
significantly	O
different	O
between	O
the	O
high	B-LIVB
-	I-LIVB
end	I-LIVB
and	I-LIVB
general	I-LIVB
population	I-LIVB
of	O
coffee	B-OBJC
drinkers	B-DISO
.	O

Conclusion	O
:	O
Students	B-LIVB
with	O
delayed	O
sleep	B-DISO
patterns	I-DISO
,	O
mental	B-DISO
illness	I-DISO
,	O
and	O
higher	O
frequency	O
of	O
substance	B-DISO
use	I-DISO
and	O
risk	O
behaviors	O
were	O
more	O
likely	O
to	O
be	O
regular	O
energy	B-OBJC
drink	I-OBJC
users	B-LIVB
but	O
not	O
regular	B-DISO
coffee	I-DISO
drinkers	I-DISO
.	O

It	O
is	O
unclear	B-DISO
whether	O
the	O
psychoactive	B-CHEM
content	O
in	O
energy	B-OBJC
drinks	I-OBJC
results	O
in	O
different	O
behavioral	O
effects	O
than	O
just	O
caffeine	B-CHEM
in	O
coffee	B-OBJC
,	O
and	O
/	O
or	O
different	O
personality	B-PHYS
/	O
health	B-LIVB
populations	I-LIVB
are	O
drawn	O
to	O
the	O
two	O
types	O
of	O
beverages	B-OBJC
.	O

Eosinophilic	B-DISO
Gastroenteritis	I-DISO
as	O
a	O
Rare	O
Cause	O
of	O
Recurrent	O
Epigastric	O
Pain	O
Eosinophilic	B-DISO
gastroenteritis	I-DISO
(	O
EGE	B-DISO
)	O
is	O
a	O
rare	O
inflammatory	B-DISO
disorder	I-DISO
of	O
gastrointestinal	B-ANAT
tract	I-ANAT
characterized	O
by	O
eosinophilic	B-DISO
infiltration	I-DISO
of	O
the	O
bowel	B-ANAT
wall	I-ANAT
.	O

It	O
can	O
mimic	O
many	O
gastrointestinal	B-DISO
disorders	I-DISO
due	O
to	O
its	O
wide	B-DISO
spectrum	I-DISO
of	I-DISO
presentations	I-DISO
.	O

Diagnose	B-DISO
is	O
mostly	O
based	O
on	O
excluding	O
other	O
disorders	B-DISO
and	O
a	O
high	O
suspicion	B-PHYS
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
26	O
year	O
old	O
man	B-LIVB
with	O
a	O
history	B-DISO
of	O
sever	B-DISO
epigastric	I-DISO
pain	I-DISO
followed	O
by	O
nausea	B-DISO
,	O
vomiting	B-DISO
since	O
a	O
few	O
days	O
before	O
admission	B-PROC
with	O
final	O
diagnosis	B-DISO
of	O
EGE	B-DISO
.	O

Biochemical	O
characteristics	O
of	O
AtFAR2	B-CHEM
,	O
a	O
fatty	B-CHEM
acid	I-CHEM
reductase	I-CHEM
from	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
that	O
reduces	O
fatty	B-CHEM
acyl	I-CHEM
-	I-CHEM
CoA	I-CHEM
and	O
-	O
ACP	B-CHEM
substrates	I-CHEM
into	O
fatty	B-CHEM
alcohols	I-CHEM
Fatty	B-CHEM
alcohols	I-CHEM
and	O
derivatives	B-CHEM
are	O
important	O
for	O
proper	O
deposition	O
of	O
a	O
functional	O
pollen	B-ANAT
wall	I-ANAT
.	O

Mutations	B-PHYS
in	O
specific	O
genes	O
encoding	O
fatty	B-CHEM
acid	I-CHEM
reductases	I-CHEM
(	O
FAR	B-CHEM
)	O
responsible	O
for	O
fatty	B-CHEM
alcohol	I-CHEM
production	O
cause	O
abnormal	B-DISO
development	O
of	O
pollen	B-LIVB
.	O

A	O
disrupted	O
AtFAR2	O
(	O
MS2	O
)	O
gene	O
in	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
results	O
in	O
pollen	B-LIVB
developing	O
an	O
abnormal	B-DISO
exine	B-ANAT
layer	I-ANAT
and	O
a	O
reduced	B-DISO
fertility	I-DISO
phenotype	B-PHYS
.	O

AtFAR2	B-CHEM
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
chloroplasts	B-ANAT
and	O
in	O
a	O
purified	O
form	O
to	O
be	O
specific	O
for	O
acyl	B-CHEM
-	I-CHEM
ACP	I-CHEM
substrates	I-CHEM
.	O

Here	O
,	O
we	O
present	O
data	O
on	O
the	O
in	O
vitro	O
and	O
in	O
planta	B-LIVB
characterizations	O
of	O
AtFAR2	B-CHEM
from	O
A	B-LIVB
.	I-LIVB

thaliana	I-LIVB
and	O
show	O
that	O
this	O
enzyme	B-CHEM
has	O
the	O
ability	O
to	O
use	O
both	O
,	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
-	I-CHEM
ACP	I-CHEM
and	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
-	I-CHEM
CoA	I-CHEM
,	O
as	O
substrates	B-CHEM
to	O
produce	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
-	I-CHEM
alcohol	I-CHEM
.	O

Our	O
results	O
further	O
show	O
that	O
AtFAR2	B-CHEM
is	O
highly	O
similar	O
in	O
properties	O
and	O
substrate	B-CHEM
specificity	O
to	O
AtFAR6	B-CHEM
for	O
which	O
in	O
vitro	O
data	O
has	O
been	O
published	O
,	O
and	O
which	O
is	O
also	O
a	O
chloroplast	B-ANAT
localized	O
enzyme	B-CHEM
.	O

This	O
suggests	O
that	O
although	O
AtFAR2	B-CHEM
is	O
the	O
major	O
enzyme	B-CHEM
responsible	O
for	O
exine	B-ANAT
layer	I-ANAT
functionality	O
,	O
AtFAR6	B-CHEM
might	O
provide	O
functional	O
redundancy	O
to	O
AtFAR2	B-CHEM
.	O

Comparing	O
Time	B-PHYS
Perception	I-PHYS
among	O
Morphine	B-CHEM
-	O
Derived	O
Drugs	B-CHEM
Addicts	B-LIVB
and	O
Controls	B-LIVB
The	O
aim	O
of	O
the	O
present	O
study	B-PROC
is	O
to	O
compare	O
time	B-PHYS
perception	I-PHYS
among	O
drug	B-DISO
addicts	I-DISO
and	O
controls	B-LIVB
.	O

30	O
drug	B-DISO
addicts	I-DISO
were	O
selected	O
,	O
and	O
30	O
non	B-LIVB
-	I-LIVB
addict	I-LIVB
individuals	I-LIVB
were	O
selected	O
as	O
the	O
control	B-LIVB
group	I-LIVB
.	O

The	O
two	O
groups	O
performed	O
three	O
tests	O
of	O
time	O
reproduction	B-PHYS
,	O
time	O
estimation	O
,	O
and	O
time	O
discrimination	B-PHYS
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
addicts	B-LIVB
group	O
and	O
the	O
control	B-LIVB
group	I-LIVB
regarding	O
the	O
error	O
of	O
time	O
reproduction	B-PHYS
and	O
time	O
estimation	O
.	O

The	O
addict	B-LIVB
group	O
in	O
comparison	O
to	O
the	O
control	B-LIVB
group	I-LIVB
had	O
a	O
lower	O
under	O
-	O
reproduction	B-PHYS
and	O
a	O
higher	O
over	O
-	O
reproduction	B-PHYS
error	O
,	O
and	O
also	O
a	O
lower	O
under	O
-	O
estimation	B-PHYS
and	O
higher	O
over	O
-	O
estimation	B-PHYS
error	O
.	O

However	O
,	O
regarding	O
time	O
discrimination	B-PHYS
,	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
errors	O
committed	O
by	O
both	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
showing	O
images	O
of	O
drug	O
consumption	O
tools	B-OBJC
and	O
normal	O
images	O
with	O
same	O
durations	O
,	O
the	O
normal	O
group	O
believed	O
that	O
the	O
images	O
related	O
to	O
drug	O
consumption	O
tools	B-OBJC
were	O
shown	O
for	O
a	O
shorter	O
period	O
of	O
time	O
.	O

Time	B-PHYS
perception	I-PHYS
is	O
different	O
between	O
morphine	B-CHEM
-	O
derived	O
drugs	B-CHEM
addicts	B-LIVB
and	O
controls	B-LIVB
.	O

Comparison	O
of	O
sonoelastography	B-PROC
with	O
sonourethrography	B-PROC
and	O
retrograde	B-PROC
urethrography	I-PROC
in	O
the	O
evaluation	B-PROC
of	O
male	B-PHYS
anterior	B-DISO
urethral	I-DISO
strictures	I-DISO
Retrograde	B-PROC
urethrography	I-PROC
(	O
RUG	B-PROC
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	O
modality	O
for	O
imaging	B-PROC
of	O
the	O
anterior	B-DISO
urethral	I-DISO
strictures	I-DISO
despite	O
its	O
well	O
-	O
known	O
limitations	O
and	O
disadvantages	O
.	O

Sonourethrography	B-PROC
(	O
SUG	B-PROC
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	O
the	O
limitations	O
of	O
RUG	B-PROC
and	O
to	O
provide	O
more	O
accurate	O
results	O
.	O

As	O
proper	O
selection	O
of	O
imaging	O
modality	O
is	O
very	O
important	O
for	O
planning	O
the	O
treatment	O
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O

One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	B-PHEN
of	O
stricture	B-DISO
disease	I-DISO
is	O
spongiofibrosis	B-DISO
.	O

Sonoelastography	B-PROC
(	O
SE	B-PROC
)	O
is	O
a	O
newer	B-PROC
technique	I-PROC
,	O
tried	O
in	O
various	O
other	O
pathologies	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	O
in	O
the	O
evaluation	O
of	O
anterior	B-DISO
urethral	I-DISO
stricture	I-DISO
disease	I-DISO
by	O
comparison	O
with	O
RUG	B-PROC
and	O
SUG	B-PROC
.	O

Between	O
August	O
2014	O
and	O
May	O
2015	O
,	O
77	O
patients	B-LIVB
with	O
clinical	O
features	O
of	O
anterior	B-DISO
urethral	I-DISO
stricture	I-DISO
disease	I-DISO
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	B-PROC
followed	O
by	O
SUG	B-PROC
and	O
SE	B-PROC
for	O
stricture	B-DISO
location	O
,	O
length	O
,	O
depth	B-PHYS
of	O
spongiofibrosis	B-DISO
and	O
periurethral	B-ANAT
pathologies	O
.	O

The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	O
findings	O
.	O

Overall	O
diagnostic	O
accuracy	O
of	O
SE	B-PROC
,	O
SUG	B-PROC
,	O
and	O
RGU	B-PROC
for	O
the	O
estimation	O
of	O
stricture	B-DISO
location	O
,	O
and	O
length	O
were	O
estimated	O
92	O
.	O

68	O
%	O
vs	O
.	O

91	O
.	O
54	O
%	O
,	O
79	O
%	O
vs	O
.	O

78	O
.	O
87	O
%	O
and	O
80	O
.	O
48	O
%	O
vs	O
.	O

43	O
.	O
66	O
%	O
,	O
respectively	O
,	O
while	O
for	O
depth	B-PHYS
of	O
spongiofibrosis	B-DISO
SE	B-PROC
,	O
and	O
SUG	B-PROC
had	O
accuracy	O
rates	O
of	O
87	O
.	O
3	O
%	O
,	O
48	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
length	O
measured	O
on	O
SE	B-PROC
was	O
nearest	O
to	O
the	O
mean	O
intra	O
-	O
operative	O
stricture	B-DISO
length	O
(	O
21	O
.	O
34	O
+	O
11	O
.	O

8	O
mm	O
)	O
.	O

SE	B-PROC
findings	O
significantly	O
correlated	O
with	O
the	O
colour	B-DISO
of	I-DISO
bladder	I-DISO
mucosa	I-DISO
on	O
cystoscopic	B-PROC
examination	I-PROC
(	O
p	O
=	O
0	O
.	O
003	O
)	O
whereas	O
the	O
association	O
was	O
non	O
-	O
significant	O
(	O
p	O
=	O
0	O
.	O

127	O
)	O
for	O
difficulty	O
in	O
incision	B-PROC
.	O

While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-PROC
findings	O
related	O
both	O
to	O
the	O
colour	B-DISO
of	I-DISO
the	I-DISO
bladder	I-DISO
mucosa	I-DISO
and	O
difficulty	O
in	O
incision	B-PROC
on	O
cystoscopy	B-PROC
,	O
SE	B-PROC
findings	O
had	O
a	O
significant	O
association	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
with	O
histopathology	O
findings	O
for	O
severe	O
degree	B-PROC
of	I-PROC
fibrosis	I-PROC
.	O

Sonoelastography	B-PROC
estimates	O
stricture	O
site	O
and	O
length	O
better	O
in	O
comparison	O
with	O
RUG	B-PROC
and	O
SUG	B-PROC
.	O

It	O
estimates	O
degree	O
of	O
spongiofibrosis	B-DISO
which	O
serves	O
as	O
an	O
important	O
prognostic	B-PHYS
factor	I-PHYS
for	O
stricture	B-PHEN
recurrence	I-PHEN
more	O
accurately	O
than	O
SUG	B-PROC
.	O

Phytoplankton	B-LIVB
production	O
and	O
taxon	O
-	O
specific	O
growth	O
rates	O
in	O
the	O
Costa	B-GEOG
Rica	I-GEOG
Dome	I-GEOG
During	O
summer	O
2010	O
,	O
we	O
investigated	O
phytoplankton	B-LIVB
production	O
and	O
growth	O
rates	O
at	O
19	O
stations	O
in	O
the	O
eastern	O
tropical	O
Pacific	O
,	O
where	O
winds	B-PHEN
and	O
strong	O
opposing	B-PHEN
currents	I-PHEN
generate	O
the	O
Costa	B-GEOG
Rica	I-GEOG
Dome	I-GEOG
(	O
CRD	B-GEOG
)	O
,	O
an	O
open	O
-	O
ocean	B-GEOG
upwelling	B-PHEN
feature	I-PHEN
.	O

Primary	O
production	O
(	O
(	B-CHEM
14	I-CHEM
)	I-CHEM
C	I-CHEM
-	O
incorporation	O
)	O
and	O
group	O
-	O
specific	O
growth	B-PHYS
and	O
net	O
growth	O
rates	O
(	O
two	O
-	O
treatment	O
seawater	B-OBJC
dilution	B-PROC
method	I-PROC
)	O
were	O
estimated	O
from	O
samples	B-LIVB
incubated	B-PROC
in	O
situ	O
at	O
eight	O
depths	O
.	O

Our	O
cruise	O
coincided	O
with	O
a	O
mild	O
El	B-PHEN
Niño	I-PHEN
event	O
,	O
and	O
only	O
weak	O
upwelling	B-PHEN
was	O
observed	O
in	O
the	O
CRD	B-GEOG
.	O

Nevertheless	O
,	O
the	O
highest	O
phytoplankton	B-LIVB
abundances	O
were	O
found	O
near	O
the	O
dome	O
center	O
.	O

However	O
,	O
mixed	O
-	O
layer	O
growth	O
rates	O
were	O
lowest	O
in	O
the	O
dome	O
center	O
(	O
∼0	O
.	O
5	O
-	O
0	O
.	O
9	O
day	O
(	O
-	O
1	O
)	O
)	O
,	O
but	O
higher	O
on	O
the	O
edge	O
of	O
the	O
dome	O
(	O
∼0	O
.	O
9	O
-	O
1	O
.	O
0	O
day	O
(	O
-	O
1	O
)	O
)	O
and	O
in	O
adjacent	O
coastal	B-GEOG
waters	I-GEOG
(	O
0	O
.	O
9	O
-	O
1	O
.	O
3	O
day	O
(	O
-	O
1	O
)	O
)	O
.	O

We	O
found	O
good	O
agreement	O
between	O
independent	O
methods	O
to	O
estimate	O
growth	O
rates	O
.	O

Mixed	O
-	O
layer	O
growth	O
rates	O
of	O
Prochlorococcus	B-LIVB
and	O
Synechococcus	B-LIVB
were	O
largely	O
balanced	O
by	O
mortality	O
,	O
whereas	O
eukaryotic	B-LIVB
phytoplankton	I-LIVB
showed	O
positive	B-DISO
net	B-PHYS
growth	I-PHYS
(	O
∼0	O
.	O
5	O
-	O
0	O
.	O
6	O
day	O
(	O
-	O
1	O
)	O
)	O
,	O
that	O
is	O
,	O
growth	B-PHYS
available	O
to	O
support	O
larger	O
(	O
mesozooplankton	O
)	O
consumer	O
biomass	O
.	O

These	O
are	O
the	O
first	O
group	O
-	O
specific	O
phytoplankton	B-LIVB
rate	O
estimates	O
in	O
this	O
region	B-GEOG
,	O
and	O
they	O
demonstrate	O
that	O
integrated	O
primary	O
production	O
is	O
high	O
,	O
exceeding	O
1	O
g	O
C	O
m	O
(	O
-	O
2	O
)	O
day	O
(	O
-	O
1	O
)	O
on	O
average	O
,	O
even	O
during	O
a	O
period	O
of	O
reduced	O
upwelling	B-PHEN
.	O

Incidence	O
and	O
Impact	O
of	O
Patient	B-LIVB
-	O
Prosthesis	B-DEVI
Mismatch	O
in	O
Isolated	B-PROC
Aortic	I-PROC
Valve	I-PROC
Surgery	I-PROC
The	O
mains	O
topics	O
of	O
this	O
work	O
are	O
the	O
incidence	O
of	O
patient	B-LIVB
-	O
prosthesis	B-DEVI
mismatch	O
and	O
the	O
influence	O
in	O
the	O
early	O
results	O
of	O
isolated	B-PROC
aortic	I-PROC
valve	I-PROC
surgery	I-PROC
.	O

In	O
193	O
patients	B-LIVB
isolated	B-PROC
aortic	I-PROC
valve	I-PROC
surgery	I-PROC
was	O
performed	O
.	O

The	O
study	B-LIVB
population	I-LIVB
was	O
divided	O
in	O
three	O
subgroups	O
:	O
20	O
patients	B-LIVB
with	O
severe	O
,	O
131	O
patients	B-LIVB
with	O
moderate	O
and	O
42	O
patients	B-LIVB
without	O
patient	B-LIVB
-	O
prosthesis	B-DEVI
mismatch	O
.	O

The	O
indexed	O
effective	B-PHYS
orifice	I-PHYS
area	I-PHYS
was	O
used	O
to	O
define	O
the	O
subgroups	O
.	O

Operative	O
mortality	O
and	O
perioperative	B-DISO
complications	I-DISO
were	O
considered	O
the	O
indicators	O
of	O
the	O
early	O
results	O
of	O
aortic	B-PROC
valve	I-PROC
surgery	I-PROC
.	O

The	O
incidence	O
of	O
severe	O
and	O
moderate	O
patient	B-LIVB
-	O
prosthesis	B-DEVI
mismatch	O
was	O
respectively	O
10	O
.	O

3	O
%	O
and	O
67	O
.	O

8	O
%	O
.	O

Hospital	O
mortality	O
and	O
perioperative	B-DISO
complications	I-DISO
were	O
:	O
mortality	O
5	O
%	O
vs	O
.	O

3	O
.	O
1	O
%	O
vs	O
.	O

2	O
.	O
4	O
%	O
(	O
p	O
=	O
0	O
.	O
855	O
)	O
,	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
5	O
%	O
vs	O
.	O

6	O
.	O
9	O
%	O
vs	O
.	O

4	O
.	O
8	O
%	O
(	O
p	O
=	O
0	O
.	O
861	O
)	O
;	O
pulmonary	B-DISO
complications	I-DISO
5	O
%	O
vs	O
.	O

3	O
.	O
1	O
vs	O
.	O

0	O
.	O
0	O
%	O
(	O
p	O
=	O
0	O
.	O
430	O
)	O
;	O
exploration	B-PROC
for	O
bleeding	B-DISO
5	O
%	O
vs	O
.	O

0	O
.	O
8	O
%	O
vs	O
.	O

2	O
.	O
4	O
%	O
(	O
p	O
=	O
0	O
.	O
319	O
)	O
;	O
atrial	B-DISO
fibrillation	I-DISO
30	O
%	O
vs	O
.	O

19	O
.	O
8	O
%	O
vs	O
.	O

11	O
.	O

9	O
%	O
(	O
p	O
=	O
0	O
.	O
225	O
)	O
;	O
wound	B-DISO
infection	I-DISO
5	O
%	O
vs	O
.	O

0	O
.	O
8	O
%	O
vs	O
.	O

0	O
.	O
00	O
%	O
(	O
p	O
=	O
0	O
.	O
165	O
)	O
,	O
respectively	O
for	O
the	O
group	O
with	O
severe	O
,	O
moderate	O
and	O
without	O
patient	B-LIVB
-	O
prosthesis	B-DEVI
mismatch	O
.	O

Patient	B-LIVB
-	O
prosthesis	B-DEVI
mismatch	O
is	O
a	O
common	O
occurrence	O
in	O
aortic	B-PROC
valve	I-PROC
surgery	I-PROC
.	O

This	O
phenomenon	B-PHEN
does	O
not	O
affect	O
the	O
early	O
results	O
of	O
aortic	B-PROC
valve	I-PROC
surgery	I-PROC
.	O

Nutrient	O
Intakes	O
in	O
Early	O
Life	O
and	O
Risk	O
of	O
Obesity	B-DISO
There	O
is	O
increasing	O
evidence	O
that	O
environmental	O
factors	O
in	O
early	O
life	O
predict	O
later	O
health	O
.	O

The	O
early	O
adiposity	O
rebound	O
recorded	O
in	O
most	O
obese	B-DISO
subjects	B-LIVB
suggests	O
that	O
factors	O
promoting	O
body	B-PHYS
fat	I-PHYS
development	B-PHYS
have	O
operated	O
in	O
the	O
first	O
years	O
of	O
life	O
.	O

Birth	B-PHYS
weight	I-PHYS
,	O
growth	B-DISO
velocity	I-DISO
and	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O
BMI	B-PHYS
)	O
trajectories	O
seem	O
to	O
be	O
highly	O
sensitive	O
to	O
the	O
environmental	O
conditions	O
present	B-DISO
during	O
pregnancy	B-PHYS
and	O
in	O
early	O
life	O
(	O
""""	O
The	O
first	O
1000	O
days	O
""""	O
)	O
.	O

Particularly	O
,	O
nutritional	O
exposure	O
can	O
have	O
a	O
long	B-PHEN
-	I-PHEN
term	I-PHEN
effect	I-PHEN
on	O
health	O
in	O
adulthood	O
.	O

The	O
high	B-OBJC
protein	I-OBJC
-	I-OBJC
low	I-OBJC
fat	I-OBJC
diet	I-OBJC
often	O
recorded	O
in	O
young	O
children	B-LIVB
may	O
have	O
contributed	O
to	O
the	O
rapid	O
rise	O
of	O
childhood	O
obesity	B-DISO
prevalence	O
during	O
the	O
last	O
decades	O
.	O

Metabolic	O
programming	O
by	O
early	O
nutrition	B-PHYS
could	O
explain	O
the	O
development	B-PHYS
of	O
later	O
obesity	B-DISO
and	O
adult	B-DISO
diseases	I-DISO
.	O

Characteristics	O
of	O
the	O
fibroplasia	B-PHEN
and	O
collagen	B-CHEM
expression	B-PHYS
in	O
the	O
abdominal	B-ANAT
wall	I-ANAT
after	O
implant	B-PROC
of	O
the	O
polypropylene	B-CHEM
mesh	I-CHEM
and	O
polypropylene	B-CHEM
/	O
polyglecaprone	B-CHEM
mesh	I-CHEM
in	O
rats	B-LIVB
To	O
compare	O
fibroplasia	B-PHEN
and	O
the	O
resistance	B-PHYS
of	O
the	O
abdominal	B-ANAT
wall	I-ANAT
when	O
polypropylene	B-CHEM
meshes	I-CHEM
and	O
polypropylene	B-CHEM
/	O
poliglecaprone	B-CHEM
are	O
used	O
.	O

Seventy	O
-	O
seven	O
male	B-PHYS
Wistar	B-LIVB
rats	I-LIVB
were	O
divided	O
into	O
three	O
groups	B-LIVB
:	O
Control	B-LIVB
Group	I-LIVB
(	O
for	O
resistance	B-PHYS
)	O
;	O
Group	B-LIVB
E	I-LIVB
(	O
polypropylene	B-CHEM
mesh	I-CHEM
)	O
;	O
and	O
Group	B-LIVB
U	I-LIVB
(	O
polypropylene	B-CHEM
/	O
poliglecaprone	B-CHEM
mesh	I-CHEM
)	O
.	O

The	O
animals	B-LIVB
in	O
Groups	B-LIVB
E	I-LIVB
and	O
U	B-LIVB
had	O
a	O
standard	O
muscular	O
and	O
aponeurotic	B-ANAT
defect	O
,	O
with	O
integral	O
peritoneum	O
,	O
and	O
correction	O
with	O
the	O
mesh	B-DEVI
.	O

Measurements	O
were	O
taken	O
4	O
,	O
7	O
,	O
14	O
,	O
28	O
and	O
56	O
days	O
after	O
surgery	B-PROC
.	O

The	O
resistance	B-PHYS
,	O
and	O
collagen	B-CHEM
density	O
were	O
studied	B-PROC
.	O

Resistance	B-PHYS
on	O
the	O
56th	O
day	O
was	O
similar	O
in	O
both	O
meshes	B-DEVI
.	O

The	O
gain	O
in	O
resistance	B-PHYS
described	O
an	O
ascending	O
curve	O
for	O
the	O
polypropylene	B-CHEM
mesh	I-CHEM
and	O
was	O
irregular	O
in	O
the	O
case	O
of	O
the	O
polypropylene	B-CHEM
/	O
poliglecaprone	B-CHEM
.	O

Fibroplasia	B-PHEN
showed	O
a	O
gain	O
in	O
type	B-CHEM
I	I-CHEM
and	O
type	B-CHEM
III	I-CHEM
collagen	I-CHEM
in	O
both	O
groups	B-LIVB
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Collagen	B-CHEM
III	I-CHEM
stabilized	B-DISO
in	O
the	O
14th	O
day	O
and	O
collagen	B-CHEM
I	I-CHEM
continued	O
to	O
ascend	O
.	O

The	O
gain	O
in	O
resistance	B-PHYS
of	O
the	O
polypropylene	B-CHEM
mesh	I-CHEM
is	O
regular	O
and	O
ascending	O
,	O
whereas	O
the	O
polypropylene	B-CHEM
/	O
poliglecaprone	B-CHEM
is	O
not	O
regular	O
.	O

The	O
final	O
resistance	B-PHYS
of	O
both	O
meshes	B-DEVI
is	O
similar	O
;	O
the	O
collagen	B-CHEM
density	O
increases	O
over	O
time	O
,	O
and	O
show	O
the	O
same	O
inflammatory	O
potential	O
.	O

Co	O
-	O
delivery	O
of	O
pemetrexed	B-CHEM
and	O
miR	B-CHEM
-	I-CHEM
21	I-CHEM
antisense	I-CHEM
oligonucleotide	I-CHEM
by	O
lipid	B-CHEM
-	O
polymer	B-CHEM
hybrid	B-OBJC
nanoparticles	I-OBJC
and	O
effects	O
on	O
glioblastoma	B-DISO
cells	B-ANAT
Combination	B-PROC
therapy	I-PROC
using	O
anticancer	B-CHEM
drugs	I-CHEM
and	O
nucleic	B-CHEM
acid	I-CHEM
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug	B-PHYS
resistance	I-PHYS
in	O
cancer	B-DISO
and	O
to	O
enhance	O
apoptosis	B-PHYS
.	O

In	O
this	O
study	B-PROC
,	O
lipid	B-CHEM
-	O
polymer	B-CHEM
hybrid	B-OBJC
nanoparticles	I-OBJC
(	O
LPNs	B-CHEM
)	O
,	O
which	O
contain	O
both	O
pemetrexed	B-CHEM
and	O
miR	B-CHEM
-	I-CHEM
21	I-CHEM
antisense	I-CHEM
oligonucleotide	I-CHEM
(	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
)	O
,	O
have	O
been	O
developed	O
for	O
treatment	O
of	O
glioblastoma	B-DISO
,	O
the	O
most	O
aggressive	B-DISO
type	O
of	O
brain	B-DISO
tumor	I-DISO
.	O

Prepared	O
LPNs	B-CHEM
have	O
been	O
well	O
characterized	O
by	O
particle	O
size	O
distribution	O
and	O
zeta	B-PHEN
potential	I-PHEN
measurements	O
,	O
determination	O
of	O
encapsulation	B-PHEN
efficiency	O
,	O
and	O
in	O
vitro	O
release	B-PROC
experiments	I-PROC
.	O

Morphology	O
of	O
LPNs	B-CHEM
was	O
determined	O
by	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
.	O

LPNs	B-CHEM
had	O
a	O
hydrodynamic	B-PHEN
size	O
below	O
100	O
nm	O
and	O
exhibited	O
sustained	O
release	O
of	O
pemetrexed	B-CHEM
up	O
to	O
10	O
h	O
.	O

Encapsulation	B-PHEN
of	O
pemetrexed	B-CHEM
in	O
LPNs	B-CHEM
increased	O
cellular	B-PHYS
uptake	I-PHYS
from	O
6	O
%	O
to	O
78	O
%	O
.	O

Results	O
of	O
confocal	B-PROC
microscopy	I-PROC
analysis	I-PROC
have	O
shown	O
that	O
co	O
-	O
delivery	O
of	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
significantly	O
improved	O
accumulation	B-DISO
of	O
LPNs	B-CHEM
in	O
the	O
nucleus	B-ANAT
of	O
U87MG	B-ANAT
cells	I-ANAT
.	O

Nevertheless	O
,	O
more	O
effective	O
cytotoxicity	B-DISO
results	O
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	O
of	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
,	O
loaded	O
in	O
LPNs	B-CHEM
.	O

We	O
expect	O
that	O
the	O
effective	O
drug	B-DEVI
delivery	I-DEVI
systems	I-DEVI
can	O
be	O
obtained	O
with	O
higher	O
concentration	O
of	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
for	O
the	O
treatment	B-PROC
of	O
glioblastoma	B-DISO
.	O

Expert	B-LIVB
position	O
paper	O
on	O
prolonged	O
dual	B-PROC
antiplatelet	I-PROC
therapy	I-PROC
in	O
secondary	B-PROC
prevention	I-PROC
following	O
myocardial	B-DISO
infarction	I-DISO
The	O
protective	O
effect	O
of	O
dual	B-PROC
antiplatelet	I-PROC
therapy	I-PROC
(	O
DAPT	B-PROC
)	O
following	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
is	O
undisputed	O
,	O
but	O
its	O
duration	O
is	O
subject	O
of	O
debate	O
.	O

Several	O
studies	B-PROC
show	O
that	O
prolonged	O
therapy	B-PROC
provides	O
a	O
clinical	O
benefit	O
in	O
patients	B-LIVB
following	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O

The	O
aim	O
of	O
this	O
position	O
paper	O
authored	O
by	O
Austrian	B-LIVB
experts	B-LIVB
is	O
to	O
outline	O
the	O
current	O
evidence	O
and	O
provide	O
an	O
overview	O
of	O
recent	O
studies	B-PROC
.	O

It	O
is	O
also	O
intended	O
to	O
serve	O
as	O
a	O
practical	O
guide	O
to	O
identify	O
those	O
patients	B-LIVB
who	O
may	O
benefit	O
from	O
prolonged	O
DAPT	B-PROC
.	O

Clinical	B-PROC
evaluation	I-PROC
of	O
the	O
AutoPulse	B-DEVI
automated	B-DEVI
chest	I-DEVI
compression	I-DEVI
device	I-DEVI
for	O
out	B-DISO
-	I-DISO
of	I-DISO
-	I-DISO
hospital	I-DISO
cardiac	I-DISO
arrest	I-DISO
in	O
the	O
northern	O
district	O
of	O
Shanghai	B-GEOG
,	O
China	B-GEOG
Whether	O
the	O
AutoPulse	B-DEVI
automated	B-DEVI
chest	I-DEVI
compression	I-DEVI
device	I-DEVI
is	O
worthy	O
of	O
clinical	O
use	O
for	O
out	B-DISO
-	I-DISO
of	I-DISO
-	I-DISO
hospital	I-DISO
cardiac	I-DISO
arrest	I-DISO
(	O
OHCA	B-DISO
)	O
remains	O
controversial	O
.	O

A	O
prospective	B-PROC
controlled	I-PROC
study	I-PROC
was	O
conducted	O
to	O
evaluate	B-PROC
the	O
effect	O
of	O
AutoPulse	B-DEVI
versus	O
manual	O
chest	B-ANAT
compression	B-PROC
for	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
(	O
CPR	B-PROC
)	O
of	O
OHCA	B-DISO
patients	B-LIVB
in	O
the	O
northern	O
district	O
of	O
Shanghai	B-GEOG
,	O
China	B-GEOG
.	O

A	O
total	O
of	O
133	O
patients	B-LIVB
with	O
OHCA	B-DISO
who	O
were	O
treated	O
at	O
the	O
Emergency	B-OBJC
Medical	I-OBJC
Center	I-OBJC
of	I-OBJC
the	I-OBJC
Tenth	I-OBJC
People	I-OBJC
's	I-OBJC
Hospital	I-OBJC
Affiliated	O
with	O
Tongji	B-OBJC
University	I-OBJC
between	O
March	O
2011	O
and	O
March	O
2012	O
were	O
included	O
.	O

The	O
patients	B-LIVB
were	O
randomly	O
assigned	O
to	O
the	O
Manual	O
CPR	B-PROC
(	O
n	O
=	O
64	O
)	O
and	O
AutoPulse	B-DEVI
CPR	B-PROC
groups	O
(	O
n	O
=	O
69	O
)	O
in	O
accordance	O
with	O
the	O
approach	O
of	O
chest	B-ANAT
compression	B-PROC
received	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
return	B-DISO
of	I-DISO
spontaneous	I-DISO
circulation	I-DISO
(	O
ROSC	B-DISO
)	O
,	O
and	O
the	O
secondary	O
outcome	O
measures	O
included	O
24	O
-	O
h	O
survival	O
rate	O
,	O
hospital	O
discharge	O
rate	O
,	O
and	O
neurological	O
prognosis	B-PROC
at	O
hospital	B-PROC
discharge	I-PROC
.	O

The	O
ROSC	B-DISO
rate	O
of	O
patients	B-LIVB
with	O
OHCA	B-DISO
was	O
significantly	O
higher	O
in	O
the	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O
in	O
the	O
Manual	O
CPR	B-PROC
group	O
(	O
44	O
.	O
9	O
%	O
vs	O
.	O

23	O
.	O
4	O
%	O
;	O
p	O
=	O
0	O
.	O

009	O
)	O
.	O

The	O
24	O
-	O
h	O
survival	O
rate	O
of	O
OHCA	B-DISO
patients	B-LIVB
was	O
significantly	O
higher	O
in	O
the	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O
in	O
the	O
Manual	O
CPR	B-PROC
group	O
(	O
39	O
.	O

1	O
%	O
vs	O
.	O

21	O
.	O
9	O
%	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
hospital	O
discharge	O
rate	O
of	O
the	O
patients	B-LIVB
with	O
OHCA	B-DISO
was	O
significantly	O
higher	O
in	O
the	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O
in	O
the	O
Manual	O
CPR	B-PROC
group	O
(	O
18	O
.	O

8	O
%	O
vs	O
.	O

6	O
.	O

3	O
%	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
proportion	O
of	O
patients	B-LIVB
with	O
OHCA	B-DISO
and	O
a	O
cerebral	O
performance	O
category	O
score	O
of	O
1	O
or	O
2	O
points	O
at	O
hospital	B-PROC
discharge	I-PROC
was	O
higher	O
in	O
the	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O
in	O
the	O
Manual	O
CPR	B-PROC
group	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
16	O
.	O
2	O
%	O
vs	O
.	O

13	O
.	O
4	O
%	O
,	O
p	O
=	O
1	O
.	O
00	O
)	O
.	O

Use	O
of	O
the	O
AutoPulse	B-DEVI
increases	O
CPR	B-PROC
success	O
and	O
survival	O
rates	O
in	O
patients	B-LIVB
with	O
OHCA	B-DISO
,	O
but	O
its	O
ability	O
to	O
improve	B-DISO
cerebral	B-ANAT
performance	O
requires	O
further	O
evaluation	B-PROC
.	O

Medulloblastoma	B-DISO
:	O
molecular	B-PHYS
pathways	I-PHYS
and	O
histopathological	O
classification	O
Malignant	B-DISO
brain	I-DISO
tumors	I-DISO
are	O
the	O
leading	O
cause	O
of	O
cancer	B-DISO
death	B-DISO
among	O
pediatric	O
patients	B-LIVB
,	O
and	O
medulloblastoma	B-DISO
constitutes	O
20	O
%	O
of	O
them	O
.	O

Currently	O
,	O
the	O
treatment	B-PROC
is	O
risk	O
-	O
adapted	O
.	O

Maximum	O
surgical	B-PROC
resection	I-PROC
is	O
recommended	O
,	O
always	O
followed	O
by	O
chemotherapy	B-PROC
and	O
neuroaxis	B-ANAT
radiotherapy	B-PROC
.	O

In	O
spite	O
of	O
the	O
improving	O
survival	O
rate	O
,	O
survivors	B-LIVB
succumb	O
to	O
treatment	B-PROC
-	O
induced	O
side	B-DISO
effects	I-DISO
.	O

To	O
reduce	O
toxic	B-DISO
effects	I-DISO
,	O
molecular	B-PROC
-	I-PROC
targeted	I-PROC
treatment	I-PROC
is	O
proposed	O
.	O

Medulloblastoma	B-DISO
research	B-PROC
is	O
very	O
robust	O
,	O
and	O
new	O
articles	O
on	O
the	O
subject	O
are	O
published	O
daily	O
.	O

In	O
the	O
current	O
review	O
we	O
have	O
tried	O
to	O
bring	O
together	O
molecular	O
pathophysiology	O
of	O
the	O
neoplasm	B-DISO
and	O
current	O
pathological	O
classification	O
,	O
thus	O
making	O
an	O
effort	O
to	O
relate	O
tumor	B-PROC
biology	I-PROC
and	O
the	O
histological	B-PHYS
picture	I-PHYS
.	O

Expression	B-PHYS
of	O
the	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
and	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
could	O
be	O
affected	O
by	O
swimming	O
training	B-PROC
in	O
the	O
heart	B-ANAT
of	O
ovariectomized	B-LIVB
rats	I-LIVB
The	O
beneficial	O
and	O
more	O
potent	O
role	O
of	O
exercise	O
to	O
prevent	O
heart	B-ANAT
apoptosis	B-PHYS
in	O
ovariectomized	B-LIVB
rats	I-LIVB
has	O
been	O
known	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
swimming	O
training	B-PROC
on	O
cardiac	B-ANAT
expression	B-PHYS
of	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
and	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
levels	O
and	O
glycogen	B-CHEM
changes	O
in	O
the	O
myocyte	B-ANAT
.	O

Forty	O
animals	B-LIVB
were	O
separated	O
into	O
four	O
groups	O
as	O
control	B-LIVB
,	O
sham	O
,	O
ovariectomy	O
(	O
OVX	O
)	O
and	O
ovariectomized	O
group	O
with	O
8	O
weeks	O
swimming	O
training	B-PROC
(	O
OVX	O
.	O

E	O
)	O
.	O

Training	B-PROC
effects	O
were	O
evaluated	O
by	O
measuring	O
lipid	B-PROC
profiles	I-PROC
,	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
expression	O
levels	O
in	O
the	O
cardiac	O
tissue	O
.	O

Grafts	O
were	O
analyzed	O
by	O
reverse	B-PROC
transcription	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
for	O
Bcl	O
-	O
2	O
mRNA	O
and	O
Mir	O
-	O
133	O
and	O
by	O
Western	B-PROC
blot	I-PROC
for	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
protein	I-CHEM
.	O

Ovariectomy	B-PROC
down	B-PHYS
-	I-PHYS
regulated	I-PHYS
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
expression	O
levels	O
in	O
the	O
cardiac	O
tissue	O
,	O
and	O
swimming	O
training	B-PROC
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
their	O
expression	B-PHYS
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
results	O
showed	O
that	O
regular	O
exercise	O
as	O
a	O
physical	B-PROC
replacement	I-PROC
therapy	I-PROC
could	O
prevent	O
and	O
improve	O
the	O
effects	O
of	O
estrogen	B-DISO
deficiency	I-DISO
in	O
the	O
cardia	B-ANAT
.	O

Changes	O
in	O
risk	B-DISO
factors	I-DISO
for	O
young	O
male	B-PHYS
suicide	B-DISO
in	O
Newcastle	B-GEOG
upon	I-GEOG
Tyne	I-GEOG
,	O
1961	O
-	O
2009	O
Aims	O
and	O
method	O
To	O
ascertain	O
differences	O
in	O
patterns	B-DISO
of	I-DISO
suicide	I-DISO
in	O
young	O
men	B-LIVB
over	O
three	O
decades	O
(	O
1960s	O
,	O
1990s	O
and	O
2000s	O
)	O
and	O
discuss	O
implications	O
for	O
suicide	B-DISO
prevention	O
.	O

Data	O
on	O
suicides	B-DISO
and	O
open	O
verdicts	O
in	O
men	B-LIVB
aged	O
15	O
-	O
34	O
were	O
obtained	O
from	O
coroner	O
's	O
records	O
in	O
Newcastle	B-GEOG
upon	I-GEOG
Tyne	I-GEOG
and	O
analysed	B-PROC
using	O
SPSS	B-OBJC
software	I-OBJC
.	O

Results	O
An	O
increase	O
in	O
suicide	B-DISO
rates	I-DISO
from	O
the	O
first	O
to	O
the	O
second	O
decade	O
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	O
.	O

This	O
was	O
associated	O
with	O
an	O
increasing	O
proportion	O
of	O
single	O
men	B-LIVB
,	O
those	O
living	B-DISO
alone	I-DISO
,	O
unemployment	B-DISO
,	O
consumption	O
of	O
alcohol	O
,	O
use	O
of	O
hanging	B-DISO
,	O
previous	O
suicide	B-DISO
attempt	I-DISO
and	O
history	O
of	O
treatment	O
for	O
mental	B-DISO
illness	I-DISO
.	O

Clinical	O
implications	O
This	O
study	B-PROC
highlights	O
the	O
need	O
for	O
more	O
interventions	B-PROC
and	O
focus	B-PHYS
to	O
be	O
given	O
to	O
young	O
males	B-PHYS
in	O
the	O
suicide	B-DISO
prevention	O
area	O
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field	O
of	O
public	O
health	O
.	O

Areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	O
access	O
to	O
means	O
of	O
suicide	B-DISO
,	O
reducing	O
alcohol	O
use	O
,	O
support	O
for	O
relationship	O
difficulties	O
,	O
engagement	B-PROC
with	O
mental	B-PROC
health	I-PROC
services	I-PROC
and	O
management	B-PROC
of	O
chronic	B-DISO
illness	I-DISO
.	O

Spatio	B-PROC
-	I-PROC
Temporal	I-PROC
History	I-PROC
of	O
HIV	B-PHEN
-	I-PHEN
1	I-PHEN
CRF35	I-PHEN
_	I-PHEN
AD	I-PHEN
in	O
Afghanistan	B-GEOG
and	O
Iran	B-GEOG
HIV	B-LIVB
-	I-LIVB
1	I-LIVB
Circulating	I-LIVB
Recombinant	I-LIVB
Form	I-LIVB
35	I-LIVB
_	I-LIVB
AD	I-LIVB
(	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
)	O
has	O
an	O
important	O
position	O
in	O
the	O
epidemiological	O
profile	O
of	O
Afghanistan	B-GEOG
and	O
Iran	B-GEOG
.	O

Despite	O
the	O
presence	O
of	O
this	O
clade	B-LIVB
in	O
Afghanistan	B-GEOG
and	O
Iran	B-GEOG
for	O
over	O
a	O
decade	O
,	O
our	O
understanding	O
of	O
its	O
origin	O
and	O
dissemination	O
patterns	O
is	O
limited	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
Bayesian	O
phylogeographic	O
analysis	O
to	O
reconstruct	O
the	O
spatio	O
-	O
temporal	O
dispersion	O
pattern	O
of	O
this	O
clade	B-LIVB
using	O
eligible	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
gag	O
and	O
pol	O
sequences	O
available	O
in	O
the	O
Los	B-GEOG
Alamos	I-GEOG
HIV	O
database	O
(	O
432	O
sequences	O
available	O
from	O
Iran	B-GEOG
,	O
16	O
sequences	O
available	O
from	O
Afghanistan	B-GEOG
,	O
and	O
a	O
single	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
-like	O
pol	O
sequence	O
available	O
from	O
USA	B-GEOG
)	O
.	O

Bayesian	O
Markov	O
Chain	O
Monte	O
Carlo	O
algorithm	O
was	O
implemented	O
in	O
BEAST	B-OBJC
v1	I-OBJC
.	I-OBJC

8	I-OBJC
.	I-OBJC

1	I-OBJC
.	O
Between	O
-	O
country	O
dispersion	O
rates	O
were	O
tested	O
with	O
Bayesian	O
stochastic	O
search	O
variable	O
selection	O
method	O
and	O
were	O
considered	O
significant	O
where	O
Bayes	O
factor	O
values	O
were	O
greater	O
than	O
three	O
.	O

The	O
findings	O
suggested	O
that	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
sequences	O
were	O
genetically	O
similar	O
to	O
parental	O
sequences	O
from	O
Kenya	B-GEOG
and	O
Uganda	B-GEOG
,	O
and	O
to	O
a	O
set	O
of	O
subtype	B-PHEN
A1	I-PHEN
sequences	O
available	O
from	O
Afghan	B-GEOG
refugees	B-LIVB
living	O
in	O
Pakistan	B-GEOG
.	O

Our	O
results	O
also	O
showed	O
that	O
across	O
all	O
phylogenies	O
,	O
Afghan	B-GEOG
and	O
Iranian	B-GEOG
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
sequences	O
formed	O
a	O
monophyletic	O
cluster	O
(	O
posterior	O
clade	O
credibility	O
>	O
0	O
.	O
7	O
)	O
.	O

The	O
divergence	O
date	O
of	O
this	O
cluster	O
was	O
estimated	O
to	O
be	O
between	O
1990	O
and	O
1992	O
.	O

Within	O
this	O
cluster	O
,	O
a	O
bidirectional	O
dispersion	O
of	O
the	O
virus	B-LIVB
was	O
observed	O
across	O
Afghanistan	B-GEOG
and	O
Iran	B-GEOG
.	O

We	O
could	O
not	O
clearly	O
identify	O
if	O
Afghanistan	B-GEOG
or	O
Iran	B-GEOG
first	O
established	O
or	O
received	O
this	O
epidemic	B-DISO
,	O
as	O
the	O
root	O
location	O
of	O
this	O
cluster	O
could	O
not	O
be	O
robustly	O
estimated	O
.	O

Three	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
sequences	O
from	O
Afghan	B-GEOG
refugees	B-LIVB
living	O
in	O
Pakistan	B-GEOG
nested	O
among	O
Afghan	B-GEOG
and	O
Iranian	B-GEOG
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
branches	O
.	O

However	O
,	O
the	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
-like	O
sequence	O
available	O
from	O
USA	B-GEOG
diverged	O
independently	O
from	O
Kenyan	B-GEOG
subtype	B-PHEN
A1	I-PHEN
sequences	O
,	O
suggesting	O
it	O
not	O
to	O
be	O
a	O
true	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
lineage	O
.	O

Potential	O
factors	O
contributing	O
to	O
viral	B-LIVB
exchange	O
between	O
Afghanistan	B-GEOG
and	O
Iran	B-GEOG
could	O
be	O
injection	O
drug	O
networks	O
and	O
mass	O
migration	O
of	O
Afghan	B-GEOG
refugees	B-LIVB
and	O
labours	O
to	O
Iran	B-GEOG
,	O
which	O
calls	O
for	O
extensive	O
preventive	O
efforts	O
.	O

Hepatitis	B-LIVB
E	I-LIVB
virus	I-LIVB
in	O
donor	B-LIVB
plasma	B-ANAT
collected	O
in	O
Japan	B-GEOG
Human	B-LIVB
hepatitis	B-LIVB
E	I-LIVB
virus	I-LIVB
(	O
HEV	B-LIVB
)	O
is	O
prevalent	B-DISO
worldwide	I-DISO
.	O

Iatrogenic	O
HEV	B-LIVB
has	O
recently	O
been	O
identified	O
based	O
on	O
the	O
reports	O
of	O
transfusion	O
-	O
transmitted	O
cases	O
.	O

The	O
detection	O
rate	O
of	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
and	O
seroprevalence	B-PROC
of	O
HEV	B-CHEM
-	I-CHEM
IgG	I-CHEM
/	O
IgM	B-CHEM
have	O
been	O
regionally	B-PROC
evaluated	I-PROC
in	O
Japan	B-GEOG
,	O
and	O
donor	B-LIVB
plasma	B-ANAT
collected	O
in	O
Hokkaido	B-GEOG
is	O
currently	O
screened	O
by	O
nucleic	B-PROC
acid	I-PROC
amplification	I-PROC
testing	I-PROC
.	O

However	O
,	O
the	O
detection	O
rate	O
of	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
in	O
blood	B-LIVB
donors	I-LIVB
in	O
Japan	B-GEOG
outside	O
of	O
Hokkaido	B-GEOG
has	O
not	O
been	O
reported	O
.	O

A	O
total	O
of	O
620	O
140	O
qualified	O
donor	B-LIVB
plasma	B-ANAT
samples	I-ANAT
from	O
Japanese	B-GEOG
regions	I-GEOG
excluding	O
Hokkaido	B-GEOG
were	O
tested	O
for	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
(	O
pools	O
of	O
50	O
or	O
500	O
)	O
between	O
2004	O
and	O
2014	O
.	O

HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
-	I-CHEM
positive	I-CHEM
plasma	B-ANAT
bags	I-ANAT
were	O
identified	O
,	O
and	O
the	O
HEV	B-LIVB
viral	B-PROC
load	I-PROC
,	O
genotype	B-PHYS
and	O
anti	B-CHEM
-	I-CHEM
HEV	I-CHEM
immunoglobulin	I-CHEM
(	I-CHEM
Ig	I-CHEM
)	I-CHEM
G	I-CHEM
/	I-CHEM
IgM	I-CHEM
were	O
evaluated	O
.	O

The	O
detection	O
rate	O
of	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
(	O
pools	O
of	O
50	O
)	O
was	O
1	O
/	O
15	O
075	O
and	O
higher	O
in	O
eastern	B-GEOG
than	O
in	O
western	B-GEOG
Japan	I-GEOG
.	O

All	O
36	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
-	I-CHEM
positive	I-CHEM
samples	B-ANAT
were	O
genotype	B-PHYS
3	I-PHYS
with	O
viral	B-DISO
load	I-DISO
ranging	O
from	O
<	O
1·69	O
to	O
7·22	O
log10	O
copies	O
/	O
ml	O
.	O

Our	O
detection	O
rate	O
of	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
in	O
donor	B-LIVB
populations	I-LIVB
in	O
Japan	B-GEOG
outside	O
Hokkaido	B-GEOG
(	O
1	O
/	O
15	O
075	O
donations	B-PROC
)	O
is	O
generally	O
lower	O
than	O
reported	O
in	O
Europe	B-GEOG
and	O
lower	O
than	O
previously	O
reported	O
for	O
Hokkaido	B-GEOG
(	O
1	O
/	O
8173	O
donations	B-PROC
)	O
.	O

As	O
methods	O
varied	O
,	O
we	O
cannot	O
exclude	O
that	O
these	O
differences	O
are	O
reflective	O
of	O
differing	O
RNA	B-CHEM
detection	O
limits	O
.	O

In	O
contrast	O
to	O
Hokkaido	B-GEOG
where	O
genotype	B-PHYS
4	I-PHYS
has	O
been	O
reported	O
among	O
blood	B-PROC
donations	I-PROC
,	O
all	O
our	O
positive	B-DISO
donations	B-PROC
were	O
genotype	B-PHYS
3	I-PHYS
,	O
which	O
is	O
less	O
pathogenic	B-DISO
.	O

Social	O
cognition	O
in	O
schizophrenia	B-DISO
:	O
Factor	O
structure	O
of	O
emotion	B-PHYS
processing	B-PHYS
and	O
theory	O
of	O
mind	O
Factor	O
analytic	O
studies	O
examining	O
social	O
cognition	O
in	O
schizophrenia	B-DISO
have	O
yielded	O
inconsistent	O
results	O
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	O
of	O
measures	O
.	O

With	O
the	O
recent	O
conclusion	O
of	O
Phase	O
3	O
of	O
the	O
Social	O
Cognition	O
Psychometric	B-PROC
Evaluation	I-PROC
(	I-PROC
SCOPE	I-PROC
)	I-PROC
Study	I-PROC
,	O
the	O
most	O
psychometrically	B-PROC
sound	B-PROC
measures	I-PROC
of	O
social	O
cognition	O
have	O
been	O
identified	O
.	O

Therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	B-PROC
were	O
to	O
:	O
1	O
)	O
examine	B-DISO
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	B-DISO
through	O
the	O
utilization	O
of	O
psychometrically	B-PROC
sound	B-PROC
measures	I-PROC
,	O
2	O
)	O
examine	B-DISO
the	O
stability	O
of	O
the	O
factor	O
structure	O
across	O
two	O
study	B-PROC
visits	O
,	O
3	O
)	O
compare	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	B-DISO
to	O
that	O
in	O
healthy	O
controls	O
,	O
and	O
4	O
)	O
examine	B-DISO
the	O
relationship	O
between	O
the	O
factors	O
and	O
relevant	O
outcome	O
measures	O
including	O
social	O
functioning	O
and	O
symptoms	B-DISO
.	O

Results	O
supported	O
a	O
one	O
-	O
factor	O
model	O
for	O
the	O
patient	B-LIVB
and	O
healthy	O
control	O
samples	O
at	O
both	O
visits	B-PROC
.	O

This	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	B-DISO
symptoms	I-DISO
in	O
the	O
schizophrenia	B-DISO
sample	B-OBJC
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	B-LIVB
at	O
both	O
study	B-PROC
visits	B-PROC
.	O

Individual	O
differences	O
in	O
behavioral	B-PHYS
activation	I-PHYS
and	O
cardiac	B-PHYS
vagal	I-PHYS
control	I-PHYS
influence	O
affective	O
startle	O
modification	O
The	O
startle	B-PHYS
response	I-PHYS
(	O
SR	B-PHYS
)	O
has	O
a	O
close	O
relationship	O
with	O
stress	B-PHYS
responses	I-PHYS
.	O

Startle	O
modification	O
(	O
SRM	O
)	O
has	O
been	O
widely	O
used	O
to	O
study	O
stress	B-DISO
disorders	I-DISO
(	O
e	O
.	O
g	O
.	O
,	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
)	O
.	O

The	O
framework	O
of	O
the	O
behavioral	B-PHYS
inhibition	I-PHYS
and	O
activation	O
systems	O
(	O
BIS	B-PHYS
/	O
BAS	O
)	O
has	O
been	O
thought	O
to	O
correspond	O
with	O
withdrawal	O
and	O
approach	O
motivational	B-PHYS
processes	I-PHYS
underlying	O
affective	O
SRM	O
and	O
can	O
influence	O
stress	B-PHYS
reactivity	I-PHYS
.	O

Vagally	B-DISO
-	I-DISO
mediated	I-DISO
cardiac	I-DISO
activity	I-DISO
as	O
indexed	O
by	O
heart	B-DISO
rate	I-DISO
variability	I-DISO
(	O
HRV	B-DISO
)	O
has	O
been	O
associated	O
with	O
SRM	O
and	O
regulatory	B-PHEN
processes	I-PHEN
during	O
stress	B-DISO
.	O

In	O
the	O
present	O
study	O
,	O
the	O
influence	O
of	O
individual	O
differences	O
in	O
the	O
BIS	B-PHYS
/	O
BAS	O
and	O
resting	O
HRV	B-DISO
on	O
affective	O
SRM	O
were	O
examined	B-DISO
.	O

Eighty	B-LIVB
-	I-LIVB
six	I-LIVB
subjects	I-LIVB
viewed	O
affective	O
pictures	B-OBJC
while	O
acoustic	B-PHEN
SR	I-PHEN
stimuli	I-PHEN
were	O
delivered	O
.	O

Individual	O
differences	O
in	O
motivation	B-PHYS
were	O
measured	O
by	O
the	O
BIS	O
/	O
BAS	O
scales	O
.	O

The	O
magnitude	O
of	O
SR	B-PHYS
was	O
assessed	O
as	O
electromyographic	B-PROC
activity	O
of	O
the	O
SR	B-PHYS
eyeblink	B-PHYS
during	O
pictures	B-OBJC
of	O
different	O
valences	O
.	O

Resting	O
HRV	B-DISO
was	O
derived	O
from	O
electrocardiography	B-PROC
.	O

In	O
contrast	O
to	O
previous	O
studies	O
,	O
the	O
present	O
results	O
showed	O
that	O
startle	B-PHYS
inhibition	I-PHYS
and	O
potentiation	B-PHYS
were	O
related	O
to	O
BAS	O
and	O
HRV	B-DISO
,	O
but	O
not	O
to	O
BIS	B-PHYS
.	O

There	O
was	O
also	O
an	O
interaction	O
of	O
BAS	O
and	O
HRV	B-DISO
,	O
indicating	O
that	O
the	O
relationship	O
between	O
HRV	B-DISO
and	O
SRM	O
strengthened	O
as	O
BAS	O
scores	O
decreased	O
.	O

The	O
present	O
findings	B-DISO
suggest	O
that	O
BAS	O
may	O
relate	O
to	O
both	O
withdrawal	O
and	O
approach	O
,	O
and	O
trait	B-PHYS
stress	B-PHYS
reactivity	I-PHYS
is	O
influence	O
d	O
by	O
BAS	O
and	O
cardiac	B-DISO
vagal	I-DISO
activity	I-DISO
.	O

In	O
addition	O
,	O
BAS	O
moderates	O
the	O
relationship	O
between	O
cardiac	B-DISO
vagal	I-DISO
activity	I-DISO
and	O
SRM	O
.	O

These	O
findings	B-DISO
have	O
both	O
theoretical	O
and	O
practical	O
implications	O
for	O
the	O
study	O
of	O
SRM	O
,	O
stress	B-DISO
disorders	I-DISO
,	O
and	O
health	O
.	O

Efficient	O
patient	B-LIVB
modeling	B-PROC
for	O
visuo	O
-	O
haptic	B-PHYS
VR	O
simulation	O
using	O
a	O
generic	O
patient	B-LIVB
atlas	B-OBJC
This	O
work	O
presents	O
a	O
new	O
time	O
-	O
saving	O
virtual	O
patient	B-LIVB
modeling	B-PROC
system	I-PROC
by	O
way	O
of	O
example	O
for	O
an	O
existing	O
visuo	O
-	O
haptic	B-PHYS
training	B-PROC
and	O
planning	O
virtual	O
reality	O
(	O
VR	O
)	O
system	O
for	O
percutaneous	B-PROC
transhepatic	I-PROC
cholangio	I-PROC
-	I-PROC
drainage	I-PROC
(	O
PTCD	B-PROC
)	O
.	O

Our	O
modeling	B-PROC
process	I-PROC
is	O
based	O
on	O
a	O
generic	O
patient	B-LIVB
atlas	B-OBJC
to	O
start	O
with	O
.	O

It	O
is	O
defined	O
by	O
organ	B-ANAT
-	O
specific	O
optimized	O
models	O
,	O
method	O
modules	O
and	O
parameters	O
,	O
i	O
.	O

e	O
.	O

mainly	O
individual	O
segmentation	O
masks	O
,	O
transfer	O
functions	O
to	O
fill	O
the	O
gaps	O
between	O
the	O
masks	O
and	O
intensity	O
image	O
data	O
.	O

In	O
this	O
contribution	O
,	O
we	O
show	O
how	O
generic	O
patient	B-LIVB
atlases	B-OBJC
can	O
be	O
generalized	O
to	O
new	O
patient	O
data	O
.	O

The	O
methodology	O
consists	O
of	O
patient	B-LIVB
-	O
specific	O
,	O
locally	O
-	O
adaptive	O
transfer	O
functions	O
and	O
dedicated	O
modeling	B-PROC
methods	I-PROC
such	O
as	O
multi	O
-	O
atlas	O
segmentation	O
,	O
vessel	O
filtering	O
and	O
spline	O
-	O
modeling	O
.	O

Our	O
full	O
image	O
volume	O
segmentation	O
algorithm	O
yields	O
median	O
DICE	O
coefficients	O
of	O
0	O
.	O

98	O
,	O
0	O
.	O
93	O
,	O
0	O
.	O
82	O
,	O
0	O
.	O
74	O
,	O
0	O
.	O
51	O
and	O
0	O
.	O
48	O
regarding	O
soft	O
-	O
tissue	O
,	O
liver	B-ANAT
,	O
bone	O
,	O
skin	B-ANAT
,	O
blood	B-ANAT
and	O
bile	B-ANAT
vessels	I-ANAT
for	O
ten	O
test	O
patients	B-LIVB
and	O
three	O
selected	O
reference	O
patients	B-LIVB
.	O

Compared	O
to	O
standard	O
slice	O
-	O
wise	O
manual	O
contouring	O
time	O
saving	O
is	O
remarkable	O
.	O

Our	O
segmentation	O
process	O
shows	O
out	O
efficiency	O
and	O
robustness	O
for	O
upper	O
abdominal	B-DISO
puncture	I-DISO
simulation	O
systems	O
.	O

This	O
marks	O
a	O
significant	O
step	O
toward	O
establishing	O
patient	B-LIVB
-	O
specific	O
training	B-PROC
and	O
hands	O
-	O
on	O
planning	O
systems	O
in	O
a	O
clinical	B-PROC
environment	I-PROC
.	O

The	O
Benefits	O
of	O
Combination	B-PROC
Therapy	I-PROC
with	O
Esomeprazole	B-CHEM
and	O
Rebamipide	B-CHEM
in	O
Symptom	B-DISO
Improvement	O
in	O
Reflux	B-DISO
Esophagitis	I-DISO
:	O
An	O
International	O
Multicenter	B-PROC
Study	I-PROC
To	O
investigate	O
the	O
effects	O
of	O
esomeprazole	B-CHEM
and	O
rebamipide	B-CHEM
combination	B-PROC
therapy	I-PROC
on	O
symptomatic	B-DISO
improvement	O
in	O
patients	B-LIVB
with	O
reflux	B-DISO
esophagitis	I-DISO
.	O

A	O
total	O
of	O
501	O
patients	B-LIVB
with	O
reflux	B-DISO
esophagitis	I-DISO
were	O
randomized	B-PROC
into	O
one	O
of	O
the	O
following	O
two	O
treatment	B-PROC
regimens	I-PROC
:	O
40	O
mg	O
esomeprazole	B-CHEM
plus	O
300	O
mg	O
rebamipide	B-CHEM
daily	O
(	O
combination	B-PROC
therapy	I-PROC
group	O
)	O
or	O
40	O
mg	O
esomeprazole	B-CHEM
daily	O
(	O
monotherapy	B-PROC
group	O
)	O
.	O

We	O
used	O
a	O
symptom	B-DISO
questionnaire	O
that	O
evaluated	O
heartburn	B-DISO
,	O
acid	B-DISO
regurgitation	I-DISO
,	O
and	O
four	O
upper	B-DISO
gastrointestinal	I-DISO
symptoms	I-DISO
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
mean	O
decrease	O
in	O
the	O
total	O
symptom	B-DISO
score	I-DISO
.	O

The	O
mean	O
decreases	O
in	O
the	O
total	O
symptom	B-DISO
score	I-DISO
at	O
4	O
weeks	O
were	O
estimated	O
to	O
be	O
-18	O
.	O

1±13	O
.	O

8	O
in	O
the	O
combination	B-PROC
therapy	I-PROC
group	O
and	O
-15	O
.	O

1±11	O
.	O

9	O
in	O
the	O
monotherapy	B-PROC
group	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

Changes	O
in	O
reflux	B-DISO
symptom	B-DISO
s	O
from	O
baseline	O
after	O
4	O
weeks	O
of	O
treatment	B-PROC
were	O
-8	O
.	O

4±6	O
.	O

6	O
in	O
the	O
combination	B-PROC
therapy	I-PROC
group	O
and	O
-6	O
.	O

8±5	O
.	O

9	O
in	O
the	O
monotherapy	B-PROC
group	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
.	O

Over	O
a	O
4	O
-	O
week	O
treatment	B-PROC
course	O
,	O
esomeprazole	B-CHEM
and	O
rebamipide	B-CHEM
combination	B-PROC
therapy	I-PROC
was	O
more	O
effective	O
in	O
decreasing	B-DISO
the	O
symptoms	B-DISO
of	O
reflux	B-DISO
esophagitis	I-DISO
than	O
esomeprazole	B-CHEM
monotherapy	B-PROC
.	O

Achilles	B-ANAT
tendon	I-ANAT
material	B-PHEN
properties	I-PHEN
are	O
greater	O
in	O
the	O
jump	B-ANAT
leg	I-ANAT
of	O
jumping	O
athletes	B-LIVB
The	O
Achilles	B-ANAT
tendon	I-ANAT
(	O
AT	B-ANAT
)	O
must	O
adapt	O
to	O
meet	B-PHEN
changes	O
in	O
demands	O
.	O

This	O
study	O
explored	O
AT	B-ANAT
adaptation	B-PHYS
by	O
comparing	O
properties	O
within	O
the	O
jump	O
and	O
non	B-DISO
-	I-DISO
jump	I-DISO
legs	B-ANAT
of	O
jumping	O
athletes	B-LIVB
.	O

Non	B-DISO
-	I-DISO
jumping	I-DISO
control	B-LIVB
athletes	I-LIVB
were	O
included	O
to	O
control	O
limb	B-ANAT
dominance	O
effects	O
.	O

AT	B-ANAT
properties	O
were	O
assessed	O
in	O
the	O
preferred	O
(	O
jump	O
)	O
and	O
non	B-DISO
-	I-DISO
preferred	I-DISO
(	O
lead	O
)	O
jumping	O
legs	B-ANAT
of	O
male	B-PHYS
collegiate	O
-	O
level	O
long	O
and	O
/	O
or	O
high	O
jump	O
(	O
jumpers	B-LIVB
;	O
n	O
=	O
10	O
)	O
and	O
cross	B-GEOG
-	I-GEOG
country	I-GEOG
(	O
controls	B-LIVB
;	O
n	O
=	O
10	O
)	O
athletes	B-LIVB
.	O

Cross	O
-	O
sectional	O
area	O
(	O
CSA	O
)	O
,	O
elongation	B-PHEN
,	O
and	O
force	B-PHEN
during	O
isometric	B-PHYS
contractions	I-PHYS
were	O
used	O
to	O
estimate	O
the	O
morphological	O
,	O
mechanical	B-PHEN
and	O
material	B-PHEN
properties	I-PHEN
of	O
the	O
ATs	B-ANAT
bilaterally	O
.	O

Jumpers	B-LIVB
exposed	O
their	O
ATs	B-ANAT
to	O
more	O
force	B-PHEN
and	O
stress	B-DISO
than	O
controls	B-LIVB
(	O
all	O
p≤0	O
.	O
03	O
)	O
.	O

AT	B-ANAT
force	B-PHEN
and	O
stress	B-DISO
were	O
also	O
greater	O
in	O
the	O
jump	O
leg	B-ANAT
of	O
both	O
jumpers	B-LIVB
and	O
controls	B-LIVB
than	O
in	O
the	O
lead	B-ANAT
leg	I-ANAT
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Jumpers	B-LIVB
had	O
17	O
.	O

8	O
%	O
greater	O
AT	B-ANAT
stiffness	B-DISO
and	O
24	O
.	O

4	O
%	O
greater	O
Young	O
's	O
modulus	O
in	O
their	O
jump	O
leg	B-ANAT
compared	O
to	O
lead	B-ANAT
leg	I-ANAT
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
were	O
no	O
jump	O
versus	O
lead	B-ANAT
leg	I-ANAT
differences	O
in	O
AT	B-ANAT
stiffness	B-DISO
or	O
Young	O
's	O
modulus	O
within	O
controls	B-LIVB
(	O
all	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

ATs	B-ANAT
chronically	O
exposed	O
to	O
elevated	O
mechanical	B-PHEN
loading	I-PHEN
were	O
found	O
to	O
exhibit	O
greater	O
mechanical	B-PHEN
(	O
stiffness	B-DISO
)	O
and	O
material	B-PHEN
(	O
Young	O
's	O
modulus	O
)	O
properties	O
.	O

Assessment	B-PROC
of	O
Residual	B-DISO
Disease	I-DISO
With	O
Molecular	B-PROC
Breast	I-PROC
Imaging	I-PROC
in	O
Patients	B-LIVB
Undergoing	O
Neoadjuvant	B-PROC
Therapy	I-PROC
:	O
Association	O
With	O
Molecular	O
Subtypes	O
Assessment	B-PROC
of	O
residual	B-DISO
disease	I-DISO
after	O
neoadjuvant	B-PROC
therapy	I-PROC
for	O
breast	B-DISO
cancer	I-DISO
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-ANAT
imaging	B-PROC
.	O

This	O
study	B-PROC
evaluates	B-PROC
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-PROC
breast	I-PROC
imaging	I-PROC
(	O
MBI	B-PROC
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	B-CHEM
zinc	I-CHEM
telluride	I-CHEM
detectors	B-OBJC
in	O
assessing	O
residual	B-DISO
disease	I-DISO
after	O
neoadjuvant	B-PROC
therapy	I-PROC
in	O
patients	B-LIVB
with	O
breast	B-DISO
cancer	I-DISO
.	O

Clinical	O
data	O
,	O
imaging	B-PROC
,	O
surgical	O
,	O
and	O
pathological	O
findings	B-DISO
of	O
51	O
women	B-LIVB
with	O
breast	B-DISO
cancer	I-DISO
undergoing	O
neoadjuvant	B-PROC
therapy	I-PROC
were	O
recorded	O
.	O

MBI	B-PROC
findings	B-DISO
were	O
correlated	O
with	O
surgical	O
pathology	O
results	O
.	O

Accuracy	O
of	O
MBI	B-PROC
in	O
predicting	O
complete	B-DISO
pathological	I-DISO
response	I-DISO
and	O
size	O
of	O
residual	B-DISO
disease	I-DISO
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	O
.	O

The	O
size	O
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-PROC
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0	O
.	O
55	O
;	O
P	O
<	O
.001	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	B-DISO
negative	I-DISO
and	O
HER2	B-PHYS
/	I-PHYS
neu	I-PHYS
positive	I-PHYS
subtypes	O
(	O
r	O
=	O
0	O
.	O
92	O
and	O
0	O
.	O
62	O
,	O
respectively	O
)	O
.	O

Sixteen	O
patients	B-LIVB
(	O
31	O
%	O
)	O
had	O
complete	B-DISO
pathological	I-DISO
response	I-DISO
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MBI	B-PROC
for	O
detecting	O
residual	B-DISO
disease	I-DISO
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66	O
-	O
93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
-	O
88	O
)	O
,	O
respectively	O
.	O

For	O
triple	B-DISO
negative	I-DISO
or	O
HER2	B-PHYS
/	I-PHYS
neu	I-PHYS
positive	I-PHYS
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62	O
-	O
98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
93	O
)	O
,	O
respectively	O
.	O

The	O
accuracy	O
of	O
MBI	B-PROC
in	O
assessing	O
residual	B-DISO
disease	I-DISO
after	O
neoadjuvant	B-PROC
treatment	I-PROC
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	O
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	B-DISO
negative	I-DISO
and	O
HER2	B-PHYS
/	I-PHYS
neu	I-PHYS
positive	I-PHYS
subtypes	O
.	O

Sinus	B-PROC
augmentation	I-PROC
using	O
a	O
histone	B-CHEM
deacetylase	I-CHEM
inhibitor	I-CHEM
in	O
a	O
calcium	B-CHEM
sulfate	I-CHEM
carrier	B-CHEM
in	O
rabbit	B-LIVB
:	O
A	O
pilot	B-PROC
study	I-PROC
Histone	B-CHEM
deacetylase	I-CHEM
inhibitors	I-CHEM
such	O
as	O
sodium	B-CHEM
butyrate	I-CHEM
(	O
SB	B-CHEM
)	O
have	O
been	O
suggested	O
to	O
be	O
promising	O
candidate	B-CHEM
small	I-CHEM
molecules	I-CHEM
for	O
bone	B-PHYS
regeneration	I-PHYS
.	O

In	O
this	O
study	O
,	O
the	O
capacity	O
of	O
SB	B-CHEM
loaded	O
onto	O
calcium	B-CHEM
sulfate	I-CHEM
(	O
CaS	B-CHEM
)	O
to	O
enhance	O
bone	B-PHYS
formation	I-PHYS
was	O
investigated	O
in	O
a	O
rabbit	B-LIVB
sinus	I-LIVB
model	I-LIVB
.	O

Following	O
preparation	O
of	O
the	O
sinus	B-ANAT
access	O
window	O
on	O
a	O
randomly	O
selected	O
side	O
,	O
SB	B-CHEM
loaded	O
onto	O
CaS	B-CHEM
(	O
CaS	B-CHEM
/	O
SB	B-CHEM
)	O
was	O
grafted	B-PROC
in	O
five	O
rabbits	B-LIVB
,	O
and	O
CaS	B-CHEM
alone	O
(	O
control	B-LIVB
)	O
was	O
grafted	B-PROC
in	O
another	O
five	O
rabbits	B-LIVB
.	O

The	O
animals	B-LIVB
were	O
euthanized	B-PROC
after	O
4	O
weeks	O
for	O
radiographic	B-PROC
,	O
histometric	B-PROC
,	O
and	O
immunohistochemical	B-PROC
analyses	B-PROC
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
total	O
augmented	O
volume	O
between	O
the	O
groups	O
in	O
the	O
radiographic	B-PROC
analysis	I-PROC
(	O
158	O
.	O
22	O
±	O
39	O
.	O
31	O
mm	O
(	O
3	O
)	O
and	O
107	O
.	O
09	O
±	O
39	O
.	O
69	O
mm	O
(	O
3	O
)	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
040	O
)	O
.	O

The	O
CaS	B-CHEM
/	O
SB	B-CHEM
group	O
showed	O
a	O
larger	O
portion	O
of	O
mature	O
lamellar	O
bone	O
and	O
a	O
higher	O
level	O
of	O
mineralization	B-PHYS
of	O
bone	O
trabeculae	O
,	O
characterized	O
by	O
more	O
intense	O
labeling	B-PROC
with	O
osteocalcin	B-CHEM
compared	O
with	O
the	O
control	B-LIVB
group	I-LIVB
in	O
the	O
immunohistochemical	B-PROC
analysis	B-PROC
.	O

The	O
number	O
of	O
osteocalcin	B-CHEM
-	I-CHEM
positive	I-CHEM
cells	B-ANAT
within	O
the	O
central	O
area	O
of	O
the	O
augmented	O
sinus	B-ANAT
was	O
significantly	O
higher	O
in	O
the	O
CaS	B-CHEM
/	O
SB	B-CHEM
group	O
than	O
in	O
the	O
control	B-LIVB
group	I-LIVB
(	O
179	O
±	O
26	O
.	O
0	O
mm	O
(	O
2	O
)	O
and	O
123	O
±	O
33	O
.	O

2	O
mm	O
(	O
2	O
)	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O

In	O
conclusion	O
,	O
CaS	B-CHEM
/	O
SB	B-CHEM
exhibited	O
superior	O
osteogenic	B-PHYS
potential	I-PHYS
,	O
especially	O
in	O
the	O
central	O
portion	O
of	O
the	O
augmented	O
sinus	B-ANAT
as	O
well	O
as	O
improvement	O
of	O
the	O
volume	O
maintenance	O
for	O
sinus	B-PROC
augmentation	I-PROC
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2016	O
.	O

Integrating	O
Palliative	O
Care	O
in	O
Pediatric	O
Oncology	O
:	O
Evidence	O
for	O
an	O
Evolving	O
Paradigm	B-PROC
for	O
Comprehensive	B-PROC
Cancer	B-PROC
Care	I-PROC
The	O
demonstrated	O
benefit	O
of	O
integrating	O
palliative	O
care	O
(	O
PC	O
)	O
into	O
cancer	B-PROC
treatment	I-PROC
has	O
triggered	O
an	O
increased	O
need	O
for	O
PC	O
services	O
.	O

The	O
trajectory	O
of	O
integrating	O
PC	O
in	O
comprehensive	B-PROC
cancer	B-OBJC
centers	I-OBJC
,	I-OBJC
particularly	O
pediatric	O
centers	O
,	O
is	O
unknown	O
.	O

We	O
describe	O
our	O
8	O
-	O
year	O
experience	O
of	O
initiating	O
and	O
establishing	O
PC	O
with	O
the	O
Quality	B-PROC
of	I-PROC
Life	I-PROC
Service	I-PROC
(	O
QoLS	B-PROC
)	O
at	O
St	O
.	O

Jude	O
Children	O
's	O
Research	O
Hospital	O
.	O

We	O
retrospectively	O
reviewed	O
records	O
of	O
patients	O
seen	O
by	O
the	O
QoLS	B-PROC
(	O
n	O
=	O
615	O
)	O
from	O
March	O
2007	O
to	O
December	O
2014	O
.	O

Variables	O
analyzed	O
for	O
each	O
year	O
,	O
using	O
descriptive	O
statistics	O
,	O
included	O
diagnostic	O
groups	O
,	O
QoLS	B-PROC
encounters	B-PROC
,	O
goals	B-PROC
of	I-PROC
care	I-PROC
,	O
duration	B-PHYS
of	I-PHYS
survival	I-PHYS
,	O
and	O
location	O
of	O
death	O
.	O

Total	O
QoLS	B-PROC
patient	B-LIVB
encounters	B-PROC
increased	O
from	O
58	O
(	O
2007	O
)	O
to	O
1	O
,	O
297	O
(	O
2014	O
)	O
,	O
new	O
consults	B-PROC
increased	O
from	O
17	O
(	O
2007	O
)	O
to	O
115	O
(	O
2014	O
)	O
,	O
and	O
mean	O
encounters	B-PROC
per	O
patient	B-LIVB
increased	O
from	O
5	O
.	O

06	O
(	O
2007	O
)	O
to	O
16	O
.	O
11	O
(	O
2014	O
)	O
.	O

Goal	B-PROC
of	I-PROC
care	I-PROC
at	O
initial	B-PROC
consultation	I-PROC
shifted	O
from	O
primarily	O
comfort	B-PHYS
to	O
an	O
increasing	O
goal	O
of	O
cure	O
.	O

The	O
median	O
number	O
of	O
days	O
from	O
initial	B-PROC
consult	I-PROC
to	O
death	B-DISO
increased	O
from	O
52	O
days	O
(	O
2008	O
)	O
to	O
223	O
days	O
(	O
2014	O
)	O
.	O

A	O
trend	O
toward	O
increased	O
outpatient	B-LIVB
location	O
of	O
death	O
was	O
noted	O
with	O
42	O
%	O
outpatient	B-LIVB
deaths	B-DISO
in	O
2007	O
,	O
increasing	O
to	O
a	O
majority	O
in	O
each	O
subsequent	O
year	O
(	O
range	O
,	O
51	O
%	O
-	O
74	O
%	O
)	O
.	O

Hospital	O
-	O
wide	O
,	O
patients	B-LIVB
receiving	O
PC	O
services	O
before	O
death	B-DISO
increased	O
from	O
approximately	O
50	O
%	O
to	O
nearly	O
100	O
%	O
.	O

Since	O
its	O
inception	O
,	O
the	O
QoLS	B-PROC
experienced	O
a	O
dramatic	O
increase	O
in	O
referrals	B-PROC
and	O
encounters	B-PROC
per	O
patient	B-LIVB
,	O
increased	O
use	O
by	O
all	O
clinical	B-PROC
services	I-PROC
,	O
a	O
trend	O
toward	O
earlier	O
consultation	B-PROC
and	O
longer	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
increasing	O
outpatient	B-LIVB
location	O
of	O
death	O
,	O
and	O
near	O
-	O
universal	O
PC	O
involvement	O
at	O
the	O
end	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
life	I-PROC
.	O

The	O
successful	O
integration	O
of	O
PC	O
in	O
a	O
comprehensive	B-PROC
cancer	B-OBJC
center	I-OBJC
,	O
and	O
the	O
resulting	O
potential	O
for	O
improved	O
care	B-PROC
provision	I-PROC
over	O
time	O
,	O
can	O
serve	O
as	O
a	O
model	O
for	O
other	O
programs	B-PROC
on	O
a	O
broad	O
scale	O
.	O

Juglone	B-CHEM
ameliorates	O
skin	B-ANAT
wound	B-PHYS
healing	I-PHYS
by	O
promoting	O
skin	B-ANAT
cell	B-PHYS
migration	I-PHYS
through	O
Rac1	B-CHEM
/	O
Cdc42	B-CHEM
/	O
PAK	B-CHEM
pathway	B-PHYS
Skin	B-ANAT
cell	I-ANAT
regeneration	B-PHYS
and	O
wound	B-PHYS
healing	I-PHYS
are	O
key	O
processes	O
in	O
the	O
recovery	B-PHYS
from	O
skin	B-DISO
injuries	I-DISO
.	O

Rapid	O
cell	B-PHYS
migration	I-PHYS
and	O
regeneration	B-PHYS
of	O
skin	B-ANAT
cells	I-ANAT
lead	O
to	O
faster	O
and	O
better	O
healing	B-PHYS
of	O
wounded	B-DISO
skin	B-ANAT
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
wound	B-PHYS
healing	I-PHYS
potential	O
of	O
juglone	B-CHEM
,	O
a	O
naturally	O
occurring	O
Pin1	B-CHEM
inhibitor	B-CHEM
found	O
in	O
walnuts	B-OBJC
.	O

Cultured	B-ANAT
skin	I-ANAT
cells	I-ANAT
(	O
NHDF	B-ANAT
and	O
HaCaT	B-ANAT
)	O
and	O
hairless	B-LIVB
mice	I-LIVB
were	O
treated	B-PROC
with	I-PROC
juglone	B-CHEM
after	O
wound	O
creation	O
to	O
examine	O
its	O
effects	O
on	O
cell	B-PHYS
migration	I-PHYS
and	O
wound	O
healing	O
rate	O
.	O

The	O
expressions	B-PHYS
of	O
cell	B-PHYS
migration	I-PHYS
related	O
proteins	B-CHEM
(	O
Rac1	B-CHEM
,	O
Cdc42	B-CHEM
,	O
and	O
α	B-CHEM
-	I-CHEM
PAK	I-CHEM
)	O
,	O
collagen	B-CHEM
deposition	O
,	O
and	O
angiogenesis	B-PHYS
were	O
analyzed	B-PROC
.	O

Juglone	B-CHEM
treatment	B-PROC
resulted	O
in	O
faster	O
rate	O
of	O
growth	B-PHYS
and	O
migration	B-PHYS
and	O
recovered	O
cell	B-PHYS
morphology	I-PHYS
,	O
particularly	O
at	O
a	O
concentration	O
of	O
5	O
µM	O
,	O
in	O
skin	B-ANAT
cells	I-ANAT
compared	O
to	O
the	O
untreated	B-DISO
group	B-LIVB
.	O

In	O
vivo	O
experiments	B-PROC
showed	O
that	O
mice	B-LIVB
treated	B-PROC
with	I-PROC
juglone	B-CHEM
showed	O
faster	O
wound	B-PHYS
healing	I-PHYS
rate	O
with	O
better	O
skin	B-ANAT
morphology	O
and	O
collagen	B-CHEM
deposition	O
than	O
the	O
vehicle	B-LIVB
group	I-LIVB
.	O

Furthermore	O
,	O
juglone	B-CHEM
increased	O
the	O
activation	B-PHYS
and	O
/	O
or	O
expression	B-PHYS
of	O
Cdc42	B-CHEM
,	O
Rac1	B-CHEM
,	O
and	O
α	B-CHEM
-	I-CHEM
pak	I-CHEM
in	O
HaCaT	B-ANAT
cells	I-ANAT
,	O
and	O
resulted	O
in	O
enhanced	O
angiogenesis	B-PHYS
in	O
endothelial	B-ANAT
cells	I-ANAT
(	O
HUVECs	B-ANAT
)	O
.	O

Juglone	B-CHEM
also	O
activated	O
MAPKs	B-PHYS
signaling	I-PHYS
by	O
activation	B-PHYS
of	O
ERK	B-CHEM
,	O
JNK	B-CHEM
,	O
and	O
p38	B-CHEM
proteins	B-CHEM
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
juglone	B-CHEM
may	O
be	O
a	O
potential	O
candidate	O
for	O
wound	B-PHYS
healing	I-PHYS
and	O
skin	B-ANAT
regeneration	B-PHYS
which	O
ameliorates	O
wound	B-PHYS
healing	I-PHYS
mainly	O
by	O
promoting	O
skin	B-ANAT
cell	B-PHYS
migration	I-PHYS
through	O
Rac1	B-CHEM
/	O
Cdc42	B-CHEM
/	O
PAK	B-CHEM
pathway	B-PHYS
.	O

Tibia	B-DISO
stress	I-DISO
fracture	I-DISO
secondary	O
to	O
obsessive	B-DISO
compulsive	I-DISO
disorder	I-DISO
Obsessive	B-DISO
compulsive	I-DISO
disorder	I-DISO
(	O
OCD	B-DISO
)	O
is	O
a	O
chronic	B-DISO
psychiatric	I-DISO
disorder	I-DISO
characterized	O
by	O
obsessions	B-DISO
and	O
compulsions	B-DISO
.	O

Early	B-DISO
-	I-DISO
onset	I-DISO
OCD	B-DISO
is	O
one	O
of	O
the	O
most	O
common	O
mental	B-DISO
illnesses	I-DISO
of	O
children	B-LIVB
and	O
adolescents	B-LIVB
,	O
with	O
a	O
prevalence	O
of	O
1	O
%	O
to	O
3	O
%	O
.	O

It	O
is	O
related	O
to	O
worse	O
lifespan	O
symptoms	B-DISO
and	O
prognosis	B-PROC
.	O

Therefore	O
,	O
the	O
treatment	B-PROC
of	O
OCD	B-DISO
in	O
children	B-LIVB
and	O
adolescent	B-LIVB
has	O
gained	O
importance	O
.	O

If	O
it	O
is	O
not	O
treated	O
successfully	O
,	O
the	O
compulsive	B-DISO
behaviors	I-DISO
may	O
cause	O
extreme	O
stress	B-DISO
for	O
children	B-LIVB
and	O
their	O
parents	B-LIVB
.	O

Although	O
minor	O
complications	O
of	O
OCD	B-DISO
are	O
commonly	O
observed	O
,	O
major	O
complications	O
are	O
considerably	O
rare	O
due	O
to	O
the	O
nature	O
of	O
compulsive	B-DISO
behaviors	I-DISO
.	O

Apparently	O
,	O
loss	B-DISO
of	I-DISO
vision	I-DISO
,	O
autocastration	B-DISO
,	O
rectal	B-DISO
prolapse	I-DISO
are	O
examples	O
of	O
major	O
complications	O
secondary	O
to	O
OCD	B-DISO
.	O

As	O
far	O
as	O
we	O
know	O
,	O
it	O
is	O
the	O
first	O
case	O
of	O
tibia	B-DISO
stress	I-DISO
fracture	I-DISO
secondary	O
to	O
OCD	B-DISO
.	O

In	O
the	O
present	O
case	O
report	O
,	O
we	O
will	O
discuss	O
tibia	B-DISO
stress	I-DISO
fracture	I-DISO
developing	O
secondary	O
to	O
compulsive	B-DISO
behavior	I-DISO
due	O
to	O
OCD	B-DISO
.	O

Mutation	B-PHYS
profiles	O
of	O
synchronous	B-DISO
colorectal	B-DISO
cancers	I-DISO
from	O
a	O
patient	B-LIVB
with	O
Lynch	B-DISO
syndrome	I-DISO
suggest	O
distinct	O
oncogenic	B-DISO
pathways	O
Patients	B-LIVB
with	O
Lynch	B-DISO
syndrome	I-DISO
often	O
present	O
with	O
multiple	B-DISO
synchronous	I-DISO
or	O
metachronous	B-DISO
colorectal	B-DISO
cancers	I-DISO
(	O
CRCs	B-DISO
)	O
.	O

The	O
presence	O
of	O
multiple	O
CRCs	B-DISO
with	O
distinct	O
genetic	B-PROC
profiles	I-PROC
and	O
driver	O
mutations	B-PHYS
could	O
complicate	O
treatment	O
as	O
each	O
cancer	B-DISO
may	O
respond	B-PHYS
differently	O
to	O
therapy	B-PROC
.	O

Studies	O
of	O
sporadic	B-DISO
CRCs	B-DISO
suggested	O
that	O
synchronous	B-DISO
tumors	I-DISO
have	O
distinct	O
etiologies	O
,	O
but	O
could	O
not	O
rule	O
out	O
differences	O
in	O
genetic	B-PHYS
background	I-PHYS
.	O

The	O
presence	O
of	O
multiple	B-DISO
cancers	I-DISO
in	O
a	O
patient	B-LIVB
with	O
a	O
predisposing	O
mutation	B-PHYS
provides	O
an	O
opportunity	B-PROC
to	O
profile	O
synchronous	B-DISO
cancers	I-DISO
in	O
the	O
same	O
genetic	B-PHYS
background	I-PHYS
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
patient	B-LIVB
with	O
Lynch	B-DISO
syndrome	I-DISO
that	O
presented	O
with	O
six	O
synchronous	B-DISO
CRCs	B-DISO
.	O

Microsatellite	B-DISO
instability	I-DISO
(	O
MSI	B-DISO
)	O
and	O
genomic	B-PROC
profiling	I-PROC
indicated	O
that	O
each	O
lesion	B-DISO
had	O
a	O
unique	O
pattern	O
of	O
instability	B-DISO
and	O
a	O
distinct	O
profile	O
of	O
affected	O
genes	O
.	O

These	O
findings	O
support	O
the	O
idea	O
that	O
in	O
Lynch	B-DISO
syndrome	I-DISO
,	O
synchronous	B-DISO
CRCs	I-DISO
can	O
develop	O
in	O
parallel	O
with	O
distinct	O
mutation	B-PHYS
profiles	O
and	O
that	O
these	O
differences	O
may	O
inform	O
treatment	B-DISO
decisions	I-DISO
.	O

Sensitization	B-PHYS
to	O
the	O
motor	B-ANAT
stimulant	B-CHEM
effects	O
of	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O
MDPV	B-CHEM
)	O
and	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
to	O
methamphetamine	B-CHEM
in	O
rats	B-LIVB
In	O
recent	O
years	O
,	O
there	O
has	O
been	O
a	O
dramatic	O
increase	O
in	O
abuse	B-DISO
of	O
the	O
synthetic	B-CHEM
cathinone	I-CHEM
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O
MDPV	B-CHEM
)	O
,	O
often	O
in	O
combination	O
with	O
other	O
illicit	O
stimulants	B-CHEM
.	O

We	O
sought	O
to	O
determine	O
if	O
repeated	O
exposure	O
to	O
MDPV	B-CHEM
would	O
produce	O
sensitization	B-PHYS
to	O
the	O
motor	B-ANAT
stimulant	B-CHEM
effects	O
of	O
the	O
drug	B-CHEM
,	O
and	O
whether	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
would	O
develop	O
with	O
the	O
stimulant	B-CHEM
effects	O
of	O
methamphetamine	B-CHEM
(	O
METH	B-CHEM
)	O
.	O

Male	B-PHYS
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
were	O
administered	O
MDPV	B-CHEM
(	O
1	O
or	O
5	O
mg	O
/	O
kg	O
)	O
or	O
saline	B-OBJC
once	O
daily	O
for	O
5	O
days	O
at	O
24	O
hour	O
intervals	O
,	O
or	O
were	O
administered	O
MDPV	B-CHEM
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
saline	B-OBJC
once	O
daily	O
for	O
5	O
days	O
at	O
48	O
hour	O
intervals	O
.	O

For	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
experiments	B-PROC
,	O
rats	B-LIVB
were	O
administered	O
METH	B-CHEM
(	O
1	O
mg	O
/	O
kg	O
)	O
or	O
MDPV	B-CHEM
(	O
1	O
or	O
5	O
mg	O
/	O
kg	O
)	O
once	O
daily	O
for	O
5	O
days	O
at	O
48	O
hour	O
intervals	O
,	O
and	O
following	O
a	O
5	O
day	O
incubation	B-DISO
period	I-DISO
,	O
were	O
given	O
an	O
acute	O
challenge	O
injection	B-CHEM
of	O
either	O
MDPV	B-CHEM
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
METH	B-CHEM
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
,	O
respectively	O
.	O

Rats	B-LIVB
repeatedly	O
administered	O
MDPV	B-CHEM
(	O
1	O
mg	O
/	O
kg	O
)	O
every	O
48	O
hours	O
,	O
but	O
not	O
every	O
24	O
hours	O
,	O
demonstrated	O
increased	O
motor	B-DISO
activity	I-DISO
when	O
given	O
either	O
a	O
subsequent	O
challenge	O
of	O
MDPV	B-CHEM
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
i	O
.	O

p	O
.	O
)	O
or	O
METH	B-CHEM
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
,	O
indicating	O
the	O
development	B-PHYS
of	I-PHYS
behavioral	I-PHYS
sensitization	B-PHYS
and	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
,	O
respectively	O
.	O

Moreover	O
,	O
rats	B-LIVB
repeatedly	O
administered	O
METH	B-CHEM
(	O
1	O
mg	O
/	O
kg	O
)	O
every	O
48	O
hours	O
did	O
not	O
exhibit	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
to	O
the	O
motor	B-ANAT
stimulating	B-PHEN
effects	O
of	O
a	O
subsequent	O
challenge	O
with	O
MDPV	B-CHEM
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
.	O

These	O
results	O
suggest	O
that	O
specific	O
patterns	O
of	O
MDPV	B-CHEM
administration	O
may	O
lead	O
to	O
lasting	O
changes	O
in	O
behavioral	O
responses	B-PHYS
to	O
subsequent	O
METH	B-CHEM
exposure	O
.	O

Nonamplification	B-DISO
ERBB2	O
genomic	B-PHYS
alterations	I-PHYS
in	O
5605	O
cases	O
of	O
recurrent	B-DISO
and	O
metastatic	B-DISO
breast	I-DISO
cancer	I-DISO
:	O
An	O
emerging	O
opportunity	O
for	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
targeted	B-PROC
therapies	I-PROC
Activating	O
,	O
nonamplification	B-DISO
ERBB2	O
mutations	B-PHYS
(	O
ERBB2mut	O
)	O
are	O
not	O
detected	O
by	O
immunohistochemistry	B-PROC
(	O
IHC	B-PROC
)	O
or	O
fluorescence	B-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
(	O
FISH	B-PROC
)	O
,	O
but	O
are	O
detected	O
by	O
DNA	B-PROC
sequencing	I-PROC
and	O
may	O
predict	O
clinical	B-DISO
responses	I-DISO
to	O
human	B-CHEM
epidermal	I-CHEM
growth	I-CHEM
factor	I-CHEM
receptor	I-CHEM
(	O
HER2	B-CHEM
)	O
-	O
targeted	B-PROC
therapy	I-PROC
.	O

The	O
authors	O
queried	O
5605	O
advanced	B-DISO
/	I-DISO
metastatic	I-DISO
breast	I-DISO
cancers	I-DISO
(	O
mBC	B-DISO
)	O
to	O
uncover	O
the	O
frequency	O
of	O
ERBB2mut	O
genomic	B-PHYS
alterations	I-PHYS
.	O

Clinical	B-DISO
responses	I-DISO
to	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
therapeutics	B-PROC
were	O
identified	O
.	O

DNA	B-CHEM
was	O
extracted	O
from	O
40	O
µm	O
of	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
sections	O
.	O

Comprehensive	B-PROC
genomic	I-PROC
profiling	I-PROC
(	O
CGP	B-PROC
)	O
was	O
used	O
to	O
evaluate	O
up	O
to	O
315	O
genes	O
(	O
592×	O
mean	O
coverage	O
depth	O
)	O
.	O

Results	O
were	O
analyzed	O
for	O
base	B-PHYS
substitutions	I-PHYS
,	O
short	B-PHYS
indels	I-PHYS
,	O
copy	B-PHYS
number	I-PHYS
changes	I-PHYS
,	O
and	O
selected	B-PHYS
rearrangements	I-PHYS
.	O

Of	O
5605	O
cases	O
,	O
698	O
(	O
12	O
.	O

5	O
%	O
)	O
featured	O
ERBB2	O
alterations	B-PHYS
,	O
including	O
596	O
(	O
10	O
.	O
6	O
%	O
)	O
ERBB2	O
amplifications	B-PHYS
(	O
ERBB2amp	B-PHYS
)	O
and	O
138	O
(	O
2	O
.	O
4	O
%	O
)	O
ERBB2mut	O
;	O
38	O
cases	O
(	O
0	O
.	O

7	O
%	O
)	O
had	O
co	O
-	O
occurring	O
ERBB2amp	B-PHYS
and	O
ERBB2mut	O
.	O

ERBB2mut	O
predominantly	O
affected	O
the	O
kinase	B-CHEM
(	O
124	O
cases	O
;	O
90	O
%	O
)	O
or	O
extracellular	B-ANAT
(	O
15	O
cases	O
;	O
11	O
%	O
)	O
domains	O
.	O

Both	O
primary	B-DISO
BC	I-DISO
(	O
52	O
cases	O
;	O
38	O
%	O
)	O
and	O
metastatic	B-DISO
site	I-DISO
biopsies	B-PROC
(	O
86	O
cases	O
;	O
62	O
%	O
)	O
were	O
found	O
to	O
harbor	O
ERBB2mut	O
,	O
which	O
were	O
distributed	O
across	O
carcinoma	B-DISO
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
(	O
69	O
cases	O
;	O
50	O
%	O
)	O
,	O
invasive	B-DISO
ductal	I-DISO
carcinoma	I-DISO
(	O
IDC	B-DISO
)	O
(	O
40	O
cases	O
;	O
29	O
%	O
)	O
,	O
invasive	B-DISO
lobular	I-DISO
carcinoma	I-DISO
(	O
ILC	B-DISO
)	O
(	O
27	O
cases	O
;	O
20	O
%	O
)	O
,	O
and	O
mucinous	B-DISO
mBC	I-DISO
(	O
2	O
cases	O
;	O
1	O
%	O
)	O
.	O

Genes	O
commonly	O
coaltered	O
with	O
ERBB2	O
were	O
tumor	O
protein	O
53	O
(	O
TP53	O
)	O
(	O
49	O
%	O
)	O
;	O
phosphatidylinositol	O
3	O
-	O
kinase	O
catalytic	O
subunit	O
alpha	O
(	O
PIK3CA	O
)	O
(	O
42	O
%	O
)	O
;	O
cadherin	O
1	O
,	O
type	O
1	O
(	O
CDH1	O
)	O
(	O
37	O
%	O
)	O
;	O
MYC	O
(	O
17	O
%	O
)	O
;	O
and	O
cyclin	O
D1	O
protein	O
(	O
CCND1	O
)	O
(	O
16	O
%	O
)	O
.	O

CDH1	O
mutations	B-PHYS
were	O
enriched	O
in	O
ERBB2mut	O
mBC	B-DISO
(	O
P	O
<	O
0	O
.	O
0006	O
)	O
and	O
associated	O
with	O
recurrent	O
mBC	O
.	O

Selected	O
patients	B-LIVB
with	O
ERBB2mut	O
,	O
without	O
ERBB2amp	B-PHYS
,	O
who	O
responded	O
to	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
targeted	B-PROC
therapies	I-PROC
are	O
presented	O
herein	O
.	O

Within	O
this	O
large	O
series	O
,	O
1	O
.	O
8	O
%	O
of	O
cases	O
harbored	O
ERBB2mut	O
,	O
which	O
are	O
undetectable	O
by	O
standard	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
care	I-PROC
IHC	B-PROC
or	O
FISH	B-PROC
tests	I-PROC
.	O

Metastatic	B-DISO
BC	I-DISO
driven	O
by	O
ERBB2mut	O
respond	O
to	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
targeted	B-PROC
therapies	I-PROC
,	O
and	O
expanding	O
clinical	B-PROC
trials	I-PROC
designed	O
to	O
detect	O
ERBB2mut	O
by	O
CGP	B-PROC
and	O
optimize	O
targeted	B-PROC
treatments	I-PROC
are	O
warranted	O
.	O

Cancer	O
2016	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O
Cancer	O
2016	O
;	O
122	O
:	O
2654	O
-	O
2662	O
.	O

©	O
2016	O
American	O
Cancer	O
Society	O
.	O

PROTECTIVE	O
EFFECTS	O
OF	O
DIPEPTIDYL	B-CHEM
PEPTIDASE	I-CHEM
-	I-CHEM
4	I-CHEM
INHIBITORS	I-CHEM
ON	O
PROGRESSION	B-DISO
OF	O
DIABETIC	B-DISO
RETINOPATHY	I-DISO
IN	O
PATIENTS	B-LIVB
WITH	O
TYPE	B-DISO
2	I-DISO
DIABETES	I-DISO
To	O
investigate	O
the	O
effects	O
of	O
dipeptidyl	B-CHEM
peptidase	I-CHEM
-	I-CHEM
4	I-CHEM
inhibitors	I-CHEM
(	O
DPP4	B-CHEM
)	O
on	O
the	O
progression	B-DISO
of	O
diabetic	B-DISO
retinopathy	I-DISO
(	O
DR	B-DISO
)	O
in	O
patients	B-LIVB
with	O
Type	B-DISO
2	I-DISO
diabetes	I-DISO
based	O
on	O
the	O
DR	B-DISO
severity	O
scale	O
.	O

The	O
medical	O
records	O
of	O
82	O
patients	B-LIVB
with	O
Type	B-DISO
2	I-DISO
diabetes	I-DISO
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

Fundus	B-PROC
photographs	I-PROC
were	O
graded	O
using	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
methods	O
.	O

The	O
associations	O
between	O
baseline	O
risk	B-DISO
factors	I-DISO
and	O
progression	B-DISO
of	O
DR	B-DISO
were	O
investigated	O
.	O

Seven	O
of	O
28	O
patients	B-LIVB
treated	O
with	O
DPP4	B-CHEM
inhibitors	I-CHEM
and	O
26	O
of	O
54	O
treated	O
with	O
other	O
hypoglycemic	B-CHEM
agents	I-CHEM
showed	O
progression	B-DISO
of	O
retinopathy	B-DISO
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
scale	O
(	O
P	O
=	O
0	O
.	O
043	O
)	O
.	O

Only	O
treatment	O
with	O
DPP4	B-CHEM
inhibitors	I-CHEM
significantly	O
reduced	O
the	O
progression	B-DISO
of	O
DR	B-DISO
in	O
patients	B-LIVB
after	O
propensity	O
score	O
matching	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O

Treatment	O
with	O
DPP4	B-CHEM
inhibitors	I-CHEM
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
DR	B-DISO
progression	B-DISO
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Treatment	O
with	O
DPP4	B-CHEM
inhibitors	I-CHEM
was	O
the	O
independent	O
protective	O
factor	O
against	O
the	O
progression	B-DISO
of	O
DR	B-DISO
,	O
aside	O
from	O
improving	B-DISO
glycemic	I-DISO
control	I-DISO
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	O
of	O
DPP4	B-CHEM
inhibitors	I-CHEM
in	O
reducing	O
DR	B-DISO
progression	B-DISO
,	O
and	O
provides	O
encouraging	O
preliminary	O
data	O
for	O
further	O
evaluation	B-PROC
of	O
DPP4	B-CHEM
inhibitors	I-CHEM
in	O
the	O
progression	B-DISO
of	O
DR	B-DISO
in	O
a	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
trial	I-PROC
.	O

Parasympathetic	B-ANAT
Activity	B-PHYS
and	O
Bronchial	B-DISO
Hyperresponsiveness	I-DISO
in	O
Athletes	B-LIVB
A	O
high	O
prevalence	O
of	O
asthma	B-DISO
and	O
bronchial	B-DISO
hyperresponsiveness	I-DISO
(	O
BHR	B-DISO
)	O
is	O
reported	O
in	O
swimmers	B-LIVB
and	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
.	O

It	O
has	O
been	O
suggested	O
that	O
increased	O
parasympathetic	B-ANAT
nervous	B-PHYS
activity	I-PHYS
is	O
involved	O
in	O
asthma	B-DISO
development	O
in	O
endurance	B-DISO
athletes	B-LIVB
.	O

We	O
aimed	O
to	O
assess	B-PROC
the	O
associations	O
of	O
BHR	B-DISO
to	O
parasympathetic	B-ANAT
activity	B-PHYS
in	O
healthy	O
and	O
asthmatic	B-DISO
swimmers	B-LIVB
and	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
and	O
healthy	O
non	O
athletes	B-LIVB
.	O

Parasympathetic	B-ANAT
activity	B-PHYS
was	O
measured	O
by	O
pupillometry	B-PROC
and	O
heart	B-PHYS
rate	I-PHYS
variability	O
at	O
the	O
onset	O
of	O
exercise	O
with	O
the	O
cardiac	O
vagal	O
index	O
calculated	O
in	O
28	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
(	O
♂	O
18	O
/	O
♀10	O
)	O
,	O
29	O
swimmers	O
(	O
♂	O
17	O
/	O
♀12	O
)	O
,	O
and	O
30	O
healthy	O
nonathlete	O
controls	O
(	O
♂	O
14	O
/	O
♀16	O
)	O
on	O
two	O
different	O
days	O
.	O

All	O
subjects	O
performed	O
a	O
methacholine	B-CHEM
bronchial	B-PROC
challenge	I-PROC
with	O
the	O
provocation	B-PHEN
dose	O
causing	O
20	O
%	O
decrease	O
in	O
the	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
calculated	O
(	O
PD20met	B-CHEM
)	O
.	O

Data	O
were	O
analyzed	B-PROC
by	O
robust	O
regression	O
analysis	O
and	O
presented	O
as	O
β	O
coefficients	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O

PD20met	B-CHEM
was	O
negatively	O
associated	O
with	O
cardiac	O
vagal	O
index	O
(	O
-13	O
.	O
9	O
,	O
95	O
%	O
CI	O
=	O
-26	O
.	O

8	O
to	O
-1	O
.	O
0	O
)	O
in	O
all	O
subjects	B-LIVB
.	O

When	O
adjusted	O
to	O
the	O
type	O
of	O
sport	O
,	O
this	O
association	O
was	O
stronger	O
in	O
swimmers	B-LIVB
(	O
-8	O
.	O
3	O
,	O
95	O
%	O
CI	O
=	O
-13	O
.	O

0	O
to	O
-3	O
.	O
6	O
)	O
as	O
compared	O
with	O
controls	B-LIVB
and	O
nonsignificant	O
in	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
.	O

Percent	O
pupil	B-DISO
constriction	I-DISO
was	O
significantly	O
associated	O
with	O
PD20met	B-CHEM
in	O
swimmers	B-LIVB
(	O
-9	O
.	O
4	O
,	O
95	O
%	O
CI	O
=	O
-15	O
.	O

4	O
to	O
-3	O
.	O

4	O
)	O
only	O
after	O
adjusting	O
for	O
the	O
type	O
of	O
sport	O
.	O

Fourteen	O
swimmers	B-LIVB
(	O
48	O
%	O
)	O
and	O
16	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
(	O
57	O
%	O
)	O
had	O
doctor	B-DISO
-	I-DISO
diagnosed	I-DISO
asthma	I-DISO
in	O
combination	O
with	O
current	O
BHR	B-DISO
and	O
/	O
or	O
current	O
use	O
of	O
asthma	B-DISO
drugs	B-CHEM
.	O

Seventy	O
-	O
two	O
percent	O
swimmers	B-LIVB
,	O
44	O
%	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
,	O
and	O
39	O
%	O
controls	B-LIVB
had	O
a	O
PD20met	B-CHEM
≤8	O
μmol	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

Fourteen	O
swimmers	B-LIVB
had	O
a	O
PD20met	B-CHEM
≤2	O
μmol	O
as	O
compared	O
with	O
one	O
cross	B-DISO
-	I-DISO
country	I-DISO
skier	I-DISO
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Parasympathetic	B-ANAT
activity	B-PHYS
measured	O
in	O
the	O
heart	B-ANAT
is	O
more	O
closely	O
related	O
to	O
BHR	B-DISO
as	O
compared	O
with	O
parasympathetic	B-ANAT
activity	B-PHYS
measured	O
in	O
the	O
pupils	B-ANAT
.	O

The	O
type	O
of	O
sport	O
influences	O
BHR	B-DISO
severity	O
and	O
its	O
relationship	O
to	O
parasympathetic	B-ANAT
activity	B-PHYS
.	O

The	O
relationship	O
between	O
histological	O
prostatitis	B-DISO
and	O
lower	B-DISO
urinary	I-DISO
tract	I-DISO
symptoms	I-DISO
and	O
sexual	B-PHYS
function	I-PHYS
This	O
prospective	B-PROC
analysis	I-PROC
assessed	O
the	O
effect	O
of	O
histological	O
prostatitis	B-DISO
on	O
lower	B-ANAT
urinary	I-ANAT
tract	I-ANAT
functions	O
and	O
sexual	B-PHYS
function	I-PHYS
.	O

The	O
patients	B-LIVB
were	O
separated	O
into	O
two	O
groups	O
as	O
histologically	O
observed	O
prostatitis	B-DISO
(	O
Group	O
A	O
)	O
and	O
no	B-DISO
prostatitis	I-DISO
(	O
Group	O
B	O
)	O
according	O
to	O
the	O
biopsy	B-PROC
outcomes	O
.	O

International	O
prostate	O
symptom	O
score	O
,	O
international	B-PHYS
index	I-PHYS
of	I-PHYS
erectile	I-PHYS
function	I-PHYS
-	I-PHYS
5	I-PHYS
scores	I-PHYS
,	O
maximal	B-DISO
and	O
average	B-DISO
flow	I-DISO
rate	I-DISO
,	O
and	O
residual	B-DISO
urine	I-DISO
volumes	I-DISO
were	O
compared	O
statistically	O
between	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
in	O
baseline	O
age	B-PHYS
(	O
t	O
=	O
0	O
.	O
64	O
)	O
,	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
value	I-PHYS
(	O
t	O
=	O
0	O
.	O
51	O
)	O
,	O
prostate	O
volume	O
(	O
t	O
=	O
0	O
.	O
87	O
)	O
,	O
prostate	B-PROC
-	I-PROC
specific	I-PROC
antigen	I-PROC
levels	I-PROC
(	O
t	O
=	O
0	O
.	O
43	O
)	O
,	O
maximal	B-DISO
(	O
t	O
=	O
0	O
.	O
84	O
)	O
and	O
average	B-DISO
flow	I-DISO
rate	I-DISO
(	O
t	O
=	O
0	O
.	O
59	O
)	O
,	O
and	O
post	O
-	O
void	O
residual	B-DISO
urine	I-DISO
volume	I-DISO
(	O
t	O
=	O
0	O
.	O
71	O
)	O
.	O

Mean	O
international	O
prostate	O
symptom	O
score	O
in	O
patients	B-LIVB
with	O
prostatitis	B-DISO
was	O
numerically	O
but	O
not	O
significantly	O
higher	O
than	O
that	O
in	O
those	O
without	O
prostatitis	B-DISO
(	O
t	O
=	O
0	O
.	O
794	O
,	O
P	O
=	O
0	O
.	O
066	O
)	O
.	O

Mean	O
international	B-PHYS
index	I-PHYS
of	I-PHYS
erectile	I-PHYS
function	I-PHYS
-	I-PHYS
5	I-PHYS
score	I-PHYS
in	O
the	O
prostatitis	B-DISO
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
those	O
without	O
prostatitis	B-DISO
(	O
t	O
=	O
1	O
.	O
854	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Histological	O
prostatitis	B-DISO
notably	O
affected	O
sexual	B-PHYS
function	I-PHYS
of	O
patients	B-LIVB
and	O
may	O
serve	O
as	O
a	O
major	O
risk	B-DISO
factor	I-DISO
for	O
sexual	B-DISO
dysfunction	I-DISO
while	O
having	O
little	O
effect	O
on	O
lower	B-DISO
urinary	I-DISO
tract	I-DISO
symptoms	I-DISO
.	O

Beyond	O
""""	O
Median	O
Waiting	O
Time	O
""""	O
:	O
Development	O
and	O
Validation	B-PROC
of	O
a	O
Competing	O
Risk	O
Model	O
to	O
Predict	O
Outcomes	O
on	O
the	O
Kidney	B-ANAT
Transplant	O
Waiting	O
List	O
Median	O
historical	O
time	O
to	O
kidney	B-PROC
transplant	I-PROC
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	O
of	O
death	B-PHYS
or	O
removal	B-DISO
from	I-DISO
the	I-DISO
waiting	I-DISO
list	I-DISO
.	O

We	O
developed	O
and	O
validated	O
a	O
competing	O
risk	O
model	O
to	O
calculate	O
likelihood	O
of	O
outcomes	O
for	O
kidney	B-PROC
transplant	I-PROC
candidates	B-LIVB
and	O
demonstrate	O
how	O
this	O
information	O
differs	O
from	O
median	O
time	O
to	O
transplant	B-PROC
.	O

Data	O
were	O
obtained	O
from	O
the	O
US	O
Scientific	O
Registry	O
of	O
Transplant	B-LIVB
Recipients	I-LIVB
.	O

The	O
retrospective	B-PROC
cohort	I-PROC
included	O
163	O
636	O
adults	B-LIVB
listed	O
for	O
kidney	B-PROC
transplant	I-PROC
before	O
December	O
31	O
,	O
2011	O
.	O

Predictors	B-DISO
were	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
blood	B-PHYS
type	I-PHYS
,	O
calculated	B-PROC
panel	B-PROC
-	I-PROC
reactive	I-PROC
antibodies	I-PROC
,	O
donation	B-PROC
service	B-GEOG
area	I-GEOG
,	O
dialysis	B-PROC
duration	O
,	O
comorbid	B-DISO
conditions	I-DISO
,	O
and	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
.	O

Outcomes	O
were	O
deceased	O
or	O
living	B-LIVB
donor	I-LIVB
transplant	B-PROC
,	O
death	B-PHYS
or	O
removal	B-DISO
from	I-DISO
the	I-DISO
list	I-DISO
due	O
to	O
deteriorating	O
medical	O
condition	O
,	O
or	O
removal	B-DISO
due	O
to	O
other	B-DISO
reasons	I-DISO
.	O

We	O
calculated	O
hazards	O
for	O
the	O
possible	B-DISO
outcomes	O
,	O
then	O
the	O
cumulative	O
incidence	O
function	B-PHYS
for	O
a	O
given	O
candidate	B-LIVB
using	O
competing	O
risk	O
methodology	O
.	O

Discrimination	B-PHYS
and	O
calibration	O
were	O
assessed	O
through	O
C	O
statistics	O
and	O
calibration	O
plots	O
for	O
each	O
cause	O
-	O
specific	O
Cox	O
proportional	O
hazard	O
model	O
.	O

C	O
statistics	O
ranged	O
from	O
0	O
.	O

64	O
to	O
0	O
.	O
73	O
.	O

Calibration	O
plots	O
showed	O
good	O
calibration	O
.	O

The	O
competing	O
risk	O
model	O
shows	O
probability	O
of	O
all	O
possible	B-DISO
outcomes	O
for	O
up	O
to	O
12	O
years	O
given	O
a	O
candidate	B-LIVB
's	I-LIVB
characteristics	O
,	O
contrasted	O
with	O
the	O
median	O
waiting	O
time	O
for	O
that	O
candidate	B-LIVB
's	I-LIVB
donation	B-PROC
service	B-GEOG
area	I-GEOG
.	O

A	O
competing	O
risk	O
model	O
conveys	O
more	O
relevant	O
information	O
than	O
the	O
median	O
waiting	O
time	O
for	O
a	O
given	O
transplant	O
center	O
.	O

This	O
model	O
will	O
be	O
updated	O
to	O
create	O
a	O
calculator	O
reflecting	O
the	O
most	O
recent	O
outcomes	O
and	O
changes	O
in	O
allocation	O
policy	O
.	O

It	O
illustrates	O
the	O
conversations	O
that	O
should	O
be	O
initiated	O
with	O
transplant	B-PROC
candidates	B-LIVB
.	O

Chemical	B-PHEN
Composition	I-PHEN
and	O
Biological	O
Activity	O
of	O
Essential	B-CHEM
Oils	I-CHEM
from	O
Different	O
Species	O
of	O
Piper	B-LIVB
from	O
Panama	B-GEOG
The	O
chemical	B-PHEN
composition	I-PHEN
of	O
leaf	B-LIVB
essential	B-CHEM
oils	I-CHEM
from	O
11	O
species	O
of	O
Piper	B-LIVB
from	O
Panama	B-GEOG
was	O
analyzed	O
by	O
a	O
combination	O
GC	B-PROC
-	I-PROC
FID	I-PROC
and	O
GC	B-PROC
-	I-PROC
MS	I-PROC
procedures	I-PROC
.	O

Six	O
of	O
them	O
had	O
sesquiterpene	B-CHEM
hydrocarbons	B-CHEM
as	O
major	B-OBJC
constituents	I-OBJC
,	O
three	O
were	O
characterized	O
by	O
monoterpene	B-CHEM
hydrocarbons	B-CHEM
,	O
one	O
by	O
a	O
diterpene	B-CHEM
,	O
and	O
one	O
by	O
a	O
phenylpropanoid	B-CHEM
,	O
dillapiole	B-CHEM
.	O

The	O
main	O
components	O
identified	O
in	O
each	O
species	O
were	O
:	O
cembratrienol	B-CHEM
(	O
25	O
.	O

4	O
%	O
)	O
in	O
Piper	B-LIVB
augustum	I-LIVB
;	O
β	B-CHEM
-	I-CHEM
pinene	I-CHEM
(	O
26	O
.	O
6	O
%	O
)	O
in	O
Piper	B-LIVB
corrugatum	I-LIVB
;	O
α	B-CHEM
-	I-CHEM
pinene	I-CHEM
(	O
19	O
.	O

4	O
%	O
)	O
in	O
Piper	B-LIVB
curtispicum	I-LIVB
;	O
trans	B-CHEM
-	I-CHEM
β	I-CHEM
-	I-CHEM
farnesene	I-CHEM
(	O
63	O
.	O
7	O
%	O
)	O
in	O
Piper	B-LIVB
darienense	I-LIVB
;	O
p	B-CHEM
-	I-CHEM
cymene	I-CHEM
(	O
43	O
.	O
9	O
%	O
)	O
in	O
Piper	B-LIVB
grande	I-LIVB
;	O
dillapiole	B-CHEM
(	O
57	O
.	O
7	O
%	O
)	O
in	O
Piper	B-LIVB
hispidum	I-LIVB
;	O
linalool	B-CHEM
(	O
14	O
.	O
5	O
%	O
)	O
,	O
α	B-CHEM
-	I-CHEM
phellandrene	I-CHEM
(	O
13	O
.	O
8	O
%	O
)	O
,	O
and	O
limonene	B-CHEM
(	O
12	O
.	O
2	O
%	O
)	O
in	O
Piper	B-LIVB
jacquemontianum	I-LIVB
;	O
β	B-CHEM
-	I-CHEM
caryophyllene	I-CHEM
(	O
45	O
.	O
2	O
%	O
)	O
in	O
Piper	B-LIVB
longispicum	I-LIVB
;	O
linalool	B-CHEM
(	O
16	O
.	O
5	O
%	O
)	O
,	O
α	B-CHEM
-	I-CHEM
phellandrene	I-CHEM
(	O
11	O
.	O
8	O
%	O
)	O
,	O
limonene	B-CHEM
(	O
11	O
.	O
4	O
%	O
)	O
,	O
and	O
p	B-CHEM
-	I-CHEM
cymene	I-CHEM
(	O
9	O
.	O
0	O
%	O
)	O
in	O
Piper	B-LIVB
multiplinervium	I-LIVB
;	O
β	B-CHEM
-	I-CHEM
selinene	I-CHEM
(	O
19	O
.	O
0	O
%	O
)	O
,	O
β	B-CHEM
-	I-CHEM
elemene	I-CHEM
(	O
16	O
.	O
1	O
%	O
)	O
,	O
and	O
α	B-CHEM
-	I-CHEM
selinene	I-CHEM
(	O
15	O
.	O

5	O
%	O
)	O
in	O
Piper	B-LIVB
reticulatum	I-LIVB
;	O
and	O
germacrene	B-CHEM
D	I-CHEM
(	O
19	O
.	O
7	O
%	O
)	O
in	O
Piper	B-LIVB
trigonum	I-LIVB
.	O

The	O
essential	B-CHEM
oils	I-CHEM
of	O
P	B-LIVB
.	I-LIVB

hispidum	I-LIVB
and	O
P	B-LIVB
.	I-LIVB

longispicum	I-LIVB
at	O
a	O
concentration	O
of	O
250	O
µg	O
/	O
mL	O
showed	O
larvicidal	B-DISO
activity	I-DISO
against	O
Aedes	O
aegypti	O
,	O
while	O
the	O
oils	B-CHEM
from	O
P	B-LIVB
.	I-LIVB

curtispicum	I-LIVB
,	O
P	B-LIVB
.	I-LIVB

multiplinervium	I-LIVB
,	O
P	B-LIVB
.	I-LIVB

reticulatum	I-LIVB
,	O
and	O
P	B-LIVB
.	I-LIVB

trigonum	I-LIVB
were	O
inactive	O
(	O
LC100	O
≥	O
500	O
µg	O
/	O
mL	O
)	O
.	O

The	O
essential	B-CHEM
oils	I-CHEM
of	O
P	B-LIVB
.	I-LIVB

grande	I-LIVB
,	O
P	B-LIVB
.	I-LIVB

jacquemontianum	I-LIVB
,	O
and	O
P	B-LIVB
.	I-LIVB

multiplinervium	I-LIVB
showed	O
no	O
significant	O
antifungal	B-PHYS
activity	I-PHYS
(	O
MIC	O
>	O
250	O
µg	O
/	O
mL	O
)	O
against	O
several	O
yeasts	B-LIVB
and	O
filamentous	B-LIVB
fungal	I-LIVB
strains	I-LIVB
.	O

Spatial	B-PROC
analysis	I-PROC
of	O
drug	B-DISO
poisoning	I-DISO
deaths	B-PHYS
in	O
the	O
American	B-GEOG
West	I-GEOG
,	O
particularly	O
Utah	B-GEOG
Most	O
states	B-GEOG
in	O
the	O
Western	B-GEOG
US	I-GEOG
have	O
high	O
rates	O
of	O
drug	B-DISO
poisoning	I-DISO
death	B-PHYS
(	O
DPD	B-PHYS
)	O
,	O
especially	O
New	B-GEOG
Mexico	I-GEOG
,	O
Nevada	B-GEOG
,	O
Arizona	B-GEOG
and	O
Utah	B-GEOG
(	O
UT	B-GEOG
)	O
.	O

This	O
seems	O
paradoxical	O
in	O
UT	B-GEOG
where	O
illicit	O
drug	O
use	O
,	O
smoking	O
and	O
drinking	O
rates	O
are	O
low	O
.	O

To	O
investigate	O
this	O
,	O
spatial	B-PROC
analysis	I-PROC
of	O
county	B-GEOG
level	O
DPD	B-PHYS
data	O
and	O
other	O
relevant	O
factors	O
in	O
the	O
Western	B-GEOG
US	I-GEOG
and	O
UT	B-GEOG
was	O
undertaken	O
.	O

Poisson	B-PROC
kriging	I-PROC
was	O
used	O
to	O
smooth	O
the	O
DPD	B-PHYS
data	O
,	O
populate	O
data	O
gaps	O
and	O
improve	O
the	O
reliability	O
of	O
rates	O
recorded	O
in	O
sparsely	B-GEOG
populated	I-GEOG
counties	I-GEOG
.	O

Links	O
between	O
DPD	B-PHYS
and	O
economic	O
,	O
environmental	O
,	O
health	O
,	O
lifestyle	O
,	O
and	O
demographic	O
factors	O
were	O
investigated	O
at	O
four	O
scales	O
using	O
multiple	O
linear	O
regression	O
.	O

LDS	O
church	O
membership	O
and	O
altitude	O
,	O
factors	O
not	O
previously	O
considered	O
,	O
were	O
included	O
.	O

Spatial	O
change	O
in	O
the	O
strength	O
and	O
sign	O
of	O
relationships	O
was	O
investigated	O
using	O
geographically	O
weighted	O
regression	O
and	O
significant	O
DPD	B-PHYS
clusters	O
were	O
identified	O
using	O
the	O
Local	B-PROC
Moran	I-PROC
's	I-PROC
I	I-PROC
.	O

Economic	O
factors	O
,	O
like	O
the	O
sharp	O
social	O
gradient	O
between	O
rural	O
and	O
urban	O
areas	O
were	O
important	O
to	O
DPD	B-PHYS
throughout	O
the	O
west	O
.	O

Higher	O
DPD	O
rates	O
were	O
also	O
found	O
in	O
areas	O
of	O
higher	O
elevation	O
and	O
the	O
desert	O
rural	O
areas	O
in	O
the	O
south	O
.	O

The	O
unique	O
characteristics	O
of	O
DPD	B-PHYS
in	O
UT	B-GEOG
in	O
terms	O
of	O
health	B-DISO
and	O
lifestyle	O
factors	O
,	O
as	O
well	O
as	O
the	O
demographic	O
structure	O
of	O
DPD	B-PHYS
in	O
the	O
most	O
LDS	B-GEOG
populous	I-GEOG
states	I-GEOG
(	O
UT	B-GEOG
,	O
Idaho	B-GEOG
,	O
Wyoming	B-GEOG
)	O
,	O
suggest	O
that	O
high	O
DPD	B-PHYS
in	O
heavily	B-GEOG
LDS	I-GEOG
areas	I-GEOG
are	O
predominantly	O
prescription	O
opioid	B-CHEM
related	O
whereas	O
in	O
other	O
Western	B-GEOG
states	I-GEOG
a	O
larger	O
proportion	O
of	O
DPD	B-PHYS
might	O
come	O
from	O
illicit	B-CHEM
drugs	I-CHEM
.	O

Drug	O
policies	O
need	O
to	O
be	O
adapted	O
to	O
the	O
geographical	B-DISO
differences	I-DISO
in	O
the	O
dominant	O
type	O
of	O
drug	B-CHEM
causing	O
death	B-PHYS
.	O

Educational	B-PROC
materials	I-PROC
need	O
to	O
be	O
marketed	O
to	O
the	O
demographic	O
groups	O
at	O
greatest	O
risk	O
and	O
take	O
into	O
account	O
differences	O
in	O
population	O
characteristics	O
between	O
and	O
within	O
States	B-GEOG
.	O

Some	O
suggestions	O
about	O
how	O
such	O
adaptations	O
can	O
be	O
made	O
are	O
given	O
and	O
future	O
research	O
needs	O
outlined	O
.	O

Electrochemically	O
assisted	O
deposition	O
of	O
strontium	B-CHEM
modified	O
magnesium	B-CHEM
phosphate	I-CHEM
on	O
titanium	B-CHEM
surfaces	O
Electrochemically	O
assisted	O
deposition	O
was	O
utilized	O
to	O
produce	O
ceramic	B-OBJC
coatings	O
on	O
the	O
basis	O
of	O
magnesium	B-CHEM
ammonium	I-CHEM
phosphate	I-CHEM
(	O
struvite	B-CHEM
)	O
on	O
corundum	B-CHEM
-	O
blasted	B-PHEN
titanium	B-CHEM
surfaces	O
.	O

By	O
the	O
addition	O
of	O
defined	O
concentrations	O
of	O
strontium	B-CHEM
nitrate	I-CHEM
to	O
the	O
coating	O
electrolyte	B-CHEM
Sr	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ions	I-CHEM
were	O
successfully	O
incorporated	O
into	O
the	O
struvite	B-CHEM
matrix	B-CHEM
.	O

By	O
variation	O
of	O
deposition	O
parameters	O
it	O
was	O
possible	O
to	O
fabricate	O
coatings	O
with	O
different	O
kinetics	B-PHEN
of	O
Sr	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
into	O
physiological	O
media	O
,	O
whereas	O
the	O
release	O
of	O
therapeutically	O
relevant	O
strontium	B-CHEM
doses	O
could	O
be	O
sustained	O
over	O
several	O
weeks	O
.	O

Morphological	O
and	O
crystallographic	B-PROC
examinations	I-PROC
of	O
the	O
immersed	O
coatings	O
revealed	O
that	O
the	O
degradation	O
of	O
struvite	B-CHEM
and	O
the	O
release	O
of	O
Sr	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ions	I-CHEM
were	O
accompanied	O
by	O
a	O
transformation	B-PHYS
of	O
the	O
coating	O
to	O
a	O
calcium	B-CHEM
phosphate	I-CHEM
based	O
phase	O
similar	O
to	O
low	B-CHEM
-	I-CHEM
crystalline	I-CHEM
hydroxyapatite	I-CHEM
.	O

These	O
findings	O
showed	O
that	O
strontium	B-CHEM
doped	O
struvite	B-CHEM
coatings	O
may	O
provide	O
a	O
promising	O
degradable	O
coating	O
system	O
for	O
the	O
local	O
application	O
of	O
strontium	B-CHEM
or	O
other	O
biologically	B-CHEM
active	I-CHEM
metal	B-CHEM
ions	I-CHEM
in	O
the	O
implant	B-ANAT
-	I-ANAT
bone	I-ANAT
interface	I-ANAT
.	O

Inflamed	O
skin	B-ANAT
predisposes	O
to	O
sensitization	B-PHYS
to	O
less	O
potent	O
allergens	B-CHEM
Irritant	B-DISO
dermatitis	I-DISO
,	O
caused	O
by	O
genetic	O
barrier	O
dysfunction	O
in	O
atopic	B-DISO
dermatitis	I-DISO
or	O
wet	O
work	O
in	O
hand	B-DISO
dermatitis	I-DISO
,	O
induces	O
innate	B-PHYS
immune	I-PHYS
response	I-PHYS
that	O
might	O
predispose	O
to	O
allergic	B-DISO
contact	I-DISO
sensitization	B-PHYS
to	O
less	O
potent	O
sensitizers	B-CHEM
.	O

We	O
sought	O
to	O
determine	O
if	O
positive	B-PHEN
patch	I-PHEN
test	I-PHEN
results	O
to	O
less	O
potent	O
allergens	B-CHEM
are	O
more	O
prevalent	O
in	O
patients	B-LIVB
with	O
a	O
history	B-DISO
of	I-DISO
childhood	I-DISO
flexural	B-DISO
dermatitis	I-DISO
or	O
current	O
wet	O
work	O
.	O

We	O
examined	O
our	O
database	O
of	O
patients	B-LIVB
presenting	O
to	O
a	O
contact	B-DISO
dermatitis	I-DISO
clinic	B-OBJC
tested	O
to	O
potential	O
contact	B-CHEM
allergens	I-CHEM
as	O
indicated	O
by	O
their	O
history	B-PROC
.	O

Allergens	B-CHEM
from	O
our	O
most	O
recent	O
standard	O
were	O
studied	B-PROC
if	O
they	O
could	O
be	O
classified	O
as	O
weak	O
,	O
moderate	O
,	O
or	O
strong	O
sensitizers	B-CHEM
based	O
on	O
published	O
data	O
from	O
the	O
local	O
lymph	O
node	O
assay	O
.	O

Patients	O
were	O
stratified	O
by	O
a	O
history	B-DISO
of	I-DISO
childhood	I-DISO
-	O
onset	B-DISO
flexural	I-DISO
dermatitis	I-DISO
as	O
a	O
proxy	O
for	O
atopic	B-DISO
dermatitis	I-DISO
and	O
by	O
occupation	B-DISO
.	O

History	B-DISO
of	I-DISO
childhood	I-DISO
-	O
onset	B-DISO
dermatitis	I-DISO
predisposed	O
to	O
contact	B-DISO
allergy	I-DISO
to	O
weak	O
sensitizers	B-CHEM
and	O
wet	O
work	O
to	O
medium	O
-	O
potency	O
sensitizers	B-CHEM
.	O

Neither	O
predisposed	O
to	O
contact	B-DISO
allergy	I-DISO
from	O
strong	O
sensitizers	B-CHEM
.	O

Association	O
cannot	O
prove	O
causation	O
.	O

We	O
conclude	O
that	O
strong	O
sensitizers	B-CHEM
do	O
not	O
require	O
wet	O
work	O
or	O
atopy	B-DISO
to	O
cause	O
sensitization	B-PHYS
.	O

Barrier	O
defects	O
associated	O
with	O
childhood	B-DISO
eczema	I-DISO
and	O
wet	O
work	O
may	O
promote	O
sensitization	B-PHYS
to	O
weak	O
antigens	B-CHEM
.	O

Transcription	B-PHYS
rate	O
and	O
transcript	B-CHEM
length	O
drive	O
formation	O
of	O
chromosomal	B-ANAT
interaction	I-ANAT
domain	I-ANAT
boundaries	I-ANAT
Chromosomes	B-ANAT
in	O
all	O
organisms	B-LIVB
are	O
highly	O
organized	O
and	O
divided	O
into	O
multiple	O
chromosomal	B-ANAT
interaction	I-ANAT
domains	I-ANAT
,	O
or	O
topological	B-ANAT
domains	I-ANAT
.	O

Regions	O
of	O
active	O
,	O
high	O
transcription	B-PHYS
help	O
establish	O
and	O
maintain	O
domain	B-ANAT
boundaries	I-ANAT
,	O
but	O
precisely	O
how	O
this	O
occurs	O
remains	O
unclear	B-DISO
.	O

Here	O
,	O
using	O
fluorescence	B-PROC
microscopy	I-PROC
and	O
chromosome	O
conformation	O
capture	O
in	O
conjunction	O
with	O
deep	B-PROC
sequencing	I-PROC
(	O
Hi	O
-	O
C	O
)	O
,	O
we	O
show	O
that	O
in	O
Caulobacter	B-LIVB
crescentus	I-LIVB
,	O
both	O
transcription	B-PHYS
rate	O
and	O
transcript	B-CHEM
length	O
,	O
independent	O
of	O
concurrent	O
translation	B-PHYS
,	O
drive	O
the	O
formation	O
of	O
domain	B-ANAT
boundaries	I-ANAT
.	O

We	O
find	O
that	O
long	O
,	O
highly	O
expressed	O
genes	O
do	O
not	O
form	O
topological	B-ANAT
boundaries	I-ANAT
simply	O
through	O
the	O
inhibition	O
of	O
supercoil	O
diffusion	O
.	O

Instead	O
,	O
our	O
results	O
support	O
a	O
model	O
in	O
which	O
long	O
,	O
active	O
regions	O
of	O
transcription	B-PHYS
drive	O
local	O
decompaction	O
of	O
the	O
chromosome	O
,	O
with	O
these	O
more	O
open	O
regions	B-ANAT
of	I-ANAT
the	I-ANAT
chromosome	I-ANAT
forming	O
spatial	O
gaps	O
in	O
vivo	O
that	O
diminish	O
contacts	O
between	O
DNA	B-CHEM
in	O
neighboring	O
domains	B-ANAT
.	O

These	O
insights	O
into	O
the	O
molecular	B-PHEN
forces	I-PHEN
responsible	O
for	O
domain	B-ANAT
formation	O
in	O
Caulobacter	B-LIVB
likely	O
generalize	O
to	O
other	O
bacteria	B-LIVB
and	O
possibly	O
eukaryotes	O
.	O

Tead1	O
regulates	O
the	O
expression	B-PHYS
of	O
Peripheral	O
Myelin	O
Protein	O
22	O
during	O
Schwann	B-PHYS
cell	I-PHYS
development	I-PHYS
Schwann	B-ANAT
cells	I-ANAT
are	O
myelinating	B-ANAT
glia	I-ANAT
in	O
the	O
peripheral	B-ANAT
nervous	I-ANAT
system	I-ANAT
that	O
form	O
the	O
myelin	B-ANAT
sheath	I-ANAT
.	O

A	O
major	O
cause	O
of	O
peripheral	B-DISO
neuropathy	I-DISO
is	O
a	O
copy	O
number	O
variant	O
involving	O
the	O
Peripheral	O
Myelin	O
Protein	O
22	O
(	O
PMP22	O
)	O
gene	O
,	O
which	O
is	O
located	O
within	O
a	O
1	O
.	O
4	O
-	O
Mb	O
duplication	B-PHYS
on	O
chromosome	B-ANAT
17	I-ANAT
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
Charcot	B-DISO
-	I-DISO
Marie	I-DISO
-	I-DISO
Tooth	I-DISO
Disease	I-DISO
(	O
CMT1A	B-DISO
)	O
.	O

Rodent	B-DISO
models	I-DISO
of	O
CMT1A	B-DISO
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
Pmp22	O
overexpression	B-PHYS
mitigates	O
several	O
aspects	O
of	O
a	O
CMT1A	B-DISO
-related	O
phenotype	B-PHYS
.	O

Mechanistic	O
studies	B-PROC
of	O
Pmp22	O
regulation	B-PHYS
identified	O
enhancers	B-CHEM
regulated	O
by	O
the	O
Sox10	B-CHEM
(	O
SRY	B-CHEM
sex	I-CHEM
determining	I-CHEM
region	I-CHEM
Y	I-CHEM
-	I-CHEM
box	I-CHEM
10	I-CHEM
)	O
and	O
Egr2	B-CHEM
/	O
Krox20	B-CHEM
(	O
Early	B-CHEM
growth	I-CHEM
response	I-CHEM
protein	I-CHEM
2	I-CHEM
)	O
transcription	B-CHEM
factors	I-CHEM
in	O
myelinated	B-ANAT
nerves	I-ANAT
.	O

However	O
,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription	B-CHEM
factors	I-CHEM
induce	O
Pmp22	O
expression	B-PHYS
during	O
Schwann	B-PHYS
cell	I-PHYS
development	I-PHYS
and	O
myelination	B-PHYS
.	O

Here	O
,	O
we	O
examined	O
Pmp22	O
enhancers	B-CHEM
as	O
a	O
function	O
of	O
cell	B-PHYS
type	I-PHYS
-	I-PHYS
specificity	I-PHYS
,	O
nerve	B-DISO
injury	I-DISO
and	O
development	O
.	O

While	O
Pmp22	O
enhancers	B-CHEM
marked	O
by	O
active	O
histone	B-PHYS
modifications	I-PHYS
were	O
lost	O
or	O
remodeled	O
after	O
injury	B-DISO
,	O
we	O
found	O
that	O
these	O
enhancers	B-CHEM
were	O
permissive	O
in	O
early	O
development	O
prior	O
to	O
Pmp22	O
upregulation	B-PHYS
.	O

Pmp22	O
enhancers	B-CHEM
contain	O
binding	B-CHEM
motifs	I-CHEM
for	O
TEA	B-CHEM
domain	I-CHEM
(	O
Tead	B-CHEM
)	O
transcription	B-CHEM
factors	I-CHEM
of	O
the	O
Hippo	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
.	O

We	O
discovered	O
that	O
Tead1	O
and	O
co	O
-	O
activators	O
Yap	O
and	O
Taz	O
are	O
required	O
for	O
Pmp22	O
expression	B-PHYS
,	O
as	O
well	O
as	O
for	O
the	O
expression	B-PHYS
of	O
Egr2	O
Tead1	O
directly	O
binds	O
Pmp22	O
and	O
Egr2	O
enhancers	B-CHEM
early	O
in	O
development	O
and	O
Tead1	O
binding	B-PHYS
is	O
induced	O
during	O
myelination	B-PHYS
,	O
correlating	O
with	O
Pmp22	O
expression	B-PHYS
.	O

The	O
data	O
identify	O
Tead1	O
as	O
a	O
novel	O
regulator	O
of	O
Pmp22	O
expression	B-PHYS
during	O
development	O
in	O
concert	O
with	O
Sox10	O
and	O
Egr2	O
.	O

Molecular	O
characterization	O
of	O
a	O
novel	O
putative	B-LIVB
ampelovirus	I-LIVB
tentatively	O
named	O
grapevine	B-LIVB
leafroll	I-LIVB
-	I-LIVB
associated	I-LIVB
virus	I-LIVB
13	I-LIVB
A	O
novel	O
putative	B-LIVB
ampelovirus	I-LIVB
was	O
detected	B-DISO
in	O
grapevines	B-LIVB
that	O
showed	O
typical	O
leafroll	B-DISO
symptoms	I-DISO
and	O
was	O
tentatively	O
named	O
grapevine	B-LIVB
leafroll	I-LIVB
-	I-LIVB
associated	I-LIVB
virus	I-LIVB
(	I-LIVB
GLRaV	I-LIVB
)	I-LIVB
-	I-LIVB
13	I-LIVB
following	O
the	O
series	O
of	O
numbering	O
of	O
other	O
GLRaVs	B-LIVB
.	O

The	O
complete	O
genome	O
of	O
GLRaV	B-LIVB
-	I-LIVB
13	I-LIVB
comprised	O
17	O
,	O
608	O
nt	O
and	O
contained	O
eleven	O
putative	O
open	O
reading	O
frames	O
,	O
showing	O
genetic	O
features	O
similar	O
to	O
those	O
of	O
viruses	B-LIVB
belonging	O
to	O
subgroup	O
I	O
of	O
genus	O
Ampelovirus	B-LIVB
.	O

Phylogenetic	O
trees	O
based	O
on	O
the	O
RNA	B-CHEM
-	I-CHEM
dependent	I-CHEM
RNA	I-CHEM
polymerase	I-CHEM
,	O
heat	B-CHEM
shock	I-CHEM
protein	I-CHEM
70	I-CHEM
homolog	O
,	O
and	O
coat	B-CHEM
protein	I-CHEM
showed	O
that	O
GLRaV	B-LIVB
-	I-LIVB
13	I-LIVB
had	O
the	O
closest	O
,	O
but	O
still	O
distant	O
,	O
relationship	O
to	O
GLRaV	B-LIVB
-	I-LIVB
1	I-LIVB
in	O
the	O
subgroup	O
I	O
cluster	O
.	O

Neutrophil	B-CHEM
gelatinase	I-CHEM
-	I-CHEM
associated	I-CHEM
lipocalin	I-CHEM
in	O
a	O
triphasic	O
rat	B-LIVB
model	I-LIVB
of	O
adenine	B-CHEM
-	O
induced	O
kidney	B-DISO
injury	I-DISO
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	B-CHEM
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	B-PHYS
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	B-DISO
tubulointerstitial	I-DISO
insult	I-DISO
caused	O
by	O
adenine	B-CHEM
.	O

Subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	B-CHEM
as	O
a	O
biomarker	B-PHYS
of	O
any	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
,	O
on	O
top	O
of	O
chronic	B-DISO
interstitial	I-DISO
disease	I-DISO
,	O
if	O
NGAL	B-CHEM
levels	O
are	O
stable	O
through	O
the	O
chronic	O
phase	O
of	O
our	O
adenine	B-LIVB
model	I-LIVB
.	O

Study	B-LIVB
group	I-LIVB
rats	B-LIVB
were	O
fed	O
an	O
adenine	B-CHEM
diet	B-OBJC
,	O
and	O
control	B-LIVB
group	I-LIVB
rats	B-LIVB
were	O
fed	O
a	O
regular	O
diet	O
only	O
.	O

Blood	B-ANAT
and	O
urine	B-ANAT
samples	I-ANAT
for	O
urea	B-CHEM
,	O
creatinine	B-CHEM
and	O
NGAL	B-CHEM
were	O
drawn	O
from	O
each	O
rat	B-LIVB
at	O
the	O
beginning	O
of	O
the	O
study	B-PROC
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O

Kidney	B-ANAT
slices	B-OBJC
from	O
these	O
rats	B-LIVB
were	O
stained	B-PROC
with	O
Hematoxylin	B-PROC
-	I-PROC
eosin	I-PROC
(	O
HE	B-PROC
)	O
and	O
β	B-CHEM
-	I-CHEM
actin	I-CHEM
stainings	B-PROC
.	O

Serum	B-PHEN
urea	I-PHEN
,	O
creatinine	B-PROC
and	O
NGAL	B-CHEM
levels	O
and	O
urinary	B-PHYS
NGAL	I-PHYS
/	I-PHYS
creatinine	I-PHYS
ratio	I-PHYS
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	O
and	O
than	O
in	O
the	O
control	B-LIVB
group	I-LIVB
;	O
these	O
differences	O
were	O
statistically	O
significant	O
in	O
some	O
of	O
the	O
intervals	O
.	O

Tubulointerstitial	B-DISO
changes	O
and	O
adenine	B-CHEM
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	B-LIVB
.	O

In	O
the	O
rats	B-LIVB
fed	O
adenine	B-CHEM
,	O
serum	B-PHEN
urea	I-PHEN
,	O
creatinine	B-PROC
and	O
NGAL	B-CHEM
levels	O
and	O
urinary	B-PHYS
NGAL	I-PHYS
/	I-PHYS
creatinine	I-PHYS
ratio	I-PHYS
followed	O
a	O
triphasic	B-DISO
pattern	I-DISO
of	O
kidney	B-DISO
injury	I-DISO
:	O
an	O
acute	O
phase	O
while	O
on	O
the	O
adenine	B-CHEM
diet	B-OBJC
,	O
a	O
partial	O
recovery	B-PHYS
phase	O
after	O
switching	O
to	O
the	O
regular	O
diet	O
and	O
a	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
phase	O
after	O
stabilization	O
of	O
renal	B-PHYS
function	I-PHYS
.	O

NGAL	B-CHEM
can	O
serve	O
a	O
biomarker	B-PHYS
for	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
and	O
possibly	O
for	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
in	O
the	O
tubulointerstitial	B-DISO
rat	B-LIVB
model	I-LIVB
.	O

Talking	O
or	O
Keeping	O
Silent	O
About	O
Parental	B-LIVB
Mental	B-DISO
Health	I-DISO
Problems	I-DISO
-A	O
Grounded	O
Theory	O
of	O
Parents	B-LIVB
'	O
Decision	B-PHYS
Making	I-PHYS
and	O
Experiences	B-PHYS
with	O
Their	O
Children	B-LIVB
This	O
grounded	O
theory	O
study	B-PROC
explored	O
parents	B-LIVB
'	O
experiences	B-PHYS
of	O
responding	O
to	O
their	O
children	B-LIVB
's	I-LIVB
need	O
for	O
understanding	O
parental	B-LIVB
mental	B-PHYS
health	I-PHYS
concerns	O
.	O

Fifteen	O
parents	B-LIVB
with	O
severe	O
and	O
enduring	O
mental	B-DISO
health	I-DISO
difficulties	I-DISO
participated	O
in	O
the	O
study	B-PROC
.	O

The	O
findings	B-DISO
suggest	O
four	O
main	O
social	B-PHEN
processes	I-PHEN
that	O
influence	O
parents	B-LIVB
'	O
talk	O
with	O
their	O
children	B-LIVB
about	O
parental	B-LIVB
mental	B-DISO
health	I-DISO
issues	I-DISO
,	O
namely	O
""""	O
Protecting	B-PHYS
and	O
being	B-PHYS
protected	I-PHYS
,	O
""""	O
""""	O
Responding	B-PHYS
to	O
children	B-LIVB
's	I-LIVB
search	O
for	O
understanding	B-PHYS
,	O
""""	O
""""	O
Prioritizing	O
family	O
life	O
,	O
""""	O
and	O
""""	O
Relating	O
to	O
others	O
.	O
""""	O
Implications	O
of	O
the	O
findings	B-DISO
for	O
clinical	B-PROC
practice	I-PROC
and	O
future	O
research	B-PROC
are	O
considered	O
.	O

In	O
particular	O
,	O
the	O
need	O
for	O
more	O
family	B-PROC
-	I-PROC
orientated	I-PROC
services	I-PROC
where	O
parents	B-LIVB
experience	B-PHYS
parental	B-LIVB
mental	B-DISO
health	I-DISO
problems	I-DISO
is	O
highlighted	O
.	O

Joint	B-ANAT
Development	O
Involves	O
a	O
Continuous	O
Influx	O
of	O
Gdf5	O
-	O
Positive	B-ANAT
Cells	I-ANAT
Synovial	B-ANAT
joints	I-ANAT
comprise	O
several	O
tissue	O
types	O
,	O
including	O
articular	O
cartilage	O
,	O
the	O
capsule	B-ANAT
,	O
and	O
ligaments	O
.	O

All	O
of	O
these	O
compartments	B-ANAT
are	O
commonly	O
assumed	O
to	O
originate	O
from	O
an	O
early	O
set	O
of	O
Gdf5	O
-	O
expressing	B-PHYS
progenitors	B-ANAT
populating	O
the	O
interzone	O
domain	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
joints	B-ANAT
develop	O
through	O
a	O
continuous	O
influx	O
of	O
cells	B-ANAT
into	O
the	O
interzone	O
,	O
where	O
they	O
contribute	O
differentially	O
to	O
forming	O
joint	O
tissues	O
.	O

Using	O
a	O
knockin	B-PROC
Gdf5	O
-	O
CreER	O
(	O
T2	O
)	O
mouse	B-LIVB
,	O
we	O
show	O
that	O
early	O
labeling	O
of	O
Gdf5	O
-	O
positive	B-DISO
interzone	O
cells	B-ANAT
failed	O
to	O
mark	O
the	O
entire	B-ANAT
organ	I-ANAT
.	O

Conversely	O
,	O
multiple	O
Cre	O
activation	B-PHYS
steps	O
indicated	B-DISO
a	O
contribution	O
of	O
these	O
cells	B-ANAT
to	O
various	O
joint	B-ANAT
compartments	I-ANAT
later	O
in	O
development	O
.	O

Spatiotemporal	O
differences	O
between	O
Gdf5	O
and	O
tdTomato	O
reporter	O
expression	B-PHYS
support	O
the	O
notion	O
of	O
a	O
continuous	O
recruitment	O
process	B-PHEN
.	O

Finally	O
,	O
differential	O
contribution	O
of	O
Gdf5	O
-	O
positive	B-DISO
cells	B-ANAT
to	O
various	O
tissues	O
suggests	O
that	O
the	O
spatiotemporal	B-PROC
dynamics	I-PROC
of	O
Gdf5	O
expression	B-PHYS
may	O
instruct	O
lineage	O
divergence	O
.	O

This	O
work	O
supports	O
the	O
influx	O
model	O
of	O
joint	B-ANAT
development	O
,	O
which	O
may	O
apply	O
to	O
other	O
organogenic	B-PHEN
processes	B-PHEN
.	O

Everyday	O
(	O
in	O
)	O
equality	O
at	O
home	O
:	O
complex	O
constructions	O
of	O
gender	B-PHYS
in	O
South	B-LIVB
African	I-LIVB
families	B-LIVB
High	O
rates	O
of	O
violence	B-DISO
and	O
HIV	B-DISO
have	O
been	O
documented	B-PROC
within	O
the	O
South	B-LIVB
African	I-LIVB
context	I-LIVB
.	O

Constructions	O
of	O
masculinity	B-PHYS
and	O
femininity	B-PHYS
that	O
position	O
men	B-LIVB
as	O
dominant	O
and	O
highly	O
sexually	B-DISO
active	I-DISO
and	O
women	B-LIVB
as	O
subordinate	O
and	O
acquiescent	B-DISO
have	O
been	O
found	O
to	O
contribute	O
towards	O
gender	O
inequality	O
.	O

This	O
inequality	O
is	O
in	O
turn	O
related	O
to	O
negative	O
health	O
consequences	O
,	O
specifically	O
violence	B-DISO
against	O
women	B-LIVB
,	O
children	B-LIVB
,	O
and	O
other	O
men	B-LIVB
,	O
as	O
well	O
as	O
sexual	B-DISO
risk	I-DISO
.	O

Within	O
this	O
context	O
it	O
becomes	O
important	O
to	O
explore	O
how	O
problematic	O
constructions	O
of	O
gender	B-PHYS
are	O
being	O
(	O
re	O
)	O
produced	O
and	O
how	O
these	O
constructions	O
are	O
being	O
challenged	O
.	O

Families	B-LIVB
have	O
been	O
identified	O
as	O
key	O
sites	O
in	O
which	O
gender	B-PHYS
is	O
both	O
constructed	O
and	O
enacted	O
on	O
a	O
daily	O
basis	O
and	O
it	O
is	O
within	O
this	O
space	O
that	O
children	B-LIVB
are	O
first	O
exposed	O
to	O
notions	O
of	O
gender	B-PHYS
.	O

This	O
article	O
draws	O
from	O
a	O
study	B-PROC
that	O
was	O
intended	O
to	O
expand	O
on	O
the	O
limited	O
understandings	O
of	O
the	O
ways	O
in	O
which	O
gender	O
(	O
in	O
)	O
equality	O
is	O
constructed	O
and	O
conveyed	O
within	O
the	O
context	B-LIVB
of	I-LIVB
South	I-LIVB
African	I-LIVB
families	B-LIVB
on	O
an	O
everyday	O
basis	O
.	O

Children	B-LIVB
and	O
parents	B-LIVB
in	O
18	O
families	B-LIVB
from	O
a	O
range	O
of	O
different	O
material	O
and	O
cultural	O
backgrounds	O
were	O
interviewed	O
about	O
the	O
meanings	O
and	O
practices	O
of	O
gender	B-PHYS
within	O
their	O
homes	O
.	O

Data	O
were	O
analysed	B-PROC
using	O
a	O
Foucauldian	B-PROC
discourse	I-PROC
analysis	I-PROC
.	O

The	O
data	O
reveal	O
how	O
problematic	O
constructions	O
of	O
masculinity	B-PHYS
and	O
femininity	B-PHYS
are	O
(	O
re	O
)	O
produced	O
but	O
also	O
challenged	O
within	O
a	O
range	O
of	O
different	O
families	B-LIVB
.	O

Gender	B-PHYS
and	O
gender	O
(	O
in	O
)	O
equality	O
are	O
therefore	O
routinely	O
accomplished	O
in	O
complex	O
ways	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
promoting	O
gender	B-PHYS
equality	O
and	O
therefore	O
for	O
disrupting	O
violence	B-DISO
and	O
sexual	B-DISO
risk	I-DISO
as	O
gendered	O
health	O
issues	O
.	O

A	O
Support	O
Vector	O
Machine	O
Classification	O
of	O
Thyroid	B-ANAT
Bioptic	O
Specimens	O
Using	O
MALDI	B-PROC
-	I-PROC
MSI	I-PROC
Data	O
Biomarkers	B-PHYS
able	O
to	O
characterise	O
and	O
predict	O
multifactorial	O
diseases	B-DISO
are	O
still	O
one	O
of	O
the	O
most	O
important	O
targets	O
for	O
all	O
the	O
""""	O
omics	O
""""	O
investigations	O
.	O

In	O
this	O
context	O
,	O
Matrix	B-PROC
-	I-PROC
Assisted	I-PROC
Laser	I-PROC
Desorption	I-PROC
/	I-PROC
Ionisation	I-PROC
-	I-PROC
Mass	I-PROC
Spectrometry	I-PROC
Imaging	I-PROC
(	O
MALDI	B-PROC
-	I-PROC
MSI	I-PROC
)	O
has	O
gained	O
considerable	O
attention	B-PHYS
in	O
recent	O
years	O
,	O
but	O
it	O
also	O
led	O
to	O
a	O
huge	O
amount	O
of	O
complex	O
data	O
to	O
be	O
elaborated	O
and	O
interpreted	O
.	O

For	O
this	O
reason	O
,	O
computational	B-PROC
and	O
machine	O
learning	O
procedures	O
for	O
biomarker	B-PHYS
discovery	O
are	O
important	O
tools	O
to	O
consider	O
,	O
both	O
to	O
reduce	O
data	O
dimension	O
and	O
to	O
provide	O
predictive	O
markers	B-PHYS
for	O
specific	O
diseases	B-DISO
.	O

For	O
instance	O
,	O
the	O
availability	O
of	O
protein	B-CHEM
and	O
genetic	O
markers	B-PHYS
to	O
support	O
thyroid	B-ANAT
lesion	B-DISO
diagnoses	B-PROC
would	O
impact	O
deeply	O
on	O
society	B-LIVB
due	O
to	O
the	O
high	O
presence	O
of	O
undetermined	O
reports	O
(	O
THY3	O
)	O
that	O
are	O
generally	O
treated	O
as	O
malignant	O
patients	B-LIVB
.	O

In	O
this	O
paper	O
we	O
show	O
how	O
an	O
accurate	O
classification	O
of	O
thyroid	B-ANAT
bioptic	O
specimens	O
can	O
be	O
obtained	O
through	O
the	O
application	O
of	O
a	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
machine	O
learning	O
approach	O
(	O
i	O
.	O
e	O
.	O
,	O
Support	O
Vector	O
Machines	O
)	O
on	O
MALDI	B-PROC
-	I-PROC
MSI	I-PROC
data	O
,	O
together	O
with	O
a	O
particular	O
wrapper	O
feature	O
selection	O
algorithm	O
(	O
i	O
.	O
e	O
.	O
,	O
recursive	O
feature	O
elimination	O
)	O
.	O

The	O
model	B-DEVI
is	O
able	O
to	O
provide	O
an	O
accurate	O
discriminatory	O
capability	O
using	O
only	O
20	O
out	O
of	O
144	O
features	O
,	O
resulting	O
in	O
an	O
increase	O
of	O
the	O
model	B-DEVI
performances	O
,	O
reliability	O
,	O
and	O
computational	O
efficiency	O
.	O

Finally	O
,	O
tissue	O
areas	O
rather	O
than	O
average	O
proteomic	B-PHEN
profiles	I-PHEN
are	O
classified	O
,	O
highlighting	O
potential	O
discriminating	O
areas	O
of	O
clinical	O
interest	B-PHYS
.	O

Production	O
of	O
Laccase	B-CHEM
by	O
Cochliobolus	B-LIVB
sp	I-LIVB
.	I-LIVB

Isolated	O
from	O
Plastic	B-OBJC
Dumped	B-OBJC
Soils	I-OBJC
and	O
Their	O
Ability	B-PHYS
to	O
Degrade	O
Low	B-CHEM
Molecular	I-CHEM
Weight	I-CHEM
PVC	I-CHEM
One	O
of	O
the	O
utmost	O
man	B-PHEN
-	I-PHEN
made	I-PHEN
problems	I-PHEN
faced	O
today	O
has	O
been	O
the	O
ever	O
-	O
increasing	O
plastic	B-OBJC
waste	B-OBJC
filling	O
the	O
world	O
.	O

It	O
accounts	O
for	O
an	O
estimated	O
20	O
-	O
30	O
%	O
(	O
by	O
volume	O
)	O
of	O
municipal	B-OBJC
solid	I-OBJC
waste	I-OBJC
in	O
landfill	B-OBJC
sites	I-OBJC
worldwide	O
.	O

Research	O
on	O
plastic	B-OBJC
biodegradation	B-PHEN
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades	O
.	O

Several	O
fungi	B-LIVB
have	O
been	O
identified	O
that	O
produce	O
enzymes	B-CHEM
capable	O
of	O
plastic	B-OBJC
degradation	B-PHEN
in	O
various	O
laboratory	O
conditions	O
.	O

This	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	B-PHYS
of	O
fungi	B-LIVB
to	O
degrade	O
low	B-CHEM
molecular	I-CHEM
weight	I-CHEM
polyvinyl	I-CHEM
chloride	I-CHEM
(	O
PVC	B-CHEM
)	O
by	O
the	O
enzyme	B-CHEM
laccase	I-CHEM
.	O

We	O
have	O
isolated	O
a	O
fungal	B-LIVB
species	O
,	O
Cochliobolus	B-LIVB
sp	I-LIVB
.	I-LIVB
,	O
from	O
plastic	B-OBJC
dumped	B-OBJC
soils	I-OBJC
and	O
they	O
were	O
cultured	B-PROC
on	O
Czapek	B-CHEM
Dox	I-CHEM
Agar	I-CHEM
slants	I-CHEM
at	O
30°C	O
.	O

The	O
effectiveness	O
of	O
this	O
fungal	B-LIVB
species	O
on	O
the	O
degradation	B-PHEN
of	O
commercial	O
low	B-CHEM
molecular	I-CHEM
weight	I-CHEM
polyvinyl	I-CHEM
chloride	I-CHEM
(	O
PVC	B-CHEM
)	O
was	O
studied	O
under	O
laboratory	O
conditions	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
the	O
FTIR	B-PROC
,	O
GC	B-PROC
-	I-PROC
MS	I-PROC
,	O
and	O
SEM	B-PROC
results	O
in	O
between	O
control	B-OBJC
and	O
Cochliobolus	B-LIVB
sp	I-LIVB
.	I-LIVB

treated	O
PVC	B-CHEM
.	O

Conformers	O
of	O
Gaseous	B-CHEM
Serine	B-CHEM
The	O
myriad	O
conformers	O
of	O
the	O
neutral	B-PHEN
form	I-PHEN
of	O
natural	O
amino	B-CHEM
acid	I-CHEM
serine	B-CHEM
(	O
Ser	B-CHEM
)	O
have	O
been	O
investigated	O
by	O
systematic	O
computations	O
with	O
reliable	O
electronic	O
wave	O
function	O
methods	O
.	O

A	O
total	O
of	O
85	O
unique	O
conformers	O
were	O
located	O
using	O
the	O
MP2	O
/	O
cc	O
-	O
pVTZ	O
level	O
of	O
theory	O
.	O

The	O
12	O
lowest	O
-	O
energy	O
conformers	O
of	O
serine	B-CHEM
fall	O
within	O
a	O
8	O
kJ	O
mol	O
(	O
-	O
1	O
)	O
window	O
,	O
and	O
for	O
these	O
species	B-CHEM
,	O
geometric	O
structures	O
,	O
precise	O
relative	O
energies	O
,	O
equilibrium	O
and	O
vibrationally	O
averaged	O
rotational	O
constants	O
,	O
anharmonic	O
vibrational	O
frequencies	O
,	O
infrared	B-PHEN
intensities	I-PHEN
,	O
quartic	O
and	O
sextic	O
centrifugal	O
distortion	O
constants	O
,	O
dipole	O
moments	O
,	O
and	O
(	O
14	O
)	O
N	O
nuclear	O
quadrupole	O
coupling	O
constants	O
were	O
computed	O
.	O

The	O
relative	O
energies	O
were	O
refined	O
through	O
composite	B-PROC
focal	I-PROC
-	I-PROC
point	I-PROC
analyses	I-PROC
employing	O
basis	O
sets	O
as	O
large	O
as	O
aug	O
-	O
cc	O
-	O
pV5Z	O
and	O
correlation	B-PROC
treatments	I-PROC
through	O
CCSD	O
(	O
T	O
)	O
.	O

The	O
rotational	O
constants	O
for	O
seven	O
conformers	O
measured	O
by	O
Fourier	O
-	O
transform	O
microwave	O
spectroscopy	O
are	O
in	O
good	O
agreement	O
with	O
the	O
vibrationally	O
averaged	O
rotational	O
constants	O
computed	O
in	O
this	O
study	O
.	O

Our	O
anharmonic	O
vibrational	O
frequencies	O
are	O
compared	O
to	O
the	O
large	O
number	O
of	O
experimental	O
vibrational	B-PHEN
absorptions	I-PHEN
attributable	O
to	O
at	O
least	O
six	O
conformers	O
.	O

Interpretation	O
of	O
verbal	O
descriptors	O
for	O
response	B-PHYS
options	O
commonly	O
used	O
in	O
verbal	O
rating	O
scales	O
in	O
patient	B-LIVB
-reported	O
outcome	O
instruments	O
To	O
assess	B-PROC
the	O
variation	O
in	O
the	O
interpretation	O
of	O
common	O
verbal	O
descriptors	O
(	O
VDs	O
)	O
used	O
in	O
response	O
scales	O
and	O
examine	O
factors	O
associated	O
with	O
those	O
interpretations	O
.	O

Subjects	B-LIVB
were	O
recruited	O
through	O
MediGuard	O
and	O
they	O
assigned	O
interpretation	O
scores	O
(	O
11	O
-	O
point	O
scale	O
;	O
0	O
=	O
lowest	O
possible	O
,	O
10	O
=	O
highest	O
possible	O
)	O
to	O
five	O
common	O
sets	O
of	O
VDs	O
:	O
set	O
one	O
(	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
severe	O
,	O
very	O
severe	O
)	O
;	O
set	O
two	O
(	O
never	O
,	O
rarely	O
,	O
sometimes	O
,	O
often	O
,	O
always	O
)	O
;	O
set	O
three	O
(	O
poor	O
,	O
fair	O
,	O
good	O
,	O
very	O
good	O
,	O
excellent	O
)	O
;	O
set	O
four	O
(	O
not	B-DISO
at	I-DISO
all	I-DISO
,	O
a	B-DISO
little	I-DISO
bit	I-DISO
,	O
moderately	O
,	O
quite	B-DISO
a	I-DISO
bit	I-DISO
,	O
extremely	O
)	O
;	O
and	O
set	O
five	O
(	O
not	B-DISO
at	I-DISO
all	I-DISO
,	O
a	B-DISO
little	I-DISO
bit	I-DISO
,	O
somewhat	B-DISO
,	O
quite	B-DISO
a	I-DISO
bit	I-DISO
,	O
very	O
much	O
)	O
.	O

One	O
-	O
sample	O
test	O
for	O
proportions	O
and	O
T	O
-	O
tests	O
examined	O
equality	O
of	O
proportions	O
(	O
anchors	B-LIVB
)	O
and	O
means	O
scores	O
(	O
non	B-LIVB
-	I-LIVB
anchors	I-LIVB
)	O
with	O
the	O
fixed	O
intervals	O
(	O
0	O
.	O
0	O
,	O
2	O
.	O
5	O
,	O
5	O
.	O
0	O
,	O
7	O
.	O
5	O
,	O
and	O
10	O
.	O
0	O
)	O
.	O

Ordinal	O
regression	O
examined	O
adjusted	O
associations	O
between	O
demographic	O
/	O
clinical	O
factors	O
and	O
VD	O
scores	O
.	O

Of	O
the	O
350	O
subjects	B-LIVB
,	O
68	O
%	O
were	O
females	B-PHYS
and	O
mean	O
(	O
SD	O
)	O
age	B-PHYS
was	O
56	O
.	O

9	O
(	O
12	O
.	O
1	O
)	O
.	O

Two	O
sets	O
had	O
two	O
VDs	O
with	O
mean	O
(	O
95	O
%	O
CI	O
)	O
scores	O
not	O
different	O
than	O
the	O
fixed	O
intervals	O
.	O

Set	O
one	O
had	O
mild	O
=	O
2	O
.	O

50	O
(	O
2	O
.	O
33	O
;	O
2	O
.	O
66	O
)	O
and	O
moderate	O
=	O
5	O
.	O
01	O
(	O
4	O
.	O
89	O
;	O
5	O
.	O
13	O
)	O
with	O
98	O
.	O
8	O
%	O
(	O
97	O
.	O
3	O
%	O
;	O
100	O
%	O
)	O
assigning	O
none	O
=	O
0	O
.	O

Set	O
five	O
had	O
a	B-DISO
little	I-DISO
bit	I-DISO
=	O
2	O
.	O

35	O
(	O
2	O
.	O
17	O
;	O
2	O
.	O
53	O
)	O
and	O
quite	B-DISO
a	I-DISO
bit	I-DISO
=	O
7	O
.	O
65	O
(	O
7	O
.	O
43	O
;	O
7	O
.	O
87	O
)	O
with	O
95	O
.	O

0	O
%	O
(	O
95	O
%	O
CI	O
91	O
.	O
7	O
;	O
98	O
.	O
2	O
)	O
assigning	O
not	B-DISO
at	I-DISO
all	I-DISO
=	O
0	O
.	O

Significant	O
associations	O
(	O
p	O
≤	O
0	O
.	O
05	O
)	O
included	O
age	B-PHYS
and	O
education	B-DISO
with	O
somewhat	O
and	O
income	O
and	O
comorbidities	O
with	O
very	O
severe	O
.	O

Age	B-PHYS
,	O
sex	B-PHYS
,	O
and	O
education	B-DISO
showed	O
associations	O
with	O
other	O
VDs	O
albeit	O
in	O
nonsignificant	O
models	O
.	O

Sets	O
one	O
and	O
five	O
yielded	O
data	O
closest	O
to	O
the	O
fixed	O
intervals	O
.	O

Demographic	O
and	O
clinical	O
factors	O
are	O
associated	O
with	O
the	O
interpretation	O
of	O
some	O
VDs	O
and	O
should	O
be	O
adjusted	O
for	O
in	O
analyses	B-PROC
of	O
non	O
-	O
randomized	O
data	O
.	O

Glycolysis	B-PHYS
determines	O
dichotomous	O
regulation	O
of	O
T	B-ANAT
cell	I-ANAT
subsets	I-ANAT
in	O
hypoxia	B-DISO
Hypoxia	B-DISO
occurs	O
in	O
many	O
pathological	B-DISO
conditions	I-DISO
,	O
including	O
chronic	B-DISO
inflammation	I-DISO
and	O
tumors	B-DISO
,	O
and	O
is	O
considered	O
to	O
be	O
an	O
inhibitor	O
of	O
T	B-ANAT
cell	I-ANAT
function	B-PHYS
.	O

However	O
,	O
robust	O
T	B-ANAT
cell	I-ANAT
responses	B-PHYS
occur	O
at	O
many	O
hypoxic	B-DISO
inflammatory	O
sites	O
,	O
suggesting	O
that	O
functions	O
of	O
some	O
subsets	B-ANAT
are	O
stimulated	B-PHEN
under	O
low	B-DISO
oxygen	I-DISO
conditions	I-DISO
.	O

Here	O
,	O
we	O
investigated	O
how	O
hypoxic	B-DISO
conditions	O
influence	O
human	B-LIVB
T	B-ANAT
cell	I-ANAT
functions	B-PHYS
and	O
found	O
that	O
,	O
in	O
contrast	O
to	O
naive	B-ANAT
and	O
central	B-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
(	O
TN	B-ANAT
and	O
TCM	B-ANAT
)	O
,	O
hypoxia	B-DISO
enhances	O
the	O
proliferation	B-PHYS
,	O
viability	B-PHYS
,	O
and	O
cytotoxic	O
action	O
of	O
effector	B-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
(	O
TEM	B-ANAT
)	O
.	O

Enhanced	O
TEM	B-ANAT
expansion	B-PHYS
in	O
hypoxia	B-DISO
corresponded	O
to	O
high	O
hypoxia	O
-	O
inducible	O
factor	O
1α	O
(	O
HIF1α	O
)	O
expression	B-PHYS
and	O
glycolytic	B-PHYS
activity	O
compared	O
with	O
that	O
observed	O
in	O
TN	B-ANAT
and	O
TCM	B-ANAT
.	O

We	O
determined	O
that	O
the	O
glycolytic	B-PHYS
enzyme	B-CHEM
GAPDH	I-CHEM
negatively	O
regulates	O
HIF1A	O
expression	B-PHYS
by	O
binding	B-PHYS
to	I-PHYS
adenylate	I-PHYS
-	I-PHYS
uridylate	I-PHYS
-	I-PHYS
rich	I-PHYS
elements	I-PHYS
in	O
the	O
3	O
'	O
-	O
UTR	O
region	O
of	O
HIF1A	O
mRNA	O
in	O
glycolytically	B-PHYS
inactive	O
TN	B-ANAT
and	O
TCM	B-ANAT
.	O

Conversely	O
,	O
active	O
glycolysis	B-PHYS
with	O
decreased	O
GAPDH	B-CHEM
availability	O
in	O
TEM	B-ANAT
resulted	O
in	O
elevated	O
HIF1α	O
expression	B-PHYS
.	O

Furthermore	O
,	O
GAPDH	B-CHEM
overexpression	B-PHYS
reduced	O
HIF1α	O
expression	B-PHYS
and	O
impaired	O
proliferation	B-PHYS
and	O
survival	B-PHYS
of	O
T	B-ANAT
cells	I-ANAT
in	O
hypoxia	B-DISO
,	O
indicating	O
that	O
high	B-PHYS
glycolytic	I-PHYS
metabolism	B-PHYS
drives	O
increases	O
in	O
HIF1α	O
to	O
enhance	O
TEM	B-ANAT
function	B-PHYS
during	O
hypoxia	B-DISO
.	O

This	O
work	O
demonstrates	O
that	O
glycolytic	B-PHYS
metabolism	B-PHYS
regulates	O
the	O
translation	B-PHYS
of	O
HIF1A	O
to	O
determine	O
T	B-ANAT
cell	I-ANAT
responses	B-PHYS
to	O
hypoxia	B-DISO
and	O
implicates	O
GAPDH	B-CHEM
as	O
a	O
potential	O
mechanism	B-PHYS
for	O
controlling	O
T	B-ANAT
cell	I-ANAT
function	B-PHYS
in	O
peripheral	O
tissue	O
.	O

Nanocatalysts	B-PHEN
promote	O
Streptococcus	B-LIVB
mutans	I-LIVB
biofilm	O
matrix	O
degradation	O
and	O
enhance	O
bacterial	B-PHEN
killing	I-PHEN
to	O
suppress	O
dental	B-DISO
caries	I-DISO
in	O
vivo	O
Dental	O
biofilms	B-LIVB
(	O
known	O
as	O
plaque	B-DISO
)	O
are	O
notoriously	O
difficult	O
to	O
remove	O
or	O
treat	O
because	O
the	O
bacteria	B-LIVB
can	O
be	O
enmeshed	O
in	O
a	O
protective	O
extracellular	O
matrix	O
.	O

It	O
can	O
also	O
create	O
highly	O
acidic	O
microenvironments	O
that	O
cause	O
acid	O
-	O
dissolution	O
of	O
enamel	B-ANAT
-	O
apatite	B-CHEM
on	O
teeth	B-ANAT
,	O
leading	O
to	O
the	O
onset	O
of	O
dental	B-DISO
caries	I-DISO
.	O

Current	O
antimicrobial	B-CHEM
agents	I-CHEM
are	O
incapable	B-DISO
of	O
disrupting	O
the	O
matrix	O
and	O
thereby	O
fail	O
to	O
efficiently	O
kill	O
the	O
microbes	B-LIVB
within	O
plaque	B-DISO
-	O
biofilms	B-LIVB
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
strategy	O
to	O
control	O
plaque	B-DISO
-	O
biofilms	B-LIVB
using	O
catalytic	B-PHEN
nanoparticles	I-PHEN
(	O
CAT	B-PHEN
-	I-PHEN
NP	I-PHEN
)	O
with	O
peroxidase	B-CHEM
-like	O
activity	O
that	O
trigger	O
extracellular	O
matrix	O
degradation	O
and	O
cause	O
bacterial	B-DISO
death	I-DISO
within	O
acidic	O
niches	O
of	O
caries	B-DISO
-causing	O
biofilm	B-LIVB
.	O

CAT	B-PHEN
-	I-PHEN
NP	I-PHEN
containing	O
biocompatible	B-CHEM
Fe3O4	B-CHEM
were	O
developed	O
to	O
catalyze	B-PHEN
H2O2	B-CHEM
to	O
generate	O
free	B-CHEM
-	I-CHEM
radicals	I-CHEM
in	O
situ	O
that	O
simultaneously	O
degrade	O
the	O
biofilm	O
matrix	O
and	O
rapidly	O
kill	O
the	O
embedded	B-LIVB
bacteria	I-LIVB
with	O
exceptional	O
efficacy	O
(	O
>	O
5	O
-	O
log	O
reduction	O
of	O
cell	B-PHYS
-	I-PHYS
viability	I-PHYS
)	O
.	O

Moreover	O
,	O
it	O
displays	O
an	O
additional	O
property	O
of	O
reducing	O
apatite	B-CHEM
demineralization	B-DISO
in	O
acidic	O
conditions	O
.	O

Using	O
1	O
-	O
min	O
topical	O
daily	O
treatments	O
akin	O
to	O
a	O
clinical	B-PHYS
situation	I-PHYS
,	O
we	O
demonstrate	O
that	O
CAT	B-PHEN
-	I-PHEN
NP	I-PHEN
in	O
combination	O
with	O
H2O2	B-CHEM
effectively	O
suppress	O
the	O
onset	O
and	O
severity	O
of	O
dental	B-DISO
caries	I-DISO
while	O
sparing	O
normal	O
tissues	O
in	O
vivo	O
.	O

Our	O
results	B-PHEN
reveal	O
the	O
potential	O
to	O
exploit	O
nanocatalysts	B-PHEN
with	O
enzyme	B-PHYS
-	I-PHYS
like	I-PHYS
activity	I-PHYS
as	O
a	O
potent	O
alternative	O
approach	O
for	O
treatment	B-PROC
of	O
a	O
prevalent	O
biofilm	B-LIVB
-associated	O
oral	B-DISO
disease	I-DISO
.	O

N	B-PHYS
-	I-PHYS
linked	I-PHYS
glycosylation	I-PHYS
of	O
SV2	B-CHEM
is	O
required	O
for	O
binding	B-PHYS
and	O
uptake	B-PHYS
of	O
botulinum	B-CHEM
neurotoxin	I-CHEM
A	I-CHEM
Botulinum	B-CHEM
neurotoxin	I-CHEM
serotype	I-CHEM
A1	I-CHEM
(	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
)	O
,	O
a	O
licensed	O
drug	B-CHEM
widely	O
used	O
for	O
medical	B-CHEM
and	O
cosmetic	B-OBJC
applications	I-OBJC
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	B-ANAT
.	O

Here	O
we	O
report	O
a	O
2	O
.	O
0	O
-	O
Å	O
-	O
resolution	O
crystal	B-CHEM
structure	I-CHEM
of	O
the	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
receptor	I-CHEM
-	O
binding	O
domain	O
in	O
complex	B-CHEM
with	O
its	O
neuronal	B-ANAT
receptor	I-ANAT
,	O
glycosylated	B-PHYS
human	B-CHEM
SV2C	I-CHEM
.	O

We	O
found	O
that	O
the	O
neuronal	B-CHEM
tropism	B-PHYS
of	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
requires	O
recognition	B-PHYS
of	O
both	O
the	O
peptide	B-CHEM
moiety	I-CHEM
and	O
an	O
N	B-CHEM
-	I-CHEM
linked	I-CHEM
glycan	I-CHEM
on	O
SV2	B-CHEM
.	O

This	O
N	B-CHEM
-	I-CHEM
glycan	I-CHEM
-which	O
is	O
conserved	O
in	O
all	O
SV2	B-CHEM
isoforms	B-CHEM
across	O
vertebrates	B-LIVB
-is	O
essential	O
for	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
binding	B-PHYS
to	O
neurons	B-ANAT
and	O
for	O
its	O
potent	O
neurotoxicity	B-DISO
.	O

The	O
glycan	B-CHEM
-	O
binding	B-PHYS
interface	O
on	O
SV2	B-CHEM
is	O
targeted	O
by	O
a	O
human	B-LIVB
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
-	O
neutralizing	B-CHEM
antibody	I-CHEM
currently	O
licensed	O
as	O
an	O
antibotulism	B-CHEM
drug	I-CHEM
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	B-PROC
of	O
host	B-PHYS
-	I-PHYS
pathogen	I-PHYS
interactions	I-PHYS
,	O
in	O
which	O
pathogens	B-LIVB
exploit	O
conserved	O
host	B-LIVB
post	B-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	B-PHYS
binding	I-PHYS
while	O
also	O
tolerating	O
genetic	B-DISO
changes	I-DISO
across	O
multiple	O
isoforms	B-CHEM
of	O
receptors	B-CHEM
.	O

Accuracy	O
of	O
Currently	O
Used	O
Paper	B-OBJC
Burn	B-DISO
Diagram	O
vs	O
a	O
Three	O
-	O
Dimensional	O
Computerized	O
Model	O
Burn	B-OBJC
units	I-OBJC
have	O
historically	O
used	O
paper	B-OBJC
diagrams	O
to	O
estimate	O
percent	O
burn	B-DISO
;	O
however	O
,	O
unintentional	O
errors	O
can	O
occur	O
.	O

The	O
use	O
of	O
a	O
computer	B-OBJC
program	I-OBJC
that	O
incorporates	O
wound	B-DISO
mapping	O
from	O
photographs	B-OBJC
onto	O
a	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
human	B-LIVB
diagram	O
could	O
decrease	O
subjectivity	O
in	O
preparing	O
burn	B-DISO
diagrams	O
and	O
subsequent	O
calculations	O
of	O
TBSA	B-PHYS
burned	B-DISO
.	O

Analyses	B-PROC
were	O
done	O
on	O
19	O
burned	B-DISO
patients	B-LIVB
who	O
had	O
an	O
estimated	O
TBSA	B-PHYS
burned	B-DISO
of	O
≥20	O
%	O
.	O

The	O
patients	B-LIVB
were	O
admitted	B-PROC
to	O
Shriners	B-OBJC
Hospitals	I-OBJC
for	O
Children	B-LIVB
or	O
the	O
University	O
of	O
Texas	O
Medical	O
Branch	O
in	O
Galveston	B-GEOG
,	I-GEOG
Texas	I-GEOG
,	O
from	O
July	O
2012	O
to	O
September	O
2013	O
for	O
treatment	B-PROC
.	O

Digital	O
photographs	B-OBJC
were	O
collected	O
before	O
the	O
patient	B-LIVB
's	I-LIVB
first	O
surgery	B-PROC
.	O

Using	O
BurnCase	O
3D	O
(	O
RISC	B-OBJC
Software	I-OBJC
GmbH	I-OBJC
,	O
Hagenberg	O
,	O
Austria	B-GEOG
)	O
,	O
a	O
burn	B-DISO
mapping	O
software	B-OBJC
,	O
the	O
user	B-LIVB
traced	O
partial	O
-	O
and	O
full	O
-	O
thickness	O
burns	B-DISO
from	O
photographs	B-OBJC
.	O

The	O
program	B-OBJC
then	O
superimposed	O
tracings	O
onto	O
a	O
3D	O
model	O
and	O
calculated	O
percent	O
burned	B-DISO
.	O

The	O
results	O
were	O
compared	O
with	O
the	O
Lund	O
and	O
Browder	O
diagrams	O
completed	O
after	O
the	O
first	O
operation	B-PROC
.	O

A	O
two	O
-	O
tailed	O
t	O
-	O
test	O
was	O
used	O
to	O
calculate	O
statistical	O
differences	O
.	O

For	O
partial	O
-	O
thickness	O
burns	B-DISO
,	O
burn	B-DISO
sizes	O
calculated	O
using	O
Lund	O
and	O
Browder	O
diagrams	O
were	O
significantly	O
larger	O
than	O
those	O
calculated	O
using	O
BurnCase	O
3D	O
(	O
15	O
%	O
difference	O
,	O
P	O
<	O
.01	O
)	O
.	O

The	O
opposite	O
was	O
found	O
for	O
full	O
-	O
thickness	O
burns	B-DISO
,	O
with	O
burn	B-DISO
sizes	O
being	O
smaller	O
when	O
calculated	O
using	O
Lund	O
and	O
Browder	O
diagrams	O
(	O
11	O
%	O
difference	O
,	O
P	O
<	O
.05	O
)	O
.	O

In	O
conclusion	O
,	O
substantial	O
differences	O
exist	O
in	O
percent	O
burn	B-DISO
estimations	B-PHYS
derived	O
from	O
BurnCase	O
3D	O
and	O
paper	B-OBJC
diagram	O
s	O
.	O

In	O
our	O
studied	B-LIVB
cohort	I-LIVB
,	O
paper	B-OBJC
diagram	O
s	O
were	O
associated	O
with	O
overestimation	B-PHYS
of	O
partial	O
-	O
thickness	O
burn	B-DISO
size	O
and	O
underestimation	B-PHYS
of	O
full	O
-	O
thickness	O
burn	B-DISO
size	O
.	O

Additional	O
studies	B-PROC
comparing	O
BurnCase	O
3D	O
with	O
other	O
commonly	O
used	O
methods	O
are	O
warranted	O
.	O

Field	O
Measurements	O
and	O
Numerical	O
Simulations	O
of	O
Temperature	O
and	O
Moisture	B-OBJC
in	O
Highway	O
Engineering	O
Using	O
a	O
Frequency	B-OBJC
Domain	I-OBJC
Reflectometry	I-OBJC
Sensor	I-OBJC
This	O
paper	O
presents	O
a	O
systematic	O
pioneering	B-PROC
study	I-PROC
on	O
the	O
use	O
of	O
agricultural	O
-	O
purpose	O
frequency	B-OBJC
domain	I-OBJC
reflectometry	I-OBJC
(	I-OBJC
FDR	I-OBJC
)	I-OBJC
sensors	I-OBJC
to	O
monitor	O
temperature	O
and	O
moisture	B-OBJC
of	O
a	O
subgrade	O
in	O
highway	O
extension	O
and	O
reconstruction	O
engineering	O
.	O

The	O
principle	O
of	O
agricultural	O
-	O
purpose	O
FDR	B-OBJC
sensors	I-OBJC
and	O
the	O
process	B-PHEN
for	O
embedding	B-PROC
this	O
kind	O
of	O
sensors	B-OBJC
for	O
subgrade	O
engineering	O
purposes	O
are	O
introduced	O
.	O

Based	O
on	O
field	O
measured	O
weather	B-PHEN
data	O
,	O
a	O
numerical	O
analysis	O
model	O
for	O
temperature	O
and	O
moisture	B-OBJC
content	O
in	O
the	O
subgrade	O
's	O
soil	B-OBJC
is	O
built	O
.	O

Comparisons	O
of	O
the	O
temperature	O
and	O
moisture	B-OBJC
data	O
obtained	O
from	O
numerical	O
simulation	O
and	O
FDR	B-OBJC
-based	O
measurements	O
are	O
conducted	O
.	O

The	O
results	O
show	O
that	O
:	O
(	O
1	O
)	O
the	O
embedding	B-PROC
method	I-PROC
and	O
process	B-PHEN
,	O
data	B-PHEN
acquisition	I-PHEN
,	O
and	O
remote	B-PHEN
transmission	I-PHEN
presented	O
are	O
reasonable	O
;	O
(	O
2	O
)	O
the	O
temperature	O
and	O
moisture	B-OBJC
changes	O
are	O
coordinated	O
with	O
the	O
atmospheric	O
environment	O
and	O
they	O
are	O
also	O
in	O
close	O
agreement	O
with	O
numerical	O
calculations	O
;	O
(	O
3	O
)	O
the	O
change	O
laws	O
of	O
both	O
are	O
consistent	O
at	O
positions	O
where	O
the	O
subgrade	O
is	O
compacted	B-DISO
uniformly	O
.	O

These	O
results	O
suggest	O
that	O
the	O
data	O
measured	O
by	O
the	O
agricultural	O
-	O
purpose	O
FDR	B-OBJC
sensors	I-OBJC
are	O
reliable	O
.	O

The	O
findings	B-DISO
of	O
this	O
paper	O
enable	O
a	O
new	O
and	O
effective	O
real	O
-	O
time	O
monitoring	O
method	O
for	O
a	O
subgrade	O
's	O
temperature	O
and	O
moisture	B-OBJC
changes	O
,	O
and	O
thus	O
broaden	O
the	O
application	O
of	O
agricultural	O
-	O
purpose	O
FDR	B-OBJC
sensors	I-OBJC
.	O

Effects	O
of	O
Cerium	B-CHEM
and	O
Titanium	B-CHEM
Oxide	I-CHEM
Nanoparticles	B-OBJC
in	O
Soil	B-OBJC
on	O
the	O
Nutrient	B-OBJC
Composition	B-PHYS
of	O
Barley	B-LIVB
(	O
Hordeum	B-LIVB
vulgare	I-LIVB
L	I-LIVB
.	O
)	O
Kernels	B-OBJC
The	O
implications	O
of	O
metal	B-OBJC
nanoparticles	I-OBJC
(	O
MeNPs	B-OBJC
)	I-OBJC
are	O
still	O
unknown	O
for	O
many	O
food	B-LIVB
crops	I-LIVB
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	O
the	O
effects	O
of	O
cerium	B-CHEM
oxide	I-CHEM
(	O
nCeO₂	B-CHEM
)	O
and	O
titanium	B-CHEM
oxide	I-CHEM
(	O
nTiO₂	B-CHEM
)	O
nanoparticles	B-OBJC
in	O
soil	B-OBJC
at	O
0	O
,	O
500	O
and	O
1000	O
mg·kg	O
(	O
-	O
1	O
)	O
on	O
the	O
nutritional	O
parameters	O
of	O
barley	B-LIVB
(	O
Hordeum	B-LIVB
vulgare	I-LIVB
L	I-LIVB
.	I-LIVB

)	O
kernels	B-OBJC
.	O

Mineral	B-CHEM
nutrients	I-CHEM
,	O
amylose	B-CHEM
,	O
β	B-CHEM
-	I-CHEM
glucans	I-CHEM
,	O
amino	B-CHEM
acid	I-CHEM
and	O
crude	B-CHEM
protein	I-CHEM
(	O
CP	B-CHEM
)	O
concentrations	O
were	O
measured	O
in	O
kernels	B-OBJC
.	O

Whole	O
flour	B-OBJC
samples	O
were	O
analyzed	O
by	O
ICP	B-PROC
-	I-PROC
AES	I-PROC
/	I-PROC
MS	I-PROC
,	O
HPLC	B-PROC
and	O
Elemental	B-OBJC
CHNS	I-OBJC
Analyzer	I-OBJC
.	O

Results	O
showed	O
that	O
Ce	B-CHEM
and	O
Ti	B-CHEM
accumulation	B-DISO
under	O
MeNPs	B-OBJC
treatments	O
did	O
not	O
differ	O
from	O
the	O
control	O
treatment	O
.	O

However	O
,	O
nCeO₂	B-CHEM
and	O
nTiO₂	B-CHEM
had	O
an	O
impact	O
on	O
composition	B-PHYS
and	O
nutritional	O
quality	O
of	O
barley	B-LIVB
kernels	B-OBJC
in	O
contrasting	O
ways	O
.	O

Both	O
MeNPs	B-OBJC
left	O
β	B-CHEM
-	I-CHEM
glucans	I-CHEM
unaffected	O
but	O
reduced	O
amylose	B-CHEM
content	O
by	O
approximately	O
21	O
%	O
.	O

Most	O
amino	B-CHEM
acids	I-CHEM
and	O
CP	B-CHEM
increased	O
.	O

Among	O
amino	B-CHEM
acids	I-CHEM
,	O
lysine	B-CHEM
followed	O
by	O
proline	B-CHEM
saw	O
the	O
largest	O
increase	O
(	O
51	O
%	O
and	O
37	O
%	O
,	O
respectively	O
)	O
.	O

Potassium	B-CHEM
and	O
S	B-CHEM
were	O
both	O
negatively	O
impacted	O
by	O
MeNPs	B-OBJC
,	O
while	O
B	O
was	O
only	O
affected	O
by	O
500	O
mg	O
nCeO₂	B-CHEM
·	O
kg	O
(	O
-	O
1	O
)	O
.	O

On	O
the	O
contrary	O
Zn	B-PROC
and	O
Mn	B-PROC
concentrations	I-PROC
were	O
improved	O
by	O
500	O
mg	O
nTiO₂	B-CHEM
·	O
kg	O
(	O
-	O
1	O
)	O
,	O
and	O
Ca	O
by	O
both	O
nTiO₂	B-CHEM
treatments	O
.	O

Generally	O
,	O
our	O
findings	O
demonstrated	O
that	O
kernels	B-OBJC
are	O
negatively	B-DISO
affected	I-DISO
by	O
nCeO₂	B-CHEM
while	O
nTiO₂	B-CHEM
can	O
potentially	O
have	O
beneficial	O
effects	O
.	O

However	O
,	O
both	O
MeNPs	B-OBJC
have	O
the	O
potential	O
to	O
negatively	O
impact	O
malt	B-OBJC
and	O
feed	O
production	O
.	O

Smart	B-CHEM
Thin	I-CHEM
Hydrogel	I-CHEM
Coatings	I-CHEM
Harnessing	O
Hydrophobicity	O
and	O
Topography	O
to	O
Capture	O
and	O
Release	O
Cancer	B-ANAT
Cells	I-ANAT
Smart	B-CHEM
thin	I-CHEM
hydrogel	I-CHEM
coatings	I-CHEM
are	O
fabricated	O
to	O
capture	O
and	O
release	O
targeted	O
cancer	B-ANAT
cells	I-ANAT
by	O
simultaneously	O
tuning	O
surface	O
hydrophobicity	O
and	O
topography	O
.	O

At	O
physiological	B-PHYS
temperature	I-PHYS
,	O
the	O
targeted	O
cancer	B-ANAT
cells	I-ANAT
are	O
capture	O
d	O
on	O
the	O
hydrophobic	B-PHEN
and	O
wrinkled	O
coating	O
surface	O
.	O

At	O
room	O
temperature	O
,	O
the	O
captured	O
cells	B-ANAT
are	O
released	O
from	O
the	O
hydrophilic	O
and	O
smooth	O
coating	O
surface	O
.	O

Parametric	B-PROC
Surface	I-PROC
Diffeomorphometry	I-PROC
for	O
Low	B-PROC
Dimensional	I-PROC
Embeddings	I-PROC
of	O
Dense	O
Segmentations	O
and	O
Imagery	B-PHYS
In	O
the	O
field	O
of	O
Computational	B-PROC
Anatomy	I-PROC
,	O
biological	O
form	O
(	O
including	O
our	O
focus	O
,	O
neuroanatomy	O
)	O
is	O
studied	B-PROC
quantitatively	O
through	O
the	O
action	O
of	O
the	O
diffeomorphism	O
group	O
on	O
example	O
anatomies	B-ANAT
-	O
a	O
technique	O
called	O
diffeomorphometry	B-PROC
.	O

Here	O
we	O
design	O
an	O
algorithm	O
within	O
this	O
framework	O
to	O
pass	O
from	O
dense	O
objects	O
common	O
in	O
neuromaging	B-PROC
studies	B-PROC
(	O
binary	O
segmentations	O
,	O
structural	O
images	O
)	O
to	O
a	O
sparse	O
representation	O
defined	O
on	O
the	O
surface	O
boundaries	O
of	O
anatomical	B-ANAT
structures	I-ANAT
,	O
and	O
embedded	B-PROC
into	O
the	O
low	O
dimensional	O
coordinates	O
of	O
a	O
parametric	O
model	O
.	O

Our	O
main	O
new	O
contribution	O
is	O
to	O
introduce	O
an	O
expanded	O
group	O
action	O
to	O
simultaneously	O
deform	O
surfaces	O
through	O
direct	O
mapping	O
of	O
points	O
,	O
as	O
well	O
as	O
images	O
through	O
functional	O
composition	B-PHYS
with	O
the	O
inverse	O
.	O

This	O
allows	O
us	O
to	O
index	O
the	O
diffeomorphisms	O
with	O
respect	O
to	O
two	O
-	O
dimensional	O
surface	O
geometries	O
like	O
subcortical	B-ANAT
gray	I-ANAT
matter	I-ANAT
structures	I-ANAT
,	O
but	O
explicitly	O
map	O
onto	O
cost	O
functions	O
determined	O
by	O
noisy	B-DISO
3	I-DISO
-	I-DISO
dimensional	I-DISO
measurements	I-DISO
.	O

We	O
consider	O
models	B-DEVI
generated	O
from	O
empirical	O
covariance	O
of	O
training	O
data	O
,	O
as	O
well	O
as	O
bandlimited	B-DEVI
(	I-DEVI
Laplace	I-DEVI
-	I-DEVI
Beltrami	I-DEVI
eigenfunction	I-DEVI
)	I-DEVI
models	I-DEVI
when	O
no	O
such	O
data	O
is	O
available	O
.	O

We	O
show	O
applications	O
to	O
noisy	O
or	O
anomalous	B-DISO
segmentations	O
,	O
and	O
other	O
typical	O
problems	O
in	O
neuroimaging	B-PROC
studies	B-PROC
.	O

We	O
reproduce	O
statistical	O
results	O
detecting	O
changes	O
in	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
,	O
despite	O
dimensionality	O
reduction	O
.	O

Lastly	O
we	O
apply	O
our	O
algorithm	O
to	O
the	O
common	O
problem	O
of	O
segmenting	O
subcortical	B-ANAT
structures	I-ANAT
from	O
T1	B-PROC
MR	I-PROC
images	I-PROC
.	O

Fathers	O
'	O
Roles	O
in	O
the	O
Care	O
and	O
Development	B-PHYS
of	O
Their	O
Children	B-LIVB
:	O
The	O
Role	O
of	O
Pediatricians	O
Fathers	B-LIVB
'	I-LIVB
involvement	O
in	O
and	O
influence	O
on	O
the	O
health	O
and	O
development	B-PHYS
of	O
their	O
children	B-LIVB
have	O
increased	O
in	O
a	O
myriad	O
of	O
ways	O
in	O
the	O
past	O
10	O
years	O
and	O
have	O
been	O
widely	O
studied	B-PROC
.	O

The	O
role	O
of	O
pediatricians	O
in	O
working	O
with	O
fathers	B-LIVB
has	O
correspondingly	O
increased	O
in	O
importance	O
.	O

This	O
report	O
reviews	O
new	O
studies	B-PROC
of	O
the	O
epidemiology	B-PROC
of	O
father	B-LIVB
involvement	O
,	O
including	O
nonresidential	B-DISO
as	O
well	O
as	O
residential	B-DISO
fathers	I-DISO
.	O

The	O
effects	O
of	O
father	B-LIVB
involvement	O
on	O
child	B-PHYS
outcomes	I-PHYS
are	O
discussed	O
within	O
each	O
phase	O
of	O
a	O
child	B-PHYS
's	I-PHYS
development	I-PHYS
.	O

Particular	O
emphasis	O
is	O
placed	O
on	O
(	O
1	O
)	O
fathers	B-LIVB
'	I-LIVB
involvement	O
across	O
childhood	O
ages	B-PHYS
and	O
(	O
2	O
)	O
the	O
influence	O
of	O
fathers	B-LIVB
'	I-LIVB
physical	B-DISO
and	O
mental	B-PHYS
health	I-PHYS
on	O
their	O
children	B-LIVB
.	O

Implications	O
and	O
advice	B-PROC
for	O
all	O
child	B-LIVB
health	B-LIVB
providers	I-LIVB
to	O
encourage	O
and	O
support	O
father	B-LIVB
involvement	O
are	O
outlined	O
.	O

Prediction	O
of	O
Clinically	B-DISO
Significant	I-DISO
Bleeding	I-DISO
Following	O
Wide	B-PROC
-	I-PROC
Field	I-PROC
Endoscopic	I-PROC
Resection	I-PROC
of	O
Large	O
Sessile	O
and	O
Laterally	O
Spreading	O
Colorectal	B-DISO
Lesions	I-DISO
:	O
A	O
Clinical	O
Risk	O
Score	O
Clinically	B-DISO
significant	I-DISO
bleeding	I-DISO
(	O
CSPEB	B-DISO
)	O
is	O
the	O
most	O
frequent	O
adverse	B-DISO
event	I-DISO
following	O
wide	B-PROC
-	I-PROC
field	I-PROC
endoscopic	I-PROC
mucosal	I-PROC
resection	I-PROC
(	O
WF	B-PROC
-	I-PROC
EMR	I-PROC
)	O
of	O
large	O
sessile	O
and	O
laterally	O
spreading	O
colorectal	B-DISO
lesions	I-DISO
(	O
LSL	B-DISO
)	O
.	O

There	O
is	O
limited	O
knowledge	O
regarding	O
accurate	O
prediction	O
of	O
CSPEB	B-DISO
.	O

We	O
aimed	O
to	O
derive	O
a	O
score	O
to	O
predict	O
the	O
risk	O
of	O
CSPEB	B-DISO
.	O

Data	O
on	O
patient	B-LIVB
and	O
lesion	B-DISO
characteristics	O
and	O
outcomes	O
from	O
WF	B-PROC
-	I-PROC
EMRs	I-PROC
of	O
LSL	B-DISO
≥20	O
mm	O
at	O
8	O
referral	B-OBJC
hospitals	I-OBJC
were	O
analyzed	B-PROC
.	O

The	O
cohort	B-LIVB
was	O
divided	O
at	O
random	O
into	O
equal	O
sized	O
training	O
and	O
test	O
groups	O
.	O

Independent	O
predictors	O
of	O
CSPEB	B-DISO
in	O
the	O
training	B-LIVB
cohort	I-LIVB
were	O
identified	O
by	O
multiple	O
logistic	O
regression	O
analysis	O
and	O
used	O
to	O
develop	O
a	O
risk	O
score	O
.	O

The	O
performance	O
of	O
this	O
score	O
was	O
assessed	O
in	O
the	O
independent	O
test	B-LIVB
cohort	I-LIVB
.	O

Over	O
80	O
months	O
to	O
June	O
2015	O
,	O
2	O
,	O
128	O
patients	B-LIVB
with	O
2	O
,	O
424	O
LSL	B-DISO
were	O
referred	O
for	O
WF	B-PROC
-	I-PROC
EMR	I-PROC
.	O

Two	O
thousand	O
and	O
twelve	O
patients	B-LIVB
were	O
eligible	O
for	O
analysis	B-PROC
.	O

There	O
were	O
135	O
cases	O
of	O
CSPEB	B-DISO
(	O
6	O
.	O
7	O
%	O
)	O
.	O

In	O
the	O
training	B-LIVB
cohort	I-LIVB
of	O
1	O
,	O
006	O
patients	B-LIVB
,	O
the	O
independent	O
predictors	O
of	O
CSPEB	B-DISO
were	O
lesion	O
size	O
>	O
30	O
mm	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
2	O
.	O
5	O
)	O
,	O
proximal	O
colonic	O
location	O
(	O
OR	O
2	O
.	O
3	O
)	O
,	O
presence	O
of	O
a	O
major	O
comorbidity	O
(	O
OR	O
1	O
.	O
5	O
)	O
,	O
and	O
epinephrine	B-CHEM
in	O
injection	B-CHEM
solution	I-CHEM
(	O
OR	O
0	O
.	O
57	O
)	O
.	O

The	O
derived	O
risk	O
score	O
comprised	O
lesion	O
size	O
>	O
30	O
mm	O
(	O
2	O
points	O
)	O
,	O
proximal	O
colon	B-ANAT
(	O
2	O
points	O
)	O
,	O
presence	O
of	O
major	O
comorbidity	O
(	O
1	O
point	O
)	O
,	O
and	O
absence	O
of	O
epinephrine	B-CHEM
use	O
(	O
1	O
point	O
)	O
.	O

The	O
probabilities	O
of	O
CSPEB	B-DISO
for	O
scores	O
of	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
≥5	O
in	O
the	O
training	B-LIVB
cohort	I-LIVB
were	O
1	O
.	O
5	O
,	O
2	O
.	O
0	O
,	O
5	O
.	O
6	O
,	O
7	O
.	O
8	O
,	O
9	O
.	O
1	O
,	O
and	O
17	O
.	O

5	O
%	O
and	O
were	O
0	O
.	O
9	O
,	O
6	O
.	O
7	O
,	O
4	O
.	O
9	O
,	O
6	O
.	O
2	O
,	O
9	O
.	O
0	O
,	O
and	O
15	O
.	O
7	O
%	O
in	O
the	O
test	B-LIVB
cohort	I-LIVB
.	O

The	O
probabilities	O
of	O
CSPEB	B-DISO
in	O
those	O
with	O
low	O
(	O
score	O
0	O
-	O
1	O
)	O
,	O
medium	O
(	O
score	O
2	O
-	O
4	O
)	O
,	O
and	O
elevated	O
(	O
score	O
5	O
-	O
6	O
)	O
risk	B-DISO
levels	I-DISO
were	O
1	O
.	O
7	O
,	O
7	O
.	O
1	O
,	O
and	O
17	O
.	O

5	O
%	O
in	O
the	O
training	B-LIVB
cohort	I-LIVB
and	O
3	O
.	O
4	O
,	O
6	O
.	O
2	O
,	O
and	O
15	O
.	O

7	O
%	O
in	O
the	O
cohort	B-LIVB
.	O

Patients	B-LIVB
at	O
elevated	O
risk	O
of	O
CSPEB	B-DISO
can	O
be	O
identified	O
using	O
four	O
readily	O
available	O
variables	O
.	O

This	O
knowledge	O
may	O
improve	O
the	O
management	B-PROC
of	O
those	O
undergoing	O
WF	B-PROC
-	I-PROC
EMR	I-PROC
and	O
assist	O
in	O
designing	B-PROC
studies	I-PROC
evaluating	B-PROC
CSPEB	B-DISO
.	O

A	O
case	O
of	O
bilateral	O
pneumothoraces	B-DISO
resulting	O
from	O
tracheostomy	B-PROC
for	O
advanced	O
laryngeal	B-DISO
cancer	I-DISO
Pneumothorax	B-DISO
is	O
a	O
possible	O
complication	B-DISO
of	O
tracheostomy	B-PROC
.	O

We	O
report	B-PROC
a	O
rare	O
case	O
of	O
bilateral	O
pneumothoraces	B-DISO
resulting	O
from	O
tracheostomy	B-PROC
in	O
an	O
advanced	O
laryngeal	B-DISO
cancer	I-DISO
patient	B-LIVB
.	O

A	O
59	O
-	O
year	O
-	O
old	O
man	B-PHYS
was	O
referred	O
to	O
our	O
clinic	B-OBJC
for	O
evaluation	B-PROC
and	O
treatment	B-PROC
of	O
laryngeal	B-DISO
tumor	I-DISO
.	O

Laryngeal	B-PROC
endoscopy	I-PROC
showed	O
limited	B-DISO
movement	I-DISO
of	O
bilateral	B-ANAT
vocal	I-ANAT
cords	I-ANAT
,	O
and	O
computed	B-PROC
tomography	I-PROC
revealed	O
a	O
tumor	B-DISO
lesion	B-DISO
extending	O
from	O
the	O
vocal	B-ANAT
cords	I-ANAT
to	O
the	O
subglottic	B-ANAT
area	I-ANAT
.	O

Three	O
days	O
after	O
the	O
first	B-DISO
visit	I-DISO
,	O
the	O
patient	B-LIVB
developed	O
respiratory	B-DISO
difficulty	I-DISO
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	B-PROC
tracheostomy	I-PROC
for	O
airway	B-PROC
management	I-PROC
.	O

Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-PROC
,	O
he	O
began	O
hyperventilating	B-DISO
,	O
and	O
complained	O
of	O
respiratory	B-DISO
discomfort	I-DISO
and	O
chest	B-DISO
pain	I-DISO
.	O

We	O
then	O
recognized	O
a	O
mediastinal	B-ANAT
air	B-DISO
leak	I-DISO
,	O
and	O
we	O
suspected	O
pneumothorax	B-DISO
resulting	O
from	O
the	O
tracheostomy	B-PROC
.	O

Chest	B-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
showed	O
bilateral	O
pneumothoraces	B-DISO
;	O
therefore	O
,	O
we	O
inserted	B-PROC
bilateral	O
chest	B-ANAT
drainage	B-DEVI
tubes	I-DEVI
,	O
which	O
stabilized	B-DISO
his	O
respiratory	B-DISO
condition	I-DISO
.	O

We	O
speculated	O
that	O
the	O
pathogenesis	B-DISO
of	O
the	O
bilateral	O
pneumothoraces	B-DISO
was	O
weakened	O
alveolar	B-ANAT
walls	I-ANAT
secondary	O
to	O
long	O
-	O
term	O
smoking	O
,	O
and	O
a	O
significant	O
rise	O
in	O
airway	B-PHYS
pressure	I-PHYS
because	O
of	O
airway	B-DISO
constriction	I-DISO
by	O
the	O
neck	O
-	O
extended	O
position	O
and	O
hyperventilation	B-DISO
,	O
during	O
tracheostomy	B-PROC
.	O

Therapeutic	O
Review	O
of	O
Methylprednisolone	B-CHEM
Acetate	I-CHEM
Intra	I-CHEM
-	I-CHEM
Articular	I-CHEM
Injection	I-CHEM
in	O
the	O
Management	B-PROC
of	O
Osteoarthritis	B-DISO
of	I-DISO
the	I-DISO
Knee	I-DISO
-	O
Part	O
1	O
:	O
Clinical	O
Effectiveness	O
Intra	B-PROC
-	I-PROC
articular	I-PROC
(	I-PROC
IA	I-PROC
)	I-PROC
corticosteroid	I-PROC
injections	I-PROC
are	O
a	O
common	O
approach	O
in	O
the	O
management	B-PROC
of	O
osteoarthritis	B-DISO
(	I-DISO
OA	I-DISO
)	I-DISO
of	I-DISO
the	I-DISO
knee	I-DISO
.	O

The	O
effectiveness	O
of	O
injections	B-CHEM
and	O
particular	O
injection	B-CHEM
products	B-OBJC
is	O
often	O
discussed	O
and	O
debated	O
in	O
clinical	B-PHYS
arenas	I-PHYS
.	O

The	O
following	O
therapeutic	O
review	O
examines	O
the	O
evidence	O
for	O
intra	O
-	O
articular	O
methylprednisolone	B-CHEM
acetate	I-CHEM
(	I-CHEM
MPA	I-CHEM
)	I-CHEM
injections	I-CHEM
in	O
the	O
management	B-PROC
of	O
OA	B-DISO
knee	I-DISO
.	O

A	O
review	O
of	O
research	O
evidence	O
,	O
published	O
guidelines	O
and	O
clinical	O
literature	O
was	O
undertaken	O
following	O
an	O
electronic	O
database	O
and	O
relevant	O
literature	O
search	O
.	O

The	O
review	O
found	O
that	O
there	O
is	O
limited	O
evidence	O
which	O
indicates	O
that	O
a	O
single	O
dose	O
intra	O
-	O
articular	O
MPA	B-CHEM
injection	I-CHEM
can	O
provide	O
short	O
to	O
medium	O
term	O
benefits	O
for	O
pain	B-DISO
,	O
with	O
less	O
evidence	O
for	O
beneficial	O
effects	O
on	O
function	B-PHYS
or	O
stiffness	B-DISO
.	O

There	O
is	O
heterogeneity	O
across	O
studies	O
and	O
until	O
recently	O
,	O
most	O
studies	O
had	O
only	O
short	O
to	O
medium	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
periods	I-PROC
,	O
thus	O
limiting	O
the	O
evidence	O
available	O
on	O
longer	O
term	O
benefit	O
.	O

There	O
was	O
also	O
evidence	O
indicating	O
equivalent	O
overall	O
efficacy	O
of	O
MPA	B-CHEM
to	O
that	O
of	O
other	O
corticosteroid	B-CHEM
products	I-CHEM
.	O

Most	O
guideline	O
recommendations	O
concerning	O
IA	B-PROC
injections	I-PROC
for	O
OA	B-DISO
knee	I-DISO
have	O
drawn	O
on	O
evidence	O
from	O
pooled	O
data	O
for	O
several	O
corticosteroid	B-CHEM
products	I-CHEM
.	O

The	O
review	O
also	O
found	O
there	O
was	O
limited	O
reporting	O
of	O
the	O
incidence	O
of	O
adverse	B-DISO
events	I-DISO
in	O
most	O
studies	O
.	O

Overall	O
,	O
MPA	B-CHEM
shows	O
efficacy	O
for	O
symptom	B-DISO
relief	B-PROC
in	O
OA	B-DISO
knee	I-DISO
.	O

At	O
an	O
individual	B-LIVB
management	B-PROC
level	O
,	O
evidence	O
for	O
a	O
limited	O
duration	O
of	O
effect	O
needs	O
consideration	O
in	O
injections	B-CHEM
decisions	O
.	O

Furthermore	O
,	O
consensus	O
across	O
clinical	O
guidelines	O
suggests	O
that	O
the	O
management	B-PROC
of	O
OA	B-DISO
knee	I-DISO
should	O
be	O
individualized	O
to	O
a	O
person	B-LIVB
'	O
s	O
clinical	B-PHYS
history	I-PHYS
,	O
degree	O
of	O
disability	B-DISO
,	O
risk	B-DISO
factors	I-DISO
,	O
quality	O
of	O
life	O
and	O
personal	B-DISO
preferences	I-DISO
,	O
whereby	O
injecting	O
involves	O
a	O
shared	O
decision	O
and	O
forms	O
part	O
of	O
a	O
multimodal	B-PROC
approach	I-PROC
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
Ltd	O
.	O

Arsenic	B-CHEM
Triglutathione	I-CHEM
[	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
]	O
Transport	B-PHYS
by	O
Multidrug	B-CHEM
Resistance	I-CHEM
Protein	I-CHEM
1	I-CHEM
(	O
MRP1	B-CHEM
/	O
ABCC1	B-CHEM
)	O
Is	O
Selectively	O
Modified	O
by	O
Phosphorylation	B-PHYS
of	O
Tyr920	O
/	O
Ser921	O
and	O
Glycosylation	B-PHYS
of	O
Asn19	O
/	O
Asn23	O
The	O
ATP	B-CHEM
-	I-CHEM
binding	I-CHEM
cassette	I-CHEM
(	I-CHEM
ABC	I-CHEM
)	I-CHEM
transporter	I-CHEM
multidrug	B-CHEM
resistance	I-CHEM
protein	I-CHEM
1	I-CHEM
(	O
MRP1	B-CHEM
/	O
ABCC1	B-CHEM
)	O
is	O
responsible	O
for	O
the	O
cellular	B-ANAT
export	B-PHEN
of	O
a	O
chemically	O
diverse	O
array	O
of	O
xenobiotics	B-CHEM
and	O
endogenous	O
compounds	B-OBJC
.	O

Arsenic	B-CHEM
,	O
a	O
human	B-LIVB
carcinogen	B-CHEM
,	O
is	O
a	O
high	O
-	O
affinity	O
MRP1	B-CHEM
substrate	B-OBJC
as	O
arsenic	B-CHEM
triglutathione	I-CHEM
[	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
]	O
.	O

In	O
this	O
study	O
,	O
marked	O
differences	O
in	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transport	B-PHYS
kinetics	O
were	O
observed	O
between	O
MRP1	B-CHEM
-enriched	O
membrane	B-ANAT
vesicles	B-ANAT
prepared	O
from	O
human	B-LIVB
embryonic	B-ANAT
kidney	B-ANAT
293	B-ANAT
(	I-ANAT
HEK	I-ANAT
)	I-ANAT
(	O
Km	O
3	O
.	O
8	O
µM	O
and	O
Vmax	B-PHEN
307	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
and	O
HeLa	B-ANAT
(	O
Km	O
0	O
.	O

32	O
µM	O
and	O
Vmax	B-PHEN
42	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
cells	B-ANAT
.	O

Mutant	B-CHEM
MRP1	B-CHEM
lacking	O
N	O
-	O
linked	O
glycosylation	B-PHYS
[	O
Asn19	O
/	O
23	O
/	O
1006Gln	O
;	O
sugar	O
-	O
free	O
(	B-CHEM
SF	I-CHEM
)	I-CHEM
-	I-CHEM
MRP1	I-CHEM
]	O
expressed	B-PHYS
in	O
either	O
HEK293	B-ANAT
or	O
HeLa	B-ANAT
cells	I-ANAT
had	O
low	O
Km	O
and	O
Vmax	B-PHEN
values	O
for	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
,	O
similar	O
to	O
HeLa	B-ANAT
wild	I-ANAT
-	I-ANAT
type	I-ANAT
(	O
WT	O
)	O
MRP1	B-CHEM
.	O

When	O
prepared	O
in	O
the	O
presence	B-DISO
of	O
phosphatase	B-CHEM
inhibitors	I-CHEM
,	O
both	O
WT	B-CHEM
-	I-CHEM
and	O
SF	B-CHEM
-	I-CHEM
MRP1	I-CHEM
-enriched	O
membrane	B-ANAT
vesicles	B-ANAT
had	O
a	O
high	O
Km	O
value	O
for	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
(	O
3	O
-	O
6	O
µM	O
)	O
,	O
regardless	O
of	O
the	O
cell	B-ANAT
line	I-ANAT
.	O

Kinetic	B-DISO
parameters	I-DISO
of	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
for	O
HEK	B-ANAT
-	O
Asn19	B-CHEM
/	I-CHEM
23Gln	I-CHEM
-	I-CHEM
MRP1	I-CHEM
were	O
similar	O
to	O
those	O
of	O
HeLa	B-ANAT
/	O
HEK	B-ANAT
-	O
SF	B-CHEM
-	I-CHEM
MRP1	I-CHEM
and	O
HeLa	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O
MRP1	B-CHEM
,	O
whereas	O
those	O
of	O
single	O
glycosylation	B-PHYS
mutants	B-CHEM
were	O
like	O
those	O
of	O
HEK	B-ANAT
-	I-ANAT
WT	I-ANAT
-MRP1	O
.	O

Mutation	B-PHYS
of	O
19	O
potential	O
MRP1	O
phosphorylation	B-PHYS
sites	O
revealed	O
that	O
HEK	B-ANAT
-	O
Tyr920Phe	B-CHEM
/	I-CHEM
Ser921Ala	I-CHEM
-	I-CHEM
MRP1	I-CHEM
transported	B-PHYS
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
like	O
HeLa	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O
MRP1	B-CHEM
,	O
whereas	O
individual	O
HEK	B-ANAT
-	O
Tyr920Phe	B-CHEM
-	I-CHEM
and	O
-	O
Ser921Ala	B-CHEM
-	I-CHEM
MRP1	I-CHEM
mutants	B-CHEM
were	O
similar	O
to	O
HEK	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O
MRP1	B-CHEM
.	O

Together	O
,	O
these	O
results	B-DISO
suggest	O
that	O
Asn19	O
/	O
Asn23	O
glycosylation	B-PHYS
and	O
Tyr920	O
/	O
Ser921	O
phosphorylation	B-PHYS
are	O
responsible	O
for	O
altering	O
the	O
kinetics	O
of	O
MRP1	B-CHEM
-mediated	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transport	B-PHYS
.	O

The	O
kinetics	O
of	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transport	B-PHYS
by	O
HEK	B-ANAT
-	O
Asn19	O
/	O
23Gln	O
/	O
Tyr920Glu	O
/	O
Ser921Glu	O
were	O
similar	O
to	O
HEK	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O
MRP1	B-CHEM
,	O
indicating	O
that	O
the	O
phosphorylation	B-PHYS
-mimicking	O
substitutions	O
abrogated	O
the	O
influence	O
of	O
Asn19	O
/	O
23Gln	O
glycosylation	B-PHYS
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
cross	O
-	O
talk	O
between	O
MRP1	B-CHEM
glycosylation	B-PHYS
and	O
phosphorylation	B-PHYS
occurs	O
and	O
that	O
phosphorylation	B-PHYS
of	O
Tyr920	O
and	O
Ser921	O
can	O
switch	O
MRP1	B-CHEM
to	O
a	O
lower	O
-	O
affinity	O
,	O
higher	O
-	O
capacity	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transporter	B-CHEM
,	O
allowing	O
arsenic	B-CHEM
detoxification	B-PHYS
over	O
a	O
broad	O
concentration	O
range	O
.	O

Twelve	O
ways	O
to	O
confirm	O
targets	O
of	O
activity	B-CHEM
-	I-CHEM
based	I-CHEM
probes	I-CHEM
in	O
plants	B-LIVB
Activity	B-CHEM
-	I-CHEM
based	I-CHEM
probes	I-CHEM
are	O
powerful	O
tools	O
to	O
interrogate	O
the	O
functional	O
proteome	B-CHEM
.	O

Their	O
covalent	B-PHYS
and	O
often	O
irreversible	B-PROC
labeling	I-PROC
of	O
proteins	B-CHEM
facilitates	O
the	O
purification	B-PROC
,	O
identification	B-PROC
and	O
quantification	O
of	O
labeled	B-CHEM
proteins	B-CHEM
.	O

However	O
,	O
the	O
detection	B-PROC
of	O
labeled	B-CHEM
proteins	B-CHEM
often	O
requires	O
a	O
confirmation	B-DISO
,	O
especially	O
when	O
unexpected	B-DISO
proteins	B-CHEM
are	O
identified	O
,	O
or	O
to	O
unravel	O
fluorescent	B-PHEN
activity	I-PHEN
profiles	O
.	O

Here	O
,	O
we	O
review	O
twelve	O
approaches	O
towards	O
target	O
confirmation	O
,	O
grouped	O
in	O
approaches	O
by	O
direct	O
target	O
detection	B-DISO
,	O
target	O
expression	B-PHYS
or	O
target	O
depletion	O
.	O

We	O
discuss	O
their	O
proper	O
use	O
and	O
limitations	O
and	O
illustrate	O
these	O
approaches	O
with	O
examples	O
from	O
plant	O
science	O
.	O

Naphthohydroquinones	B-CHEM
,	O
naphthoquinones	B-CHEM
,	O
anthraquinones	B-CHEM
,	O
and	O
a	O
naphthohydroquinone	B-CHEM
dimer	B-CHEM
isolated	O
from	O
the	O
aerial	B-LIVB
parts	I-LIVB
of	O
Morinda	B-LIVB
parvifolia	I-LIVB
and	O
their	O
cytotoxic	B-DISO
effects	I-DISO
through	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
p53	O
Five	O
unknown	O
compounds	B-CHEM
,	O
morindaparvins	B-CHEM
C	I-CHEM
-	I-CHEM
G	I-CHEM
,	O
consisting	O
of	O
naphthohydroquinones	B-CHEM
,	O
a	O
naphthoquinone	B-CHEM
,	O
an	O
anthraquinone	B-CHEM
,	O
and	O
a	O
naphthohydroquinone	B-CHEM
dimer	B-CHEM
,	O
together	O
with	O
three	O
known	O
quinones	B-CHEM
and	O
seven	O
other	O
known	O
compounds	B-CHEM
,	O
were	O
isolated	O
from	O
the	O
aerial	B-LIVB
parts	I-LIVB
of	O
Morinda	B-LIVB
parvifolia	I-LIVB
.	O

The	O
structures	O
of	O
morindaparvins	B-CHEM
C	I-CHEM
,	O
D	B-CHEM
,	O
E	B-CHEM
,	O
F	B-CHEM
,	O
and	O
G	B-CHEM
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-PROC
or	O
X	B-PROC
-	I-PROC
ray	I-PROC
diffraction	I-PROC
analysis	I-PROC
as	O
methyl	B-CHEM
4	I-CHEM
-	I-CHEM
hydroxy	I-CHEM
-	I-CHEM
1	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
dimethoxy	I-CHEM
-	I-CHEM
naphthalene	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
carboxylate	I-CHEM
,	O
methyl	B-CHEM
4	I-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxy	I-CHEM
-	I-CHEM
1	I-CHEM
-	I-CHEM
methoxy	I-CHEM
-	I-CHEM
naphthalene	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
carboxylate	I-CHEM
,	O
3	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
6	I-CHEM
-	I-CHEM
methoxy	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
methoxycarbonyl	I-CHEM
-	I-CHEM
1	I-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
naphthoquinone	I-CHEM
,	O
1	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
dihydroxy	I-CHEM
-	I-CHEM
7	I-CHEM
-	I-CHEM
hydroxymethyl	I-CHEM
-	I-CHEM
anthraquinone	I-CHEM
,	O
and	O
dimethyl	B-CHEM
1	I-CHEM
,	I-CHEM
1	I-CHEM
'	I-CHEM
-	I-CHEM
dihydroxy	I-CHEM
-	I-CHEM
4	I-CHEM
,	I-CHEM
4	I-CHEM
'	I-CHEM
,	I-CHEM
7	I-CHEM
,	I-CHEM
7	I-CHEM
'	I-CHEM
-	I-CHEM
tetramethoxy	I-CHEM
-	I-CHEM
2	I-CHEM
,	I-CHEM
2	I-CHEM
'	I-CHEM
-	I-CHEM
binaphthalene	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
3	I-CHEM
'	I-CHEM
-	I-CHEM
dicarboxylate	I-CHEM
,	O
respectively	O
.	O

Naphthoquinones	B-CHEM
and	O
naphthohydroquinone	B-CHEM
dimers	B-CHEM
were	O
previously	O
unknown	O
in	O
the	O
genus	O
Morinda	B-LIVB
.	O

In	O
addition	O
,	O
the	O
compounds	B-CHEM
were	O
tested	O
for	O
cytotoxicity	B-DISO
against	O
four	O
human	B-LIVB
cancer	B-ANAT
cell	I-ANAT
lines	I-ANAT
HeLa	B-ANAT
,	O
A2780	B-ANAT
,	O
Ketr3	B-ANAT
and	O
MCF	B-ANAT
-	I-ANAT
7	I-ANAT
and	O
their	O
effects	O
on	O
p53	O
-	O
activated	O
transcription	B-PHYS
.	O

Three	O
naphthoquinones	B-CHEM
had	O
moderate	O
cytotoxic	B-DISO
effects	I-DISO
with	O
IC50	O
values	O
ranging	O
from	O
1	O
.	O

51	O
to	O
9	O
.	O

56	O
μM	O
,	O
through	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
p53	O
transcriptional	B-PHYS
activity	I-PHYS
.	O

Common	O
and	O
Uncommon	O
Anatomical	B-ANAT
Variants	I-ANAT
of	O
Intrahepatic	B-ANAT
Bile	I-ANAT
Ducts	I-ANAT
in	O
Magnetic	B-PROC
Resonance	I-PROC
Cholangiopancreatography	I-PROC
and	O
its	O
Clinical	B-DISO
Implication	I-DISO
Preoperative	O
knowledge	O
of	O
intrahepatic	B-ANAT
bile	I-ANAT
duct	I-ANAT
(	O
IHD	B-ANAT
)	O
anatomy	B-ANAT
is	O
critical	O
for	O
planning	O
liver	B-PROC
resections	I-PROC
,	O
liver	B-PROC
transplantations	I-PROC
and	O
complex	B-PROC
biliary	I-PROC
reconstructive	I-PROC
surgery	I-PROC
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
imaging	O
features	O
of	O
various	O
anatomical	B-ANAT
variants	I-ANAT
of	O
IHD	B-ANAT
using	O
magnetic	B-PROC
resonance	I-PROC
cholangio	I-PROC
-	I-PROC
pancreatography	I-PROC
(	O
MRCP	B-PROC
)	O
and	O
their	O
prevalence	O
in	O
our	O
population	B-LIVB
.	O

This	O
observational	O
clinical	B-PROC
evaluation	I-PROC
study	O
included	O
224	O
patients	B-LIVB
who	O
were	O
referred	O
for	O
MRCP	B-PROC
.	O

MRCP	B-PROC
was	O
performed	O
in	O
a	O
1	B-DEVI
.	I-DEVI
5	I-DEVI
-	I-DEVI
Tesla	I-DEVI
magnet	I-DEVI
(	O
Philips	O
)	O
with	O
SSH	B-PROC
MRCP	I-PROC
3DHR	O
and	O
SSHMRCP	B-PROC
rad	O
protocol	O
.	O

A	O
senior	O
radiologist	B-LIVB
assessed	O
the	O
biliary	B-ANAT
passage	O
for	O
anatomical	B-DISO
variations	I-DISO
.	O

The	O
branching	O
pattern	O
of	O
the	O
right	B-ANAT
hepatic	I-ANAT
duct	I-ANAT
(	O
RHD	B-ANAT
)	O
was	O
typical	O
in	O
55	O
.	O

3	O
%	O
of	O
subjects	B-LIVB
.	O

The	O
most	O
common	O
variant	B-ANAT
was	O
right	B-ANAT
posterior	I-ANAT
sectoral	I-ANAT
duct	I-ANAT
(	O
RPSD	B-ANAT
)	O
draining	O
into	O
the	O
left	B-ANAT
hepatic	I-ANAT
duct	I-ANAT
(	O
LHD	B-ANAT
)	O
in	O
27	O
.	O

6	O
%	O
of	O
subjects	B-LIVB
.	O

Trifurcation	O
pattern	O
was	O
noted	O
in	O
9	O
.	O

3	O
%	O
of	O
subjects	B-LIVB
.	O

In	O
4	O
%	O
of	O
subjects	B-LIVB
,	O
RPSD	B-ANAT
was	O
draining	O
into	O
the	O
common	B-ANAT
hepatic	I-ANAT
duct	I-ANAT
(	O
CHD	B-ANAT
)	O
and	O
in	O
0	O
.	O

8	O
%	O
of	O
subjects	B-LIVB
into	O
the	O
cystic	B-ANAT
duct	I-ANAT
.	O

Other	O
variants	B-ANAT
were	O
noted	O
in	O
2	O
.	O

6	O
%	O
of	O
subjects	B-LIVB
.	O

In	O
4	O
.	O
9	O
%	O
of	O
cases	O
there	O
was	O
an	O
accessory	B-DISO
duct	I-DISO
.	O

The	O
most	O
common	O
type	O
of	O
LHD	B-ANAT
branching	O
pattern	O
was	O
a	O
common	O
trunk	O
of	O
segment	O
2	O
and	O
3	O
ducts	B-ANAT
joining	O
the	O
segment	O
4	O
duct	B-ANAT
in	O
67	O
.	O

8	O
%	O
of	O
subjects	B-LIVB
.	O

In	O
23	O
.	O

2	O
%	O
of	O
subjects	B-LIVB
,	O
segment	O
2	O
duct	B-ANAT
united	O
with	O
the	O
common	O
trunk	O
of	O
segment	O
3	O
and	O
4	O
and	O
in	O
3	O
.	O

4	O
%	O
of	O
subjects	B-LIVB
segment	O
2	O
,	O
3	O
,	O
and	O
4	O
ducts	B-ANAT
united	O
together	O
to	O
form	O
LHD	B-ANAT
.	O

Other	O
uncommon	O
branching	O
patterns	O
of	O
LHD	B-ANAT
were	O
seen	O
in	O
4	O
.	O

9	O
%	O
of	O
subjects	B-LIVB
.	O

Intrahepatic	B-ANAT
bile	I-ANAT
duct	I-ANAT
anatomy	B-ANAT
is	O
complex	O
with	O
many	O
common	O
and	O
uncommon	O
variations	O
.	O

MRCP	B-PROC
is	O
a	O
reliable	O
non	O
-	O
invasive	O
imaging	B-PROC
method	I-PROC
for	O
demonstration	O
of	O
bile	B-ANAT
duct	I-ANAT
morpholog	O
y	O
,	O
which	O
is	O
useful	O
to	O
plan	O
complex	O
surgeries	B-PROC
and	O
to	O
prevent	O
iatrogenic	B-DISO
injuries	I-DISO
.	O

Cortical	B-ANAT
Reorganization	O
following	O
Injury	B-DISO
Early	O
in	O
Life	O
The	O
brain	B-ANAT
has	O
a	O
remarkable	O
capacity	O
for	O
reorganization	O
following	O
injury	B-DISO
,	O
especially	O
during	O
the	O
first	O
years	O
of	O
life	O
.	O

Knowledge	O
of	O
structural	O
reorganization	O
and	O
its	O
consequences	O
following	O
perinatal	B-DISO
injury	I-DISO
is	O
sparse	O
.	O

Here	O
we	O
studied	O
changes	O
in	O
brain	B-ANAT
tissue	I-ANAT
volume	O
,	O
morphology	O
,	O
perfusion	B-PROC
,	O
and	O
integrity	O
in	O
children	B-LIVB
with	O
hemiplegia	B-DISO
compared	O
to	O
typically	O
developing	O
children	B-LIVB
,	O
using	O
MRI	B-PROC
.	O

Children	B-LIVB
with	O
hemiplegia	B-DISO
demonstrated	O
reduced	B-DISO
total	I-DISO
cerebral	I-DISO
volume	I-DISO
,	O
with	O
increased	B-DISO
cerebrospinal	I-DISO
fluid	I-DISO
(	O
CSF	B-ANAT
)	O
and	O
reduced	B-DISO
total	I-DISO
white	I-DISO
matter	I-DISO
volumes	I-DISO
,	O
with	O
no	B-DISO
differences	I-DISO
in	O
total	O
gray	O
matter	O
volume	O
,	O
compared	O
to	O
typically	O
developing	O
children	B-LIVB
.	O

An	O
increase	O
in	O
cortical	B-ANAT
thickness	O
at	O
the	O
hemisphere	B-ANAT
contralateral	O
to	O
the	O
lesion	B-DISO
(	O
CLH	B-ANAT
)	O
was	O
detected	B-DISO
in	O
motor	B-ANAT
and	O
language	B-ANAT
areas	I-ANAT
,	O
which	O
may	O
reflect	O
compensation	O
for	O
the	O
gray	O
matter	O
loss	O
in	O
the	O
lesion	B-DISO
area	O
or	O
retention	O
of	O
ipsilateral	O
pathways	B-ANAT
.	O

In	O
addition	O
,	O
reduced	O
cortical	B-ANAT
thickness	O
,	O
perfusion	B-PROC
,	O
and	O
surface	O
area	O
were	O
detected	B-DISO
in	O
limbic	B-ANAT
areas	B-ANAT
.	O

Increased	B-DISO
CSF	I-DISO
volume	I-DISO
and	O
precentral	B-ANAT
cortical	I-ANAT
thickness	O
and	O
reduced	B-DISO
white	I-DISO
matter	I-DISO
volume	I-DISO
were	O
correlated	O
with	O
worse	O
motor	B-PHYS
performance	I-PHYS
.	O

Brain	B-ANAT
reorganization	O
of	O
the	O
gray	O
matter	O
within	O
the	O
CLH	B-ANAT
,	O
while	O
not	O
necessarily	O
indicating	O
better	O
outcome	O
,	O
is	O
suggested	O
as	O
a	O
response	O
to	O
neuronal	B-ANAT
deficits	O
following	O
injury	B-DISO
early	O
in	O
life	O
.	O

Simultaneous	O
Bilateral	O
Femur	B-DISO
Neck	I-DISO
Fracture	I-DISO
in	O
A	O
Young	B-LIVB
Adult	I-LIVB
with	O
Chronic	B-DISO
Renal	I-DISO
Failure	I-DISO
-	O
A	O
Case	O
Report	O
and	O
Review	O
of	O
Literature	O
Pathological	O
bilateral	O
femoral	B-DISO
neck	I-DISO
fracture	I-DISO
due	O
to	O
renal	B-DISO
osteodystrophy	I-DISO
is	O
rare	O
.	O

This	O
is	O
a	O
report	O
of	O
a	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
patient	B-LIVB
who	O
had	O
sustained	O
bilateral	O
intra	O
-	O
capsular	O
displaced	O
fracture	B-DISO
neck	I-DISO
of	I-DISO
femur	I-DISO
following	O
an	O
episode	O
of	O
convulsion	B-DISO
and	O
the	O
difficulties	B-PROC
encountered	I-PROC
in	O
early	B-PROC
diagnosis	I-PROC
and	O
treatment	B-PROC
.	O

The	O
pathophysiology	B-DISO
of	O
renal	B-DISO
osteodystrophy	I-DISO
and	O
the	O
treatment	B-PROC
of	O
hip	B-DISO
fractures	I-DISO
in	O
patients	B-LIVB
with	O
renal	B-DISO
failure	I-DISO
are	O
also	O
discussed	O
.	O

A	O
23	O
years	O
old	O
male	B-PHYS
patient	B-LIVB
admitted	O
with	O
h	B-DISO
/	I-DISO
o	I-DISO
dysuria	I-DISO
,	O
pyuria	B-DISO
and	O
loss	B-DISO
of	I-DISO
appetite	I-DISO
since	O
3	O
months	O
.	O

He	O
was	O
a	O
known	O
case	O
of	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
and	O
reflux	B-DISO
nephropathy	I-DISO
.	O

On	O
investigating	O
,	O
patient	B-LIVB
's	I-LIVB
renal	B-ANAT
parameters	O
were	O
high	O
and	O
he	O
was	O
started	O
with	O
haemodialysis	B-PROC
.	O

The	O
next	O
day	O
patient	B-LIVB
had	O
c	O
/	O
o	O
bilateral	O
hip	B-DISO
pain	I-DISO
and	O
inability	B-DISO
to	I-DISO
move	I-DISO
bilateral	O
lower	B-ANAT
limbs	I-ANAT
following	O
an	O
episode	O
of	O
seizure	B-DISO
.	O

Radiograph	B-PROC
of	I-PROC
pelvis	I-PROC
showed	O
vertical	B-DISO
sub	I-DISO
capital	I-DISO
fractures	I-DISO
of	O
bilateral	O
neck	B-ANAT
of	I-ANAT
femur	I-ANAT
.	O

In	O
this	O
patient	B-LIVB
,	O
considering	O
his	O
age	B-PHYS
,	O
general	B-DISO
condition	I-DISO
&	O
prognosis	B-PROC
,	O
an	O
elective	B-PROC
surgery	I-PROC
in	O
the	O
form	O
of	O
bilateral	O
uncemented	O
modular	O
bipolar	O
hemiarthroplasty	B-PROC
was	O
done	O
.	O

Overall	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
among	O
patients	B-LIVB
with	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
is	O
considerably	O
higher	O
than	O
in	O
the	O
general	B-LIVB
population	I-LIVB
,	O
independent	O
of	O
age	B-PHYS
and	O
gender	B-PHYS
.	O

Simultaneous	O
spontaneous	O
bilateral	O
fractures	B-DISO
of	I-DISO
the	I-DISO
femoral	I-DISO
neck	I-DISO
are	O
rare	O
and	O
a	O
delayed	O
diagnosis	O
is	O
usual	O
.	O

The	O
study	B-PROC
of	O
etiological	O
factors	O
of	O
these	O
fractures	B-DISO
is	O
essential	O
to	O
guide	O
us	O
in	O
choosing	O
the	O
treatment	B-PROC
of	O
choice	O
.	O

Obviously	O
patient	B-LIVB
's	I-LIVB
age	B-PHYS
,	O
life	O
expectancy	O
as	O
well	O
as	O
renal	O
co	O
morbidity	O
has	O
an	O
influence	O
over	O
deciding	O
treatment	B-PROC
and	O
outcome	O
.	O

Anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
and	O
antimicrobial	B-CHEM
coumarins	B-CHEM
from	O
the	O
stems	B-LIVB
of	O
Eurya	B-LIVB
chinensis	I-LIVB
Two	O
new	O
coumarins	B-CHEM
,	O
named	O
(	B-CHEM
±	I-CHEM
)	I-CHEM
-	I-CHEM
euryacoumarin	I-CHEM
A	I-CHEM
(	O
1	O
)	O
and	O
6	B-CHEM
-	I-CHEM
demethylobtusinin	I-CHEM
(	O
2	O
)	O
,	O
and	O
one	O
new	O
natural	B-CHEM
coumarin	I-CHEM
,	O
named	O
euryacoumarin	B-CHEM
B	I-CHEM
(	O
3	O
)	O
,	O
along	O
with	O
two	O
known	O
compounds	O
,	O
scopoletin	B-CHEM
(	O
4	O
)	O
and	O
obtusinol	B-CHEM
(	O
5	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	B-LIVB
of	O
Eurya	B-LIVB
chinensis	I-LIVB
.	O

Their	O
structures	O
were	O
elucidated	O
by	O
means	O
of	O
extensive	O
spectroscopic	B-PROC
methods	I-PROC
and	O
comparison	O
with	O
data	O
reported	O
in	O
the	O
literatures	O
.	O

Compound	B-CHEM
1	I-CHEM
exhibited	O
significant	O
inhibition	O
of	O
LPS	B-PHYS
-	I-PHYS
induced	I-PHYS
nitric	I-PHYS
oxide	I-PHYS
(	I-PHYS
NO	I-PHYS
)	I-PHYS
production	I-PHYS
in	O
RAW264	B-ANAT
.	I-ANAT

7	I-ANAT
cells	I-ANAT
with	O
IC50	O
value	O
of	O
35	O
.	O

64	O
±	O
1	O
.	O
73	O
μM	O
,	O
and	O
showed	O
marginal	O
antibacterial	B-CHEM
activities	O
against	O
Bacillus	B-LIVB
subtilis	I-LIVB
and	O
B	B-LIVB
.	I-LIVB

cereus	I-LIVB
with	O
MIC	B-PHEN
values	I-PHEN
of	O
50	O
.	O
59	O
±	O
2	O
.	O
12	O
and	O
35	O
.	O

42	O
±	O
0	O
.	O
96	O
μM	O
,	O
respectively	O
.	O

Extrapulmonary	B-DISO
Small	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
of	O
the	O
Seminal	B-ANAT
Vesicles	I-ANAT
and	O
Prostate	B-ANAT
Demonstrated	O
on	O
18F	B-PROC
-	I-PROC
FDG	I-PROC
Positron	I-PROC
Emission	I-PROC
Tomography	I-PROC
/	I-PROC
Computed	I-PROC
Tomography	I-PROC
Extrapulmonary	B-DISO
primary	I-DISO
small	I-DISO
cell	I-DISO
carcinomas	I-DISO
arising	O
from	O
the	O
urogenital	B-ANAT
tract	I-ANAT
is	O
infrequent	O
.	O

It	O
can	O
rarely	O
arise	O
from	O
the	O
prostate	B-ANAT
and	O
even	O
more	O
rarely	O
from	O
the	O
seminal	B-ANAT
vesicles	I-ANAT
.	O

We	O
present	O
a	O
79	O
-	O
year	O
-old	O
male	B-PHYS
who	O
was	O
admitted	B-PROC
due	O
to	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
with	O
a	O
history	B-DISO
of	O
radical	B-PROC
radiotherapy	I-PROC
for	O
prostate	B-DISO
adenocarcinoma	I-DISO
13	O
years	O
ago	O
.	O

The	O
prostate	B-CHEM
specific	I-CHEM
antigen	I-CHEM
level	O
was	O
not	O
elevated	O
.	O

An	O
abdominopelvic	B-PROC
computed	I-PROC
tomography	I-PROC
(	I-PROC
CT	I-PROC
)	I-PROC
scan	I-PROC
showed	O
markedly	O
enlarged	O
seminal	B-ANAT
vesicles	I-ANAT
causing	O
bilateral	B-ANAT
ureteral	I-ANAT
obstruction	B-DISO
and	O
a	O
mildly	O
enlarged	O
prostate	B-ANAT
.	O

Further	O
evaluation	O
with	O
fluorine	B-PROC
-	I-PROC
18	I-PROC
-	I-PROC
fluorodeoxyglucose	I-PROC
(	I-PROC
18F	I-PROC
-	I-PROC
FDG	I-PROC
)	I-PROC
positron	I-PROC
emission	I-PROC
tomography	I-PROC
/	I-PROC
CT	I-PROC
demonstrated	O
extensive	O
18F	B-CHEM
-	I-CHEM
FDG	I-CHEM
uptake	B-PHYS
in	O
the	O
pelvis	B-ANAT
with	O
diffuse	B-DISO
involvement	I-DISO
of	O
both	O
seminal	B-ANAT
vesicles	I-ANAT
and	O
the	O
prostate	B-ANAT
without	O
pathologic	O
uptake	B-PHYS
in	O
the	O
lungs	B-ANAT
or	O
elsewhere	O
in	O
the	O
body	B-LIVB
.	O

Core	B-PROC
biopsies	I-PROC
of	O
the	O
prostate	B-ANAT
and	O
both	O
seminal	B-ANAT
vesicles	I-ANAT
revealed	O
diffuse	B-DISO
involvement	I-DISO
by	O
small	B-DISO
cell	I-DISO
carcinoma	I-DISO
.	O

Therapy	B-PROC
could	O
not	O
be	O
instituted	O
due	O
to	O
a	O
rapid	O
deterioration	B-PHEN
in	O
the	O
patient	B-LIVB
's	I-LIVB
clinical	O
condition	O
.	O

Phosphodiesterase	B-CHEM
Type	I-CHEM
5	I-CHEM
Inhibitors	I-CHEM
and	O
Risk	O
of	O
Malignant	B-DISO
Melanoma	I-DISO
:	O
Matched	B-PROC
Cohort	O
Study	O
Using	O
Primary	B-PROC
Care	I-PROC
Data	O
from	O
the	O
UK	B-GEOG
Clinical	O
Practice	O
Research	O
Datalink	O
Laboratory	B-OBJC
evidence	O
suggests	O
that	O
reduced	O
phosphodiesterase	B-CHEM
type	I-CHEM
5	I-CHEM
(	O
PDE5	B-CHEM
)	O
expression	B-PHYS
increases	O
the	O
invasiveness	B-DISO
of	O
melanoma	B-ANAT
cells	I-ANAT
;	O
hence	O
,	O
pharmacological	O
inhibition	B-PHYS
of	O
PDE5	B-CHEM
could	O
affect	O
melanoma	B-DISO
risk	O
.	O

Two	O
major	O
epidemiological	B-PROC
studies	I-PROC
have	O
investigated	O
this	O
and	O
come	O
to	O
differing	O
conclusions	O
.	O

We	O
therefore	O
aimed	O
to	O
investigate	O
whether	O
PDE5	B-CHEM
inhibitor	I-CHEM
use	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
malignant	B-DISO
melanoma	I-DISO
,	O
and	O
whether	O
any	O
increase	O
in	O
risk	O
is	O
likely	O
to	O
represent	O
a	O
causal	O
relationship	O
.	O

We	O
conducted	O
a	O
matched	B-PROC
cohort	O
study	O
using	O
primary	B-PROC
care	I-PROC
data	O
from	O
the	O
UK	B-GEOG
Clinical	O
Practice	O
Research	O
Datalink	O
.	O

All	O
men	B-LIVB
initiating	O
a	O
PDE5	B-CHEM
inhibitor	I-CHEM
and	O
with	O
no	O
prior	O
cancer	B-PROC
diagnosis	I-PROC
were	O
identified	O
and	O
matched	O
on	O
age	B-PHYS
,	O
diabetes	B-DISO
status	I-DISO
,	O
and	O
general	O
practice	O
to	O
up	O
to	O
four	O
unexposed	B-LIVB
controls	I-LIVB
.	O

Ever	O
use	O
of	O
a	O
PDE5	B-CHEM
inhibitor	I-CHEM
and	O
time	O
-	O
updated	O
cumulative	O
number	O
of	O
PDE5	B-CHEM
inhibitor	I-CHEM
prescriptions	O
were	O
investigated	O
as	O
exposures	B-DISO
,	O
and	O
the	O
primary	O
outcome	O
was	O
malignant	B-DISO
melanoma	I-DISO
.	O

Basal	B-DISO
cell	I-DISO
carcinoma	I-DISO
,	O
solar	B-DISO
keratosis	I-DISO
,	O
and	O
colorectal	B-DISO
cancer	I-DISO
were	O
investigated	O
as	O
negative	O
control	O
outcomes	B-PROC
to	O
exclude	O
bias	O
.	O

Hazard	O
ratios	O
(	O
HRs	O
)	O
were	O
estimated	O
from	O
Cox	O
models	O
stratified	O
by	O
matched	O
set	O
and	O
adjusted	O
for	O
potential	O
confounders	O
.	O

145	O
,	O
104	O
men	B-LIVB
with	O
≥1	O
PDE5	B-CHEM
inhibitor	I-CHEM
prescription	O
,	O
and	O
560	O
,	O
933	O
unexposed	B-LIVB
matched	I-LIVB
controls	I-LIVB
were	O
included	O
.	O

In	O
total	O
,	O
1	O
,	O
315	O
incident	B-PHEN
malignant	B-DISO
melanoma	I-DISO
diagnoses	B-DISO
were	O
observed	O
during	O
3	O
.	O
44	O
million	O
person	O
-	O
years	O
of	O
follow	B-PROC
-	I-PROC
up	I-PROC
(	O
mean	O
4	O
.	O

9	O
y	O
per	O
person	O
)	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
there	O
was	O
weak	O
evidence	O
of	O
a	O
small	O
positive	O
association	O
between	O
PDE5	B-CHEM
inhibitor	I-CHEM
use	O
and	O
melanoma	B-DISO
risk	O
(	O
HR	O
=	O
1	O
.	O
14	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
1	O
.	O
29	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O

A	O
similar	O
increase	O
in	O
risk	O
was	O
seen	O
for	O
the	O
two	O
negative	O
control	O
outcomes	B-PROC
related	O
to	O
sun	B-DISO
exposure	I-DISO
(	O
HR	O
=	O
1	O
.	O
15	O
,	O
95	O
%	O
CI	O
1	O
.	O
11	O
-	O
1	O
.	O
19	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
for	O
basal	B-DISO
cell	I-DISO
carcinoma	I-DISO
;	O
HR	O
=	O
1	O
.	O
21	O
,	O
95	O
%	O
CI	O
1	O
.	O
17	O
-	O
1	O
.	O
25	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
for	O
solar	B-DISO
keratosis	I-DISO
)	O
,	O
but	O
there	O
was	O
no	O
increased	O
risk	O
for	O
colorectal	B-DISO
cancer	I-DISO
(	O
HR	O
=	O
0	O
.	O
91	O
,	O
95	O
%	O
CI	O
0	O
.	O
85	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
no	O
evidence	O
that	O
risk	O
increased	O
with	O
number	O
of	O
prescriptions	O
received	O
(	O
p	O
-	O
trend	O
=	O
0	O
.	O

83	O
)	O
.	O

In	O
a	O
post	B-PROC
hoc	I-PROC
analysis	I-PROC
,	O
there	O
was	O
strong	O
evidence	O
that	O
solar	B-DISO
keratosis	I-DISO
was	O
associated	O
with	O
future	O
PDE5	B-CHEM
inhibitor	I-CHEM
use	O
(	O
odds	O
ratio	O
=	O
1	O
.	O
28	O
,	O
95	O
%	O
CI	O
1	O
.	O
23	O
-	O
1	O
.	O

34	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O

suggesting	O
that	O
men	B-LIVB
with	O
higher	O
sun	B-DISO
exposure	I-DISO
were	O
more	O
likely	O
to	O
become	O
PDE5	B-CHEM
inhibitor	I-CHEM
users	B-LIVB
.	O

However	O
,	O
a	O
limitation	O
of	O
our	O
study	B-PROC
was	O
that	O
we	O
did	O
not	O
have	O
individual	O
-	O
level	O
data	O
on	O
sun	B-DISO
exposure	I-DISO
,	O
so	O
we	O
could	O
not	O
directly	O
control	O
for	O
this	O
in	O
the	O
primary	B-PROC
analysis	I-PROC
.	O

Our	O
results	O
were	O
not	O
consistent	O
with	O
PDE5	B-CHEM
inhibitors	I-CHEM
being	O
causally	O
associated	O
with	O
melanoma	B-DISO
risk	O
,	O
and	O
strongly	O
suggest	O
that	O
observed	O
risk	O
increases	O
are	O
driven	O
by	O
greater	O
sun	B-DISO
exposure	I-DISO
among	O
patients	B-LIVB
exposed	O
to	O
a	O
PDE5	B-CHEM
inhibitor	I-CHEM
.	O

Parent	B-LIVB
-	O
Youth	B-LIVB
Differences	O
in	O
Familism	O
Values	O
from	O
Adolescence	O
into	O
Young	B-LIVB
Adulthood	I-LIVB
:	O
Developmental	O
Course	O
and	O
Links	O
with	O
Parent	B-LIVB
-	O
Youth	B-LIVB
Conflict	O
A	O
critical	O
step	O
in	O
capturing	B-PROC
family	I-PROC
processes	I-PROC
is	O
to	O
incorporate	O
the	O
perspectives	O
and	O
experiences	B-PHYS
of	O
multiple	O
family	B-LIVB
members	I-LIVB
toward	O
characterizing	O
how	O
families	B-LIVB
operate	O
as	O
systems	B-LIVB
.	O

Although	O
some	O
research	B-PROC
has	O
examined	B-DISO
differences	O
between	O
parents	B-LIVB
'	I-LIVB
and	O
youth	B-LIVB
's	I-LIVB
family	B-LIVB
experiences	B-PHYS
,	O
most	O
studies	B-PROC
have	O
focused	O
on	O
European	B-LIVB
American	I-LIVB
families	B-LIVB
,	O
and	O
we	O
know	O
little	O
about	O
the	O
nature	O
and	O
implications	O
of	O
divergent	O
parent	B-LIVB
-	O
youth	B-LIVB
experiences	B-PHYS
in	O
other	O
ethnic	B-LIVB
groups	I-LIVB
.	O

Accordingly	O
,	O
we	O
focused	O
on	O
Mexican	B-LIVB
-origin	O
families	B-LIVB
and	O
assessed	O
the	O
links	O
between	O
mother	B-LIVB
-	O
youth	B-LIVB
and	O
father	B-LIVB
-	O
youth	B-LIVB
differences	O
in	O
familism	O
values	O
and	O
parent	B-LIVB
-	O
youth	B-LIVB
conflict	O
from	O
early	O
adolescence	O
into	O
young	B-LIVB
adulthood	I-LIVB
.	O

Participants	B-LIVB
were	O
mothers	B-LIVB
,	O
fathers	B-LIVB
,	O
and	O
two	O
siblings	B-LIVB
(	O
248	O
female	B-LIVB
and	O
244	O
male	B-LIVB
,	O
51	O
%	O
female	B-LIVB
;	O
M	O
age	B-PHYS
=	O
14	O
.	O
02	O
years	O
)	O
from	O
246	O
families	B-LIVB
who	O
were	O
interviewed	O
in	O
their	O
homes	O
on	O
three	O
occasions	O
over	O
8	O
years	O
.	O

We	O
operationalized	O
parent	B-LIVB
-	O
youth	B-LIVB
differences	O
in	O
familism	O
values	O
using	O
difference	O
scores	O
,	O
controlling	O
for	O
mean	O
levels	O
of	O
familism	O
.	O

Multilevel	O
models	O
revealed	O
that	O
mothers	B-LIVB
'	O
and	O
fathers	B-LIVB
'	O
familism	O
values	O
remained	O
relatively	O
stable	O
over	O
time	O
,	O
but	O
youth	B-LIVB
's	I-LIVB
familism	O
values	O
declined	O
until	O
age	B-PHYS
17	O
,	O
stabilized	B-DISO
,	O
and	O
then	O
increased	O
slightly	O
in	O
young	B-LIVB
adulthood	I-LIVB
.	O

Lagged	O
models	O
tested	O
directions	O
of	O
effect	O
by	O
examining	B-DISO
whether	O
parent	B-LIVB
-	O
youth	B-LIVB
differences	O
in	O
familism	O
values	O
predicted	O
parent	B-LIVB
-	O
youth	B-LIVB
conflict	O
or	O
vice	O
versa	O
.	O

The	O
findings	B-DISO
revealed	O
that	O
parent	B-LIVB
-	O
youth	B-LIVB
conflict	O
predicted	O
greater	O
differences	O
in	O
parent	B-LIVB
-	O
youth	B-LIVB
familism	O
values	O
,	O
but	O
differences	O
in	O
familism	O
values	O
did	O
not	O
predict	O
conflict	O
.	O

Our	O
findings	B-DISO
align	O
with	O
a	O
family	B-LIVB
systems	I-LIVB
perspective	O
in	O
documenting	B-PROC
the	O
significance	O
of	O
differences	O
between	O
family	B-LIVB
members	I-LIVB
'	O
perspectives	O
and	O
highlighting	O
that	O
such	O
processes	B-PHEN
are	O
dynamic	O
.	O

Further	O
,	O
by	O
testing	O
bi	O
-	O
directional	O
associations	O
in	O
longitudinal	O
models	O
,	O
we	O
were	O
able	O
to	O
disentangle	O
the	O
temporal	O
ordering	O
of	O
differences	O
in	O
familism	O
values	O
and	O
parent	B-LIVB
-	O
youth	B-LIVB
conflict	O
thereby	O
advancing	O
understanding	B-PHYS
of	O
parent	B-LIVB
-	O
youth	B-LIVB
discrepancies	B-DISO
in	O
cultural	O
values	O
.	O

Low	O
Soluble	O
Syndecan	B-CHEM
-	I-CHEM
1	I-CHEM
Precedes	O
Preeclampsia	B-DISO
Syndecan	B-CHEM
-	I-CHEM
1	I-CHEM
(	O
Sdc1	B-CHEM
;	O
CD138	B-CHEM
)	O
is	O
a	O
major	O
transmembrane	B-CHEM
heparan	I-CHEM
sulfate	I-CHEM
proteoglycan	I-CHEM
expressed	B-PHYS
on	O
the	O
extracellular	B-ANAT
,	O
luminal	O
surface	O
of	O
epithelial	B-ANAT
cells	I-ANAT
and	O
syncytiotrophoblast	B-ANAT
,	O
thus	O
comprising	O
a	O
major	O
component	O
of	O
the	O
glycocalyx	B-ANAT
of	O
these	O
cells	B-ANAT
.	O

The	O
""""	O
soluble	O
""""	O
(	O
shed	O
)	O
form	O
of	O
Sdc1	B-CHEM
has	O
paracrine	B-PHYS
and	O
autocrine	B-PHYS
functions	I-PHYS
and	O
is	O
normally	O
produced	O
in	O
a	O
regulated	O
fashion	O
.	O

We	O
compared	O
plasma	B-ANAT
soluble	O
Sdc1	B-CHEM
concentrations	O
,	O
in	O
relation	O
to	O
placental	B-ANAT
Sdc1	B-CHEM
expression	B-PHYS
,	O
in	O
uncomplicated	B-DISO
(	O
control	B-LIVB
)	O
and	O
preeclamptic	B-DISO
pregnancies	B-PHYS
.	O

We	O
evaluated	O
soluble	O
Sdc1	B-CHEM
across	O
uncomplicated	B-DISO
pregnancy	I-DISO
,	O
and	O
between	O
preeclamptic	B-DISO
,	O
gestational	B-DISO
hypertensive	I-DISO
and	O
control	B-LIVB
patients	B-LIVB
at	O
mid	O
-	O
pregnancy	O
(	O
20	O
weeks	O
)	O
and	O
3rd	O
trimester	O
by	O
ELISA	B-PROC
.	O

Placental	B-ANAT
expression	B-PHYS
level	O
of	O
Sdc1	B-CHEM
was	O
compared	O
between	O
groups	B-LIVB
in	O
relation	O
to	O
pre	O
-	O
delivery	O
plasma	B-ANAT
soluble	O
Sdc1	B-CHEM
.	O

Participants	B-LIVB
were	O
recruited	O
from	O
Magee	B-OBJC
-	I-OBJC
Womens	I-OBJC
Hospital	I-OBJC
.	O

In	O
uncomplicated	B-DISO
pregnancy	I-DISO
,	O
plasma	B-ANAT
soluble	O
Sdc1	B-CHEM
rose	O
significantly	O
in	O
the	O
1st	O
trimester	O
,	O
and	O
reached	O
an	O
approximate	O
50	O
-	O
fold	O
increase	O
at	O
term	O
compared	O
to	O
post	O
pregnancy	O
levels	O
.	O

Soluble	O
Sdc1	B-CHEM
was	O
lower	O
at	O
mid	O
-	O
pregnancy	O
in	O
women	B-LIVB
who	O
later	O
developed	O
preeclampsia	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
not	O
gestational	B-DISO
hypertension	I-DISO
,	O
compared	O
to	O
controls	B-LIVB
,	O
and	O
remained	O
lower	O
at	O
late	B-DISO
pregnancy	I-DISO
in	O
preeclampsia	B-DISO
(	O
P	O
<	O
0	O
.	O
01	O
)	O
compared	O
to	O
controls	B-LIVB
.	O

Sdc1	B-CHEM
was	O
prominently	O
expressed	B-PHYS
on	O
syncytiotrophoblast	B-ANAT
of	O
microvilli	B-ANAT
.	O

Syncytiotrophoblast	B-ANAT
Sdc1	B-CHEM
immunostaining	B-PROC
intensities	I-PROC
,	O
and	O
mRNA	B-CHEM
content	O
in	O
villous	O
homogenates	O
,	O
were	O
lower	O
in	O
preeclampsia	B-DISO
vs	O
.	O

controls	B-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Soluble	O
Sdc1	B-CHEM
and	O
Sdc1	B-CHEM
immunostaining	B-PROC
scores	O
were	O
inversely	O
associated	O
with	O
systolic	B-PHYS
blood	I-PHYS
pressures	I-PHYS
,	O
and	O
positively	O
correlated	O
with	O
infant	B-LIVB
birth	B-PHYS
weight	I-PHYS
percentile	O
.	O

Soluble	O
Sdc1	B-CHEM
is	O
significantly	O
lower	O
before	O
the	O
clinical	O
onset	O
of	O
preeclampsia	B-DISO
,	O
with	O
reduced	O
expression	B-PHYS
of	O
Sdc1	B-CHEM
in	O
the	O
delivered	B-DISO
placenta	B-ANAT
,	O
suggesting	O
a	O
role	O
for	O
glycocalyx	B-ANAT
disturbance	O
in	O
preeclampsia	B-DISO
pathophysiology	B-DISO
.	O

Identification	B-PHYS
and	O
SAR	O
Evaluation	B-PROC
of	O
Hemozoin	B-CHEM
-	O
Inhibiting	O
Benzamides	B-CHEM
Active	O
against	O
Plasmodium	O
falciparum	O
Quinoline	B-CHEM
antimalarials	B-CHEM
target	O
hemozoin	B-CHEM
formation	O
causing	O
a	O
cytotoxic	O
accumulation	B-DISO
of	O
ferriprotoporphyrin	B-CHEM
IX	I-CHEM
(	O
Fe	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
PPIX	I-CHEM
)	O
.	O

Well	O
-	O
developed	O
SAR	O
models	O
exist	O
for	O
β	B-CHEM
-	I-CHEM
hematin	I-CHEM
inhibition	O
,	O
parasite	O
activity	O
,	O
and	O
cellular	B-PHYS
mechanisms	I-PHYS
for	O
this	O
compound	O
class	O
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-DISO
exist	O
for	O
other	O
hemozoin	B-CHEM
inhibiting	O
chemotypes	B-CHEM
.	O

Here	O
,	O
benzamide	B-CHEM
analogues	B-CHEM
based	O
on	O
previous	O
HTS	B-PROC
hits	O
have	O
been	O
purchased	O
or	O
synthesized	O
.	O

Only	O
derivatives	B-CHEM
containing	I-CHEM
an	I-CHEM
electron	I-CHEM
deficient	I-CHEM
aromatic	I-CHEM
ring	I-CHEM
and	O
capable	O
of	O
adopting	O
flat	O
conformations	O
,	O
optimal	O
for	O
π	O
-	O
π	O
interactions	O
with	O
Fe	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
PPIX	I-CHEM
,	O
inhibited	O
β	B-CHEM
-	I-CHEM
hematin	I-CHEM
formation	O
.	O

The	O
two	O
most	O
potent	O
analogues	B-CHEM
showed	O
nanomolar	O
parasite	O
activity	O
,	O
with	O
little	O
CQ	B-CHEM
cross	B-DISO
-	I-DISO
resistance	I-DISO
,	O
low	O
cytotoxicity	B-DISO
,	O
and	O
high	O
in	O
vitro	O
microsomal	O
stability	O
.	O

Selected	O
analogues	B-CHEM
inhibited	O
hemozoin	B-CHEM
formation	O
in	O
Plasmodium	O
falciparum	O
causing	O
high	O
levels	O
of	O
free	O
heme	B-CHEM
.	O

In	O
contrast	O
to	O
quinolines	B-CHEM
,	O
introduction	O
of	O
amine	B-CHEM
side	I-CHEM
chains	I-CHEM
did	O
not	O
lead	O
to	O
benzamide	B-CHEM
accumulation	B-DISO
in	O
the	O
parasite	O
.	O

These	O
data	O
reveal	O
complex	O
relationships	O
between	O
heme	B-PHYS
binding	I-PHYS
,	O
free	O
heme	B-CHEM
levels	O
,	O
cellular	B-PHYS
accumulation	I-PHYS
,	O
and	O
in	O
vitro	O
activity	O
of	O
potential	O
novel	O
antimalarials	B-CHEM
.	O

Synthesis	O
and	O
Photophysical	B-PHYS
Properties	I-PHYS
of	O
Fluorescence	B-PHEN
Molecular	B-CHEM
Probe	I-CHEM
for	O
Turn	B-PROC
-	I-PROC
ON	I-PROC
-	I-PROC
Type	I-PROC
Detection	I-PROC
of	O
Cytosine	B-CHEM
Bulge	I-CHEM
DNA	B-CHEM
A	O
fluorescent	B-CHEM
molecule	I-CHEM
DANP	I-CHEM
that	O
binds	O
to	O
cytosine	B-CHEM
bulge	I-CHEM
DNA	B-CHEM
and	O
emits	O
characteristic	O
fluorescence	B-PHEN
was	O
conjugated	O
to	O
pyrene	B-CHEM
to	O
give	O
a	O
new	O
fluorescence	B-CHEM
probe	I-CHEM
PyDANP	I-CHEM
.	O

Temperature	O
-	O
and	O
solvent	B-CHEM
-dependent	O
absorption	O
changes	O
showed	O
that	O
DANP	B-CHEM
and	O
pyrene	B-CHEM
chromophores	I-CHEM
stacked	O
at	O
room	B-DISO
temperature	I-DISO
in	O
an	O
aqueous	B-CHEM
buffer	I-CHEM
solution	I-CHEM
and	O
quenched	B-PROC
fluorescence	I-PROC
.	O

Upon	O
binding	O
of	O
DANP	B-CHEM
moiety	O
in	O
PyDANP	B-CHEM
to	O
cytosine	B-CHEM
bulge	I-CHEM
DNA	B-CHEM
,	O
the	O
fluorescence	B-PHEN
from	O
DANP	B-CHEM
bound	O
to	O
C	B-CHEM
-	I-CHEM
bulge	I-CHEM
increased	O
by	O
∼12	O
-	O
fold	O
,	O
showing	O
that	O
PyDANP	B-CHEM
is	O
a	O
turn	B-PROC
-	I-PROC
ON	I-PROC
probe	I-PROC
for	I-PROC
the	I-PROC
detection	I-PROC
of	O
C	B-CHEM
-	I-CHEM
bulge	I-CHEM
DNA	B-CHEM
.	I-CHEM

Bispectral	B-PROC
pairwise	I-PROC
interacting	I-PROC
source	I-PROC
analysis	I-PROC
for	O
identifying	O
systems	O
of	O
cross	O
-	O
frequency	O
interacting	O
brain	B-ANAT
sources	B-DISO
from	O
electroencephalographic	B-PROC
or	O
magnetoencephalographic	B-PROC
signals	B-PHEN
Brain	B-ANAT
cognitive	B-PHYS
functions	I-PHYS
arise	O
through	O
the	O
coordinated	B-PHYS
activity	I-PHYS
of	O
several	O
brain	B-ANAT
regions	I-ANAT
,	O
which	O
actually	O
form	O
complex	O
dynamical	O
systems	O
operating	O
at	O
multiple	O
frequencies	O
.	O

These	O
systems	O
often	O
consist	O
of	O
interacting	O
subsystems	O
,	O
whose	O
characterization	O
is	O
of	O
importance	O
for	O
a	O
complete	O
understanding	O
of	O
the	O
brain	B-PHYS
interaction	I-PHYS
processes	I-PHYS
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
present	O
a	O
technique	O
,	O
namely	O
the	O
bispectral	B-PROC
pairwise	I-PROC
interacting	I-PROC
source	I-PROC
analysis	I-PROC
(	O
biPISA	B-PROC
)	O
,	O
for	O
analyzing	O
systems	O
of	O
cross	O
-	O
frequency	O
interacting	O
brain	B-ANAT
sources	B-DISO
when	O
multichannel	B-PROC
electroencephalographic	I-PROC
(	O
EEG	B-PROC
)	O
or	O
magnetoencephalographic	B-PROC
(	O
MEG	B-PROC
)	O
data	O
are	O
available	O
.	O

Specifically	O
,	O
the	O
biPISA	B-PROC
makes	O
it	O
possible	O
to	O
identify	O
one	O
or	O
many	O
subsystems	O
of	O
cross	O
-	O
frequency	O
interacting	O
sources	B-DISO
by	O
decomposing	O
the	O
antisymmetric	O
components	O
of	O
the	O
cross	B-PROC
-	I-PROC
bispectra	I-PROC
between	O
EEG	B-PROC
or	O
MEG	B-PROC
signals	B-PHEN
,	O
based	O
on	O
the	O
assumption	O
that	O
interactions	O
are	O
pairwise	O
.	O

Thanks	O
to	O
the	O
properties	O
of	O
the	O
antisymmetric	O
components	O
of	O
the	O
cross	B-PROC
-	I-PROC
bispectra	I-PROC
,	O
biPISA	B-PROC
is	O
also	O
robust	O
to	O
spurious	O
interactions	O
arising	O
from	O
mixing	O
artifacts	O
,	O
i	O
.	O

e	O
.	O
,	O
volume	O
conduction	O
or	O
field	O
spread	O
,	O
which	O
always	O
affect	O
EEG	B-PROC
or	O
MEG	B-PROC
functional	O
connectivity	O
estimates	O
.	O

This	O
method	O
is	O
an	O
extension	O
of	O
the	O
pairwise	B-PROC
interacting	I-PROC
source	I-PROC
analysis	I-PROC
(	I-PROC
PISA	I-PROC
)	I-PROC
,	O
which	O
was	O
originally	O
introduced	O
for	O
investigating	O
interactions	O
at	O
the	O
same	O
frequency	O
,	O
to	O
the	O
study	O
of	O
cross	O
-	O
frequency	O
interactions	O
.	O

The	O
effectiveness	O
of	O
this	O
approach	O
is	O
demonstrated	O
in	O
simulations	B-PROC
for	O
up	O
to	O
three	O
interacting	O
source	O
pairs	O
and	O
for	O
real	O
MEG	B-PROC
recordings	O
of	O
spontaneous	O
brain	B-PHYS
activity	I-PHYS
.	O

Simulations	B-PROC
show	O
that	O
the	O
performances	O
of	O
biPISA	B-PROC
in	O
estimating	O
the	O
phase	O
difference	O
between	O
the	O
interacting	O
sources	B-DISO
are	O
affected	O
by	O
the	O
increasing	O
level	O
of	O
noise	B-PHEN
rather	O
than	O
by	O
the	O
number	O
of	O
the	O
interacting	O
subsystems	O
.	O

The	O
analysis	B-PROC
of	O
real	O
MEG	B-PROC
data	O
reveals	O
an	O
interaction	O
between	O
two	O
pairs	O
of	O
sources	B-DISO
of	O
central	B-PHYS
mu	I-PHYS
and	O
beta	B-PHYS
rhythms	I-PHYS
,	O
localizing	O
in	O
the	O
proximity	O
of	O
the	O
left	B-ANAT
and	O
right	B-ANAT
central	I-ANAT
sulci	I-ANAT
.	O

Shear	O
modulus	O
of	O
structured	O
electrorheological	B-OBJC
fluid	I-OBJC
mixtures	B-OBJC
Some	O
immiscible	B-OBJC
blends	I-OBJC
under	O
a	O
strong	O
electric	B-PHEN
field	I-PHEN
often	O
exhibit	O
periodic	O
structures	O
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	B-DEVI
.	O

Upon	O
shear	B-PHEN
,	O
the	O
structures	O
tilt	O
,	O
and	O
exhibit	O
an	O
elastic	O
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric	B-PHEN
energy	I-PHEN
.	O

Assuming	O
a	O
two	O
-	O
dimensional	O
stripe	O
structure	O
,	O
we	O
calculate	O
the	O
Maxwell	B-PHEN
stress	I-PHEN
,	O
and	O
derive	O
an	O
expression	O
for	O
the	O
shear	O
modulus	O
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric	B-PHEN
field	I-PHEN
,	O
the	O
composition	B-PHEN
,	O
and	O
the	O
dielectric	O
properties	O
of	O
the	O
blend	B-OBJC
.	O

We	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial	B-PHEN
tension	I-PHEN
,	O
which	O
renormalizes	O
the	O
effect	O
of	O
the	O
electric	B-PHEN
field	I-PHEN
.	O

This	O
leads	O
to	O
a	O
simple	O
derivation	O
of	O
the	O
scaling	O
law	O
for	O
the	O
selection	O
of	O
the	O
wavelength	O
of	O
the	O
structure	O
formed	O
under	O
an	O
electric	B-PHEN
field	I-PHEN
.	O

Palmitoyl	B-CHEM
Glycol	I-CHEM
Chitosan	I-CHEM
Micelles	B-CHEM
for	O
Corneal	B-ANAT
Delivery	O
of	O
Cyclosporine	B-CHEM
Different	O
substitution	B-PHYS
degrees	O
of	O
palmitoyl	B-CHEM
glycol	I-CHEM
chitosan	I-CHEM
(	O
PGC	B-CHEM
)	O
,	O
prepared	B-DISO
according	O
to	O
the	O
literature	O
,	O
were	O
used	O
to	O
obtain	O
polymeric	B-CHEM
micelles	B-CHEM
that	O
have	O
been	O
assessed	O
in	O
comparison	O
with	O
Pluronic	B-CHEM
F127	I-CHEM
micelles	B-CHEM
as	O
possible	O
carriers	B-CHEM
for	O
poorly	O
soluble	O
drugs	B-CHEM
,	O
such	O
as	O
cyclosporine	B-CHEM
A	I-CHEM
.	O

Both	O
PGC	B-CHEM
and	O
Pluronic	B-CHEM
micelles	B-CHEM
were	O
studied	O
for	O
their	O
interactions	B-PHYS
with	O
cell	B-PROC
culture	I-PROC
substrates	B-OBJC
.	O

The	O
least	O
substituted	B-PHYS
and	O
most	O
hydrophilic	O
derivative	O
,	O
PGC21	B-CHEM
(	O
approximately	O
5	O
%	O
substitution	B-PHYS
)	O
,	O
showed	O
a	O
strong	O
association	O
with	O
cyclosporine	B-CHEM
,	O
more	O
than	O
tripling	O
the	O
colloidal	B-CHEM
concentration	O
with	O
respect	O
to	O
the	O
saturated	B-PHEN
solution	B-OBJC
.	O

It	O
showed	O
a	O
greater	O
ability	B-PHYS
to	O
open	O
Caco	B-ANAT
-	I-ANAT
2	I-ANAT
tight	B-ANAT
junctions	I-ANAT
and	O
to	O
enhance	O
the	O
permeability	B-PHEN
of	O
Caco	B-ANAT
-	I-ANAT
2	I-ANAT
substrates	B-OBJC
with	O
respect	O
to	O
micelles	B-CHEM
based	O
on	O
higher	O
palmitoyl	B-CHEM
substitution	B-PHYS
,	O
conceivably	O
due	O
to	O
the	O
lower	O
modification	O
of	O
the	O
chitosan	B-CHEM
chains	I-CHEM
.	O

Permeation	B-PHEN
and	O
penetration	O
experiments	B-PROC
were	O
performed	O
with	O
PGC21	B-CHEM
and	O
Pluronic	B-CHEM
micelles	B-CHEM
on	O
a	O
rabbit	B-LIVB
corneal	B-ANAT
epithelial	I-ANAT
cell	I-ANAT
line	I-ANAT
(	O
RCE	B-ANAT
)	O
and	O
on	O
excised	O
pig	B-LIVB
corneas	B-ANAT
.	O

It	O
was	O
found	O
that	O
both	O
PGC	B-CHEM
and	O
Pluronic	B-CHEM
micelles	B-CHEM
could	O
increase	O
the	O
permeation	B-PHEN
of	O
the	O
fluorescent	B-CHEM
probe	I-CHEM
rhodamine	B-CHEM
B	I-CHEM
through	O
RCE	B-ANAT
cells	I-ANAT
by	O
more	O
than	O
ten	O
-	O
fold	O
.	O

In	O
RCE	B-ANAT
and	O
in	O
pig	B-LIVB
cornea	B-ANAT
,	O
the	O
micelles	B-CHEM
improved	B-DISO
the	O
penetration	O
of	O
both	O
rhodamine	B-CHEM
andr	O
cyclosporine	B-CHEM
.	O

For	O
cyclosporine	B-CHEM
,	O
the	O
PGC21	B-CHEM
micelles	B-CHEM
allowed	O
penetration	O
of	O
approximately	O
1	O
μg	O
/	O
mg	O
cyclosporine	B-CHEM
A	I-CHEM
in	O
corneal	B-ANAT
tissue	O
,	O
demonstrating	O
a	O
potential	O
for	O
use	O
in	O
immunosuppression	B-PROC
therapies	I-PROC
.	O

Plasmodium	O
falciparum	O
parasite	O
population	O
structure	O
and	O
gene	B-PHYS
flow	I-PHYS
associated	O
to	O
anti	B-CHEM
-	I-CHEM
malarial	I-CHEM
drugs	B-PHEN
resistance	I-PHEN
in	O
Cambodia	B-GEOG
Western	B-GEOG
Cambodia	I-GEOG
is	O
recognized	O
as	O
the	O
epicentre	O
of	O
emergence	B-DISO
of	O
Plasmodium	O
falciparum	O
multi	B-PHYS
-	I-PHYS
drug	I-PHYS
resistance	I-PHYS
.	O

The	O
emergence	B-DISO
of	O
artemisinin	B-CHEM
resistance	B-PHEN
has	O
been	O
observed	O
in	O
this	O
area	B-GEOG
since	O
2008	O
-	O
2009	O
and	O
molecular	O
signatures	O
associated	O
to	O
artemisinin	B-CHEM
resistance	B-PHEN
have	O
been	O
characterized	O
in	O
k13	O
gene	O
.	O

At	O
present	O
,	O
one	O
of	O
the	O
major	O
threats	O
faced	O
,	O
is	O
the	O
possible	O
spread	O
of	O
Asian	B-GEOG
artemisinin	B-CHEM
resistant	B-PHEN
parasites	O
over	O
the	O
world	O
threatening	O
millions	O
of	O
people	B-LIVB
and	O
jeopardizing	O
malaria	B-DISO
elimination	B-PROC
programme	I-PROC
efforts	O
.	O

To	O
anticipate	O
the	O
diffusion	O
of	O
artemisinin	B-CHEM
resistance	B-PHEN
,	O
the	O
identification	O
of	O
the	O
P	O
.	O

falciparum	O
population	O
structure	O
and	O
the	O
gene	B-PHYS
flow	I-PHYS
among	O
the	O
parasite	O
population	O
in	O
Cambodia	B-GEOG
are	O
essential	O
.	O

To	O
this	O
end	O
,	O
a	O
mid	O
-	O
throughput	O
PCR	B-PROC
-	O
LDR	B-PROC
-	I-PROC
FMA	I-PROC
approach	O
based	O
on	O
LUMINEX	B-PROC
technology	I-PROC
was	O
developed	O
to	O
screen	O
for	O
genetic	O
barcode	O
in	O
533	O
blood	B-ANAT
samples	I-ANAT
collected	O
in	O
2010	O
-	O
2011	O
from	O
16	O
health	B-OBJC
centres	I-OBJC
in	O
malaria	B-DISO
endemics	O
areas	O
in	O
Cambodia	B-GEOG
.	O

Based	O
on	O
successful	O
typing	B-PROC
of	O
282	O
samples	B-ANAT
,	O
subpopulations	O
were	O
characterized	O
along	O
the	O
borders	O
of	O
the	O
country	B-GEOG
.	O

Each	O
11	O
-	O
loci	O
barcode	O
provides	O
evidence	O
supporting	O
allele	O
distribution	O
gradient	O
related	O
to	O
subpopulations	O
and	O
gene	B-PHYS
flow	I-PHYS
.	O

The	O
11	O
-	O
loci	O
barcode	O
successfully	O
identifies	O
recently	O
emerging	O
parasite	O
subpopulations	O
in	O
western	B-GEOG
Cambodia	I-GEOG
that	O
are	O
associated	O
with	O
the	O
C580Y	O
dominant	O
allele	O
for	O
artemisinin	B-CHEM
resistance	B-PHEN
in	O
k13	O
gene	O
.	O

A	O
subpopulation	O
was	O
identified	O
in	O
northern	B-GEOG
Cambodia	I-GEOG
that	O
was	O
associated	O
to	O
artemisinin	B-CHEM
(	O
R539	O
T	O
resistant	O
allele	O
of	O
k13	O
gene	O
)	O
and	O
mefloquine	B-CHEM
resistance	B-PHEN
.	O

The	O
gene	B-PHYS
flow	I-PHYS
between	O
these	O
subpopulations	O
might	O
have	O
driven	O
the	O
spread	O
of	O
artemisinin	B-CHEM
resistance	B-PHEN
over	O
Cambodia	B-GEOG
.	O

Sequence	B-PHYS
-	I-PHYS
specific	I-PHYS
DNA	I-PHYS
binding	I-PHYS
by	O
long	B-CHEM
hairpin	I-CHEM
pyrrole	B-CHEM
-	I-CHEM
imidazole	I-CHEM
polyamides	I-CHEM
containing	O
an	O
8	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
dioxaoctanoic	I-CHEM
acid	I-CHEM
unit	O
With	O
the	O
aim	O
of	O
improving	O
aqueous	O
solubility	O
,	O
we	O
designed	O
and	O
synthesized	O
five	O
N	B-CHEM
-	I-CHEM
methylpyrrole	I-CHEM
(	I-CHEM
Py	I-CHEM
)	I-CHEM
-	I-CHEM
N	I-CHEM
-	I-CHEM
methylimidazole	I-CHEM
(	I-CHEM
Im	I-CHEM
)	I-CHEM
polyamides	I-CHEM
capable	O
of	O
recognizing	O
9	O
-	O
bp	O
sequences	O
.	O

Their	O
DNA	B-PHYS
-	I-PHYS
binding	I-PHYS
affinities	B-PHEN
and	O
sequence	O
specificities	O
were	O
evaluated	O
by	O
SPR	B-PROC
and	O
Bind	B-PROC
-	I-PROC
n	I-PROC
-	I-PROC
Seq	I-PROC
analyses	I-PROC
.	O

The	O
design	O
of	O
polyamide	B-CHEM
1	I-CHEM
was	O
based	O
on	O
a	O
conventional	O
model	O
,	O
with	O
three	O
consecutive	O
Py	B-CHEM
or	O
Im	B-CHEM
rings	O
separated	O
by	O
a	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
to	O
match	O
the	O
curvature	O
and	O
twist	O
of	O
long	O
DNA	B-CHEM
helices	O
.	O

Polyamides	B-CHEM
2	I-CHEM
and	I-CHEM
3	I-CHEM
contained	O
an	O
8	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
dioxaoctanoic	I-CHEM
acid	I-CHEM
(	O
AO	B-CHEM
)	O
unit	O
,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	B-CHEM
within	O
linear	O
Py	B-CHEM
-	I-CHEM
Im	I-CHEM
polyamides	I-CHEM
or	O
between	O
Py	B-CHEM
-	I-CHEM
Im	I-CHEM
hairpin	I-CHEM
motifs	I-CHEM
for	O
tandem	B-CHEM
hairpin	I-CHEM
.	O

It	O
is	O
demonstrated	O
herein	O
that	O
AO	B-CHEM
also	O
functions	O
as	O
a	O
linker	B-CHEM
element	I-CHEM
that	O
can	O
extend	O
to	O
2	O
-	O
bp	O
in	O
hairpin	B-CHEM
motifs	I-CHEM
.	O

Notably	O
,	O
although	O
the	O
AO	B-CHEM
-containing	O
unit	O
can	O
fail	O
to	O
bind	O
the	O
expected	O
sequence	O
,	O
polyamide	B-CHEM
4	I-CHEM
,	O
which	O
has	O
two	O
AO	B-CHEM
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin	O
form	O
,	O
successfully	O
showed	O
the	O
expected	O
motif	O
and	O
a	O
KD	O
value	O
of	O
16nM	O
was	O
recorded	O
.	O

Polyamide	B-CHEM
5	I-CHEM
,	O
containing	O
a	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
-	I-CHEM
β	I-CHEM
-	I-CHEM
alanine	I-CHEM
unit	O
instead	O
of	O
the	O
AO	B-CHEM
of	O
polyamide	B-CHEM
2	I-CHEM
,	O
was	O
synthesized	O
for	O
comparison	O
.	O

The	O
aqueous	O
solubilities	O
and	O
nuclear	B-PHEN
localization	I-PHEN
of	O
three	O
of	O
the	O
polyamides	B-CHEM
were	O
also	O
examined	O
.	O

The	O
results	O
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
AO	B-CHEM
unit	O
in	O
the	O
core	O
of	O
Py	B-CHEM
-	I-CHEM
Im	I-CHEM
polyamide	I-CHEM
compounds	I-CHEM
.	O

Mining	O
Health	O
App	O
Data	O
to	O
Find	O
More	O
and	O
Less	O
Successful	O
Weight	B-DISO
Loss	I-DISO
Subgroups	O
More	O
than	O
half	O
of	O
all	O
smartphone	O
app	O
downloads	O
involve	O
weight	B-PHYS
,	O
diet	B-OBJC
,	I-OBJC
and	O
exercise	O
.	O

If	O
successful	O
,	O
these	O
lifestyle	O
apps	O
may	O
have	O
far	O
-	O
reaching	O
effects	O
for	O
disease	B-PROC
prevention	I-PROC
and	O
health	O
cost	O
-	O
savings	O
,	O
but	O
few	O
researchers	B-LIVB
have	O
analyzed	O
data	O
from	O
these	O
apps	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
analyze	O
data	O
from	O
a	O
commercial	O
health	O
app	O
(	O
Lose	O
It	O
!	O
)	O
in	O
order	O
to	O
identify	O
successful	B-DISO
weight	I-DISO
loss	I-DISO
subgroups	O
via	O
exploratory	B-PROC
analyses	I-PROC
and	O
to	O
verify	O
the	O
stability	O
of	O
the	O
results	O
.	O

Cross	O
-	O
sectional	O
,	O
de	O
-	O
identified	O
data	O
from	O
Lose	O
It	O
!	O
were	O
analyzed	O
.	O

This	O
dataset	O
(	O
n	O
=	O
12	O
,	O
427	O
,	O
196	O
)	O
was	O
randomly	O
split	O
into	O
24	O
subsamples	O
,	O
and	O
this	O
study	O
used	O
3	O
subsamples	O
(	O
combined	O
n	O
=	O
972	O
,	O
687	O
)	O
.	O

Classification	O
and	O
regression	O
tree	O
methods	O
were	O
used	O
to	O
explore	O
groupings	O
of	O
weight	B-DISO
loss	I-DISO
with	O
one	O
subsample	O
,	O
with	O
descriptive	B-PROC
analyses	I-PROC
to	O
examine	O
other	O
group	O
characteristics	O
.	O

Data	O
mining	O
validation	O
methods	O
were	O
conducted	O
with	O
2	O
additional	O
subsamples	O
.	O

In	O
subsample	O
1	O
,	O
14	O
.	O
96	O
%	O
of	O
users	B-LIVB
lost	B-DISO
5	O
%	O
or	O
more	O
of	O
their	O
starting	O
body	B-PHYS
weight	I-PHYS
.	O

Classification	O
and	O
regression	O
tree	O
analysis	O
identified	O
3	O
distinct	O
subgroups	O
:	O
""""	O
the	O
occasional	O
users	B-LIVB
""""	O
had	O
the	O
lowest	O
proportion	O
(	O
4	O
.	O
87	O
%	O
)	O
of	O
individuals	B-LIVB
who	O
successfully	O
lost	B-DISO
weight	I-DISO
;	O
""""	O
the	O
basic	O
users	B-LIVB
""""	O
had	O
37	O
.	O
61	O
%	O
weight	B-DISO
loss	I-DISO
success	O
;	O
and	O
""""	O
the	O
power	B-LIVB
users	I-LIVB
""""	O
achieved	O
the	O
highest	O
percentage	O
of	O
weight	B-DISO
loss	I-DISO
success	I-DISO
at	O
72	O
.	O

70	O
%	O
.	O

Behavioral	O
factors	O
delineated	O
the	O
subgroups	O
,	O
though	O
app	O
-related	O
behavioral	O
characteristics	O
further	O
distinguished	O
them	O
.	O

Results	O
were	O
replicated	O
in	O
further	O
analyses	B-PROC
with	O
separate	O
subsamples	O
.	O

This	O
study	B-PROC
demonstrates	O
that	O
distinct	O
subgroups	O
can	O
be	O
identified	O
in	O
""""	O
messy	O
""""	O
commercial	O
app	O
data	O
and	O
the	O
identified	O
subgroups	O
can	O
be	O
replicated	O
in	O
independent	O
samples	O
.	O

Behavioral	O
factors	O
and	O
use	O
of	O
custom	O
app	O
features	O
characterized	O
the	O
subgroups	O
.	O

Targeting	O
and	O
tailoring	O
information	O
to	O
particular	O
subgroups	O
could	O
enhance	O
weight	O
loss	O
success	O
.	O

Future	O
studies	B-PROC
should	O
replicate	O
data	O
mining	O
analyses	B-PROC
to	O
increase	O
methodology	O
rigor	O
.	O

Recognising	B-PHYS
and	O
responding	B-PHYS
to	O
'	O
cutting	O
corners	O
'	O
when	O
providing	O
nursing	B-PROC
care	I-PROC
:	O
a	O
qualitative	B-PROC
study	I-PROC
The	O
aim	O
of	O
this	O
study	B-PROC
is	O
to	O
report	O
on	O
a	O
key	O
finding	B-DISO
of	O
a	O
larger	B-PROC
study	I-PROC
investigating	O
the	O
'	O
gaps	O
'	O
in	O
patient	B-PROC
care	I-PROC
that	O
registered	B-LIVB
nurses	I-LIVB
encounter	O
during	O
the	O
course	O
of	O
their	O
practice	O
.	O

A	O
key	O
finding	B-DISO
of	O
this	O
larger	B-PROC
study	I-PROC
was	O
that	O
'	O
cutting	O
corners	O
'	O
was	O
a	O
gap	O
discerned	O
by	O
nurses	B-LIVB
.	O
'	O
Cutting	O
corners	O
'	O
has	O
been	O
characterised	O
as	O
a	O
'	O
violation	O
'	O
and	O
threat	O
to	O
patient	B-PROC
safety	I-PROC
,	O
although	O
there	O
is	O
a	O
paucity	O
of	O
research	B-PROC
on	O
this	O
issue	O
.	O

Naturalistic	B-PROC
inquiry	I-PROC
using	O
a	O
qualitative	O
exploratory	O
descriptive	O
approach	O
.	O

Data	O
were	O
collected	O
from	O
a	O
purposeful	O
sample	O
of	O
71	O
registered	B-LIVB
nurses	I-LIVB
from	O
emergency	B-OBJC
department	I-OBJC
,	O
critical	B-PROC
care	I-PROC
,	O
perioperative	O
,	O
rehabilitation	O
and	O
transitional	B-PROC
care	I-PROC
and	O
neurosciences	B-PROC
settings	I-PROC
in	O
Australia	B-GEOG
and	O
analysed	O
using	O
content	B-PROC
and	O
thematic	B-PROC
analysis	I-PROC
strategies	O
.	O

Cutting	O
corners	O
was	O
a	O
common	O
practice	O
that	O
encompassed	O
(	O
1	O
)	O
the	O
partial	O
or	O
complete	O
omission	B-DISO
of	O
patient	B-PROC
care	I-PROC
,	O
(	O
2	O
)	O
delays	O
in	O
providing	B-PROC
care	I-PROC
and	O
(	O
3	O
)	O
the	O
failure	O
to	O
do	O
things	O
correctly	O
.	O

Corners	O
were	O
cut	O
in	O
patient	B-LIVB
assessment	B-PROC
,	O
essential	O
nursing	B-PROC
care	I-PROC
,	O
the	O
care	B-PROC
of	I-PROC
central	I-PROC
venous	I-PROC
catheters	I-PROC
and	O
medication	B-PROC
administration	I-PROC
.	O

The	O
practice	O
of	O
cutting	O
corners	O
was	O
perceived	O
as	O
contributing	O
to	O
preventable	B-DISO
adverse	B-DISO
events	I-DISO
.	O

The	O
study	B-PROC
found	O
that	O
cutting	O
corners	O
created	O
gaps	O
that	O
contributed	O
to	O
unfinished	O
nursing	B-PROC
care	I-PROC
and	O
preventable	B-DISO
adverse	B-DISO
events	I-DISO
.	O

The	O
findings	B-DISO
of	O
the	O
study	B-PROC
raise	O
the	O
possibility	O
that	O
cutting	O
corners	O
is	O
a	O
salient	O
but	O
underinvestigated	O
characteristic	O
of	O
nursing	B-PROC
practice	I-PROC
.	O

Further	O
research	B-PROC
and	O
inquiry	O
are	O
needed	O
to	O
deepen	O
understanding	O
of	O
cutting	O
corners	O
and	O
its	O
impact	O
on	O
patient	B-PROC
safety	I-PROC
.	O

Identifying	O
the	O
nature	O
and	O
implications	B-DISO
of	O
cutting	O
corners	O
when	O
providing	O
nursing	B-PROC
care	I-PROC
is	O
an	O
important	O
contributing	O
factor	O
to	O
improving	O
patient	B-PROC
safety	I-PROC
and	O
quality	B-PROC
care	I-PROC
.	O

The	O
PP	B-CHEM
-	O
motif	O
in	O
luminal	O
loop	O
2	O
of	O
ZnT	B-CHEM
transporters	I-CHEM
plays	O
a	O
pivotal	O
role	O
in	O
TNAP	B-CHEM
activation	B-PHYS
Secretory	B-CHEM
and	O
membrane	B-ANAT
-	O
bound	O
zinc	B-CHEM
-requiring	O
enzymes	B-CHEM
are	O
thought	O
to	O
be	O
activated	B-PHYS
by	O
binding	B-PHYS
zinc	B-CHEM
in	O
the	O
early	O
secretory	B-PHYS
pathway	I-PHYS
.	O

One	O
such	O
enzyme	B-CHEM
,	O
tissue	B-CHEM
-	I-CHEM
non	I-CHEM
-	I-CHEM
specific	I-CHEM
alkaline	I-CHEM
phosphatase	I-CHEM
(	O
TNAP	B-CHEM
)	O
,	O
is	O
activated	B-PHYS
through	O
a	O
two	O
-	O
step	O
mechanism	O
,	O
via	O
protein	B-PHYS
stabilization	I-PHYS
and	O
subsequent	O
enzyme	B-PHYS
activation	I-PHYS
through	O
metalation	B-PHEN
,	O
by	O
ZnT5	B-CHEM
-	O
ZnT6	B-CHEM
heterodimers	B-CHEM
or	O
ZnT7	B-CHEM
homodimers	B-CHEM
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
basis	O
underlying	O
the	O
activation	B-PHYS
process	B-PHEN
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
found	O
that	O
the	O
di	B-CHEM
-	I-CHEM
proline	I-CHEM
motif	O
(	O
PP	B-CHEM
-	O
motif	O
)	O
in	O
luminal	O
loop	O
2	O
of	O
ZnT5	B-CHEM
and	O
ZnT7	B-CHEM
is	O
important	O
for	O
TNAP	B-CHEM
activation	B-PHYS
.	O

TNAP	B-CHEM
activity	B-PHYS
was	O
significantly	O
reduced	O
in	O
cells	B-ANAT
lacking	O
ZnT5	B-CHEM
-	O
ZnT6	B-CHEM
heterodimers	B-CHEM
and	O
ZnT7	B-CHEM
homodimers	B-CHEM
[	O
triple	O
knockout	O
(	O
TKO	O
)	O
cells	B-ANAT
]	O
.	O

The	O
decreased	O
TNAP	B-CHEM
activity	B-PHYS
was	O
restored	O
by	O
expressing	B-PHYS
hZnT5	O
with	O
hZnT6	O
or	O
hZnT7	O
,	O
but	O
significantly	O
less	O
so	O
(	O
almost	O
90	O
%	O
less	O
)	O
by	O
expressing	B-PHYS
mutants	B-DISO
thereof	O
in	O
which	O
the	O
PP	B-CHEM
-	O
motif	O
was	O
mutated	B-PHYS
to	O
alanine	B-CHEM
(	O
PP	B-CHEM
-	O
AA	B-CHEM
)	O
.	O

In	O
TKO	O
cells	B-ANAT
,	O
overexpressed	B-PHYS
hTNAP	B-CHEM
was	O
not	O
completely	O
activated	B-PHYS
,	O
and	O
it	O
was	O
converted	O
less	O
efficiently	O
into	O
the	O
holo	O
form	O
by	O
expressing	B-PHYS
a	O
PP	B-CHEM
-	O
AA	B-CHEM
mutant	B-DISO
of	O
hZnT5	O
with	O
hZnT6	O
,	O
whose	O
defects	O
were	O
not	O
restored	B-PROC
by	O
zinc	B-CHEM
supplementation	B-PROC
.	O

The	O
zinc	B-PHYS
transport	I-PHYS
activity	B-PHYS
of	O
hZnT7	O
was	O
not	B-DISO
significantly	I-DISO
impaired	O
by	O
the	O
PP	B-CHEM
-	O
AA	B-CHEM
mutation	B-PHYS
,	O
indicating	O
that	O
the	O
PP	B-CHEM
-	O
motif	O
is	O
involved	O
in	O
the	O
TNAP	B-CHEM
maturation	B-PHYS
process	B-PHEN
,	O
although	O
it	O
does	O
not	O
control	O
zinc	B-PHYS
transport	I-PHYS
activity	B-PHYS
.	O

The	O
PP	B-CHEM
-	O
motif	O
is	O
highly	O
conserved	O
in	O
ZnT5	B-CHEM
and	O
ZnT7	B-CHEM
orthologues	O
,	O
and	O
its	O
importance	O
for	O
TNAP	B-CHEM
activation	B-PHYS
is	O
conserved	O
in	O
the	O
Caenorhabditis	O
elegans	O
hZnT5	B-CHEM
orthologue	O
CDF5	B-LIVB
.	O

These	O
results	O
provide	O
novel	O
molecular	O
insights	O
into	O
the	O
TNAP	B-CHEM
activation	B-PHYS
process	B-PHEN
in	O
the	O
early	O
secretory	B-PHYS
pathway	I-PHYS
.	O

Novel	O
protein	B-CHEM
-	O
inhibitor	B-CHEM
interactions	O
in	O
site	B-CHEM
3	I-CHEM
of	I-CHEM
Ca	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	I-CHEM
bound	I-CHEM
S100B	I-CHEM
as	O
discovered	O
by	O
X	B-PROC
-	I-PROC
ray	I-PROC
crystallography	I-PROC
Structure	B-PROC
-	I-PROC
based	I-PROC
drug	I-PROC
discovery	I-PROC
is	O
under	O
way	O
to	O
identify	O
and	O
develop	O
small	B-CHEM
-	I-CHEM
molecule	I-CHEM
S100B	B-CHEM
inhibitors	B-CHEM
(	O
SBiXs	B-CHEM
)	O
.	O

Such	O
inhibitors	B-CHEM
have	O
therapeutic	O
potential	O
for	O
treating	O
malignant	B-DISO
melanoma	I-DISO
,	O
since	O
high	O
levels	O
of	O
S100B	B-CHEM
downregulate	B-PHYS
wild	B-CHEM
-	I-CHEM
type	I-CHEM
p53	I-CHEM
tumor	B-PHYS
suppressor	I-PHYS
function	I-PHYS
in	O
this	O
cancer	B-DISO
.	O

Computational	B-PROC
and	O
X	B-PROC
-	I-PROC
ray	I-PROC
crystallographic	I-PROC
studies	I-PROC
of	O
two	O
S100B	B-CHEM
-	O
SBiX	B-CHEM
complexes	B-CHEM
are	O
described	O
,	O
and	O
both	O
compounds	O
(	O
apomorphine	B-CHEM
hydrochloride	I-CHEM
and	O
ethidium	B-CHEM
bromide	I-CHEM
)	O
occupy	O
an	O
area	O
of	O
the	O
S100B	B-CHEM
hydrophobic	O
cleft	O
which	O
is	O
termed	O
site	O
3	O
.	O

These	O
data	O
also	O
reveal	O
novel	O
protein	B-CHEM
-	O
inhibitor	B-CHEM
interactions	O
which	O
can	O
be	O
used	O
in	O
future	O
drug	O
-	O
design	O
studies	O
to	O
improve	B-DISO
SBiX	B-CHEM
affinity	B-PHEN
and	O
specificity	O
.	O

Of	O
particular	O
interest	O
,	O
apomorphine	B-CHEM
hydrochloride	I-CHEM
showed	O
S100B	B-CHEM
-dependent	O
killing	B-PHYS
in	O
melanoma	B-ANAT
cell	I-ANAT
assays	B-PROC
,	O
although	O
the	O
efficacy	O
exceeds	O
its	O
affinity	B-PHEN
for	O
S100B	B-CHEM
and	O
implicates	O
possible	O
off	O
-	O
target	O
contributions	O
.	O

Because	O
there	O
are	O
no	O
structural	O
data	O
available	O
for	O
compounds	O
occupying	O
site	O
3	O
alone	O
,	O
these	O
studies	B-PROC
contribute	O
towards	O
the	O
structure	O
-	O
based	O
approach	O
to	O
targeting	O
S100B	B-CHEM
by	O
including	O
interactions	O
with	O
residues	O
in	O
site	O
3	O
of	O
S100B	B-CHEM
.	O

Ownership	O
and	O
Agency	O
of	O
an	O
Independent	B-OBJC
Supernumerary	I-OBJC
Hand	I-OBJC
Induced	O
by	O
an	O
Imitation	B-DEVI
Brain	I-DEVI
-	I-DEVI
Computer	I-DEVI
Interface	I-DEVI
To	O
study	O
body	B-ANAT
ownership	O
and	O
control	O
,	O
illusions	B-DISO
that	O
elicit	O
these	O
feelings	B-PHYS
in	O
non	B-OBJC
-	I-OBJC
body	I-OBJC
objects	I-OBJC
are	O
widely	O
used	O
.	O

Classically	O
introduced	O
with	O
the	O
Rubber	B-DISO
Hand	I-DISO
Illusion	I-DISO
,	O
these	O
illusions	B-DISO
have	O
been	O
replicated	O
more	O
recently	O
in	O
virtual	O
reality	O
and	O
by	O
using	O
brain	B-DEVI
-	I-DEVI
computer	I-DEVI
interfaces	I-DEVI
.	O

Traditionally	O
these	O
illusions	B-DISO
investigate	O
the	O
replacement	O
of	O
a	O
body	B-ANAT
part	I-ANAT
by	O
an	O
artificial	B-DEVI
counterpart	I-DEVI
,	O
however	O
as	O
brain	B-DEVI
-	I-DEVI
computer	I-DEVI
interface	I-DEVI
research	B-PROC
develops	O
it	O
offers	O
us	O
the	O
possibility	O
to	O
explore	O
the	O
case	O
where	O
non	B-OBJC
-	I-OBJC
body	I-OBJC
objects	I-OBJC
are	O
controlled	O
in	O
addition	O
to	O
movements	B-PHYS
of	I-PHYS
our	I-PHYS
own	I-PHYS
limbs	I-PHYS
.	O

Therefore	O
we	O
propose	O
a	O
new	O
illusion	B-DISO
designed	O
to	O
test	O
the	O
feeling	B-PHYS
of	O
ownership	O
and	O
control	O
of	O
an	O
independent	B-OBJC
supernumerary	I-OBJC
hand	I-OBJC
.	O

Subjects	B-LIVB
are	O
under	O
the	O
impression	O
they	O
control	O
a	O
virtual	B-OBJC
reality	I-OBJC
hand	I-OBJC
via	O
a	O
brain	B-DEVI
-	I-DEVI
computer	I-DEVI
interface	I-DEVI
,	O
but	O
in	O
reality	O
there	O
is	O
no	O
causal	O
connection	O
between	O
brain	B-PHYS
activity	I-PHYS
and	O
virtual	O
hand	O
movement	O
but	O
correct	O
movements	B-PHYS
are	O
observed	O
with	O
80	O
%	O
probability	O
.	O

These	O
imitation	B-PROC
brain	I-PROC
-	I-PROC
computer	I-PROC
interface	I-PROC
trials	I-PROC
are	O
interspersed	O
with	O
movements	B-PHYS
in	O
both	O
the	O
subjects	B-LIVB
'	O
real	B-ANAT
hands	I-ANAT
,	O
which	O
are	O
in	O
view	O
throughout	O
the	O
experiment	B-PROC
.	O

We	O
show	O
that	O
subjects	B-LIVB
develop	O
strong	B-PHYS
feelings	I-PHYS
of	O
ownership	O
and	O
control	O
over	O
the	O
third	B-OBJC
hand	I-OBJC
,	O
despite	O
only	O
receiving	O
visual	B-PHYS
feedback	I-PHYS
with	O
no	O
causal	O
link	O
to	O
the	O
actual	O
brain	B-ANAT
signals	B-PHEN
.	O

Our	O
illusion	B-DISO
is	O
crucially	O
different	O
from	O
previously	O
reported	O
studies	O
as	O
we	O
demonstrate	O
independent	B-DISO
ownership	O
and	O
control	O
of	O
the	O
third	B-OBJC
hand	I-OBJC
without	O
loss	O
of	O
ownership	O
in	O
the	O
real	B-ANAT
hands	I-ANAT
.	O

Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
in	O
pregnancy	B-PHYS
may	O
affect	O
fetal	B-ANAT
thymus	B-ANAT
development	O
The	O
aim	O
of	O
our	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
the	O
association	O
of	O
vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
(	O
VDD	B-DISO
)	O
during	O
pregnancy	B-PHYS
with	O
thymus	B-ANAT
size	O
in	O
full	O
-	O
term	O
fetuses	O
.	O

In	O
this	O
prospective	O
study	O
,	O
we	O
evaluated	B-PROC
mid	O
-	O
pregnancy	O
serum	O
25	B-PROC
-	I-PROC
hydroxyvitamin	I-PROC
D3	I-PROC
(	I-PROC
25	I-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
)	I-PROC
concentrations	I-PROC
.	O

The	O
fetal	B-ANAT
thymus	B-ANAT
size	O
was	O
measured	O
by	O
ultrasound	B-PROC
in	O
the	O
third	O
trimester	O
.	O

Neonatal	O
25	B-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
levels	I-PROC
were	O
evaluated	B-PROC
by	O
umbilical	B-ANAT
cord	I-ANAT
blood	B-PROC
sampling	I-PROC
.	O

Correlation	O
of	O
maternal	B-DISO
and	O
neonatal	O
vitamin	B-PROC
D	I-PROC
levels	I-PROC
and	O
association	O
between	O
thymus	B-ANAT
size	O
and	O
both	O
,	O
maternal	B-DISO
and	O
neonatal	O
vitamin	B-PROC
D	I-PROC
concentrations	I-PROC
were	O
investigated	O
.	O

Serum	B-PROC
25	I-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
concentrations	I-PROC
were	O
within	O
the	O
normal	O
range	O
in	O
48	O
(	O
29	O
.	O

8	O
%	O
)	O
mothers	B-LIVB
and	O
10	O
(	O
13	O
.	O

1	O
%	O
)	O
new	B-LIVB
-	I-LIVB
borns	I-LIVB
.	O

A	O
strong	O
correlation	O
between	O
mid	O
-	O
pregnancy	O
maternal	B-DISO
and	O
neonatal	O
25	B-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
concentration	I-PROC
(	O
r	O
=	O
0	O
.	O
8	O
,	O
p	O
<	O
0	O
.	O

001	O
)	O
was	O
found	O
.	O

A	O
significant	O
linear	O
correlation	O
was	O
observed	O
between	O
both	O
,	O
maternal	B-DISO
and	O
neonatal	O
25	B-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
concentrations	I-PROC
and	O
thymus	B-ANAT
perimeter	O
length	O
(	O
r	O
=	O
0	O
.	O
45	O
,	O
p	O
=	O
0	O
.	O
04	O
and	O
r	O
=	O
0	O
.	O

43	O
,	O
p	O
<	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

Both	O
,	O
maternal	B-DISO
and	O
fetal	B-ANAT
VDDs	B-DISO
were	O
associated	O
with	O
decreased	O
thymus	B-ANAT
perimeter	O
(	O
p	O
=	O
0	O
.	O

04	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
during	O
pregnancy	B-PHYS
may	O
be	O
associated	O
with	O
smaller	O
fetal	B-ANAT
thymus	B-ANAT
.	O

Our	O
data	O
suggest	O
that	O
VDD	B-DISO
in	O
pregnancy	B-PHYS
may	O
lead	O
to	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
in	O
the	O
fetus	B-ANAT
.	O

Causes	B-DISO
of	I-DISO
Death	I-DISO
among	O
Children	B-LIVB
Aged	B-PHYS
5	O
to	O
14	O
Years	O
Old	O
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
,	O
Ethiopia	B-GEOG
The	O
global	O
burden	O
of	O
mortality	O
among	O
children	O
is	O
still	O
very	O
huge	O
though	O
its	O
trend	O
has	O
started	O
declining	O
following	O
the	O
improvements	O
in	O
the	O
living	O
standard	O
.	O

It	O
presents	O
serious	O
challenges	B-PROC
to	O
the	O
well	O
-	O
being	O
of	O
children	B-LIVB
in	O
many	O
African	B-GEOG
countries	I-GEOG
.	O

Today	O
,	O
Sub	B-GEOG
-	I-GEOG
Saharan	I-GEOG
Africa	I-GEOG
alone	O
accounts	O
for	O
about	O
50	O
%	O
of	O
global	O
child	O
mortality	O
.	O

The	O
overall	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	O
and	O
distribution	O
of	O
causes	B-DISO
of	I-DISO
death	I-DISO
among	O
children	B-LIVB
aged	B-PHYS
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	B-LIVB
of	O
Kersa	O
HDSS	O
using	O
verbal	O
autopsy	B-PROC
method	O
for	O
the	O
period	O
2008	O
to	O
2013	O
.	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
was	O
established	O
in	O
September	O
2007	O
.	O

The	O
center	O
consists	O
of	O
10	O
rural	O
and	O
2	O
urban	O
kebeles	B-LIVB
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	B-LIVB
in	O
the	O
district	B-GEOG
.	O

Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	O
was	O
taken	O
from	O
Kersa	O
HDSS	O
database	O
.	O

The	O
study	B-PROC
population	B-LIVB
included	O
all	O
children	B-LIVB
aged	B-PHYS
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	O
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	B-PHYS
specific	O
VA	O
questionnaires	O
.	O

Data	O
were	O
extracted	O
from	O
SPSS	O
database	O
and	O
analyzed	O
using	O
STATA	O
.	O

A	O
total	O
of	O
229	O
deaths	B-DISO
were	O
recorded	O
over	O
the	O
period	O
of	O
six	O
years	O
with	O
a	O
crude	O
death	O
rate	O
of	O
219	O
.	O

6	O
per	O
100	O
,	O
000	O
population	B-LIVB
of	O
this	O
age	B-LIVB
group	I-LIVB
over	O
the	O
study	B-PROC
period	O
.	O

This	O
death	O
rate	O
was	O
217	O
.	O
5	O
and	O
221	O
.	O

5	O
per	O
100	O
,	O
000	O
populations	B-LIVB
for	O
females	B-PHYS
and	O
males	B-PHYS
,	O
respectively	O
.	O

75	O
%	O
of	O
deaths	B-DISO
took	O
place	O
at	O
home	O
.	O

The	O
study	B-PROC
identified	O
severe	O
malnutrition	B-DISO
(	O
33	O
.	O
9	O
%	O
)	O
,	O
intestinal	B-DISO
infectious	I-DISO
diseases	I-DISO
(	O
13	O
.	O
8	O
%	O
)	O
and	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
infections	I-DISO
(	O
9	O
.	O
2	O
%	O
)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	B-DISO
of	I-DISO
death	I-DISO
.	O

In	O
broad	O
causes	B-DISO
of	I-DISO
death	I-DISO
classification	O
,	O
injuries	B-DISO
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	B-DISO
of	I-DISO
death	I-DISO
next	O
to	O
communicable	B-DISO
diseases	I-DISO
(	O
56	O
.	O

3	O
%	O
)	O
attributing	O
to	O
13	O
.	O

1	O
%	O
of	O
the	O
total	O
deaths	B-DISO
.	O

In	O
specific	O
causes	B-DISO
of	I-DISO
death	I-DISO
classification	O
severe	O
malnutrition	B-DISO
,	O
intestinal	B-DISO
infectious	I-DISO
diseases	I-DISO
and	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
infections	I-DISO
were	O
the	O
three	O
leading	O
causes	B-DISO
of	I-DISO
death	I-DISO
where	O
,	O
in	O
broad	O
causes	B-DISO
of	I-DISO
death	I-DISO
communicable	B-DISO
diseases	I-DISO
and	O
injuries	B-DISO
were	O
among	O
the	O
leading	O
causes	B-DISO
of	I-DISO
death	I-DISO
.	O

Hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	O
from	O
these	O
causes	B-DISO
of	I-DISO
death	I-DISO
and	O
further	O
inferential	B-PROC
analysis	I-PROC
into	O
the	O
prevention	B-PROC
and	O
management	B-PROC
of	O
infectious	B-DISO
diseases	I-DISO
should	O
also	O
be	O
taken	O
.	O

What	O
will	O
it	O
take	O
to	O
improve	O
prevention	O
of	O
chronic	O
diseases	O
in	O
Australia	B-GEOG
?	O

A	O
case	O
study	O
of	O
two	O
national	O
approaches	O
Objective	O
Despite	O
being	O
a	O
healthy	O
country	O
by	O
international	O
standards	O
,	O
Australia	B-GEOG
has	O
a	O
growing	O
and	O
serious	O
burden	O
from	O
chronic	B-DISO
diseases	I-DISO
.	O

There	O
have	O
been	O
several	O
national	O
efforts	O
to	O
tackle	O
this	O
problem	O
,	O
but	O
despite	O
some	O
important	O
advances	O
much	O
more	O
needs	O
to	O
be	O
done	O
.	O

From	O
the	O
viewpoint	O
of	O
diverse	O
stakeholders	O
,	O
the	O
present	O
study	O
examined	O
two	O
approaches	O
to	O
controlling	B-DISO
chronic	I-DISO
disease	I-DISO
in	O
Australia	B-GEOG
:	O
(	O
1	O
)	O
the	O
2005	O
National	O
Chronic	O
Disease	O
Strategy	O
(	O
NCDS	O
)	O
;	O
and	O
(	O
2	O
)	O
the	O
2008	O
National	B-PROC
Partnership	I-PROC
Agreement	I-PROC
on	I-PROC
Preventive	I-PROC
Health	I-PROC
(	O
NPAPH	B-PROC
)	O
.	O

Methods	O
Individual	O
and	O
small	B-PROC
group	I-PROC
semistructured	I-PROC
interviews	I-PROC
were	O
undertaken	O
with	O
29	O
leaders	O
across	O
Australia	B-GEOG
,	O
reflecting	O
a	O
diverse	O
cross	O
-	O
section	O
of	O
senior	B-LIVB
public	I-LIVB
health	I-LIVB
managers	I-LIVB
and	O
program	O
implementation	O
staff	O
from	O
state	O
and	O
territory	O
health	O
departments	O
,	O
as	O
well	O
as	O
academics	O
,	O
thought	O
leaders	O
and	O
public	B-LIVB
health	I-LIVB
advocates	I-LIVB
.	O

A	O
grounded	O
theory	O
approach	O
was	O
used	O
to	O
generate	O
themes	O
relevant	O
to	O
the	O
research	O
.	O

Results	O
There	O
is	O
general	O
support	O
for	O
national	O
approaches	O
to	O
the	O
prevention	O
of	O
chronic	B-DISO
disease	I-DISO
.	O

The	O
NCDS	O
was	O
viewed	O
as	O
necessary	O
and	O
useful	O
for	O
national	O
coordination	O
,	O
setting	O
a	O
common	O
agenda	O
and	O
serving	O
as	O
an	O
anchor	O
to	O
align	O
jurisdictional	O
priorities	O
and	O
action	O
.	O

However	O
,	O
without	O
funding	O
or	O
other	O
infrastructure	O
commitments	O
or	O
implementation	B-PROC
plans	I-PROC
,	O
any	O
expectations	O
as	O
to	O
what	O
could	O
be	O
meaningfully	O
achieved	O
were	O
limited	O
.	O

In	O
contrast	O
,	O
although	O
jurisdictions	O
welcomed	O
the	O
NPAPH	B-PROC
,	O
its	O
associated	O
funding	O
and	O
the	O
opportunity	O
to	O
tailor	O
strategy	O
to	O
their	O
unique	O
needs	O
and	O
populations	B-LIVB
,	O
there	O
were	O
calls	O
for	O
greater	O
national	O
leadership	O
as	O
well	O
as	O
guidance	B-PROC
on	O
the	O
evidence	O
base	O
to	O
inform	O
decision	O
making	O
.	O

Key	O
aspects	O
of	O
successful	O
national	O
action	O
were	O
strong	O
Australian	O
Government	O
leadership	O
and	O
coordination	O
,	O
setting	O
a	O
common	O
agenda	O
,	O
national	O
alignment	O
on	O
priorities	O
,	O
evidence	O
-	O
informed	O
implementation	B-PROC
strategies	I-PROC
,	O
partnerships	O
within	O
and	O
across	O
governments	O
,	O
as	O
well	O
as	O
with	O
other	B-LIVB
sectors	I-LIVB
,	O
and	O
funding	O
and	O
infrastructure	O
to	O
support	O
implementation	O
.Conclusions	O
Both	O
the	O
NCDS	O
and	O
NPAPH	B-PROC
were	O
seen	O
to	O
have	O
overlapping	O
strengths	O
and	O
weaknesses	O
.	O

A	O
key	O
need	O
identified	O
was	O
for	O
future	O
approaches	O
to	O
focus	O
on	O
generating	O
more	O
sustainable	O
,	O
system	O
-	O
wide	O
change	O
.	O

What	O
is	O
known	O
about	O
the	O
topic	O
?	O

Despite	O
some	O
important	O
advances	O
,	O
chronic	B-DISO
diseases	I-DISO
remain	O
Australia	B-GEOG
'	O
s	O
greatest	O
health	B-PROC
challenge	I-PROC
.	O

In	O
efforts	O
to	O
tackle	O
this	O
increasing	O
burden	O
from	O
chronic	B-DISO
diseases	I-DISO
,	O
several	O
large	O
-	O
scale	O
,	O
national	B-PHYS
initiatives	I-PHYS
have	O
been	O
released	O
in	O
Australia	B-GEOG
over	O
recent	O
years	O
,	O
including	O
the	O
2005	O
NCDS	O
and	O
the	O
2008	O
NPAPH	B-PROC
.What	O
does	O
this	O
paper	O
add	O
?	O
From	O
the	O
viewpoint	O
of	O
practitioners	B-LIVB
,	O
policy	B-LIVB
makers	I-LIVB
,	O
advocates	O
,	O
researchers	B-LIVB
and	O
public	O
health	O
thought	O
leaders	O
,	O
this	O
paper	O
examines	O
the	O
usefulness	O
and	O
significance	O
of	O
the	O
NCDS	O
and	O
NPAPH	B-PROC
as	O
national	B-PHYS
initiatives	I-PHYS
for	O
achieving	O
improvements	O
to	O
the	O
prevention	O
of	O
chronic	O
disease	O
.What	O
are	O
the	O
implications	O
for	O
practitioners	B-LIVB
?	O

By	O
better	O
understanding	O
how	O
previous	O
countrywide	O
chronic	B-DISO
disease	I-DISO
initiatives	B-PHYS
were	O
viewed	O
and	O
used	O
at	O
national	O
,	O
state	O
and	O
local	O
levels	O
,	O
this	O
research	O
is	O
well	O
placed	O
to	O
inform	O
current	O
,	O
planned	O
and	O
future	O
large	O
-	O
scale	O
,	O
population	O
-	O
level	O
health	O
initiatives	O
.	O

Quantifying	O
Nonlinear	O
Contributions	O
to	O
Cortical	B-PROC
Responses	I-PROC
Evoked	I-PROC
by	O
Continuous	B-PROC
Wrist	I-PROC
Manipulation	I-PROC
Cortical	B-PROC
responses	I-PROC
to	O
continuous	B-PHYS
stimuli	I-PHYS
as	O
recorded	O
using	O
either	O
magneto	B-PROC
-	I-PROC
or	O
electroencephalography	B-PROC
(	O
EEG	B-PROC
)	O
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated	O
frequency	O
,	O
indicating	O
nonlinear	O
behavior	O
.	O

Even	O
though	O
the	O
selection	O
of	O
analysis	B-PROC
techniques	O
depends	O
on	O
the	O
linearity	O
of	O
the	O
system	O
under	O
study	O
,	O
the	O
importance	O
of	O
nonlinear	O
contributions	O
to	O
cortical	B-PROC
responses	I-PROC
has	O
not	O
been	O
formally	O
addressed	O
.	O

The	O
goal	O
of	O
this	O
paper	O
is	O
to	O
quantify	O
the	O
nonlinear	O
contributions	O
to	O
the	O
cortical	B-PROC
response	I-PROC
obtained	O
from	O
continuous	O
sensory	B-PROC
stimulation	I-PROC
.	O

EEG	B-PROC
was	O
used	O
to	O
record	O
the	O
cortical	B-PROC
response	I-PROC
evoked	I-PROC
by	O
continuous	B-DISO
movement	I-DISO
of	I-DISO
the	I-DISO
wrist	I-DISO
joint	I-DISO
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic	B-OBJC
manipulator	I-OBJC
.	O

Multisine	O
stimulus	B-PHEN
signals	I-PHEN
(	O
i	O
.	O
e	O
.	O
,	O
the	O
sum	O
of	O
several	O
sinusoids	B-ANAT
)	O
elicit	O
a	O
periodic	O
cortical	B-PROC
response	I-PROC
and	O
allow	O
to	O
assess	O
the	O
nonlinear	O
contributions	O
to	O
the	O
response	O
.	O

Wrist	B-PROC
dynamics	I-PROC
(	O
relation	O
between	O
joint	B-ANAT
angle	I-ANAT
and	O
torque	B-PHEN
)	O
were	O
successfully	O
linearized	O
,	O
explaining	O
99	O
%	O
of	O
the	O
response	O
.	O

In	O
contrast	O
,	O
the	O
cortical	B-PROC
response	I-PROC
revealed	O
a	O
highly	O
nonlinear	O
relation	O
;	O
where	O
most	O
power	O
(	O
∼	O
80	O
%	O
)	O
occurred	O
at	O
non	O
-	O
stimulated	O
frequencies	O
.	O

Moreover	O
,	O
only	O
10	O
%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric	O
linear	O
model	O
.	O

These	O
results	B-DISO
indicate	O
that	O
the	O
recorded	O
evoked	B-PROC
cortical	I-PROC
responses	I-PROC
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	O
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical	B-PHEN
stimulus	I-PHEN
and	O
cortical	B-DISO
response	I-DISO
.	O

Directed	O
Functional	O
Networks	O
in	O
Alzheimer	B-DISO
's	I-DISO
Disease	I-DISO
:	O
Disruption	O
of	O
Global	O
and	O
Local	O
Connectivity	O
Measures	O
Techniques	O
available	O
in	O
graph	O
theory	O
can	O
be	O
applied	O
to	O
signals	B-PHEN
recorded	I-PHEN
from	O
human	B-ANAT
brain	I-ANAT
.	O

In	O
network	B-PROC
analysis	I-PROC
of	O
EEG	B-PROC
signals	B-PHEN
,	O
the	O
individual	O
nodes	O
are	O
EEG	B-PROC
sensor	B-OBJC
locations	O
and	O
the	O
edges	O
correspond	O
to	O
functional	O
relations	O
between	O
them	O
that	O
are	O
extracted	O
from	O
EEG	B-PROC
time	O
series	O
.	O

In	O
this	O
work	O
,	O
we	O
study	O
EEG	B-PROC
-based	O
directed	O
functional	O
networks	O
in	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O
AD	B-DISO
)	O
.	O

To	O
this	O
end	O
,	O
directed	O
connectivity	O
matrices	O
of	O
25	O
AD	B-DISO
patients	B-LIVB
and	O
26	O
healthy	B-LIVB
subjects	I-LIVB
are	O
processed	B-PHEN
and	O
a	O
number	O
of	O
neurophysiologically	B-PHYS
meaningful	O
graph	O
theory	O
metrics	O
are	O
studied	O
.	O

Our	O
data	O
show	O
that	O
functional	O
networks	O
of	O
AD	B-DISO
brains	B-ANAT
have	O
significantly	O
reduced	O
global	O
connectivity	O
in	O
alpha	O
and	O
beta	O
bands	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
AD	B-DISO
brains	B-ANAT
have	O
significantly	O
higher	O
local	O
connectivity	O
than	O
healthy	O
controls	O
in	O
alpha	O
and	O
beta	O
bands	O
.	O

This	O
decreased	B-DISO
profile	I-DISO
in	O
global	O
connectivity	O
can	O
be	O
linked	O
to	O
compensatory	O
increased	O
local	O
connectivity	O
as	O
a	O
result	O
of	O
widespread	O
decline	O
in	O
the	O
long	O
-	O
range	O
connections	O
.	O

We	O
also	O
study	O
resiliency	O
of	O
brain	B-ANAT
networks	I-ANAT
against	O
targeted	B-DISO
attack	I-DISO
to	O
hub	O
nodes	O
and	O
find	O
that	O
AD	B-DISO
networks	B-ANAT
are	O
less	B-DISO
resilient	I-DISO
than	O
healthy	O
brains	B-ANAT
in	O
alpha	O
and	O
beta	O
bands	O
.	O

Assessment	O
of	O
Interleukin	B-CHEM
-	I-CHEM
17A	I-CHEM
,	O
Interleukin	B-CHEM
-	I-CHEM
10	I-CHEM
and	O
Transforming	B-CHEM
Growth	I-CHEM
Factor	I-CHEM
-	I-CHEM
Beta1	I-CHEM
Serum	B-ANAT
Titers	O
in	O
Relapsing	B-PHEN
Remitting	O
Multiple	B-DISO
Sclerosis	I-DISO
Patients	B-LIVB
Treated	O
with	O
Avonex	B-CHEM
,	O
Possible	B-DISO
Biomarkers	B-PHYS
for	O
Treatment	B-PHYS
Response	I-PHYS
Individual	B-LIVB
response	B-PHYS
to	O
interferon	B-CHEM
beta	I-CHEM
(	I-CHEM
IFN	I-CHEM
-	I-CHEM
β	I-CHEM
)	I-CHEM
1a	I-CHEM
treatment	O
is	O
heterogeneous	O
in	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	B-DISO
)	O
.	O

Our	O
objective	O
was	O
to	O
find	O
a	O
connection	O
between	O
serum	B-ANAT
levels	O
of	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
10	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
beta	I-CHEM
(	I-CHEM
TGF	I-CHEM
-	I-CHEM
β	I-CHEM
)	I-CHEM
1	I-CHEM
in	O
MS	B-DISO
patients	B-LIVB
treated	O
with	O
IFN	B-CHEM
-	I-CHEM
β	I-CHEM
in	O
order	O
to	O
identify	B-DISO
the	O
nonresponders	B-DISO
(	O
NR	B-DISO
)	O
.	O

We	O
included	O
in	O
the	O
study	B-PROC
32	O
healthy	B-LIVB
subjects	I-LIVB
and	O
32	O
MS	B-DISO
patients	B-LIVB
:	O
10	O
naive	O
,	O
10	O
early	O
treated	O
and	O
12	O
late	O
treated	O
with	O
INF	B-CHEM
-	I-CHEM
β1a	I-CHEM
.	O

Serum	B-ANAT
determination	B-PROC
of	O
cytokines	B-CHEM
and	O
brain	B-PROC
MRI	I-PROC
were	O
performed	O
at	O
the	O
beginning	O
of	O
the	O
study	B-PROC
,	O
after	O
6	O
and	O
12	O
months	O
.	O

Rio	O
score	O
was	O
calculated	O
at	O
the	O
end	O
of	O
the	O
study	B-PROC
.	O

MS	B-DISO
patients	B-LIVB
had	O
initially	O
a	O
significant	O
higher	O
level	O
of	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O
a	O
lower	O
level	O
of	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
compared	O
to	O
healthy	B-LIVB
subjects	I-LIVB
.	O

IL	B-CHEM
-	I-CHEM
17	I-CHEM
level	O
in	O
early	O
treated	O
patients	B-LIVB
was	O
significantly	O
lower	O
compared	O
to	O
the	O
naive	O
and	O
late	O
treated	O
groups	B-LIVB
.	O

INF	B-CHEM
-	I-CHEM
β1a	I-CHEM
treatment	O
significantly	O
increased	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O
decreased	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
levels	O
.	O

Initial	O
low	O
levels	O
of	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
were	O
associated	O
with	O
an	O
increase	O
in	O
physical	B-DISO
disability	I-DISO
.	O

IL	B-CHEM
-	I-CHEM
17	I-CHEM
levels	O
positively	O
correlated	O
with	O
the	O
number	O
of	O
relapses	B-PHEN
and	O
MRI	B-PROC
activity	O
.	O

Nine	O
patients	B-LIVB
were	O
NR	B-DISO
to	O
Avonex	B-CHEM
.	O

Patients	B-LIVB
with	O
a	O
Rio	O
score	O
of	O
3	O
had	O
higher	O
initial	O
levels	O
of	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O
those	O
with	O
a	O
Rio	O
score	O
of	O
0	O
had	O
higher	O
initial	O
levels	O
of	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
.	O

IFN	B-CHEM
-	I-CHEM
β1a	I-CHEM
decreased	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O
increased	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
seric	B-ANAT
levels	O
;	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
significantly	O
correlated	O
with	O
MS	B-DISO
activity	O
;	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
activity	O
is	O
titer	O
-	O
dependent	O
,	O
increased	O
levels	O
were	O
associated	O
with	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
inhibition	O
;	O
NR	B-DISO
patients	B-LIVB
to	O
IFN	B-CHEM
-	I-CHEM
β1a	I-CHEM
will	O
have	O
initial	O
high	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O
low	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
seric	B-ANAT
levels	O
.	O

Cardiovascular	B-PROC
magnetic	I-PROC
resonance	I-PROC
features	O
of	O
mechanical	B-ANAT
dyssynchrony	B-DISO
in	O
patients	B-LIVB
with	O
left	B-DISO
bundle	I-DISO
branch	I-DISO
block	I-DISO
Patients	B-LIVB
with	O
left	B-DISO
bundle	I-DISO
branch	I-DISO
block	I-DISO
(	O
LBBB	B-DISO
)	O
can	O
exhibit	O
mechanical	B-ANAT
dyssynchrony	B-DISO
which	O
may	O
contribute	O
to	O
heart	B-DISO
failure	I-DISO
;	O
such	O
patients	B-LIVB
may	O
benefit	O
from	O
cardiac	B-PROC
resynchronization	I-PROC
treatment	I-PROC
(	O
CRT	B-PROC
)	O
.	O

While	O
cardiac	B-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O
CMR	B-PROC
)	O
has	O
become	O
a	O
common	O
part	O
of	O
heart	B-DISO
failure	I-DISO
work	B-PROC
-	I-PROC
up	I-PROC
,	O
CMR	B-PROC
features	O
of	O
mechanical	B-ANAT
dyssynchrony	B-DISO
in	O
patients	B-LIVB
with	O
LBBB	B-DISO
have	O
not	O
been	O
well	O
characterized	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
potential	O
of	O
CMR	B-PROC
to	O
characterize	O
mechanical	B-ANAT
features	O
of	O
LBBB	B-DISO
.	O

CMR	B-PROC
examinations	O
from	O
43	O
patients	B-LIVB
with	O
LBBB	B-DISO
on	O
their	O
electrocardiogram	B-DISO
,	O
but	O
without	O
significant	O
focal	O
structural	B-DISO
abnormalities	I-DISO
,	O
and	O
from	O
43	O
age	O
-	O
and	O
gender	B-PHYS
-matched	O
normal	O
controls	O
were	O
retrospectively	B-PROC
reviewed	I-PROC
.	O

The	O
following	O
mechanical	B-ANAT
features	O
of	O
LBBB	B-DISO
were	O
evaluated	O
:	O
septal	B-DISO
flash	I-DISO
(	O
SF	B-DISO
)	O
,	O
apical	B-DISO
rocking	I-DISO
(	O
AR	B-DISO
)	O
,	O
delayed	B-DISO
aortic	I-DISO
valve	I-DISO
opening	I-DISO
measured	I-DISO
relative	I-DISO
to	I-DISO
both	I-DISO
end	I-DISO
-	I-DISO
diastole	I-DISO
(	O
AVOED	B-DISO
)	O
and	O
pulmonic	B-DISO
valve	I-DISO
opening	I-DISO
(	O
AVOPVO	B-DISO
)	O
,	O
delayed	B-DISO
left	I-DISO
-	I-DISO
ventricular	I-DISO
(	I-DISO
LV	I-DISO
)	I-DISO
free	I-DISO
-	I-DISO
wall	I-DISO
contraction	I-DISO
,	O
and	O
curvatures	B-DISO
of	I-DISO
the	I-DISO
septum	I-DISO
and	I-DISO
LV	I-DISO
free	I-DISO
-	I-DISO
wall	I-DISO
.	O

Septal	B-PHYS
displacement	I-PHYS
curves	I-PHYS
were	O
also	O
generated	O
,	O
using	O
feature	O
-tracking	O
techniques	O
.	O

The	O
echocardiographic	B-PROC
findings	O
of	O
LBBB	B-DISO
were	O
also	O
reviewed	O
in	O
those	O
subjects	O
for	O
whom	O
they	O
were	O
available	O
.	O

LBBB	B-DISO
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
SF	B-DISO
and	O
AR	B-DISO
;	O
within	O
the	O
LBBB	B-DISO
group	O
,	O
79	O
%	O
had	O
SF	B-DISO
and	O
65	O
%	O
had	O
AR	B-DISO
.	O

Delayed	B-DISO
AVOED	I-DISO
,	O
AVOPVO	B-DISO
,	O
and	O
delayed	B-DISO
LV	I-DISO
free	I-DISO
-	I-DISO
wall	I-DISO
contraction	I-DISO
were	O
significantly	O
associated	O
with	O
LBBB	B-DISO
.	O

AVOED	B-DISO
and	O
AVOPVO	B-DISO
positively	O
correlated	O
with	O
QRS	B-PHYS
duration	I-PHYS
and	O
negatively	O
correlated	O
with	O
ejection	B-PROC
fraction	I-PROC
.	O

Hearts	B-ANAT
with	O
electrocardiographic	B-PROC
evidence	O
of	O
LBBB	B-DISO
showed	O
lower	O
septal	O
-	O
to	O
-	O
LV	O
free	O
-	O
wall	O
curvature	O
ratios	O
at	O
end	O
-	O
diastole	O
compared	O
to	O
normal	O
controls	O
.	O

CMR	B-PROC
can	O
be	O
used	O
to	O
identify	O
and	O
evaluate	O
mechanical	B-ANAT
dyssynchrony	B-DISO
in	O
patients	B-LIVB
with	O
LBBB	B-DISO
.	O

None	O
of	O
the	O
normal	O
controls	O
showed	O
the	O
mechanical	B-ANAT
features	O
associated	O
with	O
LBBB	B-DISO
.	O

Moreover	O
,	O
not	O
all	O
patients	B-LIVB
with	O
LBBB	B-DISO
showed	O
the	O
same	O
degree	O
of	O
mechanical	B-ANAT
dyssynchrony	B-DISO
,	O
which	O
could	O
have	O
implications	O
for	O
CRT	B-PROC
.	O

Delayed	O
progression	B-DISO
of	O
rabies	B-DISO
transmitted	B-DISO
by	O
a	O
vampire	B-LIVB
bat	I-LIVB
Here	O
,	O
we	O
compared	O
the	O
growth	B-PHYS
kinetics	B-PHEN
,	O
cell	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
cell	I-PHYS
spread	I-PHYS
,	O
and	O
virus	B-PHEN
internalization	I-PHEN
kinetics	B-PHEN
in	O
N2a	B-ANAT
cells	I-ANAT
of	O
RABV	B-LIVB
variants	B-DISO
isolated	O
from	O
vampire	B-LIVB
bats	I-LIVB
(	O
V	B-DISO
-	I-DISO
3	I-DISO
)	O
,	O
domestic	B-LIVB
dogs	I-LIVB
(	O
V	B-DISO
-	I-DISO
2	I-DISO
)	O
and	O
marmosets	B-LIVB
(	O
V	B-DISO
-	I-DISO
M	I-DISO
)	O
as	O
well	O
as	O
the	O
clinical	O
symptoms	B-DISO
and	O
mortality	O
caused	O
by	O
these	O
variants	B-DISO
.	O

The	O
replication	B-PHYS
rate	O
of	O
V	B-DISO
-	I-DISO
3	I-DISO
was	O
significantly	O
higher	O
than	O
those	O
of	O
V	B-DISO
-	I-DISO
2	I-DISO
and	O
V	B-DISO
-	I-DISO
M	I-DISO
.	O

However	O
,	O
the	O
uptake	B-PHYS
and	O
spread	B-PHYS
of	O
these	O
RABV	B-LIVB
variants	B-DISO
into	O
N2a	B-ANAT
cells	I-ANAT
were	O
inversely	O
proportional	O
.	O

Nevertheless	O
,	O
V	B-DISO
-	I-DISO
3	I-DISO
had	O
longer	O
incubation	B-DISO
and	O
evolution	B-PHYS
periods	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
the	O
clinical	O
manifestations	O
of	O
infection	B-DISO
with	O
bat	B-LIVB
RABV	B-LIVB
variant	B-DISO
occur	O
at	O
a	O
later	O
time	O
when	O
compared	O
to	O
what	O
was	O
observed	O
with	O
canine	B-LIVB
and	O
marmoset	B-LIVB
rabies	B-LIVB
virus	I-LIVB
variants	B-DISO
.	O

Using	O
melanopsin	B-CHEM
to	O
study	B-PROC
G	B-PHYS
protein	I-PHYS
signaling	I-PHYS
in	O
cortical	B-ANAT
neurons	B-ANAT
Our	O
understanding	B-PHYS
of	O
G	B-CHEM
protein	I-CHEM
-	I-CHEM
coupled	I-CHEM
receptors	I-CHEM
(	O
GPCRs	B-CHEM
)	O
in	O
the	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
(	O
CNS	B-ANAT
)	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	B-OBJC
allowing	O
for	O
the	O
study	B-PROC
of	O
their	O
signaling	B-PHEN
with	O
precise	O
temporal	O
control	O
.	O

To	O
overcome	O
this	O
,	O
we	O
tested	O
the	O
utility	O
of	O
the	O
bistable	O
mammalian	B-LIVB
opsin	B-CHEM
melanopsin	B-CHEM
to	O
examine	O
G	B-PHYS
protein	I-PHYS
signaling	I-PHYS
in	O
CNS	B-ANAT
neurons	B-ANAT
.	O

Specifically	O
,	O
we	O
used	O
biolistic	B-PROC
(	O
gene	B-DEVI
gun	I-DEVI
)	O
approaches	O
to	O
transfect	B-CHEM
melanopsin	I-CHEM
into	O
cortical	B-ANAT
pyramidal	B-ANAT
cells	I-ANAT
maintained	O
in	O
organotypic	B-PROC
slice	I-PROC
culture	I-PROC
.	O

Whole	B-PROC
cell	I-PROC
recordings	I-PROC
from	O
transfected	B-ANAT
neurons	I-ANAT
indicated	O
that	O
application	O
of	O
blue	B-PHEN
light	I-PHEN
effectively	O
activated	O
the	O
transfected	B-CHEM
melanopsin	I-CHEM
to	O
elicit	O
the	O
canonical	O
biphasic	O
modulation	O
of	O
membrane	B-ANAT
excitability	B-DISO
previously	O
associated	O
with	O
the	O
activation	O
of	O
GPCRs	B-CHEM
coupling	O
to	O
Gαq	B-CHEM
-	I-CHEM
11	I-CHEM
Remarkably	O
,	O
full	O
mimicry	O
of	O
exogenous	O
agonist	B-CHEM
concentration	O
could	O
be	O
obtained	O
with	O
pulses	B-PHEN
as	O
short	O
as	O
a	O
few	O
milliseconds	O
,	O
suggesting	O
that	O
their	O
triggering	O
required	O
a	O
single	O
melanopsin	B-CHEM
activation	O
-	O
deactivation	O
cycle	O
.	O

The	O
resulting	O
temporal	O
control	O
over	O
melanopsin	B-CHEM
activation	O
allowed	O
us	O
to	O
compare	O
the	O
activation	O
kinetics	B-PHEN
of	O
different	O
components	O
of	O
the	O
electrophysiological	B-PHYS
response	B-PHYS
.	O

We	O
also	O
replaced	O
the	O
intracellular	O
loops	O
of	O
melanopsin	B-CHEM
with	O
those	O
of	O
the	O
5	B-CHEM
-	I-CHEM
HT2A	I-CHEM
receptor	I-CHEM
to	O
create	O
a	O
light	B-PHEN
-	I-PHEN
activated	I-PHEN
GPCR	B-CHEM
capable	O
of	O
interacting	O
with	O
the	O
5	B-CHEM
-	I-CHEM
HT2A	I-CHEM
receptor	I-CHEM
interacting	O
proteins	B-CHEM
.	O

The	O
resulting	O
chimera	B-CHEM
expressed	O
weak	O
activity	O
but	O
validated	B-PROC
the	O
potential	O
usefulness	O
of	O
melanopsin	B-CHEM
as	O
a	O
tool	B-OBJC
for	O
the	O
study	B-PROC
of	O
G	B-PHYS
protein	I-PHYS
signaling	I-PHYS
in	O
CNS	B-ANAT
neurons	B-ANAT
.	O

Naïve	B-ANAT
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cell	I-ANAT
derived	O
tumor	B-DISO
-	O
specific	O
cytotoxic	B-ANAT
effectors	I-ANAT
as	O
a	O
potential	O
remedy	O
for	O
overcoming	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
immunosuppression	B-DISO
in	O
the	O
tumor	B-PHEN
microenvironment	I-PHEN
Despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer	B-PROC
immunotherapy	I-PROC
,	O
conventional	O
approaches	O
using	O
in	O
vitro	O
expanded	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
have	O
suboptimal	O
outcomes	O
,	O
mostly	O
due	O
to	O
loss	O
of	O
functionality	O
from	O
cellular	B-ANAT
exhaustion	O
.	O

We	O
therefore	O
investigated	O
the	O
phenotypic	B-PHYS
and	O
functional	O
differences	O
among	O
in	O
vitro	O
activated	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
of	O
three	O
different	O
sources	B-DISO
,	O
namely	O
naïve	B-ANAT
(	O
NTeff	B-ANAT
)	O
,	O
memory	B-ANAT
(	O
MTeff	B-ANAT
)	O
and	O
tumor	B-ANAT
-	I-ANAT
infiltrating	I-ANAT
lymphocytes	I-ANAT
(	O
TILeff	B-ANAT
)	O
from	O
human	B-LIVB
and	O
mice	B-LIVB
,	O
to	O
better	O
understand	O
mechanisms	O
behind	O
potent	O
effector	B-ANAT
functions	O
and	O
potential	O
for	O
overcoming	O
current	O
limitations	O
.	O

In	O
line	O
with	O
the	O
greater	O
proliferation	B-PHYS
activity	O
and	O
longer	O
telomere	B-ANAT
lengths	O
of	O
NTeff	B-ANAT
populations	I-ANAT
,	O
cells	B-ANAT
of	O
naïve	O
origin	O
exhibited	O
significantly	O
less	O
amounts	O
of	O
T	B-ANAT
cell	I-ANAT
exhaustion	O
markers	B-PHYS
than	O
those	O
of	O
MTeff	B-ANAT
and	O
TILeff	B-ANAT
,	O
and	O
moreover	O
,	O
acquired	O
distinct	O
expression	B-PHYS
patterns	I-PHYS
of	O
memory	B-CHEM
-	I-CHEM
promoting	I-CHEM
transcription	I-CHEM
factors	I-CHEM
,	O
T	B-CHEM
-	I-CHEM
bet	I-CHEM
and	O
Eomes	B-CHEM
,	O
induced	O
in	O
a	O
rapid	O
and	O
sustainable	O
manner	O
.	O

NTeff	B-ANAT
cells	I-ANAT
appeared	O
to	O
have	O
lower	O
expression	B-PHYS
of	O
Foxp1	B-CHEM
and	O
were	O
refractory	O
to	O
apoptosis	B-PHYS
upon	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
conditioning	O
,	O
implying	O
better	O
survival	B-PHYS
potential	O
and	O
resistance	O
to	O
tumor	B-DISO
-	O
induced	O
immune	B-DISO
suppression	I-DISO
.	O

Of	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cell	I-ANAT
pools	O
activated	O
to	O
tumor	B-DISO
-	O
specific	O
CTLs	B-ANAT
,	O
naïve	B-ANAT
cell	I-ANAT
generated	O
effectors	B-ANAT
possessed	O
the	O
most	O
potent	O
cytotoxic	B-DISO
activity	I-DISO
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	O
of	O
adoptive	B-PROC
immunotherapy	I-PROC
.	O

SHOT	B-CHEM
-	O
RNAs	B-CHEM
:	O
A	O
novel	O
class	O
of	O
tRNA	B-CHEM
-derived	O
functional	O
RNAs	B-CHEM
expressed	B-PHYS
in	O
hormone	B-DISO
-	I-DISO
dependent	I-DISO
cancers	I-DISO
Sex	B-CHEM
hormones	I-CHEM
and	O
their	O
receptors	B-CHEM
play	O
critical	O
roles	O
in	O
the	O
genesis	B-DISO
and	O
progression	B-DISO
of	O
breast	B-DISO
and	O
prostate	B-DISO
cancers	I-DISO
.	O

We	O
recently	O
discovered	O
that	O
sex	B-CHEM
hormone	I-CHEM
signaling	B-PHYS
pathways	I-PHYS
promote	O
the	O
expression	B-PHYS
of	O
specific	O
tRNA	B-CHEM
halves	O
termed	O
Sex	B-CHEM
HOrmone	I-CHEM
-dependent	O
TRNA	B-CHEM
-derived	O
RNAs	B-CHEM
(	O
SHOT	B-CHEM
-	O
RNAs	B-CHEM
)	O
.	O

Functional	O
involvement	O
of	O
SHOT	B-CHEM
-	O
RNAs	B-CHEM
in	O
cell	B-PHYS
proliferation	I-PHYS
suggests	O
a	O
novel	O
tRNA	B-CHEM
-engaged	O
pathway	B-PHYS
in	O
tumorigenesis	B-DISO
.	O

Maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
and	O
the	O
risk	O
of	O
perinatal	B-DISO
death	I-DISO
To	O
determine	O
the	O
association	O
between	O
maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
and	O
perinatal	B-DISO
death	I-DISO
.	O

A	O
retrospective	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
of	O
all	O
non	O
-	O
anomalous	O
,	O
singleton	B-LIVB
births	B-PHYS
(	O
≥24	O
weeks	O
)	O
with	O
perinatal	B-DISO
death	I-DISO
compared	O
to	O
a	O
matched	O
control	B-LIVB
group	I-LIVB
.	O

Only	O
pregnancies	B-PHYS
with	O
a	O
recorded	O
vitamin	B-CHEM
D	I-CHEM
level	O
at	O
booking	O
(	O
8	O
-	O
19	O
weeks	O
gestation	B-PHYS
)	O
were	O
included	O
for	O
analysis	B-PROC
.	O

Maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
were	O
categorized	O
into	O
normal	O
,	O
deficient	O
and	O
insufficient	O
cohorts	B-LIVB
and	O
variables	O
compared	O
between	O
the	O
three	O
groups	B-LIVB
.	O

There	O
were	O
31	O
perinatal	B-DISO
deaths	I-DISO
which	O
were	O
compared	O
to	O
111	O
controls	B-LIVB
.	O

Median	O
vitamin	B-CHEM
D	I-CHEM
levels	O
were	O
lower	O
in	O
the	O
perinatal	B-DISO
death	I-DISO
cohort	B-LIVB
compared	O
to	O
the	O
control	B-LIVB
group	I-LIVB
(	O
55	O
nmol	O
/	O
L	O
versus	O
64	O
nmol	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
43	O
)	O
.	O

There	O
was	O
no	O
significant	O
increase	O
in	O
deaths	B-PHYS
between	O
the	O
normal	O
and	O
deficient	O
(	O
p	O
=	O
0	O
.	O

33	O
)	O
or	O
insufficient	O
(	O
p	O
=	O
0	O
.	O
09	O
)	O
groups	B-LIVB
.	O

Low	O
maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
at	O
booking	O
were	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
perinatal	B-DISO
demise	I-DISO
.	O

Antiadipogenic	B-DISO
Activity	I-DISO
of	O
γ	B-CHEM
-	I-CHEM
Oryzanol	I-CHEM
and	O
Its	O
Stability	O
in	O
Pigmented	O
Rice	B-OBJC
γ	B-CHEM
-	I-CHEM
Oryzanol	I-CHEM
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	O
rice	B-OBJC
varieties	O
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity	B-DISO
-	I-DISO
associated	I-DISO
metabolic	I-DISO
disorders	I-DISO
.	O

Antiadipogenic	B-DISO
activities	I-DISO
of	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
were	O
determined	O
in	O
human	B-LIVB
adipose	O
-	O
derived	O
mesenchymal	B-ANAT
stem	I-ANAT
cells	I-ANAT
and	O
mouse	B-LIVB
-	O
derived	O
3T3	B-ANAT
-	I-ANAT
L1	I-ANAT
cells	I-ANAT
.	O

γ	B-CHEM
-	I-CHEM
Oryzanol	I-CHEM
significantly	O
decreased	O
lipid	B-DISO
accumulation	I-DISO
and	O
reduced	O
glycerol	B-PHYS
-	I-PHYS
3	I-PHYS
-	I-PHYS
phosphate	I-PHYS
dehydrogenase	I-PHYS
activities	I-PHYS
in	O
both	O
adipocytes	B-ANAT
.	O

In	O
addition	O
,	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
in	O
four	O
pigmented	O
rice	B-OBJC
varieties	O
(	O
black	B-OBJC
with	I-OBJC
giant	I-OBJC
embryo	I-OBJC
,	O
brown	B-OBJC
,	O
sugary	B-OBJC
brown	I-OBJC
,	O
and	O
red	B-OBJC
)	O
was	O
stable	O
when	O
stored	O
at	O
4°C	O
and	O
also	O
at	O
room	O
temperature	O
for	O
22	O
weeks	O
,	O
whereas	O
other	O
bioactives	B-OBJC
such	O
as	O
lutein	B-CHEM
and	O
β	B-CHEM
-	I-CHEM
carotene	I-CHEM
were	O
stable	O
only	O
at	O
-80°C	O
.	O

Furthermore	O
,	O
the	O
yield	O
of	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
from	O
these	O
rice	B-OBJC
varieties	O
was	O
significantly	O
increased	O
through	O
steaming	B-PHEN
and	O
roasting	B-PHEN
processes	I-PHEN
.	O

Therefore	O
,	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
exerts	O
antiadipogenic	B-DISO
activity	I-DISO
by	O
suppressing	O
adipocyte	B-PHYS
differentiations	I-PHYS
and	O
is	O
stable	O
in	O
pigmented	O
rice	B-OBJC
for	O
an	O
extended	O
period	O
of	O
time	O
during	O
storage	O
and	O
after	O
cooking	O
.	O

Thus	O
,	O
the	O
intake	O
of	O
pigmented	O
rice	B-OBJC
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	O
obesity	B-DISO
.	O

Upstream	B-PHYS
Pathways	I-PHYS
Controlling	O
Mitochondrial	O
Function	O
in	O
Major	O
Psychosis	B-DISO
:	O
A	O
Focus	O
on	O
Bipolar	B-DISO
Disorder	I-DISO
Mitochondrial	B-DISO
dysfunction	I-DISO
is	O
commonly	O
observed	O
in	O
bipolar	B-DISO
disorder	I-DISO
(	O
BD	B-DISO
)	O
and	O
schizophrenia	B-DISO
(	O
SCZ	B-DISO
)	O
and	O
may	O
be	O
a	O
central	O
feature	O
of	O
psychosis	B-DISO
.	O

These	O
illnesses	B-DISO
are	O
complex	O
and	O
heterogeneous	B-DISO
,	O
which	O
is	O
reflected	O
by	O
the	O
complexity	O
of	O
the	O
processes	B-PHEN
regulating	O
mitochondrial	O
function	O
.	O

Mitochondria	B-ANAT
are	O
typically	O
associated	O
with	O
energy	B-PHYS
production	I-PHYS
;	O
however	O
,	O
dysfunction	O
of	O
mitochondria	B-ANAT
affects	O
not	O
only	O
energy	B-PHYS
production	I-PHYS
but	O
also	O
vital	O
cellular	B-PHYS
processes	I-PHYS
,	O
including	O
the	O
formation	B-PHEN
of	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
,	O
cell	B-PHYS
cycle	I-PHYS
and	O
survival	B-PHYS
,	O
intracellular	B-PHYS
Ca	I-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
homeostasis	I-PHYS
,	O
and	O
neurotransmission	B-PHYS
.	O

In	O
this	O
review	O
,	O
we	O
characterize	O
the	O
upstream	B-CHEM
components	I-CHEM
controlling	O
mitochondrial	O
function	O
,	O
including	O
1	O
)	O
mutations	B-PHYS
in	O
nuclear	B-CHEM
and	O
mitochondrial	B-CHEM
DNA	I-CHEM
,	O
2	O
)	O
mitochondrial	B-PHYS
dynamics	I-PHYS
,	O
and	O
3	O
)	O
intracellular	B-PHYS
Ca	I-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
homeostasis	I-PHYS
.	O

Characterizing	O
and	O
understanding	O
the	O
upstream	B-CHEM
factors	I-CHEM
that	O
regulate	O
mitochondrial	O
function	O
is	O
essential	O
to	O
understand	O
progression	B-DISO
of	O
these	O
illnesses	B-DISO
and	O
develop	O
biomarkers	B-PHYS
and	O
therapeutics	B-PROC
.	O

Impact	O
of	O
Chemotherapy	B-PROC
on	O
Diet	B-OBJC
and	O
Nutritional	B-DISO
Status	I-DISO
of	O
Women	B-LIVB
with	O
Breast	B-DISO
Cancer	I-DISO
:	O
A	O
Prospective	B-PROC
Study	I-PROC
Certain	O
food	B-OBJC
groups	I-OBJC
are	O
often	O
rejected	O
during	O
chemotherapy	B-PROC
(	O
CT	B-PROC
)	O
due	O
to	O
the	O
side	B-DISO
effects	I-DISO
of	I-DISO
treatment	I-DISO
,	O
which	O
may	O
interfere	O
with	O
adequate	O
diet	O
and	O
nutritional	B-DISO
status	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
the	O
treatment	O
impact	O
on	O
the	O
diet	B-OBJC
and	O
nutritional	B-DISO
status	I-DISO
of	O
women	B-LIVB
with	O
breast	B-DISO
cancer	I-DISO
(	O
BC	B-DISO
)	O
.	O

In	O
this	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
,	O
conducted	O
in	O
2014	O
-	O
2015	O
,	O
55	O
women	B-LIVB
diagnosed	O
with	O
BC	B-DISO
,	O
with	O
a	O
mean	O
age	B-PHYS
51	O
.	O

5±10	O
.	O

1	O
years	O
,	O
were	O
followed	O
and	O
data	O
were	O
collected	O
at	O
three	O
different	O
times	O
.	O

Anthropometric	O
and	O
dietary	B-PROC
assessments	I-PROC
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	B-PROC
recall	I-PROC
s	O
,	O
by	O
using	O
the	O
Brazilian	O
Healthy	O
Eating	O
Index	O
Revised	O
(	O
BHEI	O
-	O
R	O
)	O
,	O
and	O
calculating	O
the	O
prevalence	O
of	O
inadequacy	O
by	O
the	O
EAR	O
cut	O
-	O
off	O
point	O
method	O
.	O

Regarding	O
the	O
BHEI	O
-	O
R	O
analysis	B-PROC
,	O
the	O
majority	O
of	O
women	B-LIVB
had	O
a	O
""""	O
diet	B-OBJC
requires	O
modification	B-DISO
'	O
,	O
both	O
at	O
the	O
beginning	O
(	O
T0	O
,	O
58	O
.	O
2	O
%	O
,	O
n	O
=	O
32	O
)	O
and	O
during	O
treatment	O
(	O
T1	O
,	O
54	O
.	O

5	O
%	O
,	O
n	O
=	O
30	O
)	O
.	O

However	O
,	O
after	O
the	O
end	O
of	O
the	O
CT	B-PROC
,	O
the	O
greater	O
percentage	O
of	O
patients	B-LIVB
(	O
T2	O
,	O
49	O
.	O
1	O
%	O
,	O
n	O
=	O
27	O
)	O
were	O
classified	O
as	O
having	O
an	O
""""	O
inadequate	B-DISO
diet	I-DISO
""""	O
,	O
since	O
the	O
Total	O
Fruit	B-OBJC
consumption	O
as	O
well	O
as	O
the	O
Dark	B-OBJC
Green	I-OBJC
and	O
Orange	B-OBJC
Vegetable	I-OBJC
and	O
Legume	B-LIVB
consumption	O
decreased	O
significantly	O
during	O
treatment	O
(	O
p	O
=	O
0	O
.	O

043	O
and	O
p	O
=	O
0	O
.	O

026	O
,	O
respectively	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
intake	O
of	O
macro	O
and	O
micronutrients	B-CHEM
,	O
with	O
a	O
high	O
prevalence	O
of	O
inadequacy	O
,	O
of	O
up	O
to	O
100	O
%	O
,	O
for	O
calcium	B-CHEM
,	O
iron	B-CHEM
,	O
phosphorus	B-CHEM
,	O
magnesium	B-CHEM
,	O
niacin	B-CHEM
,	O
riboflavin	B-CHEM
,	O
thiamin	B-CHEM
,	O
vitamin	B-CHEM
B6	I-CHEM
,	O
vitamin	B-CHEM
C	I-CHEM
and	O
zinc	B-CHEM
.	O

Assessment	B-PROC
of	O
the	O
nutritional	B-DISO
status	I-DISO
indicated	O
that	O
56	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
patients	B-LIVB
were	O
overweight	B-DISO
at	O
these	O
three	O
different	O
times	O
.	O

Weight	B-PHYS
,	O
BMI	B-PHYS
and	O
Waist	B-PHYS
Circumference	I-PHYS
increased	O
significantly	O
,	O
indicating	O
a	O
worse	B-DISO
nutritional	B-DISO
status	I-DISO
,	O
and	O
there	O
was	O
a	O
correlation	O
between	O
poor	O
diet	O
quality	O
and	O
higher	O
values	O
for	O
BMI	B-PHYS
,	O
Waist	B-PHYS
-	I-PHYS
Hip	I-PHYS
Ratio	I-PHYS
and	O
Waist	B-DISO
-	I-DISO
to	I-DISO
-	I-DISO
Height	I-DISO
Ratio	I-DISO
.	O

Chemotherapy	B-PROC
interferes	O
in	O
the	O
patients	B-LIVB
'	O
diet	B-OBJC
generating	O
a	O
negative	O
impact	O
on	O
the	O
quality	O
and	O
intake	O
of	O
micro	B-CHEM
and	O
macronutrients	O
,	O
as	O
well	O
as	O
an	O
impact	O
on	O
their	O
nutritional	B-DISO
status	I-DISO
,	O
with	O
an	O
increase	O
in	O
anthropometric	O
measurements	O
.	O

The	O
Origin	O
of	O
Selectivity	O
in	O
the	O
Complexation	O
of	O
N	B-CHEM
-	I-CHEM
Methyl	I-CHEM
Amino	I-CHEM
Acids	I-CHEM
by	O
Tetraphosphonate	B-CHEM
Cavitands	I-CHEM
We	O
report	O
on	O
the	O
eligibility	O
of	O
tetraphosphonate	B-CHEM
resorcinarene	I-CHEM
cavitands	I-CHEM
for	O
the	O
molecular	B-PHYS
recognition	I-PHYS
of	O
amino	B-CHEM
acids	I-CHEM
.	O

We	O
determined	O
the	O
crystal	B-CHEM
structure	I-CHEM
of	O
13	O
complexes	O
of	O
the	O
tetraphosphonate	B-CHEM
cavitand	I-CHEM
Tiiii	B-CHEM
[	I-CHEM
H	I-CHEM
,	I-CHEM
CH3	I-CHEM
,	I-CHEM
CH3	I-CHEM
]	I-CHEM
with	O
amino	B-CHEM
acids	I-CHEM
.	O

(	O
1	O
)	O
H	B-CHEM
NMR	B-PHEN
and	O
(	O
31	O
)	O
P	B-CHEM
NMR	B-PHEN
experiments	B-PROC
and	O
ITC	B-DEVI
analysis	B-PROC
were	O
performed	O
to	O
probe	B-PROC
the	O
binding	B-PHYS
between	O
cavitand	B-CHEM
Tiiii	B-CHEM
[	I-CHEM
C3H7	I-CHEM
,	I-CHEM
CH3	I-CHEM
,	I-CHEM
C2H5	I-CHEM
]	I-CHEM
or	O
the	O
water	B-CHEM
-	O
soluble	O
counterpart	O
Tiiii	B-CHEM
[	I-CHEM
C3H6Py	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
Cl	I-CHEM
(	I-CHEM
-	I-CHEM
)	I-CHEM
,	I-CHEM
CH3	I-CHEM
,	I-CHEM
C2H5	I-CHEM
]	I-CHEM
and	O
a	O
selection	O
of	O
representative	O
amino	B-CHEM
acids	I-CHEM
.	O

The	O
reported	O
studies	B-PROC
and	O
results	B-DISO
allowed	O
us	O
(	O
i	O
)	O
to	O
highlight	O
the	O
noncovalent	B-PHEN
interactions	I-PHEN
involved	O
in	O
the	O
binding	B-PHYS
event	O
in	O
each	O
case	O
;	O
(	O
ii	O
)	O
to	O
investigate	O
the	O
ability	B-PHYS
of	O
tetraphosphonate	B-CHEM
cavitand	I-CHEM
receptors	B-CHEM
to	O
discriminate	O
between	O
the	O
different	O
amino	B-CHEM
acids	I-CHEM
;	O
(	O
iii	O
)	O
to	O
calculate	O
the	O
Ka	O
values	O
of	O
the	O
different	O
complexes	O
formed	O
and	O
evaluate	B-PROC
the	O
thermodynamic	O
parameters	O
of	O
the	O
complexation	O
process	B-PHEN
,	O
dissecting	O
the	O
entropic	B-PHEN
and	O
enthalpic	O
contributions	O
;	O
and	O
(	O
iv	O
)	O
to	O
determine	B-PROC
the	O
solvent	B-CHEM
influence	O
on	O
the	O
complexation	O
selectivity	O
.	O

By	O
moving	B-PHYS
from	O
methanol	B-CHEM
to	O
water	B-CHEM
,	O
the	O
complexation	O
changed	O
from	O
entropy	B-PHEN
driven	O
to	O
entropy	B-PHEN
opposed	O
,	O
leading	O
to	O
a	O
drop	O
of	O
almost	O
three	O
orders	B-PHEN
in	O
the	O
magnitude	O
of	O
the	O
Ka	O
.	O

However	O
,	O
this	O
reduction	O
in	O
binding	B-PHYS
affinity	B-PHEN
is	O
associated	O
with	O
a	O
dramatic	O
increase	O
in	O
selectivity	O
,	O
since	O
in	O
aqueous	B-CHEM
solutions	I-CHEM
only	O
N	B-CHEM
-	I-CHEM
methylated	I-CHEM
amino	I-CHEM
acids	I-CHEM
are	O
effectively	O
recognized	B-PHYS
.	O

The	O
thermodynamic	O
profile	B-PROC
of	O
the	O
binding	B-PHYS
does	O
not	O
change	O
in	O
PBS	B-OBJC
solution	I-OBJC
.	O

The	O
pivotal	O
role	O
played	O
by	O
cation	B-PHEN
-	I-PHEN
π	I-PHEN
interactions	I-PHEN
is	O
demonstrated	O
by	O
the	O
linear	O
correlation	O
found	O
between	O
the	O
log	O
Ka	O
in	O
methanol	B-CHEM
solution	B-OBJC
and	O
the	O
depth	O
of	O
(	B-CHEM
+	I-CHEM
)	I-CHEM
N	I-CHEM
-	I-CHEM
CH3	I-CHEM
cavity	B-DISO
inclusion	O
in	O
the	O
molecular	O
structures	O
.	O

These	O
findings	B-DISO
are	O
relevant	O
for	O
the	O
potential	O
use	O
of	O
phosphonate	B-CHEM
cavitands	I-CHEM
as	O
synthetic	O
receptors	B-CHEM
for	O
the	O
detection	B-PROC
of	O
epigenetic	B-PHYS
modifications	B-DISO
of	O
histones	B-CHEM
in	O
physiological	O
media	B-OBJC
.	O

Computed	B-PROC
Tomography	I-PROC
Imaging	I-PROC
Features	O
and	O
Changes	O
in	O
Hemostatic	B-CHEM
Agents	I-CHEM
After	O
Laparoscopic	B-PROC
Partial	I-PROC
Nephrectomy	I-PROC
Urologists	B-LIVB
and	O
radiologists	B-LIVB
should	O
be	O
aware	O
of	O
the	O
CT	B-PROC
scan	I-PROC
appearance	O
of	O
laparoscopic	B-PROC
partial	I-PROC
nephrectomy	I-PROC
(	O
LPN	B-PROC
)	O
with	O
the	O
various	O
hemostatic	B-CHEM
agents	I-CHEM
since	O
they	O
may	O
confound	O
the	O
interpretation	O
of	O
these	O
radiographic	B-DISO
findings	I-DISO
.	O

We	O
report	O
the	O
various	O
postoperative	O
CT	B-PROC
scan	I-PROC
appearance	O
and	O
changes	O
after	O
LPN	B-PROC
.	O

We	O
reviewed	O
CT	B-PROC
scans	I-PROC
retrospectively	O
(	O
within	O
3	O
months	O
)	O
of	O
86	O
patients	B-LIVB
who	O
underwent	O
LPN	B-PROC
using	O
various	O
hemostatic	B-CHEM
agents	I-CHEM
between	O
March	O
2008	O
and	O
July	O
2014	O
.	O

We	O
analyzed	O
the	O
CT	B-PROC
findings	B-DISO
after	O
LPN	B-PROC
,	O
including	O
postoperative	O
changes	O
,	O
tumor	B-DISO
recurrence	I-DISO
,	O
and	O
complications	B-DISO
.	O

We	O
also	O
discuss	O
changes	O
in	O
abnormal	B-DISO
features	O
,	O
such	O
as	O
mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
and	O
gas	O
formation	O
,	O
on	O
follow	B-PROC
-	I-PROC
up	I-PROC
CT	B-PROC
scans	I-PROC
.	O

To	O
categorize	O
the	O
postoperative	O
changes	O
,	O
we	O
classified	O
them	O
according	O
to	O
their	O
specific	O
CT	B-PROC
findings	B-DISO
:	O
(	O
1	O
)	O
a	O
combination	O
of	O
perinephric	B-DISO
stranding	I-DISO
and	O
postsurgical	B-DISO
fluid	B-ANAT
collection	O
(	O
n	O
=	O
46	O
)	O
,	O
(	O
2	O
)	O
mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
(	O
n	O
=	O
35	O
)	O
,	O
(	O
3	O
)	O
a	O
parenchymal	B-ANAT
defect	O
(	O
n	O
=	O
2	O
)	O
,	O
(	O
4	O
)	O
local	B-PHEN
recurrence	I-PHEN
at	O
the	O
surgical	O
site	O
(	O
n	O
=	O
1	O
)	O
,	O
(	O
5	O
)	O
a	O
large	O
hematoma	B-DISO
as	O
a	O
complication	B-DISO
after	O
LPN	B-PROC
(	O
n	O
=	O
2	O
)	O
,	O
(	O
6	O
)	O
gas	O
pockets	O
,	O
which	O
may	O
be	O
a	O
response	B-PHYS
to	I-PHYS
postsurgical	B-DISO
fluid	B-ANAT
collection	O
around	O
soft	O
tissue	O
(	O
n	O
=	O
35	O
)	O
,	O
(	O
7	O
)	O
fat	B-PHYS
at	O
the	O
excision	B-DISO
site	I-DISO
(	O
n	O
=	O
2	O
;	O
Fig	O
.	O
7	O
)	O
,	O
and	O
(	O
8	O
)	O
contrast	B-DISO
extravasation	I-DISO
in	O
the	O
delayed	O
phase	O
(	O
n	O
=	O
1	O
)	O
.	O

Mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
were	O
visible	O
in	O
35	O
cases	O
.	O

The	O
average	O
change	O
in	O
size	O
of	O
bolster	B-DISO
masses	I-DISO
was	O
-1	O
.	O

19	O
mm	O
/	O
month	O
.	O

However	O
,	O
the	O
overall	O
change	O
in	O
enhancement	O
of	O
mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
was	O
not	B-DISO
significant	I-DISO
over	O
time	O
.	O

Foci	O
of	O
gas	O
were	O
noted	O
in	O
16	O
patients	B-LIVB
at	O
the	O
resection	B-PROC
site	O
in	O
the	O
first	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	I-PROC
(	O
<	O
3	O
months	O
)	O
,	O
as	O
late	O
as	O
40	O
days	O
after	O
the	O
procedure	B-PROC
.	O

Knowledge	O
of	O
CT	B-PROC
imaging	I-PROC
features	O
and	O
changes	O
in	O
hemostatic	B-CHEM
agents	I-CHEM
following	O
LPN	B-PROC
is	O
important	O
in	O
interpreting	O
postoperative	O
CT	B-PROC
scans	I-PROC
,	O
as	O
postoperative	O
changes	O
can	O
be	O
confused	O
with	O
tumor	B-DISO
recurrence	I-DISO
and	O
can	O
mimic	O
abscesses	O
.	O

Benefit	O
and	O
risk	B-PROC
in	O
short	O
term	O
after	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
by	O
direct	O
anterior	O
approach	O
combined	O
with	O
dual	B-DEVI
mobility	I-DEVI
cup	I-DEVI
No	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-PROC
associated	O
with	O
the	O
dual	B-DEVI
mobility	I-DEVI
cup	I-DEVI
(	O
DMC	B-DEVI
)	O
in	O
primary	O
THA	B-PROC
via	O
direct	O
anterior	O
approach	O
(	O
DAA	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
compare	O
the	O
safety	B-PROC
and	O
rate	O
of	O
early	O
postoperative	B-DISO
complication	I-DISO
of	O
the	O
DAA	O
with	O
the	O
DMC	B-DEVI
for	O
THA	B-PROC
with	O
those	O
of	O
the	O
DAA	O
with	O
a	O
single	B-DEVI
standard	I-DEVI
cup	I-DEVI
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-DEVI
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O

We	O
retrospectively	O
investigated	O
60	O
hips	B-ANAT
treated	B-PROC
in	O
the	O
single	O
-	O
DAA	O
group	O
and	O
60	O
hips	B-ANAT
treated	B-PROC
in	O
the	O
dual	O
-	O
DAA	O
group	O
.	O

A	O
primary	O
/	O
secondary	O
outcome	O
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	B-DISO
-	O
or	O
perioperative	O
complication	B-DISO
within	O
the	O
first	O
6	O
months	O
/the	O
operative	O
time	O
and	O
hip	O
function	O
at	O
6	O
months	O
postoperatively	O
.	O

We	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-DEVI
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O

No	B-DISO
intraoperative	B-DISO
complications	I-DISO
were	O
observed	O
in	O
either	O
group	O
.	O

One	O
anterior	B-DISO
dislocation	I-DISO
and	O
one	O
periprosthetic	B-DISO
hip	I-DISO
fracture	I-DISO
were	O
occurred	O
in	O
the	O
single	O
-	O
DAA	O
group	O
.	O

The	O
surgical	O
times	O
in	O
the	O
single	O
-	O
DAA	O
and	O
dual	O
-	O
DAA	O
groups	O
were	O
112	O
.	O

0	O
±	O
20	O
.	O
9	O
and	O
121	O
.	O

0	O
±	O
26	O
.	O

9	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6	O
-	O
month	O
postoperative	O
hip	O
function	O
scores	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-DEVI
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O

We	O
have	O
demonstrated	O
the	O
short	O
-	O
term	O
safety	B-PROC
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
DMC	B-DEVI
in	O
the	O
DAA	O
compared	O
with	O
the	O
standard	B-DEVI
single	I-DEVI
mobility	I-DEVI
cup	I-DEVI
.	O

Incidence	O
of	O
an	O
Anomalous	B-DISO
Course	O
of	O
the	O
Palmar	B-ANAT
Cutaneous	I-ANAT
Branch	I-ANAT
of	I-ANAT
the	I-ANAT
Median	I-ANAT
Nerve	I-ANAT
During	O
Volar	B-ANAT
Plate	B-PROC
Fixation	I-PROC
of	O
Distal	B-DISO
Radius	I-DISO
Fractures	I-DISO
Volar	B-PROC
plating	I-PROC
of	O
distal	B-DISO
radius	I-DISO
fractures	I-DISO
using	O
an	O
approach	O
through	O
the	O
flexor	B-ANAT
carpi	I-ANAT
radialis	I-ANAT
(	O
FCR	B-ANAT
)	O
sheath	B-ANAT
is	O
commonplace	O
.	O

The	O
palmar	B-ANAT
cutaneous	I-ANAT
branch	I-ANAT
of	I-ANAT
the	I-ANAT
median	I-ANAT
nerve	I-ANAT
(	O
PCB	B-ANAT
)	O
is	O
considered	O
to	O
run	O
in	O
a	O
position	O
adjacent	O
to	O
,	O
but	O
outside	O
,	O
the	O
ulnar	B-ANAT
FCR	B-ANAT
sheath	B-ANAT
.	O

Anatomic	O
studies	B-PROC
have	O
not	O
identified	O
anatomic	B-DISO
abnormalities	I-DISO
relevant	O
to	O
volar	B-PROC
plating	I-PROC
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
of	O
anomalous	B-DISO
PCB	B-ANAT
branches	I-ANAT
entering	O
the	O
FCR	B-ANAT
sheath	B-ANAT
during	O
volar	B-PROC
plating	I-PROC
.	O

This	O
observational	B-PROC
study	I-PROC
involved	O
10	O
attending	O
hand	B-LIVB
surgeons	I-LIVB
during	O
a	O
7	O
-	O
month	O
period	O
(	O
July	O
2015	O
-	O
January	O
2016	O
)	O
.	O

Surgeons	B-LIVB
assessed	O
,	O
documented	B-PROC
,	O
and	O
reported	O
any	O
PCB	B-ANAT
anomalies	B-DISO
that	O
were	O
encountered	O
during	O
volar	B-PROC
plating	I-PROC
through	O
a	O
trans	O
-	O
FCR	B-ANAT
approach	O
.	O

There	O
were	O
182	O
volar	B-ANAT
plates	I-ANAT
applied	O
that	O
made	O
up	O
the	O
study	O
group	O
.	O

There	O
were	O
10	O
cases	O
(	O
5	O
.	O
5	O
%	O
)	O
of	O
anomalous	B-DISO
PCBs	B-ANAT
entering	O
the	O
FCR	B-ANAT
sheath	B-ANAT
.	O

In	O
4	O
cases	O
,	O
the	O
PCB	B-ANAT
pierced	O
the	O
radial	O
FCR	B-ANAT
sheath	B-ANAT
proximally	O
,	O
crossed	O
beneath	O
the	O
tendon	B-ANAT
,	O
and	O
traveled	O
distally	O
on	O
the	O
ulnar	B-ANAT
side	O
.	O

In	O
4	O
other	O
cases	O
,	O
the	O
PCB	B-ANAT
entered	O
the	O
FCR	B-ANAT
sheath	B-ANAT
proximally	O
on	O
the	O
ulnar	B-ANAT
or	O
central	O
aspect	O
of	O
the	O
sheath	B-ANAT
and	O
remained	O
within	O
the	O
sheath	B-ANAT
,	O
staying	O
along	O
the	O
ulnar	B-ANAT
or	O
dorsal	B-ANAT
side	I-ANAT
of	O
the	O
tendon	B-ANAT
.	O

In	O
1	O
case	O
,	O
the	O
PCB	B-ANAT
pierced	B-DISO
the	O
ulnar	B-ANAT
distal	O
aspect	O
of	O
the	O
sheath	B-ANAT
and	O
split	O
into	O
2	O
branches	O
.	O

In	O
1	O
case	O
,	O
the	O
PCB	B-ANAT
ran	O
within	O
the	O
sheath	B-ANAT
along	O
the	O
radial	O
aspect	O
of	O
the	O
FCR	B-ANAT
.	O

Anomalies	B-DISO
in	O
the	O
course	O
of	O
the	O
PCB	B-ANAT
are	O
more	O
common	O
than	O
often	O
considered	O
.	O

These	O
variants	O
are	O
at	O
risk	O
during	O
volar	B-ANAT
surgical	O
approaches	O
to	O
the	O
wrist	B-ANAT
that	O
proceed	O
through	O
the	O
FCR	B-ANAT
sheath	B-ANAT
.	O

Although	O
dissecting	O
along	O
the	O
radial	O
side	O
of	O
the	O
FCR	B-ANAT
sheath	B-ANAT
may	O
protect	O
the	O
PCB	B-ANAT
in	O
most	O
cases	O
,	O
care	O
must	O
be	O
taken	O
to	O
identify	O
anomalous	B-DISO
branches	O
(	O
if	O
present	O
)	O
and	O
protect	O
them	O
during	O
surgery	B-PROC
.	O

Individualizing	O
drug	O
dosage	O
with	O
longitudinal	O
data	O
We	O
propose	O
a	O
two	O
-	O
step	O
procedure	O
to	O
personalize	O
drug	O
dosage	O
over	O
time	O
under	O
the	O
framework	O
of	O
a	O
log	O
-	O
linear	O
mixed	O
-	O
effect	O
model	O
.	O

We	O
model	B-PROC
patients	B-LIVB
'	O
heterogeneity	O
using	O
subject	O
-	O
specific	O
random	O
effects	O
,	O
which	O
are	O
treated	O
as	O
the	O
realizations	O
of	O
an	O
unspecified	O
stochastic	O
process	O
.	O

We	O
extend	O
the	O
conditional	O
quadratic	O
inference	O
function	O
to	O
estimate	O
both	O
fixed	O
-	O
effect	O
coefficients	O
and	O
individual	O
random	O
effects	O
on	O
a	O
longitudinal	O
training	O
data	O
sample	O
in	O
the	O
first	O
step	O
and	O
propose	O
an	O
adaptive	O
procedure	O
to	O
estimate	O
new	O
patients	B-LIVB
'	O
random	O
effects	O
and	O
provide	O
dosage	O
recommendations	O
for	O
new	O
patients	B-LIVB
in	O
the	O
second	O
step	O
.	O

An	O
advantage	O
of	O
our	O
approach	O
is	O
that	O
we	O
do	O
not	O
impose	O
any	O
distribution	O
assumption	O
on	O
estimating	O
random	O
effects	O
.	O

Moreover	O
,	O
the	O
new	O
approach	O
can	O
accommodate	O
more	O
general	O
time	O
-varying	O
covariates	O
corresponding	O
to	O
random	O
effects	O
.	O

We	O
show	O
in	O
theory	O
and	O
numerical	B-PROC
studies	I-PROC
that	O
the	O
proposed	O
method	O
is	O
more	O
efficient	O
compared	O
with	O
existing	O
approaches	O
,	O
especially	O
when	O
covariates	O
are	O
time	O
varying	O
.	O

In	O
addition	O
,	O
a	O
real	O
data	O
example	O
of	O
a	O
clozapine	B-CHEM
study	B-PROC
confirms	O
that	O
our	O
two	O
-	O
step	O
procedure	O
leads	O
to	O
more	O
accurate	O
drug	O
dosage	O
recommendations	O
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Association	O
of	O
Low	O
Ficolin	B-CHEM
-	O
Lectin	B-CHEM
Pathway	B-PHYS
Parameters	O
with	O
Cardiac	B-DISO
Syndrome	I-DISO
X	I-DISO
In	O
patients	B-LIVB
with	O
typical	B-DISO
angina	I-DISO
pectoris	I-DISO
,	O
inducible	O
myocardial	B-DISO
ischaemia	I-DISO
and	O
macroscopically	O
normal	O
coronaries	B-ANAT
(	O
cardiac	B-DISO
syndrome	I-DISO
X	I-DISO
(	O
CSX	B-DISO
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	B-ANAT
level	O
of	O
terminal	B-CHEM
complement	I-CHEM
complex	I-CHEM
(	O
TCC	B-CHEM
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	B-PHYS
activation	I-PHYS
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	B-PHYS
or	O
the	O
alternative	B-PHYS
pathways	I-PHYS
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	B-CHEM
-	O
lectin	B-CHEM
pathway	B-PHYS
in	O
CSX	B-DISO
.	O

Eighteen	O
patients	B-LIVB
with	O
CSX	B-DISO
,	O
37	O
stable	O
angina	B-DISO
patients	B-LIVB
with	O
significant	O
coronary	B-DISO
stenosis	I-DISO
(	O
CHD	B-DISO
)	O
and	O
54	O
healthy	B-LIVB
volunteers	I-LIVB
(	O
HC	B-LIVB
)	O
were	O
enrolled	B-PROC
.	O

Serum	B-ANAT
levels	O
of	O
ficolin	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
,	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
/	O
MASP	B-CHEM
-	I-CHEM
2	I-CHEM
complex	B-CHEM
and	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
-mediated	O
TCC	B-CHEM
deposition	O
(	O
FCN3	B-CHEM
-	O
TCC	B-CHEM
)	O
were	O
determined	O
.	O

Plasma	B-ANAT
level	O
of	O
TCC	B-CHEM
was	O
significantly	O
higher	O
in	O
the	O
CSX	O
than	O
in	O
the	O
HC	B-LIVB
or	O
CHD	O
group	O
(	O
5	O
.	O
45	O
versus	O
1	O
.	O
30	O
versus	O
2	O
.	O
04	O
AU	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Serum	B-ANAT
levels	O
of	O
ficolin	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
were	O
significantly	O
lower	O
in	O
the	O
CSX	O
compared	O
to	O
the	O
HC	B-LIVB
or	O
CHD	O
group	O
(	O
3	O
.	O
60	O
versus	O
5	O
.	O
80	O
or	O
5	O
.	O
20	O
μg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
05	O
;	O
17	O
.	O
80	O
versus	O
24	O
.	O
10	O
or	O
26	O
.	O
80	O
μg	O
/	O
ml	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
/	O
MASP	B-CHEM
-	I-CHEM
2	I-CHEM
complex	B-CHEM
was	O
significantly	O
lower	O
in	O
the	O
CSX	B-DISO
group	O
compared	O
to	O
the	O
HC	B-LIVB
group	I-LIVB

(	O
92	O
.	O
90	O
versus	O
144	O
.	O

90	O
AU	O
/	O
ml	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

FCN3	B-CHEM
-	O
TCC	B-CHEM
deposition	O
was	O
significantly	O
lower	O
in	O
the	O
CSX	B-DISO
group	O
compared	O
to	O
the	O
HC	B-LIVB
and	O
CHD	O
groups	O
(	O
67	O
.	O
8	O
%	O
versus	O
143	O
.	O

3	O
%	O
or	O
159	O
.	O

7	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
CSX	B-DISO
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
TCC	B-CHEM
and	O
FCN3	B-CHEM
-	O
TCC	B-CHEM
level	O
(	O
r	O
=	O
0	O
.	O
507	O
,	O
P	O
=	O
0	O
.	O
032	O
)	O
and	O
between	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
/	O
MASP	B-CHEM
-	I-CHEM
2	I-CHEM
complex	B-CHEM
level	O
and	O
FCN3	B-CHEM
-	O
TCC	B-CHEM
deposition	O
(	O
r	O
=	O
0	O
.	O
651	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
.	O

In	O
conclusion	O
,	O
in	O
patients	B-LIVB
with	O
typical	B-DISO
angina	I-DISO
and	O
myocardial	B-DISO
ischaemia	I-DISO
despite	O
macroscopically	O
normal	B-DISO
coronary	I-DISO
arteries	I-DISO
,	O
low	O
levels	O
of	O
several	O
lectin	B-CHEM
pathway	B-PHYS
parameters	O
were	O
observed	O
,	O
indicating	O
complement	B-PHYS
activation	I-PHYS
and	O
consumption	B-PHYS
.	O

Complement	B-PHYS
activation	I-PHYS
through	O
the	O
ficolin	B-CHEM
-	O
lectin	B-CHEM
pathway	B-PHYS
might	O
play	O
a	O
role	O
in	O
the	O
complex	O
pathomechanism	O
of	O
CSX	B-DISO
.	O

Specialized	O
morphology	O
corresponds	O
to	O
a	O
generalist	O
diet	B-OBJC
:	O
linking	O
form	O
and	O
function	B-PHYS
in	O
smashing	O
mantis	O
shrimp	O
crustaceans	O
Many	O
animals	B-LIVB
are	O
considered	O
to	O
be	O
specialists	O
because	O
they	O
have	O
feeding	O
structures	O
that	O
are	O
fine	O
-	O
tuned	O
for	O
consuming	B-PHYS
specific	O
prey	B-LIVB
.	O

For	O
example	O
,	O
""""	O
smasher	O
""""	O
mantis	O
shrimp	O
have	O
highly	O
specialized	O
predatory	B-PHYS
appendages	B-ANAT
that	O
generate	O
forceful	O
strikes	O
to	O
break	O
apart	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
prey	I-LIVB
.	O

Anecdotal	O
observations	O
suggest	O
,	O
however	O
,	O
that	O
the	O
diet	B-OBJC
of	O
smashers	O
may	O
include	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
as	O
well	O
.	O

Our	O
goal	O
was	O
to	O
examine	O
the	O
diet	O
breadth	O
of	O
the	O
smasher	O
mantis	O
shrimp	O
,	O
Neogonodactylus	O
bredini	O
,	O
to	O
determine	O
whether	O
it	O
has	O
a	O
narrow	O
diet	B-OBJC
of	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
prey	I-LIVB
.	O

We	O
combined	O
studies	O
of	O
prey	B-LIVB
abundance	O
,	O
feeding	O
behavior	O
,	O
and	O
stable	B-PROC
isotope	I-PROC
analyses	I-PROC
of	O
diet	B-OBJC
in	O
both	O
seagrass	O
and	O
coral	O
rubble	O
to	O
determine	O
if	O
N	O
.	O
bredini	O
's	O
diet	B-OBJC
was	O
consistent	O
across	O
different	O
habitat	O
types	O
.	O

The	O
abundances	O
of	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
and	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
varied	O
between	O
habitats	O
.	O

In	O
feeding	O
experiments	B-PROC
,	O
N	O
.	O
bredini	O
consumed	B-PHYS
both	O
prey	B-LIVB
types	I-LIVB
.	O

N	O
.	O
bredini	O
consumed	B-PHYS
a	O
range	O
of	O
different	O
prey	B-LIVB
in	O
the	O
field	O
as	O
well	O
and	O
,	O
unexpectedly	B-DISO
,	O
the	O
stable	B-PROC
isotope	I-PROC
analysis	I-PROC
demonstrated	O
that	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
comprised	O
a	O
large	O
proportion	O
(	O
29	O
-	O
53	O
%	O
)	O
of	O
the	O
diet	B-OBJC
in	O
both	O
habitats	O
.	O

Using	O
a	O
Bayesian	O
mixing	O
model	O
framework	O
(	O
MixSIAR	O
)	O
,	O
we	O
found	O
that	O
this	O
result	O
held	O
even	O
when	O
we	O
used	O
uninformative	O
,	O
or	O
generalist	O
,	O
priors	O
and	O
informative	O
priors	O
reflecting	O
a	O
specialist	O
diet	B-OBJC
on	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
prey	I-LIVB
and	O
prey	B-LIVB
abundances	O
in	O
the	O
field	O
.	O

Thus	O
,	O
contrary	O
to	O
expectation	O
,	O
the	O
specialized	O
feeding	O
morphology	O
of	O
N	O
.	O

bredini	O
corresponds	O
to	O
a	O
broad	O
diet	B-OBJC
of	O
both	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
and	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
.	O

Using	O
multiple	O
lines	O
of	O
study	O
to	O
describe	O
the	O
natural	O
diets	B-OBJC
of	O
other	O
presumed	O
specialists	O
may	O
demonstrate	O
that	O
specialized	O
morphology	O
often	O
broadens	O
rather	O
than	O
narrows	O
diet	O
breadth	O
.	O

Toxicity	B-DISO
assessment	O
of	O
water	B-OBJC
-	I-OBJC
accommodated	I-OBJC
fractions	I-OBJC
from	O
two	O
different	O
oils	B-CHEM
using	O
a	O
zebrafish	B-LIVB
(	O
Danio	B-LIVB
rerio	I-LIVB
)	O
embryo	B-ANAT
-	O
larval	O
bioassay	B-PROC
with	O
a	O
multilevel	B-PROC
approach	I-PROC
Petroleum	B-CHEM
compounds	I-CHEM
from	O
chronic	O
discharges	O
and	O
oil	B-PHEN
spills	I-PHEN
represent	O
an	O
important	O
source	O
of	O
environmental	B-PHEN
pollution	I-PHEN
.	O

To	O
better	O
understand	O
the	O
deleterious	O
effects	O
of	O
these	O
compounds	B-CHEM
,	O
the	O
toxicity	B-DISO
of	O
water	B-OBJC
-	I-OBJC
accommodated	I-OBJC
fractions	I-OBJC
(	O
WAF	B-OBJC
)	O
from	O
two	O
different	O
oils	B-CHEM
(	O
brut	B-CHEM
Arabian	I-CHEM
Light	I-CHEM
and	O
Erika	B-CHEM
heavy	I-CHEM
fuel	I-CHEM
oils	I-CHEM
)	O
were	O
used	O
in	O
this	O
study	B-PROC
.	O

Zebrafish	B-LIVB
embryos	B-ANAT
(	O
Danio	B-LIVB
rerio	I-LIVB
)	O
were	O
exposed	O
during	O
96	O
h	O
at	O
three	O
WAF	B-OBJC
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
%	O
for	O
Arabian	B-CHEM
Light	I-CHEM
and	O
10	O
,	O
50	O
and	O
100	O
%	O
for	O
Erika	B-CHEM
)	O
in	O
order	O
to	O
cover	O
a	O
wide	O
range	O
of	O
polycyclic	B-CHEM
aromatic	I-CHEM
hydrocarbon	I-CHEM
(	O
PAH	B-CHEM
)	O
concentrations	O
,	O
representative	O
of	O
the	O
levels	O
found	O
after	O
environmental	O
oil	B-PHEN
spills	I-PHEN
.	O

Several	O
endpoints	O
were	O
recorded	O
at	O
different	O
levels	O
of	O
biological	B-PHYS
organization	I-PHYS
,	O
including	O
lethal	B-DISO
endpoints	O
,	O
morphological	B-DISO
abnormalities	I-DISO
,	O
photomotor	O
behavioral	O
responses	O
,	O
cardiac	B-DISO
activity	I-DISO
,	O
DNA	B-DISO
damage	I-DISO
and	O
exposure	O
level	O
measurements	O
(	O
EROD	B-CHEM
activity	B-PHYS
,	O
cyp1a	B-CHEM
and	O
PAH	B-CHEM
metabolites	B-CHEM
)	O
.	O

Neither	O
morphological	O
nor	O
behavioral	O
or	O
physiological	O
alterations	O
were	O
observed	O
after	O
exposure	O
to	O
Arabian	B-CHEM
Light	I-CHEM
fractions	B-OBJC
.	O

In	O
contrast	O
,	O
the	O
Erika	B-CHEM
fractions	B-OBJC
led	O
a	O
high	O
degree	O
of	O
toxicity	B-DISO
in	O
early	O
life	O
stages	O
of	O
zebrafish	B-LIVB
.	O

Despite	O
of	O
defense	O
mechanisms	O
induced	O
by	O
oil	B-CHEM
,	O
acute	O
toxic	B-DISO
effects	I-DISO
have	O
been	O
recorded	O
including	O
mortality	O
,	O
delayed	O
hatching	B-PHYS
,	O
high	O
rates	O
of	O
developmental	B-DISO
abnormalities	I-DISO
,	O
disrupted	O
locomotor	B-PHYS
activity	I-PHYS
and	O
cardiac	B-DISO
failures	I-DISO
at	O
the	O
highest	O
PAH	B-CHEM
concentrations	O
(	O
∑TPAHs	O
=	O
257	O
,	O
029±47	O
,	O
231ng·L	O
(	O
-	O
1	O
)	O
)	O
.	O

Such	O
differences	O
in	O
toxicity	B-DISO
are	O
likely	O
related	O
to	O
the	O
oil	B-CHEM
composition	B-PHEN
.	O

The	O
use	O
of	O
developing	O
zebrafish	B-LIVB
is	O
a	O
good	O
tool	O
to	O
identify	O
wide	O
range	O
of	O
detrimental	O
effects	O
and	O
elucidate	O
their	O
underlying	O
foundations	O
.	O

Our	O
work	O
highlights	O
once	O
more	O
,	O
the	O
cardiotoxic	B-CHEM
action	I-CHEM
(	O
and	O
potentially	O
neurotoxic	B-CHEM
)	O
of	O
petroleum	B-CHEM
-related	O
PAHs	B-CHEM
.	O

Effect	O
of	O
constitutive	B-PHYS
inactivation	I-PHYS
of	O
the	O
myostatin	O
gene	O
on	O
the	O
gain	O
in	O
muscle	B-PHYS
strength	I-PHYS
during	O
postnatal	B-PHYS
growth	I-PHYS
in	O
two	O
murine	B-LIVB
models	B-LIVB
The	O
effect	O
of	O
constitutive	B-PHYS
inactivation	I-PHYS
of	O
the	O
gene	O
encoding	O
myostatin	O
on	O
the	O
gain	O
in	O
muscle	B-PHYS
performance	I-PHYS
during	O
postnatal	B-PHYS
growth	I-PHYS
has	O
not	O
been	O
well	O
characterized	O
.	O

We	O
analyzed	O
2	O
murine	B-LIVB
myostatin	O
knockout	B-LIVB
(	I-LIVB
KO	I-LIVB
)	I-LIVB
models	I-LIVB
,	O
(	O
i	O
)	O
the	O
Lee	B-LIVB
model	I-LIVB
(	O
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	O
)	O
and	O
(	O
ii	O
)	O
the	O
Grobet	B-LIVB
model	I-LIVB
(	O
KO	B-LIVB
(	I-LIVB
Grobet	I-LIVB
)	I-LIVB
)	O
,	O
and	O
measured	O
the	O
contraction	B-PHYS
of	O
tibialis	B-ANAT
anterior	I-ANAT
muscle	I-ANAT
in	O
situ	O
.	O

Absolute	B-PHYS
maximal	I-PHYS
isometric	I-PHYS
force	I-PHYS
was	O
increased	O
in	O
6	O
-	O
month	O
-	O
old	O
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	I-LIVB
and	O
KO	B-LIVB
(	I-LIVB
Grobet	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O
as	O
compared	O
to	O
wild	B-LIVB
-	I-LIVB
type	I-LIVB
mice	I-LIVB
.	O

Similarly	O
,	O
absolute	B-PHYS
maximal	I-PHYS
power	I-PHYS
was	O
increased	O
in	O
6	O
-	O
month	O
-	O
old	O
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	I-LIVB
mice	I-LIVB
.	O

In	O
contrast	O
,	O
specific	O
maximal	B-PHYS
force	I-PHYS
(	O
relative	O
maximal	B-PHYS
force	I-PHYS
per	O
unit	O
of	O
muscle	O
mass	B-DISO
was	O
decreased	O
in	O
all	O
6	O
-	O
month	O
-	O
old	O
male	B-PHYS
and	O
female	B-PHYS
KO	B-LIVB
mice	I-LIVB
,	O
except	O
in	O
6	O
-	O
month	O
-old	O
female	B-PHYS
KO	B-LIVB
(	I-LIVB
Grobet	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O
whereas	O
specific	O
maximal	B-PHYS
power	I-PHYS
was	O
reduced	O
only	O
in	O
male	B-PHYS
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	I-LIVB
mice	I-LIVB
.	O

Genetic	B-PHYS
inactivation	I-PHYS
of	O
myostatin	O
increases	O
maximal	B-PHYS
force	I-PHYS
and	O
power	B-PHYS
,	O
but	O
in	O
return	O
it	O
reduces	O
muscle	O
quality	O
,	O
particularly	O
in	O
male	B-PHYS
mice	B-LIVB
.	O

Muscle	O
Nerve	O
55	O
:	O
254	O
-	O
261	O
,	O
2017	O
.	O

Evaluation	B-PROC
of	O
the	O
in	O
vitro	O
growth	B-PHYS
of	O
urinary	B-DISO
tract	I-DISO
infection	I-DISO
-causing	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
and	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
in	O
a	O
proposed	O
synthetic	O
human	B-LIVB
urine	B-ANAT
(	O
SHU	B-ANAT
)	O
medium	B-CHEM
Bacteriuria	B-DISO
is	O
a	O
hallmark	O
of	O
urinary	B-DISO
tract	I-DISO
infection	I-DISO
(	O
UTI	B-DISO
)	O
and	O
asymptomatic	B-DISO
bacteriuria	I-DISO
(	O
ABU	B-DISO
)	O
,	O
which	O
are	O
among	O
the	O
most	O
frequent	O
infections	B-DISO
in	O
humans	B-LIVB
.	O

A	O
variety	O
of	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
and	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
are	O
associated	O
with	O
these	O
infections	B-DISO
but	O
Escherichia	B-LIVB
coli	I-LIVB
contributes	O
up	O
to	O
80	O
%	O
of	O
cases	O
.	O

Multiple	O
bacterial	B-LIVB
species	I-LIVB
including	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
can	O
grow	B-PHYS
in	O
human	B-LIVB
urine	B-ANAT
as	O
a	O
means	O
to	O
maintain	O
colonization	B-DISO
during	O
infections	B-DISO
.	O

In	O
vitro	O
bacteriuria	B-DISO
studies	B-PROC
aimed	O
at	O
modeling	B-PROC
microbial	B-PHYS
growth	I-PHYS
in	O
urine	B-ANAT
have	O
utilized	O
various	O
compositions	B-PHYS
of	O
synthetic	O
human	B-LIVB
urine	B-ANAT
(	O
SHU	B-ANAT
)	O
and	O
a	O
Composite	O
SHU	B-ANAT
formulation	B-OBJC
was	O
recently	O
proposed	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
sought	O
to	O
validate	B-PROC
the	O
recently	O
proposed	O
Composite	O
SHU	B-ANAT
as	O
a	O
medium	B-CHEM
that	O
supports	O
the	O
growth	B-PHYS
of	O
several	O
bacterial	B-LIVB
species	I-LIVB
that	O
are	O
known	O
to	O
grow	B-PHYS
in	O
normal	O
human	B-LIVB
urine	B-ANAT
and	O
/	O
or	O
artificial	O
urine	B-ANAT
.	O

Comparative	B-PROC
growth	B-PHEN
assays	I-PHEN
of	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
and	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
E	B-LIVB
.	I-LIVB

coli	I-LIVB
,	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
,	O
Proteus	B-LIVB
mirabilis	I-LIVB
,	O
Streptococcus	B-LIVB
agalactiae	I-LIVB
,	O
Staphylococcus	B-LIVB
saprophyticus	I-LIVB
and	O
Enterococcus	B-LIVB
faecalis	I-LIVB
were	O
undertaken	O
using	O
viable	O
bacterial	B-PROC
count	I-PROC
and	O
optical	B-PROC
density	I-PROC
measurements	I-PROC
over	O
a	O
48h	O
culture	B-PROC
period	O
.	O

Three	O
different	O
SHU	B-ANAT
formulations	B-OBJC
were	O
tested	O
in	O
various	O
culture	B-DEVI
vessels	I-DEVI
,	O
shaking	O
conditions	O
and	O
volumes	O
and	O
showed	O
that	O
Composite	O
SHU	B-ANAT
can	O
support	O
the	O
robust	O
growth	B-PHYS
of	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
bacteria	I-LIVB
but	O
requires	O
supplementation	O
with	O
0	O
.	O

2	O
%	O
yeast	B-LIVB
extract	I-LIVB
to	O
support	O
the	O
growth	B-PHYS
of	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
.	O

Experiments	B-PROC
are	O
also	O
presented	O
that	O
show	O
an	O
unexpected	O
but	O
major	O
influence	O
of	O
P	B-LIVB
.	I-LIVB

mirabilis	I-LIVB
towards	O
the	O
ability	O
to	O
measure	B-PHEN
bacterial	I-PHEN
growth	I-PHEN
in	O
generally	O
accepted	O
multiwell	B-PROC
assays	I-PROC
using	O
absorbance	B-PHYS
readings	I-PHYS
,	O
predicted	O
to	O
have	O
a	O
basis	O
in	O
the	O
release	O
of	O
volatile	B-CHEM
organic	I-CHEM
compound	I-CHEM
(	I-CHEM
s	I-CHEM
)	I-CHEM
from	O
P	B-LIVB
.	I-LIVB

mirabilis	I-LIVB
during	O
growth	B-PHYS
in	O
Composite	O
SHU	B-ANAT
medium	B-CHEM
.	O

This	O
study	B-PROC
represents	O
an	O
essential	O
methodological	O
validation	B-PROC
of	O
a	O
more	O
chemically	B-CHEM
defined	O
type	O
of	O
synthetic	O
urine	B-ANAT
that	O
can	O
be	O
applied	O
to	O
study	B-PROC
mechanisms	O
of	O
bacteriuria	B-DISO
and	O
we	O
conclude	O
will	O
offer	O
a	O
useful	O
in	B-PROC
vitro	I-PROC
model	I-PROC
to	O
investigate	O
the	O
basis	O
of	O
some	O
of	O
the	O
most	O
common	O
infections	B-DISO
of	O
humans	B-LIVB
.	O

Osteopontin	B-CHEM
expression	B-PHYS
in	O
co	B-ANAT
-	I-ANAT
cultures	I-ANAT
of	O
human	B-LIVB
squamous	B-DISO
cell	I-DISO
carcinoma	I-DISO
-derived	O
cells	B-ANAT
and	O
osteoblastic	B-ANAT
cells	I-ANAT
and	O
its	O
effects	O
on	O
the	O
neoplastic	B-ANAT
cell	I-ANAT
phenotype	B-PHYS
and	O
osteoclastic	B-ANAT
activation	B-PHYS
This	O
study	B-PROC
evaluated	O
the	O
temporal	O
expression	B-PHYS
of	O
osteopontin	B-CHEM
(	O
OPN	B-CHEM
)	O
in	O
co	B-ANAT
-	I-ANAT
cultures	I-ANAT
of	O
human	B-LIVB
osteoblastic	B-ANAT
cells	I-ANAT
(	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
)	O
and	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
OSCC	B-DISO
)	O
-	O
derived	O
cells	B-ANAT
(	O
SCC9	B-ANAT
)	O
and	O
examined	B-DISO
the	O
effects	O
of	O
osteoblast	B-ANAT
-derived	O
OPN	B-CHEM
on	O
the	O
neoplastic	B-ANAT
cell	I-ANAT
phenotype	B-PHYS
.	O

Additionally	O
,	O
the	O
effects	O
of	O
these	O
co	B-ANAT
-	I-ANAT
cultures	I-ANAT
on	O
subsequent	O
osteoclastic	B-ANAT
activity	B-PHYS
were	O
explored	O
.	O

SCC9	B-ANAT
cells	I-ANAT
were	O
plated	O
on	O
Transwell	B-OBJC
®	I-OBJC
membranes	I-OBJC
that	O
were	O
either	O
coated	O
or	O
not	O
coated	O
with	O
Matrigel	B-CHEM
and	O
were	O
then	O
co	B-PROC
-	I-PROC
cultured	I-PROC
with	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
during	O
the	O
peak	O
of	O
OPN	B-CHEM
expression	B-PHYS
.	O

SCC9	B-ANAT
cells	I-ANAT
exposed	O
to	O
OPN	B-CHEM
-silenced	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cultures	B-ANAT
and	O
SCC9	B-ANAT
cells	I-ANAT
cultured	B-PROC
alone	O
served	O
as	O
controls	B-LIVB
.	O

SCC9	B-ANAT
cells	I-ANAT
were	O
quantitatively	O
evaluated	O
for	O
cell	B-PHYS
adhesion	I-PHYS
,	O
proliferation	B-PHYS
,	O
migration	B-PHYS
,	O
and	O
invasion	B-DISO
into	O
Matrigel	B-CHEM
.	O

The	O
impact	O
of	O
co	B-PROC
-	I-PROC
culturing	I-PROC
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
and	O
SCC9	B-ANAT
cells	I-ANAT
on	O
the	O
resorptive	O
capacity	O
of	O
U	B-ANAT
-	I-ANAT
937	I-ANAT
-derived	O
osteoclastic	B-ANAT
cells	I-ANAT
was	O
also	O
investigated	O
.	O

Furthermore	O
,	O
a	O
reciprocal	O
induction	O
of	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
and	O
SCC9	B-ANAT
cells	I-ANAT
in	O
terms	O
of	O
OPN	B-CHEM
expression	B-PHYS
over	O
the	O
co	B-ANAT
-	I-ANAT
culture	I-ANAT
interval	O
was	O
identified	O
.	O

SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
-secreted	O
OPN	B-CHEM
altered	O
the	O
SCC9	B-ANAT
cell	I-ANAT
phenotype	B-PHYS
,	O
leading	O
to	O
enhanced	O
cell	B-PHYS
adhesion	I-PHYS
and	O
proliferation	B-PHYS
and	O
higher	O
Matrigel	B-CHEM
invasion	B-DISO
.	O

This	O
invasion	B-DISO
was	O
also	O
enhanced	O
,	O
albeit	O
to	O
a	O
lesser	O
degree	O
,	O
by	O
co	B-ANAT
-	I-ANAT
culture	I-ANAT
with	O
OPN	O
-	O
silenced	B-PHYS
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
.	O

Cell	B-PHYS
migration	I-PHYS
was	O
not	O
affected	O
.	O

Co	B-ANAT
-	I-ANAT
culture	I-ANAT
with	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
-mainly	O
during	O
the	O
period	O
of	O
peak	O
OPN	B-CHEM
expression	B-PHYS
-promoted	O
over	B-PHYS
-	I-PHYS
expression	I-PHYS
of	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
8	I-CHEM
by	O
SCC9	B-ANAT
cells	I-ANAT
and	O
enhanced	O
the	O
resorptive	O
capacity	O
of	O
osteoclastic	B-ANAT
cells	I-ANAT
.	O

Taken	O
together	O
,	O
these	O
results	B-DISO
suggest	O
that	O
osteoblast	B-ANAT
-derived	O
OPN	B-CHEM
affects	O
the	O
interactions	B-PHYS
among	O
OSCC	B-DISO
-derived	O
epithelial	B-ANAT
cells	I-ANAT
,	O
osteoblasts	B-ANAT
,	O
and	O
osteoclasts	B-ANAT
,	O
which	O
could	O
contribute	O
to	O
the	O
process	B-PHEN
of	O
bone	B-DISO
destruction	I-DISO
during	O
bone	B-ANAT
invasion	B-DISO
by	O
OSCC	B-DISO
.	O

Traumatic	B-DISO
Brain	I-DISO
Injury	I-DISO
Induces	O
Alterations	O
in	O
Cortical	B-ANAT
Glutamate	B-CHEM
Uptake	B-PHYS
without	O
a	O
Reduction	O
in	O
Glutamate	B-CHEM
Transporter	I-CHEM
-	I-CHEM
1	I-CHEM
Protein	I-CHEM
Expression	B-PHYS
We	O
hypothesize	O
that	O
the	O
primary	O
mechanism	O
for	O
removal	O
of	O
glutamate	B-CHEM
from	O
the	O
extracellular	B-ANAT
space	I-ANAT
is	O
altered	O
after	O
traumatic	B-DISO
brain	I-DISO
injury	I-DISO
(	O
TBI	B-DISO
)	O
.	O

To	O
evaluate	B-PROC
this	O
hypothesis	O
,	O
we	O
initiated	O
TBI	B-DISO
in	O
adult	B-LIVB
male	I-LIVB
rats	I-LIVB
using	O
a	O
2	O
.	O
0	O
atm	O
lateral	O
fluid	O
percussion	O
injury	O
(	O
LFPI	O
)	O
model	O
.	O

In	O
the	O
ipsilateral	O
cortex	B-ANAT
and	O
hippocampus	B-ANAT
,	O
we	O
found	O
no	B-DISO
differences	I-DISO
in	O
expression	B-PHYS
of	O
the	O
primary	B-CHEM
glutamate	I-CHEM
transporter	I-CHEM
in	O
the	O
brain	B-ANAT
(	O
GLT	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
24	O
h	O
after	O
TBI	B-DISO
.	O

In	O
contrast	O
,	O
we	O
found	O
a	O
decrease	O
in	O
glutamate	B-CHEM
uptake	B-PHYS
in	O
the	O
cortex	B-ANAT
,	O
but	O
not	O
the	O
hippocampus	B-ANAT
,	O
24	O
h	O
after	O
injury	B-DISO
.	O

Because	O
glutamate	B-CHEM
uptake	B-PHYS
is	O
potently	O
regulated	O
by	O
protein	B-CHEM
kinases	I-CHEM
,	O
we	O
assessed	O
global	O
serine	B-CHEM
-	I-CHEM
threonine	I-CHEM
protein	I-CHEM
kinase	I-CHEM
activity	B-PHYS
using	O
a	O
kinome	O
array	O
platform	O
.	O

Twenty	O
-	O
five	O
kinome	O
array	O
peptide	B-CHEM
substrates	I-CHEM
were	O
differentially	O
phoshorylated	B-PHYS
between	O
LFPI	O
and	O
controls	B-LIVB
in	O
the	O
cortex	B-ANAT
,	O
whereas	O
19	O
peptide	B-CHEM
substrates	I-CHEM
were	O
differentially	O
phosphorylated	B-PHYS
in	O
the	O
hippocampus	B-ANAT
(	O
fold	O
change	O
≥	O
±	O
1	O
.	O
15	O
)	O
.	O

We	O
identified	O
several	B-CHEM
kinases	I-CHEM
as	O
likely	O
to	O
be	O
involved	O
in	O
acute	O
TBI	B-DISO
,	O
including	O
protein	B-CHEM
kinase	I-CHEM
B	I-CHEM
(	O
Akt	B-CHEM
)	O
and	O
protein	B-CHEM
kinase	I-CHEM
C	I-CHEM
(	O
PKC	B-CHEM
)	O
,	O
which	O
are	O
well	O
-	O
characterized	O
modulators	B-CHEM
of	O
GLT	B-CHEM
-	I-CHEM
1	I-CHEM
.	O

Exploratory	B-PROC
studies	I-PROC
using	O
an	O
inhibitor	O
of	O
Akt	B-CHEM
suggest	O
selective	O
activation	O
of	O
kinases	B-CHEM
in	O
LFPI	O
versus	O
controls	B-LIVB
.	O

Ingenuity	O
pathway	O
analyses	O
of	O
implicated	O
kinases	B-CHEM
from	O
our	O
network	O
model	O
found	O
apoptosis	B-PHYS
and	O
cell	B-PHYS
death	I-PHYS
pathways	O
as	O
top	O
functions	O
in	O
acute	O
LFPI	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
diminished	O
activity	O
of	O
glutamate	B-CHEM
transporters	O
in	O
the	O
prefrontal	B-ANAT
cortex	I-ANAT
,	O
with	O
no	B-DISO
changes	I-DISO
in	O
protein	B-PHYS
expression	I-PHYS
of	O
the	O
primary	O
glutamate	B-CHEM
transporter	I-CHEM
GLT	B-CHEM
-	I-CHEM
1	I-CHEM
,	O
and	O
global	O
alteration	O
s	O
in	O
signaling	B-PHYS
networks	I-PHYS
that	O
include	O
serine	B-CHEM
-	I-CHEM
threonine	I-CHEM
kinases	I-CHEM
that	O
are	O
known	O
modulators	B-CHEM
of	O
glutamate	B-PHYS
transport	I-PHYS
activity	I-PHYS
.	O

Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	O
Clock	B-PHYS
-	I-PHYS
Dependent	I-PHYS
Pacemaking	B-PROC
in	O
the	O
Sinus	B-ANAT
Node	I-ANAT
Is	O
Impaired	O
in	O
Mice	B-LIVB
with	O
a	O
Cardiac	B-ANAT
Specific	O
Reduction	O
in	O
SERCA2	B-CHEM
Abundance	O
The	O
sarcoplasmic	B-CHEM
reticulum	I-CHEM
Ca	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	I-CHEM
ATPase	I-CHEM

Frequency	O
of	O
BCR	O
-	O
ABL	O
Transcript	B-CHEM
Types	O
in	O
Syrian	B-LIVB
CML	B-DISO
Patients	B-LIVB
Background	O
.	O

In	O
Syria	B-GEOG
,	O
CML	B-DISO
patients	B-LIVB
are	O
started	O
on	O
tyrosine	B-PHYS
kinase	I-PHYS
inhibitors	I-PHYS
(	O
TKIs	B-PHYS
)	O
and	O
monitored	O
until	O
complete	O
molecular	B-DISO
response	I-DISO
is	O
achieved	O
.	O

BCR	O
-	O
ABL	O
mRNA	B-CHEM
transcript	B-CHEM
type	O
is	O
not	O
routinely	O
identified	O
,	O
contrary	O
to	O
the	O
recommendations	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
identify	O
the	O
frequency	O
of	O
different	O
BCR	O
-	O
ABL	O
transcripts	B-CHEM
in	O
Syrian	B-LIVB
CML	B-DISO
patients	B-LIVB
and	O
highlight	O
their	O
significance	O
on	O
monitoring	O
and	O
treatment	B-PROC
protocols	I-PROC
.	O

Methods	O
.	O

CML	B-DISO
patients	B-LIVB
positive	B-DISO
for	O
BCR	O
-	O
ABL	O
transcripts	B-CHEM
by	O
quantitative	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
were	O
enrolled	O
.	O

BCR	O
-	O
ABL	O
transcript	B-CHEM
types	O
were	O
investigated	O
using	O
a	O
home	O
-	O
made	O
PCR	B-PROC
method	O
that	O
was	O
adapted	O
from	O
published	O
protocols	O
and	O
optimized	O
.	O

The	O
transcript	B-CHEM
types	O
were	O
then	O
confirmed	O
using	O
a	O
commercially	O
available	O
research	B-DEVI
kit	I-DEVI
.	O

Results	O
.	O

Twenty	O
-	O
four	O
transcripts	B-CHEM
were	O
found	O
in	O
21	O
patients	B-LIVB
.	O

The	O
most	O
common	O
was	O
b2a2	B-CHEM
,	O
followed	O
by	O
b3a2	B-CHEM
,	O
b3a3	B-CHEM
,	O
and	O
e1a3	B-CHEM
present	O
solely	O
in	O
12	O
(	O
57	O
.	O
1	O
%	O
)	O
,	O
3	O
(	O
14	O
.	O

3	O
%	O
)	O
,	O
2	O
(	O
9	O
.	O
5	O
%	O
)	O
,	O
and	O
1	O
(	O
4	O
.	O
8	O
%	O
)	O
,	O
respectively	O
.	O

Three	O
samples	O
(	O
14	O
.	O
3	O
%	O
)	O
contained	O
dual	O
transcripts	B-CHEM
.	O

While	O
b3a2	B-CHEM
transcript	I-CHEM
was	O
apparently	O
associated	O
with	O
warning	O
molecular	B-DISO
response	I-DISO
to	O
imatinib	B-CHEM
treatment	B-PROC
,	O
b2a2	B-CHEM
,	O
b3a3	B-CHEM
,	O
and	O
e1a3	B-CHEM
transcripts	I-CHEM
collectively	O
proved	O
otherwise	O
(	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

Conclusion	O
.	O

It	O
might	O
be	O
advisable	O
to	O
identify	O
the	O
BCR	O
-	O
ABL	O
transcript	B-CHEM
type	O
in	O
CML	B-DISO
patients	B-LIVB
at	O
diagnosis	O
,	O
using	O
an	O
empirically	O
verified	O
method	O
,	O
in	O
order	O
to	O
link	O
the	O
detected	O
transcript	B-CHEM
with	O
the	O
clinical	O
findings	O
,	O
possible	O
resistance	O
to	O
treatment	B-PROC
,	O
and	O
appropriate	O
monitoring	B-PROC
methods	I-PROC
.	O

Steamed	B-PHEN
and	I-PHEN
Fermented	I-PHEN
Ethanolic	B-CHEM
Extract	I-CHEM
from	O
Codonopsis	B-LIVB
lanceolata	I-LIVB
Attenuates	O
Amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O
Induced	O
Memory	B-DISO
Impairment	I-DISO
in	O
Mice	B-LIVB
Codonopsis	B-LIVB
lanceolata	I-LIVB
(	O
C	B-LIVB
.	I-LIVB

lanceolata	I-LIVB
)	O
is	O
a	O
traditional	O
medicinal	B-LIVB
plant	I-LIVB
used	O
for	O
the	O
treatment	O
of	O
certain	O
inflammatory	B-DISO
diseases	I-DISO
such	O
as	O
asthma	B-DISO
,	O
tonsillitis	B-DISO
,	O
and	O
pharyngitis	B-DISO
.	O

We	O
evaluated	O
whether	O
steamed	B-PHEN
and	I-PHEN
fermented	I-PHEN
C	B-LIVB
.	I-LIVB

lanceolata	I-LIVB
(	O
SFC	B-LIVB
)	O
extract	B-CHEM
improves	B-DISO
amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O
(	O
Aβ	B-CHEM
-	I-CHEM
)	O
induced	O
learning	B-PHYS
and	O
memory	B-DISO
impairment	I-DISO
in	O
mice	B-LIVB
.	O

The	O
Morris	B-PROC
water	I-PROC
maze	I-PROC
and	O
passive	B-PHYS
avoidance	I-PHYS
tests	B-PROC
were	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
SFC	B-CHEM
extract	I-CHEM
.	O

Moreover	O
,	O
we	O
investigated	O
acetylcholinesterase	B-PHYS
(	I-PHYS
AChE	I-PHYS
)	I-PHYS
activity	I-PHYS
and	O
brain	B-CHEM
-	I-CHEM
derived	I-CHEM
neurotrophic	I-CHEM
factor	I-CHEM
(	O
BDNF	B-CHEM
)	O
,	O
cyclic	B-CHEM
AMP	I-CHEM
response	I-CHEM
element	I-CHEM
-	I-CHEM
binding	I-CHEM
protein	I-CHEM
(	O
CREB	B-CHEM
)	O
,	O
and	O
extracellular	B-CHEM
signal	I-CHEM
-	I-CHEM
regulated	I-CHEM
kinase	I-CHEM
(	O
ERK	B-CHEM
)	O
signaling	B-PHYS
in	O
the	O
hippocampus	B-ANAT
of	O
mice	B-LIVB
to	O
determine	O
a	O
possible	O
mechanism	O
for	O
the	O
cognitive	B-PHYS
-	O
enhancing	O
effect	O
.	O

Saponin	B-CHEM
compounds	B-CHEM
in	O
SFC	B-LIVB
were	O
identified	O
by	O
Ultra	B-PROC
Performance	I-PROC
Liquid	I-PROC
Chromatography	I-PROC
-	I-PROC
Quadrupole	I-PROC
-	I-PROC
Time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
Flight	I-PROC
Mass	I-PROC
Spectrometry	I-PROC
(	O
UPLC	B-PROC
-	I-PROC
Q	I-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
)	O
.	O

SFC	B-CHEM
extract	I-CHEM
ameliorated	B-DISO
amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O
induced	O
memory	B-DISO
impairment	I-DISO
in	O
the	O
Morris	B-PROC
water	I-PROC
maze	I-PROC
and	O
passive	B-PHYS
avoidance	I-PHYS
tests	B-PROC
.	O

SFC	B-CHEM
extract	I-CHEM
inhibited	O
AChE	B-PHYS
activity	I-PHYS
and	O
also	O
significantly	O
increased	O
the	O
level	O
of	O
CREB	B-CHEM
phosphorylation	B-PHYS
,	O
BDNF	B-CHEM
expression	B-PHYS
,	O
and	O
ERK	B-CHEM
activation	B-PHYS
in	O
hippocampal	B-ANAT
tissue	I-ANAT
of	O
amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O
treated	O
mice	B-LIVB
.	O

Lancemasides	B-CHEM
A	I-CHEM
,	O
B	B-CHEM
,	O
C	B-CHEM
,	O
D	B-CHEM
,	O
E	B-CHEM
,	O
and	O
G	B-CHEM
and	O
foetidissimoside	B-CHEM
A	I-CHEM
compounds	B-CHEM
present	O
in	O
SFC	B-LIVB
were	O
determined	O
by	O
UPLC	B-PROC
-	I-PROC
Q	I-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
.	O

These	O
results	O
indicate	O
that	O
SFC	B-CHEM
extract	I-CHEM
improves	B-DISO
Aβ	B-CHEM
-	O
induced	O
memory	B-DISO
deficits	I-DISO
and	O
that	O
AChE	B-CHEM
inhibition	O
and	O
CREB	B-CHEM
/	O
BDNF	B-CHEM
/	O
ERK	B-CHEM
expression	B-PHYS
is	O
important	O
for	O
the	O
effect	O
of	O
the	O
SFC	B-CHEM
extract	I-CHEM
.	O

In	O
addition	O
,	O
lancemaside	B-CHEM
A	I-CHEM
specifically	O
may	O
be	O
responsible	O
for	O
efficacious	O
effect	O
of	O
SFC	B-LIVB
.	O

Significance	O
of	O
ETV6	O
rearrangement	B-PHYS
in	O
acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
with	O
t	O
(	O
15	O
;	O
17	O
)	O
/	O
promyelocytic	B-DISO
leukemia	I-DISO
/	O
retinoic	B-CHEM
acid	I-CHEM
receptor	I-CHEM
alpha	I-CHEM
Acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
(	O
APL	B-DISO
)	O
is	O
a	O
common	O
subtype	O
of	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
in	O
China	B-GEOG
.	O

Since	O
the	O
application	O
of	O
arsenic	B-CHEM
trioxide	I-CHEM
and	O
all	B-CHEM
-	I-CHEM
trans	I-CHEM
retinoic	I-CHEM
acid	I-CHEM
in	O
the	O
treatment	O
of	O
APL	B-DISO
,	O
the	O
prognosis	B-PROC
has	O
greatly	O
improved	O
.	O

However	O
,	O
~20	O
%	O
of	O
patients	B-LIVB
with	O
APL	B-DISO
relapse	B-PHEN
upon	O
completing	O
chemotherapy	B-PROC
.	O

Decreasing	O
the	O
relapse	B-PHEN
rate	O
and	O
incidence	O
of	O
early	B-DISO
mortality	I-DISO
may	O
pose	O
the	O
greatest	O
challenges	B-PROC
for	O
the	O
future	O
management	B-PROC
of	O
APL	B-DISO
.	O

Recently	O
,	O
Ets	O
variant	O
6	O
(	O
ETV6	O
)	O
was	O
reported	B-PROC
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
translocations	B-PHYS
associated	O
with	O
hematological	B-DISO
malignancies	I-DISO
of	O
myeloid	O
and	O
lymphoid	O
origin	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
clinical	O
implication	O
of	O
ETV6	O
rearrangement	B-PHYS
in	O
APL	B-DISO
.	O

In	O
the	O
present	O
study	B-PROC
,	O
ETV6	O
rearrangement	B-PHYS
was	O
examined	O
by	O
split	B-PROC
-	I-PROC
signal	I-PROC
fluorescence	I-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
in	O
258	O
adults	B-LIVB
with	O
APL	B-DISO
,	O
and	O
its	O
association	O
with	O
the	O
clinical	B-PHYS
features	I-PHYS
and	O
outcomes	O
of	O
the	O
patients	B-LIVB
was	O
analyzed	B-PROC
.	O

The	O
data	O
suggested	O
that	O
ETV6	O
rearrangement	B-PHYS
may	O
be	O
an	O
independent	O
unfavorable	O
prognostic	B-PHYS
factor	I-PHYS
for	O
overall	O
survival	O
in	O
APL	B-DISO
patients	B-LIVB
.	O

Early	O
Cognitive	B-DISO
Deficits	I-DISO
in	O
Type	B-DISO
2	I-DISO
Diabetes	I-DISO
:	O
A	O
Population	B-PROC
-	I-PROC
Based	I-PROC
Study	I-PROC
Evidence	O
links	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
to	O
dementia	B-DISO
risk	I-DISO
.	O

However	O
,	O
our	O
knowledge	O
on	O
the	O
initial	O
cognitive	B-DISO
deficits	I-DISO
in	O
diabetic	B-DISO
individuals	B-LIVB
and	O
the	O
factors	O
that	O
might	O
promote	O
such	O
deficits	B-DISO
is	O
still	O
limited	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
cognitive	B-PHYS
domains	I-PHYS
initially	O
impaired	O
by	O
diabetes	B-DISO
and	O
the	O
factors	O
that	O
play	O
a	O
role	O
in	O
this	O
first	O
stage	O
.	O

Within	O
the	O
population	B-PROC
-	I-PROC
based	I-PROC
Swedish	I-PROC
National	I-PROC
Study	I-PROC
on	I-PROC
Aging	I-PROC
and	I-PROC
Care	I-PROC
-	I-PROC
Kungsholmen	I-PROC
,	O
2305	O
cognitively	O
intact	O
participants	B-LIVB
aged	O
≥60	O
y	O
were	O
identified	O
.	O

Attention	B-PHYS
/	O
working	B-PHYS
memory	I-PHYS
,	O
perceptual	B-PHYS
speed	B-DISO
,	O
category	O
fluency	O
,	O
letter	O
fluency	O
,	O
semantic	B-PHYS
memory	I-PHYS
,	O
and	O
episodic	B-PHYS
memory	I-PHYS
were	O
assessed	O
.	O

Diabetes	B-DISO
(	O
controlled	O
and	O
uncontrolled	O
)	O
and	O
prediabetes	B-DISO
were	O
ascertained	O
by	O
clinicians	B-LIVB
,	O
who	O
also	O
collected	O
information	O
on	O
vascular	B-DISO
disorders	I-DISO
(	O
hypertension	B-DISO
,	O
heart	B-DISO
diseases	I-DISO
,	O
and	O
stroke	B-DISO
)	O
and	O
vascular	B-DISO
risk	I-DISO
factors	I-DISO
(	O
VRFs	B-DISO
,	O
including	O
smoking	O
and	O
overweight	B-DISO
/	O
obesity	B-DISO
)	O
.	O

Data	O
were	O
analyzed	B-PROC
with	O
linear	O
regression	O
models	O
.	O

Overall	O
,	O
196	O
participants	B-LIVB
(	O
8	O
.	O
5	O
%	O
)	O
had	O
diabetes	B-DISO
,	O
of	O
which	O
144	O
(	O
73	O
.	O
5	O
%	O
)	O
had	O
elevated	O
glycaemia	B-CHEM
(	O
uncontrolled	O
diabetes	B-DISO
)	O
;	O

571	O
(	O
24	O
.	O

8	O
%	O
)	O
persons	O
had	O
prediabetes	B-DISO
.	O

In	O
addition	O
,	O
diabetes	B-DISO
,	O
mainly	O
uncontrolled	O
,	O
was	O
related	O
to	O
lower	O
performance	O
in	O
perceptual	B-PHYS
speed	B-DISO
(	O
β	O
-	O
1	O
.	O
10	O
[	O
95	O
%	O
CI	O
-	O
1	O
.	O
98	O
,	O
-	O
0	O
.	O
23	O
]	O
)	O
,	O
category	O
fluency	O
(	O
β	O
-	O
1	O
.	O
27	O
[	O
95	O
%	O
CI	O
-	O
2	O
.	O
52	O
,	O
-	O
0	O
.	O
03	O
]	O
)	O
,	O
and	O
digit	B-PHYS
span	I-PHYS
forward	I-PHYS
(	O
β	O
-	O
0	O
.	O
35	O
[	O
95	O
%	O
CI	O
-	O
0	O
.	O
54	O
,	O
-	O
0	O
.	O
17	O
]	O
)	O
.	O

Critically	O
,	O
these	O
associations	O
were	O
present	O
only	O
among	O
APOEɛ4	B-CHEM
non	O
-	O
carriers	O
.	O

The	O
associations	O
of	O
diabetes	B-DISO
with	O
perceptual	B-PHYS
speed	B-DISO
and	O
category	O
fluency	O
were	O
present	O
only	O
among	O
participants	B-LIVB
with	O
VRFs	B-DISO
or	O
vascular	B-DISO
disorders	I-DISO
.	O

Diabetes	B-DISO
,	O
especially	O
uncontrolled	O
diabetes	B-DISO
,	O
is	O
associated	O
with	O
poorer	O
performance	O
in	O
perceptual	B-PHYS
speed	B-DISO
,	O
category	O
fluency	O
,	O
and	O
attention	B-PHYS
/	O
primary	B-PHYS
memory	I-PHYS
.	O

VRFs	B-DISO
,	O
vascular	B-DISO
disorders	I-DISO
,	O
and	O
APOE	B-CHEM
status	O
play	O
a	O
role	O
in	O
these	O
associations	O
.	O

Methylation	B-PHYS
status	O
of	O
the	O
promoter	B-CHEM
region	I-CHEM
of	O
the	O
human	B-LIVB
frizzled	O
9	O
gene	O
in	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
The	O
FZD9	O
gene	O
is	O
located	O
at	O
chromosome	O
7q11	O
.	O

23	O
,	O
and	O

has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	O
suppressor	O
gene	O
.	O

The	O
present	O
study	B-PROC
examined	B-DISO
the	O
involvement	O
of	O
FZD9	O
promoter	B-CHEM
methylation	B-PHYS
in	O
the	O
downregulation	B-PHYS
of	O
FZD9	O
expression	B-PHYS
in	O
leukemia	B-DISO
cells	B-ANAT
.	O

The	O
expression	B-PHYS
of	O
the	O
FZD9	O
gene	O
was	O
absent	O
in	O
various	O
leukemic	B-DISO
cell	B-ANAT
lines	I-ANAT
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	O
with	O
DNA	B-CHEM
demethylating	I-CHEM
agent	I-CHEM
5	B-CHEM
-	I-CHEM
aza	I-CHEM
-	I-CHEM
2	I-CHEM
'	I-CHEM
-	I-CHEM
deoxycytidine	I-CHEM
.	O

Bisulfite	B-PROC
sequencing	I-PROC
analysis	I-PROC
of	O
the	O
FZD9	O
promoter	B-CHEM
region	I-CHEM
showed	O
that	O
it	O
was	O
partially	O
methylated	B-PHYS
in	O
cell	B-ANAT
lines	I-ANAT
in	O
which	O
FZD9	O
gene	O
was	O
not	O
expressed	B-PHYS
.	O

Thus	O
,	O
DNA	B-PHYS
methylation	I-PHYS
in	O
the	O
promoter	B-CHEM
region	I-CHEM
may	O
lead	O
to	O
inactivation	O
of	O
the	O
FZD9	O
gene	O
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	O
with	O
leukemia	B-DISO
,	O
since	O
DNA	B-CHEM
was	O
not	O
methylated	B-PHYS
in	O
normal	O
peripheral	B-ANAT
blood	I-ANAT
mononuclear	I-ANAT
cells	I-ANAT
.	O

Methylation	B-PHYS
-specific	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
analysis	I-PROC
revealed	O
that	O
the	O
promoter	B-CHEM
region	I-CHEM
of	O
the	O
FZD9	O
gene	O
was	O
frequently	O
methylated	B-PHYS
in	O
primary	O
or	O
relapse	B-PHEN
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
(	O
52	O
.	O

9	O
%	O
;	O
excluding	O
acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
)	O
;	O
however	O
,	O
methylation	B-PHYS
was	O
infrequent	O
in	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
acute	B-DISO
lymphocytic	I-DISO
leukemia	I-DISO
(	O
5	O
.	O
6	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	B-PROC
indicated	O
that	O
the	O
methylation	B-PHYS
profile	B-PROC
of	O
the	O
FZD9	O
gene	O
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor	O
-	O
suppressor	O
gene	O
in	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
.	O

Functional	O
conservation	O
of	O
the	O
lncRNA	B-CHEM
NEAT1	O
in	O
the	O
ancestrally	O
diverged	O
marsupial	B-LIVB
lineage	O
:	O
Evidence	O
for	O
NEAT1	O
expression	B-PHYS
and	O
associated	O
paraspeckle	B-ANAT
assembly	B-PHYS
during	O
late	O
gestation	B-PHYS
in	O
the	O
opossum	B-LIVB
Monodelphis	B-LIVB
domestica	I-LIVB
Long	B-CHEM
non	I-CHEM
-	I-CHEM
coding	I-CHEM
RNAs	I-CHEM
(	O
lncRNAs	B-CHEM
)	O
are	O
widely	O
expressed	B-PHYS
and	O
play	O
various	O
roles	O
in	O
cell	B-PHYS
homeostasis	I-PHYS
.	O

However	O
,	O
because	O
of	O
their	O
low	O
conservation	O
at	O
the	O
sequence	O
level	O
,	O
recapitulating	O
lncRNA	B-CHEM
evolutionary	O
history	O
is	O
often	O
challenging	O
.	O

While	O
performing	O
an	O
ultrastructural	B-ANAT
analysis	B-PROC
of	O
viral	B-ANAT
particles	I-ANAT
present	O
in	O
uterine	B-ANAT
glands	I-ANAT
of	O
gestating	O
opossum	B-LIVB
females	B-PHYS
,	O
we	O
serendipitously	O
noticed	O
the	O
presence	B-DISO
of	O
numerous	O
structures	B-ANAT
similar	O
to	O
paraspeckles	B-ANAT
,	O
nuclear	B-ANAT
bodies	I-ANAT
which	O
in	O
human	B-PHEN
and	O
mouse	B-ANAT
cells	I-ANAT
are	O
assembled	O
around	O
an	O
architectural	O
NEAT1	O
/	O
MENϵ	O
/	O
β	O
lncRNA	B-CHEM
.	O

Here	O
,	O
using	O
an	O
opossum	B-LIVB
kidney	B-ANAT
(	O
OK	B-ANAT
)	O
cell	O
line	O
,	O
we	O
confirmed	O
by	O
immuno	B-PROC
-	I-PROC
electron	I-PROC
microscopy	I-PROC
the	O
presence	B-DISO
of	O
paraspeckles	B-ANAT
in	O
marsupials	B-LIVB
.	O

We	O
then	O
identified	O
the	O
orthologous	O
opossum	B-LIVB
NEAT1	O
gene	O
which	O
,	O
although	O
poorly	O
conserved	O
at	O
the	O
sequence	O
level	O
,	O
displays	O
NEAT1	B-CHEM
characteristic	O
features	O
such	O
as	O
short	O
and	O
long	O
isoforms	B-CHEM
expressed	B-PHYS
from	O
a	O
unique	O
promoter	B-CHEM
and	O
for	O
the	O
latter	O
an	O
RNase	B-CHEM
P	I-CHEM
cleavage	B-PHYS
site	O
at	O
its	O
3	O
'	O
-	O
end	O
.	O

Combining	O
tissue	O
-	O
specific	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
,	O
in	B-PROC
situ	I-PROC
hybridization	I-PROC
at	O
the	O
optical	B-PROC
and	O
electron	B-PROC
microscopic	I-PROC
levels	O
,	O
we	O
show	O
that	O
(	O
i	O
)	O
NEAT1	O
is	O
paraspeckle	B-ANAT
-	O
associated	O
in	O
opossum	B-LIVB
(	O
ii	O
)	O
NEAT1	O
expression	B-PHYS
is	O
strongly	O
induced	O
in	O
late	O
gestation	B-PHYS
in	O
uterine	B-OBJC
/	O
placental	B-CHEM
extracts	I-CHEM
(	O
iii	O
)	O
NEAT1	O
induction	B-PHYS
occurs	O
in	O
the	O
uterine	B-ANAT
gland	I-ANAT
nuclei	B-ANAT
in	O
which	O
paraspeckles	B-ANAT
were	O
detected	O
.	O

Finally	O
,	O
treatment	B-PROC
of	O
OK	B-ANAT
cells	O
with	O
proteasome	B-CHEM
inhibitors	I-CHEM
induces	O
paraspeckle	B-ANAT
assembly	B-PHYS
,	O
as	O
previously	O
observed	O
in	O
human	B-PHEN
cells	I-PHEN
.	O

Altogether	O
,	O
these	O
results	O
demonstrate	O
that	O
paraspeckles	B-ANAT
are	O
tissue	O
-	O
specific	O
,	O
stress	B-DISO
-responding	O
nuclear	B-ANAT
bodies	I-ANAT
in	O
marsupials	B-LIVB
,	O
illustrating	O
their	O
structural	O
and	O
functional	O
continuity	O
over	O
200	O
My	O
of	O
evolution	O
throughout	O
the	O
mammalian	B-LIVB
lineage	O
.	O

In	O
contrast	O
,	O
the	O
rapid	O
evolution	B-PHYS
of	O
the	O
NEAT1	O
transcripts	B-CHEM
highlights	O
the	O
relaxed	O
constraint	O
that	O
,	O
despite	O
functional	O
conservation	O
,	O
is	O
exerted	O
on	O
this	O
lncRNA	B-CHEM
.	O

Ag	B-CHEM
nanoclusters	B-OBJC
could	O
efficiently	O
quench	B-PHYS
the	O
photoresponse	B-PHEN
of	O
CdS	B-CHEM
quantum	B-OBJC
dots	I-OBJC
for	O
novel	O
energy	B-PHYS
transfer	I-PHYS
-based	O
photoelectrochemical	O
bioanalysis	O
Herein	O
the	O
influence	O
of	O
ultrasmall	O
Ag	B-CHEM
nanoclusters	B-OBJC
(	O
Ag	B-CHEM
NCs	B-OBJC
)	O
against	O
CdS	B-CHEM
quantum	B-OBJC
dots	I-OBJC
(	O
QDs	B-OBJC
)	O
in	O
a	O
photoelectrochemical	O
(	O
PEC	O
)	O
nanosystem	B-OBJC
was	O
exploited	O
for	O
the	O
first	O
time	O
,	O
based	O
on	O
which	O
a	O
novel	O
PEC	O
bioanalysis	O
was	O
successfully	O
developed	O
via	O
the	O
efficient	O
quenching	B-PHYS
effect	O
of	O
Ag	B-CHEM
NCs	B-OBJC
against	O
the	O
CdS	B-CHEM
QDs	B-OBJC
.	O

In	O
a	O
model	B-DEVI
system	I-DEVI
,	O
DNA	B-PROC
assay	I-PROC
was	O
achieved	O
by	O
using	O
molecular	B-CHEM
beacon	I-CHEM
(	O
MB	B-CHEM
)	O
probes	B-DEVI
anchored	B-PROC
on	O
a	O
CdS	B-CHEM
QDs	B-OBJC
modified	O
electrode	B-OBJC
,	O
and	O
the	O
MB	B-CHEM
probes	B-DEVI
contain	O
two	O
segments	O
that	O
can	O
hybridize	B-PHEN
with	O
both	O
target	O
DNA	O
sequence	O
and	O
the	O
label	B-OBJC
of	O
DNA	B-CHEM
encapsulated	O
Ag	B-CHEM
NCs	B-OBJC
.	O

After	O
the	O
MB	B-CHEM
probe	B-DEVI
was	O
unfolded	O
by	O
the	O
target	O
DNA	O
sequence	O
,	O
the	O
labels	B-OBJC
of	O
oligonucleotide	B-CHEM
encapsulated	O
Ag	B-CHEM
NCs	B-OBJC
would	O
be	O
brought	O
in	O
close	O
proximity	O
to	O
the	O
CdS	B-CHEM
QDs	B-OBJC
electrode	B-OBJC
surface	I-OBJC
,	O
and	O
efficient	O
photocurrent	B-PHEN
quenching	I-PHEN
of	O
QDs	B-OBJC
could	O
be	O
resulted	O
from	O
an	O
energy	B-PHYS
transfer	I-PHYS
process	B-PHEN
that	O
originated	O
from	O
NCs	B-OBJC
.	O

Thus	O
,	O
by	O
monitoring	B-PROC
the	O
attenuation	O
in	O
the	O
photocurrent	B-PHEN
signal	I-PHEN
,	O
an	O
elegant	O
and	O
sensitive	O
PEC	O
DNA	B-PROC
bioanalysis	I-PROC
could	O
be	O
accomplished	O
.	O

The	O
developed	O
biosensor	B-DEVI
displayed	O
a	O
linear	O
range	O
from	O
1	O
.	O

0pM	O
to	O
10nM	O
and	O
the	O
detection	B-PROC
limit	O
was	O
experimentally	O
found	B-DISO
to	O
be	O
of	O
0	O
.	O

3pM	O
.	O

This	O
work	O
presents	O
a	O
feasible	O
signaling	O
principle	O
that	O
could	O
act	O
as	O
a	O
common	O
basis	O
for	O
general	O
PEC	O
bioanalysis	O
development	O
.	O

Does	O
obtaining	O
an	O
initial	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
decrease	O
the	O
reamputation	B-PROC
rates	O
in	O
the	O
diabetic	B-DISO
foot	I-DISO
?	O

Diabetes	B-DISO
mellitus	I-DISO
(	O
DM	B-DISO
)	O
through	O
its	O
over	O
glycosylation	B-PHEN
of	O
neurovascular	B-ANAT
structures	I-ANAT
and	O
resultant	O
peripheral	B-DISO
neuropathy	I-DISO
continues	O
to	O
be	O
the	O
major	O
risk	B-DISO
factor	I-DISO
for	O
pedal	B-PROC
amputation	I-PROC
.	O

Repetitive	B-DISO
trauma	B-DISO
to	O
the	O
insensate	B-DISO
foot	B-ANAT
results	O
in	O
diabetic	B-DISO
foot	I-DISO
ulcers	I-DISO
,	O
which	O
are	O
at	O
high	B-DISO
risk	I-DISO
to	O
develop	O
osteomyelitis	B-DISO
.	O

Many	O
patients	B-LIVB
who	O
present	O
with	O
diabetic	B-DISO
foot	I-DISO
complications	B-DISO
will	O
undergo	O
one	O
or	O
more	O
pedal	B-PROC
amputations	I-PROC
during	O
the	O
course	O
of	O
their	O
disease	B-DISO
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	O
if	O
obtaining	O
an	O
initial	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
(	O
MRI	B-PROC
)	O
,	O
prior	O
to	O
the	O
first	O
amputation	B-PROC
,	O
is	O
associated	O
with	O
a	O
decreased	O
rate	O
of	O
reamputation	B-PROC
in	O
the	O
diabetic	B-DISO
foot	I-DISO
.	O

Our	O
hypothesis	O
was	O
that	O
the	O
rate	O
of	O
reamputation	B-PROC
may	O
be	O
associated	O
with	O
underutilization	O
of	O
obtaining	O
an	O
initial	O
MRI	B-PROC
,	O
useful	O
in	O
presurgical	B-PROC
planning	O
.	O

This	O
study	B-PROC
was	O
designed	O
to	O
determine	O
whether	O
there	O
was	O
an	O
association	O
between	O
the	O
reamputation	B-PROC
rate	O
in	O
diabetic	B-DISO
patients	B-LIVB
and	O
utilization	O
of	O
MRI	B-PROC
in	O
the	O
presurgical	B-PROC
planning	O
and	O
prior	O
to	O
initial	O
forefoot	B-PROC
amputations	I-PROC
.	O

Following	O
approval	O
by	O
our	O
institutional	B-LIVB
review	I-LIVB
board	I-LIVB
,	O
our	O
study	B-PROC
design	I-PROC
consisted	O
of	O
a	O
retrospective	B-PROC
cohort	I-PROC
analysis	I-PROC
of	O
413	O
patients	B-LIVB
at	O
Staten	B-OBJC
Island	I-OBJC
University	I-OBJC
Hospital	I-OBJC
,	O
a	O
700	B-OBJC
-	I-OBJC
bed	I-OBJC
tertiary	I-OBJC
referral	I-OBJC
center	I-OBJC
between	O
2008	O
and	O
2013	O
who	O
underwent	O
an	O
initial	O
great	B-PROC
toe	I-PROC
(	I-PROC
hallux	I-PROC
)	I-PROC
amputation	I-PROC
.	O

Of	O
the	O
413	O
patients	B-LIVB
with	O
a	O
hallux	B-PROC
amputation	I-PROC
,	O
there	O
were	O
368	O
eligible	O
patients	B-LIVB
who	O
had	O
a	O
history	B-DISO
of	O
DM	B-DISO
with	O
documented	O
hemoglobin	B-CHEM
A1c	I-CHEM
(	O
HbA1c	B-CHEM
)	O
within	O
3	O
months	O
of	O
the	O
initial	O
first	B-ANAT
ray	I-ANAT
(	O
hallux	B-ANAT
and	O
first	B-ANAT
metatarsal	I-ANAT
)	O
amputation	B-PROC
and	O
available	O
radiographic	B-PHEN
data	O
.	O

Statistical	B-PROC
analysis	I-PROC
compared	O
the	O
incidence	O
rates	O
of	O
reamputation	B-PROC
between	O
patients	B-LIVB
who	O
underwent	O
initial	O
MRI	B-PROC
and	O
those	O
who	O
did	O
not	O
obtain	O
an	O
initial	O
MRI	B-PROC
prior	O
to	O
their	O
first	O
amputation	B-PROC
.	O

The	O
reamputation	B-PROC
rate	O
was	O
compared	O
after	O
adjustment	O
for	O
age	B-PHYS
,	O
gender	B-PHYS
,	O
ethnicity	O
,	O
HbA1c	B-CHEM
,	O
cardiovascular	B-DISO
disease	I-DISO
,	O
hypoalbuminemia	B-DISO
,	O
smoking	O
,	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
,	O
and	O
prior	O
antibiotic	B-PROC
treatment	I-PROC
.	O

The	O
results	B-DISO
of	O
our	O
statistical	B-PROC
analysis	I-PROC
failed	O
to	O
reveal	O
a	O
significant	O
association	O
between	O
obtaining	O
an	O
initial	O
MRI	B-PROC
and	O
the	O
reamputation	B-PROC
rate	O
.	O

We	O
did	O
,	O
however	O
,	O
find	O
a	O
statistical	O
association	O
between	O
obtaining	O
an	O
early	O
MRI	B-PROC
and	O
decreased	O
mortality	O
rates	O
.	O

Obtaining	O
an	O
early	O
MRI	B-PROC
was	O
not	O
associated	O
with	O
the	O
reamputation	B-PROC
rate	O
incidence	O
in	O
the	O
treatment	B-PROC
of	O
the	O
diabetic	B-DISO
foot	I-DISO
.	O

It	O
did	O
,	O
however	O
,	O
have	O
a	O
statistically	O
significant	O
association	O
with	O
the	O
mortality	O
rate	O
as	O
demonstrated	O
by	O
the	O
increased	O
survival	O
rate	O
in	O
patients	B-LIVB
undergoing	O
MRI	B-PROC
prior	O
to	O
initial	O
amputation	B-PROC
.	O

Diffuse	B-DISO
traumatic	I-DISO
brain	I-DISO
injury	I-DISO
affects	O
chronic	O
corticosterone	B-CHEM
function	O
in	O
the	O
rat	B-LIVB
As	O
many	O
as	O
20	O
-	O
55	O
%	O
of	O
patients	B-LIVB
with	O
a	O
history	B-DISO
of	O
traumatic	B-DISO
brain	I-DISO
injury	I-DISO
(	O
TBI	B-DISO
)	O
experience	O
chronic	O
endocrine	B-DISO
dysfunction	I-DISO
,	O
leading	O
to	O
impaired	O
quality	O
of	O
life	O
,	O
impaired	O
rehabilitation	O
efforts	O
and	O
lowered	B-DISO
life	I-DISO
expectancy	I-DISO
.	O

Endocrine	B-DISO
dysfunction	I-DISO
after	O
TBI	B-DISO
is	O
thought	O
to	O
result	O
from	O
acceleration	B-PHEN
-	O
deceleration	B-PHEN
forces	B-PHEN
to	O
the	O
brain	B-ANAT
within	O
the	O
skull	B-ANAT
,	O
creating	O
enduring	O
hypothalamic	B-ANAT
and	O
pituitary	B-ANAT
neuropathology	B-DISO
,	O
and	O
subsequent	O
hypothalamic	B-ANAT
-pituitary	I-ANAT
endocrine	I-ANAT
(	O
HPE	B-ANAT
)	O
dysfunction	B-DISO
.	O

These	O
experiments	B-PROC
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	B-DISO
TBI	I-DISO
results	O
in	O
chronic	O
dysfunction	B-DISO
of	O
corticosterone	B-CHEM
(	O
CORT	B-CHEM
)	O
,	O
a	O
glucocorticoid	B-CHEM
released	O
in	O
response	O
to	O
stress	B-DISO
and	O
testosterone	B-CHEM
.	O

We	O
used	O
a	O
rodent	B-DISO
model	I-DISO
of	O
diffuse	B-DISO
TBI	I-DISO
induced	O
by	O
midline	B-DISO
fluid	I-DISO
percussion	I-DISO
injury	I-DISO
(	O
mFPI	B-DISO
)	O
.	O

At	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	B-LIVB
control	I-LIVB
animals	I-LIVB
,	O
circulating	O
levels	O
of	O
CORT	B-CHEM
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	B-DISO
stress	I-DISO
and	O
in	O
response	O
to	O
dexamethasone	B-CHEM
,	O
a	O
synthetic	B-CHEM
glucocorticoid	I-CHEM
commonly	O
used	O
to	O
test	O
HPE	B-ANAT
axis	O
regulation	B-PHEN
.	O

Testosterone	B-CHEM
was	O
evaluated	O
at	O
rest	O
.	O

Further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	B-DISO
-	O
induced	O
neuron	B-ANAT
morphology	O
(	O
Golgi	B-PROC
stain	I-PROC
)	O
,	O
neuropathology	B-DISO
(	O
silver	B-PROC
stain	I-PROC
)	O
and	O
activated	B-PHYS
astrocytes	B-ANAT
(	O
GFAP	B-PROC
)	O
in	O
the	O
paraventricular	B-ANAT
nucleus	I-ANAT
(	O
PVN	B-ANAT
)	O
of	O
the	O
hypothalamus	B-ANAT
.	O

Resting	O
plasma	B-ANAT
CORT	B-CHEM
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
CORT	B-CHEM
increase	O
in	O
response	O
to	O
restraint	B-DISO
induced	I-DISO
stress	I-DISO
.	O

No	B-DISO
changes	I-DISO
in	O
testosterone	B-CHEM
were	O
measured	O
.	O

These	O
changes	O
in	O
CORT	B-CHEM
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	B-ANAT
processes	B-PHYS
in	O
the	O
PVN	B-ANAT
over	O
time	O
,	O
devoid	O
of	O
neuropathology	B-DISO
or	O
astrocytosis	B-DISO
.	O

Results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	B-DISO
TBI	I-DISO
leads	O
to	O
changes	O
in	O
CORT	B-CHEM
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	B-DISO
of	I-DISO
symptoms	I-DISO
related	O
to	O
endocrine	B-DISO
dysfunction	I-DISO
.	O

Future	O
experiments	B-PROC
aim	O
to	O
evaluate	O
additional	O
HP	B-CHEM
-	I-CHEM
related	I-CHEM
hormones	I-CHEM
and	O
endocrine	B-ANAT
circuit	O
pathology	O
following	O
diffuse	B-DISO
TBI	I-DISO
.	O

Systematic	O
and	O
detailed	B-PROC
analysis	I-PROC
of	O
behavioural	B-PROC
tests	I-PROC
in	O
the	O
rat	B-LIVB
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
model	B-LIVB
of	O
stroke	B-DISO
:	O
Tests	O
for	O
long	O
-	O
term	O
assessment	O
In	O
order	O
to	O
test	O
therapeutics	B-PROC
,	O
functional	B-PROC
assessments	I-PROC
are	O
required	O
.	O

In	O
pre	O
-	O
clinical	O
stroke	B-DISO
research	B-PROC
,	O
there	O
is	O
little	O
consensus	O
regarding	O
the	O
most	O
appropriate	O
behavioural	B-PROC
tasks	I-PROC
to	O
assess	O
deficits	O
,	O
especially	O
when	O
testing	O
over	O
extended	O
times	O
in	O
milder	O
models	B-LIVB
with	O
short	O
occlusion	O
times	O
and	O
small	O
lesion	O
volumes	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
comprehensively	O
assessed	O
16	O
different	O
behavioural	B-PROC
tests	I-PROC
,	O
with	O
the	O
aim	O
of	O
identifying	O
those	O
that	O
show	O
robust	O
,	O
reliable	O
and	O
stable	O
deficits	O
for	O
up	O
to	O
two	O
months	O
.	O

These	O
tasks	O
are	O
regularly	O
used	O
in	O
stroke	B-DISO
research	B-PROC
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
examining	O
striatal	B-DISO
dysfunction	I-DISO
in	O
models	B-LIVB
of	O
Huntington	B-DISO
's	I-DISO
and	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
.	O

Two	O
cohorts	B-LIVB
of	O
male	B-PHYS
Wistar	B-LIVB
rats	I-LIVB
underwent	O
the	O
intraluminal	O
filament	O
model	O
of	O
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
(	O
30	O
min	O
)	O
and	O
were	O
imaged	B-PROC
24	O
h	O
later	O
.	O

This	O
resulted	O
in	O
primarily	O
subcortical	B-DISO
infarcts	I-DISO
,	O
with	O
a	O
small	O
amount	O
of	O
cortical	B-DISO
damage	I-DISO
.	O

Animals	B-LIVB
were	O
tested	O
,	O
along	O
with	O
sham	B-LIVB
and	I-LIVB
naïve	I-LIVB
groups	I-LIVB
at	O
24	O
h	O
,	O
seven	O
days	O
,	O
and	O
one	O
and	O
two	O
months	O
.	O

Following	O
behavioural	B-PROC
testing	I-PROC
,	O
brains	B-ANAT
were	O
processed	O
and	O
striatal	O
neuronal	O
counts	O
were	O
performed	O
alongside	O
measurements	O
of	O
total	O
brain	B-ANAT
and	O
white	B-DISO
matter	I-DISO
atrophy	I-DISO
.	O

The	O
staircase	B-PROC
,	O
adjusting	B-PROC
steps	I-PROC
,	O
rotarod	B-PROC
and	O
apomorphine	B-PROC
-induced	I-PROC
rotations	I-PROC
were	O
the	O
most	O
reliable	O
for	O
assessing	O
long	O
-	O
term	O
deficits	O
in	O
the	O
30	O
min	O
transient	O
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
model	B-LIVB
of	O
stroke	B-DISO
.	O

The	O
next	O
frontier	O
of	O
office	B-OBJC
-based	O
inferior	O
vena	O
cava	O
filter	O
placement	O
There	O
is	O
an	O
increasing	O
number	O
of	O
procedures	B-PROC
that	O
traditionally	O
were	O
performed	O
in	O
the	O
inpatient	B-LIVB
setting	O
that	O
are	O
now	O
becoming	O
office	B-OBJC
-based	O
procedures	B-PROC
.	O

These	O
include	O
peripheral	O
endovascular	B-PROC
procedures	I-PROC
such	O
as	O
angiograms	B-PROC
,	O
angioplasties	B-PROC
,	O
dialysis	O
access	O
interventions	B-PROC
,	O
and	O
treatment	B-PROC
for	O
venous	B-DISO
insufficiency	I-DISO
.	O

We	O
chose	O
to	O
evaluate	O
the	O
feasibility	B-PROC
,	O
safety	B-PHEN
of	O
inferior	O
vena	O
cava	O
(	O
IVC	O
)	O
filter	O
placement	O
in	O
the	O
office	B-OBJC
-	I-OBJC
based	I-OBJC
setting	I-OBJC
.	O

All	O
procedures	B-PROC
were	O
performed	O
using	O
local	B-PROC
anesthesia	I-PROC
,	O
and	O
ultrasound	B-PROC
guidance	I-PROC
for	O
puncture	B-PROC
.	O

All	O
venograms	B-PROC
were	O
performed	O
with	O
manual	B-PROC
injection	I-PROC
of	O
iodinated	B-CHEM
contrast	I-CHEM
.	O

An	O
IVC	B-DEVI
filter	I-DEVI
was	O
placed	O
in	O
the	O
cases	O
(	O
except	O
one	O
failure	O
of	O
placement	B-PROC
)	O
using	O
fluoroscopy	B-PROC
in	O
the	O
infrarenal	B-ANAT
position	I-ANAT
.	O

Patients	B-LIVB
were	O
observed	O
in	O
a	O
recovery	B-PHYS
area	O
and	O
then	O
discharged	B-PROC
.	O

Follow	O
-	O
up	O
data	O
were	O
obtained	O
through	O
an	O
interview	O
,	O
physical	B-PROC
examination	I-PROC
,	O
and	O
24	B-PROC
-	I-PROC
hour	I-PROC
postoperative	I-PROC
phone	I-PROC
call	I-PROC
.	O

Over	O
the	O
course	O
of	O
27	O
months	O
,	O
29	O
Greenfield	B-DEVI
filters	I-DEVI
(	O
Boston	O
Scientific	O
,	O
Marlborough	O
,	O
Mass	O
)	O
and	O
three	O
Celect	B-DEVI
temporary	I-DEVI
filters	I-DEVI
(	O
Cook	O
,	O
Bloomington	O
,	O
Ind	O
)	O
were	O
placed	O
in	O
the	O
infrarenal	B-ANAT
IVC	B-ANAT
for	O
18	O
women	B-LIVB
and	O
14	O
men	B-LIVB
,	O
with	O
an	O
average	O
age	B-PHYS
of	O
75	O
.	O

3	O
±	O
15	O
.	O
6	O
years	O
(	O
range	O
,	O
38	O
-	O
97	O
years	O
)	O
.	O

Twenty	O
-	O
four	O
acute	O
,	O
6	O
recent	O
(	O
<	O
6	O
months	O
ago	O
)	O
and	O
three	O
subacute	B-ANAT
lower	I-ANAT
extremity	I-ANAT
deep	B-DISO
vein	I-DISO
thromboses	I-DISO
(	O
DVTs	B-DISO
)	O
were	O
identified	O
.	O

The	O
indications	O
for	O
the	O
procedure	B-PROC
were	O
patients	B-LIVB
with	O
:	O
DVT	B-DISO
who	O
were	O
to	O
undergo	O
surgery	B-PROC
(	O
n	O
=	O
6	O
)	O
,	O
acute	O
large	O
free	O
-	O
floating	O
iliofemoral	B-DISO
DVT	I-DISO
(	O
deemed	O
high	B-DISO
-	I-DISO
risk	I-DISO
for	O
long	O
-	O
term	O
anticoagulation	B-PHYS
)	O
(	O
n	O
=	O
7	O
)	O
,	O
new	O
DVT	B-DISO
during	O
anticoagulation	B-PROC
therapy	I-PROC
(	O
n	O
=	O
6	O
)	O
,	O
DVT	B-DISO
with	O
gastrointestinal	B-DISO
bleeding	I-DISO
(	O
n	O
=	O
4	O
)	O
,	O
DVT	B-DISO
with	O
hematuria	B-DISO
(	O
n	O
=	O
2	O
)	O
,	O
recent	O
DVT	B-DISO
(	O
which	O
extended	O
during	O
full	O
dose	O
anticoagulation	B-PROC
treatment	I-PROC
)	O
while	O
undergoing	O
a	O
long	O
flight	O
(	O
n	O
=	O
1	O
)	O
(	O
temporary	O
filter	B-DEVI
placement	B-PROC
)	O
,	O
DVT	B-DISO
with	O
arm	B-ANAT
hematoma	B-DISO
(	O
n	O
=	O
1	O
)	O
,	O
DVT	B-DISO
with	O
unsteady	B-DISO
gait	I-DISO
and	O
history	B-DISO
of	I-DISO
falls	I-DISO
(	O
n	O
=	O
2	O
)	O
,	O
DVT	B-DISO
with	O
nose	B-DISO
bleeding	I-DISO
(	O
n	O
=	O
1	O
)	O
,	O
DVT	B-DISO
with	O
dementia	B-DISO
and	O
inability	B-DISO
to	O
receive	O
anticoagulation	B-PROC
treatment	I-PROC
(	O
n	O
=	O
1	O
)	O
,	O
DVT	B-DISO
and	O
receiving	O
chemotherapy	B-PROC
and	O
with	O
thrombocytopenia	B-DISO
(	O
n	O
=	O
1	O
)	O
,	O
and	O
DVT	B-DISO
and	O
refusal	O
to	O
take	O
anticoagulation	B-PROC
medication	I-PROC
(	O
n	O
=	O
1	O
)	O
.	O

One	O
patient	B-LIVB
had	O
a	O
failure	O
to	O
place	O
a	O
filter	B-DEVI
because	O
of	O
chronic	O
IVC	B-ANAT
occlusion	B-DISO
found	O
on	O
venogram	B-PROC
.	O

One	O
patient	B-LIVB
with	O
history	B-DISO
of	O
gastrointestinal	B-DISO
bleeding	I-DISO
,	O
acute	O
DVT	B-DISO
,	O
and	O
atrial	B-DISO
fibrillation	I-DISO
suffered	O
IVC	B-DEVI
filter	I-DEVI
thrombosis	B-DISO
1	O
month	O
after	O
the	O
procedure	B-PROC
.	O

We	O
attempted	O
removal	B-PROC
of	O
the	O
temporary	O
filters	B-DEVI
in	O
the	O
hospital	B-OBJC
in	O
two	O
patients	B-LIVB
but	O
failed	O
to	O
retrieve	O
the	O
filter	B-DEVI
in	O
these	O
two	O
cases	O
.	O

We	O
noted	O
no	O
insertion	O
site	O
DVT	B-DISO
,	O
extension	O
of	O
DVT	B-DISO
,	O
or	O
pulmonary	B-DISO
embolism	I-DISO
.	O

Our	O
preliminary	O
experience	B-PHYS
suggests	O
that	O
placement	B-PROC
of	O
IVC	B-DEVI
filters	I-DEVI
for	O
treatment	B-PROC
of	O
venous	B-DISO
thrombotic	I-DISO
events	I-DISO
in	O
an	O
office	B-OBJC
-	I-OBJC
based	I-OBJC
facility	I-OBJC
is	O
safe	O
and	O
efficacious	O
with	O
basic	O
endovascular	B-DEVI
equipment	I-DEVI
.	O

Long	O
-	O
term	O
outcome	O
cannot	O
be	O
determined	O
at	O
this	O
point	O
.	O

Insensitivity	B-DISO
of	O
astrocytes	B-ANAT
to	O
interleukin	B-CHEM
10	I-CHEM
signaling	B-PHEN
following	O
peripheral	O
immune	B-ANAT
challenge	O
results	O
in	O
prolonged	O
microglial	B-PHYS
activation	I-PHYS
in	O
the	O
aged	B-PHYS
brain	B-ANAT
Immune	B-PHYS
-	I-PHYS
activated	I-PHYS
microglia	B-ANAT
from	O
aged	B-PHYS
mice	B-LIVB
produce	O
exaggerated	O
levels	O
of	O
cytokines	B-CHEM
.	O

Despite	O
high	O
levels	O
of	O
microglia	B-ANAT
l	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
10	I-CHEM
in	O
the	O
aged	B-PHYS
brain	B-ANAT
,	O
neuroinflammation	B-DISO
was	O
prolonged	O
and	O
associated	O
with	O
depressive	B-DISO
-	I-DISO
like	I-DISO
deficits	I-DISO
.	O

Because	O
astrocytes	B-ANAT
respond	O
to	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O
,	O
in	O
turn	O
,	O
attenuate	O
microglial	B-PHYS
activation	I-PHYS
,	O
we	O
investigated	O
if	O
astrocyte	B-PHYS
-	I-PHYS
mediated	I-PHYS
resolution	I-PHYS
of	I-PHYS
microglial	I-PHYS
activation	I-PHYS
was	O
impaired	O
with	O
age	B-PHYS
.	O

Here	O
,	O
aged	B-PHYS
astrocytes	B-ANAT
had	O
a	O
dysfunctional	B-DISO
profile	I-DISO
with	O
higher	O
glial	B-CHEM
fibrillary	I-CHEM
acidic	I-CHEM
protein	I-CHEM
,	O
lower	O
glutamate	B-CHEM
transporter	I-CHEM
expression	B-PHYS
,	O
and	O
significant	O
cytoskeletal	O
re	O
-	O
arrangement	O
.	O

Moreover	O
,	O
aged	B-PHYS
astrocytes	B-ANAT
had	O
reduced	O
expression	B-PHYS
of	O
growth	B-CHEM
factors	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
receptor	I-CHEM
-	I-CHEM
1	I-CHEM
(	B-CHEM
IL	I-CHEM
-	I-CHEM
10R1	I-CHEM
)	O
.	O

After	O
in	O
vivo	O
lipopolysaccharide	B-CHEM
immune	B-ANAT
challenge	O
,	O
aged	B-PHYS
astrocytes	B-ANAT
had	O
a	O
molecular	O
signature	O
associated	O
with	O
reduced	B-DISO
responsiveness	I-DISO
to	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
.	O

This	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
insensitivity	B-DISO
of	O
aged	B-PHYS
astrocytes	B-ANAT
resulted	O
in	O
a	O
failure	O
to	O
induce	O
IL	B-CHEM
-	I-CHEM
10R1	I-CHEM
and	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
β	I-CHEM
and	O
resolve	O
microglial	B-PHYS
activation	I-PHYS
.	O

In	O
addition	O
,	O
adult	B-LIVB
astrocytes	B-ANAT
reduced	O
microglial	B-PHYS
activation	I-PHYS
when	O
co	B-PROC
-	I-PROC
cultured	I-PROC
ex	O
vivo	O
,	O
whereas	O
aged	B-PHYS
astrocytes	B-ANAT
did	O
not	O
.	O

Consistent	O
with	O
the	O
aging	O
studies	O
,	O
IL	O
-	O
10R	O
(	O
KO	O
)	O
astrocytes	B-ANAT
did	O
not	O
augment	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
β	I-CHEM
after	O
immune	B-ANAT
challenge	O
and	O
failed	O
to	O
resolve	O
microglial	B-PHYS
activation	I-PHYS
.	O

Collectively	O
,	O
a	O
major	O
cytokine	B-CHEM
-	O
regulatory	O
loop	O
between	O
activated	O
microglia	B-ANAT
and	O
astrocytes	B-ANAT
is	O
impaired	O
in	O
the	O
aged	B-PHYS
brain	B-ANAT
.	O

Identification	O
of	O
a	O
group	O
of	O
XTHs	B-CHEM
genes	O
responding	O
to	O
heavy	B-CHEM
metal	I-CHEM
mercury	B-CHEM
,	O
salinity	B-PHEN
and	I-PHEN
drought	I-PHEN
stresses	I-PHEN
in	O
Medicago	B-LIVB
truncatula	I-LIVB
Xyloglucan	B-CHEM
endotransglucosylase	I-CHEM
/	I-CHEM
hydrolases	I-CHEM
(	O
XTH	B-CHEM
)	O
are	O
one	O
of	O
the	O
key	O
enzymes	B-CHEM
regulating	B-PHEN
cell	B-PHYS
wall	I-PHYS
construction	I-PHYS
,	O
extension	O
and	O
metabolism	B-ANAT
.	O

In	O
the	O
study	B-PROC
,	O
44	O
XTH	B-CHEM
protein	I-CHEM
genes	O
from	O
Medicago	B-LIVB
truncatula	I-LIVB
genome	O
were	O
identified	O
using	O
bioinformatics	O
,	O
microarray	B-OBJC
and	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
.	O

Each	O
XTH	B-CHEM
was	O
showed	O
to	O
possess	O
a	O
highly	O
conserved	O
domain	O
(	O
(	O
D	O
/	O
N	O
)	O
-	O
E	O
-	O
(	O
I	O
/	O
L	O
/	O
F	O
/	O
V	O
)	O
-	O
D	O
-	O
(	O
F	O
/	O
I	O
/	O
L	O
)	O
-	O
E	O
-	O
(	O
F	O
/	O
L	O
)	O
-	O
L	O
-	O
G	O
)	O
,	O
and	O
most	O
of	O
XTHs	B-CHEM
possess	O
four	O
Cys	B-CHEM
in	O
the	O
C	O
terminal	O
region	O
,	O
which	O
suggests	O
the	O
potential	O
for	O
generating	O
disulfide	O
bonds	O
.	O

Based	O
on	O
the	O
XTH	B-CHEM
protein	O
sequences	O
,	O
these	O
XTHs	B-CHEM
can	O
be	O
classified	O
into	O
three	O
major	O
families	B-CHEM
and	O
each	O
family	B-CHEM
can	O
be	O
subdivided	O
into	O
more	O
groups	O
.	O

Examination	O
of	O
the	O
genomic	O
location	O
of	O
XTH	O
genes	O
on	O
M	B-LIVB
.	I-LIVB

truncatula	I-LIVB
chromosomes	B-ANAT
showed	O
that	O
the	O
evolutional	B-PHEN
expansion	I-PHEN
of	O
the	O
genes	O
was	O
possibly	O
attributed	O
to	O
localized	O
gene	B-PHYS
duplications	I-PHYS
.	O

To	O
investigate	O
the	O
possible	O
involvement	O
of	O
the	O
XTHs	B-CHEM
responding	O
to	O
heavy	B-CHEM
metals	I-CHEM
and	O
other	O
abiotic	B-PHEN
stresses	I-PHEN
,	O
the	O
XTH	O
genes	O
were	O
exposed	O
to	O
heavy	B-CHEM
metal	I-CHEM
(	O
Hg	B-CHEM
or	O
Cu	B-CHEM
)	O
,	O
salt	B-PHEN
and	I-PHEN
drought	I-PHEN
stresses	I-PHEN
.	O

There	O
were	O
28	O
,	O
21	O
and	O
21	O
MtXTH	O
genes	O
found	O
to	O
respond	O
to	O
HgCl2	B-CHEM
,	O
salt	B-PHEN
and	I-PHEN
drought	I-PHEN
stresses	I-PHEN
,	O
respectively	O
,	O
but	O
their	O
expression	B-PHYS
were	O
different	O
under	O
the	O
stresses	B-PHEN
.	O

Some	O
of	O
the	O
XTH	O
genes	O
were	O
well	O
confirmed	O
by	O
quantitative	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
(	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
)	O
.	O

We	O
further	O
specified	O
expression	B-PHYS
of	O
a	O
XTH	O
gene	O
Medtr4g128580	O
(	O
MtXTH3	O
)	O
under	O
different	O
environmental	B-PHEN
stresses	I-PHEN
,	O
and	O
showed	O
that	O
MtXTH3	O
was	O
induced	O
by	O
Hg	B-CHEM
exposure	O
.	O

These	O
results	O
indicated	O
that	O
a	O
group	O
of	O
MtXTHs	O
could	O
be	O
differentially	O
expressed	B-PHYS
under	O
the	O
environmental	B-PHEN
stresses	I-PHEN
.	O

Vestibular	B-DISO
disorders	I-DISO
and	O
nausea	B-DISO
during	O
head	B-DISO
and	O
neck	B-DISO
intensity	B-PROC
-	I-PROC
modulated	I-PROC
radiation	I-PROC
therapy	I-PROC
We	O
studied	O
whether	O
there	O
is	O
a	O
relationship	O
between	O
nausea	B-DISO
and	O
vestibular	B-DISO
disorders	I-DISO
in	O
patients	B-LIVB
treated	B-PROC
with	I-PROC
intensity	B-PROC
modulated	I-PROC
radiation	I-PROC
therapy	I-PROC
(	O
IMRT	B-PROC
)	O
for	O
head	B-DISO
and	O
neck	B-DISO
cancer	I-DISO
.	O

We	O
performed	O
a	O
prospective	B-PROC
single	I-PROC
-	I-PROC
centre	I-PROC
study	I-PROC
that	O
enrolled	B-PROC
31	O
patients	B-LIVB
.	O

A	O
videonystagmography	B-PROC
was	O
carried	O
out	O
before	O
and	O
within	O
15	O
days	O
after	O
radiation	B-PROC
therapy	I-PROC
for	O
each	O
patient	B-LIVB
.	O

Nausea	B-DISO
was	O
assessed	O
at	O
baseline	O
,	O
every	O
week	O
,	O
and	O
at	O
the	O
post	B-PROC
-	I-PROC
radiotherapy	I-PROC
videonystagmography	B-PROC
visit	O
.	O

Twenty	O
-	O
six	O
patients	B-LIVB
had	O
benefited	O
from	O
a	O
complete	O
interpretable	O
videonystagmography	B-PROC
.	O

For	O
14	O
of	O
these	O
patients	B-LIVB
vestibular	B-DISO
damage	I-DISO
was	O
diagnosed	B-DISO
post	B-PROC
-	I-PROC
radiotherapy	I-PROC
.	O

During	O
irradiation	B-PHEN
,	O
six	O
patients	B-LIVB
felt	O
nauseous	B-DISO
,	O
but	O
without	O
dizziness	B-DISO
.	O

In	O
univariate	B-PROC
analysis	I-PROC
,	O
we	O
found	O
a	O
relationship	O
statistically	O
significant	O
between	O
the	O
average	O
dose	O
received	O
by	O
the	O
vestibules	B-ANAT
and	O
vestibular	B-DISO
disorder	I-DISO
videonystagmography	B-PROC
(	O
P	O
=	O
0	O
.	O

001	O
,	O
odds	O
ratio	O
[	O
OR	O
]	O
:	O
1	O
.	O
08	O
[	O
1	O
.	O
025	O
-	O
.	O
138	O
]	O
)	O
,	O
but	O
there	O
was	O
no	B-DISO
relationship	O
between	O
vestibular	B-DISO
disorder	I-DISO
videonystagmography	B-PROC
and	O
nausea	B-DISO
(	O
P	O
=	O
0	O
.	O
701	O
)	O
.	O

Irradiation	B-PHEN
of	O
the	O
vestibular	B-ANAT
system	I-ANAT
during	O
IMRT	B-PROC
does	O
not	O
seem	O
to	O
explain	O
the	O
nausea	B-DISO
.	O

Preventing	O
Youth	B-LIVB
Internalizing	B-DISO
Symptoms	I-DISO
Through	O
the	O
Familias	O
Unidas	O
Intervention	O
:	O
Examining	O
Variation	O
in	O
Response	B-PHYS
Prevention	O
programs	O
that	O
strengthen	O
parenting	O
and	O
family	O
functioning	O
have	O
been	O
found	O
to	O
reduce	B-PROC
poor	B-DISO
behavioral	I-DISO
outcomes	O
in	O
adolescents	B-LIVB
,	O
including	O
substance	B-DISO
use	I-DISO
,	O
HIV	B-DISO
risk	I-DISO
,	O
externalizing	O
and	O
internalizing	B-DISO
problems	I-DISO
.	O

However	O
,	O
there	O
is	O
evidence	O
that	O
not	O
all	O
youth	B-LIVB
benefit	O
similarly	O
from	O
these	O
programs	O
.	O

Familias	O
Unidas	O
is	O
a	O
family	O
-	O
focused	O
intervention	O
designed	O
to	O
prevent	O
substance	B-DISO
use	I-DISO
and	O
sexual	B-DISO
risk	I-DISO
among	O
Hispanic	B-LIVB
youth	B-LIVB
and	O
has	O
recently	O
demonstrated	O
unanticipated	O
reductions	B-PROC
in	O
internalizing	B-DISO
symptoms	I-DISO
for	O
some	O
youth	B-LIVB
.	O

This	O
paper	O
examines	O
variation	O
in	O
intervention	O
response	O
for	O
internalizing	B-DISO
symptoms	I-DISO
using	O
individual	O
-	O
level	O
data	O
pooled	O
across	O
four	O
distinct	O
Familias	O
Unidas	O
trials	B-PROC
:	O
(	O
1	O
)	O
266	O
eighth	B-DISO
grade	I-DISO
students	B-LIVB
recruited	O
from	O
the	O
general	O
school	B-LIVB
population	I-LIVB
;	O
(	O
2	O
)	O
160	O
ninth	B-DISO
grade	I-DISO
students	B-LIVB
from	O
the	O
general	O
school	B-LIVB
population	I-LIVB
;	O
(	O
3	O
)	O
213	O
adolescents	B-LIVB
with	O
conduct	B-DISO
,	O
aggression	O
,	O
and	O
/	O
or	O
attention	B-DISO
problems	I-DISO
;	O
and	O
(	O
4	O
)	O
242	O
adolescents	B-LIVB
with	O
a	O
delinquency	B-DISO
history	O
.	O

Causal	O
inference	O
growth	O
mixture	O
modeling	O
suggests	O
a	O
three	O
-	O
class	O
model	O
.	O

The	O
two	O
largest	O
classes	O
represent	O
youth	B-LIVB
with	O
low	O
(	O
60	O
%	O
)	O
and	O
medium	O
(	O
27	O
%	O
)	O
internalizing	B-DISO
symptoms	I-DISO
at	O
baseline	O
,	O
and	O
both	O
intervention	O
and	O
control	B-LIVB
participants	B-LIVB
show	O
reductions	B-PROC
in	O
internalizing	B-DISO
symptoms	I-DISO
.	O

The	O
third	O
class	O
(	O
13	O
%	O
)	O
represents	O
youth	B-LIVB
with	O
high	O
levels	O
of	O
baseline	O
internalizing	B-DISO
symptoms	I-DISO
who	O
remain	O
at	O
steady	O
levels	O
of	O
internalizing	B-DISO
symptoms	I-DISO
when	O
exposed	O
to	O
the	O
intervention	O
,	O
but	O
who	O
experience	O
an	O
increase	O
in	O
symptoms	B-DISO
under	O
the	O
control	O
condition	O
.	O

Female	B-PHYS
gender	I-PHYS
,	O
low	O
baseline	O
levels	O
of	O
parent	B-LIVB
-	O
adolescent	B-LIVB
communication	O
,	O
and	O
older	B-LIVB
age	I-LIVB
were	O
associated	O
with	O
membership	O
in	O
the	O
high	B-DISO
-	I-DISO
risk	I-DISO
class	O
.	O

These	O
synthesis	O
analyses	O
involving	O
a	O
large	O
sample	O
of	O
youth	B-LIVB
with	O
varying	O
initial	O
risk	O
levels	O
represent	O
a	O
further	O
step	O
toward	O
strengthening	O
our	O
knowledge	O
of	O
preventive	O
intervention	O
response	B-PHYS
and	O
improving	O
preventive	O
interventions	O
.	O

Percutaneous	B-PROC
Bullectomy	I-PROC
in	O
Conjunction	O
with	O
Endobronchial	B-DEVI
Valve	I-DEVI
Placement	B-PROC
as	O
an	O
Alternative	O
to	O
Surgical	B-PROC
Management	I-PROC
of	O
Giant	B-DISO
Bullae	I-DISO
We	O
present	O
the	O
first	O
reported	O
case	O
of	O
the	O
treatment	B-PROC
and	O
management	B-PROC
of	O
a	O
giant	B-DISO
bulla	I-DISO
using	O
percutaneous	B-PROC
bullectomy	I-PROC
and	O
endobronchial	B-DEVI
valve	I-DEVI
placement	B-PROC
.	O

A	O
74	O
-	O
year	O
-old	O
woman	B-LIVB
with	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O
a	O
known	O
large	O
bulla	B-DISO
in	O
the	O
left	O
chest	B-ANAT
presented	O
to	O
the	O
emergency	B-OBJC
department	I-OBJC
with	O
acute	B-DISO
-	I-DISO
onset	I-DISO
confusion	I-DISO
after	O
a	O
traumatic	O
fall	B-DISO
.	O

She	O
was	O
subsequently	O
diagnosed	B-DISO
with	O
an	O
intracranial	B-DISO
hemorrhage	I-DISO
in	O
the	O
distribution	O
of	O
the	O
right	B-ANAT
basal	I-ANAT
ganglia	I-ANAT
.	O

Chest	B-PROC
imaging	I-PROC
revealed	O
a	O
giant	B-DISO
apical	I-DISO
bulla	I-DISO
occupying	O
80	O
%	O
of	O
the	O
left	B-ANAT
hemithorax	I-ANAT
.	O

In	O
addition	O
,	O
there	O
was	O
midline	B-DISO
shift	I-DISO
away	O
from	O
the	O
affected	B-DISO
side	I-DISO
associated	O
with	O
volume	O
loss	O
in	O
the	O
right	B-ANAT
hemithorax	I-ANAT
and	O
no	O
radiographic	O
evidence	O
of	O
aeration	B-PHYS
in	O
the	O
remainder	O
of	O
the	O
left	B-ANAT
lung	I-ANAT
.	O

Arterial	B-PROC
blood	I-PROC
gas	I-PROC
analysis	I-PROC
revealed	O
significant	O
hypercapnia	B-DISO
.	O

Surgical	B-PROC
bullectomy	B-PROC
was	O
not	O
an	O
option	O
,	O
and	O
thus	O
,	O
a	O
novel	O
approach	O
was	O
utilized	O
to	O
treat	O
this	O
patient	B-LIVB
.	O

Acute	B-DISO
Kidney	I-DISO
Injury	I-DISO
Severity	O
and	O
Long	O
-	O
Term	O
Readmission	B-PROC
and	O
Mortality	O
After	O
Cardiac	B-PROC
Surgery	I-PROC
Acute	B-DISO
kidney	I-DISO
injury	I-DISO
(	O
AKI	B-DISO
)	O
is	O
a	O
common	O
complication	B-DISO
after	O
cardiac	B-PROC
surgery	I-PROC
.	O

While	O
AKI	B-DISO
severity	O
is	O
known	O
to	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
short	O
-	O
term	O
outcomes	O
,	O
its	O
long	O
-	O
term	O
impact	O
is	O
less	O
well	O
understood	O
.	O

Adult	O
patients	B-LIVB
undergoing	O
isolated	O
coronary	B-PROC
artery	I-PROC
bypass	I-PROC
graft	I-PROC
surgery	I-PROC
at	O
eight	O
centers	O
were	O
enrolled	O
into	O
the	O
Northern	O
New	O
England	O
biomarker	O
registry	O
(	O
n	O
=	O
1	O
,	O
610	O
)	O
.	O

Patients	B-LIVB
were	O
excluded	O
if	O
they	O
had	O
renal	B-DISO
failure	I-DISO
(	O
n	O
=	O
15	O
)	O
or	O
died	B-DISO
during	O
index	B-PROC
admission	I-PROC
(	O
n	O
=	O
38	O
)	O
.	O

Severity	O
of	O
AKI	B-DISO
was	O
defined	O
using	O
the	O
Acute	O
Kidney	O
Injury	O
Network	O
(	O
AKIN	O
)	O
.	O

We	O
linked	O
our	O
cohort	O
to	O
national	O
Medicare	O
and	O
state	O
all	O
-	O
payer	O
claims	O
to	O
ascertain	O
readmissions	B-PROC
and	O
to	O
the	O
National	O
Death	O
Index	O
to	O
ascertain	O
survival	O
.	O

Kaplan	O
-	O
Meier	O
and	O
multivariate	O
Cox	O
proportional	O
hazards	O
modeling	O
was	O
conducted	O
for	O
time	O
to	O
readmission	B-PROC
and	O
death	B-DISO
over	O
5	O
years	O
.	O

Within	O
5	O
years	O
,	O
513	O
patients	B-LIVB
(	O
33	O
.	O
8	O
%	O
)	O
had	O
AKI	B-DISO
with	O
AKIN	O
stage	O
1	O
(	O
29	O
.	O
9	O
%	O
)	O
and	O
stage	O
2	O
to	O
3	O
(	O
3	O
.	O
9	O
%	O
)	O
.	O

There	O
were	O
620	O
readmissions	B-PROC
(	O
39	O
.	O

9	O
%	O
)	O
and	O
370	O
deaths	B-DISO
(	O
23	O
.	O
8	O
%	O
)	O
.	O

After	O
adjustment	O
,	O
stage	O
1	O
AKI	B-DISO
patients	B-LIVB
had	O
a	O
31	O
%	O
increased	O
risk	O
of	O
readmission	B-PROC
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1	O
.	O
10	O
to	O
1	O
.	O
57	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-LIVB
had	O
a	O
98	O
%	O
increased	O
risk	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
41	O
to	O
2	O
.	O
78	O
)	O
compared	O
with	O
patients	B-LIVB
having	O
no	B-DISO
AKI	B-DISO
.	O

Relative	O
to	O
patients	B-LIVB
without	O
AKI	B-DISO
,	O
stage	O
1	O
patients	B-LIVB
had	O
a	O
56	O
%	O
increased	O
risk	O
of	O
mortality	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
14	O
to	O
2	O
.	O
13	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-LIVB
had	O
a	O
3	O
.	O
5	O
times	O
higher	O
risk	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
16	O
to	O
5	O
.	O
60	O
)	O
.	O

Severity	O
of	O
AKI	B-DISO
using	O
the	O
AKIN	O
stage	O
criteria	O
is	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
5	O
-	O
year	O
readmission	B-PROC
and	O
mortality	O
.	O

Our	O
findings	O
suggest	O
that	O
efforts	O
to	O
reduce	O
AKI	B-DISO
in	O
the	O
perioperative	O
period	O
may	O
have	O
a	O
significant	O
long	O
-	O
term	O
impact	O
on	O
patients	B-LIVB
and	O
payers	O
in	O
reducing	O
mortality	O
and	O
health	B-PROC
care	I-PROC
utilization	I-PROC
.	O

Methamphetamine	B-CHEM
,	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxymethamphetamine	I-CHEM
(	O
MDMA	B-CHEM
)	O
and	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O
MDPV	B-CHEM
)	O
induce	O
differential	O
cytotoxic	B-DISO
effects	I-DISO
in	O
bovine	B-LIVB
brain	B-ANAT
microvessel	B-ANAT
endothelial	B-ANAT
cells	I-ANAT
Designer	B-CHEM
drugs	I-CHEM
such	O
as	O
synthetic	B-CHEM
psychostimulants	I-CHEM
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-DISO
of	O
drug	B-DISO
abuse	I-DISO
and	O
addiction	B-DISO
.	O

In	O
addition	O
to	O
methamphetamine	B-CHEM
(	O
METH	B-CHEM
)	O
,	O
these	O
drugs	B-CHEM
include	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxy	I-CHEM
-	I-CHEM
methamphetamine	I-CHEM
(	O
MDMA	B-CHEM
)	O
and	O
commercial	O
preparations	O
of	O
synthetic	B-CHEM
cathinones	I-CHEM
including	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O
MDPV	B-CHEM
)	O
,	O
typically	O
referred	O
to	O
as	O
""""	O
bath	B-CHEM
salts	I-CHEM
.	O
""""	O
These	O
psychostimulants	B-CHEM
exert	O
neurotoxic	B-DISO
effects	I-DISO
by	O
altering	O
monoamine	O
systems	O
in	O
the	O
brain	B-ANAT
.	O

Additionally	O
,	O
METH	B-CHEM
and	O
MDMA	B-CHEM
adversely	B-DISO
affect	I-DISO
the	O
integrity	O
of	O
the	O
blood	B-ANAT
-	I-ANAT
brain	I-ANAT
barrier	I-ANAT
(	O
BBB	B-ANAT
)	O
:	O
there	O
are	O
no	O
current	O
reports	O
on	O
the	O
effects	O
of	O
MDPV	B-CHEM
on	O
the	O
BBB	B-ANAT
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
compare	O
the	O
effects	O
of	O
METH	B-CHEM
,	O
MDMA	B-CHEM
and	O
MDPV	B-CHEM
on	O
bovine	B-LIVB
brain	B-ANAT
microvessel	B-ANAT
endothelial	B-ANAT
cells	I-ANAT
(	O
bBMVECs	B-ANAT
)	O
,	O
an	O
accepted	O
in	B-PROC
vitro	I-PROC
model	I-PROC
of	O
the	O
BBB	B-ANAT
.	O

Confluent	O
bBMVEC	B-ANAT
monolayers	B-ANAT
were	O
treated	O
with	O
METH	B-CHEM
,	O
MDMA	B-CHEM
and	O
MDPV	B-CHEM
(	O
0	O
.	O
5mM	O
-	O
2	O
.	O
5mM	O
)	O
for	O
24h	O
.	O

METH	B-CHEM
and	O
MDMA	B-CHEM
increased	O
lactate	B-CHEM
dehydrogenase	I-CHEM
release	O
only	O
at	O
the	O
highest	O
concentration	O
(	O
2	O
.	O
5mM	O
)	O
,	O
whereas	O
MDPV	B-CHEM
induced	O
cytotoxicity	B-DISO
at	O
all	O
concentration	O
s	O
.	O

MDMA	B-CHEM
and	O
METH	B-CHEM
decreased	O
cellular	B-PHYS
proliferation	I-PHYS
only	O
at	O
2	O
.	O

5mM	O
,	O
with	O
similar	O
effects	O
observed	O
after	O
MDPV	B-CHEM
exposures	O
starting	O
at	O
1mM	O
.	O

Only	O
MDPV	B-CHEM
increased	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
production	O
at	O
all	O
concentrations	O
tested	O
whereas	O
all	O
3	O
drugs	B-CHEM
increased	O
nitric	B-CHEM
oxide	I-CHEM
production	O
.	O

Morphological	B-PROC
analysis	I-PROC
revealed	O
different	O
patterns	O
of	O
compound	B-CHEM
-	O
induced	O
cell	B-DISO
damage	I-DISO
.	O

METH	B-CHEM
induced	O
vacuole	B-ANAT
formatio	O
n	O
at	O
1mM	O
and	O
disruption	O
of	O
the	O
monolayer	B-ANAT
at	O
2	O
.	O

5mM	O
.	O

MDMA	B-CHEM
induced	O
disruption	O
of	O
the	O
endothelial	B-ANAT
monolayer	B-ANAT
from	O
1mM	O
without	O
vacuolization	B-DISO
.	O

On	O
the	O
other	O
hand	O
,	O
MDPV	B-CHEM
induced	O
monolayer	B-ANAT
disruption	O
at	O
doses	O
≥0	O
.	O

5mM	O
without	O
vacuole	B-ANAT
formation	O
;	O
at	O
2	O
.	O
5mM	O
,	O
the	O
few	O
remaining	O
cells	B-ANAT
lacked	O
endothelial	O
morphology	O
.	O

These	O
data	O
suggest	O
that	O
even	O
though	O
these	O
synthetic	B-CHEM
psychostimulants	I-CHEM
alter	O
monoaminergic	O
systems	O
,	O
they	O
each	O
induce	O
BBB	B-ANAT
toxicity	B-DISO
by	O
different	O
mechanisms	O
with	O
MDPV	B-CHEM
being	O
the	O
most	O
toxic	O
.	O

Alleviation	O
of	O
hepatic	B-ANAT
fat	B-DISO
accumulation	I-DISO
by	O
betaine	B-CHEM
involves	O
reduction	O
of	O
homocysteine	B-CHEM
via	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
betaine	B-CHEM
-	I-CHEM
homocysteine	I-CHEM
methyltransferase	I-CHEM
(	O
BHMT	B-CHEM
)	O
We	O
investigated	O
the	O
anti	O
-	O
lipogenic	O
effect	O
of	O
betaine	B-CHEM
in	O
rats	B-LIVB
fed	O
methionine	B-CHEM
and	O
choline	B-CHEM
-	O
deficient	O
diet	B-OBJC
(	O
MCD	B-OBJC
)	O
.	O

Intake	O
of	O
MCD	B-OBJC
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	O
accumulation	B-DISO
of	O
hepatic	B-ANAT
lipids	B-CHEM
,	O
which	O
was	O
prevented	O
by	O
betaine	B-CHEM
supplementation	B-PROC
in	O
drinking	B-OBJC
water	I-OBJC
(	O
1	O
%	O
)	O
.	O

Phosphorylation	B-PHYS
of	O
AMP	B-CHEM
-	I-CHEM
activated	I-CHEM
protein	I-CHEM
kinase	I-CHEM
(	O
AMPK	B-CHEM
)	O
,	O
acetyl	B-CHEM
-	I-CHEM
CoA	I-CHEM
carboxylase	I-CHEM
(	O
ACC	B-CHEM
)	O
,	O
sterol	B-CHEM
regulatory	I-CHEM
element	I-CHEM
-	I-CHEM
binding	I-CHEM
protein	I-CHEM
1c	I-CHEM
(	O
SREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
)	O
,	O
and	O
liver	B-CHEM
kinase	I-CHEM
B1	I-CHEM
(	O
LKB1	B-CHEM
)	O
was	O
inhibited	O
by	O
MCD	B-OBJC
intake	O
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	O
by	O
betaine	B-CHEM
feeding	B-PROC
.	O

Meanwhile	O
,	O
betaine	B-CHEM
supplementation	B-PROC
reversed	O
the	O
reduction	O
of	O
methionine	B-PHYS
and	I-PHYS
S	I-PHYS
-	I-PHYS
adenosylmethionine	I-PHYS
(	O
SAM	B-PHYS
)	O
,	O
and	O
the	O
elevation	O
of	O
homocysteine	B-PROC
levels	I-PROC
in	O
the	O
liver	B-ANAT
,	I-ANAT
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	B-PHYS
of	O
betaine	B-CHEM
-	I-CHEM
homocysteine	I-CHEM
methyltransfease	I-CHEM
(	O
BHMT	B-CHEM
)	O
and	O
methionine	B-CHEM
adenosyltransferase	I-CHEM
(	O
MAT	B-CHEM
)	O
.	O

Different	O
cell	B-ANAT
lines	I-ANAT
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	B-CHEM
on	O
activation	B-PHYS
of	O
the	O
AMPK	B-CHEM
pathway	B-PHYS
.	O

Homocysteine	B-CHEM
treatment	O
decreased	O
pAMPK	B-CHEM
,	O
pACC	B-CHEM
,	O
pSREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
and	O
pLKB1	B-CHEM
in	O
HepG2	B-ANAT
cells	I-ANAT
.	O

Metformin	B-CHEM
-	O
induced	O
activation	B-PHYS
of	O
AMPK	B-CHEM
was	O
also	O
inhibited	O
by	O
homocysteine	B-CHEM
.	O

Treatment	O
with	O
hydroxylamine	B-CHEM
,	O
a	O
cystathionine	B-CHEM
β	I-CHEM
-	I-CHEM
synthase	I-CHEM
inhibitor	B-CHEM
,	O
resulted	O
in	O
a	O
reduction	O
of	O
pAMPK	B-CHEM
,	O
pACC	B-CHEM
and	O
pSREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
,	O
accompanied	O
by	O
an	O
elevation	O
of	O
intracellular	O
homocysteine	B-CHEM
.	O

Betaine	B-CHEM
treatment	B-PROC
prevented	O
the	O
homocysteine	B-CHEM
-	O
induced	O
reduction	O
of	O
pAMPK	B-CHEM
,	O
pACC	B-CHEM
,	O
pSREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
and	O
pLKB1	B-CHEM
in	O
H4IIE	B-ANAT
cells	I-ANAT
,	O
but	O
not	O
in	O
HepG2	B-ANAT
cells	I-ANAT
.	O

Also	O
the	O
elevation	O
of	O
cellular	O
homocysteine	B-CHEM
and	O
inhibition	O
of	O
protein	B-PHYS
expression	I-PHYS
of	O
BHMT	B-CHEM
were	O
prevented	O
by	O
betaine	B-CHEM
only	O
in	O
H4IIE	B-ANAT
cells	I-ANAT
which	O
express	B-PHYS
BHMT	B-CHEM
.	O

The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-CHEM
against	O
hepatic	B-ANAT
lipid	B-CHEM
accumulation	B-DISO
may	O
be	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	O
of	O
homocysteine	B-CHEM
via	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
BHMT	B-CHEM
in	O
hepatocytes	B-ANAT
.	O

Constitutive	O
expression	B-PHYS
of	O
cytochrome	B-CHEM
P450	I-CHEM
in	O
foetal	B-ANAT
and	O
adult	B-LIVB
porcine	B-LIVB
livers	B-ANAT
-	O
Effects	O
of	O
body	B-PHYS
weight	I-PHYS
The	O
liver	B-ANAT
hosts	O
a	O
great	O
number	O
of	O
enzymatically	B-CHEM
driven	O
processes	B-PHEN
,	O
including	O
detoxification	B-PHYS
.	O

The	O
super	O
-	O
family	O
of	O
enzymes	B-CHEM
named	O
cytochrome	B-CHEM
P450	I-CHEM
(	O
CYP	B-CHEM
)	O
is	O
the	O
major	O
participant	O
in	O
that	O
process	B-PHYS
.	O

The	O
expression	B-PHYS
of	O
CYPs	B-CHEM
is	O
affected	O
by	O
several	O
factors	O
including	O
life	O
-	O
stage	O
(	O
foetal	B-ANAT
vs	O
.	O

adult	B-LIVB
)	O
.	O

In	O
the	O
present	O
study	B-PROC
we	O
investigated	O
the	O
impact	O
of	O
birth	B-PHYS
-	I-PHYS
weight	I-PHYS
(	O
high	O
or	O
low	O
birth	B-PHYS
weight	I-PHYS
)	O
and	O
life	O
-	O
stage	O
on	O
constitutive	O
expression	B-PHYS
of	O
porcine	B-LIVB
hepatic	B-ANAT
CYP1A1	B-CHEM
,	O
CYP1A2	B-CHEM
,	O
CYP2A19	B-CHEM
,	O
CYP2B22	B-CHEM
,	O
CYP2C33	B-CHEM
,	O
CYP2D25	B-CHEM
,	O
CYP2E1	B-CHEM
and	O
CYP3A29	B-CHEM
,	O
as	O
well	O
as	O
the	O
transcription	B-CHEM
factors	I-CHEM
controlling	O
their	O
expression	B-PHYS
;	O
aryl	B-CHEM
hydrocarbon	I-CHEM
receptor	I-CHEM
,	O
constitutive	B-CHEM
androstane	I-CHEM
receptor	I-CHEM
,	O
pregnane	B-CHEM
X	I-CHEM
receptor	I-CHEM
,	O
C	B-CHEM
/	I-CHEM
EBP	I-CHEM
and	O
hepatocyte	B-CHEM
nuclear	I-CHEM
factors	I-CHEM
1	I-CHEM
and	O
4	B-CHEM
.	O

Both	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
and	O
western	B-PROC
blotting	I-PROC
showed	O
a	O
marked	O
increase	O
in	O
the	O
expression	B-PHYS
of	O
the	O
adult	B-LIVB
pigs	I-LIVB
compared	O
with	O
prenatal	B-LIVB
pigs	B-LIVB
.	O

Moreover	O
,	O
CYP2E1	B-CHEM
mRNA	B-PHYS
expression	I-PHYS
was	O
7	O
.	O

5	O
fold	O
higher	O
in	O
foetuses	B-ANAT
with	O
low	O
birth	B-PHYS
weight	I-PHYS
compared	O
with	O
foetuses	B-ANAT
with	O
high	O
birth	B-PHYS
weight	I-PHYS
.	O

Gender	B-PHYS
did	O
not	O
affect	O
the	O
mRNA	B-PHYS
expression	I-PHYS
within	O
the	O
different	O
life	O
-	O
stages	O
.	O

These	O
results	O
indicate	O
a	O
similarity	O
to	O
what	O
is	O
observed	O
in	O
humans	B-LIVB
and	O
porcine	B-LIVB
foetuses	B-ANAT
may	O
therefore	O
be	O
a	O
model	B-DEVI
for	O
humans	B-LIVB
when	O
studying	B-PROC
expression	B-PHYS
of	O
CYPs	B-CHEM
.	O

Association	O
of	O
abdominal	O
fat	O
with	O
serum	B-ANAT
amylase	B-CHEM
in	O
an	O
older	B-LIVB
cohort	B-LIVB
:	O
The	O
Baltimore	B-GEOG
Longitudinal	B-PROC
Study	I-PROC
of	O
Aging	B-PHYS
Abdominal	O
fat	O
is	O
a	O
major	O
determinant	O
of	O
metabolic	B-DISO
diseases	I-DISO
in	O
older	B-LIVB
individuals	B-LIVB
.	O

Obesity	B-DISO
and	O
diabetes	B-DISO
are	O
associated	O
with	O
low	O
serum	B-DISO
amylase	I-DISO
(	I-DISO
SA	I-DISO
)	I-DISO
levels	I-DISO
,	O
but	O
the	O
association	O
between	O
SA	B-DISO
and	O
metabolic	B-DISO
disease	I-DISO
is	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
association	O
of	O
low	O
SA	B-DISO
with	O
diabetes	B-DISO
and	O
sex	B-PHYS
-	O
specific	O
associations	O
of	O
serum	B-ANAT
amylase	B-CHEM
with	O
abdominal	O
fat	O
in	O
older	B-LIVB
adults	I-LIVB
.	O

In	O
community	O
-	O
dwelling	O
volunteers	B-LIVB
from	O
the	O
Baltimore	B-GEOG
Longitudinal	B-PROC
Study	I-PROC
of	O
Aging	B-PHYS
(	O
778	O
participants	B-LIVB
,	O
age	B-PHYS
66	O
.	O

8±13	O
.	O
6	O
years	O
)	O
,	O
we	O
assessed	O
abdominal	O
fat	O
by	O
computed	B-PROC
tomography	I-PROC
and	O
diabetes	B-DISO
status	I-DISO
using	O
the	O
American	O
Diabetes	O
Association	O
criteria	O
.	O

Linear	O
regression	O
analyses	O
assessed	O
the	O
cross	O
-	O
sectional	O
associations	O
between	O
abdominal	O
fat	O
and	O
SA	B-DISO
,	O
and	O
logistic	B-PROC
regression	I-PROC
assessed	O
the	O
odds	O
of	O
diabetes	B-DISO
,	O
given	O
low	O
SA	B-DISO
.	O

In	O
unadjusted	B-PROC
analyses	I-PROC
,	O
individuals	B-LIVB
in	O
the	O
lowest	O
SA	B-DISO
quartile	O
(	O
<	O
48μ	O
/	O
L	O
)	O
had	O
1	O
.	O

97	O
greater	O
odds	O
of	O
diabetes	B-DISO
,	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
3	O
.	O
83	O
)	O
than	O
those	O
in	O
the	O
highest	O
quartile	O
(	O
⩾80μ	O
/	O
L	O
)	O
.	O

This	O
association	O
was	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
visceral	O
adipose	O
tissue	O
area	O
(	O
VAT	O
,	O
dm	O
(	O
2	O
)	O
)	O
,	O
abdominal	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
,	O
dm	O
(	O
2	O
)	O
)	O
or	O
BMI	B-PHYS
.	O

In	O
adjusted	B-PROC
analyses	I-PROC
,	O
VAT	O
and	O
SAT	O
were	O
significantly	O
associated	O
with	O
SA	B-DISO
in	O
both	O
sexes	B-PHYS
.	O

Among	O
women	B-LIVB
,	O
SA	B-DISO
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
SAT	O
or	O
BMI	B-PHYS
;	O
VAT	O
(	O
β	O
=	O
-	O
0	O
.	O
117±0	O
.	O
048	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
SAT	O
(	O
β	O
=	O
-	O
0	O
.	O

023±0	O
.	O
025	O
,	O
P	O
=	O
0	O
.	O
346	O
)	O
and	O
BMI	B-PHYS
(	O
β	O
=	O
-	O
0	O
.	O

0052±0	O
.	O

075	O
,	O
P	O
=	O
0	O
.	O
49	O
)	O
.	O

The	O
association	O
between	O
SA	B-CHEM
and	O
diabetes	B-DISO
was	O
explained	O
mainly	O
by	O
abdominal	O
visceral	O
fat	O
.	O

In	O
women	B-LIVB
,	O
SA	B-CHEM
was	O
more	O
strongly	O
associated	O
with	O
VAT	O
than	O
with	O
BMI	B-PHYS
or	O
SAT	O
.	O

These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	O
studies	O
on	O
SA	B-CHEM
's	I-CHEM
role	O
in	O
metabolic	B-DISO
diseases	I-DISO
.	O

Efficacy	O
of	O
Intravenous	O
Chlorothiazide	B-CHEM
for	O
Refractory	O
Acute	B-DISO
Decompensated	I-DISO
Heart	I-DISO
Failure	I-DISO
Unresponsive	O
to	O
Adjunct	O
Metolazone	B-CHEM
To	O
assess	O
the	O
efficacy	O
of	O
intravenous	O
chlorothiazide	B-CHEM
in	O
patients	B-LIVB
with	O
acute	B-DISO
decompensated	I-DISO
heart	I-DISO
failure	I-DISO
(	O
ADHF	B-DISO
)	O
who	O
were	O
determined	O
to	O
be	O
loop	B-CHEM
diuretic	I-CHEM
resistant	O
and	O
refractory	O
to	O
metolazone	B-CHEM
.	O

Retrospective	B-PROC
cohort	I-PROC
study	I-PROC
with	O
patients	B-LIVB
serving	O
as	O
their	O
own	O
controls	B-LIVB
.	O

Large	O
,	O
academic	O
,	O
tertiary	B-OBJC
care	I-OBJC
hospital	I-OBJC
.	O

Forty	O
-	O
five	O
patients	B-LIVB
with	O
ADHF	B-DISO
who	O
had	O
an	O
inadequate	O
response	B-PHYS
to	O
high	O
-	O
dose	O
loop	B-CHEM
diuretics	I-CHEM
and	O
then	O
received	O
at	O
least	O
one	O
dose	O
of	O
oral	O
metolazone	B-CHEM
5	O
mg	O
or	O
greater	O
(	O
metolazone	B-CHEM
index	O
dose	O
)	O
followed	O
by	O
at	O
least	O
one	O
dose	O
of	O
intravenous	O
chlorothiazide	B-CHEM
500	O
mg	O
(	O
chlorothiazide	B-CHEM
index	O
dose	O
)	O
if	O
the	O
response	O
to	O
metolazone	B-CHEM
was	O
considered	O
inadequate	O
,	O
according	O
to	O
the	O
institutional	O
protocol	O
,	O
between	O
February	O
4	O
,	O
2013	O
,	O
and	O
February	O
28	O
,	O
2015	O
,	O
were	O
included	O
.	O

If	O
multiple	O
doses	O
of	O
metolazone	B-CHEM
were	O
administered	B-PROC
,	O
the	O
last	O
dose	O
given	O
before	O
the	O
chlorothiazide	B-CHEM
index	O
dose	O
was	O
considered	O
the	O
index	O
dose	O
;	O
the	O
metolazone	B-CHEM
index	O
dose	O
had	O
to	O
have	O
been	O
administered	B-PROC
more	O
than	O
2	O
hours	O
before	O
the	O
chlorothiazide	B-CHEM
index	O
dose	O
.	O

Data	O
for	O
a	O
total	O
of	O
90	O
diuretic	B-CHEM
doses	O
(	O
45	O
metolazone	B-CHEM
,	O
45	O
chlorothiazide	B-CHEM
)	O
were	O
included	O
in	O
the	O
analysis	B-PROC
.	O

The	O
median	O
dose	O
of	O
loop	B-CHEM
diuretic	I-CHEM
in	O
intravenous	O
furosemide	B-CHEM
equivalents	O
given	O
over	O
the	O
24	O
-	O
hour	O
period	O
before	O
the	O
metolazone	B-CHEM
index	O
dose	O
was	O
400	O
mg	O
.	O

The	O
average	O
length	O
of	O
stay	O
was	O
34	O
.	O

7	O
days	O
,	O
and	O
in	O
-	O
hospital	O
mortality	O
was	O
35	O
.	O

6	O
%	O
(	O
16	O
/	O
45	O
patients	B-LIVB
)	O
.	O

The	O
primary	O
end	O
point	O
of	O
a	O
net	B-DISO
-	I-DISO
negative	I-DISO
urine	B-PHYS
output	I-PHYS
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	O
after	O
the	O
index	O
dose	O
occurred	O
in	O
42	O
.	O

2	O
%	O
(	O
19	O
/	O
45	O
patients	B-LIVB
)	O
and	O
35	O
.	O
5	O
%	O
(	O
16	O
/	O
45	O
patients	B-LIVB
)	O
for	O
the	O
chlorothiazide	B-CHEM
and	O
metolazone	B-CHEM
doses	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
581	O
)	O
.	O

The	O
median	O
12	O
-	O
hour	O
urine	B-PHYS
output	I-PHYS
following	O
administration	O
of	O
metolazone	B-CHEM
was	O
810	O
ml	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
866	O
ml	O
)	O
versus	O
1075	O
ml	O
(	O
IQR	O
940	O
ml	O
)	O
following	O
administration	O
of	O
chlorothiazide	B-CHEM
(	O
p	O
=	O
0	O
.	O
363	O
)	O
.	O

Compared	O
with	O
metolazone	B-CHEM
,	O
the	O
chlorothiazide	B-CHEM
doses	O
did	O
not	O
result	O
in	O
an	O
increase	O
in	O
urine	B-PHYS
output	I-PHYS
of	O
at	O
least	O
500	O
ml	O
during	O
the	O
12	O
hours	O
following	O
the	O
dose	O
relative	O
to	O
the	O
12	O
hours	O
before	O
the	O
dose	O
(	O
31	O
.	O
1	O
%	O
vs	O
22	O
.	O
2	O
%	O
,	O
p	O
=	O
0	O
.	O
754	O
)	O
.	O

No	O
significant	O
difference	O
in	O
achievement	O
of	O
net	B-DISO
-	I-DISO
negative	I-DISO
urine	B-PHYS
output	I-PHYS
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	O
following	O
the	O
chlorothiazide	B-CHEM
or	O
metolazone	B-CHEM
dose	O
was	O
noted	O
(	O
42	O
.	O
2	O
%	O
for	O
chlorothiazide	B-CHEM
vs	O
35	O
.	O

5	O
%	O
for	O
metolazone	B-CHEM
,	O
p	O
=	O
0	O
.	O
581	O
)	O
.	O

The	O
addition	O
of	O
intravenous	O
chlorothiazide	B-CHEM
did	O
not	O
result	O
in	O
improved	B-DISO
diuresis	B-PHYS
in	O
patients	B-LIVB
with	O
ADHF	B-DISO
determined	O
to	O
be	O
refractory	O
to	O
loop	B-CHEM
diuretic	I-CHEM
s	O
and	O
adjunctive	O
oral	O
metolazone	B-CHEM
.	O

Antipsychotic	B-CHEM
Drugs	I-CHEM
and	O
Risk	O
of	O
Hip	B-DISO
Fracture	I-DISO
in	O
People	B-LIVB
Aged	B-PHYS
60	O
and	O
Older	B-LIVB
in	O
Norway	B-GEOG
To	O
examine	O
associations	O
between	O
exposure	O
to	O
various	O
subgroups	O
of	O
antipsychotic	B-CHEM
drugs	I-CHEM
and	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
in	O
older	B-LIVB
adults	B-LIVB
.	O

Nationwide	O
cohort	O
study	O
.	O

Norway	B-GEOG
,	O
2005	O
-	O
2010	O
.	O

Everyone	O
living	O
in	O
Norway	B-GEOG
born	O
before	O
1945	O
(	O
N	O
=	O
906	O
,	O
422	O
)	O
.	O

Information	O
was	O
obtained	O
on	O
all	O
prescriptions	O
of	O
antipsychotic	B-CHEM
drugs	I-CHEM
dispensed	O
from	O
2004	O
to	O
2010	O
(	O
Norwegian	O
Prescription	O
Database	O
)	O
and	O
data	O
on	O
all	O
primary	O
hip	B-DISO
fractures	I-DISO
from	O
2005	O
to	O
2010	O
(	O
Norwegian	O
Hip	O
Fracture	O
Registry	O
)	O
.	O

Incidence	O
rates	O
of	O
hip	B-DISO
fracture	I-DISO
during	O
person	O
-	O
time	O
exposed	O
and	O
unexposed	O
to	O
antipsychotic	B-CHEM
drugs	I-CHEM
were	O
compared	O
by	O
calculating	O
the	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
.	O

Thirty	O
-	O
nine	O
thousand	O
nine	O
hundred	O
thirty	O
-	O
eight	O
(	O
4	O
.	O
4	O
%	O
)	O
participants	B-LIVB
experienced	O
a	O
primary	O
hip	B-DISO
fracture	I-DISO
.	O

Greater	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
was	O
associated	O
with	O
exposure	O
to	O
any	O
antipsychotic	B-CHEM
(	O
SIR	O
=	O
2	O
.	O
1	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
9	O
-	O
2	O
.	O
1	O
)	O
,	O
first	O
-	O
generation	O
antipsychotics	B-CHEM
(	O
SIR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
8	O
-	O
2	O
.	O
2	O
)	O
,	O
second	O
-	O
generation	O
antipsychotics	B-CHEM
(	O
SIR	O
=	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O

9	O
-	O
2	O
.	O
4	O
)	O
,	O
prolactin	B-CHEM
-sparing	O
antipsychotics	B-CHEM
(	O
SIR	O
=	O
2	O
.	O
4	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
8	O
-	O
3	O
.	O
1	O
)	O
and	O
prolactin	B-CHEM
-elevating	O
antipsychotics	B-CHEM
(	O
SIR	O
=	O
2	O
.	O
0	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O

9	O
-	O
2	O
.	O
2	O
)	O
.	O

In	O
people	B-LIVB
aged	B-PHYS
60	O
and	O
older	B-LIVB
in	O
Norway	B-GEOG
,	O
those	O
who	O
took	O
an	O
antipsychotic	B-CHEM
drug	I-CHEM
had	O
twice	O
the	O
risk	O
of	O
sustaining	O
a	O
hip	B-DISO
fracture	I-DISO
during	O
exposure	O
than	O
during	O
nonexposure	O
.	O

Although	O
confounding	O
by	O
indication	O
,	O
comorbidity	O
,	O
or	O
other	O
drugs	B-CHEM
used	O
cannot	O
be	O
excluded	O
,	O
this	O
association	O
is	O
relevant	O
for	O
clinical	O
practice	O
because	O
hip	B-DISO
fracture	I-DISO
and	O
antipsychotic	B-CHEM
drug	I-CHEM
use	B-DISO
are	O
prevalent	O
in	O
vulnerable	O
older	B-LIVB
individuals	B-LIVB
.	O

Clinical	B-PROC
studies	I-PROC
examining	O
mechanisms	O
or	O
causality	O
of	O
the	O
observed	O
association	O
between	O
antipsychotic	B-CHEM
drug	I-CHEM
use	O
and	O
excess	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
are	O
needed	O
.	O

Bisphenol	B-CHEM
-	I-CHEM
A	I-CHEM
removal	B-PROC
by	O
the	O
halophyte	B-LIVB
Juncus	B-LIVB
acutus	I-LIVB
in	O
a	O
phytoremediation	B-PHEN
pilot	B-PROC
:	O
Characterization	O
and	O
potential	O
role	O
of	O
the	O
endophytic	B-LIVB
community	B-LIVB
A	O
phytoremediation	B-PHEN
pilot	B-PROC
emulating	O
a	O
shallow	O
aquifer	B-PHEN
planted	O
with	O
Juncus	B-LIVB
acutus	I-LIVB
showed	O
to	O
be	O
effective	O
for	O
remediating	B-PHEN
Bisphenol	B-CHEM
-	I-CHEM
A	I-CHEM
(	O
BPA	B-CHEM
)	O
contaminated	O
groundwater	B-CHEM
.	O

Biostimulation	O
with	O
root	B-LIVB
exudates	B-OBJC
,	O
low	O
molecular	O
weight	O
organic	B-CHEM
acids	I-CHEM
,	O
of	O
J	B-LIVB
.	I-LIVB

acutus	I-LIVB
did	O
not	O
improve	B-DISO
BPA	B-CHEM
-	O
degradation	O
rates	O
.	O

Furthermore	O
,	O
the	O
endophytic	B-LIVB
bacterial	B-LIVB
community	B-LIVB
of	O
J	B-LIVB
.	I-LIVB

acutus	I-LIVB
was	O
isolated	O
and	O
characterized	O
.	O

Many	O
strains	B-LIVB
were	O
found	O
to	O
possess	O
increased	B-DISO
tolerance	I-DISO
to	O
metals	B-CHEM
such	O
as	O
Zn	B-CHEM
,	O
Ni	B-CHEM
,	O
Pb	B-CHEM
and	O
Cd	B-CHEM
.	O

Moreover	O
,	O
several	O
endophytic	B-LIVB
bacterial	B-LIVB
strains	B-LIVB
tolerated	O
and	O
even	O
used	O
BPA	B-CHEM
and	O
/	O
or	O
two	O
antibiotics	B-CHEM
(	O
ciprofloxacin	B-CHEM
and	O
sulfamethoxazole	B-CHEM
)	O
as	O
a	O
sole	O
carbon	B-CHEM
source	B-DISO
.	O

Our	O
results	B-DISO
demonstrate	O
that	O
the	O
cultivable	O
bacterial	B-LIVB
endophytic	B-LIVB
community	B-LIVB
of	O
J	B-LIVB
.	I-LIVB

acutus	I-LIVB
is	O
able	O
to	O
use	O
organic	B-CHEM
contaminants	B-OBJC
as	O
carbon	B-CHEM
sources	B-DISO
,	O
tolerates	O
metals	B-CHEM
and	O
is	O
equipped	O
with	O
plant	B-PHYS
-	I-PHYS
growth	I-PHYS
promoting	O
traits	B-PHYS
.	O

Therefore	O
,	O
J	B-LIVB
.	I-LIVB
acutus	I-LIVB
has	O
potential	O
to	O
be	O
exploited	O
in	O
constructed	O
wetlands	B-PHEN
when	O
co	O
-	O
contamination	O
is	O
one	O
of	O
the	O
restricting	O
factors	O
.	O

Dual	B-PROC
-	I-PROC
color	I-PROC
STED	I-PROC
microscopy	I-PROC
reveals	O
a	O
sandwich	O
structure	O
of	O
Bassoon	B-CHEM
and	O
Piccolo	B-CHEM
in	O
active	B-ANAT
zones	I-ANAT
of	O
adult	B-LIVB
and	O
aged	B-PHYS
mice	B-LIVB
Presynaptic	B-ANAT
active	I-ANAT
zones	I-ANAT
play	O
a	O
pivotal	O
role	O
as	O
synaptic	B-ANAT
vesicle	I-ANAT
release	B-ANAT
sites	I-ANAT
for	O
synaptic	B-PHYS
transmission	I-PHYS
,	O
but	O
the	O
molecular	O
architecture	O
of	O
active	B-ANAT
zones	I-ANAT
in	O
mammalian	B-LIVB
neuromuscular	B-ANAT
junctions	I-ANAT
(	O
NMJs	B-ANAT
)	O
at	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
remains	O
unknown	O
.	O

Bassoon	B-CHEM
and	O
Piccolo	B-CHEM
are	O
active	B-ANAT
zone	I-ANAT
specific	O
cytosolic	B-ANAT
proteins	B-CHEM
essential	O
for	O
active	B-PHYS
zone	I-PHYS
assembly	I-PHYS
in	O
NMJs	B-ANAT
,	O
ribbon	B-ANAT
synapses	I-ANAT
,	O
and	O
brain	B-ANAT
synapses	B-ANAT
.	O

These	O
proteins	B-CHEM
are	O
thought	O
to	O
colocalize	O
and	O
share	O
some	O
functions	O
at	O
active	B-ANAT
zones	I-ANAT
.	O

Here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non	B-PHYS
-	I-PHYS
overlapping	I-PHYS
localization	I-PHYS
of	O
these	O
two	O
proteins	B-CHEM
in	O
mouse	B-LIVB
NMJs	B-ANAT
revealed	O
using	O
dual	B-PHEN
-	I-PHEN
color	I-PHEN
stimulated	I-PHEN
emission	I-PHEN
depletion	I-PHEN
(	O
STED	B-PHEN
)	O
super	B-PROC
resolution	I-PROC
microscopy	I-PROC
.	O

Piccolo	B-CHEM
puncta	B-DISO
sandwiched	O
Bassoon	B-CHEM
puncta	B-DISO
and	O
aligned	O
in	O
a	O
Piccolo	B-CHEM
-	O
Bassoon	B-CHEM
-	O
Piccolo	B-CHEM
structure	O
in	O
adult	B-LIVB
NMJs	B-ANAT
.	O

P	B-CHEM
/	I-CHEM
Q	I-CHEM
-	I-CHEM
type	I-CHEM
voltage	I-CHEM
-	I-CHEM
gated	I-CHEM
calcium	I-CHEM
channel	I-CHEM
(	O
VGCC	B-CHEM
)	O
puncta	B-DISO
colocalized	O
with	O
Bassoon	B-CHEM
puncta	B-DISO
.	O

The	O
P	B-CHEM
/	I-CHEM
Q	I-CHEM
-	I-CHEM
type	I-CHEM
VGCC	I-CHEM
and	O
Bassoon	B-CHEM
protein	B-PHEN
levels	I-PHEN
decreased	O
significantly	O
in	O
NMJs	B-ANAT
from	O
aged	B-PHYS
mouse	B-LIVB
.	O

In	O
contrast	O
,	O
the	O
Piccolo	B-CHEM
levels	B-PHEN
in	O
NMJs	B-ANAT
from	O
aged	B-PHYS
mice	B-LIVB
were	O
comparable	O
to	O
levels	B-PHEN
in	O
adult	B-LIVB
mice	B-LIVB
.	O

This	O
study	O
revealed	O
the	O
molecular	O
architecture	O
of	O
active	B-ANAT
zones	I-ANAT
in	O
mouse	B-LIVB
NMJs	B-ANAT
at	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
,	O
and	O
described	O
the	O
selective	B-PHYS
degeneration	I-PHYS
mechanism	I-PHYS
of	O
active	B-ANAT
zone	I-ANAT
proteins	B-CHEM
in	O
NMJs	B-ANAT
from	O
aged	B-PHYS
mice	B-LIVB
.	O

Interestingly	O
,	O
the	O
localization	B-PHYS
pattern	I-PHYS
of	O
active	B-ANAT
zone	I-ANAT
proteins	B-CHEM
described	O
herein	O
is	O
similar	O
to	O
active	B-ANAT
zone	I-ANAT
structures	O
described	O
using	O
electron	B-PROC
microscope	I-PROC
tomography	I-PROC
.	O

Structure	O
of	O
Carbon	B-CHEM
Nanotube	I-CHEM
Porins	B-CHEM
in	O
Lipid	B-ANAT
Bilayers	I-ANAT
:	O
An	O
in	O
Situ	O
Small	B-PROC
-	I-PROC
Angle	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
Scattering	I-PROC
(	O
SAXS	B-PROC
)	O
Study	B-PROC
Carbon	B-CHEM
nanotube	I-CHEM
porins	B-CHEM
(	O
CNTPs	B-CHEM
)	I-CHEM
,	O
small	O
segments	O
of	O
carbon	B-CHEM
nanotubes	I-CHEM
capable	O
of	O
forming	O
defined	O
pores	B-ANAT
in	O
lipid	B-ANAT
membranes	I-ANAT
,	O
are	O
important	O
future	O
components	B-OBJC
for	O
bionanoelectronic	B-DEVI
devices	I-DEVI
as	O
they	O
could	O
provide	O
a	O
robust	O
analog	B-CHEM
of	O
biological	B-ANAT
membrane	I-ANAT
channels	B-CHEM
.	O

In	O
order	O
to	O
control	O
the	O
incorporation	O
of	O
these	O
CNT	B-CHEM
channels	B-CHEM
into	O
lipid	B-ANAT
bilayers	I-ANAT
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
structure	O
of	O
the	O
CNTPs	B-CHEM
before	O
and	O
after	O
insertion	O
into	O
the	O
lipid	B-ANAT
bilayer	I-ANAT
as	O
well	O
as	O
the	O
impact	O
of	O
such	O
insertion	O
on	O
the	O
bilayer	B-ANAT
structure	O
.	O

Here	O
we	O
employed	O
a	O
noninvasive	O
in	O
situ	O
probe	B-DEVI
,	O
small	B-PROC
-	I-PROC
angle	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
scattering	I-PROC
,	O
to	O
study	B-PROC
the	O
integration	O
of	O
CNT	B-CHEM
porins	B-CHEM
into	O
dioleoylphosphatidylcholine	B-CHEM
bilayers	I-CHEM
.	O

Our	O
results	B-DISO
show	O
that	O
CNTPs	B-CHEM
in	O
solution	B-OBJC
are	O
stabilized	B-DISO
by	O
a	O
monolayer	B-ANAT
of	O
lipid	B-CHEM
molecules	I-CHEM
wrapped	O
around	O
their	O
outer	O
surface	O
.	O

We	O
also	O
demonstrate	O
that	O
insertion	O
of	O
CNTPs	B-CHEM
into	O
the	O
lipid	B-ANAT
bilayer	I-ANAT
results	O
in	O
decreased	O
bilayer	B-ANAT
thickness	O
with	O
the	O
magnitude	O
of	O
this	O
effect	O
increasing	O
with	O
the	O
concentration	O
of	O
CNTPs	B-CHEM
.	O

Comparisons	O
of	O
Safety	B-PHEN
and	O
Clinical	O
Outcomes	O
Between	O
Multiple	B-PROC
-	I-PROC
level	I-PROC
and	O
Single	B-PROC
-	I-PROC
level	I-PROC
Cervical	I-PROC
Disk	I-PROC
Replacement	I-PROC
for	O
Cervical	B-DISO
Spondylosis	I-DISO
:	O
A	O
Systematic	O
Review	O
and	O
Meta	O
-	O
analysis	O
This	O
is	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	B-PHEN
of	O
multiple	B-PROC
-	I-PROC
level	I-PROC
cervical	I-PROC
disk	I-PROC
replacement	I-PROC
(	O
CDR	B-PROC
)	O
over	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
for	O
the	O
treatment	B-PROC
of	O
cervical	B-DISO
spondylosis	I-DISO
.	O

Some	O
authors	O
advocate	O
for	O
the	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
instead	O
of	O
anterior	O
decompression	B-PROC
and	O
fusion	B-PROC
in	O
cervical	B-DISO
multiple	I-DISO
-	I-DISO
level	I-DISO
spondylosis	I-DISO
.	O

However	O
,	O
whether	O
the	O
efficacy	O
and	O
safety	B-PHEN
of	O
multi	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
are	O
as	O
favorable	O
as	O
that	O
of	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
remains	O
controversial	O
.	O

MEDLINE	O
,	O
EMBASE	O
,	O
and	O
Cochrane	O
library	O
databases	O
were	O
searched	O
up	O
to	O
November	O
2015	O
for	O
controlled	B-PROC
studies	I-PROC
that	O
compared	O
the	O
clinical	O
outcomes	O
of	O
single	B-PROC
-	I-PROC
level	I-PROC
and	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
for	O
the	O
treatment	B-PROC
of	O
cervical	B-DISO
spondylosis	I-DISO
.	O

The	O
following	O
outcomes	O
were	O
extracted	O
and	O
analyzed	B-PROC
:	O
prevalence	O
of	O
heterotopic	B-DISO
ossification	I-DISO
and	O
reoperation	B-PROC
,	O
preoperative	O
and	O
postoperative	O
Neck	B-DISO
Disability	I-DISO
Index	I-DISO
scores	I-DISO
,	O
preoperative	O
and	O
postoperative	O
Visual	B-PHYS
Analog	I-PHYS
Scale	I-PHYS
scores	I-PHYS
,	O
and	O
success	O
rate	O
using	O
the	O
Odom	O
grading	O
system	O
.	O

Ten	O
studies	B-PROC
involving	O
1402	O
patients	B-LIVB
were	O
included	O
:	O
including	O
3	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
,	O
5	O
prospective	B-PROC
studies	I-PROC
,	O
and	O
3	O
retrospective	B-PROC
studies	I-PROC
.	O

No	O
significant	O
differences	O
between	O
single	B-PROC
-	I-PROC
level	I-PROC
and	O
multiple	B-PROC
-	I-PROC
level	I-PROC
groups	O
were	O
found	O
in	O
terms	O
of	O
the	O
prevalence	O
of	O
heterotopic	B-DISO
ossification	I-DISO
and	O
reoperation	B-PROC
rate	O
,	O
Neck	B-DISO
Disability	I-DISO
Index	I-DISO
score	I-DISO
,	O
Visual	B-PHYS
Analog	I-PHYS
Scale	I-PHYS
score	I-PHYS
,	O
and	O
success	O
rate	O
using	O
the	O
Odom	O
grading	O
system	O
.	O

On	O
the	O
basis	O
of	O
this	O
meta	O
-	O
analysis	O
,	O
clinical	O
outcomes	O
of	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
are	O
similar	O
to	O
those	O
of	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
for	O
cervical	B-DISO
spondylosis	I-DISO
,	O
which	O
suggests	O
the	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
is	O
as	O
effective	O
and	O
safe	B-PHEN
as	O
the	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
.	O

Nonetheless	O
,	O
more	O
well	O
-	O
designed	O
studies	B-PROC
are	O
needed	O
for	O
further	O
evaluation	B-PROC
.	O

The	O
anti	B-PHYS
-	I-PHYS
apoptotic	I-PHYS
PON2	B-CHEM
protein	I-CHEM
is	O
Wnt	B-CHEM
/	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
-	O
regulated	B-PHEN
and	O
correlates	O
with	O
radiotherapy	B-PROC
resistance	O
in	O
OSCC	O
patients	B-LIVB
Aberrant	O
Wnt	B-PHYS
signaling	I-PHYS
and	O
control	O
of	O
anti	B-PHYS
-	I-PHYS
apoptotic	I-PHYS
mechanisms	O
are	O
pivotal	O
features	O
in	O
different	O
types	O
of	O
cancer	B-DISO
to	O
undergo	O
cell	B-PHYS
death	I-PHYS
programs	O
.	O

The	O
intracellular	O
human	B-LIVB
enzyme	B-CHEM
Paraoxonase	B-CHEM
-	I-CHEM
2	I-CHEM
(	O
PON2	B-CHEM
)	O
is	O
known	O
to	O
have	O
anti	B-PHYS
-	I-PHYS
apoptotic	I-PHYS
properties	O
in	O
leukemia	B-DISO
and	O
oral	O
squamous	O
cell	O
cancer	O
(	O
OSCC	O
)	O
cells	B-ANAT
.	O

However	O
,	O
the	O
distinct	O
regulating	B-PHEN
pathways	O
are	O
poorly	O
understood	O
.	O

First	O
,	O
we	O
present	O
a	O
so	O
far	O
unknown	O
regulation	B-PHEN
of	O
PON2	B-CHEM
protein	I-CHEM
expression	B-PHYS
through	O
the	O
Wnt	B-PHYS
/	O
GSK3β	B-CHEM
/	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
pathway	B-PHYS
in	O
leukemia	B-DISO
and	O
OSCC	O
cells	B-ANAT
.	O

This	O
was	O
confirmed	O
via	O
in	O
silico	B-PROC
analysis	I-PROC
,	O
promoter	B-PROC
reporter	I-PROC
studies	I-PROC
and	O
treatment	B-PROC
of	O
multiple	O
cell	B-ANAT
lines	I-ANAT
(	O
K562	B-ANAT
,	O
SCC	B-ANAT
-	I-ANAT
4	I-ANAT
,	O
PCI	B-ANAT
-	I-ANAT
13	I-ANAT
)	O
with	O
different	O
Wnt	B-CHEM
ligands	B-PHYS
/	O
inhibitors	B-CHEM
in	O
vitro	O
.	O

Ex	O
vivo	O
analysis	B-PROC
of	O
OSCC	O
patients	B-LIVB
revealed	O
a	O
correlation	O
between	O
PON2	B-CHEM
and	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
expression	B-PHYS
in	O
tumor	O
tissue	O
.	O

Higher	O
PON2	B-CHEM
expression	B-PHYS
in	O
OSCC	O
is	O
associated	O
with	O
relapse	B-PHEN
independently	O
of	O
treatment	B-PROC
(	O
e	O
.	O

g	O
.	O
surgery	B-PROC
/	O
radio	B-PROC
-	O
/	O
chemotherapy	B-PROC
)	O
.	O

These	O
results	O
emphasize	O
the	O
clinical	O
impact	O
of	O
the	O
newly	O
described	O
regulation	B-PHEN
of	O
PON2	B-CHEM
through	O
Wnt	B-CHEM
/	O
GSK3β	B-CHEM
/	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
.	O

More	O
importantly	O
,	O
the	O
study	O
revealed	O
the	O
fundamental	B-DISO
finding	I-DISO
of	O
an	O
overall	O
Wnt	B-CHEM
/	O
GSK3β	B-CHEM
/	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
dependent	O
regulation	B-PHEN
of	O
PON2	B-CHEM
in	O
different	O
cancers	B-DISO
,	O
which	O
was	O
confirmed	O
by	O
systematic	O
and	O
multimethodological	O
approaches	O
.	O

Thus	O
,	O
the	O
herein	O
presented	O
mechanistic	O
insight	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
tumor	B-DISO
specific	O
escape	O
from	O
cell	B-PHYS
death	I-PHYS
strategies	O
and	O
suggests	O
PON2	B-CHEM
as	O
a	O
new	O
potential	O
biomarker	B-PHYS
for	O
therapy	B-PROC
resistance	O
or	O
as	O
a	O
prognostic	O
tumor	B-CHEM
marker	I-CHEM
.	O

Has	O
dementia	B-DISO
research	B-PROC
lost	O
its	O
sense	O
of	O
reality	O
?	O

A	O
descriptive	O
analysis	O
of	O
eligibility	O
criteria	O
of	O
Dutch	B-LIVB
dementia	B-DISO
research	B-PROC
protocols	I-PROC
A	O
substantial	O
proportion	O
of	O
dementia	B-DISO
patients	B-LIVB
are	O
excluded	O
from	O
research	B-PROC
participation	O
,	O
while	O
for	O
extrapolation	B-DISO
of	O
the	O
study	B-PROC
findings	O
,	O
it	O
is	O
important	O
that	O
the	O
research	B-PROC
population	O
represents	O
the	O
patient	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
is	O
to	O
provide	O
an	O
analysis	O
of	O
dementia	B-DISO
research	B-PROC
and	O
its	O
exclusion	O
criteria	O
in	O
order	O
to	O
get	O
a	O
clearer	O
picture	O
whether	O
the	O
research	B-PROC
participants	B-LIVB
represent	O
the	O
general	O
dementia	B-DISO
population	O
.	O

Dementia	B-DISO
studies	B-PROC
registered	O
at	O
ToetsingOnline	O
.	O

nl	O
between	O
2006	O
-	O
2015	O
were	O
analysed	B-PROC
.	O

Study	B-PROC
characteristics	O
,	O
funding	O
and	O
eligibility	O
criteria	O
were	O
described	O
and	O
analysed	O
using	O
a	O
standardised	O
score	O
sheet	O
.	O

The	O
search	O
yielded	O
103	O
usable	O
study	O
protocols	O
.	O

The	O
number	O
of	O
trials	B-PROC
has	O
increased	O
over	O
the	O
years	O
,	O
and	O
35	O
%	O
of	O
the	O
studies	B-PROC
were	O
industry	O
-	O
financed	O
.	O

Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
was	O
the	O
most	O
researched	B-PROC
type	O
of	O
dementia	B-DISO
(	O
84	O
%	O
)	O
.	O

In	O
observational	O
studies	O
the	O
most	O
frequently	O
observed	O
exclusion	O
criterion	O
is	O
a	O
neurological	B-DISO
condition	I-DISO
,	O
while	O
in	O
drug	B-PROC
studies	I-PROC
and	O
other	O
intervention	B-PROC
studies	I-PROC
this	O
is	O
a	O
somatic	O
condition	O
.	O

Of	O
all	O
protocols	O
,	O
86	O
%	O
had	O
at	O
least	O
one	O
exclusion	O
criterion	O
concerning	O
comorbidity	O
.	O

Most	O
studies	B-PROC
focused	O
on	O
mild	B-DISO
or	O
moderate	B-DISO
dementia	I-DISO
(	O
78	O
%	O
)	O
.	O

Our	O
study	B-PROC
has	O
shown	O
that	O
the	O
distribution	O
of	O
dementia	B-DISO
research	B-PROC
over	O
the	O
different	O
subtypes	O
of	O
dementia	B-DISO
does	O
not	O
correspond	O
with	O
the	O
prevalence	O
of	O
these	O
subtypes	O
in	O
clinical	B-PROC
practice	I-PROC
.	O

The	O
research	B-PROC
population	O
in	O
the	O
protocols	O
is	O
not	O
representative	O
of	O
the	O
larger	O
patient	O
population	O
.	O

A	O
greater	O
number	O
of	O
dementia	B-DISO
patients	B-LIVB
could	O
derive	O
benefit	O
from	O
the	O
conducted	O
research	B-PROC
if	O
the	O
research	B-PROC
agenda	I-PROC
were	O
more	O
closely	O
aligned	O
with	O
disease	O
prevalence	O
.	O

A	O
better	O
representation	O
of	O
all	O
dementia	B-DISO
patients	B-LIVB
in	O
research	B-PROC
will	O
help	O
to	O
meet	O
the	O
needs	O
of	O
these	O
patients	B-LIVB
.	O

Tissue	O
-selective	O
inflammation	B-DISO
in	O
the	O
oral	B-ANAT
cavity	I-ANAT
of	O
the	O
rat	B-LIVB
In	O
the	O
current	O
study	O
,	O
carrageenan	B-CHEM
(	O
CG	B-CHEM
;	O
100	O
-	O
1000	O
μg	O
/	O
site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	B-ANAT
of	O
Holtzman	B-LIVB
or	O
Wistar	B-LIVB
rats	I-LIVB
to	O
evaluate	O
the	O
consequences	O
of	O
administration	B-PROC
of	O
a	O
non	B-DISO
-	I-DISO
immunogenic	I-DISO
stimulus	B-PHEN
in	O
the	O
orofacial	O
region	O
.	O

Subsequent	O
inflammation	B-DISO
was	O
measured	O
as	O
oedema	B-DISO
(	O
increased	B-DISO
thickness	I-DISO
of	O
the	O
cheek	B-ANAT
wall	I-ANAT
using	O
digital	B-DEVI
calipers	I-DEVI
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	B-ANAT
injected	O
with	O
saline	B-OBJC
.	O

Oedema	B-DISO
formation	O
and	O
tissue	O
collection	O
for	O
histopathological	O
studies	O
were	O
assessed	O
at	O
0	O
.	O

5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
24	O
,	O
48	O
,	O
72	O
,	O
96	O
,	O
120	O
and	O
144	O
h	O
after	O
injection	B-PROC
.	O

In	O
parallel	O
,	O
other	O
groups	O
of	O
rats	B-LIVB
were	O
injected	O
with	O
CG	B-CHEM
in	O
the	O
hind	B-ANAT
paw	I-ANAT
,	O
to	O
provide	O
a	O
reference	O
response	O
.	O

The	O
inhibitor	B-CHEM
of	O
prostaglandin	B-PHYS
biosynthesis	I-PHYS
,	O
indomethacin	B-CHEM
,	O
and	O
antagonists	B-CHEM
of	I-CHEM
histamine	I-CHEM
,	O
serotonin	B-CHEM
and	O
NK1	B-PHYS
receptors	I-PHYS
were	O
injected	O
s	O
.	O

c	O
.	O
,	O
0	O
.	O
5	O
h	O
before	O
CG	B-CHEM
.	O

CG	B-CHEM
induced	O
a	O
dose	O
-related	O
oedema	B-DISO
more	O
rapidly	O
from	O
0	O
to	O
2	O
h	O
which	O
lasted	O
for	O
at	O
least	O
72	O
h	O
,	O
showing	O
a	O
biphasic	O
profile	O
(	O
peak	O
at	O
2	O
and	O
24	O
h	O
)	O
,	O
compared	O
with	O
the	O
monophasic	O
oedema	B-DISO
induced	O
in	O
rat	B-LIVB
paws	B-ANAT
(	O
maximal	O
duration	O
of	O
24	O
h	O
)	O
.	O

Histopathological	O
analysis	B-PROC
of	O
the	O
CG	B-CHEM
-	O
injected	O
cheek	B-ANAT
revealed	O
oedema	B-DISO
formation	O
with	O
little	O
leukocyte	B-ANAT
recruitment	B-PHYS
at	O
1	O
-	O
3	O
h	O
,	O
mast	B-PHYS
cell	I-PHYS
degranulation	I-PHYS
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	B-DISO
and	O
mononuclear	B-DISO
cell	I-DISO
infiltrate	I-DISO
by	O
24	O
h	O
.	O

Histamine	B-CHEM
and	O
serotonin	B-CHEM
antagonists	I-CHEM
and	O
indomethacin	B-CHEM
,	O
but	O
not	O
the	O
NK1	B-PHYS
antagonist	I-PHYS
,	O
decreased	O
cheek	B-ANAT
oedema	B-DISO
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	B-CHEM
.	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
important	O
differences	O
in	O
the	O
pattern	O
of	O
inflammation	B-DISO
between	O
the	O
oral	B-ANAT
cavity	I-ANAT
and	O
the	O
paw	B-ANAT
which	O
will	O
determine	O
the	O
therapeutic	O
approach	O
to	O
the	O
treatment	B-PROC
of	O
inflammatory	O
conditions	O
in	O
the	O
oral	B-ANAT
cavity	I-ANAT
.	O

Mercury	B-CHEM
Mining	O
in	O
Mexico	B-GEOG
:	O
I	O
.	O

Community	O
Engagement	O
to	O
Improve	B-DISO
Health	B-DISO
Outcomes	I-DISO
from	O
Artisanal	O
Mining	O
Mercury	B-CHEM
is	O
an	O
element	B-CHEM
that	O
cannot	O
be	O
destroyed	O
and	O
is	O
a	O
global	O
threat	O
to	O
human	B-LIVB
and	O
environmental	O
health	O
.	O

In	O
Latin	B-GEOG
America	I-GEOG
and	O
the	O
Caribbean	B-GEOG
,	O
artisanal	O
and	O
small	O
-	O
scale	O
gold	B-CHEM
mining	O
represents	O
the	O
main	O
source	B-DISO
of	O
mercury	B-CHEM
emissions	B-CHEM
,	O
releases	B-PHEN
,	O
and	O
consumption	O
.	O

However	O
,	O
another	O
source	B-DISO
of	O
concern	O
is	O
the	O
primary	O
production	B-CHEM
of	O
mercury	B-CHEM
.	O

In	O
the	O
case	O
of	O
Mexico	B-GEOG
,	O
in	O
the	O
past	O
2	O
years	O
the	O
informal	O
production	B-CHEM
of	O
mercury	B-CHEM
mining	O
has	O
increased	O
10	O
-	O
fold	O
.	O

Considering	O
this	O
scenario	O
,	O
an	O
intervention	B-PROC
program	I-PROC
was	O
initiated	O
to	O
reduce	O
health	O
risks	O
in	O
the	O
mining	O
communities	B-LIVB
.	O

The	O
program	B-PROC
's	I-PROC
final	O
goal	O
is	O
to	O
introduce	O
different	O
alternatives	O
in	O
line	O
to	O
stop	O
the	O
mining	O
of	O
mercury	B-CHEM
,	O
but	O
introducing	O
at	O
the	O
same	O
time	O
,	O
a	O
community	B-LIVB
-based	O
development	O
program	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
present	O
results	B-DISO
from	O
a	O
preliminary	O
study	B-PROC
in	O
the	O
community	B-LIVB
of	O
Plazuela	B-GEOG
,	O
located	O
in	O
the	O
municipality	B-GEOG
of	O
Peñamiller	B-GEOG
in	O
the	O
State	B-GEOG
of	I-GEOG
Queretaro	I-GEOG
,	O
Mexico	B-GEOG
.	O

Total	O
mercury	B-CHEM
was	O
measured	O
in	O
urine	B-ANAT
and	O
environmental	O
samples	B-OBJC
using	O
atomic	B-PROC
absorption	I-PROC
spectrometry	I-PROC
by	I-PROC
cold	I-PROC
vapor	I-PROC
technique	I-PROC
.	O

Urine	B-ANAT
samples	I-ANAT
were	O
collected	O
from	O
children	B-LIVB
aged	O
6	O
-	O
14	O
years	O
and	O
who	O
had	O
lived	O
in	O
the	O
selected	O
area	B-GEOG
from	O
birth	B-PHYS
.	O

Urine	B-ANAT
samples	I-ANAT
were	O
also	O
collected	O
from	O
miners	B-LIVB
who	O
were	O
currently	O
working	O
in	O
the	O
mine	O
.	O

To	O
confirm	B-DISO
the	O
presence	B-DISO
of	O
mercury	B-CHEM
in	O
the	O
community	B-LIVB
,	O
mining	B-OBJC
waste	I-OBJC
,	O
water	B-CHEM
,	O
soil	B-OBJC
,	O
and	O
sediment	B-OBJC
samples	I-OBJC
were	O
collected	O
from	O
those	O
high	B-DISO
-	I-DISO
risk	I-DISO
areas	I-DISO
identified	O
by	O
members	B-LIVB
of	O
the	O
community	B-LIVB
.	O

Children	B-LIVB
,	O
women	B-LIVB
,	O
and	O
miners	B-LIVB
were	O
heavily	O
exposed	O
to	O
mercury	B-CHEM
(	O
urine	B-ANAT
samples	I-ANAT
)	O
;	O
and	O
in	O
agreement	O
,	O
we	O
registered	B-PROC
high	O
concentrations	O
of	O
mercury	B-CHEM
in	O
soils	B-OBJC
and	O
sediments	B-OBJC
.	O

Considering	O
these	O
results	B-DISO
and	O
taking	O
into	O
account	O
that	O
the	O
risk	O
perception	O
toward	O
mercury	B-CHEM
toxicity	O
is	O
very	B-DISO
low	I-DISO
in	O
the	O
community	B-LIVB
(	O
mining	O
is	O
the	O
only	O
economic	O
activity	O
)	O
,	O
an	O
integral	B-PROC
intervention	I-PROC
program	I-PROC
has	O
started	O
.	O

Molecular	O
serum	B-ANAT
signature	B-PHYS
of	O
treatment	B-DISO
resistant	I-DISO
depression	I-DISO
A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B-DISO
depressive	I-DISO
disorder	I-DISO
(	O
MDD	B-DISO
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	B-PROC
of	O
anti	B-CHEM
-	I-CHEM
depressants	I-CHEM
,	O
develop	O
a	O
chronic	O
course	B-DISO
of	I-DISO
disease	I-DISO
and	O
become	O
treatment	B-PROC
resistant	B-PHYS
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment	B-DISO
-	I-DISO
resistant	I-DISO
depression	I-DISO
(	O
TRD	B-DISO
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	O
.	O

Consequently	O
,	O
biomarkers	B-PHYS
associated	O
with	O
TRD	B-DISO
are	O
still	O
lacking	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	O
-	O
throughput	O
proteomic	O
platforms	O
to	O
identify	O
peripheral	O
biomarkers	B-PHYS
of	O
TRD	B-DISO
defined	O
by	O
two	O
staging	O
models	O
,	O
the	O
Thase	O
and	O
Rush	O
staging	O
model	O
(	O
TRM	O
)	O
and	O
the	O
Maudsley	O
Staging	O
Model	O
(	O
MSM	O
)	O
.	O

Serum	B-ANAT
collected	O
from	O
an	O
inpatient	B-LIVB
cohort	O
of	O
65	O
individuals	B-LIVB
suffering	O
from	O
MDD	B-DISO
was	O
analysed	O
using	O
two	O
different	O
mass	B-PROC
spectrometric	I-PROC
-	I-PROC
based	I-PROC
platforms	I-PROC
,	O
label	B-PROC
-	I-PROC
free	I-PROC
liquid	I-PROC
chromatography	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O
LC	B-PROC
-	I-PROC
MS	I-PROC
(	I-PROC
E	I-PROC
)	I-PROC
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B-PROC
bead	I-PROC
based	I-PROC
assay	I-PROC
.	O

In	O
the	O
LC	B-PROC
-	I-PROC
MS	I-PROC
(	I-PROC
E	I-PROC
)	I-PROC
analysis	I-PROC
,	O
proteins	B-CHEM
involved	O
in	O
the	O
acute	B-DISO
phase	I-DISO
response	I-DISO
and	O
complement	B-PHYS
activation	I-PHYS
and	O
coagulation	B-PHYS
were	O
significantly	O
different	O
between	O
the	O
staging	O
groups	O
in	O
both	O
models	O
.	O

In	O
the	O
multiplex	B-PROC
bead	I-PROC
-	I-PROC
based	I-PROC
assay	I-PROC
analysis	O
TNF	B-PROC
-	I-PROC
α	I-PROC
levels	I-PROC
(	O
log	O
(	O
odds	O
)	O
=	O
-4	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O

045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
TRM	O
comparison	O
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	B-CHEM
A	I-CHEM
-	I-CHEM
I	I-CHEM
(	O
β	O
=	O
0	O
.	O

029	O
,	O
p	O
=	O
0	O
.	O
035	O
)	O
,	O
M	B-CHEM
(	O
β	O
=	O
-0	O
.	O

017	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
F	B-CHEM
(	O
β	O
=	O
-0	O
.	O
031	O
,	O
p	O
=	O
0	O
.	O
024	O
)	O
were	O
associated	O
with	O
the	O
TRM	O
but	O
not	O
the	O
MSM	O
.	O

Overall	O
,	O
our	O
findings	B-DISO
suggest	O
that	O
proteins	B-CHEM
,	O
which	O
are	O
involved	O
in	O
immune	B-PHYS
and	O
complement	B-PHYS
activation	I-PHYS
,	O
may	O
represent	O
potential	O
biomarkers	B-PHYS
that	O
could	O
be	O
used	O
by	O
clinicians	B-LIVB
to	O
identify	O
high	B-DISO
-	I-DISO
risk	I-DISO
patients	B-LIVB
.	O

Nevertheless	O
,	O
given	O
that	O
the	O
molecular	O
changes	O
between	O
the	O
staging	O
groups	O
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	O
cautiously	O
.	O

Benchmark	O
study	B-PROC
on	O
fine	B-OBJC
-	I-OBJC
mode	I-OBJC
aerosol	I-OBJC
in	O
a	O
big	O
urban	O
area	O
and	O
relevant	O
doses	O
deposited	O
in	O
the	O
human	B-LIVB
respiratory	B-ANAT
tract	I-ANAT
It	O
is	O
well	O
-	O
known	O
that	O
the	O
health	O
effects	O
of	O
PM	B-CHEM
increase	O
as	O
particle	O
size	O
decreases	O
:	O
particularly	O
,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
UltraFine	B-CHEM
Particles	I-CHEM
(	O
UFPs	B-CHEM
)	O
.	O

Starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction	O
of	O
atmospheric	B-PHEN
aerosol	B-OBJC
in	O
Rome	B-GEOG
is	O
characterized	O
by	O
significant	O
levels	O
of	O
PM2	B-CHEM
.	I-CHEM

5	I-CHEM
(	O
almost	O
75	O
%	O
of	O
PM10	B-CHEM
fraction	O
is	O
PM2	B-CHEM
.	I-CHEM

5	I-CHEM
)	O
,	O
the	O
paper	O
is	O
focused	O
on	O
submicron	B-CHEM
particles	I-CHEM
in	O
such	O
great	O
urban	O
area	O
.	O

The	O
daytime	O
/	O
nighttime	O
,	O
work	O
-	O
/	O
weekdays	O
and	O
cold	B-PHEN
/	O
hot	B-PHEN
seasonal	O
trends	O
of	O
submicron	B-CHEM
particles	I-CHEM
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
NOx	B-CHEM
and	O
total	O
PAH	B-CHEM
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
UFPs	B-CHEM
from	O
combustion	B-PHEN
processes	I-PHEN
.	O

Furthermore	O
,	O
moving	O
from	O
these	O
data	O
,	O
the	O
total	O
dose	O
of	O
submicron	B-CHEM
particles	I-CHEM
deposited	O
in	O
the	O
respiratory	B-ANAT
system	I-ANAT
(	O
i	O
.	O
e	O
.	O
,	O
head	B-ANAT
,	O
tracheobronchial	B-ANAT
and	O
alveolar	B-ANAT
regions	I-ANAT
in	O
different	O
lung	B-ANAT
lobes	I-ANAT
)	O
has	O
been	O
estimated	O
.	O

Dosimeter	B-DEVI
estimates	O
were	O
performed	O
with	O
the	O
Multiple	O
-	O
Path	O
Particle	O
Dosimetry	O
model	O
(	O
MPPD	O
v	O
.	O
2	O
.	O
1	O
)	O
.	O

The	O
paper	O
discusses	O
the	O
aerosol	B-OBJC
doses	O
deposited	O
in	O
the	O
respiratory	B-ANAT
system	I-ANAT
of	O
individuals	B-LIVB
exposed	O
in	O
proximity	O
of	O
traffic	B-DISO
.	O

During	O
traffic	B-DISO
peak	O
hours	O
,	O
about	O
6	O
.	O

6	O
×	O
10	O
(	O
10	O
)	O
particles	B-CHEM
are	O
deposited	O
into	O
the	O
respiratory	B-ANAT
system	I-ANAT
.	O

Such	O
dose	O
is	O
almost	O
entirely	O
made	O
of	O
UFPs	B-CHEM
.	O

According	O
to	O
the	O
greater	O
dose	O
estimated	O
,	O
right	B-ANAT
lung	I-ANAT
lobes	I-ANAT
are	O
expected	O
to	O
be	O
more	O
susceptible	O
to	O
respiratory	O
pathologies	B-DISO
than	O
left	B-ANAT
lobes	I-ANAT
.	O

Anomalous	B-DISO
Left	B-ANAT
Anterior	I-ANAT
Descending	I-ANAT
Coronary	I-ANAT
Artery	I-ANAT
Arising	O
from	O
Pulmonary	B-ANAT
Artery	I-ANAT
in	O
a	O
63	O
Year	O
-	O
old	O
Male	B-PHYS
Patient	I-PHYS
:	O
Case	O
Report	O
and	O
Literature	O
Review	O
To	O
present	O
a	O
case	O
of	O
a	O
rare	O
congenital	B-DISO
coronary	I-DISO
anomaly	I-DISO
in	O
an	O
adult	B-LIVB
patient	B-LIVB
,	O
which	O
was	O
not	O
reported	B-PROC
before	O
in	O
Palestine	B-GEOG
,	O
review	O
the	O
literature	O
,	O
and	O
compare	O
with	O
previously	O
reported	O
cases	O
.	O

International	O
Liver	O
Transplant	O
Society	O
Practice	O
Guidelines	O
:	O
Diagnosis	B-DISO
and	O
Management	B-PROC
of	O
Hepatopulmonary	B-DISO
Syndrome	I-DISO
and	O
Portopulmonary	B-DISO
Hypertension	I-DISO
Two	O
distinct	O
pulmonary	B-DISO
vascular	I-DISO
disorders	I-DISO
,	O
hepatopulmonary	B-DISO
syndrome	I-DISO
(	O
HPS	B-DISO
)	O
and	O
portopulmonary	B-DISO
hypertension	I-DISO
(	O
POPH	B-DISO
)	O
may	O
occur	O
as	O
a	O
consequence	O
of	O
hepatic	B-ANAT
parenchymal	I-ANAT
or	O
vascular	B-DISO
abnormalities	I-DISO
.	O

HPS	B-DISO
and	O
POPH	B-DISO
have	O
major	O
clinical	O
implications	B-DISO
for	O
liver	B-PROC
transplantation	I-PROC
.	O

A	O
European	O
Respiratory	O
Society	O
Task	O
Force	O
on	O
Pulmonary	B-DISO
-	I-DISO
Hepatic	I-DISO
Disorders	I-DISO
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-DISO
and	O
guide	O
management	O
of	O
these	O
disorders	B-DISO
.	O

These	O
International	O
Liver	O
Transplant	O
Society	O
diagnostic	O
and	O
management	O
guidelines	O
are	O
based	O
on	O
that	O
task	O
force	O
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	O
experience	O
dictates	O
.	O

Based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
HPS	B-DISO
and	O
POPH	B-DISO
articles	O
identified	O
via	O
a	O
MEDLINE	O
search	O
(	O
1985	O
-	O
2015	O
)	O
,	O
clinical	O
guidelines	O
were	O
based	O
on	O
,	O
selected	B-PROC
single	I-PROC
care	I-PROC
reports	I-PROC
,	O
small	O
series	O
,	O
registries	O
,	O
databases	O
,	O
and	O
expert	O
opinion	O
.	O

The	O
paucity	O
of	O
randomized	B-PROC
,	I-PROC
controlled	I-PROC
trials	I-PROC
in	O
either	O
of	O
these	O
disorders	B-DISO
was	O
noted	O
.	O

Guidelines	O
are	O
presented	O
in	O
5	O
parts	O
;	O
I	O
.	O

Definitions	O
/	O
Diagnostic	O
criteria	O
;	O
II	O
.	O

Hepatopulmonary	B-DISO
syndrome	I-DISO
;	O
III	O
.	O

Portopulmonary	B-DISO
hypertension	I-DISO
;	O
IV	O
.	O

Implications	B-DISO
for	O
liver	B-PROC
transplantation	I-PROC
;	O
and	O
V	O
.	O

Suggestions	O
for	O
future	O
clinical	B-PROC
research	I-PROC
.	O

Prevalence	O
of	O
Coronary	B-DISO
Artery	I-DISO
to	O
Pulmonary	B-DISO
Artery	I-DISO
Collaterals	I-DISO
in	O
Patients	B-LIVB
with	O
Chronic	B-DISO
Thromboembolic	I-DISO
Pulmonary	I-DISO
Hypertension	I-DISO
:	O
Retrospective	B-PROC
Analysis	I-PROC
from	O
a	O
Single	O
Center	O
Background	O
Our	O
aim	O
was	O
to	O
determine	O
the	O
prevalence	O
of	O
coronary	B-DISO
artery	I-DISO
-	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
in	O
patients	B-LIVB
with	O
chronic	B-DISO
thromboembolic	I-DISO
pulmonary	I-DISO
hypertension	I-DISO
(	O
CTEPH	B-DISO
)	O
by	O
retrospectively	B-PROC
evaluating	O
coronary	B-PROC
angiograms	I-PROC
of	O
eligible	O
consecutive	O
patients	B-LIVB
who	O
had	O
undergone	O
pulmonary	B-PROC
endarterectomy	I-PROC
(	O
PEA	B-PROC
)	O
.	O

We	O
also	O
aimed	O
to	O
evaluate	B-PROC
predictors	O
and	O
potential	O
clinical	O
associates	O
of	O
these	O
collaterals	B-ANAT
.	O

Methods	O
Coronary	B-PROC
angiograms	I-PROC
of	O
83	O
consecutive	O
CTEPH	B-DISO
patients	B-LIVB
who	O
had	O
undergone	O
coronary	B-PROC
angiography	I-PROC
before	O
PEA	B-PROC
operation	B-PROC
between	O
January	O
1	O
,	O
2012	O
and	O
June	O
1	O
,	O
2015	O
were	O
retrospectively	B-PROC
evaluated	B-PROC
for	O
presence	O
of	O
coronary	B-DISO
artery	I-DISO
-	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
.	O

Medical	O
records	O
of	O
all	O
patients	B-LIVB
were	O
also	O
retrospectively	B-PROC
reviewed	O
for	O
demographic	B-DISO
information	I-DISO
,	O
cardiovascular	B-DISO
risk	I-DISO
factors	I-DISO
,	O
preoperative	O
right	O
heart	O
catheterization	O
reports	O
,	O
operation	O
reports	O
,	O
and	O
follow	O
-	O
up	O
data	O
.	O

Data	O
of	O
CTEPH	B-DISO
patients	B-LIVB
with	O
coronary	B-DISO
artery	I-DISO
-	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
were	O
compared	O
with	O
data	O
of	O
CTEPH	B-DISO
patients	B-LIVB
without	O
such	O
collaterals	B-ANAT
.	O

Results	O
There	O
were	O
15	O
patients	B-LIVB
(	O
18	O
.	O
1	O
%	O
)	O
with	O
definite	O
and	O
4	O
patients	B-LIVB
(	O
4	O
.	O
8	O
%	O
)	O
with	O
probable	O
coronary	B-DISO
artery	I-DISO
-	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
among	O
the	O
study	B-LIVB
population	I-LIVB
.	O

CTEPH	B-DISO
patients	B-LIVB
with	O
collaterals	B-ANAT
had	O
higher	O
preoperative	O
pulmonary	B-PHEN
artery	I-PHEN
pressures	I-PHEN
,	O
higher	O
pulmonary	B-DISO
vascular	I-DISO
resistance	I-DISO
(	O
PVR	B-DISO
)	O
and	O
lower	O
cardiac	B-DISO
index	I-DISO
values	I-DISO
compared	O
with	O
CTEPH	B-DISO
patients	B-LIVB
without	O
collaterals	B-ANAT
.	O

However	O
,	O
CTEPH	B-DISO
patients	B-LIVB
with	O
collaterals	B-ANAT
displayed	O
higher	O
amount	O
of	O
reduction	B-DISO
in	I-DISO
PVR	I-DISO
after	O
PEA	B-PROC
compared	O
with	O
patients	B-LIVB
without	O
collaterals	B-ANAT
.	O

There	O
were	O
no	B-DISO
significant	I-DISO
differences	I-DISO
between	O
groups	O
regarding	O
incidence	O
of	O
reperfusion	B-DISO
injury	I-DISO
or	O
mortality	O
.	O

Conclusion	O
Prevalence	O
of	O
coronary	B-DISO
artery	I-DISO
-	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
seems	O
to	O
be	O
increased	O
in	O
our	O
CTEPH	B-DISO
patients	B-LIVB
compared	O
with	O
the	O
general	B-LIVB
population	I-LIVB
.	O

The	O
presence	O
of	O
coronary	B-DISO
artery	I-DISO
-	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
is	O
often	O
combined	O
with	O
proximal	O
disease	B-DISO
with	O
the	O
possibility	O
of	O
increased	O
reduction	B-DISO
of	I-DISO
PVR	I-DISO
after	O
PEA	B-PROC
operation	O
.	O

Uveitis	B-DISO
in	O
children	B-LIVB
The	O
review	O
provides	O
updates	O
on	O
novel	O
risk	O
markers	O
for	O
the	O
development	O
of	O
pediatric	O
inflammatory	B-DISO
uveitis	I-DISO
and	O
a	O
severe	B-DISO
disease	I-DISO
course	I-DISO
,	O
on	O
treatment	B-PROC
of	O
refractory	B-DISO
disease	I-DISO
,	O
and	O
on	O
the	O
measurement	O
of	O
visual	O
outcomes	O
.	O

There	O
are	O
several	O
new	O
genetic	B-PHYS
markers	I-PHYS
,	O
biomarkers	B-PHYS
,	O
and	O
clinical	O
factors	O
that	O
may	O
influence	O
a	O
child	B-LIVB
's	I-LIVB
uveitis	B-DISO
disease	B-DISO
course	I-DISO
.	O

It	O
is	O
important	O
to	O
identify	O
children	B-LIVB
at	O
risk	O
for	O
poor	O
visual	O
outcomes	O
and	O
who	O
are	O
refractory	O
to	O
traditional	B-PROC
therapy	I-PROC
.	O

Racial	B-DISO
disparities	I-DISO
have	O
recently	O
been	O
reported	O
.	O

We	O
describe	O
agents	B-CHEM
of	O
potential	O
benefit	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
importance	O
of	O
patient	O
reported	O
outcomes	O
in	O
this	O
population	B-LIVB
.	O

Uveitis	B-DISO
can	O
lead	O
to	O
vision	B-DISO
-	I-DISO
threatening	I-DISO
complications	I-DISO
.	O

Timely	B-PROC
and	I-PROC
aggressive	I-PROC
treatment	I-PROC
of	O
children	B-LIVB
identified	O
to	O
be	O
at	O
risk	O
for	O
a	O
severe	B-DISO
uveitis	I-DISO
course	I-DISO
may	O
lead	O
to	O
improved	O
outcomes	O
.	O

The	O
integration	O
of	O
cyanide	B-CHEM
hydratase	I-CHEM
and	O
tyrosinase	B-CHEM
catalysts	B-PHEN
enables	O
effective	O
degradation	O
of	O
cyanide	B-CHEM
and	O
phenol	B-CHEM
in	O
coking	B-PHEN
wastewaters	I-PHEN
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
design	O
an	O
effective	O
method	O
for	O
the	O
bioremediation	B-PHEN
of	O
coking	B-PHEN
wastewaters	I-PHEN
,	O
specifically	O
for	O
the	O
concurrent	O
elimination	B-PHEN
of	O
their	O
highly	O
toxic	O
components	O
-	O
cyanide	B-CHEM
and	O
phenols	B-CHEM
.	O

Almost	O
full	O
degradation	O
of	O
free	B-CHEM
cyanide	I-CHEM
(	O
0	O
.	O
32	O
-	O
20	O
mM	O
;	O
8	O
.	O
3	O
-	O
520	O
mg	O
L	O
(	O
-	O
1	O
)	O
)	O
in	O
the	O
model	B-DEVI
and	O
the	O
real	O
coking	B-PHEN
wastewaters	I-PHEN
was	O
achieved	O
by	O
using	O
a	O
recombinant	B-CHEM
cyanide	B-CHEM
hydratase	I-CHEM
in	O
the	O
first	O
step	O
.	O

The	O
removal	O
of	O
cyanide	B-CHEM
,	O
a	O
strong	O
inhibitor	O
of	O
tyrosinase	B-CHEM
,	O
enabled	O
an	O
effective	O
degradation	O
of	O
phenols	B-CHEM
by	O
this	O
enzyme	B-CHEM
in	O
the	O
second	O
step	O
.	O

Phenol	B-CHEM
(	O
16	O
.	O
5	O
mM	O
,	O
1	O
,	O
552	O
mg	O
L	O
(	O
-	O
1	O
)	O
)	O
was	O
completely	O
removed	O
from	O
a	O
real	O
coking	B-PHEN
wastewater	I-PHEN
within	O
20	O
h	O
and	O
cresols	B-CHEM
(	O
5	O
.	O
0	O
mM	O
,	O
540	O
mg	O
L	O
(	O
-	O
1	O
)	O
)	O
were	O
removed	O
by	O
66	O
%	O
under	O
the	O
same	O
conditions	O
.	O

The	O
integration	O
of	O
cyanide	B-CHEM
hydratase	I-CHEM
and	O
tyrosinase	B-CHEM
open	O
up	O
new	O
possibilities	O
for	O
the	O
bioremediation	B-PHEN
of	O
wastewaters	B-PHEN
with	O
complex	O
pollution	B-PHEN
.	O

Utility	O
of	O
a	O
mHealth	O
App	O
for	O
Self	B-PROC
-	I-PROC
Management	I-PROC
and	O
Education	B-PROC
of	O
Cardiac	B-DISO
Diseases	I-DISO
in	O
Spanish	B-GEOG
Urban	B-GEOG
and	I-GEOG
Rural	I-GEOG
Areas	I-GEOG
Analyze	B-PROC
the	O
utility	O
of	O
a	O
mobile	O
health	O
app	O
named	O
HeartKeeper	O
in	O
several	B-LIVB
groups	I-LIVB
of	I-LIVB
population	I-LIVB
and	O
obtain	O
conclusions	O
to	O
be	O
applied	O
to	O
other	O
similar	O
apps	O
.	O

A	O
questionnaire	O
has	O
been	O
designed	O
to	O
evaluate	O
the	O
usage	O
and	O
utility	O
of	O
the	O
HeartKeeper	O
app	O
.	O

The	O
questionnaire	O
information	O
was	O
collected	O
by	O
collaborating	O
cardiologists	B-LIVB
from	O
32	O
patients	B-LIVB
before	O
and	O
after	O
they	O
used	O
the	O
app	O
.	O

Patients	B-LIVB
were	O
randomly	B-PROC
selected	I-PROC
with	O
established	O
quotas	B-PROC
within	O
interest	B-LIVB
groups	I-LIVB
,	O
so	O
that	O
men	B-LIVB
and	O
women	B-LIVB
,	O
patients	B-LIVB
older	B-LIVB
or	O
younger	O
than	O
60	O
years	O
old	O
and	O
patients	B-LIVB
living	O
in	O
urban	B-GEOG
or	I-GEOG
rural	I-GEOG
areas	I-GEOG
were	O
equally	O
represented	O
.	O

Using	O
the	O
appropriate	O
statistical	B-PROC
techniques	I-PROC
we	O
see	O
that	O
the	O
HeartKeeper	O
app	O
was	O
useful	O
for	O
patients	B-LIVB
as	O
they	O
qualify	O
with	O
70	O
points	O
(	O
out	O
of	O
100	O
)	O
the	O
overall	B-DISO
opinion	I-DISO
of	O
the	O
app	O
,	O
it	O
helps	O
them	O
remember	B-PHYS
more	O
easily	O
taking	O
their	O
pills	B-CHEM
with	O
a	O
mean	O
improvement	O
of	O
20	O
.	O

94	O
points	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
they	O
perceive	O
a	O
global	O
improvement	O
of	O
their	O
health	O
(	O
8	O
.	O
28	O
points	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
also	O
observe	O
that	O
these	O
improvements	O
do	O
not	O
depend	O
,	O
in	O
general	O
,	O
on	O
the	O
area	B-GEOG
(	I-GEOG
urban	I-GEOG
or	I-GEOG
rural	I-GEOG
)	I-GEOG
where	O
the	O
patient	B-LIVB
comes	O
from	O
or	O
on	O
their	O
sex	B-PHYS
.	O

Although	O
older	B-LIVB
patients	I-LIVB
needed	O
more	O
help	O
to	O
use	O
the	O
app	O
and	O
used	O
it	O
slightly	O
less	O
frequently	O
,	O
the	O
improvements	O
on	O
several	O
measures	O
considered	O
,	O
such	O
as	O
remembering	B-PHYS
taking	O
pills	B-CHEM
,	O
breathing	B-DISO
problems	I-DISO
or	O
trouble	B-DISO
developing	I-DISO
activities	I-DISO
,	O
depend	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
on	O
age	O
with	O
older	B-LIVB
patients	I-LIVB
reporting	O
higher	O
improvements	O
than	O
younger	B-LIVB
ones	I-LIVB
.	O

The	O
results	O
obtained	O
with	O
the	O
sample	O
of	O
patients	B-LIVB
considered	O
in	O
this	O
research	B-PROC
prove	O
the	O
utility	O
of	O
the	O
HeartKeeper	O
app	O
.	O

This	O
utility	O
is	O
similar	O
in	O
urban	B-GEOG
and	I-GEOG
rural	I-GEOG
areas	I-GEOG
and	O
for	O
patients	B-LIVB
of	O
both	B-PHYS
sexes	I-PHYS
and	O
,	O
to	O
some	O
extent	O
,	O
depends	O
on	O
the	O
age	B-LIVB
of	O
the	O
patient	B-LIVB
with	O
older	B-LIVB
patients	I-LIVB
reporting	O
slightly	O
lower	O
frequency	O
of	O
use	O
but	O
higher	O
health	O
improvements	O
than	O
younger	B-LIVB
ones	I-LIVB
.	O

MiR	O
-	O
4638	O
-	O
5p	O
inhibits	O
castration	B-DISO
resistance	I-DISO
of	I-DISO
prostate	I-DISO
cancer	I-DISO
through	O
repressing	O
Kidins220	O
expression	B-PHYS
and	O
PI3K	O
/	O
AKT	O
pathway	O
activity	O
MicroRNAs	B-CHEM
(	O
miRNAs	B-CHEM
)	O
are	O
short	O
,	O
conserved	O
segments	O
of	O
non	B-CHEM
-	I-CHEM
coding	I-CHEM
RNA	I-CHEM
which	O
play	O
a	O
significant	O
role	O
in	O
prostate	B-DISO
cancer	I-DISO
development	O
and	O
progression	B-DISO
.	O

To	O
identify	O
miRNAs	B-CHEM
associated	O
with	O
castration	B-DISO
resistance	I-DISO
,	O
we	O
performed	O
miRNA	B-PROC
microarray	I-PROC
analysis	I-PROC
comparing	O
castration	B-DISO
resistant	I-DISO
prostate	I-DISO
cancer	I-DISO
(	O
CRPC	B-DISO
)	O
with	O
androgen	B-DISO
dependent	I-DISO
prostate	I-DISO
cancer	I-DISO
(	O
ADPC	B-DISO
)	O
.	O

We	O
identified	O
common	O
underexpression	B-PHYS
of	O
miR	O
-	O
4638	O
-	O
5p	O
in	O
CRPC	B-DISO
compared	O
to	O
ADPC	B-DISO
samples	O
,	O
which	O
were	O
further	O
confirmed	O
by	O
quantitative	B-PROC
PCR	I-PROC
analysis	I-PROC
.	O

The	O
role	O
of	O
miR	O
-	O
4638	O
-	O
5p	O
in	O
prostate	B-DISO
cancer	I-DISO
androgen	B-DISO
-	I-DISO
independent	I-DISO
growth	I-DISO
has	O
been	O
demonstrated	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
identified	O
Kidins220	O
as	O
a	O
target	O
gene	O
directly	O
regulated	O
by	O
miR	O
-	O
4638	O
-	O
5p	O
and	O
shRNA	B-CHEM
-mediated	O
knockdown	B-PROC
of	O
Kidins220	O
phenocopied	O
miR	O
-	O
4638	O
-	O
5p	O
restoration	O
.	O

Subsequently	O
,	O
we	O
revealed	O
that	O
Kidins220	O
activates	O
PI3K	O
/	O
AKT	O
pathway	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
CRPC	B-DISO
.	O

Loss	O
of	O
miR	O
-	O
4638	O
-	O
5p	O
may	O
lead	O
to	O
CRPC	B-DISO
through	O
the	O
activity	O
of	O
Kidins220	O
and	O
PI3K	O
/	O
AKT	O
pathway	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
miR	O
-	O
4638	O
-	O
5p	O
,	O
through	O
regulating	O
Kidins220	O
and	O
the	O
downstream	O
activity	O
of	O
VEGF	B-CHEM
and	O
PI3K	O
/	O
AKT	O
pathway	O
,	O
influences	O
prostate	B-DISO
cancer	I-DISO
progression	I-DISO
via	O
angiogenesis	B-PHYS
.	O

The	O
identification	O
of	O
miR	O
-	O
4638	O
-	O
5p	O
down	B-PHYS
-	I-PHYS
regulation	I-PHYS
in	O
CRPC	B-DISO
and	O
the	O
understanding	O
of	O
the	O
functional	O
role	O
of	O
miR	O
-	O
4638	O
-	O
5p	O
and	O
its	O
downstream	O
genes	O
/	O
pathways	B-PHYS
have	O
the	O
potential	O
to	O
develop	O
biomarkers	B-PHYS
for	O
CRPC	B-DISO
onset	O
and	O
to	O
identify	O
novel	O
targets	O
for	O
novel	O
forms	O
of	O
treatments	B-PROC
of	O
this	O
lethal	O
form	O
of	O
PCa	B-DISO
.	O

Evaluation	B-PROC
of	O
the	O
Effects	O
of	O
Intravenous	O
and	O
Percutaneous	O
Low	B-PROC
Level	I-PROC
Laser	I-PROC
Therapy	I-PROC
in	O
the	O
Management	B-PROC
of	O
Shoulder	B-ANAT
Myofascial	B-DISO
Pain	I-DISO
Syndrome	I-DISO
Myofascial	B-DISO
pain	I-DISO
syndrome	I-DISO
(	O
MPS	B-DISO
)	O
treatment	B-PROC
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment	B-PROC
frame	I-PROC
.	O

Therefore	O
research	O
on	O
new	O
,	O
more	O
efficient	O
and	O
long	O
lasting	O
effect	O
treatment	B-PROC
modalities	O
is	O
necessary	O
.	O

This	O
study	O
looked	O
at	O
the	O
effects	O
of	O
intravenous	O
laser	B-PROC
therapy	I-PROC
(	O
IVL	B-PROC
)	O
and	O
percutaneous	O
low	B-PROC
level	I-PROC
laser	I-PROC
(	O
PLLL	B-PROC
)	O
in	O
the	O
management	B-PROC
of	O
shoulder	B-ANAT
MPS	B-DISO
.	O

In	O
this	O
randomized	B-PROC
controlled	I-PROC
trial	I-PROC
,	O
30	O
patients	B-LIVB
fulfilling	O
inclusion	O
criteria	O
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups	O
,	O
control	B-LIVB
,	O
IVL	B-LIVB
and	O
PLLL	B-LIVB
.	O

Control	B-LIVB
group	I-LIVB
received	O
12	O
sessions	O
of	O
placebo	B-PROC
low	B-PROC
level	I-PROC
laser	I-PROC
,	O
IVL	B-LIVB
group	I-LIVB
received	O
12	O
sessions	O
of	O
IVL	B-PROC
therapy	I-PROC
,	O
and	O
PLLL	B-LIVB
group	I-LIVB
received	O
12	O
sessions	O
of	O
PLLL	B-PROC
therapy	I-PROC
.	O

All	O
patients	B-LIVB
were	O
trained	O
for	O
better	O
body	B-PHYS
posture	I-PHYS
,	O
body	B-ANAT
mechanics	I-ANAT
,	O
gentle	B-PROC
massage	I-PROC
of	O
trigger	B-ANAT
points	I-ANAT
,	O
stretching	B-PROC
exercises	I-PROC
of	O
affected	O
muscle	O
(	O
trapezius	B-ANAT
)	O
,	O
and	O
received	O
10	O
mg	O
of	O
oral	O
nortriptyline	B-CHEM
regimen	B-PROC
every	O
night	O
for	O
3	O
months	O
.	O

Outcomes	O
included	O
pain	O
severity	O
,	O
functional	B-DISO
disability	I-DISO
,	O
and	O
quality	O
of	O
life	O
.	O

Patients	B-LIVB
were	O
assessed	O
using	O
Numeric	O
Rating	O
Scale	O
(	O
NRS	O
)	O
,	O
Pain	O
Disability	O
Index	O
(	O
PDI	O
)	O
,	O
and	O
Short	O
Form	O
Health	O
Survey	O
(	O
SF	O
-	O
12	O
)	O
.	O

Data	B-DISO
collected	I-DISO
were	O
analyzed	B-PROC
using	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
Mann	O
-	O
Whitney	O
and	O
t	O
tests	O
.	O

The	O
mean	O
of	O
PDI	O
and	O
maximum	O
pain	B-PHYS
intensity	I-PHYS
during	O
day	O
and	O
night	O
significantly	O
reduced	O
in	O
both	O
PLLL	B-LIVB
and	O
IVL	B-LIVB
groups	I-LIVB
compared	O
to	O
control	B-LIVB
group	I-LIVB
.	O

Although	O
pain	O
severity	O
and	O
PDI	O
reduction	O
was	O
more	O
pronounced	O
in	O
IVL	B-LIVB
group	I-LIVB
compared	O
to	O
PLLL	B-LIVB
group	I-LIVB
,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

Also	O
,	O
quality	O
of	O
life	O
statistically	O
significantly	O
improved	O
in	O
both	O
IVL	B-LIVB
and	O
PLLL	B-LIVB
groups	I-LIVB
compared	O
to	O
control	B-LIVB
group	I-LIVB
was	O
more	O
,	O
and	O
although	O
higher	O
in	O
IVL	B-LIVB
group	I-LIVB
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
when	O
compared	O
to	O
PLLL	B-LIVB
group	I-LIVB
.	O

No	B-DISO
side	I-DISO
effects	I-DISO
were	O
observed	O
in	O
the	O
intervention	B-LIVB
groups	I-LIVB
.	O

Intravenous	O
laser	B-PROC
and	O
PLLL	B-PROC
therapy	I-PROC
had	O
a	O
positive	O
effect	O
on	O
pain	O
severity	O
and	O
PDI	O
reduction	O
,	O
and	O
quality	O
of	O
life	O
in	O
this	O
study	O
.	O

Also	O
no	B-DISO
adverse	I-DISO
event	I-DISO
was	O
recorded	O
.	O

Thus	O
,	O
intravenous	O
lasers	B-PROC
and	O
PLLL	B-PROC
therapy	I-PROC
seem	O
to	O
be	O
effective	O
complementary	O
modalities	O
in	O
managing	B-PROC
patients	B-LIVB
with	O
shoulder	B-ANAT
MPS	B-DISO
.	O

Comparison	O
of	O
the	O
Antibacterial	B-PHYS
Effect	I-PHYS
of	O
810	O
nm	O
Diode	B-DEVI
Laser	I-DEVI
and	O
Photodynamic	B-DEVI
Therapy	I-DEVI
in	O
Reducing	O
the	O
Microbial	B-LIVB
Flora	I-LIVB
of	O
Root	B-ANAT
Canal	I-ANAT
in	O
Endodontic	B-PROC
Retreatment	I-PROC
in	O
Patients	B-LIVB
With	O
Periradicular	B-DISO
Lesions	I-DISO
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
compare	O
the	O
antibacterial	B-PHYS
efficacy	I-PHYS
of	O
diode	B-DEVI
laser	I-DEVI
810	O
nm	O
and	O
photodynamic	B-DEVI
therapy	I-DEVI
(	O
PDT	B-DEVI
)	O
in	O
reducing	O
bacterial	B-LIVB
microflora	I-LIVB
in	O
endodontic	B-PROC
retreatment	I-PROC
of	O
teeth	B-ANAT
with	O
periradicular	B-DISO
lesion	I-DISO
.	O

In	O
this	O
in	O
vivo	O
clinical	B-PROC
trial	I-PROC
,	O
20	O
patients	B-LIVB
who	O
needed	O
endodontic	B-PROC
retreatment	I-PROC
were	O
selected	O
.	O

After	O
conventional	O
chemo	B-PROC
mechanical	I-PROC
preparation	I-PROC
of	O
root	B-ANAT
canals	I-ANAT
,	O
microbiological	O
samples	O
were	O
taken	O
with	O
sterile	B-CHEM
paper	I-CHEM
point	I-CHEM
(	O
PP	B-CHEM
)	O
,	O
held	O
in	O
thioglycollate	B-CHEM
broth	I-CHEM
,	O
and	O
then	O
were	O
transferred	O
to	O
the	O
microbiological	B-OBJC
lab	I-OBJC
.	O

In	O
the	O
first	O
group	O
,	O
PDT	B-DEVI
with	O
methylene	B-CHEM
blue	I-CHEM
(	O
MB	B-CHEM
)	O
and	O
diode	B-DEVI
laser	I-DEVI
(	O
810	O
nm	O
,	O
0	O
.	O
2	O
W	O
,	O
40	O
seconds	O
)	O
was	O
performed	O
and	O
in	O
the	O
second	O
group	O
diode	B-DEVI
laser	I-DEVI
(	O
810	O
nm	O
,	O
1	O
.	O
2	O
W	O
,	O
30	O
seconds	O
)	O
was	O
irradiated	B-PHEN
.	O

Then	O
second	O
samples	O
were	O
taken	O
from	O
all	O
canals	B-ANAT
.	O

CFU	O
/	O
ml	O
amounts	O
showed	O
statistically	O
significant	O
reduction	O
in	O
both	O
groups	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CFU	O
/	O
ml	O
amounts	O
were	O
compared	O
between	O
the	O
two	O
groups	O
and	O
there	O
was	O
no	O
statistical	O
difference	O
.	O

PDT	B-DEVI
and	O
diode	B-DEVI
laser	I-DEVI
810	O
nm	O
irradiation	B-PHEN
are	O
effective	O
methods	O
for	O
root	B-ANAT
canal	I-ANAT
disinfection	B-PROC
.	O

PDT	B-DEVI
is	O
a	O
suitable	O
alternative	O
for	O
diode	B-DEVI
laser	I-DEVI
810	O
nm	O
irradiation	B-PHEN
,	O
because	O
of	O
lower	O
thermal	B-DISO
risk	I-DISO
on	O
root	B-ANAT
dentin	I-ANAT
.	O

A	O
comparative	B-PROC
analysis	I-PROC
of	O
lncRNAs	B-CHEM
in	O
prostate	B-DISO
cancer	I-DISO
exosomes	B-ANAT
and	O
their	O
parental	O
cell	B-ANAT
lines	I-ANAT
Prostate	B-DISO
cancer	I-DISO
is	O
the	O
second	O
leading	O
cancer	B-DISO
in	O
men	B-LIVB
world	B-LIVB
-	O
wide	O
.	O

Due	O
to	O
its	O
heterogeneous	O
nature	O
,	O
a	O
considerable	O
amount	O
of	O
research	B-PROC
effort	B-PHYS
has	O
been	O
dedicated	O
in	O
identifying	O
effective	O
clinical	O
biomarkers	B-PHYS
with	O
a	O
focus	O
on	O
proteins	B-CHEM
,	O
messenger	B-CHEM
RNA	I-CHEM
and	O
microRNAs	B-CHEM
[	O
1	O
]	O
.	O

However	O
,	O
there	O
is	O
limited	O
data	O
on	O
the	O
role	O
and	O
expression	B-PHYS
of	O
long	B-CHEM
noncoding	I-CHEM
RNAs	I-CHEM
(	O
lncRNAs	B-CHEM
)	O
in	O
prostate	B-DISO
cancer	I-DISO
exosomes	B-ANAT
[	O
2	O
]	O
.	O

This	O
array	O
dataset	O
which	O
is	O
linked	O
to	O
our	O
publication	B-OBJC
describes	O
the	O
profiling	O
of	O
human	B-LIVB
lncRNAs	B-CHEM
in	O
prostate	B-DISO
cancer	I-DISO
and	O
their	O
exosomes	B-ANAT
from	O
five	O
different	O
cell	B-ANAT
lines	I-ANAT
[	O
3	O
]	O
.	O

From	O
this	O
dataset	O
,	O
we	O
identified	O
a	O
list	O
of	O
statistically	O
significant	O
prostate	B-DISO
cancer	I-DISO
lncRNAs	B-CHEM
which	O
are	O
differentially	O
expressed	B-PHYS
in	O
the	O
exosomes	B-ANAT
compared	O
to	O
their	O
parent	O
cell	B-ANAT
lines	I-ANAT
.	O

This	O
dataset	O
has	O
been	O
deposited	O
into	O
Gene	O
Expression	O
Omnibus	O
(	O
GSE81034	O
)	O
.	O

Structural	O
Insights	B-PHYS
into	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
/	O
D4	B-CHEM
Selectivity	B-PHEN
of	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
Analogues	B-CHEM
:	O
Molecular	B-PROC
Modeling	I-PROC
,	O
Synthesis	O
,	O
and	O
in	O
Vitro	O
Binding	B-PHYS
The	O
resurgence	O
of	O
interest	O
in	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
receptors	I-CHEM
as	O
a	O
therapeutic	O
target	O
requires	O
the	O
existence	O
of	O
highly	O
selective	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
ligands	B-CHEM
.	O

To	O
date	O
,	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
has	O
been	O
the	O
prototypical	B-CHEM
antagonist	I-CHEM
of	O
these	O
receptors	B-CHEM
.	O

However	O
,	O
this	O
compound	O
also	O
has	O
significant	O
affinity	O
for	O
and	O
activity	O
at	O
D4	B-CHEM
dopamine	I-CHEM
receptors	I-CHEM
.	O

In	O
this	O
context	O
,	O
this	O
work	O
was	O
aimed	O
at	O
better	O
understanding	O
the	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
/	O
D4	B-CHEM
selectivity	B-PHEN
of	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
and	O
analogues	B-CHEM
from	O
a	O
structural	O
point	O
of	O
view	O
.	O

In	O
silico	O
investigations	O
revealed	O
two	O
key	O
interactions	O
for	O
the	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
/	O
D4	B-CHEM
selectivity	B-PHEN
of	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
and	O
analogues	B-CHEM
.	O

First	O
,	O
a	O
hydrogen	B-PHEN
bond	I-PHEN
only	O
found	O
with	O
the	O
Ser	B-CHEM
7	I-CHEM
.	I-CHEM

36	I-CHEM
of	O
D4	B-CHEM
receptor	I-CHEM
appeared	O
to	O
be	O
the	O
key	O
for	O
a	O
higher	O
D4	B-CHEM
affinity	O
for	O
newly	O
synthesized	O
aza	B-CHEM
analogues	B-CHEM
.	O

The	O
role	O
of	O
Ser	B-CHEM
7	I-CHEM
.	I-CHEM

36	I-CHEM
was	O
confirmed	O
as	O
the	O
affinity	O
of	O
aza	B-CHEM
analogues	B-CHEM
for	O
the	O
mutant	B-DISO
D4	B-CHEM
receptor	I-CHEM
S7	I-CHEM
.	I-CHEM

36A	I-CHEM
was	O
reduced	O
.	O

Then	O
,	O
the	O
formation	O
of	O
another	O
hydrogen	B-PHEN
bond	I-PHEN
with	O
the	O
conserved	O
Ser	B-CHEM
5	I-CHEM
.	I-CHEM

42	I-CHEM
residue	I-CHEM
appeared	O
to	O
be	O
also	O
critical	O
for	O
D4	B-CHEM
binding	B-PHYS
.	O

Differential	O
Apoptosis	B-PHYS
Radiosensitivity	B-PHYS
of	O
Neural	B-ANAT
Progenitors	I-ANAT
in	O
Adult	B-LIVB
Mouse	I-LIVB
Hippocampus	B-ANAT
Mammalian	B-LIVB
tissue	O
-	O
specific	O
stem	B-ANAT
cells	I-ANAT
and	O
progenitors	B-ANAT
demonstrate	O
differential	O
DNA	B-PHYS
damage	I-PHYS
response	I-PHYS
.	O

Neural	B-ANAT
progenitors	I-ANAT
in	O
dentate	B-ANAT
gyrus	I-ANAT
of	O
the	O
hippocampus	B-ANAT
are	O
known	O
to	O
undergo	O
apoptosis	B-PHYS
after	O
irradiation	B-PHEN
.	O

Using	O
a	O
mouse	B-DISO
model	I-DISO
of	O
hippocampal	B-ANAT
neuronal	B-PHYS
development	I-PHYS
,	O
we	O
characterized	O
the	O
apoptosis	B-PHYS
sensitivity	B-PHYS
of	O
the	O
different	O
neural	B-ANAT
progenitor	I-ANAT
subpopulations	B-LIVB
in	O
adult	B-LIVB
mouse	I-LIVB
dentate	B-ANAT
gyrus	I-ANAT
after	O
irradiation	B-PHEN
.	O

Two	O
different	O
bromodeoxyuridine	B-CHEM
incorporation	O
paradigms	B-PROC
were	O
used	O
for	O
cell	B-PHYS
fate	I-PHYS
mapping	I-PHYS
.	O

We	O
identified	O
two	O
apoptosis	B-PHYS
sensitive	B-PHYS
neural	B-ANAT
progenitor	I-ANAT
subpopulations	B-LIVB
after	O
irradiation	B-PHEN
.	O

The	O
first	O
represented	O
non	B-PHYS
-	I-PHYS
proliferative	I-PHYS
and	O
non	B-DISO
-	I-DISO
newborn	I-DISO
neuroblasts	B-ANAT
and	O
immature	B-ANAT
neurons	I-ANAT
that	O
expressed	O
doublecortin	B-CHEM
,	O
calretinin	B-CHEM
or	O
both	O
.	O

The	O
second	O
consisted	O
of	O
proliferative	O
intermediate	B-ANAT
neural	I-ANAT
progenitors	I-ANAT
.	O

The	O
putative	O
radial	B-ANAT
glia	I-ANAT
-	I-ANAT
like	I-ANAT
neural	I-ANAT
stem	I-ANAT
cells	I-ANAT
or	O
type	B-ANAT
-	I-ANAT
1	I-ANAT
cells	I-ANAT
,	O
regardless	O
of	O
proliferation	O
status	O
,	O
were	O
apoptosis	B-PHYS
resistant	O
after	O
irradiation	B-PHEN
.	O

There	O
was	O
no	O
evidence	O
of	O
radiation	B-PHEN
-	O
induced	O
apoptosis	B-PHYS
in	O
the	O
absence	O
of	O
the	O
Trp53	O
(	O
p53	O
)	O
gene	O
but	O
absence	O
of	O
Cdkn1a	O
(	O
p21	O
)	O
did	O
not	O
alter	O
the	O
apoptotic	B-PHYS
response	O
.	O

Upregulation	B-PHYS
of	O
nuclear	B-CHEM
p53	I-CHEM
was	O
observed	O
in	O
neuroblasts	B-ANAT
after	O
irradiation	B-PHEN
.	O

We	O
conclude	O
that	O
adult	B-ANAT
hippocampal	I-ANAT
neural	B-ANAT
progenitors	I-ANAT
may	O
demonstrate	O
differential	O
p53	B-CHEM
-dependent	O
apoptosis	B-PHYS
sensitivity	B-PHYS
after	O
irradiation	B-PHEN
.	O

Information	B-PHYS
Literacy	I-PHYS
in	O
a	O
Digital	O
Era	O
:	O
Understanding	B-PHYS
the	O
Impact	O
of	O
Mobile	B-OBJC
Information	O
for	O
Undergraduate	B-PROC
Nursing	I-PROC
Students	I-PROC
Recent	O
entry	O
-to	O
-	O
practice	B-PHYS
nursing	O
informatics	O
competencies	O
for	O
Registered	B-LIVB
Nurses	I-LIVB
in	O
Canada	B-GEOG
mean	O
nurse	B-LIVB
educators	I-LIVB
need	O
educational	B-PROC
strategies	I-PROC
to	O
promote	O
student	B-LIVB
competency	O
within	O
the	O
rapidly	O
evolving	O
informatics	O
field	O
.	O

A	O
collaborative	B-PROC
research	I-PROC
team	B-LIVB
from	O
three	O
Canadian	B-DISO
nursing	B-PROC
programs	I-PROC
completed	O
a	O
mixed	O
method	O
survey	O
to	O
describe	O
how	O
nursing	B-LIVB
students	I-LIVB
used	O
mobile	B-OBJC
nursing	O
information	O
support	O
and	O
the	O
extent	O
of	O
this	O
support	O
for	O
learning	B-PHYS
.	O

The	O
Mobile	O
Information	O
Support	O
Evaluation	O
Tool	O
(	O
MISET	O
)	O
assessed	O
Usefulness	O
/	O
Helpfulness	O
,	O
Information	B-PHYS
Literacy	I-PHYS
Support	O
,	O
and	O
Use	O
of	O
Evidence	O
-Based	O
Sources	B-DISO
.	O

The	O
quantitative	O
and	O
qualitative	O
data	O
were	O
analyzed	B-PROC
to	O
describe	O
students	B-LIVB
'	I-LIVB
perspectives	O
and	O
the	O
ways	O
they	O
used	O
mobile	B-OBJC
resources	O
in	O
learning	B-PHYS
situations	O
.	O

Findings	B-DISO
suggest	O
nursing	B-LIVB
students	I-LIVB
mainly	O
accessed	O
mobile	B-OBJC
resources	O
to	O
support	O
clinical	O
learning	B-PHYS
,	O
and	O
specifically	O
for	O
task	O
-	O
oriented	B-DISO
information	O
such	O
as	O
drug	B-PROC
medication	I-PROC
or	O
patient	O
conditions	O
/	O
diagnoses	O
.	O

Researchers	B-LIVB
recommend	O
a	O
paradigm	B-PROC
shift	I-PROC
whereby	O
educators	B-LIVB
emphasize	O
information	B-PHYS
literacy	I-PHYS
in	O
a	O
way	O
that	O
supports	O
evidence	O
-based	O
quality	B-PROC
care	I-PROC
.	O

Improving	O
EMR	O
Usability	O
:	O
Critical	O
Elements	O
When	O
Designing	O
Perioperative	O
Emergencies	B-PHEN
Template	O
Perianesthesia	B-PROC
nursing	I-PROC
care	I-PROC
involves	O
monitoring	O
of	O
unexpected	O
outcomes	O
before	O
and	O
after	O
surgical	B-PROC
and	O
anesthetic	B-PROC
procedures	I-PROC
.	O

When	O
adverse	B-DISO
events	I-DISO
occur	O
,	O
reviewing	O
patient	O
data	O
is	O
critical	O
to	O
provide	O
appropriate	O
intervention	B-PROC
.	O

Current	O
EMR	O
software	B-OBJC
systems	I-OBJC
are	O
limited	O
in	O
structure	O
and	O
are	O
not	O
cohesive	O
in	O
recording	O
adverse	B-DISO
events	I-DISO
.	O

Users	B-LIVB
tend	O
to	O
develop	O
workarounds	O
when	O
systems	B-OBJC
fail	O
to	O
capture	O
workflow	O
.	O

Analysis	B-PROC
of	O
adverse	B-DISO
incident	I-DISO
is	O
incomplete	O
because	O
data	O
entered	O
is	O
not	O
retrievable	O
.	O

Narrative	O
data	O
,	O
while	O
sometimes	O
necessary	O
,	O
cannot	O
easily	O
be	O
analyzed	B-PROC
or	O
linked	O
to	O
the	O
structured	O
portion	O
of	O
the	O
record	O
.	O

Designing	O
templates	O
to	O
capture	O
essential	O
data	O
during	O
emergency	B-PHEN
situations	I-PHEN
improves	O
usability	O
and	O
compliance	B-DISO
.	O

The	O
presentation	O
of	O
information	O
in	O
terms	O
of	O
layout	O
and	O
structure	O
is	O
important	O
because	O
it	O
can	O
influence	O
data	O
retrieval	B-PROC
,	O
interpretation	O
and	O
clinical	B-PHYS
decision	I-PHYS
making	I-PHYS
in	O
fundamental	O
ways	O
.	O

Sewage	B-PHEN
sludge	B-PHEN
pretreatment	O
by	O
microwave	B-PHEN
irradiation	I-PHEN
combined	O
with	O
activated	B-CHEM
carbon	I-CHEM
fibre	I-CHEM
at	O
alkaline	O
pH	O
for	O
anaerobic	O
digestion	B-PHEN
This	O
research	B-PROC
focuses	O
on	O
the	O
effects	O
of	O
microwave	B-PHEN
-assisted	O
activated	B-CHEM
carbon	I-CHEM
fibre	I-CHEM
(	O
ACF	B-CHEM
)	O
(	O
MW	B-PHEN
-	O
ACF	B-CHEM
)	O
treatment	O
on	O
sewage	B-PHEN
sludge	B-PHEN
at	O
alkaline	O
pH	O
.	O

The	O
disintegration	O
and	O
biodegradability	B-PHEN
of	O
sewage	B-PHEN
sludge	B-PHEN
were	O
studied	O
.	O

It	O
was	O
found	O
that	O
the	O
MW	O
-	O
ACF	O
process	O
at	O
alkaline	O
pH	O
provided	O
a	O
rapid	O
and	O
efficient	O
process	B-PHEN
to	O
disrupt	O
the	O
microbial	B-LIVB
cells	B-ANAT
in	O
the	O
sludge	B-PHEN
.	O

The	O
results	O
suggested	O
that	O
when	O
irradiated	B-PHEN
at	O
800	O
W	O
MW	O
for	O
110	O
s	O
with	O
a	O
dose	O
of	O
1	O
.	O

0	O
g	O
ACF	B-CHEM
/g	O
solid	O
concentration	O
(	O
SS	O
)	O
at	O
pH	O
10	O
.	O

5	O
,	O
the	O
MW	B-PHEN
-	O
ACF	B-CHEM
pretreatment	O
achieved	O
55	O
%	O
SS	O
disintegration	O
,	O
23	O
%	O
greater	O
than	O
the	O
value	O
of	O
MW	O
alone	O
(	O
32	O
%	O
)	O
.	O

The	O
concentration	O
of	O
total	B-PROC
nitrogen	I-PROC
,	O
total	B-PROC
phosphorus	I-PROC
,	O
supernatant	B-PROC
soluble	I-PROC
chemical	I-PROC
oxygen	I-PROC
demand	I-PROC
,	O
protein	B-PROC
,	O
and	O
polysaccharide	B-CHEM
increased	O
by	O
60	O
%	O
,	O
144	O
%	O
,	O
145	O
%	O
,	O
74	O
%	O
,	O
and	O
77	O
%	O
,	O
respectively	O
.	O

An	O
increase	O
in	O
biogas	B-CHEM
production	O
by	O
63	O
.	O

7	O
%	O
was	O
achieved	O
after	O
20	O
days	O
of	O
anaerobic	O
digestion	B-PHEN
(	O
AD	B-PHEN
)	O
,	O
compared	O
to	O
the	O
control	O
.	O

The	O
results	O
indicated	O
that	O
the	O
MW	O
-	O
ACF	O
pretreatment	O
process	O
at	O
alkaline	O
pH	O
provides	O
novel	O
sludge	B-PHEN
management	O
options	O
in	O
disintegration	O
of	O
sewage	B-PHEN
sludge	B-PHEN
for	O
further	O
AD	B-PHEN
.	O

The	O
Effects	O
of	O
Sequential	O
Environmental	B-DISO
and	O
Harvest	O
Stressors	O
on	O
the	O
Sensory	O
Characteristics	O
of	O
Cultured	B-LIVB
Channel	I-LIVB
Catfish	I-LIVB
(	O
Ictalurus	B-LIVB
Punctatus	I-LIVB
)	O
Fillets	B-OBJC
Stress	B-DISO
during	O
fish	O
culture	O
alters	O
physiological	B-PHEN
homeostasis	I-PHEN
and	O
affects	O
fillet	B-OBJC
quality	O
.	O

Maintenance	O
of	O
high	O
-	O
quality	O
seafood	B-OBJC
is	O
important	O
to	O
ensure	O
the	O
production	O
of	O
a	O
marketable	B-OBJC
product	I-OBJC
.	O

This	O
study	O
assessed	O
how	O
sequential	O
stressors	B-DISO
affect	O
the	O
sensory	O
and	O
quality	O
characteristics	O
of	O
catfish	B-LIVB
(	O
Ictalurus	B-LIVB
punctatus	I-LIVB
)	O
fillets	B-OBJC
.	O

Three	O
stress	O
trials	O
were	O
conducted	O
where	O
temperature	O
(	O
25	O
or	O
33	O
°	O
C	O
)	O
and	O
dissolved	B-CHEM
oxygen	I-CHEM
(	O
DO	B-CHEM
,	O
approximately	O
2	O
.	O
5	O
or	O
>	O
5	O
mg	O
/	O
L	O
)	O
were	O
manipulated	O
followed	O
by	O
socking	B-PHEN
and	O
transport	B-DISO
stress	I-DISO
.	O

After	O
each	O
stage	O
of	O
harvest	B-PHEN
(	O
environmental	B-PHEN
stress	I-PHEN
,	O
socking	B-PHEN
,	O
and	O
transport	O
)	O
,	O
fillet	B-OBJC
yield	O
,	O
consumer	B-LIVB
acceptability	O
,	O
descriptive	O
evaluation	O
,	O
cook	O
loss	O
,	O
tenderness	O
,	O
and	O
pH	O
were	O
evaluated	O
.	O

Fillet	B-OBJC
yield	O
decreased	O
with	O
increasing	O
severity	O
of	O
environmental	B-PHEN
stress	I-PHEN
.	O

Fillets	B-OBJC
from	O
the	O
severe	O
stress	B-PROC
treatment	I-PROC
(	O
33	O
°	O
C	O
,	O
approximately	O
2	O
.	O
5	O
mg	O
/	O
L	O
)	O
received	O
the	O
highest	O
acceptability	O
scores	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Control	B-LIVB
fillets	B-OBJC
(	O
25	O
°	O
C	O
,	O
>	O
5	O
mg	O
/	O
L	O
)	O
were	O
the	O
least	B-DISO
acceptable	I-DISO
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	O
intensity	O
of	O
less	O
favorable	O
flavor	O
attributes	O
commonly	O
associated	O
with	O
catfish	B-LIVB
resulted	O
in	O
the	O
differences	O
in	O
acceptability	O
among	O
treatments	O
.	O

As	O
fish	O
progressed	O
through	O
the	O
harvest	B-PHEN
event	O
,	O
cook	O
loss	O
decreased	O
,	O
tenderness	O
increased	O
,	O
and	O
pH	O
increased	O
,	O
indicating	O
that	O
stress	B-PHEN
induced	O
textural	O
changes	O
.	O

The	O
data	O
suggest	O
that	O
although	O
environmental	B-PHEN
stress	I-PHEN
results	O
in	O
slight	O
changes	O
in	O
flavor	O
attributes	O
,	O
its	O
effects	O
on	O
acceptability	O
are	O
minor	O
with	O
fillets	B-OBJC
from	O
all	O
treatments	O
still	O
liked	O
(	O
>	O
6	O
on	O
a	O
9	O
point	O
scale	O
)	O
.	O

Socking	B-PHEN
and	O
transport	O
were	O
identified	O
to	O
positively	B-DISO
affect	O
textural	O
characteristics	O
of	O
catfish	B-LIVB
fillets	B-OBJC
.	O

Although	O
the	O
effects	O
observed	O
were	O
not	O
likely	O
to	O
negatively	B-DISO
impact	O
consumer	B-LIVB
acceptance	O
,	O
a	O
strict	O
management	O
plan	O
should	O
be	O
followed	O
to	O
maintain	O
consistency	O
in	O
the	O
product	O
and	O
avoid	O
changes	O
in	O
stressors	O
that	O
might	O
alter	O
quality	O
more	O
drastically	O
.	O

Proteomic	O
analysis	B-PROC
of	O
docetaxel	B-CHEM
resistance	B-PHEN
in	O
human	B-LIVB
nasopharyngeal	B-DISO
carcinoma	I-DISO
cells	B-ANAT
using	O
the	O
two	B-PROC
-	I-PROC
dimensional	I-PROC
gel	I-PROC
electrophoresis	I-PROC
method	I-PROC
Docetaxel	B-CHEM
-based	O
chemotherapy	B-PROC
has	O
been	O
recommended	O
for	O
advanced	O
nasopharyngeal	B-DISO
carcinoma	I-DISO
(	O
NPC	B-DISO
)	O
.	O

However	O
,	O
treatment	B-DISO
failure	I-DISO
often	O
occurs	O
because	O
of	O
acquired	O
drug	B-PHEN
resistance	I-PHEN
.	O

In	O
this	O
study	B-PROC
,	O
a	O
docetaxel	B-CHEM
-	O
resistant	B-PHEN
NPC	B-DISO
cell	B-ANAT
line	I-ANAT
CNE	I-ANAT
-	I-ANAT
2R	I-ANAT
was	O
established	O
with	O
increasing	O
doses	O
of	O
docetaxel	B-CHEM
for	O
more	O
than	O
6	O
months	O
.	O

Two	B-PROC
-	I-PROC
dimensional	I-PROC
gel	I-PROC
electrophoresis	I-PROC
and	O
ESI	B-PROC
-	I-PROC
Q	I-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
were	O
used	O
to	O
compare	O
the	O
differential	O
expression	B-PHYS
of	O
docetaxel	B-CHEM
-	O
resistance	B-PHEN
-	O
associated	B-CHEM
proteins	I-CHEM
between	O
human	B-LIVB
NPC	B-DISO
CNE	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
and	O
docetaxel	B-CHEM
-	O
resistant	B-PHEN
CNE	B-ANAT
-	I-ANAT
2R	I-ANAT
cells	I-ANAT
.	O

As	O
a	O
result	B-DISO
,	O
24	O
differentially	O
expressed	B-PHYS
proteins	I-PHYS
were	O
identified	O
,	O
including	O
11	O
proteins	B-CHEM
with	O
increased	O
expression	B-PHYS
and	O
13	O
proteins	B-CHEM
with	O
decreased	O
expression	B-PHYS
.	O

These	O
proteins	B-PHYS
function	I-PHYS
in	O
diverse	O
biological	B-PHEN
processes	I-PHEN
such	O
as	O
metabolism	O
,	O
signal	B-PHYS
transduction	I-PHYS
,	O
calcium	B-PHYS
ion	I-PHYS
binding	I-PHYS
,	O
immune	B-PHYS
response	I-PHYS
,	O
proteolysis	B-PHYS
,	O
and	O
so	O
on	O
.	O

Among	O
these	O
,	O
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
(	O
ENO1	B-CHEM
)	O
,	O
significantly	O
upregulated	O
in	O
CNE	B-ANAT
-	I-ANAT
2R	I-ANAT
,	O
was	O
selected	O
for	O
detailed	O
analysis	B-PROC
.	O

Inhibition	O
of	O
ENO1	B-CHEM
by	O
shRNA	B-CHEM
restored	O
CNE	B-ANAT
-	I-ANAT
2R	I-ANAT
cells	I-ANAT
'	O
sensitivity	O
to	O
docetaxel	B-CHEM
.	O

Moreover	O
,	O
overexpression	B-PHYS
of	O
ENO1	B-CHEM
could	O
facilitate	O
the	O
development	O
of	O
acquired	O
resistance	B-PHEN
of	O
docetaxel	B-CHEM
in	O
CNE	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
.	O

Western	B-PROC
blot	I-PROC
and	O
reverse	B-PROC
-	I-PROC
transcription	I-PROC
PCR	I-PROC
data	O
of	O
clinical	O
samples	O
confirmed	O
that	O
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
was	O
upregulated	O
in	O
docetaxel	B-CHEM
-	O
resistant	B-PHEN
human	B-LIVB
NPC	B-DISO
tissues	O
.	O

Finding	B-DISO
such	O
proteins	B-CHEM
might	O
improve	B-DISO
interpretation	O
of	O
the	O
molecular	B-PHYS
mechanisms	I-PHYS
leading	O
to	O
the	O
acquisition	O
of	O
docetaxel	B-CHEM
chemoresistance	B-PHEN
.	O

A	O
holistic	O
approach	O
to	O
age	B-PHYS
estimation	B-PHYS
in	O
refugee	B-LIVB
children	B-LIVB
Many	O
refugee	B-LIVB
children	B-LIVB
arriving	O
in	O
Australia	B-GEOG
have	O
an	O
inaccurately	O
documented	B-PROC
date	O
of	O
birth	O
(	O
DOB	O
)	O
.	O

A	O
medical	B-PROC
assessment	I-PROC
of	O
a	O
child	B-PHYS
's	I-PHYS
age	I-PHYS
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	O
that	O
their	O
documented	B-PROC
DOB	O
is	O
incorrect	O
.	O

This	O
study	O
's	O
aim	O
was	O
to	O
assess	B-PROC
the	O
accuracy	O
a	O
holistic	O
age	O
assessment	O
tool	O
(	O
AAT	O
)	O
in	O
estimating	B-PHYS
the	O
age	B-PHYS
of	O
refugee	B-LIVB
children	B-LIVB
newly	O
settled	O
in	O
Australia	B-GEOG
.	O

A	O
holistic	O
AAT	O
that	O
combines	O
medical	O
and	O
non	O
-	O
medical	O
approaches	O
was	O
used	O
to	O
estimate	B-PHYS
the	O
ages	B-PHYS
of	O
60	O
refugee	B-LIVB
children	B-LIVB
with	O
a	O
known	O
DOB	O
.	O

The	O
tool	O
used	O
four	O
components	O
to	O
assess	B-PROC
age	B-PHYS
:	O
an	O
oral	O
narrative	O
,	O
developmental	O
assessment	B-PROC
,	O
anthropometric	O
measures	O
and	O
pubertal	B-DISO
assessment	B-PROC
.	O

Assessors	B-LIVB
were	O
blinded	B-PROC
to	O
the	O
true	O
age	B-PHYS
of	O
the	O
child	B-LIVB
.	O

Correlation	O
coefficients	O
for	O
the	O
actual	O
and	O
estimated	B-PHYS
age	B-PHYS
were	O
calculated	O
for	O
the	O
tool	O
overall	O
and	O
individual	O
components	O
.	O

The	O
correlation	O
coefficient	O
between	O
the	O
actual	O
and	O
estimated	B-PHYS
age	B-PHYS
from	O
the	O
AAT	O
was	O
very	O
strong	O
at	O
0	O
.	O

9802	O
(	O
boys	B-LIVB
0	O
.	O
9748	O
,	O
girls	B-LIVB
0	O
.	O
9876	O
)	O
.	O

The	O
oral	O
narrative	O
component	O
of	O
the	O
tool	O
performed	O
best	O
(	O
R	O
=	O
0	O
.	O
9603	O
)	O
.	O

Overall	O
,	O
86	O
.	O
7	O
%	O
of	O
age	B-PHYS
estimates	B-PHYS
were	O
within	O
1	O
year	O
of	O
the	O
true	O
age	B-PHYS
.	O

The	O
range	O
of	O
differences	O
was	O
-1	O
.	O

43	O
to	O
3	O
.	O

92	O
years	O
with	O
a	O
standard	O
deviation	O
of	O
0	O
.	O

77	O
years	O
(	O
9	O
.	O

24	O
months	O
)	O
.	O

The	O
AAT	O
is	O
a	O
holistic	O
,	O
simple	O
and	O
safe	O
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	B-PHYS
age	B-PHYS
in	O
refugee	B-LIVB
children	B-LIVB
with	O
results	O
comparable	O
with	O
radiological	O
methods	O
currently	O
used	O
.	O

Genomic	B-PROC
analysis	I-PROC
of	O
nontypeable	B-LIVB
pneumococci	I-LIVB
causing	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O
South	B-GEOG
Africa	I-GEOG
,	O
2003	O
-	O
2013	O
The	O
capsular	B-CHEM
polysaccharide	I-CHEM
is	O
the	O
principal	O
virulence	B-CHEM
factor	I-CHEM
of	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
and	O
a	O
target	O
for	O
current	O
pneumococcal	B-CHEM
vaccines	I-CHEM
.	O

However	O
,	O
some	O
pathogenic	B-DISO
pneumococci	B-LIVB
are	O
serologically	O
nontypeable	O
[	O
nontypeable	B-LIVB
pneumococci	I-LIVB
(	O
NTPn	B-LIVB
)	O
]	O
.	O

Due	O
to	O
their	O
relative	O
rarity	O
,	O
NTPn	B-LIVB
are	O
poorly	O
characterized	O
,	O
and	O
,	O
as	O
such	O
,	O
limited	O
data	O
exist	O
which	O
describe	O
these	O
organisms	B-LIVB
.	O

We	O
aimed	O
to	O
describe	O
disease	B-DISO
and	O
genotypically	B-PHYS
characterize	O
NTPn	B-LIVB
causing	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O
South	B-GEOG
Africa	I-GEOG
.	O

Isolates	B-CHEM
were	O
detected	O
through	O
national	O
,	O
laboratory	B-OBJC
-	O
based	O
surveillance	O
for	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O
South	B-GEOG
Africa	I-GEOG
and	O
characterized	O
by	O
whole	O
genome	B-PROC
analysis	I-PROC
.	O

We	O
predicted	O
ancestral	O
serotypes	O
(	O
serotypes	O
from	O
which	O
NTPn	B-LIVB
may	O
have	O
originated	O
)	O
for	O
Group	O
I	O
NTPn	B-LIVB
using	O
multilocus	B-PROC
sequence	I-PROC
typing	I-PROC
and	O
capsular	O
region	O
sequence	B-PROC
analyses	I-PROC
.	O

Antimicrobial	B-PHYS
resistance	I-PHYS
patterns	O
and	O
mutations	B-PHYS
potentially	O
causing	O
nontypeability	O
were	O
identified	O
.	O

From	O
2003	O
-	O
2013	O
,	O
39	O
(	O
0	O
.	O
1	O
%	O
,	O
39	O
/	O
32	O
,	O
824	O
)	O
NTPn	B-LIVB
were	O
reported	O
.	O

Twenty	O
-	O
two	O
(	O
56	O
%	O
)	O
had	O
partial	O
capsular	O
genes	O
(	O
Group	O
I	O
)	O
and	O
17	O
(	O
44	O
%	O
)	O
had	O
complete	O
capsular	B-PHYS
deletion	I-PHYS
of	O
which	O
15	O
had	O
replacement	O
by	O
other	O
genes	O
(	O
Group	O
II	O
)	O
.	O

Seventy	O
-	O
nine	O
percent	O
(	O
31	O
/	O
39	O
)	O
of	O
our	O
NTPn	B-LIVB
isolates	B-CHEM
were	O
derived	O
from	O
encapsulated	O
S	B-LIVB
.	I-LIVB

pneumoniae	I-LIVB
.	O

Ancestral	O
serotypes	O
1	O
(	O
27	O
%	O
,	O
6	O
/	O
22	O
)	O
and	O
8	O
(	O
14	O
%	O
,	O
3	O
/	O
22	O
)	O
were	O
most	O
prevalent	O
,	O
and	O
59	O
%	O
(	O
13	O
/	O
22	O
)	O
of	O
ancestral	O
serotypes	O
were	O
serotypes	O
included	O
in	O
the	O
13	B-CHEM
-	I-CHEM
valent	I-CHEM
pneumococcal	I-CHEM
conjugate	I-CHEM
vaccine	I-CHEM
.	O

We	O
identified	O
a	O
variety	O
of	O
mutations	B-PHYS
within	O
the	O
capsular	O
region	O
of	O
Group	O
I	O
NTPn	B-LIVB
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	O
phenotype	B-PHYS
.	O

Nonsusceptibility	B-PHEN
to	O
tetracycline	B-CHEM
and	O
erythromycin	B-CHEM
was	O
higher	O
in	O
NTPn	B-LIVB
than	O
encapsulated	O
S	B-LIVB
.	I-LIVB

pneumoniae	I-LIVB
.	O

NTPn	B-LIVB
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O
South	B-GEOG
Africa	I-GEOG
and	O
represent	O
a	O
genetically	O
diverse	O
collection	O
of	O
isolates	O
.	O

CAGEd	O
-	O
oPOSSUM	O
:	O
motif	B-PROC
enrichment	I-PROC
analysis	I-PROC
from	O
CAGE	O
-derived	O
TSSs	B-CHEM
With	O
the	O
emergence	O
of	O
large	O
-	O
scale	O
Cap	O
Analysis	O
of	O
Gene	O
Expression	O
(	O
CAGE	O
)	O
datasets	O
from	O
individual	B-OBJC
labs	I-OBJC
and	O
the	O
FANTOM	O
consortium	O
,	O
one	O
can	O
now	O
analyze	O
the	O
cis	B-CHEM
-	I-CHEM
regulatory	I-CHEM
regions	I-CHEM
associated	O
with	O
gene	B-PHYS
transcription	I-PHYS
at	O
an	O
unprecedented	O
level	O
of	O
refinement	O
.	O

By	O
coupling	O
transcription	B-PHYS
factor	I-PHYS
binding	I-PHYS
site	I-PHYS
(	O
TFBS	B-PHYS
)	O
enrichment	B-PROC
analysis	I-PROC
with	O
CAGE	O
-derived	O
genomic	O
regions	O
,	O
CAGEd	O
-	O
oPOSSUM	O
can	O
identify	O
TFs	B-CHEM
that	O
act	O
as	O
key	O
regulators	O
of	O
genes	O
involved	O
in	O
specific	O
mammalian	B-ANAT
cell	I-ANAT
and	O
tissue	O
types	O
.	O

The	O
webtool	O
allows	O
for	O
the	O
analysis	B-PROC
of	O
CAGE	O
-derived	O
transcription	B-CHEM
start	I-CHEM
sites	I-CHEM
(	O
TSSs	B-CHEM
)	O
either	O
provided	O
by	O
the	O
user	B-LIVB
or	O
selected	O
from	O
∼1300	O
mammalian	B-LIVB
samples	B-OBJC
from	O
the	O
FANTOM5	O
project	O
with	O
pre	O
-	O
computed	O
TFBS	B-PHYS
predicted	O
with	O
JASPAR	O
TF	O
binding	O
profiles	O
.	O

The	O
tool	O
helps	O
power	O
insights	B-PHYS
into	O
the	O
regulation	B-PHYS
of	I-PHYS
genes	I-PHYS
through	O
the	O
study	B-PROC
of	O
the	O
specific	O
usage	O
of	O
TSSs	B-CHEM
within	O
specific	O
cell	O
types	O
and	O
/	O
or	O
under	O
specific	O
conditions	O
.	O

The	O
CAGEd	O
-	O
oPOSUM	O
web	O
tool	O
is	O
implemented	O
in	O
Perl	O
,	O
MySQL	O
and	O
Apache	O
and	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
cagedop	O
.	O

cmmt	O
.	O

ubc	O
.	O
ca	O
/	O
CAGEd	O
_	O
oPOSSUM	O
CONTACTS	O
:	O
anthony	O
.	O

mathelier	O
@	O
ncmm	O
.	O

uio	O
.	O
no	O
or	O
wyeth	O
@	O
cmmt	O
.	O

ubc	O
.	O
ca	O
Supplementary	O
information	O
:	O
Supplementary	O
data	O
are	O
available	O
at	O
Bioinformatics	O
online	B-OBJC
.	O

Pre	B-DISO
-	I-DISO
hypertension	I-DISO
,	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
or	O
both	O
:	O
which	O
is	O
best	O
at	O
predicting	O
cardiovascular	B-DISO
events	I-DISO
in	O
the	O
long	O
term	O
?	O

The	O
present	O
study	B-PROC
aimed	O
to	O
assess	O
the	O
value	O
of	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
and	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
in	O
predicting	O
cardiovascular	B-DISO
events	I-DISO
.	O

A	O
population	O
-based	O
,	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
survey	I-PROC
was	O
conducted	O
,	O
representing	O
a	O
large	O
sample	O
of	O
the	O
general	O
Iranian	B-LIVB
population	B-LIVB
aged	O
35	O
years	O
and	O
older	O
from	O
the	O
Isfahan	B-GEOG
Province	I-GEOG
and	O
determined	O
using	O
a	O
random	B-PROC
,	I-PROC
multistage	I-PROC
cluster	I-PROC
-	I-PROC
sampling	I-PROC
10	O
-	O
year	O
cohort	B-LIVB
.	O

The	O
five	O
end	O
points	O
considered	O
as	O
study	O
outcome	O
were	O
unstable	B-DISO
angina	I-DISO
(	O
UA	B-DISO
)	O
,	O
acute	O
occurrence	O
of	O
myocardial	B-DISO
infarction	I-DISO
(	O
MI	B-DISO
)	O
,	O
sudden	B-DISO
cardiac	I-DISO
death	I-DISO
(	O
SCD	B-DISO
)	O
,	O
brain	B-DISO
stroke	I-DISO
and	O
cardiovascular	B-DISO
disease	I-DISO
(	O
CVD	B-DISO
)	O
.	O

Of	O
the	O
6323	O
subjects	O
scheduled	O
for	O
assessment	B-PROC
of	O
diabetes	B-DISO
state	I-DISO
617	O
were	O
diabetics	B-DISO
and	O
712	O
were	O
pre	B-DISO
-	I-DISO
diabetic	I-DISO
.	O

In	O
addition	O
,	O
of	O
these	O
subjects	O
,	O
1754	O
had	O
hypertension	B-DISO
and	O
2500	O
had	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
.	O

Analysing	O
only	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
,	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
and	O
its	O
combination	O
and	O
adjusted	O
for	O
gender	B-PHYS
and	O
age	O
variables	O
,	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
and	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
status	O
together	O
,	O
could	O
only	O
effectively	O
predict	O
occurrence	O
of	O
MI	B-DISO
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
3	O
.	O
21	O
,	O

95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1	O
.	O
06	O
-	O
9	O
.	O
76	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

In	O
the	O
same	O
COX	O
regression	O
models	O
,	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
status	O
could	O
predict	O
UA	B-DISO
and	O
CVD	B-DISO
occurrence	O
(	O
HR	O
=	O
2	O
.	O
94	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
68	O
-	O
5	O
.	O
14	O
,	O
P	O
<	O
0	O
.	O
001	O
and	O
HR	O
=	O
1	O
.	O
74	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
23	O
-	O
2	O
.	O
47	O
,	O
P	O
=	O
0	O
.	O
002	O
,	O
respectively	O
)	O
.	O

However	O
,	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
status	O
could	O
not	O
predict	O
any	O
of	O
these	O
events	O
after	O
adjustment	O
for	O
gender	B-PHYS
and	O
age	B-PHYS
.	O

Our	O
data	O
provide	O
valuable	O
evidence	O
of	O
the	O
triggering	O
role	O
of	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
and	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
together	O
,	O
on	O
appearance	O
and	O
progression	B-DISO
of	O
MI	B-DISO
even	O
in	O
healthy	B-LIVB
individuals	I-LIVB
and	O
the	O
significant	O
predicting	O
value	O
of	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
on	O
the	O
occurrence	O
of	O
UA	B-DISO
and	O
CVD	B-DISO
.	O

In	O
this	O
regard	O
,	O
the	O
value	O
of	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
and	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
together	O
,	O
and	O
the	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
state	O
alone	O
,	O
are	O
clearly	O
superior	O
to	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
state	O
alone	O
in	O
predicting	O
cardiovascular	B-DISO
events	I-DISO
.	O

Self	B-PHYS
-	I-PHYS
assembled	I-PHYS
polymeric	B-CHEM
vectors	B-DEVI
mixtures	B-OBJC
:	O
characterization	O
of	O
the	O
polymorphism	O
and	O
existence	O
of	O
synergistic	O
effects	O
in	O
photodynamic	B-PROC
therapy	I-PROC
The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	O
of	O
polymeric	B-CHEM
self	B-PHYS
-	I-PHYS
assemblies	I-PHYS
vectors	B-DEVI
solution	B-OBJC
and	O
their	O
photodynamic	B-PROC
therapeutic	I-PROC
efficiency	O
.	O

For	O
this	O
,	O
several	O
amphiphilic	B-CHEM
block	B-CHEM
copolymers	I-CHEM
of	O
poly	B-CHEM
(	I-CHEM
ethyleneoxide	I-CHEM
-	I-CHEM
b	I-CHEM
-	I-CHEM
ε	I-CHEM
-	I-CHEM
caprolactone	I-CHEM
)	I-CHEM
have	O
been	O
used	O
to	O
form	O
self	B-PHYS
-	I-PHYS
assemblies	I-PHYS
with	O
different	O
morphologies	O
(	O
micelles	B-CHEM
,	O
worm	B-CHEM
-	I-CHEM
like	I-CHEM
micelles	I-CHEM
or	O
vesicles	O
)	O
.	O

In	O
a	O
first	O
step	O
,	O
controlled	B-OBJC
mixtures	I-OBJC
of	O
preformed	O
micelles	B-CHEM
and	O
vesicles	O
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-PROC
light	I-PROC
scattering	I-PROC
and	O
asymmetrical	B-PROC
flow	I-PROC
field	I-PROC
flow	I-PROC
fractionation	I-PROC
(	O
AsFlFFF	B-PROC
)	O
.	O

For	O
this	O
,	O
a	O
custom	O
-	O
made	O
program	B-OBJC
,	O
STORMS	B-OBJC
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-PROC
data	O
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	O
.	O

This	O
showed	O
that	O
DLS	B-PROC
only	O
sensed	O
the	O
larger	O
vesicles	O
when	O
the	O
micelles	B-CHEM
/	O
vesicles	O
ratio	O
was	O
80	O
/	O
20	O
w	O
/	O
w	O
.	O

On	O
the	O
other	O
hand	O
,	O
AsFlFFF	B-PROC
allowed	O
clear	O
detection	B-DISO
of	O
the	O
presence	O
of	O
micelles	B-CHEM
when	O
this	O
same	O
ratio	O
was	O
as	O
low	O
as	O
10	O
/	O
90	O
.	O

Subsequently	O
,	O
the	O
photodynamic	B-PROC
therapy	I-PROC
efficiency	O
of	O
various	O
controlled	B-OBJC
mixtures	I-OBJC
was	O
assessed	O
using	O
multicellular	O
spheroids	B-DISO
when	O
a	O
photosensitizer	B-CHEM
,	O
pheophorbide	B-CHEM
a	I-CHEM
,	O
was	O
encapsulated	O
in	O
the	O
polymer	B-CHEM
self	B-PHYS
-	I-PHYS
assemblies	I-PHYS
.	O

Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	O
as	O
monomorphous	B-DISO
systems	I-DISO
.	O

In	O
some	O
cases	O
,	O
mixtures	B-OBJC
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	B-PROC
efficiency	O
compared	O
to	O
the	O
individual	O
nano	O
-	O
objects	B-OBJC
,	O
revealing	O
a	O
synergistic	O
effect	O
for	O
the	O
efficient	O
delivery	B-PHEN
of	O
the	O
photosensitizer	B-CHEM
.	O

Polymorphous	O
vectors	B-DEVI
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	O
applications	O
.	O

Fuzheng	B-CHEM
Qingjie	I-CHEM
Granules	I-CHEM
Inhibit	O
Growth	B-PHYS
of	O
Hepatoma	B-ANAT
Cells	I-ANAT
via	O
Inducing	O
Mitochondria	B-ANAT
-Mediated	O
Apoptosis	B-PHYS
and	O
Enhancing	O
Immune	B-PHYS
Function	I-PHYS
Fuzheng	B-CHEM
Qingjie	I-CHEM
(	B-CHEM
FZQJ	I-CHEM
)	I-CHEM
granules	I-CHEM
,	O
a	O
compound	B-CHEM
Chinese	O
medicine	O
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant	B-PROC
therapy	I-PROC
for	O
alimentary	B-ANAT
tract	I-ANAT
cancers	B-DISO
.	O

However	O
,	O
the	O
underlying	O
anticancer	B-DISO
mechanisms	O
are	O
still	O
not	O
well	O
understood	O
.	O

In	O
the	O
present	O
study	B-PROC
,	O
HepG2	B-ANAT
cells	I-ANAT
were	O
treated	O
with	O
FZQJ	B-CHEM
-	O
containing	O
serum	B-ANAT
.	O

Cell	B-PHYS
proliferation	I-PHYS
was	O
evaluated	B-PROC
using	O
MTT	B-PROC
assay	I-PROC
.	O

Apoptosis	B-PHYS
was	O
analyzed	B-PROC
using	O
a	O
flow	B-DEVI
cytometer	I-DEVI
.	O

Cell	B-ANAT
ultrastructure	I-ANAT
was	O
observed	O
under	O
a	O
transmission	B-DEVI
electron	I-DEVI
microscope	I-DEVI
.	O

The	O
mitochondrial	B-PHYS
membrane	I-PHYS
potential	I-PHYS
(	O
Δψ	B-PHYS
)	O
was	O
examined	B-DISO
with	O
JC	B-CHEM
-	I-CHEM
1	I-CHEM
dye	I-CHEM
.	O

In	O
H22	B-DISO
tumor	I-DISO
-	I-DISO
bearing	I-DISO
mice	I-DISO
,	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
,	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
,	O
CD3	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
,	O
and	O
natural	B-ANAT
killer	I-ANAT
cells	I-ANAT
(	O
NK	B-ANAT
)	O
in	O
peripheral	B-ANAT
blood	I-ANAT
were	O
evaluated	O
cytometrically	B-DEVI
.	O

Interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
2	I-CHEM
and	O
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	B-CHEM
TNF	I-CHEM
)	I-CHEM
-	I-CHEM
α	I-CHEM
levels	O
were	O
measured	O
using	O
radioimmunoassay	B-PROC
.The	O

mRNA	B-CHEM
levels	O
of	O
Bax	O
and	O
Bcl	O
-	O
2	O
were	O
examined	B-DISO
by	O
reverse	B-PROC
transcription	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
.	O

The	O
protein	B-CHEM
levels	O
of	O
Bax	B-CHEM
,	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
cytochrome	B-CHEM
C	I-CHEM
,	O
caspase	B-CHEM
3	I-CHEM
and	O
9	B-CHEM
,	O
PARP	B-CHEM
,	O
and	O
CD69	B-CHEM
were	O
examined	B-DISO
by	O
Western	B-PROC
blotting	I-PROC
.	O

The	O
apoptotic	O
cells	B-ANAT
in	O
tissues	O
were	O
observed	O
using	O
TUNEL	B-PROC
method	I-PROC
.	O

Alanine	B-CHEM
transaminase	I-CHEM
(	O
ALT	B-CHEM
)	O
,	O
aspartate	B-CHEM
transaminase	I-CHEM
(	O
AST	B-CHEM
)	O
,	O
blood	B-CHEM
urea	I-CHEM
nitrogen	I-CHEM
(	O
BUN	B-CHEM
)	O
,	O
and	O
creatinine	B-CHEM
(	O
CRE	B-CHEM
)	O
were	O
detected	B-DISO
by	O
an	O
automatic	O
biochemical	O
analyzer	B-DEVI
.	O

The	O
results	O
showed	O
that	O
FZQJ	B-CHEM
-	O
containing	O
serum	B-ANAT
remarkably	O
inhibited	O
proliferation	B-PHYS
of	O
HepG2	B-ANAT
cells	I-ANAT
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manners	O
,	O
induced	O
HepG2	B-ANAT
cell	I-ANAT
apoptosis	B-PHYS
and	O
caused	O
a	O
decrease	O
of	O
Δψ	B-PHYS
.	O

Analysis	B-PROC
of	O
tumor	O
tissue	O
showed	O
that	O
FZQJ	B-CHEM
-	O
induced	O
apoptosis	B-PHYS
was	O
accompanied	O
by	O
downregulation	B-PHYS
of	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
upregulation	B-PHYS
of	O
Bax	B-CHEM
,	O
release	O
of	O
cytochrome	B-CHEM
c	I-CHEM
,	O
activation	B-PHYS
of	O
caspase	B-CHEM
3	I-CHEM
and	O
9	B-CHEM
,	O
and	O
cleavage	B-PHYS
of	O
PARP	B-CHEM
.	O

In	O
addition	O
,	O
FZQJ	B-CHEM
increased	O
the	O
percentages	O
of	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
and	O
NK	B-ANAT
cells	I-ANAT
,	O
the	O
ratio	O
of	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
/	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
as	O
well	O
as	O
the	O
levels	O
of	O
serum	B-ANAT
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
.	O

FZQJ	B-CHEM
also	O
increased	O
CD69	B-CHEM
expression	B-PHYS
in	O
tumor	O
tissue	O
.	O

No	B-DISO
hepatorenal	I-DISO
toxicity	I-DISO
was	O
observed	O
in	O
H22	B-DISO
tumor	I-DISO
-	I-DISO
bearing	I-DISO
mice	I-DISO
.	O

These	O
results	O
indicated	B-DISO
that	O
FZQJ	B-CHEM
could	O
inhibit	O
the	O
growth	B-PHYS
of	O
hepatoma	B-ANAT
cells	I-ANAT
via	O
regulating	O
immune	B-PHYS
function	I-PHYS
and	O
inducing	O
mitochondria	B-ANAT
mediated	O
apoptosis	B-PHYS
.	O

A	O
simple	O
and	O
biosafe	O
method	O
for	O
isolation	O
of	O
human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
Human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
(	O
HUVECS	B-ANAT
)	O
are	O
used	O
as	O
an	O
irreplaceable	O
tool	O
for	O
the	O
study	B-PROC
of	O
vascular	B-DISO
diseases	I-DISO
.	O

However	O
,	O
the	O
technicians	O
who	O
isolate	B-PROC
HUVECs	B-ANAT
are	O
largely	O
exposed	O
to	O
potential	O
infectious	O
threats	O
.	O

Here	O
we	O
report	B-PROC
the	O
development	O
of	O
a	O
specialized	O
instrument	O
to	O
protect	B-PROC
researchers	B-LIVB
from	O
known	O
or	O
unknown	O
infectious	B-LIVB
agents	I-LIVB
when	O
they	O
operate	O
on	O
human	B-LIVB
umbilical	B-ANAT
cords	I-ANAT
.	O

This	O
instrument	B-DEVI
can	O
be	O
assembled	B-PROC
by	O
common	O
laboratory	B-DEVI
supplies	I-DEVI
and	O
adapted	O
to	O
accommodate	O
umbilical	B-ANAT
cords	I-ANAT
of	O
different	O
lengths	O
.	O

When	O
the	O
cord	B-ANAT
is	O
enclosed	O
within	O
the	O
instrument	B-DEVI
,	O
the	O
risk	O
of	O
sample	B-OBJC
contamination	O
and	O
operator	B-LIVB
infection	B-DISO
is	O
greatly	O
reduced	O
.	O

Using	O
our	O
instrument	B-DEVI
,	O
endothelial	B-ANAT
cells	I-ANAT
were	O
successfully	O
isolated	O
from	O
human	B-LIVB
umbilical	B-ANAT
veins	I-ANAT
without	O
contamination	O
.	O

The	O
cells	B-ANAT
were	O
verified	O
by	O
their	O
cobblestone	O
-	O
like	O
morphology	O
and	O
by	O
immunofluorescence	B-PROC
staining	I-PROC
(	O
Factor	B-PROC
VIII	I-PROC
and	O
CD31	B-PHEN
positivity	I-PHEN
and	O
α	B-PHEN
-	I-PHEN
SMA	I-PHEN
negativity	I-PHEN
)	O
.	O

Our	O
instrument	B-DEVI
simplifies	O
and	O
optimizes	O
the	O
cell	B-ANAT
extraction	B-PROC
process	I-PROC
,	O
and	O
most	O
importantly	O
elevates	O
the	O
biosafety	O
to	O
a	O
higher	O
level	O
during	O
the	O
isolation	B-PROC
of	O
human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
.	O

Iron	B-DISO
Deficiency	I-DISO
Is	O
Common	O
During	O
Remission	B-DISO
in	O
Children	B-LIVB
With	O
Inflammatory	B-DISO
Bowel	I-DISO
Disease	I-DISO
The	O
aim	O
was	O
to	O
study	B-PROC
prevalence	O
of	O
iron	B-DISO
deficiency	I-DISO
in	O
children	B-LIVB
with	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
(	O
IBD	B-DISO
)	O
during	O
remission	B-DISO
.	O

In	O
addition	O
,	O
there	O
was	O
an	O
observational	B-PROC
evaluation	B-PROC
of	O
hematological	B-PROC
response	B-PHYS
to	O
oral	O
iron	B-CHEM
.	O

A	O
population	B-PROC
-	I-PROC
based	I-PROC
retrospective	B-PROC
study	I-PROC
including	O
90	O
Swedish	B-LIVB
children	B-LIVB
(	O
median	O
13	O
years	O
)	O
with	O
IBD	B-DISO
was	O
performed	O
.	O

Patient	O
records	O
covered	O
in	O
median	O
25	O
months	O
.	O

Iron	B-DISO
deficiency	I-DISO
was	O
present	O
in	O
70	O
/	O
77	O
children	B-LIVB
(	O
91	O
%	O
)	O
in	O
which	O
iron	B-PROC
status	I-PROC
could	O
be	O
assessed	O
.	O

In	O
clinical	O
and	O
biochemical	O
remission	B-DISO
,	O
iron	B-DISO
deficiency	I-DISO
was	O
found	O
in	O
57	O
/	O
67	O
(	O
85	O
%	O
)	O
of	O
children	B-LIVB
,	O
and	O
23	O
(	O
34	O
%	O
)	O
of	O
them	O
had	O
iron	B-DISO
deficiency	I-DISO
anemia	I-DISO
.	O

Thirty	O
-	O
six	O
iron	B-DISO
-	I-DISO
deficient	I-DISO
children	B-LIVB
were	O
prescribed	B-PROC
oral	B-PROC
iron	B-PROC
supplementation	I-PROC
and	O
32	O
(	O
89	O
%	O
)	O
improved	O
hemoglobin	B-PHEN
levels	I-PHEN
over	O
6	O
months	O
.	O

In	O
conclusion	O
,	O
iron	B-DISO
deficiency	I-DISO
is	O
common	O
during	O
clinical	O
remission	B-DISO
in	O
children	B-LIVB
with	O
IBD	B-DISO
,	O
even	O
in	O
cohorts	B-LIVB
with	O
low	O
prevalence	O
of	O
anemia	B-DISO
.	O

Therefore	O
,	O
regular	O
biochemical	B-PROC
screening	I-PROC
for	O
iron	B-DISO
deficiency	I-DISO
is	O
warranted	O
during	O
all	O
stages	O
of	O
disease	B-DISO
,	O
irrespective	O
of	O
symptoms	B-DISO
and	O
inflammatory	O
blood	B-ANAT
markers	B-PHYS
.	O

Chemisorption	O
of	O
Perfluorooctanoic	B-CHEM
Acid	I-CHEM
on	O
Powdered	B-CHEM
Activated	I-CHEM
Carbon	I-CHEM
Initiated	O
by	O
Persulfate	B-CHEM
in	O
Aqueous	O
Solution	B-OBJC
Perfluorooctanoic	B-CHEM
acid	I-CHEM
(	O
PFOA	B-CHEM
)	O
is	O
a	O
perfluorocarboxylic	B-CHEM
acid	I-CHEM
that	O
is	O
difficult	O
to	O
treat	O
by	O
most	O
conventional	O
methods	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
often	O
removed	O
from	O
solution	B-OBJC
by	O
adsorption	B-PROC
on	O
powdered	B-CHEM
activated	I-CHEM
carbon	I-CHEM
(	O
PAC	B-CHEM
)	O
,	O
followed	O
by	O
incineration	B-PHEN
of	O
the	O
spent	O
carbon	B-CHEM
.	O

To	O
provide	O
a	O
new	O
approach	O
for	O
treatment	O
,	O
PFOA	B-CHEM
was	O
exposed	O
to	O
sulfate	B-CHEM
radicals	I-CHEM
(	O
SO4	B-CHEM
(	I-CHEM
-	I-CHEM
•	I-CHEM
)	I-CHEM
)	O
produced	O
by	O
thermolysis	B-PHEN
of	O
persulfate	B-CHEM
(	O
S2O8	B-CHEM
(	I-CHEM
2	I-CHEM
-	I-CHEM
)	I-CHEM
)	O
in	O
the	O
presence	O
of	O
PAC	B-CHEM
.	O

Under	O
acidic	O
conditions	O
,	O
thermal	B-PHEN
activation	O
of	O
persulfate	B-CHEM
resulted	O
in	O
transformation	O
of	O
PFOA	B-CHEM
to	O
shorter	O
-	O
chain	O
-	O
length	O
perfluorinated	B-CHEM
compounds	I-CHEM
,	O
as	O
previously	O
reported	O
.	O

However	O
,	O
when	O
thermolysis	B-PHEN
of	O
persulfate	B-CHEM
occurred	O
under	O
circumneutral	O
pH	O
conditions	O
in	O
the	O
presence	O
of	O
PAC	B-CHEM
,	O
a	O
new	O
removal	O
pathway	O
for	O
PFOA	B-CHEM
was	O
observed	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
removal	O
of	O
PFOA	B-CHEM
was	O
attributable	O
to	O
chemisorption	O
,	O
a	O
process	O
in	O
which	O
PAC	B-CHEM
catalyzed	B-PHEN
persulfate	B-CHEM
decomposition	O
and	O
reacted	O
with	O
the	O
transformation	O
products	O
to	O
produce	O
covalently	B-PHEN
bound	I-PHEN
PFOA	B-CHEM
.	O

At	O
PAC	B-CHEM
concentrations	O
between	O
200	O
and	O
1000	O
mg	O
/	O
L	O
and	O
an	O
initial	O
PFOA	B-CHEM
concentration	O
of	O
0	O
.	O

5	O
μM	O
,	O
covalent	B-PHEN
bonding	I-PHEN
resulted	O
in	O
removal	O
of	O
10	O
-	O
40	O
%	O
of	O
the	O
PFOA	B-CHEM
.	O

Under	O
these	O
conditions	O
,	O
the	O
process	O
resulted	O
in	O
removal	O
of	O
more	O
than	O
half	O
of	O
a	O
more	O
hydrophilic	O
perfluoroalkyl	B-CHEM
acid	I-CHEM
(	O
i	O
.	O
e	O
.	O
,	O
perfluorobutanoic	B-CHEM
acid	I-CHEM
,	O
PFBA	B-CHEM
)	O
,	O
which	O
was	O
greater	O
than	O
the	O
amount	O
of	O
PFBA	B-CHEM
removed	O
by	O
physical	O
adsorption	B-PROC
on	O
PAC	B-CHEM
.	O

Although	O
the	O
high	O
reaction	B-PHEN
temperatures	O
(	O
i	O
.	O
e	O
.	O
,	O
80	O
°	O
C	O
)	O
and	O
relatively	O
high	O
doses	O
of	O
PAC	B-CHEM
used	O
in	O
this	O
study	O
may	O
be	O
impractical	O
for	O
drinking	B-OBJC
water	I-OBJC
treatment	O
,	O
this	O
process	O
may	O
be	O
applied	O
to	O
the	O
treatment	O
of	O
these	O
recalcitrant	O
compounds	O
in	O
industrial	O
wastewater	B-PHEN
,	O
reverse	B-PHEN
osmosis	I-PHEN
concentrate	O
,	O
and	O
other	O
waters	B-CHEM
that	O
contain	O
high	O
concentrations	O
of	O
PFOA	B-CHEM
and	O
other	O
perfluorocarboxylic	B-CHEM
acids	I-CHEM
.	O

Professional	O
reinventions	O
:	O
Swedish	B-LIVB
psychologists	B-LIVB
,	O
1990	O
-	O
2010	O
Since	O
the	O
early	O
20th	O
century	O
,	O
the	O
Swedish	B-LIVB
psychology	O
profession	O
has	O
undergone	O
several	O
changes	O
in	O
its	O
essential	O
tasks	O
,	O
epistemological	O
foundations	O
,	O
and	O
social	O
roles	O
.	O

These	O
changes	O
occurred	O
through	O
an	O
ongoing	O
""""	O
tuning	O
""""	O
with	O
Swedish	B-LIVB
society	O
,	O
in	O
which	O
the	O
profession	O
strove	O
to	O
appear	O
relevant	O
to	O
society	O
's	O
concerns	O
and	O
problems	B-DISO
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession	O
's	O
goals	O
and	O
aims	O
.	O

Studying	O
the	O
history	O
of	O
the	O
profession	O
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	O
definitions	O
and	O
contours	O
of	O
the	O
psychology	O
profession	O
itself	O
as	O
well	O
as	O
on	O
the	O
organization	O
of	O
the	O
society	O
in	O
which	O
it	O
acts	O
.	O

This	O
article	O
examines	O
the	O
history	O
of	O
the	O
Swedish	B-LIVB
psychology	O
profession	O
from	O
1990	O
to	O
2010	O
,	O
through	O
an	O
analysis	B-PROC
of	O
the	O
discussions	O
and	O
debates	O
taking	O
place	O
in	O
the	O
Swedish	B-LIVB
Psychological	B-OBJC
Association	I-OBJC
's	I-OBJC
journal	I-OBJC
.	O

The	O
analytical	O
framework	O
used	O
draws	O
on	O
work	O
done	O
within	O
actor	O
-	O
network	O
theory	O
and	O
science	B-PROC
studies	I-PROC
.	O

We	O
argue	O
that	O
the	O
profession	O
's	O
institutional	O
connections	O
,	O
defining	O
tasks	O
,	O
epistemological	O
underpinnings	O
,	O
and	O
social	O
position	O
have	O
changed	O
in	O
major	O
ways	O
during	O
these	O
2	O
decades	O
.	O

Overall	O
,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	B-PHYS
,	O
the	O
profession	O
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	O
itself	O
to	O
politicians	B-LIVB
,	O
the	O
media	O
,	O
patients	B-LIVB
,	O
and	O
customers	O
through	O
means	O
such	O
as	O
a	O
more	O
economized	O
vocabulary	O
and	O
novel	O
forms	O
of	O
empirical	B-PROC
research	I-PROC
.	O

These	O
changes	O
have	O
led	O
to	O
a	O
more	O
socialized	O
profession	O
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	B-LIVB
in	O
Swedish	B-LIVB
society	O
,	O
leading	O
to	O
conflicts	O
within	O
the	O
profession	O
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	O
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss	B-DISO
of	I-DISO
autonomy	I-DISO
.	O

(	O
PsycINFO	O
Database	O
Record	O

Clinical	O
manifestations	O
,	O
course	O
,	O
and	O
outcome	O
of	O
patients	O
with	O
neutralizing	B-CHEM
anti	I-CHEM
-	I-CHEM
interferon	I-CHEM
-	I-CHEM
γ	I-CHEM
autoantibodies	I-CHEM
and	O
disseminated	O
nontuberculous	B-LIVB
mycobacterial	I-LIVB
infections	B-DISO
Neutralizing	B-CHEM
anti	I-CHEM
-	I-CHEM
interferon	I-CHEM
-	I-CHEM
γ	I-CHEM
autoantibody	I-CHEM
(	O
nAIGA	B-CHEM
)	O
-	O
associated	O
immunodeficiency	B-DISO
is	O
an	O
emerging	O
medical	B-PROC
issue	I-PROC
worldwide	O
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
describe	O
and	O
discuss	O
the	O
clinical	B-DISO
features	I-DISO
and	O
outcomes	B-DISO
of	O
patients	B-LIVB
with	O
nAIGAs	B-CHEM
and	O
disseminated	O
infections	B-DISO
by	O
nontuberculous	B-LIVB
mycobacteria	I-LIVB
(	O
dNTM	B-LIVB
)	O
.	O

We	O
thoroughly	O
reviewed	O
the	O
medical	B-PHYS
records	I-PHYS
of	O
all	O
patients	B-LIVB
.	O

Microorganisms	B-LIVB
and	O
nAIGAs	B-CHEM
were	O
identified	O
using	O
previously	O
described	O
methods	O
with	O
modifications	O
.	O

All	O
data	O
were	O
calculated	O
and	O
analyzed	B-PROC
using	O
SPSS	O
software	O
.Among	O
46	O
adult	O
patients	B-LIVB
with	O
dNTM	B-LIVB
infections	B-DISO
,	O
we	O
identified	O
45	O
cases	O
(	O
97	O
.	O
8	O
%	O
)	O
with	O
nAIGAs	B-CHEM
.	O

The	O
average	O
patient	B-LIVB
age	O
was	O
58	O
.	O

6	O
years	O
,	O
and	O
there	O
was	O
no	B-DISO
sex	B-PHYS
predominance	B-DISO
.	O

Cervical	B-DISO
lymphadenitis	I-DISO
(	O
81	O
.	O

8	O
%	O
)	O
was	O
the	O
most	O
common	O
clinical	O
manifestation	O
.	O

Endocrine	B-DISO
disorder	I-DISO
was	O
the	O
leading	O
comorbidity	O
(	O
7	O
cases	O
)	O
.	O

Malignancies	B-DISO
were	O
found	O
in	O
4	O
patients	B-LIVB
,	O
and	O
all	O
of	O
the	O
malignancies	B-DISO
originated	O
from	O
the	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
/	O
macrophage	B-ANAT
lineage	O
.	O

More	O
than	O
half	O
of	O
the	O
identifiable	O
isolates	B-CHEM
were	O
slow	B-DISO
-	I-DISO
growing	I-DISO
NTMs	B-LIVB
.	O

Twenty	O
-	O
eight	O
(	O
62	O
.	O
2	O
%	O
)	O
and	O
18	O
(	O
40	O
.	O
0	O
%	O
)	O
patients	B-LIVB
had	O
a	O
history	O
of	O
zoster	B-DISO
and	O
salmonellosis	B-DISO
,	O
respectively	O
.	O

A	O
high	O
proportion	O
of	O
patients	B-LIVB
with	O
recurrent	O
episodes	O
of	O
NTM	B-LIVB
infection	B-DISO
or	O
a	O
history	O
of	O
zoster	B-DISO
and	O
dNTM	B-LIVB
infection	B-DISO
had	O
initial	O
nAIGA	B-PROC
titers	I-PROC
≥10	O
dilution	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Twenty	O
-	O
seven	O
patients	B-LIVB
(	O
60	O
.	O

0	O
%	O
)	O
required	O
long	O
-	O
term	O
antimycobacterial	B-CHEM
therapy	B-PROC
and	O
had	O
at	O
least	O
1	O
episode	O
of	O
recurrent	O
NTM	B-LIVB
disease	B-DISO
.	O

No	O
mortality	O
was	O
related	O
to	O
dNTM	B-LIVB
infection	B-DISO
.In	O

Taiwan	B-GEOG
,	O
nAIGAs	B-CHEM
are	O
a	O
recently	O
recognized	O
mechanism	O
of	O
dNTM	B-LIVB
infection	B-DISO
.	O

Long	O
term	O
of	O
antibiotic	B-PROC
treatment	I-PROC
and	O
adherence	O
to	O
medical	B-DISO
advice	I-DISO
are	O
necessary	O
to	O
improve	O
the	O
clinical	O
outcome	O
of	O
patients	O
with	O
nAIGAs	B-CHEM
.	O

Strategies	B-PROC
for	O
Successful	O
Clinical	O
Teaching	B-PROC
This	O
article	O
is	O
one	O
in	O
a	O
series	O
on	O
the	O
roles	O
of	O
adjunct	B-LIVB
clinical	I-LIVB
faculty	I-LIVB
and	O
preceptors	B-LIVB
,	O
who	O
teach	B-PROC
nursing	B-LIVB
students	I-LIVB
and	O
new	O
graduates	B-LIVB
to	O
apply	O
knowledge	O
in	O
clinical	O
settings	O
.	O

This	O
article	O
describes	O
teaching	B-PROC
strategies	I-PROC
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
learning	O
environment	O
.	O

Personally	O
Meaningful	O
Rituals	O
:	O
A	O
Way	O
to	O
Increase	O
Compassion	O
and	O
Decrease	O
Burnout	B-DISO
among	O
Hospice	B-PROC
Staff	B-LIVB
and	O
Volunteers	B-LIVB
Rituals	O
can	O
increase	O
a	O
sense	O
of	O
connectedness	O
,	O
meaning	O
,	O
and	O
support	O
,	O
especially	O
after	O
the	O
death	B-PHYS
of	O
those	O
for	O
whom	O
we	O
care	O
.	O

Hospice	B-PROC
staff	B-LIVB
may	O
benefit	O
from	O
the	O
use	O
of	O
personal	O
rituals	O
as	O
they	O
cope	O
with	O
the	O
frequent	O
deaths	O
of	O
their	O
patients	B-LIVB
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate	O
care	O
while	O
minimizing	O
burnout	B-DISO
.	O

This	O
study	O
investigated	O
the	O
role	O
of	O
personally	O
meaningful	O
rituals	O
in	O
increasing	O
compassion	O
and	O
decreasing	O
burnout	B-DISO
among	O
hospice	B-PROC
staff	B-LIVB
and	O
volunteers	B-LIVB
.	O

An	O
online	O
survey	O
was	O
completed	O
by	O
members	O
of	O
the	O
National	B-OBJC
Hospice	I-OBJC
and	I-OBJC
Palliative	I-OBJC
Care	I-OBJC
Organization	I-OBJC
(	O
NHPCO	B-OBJC
)	O
which	O
inquired	O
about	O
personal	O
ritual	O
practices	O
,	O
and	O
included	O
the	O
Professional	O
Quality	O
of	O
Life	O
(	O
ProQOL	O
)	O
scale	O
to	O
measure	O
current	O
levels	O
of	O
Compassion	O
Satisfaction	B-PHYS
,	O
Burnout	B-DISO
,	O
and	O
Secondary	B-DISO
Traumatic	I-DISO
Stress	I-DISO
.	O

Three	O
hundred	O
ninety	O
hospice	B-PROC
staff	B-LIVB
and	O
volunteers	B-LIVB
from	O
across	O
38	O
states	B-GEOG
completed	O
the	O
online	O
survey	O
.	O

The	O
majority	O
of	O
participants	B-LIVB
were	O
Caucasian	B-LIVB
and	O
female	B-PHYS
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	B-OBJC
and	I-OBJC
palliative	I-OBJC
care	I-OBJC
.	O

The	O
majority	O
of	O
hospice	B-PROC
staff	B-LIVB
and	O
volunteers	B-LIVB
used	O
personally	O
meaningful	O
rituals	O
after	O
the	O
death	B-PHYS
of	O
their	O
patients	B-LIVB
to	O
help	O
them	O
cope	O
(	O
71	O
%	O
)	O
.	O

Those	O
who	O
used	O
rituals	O
demonstrated	O
significantly	O
higher	O
Compassion	O
Satisfaction	B-PHYS
and	O
significantly	O
lower	O
Burnout	B-DISO
as	O
measured	O
by	O
the	O
ProQOL	O
,	O
with	O
professional	B-DISO
support	I-DISO
,	O
social	O
support	O
,	O
and	O
age	B-PHYS
playing	O
significant	B-DISO
roles	I-DISO
as	O
well	O
.	O

Rituals	O
may	O
be	O
an	O
important	O
way	O
to	O
increase	O
compassion	O
and	O
decrease	O
burnout	B-DISO
among	O
hospice	B-PROC
staff	B-LIVB
and	O
volunteers	B-LIVB
.	O

Organizations	B-OBJC
may	O
benefit	O
from	O
providing	O
training	B-PROC
and	I-PROC
support	I-PROC
for	O
personalized	O
rituals	O
among	O
team	O
members	O
,	O
especially	O
new	B-LIVB
staff	I-LIVB
who	O
may	O
be	O
at	O
greater	O
risk	O
for	O
burnout	B-DISO
.	O

Learned	B-PHYS
helplessness	I-PHYS
at	O
fifty	O
:	O
Insights	B-PHYS
from	O
neuroscience	O
Learned	B-PHYS
helplessness	I-PHYS
,	O
the	O
failure	O
to	O
escape	B-PHYS
shock	B-DISO
induced	O
by	O
uncontrollable	O
aversive	O
events	O
,	O
was	O
discovered	O
half	O
a	O
century	O
ago	O
.	O

Seligman	B-LIVB
and	I-LIVB
Maier	I-LIVB
(	O
1967	O
)	O
theorized	O
that	O
animals	B-LIVB
learned	B-PHYS
that	O
outcomes	O
were	O
independent	O
of	O
their	O
responses	B-PHYS
-that	O
nothing	O
they	O
did	O
mattered	O
-	O
and	O
that	O
this	O
learning	B-PHYS
undermined	O
trying	O
to	O
escape	B-PHYS
.	O

The	O
mechanism	O
of	O
learned	B-PHYS
helplessness	I-PHYS
is	O
now	O
very	O
well	O
-	O
charted	O
biologically	O
,	O
and	O
the	O
original	O
theory	O
got	O
it	O
backward	O
.	O

Passivity	O
in	O
response	B-PHYS
to	O
shock	B-DISO
is	O
not	O
learned	B-PHYS
.	O

It	O
is	O
the	O
default	O
,	O
unlearned	O
response	B-PHYS
to	O
prolonged	O
aversive	O
events	O
and	O
it	O
is	O
mediated	O
by	O
the	O
serotonergic	B-PHYS
activity	I-PHYS
of	O
the	O
dorsal	B-ANAT
raphe	I-ANAT
nucleus	I-ANAT
,	O
which	O
in	O
turn	O
inhibits	O
escape	B-PHYS
.	O

This	O
passivity	O
can	O
be	O
overcome	O
by	O
learning	B-PHYS
control	O
,	O
with	O
the	O
activity	O
of	O
the	O
medial	B-ANAT
prefrontal	I-ANAT
cortex	I-ANAT
,	O
which	O
subserves	O
the	O
detection	B-DISO
of	O
control	O
leading	O
to	O
the	O
automatic	O
inhibition	O
of	O
the	O
dorsal	B-ANAT
raphe	I-ANAT
nucleus	I-ANAT
.	O

So	O
animals	B-LIVB
learn	B-PHYS
that	O
they	O
can	O
control	O
aversive	O
events	O
,	O
but	O
the	O
passive	O
failure	O
to	O
learn	B-PHYS
to	O
escape	B-PHYS
is	O
an	O
unlearned	O
reaction	O
to	O
prolonged	O
aversive	B-PROC
stimulation	I-PROC
.	O

In	O
addition	O
,	O
alterations	O
of	O
the	O
ventromedial	B-ANAT
prefrontal	I-ANAT
cortex	I-ANAT
-	O
dorsal	B-ANAT
raphe	I-ANAT
pathway	O
can	O
come	O
to	O
subserve	O
the	O
expectation	O
of	O
control	O
.	O

We	O
speculate	O
that	O
default	O
passivity	O
and	O
the	O
compensating	O
detection	B-DISO
and	O
expectation	O
of	O
control	O
may	O
have	O
substantial	O
implications	O
for	O
how	O
to	O
treat	O
depression	B-DISO
.	O

(	O
PsycINFO	O
Database	O
Record	O

STRANGULATION	O
-INDUCED	O
CENTRAL	B-DISO
RETINAL	I-DISO
ARTERY	I-DISO
OCCLUSION	I-DISO
:	O
CASE	O
REPORT	O
AND	O
REVIEW	O
OF	O
THE	O
LITERATURE	O
To	O
describe	O
a	O
patient	B-LIVB
with	O
central	B-DISO
retinal	I-DISO
artery	I-DISO
occlusion	I-DISO
following	O
an	O
episode	O
of	O
mechanical	O
strangulation	O
.	O

A	O
retrospective	B-PROC
case	O
report	O
.	O

An	O
83	O
-	O
year	B-LIVB
-	I-LIVB
old	I-LIVB
man	B-LIVB
presented	O
with	O
acute	B-DISO
vision	I-DISO
loss	I-DISO
in	O
his	O
right	B-ANAT
eye	I-ANAT
after	O
a	O
strangling	O
episode	O
.	O

Multimodal	B-PROC
clinical	I-PROC
imaging	I-PROC
was	O
performed	O
.	O

Visual	B-PHYS
acuity	I-PHYS
in	O
the	O
affected	O
right	B-ANAT
eye	I-ANAT
was	O
no	B-PHEN
light	I-PHEN
perception	I-PHEN
.	O

Examination	B-PROC
revealed	O
optic	B-DISO
nerve	I-DISO
edema	I-DISO
and	O
optic	B-DISO
nerve	I-DISO
pallor	I-DISO
and	O
also	O
severe	O
vascular	B-DISO
attenuation	I-DISO
and	O
a	O
cherry	B-DISO
-	I-DISO
red	I-DISO
spot	I-DISO
in	O
the	O
macula	B-ANAT
.	O

Mechanical	B-PROC
disruption	I-PROC
of	O
carotid	B-DISO
plaque	I-DISO
can	O
lead	O
to	O
occlusion	B-DISO
of	I-DISO
the	I-DISO
central	I-DISO
retinal	I-DISO
artery	I-DISO
,	O
which	O
may	O
portend	O
a	O
dismal	B-DISO
visual	O
prognosis	B-PHYS
.	O

Glomerulonephritis	B-DISO
With	O
Masked	O
Monotypic	B-DISO
Immunoglobulin	I-DISO
Deposits	I-DISO
and	O
Concurrent	O
Lymphomatous	B-DISO
Infiltration	I-DISO
Kidney	B-DISO
injury	I-DISO
can	O
be	O
a	O
complication	B-DISO
of	O
hematopoietic	B-DISO
neoplasia	I-DISO
by	O
both	O
direct	O
and	O
indirect	O
mechanisms	O
.	O

Virtually	O
all	O
lymphomas	B-DISO
and	O
plasma	B-DISO
cell	I-DISO
dyscrasias	I-DISO
can	O
show	O
kidney	B-ANAT
involvement	O
,	O
including	O
parenchymal	B-DISO
infiltration	I-DISO
and	O
by	O
secondary	O
injury	B-DISO
.	O

Recently	O
,	O
a	O
unique	O
form	O
of	O
glomerulonephritis	B-DISO
with	O
masked	O
monotypic	B-DISO
immunoglobulin	I-DISO
deposits	I-DISO
has	O
been	O
reported	O
,	O
which	O
shows	O
frequent	O
association	O
with	O
hematopoietic	B-DISO
neoplasia	I-DISO
and	O
a	O
propensity	O
for	O
progressive	O
kidney	B-DISO
disease	I-DISO
.	O

In	O
many	O
instances	O
,	O
these	O
cases	O
are	O
likely	O
diagnosed	B-DISO
as	O
glomerulonephritis	B-DISO
with	O
dominant	O
C3	B-DISO
due	O
to	O
the	O
absence	O
of	O
immunoglobulin	B-DISO
staining	I-DISO
by	O
routine	O
immunofluorescence	B-PROC
microscopy	I-PROC
.	O

The	O
patient	B-LIVB
reported	O
here	O
showed	O
lymphomatous	B-DISO
infiltration	I-DISO
on	O
kidney	B-PROC
biopsy	I-PROC
and	O
mesangial	B-DISO
proliferative	I-DISO
glomerulonephritis	I-DISO
with	O
dominant	O
staining	B-DISO
for	O
C3	B-DISO
without	O
immunoglobulins	B-CHEM
on	O
initial	O
immunofluorescence	B-PROC
;	O
however	O
,	O
monotypic	B-CHEM
immunoglobulin	I-CHEM
G	I-CHEM
κ	I-CHEM
light	B-CHEM
chain	I-CHEM
was	O
revealed	O
after	O
additional	O
immunofluorescence	B-PROC
staining	I-PROC
was	O
performed	O
on	O
the	O
paraffin	O
-	O
embedded	O
tissue	O
.	O

This	O
patient	B-LIVB
's	I-LIVB
case	O
highlights	O
the	O
evolving	O
state	O
of	O
kidney	B-PROC
biopsy	I-PROC
interpretation	O
and	O
the	O
expanding	O
spectrum	O
of	O
kidney	B-DISO
disease	I-DISO
in	O
the	O
setting	O
of	O
hematopoietic	B-DISO
neoplasia	I-DISO
.	O

Does	O
genistein	B-CHEM
lower	O
plasma	B-PROC
lipids	I-PROC
and	O
homocysteine	B-PROC
levels	I-PROC
in	O
postmenopausal	B-PHYS
women	B-LIVB
?	O

A	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
To	O
perform	O
a	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
examining	B-DISO
the	O
effects	O
of	O
genistein	B-CHEM
on	O
homocysteine	O
and	O
lipid	B-PROC
levels	I-PROC
in	O
postmenopausal	B-PHYS
women	B-LIVB
.	O

We	O
systematically	O
searched	O
the	O
PubMed	O
,	O
MEDLINE	O
,	O
and	O
Cochrane	O
Library	O
databases	O
and	O
the	O
ClinicalTrials	O
.	O

gov	O
website	O
for	O
studies	B-PROC
.	O

We	O
performed	O
a	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
using	O
weighted	O
mean	O
differences	O
(	O
WMD	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
in	O
a	O
random	O
-	O
effects	O
model	O
.	O

We	O
assessed	O
between	O
-	O
study	B-PROC
heterogeneity	O
using	O
the	O
Cochran	O
's	O
Q	O
and	O
I	O
(	O
2	O
)	O
statistics	O
.	O

Eight	O
randomized	B-PROC
,	I-PROC
controlled	I-PROC
trials	I-PROC
with	O
a	O
total	O
of	O
476	O
subjects	O
were	O
included	O
in	O
the	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O

Compared	O
with	O
placebos	B-PROC
,	O
genistein	B-CHEM
was	O
effective	O
in	O
reducing	O
plasma	B-ANAT
levels	O
of	O
homocysteine	B-CHEM
(	O
WMD	O
,	O
-0	O
.	O
58	O
μmol	O
/	O
l	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
increasing	O
high	B-CHEM
density	I-CHEM
lipoprotein	I-CHEM
(	I-CHEM
HDL	I-CHEM
)	I-CHEM
cholesterol	I-CHEM
levels	O
(	O
WMD	O
,	O
4	O
.	O
9	O
mg	O
/	O
dl	O
;	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

Subgroup	B-PROC
analyses	I-PROC
revealed	O
that	O
genistein	B-CHEM
significantly	O
decreased	O
the	O
levels	O
of	O
low	B-CHEM
density	I-CHEM
lipoprotein	I-CHEM
(	I-CHEM
LDL	I-CHEM
)	I-CHEM
cholesterol	I-CHEM
(	O
WMD	O
,	O
-16	O
.	O
90	O
mg	O
/	O
dl	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
total	B-CHEM
cholesterol	I-CHEM
(	O
WMD	O
,	O
-15	O
.	O
83	O
mg	O
/	O
dl	O
;	O
p	O
=	O
0	O
.	O

008	O
)	O
,	O
and	O
triglycerides	B-CHEM
(	O
WMD	O
,	O
-46	O
.	O
58	O
mg	O
/	O
dl	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
in	O
postmenopausal	B-PHYS
women	B-LIVB
with	O
metabolic	B-DISO
syndrome	I-DISO
,	O
but	O

had	O
no	O
significant	O
effects	O
in	O
those	O
with	O
no	B-DISO
metabolic	I-DISO
syndrome	I-DISO
.	O

Our	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
demonstrates	O
that	O
genistein	B-CHEM
significantly	O
reduces	O
homocysteine	B-PROC
levels	I-PROC
and	O
increases	O
HDL	B-PROC
cholesterol	I-PROC
levels	I-PROC
in	O
postmenopausal	B-PHYS
women	B-LIVB
.	O

Genistein	B-CHEM
also	O
significantly	O
decreases	O
LDL	B-PROC
cholesterol	I-PROC
,	O
total	B-PROC
cholesterol	I-PROC
and	O
triglyceride	B-PROC
levels	I-PROC
in	O
postmenopausal	B-PHYS
women	B-LIVB
with	O
metabolic	B-DISO
syndrome	I-DISO
.	O

Neonatal	B-DISO
Heart	I-DISO
-Enriched	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
Promotes	O
Differentiation	B-PHYS
of	O
Cardiac	B-ANAT
Progenitor	I-ANAT
Cells	I-ANAT
in	O
Rats	B-LIVB
Cardiovascular	B-DISO
disease	I-DISO
is	O
becoming	O
the	O
leading	O
cause	B-DISO
of	I-DISO
death	I-DISO
throughout	O
the	O
world	B-LIVB
.	O

However	O
,	O
adult	B-LIVB
hearts	B-ANAT
have	O
limited	O
potential	O
for	O
regeneration	B-PHYS
after	O
pathological	O
injury	B-DISO
,	O
partly	O
due	O
to	O
the	O
quiescent	O
status	O
of	O
stem	B-ANAT
/	O
progenitor	B-ANAT
cells	I-ANAT
.	O

Reactivation	O
of	O
cardiac	B-ANAT
stem	I-ANAT
/	O
progenitor	B-ANAT
cells	I-ANAT
to	O
create	O
more	O
myocyte	B-ANAT
progeny	B-ANAT
is	O
one	O
of	O
the	O
key	O
steps	O
in	O
the	O
regeneration	B-PHYS
of	O
a	O
damaged	O
heart	B-ANAT
.	O

In	O
this	O
study	O
,	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
was	O
identified	O
to	O
be	O
enriched	O
in	O
the	O
neonatal	O
cardiomyocytes	B-ANAT
of	O
rats	B-LIVB
,	O
but	O
this	O
has	O
not	O
yet	O
been	O
proven	O
in	O
adult	B-LIVB
humans	B-LIVB
.	O

A	O
lower	O
level	O
of	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
in	O
c	O
-	O
kit	O
(	O
+	O
)	O
stem	B-ANAT
/	O
progenitor	B-ANAT
cells	I-ANAT
was	O
detected	O
compared	O
to	O
non	B-ANAT
-	I-ANAT
progenitors	I-ANAT
.	O

Overexpression	B-PHYS
of	O
miR	O
-	O
708	O
induced	O
cardiomyocyte	B-ANAT
differentiation	O
of	O
cardiac	B-ANAT
stem	I-ANAT
/	O
progenitor	B-ANAT
cells	I-ANAT
.	O

This	O
finding	O
strengthened	O
the	O
potential	O
of	O
applying	O
miRNAs	B-CHEM
in	O
the	O
regeneration	B-PHYS
of	O
injured	O
hearts	B-ANAT
,	O
and	O
this	O
indicates	O
that	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
could	O
be	O
a	O
novel	O
candidate	O
for	O
treatment	B-PROC
of	O
heart	B-DISO
diseases	I-DISO
.	O

Coarse	O
Fraction	O
Particle	B-OBJC
Matter	I-OBJC
and	O
Exhaled	B-PHYS
Nitric	B-CHEM
Oxide	I-CHEM
in	O
Non	B-DISO
-	O
Asthmatic	B-DISO
Children	B-LIVB
Coarse	O
particle	B-OBJC
matter	I-OBJC
,	O
PMcoarse	B-OBJC
,	O
is	O
associated	O
with	O
increased	O
respiratory	B-DISO
morbidity	I-DISO
and	O
mortality	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
investigate	O
the	O
association	O
between	O
short	O
-	O
term	O
changes	O
in	O
PMcoarse	B-OBJC
and	O
sub	O
-	O
clininal	O
airway	B-ANAT
inflammation	B-DISO
in	O
children	B-LIVB
.	O

Healthy	B-DISO
children	I-DISO
aged	B-PHYS
11	O
years	O
from	O
two	O
northern	B-GEOG
Swedish	I-GEOG
elementary	B-OBJC
schools	I-OBJC
underwent	O
fraction	O
of	O
exhaled	B-PHYS
nitrogen	B-CHEM
oxide	I-CHEM
(	O
FENO	O
)	O
measurements	O
to	O
determine	O
levels	O
of	O
airway	B-ANAT
inflammation	B-DISO
twice	O
weekly	O
during	O
the	O
study	B-PROC
period	O
from	O
11	O
April	O
-	O
6	O
June	O
2011	O
.	O

Daily	O
exposure	O
to	O
PMcoarse	B-OBJC
,	O
PM2	B-OBJC
.	I-OBJC

5	I-OBJC
,	O
NO₂	B-CHEM
,	O
NOx	B-CHEM
,	O
NO	B-CHEM
and	O
O₃	B-CHEM
and	O
birch	B-LIVB
pollen	I-LIVB
was	O
estimated	O
.	O

Multiple	O
linear	O
regression	O
was	O
used	O
.	O

Personal	O
covariates	O
were	O
included	O
as	O
fixed	O
effects	O
and	O
subjects	B-LIVB
were	O
included	O
as	O
a	O
random	O
effect	O
.	O

In	O
total	O
,	O
95	O
children	B-LIVB
participated	O
in	O
the	O
study	B-PROC
,	O
and	O
in	O
all	O
493	O
FENO	O
measurements	O
were	O
made	O
.	O

The	O
mean	O
level	O
of	O
PMcoarse	B-OBJC
was	O
16	O
.	O

1	O
μg	O
/	O
m³	O
(	O
range	O
4	O
.	O
1	O
-	O
42	O
.	O
3	O
)	O
,	O
and	O
that	O
of	O
O₃	B-CHEM
was	O
75	O
.	O
0	O
μg	O
/	O
m³	O
(	O
range	O
:	O
51	O
.	O
3	O
-	O
106	O
.	O
3	O
)	O
.	O

That	O
of	O
NO₂	B-CHEM
was	O
17	O
.	O
0	O
μg	O
/	O
m³	O
(	O
range	O
:	O
4	O
.	O
7	O
-	O
31	O
.	O

3	O
)	O
,	O
NOx	B-CHEM
was	O
82	O
.	O

1	O
μg	O
/	O
m³	O
(	O
range	O
:	O
13	O
.	O
3	O
-	O
165	O
.	O
3	O
)	O
,	O
and	O
NO	B-CHEM
was	O
65	O
μg	O
/	O
m³	O
(	O
range	O
:	O
8	O
.	O
7	O
-	O
138	O
.	O
4	O
)	O
during	O
the	O
study	B-PROC
period	O
.	O

In	O
multi	B-CHEM
-	I-CHEM
pollutant	I-CHEM
models	O
an	O
interquartile	O
range	O
increase	O
in	O
24	O
h	O
PMcoarse	B-OBJC
was	O
associated	O
with	O
increases	O
in	O
FENO	O
by	O
between	O
6	O
.	O

9	O
ppb	O
(	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
0	O
-	O
14	O
)	O
and	O
7	O
.	O

3	O
ppb	O
(	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
4	O
-	O
14	O
.	O
9	O
)	O
.	O

PMcoarse	B-OBJC
was	O
associated	O
with	O
an	O
increase	O
in	O
FENO	O
,	O
indicating	O
sub	O
-	O
clinical	O
airway	B-ANAT
inflammation	B-DISO
in	O
healthy	B-DISO
children	I-DISO
.	O

NLRC5	B-CHEM
promotes	O
cell	B-PHYS
proliferation	I-PHYS
via	O
regulating	O
the	O
AKT	B-PHYS
/	O
VEGF	B-PHYS
-	I-PHYS
A	I-PHYS
signaling	I-PHYS
pathway	I-PHYS
in	O
hepatocellular	B-DISO
carcinoma	I-DISO
NLRC5	B-CHEM
,	O
a	O
newly	O
found	O
member	B-LIVB
of	O
the	O
NLR	B-CHEM
family	I-CHEM
and	O
the	O
largest	O
member	B-LIVB
of	O
nucleotide	B-PHYS
-	I-PHYS
binding	I-PHYS
,	O
has	O
been	O
reported	O
to	O
regulate	O
immune	B-PHYS
responses	I-PHYS
and	O
is	O
associated	O
with	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O
HCC	B-DISO
)	O
.	O

We	O
investigated	O
the	O
mechanisms	O
and	O
signaling	B-PHYS
pathways	I-PHYS
of	O
NLRC5	B-CHEM
in	O
HCC	B-DISO
progression	B-DISO
.	O

Increased	O
expression	B-PHYS
of	O
NLRC5	B-CHEM
,	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
-	I-CHEM
A	I-CHEM
(	O
VEGF	B-CHEM
-	I-CHEM
A	I-CHEM
)	O
were	O
found	O
in	O
human	B-LIVB
HCC	B-DISO
tissue	O
.	O

There	O
was	O
a	O
positive	B-DISO
correlation	O
between	O
NLRC5	B-CHEM
and	O
VEGF	B-CHEM
-	I-CHEM
A	I-CHEM
expression	B-PHYS
and	O
cell	B-PHYS
proliferation	I-PHYS
were	O
enhanced	O
in	O
NLRC5	B-CHEM
-	O
overexpressing	B-PHYS
HepG2	B-ANAT
cells	I-ANAT
,	O
but	O
inhibited	O
in	O
cells	B-ANAT
with	O
NLRC5	B-CHEM
silencing	B-PHYS
treatment	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
NLRC5	B-CHEM
also	O
coordinated	O
the	O
activation	O
of	O
PI3K	O
/	O
AKT	O
signaling	O
pathway	O
.	O

An	O
AKT	B-CHEM
inhibitor	I-CHEM
LY294002	I-CHEM
blocked	O
VEGF	B-CHEM
-	I-CHEM
A	I-CHEM
expression	B-PHYS
and	O
AKT	B-CHEM
phosphorylation	B-PHYS
in	O
HepG2	B-ANAT
cells	I-ANAT
and	O
NLRC5	B-CHEM
-	O
overexpressing	B-PHYS
HepG2	B-ANAT
cells	I-ANAT
.	O

These	O
results	B-DISO
demonstrate	O
that	O
NLRC5	B-CHEM
promotes	O
HCC	B-DISO
progression	B-DISO
via	O
the	O
AKT	B-PHYS
/	O
VEGF	B-PHYS
-	I-PHYS
A	I-PHYS
signaling	I-PHYS
pathway	I-PHYS
.	O

Community	B-LIVB
Design	O
Impacts	O
on	O
Health	O
Habits	O
in	O
Low	B-DISO
-	I-DISO
income	I-DISO
Southern	B-LIVB
Nevadans	I-LIVB
The	O
purposes	O
of	O
this	O
exploratory	B-PROC
study	I-PROC
were	O
to	O
:	O
(	O
1	O
)	O
characterize	O
selected	O
community	B-LIVB
design	O
features	O
;	O
and	O
(	O
2	O
)	O
determine	O
the	O
relationship	O
between	O
select	O
features	O
and	O
physical	O
activity	O
(	O
PA	O
)	O
levels	O
and	O
nutrition	O
habits	O
for	O
a	O
small	O
sample	O
of	O
low	B-DISO
-	I-DISO
income	I-DISO
southern	B-LIVB
Nevadans	I-LIVB
.	O

Secondary	O
analysis	O
was	O
conducted	O
on	O
data	O
from	O
selected	O
participants	B-LIVB
of	O
the	O
Nevada	O
Healthy	O
Homes	O
Partnership	O
program	O
;	O
self	B-PROC
-	I-PROC
report	I-PROC
data	O
on	O
PA	O
and	O
diet	O
habits	O
were	O
compared	O
to	O
national	O
guidelines	O
.	O

Community	B-LIVB
design	O
features	O
were	O
identified	O
via	O
GIS	O
within	O
a	O
one	O
-	O
mile	O
radius	O
of	O
participants	B-LIVB
'	O
homes	B-OBJC
.	O

Descriptive	O
statistics	O
characterized	O
these	O
features	O
and	O
chi	O
-	O
square	O
analyses	O
were	O
conducted	O
to	O
determine	O
the	O
relationship	O
between	O
select	O
features	O
and	O
habits	O
.	O

Data	O
from	O
71	O
participants	B-LIVB
were	O
analyzed	B-PROC
;	O
the	O
majority	O
failed	O
to	O
reach	O
either	O
PA	O
or	O
fruit	O
and	O
vegetable	O
guidelines	O
(	O
81	O
.	O

7	O
%	O
and	O
93	O
.	O

0	O
%	O
,	O
respectively	O
)	O
.	O

Many	O
neighborhoods	B-GEOG
were	O
absent	O
of	O
parks	B-GEOG
(	O
71	O
.	O
8	O
%	O
)	O
,	O
trailheads	O
(	O
36	O
.	O
6	O
%	O
)	O
,	O
or	O
pay	B-OBJC
-	I-OBJC
for	I-OBJC
-	I-OBJC
use	I-OBJC
PA	I-OBJC
facilities	I-OBJC
(	O
47	O
.	O
9	O
%	O
)	O
.	O

The	O
mean	O
number	O
of	O
grocery	B-OBJC
stores	I-OBJC
was	O
3	O
.	O
4	O
±	O
2	O
.	O
3	O
per	O
neighborhood	B-GEOG
.	O

Chi	O
-	O
square	O
analyses	O
were	O
not	O
statistically	O
significant	O
.	O

Findings	B-DISO
were	O
insufficient	O
to	O
make	O
meaningful	O
conclusions	O
,	O
but	O
support	O
the	O
need	O
for	O
health	B-PROC
promotion	I-PROC
to	O
meet	O
guidelines	O
.	O

More	O
research	B-PROC
is	O
needed	O
to	O
assess	O
the	O
impact	O
of	O
health	B-PROC
-	I-PROC
promoting	I-PROC
community	B-LIVB
design	O
and	O
healthy	O
behaviors	O
,	O
particularly	O
in	O
vulnerable	B-LIVB
populations	I-LIVB
.	O

A	O
peptide	B-CHEM
from	O
human	B-CHEM
β	I-CHEM
thymosin	I-CHEM
as	O
a	O
platform	O
for	O
the	O
development	O
of	O
new	O
anti	B-CHEM
-	I-CHEM
biofilm	I-CHEM
agents	I-CHEM
for	O
Staphylococcus	B-LIVB
spp	I-LIVB
.	I-LIVB

and	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
Conventional	O
antibiotics	B-CHEM
might	O
fail	O
in	O
the	O
treatment	O
of	O
biofilm	B-LIVB
-associated	O
infections	B-DISO
causing	O
infection	B-DISO
recurrence	B-DISO
and	O
chronicity	O
.	O

The	O
search	O
for	O
antimicrobial	B-CHEM
peptides	I-CHEM
has	O
been	O
performed	O
with	O
the	O
aim	O
to	O
discover	O
novel	O
anti	B-CHEM
-	I-CHEM
infective	I-CHEM
agents	I-CHEM
active	O
on	O
pathogens	B-LIVB
in	O
both	O
planktonic	B-LIVB
and	O
biofilm	B-LIVB
associated	O
forms	O
.	O

The	O
fragment	B-CHEM
9	O
-	O
19	O
of	O
human	B-CHEM
thymosin	I-CHEM
β4	I-CHEM
was	O
studied	B-PROC
through	O
1	O
μs	O
MD	O
simulation	O
.	O

Two	O
main	O
conformations	O
of	O
the	O
peptide	O
were	O
detected	O
,	O
both	O
constituted	O
by	O
a	O
central	O
hydrophobic	O
core	O
and	O
by	O
the	O
presence	O
of	O
peripheral	O
charged	O
residues	O
suggesting	O
a	O
possible	O
mechanism	O
of	O
interaction	O
with	O
two	O
models	O
of	O
biological	B-ANAT
membranes	I-ANAT
,	O
related	O
to	O
eukaryotic	O
or	O
bacterial	B-ANAT
membrane	I-ANAT
respectively	O
.	O

In	O
addition	O
,	O
the	O
peptide	B-CHEM
was	O
chemically	O
synthesized	O
and	O
its	O
antimicrobial	B-PHEN
activity	I-PHEN
was	O
tested	O
in	B-PROC
vitro	I-PROC
against	O
planktonic	B-LIVB
and	O
biofilm	B-LIVB
form	O
of	O
a	O
group	O
of	O
reference	O
strains	B-LIVB
of	O
Staphylococcus	B-LIVB
spp	I-LIVB
.	I-LIVB

and	O

one	O
P	B-LIVB
.	I-LIVB

aeruginosa	I-LIVB
strain	B-LIVB
.	O

The	O
human	B-CHEM
thymosin	I-CHEM
β4	I-CHEM
fragment	B-CHEM
EIEKFDKSKLK	O
showed	O
antibacterial	B-PHYS
activity	I-PHYS
against	O
staphylococcal	B-LIVB
strains	B-LIVB
and	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
ATCC	O
15442	O
at	O
concentrations	O
from	O
12	O
.	O

5	O
to	O
6	O
.	O
2	O
mg	O
/	O
ml	O
and	O
inhibited	O
biofilm	B-PHYS
formation	I-PHYS
at	O
sub	O
-	O
inhibitory	O
concentrations	O
(	O
3	O
.	O
1	O
-	O
0	O
.	O
75	O
mg	O
/	O
ml	O
)	O
.	O

The	O
activity	O
of	O
the	O
fragment	B-CHEM
in	O
inhibiting	O
biofilm	B-PHYS
formation	I-PHYS
,	O
could	O
be	O
due	O
to	O
the	O
conformations	O
highlighted	O
by	O
the	O
MD	O
simulations	O
,	O
suggesting	O
its	O
interaction	O
with	O
the	O
bacterial	B-ANAT
membrane	I-ANAT
.	O

Human	B-CHEM
thymosin	I-CHEM
β4	I-CHEM
fragment	B-CHEM
can	O
be	O
considered	O
a	O
promising	O
lead	B-CHEM
compound	I-CHEM
to	O
develop	O
novel	O
synthetic	O
or	O
recombinant	B-CHEM
derivatives	I-CHEM
with	O
improved	O
pharmaceutical	O
potential	O
.	O

Identification	B-PROC
of	O
yeasts	B-LIVB
isolated	O
from	O
raffia	B-OBJC
wine	I-OBJC
(	O
Raphia	B-LIVB
hookeri	I-LIVB
)	O
produced	O
in	O
Côte	B-GEOG
d	I-GEOG
'	I-GEOG
Ivoire	I-GEOG
and	O
genotyping	B-PROC
of	O
Saccharomyces	B-LIVB
cerevisiae	I-LIVB
strains	B-LIVB
by	O
PCR	B-PROC
inter	I-PROC
-	I-PROC
delta	I-PROC
Raffia	B-OBJC
wine	I-OBJC
is	O
a	O
traditional	O
alcoholic	B-OBJC
beverage	I-OBJC
produced	O
in	O
several	O
African	B-GEOG
countries	I-GEOG
where	O
it	O
plays	O
a	O
significant	O
role	O
in	O
traditional	O
customs	O
and	O
population	O
diet	B-OBJC
.	O

Alcoholic	B-PHYS
fermentation	I-PHYS
of	O
this	O
beverage	B-OBJC
is	O
ensured	O
by	O
a	O
complex	O
natural	O
yeast	B-LIVB
flora	O
which	O
plays	O
a	O
decisive	O
role	O
in	O
the	O
quality	O
of	O
the	O
final	O
product	B-OBJC
.	O

This	O
present	O
study	B-PROC
aims	O
to	O
evaluate	O
the	O
distribution	O
and	O
the	O
diversity	O
of	O
the	O
yeast	B-LIVB
strains	B-LIVB
isolated	O
in	O
raffia	B-OBJC
wine	I-OBJC
from	O
four	O
sampling	O
areas	O
(	O
Abengourou	O
,	O
Alépé	O
,	O
Grand	O
-	O
Lahou	O
and	O
Adzopé	O
)	O
in	O
Côte	B-GEOG
d	I-GEOG
'	I-GEOG
Ivoire	I-GEOG
.	O

Based	O
on	O
the	O
D1	O
/	O
D2	O
domain	O
of	O
the	O
LSU	B-PROC
rDNA	I-PROC
sequence	I-PROC
analysis	I-PROC
,	O
nine	O
species	O
belonging	O
to	O
six	O
genera	O
were	O
distinguished	O
.	O

With	O
a	O
percentage	O
of	O
69	O
.	O

5	O
%	O
out	O
of	O
171	O
yeast	B-LIVB
isolates	B-CHEM
,	O
Saccharomyces	B-LIVB
cerevisiae	I-LIVB
was	O
the	O
predominant	O
species	O
in	O
the	O
raffia	B-OBJC
wine	I-OBJC
,	O
followed	O
by	O
Kodamaea	B-LIVB
ohmeri	I-LIVB
(	O
20	O
.	O
4	O
%	O
)	O
.	O

The	O
other	O
species	O
isolated	O
were	O
Candida	B-LIVB
haemulonii	I-LIVB
(	O
4	O
.	O
1	O
%	O
)	O
,	O
Candida	B-LIVB
phangngensis	I-LIVB
(	O
1	O
.	O
8	O
%	O
)	O
,	O
Pichia	B-LIVB
kudriavzevii	I-LIVB
(	O
1	O
.	O

2	O
%	O
)	O
,	O
Hanseniaspora	B-LIVB
jakobsenii	I-LIVB
(	O
1	O
.	O
2	O
%	O
)	O
,	O
Candida	B-LIVB
silvae	I-LIVB
(	O
0	O
.	O
6	O
%	O
)	O
,	O
Hanseniaspora	B-LIVB
guilliermondii	I-LIVB
(	O
0	O
.	O
6	O
%	O
)	O
and	O
Meyerozyma	B-LIVB
caribbica	I-LIVB
(	O
0	O
.	O

6	O
%	O
)	O
.	O

The	O
molecular	O
characterization	O
of	O
S	B-LIVB
.	I-LIVB

cerevisiae	I-LIVB
isolates	B-CHEM
at	O
the	O
strain	B-LIVB
level	O
using	O
the	O
PCR	B-PROC
-	I-PROC
interdelta	I-PROC
method	O
revealed	O
the	O
presence	B-DISO
of	O
21	O
profiles	B-PROC
(	O
named	O
I	O
to	O
XXI	O
)	O
within	O
115	O
isolates	B-CHEM
.	O

Only	O
four	O
profiles	B-PROC
(	O
I	O
,	O
III	O
,	O
V	O
and	O
XI	O
)	O
were	O
shared	O
by	O
the	O
four	O
areas	O
under	O
study	B-PROC
.	O

Phenotypic	O
characterization	O
of	O
K	B-LIVB
.	I-LIVB

ohmeri	I-LIVB
strains	B-LIVB
showed	O
two	O
subgroups	O
for	O
sugar	O
fermentation	O
and	O
no	O
diversity	O
for	O
the	O
nitrogen	B-CHEM
compound	I-CHEM
assimilations	O
and	O
the	O
growth	B-PHYS
at	O
different	O
temperatures	O
.	O

Structural	O
Basis	O
for	O
Simvastatin	B-CHEM
Competitive	B-PHYS
Antagonism	I-PHYS
of	O
Complement	B-CHEM
Receptor	I-CHEM
3	I-CHEM
The	O
complement	B-CHEM
system	I-CHEM
is	O
an	O
important	O
part	O
of	O
the	O
innate	B-PHYS
immune	I-PHYS
response	I-PHYS
to	O
infection	B-DISO
but	O
may	O
also	O
cause	O
severe	B-DISO
complications	I-DISO
during	O
inflammation	B-DISO
.	O

Small	B-CHEM
molecule	I-CHEM
antagonists	B-CHEM
to	O
complement	B-CHEM
receptor	I-CHEM
3	I-CHEM
(	O
CR3	B-CHEM
)	O
have	O
been	O
widely	O
sought	O
,	O
but	O
a	O
structural	O
basis	O
for	O
their	O
mode	O
of	O
action	O
is	O
not	O
available	O
.	O

We	O
report	O
here	O
on	O
the	O
structure	O
of	O
the	O
human	B-LIVB
CR3	B-CHEM
ligand	O
-	O
binding	O
I	O
domain	O
in	O
complex	B-CHEM
with	O
simvastatin	B-CHEM
.	O

Simvastatin	B-CHEM
targets	O
the	O
metal	B-CHEM
ion	O
-	O
dependent	O
adhesion	O
site	O
of	O
the	O
open	O
,	O
ligand	B-PHYS
-	I-PHYS
binding	I-PHYS
conformation	O
of	O
the	O
CR3	B-CHEM
I	O
domain	O
by	O
direct	O
contact	O
with	O
the	O
chelated	B-CHEM
Mg	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ion	I-CHEM
.	O

Simvastatin	B-CHEM
antagonizes	B-DISO
I	O
domain	O
binding	O
to	O
the	O
complement	B-CHEM
fragments	I-CHEM
iC3b	B-CHEM
and	O
C3d	B-CHEM
but	O
not	O
to	O
intercellular	B-CHEM
adhesion	I-CHEM
molecule	I-CHEM
-	I-CHEM
1	I-CHEM
.	O

By	O
virtue	O
of	O
the	O
I	O
domain	O
's	O
wide	O
distribution	O
in	O
binding	B-PHYS
kinetics	I-PHYS
to	O
ligands	B-CHEM
,	O
it	O
was	O
possible	B-DISO
to	O
identify	O
ligand	B-PHYS
binding	I-PHYS
kinetics	B-PHYS
as	O
discriminator	O
for	O
simvastatin	B-CHEM
antagonism	B-PHYS
.	O

In	O
static	O
cellular	B-PROC
experiments	B-PROC
,	O
15	O
-	O
25	O
μm	O
simvastatin	B-CHEM
reduced	O
adhesion	B-PHEN
by	O
K562	B-ANAT
cells	I-ANAT
expressing	B-PHYS
recombinant	B-LIVB
CR3	B-CHEM
and	O
by	O
primary	O
human	B-LIVB
monocytes	B-ANAT
,	O
with	O
an	O
endogenous	O
expression	B-PHYS
of	O
this	O
receptor	B-CHEM
.	O

Application	B-PROC
of	O
force	B-PHEN
to	O
adhering	B-PHEN
monocytes	B-ANAT
potentiated	O
the	O
effects	O
of	O
simvastatin	B-CHEM
where	O
only	O
a	O
50	O
-	O
100	O
nm	O
concentration	O
of	O
the	O
drug	B-CHEM
reduced	O
the	O
adhesion	B-PHEN
by	O
20	O
-	O
40	O
%	O
compared	O
with	O
untreated	O
cells	B-ANAT
.	O

The	O
ability	B-PHYS
of	O
simvastatin	B-CHEM
to	O
target	O
CR3	B-CHEM
in	O
its	O
ligand	B-PHYS
binding	I-PHYS
-	O
activated	O
conformation	O
is	O
a	O
novel	O
mechanism	B-PHYS
to	O
explain	O
the	O
known	O
anti	O
-	O
inflammatory	O
effects	O
of	O
this	O
compound	B-CHEM
,	O
in	O
particular	O
because	O
this	O
CR3	B-CHEM
conformation	O
is	O
found	O
in	O
pro	O
-	O
inflammatory	O
environments	O
.	O

Our	O
report	O
points	O
to	O
new	O
designs	O
of	O
CR3	B-CHEM
antagonists	B-CHEM
and	O
opens	O
new	O
perspectives	O
and	O
identifies	B-DISO
druggable	O
receptors	B-CHEM
from	O
characterization	O
of	O
the	O
ligand	B-PHYS
binding	I-PHYS
kinetics	B-PHYS
in	O
the	O
presence	O
of	O
antagonists	B-CHEM
.	O

Inducement	O
of	O
tissue	B-PHYS
regeneration	I-PHYS
of	O
harvested	B-PROC
hamstring	B-ANAT
tendons	I-ANAT
in	O
a	O
rabbit	B-LIVB
model	B-DEVI
The	O
objective	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	O
if	O
the	O
use	O
of	O
fascia	B-ANAT
lata	I-ANAT
as	O
a	O
tendon	B-ANAT
regeneration	B-PROC
guide	O
(	O
placed	O
into	O
the	O
tendon	B-ANAT
canal	I-ANAT
following	O
harvesting	B-PROC
the	O
semitendinosus	B-ANAT
tendon	I-ANAT
)	O
would	O
improve	B-DISO
the	O
incidence	O
of	O
tissue	B-PHYS
regeneration	I-PHYS
and	O
prevent	O
fatty	B-DISO
degeneration	I-DISO
of	O
the	O
semitendinosus	B-ANAT
muscle	I-ANAT
.	O

Bilateral	O
semitendinosus	B-ANAT
tendons	I-ANAT
were	O
harvested	B-PROC
from	O
rabbits	B-LIVB
using	O
a	O
tendon	B-DEVI
stripper	I-DEVI
.	O

On	O
the	O
inducing	O
graft	O
(	O
IG	O
)	O
side	O
,	O
the	O
tendon	B-ANAT
canal	I-ANAT
and	O
semitendinosus	B-ANAT
tibial	B-ANAT
attachment	O
site	O
were	O
connected	O
by	O
the	O
fascia	B-ANAT
lata	I-ANAT
,	O
which	O
was	O
harvested	B-PROC
at	O
the	O
same	O
width	O
as	O
the	O
semitendinosus	B-ANAT
tendon	I-ANAT
.	O

On	O
the	O
control	O
side	O
,	O
no	O
special	O
procedures	O
were	O
performed	O
.	O

Two	O
groups	O
of	O
six	O
rabbits	B-LIVB
were	O
killed	B-DISO
at	O
post	O
-	O
operative	O
weeks	O
4	O
and	O
8	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
three	O
healthy	O
rabbits	B-LIVB
were	O
killed	B-DISO
to	O
obtain	O
normal	O
tissue	O
.	O

We	O
evaluated	O
the	O
incidence	O
of	O
tendon	B-ANAT
tissue	B-PHYS
regeneration	I-PHYS
,	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
regenerated	O
tendon	B-ANAT
tissue	I-ANAT
and	O
proportion	O
of	O
fatty	O
tissue	O
in	O
the	O
semitendinosus	B-ANAT
muscle	I-ANAT
.	O

At	O
post	O
-	O
operative	O
week	O
8	O
,	O
the	O
distal	O
end	O
of	O
the	O
regenerated	O
tissue	O
reached	O
the	O
vicinity	O
of	O
the	O
tibial	B-ANAT
insertion	B-PROC
on	O
the	O
control	O
side	O
in	O
two	O
of	O
six	O
specimens	B-LIVB
.	O

On	O
the	O
IG	O
side	O
,	O
the	O
regenerated	O
tissue	O
maintained	O
continuity	O
with	O
the	O
tibial	B-ANAT
insertion	B-PROC
in	O
all	O
specimens	B-LIVB
.	O

The	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
IG	O
side	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
control	O
side	O
.	O

The	O
proportion	O
of	O
fatty	O
tissue	O
in	O
the	O
semitendinosus	B-ANAT
muscle	I-ANAT
on	O
the	O
IG	O
side	O
was	O
comparable	O
with	O
that	O
of	O
the	O
control	O
side	O
,	O
but	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
normal	O
muscle	O
.	O

Tendon	B-ANAT
tissue	I-ANAT
regenerated	O
with	O
the	O
fascia	B-ANAT
lata	I-ANAT
graft	O
was	O
thicker	O
than	O
naturally	O
occurring	O
regenerated	O
tissue	O
.	O

However	O
,	O
the	O
proportion	O
of	O
fatty	O
tissue	O
in	O
the	O
semitendinosus	B-ANAT
muscle	I-ANAT
was	O
greater	O
than	O
that	O
of	O
normal	O
muscle	O
.Cite	O
this	O
article	O
:	O
K	O
.	O

Tabuchi	O
,	O
T	O
.	O

Soejima	O
,	O
H	O
.	O

Murakami	O
,	O
K	O
.	O

Noguchi	O
,	O
N	O
.	O

Shiba	O
,	O
K	O
.	O

Nagata	O
.	O

Inducement	O
of	O
tissue	B-PHYS
regeneration	I-PHYS
of	O
harvested	B-PROC
hamstring	B-ANAT
tendons	I-ANAT
in	O
a	O
rabbit	B-LIVB
model	B-DEVI
.	O

Bone	O
Joint	O
Res	O
2016	O
;	O
5	O
:	O
247	O
-	O
252	O
.	O

DOI	O
:	O
10	O
.	O
1302	O
/	O
2046	O
-	O
3758	O
.	O
56	O
.	O

2000585	O
.	O

Immediate	O
and	O
Delayed	O
Effects	O
of	O
Diode	B-DEVI
Laser	I-DEVI
on	O
Debonding	B-PROC
of	O
Ceramic	B-DEVI
Brackets	I-DEVI
:	O
An	O
in	B-PROC
vitro	I-PROC
Study	I-PROC
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-PROC
the	O
immediate	O
and	O
delayed	O
effects	O
of	O
diode	B-DEVI
laser	I-DEVI
on	O
debonding	B-PROC
of	O
ceramic	B-DEVI
brackets	I-DEVI
.	O

A	O
total	O
of	O
60	O
human	B-LIVB
extracted	O
premolar	B-ANAT
teeth	I-ANAT
were	O
randomly	B-PROC
assigned	I-PROC
to	O
three	O
different	O
treatment	O
groups	O
.	O

All	O
teeth	B-ANAT
were	O
bonded	B-PROC
with	I-PROC
adhesive	B-CHEM
precoated	I-CHEM
(	O
APC	B-CHEM
)	O
ceramic	B-DEVI
brackets	I-DEVI
(	O
3	B-CHEM
M	I-CHEM
Unitek	I-CHEM
)	O
.	O

A	O
total	O
of	O
20	O
teeth	B-ANAT
were	O
debonded	B-PROC
without	O
lasing	B-PHEN
(	O
group	O
1	O
)	O
,	O
20	O
immediately	O
after	O
lasing	B-PHEN
(	O
group	O
2	O
)	O
,	O
and	O
20	O
1	O
hour	O
after	O
lasing	B-PHEN
(	O
group	O
3	O
)	O
.	O

For	O
the	O
lasing	B-PHEN
groups	O
(	O
groups	O
2	O
and	O
3	O
)	O
,	O
access	B-PROC
cavity	I-PROC
was	I-PROC
prepared	I-PROC
on	O
the	O
occlusal	B-ANAT
surface	I-ANAT
to	O
a	O
2	O
mm	O
diameter	O
.	O

A	O
transbond	B-CHEM
plus	I-CHEM
self	I-CHEM
-	I-CHEM
etching	I-CHEM
primer	I-CHEM
(	O
3	B-CHEM
M	I-CHEM
Unitek	I-CHEM
,	O
Monrovia	B-GEOG
,	O
CA	B-GEOG
,	O
USA	B-GEOG
)	O
and	O
APC	B-CHEM
PLUS	I-CHEM
clarity	B-DEVI
advanced	I-DEVI
brackets	I-DEVI
(	O
3	B-CHEM
M	I-CHEM
,	I-CHEM
Unitek	I-CHEM
,	O
Monrovia	B-GEOG
,	O
CA	B-GEOG
,	O
USA	B-GEOG
)	O
were	O
used	O
.	O

The	O
shear	O
bond	O
strength	O
(	O
SBS	O
)	O
and	O
adhesive	B-DISO
remnant	I-DISO
index	I-DISO
(	I-DISO
ARI	I-DISO
)	I-DISO
were	O
measured	O
.	O

The	O
internal	O
pulpal	B-ANAT
wall	I-ANAT
temperature	O
was	O
noted	O
for	O
the	O
laser	O
groups	O
.	O

The	O
mean	O
SBS	O
was	O
15	O
.	O
4	O
,	O
11	O
.	O
57	O
,	O
and	O
11	O
.	O

79	O
MPa	O
for	O
groups	O
1	O
to	O
3	O
respectively	O
.	O

Post	O
hoc	O
test	O
showed	O
significant	O
difference	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
between	O
the	O
control	B-LIVB
group	I-LIVB
and	O
the	O
lased	O
groups	O
.	O

For	O
groups	O
2	O
and	O
3	O
,	O
the	O
rise	O
in	O
temperature	O
was	O
at	O
an	O
average	O
of	O
1	O
.	O
4	O
and	O
1	O
.	O

3°C	O
respectively	O
.	O

The	O
SBS	O
of	O
APC	B-CHEM
brackets	B-DEVI
decreased	O
by	O
33	O
.	O

3	O
%	O
on	O
application	O
of	O
diode	B-DEVI
laser	I-DEVI
without	O
increasing	O
the	O
internal	O
pulp	B-ANAT
chamber	I-ANAT
wall	I-ANAT
temperature	O
significantly	O
.	O

Shear	O
bond	O
strength	O
remains	O
more	O
or	O
less	O
the	O
same	O
whether	O
debonding	B-PROC
is	O
done	O
immediately	O
after	O
lasing	B-PHEN
or	O
1	O
hour	O
after	O
lasing	B-PHEN
.	O

Diode	B-DEVI
lasers	I-DEVI
increased	O
the	O
ARI	B-DISO
scores	I-DISO
and	O
thus	O
decreased	O
the	O
risk	O
of	O
enamel	B-DISO
fracture	I-DISO
.	O

Activation	O
of	O
the	O
orphan	B-CHEM
receptor	I-CHEM
GPR55	I-CHEM
by	O
lysophosphatidylinositol	B-CHEM
promotes	O
metastasis	B-DISO
in	O
triple	B-DISO
-	I-DISO
negative	I-DISO
breast	I-DISO
cancer	I-DISO
The	O
orphan	B-CHEM
G	I-CHEM
protein	I-CHEM
-	I-CHEM
coupled	I-CHEM
receptor	I-CHEM
GPR55	B-CHEM
has	O
been	O
directly	O
or	O
indirectly	O
related	O
to	O
basic	O
alterations	O
that	O
drive	O
malignant	O
growth	B-PHYS
:	O
uncontrolled	O
cancer	O
cell	B-PHYS
proliferation	I-PHYS
,	O
sustained	B-PHYS
angiogenesis	I-PHYS
,	O
and	O
cancer	O
cell	B-PHYS
adhesion	I-PHYS
and	O
migration	B-PHEN
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
involvement	O
of	O
this	O
receptor	B-CHEM
in	O
metastasis	B-DISO
.	O

Here	O
,	O
we	O
show	O
that	O
elevated	O
GPR55	B-PHYS
expression	I-PHYS
in	O
human	B-LIVB
tumors	B-DISO
is	O
associated	O
with	O
the	O
aggressive	B-DISO
basal	I-DISO
/	O
triple	B-DISO
-	I-DISO
negative	I-DISO
breast	I-DISO
cancer	I-DISO
population	B-LIVB
,	O
higher	O
probability	O
to	O
develop	O
metastases	B-DISO
,	O
and	O
therefore	O
poor	O
patient	B-LIVB
prognosis	B-PROC
.	O

Activation	O
of	O
GPR55	B-CHEM
by	O
its	O
proposed	O
endogenous	O
ligand	B-CHEM
lysophosphatidylinositol	B-CHEM
confers	O
pro	O
-	O
invasive	O
features	O
on	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Specifically	O
,	O
this	O
effect	O
is	O
elicited	O
by	O
coupling	O
to	O
Gq	B-CHEM
/	I-CHEM
11	I-CHEM
heterotrimeric	I-CHEM
proteins	I-CHEM
and	O
the	O
subsequent	O
activation	O
,	O
through	O
ERK	B-CHEM
,	O
of	O
the	O
transcription	B-CHEM
factor	I-CHEM
ETV4	I-CHEM
/	O
PEA3	B-CHEM
.	O

Together	O
,	O
these	O
data	O
show	O
that	O
GPR55	B-CHEM
promotes	O
breast	B-DISO
cancer	I-DISO
metastasis	B-DISO
,	O
and	O
supports	O
the	O
notion	O
that	O
this	O
orphan	B-CHEM
receptor	I-CHEM
may	O
constitute	O
a	O
new	O
therapeutic	O
target	O
and	O
potential	O
biomarker	B-PHYS
in	O
the	O
highly	O
aggressive	O
triple	O
-	O
negative	O
subtype	O
.	O

The	O
number	O
of	O
tumorspheres	B-ANAT
cultured	O
from	O
peripheral	B-ANAT
blood	I-ANAT
is	O
a	O
predictor	O
for	O
presence	O
of	O
metastasis	B-DISO
in	O
patients	B-LIVB
with	O
breast	B-DISO
cancer	I-DISO
Tumor	B-DISO
metastases	I-DISO
are	O
the	O
major	O
cause	O
of	O
cancer	B-DISO
morbidity	I-DISO
and	O
mortality	O
.	O

A	O
subpopulation	B-LIVB
of	O
tumor	B-ANAT
cells	I-ANAT
with	I-ANAT
stem	I-ANAT
-	I-ANAT
like	I-ANAT
properties	I-ANAT
is	O
assumed	O
to	O
be	O
responsible	O
for	O
tumor	B-DISO
invasion	I-DISO
,	O
metastasis	B-DISO
,	O
heterogeneity	O
and	O
therapeutic	B-PROC
resistance	B-PHYS
.	O

This	O
population	O
is	O
termed	O
cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
(	O
CSCs	B-ANAT
)	O
.	O

We	O
have	O
developed	O
a	O
simple	O
method	O
for	O
identification	O
and	O
characterization	O
of	O
circulating	O
cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
among	O
circulating	B-ANAT
epithelial	I-ANAT
tumor	I-ANAT
cells	I-ANAT
(	O
CETCs	B-ANAT
)	O
.	O

CETCs	B-ANAT
were	O
cultured	O
under	O
conditions	O
favoring	O
growth	B-PHYS
of	O
tumorspheres	B-ANAT
from	O
72	O
patients	B-LIVB
with	O
breast	B-DISO
cancer	I-DISO
,	O
including	O
a	O
subpopulation	B-LIVB
of	O
23	O
patients	B-LIVB
with	O
metastatic	B-DISO
disease	I-DISO
.	O

CETCs	B-ANAT
were	O
determined	O
using	O
the	O
maintrac	B-PROC
®	I-PROC
method	I-PROC
.	O

Gene	O
expression	O
profiles	O
of	O
single	O
CETCs	B-ANAT
and	O
tumorspheres	B-ANAT
of	O
the	O
same	O
patients	B-LIVB
were	O
analyzed	O
using	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
.	O

Sphere	O
formation	O
was	O
observed	O
in	O
79	O
%	O
of	O
patients	B-LIVB
.	O

We	O
found	O
that	O
the	O
number	O
of	O
tumorspheres	B-ANAT
depended	O
on	O
stage	B-PROC
of	I-PROC
disease	I-PROC
.	O

Furthermore	O
,	O
the	O
most	O
important	O
factor	O
for	O
growing	O
of	O
tumorspheres	B-ANAT
is	O
obtaining	O
chemotherapy	B-PROC
.	O

Patients	B-LIVB
with	O
chemotherapy	B-PROC
treatment	B-PROC
had	O
lower	O
numbers	O
of	O
tumorspheres	B-ANAT
compared	O
to	O
patients	B-LIVB
without	B-DISO
chemotherapy	I-DISO
.	O

Patients	B-LIVB
with	O
HER2	B-DISO
positive	I-DISO
primary	I-DISO
tumor	I-DISO
had	O
higher	O
number	O
of	O
tumorspheres	B-ANAT
.	O

Analysis	O
of	O
surface	B-PHYS
marker	I-PHYS
expression	B-PHYS
profile	O
of	O
tumorspheres	B-ANAT
showed	O
that	O
cells	B-ANAT
in	O
the	O
spheres	O
had	O
typical	O
phenotype	B-PHYS
of	O
cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
.	O

There	O
was	O
no	B-DISO
sphere	I-DISO
formation	I-DISO
in	O
a	O
control	B-LIVB
group	I-LIVB
with	O
50	O
healthy	O
donors	B-LIVB
.	O

This	O
study	B-PROC
demonstrates	O
that	O
a	O
small	O
fraction	O
of	O
CETCs	B-ANAT
has	O
proliferative	B-PHEN
activity	I-PHEN
.	O

Identifying	O
the	O
CETC	B-ANAT
subset	O
with	O
cancer	B-ANAT
stem	I-ANAT
cell	I-ANAT
properties	O
may	O
provide	O
more	O
clinically	O
useful	O
prognostic	O
information	O
.	O

Chemotherapy	B-PROC
is	O
the	O
most	O
important	O
component	O
in	O
cancer	B-PROC
therapy	I-PROC
because	O
it	O
frequently	O
reduces	O
the	O
number	O
of	O
tumorspheres	B-ANAT
.	O

Undiagnosed	B-DISO
Primary	B-DISO
Open	I-DISO
-	I-DISO
Angle	I-DISO
Glaucoma	I-DISO
in	O
Korea	B-GEOG
:	O
The	O
Korean	B-PROC
National	I-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
2008	O
-	O
2009	O
To	O
evaluate	B-PROC
the	O
characteristics	O
of	O
patients	B-LIVB
with	O
previously	O
undiagnosed	B-DISO
primary	B-DISO
open	I-DISO
-	I-DISO
angle	I-DISO
glaucoma	I-DISO
(	O
POAG	B-DISO
)	O
in	O
Korea	B-GEOG
.	O

This	O
study	B-PROC
examined	O
data	O
from	O
391	O
subjects	B-LIVB
obtained	O
from	O
the	O
2008	O
-	O
2009	O
Korean	B-PROC
National	I-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
(	O
KNHANES	B-PROC
)	O
.	O

The	O
KNHANES	B-PROC
is	O
a	O
population	B-PROC
-	I-PROC
based	I-PROC
,	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
epidemiological	I-PROC
survey	I-PROC
.	O

Participants	B-LIVB
aged	B-PHYS
19	O
years	O
or	O
older	B-LIVB
completed	O
standardized	O
interviews	O
and	O
dilated	B-PROC
ocular	I-PROC
examinations	I-PROC
,	O
including	O
measurement	O
of	O
intraocular	B-PHYS
pressure	I-PHYS
,	O
visual	O
fields	O
with	O
frequency	B-PROC
doubling	I-PROC
perimetry	I-PROC
,	O
and	O
fundus	B-PROC
photography	I-PROC
.	O

Data	O
from	O
the	O
361	O
patients	B-LIVB
with	O
previously	O
undiagnosed	B-DISO
POAG	B-DISO
were	O
analyzed	B-PROC
and	O
compared	O
with	O
data	O
from	O
the	O
30	O
patients	B-LIVB
with	O
previously	O
diagnosed	B-DISO
glaucoma	B-DISO
.	O

A	O
total	O
of	O
92	O
.	O

3	O
%	O
of	O
POAG	B-DISO
cases	O
were	O
undiagnosed	B-DISO
before	O
this	O
study	B-PROC
.	O

Adjusted	O
for	O
age	B-PHYS
and	O
sex	B-PHYS
,	O
the	O
strongest	B-DISO
risk	I-DISO
factor	I-DISO
for	O
undiagnosed	B-DISO
glaucoma	B-DISO
was	O
longer	O
elapsed	O
time	O
since	O
last	O
eye	B-PROC
doctor	I-PROC
visit	I-PROC
.	O

Glaucoma	B-DISO
patients	B-LIVB
who	O
had	O
not	O
visited	B-PROC
an	I-PROC
eye	I-PROC
specialist	I-PROC
in	O
the	O
last	O
3	O
years	O
were	O
22	O
times	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
,	O
4	O
.	O
49	O
-	O
105	O
.	O
64	O
,	O
p	O
<	O
0	O
.	O

001	O
)	O
more	O
likely	O
to	O
have	O
undiagnosed	B-DISO
disease	B-DISO
compared	O
with	O
patients	B-LIVB
who	O
had	O
visited	B-PROC
an	I-PROC
eye	I-PROC
specialist	I-PROC
in	O
the	O
last	O
month	O
.	O

Another	O
significant	O
factor	O
for	O
previously	O
undiagnosed	B-DISO
glaucoma	B-DISO
was	O
smaller	O
cup	B-DISO
-	I-DISO
to	I-DISO
-	I-DISO
disc	I-DISO
ratio	I-DISO
(	O
odds	O
ratio	O
,	O
OR	O
,	O
0	O
.	O
60	O
/	O
0	O
.	O
1	O
units	O
,	O
95	O
%	O
CI	O
0	O
.	O
43	O
-	O
0	O
.	O
85	O
/	O
0	O
.	O
1	O
units	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O

The	O
higher	O
vertical	B-PHYS
cup	I-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
disc	I-PHYS
ratio	I-PHYS
of	O
a	O
subject	B-LIVB
's	I-LIVB
two	O
eyes	B-ANAT
was	O
significantly	O
different	O
between	O
those	O
with	O
previously	O
undiagnosed	B-DISO
(	O
0	O
.	O
69	O
)	O
and	O
diagnosed	B-DISO
(	O
0	O
.	O
78	O
)	O
POAG	B-DISO
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
undiagnosed	B-DISO
POAG	B-DISO
group	O
had	O
a	O
longer	O
interval	O
from	O
last	O
eye	B-PROC
doctor	I-PROC
visit	I-PROC
and	O
smaller	O
vertical	B-PHYS
cup	I-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
disc	I-PHYS
ratio	I-PHYS
compared	O
to	O
the	O
diagnosed	B-DISO
group	I-DISO
.	O

Nest	O
-	O
site	O
competition	O
between	O
invasive	O
and	O
native	O
cavity	O
nesting	O
birds	B-LIVB
and	O
its	O
implication	O
for	O
conservation	O
Nesting	O
cavities	O
are	O
often	O
a	O
limited	O
resource	O
that	O
multiple	O
species	O
use	O
.	O

There	O
is	O
an	O
ongoing	O
discussion	O
on	O
whether	O
invasive	O
cavity	O
nesting	O
birds	B-LIVB
restrict	O
the	O
availability	O
of	O
this	O
key	O
limited	O
resource	O
.	O

While	O
the	O
answer	O
to	O
this	O
question	O
has	O
important	O
conservation	O
implications	O
,	O
little	O
experimental	B-PROC
work	I-PROC
has	O
been	O
done	O
to	O
examine	B-DISO
it	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
experimentally	O
test	O
whether	O
alien	B-LIVB
cavity	O
nesting	O
birds	B-LIVB
affect	O
the	O
occupancy	O
of	O
cavities	O
and	O
the	O
resulting	O
breeding	B-PHYS
success	O
of	O
native	O
cavity	O
breeders	B-LIVB
in	O
a	O
large	O
urban	B-GEOG
park	B-OBJC
located	O
in	O
Tel	O
Aviv	O
,	O
Israel	B-GEOG
.	O

Over	O
three	O
breeding	B-PHYS
seasons	O
,	O
we	O
manipulated	O
the	O
entry	O
size	O
of	O
nest	B-OBJC
boxes	I-OBJC
and	O
compared	O
the	O
occupancy	O
and	O
breeding	B-PHYS
success	O
of	O
birds	B-LIVB
in	O
nest	B-OBJC
boxes	I-OBJC
of	O
two	O
treatments	O
.	O

These	O
included	O
nest	B-OBJC
boxes	I-OBJC
with	O
large	O
-	O
entrance	O
and	O
small	O
-	O
entrance	O
holes	O
.	O

The	O
large	O
-	O
entrance	O
holes	O
allowed	O
access	O
for	O
both	O
the	O
native	O
and	O
invasive	O
birds	B-LIVB
(	O
the	O
two	O
main	O
aliens	B-LIVB
in	O
the	O
park	B-OBJC
are	O
the	O
common	B-LIVB
mynas	I-LIVB
and	O
rose	B-LIVB
-	I-LIVB
ringed	I-LIVB
parakeets	I-LIVB
)	O
.	O

The	O
smaller	O
-	O
entrance	O
boxes	B-OBJC
,	O
on	O
the	O
other	O
hand	O
,	O
allowed	O
only	O
the	O
smaller	O
sized	O
native	O
cavity	O
breeders	B-LIVB
(	O
great	B-LIVB
tits	I-LIVB
and	O
house	B-LIVB
sparrows	I-LIVB
)	O
to	O
enter	O
the	O
boxes	B-OBJC
but	O
prevented	O
the	O
alien	O
species	O
from	O
entering	O
.	O

We	O
found	O
that	O
the	O
large	O
-	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
were	O
occupied	O
by	O
five	O
different	O
bird	B-LIVB
species	I-LIVB
,	O
comprising	O
three	O
natives	O
(	O
great	B-LIVB
tit	I-LIVB
,	O
house	B-LIVB
sparrow	I-LIVB
,	O
Scops	B-LIVB
owl	I-LIVB
)	O
and	O
two	O
invasive	O
species	O
(	O
common	B-LIVB
myna	I-LIVB
,	O
rose	B-LIVB
-	I-LIVB
ringed	I-LIVB
parakeet	I-LIVB
)	O
while	O
the	O
small	O
-	O
entrance	O
boxes	B-OBJC
were	O
only	O
occupied	O
by	O
the	O
two	O
native	O
species	O
.	O

The	O
alien	B-LIVB
common	B-LIVB
mynas	I-LIVB
and	O
rose	B-LIVB
-	I-LIVB
ringed	I-LIVB
parakeets	I-LIVB
occupied	O
77	O
.	O

5	O
%	O
of	O
the	O
large	O
-	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
whereas	O
native	O
species	B-LIVB
,	O
mainly	O
great	B-LIVB
tits	I-LIVB
,	O
occupied	O
less	O
than	O
9	O
%	O
of	O
the	O
large	O
-	O
entrance	O
boxes	B-OBJC
and	O
36	O
.	O

5	O
%	O
of	O
the	O
small	O
-	O
entrance	O
boxes	B-OBJC
.	O

When	O
examining	B-DISO
the	O
occupancy	O
of	O
those	O
cavities	O
that	O
were	O
not	O
occupied	O
by	O
the	O
aliens	B-LIVB
,	O
natives	O
occupied	O
both	O
the	O
small	O
and	O
large	O
-	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
equally	O
.	O

Three	O
quarters	O
(	O
78	O
%	O
)	O
of	O
the	O
great	B-LIVB
tits	I-LIVB
breeding	B-PHYS
in	O
the	O
large	O
-	O
entrance	O
boxes	B-OBJC
were	O
usurped	O
by	O
common	B-LIVB
mynas	I-LIVB
during	O
the	O
breeding	B-PHYS
season	O
and	O
as	O
a	O
result	O
breeding	B-PHYS
success	O
was	O
significantly	O
lower	O
for	O
great	B-LIVB
tits	I-LIVB
breeding	B-PHYS
in	O
the	O
large	O
-	O
entrance	O
boxes	B-OBJC
compared	O
with	O
the	O
small	O
-	O
entrance	O
boxes	B-OBJC
.	O

The	O
results	O
of	O
this	O
study	O
suggests	O
that	O
the	O
invasive	O
alien	O
species	O
can	O
reduce	O
the	O
breeding	B-PHYS
potential	O
of	O
native	O
cavity	O
breeders	B-LIVB
both	O
by	O
exploiting	O
the	O
limited	O
breeding	B-PHYS
resource	O
(	O
nest	O
cavities	O
)	O
and	O
by	O
directly	O
usurping	O
cavities	O
already	O
occupied	O
by	O
the	O
native	O
species	O
.	O

Since	O
the	O
majority	O
of	O
large	O
-	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
were	O
occupied	O
by	O
the	O
large	O
r	O
alien	B-LIVB
birds	I-LIVB
,	O
less	O
native	O
species	B-LIVB
bred	B-PHYS
in	O
the	O
limited	O
number	O
of	O
unoccupied	O
large	O
-	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
because	O
of	O
exploitation	O
competition	O
.	O

We	O
propose	O
that	O
for	O
management	O
purposes	O
,	O
nest	B-OBJC
-	I-OBJC
box	I-OBJC
programs	O
that	O
alter	O
the	O
entrance	O
size	O
of	O
available	O
natural	O
cavities	O
may	O
be	O
a	O
practical	O
approach	O
,	O
reducing	O
the	O
competition	O
between	O
native	O
cavity	O
breeders	B-LIVB
and	O
alien	B-LIVB
invasive	I-LIVB
birds	I-LIVB
,	O
and	O
especially	O
benefiting	O
the	O
smaller	O
native	O
cavity	O
breeders	B-LIVB
.	O

Family	B-LIVB
Psychosocial	O
Risk	B-PROC
Screening	I-PROC
in	O
Infants	B-LIVB
and	O
Older	B-LIVB
Children	I-LIVB
in	O
the	O
Acute	O
Pediatric	O
Hospital	O
Setting	O
Using	O
the	O
Psychosocial	O
Assessment	O
Tool	O
To	O
examine	O
the	O
validity	O
of	O
the	O
Psychosocial	O
Assessment	O
Tool	O
(	O
PAT	O
)	O
with	O
families	B-LIVB
of	O
infants	B-LIVB
(	O
<	B-DISO
2	I-DISO
years	I-DISO
)	O
and	O
children	B-LIVB
admitted	B-PROC
to	I-PROC
hospital	I-PROC
with	O
acute	O
life	B-DISO
-	I-DISO
threatening	I-DISO
illnesses	B-DISO
.	O

METHODS	O
:	O
A	O
total	O
of	O
235	O
parents	B-LIVB
of	O
177	O
children	B-LIVB
admitted	B-PROC
to	O
oncology	O
,	O
cardiology	O
,	O
or	O
pediatric	O
intensive	O
care	O
completed	O
the	O
PAT	O
and	O
measures	O
of	O
acute	B-DISO
stress	I-DISO
,	O
trait	B-PHYS
anxiety	B-DISO
,	O
family	O
functioning	O
,	O
and	O
quality	O
of	O
life	O
,	O
a	O
mean	O
3	O
.	O
7	O
weeks	O
following	O
diagnosis	B-DISO
.	O

A	O
modified	O
PAT	O
was	O
used	O
for	O
families	B-LIVB
of	O
infants	B-LIVB
,	O
rendering	O
two	O
forms	O
,	O
PAT	O
(	O
<	B-DISO
2	I-DISO
)	O
and	O
PAT	O
(	O
2	B-DISO
+	I-DISO
)	O
.	O

RESULTS	B-PHEN
:	O
Psychometrics	B-PROC
for	O
PAT	O
(	O
<	B-DISO
2	I-DISO
)	O
and	O
PAT	O
(	O
2	B-DISO
+	I-DISO
)	O
were	O
acceptable	O
.	O

PAT	O
Total	O
and	O
Subscale	O
scores	O
for	O
each	O
version	B-DISO
were	O
significantly	O
correlated	O
with	O
validation	B-PROC
measures	O
.	O

Internal	O
consistency	O
for	O
PAT	O
subscales	O
was	O
variable	O
.	O

Receiver	O
Operating	O
Characteristics	O
provided	O
some	O
support	O
for	O
PAT	O
cutoffs	O
.	O

PAT	O
scores	O
across	O
illness	B-DISO
groups	B-LIVB
were	O
comparable	O
.	O

CONCLUSIONS	O
:	O
This	O
study	B-PROC
provides	O
promising	O
support	O
for	O
the	O
PAT	O
as	O
a	O
psychosocial	O
screener	B-PROC
for	O
families	B-LIVB
of	O
infants	B-LIVB
and	O
older	B-LIVB
children	I-LIVB
across	O
illness	B-DISO
conditions	O
.	O

Design	O
and	O
synthesis	O
of	O
pH	O
-	O
sensitive	O
polymeric	B-CHEM
micelles	B-CHEM
for	O
oral	B-ANAT
delivery	B-DEVI
of	O
poorly	O
water	B-CHEM
-	O
soluble	O
drugs	B-CHEM
pH	O
-	O
sensitive	O
polymer	B-CHEM
poly	B-CHEM
(	I-CHEM
polylactide	I-CHEM
-	I-CHEM
co	I-CHEM
-	I-CHEM
methacrylic	I-CHEM
acid	I-CHEM
)	I-CHEM
-	I-CHEM
b	I-CHEM
-	I-CHEM
poly	I-CHEM
(	I-CHEM
acrylic	I-CHEM
acid	I-CHEM
)	I-CHEM
was	O
synthesized	O
using	O
atom	B-PHEN
transfer	I-PHEN
radical	I-PHEN
polymerization	I-PHEN
and	O
ring	B-PHEN
-	I-PHEN
opening	I-PHEN
polymerization	I-PHEN
and	O
characterized	O
by	O
gel	B-PROC
permeation	I-PROC
chromatography	I-PROC
and	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
.	O

The	O
polymers	B-CHEM
can	O
self	O
-	O
assemble	O
to	O
form	O
micelles	B-CHEM
in	O
aqueous	B-CHEM
medium	I-CHEM
,	O
which	O
respond	O
rapidly	O
to	O
pH	O
change	O
within	O
the	O
gastrointestinal	O
relevant	O
pH	O
range	O
.	O

Critical	O
micelle	B-CHEM
concentrations	O
and	O
pH	O
response	O
behavior	O
of	O
the	O
polymeri	B-CHEM
c	O
micelle	B-CHEM
were	O
investigated	O
.	O

Water	B-CHEM
-	O
insoluble	B-DISO
drug	B-CHEM
nifedipine	B-CHEM
was	O
loaded	O
and	O
the	O
drug	B-CHEM
-	O
loading	O
content	O
can	O
be	O
controlled	O
by	O
tuning	O
the	O
composition	B-PHYS
of	O
the	O
polymers	B-CHEM
.	O

The	O
in	O
vitro	O
release	B-PHEN
studies	B-PROC
indicate	O
pH	O
sensitivity	O
enabled	O
rapid	O
drug	B-PHEN
release	I-PHEN
at	O
the	O
environment	O
of	O
simulated	O
intestinal	B-ANAT
fluid	I-ANAT
(	O
pH	O
7	O
.	O
36	O
)	O
,	O
the	O
cumulative	O
released	O
amount	O
of	O
NFD	B-CHEM
reached	O
more	O
than	O
80	O
%	O
within	O
24	O
h	O
,	O
while	O
only	O
35	O
%	O
in	O
the	O
simulated	O
gastric	B-ANAT
fluid	I-ANAT
(	O
pH	O
1	O
.	O
35	O
)	O
.	O

All	O
the	O
results	O
showed	O
that	O
the	O
pH	O
-	O
sensitive	O
P	B-CHEM
(	I-CHEM
PLAMA	I-CHEM
-	I-CHEM
co	I-CHEM
-	I-CHEM
MAA	I-CHEM
)	I-CHEM
-	I-CHEM
b	I-CHEM
-	I-CHEM
PAA	I-CHEM
micelle	B-CHEM
may	O
be	O
a	O
prospective	O
candidate	O
as	O
oral	B-ANAT
drug	B-CHEM
delivery	B-CHEM
carrier	I-CHEM
for	O
hydrophobic	O
drugs	B-CHEM
with	O
controlled	O
release	O
behavior	O
.	O

Effect	O
of	O
ultrasonic	O
processing	O
on	O
the	O
changes	O
in	O
activity	B-PHYS
,	O
aggregation	O
and	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
polyphenol	B-CHEM
oxidase	I-CHEM
in	O
oriental	B-GEOG
sweet	B-OBJC
melon	I-OBJC
(	O
Cucumis	B-LIVB
melo	I-LIVB
var	I-LIVB
.	I-LIVB

makuwa	I-LIVB
Makino	I-LIVB
)	O
Polyphenol	B-CHEM
oxidase	I-CHEM
(	O
PPO	B-CHEM
)	O
mainly	O
contributes	O
to	O
the	O
browning	B-PHEN
reaction	I-PHEN
of	O
fruits	B-OBJC
and	O
vegetables	B-OBJC
and	O
causes	O
serious	O
damage	O
to	O
the	O
quality	O
of	O
sweet	B-OBJC
melon	I-OBJC
products	B-OBJC
.	O

However	O
,	O
traditional	O
methods	O
to	O
inactivate	O
browning	B-PHEN
may	O
induce	O
more	O
unexpected	O
risks	O
than	O
ultrasonic	O
processing	O
.	O

Meanwhile	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
effect	O
of	O
ultrasound	B-PHEN
on	O
PPO	B-CHEM
directly	O
purified	O
from	O
sweet	B-OBJC
melon	I-OBJC
.	O

The	O
PPO	B-CHEM
in	O
the	O
original	O
juice	B-OBJC
was	O
less	O
inactivated	O
than	O
the	O
purified	O
form	O
when	O
treated	B-PROC
with	I-PROC
ultrasound	B-PHEN
.	O

As	O
for	O
purified	O
PPO	B-CHEM
,	O
superior	O
to	O
thermal	B-PROC
treatment	I-PROC
,	O
less	O
heat	B-PHEN
was	O
needed	O
to	O
inactivate	O
the	O
PPO	B-CHEM
with	O
ultrasonic	O
treatment	B-PROC
.	O

At	O
intensity	B-DISO
lower	I-DISO
than	O
200	O
W	O
,	O
ultrasound	B-PHEN
did	O
not	O
significantly	O
affect	O
the	O
structure	O
and	O
activity	O
of	O
PPO	B-CHEM
(	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
and	O
latent	O
PPO	B-CHEM
was	O
activated	O
.	O

At	O
intensity	B-DISO
higher	I-DISO
than	O
200	O
W	O
,	O
ultrasound	B-PHEN
inactivated	O
PPO	B-CHEM
,	O
induced	O
aggregation	O
and	O
dissociation	B-PHYS
of	O
PPO	B-CHEM
particles	B-CHEM
and	O
significantly	O
decreased	O
the	O
α	O
-	O
helix	O
structure	O
content	O
.	O

Low	O
-	O
frequency	O
high	O
-	O
intensity	O
ultrasound	B-PHEN
caused	O
an	O
inactivation	O
effect	O
and	O
conformational	B-PHYS
changes	I-PHYS
of	O
purified	O
PPO	B-CHEM
from	O
oriental	B-GEOG
sweet	B-OBJC
melons	I-OBJC
.	O

Changes	O
in	O
the	O
PPO	B-CHEM
structure	O
induced	O
by	O
ultrasound	B-PHEN
eventually	O
inactivated	O
the	O
enzyme	B-CHEM
.	O

Ultrasound	B-PHEN
may	O
be	O
a	O
potential	O
method	O
to	O
inactivate	O
PPO	B-CHEM
in	O
oriental	B-GEOG
sweet	B-OBJC
melons	I-OBJC
.	O

©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Phylogeography	O
of	O
the	O
Spanish	B-LIVB
Moon	O
Moth	O
Graellsia	O
isabellae	O
(	O
Lepidoptera	O
,	O
Saturniidae	O
)	O
Geographic	O
and	O
demographic	O
factors	O
as	O
well	O
as	O
specialisation	O
to	O
a	O
new	O
host	O
-	O
plant	O
may	O
lead	O
to	O
host	O
-	O
associated	O
differentiation	O
in	O
plant	B-LIVB
-feeding	O
insects	O
.	O

We	O
explored	O
the	O
phylogeography	O
of	O
a	O
protected	O
moth	O
,	O
Graellsia	O
isabellae	O
,	O
and	O
its	O
two	O
recognised	O
host	O
-	O
plant	O
species	O
(	O
Pinus	B-LIVB
sylvestris	I-LIVB
and	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
)	O
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary	O
history	O
of	O
this	O
iconic	O
lepidopteran	O
.	O

DNA	B-CHEM
variation	B-PHEN
in	O
one	O
mitochondrial	B-ANAT
marker	O
and	O
nine	O
nuclear	B-ANAT
microsatellite	O
loci	O
revealed	O
a	O
strong	O
phylogeographic	B-DISO
pattern	I-DISO
across	O
28	O
populations	O
of	O
G	O
.	O

isabellae	O
studied	O
in	O
Spain	B-GEOG
and	O
France	B-GEOG
comprising	O
six	O
groups	O
mostly	O
distributed	O
along	O
different	O
mountain	B-GEOG
ranges	I-GEOG
.	O

Reanalysis	B-PROC
of	O
a	O
previously	O
published	O
chloroplast	B-ANAT
microsatellite	O
dataset	O
revealed	O
a	O
three	O
and	O
two	O
-	O
group	O
structure	O
for	O
Spanish	B-LIVB
P	B-LIVB
.	I-LIVB

sylvestris	I-LIVB
and	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
,	O
respectively	O
.	O

Overall	O
,	O
the	O
population	O
groupings	O
of	O
this	O
protected	O
moth	O
did	O
not	O
match	O
the	O
ones	O
of	O
P	B-LIVB
.	I-LIVB

sylvestris	I-LIVB
and	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
.	O

There	O
was	O
no	O
evidence	O
of	O
host	O
-	O
associated	O
differentiation	O
between	O
populations	O
using	O
P	B-LIVB
.	I-LIVB

sylvestris	I-LIVB
and	O
the	O
ones	O
inhabiting	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
.	O

The	O
two	O
major	O
mitochondrial	B-ANAT
clades	O
of	O
G	O
.	O

isabellae	O
likely	O
diverged	O
before	O
the	O
Last	O
Glacial	O
Maximum	O
and	O
geographically	O
separated	O
the	O
species	O
into	O
a	O
""""	O
southern	O
""""	O
(	O
Central	O
and	O
Southern	O
Iberian	O
clusters	O
)	O
and	O
a	O
""""	O
northern	O
""""	O
lineage	O
(	O
Eastern	O
Iberian	O
,	O
Pyrenean	O
and	O
French	O
Alpine	O
clusters	O
)	O
.	O

The	O
Eastern	O
Iberian	O
System	O
,	O
where	O
this	O
insect	O
uses	O
both	O
host	O
-	O
plants	O
,	O
harboured	O
the	O
highest	O
level	O
of	O
genetic	O
diversity	O
.	O

Such	O
a	O
group	O
independently	O
colonised	B-DISO
the	O
West	O
and	O
East	O
parts	O
of	O
the	O
Pyrenees	O
.	O

Our	O
results	O
point	O
to	O
a	O
native	O
origin	O
for	O
the	O
French	O
populations	O
occurring	O
in	O
the	O
Alps	B-GEOG
,	O
genetically	O
related	O
to	O
the	O
Eastern	O
Iberian	O
and	O
Pyrenean	O
sites	O
.	O

The	O
Central	O
Iberian	O
group	O
derived	O
from	O
Southern	O
Iberian	O
ancestors	B-LIVB
.	O

Secondary	O
contacts	O
were	O
inferred	O
between	O
the	O
Southern	O
/	O
Central	O
Iberian	O
populations	O
and	O
Eastern	O
Iberian	O
cluster	O
as	O
well	O
as	O
between	O
the	O
two	O
Pyrenean	O
ones	O
.	O

The	O
mito	O
-	O
nuclear	O
discordance	O
observed	O
with	O
regard	O
to	O
the	O
Eastern	O
Iberian	O
cluster	O
is	O
congruent	O
with	O
a	O
secondary	O
contact	O
after	O
the	O
evolution	B-PHYS
of	O
mito	O
-	O
nuclear	O
incompatibilities	O
in	O
geographically	O
isolated	O
areas	O
.	O

Prevalence	O
of	O
Physical	O
Activity	O
and	O
Sitting	B-PHYS
Time	O
Among	O
South	B-LIVB
Korean	I-LIVB
Adolescents	B-LIVB
:	O
Results	B-DISO
From	O
the	O
Korean	B-LIVB
National	B-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
,	O
2013	O
This	O
study	O
aimed	O
to	O
describe	O
physical	O
activity	O
(	O
PA	O
)	O
and	O
sitting	B-PHYS
time	O
,	O
and	O
to	O
examine	O
associations	O
between	O
sociodemographic	O
factors	O
,	O
weight	B-PHYS
status	O
,	O
PA	O
,	O
and	O
sitting	B-PHYS
time	O
among	O
South	B-LIVB
Korean	I-LIVB
adolescents	B-LIVB
(	O
12	O
-	O
18	O
years	O
)	O
.	O

Findings	O
are	O
based	O
on	O
self	B-PROC
-	I-PROC
report	I-PROC
data	I-PROC
from	O
638	O
participants	B-LIVB
in	O
the	O
2013	O
Korea	B-GEOG
National	B-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
.	O

Only	O
4	O
.	O
9	O
%	O
of	O
adolescents	B-LIVB
accumulated	O
60	O
minutes	O
of	O
moderate	O
-	O
to	O
-	O
vigorous	O
PA	O
daily	O
.	O

Adolescents	B-LIVB
spent	O
532	O
.	O

4	O
±	O
9	O
.	O

3	O
mins	O
/	O
d	O
sitting	B-PHYS
.	O

After	O
controlling	O
for	O
age	B-PHYS
and	O
sex	B-PHYS
,	O
individuals	B-LIVB
in	O
higher	B-LIVB
income	I-LIVB
groups	I-LIVB
compared	O
with	O
the	O
lowest	B-LIVB
income	I-LIVB
group	I-LIVB
,	O
living	O
in	O
nonmetro	O
Seoul	B-GEOG
compared	O
with	O
metro	O
Seoul	B-GEOG
,	O
and	O
who	O
were	O
overweight	B-DISO
compared	O
with	O
nonoverweight	B-PHYS
were	O
more	O
likely	O
to	O
meet	O
PA	O
guidelines	O
.	O

Participants	B-LIVB
in	O
the	O
highest	B-LIVB
income	I-LIVB
group	I-LIVB
compared	O
with	O
lowest	B-LIVB
income	I-LIVB
group	I-LIVB
,	O
and	O
residing	O
in	O
nonmetro	O
Seoul	B-GEOG
compared	O
with	O
metro	O
Seoul	B-GEOG
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	B-PHYS
time	O
group	O
(	O
>	O
720	O
min	O
/	O
d	O
)	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increasing	O
PA	O
and	O
reducing	O
sitting	B-PHYS
should	O
be	O
a	O
public	O
health	O
priority	O
in	O
South	B-GEOG
Korea	I-GEOG
.	O

Graphene	B-CHEM
/	O
Nafion	B-CHEM
composite	B-OBJC
film	I-OBJC
modified	O
glassy	O
carbon	B-DEVI
electrode	I-DEVI
for	O
simultaneous	O
determination	B-PROC
of	O
paracetamol	B-CHEM
,	O
aspirin	B-CHEM
and	O
caffeine	B-CHEM
in	O
pharmaceutical	O
formulations	O
A	O
graphene	B-CHEM
-	O
Nafion	B-CHEM
composite	B-OBJC
film	I-OBJC
was	O
fabricated	O
on	O
the	O
glassy	O
carbon	B-DEVI
electrode	I-DEVI
(	O
GR	B-DEVI
-	I-DEVI
NF	I-DEVI
/	I-DEVI
GCE	I-DEVI
)	O
,	O
and	O
used	O
for	O
simultaneous	O
determination	B-PROC
of	O
paracetamol	B-CHEM
(	O
PAR	B-CHEM
)	O
,	O
aspirin	B-CHEM
(	O
ASA	B-CHEM
)	O
and	O
caffeine	B-CHEM
(	O
CAF	B-CHEM
)	O
.	O

The	O
electrochemical	O
behaviors	O
of	O
PAR	B-CHEM
,	O
ASA	B-CHEM
and	O
CAF	B-CHEM
were	O
investigated	O
by	O
cyclic	O
voltammetry	O
and	O
square	B-PROC
-	I-PROC
wave	I-PROC
adsorptive	I-PROC
anodic	I-PROC
stripping	I-PROC
voltammetry	I-PROC
.	O

By	O
using	O
stripping	B-PROC
one	O
for	O
simultaneous	O
determination	B-PROC
of	O
PAR	B-CHEM
,	O
ASA	B-CHEM
and	O
CAF	B-CHEM
,	O
their	O
electrochemical	O
oxidation	O
peaks	O
appeared	O
at	O
+0	O
.	O

64	O
,	O
1	O
.	O
04	O
and	O
1	O
.	O
44V	O
,	O
and	O
good	O
linear	O
current	O
responses	O
were	O
obtained	O
with	O
the	O
detection	O
limits	O
of	O
18ngmL	O
(	O
-	O
1	O
)	O
(	O
1	O
.	O
2×10	O
(	O
-	O
9	O
)	O
M	O
)	O
,	O
11	O
.	O

7ngmL	O
(	O
-	O
1	O
)	O
(	O
6	O
.	O

5×10	O
(	O
-	O
8	O
)	O
M	O
)	O
and	O
7	O
.	O

3ngmL	O
(	O
-	O
1	O
)	O
(	O
3	O
.	O
8×10	O
(	O
-	O
8	O
)	O
M	O
)	O
,	O
respectively	O
.	O

Finally	O
,	O
the	O
proposed	O
electrochemical	B-OBJC
sensor	I-OBJC
was	O
successfully	O
applied	O
for	O
quantifying	O
PAR	B-CHEM
,	O
ASA	B-CHEM
and	O
CAF	B-CHEM
in	O
commercial	O
tablet	O
formulations	O
.	O

Targeting	O
tumor	B-DISO
tolerance	O
:	O
A	O
new	O
hope	O
for	O
pancreatic	B-DISO
cancer	I-DISO
therapy	B-PROC
?	O
With	O
a	O
5	O
-	O
year	O
survival	O
rate	O
of	O
just	O
8	O
%	O
,	O
pancreatic	B-DISO
cancer	I-DISO
(	O
PC	B-DISO
)	O
is	O
projected	O
to	O
be	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
deaths	O
by	O
2030	O
.	O

Most	O
PC	B-DISO
patients	B-LIVB
are	O
not	O
eligible	O
for	O
surgery	B-PROC
with	O
curative	B-PROC
intent	I-PROC
upon	O
diagnosis	B-DISO
,	O
emphasizing	O
a	O
need	O
for	O
more	O
effective	O
therapies	B-PROC
.	O

However	O
,	O
PC	B-DISO
is	O
notoriously	O
resistant	B-PHYS
to	O
chemoradiation	B-PROC
regimens	I-PROC
.	O

As	O
an	O
alternative	O
,	O
immune	B-PHYS
modulating	I-PHYS
strategies	B-PHYS
have	O
recently	O
achieved	O
success	O
in	O
melanoma	B-DISO
,	O
prompting	O
their	O
application	O
to	O
other	O
solid	B-DISO
tumors	I-DISO
.	O

For	O
such	O
therapeutic	B-PROC
approaches	O
to	O
succeed	O
,	O
a	O
state	O
of	O
immunologic	B-DISO
tolerance	I-DISO
must	O
be	O
reversed	O
in	O
the	O
tumor	B-PHEN
microenvironment	I-PHEN
and	O
that	O
has	O
been	O
especially	O
challenging	O
in	O
PC	B-DISO
.	O

Nonetheless	O
,	O
knowledge	O
of	O
the	O
PC	B-DISO
immune	O
microenvironment	O
has	O
advanced	O
considerably	O
over	O
the	O
past	O
decade	O
,	O
yielding	O
new	O
insights	B-PHYS
and	O
perspectives	O
to	O
guide	O
multimodal	B-PROC
therapies	I-PROC
.	O

In	O
this	O
review	O
,	O
we	O
catalog	O
the	O
historical	O
groundwork	O
and	O
discuss	O
the	O
evolution	B-PROC
of	O
the	O
cancer	O
immunology	O
field	O
to	O
its	O
present	O
state	O
with	O
a	O
specific	O
focus	O
on	O
PC	B-DISO
.	O

Strategies	B-PHYS
currently	O
employing	O
immune	B-PHYS
modulation	I-PHYS
in	O
PC	B-DISO
are	O
reviewed	O
,	O
specifically	O
highlighting	O
66	O
clinical	B-PROC
trials	I-PROC
across	O
the	O
United	B-GEOG
States	I-GEOG
and	O
Europe	B-GEOG
.	O

Parent	B-LIVB
's	I-LIVB
pro	B-DISO
-	I-DISO
health	I-DISO
awareness	I-DISO
concerning	O
oral	B-PROC
health	I-PROC
of	O
their	O
children	B-LIVB
in	O
the	O
light	O
of	O
survey	B-PROC
research	I-PROC
Oral	O
hygiene	O
is	O
a	O
crucial	O
part	O
of	O
caring	O
for	O
young	O
children	B-LIVB
.	O

This	O
problem	B-DISO
is	O
frequently	O
marginalized	O
or	O
even	O
ignored	O
by	O
parents	B-LIVB
/	O
guardians	B-LIVB
,	O
what	O
affects	O
child	B-LIVB
's	I-LIVB
whole	O
further	O
life	O
.	O

The	O
assessment	O
of	O
parents	B-LIVB
'	I-LIVB
knowledge	B-DISO
concerning	O
oral	O
hygiene	O
and	O
prevention	O
of	O
dental	B-DISO
caries	I-DISO
in	O
infants	B-LIVB
and	O
young	O
children	B-LIVB
.	O

The	O
test	O
group	O
consisted	O
of	O
parents	B-LIVB
,	O
as	O
well	O
as	O
men	B-LIVB
and	O
women	B-LIVB
currently	O
expecting	O
a	O
child	B-LIVB
.	O

The	O
study	B-PROC
was	O
conducted	O
in	O
a	O
form	O
of	O
a	O
survey	O
,	O
using	O
an	O
original	O
questionnaire	O
,	O
which	O
was	O
carried	O
out	O
in	O
several	O
hospitals	B-OBJC
in	O
Lodz	O
and	O
online	O
,	O
on	O
a	O
popular	O
local	O
forum	O
for	O
parents	B-LIVB
.	O

The	O
data	O
obtained	O
were	O
analyzed	B-PROC
statistically	I-PROC
,	O
allowing	O
the	O
assessment	O
of	O
health	B-DISO
awareness	I-DISO
of	O
respondents	B-LIVB
and	O
the	O
creation	O
of	O
various	O
profiles	O
of	O
parental	B-DISO
knowledge	I-DISO
on	O
the	O
subject	O
investigated	O
.	O

Most	O
of	O
respondents	B-LIVB
knew	O
the	O
age	B-PHYS
at	O
which	O
milk	B-ANAT
and	O
permanent	B-ANAT
teeth	I-ANAT
erupt	O
,	O
gave	O
the	O
correct	O
frequency	O
of	O
brushing	B-PROC
child	B-LIVB
's	I-LIVB
teeth	B-ANAT
and	O
were	O
in	O
favor	O
of	O
limiting	O
sweets	B-OBJC
in	O
the	O
diet	B-OBJC
.	O

A	O
total	O
of	O
59	O
%	O
correctly	O
gave	O
the	O
number	O
of	O
deciduous	B-ANAT
teeth	I-ANAT
and	O
66	O
%	O
had	O
heard	O
of	O
the	O
""""	O
bottle	B-DISO
tooth	I-DISO
decay	I-DISO
""""	O
.	O

All	O
respondents	B-LIVB
thought	O
that	O
helping	O
and	O
controlling	O
a	O
child	B-LIVB
while	O
brushing	B-PROC
their	O
teeth	B-ANAT
is	O
indispensable	O
,	O
but	O
they	O
did	O
not	O
know	O
the	O
best	O
time	O
to	O
start	O
using	O
the	O
toothpaste	B-CHEM
with	I-CHEM
fluoride	I-CHEM
.	O

The	O
information	O
about	O
child	B-LIVB
's	I-LIVB
oral	O
hygiene	O
was	O
more	O
often	O
looked	O
for	O
by	O
women	B-LIVB
(	O
67	O
%	O
)	O
than	O
by	O
men	B-LIVB
(	O
29	O
%	O
)	O
.	O

The	O
study	B-PROC
also	O
showed	O
that	O
if	O
a	O
training	B-PROC
on	O
the	O
given	O
subject	O
was	O
organized	O
,	O
60	O
%	O
of	O
respondents	B-LIVB
would	O
be	O
willing	B-DISO
to	O
participate	O
in	O
it	O
.	O

In	O
the	O
test	O
group	O
,	O
pro	B-DISO
-	I-DISO
health	I-DISO
awareness	I-DISO
is	O
insufficient	O
to	O
maintain	O
the	O
oral	B-PROC
health	I-PROC
of	O
the	O
offspring	B-LIVB
and	O
requires	O
constant	O
developing	O
.	O

oral	B-PHYS
health	I-PHYS
behaviors	I-PHYS
,	O
oral	B-PROC
health	I-PROC
,	O
prophylaxis	B-PROC
of	O
dental	B-DISO
caries	I-DISO
,	O
parent	B-LIVB
questionnaire	O
survey	O
.	O

Depressive	B-DISO
symptoms	I-DISO
and	O
long	O
-	O
term	O
income	O
:	O
The	O
Young	O
Finns	O
Study	O
Higher	O
depressive	B-DISO
symptoms	I-DISO
have	O
been	O
associated	O
with	O
lower	O
future	O
income	O
.	O

However	O
,	O
studies	B-PROC
examining	B-DISO
this	O
issue	B-DISO
have	O
had	O
limited	O
follow	B-PROC
-	I-PROC
up	I-PROC
times	O
and	O
have	O
used	O
self	B-PROC
-	I-PROC
reported	I-PROC
measures	O
of	O
income	O
.	O

Also	O
,	O
possible	B-DISO
confounders	O
or	O
mediators	O
have	O
not	O
been	O
accounted	O
.	O

971	O
women	B-LIVB
and	O
738	O
men	B-LIVB
were	O
selected	O
from	O
the	O
ongoing	O
prospective	B-PROC
Young	O
Finns	O
Study	O
(	O
YFS	O
)	O
that	O
began	O
in	O
1980	O
.	O

Depressive	B-DISO
symptoms	I-DISO
were	O
measured	O
in	O
1992	O
when	O
participants	B-LIVB
were	O
from	O
15	O
to	O
30	O
years	O
old	O
.	O

Information	O
on	O
annual	O
income	O
and	O
earnings	O
from	O
1993	O
to	O
2010	O
were	O
obtained	O
from	O
the	O
Finnish	O
Longitudinal	O
Employer	O
-	O
Employee	O
Data	O
(	O
FLEED	O
)	O
of	O
Statistics	O
Finland	B-GEOG
and	O
linked	O
to	O
the	O
YFS	O
.	O

Higher	O
depressive	B-DISO
symptoms	I-DISO
were	O
associated	O
with	O
lower	O
future	O
income	O
and	O
earnings	O
.	O

For	O
men	B-LIVB
,	O
the	O
associations	B-PHYS
were	O
robust	O
for	O
controlling	B-PHEN
childhood	O
parental	B-LIVB
socioeconomic	O
status	O
,	O
history	O
of	O
unemployment	B-DISO
,	O
and	O
adulthood	O
health	O
behavior	O
,	O
but	O
attenuated	O
circa	O
35	O
%	O
when	O
three	O
major	O
temperament	B-PHYS
traits	B-PHYS
were	O
taken	O
into	O
account	O
.	O

For	O
women	B-LIVB
,	O
similar	O
pattern	O
was	O
found	O
,	O
however	O
,	O
in	O
the	O
models	O
adjusted	O
for	O
temperament	B-PHYS
traits	B-PHYS
the	O
associations	O
did	O
not	O
remain	O
statistically	O
significant	O
.	O

The	O
association	B-PHYS
between	O
depressive	B-DISO
symptoms	I-DISO
and	O
earnings	O
was	O
three	O
times	O
stronger	O
for	O
men	B-LIVB
than	O
women	B-LIVB
.	O

Previous	O
depressive	B-DISO
episodes	I-DISO
could	O
have	O
influenced	O
on	O
some	O
participants	B-LIVB
'	O
economic	O
and	O
educational	B-PROC
choices	O
.	O

Higher	O
depressive	B-DISO
symptoms	I-DISO
in	O
adolescence	O
and	O
early	O
adulthood	O
lead	O
to	O
significant	O
future	O
losses	O
of	O
total	O
income	O
and	O
earnings	O
,	O
and	O
this	O
association	B-PHYS
is	O
particularly	O
strong	O
for	O
men	B-LIVB
.	O

miR	B-CHEM
-	I-CHEM
376c	I-CHEM
inhibits	O
cervical	B-DISO
cancer	I-DISO
cell	B-PHYS
proliferation	I-PHYS
and	O
invasion	B-DISO
by	O
targeting	O
BMI1	O
MicroRNAs	B-CHEM
(	O
miRNAs	B-CHEM
)	O
play	O
crucial	O
roles	O
in	O
cancer	B-DISO
development	O
and	O
progression	B-DISO
.	O

The	O
purposes	O
of	O
this	O
study	B-PROC
were	O
to	O
explore	O
the	O
role	O
of	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
in	O
cervical	B-DISO
cancer	I-DISO
and	O
to	O
clarify	O
the	O
regulation	B-PHYS
of	O
BMI1	O
by	O
miR	O
-	O
376c	O
.	O

Quantitative	B-PROC
RT	I-PROC
-	I-PROC
PCR	I-PROC
was	O
used	O
to	O
measure	O
miR	O
-	O
376c	O
expression	B-PHYS
in	O
cervical	B-DISO
cancer	I-DISO
tissues	O
and	O
cell	B-ANAT
lines	I-ANAT
.	O

The	O
cell	B-PROC
proliferation	I-PROC
,	O
cell	B-PROC
cycle	I-PROC
and	O
Transwell	B-PROC
invasion	I-PROC
assays	I-PROC
were	O
performed	O
.	O

A	O
luciferase	B-PROC
reporter	I-PROC
assay	I-PROC
was	O
conducted	O
to	O
confirm	O
the	O
target	O
gene	O
of	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
,	O
and	O
the	O
results	O
were	O
validated	O
in	O
cervical	B-DISO
cancer	I-DISO
cell	B-ANAT
lines	I-ANAT
and	O
tissues	O
.	O

MiR	O
-	O
376c	O
was	O
significantly	O
downregulated	B-PHYS
in	O
cervical	B-DISO
cancer	I-DISO
cell	B-ANAT
lines	I-ANAT
and	O
clinical	O
tissues	O
.	O

Upregulation	B-PHYS
of	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
impaired	O
cell	B-PHYS
proliferation	I-PHYS
,	O
blocked	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
checkpoint	I-PHYS
of	O
cell	B-PHYS
cycle	I-PHYS
and	O
suppressed	O
cell	B-DISO
invasion	I-DISO
in	O
vitro	O
.	O

BMI1	O
was	O
verified	O
as	O
a	O
direct	O
target	O
of	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
,	O
which	O
was	O
further	O
confirmed	O
by	O
the	O
inverse	B-PHYS
expression	I-PHYS
of	O
miR	O
-	O
376c	O
and	O
BMI1	O
in	O
patient	B-LIVB
specimens	B-OBJC
.	O

The	O
newly	O
identified	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
/	O
BMI1	O
pathway	B-PHYS
provides	O
an	O
insight	O
into	O
cervical	B-DISO
cancer	I-DISO
progression	B-DISO
and	O
may	O
represent	O
a	O
novel	O
therapeutic	O
target	O
.	O

Phenol	B-CHEM
red	I-CHEM
-	O
silk	B-CHEM
tyrosine	I-CHEM
cross	B-PHEN
-	I-PHEN
linked	I-PHEN
hydrogels	B-CHEM
Phenol	B-CHEM
red	I-CHEM
is	O
a	O
cytocompatible	O
pH	B-CHEM
sensing	I-CHEM
dye	I-CHEM
that	O
is	O
commonly	O
added	O
to	O
cell	B-CHEM
culture	I-CHEM
media	I-CHEM
,	O
but	O
removed	O
from	O
some	O
media	B-CHEM
formulations	O
due	O
to	O
its	O
structural	O
mimicry	B-PHYS
of	O
estrogen	B-CHEM
.	O

Phenol	B-CHEM
red	I-CHEM
free	O
media	B-CHEM
is	O
also	O
used	O
during	O
live	B-PROC
cell	I-PROC
imaging	I-PROC
,	O
to	O
avoid	O
absorbance	B-PHEN
and	O
fluorescence	B-PHYS
quenching	I-PHYS
of	O
fluorophores	B-CHEM
.	O

To	O
overcome	O
these	O
complications	B-DISO
,	O
we	O
developed	O
cytocompatible	O
and	O
degradable	O
phenol	B-CHEM
red	I-CHEM
-	O
silk	B-CHEM
tyrosine	I-CHEM
cross	B-PHEN
-	I-PHEN
linked	I-PHEN
hydrogels	B-CHEM
using	O
horseradish	B-CHEM
peroxidase	I-CHEM
(	I-CHEM
HRP	I-CHEM
)	I-CHEM
enzyme	I-CHEM
and	O
hydrogen	B-CHEM
peroxide	I-CHEM
(	O
H2O2	B-CHEM
)	O
.	O

Phenol	B-CHEM
red	I-CHEM
added	O
to	O
silk	B-CHEM
during	O
tyrosine	B-CHEM
crosslinking	B-PHEN
accelerated	O
di	B-CHEM
-	I-CHEM
tyrosine	I-CHEM
formation	O
in	O
a	O
concentration	O
-	O
dependent	B-PHEN
reaction	I-PHEN
.	O

Phenol	B-CHEM
red	I-CHEM
diffusion	B-PHEN
studies	B-PROC
and	O
UV	B-PROC
-	I-PROC
Vis	I-PROC
spectra	I-PROC
of	O
phenol	B-CHEM
red	I-CHEM
-	O
silk	B-CHEM
tyrosine	I-CHEM
hydrogels	B-CHEM
at	O
different	O
pHs	O
showed	O
altered	O
absorption	B-PHEN
bands	O
,	O
confirming	B-DISO
entrapment	B-DISO
of	O
dye	B-CHEM
within	O
the	O
hydrogel	B-CHEM
network	I-CHEM
.	O

LC	B-PROC
-	I-PROC
MS	I-PROC
of	O
HRP	B-CHEM
-reacted	O
phenol	B-CHEM
red	I-CHEM
and	O
N	B-CHEM
-	I-CHEM
acetyl	I-CHEM
-	I-CHEM
l	I-CHEM
-	I-CHEM
tyrosine	I-CHEM
reaction	B-OBJC
products	I-OBJC
confirmed	B-DISO
covalent	B-PHEN
bonds	I-PHEN
between	O
the	O
phenolic	B-CHEM
hydroxyl	I-CHEM
group	I-CHEM
of	O
phenol	B-CHEM
red	I-CHEM
and	O
tyrosine	B-CHEM
on	O
the	O
silk	B-CHEM
.	O

At	O
lower	O
phenol	B-CHEM
red	I-CHEM
concentrations	O
,	O
leak	O
-	O
proof	O
hydrogels	B-CHEM
which	O
did	O
not	O
release	O
phenol	B-CHEM
red	I-CHEM
were	O
fabricated	O
and	O
found	O
to	O
be	O
cytocompatible	O
based	O
on	O
live	B-PROC
-	I-PROC
dead	I-PROC
staining	I-PROC
and	O
alamar	B-CHEM
blue	I-CHEM
assessments	O
of	O
encapsulated	O
fibroblasts	B-ANAT
.	O

Due	O
to	O
the	O
spectral	B-DISO
overlap	I-DISO
between	O
phenol	B-CHEM
red	I-CHEM
absorbance	B-PHEN
at	O
415	O
nm	O
and	O
di	B-CHEM
-	I-CHEM
tyrosine	I-CHEM
fluorescence	B-PHEN
at	O
417	O
nm	O
,	O
phenol	B-CHEM
red	I-CHEM
-	O
silk	B-CHEM
hydrogels	B-CHEM
provide	O
both	O
absorbance	B-PHEN
and	O
fluorescence	B-PHEN
-based	O
pH	O
sensing	O
.	O

With	O
an	O
average	O
pKa	O
of	O
6	O
.	O

8	O
and	O
good	O
cytocompatibiltiy	O
,	O
phenol	B-CHEM
red	I-CHEM
-	O
silk	B-CHEM
hydrogels	B-CHEM
are	O
useful	O
for	O
pH	O
sensing	O
in	O
phenol	O
red	O
free	O
systems	O
,	O
cellular	B-PHEN
microenvironments	I-PHEN
and	O
bioreactors	B-DEVI
.	O

Phenol	B-CHEM
red	I-CHEM
entrapped	B-DISO
within	O
hydrogels	B-CHEM
facilitates	O
pH	O
sensing	O
in	O
phenol	B-CHEM
red	I-CHEM
free	O
environments	O
.	O

Leak	O
-	O
proof	O
phenol	B-CHEM
red	I-CHEM
based	O
pH	B-OBJC
sensors	I-OBJC
require	O
covalent	O
binding	O
techniques	O
,	O
but	O
are	O
complicated	O
due	O
to	O
the	O
lack	O
of	O
amino	B-CHEM
or	O
carboxyl	B-CHEM
groups	I-CHEM
on	O
phenol	B-CHEM
red	I-CHEM
.	O

Currently	O
,	O
there	O
is	O
no	O
simple	O
,	O
reliable	O
technique	O
to	O
covalently	B-PHEN
link	B-PHEN
phenol	B-CHEM
red	I-CHEM
to	O
hydrogel	B-CHEM
matrices	O
,	O
for	O
real	O
-	O
time	O
pH	O
sensing	O
in	O
cell	B-PROC
culture	I-PROC
environments	O
.	O

Herein	O
,	O
we	O
take	O
advantage	O
of	O
phenolic	B-CHEM
groups	I-CHEM
for	O
covalent	B-PHEN
linkage	O
of	O
phenol	B-CHEM
red	I-CHEM
to	O
silk	B-CHEM
tyrosine	I-CHEM
in	O
the	O
presence	O
of	O
HRP	B-CHEM
and	O
H2O2	B-CHEM
.	O

The	O
novelty	O
of	O
the	O
current	B-OBJC
system	I-OBJC
stems	O
from	O
its	O
simplicity	O
and	O
the	O
use	O
of	O
silk	B-CHEM
protein	I-CHEM
to	O
create	O
a	O
cytocompatible	O
,	O
degradable	O
sensor	B-OBJC
capable	O
of	O
real	O
-	O
time	O
pH	O
sensing	O
in	O
cell	B-PHEN
culture	I-PHEN
microenvironments	I-PHEN
.	O

Common	O
Laboratory	B-OBJC
Parameters	B-DISO
for	O
Differentiating	O
Between	O
Community	B-DISO
-	I-DISO
Acquired	I-DISO
and	O
Healthcare	B-DISO
-	I-DISO
Associated	I-DISO
Pneumonia	I-DISO
The	O
correct	O
diagnosis	B-DISO
of	O
healthcare	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O
HCAP	B-DISO
)	O
as	O
opposed	O
to	O
community	B-DISO
-	I-DISO
acquired	I-DISO
pneumonia	I-DISO
is	O
essential	O
for	O
the	O
selection	O
of	O
a	O
correct	O
empirical	O
antimicrobial	B-CHEM
approach	O
,	O
reserving	O
the	O
broad	O
-	O
spectrum	O
or	O
highly	O
potent	O
antimicrobial	B-PROC
therapies	I-PROC
for	O
resistant	O
strains	B-LIVB
most	O
commonly	O
present	O
in	O
HCAP	B-DISO
,	O
whereas	O
treating	O
the	O
less	O
resistant	O
strains	B-LIVB
,	O
most	O
commonly	O
associated	O
with	O
community	B-LIVB
and	O
long	B-OBJC
-	I-OBJC
term	I-OBJC
care	I-OBJC
facility	I-OBJC
-	O
acquired	B-DISO
infections	I-DISO
,	O
with	O
a	O
more	O
targeted	O
empirical	B-PROC
approach	I-PROC
.	O

The	O
standard	O
approach	O
today	O
is	O
to	O
differentiate	O
between	O
the	O
two	O
based	O
on	O
the	O
medical	B-DISO
history	I-DISO
of	O
the	O
past	O
90	O
days	O
prior	O
to	O
admission	B-PROC
.	O

Measurable	O
,	O
quantitative	O
assessment	B-PROC
may	O
be	O
able	O
to	O
assist	O
in	O
this	O
decision	B-PHYS
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	O
method	O
of	O
differentiating	O
between	O
community	B-DISO
-	I-DISO
acquired	I-DISO
and	O
healthcare	B-DISO
-	I-DISO
associated	I-DISO
pneumonias	I-DISO
.	O

The	O
records	O
of	O
126	O
patients	B-LIVB
admitted	B-PROC
with	O
a	O
diagnosis	B-DISO
of	O
pneumonia	B-DISO
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
the	O
probable	O
cause	O
of	O
their	O
disease	O
,	O
in	O
accordance	O
with	O
common	B-PHYS
practice	I-PHYS
.	O

The	O
routine	O
laboratory	B-PROC
work	I-PROC
taken	O
upon	O
admittance	B-PROC
was	O
analyzed	B-PROC
using	O
logistical	B-PROC
regression	I-PROC
and	O
Student	O
's	O
t	O
-	O
test	O
.	O

We	O
have	O
found	O
that	O
the	O
red	B-PROC
blood	I-PROC
cell	I-PROC
distribution	I-PROC
width	I-PROC
and	O
the	O
neutrophil	O
-to	O
-	O
lymphocyte	O
ratio	O
,	O
both	O
routine	B-DISO
parameters	I-DISO
obtained	O
in	O
a	O
simple	O
blood	B-PROC
count	I-PROC
,	O
can	O
each	O
assist	O
in	O
differentiating	O
between	O
community	B-DISO
-	I-DISO
acquired	I-DISO
and	O
healthcare	B-DISO
-	I-DISO
associated	I-DISO
pneumonias	I-DISO
.	O

We	O
have	O
found	O
two	O
statistically	O
significant	O
parameters	O
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical	B-DISO
history	I-DISO
,	O
chest	B-PROC
radiography	I-PROC
and	O
other	B-DISO
parameters	I-DISO
in	O
forming	O
an	O
immediate	O
clinical	B-DISO
impression	I-DISO
of	O
a	O
patient	B-LIVB
presenting	O
with	O
pneumonia	B-DISO
.	O

Long	O
-	O
term	O
antibiofilm	O
activity	O
of	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
on	O
mixed	B-LIVB
biofilm	I-LIVB
on	O
silicone	B-CHEM
Silicone	B-CHEM
voice	B-DEVI
prostheses	I-DEVI
are	O
most	O
frequently	O
used	O
in	O
voice	B-PROC
rehabilitation	I-PROC
of	O
laryngectomized	B-PROC
patients	B-LIVB
.	O

However	O
,	O
the	O
functional	B-DISO
device	I-DISO
lifetimes	O
are	O
limited	O
due	O
to	O
formation	O
of	O
mixed	B-LIVB
biofilms	I-LIVB
.	O

Existing	O
in	B-PROC
vitro	I-PROC
models	I-PROC
simulating	O
biofilm	B-PHYS
formation	I-PHYS
are	O
restricted	O
to	O
only	O
short	O
-	O
term	O
periods	O
.	O

The	O
goal	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	O
the	O
effect	O
of	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
on	O
mixed	B-PHYS
biofilm	I-PHYS
formation	I-PHYS
of	O
fungi	B-LIVB
and	O
bacteria	B-LIVB
on	O
silicone	B-CHEM
over	O
a	O
long	O
-	O
term	O
period	O
.	O

Mixed	O
species	O
biofilms	B-LIVB
of	O
Candida	B-LIVB
albicans	I-LIVB
,	O
Candida	B-LIVB
tropicalis	I-LIVB
,	O
Lactobacillus	B-LIVB
gasseri	I-LIVB
,	O
Streptococcus	B-LIVB
salivarius	I-LIVB
,	O
Rothia	B-LIVB
dentocariosa	I-LIVB
,	O
and	O
Staphylococcus	B-LIVB
epidermidis	I-LIVB
were	O
cultivated	B-PHEN
on	O
the	O
surfaces	O
of	O
medical	B-CHEM
-	I-CHEM
grade	I-CHEM
silicone	I-CHEM
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
.	O

Biofilm	B-PHEN
kinetics	I-PHEN
was	O
monitored	O
using	O
specially	O
designed	O
image	O
analysis	O
software	O
to	O
calculate	O
the	O
percentual	O
surface	O
covering	O
of	O
each	O
platelet	B-ANAT
.	O

Biofilm	O
architecture	O
was	O
investigated	O
by	O
scanning	B-PROC
electron	I-PROC
microscopy	I-PROC
.	O

A	O
cover	O
of	O
living	O
mixed	B-LIVB
biofilm	I-LIVB
could	O
be	O
generated	O
over	O
22	O
days	O
on	O
silicone	B-CHEM
and	O
the	O
maximum	O
of	O
22	O
%	O
biofilm	B-LIVB
surface	O
covering	O
at	O
day	O
22	O
.	O

However	O
,	O
less	O
than	O
4	O
%	O
surface	O
coverage	O
was	O
observed	O
on	O
the	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
-	O
treated	O
plates	O
in	O
the	O
testing	O
period	O
.	O

Scanning	B-PROC
electron	I-PROC
microscopy	I-PROC
confirms	B-DISO
that	O
,	O
on	O
surfaces	O
treated	O
by	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
,	O
the	O
biofilm	B-LIVB
was	O
less	O
dense	O
.	O

In	O
addition	O
,	O
there	O
were	O
fewer	O
layers	O
of	O
cells	B-ANAT
and	O
profuse	B-DISO
cellular	I-DISO
debris	I-DISO
,	O
together	O
with	O
degrading	O
and	O
morphologically	B-DISO
altered	I-DISO
yeast	B-ANAT
cells	I-ANAT
.	O

Carboxymethyl	B-CHEM
chitosan	I-CHEM
may	O
serve	O
as	O
a	O
possible	B-DISO
antibiofilm	B-OBJC
agent	I-OBJC
to	O
limit	O
biofilm	B-PHYS
formation	I-PHYS
on	O
voice	B-DEVI
prostheses	I-DEVI
.	O

NA	O
Laryngoscope	B-DEVI
,	O
126	O
:	O
E404	O
-	O
E408	O
,	O
2016	O
.	O

Online	B-DISO
public	I-DISO
reactions	I-DISO
to	O
frequency	O
of	O
diagnostic	O
errors	O
in	O
US	B-GEOG
outpatient	B-OBJC
care	I-OBJC
Diagnostic	O
errors	O
pose	O
a	O
significant	O
threat	O
to	O
patient	B-PROC
safety	I-PROC
but	O
little	O
is	O
known	O
about	O
public	O
perceptions	B-PHYS
of	O
diagnostic	O
errors	O
.	O

A	O
study	B-PROC
published	O
in	O
BMJ	O
Quality	O
&	O
Safety	O
in	O
2014	O
estimated	O
that	O
diagnostic	O
errors	O
affect	O
at	O
least	O
5	O
%	O
of	O
US	B-GEOG
adults	B-LIVB
(	O
or	O
12	O
million	O
)	O
per	O
year	O
.	O

We	O
sought	O
to	O
explore	O
online	B-DISO
public	I-DISO
reactions	I-DISO
to	O
media	O
reports	O
on	O
the	O
reported	O
frequency	O
of	O
diagnostic	O
errors	O
in	O
the	O
US	B-GEOG
adult	B-LIVB
population	O
.	O

We	O
searched	O
the	O
World	B-OBJC
Wide	I-OBJC
Web	I-OBJC
for	O
any	O
news	O
article	O
reporting	O
findings	O
from	O
the	O
study	B-PROC
.	O

We	O
then	O
gathered	O
all	O
the	O
online	B-OBJC
comments	O
made	O
in	O
response	O
to	O
the	O
news	O
articles	O
to	O
evaluate	B-PROC
public	B-DISO
reaction	I-DISO
to	O
the	O
newly	O
reported	O
diagnostic	O
error	O
frequency	O
(	O
n	O
=	O
241	O
)	O
.	O

Two	O
coders	B-LIVB
conducted	O
content	B-PROC
analyses	I-PROC
of	O
the	O
comments	O
and	O
an	O
experienced	B-PHYS
qualitative	O
researcher	B-LIVB
resolved	B-DISO
differences	O
.	O

Overall	O
,	O
there	O
were	O
few	O
comments	O
made	O
regarding	O
the	O
frequency	O
of	O
diagnostic	O
errors	O
.	O

However	O
,	O
in	O
response	O
to	O
the	O
media	O
coverage	O
,	O
44	O
commenters	B-LIVB
shared	O
personal	O
experiences	O
of	O
diagnostic	O
errors	O
.	O

Additionally	O
,	O
commentary	O
centered	O
on	O
diagnosis	O
-	O
related	O
quality	B-PROC
of	I-PROC
care	I-PROC
as	O
affected	O
by	O
two	O
emergent	O
categories	O
:	O
(	O
1	O
)	O
US	B-GEOG
health	B-LIVB
care	I-LIVB
providers	I-LIVB
(	O
n	O
=	O
79	O
;	O
63	O
commenters	B-LIVB
)	O
and	O
(	O
2	O
)	O
US	B-GEOG
health	O
care	O
reform	O
-	O
related	O
policies	O
,	O
most	O
commonly	O
the	O
Affordable	O
Care	O
Act	O
(	O
ACA	O
)	O
and	O
insurance	O
/	O
reimbursement	O
issues	O
(	O
n	O
=	O
62	O
;	O
47	O
commenters	B-LIVB
)	O
.	O

The	O
public	O
appears	O
to	O
have	O
substantial	O
concerns	O
about	O
the	O
impact	O
of	O
the	O
ACA	O
and	O
other	O
reform	B-PHYS
initiatives	I-PHYS
on	O
the	O
diagnosis	O
-	O
related	O
quality	B-PROC
of	I-PROC
care	I-PROC
.	O

However	O
,	O
policy	O
discussions	O
on	O
diagnostic	O
errors	O
are	O
largely	O
absent	O
from	O
the	O
current	O
national	O
conversation	O
on	O
improving	O
quality	O
and	O
safety	B-PHEN
.	O

Because	O
outpatient	B-LIVB
diagnostic	O
errors	O
have	O
emerged	O
as	O
a	O
major	O
safety	B-PHEN
concern	O
,	O
researchers	B-LIVB
and	O
policymakers	B-LIVB
should	O
consider	O
evaluating	B-PROC
the	O
effects	O
of	O
policy	O
and	O
practice	B-PHYS
changes	O
on	O
diagnostic	O
accuracy	O
.	O

Retroperitoneal	B-DISO
hemorrhage	I-DISO
after	O
ureteroscopy	B-PROC
without	O
laser	B-PROC
lithotripsy	I-PROC
:	O
an	O
extreme	O
example	O
of	O
an	O
underreported	O
event	O
?	O

Retroperitoneal	B-DISO
hemorrhage	I-DISO
and	O
an	O
associated	O
hematoma	B-DISO
are	O
uncommon	O
but	O
potentially	O
serious	O
complications	B-DISO
following	O
ureteroscopy	B-PROC
with	O
laser	B-PROC
lithotripsy	I-PROC
.	O

However	O
,	O
no	O
reports	O
of	O
serious	O
bleeding	B-DISO
complications	B-DISO
have	O
been	O
published	O
regarding	O
ureteroscopy	B-PROC
without	O
laser	B-PROC
lithotripsy	I-PROC
in	O
the	O
management	B-PROC
of	O
stone	B-ANAT
disease	I-ANAT
.	O

We	O
report	O
of	O
such	O
a	O
case	O
here	O
and	O
then	O
review	O
the	O
current	O
literature	O
in	O
order	O
to	O
discuss	O
the	O
incidence	O
,	O
risk	B-DISO
factors	I-DISO
,	O
and	O
management	B-PROC
of	O
such	O
events	O
.	O

Spectral	B-PROC
fingerprints	I-PROC
of	O
large	O
-	O
scale	O
cortical	B-ANAT
dynamics	B-PHEN
during	O
ambiguous	O
motion	B-PHYS
perception	I-PHYS
Ambiguous	O
stimuli	B-PHEN
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	B-ANAT
correlates	O
of	O
consciousness	B-PHYS
.	O

Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	B-PHYS
perception	B-PHYS
might	O
arise	O
from	O
the	O
dynamic	O
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	B-ANAT
areas	I-ANAT
.	O

While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	B-PHYS
coupling	I-PHYS
as	O
a	O
correlate	O
of	O
cortical	B-ANAT
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	B-PHYS
modes	I-PHYS
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	B-PHYS
functions	I-PHYS
.	O

Here	O
,	O
we	O
studied	O
two	O
coupling	B-PHYS
modes	I-PHYS
,	O
namely	O
phase	B-PHYS
and	I-PHYS
envelope	I-PHYS
coupling	I-PHYS
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	B-PHEN
.	O

Therefore	O
,	O
we	O
recorded	O
128	O
-	O
channel	O
EEG	B-PROC
while	O
participants	B-LIVB
performed	O
a	O
bistable	B-PROC
motion	I-PROC
task	I-PROC
and	O
utilized	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
source	O
-	O
space	O
connectivity	O
analysis	B-PROC
techniques	O
to	O
study	O
the	O
functional	O
relevance	O
of	O
different	O
coupling	B-PHYS
modes	I-PHYS
for	O
cortical	B-ANAT
communication	O
.	O

Our	O
results	O
indicate	O
that	O
gamma	B-PHYS
-	I-PHYS
band	I-PHYS
phase	I-PHYS
coupling	I-PHYS
in	O
extrastriate	B-ANAT
visual	B-ANAT
cortex	I-ANAT
might	O
mediate	O
the	O
integration	O
of	O
visual	B-PROC
tokens	I-PROC
into	O
a	O
moving	B-PHYS
stimulus	B-PHEN
during	O
ambiguous	O
visual	B-PROC
stimulation	I-PROC
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long	O
-	O
range	O
fronto	O
-	O
occipital	O
gamma	O
-	O
band	O
envelope	B-PHYS
coupling	I-PHYS
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	O
motion	B-PHYS
perception	I-PHYS
.	O

Additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	B-ANAT
parieto	I-ANAT
-	I-ANAT
occipital	I-ANAT
alpha	B-PHYS
-	I-PHYS
band	I-PHYS
phase	I-PHYS
coupling	I-PHYS
controls	O
the	O
inter	O
-	O
hemispheric	O
information	O
transfer	O
.	O

These	O
findings	O
provide	O
correlative	O
evidence	O
for	O
the	O
notion	O
that	O
synchronized	O
oscillatory	O
brain	B-PHYS
activity	I-PHYS
reflects	O
the	O
processing	B-PHYS
of	I-PHYS
sensory	I-PHYS
input	O
as	O
well	O
as	O
the	O
information	B-PHYS
integration	I-PHYS
across	O
several	O
spatiotemporal	B-PROC
scales	I-PROC
.	O

The	O
results	O
indicate	O
that	O
distinct	O
coupling	O
modes	O
are	O
involved	O
in	O
different	O
cortical	B-ANAT
computations	O
and	O
that	O
the	O
rich	O
spatiotemporal	B-PROC
correlation	I-PROC
structure	B-ANAT
of	I-ANAT
the	I-ANAT
brain	I-ANAT
might	O
constitute	O
the	O
functional	O
architecture	O
for	O
cortical	B-ANAT
processing	O
and	O
specific	O
multi	O
-	O
site	O
communication	O
.	O

Hum	O
Brain	O
Mapp	O
37	O
:	O
4099	O
-	O
4111	O
,	O
2016	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

A	O
quasi	B-PROC
-	I-PROC
experimental	I-PROC
study	I-PROC
of	O
a	O
reminiscence	B-PROC
program	I-PROC
focused	O
on	O
autobiographical	B-PHYS
memory	I-PHYS
in	O
institutionalized	O
older	B-LIVB
adults	I-LIVB
with	O
cognitive	B-DISO
impairment	I-DISO
Working	O
with	O
past	B-PHYS
memories	I-PHYS
through	O
reminiscence	B-PROC
interventions	I-PROC
has	O
been	O
practiced	O
for	O
several	O
decades	O
with	O
successful	O
outcomes	O
on	O
mental	B-PHYS
health	I-PHYS
in	O
older	B-LIVB
adults	I-LIVB
.	O

Few	O
studies	B-PROC
however	O
have	O
focused	O
on	O
autobiographical	B-PHYS
memory	I-PHYS
recall	B-PHYS
in	O
older	B-LIVB
individuals	I-LIVB
with	O
cognitive	B-DISO
impairment	I-DISO
.	O

This	O
study	B-PROC
aims	O
to	O
analyze	O
the	O
impact	O
of	O
an	O
individual	B-LIVB
reminiscence	B-PROC
program	I-PROC
in	O
a	O
group	O
of	O
older	B-LIVB
persons	I-LIVB
with	O
cognitive	B-DISO
decline	I-DISO
living	O
in	O
nursing	B-OBJC
homes	I-OBJC
on	O
the	O
dimensions	O
of	O
cognition	B-PHYS
,	O
autobiographical	B-PHYS
memory	I-PHYS
,	O
mood	B-PHYS
,	O
behavior	O
and	O
anxiety	B-DISO
.	O

A	O
two	O
-	O
group	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
design	O
with	O
single	B-PROC
blinded	I-PROC
assessment	I-PROC
was	O
conducted	O
.	O

Forty	O
-	O
one	O
participants	B-LIVB
were	O
randomized	O
to	O
an	O
experimental	B-LIVB
group	I-LIVB
(	O
n	O
=	O
20	O
)	O
and	O
a	O
control	B-LIVB
group	I-LIVB
(	O
n	O
=	O
21	O
)	O
.	O

The	O
first	O
group	O
attended	O
five	O
weekly	O
individual	B-LIVB
reminiscence	B-PHYS
sessions	O
.	O

Changes	O
in	O
the	O
outcome	O
measures	O
were	O
examined	B-DISO
for	O
cognition	B-PHYS
(	O
Montreal	O
Cognitive	O
Assessment	O
;	O
Autobiographical	O
Memory	O
Test	O
)	O
,	O
behavior	O
(	O
Alzheimer	O
Disease	O
Assessment	O
Subscale	O
Non	O
-	O
Cog	O
)	O
and	O
emotional	B-DISO
status	I-DISO
(	O
Cornell	O
Scale	O
for	O
Depression	O
in	O
Dementia	B-DISO
;	O
Geriatric	O
Depression	O
Scale	O
,	O
and	O
Geriatric	O
Anxiety	O
Inventory	O
)	O
.	O

Participants	B-LIVB
attending	O
reminiscence	O
sessions	O
exhibited	O
better	O
outcomes	O
compared	O
to	O
the	O
control	B-LIVB
group	I-LIVB
in	O
cognition	B-PHYS
,	O
anxiety	B-DISO
and	O
depression	B-DISO
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
presented	O
a	O
higher	O
number	O
of	O
retrieved	B-PHYS
autobiographical	O
events	O
,	O
specificity	O
of	O
evoked	O
memories	B-PHYS
and	O
positive	O
valence	O
of	O
events	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
also	O
presented	O
lower	O
latency	O
time	O
for	O
recalling	B-PHYS
events	O
,	O
and	O
lower	O
negative	O
recalled	B-PHYS
events	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
study	O
supports	O
the	O
potential	O
value	O
of	O
reminiscence	B-PROC
therapy	I-PROC
in	O
improving	O
the	O
recall	B-PHYS
of	O
autobiographical	B-PHYS
memory	I-PHYS
.	O

Reminiscence	B-PROC
therapy	I-PROC
can	O
be	O
helpful	O
to	O
maintain	O
or	O
improve	O
cognitive	B-PHYS
function	I-PHYS
,	O
decrease	O
anxiety	B-DISO
and	O
manage	O
depressive	B-DISO
symptoms	I-DISO
and	O
altered	O
behavior	O
,	O
but	O
further	O
investigation	O
is	O
needed	O
to	O
clarify	O
long	O
-	O
term	O
effects	O
.	O

Characterization	O
and	O
Genomic	B-PROC
Analysis	I-PROC
of	O
a	O
Highly	O
Efficient	O
Dibutyl	B-CHEM
Phthalate	I-CHEM
-	O
Degrading	B-PHYS
Bacterium	B-LIVB
Gordonia	I-LIVB
sp	I-LIVB
.	I-LIVB

Strain	I-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
A	O
bacterial	B-LIVB
strain	I-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
isolated	O
from	O
activated	B-PHEN
sludge	I-PHEN
was	O
identified	O
as	O
Gordonia	B-LIVB
sp	I-LIVB
.	I-LIVB

based	O
on	O
analysis	B-PROC
of	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequence	O
and	O
was	O
found	O
to	O
be	O
capable	O
of	O
utilizing	O
dibutyl	B-CHEM
phthalate	I-CHEM
(	O
DBP	B-CHEM
)	O
and	O
other	O
common	O
phthalate	B-CHEM
esters	I-CHEM
(	O
PAEs	B-CHEM
)	O
as	O
the	O
sole	O
carbon	B-CHEM
and	O
energy	B-DISO
source	I-DISO
.	O

The	O
degradation	B-PHYS
kinetics	B-PHEN
of	O
DBP	B-CHEM
under	O
different	O
concentrations	O
by	O
the	O
strain	B-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
fit	O
well	O
with	O
the	O
modified	O
Gompertz	O
model	O
(	O
R²	O
>	O
0	O
.	O
98	O
)	O
.	O

However	O
,	O
strain	B-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
could	O
not	O
utilize	O
the	O
major	B-OBJC
intermediate	I-OBJC
product	I-OBJC
phthalate	B-CHEM
(	O
phthalic	B-CHEM
acid	I-CHEM
;	O
PA	B-CHEM
)	O
as	O
the	O
sole	O
carbon	B-CHEM
and	O
energy	B-DISO
source	I-DISO
,	O
and	O
only	O
a	O
little	O
amount	O
of	O
PA	B-CHEM
was	O
detected	B-DISO
.	O

The	O
QH	B-LIVB
-	I-LIVB
12	I-LIVB
genome	B-PROC
analysis	I-PROC
revealed	O
the	O
presence	O
of	O
putative	O
hydrolase	O
/	O
esterase	O
genes	O
involved	O
in	O
PAEs	B-CHEM
-	O
degradation	B-PHYS
but	O
no	O
phthalic	B-CHEM
acid	I-CHEM
catabolic	O
gene	O
cluster	O
was	O
found	O
,	O
suggesting	O
that	O
a	O
novel	O
degradation	O
pathway	O
of	O
PAEs	B-CHEM
was	O
present	O
in	O
Gordonia	B-LIVB
sp	I-LIVB
.	I-LIVB

QH	I-LIVB
-	I-LIVB
12	I-LIVB
.	O

This	O
information	O
will	O
be	O
valuable	O
for	O
obtaining	O
a	O
more	O
holistic	O
understanding	O
on	O
diverse	O
genetic	O
mechanisms	O
of	O
PAEs	B-CHEM
-degrading	O
Gordonia	B-LIVB
sp	I-LIVB
.	I-LIVB

strains	I-LIVB
.	O

Multimorbidity	O
in	O
Heart	B-DISO
Failure	I-DISO
:	O
Effect	O
on	O
Outcomes	B-DISO
To	O
investigate	O
the	O
effect	O
of	O
the	O
number	O
and	O
type	O
of	O
comorbid	B-DISO
conditions	I-DISO
on	O
death	B-PHYS
and	O
hospitalizations	B-PROC
in	O
individuals	B-LIVB
with	O
incident	O
heart	B-DISO
failure	I-DISO
(	O
HF	B-DISO
)	O
.	O

Population	B-PROC
-	I-PROC
based	I-PROC
cohort	O
study	O
.	O

Olmsted	B-GEOG
County	I-GEOG
,	I-GEOG
Minnesota	I-GEOG
.	O

Olmsted	B-GEOG
County	I-GEOG
,	I-GEOG
Minnesota	I-GEOG
,	O
residents	O
with	O
incident	O
HF	B-DISO
from	O
2000	O
to	O
2010	O
(	O
mean	O
age	B-PHYS
76	O
±	O
14	O
,	O
56	O
%	O
female	B-PHYS
)	O
(	O
N	O
=	O
1	O
,	O
714	O
)	O
.	O

The	O
prevalence	O
of	O
16	O
chronic	O
conditions	B-DISO
obtained	O
at	O
HF	B-DISO
diagnosis	B-PROC
classified	O
into	O
three	O
groups	O
:	O
cardiovascular	B-ANAT
(	O
CV	B-ANAT
)	O
related	O
,	O
other	O
physical	O
,	O
and	O
mental	B-PHYS
.	O

The	O
mean	O
number	O
of	O
conditions	B-DISO
per	O
participant	B-LIVB
was	O
2	O
.	O
6	O
±	O
1	O
.	O

5	O
for	O
CV	B-ANAT
-related	O
conditions	B-DISO
,	O
1	O
.	O
3	O
±	O
1	O
.	O
1	O
for	O
other	O
physical	B-PHYS
conditions	I-PHYS
,	O
and	O
0	O
.	O
30	O
±	O
0	O
.	O
61	O
for	O
mental	O
conditions	O
.	O

After	O
a	O
mean	O
follow	O
-	O
up	O
of	O
4	O
.	O
2	O
years	O
,	O
1	O
,	O
073	O
death	B-PHYS
s	O
and	O
6	O
,	O
306	O
hospitalizations	B-PROC
had	O
occurred	O
.	O

After	O
adjustment	O
for	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
ejection	B-PROC
fraction	I-PROC
,	O
in	O
-	O
or	O
outpatient	B-LIVB
status	O
,	O
and	O
number	O
of	O
other	O
conditions	B-DISO
,	O
an	O
increase	O
of	O
one	O
other	O
physical	B-PHYS
condition	I-PHYS
was	O
associated	O
with	O
a	O
14	O
%	O
(	O
HR	B-PHYS
=	O
1	O
.	O
14	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
08	O
-	O
1	O
.	O
20	O
)	O
greater	O
risk	O
of	O
death	B-PHYS
and	O
a	O
26	O
%	O
(	O
HR	B-PHYS
=	O
1	O
.	O
26	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
20	O
-	O
1	O
.	O
32	O
)	O
greater	O
risk	O
of	O
hospitalization	B-PROC
,	O
and	O
an	O
increase	O
of	O
one	O
mental	O
condition	O
was	O
associated	O
with	O
a	O
31	O
%	O
(	O
HR	B-PHYS
=	O
1	O
.	O
31	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
19	O
-	O
1	O
.	O
44	O
)	O
greater	O
risk	O
of	O
death	B-PHYS
and	O
an	O
18	O
%	O
(	O
HR	B-PHYS
=	O
1	O
.	O
18	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
07	O
-	O
1	O
.	O
29	O
)	O
greater	O
risk	O
of	O
hospitalization	B-PROC
.	O

In	O
contrast	O
,	O
an	O
increase	O
of	O
one	O
CV	B-ANAT
-related	O
condition	B-DISO
was	O
not	O
associated	O
with	O
greater	O
risk	O
of	O
death	B-PHYS
and	O
was	O
associated	O
with	O
a	O
10	O
%	O
(	O
HR	B-PHYS
=	O
1	O
.	O
10	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
06	O
-	O
1	O
.	O
15	O
)	O
greater	O
risk	O
of	O
hospitalization	B-PROC
.	O

CV	B-ANAT
-related	O
conditions	B-DISO
are	O
the	O
most	O
common	O
type	O
of	O
comorbid	B-DISO
conditions	I-DISO
in	O
individuals	B-LIVB
with	O
HF	B-DISO
,	O
but	O
other	O
physical	O
and	O
mental	O
conditions	O
are	O
more	O
strongly	O
associated	O
with	O
death	B-PHYS
and	O
hospitalizations	B-PROC
.	O

This	O
underscores	O
the	O
effect	O
of	O
non	B-DISO
-	I-DISO
CV	I-DISO
conditions	I-DISO
on	O
outcomes	O
in	O
HF	B-DISO
.	O

Economic	O
Burden	O
of	O
Illness	B-DISO
Among	O
Patients	B-LIVB
with	O
Severe	B-DISO
Asthma	I-DISO
in	O
a	O
Managed	O
Care	B-OBJC
Setting	I-OBJC
Despite	O
intensive	O
pharmacotherapy	B-PROC
,	O
a	O
considerable	O
number	O
of	O
patients	B-LIVB
with	O
severe	B-DISO
asthma	I-DISO
have	O
inadequate	O
disease	B-DISO
control	O
.	O

Patients	B-LIVB
with	O
severe	B-DISO
asthma	I-DISO
who	O
experience	B-PHYS
exacerbations	B-DISO
consume	O
significant	O
health	O
care	O
resources	O
.	O

To	O
assess	O
health	O
care	O
resource	O
utilization	O
and	O
associated	O
costs	O
among	O
patients	B-LIVB
with	O
persistent	O
severe	B-DISO
asthma	I-DISO
who	O
experienced	B-PHYS
exacerbations	B-DISO
compared	O
with	O
patients	B-LIVB
with	O
persistent	O
but	O
nonsevere	O
asthma	B-DISO
.	O

This	O
retrospective	O
analysis	B-PROC
of	O
a	O
national	O
administrative	O
claims	O
database	O
identified	O
patients	B-LIVB
aged	B-PHYS
≥	O
12	O
years	O
who	O
had	O
at	O
least	O
1	O
medical	O
claim	O
with	O
an	O
asthma	B-DISO
diagnosis	B-DISO
in	O
2012	O
and	O
had	O
continuous	O
medical	B-DISO
and	O
pharmacy	B-DISO
coverage	I-DISO
under	O
a	O
commercial	O
or	O
Medicare	O
Advantage	O
plan	O
from	O
January	O
1	O
,	O
2012	O
,	O
to	O
December	O
31	O
,	O
2013	O
.	O

Patients	B-LIVB
were	O
assigned	O
to	O
1	O
of	O
2	O
mutually	O
exclusive	O
cohorts	B-LIVB
-	O
persistent	B-DISO
asthma	I-DISO
(	O
PA	B-DISO
)	O
or	O
severe	B-DISO
asthma	I-DISO
(	O
SA	B-DISO
)	O
-	O
according	O
to	O
an	O
established	O
algorithm	O
based	O
on	O
asthma	B-DISO
-related	O
health	O
care	O
resource	O
use	O
and	O
pharmacy	B-DISO
claims	I-DISO
for	O
controller	B-CHEM
medication	I-CHEM
.	O

SA	B-DISO
patients	B-LIVB
were	O
required	O
to	O
meet	B-PHEN
PA	B-DISO
criteria	O
and	O
also	O
have	O
evidence	O
of	O
≥2	O
asthma	B-DISO
exacerbations	I-DISO
in	O
2012	O
.	O

Asthma	B-DISO
-related	O
health	O
care	O
resource	O
utilization	O
and	O
costs	O
were	O
computed	O
from	O
asthma	B-DISO
medication	B-PROC
use	O
(	O
rescue	O
and	O
controller	O
therapy	O
)	O
and	O
medical	O
claims	O
with	O
an	O
asthma	B-DISO
diagnosis	B-DISO
in	O
the	O
primary	O
position	O
in	O
2012	O
and	O
2013	O
.	O

Adherence	O
to	O
controller	O
therapy	O
was	O
assessed	O
over	O
365	O
days	O
by	O
using	O
the	O
proportion	O
of	O
days	O
covered	O
(	O
PDC	O
)	O
,	O
starting	O
with	O
the	O
first	O
claim	O
for	O
controller	O
therapy	O
in	O
2012	O
.	O

Differences	O
between	O
the	O
PA	B-DISO
and	O
SA	B-DISO
cohorts	B-LIVB
were	O
analyzed	B-PROC
by	O
t	O
-	O
test	O
for	O
continuous	O
variables	O
and	O
chi	O
-	O
square	O
test	O
for	O
categorical	O
variables	O
.	O

Asthma	B-DISO
-related	O
costs	O
in	O
2013	O
were	O
also	O
analyzed	B-PROC
using	O
a	O
generalized	O
linear	O
model	O
with	O
a	O
gamma	O
distribution	O
and	O
log	O
link	O
,	O
adjusted	O
for	O
patient	B-LIVB
demographics	O
(	O
age	B-PHYS
,	O
gender	B-PHYS
,	O
region	B-GEOG
,	O
and	O
insurance	O
type	O
)	O
and	O
Quan	O
-	O
Charlson	O
comorbidity	O
score	O
.	O

A	O
total	O
of	O
65	O
,	O
359	O
patients	B-LIVB
were	O
included	O
:	O
63	O
,	O
597	O
(	O
97	O
.	O
3	O
%	O
)	O
PA	B-DISO
patients	B-LIVB
and	O
1	O
,	O
762	O
SA	B-DISO
patients	B-LIVB
(	O
2	O
.	O

7	O
%	O
)	O
.	O

Compared	O
with	O
the	O
PA	B-DISO
cohort	B-LIVB
,	O
the	O
SA	B-DISO
cohort	B-LIVB
was	O
older	B-LIVB
(	O
mean	B-PHYS
age	I-PHYS
=	O
50	O
.	O

8	O
years	O
vs	O
.	O

46	O
.	O
5	O
years	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
had	O
higher	O
mean	O
comorbidity	O
score	O
(	O
1	O
.	O
47	O
vs	O
.	O

1	O
.	O
31	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
count	O
of	O
all	O
asthma	B-DISO
medications	B-PROC
fills	O
was	O
2	O
.	O
2	O
-	O
fold	O
(	O
2012	O
)	O
and	O
2	O
.	O
1	O
-	O
fold	O
(	O
2013	O
)	O
higher	O
in	O
the	O
SA	B-DISO
cohort	B-LIVB
,	I-LIVB
compared	O
with	O
the	O
PA	B-DISO
cohort	B-LIVB
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Mean	O
PDC	O
for	O
all	O
oral	B-CHEM
and	O
inhaled	B-PHYS
controller	B-PROC
therapy	I-PROC
was	O
also	O
higher	O
in	O
the	O
SA	B-DISO
cohort	B-LIVB
compared	O
with	O
the	O
PA	B-DISO
cohort	B-LIVB
(	O
0	O
.	O
80	O
vs	O
.	O

0	O
.	O
65	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

SA	B-DISO
patients	B-LIVB
had	O
a	O
significantly	O
greater	O
mean	O
count	O
of	O
asthma	B-DISO
-related	O
hospitalizations	B-PROC
,	O
emergency	B-PROC
room	I-PROC
visits	I-PROC
,	O
and	O
ambulatory	B-DISO
visits	I-DISO
in	O
2012	O
and	O
2013	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Unadjusted	O
mean	O
annual	O
asthma	B-DISO
-related	O
costs	O
in	O
the	O
SA	B-DISO
versus	O
PA	B-DISO
cohorts	B-LIVB
were	O
$	O
6	O
,	O
496	O
versus	O
$	O
2	O
,	O
739	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
2012	O
and	O
$	O
5	O
,	O
174	O
versus	O
$	O
1	O
,	O
775	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
2013	O
.	O

Higher	O
asthma	B-DISO
-related	O
costs	O
were	O
driven	O
by	O
greater	O
mean	O
annual	O
asthma	B-DISO
medication	B-PROC
costs	O
in	O
2012	O
(	O
$	O
4	O
,	O
545	O
vs	O
.	O

$	O
1	O
,	O
738	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
2013	O
(	O
$	O
4	O
,	O
068	O
vs	O
.	O

$	O
1	O
,	O
348	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Adjusted	O
mean	O
annual	O
asthma	B-DISO
-related	O
costs	O
in	O
2013	O
were	O
$	O
3	O
,	O
336	O
greater	O
(	O
cost	O
ratio	O
=	O
2	O
.	O

878	O
,	O
P	O
<	O
0	O
.	O

001	O
)	O
in	O
the	O
SA	B-DISO
cohort	B-LIVB
,	O
and	O
adjusted	O
mean	O
annual	O
asthma	B-DISO
medication	B-PROC
costs	O
were	O
$	O
2	O
,	O
672	O
higher	O
(	O
cost	O
ratio	O
=	O
2	O
.	O
982	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
SA	B-DISO
cohort	B-LIVB
.	O

Patients	B-LIVB
with	O
SA	B-DISO
who	O
experienced	B-PHYS
2	O
or	O
more	O
exacerbations	B-DISO
had	O
2	O
.	O
1	O
-	O
fold	O
greater	O
use	O
of	O
controller	B-PROC
medications	I-PROC
across	O
both	O
study	O
years	O
and	O
were	O
more	O
adherent	O
to	O
controller	O
therapy	O
than	O
patients	B-LIVB
with	O
PA	B-DISO
.	O

Despite	O
more	O
intensive	O
pharmacotherapy	B-PROC
,	O
SA	B-DISO
patients	B-LIVB
incurred	O
2	O
.	O
9	O
-	O
fold	O
higher	O
adjusted	O
asthma	B-DISO
-related	O
costs	O
and	O
3	O
-	O
fold	O
higher	O
adjusted	O
asthma	B-DISO
medication	B-PROC
costs	O
than	O
PA	B-DISO
patients	B-LIVB
.	O

Patients	B-LIVB
with	O
SA	B-DISO
consistently	O
demonstrated	O
a	O
higher	O
rate	O
of	O
health	B-PROC
care	I-PROC
utilization	O
.	O

Funding	O
for	O
this	O
study	B-PROC
(	O
HO	O
-	O
14	O
-	O
14443	O
)	O
was	O
provided	O
by	O
GlaxoSmithKline	O
(	O
GSK	O
)	O
.	O

All	O
listed	O
authors	B-LIVB
meet	B-PHEN
the	O
criteria	O
for	O
authorship	O
set	O
forth	O
by	O
the	O
International	B-LIVB
Committee	I-LIVB
for	I-LIVB
Medical	I-LIVB
Journal	I-LIVB
Editors	I-LIVB
.	O

Albers	O
,	O
Forshag	O
,	O
and	O
Yancey	O
are	O
employees	B-LIVB
of	O
GSK	O
and	O
hold	O
stock	O
in	O
GSK	O
.	O

Dalal	O
,	O
Nagar	O
,	O
and	O
Ortega	O
were	O
employees	B-LIVB
of	O
GSK	O
at	O
the	O
time	O
this	O
research	B-PROC
was	O
conducted	O
.	O

Chastek	O
and	O
Korrer	O
are	O
employees	B-LIVB
of	O
Optum	O
,	O
which	O
received	O
consulting	O
fees	O
from	O
GSK	O
for	O
research	B-PROC
related	O
to	O
this	O
study	B-PROC
.	O

Study	O
concept	O
and	O
design	O
were	O
contributed	O
by	O
Chastek	O
,	O
Nagar	O
,	O
and	O
Dalal	O
.	O

Korrer	O
took	O
the	O
lead	O
in	O
data	B-PROC
collection	I-PROC
,	O
along	O
with	O
Chastek	O
,	O
and	O
data	O
interpretation	O
was	O
performed	O
by	O
Chastek	O
,	O
Ortega	O
,	O
Forshag	O
,	O
and	O
Dalal	O
.	O

The	O
manuscript	B-OBJC
was	O
written	O
by	O
Chastek	O
and	O
Dalal	O
and	O
revised	O
by	O
Albers	O
and	O
Yancy	O
,	O
assisted	O
by	O
the	O
other	O
authors	B-LIVB
.	O

Contemporary	O
mandibular	B-PROC
reconstruction	I-PROC
Multiple	O
disease	B-DISO
processes	I-DISO
,	O
including	O
neoplasia	B-DISO
,	O
trauma	B-DISO
,	O
and	O
medication	O
side	O
-	O
effects	O
,	O
necessitate	O
segmental	B-PROC
resection	I-PROC
and	O
subsequent	O
reconstruction	B-PROC
of	I-PROC
the	I-PROC
mandible	I-PROC
.	O

As	O
surgical	O
techniques	O
have	O
advanced	O
,	O
several	O
technologies	O
have	O
been	O
developed	O
with	O
the	O
potential	O
to	O
significantly	O
transform	O
a	O
surgeon	B-LIVB
's	I-LIVB
approach	O
to	O
the	O
restoration	O
of	O
mandibular	B-ANAT
continuity	I-ANAT
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
highlight	O
many	O
of	O
these	O
relatively	O
newer	O
tools	O
and	O
discuss	O
their	O
evolving	O
role	O
in	O
mandibular	B-PROC
reconstruction	I-PROC
.	O

Several	O
contemporary	B-PROC
studies	I-PROC
have	O
documented	B-PROC
the	O
application	O
of	O
different	O
approaches	O
and	O
modifications	O
to	O
mandibular	B-PROC
reconstruction	I-PROC
-	O
including	O
computer	O
-	O
aided	O
design	O
or	O
computer	O
-	O
aided	O
modeling	O
,	O
contemporary	O
plating	B-DEVI
systems	I-DEVI
,	O
osseointegrated	B-DEVI
implants	I-DEVI
,	O
and	O
various	O
modifications	O
to	O
existing	O
osseocutaneous	O
free	O
tissue	O
transfer	O
options	O
-	O
and	O
have	O
reported	O
relatively	O
high	O
success	O
rates	O
.	O

In	O
discussing	O
these	O
reports	O
,	O
we	O
present	O
a	O
survey	O
of	O
current	O
and	O
developing	O
technologies	O
in	O
the	O
field	O
of	O
mandibular	B-PROC
reconstruction	I-PROC
and	O
aim	O
to	O
provide	O
sufficient	O
context	O
for	O
the	O
gradual	O
integration	O
of	O
these	O
techniques	O
into	O
practice	O
.	O

Differential	B-PHYS
regulation	I-PHYS
of	O
spontaneous	O
and	O
evoked	O
inhibitory	B-PHYS
synaptic	I-PHYS
transmission	I-PHYS
in	O
somatosensory	B-ANAT
cortex	I-ANAT
by	O
retinoic	B-CHEM
acid	I-CHEM
Retinoic	B-CHEM
acid	I-CHEM
(	O
RA	B-CHEM
)	O
,	O
a	O
developmental	O
morphogen	B-CHEM
,	O
has	O
emerged	O
in	O
recent	O
studies	O
as	O
a	O
novel	O
synaptic	B-PHYS
signaling	B-CHEM
molecule	I-CHEM
that	O
acts	O
in	O
mature	O
hippocampal	B-ANAT
neurons	B-ANAT
to	O
modulate	O
excitatory	B-PHYS
and	O
inhibitory	B-PHYS
synaptic	I-PHYS
transmission	I-PHYS
in	O
the	O
context	O
of	O
homeostatic	B-PHEN
synaptic	B-PHYS
plasticity	I-PHYS
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
RA	B-CHEM
is	O
capable	O
of	O
modulating	O
neural	O
circuits	O
outside	O
of	O
the	O
hippocampus	B-ANAT
,	O
and	O
if	O
so	O
,	O
whether	O
the	O
mode	O
of	O
RA	O
's	O
action	O
at	O
synapses	B-ANAT
is	O
similar	O
to	O
that	O
within	O
the	O
hippocampal	B-ANAT
network	O
.	O

Here	O
we	O
explore	O
for	O
the	O
first	O
time	O
RA	B-CHEM
'	O
s	O
synaptic	B-PHYS
function	I-PHYS
outside	O
the	O
hippocampus	B-ANAT
and	O
uncover	O
a	O
novel	O
function	O
of	O
all	B-CHEM
-	I-CHEM
trans	I-CHEM
retinoic	I-CHEM
acid	I-CHEM
at	O
inhibitory	B-ANAT
synapses	I-ANAT
.	O

Acute	O
RA	B-CHEM
treatment	O
increases	O
spontaneous	O
inhibitory	B-PHYS
synaptic	I-PHYS
transmission	I-PHYS
in	O
L2	B-ANAT
/	I-ANAT
3	I-ANAT
pyramidal	I-ANAT
neurons	I-ANAT
of	O
the	O
somatosensory	B-ANAT
cortex	I-ANAT
,	O
and	O
this	O
effect	O
requires	O
expression	B-PHYS
of	O
RA	B-CHEM
's	I-CHEM
receptor	I-CHEM
RARα	B-CHEM
both	O
pre	B-PHYS
-	I-PHYS
and	I-PHYS
post	I-PHYS
-	I-PHYS
synaptically	I-PHYS
.	O

Intriguingly	O
,	O
RA	B-CHEM
does	O
not	O
seem	O
to	O
affect	O
evoked	O
inhibitory	B-PHYS
transmission	I-PHYS
assayed	O
with	O
either	O
extracellular	B-ANAT
stimulation	O
or	O
direct	O
activation	B-PHYS
of	I-PHYS
action	I-PHYS
potentials	I-PHYS
in	O
presynaptic	B-ANAT
interneurons	B-ANAT
at	O
connected	O
pairs	O
of	O
interneurons	B-ANAT
and	O
pyramidal	B-ANAT
neurons	I-ANAT
.	O

Taken	O
together	O
,	O
these	O
results	B-DISO
suggest	O
that	O
RA	B-CHEM
's	I-CHEM
action	O
at	O
synapses	B-ANAT
is	O
not	O
monotonous	O
,	O
but	O
is	O
diverse	O
depending	O
on	O
the	O
type	O
of	O
synaptic	B-PHYS
connection	I-PHYS
(	O
excitatory	B-PHYS
versus	O
inhibitory	B-PHYS
)	O
and	O
circuit	O
(	O
hippocampal	B-ANAT
versus	O
cortical	B-ANAT
)	I-ANAT
.	O

Thus	O
,	O
synaptic	B-PHYS
signaling	I-PHYS
of	O
RA	B-CHEM
may	O
mediate	O
multi	O
-	O
faceted	O
regulation	B-PHYS
of	I-PHYS
synaptic	I-PHYS
plasticity	I-PHYS
.	O

In	O
addition	O
to	O
its	O
classic	O
roles	O
in	O
brain	B-PHYS
development	I-PHYS
,	O
retinoic	B-CHEM
acid	I-CHEM
(	O
RA	B-CHEM
)	O
has	O
recently	O
been	O
shown	O
to	O
regulate	B-PHYS
excitatory	B-PHYS
and	O
inhibitory	B-PHYS
transmission	I-PHYS
in	O
the	O
adult	B-LIVB
brain	B-ANAT
.	O

Here	O
,	O
the	O
authors	B-LIVB
show	O
that	O
in	O
layer	B-ANAT
2	I-ANAT
/	I-ANAT
3	I-ANAT
(	O
L2	B-ANAT
/	I-ANAT
3	I-ANAT
)	O
of	O
the	O
somatosensory	B-ANAT
cortex	I-ANAT
(	O
S1	B-ANAT
)	O
,	O
acute	O
RA	B-CHEM
induces	O
increases	O
in	O
spontaneous	O
but	O
not	O
action	B-PHYS
-	I-PHYS
potential	I-PHYS
evoked	O
transmission	B-PHYS
,	O
and	O
that	O
this	O
requires	O
retinoic	B-CHEM
acid	I-CHEM
receptor	I-CHEM
(	O
RARα	B-CHEM
)	O
both	O
in	O
presynaptic	B-ANAT
PV	B-CHEM
-positive	O
interneurons	B-ANAT
and	O
postsynaptic	O
pyramidal	B-ANAT
(	I-ANAT
PN	I-ANAT
)	I-ANAT
neurons	I-ANAT
.	O

Radiolabeled	O
B9958	B-CHEM
Derivatives	I-CHEM
for	O
Imaging	B-PROC
Bradykinin	B-CHEM
B1	I-CHEM
Receptor	I-CHEM
Expression	B-PHYS
with	O
Positron	B-PROC
Emission	I-PROC
Tomography	I-PROC
:	O
Effect	O
of	O
the	O
Radiolabel	B-CHEM
-	O
Chelator	B-CHEM
Complex	B-CHEM
on	O
Biodistribution	O
and	O
Tumor	B-DISO
Uptake	B-PHYS
Bradykinin	B-CHEM
B1	I-CHEM
receptor	I-CHEM
(	O
B1R	B-CHEM
)	O
,	O
which	O
is	O
upregulated	B-PHYS
in	O
a	O
variety	O
of	O
malignancies	B-DISO
,	O
is	O
an	O
attractive	O
cancer	B-PROC
imaging	I-PROC
biomarker	B-PHYS
.	O

In	O
this	O
study	B-PROC
we	O
optimized	O
the	O
selection	O
of	O
radiolabel	B-CHEM
-	O
chelator	B-CHEM
complex	B-CHEM
to	O
improve	O
tumor	B-DISO
uptake	B-PHYS
and	O
tumor	B-DISO
-to	O
-	O
background	O
contrast	O
of	O
radiolabeled	O
analogues	B-CHEM
of	O
B9958	B-CHEM
(	O
Lys	O
-	O
Lys	O
-	O
Arg	O
-	O
Pro	O
-	O
Hyp	O
-	O
Gly	O
-	O
Cpg	O
-	O
Ser	O
-	O
d	O
-	O
Tic	O
-	O
Cpg	O
)	O
,	O
a	O
potent	O
B1R	B-CHEM
antagonist	I-CHEM
.	O

Peptide	B-CHEM
sequences	I-CHEM
were	O
assembled	O
on	O
solid	O
phase	O
.	O

Cold	O
standards	O
were	O
prepared	O
by	O
incubating	O
DOTA	B-CHEM
-	O
/	O
NODA	B-CHEM
-	O
conjugated	O
peptides	B-CHEM
with	O
GaCl3	B-CHEM
,	O
and	O
by	O
incubating	O
AlOH	B-CHEM
-	O
NODA	B-CHEM
-conjugated	O
peptide	B-CHEM
with	O
NaF	B-CHEM
.	O

Binding	B-PHYS
affinities	B-PHEN
were	O
measured	O
via	O
in	B-PROC
vitro	I-PROC
competition	I-PROC
binding	I-PROC
assays	I-PROC
.	O

(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
and	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
labeling	B-PROC
experiments	I-PROC
were	O
performed	O
in	O
acidic	B-CHEM
buffer	I-CHEM
and	O
purified	O
by	O
HPLC	B-PROC
.	O

Imaging	B-PROC
/	O
biodistribution	O
studies	B-PROC
were	O
performed	O
in	O
mice	B-LIVB
bearing	O
both	O
B1R	B-CHEM
-	I-CHEM
positive	I-CHEM
(	O
B1R	B-CHEM
+	I-CHEM
)	O
HEK293	B-ANAT
T	I-ANAT
:	O
:	O
hB1R	B-ANAT
and	O
B1R	B-DISO
-	I-DISO
negative	I-DISO
(	O
B1R	B-DISO
-	I-DISO
)	O
HEK293	B-ANAT
T	I-ANAT
tumors	B-DISO
.	O

Z02176	B-CHEM
(	O
Ga	B-CHEM
-	I-CHEM
DOTA	I-CHEM
-	I-CHEM
Pip	I-CHEM
-	I-CHEM
B9958	I-CHEM
;	O
Pip	B-CHEM
:	O
4	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
(	I-CHEM
1	I-CHEM
-	I-CHEM
carboxymethyl	I-CHEM
)	I-CHEM
piperidine	I-CHEM
)	I-CHEM
,	O
Z02137	B-CHEM
(	O
Ga	B-CHEM
-	I-CHEM
NODA	I-CHEM
-	I-CHEM
Mpaa	I-CHEM
-	I-CHEM
Pip	I-CHEM
-	I-CHEM
B9958	I-CHEM
;	O
Mpaa	B-CHEM
:	O
4	B-CHEM
-	I-CHEM
methylphenylacetic	I-CHEM
acid	I-CHEM
)	O
,	O
and	O
Z04139	B-CHEM
(	O
AlF	B-CHEM
-	I-CHEM
NODA	I-CHEM
-	I-CHEM
Mpaa	I-CHEM
-	I-CHEM
Pip	I-CHEM
-	I-CHEM
B9958	I-CHEM
)	O
bound	O
h	O
B1R	B-CHEM
with	O
high	O
affinity	B-PHEN
(	O
Ki	O
=	O
1	O
.	O
4	O
-	O
2	O
.	O
5	O
nM	O
)	O
.	O

(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O
/	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O
labeled	O
peptides	B-CHEM
were	O
obtained	O
on	O
average	O
in	O
≥32	O
%	O
decay	O
-	O
corrected	O
radiochemical	B-CHEM
yield	O
with	O
>	O
99	O
%	O
radiochemical	B-CHEM
purity	O
and	O
100	O
-	O
261	O
GBq	O
/	O
μmol	O
specific	O
activity	O
.	O

Biodistribution	O
/	O
imaging	B-PROC
studies	B-PROC
at	O
1	O
h	O
postinjection	O
showed	O
that	O
all	O
tracers	B-CHEM
cleared	O
rapidly	O
from	O
background	O
tissues	O
(	O
except	O
kidneys	B-ANAT
)	O
and	O
were	O
excreted	B-PHYS
predominantly	O
via	O
the	O
renal	B-PHYS
pathway	I-PHYS
.	O

Only	O
kidneys	B-ANAT
,	O
bladders	B-ANAT
,	O
and	O
B1R	B-CHEM
+	I-CHEM
tumors	B-DISO
were	O
clearly	O
visualized	O
in	O
PET	B-PROC
images	O
.	O

Uptake	B-PHYS
in	O
B1R	B-CHEM
+	I-CHEM
tumor	B-DISO
was	O
higher	O
by	O
using	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O
Z02176	B-CHEM
(	O
28	O
.	O
9	O
±	O
6	O
.	O

21	O
%	O
ID	O
/	O
g	O
)	O
and	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O
Z04139	B-CHEM
(	O
22	O
.	O
6	O
±	O
3	O
.	O
41	O
%	O
ID	O
/	O
g	O
)	O
than	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O
Z02137	B-CHEM
(	O
14	O
.	O
0	O
±	O
4	O
.	O

86	O
%	O
ID	O
/	O
g	O
)	O
.	O

The	O
B1R	O
+	O
tumor	O
-	O
to	O
-	O
blood	O
and	O
B1R	O
+	O
tumor	O
-	O
to	O
-	O
muscle	O
contrast	O
ratios	O
were	O
also	O
higher	O
for	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O
Z02176	B-CHEM
(	O
56	O
.	O
1	O
±	O
17	O
.	O

3	O
and	O
167	O
±	O
57	O
.	O
6	O
)	O
and	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O
Z04139	B-CHEM
(	O
58	O
.	O
0	O
±	O
20	O
.	O
9	O
and	O
173	O
±	O
42	O
.	O
9	O
)	O
than	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O
Z02137	B-CHEM
(	O
34	O
.	O

3	O
±	O
15	O
.	O
2	O
and	O
103	O
±	O
30	O
.	O
2	O
)	O
.	O

With	O
improved	O
target	O
-	O
to	O
-	O
background	O
contrast	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O
Z02176	B-CHEM
and	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O
Z04139	B-CHEM
are	O
promising	O
for	O
imaging	B-PROC
B1R	B-CHEM
expression	B-PHYS
in	O
cancers	B-DISO
with	O
PET	B-PROC
.	O

Heterogeneous	O
silicon	B-CHEM
mesostructures	B-CHEM
for	O
lipid	B-CHEM
-supported	O
bioelectric	B-DEVI
interfaces	B-PHYS
Silicon	B-CHEM
-based	O
materials	B-OBJC
have	O
widespread	O
application	O
as	O
biophysical	B-PHEN
tools	B-OBJC
and	O
biomedical	B-DEVI
devices	I-DEVI
.	O

Here	O
we	O
introduce	O
a	O
biocompatible	B-CHEM
and	O
degradable	B-CHEM
mesostructured	B-CHEM
form	O
of	O
silicon	B-CHEM
with	O
multi	O
-	O
scale	O
structural	O
and	O
chemical	O
heterogeneities	O
.	O

The	O
material	B-OBJC
was	O
synthesized	O
using	O
mesoporous	B-CHEM
silica	I-CHEM
as	O
a	O
template	O
through	O
a	O
chemical	B-PHEN
vapour	I-PHEN
deposition	I-PHEN
process	I-PHEN
.	O

It	O
has	O
an	O
amorphous	O
atomic	B-CHEM
structure	O
,	O
an	O
ordered	O
nanowire	B-OBJC
-based	O
framework	O
and	O
random	O
submicrometre	O
voids	O
,	O
and	O
shows	O
an	O
average	O
Young	O
's	O
modulus	O
that	O
is	O
2	O
-	O
3	O
orders	O
of	O
magnitude	O
smaller	O
than	O
that	O
of	O
single	B-CHEM
-	I-CHEM
crystalline	I-CHEM
silicon	B-CHEM
.	O

In	O
addition	O
,	O
we	O
used	O
the	O
heterogeneous	O
silicon	B-CHEM
mesostructures	B-CHEM
to	O
design	O
a	O
lipid	B-ANAT
-	I-ANAT
bilayer	I-ANAT
-supported	O
bioelectric	B-PHYS
interface	B-PHYS
that	O
is	O
remotely	O
controlled	O
and	O
temporally	O
transient	O
,	O
and	O
that	O
permits	O
non	O
-	O
genetic	O
and	O
subcellular	B-ANAT
optical	O
modulation	O
of	O
the	O
electrophysiology	O
dynamics	B-PHEN
in	O
single	O
dorsal	B-ANAT
root	I-ANAT
ganglia	I-ANAT
neurons	B-ANAT
.	O

Our	O
findings	O
suggest	O
that	O
the	O
biomimetic	O
expansion	O
of	O
silicon	B-CHEM
into	O
heterogeneous	O
and	O
deformable	O
forms	O
can	O
open	O
up	O
opportunities	O
in	O
extracellular	B-ANAT
biomaterial	B-CHEM
or	O
bioelectric	B-DEVI
systems	I-DEVI
.	O

Gender	B-PHYS
Authorship	O
Trends	O
of	O
Plastic	O
Surgery	O
Research	B-PROC
in	O
the	O
United	B-GEOG
States	I-GEOG
An	O
increasing	O
number	O
of	O
women	B-LIVB
are	O
entering	O
the	O
medical	O
profession	O
,	O
but	O
plastic	O
surgery	O
remains	O
a	O
male	B-PHYS
-	O
dominated	O
profession	O
,	O
especially	O
within	O
academia	O
.	O

As	O
academic	O
aspirations	B-PHYS
and	O
advancement	O
depend	O
largely	O
on	O
research	B-PROC
productivity	O
,	O
the	O
authors	B-LIVB
assessed	O
the	O
number	O
of	O
articles	O
authored	O
by	O
women	B-LIVB
published	O
in	O
the	O
journal	O
Plastic	O
and	O
Reconstructive	O
Surgery	O
.	O

Original	O
articles	O
in	O
Plastic	O
and	O
Reconstructive	O
Surgery	O
published	O
during	O
the	O
years	O
1970	O
,	O
1980	O
,	O
1990	O
,	O
2000	O
,	O
2004	O
,	O
and	O
2014	O
were	O
analyzed	O
.	O

First	O
and	O
senior	B-LIVB
authors	B-LIVB
with	O
an	O
M	O
.	O

D	O
.	O

degree	O
and	O
U	O
.	O

S	O
.	O

institutional	O
affiliation	O
were	O
categorized	O
by	O
gender	B-PHYS
.	O

Authorship	O
trends	O
were	O
compared	O
with	O
those	O
from	O
other	O
specialties	O
.	O

Findings	O
were	O
placed	O
in	O
the	O
context	O
of	O
gender	B-PHYS
trends	O
among	O
plastic	O
surgery	O
residents	O
in	O
the	O
United	B-GEOG
States	I-GEOG
.	O

The	O
percentage	O
of	O
female	B-PHYS
authors	B-LIVB
in	O
Plastic	O
and	O
Reconstructive	O
Surgery	O
increased	O
from	O
2	O
.	O
4	O
percent	O
in	O
1970	O
to	O
13	O
.	O

3	O
percent	O
in	O
2014	O
.	O

Over	O
the	O
same	O
time	O
period	O
,	O
the	O
percentage	O
of	O
female	B-PHYS
plastic	O
surgery	O
residents	O
increased	O
from	O
2	O
.	O

6	O
percent	O
to	O
32	O
.	O

5	O
percent	O
.	O

By	O
2014	O
,	O
there	O
were	O
more	O
female	B-PHYS
first	O
authors	B-LIVB
(	O
19	O
.	O
1	O
percent	O
)	O
than	O
senior	O
authors	B-LIVB
(	O
7	O
.	O

7	O
percent	O
)	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

As	O
a	O
field	O
,	O
plastic	O
surgery	O
had	O
fewer	O
female	B-PHYS
authors	B-LIVB
than	O
other	O
medical	O
specialties	O
including	O
pediatrics	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
general	O
surgery	O
,	O
internal	O
medicine	O
,	O
and	O
radiation	O
oncology	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
increase	O
in	O
representation	O
of	O
female	B-PHYS
authors	B-LIVB
in	O
plastic	O
surgery	O
is	O
encouraging	O
but	O
lags	O
behind	O
advances	O
in	O
other	O
specialties	O
.	O

Understanding	O
reasons	O
for	O
these	O
trends	O
may	O
help	O
improve	O
gender	B-PHYS
equity	O
in	O
academic	O
plastic	O
surgery	O
.	O

Utilization	O
Pattern	O
and	O
Drug	B-PHYS
Use	I-PHYS
of	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
Medicine	O
,	O
and	O
Integrated	O
Chinese	O
-	O
Western	O
Medicine	O
Treatments	B-PROC
for	O
Allergic	B-DISO
Rhinitis	I-DISO
Under	O
the	O
National	B-PROC
Health	I-PROC
Insurance	I-PROC
Program	I-PROC
in	O
Taiwan	B-GEOG
Patients	B-LIVB
in	O
Taiwan	B-GEOG
with	O
allergic	B-DISO
rhinitis	I-DISO
seek	O
not	O
only	O
Western	O
medicine	O
treatment	B-PROC
but	O
also	O
Traditional	O
Chinese	O
Medicine	O
treatment	B-PROC
or	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-PROC
.	O

Various	O
studies	O
have	O
conducted	O
pairwise	O
comparison	O
on	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
medicine	O
,	O
and	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatments	B-PROC
.	O

However	O
,	O
none	O
conducted	O
simultaneous	O
analysis	B-PROC
of	O
the	O
three	O
treatments	B-PROC
.	O

This	O
study	O
analyzed	B-PROC
patients	B-LIVB
with	O
allergic	B-DISO
rhinitis	I-DISO
receiving	O
the	O
three	O
treatments	B-PROC
to	O
identify	O
differences	O
in	O
demographic	O
characteristic	O
and	O
medical	O
use	O
and	O
thereby	O
to	O
determine	O
drug	B-PHYS
use	I-PHYS
patterns	I-PHYS
of	O
different	O
treatments	B-PROC
.	O

The	O
National	O
Health	O
Insurance	O
Research	O
Database	O
was	O
the	O
data	O
source	O
,	O
and	O
included	O
patients	B-LIVB
were	O
those	O
diagnosed	B-DISO
with	O
allergic	B-DISO
rhinitis	I-DISO
(	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
,	O
Clinical	O
Modification	O
codes	O
470	O
-	O
478	O
)	O
.	O

Chi	O
-	O
square	O
test	O
and	O
Tukey	O
studentized	O
range	O
(	O
honest	O
significant	O
difference	O
)	O
test	O
were	O
conducted	O
to	O
investigate	O
the	O
differences	O
among	O
the	O
three	O
treatments	B-PROC
.	O

Visit	O
frequency	O
for	O
allergic	B-DISO
rhinitis	I-DISO
treatment	B-PROC
was	O
higher	O
in	O
female	B-LIVB
than	O
male	B-LIVB
patients	B-LIVB
,	O
regardless	O
of	O
treatment	B-PROC
with	O
Traditional	O
Chinese	O
Medicine	O
,	O
Western	O
medicine	O
,	O
or	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
.	O

Persons	B-LIVB
aged	O
0	O
-	O
19	O
years	O
ranked	O
the	O
highest	O
in	O
proportion	O
of	O
visits	B-PROC
for	O
allergic	B-DISO
rhinitis	I-DISO
.	O

Traditional	O
Chinese	O
Medicine	O
treatment	B-PROC
had	O
more	O
medical	O
items	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
and	O
daily	O
drug	O
cost	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
and	O
had	O
the	O
lowest	O
total	O
expenditure	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
.	O

In	O
contrast	O
,	O
Western	O
medicine	O
had	O
the	O
lowest	O
daily	O
drug	O
cost	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
and	O
the	O
highest	O
total	O
expenditure	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
.	O

The	O
total	O
expenditure	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
,	O
daily	O
drug	O
cost	O
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
,	O
and	O
medical	O
items	B-OBJC
per	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
of	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-PROC
lay	O
between	O
those	O
seen	O
with	O
Traditional	O
Chinese	O
Medicine	O
and	O
Western	O
medicine	O
treatments	B-PROC
.	O

Although	O
only	O
6	O
.	O
82	O
%	O
of	O
patients	B-LIVB
with	O
allergic	B-DISO
rhinitis	I-DISO
chose	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-PROC
,	O
the	O
visit	O
frequency	O
per	O
person	O
-	O
year	O
of	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
ranked	O
highest	O
.	O

In	O
addition	O
,	O
multiple	O
-	O
composition	O
medicines	B-CHEM
were	O
used	O
more	O
frequently	O
than	O
single	O
-	O
composition	O
medicines	B-CHEM
,	O
and	O
mar	B-CHEM
huang	I-CHEM
(	O
Ephedra	B-LIVB
sinica	I-LIVB
Stapf	I-LIVB
)	O
was	O
seldom	O
used	O
to	O
decrease	O
the	O
risk	O
of	O
combining	O
medications	B-CHEM
.	O

Beneficial	O
effects	O
of	O
voglibose	B-CHEM
administration	B-PROC
on	O
body	B-PHYS
weight	I-PHYS
and	O
lipid	B-PHYS
metabolism	I-PHYS
via	O
gastrointestinal	B-ANAT
bile	B-CHEM
acid	I-CHEM
modification	O
This	O
study	B-PROC
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	B-CHEM
administration	B-PROC
on	O
body	B-PHYS
weight	I-PHYS
and	O
lipid	B-PHYS
metabolism	I-PHYS
and	O
underlying	O
mechanism	O
high	B-PROC
fat	I-PROC
diet	I-PROC
-induced	O
obese	B-LIVB
mice	I-LIVB
.	O

Male	B-PHYS
C57BL	B-LIVB
/	I-LIVB
6	I-LIVB
mice	I-LIVB
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	B-LIVB
:	O
a	O
control	B-LIVB
diet	I-LIVB
(	O
CTL	B-LIVB
)	O
,	O
high	B-LIVB
-	I-LIVB
fat	I-LIVB
diet	I-LIVB
(	O
HF	B-LIVB
)	O
,	O
high	B-LIVB
-	I-LIVB
fat	I-LIVB
diet	I-LIVB
supplemented	I-LIVB
with	I-LIVB
voglibose	I-LIVB
(	O
VO	B-LIVB
)	O
,	O
and	O
high	B-LIVB
fat	I-LIVB
diet	I-LIVB
pair	I-LIVB
-	I-LIVB
fed	I-LIVB
group	I-LIVB
(	O
PF	B-LIVB
)	O
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	B-PROC
lipid	I-PROC
and	O
glucose	B-PHEN
levels	I-PHEN
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	B-PHYS
and	O
bile	B-PHYS
acid	I-PHYS
metabolism	I-PHYS
.	O

In	O
addition	O
,	O
pyrosequencing	B-PROC
was	O
used	O
to	O
analyze	O
the	O
composition	B-PHYS
of	O
gut	B-LIVB
microbiota	I-LIVB
found	O
in	O
feces	B-ANAT
.	O

Total	B-DISO
body	I-DISO
weight	I-DISO
gain	I-DISO
was	O
significantly	O
lower	O
in	O
the	O
VO	B-LIVB
group	I-LIVB
than	O
in	O
the	O
CTL	B-LIVB
,	O
HF	B-LIVB
,	O
and	O
PF	B-LIVB
groups	I-LIVB
.	O

The	O
VO	B-LIVB
group	I-LIVB
exhibited	O
improved	O
metabolic	B-PHYS
profiles	I-PHYS
including	O
those	O
of	O
blood	B-PROC
glucose	I-PROC
,	O
triglyceride	B-PHEN
,	O
and	O
total	B-PHEN
cholesterol	I-PHEN
levels	I-PHEN
.	O

The	O
12	O
-	O
week	O
voglibose	B-CHEM
administration	B-PROC
decreased	O
the	O
ratio	O
of	O
Firmicutes	B-LIVB
to	O
Bacteroidetes	B-LIVB
found	O
in	O
feces	B-ANAT
.	O

Circulating	O
levels	O
of	O
taurocholic	B-CHEM
and	O
cholic	B-CHEM
acid	I-CHEM
were	O
significantly	O
higher	O
in	O
the	O
VO	B-LIVB
group	I-LIVB
than	O
in	O
the	O
HF	B-LIVB
and	O
CTL	B-LIVB
groups	I-LIVB
.	O

Deoxycholic	B-CHEM
acid	I-CHEM
levels	O
tended	O
to	O
be	O
higher	O
in	O
the	O
VO	B-LIVB
group	I-LIVB
than	O
in	O
the	O
HF	B-LIVB
group	I-LIVB
.	O

Voglibose	B-CHEM
administration	B-PROC
downregulated	B-PHYS
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	O
and	O
upregulated	B-PHYS
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	B-CHEM
administration	B-PROC
elicits	O
changes	O
in	O
the	O
composition	B-PHYS
of	O
the	O
intestinal	B-LIVB
microbiota	I-LIVB
and	O
circulating	B-CHEM
metabolites	I-CHEM
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	B-PHYS
weight	I-PHYS
and	O
lipid	B-PHYS
metabolism	I-PHYS
in	O
mice	B-LIVB
.	O

REST	O
levels	O
affect	B-PROC
the	O
functional	O
expression	B-PHYS
of	O
voltage	B-CHEM
dependent	I-CHEM
calcium	I-CHEM
channels	I-CHEM
and	O
the	O
migratory	O
activity	O
in	O
immortalized	B-PROC
GnRH	B-CHEM
neurons	B-ANAT
The	O
repressor	O
element	O
-	O
1	O
silencing	O
transcription	O
factor	O
(	O
REST	O
)	O
has	O
emerged	O
as	O
a	O
key	O
controller	O
of	O
neuronal	B-CHEM
differentiation	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
expression	B-PHYS
of	O
the	O
neuronal	B-CHEM
phenotype	B-PHYS
;	O
however	O
,	O
much	O
has	O
still	O
to	O
be	O
learned	O
about	O
its	O
role	O
at	O
specific	O
developmental	O
stages	O
and	O
about	O
the	O
functional	O
targets	O
affected	O
.	O

Among	O
these	O
targets	O
,	O
calcium	B-PHYS
signaling	I-PHYS
mechanisms	O
are	O
critically	O
dependent	O
on	O
the	O
developmental	O
stage	O
and	O
their	O
full	O
expression	B-PHYS
is	O
a	O
hallmark	O
of	O
the	O
mature	O
,	O
functional	O
neuron	B-ANAT
.	O

We	O
have	O
analyzed	O
the	O
role	O
played	O
by	O
REST	O
in	O
GN11	B-ANAT
cells	I-ANAT
,	O
an	O
immortalized	B-ANAT
cell	I-ANAT
line	O
derived	O
from	O
gonadotropin	B-CHEM
hormone	I-CHEM
releasing	I-CHEM
hormone	I-CHEM
(	O
GnRH	B-CHEM
)	O
neurons	B-ANAT
at	O
an	O
early	O
developmental	O
stage	O
,	O
electrically	B-PHEN
non	B-DISO
-	I-DISO
excitable	I-DISO
and	O
with	O
a	O
strong	O
migratory	O
activity	O
.	O

We	O
show	O
for	O
the	O
first	O
time	O
that	O
functional	O
voltage	B-CHEM
-	I-CHEM
dependent	I-CHEM
calcium	I-CHEM
channels	I-CHEM
are	O
expressed	B-PHYS
in	O
wild	O
type	O
GN11	B-ANAT
cells	I-ANAT
;	O
down	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
REST	O
by	O
a	O
silencing	B-PHYS
approach	O
shifts	O
these	O
cells	B-ANAT
towards	O
a	O
more	O
differentiated	O
phenotype	B-PHYS
,	O
increasing	O
the	O
functional	O
expression	B-PHYS
of	O
P	B-CHEM
/	O
Q	B-CHEM
-	I-CHEM
type	I-CHEM
channels	I-CHEM
and	O
reducing	O
their	O
migratory	O
potential	O
.	O

The	O
knee	B-DISO
joint	I-DISO
loose	I-DISO
body	I-DISO
as	O
a	O
source	O
of	O
viable	O
autologous	O
human	B-LIVB
chondrocytes	B-ANAT
Loose	B-DISO
bodies	I-DISO
are	O
fragments	O
of	O
cartilage	O
or	O
bone	B-ANAT
present	O
in	O
the	O
synovial	B-ANAT
fluid	I-ANAT
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
if	O
loose	B-DISO
bodies	I-DISO
could	O
be	O
used	O
as	O
a	O
source	O
of	O
autologous	O
human	B-LIVB
chondrocytes	B-ANAT
for	O
experimental	B-PROC
purposes	I-PROC
.	O

Histochemical	B-PROC
examination	I-PROC
of	O
loose	B-DISO
bodies	I-DISO
and	O
differential	O
enzymatic	B-PROC
digestions	I-PROC
were	O
undertaken	O
,	O
the	O
isolated	O
cells	B-ANAT
were	O
cultured	B-ANAT
in	O
alginate	B-CHEM
bead	I-CHEM
microspheres	B-DEVI
and	O
immunolocalisations	B-PROC
were	O
undertaken	O
for	O
chondrogenic	B-PHYS
markers	B-PHYS
such	O
as	O
aggrecan	B-CHEM
,	O
and	O
type	B-CHEM
II	I-CHEM
collagen	I-CHEM
.	O

Isolated	O
loose	B-DISO
body	I-DISO
cells	B-ANAT
had	O
high	O
viability	B-PHYS
(	O
≥90	O
%	O
viable	O
)	O
,	O
expressed	O
chondrogenic	B-PHYS
markers	B-PHYS
(	O
aggrecan	B-CHEM
,	O
type	B-CHEM
II	I-CHEM
collagen	I-CHEM
)	O
but	O
no	B-DISO
type	B-CHEM
I	I-CHEM
collagen	I-CHEM
.	O

Loose	B-DISO
bodies	I-DISO
may	O
be	O
a	O
useful	O
source	O
of	O
autologous	O
chondrocytes	B-ANAT
of	O
high	O
viability	B-PHYS
.	O

Supramolecular	B-PHYS
Recognition	I-PHYS
of	O
Amino	B-CHEM
Acids	I-CHEM
by	O
Twisted	B-CHEM
Cucurbit	I-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
uril	I-CHEM
Binding	B-PHYS
interactions	O
between	O
twisted	B-CHEM
cucurbit	I-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
uril	I-CHEM
(	B-CHEM
tQ	I-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
)	I-CHEM
and	O
twenty	O
standard	O
amino	B-CHEM
acids	I-CHEM
(	B-CHEM
AAs	I-CHEM
)	I-CHEM
have	O
been	O
investigated	O
by	O
NMR	B-PROC
spectroscopy	I-PROC
and	O
isothermal	B-PROC
titration	I-PROC
calorimetry	I-PROC
(	B-PROC
ITC	I-PROC
)	I-PROC
in	O
aqueous	B-CHEM
HCl	B-CHEM
solutions	I-CHEM
and	O
in	O
DMSO	B-CHEM
.	O

The	O
results	O
showed	O
that	O
tQ	B-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
displays	O
clear	O
binding	B-PHYS
affinity	B-PHEN
for	O
AAs	B-CHEM
with	O
a	O
positively	B-CHEM
charged	I-CHEM
side	I-CHEM
chain	I-CHEM
or	O
containing	O
an	O
aromatic	B-CHEM
ring	I-CHEM
,	O
but	O
weaker	O
binding	B-PHYS
affinity	B-PHEN
for	O
AAs	B-CHEM
with	O
hydrophobic	B-CHEM
or	O
polar	B-CHEM
side	I-CHEM
chains	I-CHEM
,	O
with	O
the	O
binding	B-PHYS
mode	O
depending	O
on	O
the	O
type	O
of	O
side	B-CHEM
chain	I-CHEM
present	O
in	O
the	O
AAs	B-CHEM
.	O

Comparison	O
of	O
alkaline	B-PHYS
phosphatase	I-PHYS
activity	I-PHYS
of	O
MC3T3	B-ANAT
-	I-ANAT
E1	I-ANAT
cells	I-ANAT
cultured	O
on	O
different	O
Ti	B-CHEM
surfaces	O
:	O
modified	O
sandblasted	B-PHEN
with	O
large	O
grit	B-CHEM
and	O
acid	B-PHEN
-	I-PHEN
etched	I-PHEN
(	O
MSLA	B-CHEM
)	O
,	O
laser	B-PHEN
-	I-PHEN
treated	I-PHEN
,	O
and	O
laser	B-PHEN
and	I-PHEN
acid	I-PHEN
-	I-PHEN
treated	I-PHEN
Ti	B-CHEM
surfaces	O
In	O
this	O
study	B-PROC
,	O
the	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
the	O
effect	O
of	O
implant	O
surface	O
treatment	O
on	O
cell	B-PHYS
differentiation	I-PHYS
of	O
osteoblast	B-ANAT
cells	I-ANAT
.	O

For	O
this	O
purpose	O
,	O
three	O
surfaces	O
were	O
compared	O
:	O
(	O
1	O
)	O
a	O
modified	O
SLA	O
(	O
MSLA	O
:	O
sand	O
-	O
blasted	O
with	O
large	O
grit	B-CHEM
,	O
acid	O
-	O
etched	O
,	O
and	O
immersed	O
in	O
0	O
.	O

9	O
%	O
NaCl	B-CHEM
)	O
,	O
(	O
2	O
)	O
a	O
laser	B-PHEN
treatment	I-PHEN
(	O
LT	B-PHEN
:	O
laser	B-PHEN
treatment	I-PHEN
)	O
titanium	B-CHEM
surface	O
and	O
(	O
3	O
)	O
a	O
laser	B-PHEN
and	I-PHEN
acid	I-PHEN
-	I-PHEN
treated	I-PHEN
(	O
LAT	O
:	O
laser	B-PHEN
treatment	I-PHEN
,	I-PHEN
acid	I-PHEN
-	I-PHEN
etched	I-PHEN
)	O
titanium	B-CHEM
surface	O
.	O

The	O
MSLA	B-CHEM
surfaces	O
were	O
considered	O
as	O
the	O
control	B-LIVB
group	I-LIVB
,	O
and	O
LT	B-CHEM
and	O
LAT	B-CHEM
surfaces	O
as	O
test	O
groups	O
.	O

Alkaline	B-CHEM
phosphatase	I-CHEM
expression	B-PHYS
(	O
ALP	B-CHEM
)	O
was	O
used	O
to	O
quantify	O
osteoblastic	B-PHYS
differentiation	I-PHYS
of	O
MC3T3	B-ANAT
-	I-ANAT
E1	I-ANAT
cell	I-ANAT
.	O

Surface	O
roughness	O
was	O
evaluated	B-PROC
by	O
a	O
contact	B-DEVI
profilometer	I-DEVI
(	O
URFPAK	O
-	O
SV	O
;	O
Mitutoyo	O
,	O
Kawasaki	O
,	O
Japan	B-GEOG
)	O
and	O
characterized	O
by	O
two	O
parameters	O
:	O
mean	O
roughness	O
(	O
Ra	O
)	O
and	O
maximum	O
peak	O
-	O
to	O
-	O
valley	O
height	O
(	O
Rt	O
)	O
.	O

Scanning	B-DEVI
electron	I-DEVI
microscope	I-DEVI
revealed	O
that	O
MSLA	O
(	O
control	B-LIVB
group	I-LIVB
)	O
surface	O
was	O
not	O
as	O
rough	O
as	O
LT	B-CHEM
,	O
LAT	B-CHEM
surface	O
(	O
test	O
groups	O
)	O
.	O

Alkaline	B-CHEM
phosphatase	I-CHEM
expression	B-PHYS
,	O
the	O
measure	O
of	O
osteoblastic	B-PHYS
differentiation	I-PHYS
,	O
and	O
total	O
ALP	B-CHEM
expression	B-PHYS
by	O
surface	B-ANAT
-	I-ANAT
adherent	I-ANAT
cells	I-ANAT
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	O
for	O
all	O
three	O
surfaces	O
tested	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
ALP	B-CHEM
expression	B-PHYS
levels	O
of	O
MSLA	B-CHEM
and	O
LAT	B-CHEM
surfaces	O
were	O
significantly	O
higher	O
than	O
expression	B-PHYS
levels	O
of	O
LT	B-CHEM
surface	B-ANAT
-	I-ANAT
adherent	I-ANAT
cells	I-ANAT
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
,	O
respectively	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

However	O
,	O
ALP	B-CHEM
expression	B-PHYS
levels	O
between	O
MSLA	B-CHEM
and	O
LAT	B-CHEM
surface	O
were	O
equal	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
(	O
P	O
>	O
.	O
05	O
)	O
.	O

This	O
study	B-PROC
suggested	O
that	O
MSLA	B-CHEM
and	O
LAT	B-CHEM
surfaces	O
exhibited	O
more	O
favorable	O
environment	O
for	O
osteoblast	B-PHYS
differentiation	I-PHYS
when	O
compared	O
with	O
LT	B-CHEM
surface	O
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	B-DEVI
surface	O
modification	O
studies	B-PROC
.	O

Liganded	B-ANAT
Vitamin	B-CHEM
D	I-CHEM
Receptor	I-CHEM
Through	O
Its	O
Interacting	O
Repressor	B-CHEM
Inhibits	O
the	O
Expression	B-PHYS
of	O
Type	B-CHEM
I	I-CHEM
Collagen	I-CHEM
α1	I-CHEM
Hepatic	B-DISO
fibrosis	I-DISO
is	O
a	O
reversible	O
process	B-PHEN
involving	O
plenty	O
of	O
transcription	B-CHEM
factors	I-CHEM
and	O
pathways	B-PHYS
.	O

Vitamin	B-CHEM
D	I-CHEM
receptor	I-CHEM
(	O
VDR	B-CHEM
)	O
as	O
a	O
member	O
of	O
ligand	B-CHEM
-	O
induced	O
transcription	B-CHEM
factors	I-CHEM
can	O
interact	O
with	O
9	B-CHEM
-	I-CHEM
cis	I-CHEM
retinoid	I-CHEM
X	I-CHEM
receptor	I-CHEM
(	O
RXR	B-CHEM
)	O
and	O
VDR	O
-	O
interacting	O
repressor	O
(	O
VDIR	O
)	O
to	O
mediate	O
transactivation	B-PHYS
or	O
transrepression	B-PHYS
in	O
the	O
absence	O
or	O
in	O
the	O
presence	B-DISO
of	O
VDR	B-CHEM
ligand	B-PHYS
to	O
regulate	B-PHYS
the	O
expression	B-PHYS
of	O
VDR	O
target	O
genes	O
.	O

The	O
active	O
form	O
of	O
vitamin	B-CHEM
D	I-CHEM
[	O
1α	B-CHEM
,	I-CHEM
25	I-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
2D3	I-CHEM
]	O
can	O
downregulate	B-PHYS
the	O
expression	B-PHYS
of	O
type	B-CHEM
I	I-CHEM
collagen	I-CHEM
both	I-CHEM
α1	I-CHEM
and	O
α2	B-CHEM
(	O
COLIα1	B-CHEM
and	O
COLIα2	B-CHEM
)	O
in	O
hepatic	B-ANAT
stellate	I-ANAT
cells	I-ANAT
(	O
HSC	B-ANAT
-	I-ANAT
T6	I-ANAT
)	O
in	O
a	O
time	O
-	O
dependent	O
fashion	O
,	O
which	O
provides	O
a	O
new	O
direction	O
for	O
hepatic	B-DISO
fibrosis	I-DISO
therapy	B-PROC
.	O

As	O
one	O
of	O
VDR	O
target	O
genes	O
,	O
rat	B-LIVB
COLIα1	O
gene	O
contains	O
1αnVDRE	B-CHEM
(	O
E	B-CHEM
-	I-CHEM
box1	I-CHEM
and	O
E	B-CHEM
-	I-CHEM
box2	I-CHEM
)	O
in	O
its	O
promoter	B-CHEM
,	O
and	O
unliganded	B-DISO
VDR	B-CHEM
/	O
RXR	B-CHEM
may	O
bind	B-PHYS
to	O
1αnVDRE	B-CHEM
through	O
VDIR	O
to	O
mediate	O
transactivation	B-PHYS
,	O
whereas	O
liganded	B-ANAT
VDR	B-CHEM
/	O
RXR	B-CHEM
may	O
bind	B-PHYS
to	O
1αnVDRE	B-CHEM
through	O
VDIR	O
for	O
transrepression	B-PHYS
.	O

The	O
results	O
suggested	O
a	O
sort	O
of	O
relying	O
on	O
each	O
other	O
relationship	O
between	O
VDR	B-CHEM
/	O
RXR	B-CHEM
and	O
VDIR	O
in	O
regulating	B-PHYS
the	O
expression	B-PHYS
of	O
COLIα1	O
gene	O
in	O
HSC	B-ANAT
-	I-ANAT
T6	I-ANAT
cells	I-ANAT
,	O
which	O
established	O
VDR	B-CHEM
as	O
a	O
potential	O
target	O
for	O
blocking	O
and	O
even	O
reversing	O
hepatic	B-DISO
fibrosis	I-DISO
.	O

Treatment	B-PROC
with	O
high	O
dose	O
of	O
atorvastatin	B-CHEM
reduces	O
vascular	B-DISO
injury	I-DISO
in	O
diabetic	B-DISO
rats	B-LIVB
Previous	O
reports	O
showed	O
conflicting	O
results	O
regarding	O
the	O
treatment	B-PROC
effects	O
of	O
statin	B-CHEM
on	O
Diabetes	B-DISO
mellitus	I-DISO
(	O
DM	B-DISO
)	O
.	O

We	O
investigated	O
how	O
treatment	B-PROC
with	O
high	O
dose	O
of	O
atorvastatin	B-CHEM
affects	O
the	O
impaired	O
vascular	B-PHYS
function	I-PHYS
in	O
diabetic	B-DISO
rats	B-LIVB
.	O

Atorvastatin	B-CHEM
(	O
80mg	O
/	O
kg	O
/	O
day	O
,	O
oral	O
gavage	O
,	O
4	O
weeks	O
)	O
or	O
its	O
vehicle	B-CHEM
was	O
administered	O
to	O
male	B-LIVB
control	I-LIVB
or	O
streptozotocin	B-CHEM
(	O
STZ	B-CHEM
)	O
-	O
induced	O
diabetic	B-DISO
rats	B-LIVB
.	O

Aortic	B-ANAT
segments	I-ANAT
were	O
used	O
to	O
investigate	O
the	O
vascular	B-PHYS
reactivity	I-PHYS
,	O
protein	B-PHYS
expression	I-PHYS
of	O
cyclooxygenase	B-CHEM
-	I-CHEM
2	I-CHEM
(	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
)	O
and	O
nicotinamide	B-CHEM
adenine	I-CHEM
dinucleotide	I-CHEM
phosphate	I-CHEM
oxidase	I-CHEM
(	I-CHEM
NADPH	I-CHEM
oxidase	I-CHEM
)	I-CHEM
1	I-CHEM
(	O
NOX1	B-CHEM
)	O
and	O
superoxide	B-CHEM
anions	I-CHEM
levels	O
.	O

Atorvastatin	B-CHEM
treatment	B-PROC
did	O
not	O
affect	O
glycemia	B-PROC
levels	I-PROC
.	O

In	O
diabetic	B-DISO
rats	B-LIVB
,	O
the	O
vascular	B-PHYS
reactivity	I-PHYS
to	O
phenylephrine	B-CHEM
increased	O
compared	O
with	O
controls	B-OBJC
and	O
the	O
atorvastatin	B-CHEM
treatment	B-PROC
reduced	O
this	O
response	B-PHYS
.	O

Removal	O
of	O
the	O
endothelium	O
increased	O
the	O
response	B-PHYS
to	O
phenylephrine	B-CHEM
in	O
control	B-LIVB
rats	I-LIVB
,	O
but	O
not	O
in	O
the	O
diabetic	O
group	O
.	O

Atorvastatin	B-CHEM
increased	O
the	O
endothelial	O
modulation	O
in	O
diabetic	B-DISO
rats	B-LIVB
.	O

L	B-CHEM
-	I-CHEM
NAME	I-CHEM
(	O
100μM	O
)	O
increased	O
the	O
reactivity	O
in	O
all	O
groups	O
,	O
but	O
this	O
effect	O
was	O
greater	O
in	O
atorvastatin	B-CHEM
-treated	O
diabetic	B-DISO
rats	B-LIVB
.	O

Indomethacin	B-CHEM
(	O
10μM	O
)	O
and	O
NS398	B-CHEM
(	O
1μM	O
)	O
decreased	O
the	O
contractile	B-ANAT
response	B-PHYS
in	O
diabetic	B-DISO
rats	B-LIVB
and	O
atorvastatin	B-CHEM
reversed	O
these	O
effects	O
,	O
without	O
changing	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
expression	B-PHYS
.	O

Apocynin	B-CHEM
(	O
30μM	O
)	O
decreased	O
the	O
phenylephrine	B-CHEM
response	B-PHYS
in	O
diabetic	B-DISO
rats	B-LIVB
,	O
which	O
also	O
showed	O
increased	O
NOX1	B-CHEM
and	O
superoxide	B-CHEM
anions	I-CHEM
;	O
these	O
effects	O
were	O
prevented	O
by	O
atorvastatin	B-CHEM
treatment	B-PROC
.	O

The	O
results	O
suggest	O
that	O
treatment	B-PROC
with	O
high	O
dose	O
of	O
atorvastatin	B-CHEM
,	O
independent	O
of	O
glycemia	B-CHEM
,	O
improves	O
endothelial	O
function	O
in	O
aortas	B-ANAT
from	O
diabetic	B-DISO
rats	B-LIVB
by	O
reducing	O
the	O
constrictor	B-CHEM
prostanoids	I-CHEM
derived	O
from	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
by	O
reducing	O
the	O
oxidative	B-DISO
stress	I-DISO
by	O
NADPH	B-CHEM
oxidase	I-CHEM
,	O
as	O
well	O
as	O
a	O
possible	O
increasing	O
of	O
nitric	B-CHEM
oxide	I-CHEM
participation	O
.	O

Fracture	B-DISO
Resistance	I-DISO
of	O
Endodontically	B-DISO
Treated	I-DISO
Teeth	I-DISO
Restored	B-PROC
With	O
Bulk	B-CHEM
Fill	I-CHEM
,	O
Bulk	B-CHEM
Fill	I-CHEM
Flowable	I-CHEM
,	O
Fiber	B-CHEM
-	I-CHEM
reinforced	I-CHEM
,	O
and	O
Conventional	B-CHEM
Resin	I-CHEM
Composite	I-CHEM
The	O
aim	O
of	O
this	O
in	B-PROC
vitro	I-PROC
study	I-PROC
was	O
to	O
evaluate	B-PROC
the	O
fracture	B-DISO
resistance	I-DISO
of	O
endodontically	B-DISO
treated	I-DISO
teeth	I-DISO
restored	B-PROC
with	O
different	O
types	O
of	O
restorative	B-DEVI
resins	I-DEVI
.	O

Seventy	O
-	O
two	O
sound	O
maxillary	B-ANAT
premolar	B-ANAT
teeth	I-ANAT
were	O
randomly	O
divided	O
into	O
six	O
groups	O
(	O
n	O
=	O
12	O
)	O
.	O

The	O
teeth	B-ANAT
in	O
the	O
first	O
group	O
were	O
left	O
intact	O
and	O
tested	O
as	O
unprepared	O
negative	O
control	O
(	O
group	O
I	O
)	O
specimens	B-OBJC
.	O

The	O
teeth	B-ANAT
in	O
the	O
remaining	O
five	O
groups	O
were	O
prepared	O
with	O
MOD	B-DISO
cavities	I-DISO
and	O
endodontically	B-PROC
treated	I-PROC
.	O

The	O
teeth	B-ANAT
in	O
one	O
of	O
the	O
five	O
groups	O
(	O
positive	B-LIVB
control	I-LIVB
group	I-LIVB
II	I-LIVB
)	O
were	O
unrestored	B-DISO
.	O

The	O
rest	O
of	O
the	O
prepared	O
cavities	B-DISO
were	O
restored	B-PROC
as	O
follows	O
:	O
group	O
III	O
:	O
bulk	B-CHEM
fill	I-CHEM
resin	I-CHEM
composite	I-CHEM
/	O
Filtek	B-CHEM
Bulk	I-CHEM
Fill	I-CHEM
(	O
3	O
M	O
ESPE	O
)	O
;	O
group	O
IV	O
:	O
bulk	B-CHEM
fill	I-CHEM
flowable	I-CHEM
resin	I-CHEM
composite	I-CHEM
+	O
nanohybrid	B-CHEM
/	O
SureFil	B-CHEM
SDR	I-CHEM
Flow	I-CHEM
+	O
Ceram	B-CHEM
.	I-CHEM

X	I-CHEM
Mono	I-CHEM
(	O
Dentsply	O
)	O
;	O
group	O
V	O
:	O
fiber	B-CHEM
-	I-CHEM
reinforced	I-CHEM
composite	I-CHEM
+	O
posterior	B-CHEM
resin	I-CHEM
composite	I-CHEM
/	O
GC	B-CHEM
everX	I-CHEM
posterior	I-CHEM
+	O
G	B-CHEM
-	I-CHEM
aenial	I-CHEM
posterior	I-CHEM
(	O
GC	O
Corp	O
.	O
)	O
;	O
and	O
group	O
VI	O
:	O
nanohybrid	B-CHEM
resin	I-CHEM
composite	I-CHEM
/	O
Tetric	B-CHEM
N	I-CHEM
-	I-CHEM
Ceram	I-CHEM
(	O
Ivoclar	O
/	O
Vivadent	O
)	O
.	O

Each	O
restorative	B-CHEM
material	I-CHEM
was	O
used	O
with	O
its	O
respective	O
adhesive	B-CHEM
system	I-CHEM
.	O

The	O
restored	B-PROC
teeth	B-ANAT
were	O
stored	O
in	O
distilled	B-CHEM
water	I-CHEM
for	O
24	O
hours	O
at	O
37°C	O
and	O
were	O
then	O
thermocycled	O
(	O
5	O
-	O
55°C	O
,	O
1000×	O
)	O
.	O

Specimens	B-OBJC
were	O
subjected	O
to	O
a	O
compressive	O
load	O
until	O
fracture	B-DISO
at	O
a	O
crosshead	O
speed	O
of	O
0	O
.	O
5	O
mm	O
/	O
min	O
.	O

The	O
data	O
were	O
analyzed	B-PROC
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
followed	O
by	O
the	O
post	B-PROC
hoc	I-PROC
Tukey	I-PROC
honestly	O
significantly	O
different	O
test	B-PROC
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Sound	B-ANAT
premolar	I-ANAT
teeth	I-ANAT
(	O
group	O
I	O
negative	O
control	O
)	O
showed	O
significantly	O
higher	O
fracture	B-DISO
resistance	I-DISO
than	O
did	O
the	O
other	O
tested	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	B-DISO
in	O
the	O
fracture	B-DISO
resistance	I-DISO
values	O
of	O
the	O
restored	B-PROC
groups	O
(	O
groups	O
III	O
,	O
IV	O
,	O
V	O
,	O
and	O
VI	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
values	O
were	O
obtained	O
in	O
the	O
positive	B-LIVB
control	I-LIVB
group	I-LIVB
(	O
group	O
II	O
)	O
;	O
these	O
values	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
other	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
fracture	B-DISO
resistance	I-DISO
values	O
of	O
endodontically	B-DISO
treated	I-DISO
teeth	I-DISO
restored	B-PROC
with	O
either	O
bulk	B-CHEM
fill	I-CHEM
/	O
bulk	B-CHEM
fill	I-CHEM
flowable	I-CHEM
or	O
fiber	B-CHEM
-	I-CHEM
reinforced	I-CHEM
composite	I-CHEM
were	O
not	O
different	O
from	O
those	O
restored	B-PROC
with	O
conventional	O
nanohybrid	B-CHEM
resin	I-CHEM
composite	I-CHEM
.	O

The	O
phonetic	O
landscape	O
in	O
infant	B-LIVB
consonant	O
perception	B-PHYS
is	O
an	O
uneven	B-GEOG
terrain	I-GEOG
Previous	O
research	B-PROC
revealing	O
universal	O
biases	O
in	O
infant	B-LIVB
vowel	O
perception	B-PHYS
forms	O
the	O
basis	O
of	O
the	O
Natural	O
Referent	O
Vowel	O
(	O
NRV	O
)	O
framework	O
(	O
Polka	O
&	O
Bohn	O
,	O
2011	O
)	O
.	O

To	O
explore	O
the	O
feasibility	B-PROC
of	O
extending	O
this	O
framework	O
to	O
consonant	O
manner	O
perception	B-PHYS
,	O
we	O
investigated	O
perception	B-PHYS
of	O
the	O
stop	O
vs	O
.	O

fricative	O
consonant	O
contrast	O
/b	O
/	O
-	O
/	O
v	O
/	O
to	O
test	O
the	O
hypothesis	O
that	O
young	O
infants	B-LIVB
will	O
display	O
a	O
perceptual	B-PHYS
bias	O
grounded	O
in	O
the	O
acoustic	B-PHEN
-	O
phonetic	O
properties	O
of	O
these	O
sounds	B-PHEN
.	O

We	O
examined	O
perception	B-PHYS
of	O
stop	O
-	O
initial	O
/bas	O
/	O
and	O
fricative	O
-	O
initial	O
/vas	O
/	O
syllables	O
in	O
English	O
-	O
learning	B-PHYS
and	O
French	O
-	O
learning	B-PHYS
5	O
-	O
to	O
6	O
-	O
month	O
-	O
olds	O
.	O

The	O
/b	O
/	O
and	O
/v	O
/	O
sounds	B-PHEN
distinguish	O
words	O
in	O
English	O
and	O
French	O
but	O
have	O
different	O
distributional	O
patterns	O
;	O
in	O
spoken	O
English	O
/b	O
/	O
occurs	O
more	O
frequently	O
than	O
/v	O
/	O
whereas	O
in	O
spoken	O
French	O
/v	O
/	O
occurs	O
more	O
frequently	O
than	O
/b	O
/	O
.	O

A	O
perceptual	B-PHYS
bias	O
favoring	O
/b	O
/	O
over	O
/v	O
/	O
emerged	O
in	O
two	O
experiments	B-PROC
.	O

In	O
Experiment	B-PROC
1	I-PROC
,	O
a	O
directional	O
asymmetry	O
was	O
observed	O
in	O
discrimination	B-PHYS
;	O
infants	B-LIVB
noticed	O
when	O
/vas	O
/	O
changed	O
to	O
/bas	O
/	O
but	O
not	O
when	O
/bas	O
/	O
changed	O
to	O
/vas	O
/	O
.	O

In	O
Experiment	B-PROC
2	I-PROC
,	O
a	O
robust	O
listening	B-PHYS
preference	O
favoring	O
stop	O
-	O
initial	O
/bas	O
/	O
was	O
evident	O
in	O
responses	B-PHYS
from	O
the	O
same	O
infants	B-LIVB
.	O

This	O
is	O
the	O
first	O
study	B-PROC
to	O
show	O
a	O
perceptual	B-PHYS
bias	O
related	O
to	O
consonant	O
manner	O
and	O
to	O
directly	O
measure	O
a	O
consonant	O
perception	B-PHYS
bias	O
within	O
the	O
same	O
infants	B-LIVB
.	O

These	O
data	O
encourage	O
further	O
efforts	O
to	O
extend	O
the	O
NRV	O
principles	O
to	O
perception	B-PHYS
of	O
consonant	O
manner	O
.	O

These	O
findings	O
indicate	O
that	O
we	O
need	O
to	O
reform	O
our	O
view	O
of	O
infant	B-LIVB
speech	B-PHYS
perception	B-PHYS
to	O
accommodate	O
the	O
fact	O
that	O
both	O
discrimination	B-PHYS
abilities	O
and	O
biases	O
shape	O
speech	B-PHYS
perception	B-PHYS
during	O
infancy	O
.	O

Propensity	O
-	O
matched	B-PROC
Analysis	B-PROC
of	O
Outcomes	O
and	O
Hospital	O
Charges	O
for	O
Anterior	O
Versus	O
Posterior	O
Cervical	O
Fusion	O
for	O
Cervical	B-DISO
Spondylotic	I-DISO
Myelopathy	I-DISO
Retrospective	O
analysis	B-PROC
of	O
data	O
from	O
the	O
Nationwide	O
Inpatient	B-LIVB
Sample	B-OBJC
,	O
a	O
nationally	O
representative	O
,	O
all	O
-	O
payer	O
database	O
of	O
inpatient	B-LIVB
diagnoses	B-PROC
and	I-PROC
procedures	I-PROC
in	O
the	O
United	B-GEOG
States	I-GEOG
.	O

The	O
objective	O
of	O
this	O
study	B-PROC
is	O
to	O
compare	O
anterior	O
cervical	O
fusion	O
(	O
ACF	O
)	O
to	O
posterior	O
cervical	O
fusion	O
(	O
PCF	O
)	O
in	O
the	O
treatment	B-PROC
of	O
cervical	B-DISO
spondylotic	I-DISO
myelopathy	I-DISO
(	O
CSM	B-DISO
)	O
.	O

Previous	O
studies	B-PROC
used	O
retrospective	O
single	O
-	O
institution	O
level	O
data	O
to	O
quantify	O
outcomes	O
for	O
CSM	B-DISO
patients	B-LIVB
fusion	B-PROC
.	O

It	O
is	O
unclear	B-DISO
whether	O
ACF	O
or	O
PCF	O
is	O
superior	O
with	O
regards	O
to	O
charges	O
or	O
outcomes	O
for	O
the	O
treatment	B-PROC
of	O
CSM	B-DISO
.	O

We	O
used	O
Nationwide	O
Inpatient	B-LIVB
Sample	B-OBJC
data	O
to	O
compare	O
ACF	O
to	O
PCF	O
in	O
the	O
management	B-PROC
of	O
CSM	B-DISO
.	O

All	O
patients	B-LIVB
18	B-PHYS
years	I-PHYS
or	I-PHYS
older	I-PHYS
with	O
a	O
diagnosis	B-PROC
of	O
CSM	B-DISO
between	O
1998	O
and	O
2011	O
were	O
included	O
.	O

ACF	O
patients	B-LIVB
were	O
matched	B-PROC
to	O
PCF	O
patients	B-LIVB
using	O
propensity	O
scores	O
based	O
on	O
patient	B-PHYS
characteristics	I-PHYS
(	O
number	O
of	O
levels	O
fused	O
,	O
spine	O
alignment	O
,	O
comorbidities	O
)	O
,	O
hospital	B-OBJC
characteristics	O
,	O
and	O
patient	B-PHYS
demographics	I-PHYS
.	O

Multivariable	O
regression	O
was	O
used	O
to	O
measure	O
the	O
effect	O
of	O
treatment	B-PROC
assignment	B-PROC
on	O
in	O
-	O
hospital	O
charges	O
,	O
length	O
of	O
hospital	O
stay	O
,	O
in	O
-	O
hospital	O
mortality	O
,	O
discharge	B-PHYS
disposition	I-PHYS
,	O
and	O
dysphagia	B-DISO
diagnosis	B-PROC
.	O

From	O
1998	O
to	O
2011	O
,	O
we	O
identified	O
109	O
,	O
728	O
hospitalizations	B-PROC
with	O
a	O
CSM	B-DISO
diagnosis	B-PROC
.	O

Of	O
these	O
patients	B-LIVB
,	O
45	O
,	O
629	O
(	O
41	O
.	O

6	O
%	O
)	O
underwent	O
ACF	O
and	O
14	O
,	O
439	O
(	O
13	O
.	O
2	O
%	O
)	O
underwent	O
PCF	O
.	O

The	O
PCF	O
cohort	B-LIVB
incurred	O
an	O
average	O
of	O
$	O
41	O
,	O
683	O
more	O
in	O
-	O
hospital	O
charges	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
inflation	O
adjusted	O
to	O
2011	O
dollars	O
)	O
and	O
remained	O
in	O
hospital	B-OBJC
an	O
average	O
of	O
2	O
.	O

4	O
days	O
longer	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
the	O
ACF	O
cohort	B-LIVB
.	O

The	O
ACF	O
cohort	B-LIVB
was	O
just	O
as	O
likely	O
to	O
die	B-PHYS
in	O
the	O
hospital	B-OBJC
[	O
odds	O
ratio	O
0	O
.	O
91	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0	O
.	O
68	O
-	O
1	O
.	O
2	O
]	O
,	O
3	O
.	O
0	O
times	O
more	O
likely	O
to	O
be	O
discharged	B-PROC
to	I-PROC
home	I-PROC
or	O
self	B-OBJC
-	I-OBJC
care	I-OBJC
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
9	O
-	O
3	O
.	O
2	O
)	O
,	O
and	O
2	O
.	O

5	O
times	O
more	O
likely	O
to	O
experience	B-PHYS
dysphagia	B-DISO
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
0	O
-	O
3	O
.	O

1	O
)	O
than	O
the	O
PCF	O
cohort	B-LIVB
.	O

In	O
treating	O
CSM	B-DISO
,	O
ACF	O
led	O
to	O
lower	O
hospital	O
charges	O
,	O
shorter	O
hospital	O
stays	O
,	O
and	O
an	O
increased	O
likelihood	O
of	O
being	O
discharged	B-PROC
to	I-PROC
home	I-PROC
relative	O
to	O
PCF	O
.	O

Overcoming	O
structural	O
inequalities	O
in	O
oral	B-PROC
health	I-PROC
:	O
the	O
role	O
of	O
dental	B-PROC
curricula	O
To	O
date	O
the	O
role	O
of	O
health	B-OBJC
professional	I-OBJC
schools	I-OBJC
in	O
addressing	O
oral	B-PROC
health	I-PROC
inequalities	O
have	O
been	O
minimal	O
,	O
as	O
attempts	O
have	O
focused	O
principally	O
upon	O
systemic	O
reform	O
and	O
broader	O
societal	O
obligations	O
.	O

Professionalism	O
is	O
a	O
broad	O
competency	O
that	O
is	O
taught	O
throughout	O
dental	B-OBJC
schools	I-OBJC
and	O
encompasses	O
a	O
range	O
of	O
attributes	O
.	O

Professionalism	O
as	O
a	O
competency	O
draws	O
some	O
debate	O
and	O
appears	O
to	O
be	O
a	O
shifting	O
phenomenon	O
.	O

We	O
may	O
ask	O
if	O
professionalism	O
in	O
the	O
dental	B-PROC
curricula	O
may	O
be	O
better	O
addressed	O
by	O
social	O
accountability	O
?	O

Social	O
accountability	O
directs	O
oral	B-PROC
health	I-PROC
professional	O
curricula	O
(	O
education	O
,	O
research	B-PROC
,	O
and	O
service	B-PROC
activities	I-PROC
)	O
towards	O
addressing	O
the	O
priority	O
health	O
concerns	O
of	O
the	O
community	B-LIVB
,	O
in	O
our	O
case	O
oral	B-PROC
health	I-PROC
inequalities	O
.	O

Although	O
working	O
toward	O
dental	B-OBJC
schools	I-OBJC
becoming	O
more	O
socially	O
accountable	O
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	O
oral	B-PROC
health	I-PROC
inequalities	O
,	O
it	O
might	O
have	O
limitations	O
.	O

We	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-PROC
curricula	O
by	O
considering	O
some	O
of	O
the	O
political	B-PHEN
,	O
structural	O
,	O
social	O
and	O
ethical	O
factors	O
that	O
influence	O
our	O
institutions	O
and	O
our	O
graduates	B-LIVB
.	O

Readers	O
'	O
panel	O
-	O
Should	O
nurses	B-LIVB
be	O
prosecuted	B-DISO
if	O
they	O
fail	O
to	O
report	O
child	O
abuse	O
?	O

Our	O
experts	B-LIVB
consider	O
a	O
hot	O
topic	O
of	O
the	O
day	O
.	O

Function	O
analysis	B-PROC
of	O
Mef2c	O
promoter	B-CHEM
in	O
muscle	B-PHYS
differentiation	I-PHYS
Regeneration	B-PHYS
of	I-PHYS
adult	I-PHYS
skeletal	I-PHYS
muscle	I-PHYS
following	O
injury	B-DISO
occurs	O
through	O
the	O
activation	B-PHYS
of	O
satellite	B-ANAT
cells	I-ANAT
,	O
that	O
proliferates	B-PHYS
,	O
differentiates	B-PHYS
,	O
and	O
fuses	B-PHYS
with	O
injured	O
myofibers	B-ANAT
.	O

Myocyte	B-CHEM
enhancer	I-CHEM
factor	I-CHEM
2	I-CHEM
(	I-CHEM
MEF2	I-CHEM
)	I-CHEM
proteins	I-CHEM
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	B-LIVB
muscle	B-DISO
regeneration	I-DISO
.	O

In	O
order	O
to	O
further	O
understand	O
Mef2c	O
gene	O
,	O
the	O
promoter	B-CHEM
of	O
pig	B-LIVB
Mef2c	O
gene	O
was	O
analyzed	O
in	O
this	O
paper	O
.	O

Quantitative	B-PROC
real	I-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
(	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
)	O
revealed	O
the	O
expression	B-PHYS
pattern	O
of	O
Mef2c	O
gene	O
in	O
muscle	O
of	O
eight	O
tissues	O
.	O

The	O
Mef2c	O
promoter	B-CHEM
had	O
the	O
higher	O
transcriptional	B-PHYS
activity	I-PHYS
in	O
differentiated	B-PHYS
C2C12	B-ANAT
cells	I-ANAT
than	O
that	O
in	O
proliferating	B-PHYS
C2C12	B-ANAT
cells	I-ANAT
,	O
which	O
was	O
accompanied	O
by	O
the	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
mRNA	B-PHYS
expression	I-PHYS
of	O
Mef2c	O
gene	O
.	O

Function	O
deletion	B-PHYS
and	O
mutation	B-PHYS
analyses	B-PROC
showed	O
that	O
MyoD	B-CHEM
and	O
MEF2	B-CHEM
binding	O
sites	O
within	O
the	O
Mef2c	O
promoter	B-CHEM
were	O
responsible	O
for	O
the	O
regulation	B-PHYS
of	O
Mef2c	O
transcription	B-PHYS
.	O

MEF2C	O
could	O
up	B-PHYS
-	I-PHYS
regulate	I-PHYS
the	I-PHYS
transcriptional	I-PHYS
activities	I-PHYS
of	O
Mef2c	O
promoter	B-CHEM
constructs	I-CHEM
which	O
contained	O
a	O
3	O
'	O
-	O
end	O
nucleotide	O
sequence	O
with	O
p300	B-CHEM
binding	O
site	O
.	O

The	O
Electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
(	O
EMSA	B-PROC
)	O
and	O
chromatin	B-PROC
immunoprecipitation	I-PROC
(	I-PROC
ChIP	I-PROC
)	I-PROC
assays	I-PROC
determined	O
the	O
MyoD	B-CHEM
binding	O
site	O
in	O
Mef2c	O
promoter	B-CHEM
.	O

These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	B-CHEM
of	O
the	O
pig	B-LIVB
Mef2c	O
gene	O
.	O

And	O
the	O
study	O
of	O
Mef2c	O
promoter	B-CHEM
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	B-PHYS
mechanisms	I-PHYS
of	O
Mef2c	O
in	O
muscle	B-PHYS
differentiation	I-PHYS
or	O
muscle	B-PROC
repair	I-PROC
and	O
regeneration	B-DISO
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

TLR9	O
Deficiency	O
Leads	O
to	O
Accelerated	O
Renal	B-DISO
Disease	I-DISO
and	O
Myeloid	B-ANAT
Lineage	I-ANAT
Abnormalities	B-DISO
in	O
Pristane	B-CHEM
-Induced	O
Murine	B-LIVB
Lupus	B-DISO
Systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O
SLE	B-DISO
)	I-DISO
is	O
a	O
chronic	O
,	O
life	B-DISO
-	I-DISO
threatening	I-DISO
autoimmune	B-DISO
disorder	I-DISO
,	O
leading	O
to	O
multiple	O
organ	B-ANAT
pathologies	O
and	O
kidney	B-ANAT
destruction	O
.	O

Analyses	O
of	O
numerous	O
murine	B-LIVB
models	B-DISO
of	O
spontaneous	O
SLE	B-DISO
have	O
revealed	O
a	O
critical	O
role	O
for	O
endosomal	B-ANAT
TLRs	B-CHEM
in	O
the	O
production	O
of	O
autoantibodies	B-CHEM
and	O
development	O
of	O
other	O
clinical	O
disease	B-DISO
manifestations	O
.	O

Nevertheless	O
,	O
the	O
corresponding	O
TLR9	O
-	O
deficient	O
autoimmune	B-DISO
-prone	O
strains	B-LIVB
consistently	O
develop	O
more	O
severe	O
disease	B-DISO
pathology	O
.	O

Injection	B-PROC
of	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
with	O
2	B-CHEM
,	I-CHEM
6	I-CHEM
,	I-CHEM
10	I-CHEM
,	I-CHEM
14	I-CHEM
-	I-CHEM
tetramethylpentadecane	I-CHEM
(	O
TMPD	B-CHEM
)	O
,	O
commonly	O
known	O
as	O
pristane	B-CHEM
,	O
also	O
results	O
in	O
the	O
development	O
of	O
SLE	B-DISO
-	I-DISO
like	I-DISO
disease	I-DISO
.	O

We	O
now	O
show	O
that	O
Tlr9	O
(	O
-	O
/	O
-	O
)	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
injected	B-PROC
i	I-PROC
.	I-PROC

p	I-PROC
.	I-PROC

with	O
TMPD	B-CHEM
develop	O
more	O
severe	O
autoimmunity	B-DISO
than	O
do	O
their	O
TLR	B-CHEM
-sufficient	O
cohorts	O
.	O

Early	O
indications	O
include	O
an	O
increased	O
accumulation	B-DISO
of	O
TLR7	O
-	O
expressing	B-PHYS
Ly6C	B-CHEM
(	I-CHEM
hi	I-CHEM
)	I-CHEM
inflammatory	O
monocytes	B-ANAT
at	O
the	O
site	O
of	O
injection	O
,	O
upregulation	B-PHYS
of	O
IFN	B-CHEM
-regulated	O
gene	B-PHYS
expression	I-PHYS
in	O
the	O
peritoneal	B-ANAT
cavity	I-ANAT
,	O
and	O
an	O
increased	O
production	O
of	O
myeloid	B-ANAT
lineage	I-ANAT
precursors	I-ANAT
(	O
common	B-ANAT
myeloid	I-ANAT
progenitors	I-ANAT
and	O
granulocyte	B-ANAT
myeloid	B-ANAT
precursors	I-ANAT
)	O
in	O
the	O
bone	O
marrow	O
.	O

TMPD	B-CHEM
-	O
injected	B-PROC
Tlr9	O
(	O
-	O
/	O
-	O
)	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
develop	O
higher	O
autoantibody	B-CHEM
titers	O
against	O
RNA	B-CHEM
,	O
neutrophil	B-ANAT
cytoplasmic	B-ANAT
Ags	B-CHEM
,	O
and	O
myeloperoxidase	B-CHEM
than	O
do	O
TMPD	B-CHEM
-	O
injected	B-PROC
wild	B-LIVB
-	I-LIVB
type	I-LIVB
BALB	I-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
.	O

The	O
TMP	B-CHEM
-	O
injected	B-PROC
Tlr9	O
(	O
-	O
/	O
-	O
)	O
mice	B-LIVB
,	O
and	O
not	O
the	O
wild	B-LIVB
-	I-LIVB
type	I-LIVB
mice	I-LIVB
,	O
also	O
develop	O
a	O
marked	O
increase	O
in	O
glomerular	B-CHEM
IgG	I-CHEM
deposition	O
and	O
infiltrating	O
granulocytes	B-ANAT
,	O
much	O
more	O
severe	O
glomerulonephritis	B-DISO
,	O
and	O
a	O
reduced	O
lifespan	O
.	O

Collectively	O
,	O
the	O
data	O
point	O
to	O
a	O
major	O
role	O
for	O
TLR7	O
in	O
the	O
response	B-PHYS
to	O
self	B-CHEM
-	I-CHEM
antigens	I-CHEM
in	O
this	O
model	B-DISO
of	O
experimental	O
autoimmunity	B-DISO
.	O

Therefore	O
,	O
the	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
pristane	B-CHEM
model	B-DISO
recapitulates	O
other	O
TLR7	O
-driven	O
spontaneous	O
models	B-DISO
of	O
SLE	B-DISO
and	O
is	O
negatively	B-DISO
regulated	O
by	O
TLR9	O
.	O

Novel	O
insights	O
into	O
development	O
of	O
diabetic	B-DISO
bladder	B-DISO
disorder	I-DISO
provided	O
by	O
metabolomic	O
analysis	O
of	O
the	O
rat	B-LIVB
nondiabetic	O
and	O
diabetic	B-DISO
detrusor	B-ANAT
and	O
urothelial	O
layer	O
There	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	O
in	O
bladder	B-ANAT
metabolism	B-PHYS
resulting	O
from	O
diabetes	B-DISO
.	O

Such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-DISO
bladder	B-DISO
disorder	I-DISO
(	I-DISO
DBD	I-DISO
)	I-DISO
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
metabolome	B-PHEN
of	O
detrusor	B-ANAT
and	O
urothelial	O
layer	O
in	O
a	O
1	O
-	O
mo	O
streptozotocin	B-CHEM
-induced	O
rat	B-LIVB
model	B-DISO
of	O
type	B-DISO
1	I-DISO
diabetes	I-DISO
with	O
nondiabetic	B-LIVB
controls	I-LIVB
.	O

Our	O
studies	O
revealed	O
that	O
diabetes	B-DISO
caused	O
both	O
common	O
and	O
differential	O
changes	O
in	O
the	O
detrusor	B-ANAT
and	O
urothelial	O
layer	O
's	O
metabolome	B-PHEN
.	O

Diabetes	B-DISO
resulted	O
in	O
similar	O
changes	O
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-DISO
markers	B-PHYS
in	O
both	O
tissues	O
,	O
such	O
as	O
glucose	B-CHEM
,	O
lactate	B-CHEM
,	O
2	B-CHEM
-	I-CHEM
hydroxybutyrate	I-CHEM
,	O
branched	B-CHEM
-	I-CHEM
chain	I-CHEM
amino	I-CHEM
acid	I-CHEM
degradation	I-CHEM
products	I-CHEM
,	O
bile	B-CHEM
acids	I-CHEM
,	O
and	O
1	B-CHEM
,	I-CHEM
5	I-CHEM
-	I-CHEM
anhydroglucitol	I-CHEM
,	O
as	O
well	O
as	O
markers	B-PHYS
of	O
oxidative	B-DISO
stress	I-DISO
.	O

In	O
the	O
detrusor	B-ANAT
(	O
but	O
not	O
the	O
urothelial	O
layer	O
)	O
,	O
diabetes	B-DISO
caused	O
activation	O
of	O
the	O
pentose	B-CHEM
-	I-CHEM
phosphate	I-CHEM
and	O
polyol	B-CHEM
pathways	B-PHYS
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
TCA	B-PHYS
cycle	I-PHYS
and	O
β	B-PHYS
-	I-PHYS
oxidation	I-PHYS
.	O

Changes	O
in	O
detrusor	B-ANAT
energy	B-PHYS
-	I-PHYS
generating	I-PHYS
pathways	I-PHYS
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-CHEM
that	O
,	O
through	O
generation	O
of	O
advanced	B-CHEM
glycation	I-CHEM
end	I-CHEM
products	I-CHEM
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
DBD	B-DISO
.	O

In	O
the	O
diabetic	B-DISO
urothelial	O
layer	O
there	O
was	O
decreased	O
flux	B-PHEN
of	O
glucose	B-CHEM
via	O
glycolysis	B-PHYS
and	O
changes	O
in	O
lipid	B-PHYS
metabolism	I-PHYS
,	O
particularly	O
prostaglandin	B-CHEM
synthesis	O
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	B-ANAT
dysfunction	B-DISO
.	O

Development	O
of	O
an	O
Evaluation	B-PROC
Device	B-OBJC
for	O
Phagocytic	B-ANAT
Activity	O
of	O
New	O
Phagocytes	B-ANAT
Using	O
Simple	O
and	O
pH	B-CHEM
-	I-CHEM
sensitive	I-CHEM
Particles	I-CHEM
that	O
Do	O
Not	O
Require	O
Pre	O
-	O
treatment	O
Phagocytic	B-ANAT
activity	O
is	O
affected	O
by	O
a	O
number	O
of	O
different	O
stress	B-DISO
and	O
age	B-PHYS
-dependent	O
factors	O
.	O

An	O
easy	O
measurement	O
of	O
phagocytic	B-ANAT
activity	O
is	O
thought	O
to	O
allow	O
an	O
indicator	O
of	O
an	O
individual	B-LIVB
'	O
s	O
health	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
investigated	O
conditions	O
of	O
measurement	O
to	O
easily	O
evaluate	O
the	O
activity	O
of	O
phagocytosis	B-PHYS
of	O
phagocytic	B-ANAT
cells	I-ANAT
(	O
macrophages	B-ANAT
and	O
neutrophils	B-ANAT
)	O
using	O
an	O
easy	O
-	O
to	O
-	O
use	O
prototype	O
,	O
which	O
was	O
improved	O
from	O
the	O
device	B-OBJC
by	O
Hamamatsu	O
Photonics	O
K	O
.	O

K	O
.	O
,	O
to	O
detect	O
neutrophil	B-ANAT
activity	O
using	O
subtle	O
fluorescence	B-PHEN
.	O

pH	B-CHEM
-	I-CHEM
sensitive	I-CHEM
fluorescent	I-CHEM
particles	I-CHEM
(	O
pHrodo	B-CHEM
-	I-CHEM
Green	I-CHEM
E	I-CHEM
.	I-CHEM

coli	I-CHEM
Bio	I-CHEM
particles	I-CHEM
,	O
GE	B-CHEM
particles	I-CHEM
)	O
were	O
added	O
to	O
mouse	B-LIVB
-derived	O
macrophage	B-ANAT
cell	I-ANAT
lines	I-ANAT
(	O
J774	B-ANAT
.	I-ANAT

1	I-ANAT
)	O
and	O
then	O
incubated	B-PROC
for	O
2	O
h	O
at	O
37°C	O
.	O

For	O
negative	O
control	O
,	O
the	O
phagocytosis	B-PHYS
inhibitor	O
cytochalasin	B-CHEM
D	I-CHEM
(	O
CyD	B-CHEM
)	O
,	O
was	O
added	O
prior	O
to	O
culture	B-PROC
.	O

Next	O
,	O
fluorescence	B-PHEN
intensity	O
was	O
measured	O
by	O
the	O
Prototype	O
to	O
evaluate	O
the	O
phagocytic	B-ANAT
activity	O
of	O
macrophages	B-ANAT
and	O
neutrophils	B-ANAT
.	O

Phagocytosis	B-PHYS
was	O
also	O
confirmed	O
by	O
flow	B-PROC
cytometry	I-PROC
.	O

The	O
Prototype	O
detected	O
a	O
steady	O
fluorescence	B-PHEN
increase	O
in	O
5	O
sec	O
in	O
J774	B-ANAT
.	I-ANAT

1	I-ANAT
after	O
phagocytosis	B-PHYS
,	O
using	O
GE	B-CHEM
particles	I-CHEM
as	O
a	O
negative	O
control	O
in	O
the	O
presence	O
of	O
CyD	B-CHEM
.	O

Furthermore	O
,	O
detection	B-PROC
was	O
possible	O
at	O
10	O
(	O
4	O
)	O
cells	O
/	O
test	O
,	O
a	O
concentration	O
where	O
the	O
flow	B-DEVI
cytometer	I-DEVI
had	O
difficulty	O
for	O
detection	B-PROC
.	O

The	O
Prototype	O
enables	O
measurement	O
of	O
the	O
phagocytic	B-ANAT
activity	O
within	O
a	O
short	O
period	O
of	O
time	O
,	O
even	O
with	O
a	O
small	O
sample	O
amount	O
,	O
thus	O
establishing	O
the	O
basic	O
conditions	O
of	O
measurements	O
of	O
phagocytosis	B-PHYS
.	O

Effect	O
of	O
Xenotransplantation	B-PROC
Site	O
on	O
MicroRNA	B-CHEM
Expression	B-PHYS
of	O
Human	B-LIVB
Colon	B-DISO
Cancer	I-DISO
Stem	B-ANAT
Cells	I-ANAT
Cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
(	O
CSCs	B-ANAT
)	O
have	O
a	O
high	O
tumorigenic	B-DISO
ability	B-PHYS
to	O
form	O
patient	B-DISO
-	I-DISO
derived	I-DISO
tumor	I-DISO
xenografts	I-DISO
(	O
PDXs	B-DISO
)	O
.	O

PDXs	B-DISO
are	O
an	O
attractive	O
pre	O
-	O
clinical	O
model	O
,	O
but	O
gene	B-PHYS
expression	I-PHYS
and	O
biological	B-PHEN
behavior	I-PHEN
of	O
cancer	B-ANAT
cells	I-ANAT
in	O
the	O
tumor	B-DISO
will	O
change	O
during	O
establishment	O
and	O
passage	O
of	O
PDXs	B-DISO
.	O

Human	B-LIVB
colon	B-DISO
cancer	I-DISO
PDX	B-DISO
was	O
established	O
and	O
passaged	B-PROC
either	O
subcutaneously	O
or	O
orthotopically	O
into	O
the	O
murine	B-LIVB
intestine	B-ANAT
.	O

Histology	O
and	O
flow	B-PROC
cytometric	I-PROC
profile	B-PROC
of	O
the	O
surgical	B-PROC
specimen	O
and	O
the	O
PDX	B-DISO
were	O
analyzed	B-PROC
.	O

CSCs	B-ANAT
were	O
then	O
isolated	O
from	O
the	O
tumors	B-DISO
and	O
their	O
microRNA	B-CHEM
(	O
miRNA	B-CHEM
)	O
expression	B-PHYS
was	O
analyzed	B-PROC
by	O
semi	B-PROC
-	I-PROC
quantitative	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
.	O

The	O
surgical	B-PROC
specimens	O
and	O
PDXs	B-DISO
were	O
histologically	O
similar	O
.	O

The	O
size	O
of	O
CSC	B-ANAT
population	B-LIVB
increased	O
and	O
expression	B-PHYS
of	O
miRNA	B-CHEM
s	O
in	O
CSCs	B-ANAT
changed	O
in	O
the	O
passaged	B-PROC
PDXs	B-DISO
.	O

Expression	B-PHYS
of	O
oncogenic	B-CHEM
miRNAs	B-CHEM
was	O
highly	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
in	O
the	O
CSCs	B-ANAT
of	O
the	O
orthotopically	O
passaged	B-PROC
PDXs	B-DISO
.	O

The	O
xenotransplantation	B-PROC
site	O
and	O
the	O
number	O
of	O
tumor	B-DISO
passages	B-PROC
affect	B-PHYS
the	O
miRNA	B-CHEM
expression	B-PHYS
of	O
human	B-LIVB
colon	B-ANAT
CSCs	B-ANAT
.	O

Survival	B-PROC
of	O
ovarian	B-DISO
cancer	I-DISO
patients	B-LIVB
in	O
Denmark	B-GEOG
:	O
Results	O
from	O
the	O
Danish	B-LIVB
gynaecological	I-LIVB
cancer	I-LIVB
group	I-LIVB
(	O
DGCG	O
)	O
database	O
,	O
1995	O
-	O
2012	O
Ovarian	B-DISO
cancer	I-DISO
has	O
a	O
high	O
mortality	O
rate	O
,	O
especially	O
in	O
Denmark	B-GEOG
where	O
mortality	O
rates	O
have	O
been	O
reported	O
higher	O
than	O
in	O
adjacent	B-GEOG
countries	I-GEOG
with	O
similar	O
demographics	O
.	O

This	O
study	O
therefore	O
examined	O
recent	O
survival	O
and	O
mortality	O
among	O
Danish	B-DISO
ovarian	I-DISO
cancer	I-DISO
patients	B-LIVB
over	O
an	O
18	O
-	O
year	O
study	O
period	O
.	O

This	O
nationwide	O
registry	O
-	O
based	O
observational	B-PROC
study	I-PROC
used	O
data	O
from	O
the	O
Danish	O
Gynecology	O
Cancer	O
Database	O
,	O
Danish	O
Pathology	O
Registry	O
,	O
and	O
Danish	B-PROC
National	I-PROC
Patient	I-PROC
Registry	I-PROC
.	O

All	O
patients	B-LIVB
with	O
ovarian	B-DISO
cancer	I-DISO
diagnosed	B-PROC
between	O
1995	O
and	O
2012	O
were	O
included	O
in	O
the	O
study	O
.	O

The	O
data	O
sources	O
were	O
linked	O
via	O
the	O
patients	B-LIVB
'	O
personal	O
identification	O
number	O
and	O
the	O
analyses	O
included	O
data	O
on	O
cancer	B-PROC
stage	I-PROC
,	O
age	B-PHYS
,	O
survival	B-PROC
,	O
surgery	B-DISO
status	I-DISO
and	O
comorbidity	O
.	O

The	O
computed	O
outcome	O
measures	O
were	O
age	O
-	O
adjusted	O
mortality	O
rates	O
and	O
age	O
-	O
adjusted	O
overall	O
and	O
relative	O
survival	O
rates	O
for	O
one	O
and	O
five	O
years	O
.	O

We	O
identified	O
9972	O
patients	B-LIVB
diagnosed	I-LIVB
with	O
ovarian	B-DISO
cancer	I-DISO
in	O
the	O
period	O
1995	O
-	O
2012	O
.	O

The	O
absolute	O
one	O
-	O
year	O
mortality	O
rate	O
decreased	O
from	O
42	O
.	O

8	O
(	O
CI	O
40	O
.	O
3	O
-	O
45	O
.	O
6	O
)	O
in	O
1995	O
-	O
1999	O
to	O
28	O
.	O
3	O
(	O
CI	O
25	O
.	O
9	O
-	O
30	O
.	O
9	O
)	O
in	O
2010	O
-	O
2012	O
,	O
and	O
the	O
five	O
-	O
year	O
mortality	O
rate	O
decreased	O
from	O
28	O
.	O
2	O
(	O
CI	O
27	O
.	O
0	O
-	O
29	O
.	O
5	O
)	O
in	O
1995	O
-	O
1999	O
to	O
23	O
.	O
9	O
(	O
CI	O
22	O
.	O
9	O
-	O
25	O
.	O
0	O
)	O
in	O
2005	O
-	O
2009	O
.	O

After	O
stratification	B-PROC
by	I-PROC
age	I-PROC
,	O
comorbidity	O
and	O
cancer	B-PROC
stage	I-PROC
,	O
the	O
decrease	O
in	O
one	O
-	O
year	O
mortality	O
was	O
most	O
substantial	O
in	O
the	O
65	O
-	O
74	O
year	O
old	B-LIVB
age	I-LIVB
group	I-LIVB
41	O
.	O

1	O
(	O
CI	O
38	O
.	O
8	O
-	O
43	O
.	O
5	O
)	O
to	O
26	O
.	O
5	O
(	O
CI	O
24	O
.	O
4	O
-	O
28	O
.	O
7	O
)	O
and	O
for	O
stage	B-DISO
III	I-DISO
39	O
.	O
1	O
(	O
CI	O
35	O
.	O
1	O
-	O
43	O
.	O
6	O
)	O
to	O
22	O
.	O
9	O
(	O
CI	O
19	O
.	O
9	O
-	O
26	O
.	O
5	O
)	O
and	O
stage	B-DISO
IV	I-DISO
91	O
.	O
3	O
(	O
CI	O
80	O
.	O
8	O
-	O
103	O
.	O
2	O
)	O
to	O
41	O
.	O
9	O
(	O
CI	O
35	O
.	O
5	O
-	O
49	O
.	O
5	O
)	O
.	O

For	O
overall	O
survival	O
,	O
we	O
showed	O
an	O
increase	O
in	O
one	O
-	O
year	O
survival	O
from	O
68	O
%	O
(	O
CI	O
66	O
-	O
69	O
%	O
)	O
in	O
1995	O
-	O
1999	O
to	O
76	O
%	O
(	O
CI	O
74	O
-	O
78	O
%	O
)	O
in	O
2010	O
-	O
2012	O
and	O
an	O
increase	O
in	O
five	O
-	O
year	O
survival	O
from	O
33	O
%	O
(	O
CI	O
32	O
-	O
35	O
%	O
)	O
in	O
1995	O
-	O
1999	O
to	O
36	O
%	O
(	O
CI	O
34	O
-	O
38	O
%	O
)	O
in	O
2005	O
-	O
2009	O
.	O

Relative	O
survival	O
showed	O
similar	O
increases	O
through	O
the	O
period	O
.	O

Ovarian	B-DISO
cancer	I-DISO
survival	O
in	O
Denmark	B-GEOG
has	O
improved	O
substantially	O
from	O
1995	O
to	O
2012	O
,	O
bringing	O
Denmark	B-GEOG
closer	O
to	O
the	O
standards	O
set	O
by	O
adjacent	B-GEOG
countries	I-GEOG
.	O

Proximal	B-PROC
Soil	I-PROC
Sensing	I-PROC
-	O
A	O
Contribution	O
for	O
Species	O
Habitat	O
Distribution	O
Modelling	B-PROC
of	O
Earthworms	O
in	O
Agricultural	O
Soils	B-OBJC
?	O

Earthworms	O
are	O
important	O
for	O
maintaining	O
soil	B-OBJC
ecosystem	B-PHEN
functioning	O
and	O
serve	O
as	O
indicators	B-CHEM
of	O
soil	B-OBJC
fertility	O
.	O

However	O
,	O
detection	O
of	O
earthworms	O
is	O
time	O
-	O
consuming	O
,	O
which	O
hinders	O
the	O
assessment	O
of	O
earthworm	O
abundances	O
with	O
high	O
sampling	O
density	O
over	O
entire	O
fields	O
.	O

Recent	O
developments	O
of	O
mobile	B-OBJC
terrestrial	I-OBJC
sensor	I-OBJC
platforms	I-OBJC
for	O
proximal	B-PROC
soil	I-PROC
sensing	I-PROC
(	O
PSS	B-PROC
)	O
provided	O
new	O
tools	B-OBJC
for	O
collecting	O
dense	O
spatial	O
information	O
of	O
soils	B-OBJC
using	O
various	O
sensing	O
principles	O
.	O

Yet	O
,	O
the	O
potential	O
of	O
PSS	B-PROC
for	O
assessing	O
earthworm	O
habitats	O
is	O
largely	O
unexplored	O
.	O

This	O
study	B-PROC
investigates	O
whether	O
PSS	B-PROC
data	O
contribute	O
to	O
the	O
spatial	O
prediction	O
of	O
earthworm	O
abundances	O
in	O
species	O
distribution	O
models	O
of	O
agricultural	O
soils	B-OBJC
.	O

Proximal	B-PROC
soil	I-PROC
sensing	I-PROC
data	O
,	O
e	O
.	O

g	O
.	O
,	O
soil	B-OBJC
electrical	O
conductivity	O
(	O
EC	O
)	O
,	O
pH	O
,	O
and	O
near	B-PROC
infrared	I-PROC
absorbance	I-PROC
(	O
NIR	B-PROC
)	O
,	O
were	O
collected	O
in	O
real	O
-	O
time	O
in	O
a	O
field	O
with	O
two	O
management	O
strategies	O
(	O
reduced	O
tillage	B-PHEN
/	O
conventional	O
tillage	B-PHEN
)	O
and	O
sandy	B-OBJC
to	O
loam	B-OBJC
soils	I-OBJC
.	O

PSS	B-PROC
was	O
related	O
to	O
observations	B-PROC
from	O
a	O
long	O
-	O
term	O
(	O
11	O
years	O
)	O
earthworm	O
observation	B-DISO
study	I-DISO
conducted	O
at	O
42	O
plots	O
.	O

Earthworms	O
were	O
sampled	O
from	O
0	O
.	O

5	O
x	O
0	O
.	O
5	O
x	O
0	O
.	O

2	O
m³	O
soil	B-OBJC
blocks	O
and	O
identified	O
to	O
species	O
level	O
.	O

Sensor	B-DEVI
data	O
were	O
highly	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
reduced	O
tillage	B-PHEN
but	O
less	O
correlated	O
with	O
earthworm	O
abundances	O
observed	O
in	O
conventional	B-PHEN
tillage	I-PHEN
.	O

This	O
may	O
indicate	O
that	O
management	O
influences	O
the	O
sensor	B-DEVI
-	O
earthworm	O
relationship	O
.	O

Generalized	O
additive	O
models	O
and	O
state	O
-	O
space	O
models	O
showed	O
that	O
modelling	B-PROC
based	O
on	O
data	O
fusion	O
from	O
EC	O
,	O
pH	O
,	O
and	O
NIR	B-PROC
sensors	B-DEVI
produced	O
better	O
results	B-DISO
than	O
modelling	B-PROC
without	O
sensor	B-DEVI
data	O
or	O
data	O
from	O
just	O
a	O
single	O
sensor	B-DEVI
.	O

Regarding	O
the	O
individual	O
earthworm	O
species	O
,	O
particular	O
sensor	B-DEVI
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	O
requirements	O
of	O
the	O
earthworms	O
.	O

Earthworm	O
species	O
with	O
soil	B-OBJC
-specific	O
habitat	O
preferences	O
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	O
by	O
PSS	B-PROC
than	O
more	O
ubiquitous	O
species	O
.	O

Our	O
findings	B-DISO
suggest	O
that	O
PSS	B-PROC
contributes	O
to	O
the	O
spatial	O
modelling	B-PROC
of	O
earthworm	O
abundances	O
at	O
field	O
scale	O
and	O
that	O
it	O
will	O
support	O
species	O
distribution	O
modelling	B-PROC
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	B-OBJC
-	O
earthworm	O
relationships	O
in	O
agroecosystems	B-PHEN
.	O

Chemosensitivity	B-DISO
,	O
Cardiovascular	B-DISO
Risk	I-DISO
,	O
and	O
the	O
Ventilatory	B-PHYS
Response	I-PHYS
to	O
Exercise	O
in	O
COPD	B-DISO
COPD	B-DISO
is	O
associated	O
with	O
elevated	O
cardiovascular	B-DISO
risk	I-DISO
and	O
a	O
potentiated	O
ventilatory	B-PHYS
response	I-PHYS
to	O
exercise	O
.	O

Enhanced	O
carotid	B-ANAT
chemoreceptor	B-ANAT
(	O
CC	B-ANAT
)	O
activity	B-PHYS
/	O
sensitivity	B-PHYS
is	O
present	O
in	O
other	O
clinical	B-PHYS
conditions	I-PHYS
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	B-ANAT
vasoconstrictor	B-DISO
outflow	I-DISO
,	O
and	O
is	O
predictive	O
of	O
mortality	B-DISO
.	O

CC	B-ANAT
activity	B-PHYS
/	O
sensitivity	B-PHYS
,	O
and	O
the	O
resulting	O
functional	O
significance	O
,	O
has	O
not	O
been	O
well	O
examined	O
in	O
COPD	B-DISO
.	O

We	O
hypothesized	O
that	O
CC	B-ANAT
activity	B-PHYS
/	O
sensitivity	B-PHYS
would	O
be	O
elevated	O
in	O
COPD	B-DISO
,	O
and	O
related	O
to	O
increased	O
pulse	O
wave	O
velocity	O
(	O
a	O
marker	B-PHYS
of	O
CV	B-DISO
risk	I-DISO
)	O
and	O
the	O
ventilatory	B-PHYS
response	I-PHYS
to	O
exercise	O
.	O

30	O
COPD	B-DISO
patients	B-LIVB
and	O
10	O
healthy	O
age	O
-	O
matched	O
controls	B-LIVB
were	O
examined	B-DISO
.	O

Participants	B-LIVB
performed	O
baseline	O
cardiopulmonary	B-PROC
exercise	I-PROC
and	O
pulmonary	B-PROC
function	I-PROC
testing	I-PROC
.	O

CC	B-ANAT
activity	B-PHYS
was	O
later	O
evaluated	B-PROC
by	O
the	O
drop	B-DISO
in	I-DISO
ventilation	B-PHYS
with	O
breathing	B-PHYS
100	O
%	O
O2	B-CHEM
,	O
and	O
CC	B-ANAT
sensitivity	B-PHYS
was	O
then	O
assessed	O
by	O
the	O
ventilatory	B-PROC
response	I-PROC
to	I-PROC
hypoxia	I-PROC
(	O
ΔVE	O
/	O
ΔS	O
pO2	B-PROC
)	O
.	O

Peripheral	O
arterial	B-PHYS
stiffness	I-PHYS
was	O
subsequently	O
evaluated	B-PROC
by	O
measurement	O
of	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
using	O
applanation	B-PROC
tonometry	I-PROC
while	O
the	O
subjects	O
were	O
breathing	B-PHYS
room	B-DISO
air	I-DISO
,	O
and	O
then	O
following	O
chemoreceptor	B-ANAT
inhibition	O
by	O
breathing	B-PHYS
100	O
%	O
O2	B-CHEM
for	O
2	O
minutes	O
.	O

CC	B-ANAT
activity	B-PHYS
,	O
CC	B-ANAT
sensitivity	B-PHYS
,	O
PWV	O
and	O
the	O
ventilatory	B-PHYS
response	I-PHYS
to	O
exercise	O
were	O
all	O
increased	O
in	O
COPD	B-DISO
relative	O
to	O
controls	B-LIVB
.	O

CC	B-ANAT
sensitivity	B-PHYS
was	O
related	O
to	O
PWV	O
;	O
however	O
,	O
neither	O
CC	B-ANAT
activity	B-PHYS
nor	O
CC	B-ANAT
sensitivity	B-PHYS
was	O
related	O
to	O
the	O
ventilatory	B-PHYS
response	I-PHYS
to	O
exercise	O
in	O
COPD	B-DISO
.	O

CC	B-ANAT
inhibition	O
by	O
breathing	B-PHYS
100	O
%	O
O2	B-CHEM
normalized	O
PWV	O
in	O
COPD	B-DISO
,	O
while	O
no	O
effect	O
was	O
observed	O
in	O
controls	B-LIVB
.	O

CC	B-ANAT
activity	B-PHYS
and	O
sensitivity	B-PHYS
are	O
elevated	O
in	O
COPD	B-DISO
,	O
and	O
appear	O
related	O
to	O
cardiovascular	B-DISO
risk	I-DISO
;	O
however	O
,	O
CC	B-ANAT
activity	B-PHYS
/	O
sensitivity	B-PHYS
does	O
not	O
contribute	O
to	O
the	O
potentiated	O
ventilatory	B-PHYS
response	I-PHYS
to	O
exercise	O
.	O

Size	O
matters	O
to	O
function	O
:	O
Brain	O
volume	O
correlates	O
with	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
across	O
healthy	O
individuals	B-LIVB
A	O
fundamental	O
issue	O
in	O
neuroscience	O
is	O
to	O
understand	O
the	O
structural	O
substrates	O
of	O
neural	O
activities	O
.	O

Intrinsic	O
brain	B-PHYS
activity	I-PHYS
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	B-PHYS
functions	I-PHYS
.	O

Structurally	O
,	O
cognitive	B-PHYS
functions	I-PHYS
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	O
volume	O
/	O
size	O
.	O

Therefore	O
,	O
an	O
association	O
between	O
intrinsic	O
brain	B-PHYS
activities	I-PHYS
and	O
brain	O
volume	O
/	O
size	O
can	O
be	O
hypothesized	O
,	O
and	O
brain	O
volume	O
/	O
size	O
may	O
impact	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
in	O
human	B-LIVB
brains	B-ANAT
.	O

The	O
present	O
study	B-PROC
aimed	O
to	O
explicitly	O
investigate	O
this	O
brain	B-ANAT
structure	I-ANAT
-	O
function	B-PHYS
relationship	O
using	O
two	O
large	O
independent	O
cohorts	B-LIVB
of	O
176	O
and	O
236	O
young	B-LIVB
adults	I-LIVB
.	O

Structural	O
-	O
MRI	B-PROC
was	O
performed	O
to	O
estimate	O
the	O
brain	O
volume	O
,	O
and	O
resting	B-PROC
-	I-PROC
state	I-PROC
functional	I-PROC
-	I-PROC
MRI	I-PROC
was	O
applied	O
to	O
extract	O
the	O
amplitude	O
of	O
low	O
-	O
frequency	O
fluctuations	O
(	O
ALFF	O
)	O
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
.	O

Intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	O
correlation	O
between	O
whole	O
-	O
brain	O
size	O
and	O
ALFF	O
.	O

Moreover	O
,	O
specific	O
brain	B-ANAT
lobes	I-ANAT
/	O
regions	B-ANAT
,	O
including	O
the	O
frontal	B-ANAT
lobe	I-ANAT
,	O
the	O
left	B-ANAT
middle	I-ANAT
frontal	I-ANAT
gyrus	I-ANAT
,	O
anterior	B-ANAT
cingulate	I-ANAT
gyrus	I-ANAT
,	O
Rolandic	B-ANAT
operculum	I-ANAT
,	O
and	O
insula	B-ANAT
,	O
also	O
showed	O
a	O
reliable	O
,	O
positive	B-DISO
volume	O
-	O
ALFF	O
correlation	O
in	O
the	O
two	O
cohorts	B-LIVB
.	O

These	O
findings	O
offer	O
direct	O
,	O
empirical	O
evidence	O
of	O
a	O
strong	O
association	O
between	O
brain	O
size	O
/	O
volume	O
and	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	O
substrates	O
of	O
the	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
of	O
the	O
human	B-LIVB
brain	B-ANAT
.	O

Cavity	O
partition	O
and	O
functionalization	O
of	O
a	O
[	O
2	O
+	O
3	O
]	O
organic	B-CHEM
molecular	I-CHEM
cage	I-CHEM
by	O
inserting	O
polar	B-PHYS
P	I-PHYS
[	I-PHYS
double	I-PHYS
bond	I-PHYS
,	I-PHYS
length	I-PHYS
as	I-PHYS
m	I-PHYS
-	I-PHYS
dash	I-PHYS
]	I-PHYS
O	I-PHYS
bonds	I-PHYS
The	O
cavity	O
of	O
a	O
[	O
2	O
+	O
3	O
]	O
organic	B-CHEM
molecular	I-CHEM
cage	I-CHEM
was	O
partitioned	O
and	O
functionalized	O
by	O
inserting	O
inner	O
-	O
directed	O
P	B-PHYS
[	I-PHYS
double	I-PHYS
bond	I-PHYS
,	I-PHYS
length	I-PHYS
as	I-PHYS
m	I-PHYS
-	I-PHYS
dash	I-PHYS
]	I-PHYS
O	I-PHYS
bonds	I-PHYS
,	O
which	O
shows	O
CO2	B-CHEM
capture	O
and	O
CH4	B-CHEM
exclusion	O
due	O
to	O
the	O
size	O
-	O
matching	O
and	O
polarity	O
effects	O
.	O

Computational	O
results	B-DISO
demonstrate	O
that	O
the	O
successful	O
segmentation	O
via	O
polar	B-PHYS
P	I-PHYS
[	I-PHYS
double	I-PHYS
bond	I-PHYS
,	I-PHYS
length	I-PHYS
as	I-PHYS
m	I-PHYS
-	I-PHYS
dash	I-PHYS
]	I-PHYS
O	I-PHYS
bonds	I-PHYS
facilitates	O
the	O
CO2	B-CHEM
molecules	B-OBJC
to	O
reside	O
selectively	O
inside	O
the	O
cavity	O
.	O

Succession	O
Planning	O
and	O
Financial	O
Performance	O
:	O
Does	O
Competition	O
Matter	O
?	O
Succession	O
planning	O
has	O
been	O
defined	O
as	O
the	O
process	B-PHEN
by	O
which	O
one	O
or	O
more	O
successors	B-LIVB
are	O
identified	O
for	O
key	O
positions	O
,	O
development	O
activities	O
are	O
planned	O
for	O
identified	O
successors	B-LIVB
,	O
or	O
both	O
.	O

Limited	O
research	B-PROC
exists	O
pertaining	O
to	O
the	O
relationship	O
between	O
hospital	B-OBJC
succession	O
planning	O
and	O
financial	O
performance	O
,	O
particularly	O
in	O
the	O
context	O
of	O
market	O
competition	O
.	O

We	O
used	O
the	O
resource	O
-	O
based	O
view	O
framework	O
to	O
analyze	B-PROC
the	O
differential	O
effect	O
of	O
succession	O
planning	O
on	O
hospitals	B-OBJC
'	O
financial	O
performance	O
based	O
on	O
market	O
competition	O
.	O

According	O
to	O
RBV	O
,	O
organizations	O
can	O
achieve	O
higher	O
performance	O
by	O
using	O
their	O
superior	O
resources	O
and	O
capabilities	O
.	O

We	O
used	O
a	O
panel	O
design	O
consisting	O
of	O
a	O
national	O
sample	O
of	O
hospitals	B-OBJC
in	O
the	O
United	B-GEOG
States	I-GEOG
for	O
2006	O
-	O
2010	O
.	O

We	O
analyzed	B-PROC
data	O
using	O
multivariate	O
linear	O
regression	O
with	O
facility	O
random	O
effects	O
and	O
year	O
and	O
state	B-GEOG
fixed	O
effects	O
.	O

The	O
sample	O
included	O
22	O
,	O
717	O
hospital	B-OBJC
-	O
year	O
observations	O
;	O
more	O
than	O
one	O
half	O
of	O
the	O
hospitals	B-OBJC
(	O
55	O
.	O
4	O
%	O
)	O
had	O
a	O
succession	O
planning	O
program	O
.	O

The	O
study	O
found	O
a	O
positive	B-DISO
relationship	O
between	O
the	O
presence	B-DISO
of	O
succession	O
planning	O
and	O
financial	O
performance	O
(	O
β	O
=	O
1	O
.	O
41	O
,	O
p	O
<	O
.01	O
)	O
,	O
which	O
was	O
stronger	O
in	O
competitive	O
market	O
s	O
(	O
β	O
=	O
2	O
.	O
31	O
,	O
p	O
=	O
.03	O
)	O
than	O
in	O
monopolistic	O
markets	O
(	O
β	O
=	O
1	O
.	O
06	O
,	O
p	O
=	O
.01	O
)	O
.	O

Hospitals	B-OBJC
can	O
use	O
these	O
results	O
to	O
make	O
informed	O
decisions	B-PHYS
about	O
investing	O
in	O
succession	O
planning	O
programs	O
on	O
the	O
basis	O
of	O
competition	O
in	O
their	O
market	O
.	O

On	O
the	O
Control	O
of	O
Social	O
Approach	B-DISO
-	I-DISO
Avoidance	I-DISO
Behavior	I-DISO
:	O
Neural	O
and	O
Endocrine	O
Mechanisms	O
The	O
ability	B-PHYS
to	O
control	O
our	O
automatic	O
action	O
tendencies	O
is	O
crucial	O
for	O
adequate	O
social	B-DISO
interactions	I-DISO
.	O

Emotional	B-DISO
events	O
trigger	O
automatic	O
approach	B-DISO
and	I-DISO
avoidance	I-DISO
tendencies	O
.	O

Although	O
these	O
actions	O
may	O
be	O
generally	O
adaptive	O
,	O
the	O
capacity	O
to	O
override	O
these	O
emotional	B-DISO
reactions	I-DISO
may	O
be	O
key	O
to	O
flexible	O
behavior	O
during	O
social	B-DISO
interaction	I-DISO
.	O

The	O
present	O
chapter	O
provides	O
a	O
review	O
of	O
the	O
neuroendocrine	B-ANAT
mechanisms	O
underlying	O
this	O
ability	B-PHYS
and	O
their	O
relation	O
to	O
social	O
psychopathologies	O
.	O

Aberrant	O
social	O
behavior	O
,	O
such	O
as	O
observed	O
in	O
social	B-DISO
anxiety	I-DISO
or	O
psychopathy	B-DISO
,	O
is	O
marked	O
by	O
abnormalities	B-DISO
in	O
approach	B-DISO
-	I-DISO
avoidance	I-DISO
tendencies	O
and	O
the	O
ability	B-PHYS
to	O
control	O
them	O
.	O

Key	O
neural	O
regions	O
involved	O
in	O
the	O
regulation	B-PHEN
of	O
approach	B-DISO
-	I-DISO
avoidance	I-DISO
behavior	I-DISO
are	O
the	O
amygdala	B-ANAT
,	O
widely	O
implicated	O
in	O
automatic	O
emotional	B-DISO
processing	B-PHYS
,	O
and	O
the	O
anterior	O
prefrontal	B-ANAT
cortex	I-ANAT
,	O
which	O
exerts	B-PHYS
control	O
over	O
the	O
amygdala	B-ANAT
.	O

Hormones	B-CHEM
,	O
especially	O
testosterone	B-CHEM
and	O
cortisol	B-CHEM
,	O
have	O
been	O
shown	O
to	O
affect	B-PHYS
approach	B-DISO
-	I-DISO
avoidance	I-DISO
behavior	I-DISO
and	O
the	O
associated	O
neural	O
mechanisms	O
.	O

The	O
present	O
chapter	O
also	O
discusses	O
ways	O
to	O
directly	O
influence	O
social	O
approach	B-DISO
and	I-DISO
avoidance	I-DISO
behavior	I-DISO
and	O
will	O
end	O
with	O
a	O
research	B-PROC
agenda	O
to	O
further	O
advance	O
this	O
important	O
research	B-PROC
field	I-PROC
.	O

Control	O
over	O
approach	B-DISO
-	I-DISO
avoidance	I-DISO
tendencies	O
may	O
serve	O
as	O
an	O
exemplar	O
of	O
emotional	B-DISO
action	O
regulation	B-PHEN
and	O
might	O
have	O
a	O
great	O
value	O
in	O
understanding	B-PHYS
the	O
underlying	O
mechanisms	O
of	O
the	O
development	O
of	O
affective	B-DISO
disorders	I-DISO
.	O

High	O
Occurrence	O
of	O
Non	B-DISO
-	I-DISO
Clear	I-DISO
Cell	I-DISO
Renal	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
in	O
Oman	B-GEOG
It	O
is	O
conventionally	O
accepted	O
that	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
RCC	B-DISO
)	O
occurs	O
in	O
older	B-LIVB
patients	I-LIVB
and	O
the	O
clear	B-DISO
cell	I-DISO
type	I-DISO
is	O
the	O
most	O
common	O
histology	O
.	O

However	O
,	O
ethnic	O
variations	O
exist	O
and	O
this	O
study	B-PROC
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological	O
pattern	O
of	O
RCC	B-DISO
in	O
Oman	B-GEOG
.	O

Ninety	O
RCC	B-DISO
patients	B-LIVB
who	O
presented	O
to	O
a	O
tertiary	B-OBJC
care	I-OBJC
center	I-OBJC
in	O
the	O
Sultanate	B-GEOG
of	I-GEOG
Oman	I-GEOG
from	O
2010	O
to	O
2014	O
were	O
studied	B-PROC
.	O

The	O
main	B-DISO
findings	I-DISO
were	O
that	O
the	O
median	B-PHYS
age	I-PHYS
of	O
presentation	O
was	O
low	O
,	O
more	O
patients	B-LIVB
presented	O
with	O
localized	O
stage	O
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non	B-DISO
-	I-DISO
clear	I-DISO
(	O
especially	O
papillary	B-DISO
)	O
histology	O
.	O

Data	O
from	O
other	O
Gulf	B-GEOG
countries	I-GEOG
and	O
possible	O
reasons	O
for	O
the	O
different	O
profile	O
are	O
discussed	O
.	O

""""	O
Bridge	B-CHEM
Proteins	I-CHEM
""""	O
Link	O
Inflammation	B-DISO
and	O
Metabolic	B-DISO
Diseases	I-DISO
:	O
Potential	O
Targets	O
for	O
Therapeutics	O
Clinical	B-PROC
observations	I-PROC
support	O
the	O
postulate	O
that	O
chronic	O
low	O
-	O
grade	O
inflammation	B-DISO
underlies	O
metabolic	B-DISO
diseases	I-DISO
and	O
inflammatory	B-CHEM
mediators	I-CHEM
can	O
trigger	O
some	O
metabolic	B-DISO
diseases	I-DISO
.	O

In	O
disorder	B-DISO
condition	O
,	O
what	O
is	O
the	O
first	O
one	O
:	O
metabolic	B-DISO
diseases	I-DISO
cause	O
inflammation	B-DISO
or	O
conversely	O
?	O

This	O
""""	O
chicken	O
or	O
egg	O
""""	O
type	O
question	O
was	O
hard	O
to	O
answer	O
.	O

However	O
,	O
instead	O
of	O
focusing	O
on	O
this	O
difficult	O
issue	B-DISO
,	O
we	O
should	O
ask	O
another	O
challenging	O
question	O
:	O
what	O
are	O
the	O
links	O
between	O
inflammation	B-DISO
and	O
metabolic	B-DISO
diseases	I-DISO
?	O
Seizing	O
the	O
key	O
from	O
this	O
chaos	B-DISO
may	O
be	O
the	O
best	O
way	O
to	O
solve	O
the	O
problem	B-DISO
and	O
break	O
the	O
cycle	O
.	O

To	O
answer	O
this	O
question	O
,	O
we	O
review	O
the	O
regulators	B-CHEM
(	O
such	O
as	O
NF	B-CHEM
-	I-CHEM
κB	I-CHEM
,	O
PPARs	B-CHEM
,	O
mTOR	B-CHEM
,	O
and	O
STAT3	B-CHEM
)	O
that	O
have	O
important	O
roles	O
in	O
both	O
metabolism	B-PHYS
and	O
inflammation	B-DISO
.	O

These	O
""""	O
bridge	B-CHEM
proteins	I-CHEM
""""	O
that	O
link	O
metabolic	B-DISO
diseases	I-DISO
and	O
inflammation	B-DISO
not	O
only	O
increase	O
our	O
understanding	O
of	O
these	O
two	O
diseases	B-DISO
,	O
but	O
also	O
provide	O
potential	O
targets	O
for	O
therapeutics	O
and	O
practical	O
clinical	O
applications	O
.	O

Isolation	B-PROC
of	I-PROC
Cells	I-PROC
Specialized	O
in	O
Anticancer	B-CHEM
Alkaloid	B-PHYS
Metabolism	I-PHYS
by	O
Fluorescence	B-PROC
-	I-PROC
Activated	I-PROC
Cell	I-PROC
Sorting	I-PROC
Plant	B-LIVB
specialized	O
metabolism	B-PHYS
often	O
presents	O
a	O
complex	O
cell	B-ANAT
-	O
specific	O
compartmentation	B-PHYS
essential	O
to	O
accomplish	O
the	O
biosynthesis	O
of	O
valuable	O
plant	B-LIVB
natural	B-CHEM
products	I-CHEM
.	O

Hence	O
,	O
the	O
disclosure	O
and	O
potential	O
manipulation	O
of	O
such	O
pathways	O
may	O
depend	O
on	O
the	O
capacity	O
to	O
isolate	B-PROC
and	O
characterize	O
specific	O
cell	O
types	O
.	O

Catharanthus	B-LIVB
roseus	I-LIVB
is	O
the	O
source	O
of	O
several	O
medicinal	B-CHEM
terpenoid	B-CHEM
indole	I-CHEM
alkaloids	I-CHEM
,	O
including	O
the	O
low	O
-	O
level	O
anticancer	B-CHEM
vinblastine	B-CHEM
and	O
vincristine	B-CHEM
,	O
for	O
which	O
the	O
late	O
biosynthetic	O
steps	O
occur	O
in	O
specialized	O
mesophyll	B-ANAT
cells	I-ANAT
called	O
idioblasts	B-ANAT
.	O

Here	O
,	O
the	O
optical	O
,	O
fluorescence	B-PHEN
,	O
and	O
alkaloid	B-CHEM
-	O
accumulating	B-DISO
properties	O
of	O
C	B-LIVB
.	I-LIVB

roseus	I-LIVB
leaf	B-LIVB
idioblasts	B-ANAT
are	O
characterized	O
,	O
and	O
a	O
methodology	O
for	O
the	O
isolation	B-PROC
of	O
idioblast	B-ANAT
protoplasts	B-ANAT
by	O
fluorescence	B-PROC
-	I-PROC
activated	I-PROC
cell	I-PROC
sorting	I-PROC
is	O
established	O
,	O
taking	O
advantage	O
of	O
the	O
distinctive	O
autofluorescence	B-PROC
of	O
these	O
cells	B-ANAT
.	O

This	O
achievement	O
represents	O
a	O
crucial	O
step	O
for	O
the	O
development	O
of	O
differential	O
omic	B-PROC
strategies	I-PROC
leading	O
to	O
the	O
identification	O
of	O
candidate	O
genes	O
putatively	O
involved	O
in	O
the	O
biosynthesis	O
,	O
pathway	O
regulation	B-PHEN
,	O
and	O
transmembrane	B-PHYS
transport	I-PHYS
leading	O
to	O
the	O
anticancer	B-DISO
alkaloids	B-CHEM
from	O
C	B-LIVB
.	I-LIVB

roseus	I-LIVB
.	O

Interaction	O
of	O
the	O
Antimicrobial	B-CHEM
Peptides	I-CHEM
Rhesus	B-CHEM
θ	I-CHEM
-	I-CHEM
Defensin	I-CHEM
and	O
Porcine	B-LIVB
Protegrin	B-CHEM
-	I-CHEM
1	I-CHEM
with	O
Anionic	B-CHEM
Phospholipid	I-CHEM
Monolayers	I-CHEM
A	O
combination	O
of	O
Langmuir	O
isotherm	O
,	O
Brewster	B-PROC
angle	I-PROC
microscopy	I-PROC
(	O
BAM	B-PROC
)	O
,	O
and	O
neutron	B-PROC
reflectivity	I-PROC
studies	I-PROC
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	O
bacterial	B-ANAT
cell	I-ANAT
membranes	I-ANAT
of	O
the	O
antimicrobial	B-CHEM
peptides	I-CHEM
,	O
Rhesus	B-CHEM
θ	I-CHEM
-	I-CHEM
defensin	I-CHEM
1	I-CHEM
(	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
,	O
and	O
porcine	B-LIVB
protegrin	B-CHEM
1	I-CHEM
(	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
.	O

The	O
peptides	B-CHEM
were	O
interacted	O
with	O
monolayers	B-CHEM
spread	O
at	O
the	O
air	B-OBJC
-	O
water	B-CHEM
interface	O
and	O
prepared	O
from	O
a	O
3	O
:	O
1	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	B-CHEM
and	O
phosphatidylglycerol	B-CHEM
used	O
to	O
approximate	O
the	O
cell	B-ANAT
membranes	I-ANAT
of	O
Gram	B-LIVB
positive	I-LIVB
bacteria	I-LIVB
.	O

The	O
Langmuir	B-OBJC
film	I-OBJC
balance	O
measurements	O
show	O
that	O
both	O
peptides	B-CHEM
perturb	O
the	O
lipid	B-CHEM
monolayers	I-CHEM
causing	O
an	O
increase	O
in	O
surface	B-PHEN
pressure	I-PHEN
,	O
and	O
the	O
BAM	B-PROC
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small	O
domains	O
within	O
the	O
lipid	O
films	O
,	O
around	O
5	O
μm	O
diameter	O
.	O

The	O
overall	O
change	O
in	O
monolayer	B-CHEM
surface	B-PHEN
pressure	I-PHEN
caused	O
by	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
,	O
however	O
,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
(	O
+8	O
.	O

5	O
mN·m	O
(	O
-	O
1	O
)	O
vs	O
+5	O
.	O

5	O
mN·m	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	O
with	O
the	O
monolayer	B-CHEM
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
.	O

The	O
neutron	B-DEVI
reflectivity	I-DEVI
studies	I-DEVI
also	O
show	O
differences	O
for	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
,	O
with	O
the	O
model	O
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	B-CHEM
PG	B-CHEM
-	I-CHEM
1	I-CHEM
becomes	O
fully	O
embedded	B-PROC
within	O
the	O
lipid	O
film	O
-causing	O
an	O
extension	O
of	O
the	O
lipid	B-CHEM
acyl	I-CHEM
chains	I-CHEM
but	O
leaving	O
the	O
thickness	O
of	O
the	O
lipid	B-CHEM
headgroup	I-CHEM
layer	I-CHEM
unaffected	O
-	O
while	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
is	O
seen	O
to	O
insert	O
less	O
deeply	O
-	O
causing	O
the	O
same	O
extension	O
of	O
the	O
lipid	B-CHEM
acyl	I-CHEM
chains	I-CHEM
as	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	O
of	O
the	O
lipid	B-CHEM
headgroup	I-CHEM
layer	I-CHEM
.	O

The	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	B-CHEM
on	O
anionic	B-CHEM
lipid	I-CHEM
monolayers	I-CHEM
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic	B-PROC
activities	I-PROC
,	O
and	O
their	O
proposed	O
differing	O
propensities	O
to	O
form	O
transmembrane	B-ANAT
pores	B-ANAT
.	O

Lipidomic	B-PROC
Signatures	I-PROC
and	O
Associated	O
Transcriptomic	O
Profiles	O
of	O
Clear	B-DISO
Cell	I-DISO
Renal	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
Renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
RCC	B-DISO
)	I-DISO
is	O
the	O
most	O
common	O
histological	B-PHYS
type	I-PHYS
of	O
adult	B-LIVB
kidney	B-DISO
cancer	I-DISO
.	O

In	O
this	O
study	B-PROC
,	O
we	O
obtained	O
lipidomic	B-PROC
profiles	I-PROC
of	O
clear	B-DISO
cell	I-DISO
RCC	I-DISO
(	O
ccRCC	B-DISO
)	O
,	O
a	O
major	O
RCC	B-DISO
subtype	O
,	O
by	O
performing	O
a	O
lipidomic	B-PROC
analysis	I-PROC
of	O
specimens	B-OBJC
of	O
cancerous	B-DISO
tissue	I-DISO
and	O
the	O
surrounding	O
normal	O
renal	B-ANAT
cortex	I-ANAT
obtained	O
from	O
the	O
same	O
patients	B-LIVB
(	O
N	O
=	O
49	O
)	O
.	O

We	O
also	O
compared	O
the	O
lipidomic	B-PROC
profiles	I-PROC
with	O
the	O
lipogenic	O
transcriptome	O
of	O
specimens	B-OBJC
of	O
cancerous	B-DISO
tissue	I-DISO
and	O
the	O
surrounding	O
normal	O
renal	B-ANAT
cortex	I-ANAT
for	O
an	O
additional	O
set	O
of	O
patient	B-LIVB
samples	O
(	O
N	O
=	O
95	O
)	O
.	O

Overall	O
,	O
we	O
detected	O
326	O
lipids	B-CHEM
,	O
including	O
phospholipids	B-CHEM
,	O
sphingolipids	B-CHEM
,	O
neutral	B-CHEM
lipids	I-CHEM
,	O
and	O
eicosanoids	B-CHEM
.	O

The	O
levels	O
of	O
more	O
than	O
70	O
%	O
of	O
the	O
detected	O
lipids	B-CHEM
were	O
significantly	O
different	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
corrected	O
by	O
the	O
false	O
discovery	O
rate	O
)	O
.	O

The	O
cancerous	B-DISO
tissue	I-DISO
was	O
distinguished	O
by	O
higher	O
levels	O
of	O
ether	B-CHEM
-	I-CHEM
type	I-CHEM
phospholipids	I-CHEM
,	O
cholesterol	B-CHEM
esters	I-CHEM
,	O
and	O
triacylglycerols	B-CHEM
,	O
as	O
well	O
as	O
by	O
lower	O
levels	O
of	O
phospholipids	B-CHEM
(	O
except	O
for	O
phosphatidylcholines	B-CHEM
)	O
and	O
polyunsaturated	B-CHEM
fatty	I-CHEM
acids	I-CHEM
.	O

Characteristic	O
changes	O
in	O
the	O
levels	O
of	O
mRNAs	B-CHEM
and	O
metabolites	B-CHEM
suggested	O
that	O
the	O
phosphatidylethanolamine	B-PHYS
(	I-PHYS
PE	I-PHYS
)	I-PHYS
synthesis	I-PHYS
pathway	I-PHYS
is	O
suppressed	O
in	O
ccRCC	B-DISO
and	O
associated	O
with	O
cell	B-PHYS
proliferation	I-PHYS
.	O

The	O
present	O
study	B-PROC
represents	O
the	O
lipidomic	B-PROC
profiles	I-PROC
of	O
ccRCC	B-DISO
,	O
which	O
provides	O
novel	O
information	O
about	O
the	O
metabolic	B-PHYS
changes	O
in	O
renal	B-ANAT
cancerous	B-DISO
tissue	I-DISO
and	O
RCC	B-DISO
pathophysiology	B-DISO
.	O

Patient	B-PROC
Mobility	I-PROC
for	O
Elective	O
Secondary	B-PROC
Health	I-PROC
Care	I-PROC
Services	I-PROC
in	O
Response	B-PHYS
to	O
Patient	O
Choice	O
Policies	O
:	O
A	O
Systematic	O
Review	O
Our	O
review	O
establishes	O
the	O
empirical	O
evidence	O
for	O
patient	B-PROC
mobility	I-PROC
for	O
elective	B-PROC
secondary	I-PROC
care	I-PROC
services	I-PROC
in	O
countries	B-GEOG
that	O
allow	O
patients	B-LIVB
to	O
choose	O
their	O
health	B-LIVB
care	I-LIVB
provider	I-LIVB
.	O

PubMed	O
and	O
Embase	O
were	O
searched	O
for	O
relevant	O
articles	O
between	O
1990	O
and	O
2015	O
.	O

Of	O
5	O
,	O
994	O
titles	O
/	O
abstracts	O
reviewed	O
,	O
26	O
studies	B-PROC
were	O
included	O
.	O

The	O
studies	B-PROC
used	O
three	O
main	O
methodological	O
models	O
to	O
establish	O
mobility	B-DISO
.	O

Variation	O
in	O
the	O
extent	O
of	O
patient	B-PROC
mobility	I-PROC
was	O
observed	O
across	O
the	O
studies	O
.	O

Mobility	B-DISO
was	O
positively	O
associated	O
with	O
lower	O
waiting	O
times	O
,	O
indicators	O
of	O
better	B-PROC
service	I-PROC
quality	I-PROC
,	O
and	O
access	O
to	O
advanced	O
technology	O
.	O

It	O
was	O
negatively	O
associated	O
with	O
advanced	B-LIVB
age	I-LIVB
or	O
lower	O
socioeconomic	O
backgrounds	O
.	O

From	O
a	O
policy	O
perspective	O
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	O
of	O
patients	B-LIVB
are	O
prepared	O
to	O
travel	O
beyond	O
their	O
nearest	O
provider	B-LIVB
for	O
elective	O
services	O
.	O

As	O
a	O
consequence	O
,	O
some	O
providers	B-LIVB
are	O
likely	O
to	O
be	O
""""	O
winners	B-PROC
""""	O
and	O
others	O
""""	O
losers	B-DISO
,	O
""""	O
which	O
could	O
result	O
in	O
overall	O
decreased	O
provider	B-LIVB
capacity	O
or	O
inefficient	O
utilization	O
of	O
existing	O
services	B-PROC
.	O

Equity	O
also	O
remains	O
a	O
key	O
concern	O
.	O

Bone	B-ANAT
-	O
Albumin	B-CHEM
filling	B-PROC
decreases	O
donor	B-ANAT
site	I-ANAT
morbidity	O
and	O
enhances	O
bone	B-PHYS
formation	I-PHYS
after	O
anterior	B-ANAT
cruciate	I-ANAT
ligament	I-ANAT
reconstruction	B-PROC
with	O
bone	O
-	O
patellar	O
tendon	O
-	O
bone	O
autografts	B-CHEM
Donor	B-ANAT
site	I-ANAT
pain	B-DISO
affects	O
32	O
-	O
43	O
%	O
of	O
patients	B-LIVB
after	O
anterior	B-ANAT
cruciate	I-ANAT
ligament	I-ANAT
surgery	O
when	O
the	O
autograft	B-CHEM
is	O
freshly	O
harvested	B-PROC
bone	O
-	O
patellar	O
tendon	O
-	O
bone	O
tissue	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
functional	O
and	O
morphological	O
differences	O
between	O
donor	B-ANAT
sites	I-ANAT
with	O
and	O
without	O
serum	B-CHEM
albumin	I-CHEM
-	O
coated	O
bone	B-ANAT
allograft	B-CHEM
filling	B-PROC
.	O
After	O
harvesting	B-PROC
and	O
implanting	B-PROC
the	O
graft	B-CHEM
,	O
the	O
tibia	B-ANAT
site	B-ANAT
was	O
filled	O
with	O
either	O
fresh	O
autologous	O
cancellous	O
bone	O
enhanced	O
with	O
albumin	B-CHEM
-	O
coated	O
allograft	B-CHEM
or	O
autologous	O
bone	B-ANAT
alone	O
.	O

The	O
patella	B-ANAT
site	B-ANAT
was	O
filled	O
either	O
with	O
albumin	B-CHEM
-	O
coated	O
allograft	B-CHEM
or	O
with	O
blood	B-DISO
clot	I-DISO
.	O

Knee	B-ANAT
function	B-PHYS
was	O
evaluated	B-PROC
by	O
the	O
VISA	B-PHYS
,	O
Lysholm	O
and	O
IKDC	O
scores	O
and	O
a	O
visual	B-PROC
analog	I-PROC
scale	I-PROC
of	I-PROC
pain	I-PROC
during	O
standing	O
,	O
kneeling	B-DISO
and	O
crouching	B-DISO
after	O
six	O
weeks	O
and	O
six	O
months	O
.	O

Computed	B-PROC
tomography	I-PROC
was	O
performed	O
at	O
six	O
months	O
for	O
morphological	O
evaluation	B-PROC
.	O

At	O
six	O
weeks	O
,	O
both	O
groups	O
were	O
still	O
recovering	O
from	O
surgery	O
and	O
the	O
overall	O
knee	B-ANAT
function	B-PHYS
was	O
still	O
impaired	O
but	O
the	O
functional	O
scores	O
were	O
significantly	O
higher	O
in	O
the	O
Bone	B-ANAT
-	O
Albumin	B-CHEM
group	O
.	O

The	O
pain	B-DISO
with	O
crouching	B-DISO
and	O
kneeling	B-DISO
was	O
also	O
lower	O
as	O
compared	O
to	O
controls	B-LIVB
.	O

At	O
six	O
months	O
,	O
the	O
knee	B-ANAT
function	B-PHYS
scores	O
were	O
close	O
to	O
normal	O
,	O
with	O
a	O
slight	O
decrease	O
in	O
the	O
controls	B-LIVB
.	O

Pain	B-DISO
at	O
kneeling	B-DISO
was	O
still	O
prominent	O
in	O
the	O
controls	B-LIVB
,	O
but	O
significantly	O
lower	O
in	O
the	O
Bone	B-ANAT
-	O
Albumin	B-CHEM
group	O
.	O

Computed	B-PROC
tomography	I-PROC
showed	O
significantly	O
smaller	O
bone	B-ANAT
defects	O
and	O
higher	O
bone	B-PHYS
density	I-PHYS
in	O
the	O
Bone	B-ANAT
-	O
Albumin	B-CHEM
group	O
.	O

Results	B-PHEN
from	O
the	O
present	O
study	B-PROC
indicate	O
that	O
donor	B-ANAT
site	I-ANAT
pain	B-DISO
,	O
a	O
disturbing	O
long	O
-	O
term	O
side	B-DISO
effect	I-DISO
of	O
bone	O
-	O
patellar	O
tendon	O
-	O
bone	O
surgery	O
,	O
is	O
significantly	O
reduced	O
if	O
bone	B-ANAT
buildup	O
in	O
the	O
patella	B-ANAT
and	O
the	O
tibia	B-ANAT
is	O
augmented	O
by	O
serum	B-CHEM
albumin	I-CHEM
-	O
coated	O
bone	B-ANAT
allografts	B-CHEM
.	O

Development	B-PHYS
of	O
chrysin	B-CHEM
loaded	O
poloxamer	B-CHEM
micelles	O
and	O
toxicity	O
evaluation	B-PROC
in	O
fish	B-LIVB
embryos	B-ANAT
Poloxamer	B-CHEM
micelles	B-CHEM
promise	O
safety	B-PHEN
and	O
efficacy	O
for	O
many	O
water	B-CHEM
insoluble	O
drugs	B-CHEM
.	O

Chrysin	B-CHEM
has	O
been	O
reported	O
to	O
have	O
anticancer	O
,	O
anti	O
-	O
inflammatory	O
,	O
antioxidant	B-PHYS
,	O
and	O
anti	B-PHYS
-	I-PHYS
aromatase	I-PHYS
activities	I-PHYS
but	O
its	O
water	B-CHEM
insoluble	O
properties	O
limit	O
its	O
pharmaceutical	O
application	O
.	O

In	O
the	O
present	O
study	O
,	O
chrysin	B-CHEM
loaded	O
poloxamer	B-CHEM
micelles	B-CHEM
were	O
developed	O
.	O

Two	O
types	O
of	O
poloxamers	B-CHEM
,	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
68	I-CHEM
and	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
127	I-CHEM
were	O
compared	O
.	O

It	O
was	O
found	O
that	O
chrysin	B-CHEM
loaded	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
68	I-CHEM
micelles	B-CHEM
(	O
CS	B-CHEM
-	I-CHEM
P68	I-CHEM
)	O
and	O
chrysin	B-CHEM
loaded	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
127	I-CHEM
micelles	B-CHEM
(	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
)	O
obviously	O
increase	O
the	O
aqueous	O
solubility	O
of	O
chrysin	B-CHEM
.	O

The	O
results	O
also	O
indicated	O
that	O
the	O
type	O
of	O
polymer	B-CHEM
and	O
ratio	O
of	O
drug	B-CHEM
to	O
polymer	B-CHEM
affected	O
size	O
and	O
desirable	O
characteristics	O
of	O
the	O
micelles	B-CHEM
.	O

The	O
micelle	B-CHEM
system	I-CHEM
of	O
CS	B-CHEM
-	I-CHEM
P68	I-CHEM
and	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
formed	O
at	O
drug	B-CHEM
to	O
polymer	B-CHEM
ratios	O
of	O
1	O
:	O
4	O
and	O
1	O
:	O
2	O
,	O
respectively	O
,	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
monodispersed	O
system	O
with	O
a	O
nanosize	O
-	O
range	O
diameter	O
.	O

The	O
in	B-PROC
vivo	I-PROC
study	I-PROC
in	O
zebrafish	B-LIVB
eggs	B-ANAT
indicates	O
that	O
the	O
toxicity	O
of	O
CS	B-CHEM
-	I-CHEM
P68	I-CHEM
and	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
is	O
a	O
dose	O
response	O
.	O

CS	B-CHEM
-	I-CHEM
P68	I-CHEM
and	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
at	O
a	O
drug	O
dose	O
of	O
10	O
ng	O
/	O
mL	O
or	O
less	O
is	O
safe	O
for	O
zebrafish	B-LIVB
embryo	B-ANAT
growth	B-PHYS
.	O

The	O
results	O
of	O
this	O
study	B-PROC
indicate	O
enhanced	O
water	O
solubility	O
of	O
chrysin	B-CHEM
.	O

Chrysin	B-CHEM
loaded	O
poloxamer	B-CHEM
micelles	B-CHEM
are	O
promising	O
for	O
further	O
use	O
in	O
in	B-PROC
vivo	I-PROC
studies	I-PROC
in	O
mammalian	B-LIVB
animals	B-LIVB
and	O
humans	B-LIVB
.	O

Adenoviral	B-LIVB
Delivery	B-PROC
of	O
Tumor	B-CHEM
Necrosis	I-CHEM
Factor	I-CHEM
-	I-CHEM
α	I-CHEM
and	O
Interleukin	B-CHEM
-	I-CHEM
2	I-CHEM
Enables	O
Successful	O
Adoptive	B-PROC
Cell	I-PROC
Therapy	I-PROC
of	O
Immunosuppressive	B-CHEM
Melanoma	B-DISO
Adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
is	O
a	O
promising	O
treatment	O
approach	O
for	O
metastatic	B-DISO
cancer	I-DISO
,	O
but	O
efficacy	O
in	O
solid	B-DISO
tumors	I-DISO
has	O
only	O
been	O
achieved	O
with	O
toxic	O
pre	O
-	O
and	O
postconditioning	O
regimens	O
.	O

Thus	O
,	O
adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
therapies	I-PROC
would	O
benefit	O
from	O
complementary	O
modalities	O
that	O
enable	O
their	O
full	O
potential	O
without	O
excessive	O
toxicity	O
.	O

We	O
aimed	O
to	O
improve	O
the	O
efficacy	O
and	O
safety	O
of	O
adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
by	O
using	O
adenoviral	B-CHEM
vectors	I-CHEM
for	O
direct	O
delivery	O
of	O
immunomodulatory	B-PROC
murine	B-LIVB
cytokines	B-CHEM
into	O
B16	B-ANAT
.	I-ANAT

OVA	I-ANAT
melanoma	B-DISO
tumors	I-DISO
with	O
concomitant	O
T	B-CHEM
-	I-CHEM
cell	I-CHEM
receptor	I-CHEM
transgenic	B-PROC
OT	I-PROC
-	I-PROC
I	I-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
.	O

Armed	O
adenoviruses	B-LIVB
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	B-CHEM
when	O
injected	O
into	O
B16	B-ANAT
.	I-ANAT

OVA	I-ANAT
tumors	B-DISO
,	O
suggesting	O
safety	O
of	O
virus	B-PROC
-	I-PROC
mediated	I-PROC
cytokine	I-PROC
delivery	I-PROC
.	O

Antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	B-LIVB
coding	O
for	O
murine	B-LIVB
interleukin	B-CHEM
-	I-CHEM
2	I-CHEM
(	O
mIL	B-CHEM
-	I-CHEM
2	I-CHEM
)	O
and	O
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
-	I-CHEM
α	I-CHEM
(	O
mTNFα	B-CHEM
)	O
when	O
compared	O
with	O
T	B-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
alone	O
or	O
viruses	B-LIVB
alone	O
.	O

Further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mIL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
mTNFα	B-CHEM
,	O
and	O
OT	B-ANAT
-	I-ANAT
I	I-ANAT
T	I-ANAT
-	I-ANAT
cells	I-ANAT
.	O

Mechanistic	O
studies	O
suggest	O
that	O
mIL	B-CHEM
-	I-CHEM
2	I-CHEM
has	O
an	O
important	O
role	O
in	O
activating	O
T	B-ANAT
-	I-ANAT
cells	I-ANAT
at	O
the	O
tumor	B-DISO
,	O
while	O
mTNFα	B-CHEM
induces	O
chemokine	B-CHEM
expression	B-PHYS
.	O

Furthermore	O
,	O
adenovirus	B-LIVB
treatments	B-PROC
enhanced	O
tumor	B-DISO
-	O
infiltration	O
of	O
OT	B-ANAT
-	I-ANAT
I	I-ANAT
T	I-ANAT
-	I-ANAT
cells	I-ANAT
as	O
demonstrated	O
by	O
SPECT	B-PROC
/	I-PROC
CT	I-PROC
imaging	I-PROC
of	O
(	B-ANAT
111	I-ANAT
)	I-ANAT
In	I-ANAT
-	I-ANAT
labeled	I-ANAT
cells	I-ANAT
.	O

Our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine	B-CHEM
-	I-CHEM
coding	I-CHEM
adenoviruses	B-LIVB
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
therapies	I-PROC
.	O

New	O
Breast	B-DISO
Pain	I-DISO
Chart	B-DEVI
for	O
Objective	O
Record	O
of	O
Mastalgia	B-DISO
Mastalgia	B-DISO
is	O
the	O
commonest	O
affliction	B-PHYS
of	O
mammary	B-ANAT
gland	I-ANAT
among	O
ladies	B-LIVB
of	O
the	O
reproductive	O
age	B-LIVB
group	I-LIVB
.	O

Since	O
etiopathogenesis	O
and	O
therapy	B-PROC
are	O
different	O
for	O
cyclical	B-DISO
and	O
noncyclical	B-DISO
pain	I-DISO
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly	O
.	O

This	O
is	O
usually	O
done	O
in	O
the	O
breast	B-OBJC
clinics	I-OBJC
by	O
advising	O
the	O
patient	B-LIVB
to	O
fill	O
a	O
pain	O
diary	O
over	O
a	O
period	O
of	O
2	O
months	O
over	O
two	O
menstrual	B-PHYS
cycles	I-PHYS
.	O

The	O
Cardiff	B-DEVI
pain	I-DEVI
chart	I-DEVI
records	I-DEVI
the	O
severity	O
of	O
pain	B-DISO
in	O
the	O
form	O
of	O
a	O
triangle	O
for	O
mild	O
to	O
moderate	B-DISO
pain	I-DISO
and	O
a	O
square	O
for	O
severe	B-DISO
pain	I-DISO
.	O

Moreover	O
,	O
Cardiff	B-DEVI
pain	I-DEVI
chart	I-DEVI
does	O
not	O
allow	O
a	O
patient	B-LIVB
to	O
record	O
the	O
severity	O
of	O
pain	B-DISO
on	O
days	O
of	O
menses	B-PHYS
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
""""	O
P	O
""""	O
in	O
the	O
box	O
.	O

These	O
problems	B-DISO
have	O
been	O
resolved	O
in	O
the	O
new	O
breast	B-DISO
pain	I-DISO
chart	B-DEVI
.	O

In	O
the	O
new	O
pain	B-DEVI
chart	I-DEVI
,	O
the	O
lady	B-LIVB
records	O
pain	B-DISO
severity	O
in	O
the	O
form	O
of	O
visual	B-PHYS
linear	I-PHYS
analogue	I-PHYS
scale	I-PHYS
score	I-PHYS
on	O
every	O
day	O
of	O
menstrual	B-PHYS
cycle	I-PHYS
.	O

She	O
enters	O
her	O
menstrual	B-PHYS
experience	B-PHYS
on	O
a	O
separate	O
part	O
of	O
chart	B-DEVI
,	O
which	O
allows	O
us	O
to	O
visualize	O
the	O
full	O
month	O
's	O
pain	B-DISO
severity	O
in	O
an	O
uncluttered	O
way	O
.	O

Graphene	B-CHEM
oxide	I-CHEM
/	O
multi	B-CHEM
-	I-CHEM
walled	I-CHEM
carbon	I-CHEM
nanotubes	I-CHEM
as	O
nanofeatured	B-OBJC
scaffolds	I-OBJC
for	O
the	O
assisted	O
deposition	O
of	O
nanohydroxyapatite	B-CHEM
:	O
characterization	O
and	O
biological	O
evaluation	O
Nanohydroxyapatite	B-CHEM
(	O
nHAp	B-CHEM
)	O
is	O
an	O
emergent	O
bioceramic	B-CHEM
that	O
shows	O
similar	O
chemical	B-PHEN
and	O
crystallographic	O
properties	O
as	O
the	O
mineral	B-CHEM
phase	O
present	B-DISO
in	O
bone	B-ANAT
.	O

However	O
,	O
nHAp	B-CHEM
presents	B-DISO
low	O
fracture	B-DISO
toughness	O
and	O
tensile	O
strength	O
,	O
limiting	O
its	O
application	O
in	O
bone	O
tissue	O
engineering	B-PROC
.	O

Conversely	O
,	O
multi	B-CHEM
-	I-CHEM
walled	I-CHEM
carbon	I-CHEM
nanotubes	I-CHEM
(	O
MWCNTs	B-CHEM
)	O
have	O
been	O
widely	O
used	B-DISO
for	O
composite	O
applications	O
due	O
to	O
their	O
excellent	O
mechanical	B-PHEN
and	O
physicochemical	B-PHEN
properties	O
,	O
although	O
their	O
hydrophobicity	O
usually	O
impairs	O
some	O
applications	O
.	O

To	O
improve	O
MWCNT	B-CHEM
wettability	O
,	O
oxygen	B-PHEN
plasma	I-PHEN
etching	I-PHEN
has	O
been	O
applied	O
to	O
promote	O
MWCNT	B-CHEM
exfoliation	B-PHEN
and	O
oxidation	B-PHYS
and	O
to	O
produce	O
graphene	B-CHEM
oxide	I-CHEM
(	O
GO	B-CHEM
)	O
at	O
the	O
end	O
of	O
the	O
tips	O
.	O

Here	O
,	O
we	O
prepared	B-DISO
a	O
series	O
of	O
nHAp	B-CHEM
/	O
MWCNT	B-CHEM
-	O
GO	B-CHEM
nanocomposites	B-OBJC
aimed	O
at	O
producing	O
materials	B-OBJC
that	O
combine	O
similar	O
bone	B-ANAT
characteristics	O
(	O
nHAp	B-CHEM
)	O
with	O
high	O
mechanical	O
strength	O
(	O
MWCNT	B-CHEM
-	O
GO	B-CHEM
)	O
.	O

After	O
MWCNT	B-CHEM
production	O
and	O
functionalization	O
to	O
produce	O
MWCNT	B-CHEM
-	O
GO	B-CHEM
,	O
ultrasonic	O
irradiation	B-PHEN
was	O
employed	B-DISO
to	O
precipitate	O
nHAp	B-CHEM
onto	O
the	O
MWCNT	B-CHEM
-	O
GO	B-CHEM
scaffolds	B-OBJC
(	O
at	O
1	O
-	O
3	O
wt	O
%	O
)	O
.	O

We	O
employed	B-DISO
various	O
techniques	O
to	O
characterize	O
the	O
nanocomposites	B-OBJC
,	O
including	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
(	O
TEM	B-PROC
)	O
,	O
Raman	B-PROC
spectroscopy	I-PROC
,	O
thermogravimetry	B-PROC
,	O
and	O
gas	B-PROC
adsorption	I-PROC
(	O
the	O
Brunauer	B-PROC
-	I-PROC
Emmett	I-PROC
-	I-PROC
Teller	I-PROC
method	I-PROC
)	O
.	O

We	O
used	O
simulated	B-PROC
body	B-ANAT
fluid	I-ANAT
to	O
evaluate	B-PROC
their	O
bioactivity	O
and	O
human	B-LIVB
osteoblasts	B-ANAT
(	O
bone	B-ANAT
-	I-ANAT
forming	I-ANAT
cells	I-ANAT
)	O
to	O
evaluate	B-PROC
cytocompatibility	B-DISO
.	O

We	O
also	O
investigated	O
their	O
bactericidal	B-CHEM
effect	O
against	O
Staphylococcus	B-LIVB
aureus	I-LIVB
and	O
Escherichia	B-LIVB
coli	I-LIVB
.	O

TEM	B-PROC
analysis	B-PROC
revealed	O
homogeneous	O
distributions	O
of	O
nHAp	B-CHEM
crystal	I-CHEM
grains	I-CHEM
along	O
the	O
MWCNT	B-CHEM
-	O
GO	B-CHEM
surfaces	O
.	O

All	O
nanocomposites	B-OBJC
were	O
proved	O
to	O
be	O
bioactive	B-OBJC
,	O
since	O
carbonated	B-CHEM
nHAp	I-CHEM
was	O
found	B-DISO
after	O
21	O
days	O
in	O
simulated	B-PROC
body	B-ANAT
fluid	I-ANAT
.	O

All	O
nanocomposites	B-OBJC
showed	O
potential	O
for	O
biomedical	B-CHEM
applications	O
with	O
no	O
cytotoxicity	B-DISO
toward	O
osteoblasts	B-ANAT
and	O
impressively	O
demonstrated	O
a	O
bactericidal	B-CHEM
effect	O
without	O
the	O
use	O
of	O
antibiotics	B-CHEM
.	O

All	O
of	O
the	O
aforementioned	O
properties	O
make	O
these	O
materials	B-OBJC
very	O
attractive	O
for	O
bone	B-PROC
tissue	I-PROC
engineering	I-PROC
applications	I-PROC
,	O
either	O
as	O
a	O
matrix	O
or	O
as	O
a	O
reinforcement	B-CHEM
material	I-CHEM
for	O
numerous	O
polymeric	B-CHEM
nanocomposites	B-OBJC
.	O

Diagnostic	O
value	O
of	O
diffusion	B-PROC
weighted	I-PROC
MRI	I-PROC
and	O
ADC	O
in	O
differential	B-PROC
diagnosis	I-PROC
of	O
cavernous	B-DISO
hemangioma	I-DISO
of	O
the	O
liver	B-ANAT
To	O
investigate	O
the	O
use	O
of	O
diffusion	B-PROC
weighted	I-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O
DWI	B-PROC
)	O
and	O
the	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
values	O
in	O
the	O
diagnosis	B-PROC
of	O
hemangioma	B-DISO
.	O

The	O
study	B-LIVB
population	I-LIVB
consisted	O
of	O
72	O
patients	B-LIVB
with	O
liver	B-DISO
masses	I-DISO
larger	O
than	O
1	O
cm	O
(	O
72	O
focal	B-DISO
lesions	I-DISO
)	O
.	O

DWI	B-PROC
examination	B-PROC
with	O
a	O
b	O
value	O
of	O
600	O
s	O
/	O
mm2	O
was	O
carried	O
out	O
for	O
all	O
patients	B-LIVB
.	O

After	O
DWI	B-PROC
examination	B-PROC
,	O
an	O
ADC	O
map	O
was	O
created	O
and	O
ADC	O
values	O
were	O
measured	O
for	O
72	O
liver	B-DISO
masses	I-DISO
and	O
normal	O
liver	B-ANAT
tissue	I-ANAT
(	O
control	B-LIVB
group	I-LIVB
)	O
.	O

The	O
average	O
ADC	O
values	O
of	O
normal	O
liver	B-ANAT
tissue	I-ANAT
and	O
focal	B-DISO
liver	I-DISO
lesions	I-DISO
,	O
the	O
""""	O
cut	O
-	O
off	O
""""	O
ADC	O
values	O
,	O
and	O
the	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
the	O
ADC	O
map	O
in	O
diagnosing	B-PROC
hemangioma	B-DISO
,	O
benign	O
and	O
malignant	O
lesions	B-DISO
were	O
researched	O
.	O

Of	O
the	O
72	O
liver	B-DISO
masses	I-DISO
,	O
51	O
were	O
benign	O
and	O
21	O
were	O
malignant	O
.	O

Benign	O
lesions	B-DISO
comprised	O
38	O
hemangiomas	B-DISO
and	O
13	O
simple	B-DISO
cysts	I-DISO
.	O

Malignant	O
lesions	B-DISO
comprised	O
9	O
hepatocellular	B-DISO
carcinomas	I-DISO
,	O
and	O
12	O
metastases	B-DISO
.	O

The	O
highest	O
ADC	O
values	O
were	O
measured	O
for	O
cysts	B-DISO
(	O
3	O
.	O
782±0	O
.	O

53×10	O
(	O
-	O
3	O
)	O
mm	O
(	O
2	O
)	O
/	O
s	O
)	O
and	O
hemangiomas	B-DISO
(	O
2	O
.	O
705±0	O
.	O

63×10	O
(	O
-	O
3	O
)	O
mm	O
(	O
2	O
)	O
/	O
s	O
)	O
.	O

The	O
average	O
ADC	O
value	O
of	O
hemangiomas	B-DISO
was	O
significantly	O
higher	O
than	O
malignant	O
lesions	B-DISO
and	O
the	O
normal	B-LIVB
control	I-LIVB
group	I-LIVB
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
average	O
ADC	O
value	O
of	O
cysts	B-DISO
were	O
significantly	O
higher	O
when	O
compared	O
to	O
hemangiomas	B-DISO
and	O
normal	B-LIVB
control	I-LIVB
group	I-LIVB
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

To	O
distinguish	O
hemangiomas	B-DISO
from	O
malignant	O
liver	B-DISO
lesions	I-DISO
,	O
the	O
""""	O
cut	O
-	O
off	O
""""	O
ADC	O
value	O
of	O
1	O
.	O

800×10	O
(	O
-	O
3	O
)	O
mm	O
(	O
2	O
)	O
/	O
s	O
had	O
a	O
sensitivity	O
of	O
97	O
.	O

4	O
%	O
and	O
a	O
specificity	O
of	O
90	O
.	O
9	O
%	O
.	O

To	O
distinguish	O
hemangioma	B-DISO
from	O
normal	O
liver	B-ANAT
parenchyma	I-ANAT
the	O
""""	O
cut	O
-	O
off	O
""""	O
value	O
of	O
1	O
.	O

858×10	O
(	O
-	O
3	O
)	O
mm	O
(	O
2	O
)	O
/	O
s	O
had	O
a	O
sensitivity	O
of	O
97	O
.	O

4	O
%	O
and	O
a	O
specificity	O
of	O
95	O
.	O

7	O
%	O
.	O

To	O
distinguish	O
benign	O
liver	B-DISO
lesions	I-DISO
from	O
malignant	O
liver	B-DISO
lesions	I-DISO
the	O
""""	O
cut	O
-	O
off	O
""""	O
value	O
of	O
1	O
.	O

800×10	O
(	O
-	O
3	O
)	O
mm	O
(	O
2	O
)	O
/	O
s	O
had	O
a	O
sensitivity	O
of	O
96	O
.	O

1	O
%	O
and	O
a	O
specificity	O
of	O
90	O
.	O
0	O
%	O
.	O

DWI	B-PROC
and	O
quantitative	O
measurement	O
of	O
ADC	O
values	O
can	O
be	O
used	O
in	O
differential	B-PROC
diagnosis	I-PROC
of	O
benign	O
and	O
malignant	O
liver	B-DISO
lesions	I-DISO
and	O
also	O
in	O
the	O
diagnosis	B-PROC
and	O
differentiation	O
of	O
hemangiomas	B-DISO
.	O

When	O
dynamic	B-PROC
examination	I-PROC
cannot	O
distinguish	O
cases	O
with	O
vascular	B-DISO
metastasis	I-DISO
and	O
lesions	B-DISO
from	O
hemangioma	B-DISO
,	O
DWI	B-PROC
and	O
ADC	O
values	O
can	O
be	O
useful	O
in	O
the	O
primary	O
diagnosis	O
and	O
differential	B-PROC
diagnosis	I-PROC
.	O

The	O
technique	O
does	O
not	O
require	O
contrast	B-CHEM
material	I-CHEM
,	O
so	O
it	O
can	O
safely	O
be	O
used	O
in	O
patients	B-LIVB
with	O
renal	B-DISO
failure	I-DISO
.	O

The	O
Demand	O
for	O
Cigarettes	B-OBJC
in	O
Tanzania	B-GEOG
and	O
Implications	O
for	O
Tobacco	B-CHEM
Taxation	O
Policy	O
The	O
study	B-PROC
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-OBJC
in	O
Tanzania	B-GEOG
and	O
presents	O
simulation	B-PROC
results	O
on	O
the	O
effect	O
of	O
the	O
cigarette	B-OBJC
excise	O
tax	O
on	O
smoking	O
participation	O
,	O
government	O
revenue	O
,	O
and	O
related	O
topics	O
.	O

After	O
briefly	O
summarizing	O
the	O
magnitude	O
and	O
spread	O
of	O
cigarette	B-DISO
consumption	I-DISO
in	O
the	O
country	B-GEOG
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
African	B-GEOG
and	O
other	O
countries	B-GEOG
.	O

The	O
2008	O
Tanzanian	B-GEOG
household	O
budget	O
survey	O
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-OBJC
in	O
Tanzania	B-GEOG
.	O

The	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	O
prevalence	O
for	O
Tanzania	B-GEOG
is	O
15	O
.	O
35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure	O
(	O
income	O
)	O
groups	O
.	O

Smoking	O
intensity	O
and	O
per	O
capita	O
consumption	O
were	O
estimated	O
at	O
7	O
.	O

08	O
cigarettes	B-OBJC
and	O
1	O
.	O
33	O
cigarettes	B-OBJC
,	O
respectively	O
,	O
a	O
relatively	O
low	O
value	O
.	O

A	O
two	O
-	O
part	O
demand	O
equation	O
model	O
was	O
used	O
to	O
estimate	O
various	O
elasticities	O
.	O

For	O
the	O
overall	O
equation	O
,	O
the	O
price	O
elasticities	O
of	O
smoking	O
participation	O
,	O
smoking	O
intensity	O
,	O
and	O
total	O
elasticity	O
were	O
estimated	O
at	O
-0	O
.	O

879	O
,	O
-0	O
.	O
853	O
,	O
and	O
-1	O
.	O

732	O
,	O
respectively	O
.	O

Compared	O
to	O
similar	O
results	O
in	O
other	O
developing	O
countries	O
,	O
the	O
estimates	O
appear	O
quite	O
high	O
.	O

When	O
estimated	O
by	O
expenditure	O
(	O
income	O
)	O
groups	O
,	O
the	O
magnitude	O
of	O
the	O
elasticity	O
appears	O
higher	O
among	O
high	O
expenditure	O
groups	O
than	O
among	O
low	O
expenditure	O
groups	O
.	O

Two	O
simulation	B-PROC
exercises	O
were	O
undertaken	O
.	O

First	O
,	O
the	O
effect	O
of	O
different	O
excise	O
rates	O
on	O
smoking	O
participation	O
rate	O
,	O
cigarette	B-DISO
consumption	I-DISO
,	O
tax	O
revenue	O
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted	O
.	O

Second	O
,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
a	O
given	O
increase	O
in	O
the	O
cigarette	B-OBJC
excise	O
tax	O
on	O
various	O
expenditure	O
groups	O
.	O

The	O
overall	O
results	O
suggest	O
that	O
an	O
increase	O
in	O
the	O
excise	O
tax	O
on	O
cigarettes	B-OBJC
in	O
Tanzania	B-GEOG
would	O
reduce	O
cigarette	B-DISO
consumption	I-DISO
and	O
increase	O
government	O
tax	O
revenue	O
.	O

Functional	O
Analysis	B-PROC
of	O
a	O
Bacterial	B-LIVB
Antifreeze	B-CHEM
Protein	I-CHEM
Indicates	O
a	O
Cooperative	B-DISO
Effect	O
between	O
Its	O
Two	O
Ice	B-PHYS
-	I-PHYS
Binding	I-PHYS
Domains	O
Antifreeze	B-CHEM
proteins	I-CHEM
make	O
up	O
a	O
class	O
of	O
ice	B-CHEM
-	I-CHEM
binding	I-CHEM
proteins	I-CHEM
(	O
IBPs	B-CHEM
)	O
that	O
are	O
possessed	O
and	O
expressed	B-PHYS
by	O
certain	O
cold	B-PHEN
-	O
adapted	B-PHYS
organisms	B-LIVB
to	O
enhance	O
their	O
freezing	B-PHEN
tolerance	I-PHEN
.	O

Here	O
we	O
report	O
the	O
biophysical	B-PHEN
and	O
functional	O
characterization	O
of	O
an	O
IBP	B-CHEM
discovered	O
in	O
a	O
bacterium	B-LIVB
recovered	O
from	O
a	O
deep	O
glacial	B-PHEN
ice	B-CHEM
core	I-CHEM
drilled	O
at	O
Vostok	B-GEOG
Station	I-GEOG
,	I-GEOG
Antarctica	I-GEOG
(	O
IBPv	B-CHEM
)	O
.	O

Our	O
study	B-PROC
showed	O
that	O
the	O
recombinant	B-CHEM
protein	I-CHEM
rIBPv	B-CHEM
exhibited	O
a	O
thermal	B-PHEN
hysteresis	B-DISO
of	O
2	O
°	O
C	O
at	O
concentrations	O
of	O
>	O
50	O
μM	O
,	O
effectively	O
inhibited	O
ice	B-CHEM
recrystallization	B-PHEN
,	O
and	O
enhanced	O
bacterial	B-PHEN
viability	I-PHEN
during	O
freeze	B-PHEN
-	I-PHEN
thaw	I-PHEN
cycling	I-PHEN
.	O

Circular	B-PROC
dichroism	I-PROC
scans	I-PROC
indicated	O
that	O
rIBPv	B-CHEM
mainly	O
consists	O
of	O
β	O
strands	O
,	O
and	O
its	O
denaturing	B-PHYS
temperature	O
was	O
53	O
.	O
5	O
°	O
C	O
.	O

Multiple	B-PROC
-	I-PROC
sequence	I-PROC
alignment	I-PROC
of	O
homologous	B-CHEM
IBPs	I-CHEM
predicted	O
that	O
IBPv	B-CHEM
contains	O
two	O
ice	O
-	O
binding	O
domains	O
,	O
a	O
feature	O
unique	O
among	O
known	O
IBPs	B-CHEM
.	O

To	O
examine	O
functional	O
differences	O
between	O
the	O
IBPv	O
domains	O
,	O
each	O
domain	O
was	O
cloned	B-PROC
,	O
expressed	B-PHYS
,	O
and	O
purified	O
.	O

The	O
second	O
domain	O
(	O
domain	O
B	O
)	O
expressed	B-PHYS
greater	O
ice	B-PHYS
binding	I-PHYS
activity	I-PHYS
.	O

Data	O
from	O
thermal	B-PHEN
hysteresis	B-DISO
and	O
gel	B-PROC
filtration	I-PROC
assays	I-PROC
supported	O
the	O
idea	O
that	O
the	O
two	O
domains	O
cooperate	O
to	O
achieve	O
a	O
higher	O
ice	B-PHYS
binding	I-PHYS
effect	I-PHYS
by	O
forming	O
heterodimers	B-CHEM
.	O

However	O
,	O
physical	O
linkage	O
of	O
the	O
domains	O
was	O
not	O
required	O
for	O
this	O
effect	O
.	O

Structural	B-PHYS
Remodeling	I-PHYS
of	O
Sympathetic	B-PHYS
Innervation	I-PHYS
in	O
Atherosclerotic	B-DISO
Blood	B-ANAT
Vessels	I-ANAT
:	O
Role	O
of	O
Atherosclerotic	B-DISO
Disease	B-DISO
Progression	I-DISO
and	O
Chronic	O
Social	B-DISO
Stress	I-DISO
The	O
sympathetic	B-ANAT
nervous	I-ANAT
system	I-ANAT
(	O
SNS	B-ANAT
)	O
can	O
undergo	O
dramatic	B-PHYS
structural	I-PHYS
plasticity	I-PHYS
in	O
response	O
to	O
behavioral	O
factors	O
and	O
/	O
or	O
the	O
presence	O
of	O
disease	B-DISO
,	O
leading	O
to	O
SNS	B-ANAT
hyperinnervation	B-PHYS
of	O
peripheral	O
tissues	O
.	O

The	O
SNS	B-ANAT
has	O
been	O
proposed	O
as	O
an	O
important	O
mediator	O
between	O
stressful	O
behavior	O
and	O
the	O
progression	B-DISO
of	O
atherosclerosis	B-DISO
in	O
the	O
vasculature	B-ANAT
.	O

The	O
present	O
study	B-PROC
examined	O
whether	O
structural	B-PHYS
remodeling	I-PHYS
of	O
the	O
SNS	B-ANAT
occurs	O
in	O
the	O
vasculature	B-ANAT
in	O
a	O
genetically	O
hyperlipidemic	B-DISO
animal	B-LIVB
model	I-LIVB
of	O
atherosclerosis	B-DISO
,	O
the	O
Watanabe	B-LIVB
heritable	I-LIVB
hyperlipidemic	I-LIVB
rabbit	I-LIVB
(	O
WHHL	B-LIVB
;	O
relative	O
to	O
normolipidemic	B-DISO
New	B-LIVB
Zealand	I-LIVB
white	I-LIVB
rabbits	I-LIVB
[	O
NZW	B-LIVB
]	O
)	O
,	O
and	O
whether	O
SNS	B-ANAT
plasticity	B-PHYS
is	O
driven	O
by	O
the	O
progression	B-DISO
of	I-DISO
disease	I-DISO
and	O
/	O
or	O
by	O
stressful	O
social	O
behavior	O
.	O

WHHL	B-LIVB
and	O
NZW	B-LIVB
rabbits	B-LIVB
were	O
assigned	O
to	O
an	O
unstable	B-DISO
or	O
stable	O
social	O
environment	O
for	O
4	O
months	O
.	O

Aortic	B-DISO
atherosclerosis	I-DISO
was	O
assessed	O
and	O
SNS	B-ANAT
aortic	B-ANAT
innervation	B-PHYS
quantified	O
using	O
immunofluorescent	B-PROC
microscopy	I-PROC
.	O

Numerous	O
SNS	B-ANAT
varicosities	B-DISO
were	O
observed	O
throughout	O
the	O
aorta	B-ANAT
in	O
WHHLs	B-LIVB
and	O
NZWs	B-LIVB
,	O
extending	O
into	O
the	O
vascular	O
media	O
and	O
intima	O
,	O
an	O
innervation	B-PHYS
pattern	O
not	O
previously	O
reported	O
.	O

WHHLs	B-LIVB
exhibited	O
significantly	O
greater	O
innervation	B-PHYS
than	O
NZWs	B-LIVB
(	O
F	O
(	O
1	O
,	O
41	O
)	O
=	O
55	O
.	O

3	O
,	O
p	O
<	O
.001	O
)	O
,	O
with	O
extensive	O
innervation	B-PHYS
of	O
the	O
atherosclerotic	B-DISO
neointima	B-DISO
.	O

The	O
innervation	B-PHYS
density	O
was	O
highly	O
correlated	O
with	O
the	O
extent	O
of	O
disease	B-DISO
in	O
the	O
WHHLs	B-LIVB
(	O
r	O
(	O
21	O
)	O
=	O
0	O
.	O
855	O
,	O
p	O
<	O
.001	O
)	O
.	O

Social	O
environment	O
did	O
not	O
influence	O
innervation	B-PHYS
in	O
NZWs	B-LIVB
(	O
aortic	B-ANAT
arch	I-ANAT
:	O
p	O
=	O
.078	O
,	O
thoracic	B-ANAT
aorta	I-ANAT
:	O
p	O
=	O
.34	O
)	O
or	O
WHHLs	B-LIVB
(	O
arch	B-ANAT
:	O
p	O
=	O
.97	O
,	O
thoracic	B-ANAT
:	O
p	O
=	O
.61	O
)	O
.	O

The	O
findings	B-DISO
suggest	O
that	O
hyperinnervation	B-PHYS
is	O
driven	O
largely	O
by	O
the	O
progression	B-DISO
of	I-DISO
disease	I-DISO
rather	O
than	O
social	O
environment	O
.	O

SNS	B-ANAT
innervation	B-PHYS
patterns	O
observed	O
in	O
atherosclerotic	B-DISO
human	B-LIVB
and	O
mouse	B-LIVB
aortas	B-ANAT
were	O
consistent	O
with	O
the	O
rabbit	B-LIVB
,	O
suggesting	O
that	O
SNS	B-ANAT
hyperinnervation	B-PHYS
of	O
the	O
diseased	B-DISO
vessel	B-ANAT
wall	I-ANAT
is	O
a	O
general	O
feature	O
across	O
mammalian	B-LIVB
species	I-LIVB
.	O

""""	O
You	O
get	O
to	O
know	O
the	O
people	B-LIVB
and	O
whether	O
they	O
'	O
re	O
talking	O
sense	O
or	O
not	O
""""	O
:	O
Negotiating	O
trust	O
on	O
health	O
-related	O
forums	O
The	O
internet	B-OBJC
is	O
increasingly	O
being	O
used	O
as	O
a	O
source	B-DISO
of	O
health	B-DISO
advice	I-DISO
and	O
information	B-PROC
by	O
individuals	B-LIVB
with	O
long	O
term	O
conditions	O
(	O
LTCs	O
)	O
.	O

Specifically	O
,	O
online	O
forums	O
allow	O
people	B-LIVB
to	O
interact	O
with	O
others	O
with	O
similar	O
conditions	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
how	O
online	O
health	B-PROC
information	I-PROC
is	O
assessed	O
by	O
those	O
with	O
LTCs	O
.	O

This	O
study	B-PROC
aims	O
to	O
address	O
this	O
gap	O
by	O
exploring	O
how	O
individuals	B-LIVB
with	O
contested	O
and	O
uncontested	O
LTCs	O
utilise	O
internet	O
forums	O
.	O

Semi	B-PROC
-	I-PROC
structured	I-PROC
interviews	I-PROC
were	O
conducted	O
with	O
20	O
participants	B-LIVB
with	O
ME	B-DISO
/	O
CFS	B-DISO
and	O
21	O
participants	B-LIVB
with	O
type	B-DISO
1	I-DISO
and	O
2	B-DISO
diabetes	I-DISO
and	O
analysed	B-PROC
using	O
thematic	B-PROC
analysis	I-PROC
.	O

Participants	B-LIVB
were	O
recruited	O
via	O
online	O
and	O
offline	B-DISO
routes	I-DISO
,	O
namely	O
forums	O
,	O
email	O
lists	O
,	O
newsletters	B-OBJC
,	O
and	O
face	O
-	O
to	O
-	O
face	O
support	O
groups	O
.	O

The	O
findings	B-DISO
indicate	O
that	O
the	O
use	O
of	O
online	O
forums	O
was	O
a	O
complex	O
and	O
nuanced	O
process	B-PHEN
and	O
was	O
influenced	O
by	O
a	O
number	O
of	O
individual	B-LIVB
and	O
illness	B-DISO
-	O
specific	O
factors	O
.	O

Participants	B-LIVB
trusted	O
those	O
with	O
similar	O
experiences	B-PHYS
and	O
perspectives	O
as	O
themselves	O
,	O
while	O
also	O
valuing	O
conventional	O
biomedical	O
information	O
and	O
advice	B-PROC
.	O

By	O
accessing	O
support	O
online	O
forum	O
users	B-LIVB
were	O
able	O
to	O
draw	O
on	O
a	O
personalised	B-OBJC
form	I-OBJC
of	O
support	O
based	O
on	O
the	O
lived	O
experiences	B-PHYS
of	O
their	O
peers	B-LIVB
.	O

However	O
,	O
the	O
role	O
of	O
digital	O
literacy	O
in	O
developing	O
and	O
maintaining	O
online	O
relationships	O
must	O
be	O
acknowledged	O
.	O

Colony	B-ANAT
Expansion	B-PHYS
of	O
Socially	B-PHYS
Motile	I-PHYS
Myxococcus	B-LIVB
xanthus	I-LIVB
Cells	B-ANAT
Is	O
Driven	O
by	O
Growth	B-PHYS
,	O
Motility	B-PHYS
,	O
and	O
Exopolysaccharide	B-CHEM
Production	O
Myxococcus	B-LIVB
xanthus	I-LIVB
,	O
a	O
model	O
organism	B-LIVB
for	O
studies	B-PROC
of	O
multicellular	B-PHEN
behavior	I-PHEN
in	O
bacteria	B-LIVB
,	O
moves	O
exclusively	O
on	O
solid	O
surfaces	O
using	O
two	O
distinct	O
but	O
coordinated	O
motility	B-PHYS
mechanisms	O
.	O

One	O
of	O
these	O
,	O
social	B-PHYS
(	I-PHYS
S	I-PHYS
)	I-PHYS
motility	I-PHYS
is	O
powered	O
by	O
the	O
extension	O
and	O
retraction	B-DISO
of	O
type	B-ANAT
IV	I-ANAT
pili	I-ANAT
and	O
requires	O
the	O
presence	O
of	O
exopolysaccharides	B-CHEM
(	O
EPS	B-CHEM
)	O
produced	O
by	O
neighboring	O
cells	B-ANAT
.	O

As	O
a	O
result	O
,	O
S	B-PHYS
motility	I-PHYS
requires	O
close	O
cell	B-ANAT
-	I-ANAT
to	I-ANAT
-	I-ANAT
cell	I-ANAT
proximity	O
and	O
isolated	O
cells	B-ANAT
do	O
not	O
translocate	B-PHYS
.	O

Previous	O
studies	O
measuring	O
S	B-PHYS
motility	I-PHYS
by	O
observing	O
the	O
colony	B-ANAT
expansion	B-PHYS
of	O
cells	B-ANAT
deposited	O
on	O
agar	B-CHEM
have	O
shown	O
that	O
the	O
expansion	B-PHYS
rate	O
increases	O
with	O
initial	O
cell	O
density	O
,	O
but	O
the	O
biophysical	O
mechanisms	O
involved	O
remain	O
largely	O
unknown	O
.	O

To	B-PHYS
understand	I-PHYS
the	O
dynamics	B-PHEN
of	O
S	B-PHYS
motility	I-PHYS
-driven	O
colony	B-ANAT
expansion	B-PHYS
,	O
we	O
developed	O
a	O
reaction	O
-	O
diffusion	B-PHEN
model	O
describing	O
the	O
effects	O
of	O
cell	O
density	O
,	O
EPS	B-CHEM
deposition	O
and	O
nutrient	O
exposure	O
on	O
the	O
expansion	B-PHYS
rate	O
.	O

Our	O
results	O
show	O
that	O
at	O
steady	B-PHEN
state	I-PHEN
the	O
population	B-LIVB
expands	O
as	O
a	O
traveling	O
wave	O
with	O
a	O
speed	O
determined	O
by	O
the	O
interplay	O
of	O
cell	B-PHYS
motility	I-PHYS
and	O
growth	B-PHYS
,	O
a	O
well	O
-	O
known	O
characteristic	O
of	O
Fisher	O
's	O
equation	O
.	O

The	O
model	O
explains	O
the	O
density	O
-	O
dependence	O
of	O
the	O
colony	B-ANAT
expansion	B-PHYS
by	O
demonstrating	O
the	O
presence	O
of	O
a	O
lag	O
phase	O
-a	O
transient	O
period	O
of	O
very	B-DISO
slow	I-DISO
expansion	B-PHYS
with	O
a	O
duration	B-CHEM
dependent	O
on	O
the	O
initial	O
cell	O
density	O
.	O

We	O
propose	O
that	O
at	O
a	O
low	O
initial	O
density	O
,	O
more	O
time	O
is	O
required	O
for	O
the	O
cells	B-ANAT
to	O
accumulate	B-DISO
enough	O
EPS	B-CHEM
to	O
activate	O
S	B-PHYS
-	I-PHYS
motility	I-PHYS
resulting	O
in	O
a	O
longer	O
lag	O
period	O
.	O

Furthermore	O
,	O
our	O
model	O
makes	O
the	O
novel	O
prediction	O
that	O
following	O
the	O
lag	O
phase	O
the	O
population	B-LIVB
expands	O
at	O
a	O
constant	O
rate	O
independent	O
of	O
the	O
cell	O
density	O
.	O

These	O
predictions	O
were	O
confirmed	O
by	O
S	B-PHYS
motility	I-PHYS
experiments	B-PROC
capturing	O
long	O
-	O
term	O
expansion	B-PHYS
dynamics	B-PHEN
.	O

Ultrasound	B-PROC
assessment	B-PROC
of	O
lung	B-DISO
consolidation	I-DISO
and	O
reaeration	B-PROC
after	O
pleural	B-DISO
effusion	I-DISO
drainage	B-PROC
in	O
patients	B-LIVB
with	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O
a	O
pilot	B-PROC
study	I-PROC
The	O
aim	O
of	O
the	O
pilot	B-PROC
study	I-PROC
was	O
to	O
assess	B-PROC
by	O
ultrasound	B-PROC
changes	O
in	O
dimensions	O
of	O
lung	B-DISO
consolidation	I-DISO
and	O
reaeration	B-PROC
after	O
drainage	B-PROC
of	O
large	O
pleural	B-DISO
effusion	I-DISO
in	O
patients	B-LIVB
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
.	O

Lung	B-PROC
ultrasound	I-PROC
and	O
blood	B-PROC
gas	I-PROC
were	O
performed	O
before	O
,	O
2	O
hours	O
(	O
H2	O
)	O
and	O
24	O
hours	O
(	O
H24	O
)	O
after	O
drainage	B-PROC
of	O
pleural	B-DISO
effusion	I-DISO
.	O

Lung	O
ultrasound	O
aeration	O
score	O
was	O
calculated	O
.	O

Cephalocaudal	B-ANAT
dimension	I-ANAT
and	O
diaphragmatic	B-ANAT
transversal	I-ANAT
area	I-ANAT
of	O
lung	B-DISO
consolidation	I-DISO
were	O
measured	O
.	O

Ten	O
patients	B-LIVB
were	O
studied	O
.	O

Median	O
volume	O
of	O
drained	B-PROC
effusion	B-DISO
was	O
675	O
ml	O
at	O
H2	O
and	O
895	O
at	O
H24	O
.	O

Two	O
hours	O
after	O
drainage	B-PROC
,	O
dimension	B-ANAT
of	I-ANAT
cephalocaudal	I-ANAT
consolidation	I-ANAT
and	O
diaphragmatic	B-ANAT
transversal	I-ANAT
area	I-ANAT
decreased	O
significantly	O
.	O

Lung	B-PROC
reaeration	I-PROC
after	O
drainage	B-PROC
occurred	O
mainly	O
in	O
latero	B-ANAT
-	I-ANAT
inferior	I-ANAT
and	O
postero	B-ANAT
-	I-ANAT
superior	I-ANAT
regions	I-ANAT
.	O

PaO2	B-PROC
/	I-PROC
FiO2	I-PROC
increased	O
significantly	O
at	O
H24	O
.	O

Ultrasound	B-PROC
is	O
a	O
useful	O
method	O
to	O
assess	B-PROC
lung	B-DISO
consolidation	I-DISO
after	O
pleural	B-DISO
effusion	I-DISO
drainage	B-PROC
.	O

Drainage	B-PROC
of	O
pleural	B-DISO
effusion	I-DISO
may	O
lead	O
to	O
a	O
decrease	O
of	O
lung	B-DISO
consolidation	I-DISO
and	O
improvement	O
of	O
lung	B-PROC
reaeration	I-PROC
.	O

The	O
Maternal	B-DISO
Legacy	O
:	O
Female	B-PHYS
Identity	O
Predicts	O
Offspring	B-LIVB
Sex	O
Ratio	O
in	O
the	O
Loggerhead	B-LIVB
Sea	I-LIVB
Turtle	I-LIVB
In	O
organisms	B-LIVB
with	O
temperature	O
-	O
dependent	O
sex	B-PHEN
determination	I-PHEN
,	O
the	O
incubation	O
environment	O
plays	O
a	O
key	O
role	O
in	O
determining	O
offspring	B-LIVB
sex	O
ratios	O
.	O

Given	O
that	O
global	O
temperatures	O
have	O
warmed	B-PHEN
approximately	O
0	O
.	O

6	O
°	O
C	O
in	O
the	O
last	O
century	O
,	O
it	O
is	O
necessary	O
to	O
consider	O
how	O
organisms	B-LIVB
will	O
adjust	B-DISO
to	O
climate	B-PHEN
change	I-PHEN
.	O

To	O
better	O
understand	O
the	O
degree	O
to	O
which	O
mothers	B-LIVB
influence	O
the	O
sex	O
ratios	O
of	O
their	O
offspring	B-LIVB
,	O
we	O
use	O
24	O
years	O
of	O
nesting	O
data	O
for	O
individual	B-LIVB
female	B-PHYS
loggerhead	B-LIVB
sea	I-LIVB
turtles	I-LIVB
(	O
Caretta	B-LIVB
caretta	I-LIVB
)	O
observed	O
on	O
Bald	B-GEOG
Head	I-GEOG
Island	I-GEOG
,	O
North	B-GEOG
Carolina	I-GEOG
.	O

We	O
find	O
that	O
maternal	B-DISO
identity	O
is	O
the	O
best	O
predictor	O
of	O
nest	O
sex	O
ratio	O
in	O
univariate	B-PROC
and	O
multivariate	B-PROC
predictive	I-PROC
models	I-PROC
.	O

We	O
find	O
significant	O
variability	O
in	O
estimated	O
nest	O
sex	O
ratios	O
among	O
mothers	B-LIVB
,	O
but	O
a	O
high	O
degree	O
of	O
consistency	O
within	O
mothers	B-LIVB
,	O
despite	O
substantial	O
spatial	O
and	O
temporal	O
thermal	B-PHEN
variation	I-PHEN
.	O

Our	O
results	O
suggest	O
that	O
individual	B-LIVB
differences	O
in	O
nesting	O
preferences	O
are	O
the	O
main	O
driver	O
behind	O
divergences	O
in	O
nest	O
sex	O
ratios	O
.	O

As	O
such	O
,	O
a	O
female	B-PHYS
's	I-PHYS
ability	O
to	O
plastically	O
adjust	O
her	O
nest	O
sex	O
ratios	O
in	O
response	O
to	O
environmental	O
conditions	O
is	O
constrained	O
,	O
potentially	O
limiting	O
how	O
individuals	B-LIVB
behaviorally	O
mitigate	B-PHEN
the	O
effects	O
of	O
environmental	B-DISO
change	I-DISO
.	O

Given	O
that	O
many	O
loggerhead	B-LIVB
populations	B-LIVB
already	O
show	O
female	O
-	O
biased	O
offspring	B-LIVB
sex	O
ratios	O
,	O
understanding	O
maternal	O
behavioral	O
responses	O
is	O
critical	O
for	O
predicting	O
the	O
future	O
of	O
long	O
-	O
lived	O
species	O
vulnerable	O
to	O
extinction	B-PHEN
.	O

Physicians	B-LIVB
'	I-LIVB
knowledge	O
on	O
the	O
work	B-DISO
-	I-DISO
related	I-DISO
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
Chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O
COPD	B-DISO
)	O
may	O
be	O
induced	O
by	O
the	O
work	O
environment	O
conditions	O
.	O

According	O
to	O
the	O
estimates	O
,	O
10	O
-	O
20	O
%	O
of	O
all	O
COPD	B-DISO
cases	O
are	O
associated	O
with	O
occupational	B-DISO
exposure	I-DISO
to	O
dusts	B-OBJC
and	O
irritant	B-CHEM
gases	B-CHEM
.	O

However	O
,	O
in	O
2014	O
,	O
only	O
11	O
cases	O
of	O
work	B-DISO
-	I-DISO
related	I-DISO
COPD	B-DISO
were	O
recognized	O
in	O
Poland	B-GEOG
.	O

The	O
aim	O
of	O
the	O
study	B-PROC
was	O
to	O
analyze	B-PROC
the	O
reasons	O
for	O
the	O
low	O
incidence	O
of	O
work	B-DISO
-	I-DISO
related	I-DISO
COPD	B-DISO
in	O
the	O
context	O
of	O
pulmonologists	B-LIVB
'	O
knowledge	O
about	O
occupational	O
risk	B-DISO
factors	I-DISO
and	O
procedures	O
on	O
reporting	B-PROC
suspected	B-DISO
occupational	B-DISO
diseases	I-DISO
.	O

A	O
survey	O
included	O
94	O
pulmonologists	B-LIVB
randomly	O
selected	O
out	O
of	O
225	O
specialists	B-LIVB
registered	O
at	O
the	O
Local	O
Physicians	O
Chamber	O
in	O
Łódź	O
.	O

The	O
study	B-PROC
was	O
performed	O
anonymously	O
with	O
the	O
use	O
of	O
original	O
questionnaire	O
.	O

More	O
than	O
a	O
half	O
of	O
the	O
surveyed	O
pulmonologists	B-LIVB
identified	O
environmental	O
risk	B-DISO
factors	I-DISO
for	O
COPD	B-DISO
correctly	O
,	O
while	O
only	O
23	O
.	O

4	O
%	O
properly	O
identified	O
the	O
main	O
occupational	O
risk	B-DISO
factors	I-DISO
as	O
the	O
cause	O
of	O
COPD	B-DISO
.	O

Only	O
58	O
.	O

5	O
%	O
of	O
the	O
pulmonologists	B-LIVB
always	O
asked	O
their	O
patients	B-LIVB
suffering	B-DISO
from	O
COPD	B-DISO
about	O
their	O
job	O
/	O
profession	O
and	O
60	O
.	O

6	O
%	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	O
on	O
reporting	B-PROC
suspected	B-DISO
occupational	B-DISO
diseases	I-DISO
.	O

The	O
physicians	B-LIVB
rarely	O
ask	O
patients	B-LIVB
suffering	B-DISO
from	O
COPD	B-DISO
about	O
their	O
job	O
/	O
profession	O
and	O
the	O
relationship	O
between	O
their	O
ailments	B-DISO
and	O
occupational	B-DISO
exposure	I-DISO
.	O

What	O
is	O
more	O
,	O
they	O
do	O
not	O
know	O
legal	O
regulations	O
on	O
proper	O
referral	B-PROC
of	I-PROC
a	I-PROC
patient	I-PROC
with	O
a	O
suspected	B-DISO
case	O
of	O
occupational	B-DISO
disease	I-DISO
.	O

The	O
results	O
of	O
the	O
study	B-PROC
clearly	O
indicate	O
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	O
pulmonologists	B-LIVB
'	O
knowledge	O
on	O
work	B-DISO
-	I-DISO
related	I-DISO
COPD	B-DISO
.	O

Med	O
Pr	O
2016	O
;	O
67	O
(	O
3	O
)	O
:	O
375	O
-	O
384	O
.	O

Increased	O
RhoA	B-CHEM
Activity	B-PHYS
Predicts	O
Worse	B-DISO
Overall	O
Survival	O
in	O
Patients	B-LIVB
Undergoing	O
Surgical	B-PROC
Resection	I-PROC
for	O
Lauren	O
Diffuse	B-DISO
-	I-DISO
Type	I-DISO
Gastric	I-DISO
Adenocarcinoma	I-DISO
Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	O
mutations	B-PHYS
in	O
the	O
Lauren	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
gastric	I-DISO
adenocarcinoma	I-DISO
(	O
GA	B-DISO
)	O
but	O
not	O
in	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	B-CHEM
activity	B-PHYS
is	O
prognostic	B-PHYS
for	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	B-LIVB
with	O
resectable	O
GA	B-DISO
.	O

Retrospective	B-PROC
review	I-PROC
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	B-DISO
patients	B-LIVB
who	O
underwent	O
potentially	O
curative	B-PROC
resection	I-PROC
between	O
2003	O
and	O
2012	O
at	O
a	O
single	O
institution	O
.	O

Tissue	O
microarrays	B-OBJC
were	O
constructed	O
from	O
surgical	B-PROC
specimens	I-PROC
and	O
analyzed	O
for	O
phosphorylated	B-CHEM
RhoA	B-CHEM
,	O
a	O
marker	B-PHYS
of	O
inactive	O
RhoA	B-CHEM
signaling	B-PHYS
.	O

OS	O
was	O
estimated	O
by	O
the	O
Kaplan	B-PROC
-	I-PROC
Meier	I-PROC
method	I-PROC
,	O
and	O
multivariate	O
analysis	O
was	O
performed	O
by	O
Cox	O
proportional	O
hazards	O
regression	O
modeling	O
.	O

One	O
hundred	O
thirty	O
-	O
six	O
patients	B-LIVB
with	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
and	O
129	O
patients	B-LIVB
with	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
were	O
examined	O
.	O

Compared	O
to	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
,	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
tumors	B-DISO
were	O
significantly	O
associated	O
with	O
increased	O
tumor	O
size	O
and	O
advanced	O
tumor	O
,	O
node	O
,	O
metastasis	O
(	O
TNM	O
)	O
classification	O
system	O
stage	O
.	O

In	O
patients	B-LIVB
with	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
,	O
high	O
RhoA	B-CHEM
activity	B-PHYS
was	O
associated	O
with	O
significantly	O
worse	B-DISO
OS	O
when	O
compared	O
to	O
low	O
RhoA	B-CHEM
activity	B-PHYS
(	O
5	O
-	O
year	O
OS	O
52	O
.	O

5	O
vs	O
.	O
81	O
.	O
0	O
%	O
,	O
p	O
=	O
0	O
.	O
017	O
)	O
.	O

This	O
difference	O
in	O
OS	O
was	O
not	O
observed	O
in	O
patients	B-LIVB
with	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
(	O
5	O
-	O
year	O
OS	O
83	O
.	O

9	O
vs	O
.	O

81	O
.	O
6	O
%	O
,	O
p	O
=	O
0	O
.	O
766	O
)	O
.	O

On	O
multivariate	O
analysis	O
of	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
patients	B-LIVB
,	O
high	O
RhoA	B-CHEM
activity	B-PHYS
was	O
an	O
independent	O
negative	O
prognostic	B-PHYS
factor	I-PHYS
for	O
OS	O
(	O
hazard	O
ratio	O
2	O
.	O
38	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
07	O
-	O
5	O
.	O
28	O
)	O
.	O

Increased	O
RhoA	B-CHEM
activity	B-PHYS
is	O
predictive	O
of	O
worse	B-DISO
OS	O
in	O
patients	B-LIVB
with	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
who	O
undergo	O
potentially	O
curative	B-PROC
surgical	I-PROC
resection	I-PROC
.	O

Along	O
with	O
findings	O
from	O
genomic	O
studies	O
,	O
these	O
results	O
suggest	O
RhoA	B-CHEM
may	O
be	O
a	O
novel	O
therapeutic	B-PROC
target	O
in	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
.	O

Doxifluridine	B-CHEM
-	O
conjugated	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
analog	B-CHEM
shows	O
strong	O
RNase	B-CHEM
L	I-CHEM
activation	B-PHYS
ability	O
and	O
tumor	B-PHYS
suppressive	I-PHYS
effect	O
RNase	B-CHEM
L	I-CHEM
is	O
activated	B-PHYS
by	O
2	B-CHEM
'	I-CHEM
,	I-CHEM
5	I-CHEM
'	I-CHEM
-	I-CHEM
oligoadenylates	I-CHEM
(	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
)	O
at	O
subnanomolar	O
levels	O
to	O
cleave	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
.	O

We	O
previously	O
reported	O
the	O
hypothesis	O
that	O
the	O
introduction	O
of	O
an	O
8	B-CHEM
-	I-CHEM
methyladenosine	I-CHEM
residue	O
at	O
the	O
2	O
'	O
-	O
terminus	O
of	O
the	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
tetramer	I-CHEM
shifts	O
the	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
binding	B-CHEM
site	I-CHEM
of	O
RNase	B-CHEM
L	I-CHEM
.	O

In	O
this	O
study	B-PROC
,	O
we	O
synthesized	O
various	O
5	O
'	O
-	O
modified	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
analog	B-CHEM
s	O
with	O
8	B-CHEM
-	I-CHEM
methyladenosine	I-CHEM
at	O
the	O
2	O
'	O
-	O
terminus	O
.	O

The	O
doxifluridine	B-CHEM
-	O
conjugated	O
8	B-CHEM
-	I-CHEM
methyladenosine	I-CHEM
-	O
substituted	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
analog	B-CHEM
was	O
significantly	O
more	O
effective	O
as	O
an	O
activator	O
of	O
RNase	B-CHEM
L	I-CHEM
than	O
the	O
parent	O
5	O
'	O
-	O
monophophorylated	B-PHYS
2	B-CHEM
-	I-CHEM
5A	I-CHEM
tetramer	I-CHEM
and	O
showed	O
a	O
tumor	B-PHYS
suppressive	I-PHYS
effect	O
against	O
human	B-LIVB
cervical	B-DISO
cancer	I-DISO
cells	B-ANAT
.	O

Naphthoquinone	B-CHEM
glycosides	B-CHEM
for	O
bioelectroanalytical	O
enumeration	O
of	O
the	O
faecal	B-ANAT
indicator	B-CHEM
Escherichia	B-LIVB
coli	I-LIVB
Microbial	B-LIVB
water	O
quality	O
monitoring	B-PROC
for	O
the	O
presence	O
of	O
faecal	B-LIVB
indicator	I-LIVB
bacteria	I-LIVB
(	O
FIB	B-LIVB
)	O
is	O
a	O
mandatory	O
activity	O
in	O
many	O
countries	B-GEOG
and	O
is	O
key	O
in	O
public	B-PROC
health	I-PROC
protection	I-PROC
.	O

Despite	O
technological	O
advances	O
and	O
a	O
need	O
for	O
methodological	O
improvements	O
,	O
chromogenic	B-PROC
and	O
fluorogenic	O
enzymatic	O
techniques	O
remain	O
the	O
mainstays	O
of	O
water	O
quality	O
monitoring	B-PROC
for	O
both	O
public	O
health	O
agencies	O
and	O
regulated	O
utilities	O
.	O

We	O
demonstrated	O
that	O
bioelectroanalytical	B-PROC
approaches	I-PROC
to	O
FIB	B-LIVB
enumeration	O
are	O
possible	O
and	O
can	O
be	O
achieved	O
using	O
commercially	O
available	O
enzyme	B-CHEM
-	O
specific	O
resorufin	B-CHEM
glycosides	B-CHEM
,	O
although	O
these	O
are	O
expensive	O
,	O
not	O
widely	O
available	O
or	O
designed	O
for	O
purpose	O
.	O

Following	O
this	O
,	O
we	O
designed	O
two	O
naphthoquinone	B-CHEM
glycosides	B-CHEM
which	O
performed	O
better	O
,	O
achieving	O
Escherichia	B-PROC
coli	I-PROC
detection	I-PROC
in	O
the	O
range	O
5	O
.	O

0	O
×	O
10	O
(	O
2	O
)	O
to	O
5	O
.	O
0	O
×	O
10	O
(	O
5	O
)	O
CFU	O
ml	O
(	O
-	O
1	O
)	O
22	O
-	O
54	O
%	O
quicker	O
than	O
commercially	O
available	O
resorufin	B-CHEM
glycosides	B-CHEM
.	O

The	O
molecular	O
design	O
of	O
the	O
naphthoquinone	B-CHEM
glycosides	B-CHEM
requires	O
fewer	O
synthetic	O
steps	O
allowing	O
them	O
to	O
be	O
produced	O
for	O
as	O
little	O
as	O
US$	O
50	O
per	O
kg	O
.	O

Tests	O
with	O
environmental	O
samples	B-OBJC
demonstrated	O
the	O
low	O
tendency	O
for	O
abiotic	O
interference	O
and	O
that	O
,	O
despite	O
specificity	O
being	O
maintained	O
between	O
β	B-CHEM
-	I-CHEM
glucuronidase	I-CHEM
and	O
β	B-CHEM
-	I-CHEM
galactosidase	I-CHEM
,	O
accurate	O
enumeration	O
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
in	O
environmental	O
samples	B-OBJC
necessitates	O
development	O
of	O
a	O
selective	O
medium	O
.	O

In	O
comparison	O
to	O
a	O
commercially	O
available	O
detection	B-DISO
method	O
,	O
which	O
has	O
U	O
.	O

S	O
.	O

Environmental	O
Protection	O
Agency	O
(	O
EPA	O
)	O
approval	O
,	O
our	O
approach	O
performed	O
better	O
at	O
high	O
organism	B-LIVB
concentrations	O
,	O
detecting	O
500	O
organisms	B-LIVB
in	O
9	O
h	O
compared	O
with	O
13	O
.	O

5	O
h	O
for	O
the	O
commercial	B-PROC
method	I-PROC
.	O

Bioelectroanalytical	B-PROC
detection	I-PROC
is	O
comparable	O
to	O
current	B-PROC
approved	I-PROC
methods	I-PROC
and	O
with	O
further	B-PHYS
development	I-PHYS
could	O
result	O
in	O
improved	O
detection	B-DISO
times	O
.	O

A	O
recent	O
trend	O
for	O
low	O
-	O
cost	O
open	B-OBJC
-	I-OBJC
source	I-OBJC
hardware	I-OBJC
means	O
that	O
automated	O
,	O
potentiostatically	O
controlled	O
E	B-PROC
.	I-PROC

coli	I-PROC
detection	I-PROC
systems	O
could	O
be	O
constructed	O
for	O
less	O
than	O
US$	O
100	O
per	O
channel	O
.	O

Evaluation	B-PROC
of	O
Local	O
CYP17A1	O
and	O
CYP19A1	O
Expression	O
Levels	O
as	O
Prognostic	B-PHYS
Factors	I-PHYS
in	O
Postmenopausal	B-DISO
Invasive	B-DISO
Ductal	I-DISO
Breast	I-DISO
Cancer	I-DISO
Cases	O
There	O
is	O
growing	O
attention	O
focused	O
on	O
local	O
estrogen	B-PHYS
production	I-PHYS
in	O
the	O
breast	O
tissue	O
and	O
its	O
possible	O
role	O
in	O
breast	B-DISO
cancer	I-DISO
initiation	O
and	O
progression	B-DISO
.	O

Understanding	O
the	O
underlying	O
mechanisms	O
for	O
estrogen	B-PHYS
synthesis	I-PHYS
and	O
the	O
microenvironment	B-PHEN
consisting	O
of	O
tumor	B-DISO
and	O
its	O
surrounding	O
adipose	O
tissue	O
might	O
open	O
new	O
avenues	O
in	O
breast	B-PROC
cancer	I-PROC
prevention	I-PROC
,	O
prognosis	B-PHYS
and	O
treatment	B-PROC
.	O

In	O
order	O
to	O
obtain	O
insight	O
,	O
we	O
compared	O
peritumoral	O
and	O
tumor	O
tissue	O
expressions	B-PHYS
of	O
CYP17A1	O
and	O
CYP19A1	O
genes	O
,	O
which	O
play	O
an	O
important	O
role	O
in	O
estrogen	B-PHYS
biosynthesis	I-PHYS
.	O

The	O
paired	O
tissue	O
samples	O
of	O
20	O
postmenopausal	B-DISO
ER	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	O
PR	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
patients	B-LIVB
diagnosed	B-DISO
with	O
invasive	B-DISO
ductal	I-DISO
breast	I-DISO
cancer	I-DISO
were	O
studied	O
.	O

In	O
addition	O
,	O
12	O
breast	B-ANAT
tissue	I-ANAT
samples	I-ANAT
obtained	O
from	O
premenopausal	B-DISO
women	B-LIVB
without	O
a	O
history	O
of	O
breast	B-DISO
cancer	I-DISO
were	O
also	O
investigated	O
as	O
representative	O
of	O
normal	B-DISO
conditions	I-DISO
.	O

Peritumoral	O
adipose	O
tissues	O
expressed	O
CYP19A1	O
approximately	O
threefold	O
higher	O
than	O
tumor	B-DISO
itself	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

A	O
nonsignificant	O
trend	O
toward	O
low	O
expression	B-PHYS
of	O
CYP17A1	O
was	O
observed	O
in	O
peritumoral	O
compared	O
to	O
tumor	O
tissue	O
(	O
p	O
=	O
0	O
.	O
687	O
)	O
.	O

Clinicopathological	O
parameters	O
and	O
patient	B-PHYS
characteristics	I-PHYS
which	O
are	O
accepted	O
as	O
risk	B-DISO
factors	I-DISO
for	O
breast	B-DISO
cancer	I-DISO
were	O
also	O
associated	O
with	O
individual	O
and	O
combined	O
expressions	B-PHYS
of	O
CYP17A1	O
and	O
CYP19A1	O
.	O

This	O
study	O
offers	O
that	O
evaluation	B-PROC
of	O
CYP17A1	O
and	O
CYP19A1	O
local	O
expression	O
levels	O
might	O
be	O
useful	O
for	O
deciding	O
on	O
personalized	O
treatment	O
approaches	O
and	O
more	O
accurate	O
diagnosis	B-DISO
,	O
when	O
evaluated	B-PROC
together	O
with	O
several	O
clinicopathological	O
and	O
disease	B-DISO
risk	I-DISO
factors	I-DISO
.	O

Considering	O
the	O
key	O
role	O
of	O
these	O
CYPs	O
in	O
estrogen	B-PHYS
synthesis	I-PHYS
,	O
determining	O
their	O
expression	O
levels	O
may	O
be	O
useful	O
as	O
a	O
postdiagnostic	B-PHYS
marker	I-PHYS
and	O
for	O
choosing	O
the	O
right	O
treatment	B-PROC
method	I-PROC
in	O
addition	O
to	O
the	O
conventional	O
approach	O
.	O

Case	O
Report	O
of	O
Necrotizing	B-DISO
Fasciitis	I-DISO
Associated	O
with	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
Necrotizing	B-DISO
fasciitis	I-DISO
,	O
caused	O
by	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
,	O
is	O
an	O
extremely	O
rare	O
and	O
life	B-DISO
-	I-DISO
threatening	I-DISO
bacterial	B-LIVB
soft	B-DISO
tissue	I-DISO
infection	I-DISO
.	O

We	O
report	B-PROC
a	O
case	O
of	O
early	O
necrotizing	B-DISO
fasciitis	I-DISO
associated	O
with	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
infection	B-DISO
in	O
a	O
26	O
-	O
year	O
-old	O
man	B-LIVB
who	O
was	O
immunocompromised	B-DISO
with	O
mixed	B-DISO
connective	I-DISO
tissue	I-DISO
disease	I-DISO
.	O

The	O
patient	B-LIVB
presented	O
with	O
acute	O
,	O
painful	B-DISO
,	O
erythematous	O
,	O
and	O
edematous	B-DISO
skin	I-DISO
lesions	B-DISO
of	O
his	O
right	B-ANAT
lower	I-ANAT
back	I-ANAT
,	O
which	O
rapidly	O
progressed	O
to	O
the	O
right	B-ANAT
knee	I-ANAT
.	O

The	O
patient	B-LIVB
underwent	O
surgical	B-PROC
exploration	I-PROC
,	O
and	O
a	O
diagnosis	B-DISO
of	O
necrotizing	B-DISO
fasciitis	I-DISO
was	O
confirmed	O
by	O
pathological	O
evidence	O
of	O
necrosis	B-PHYS
of	O
the	O
fascia	O
and	O
neutrophil	B-PHYS
infiltration	I-PHYS
in	O
tissue	B-PROC
biopsies	I-PROC
.	O

Cultures	B-PROC
of	O
fascial	B-ANAT
tissue	B-PROC
biopsies	I-PROC
and	O
blood	B-ANAT
samples	I-ANAT
were	O
positive	B-DISO
for	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-PROC
of	O
necrotizing	B-DISO
fasciitis	I-DISO
resulting	O
from	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
diagnosed	B-DISO
at	O
early	O
phase	O
;	O
the	O
patient	B-PHYS
recovered	I-PHYS
well	O
without	O
surgical	B-PROC
debridement	I-PROC
.	O

A	O
Comparative	B-PROC
Study	I-PROC
of	O
the	O
Efficacy	O
of	O
IV	O
Dexketoprofen	B-CHEM
,	O
Lornoxicam	B-CHEM
,	O
and	O
Diclophenac	B-CHEM
Sodium	I-CHEM
on	O
Postoperative	B-PROC
Analgesia	I-PROC
and	O
Tramadol	B-CHEM
Consumption	O
in	O
Patients	B-LIVB
Receiving	O
Patient	B-PROC
-	I-PROC
Controlled	I-PROC
Tramadol	B-CHEM
This	O
study	B-PROC
was	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
dexketoprofen	B-CHEM
,	O
lornoxicam	B-CHEM
,	O
and	O
diclophenac	B-CHEM
sodium	I-CHEM
on	O
postoperative	B-PROC
analgesia	I-PROC
and	O
tramadol	B-CHEM
consumption	O
in	O
patients	B-LIVB
receiving	O
postoperative	O
patient	B-PROC
-	I-PROC
controlled	I-PROC
tramadol	B-CHEM
after	O
a	O
major	O
abdominal	B-PROC
surgery	I-PROC
.	O

Eighty	O
patients	B-LIVB
were	O
randomized	B-DISO
to	O
receive	O
one	O
of	O
the	O
four	O
study	B-PROC
drugs	B-CHEM
.	O

Patients	B-LIVB
in	O
group	O
dexketoprofen	B-CHEM
(	O
DT	B-CHEM
)	O
received	O
IV	O
50	O
mg	O
dexketoprofen	B-CHEM
,	O
group	O
lornoxicam	B-CHEM
(	O
LR	B-CHEM
)	O
received	O
IV	O
8	O
mg	O
lornoxicam	B-CHEM
,	O
group	O
diclophenac	B-CHEM
sodium	I-CHEM
(	O
DS	B-CHEM
)	O
received	O
75	O
mg	O
IV	O
diclophenac	B-CHEM
sodium	I-CHEM
and	O
group	O
saline	B-OBJC
(	O
S	B-OBJC
)	O
received	O
0	O
.	O

9	O
%	O
saline	B-OBJC
in	O
2	O
mL	O
syringes	B-DEVI
,	O
20	O
min	O
before	O
the	O
end	O
of	O
anaesthesia	B-PROC
.	O

A	O
standardized	O
(	O
1	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
dose	O
of	O
tramadol	B-CHEM
was	O
routinely	O
administered	O
to	O
all	O
patients	B-LIVB
as	O
the	O
loading	O
dose	O
at	O
the	O
end	O
of	O
surgery	B-PROC
.	O

Postoperatively	O
,	O
whenever	O
patients	B-LIVB
requested	O
,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-CHEM
patient	B-DISO
-	I-DISO
controlled	I-DISO
analgesia	I-DISO
device	I-DISO
giving	O
a	O
bolus	B-PROC
dose	I-PROC
(	O
0	O
.	O

2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
of	O
tramadol	B-CHEM
.	O

Pain	B-DISO
,	O
discomfort	B-DISO
,	O
and	O
sedation	B-DISO
scores	O
,	O
cumulative	O
tramadol	B-CHEM
consumption	O
,	O
supplemental	O
meperidine	B-CHEM
requirement	O
,	O
and	O
side	B-DISO
effects	I-DISO
were	O
recorded	O
.	O

Visual	O
rating	O
scale	O
and	O
patient	B-LIVB
discomfort	B-DISO
scores	O
were	O
significantly	O
lower	O
in	O
DT	B-CHEM
,	O
LR	B-CHEM
and	O
DS	B-CHEM
groups	O
compared	O
to	O
those	O
in	O
in	O
group	O
S	B-OBJC
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Cumulative	O
tramadol	B-CHEM
consumption	O
was	O
significantly	O
lower	O
in	O
non	B-CHEM
-	I-CHEM
steroidal	I-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drug	I-CHEM
(	O
NSAID	B-CHEM
)	O
-	O
treated	O
groups	O
at	O
each	O
study	B-PROC
period	I-PROC
after	O
the	O
second	O
postoperative	O
hour	O
than	O
in	O
group	O
S	B-OBJC
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Supplemental	O
meperidine	B-CHEM
requirement	O
was	O
significantly	O
higher	O
in	O
group	O
S	B-OBJC
at	O
each	O
study	B-PROC
period	I-PROC
after	O
postoperative	O
30	O
min	O
than	O
in	O
NSAID	B-CHEM
-	O
treated	O
groups	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

After	O
major	O
abdominal	B-PROC
surgery	I-PROC
,	O
adding	O
IV	O
diclophenac	B-CHEM
,	O
lornoxicam	B-CHEM
or	O
dexketoprofen	B-CHEM
to	O
patient	B-PROC
-	I-PROC
controlled	I-PROC
tramadol	B-CHEM
resulted	O
in	O
lower	O
pain	B-DISO
scores	O
,	O
smaller	O
tramadol	B-CHEM
consumption	O
,	O
less	O
rescue	O
supplemental	O
analgesic	B-CHEM
requirement	O
,	O
and	O
fewer	O
side	B-DISO
effects	I-DISO
compared	O
with	O
the	O
tramadol	B-CHEM
alone	O
group	O
.	O

Does	O
Video	B-DEVI
Laryngoscopy	I-DEVI
Offer	O
Advantages	O
over	O
Direct	B-PROC
Laryngoscopy	I-PROC
during	O
Cardiopulmonary	B-PROC
Resuscitation	I-PROC
?	O
Interruption	O
of	O
chest	B-PROC
compressions	I-PROC
should	O
be	O
minimized	O
because	O
of	O
its	O
negative	B-DISO
effects	O
on	O
survival	O
.	O

This	O
randomized	B-PROC
,	O
controlled	O
,	O
cross	B-PROC
-	I-PROC
over	I-PROC
study	I-PROC
aimed	O
to	O
analyze	B-PROC
the	O
effectiveness	O
of	O
Macintosh	B-DEVI
,	O
Miller	B-DEVI
,	O
McCoy	B-DEVI
and	O
McGrath	B-DEVI
laryngoscopes	I-DEVI
during	O
with	O
or	O
without	O
chest	B-PROC
compressions	I-PROC
in	O
the	O
scope	O
of	O
a	O
simulated	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
scenario	O
.	O

The	O
time	O
required	O
for	O
successful	O
tracheal	B-PROC
intubation	I-PROC
,	O
number	B-PHYS
of	I-PHYS
attempts	I-PHYS
,	O
dental	B-DISO
trauma	I-DISO
severity	O
and	O
the	O
need	O
for	O
optimization	O
manoeuvres	O
were	O
recorded	B-DISO
during	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
with	O
and	O
without	O
chest	B-PROC
compressions	I-PROC
.	O

The	O
experience	B-PHYS
with	O
computer	B-OBJC
games	I-OBJC
during	O
the	O
last	O
10	O
years	O
were	O
asked	O
to	O
the	O
participants	B-LIVB
and	O
recorded	B-DISO
.	O

McCoy	B-DEVI
laryngoscope	I-DEVI
yielded	O
the	O
shortest	O
time	O
for	O
successful	O
tracheal	B-PROC
intubation	I-PROC
both	O
in	O
the	O
presence	B-DISO
of	O
and	O
without	O
chest	B-PROC
compressions	I-PROC
.	O

During	O
the	O
use	O
of	O
McCoy	B-DEVI
laryngoscopes	I-DEVI
,	O
fewer	O
tracheal	B-PROC
intubation	I-PROC
attempts	O
,	O
lower	O
incidence	O
of	O
dental	B-DISO
trauma	I-DISO
and	O
lower	O
visual	B-PHYS
analogue	I-PHYS
scale	I-PHYS
scores	I-PHYS
on	O
the	O
ease	O
of	O
intubation	B-PROC
were	O
recorded	B-DISO
.	O

Participants	B-LIVB
who	O
are	O
experienced	B-PHYS
computer	B-OBJC
game	I-OBJC
players	B-LIVB
using	O
Macintosh	B-DEVI
,	O
McCoy	B-DEVI
and	O
McGrath	B-DEVI
achieved	B-DISO
successful	O
tracheal	B-PROC
intubation	I-PROC
in	O
a	O
significantly	O
shorter	O
time	O
during	O
resuscitation	B-PROC
without	O
chest	B-PROC
compressions	I-PROC
.	O

Dental	B-DISO
trauma	I-DISO
incidence	O
and	O
number	O
of	O
tracheal	B-PROC
intubation	I-PROC
attempts	O
did	O
not	O
show	O
any	O
significant	O
difference	O
between	O
the	O
four	O
laryngoscopes	B-DEVI
being	O
related	O
to	O
the	O
rate	O
of	O
playing	O
computer	B-OBJC
games	I-OBJC
.	O

McGrath	B-DEVI
video	I-DEVI
laryngoscopes	I-DEVI
do	O
not	O
appear	O
to	O
have	O
advantages	O
over	O
direct	B-PROC
laryngoscopes	I-PROC
for	O
securing	O
a	O
smooth	O
and	O
successful	O
tracheal	B-PROC
intubation	I-PROC
during	O
rhythmic	B-PROC
chest	I-PROC
compressions	I-PROC
.	O

We	O
believe	O
that	O
as	O
McCoy	B-DEVI
laryngoscope	I-DEVI
provided	O
tracheal	B-PROC
intubation	I-PROC
in	O
a	O
shorter	O
time	O
and	O
with	O
fewer	O
attempts	O
,	O
this	O
laryngoscope	B-DEVI
may	O
increase	O
the	O
success	O
rate	O
of	O
resuscitation	B-PROC
.	O

Perioperative	B-PROC
Management	I-PROC
of	O
Severe	B-DISO
Hypertension	I-DISO
during	O
Laparoscopic	B-PROC
Surgery	I-PROC
for	O
Pheochromocytoma	B-DISO
Phaeochromocytoma	B-DISO
is	O
a	O
catecholamine	B-PHYS
-	I-PHYS
secreting	I-PHYS
vascular	B-DISO
tumour	I-DISO
that	O
is	O
derived	O
from	O
chromaffin	B-ANAT
cell	I-ANAT
.	O

Lethal	B-DISO
cardiovascular	B-DISO
complications	I-DISO
,	O
such	O
as	O
serious	O
hypertension	B-DISO
,	O
myocardial	B-DISO
infarction	I-DISO
and	O
aortic	B-DISO
dissection	I-DISO
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B-DISO
catecholamine	I-DISO
release	I-DISO
.	O

Each	O
stage	O
of	O
anaesthesia	B-PROC
management	I-PROC
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B-DISO
catecholamine	I-DISO
secretion	I-DISO
that	O
may	O
occur	O
during	O
induction	B-PROC
,	O
perioperative	O
stage	O
and	O
surgical	B-PROC
manipulation	I-PROC
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B-PROC
preparation	I-PROC
and	O
severe	B-PROC
,	I-PROC
persistent	I-PROC
hypertension	I-PROC
attack	I-PROC
management	I-PROC
with	O
a	O
combination	O
of	O
α	B-CHEM
-	I-CHEM
adrenergic	I-CHEM
blockade	I-CHEM
,	O
β	B-CHEM
-	I-CHEM
adrenergic	I-CHEM
blockade	I-CHEM
,	O
sodium	B-CHEM
nitroprusside	I-CHEM
and	O
remifentanil	B-CHEM
in	O
a	O
patient	B-LIVB
who	O
underwent	O
laparoscopic	B-PROC
surgery	I-PROC
for	O
phaeochromocytoma	B-DISO
.	O

A	O
case	O
study	O
of	O
the	O
introduction	O
of	O
the	O
International	O
Classification	O
for	O
Nursing	O
Practice	O
(	O
®	O
)	O
in	O
Poland	B-GEOG
The	O
development	O
of	O
a	O
nursing	B-PROC
practice	I-PROC
,	O
improvements	O
in	O
nurses	O
'	O
autonomy	O
,	O
and	O
increased	O
professional	O
and	O
personal	O
responsibility	O
for	O
the	O
medical	B-PROC
services	I-PROC
provided	O
all	O
require	O
professional	O
documentation	O
with	O
records	O
of	O
health	O
status	O
assessments	B-PROC
,	O
decisions	B-DISO
undertaken	I-DISO
,	O
actions	O
and	O
their	O
outcomes	O
for	O
each	O
patient	B-LIVB
.	O

The	O
International	O
Classification	O
for	O
Nursing	O
Practice	O
is	O
a	O
tool	O
that	O
meets	O
all	O
of	O
these	O
needs	O
,	O
and	O
although	O
it	O
requires	O
continuous	O
evaluation	B-PROC
,	O
it	O
offers	O
professional	O
documentation	O
and	O
communication	O
in	O
the	O
practitioner	B-LIVB
and	O
researcher	B-PROC
community	I-PROC
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
a	O
theoretical	B-PROC
critique	I-PROC
of	O
an	O
issue	B-DISO
related	O
to	O
policy	O
and	O
experience	O
of	O
the	O
current	O
situation	O
in	O
Polish	B-GEOG
nursing	O
-	O
especially	O
of	O
the	O
efforts	O
to	O
standardize	O
nursing	B-PROC
practices	I-PROC
through	O
the	O
introduction	O
and	O
development	O
of	O
the	O
Classification	O
in	O
Poland	B-GEOG
.	O

Despite	O
extensive	O
promotion	O
and	O
training	B-PROC
by	O
International	O
Council	O
of	O
Nurses	O
members	B-LIVB
worldwide	O
,	O
there	O
are	O
still	O
many	O
countries	B-GEOG
where	O
the	O
Classification	O
has	O
not	O
been	O
implemented	O
as	O
a	O
standard	O
tool	O
in	O
healthcare	B-OBJC
facilities	I-OBJC
.	O

Recently	O
,	O
a	O
number	O
of	O
initiatives	O
were	O
undertaken	O
in	O
cooperation	O
with	O
the	O
local	B-LIVB
and	O
state	O
authorities	O
to	O
disseminate	O
the	O
Classification	O
in	O
healthcare	B-OBJC
facilities	I-OBJC
.	O

Thanks	O
to	O
intense	O
efforts	O
by	O
the	O
Polish	O
Nurses	O
Association	O
and	O
the	O
International	O
Council	O
of	O
Nurses	O
Accredited	O
Center	O
for	O
ICNP	O
(	O
®	O
)	O
Research	B-PROC
&	I-PROC
Development	I-PROC
at	O
the	O
Medical	O
University	O
of	O
Łódź	O
,	O
the	O
Classification	O
is	O
known	O
in	O
Poland	B-GEOG
and	O
has	O
been	O
tested	O
at	O
several	O
centres	O
.	O

Nevertheless	O
,	O
an	O
actual	O
implementation	O
that	O
would	O
allow	O
for	O
national	O
and	O
international	O
interoperability	B-DISO
requires	O
strategic	O
governmental	O
decisions	O
and	O
close	O
cooperation	O
with	O
information	O
technology	O
companies	B-OBJC
operating	O
in	O
the	O
country	B-GEOG
.	O

Discussing	O
the	O
barriers	B-DISO
to	O
the	O
implementation	O
of	O
the	O
Classification	O
can	O
improve	B-DISO
understanding	O
of	O
it	O
and	O
its	O
use	O
.	O

At	O
a	O
policy	O
level	O
,	O
decision	O
makers	O
need	O
to	O
understand	O
that	O
use	O
Classification	O
in	O
eHealth	B-PROC
services	I-PROC
and	O
tools	O
it	O
is	O
necessary	O
to	O
achieve	O
interoperability	B-DISO
.	O

A	O
case	O
based	O
reflection	B-DISO
on	O
communicating	O
end	O
of	O
life	O
information	O
in	O
non	B-DISO
-	I-DISO
English	I-DISO
speaking	I-DISO
patients	B-LIVB
Mr	O
X	O
was	O
a	O
56	O
year	O
old	O
Chinese	B-LIVB
man	B-LIVB
(	O
non	B-DISO
-	I-DISO
English	I-DISO
speaking	I-DISO
)	O
,	O
who	O
presented	O
to	O
the	O
emergency	B-OBJC
department	I-OBJC
with	O
a	O
range	O
of	O
non	O
-	O
specific	O
symptoms	B-DISO
.	O

On	O
full	O
workup	O
,	O
he	O
was	O
diagnosed	B-DISO
with	O
an	O
advanced	B-DISO
cancer	I-DISO
of	I-DISO
the	I-DISO
pancreas	I-DISO
.	O

It	O
was	O
an	O
aggressive	B-DISO
,	O
highly	O
treatment	B-DISO
resistant	I-DISO
cancer	I-DISO
,	O
with	O
an	O
alarmingly	O
poor	B-DISO
prognosis	I-DISO
.	O

Before	O
the	O
diagnosis	B-DISO
had	O
been	O
made	O
,	O
the	O
family	B-LIVB
had	O
informed	O
our	O
team	B-PROC
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	O
issues	B-DISO
with	O
Mr	O
X	O
directly	O
,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-DISO
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him	O
.	O

They	O
reported	O
that	O
Mr	O
X	O
was	O
in	O
support	O
of	O
this	O
arrangement	O
.	O

Eventually	O
we	O
told	O
the	O
family	B-LIVB
about	O
Mr	O
X	O
's	O
diagnosis	B-DISO
,	O
and	O
they	O
asserted	O
their	O
collective	O
will	O
to	O
keep	O
this	O
information	O
from	O
him	O
,	O
reaffirming	O
that	O
all	O
medical	O
discussion	B-PROC
go	O
through	O
them	O
.	O

However	O
,	O
the	O
doctor	B-LIVB
in	I-LIVB
charge	I-LIVB
explained	O
the	O
diagnosis	B-DISO
to	O
Mr	O
X	O
using	O
an	O
interpreter	B-LIVB
while	O
his	O
family	B-LIVB
were	O
away	O
from	O
his	O
bed	B-OBJC
.	O

In	O
this	O
discussion	O
,	O
I	O
consider	O
this	O
case	O
from	O
the	O
perspective	O
of	O
respecting	B-PROC
patients	I-PROC
'	I-PROC
and	I-PROC
families	I-PROC
'	I-PROC
preferences	I-PROC
around	O
medical	B-PROC
treatment	I-PROC
and	I-PROC
care	I-PROC
.	O

A	O
Cyclin	B-CHEM
D2	I-CHEM
-derived	O
peptide	B-CHEM
acts	O
on	O
specific	O
cell	B-PHYS
cycle	I-PHYS
phases	I-PHYS
by	O
activating	O
ERK1	B-CHEM
/	I-CHEM
2	I-CHEM
to	O
cause	B-DISO
the	I-DISO
death	I-DISO
of	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
Protein	B-PHYS
degradation	I-PHYS
by	O
the	O
proteasome	B-PHYS
generates	O
functional	O
intracellular	O
peptides	B-CHEM
.	O

Pep5	B-CHEM
,	O
a	O
peptide	B-CHEM
derived	O
from	O
Cyclin	B-CHEM
D2	I-CHEM
,	O
induces	O
cell	B-PHYS
death	I-PHYS
in	O
tumor	B-ANAT
cell	I-ANAT
lines	I-ANAT
and	O
reduces	O
the	O
volume	O
of	O
rat	B-LIVB
C6	B-DISO
glioblastoma	I-DISO
tumors	I-DISO
in	O
vivo	O
.	O

Here	O
,	O
we	O
chose	O
the	O
human	B-DISO
MDA	I-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O
evaluate	B-PROC
the	O
mechanism	B-PHYS
of	I-PHYS
cell	I-PHYS
death	I-PHYS
induced	O
by	O
pep5	B-CHEM
in	O
different	O
phases	B-PHYS
of	I-PHYS
the	I-PHYS
cell	I-PHYS
cycle	I-PHYS
.	O

Fluorescently	B-PROC
labeled	I-PROC
pep5	B-CHEM
,	O
monitored	O
by	O
real	B-PROC
time	I-PROC
confocal	I-PROC
microscopy	I-PROC
,	O
entered	O
the	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
3min	O
after	O
application	O
and	O
localized	O
to	O
the	O
nucleus	B-ANAT
and	O
cytoplasm	B-ANAT
.	O

Pep5	B-CHEM
-	O
induced	O
cell	B-PHYS
death	I-PHYS
was	O
increased	O
when	O
the	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cell	B-ANAT
population	I-ANAT
was	O
arrested	O
at	O
the	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
transition	I-PHYS
or	O
in	O
S	O
phase	O
compared	O
to	O
asynchronous	O
cells	B-ANAT
.	O

Pep5	B-CHEM
induced	O
permanent	O
extracellular	B-CHEM
signal	I-CHEM
-	I-CHEM
regulated	I-CHEM
kinase	I-CHEM
(	O
ERK1	B-CHEM
/	I-CHEM
2	I-CHEM
)	O
phosphorylation	B-PHYS
in	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
synchronized	O
in	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
or	O
S	O
phase	O
.	O

Affinity	B-PROC
chromatography	I-PROC
followed	O
by	O
mass	B-PROC
spectrometry	I-PROC
identified	O
CLIC1	B-CHEM
and	O
Plectin	B-CHEM
as	O
the	O
only	O
two	O
proteins	B-CHEM
that	O
interacted	O
with	O
pep5	B-CHEM
in	O
both	O
asynchronous	O
and	O
synchronized	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
.	O

These	O
interactions	O
could	O
explain	O
the	O
long	O
-	O
lasting	O
ERK1	B-CHEM
/	I-CHEM
2	I-CHEM
phosphorylation	B-PHYS
and	O
the	O
cytoskeleton	B-ANAT
perturbations	O
in	O
the	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
,	O
in	O
which	O
the	O
stress	B-ANAT
fibers	I-ANAT
'	O
integrity	O
is	O
affected	O
by	O
pep5	B-CHEM
treatments	B-PROC
.	O

These	O
data	O
suggest	O
that	O
pep5	B-CHEM
has	O
potential	O
therapeutic	O
properties	O
for	O
treating	B-PROC
specific	O
types	O
of	O
cancers	B-DISO
,	O
such	O
as	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
.	O

Pep5	B-CHEM
,	O
a	O
natural	O
intracellular	O
peptide	B-CHEM
formed	O
by	O
the	O
degradation	B-PHYS
of	I-PHYS
Cyclin	I-PHYS
D2	I-PHYS
through	O
the	O
ubiquitin	B-PHYS
-	I-PHYS
proteasome	I-PHYS
system	I-PHYS
,	O
induces	O
cell	B-PHYS
death	I-PHYS
when	O
reintroduced	O
into	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
,	O
which	O
express	O
low	O
levels	O
of	O
Cyclin	B-CHEM
D2	I-CHEM
,	O
specifically	O
in	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
arrested	B-ANAT
cells	I-ANAT
or	O
in	O
cells	B-ANAT
that	O
are	O
passing	O
through	O
S	O
phase	O
.	O

Under	O
these	O
conditions	O
,	O
pep5	B-CHEM
is	O
able	O
to	O
interact	O
with	O
different	O
intracellular	O
proteins	B-CHEM
,	O
primarily	O
cytoskeleton	B-ANAT
and	O
proteasome	B-CHEM
components	I-CHEM
,	O
which	O
can	O
lead	O
to	O
cellular	B-PHYS
apoptosis	I-PHYS
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
pep5	B-CHEM
is	O
an	O
intracellular	O
peptide	B-CHEM
with	O
therapeutic	O
potential	O
for	O
treating	B-PROC
specific	O
types	O
of	O
tumors	B-DISO
with	O
low	O
expression	B-PHYS
of	O
Cyclin	B-CHEM
D2	I-CHEM
by	O
inhibiting	O
cell	B-PHYS
proliferation	I-PHYS
.	O

Maternal	B-LIVB
dietary	B-PHYS
intake	I-PHYS
during	O
pregnancy	B-PHYS
and	O
offspring	B-LIVB
body	B-PHYS
composition	I-PHYS
:	O
The	O
Healthy	B-PROC
Start	I-PROC
Study	I-PROC
Consistent	O
evidence	O
of	O
an	O
influence	O
of	O
maternal	B-LIVB
dietary	B-PHYS
intake	I-PHYS
during	O
pregnancy	B-PHYS
on	O
infant	B-LIVB
body	B-PHYS
size	I-PHYS
and	O
composition	B-PHYS
in	O
human	B-LIVB
populations	B-LIVB
is	O
lacking	O
,	O
despite	O
robust	O
evidence	O
in	O
animal	B-LIVB
models	I-LIVB
.	O

We	O
sought	O
to	O
evaluate	O
the	O
influence	O
of	O
maternal	B-LIVB
macronutrient	O
intake	B-PHYS
and	O
balance	O
during	O
pregnancy	B-PHYS
on	O
neonatal	B-LIVB
body	B-PHYS
size	I-PHYS
and	O
composition	B-PHYS
,	O
including	O
fat	B-PHYS
mass	I-PHYS
and	O
fat	B-DISO
-	I-DISO
free	I-DISO
mass	I-DISO
.	O

The	O
analysis	B-PROC
was	O
conducted	O
among	O
1040	O
mother	B-LIVB
-	O
offspring	B-LIVB
pairs	O
enrolled	O
in	O
the	O
prospective	O
prebirth	O
observational	O
cohort	O
:	O
the	O
Healthy	B-PROC
Start	I-PROC
Study	I-PROC
.	O

Diet	B-OBJC
during	O
pregnancy	B-PHYS
was	O
collected	O
using	O
repeated	O
24	O
-	O
hour	O
dietary	B-OBJC
recalls	O
(	O
up	O
to	O
8	O
)	O
.	O

Direct	O
measures	O
of	O
body	B-PHYS
composition	I-PHYS
were	O
obtained	O
using	O
air	B-PROC
displacement	I-PROC
plethysmography	I-PROC
.	O

The	O
National	O
Cancer	O
Institute	O
measurement	O
error	O
model	O
was	O
used	O
to	O
estimate	O
usual	O
dietary	B-PHYS
intake	I-PHYS
during	O
pregnancy	B-PHYS
.	O

Multivariable	O
partition	O
(	O
nonisocaloric	O
)	O
and	O
nutrient	O
density	O
(	O
isocaloric	O
)	O
linear	O
regression	O
models	O
were	O
used	O
to	O
test	O
the	O
associations	O
between	O
maternal	B-LIVB
dietary	B-PHYS
intake	I-PHYS
and	O
neonatal	B-LIVB
body	B-PHYS
composition	I-PHYS
.	O

The	O
median	O
macronutrient	O
composition	O
during	O
pregnancy	B-PHYS
was	O
32	O
.	O

2	O
%	O
from	O
fat	B-CHEM
,	O
15	O
.	O
0	O
%	O
from	O
protein	B-OBJC
,	O
and	O
47	O
.	O

8	O
%	O
from	O
carbohydrates	B-OBJC
.	O

In	O
the	O
partition	O
multivariate	O
regression	O
model	O
,	O
individual	B-LIVB
macronutrient	O
intake	B-PHYS
values	O
were	O
not	O
associated	O
with	O
birthweight	B-PHYS
or	O
fat	B-DISO
-	I-DISO
free	I-DISO
mass	I-DISO
,	O
but	O
were	O
associated	O
with	O
fat	B-PHYS
mass	I-PHYS
.	O

Respectively	O
,	O
418	O
kJ	O
increases	O
in	O
total	B-CHEM
fat	I-CHEM
,	O
saturated	O
fat	O
,	O
unsaturated	B-CHEM
fat	I-CHEM
,	O
and	O
total	B-OBJC
carbohydrates	I-OBJC
were	O
associated	O
with	O
4	O
.	O
2	O
-	O
g	O
(	O
P	O
=	O
.03	O
)	O
,	O
11	O
.	O
1	O
-	O
g	O
(	O
P	O
=	O
.003	O
)	O
,	O
5	O
.	O
9	O
-	O
g	O
(	O
P	O
=	O
.04	O
)	O
,	O
and	O
2	O
.	O
9	O
-	O
g	O
(	O
P	O
=	O
.02	O
)	O
increases	O
in	O
neonatal	B-LIVB
fat	B-PHYS
mass	I-PHYS
,	O
independent	O
of	O
prepregnancy	B-PHYS
body	I-PHYS
mass	I-PHYS
index	I-PHYS
.	O

In	O
the	O
nutrient	O
density	O
multivariate	O
regression	O
model	O
,	O
macronutrient	O
balance	O
was	O
not	O
associated	O
with	O
fat	B-PHYS
mass	I-PHYS
,	O
fat	B-DISO
-	I-DISO
free	I-DISO
mass	I-DISO
,	O
or	O
birthweight	B-PHYS
after	O
adjustment	O
for	O
prepregnancy	B-PHYS
body	I-PHYS
mass	I-PHYS
index	I-PHYS
.	O

Neonatal	B-LIVB
adiposity	B-PHYS
,	O
but	O
not	O
birthweight	B-PHYS
,	O
is	O
independently	O
associated	O
with	O
increased	O
maternal	B-LIVB
intake	B-PHYS
of	O
total	B-CHEM
fat	I-CHEM
,	O
saturated	O
fat	O
,	O
unsaturated	B-CHEM
fat	I-CHEM
,	O
and	O
total	B-OBJC
carbohydrates	I-OBJC
,	O
but	O
not	O
protein	B-OBJC
,	O
suggesting	O
that	O
most	O
forms	O
of	O
increased	O
caloric	O
intake	O
contribute	O
to	O
fetal	B-ANAT
fat	B-DISO
accretion	I-DISO
.	O

Difference	B-PROC
-	I-PROC
in	I-PROC
-	I-PROC
Differences	I-PROC
Method	I-PROC
in	O
Comparative	B-PROC
Effectiveness	I-PROC
Research	I-PROC
:	O
Utility	O
with	O
Unbalanced	O
Groups	O
Comparative	B-PROC
effectiveness	I-PROC
research	I-PROC
(	O
CER	B-PROC
)	O
often	O
includes	O
observational	O
studies	O
utilizing	O
administrative	B-DISO
data	I-DISO
.	O

Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
CER	B-PROC
to	O
adjust	O
for	O
group	O
differences	O
,	O
including	O
difference	B-PROC
-	I-PROC
in	I-PROC
-	I-PROC
differences	I-PROC
(	I-PROC
DiD	I-PROC
)	I-PROC
estimation	I-PROC
.	O

This	O
study	O
presents	O
DiD	B-PROC
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	O
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
CER	B-PROC
setting	O
by	O
utilizing	O
the	O
MarketScan	O
®	O
Databases	O
for	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	B-DISO
)	O
patients	B-LIVB
receiving	O
different	O
therapies	B-PROC
.	O

The	O
sample	O
included	O
6762	O
patients	B-LIVB
,	O
with	O
363	O
in	O
the	O
Test	B-LIVB
Cohort	I-LIVB
[	O
glatiramer	B-CHEM
acetate	I-CHEM
(	O
GA	B-CHEM
)	O
switched	B-PROC
to	O
fingolimod	B-CHEM
(	O
FTY	B-CHEM
)	O
]	O
and	O
6399	O
in	O
the	O
Control	B-LIVB
Cohort	I-LIVB
(	O
GA	B-CHEM
only	O
,	O
no	B-DISO
switch	I-DISO
)	O
from	O
a	O
US	O
administrative	O
claims	O
database	O
.	O

A	O
trend	O
analysis	O
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	O
to	O
the	O
mean	O
and	O
to	O
compare	O
relapse	B-PHEN
rates	O
among	O
treatment	B-LIVB
cohorts	I-LIVB
.	O

DiD	B-PROC
analysis	I-PROC
was	O
used	O
to	O
enable	O
comparisons	O
among	O
the	O
Test	B-LIVB
and	O
Control	B-LIVB
Cohorts	I-LIVB
.	O

Logistic	B-PROC
regression	I-PROC
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	B-PHEN
after	O
switching	B-PROC
from	O
GA	B-CHEM
to	O
FTY	B-CHEM
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O

Crude	O
DiD	B-PROC
analysis	I-PROC
showed	O
that	O
in	O
the	O
pre	O
-	O
index	O
period	O
more	O
patients	B-LIVB
in	O
the	O
Test	B-LIVB
Cohort	I-LIVB
experienced	O
an	O
MS	B-DISO
relapse	B-PHEN
and	O
had	O
a	O
higher	O
mean	O
number	O
of	O
relapses	B-PHEN
than	O
in	O
the	O
Control	B-LIVB
Cohort	I-LIVB
.	O

During	O
the	O
pre	O
-	O
index	O
period	O
,	O
numeric	O
and	O
relative	O
data	O
for	O
MS	B-DISO
relapses	B-PHEN
in	O
patients	B-LIVB
in	O
the	O
Test	B-LIVB
Cohort	I-LIVB
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	B-LIVB
Cohort	I-LIVB
,	O
while	O
no	B-DISO
significant	I-DISO
between	O
-	O
group	O
differences	O
emerged	O
during	O
the	O
post	O
-	O
index	O
period	O
.	O

Generalized	O
linear	O
modeling	O
with	O
DiD	B-PROC
regression	O
estimation	O
showed	O
that	O
the	O
mean	O
number	O
of	O
MS	B-DISO
relapses	B-PHEN
decreased	O
significantly	O
in	O
the	O
post	O
-	O
index	O
period	O
among	O
patients	B-LIVB
in	O
the	O
Test	B-LIVB
Cohort	I-LIVB
compared	O
with	O
patients	B-LIVB
in	O
the	O
Control	B-LIVB
Cohort	I-LIVB
.	O

In	O
this	O
study	O
,	O
an	O
MS	B-DISO
population	B-LIVB
was	O
utilized	O
to	O
demonstrate	O
how	O
DiD	B-PROC
can	O
be	O
applied	O
to	O
estimate	O
treatment	B-DISO
effects	I-DISO
in	O
a	O
heterogeneous	O
population	B-LIVB
,	O
where	O
the	O
Test	B-LIVB
and	O
Control	B-LIVB
Cohorts	I-LIVB
varied	O
greatly	O
.	O

The	O
results	O
show	O
that	O
DiD	B-PROC
offers	O
a	O
robust	O
method	O
for	O
comparing	O
diverse	O
cohorts	B-LIVB
when	O
other	O
risk	O
-	O
adjustment	O
methods	O
may	O
not	O
be	O
adequate	O
.	O

Variation	O
in	O
the	O
Use	O
of	O
Vestibular	B-PROC
Diagnostic	I-PROC
Testing	I-PROC
for	O
Patients	B-LIVB
Presenting	O
to	O
Otolaryngology	O
Clinics	O
with	O
Dizziness	B-DISO
We	O
used	O
a	O
national	O
otolaryngology	O
practice	O
-	O
based	O
research	O
network	O
database	O
to	O
characterize	O
the	O
utilization	O
of	O
vestibular	B-PROC
function	I-PROC
testing	I-PROC
in	O
patients	B-LIVB
diagnosed	B-DISO
with	O
dizziness	B-DISO
and	O
/	O
or	O
a	O
vestibular	B-DISO
disorder	I-DISO
.	O

Database	O
review	O
.	O

The	O
Creating	B-PROC
Healthcare	I-PROC
Excellence	I-PROC
through	O
Education	B-PROC
and	O
Research	B-PROC
(	O
CHEER	B-PROC
)	O
practice	O
-	O
based	O
research	O
network	O
of	O
academic	O
and	O
community	B-LIVB
providers	I-LIVB
Dizzy	B-LIVB
patients	I-LIVB
in	O
the	O
CHEER	B-PROC
retrospective	B-PROC
database	I-PROC
were	O
identified	O
through	O
ICD	O
-	O
9	O
codes	O
;	O
vestibular	B-PROC
testing	I-PROC
procedures	I-PROC
were	O
identified	O
with	O
CPT	O
codes	O
.	O

Demographics	O
and	O
procedures	B-PROC
per	I-PROC
patient	I-PROC
were	O
tabulated	O
.	O

Analysis	B-PROC
included	O
number	O
and	O
type	O
of	O
vestibular	B-PROC
tests	I-PROC
ordered	O
,	O
stratified	B-PROC
by	I-PROC
individual	I-PROC
clinic	I-PROC
and	O
by	O
practice	O
type	O
(	O
community	B-LIVB
vs	O
academic	O
)	O
.	O

Chi	O
-	O
square	O
tests	O
were	O
performed	O
to	O
assess	O
if	O
the	O
percentage	O
of	O
patients	B-LIVB
receiving	I-LIVB
testing	I-LIVB
was	O
statistically	O
significant	O
across	O
clinics	O
.	O

A	O
logistic	B-PROC
regression	I-PROC
model	O
was	O
used	O
to	O
examine	O
the	O
association	O
between	O
receipt	O
of	O
testing	O
and	O
being	O
tested	O
on	O
initial	O
visit	O
.	O

A	O
total	O
of	O
12	O
,	O
468	O
patients	B-LIVB
diagnosed	B-DISO
with	O
dizziness	B-DISO
and	O
/	O
or	O
a	O
vestibular	B-DISO
disorder	I-DISO
were	O
identified	O
from	O
7	O
community	B-LIVB
and	O
5	O
academic	O
CHEER	B-PROC
network	O
clinics	B-OBJC
across	O
the	O
country	O
.	O

One	O
-	O
fifth	O
of	O
these	O
patients	B-LIVB
had	O
at	O
least	O
1	O
vestibular	B-PROC
function	I-PROC
test	I-PROC
.	O

The	O
percentage	O
of	O
patients	B-LIVB
tested	O
varied	O
widely	O
by	O
site	O
,	O
from	O
3	O
%	O
to	O
72	O
%	O
;	O
academic	B-OBJC
clinics	I-OBJC
were	O
twice	O
as	O
likely	O
to	O
test	O
.	O

Initial	O
visit	O
vestibular	B-PROC
testing	I-PROC
also	O
varied	O
,	O
from	O
0	O
%	O
to	O
96	O
%	O
of	O
dizzy	B-LIVB
patients	I-LIVB
,	O
and	O
was	O
15	O
times	O
more	O
likely	O
in	O
academic	B-OBJC
clinics	I-OBJC
.	O

There	O
is	O
significant	O
variation	O
in	O
use	O
and	O
timing	O
of	O
vestibular	B-PROC
diagnostic	I-PROC
testing	I-PROC
across	O
otolaryngology	O
clinics	O
.	O

The	O
CHEER	B-PROC
network	O
research	O
database	O
does	O
not	O
contain	O
outcome	O
data	O
.	O

These	O
results	O
illustrate	O
the	O
critical	O
need	O
for	O
research	B-PROC
that	I-PROC
examines	I-PROC
outcomes	I-PROC
as	O
related	O
to	O
vestibular	B-PROC
testing	I-PROC
.	O

Metabolomic	O
analysis	O
of	O
glycerophospholipid	B-CHEM
signatures	O
of	O
inflammation	B-DISO
treated	B-PROC
with	I-PROC
non	B-CHEM
-	I-CHEM
steroidal	I-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
-induced	O
-	O
RAW264	B-ANAT
.	I-ANAT

7	I-ANAT
cells	I-ANAT
using	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
and	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
Non	B-PROC
-	I-PROC
destructive	I-PROC
proton	I-PROC
nuclear	I-PROC
magnetic	I-PROC
resonance	I-PROC
(	I-PROC
(	I-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
)	I-PROC
spectroscopy	I-PROC
and	O
highly	O
sensitive	O
ultra	B-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	B-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
)	O
coupled	O
to	O
data	O
processing	O
methods	O
were	O
applied	O
to	O
analyze	O
the	O
metabolic	O
profiling	O
changes	O
of	O
glycerophospholipids	B-CHEM
(	O
GPLs	B-CHEM
)	O
in	O
RAW264	B-ANAT
.	I-ANAT

7	I-ANAT
cells	I-ANAT
from	O
inflammation	B-DISO
to	O
prognosis	B-PROC
.	O

Analysis	B-PROC
of	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
was	O
shown	O
that	O
the	O
models	O
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non	O
-	O
targeted	O
and	O
non	O
-	O
destructively	O
advantages	O
of	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
in	O
the	O
metabolic	O
profiling	O
of	O
GPLs	B-CHEM
.	O

58	O
GPLs	B-CHEM
were	O
identified	O
by	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	B-PROC
compared	O
with	O
our	O
previous	O
results	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	B-PHYS
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B-CHEM
(	O
PC	B-CHEM
)	O
(	O
16	O
:	O
0	O
/	O
18	O
:	O
1	O
)	O
and	O
(	O
18	O
:	O
0	O
/	O
18	O
:	O
1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	B-PHYS
.	O

Compared	O
with	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
,	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-PROC
of	O
biomarkers	B-PHYS
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	B-PROC
preparation	I-PROC
steps	I-PROC
and	O
unambiguous	O
metabolite	B-CHEM
identification	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
GPLs	B-CHEM
during	O
inflammation	B-DISO
by	O
combining	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
spectroscopy	I-PROC
with	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
.	O

The	O
metabolic	O
profiling	O
of	O
GPLs	B-CHEM
provides	O
valuable	O
evidence	O
for	O
inflammation	B-DISO
diagnosis	B-DISO
and	O
prognosis	B-PROC
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	B-DISO
progression	B-DISO
.	O

Design	O
considerations	B-DISO
for	O
patient	O
-	O
specific	O
surgical	B-DEVI
templates	I-DEVI
for	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
with	O
respect	O
to	O
acetabular	B-ANAT
cartilage	O
Patient	B-DEVI
-	I-DEVI
specific	I-DEVI
instruments	I-DEVI
(	O
PSIs	B-DEVI
)	O
are	O
clinically	O
used	O
to	O
support	O
the	O
surgeon	B-LIVB
during	O
a	O
planned	O
intervention	O
.	O

The	O
planning	B-PHYS
is	O
typically	O
done	O
based	O
on	O
volumetric	O
image	O
data	O
from	O
medical	B-PROC
imaging	I-PROC
systems	O
,	O
e	O
.	O

g	O
.	O

computed	B-PROC
tomography	I-PROC
(	O
CT	B-PROC
)	O
.	O

The	O
PSI	B-DEVI
uses	O
the	O
known	O
surface	B-ANAT
structure	I-ANAT
of	I-ANAT
a	I-ANAT
bone	I-ANAT
for	O
orientation	O
during	O
the	O
intervention	B-PROC
.	O

Some	O
surfaces	B-ANAT
of	I-ANAT
human	I-ANAT
bone	I-ANAT
are	O
covered	O
with	O
a	O
layer	B-ANAT
of	O
cartilage	O
which	O
is	O
hardly	B-DISO
visible	O
in	O
clinically	O
applied	O
CT	B-PROC
-	I-PROC
imaging	I-PROC
.	O

This	O
experimental	B-PROC
study	I-PROC
investigates	O
ten	O
different	O
PSI	B-DEVI
designs	O
and	O
their	O
effect	O
to	O
the	O
overall	O
accuracy	O
when	O
neglecting	O
the	O
cartilage	O
in	O
the	O
design	O
process	B-PHEN
.	O

Therefore	O
,	O
a	O
model	B-DEVI
of	O
an	O
acetabulum	B-ANAT
is	O
used	O
to	O
simulate	B-PROC
the	O
use	O
case	O
of	O
PSI	B-DEVI
in	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
.	O

The	O
concept	O
of	O
the	O
different	O
designs	O
is	O
to	O
create	O
structural	O
elasticities	O
in	O
the	O
PSI	B-DEVI
to	O
avoid	O
shifting	O
of	O
the	O
whole	O
instrument	B-DEVI
and	O
rather	O
have	O
a	O
small	O
part	O
of	O
it	O
deformed	O
by	O
cartilage	O
.	O

A	O
needle	B-DEVI
array	I-DEVI
structure	I-DEVI
,	O
for	O
instance	O
,	O
should	O
also	O
be	O
able	O
to	O
oust	O
or	O
penetrate	O
remaining	O
soft	O
tissue	O
in	O
the	O
acetabulum	B-ANAT
.	O

The	O
nurse	O
-	O
patient	O
communication	O
:	O
voices	O
from	O
nursing	B-LIVB
students	I-LIVB
Effective	B-PHYS
communication	I-PHYS
skills	I-PHYS
have	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
pivotal	O
factors	O
in	O
building	O
positive	O
interpersonal	O
relationships	O
.	O

Little	O
is	O
known	O
about	O
nursing	B-LIVB
undergraduates	I-LIVB
'	O
perspectives	O
on	O
communicating	O
with	O
patients	B-LIVB
.	O

This	O
study	B-PROC
aimed	O
to	O
explore	O
nursing	B-LIVB
students	I-LIVB
'	I-LIVB
perspectives	O
and	O
experiences	B-PHYS
of	O
nurse	O
-	O
patient	O
communication	O
in	O
their	O
clinical	O
placement	O
.	O

The	O
participants	B-LIVB
included	O
21	O
second	B-LIVB
-	I-LIVB
year	I-LIVB
undergraduates	I-LIVB
and	O
21	O
first	B-LIVB
-	I-LIVB
year	I-LIVB
master	I-LIVB
's	I-LIVB
students	I-LIVB
.	O

Interviews	O
were	O
conducted	O
in	O
Cantonese	O
and	O
then	O
transcribed	O
in	O
Chinese	O
and	O
translated	O
into	O
English	O
.	O

A	O
content	B-PROC
analysis	I-PROC
approach	O
was	O
adopted	O
to	O
analyze	O
the	O
data	O
.	O

Five	O
themes	O
emerged	O
from	O
the	O
interview	O
data	O
.	O
'	O
The	O
necessity	O
of	O
nurse	O
-	O
patient	O
communication	O
'	O
reveals	O
why	O
the	O
students	B-LIVB
valued	O
nurse	O
-	O
patient	O
communication	O
.	O
'	O
The	O
conversation	B-DISO
contents	I-DISO
'	O
describes	O
the	O
content	B-DISO
of	I-DISO
the	I-DISO
conversations	I-DISO
that	O
students	B-LIVB
typically	O
had	O
with	O
patients	B-LIVB
.	O

The	O
third	O
theme	O
is	O
'	O
self	B-DISO
-	I-DISO
reflection	I-DISO
on	O
the	O
nurse	O
-	O
patient	O
communication	O
'	O
.	O

The	O
last	O
two	O
themes	O
,	O
'	O
the	O
communication	B-DISO
pattern	I-DISO
in	I-DISO
different	I-DISO
hospital	B-OBJC
settings	I-OBJC
'	O
and	O
'	O
the	O
obstacles	O
impeding	O
nurse	O
-	O
patient	O
communication	O
'	O
,	O
are	O
about	O
the	O
students	B-LIVB
'	I-LIVB
communication	O
styles	O
in	O
different	O
hospitals	B-OBJC
and	O
the	O
barriers	O
they	O
encounter	O
.	O

To	O
improve	B-DISO
students	B-LIVB
'	I-LIVB
communication	B-PHYS
skills	I-PHYS
,	O
educators	B-LIVB
and	O
clinical	B-LIVB
staff	I-LIVB
should	O
listen	O
to	O
students	B-LIVB
,	O
enhance	O
students	B-LIVB
'	I-LIVB
reflective	O
skills	O
and	O
strengthen	O
their	O
confidence	B-PHYS
.	O

Through	O
understanding	B-PHYS
students	B-LIVB
'	I-LIVB
difficulties	O
in	O
the	O
nurse	O
-	O
patient	O
communication	O
experience	B-PHYS
and	O
the	O
skills	O
that	O
they	O
lack	O
,	O
educators	B-LIVB
can	O
provide	O
them	O
with	O
helpful	O
recommendations	O
to	O
improve	B-DISO
their	O
communication	B-PHYS
skills	I-PHYS
in	O
clinical	O
practice	O
.	O

The	O
results	O
of	O
this	O
study	B-PROC
reveal	O
that	O
students	B-LIVB
'	I-LIVB
nurse	O
-	O
patient	O
communication	O
skills	B-PHYS
need	O
to	O
be	O
improved	B-DISO
.	O

Fabrication	B-PHEN
and	O
characterization	O
of	O
poly	B-CHEM
(	I-CHEM
vinyl	I-CHEM
alcohol	I-CHEM
)	I-CHEM
-	O
TiO2	B-CHEM
nanocomposite	B-OBJC
films	B-OBJC
for	O
orthopedic	B-PROC
applications	I-PROC
Poly	B-CHEM
(	I-CHEM
vinyl	I-CHEM
alcohol	I-CHEM
)	I-CHEM
(	O
PVA	B-CHEM
)	O
is	O
reinforced	O
with	O
TiO2	B-CHEM
nanoparticles	B-OBJC
in	O
order	O
to	O
enhance	O
thermo	O
-	O
mechanical	O
stabilities	O
,	O
surface	O
characteristics	O
and	O
osteoblastic	B-ANAT
cell	B-PHYS
adhesion	I-PHYS
.	O

PVA	B-CHEM
-	O
TiO2	B-CHEM
nanocomposite	B-OBJC
films	B-OBJC
with	O
desirable	O
mechanical	O
,	O
thermal	O
and	O
biocompatible	O
properties	O
are	O
fabricated	O
through	O
solution	B-PHEN
casting	I-PHEN
method	I-PHEN
followed	O
by	O
de	B-PHEN
-	I-PHEN
hydrothermal	I-PHEN
cross	I-PHEN
-	I-PHEN
linking	I-PHEN
treatment	I-PHEN
.	O

The	O
composition	B-PHEN
of	O
TiO2	B-CHEM
nanoparticles	B-OBJC
was	O
standardized	O
to	O
achieve	O
mechanically	O
stable	O
nanocomposite	B-OBJC
films	B-OBJC
,	O
based	O
on	O
tensile	O
strength	O
measurements	O
composition	B-PHEN
of	O
TiO2	B-CHEM
is	O
determined	O
as	O
optimal	O
at	O
3wt	O
%	O
.	O

PVA	B-CHEM
-	O
TiO2	B-CHEM
nanocomposite	B-OBJC
films	B-OBJC
were	O
characterized	O
by	O
Scanning	B-PROC
electron	I-PROC
microscopy	I-PROC
,	O
Energy	B-PROC
dispersive	I-PROC
spectroscopy	I-PROC
,	O
Atomic	B-PROC
force	I-PROC
microscopy	I-PROC
,	O
Ultra	B-PROC
violet	I-PROC
and	O
Fourier	B-PROC
transform	I-PROC
infrared	I-PROC
spectroscopic	I-PROC
techniques	I-PROC
.	O

Elemental	B-PROC
mapping	I-PROC
studies	I-PROC
substantiate	O
incorporation	O
of	O
TiO2	B-CHEM
nanoparticles	B-OBJC
within	O
the	O
PVA	B-CHEM
matrix	B-CHEM
.	O

Dimensional	O
stability	O
evaluated	O
by	O
soaking	O
films	B-OBJC
in	O
SBF	B-OBJC
for	O
24h	O
insinuates	O
the	O
role	O
of	O
TiO2	B-CHEM
in	O
the	O
direction	O
of	O
controlling	O
degree	O
of	O
swelling	O
.	O

In	B-PROC
-	I-PROC
vitro	I-PROC
bioactivity	I-PROC
test	I-PROC
and	O
cell	B-PHYS
adhesion	I-PHYS
results	O
also	O
predict	O
that	O
presence	O
of	O
TiO2	B-CHEM
is	O
advantageous	O
to	O
enhance	O
apatite	B-PHEN
growth	I-PHEN
and	O
promote	O
cell	B-ANAT
-	O
substrate	B-OBJC
interaction	O
.	O

SEM	B-PROC
studies	I-PROC
illustrate	O
improved	O
surface	O
morphology	O
of	O
PVA	B-CHEM
-	O
TiO2	B-CHEM
nanocomposite	B-OBJC
film	B-OBJC
with	O
homogenously	O
distributed	O
TiO2	B-CHEM
nanoparticles	B-OBJC
,	O
which	O
help	O
to	O
enhance	O
thermo	O
-	O
mechanical	O
behavior	O
.	O

TiO2	B-CHEM
nanoparticles	B-OBJC
construct	O
cell	O
-	O
adhesive	O
hydrophilic	O
nano	O
-	O
domains	O
that	O
act	O
as	O
potential	O
cell	B-PHYS
adhesion	I-PHYS
sites	O
and	O
promotes	O
osteointegration	O
.	O

Bio	B-PROC
compatibility	I-PROC
studies	I-PROC
proved	O
that	O
thermally	O
cross	O
-	O
linked	O
PVA	B-CHEM
is	O
non	B-DISO
-	I-DISO
toxic	I-DISO
in	O
relation	O
to	O
PVA	B-CHEM
cross	O
-	O
linked	O
with	O
glutaraldehyde	B-CHEM
.	O

Cytotoxicity	B-DISO
and	O
cell	B-PHYS
adhesion	I-PHYS
of	O
nanocomposite	B-OBJC
films	B-OBJC
evaluated	O
through	O
cell	B-PROC
viability	I-PROC
(	I-PROC
MMT	I-PROC
)	I-PROC
assay	I-PROC
and	O
crystal	B-PROC
violet	I-PROC
staining	I-PROC
revealed	O
that	O
PVA	B-CHEM
-3wt	O
%	O
TiO2	B-CHEM
nanocomposite	B-OBJC
could	O
act	O
as	O
an	O
excellent	O
composite	O
and	O
hence	O
suitable	O
to	O
be	O
used	O
in	O
bone	B-DEVI
implant	I-DEVI
applications	I-DEVI
.	O

Characterization	O
of	O
novel	O
DeoR	B-CHEM
-	I-CHEM
family	I-CHEM
member	B-LIVB
from	O
the	O
Streptomyces	B-LIVB
ahygroscopicus	I-LIVB
strain	B-LIVB
CK	I-LIVB
-	I-LIVB
15	I-LIVB
that	O
acts	O
as	O
a	O
repressor	B-CHEM
of	O
morphological	O
development	O
Wuyiencin	B-CHEM
is	O
produced	O
by	O
Streptomyces	B-LIVB
ahygroscopicus	I-LIVB
var	I-LIVB
.	I-LIVB

wuyiensis	I-LIVB
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
China	B-GEOG
as	O
an	O
industrially	O
produced	O
biopesticide	B-CHEM
to	O
control	O
various	O
fungal	B-DISO
diseases	I-DISO
.	O

Although	O
its	O
mechanism	O
of	O
action	O
,	O
breeding	B-PHYS
,	O
and	O
fermentation	B-PHYS
had	O
been	O
extensively	O
characterized	O
,	O
less	O
is	O
known	O
about	O
the	O
regulatory	B-PHYS
functions	I-PHYS
that	O
affect	O
its	O
biosynthesis	O
or	O
morphological	O
development	O
.	O

The	O
wysR3	O
gene	O
of	O
S	B-LIVB
.	I-LIVB

ahygroscopicus	I-LIVB
strain	B-LIVB
CK	I-LIVB
-	I-LIVB
15	I-LIVB
,	O
a	O
novel	O
member	B-LIVB
of	O
the	O
DeoR	B-CHEM
family	I-CHEM
of	O
regulatory	O
genes	O
,	O
was	O
assessed	O
to	O
determine	O
its	O
function	O
by	O
gene	B-PROC
knockdown	I-PROC
.	O

Herein	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
DeoR	B-CHEM
family	I-CHEM
proteins	I-CHEM
derived	O
from	O
the	O
same	O
source	B-DISO
are	O
likely	O
to	O
be	O
a	O
single	O
branch	O
in	O
a	O
phylogenetic	O
tree	O
and	O
show	O
that	O
wysR3	O
acts	O
as	O
a	O
repressor	B-CHEM
for	O
its	O
morphological	O
development	O
without	O
effecting	O
wuyiencin	B-CHEM
production	O
.	O

We	O
found	O
that	O
the	O
ΔwysR3	O
strain	B-LIVB
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	O
stage	O
of	O
maximum	O
biomass	O
at	O
60	O
h	O
,	O
which	O
is	O
~12	O
h	O
faster	O
than	O
the	O
wild	O
-	O
type	O
strain	B-LIVB
.	O

In	O
the	O
industrial	O
fermentation	B-PHYS
production	O
process	B-PHEN
,	O
the	O
ΔwysR3	O
strain	B-LIVB
can	O
reduce	O
consumption	O
and	O
save	O
both	O
time	O
and	O
money	B-OBJC
.	O

Targeting	O
the	O
ecology	O
within	O
:	O
The	O
role	O
of	O
the	O
gut	O
-	O
brain	O
axis	O
and	O
human	B-LIVB
microbiota	B-LIVB
in	O
drug	B-DISO
addiction	I-DISO
Despite	O
major	O
advances	O
in	O
our	O
understanding	B-PHYS
of	O
the	O
brain	B-ANAT
using	O
traditional	O
neuroscience	O
,	O
reliable	O
and	O
efficacious	O
treatments	B-PROC
for	O
drug	B-DISO
addiction	I-DISO
have	O
remained	B-DISO
elusive	I-DISO
.	O

Hence	O
,	O
the	O
time	O
has	O
come	O
to	O
utilize	O
novel	O
approaches	O
,	O
particularly	O
those	O
drawing	O
upon	O
contemporary	O
advances	O
in	O
fields	O
outside	O
of	O
established	O
neuroscienc	O
e	O
and	O
psychiatry	O
.	O

Put	O
another	O
way	O
,	O
the	O
time	O
has	O
come	O
for	O
a	O
paradigm	B-PROC
shift	I-PROC
in	O
the	O
addiction	B-DISO
sciences	O
.	O

Apropos	O
,	O
a	O
revolution	O
in	O
the	O
area	O
of	O
human	B-LIVB
health	O
is	O
underway	O
,	O
which	O
is	O
occurring	O
at	O
the	O
nexus	O
between	O
enteric	O
microbiology	O
and	O
neuroscience	O
.	O

It	O
has	O
become	O
increasingly	O
clear	O
that	O
the	O
human	B-LIVB
microbiota	B-LIVB
(	O
the	O
vast	O
ecology	O
of	O
bacteria	B-LIVB
residing	O
within	O
the	O
human	B-LIVB
organism	B-LIVB
)	O
,	O
plays	O
an	O
important	O
role	O
in	O
health	O
and	O
disease	B-DISO
.	O

This	O
is	O
not	O
surprising	O
,	O
as	O
it	O
has	O
been	O
estimated	O
that	O
bacteria	B-LIVB
living	O
in	O
the	O
human	B-LIVB
body	I-LIVB
(	O
approximately	O
1	O
kg	O
of	O
mass	O
,	O
roughly	O
equivalent	O
to	O
that	O
of	O
the	O
human	B-LIVB
brain	B-ANAT
)	O
outnumber	O
human	B-PHEN
cells	I-PHEN
10	O
to	O
1	O
.	O

While	O
advances	O
in	O
the	O
understanding	B-PHYS
of	O
the	O
role	O
of	O
microbiota	B-LIVB
in	O
other	O
areas	O
of	O
human	B-LIVB
health	O
have	O
yielded	O
intriguing	O
results	O
(	O
e	O
.	O
g	O
.	O
,	O
Clostridium	B-DISO
difficile	I-DISO
,	O
irritable	B-DISO
bowel	I-DISO
syndrome	I-DISO
,	O
autism	B-DISO
,	O
etc	O
.	O
)	O
,	O
to	O
date	O
,	O
no	O
systematic	O
programs	O
of	O
research	B-PROC
have	O
examined	B-DISO
the	O
role	O
of	O
microbiota	B-LIVB
in	O
drug	B-DISO
addiction	I-DISO
.	O

The	O
current	O
hypothesis	O
,	O
therefore	O
,	O
is	O
that	O
gut	B-DISO
dysbiosis	I-DISO
plays	O
a	O
key	O
role	O
in	O
addictive	B-DISO
disorders	B-DISO
.	O

In	O
the	O
context	O
of	O
this	O
hypothesis	O
,	O
this	O
paper	O
provides	O
a	O
rationale	O
for	O
future	O
research	B-PROC
to	O
target	O
the	O
""""	O
gut	B-ANAT
-	O
brain	B-ANAT
axis	O
""""	O
in	O
addiction	B-DISO
.	O

A	O
brief	O
background	O
of	O
the	O
gut	B-ANAT
-	O
brain	B-ANAT
axis	O
is	O
provided	O
,	O
along	O
with	O
a	O
series	O
of	O
hypothesis	O
-	O
driven	O
ideas	O
outlining	O
potential	O
treatments	B-PROC
for	O
addiction	B-DISO
via	O
manipulations	B-DISO
of	O
the	O
""""	O
ecology	O
within	O
.	O
""""	O

Homogeneous	O
synthesis	O
of	O
Ag	B-OBJC
nanoparticles	I-OBJC
-doped	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
cellulose	I-CHEM
acetate	I-CHEM
for	O
versatile	O
applications	O
We	O
report	O
a	O
facile	O
and	O
efficient	O
approach	O
for	O
synthesis	O
of	O
well	O
-	O
dispersed	O
and	O
stable	O
silver	B-OBJC
nanoparticles	I-OBJC
(	O
Ag	B-OBJC
NPs	I-OBJC
)	O
using	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
cellulose	I-CHEM
acetate	I-CHEM
(	O
CA	B-CHEM
)	O
as	O
both	O
reductant	B-CHEM
and	O
stabilizer	B-OBJC
.	O

Partially	O
substituted	O
CA	B-CHEM
with	O
highly	O
active	O
hydroxyl	B-CHEM
groups	I-CHEM
and	O
excellent	O
water	O
-	O
solubility	O
is	O
able	B-DISO
to	O
reduce	B-PHEN
silver	B-CHEM
ions	I-CHEM
in	O
homogeneous	O
aqueous	O
medium	B-OBJC
effectively	O
.	O

The	O
synthesized	O
Ag	B-OBJC
NPs	I-OBJC
were	O
characterized	O
by	O
UV	B-PROC
-	I-PROC
vis	I-PROC
spectroscopy	I-PROC
,	O
X	B-PROC
-	I-PROC
ray	I-PROC
diffraction	I-PROC
,	O
X	B-PROC
-	I-PROC
ray	I-PROC
photoelectron	I-PROC
spectroscopy	I-PROC
,	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
and	O
energy	B-PROC
dispersive	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
spectroscope	I-PROC
analysis	B-PROC
.	O

The	O
as	O
-	O
prepared	B-DISO
Ag	B-OBJC
NPs	I-OBJC
were	O
well	O
-	O
dispersed	O
,	O
showing	O
a	O
surface	B-PROC
plasmon	I-PROC
resonance	I-PROC
peak	O
at	O
426	O
nm	O
.	O

The	O
resulted	O
Ag	B-OBJC
NPs	I-OBJC
@	O
CA	B-CHEM
nanohybrids	B-OBJC
exhibit	O
high	O
catalytic	O
activity	O
for	O
the	O
reduction	B-PHEN
of	O
4	B-CHEM
-	I-CHEM
nitrophenol	I-CHEM
to	O
4	B-CHEM
-	I-CHEM
aminophenol	I-CHEM
in	O
the	O
presence	O
of	O
NaBH4	B-CHEM
.	O

Meanwhile	O
,	O
the	O
nanohybrids	B-OBJC
are	O
also	O
effective	O
in	O
inhibiting	O
the	O
growth	B-PHYS
of	O
bacterial	B-LIVB
.	O

This	O
environmentally	O
friendly	O
method	O
promotes	O
the	O
use	O
of	O
renewable	O
natural	O
resources	O
to	O
prepare	O
a	O
variety	O
of	O
inorganic	B-OBJC
-	I-OBJC
organic	I-OBJC
materials	I-OBJC
for	O
catalysis	B-PHEN
,	O
antibacterial	B-CHEM
,	O
sensors	B-OBJC
and	O
other	O
applications	O
.	O

Acceleration	B-PHEN
of	O
Acid	B-PHEN
-	I-PHEN
Catalyzed	I-PHEN
Hydrolysis	B-PHEN
in	O
a	O
Biphasic	O
System	O
by	O
Sodium	B-CHEM
Tetracyanocyclopentadienides	I-CHEM
The	O
hydrolysis	B-PHEN
of	O
tert	B-CHEM
-	I-CHEM
butyldimethylsilyl	I-CHEM
L	I-CHEM
-	I-CHEM
menthyl	I-CHEM
ether	I-CHEM
(	O
3	O
)	O
in	O
a	O
CH2Cl2	B-CHEM
-1	O
M	O
HCl	B-CHEM
biphasic	O
solvent	B-CHEM
system	I-CHEM
was	O
accelerated	B-PHEN
by	O
the	O
addition	O
of	O
sodium	B-CHEM
tetracyanocyclopentadienides	I-CHEM
1	I-CHEM
.	O

Particularly	O
,	O
the	O
reaction	O
rate	O
was	O
enhanced	O
using	O
sodium	B-CHEM
salt	I-CHEM
1a	I-CHEM
-	I-CHEM
c	I-CHEM
with	O
a	O
lipophilic	B-OBJC
substituent	I-OBJC
on	O
the	O
cyclopentadienide	B-CHEM
ring	I-CHEM
.	O

From	O
the	O
results	O
obtained	O
by	O
a	O
triphasic	O
experiment	B-PROC
,	O
hydrolysis	B-PHEN
proceeds	O
via	O
the	O
formation	O
of	O
hydronium	B-CHEM
ion	I-CHEM
2	I-CHEM
in	O
the	O
aqueous	O
phase	O
by	O
ion	B-PHYS
exchange	I-PHYS
,	O
followed	O
by	O
the	O
transfer	O
of	O
2	O
to	O
the	O
CH2Cl2	B-CHEM
phase	I-CHEM
.	O

A	O
novel	O
,	O
lineage	O
-	O
primed	O
prestalk	B-ANAT
cell	I-ANAT
subtype	O
involved	O
in	O
the	O
morphogenesis	B-PHYS
of	O
D	O
.	O

discoideum	O
Dictyostelium	O
morphogenesis	B-PHYS
requires	O
the	O
tip	O
,	O
which	O
acts	O
as	O
an	O
organizer	B-DEVI
and	O
conducts	O
orchestrated	B-PHYS
cell	I-PHYS
movement	I-PHYS
and	O
cell	B-PHYS
differentiation	I-PHYS
.	O

At	O
the	O
slug	O
stage	O
the	O
tip	O
region	O
contains	O
prestalk	B-ANAT
A	I-ANAT
(	I-ANAT
pstA	I-ANAT
)	I-ANAT
cells	I-ANAT
,	O
which	O
are	O
usually	O
recognized	O
by	O
their	O
expression	B-PHYS
of	O
reporter	O
constructs	O
that	O
utilize	O
a	O
fragment	O
of	O
the	O
promoter	B-CHEM
of	O
the	O
ecmA	O
gene	O
.	O

Here	O
,	O
using	O
the	O
promoter	B-CHEM
region	I-CHEM
of	O
the	O
o	O
-	O
methyl	O
transferase	O
12	O
gene	O
(	O
omt12	O
)	O
to	O
drive	O
reporter	B-PHYS
expression	I-PHYS
,	I-PHYS
we	O
demonstrate	O
the	O
presence	O
,	O
also	O
within	O
the	O
pstA	O
region	O
,	O
of	O
a	O
novel	O
prestalk	B-ANAT
cell	I-ANAT
subtype	O
:	O
the	O
pstV	B-ANAT
(	I-ANAT
A	I-ANAT
)	I-ANAT
cells	I-ANAT
.	O

Surprisingly	O
,	O
a	O
sub	O
-	O
population	O
of	O
the	O
vegetative	B-PHYS
cells	I-PHYS
express	O
a	O
pstV	B-PHYS
(	I-PHYS
A	I-PHYS
)	I-PHYS
:	I-PHYS
GFP	I-PHYS
marker	I-PHYS
and	O
,	O
sort	O
out	O
to	O
the	O
tip	O
,	O
both	O
when	O
developing	O
alone	O
and	O
when	O
co	O
-	O
developed	O
with	O
an	O
excess	O
of	O
unmarked	B-ANAT
cells	I-ANAT
.	O

The	O
development	O
of	O
such	O
a	O
purified	O
GFP	B-ANAT
-	I-ANAT
marked	I-ANAT
population	I-ANAT
is	O
greatly	O
accelerated	O
:	O
by	O
precocious	O
cell	B-PHYS
aggregation	I-PHYS
and	O
tip	O
formation	O
with	O
accompanying	O
precocious	O
elevation	O
of	O
developmental	O
gene	B-PHYS
transcription	I-PHYS
.	O

We	O
therefore	O
suggest	O
that	O
the	O
tip	O
contains	O
at	O
least	O
two	O
prestalk	B-ANAT
cell	I-ANAT
subtypes	O
:	O
the	O
developmentally	O
-	O
specified	B-ANAT
pstA	I-ANAT
cells	I-ANAT
and	O
the	O
lineage	O
-	O
primed	O
pstV	B-ANAT
(	I-ANAT
A	I-ANAT
)	I-ANAT
cells	I-ANAT
.	O

It	O
is	O
presumably	O
the	O
pstV	B-ANAT
(	I-ANAT
A	I-ANAT
)	I-ANAT
cells	I-ANAT
that	O
play	O
the	O
dominant	O
role	O
in	O
morphogenesis	B-PHYS
during	O
the	O
earlier	O
stages	O
of	O
development	B-PHYS
.	O

The	O
basis	O
for	O
the	O
lineage	O
priming	O
is	O
,	O
however	O
,	O
unclear	O
because	O
we	O
can	O
find	O
no	O
correlation	O
between	O
pstV	B-PHYS
(	I-PHYS
A	I-PHYS
)	I-PHYS
differentiation	I-PHYS
and	O
nutrient	B-OBJC
status	O
during	O
growth	B-PHYS
or	O
cell	B-PHYS
cycle	I-PHYS
position	I-PHYS
at	O
the	O
time	O
of	O
starvation	B-DISO
,	O
the	O
two	O
known	O
determinants	O
of	O
probable	O
cell	B-PHYS
fate	I-PHYS
.	O

ISX	B-CHEM
-	I-CHEM
9	I-CHEM
can	O
potentiate	O
cell	B-PHYS
proliferation	I-PHYS
and	O
neuronal	B-ANAT
commitment	B-PHYS
in	O
the	O
rat	B-LIVB
dentate	B-ANAT
gyrus	I-ANAT
Adult	B-LIVB
hippocampal	B-ANAT
neurogenesis	B-PHYS
can	O
be	O
modulated	O
by	O
various	O
physiological	B-PHYS
and	O
pathological	B-DISO
conditions	I-DISO
,	O
including	O
stress	B-DISO
,	O
affective	B-DISO
disorders	I-DISO
,	O
and	O
several	O
neurological	O
conditions	O
.	O

Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	B-PHYS
plasticity	I-PHYS
in	O
the	O
functioning	B-PHYS
of	O
the	O
hippocampus	B-ANAT
(	O
namely	O
learning	B-PHYS
and	O
memory	B-PHYS
and	O
affective	O
behaviors	O
)	O
,	O
it	O
is	O
believed	O
that	O
alterations	O
in	O
hippocampal	B-ANAT
neurogenesis	B-PHYS
might	O
underlie	O
some	O
of	O
the	O
behavioral	O
deficits	O
associated	O
with	O
these	O
psychiatric	O
and	O
neurological	O
conditions	O
.	O

Thus	O
,	O
the	O
search	O
for	O
compounds	B-CHEM
that	O
can	O
reverse	O
these	O
deficits	O
with	O
minimal	O
side	B-DISO
effects	I-DISO
has	O
become	O
a	O
recognized	O
priority	O
.	O

In	O
the	O
present	O
study	B-PROC
we	O
tested	O
the	O
pro	O
-	O
neurogenic	O
effects	O
of	O
isoxazole	B-CHEM
9	I-CHEM
(	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
)	O
,	O
a	O
small	O
synthetic	O
molecule	B-OBJC
that	O
has	O
been	O
recently	O
identified	O
through	O
the	O
screening	B-PROC
of	I-PROC
chemical	I-PROC
libraries	I-PROC
in	O
stem	B-PROC
cell	I-PROC
-	I-PROC
based	I-PROC
assays	I-PROC
.	O

We	O
found	O
that	O
administration	B-PROC
of	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	B-PHYS
proliferation	I-PHYS
and	O
increase	O
the	O
number	O
of	O
immature	O
neurons	B-ANAT
in	O
the	O
hippocampal	B-ANAT
DG	B-ANAT
of	O
adult	B-LIVB
rats	B-LIVB
.	O

In	O
addition	O
,	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
treatment	B-PROC
was	O
able	O
to	O
completely	O
reverse	O
the	O
marked	O
reduction	O
in	O
these	O
initial	O
stages	O
of	O
the	O
neurogenic	B-PHYS
process	I-PHYS
observed	O
in	O
vehicle	B-CHEM
-	O
treated	O
animals	B-LIVB
(	O
which	O
were	O
submitted	O
to	O
repeated	O
handling	B-PROC
and	O
exposure	O
to	O
daily	O
intraperitoneal	B-PROC
injections	I-PROC
)	O
.	O

Based	O
on	O
these	O
results	B-PHEN
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	B-PHYS
studies	B-PROC
that	O
require	O
repeated	O
handling	B-PROC
and	O
manipulation	B-PROC
of	O
animals	B-LIVB
should	O
include	O
a	O
naïve	O
(	O
non	O
-	O
manipulated	O
)	O
control	O
to	O
determine	O
the	O
baseline	O
levels	O
of	O
hippocampal	B-ANAT
cell	B-PHYS
proliferation	I-PHYS
and	O
neuronal	B-ANAT
differentiation	B-PHYS
.	O

Overall	O
,	O
these	O
findings	B-DISO
demonstrate	O
that	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
is	O
a	O
promising	O
synthetic	O
compound	B-CHEM
for	O
the	O
mitigation	B-PHEN
of	O
stress	B-DISO
-	O
induced	O
deficits	O
in	O
adult	B-LIVB
hippocampal	B-ANAT
neurogenesis	B-PHYS
.	O

Future	O
studies	B-PROC
are	O
thus	O
warranted	O
to	O
evaluate	B-PROC
the	O
pro	O
-	O
neurogenic	O
properties	O
of	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
in	O
animal	B-LIVB
models	I-LIVB
of	O
affective	B-DISO
and	O
neurological	B-DISO
disorders	I-DISO
associated	O
with	O
impaired	O
hippocampal	B-ANAT
structural	B-PHYS
plasticity	I-PHYS
.	O

NBLAST	O
:	O
Rapid	O
,	O
Sensitive	O
Comparison	O
of	O
Neuronal	B-ANAT
Structure	O
and	O
Construction	O
of	O
Neuron	B-ANAT
Family	O
Databases	O
Neural	O
circuit	O
mapping	O
is	O
generating	O
datasets	O
of	O
tens	O
of	O
thousands	O
of	O
labeled	O
neurons	B-ANAT
.	O

New	O
computational	O
tools	O
are	O
needed	O
to	O
search	O
and	O
organize	O
these	O
data	O
.	O

We	O
present	O
NBLAST	O
,	O
a	O
sensitive	O
and	O
rapid	O
algorithm	O
,	O
for	O
measuring	O
pairwise	O
neuronal	O
similarity	O
.	O

NBLAST	O
considers	O
both	O
position	O
and	O
local	O
geometry	O
,	O
decomposing	O
neurons	B-ANAT
into	O
short	O
segments	O
;	O
matched	O
segments	O
are	O
scored	O
using	O
a	O
probabilistic	O
scoring	O
matrix	O
defined	O
by	O
statistics	O
of	O
matches	O
and	O
non	O
-	O
matches	O
.	O

We	O
validated	O
NBLAST	O
on	O
a	O
published	O
dataset	O
of	O
16	O
,	O
129	O
single	O
Drosophila	O
neurons	B-ANAT
.	O

NBLAST	O
can	O
distinguish	O
neuronal	B-ANAT
types	O
down	O
to	O
the	O
finest	O
level	O
(	O
single	O
identified	O
neurons	B-ANAT
)	O
without	O
a	O
priori	O
information	O
.	O

Cluster	B-PROC
analysis	I-PROC
of	O
extensively	O
studied	O
neuronal	B-ANAT
classes	O
identified	O
new	O
types	O
and	O
unreported	B-DISO
topographical	O
features	O
.	O

Fully	B-PROC
automated	I-PROC
clustering	I-PROC
organized	O
the	O
validation	B-PROC
dataset	O
into	O
1	O
,	O
052	O
clusters	O
,	O
many	O
of	O
which	O
map	O
onto	O
previously	O
described	O
neuronal	B-ANAT
types	O
.	O

NBLAST	O
supports	O
additional	O
query	O
types	O
,	O
including	O
searching	O
neurons	B-ANAT
against	O
transgene	O
expression	O
patterns	O
.	O

Finally	O
,	O
we	O
show	O
that	O
NBLAST	O
is	O
effective	O
with	O
data	O
from	O
other	O
invertebrates	O
and	O
zebrafish	B-LIVB
.	O

Components	O
of	O
treatment	B-PROC
delay	O
in	O
rheumatoid	B-DISO
arthritis	I-DISO
differ	O
according	O
to	O
autoantibody	B-CHEM
status	O
:	O
validation	B-PROC
of	O
a	O
single	O
-	O
centre	O
observation	O
using	O
national	O
audit	O
data	O
To	O
determine	O
whether	O
time	O
to	O
treatment	O
following	O
symptom	O
onset	O
differs	O
between	O
RA	B-DISO
patients	B-LIVB
according	O
to	O
autoantibody	B-CHEM
status	O
.	O

A	O
single	O
-	O
centre	O
retrospective	O
analysis	B-PROC
of	O
a	O
UK	B-GEOG
early	O
RA	B-DISO
inception	O
cohort	O
was	O
first	O
undertaken	O
to	O
identify	O
those	O
components	O
of	O
the	O
patient	B-LIVB
journey	O
that	O
differed	O
by	O
serological	O
subtype	O
.	O

Data	O
from	O
a	O
UK	B-GEOG
national	O
audit	O
of	O
early	O
inflammatory	B-DISO
arthritis	I-DISO
patients	B-LIVB
was	O
accessed	O
to	O
replicate	O
the	O
key	O
finding	B-DISO
.	O

A	O
total	O
of	O
173	O
RA	B-DISO
patients	B-LIVB
were	O
diagnosed	B-PROC
over	O
a	O
31	O
-	O
month	O
period	O
,	O
of	O
whom	O
80	O
(	O
46	O
%	O
)	O
were	O
ACPA	B-PHEN
/	I-PHEN
RF	I-PHEN
double	I-PHEN
-	I-PHEN
seropositive	I-PHEN
(	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
)	O
,	O
53	O
(	O
31	O
%	O
)	O
ACPA	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
,	O
17	O
(	O
10	O
%	O
)	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
and	O
23	O
(	O
13	O
%	O
)	O
RF	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
ACPA	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
Overall	O
,	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
patients	B-LIVB
experienced	O
significantly	O
longer	O
symptom	O
duration	O
before	O
DMARD	B-CHEM
initiation	O
.	O

This	O
was	O
accounted	O
for	O
by	O
delays	O
in	O
their	O
presentation	O
to	O
primary	B-PROC
care	I-PROC
following	O
symptom	O
onset	O
-a	O
finding	B-DISO
that	O
was	O
robustly	O
confirmed	O
in	O
an	O
independent	O
dataset	O
of	O
2192	O
UK	B-GEOG
early	O
RA	B-DISO
patients	B-LIVB
.	O

In	O
contrast	O
,	O
ACPA	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
patients	I-PHEN
were	O
significantly	O
more	O
likely	O
to	O
experience	O
delays	O
in	O
DMARD	B-CHEM
initiation	O
after	O
presenting	O
to	O
secondary	B-PROC
care	I-PROC
.	O

Causes	O
of	O
treatment	B-PROC
delays	O
in	O
early	O
RA	B-DISO
differ	O
according	O
to	O
patients	B-LIVB
'	O
autoantibody	B-CHEM
status	O
.	O

More	O
insidious	O
symptom	O
onset	O
and	O
/	O
or	O
distinct	O
health	O
-	O
seeking	O
behaviours	O
among	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
patients	I-PHEN
may	O
contribute	O
to	O
late	O
presentations	O
in	O
primary	B-PROC
care	I-PROC
,	O
whereas	O
ACPA	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
patients	I-PHEN
experience	O
delayed	O
diagnosis	O
and	O
treatment	B-PROC
in	O
secondary	B-PROC
care	I-PROC
.	O

These	O
observations	O
inform	B-PROC
the	O
research	B-PROC
agenda	I-PROC
,	O
potentially	O
influencing	O
the	O
design	O
of	O
service	B-PROC
delivery	I-PROC
for	O
early	B-DISO
arthritis	I-DISO
patients	B-LIVB
.	O

Indications	O
for	O
embolization	B-PROC
in	O
a	O
French	B-OBJC
level	I-OBJC
1	I-OBJC
trauma	I-OBJC
center	I-OBJC
Abdominal	B-DISO
trauma	I-DISO
accounts	O
for	O
nearly	O
20	O
%	O
of	O
all	O
traumatic	B-DISO
injuries	I-DISO
.	O

It	O
often	O
involves	O
young	O
patients	B-LIVB
sustaining	O
multiple	B-DISO
injuries	I-DISO
,	O
with	O
a	O
high	O
associated	O
mortality	O
rate	O
.	O

Management	O
should	O
begin	O
at	O
the	O
scene	O
of	O
injury	B-DISO
and	O
relies	O
on	O
a	O
structured	O
chain	O
of	O
care	O
in	O
order	O
to	O
transport	O
the	O
trauma	B-DISO
patient	B-LIVB
to	O
the	O
appropriate	O
hospital	B-OBJC
center	I-OBJC
.	O

Management	O
is	O
multi	B-PROC
-	I-PROC
disciplinary	I-PROC
,	O
involving	O
intensive	B-LIVB
care	I-LIVB
specialists	I-LIVB
,	O
surgeons	B-LIVB
and	O
radiologists	B-LIVB
.	O

Imaging	O
to	O
precisely	O
define	O
injury	B-DISO
is	O
best	O
performed	O
with	O
whole	B-PROC
body	I-PROC
dual	I-PROC
phase	I-PROC
computed	I-PROC
tomography	I-PROC
,	O
which	O
can	O
also	O
identify	O
the	O
source	O
of	O
bleeding	B-DISO
.	O

Non	O
-	O
operative	O
management	O
has	O
developed	O
considerably	O
over	O
the	O
years	O
:	O
this	O
includes	O
selective	B-PROC
embolization	I-PROC
in	O
case	O
of	O
active	B-DISO
bleeding	I-DISO
or	O
vascular	B-DISO
anomalies	I-DISO
in	O
stable	O
or	O
stabilized	O
patients	B-LIVB
after	O
resuscitation	B-PROC
.	O

Embolization	B-PROC
has	O
become	O
one	O
of	O
the	O
corner	O
stones	O
of	O
abdominal	B-DISO
trauma	I-DISO
management	O
and	O
interventional	B-LIVB
radiologists	I-LIVB
must	O
play	O
an	O
active	O
role	O
on	O
the	O
trauma	B-LIVB
team	I-LIVB
.	O

This	O
overview	O
details	O
the	O
different	O
embolization	B-PROC
procedures	I-PROC
according	O
to	O
the	O
involved	O
organ	B-ANAT
and	O
embolic	B-CHEM
agent	I-CHEM
used	O
.	O

Early	O
hippocampal	B-ANAT
volume	B-DISO
loss	I-DISO
as	O
a	O
marker	B-PHYS
of	O
eventual	O
memory	B-DISO
deficits	I-DISO
caused	O
by	O
repeated	B-DISO
stress	I-DISO
Exposure	O
to	O
severe	O
and	O
prolonged	O
stress	B-DISO
has	O
detrimental	B-DISO
effects	I-DISO
on	O
the	O
hippocampus	B-ANAT
.	O

However	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
gradual	O
changes	O
in	O
hippocampal	B-ANAT
structure	I-ANAT
,	O
and	O
its	O
behavioral	O
consequences	O
,	O
over	O
the	O
course	O
of	O
repeated	B-DISO
stress	I-DISO
.	O

Behavioral	B-PROC
analyses	I-PROC
during	O
10	O
days	O
of	O
chronic	O
stress	O
pointed	O
to	O
a	O
delayed	O
decline	O
in	O
spatial	B-PHYS
memory	I-PHYS
,	O
the	O
full	O
impact	O
of	O
which	O
is	O
evident	O
only	O
after	O
the	O
end	O
of	O
stress	B-DISO
.	O

In	O
contrast	O
,	O
concurrent	O
volumetric	O
measurements	O
in	O
the	O
same	O
animals	B-LIVB
revealed	O
significant	O
reduction	O
in	O
hippocampal	B-ANAT
volumes	O
in	O
stressed	B-DISO
animals	B-LIVB
relative	O
to	O
their	O
unstressed	B-DISO
counterparts	I-DISO
,	O
as	O
early	O
as	O
the	O
third	O
day	O
of	O
stress	B-DISO
.	O

Notably	O
,	O
animals	B-LIVB
that	O
were	O
behaviorally	O
the	O
worst	O
affected	O
at	O
the	O
end	O
of	O
chronic	O
stress	O
suffered	B-DISO
the	O
most	O
pronounced	O
early	B-DISO
loss	I-DISO
in	I-DISO
hippocampal	I-DISO
volume	I-DISO
.	O

Together	O
,	O
these	O
findings	O
support	O
the	O
view	O
that	O
not	O
only	O
is	O
smaller	O
hippocampal	B-ANAT
volume	O
linked	O
to	O
stress	B-DISO
-	O
induced	O
memory	B-DISO
deficits	I-DISO
,	O
but	O
it	O
may	O
also	O
act	O
as	O
an	O
early	O
risk	B-DISO
factor	I-DISO
for	O
the	O
eventual	O
development	O
of	O
cognitive	B-DISO
impairments	I-DISO
seen	O
in	O
stress	B-DISO
-	I-DISO
related	I-DISO
psychiatric	I-DISO
disorders	I-DISO
.	O

A	O
novel	O
functional	O
full	B-OBJC
-	I-OBJC
fat	I-OBJC
hard	I-OBJC
cheese	I-OBJC
containing	O
liposomal	B-CHEM
nanoencapsulated	O
green	B-CHEM
tea	I-CHEM
catechins	I-CHEM
:	O
manufacture	O
and	O
recovery	O
following	O
simulated	B-PROC
digestion	O
(	B-CHEM
+	I-CHEM
)	I-CHEM
-Catechin	I-CHEM
or	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
were	O
encapsulated	O
in	O
soy	B-CHEM
lecithin	I-CHEM
nanoliposomes	B-CHEM
and	O
incorporated	O
into	O
a	O
full	B-OBJC
-	I-OBJC
fat	I-OBJC
cheese	I-OBJC
,	O
then	O
ripened	B-PHEN
at	O
8	O
°	O
C	O
for	O
90	O
days	O
.	O

Cheese	B-OBJC
samples	I-OBJC
were	O
subjected	O
to	O
simulated	B-PROC
gastrointestinal	O
digestion	O
to	O
measure	O
total	B-PHEN
phenolic	I-PHEN
conten	I-PHEN
t	O
(	O
TPC	B-PHEN
)	O
and	O
antioxidant	B-PHYS
activity	I-PHYS
of	O
the	O
cheese	B-OBJC
digesta	B-OBJC
,	O
and	O
to	O
determine	O
the	O
catechin	B-CHEM
recovery	O
after	O
digestion	O
by	O
high	B-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
(	O
HPLC	B-PROC
)	O
.	O

Addition	B-PHEN
of	O
catechin	B-CHEM
or	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
significantly	O
(	O
P	O
≤	O
0	O
.	O
05	O
)	O
increased	O
TPC	B-PHEN
and	O
antioxidant	B-PHYS
activity	I-PHYS
(	O
measured	O
by	O
ferric	B-PROC
reducing	I-PROC
antioxidant	I-PROC
power	I-PROC
and	O
oxygen	B-PROC
radical	I-PROC
absorbance	I-PROC
capacity	I-PROC
)	O
of	O
the	O
full	B-OBJC
-	I-OBJC
fat	I-OBJC
cheese	I-OBJC
without	O
affecting	O
pH	O
or	O
proximate	B-PHEN
composition	I-PHEN
.	O

HPLC	B-PROC
analysis	I-PROC
confirmed	O
retention	O
of	O
encapsulated	O
catechins	B-CHEM
in	O
the	O
cheese	B-OBJC
curd	I-OBJC
;	O
however	O
,	O
individual	O
catechins	B-CHEM
were	O
recovered	O
in	O
differing	O
amounts	O
(	O
15	O
-	O
52	O
%	O
)	O
from	O
cheese	B-OBJC
digesta	B-OBJC
after	O
6	O
h	O
of	O
digestion	O
.	O

Transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
and	O
Fourier	B-PROC
transform	I-PROC
infrared	I-PROC
spectroscopy	I-PROC
provided	O
evidence	O
for	O
association	B-PHEN
of	O
nanoliposomes	B-CHEM
with	O
the	O
surface	O
of	O
milk	B-CHEM
fat	I-CHEM
globules	I-CHEM
inside	O
the	O
cheese	B-OBJC
matrix	O
.	O

The	O
study	O
shows	O
the	O
potential	O
for	O
using	O
cheese	B-OBJC
as	O
a	O
delivery	B-CHEM
vehicle	I-CHEM
for	O
green	B-CHEM
tea	I-CHEM
antioxidants	I-CHEM
.	O

Plasmablastic	B-PHYS
transformation	I-PHYS
of	O
plasma	B-DISO
cell	I-DISO
myeloma	I-DISO
with	O
heterotropic	B-PHYS
expression	I-PHYS
of	O
CD3	B-CHEM
and	O
CD4	B-CHEM
:	O
a	O
case	O
report	O
Plasmablastic	B-DISO
lymphoma	I-DISO
(	O
PBL	B-DISO
)	O
can	O
rarely	O
be	O
seen	O
as	O
a	O
transformation	B-PHYS
from	O
plasma	B-DISO
cell	I-DISO
myeloma	I-DISO
(	O
PCM	B-DISO
)	O
,	O
especially	O
in	O
late	O
stages	O
of	O
the	O
disease	B-DISO
where	O
it	O
portends	O
a	O
poorer	B-DISO
prognosis	I-DISO
and	O
a	O
different	O
line	O
of	O
management	B-PROC
for	O
the	O
patient	B-LIVB
.	O

When	O
unrelated	O
to	O
PCM	B-DISO
,	O
PBL	B-DISO
is	O
considered	O
to	O
be	O
a	O
separate	O
aggressive	O
variant	O
of	O
B	B-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
typically	O
seen	O
in	O
the	O
oral	B-ANAT
cavity	I-ANAT
of	O
immunocompromised	B-DISO
adults	B-LIVB
.	O

We	O
describe	O
a	O
case	O
of	O
plasmablastic	B-PHYS
transformation	I-PHYS
having	O
a	O
pan	B-CHEM
T	I-CHEM
-	I-CHEM
cell	I-CHEM
phenotype	I-CHEM
with	O
CD3	B-CHEM
and	O
CD4	B-CHEM
positivity	O
,	O
in	O
an	O
immunocompetent	B-PHYS
elderly	B-LIVB
lady	I-LIVB
diagnosed	B-DISO
with	O
PCM	B-DISO
.	O

This	O
60	O
-	O
year	O
-	O
old	B-LIVB
lady	I-LIVB
presented	O
with	O
worsening	B-DISO
backache	B-DISO
and	O
a	O
2	O
-	O
cm	O
skin	B-DISO
nodule	I-DISO
in	O
the	O
left	B-ANAT
cervical	I-ANAT
region	I-ANAT
,	O
while	O
she	O
was	O
on	O
treatment	B-PROC
with	O
vincristine	B-CHEM
,	O
cyclophosphamide	B-CHEM
,	O
dexamethasone	B-CHEM
(	O
VCD	B-CHEM
)	O
,	O
and	O
bortezomib	B-CHEM
.	O

On	O
biopsy	B-PROC
,	O
the	O
skin	B-DISO
nodule	I-DISO
showed	O
an	O
infiltrating	B-DISO
lymphoid	B-DISO
tumor	I-DISO
composed	O
of	O
immunoblastic	B-ANAT
cells	I-ANAT
with	O
brisk	O
mitosis	B-PHYS
and	O
apoptosis	B-PHYS
.	O

On	O
Immunohistochemistry	B-PROC
(	O
IHC	B-PROC
)	O
,	O
lymphoid	B-ANAT
cells	I-ANAT
revealed	O
plasma	B-ANAT
cell	I-ANAT
markers	B-PHYS
CD38	B-CHEM
,	O
CD138	B-CHEM
,	O
CD56	B-CHEM
,	O
and	O
MUM1	B-CHEM
.	O

Pan	B-CHEM
-	I-CHEM
T	I-CHEM
-	I-CHEM
cell	I-CHEM
markers	I-CHEM
CD3	B-CHEM
and	O
CD4	B-CHEM
were	O
also	O
diffusely	B-PHYS
expressed	I-PHYS
in	O
tumor	B-ANAT
cells	I-ANAT
.	O

B	B-CHEM
-	I-CHEM
cell	I-CHEM
markers	I-CHEM
CD20	B-CHEM
and	O
PAX5	B-CHEM
were	O
not	O
expressed	O
;	O
c	O
-	O
Myc	O
IHC	B-PROC
and	O
EBER	B-CHEM
by	O
in	B-PROC
situ	I-PROC
hybridization	I-PROC
(	O
ISH	B-PROC
)	O
were	O
negative	B-DISO
in	O
the	O
tumor	B-DISO
.	O

Mitotic	B-PHEN
index	I-PHEN
by	O
Ki67	B-PROC
was	O
>	O
95	O
%	O
.	O

Thus	O
,	O
a	O
diagnosis	B-DISO
of	O
plasmablastic	B-PHYS
transformation	I-PHYS
in	O
a	O
known	O
PCM	B-DISO
case	O
was	O
made	O
.	O

This	O
is	O
the	O
first	O
case	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
with	O
a	O
heterotropic	B-CHEM
T	I-CHEM
-	I-CHEM
cell	I-CHEM
phenotype	I-CHEM
in	O
a	O
plasmablastic	B-PHYS
transformation	I-PHYS
from	O
PCM	B-DISO
.	O

It	O
is	O
critical	O
to	O
correctly	O
diagnose	B-DISO
such	O
cases	O
as	O
they	O
may	O
occasionally	O
be	O
misinterpreted	O
as	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
neoplasms	B-DISO
.	O

Clinically	O
,	O
a	O
more	O
aggressive	B-PROC
treatment	I-PROC
is	O
indicated	O
for	O
such	O
patients	B-LIVB
.	O

Further	O
studies	B-PROC
in	O
these	O
cases	O
may	O
enhance	O
our	O
understanding	O
of	O
complex	O
underpinnings	O
of	O
lymphoma	B-DISO
biology	O
.	O

pH	O
affects	O
bacterial	B-LIVB
community	B-LIVB
composition	B-PHYS
in	O
soils	B-OBJC
across	O
the	O
Huashan	B-GEOG
Watershed	I-GEOG
,	O
China	B-GEOG
To	O
investigate	O
soil	B-OBJC
bacterial	B-LIVB
richness	O
and	O
diversity	O
and	O
to	O
determine	O
the	O
correlations	O
between	O
bacterial	B-LIVB
communities	B-LIVB
and	O
soil	B-OBJC
properties	O
,	O
8	O
soil	B-OBJC
samples	I-OBJC
were	O
collected	O
from	O
the	O
Huashan	B-GEOG
watershed	I-GEOG
in	O
Anhui	B-GEOG
,	O
China	B-GEOG
.	O

Subsequently	O
,	O
454	O
high	B-PROC
-	I-PROC
throughput	I-PROC
pyrosequencing	I-PROC
and	O
bioinformatics	B-PROC
analyses	I-PROC
were	O
performed	O
to	O
examine	O
the	O
soil	B-OBJC
bacterial	B-LIVB
community	B-LIVB
compositions	B-PHYS
.	O

The	O
operational	B-PROC
taxonomic	I-PROC
unit	I-PROC
richness	O
of	O
the	O
bacterial	B-LIVB
community	B-LIVB
ranged	O
from	O
3664	O
to	O
5899	O
,	O
and	O
the	O
diversity	O
indices	O
,	O
including	O
Chao1	O
,	O
Shannon	O
-	O
Wiener	O
,	O
and	O
Faith	O
's	O
phylogenetic	O
diversity	O
ranged	O
from	O
7751	O
to	O
15	O
204	O
,	O
7	O
.	O

386	O
to	O
8	O
.	O
327	O
,	O
and	O
415	O
.	O
77	O
to	O
679	O
.	O
11	O
,	O
respectively	O
.	O

The	O
2	O
most	O
dominant	O
phyla	O
in	O
the	O
soil	B-OBJC
samples	I-OBJC
were	O
Actinobacteria	B-LIVB
and	O
Proteobacteria	B-LIVB
.	O

The	O
richness	O
and	O
diversity	O
of	O
the	O
bacterial	B-LIVB
community	B-LIVB
were	O
positively	O
correlated	O
with	O
soil	B-OBJC
pH	O
.	O

The	O
Mantel	O
test	O
revealed	O
that	O
the	O
soil	B-OBJC
pH	O
was	O
the	O
dominant	O
factor	O
influencing	O
the	O
bacterial	B-LIVB
community	B-LIVB
.	O

The	O
positive	O
modular	O
structure	O
of	O
co	O
-	O
occurrence	O
patterns	O
at	O
the	O
genus	O
level	O
was	O
discovered	O
by	O
network	O
analysis	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	B-PROC
provide	O
useful	O
information	O
that	O
enhances	O
our	O
understanding	O
of	O
the	O
effects	O
of	O
soil	B-OBJC
properties	O
on	O
the	O
bacterial	B-LIVB
communities	B-LIVB
.	O

Long	B-PROC
-	I-PROC
term	I-PROC
lamivudine	I-PROC
therapy	I-PROC
in	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
One	O
to	O
5	O
years	O
of	O
therapy	B-PROC
of	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
with	O
oral	O
nucleoside	B-CHEM
analogues	I-CHEM
result	O
in	O
significant	O
clinical	O
improvements	O
,	O
but	O
effects	O
of	O
more	O
prolonged	B-PROC
therapy	I-PROC
are	O
not	O
well	O
defined	O
.	O

To	O
describe	O
outcomes	B-PROC
of	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
with	O
long	B-PROC
-	I-PROC
term	I-PROC
lamivudine	I-PROC
therapy	I-PROC
.	O

Forty	O
-	O
two	O
patients	B-LIVB
with	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
treated	B-PROC
with	I-PROC
lamivudine	B-CHEM
were	O
followed	O
for	O
3	O
.	O
2	O
-	O
19	O
.	O

5	O
(	O
median	O
=	O
16	O
.	O
1	O
)	O
years	O
.	O

Therapy	B-PROC
was	O
switched	O
to	O
other	O
agents	B-CHEM
(	O
n	O
=	O
16	O
)	O
if	O
patients	B-LIVB
developed	O
lamivudine	B-CHEM
resistance	B-PHEN
and	O
relapse	B-DISO
of	I-DISO
disease	I-DISO
.	O

Among	O
22	O
HBeAg	B-PHEN
-	I-PHEN
positive	I-PHEN
patients	B-LIVB
,	O
17	O
(	O
77	O
%	O
)	O
became	O
HBeAg	B-PHEN
negative	I-PHEN
,	O
of	O
whom	O
5	O
(	O
23	O
%	O
)	O
subsequently	O
cleared	B-PHYS
HBsAg	B-CHEM
.	O

Among	O
20	O
HBeAg	B-PHEN
-	I-PHEN
negative	I-PHEN
patients	B-LIVB
,	O
10	O
(	O
50	O
%	O
)	O
cleared	B-PHYS
HBsAg	B-CHEM
.	O

The	O
time	O
to	O
HBsAg	B-CHEM
clearance	B-PHYS
ranged	O
from	O
0	O
.	O

9	O
to	O
16	O
.	O

8	O
(	O
median	O
=	O
9	O
.	O

3	O
)	O
years	O
.	O

Lamivudine	B-CHEM
resistance	B-PHEN
arose	O
in	O
24	O
patients	B-LIVB
(	O
57	O
%	O
)	O
of	O
whom	O
6	O
(	O
25	O
%	O
)	O
lost	O
HBsAg	B-CHEM
.	O

HBsAg	B-CHEM
clearance	B-PHYS
was	O
not	O
always	O
accompanied	O
by	O
seroconversion	B-PHEN
;	O
anti	B-PROC
-	I-PROC
HBs	I-PROC
appearing	O
concurrently	O
in	O
only	O
five	O
patients	B-LIVB
(	O
33	O
%	O
)	O
.	O

Nevertheless	O
,	O
HBsAg	B-CHEM
loss	O
allowed	O
for	O
stopping	O
therapy	B-PROC
in	O
all	O
patients	B-LIVB
,	O
none	O
re	O
-	O
developing	O
HBsAg	B-CHEM
or	O
suffering	O
relapse	B-DISO
;	O
all	O
having	O
normal	O
alanine	B-PROC
aminotransferase	I-PROC
levels	I-PROC
and	O
no	O
(	O
n	O
=	O
13	O
)	O
or	O
unquantifiable	O
HBV	B-PROC
DNA	I-PROC
levels	I-PROC
(	O
n	O
=	O
2	O
)	O
when	O
last	O
seen	O
.	O

In	O
contrast	O
,	O
seven	O
of	O
27	O
patients	B-LIVB
(	O
26	O
%	O
)	O
who	O
remained	O
HBsAg	B-PHEN
-	I-PHEN
positive	I-PHEN
died	B-DISO
of	O
liver	B-DISO
disease	I-DISO
or	O
liver	B-DISO
cancer	I-DISO
or	O
underwent	O
liver	B-PROC
transplantation	I-PROC
,	O
all	O
of	O
whom	O
had	O
cirrhosis	B-DISO
.	O

Long	O
-	O
term	O
viral	B-LIVB
suppression	B-PROC
with	O
nucleoside	B-CHEM
analogues	I-CHEM
leads	O
to	O
HBsAg	B-CHEM
loss	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	B-LIVB
,	O
particularly	O
if	O
HBeAg	B-PHEN
-	I-PHEN
negative	I-PHEN
.	O

Serious	O
outcomes	B-PROC
during	O
the	O
first	O
10	O
-	O
20	O
years	O
of	O
treatment	B-PROC
occur	O
largely	O
among	O
patients	B-LIVB
with	O
pre	O
-	O
existing	O
cirrhosis	B-DISO
who	O
do	O
not	O
clear	B-PHYS
HBsAg	B-CHEM
with	O
therapy	B-PROC
.	O

The	O
Enigma	O
of	O
the	O
Dichotomic	B-PHEN
Pressure	I-PHEN
Response	B-PHYS
of	O
GluN1	B-CHEM
-	I-CHEM
4a	I-CHEM
/	O
b	B-CHEM
Splice	B-CHEM
Variants	I-CHEM
of	O
NMDA	B-CHEM
Receptor	I-CHEM
:	O
Experimental	B-PROC
and	O
Statistical	B-PROC
Analyses	I-PROC
Professional	B-LIVB
deep	I-LIVB
-	I-LIVB
water	I-LIVB
divers	I-LIVB
,	O
exposed	O
to	O
hyperbaric	B-PHEN
pressure	I-PHEN
(	O
HP	B-PHEN
)	O
above	O
1	O
.	O
1	O
MPa	O
,	O
develop	O
High	B-DISO
Pressure	I-DISO
Neurological	I-DISO
Syndrome	I-DISO
(	O
HPNS	B-DISO
)	O
,	O
which	O
is	O
associated	O
with	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
(	O
CNS	B-ANAT
)	O
hyperexcitability	B-PHYS
.	O

It	O
was	O
previously	O
reported	O
that	O
HP	B-PHEN
augments	O
N	B-CHEM
-	I-CHEM
methyl	I-CHEM
-	I-CHEM
D	I-CHEM
-	I-CHEM
aspartate	I-CHEM
receptor	I-CHEM
(	O
NMDAR	B-CHEM
)	O
synaptic	B-PHYS
response	I-PHYS
,	O
increases	O
neuronal	O
excitability	B-DISO
and	O
potentially	O
causes	O
irreversible	O
neuronal	B-DISO
damage	I-DISO
.	O

Our	O
laboratory	B-OBJC
has	O
reported	O
differential	B-PHEN
current	I-PHEN
responses	B-PHYS
under	O
HP	B-PHEN
conditions	O
in	O
NMDAR	B-CHEM
subtypes	O
that	O
contain	O
either	O
GluN1	B-CHEM
-	I-CHEM
1a	I-CHEM
or	O
GluN1	B-CHEM
-	I-CHEM
1b	I-CHEM
splice	B-CHEM
variants	I-CHEM
co	B-PHYS
-	I-PHYS
expressed	I-PHYS
in	O
Xenopus	B-LIVB
laevis	I-LIVB
oocytes	B-ANAT
with	O
all	O
four	O
GluN2	B-CHEM
subunits	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
the	O
increase	O
in	O
ionic	B-PHEN
currents	I-PHEN
measured	O
under	O
HP	B-PHEN
conditions	O
is	O
also	O
dependent	O
on	O
which	O
of	O
the	O
eight	O
splice	B-CHEM
variants	I-CHEM
of	O
GluN1	B-CHEM
is	O
co	B-PHYS
-	I-PHYS
expressed	I-PHYS
with	O
the	O
GluN2	B-CHEM
subunit	O
.	O

We	O
now	O
report	O
that	O
the	O
NMDAR	B-CHEM
subtype	O
that	O
contains	O
GluN1	B-CHEM
-	I-CHEM
4a	I-CHEM
/	I-CHEM
b	I-CHEM
splice	B-CHEM
variants	I-CHEM
exhibited	O
""""	O
dichotomic	O
""""	O
(	O
either	O
increased	O
or	O
decreased	O
)	O
response	B-PHYS
s	O
at	O
HP	B-PHEN
.	O

The	O
distribution	O
of	O
the	O
results	O
is	O
not	O
normal	O
thus	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
test	O
and	O
clustering	B-PROC
analysis	I-PROC
were	O
employed	O
for	O
statistical	O
verification	O
of	O
the	O
grouping	O
.	O

Furthermore	O
,	O
the	O
calculated	O
constants	O
of	O
alpha	O
function	O
distribution	B-PROC
analysis	I-PROC
for	O
the	O
two	O
groups	O
were	O
similar	O
,	O
suggesting	O
that	O
the	O
mechanism	O
underlying	O
the	O
switch	O
between	O
an	O
increase	O
or	O
a	O
decrease	O
of	O
the	O
current	B-PHEN
at	O
HP	B-PHEN
is	O
a	O
single	O
process	B-PHEN
,	O
the	O
nature	O
of	O
which	O
is	O
still	O
unknown	O
.	O

This	O
dichotomic	B-PHYS
response	I-PHYS
of	O
the	O
GluN1	B-CHEM
-	I-CHEM
4a	I-CHEM
/	O
b	B-CHEM
splice	B-CHEM
variant	I-CHEM
may	O
be	O
used	O
as	O
a	O
model	B-DEVI
for	O
studying	O
reduced	O
response	B-PHYS
in	O
NMDAR	B-CHEM
at	O
HP	B-PHEN
.	O

Successful	O
reversal	O
of	O
other	O
NMDAR	B-CHEM
subtypes	O
response	B-PHYS
(	O
i	O
.	O
e	O
.	O

,	O
current	B-PHEN
reduction	O
)	O
may	O
allow	O
the	O
elimination	O
of	O
the	O
reversible	O
malfunctioning	O
short	O
term	O
effects	O
(	O
HPNS	B-DISO
)	O
,	O
or	O
even	O
deleterious	O
long	O
term	O
effects	O
induced	O
by	O
increased	O
NMDAR	B-CHEM
function	O
during	O
HP	B-PHEN
exposure	O
.	O

Matrix	O
metalloproteinase	O
-	O
9	O
Gene	O
-	O
1562C	O
>	O
T	O
Gene	O
Polymorphism	B-PHYS
and	O
Coronary	B-DISO
Artery	I-DISO
Disease	I-DISO
in	O
the	O
Chinese	O
Han	O
Population	O
:	O
A	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
of	O
5468	O
Subjects	B-LIVB
Multiple	O
studies	B-PROC
indicate	O
that	O
the	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
may	O
be	O
associated	O
with	O
an	O
increased	B-DISO
risk	I-DISO
of	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O
CAD	B-DISO
)	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

However	O
,	O
a	O
clear	O
consensus	O
has	O
yet	O
to	O
be	O
established	O
.	O

A	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O
5468	O
subjects	B-LIVB
from	O
10	O
separate	O
studies	B-PROC
was	O
performed	O
to	O
explore	O
the	O
possible	O
relationship	O
between	O
the	O
MMP	O
-	O
9	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
and	O
CAD	B-DISO
within	O
the	O
Chinese	O
Han	O
population	O
.	O

Pooled	O
odds	O
ratio	O
(	O
ORs	O
)	O
for	O
the	O
association	O
and	O
the	O
corresponding	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
evaluated	O
by	O
a	O
random	B-DEVI
or	O
fixed	B-DEVI
-	I-DEVI
effect	I-DEVI
model	I-DEVI
.	O

Our	O
analysis	B-PROC
confirms	O
the	O
association	O
between	O
the	O
MMP	O
-	O
9	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
and	O
an	O
increased	B-DISO
risk	I-DISO
of	O
CAD	B-DISO
within	O
the	O
Chinese	O
Han	O
population	O
under	O
allelic	O
(	O
OR	O
:	O
1	O
.	O
60	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
25	O
-	O
2	O
.	O
04	O
,	O
P	O
=	O
0	O
.	O
0002	O
)	O
,	O
recessive	O
(	O
OR	O
:	O
3	O
.	O
05	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
67	O
-	O
5	O
.	O
56	O
,	O
P	O
=	O
0	O
.	O
0003	O
)	O
,	O
dominant	O
(	O
OR	O
:	O
2	O
.	O
23	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
49	O
-	O
3	O
.	O
35	O
,	O
P	O
=	O
0	O
.	O
0001	O
)	O
,	O
homozygous	B-PHYS
(	O
OR	O
:	O
3	O
.	O
41	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
87	O
-	O
6	O
.	O

23	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
heterozygous	B-PHYS
(	O
OR	O
:	O
2	O
.	O
03	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
40	O
-	O
2	O
.	O
93	O
,	O
P	O
=	O
0	O
.	O
0002	O
)	O
,	O
and	O
additive	O
genetic	O
models	O
(	O
OR	O
:	O
1	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
33	O
-	O
2	O
.	O
39	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

In	O
the	O
Chinese	O
Han	O
population	O
,	O
the	O
MMP	O
-	O
9	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
is	O
correlated	O
with	O
an	O
increased	B-DISO
risk	I-DISO
of	O
CAD	B-DISO
.	O

Therefore	O
,	O
Han	O
Chinese	O
carriers	B-DISO
of	O
the	O
-	O
1562	O
T	O
allele	O
may	O
be	O
at	O
an	O
increased	B-DISO
risk	I-DISO
of	O
CAD	B-DISO
.	O

Changes	O
in	O
parenting	O
strategies	B-PHYS
after	O
a	O
young	O
person	B-LIVB
's	I-LIVB
self	B-DISO
-	I-DISO
harm	I-DISO
:	O
a	O
qualitative	B-PROC
study	I-PROC
When	O
faced	O
with	O
the	O
discovery	O
of	O
their	O
child	B-LIVB
's	I-LIVB
self	B-DISO
-	I-DISO
harm	I-DISO
,	O
mothers	B-LIVB
and	O
fathers	B-LIVB
may	O
re	B-PROC
-	I-PROC
evaluate	I-PROC
their	O
parenting	O
strategies	B-PHYS
.	O

This	O
can	O
include	O
changes	O
to	O
the	O
amount	O
of	O
support	O
they	O
provide	O
their	O
child	B-LIVB
and	O
changes	O
to	O
the	O
degree	O
to	O
which	O
they	O
control	O
and	O
monitor	O
their	O
child	B-LIVB
.	O

We	O
conducted	O
an	O
in	B-PROC
-	I-PROC
depth	I-PROC
qualitative	I-PROC
study	I-PROC
with	O
37	O
parents	B-LIVB
of	O
young	O
people	B-LIVB
who	O
had	O
self	B-DISO
-	I-DISO
harmed	I-DISO
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	O
changed	O
after	O
the	O
discovery	O
of	O
self	B-DISO
-	I-DISO
harm	I-DISO
.	O

Early	O
on	O
,	O
parents	B-LIVB
often	O
found	O
themselves	O
""""	O
walking	O
on	O
eggshells	O
""""	O
so	O
as	O
not	O
to	O
upset	B-PHYS
their	O
child	B-LIVB
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	O
.	O

Parents	B-LIVB
'	O
reactions	O
to	O
the	O
self	B-DISO
-	I-DISO
harm	I-DISO
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it	O
:	O
as	O
part	O
of	O
adolescence	O
,	O
as	O
a	O
mental	B-DISO
health	I-DISO
issue	I-DISO
or	O
as	O
""""	O
naughty	O
behaviour	O
""""	O
.	O

Parenting	O
of	O
other	O
children	B-LIVB
in	O
the	O
family	B-LIVB
could	O
also	O
be	O
affected	O
,	O
with	O
parents	B-LIVB
worrying	O
about	O
less	O
of	O
their	O
time	O
being	O
available	O
for	O
siblings	B-LIVB
.	O

Many	O
parents	B-LIVB
developed	O
specific	O
strategies	B-PHYS
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	B-LIVB
,	O
such	O
as	O
learning	B-PHYS
to	O
avoid	O
blaming	B-PHYS
themselves	O
or	O
their	O
child	B-LIVB
for	O
the	O
self	B-DISO
-	I-DISO
harm	I-DISO
and	O
developing	O
new	O
ways	O
to	O
communicate	B-DISO
with	O
their	O
child	B-LIVB
.	O

Parents	B-LIVB
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	O
on	O
to	O
other	O
people	B-LIVB
in	O
the	O
same	O
situation	O
.	O

Parents	B-LIVB
reported	O
changes	O
in	O
their	O
parenting	O
behaviours	O
after	O
the	O
discovery	O
of	O
a	O
child	B-LIVB
'	O
s	O
self	B-DISO
-	I-DISO
harm	I-DISO
.	O

Professionals	B-LIVB
involved	O
in	O
the	O
care	O
of	O
young	O
people	B-LIVB
who	O
self	B-DISO
-	I-DISO
harm	I-DISO
might	O
use	O
this	O
information	O
in	O
supporting	O
and	O
advising	O
parents	B-LIVB
.	O

The	O
Association	O
between	O
C9orf72	O
Repeats	O
and	O
Risk	O
of	O
Alzheimer	B-DISO
's	I-DISO
Disease	I-DISO
and	O
Amyotrophic	B-DISO
Lateral	I-DISO
Sclerosis	I-DISO
:	O
A	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
C9orf72	O
is	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
amyotrophic	B-DISO
lateral	I-DISO
sclerosis	I-DISO
(	O
ALS	B-DISO
)	O
and	O
frontotemporal	B-DISO
dementia	I-DISO
(	O
FTD	B-DISO
)	O
in	O
Caucasian	B-LIVB
populations	I-LIVB
.	O

However	O
,	O
the	O
relationship	O
between	O
C9orf72	O
repeats	O
and	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O
AD	B-DISO
)	O
was	O
not	B-DISO
clear	I-DISO
.	O

Additionally	O
,	O
there	O
were	O
few	O
articles	O
assessing	O
C9orf72	O
in	O
other	O
ethnicities	O
with	O
ALS	B-DISO
.	O

In	O
this	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
,	O
we	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
C9orf72	O
repeat	B-DISO
expansions	I-DISO
(	O
≥30	O
repeats	O
)	O
and	O
intermediate	O
repeat	O
copies	O
(	O
20	O
-	O
29	O
repeats	O
)	O
and	O
AD	B-DISO
or	O
ALS	B-DISO
.	O

The	O
results	O
suggested	O
positive	B-DISO
correlations	O
between	O
C9orf72	O
repeat	B-DISO
expansions	I-DISO
and	O
the	O
risk	O
of	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O
OR	O
=	O
6	O
.	O
36	O
,	O
95	O
%	O
CI	O
=	O
3	O
.	O
13	O
-	O
12	O
.	O
92	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
)	O
,	O
while	O
intermediate	O
repeat	O
copies	O
of	O
C9orf72	O
gene	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
the	O
disease	B-DISO
.	O

C9orf72	O
repeat	B-DISO
expansions	I-DISO
were	O
positively	B-DISO
correlated	O
with	O
the	O
risk	O
of	O
familial	B-DISO
and	O
sporadic	B-DISO
ALS	I-DISO
(	O
OR	O
=	O
293	O
.	O

25	O
,	O
95	O
%	O
CI	O
=	O
148	O
.	O
17	O
-	O
580	O
.	O
38	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
;	O
OR	O
=	O
35	O
.	O
57	O
,	O
95	O
%	O
CI	O
=	O
19	O
.	O
61	O
-	O
64	O
.	O
51	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
)	O
.	O

There	O
was	O
a	O
positive	B-DISO
correlation	O
between	O
the	O
gene	B-PHEN
variations	I-PHEN
and	O
ALS	B-DISO
risk	O
among	O
Caucasians	B-LIVB
and	O
Asians	B-LIVB
(	O
OR	O
=	O
57	O
.	O
56	O
,	O
95	O
%	O
CI	O
=	O
36	O
.	O
73	O
-	O
90	O
.	O
22	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
;	O
OR	O
=	O
6	O
.	O

35	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
39	O
-	O
29	O
.	O
02	O
,	O
and	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Variability	O
in	O
Saponin	B-CHEM
Content	O
,	O
Cancer	B-DISO
Antiproliferative	B-DISO
Activity	I-DISO
and	O
Physicochemical	O
Properties	O
of	O
Concentrated	B-OBJC
Agave	I-OBJC
Sap	I-OBJC
Concentrated	B-OBJC
agave	I-OBJC
sap	I-OBJC
(	O
CAS	B-OBJC
)	O
has	O
gained	O
popularity	O
as	O
an	O
unrefined	B-CHEM
sweetener	I-CHEM
.	O

It	O
is	O
obtained	O
by	O
boiling	B-PHEN
""""	O
aguamiel	B-LIVB
""""	O
that	O
contains	O
phytochemicals	B-CHEM
with	O
diverse	O
bioactivities	O
.	O

Saponins	B-CHEM
have	O
been	O
the	O
most	O
widely	O
studied	O
agave	B-LIVB
phytochemicals	B-CHEM
due	O
to	O
their	O
cancer	B-DISO
antiproliferative	B-DISO
effect	I-DISO
but	O
their	O
concentration	O
may	O
vary	O
due	O
to	O
maturity	O
of	O
the	O
agave	B-LIVB
plant	I-LIVB
and	O
collection	O
site	O
.	O

In	O
this	O
study	B-PROC
,	O
18	O
CAS	B-OBJC
samples	B-OBJC
produced	O
in	O
different	O
states	B-GEOG
of	O
Mexico	B-GEOG
were	O
analyzed	B-PROC
using	O
multivariate	O
methods	O
to	O
determine	O
which	O
physicochemical	B-DISO
or	O
phytochemical	B-DISO
parameters	I-DISO
were	O
responsible	B-DISO
for	O
variation	O
.	O

Additionally	O
,	O
extracts	B-CHEM
with	O
different	O
saponin	B-CHEM
profiles	B-PROC
were	O
tested	O
to	O
determine	O
possible	O
correlations	O
with	O
antiproliferative	B-DISO
activity	I-DISO
.	O

Total	O
soluble	O
solids	O
,	O
pH	O
,	O
and	O
water	O
activity	O
were	O
similar	O
to	O
those	O
reported	O
for	O
other	O
agave	B-LIVB
sweeteners	B-CHEM
.	O

Antioxidant	O
capacity	O
of	O
samples	B-OBJC
was	O
correlated	O
to	O
browning	O
index	O
.	O

Eleven	O
steroidal	B-CHEM
saponins	I-CHEM
were	O
found	O
in	O
CAS	B-OBJC
samples	B-OBJC
and	O
they	O
were	O
the	O
main	O
source	B-DISO
of	O
variability	O
.	O

Magueyoside	B-CHEM
B	I-CHEM
,	O
a	O
kammogenin	B-CHEM
tetraglycoside	I-CHEM
,	O
was	O
the	O
most	O
abundant	O
saponin	B-CHEM
in	O
all	O
samples	B-OBJC
.	O

With	O
respect	O
to	O
bioactivity	O
,	O
multivariate	O
analysis	O
indicated	O
that	O
magueyoside	B-CHEM
B	I-CHEM
and	O
a	O
gentrogenin	B-CHEM
tetraglycoside	I-CHEM
were	O
compounds	B-CHEM
strongly	O
related	O
with	O
bioactivity	O
.	O

CAS	B-OBJC
from	O
Hidalgo	B-GEOG
,	O
Puebla	B-GEOG
,	O
and	O
Veracruz	B-GEOG
had	O
higher	O
concentration	O
of	O
magueyoside	B-CHEM
B	I-CHEM
than	O
from	O
the	O
other	O
kamogenin	B-CHEM
tetraglycoside	I-CHEM
found	O
in	O
the	O
samples	B-OBJC
from	O
other	O
Mexican	B-GEOG
states	I-GEOG
.	O

These	O
results	O
could	O
be	O
used	O
as	O
a	O
first	O
approach	O
to	O
characterize	O
and	O
standardize	O
CAS	B-OBJC
to	O
validate	O
the	O
potential	O
health	O
benefits	O
derived	O
from	O
its	O
consumption	O
.	O

Association	O
of	O
CDKAL1	O
,	O
CDKN2A	O
/	O
B	O
&	O
HHEX	O
gene	B-PHYS
polymorphisms	I-PHYS
with	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
in	O
the	O
population	B-LIVB
of	O
Hyderabad	O
,	O
India	B-GEOG
The	O
genome	B-PROC
-	I-PROC
wide	I-PROC
association	I-PROC
studies	I-PROC
(	O
GWAS	B-PROC
)	O
have	O
shown	O
an	O
association	O
of	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
(	O
T2DM	B-DISO
)	O
with	O
several	O
novel	O
genes	O
.	O

We	O
report	O
here	O
the	O
findings	B-DISO
on	O
the	O
pattern	O
of	O
genetic	O
association	O
of	O
three	O
genes	O
(	O
CDKAL1	O
,	O
CDKN2A	O
/	O
B	O
and	O
HHEX	O
)	O
with	O
T2DM	B-DISO
in	O
the	O
population	B-LIVB
of	O
Hyderabad	O
,	O
south	O
India	B-GEOG
.	O

A	O
sample	B-OBJC
of	O
1379	O
individuals	B-LIVB
(	O
758	O
T2DM	B-DISO
cases	O
and	O
621	O
controls	B-LIVB
)	O
from	O
Hyderabad	O
,	O
India	B-GEOG
,	O
were	O
genotyped	B-PHYS
for	O
five	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
CDKAL1	O
(	O
rs7754840	O
,	O
rs7756992	O
)	O
CDKN2A	O
/	O
B	O
(	O
rs10811661	O
)	O
and	O
HHEX	O
(	O
rs1111875	O
,	O
rs7923837	O
)	O
genes	O
on	O
Sequenom	O
Mass	O
Array	O
platform	O
.	O

The	O
risk	O
allele	O
frequencies	O
of	O
the	O
CDKAL1	O
and	O
CDKN2A	O
/	O
B	O
SNPs	O
were	O
relatively	O
higher	O
in	O
cases	O
than	O
in	O
the	O
controls	B-LIVB
and	O
the	O
logistic	O
regression	O
analysis	O
yielded	O
significant	O
odds	O
ratios	O
suggesting	O
that	O
the	O
variant	O
alleles	O
conferred	O
risk	O
for	O
developing	O
T2DM	B-DISO
in	O
this	O
population	B-LIVB
.	O

The	O
HHEX	O
gene	O
did	O
not	O
show	O
either	O
allelic	O
or	O
genotypic	B-PHYS
association	O
with	O
T2DM	B-DISO
.	O

The	O
multivariate	O
logistic	O
regression	O
analysis	O
with	O
reference	O
to	O
both	O
alleles	O
and	O
genotypes	B-PHYS
of	O
CDKAL1	O
SNPs	O
showed	O
significant	O
association	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
this	O
gene	O
in	O
the	O
T2DM	B-DISO
pathophysiology	O
.	O

A	O
significant	O
association	O
was	O
seen	O
of	O
all	O
the	O
three	O
SNPs	O
of	O
CDKAL1	O
and	O
CDKN2A	O
/	O
B	O
genes	O
with	O
T2DM	B-DISO
but	O
none	O
of	O
the	O
two	O
SNPs	O
of	O
HHEX	O
.	O

Further	O
studies	O
are	O
required	O
to	O
cross	B-PROC
-	I-PROC
validate	I-PROC
our	O
findings	B-DISO
in	O
a	O
relatively	O
larger	O
sample	B-OBJC
.	O

It	O
is	O
also	O
necessary	O
to	O
explore	O
other	O
SNPs	O
of	O
HHEX	O
gene	O
to	O
unequivocally	O
establish	O
the	O
pattern	O
of	O
association	O
of	O
this	O
gene	O
with	O
T2DM	B-DISO
in	O
this	O
population	B-LIVB
.	O

Demonstration	O
and	O
validation	B-PROC
of	O
a	O
new	O
pressure	B-PHEN
-based	O
MRI	B-DEVI
-safe	O
pain	B-DISO
tolerance	I-DISO
device	B-DEVI
One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	O
and	O
emotional	B-PHYS
effects	O
of	O
pain	B-DISO
using	O
functional	B-PROC
Magnetic	I-PROC
Resonance	I-PROC
Imaging	I-PROC
(	O
fMRI	B-PROC
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
MRI	B-DEVI
-	O
compatible	O
,	O
pressure	B-PHEN
-based	O
algometer	B-DEVI
to	O
elicit	O
pain	B-DISO
.	O

The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	B-DEVI
-safe	O
apparatus	B-DEVI
capable	O
of	O
delivering	O
incremental	O
,	O
measurable	O
amounts	O
of	O
pressure	B-PHEN
inside	O
a	O
scanning	B-DEVI
bore	I-DEVI
.	O

We	O
introduced	O
an	O
MR	O
-	O
safe	O
device	B-DEVI
used	O
to	O
administer	O
pressure	B-PHEN
-based	O
pain	B-DISO
.	O

To	O
test	B-PROC
against	O
a	O
commercially	O
available	O
,	O
MRI	B-DEVI
-	O
incompatible	O
algometer	B-DEVI
(	O
AlgoMed	B-DEVI
)	O
,	O
199	O
participants	O
reported	O
their	O
pain	B-DISO
tolerance	I-DISO
for	O
both	O
devices	O
.	O

A	O
second	O
experiment	O
tested	B-PROC
the	O
validity	O
of	O
pressure	B-PHEN
-based	O
pain	B-DISO
in	O
an	O
MRI	B-DEVI
environment	O
by	O
comparing	O
brain	B-ANAT
activation	O
with	O
established	O
neural	B-ANAT
networks	I-ANAT
for	O
pain	B-DISO
.	O

10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-PROC
for	O
pain	B-DISO
tolerance	O
while	O
being	O
scanned	B-PROC
in	O
a	O
7	O
T	O
MRI	B-DEVI
scanner	I-DEVI
.	O

Results	O
support	O
the	O
validity	O
and	O
reliability	O
of	O
our	O
novel	O
device	B-DEVI
.	O

In	O
Study	O
1	O
,	O
pain	B-DISO
tolerance	I-DISO
with	O
this	O
device	B-DEVI
was	O
strongly	O
correlated	O
with	O
pain	B-DISO
tolerance	I-DISO
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	B-DEVI
(	O
r	O
=	O
0	O
.	O
78	O
)	O
.	O

In	O
Study	O
2	O
,	O
this	O
device	B-DEVI
yielded	O
BOLD	B-PHYS
activation	O
within	O
the	O
insula	B-ANAT
(	O
BA	B-ANAT
13	I-ANAT
)	O
and	O
anterior	B-ANAT
cingulate	I-ANAT
gyrus	I-ANAT
(	O
BA	B-ANAT
24	I-ANAT
)	O
;	O
as	O
pressure	B-PHEN
increased	O
,	O
activation	O
in	O
these	O
areas	O
parametrically	O
increased	O
.	O

These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	B-PROC
,	O
electrical	B-PROC
,	O
or	O
mechanical	B-PROC
pain	B-DISO
applications	I-DISO
.	O

Behavioral	O
and	O
functional	O
data	O
demonstrate	O
that	O
this	O
new	O
device	B-DEVI
is	O
a	O
valid	O
method	O
of	O
administering	B-PROC
pressure	B-PHEN
-related	O
pain	B-DISO
in	O
MRI	B-DEVI
environments	O
.	O

Our	O
novel	O
MRI	B-DEVI
-safe	O
device	B-DEVI
is	O
a	O
valid	O
instrument	B-DEVI
to	O
measure	O
and	O
administer	O
pressure	B-PHEN
-based	O
pain	B-DISO
.	O

Mandibular	B-DISO
dysostosis	I-DISO
without	O
microphthalmia	B-DISO
caused	O
by	O
OTX2	B-PHYS
deletion	I-PHYS
Mutations	B-PHYS
in	O
OTX2	O
are	O
mostly	O
identified	O
in	O
patients	B-LIVB
with	O
anophthalmia	B-DISO
/	O
microphthalmia	B-DISO
with	O
variable	O
severity	O
.	O

The	O
OTX2	O
homeobox	O
gene	O
plays	O
a	O
crucial	O
role	O
in	O
craniofacial	B-ANAT
morphogenesis	B-PHYS
during	O
early	O
embryo	B-PHYS
development	I-PHYS
.	O

We	O
report	O
for	O
the	O
first	O
time	O
a	O
patient	B-LIVB
with	O
a	O
mandibular	B-DISO
dysostosis	I-DISO
caused	O
by	O
a	O
120	B-PHYS
kb	I-PHYS
deletion	I-PHYS
including	O
the	O
entire	O
coding	O
sequence	O
of	O
OTX2	O
,	O
identified	O
by	O
array	B-PROC
CGH	I-PROC
.	O

No	O
ocular	B-DISO
malformations	I-DISO
were	O
identified	O
after	O
extended	O
ophthalmologic	B-PROC
examination	I-PROC
.	O

Our	O
data	O
refine	O
the	O
clinical	B-PROC
spectrum	I-PROC
associated	O
with	O
OTX2	B-PHYS
mutations	I-PHYS
and	O
suggests	O
that	O
OTX2	O
haploinsufficiency	B-DISO
should	O
be	O
considered	O
as	O
a	O
possible	O
cause	O
for	O
isolated	O
mandibular	B-DISO
dysostosis	I-DISO
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Optimizing	O
Survival	O
of	O
Patients	B-LIVB
With	O
Marginally	O
Operable	O
Stage	B-DISO
IIIA	I-DISO
Non	I-DISO
-	I-DISO
Small	I-DISO
-	I-DISO
Cell	I-DISO
Lung	I-DISO
Cancer	I-DISO
Receiving	O
Chemoradiotherapy	B-PROC
With	O
or	O
Without	O
Surgery	O
For	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
non	I-DISO
-	I-DISO
small	I-DISO
-	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
(	O
NSCLC	B-DISO
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-PROC
concurrent	B-PROC
chemoradiotherapy	I-PROC
(	O
CCRT	B-PROC
)	O
for	O
reasons	O
(	O
unresectable	B-PHYS
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

This	O
study	B-PROC
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	B-PROC
CCRT	I-PROC
protocol	I-PROC
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
NSCLC	I-DISO
and	O
to	O
care	O
for	O
reassessed	O
inoperable	B-LIVB
patients	I-LIVB
,	O
in	O
comparison	O
with	O
continuous	B-PROC
-	I-PROC
course	I-PROC
definitive	I-PROC
CCRT	I-PROC
.	O

Forty	O
-	O
seven	O
patients	B-LIVB
with	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
NSCLC	I-DISO
receiving	O
CCRT	B-PROC
were	O
included	O
.	O

Twenty	O
-	O
eight	O
patients	B-LIVB
were	O
treated	O
with	O
our	O
phased	B-PROC
CCRT	I-PROC
protocol	I-PROC
,	O
including	O
neoadjuvant	B-PROC
CCRT	B-PROC
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	B-LIVB
patients	I-LIVB
,	O
maintenance	B-DISO
chemotherapy	I-DISO
and	O
split	B-PROC
-	I-PROC
course	I-PROC
CCRT	I-PROC
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

The	O
other	O
19	O
were	O
treated	O
with	O
continuous	B-PROC
-	I-PROC
course	I-PROC
definitive	I-PROC
CCRT	I-PROC
(	O
group	O
C	O
)	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
were	O
analyzed	B-PROC
.	O

Among	O
all	O
,	O
median	O
OS	O
and	O
PFS	O
were	O
35	O
.	O
6	O
and	O
12	O
.	O

8	O
months	O
,	O
respectively	O
(	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
22	O
.	O
3	O
months	O
)	O
.	O

The	O
median	O
OS	O
of	O
group	O
A	O
(	O
not	O
reached	O
)	O
was	O
better	O
than	O
that	O
of	O
group	O
B	O
(	O
34	O
.	O
4	O
months	O
)	O
and	O
group	O
C	O
(	O
15	O
.	O

2	O
months	O
)	O
(	O
P	O
=	O
.009	O
)	O
.	O

On	O
multivariate	O
analysis	O
,	O
performance	B-PHYS
status	I-PHYS
0	O
to	O
1	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0	O
.	O
026	O
;	O
P	O
<	O
.001	O
)	O
,	O
adenocarcinoma	B-DISO
(	O
HR	O
,	O
0	O
.	O
156	O
;	O
P	O
=	O
.003	O
)	O
,	O
and	O
group	O
A	O
(	O
HR	O
,	O
0	O
.	O
199	O
;	O
P	O
=	O
.033	O
)	O
were	O
independent	B-PHYS
prognostic	I-PHYS
factors	I-PHYS
.	O

The	O
OS	O
of	O
group	O
B	O
(	O
HR	O
,	O
0	O
.	O
450	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
118	O
-	O
1	O
.	O
717	O
;	O
P	O
=	O
.243	O
)	O
was	O
not	O
statistically	O
different	O
from	O
that	O
of	O
group	O
C	O
.	O

For	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
NSCLC	I-DISO
,	O
our	O
phased	B-PROC
CCRT	I-PROC
strategy	I-PROC
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	B-LIVB
patients	I-LIVB
by	O
split	B-PROC
-	I-PROC
course	I-PROC
CCRT	I-PROC
boost	O
following	O
maintenance	B-DISO
chemotherapy	I-DISO
.	O

Anti	O
-	O
Inflammatory	O
Properties	O
of	O
Menthol	B-CHEM
and	O
Menthone	B-CHEM
in	O
Schistosoma	B-DISO
mansoni	I-DISO
Infection	I-DISO
Schistosomiasis	B-DISO
is	O
a	O
parasitic	B-DISO
disease	I-DISO
caused	O
by	O
several	O
species	O
of	O
trematode	O
worms	O
and	O
it	O
is	O
believed	O
that	O
more	O
than	O
261	O
million	O
people	B-LIVB
are	O
affected	O
worldwide	O
.	O

New	O
drug	O
development	O
has	O
become	O
essential	O
because	O
there	O
is	O
a	O
risk	O
of	O
the	O
parasite	O
becoming	O
resistant	B-PHYS
to	O
Praziquantel	B-CHEM
,	O
the	O
only	O
drug	B-CHEM
available	O
for	O
this	O
infection	B-DISO
.	O

This	O
study	B-PROC
evaluated	B-PROC
parasitological	O
,	O
immunological	O
and	O
histological	O
parameters	B-DISO
in	O
mice	B-LIVB
infected	B-DISO
with	O
Schistosoma	O
mansoni	O
and	O
treated	B-PROC
with	I-PROC
an	O
herbal	B-CHEM
commercial	I-CHEM
medicine	I-CHEM
.	O

This	O
drug	B-CHEM
consists	O
of	O
menthol	B-CHEM
(	O
30	O
-	O
55	O
%	O
)	O
and	O
menthone	B-CHEM
(	O
14	O
-	O
32	O
%	O
)	O
.	O

A	O
60	O
day	O
treatment	B-PROC
regimen	I-PROC
with	O
the	O
herbal	B-CHEM
medicine	I-CHEM
decreased	O
the	O
number	O
of	O
S	O
.	O

mansoni	O
eggs	O
in	O
the	O
feces	B-ANAT
,	O
liver	B-ANAT
,	O
and	O
intestine	B-ANAT
and	O
reduced	O
the	O
number	O
of	O
hepatic	B-DISO
granulomas	I-DISO
.	O

We	O
observed	O
a	O
reduction	B-PROC
of	O
84	O
%	O
in	O
blood	B-DISO
eosinophilia	I-DISO
and	O
a	O
decrease	O
in	O
the	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
blood	B-ANAT
levels	I-ANAT
after	O
treatment	B-PROC
.	O

Therefore	O
,	O
we	O
propose	O
that	O
schistosomiasis	B-DISO
treatment	B-PROC
with	O
this	O
herbal	B-CHEM
medicine	I-CHEM
for	O
60	O
days	O
has	O
an	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
action	O
in	O
this	O
animal	B-LIVB
model	I-LIVB
for	O
schistosomiasis	B-DISO
thus	O
contributing	O
to	O
the	O
decrease	O
in	O
physio	O
pathological	O
effects	O
caused	O
by	O
S	B-DISO
.	I-DISO

mansoni	I-DISO
infection	I-DISO
.	O

Evaluation	O
of	O
Three	O
Protein	B-PROC
-	I-PROC
Extraction	I-PROC
Methods	I-PROC
for	O
Proteome	B-CHEM
Analysis	B-PROC
of	O
Maize	B-LIVB
Leaf	B-LIVB
Midrib	O
,	O
a	O
Compound	B-ANAT
Tissue	I-ANAT
Rich	O
in	O
Sclerenchyma	B-ANAT
Cells	I-ANAT
Leaf	B-LIVB
morphology	O
is	O
closely	O
related	O
to	O
the	O
growth	B-PHYS
and	I-PHYS
development	I-PHYS
of	O
maize	B-LIVB
(	I-LIVB
Zea	I-LIVB
mays	I-LIVB
L	I-LIVB
.	I-LIVB

)	I-LIVB
plants	I-LIVB
and	O
final	O
kernel	B-OBJC
production	O
.	O

As	O
an	O
important	O
part	O
of	O
the	O
maize	B-LIVB
leaf	B-LIVB
,	O
the	O
midrib	O
holds	O
leaf	B-LIVB
blades	O
in	O
the	O
aerial	B-LIVB
position	I-LIVB
for	O
maximum	O
sunlight	B-PHEN
capture	O
.	O

Leaf	B-LIVB
midrib	O
s	O
of	O
adult	O
plants	B-LIVB
contain	O
substantial	O
sclerenchyma	B-ANAT
cells	I-ANAT
with	O
heavily	O
thickened	O
and	O
lignified	B-CHEM
secondary	B-ANAT
walls	I-ANAT
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-CHEM
,	O
making	O
protein	B-PROC
extraction	I-PROC
and	O
proteome	B-CHEM
analysis	B-PROC
difficult	O
in	O
leaf	B-LIVB
midrib	O
tissue	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
protein	B-PROC
-	I-PROC
extraction	I-PROC
methods	I-PROC
that	O
are	O
commonly	O
used	O
in	O
plant	B-LIVB
proteomics	O
,	O
i	O
.	O

e	O
.	O
,	O
phenol	B-CHEM
extraction	B-PROC
,	O
TCA	B-CHEM
/	O
acetone	B-CHEM
extraction	B-PROC
,	O
and	O
TCA	B-CHEM
/	O
acetone	B-CHEM
/	O
phenol	B-CHEM
extraction	B-PROC
,	O
were	O
qualitatively	O
and	O
quantitatively	O
evaluated	O
based	O
on	O
2DE	O
maps	O
and	O
MS	B-PROC
/	I-PROC
MS	I-PROC
analysis	I-PROC
using	O
the	O
midribs	O
of	O
the	O
10th	O
newly	O
expanded	O
leaves	B-LIVB
of	O
maize	B-LIVB
plants	I-LIVB
.	O

Microscopy	B-PROC
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	B-ANAT
underneath	O
maize	B-LIVB
midrib	O
epidermises	B-LIVB
(	O
particularly	O
abaxial	O
epidermises	B-LIVB
)	O
.	O

The	O
spot	O
-	O
number	O
order	O
obtained	O
via	O
2DE	B-PROC
mapping	I-PROC
was	O
as	O
follows	O
:	O
phenol	B-CHEM
extraction	B-PROC
(	O
655	O
)	O
>	O
TCA	B-CHEM
/	O
acetone	B-CHEM
extraction	B-PROC
(	O
589	O
)	O
>	O
TCA	B-CHEM
/	O
acetone	B-CHEM
/	O
phenol	B-CHEM
extraction	B-PROC
(	O
545	O
)	O
.	O

MS	B-PROC
/	I-PROC
MS	I-PROC
analysis	I-PROC
identified	O
a	O
total	O
of	O
17	O
spots	O
that	O
exhibited	O
2	O
-	O
fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	O
methods	O
(	O
using	O
phenol	B-CHEM
extraction	B-PROC
as	O
a	O
control	B-LIVB
)	O
.	O

Sixteen	O
of	O
the	O
proteins	B-CHEM
identified	O
were	O
hydrophilic	O
,	O
with	O
GRAVY	O
values	O
ranging	O
from	O
-0	O
.	O

026	O
to	O
-0	O
.	O
487	O
.	O

For	O
all	O
three	O
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high	O
-	O
quality	O
protein	B-CHEM
samples	O
and	O
good	O
2DE	B-PROC
maps	I-PROC
for	O
the	O
maize	B-LIVB
leaf	B-LIVB
midrib	O
.	O

However	O
,	O
phenol	B-CHEM
extraction	B-PROC
produced	O
a	O
better	O
2DE	B-PROC
map	I-PROC
with	O
greater	O
resolution	O
between	O
spots	O
,	O
and	O
TCA	B-CHEM
/	O
acetone	B-CHEM
extraction	B-PROC
produced	O
higher	O
protein	B-CHEM
yields	O
.	O

Thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	O
protein	B-PROC
extraction	I-PROC
among	O
the	O
three	O
methods	O
.	O

This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-PROC
extraction	I-PROC
methods	O
for	O
the	O
proteome	B-CHEM
analysis	B-PROC
of	O
recalcitrant	O
plant	B-ANAT
tissues	I-ANAT
that	O
are	O
rich	O
in	O
sclerenchyma	B-ANAT
cells	I-ANAT
.	O

Comparison	O
of	O
Individual	B-LIVB
Radiosensitivity	B-PHYS
to	O
γ	B-PHEN
-	I-PHEN
Rays	I-PHEN
and	O
Carbon	B-CHEM
Ions	I-CHEM
Carbon	B-CHEM
ions	I-CHEM
are	O
an	O
up	O
-	O
and	O
-	O
coming	O
ion	B-CHEM
species	I-CHEM
,	O
currently	O
being	O
used	O
in	O
charged	B-PROC
particle	I-PROC
radiotherapy	I-PROC
.	O

As	O
it	O
is	O
well	O
established	O
that	O
there	O
are	O
considerable	O
interindividual	B-LIVB
differences	O
in	O
radiosensitivity	B-PHYS
in	O
the	O
general	B-LIVB
population	I-LIVB
that	O
can	O
significantly	O
influence	O
clinical	B-PHEN
outcomes	I-PHEN
of	O
radiotherapy	B-PROC
,	O
we	O
evaluate	O
the	O
degree	O
of	O
these	O
differences	O
in	O
the	O
context	O
of	O
carbon	B-PROC
ion	I-PROC
therapy	I-PROC
compared	O
with	O
conventional	O
radiotherapy	B-PROC
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
individual	B-LIVB
radiosensitivity	B-PHYS
following	O
exposure	O
to	O
carbon	B-CHEM
-	I-CHEM
13	I-CHEM
ions	B-CHEM
or	O
γ	B-PHEN
-	I-PHEN
rays	I-PHEN
in	O
peripheral	B-ANAT
blood	I-ANAT
lymphocytes	I-ANAT
of	O
healthy	O
individuals	B-LIVB
based	O
on	O
the	O
frequency	O
of	O
ionizing	B-PHEN
radiation	I-PHEN
(	O
IR	B-PHEN
)	O
-	O
induced	O
DNA	B-DISO
double	I-DISO
strand	I-DISO
breaks	I-DISO
(	O
DSBs	B-DISO
)	O
that	O
was	O
either	O
misrepaired	O
or	O
left	O
unrepaired	O
to	O
form	O
chromosomal	B-DISO
aberrations	I-DISO
(	O
CAs	B-DISO
)	O
(	O
simply	O
referred	O
to	O
here	O
as	O
DSBs	B-DISO
for	O
brevity	O
)	O
.	O

Levels	O
of	O
DSBs	B-DISO
were	O
estimated	O
from	O
the	O
scoring	O
of	O
CAs	B-DISO
visualized	O
with	O
telomere	B-ANAT
/	O
centromere	B-ANAT
-	O
fluorescence	B-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
(	O
TC	B-PROC
-	I-PROC
FISH	I-PROC
)	O
.	O

We	O
examine	O
radiosensitivity	B-PHYS
at	O
the	O
dose	O
of	O
2	O
Gy	O
,	O
a	O
routinely	O
administered	O
dose	O
during	O
fractionated	B-PROC
radiotherapy	I-PROC
,	O
and	O
we	O
determined	O
that	O
a	O
wide	O
range	O
of	O
DSBs	B-DISO
were	O
induced	O
by	O
the	O
given	O
dose	O
among	O
healthy	O
individuals	B-LIVB
,	O
with	O
highly	O
radiosensitive	O
individuals	B-LIVB
harboring	O
more	O
IR	B-PHEN
-	O
induced	O
breaks	O
in	O
the	O
genome	O
than	O
radioresistant	O
individuals	B-LIVB
following	O
exposure	B-DISO
to	I-DISO
the	O
same	O
dose	O
.	O

Furthermore	O
,	O
we	O
determined	O
the	O
relative	O
effectiveness	O
of	O
carbon	B-CHEM
irradiation	B-PROC
in	O
comparison	O
to	O
γ	B-PROC
-	I-PROC
irradiation	I-PROC
in	O
the	O
induction	O
of	O
DSBs	B-DISO
at	O
each	O
studied	O
dose	O
(	O
isodose	O
effect	O
)	O
,	O
a	O
quality	O
we	O
term	O
""""	O
relative	O
dose	O
effect	O
""""	O
(	O
RDE	O
)	O
.	O

This	O
ratio	O
is	O
advantageous	O
,	O
as	O
it	O
allows	O
for	O
simple	O
comparison	O
of	O
dose	O
-	O
response	O
curves	O
.	O

At	O
2	O
Gy	O
,	O
carbon	B-PROC
irradiation	I-PROC
was	O
three	O
times	O
more	O
effective	O
in	O
inducing	O
DSBs	B-DISO
compared	O
with	O
γ	B-PROC
-	I-PROC
irradiation	I-PROC
(	O
RDE	O
of	O
3	O
)	O
;	O
these	O
results	O
were	O
confirmed	O
using	O
a	O
second	O
cytogenetic	B-PROC
technique	I-PROC
,	O
multicolor	B-PROC
-	I-PROC
FISH	I-PROC
.	O

We	O
also	O
analyze	O
radiosensitivity	B-PHYS
at	O
other	O
doses	O
(	O
0	O
.	O
2	O
-	O
15	O
Gy	O
)	O
,	O
to	O
represent	O
hypo	B-PROC
-	O
and	O
hyperfractionation	O
doses	O
and	O
determined	O
that	O
RDE	O
is	O
dose	O
dependent	O
:	O
high	O
ratios	O
at	O
low	B-PROC
doses	I-PROC
,	O
and	O
approaching	O
1	O
at	O
high	O
doses	O
.	O

These	O
results	O
could	O
have	O
clinical	O
implications	O
as	O
IR	B-DISO
-	I-DISO
induced	I-DISO
DNA	I-DISO
damage	I-DISO
and	O
the	O
ensuing	O
CAs	B-DISO
and	O
genomic	B-DISO
instability	I-DISO
can	O
have	O
significant	O
cellular	B-ANAT
consequences	O
that	O
could	O
potentially	O
have	O
profound	O
implications	O
for	O
long	O
-	O
term	O
human	B-DISO
health	I-DISO
after	O
IR	B-DISO
exposure	I-DISO
,	O
such	O
as	O
the	O
emergence	O
of	O
secondary	B-DISO
cancers	I-DISO
and	O
other	O
pathobiological	O
conditions	O
after	O
radiotherapy	B-PROC
.	O

Dynamic	B-PROC
Contrast	I-PROC
-	I-PROC
enhanced	I-PROC
MR	I-PROC
Imaging	I-PROC
in	O
Renal	B-DISO
Cell	I-DISO
Carcinoma	I-DISO
:	O
Reproducibility	O
of	O
Histogram	B-OBJC
Analysis	O
on	O
Pharmacokinetic	O
Parameters	O
Pharmacokinetic	O
parameters	O
derived	O
from	O
dynamic	B-PROC
contrast	I-PROC
-	I-PROC
enhanced	I-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
)	O
have	O
been	O
increasingly	O
used	O
to	O
evaluate	O
the	O
permeability	B-PHEN
of	O
tumor	B-DISO
vessel	I-DISO
.	O

Histogram	B-OBJC
metrics	O
are	O
a	O
recognized	O
promising	O
method	O
of	O
quantitative	O
MR	B-PROC
imaging	I-PROC
that	O
has	O
been	O
recently	O
introduced	O
in	O
analysis	O
of	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
pharmacokinetic	O
parameters	O
in	O
oncology	O
due	O
to	O
tumor	O
heterogeneity	O
.	O

In	O
this	O
study	O
,	O
21	O
patients	B-LIVB
with	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
RCC	B-DISO
)	O
underwent	O
paired	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
studies	O
on	O
a	O
3	O
.	O
0	O
T	O
MR	B-DEVI
system	I-DEVI
.	O

Extended	O
Tofts	O
model	O
and	O
population	B-PROC
-	I-PROC
based	I-PROC
arterial	O
input	O
function	O
were	O
used	O
to	O
calculate	O
kinetic	O
parameters	O
of	O
RCC	B-DISO
tumors	B-DISO
.	O

Mean	O
value	O
and	O
histogram	B-OBJC
metrics	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
of	O
each	O
pharmacokinetic	O
parameter	O
were	O
generated	O
automatically	O
using	O
ImageJ	O
software	O
.	O

Intra	O
-	O
and	O
inter	O
-	O
observer	O
reproducibility	O
and	O
scan	O
-	O
rescan	O
reproducibility	O
were	O
evaluated	O
using	O
intra	O
-	O
class	O
correlation	O
coefficients	O
(	O
ICCs	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CoV	O
)	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
histogram	B-OBJC
method	O
(	O
Mode	O
,	O
Skewness	O
and	O
Kurtosis	O
)	O
was	O
not	O
superior	O
to	O
the	O
conventional	O
Mean	O
value	O
method	O
in	O
reproducibility	O
evaluation	O
on	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
pharmacokinetic	O
parameters	O
(	O
K	O
(	O
trans	O
)	O
&	O
Ve	O
)	O
in	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
,	O
especially	O
for	O
Skewness	O
and	O
Kurtosis	O
which	O
showed	O
lower	O
intra	O
-	O
,	O
inter	O
-	O
observer	O
and	O
scan	O
-	O
rescan	O
reproducibility	O
than	O
Mean	O
value	O
.	O

Our	O
findings	O
suggest	O
that	O
additional	O
studies	O
are	O
necessary	O
before	O
wide	O
incorporation	O
of	O
histogram	B-OBJC
metrics	O
in	O
quantitative	O
analysis	O
of	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
pharmacokinetic	O
parameters	O
.	O

Catastrophic	B-DISO
health	O
expenditure	O
:	O
a	O
comparative	B-PROC
analysis	I-PROC
of	O
empty	O
-	O
nest	O
and	O
non	O
-	O
empty	O
-	O
nest	O
households	B-LIVB
with	O
seniors	B-LIVB
in	O
Shandong	B-GEOG
,	I-GEOG
China	I-GEOG
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
compare	O
the	O
catastrophic	B-DISO
health	O
expenditure	O
(	O
CHE	O
)	O
prevalence	O
and	O
its	O
determinants	O
between	O
empty	O
-	O
nest	O
and	O
non	O
-	O
empty	O
-	O
nest	O
elderly	B-LIVB
households	B-LIVB
.	O

Shandong	B-GEOG
province	I-GEOG
of	I-GEOG
China	I-GEOG
.	O

A	O
total	O
of	O
2761	O
elderly	B-LIVB
households	B-LIVB
are	O
included	O
in	O
the	O
analysis	B-PROC
.	O

CHE	O
incidence	O
among	O
elderly	B-LIVB
households	B-LIVB
was	O
44	O
.	O

9	O
%	O
.	O

The	O
CHE	O
incidence	O
of	O
empty	O
-	O
nest	O
singles	B-DISO
(	O
59	O
.	O
3	O
%	O
,	O
p	O
=	O
0	O
.	O

000	O
,	O
OR	O
=	O
3	O
.	O

19	O
)	O
and	O
empty	O
-	O
nest	O
couples	B-LIVB
(	O
52	O
.	O
9	O
%	O
,	O
p	O
=	O
0	O
.	O

000	O
,	O
OR	O
=	O
2	O
.	O

45	O
)	O
are	O
both	O
statistically	O
higher	O
than	O
that	O
of	O
non	O
-	O
empty	O
-	O
nest	O
elderly	B-LIVB
households	B-LIVB
(	O
31	O
.	O

4	O
%	O
)	O
.	O

An	O
inverse	O
association	O
was	O
observed	O
between	O
CHE	O
incidence	O
and	O
income	O
level	O
in	O
all	O
elderly	B-LIVB
household	B-LIVB
types	O
.	O

Factors	O
including	O
1	O
or	O
more	O
household	B-LIVB
elderly	B-LIVB
members	I-LIVB
with	O
non	B-DISO
-	I-DISO
communicable	I-DISO
chronic	I-DISO
diseases	I-DISO
in	O
the	O
past	O
6	O
months	O
,	O
1	O
or	O
more	O
elderly	B-LIVB
household	B-LIVB
members	I-LIVB
being	O
hospitalised	B-DISO
in	O
the	O
past	O
year	O
and	O
lower	O
household	B-LIVB
income	O
,	O
are	O
significant	O
risk	B-DISO
factors	I-DISO
for	O
CHE	O
in	O
all	O
3	O
household	B-LIVB
types	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Health	B-PROC
insurance	I-PROC
status	O
was	O
found	O
to	O
be	O
a	O
significant	O
determinant	O
of	O
CHE	O
among	O
empty	O
-	O
nest	O
singles	B-DISO
and	O
non	O
-	O
empty	O
-	O
nest	O
households	B-LIVB
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CHE	O
incidence	O
among	O
elderly	B-LIVB
households	B-LIVB
is	O
high	O
in	O
China	B-GEOG
.	O

Empty	O
-	O
nest	O
households	B-LIVB
are	O
at	O
higher	O
risk	O
for	O
CHE	O
than	O
non	O
-	O
empty	O
-	O
nest	O
households	B-LIVB
.	O

Based	O
on	O
these	O
findings	B-DISO
,	O
we	O
suggest	O
that	O
special	O
insurance	B-PROC
be	O
developed	O
to	O
broaden	O
the	O
coverage	O
of	O
health	B-PROC
services	I-PROC
and	O
heighten	O
the	O
reimbursement	B-PROC
rate	I-PROC
for	O
empty	O
-	O
nest	O
elderly	B-LIVB
in	O
the	O
existing	O
health	B-PROC
insurance	I-PROC
schemes	O
.	O

Financial	O
and	O
social	O
protection	O
interventions	B-PROC
are	O
also	O
essential	O
for	O
identifie	O
d	O
at	O
-	O
risk	O
subgroups	O
among	O
different	O
types	O
of	O
elderly	B-LIVB
households	B-LIVB
.	O

Antidiabetic	B-CHEM
potential	O
of	O
bioactive	B-OBJC
molecules	I-OBJC
coated	O
chitosan	B-CHEM
nanoparticles	I-CHEM
in	O
experimental	O
rats	B-LIVB
The	O
present	O
study	B-PROC
was	O
carried	O
out	O
to	O
examine	O
the	O
antidiabetic	B-CHEM
effects	O
of	O
chitosan	B-CHEM
nanoparticles	I-CHEM
(	O
CNPs	B-CHEM
)	O
loaded	O
with	O
(	O
Stevia	B-CHEM
rebaudiana	I-CHEM
leaf	I-CHEM
extract	I-CHEM
-	O
SRLE	B-CHEM
)	O
bioactive	B-OBJC
molecules	I-OBJC
in	O
a	O
rat	B-LIVB
model	B-DISO
of	O
streptozotocin	B-CHEM
(	O
STZ	B-CHEM
)	O
induced	O
diabetes	B-DISO
mellitus	I-DISO
.	O

Successful	O
crosslinking	B-PHEN
of	O
the	O
bioactive	B-OBJC
molecules	I-OBJC
to	O
the	O
chitosan	B-CHEM
nanoparticles	I-CHEM
was	O
confirmed	O
by	O
Fourier	B-PROC
Transform	I-PROC
Infrared	I-PROC
Spectroscopy	I-PROC
(	O
FTIR	B-PROC
)	O
.	O

The	O
colloidal	O
characteristics	O
of	O
the	O
synthesized	O
nanoparticles	B-CHEM
were	O
revealed	O
by	O
X	B-PROC
-	I-PROC
ray	I-PROC
Diffraction	I-PROC
(	I-PROC
XRD	I-PROC
)	I-PROC
analysis	I-PROC
.	O

Morphological	O
analysis	B-PROC
by	O
Transmission	B-PROC
Electron	I-PROC
Microscopy	I-PROC
(	O
TEM	B-PROC
)	O
revealed	O
that	O
the	O
bioactive	B-OBJC
molecule	I-OBJC
-loaded	O
CNPs	B-CHEM
were	O
well	O
-	O
dispersed	O
and	O
spherical	O
or	O
polygonal	O
in	O
shape	O
with	O
an	O
average	O
size	O
of	O
<	O
73	O
.	O
27	O
nm	O
than	O
the	O
z	O
-	O
average	O
value	O
(	O
327	O
nm	O
)	O
as	O
measured	O
by	O
Dynamic	B-PROC
Light	I-PROC
Scattering	I-PROC
(	O
DLS	B-PROC
)	O
.	O

SRLE	B-CHEM
CNP	B-CHEM
-	O
treated	O
diabetic	B-DISO
rats	B-LIVB
showed	O
a	O
significant	O
reduction	O
in	O
their	O
mean	O
fasting	B-PHEN
blood	I-PHEN
glucose	I-PHEN
level	I-PHEN
compared	O
with	O
the	O
diabetic	B-DISO
control	B-LIVB
group	I-LIVB
.	O

The	O
serum	B-ANAT
levels	O
of	O
various	O
enzymes	B-CHEM
viz	O
.	O
,	O
serum	B-CHEM
glutamic	I-CHEM
oxaloacetic	I-CHEM
transaminase	I-CHEM
(	O
SGOT	B-CHEM
)	O
,	O
serum	B-CHEM
glutamic	I-CHEM
pyruvic	I-CHEM
transaminase	I-CHEM
(	O
SGPT	B-CHEM
)	O
,	O
alkaline	B-CHEM
phosphatases	I-CHEM
(	O
ALP	B-CHEM
)	O
,	O
lipid	B-PHYS
peroxidation	I-PHYS
,	O
and	O
antioxidant	B-CHEM
such	O
as	O
catalase	B-CHEM
(	O
CAT	B-CHEM
)	O
,	O
reduced	B-PHEN
glutathione	I-PHEN
(	O
GSH	B-PHEN
)	O
,	O
and	O
superoxide	B-CHEM
dismutase	I-CHEM
(	O
SOD	B-CHEM
)	O
in	O
the	O
SRLE	B-CHEM
CNP	B-CHEM
-	O
treated	O
group	O
were	O
closer	O
to	O
normal	O
levels	O
than	O
those	O
in	O
the	O
diabetic	B-DISO
control	B-LIVB
group	I-LIVB
.	O

Role	O
of	O
agonistic	B-CHEM
autoantibodies	I-CHEM
against	O
type	B-CHEM
-	I-CHEM
1	I-CHEM
angiotensin	I-CHEM
II	I-CHEM
receptor	I-CHEM
in	O
the	O
pathogenesis	B-DISO
of	O
retinopathy	B-DISO
in	O
preeclampsia	B-DISO
To	O
investigate	O
the	O
mechanism	O
underlying	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
-induced	O
retinopathy	B-DISO
in	O
severe	O
preeclampsia	B-DISO
by	O
measuring	O
the	O
positive	O
rate	O
and	O
titer	O
of	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
in	O
plasma	B-ANAT
from	O
women	B-LIVB
with	O
severe	B-DISO
preeclampsia	I-DISO
and	O
normal	O
pregnant	B-LIVB
women	I-LIVB
to	O
see	O
whether	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
titer	O
was	O
correlated	O
with	O
the	O
grade	O
of	O
retinopathy	B-DISO
.	O

A	O
preeclampsia	B-DISO
rat	B-LIVB
model	B-LIVB
was	O
also	O
established	O
by	O
intravenous	O
injection	O
of	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
extracted	O
from	O
the	O
plasma	B-ANAT
of	O
patient	B-LIVB
suffering	O
from	O
severe	B-DISO
preeclampsia	I-DISO
.	O

The	O
results	O
showed	O
that	O
the	O
plasma	B-ANAT
titer	O
and	O
positive	O
rate	O
of	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
were	O
significantly	O
higher	O
in	O
women	B-LIVB
with	O
severe	B-DISO
preeclampsia	I-DISO
than	O
normal	O
pregnant	B-LIVB
women	I-LIVB
.	O

The	O
antibody	B-CHEM
titer	O
in	O
cases	O
of	O
severe	O
preeclampsia	B-DISO
was	O
associated	O
with	O
the	O
grade	O
of	O
retinopathy	B-DISO
,	O
and	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
and	O
VEGF	B-CHEM
.	O

The	O
animal	B-PROC
experiment	I-PROC
results	O
showed	O
that	O
the	O
modeled	B-LIVB
rats	I-LIVB
presented	O
symptoms	B-DISO
very	O
similar	O
to	O
symptoms	B-DISO
of	O
human	B-LIVB
preeclampsia	B-DISO
,	O
including	O
retinopathy	B-DISO
.	O

Ocular	B-ANAT
fundus	I-ANAT
examination	B-PROC
showed	O
retinal	B-DISO
microvascular	I-DISO
abnormalities	I-DISO
,	O
hemorrhaging	B-DISO
and	O
leakage	B-DISO
in	O
the	O
severe	B-DISO
preeclampsia	I-DISO
.	O

Morphological	O
changes	O
included	O
edema	B-DISO
,	O
thickening	B-DISO
of	O
the	O
INL	B-ANAT
and	O
ONL	B-ANAT
,	O
and	O
pigment	B-DISO
atrophy	I-DISO
.	O

TNF	B-CHEM
-	I-CHEM
α	I-CHEM
and	O
VEGF	B-CHEM
levels	O
were	O
increased	O
in	O
the	O
vitreous	B-ANAT
humor	I-ANAT
and	O
retina	B-ANAT
of	O
the	O
model	B-LIVB
rats	I-LIVB
.	O

Our	O
studies	B-PROC
results	O
suggest	O
that	O
abnormal	B-PHYS
expression	I-PHYS
of	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
could	O
induce	O
damage	O
to	O
retinal	B-ANAT
capillary	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
and	O
increase	O
vascular	B-PHYS
permeability	I-PHYS
,	O
resulting	O
in	O
retinopathy	B-DISO
.	O

Monosubstituted	B-CHEM
Benzene	I-CHEM
Derivatives	I-CHEM
from	O
Fruits	B-OBJC
of	O
Ficus	B-LIVB
hirta	I-LIVB
and	O
Their	O
Antifungal	B-DISO
Activity	I-DISO
against	O
Phytopathogen	B-LIVB
Penicillium	B-LIVB
italicum	I-LIVB
Ficus	B-LIVB
hirta	I-LIVB
,	O
a	O
widely	O
consumed	O
food	B-OBJC
by	O
Hakka	O
people	B-LIVB
,	O
has	O
been	O
reported	B-PROC
to	O
show	O
potent	O
antifungal	B-DISO
activity	I-DISO
against	O
phytopathogen	B-LIVB
Penicillium	B-LIVB
italicum	I-LIVB
.	O

However	O
,	O
there	O
is	O
no	O
report	B-PROC
of	O
chemical	B-OBJC
constituents	I-OBJC
responsible	O
for	O
the	O
antifungal	B-DISO
activity	I-DISO
.	O

In	O
the	O
current	O
study	B-PROC
,	O
nine	O
monosubstituted	B-CHEM
benzene	I-CHEM
derivatives	I-CHEM
,	O
including	O
three	O
new	O
derivatives	B-CHEM
(	O
1	O
-	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
fruits	B-OBJC
of	O
F	B-LIVB
.	I-LIVB

hirta	I-LIVB
.	O

The	O
structures	O
of	O
these	O
isolates	B-CHEM
were	O
elucidated	O
on	O
the	O
basis	O
of	O
the	O
analysis	B-PROC
of	O
spectroscopic	O
data	O
(	O
mass	B-PROC
spectrometry	I-PROC
and	O
nuclear	B-PHEN
magnetic	I-PHEN
resonance	I-PHEN
)	O
.	O

All	O
of	O
the	O
isolates	B-CHEM
were	O
evaluated	B-PROC
for	O
antifungal	B-DISO
activities	I-DISO
against	O
P	B-LIVB
.	I-LIVB

italicum	I-LIVB
.	O

At	O
an	O
equivalent	O
concentration	O
,	O
compound	O
1	O
exhibited	O
stronger	O
antifungal	B-DISO
activity	I-DISO
than	O
that	O
of	O
the	O
ethanol	B-CHEM
extract	B-OBJC
of	O
F	B-LIVB
.	I-LIVB

hirta	I-LIVB
fruits	B-OBJC
.	O

Characterizing	O
sexual	B-PHYS
function	I-PHYS
in	O
patients	B-LIVB
with	O
generalized	B-DISO
anxiety	I-DISO
disorder	I-DISO
:	O
a	O
pooled	B-PROC
analysis	I-PROC
of	O
three	O
vilazodone	B-CHEM
studies	B-PROC
Vilazodone	B-CHEM
has	O
been	O
shown	O
to	O
reduce	O
core	B-DISO
symptoms	I-DISO
of	O
generalized	B-DISO
anxiety	I-DISO
disorder	I-DISO
(	O
GAD	B-DISO
)	O
in	O
three	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
trials	I-PROC
.	O

Since	O
sexual	B-DISO
dysfunction	I-DISO
(	O
SD	B-DISO
)	O
is	O
not	O
well	O
characterized	O
in	O
GAD	B-DISO
,	O
a	O
post	B-PROC
hoc	I-PROC
analysis	I-PROC
of	O
these	O
trials	B-PROC
was	O
conducted	O
to	O
evaluate	B-PROC
the	O
effects	O
of	O
vilazodone	B-CHEM
on	O
sexual	B-PHYS
functioning	I-PHYS
in	O
GAD	B-DISO
patients	B-LIVB
.	O

Data	O
were	O
pooled	O
from	O
one	O
fixed	B-PROC
-	I-PROC
dose	I-PROC
trial	I-PROC
of	O
vilazodone	B-CHEM
20	O
and	O
40	O
mg	O
/	O
day	O
(	O
NCT01629966	O
)	O
and	O
two	O
flexible	B-PROC
-	I-PROC
dose	I-PROC
studies	I-PROC
of	O
vilazodone	B-CHEM
20	O
-	O
40	O
mg	O
/	O
day	O
(	O
NCT01766401	O
,	O
NCT01844115	O
)	O
in	O
adults	B-LIVB
with	O
GAD	B-DISO
.	O

Sexual	B-PHYS
functioning	I-PHYS
was	O
assessed	O
using	O
the	O
Changes	O
in	O
Sexual	O
Functioning	O
Questionnaire	O
(	O
CSFQ	O
)	O
.	O

Outcomes	B-PROC
included	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
of	O
treatment	O
(	O
EOT	O
)	O
in	O
CSFQ	B-DISO
total	I-DISO
score	I-DISO
and	O
percentage	O
of	O
patients	B-LIVB
shifting	O
from	O
SD	B-DISO
at	O
baseline	O
(	O
CSFQ	B-DISO
total	I-DISO
score	I-DISO
≤47	O
for	O
males	B-LIVB
,	O
≤41	O
for	O
females	B-LIVB
)	O
to	O
normal	B-DISO
functioning	I-DISO
at	O
EOT	O
.	O

Treatment	B-DISO
-	I-DISO
emergent	I-DISO
adverse	I-DISO
events	I-DISO
related	O
to	O
sexual	B-PHYS
functioning	I-PHYS
were	O
also	O
analyzed	B-PROC
.	O

A	O
total	O
of	O
1	O
,	O
373	O
patients	B-LIVB
were	O
included	O
in	O
the	O
analyses	B-PROC
.	O

SD	B-DISO
at	O
baseline	O
was	O
more	O
common	O
in	O
females	B-LIVB
(	O
placebo	B-CHEM
,	O
46	O
.	O
4	O
%	O
;	O
vilazodone	B-CHEM
,	O
49	O
%	O
)	O
than	O
in	O
males	B-LIVB
(	O
placebo	B-CHEM
,	O
35	O
.	O
1	O
%	O
;	O
vilazodone	B-CHEM
,	O
40	O
.	O
9	O
%	O
)	O
.	O

CSFQ	B-DISO
total	I-DISO
score	I-DISO
improvement	O
was	O
found	O
in	O
both	O
females	B-LIVB
(	O
placebo	B-CHEM
,	O
+1	O
.	O

2	O
;	O
vilazodone	B-CHEM
,	O
+1	O
.	O

6	O
)	O
and	O
males	B-LIVB
(	O
placebo	B-CHEM
,	O
+2	O
.	O
1	O
;	O
vilazodone	B-CHEM
,	O
+1	O
.	O

0	O
)	O
,	O
with	O
no	B-DISO
statistically	I-DISO
significant	I-DISO
differences	I-DISO
between	O
treatment	O
groups	O
.	O

The	O
percentage	O
of	O
patients	B-LIVB
who	O
shifted	O
from	O
SD	B-DISO
at	O
baseline	O
to	O
normal	O
sexual	B-PHYS
functioning	I-PHYS
at	O
EOT	O
was	O
higher	O
in	O
males	B-LIVB
(	O
placebo	B-CHEM
,	O
40	O
.	O

6	O
%	O
;	O
vilazodone	B-CHEM
,	O
35	O
.	O
7	O
%	O
)	O
than	O
in	O
females	B-LIVB
(	O
placebo	B-CHEM
,	O
24	O
.	O
9	O
%	O
;	O
vilazodone	B-CHEM
,	O
34	O
.	O
9	O
%	O
)	O
;	O
no	B-DISO
statistical	I-DISO
testing	I-DISO
was	O
performed	O
.	O

Except	O
for	O
erectile	B-DISO
dysfunction	I-DISO
and	O
delayed	B-DISO
ejaculation	I-DISO
in	O
vilazodone	B-CHEM
-	O
treated	O
males	B-LIVB
(	O
2	O
.	O
4	O
%	O
and	O
2	O
.	O
1	O
%	O
,	O
respectively	O
)	O
,	O
no	B-DISO
treatment	I-DISO
-	I-DISO
emergent	I-DISO
adverse	I-DISO
events	I-DISO
related	O
to	O
sexual	B-PHYS
functioning	I-PHYS
occurred	O
in	O
≥2	O
%	O
of	O
patients	B-LIVB
in	O
either	O
treatment	O
group	O
.	O

Approximately	O
35	O
%	O
-	O
50	O
%	O
of	O
patients	B-LIVB
in	O
the	O
vilazodone	B-CHEM
GAD	B-DISO
studies	B-PROC
had	O
SD	B-DISO
at	O
baseline	O
.	O

Vilazodone	B-CHEM
and	O
placebo	B-CHEM
had	O
similar	O
effects	O
on	O
CSFQ	O
outcomes	B-PROC
in	O
both	O
females	B-LIVB
and	O
males	B-LIVB
,	O
indicating	O
a	O
limited	O
adverse	B-DISO
impact	I-DISO
on	O
sexual	B-PHYS
functioning	I-PHYS
with	O
vilazodone	B-CHEM
.	O

Effects	O
of	O
analgesics	B-CHEM
and	O
antidepressants	B-CHEM
on	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
currents	B-PHYS
TWIK	B-CHEM
-	I-CHEM
related	I-CHEM
K	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
channel	I-CHEM
-	I-CHEM
2	I-CHEM
(	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
)	O
and	O
TWIK	B-CHEM
-	I-CHEM
related	I-CHEM
spinal	I-CHEM
cord	I-CHEM
K	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
(	I-CHEM
TRESK	I-CHEM
)	I-CHEM
channel	I-CHEM
are	O
members	O
of	O
two	B-CHEM
-	I-CHEM
pore	I-CHEM
domain	I-CHEM
K	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
channel	I-CHEM
family	I-CHEM
.	O

They	O
are	O
well	O
expressed	B-PHYS
and	O
help	O
to	O
set	O
the	O
resting	B-PHYS
membrane	I-PHYS
potential	I-PHYS
in	O
sensory	B-ANAT
neurons	I-ANAT
.	O

Modulation	B-PHEN
of	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
channels	I-CHEM
are	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
pain	B-DISO
,	O
and	O
specifi	O
c	O
activators	B-CHEM
of	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
may	O
be	O
benefi	O
cial	O
for	O
the	O
treatment	B-PROC
of	O
pain	B-DISO
symptoms	B-DISO
.	O

However	O
,	O
the	O
effect	O
of	O
commonly	O
used	O
analgesics	B-CHEM
on	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
channels	I-CHEM
are	O
not	O
known	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
analgesics	B-CHEM
on	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
channels	B-CHEM
.	O

The	O
effects	O
of	O
analgesics	B-CHEM
were	O
examined	O
in	O
HEK	B-ANAT
cells	I-ANAT
transfected	B-PROC
with	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
or	O
TRESK	B-CHEM
.	O

Amitriptyline	B-CHEM
,	O
citalopram	B-CHEM
,	O
escitalopram	B-CHEM
,	O
and	O
fluoxetine	B-CHEM
significantly	O
inhibited	B-PHYS
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
currents	B-PHYS
in	O
HEK	B-ANAT
cells	I-ANAT
(	O
p	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
10	O
)	O
.	O

Acetaminophen	B-CHEM
,	O
ibuprofen	B-CHEM
,	O
nabumetone	B-CHEM
,	O
and	O
bupropion	B-CHEM
inhibited	O
TRESK	B-CHEM
,	O
but	O
had	O
no	O
effect	O
on	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
.	O

These	O
results	O
show	O
that	O
all	O
analgesics	B-CHEM
tested	O
in	O
this	O
study	O
inhibit	B-PHYS
TRESK	B-CHEM
activity	B-PHYS
.	O

Further	O
study	O
is	O
needed	O
to	O
identify	O
the	O
mechanisms	B-PHYS
by	O
which	O
the	O
analgesics	B-CHEM
modulate	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
TRESK	B-CHEM
differently	O
.	O

Establishment	O
of	O
a	O
mouse	B-DISO
model	I-DISO
of	O
70	O
%	O
lethal	O
dose	O
by	O
total	B-PROC
-	I-PROC
body	I-PROC
irradiation	I-PROC
Whereas	O
increasing	O
concerns	O
about	O
radiation	B-DISO
exposure	I-DISO
to	O
nuclear	B-PHEN
disasters	I-PHEN
or	O
side	B-DISO
effects	I-DISO
of	O
anticancer	B-PROC
radiotherapy	B-PROC
,	O
relatively	O
little	O
research	B-PROC
for	O
radiation	B-DISO
damages	I-DISO
or	O
remedy	O
has	O
been	O
done	O
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
establish	O
level	O
of	O
LD	O
70	O
/	O
30	O
(	O
a	O
lethal	O
dose	O
for	O
70	O
%	O
of	O
mice	B-LIVB
within	O
30	O
days	O
)	O
by	O
total	B-PROC
-	I-PROC
body	I-PROC
γ	I-PROC
irradiation	I-PROC
(	O
TBI	B-PROC
)	O
in	O
a	O
mouse	B-DISO
model	I-DISO
.	O

For	O
this	O
purpose	O
,	O
at	O
first	O
,	O
8	O
-	O
week	O
-	O
old	O
male	B-PHYS
ICR	B-LIVB
and	O
C57BL	B-LIVB
/	I-LIVB
6N	I-LIVB
mice	I-LIVB
from	O
A	B-OBJC
and	O
B	B-OBJC
companies	I-OBJC
were	O
received	O
high	O
dose	O
(	O
10	O
,	O
11	O
,	O
12	O
Gy	O
)	O
TBI	B-PROC
.	O

After	O
irradiation	B-PHEN
,	O
the	O
body	B-PHYS
weight	I-PHYS
and	O
survival	O
rate	O
were	O
monitored	B-PROC
for	O
30	O
days	O
consecutively	O
.	O

In	O
next	O
experiment	B-PROC
,	O
5	O
-	O
week	O
-	O
old	O
male	B-PHYS
ICR	B-LIVB
and	O
C57BL	B-LIVB
/	I-LIVB
6N	I-LIVB
mice	I-LIVB
from	O
B	B-OBJC
company	I-OBJC
were	O
received	O
same	O
dose	O
irradiation	B-PHEN
.	O

Results	O
showed	O
that	O
survival	O
rate	O
and	O
body	B-DISO
weight	I-DISO
change	I-DISO
rate	O
in	O
inbred	B-LIVB
C57BL	I-LIVB
/	I-LIVB
6N	I-LIVB
mice	I-LIVB
were	O
similar	O
between	O
A	B-OBJC
and	O
B	B-OBJC
company	I-OBJC
.	O

In	O
ICR	B-LIVB
mice	I-LIVB
,	O
however	O
,	O
survival	O
rate	O
and	O
body	B-DISO
weight	I-DISO
change	I-DISO
rate	O
were	O
completely	O
different	O
among	O
the	O
companies	B-OBJC
.	O

Significant	O
difference	O
of	O
survival	O
rate	O
both	O
ICR	B-LIVB
and	O
C57BL6N	B-LIVB
mice	I-LIVB
was	O
not	O
observed	O
in	O
between	O
5	O
-	O
week	O
-	O
old	O
and	O
8	O
-	O
week	O
-	O
old	O
groups	O
receiving	O
10	O
or	O
12	O
Gy	O
TBI	B-PROC
.	O

Our	O
results	O
indicate	O
that	O
the	O
strain	B-LIVB
and	O
age	B-PHYS
of	O
mice	B-LIVB
,	O
and	O
even	O
purchasing	O
company	B-OBJC
(	O
especially	O
outbred	B-LIVB
)	O
,	O
should	O
be	O
matched	O
over	O
experimental	O
groups	O
in	O
TBI	B-PROC
experiment	B-PROC
.	O

Based	O
on	O
our	O
results	O
,	O
8	O
-	O
week	O
-	O
old	O
male	B-PHYS
ICR	B-LIVB
mice	O
from	O
B	B-OBJC
company	I-OBJC
subjected	O
to	O
12	O
Gy	O
of	O
TBI	B-PROC
showed	O
LD	O
70	O
/	O
30	O
and	O
suitable	O
as	O
a	O
mouse	B-DISO
model	I-DISO
for	O
further	O
development	O
of	O
new	O
drug	B-CHEM
using	O
the	O
ideal	O
total	B-PROC
-	I-PROC
body	I-PROC
irradiation	I-PROC
model	O
.	O

Dominant	B-DISO
and	O
Non	O
-	O
Dominant	B-DISO
Frequency	O
Structure	O
of	O
Evoked	O
Ventricular	B-DISO
Fibrillation	I-DISO
in	O
Dogs	B-LIVB
with	O
Myocardial	B-DISO
Ischemia	I-DISO
The	O
first	O
10	O
min	O
of	O
electrically	B-PROC
provoked	I-PROC
ventricular	B-DISO
fibrillation	I-DISO
in	O
dogs	B-LIVB
with	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
were	O
characterized	O
by	O
organized	O
myocardial	B-PHYS
activity	I-PHYS
evidenced	O
by	O
the	O
dominant	B-DISO
ECG	I-DISO
frequency	I-DISO
structure	O
.	O

During	O
the	O
first	O
2	O
min	O
of	O
ventricular	B-DISO
fibrillation	I-DISO
,	O
low	O
-	O
frequency	O
oscillations	O
(	O
4	O
-	O
7	O
Hz	O
)	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-DISO
,	O
the	O
dominant	B-DISO
frequencies	I-DISO
were	O
low	O
and	O
medium	O
(	O
4	O
-	O
12	O
Hz	O
)	O
.	O

After	O
10	O
-	O
min	O
fibrillation	B-DISO
,	O
the	O
oscillations	B-PROC
became	O
non	O
-	O
dominant	B-DISO
.	O

Thus	O
,	O
ischemic	B-DISO
myocardium	I-DISO
maintains	O
the	O
organized	O
structure	O
of	O
ventricular	B-DISO
fibrillation	I-DISO
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	O
of	O
automatic	B-PROC
diagnostics	I-PROC
of	O
abnormal	B-DISO
cardiac	I-DISO
activity	I-DISO
in	O
humans	B-LIVB
.	O

Adverse	B-DISO
events	I-DISO
risk	O
associated	O
with	O
angiogenesis	B-CHEM
inhibitors	I-CHEM
addition	O
to	O
therapy	B-PROC
in	O
ovarian	B-DISO
cancer	I-DISO
:	O
a	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
Inhibition	B-PHYS
of	I-PHYS
angiogenesis	I-PHYS
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-PROC
strategy	I-PROC
for	O
advanced	B-DISO
or	O
recurrent	B-DISO
ovarian	I-DISO
cancer	I-DISO
.	O

We	O
conduct	O
this	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
to	O
investigate	O
the	O
risk	O
of	O
adverse	B-DISO
events	I-DISO
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B-CHEM
inhibitors	I-CHEM
(	O
AIs	B-CHEM
)	O
in	O
ovarian	B-DISO
cancer	I-DISO
.	O

Databases	O
from	O
PubMed	O
,	O
Web	O
of	O
Science	O
and	O
Cochrane	B-OBJC
library	I-OBJC
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	B-PROC
.	O

Eligible	O
studies	B-PROC
included	O
prospective	B-PROC
randomized	I-PROC
controlled	I-PROC
phase	I-PROC
II	I-PROC
/	I-PROC
III	I-PROC
clinical	I-PROC
trials	I-PROC
evaluating	B-PROC
therapy	B-PROC
with	O
or	O
without	O
AIs	B-CHEM
for	O
ovarian	B-DISO
cancer	I-DISO
.	O

Summary	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
using	O
random	O
-	O
effects	O
or	O
fixed	O
-	O
effects	O
according	O
to	O
the	O
heterogeneity	O
among	O
included	O
trials	B-PROC
.	O

A	O
total	O
of	O
7	O
,	O
761	O
patients	B-LIVB
from	O
ten	O
clinical	B-PROC
trials	I-PROC
were	O
included	O
in	O
the	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
AIs	B-CHEM
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	B-DISO
thromboembolic	I-DISO
events	O
(	O
RR	O
=	O
2	O
.	O
0	O
)	O
,	O
gastrointestinal	B-DISO
(	I-DISO
GI	I-DISO
)	I-DISO
perforation	I-DISO
(	O
RR	O
=	O
3	O
.	O
86	O
)	O
,	O
proteinuria	B-DISO
(	O
RR	O
=	O
2	O
.	O
44	O
)	O
,	O
and	O
hypertension	B-DISO
(	O
RR	O
=	O
5	O
.	O
39	O
)	O
.	O

No	B-DISO
statistically	I-DISO
significant	I-DISO
differences	O
were	O
found	O
for	O
hemorrhagic	B-DISO
events	O
(	O
p	O
=	O
0	O
.	O

07	O
)	O
,	O
venous	B-DISO
thromboembolic	I-DISO
events	O
(	O
p	O
=	O
0	O
.	O
13	O
)	O
,	O
or	O
fatal	O
adverse	B-DISO
events	I-DISO
(	O
p	O
=	O
0	O
.	O
26	O
)	O
.	O

The	O
addition	O
of	O
AIs	B-CHEM
to	O
therapy	B-PROC
in	O
ovarian	B-DISO
cancer	I-DISO
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	B-DISO
thromboembolic	I-DISO
events	O
,	O
GI	B-DISO
perforation	I-DISO
,	O
proteinuria	B-DISO
and	O
hypertension	B-DISO
,	O
but	O
not	O
for	O
venous	B-DISO
thromboembolic	I-DISO
events	O
,	O
hemorrhagic	B-DISO
events	O
,	O
or	O
fatal	O
adverse	B-DISO
events	I-DISO
.	O

Phytochemical	B-CHEM
screening	B-PROC
,	O
antiglycation	B-PHEN
and	O
antioxidant	B-PHEN
activities	I-PHEN
of	O
whole	B-LIVB
plant	I-LIVB
of	O
Boerhavia	B-LIVB
repens	I-LIVB
L	I-LIVB
.	I-LIVB
from	O
Cholistan	B-GEOG
,	O
Pakistan	B-GEOG
Present	O
study	B-PROC
was	O
aimed	O
to	O
explore	O
a	O
traditionally	O
used	O
indigenous	O
medicinal	B-LIVB
plant	I-LIVB
Boerhavia	B-LIVB
repens	I-LIVB
(	O
Nyctaginaceae	B-LIVB
family	B-LIVB
)	O
of	O
the	O
Cholistan	B-GEOG
desert	I-GEOG
,	O
Pakistan	B-GEOG
.	O

Crude	B-OBJC
aqueous	I-OBJC
and	O
methanolic	B-OBJC
extracts	I-OBJC
of	O
the	O
whole	B-LIVB
plant	I-LIVB
were	O
investigated	O
in	O
vitro	O
for	O
preliminary	O
phytochemical	B-CHEM
screening	B-PROC
,	O
antioxidant	B-PHYS
and	O
antiglycation	B-PHEN
activities	I-PHEN
.	O

Antioxidant	B-PHYS
activities	I-PHYS
were	O
determined	O
by	O
total	O
phenolic	B-CHEM
contents	O
,	O
1	B-CHEM
,	I-CHEM
1	I-CHEM
-	I-CHEM
diphenyl	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
picrylhydrazyl	I-CHEM
(	I-CHEM
DPPH	I-CHEM
)	I-CHEM
free	I-CHEM
radical	I-CHEM
scavenging	B-PHEN
and	O
inhibition	O
of	O
lipid	B-CHEM
peroxidation	B-PHEN
.	O

For	O
antiglycation	B-PHEN
activities	I-PHEN
browning	B-PHEN
production	O
was	O
noted	O
and	O
thiobarbituric	B-CHEM
acid	I-CHEM
(	O
TBA	B-CHEM
)	O
technique	B-PROC
was	O
used	O
to	O
determine	O
glycation	O
level	O
.	O

Boerhavia	B-LIVB
repens	I-LIVB
expressed	O
considerable	O
amounts	O
of	O
phytochemicals	B-CHEM
.	O

Extract	B-OBJC
yield	O
was	O
found	O
to	O
be	O
4	O
.	O

59	O
%	O
-	O
7	O
.	O

85	O
%	O
g	O
/	O
100	O
g	O
of	O
dry	B-OBJC
matter	I-OBJC
with	O
total	O
phenolics	B-CHEM
ranging	O
from	O
47	O
.	O

9	O
-	O
190	O
.	O

77mg	O
/	O
GAE	O
per	O
g	O
for	O
aqueous	B-OBJC
and	O
methanol	B-OBJC
extract	I-OBJC
respectively	O
.	O

Strong	O
inhibitory	O
effect	O
was	O
exhibited	O
by	O
methanolic	B-OBJC
extract	I-OBJC
in	O
linoleic	B-CHEM
acid	I-CHEM
per	B-PHEN
oxidation	I-PHEN
system	O
(	O
86	O
.	O
11	O
%	O
,	O
EC50	O
=	O
0	O
.	O
99mg	O
/	O
mL	O
)	O
and	O
DPPH	B-CHEM
assay	B-PROC
(	O
88	O
.	O
65	O
%	O
,	O
EC50	O
=	O
212	O
.	O

33μg	O
/	O
ml	O
)	O
.	O

In	O
term	O
of	O
browning	B-PHEN
maximum	O
inhibition	O
(	O
81	O
.	O

50	O
%	O
)	O
was	O
exhibited	O
by	O
methanolic	B-OBJC
extract	I-OBJC
at	O
37°C	O
at	O
third	O
week	O
of	O
incubation	B-PROC
.	O

Both	O
extracts	B-OBJC
expressed	O
significant	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
and	O
comparable	O
inhibition	O
of	O
glycation	O
level	O
.	O

In	O
conclusion	O
,	O
Boerhavia	B-LIVB
repens	I-LIVB
showed	O
promising	O
antioxidant	B-PHYS
and	O
antiglycation	B-PHEN
activities	I-PHEN
validating	O
its	O
therapeutic	O
potential	O
.	O

In	O
vitro	O
genotoxicity	B-DISO
of	O
pyridine	B-CHEM
in	O
human	B-LIVB
lymphocytes	B-ANAT
This	O
work	O
was	O
carried	O
out	O
to	O
study	O
the	O
genotoxicity	B-DISO
of	O
pyridine	B-CHEM
in	O
vitro	O
on	O
human	B-LIVB
leucocyte	B-ANAT
culture	O
.	O

Cyclophosphamide	B-CHEM
,	O
a	O
well	O
-	O
known	O
carcinogen	B-CHEM
was	O
used	O
as	O
positive	O
control	O
.	O

The	O
four	O
different	O
concentrations	O
of	O
pyridine	B-CHEM
and	O
cyclophosphamide	B-CHEM
showed	O
breaks	B-DISO
and	O
pulverization	B-DISO
of	I-DISO
chromosomes	I-DISO
in	O
dose	O
dependent	O
manner	O
.	O

Higher	O
number	O
of	O
pulverization	B-DISO
was	O
observed	O
with	O
higher	O
concentration	O
of	O
pyridine	B-CHEM

(	O
3	O
.	O
25μg	O
/	O
mL	O
)	O
.	O

Based	O
on	O
this	O
data	O
,	O
our	O
results	O
confirm	O
that	O
both	O
pyridine	B-CHEM
and	O
its	O
precursor	O
showed	O
genotoxicity	B-DISO
against	O
human	B-LIVB
lymphocytes	B-ANAT
.	O

Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
against	O
peptides	B-CHEM
products	I-CHEM
of	O
enzymatic	B-CHEM
cleavage	B-PHYS
of	O
APP	B-CHEM
protein	I-CHEM
.	O

Forming	O
and	O
variety	O
of	O
fibrillating	B-CHEM
peptides	I-CHEM
-	O
some	O
aspects	O
Various	O
and	O
different	O
peptides	B-CHEM
products	I-CHEM
resulting	O
from	O
enzymatic	B-CHEM
protein	B-PHYS
cleavage	I-PHYS
of	O
Amyloid	B-CHEM
Precursor	I-CHEM
Proteins	I-CHEM
(	O
APP	B-CHEM
)	O
are	O
the	O
main	O
agents	B-CHEM
in	O
the	O
pathophysiology	O
of	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O
AD	B-DISO
)	O
.	O

Although	O
relatively	O
well	O
-	O
known	O
,	O
they	O
still	O
arouse	O
interest	O
leading	O
to	O
further	O
intense	O
and	O
wide	O
-	O
ranging	O
research	B-PROC
.	O

Their	O
biology	B-PHYS
and	O
physico	O
-	O
chemical	O
properties	O
still	O
are	O
challenging	O
for	O
basic	O
,	O
experimental	B-PROC
research	I-PROC
and	O
are	O
matter	O
of	O
scientific	O
debate	O
.	O

The	O
APP	B-CHEM
itself	O
and	O
its	O
functions	B-PHYS
are	O
still	O
somewhat	O
enigmatic	O
and	O
therefore	O
it	O
is	O
also	O
called	O
the	O
All	O
Purpose	O
Protein	B-CHEM
.	O

Apart	O
from	O
well	O
known	O
amyloidogenic	B-PHYS
and	O
antiamyloidogenic	B-PHYS
(	I-PHYS
non	I-PHYS
-	I-PHYS
amyloidogenic	I-PHYS
)	I-PHYS
enzymatic	I-PHYS
cleavage	I-PHYS
pathways	I-PHYS
of	O
APP	B-CHEM
protein	I-CHEM
this	O
paper	O
deals	O
with	O
issues	B-DISO
connected	O
with	O
other	O
,	O
alternative	O
pathways	B-PHYS
that	O
seem	O
to	O
be	O
interesting	O
and	O
important	O
as	O
well	O
.	O

They	O
lead	O
to	O
other	O
than	O
Aβ	B-CHEM
forms	I-CHEM
of	I-CHEM
peptide	I-CHEM
products	I-CHEM
such	O
as	O
:	O
N	B-CHEM
-	I-CHEM
APP	I-CHEM
,	O
N	O
-	O
terminally	O
cleavage	O
products	O
of	O
APP	B-CHEM
(	O
N	B-CHEM
-	I-CHEM
terminally	I-CHEM
truncated	I-CHEM
)	O
Aβ	B-CHEM
'	I-CHEM
,	O
γ	B-CHEM
-	I-CHEM
secretase	I-CHEM
-independent	I-CHEM
pathway	I-CHEM
products	I-CHEM
that	O
involve	O
concerted	O
cleavages	B-PHYS
of	O
APP	B-CHEM
by	O
α	B-CHEM
-	I-CHEM
and	O
β	B-CHEM
-	I-CHEM
secretase	I-CHEM
or	O
products	B-CHEM
that	O
emerge	O
after	O
caspase	B-PHYS
activity	I-PHYS
.	O

Presence	O
of	O
all	O
these	O
peptides	B-CHEM
in	O
CSF	B-ANAT
,	O
ISF	B-ANAT
,	O
blood	B-ANAT
serum	I-ANAT
and	O
urine	B-ANAT
of	O
the	O
AD	B-DISO
patients	B-LIVB
is	O
crucial	O
for	O
successful	O
diagnosis	B-PROC
,	O
giving	O
rise	O
to	O
hope	O
of	O
their	O
better	O
detection	B-DISO
and	O
potentially	O
better	O
treatment	B-PROC
of	O
AD	B-DISO
.	O

Therefore	O
,	O
newly	O
discovered	O
products	B-CHEM
of	O
the	O
AβT	B-PHYS
domain	I-PHYS
cleavage	I-PHYS
(	O
Aβ	B-CHEM
total	I-CHEM
i	O
.	O

e	O
.	O

full	O
fibrillating	B-CHEM
domain	I-CHEM
of	I-CHEM
APP	I-CHEM
)	O
,	O
Aβ	B-CHEM
type	I-CHEM
products	I-CHEM
and	O
other	O
peptides	B-CHEM
because	O
of	O
their	O
biology	B-PHYS
and	O
physico	O
-	O
chemical	O
properties	O
are	O
very	O
intriguing	O
and	O
deserve	O
further	O
experimental	B-PROC
research	I-PROC
.	O

On	O
the	O
other	O
hand	O
after	O
better	O
recognition	O
and	O
better	O
understanding	O
their	O
biology	B-PHYS
they	O
might	O
be	O
enormously	O
useful	O
in	O
the	O
future	O
for	O
diagnosis	B-PROC
and	O
therapy	B-PROC
for	O
example	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
.	O

Clinical	B-DISO
Significance	I-DISO
of	O
2	O
Deep	B-ANAT
Posterior	I-ANAT
Perianal	I-ANAT
Spaces	I-ANAT
to	O
Complex	O
Cryptoglandular	B-ANAT
Fistulas	B-DISO
Confusion	O
exists	O
regarding	O
the	O
clinical	B-DISO
significance	I-DISO
of	O
the	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
and	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
to	O
complex	O
perianal	B-DISO
fistulas	I-DISO
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
assess	O
the	O
clinical	B-DISO
significance	I-DISO
of	O
the	O
2	O
deep	B-ANAT
posterior	I-ANAT
perianal	I-ANAT
spaces	I-ANAT
and	O
to	O
describe	O
in	O
detail	O
the	O
courses	O
of	O
posterior	O
complex	O
cryptoglandular	B-ANAT
fistula	B-DISO
extensions	O
.	O

This	O
was	O
a	O
retrospective	B-PROC
study	I-PROC
.	O

MRI	B-PROC
-	O
based	O
characteristics	O
of	O
selected	O
perianal	B-DISO
fistulas	I-DISO
were	O
independently	O
evaluated	B-PROC
by	O
examiners	B-LIVB
who	O
focused	O
on	O
lesions	B-DISO
in	O
these	O
2	O
spaces	B-ANAT
and	O
were	O
blinded	O
to	O
each	O
other	O
's	O
findings	O
.	O

This	O
study	B-PROC
was	O
conducted	O
in	O
the	O
colorectal	O
surgery	O
and	O
radiology	O
departments	O
of	O
a	O
large	O
university	B-OBJC
teaching	I-OBJC
hospital	I-OBJC
in	O
China	B-GEOG
.	O

Included	O
in	O
the	O
study	O
were	O
patients	B-LIVB
who	O
underwent	O
pelvic	B-PROC
MRI	I-PROC
for	O
posterior	O
perianal	B-DISO
fistula	I-DISO
between	O
October	O
2012	O
and	O
December	O
2014	O
.	O

The	O
occurrence	O
rates	O
of	O
these	O
2	O
deep	B-ANAT
perianal	I-ANAT
space	I-ANAT
lesions	B-DISO
in	O
posterior	O
cryptoglandular	B-ANAT
fistulas	B-DISO
were	O
determined	O
.	O

A	O
total	O
of	O
513	O
primary	O
posterior	O
cryptoglandular	B-ANAT
fistulas	B-DISO
were	O
identified	O
in	O
508	O
patients	B-LIVB
,	O
including	O
167	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
lesions	B-DISO
(	O
32	O
.	O

6	O
%	O
)	O
and	O
23	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
lesions	B-DISO
(	O
4	O
.	O
5	O
%	O
)	O
.	O

Of	O
those	O
,	O
173	O
fistulas	B-DISO
(	O
33	O
.	O
7	O
%	O
)	O
were	O
evaluated	B-PROC
as	O
complex	O
.	O

The	O
former	O
and	O
latter	O
spaces	B-ANAT
were	O
involved	O
in	O
79	O
.	O

2	O
%	O
(	O
137	O
/	O
173	O
)	O
and	O
13	O
.	O

3	O
%	O
(	O
23	O
/	O
173	O
)	O
of	O
posterior	O
complex	O
fistulas	B-DISO
.	O

Compared	O
with	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
lesions	B-DISO
,	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
lesions	B-DISO
were	O
more	O
common	O
in	O
cases	O
with	O
high	O
transsphincteric	B-DISO
or	O
suprasphincteric	B-DISO
fistulas	I-DISO
(	O
80	O
.	O
1	O
%	O
vs	O
15	O
.	O
8	O
%	O
)	O
,	O
synchronous	O
multiple	O
transsphincteric	B-DISO
fistulas	I-DISO
(	O
82	O
.	O
4	O
%	O
vs	O
20	O
.	O

6	O
%	O
)	O
,	O
horseshoe	B-DISO
-	I-DISO
like	I-DISO
fistulas	I-DISO
(	O
85	O
.	O
5	O
%	O
vs	O
14	O
.	O
5	O
%	O
)	O
,	O
and	O
supralevator	B-ANAT
fistulas	B-DISO
(	O
93	O
.	O
5	O
%	O
vs	O
16	O
.	O
1	O
%	O
)	O
.	O

Similar	O
incidences	O
were	O
also	O
seen	O
in	O
cases	O
with	O
ischioanal	B-ANAT
-	O
involved	O
horseshoe	B-DISO
-	I-DISO
like	I-DISO
fistulas	I-DISO
(	O
75	O
.	O
0	O
%	O
vs	O
25	O
.	O
0	O
%	O
)	O
.	O

This	O
study	B-PROC
was	O
limited	O
by	O
its	O
retrospective	O
nature	O
.	O

The	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
is	O
more	O
likely	O
than	O
the	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
to	O
be	O
involved	O
in	O
complex	O
cryptoglandular	B-ANAT
fistulas	B-DISO
and	O
is	O
likely	O
to	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
management	B-PROC
of	O
complex	O
cryptoglandular	B-ANAT
fistulas	B-DISO
.	O

Conditional	O
ablation	B-PROC
of	O
myeloid	O
TNF	B-CHEM
increases	O
lesion	B-DISO
volume	O
after	O
experimental	B-DISO
stroke	I-DISO
in	I-DISO
mice	I-DISO
,	O
possibly	O
via	O
altered	O
ERK1	B-PHYS
/	I-PHYS
2	I-PHYS
signaling	I-PHYS
Microglia	B-ANAT
are	O
activated	O
following	O
cerebral	B-DISO
ischemia	I-DISO
and	O
increase	O
their	O
production	O
of	O
the	O
neuro	B-CHEM
-	O
and	O
immunomodulatory	B-CHEM
cytokine	B-CHEM
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	O
TNF	B-CHEM
)	O
.	O

To	O
address	O
the	O
function	O
of	O
TNF	B-CHEM
from	O
this	O
cellular	B-DISO
source	I-DISO
in	O
focal	B-DISO
cerebral	I-DISO
ischemia	I-DISO
we	O
used	O
TNF	B-CHEM
conditional	O
knock	B-LIVB
out	I-LIVB
mice	I-LIVB
(	I-LIVB
LysMcreTNF	I-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
)	I-LIVB
in	O
which	O
the	O
TNF	O
gene	O
was	O
deleted	O
in	O
cells	B-ANAT
of	O
the	O
myeloid	O
lineage	O
,	O
including	O
microglia	B-ANAT
.	O

The	O
deletion	B-PHYS
reduced	O
secreted	O
TNF	B-CHEM
levels	O
in	O
lipopolysaccharide	B-CHEM
-stimulated	O
cultured	B-ANAT
primary	I-ANAT
microglia	I-ANAT
by	O
~93	O
%	O
.	O

Furthermore	O
,	O
phosphorylated	B-CHEM
-	I-CHEM
ERK	I-CHEM
/	O
ERK	B-CHEM
ratios	O
were	O
significantly	O
decreased	O
in	O
naïve	B-LIVB
LysMcreTNF	I-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
demonstrating	O
altered	O
ERK	B-CHEM
signal	B-PHYS
transduction	I-PHYS
.	O

Micro	B-PROC
-	I-PROC
PET	I-PROC
using	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
[	I-CHEM
F	I-CHEM
]	I-CHEM
-	I-CHEM
fluorodeoxyglucose	I-CHEM
immediately	O
after	O
focal	B-DISO
cerebral	I-DISO
ischemia	I-DISO
showed	O
increased	O
glucose	B-PHYS
uptake	I-PHYS
in	O
LysMcreTNF	B-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O
representing	O
significant	O
metabolic	B-PHYS
changes	O
,	O
that	O
translated	O
into	O
increased	O
infarct	B-DISO
volumes	O
at	O
24	O
hours	O
and	O
5	O
days	O
compared	O
to	O
littermates	B-LIVB
(	I-LIVB
TNFfl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
.	O

In	O
naïve	B-LIVB
LysMcreTNF	I-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
cytokine	B-CHEM
levels	O
were	O
low	O
and	O
comparable	O
to	O
littermates	B-LIVB
.	O

At	O
6	O
hours	O
,	O
TNF	B-CHEM
producing	O
microglia	B-ANAT
were	O
reduced	O
by	O
56	O
%	O
in	O
the	O
ischemic	B-DISO
cortex	I-DISO
in	O
LysMcreTNF	B-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
compared	O
to	O
littermate	B-LIVB
mice	I-LIVB
,	O
whereas	O
no	O
TNF	O
(	O
+	O
)	O
leukocytes	B-ANAT
were	O
detected	O
.	O

At	O
24	O
hours	O
,	O
pro	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
cytokine	I-CHEM
(	O
TNF	B-CHEM
,	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
5	I-CHEM
and	O
CXCL1	B-CHEM
)	O
levels	O
were	O
significantly	O
lower	O
in	O
LysMcreTNF	B-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O
despite	O
comparable	O
infiltrating	O
leukocyte	B-ANAT
populations	I-ANAT
.	O

Our	O
results	O
identify	O
microglia	B-ANAT
l	O
TNF	B-CHEM
as	O
beneficial	O
and	O
neuroprotective	O
in	O
the	O
acute	O
phase	O
and	O
as	O
a	O
modulator	O
of	O
neuroinflammation	B-DISO
at	O
later	O
time	O
points	O
after	O
experimental	O
ischemia	B-DISO
,	O
which	O
may	O
contribute	O
to	O
regenerative	B-PHYS
recovery	I-PHYS
.	O

Screening	B-PROC
of	O
Conditionally	O
Reprogrammed	O
Patient	B-LIVB
-Derived	O
Carcinoma	B-ANAT
Cells	I-ANAT
Identifies	O
ERCC3	B-CHEM
-	O
MYC	B-CHEM
Interactions	O
as	O
a	O
Target	O
in	O
Pancreatic	B-DISO
Cancer	I-DISO
Even	O
when	O
diagnosed	B-PROC
prior	O
to	O
metastasis	B-DISO
,	O
pancreatic	B-DISO
ductal	I-DISO
adenocarcinoma	I-DISO
(	O
PDAC	B-DISO
)	O
is	O
a	O
devastating	B-DISO
malignancy	I-DISO
with	O
almost	O
90	O
%	O
lethality	B-DISO
,	O
emphasizing	O
the	O
need	O
for	O
new	O
therapies	B-PROC
optimally	O
targeting	O
the	O
tumors	B-DISO
of	O
individual	O
patients	B-LIVB
.	O

We	O
first	O
developed	O
a	O
panel	O
of	O
new	O
physiologic	O
models	O
for	O
study	B-PROC
of	O
PDAC	B-DISO
,	O
expanding	O
surgical	O
PDAC	B-DISO
tumor	O
samples	O
in	O
culture	B-PROC
using	O
short	O
-	O
term	O
culture	B-PROC
and	O
conditional	O
reprogramming	O
with	O
the	O
Rho	B-CHEM
kinase	I-CHEM
inhibitor	B-CHEM
Y	B-CHEM
-	I-CHEM
27632	I-CHEM
,	O
and	O
creating	O
matched	O
patient	B-CHEM
-	I-CHEM
derived	I-CHEM
xenografts	I-CHEM
(	O
PDX	B-CHEM
)	O
.	O

These	O
were	O
evaluated	B-PROC
for	O
sensitivity	O
to	O
a	O
large	O
panel	O
of	O
clinical	B-CHEM
agents	I-CHEM
,	O
and	O
promising	O
leads	O
further	O
evaluated	B-PROC
mechanistically	O
.	O

Only	O
a	O
small	O
minority	O
of	O
tested	B-CHEM
agents	I-CHEM
was	O
cytotoxic	O
in	O
minimally	O
passaged	O
PDAC	B-DISO
cultures	B-PROC
in	O
vitro	O
Drugs	B-CHEM
interfering	O
with	O
protein	B-PHYS
turnover	I-PHYS
and	O
transcription	B-PHYS
were	O
among	O
most	O
cytotoxic	O
.	O

Among	O
transcriptional	B-CHEM
repressors	I-CHEM
,	O
triptolide	B-CHEM
,	O
a	O
covalent	B-CHEM
inhibitor	I-CHEM
of	O
ERCC3	B-CHEM
,	O
was	O
most	O
consistently	O
effective	O
in	O
vitro	O
and	O
in	O
vivo	O
causing	O
prolonged	B-DISO
complete	I-DISO
regression	I-DISO
in	O
multiple	O
PDX	B-PROC
models	O
resistant	O
to	O
standard	O
PDAC	B-DISO
therapies	B-PROC
.	O

Importantly	O
,	O
triptolide	B-CHEM
showed	O
superior	O
activity	O
in	O
MYC	B-CHEM
-	I-CHEM
amplified	I-CHEM
PDX	B-CHEM
models	O
and	O
elicited	O
rapid	O
and	O
profound	O
depletion	O
of	O
the	O
oncoprotein	B-CHEM
MYC	I-CHEM
,	O
a	O
transcriptional	B-PHYS
regulator	I-PHYS
.	O

Expression	B-PHYS
of	O
ERCC3	B-CHEM
and	O
MYC	B-CHEM
was	O
interdependent	O
in	O
PDACs	B-DISO
,	O
and	O
acquired	B-PHEN
resistance	I-PHEN
to	O
triptolide	B-CHEM
depended	O
on	O
elevated	O
ERCC3	B-CHEM
and	O
MYC	B-CHEM
expression	B-PHYS
.	O

The	B-PROC
Cancer	I-PROC
Genome	I-PROC
Atlas	I-PROC
analysis	I-PROC
indicates	O
ERCC3	B-CHEM
expression	B-PHYS
predicts	O
poor	B-DISO
prognosis	I-DISO
,	O
particularly	O
in	O
CDKN2A	B-DISO
-	I-DISO
null	I-DISO
,	O
highly	B-DISO
proliferative	I-DISO
tumors	I-DISO
.	O

This	O
provides	O
initial	O
preclinical	O
evidence	O
for	O
an	O
essential	O
role	O
of	O
MYC	B-CHEM
-	O
ERCC3	B-CHEM
interactions	O
in	O
PDAC	B-DISO
,	O
and	O
suggests	O
a	O
new	O
mechanistic	O
approach	O
for	O
disruption	O
of	O
critical	O
survival	O
signaling	B-PHEN
in	O
MYC	B-CHEM
-dependent	O
cancers	B-DISO
.	O

Clin	O
Cancer	O
Res	O
;	O
22	O
(	O
24	O
)	O
;	O
6153	O
-	O
63	O
.	O

©	O
2016	O
AACR	O
.	O

Relationship	O
between	O
LRRK2	O
R1628P	O
polymorphism	O
and	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
in	O
Asian	B-LIVB
populations	I-LIVB
Although	O
the	O
leucine	O
-	O
rich	O
repeat	O
kinase	O
2	O
(	O
LRRK2	O
)	O
R1628P	O
polymorphism	O
has	O
been	O
associated	O
with	O
the	O
risk	O
of	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
(	O
PD	B-DISO
)	O
in	O
Taiwan	B-GEOG
,	O
China	B-GEOG
,	O
and	O
Singapore	B-GEOG
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
was	O
to	O
evaluate	O
the	O
associations	O
between	O
the	O
LRRK2	O
R1628P	O
polymorphism	O
(	O
rs33949390	O
)	O
and	O
PD	B-DISO
in	O
Asian	B-LIVB
populations	I-LIVB
.	O

A	O
search	O
for	O
eligible	O
studies	B-PROC
was	O
performed	O
in	O
PubMed	O
,	O
Embase	O
,	O
SinoMed	O
,	O
and	O
the	O
China	O
Knowledge	O
Resource	O
Integrated	O
Database	O
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	O
between	O
the	O
R1628P	O
polymorphism	O
and	O
PD	B-DISO
.	O

This	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
assessed	O
19	O
studies	B-PROC
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9	O
,	O
927	O
PD	B-DISO
patients	B-LIVB
and	O
8	O
,	O
602	O
controls	B-LIVB
and	O
found	O
that	O
the	O
R1628P	O
polymorphism	O
was	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
PD	B-DISO
in	O
Asian	B-LIVB
populations	I-LIVB
.	O

Moreover	O
,	O
stratification	B-PROC
analyses	I-PROC
indicated	O
that	O
the	O
R1628P	O
polymorphism	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
PD	B-DISO
among	O
Chinese	B-LIVB
as	O
well	O
as	O
non	B-LIVB
-	I-LIVB
Chinese	I-LIVB
Asian	I-LIVB
populations	I-LIVB
and	O
an	O
increased	O
risk	O
of	O
PD	B-DISO
in	O
Chinese	B-LIVB
patients	I-LIVB
from	O
China	B-GEOG
,	O
Taiwan	B-GEOG
,	O
and	O
Singapore	B-GEOG
.	O

In	O
a	O
stratified	B-PROC
analysis	I-PROC
conducted	O
according	O
to	O
age	B-PHYS
,	O
significant	O
associations	O
were	O
found	O
for	O
both	O
late	O
-	O
onset	O
PD	B-DISO
and	O
early	O
-	O
onset	O
PD	B-DISO
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
R1628P	O
polymorphism	O
of	O
the	O
LRRK2	O
gene	O
contributes	O
to	O
PD	B-DISO
susceptibility	B-PHYS
in	O
Asian	B-LIVB
,	O
especially	O
Chinese	B-LIVB
,	O
populations	B-LIVB
.	O

Efficacy	O
and	O
safety	O
of	O
cisplatin	B-CHEM
,	O
dexamethasone	B-CHEM
,	O
gemcitabine	B-CHEM
and	O
pegaspargase	B-CHEM
(	O
DDGP	B-CHEM
)	O
regimen	B-PROC
in	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
extranodal	B-DISO
natural	I-DISO
killer	I-DISO
/	I-DISO
T	I-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
:	O
interim	O
analysis	B-PROC
of	O
a	O
phase	O
4	O
study	B-PROC
NCT01501149	O
To	O
explore	O
a	O
more	O
effective	O
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
extranodal	B-DISO
natural	I-DISO
killer	I-DISO
/	I-DISO
T	I-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
,	I-DISO
nasal	I-DISO
type	I-DISO
(	O
ENKTL	B-DISO
)	O
,	O
we	O
conducted	O
a	O
phase	O
4	O
study	B-PROC
of	O
the	O
cisplatin	B-CHEM
,	O
dexamethasone	B-CHEM
,	O
gemcitabine	B-CHEM
,	O
pegaspargase	B-CHEM
(	O
DDGP	B-CHEM
)	O
regimen	B-PROC
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
after	O
the	O
protocol	B-PROC
treatment	I-PROC
.	O

Secondary	O
endpoints	O
included	O
response	O
rate	O
(	O
RR	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
median	O
survival	O
time	O
(	O
MST	O
)	O
.	O

The	O
interim	O
analysis	B-PROC
included	O
data	O
only	O
from	O
March	O
2011	O
to	O
September	O
2013	O
,	O
who	O
received	O
six	O
cycles	O
of	O
DDGP	B-CHEM
chemotherapy	B-PROC
.	O

A	O
total	O
of	O
25	O
eligible	O
patients	B-LIVB
were	O
enrolled	O
.	O

Seventeen	O
patients	B-LIVB
(	O
17	O
/	O
24	O
,	O
70	O
.	O

83	O
%	O
)	O
achieved	O
complete	B-DISO
response	I-DISO
(	O
CR	B-DISO
)	O
and	O
four	O
(	O
4	O
/	O
24	O
,	O
16	O
.	O
67	O
%	O
)	O
achieved	O
partial	B-DISO
response	I-DISO
(	O
PR	B-DISO
)	O
,	O
three	O
(	O
3	O
/	O
24	O
,	O
12	O
.	O

50	O
%	O
)	O
had	O
progressive	B-DISO
disease	I-DISO
(	O
PD	B-DISO
)	O
.	O

The	O
RR	O
after	O
treatment	O
was	O
87	O
.	O

50	O
%	O
.	O

After	O
a	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
duration	O
of	O
24	O
.	O
67	O
months	O
(	O
range	O
4	O
-	O
48	O
months	O
)	O
.	O

The	O
2	O
-	O
year	O
PFS	O
and	O
OS	O
rate	O
were	O
61	O
.	O
80	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
.	O
00	O
%	O
to	O
81	O
.	O
60	O
%	O
)	O
and	O
68	O
.	O

50	O
%	O
(	O
95	O
%	O
CI	O
,	O
48	O
.	O
70	O
%	O
to	O
88	O
.	O
30	O
%	O
)	O
,	O
respectively	O
.	O

The	O
MST	O
was	O
36	O
.	O
55	O
months	O
(	O
95	O
%	O
CI	O
,	O
29	O
.	O
41	O
months	O
to	O
43	O
.	O
70	O
months	O
)	O
.	O

Grade	O
3	O
/	O
4	O
leukopenia	B-DISO
occurred	O
in	O
fourteen	O
patients	B-LIVB
(	O
58	O
.	O
33	O
%	O
)	O
and	O
grade	O
3	O
/	O
4	O
thrombocytopenia	B-DISO
occurred	O
in	O
eleven	O
patients	B-LIVB
(	O
45	O
.	O
83	O
%	O
)	O
.	O

Twelve	O
patients	B-LIVB
(	O
50	O
.	O
00	O
%	O
)	O
experienced	O
Activated	B-PROC
Partial	I-PROC
Phromboplastin	I-PROC
Ptime	I-PROC
(	O
APTT	B-PROC
)	O
elongation	B-DISO
and	O
fourteen	O
patients	B-LIVB
(	O
58	O
.	O
33	O
%	O
)	O
experienced	O
hypofibrinogenemia	B-DISO
.	O

In	O
conclusion	O
,	O
DDGP	B-CHEM
regimen	B-PROC
is	O
an	O
effective	O
and	O
tolerated	B-DISO
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
ENKTL	B-DISO
.	O

This	O
trial	B-PROC
was	O
registered	B-PROC
at	O
www	O
.	O

ClinicalTrials	O
.	O

gov	O
as	O
#	O
NCT01501149	O
.	O

Biogeochemical	O
Controls	O
of	O
Uranium	B-CHEM
Bioavailability	O
from	O
the	O
Dissolved	O
Phase	O
in	O
Natural	O
Freshwaters	B-OBJC
To	O
gain	O
insights	O
into	O
the	O
risks	O
associated	O
with	O
uranium	B-CHEM
(	O
U	B-CHEM
)	O
mining	O
and	O
processing	O
,	O
we	O
investigated	O
the	O
biogeochemical	O
controls	O
of	O
U	B-CHEM
bioavailability	O
in	O
the	O
model	O
freshwater	B-OBJC
species	O
Lymnaea	O
stagnalis	O
(	O
Gastropoda	O
)	O
.	O

Bioavailability	O
of	O
dissolved	B-CHEM
U	I-CHEM
(	I-CHEM
VI	I-CHEM
)	I-CHEM
was	O
characterized	O
in	O
controlled	O
laboratory	B-OBJC
experiments	B-PROC
over	O
a	O
range	O
of	O
water	B-CHEM
hardness	O
,	O
pH	O
,	O
and	O
in	O
the	O
presence	B-DISO
of	O
complexing	B-CHEM
ligands	I-CHEM
in	O
the	O
form	O
of	O
dissolved	B-OBJC
natural	I-OBJC
organic	I-OBJC
matter	I-OBJC
(	O
DOM	B-OBJC
)	O
.	O

Results	B-PHEN
show	O
that	O
dissolved	B-CHEM
U	I-CHEM
is	O
bioavailable	O
under	O
all	O
the	O
geochemical	O
conditions	O
tested	O
.	O

Uranium	B-CHEM
uptake	B-PHYS
rates	O
follow	O
first	O
order	O
kinetics	O
over	O
a	O
range	O
encompassing	O
most	O
environmental	O
concentrations	O
.	O

Uranium	B-CHEM
uptake	B-PHYS
rates	O
in	O
L	O
.	O

stagnalis	O
ultimately	O
demonstrate	O
saturation	B-PHEN
uptake	B-PHYS
kinetics	B-PHEN
when	O
exposure	O
concentrations	O
exceed	O
100	O
nM	O
,	O
suggesting	O
uptake	B-PHYS
via	O
a	O
finite	O
number	O
of	O
carriers	O
or	O
ion	B-CHEM
channels	I-CHEM
.	O

The	O
lack	O
of	O
a	O
relationship	O
between	O
U	B-CHEM
uptake	B-PHYS
rate	O
constants	O
and	O
Ca	B-CHEM
uptake	B-PHYS
rates	O
suggest	O
that	O
U	B-CHEM
does	O
not	O
exclusively	O
use	O
Ca	B-CHEM
membrane	B-CHEM
transporters	I-CHEM
.	O

In	O
general	O
,	O
U	B-CHEM
bioavailability	O
decreases	B-DISO
with	O
increasing	O
pH	O
,	O
increasing	O
Ca	B-CHEM
and	O
Mg	B-CHEM
concentrations	O
,	O
and	O
when	O
DOM	B-OBJC
is	O
present	B-DISO
.	O

Competing	O
ions	B-CHEM
did	O
not	O
affect	O
U	B-CHEM
uptake	B-PHYS
rates	O
.	O

Speciation	B-PROC
modeling	I-PROC
that	O
includes	O
formation	O
constants	O
for	O
U	B-CHEM
ternary	B-CHEM
complexes	I-CHEM
reveals	O
that	O
the	O
aqueous	O
concentration	O
of	O
dicarbonato	B-CHEM
U	I-CHEM
species	O
(	O
UO2	O
(	O
CO3	O
)	O
2	O
(	O
-	O
2	O
)	O
)	O
best	O
predicts	O
U	B-CHEM
bioavailability	O
to	O
L	O
.	O

stagnalis	O
,	O
challenging	O
the	O
free	O
-	O
ion	O
activity	O
model	O
postulate	O
.	O

Subluxation	B-DISO
and	O
semantics	O
:	O
a	O
corpus	B-PROC
linguistics	O
study	B-PROC
The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
analyze	B-PROC
the	O
curriculum	B-PROC
of	O
one	O
chiropractic	O
college	B-OBJC
in	O
order	O
to	O
discover	O
if	O
there	O
were	O
any	O
implicit	B-PHYS
consensus	O
definitions	O
of	O
the	O
term	O
subluxation	B-DISO
.	O

Using	O
the	O
software	O
WordSmith	O
Tools	O
,	O
the	O
corpus	B-PROC
of	O
an	O
undergraduate	O
chiropractic	O
curriculum	B-PROC
was	O
analyzed	B-PROC
by	O
reviewing	O
collocated	O
terms	O
and	O
through	O
discourse	B-PROC
analysis	I-PROC
of	O
text	O
blocks	O
containing	O
words	O
based	O
on	O
the	O
root	O
'	O
sublux	O
.	O
'	O
It	O
was	O
possible	B-DISO
to	O
identify	B-PHYS
3	O
distinct	O
concepts	O
which	O
were	O
each	O
referred	O
to	O
as	O
'	O
subluxation	B-DISO
:	O
'	O
i	O
)	O
an	O
acute	O
or	O
instantaneous	O
injurious	B-DISO
event	O
;	O
ii	O
)	O
a	O
clinical	O
syndrome	O
which	O
manifested	O
post	O
-	O
injury	B-DISO
;	O
iii	O
)	O
a	O
physical	O
lesion	B-DISO
,	O
i	O
.	O

e	O
.	O

an	O
anatomical	O
or	O
physiological	O
derangement	B-DISO
which	O
in	O
most	O
instances	O
acted	O
as	O
a	O
pain	B-DISO
generator	O
.	O

In	O
fact	O
,	O
coherent	B-DISO
implicit	B-PHYS
definitions	O
of	O
subluxation	B-DISO
exist	O
and	O
may	O
enjoy	O
broad	O
but	O
subconscious	B-PHYS
acceptance	B-DISO
.	O

However	O
,	O
confusion	B-DISO
likely	O
arises	O
from	O
failure	O
to	O
distinguish	B-PHYS
which	O
concept	O
an	O
author	B-LIVB
or	O
speaker	B-LIVB
is	O
referring	O
to	O
when	O
they	O
employ	O
the	O
term	O
subluxation	B-DISO
.	O

Espindolol	B-CHEM
for	O
the	O
treatment	B-PROC
and	O
prevention	B-PROC
of	O
cachexia	B-DISO
in	O
patients	B-LIVB
with	O
stage	B-DISO
III	I-DISO
/	I-DISO
IV	I-DISO
non	I-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
or	O
colorectal	B-DISO
cancer	I-DISO
:	O
a	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
,	O
international	B-PROC
multicentre	I-PROC
phase	I-PROC
II	I-PROC
study	I-PROC
(	I-PROC
the	I-PROC
ACT	I-PROC
-	I-PROC
ONE	I-PROC
trial	I-PROC
)	I-PROC
Cancer	B-DISO
cachexia	I-DISO
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
with	O
no	O
widely	O
approved	O
treatment	B-PROC
.	O

The	O
ACT	B-PROC
-	I-PROC
ONE	I-PROC
trial	I-PROC
is	O
a	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
parallel	B-PROC
group	I-PROC
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
,	O
phase	B-PROC
II	I-PROC
multicentre	I-PROC
trial	I-PROC
in	O
patients	B-LIVB
(	O
25	O
-	O
80	O
years	O
)	O
with	O
stages	B-DISO
III	I-DISO
or	I-DISO
IV	I-DISO
colorectal	I-DISO
cancer	I-DISO
or	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
-related	O
cachexia	B-DISO
that	O
tested	O
two	O
doses	O
of	O
espindolol	B-CHEM
(	O
a	O
novel	O
non	B-CHEM
-	I-CHEM
selective	I-CHEM
β	I-CHEM
blocker	I-CHEM
with	O
central	B-CHEM
5	I-CHEM
-	I-CHEM
HT1a	I-CHEM
and	O
partial	O
β2	B-CHEM
receptor	I-CHEM
agonist	I-CHEM
effects	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
difference	O
in	O
the	O
rate	O
of	O
weight	B-DISO
change	I-DISO
over	O
16	O
weeks	O
(	O
linear	B-DEVI
mixed	I-DEVI
-	I-DEVI
effect	I-DEVI
model	I-DEVI
for	O
repeated	O
measures	O
)	O
between	O
high	O
-	O
dose	O
espindolol	B-CHEM
and	O
placebo	B-CHEM
.	O

Eighty	O
-	O
seven	O
patients	B-LIVB
were	O
randomized	B-PROC
centrally	O
in	O
blocks	O
in	O
a	O
ratio	O
3	O
:	O
2	O
:	O
1	O
[	O
42	O
high	O
dose	O
,	O
10	O
mg	O
twice	O
daily	O
(	O
bd	O
)	O
:	O
31	O
placebo	B-CHEM
:	O
14	O
low	O
dose	O
,	O
2	O
.	O
5	O
mg	O
bd	O
]	O
.	O

High	O
-	O
dose	O
espindolol	B-CHEM
produced	O
a	O
statistically	O
and	O
clinically	O
significant	O
weight	B-DISO
gain	I-DISO
(	O
+0	O
.	O
54	O
kg	O
/	O
4	O
weeks	O
,	O
95	O
%	O
CI	O
0	O
.	O
38	O
-	O
0	O
.	O
70	O
)	O
compared	O
with	O
a	O
weight	B-DISO
loss	I-DISO
on	O
placebo	B-CHEM
(	O
-0	O
.	O
21	O
kg	O
/	O
4	O
weeks	O
,	O
95	O
%	O
CI	O
-0	O
.	O
37	O
-	O
0	O
.	O
05	O
)	O
;	O
P	O
<	O
0	O
.	O
0001	O
.	O

High	O
-	O
dose	O
espindolol	B-CHEM
produced	O
a	O
statistically	O
significant	O
increase	O
in	O
lean	B-PHYS
body	I-PHYS
mass	I-PHYS
,	O
whilst	O
changes	O
in	O
fat	B-PHYS
mass	I-PHYS
were	O
neutral	O
.	O

Hand	B-DISO
grip	I-DISO
strength	I-DISO
significantly	O
(	O
high	O
dose	O
-1	O
.	O

15	O
±	O
0	O
.	O

7	O
kg	O
,	O
placebo	B-CHEM
-3	O
.	O

51	O
±	O
0	O
.	O

8	O
kg	O
change	O
per	O
4	O
weeks	O
;	O
P	O
=	O
0	O
.	O

0134	O
)	O
,	O
stair	B-DISO
climbing	I-DISO
power	O
,	O
and	O
6	B-PROC
-	I-PROC
min	I-PROC
walk	I-PROC
test	I-PROC
non	O
-	O
significantly	O
were	O
all	O
directionally	O
in	O
favour	O
of	O
high	O
-	O
dose	O
espindolol	B-CHEM
.	O

There	O
were	O
no	O
clinically	O
significant	O
differences	O
in	O
safety	O
signals	O
or	O
survival	O
between	O
treatment	B-PROC
groups	O
,	O
although	O
a	O
numerical	O
excess	O
of	O
dyspnoea	B-DISO
was	O
seen	O
with	O
high	O
-	O
dose	O
espindolol	B-CHEM
(	O
19	O
.	O
1	O
%	O
)	O
compared	O
with	O
placebo	B-CHEM
(	O
3	O
.	O
2	O
%	O
)	O
.	O

This	O
positive	B-PROC
trial	I-PROC
showed	O
that	O
espindolol	B-CHEM
10	O
mg	O
bd	O
significantly	O
reversed	O
weight	B-DISO
loss	I-DISO
,	O
improved	O
fat	B-DISO
free	I-DISO
mass	I-DISO
,	O
and	O
maintained	O
fat	B-PHYS
mass	I-PHYS
in	O
advanced	O
colorectal	B-DISO
cancer	I-DISO
and	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
-related	O
cachexia	B-DISO
.	O

This	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
handgrip	B-DISO
strength	I-DISO
,	O
supporting	O
the	O
further	O
investigation	O
of	O
10	O
mg	O
bd	O
espindolol	B-CHEM
for	O
the	O
treatment	B-PROC
of	O
cancer	B-DISO
cachexia	I-DISO
.	O

Although	O
not	O
powered	O
to	O
look	O
at	O
dose	B-PROC
response	I-PROC
,	O
most	O
treatment	B-PROC
effects	O
for	O
low	O
dose	O
lay	O
between	O
high	O
dose	O
and	O
placebo	B-CHEM
,	O
suggesting	O
that	O
there	O
may	O
be	O
a	O
dose	B-PROC
response	I-PROC
in	O
the	O
effects	O
of	O
espindolol	B-CHEM
.	O

Interleukin	B-CHEM
-	I-CHEM
21	I-CHEM
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	B-DISO
and	O
severity	O
of	O
type	B-DISO
I	I-DISO
autoimmune	I-DISO
hepatitis	I-DISO
Recently	O
,	O
the	O
number	O
of	O
follicular	B-ANAT
helper	B-ANAT
T	I-ANAT
(	I-ANAT
Tfh	I-ANAT
)	I-ANAT
cells	I-ANAT
expressing	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
21	I-CHEM
was	O
found	O
to	O
increase	O
in	O
peripheral	B-ANAT
blood	I-ANAT
of	O
human	B-LIVB
and	O
murine	B-LIVB
models	B-DISO
of	O
autoimmune	B-DISO
hepatitis	I-DISO
(	O
AIH	B-DISO
)	O
.	O

IL	B-CHEM
-	I-CHEM
21	I-CHEM
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type	B-CHEM
-	I-CHEM
I	I-CHEM
cytokine	I-CHEM
family	I-CHEM
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	B-ANAT
system	I-ANAT
,	O
including	O
B	B-PHYS
cell	I-PHYS
activation	I-PHYS
,	O
plasma	B-PHYS
cell	I-PHYS
differentiation	I-PHYS
,	O
and	O
immunoglobulin	B-PHEN
production	I-PHEN
.	O

We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
in	O
patients	B-LIVB
with	O
type	B-DISO
I	I-DISO
AIH	I-DISO
with	O
clinical	O
and	O
laboratory	B-OBJC
parameters	O
and	O
histology	O
.	O

Ninety	O
-	O
two	O
Japanese	B-LIVB
patients	B-LIVB
with	O
liver	B-DISO
disease	I-DISO
(	O
22	O
AIH	B-DISO
,	O
20	O
primary	B-DISO
biliary	I-DISO
cholangitis	I-DISO
,	O
19	O
drug	B-DISO
-	I-DISO
induced	I-DISO
liver	I-DISO
injury	I-DISO
,	O
8	O
acute	B-DISO
hepatitis	I-DISO
B	I-DISO
,	O
8	O
chronic	B-DISO
hepatitis	I-DISO
C	I-DISO
,	O
10	O
non	B-DISO
-	I-DISO
alcoholic	I-DISO
steatohepatitis	I-DISO
,	O
5	O
viral	B-DISO
hepatitis	I-DISO
)	O
and	O
10	O
healthy	B-LIVB
volunteers	I-LIVB
were	O
recruited	O
.	O

Serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
were	O
detected	O
by	O
enzyme	B-PROC
-	I-PROC
linked	I-PROC
immunosorbent	I-PROC
assay	I-PROC
.	O

Real	B-PROC
-	I-PROC
time	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
measured	O
mRNA	B-CHEM
levels	O
of	O
Bcl	O
-	O
6	O
,	O
IL	O
-	O
21	O
,	O
and	O
CXCR5	O
(	O
Tfh	B-CHEM
-	I-CHEM
related	I-CHEM
factors	I-CHEM
)	O
in	O
peripheral	O
mononuclear	B-ANAT
cells	I-ANAT
.	O

Mean	O
age	O
at	O
diagnosis	B-DISO
of	O
AIH	B-DISO
was	O
58	O
.	O

6	O
years	O
,	O
male	B-DISO
-	I-DISO
to	I-DISO
-	I-DISO
female	I-DISO
ratio	I-DISO
was	O
4	O
:	O
18	O
,	O
18	O
.	O
2	O
%	O
of	O
participants	O
had	O
cirrhosis	B-DISO
,	O
and	O
22	O
.	O

7	O
%	O
had	O
severe	O
disease	B-DISO
.	O

IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
were	O
significantly	O
increased	O
in	O
the	O
serum	B-ANAT
of	O
patients	B-LIVB
with	O
AIH	B-DISO
compared	O
to	O
those	O
with	O
other	O
liver	O
diseases	O
and	O
controls	B-LIVB
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Particularly	O
,	O
serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
were	O
significantly	O
increased	O
in	O
severe	O
AIH	B-DISO
cases	O
compared	O
to	O
non	O
-	O
severe	O
cases	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
correlated	O
positively	O
with	O
total	O
serum	B-ANAT
bilirubin	B-PROC
levels	I-PROC
(	O
r	O
=	O
0	O
.	O
46	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
grading	B-DISO
of	I-DISO
necroinflammatory	I-DISO
activity	I-DISO
(	O
r	O
=	O
0	O
.	O
68	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
negatively	O
with	O
serum	B-PHEN
albumin	I-PHEN
levels	I-PHEN
in	O
patients	B-LIVB
with	O
AIH	B-DISO
(	O
r	O
=	O
-0	O
.	O

49	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	B-LIVB
with	O
biochemical	O
remission	B-DISO
of	O
AIH	B-DISO
,	O
serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
remained	O
elevated	O
and	O
correlated	O
positively	B-DISO
with	O
serum	B-PROC
IgG	I-PROC
levels	I-PROC
(	O
r	O
=	O
0	O
.	O
84	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Expression	B-PHYS
of	O
Tfh	B-CHEM
-	I-CHEM
related	I-CHEM
factors	I-CHEM
,	O
such	O
as	O
Bcl	B-CHEM
-	I-CHEM
6	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
21	I-CHEM
,	O
in	O
peripheral	B-ANAT
blood	I-ANAT
mononuclear	I-ANAT
cells	I-ANAT
of	O
patients	B-LIVB
with	O
AIH	B-DISO
was	O
significantly	O
higher	O
than	O
that	O
in	O
healthy	B-LIVB
volunteers	I-LIVB
.	O

IL	B-CHEM
-	I-CHEM
21	I-CHEM
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-DISO
and	O
severity	O
of	O
AIH	B-DISO
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	B-DISO
therapy	O
.	O

Mono	B-CHEM
-	I-CHEM
sulfonated	I-CHEM
tetrazolium	I-CHEM
salt	I-CHEM
based	O
NAD	B-CHEM
(	I-CHEM
P	I-CHEM
)	I-CHEM
H	I-CHEM
detection	B-PROC
reagents	B-CHEM
suitable	O
for	O
dehydrogenase	B-CHEM
and	O
real	O
-	O
time	O
cell	B-PROC
viability	I-PROC
assays	I-PROC
Glutamate	B-CHEM
dehydrogenase	I-CHEM
(	O
GDH	B-CHEM
)	O
catalyzes	O
the	O
oxidative	O
deamination	B-PHEN
of	O
L	B-CHEM
-	I-CHEM
glutamate	I-CHEM
and	O
is	O
important	O
for	O
several	O
biological	B-PHEN
processes	I-PHEN
.	O

For	O
GDH	B-CHEM
inhibitor	B-CHEM
screening	B-PROC
,	O
we	O
developed	O
a	O
novel	O
mono	B-CHEM
-	I-CHEM
sulfonated	I-CHEM
tetrazolium	I-CHEM
salt	I-CHEM
(	O
EZMTT	B-CHEM
)	O
,	O
which	O
can	O
be	O
synthesized	O
using	O
H2O2	B-CHEM
oxidation	B-PHYS
and	O
purified	O
easily	O
on	O
silica	B-CHEM
gel	I-CHEM
in	O
large	O
quantities	O
.	O

The	O
EZMTT	B-CHEM
detection	O
method	O
showed	O
linear	B-PHEN
dose	I-PHEN
responses	I-PHEN
to	O
NAD	B-CHEM
(	I-CHEM
P	I-CHEM
)	I-CHEM
H	I-CHEM
,	O
dehydrogenase	B-CHEM
concentration	O
and	O
cell	B-PROC
numbers	I-PROC
.	O

In	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
GDH	B-PROC
assay	I-PROC
,	O
the	O
EZMTT	B-CHEM
method	O
showed	O
excellent	O
assay	O
reproducibility	O
with	O
a	O
Z	O
factor	O
of	O
0	O
.	O
9	O
and	O
caused	O
no	B-PHEN
false	I-PHEN
positives	I-PHEN
in	O
the	O
presence	O
of	O
antioxidants	B-CHEM
(	O
such	O
as	O
BME	B-CHEM
)	O
.	O

Using	O
the	O
EZMTT	B-CHEM
-	O
formazan	B-CHEM
-	O
NAD	B-CHEM
(	I-CHEM
P	I-CHEM
)	I-CHEM
H	I-CHEM
system	O
,	O
we	O
showed	O
that	O
EGCG	B-CHEM
is	O
a	O
potent	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
GDH	B-CHEM
inhibitor	B-CHEM
(	O
IC50	O
45	O
nM	O
)	O
and	O
identified	O
that	O
Ebselen	B-CHEM
,	O
a	O
multifunctional	O
thioredoxin	B-CHEM
reductase	I-CHEM
inhibitor	B-CHEM
,	O
inactivated	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
GDH	B-CHEM
(	O
IC50	O
213	O
nM	O
)	O
.	O

In	O
cell	B-PROC
-	I-PROC
based	I-PROC
assays	I-PROC
at	O
0	O
.	O

5	O
mM	O
tetrazolium	B-CHEM
concentration	O
,	O
EZMTT	B-CHEM
showed	O
essentially	O
no	O
toxicity	O
after	O
a	O
3	O
-	O
day	O
incubation	B-DISO
,	O
whereas	O
40	O
%	O
of	O
inhibition	B-PHYS
was	O
observed	O
for	O
WST	B-CHEM
-	I-CHEM
8	I-CHEM
.	O

In	O
conclusion	O
,	O
EZMTT	B-CHEM
is	O
a	O
novel	O
tetrazolium	B-CHEM
salt	I-CHEM
which	O
provides	O
improved	O
features	O
that	O
are	O
suitable	O
for	O
dehydrogenases	B-CHEM
and	O
real	O
-	O
time	O
cell	B-PROC
-	I-PROC
based	I-PROC
high	B-PROC
-	I-PROC
throughput	I-PROC
screening	I-PROC
(	O
HTS	O
)	O
.	O

Is	O
Localized	B-DISO
Scleroderma	I-DISO
Caused	O
by	O
Borrelia	B-LIVB
burgdorferi	I-LIVB
?	O
Despite	O
considerable	O
achievements	O
in	O
the	O
study	B-PROC
of	O
localized	B-DISO
scleroderma	I-DISO
,	O
the	O
etiology	O
of	O
the	O
disease	B-DISO
has	O
not	O
been	O
investigated	O
completely	O
.	O

Borrelia	B-LIVB
burgdorferi	I-LIVB
-the	O
agent	O
of	O
Lyme	B-DISO
disease	I-DISO
-is	O
suggested	O
to	O
be	O
one	O
of	O
the	O
possible	O
etiological	O
factors	O
of	O
localized	B-DISO
scleroderma	I-DISO
.	O

However	O
,	O
among	O
scientists	B-LIVB
,	O
this	O
hypothesis	O
is	O
quite	O
controversial	O
.	O

We	O
have	O
conducted	O
investigations	B-PROC
of	O
the	O
level	O
of	O
IgM	B-CHEM
and	O
IgG	B-CHEM
class	O
antibodies	B-CHEM
to	O
B	B-LIVB
.	I-LIVB

burgdorferi	I-LIVB
in	O
the	O
serum	B-ANAT
of	O
patients	B-LIVB
with	O
localized	B-DISO
scleroderma	I-DISO
.	O

To	O
rationally	O
substantiate	O
the	O
role	O
of	O
B	B-LIVB
.	I-LIVB

burgdorferi	I-LIVB
in	O
the	O
occurrence	O
of	O
localized	B-DISO
scleroderma	I-DISO
,	O
thirty	O
-	O
two	O
patients	B-LIVB
with	O
localized	B-DISO
scleroderma	I-DISO
treated	O
at	O
an	O
in	B-LIVB
-	I-LIVB
patient	I-LIVB
department	O
were	O
examined	O
.	O

The	O
level	O
of	O
anti	B-CHEM
-	I-CHEM
Borrelia	I-CHEM
antibodies	I-CHEM
was	O
determined	O
in	O
ELISA	B-PROC
.	O

Diagnostic	O
levels	O
of	O
IgM	B-CHEM
and	O
/	O
or	O
IgG	B-CHEM
were	O
detected	O
in	O
18	O
.	O

8	O
%	O
of	O
patients	B-LIVB
with	O
localized	B-DISO
scleroderma	I-DISO
,	O
which	O
is	O
more	O
than	O
in	O
the	O
population	B-LIVB
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Positive	B-DISO
levels	I-DISO
of	O
anti	B-CHEM
-	I-CHEM
Borrelia	I-CHEM
antibodies	I-CHEM
in	O
patients	B-LIVB
with	O
localized	B-DISO
scleroderma	I-DISO
confirm	O
the	O
borreliosis	B-DISO
nature	O
of	O
the	O
disease	O
,	O
requiring	O
conduction	O
of	O
complex	O
antimicrobial	B-CHEM
treatment	B-PROC
.	O

RF	B-PROC
Ablation	I-PROC
of	O
Giant	B-DISO
Hemangiomas	I-DISO
Inducing	O
Acute	B-DISO
Renal	I-DISO
Failure	I-DISO
:	O
A	O
Report	O
of	O
Two	O
Cases	O
In	O
patients	B-LIVB
that	O
require	O
treatment	O
for	O
hepatic	B-ANAT
giant	B-DISO
cavernous	I-DISO
hemangiomas	I-DISO
(	O
GCH	B-DISO
)	O
,	O
radiofrequency	B-PROC
ablation	I-PROC
(	O
RFA	B-PROC
)	O
has	O
been	O
suggested	O
to	O
represent	O
a	O
safe	O
and	O
effective	O
alternative	O
to	O
invasive	O
surgery	B-PROC
.	O

In	O
a	O
recent	O
report	O
of	O
bipolar	B-PROC
RFA	I-PROC
,	O
using	O
two	O
expandable	B-DEVI
needle	I-DEVI
electrodes	I-DEVI
,	O
was	O
uneventfully	O
performed	O
in	O
patients	B-LIVB
with	O
large	O
GCH	B-DISO
(	O
>	O
10	O
cm	O
)	O
.	O

The	O
objective	O
of	O
this	O
report	O
is	O
to	O
present	O
two	O
cases	O
in	O
which	O
bipolar	B-PROC
RFA	I-PROC
of	O
symptomatic	O
GCH	B-DISO
was	O
complicated	O
by	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
.	O

In	O
2015	O
we	O
treated	O
two	O
patients	B-LIVB
for	O
very	O
large	O
symptomatic	O
GCH	B-DISO
(	O
15	O
.	O
7	O
and	O
25	O
.	O
0	O
cm	O
)	O
with	O
bipolar	B-PROC
RFA	I-PROC
during	O
open	B-PROC
laparotomy	I-PROC
.	O

In	O
both	O
patients	B-LIVB
the	O
urine	B-ANAT
showed	O
a	O
red	B-DISO
-	I-DISO
brown	I-DISO
discoloration	I-DISO
directly	O
after	O
the	O
ablation	B-PROC
.	O

They	O
became	O
anuric	B-DISO
and	O
presented	O
with	O
progressive	B-DISO
dyspnea	I-DISO
,	O
tachypnea	B-DISO
,	O
and	O
tachycardia	B-DISO
,	O
requiring	O
hemodialysis	B-PROC
for	O
a	O
period	O
of	O
1	O
month	O
in	O
one	O
case	O
.	O

Lab	O
results	O
revealed	O
hemepigment	B-CHEM
-	O
induced	O
acute	B-DISO
kidney	I-DISO
.	O

Both	O
patients	B-LIVB
fully	O
recovered	O
and	O
both	O
showed	O
a	O
complete	O
relief	B-DISO
of	O
symptoms	B-DISO
at	O
3	O
months	O
following	O
the	O
procedure	O
.	O

RFA	B-PROC
for	O
large	O
GCHs	B-DISO
can	O
cause	O
hemepigment	B-CHEM
-	O
induced	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
due	O
to	O
massive	O
intravascular	B-DISO
hemolysis	I-DISO
.	O

The	O
presented	O
cases	O
suggest	O
that	O
caution	O
is	O
warranted	O
and	O
advocate	O
an	O
upper	O
limit	O
regarding	O
the	O
volume	O
of	O
GCHs	B-DISO
that	O
can	O
be	O
safely	O
ablated	B-PROC
.	O

Effect	O
of	O
Hepatitis	B-DISO
C	I-DISO
Virus	I-DISO
Coinfection	I-DISO
on	O
the	O
Content	O
of	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
and	I-ANAT
CD8	I-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	B-ANAT
Cell	I-ANAT
Subpopulations	O
in	O
HIV	B-LIVB
-	O
Infected	B-DISO
Patients	B-LIVB
Receiving	O
Antiretroviral	B-PROC
Therapy	I-PROC
We	O
studied	O
the	O
effect	O
of	O
hepatitis	B-DISO
C	I-DISO
virus	I-DISO
coinfection	I-DISO
on	O
T	B-ANAT
cell	I-ANAT
subpopulations	O
in	O
HIV	B-LIVB
-	O
infected	B-DISO
patients	B-LIVB
receiving	O
antiretroviral	B-PROC
therapy	I-PROC
.	O

Coinfection	B-DISO
with	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
was	O
followed	O
by	O
a	O
decrease	O
in	O
the	O
number	O
of	O
naive	B-ANAT
CD4	I-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
and	O
an	O
increase	O
in	O
the	O
count	O
of	O
central	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
in	O
these	O
patients	B-LIVB
.	O

Hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
had	O
no	O
effect	O
on	O
the	O
number	O
of	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
(	O
main	O
target	O
for	O
HIV	B-LIVB
)	O
.	O

This	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-DISO
effect	O
of	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
on	O
the	O
course	O
of	O
HIV	B-LIVB
infection	B-DISO
.	O

Examining	O
the	O
contribution	O
of	O
motor	O
movement	O
and	O
language	O
dominance	O
to	O
increased	O
left	O
lateralization	B-PHYS
during	O
sign	O
generation	O
in	O
native	O
signers	B-LIVB
The	O
neural	B-ANAT
systems	I-ANAT
supporting	O
speech	B-PHYS
and	O
sign	O
processing	B-PHYS
are	O
very	O
similar	O
,	O
although	O
not	O
identical	O
.	O

In	O
a	O
previous	O
fTCD	B-PROC
study	I-PROC
of	O
hearing	B-PHYS
native	O
signers	B-LIVB
(	O
Gutierrez	O
-	O
Sigut	O
,	O
Daws	O
,	O
et	O
al	O
.	O
,	O
2015	O
)	O
we	O
found	O
stronger	O
left	O
lateralization	B-PHYS
for	O
sign	O
than	O
speech	B-PHYS
.	O

Given	O
that	O
this	O
increased	O
lateralization	B-PHYS
could	O
not	O
be	O
explained	O
by	O
hand	B-ANAT
movement	B-PHYS
alone	O
,	O
the	O
contribution	O
of	O
motor	O
movement	O
versus	O
'	O
linguistic	O
'	O
processes	B-PHYS
to	O
the	O
strength	O
of	O
hemispheric	O
lateralization	B-PHYS
during	O
sign	O
production	B-PHYS
remains	O
unclear	O
.	O

Here	O
we	O
directly	O
contrast	O
lateralization	B-PHYS
strength	O
of	O
covert	O
versus	O
overt	O
signing	O
during	O
phonological	O
and	O
semantic	O
fluency	O
tasks	O
.	O

To	O
address	O
the	O
possibility	O
that	O
hearing	B-PHYS
native	O
signers	B-LIVB
'	O
elevated	O
lateralization	O
indices	O
(	O
LIs	O
)	O
were	O
due	O
to	O
performing	O
a	O
task	O
in	O
their	O
less	O
dominant	O
language	O
,	O
here	O
we	O
test	O
deaf	B-LIVB
native	O
signers	B-LIVB
,	O
whose	O
dominant	O
language	O
is	O
British	O
Sign	O
Language	O
(	O
BSL	O
)	O
.	O

Signers	B-LIVB
were	O
more	O
strongly	O
left	O
lateralized	B-PHYS
for	O
overt	O
than	O
covert	O
sign	O
generation	O
.	O

However	O
,	O
the	O
strength	O
of	O
lateralization	B-PHYS
was	O
not	O
correlated	O
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	B-PHYS
of	O
the	O
right	B-ANAT
hand	I-ANAT
.	O

Comparisons	O
with	O
previous	O
data	O
from	O
hearing	B-PHYS
native	O
English	O
speakers	B-LIVB
suggest	O
stronger	O
laterality	O
indices	O
for	O
sign	O
than	O
speech	B-PHYS
in	O
both	O
covert	O
and	O
overt	O
tasks	O
.	O

This	O
increased	O
left	O
lateralization	B-PHYS
may	O
be	O
driven	O
by	O
specific	O
properties	O
of	O
sign	O
production	B-PHYS
such	O
as	O
the	O
increased	O
use	O
of	O
self	O
-	O
monitoring	O
mechanisms	O
or	O
the	O
nature	O
of	O
phonological	B-PHYS
encoding	I-PHYS
of	O
signs	O
.	O

Resistance	O
Exercise	O
in	O
Pregnancy	B-PHYS
and	O
Outcome	B-DISO
As	O
the	O
health	O
benefits	O
of	O
exercise	O
are	O
increasingly	O
recognized	O
,	O
the	O
traditional	B-PROC
advice	I-PROC
to	O
rest	O
during	O
pregnancy	B-PHYS
has	O
changed	O
toward	O
a	O
more	O
healthy	O
and	O
active	O
pregnancy	B-PHYS
,	O
therefore	O
different	O
forms	O
of	O
exercise	O
have	O
been	O
integrated	O
into	O
the	O
life	O
of	O
the	O
pregnant	B-LIVB
woman	I-LIVB
.	O

Although	O
the	O
benefits	O
of	O
using	O
a	O
combination	O
of	O
resistance	O
and	O
aerobic	B-PROC
exercises	I-PROC
are	O
not	O
yet	O
determined	O
,	O
studies	B-PROC
about	O
resistance	O
and	O
strengthen	O
training	B-PROC
programs	I-PROC
are	O
few	O
although	O
no	B-DISO
adverse	I-DISO
outcomes	B-DISO
were	O
reported	O
.	O

Identifying	O
and	O
integrating	O
patient	B-LIVB
and	O
caregiver	B-LIVB
perspectives	O
for	O
clinical	O
practice	O
guidelines	O
on	O
the	O
screening	B-PROC
and	O
management	O
of	O
infectious	O
microorganisms	B-LIVB
in	O
hemodialysis	B-OBJC
units	I-OBJC
The	O
integration	O
of	O
patient	B-LIVB
and	O
caregiver	B-LIVB
input	O
into	O
guideline	O
development	O
can	O
help	O
to	O
ensure	O
that	O
clinical	O
care	O
addresses	O
patient	B-LIVB
expectations	O
,	O
priorities	O
,	O
and	O
needs	O
.	O

We	O
aimed	O
to	O
identify	O
topics	O
and	O
outcomes	O
salient	O
to	O
patients	B-LIVB
and	O
caregivers	B-LIVB
for	O
inclusion	O
in	O
the	O
Kidney	O
Health	O
Australia	O
Caring	B-PROC
for	I-PROC
Australasians	I-PROC
with	I-PROC
Renal	I-PROC
Impairment	I-PROC
(	O
KHA	O
-	O
CARI	B-PROC
)	O
clinical	O
practice	O
guideline	O
on	O
the	O
screening	B-PROC
and	O
management	O
of	O
infectious	O
microorganisms	B-LIVB
in	O
hemodialysis	B-OBJC
units	I-OBJC
.	O

A	O
facilitated	O
workshop	O
was	O
conducted	O
with	O
11	O
participants	B-LIVB
(	O
patients	B-LIVB
[	O
n	O
=	O
8	O
]	O
,	O
caregivers	B-LIVB
[	O
n	O
=	O
3	O
]	O
)	O
.	O

Participants	B-LIVB
identified	O
and	O
discussed	O
potential	O
topics	O
for	O
inclusion	O
in	O
the	O
guidelines	O
,	O
which	O
were	O
compared	O
to	O
those	O
developed	O
by	O
the	O
guideline	O
working	B-LIVB
group	I-LIVB
.	O

The	O
workshop	O
transcript	O
was	O
thematically	O
analyzed	O
to	O
identify	O
and	O
describe	O
the	O
reasons	O
underpinning	O
their	O
priorities	O
.	O

Patients	B-LIVB
and	O
caregivers	B-LIVB
identified	O
a	O
range	O
of	O
topics	O
already	O
covered	O
by	O
the	O
scope	O
of	O
the	O
proposed	O
guidelines	O
and	O
also	O
suggested	O
additional	O
topics	O
:	O
privacy	O
and	O
confidentiality	O
,	O
psychosocial	B-PROC
care	I-PROC
during	O
/	O
after	O
disease	B-PROC
notification	I-PROC
,	O
quality	O
of	O
transportation	B-PROC
,	O
psychosocial	O
treatment	O
of	O
patients	B-LIVB
in	O
isolation	B-PROC
,	O
patient	B-LIVB
/	O
caregiver	B-PROC
education	I-PROC
and	O
engagement	B-PROC
,	O
and	O
patient	B-PROC
advocacy	I-PROC
.	O

Five	O
themes	O
characterized	O
discussion	O
and	O
underpinned	O
their	O
choices	O
:	O
shock	B-DISO
and	O
vulnerability	B-DISO
,	O
burden	B-DISO
of	I-DISO
isolation	I-DISO
,	O
fear	B-PHYS
of	I-PHYS
infection	I-PHYS
,	O
respect	B-PROC
for	I-PROC
privacy	I-PROC
and	O
confidentiality	O
,	O
and	O
confusion	B-DISO
over	I-DISO
procedural	I-DISO
inconsistencies	I-DISO
.	O

Patients	B-LIVB
and	O
caregivers	B-LIVB
emphasized	O
the	O
need	O
for	O
guidelines	O
to	O
address	O
patient	B-PROC
education	I-PROC
and	O
engagement	B-PROC
,	O
and	O
the	O
psychosocial	O
implications	O
of	O
communication	O
and	O
provision	B-PROC
of	I-PROC
care	I-PROC
in	O
the	O
context	O
of	O
infectious	O
microorganisms	B-LIVB
in	O
hemodialysis	B-OBJC
units	I-OBJC
.	O

Integrating	O
patient	B-LIVB
and	O
caregiver	B-LIVB
perspectives	O
can	O
help	O
to	O
improve	O
the	O
relevance	O
of	O
guidelines	O
to	O
enhance	O
quality	B-PROC
of	I-PROC
care	I-PROC
,	O
patient	B-LIVB
experiences	O
,	O
and	O
health	O
and	O
psychosocial	O
outcomes	O
.	O

Longitudinal	B-PROC
live	I-PROC
imaging	I-PROC
of	O
retinal	B-ANAT
α	B-CHEM
-	I-CHEM
synuclein	I-CHEM
:	O
:	O
GFP	B-CHEM
deposits	B-DISO
in	O
a	O
transgenic	B-LIVB
mouse	I-LIVB
model	I-LIVB
of	O
Parkinson	B-DISO
's	I-DISO
Disease	I-DISO
/	O
Dementia	B-DISO
with	I-DISO
Lewy	I-DISO
Bodies	I-DISO
Abnormal	B-CHEM
α	B-CHEM
-	I-CHEM
synuclein	I-CHEM
(	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
)	O
accumulation	B-DISO
in	O
the	O
CNS	B-ANAT
may	O
underlie	O
neuronal	B-ANAT
cell	I-ANAT
and	O
synaptic	B-ANAT
dysfunction	B-DISO
leading	O
to	O
motor	B-DISO
and	O
cognitive	B-DISO
deficits	I-DISO
in	O
synucleinopathies	B-DISO
including	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
(	O
PD	B-DISO
)	O
and	O
Dementia	B-DISO
with	I-DISO
Lewy	I-DISO
Bodies	I-DISO
(	O
DLB	B-DISO
)	O
.	O

Multiple	O
groups	O
demonstrated	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
accumulation	B-DISO
in	O
CNS	B-ANAT
accessory	B-ANAT
structures	I-ANAT
,	O
including	O
the	O
eyes	B-ANAT
and	O
olfactory	B-ANAT
terminals	I-ANAT
,	O
as	O
well	O
as	O
in	O
peripheral	O
organs	B-ANAT
of	O
Parkinsonian	B-DISO
patients	B-LIVB
.	O

Retinal	B-ANAT
imaging	B-PROC
studies	I-PROC
of	O
mice	B-LIVB
overexpressing	B-PHYS
fused	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O
:	O
GFP	B-CHEM
were	O
conducted	O
to	O
evaluate	B-PROC
the	O
presence	O
and	O
progression	O
of	O
retinal	B-ANAT
pathology	O
in	O
a	O
PD	B-DISO
/	O
DLB	B-DISO
transgenic	B-LIVB
mouse	I-LIVB
model	I-LIVB
.	O

Bright	B-PROC
-	I-PROC
field	I-PROC
image	I-PROC
retinal	B-PHEN
maps	I-PHEN
and	O
fluorescent	B-PROC
images	I-PROC
were	O
acquired	O
at	O
1	O
-	O
month	O
intervals	O
for	O
3	O
months	O
.	O

Retinal	B-ANAT
imaging	B-PROC
revealed	O
the	O
accumulation	B-DISO
of	O
GFP	B-CHEM
-tagged	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
in	O
retinal	B-ANAT
ganglion	I-ANAT
cell	I-ANAT
layer	I-ANAT
and	O
in	O
the	O
edges	O
of	O
arterial	O
blood	B-ANAT
vessels	I-ANAT
in	O
the	O
transgenic	B-LIVB
mice	I-LIVB
.	O

Double	B-PROC
labeling	I-PROC
studies	I-PROC
confirmed	O
that	O
the	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O
:	O
GFP	B-CHEM
-positive	O
cells	B-ANAT
were	O
retinal	B-ANAT
ganglion	I-ANAT
cells	I-ANAT
containing	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
.	O

Accumulation	B-DISO
of	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
persisted	O
in	O
the	O
same	O
cells	B-ANAT
and	O
increased	O
with	O
age	B-PHYS
.	O

Accumulation	B-DISO
of	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O
:	O
GFP	B-CHEM
was	O
reduced	O
by	O
immunization	B-PROC
with	O
single	B-CHEM
chain	I-CHEM
antibodies	I-CHEM
against	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
.	O

In	O
conclusion	O
,	O
longitudinal	B-PROC
live	I-PROC
imaging	I-PROC
of	O
the	O
retina	B-ANAT
in	O
the	O
PDGF	B-CHEM
-	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O
:	O
GFP	B-CHEM
mice	B-LIVB
might	O
represent	O
a	O
useful	O
,	O
non	O
-	O
invasive	O
tool	O
to	O
monitor	O
the	O
fate	O
of	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
accumulation	B-DISO
in	O
the	O
CNS	B-ANAT
and	O
to	O
evaluate	B-PROC
the	O
therapeutic	B-PHYS
effects	I-PHYS
of	O
compounds	B-CHEM
targeting	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
.	O

Custom	O
ocular	B-DEVI
prosthesis	I-DEVI
in	O
rehabilitation	B-PROC
of	O
a	O
child	B-LIVB
operated	O
for	O
retinoblastoma	B-DISO
A	O
maxillofacial	B-PROC
prosthodontist	I-PROC
forms	O
an	O
important	O
link	O
in	O
the	O
interdisciplinary	O
management	B-PROC
of	I-PROC
a	I-PROC
patient	I-PROC
with	O
anopthalmosis	B-DISO
.	O

Prosthetic	B-PROC
management	I-PROC
of	O
an	O
anopthalmic	B-DISO
defect	I-DISO
aims	O
to	O
deliver	O
a	O
well	O
-	O
fitting	O
ocular	B-DEVI
prosthesis	I-DEVI
that	O
can	O
mimic	O
the	O
original	O
eye	B-ANAT
as	O
closely	O
as	O
possible	O
,	O
and	O
thus	O
restoring	O
the	O
patient	B-LIVB
's	I-LIVB
self	B-PHYS
-	I-PHYS
confidence	I-PHYS
and	O
thereby	O
rehabilitating	O
them	O
in	O
the	O
society	O
.	O

The	O
fabrication	B-PROC
of	O
a	O
custom	O
ocular	B-DEVI
prosthesis	I-DEVI
is	O
a	O
demanding	O
art	O
.	O

This	O
case	O
report	O
presents	O
a	O
simplified	O
technique	O
for	O
the	O
fabrication	B-PROC
of	O
a	O
custom	O
ocular	B-DEVI
prosthesis	I-DEVI
for	O
a	O
child	B-LIVB
who	O
had	O
lost	O
his	O
eye	B-ANAT
to	O
enucleation	B-PROC
following	O
retinoblastoma	B-DISO
.	O

Early	O
and	O
effective	O
rehabilitation	B-PROC
of	O
the	O
defect	O
goes	O
a	O
long	O
way	O
in	O
restoring	O
the	O
self	B-PROC
-	I-PROC
image	I-PROC
of	O
a	O
child	B-LIVB
in	O
its	O
early	O
character	O
building	O
age	O
.	O

Health	B-PROC
technology	I-PROC
assessment	I-PROC
:	O
Off	O
-	O
site	O
sterilization	B-PROC
Every	O
year	O
millions	O
of	O
dollars	O
are	O
expended	O
to	O
equip	O
and	O
maintain	O
the	O
hospital	B-OBJC
sterilization	B-PROC
centers	B-OBJC
,	O
and	O
our	O
country	B-GEOG
is	O
not	O
an	O
exception	O
of	O
this	O
matter	O
.	O

According	O
to	O
this	O
,	O
it	O
is	O
important	O
to	O
use	O
more	O
effective	O
technologies	O
and	O
methods	O
in	O
health	O
system	O
in	O
order	O
to	O
reach	O
more	O
effectiveness	O
and	O
saving	O
in	O
costs	O
.	O

This	O
study	B-PROC
was	O
conducted	O
with	O
the	O
aim	O
of	O
evaluating	B-PROC
the	O
technology	O
of	O
regional	O
sterilization	B-PROC
centers	B-OBJC
.	O

This	O
study	B-PROC
was	O
done	O
in	O
four	O
steps	O
.	O

At	O
the	O
first	O
step	O
,	O
safety	B-PHEN
and	O
effectiveness	O
of	O
technology	O
was	O
studied	B-PROC
via	O
systematic	O
study	B-PROC
of	O
evidence	O
.	O

The	O
next	O
step	O
was	O
done	O
to	O
evaluate	B-PROC
the	O
economical	O
aspect	O
of	O
off	O
-	O
site	O
sterilization	B-PROC
technology	O
using	O
gathered	O
data	O
from	O
systematic	O
review	O
of	O
the	O
texts	O
which	O
were	O
related	O
to	O
the	O
technology	O
and	O
costs	O
of	O
off	O
-	O
site	O
and	O
in	O
-	O
site	O
hospital	B-OBJC
sterilization	B-PROC
.	O

Third	O
step	O
was	O
conducted	O
to	O
collect	O
experiences	B-PHYS
of	O
using	O
technology	O
in	O
some	O
selected	O
hospitals	B-OBJC
around	O
the	O
world	B-LIVB
.	O

And	O
in	O
the	O
last	O
step	O
different	O
aspects	O
of	O
acceptance	B-DISO
and	O
use	O
of	O
this	O
technology	O
in	O
Iran	B-GEOG
were	O
evaluated	B-PROC
.	O

Review	O
of	O
the	O
selected	O
articles	O
indicated	B-DISO
that	O
efficacy	B-PROC
and	O
effectiveness	O
of	O
this	O
technology	O
is	O
Confirmed	B-DISO
.	O

The	O
results	B-DISO
also	O
showed	O
that	O
using	O
this	O
method	O
is	O
not	O
economical	O
in	O
Iran	B-GEOG
.	O

According	O
to	O
the	O
revealed	O
evidences	O
and	O
also	O
cost	O
analysis	O
,	O
due	O
to	O
shortage	B-DISO
of	O
necessary	O
substructures	O
and	O
economical	O
aspect	O
,	O
installing	O
the	O
off	O
-	O
site	O
sterilization	B-PROC
health	B-PROC
technology	I-PROC
in	O
hospitals	B-OBJC
is	O
not	B-DISO
possible	B-DISO
currently	O
.	O

But	O
this	O
method	O
can	O
be	O
used	O
to	O
provide	O
sterilization	B-PROC
services	B-PROC
for	O
clinics	B-OBJC
and	O
outpatients	B-LIVB
centers	B-OBJC
.	O

Pulmonary	B-PHYS
function	I-PHYS
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
1	O
-	O
year	O
follow	B-PROC
up	I-PROC
after	O
cardiac	B-PROC
surgery	I-PROC
Pulmonary	B-PHYS
function	I-PHYS
is	O
severely	O
reduced	O
in	O
the	O
early	O
period	O
after	O
cardiac	B-PROC
surgery	I-PROC
,	O
and	O
impairments	B-DISO
have	O
been	O
described	O
up	O
to	O
4	O
-	O
6	O
months	O
after	O
surgery	O
.	O

Evaluation	B-PROC
of	O
pulmonary	B-PHYS
function	I-PHYS
in	O
a	O
longer	O
perspective	O
is	O
lacking	O
.	O

In	O
this	O
prospective	B-PROC
study	I-PROC
pulmonary	B-PHYS
function	I-PHYS
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
were	O
investigated	O
1	O
year	O
after	O
cardiac	B-PROC
surgery	I-PROC
.	O

Pulmonary	B-PHYS
function	I-PHYS
measurements	O
,	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
SF	O
-	O
36	O
)	O
,	O
dyspnoea	B-DISO
,	O
subjective	O
breathing	B-PHYS
and	O
coughing	B-DISO
ability	B-PHYS
and	O
pain	B-DISO
were	O
evaluated	B-PROC
before	O
and	O
1	O
year	O
after	O
surgery	O
in	O
150	O
patients	B-LIVB
undergoing	O
coronary	B-PROC
artery	I-PROC
bypass	I-PROC
grafting	I-PROC
,	O
valve	B-PROC
surgery	I-PROC
or	O
combined	O
surgery	B-PROC
.	O

One	O
year	O
after	O
surgery	O
the	O
forced	B-PHYS
vital	I-PHYS
capacity	I-PHYS
and	O
forced	B-PHYS
expiratory	I-PHYS
volume	I-PHYS
in	O
1	O
s	O
were	O
significantly	O
decreased	O
(	O
by	O
4	O
-	O
5	O
%	O
)	O
compared	O
to	O
preoperative	O
values	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Saturation	B-PHYS
of	I-PHYS
peripheral	I-PHYS
oxygen	I-PHYS
was	O
unchanged	B-DISO
1	O
year	O
postoperatively	O
compared	O
to	O
baseline	O
.	O

A	O
significantly	O
improved	B-DISO
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
found	O
1	O
year	O
after	O
surgery	O
,	O
with	O
improvements	O
in	O
all	O
eight	O
aspects	O
of	O
SF	O
-	O
36	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Sternotomy	B-PROC
-related	O
pain	B-DISO
was	O
low	O
1	O
year	O
postoperatively	O
at	O
rest	O
(	O
median	O
0	O
[	O
min	O
-	O
max	O
;	O
0	O
-	O
7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	B-DISO
breath	I-DISO
(	O
0	O
[	O
0	O
-	O
4	O
]	O
)	O
and	O
while	O
coughing	B-DISO
(	O
0	O
[	O
0	O
-	O
8	O
]	O
)	O
.	O

A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	B-PHYS
function	I-PHYS
was	O
associated	O
with	O
dyspnoea	B-DISO
limitations	O
and	O
impaired	B-DISO
subjective	O
breathing	B-PHYS
and	O
coughing	B-DISO
ability	B-PHYS
.	O

One	O
year	O
after	O
cardiac	B-PROC
surgery	I-PROC
static	O
and	O
dynamic	O
lung	B-PROC
function	I-PROC
measurements	I-PROC
were	O
slightly	O
decreased	O
,	O
while	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
improved	B-DISO
in	O
comparison	O
to	O
preoperative	O
values	O
.	O

Measured	O
levels	O
of	O
pain	B-DISO
were	O
low	O
and	O
saturation	B-PHYS
of	I-PHYS
peripheral	I-PHYS
oxygen	I-PHYS
was	O
same	O
as	O
preoperatively	O
.	O

Weed	B-LIVB
seed	B-LIVB
inactivation	O
in	O
soil	B-OBJC
mesocosms	O
via	O
biosolarization	O
with	O
mature	B-OBJC
compost	I-OBJC
and	O
tomato	B-OBJC
processing	I-OBJC
waste	I-OBJC
amendments	I-OBJC
Biosolarization	O
is	O
a	O
fumigation	B-PHEN
alternative	O
that	O
combines	O
passive	O
solar	B-PHEN
heating	B-PHEN
with	O
amendment	O
-	O
driven	O
soil	B-OBJC
microbial	B-PHEN
activity	I-PHEN
to	O
temporarily	O
create	O
antagonistic	O
soil	O
conditions	O
,	O
such	O
as	O
elevated	B-DISO
temperature	I-DISO
and	O
acidity	O
,	O
that	O
can	O
inactivate	O
weed	B-LIVB
seeds	B-LIVB
and	O
other	O
pest	B-LIVB
propagules	I-LIVB
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
use	O
a	O
mesocosm	O
-based	O
field	O
trial	O
to	O
assess	O
soil	B-OBJC
heating	B-PHEN
,	O
pH	O
,	O
volatile	B-CHEM
fatty	I-CHEM
acid	I-CHEM
accumulation	B-DISO
and	O
weed	B-LIVB
seed	B-LIVB
inactivation	O
during	O
biosolarization	O
.	O

Biosolarization	O
for	O
8	O
days	O
using	O
2	O
%	O
mature	B-OBJC
green	I-OBJC
waste	I-OBJC
compost	I-OBJC
and	O
2	O
or	O
5	O
%	O
tomato	B-OBJC
processing	I-OBJC
residues	I-OBJC
in	O
the	O
soil	B-OBJC
resulted	O
in	O
accumulation	B-DISO
of	O
volatile	B-CHEM
fatty	I-CHEM
acids	I-CHEM
in	O
the	O
soil	B-OBJC
,	O
particularly	O
acetic	B-CHEM
acid	I-CHEM
,	O
and	O
>	O
95	O
%	O
inactivation	O
of	O
Brassica	B-LIVB
nigra	I-LIVB
and	O
Solanum	B-LIVB
nigrum	I-LIVB
seeds	B-LIVB
.	O

Inactivation	O
kinetics	B-PHEN
data	O
showed	O
that	O
near	O
complete	O
weed	B-LIVB
seed	B-LIVB
inactivation	O
in	O
soil	B-OBJC
was	O
achieved	O
within	O
the	O
first	O
5	O
days	O
of	O
biosolarization	O
.	O

This	O
was	O
significantly	O
greater	O
than	O
the	O
inactivation	O
achieved	O
in	O
control	B-OBJC
soils	I-OBJC
that	O
were	O
solar	B-PHEN
heated	O
without	O
amendment	O
or	O
were	O
amended	O
but	O
not	O
solar	B-PHEN
heated	O
.	O

The	O
composition	B-PHEN
and	O
concentration	O
of	O
organic	B-LIVB
matter	I-LIVB
amendments	I-LIVB
in	O
soil	B-OBJC
significantly	O
affected	O
volatile	B-CHEM
fatty	I-CHEM
acid	I-CHEM
accumulation	B-DISO
at	O
various	O
soil	B-OBJC
depths	O
during	O
biosolarization	O
.	O

Combining	O
solar	B-PHEN
heating	B-PHEN
with	O
organic	B-LIVB
matter	I-LIVB
amendment	I-LIVB
resulted	O
in	O
accelerated	O
weed	B-LIVB
seed	B-LIVB
inactivation	O
compared	O
with	O
either	O
approach	O
alone	O
.	O

©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Phenotypic	B-DISO
and	O
genetic	B-PHYS
heterogeneity	I-PHYS
of	O
tumor	O
tissue	O
and	O
circulating	B-ANAT
tumor	I-ANAT
cells	I-ANAT
in	O
patients	B-LIVB
with	O
metastatic	B-DISO
castration	I-DISO
-	I-DISO
resistant	I-DISO
prostate	I-DISO
cancer	I-DISO
:	O
A	O
report	O
from	O
the	O
PETRUS	B-PROC
prospective	I-PROC
study	I-PROC
Molecular	O
characterization	O
of	O
cancer	O
samples	O
is	O
hampered	O
by	O
tumor	O
tissue	O
availability	O
in	O
metastatic	B-DISO
castration	I-DISO
-	I-DISO
resistant	I-DISO
prostate	I-DISO
cancer	I-DISO
(	O
mCRPC	B-DISO
)	O
patients	B-LIVB
.	O

We	O
reported	B-PROC
the	O
results	O
of	O
prospective	B-PROC
PETRUS	I-PROC
study	I-PROC
of	O
biomarker	B-PROC
assessment	I-PROC
in	O
paired	O
primary	O
prostatic	B-DISO
tumors	I-DISO
,	O
metastatic	B-DISO
biopsies	B-PROC
and	O
circulating	B-ANAT
tumor	I-ANAT
cells	I-ANAT
(	O
CTCs	B-ANAT
)	O
.	O

Among	O
54	O
mCRPC	B-DISO
patients	B-LIVB
enrolled	O
,	O
38	O
(	O
70	O
%	O
)	O
had	O
biopsies	B-PROC
containing	O
more	O
than	O
50	O
%	O
tumour	B-ANAT
cells	I-ANAT
.	O

28	O
(	O
52	O
%	O
)	O
patients	B-LIVB
were	O
analyzed	B-PROC
for	O
both	O
tissue	O
samples	O
and	O
CTCs	B-ANAT
.	O

FISH	B-PROC
for	O
AR	O
-	O
amplification	B-PROC
and	O
TMPRSS2	O
-	O
ERG	O
translocation	B-PHYS
were	O
successful	O
in	O
54	O
%	O
and	O
32	O
%	O
in	O
metastatic	B-DISO
biopsies	B-PROC
and	O
primary	B-DISO
tumors	I-DISO
,	O
respectively	O
.	O

By	O
comparing	O
CellSearch	B-PROC
and	O
filtration	B-PROC
(	I-PROC
ISET	I-PROC
)	O
-	O
enrichment	O
combined	O
to	O
four	O
color	O
immunofluorescent	B-PROC
staining	I-PROC
,	O
we	O
showed	O
that	O
CellSearch	B-PROC
and	O
ISET	B-PROC
isolated	O
distinct	O
subpopulations	B-PROC
of	O
CTCs	B-ANAT
:	O
CTCs	B-ANAT
undergoing	O
epithelial	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
,	O
CTC	B-ANAT
clusters	I-ANAT
and	O
large	O
CTCs	B-ANAT
with	O
cytomorphological	O
characteristics	O
but	O
no	O
detectable	B-PHYS
markers	B-PHYS
were	O
isolated	O
using	O
ISET	B-PROC
.	O

Epithelial	O
CTCs	B-ANAT
detected	B-DISO
by	O
the	O
CellSearch	B-PROC
were	O
mostly	O
lost	O
during	O
the	O
ISET	B-PROC
-	I-PROC
filtration	I-PROC
.	O

AR	O
-	O
amplification	B-PROC
was	O
detected	B-DISO
in	O
CellSearch	B-PROC
-captured	O
CTCs	B-ANAT
,	O
but	O
not	O
in	O
ISET	B-PROC
-enriched	O
CTCs	B-ANAT
which	O
harbor	O
exclusively	O
AR	O
gain	O
of	O
copies	O
.	O

Eighty	O
-	O
eight	O
percent	O
concordance	O
for	O
ERG	B-DISO
-	I-DISO
rearrangement	I-DISO
was	O
observed	O
between	O
metastatic	B-DISO
biopsies	B-PROC
and	O
CTCs	B-ANAT
even	O
if	O
additional	O
ERG	B-DISO
-	I-DISO
alteration	I-DISO
patterns	O
were	O
detected	B-DISO
in	O
ISET	B-PROC
-enriched	O
CTCs	B-ANAT
indicating	O
a	O
higher	O
heterogeneity	O
in	O
CTCs	B-ANAT
.	O

Molecular	O
screening	B-PROC
of	O
metastatic	B-DISO
biopsies	B-PROC
is	O
achievable	O
in	O
a	O
multicenter	B-PROC
context	I-PROC
.	O

Our	O
data	O
indicate	O
that	O
CTCs	B-ANAT
detected	B-DISO
by	O
the	O
CellSearch	B-PROC
and	O
the	O
ISET	B-PROC
-	I-PROC
filtration	I-PROC
systems	I-PROC
are	O
not	O
only	O
phenotypically	B-PHYS
but	O
also	O
genetically	O
different	O
.	O

Close	O
attention	O
must	O
be	O
paid	O
to	O
CTC	B-ANAT
characterization	O
since	O
neither	O
approach	O
tested	O
here	O
fully	O
reflects	O
the	O
tremendous	O
phenotypic	B-DISO
and	O
genetic	B-PHYS
heterogeneity	I-PHYS
present	O
in	O
CTCs	B-ANAT
from	O
mCRPC	B-DISO
patients	B-LIVB
.	O

Impact	O
of	O
Soil	B-OBJC
Salinity	O
on	O
the	O
Structure	O
of	O
the	O
Bacterial	B-LIVB
Endophytic	B-LIVB
Community	B-LIVB
Identified	O
from	O
the	O
Roots	B-LIVB
of	O
Caliph	B-LIVB
Medic	I-LIVB
(	O
Medicago	B-LIVB
truncatula	I-LIVB
)	O
In	O
addition	O
to	O
being	O
a	O
forage	B-LIVB
crop	I-LIVB
,	O
Caliph	B-LIVB
medic	I-LIVB
(	O
Medicago	B-LIVB
truncatula	I-LIVB
)	O
is	O
also	O
a	O
model	B-PROC
legume	I-PROC
plant	I-PROC
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	O
characterization	O
of	O
the	O
interaction	O
between	O
rhizobia	B-LIVB
and	O
plants	B-LIVB
.	O

However	O
,	O
the	O
endophytic	B-LIVB
microbiome	I-LIVB
in	O
this	O
plant	B-LIVB
is	O
poorly	O
defined	O
.	O

Endophytic	B-LIVB
bacteria	B-LIVB
play	O
a	O
role	O
in	O
supplying	O
plants	B-LIVB
with	O
the	O
basic	O
requirements	O
necessary	O
for	O
growth	B-PHYS
and	O
development	B-PHYS
.	O

Moreover	O
,	O
these	O
bacteria	B-LIVB
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	O
of	O
salinity	B-PHEN
stress	I-PHEN
adaptation	B-PHEN
in	O
plants	B-LIVB
.	O

As	O
a	O
prelude	O
to	O
the	O
isolation	B-PROC
and	O
utilization	O
of	O
these	O
bacteria	B-LIVB
in	O
Caliph	B-LIVB
medic	I-LIVB
farming	O
,	O
41	O
bacterial	B-LIVB
OTUs	O
were	O
identified	O
in	O
this	O
project	O
from	O
within	O
the	O
interior	O
of	O
the	O
roots	B-LIVB
of	O
this	O
plant	B-LIVB
by	O
pyrosequencing	B-PROC
of	O
the	O
small	O
ribosomal	O
subunit	O
gene	O
(	O
16S	O
rDNA	O
)	O
using	O
a	O
cultivation	B-PROC
-	I-PROC
independent	I-PROC
approach	I-PROC
.	O

In	O
addition	O
,	O
the	O
differential	O
abundance	O
of	O
these	O
bacteria	B-LIVB
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	B-LIVB
to	O
salinity	B-PHEN
stress	I-PHEN
.	O

About	O
29	O
,	O
064	O
high	O
-	O
quality	O
reads	O
were	O
obtained	O
from	O
the	O
sequencing	B-PROC
of	O
six	O
libraries	O
prepared	O
from	O
control	O
and	O
salinity	O
-	O
treated	O
tissues	O
.	O

Statistical	B-PROC
analysis	I-PROC
revealed	O
that	O
the	O
abundance	O
of	O
~70	O
%	O
of	O
the	O
OTUs	O
was	O
significantly	O
(	O
p	O
≤	O
0	O
.	O

05	O
)	O
altered	O
in	O
roots	B-LIVB
that	O
were	O
exposed	O
to	O
salinity	B-PHEN
stress	I-PHEN
.	O

Sequence	B-PROC
analysis	I-PROC
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	O
species	O
and	O
other	O
,	O
known	O
,	O
growth	B-LIVB
-	I-LIVB
promoting	I-LIVB
bacteria	I-LIVB
,	O
marine	B-LIVB
and	O
salt	B-LIVB
-	I-LIVB
stressed	I-LIVB
soil	I-LIVB
-	I-LIVB
borne	I-LIVB
bacteria	I-LIVB
,	O
and	O
nitrogen	B-LIVB
-	I-LIVB
fixing	I-LIVB
bacterial	I-LIVB
isolates	B-CHEM
.	O

Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	B-LIVB
l	O
community	B-LIVB
due	O
to	O
salinity	B-PHEN
stress	I-PHEN
in	O
Caliph	B-LIVB
medic	I-LIVB
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	O
of	O
these	O
endophytes	B-LIVB
,	O
under	O
salt	B-PHEN
stress	I-PHEN
conditions	I-PHEN
,	O
in	O
this	O
model	B-PROC
plant	I-PROC
.	O

To	O
provide	O
direct	O
evidence	O
regarding	O
their	O
growth	O
promoting	O
activity	O
,	O
a	O
group	O
of	O
endophytic	B-LIVB
bacteria	B-LIVB
were	O
isolated	O
from	O
inside	O
of	O
plant	B-LIVB
roots	I-LIVB
using	O
a	O
cultivation	B-PROC
-	I-PROC
dependent	I-PROC
approach	I-PROC
.	O

Several	O
of	O
these	O
isolates	B-CHEM
were	O
able	O
to	O
produce	O
ACC	B-CHEM
-	I-CHEM
deaminase	I-CHEM
,	O
ammonia	B-CHEM
and	O
IAA	B-CHEM
;	O
and	O
to	O
solubilize	O
Zn	B-CHEM
+	I-CHEM
2	I-CHEM
and	O
PO4	B-CHEM
-	I-CHEM
3	I-CHEM
.	O

This	O
data	O
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	O
(	O
based	O
on	O
cultivation	B-PROC
-	I-PROC
independent	I-PROC
techniques	I-PROC
)	O
of	O
these	O
bacteria	B-LIVB
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	B-LIVB
bacteria	B-LIVB
in	O
Caliph	B-LIVB
medic	I-LIVB
when	O
grown	O
under	O
normal	O
and	O
saline	B-OBJC
conditions	O
.	O

Role	O
of	O
the	O
Membrane	B-ANAT
for	O
Mechanosensing	B-PHYS
by	O
Tethered	O
Channels	B-CHEM
Biologically	O
important	O
membrane	B-CHEM
channels	I-CHEM
are	O
gated	B-PHYS
by	O
force	B-PHEN
at	O
attached	B-PHEN
tethers	O
.	O

Here	O
,	O
we	O
generically	O
characterize	O
the	O
nontrivial	O
interplay	O
of	O
force	B-PHEN
,	O
membrane	B-PHYS
tension	I-PHYS
,	O
and	O
channel	B-CHEM
deformations	B-DISO
that	O
can	O
affect	O
gating	B-PHYS
.	O

A	O
central	O
finding	O
is	O
that	O
minute	O
conical	B-CHEM
channel	I-CHEM
deformation	B-DISO
under	O
force	B-PHEN
leads	O
to	O
significant	O
energy	B-PHYS
release	I-PHYS
during	O
opening	B-PHYS
.	O

We	O
also	O
calculate	O
channel	B-PHYS
-	I-PHYS
channel	I-PHYS
interactions	I-PHYS
and	O
show	O
that	O
they	O
can	O
amplify	O
the	O
force	B-PHEN
sensitivity	B-PHYS
of	O
tethered	O
channels	B-CHEM
.	O

Caregiver	B-DISO
satisfaction	I-DISO
with	O
paediatric	B-DISO
HIV	I-DISO
treatment	B-PROC
and	O
care	O
in	O
Nigeria	B-GEOG
and	O
equity	O
implications	O
for	O
children	B-LIVB
living	O
with	O
HIV	B-DISO
Caregiver	B-DISO
satisfaction	I-DISO
has	O
the	O
potential	O
to	O
promote	O
equity	O
for	O
children	B-LIVB
living	O
with	O
HIV	B-DISO
,	O
by	O
influencing	O
health	O
-	O
seeking	O
behaviour	O
.	O

We	O
measured	O
dimensions	O
of	O
caregiver	B-DISO
satisfaction	I-DISO
with	O
paediatric	B-DISO
HIV	I-DISO
treatment	B-PROC
in	O
Nigeria	B-GEOG
,	O
and	O
discuss	O
its	O
implications	O
for	O
equity	O
by	O
conducting	O
facility	O
-	O
based	O
exit	O
interviews	O
for	O
caregivers	B-LIVB
of	O
children	B-LIVB
receiving	O
antiretroviral	B-PROC
therapy	I-PROC
in	O
20	O
purposively	O
selected	O
facilities	B-OBJC
within	O
5	O
geopolitical	B-GEOG
zones	I-GEOG
.	O

Descriptive	O
analysis	B-PROC
and	O
factor	O
analysis	O
were	O
performed	O
.	O

Due	O
to	O
the	O
hierarchical	O
nature	O
of	O
the	O
data	O
,	O
multilevel	B-PROC
regression	I-PROC
modelling	I-PROC
was	O
performed	O
to	O
investigate	O
relationships	O
between	O
satisfaction	B-PHYS
factors	I-PHYS
and	O
socio	O
-	O
demographic	O
variables	O
.	O

Of	O
1550	O
caregivers	B-LIVB
interviewed	O
,	O
63	O
%	O
(	O
95	O
%	O
CI	O
:	O
60	O
.	O
6	O
-	O
65	O
.	O

4	O
)	O
reported	O
being	O
very	O
satisfied	O
overall	O
;	O
however	O
,	O
satisfaction	B-PHYS
varied	O
in	O
some	O
dimensions	O
:	O
only	O
55	O
.	O

6	O
%	O
(	O
53	O
.	O
1	O
-	O
58	O
.	O
1	O
)	O
of	O
caregivers	B-LIVB
could	O
talk	O
privately	O
with	O
health	B-LIVB
workers	I-LIVB
,	O
56	O
.	O

9	O
%	O
(	O
54	O
.	O
4	O
-	O
59	O
.	O
3	O
)	O
reported	O
that	O
queues	O
to	O
see	O
health	B-LIVB
workers	I-LIVB
were	O
too	O
long	O
,	O
and	O
89	O
.	O

9	O
%	O
(	O
88	O
.	O
4	O
-	O
91	O
.	O
4	O
)	O
said	O
that	O
some	O
health	B-LIVB
workers	I-LIVB
did	O
not	O
treat	O
patients	B-LIVB
living	O
with	O
HIV	B-DISO
with	O
sufficient	O
respect	O
.	O

Based	O
on	O
factor	O
analysis	O
,	O
two	O
underlying	O
factors	O
,	O
labelled	O
Availability	O
and	O
Attitude	B-PHYS
,	O
were	O
identified	O
.	O

In	O
multilevel	B-PROC
regression	I-PROC
,	O
the	O
satisfaction	B-PHYS
with	O
availability	O
of	O
services	O
correlated	O
with	O
formal	O
employment	B-DISO
status	I-DISO
(	O
p	O
<	O
.01	O
)	O
,	O
whereas	O
caregivers	B-LIVB
receiving	O
care	O
in	O
private	B-OBJC
facilities	I-OBJC
were	O
less	O
likely	O
satisfied	O
with	O
both	O
availability	O
(	O
p	O
<	O
.01	O
)	O
and	O
attitude	B-PHYS
of	O
health	B-LIVB
workers	I-LIVB
(	O
p	O
<	O
.05	O
)	O
.	O

State	B-GEOG
and	O
facility	B-OBJC
levels	O
influenced	O
attitudes	B-PHYS
of	O
the	O
health	B-LIVB
workers	I-LIVB
(	O
p	O
<	O
.01	O
)	O
,	O
but	O
not	O
availability	O
of	O
services	O
.	O

We	O
conclude	O
that	O
high	O
levels	O
of	O
overall	O
satisfaction	B-PHYS
among	O
caregivers	B-LIVB
masked	O
dissatisfaction	B-PHYS
with	O
some	O
aspects	O
of	O
services	O
.	O

The	O
two	O
underlying	O
satisfaction	B-PHYS
factors	O
are	O
part	O
of	O
access	O
typology	B-PROC
critical	O
for	O
closing	O
equity	O
gaps	O
in	O
access	O
to	O
HIV	B-DISO
treatment	B-PROC
between	O
adults	B-LIVB
and	O
children	B-LIVB
,	O
and	O
across	O
socio	B-LIVB
-	I-LIVB
economic	I-LIVB
groups	I-LIVB
.	O

Eliminating	O
Cancer	B-ANAT
Stem	I-ANAT
Cells	I-ANAT
in	O
CML	B-DISO
with	O
Combination	O
Transcriptional	B-PHYS
Therapy	B-PROC
Leukemia	B-DISO
stem	B-ANAT
cells	I-ANAT
(	O
LSCs	B-ANAT
)	O
are	O
resistant	O
to	O
current	O
therapies	B-PROC
used	O
to	O
treat	O
chronic	B-DISO
myeloid	I-DISO
leukemia	I-DISO
(	O
CML	B-DISO
)	O
.	O

Abraham	O
et	O
al	O
.	O
(	O
2016	O
)	O
have	O
identified	O
a	O
molecular	B-PHYS
network	I-PHYS
critical	O
for	O
CML	B-DISO
LSC	B-ANAT
survival	B-PHYS
and	O
propose	O
that	O
simultaneously	O
targeting	O
two	O
of	O
their	O
major	O
transcriptional	B-CHEM
regulators	I-CHEM
,	O
p53	O
and	O
c	B-CHEM
-	I-CHEM
Myc	I-CHEM
,	O
may	O
facilitate	O
their	O
eradication	B-PHYS
.	O

Energy	B-PHYS
Expenditure	I-PHYS
and	O
Intensity	O
of	O
Classroom	B-OBJC
Physical	O
Activity	O
in	O
Elementary	O
School	O
Children	B-LIVB
There	O
is	O
limited	O
data	O
regarding	O
objectively	O
measured	O
energy	O
cost	O
and	O
intensity	O
of	O
classroom	B-PROC
instruction	I-PROC
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
current	O
study	B-PROC
was	O
to	O
objectively	O
measure	O
energy	O
cost	O
and	O
subsequently	O
calculate	O
MET	B-PROC
values	I-PROC
using	O
a	O
portable	O
indirect	B-DEVI
calorimeter	I-DEVI
(	O
IC	B-DEVI
)	O
for	O
both	O
normal	O
classroom	B-PROC
instruction	I-PROC
(	O
NCI	B-PROC
)	O
and	O
active	O
classroom	B-PROC
instruction	I-PROC
(	O
ACI	B-PROC
)	O
.	O

We	O
assessed	O
energy	B-PHYS
expenditure	I-PHYS
(	O
EE	B-PHYS
)	O
and	O
intensity	O
levels	O
(	O
METs	B-PROC
)	O
in	O
elementary	O
school	O
children	B-LIVB
(	O
17	O
boys	B-LIVB
and	O
15	O
girls	B-LIVB
)	O
using	O
an	O
IC	B-DEVI
(	O
COSMED	B-DEVI
K4b2	I-DEVI
)	O
.	O

Independent	O
t	O
-	O
tests	O
were	O
used	O
to	O
evaluate	B-PROC
potential	O
sex	B-PHYS
and	O
grade	O
level	O
differences	O
for	O
age	B-PHYS
,	O
BMI	B-PHYS
,	O
VO2	B-PROC
,	O
EE	B-PHYS
,	O
and	O
METs	B-PROC
.	O

The	O
average	O
EE	B-PHYS
for	O
NCI	B-PROC
and	O
ACI	B-PROC
were	O
1	O
.	O
8	O
±	O
0	O
.	O
4	O
and	O
3	O
.	O

9	O
±	O
1	O
.	O
0	O
,	O
respectively	O
.	O

The	O
average	O
intensity	O
level	O
for	O
NCI	B-PROC
and	O
ACI	B-PROC
were	O
1	O
.	O
9	O
±	O
0	O
.	O
4	O
and	O
4	O
.	O
2	O
±	O
0	O
.	O

9	O
METs	B-PROC
,	O
respectively	O
.	O

PA	O
delivered	O
through	O
ACI	B-PROC
can	O
elicit	O
EE	B-PHYS
at	O
a	O
moderate	O
intensity	O
level	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
ACI	B-PROC
as	O
a	O
convenient	O
/	O
feasible	O
avenue	O
for	O
increasing	O
PA	O
in	O
youth	B-LIVB
without	O
decreasing	B-DISO
instruction	O
time	O
.	O

Liver	B-ANAT
-	O
specific	O
mono	B-CHEM
-	I-CHEM
unsaturated	I-CHEM
fatty	I-CHEM
acid	I-CHEM
synthase	I-CHEM
-	I-CHEM
1	I-CHEM
inhibitor	B-CHEM
for	O
anti	B-DISO
-	I-DISO
hepatitis	I-DISO
C	I-DISO
treatment	B-PROC
Recently	O
,	O
direct	O
antiviral	B-CHEM
agents	I-CHEM
against	O
hepatitis	B-DISO
C	I-DISO
virus	I-DISO
(	I-DISO
HCV	I-DISO
)	I-DISO
infection	I-DISO
have	O
been	O
developed	O
as	O
highly	O
effective	O
anti	B-CHEM
-	I-CHEM
HCV	I-CHEM
drugs	I-CHEM
.	O

However	O
,	O
the	O
appearance	O
of	O
resistant	O
viruses	B-LIVB
against	O
direct	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
is	O
an	O
unsolved	O
problem	B-DISO
.	O

One	O
of	O
the	O
strategies	O
considered	O
to	O
suppress	O
the	O
emergence	O
of	O
the	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
viruses	B-LIVB
is	O
to	O
use	O
drugs	B-CHEM
inhibiting	O
the	O
host	B-LIVB
factor	O
,	O
which	O
contributes	O
to	O
HCV	B-LIVB
proliferation	O
,	O
in	O
combination	O
with	O
direct	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
.	O

The	O
replication	B-ANAT
complex	I-ANAT
was	O
reported	O
to	O
be	O
present	B-DISO
in	O
the	O
membranous	O
compartment	O
in	O
the	O
cells	B-ANAT
.	O

Thus	O
,	O
lipid	B-PHYS
metabolism	I-PHYS
modulators	B-CHEM
are	O
good	O
candidates	O
to	O
regulate	O
virus	B-PHEN
assembly	I-PHEN
and	O
HCV	B-LIVB
replication	B-PHYS
.	O

Recent	O
studies	O
have	O
shown	O
that	O
stearoyl	B-CHEM
-	I-CHEM
CoA	I-CHEM
desaturase	I-CHEM
(	O
SCD	B-CHEM
)	O
,	O
an	O
enzyme	B-CHEM
for	O
long	B-CHEM
-	I-CHEM
chain	I-CHEM
mono	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
fatty	I-CHEM
acid	I-CHEM
(	O
LCMUFA	B-CHEM
)	O
synthesis	B-PHEN
,	O
is	O
a	O
key	O
factor	O
that	O
defines	O
HCV	B-LIVB
replication	B-PHYS
efficiency	O
.	O

Systemic	O
exposure	O
to	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibor	B-CHEM
induces	O
some	O
side	B-DISO
effects	I-DISO
in	O
the	O
eyes	B-ANAT
and	O
skin	B-ANAT
.	O

Thus	O
,	O
systemic	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitors	B-CHEM
are	O
considered	O
inappropriate	O
for	O
HCV	B-DISO
therapy	O
.	O

To	O
avoid	O
the	O
side	B-DISO
effects	I-DISO
of	O
systemic	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitors	B-CHEM
,	O
the	O
liver	B-ANAT
-	O
specific	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitor	B-CHEM
,	O
MK8245	B-CHEM
,	O
was	O
synthesized	O
;	O
it	O
showed	O
antidiabetic	B-DISO
effects	I-DISO
in	O
diabetic	B-DISO
model	B-LIVB
mice	I-LIVB
with	O
no	B-DISO
side	B-DISO
effects	I-DISO
.	O

In	O
the	O
phase	O
1	O
clinical	B-PROC
study	I-PROC
on	O
measurement	O
of	O
MK8245	B-CHEM
tolerability	B-PROC
,	O
no	B-DISO
significant	I-DISO
side	B-DISO
effects	I-DISO
were	O
reported	O
(	O
ClinicalTrials	O
.	O
gov	O
Identifier	O
:	O
NCT00790556	O
)	O
.	O

Therefore	O
,	O
we	O
thought	O
liver	B-ANAT
-	O
specific	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitors	B-CHEM
would	O
be	O
suitable	O
agents	B-CHEM
for	O
HCV	B-LIVB
-	O
infected	B-DISO
patients	B-LIVB
.	O

MK8245	B-CHEM
was	O
evaluated	O
using	O
recombinant	B-LIVB
HCV	I-LIVB
culture	B-PROC
systems	I-PROC
.	O

Considering	O
current	O
HCV	B-LIVB
treatments	B-PROC
,	O
to	O
avoid	O
the	O
emergence	O
of	O
direct	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
-	O
resistant	O
viruses	B-LIVB
,	O
combination	B-PROC
therapy	I-PROC
with	O
direct	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
and	O
host	B-LIVB
-	O
targeted	O
agents	B-CHEM
would	O
be	O
optimal	O
.	O

With	O
this	O
viewpoint	O
,	O
we	O
confirmed	O
MK8245	B-CHEM
'	O
s	O
additive	O
or	O
synergistic	O
anti	B-DISO
-	I-DISO
HCV	I-DISO
effects	I-DISO
on	O
current	O
direct	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
and	O
interferon	B-PROC
-	I-PROC
alpha	I-PROC
therapy	I-PROC
.	O

The	O
results	O
suggest	O
that	O
MK8245	B-CHEM
is	O
an	O
option	O
for	O
anti	B-DISO
-	I-DISO
HCV	I-DISO
multi	B-PROC
-	I-PROC
drug	I-PROC
therapy	I-PROC
with	O
a	O
low	O
risk	O
of	O
emergence	O
of	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
HCV	B-LIVB
without	O
significant	O
side	B-DISO
effects	I-DISO
.	O

Relation	O
of	O
Left	B-DISO
Ventricular	I-DISO
Mass	I-DISO
and	O
Infarct	B-DISO
Size	I-DISO
in	O
Anterior	B-DISO
Wall	I-DISO
ST	I-DISO
-	I-DISO
Segment	I-DISO
Elevation	I-DISO
Acute	I-DISO
Myocardial	I-DISO
Infarction	I-DISO
(	O
from	O
the	O
EMBRACE	O
STEMI	B-DISO
Clinical	B-PROC
Trial	I-PROC
)	O
Biomarker	B-PHYS
measures	O
of	O
infarct	B-DISO
size	I-DISO
and	O
myocardial	O
salvage	O
index	O
(	O
MSI	O
)	O
are	O
important	O
surrogate	O
measures	O
of	O
clinical	O
outcomes	O
after	O
a	O
myocardial	B-DISO
infarction	I-DISO
.	O

However	O
,	O
there	O
is	O
variability	O
in	O
infarct	B-DISO
size	I-DISO
unaccounted	O
for	O
by	O
conventional	O
adjustment	O
factors	O
.	O

This	O
post	O
hoc	O
analysis	O
of	O
Evaluation	O
of	O
Myocardial	O
Effects	O
of	O
Bendavia	B-CHEM
for	O
Reducing	O
Reperfusion	B-DISO
Injury	I-DISO
in	O
Patients	B-LIVB
With	O
Acute	B-DISO
Coronary	I-DISO
Events	I-DISO
(	O
EMBRACE	O
)	O
ST	B-DISO
-	I-DISO
Segment	I-DISO
Elevation	I-DISO
Myocardial	I-DISO
Infarction	I-DISO
(	O
STEMI	B-DISO
)	O
trial	B-PROC
evaluates	O
the	O
association	O
between	O
left	B-DISO
ventricular	I-DISO
(	I-DISO
LV	I-DISO
)	I-DISO
mass	I-DISO
and	O
infarct	B-DISO
size	I-DISO
as	O
assessed	O
by	O
areas	O
under	O
the	O
curve	O
for	O
creatine	B-PROC
kinase	I-PROC
-	I-PROC
MB	I-PROC
(	O
CK	B-PROC
-	I-PROC
MB	I-PROC
)	O
and	O
troponin	B-PROC
I	I-PROC
release	I-PROC
over	O
the	O
first	O
72	O
hours	O
(	O
CK	B-PROC
-	I-PROC
MB	I-PROC
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
and	O
troponin	B-CHEM
I	I-CHEM
[	O
TnI	B-CHEM
]	O
AUC	O
)	O
and	O
the	O
MSI	O
.	O

Patients	B-LIVB
with	O
first	O
anterior	B-DISO
STEMI	I-DISO
,	O
occluded	O
left	B-ANAT
anterior	I-ANAT
descending	I-ANAT
artery	I-ANAT
,	O
and	O
available	O
LV	B-DISO
mass	I-DISO
measurement	O
in	O
EMBRACE	O
STEMI	B-DISO
trial	B-PROC
were	O
included	O
(	O
n	O
=	O
100	O
)	O
(	O
ClinicalTrials	O
.	O
govNCT01572909	O
)	O
.	O

MSI	O
,	O
end	B-PHYS
-	I-PHYS
diastolic	I-PHYS
LV	B-DISO
mass	I-DISO
on	O
day	O
4	O
cardiac	B-PROC
magnetic	I-PROC
resonance	I-PROC
,	O
and	O
CK	B-PROC
-	I-PROC
MB	I-PROC
and	O
troponin	B-CHEM
I	I-CHEM
concentrations	O
were	O
evaluated	O
by	O
a	O
core	B-OBJC
laboratory	I-OBJC
.	O

After	O
saturated	O
multivariate	O
analysis	O
,	O
dominance	B-PROC
analysis	I-PROC
was	O
performed	O
to	O
estimate	O
the	O
contribution	O
of	O
each	O
independent	O
variable	O
to	O
the	O
predicted	O
variance	O
of	O
each	O
outcome	O
.	O

In	O
multivariate	O
models	O
that	O
included	O
age	B-PHYS
,	O
gender	B-PHYS
,	O
body	B-PHYS
surface	I-PHYS
area	I-PHYS
,	O
lesion	B-DISO
location	I-DISO
,	O
smoking	O
,	O
and	O
ischemia	B-DISO
time	O
,	O
LV	B-DISO
mass	I-DISO
remained	O
independently	O
associated	O
with	O
biomarker	B-PHYS
measures	O
of	O
infarct	B-DISO
size	I-DISO
(	O
CK	B-PROC
-	I-PROC
MB	I-PROC
AUC	O
p	O
=	O
0	O
.	O

02	O
,	O
TnI	B-CHEM
AUC	O
p	O
=	O
0	O
.	O
03	O
)	O
and	O
MSI	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O

Dominance	B-PROC
analysis	I-PROC
demonstrated	O
that	O
LV	B-DISO
mass	I-DISO
accounted	O
for	O
58	O
%	O
,	O
47	O
%	O
,	O
and	O
60	O
%	O
of	O
the	O
predicted	O
variances	O
for	O
CK	B-PROC
-	I-PROC
MB	I-PROC
AUC	O
,	O
TnI	B-CHEM
AUC	O
,	O
and	O
MSI	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
LV	B-DISO
mass	I-DISO
accounts	O
for	O
approximately	O
half	O
of	O
the	O
predicted	O
variance	O
in	O
biomarker	B-PHYS
measures	O
of	O
infarct	B-DISO
size	I-DISO
.	O

It	O
should	O
be	O
considered	O
as	O
an	O
adjustment	O
variable	O
in	O
studies	B-PROC
evaluating	O
infarct	B-DISO
size	I-DISO
.	O

Hard	O
ticks	O
(	O
Acari	O
:	O
Ixodidae	O
)	O
of	O
livestock	B-LIVB
in	O
Nicaragua	B-GEOG
,	O
with	O
notes	O
about	O
distribution	O
We	O
document	O
the	O
species	O
of	O
ticks	O
that	O
parasitize	B-DISO
livestock	B-LIVB
in	O
Nicaragua	B-GEOG
.	O

The	O
study	B-PROC
was	O
based	O
on	O
tick	O
collection	O
on	O
cattle	B-LIVB
and	O
horses	B-LIVB
from	O
437	O
farms	O
in	O
nine	O
departments	O
.	O

Of	O
4841	O
animals	B-LIVB
examined	O
(	O
4481	O
cows	B-LIVB
and	O
360	O
horses	B-LIVB
)	O
,	O
3299	O
were	O
parasitized	B-DISO
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	B-LIVB
and	O
67	O
%	O
of	O
the	O
equines	B-LIVB
in	O
study	B-PROC
:	O
59	O
cows	B-LIVB
and	O
25	O
horses	B-LIVB
were	O
parasitized	B-DISO
by	O
more	O
than	O
one	O
species	O
.	O

In	O
addition	O
,	O
280	O
specimens	B-OBJC
of	O
the	O
entomological	O
museum	B-OBJC
in	O
León	B-GEOG
were	O
examined	O
.	O

The	O
ticks	O
found	O
on	O
cattle	B-LIVB
were	O
Rhipicephalus	O
microplus	O
(	O
75	O
.	O
2	O
%	O
of	O
the	O
ticks	O
collected	O
)	O
,	O
Amblyomma	O
mixtum	O
(	O
20	O
.	O
8	O
%	O
)	O
,	O
A	O
.	O

parvum	O
(	O
2	O
.	O
6	O
%	O
)	O
,	O
A	O
.	O

tenellum	O
(	O
0	O
.	O
7	O
%	O
)	O
,	O
A	O
.	O

maculatum	O
(	O
0	O
.	O

7	O
%	O
)	O
.	O

While	O
the	O
ticks	O
collected	O
from	O
the	O
horses	B-LIVB
were	O
:	O
Dermacentor	O
nitens	O
(	O
41	O
.	O
5	O
%	O
)	O
,	O
A	O
.	O

mixtum	O
(	O
31	O
.	O
7	O
%	O
)	O
,	O
R	O
.	O

microplus	O
(	O
13	O
.	O
8	O
%	O
)	O
,	O
A	O
.	O

parvum	O
(	O
6	O
.	O
5	O
%	O
)	O
,	O
A	O
.	O

tenellum	O
(	O
3	O
.	O
3	O
%	O
)	O
,	O
D	O
.	O

dissimilis	O
(	O
2	O
.	O
4	O
%	O
)	O
and	O
A	O
.	O

maculatum	O
(	O
0	O
.	O

8	O
%	O
)	O
.	O

Crocetin	B-CHEM
improves	B-DISO
the	O
quality	O
of	O
in	O
vitro	O
-	O
produced	O
bovine	B-LIVB
embryos	B-ANAT
:	O
Implications	O
for	O
blastocyst	B-PHYS
development	I-PHYS
,	O
cryotolerance	O
,	O
and	O
apoptosis	B-PHYS
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	B-PROC
the	O
effect	O
of	O
supplementation	B-PROC
of	O
bovine	B-LIVB
culture	B-CHEM
medium	I-CHEM
with	O
the	O
natural	B-CHEM
antioxidant	I-CHEM
crocetin	B-CHEM
on	O
in	O
vitro	O
blastocyst	B-PHYS
development	I-PHYS
and	O
quality	O
.	O

This	O
was	O
evaluated	B-PROC
as	O
cryotolerance	O
,	O
apoptosis	O
index	O
,	O
and	O
total	B-PROC
cells	I-PROC
number	I-PROC
and	O
allocation	O
.	O

Abattoir	B-OBJC
-derived	O
oocytes	B-ANAT
were	O
matured	O
and	O
fertilized	O
in	O
vitro	O
according	O
to	O
standard	O
procedure	O
.	O

Twenty	O
hours	O
after	O
IVF	B-PROC
,	O
presumptive	O
zygotes	B-ANAT
were	O
cultured	B-PROC
in	O
synthetic	B-ANAT
oviduct	I-ANAT
fluid	B-OBJC
medium	I-OBJC
,	O
supplemented	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
crocetin	B-CHEM
(	O
experiment	O
1	O
)	O
at	O
39	O
°	O
C	O
under	O
humidified	B-PROC
air	I-PROC
with	O
5	O
%	O
CO2	B-CHEM
,	O
7	O
%	O
O2	B-CHEM
,	O
and	O
88	O
%	O
N2	B-CHEM
.	O

On	O
Day	O
7	O
,	O
embryo	O
yields	O
were	O
assessed	O
and	O
the	O
blastocysts	B-ANAT
were	O
vitrified	O
by	O
Cryotop	O
method	O
in	O
16	O
.	O

5	O
%	O
ethylene	B-CHEM
glycol	I-CHEM
,	O
16	O
.	O

5	O
%	O
DMSO	B-CHEM
,	O
and	O
0	O
.	O

5	O
M	O
sucrose	B-CHEM
.	O

Finally	O
,	O
blastocysts	B-ANAT
produced	O
on	O
Day	O
8	O
in	O
the	O
absence	O
(	O
control	B-LIVB
)	O
and	O
presence	B-DISO
of	O
1	O
μM	O
crocetin	B-CHEM
were	O
used	O
for	O
terminal	B-PROC
deoxynucleotidyl	I-PROC
transferase	I-PROC
-	I-PROC
mediated	I-PROC
dUTP	I-PROC
nick	I-PROC
end	I-PROC
labelling	I-PROC
and	O
differential	B-PROC
staining	I-PROC
to	O
evaluate	B-PROC
,	O
respectively	O
,	O
the	O
apoptotic	O
rate	O
and	O
the	O
allocation	O
of	O
cells	B-ANAT
into	O
inner	B-ANAT
cell	I-ANAT
mass	I-ANAT
(	O
ICM	B-ANAT
)	O
and	O
trophectoderm	B-ANAT
(	O
TE	B-ANAT
)	O
lineages	O
(	O
experiment	O
2	O
)	O
.	O

Embryo	B-PHYS
development	I-PHYS
was	O
higher	O
in	O
the	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	B-LIVB
,	O
both	O
in	O
terms	O
of	O
total	O
embryo	B-ANAT
output	B-DISO
(	O
37	O
.	O
7	O
±	O
4	O
.	O
2	O
%	O
,	O
52	O
.	O
9	O
±	O
6	O
.	O

3	O
%	O
,	O
40	O
.	O
9	O
±	O
7	O
.	O
6	O
%	O
,	O
and	O
42	O
.	O
4	O
±	O
8	O
.	O

7	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
grade	O
1	O
and	O
2	O
blastocysts	B-ANAT
(	O
33	O
.	O
6	O
±	O
4	O
.	O
9	O
%	O
,	O
46	O
.	O
1	O
±	O
7	O
.	O

3	O
%	O
,	O
37	O
.	O
8	O
±	O
7	O
.	O
9	O
%	O
,	O
and	O
39	O
.	O
4	O
±	O
7	O
.	O
9	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Moreover	O
,	O
the	O
percentage	O
of	O
fast	B-PHYS
-	I-PHYS
developing	I-PHYS
embryos	I-PHYS
increased	O
in	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	B-LIVB
(	O
23	O
.	O
4	O
±	O
4	O
.	O

7	O
%	O
,	O
32	O
.	O

7	O
±	O
6	O
.	O

6	O
%	O
,	O
27	O
.	O
2	O
±	O
6	O
.	O

6	O
%	O
,	O
and	O
30	O
.	O
1	O
±	O
7	O
.	O
2	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
the	O
enrichment	B-CHEM
of	I-CHEM
culture	I-CHEM
medium	I-CHEM
with	O
1	O
μM	O
crocetin	B-CHEM
improved	B-DISO
embryo	B-ANAT
cryotolerance	O
compared	O
to	O
the	O
control	B-LIVB
,	O
as	O
indicated	O
by	O
higher	O
hatching	B-PHYS
rates	O
recorded	O
after	O
48	O
hours	O
postwarming	B-CHEM
culture	I-CHEM
(	O
46	O
.	O
5	O
%	O
vs	O
.	O

60	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
1	O
μM	O
crocetin	B-CHEM
decreased	O
both	O
the	O
average	O
number	O
(	O
9	O
.	O
9	O
±	O
0	O
.	O

4	O
vs	O
.	O

7	O
.	O
1	O
±	O
0	O
.	O
3	O
)	O
and	O
the	O
percentage	O
of	O
apoptotic	O
cells	B-ANAT
(	O
7	O
.	O
1	O
±	O
0	O
.	O
4	O
vs	O
.	O

4	O
.	O
2	O
±	O
0	O
.	O
2	O
)	O
in	O
blastocysts	B-ANAT
compared	O
to	O
the	O
control	B-LIVB
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
ICM	B-ANAT
,	O
TE	B-ANAT
,	O
and	O
total	O
cells	B-ANAT
between	O
1	O
μM	O
crocetin	B-CHEM
and	O
control	B-LIVB
groups	O
.	O

In	O
conclusion	O
,	O
the	O
enrichment	B-CHEM
of	I-CHEM
bovine	I-CHEM
culture	I-CHEM
medium	I-CHEM
with	O
1	O
μM	O
crocetin	B-CHEM
increased	O
both	O
blastocyst	O
yield	O
and	O
quality	O
,	O
as	O
indicated	O
by	O
the	O
improved	B-DISO
chronology	O
of	O
embryo	B-PHYS
development	I-PHYS
,	O
increased	O
resistance	O
to	O
cryopreservation	B-PROC
,	O
and	O
reduced	O
incidence	O
of	O
apoptosis	B-PHYS
.	O

Parkinson	B-DISO
subtype	O
-specific	O
Granger	B-PROC
-	I-PROC
causal	I-PROC
coupling	I-PROC
and	O
coherence	B-PHYS
frequency	O
in	O
the	O
subthalamic	B-ANAT
area	O
Previous	O
work	O
on	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
(	O
PD	B-DISO
)	O
has	O
indicated	O
a	O
predominantly	O
afferent	O
coupling	O
between	O
affected	O
arm	B-ANAT
muscle	B-PHYS
activity	I-PHYS
and	O
electrophysiological	B-PHYS
activity	I-PHYS
within	O
the	O
subthalamic	B-ANAT
nucleus	I-ANAT
(	O
STN	B-ANAT
)	O
.	O

So	O
far	O
,	O
no	O
information	O
is	O
available	O
indicating	O
which	O
frequency	O
components	O
drive	O
the	O
afferent	O
information	O
flow	O
in	O
PD	B-DISO
patients	B-LIVB
.	O

Non	O
-	O
directional	O
coupling	O
e	O
.	O

g	O
.	O

by	O
measuring	O
coherence	B-PHYS
is	O
primarily	O
established	O
in	O
the	O
beta	B-ANAT
band	I-ANAT
as	O
well	O
as	O
at	O
tremor	B-DISO
frequency	O
.	O

Based	O
on	O
previous	O
evidence	O
it	O
is	O
likely	O
that	O
different	O
subtypes	O
of	O
the	O
disease	B-DISO
are	O
associated	O
with	O
different	O
connectivity	O
patterns	O
.	O

Therefore	O
,	O
we	O
determined	O
coherence	B-PHYS
and	O
causality	O
between	O
local	B-PHYS
field	I-PHYS
potentials	I-PHYS
(	O
LFPs	B-PHYS
)	O
in	O
the	O
STN	B-ANAT
and	O
surface	O
electromyograms	B-DISO
(	O
EMGs	B-DISO
)	O
from	O
the	O
contralateral	O
arm	O
in	O
18	O
akinetic	B-DISO
-	I-DISO
rigid	I-DISO
(	O
AR	B-DISO
)	O
PD	B-DISO
patients	B-LIVB
and	O
8	O
tremor	B-DISO
-	I-DISO
dominant	I-DISO
(	O
TD	B-DISO
)	O
PD	B-DISO
patients	B-LIVB
.	O

During	O
the	O
intraoperative	O
recording	O
,	O
patients	B-LIVB
were	O
asked	O
to	O
lift	O
their	O
forearm	B-ANAT
contralateral	O
to	O
the	O
recording	O
side	O
.	O

Significantly	O
more	O
afferent	O
connections	O
were	O
detected	O
for	O
the	O
TD	B-DISO
patients	B-LIVB
for	O
tremor	B-DISO
-periods	O
and	O
non	O
-	O
tremor	B-DISO
-periods	O
combined	O
as	O
well	O
as	O
for	O
only	O
tremor	B-DISO
periods	O
.	O

Within	O
the	O
STN	B-ANAT
74	O
%	O
and	O
63	O
%	O
of	O
the	O
afferent	O
connections	O
are	O
associated	O
with	O
coherence	B-PHYS
from	O
4	O
-	O
8Hz	O
and	O
8	O
-	O
12Hz	O
,	O
respectively	O
.	O

However	O
,	O
when	O
considering	O
only	O
tremor	B-DISO
-periods	O
significantly	O
more	O
afferent	O
than	O
efferent	O
connections	O
were	O
associated	O
with	O
coherence	B-PHYS
from	O
12	O
to	O
20Hz	O
across	O
all	O
recording	O
heights	O
.	O

No	O
difference	O
between	O
efferent	O
and	O
afferent	O
connections	O
is	O
seen	O
in	O
the	O
frequency	O
range	O
from	O
4	O
to	O
12Hz	O
for	O
all	O
recording	O
heights	O
.	O

For	O
the	O
AR	B-DISO
patients	B-LIVB
,	O
no	O
significant	O
difference	O
in	O
afferent	O
and	O
efferent	O
connections	O
within	O
the	O
STN	B-ANAT
was	O
found	O
for	O
the	O
different	O
frequency	O
bands	O
.	O

Still	O
,	O
for	O
the	O
AR	B-DISO
patients	B-LIVB
dorsal	O
of	O
the	O
STN	B-ANAT
significantly	O
more	O
afferent	O
than	O
efferent	O
connections	O
were	O
associated	O
with	O
coherence	B-PHYS
in	O
the	O
frequency	O
range	O
from	O
12	O
to	O
16Hz	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
for	O
the	O
differential	O
pathological	O
oscillations	O
and	O
pathways	O
present	O
in	O
AR	B-DISO
and	O
TD	B-DISO
Parkinson	B-DISO
patients	B-LIVB
.	O

Incidence	O
and	O
growth	B-PHYS
of	O
Salmonella	B-LIVB
enterica	I-LIVB
on	O
the	O
peel	B-OBJC
and	O
pulp	B-OBJC
of	O
avocado	B-OBJC
(	O
Persea	B-LIVB
americana	I-LIVB
)	O
and	O
custard	B-OBJC
apple	I-OBJC
(	O
Annona	B-LIVB
squamosa	I-LIVB
)	O
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
assess	O
the	O
incidence	O
and	O
to	O
estimate	O
the	O
growth	O
kinetic	O
parameters	O
(	O
maximum	O
growth	O
rate	O
,	O
μ	O
;	O
lag	O
time	O
,	O
λ	O
;	O
and	O
maximum	O
population	O
,	O
κ	O
)	O
of	O
Salmonella	B-LIVB
on	O
the	O
peel	B-OBJC
and	O
pulp	B-OBJC
of	O
avocado	B-OBJC
(	O
Perseaamericana	B-LIVB
var	I-LIVB
.	I-LIVB

americana	I-LIVB
)	O
and	O
custard	B-OBJC
apple	I-OBJC
(	O
Annona	B-LIVB
squamosa	I-LIVB
L	I-LIVB
.	I-LIVB
)	O
as	O
affected	O
by	O
temperature	O
(	O
10	O
-	O
30°C	O
)	O
.	O

The	O
incidence	O
of	O
Salmonella	B-LIVB
was	O
assessed	O
on	O
the	O
peel	B-OBJC
and	O
pulp	B-OBJC
of	O
the	O
fruits	B-OBJC
(	O
n	O
=	O
200	O
of	O
each	O
fruit	B-OBJC
)	O
,	O
separately	O
,	O
totalizing	O
800	O
analyses	O
.	O

Only	O
three	O
samples	O
of	O
custard	B-OBJC
apple	I-OBJC
pulp	B-OBJC
were	O
positive	O
for	O
Salmonella	B-LIVB
enterica	I-LIVB
and	O
the	O
three	O
isolates	B-CHEM
recovered	O
belonged	O
to	O
serotype	O
S	B-LIVB
.	I-LIVB

Typhimurium	I-LIVB
.	O

Salmonella	B-LIVB
was	O
not	O
recovered	O
from	O
avocado	B-OBJC
and	O
custard	B-OBJC
apple	I-OBJC
peel	B-OBJC
s	O
and	O
from	O
avocado	B-OBJC
pulp	B-OBJC
.	O

Generally	O
,	O
the	O
substrate	B-OBJC
(	O
pulp	B-OBJC
or	O
peel	B-OBJC
)	O
of	O
growth	O
did	O
not	O
affect	O
μ	O
values	O
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Very	O
similar	O
μ	O
values	O
were	O
found	O
for	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
inoculated	O
in	O
custard	B-OBJC
apple	I-OBJC
and	O
avocado	B-OBJC
.	O

S	B-LIVB
.	I-LIVB

enterica	I-LIVB
presented	O
the	O
highest	O
λ	O
in	O
the	O
peel	B-OBJC
of	O
the	O
fruits	O
.	O

The	O
growth	B-PHYS
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
resulted	O
in	O
larger	O
λ	O
in	O
custard	B-OBJC
apple	I-OBJC
in	O
comparison	O
to	O
avocado	B-OBJC
.	O

For	O
example	O
,	O
the	O
λ	O
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O
the	O
pulp	B-OBJC
of	O
custard	B-OBJC
apple	I-OBJC
and	O
avocado	B-OBJC
were	O
47	O
.	O

0±0	O
.	O

78h	O
and	O
10	O
.	O

0±3	O
.	O

78h	O
,	O
respectively	O
.	O

The	O
lowest	O
values	O
of	O
κ	O
were	O
obtained	O
at	O
the	O
lower	O
storage	O
temperature	O
conditions	O
(	O
10°C	O
)	O
.	O

For	O
instance	O
,	O
κ	O
values	O
of	O
3	O
.	O

7±0	O
.	O

06log	O
CFU	O
/	O
g	O
and	O
2	O
.	O

9±0	O
.	O

03log	O
CFU	O
/	O
g	O
were	O
obtained	O
from	O
the	O
growth	B-PHYS
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O
avocado	B-OBJC
and	O
custard	B-OBJC
apple	I-OBJC
pulps	B-OBJC
at	O
10°C	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
at	O
30°C	O
,	O
κ	O
values	O
were	O
6	O
.	O

5±0	O
.	O

25log	O
CFU	O
/	O
g	O
and	O
6	O
.	O

5±0	O
.	O

05log	O
CFU	O
/	O
g	O
,	O
respectively	O
.	O

Significantly	O
higher	O
κ	O
were	O
obtained	O
from	O
the	O
growth	B-PHYS
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O
the	O
pulp	B-OBJC
than	O
in	O
the	O
peel	B-OBJC
of	O
the	O
fruits	B-OBJC
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

For	O
instance	O
,	O
the	O
growth	B-PHYS
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O
the	O
pulp	B-OBJC
of	O
avocado	B-OBJC
led	O
to	O
a	O
κ	O
value	O
of	O
6	O
.	O

5±0	O
.	O

25log	O
CFU	O
/	O
g	O
,	O
while	O
in	O
the	O
peel	B-OBJC
led	O
to	O
a	O
κ	O
value	O
of	O
4	O
.	O

6±0	O
.	O

23log	O
CFU	O
/	O
g	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
general	O
,	O
growth	O
kinetic	O
parameters	O
indicated	O
that	O
avocado	B-OBJC
comprises	O
a	O
better	O
substrate	B-OBJC
than	O
custard	B-OBJC
apple	I-OBJC
for	O
the	O
growth	B-PHYS
of	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
.	O

The	O
square	O
root	O
model	O
fitted	O
to	O
the	O
data	O
obtained	O
in	O
this	O
study	B-PROC
and	O
to	O
the	O
growth	O
data	O
available	O
in	O
the	O
literature	O
for	O
other	O
tropical	B-OBJC
low	I-OBJC
acid	I-OBJC
fruits	I-OBJC
indicated	O
high	O
variability	O
in	O
μ	O
and	O
λ	O
of	O
Salmonella	B-LIVB
.	O

The	O
results	O
obtained	O
in	O
this	O
study	B-PROC
show	O
that	O
whole	O
low	B-OBJC
acid	I-OBJC
tropical	I-OBJC
fruits	I-OBJC
can	O
harbor	O
Salmonella	B-LIVB
,	O
and	O
that	O
this	O
foodborne	O
pathogen	B-LIVB
can	O
not	O
only	O
survive	O
but	O
also	O
grow	O
both	O
on	O
the	O
peel	B-OBJC
and	O
pulp	B-OBJC
of	O
low	B-OBJC
acid	I-OBJC
tropical	I-OBJC
fruits	I-OBJC
,	O
such	O
as	O
avocado	B-OBJC
and	O
custard	B-OBJC
apple	I-OBJC
.	O

Photocatalytic	O
and	O
antibacterial	B-DISO
response	I-DISO
of	O
biosynthesized	O
gold	B-CHEM
nanoparticles	B-OBJC
Increase	O
in	O
the	O
bacterial	B-DISO
resistance	I-DISO
to	O
available	O
antibiotics	B-CHEM
and	O
water	B-PHEN
contamination	I-PHEN
by	O
different	O
toxic	O
organic	B-CHEM
dyes	I-CHEM
are	O
both	O
severe	O
problems	B-DISO
throughout	O
the	O
world	O
.	O

To	O
overcome	O
these	O
concerns	O
,	O
new	O
methodologies	B-PROC
including	O
synthesis	O
of	O
nontoxic	O
,	O
human	B-LIVB
friendly	O
and	O
efficient	O
nanoparticles	B-OBJC
is	O
required	O
.	O

These	O
nanoparticles	B-OBJC
not	O
even	O
inhibit	O
the	O
growth	B-PHYS
of	I-PHYS
microorganisms	I-PHYS
but	O
are	O
also	O
effective	O
in	O
the	O
degradation	O
of	O
toxic	O
organics	B-CHEM
in	O
waste	B-GEOG
water	I-GEOG
thus	O
providing	O
a	O
clean	O
and	O
human	B-LIVB
friendly	O
environment	O
.	O

The	O
use	O
of	O
plants	B-CHEM
extracts	I-CHEM
to	O
synthesize	O
and	O
stabilize	B-DISO
noble	O
metal	B-OBJC
nanoparticles	I-OBJC
have	O
been	O
considered	O
as	O
safe	O
,	O
cost	O
-	O
effective	O
,	O
eco	O
-	O
benign	O
and	O
green	O
approach	O
nowadays	O
.	O

In	O
the	O
present	O
study	O
,	O
Longan	B-LIVB
fruit	B-CHEM
juice	I-CHEM
proficiently	O
reduced	O
ionic	B-CHEM
gold	I-CHEM
(	B-CHEM
Au	I-CHEM
(	I-CHEM
+	I-CHEM
3	I-CHEM
)	I-CHEM
)	I-CHEM
to	O
gold	B-CHEM
nanoparticles	B-OBJC
(	O
AuNPs	B-OBJC
)	O
as	O
well	O
as	O
mediated	O
the	O
stabilization	O
of	O
AuNPs	B-OBJC
.	O

The	O
antibacterial	B-DISO
activity	I-DISO
of	O
AuNPs	B-OBJC
was	O
carried	O
out	O
against	O
both	O
gram	B-LIVB
positive	I-LIVB
and	O
gram	B-LIVB
negative	I-LIVB
bacteria	I-LIVB
using	O
agar	B-PROC
well	I-PROC
diffusion	I-PROC
method	I-PROC
,	O
followed	O
by	O
the	O
determination	O
of	O
Minimum	B-PROC
inhibitory	I-PROC
concentration	I-PROC
(	O
MIC	B-PROC
)	O
values	O
.	O

AuNPs	B-OBJC
were	O
found	B-DISO
to	O
have	O
significant	O
antibacterial	B-DISO
activity	I-DISO
against	O
Escherichia	B-LIVB
coli	I-LIVB
with	O
MIC	B-PROC
values	O
of	O
75μg	O
/	O
ml	O
while	O
outstanding	O
MIC	B-PROC
values	O
of	O
50μg	O
/	O
ml	O
against	O
Staphylococcus	B-LIVB
areous	I-LIVB
and	O
Basilus	B-LIVB
subtilus	I-LIVB
.	O

AuNPs	B-OBJC
revealed	O
significant	O
photocatalytic	O
degradation	O
(	O
76	O
%	O
)	O
of	O
methylene	B-CHEM
blue	I-CHEM
in	O
time	O
period	O
of	O
55	O
min	O
,	O
indicating	O
the	O
effective	O
photocatalytic	O
property	O
of	O
biosynthesized	O
AuNPs	B-OBJC
(	O
K	O
=	O
0	O
.	O
29	O
/	O
min	O
,	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
95	O
)	O
.	O

The	O
considerable	O
antibacterial	B-DISO
and	O
photocatalytic	O
activities	O
of	O
the	O
photosynthesized	O
AuNPs	B-OBJC
can	O
be	O
attributed	O
towards	O
their	O
small	B-DISO
size	I-DISO
,	O
spherical	O
morphology	O
and	O
uniform	O
dispersion	O
.	O

Our	O
finding	O
suggests	O
the	O
possible	O
therapeutic	O
potential	O
of	O
biogenic	B-OBJC
AuNPs	I-OBJC
in	O
the	O
development	O
of	O
new	O
antibacterial	B-CHEM
agents	I-CHEM
as	O
well	O
as	O
in	O
the	O
development	O
of	O
effective	O
photocatalysts	B-PHEN
.	O

Ictal	B-DISO
unilateral	O
blinking	B-PHYS
is	O
an	O
unreliable	O
lateralizing	B-DISO
sign	I-DISO
in	O
tuberous	B-DISO
sclerosis	I-DISO
complex	I-DISO
Ictal	B-DISO
unilateral	O
blinking	B-PHYS
is	O
an	O
uncommon	O
but	O
reportedly	O
reliable	O
lateralizing	B-DISO
sign	I-DISO
,	O
indicating	O
an	O
ipsilateral	O
seizure	B-DISO
focus	I-DISO
.	O

We	O
aimed	O
to	O
determine	O
its	O
lateralizing	B-DISO
utility	I-DISO
in	O
patients	B-LIVB
with	O
tuberous	B-DISO
sclerosis	I-DISO
complex	I-DISO
(	O
TSC	B-DISO
)	O
.	O

We	O
reviewed	O
the	O
video	B-PROC
-	I-PROC
EEGs	I-PROC
of	O
92	O
children	B-LIVB
with	O
TSC	B-DISO
and	O
drug	B-DISO
-	I-DISO
resistant	I-DISO
epilepsy	I-DISO
.	O

Eleven	O
(	O
12	O
%	O
)	O
had	O
seizures	B-DISO
with	O
unilateral	O
blinking	B-PHYS
,	O
of	O
which	O
10	O
underwent	O
epilepsy	B-DISO
surgery	B-PROC
.	O

Lateralization	B-DISO
of	O
seizures	B-DISO
was	O
inferred	O
from	O
other	O
semiology	B-DISO
,	O
ictal	B-DISO
scalp	B-PROC
EEG	I-PROC
and	O
outcome	O
following	O
tuberectomy	B-PROC
.	O

Seizures	B-DISO
manifesting	O
with	O
unilateral	O
blinking	B-PHYS
were	O
focal	B-DISO
motor	I-DISO
in	O
four	O
patients	B-LIVB
,	O
focal	B-DISO
motor	I-DISO
evolving	O
into	O
epileptic	B-DISO
spasms	I-DISO
in	O
six	O
,	O
and	O
epileptic	B-DISO
spasms	I-DISO
with	O
focal	B-DISO
features	I-DISO
in	O
one	O
.	O

Associated	O
unilateral	O
facial	B-DISO
contraction	I-DISO
was	O
seen	O
in	O
five	O
patients	B-LIVB
and	O
arm	B-DISO
jerking	I-DISO
in	O
four	O
.	O

Lateralized	B-DISO
scalp	B-ANAT
ictal	B-DISO
rhythms	B-DISO
were	O
seen	O
in	O
seven	O
patients	B-LIVB
.	O

Following	O
tuberectomies	B-PROC
,	O
seven	O
patients	B-LIVB
are	O
seizure	B-DISO
free	I-DISO
and	O
two	O
had	O
>	O
90	O
%	O
reduction	O
.	O

Overall	B-DISO
lateralization	I-DISO
of	O
seizures	B-DISO
with	O
unilateral	O
blinking	B-PHYS
was	O
contralateral	O
in	O
six	O
patients	B-LIVB
and	O
ipsilateral	O
in	O
four	O
.	O

When	O
unilateral	O
blinking	B-PHYS
was	O
early	O
in	O
seizures	B-DISO
,	O
overall	B-DISO
lateralization	I-DISO
was	O
more	O
often	O
contralateral	O
(	O
6	O
/	O
7	O
patients	B-LIVB
,	O
PPV	O
85	O
%	O
)	O
.	O

Ictal	B-DISO
unilateral	O
blinking	B-PHYS
is	O
not	O
infrequent	O
but	O
unreliable	O
in	O
lateralizing	B-DISO
seizures	B-DISO
in	O
TSC	B-DISO
.	O

Unrecognized	O
seizure	B-DISO
propagation	O
to	O
contralateral	O
symptomatogenic	O
regions	O
and	O
potentially	O
different	O
mechanisms	O
may	O
account	O
for	O
the	O
variable	O
lateralization	B-DISO
.	O

Assessment	B-PROC
the	O
Exposure	O
Level	O
of	O
Rare	B-CHEM
Earth	I-CHEM
Elements	I-CHEM
in	O
Workers	B-LIVB
Producing	O
Cerium	B-CHEM
,	O
Lanthanum	B-CHEM
Oxide	I-CHEM
Ultrafine	B-CHEM
and	O
Nanoparticles	B-OBJC
In	O
order	O
to	O
assess	B-PROC
occupational	O
exposure	O
level	O
of	O
15	O
rare	B-CHEM
earth	I-CHEM
elements	I-CHEM
(	O
REEs	B-CHEM
)	O
and	O
identify	O
the	O
associated	O
influence	O
,	O
we	O
used	O
inductively	B-PROC
coupled	I-PROC
plasma	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O
ICP	B-PROC
-	I-PROC
MS	I-PROC
)	O
based	O
on	O
closed	O
-	O
vessel	B-OBJC
microwave	B-PHEN
-	O
assisted	O
wet	O
digestion	O
procedure	O
to	O
determinate	B-PROC
the	O
concentration	O
of	O
Y	B-CHEM
,	O
La	B-CHEM
,	O
Ce	B-CHEM
,	O
Pr	B-CHEM
,	O
Nd	B-CHEM
,	O
Sm	B-CHEM
,	O
Eu	B-CHEM
,	O
Gd	B-CHEM
,	O
Tb	B-CHEM
,	O
Dy	B-CHEM
,	O
Ho	B-CHEM
,	O
Er	B-CHEM
,	O
Tm	B-CHEM
,	O
Yb	B-CHEM
and	O
Lu	B-CHEM
in	O
urinary	B-ANAT
samples	I-ANAT
obtained	O
from	O
workers	B-LIVB
producing	O
ultrafine	B-CHEM
and	O
nanoparticles	B-OBJC
containing	O
cerium	B-CHEM
and	O
lanthanum	B-CHEM
oxide	I-CHEM
.	O

The	O
results	B-PHEN
suggest	O
that	O
La	B-CHEM
and	O
Ce	B-CHEM
were	O
the	O
primary	O
component	O
,	O
together	O
accounting	O
for	O
97	O
%	O
of	O
total	O
REEs	B-CHEM
in	O
workers	B-LIVB
.	O

The	O
urinary	B-ANAT
levels	O
of	O
La	B-CHEM
,	O
and	O
Ce	B-CHEM
among	O
the	O
workers	B-LIVB
(	O
6	O
.	O
36	O
,	O
15	O
.	O

32	O
μg	O
.	O

g	O
(	O
-	O
1	O
)	O
creatinine	B-CHEM
,	O
respectively	O
)	O
were	O
significantly	O
enriched	O
compared	O
to	O
those	O
levels	O
measured	O
in	O
the	O
control	B-LIVB
subjects	B-LIVB
(	O
1	O
.	O
52	O
,	O
4	O
.	O
04	O
μg	O
.	O

g	O
(	O
-	O
1	O
)	O
creatinine	B-CHEM
,	O
respectively	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
study	B-PROC
simultaneously	O
identified	O
the	O
associated	O
individual	B-LIVB
factors	O
,	O
the	O
results	B-PHEN
indicate	O
that	O
the	O
concentrations	O
in	O
over	O
5	O
years	O
group	O
(	O
11	O
.	O
64	O
±	O
10	O
.	O
93	O
for	O
La	B-CHEM
,	O
27	O
.	O
83	O
±	O
24	O
.	O
38	O
for	O
Ce	B-CHEM
)	O
were	O
significantly	O
elevated	O
compared	O
to	O
1	O
-	O
5	O
years	O
group	O
(	O
2	O
.	O
58	O
±	O
1	O
.	O

51	O
for	O
La	B-CHEM
,	O
6	O
.	O
87	O
±	O
3	O
.	O
90	O
for	O
Ce	B-CHEM
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Compared	O
the	O
urinary	B-ANAT
levels	O
of	O
La	B-CHEM
and	O
Ce	B-CHEM
at	O
the	O
separation	O
and	O
packaging	B-PHEN
locations	O
(	O
9	O
.	O
10	O
±	O
9	O
.	O
51	O
for	O
La	B-CHEM
,	O
22	O
.	O
29	O
±	O
21	O
.	O

01	O
for	O
Ce	B-CHEM
)	O
with	O
the	O
other	O
locations	O
(	O
2	O
.	O
85	O
±	O
0	O
.	O

98	O
for	O
La	B-CHEM
,	O
6	O
.	O

37	O
±	O
2	O
.	O
12	O
for	O
Ce	B-CHEM
)	O
,	O
the	O
results	B-PHEN
show	O
urinary	B-ANAT
concentrations	O
were	O
significantly	O
higher	O
in	O
workers	B-LIVB
at	O
separation	O
and	O
packaging	B-PHEN
locations	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Inter	O
-	O
individual	B-LIVB
variation	O
in	O
levels	O
of	O
La	B-CHEM
and	O
Ce	B-CHEM
in	O
urine	B-ANAT
is	O
the	O
result	O
of	O
multi	O
-	O
factorial	O
comprehensive	O
action	O
.	O

Further	O
researches	B-LIVB
should	O
focus	O
on	O
the	O
multiple	O
factors	O
contributing	O
to	O
the	O
REEs	B-CHEM
levels	O
of	O
the	O
occupationally	O
exposed	O
workers	B-LIVB
.	O

A	O
remarkable	O
new	O
species	O
of	O
Eutrichopoda	O
Townsend	O
,	O
1908	O
(	O
Diptera	O
:	O
Tachinidae	O
:	O
Phasiinae	O
)	O
A	O
new	O
Tachinidae	O
species	O
,	O
Eutrichopoda	O
flavipenna	O
sp	O
.	O

nov	O
.	O
(	O
Diptera	O
:	O
Tachinidae	O
:	O
Phasiinae	O
)	O
,	O
from	O
Brazil	B-GEOG
and	O
Paraguay	B-GEOG
is	O
described	O
and	O
illustrated	O
by	O
photographs	B-OBJC
and	O
line	O
drawings	O
.	O

The	O
remarkable	O
yellow	O
,	O
feather	O
-	O
like	O
setae	B-ANAT
on	O
the	O
hind	B-ANAT
tibia	I-ANAT
distinguishes	O
the	O
new	O
species	O
from	O
all	O
other	O
species	O
in	O
the	O
tribe	O
Trichopodini	O
.	O

Two	O
known	O
and	O
one	O
new	O
species	O
of	O
Draconematidae	O
and	O
Epsilonematida	O
(	O
Nematoda	O
,	O
Desmodorida	O
)	O
from	O
the	O
White	B-GEOG
Sea	I-GEOG
,	O
North	B-GEOG
Russia	I-GEOG
Morphological	O
descriptions	O
of	O
three	O
""""	O
walking	O
nematode	O
""""	O
species	O
found	O
for	O
the	O
first	O
time	O
in	O
the	O
White	B-GEOG
Sea	I-GEOG
are	O
presented	O
.	O

Draconema	O
ophicephalum	O
(	O
Claparède	O
,	O
1863	O
)	O
(	O
Draconematidae	O
)	O
and	O
Epsilonema	O
steineri	O
Chitwood	O
,	O
1935	O
(	O
Epsilonematidae	O
)	O
,	O
both	O
known	O
from	O
insufficient	O
material	O
and	O
females	B-PHYS
only	O
,	O
are	O
re	O
-	O
described	O
and	O
problems	B-DISO
of	O
their	O
taxonomic	O
identification	O
as	O
well	O
as	O
species	O
compositions	B-PHYS
of	O
respective	O
genera	O
are	O
discussed	O
.	O

The	O
new	O
species	O
Prochaetosoma	O
marisalbi	O
sp	O
.	O

n	O
.	O
(	O
Draconematidae	O
)	O
differs	O
from	O
other	O
Prochaetosoma	O
species	O
except	O
P	O
.	O

longicapitatum	O
(	O
Allgén	O
,	O
1935	O
)	O
in	O
that	O
the	O
pharyngeal	B-ANAT
bulb	B-ANAT
lumen	B-ANAT
is	O
not	B-DISO
cuticularised	I-DISO
,	O
from	O
P	O
.	O

longicapitatum	O
by	O
shape	B-ANAT
of	I-ANAT
body	I-ANAT
and	O
rostrum	B-ANAT
,	O
greater	O
number	O
of	O
cephalic	O
adhesive	B-ANAT
tubes	I-ANAT
,	O
and	O
from	O
P	O
.	O

maertensi	O
Decraemer	O
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	O
tail	B-ANAT
,	O
fewer	O
anterior	O
adhesive	B-ANAT
tubes	I-ANAT
and	O
longer	O
spicules	O
,	O
besides	O
lacking	O
cuticular	B-PHYS
thickening	I-PHYS
in	O
the	O
pharyngeal	B-ANAT
bulb	B-ANAT
.	O

Draconema	O
hoonsooi	O
,	O
D	O
.	O

youngeouni	O
,	O
P	O
.	O

rochaetosoma	O
beomseomense	O
,	O
P	O
.	O

brevicaudatum	O
,	O
P	O
.	O

byungilli	O
,	O
P	O
.	O

cracense	O
,	O
P	O
.	O

saheungi	O
,	O
P	O
.	O

sujungi	O
,	O
P	O
.	O

supseomense	O
erected	O
by	O
Rho	O
&	O
Min	O
(	O
2011	O
)	O
are	O
considered	O
as	O
invalid	O
species	O
while	O
Prochaetosoma	O
arcticum	O
,	O
P	O
.	O

lugubre	O
and	O
Epsilonema	O
cygnoides	O
are	O
assumed	O
as	O
species	O
inquirenda	O
.	O

From	O
a	O
phylogenetic	B-PROC
tree	I-PROC
based	O
on	O
the	O
18S	O
rRNA	O
gene	O
,	O
all	O
three	O
White	B-GEOG
Sea	I-GEOG
species	O
adjoin	O
to	O
unidentified	O
species	O
of	O
their	O
respective	O
genera	O
.	O

Differential	O
effects	O
of	O
crude	B-CHEM
oil	I-CHEM
on	O
denitrification	B-PHEN
and	O
anammox	B-PHYS
,	O
and	O
the	O
impact	O
on	O
N2O	B-CHEM
production	B-PHEN
Denitrification	B-PHEN
and	O
anammox	B-PHYS
are	O
key	O
processes	B-PHEN
for	O
reducing	O
the	O
external	O
nitrogen	B-CHEM
loads	O
delivered	O
to	O
coastal	O
ecosystems	B-PHEN
,	O
and	O
these	O
processes	B-PHEN
can	O
be	O
affected	O
by	O
pollutants	B-CHEM
.	O

In	O
this	O
study	B-PROC
,	O
we	O
investigated	O
the	O
effect	O
of	O
crude	B-CHEM
oil	I-CHEM
on	O
denitrification	B-PHEN
and	O
anammox	B-PHYS
.	O

Controlled	B-PROC
laboratory	I-PROC
experiments	I-PROC
were	O
performed	O
using	O
sediment	B-OBJC
slurries	B-OBJC
from	O
the	O
Lima	B-GEOG
Estuary	B-PHEN
(	O
NW	O
Portugal	B-GEOG
)	O
.	O

Anammox	B-PHYS
and	O
denitrification	B-PHEN
rates	O
were	O
measured	O
using	O
(	B-CHEM
15	I-CHEM
)	I-CHEM
N	I-CHEM
-	I-CHEM
labeled	I-CHEM
NO3	B-CHEM
(	I-CHEM
-	I-CHEM
)	I-CHEM
,	O
and	O
the	O
production	B-PHEN
of	O
(	B-CHEM
29	I-CHEM
)	I-CHEM
N2	I-CHEM
and	O
(	B-CHEM
30	I-CHEM
)	I-CHEM
N2	I-CHEM
quantified	O
by	O
membrane	B-PROC
inlet	I-PROC
mass	I-PROC
spectrometry	I-PROC
.	O

Results	O
revealed	O
that	O
while	O
denitrification	B-PHEN
rates	O
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	B-CHEM
oil	I-CHEM
amendment	O
,	O
anammox	B-PHYS
activity	O
was	O
partially	O
(	O
between	O
2	O
and	O
5	O
times	O
)	O
or	O
completely	O
inhibited	O
by	O
the	O
addition	O
of	O
crude	B-CHEM
oil	I-CHEM
when	O
comparing	O
to	O
rates	O
in	O
unamended	O
controls	O
.	O

Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	O
sediment	B-OBJC
types	O
,	O
despite	O
their	O
different	O
physical	O
-	O
chemical	O
characteristics	O
.	O

Moreover	O
,	O
N2O	B-CHEM
production	B-PHEN
was	O
reduced	O
by	O
2	O
-	O
36	O
times	O
following	O
crude	B-CHEM
oil	I-CHEM
addition	O
.	O

Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
the	O
observed	O
reduction	O
in	O
N2O	B-CHEM
production	B-PHEN
.	O

This	O
study	B-PROC
represents	O
one	O
of	O
the	O
first	O
contributions	O
to	O
the	O
understanding	O
of	O
the	O
impact	O
of	O
crude	B-CHEM
oil	I-CHEM
pollution	B-PHEN
on	O
denitrification	B-PHEN
and	O
anammox	B-PHYS
,	O
with	O
profound	O
implications	O
for	O
the	O
management	O
of	O
aquatic	B-PHEN
ecosystems	B-PHEN
regarding	O
eutrophication	B-PHEN
(	O
N	O
-	O
removal	O
)	O
.	O

Lateral	B-ANAT
hypothalamus	I-ANAT
orexinergic	I-ANAT
system	I-ANAT
modulates	O
the	O
stress	B-DISO
effect	O
on	O
pentylenetetrazol	B-CHEM
induced	O
seizures	B-DISO
through	O
corticotropin	B-CHEM
releasing	I-CHEM
hormone	I-CHEM
receptor	I-CHEM
type	I-CHEM
1	I-CHEM
Stress	B-DISO
is	O
a	O
trigger	B-PHYS
factor	I-PHYS
for	I-PHYS
seizure	I-PHYS
initiation	O
which	O
activates	O
hypothalamic	B-ANAT
pituitary	I-ANAT
adrenal	I-ANAT
(	I-ANAT
HPA	I-ANAT
)	I-ANAT
axis	I-ANAT
as	O
well	O
other	O
brain	B-ANAT
areas	O
.	O

In	O
this	O
respect	O
,	O
corticotropin	B-CHEM
releasing	I-CHEM
hormone	I-CHEM
(	B-CHEM
CRH	I-CHEM
)	I-CHEM
and	O
lateral	B-ANAT
hypothalamus	I-ANAT
(	I-ANAT
LH	I-ANAT
)	I-ANAT
orexinergic	I-ANAT
system	I-ANAT
are	O
involved	O
in	O
seizure	B-DISO
occurrence	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
investigated	O
the	O
role	O
of	O
LH	B-ANAT
area	I-ANAT
and	O
orexin	B-CHEM
expression	B-PHYS
in	O
(	O
mediation	O
of	O
)	O
stress	B-DISO
effect	O
on	O
pentylenetetrazol	B-CHEM
(	B-CHEM
PTZ	I-CHEM
)	I-CHEM
-	O
induced	O
seizures	B-DISO
with	O
hippocampal	B-ANAT
involvement	O
.	O

Two	O
mild	O
foot	B-DISO
shock	I-DISO
stresses	I-DISO
were	O
applied	O
to	O
intact	O
and	O
adrenalectomized	B-PROC
animals	B-LIVB
;	O
with	O
or	O
without	O
CRHr1	B-CHEM
blocking	O
(	O
NBI	B-CHEM
27914	I-CHEM
)	O
in	O
the	O
LH	B-ANAT
area	I-ANAT
.	O

Then	O
,	O
changes	O
in	O
orexin	B-CHEM
production	O
were	O
evaluated	B-PROC
by	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
.	O

Intravenous	O
PTZ	B-CHEM
infusion	B-PROC
(	O
25	O
mg	O
/	O
ml	O
)	O
-	O
induced	O
convulsions	B-DISO
were	O
scored	O
upon	O
modified	O
Racine	O
scale	O
.	O

Finally	O
,	O
hippocampal	B-ANAT
glutamate	B-CHEM
and	O
GABA	B-CHEM
were	O
evaluated	B-PROC
to	O
study	B-PROC
excitability	B-DISO
changes	O
.	O

We	O
demonstrated	O
that	O
the	O
duration	O
and	O
severity	O
of	O
convulsions	B-DISO
in	O
stress	B-DISO
-	O
induced	O
as	O
well	O
as	O
adrenalectomized	B-PROC
group	O
were	O
increased	O
.	O

Plasma	B-ANAT
corticosterone	B-CHEM
(	B-CHEM
CRT	I-CHEM
)	I-CHEM
level	O
and	O
orexin	O
mRNA	B-PHYS
expression	I-PHYS
were	O
built	O
up	O
in	O
the	O
stress	B-DISO
and	O
/	O
or	O
seizure	B-DISO
groups	O
.	O

Furthermore	O
,	O
glutamate	B-CHEM
and	O
GABA	B-CHEM
content	O
was	O
increased	O
and	O
decreased	O
respectively	O
due	O
to	O
stress	B-DISO
and	O
seizures	B-DISO
.	O

In	O
contrast	O
,	O
rats	B-LIVB
receiving	O
CRHr1	B-CHEM
inhibitor	O
showed	O
reduced	O
severity	O
and	O
duration	O
of	O
seizures	B-DISO
,	O
increased	O
GABA	B-CHEM
,	O
decreased	O
glutamate	B-CHEM
and	O
corticosterone	B-CHEM
and	O
also	O
orexin	B-CHEM
mRNA	B-CHEM
compared	O
to	O
the	O
inhibitor	O
free	O
rats	B-LIVB
.	O

Stress	B-DISO
and	O
adrenalectomy	B-PROC
induced	O
augmenting	O
effect	O
on	O
seizure	B-DISO
severity	O
and	O
duration	O
and	O
the	O
subsequent	O
reduction	O
due	O
to	O
CRHr1	B-CHEM
blocking	O
with	O
parallel	O
orexin	O
mRNA	B-CHEM
changes	O
,	O
indicated	B-DISO
the	O
likely	O
involvement	O
of	O
CRH1r	B-CHEM
induced	O
orexin	B-CHEM
expression	B-PROC
of	O
the	O
LH	B-ANAT
in	O
gating	O
stress	B-DISO
effect	O
on	O
convulsions	B-DISO
.	O

Shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	O
leadership	O
-	O
a	O
qualitative	B-PROC
study	I-PROC
in	O
Australia	B-GEOG
Purpose	O
The	O
paper	O
aims	O
to	O
explore	O
the	O
beliefs	O
of	O
doctors	B-LIVB
in	O
leadership	O
roles	O
of	O
the	O
concept	O
of	O
""""	O
the	O
dark	O
side	O
""""	O
,	O
using	O
data	O
collected	O
from	O
interviews	O
carried	O
out	O
with	O
45	O
doctors	B-LIVB
in	O
medical	O
leadership	O
roles	O
across	O
Australia	B-GEOG
.	O

The	O
paper	O
looks	O
at	O
the	O
beliefs	O
from	O
the	O
perspectives	O
of	O
doctors	B-LIVB
who	O
are	O
already	O
in	O
leadership	O
roles	O
themselves	O
;	O
to	O
identify	O
potential	O
barriers	B-DISO
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better	O
-	O
informed	O
strategies	O
to	O
engage	O
more	O
doctors	B-LIVB
in	O
the	O
leadership	O
of	O
the	O
Australian	B-LIVB
health	O
system	O
.	O

The	O
research	B-PROC
question	O
is	O
:	O
""""	O
What	O
are	O
the	O
beliefs	O
of	O
medical	O
leaders	B-LIVB
that	O
form	O
the	O
key	O
themes	O
or	O
dimensions	O
of	O
the	O
negative	O
perception	O
of	O
the	O
'	O
dark	O
side	O
'	O
?	O
""""	O
.	O

Design	O
/	O
methodology	O
/	O
approach	O
The	O
paper	O
analysed	O
data	O
from	O
two	O
similar	O
qualitative	B-PROC
studies	I-PROC
examining	O
medical	O
leadership	O
and	O
engagement	O
in	O
Australia	B-GEOG
by	O
the	O
same	O
author	O
,	O
in	O
collaboration	O
with	O
other	O
researchers	B-LIVB
,	O
which	O
used	O
in	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
with	O
45	O
purposively	O
sampled	O
senior	O
medical	O
leaders	B-LIVB
in	O
leadership	O
roles	O
across	O
Australia	B-GEOG
in	O
health	B-PROC
services	I-PROC
,	O
private	B-OBJC
and	O
public	B-OBJC
hospitals	I-OBJC
,	O
professional	O
associations	O
and	O
health	O
departments	O
.	O

The	O
data	O
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	O
through	O
a	O
coding	O
framework	O
based	O
on	O
the	O
interview	O
data	O
and	O
literature	O
review	O
,	O
with	O
all	O
sections	O
of	O
coded	O
data	O
grouped	O
into	O
themes	O
.	O

Findings	O
Medical	O
leaders	B-LIVB
had	O
four	O
key	O
beliefs	O
about	O
the	O
""""	O
dark	O
side	O
""""	O
as	O
perceived	O
through	O
the	O
eyes	B-ANAT
of	O
their	O
own	O
past	O
clinical	O
experience	O
and	O
/	O
or	O
their	O
clinical	O
colleagues	B-LIVB
.	O

These	O
four	O
beliefs	O
or	O
dimensions	O
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
""""	O
the	O
dark	O
side	O
""""	O
are	O
the	O
belief	O
that	O
they	O
lack	O
both	O
managerial	O
and	O
clinical	O
credibility	O
,	O
they	O
have	O
confused	O
identities	O
,	O
they	O
may	O
be	O
in	O
conflict	O
with	O
clinicians	B-LIVB
,	O
their	O
clinical	O
colleagues	B-LIVB
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	O
leadership	O
and	O
,	O
as	O
a	O
result	O
,	O
doctors	B-LIVB
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical	O
practice	O
to	O
medical	O
leadership	O
roles	O
in	O
the	O
first	O
place	O
.	O

Research	O
limitations	O
/	O
implications	O
This	O
research	B-PROC
was	O
conducted	O
within	O
the	O
Western	O
developed	O
-	O
nation	O
setting	O
of	O
Australia	B-GEOG
and	O
only	O
involved	O
interviews	O
with	O
doctors	B-LIVB
in	O
medical	O
leadership	O
roles	O
.	O

The	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	B-LIVB
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	O
.	O

Future	O
research	B-PROC
involving	O
doctors	B-LIVB
who	O
have	O
not	O
chosen	O
to	O
transition	O
to	O
leadership	O
roles	O
,	O
or	O
other	O
health	B-LIVB
practitioners	I-LIVB
in	O
other	O
settings	O
,	O
may	O
provide	O
a	O
broader	O
perspective	O
.	O

Also	O
,	O
this	O
research	B-PROC
was	O
exploratory	O
and	O
descriptive	B-DISO
in	O
nature	O
using	O
qualitative	B-PROC
methods	I-PROC
,	O
and	O
quantitative	B-PROC
research	I-PROC
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	B-PROC
for	O
statistical	B-PROC
generalisation	I-PROC
.	O

Practical	O
implications	O
The	O
paper	O
includes	O
implications	O
for	O
health	B-OBJC
organisations	I-OBJC
,	O
training	O
providers	O
,	O
medical	O
employers	B-LIVB
and	O
health	O
departments	O
and	O
describes	O
a	O
multi	O
-	O
prong	O
strategy	O
to	O
address	O
this	O
important	O
issue	O
.	O

Originality	O
/	O
value	O
This	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	B-PROC
the	O
concept	O
of	O
""""	O
moving	O
to	O
the	O
dark	O
side	O
""""	O
as	O
a	O
negative	O
perception	O
of	O
medical	O
leadership	O
and	O
contributes	O
to	O
the	O
evidence	O
in	O
this	O
under	O
-	O
researched	B-PROC
area	O
.	O

This	O
paper	O
has	O
used	O
data	O
from	O
two	O
similar	O
studies	B-PROC
,	O
combined	O
together	O
for	O
the	O
first	O
time	O
,	O
with	O
new	O
analysis	B-PROC
and	O
coding	O
,	O
looking	O
at	O
the	O
concept	O
of	O
the	O
""""	O
dark	O
side	O
""""	O
to	O
discover	O
new	O
emergent	O
findings	O
.	O

A	O
parametric	O
ribcage	B-ANAT
geometry	O
model	O
accounting	O
for	O
variations	O
among	O
the	O
adult	B-LIVB
population	B-LIVB
The	O
objective	O
of	O
this	O
study	B-PROC
is	O
to	O
develop	O
a	O
parametric	O
ribcage	B-ANAT
model	O
that	O
can	O
account	O
for	O
morphological	O
variations	O
among	O
the	O
adult	B-LIVB
population	B-LIVB
.	O

Ribcage	B-ANAT
geometries	O
,	O
including	O
12	O
pair	B-ANAT
of	I-ANAT
ribs	I-ANAT
,	O
sternum	B-ANAT
,	O
and	O
thoracic	B-ANAT
spine	I-ANAT
,	O
were	O
collected	O
from	O
CT	B-PROC
scans	I-PROC
of	O
101	O
adult	B-LIVB
subjects	B-LIVB
through	O
image	O
segmentation	O
,	O
landmark	B-ANAT
identification	O
(	O
1016	O
for	O
each	O
subject	B-LIVB
)	O
,	O
symmetry	B-DISO
adjustment	O
,	O
and	O
template	O
mesh	O
mapping	O
(	O
26	O
,	O
180	O
elements	O
for	O
each	O
subject	B-LIVB
)	O
.	O

Generalized	O
procrustes	O
analysis	O
(	O
GPA	O
)	O
,	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
and	O
regression	O
analysis	O
were	O
used	O
to	O
develop	O
a	O
parametric	O
ribcage	B-ANAT
model	O
,	O
which	O
can	O
predict	O
nodal	O
locations	O
of	O
the	O
template	O
mesh	O
according	O
to	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
height	B-PHYS
,	O
and	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O
BMI	B-PHYS
)	O
.	O

Two	O
regression	O
models	O
,	O
a	O
quadratic	O
model	O
for	O
estimating	O
the	O
ribcage	B-ANAT
size	O
and	O
a	O
linear	O
model	O
for	O
estimating	O
the	O
ribcage	B-ANAT
shape	O
,	O
were	O
developed	O
.	O

The	O
results	O
showed	O
that	O
the	O
ribcage	B-ANAT
size	O
was	O
dominated	O
by	O
the	O
height	B-PHYS
(	O
p	O
=	O
0	O
.	O
000	O
)	O
and	O
age	B-PHYS
-	O
sex	B-PHYS
-	O
interaction	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
the	O
ribcage	B-ANAT
shape	O
was	O
significantly	O
affected	O
by	O
the	O
age	B-PHYS
(	O
p	O
=	O
0	O
.	O
0005	O
)	O
,	O
sex	B-PHYS
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
,	O
height	B-PHYS
(	O
p	O
=	O
0	O
.	O
0064	O
)	O
and	O
BMI	B-PHYS
(	O
p	O
=	O
0	O
.	O
0000	O
)	O
.	O

Along	O
with	O
proper	O
assignment	O
of	O
cortical	B-ANAT
bone	I-ANAT
thickness	O
,	O
material	B-OBJC
properties	O
and	O
failure	O
properties	O
,	O
this	O
parametric	O
ribcage	B-ANAT
model	O
can	O
directly	O
serve	O
as	O
the	O
mesh	O
of	O
finite	O
element	O
ribcage	B-ANAT
models	O
for	O
quantifying	O
effects	O
of	O
human	B-LIVB
characteristics	O
on	O
thoracic	B-DISO
injury	I-DISO
risks	O
.	O

Hyaluronan	B-CHEM
Depolymerization	B-PHYS
by	O
Megakaryocyte	B-ANAT
Hyaluronidase	B-CHEM
-	I-CHEM
2	I-CHEM
Is	O
Required	O
for	O
Thrombopoiesis	B-PHYS
Hyaluronan	B-CHEM
is	O
the	O
predominant	O
glycosaminoglycan	B-CHEM
component	I-CHEM
of	O
the	O
extracellular	O
matrix	O
with	O
an	O
emerging	O
role	O
in	O
hematopoiesis	B-PHYS
.	O

Modulation	O
of	O
hyaluronan	B-CHEM
polymer	O
size	O
is	O
responsible	O
for	O
its	O
control	O
over	O
cellular	B-PHYS
functions	I-PHYS
,	O
and	O
the	O
balance	O
of	O
hyaluronan	B-CHEM
synthesis	B-PHEN
and	O
degradation	B-PHYS
determines	O
its	O
molecular	O
size	O
.	O

Although	O
two	O
active	O
somatic	O
hyaluronidases	B-CHEM
are	O
expressed	B-PHYS
in	O
mammals	B-LIVB
,	O
only	O
deficiency	O
in	O
hyaluronidase	B-CHEM
-	I-CHEM
2	I-CHEM
(	O
Hyal	B-CHEM
-	I-CHEM
2	I-CHEM
)	O
results	O
in	O
thrombocytopenia	B-DISO
of	O
unknown	O
mechanism	O
.	O

Our	O
results	O
reveal	O
that	O
Hyal	O
-	O
2	O
knockout	B-LIVB
mice	I-LIVB
accumulate	O
hyaluronan	B-CHEM
within	O
their	O
bone	O
marrow	O
and	O
within	O
megakaryocytes	B-ANAT
,	O
the	O
cells	B-ANAT
responsible	O
for	O
platelet	B-PHYS
generation	I-PHYS
.	O

Proplatelet	B-PHYS
formation	I-PHYS
by	O
Hyal	O
-	O
2	O
knockout	B-DISO
megakaryocytes	B-ANAT
was	O
disrupted	O
because	O
of	O
abnormal	B-DISO
formation	O
of	O
the	O
demarcation	B-ANAT
membrane	I-ANAT
system	I-ANAT
,	O
which	O
was	O
dilated	O
and	O
poorly	O
developed	O
.	O

Importantly	O
,	O
peptide	B-PROC
-	I-PROC
mediated	I-PROC
delivery	I-PROC
of	O
exogenous	O
hyaluronidase	B-CHEM
rescued	O
deficient	O
proplatelet	B-PHYS
formation	I-PHYS
in	O
murine	B-LIVB
and	O
human	B-LIVB
megakaryocytes	B-ANAT
lacking	O
Hyal	B-CHEM
-	I-CHEM
2	I-CHEM
.	O

Together	O
,	O
our	O
data	O
uncover	O
a	O
previously	O
unsuspected	O
mechanism	O
of	O
how	O
hyaluronan	B-CHEM
and	O
Hyal	B-CHEM
-	I-CHEM
2	I-CHEM
control	O
platelet	B-PHYS
generation	I-PHYS
.	O

Vitamin	B-CHEM
D	I-CHEM
serum	B-ANAT
level	O
is	O
associated	O
with	O
Child	O
-	O
Pugh	O
score	O
and	O
metabolic	O
enzyme	B-CHEM
imbalances	B-DISO
,	O
but	O
not	O
viral	B-DISO
load	I-DISO
in	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
patients	B-LIVB
Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
is	O
common	O
in	O
patients	B-LIVB
with	O
chronic	B-DISO
liver	I-DISO
diseases	I-DISO
.	O

However	O
,	O
vitamin	B-CHEM
D	I-CHEM
status	O
in	O
persons	B-LIVB
with	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
virus	I-DISO
(	I-DISO
HBV	I-DISO
)	I-DISO
infection	I-DISO
is	O
not	O
consistently	O
reported	O
.	O

Specifically	O
,	O
the	O
impact	O
of	O
liver	B-DISO
dysfunction	I-DISO
on	O
vitamin	B-CHEM
D	I-CHEM
status	O
has	O
not	O
been	O
well	O
addressed	O
.	O

We	O
recruited	O
a	O
group	B-LIVB
of	O
patients	B-LIVB
(	O
n	O
=	O
345	O
)	O
with	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
(	O
n	O
=	O
115	O
)	O
,	O
hepatitis	B-DISO
B	I-DISO
related	I-DISO
cirrhosis	I-DISO
(	O
n	O
=	O
115	O
)	O
,	O
and	O
age	B-PHYS
-	O
and	O
gender	B-PHYS
-matched	O
healthy	O
controls	O
(	O
n	O
=	O
115	O
)	O
.	O

Serum	B-ANAT
25	B-CHEM
-	I-CHEM
hydroxyvitamin	I-CHEM
D3	I-CHEM
[	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
]	O
,	O
its	O
related	O
metabolic	O
enzymes	B-CHEM
,	O
intact	O
parathyroid	B-CHEM
hormone	I-CHEM
were	O
measured	O
.	O

Calcium	B-PHEN
,	O
magnesium	B-PHEN
,	O
and	O
phosphorus	B-PHEN
were	O
obtained	O
from	O
medical	O
record	O
.	O

Serum	B-ANAT
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
levels	O
in	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
patients	B-LIVB
(	O
7	O
.	O
83	O
±	O
3	O
.	O
47	O
ng	O
/	O
mL	O
)	O
were	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
(	O
9	O
.	O
76	O
±	O
4	O
.	O

36	O
ng	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
significantly	O
higher	O
than	O
that	O
in	O
hepatitis	B-DISO
B	I-DISO
-	I-DISO
related	I-DISO
cirrhotic	I-DISO
patients	B-LIVB
(	O
5	O
.	O
21	O
±	O
3	O
.	O
67	O
ng	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Furthermore	O
,	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
decreased	O
stepwise	O
with	O
higher	O
Child	O
-	O
Pugh	O
classification	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
levels	O
between	O
(	O
1	O
)	O
hepatitis	B-PHEN
B	I-PHEN
e	I-PHEN
antigen	I-PHEN
(	I-PHEN
HBeAg	I-PHEN
+	I-PHEN
)	I-PHEN
and	O
HBeAg	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
persons	B-LIVB
,	O
or	O
(	O
2	O
)	O
among	O
persons	B-LIVB
with	O
different	O
HBV	B-LIVB
viral	B-DISO
load	I-DISO
,	O
or	O
(	O
3	O
)	O
between	O
treatment	B-PHYS
naïve	I-PHYS
and	O
patients	B-LIVB
on	O
antiviral	B-PROC
therapy	I-PROC
.	O

Multiple	O
logistic	O
regression	O
analyses	O
confirmed	O
that	O
higher	O
Child	O
-	O
Pugh	O
score	O
was	O
independently	O
associated	O
with	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
deficiency	O
(	O
<	O
10	O
ng	O
/	O
mL	O
)	O
with	O
an	O
odds	O
ratio	O
of	O
1	O
.	O

20	O
(	O
confidence	O
interval	O
1	O
.	O
03	O
-	O
1	O
.	O
39	O
,	O
P	O
=	O
0	O
.	O
016	O
)	O
.	O

Levels	O
of	O
cytochrome	B-CHEM
P450	I-CHEM
(	I-CHEM
CYP	I-CHEM
)	I-CHEM
27A1	I-CHEM
were	O
significantly	O
decreased	O
,	O
whereas	O
levels	O
of	O
CYP24A1	B-CHEM
were	O
significantly	O
elevated	O
in	O
cirrhotic	B-DISO
patients	B-LIVB
.These	O

results	O
suggest	O
that	O
decreasing	B-DISO
vitamin	B-CHEM
D	I-CHEM
levels	O
are	O
likely	O
to	O
be	O
a	O
result	O
,	O
rather	O
than	O
a	O
cause	O
,	O
of	O
liver	B-DISO
dysfunction	I-DISO
and	O
irrespective	O
of	O
HBV	B-LIVB
viral	B-DISO
load	I-DISO
.	O

Reduction	O
in	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
levels	O
is	O
possibly	O
due	O
to	O
downregulation	B-PHYS
of	O
the	O
synthetic	B-CHEM
hydroxylase	I-CHEM
CYP27A1	B-CHEM
and	O
concurrent	O
upregulation	B-PHYS
of	O
degrading	B-PHYS
CYP24A1	B-CHEM
in	O
patients	B-LIVB
with	O
liver	B-DISO
cirrhosis	I-DISO
.	O

359	O
Delayed	B-DISO
Treatment	I-DISO
of	O
Ruptured	B-DISO
Arteriovenous	B-DISO
Malformations	I-DISO
:	O
Is	O
It	O
Ok	O
to	O
Wait	O
?	O
Emergent	O
surgery	B-PROC
on	O
a	O
ruptured	B-DISO
brain	B-ANAT
arteriovenous	B-DISO
malformation	I-DISO
(	O
AVM	B-DISO
)	O
is	O
indicated	O
for	O
a	O
large	O
hematoma	B-DISO
in	O
an	O
acutely	O
deteriorating	B-DISO
patient	B-LIVB
.	O

The	O
majority	O
of	O
ruptured	B-DISO
AVMs	B-DISO
,	O
however	O
,	O
present	O
in	O
clinically	O
stable	O
patients	B-LIVB
with	O
neurological	B-DISO
deficits	I-DISO
.	O

Controversy	O
exists	O
with	O
respect	O
to	O
the	O
timing	O
of	O
treatment	O
for	O
ruptured	B-DISO
AVMs	B-DISO
in	O
these	O
stable	O
patients	B-LIVB
.	O

This	O
study	B-PROC
aims	O
to	O
determine	O
the	O
safety	B-PHEN
of	O
delaying	O
AVM	B-DISO
treatment	O
in	O
clinically	O
stable	O
patients	B-LIVB
by	O
investigating	O
the	O
rate	O
of	O
rehemorrhage	B-DISO
in	O
a	O
cohort	B-LIVB
of	O
patients	B-LIVB
with	O
ruptured	B-DISO
brain	B-ANAT
AVMs	B-DISO
.	O

Patients	B-LIVB
presenting	O
to	O
our	O
institution	O
from	O
January	O
2000	O
to	O
December	O
2015	O
with	O
ruptured	B-DISO
brain	B-ANAT
AVMs	B-DISO
treated	O
at	O
least	O
4	O
weeks	O
posthemorrhage	B-DISO
were	O
included	O
in	O
the	O
analysis	B-PROC
.	O

Exclusion	O
criteria	O
were	O
ruptured	B-DISO
AVMs	B-DISO
that	O
required	O
emergent	O
surgery	B-PROC
involving	O
AVM	B-DISO
resection	B-PROC
,	O
previous	O
treatment	O
at	O
another	O
institution	O
,	O
or	O
subacute	O
AVM	B-DISO
treatment	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
time	O
from	O
initial	O
hemorrhage	B-DISO
to	O
rehemorrhage	B-DISO
.	O

Patient	B-LIVB
follow	B-PROC
-	I-PROC
up	I-PROC
data	O
were	O
included	O
up	O
until	O
the	O
point	O
of	O
AVM	B-DISO
treatment	O
.	O

Of	O
the	O
103	O
ruptured	B-DISO
AVMs	B-DISO
(	O
49	O
M	O
:	O
54	O
F	O
)	O
meeting	O
inclusion	O
criteria	O
,	O
the	O
median	O
time	O
from	O
rupture	B-DISO
to	O
treatment	O
or	O
rehemorrhage	B-DISO
was	O
112	O
days	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
:	O
110	O
)	O
.	O

Six	O
(	O
5	O
.	O
8	O
%	O
)	O
patients	B-LIVB
rehemorrhaged	B-DISO
in	O
a	O
median	O
of	O
248	O
days	O
(	O
IQR	O
:	O
1331	O
)	O
.	O

Two	O
of	O
these	O
patients	B-LIVB
rehemorrhaged	B-DISO
on	O
the	O
same	O
day	O
of	O
their	O
index	O
hemorrhage	B-DISO
.	O

The	O
total	O
at	O
-	O
risk	O
period	O
was	O
19	O
445	O
patient	B-LIVB
-	O
days	O
,	O
yielding	O
a	O
rehemorrhage	B-DISO
risk	O
of	O
11	O
.	O

3	O
%	O
per	O
patient	B-LIVB
-	O
year	O
,	O
or	O
0	O
.	O

93	O
%	O
per	O
patient	B-LIVB
-	O
month	O
.	O

Our	O
data	O
support	O
stabilizing	O
a	O
patient	B-LIVB
after	O
the	O
initial	O
AVM	B-DISO
rupture	B-DISO
.	O

It	O
is	O
safe	O
to	O
closely	B-PROC
monitor	I-PROC
the	I-PROC
patient	I-PROC
,	O
initiate	O
the	O
rehabilitation	O
process	O
,	O
and	O
then	O
,	O
in	O
a	O
semielective	O
manner	O
,	O
bring	O
the	O
patient	B-LIVB
back	O
for	O
treatment	O
.	O

Delaying	O
intervention	O
for	O
4	O
weeks	O
after	O
initial	O
hemorrhage	B-DISO
subjects	O
the	O
patient	B-LIVB
to	O
a	O
low	O
(	O
<	O
1	O
%	O
)	O
risk	O
of	O
rehemorrhage	B-DISO
.	O

Prescribing	O
Patterns	O
in	O
Outpatient	B-OBJC
Clinics	I-OBJC
of	O
Township	O
Hospitals	B-OBJC
in	O
China	B-GEOG
:	O
A	O
Comparative	B-PROC
Study	I-PROC
before	O
and	O
after	O
the	O
2009	O
Health	O
System	O
Reform	O
Objective	O
:	O
China	B-GEOG
introduced	O
a	O
series	O
of	O
health	O
reforms	O
in	O
2009	O
,	O
including	O
a	O
national	O
essential	O
medicines	O
policy	O
and	O
a	O
medical	B-DISO
insurance	I-DISO
system	O
for	O
primary	B-OBJC
care	I-OBJC
institutions	I-OBJC
.	O

This	O
study	B-PROC
aimed	O
to	O
determine	O
the	O
changing	O
prescribing	O
patterns	O
associated	O
with	O
those	O
reforms	O
in	O
township	O
hospitals	B-OBJC
.	O

Methods	O
:	O
A	O
multi	O
-	O
stage	O
stratified	B-PROC
random	I-PROC
cluster	I-PROC
sampling	I-PROC
method	I-PROC
was	O
adopted	O
to	O
identify	O
29	O
township	O
hospitals	B-OBJC
from	O
six	O
counties	B-GEOG
in	O
three	O
provinces	B-GEOG
.	O

A	O
total	O
of	O
2899	O
prescriptions	O
were	O
collected	O
from	O
the	O
participating	O
township	O
hospitals	B-OBJC
using	O
a	O
systematic	B-PROC
random	I-PROC
sampling	I-PROC
strategy	I-PROC
.	O

Seven	O
prescribing	B-DISO
indicators	I-DISO
were	O
calculated	O
and	O
compared	O
between	O
2008	O
and	O
2013	O
,	O
assessing	O
use	O
of	O
medicines	B-CHEM
(	O
antibiotics	B-CHEM
and	O
adrenal	B-CHEM
corticosteroids	I-CHEM
)	O
and	O
polypharmacy	B-DISO
,	O
administration	O
route	O
of	O
medicines	O
(	O
injections	O
)	O
,	O
and	O
affordability	O
of	O
medicines	B-CHEM
.	O

Results	O
:	O
Significant	O
changes	O
in	O
prescribing	O
patterns	O
were	O
found	O
.	O

The	O
average	O
number	O
of	O
medicines	B-CHEM
and	O
costs	O
per	O
-	O
prescription	O
dropped	O
by	O
about	O
50	O
%	O
.	O

The	O
percentage	O
of	O
prescriptions	O
requiring	O
antibiotics	B-CHEM
declined	O
from	O
54	O
%	O
to	O
38	O
%	O
.	O

The	O
percentage	O
of	O
prescriptions	O
requiring	O
adrenal	B-CHEM
corticosteroid	I-CHEM
declined	O
from	O
14	O
%	O
to	O
4	O
%	O
.	O

The	O
percentage	O
of	O
prescriptions	O
requiring	O
injections	O
declined	O
from	O
54	O
%	O
to	O
25	O
%	O
.	O

Despite	O
similar	O
changing	O
patterns	O
,	O
significant	B-DISO
regional	I-DISO
differences	I-DISO
were	O
observed	O
.	O

Conclusions	O
:	O
Significant	O
changes	O
in	O
prescribing	O
patterns	O
are	O
evident	O
in	O
township	O
hospitals	B-OBJC
in	O
China	B-GEOG
.	O

Overprescription	B-PROC
of	O
antibiotics	B-CHEM
,	O
injections	O
and	O
adrenal	B-CHEM
corticosteroids	I-CHEM
has	O
been	O
reduced	O
.	O

However	O
,	O
salient	O
regional	O
disparities	O
still	O
exist	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
determine	O
potential	O
shifts	O
in	O
the	O
risk	O
of	O
the	O
inappropriate	O
use	O
of	O
medicines	B-CHEM
from	O
primary	B-OBJC
care	I-OBJC
settings	I-OBJC
to	O
metropolitan	O
hospitals	O
.	O

Neural	O
activity	O
promotes	O
long	O
-	O
distance	O
,	O
target	O
-	O
specific	O
regeneration	B-PHYS
of	O
adult	O
retinal	B-ANAT
axons	B-ANAT
Axons	B-ANAT
in	O
the	O
mammalian	B-LIVB
CNS	B-ANAT
fail	O
to	O
regenerate	B-PHYS
after	O
injury	B-DISO
.	O

Here	O
we	O
show	O
that	O
if	O
the	O
activity	O
of	O
mouse	B-LIVB
retinal	B-ANAT
ganglion	I-ANAT
cells	I-ANAT
(	O
RGCs	B-ANAT
)	O
is	O
increased	O
by	O
visual	B-PROC
stimulation	I-PROC
or	O
using	O
chemogenetics	O
,	O
their	O
axons	B-ANAT
regenerate	B-PHYS
.	O

We	O
also	O
show	O
that	O
if	O
enhancement	O
of	O
neural	O
activity	O
is	O
combined	O
with	O
elevation	O
of	O
the	O
cell	B-PHYS
-	I-PHYS
growth	I-PHYS
-promoting	O
pathway	B-PHYS
involving	O
mammalian	B-CHEM
target	I-CHEM
of	I-CHEM
rapamycin	I-CHEM
(	O
mTOR	B-CHEM
)	O
,	O
RGC	B-ANAT
axons	B-ANAT
regenerate	B-PHYS
long	O
distances	O
and	O
re	O
-	O
innervate	O
the	O
brain	B-ANAT
.	O

Analysis	B-PROC
of	O
genetically	O
labeled	O
RGCs	B-ANAT
revealed	O
that	O
this	O
regrowth	B-PHYS
can	O
be	O
target	O
specific	O
:	O
RGC	B-ANAT
axons	B-ANAT
navigated	O
back	O
to	O
their	O
correct	O
visual	O
targets	O
and	O
avoided	O
targets	O
incorrect	O
for	O
their	O
function	O
.	O

Moreover	O
,	O
these	O
regenerated	O
connections	B-ANAT
were	O
successful	O
in	O
partially	O
rescuing	O
a	O
subset	O
of	O
visual	O
behaviors	O
.	O

Our	O
findings	B-DISO
indicate	O
that	O
combining	O
neural	O
activity	O
with	O
activation	O
of	O
mTOR	B-CHEM
can	O
serve	O
as	O
powerful	O
tool	O
for	O
enhancing	O
axon	B-PHYS
regeneration	I-PHYS
,	O
and	O
they	O
highlight	O
the	O
remarkable	O
capacity	O
of	O
CNS	B-ANAT
neurons	B-ANAT
to	O
re	O
-	O
establish	O
accurate	O
circuit	O
connections	B-ANAT
in	O
adulthood	O
.	O

Expression	B-PHYS
of	O
WNT10A	O
Gene	O
in	O
Oral	B-DISO
Squamous	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
Oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
OSCC	B-DISO
)	O
constitutes	O
the	O
most	O
frequent	O
malignant	B-DISO
tumour	I-DISO
of	O
the	O
oral	B-ANAT
cavity	I-ANAT
.	O

Considering	O
the	O
significant	O
roles	O
the	O
Wnt	O
family	O
plays	O
in	O
physiological	B-PHYS
and	O
pathological	O
events	O
,	O
this	O
study	B-PROC
aims	O
to	O
investigate	O
WNT10A	O
gene	O
expression	B-PHYS
in	O
OSCC	B-DISO
.	O

The	O
cohort	O
was	O
composed	O
of	O
59	O
specimens	B-OBJC
:	O
49	O
with	O
OSCC	B-DISO
and	O
10	O
controls	O
.	O

Total	O
RNA	B-CHEM
from	O
the	O
samples	B-OBJC
was	O
extracted	B-PROC
,	O
cDNA	B-CHEM
was	O
synthesized	O
and	O
Real	B-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
analyses	I-PROC
were	O
performed	O
,	O
with	O
β	O
-	O
ACTIN	O
as	O
internal	O
control	O
.	O

The	O
number	O
of	O
OSCC	B-DISO
samples	B-OBJC
for	O
the	O
4	O
TNM	O
stages	O
was	O
:	O
5	O
(	O
10	O
.	O
2	O
%	O
)	O
stage	B-DISO
I	I-DISO
,	O
10	O
(	O
20	O
.	O
4	O
%	O
)	O
stage	B-DISO
II	I-DISO
,	O
9	O
(	O
18	O
.	O
3	O
%	O
)	O
stage	B-DISO
III	I-DISO
,	O
and	O
25	O
(	O
51	O
.	O
1	O
%	O
)	O
stage	B-DISO
IV	I-DISO
.	O

For	O
Real	B-PROC
-	I-PROC
Time	I-PROC
PCR	I-PROC
analysis	I-PROC
,	O
significant	O
difference	O
was	O
found	B-DISO
between	O
control	O
samples	O
and	O
OSCC	B-DISO
stage	I-DISO
IV	I-DISO
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Higher	O
levels	O
of	O
WNT10A	O
expression	B-PHYS
was	O
observed	O
in	O
OSCC	B-DISO
stage	I-DISO
IV	I-DISO
suggesting	O
a	O
potential	O
role	O
in	O
tumour	B-DISO
progression	I-DISO
.	O

Erlotinib	B-CHEM
plus	O
gemcitabine	B-CHEM
versus	O
gemcitabine	B-CHEM
for	O
pancreatic	B-DISO
cancer	I-DISO
:	O
real	O
-	O
world	B-LIVB
analysis	B-PROC
of	O
Korean	B-GEOG
national	O
database	O
A	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
has	O
found	O
that	O
the	O
addition	B-PHEN
of	O
erlotinib	B-CHEM
to	O
gemcitabine	B-CHEM
(	O
GEM	B-CHEM
-	O
E	B-CHEM
)	O
for	O
pancreatic	B-DISO
cancer	I-DISO
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	B-LIVB
-	O
based	O
retrospective	B-PROC
study	I-PROC
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	B-CHEM
-	O
E	B-CHEM
to	O
GEM	B-CHEM
alone	O
for	O
pancreatic	B-DISO
cancer	I-DISO
patients	B-LIVB
in	O
real	O
clinical	O
practice	O
.	O

Patients	B-LIVB
with	O
pancreatic	B-DISO
cancer	I-DISO
(	O
ICD	O
-	O
10	O
:	O
C25	O
)	O
with	O
prescription	O
claims	O
of	O
gemcitabine	B-CHEM
or	O
erlotinib	B-CHEM
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	B-GEOG
Health	B-PROC
Insurance	I-PROC
claims	O
database	O
.	O

To	O
be	O
included	O
in	O
the	O
study	B-PROC
population	B-LIVB
,	O
patients	B-LIVB
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	B-DISO
diagnosis	I-DISO
within	O
one	O
year	O
before	O
chemotherapy	B-PROC
.	O

Patients	B-LIVB
treated	B-DISO
with	I-DISO
prior	O
radiotherapy	B-PROC
,	O
surgery	B-PROC
,	O
or	O
chemotherapy	B-PROC
were	O
excluded	O
to	O
reduce	B-PROC
heterogeneity	O
.	O

Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	B-PROC
and	O
the	O
medical	O
costs	O
of	O
GEM	B-CHEM
-	O
E	B-CHEM
and	O
GEM	B-CHEM
were	O
compared	O
.	O

A	O
total	O
of	O
4	O
,	O
267	O
patients	B-LIVB
were	O
included	O
in	O
the	O
analysis	B-PROC
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	B-LIVB
treated	B-DISO
with	O
GEM	B-CHEM
-	O
E	B-CHEM
(	O
median	O
6	O
.	O

77	O
months	O
for	O
GEM	B-CHEM
-	O
E	B-CHEM
vs	O
.	O

6	O
.	O
68	O
months	O
for	O
GEM	B-CHEM
,	O
p	O
=	O
0	O
.	O
0977	O
)	O
.	O

There	O
was	O
also	O
no	B-DISO
significant	I-DISO
difference	O
in	O
the	O
respective	O
one	O
-	O
year	O
survival	O
rates	O
(	O
27	O
.	O
0	O
%	O
vs	O
.	O

27	O
.	O
3	O
%	O
;	O
p	O
=	O
0	O
.	O
5988	O
)	O
.	O

Multivariate	O
analysis	O
using	O
age	B-PHYS
,	O
gender	B-PHYS
,	O
and	O
comorbidities	O
as	O
covariates	O
did	O
not	O
reveal	O
any	O
significant	O
differences	O
in	O
survival	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	B-CHEM
was	O
estimated	O
at	O
USD	O
70	O
,	O
843	O
.	O

64	O
for	O
GEM	B-CHEM
-	O
E	B-CHEM
.	O

GEM	B-CHEM
-	O
E	B-CHEM
for	O
pancreatic	B-DISO
cancer	I-DISO
is	O
not	O
more	O
effective	O
than	O
GEM	B-CHEM
in	O
a	O
real	O
-	O
world	B-LIVB
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	B-DISO
cost	O
-	O
effectiveness	O
over	O
GEM	B-CHEM
.	O

Predicting	O
Risk	O
of	O
Suicide	B-DISO
Attempt	I-DISO
Using	O
History	B-DISO
of	O
Physical	B-DISO
Illnesses	I-DISO
From	O
Electronic	O
Medical	O
Records	O
Although	O
physical	B-DISO
illnesses	I-DISO
,	O
routinely	O
documented	B-PROC
in	O
electronic	O
medical	O
records	O
(	O
EMR	O
)	O
,	O
have	O
been	O
found	O
to	O
be	O
a	O
contributing	O
factor	O
to	O
suicides	B-DISO
,	O
no	O
automated	O
systems	O
use	O
this	O
information	O
to	O
predict	O
suicide	B-DISO
risk	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
is	O
to	O
quantify	O
the	O
impact	O
of	O
physical	B-DISO
illnesses	I-DISO
on	O
suicide	B-DISO
risk	I-DISO
,	O
and	O
develop	O
a	O
predictive	B-DEVI
model	I-DEVI
that	O
captures	O
this	O
relationship	O
using	O
EMR	O
data	O
.	O

We	O
used	O
history	B-DISO
of	O
physical	B-DISO
illnesses	I-DISO
(	O
except	B-DISO
chapter	I-DISO
V	I-DISO
:	I-DISO
Mental	I-DISO
and	I-DISO
behavioral	I-DISO
disorders	I-DISO
)	O
from	O
EMR	O
data	O
over	O
different	O
time	O
-	O
periods	O
to	O
build	O
a	O
lookup	O
table	O
that	O
contains	O
the	O
probability	O
of	O
suicide	B-DISO
risk	I-DISO
for	O
each	O
chapter	O
of	O
the	O
International	O
Statistical	O
Classification	O
of	O
Diseases	O
and	O
Related	O
Health	O
Problems	O
,	O
10th	O
Revision	O
(	O
ICD	O
-	O
10	O
)	O
codes	O
.	O

The	O
lookup	O
table	O
was	O
then	O
used	O
to	O
predict	O
the	O
probability	O
of	O
suicide	B-DISO
risk	I-DISO
for	O
any	O
new	O
assessment	B-PROC
.	O

Based	O
on	O
the	O
different	O
lengths	O
of	O
history	B-DISO
of	O
physical	B-DISO
illnesses	I-DISO
,	O
we	O
developed	O
six	O
different	O
models	B-DEVI
to	O
predict	O
suicide	B-DISO
risk	I-DISO
.	O

We	O
tested	O
the	O
performance	O
of	O
developed	O
models	B-DEVI
to	O
predict	O
90	O
-	O
day	O
risk	B-DISO
using	O
historical	B-DISO
data	O
over	O
differing	O
time	O
-	O
periods	O
ranging	O
from	O
3	O
to	O
48	O
months	O
.	O

A	O
total	O
of	O
16	O
,	O
858	O
assessments	B-PROC
from	O
7399	O
mental	B-PHYS
health	I-PHYS
patients	B-LIVB
with	O
at	O
least	O
one	O
risk	B-DISO
assessment	B-PROC
was	O
used	O
for	O
the	O
validation	B-PROC
of	O
the	O
developed	O
model	B-DEVI
.	O

The	O
performance	O
was	O
measured	O
using	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
)	O
.	O

The	O
best	O
predictive	O
results	O
were	O
derived	O
(	O
AUC	O
=	O
0	O
.	O
71	O
)	O
using	O
combined	O
data	O
across	O
all	O
time	O
-	O
periods	O
,	O
which	O
significantly	O
outperformed	O
the	O
clinical	O
baseline	O
derived	O
from	O
routine	O
risk	B-PROC
assessment	I-PROC
(	O
AUC	O
=	O
0	O
.	O
56	O
)	O
.	O

The	O
proposed	O
approach	O
thus	O
shows	O
potential	O
to	O
be	O
incorporated	O
in	O
the	O
broader	O
risk	B-PROC
assessment	I-PROC
processes	B-PHEN
used	O
by	O
clinicians	B-LIVB
.	O

This	O
study	B-PROC
provides	O
a	O
novel	O
approach	O
to	O
exploit	O
the	O
history	B-DISO
of	O
physical	B-DISO
illnesses	I-DISO
extracted	O
from	O
EMR	O
(	O
ICD	O
-	O
10	O
codes	O
without	B-DISO
chapter	I-DISO
V	I-DISO
-	I-DISO
mental	I-DISO
and	I-DISO
behavioral	I-DISO
disorders	I-DISO
)	O
to	O
predict	O
suicide	B-DISO
risk	I-DISO
,	O
and	O
this	O
model	B-DEVI
outperforms	O
existing	O
clinical	O
assessments	B-PROC
of	O
suicide	B-DISO
risk	I-DISO
.	O

Development	O
of	O
a	O
Novel	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
Model	O
to	O
Accurately	O
Predict	O
Pulmonary	B-PHYS
Absorption	I-PHYS
and	O
Replace	O
Routine	O
Use	O
of	O
the	O
Isolated	O
Perfused	O
Respiring	B-PHYS
Rat	B-ANAT
Lung	I-ANAT
Model	O
We	O
developed	O
and	O
tested	O
a	O
novel	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
(	O
QSAR	O
)	O
model	O
to	O
better	O
understand	O
the	O
physicochemical	B-PHEN
drivers	O
of	O
pulmonary	B-PHYS
absorption	I-PHYS
,	O
and	O
to	O
facilitate	O
compound	O
design	O
through	O
improved	O
prediction	O
of	O
absorption	B-PHEN
.	O

The	O
model	O
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-CHEM
.	O

Pulmonary	B-PHYS
absorption	I-PHYS
data	O
was	O
generated	O
using	O
the	O
isolated	O
perfused	O
respiring	B-PHYS
rat	B-ANAT
lung	I-ANAT
(	O
IPRLu	B-ANAT
)	O
model	O
for	O
82	O
drug	B-PROC
discovery	I-PROC
compounds	B-CHEM
and	O
17	O
marketed	B-CHEM
drugs	I-CHEM
.	O

This	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
QSAR	O
model	O
based	O
on	O
calculated	O
physicochemical	B-PHEN
properties	I-PHEN
.	O

A	O
further	O
9	O
compounds	B-CHEM
were	O
used	O
to	O
test	O
the	O
model	O
's	O
predictive	O
capability	O
.	O

The	O
QSAR	O
model	O
performed	O
well	O
on	O
the	O
9	O
compounds	B-CHEM
in	O
the	O
""""	O
Test	O
set	O
""""	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	O
of	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
85	O
,	O
and	O
>	O
65	O
%	O
of	O
compounds	B-CHEM
correctly	O
categorised	O
.	O

Calculated	O
descriptors	O
associated	O
with	O
permeability	B-PHEN
and	O
hydrophobicity	O
positively	O
correlated	O
with	O
pulmonary	B-PHYS
absorption	I-PHYS
,	O
whereas	O
those	O
associated	O
with	O
charge	O
,	O
ionisation	B-PHEN
and	O
size	O
negatively	O
correlated	O
.	O

The	O
novel	O
QSAR	O
model	O
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
IPRLu	B-ANAT
model	O
data	O
for	O
ranking	O
and	O
classifying	O
compounds	B-CHEM
prior	O
to	O
synthesis	O
.	O

It	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled	B-PROC
drug	I-PROC
discovery	I-PROC
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	B-PHEN
drivers	O
of	O
pulmonary	B-PHYS
absorption	I-PHYS
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-CHEM
dataset	O
.	O

Matrix	B-PROC
solid	I-PROC
-	I-PROC
phase	I-PROC
dispersion	I-PROC
combined	O
to	O
liquid	B-PROC
chromatography	I-PROC
-	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
for	O
the	O
determination	B-PROC
of	O
paraben	B-CHEM
preservatives	B-CHEM
in	O
mollusks	O
A	O
method	O
for	O
the	O
extraction	O
and	O
determination	B-PROC
of	O
seven	O
parabens	B-CHEM
,	O
esters	B-CHEM
of	O
4	B-CHEM
-	I-CHEM
hydroxybenzoic	I-CHEM
acid	I-CHEM
,	O
widely	O
used	O
as	O
preservatives	B-CHEM
in	O
personal	B-OBJC
care	I-OBJC
products	I-OBJC
,	O
pharmaceuticals	B-CHEM
,	O
etc	O
.	O
,	O
and	O
two	O
chlorinated	B-CHEM
derivatives	I-CHEM
(	O
mono	B-CHEM
-	I-CHEM
and	O
di	B-CHEM
-	I-CHEM
chloro	I-CHEM
methyl	I-CHEM
paraben	I-CHEM
)	O
from	O
mollusk	O
samples	O
was	O
developed	O
by	O
combining	O
matrix	B-PROC
solid	I-PROC
-	I-PROC
phase	I-PROC
dispersion	I-PROC
(	O
MSPD	B-PROC
)	O
and	O
liquid	B-PROC
chromatography	I-PROC
-	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
.	O

MSPD	O
parameters	O
,	O
such	O
as	O
solvent	B-CHEM
,	O
solid	B-CHEM
support	I-CHEM
and	O
clean	B-CHEM
-	I-CHEM
up	I-CHEM
sorbent	I-CHEM
,	O
were	O
optimized	O
.	O

Besides	O
,	O
since	O
blank	O
problems	O
were	O
observed	O
for	O
some	O
parabens	B-CHEM
,	O
these	O
were	O
investigated	O
and	O
blanks	O
were	O
tackled	O
by	O
precleaning	O
all	O
sorbents	B-CHEM
prior	O
to	O
use	O
.	O

Under	O
final	O
conditions	O
,	O
0	O
.	O
5	O
g	O
of	O
freeze	B-PROC
-	I-PROC
dried	I-PROC
mollusk	O
were	O
dispersed	O
with	O
1	O
.	O

2	O
g	O
of	O
silica	B-CHEM
and	O
packed	O
into	O
a	O
cartridge	O
containing	O
3	O
g	O
of	O
C18	B-CHEM
,	O
as	O
on	O
-	O
line	O
clean	B-CHEM
-	I-CHEM
up	I-CHEM
sorbent	I-CHEM
.	O

This	O
cartridge	O
was	O
eluted	O
with	O
10mL	O
of	O
acetonitrile	B-CHEM
,	O
evaporated	B-PHEN
and	O
reconstituted	O
in	O
methanol	B-CHEM
for	O
analysis	B-PROC
.	O

In	O
the	O
validation	B-PROC
stage	O
,	O
successful	O
linearity	O
(	O
R	O
(	O
2	O
)	O
>	O
0	O
.	O
999	O
)	O
,	O
recoveries	O
(	O
between	O
71	O
and	O
117	O
%	O
for	O
most	O
analytes	B-OBJC
)	O
,	O
precision	O
(	O
RSD	O
lower	O
than	O
21	O
%	O
)	O
and	O
limits	O
of	O
detection	O
and	O
quantification	O
(	O
LOD	O
and	O
LOQ	B-PROC
,	O
lower	O
than	O
0	O
.	O
4	O
and	O
1	O
.	O

4ngg	O
(	O
-	O
1	O
)	O
dry	O
weight	O
respectively	O
)	O
levels	O
were	O
achieved	O
.	O

Finally	O
,	O
the	O
new	O
methodology	O
was	O
applied	O
to	O
mussel	O
,	O
clam	O
and	O
cockle	O
samples	O
.	O

Methyl	B-CHEM
paraben	I-CHEM
was	O
above	O
the	O
LOQ	O
in	O
five	O
of	O
the	O
six	O
samples	O
(	O
not	O
found	O
in	O
one	O
clam	O
sample	O
)	O
at	O
concentrations	O
up	O
to	O
7ngg	O
(	O
-	O
1	O
)	O
dry	O
weight	O
.	O

Ethyl	B-CHEM
paraben	I-CHEM
was	O
found	O
above	O
the	O
LOQ	O
in	O
mussel	O
and	O
cockle	O
samples	O
at	O
a	O
concentration	O
level	O
around	O
0	O
.	O

3ngg	O
(	O
-	O
1	O
)	O
.	O

n	B-CHEM
-	I-CHEM
Propyl	I-CHEM
paraben	I-CHEM
was	O
only	O
above	O
the	O
LOQ	O
in	O
one	O
mussel	O
sample	O
.	O

The	O
EpiDerm	O
™	O
3D	B-PROC
human	I-PROC
reconstructed	I-PROC
skin	I-PROC
micronucleus	I-PROC
(	I-PROC
RSMN	I-PROC
)	I-PROC
assay	I-PROC
:	O
Historical	B-PROC
control	I-PROC
data	O
and	O
proof	B-DISO
of	O
principle	B-PROC
studies	I-PROC
for	O
mechanistic	B-PROC
assay	I-PROC
adaptations	O
The	O
in	B-PROC
vitro	I-PROC
human	I-PROC
reconstructed	I-PROC
skin	I-PROC
micronucleus	I-PROC
(	I-PROC
RSMN	I-PROC
)	I-PROC
assay	I-PROC
in	O
EpiDerm	O
™	O
is	O
a	O
promising	O
novel	O
animal	B-PROC
alternative	I-PROC
for	O
evaluating	O
genotoxicity	B-DISO
of	O
topically	B-PROC
applied	I-PROC
chemicals	B-CHEM
.	O

It	O
is	O
particularly	O
useful	O
for	O
assessing	B-PROC
cosmetic	B-CHEM
ingredients	I-CHEM
that	O
can	O
no	O
longer	O
be	O
tested	O
using	O
in	O
vivo	O
assays	B-PROC
.	O

To	O
advance	O
the	O
use	O
of	O
this	O
test	O
especially	O
for	O
regulatory	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
,	O
we	O
have	O
established	O
the	O
RSMN	B-PROC
assay	I-PROC
in	O
our	O
laboratory	B-OBJC
according	O
to	O
Good	O
Laboratory	O
Practice	O
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	O
test	O
guideline	O
487	O
in	O
vitro	O
mammalian	B-ANAT
cell	I-ANAT
micronucleus	B-PROC
test	I-PROC
.	O

Proficiency	O
with	O
the	O
assay	B-PROC
was	O
established	O
by	O
correctly	O
identifying	O
direct	B-CHEM
-	I-CHEM
acting	I-CHEM
genotoxins	I-CHEM
and	O
genotoxins	B-CHEM
requiring	O
metabolism	B-PHYS
,	O
as	O
well	O
as	O
non	B-DISO
-	I-DISO
genotoxic	I-DISO
/	O
non	B-DISO
-	I-DISO
carcinogenic	I-DISO
chemicals	B-CHEM
.	O

We	O
also	O
report	O
the	O
analysis	B-PROC
of	O
our	O
historical	B-PROC
control	I-PROC
data	O
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	O
control	O
values	O
for	O
%	O
micronuclei	B-ANAT
in	O
binucleated	B-DISO
cells	I-DISO
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O

Technical	B-PHEN
issues	I-PHEN
including	O
evaluating	O
various	O
solvents	B-CHEM
with	O
both	O
48h	O
and	O
72h	O
treatment	B-PROC
regimens	I-PROC
were	O
investigated	O
.	O

For	O
the	O
first	O
time	O
,	O
mechanistic	O
studies	O
using	O
CREST	B-PROC
analysis	I-PROC
revealed	O
that	O
the	O
RSMN	B-PROC
assay	I-PROC
is	O
suitable	O
for	O
distinguishing	O
aneugens	B-CHEM
and	O
clastogens	B-CHEM
.	O

Moreover	O
,	O
the	O
assay	B-PROC
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	B-CHEM
as	O
markers	O
for	O
proliferative	B-DISO
and	O
toxic	B-DISO
effects	I-DISO
of	O
chemicals	B-CHEM
.	O

Two	O
-	O
stage	O
reconstructive	B-PROC
overlapping	B-DEVI
stent	I-DEVI
LEO	B-DEVI
+	I-DEVI
and	O
SILK	B-DEVI
for	O
treatment	B-PROC
of	O
intracranial	B-ANAT
circumferential	O
fusiform	B-DISO
aneurysms	I-DISO
in	O
the	O
posterior	O
circulation	B-PHYS
Intracranial	B-ANAT
circumferential	O
fusiform	B-DISO
aneurysms	I-DISO
of	O
the	O
posterior	O
circulation	B-PHYS
involving	O
arterial	B-ANAT
branches	I-ANAT
or	O
perforating	B-DISO
vessels	B-ANAT
are	O
difficult	O
to	O
treat	O
.	O

This	O
article	O
shows	O
an	O
endovascular	B-ANAT
reconstruction	B-PROC
technique	I-PROC
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	B-DEVI
self	I-DEVI
-	I-DEVI
expandable	I-DEVI
stent	I-DEVI
(	O
LEO	B-DEVI
+	I-DEVI
)	O
and	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
(	O
SILK	B-DEVI
)	O
at	O
different	O
surgical	O
times	O
.	O

Two	O
patients	B-LIVB
with	O
circumferential	O
fusiform	B-DISO
aneurysm	I-DISO
,	O
one	O
being	O
an	O
aneurysm	B-DISO
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	B-ANAT
cerebral	I-ANAT
artery	I-ANAT
,	O
diagnosed	B-DISO
after	O
a	O
headache	B-DISO
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	B-DISO
aneurysm	I-DISO
of	O
the	O
lower	B-ANAT
basilar	B-ANAT
artery	I-ANAT
,	O
diagnosed	B-DISO
following	O
ischemia	B-DISO
of	O
the	O
brain	B-ANAT
stem	I-ANAT
.	O

Endovascular	B-ANAT
treatment	B-PROC
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	B-ANAT
reconstruction	B-PROC
technique	I-PROC
that	O
used	O
at	O
different	O
surgical	O
times	O
:	O
overlapping	B-PROC
;	I-PROC
a	I-PROC
telescoped	I-PROC
self	I-PROC
-	I-PROC
expandable	I-PROC
stent	I-PROC
,	O
LEO	B-DEVI
+	I-DEVI
;	O
and	O
a	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
,	O
SILK	B-DEVI
.	O

Angiographic	B-PROC
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	B-PHYS
patency	I-PHYS
,	O
flow	B-PHEN
maintenance	O
in	O
the	O
arterial	B-ANAT
branches	I-ANAT
and	O
perforating	B-DISO
vessels	B-ANAT
,	O
and	O
thrombosis	B-DISO
of	O
the	O
aneurysm	B-DISO
.	O

The	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self	B-DEVI
-	I-DEVI
expandable	I-DEVI
stent	I-DEVI
and	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
was	O
technically	O
successful	O
in	O
both	O
patients	B-LIVB
.	O

There	O
were	O
no	O
complications	B-DISO
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long	O
-	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
with	O
full	O
arterial	B-ANAT
vascular	B-ANAT
reconstruction	B-PROC
,	O
maintenance	O
of	O
cerebral	B-PROC
perfusion	I-PROC
and	O
complete	O
aneurysm	B-DISO
occlusion	O
at	O
the	O
6	O
-	O
and	O
12	O
-	O
month	O
angiographic	B-PROC
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

There	O
was	O
no	O
aneurysm	B-DISO
recanalization	I-DISO
nor	O
intra	B-DISO
-	I-DISO
stent	I-DISO
stenosis	I-DISO
.	O

Circumferential	O
fusiform	B-DISO
aneurysm	I-DISO
of	O
the	O
posterior	O
circulation	B-PHYS
involving	O
arterial	B-ANAT
branches	I-ANAT
or	O
perforating	B-DISO
vessels	B-ANAT
to	O
the	O
brain	B-ANAT
stem	I-ANAT
may	O
be	O
treated	O
with	O
this	O
arterial	B-ANAT
reconstruction	B-PROC
technique	I-PROC
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self	B-DEVI
-	I-DEVI
expandable	I-DEVI
stent	I-DEVI
called	O
LEO	B-DEVI
+	I-DEVI
and	O
the	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
SILK	B-DEVI
,	O
minimizing	O
the	O
risk	O
of	O
complications	B-DISO
and	O
failure	O
of	O
the	O
endovascular	B-ANAT
technique	B-PROC
,	O
with	O
the	O
potential	O
for	O
arterial	B-PROC
reconstruction	I-PROC
with	O
thrombosis	B-DISO
of	O
the	O
aneurysmatic	B-DISO
sac	I-DISO
,	O
as	O
well	O
as	O
flow	B-PHEN
maintenance	O
in	O
the	O
eloquent	B-ANAT
arteries	I-ANAT
,	O
in	O
this	O
type	O
of	O
cerebral	B-DISO
aneurysm	I-DISO
.	O

Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
/	O
Frizzled9	B-CHEM
receptor	B-PHYS
signaling	I-PHYS
through	O
the	O
Gαo	B-CHEM
/	O
Gβγ	B-CHEM
complex	I-CHEM
regulates	B-PHEN
dendritic	B-ANAT
spine	I-ANAT
formation	B-PHYS
Wnt	B-CHEM
ligands	I-CHEM
play	O
crucial	O
roles	O
in	O
the	O
development	B-PHYS
and	O
regulation	B-PHYS
of	I-PHYS
synapse	I-PHYS
structure	I-PHYS
and	I-PHYS
function	I-PHYS
.	O

Specifically	O
,	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
acts	O
as	O
a	O
secreted	B-CHEM
growth	I-CHEM
factor	I-CHEM
that	O
regulates	B-PHEN
dendritic	B-ANAT
spine	I-ANAT
formation	B-PHYS
in	O
rodent	B-LIVB
hippocampal	B-ANAT
neurons	B-ANAT
,	O
resulting	O
in	O
postsynaptic	B-ANAT
development	B-PHYS
that	O
promotes	O
the	O
clustering	B-PHYS
of	I-PHYS
the	I-PHYS
postsynaptic	I-PHYS
density	I-PHYS
protein	I-PHYS
-	I-PHYS
95	I-PHYS
(	I-PHYS
PSD	I-PHYS
-	I-PHYS
95	I-PHYS
)	I-PHYS
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
early	O
events	O
occurring	O
after	O
the	O
interaction	B-PHYS
between	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
and	O
its	O
Frizzled	B-CHEM
receptor	I-CHEM
at	O
the	O
neuronal	B-ANAT
cell	B-ANAT
surface	I-ANAT
.	O

Additionally	O
,	O
we	O
studied	O
the	O
role	O
of	O
heterotrimeric	B-CHEM
G	I-CHEM
proteins	I-CHEM
in	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-dependent	O
synaptic	B-ANAT
development	B-PHYS
.	O

We	O
report	O
that	O
Frizzled9	B-CHEM
(	O
FZD9	B-CHEM
)	O
,	O
a	O
Wnt	B-CHEM
receptor	B-CHEM
related	O
to	O
Williams	B-DISO
'	I-DISO
syndrome	I-DISO
,	O
is	O
localized	O
in	O
the	O
postsynaptic	O
region	O
,	O
where	O
it	O
interacts	B-PHYS
with	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
.	O

Functionally	O
,	O
FZD9	B-CHEM
is	O
required	O
for	O
the	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-mediated	O
increase	O
in	O
dendritic	B-ANAT
spine	I-ANAT
density	I-ANAT
.	O

FZD9	B-CHEM
forms	O
a	O
pre	B-ANAT
-	I-ANAT
coupled	I-ANAT
complex	I-ANAT
with	O
Gαo	B-CHEM
under	O
basal	B-PHEN
conditions	I-PHEN
that	O
dissociates	B-PHYS
after	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
stimulation	B-PHYS
.	O

Accordingly	O
,	O
we	O
found	O
that	O
G	B-PHYS
-	I-PHYS
protein	I-PHYS
inhibition	I-PHYS
abrogates	I-PHYS
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-dependent	O
pathway	B-PHYS
in	O
hippocampal	B-ANAT
neurons	B-ANAT
.	O

In	O
particular	O
,	O
the	O
activation	O
of	O
Gαo	B-CHEM
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	B-PHEN
the	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-	O
induced	O
dendritic	B-ANAT
spine	I-ANAT
density	I-ANAT
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
Gβγ	B-CHEM
is	O
required	O
for	O
the	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-mediated	O
increase	O
in	O
cytosolic	B-ANAT
calcium	B-CHEM
levels	O
and	O
spinogenesis	B-PHYS
.	O

Our	O
findings	O
reveal	O
that	O
FZD9	B-CHEM
and	O
heterotrimeric	B-CHEM
G	I-CHEM
proteins	I-CHEM
regulate	B-PHEN
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
signaling	B-PHYS
and	O
dendritic	B-ANAT
spines	I-ANAT
in	O
cultured	B-ANAT
hippocampal	B-ANAT
neurons	B-ANAT
.	O

A	O
Delayed	O
Diagnosis	B-DISO
of	O
Chronic	B-DISO
Mesenteric	I-DISO
Ischaemia	I-DISO
:	O
The	O
Role	O
of	O
Clinicians	B-LIVB
'	O
Cognitive	O
Errors	O
Chronic	O
diarrhoeal	B-DISO
illnesses	I-DISO
with	O
nausea	B-DISO
and	O
weight	B-DISO
loss	I-DISO
are	O
a	O
common	O
indication	O
for	O
gastroenterology	O
review	O
.	O

While	O
many	O
such	O
cases	O
have	O
intra	O
-	O
luminal	O
aetiologies	O
,	O
such	O
as	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
,	O
coeliac	B-DISO
disease	I-DISO
or	O
other	O
malabsorptive	B-DISO
conditions	I-DISO
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	O
gut	B-ANAT
disorders	B-DISO
or	O
systemic	O
malignancy	B-DISO
,	O
clinicians	B-LIVB
must	O
also	O
keep	O
vascular	B-DISO
disorders	I-DISO
in	O
mind	O
.	O

Here	O
we	O
report	O
a	O
patient	B-LIVB
with	O
a	O
delayed	O
diagnosis	B-DISO
of	O
chronic	B-DISO
mesenteric	I-DISO
ischaemia	I-DISO
after	O
6	O
months	O
of	O
gastrointestinal	B-DISO
symptoms	I-DISO
strongly	O
mimicking	O
an	O
alternative	O
diagnosis	B-DISO
such	O
as	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
due	O
an	O
atypical	O
predominance	O
of	O
nausea	B-DISO
and	O
diarrhoea	B-DISO
rather	O
than	O
pain	B-DISO
.	O

We	O
briefly	O
review	O
the	O
literature	O
on	O
treatment	O
of	O
this	O
condition	B-DISO
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	O
of	O
cognitive	O
errors	O
made	O
by	O
clinicians	B-LIVB
that	O
led	O
to	O
a	O
diagnostic	B-DISO
delay	O
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	O
can	O
be	O
minimised	O
in	O
their	O
practice	O
.	O

Evaluation	B-PROC
of	O
Choroidal	B-ANAT
Thickness	O
in	O
Patients	B-LIVB
with	O
Pseudoexfoliation	B-DISO
Syndrome	I-DISO
and	O
Pseudoexfoliation	B-DISO
Glaucoma	I-DISO
Purpose	O
.	O

To	O
compare	O
the	O
macular	O
and	O
peripapillary	O
choroidal	B-ANAT
thickness	O
in	O
eyes	B-ANAT
with	O
pseudoexfoliation	B-DISO
(	I-DISO
PEX	I-DISO
)	I-DISO
syndrome	I-DISO
and	O
PEX	B-DISO
glaucoma	I-DISO
with	O
the	O
normal	O
eyes	B-ANAT
of	O
healthy	O
controls	B-LIVB
.	O

Materials	O
and	O
Methods	O
.	O

In	O
this	O
prospective	B-PROC
study	I-PROC
,	O
30	O
eyes	B-ANAT
of	O
30	O
patients	B-LIVB
with	O
PEX	B-DISO
syndrome	I-DISO
,	O
28	O
eyes	B-ANAT
of	O
28	O
patients	B-LIVB
with	O
PEX	B-DISO
glaucoma	I-DISO
,	O
and	O
30	O
eyes	B-ANAT
of	O
30	O
age	B-PHYS
-matched	O
healthy	O
subjects	B-LIVB
were	O
enrolled	O
.	O

Choroidal	B-ANAT
thicknesses	O
in	O
the	O
macular	O
and	O
peripapillary	O
areas	O
were	O
measured	O
by	O
using	O
spectral	B-DEVI
domain	I-DEVI
optical	I-DEVI
coherence	I-DEVI
tomography	I-DEVI
.	O

Results	O
.	O

Gender	B-PHYS
,	O
age	B-PHYS
,	O
and	O
axial	O
length	O
did	O
not	B-DISO
significantly	I-DISO
differ	O
between	O
the	O
groups	O
(	O
all	O
,	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
values	O
of	O
choroidal	B-ANAT
thickness	O
in	O
the	O
macular	O
and	O
peripapillary	O
areas	O
(	O
except	O
the	O
superior	O
quadrant	O
)	O
in	O
the	O
patients	B-LIVB
with	O
PEX	B-DISO
syndrome	I-DISO
and	O
PEX	B-DISO
glaucoma	I-DISO
were	O
lower	O
compared	O
with	O
controls	B-LIVB
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
values	O
of	O
the	O
macular	O
and	O
peripapillary	O
choroidal	B-ANAT
thickness	O
in	O
the	O
PEX	B-DISO
glaucoma	I-DISO
group	O
were	O
lower	O
compared	O
with	O
PEX	B-DISO
syndrome	I-DISO
group	O
;	O
however	O
this	O
difference	O
was	O
not	B-DISO
significant	I-DISO
.	O

Conclusions	O
.	O

The	O
findings	B-DISO
of	O
this	O
study	B-PROC
revealed	O
that	O
macular	O
and	O
peripapillary	O
choroidal	B-ANAT
thicknesses	O
were	O
decreased	O
in	O
PEX	B-DISO
syndrome	I-DISO
and	O
PEX	B-DISO
glaucoma	I-DISO
cases	O
.	O

The	O
role	O
of	O
choroid	B-ANAT
in	O
the	O
development	O
of	O
glaucomatous	B-DISO
damage	O
in	O
patients	B-LIVB
with	O
PEX	B-DISO
syndrome	I-DISO
remains	O
unclear	B-DISO
.	O

Polysaccharide	B-CHEM
-	O
Specific	O
Memory	B-ANAT
B	I-ANAT
Cells	I-ANAT
Predict	O
Protection	B-DISO
against	O
Experimental	O
Human	B-LIVB
Pneumococcal	B-LIVB
Carriage	B-DISO
We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
pneumococcal	B-LIVB
carriage	B-DISO
enhances	O
immunity	B-PHYS
and	O
protects	B-DISO
healthy	O
adults	B-LIVB
against	O
carriage	B-DISO
reacquisition	O
after	O
rechallenge	B-PROC
with	O
a	O
homologous	B-PHYS
strain	B-LIVB
.	O

To	O
investigate	O
the	O
role	O
of	O
naturally	O
acquired	O
pneumococcal	B-CHEM
protein	I-CHEM
and	O
polysaccharide	B-CHEM
(	O
PS	B-CHEM
)	O
-	O
specific	O
immunity	B-PHYS
in	O
protection	B-DISO
against	O
carriage	B-DISO
acquisition	O
using	O
a	O
heterologous	B-PHYS
challenge	I-PHYS
model	O
.	O

We	O
identified	O
healthy	B-LIVB
volunteers	I-LIVB
that	O
were	O
naturally	O
colonized	B-ANAT
with	O
pneumococcus	B-LIVB
and	O
,	O
after	O
clearance	O
of	O
their	O
natural	O
carriage	B-DISO
episode	O
,	O
challenged	O
them	O
with	O
a	O
heterologous	B-PHYS
6B	B-LIVB
strain	I-LIVB
.	O

In	O
another	O
cohort	B-LIVB
of	O
volunteers	B-LIVB
we	O
assessed	O
6BPS	B-CHEM
-	O
specific	O
,	O
PspA	B-CHEM
-	O
specific	O
,	O
and	O
PspC	B-CHEM
-	O
specific	O
IgG	B-CHEM
and	O
IgA	B-CHEM
plasma	B-ANAT
and	O
memory	B-ANAT
B	I-ANAT
-	I-ANAT
cell	I-ANAT
populations	I-ANAT
before	O
and	O
7	O
,	O
14	O
,	O
and	O
35	O
days	O
after	O
experimental	O
pneumococcal	B-LIVB
inoculation	B-PROC
.	O

Heterologous	B-PHYS
challenge	I-PHYS
with	O
6B	B-LIVB
resulted	O
in	O
50	O
%	O
carriage	B-DISO
among	O
volunteers	B-LIVB
with	O
previous	O
natural	O
pneumococcal	B-LIVB
carriage	B-DISO
.	O

Protection	B-DISO
from	O
carriage	B-DISO
was	O
associated	O
with	O
a	O
high	O
number	O
of	O
circulating	O
6BPS	B-CHEM
IgG	B-CHEM
-	O
secreting	B-PHYS
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
at	O
baseline	O
.	O

There	O
were	O
no	O
associations	O
between	O
protection	B-DISO
from	O
carriage	B-DISO
and	O
baseline	O
levels	O
of	O
6BPS	B-CHEM
IgG	B-CHEM
in	O
serum	B-ANAT
or	O
nasal	B-ANAT
wash	I-ANAT
,	O
PspA	B-CHEM
-	O
specific	O
,	O
or	O
PspC	B-CHEM
-	O
specific	O
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
or	O
plasma	B-ANAT
cells	I-ANAT
.	O

In	O
volunteers	B-LIVB
who	O
did	O
not	B-DISO
develop	I-DISO
carriage	B-DISO
,	O
the	O
number	O
of	O
circulating	O
6BPS	B-CHEM
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
decreased	O
and	O
the	O
number	O
of	O
6BPS	B-CHEM
plasma	B-ANAT
cells	I-ANAT
increased	O
postinoculation	B-DISO
.	O

Our	O
data	O
indicate	O
that	O
naturally	O
acquired	O
PS	B-CHEM
-	O
specific	O
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
,	O
but	O
not	B-DISO
levels	I-DISO
of	O
circulating	O
IgG	B-CHEM
at	O
time	O
of	O
pneumococcal	B-LIVB
exposure	O
,	O
are	O
associated	O
with	O
protection	B-DISO
against	O
carriage	B-DISO
acquisition	O
.	O

A	O
Retrospective	O
Review	O
of	O
Forensic	O
Odontology	O
Reports	O
Written	O
by	O
the	O
Joint	O
POW	O
/	O
MIA	O
Accounting	O
Command	O
Central	B-OBJC
Identification	I-OBJC
Laboratory	I-OBJC
for	O
Remains	B-ANAT
Identified	O
from	O
the	O
Korean	O
War	O
As	O
of	O
August	O
2014	O
,	O
the	O
Joint	O
POW	O
/	O
MIA	O
Accounting	O
Command	O
has	O
identified	O
the	O
remains	B-ANAT
of	O
1980	O
previously	O
unknown	O
U	B-GEOG
.	I-GEOG

S	I-GEOG
.	I-GEOG

service	B-LIVB
members	I-LIVB
;	O
280	O
were	O
from	O
the	O
Korean	O
War	O
.	O

To	O
determine	O
the	O
accuracy	O
and	O
completeness	O
of	O
the	O
available	O
antemortem	O
(	O
AM	O
)	O
dental	O
records	O
,	O
a	O
review	O
of	O
the	O
AM	O
/	O
postmortem	O
(	O
AM	O
/	O
PM	O
)	O
dental	O
record	O
comparisons	O
from	O
233	O
Forensic	O
Odontology	O
Reports	O
written	O
in	O
support	O
of	O
remains	B-ANAT
identified	O
from	O
the	O
Korean	O
War	O
was	O
performed	O
.	O

Seventy	O
-	O
two	O
AM	O
/	O
PM	O
comparisons	O
resulted	O
in	O
exact	O
dental	O
chartings	O
while	O
161	O
contained	O
discrepancies	B-DISO
which	O
were	O
explainable	O
.	O

Explainable	O
discrepancies	B-DISO
include	O
undocumented	B-DISO
treatment	B-PROC
(	O
103	O
)	O
,	O
incorrectly	O
charted	O
third	O
molars	B-ANAT
as	O
missing	O
(	O
82	O
)	O
,	O
differing	O
opinions	O
of	O
specific	O
molars	B-ANAT
present	B-DISO
/	O
missing	O
(	O
20	O
)	O
,	O
and	O
erroneous	O
treatment	B-PROC
documentation	O
and	O
/	O
or	O
misidentification	B-DISO
of	O
teeth	B-ANAT
present	B-DISO
/	O
missing	O
(	O
22	O
,	O
other	O
than	O
molars	B-ANAT
)	O
.	O

Reassessment	O
has	O
revealed	O
varying	O
levels	O
of	O
completeness	O
for	O
our	O
available	O
AM	O
dental	O
records	O
,	O
the	O
need	O
to	O
thoroughly	O
review	O
our	O
computerized	O
comparisons	O
,	O
adjust	O
our	O
comparisons	O
to	O
include	O
molar	B-ANAT
pattern	O
variations	O
/	O
third	O
molars	B-ANAT
,	O
and	O
updating	O
our	O
database	O
comparison	O
program	O
.	O

Predicting	O
Sources	B-DISO
of	O
Dissolved	O
Organic	B-CHEM
Nitrogen	I-CHEM
to	O
an	O
Estuary	O
from	O
an	O
Agro	O
-	O
Urban	B-GEOG
Coastal	B-GEOG
Watershed	I-GEOG
Dissolved	O
organic	B-CHEM
nitrogen	I-CHEM
(	O
DON	B-CHEM
)	O
is	O
the	O
nitrogen	B-CHEM
(	I-CHEM
N	I-CHEM
)	I-CHEM
-containing	O
component	O
of	O
dissolved	O
organic	B-CHEM
matter	I-CHEM
(	O
DOM	B-CHEM
)	O
and	O
in	O
aquatic	B-PHEN
ecosystems	I-PHEN
is	O
part	O
of	O
the	O
biologically	B-CHEM
-	I-CHEM
reactive	I-CHEM
nitrogen	B-CHEM
pool	O
that	O
can	O
degrade	O
water	O
quality	O
in	O
N	B-CHEM
-	O
sensitive	O
waters	B-CHEM
.	O

Unlike	O
inorganic	B-CHEM
N	I-CHEM
(	O
nitrate	B-CHEM
and	O
ammonium	B-CHEM
)	O
DON	B-CHEM
is	O
comprised	O
of	O
many	O
different	O
molecules	O
of	O
variable	O
reactivity	O
.	O

Few	O
methods	O
exist	O
to	O
track	O
the	O
sources	B-DISO
of	O
DON	B-CHEM
in	O
watersheds	O
.	O

In	O
this	O
study	O
,	O
DOM	B-CHEM
excitation	B-PROC
-	I-PROC
emission	I-PROC
matrix	I-PROC
(	I-PROC
EEM	I-PROC
)	I-PROC
fluorescence	I-PROC
of	O
eight	O
discrete	O
DON	B-CHEM
sources	B-DISO
was	O
measured	O
and	O
modeled	O
with	O
parallel	O
factor	O
analysis	O
(	O
PARAFAC	O
)	O
and	O
the	O
resulting	O
model	O
(	O
""""	O
FluorMod	O
""""	O
)	O
was	O
fit	O
to	O
516	O
EEMs	B-PROC
measured	O
in	O
surface	O
waters	B-CHEM
from	O
the	O
main	O
stem	O
of	O
the	O
Neuse	B-PHEN
River	I-PHEN
and	O
its	O
tributaries	B-PHEN
,	O
located	O
in	O
eastern	O
North	B-GEOG
Carolina	I-GEOG
.	O

PARAFAC	O
components	O
were	O
positively	O
correlated	O
to	O
DON	B-CHEM
concentration	O
and	O
principle	O
components	O
analysis	O
(	O
PCA	O
)	O
was	O
used	O
to	O
confirm	O
separation	O
of	O
the	O
eight	O
sources	B-DISO
.	O

Model	O
validation	B-PROC
was	O
achieved	O
by	O
measurement	O
of	O
source	B-DISO
samples	B-OBJC
not	O
included	O
in	O
the	O
model	O
development	O
with	O
an	O
error	O
of	O
<	O
10	O
%	O
.	O

Application	O
of	O
FluorMod	O
to	O
surface	O
waters	B-CHEM
of	O
streams	B-PHEN
within	O
the	O
Neuse	B-PHEN
River	I-PHEN
Basin	O
showed	O
while	O
>	O
70	O
%	O
of	O
DON	B-CHEM
was	O
attributed	O
to	O
natural	O
sources	B-DISO
,	O
non	O
-	O
point	O
sources	B-DISO
,	O
such	O
as	O
soil	B-OBJC
and	O
poultry	B-LIVB
litter	B-OBJC
leachates	B-CHEM
and	O
street	B-OBJC
runoff	I-OBJC
,	O
accounted	O
for	O
the	O
remaining	O
30	O
%	O
.	O

This	O
result	O
was	O
consistent	O
with	O
changes	O
in	O
land	O
use	O
from	O
urbanized	B-PHEN
Raleigh	B-GEOG
metropolitan	I-GEOG
area	I-GEOG
to	O
the	O
largely	O
agricultural	O
Southeastern	O
coastal	O
plain	O
.	O

Overall	O
,	O
the	O
predicted	O
fraction	O
of	O
non	O
-	O
point	O
DON	B-CHEM
sources	B-DISO
was	O
consistent	O
with	O
previous	O
reports	O
of	O
increased	O
organic	B-CHEM
N	I-CHEM
inputs	O
in	O
this	O
river	B-PHEN
basin	I-PHEN
,	O
which	O
are	O
suspected	O
of	O
impacting	O
the	O
water	O
quality	O
of	O
its	O
estuary	B-PHEN
.	O

Clinical	B-DISO
Features	I-DISO
and	O
Complications	B-DISO
of	O
the	O
HLA	B-CHEM
-	I-CHEM
B27	I-CHEM
-associated	O
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
:	O
A	O
Metanalysis	B-PROC
In	O
this	O
article	O
,	O
we	O
report	O
a	O
literature	O
-	O
based	O
metanalysis	B-PROC
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B-DISO
features	I-DISO
of	O
the	O
HLA	B-CHEM
-	I-CHEM
B27	I-CHEM
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
(	O
AAU	B-DISO
)	O
.	O

The	O
examined	B-DISO
material	O
was	O
based	O
on	O
observational	B-PROC
studies	I-PROC
in	O
which	O
participants	B-LIVB
were	O
affected	O
by	O
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
and	O
divided	O
into	O
HLA	B-PHEN
B27	I-PHEN
+	I-PHEN
and	O
HLA	B-PHEN
B27	I-PHEN
-	I-PHEN
.	O

We	O
performed	O
a	O
search	O
on	O
articles	O
with	O
the	O
words	O
""""	O
HLA	B-DISO
B27	I-DISO
uveitis	I-DISO
""""	O
dated	O
before	O
May	O
2014	O
.	O

Among	O
these	O
,	O
29	O
articles	O
were	O
selected	O
for	O
a	O
second	O
review	O
.	O

After	O
a	O
further	O
evaluation	O
,	O
22	O
articles	O
were	O
analyzed	B-PROC
.	O

The	O
clinical	B-PHYS
characteristics	I-PHYS
studied	O
in	O
the	O
metanalysis	B-PROC
were	O
:	O
(	O
1	O
)	O
systemic	B-DISO
disease	I-DISO
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	B-PHYS
;	O
(	O
4	O
)	O
visual	B-PHYS
acuity	I-PHYS
;	O
(	O
5	O
)	O
hypopion	B-DISO
;	O
(	O
6	O
)	O
anterior	B-CHEM
chamber	I-CHEM
's	I-CHEM
fibrin	I-CHEM
;	O
(	O
7	O
)	O
elevated	B-DISO
intraocular	I-DISO
pressure	I-DISO
(	O
IOP	B-PHYS
)	O
during	O
inflammation	B-DISO
;	O
(	O
8	O
)	O
glaucoma	B-DISO
;	O
(	O
9	O
)	O
posterior	B-DISO
synechiae	I-DISO
;	O
(	O
10	O
)	O
cataract	B-DISO
;	O
(	O
11	O
)	O
cystoid	B-DISO
macular	I-DISO
edema	I-DISO
;	O
(	O
12	O
)	O
papillitis	B-DISO
.	O

We	O
have	O
calculated	O
a	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
each	O
outcome	O
measured	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	B-CHEM
B27	I-CHEM
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	B-DISO
spondylitis	I-DISO

(	O
RR	O
=	O
6	O
.	O
80	O
)	O
and	O
systemic	B-DISO
diseases	I-DISO
(	O
RR	O
=	O
9	O
.	O
9	O
)	O
,	O
male	B-PHYS
prevalence	O
(	O
RR	O
=	O
1	O
.	O
2	O
)	O
,	O
unilateral	O
(	O
RR	O
=	O
1	O
.	O
1	O
)	O
or	O
alternating	O
bilateral	O
(	O
RR	O
=	O
2	O
.	O
2	O
)	O
involvement	O
,	O
hypopion	B-DISO
(	O
RR	O
=	O
5	O
.	O
5	O
)	O
,	O
fibrinous	B-CHEM
reaction	O
and	O
even	O
papillitis	B-DISO
(	O
R	O
=	O
7	O
.	O
7	O
)	O
.	O

Simultaneous	O
bilateral	O
(	O
RR	O
=	O
0	O
.	O
3	O
)	O
AAU	B-DISO
is	O
more	O
frequent	O
in	O
HLA	B-CHEM
-	I-CHEM
B27	I-CHEM
negative	B-DISO
form	O
.	O

We	O
report	O
higher	O
risk	O
of	O
elevated	B-DISO
IOP	I-DISO
and	O
glaucoma	B-DISO
(	O
RR	O
=	O
0	O
.	O
6	O
)	O
in	O
B27	B-DISO
-	I-DISO
Acute	I-DISO
Anterior	I-DISO
Uveitis	I-DISO
.	O

No	O
significant	O
difference	O
between	O
HLA	B-DISO
B	I-DISO
27	I-DISO
positive	I-DISO
and	O
negative	B-DISO
AAU	B-DISO
was	O
observed	O
according	O
to	O
final	O
visual	B-PHYS
acuity	I-PHYS
and	O
complications	B-DISO
such	O
as	O
posterior	B-DISO
synechiae	I-DISO
,	O
cataract	B-DISO
,	O
and	O
maculare	B-DISO
edema	I-DISO
.	O

We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B-PROC
evaluation	I-PROC
and	O
therapeutic	O
decision	B-PHYS
in	O
addressing	O
a	O
still	O
ill	O
-	O
defined	O
ophthalmologic	O
condition	O
.	O

Effect	O
of	O
nivolumab	B-CHEM
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
in	O
patients	B-LIVB
with	O
treatment	B-PHYS
-	I-PHYS
naïve	I-PHYS
advanced	O
melanoma	B-DISO
:	O
results	O
from	O
the	O
phase	B-PROC
III	I-PROC
CheckMate	I-PROC
066	I-PROC
study	I-PROC
Nivolumab	B-CHEM
has	O
shown	O
significant	O
survival	O
benefit	O
and	O
a	O
favorable	O
safety	B-PROC
profile	I-PROC
compared	O
with	O
dacarbazine	B-CHEM
chemotherapy	B-PROC
among	O
treatment	B-PHYS
-	I-PHYS
naïve	I-PHYS
patients	B-LIVB
with	O
metastatic	B-DISO
melanoma	I-DISO
in	O
the	O
CheckMate	B-PROC
066	I-PROC
phase	I-PROC
III	I-PROC
study	I-PROC
.	O

Results	O
from	O
the	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
analyses	B-PROC
from	O
CheckMate	B-PROC
066	I-PROC
are	O
presented	O
.	O

HRQoL	O
was	O
evaluated	B-PROC
at	O
baseline	O
and	O
every	O
6	O
weeks	O
while	O
on	O
treatment	B-PROC
using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Care	O
(	O
EORTC	O
)	O
Core	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
QLQ	O
-	O
C30	O
)	O
and	O
the	O
EuroQoL	O
Five	O
Dimensions	O
Questionnaire	O
(	O
EQ	O
-	O
5D	O
)	O
.	O

Via	O
a	O
multi	O
-	O
step	O
statistical	O
plan	O
,	O
data	O
were	O
analyzed	B-PROC
descriptively	O
,	O
cross	B-PROC
-	I-PROC
sectionally	I-PROC
,	O
and	O
longitudinally	B-PROC
,	O
adjusting	O
for	O
baseline	O
covariates	O
,	O
in	O
patients	B-LIVB
having	O
baseline	O
plus	O
≥1	O
post	O
-	O
baseline	O
assessment	B-PROC
.	O

Baseline	O
-	O
adjusted	O
completion	O
rates	O
for	O
all	O
HRQoL	O
questionnaires	O
across	O
treatment	B-PROC
arms	I-PROC
were	O
65	O
%	O
and	O
70	O
%	O
for	O
dacarbazine	B-CHEM
and	O
nivolumab	B-CHEM
,	O
respectively	O
,	O
and	O
remained	O
similar	O
throughout	O
treatment	B-PROC
.	O

The	O
mean	O
baseline	O
HRQoL	O
scores	O
were	O
similar	O
for	O
patients	B-LIVB
treated	B-PROC
with	O
nivolumab	B-CHEM
and	O
dacarbazine	B-CHEM
.	O

Baseline	O
HRQoL	O
levels	O
with	O
nivolumab	B-CHEM
were	O
maintained	O
over	O
time	O
.	O

This	O
exploratory	B-PROC
analysis	I-PROC
showed	O
a	O
between	O
-	O
arm	O
difference	O
in	O
favor	O
of	O
nivolumab	B-CHEM
on	O
the	O
EQ	O
-	O
5D	O
utility	O
index	O
and	O
clinically	O
meaningful	O
EQ	O
-	O
5D	O
improvements	O
from	O
baseline	O
at	O
several	O
time	O
points	O
for	O
patients	B-LIVB
receiving	O
nivolumab	B-CHEM
.	O

Patients	B-LIVB
treated	B-PROC
with	O
nivolumab	B-CHEM
did	O
not	O
show	O
increased	O
symptom	B-DISO
burden	O
as	O
assessed	O
by	O
the	O
EORTC	O
QLQ	O
-	O
C30	O
.	O

No	O
HRQoL	O
change	O
was	O
noted	O
with	O
dacarbazine	B-CHEM
patients	B-LIVB
up	O
to	O
week	O
43	O
,	O
although	O
the	O
high	O
attrition	O
rate	O
after	O
week	O
13	O
did	O
not	O
allow	O
any	O
meaningful	O
analyses	B-PROC
.	O

Patients	B-LIVB
receiving	O
nivolumab	B-CHEM
deteriorated	O
significantly	O
later	O
than	O
those	O
receiving	O
dacarbazine	B-CHEM
on	O
several	O
EORTC	O
QLQ	O
-	O
C30	O
scales	O
and	O
the	O
EQ	O
-	O
5D	O
utility	O
index	O
.	O

In	O
addition	O
to	O
prolonged	O
survival	O
,	O
these	O
exploratory	O
HRQoL	O
results	O
show	O
that	O
nivolumab	B-CHEM
maintains	O
baseline	O
HRQoL	O
levels	O
to	O
provide	O
long	O
-	O
term	O
quality	B-DISO
of	I-DISO
survival	I-DISO
benefit	I-DISO
,	O
compared	O
with	O
dacarbazine	B-CHEM
in	O
patients	B-LIVB
with	O
advanced	O
melanoma	B-DISO
.	O

Risk	O
stratification	B-PROC
of	O
prostate	B-DISO
cancer	I-DISO
utilizing	O
apparent	O
diffusion	O
coefficient	O
value	O
and	O
lesion	B-DISO
volume	I-DISO
on	O
multiparametric	B-PROC
MRI	I-PROC
To	O
evaluate	B-PROC
the	O
performance	O
of	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
and	O
lesion	B-DISO
volume	I-DISO
in	O
potentially	O
risk	O
-	O
stratifying	B-PROC
patients	B-LIVB
with	O
prostate	B-DISO
cancer	I-DISO
(	O
PCa	B-DISO
)	O
.	O

Men	B-LIVB
with	O
elevated	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
antigen	I-CHEM
or	O
abnormal	B-PROC
digital	I-PROC
rectal	I-PROC
exam	I-PROC
underwent	O
a	O
3	B-PROC
T	I-PROC
multiparametric	I-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O
mpMRI	B-PROC
)	O
with	O
endorectal	B-DEVI
coil	I-DEVI
.	O

ADC	O
maps	O
were	O
calculated	O
using	O
b	O
values	O
of	O
0	O
,	O
500	O
,	O
1000	O
,	O
and	O
1500	O
;	O
additional	O
images	O
were	O
obtained	O
with	O
b	O
value	O
of	O
2000	O
.	O

We	O
prospectively	O
enrolled	O
312	O
men	B-LIVB
with	O
lesions	B-DISO
suspicious	O
for	O
cancer	B-DISO
(	O
suspicion	O
score	O
2	O
-	O
5	O
)	O
on	O
mpMRI	B-PROC
.	O

MRI	B-PROC
/	I-PROC
ultrasound	I-PROC
fusion	I-PROC
-	I-PROC
guided	I-PROC
prostate	I-PROC
biopsies	I-PROC
were	O
performed	O
.	O

Mean	O
ADC	O
of	O
suspicious	O
lesions	B-DISO
were	O
correlated	O
against	O
lesion	B-DISO
volume	I-DISO
,	O
Gleason	O
and	O
D	O
'	O
Amico	O
risk	O
.	O

The	O
cancer	B-DISO
detection	O
rate	O
of	O
fusion	B-PROC
biopsy	I-PROC
per	O
lesion	B-DISO
was	O
45	O
.	O

6	O
%	O
(	O
206	O
/	O
452	O
)	O
.	O

Cancerous	B-DISO
lesions	B-DISO
were	O
larger	O
(	O
median	O
volume	O
:	O
0	O
.	O
40	O
vs	O
.	O

0	O
.	O
30	O
cm	O
(	O
3	O
)	O
;	O
P	O
=	O
0	O
.	O
016	O
)	O
.	O

The	O
median	O
ADC	O
(	O
×10	O
(	O
-	O
6	O
)	O
mm	O
(	O
2	O
)	O
/sec	O
)	O
for	O
lesions	B-DISO
negative	B-DISO
and	I-DISO
positive	I-DISO
for	O
PCa	B-DISO
were	O
984	O
.	O
5	O
and	O
666	O
.	O
5	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
AUC	O
of	O
ADC	O
in	O
predicting	O
PCa	B-DISO
was	O
0	O
.	O
79	O
.	O

Larger	O
lesions	B-DISO
were	O
associated	O
with	O
higher	B-DISO
risk	I-DISO
PCa	B-DISO
(	O
Gleason	O
and	O
D	O
'	O
Amico	O
)	O
and	O
lower	B-DISO
ADC	I-DISO
(	O
all	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
mean	O
ADC	O
of	O
suspicious	O
lesions	B-DISO
on	O
mpMRI	B-PROC
was	O
inversely	O
correlated	O
,	O
while	O
lesion	B-DISO
volume	I-DISO
had	O
a	O
direct	O
correlation	O
with	O
PCa	B-DISO
detection	B-DISO
.	O

Future	O
follow	B-PROC
-	I-PROC
up	I-PROC
studies	I-PROC
are	O
needed	O
to	O
assess	O
longitudinal	B-DISO
cancer	I-DISO
risks	O
of	O
suspicious	O
mpMRI	B-PROC
lesions	B-DISO
.	O

2	O
J	O
.	O
Magn	O
.	O

Reson	O
.	O

Imaging	O
2017	O
;	O
45	O
:	O
610	O
-	O
616	O
.	O

Hounsfield	O
unit	O
recovery	O
in	O
clinical	O
cone	B-PROC
beam	I-PROC
CT	I-PROC
images	O
of	O
the	O
thorax	B-ANAT
acquired	O
for	O
image	B-PROC
guided	I-PROC
radiation	I-PROC
therapy	I-PROC
A	O
comprehensive	O
artefact	B-PHEN
correction	O
method	O
for	O
clinical	O
cone	B-PROC
beam	I-PROC
CT	I-PROC
(	O
CBCT	B-PROC
)	O
images	O
acquired	O
for	O
image	B-PROC
guided	I-PROC
radiation	I-PROC
therapy	I-PROC
(	O
IGRT	B-PROC
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O

The	O
method	O
is	O
demonstrated	O
to	O
reduce	O
artefacts	B-PHEN
and	O
recover	O
CT	B-PROC
-like	O
Hounsfield	O
units	O
(	O
HU	O
)	O
in	O
reconstructed	O
CBCT	B-PROC
images	O
of	O
five	O
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O

Projection	O
image	O
based	O
artefact	B-PHEN
corrections	O
of	O
image	B-PHEN
lag	I-PHEN
,	O
detector	B-PHEN
scatter	I-PHEN
,	O
body	B-PHEN
scatter	I-PHEN
and	O
beam	B-DISO
hardening	I-DISO
are	O
described	O
and	O
applied	O
to	O
CBCT	B-PROC
images	O
of	O
five	O
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O

Image	O
quality	O
is	O
evaluated	B-PROC
through	O
visual	O
appearance	O
of	O
the	O
reconstructed	O
images	O
,	O
HU	O
-correspondence	O
with	O
the	O
planning	O
CT	B-PROC
images	O
,	O
and	O
total	O
volume	O
HU	O
error	O
.	O

Artefacts	B-PHEN
are	O
reduced	O
and	O
CT	B-PROC
-like	O
HUs	O
are	O
recovered	O
in	O
the	O
artefact	B-PHEN
corrected	O
CBCT	B-PROC
images	O
.	O

Visual	B-PROC
inspection	I-PROC
confirms	B-DISO
that	O
artefacts	B-PHEN
are	O
indeed	O
suppressed	O
by	O
the	O
proposed	O
method	O
,	O
and	O
the	O
HU	O
root	O
mean	O
square	O
difference	O
between	O
reconstructed	O
CBCTs	B-PROC
and	O
the	O
reference	O
CT	B-PROC
images	O
are	O
reduced	O
by	O
31	O
%	O
when	O
using	O
the	O
artefact	B-PHEN
corrections	O
compared	O
to	O
the	O
standard	O
clinical	O
CBCT	B-PROC
reconstruction	O
.	O

A	O
versatile	O
artefact	B-PHEN
correction	O
method	O
for	O
clinical	O
CBCT	B-PROC
images	O
acquired	O
for	O
IGRT	B-PROC
has	O
been	O
developed	O
.	O

HU	O
values	O
are	O
recovered	O
in	O
the	O
corrected	O
CBCT	B-PROC
images	O
.	O

The	O
proposed	O
method	O
relies	O
on	O
post	O
processing	O
of	O
clinical	O
projection	O
images	O
,	O
and	O
does	O
not	O
require	O
patient	B-LIVB
specific	O
optimisation	O
.	O

It	O
is	O
thus	O
a	O
powerful	O
tool	O
for	O
image	O
quality	O
improvement	O
of	O
large	O
numbers	O
of	O
CBCT	B-PROC
images	O
.	O

Vestibular	B-ANAT
ablation	B-PROC
and	O
a	O
semicircular	B-ANAT
canal	I-ANAT
prosthesis	B-DEVI
affect	O
postural	B-PHYS
stability	I-PHYS
during	O
head	B-PHYS
turns	I-PHYS
In	O
our	O
study	O
,	O
we	O
examined	O
postural	B-PHYS
stability	I-PHYS
during	O
head	B-PHYS
turns	I-PHYS
for	O
two	O
rhesus	B-LIVB
monkeys	I-LIVB
:	O
one	O
animal	B-LIVB
study	I-LIVB
contrasted	O
normal	O
and	O
mild	O
bilateral	O
vestibular	B-ANAT
ablation	B-PROC
and	O
a	O
second	O
animal	B-LIVB
study	I-LIVB
contrasted	O
severe	O
bilateral	O
vestibular	B-ANAT
ablation	B-PROC
with	O
and	O
without	O
prosthetic	B-DEVI
stimulation	B-PROC
.	O

The	O
monkeys	B-LIVB
freely	O
stood	O
,	O
unrestrained	O
on	O
a	O
balance	B-DEVI
platform	O
and	O
made	O
voluntary	O
head	B-PHYS
turns	I-PHYS
between	O
visual	O
targets	O
.	O

To	O
quantify	O
each	O
animals	B-LIVB
'	O
posture	B-PHYS
,	O
motions	B-PHEN
of	O
the	O
head	B-ANAT
and	O
trunk	B-ANAT
,	O
as	O
well	O
as	O
torque	B-PHEN
about	O
the	O
body	B-PHYS
's	I-PHYS
center	I-PHYS
of	I-PHYS
mass	I-PHYS
,	O
were	O
measured	O
.	O

In	O
the	O
mildly	O
ablated	B-PROC
animal	B-LIVB
,	O
we	O
observed	O
less	O
foretrunk	B-ANAT
sway	B-DISO
in	O
comparison	O
with	O
the	O
normal	O
state	O
.	O

When	O
the	O
canal	B-DEVI
prosthesis	I-DEVI
provided	O
electric	B-PROC
stimulation	I-PROC
to	O
the	O
severely	O
ablated	B-LIVB
animal	I-LIVB
,	O
it	O
showed	O
a	O
decrease	O
in	O
trunk	B-ANAT
sway	B-DISO
during	O
head	B-PHYS
turns	I-PHYS
.	O

Because	O
the	O
rhesus	B-LIVB
monkey	I-LIVB
with	O
severe	O
bilateral	B-DISO
vestibular	I-DISO
loss	I-DISO
exhibited	O
a	O
decrease	O
in	O
trunk	B-ANAT
sway	B-DISO
when	O
receiving	O
vestibular	B-ANAT
prosthetic	B-DEVI
stimulation	B-PROC
,	O
we	O
propose	O
that	O
the	O
prosthetic	B-DEVI
electrical	B-PROC
stimulation	I-PROC
partially	O
restored	B-PROC
head	B-PHYS
velocity	I-PHYS
information	O
.	O

Our	O
results	O
provide	O
an	O
indication	B-DISO
that	O
a	O
semicircular	B-ANAT
canal	I-ANAT
prosthesis	B-DEVI
may	O
be	O
an	O
effective	O
way	O
to	O
improve	O
postural	B-PHYS
stability	I-PHYS
in	O
patients	B-LIVB
with	O
severe	O
peripheral	B-DISO
vestibular	I-DISO
dysfunction	I-DISO
.	O

Expression	B-PHYS
of	O
metalloproteinases	B-CHEM
(	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
)	O
in	O
basal	B-DISO
-	I-DISO
cell	I-DISO
carcinoma	I-DISO
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
compare	O
the	O
expressions	B-PHYS
of	O
mRNA	O
for	O
metalloproteinases	B-CHEM
(	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
)	O
and	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
in	O
two	O
different	O
histological	B-PHYS
types	I-PHYS
of	O
basal	B-DISO
-	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
BCCs	B-DISO
;	O
nodular	B-DISO
and	O
infiltrative	B-DISO
)	O
and	O
in	O
normal	B-DISO
tissues	I-DISO
from	O
the	O
tumor	B-DISO
interface	O
.	O

The	O
study	B-PROC
included	O
biopsy	O
specimens	O
of	O
the	O
skin	B-ANAT
involved	O
with	O
BCC	B-DISO
and	O
normal	B-ANAT
skin	I-ANAT
adjacent	O
the	O
lesion	B-DISO
.	O

The	O
expressions	B-PHYS
of	O
mRNA	O
for	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
and	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
were	O
determined	O
by	O
means	O
of	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
(	O
Reverse	B-PROC
transcription	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
)	O
.	O

The	O
level	O
of	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
mRNA	O
in	O
nodular	B-DISO
and	O
infiltrative	B-DISO
BCCs	I-DISO
turned	O
out	O
to	O
be	O
significantly	O
lower	O
,	O
and	O
the	O
expressions	B-PHYS
of	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
mRNA	O
significantly	O
higher	O
than	O
in	O
normal	B-DISO
tissues	I-DISO
adjacent	O
to	O
these	O
tumors	B-DISO
.	O

The	O
expression	B-PHYS
of	O
mRNA	O
for	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
but	O
not	O
for	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
was	O
significantly	O
higher	O
in	O
infiltrative	B-DISO
BCCs	I-DISO
than	O
in	O
the	O
nodular	B-DISO
BCCs	I-DISO
.	O

In	O
turn	O
,	O
normal	B-DISO
tissues	I-DISO
adjacent	O
to	O
nodular	B-DISO
BCCs	I-DISO
showed	O
significantly	O
higher	O
levels	O
of	O
mRNA	O
for	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
significantly	O
lower	O
levels	O
of	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
mRNA	O
than	O
the	O
normal	B-DISO
tissues	I-DISO
from	O
the	O
interface	O
of	O
infiltrative	B-DISO
BCCs	I-DISO
.	O

The	O
findings	B-DISO
suggest	O
that	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
could	O
be	O
used	O
as	O
prognostic	B-PHYS
factors	I-PHYS
of	O
BCCs	B-DISO
.	O

Effects	O
of	O
Covering	O
Surgical	B-DISO
Wounds	I-DISO
with	O
Polyglycolic	B-CHEM
Acid	I-CHEM
Sheets	B-DEVI
for	O
Posttonsillectomy	B-DISO
Pain	I-DISO
Postoperative	B-DISO
pain	I-DISO
is	O
a	O
remaining	O
issue	O
in	O
tonsillectomy	B-PROC
.	O

Polyglycolic	B-CHEM
acid	I-CHEM
(	O
PGA	B-CHEM
)	O
is	O
a	O
biocompatible	B-CHEM
material	I-CHEM
used	O
for	O
absorbent	B-DEVI
suture	I-DEVI
reinforcement	B-PROC
,	O
and	O
its	O
sheet	B-DEVI
has	O
been	O
applied	O
for	O
covering	O
defects	O
after	O
resection	B-PROC
of	O
oral	B-DISO
carcinoma	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
whether	O
the	O
attachment	O
of	O
a	O
PGA	B-CHEM
sheet	B-DEVI
to	O
surgical	B-DISO
wounds	I-DISO
would	O
reduce	O
posttonsillectomy	B-DISO
pain	I-DISO
.	O

In	O
this	O
prospective	B-PROC
single	I-PROC
-	I-PROC
blind	I-PROC
study	I-PROC
,	O
17	O
consecutive	O
adult	O
patients	B-LIVB
were	O
recruited	O
who	O
needed	O
to	O
undergo	O
tonsillectomy	B-PROC
,	O
mainly	O
due	O
to	O
habitual	O
tonsillitis	B-DISO
.	O

Following	O
bilateral	B-PROC
tonsillectomies	I-PROC
,	O
a	O
PGA	B-CHEM
sheet	B-DEVI
was	O
attached	O
with	O
fibrin	B-CHEM
glue	I-CHEM
to	O
only	O
1	O
side	O
,	O
without	O
notification	O
to	O
patients	B-LIVB
of	O
which	O
side	O
.	O

Postoperative	B-DISO
pain	I-DISO
of	O
each	O
side	O
was	O
separately	O
evaluated	B-PROC
with	O
a	O
visual	B-PROC
analog	I-PROC
scale	I-PROC
at	O
4	O
time	O
points	O
:	O
before	O
each	O
meal	O
and	O
before	O
sleep	O
.	O

Postoperative	B-DISO
pain	I-DISO
of	O
both	O
the	O
PGA	B-CHEM
sheet	B-DEVI
-attached	O
and	O
nonattached	O
sides	O
was	O
most	O
severe	O
before	O
breakfast	O
among	O
4	O
time	O
points	O
.	O

Postoperative	B-DISO
pain	I-DISO
measured	O
before	O
breakfast	O
was	O
significantly	O
more	O
severe	O
in	O
the	O
PGA	B-CHEM
sheet	B-DEVI
-attached	O
side	O
than	O
the	O
nonattached	O
side	O
.	O

As	O
such	O
,	O
this	O
study	O
provided	O
solid	O
data	O
on	O
the	O
negative	O
effects	O
of	O
PGA	B-CHEM
sheeting	B-DEVI
on	O
posttonsillectomy	B-DISO
pain	I-DISO
.	O

Risk	B-DISO
Factors	I-DISO
for	O
Infection	B-DISO
After	O
Knee	B-PROC
Arthroscopy	I-PROC
:	O
Analysis	B-PROC
of	O
595	O
,	O
083	O
Cases	O
From	O
3	O
United	B-GEOG
States	I-GEOG
Databases	O
To	O
identify	O
and	O
quantify	O
patient	B-DISO
-	I-DISO
and	O
procedure	B-DISO
-	I-DISO
related	I-DISO
risk	I-DISO
factors	I-DISO
for	O
post	O
-	O
arthroscopic	O
knee	B-DISO
infections	I-DISO
using	O
a	O
large	O
dataset	O
.	O

An	O
administrative	O
health	O
care	O
database	O
including	O
8	O
years	O
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	O
and	O
Medicare	O
(	O
a	O
5	O
%	O
random	B-PROC
sample	I-PROC
)	O
was	O
queried	O
to	O
identify	O
all	O
knee	B-PROC
arthroscopies	I-PROC
performed	O
on	O
patients	B-LIVB
aged	B-PHYS
at	O
least	O
15	O
years	O
using	O
Current	O
Procedural	O
Terminology	O
(	O
CPT	O
)	O
codes	O
.	O

Each	O
CPT	O
code	O
was	O
designated	O
as	O
a	O
high	B-PROC
-	I-PROC
or	O
low	B-PROC
-	I-PROC
complexity	I-PROC
procedure	I-PROC
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	B-PROC
or	O
increased	O
operative	O
time	O
.	O

Deep	O
infections	B-DISO
were	O
identified	O
by	O
a	O
CPT	O
code	O
for	O
incision	B-PROC
and	O
drainage	B-PROC
within	O
90	O
days	O
of	O
surgery	O
.	O

Superficial	B-DISO
infections	I-DISO
were	O
identified	O
by	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
infection	O
codes	O
without	O
any	O
record	O
of	O
incision	B-PROC
and	O
drainage	B-PROC
.	O

Patients	B-LIVB
were	O
compared	O
based	O
on	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
,	O
tobacco	O
use	O
,	O
presence	O
of	O
diabetes	B-DISO
,	O
and	O
Charlson	O
Comorbidity	O
Index	O
.	O

A	O
total	O
of	O
526	O
,	O
537	O
patients	B-LIVB
underwent	O
595	O
,	O
083	O
arthroscopic	B-PROC
knee	I-PROC
procedures	I-PROC
.	O

Deep	O
postoperative	B-DISO
infections	I-DISO
occurred	O
at	O
a	O
rate	O
of	O
0	O
.	O

22	O
%	O
.	O

Superficial	B-DISO
infections	I-DISO
occurred	O
at	O
a	O
rate	O
of	O
0	O
.	O

29	O
%	O
.	O

Tobacco	O
use	O
and	O
morbid	B-DISO
obesity	I-DISO
were	O
the	O
largest	O
risk	B-DISO
factors	I-DISO
for	O
deep	B-DISO
and	O
superficial	B-DISO
infections	I-DISO
,	O
respectively	O
(	O
P	O
<	O
.001	O
;	O
relative	O
risk	O
of	O
1	O
.	O
90	O
and	O
2	O
.	O
19	O
,	O
respectively	O
)	O
.	O

There	O
were	O
also	O
higher	O
infection	B-DISO
rates	I-DISO
among	O
patients	B-LIVB
undergoing	O
relatively	O
high	B-PROC
-	I-PROC
complexity	I-PROC
arthroscopies	I-PROC
,	O
men	B-LIVB
,	O
obese	B-DISO
patients	B-LIVB
,	O
diabetic	B-DISO
patients	B-LIVB
,	O
and	O
younger	O
patients	B-LIVB
(	O
in	O
order	O
of	O
decreasing	O
relative	O
risk	O
)	O
.	O

Increased	O
Charlson	O
Comorbidity	O
Index	O
was	O
associated	O
with	O
superficial	B-DISO
and	O
total	B-DISO
infections	I-DISO
(	O
P	O
<	O
.001	O
)	O
.	O

Post	O
-	O
arthroscopic	O
knee	B-DISO
infections	I-DISO
were	O
more	O
frequent	O
among	O
morbidly	B-DISO
obese	I-DISO
patients	B-LIVB
,	O
tobacco	B-DISO
users	I-DISO
,	O
patients	B-LIVB
undergoing	O
relatively	O
complex	B-PROC
procedures	I-PROC
,	O
men	B-LIVB
,	O
obese	B-LIVB
patients	I-LIVB
,	O
diabetic	B-LIVB
patients	I-LIVB
,	O
relatively	O
young	B-LIVB
patients	I-LIVB
,	O
and	O
patients	B-LIVB
with	O
increased	O
comorbidity	O
burdens	O
in	O
this	O
study	O
population	O
.	O

This	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative	B-PROC
counseling	I-PROC
,	O
aid	B-LIVB
surgeons	I-LIVB
in	O
patient	B-PROC
selection	I-PROC
,	O
and	O
facilitate	O
infection	B-PROC
prevention	I-PROC
by	O
targeting	O
individuals	B-LIVB
with	O
higher	O
inherent	O
risk	O
.	O

Level	O
IV	O
,	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
.	O

A	O
Case	O
Presenting	O
with	O
Splenic	B-DISO
Infarct	I-DISO
Diagnosed	B-DISO
as	O
Primary	O
Bone	O
Marrow	O
CD5	B-ANAT
Positive	I-ANAT
DLBCL	B-DISO
:	O
A	O
Clinicopathological	O
Correlation	O
De	O
novo	O
CD5	B-ANAT
+	I-ANAT
Diffuse	B-DISO
large	I-DISO
B	I-DISO
cell	I-DISO
lymphoma	I-DISO
(	O
DLBCL	B-DISO
)	O
is	O
a	O
rare	O
and	O
aggressive	B-DISO
subtype	I-DISO
of	O
DLBCL	B-DISO
.	O

It	O
is	O
a	O
distinct	O
clinicopathologic	B-DISO
entity	B-OBJC
with	O
complex	O
molecular	O
profile	O
and	O
poor	B-DISO
prognosis	I-DISO
.	O

A	O
59	O
year	O
old	O
female	B-PHYS
presented	B-DISO
with	I-DISO
pyrexia	B-DISO
of	I-DISO
unknown	I-DISO
origin	I-DISO
since	O
1	O
month	O
.	O

On	O
examination	B-PROC
,	O
there	O
was	O
severe	B-DISO
pallor	I-DISO
,	O
hepatosplenomegaly	B-DISO
and	O
no	O
palpable	O
lymphadenopathy	B-DISO
.	O

Complete	B-PROC
blood	I-PROC
count	I-PROC
revealed	O
bicytopenia	B-PHEN
with	O
normal	B-DISO
total	I-DISO
leucocyte	I-DISO
count	I-DISO
.	O

Liver	B-PROC
and	O
renal	B-PROC
function	I-PROC
tests	I-PROC
were	O
normal	O
.	O

Ultrasonography	B-PROC
abdomen	I-PROC
revealed	O
splenic	B-DISO
enlargement	I-DISO
with	O
two	B-DISO
focal	I-DISO
lesions	I-DISO
attributed	O
to	O
either	O
splenic	B-DISO
abscess	I-DISO
or	O
infarcts	B-DISO
.	O

Patient	B-LIVB
was	O
being	O
managed	O
as	O
splenic	B-DISO
infarct	I-DISO
but	O
continued	O
to	O
have	O
bicytopenia	B-PHEN
.	O

Further	O
investigation	B-PROC
showed	O
elevated	B-DISO
serum	I-DISO
ferritin	I-DISO
,	O
triglycerides	B-DISO
and	O
LDH	B-PHEN
.	O

With	O
a	O
clinical	O
suspicion	B-PHYS
of	O
infection	B-DISO
and	O
haemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
bone	B-PROC
marrow	I-PROC
aspiration	I-PROC
(	I-PROC
BMA	I-PROC
)	I-PROC
and	I-PROC
biopsy	I-PROC
(	I-PROC
BMBx	I-PROC
)	I-PROC
was	O
done	O
.	O

BMA	O
showed	O
extensive	O
haemophagocytosis	B-DISO
and	O
~7	O
.	O

4	O
%	O
large	B-DISO
lymphoma	I-DISO
-	I-DISO
like	I-DISO
cells	I-DISO
.	O

On	O
this	O
basis	O
PET	B-PROC
-	I-PROC
CT	I-PROC
was	O
suggested	O
which	O
showed	O
enlarged	B-DISO
spleen	I-DISO
with	O
diffuse	B-DISO
uptake	I-DISO
.	O

BMBx	B-PROC
showed	O
nodular	B-DISO
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	B-ANAT
lymphoid	I-ANAT
cells	I-ANAT
.	O

On	O
immunohistochemistry	B-PROC
,	O
these	O
cells	B-ANAT
were	O
positive	B-PHEN
for	I-PHEN
CD20	I-PHEN
,	O
CD5	B-CHEM
,	O
MUM1	B-CHEM
,	O
BCL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
BCL	B-CHEM
-	I-CHEM
6	I-CHEM
and	O
negative	B-DISO
for	O
CD3	B-CHEM
,	O
CD10	B-CHEM
and	O
CD23	B-CHEM
.	O

CD34	B-CHEM
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O

The	O
complete	O
clinicopathological	B-PROC
profile	I-PROC
suggested	O
the	O
diagnosis	B-DISO
of	O
de	O
novo	O
CD5	B-ANAT
+	I-ANAT
DLBCL	B-DISO
,	O
with	O
primary	B-DISO
hepatosplenic	I-DISO
pattern	O
of	O
involvement	O
.	O

CD5	B-ANAT
+	I-ANAT
DLBCL	B-DISO
presenting	O
as	O
splenic	B-DISO
infarct	I-DISO
is	O
very	B-DISO
rare	I-DISO
.	O

This	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	B-DISO
of	O
a	O
primary	B-DISO
aggressive	I-DISO
lymphoma	I-DISO
with	O
haemophagocytosis	B-DISO
was	O
established	O
in	O
a	O
patient	B-LIVB
who	O
presented	O
with	O
fever	B-DISO
and	O
splenic	B-DISO
infarct	I-DISO
without	O
lymphadenopathy	B-DISO
.	O

This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	B-ANAT
marrow	I-ANAT
aspirate	I-ANAT
and	O
biopsy	B-PROC
to	O
make	O
a	O
correct	B-DISO
diagnosis	I-DISO
.	O

Slow	B-DISO
-	I-DISO
Growing	I-DISO
Large	O
Irritation	B-DISO
Fibroma	I-DISO
of	O
the	O
Anterior	B-ANAT
Hard	I-ANAT
Palate	I-ANAT
:	O
A	O
Case	O
Report	O
Using	O
Immunohistochemical	B-PROC
Analysis	I-PROC
Irritation	B-DISO
fibromas	I-DISO
are	O
recognized	O
as	O
fibrous	O
lesions	B-DISO
,	O
usually	O
reactive	B-DISO
hyperplasias	I-DISO
;	O
however	O
,	O
the	O
mechanism	B-PROC
of	I-PROC
enlargement	I-PROC
is	O
unclear	O
.	O

This	O
paper	O
reports	O
on	O
an	O
abnormally	B-DISO
large	O
irritation	B-DISO
fibroma	I-DISO
of	O
extremely	O
gradual	B-DISO
growth	I-DISO
.	O

The	O
immunohistochemical	B-PROC
features	O
(	O
CD34	B-CHEM
,	O
α	B-CHEM
-	I-CHEM
SMA	I-CHEM
,	O
vimentin	B-CHEM
,	O
Ki	B-CHEM
-	I-CHEM
67	I-CHEM
,	O
and	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
)	O
of	O
this	O
irritation	B-DISO
fibroma	I-DISO
are	O
presented	O
to	O
distinguish	O
reactive	O
hyperplasia	B-DISO
from	O
other	O
true	B-DISO
fibrous	I-DISO
neoplasm	I-DISO
diseases	I-DISO
.	O

In	O
the	O
only	O
previous	O
study	O
,	O
it	O
was	O
reported	B-PROC
that	O
the	O
expression	B-PHYS
of	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
might	O
be	O
associated	O
with	O
the	O
development	O
of	O
oral	B-DISO
fibromas	I-DISO
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
this	O
exceptionally	O
-	O
large	O
fibrous	O
lesion	B-DISO
of	O
extremely	O
slow	B-DISO
growth	I-DISO
and	O
the	O
immunohistochemical	O
reactivity	O
of	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
,	O
finding	O
that	O
,	O
in	O
contrast	O
to	O
the	O
previous	O
study	O
,	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
was	O
not	O
expressed	B-PHYS
.	O

This	O
is	O
the	O
first	O
study	O
to	O
evaluate	B-PROC
the	O
enlargement	B-PROC
mechanism	I-PROC
of	O
such	O
a	O
large	O
irritation	B-DISO
fibroma	I-DISO
using	O
the	O
approach	O
of	O
immunohistochemical	B-PROC
analysis	I-PROC
,	O
and	O
it	O
indicates	O
that	O
such	O
analysis	B-PROC
can	O
help	O
elucidate	O
the	O
diverse	O
causes	O
and	O
enlargement	B-PROC
mechanisms	I-PROC
of	O
irritation	B-DISO
fibromas	I-DISO
.	O

Mass	B-PROC
-	I-PROC
spectrometry	I-PROC
analysis	B-PROC
of	O
histone	B-PHYS
post	I-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
in	O
pathology	O
tissue	O
using	O
the	O
PAT	B-PROC
-	I-PROC
H	I-PROC
-	I-PROC
MS	I-PROC
approach	O
Aberrant	O
histone	B-PHYS
post	I-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
(	O
hPTMs	B-PHYS
)	O
have	O
been	O
implicated	O
with	O
various	O
pathologies	O
,	O
including	O
cancer	B-DISO
,	O
and	O
may	O
represent	O
useful	O
epigenetic	B-PHYS
biomarkers	I-PHYS
.	O

The	O
data	O
described	O
here	O
provide	O
a	O
mass	B-PROC
spectrometry	I-PROC
-based	O
quantitative	O
analysis	B-PROC
of	O
hPTMs	B-PHYS
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
tissues	O
,	O
from	O
which	O
histones	B-CHEM
were	O
extracted	B-PROC
through	O
the	O
recently	O
developed	O
PAT	B-PROC
-	I-PROC
H	I-PROC
-	I-PROC
MS	I-PROC
method	I-PROC
.	O

First	O
,	O
we	O
analyzed	B-PROC
FFPE	O
samples	O
from	O
mouse	O
spleen	O
and	O
liver	B-ANAT
or	O
human	B-LIVB
breast	B-DISO
cancer	I-DISO
up	O
to	O
six	O
years	O
old	O
,	O
together	O
with	O
their	O
corresponding	O
fresh	B-ANAT
frozen	O
tissue	O
.	O

We	O
then	O
combined	O
the	O
PAT	B-PROC
-	I-PROC
H	I-PROC
-	I-PROC
MS	I-PROC
approach	O
with	O
a	O
histone	B-CHEM
-focused	O
version	O
of	O
the	O
super	B-PROC
-	I-PROC
SILAC	I-PROC
strategy	I-PROC
-using	O
a	O
mix	O
of	O
histones	B-CHEM
from	O
four	O
breast	B-ANAT
cancer	I-ANAT
cell	I-ANAT
lines	I-ANAT
as	O
a	O
spike	O
-	O
in	O
standard	O
-	O
to	O
accurately	O
quantify	O
hPTMs	B-PHYS
from	O
breast	B-DISO
cancer	I-DISO
specimens	B-OBJC
belonging	O
to	O
different	O
subtypes	O
.	O

The	O
data	O
,	O
which	O
are	O
associated	O
with	O
a	O
recent	O
publication	B-OBJC
(	O
Pathology	O
tissue	O
-	O
quantitative	B-PROC
mass	I-PROC
spectrometry	I-PROC
analysis	B-PROC
to	O
profile	B-PROC
histone	B-CHEM
post	B-PHYS
-	I-PHYS
translational	I-PHYS
modification	I-PHYS
patterns	I-PHYS
in	O
patient	B-LIVB
samples	B-OBJC
(	O
Noberini	O
,	O
2015	O
)	O
[	O
1	O
]	O
)	O
,	O
are	O
deposited	O
at	O
the	O
ProteomeXchange	B-LIVB
Consortium	I-LIVB
via	O
the	O
PRIDE	O
partner	O
repository	B-OBJC
with	O
the	O
dataset	O
identifier	O
PXD002669	O
.	O

Pregnancy	B-PHYS
suppresses	O
the	O
daily	B-PHYS
rhythmicity	I-PHYS
of	O
core	B-DISO
body	I-DISO
temperature	I-DISO
and	O
adipose	O
metabolic	B-PHYS
gene	I-PHYS
expression	I-PHYS
in	O
the	O
mouse	B-LIVB
Maternal	B-DISO
adaptations	B-PHEN
in	O
lipid	B-PHYS
metabolism	I-PHYS
are	O
crucial	O
for	O
pregnancy	B-PHYS
success	O
due	O
to	O
the	O
role	O
of	O
white	O
adipose	O
tissue	O
as	O
an	O
energy	O
store	O
and	O
the	O
dynamic	O
nature	O
of	O
energy	O
needs	O
across	O
gestation	B-PHYS
.	O

Because	O
lipid	B-PHYS
metabolism	I-PHYS
is	O
regulated	O
by	O
the	O
rhythmic	B-PHYS
expression	B-PHYS
of	O
clock	O
genes	O
,	O
it	O
was	O
hypothesised	O
that	O
maternal	B-DISO
metabolic	B-PHEN
adaptations	I-PHEN
involve	O
changes	O
in	O
both	O
adipose	O
clock	O
gene	B-PHYS
expression	I-PHYS
and	O
the	O
rhythmic	B-PHYS
expression	B-PHYS
of	O
downstream	O
metabolic	O
genes	O
.	O

Maternal	B-DISO
core	B-DISO
body	I-DISO
temperature	I-DISO
(	O
Tc	B-DISO
)	O
was	O
investigated	O
as	O
a	O
possible	O
mechanism	O
driving	O
pregnancy	B-PHYS
-induced	O
changes	O
in	O
clock	O
gene	B-PHYS
expression	I-PHYS
.	O

Gonadal	B-ANAT
adipose	O
tissue	O
and	O
plasma	B-ANAT
were	O
collected	O
from	O
C57Bl	B-LIVB
/	I-LIVB
6J	I-LIVB
mice	I-LIVB
before	O
and	O
on	O
days	O
6	O
,	O
10	O
,	O
14	O
and	O
18	O
of	O
pregnancy	B-PHYS
(	O
term	O
=	O
d19	O
)	O
at	O
4	O
hourly	O
intervals	O
across	O
a	O
24	O
-	O
h	O
period	O
.	O

Adipose	O
expression	B-PHYS
of	O
clock	O
genes	O
and	O
downstream	O
metabolic	O
genes	O
were	O
determined	O
by	O
RT	B-PROC
-	I-PROC
qPCR	I-PROC
and	O
Tc	B-DISO
was	O
measured	O
by	O
intraperitoneal	O
temperature	B-PHYS
loggers	O
.	O

Adipose	O
clock	O
gene	B-PHYS
expression	I-PHYS
showed	O
robust	O
rhythmicity	O
throughout	O
pregnancy	B-PHYS
,	O
but	O
absolute	O
levels	O
varied	O
substantially	O
across	O
gestation	B-PHYS
.	O

Rhythmic	B-PHYS
expression	B-PHYS
of	O
the	O
metabolic	O
genes	O
Lipe	O
,	O
Pnpla2	O
and	O
Lpl	O
was	O
clearly	O
evident	O
before	O
pregnancy	B-PHYS
;	O
however	O
,	O
this	O
rhythmicity	O
was	O
lost	O
with	O
the	O
onset	O
of	O
pregnancy	B-PHYS
.	O

Tc	B-DISO
rhythm	B-PHYS
was	O
significantly	O
altered	O
by	O
pregnancy	B-PHYS
with	O
a	O
65	O
%	O
decrease	O
in	O
amplitude	O
by	O
term	O
and	O
a	O
0	O
.	O

61°C	O
decrease	O
in	O
mesor	O
between	O
days	O
6	O
and	O
18	O
.	O

These	O
changes	O
in	O
Tc	B-DISO
,	O
however	O
,	O
did	O
not	O
appear	O
to	O
be	O
linked	O
to	O
adipose	O
clock	O
gene	B-PHYS
expression	I-PHYS
across	O
pregnancy	B-PHYS
.	O

Overall	O
,	O
our	O
data	O
show	O
marked	O
adaptations	B-PHEN
in	O
the	O
adipose	O
clock	O
in	O
pregnancy	B-PHYS
,	O
with	O
an	O
apparent	O
decoupling	O
of	O
adipose	O
clock	O
and	O
lipolytic	O
/	O
lipogenic	O
gene	O
rhythms	B-PHYS
from	O
early	O
in	O
gestation	B-PHYS
.	O

Bilateral	O
en	B-PROC
-	I-PROC
masse	I-PROC
distalization	I-PROC
of	O
maxillary	B-ANAT
posterior	I-ANAT
teeth	I-ANAT
with	O
skeletal	O
anchorage	O
:	O
a	O
case	O
report	O
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
introduce	O
a	O
new	O
method	O
for	O
bilateral	O
distal	O
movement	B-PROC
of	O
the	O
entire	B-ANAT
maxillary	I-ANAT
posterior	I-ANAT
segment	I-ANAT
.	O

A	O
17	O
-	O
year	O
-	O
old	B-LIVB
girl	I-LIVB
with	O
Class	O
I	O
skeletal	B-DISO
malocclusion	I-DISO
(	O
end	O
-	O
to	O
-	O
end	O
molar	O
relationships	O
,	O
deviated	O
midline	O
and	O
space	B-ANAT
deficiency	O
for	O
left	B-ANAT
maxillary	I-ANAT
canine	I-ANAT
)	O
was	O
referred	O
for	O
orthodontic	B-PROC
treatment	I-PROC
.	O

She	O
did	O
not	O
accept	O
maxillary	B-ANAT
first	O
premolars	B-PROC
extraction	I-PROC
.	O

A	O
modified	O
Hyrax	B-DEVI
appliance	I-DEVI
(	O
Dentaurum	O
Ispringen	O
,	O
Germany	B-GEOG
)	O
was	O
used	O
for	O
bilateral	O
distalization	B-PROC
of	O
maxillary	B-ANAT
posterior	I-ANAT
teeth	I-ANAT
simultaneously	O
.	O

Expansion	O
vector	O
was	O
set	O
anteroposteriorly	O
.	O

Posterior	B-DEVI
legs	I-DEVI
of	I-DEVI
Hyrax	I-DEVI
were	O
welded	O
to	O
first	O
maxillary	B-ANAT
molar	I-ANAT
bands	I-ANAT
.	O

All	O
posterior	O
teeth	B-ANAT
on	O
each	O
side	O
consolidated	O
with	O
a	O
segment	O
of	O
0	O
.	O

017	O
×	O
0	O
.	O
025	O
-	O
in	O
stainless	B-DEVI
steel	I-DEVI
wire	I-DEVI
from	O
the	O
buccal	O
side	O
.	O

Anterior	B-DEVI
legs	I-DEVI
of	I-DEVI
Hyrax	I-DEVI
were	O
bent	O
into	O
eyelet	O
form	O
and	O
attached	O
to	O
the	O
anterior	O
palate	B-ANAT
with	O
two	O
mini	O
-	O
screws	O
(	O
2	O
×	O
10	O
mm	O
)	O
(	O
Jeil	O
Medical	O
Corporation	O
Seoul	B-GEOG
,	O
South	B-GEOG
Korea	I-GEOG
)	O
.	O

Hyrax	O
opening	O
rate	O
was	O
0	O
.	O

8	O
mm	O
per	O
month	O
.	O

Lateral	B-DEVI
cephalometric	I-DEVI
radiographs	I-DEVI
were	O
used	O
to	O
evaluate	O
the	O
extent	O
of	O
distal	O
movement	B-PROC
.	O

3	O
.	O
5	O
-	O
mm	O
distalization	B-PROC
of	O
posterior	B-ANAT
maxillary	I-ANAT
teeth	I-ANAT
was	O
achieved	O
in	O
five	O
months	O
.	O

A	O
nearly	O
bodily	O
distal	O
movement	B-PROC
without	O
anchorage	O
loss	O
was	O
obtained	O
.	O

The	O
mini	O
-	O
screw	O
-supported	O
modified	O
Hyrax	B-DEVI
appliance	I-DEVI
was	O
found	O
to	O
be	O
helpful	O
for	O
achieving	O
en	O
-	O
masse	O
distal	O
movement	B-PROC
of	O
maxillary	B-ANAT
posterior	I-ANAT
teeth	I-ANAT
.	O

Histone	B-CHEM
deacetylase	I-CHEM
inhibitors	I-CHEM
regulate	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
expression	B-PHYS
in	O
colorectal	B-DISO
cancer	I-DISO
via	O
transcriptional	B-PHYS
activation	I-PHYS
and	O
mRNA	B-PHYS
stabilization	I-PHYS
Histone	B-CHEM
deacetylase	I-CHEM
inhibitors	I-CHEM
(	O
HDACIs	B-CHEM
)	O
are	O
emerging	O
as	O
a	O
novel	O
class	O
of	O
anti	B-CHEM
-	I-CHEM
tumor	I-CHEM
drugs	I-CHEM
.	O

But	O
the	O
effect	O
of	O
HDACIs	B-CHEM
in	O
tumors	B-DISO
treatment	B-PROC
has	O
been	O
disappointing	O
,	O
which	O
mainly	O
due	O
to	O
the	O
acquisition	O
of	O
resistance	B-PHEN
to	O
HDACIs	B-CHEM
.	O

However	O
,	O
the	O
underlying	O
mechanisms	B-DISO
have	O
not	O
been	O
clearly	O
understood	O
.	O

In	O
this	O
study	B-PROC
,	O
it	O
was	O
found	O
that	O
HDACIs	B-CHEM
SAHA	B-CHEM
and	O
TSA	B-CHEM
increased	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
expression	B-PHYS
in	O
CRC	B-ANAT
cells	I-ANAT
,	O
which	O
has	O
been	O
well	O
known	O
to	O
contribute	O
to	O
drug	B-PHEN
resistant	I-PHEN
.	O

The	O
mechanisms	B-DISO
underlying	O
these	O
effects	O
were	O
investigated	O
.	O

We	O
showed	O
that	O
HDACIs	B-CHEM
enhanced	O
transcriptional	B-PHYS
activity	I-PHYS
of	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
protein	O
encoding	O
gene	O
ABCB1	O
.	O

HDACIs	B-CHEM
treatment	B-PROC
also	O
increased	O
the	O
protein	B-CHEM
and	O
mRNA	B-PHYS
expression	I-PHYS
of	O
STAT3	B-CHEM
,	O
but	O
not	O
PXR	B-CHEM
,	O
CAR	B-CHEM
,	O
Foxo3a	B-CHEM
or	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
ABCB	B-PHYS
transcription	I-PHYS
regulation	I-PHYS
.	O

Interestingly	O
,	O
knockdown	B-PROC
of	O
STAT3	B-CHEM
significantly	O
attenuated	O
HDACIs	B-CHEM
-	O
induced	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
in	O
colorectal	B-ANAT
cancer	I-ANAT
cells	I-ANAT
,	O
suggesting	O
that	O
STAT3	B-CHEM
plays	O
a	O
crucial	O
role	O
in	O
HDACIs	B-CHEM
-	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
P	B-CHEM
-	I-CHEM
gp	I-CHEM
.	O

Furthermore	O
,	O
this	O
study	B-PROC
revealed	O
for	O
the	O
first	O
time	O
that	O
HDACIs	B-CHEM
enhanced	O
the	O
stability	B-PHYS
of	I-PHYS
ABCB1	I-PHYS
at	O
post	B-PHYS
-	I-PHYS
transcriptional	I-PHYS
level	I-PHYS
.	O

Taken	O
together	O
,	O
these	O
results	B-DISO
proved	O
that	O
HDACIs	B-CHEM
induced	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
expression	B-PHYS
by	O
two	O
distinct	O
ways	O
,	O
transcriptional	B-PHYS
activation	I-PHYS
and	O
mRNA	B-PHYS
stabilization	I-PHYS
.	O

Our	O
results	B-DISO
suggested	O
that	O
more	O
attention	O
should	O
be	O
paid	O
to	O
the	O
cancer	B-PROC
treatment	I-PROC
using	O
HDACIs	B-CHEM
since	O
they	O
will	O
induce	O
multidrug	B-PHYS
resistance	I-PHYS
in	O
cancer	B-ANAT
cells	I-ANAT
.	O

Mother	B-LIVB
-	O
Infant	B-LIVB
Emotion	B-PHYS
Regulation	I-PHYS
at	O
Three	O
Months	O
:	O
The	O
Role	O
of	O
Maternal	B-PHYS
Anxiety	I-PHYS
,	O
Depression	B-DISO
and	O
Parenting	B-DISO
Stress	I-DISO
While	O
the	O
association	O
between	O
anxiety	B-PHYS
and	O
postpartum	B-DISO
depression	I-DISO
is	O
well	O
known	O
,	O
few	O
studies	B-PROC
have	O
investigated	O
the	O
relationship	O
between	O
these	O
two	O
states	O
and	O
parenting	B-DISO
stress	I-DISO
.	O

Furthermore	O
,	O
a	O
number	O
of	O
studies	B-PROC
have	O
found	O
that	O
postpartum	B-DISO
depression	I-DISO
affects	O
mother	B-LIVB
-	O
infant	B-LIVB
emotion	B-PHYS
regulation	I-PHYS
,	O
but	O
there	O
has	O
been	O
only	O
one	O
study	B-PROC
on	O
anxiety	B-PHYS
and	O
emotion	B-PHYS
regulation	I-PHYS
and	O
no	O
studies	B-PROC
at	O
all	O
on	O
parenting	B-DISO
stress	I-DISO
and	O
emotion	B-PHYS
regulation	I-PHYS
.	O

Therefore	O
,	O
the	O
primary	O
aim	O
of	O
our	O
study	B-PROC
is	O
to	O
identify	O
,	O
in	O
a	O
community	B-LIVB
sample	B-OBJC
of	O
71	O
mothers	B-LIVB
,	O
the	O
relationship	O
between	O
maternal	B-DISO
depression	I-DISO
,	O
anxiety	B-PHYS
,	O
and	O
parenting	B-DISO
stress	I-DISO
.	O

The	O
second	O
aim	O
is	O
to	O
examine	O
the	O
relationship	O
between	O
anxiety	B-PHYS
,	O
postpartum	B-DISO
depression	I-DISO
,	O
and	O
parenting	B-DISO
stress	I-DISO
and	O
mother	B-LIVB
-	O
infant	B-LIVB
emotion	B-PHYS
regulation	I-PHYS
assessed	O
at	O
3	O
months	O
.	O

Mother	B-LIVB
-	O
infant	B-LIVB
interaction	O
was	O
coded	O
with	O
a	O
modified	O
version	O
of	O
the	O
Infant	O
Caregiver	O
and	O
Engagement	O
Phases	O
(	O
ICEP	O
)	O
using	O
a	O
microanalytic	B-PROC
approach	I-PROC
.	O

The	O
Edinburgh	O
Postnatal	O
Depression	O
Scale	O
(	O
EPDS	O
)	O
,	O
State	B-PROC
-	I-PROC
Trait	I-PROC
Anxiety	I-PROC
Inventory	I-PROC
(	O
STAI	B-PROC
)	O
,	O
and	O
Parenting	O
Stress	O
Index	O
-	O
Short	O
Form	O
(	O
PSI	O
-	O
SF	O
)	O
were	O
administered	O
to	O
the	O
mothers	B-LIVB
to	O
assess	B-PROC
depression	B-DISO
,	O
anxiety	B-PHYS
,	O
and	O
parenting	B-DISO
stress	I-DISO
,	O
respectively	O
.	O

Analysis	B-PROC
revealed	O
correlations	O
between	O
anxiety	B-PHYS
and	O
depression	B-DISO
,	O
showing	O
that	O
parenting	B-DISO
stress	I-DISO
is	O
associated	O
with	O
both	O
states	O
.	O

In	O
a	O
laboratory	B-PHEN
observation	I-PHEN
,	O
depression	B-DISO
was	O
correlated	O
with	O
both	O
negative	B-DISO
maternal	B-DISO
states	O
and	O
negative	B-DISO
dyadic	O
matches	O
as	O
well	O
as	O
infant	B-LIVB
positive	B-DISO
/	O
mother	B-LIVB
negative	B-DISO
mismatches	O
;	O
anxiety	B-PHYS
was	O
correlated	O
with	O
both	O
negative	B-DISO
maternal	B-DISO
states	O
and	O
infant	B-LIVB
negative	B-DISO
states	O
as	O
well	O
as	O
mismatches	O
involving	O
one	O
of	O
the	O
partners	B-LIVB
having	O
a	O
negative	B-DISO
state	O
.	O

Multiple	O
regression	O
analysis	O
showed	O
that	O
anxiety	B-PHYS
is	O
a	O
greater	O
predictor	O
than	O
depression	B-DISO
of	O
less	O
adequate	O
styles	O
of	O
mother	B-LIVB
-	O
infant	B-LIVB
emotion	B-PHYS
regulation	I-PHYS
.	O

Parenting	B-DISO
stress	I-DISO
was	O
not	O
shown	O
to	O
predict	O
such	O
regulation	B-PHYS
.	O

Medical	B-DEVI
Devices	I-DEVI
;	O
Gastroenterology	B-DEVI
-	I-DEVI
Urology	I-DEVI
Devices	I-DEVI
;	O
Classification	O
of	O
the	O
Metallic	B-CHEM
Biliary	B-DEVI
Stent	I-DEVI
System	O
for	O
Benign	B-DISO
Strictures	I-DISO
.	O

Final	O
order	O
The	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
is	O
classifying	O
the	O
metallic	B-CHEM
biliary	B-DEVI
stent	I-DEVI
system	O
for	O
benign	B-DISO
strictures	I-DISO
into	O
class	O
II	O
(	O
special	O
controls	O
)	O
.	O

The	O
special	O
controls	O
that	O
will	O
apply	O
to	O
the	O
device	B-DEVI
are	O
identified	O
in	O
this	O
order	O
and	O
will	O
be	O
part	O
of	O
the	O
codified	O
language	O
for	O
the	O
metallic	B-CHEM
biliary	B-DEVI
stent	I-DEVI
system	O
for	O
benign	B-DISO
strictures	I-DISO
'	O
classification	O
.	O

The	O
Agency	O
is	O
classifying	O
the	O
device	B-DEVI
into	O
class	O
II	O
(	O
special	O
controls	O
)	O
in	O
order	O
to	O
provide	O
a	O
reasonable	O
assurance	O
of	O
safety	B-PROC
and	O
effectiveness	O
of	O
the	O
device	B-DEVI
.	O

Environmental	B-DISO
Exposure	I-DISO
to	O
Cadmium	B-CHEM
:	O
Health	B-PROC
Risk	I-PROC
Assessment	I-PROC
and	O
its	O
Associations	O
with	O
Hypertension	B-DISO
and	O
Impaired	B-DISO
Kidney	I-DISO
Function	I-DISO
Cadmium	B-CHEM
(	O
Cd	B-CHEM
)	O
is	O
a	O
toxic	O
metal	B-CHEM
.	O

This	O
study	B-PROC
was	O
aimed	O
to	O
estimate	O
the	O
potential	O
health	O
risks	O
in	O
a	O
Cd	B-CHEM
-	O
polluted	B-PHEN
district	O
in	O
China	B-GEOG
,	O
and	O
examine	O
the	O
relationship	O
between	O
urinary	B-CHEM
cadmium	I-CHEM
(	O
UCd	B-CHEM
)	O
and	O
hypertension	B-DISO
and	O
impaired	B-DISO
kidney	I-DISO
function	I-DISO
at	O
low	O
exposure	O
levels	O
(	O
UCd	B-CHEM
:	O
GM	O
1	O
.	O
3	O
μg	O
/	O
g	O
creatinine	B-CHEM
)	O
.	O

Blood	B-PROC
pressure	I-PROC
measurement	I-PROC
,	O
questionnaires	O
,	O
and	O
collection	O
of	O
urinary	B-ANAT
samples	I-ANAT
were	O
conducted	O
from	O
217	O
residents	B-LIVB
.	O

Environmental	O
samples	B-OBJC
,	O
food	B-OBJC
,	O
and	O
cigarette	B-OBJC
samples	B-OBJC
were	O
collected	O
and	O
detected	B-DISO
to	O
estimate	O
the	O
risks	O
posed	O
by	O
Cd	B-CHEM
and	O
the	O
contribution	O
of	O
inhalation	B-DISO
,	O
ingestion	B-DISO
,	O
and	O
dermal	B-DISO
contact	I-DISO
pathways	I-DISO
to	O
these	O
risks	O
.	O

A	O
logistic	O
regression	O
model	O
was	O
used	O
in	O
examining	O
associations	O
between	O
exposure	O
and	O
hypertension	B-DISO
and	O
impaired	B-DISO
kidney	I-DISO
function	I-DISO
.	O

Results	O
show	O
that	O
this	O
population	B-LIVB
is	O
at	O
high	O
risk	O
.	O

For	O
non	B-DISO
-	I-DISO
smokers	I-DISO
,	O
incremental	O
lifetime	O
cancer	O
risk	O
(	O
ILCR	O
)	O
and	O
hazard	O
quotient	O
(	O
HQ	O
)	O
are	O
1	O
.	O

74E	O
-	O
04	O
and	O
2	O
.	O
96	O
,	O
and	O
for	O
smokers	B-DISO
,	O
they	O
are	O
1	O
.	O

07E	O
-	O
03	O
and	O
52	O
.	O
5	O
,	O
respectively	O
.	O

Among	O
all	O
exposure	O
pathways	O
,	O
smoking	O
and	O
foods	B-OBJC
cause	O
the	O
major	O
increases	O
in	O
ILCR	O
and	O
HQ	O
.	O

UCd	B-CHEM
is	O
significantly	O
associated	O
with	O
hypertension	B-DISO
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1	O
.	O
468	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1	O
.	O
104	O
,	O
1	O
.	O
953	O
;	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
impaired	B-DISO
kidney	I-DISO
function	I-DISO
(	O
OR	O
=	O
1	O
.	O
902	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
054	O
,	O
3	O
.	O
432	O
;	O
P	O
=	O
0	O
.	O
033	O
)	O
.	O

The	O
results	O
demonstrate	O
that	O
Cd	B-CHEM
can	O
potentially	O
lead	O
to	O
adverse	O
health	O
effects	O
.	O

Altererythrobacter	B-LIVB
confluentis	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O
isolated	O
from	O
water	O
of	O
an	O
estuary	B-PHEN
environment	O
A	O
Gram	B-DISO
-	I-DISO
stain	I-DISO
-	I-DISO
negative	I-DISO
,	O
aerobic	O
,	O
non	B-LIVB
-	I-LIVB
motile	I-LIVB
and	O
ovoid	O
or	O
rod	O
-	O
shaped	O
bacterial	O
strain	O
,	O
designated	O
KEM	B-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
,	O
was	O
isolated	O
from	O
water	O
of	O
an	O
estuary	B-PHEN
environment	O
on	O
the	O
Yellow	B-GEOG
Sea	I-GEOG
,	O
South	B-GEOG
Korea	I-GEOG
,	O
and	O
subjected	O
to	O
a	O
polyphasic	B-PROC
taxonomic	I-PROC
study	I-PROC
.	O

Strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
grew	O
optimally	O
at	O
pH	O
7	O
.	O

0	O
-	O
8	O
.	O
0	O
,	O
at	O
30	O
°	O
C	O
and	O
in	O
the	O
presence	O
of	O
1	O
.	O
0	O
-	O
2	O
.	O
0	O
%	O
(	O
w	O
/	O
v	O
)	O
NaCl	O
.	O

The	O
phylogenetic	O
trees	O
based	O
on	O
16S	B-CHEM
rRNA	I-CHEM
gene	I-CHEM
sequences	I-CHEM
showed	O
that	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
fell	O
within	O
the	O
clade	O
comprising	O
the	O
type	O
strains	O
of	O
Altererythrobacter	B-LIVB
species	I-LIVB
,	O
clustering	O
with	O
the	O
type	O
strains	O
of	O
Altererythrobacter	B-LIVB
aestiaquae	I-LIVB
,	O
Altererythrobacter	B-LIVB
gangjinensis	I-LIVB
and	O
Altererythrobacter	B-LIVB
luteolus	I-LIVB
showing	O
95	O
.	O
0	O
-	O
96	O
.	O

5	O
%	O
sequence	O
similarity	O
.	O

Sequences	O
similarities	O
to	O
the	O
type	O
strains	O
of	O
the	O
other	O
Altererythrobacter	B-LIVB
species	I-LIVB
were	O
93	O
.	O
1	O
-	O
95	O
.	O
1	O
%	O
.	O

Strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
contained	O
Q	B-CHEM
-	I-CHEM
10	I-CHEM
as	O
the	O
predominant	O
ubiquinone	B-CHEM
and	O
C18	B-CHEM
:	I-CHEM
1	I-CHEM
ω7c	I-CHEM
,	O
summed	O
feature	O
3	O
(	O
C16	B-CHEM
:	I-CHEM
1	I-CHEM
ω6c	I-CHEM
and	O
/	O
or	O
C16	B-CHEM
:	I-CHEM
1	I-CHEM
ω7c	I-CHEM
)	O
and	O
C17	B-CHEM
:	I-CHEM
1	I-CHEM
ω6c	I-CHEM
as	O
the	O
major	O
fatty	B-CHEM
acids	I-CHEM
.	O

The	O
major	O
polar	O
lipids	B-CHEM
were	O
phosphatidylcholine	B-CHEM
,	O
phosphatidylethanolamine	B-CHEM
,	O
phosphatidylglycerol	B-CHEM
and	O
sphingoglycolipid	B-CHEM
.	O

The	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
was	O
59	O
.	O

5	O
mol	O
%	O
.	O

Differential	O
phenotypic	B-DISO
properties	I-DISO
,	O
together	O
with	O
the	O
phylogenetic	O
distinctiveness	O
,	O
revealed	O
that	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
is	O
separated	O
from	O
recognized	O
Altererythrobacter	B-LIVB
species	I-LIVB
.	O

On	O
the	O
basis	O
of	O
the	O
data	O
presented	O
,	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
is	O
considered	O
to	O
represent	O
a	O
novel	O
species	O
of	O
the	O
genus	O
Altererythrobacter	B-LIVB
,	O
for	O
which	O
the	O
name	O
Altererythrobacter	B-LIVB
confluentis	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O
proposed	O
.	O

The	O
type	O
strain	O
of	O
is	O
KEM	B-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
(	O
=	O
KCTC	O
52259	O
T	O
=	O
NBRC	O
112305	O
T	O
)	O
.	O

Nonstenotic	B-DISO
carotid	B-DISO
plaque	I-DISO
on	O
CT	B-PROC
angiography	I-PROC
in	O
patients	B-LIVB
with	O
cryptogenic	O
stroke	B-DISO
To	O
determine	O
whether	O
large	O
(	O
≥3	O
mm	O
thick	O
)	O
but	O
nonstenotic	B-DISO
(	O
<	O
50	O
%	O
)	O
carotid	B-DISO
artery	I-DISO
atherosclerotic	I-DISO
plaque	I-DISO
predominantly	O
occurs	O
ipsilateral	O
rather	O
than	O
contralateral	O
to	O
cryptogenic	O
stroke	B-DISO
.	O

This	O
was	O
a	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
observational	I-PROC
study	I-PROC
.	O

Using	O
a	O
stroke	B-DISO
registry	O
,	O
we	O
identified	O
consecutive	O
patients	B-LIVB
with	O
anterior	B-DISO
circulation	I-DISO
embolic	I-DISO
stroke	I-DISO
of	I-DISO
undetermined	I-DISO
source	I-DISO
(	O
ESUS	B-DISO
)	O
.	O

Using	O
CT	B-PROC
angiography	I-PROC
,	O
we	O
measured	O
carotid	B-DISO
plaque	I-DISO
size	O
(	O
thickness	O
,	O
mm	O
)	O
and	O
carotid	B-DISO
artery	I-DISO
stenosis	I-DISO
(	O
North	O
American	O
Symptomatic	O
Carotid	O
Endarterectomy	O
Trial	O
method	O
)	O
for	O
each	O
patient	B-LIVB
.	O

We	O
dichotomized	O
plaque	B-DISO
size	O
at	O
several	O
predefined	O
thresholds	O
and	O
calculated	O
the	O
frequency	O
of	O
plaque	B-DISO
size	O
above	O
each	O
threshold	O
ipsilateral	O
vs	O
contralateral	O
to	O
stroke	B-DISO
.	O

We	O
included	O
85	O
patients	B-LIVB
with	O
ESUS	B-DISO
.	O

Plaque	B-DISO
with	O
thickness	O
≥5	O
mm	O
was	O
present	O
ipsilateral	O
to	O
stroke	B-DISO
in	O
11	O
%	O
of	O
patients	B-LIVB
,	O
and	O
contralateral	O
in	O
1	O
%	O
(	O
9	O
/	O
85	O
vs	O
1	O
/	O
85	O
;	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

Plaque	B-DISO
with	O
thickness	O
≥4	O
mm	O
was	O
present	O
ipsilateral	O
to	O
stroke	B-DISO
in	O
19	O
%	O
of	O
patients	B-LIVB
,	O
and	O
contralateral	O
in	O
5	O
%	O
(	O
16	O
/	O
85	O
vs	O
4	O
/	O
85	O
;	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

Plaque	B-DISO
with	O
thickness	O
≥3	O
mm	O
was	O
present	O
ipsilateral	O
to	O
stroke	B-DISO
in	O
35	O
%	O
of	O
patients	B-LIVB
,	O
and	O
contralateral	O
in	O
15	O
%	O
(	O
30	O
/	O
85	O
vs	O
13	O
/	O
85	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
percentage	O
stenosis	B-DISO
ipsilateral	O
vs	O
contralateral	O
to	O
stroke	B-DISO
(	O
p	O
=	O
0	O
.	O
98	O
)	O
,	O
and	O
weak	O
correlation	O
between	O
plaque	B-DISO
size	O
and	O
stenosis	B-DISO
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
26	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Large	O
but	O
nonstenotic	B-DISO
carotid	B-DISO
artery	I-DISO
plaque	I-DISO
is	O
considerably	O
more	O
common	O
ipsilateral	O
than	O
contralateral	O
to	O
cryptogenic	O
stroke	B-DISO
,	O
suggesting	O
that	O
nonstenotic	B-DISO
plaque	B-DISO
is	O
an	O
underrecognized	O
cause	O
of	O
stroke	B-DISO
.	O

We	O
measured	O
plaque	B-DISO
size	O
using	O
CT	B-PROC
angiography	I-PROC
,	O
a	O
method	O
that	O
could	O
be	O
easily	O
implemented	O
in	O
clinical	B-PHYS
practice	I-PHYS
.	O

Association	O
of	O
prenatal	B-LIVB
and	O
early	O
life	O
exposure	O
to	O
tetrachloroethylene	B-CHEM
(	O
PCE	B-CHEM
)	O
with	O
polycystic	B-DISO
ovary	I-DISO
syndrome	I-DISO
and	O
other	O
reproductive	B-DISO
disorders	I-DISO
in	O
the	O
cape	B-GEOG
cod	I-GEOG
health	B-PROC
study	I-PROC
:	O
A	O
retrospective	B-PROC
cohort	I-PROC
study	I-PROC
Tetrachloroethylene	B-CHEM
(	O
PCE	B-CHEM
)	O
is	O
an	O
organic	O
lipophilic	O
solvent	B-CHEM
with	O
possible	O
neuroendocrine	B-ANAT
toxicity	O
.	O

The	O
objective	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	O
the	O
association	O
of	O
prenatal	B-LIVB
and	O
early	O
childhood	O
exposure	O
to	O
PCE	B-CHEM
-	O
contaminated	O
drinking	B-OBJC
water	I-OBJC
and	O
development	B-PHYS
of	O
adult	B-DISO
-	I-DISO
onset	I-DISO
Polycystic	B-DISO
Ovary	I-DISO
Syndrome	I-DISO
(	O
PCOS	B-DISO
)	O
,	O
endometriosis	B-DISO
,	O
difficulty	B-DISO
conceiving	I-DISO
and	O
miscarriage	B-DISO
.	O

Five	O
-	O
hundred	O
exposed	O
and	O
331	O
unexposed	B-LIVB
female	B-PHYS
participants	B-LIVB
born	O
between	O
1969	O
and	O
1983	O
completed	O
questionnaires	O
on	O
demographic	O
and	O
lifestyle	O
characteristics	O
,	O
and	O
reproductive	B-DISO
disorders	I-DISO
.	O

Residential	O
locations	O
from	O
the	O
prenatal	B-LIVB
period	O
through	O
five	O
years	O
of	O
age	B-PHYS
were	O
used	O
to	O
estimate	O
early	O
life	O
PCE	B-CHEM
exposure	O
with	O
water	B-OBJC
modeling	I-OBJC
software	I-OBJC
.	O

For	O
any	O
early	O
life	O
exposure	O
to	O
PCE	B-CHEM
,	O
the	O
adjusted	O
risk	O
ratio	O
for	O
PCOS	B-DISO
was	O
0	O
.	O

9	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
5	O
-	O
1	O
.	O
6	O
)	O
.	O

No	O
statistically	O
significan	O
t	O
associations	O
were	O
observed	O
for	O
increasing	O
levels	O
of	O
exposure	O
with	O
PCOS	B-DISO
or	O
the	O
other	O
reproductive	B-DISO
disorders	I-DISO
.	O

No	O
meaningful	O
associations	O
were	O
found	B-DISO
among	O
adult	B-LIVB
women	B-LIVB
with	O
early	O
life	O
exposure	O
to	O
PCE	B-CHEM
-	O
contaminated	O
drinking	B-OBJC
water	I-OBJC
and	O
adult	B-DISO
-	I-DISO
onset	I-DISO
reproductive	B-DISO
disorders	I-DISO
.	O

Host	B-LIVB
plant	I-LIVB
affects	O
the	O
sexual	B-LIVB
attractiveness	I-LIVB
of	O
the	O
female	B-PHYS
white	O
-	O
spotted	O
longicorn	O
beetle	O
,	O
Anoplophora	O
malasiaca	O
Anoplophora	O
malasiaca	O
(	O
Coleoptera	O
:	O
Cerambycidae	O
)	O
is	O
a	O
serious	O
pest	O
that	O
destroys	O
various	O
landscape	O
and	O
crop	B-LIVB
trees	B-LIVB
in	O
Japan	B-GEOG
.	O

We	O
evaluated	O
the	O
precopulatory	O
responses	B-PHYS
of	O
three	O
different	O
A	O
.	O

malasiaca	O
populations	B-LIVB
collected	O
from	O
mandarin	B-LIVB
orange	I-LIVB
,	O
willow	B-LIVB
and	O
blueberry	B-LIVB
trees	I-LIVB
.	O

Most	O
of	O
the	O
males	B-PHYS
accepted	O
mates	O
from	O
within	O
the	O
same	O
host	B-LIVB
plant	I-LIVB
population	B-LIVB
as	O
well	O
as	O
females	B-PHYS
from	O
the	O
willow	B-LIVB
and	O
blueberry	B-LIVB
populations	O
.	O

However	O
,	O
significant	O
number	O
of	O
males	B-PHYS
from	O
the	O
blueberry	B-LIVB
and	O
willow	B-LIVB
populations	B-LIVB
rejected	O
females	B-PHYS
from	O
the	O
mandarin	B-LIVB
orange	I-LIVB
population	O
immediately	O
after	O
touching	O
them	O
with	O
their	O
antennae	B-ANAT
.	O

Because	O
all	O
three	O
of	O
the	O
female	B-PHYS
populations	B-LIVB
produced	O
contact	O
sex	B-CHEM
pheromones	I-CHEM
on	O
their	O
elytra	B-ANAT
,	O
the	O
females	B-PHYS
of	O
the	O
mandarin	B-LIVB
orange	I-LIVB
population	O
were	O
predicted	O
to	O
possess	O
extra	O
chemicals	B-CHEM
that	O
repelled	O
the	O
males	B-PHYS
of	O
the	O
other	O
two	O
populations	O
.	O

β	B-CHEM
-	I-CHEM
Elemene	I-CHEM
was	O
identified	O
as	O
a	O
key	O
component	O
that	O
was	O
only	O
found	O
in	O
mandarin	B-LIVB
orange	I-LIVB
-fed	O
females	B-PHYS
and	O
induced	O
a	O
rejection	O
response	B-PHYS
in	O
willow	B-LIVB
-fed	O
males	B-PHYS
.	O

Our	O
results	O
represent	O
the	O
first	O
example	O
of	O
a	O
female	B-PHYS
-acquired	O
repellent	B-CHEM
against	O
conspecific	O
males	B-PHYS
of	O
different	O
host	B-LIVB
plant	I-LIVB
populations	O
,	O
indicating	O
that	O
the	O
host	B-LIVB
plant	I-LIVB
greatly	O
affects	O
the	O
female	B-PHYS
's	I-PHYS
sexual	B-LIVB
attractiveness	I-LIVB
.	O

Variability	O
in	O
conditioned	B-PROC
pain	I-PROC
modulation	I-PROC
predicts	O
response	B-PHYS
to	O
NSAID	B-CHEM
treatment	B-PROC
in	O
patients	B-LIVB
with	O
knee	B-DISO
osteoarthritis	I-DISO
Patients	B-LIVB
with	O
painful	B-DISO
knee	B-DISO
osteoarthritis	I-DISO
(	O
OA	B-DISO
)	O
demonstrate	O
hyperalgesia	B-DISO
and	O
altered	O
pain	B-PROC
-	I-PROC
modulatory	I-PROC
responses	B-PHYS
.	O

While	O
some	O
prior	O
work	O
has	O
demonstrated	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
associations	I-PROC
between	O
laboratory	B-OBJC
and	O
clinical	O
pain	O
measures	O
,	O
it	O
is	O
unknown	O
whether	O
individual	O
variability	O
in	O
quantitative	B-PROC
sensory	I-PROC
testing	I-PROC
(	O
QST	B-PROC
)	O
responses	B-PHYS
at	O
baseline	O
can	O
prospectively	O
predict	O
analgesic	B-CHEM
treatment	B-PHYS
responses	I-PHYS
.	O

Patients	B-LIVB
with	O
knee	B-DISO
OA	I-DISO
(	O
n	O
=	O
35	O
)	O
were	O
compared	O
on	O
QST	B-PROC
responses	B-PHYS
to	O
a	O
demographically	O
-matched	O
pain	O
-	O
free	O
control	B-LIVB
group	I-LIVB
(	O
n	O
=	O
39	O
)	O
,	O
after	O
which	O
patients	B-LIVB
completed	O
a	O
month	O
-	O
long	O
treatment	B-PROC
study	I-PROC
of	O
diclofenac	B-CHEM
sodium	I-CHEM
topical	I-CHEM
gel	I-CHEM
(	O
1	O
%	O
)	O
,	O
applied	O
up	O
to	O
4	O
times	O
daily	O
.	O

OA	B-DISO
patients	B-LIVB
demonstrated	O
reduced	O
pain	B-DISO
thresholds	I-DISO
at	O
multiple	O
anatomic	B-ANAT
sites	I-ANAT
,	O
as	O
well	O
as	O
reduced	O
conditioned	B-PROC
pain	I-PROC
modulation	I-PROC
(	O
CPM	B-PROC
)	O
and	O
enhanced	O
temporal	B-PHYS
summation	I-PHYS
of	O
pain	B-DISO
.	O

The	O
most	O
pain	B-DISO
-	I-DISO
sensitive	I-DISO
patients	B-LIVB
tended	O
to	O
report	O
the	O
most	O
intense	O
and	O
neuropathic	B-DISO
OA	B-DISO
pain	B-DISO
.	O

Following	O
diclofenac	B-CHEM
treatment	B-PROC
,	O
the	O
knee	B-DISO
OA	I-DISO
cohort	B-LIVB
showed	O
a	O
roughly	O
30	O
%	O
improvement	O
in	O
pain	B-DISO
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
neuropathic	B-DISO
symptoms	I-DISO
.	O

Baseline	O
CPM	B-PROC
scores	O
,	O
an	O
index	O
of	O
endogenous	O
pain	B-PHYS
-	I-PHYS
inhibitory	I-PHYS
capacity	I-PHYS
,	O
were	O
prospectively	O
associated	O
with	O
treatment	B-PROC
-related	O
changes	O
in	O
clinical	O
pain	B-DISO
.	O

Specifically	O
,	O
participants	B-LIVB
with	O
higher	O
CPM	B-PROC
at	O
baseline	O
(	O
i	O
.	O
e	O
.	O

,	O
better	O
functioning	O
endogenous	O
pain	B-DISO
-	O
inhibitory	B-CHEM
systems	I-CHEM
)	O
showed	O
more	O
reduction	B-PROC
in	O
pain	B-DISO
at	O
the	O
end	O
of	O
treatment	B-PROC
(	O
p	O
<	O
.05	O
)	O
.	O

These	O
results	B-PHEN
support	O
prior	O
findings	B-DISO
of	O
amplified	B-DISO
pain	I-DISO
sensitivity	I-DISO
and	O
reduced	O
pain	B-PHYS
-	I-PHYS
inhibition	I-PHYS
in	O
OA	B-DISO
patients	B-LIVB
.	O

Moreover	O
,	O
the	O
moderate	O
to	O
strong	O
associations	O
between	O
laboratory	B-OBJC
-	I-OBJC
based	I-OBJC
measures	O
of	O
pain	B-DISO
sensitivity	I-DISO
and	O
indices	O
of	O
clinical	O
pain	B-DISO
highlight	O
the	O
clinical	O
relevance	O
of	O
QST	B-PROC
in	O
this	O
sample	O
.	O

Finally	O
,	O
the	O
prospective	O
association	O
between	O
CPM	B-PROC
and	O
diclofenac	B-CHEM
response	B-PHYS
suggests	O
that	O
QST	B-PROC
-	I-PROC
based	I-PROC
phenotyping	O
may	O
have	O
utility	O
in	O
explaining	O
inter	B-LIVB
-	I-LIVB
patient	I-LIVB
variability	O
in	O
long	O
-	O
term	O
analgesic	B-CHEM
treatment	O
outcomes	O
.	O

ClinicalTrials	B-PROC
.Gov	O
Identifier	O
:	O
NCT01383954	O
.	O

Registered	O
June	O
22	O
,	O
2011	O
.	O

In	B-PROC
Vitro	I-PROC
Assays	I-PROC
for	O
the	O
Discovery	O
of	O
PCSK9	B-CHEM
Autoprocessing	I-CHEM
Inhibitors	I-CHEM
PCSK9	B-CHEM
plays	O
a	O
significant	O
role	O
in	O
regulating	B-PHEN
low	B-PROC
-	I-PROC
density	I-PROC
lipoprotein	I-PROC
(	I-PROC
LDL	I-PROC
)	I-PROC
cholesterol	I-PROC
levels	I-PROC
and	O
has	O
become	O
an	O
important	O
drug	O
target	O
for	O
treating	O
hypercholesterolemia	B-DISO
.	O

Although	O
a	O
member	O
of	O
the	O
serine	B-CHEM
protease	I-CHEM
family	I-CHEM
,	O
PCSK9	B-CHEM
only	O
catalyzes	B-PHEN
a	O
single	O
reaction	O
,	O
the	O
autocleavage	B-PHEN
of	O
its	O
prodomain	O
.	O

The	O
maturation	B-PHYS
of	O
the	O
proprotein	B-CHEM
is	O
an	O
essential	O
prerequisite	O
for	O
the	O
secretion	B-PHEN
of	O
PCSK9	B-CHEM
to	O
the	O
extracellular	B-ANAT
space	I-ANAT
where	O
it	O
binds	O
the	O
LDL	B-CHEM
receptor	I-CHEM
and	O
targets	O
it	O
for	O
degradation	O
.	O

We	O
have	O
found	O
that	O
a	O
construct	B-CHEM
of	I-CHEM
proPCSK9	I-CHEM
where	O
the	O
C	O
-	O
terminal	O
domain	O
has	O
been	O
truncated	O
has	O
sufficient	O
stability	O
to	O
be	O
expressed	B-PHYS
and	O
purified	O
from	O
Escherichia	B-LIVB
coli	I-LIVB
for	O
the	O
in	B-PROC
vitro	I-PROC
study	I-PROC
of	O
autoprocessing	B-PHEN
.	O

Using	O
automated	B-PROC
Western	I-PROC
analysis	I-PROC
,	O
we	O
demonstrate	O
that	O
autoprocessing	B-PHEN
exhibits	O
the	O
anticipated	B-DISO
first	O
-	O
order	O
kinetics	O
.	O

A	O
high	B-PROC
-	I-PROC
throughput	I-PROC
time	B-PROC
-	I-PROC
resolved	I-PROC
fluorescence	I-PROC
resonance	I-PROC
energy	I-PROC
transfer	I-PROC
assay	I-PROC
for	O
autocleavage	B-PHEN
has	O
been	O
developed	O
using	O
a	O
PCSK9	B-CHEM
monoclonal	I-CHEM
antibody	I-CHEM
that	O
is	O
sensitive	O
to	O
the	O
conformational	B-PHYS
changes	I-PHYS
that	O
occur	O
upon	O
maturation	B-PHYS
of	O
the	O
proprotein	B-CHEM
.	O

Kinetic	B-PHEN
theory	I-PHEN
has	O
been	O
developed	O
that	O
describes	O
the	O
behavior	O
of	O
both	O
reversible	B-CHEM
and	O
irreversible	B-CHEM
inhibitors	I-CHEM
of	O
autocleavage	B-PHEN
.	O

The	O
analysis	B-PROC
of	O
an	O
irreversible	B-CHEM
lactone	I-CHEM
inhibitor	I-CHEM
validates	O
the	O
expected	O
relationship	O
between	O
potency	O
and	O
the	O
reaction	O
end	O
point	O
.	O

An	O
orthogonal	B-PROC
liquid	I-PROC
chromatography	I-PROC
-	I-PROC
mass	I-PROC
spectrometry	I-PROC
assay	I-PROC
has	O
also	O
been	O
implemented	B-DISO
for	O
the	O
confirmation	O
of	O
hits	O
from	O
the	O
antibody	B-PROC
-	I-PROC
based	I-PROC
assays	I-PROC
.	O

The	O
cost	O
-	O
effectiveness	O
of	O
family	B-LIVB
/	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
for	O
treatment	O
of	O
externalizing	B-DISO
disorders	I-DISO
,	O
substance	B-DISO
use	I-DISO
disorders	I-DISO
and	O
delinquency	B-DISO
:	O
a	O
systematic	O
review	O
Family	B-PROC
therapy	I-PROC
and	O
family	O
-	O
based	O
treatment	O
has	O
been	O
commonly	O
applied	O
in	O
children	B-LIVB
and	O
adolescents	B-LIVB
in	O
mental	B-PROC
health	I-PROC
care	I-PROC
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O

There	O
is	O
an	O
increased	O
interest	O
in	O
economic	O
evaluations	O
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	B-PROC
.	O

The	O
aim	O
of	O
this	O
systematic	O
review	O
is	O
to	O
summarize	O
and	O
evaluate	B-PROC
the	O
evidence	O
on	O
cost	O
-	O
effectiveness	O
of	O
family	B-LIVB
/	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
for	O
externalizing	B-DISO
disorders	I-DISO
,	O
substance	B-DISO
use	I-DISO
disorders	I-DISO
and	O
delinquency	B-DISO
.	O

A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
PubMed	O
,	O
Education	B-OBJC
Resource	I-OBJC
information	I-OBJC
Centre	I-OBJC
(	O
ERIC	B-OBJC
)	O
,	O
Psycinfo	O
and	O
Cochrane	O
reviews	O
including	O
studies	B-PROC
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
August	O
of	O
2013	O
.	O

Full	O
economic	O
evaluations	O
investigating	O
family	B-LIVB
/	O
family	B-PROC
-	I-PROC
based	I-PROC
interventions	I-PROC
for	O
adolescents	B-LIVB
between	O
10	O
and	O
20	O
years	O
treated	O
for	O
substance	B-DISO
use	I-DISO
disorders	I-DISO
,	O
delinquency	B-DISO
or	O
externalizing	B-DISO
disorders	I-DISO
were	O
included	O
.	O

Seven	O
hundred	O
thirty	O
-	O
one	O
articles	O
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-PROC
were	O
initially	O
selected	O
.	O

The	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-PROC
.	O

The	O
quality	O
of	O
these	O
studies	B-PROC
was	O
assessed	O
.	O

Within	O
the	O
identified	O
studies	B-PROC
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	B-LIVB
/	O
family	B-PROC
-	I-PROC
based	I-PROC
interventions	I-PROC
and	O
disorders	B-DISO
.	O

According	O
to	O
the	O
outcomes	O
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	O
of	O
the	O
economic	O
evaluations	O
was	O
low	O
.	O

Results	O
varied	O
by	O
study	B-PROC
.	O

Due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O

The	O
quality	O
of	O
the	O
identified	O
economic	O
evaluations	O
of	O
family	B-LIVB
/	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
for	O
treatment	O
of	O
externalizing	B-DISO
disorders	I-DISO
,	O
adolescent	B-LIVB
substance	B-DISO
use	I-DISO
disorders	I-DISO
and	O
delinquency	B-DISO
was	O
insufficient	O
to	O
determine	O
the	O
cost	O
-	O
effectiveness	O
.	O

Although	O
commonly	O
applied	O
,	O
family	B-LIVB
/	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	O
is	O
needed	O
.	O

Molecular	O
detection	B-PROC
of	O
infection	B-DISO
homogeneity	O
and	O
impact	O
of	O
miltefosine	B-CHEM
treatment	O
in	O
a	O
Syrian	B-LIVB
golden	I-LIVB
hamster	I-LIVB
model	O
of	O
Leishmania	O
donovani	O
and	O
L	O
.	O

infantum	O
visceral	B-DISO
leishmaniasis	I-DISO
Control	O
of	O
visceral	B-DISO
leishmaniasis	I-DISO
caused	O
by	O
Leishmania	O
infantum	O
and	O
Leishmania	O
donovani	O
primarily	O
relies	O
on	O
chemotherapy	B-PROC
using	O
an	O
increasingly	O
compromised	B-DISO
repertoire	O
of	O
antileishmanial	B-CHEM
compounds	I-CHEM
.	O

For	O
evaluation	B-PROC
of	O
novel	O
drugs	B-CHEM
,	O
the	O
Syrian	B-LIVB
golden	I-LIVB
hamster	I-LIVB
is	O
considered	O
as	O
a	O
clinically	O
relevant	O
laboratory	O
model	O
.	O

In	O
this	O
study	B-PROC
,	O
two	O
molecular	B-PROC
parasite	I-PROC
detection	I-PROC
assays	I-PROC
were	O
developed	O
targeting	O
cathepsin	B-CHEM
-	I-CHEM
like	I-CHEM
cysteine	I-CHEM
protease	I-CHEM
B	I-CHEM
(	O
CPB	B-CHEM
)	O
DNA	B-CHEM
and	O
18S	O
rRNA	B-CHEM
to	O
achieve	O
absolute	O
amastigote	O
quantification	O
in	O
the	O
major	O
target	O
organs	B-ANAT
liver	B-ANAT
and	O
spleen	B-ANAT
.	O

Both	O
quantitative	B-PROC
PCR	I-PROC
(	B-PROC
qPCR	I-PROC
)	I-PROC
techniques	I-PROC
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	O
with	O
the	O
conventional	O
microscopic	B-PROC
reading	I-PROC
of	O
Giemsa	B-PROC
-	I-PROC
stained	I-PROC
tissue	O
smears	B-PROC
.	O

Using	O
multiple	O
single	O
tissue	O
pieces	O
and	O
all	O
three	O
detection	B-DISO
methods	O
,	O
we	O
confirmed	O
homogeneity	O
of	O
infection	B-DISO
in	O
liver	B-ANAT
and	O
spleen	B-ANAT
and	O
the	O
robustness	O
of	O
extrapolating	O
whole	O
organ	O
burdens	O
from	O
a	O
small	O
single	O
tissue	O
piece	O
.	O

Comparison	O
of	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
burdens	O
in	O
infected	B-DISO
hamsters	B-LIVB
using	O
the	O
three	O
detection	B-DISO
methods	O
consistently	O
revealed	O
a	O
stronger	O
parasite	O
reduction	O
in	O
the	O
spleen	B-ANAT
compared	O
to	O
the	O
liver	B-ANAT
,	O
indicating	O
an	O
organ	B-ANAT
-	O
dependent	O
clearance	O
efficacy	O
for	O
miltefosine	B-CHEM
.	O

In	O
conclusion	O
,	O
this	O
study	B-PROC
in	O
the	O
hamster	B-LIVB
demonstrated	O
high	O
homogeneity	O
of	O
infection	B-DISO
in	O
liver	B-ANAT
and	O
spleen	B-ANAT
and	O
advocates	O
the	O
use	O
of	O
molecular	O
detection	B-PROC
methods	O
for	O
assessment	B-PROC
of	O
low	O
(	O
post	O
-	O
treatment	O
)	O
tissue	O
burdens	O
.	O

Abstract	B-PHYS
and	O
Effector	B-PHYS
-	I-PHYS
Selective	I-PHYS
Decision	I-PHYS
Signals	I-PHYS
Exhibit	O
Qualitatively	O
Distinct	O
Dynamics	B-PHEN
before	O
Delayed	O
Perceptual	B-PHYS
Reports	O
Electrophysiological	B-PROC
research	I-PROC
has	O
isolated	O
neural	O
signatures	B-PHYS
of	O
decision	B-PHYS
formation	I-PHYS
in	O
a	O
variety	O
of	O
brain	B-ANAT
regions	I-ANAT
.	O

Studies	B-PROC
in	O
rodents	B-LIVB
and	O
monkeys	B-LIVB
have	O
focused	O
primarily	O
on	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
signals	I-PHYS
that	O
translate	O
the	O
emerging	O
decision	B-PHYS
into	O
a	O
specific	O
motor	O
plan	O
,	O
but	O
,	O
more	O
recently	O
,	O
research	B-PROC
on	O
the	O
human	B-LIVB
brain	B-ANAT
has	O
identified	O
an	O
abstract	B-PHYS
signature	B-PHYS
of	O
evidence	O
accumulation	B-DISO
that	O
does	O
not	O
appear	O
to	O
play	O
any	O
direct	O
role	O
in	O
action	O
preparation	O
.	O

The	O
functional	O
dissociations	B-PHYS
between	O
these	O
distinct	O
signal	B-PHEN
types	O
have	O
only	O
begun	O
to	O
be	O
characterized	O
,	O
and	O
their	O
dynamics	B-PHEN
during	O
decisions	B-PHYS
with	O
deferred	O
actions	O
with	O
or	O
without	O
foreknowledge	B-PHYS
of	O
stimulus	B-PHYS
-	I-PHYS
effector	I-PHYS
mapping	I-PHYS
,	O
a	O
commonly	O
studied	B-PROC
task	O
scenario	O
in	O
single	B-PROC
-	I-PROC
unit	I-PROC
and	O
functional	B-PROC
imaging	I-PROC
investigations	B-PROC
,	O
have	O
not	O
been	O
established	O
.	O

Here	O
we	O
traced	B-DISO
the	O
dynamics	B-PHEN
of	O
distinct	O
abstract	B-PHYS
and	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
decision	I-PHYS
signals	I-PHYS
in	O
the	O
form	O
of	O
the	O
broad	O
-	O
band	O
centro	B-DISO
-	I-DISO
parietal	I-DISO
positivity	I-DISO
(	O
CPP	B-DISO
)	O
and	O
limb	B-DISO
-	I-DISO
selective	I-DISO
β	I-DISO
-	I-DISO
band	I-DISO
(	O
8	O
-	O
16	O
and	O
18	O
-	O
30	O
Hz	O
)	O
EEG	B-PROC
activity	O
,	O
respectively	O
,	O
during	O
delayed	O
-	O
reported	B-PROC
motion	O
direction	O
decisions	B-PHYS
with	O
and	O
without	O
foreknowledge	B-PHYS
of	O
direction	O
-	O
response	B-PHYS
mapping	O
.	O

With	O
foreknowledge	B-PHYS
,	O
the	O
CPP	B-DISO
and	O
β	B-PHEN
-	I-PHEN
band	I-PHEN
signals	I-PHEN
exhibited	O
a	O
similar	O
gradual	O
build	O
-	O
up	O
following	O
evidence	O
onset	O
,	O
but	O
whereas	O
choice	O
-	O
predictive	O
β	O
-	O
band	O
activity	O
persisted	O
up	O
until	O
the	O
delayed	O
response	B-PHYS
,	O
the	O
CPP	B-DISO
dropped	O
toward	O
baseline	O
after	O
peaking	O
.	O

Without	O
foreknowledge	B-PHYS
,	O
the	O
CPP	B-DISO
exhibited	O
identical	O
dynamics	B-PHEN
,	O
whereas	O
choice	O
-	O
selective	O
β	O
-	O
band	O
activity	O
was	O
eliminated	O
.	O

These	O
findings	B-DISO
highlight	O
qualitative	O
functional	O
distinctions	O
between	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
and	O
abstract	B-PHYS
decision	B-PHYS
signals	B-PHEN
and	O
are	O
of	O
relevance	O
to	O
the	O
assumptions	O
founding	B-DISO
functional	B-PROC
neuroimaging	I-PROC
investigations	B-PROC
of	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
.	O

Neural	O
signatures	B-PHYS
of	O
evidence	O
accumulation	B-DISO
have	O
been	O
isolated	O
in	O
numerous	O
brain	B-ANAT
regions	I-ANAT
.	O

Although	O
animal	B-LIVB
neurophysiology	B-PHYS
has	O
largely	O
concentrated	O
on	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
decision	I-PHYS
signals	I-PHYS
that	O
translate	O
the	O
emerging	O
decision	B-PHYS
into	O
a	O
specific	O
motor	O
plan	O
,	O
recent	O
research	B-PROC
on	O
the	O
human	B-LIVB
brain	B-ANAT
has	O
isolated	O
abstract	B-PHYS
neural	O
signatures	B-PHYS
of	O
decision	B-PHYS
formation	I-PHYS
that	O
are	O
independent	O
of	O
specific	O
sensory	O
and	O
motor	O
requirements	O
.	O

Here	O
,	O
we	O
examine	B-PROC
the	O
functional	O
distinctions	O
between	O
the	O
two	O
distinct	O
classes	O
of	O
decision	B-PHYS
variable	O
signal	B-PHEN
during	O
decisions	B-PHYS
with	O
deferred	O
actions	O
with	O
and	O
without	O
foreknowledge	B-PHYS
of	O
stimulus	B-PHYS
-	I-PHYS
effector	I-PHYS
mapping	I-PHYS
.	O

We	O
find	O
salient	O
distinctions	O
in	O
the	O
dynamics	B-PHEN
of	O
abstract	B-PHYS
versus	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
decision	I-PHYS
signals	I-PHYS
in	O
the	O
human	B-LIVB
brain	B-ANAT
,	O
in	O
terms	O
of	O
sustainment	O
through	O
response	B-PHYS
delays	O
and	O
contingency	O
on	O
foreknowledge	B-PHYS
of	O
stimulus	B-PHYS
-	I-PHYS
response	I-PHYS
mapping	I-PHYS
.	O

Prevalence	O
of	O
gastrointestinal	B-ANAT
parasites	O
in	O
dogs	B-LIVB
of	O
Palampur	B-GEOG
,	O
Himachal	B-GEOG
Pradesh	I-GEOG
A	O
total	O
of	O
246	O
faecal	B-ANAT
/	O
scat	B-ANAT
samples	I-ANAT
of	O
the	O
dogs	B-LIVB
were	O
screened	B-PROC
by	O
direct	O
and	O
floatation	B-PROC
concentration	I-PROC
technique	I-PROC
to	O
study	O
the	O
gastrointestinal	B-ANAT
(	I-ANAT
GI	I-ANAT
)	I-ANAT
tract	I-ANAT
parasitism	B-PHEN
in	O
dogs	B-LIVB
of	O
Palampur	B-GEOG
,	O
Himachal	B-GEOG
Pradesh	I-GEOG
,	O
India	B-GEOG
.	O

Detailed	O
coprological	B-PROC
examination	I-PROC
targeting	O
different	O
seasons	O
,	O
age	B-LIVB
groups	I-LIVB
and	O
living	O
styles	O
of	O
the	O
dogs	B-LIVB
revealed	O
an	O
overall	O
28	O
.	O
04	O
%	O
of	O
GI	B-ANAT
parasitism	B-PHEN
with	O
highest	O
prevalence	O
in	O
summer	O
season	O
(	O
37	O
.	O
87	O
%	O
)	O
.	O

Stray	B-LIVB
dogs	I-LIVB
harbored	O
47	O
.	O

29	O
%	O
GI	B-ANAT
parasites	O
in	O
comparison	O
to	O
19	O
.	O

19	O
%	O
of	O
pet	B-LIVB
dogs	I-LIVB
.	O

Highest	O
prevalence	O
of	O
GI	B-ANAT
parasitism	B-PHEN
was	O
observed	O
in	O
the	O
pups	B-LIVB
,	O
below	O
3	O
months	O
of	O
age	B-PHYS
(	O
39	O
.	O
13	O
%	O
)	O
,	O
followed	O
by	O
the	O
dogs	B-LIVB
with	O
the	O
age	B-PHYS
ranging	O
from	O
3	O
months	O
to	O
1	O
year	O
(	O
26	O
.	O
38	O
%	O
)	O
and	O
lowest	O
in	O
dogs	B-LIVB
of	O
the	O
age	B-PHYS
ranging	O
from	O
1	O
to	O
3	O
years	O
(	O
6	O
.	O
77	O
%	O
)	O
.	O

Amongst	O
all	O
the	O
parasites	O
,	O
Toxocara	B-DISO
canis	I-DISO
(	I-DISO
44	I-DISO
.	I-DISO
93	I-DISO
%	I-DISO
)	I-DISO
infection	I-DISO
was	O
highest	O
,	O
followed	O
by	O
Dipylidium	O
caninum	O
(	O
17	O
.	O
39	O
%	O
)	O
and	O
hookworms	O
(	O
15	O
.	O
94	O
%	O
)	O
.	O

Developing	O
Community	O
-	O
Level	O
Policy	O
and	O
Practice	B-PHYS
to	O
Reduce	O
Traffic	B-DISO
-	O
Related	O
Air	B-DISO
Pollution	I-DISO
Exposure	I-DISO
The	O
literature	O
consistently	O
shows	O
associations	O
of	O
adverse	B-DISO
cardiovascular	B-ANAT
and	O
pulmonary	B-ANAT
outcomes	O
with	O
residential	O
proximity	O
to	O
highways	O
and	O
major	O
roadways	B-OBJC
.	O

Air	O
monitoring	O
shows	O
that	O
traffic	B-DISO
-	O
related	O
pollutants	B-CHEM
(	O
TRAP	B-CHEM
)	O
are	O
elevated	O
within	O
200	O
-	O
400	O
m	O
of	O
these	O
roads	B-OBJC
.	O

Community	B-LIVB
-	O
level	O
tactics	B-PHYS
for	O
reducing	O
exposure	B-DISO
include	O
the	O
following	O
:	O
1	O
)	O
HEPA	B-OBJC
filtration	I-OBJC
;	O
2	O
)	O
Appropriate	O
air	B-PHEN
-	I-PHEN
intake	I-PHEN
locations	O
;	O
3	O
)	O
Sound	B-PHEN
proofing	B-OBJC
,	O
insulation	B-OBJC
and	O
other	O
features	O
;	O
4	O
)	O
Land	O
-	O
use	O
buffers	B-OBJC
;	O
5	O
)	O
Vegetation	B-LIVB
or	O
wall	B-OBJC
barriers	B-OBJC
;	O
6	O
)	O
Street	O
-	O
side	O
trees	B-LIVB
,	O
hedges	B-OBJC
and	O
vegetation	B-LIVB
;	O
7	O
)	O
Decking	B-OBJC
over	O
highways	B-DISO
;	O
8	O
)	O
Urban	O
design	O
including	O
placement	O
of	O
buildings	B-OBJC
;	O
9	O
)	O
Garden	O
and	O
park	B-OBJC
locations	O
;	O
and	O
10	O
)	O
Active	O
travel	O
locations	O
,	O
including	O
bicycling	O
and	O
walking	O
paths	O
.	O

A	O
multidisciplinary	O
design	O
charrette	O
was	O
held	O
to	O
test	O
the	O
feasibility	O
of	O
incorporating	O
these	O
tactics	B-PHYS
into	O
near	O
-	O
highway	O
housing	B-OBJC
and	O
school	B-OBJC
developments	O
that	O
were	O
in	O
the	O
planning	B-PHYS
stages	O
.	O

The	O
resulting	O
designs	O
successfully	O
utilized	O
many	O
of	O
the	O
protective	O
tactics	B-PHYS
and	O
also	O
led	O
to	O
engagement	B-DISO
with	O
the	O
designers	B-LIVB
and	I-LIVB
developers	I-LIVB
of	O
the	O
sites	O
.	O

There	O
is	O
a	O
need	O
to	O
increase	O
awareness	B-PHYS
of	O
TRAP	B-CHEM
in	O
terms	O
of	O
building	O
design	O
and	O
urban	O
planning	O
.	O

Learning	B-PHYS
Is	O
Better	O
with	O
the	O
Hands	O
Free	O
:	O
The	O
Role	O
of	O
Posture	B-PHYS
in	O
the	O
Memory	B-PHYS
of	O
Manipulable	B-OBJC
Objects	I-OBJC
Grounded	O
cognition	B-PHYS
proposes	O
that	O
memory	B-PHYS
shares	O
processing	O
resources	O
with	O
sensorimotor	B-ANAT
systems	I-ANAT
.	O

The	O
aim	O
of	O
the	O
present	O
study	B-PROC
was	O
to	O
show	O
that	O
motor	B-ANAT
simulation	B-PROC
participates	O
in	O
the	O
conceptual	B-PHYS
representation	I-PHYS
of	O
manipulable	B-OBJC
objects	I-OBJC
in	O
long	B-PHYS
-	I-PHYS
term	I-PHYS
memory	I-PHYS
.	O

In	O
two	O
experiments	B-PROC
,	O
lists	O
of	O
manipulable	B-OBJC
and	O
nonmanipulable	B-OBJC
objects	I-OBJC
were	O
presented	O
.	O

Participants	B-LIVB
were	O
instructed	O
to	O
memorize	O
the	O
items	B-OBJC
while	O
adopting	O
different	O
postures	B-PHYS
.	O

In	O
the	O
control	O
condition	O
,	O
they	O
had	O
to	O
keep	O
their	O
hands	B-ANAT
at	O
rest	O
in	O
front	O
of	O
them	O
.	O

In	O
the	O
interference	B-PHYS
condition	I-PHYS
,	O
participants	B-LIVB
had	O
to	O
keep	O
their	O
hands	B-ANAT
crossed	O
behind	O
their	O
back	B-ANAT
to	O
make	O
their	O
hands	B-ANAT
less	O
free	O
for	O
action	O
.	O

After	O
each	O
list	O
,	O
participants	B-LIVB
had	O
to	O
perform	O
first	O
a	O
distractive	O
task	O
,	O
and	O
then	O
an	O
oral	O
free	O
recall	B-PHYS
.	O

The	O
results	O
showed	O
that	O
the	O
interfering	O
posture	B-PHYS
produced	O
a	O
specific	O
decrease	O
in	O
the	O
recall	B-PHYS
of	O
manipulable	B-OBJC
objects	I-OBJC
,	O
but	O
not	O
of	O
nonmanipulable	B-OBJC
ones	I-OBJC
.	O

This	O
decrease	O
was	O
similar	O
when	O
the	O
items	B-OBJC
were	O
presented	O
as	O
pictures	B-OBJC
(	O
Experiment	B-PROC
1	O
)	O
or	O
as	O
words	O
(	O
Experiment	B-PROC
2	O
)	O
,	O
thus	O
excluding	O
a	O
purely	O
visual	O
effect	O
.	O

These	O
results	O
provide	O
strong	O
evidence	O
that	O
the	O
motor	B-ANAT
simulation	B-PROC
plays	O
a	O
role	O
in	O
the	O
memory	B-PHYS
trace	I-PHYS
of	O
the	O
object	B-OBJC
.	O

Approximate	O
Bayesian	O
computation	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
nanoparticles	B-OBJC
in	O
suspension	B-OBJC
by	O
optical	B-PROC
microscopy	I-PROC
We	O
present	O
an	O
approximate	O
Bayesian	O
computation	O
scheme	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
diffusing	B-PHEN
nanoparticles	B-OBJC
in	O
suspension	B-OBJC
by	O
optical	B-PROC
particle	I-PROC
tracking	I-PROC
microscopy	I-PROC
.	O

The	O
method	O
is	O
based	O
on	O
the	O
probability	O
distribution	O
of	O
the	O
time	O
spent	O
by	O
a	O
particle	B-CHEM
inside	O
a	O
detection	B-PROC
region	O
.	O

We	O
validate	O
the	O
method	O
on	O
suspensions	B-OBJC
of	O
well	O
-	O
controlled	O
reference	O
particles	B-CHEM
.	O

We	O
illustrate	O
its	O
usefulness	O
with	O
an	O
application	O
in	O
gene	B-PROC
therapy	I-PROC
,	O
applying	O
the	O
method	O
to	O
estimate	O
number	O
concentrations	O
of	O
plasmid	B-CHEM
DNA	B-CHEM
molecules	I-CHEM
and	O
the	O
average	O
number	O
of	O
DNA	B-CHEM
molecules	I-CHEM
complexed	B-CHEM
with	O
liposomal	B-CHEM
drug	B-DEVI
delivery	I-DEVI
particles	B-CHEM
.	O

Developing	O
and	O
Field	O
Testing	O
a	O
Community	B-PROC
Based	I-PROC
Youth	B-PROC
Initiative	I-PROC
to	O
Increase	O
Tuberculosis	B-DISO
Awareness	B-PHYS
in	O
Remote	O
Arctic	B-GEOG
Inuit	B-LIVB
Communities	I-LIVB
Inuit	B-LIVB
in	O
Canada	B-GEOG
have	O
the	O
highest	O
reported	B-PROC
tuberculosis	B-DISO
(	O
TB	B-DISO
)	O
incidence	O
rate	O
in	O
Canada	B-GEOG
,	O
even	O
higher	O
than	O
other	O
Canadian	B-LIVB
Indigenous	I-LIVB
groups	I-LIVB
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
increase	O
TB	B-DISO
awareness	B-PHYS
among	O
Inuit	B-LIVB
youth	I-LIVB
and	O
their	O
communities	B-LIVB
by	O
equipping	O
those	O
who	O
can	O
best	O
reach	O
this	O
population	O
with	O
a	O
community	B-LIVB
based	O
,	O
youth	B-LIVB
focused	O
,	O
education	B-PROC
initiative	I-PROC
built	O
on	O
interventions	B-PROC
adapted	O
from	O
a	O
previous	O
TB	B-DISO
awareness	B-PHYS
study	B-PROC
.	O

The	O
Taima	B-PROC
TB	I-PROC
Youth	I-PROC
Education	I-PROC
Initiative	I-PROC
was	O
a	O
field	O
test	O
case	O
study	O
of	O
a	O
knowledge	B-PROC
translation	I-PROC
(	O
KT	B-PROC
)	O
strategy	O
aimed	O
at	O
community	B-LIVB
members	I-LIVB
who	O
provide	O
health	B-PROC
education	I-PROC
in	O
these	O
communities	B-LIVB
.	O

In	O
the	O
first	O
stage	O
of	O
this	O
study	B-PROC
,	O
interventions	B-PROC
from	O
a	O
larger	O
TB	B-DISO
awareness	B-PROC
campaign	I-PROC
were	O
adapted	O
to	O
focus	O
on	O
youth	B-LIVB
living	O
in	O
remote	O
Inuit	B-LIVB
communities	I-LIVB
.	O

During	O
the	O
second	O
stage	O
of	O
the	O
study	B-PROC
,	O
investigators	B-LIVB
field	O
tested	O
the	O
initiative	B-DISO
in	O
two	O
isolated	O
Inuit	B-LIVB
communities	I-LIVB
.	O

It	O
was	O
then	O
applied	O
by	O
local	O
implementation	O
teams	O
in	O
two	O
other	O
communities	B-LIVB
.	O

Evaluation	O
criteria	O
included	O
feasibility	B-PROC
,	O
acceptability	O
,	O
knowledge	B-DISO
uptake	I-DISO
and	O
health	O
behavior	O
change	O
.	O

Implementation	O
of	O
the	O
adapted	O
KT	B-PROC
interventions	B-PROC
resulted	O
in	O
participation	O
of	O
a	O
total	O
of	O
41	O
youth	B-LIVB
(	O
19	O
females	O
,	O
22	O
males	O
)	O
with	O
an	O
average	O
age	B-PHYS
of	O
16	O
years	O
(	O
range	O
12	O
-	O
21	O
years	O
)	O
in	O
four	O
different	O
communities	B-LIVB
in	O
Nunavut	B-GEOG
.	O

Community	B-LIVB
celebration	O
events	O
were	O
attended	O
by	O
271	O
community	B-LIVB
members	I-LIVB
where	O
TB	B-DISO
messaging	O
were	O
presented	O
and	O
discussed	O
.	O

All	O
of	O
the	O
health	O
care	O
workers	O
and	O
community	B-PROC
members	I-PROC
surveyed	I-PROC
reported	B-PROC
that	O
the	O
adapted	O
interventions	B-PROC
were	O
acceptable	O
and	O
a	O
useful	O
way	B-PHYS
of	I-PHYS
learning	I-PHYS
to	O
some	O
extent	O
.	O

Knowledge	B-DISO
uptake	I-DISO
measures	O
indicated	B-DISO
an	O
average	O
TB	B-DISO
knowledge	B-DISO
score	I-DISO
of	O
64	O
out	O
of	O
100	O
.	O

Local	B-LIVB
partners	I-LIVB
in	O
all	O
four	O
communities	B-LIVB
indicated	B-DISO
that	O
they	O
would	O
use	O
the	O
Taima	B-PROC
TB	I-PROC
Youth	I-PROC
Education	I-PROC
Initiative	I-PROC
again	O
to	O
raise	O
awareness	B-PHYS
about	O
TB	B-DISO
among	O
youth	B-LIVB
in	O
their	O
communities	B-LIVB
.	O

The	O
TB	B-DISO
awareness	B-PHYS
interventions	B-PROC
adapted	O
for	O
the	O
Taima	B-PROC
TB	I-PROC
Youth	I-PROC
Education	I-PROC
Initiative	I-PROC
were	O
acceptable	O
to	O
the	O
Inuit	B-LIVB
communities	I-LIVB
involved	O
in	O
the	O
study	B-PROC
.	O

They	O
resulted	O
in	O
uptake	B-DISO
of	I-DISO
knowledge	I-DISO
among	O
participants	B-LIVB
.	O

Implementation	O
by	O
local	O
implementation	O
teams	O
was	O
feasible	O
as	O
evidenced	O
by	O
the	O
participation	O
and	O
attendance	O
of	O
youth	B-LIVB
and	O
community	B-LIVB
members	I-LIVB
in	O
all	O
communities	B-LIVB
.	O

The	O
ability	O
to	O
implement	O
the	O
interventions	B-PROC
by	O
local	O
implementation	O
teams	O
indicates	B-DISO
there	O
is	O
potential	O
to	O
scale	O
up	O
in	O
other	O
remote	O
communities	B-LIVB
in	O
the	O
arctic	B-GEOG
setting	I-GEOG
.	I-GEOG

An	O
efficient	O
approach	O
to	O
identify	O
different	O
chemical	B-CHEM
markers	I-CHEM
between	O
fibrous	B-LIVB
root	I-LIVB
and	O
rhizome	B-LIVB
of	O
Anemarrhena	B-LIVB
asphodeloides	I-LIVB
by	O
ultra	B-PROC
high	I-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	I-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
with	O
multivariate	O
statistical	O
analysis	O
An	O
ultra	B-PROC
high	I-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	I-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
approach	O
coupled	O
with	O
multivariate	O
statistical	O
analysis	O
was	O
established	O
and	O
applied	O
to	O
rapidly	O
distinguish	O
the	O
chemical	O
differences	O
between	O
fibrous	B-LIVB
root	I-LIVB
and	O
rhizome	B-LIVB
of	O
Anemarrhena	B-LIVB
asphodeloides	I-LIVB
.	O

The	O
datasets	O
of	O
tR	O
-	O
m	O
/	O
z	O
pairs	O
,	O
ion	B-CHEM
intensity	O
and	O
sample	O
code	O
were	O
processed	B-PHEN
by	O
principal	O
component	O
analysis	O
and	O
orthogonal	B-PROC
partial	I-PROC
least	I-PROC
squares	I-PROC
discriminant	I-PROC
analysis	I-PROC
.	O

Chemical	B-CHEM
markers	I-CHEM
could	O
be	O
identified	O
based	O
on	O
their	O
exact	O
mass	O
data	O
,	O
fragmentation	O
characteristics	O
,	O
and	O
retention	O
times	O
.	O

And	O
the	O
new	O
compounds	O
among	O
chemical	B-CHEM
markers	I-CHEM
could	O
be	O
isolated	O
rapidly	O
guided	O
by	O
the	O
ultra	B-PROC
high	I-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	I-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
and	O
their	O
definitive	O
structures	O
would	O
be	O
further	O
elucidated	O
by	O
NMR	B-PROC
spectra	I-PROC
.	O

Using	O
this	O
approach	O
,	O
twenty	O
-	O
four	O
markers	B-CHEM
were	O
identified	O
on	O
line	O
including	O
nine	O
new	O
saponins	B-CHEM
and	O
five	O
new	O
steroidal	B-CHEM
saponins	I-CHEM
of	O
them	O
were	O
obtained	O
in	O
pure	O
form	O
.	O

The	O
study	B-PROC
validated	O
this	O
proposed	O
approach	O
as	O
a	O
suitable	O
method	B-PROC
for	O
identification	O
of	O
the	O
chemical	O
differences	O
between	O
various	O
medicinal	B-LIVB
parts	I-LIVB
in	O
order	O
to	O
expand	O
medicinal	B-LIVB
parts	I-LIVB
and	O
increase	O
the	O
utilization	O
rate	O
of	O
resources	O
.	O

Gestational	B-PHYS
age	I-PHYS
specific	O
stillbirth	B-DISO
risk	O
among	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-LIVB
in	O
Queensland	B-GEOG
,	O
Australia	B-GEOG
:	O
a	O
population	B-PROC
based	I-PROC
study	I-PROC
In	O
Australia	B-GEOG
,	O
significant	O
disparity	O
persists	O
in	O
stillbirth	B-DISO
rates	O
between	O
Aboriginal	B-LIVB
and	O
Torres	B-LIVB
Strait	I-LIVB
Islander	I-LIVB
(	O
Indigenous	B-LIVB
Australian	I-LIVB
)	O
and	O
non	O
-	O
Indigenous	O
women	B-LIVB
.	O

Diabetes	B-DISO
,	O
hypertension	B-DISO
,	O
antepartum	B-DISO
haemorrhage	I-DISO
and	O
small	B-DISO
-	I-DISO
for	I-DISO
-	I-DISO
gestational	I-DISO
age	I-DISO
(	O
SGA	B-DISO
)	O
have	O
been	O
identified	O
as	O
important	O
contributors	O
to	O
higher	O
rates	O
among	O
Indigenous	O
women	B-LIVB
.	O

The	O
objective	O
of	O
this	O
study	B-PROC
was	O
to	O
examine	O
gestational	B-PHYS
age	I-PHYS
specific	O
risk	O
of	O
stillbirth	B-DISO
associated	O
with	O
these	O
conditions	O
among	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-LIVB
.	O

Retrospective	O
population	B-PROC
-	I-PROC
based	I-PROC
study	I-PROC
of	O
all	O
singleton	B-LIVB
births	O
of	O
at	O
least	O
20	O
weeks	O
gestation	B-PHYS
or	O
at	O
least	O
400	O
grams	O
birthweight	B-PHYS
in	O
Queensland	B-GEOG
between	O
July	O
2005	O
and	O
December	O
2011	O
using	O
data	O
from	O
the	O
Queensland	B-GEOG
Perinatal	O
Data	B-PROC
Collection	I-PROC
,	O
which	O
is	O
a	O
routinely	O
-	O
maintained	O
database	O
that	O
collects	O
data	O
on	O
all	O
births	O
in	O
Queensland	B-GEOG
.	O

Multivariate	B-PROC
logistic	I-PROC
regression	I-PROC
was	O
used	O
to	O
calculate	O
adjusted	O
odds	O
ratios	O
(	O
aOR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
,	O
adjusting	O
for	O
maternal	B-DISO
demographic	O
and	O
pregnancy	B-DISO
factors	I-DISO
.	O

Of	O
360987	O
births	O
analysed	B-PROC
,	O
20273	O
(	O
5	O
.	O
6	O
%	O
)	O
were	O
to	O
Indigenous	O
women	B-LIVB
and	O
340714	O
(	O
94	O
.	O
4	O
%	O
)	O
were	O
to	O
non	O
-	O
Indigenous	O
women	B-LIVB
.	O

Stillbirth	B-DISO
rates	O
were	O
7	O
.	O
9	O
(	O
95	O
%	O
CI	O
6	O
.	O
8	O
-	O
9	O
.	O
2	O
)	O
and	O
4	O
.	O
1	O
(	O
95	O
%	O
CI	O
3	O
.	O
9	O
-	O
4	O
.	O
3	O
)	O
per	O
1000	O
births	O
,	O
respectively	O
.	O

For	O
both	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-LIVB
across	O
most	O
gestational	O
age	B-LIVB
groups	I-LIVB
,	O
antepartum	B-DISO
haemorrhage	I-DISO
,	O
SGA	B-DISO
,	O
pre	B-DISO
-	I-DISO
existing	I-DISO
diabetes	I-DISO
and	O
pre	B-DISO
-	I-DISO
existing	I-DISO
hypertension	I-DISO
were	O
associated	O
with	O
increased	O
risk	O
of	O
stillbirth	B-DISO
.	O

There	O
were	O
mixed	O
results	O
for	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
and	O
eclampsia	B-DISO
and	O
a	O
consistently	O
raised	O
risk	O
of	O
stillbirth	B-DISO
was	O
not	O
seen	O
for	O
gestational	B-DISO
diabetes	I-DISO
.	O

This	O
study	B-PROC
highlights	O
gestational	B-PHYS
age	I-PHYS
specific	O
stillbirth	B-DISO
risk	O
for	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-LIVB
;	O
and	O
disparity	O
in	O
risk	O
at	O
term	B-PHYS
gestations	I-PHYS
.	O

Improving	O
access	O
to	O
and	O
utilisation	O
of	O
appropriate	O
and	O
responsive	O
healthcare	B-PROC
may	O
help	O
to	O
address	O
disparities	O
in	O
stillbirth	B-DISO
risk	O
for	O
Indigenous	O
women	B-LIVB
.	O

Defining	B-PROC
,	O
Describing	O
,	O
and	O
Categorizing	O
Public	B-PROC
Health	I-PROC
Infrastructure	I-PROC
Priorities	O
for	O
Tropical	B-PHEN
Cyclone	I-PHEN
,	O
Flood	B-PHEN
,	O
Storm	B-PHEN
,	O
Tornado	B-PHEN
,	O
and	O
Tsunami	B-PHEN
-	I-PHEN
Related	I-PHEN
Disasters	I-PHEN
The	O
study	B-PROC
aim	O
was	O
to	O
undertake	O
a	O
qualitative	O
research	O
literature	O
review	O
to	O
analyze	O
available	O
databases	O
to	O
define	B-PROC
,	O
describe	O
,	O
and	O
categorize	O
public	B-PROC
health	I-PROC
infrastructure	I-PROC
(	O
PHI	B-PROC
)	O
priorities	O
for	O
tropical	B-PHEN
cyclone	I-PHEN
,	O
flood	B-PHEN
,	O
storm	B-PHEN
,	O
tornado	B-PHEN
,	O
and	O
tsunami	B-PHEN
-	I-PHEN
related	I-PHEN
disasters	I-PHEN
.	O

Five	O
electronic	O
publication	O
databases	O
were	O
searched	O
to	O
define	B-PROC
,	O
describe	O
,	O
or	O
categorize	O
PHI	B-PROC
and	O
discuss	O
tropical	B-PHEN
cyclone	I-PHEN
,	O
flood	B-PHEN
,	O
storm	B-PHEN
,	O
tornado	B-PHEN
,	O
and	O
tsunami	B-PHEN
-	I-PHEN
related	I-PHEN
disasters	I-PHEN
and	O
their	O
impact	O
on	O
PHI	B-PROC
.	O

The	O
data	O
were	O
analyzed	O
through	O
aggregation	O
of	O
individual	O
articles	O
to	O
create	O
an	O
overall	O
data	O
description	O
.	O

The	O
data	O
were	O
grouped	O
into	O
PHI	B-PROC
themes	O
,	O
which	O
were	O
then	O
prioritized	O
on	O
the	O
basis	O
of	O
degree	O
of	O
interdependency	O
.	O

Sixty	O
-	O
seven	O
relevant	O
articles	O
were	O
identified	O
.	O

PHI	B-PROC
was	O
categorized	O
into	O
13	O
themes	O
with	O
a	O
total	O
of	O
158	O
descriptors	O
.	O

The	O
highest	O
priority	O
PHI	B-PROC
identified	O
was	O
workforce	O
.	O

This	O
was	O
followed	O
by	O
water	B-OBJC
,	O
sanitation	O
,	O
equipment	B-OBJC
,	O
communication	O
,	O
physical	B-OBJC
structure	I-OBJC
,	O
power	B-OBJC
,	O
governance	O
,	O
prevention	O
,	O
supplies	O
,	O
service	O
,	O
transport	B-OBJC
,	O
and	O
surveillance	O
.	O

This	O
review	O
identified	O
workforce	O
as	O
the	O
most	O
important	O
of	O
the	O
13	O
thematic	O
areas	O
related	O
to	O
PHI	B-PROC
and	O
disasters	B-PHEN
.	O

If	O
its	O
functionality	O
fails	O
,	O
workforce	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
performance	O
of	O
health	B-PROC
services	I-PROC
.	O

If	O
addressed	O
post	O
-	O
disaster	O
,	O
the	O
remaining	O
forms	O
of	O
PHI	B-PROC
will	O
then	O
be	O
progressively	O
addressed	O
.	O

These	O
findings	O
are	O
a	O
step	O
toward	O
providing	O
an	O
evidence	O
base	O
to	O
inform	O
PHI	B-PROC
priorities	O
in	O
the	O
disaster	B-PHEN
setting	O
.	O

(	O
Disaster	O
Med	O
Public	O
Health	O
Preparedness	O
.	O
2016	O
;	O
10	O
:	O
598	O
-	O
610	O
)	O
.	O

Baby	O
FaceTime	O
:	O
can	O
toddlers	B-LIVB
learn	B-PHYS
from	O
online	O
video	O
chat	O
?	O
There	O
is	O
abundant	O
evidence	O
for	O
the	O
'	O
video	O
deficit	O
'	O
:	O
children	B-LIVB
under	B-DISO
2	I-DISO
years	I-DISO
old	O
learn	B-PHYS
better	I-PHYS
in	O
person	O
than	O
from	O
video	O
.	O

We	O
evaluated	O
whether	O
these	O
findings	B-DISO
applied	O
to	O
video	O
chat	O
by	O
testing	O
whether	O
children	B-LIVB
aged	O
12	O
-	O
25	O
months	O
could	O
form	O
relationships	O
with	O
and	O
learn	B-PHYS
from	O
on	O
-	O
screen	O
partners	O
.	O

We	O
manipulated	O
social	O
contingency	O
:	O
children	B-LIVB
experienced	O
either	O
real	O
-	O
time	O
FaceTime	O
conversations	O
or	O
pre	B-OBJC
-	I-OBJC
recorded	I-OBJC
Videos	I-OBJC
as	O
the	O
partner	O
taught	O
novel	O
words	O
,	O
actions	O
and	O
patterns	O
.	O

Children	B-LIVB
were	O
attentive	B-PHYS
and	O
responsive	O
in	O
both	O
conditions	O
,	O
but	O
only	O
children	B-LIVB
in	O
the	O
FaceTime	O
group	O
responded	O
to	O
the	O
partner	O
in	O
a	O
temporally	O
synced	O
manner	O
.	O

After	O
one	O
week	O
,	O
children	B-LIVB
in	O
the	O
FaceTime	O
condition	O
(	O
but	O
not	O
the	O
Video	O
condition	O
)	O
preferred	O
and	O
recognized	B-PHYS
their	O
Partner	O
,	O
learned	B-DISO
more	O
novel	O
patterns	O
,	O
and	O
the	O
oldest	O
children	B-LIVB
learned	B-DISO
more	O
novel	O
words	O
.	O

Results	O
extend	O
previous	O
studies	B-PROC
to	O
demonstrate	O
that	O
children	B-LIVB
under	O
2	O
years	O
show	O
social	B-PHYS
and	O
cognitive	B-PHYS
learning	I-PHYS
from	O
video	O
chat	O
because	O
it	O
retains	O
social	O
contingency	O
.	O

A	O
video	O
abstract	O
of	O
this	O
article	O
can	O
be	O
viewed	O
at	O
:	O
https	O
:	O
/	O
/	O
youtu	O
.	O

be	O
/	O
rTXaAYd5adA	O
.	O

Fragment	B-CHEM
-Based	O
Discovery	O
of	O
5	B-CHEM
-	I-CHEM
Arylisatin	I-CHEM
-Based	O
Inhibitors	B-CHEM
of	O
Matrix	B-CHEM
Metalloproteinases	I-CHEM
2	I-CHEM
and	O
13	B-CHEM
Matrix	B-CHEM
metalloproteinases	I-CHEM
(	O
MMPs	B-CHEM
)	O
are	O
well	O
-	O
established	O
targets	O
for	O
several	O
pathologies	B-DISO
.	O

In	O
particular	O
,	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O
MMP	B-CHEM
-	I-CHEM
13	I-CHEM
play	O
a	O
prominent	O
role	O
in	O
cancer	B-DISO
progression	I-DISO
.	O

In	O
this	O
study	B-PROC
,	O
a	O
structure	B-PROC
-	I-PROC
based	I-PROC
screening	I-PROC
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	B-CHEM
-oriented	O
fragments	B-CHEM
.	O

This	O
computational	O
model	O
was	O
applied	O
to	O
a	O
representative	O
fragment	B-CHEM
set	O
from	O
the	O
publically	O
available	O
EDASA	O
Scientific	O
compound	O
library	O
.	O

These	O
fragments	B-CHEM
were	O
prioritized	O
,	O
and	O
the	O
top	O
-	O
ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-PROC
assay	I-PROC
to	O
validate	B-PROC
the	O
model	O
.	O

Two	O
scaffolds	B-CHEM
showed	O
consistent	O
activity	O
in	O
the	O
assay	B-PROC
,	O
and	O
the	O
isatin	B-CHEM
-	I-CHEM
based	I-CHEM
compounds	I-CHEM
were	O
the	O
most	O
interesting	O
.	O

These	O
latter	O
fragments	B-CHEM
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	O
and	O
realization	O
of	O
novel	O
MMP	B-CHEM
inhibitors	I-CHEM
.	O

In	O
addition	O
to	O
their	O
micromolar	O
activity	O
,	O
the	O
chemical	B-PHEN
synthesis	I-PHEN
affords	O
flexible	O
and	O
creative	O
access	O
to	O
their	O
analogues	B-CHEM
.	O

Dental	B-LIVB
Students	I-LIVB
'	O
Educational	B-PHEN
Environment	I-PHEN
and	O
Perceived	B-PHYS
Stress	B-DISO
:	O
The	O
University	B-OBJC
of	I-OBJC
Malaya	I-OBJC
Experience	B-PHYS
An	O
equitable	O
and	O
positive	O
learning	O
environment	O
fosters	O
deep	O
self	B-PROC
-	I-PROC
directed	I-PROC
learning	I-PROC
in	O
students	B-LIVB
and	O
,	O
consequently	O
,	O
good	O
practice	B-PHYS
in	O
their	O
profession	O
.	O

Although	O
demotivating	O
weaknesses	O
may	O
lead	O
to	O
repeated	O
day	O
-	O
to	O
-	O
day	O
stress	B-DISO
with	O
a	O
cascade	O
of	O
deleterious	O
consequences	O
at	O
both	O
personal	B-PHYS
and	O
professional	O
levels	O
,	O
a	O
possible	O
relationship	O
between	O
these	O
parameters	B-DISO
has	O
not	O
been	O
reported	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
relationship	O
between	O
students	B-LIVB
'	O
perceptions	B-PHYS
of	O
their	O
educational	B-PHEN
environment	I-PHEN
and	O
their	O
stress	B-DISO
levels	O
.	O

Sixty	O
-	O
one	O
first	O
year	O
students	B-LIVB
at	O
the	O
Dental	B-LIVB
Faculty	I-LIVB
,	O
University	B-OBJC
of	I-OBJC
Malaya	I-OBJC
,	O
Malaysia	B-GEOG
participated	O
.	O

The	O
Dundee	O
Ready	O
Education	O
Environment	O
Measure	O
(	O
DREEM	O
)	O
was	O
used	O
to	O
determine	O
educational	B-PHEN
environment	I-PHEN
while	O
self	O
-	O
rated	O
perceived	B-PHYS
stress	B-DISO
level	O
was	O
measured	O
by	O
the	O
Depression	O
Anxiety	O
Stress	O
Scale	O
(	O
DASS	O
)	O
.	O

Most	O
students	B-LIVB
(	O
62	O
.	O
39	O
%	O
)	O
showed	O
positive	O
perceptions	B-PHYS
for	O
the	O
total	O
and	O
five	O
domains	O
of	O
DREEM	O
.	O

The	O
highest	O
percentage	O
was	O
observed	O
for	O
""""	O
Students	B-LIVB
perception	B-PHYS
of	O
learning	B-PHYS
""""	O
(	O
64	O
.	O
04	O
%	O
)	O
while	O
the	O
lowest	O
was	O
for	O
""""	O
Students	B-LIVB
'	O
social	O
self	O
-	O
perception	B-PHYS
""""	O
(	O
60	O
.	O
32	O
%	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
61	O
%	O
of	O
students	B-LIVB
showed	O
high	O
perceived	B-PHYS
stress	B-DISO
levels	I-DISO
.	O

However	O
,	O
this	O
was	O
not	O
associated	O
with	O
their	O
DREEM	O
scores	O
.	O

Although	O
a	O
positive	O
perception	B-PHYS
of	O
their	O
educational	B-PHEN
environment	I-PHEN
was	O
found	O
,	O
minor	O
corrective	O
measures	O
need	O
to	O
be	O
implemented	O
.	O

Furthermore	O
,	O
longitudinal	B-PROC
studies	I-PROC
on	O
an	O
annual	O
basis	O
would	O
provide	O
useful	O
input	O
for	O
strategic	O
planning	O
purposes	O
.	O

Bacterial	O
Suppression	O
of	O
RNA	B-CHEM
Polymerase	I-CHEM
II	I-CHEM
-	O
Dependent	O
Host	B-LIVB
Gene	B-PHYS
Expression	I-PHYS
Asymptomatic	B-DISO
bacteriuria	I-DISO
(	O
ABU	B-DISO
)	O
is	O
a	O
bacterial	O
carrier	O
state	O
in	O
the	O
urinary	B-ANAT
tract	I-ANAT
that	O
resembles	O
commensalism	B-PHEN
at	O
other	O
mucosal	O
sites	O
.	O

ABU	B-DISO
strains	B-LIVB
often	O
lack	O
the	O
virulence	B-CHEM
factors	I-CHEM
that	O
characterize	O
uropathogenic	B-LIVB
Escherichia	I-LIVB
coli	I-LIVB
(	I-LIVB
E	I-LIVB
.	I-LIVB
coli	I-LIVB
)	I-LIVB
strains	I-LIVB
and	O
therefore	O
elicit	O
weak	O
innate	B-PHYS
immune	I-PHYS
responses	I-PHYS
in	O
the	O
urinary	B-ANAT
tract	I-ANAT
.	O

In	O
addition	O
,	O
ABU	B-DISO
strains	B-LIVB
are	O
active	O
modifiers	O
of	O
the	O
host	B-LIVB
environment	O
,	O
which	O
they	O
influence	O
by	O
suppressing	O
RNA	B-CHEM
polymerase	I-CHEM
II	I-CHEM
(	O
Pol	B-CHEM
II	I-CHEM
)	O
-	O
dependent	O
host	B-LIVB
gene	B-PHYS
expression	I-PHYS
.	O

In	O
patients	B-LIVB
inoculated	O
with	O
the	O
ABU	B-DISO
strain	B-LIVB
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB

,	O
gene	B-PHYS
expression	I-PHYS
was	O
markedly	O
reduced	O
after	O
24	O
h	O
(	O
>	O
60	O
%	O
of	O
all	O
regulated	O
genes	O
)	O
.	O

Specific	O
repressors	B-CHEM
and	O
activators	B-CHEM
of	O
Pol	B-CHEM
II	I-CHEM
-	O
dependent	O
transcription	B-PHYS
were	O
modified	O
,	O
and	O
Pol	B-PHYS
II	I-PHYS
Serine	I-PHYS
2	I-PHYS
phosphorylation	I-PHYS
was	O
significantly	O
inhibited	O
,	O
indicating	O
reduced	O
activity	B-PHYS
of	O
the	O
polymerase	B-CHEM
.	O

This	O
active	O
inhibition	O
included	O
disease	B-DISO
-associated	O
innate	B-PHYS
immune	I-PHYS
response	I-PHYS
pathways	B-PHYS
,	O
defined	O
by	O
TLR4	B-CHEM
,	O
IRF	B-CHEM
-	I-CHEM
3	I-CHEM
and	O
IRF	B-CHEM
-	I-CHEM
7	I-CHEM
,	O
suggesting	O
that	O
ABU	B-DISO
strains	B-LIVB
persist	O
in	O
human	B-LIVB
hosts	B-LIVB
by	O
active	O
suppression	O
of	O
the	O
antibacterial	B-PHYS
defense	I-PHYS
.	O

In	O
a	O
search	O
for	O
the	O
mechanism	O
of	O
inhibition	O
,	O
we	O
compared	O
the	O
whole	O
genome	O
sequences	O
of	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB
and	O
the	O
uropathogenic	B-LIVB
strain	I-LIVB
E	I-LIVB
.	I-LIVB

coli	I-LIVB
CFT073	I-LIVB
.	O

In	O
addition	O
to	O
the	O
known	O
loss	O
of	O
virulence	B-PHEN
genes	O
,	O
we	O
observed	O
that	O
the	O
ABU	B-DISO
strain	B-LIVB
has	O
acquired	O
several	O
phages	B-LIVB
and	O
identified	O
the	O
lytic	B-LIVB
Prophage	I-LIVB
3	I-LIVB
as	O
a	O
candidate	O
Pol	B-CHEM
II	I-CHEM
inhibitor	O
.	O

Intact	O
phage	B-LIVB
particles	O
were	O
released	O
by	O
ABU	B-DISO
during	O
in	O
vitro	O
growth	B-PHYS
in	O
human	B-LIVB
urine	B-ANAT
.	O

To	O
address	O
if	O
Prophage	B-LIVB
3	I-LIVB
affects	O
Pol	B-CHEM
II	I-CHEM
activity	B-PHYS
,	O
we	O
constructed	O
a	O
Prophage	B-LIVB
3	I-LIVB
negative	O
deletion	B-PHYS
mutant	I-PHYS
in	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB
and	O
compared	O
the	O
effect	O
on	O
Pol	B-PHYS
II	I-PHYS
phosphorylation	I-PHYS
between	O
the	O
mutant	O
and	O
the	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB
wild	O
type	O
(	O
WT	O
)	O
strains	B-LIVB
.	O

No	O
difference	O
was	O
detected	O
,	O
suggesting	O
that	O
the	O
Pol	B-CHEM
II	I-CHEM
inhibitor	O
is	O
not	O
encoded	O
by	O
the	O
phage	B-LIVB
.	O

The	O
review	O
summarizes	O
the	O
evidence	O
that	O
the	O
ABU	B-DISO
strain	B-LIVB
E	B-LIVB
.	I-LIVB
coli	I-LIVB
83972	I-LIVB
modifies	O
host	B-LIVB
gene	B-PHYS
expression	I-PHYS
by	O
inhibition	O
of	O
Pol	B-PHYS
II	I-PHYS
phosphorylation	I-PHYS
,	O
and	O
discusses	O
the	O
ability	O
of	O
ABU	B-DISO
strains	B-LIVB
to	O
actively	O
create	O
an	O
environment	O
that	O
enhances	O
their	O
persistence	B-PHYS
.	O

Regulation	B-PHYS
of	O
ABCA1	O
and	O
ABCG1	O
gene	B-PHYS
expression	I-PHYS
in	O
the	O
intraabdominal	O
adipose	O
tissue	O
Tissue	B-PHYS
specific	I-PHYS
expression	I-PHYS
of	I-PHYS
genes	I-PHYS
encoding	O
cholesterol	B-CHEM
transporters	B-CHEM
ABCA1	B-CHEM
and	O
ABCG1	B-CHEM
as	O
well	O
as	O
genes	O
encoding	O
the	O
most	O
important	O
transcriptional	B-PHYS
regulators	B-CHEM
of	O
adipogenesis	B-PHYS
-	O
LXRa	B-CHEM
,	O
LXRb	B-CHEM
,	O
PPARg	B-CHEM
and	O
RORa	B-CHEM
has	O
been	O
investigated	O
in	O
intraabdominal	O
adipose	O
tissue	O
(	O
IAT	O
)	O
samples	B-OBJC
.A	O

direct	O
correlation	O
between	O
the	O
content	O
of	O
ABCA1	B-CHEM
and	O
ABCG1	B-CHEM
proteins	I-CHEM
with	O
RORa	B-CHEM
protein	I-CHEM
level	O
(	O
r	O
=	O
0	O
.	O
480	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
435	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
suggests	O
the	O
role	O
of	O
the	O
transcription	B-CHEM
factor	I-CHEM
RORa	B-CHEM
in	O
the	O
regulation	B-PHEN
of	O
IAT	O
ABCA1	B-CHEM
and	O
ABCG1	B-CHEM
protein	I-CHEM
levels	O
.	O

ABCA1	O
and	O
ABCG1	O
gene	B-PHYS
expression	I-PHYS
positively	O
correlated	O
with	O
obesity	B-DISO
indicators	B-CHEM
such	O
as	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O
BMI	B-PHYS
)	O
(	O
r	O
=	O
0	O
.	O

522	O
,	O
p	O
=	O
0	O
.	O
004	O
;	O
r	O
=	O
0	O
.	O

594	O
,	O
p	O
=	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
waist	B-PHYS
circumference	I-PHYS
(	O
r	O
=	O
0	O
.	O
403	O
,	O
p	O
=	O
0	O
.	O
033	O
;	O
r	O
=	O
0	O
.	O

474	O
,	O
p	O
=	O
0	O
.	O
013	O
,	O
respectively	O
)	O
.	O

The	O
development	O
of	O
obesity	B-DISO
is	O
associated	O
with	O
decreased	O
IAT	O
levels	O
of	O
RORa	O
and	O
LXRb	O
mRNA	B-CHEM
(	O
p	O
=	O
0	O
.	O
016	O
and	O
p	O
=	O
0	O
.	O

002	O
,	O
respectively	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
nuclear	B-CHEM
factor	I-CHEM
RORa	I-CHEM
can	O
play	O
a	O
significant	O
role	O
in	O
the	O
regulation	B-PHEN
of	O
cholesterol	B-PHYS
metabolism	I-PHYS
and	O
control	O
IAT	O
expression	B-PHYS
of	O
ABCA1	B-CHEM
and	O
ABCG1	B-CHEM
,	O
while	O
the	O
level	O
of	O
IAT	O
LXRb	O
gene	B-PHYS
expression	I-PHYS
may	O
be	O
an	O
important	O
factor	O
associated	O
with	O
the	O
development	O
of	O
obesity	B-DISO
.	O

Evaluation	O
of	O
the	O
effects	O
of	O
an	O
offer	O
of	O
a	O
monetary	B-OBJC
incentive	O
on	O
the	O
rate	O
of	O
questionnaire	O
return	O
during	O
follow	B-PROC
-	I-PROC
up	I-PROC
of	O
a	O
clinical	B-PROC
trial	I-PROC
:	O
a	O
randomised	B-PROC
study	I-PROC
within	I-PROC
a	I-PROC
trial	I-PROC
A	O
systematic	O
review	O
on	O
the	O
use	O
of	O
incentives	O
to	O
promote	O
questionnaire	O
return	O
in	O
clinical	B-PROC
trials	I-PROC
suggest	O
they	O
are	O
effective	O
,	O
but	O
not	O
all	O
studies	B-PROC
have	O
sufficient	O
funds	O
to	O
use	O
them	O
.	O

Promising	O
an	O
incentive	O
once	O
data	O
are	O
returned	O
can	O
reduce	O
the	O
cost	O
-	O
burden	O
of	O
this	O
approach	O
,	O
with	O
possible	O
further	O
cost	O
-	O
savings	O
if	O
the	O
offer	O
were	O
restricted	O
to	O
reminder	O
letters	O
only	O
.	O

This	O
study	B-PROC
aimed	O
to	O
evaluate	B-PROC
the	O
effect	O
of	O
promising	O
a	O
monetary	B-OBJC
incentive	O
at	O
first	O
mailout	B-OBJC
versus	O
a	O
promise	O
on	O
reminder	O
letters	O
only	O
.	O

This	O
was	O
a	O
randomised	B-PROC
Study	I-PROC
Within	I-PROC
A	I-PROC
Trial	I-PROC
(	O
SWAT	B-PROC
)	O
nested	O
within	O
BUMPES	B-PROC
,	O
a	O
multicentre	B-PROC
randomised	I-PROC
controlled	I-PROC
trial	I-PROC
of	O
maternal	B-DISO
position	O
in	O
the	O
late	O
stage	O
of	O
labour	B-PHYS
in	O
women	B-LIVB
with	O
an	O
epidural	B-ANAT
.	O

The	O
follow	B-PROC
-	I-PROC
up	I-PROC
questionnaire	O
asked	O
for	O
information	O
on	O
the	O
women	O
's	O
health	O
,	O
wellbeing	O
and	O
health	B-PROC
service	I-PROC
use	O
one	O
year	O
following	O
the	O
birth	B-PHYS
of	O
their	O
baby	B-LIVB
.	O

Women	B-LIVB
who	O
consented	O
to	O
be	O
contacted	O
were	O
randomised	B-PROC
to	O
a	O
promise	O
of	O
a	O
monetary	B-OBJC
incentive	O
at	O
first	O
mailout	B-OBJC
or	O
a	O
promise	O
on	O
reminder	O
letters	O
only	O
.	O

Women	B-LIVB
were	O
given	O
an	O
option	O
of	O
completing	O
the	O
questionnaire	O
on	O
paper	B-OBJC
or	O
on	O
online	B-OBJC
.	O

The	O
incentive	O
was	O
posted	B-OBJC
out	I-OBJC
on	O
receipt	O
of	O
a	O
completed	O
questionnaire	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
overall	O
return	O
rate	O
,	O
and	O
secondary	O
outcomes	O
were	O
the	O
return	O
rate	O
without	O
any	O
chasing	O
from	O
the	O
study	B-OBJC
office	I-OBJC
,	O
and	O
the	O
total	O
cost	O
of	O
the	O
vouchers	O
.	O

A	O
total	O
of	O
1	O
,	O
029	O
women	B-LIVB
were	O
randomised	B-PROC
,	O
508	O
to	O
the	O
first	O
mailout	B-OBJC
group	O
and	O
518	O
to	O
the	O
reminder	O
group	O
.	O

There	O
was	O
no	O
evidence	O
to	O
suggest	O
a	O
difference	O
between	O
groups	O
in	O
the	O
overall	O
return	O
rate	O
(	O
adjusted	O
RR	O
1	O
.	O
03	O
(	O
95	O
%	O
CI	O
0	O
.	O
96	O
to	O
1	O
.	O
11	O
)	O
,	O
however	O
the	O
proportion	O
returned	O
without	O
chasing	O
was	O
higher	O
in	O
the	O
first	O
mailout	B-OBJC
group	O
(	O
adjusted	O
RR	O
1	O
.	O
22	O
,	O
95	O
%	O
CI	O
1	O
.	O

07	O
to	O
1	O
.	O
39	O
)	O
.	O

The	O
total	O
cost	O
of	O
the	O
vouchers	O
per	O
participant	B-LIVB
was	O
higher	O
in	O
the	O
first	O
mailout	B-OBJC
group	O
(	O
mean	O
difference	O
£	O
4	O
.	O
56	O
,	O
95	O
%	O
CI	O
£	O
4	O
.	O

02	O
to	O
£	O
5	O
.	O
11	O
)	O
.	O

Offering	O
a	O
monetary	B-OBJC
incentive	O
when	O
a	O
reminder	O
is	O
required	O
could	O
be	O
cost	O
-	O
effective	O
depending	O
on	O
the	O
sample	O
size	O
of	O
the	O
study	B-PROC
and	O
the	O
resources	O
available	O
to	O
administer	O
the	O
reminder	O
letters	O
.	O

The	O
BUMPES	B-PROC
Trial	I-PROC
is	O
registered	B-PROC
with	O
Current	B-PROC
Controlled	I-PROC
Trials	I-PROC
:	O
ISRCTN35706297	O
,	O
26	O
(	O
th	O
)	O
August	O
2009	O
.	O

HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
expression	B-PHYS
and	O
high	O
microvessel	O
density	O
are	O
characteristic	O
features	O
in	O
serrated	B-DISO
colorectal	I-DISO
cancer	I-DISO
Serrated	B-DISO
colorectal	I-DISO
adenocarcinoma	I-DISO
(	O
SAC	B-DISO
)	O
is	O
a	O
morphologically	O
distinct	O
subtype	O
of	O
colorectal	B-DISO
cancer	I-DISO
(	O
CRC	B-DISO
)	O
,	O
in	O
which	O
increased	O
HIF	O
-	O
1α	O
mRNA	B-PHYS
expression	I-PHYS
and	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	I-CHEM
stabilization	B-PHYS
are	O
typical	O
features	O
.	O

Here	O
we	O
aimed	O
to	O
further	O
elucidate	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	B-PHYS
expression	I-PHYS
in	O
serrated	B-DISO
and	O
non	B-DISO
-	I-DISO
serrated	I-DISO
colorectal	I-DISO
carcinomas	I-DISO
(	O
CRCs	B-DISO
)	O
and	O
their	O
precursor	B-DISO
lesions	I-DISO
and	O
its	O
association	O
with	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
(	O
VEGF	B-CHEM
)	O
and	O
microvascular	O
density	O
(	O
MVD	O
)	O
.	O

HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
and	O
VEGF	B-CHEM
expressions	B-PHYS
were	O
determined	O
immunohistochemically	B-PROC
in	O
134	O
serrated	B-DISO
polyps	I-DISO
(	O
SPs	B-DISO
)	O
,	O
104	O
non	B-DISO
-	I-DISO
serrated	I-DISO
adenomas	I-DISO
(	O
NSAs	B-DISO
)	O
,	O
81	O
SACs	B-DISO
,	O
and	O
74	O
matched	O
conventional	B-DISO
adenocarcinomas	I-DISO
(	O
CCs	B-DISO
)	O
and	O
were	O
correlated	O
with	O
morphology	O
,	O
clinicopathological	O
features	O
,	O
and	O
MVD	O
.	O

In	O
premalignant	B-DISO
lesions	I-DISO
,	O
both	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
and	O
VEGF	B-CHEM
were	O
expressed	B-PHYS
in	O
the	O
vast	O
majority	O
of	O
SPs	B-DISO
and	O
NSAs	B-DISO
.	O

In	O
CRCs	B-DISO
,	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	I-CHEM
was	O
also	O
present	O
in	O
77	O
.	O

8	O
%	O
of	O
SACs	B-DISO
,	O
while	O
only	O
20	O
.	O
3	O
%	O
of	O
CCs	B-DISO
were	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
proficient	O
.	O

MVD	O
was	O
significantly	O
higher	O
in	O
SACs	B-DISO
,	O
but	O
the	O
serrated	B-DISO
morphology	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
MVD	O
in	O
CRC	B-DISO
in	O
multivariate	O
analyses	O
.	O

HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	I-CHEM
is	O
often	O
stabilized	B-PROC
in	O
well	O
-	O
vascularized	O
SACs	B-DISO
,	O
suggesting	O
hypoxia	B-DISO
-	O
independent	B-PROC
stabilization	I-PROC
of	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
.	O

Moreover	O
,	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
stabilization	B-PHYS
did	O
not	O
associate	O
with	O
oncogenic	B-CHEM
activation	B-PHYS
of	O
BRAF	O
or	O
KRAS	O
or	O
Von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
mutation	B-PHYS
.	O

Prevalent	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
expression	B-PHYS
in	O
SAC	B-DISO
and	O
its	O
precursors	O
support	O
the	O
importance	O
of	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
-mediated	O
pathways	B-PHYS
for	O
the	O
serrated	B-DISO
route	I-DISO
of	I-DISO
colorectal	I-DISO
carcinogenesis	I-DISO
.	O

Structure	O
-	O
Activity	O
Studies	O
of	O
β	B-CHEM
-	I-CHEM
Hairpin	I-CHEM
Peptide	B-CHEM
Inhibitors	B-CHEM
of	O
the	O
Plasmodium	O
falciparum	O
AMA1	B-CHEM
-	O
RON2	B-CHEM
Interaction	B-PHYS
The	O
interaction	B-PHYS
between	O
apical	B-CHEM
membrane	I-CHEM
antigen	I-CHEM
1	I-CHEM
(	O
AMA1	B-CHEM
)	O
and	O
rhoptry	B-CHEM
neck	I-CHEM
protein	I-CHEM
2	I-CHEM
(	O
RON2	B-CHEM
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
invasion	B-DISO
of	O
red	B-ANAT
blood	I-ANAT
cells	I-ANAT
by	O
Plasmodium	O
parasites	O
.	O

Disruption	O
of	O
this	O
critical	O
protein	B-PHYS
-	I-PHYS
protein	I-PHYS
interaction	I-PHYS
represents	O
a	O
promising	O
avenue	O
for	O
antimalarial	B-CHEM
drug	B-PROC
discovery	I-PROC
.	O

In	O
this	O
work	O
,	O
we	O
exploited	O
a	O
13	B-CHEM
-	I-CHEM
residue	I-CHEM
β	I-CHEM
-	I-CHEM
hairpin	I-CHEM
based	O
on	O
the	O
C	O
-	O
terminal	O
loop	O
of	O
RON2	B-CHEM
to	O
probe	B-DEVI
a	O
conserved	O
binding	B-CHEM
site	I-CHEM
on	O
Plasmodium	O
falciparum	O
AMA1	B-CHEM
.	O

A	O
series	O
of	O
mutations	B-PHYS
was	O
synthetically	O
engineered	B-PROC
into	O
β	B-CHEM
-	I-CHEM
hairpin	I-CHEM
peptides	B-CHEM
to	O
establish	O
structure	O
-	O
activity	O
relationships	O
.	O

The	O
best	O
mutations	B-PHYS
improved	O
the	O
binding	O
affinity	B-PHEN
of	O
the	O
β	B-CHEM
-	I-CHEM
hairpin	I-CHEM
peptide	B-CHEM
by	O
~7	O
-	O
fold	O
for	O
3D7	O
AMA1	B-CHEM
and	O
~14	O
-	O
fold	O
for	O
FVO	O
AMA1	B-CHEM
.	O

We	O
determined	O
the	O
crystal	B-CHEM
structures	I-CHEM
of	O
several	O
β	B-CHEM
-	I-CHEM
hairpin	I-CHEM
peptides	B-CHEM
in	O
complex	O
with	O
AMA1	B-CHEM
in	O
order	O
to	O
define	O
the	O
structural	B-CHEM
features	I-CHEM
and	O
specific	O
interactions	B-PHYS
that	O
contribute	O
to	O
improved	B-DISO
binding	O
affinity	B-PHEN
.	O

The	O
same	O
mutations	B-PHYS
in	O
the	O
longer	O
RON2sp2	B-CHEM
peptide	I-CHEM
(	O
residues	O
2027	O
-	O
2055	O
of	O
RON2	B-CHEM
)	O
increased	O
the	O
binding	O
affinity	B-PHEN
by	O
>	O
30	O
-	O
fold	O
for	O
3D7	O
and	O
FVO	O
AMA1	B-CHEM
,	O
producing	O
KD	O
values	O
of	O
2	O
.	O

1nM	O
and	O
0	O
.	O
4nM	O
,	O
respectively	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
most	O
potent	O
strain	O
-transcending	O
peptide	B-CHEM
reported	O
to	O
date	O
and	O
represents	O
a	O
valuable	O
tool	O
to	O
characterize	O
the	O
AMA1	B-CHEM
-	O
RON2	B-CHEM
interaction	B-PHYS
.	O

Haemophilus	B-DISO
influenzae	I-DISO
type	I-DISO
b	I-DISO
meningitis	I-DISO
in	O
a	O
vaccinated	B-PROC
and	O
immunocompetent	B-PHYS
child	B-LIVB
Invasive	B-DISO
Haemophilus	I-DISO
influenzae	I-DISO
type	I-DISO
b	I-DISO
(	I-DISO
Hib	I-DISO
)	I-DISO
disease	I-DISO
decreased	O
dramatically	O
after	O
the	O
introduction	O
of	O
conjugate	B-CHEM
vaccine	I-CHEM
in	O
routine	O
immunization	B-PROC
schedules	I-PROC
.	O

We	O
report	O
a	O
case	O
of	O
a	O
fifteen	O
-	O
months	O
-	O
old	O
girl	B-LIVB
,	O
previously	O
healthy	O
and	O
vaccinated	B-PROC
,	O
admitted	B-PROC
in	O
the	O
emergency	B-OBJC
room	I-OBJC
with	O
fever	B-DISO
and	O
vomiting	B-DISO
.	O

She	O
was	O
irritable	B-DISO
and	O
the	O
Brudzinski	B-DISO
's	I-DISO
sign	I-DISO
was	O
positive	B-DISO
.	O

The	O
cerebrospinal	B-ANAT
fluid	I-ANAT
(	O
CSF	B-ANAT
)	O
analysis	O
showed	O
pleocytosis	B-DISO
and	O
high	B-PHEN
protein	I-PHEN
level	I-PHEN
.	O

Empiric	O
intravenous	O
antibiotics	B-CHEM
(	O
ceftriaxone	B-CHEM
and	O
vancomycin	B-CHEM
)	O
were	O
administered	B-PROC
for	O
suspected	O
bacterial	B-DISO
meningitis	I-DISO
during	O
10	O
days	O
.	O

Serotyping	B-PROC
of	O
the	O
Haemophilus	B-LIVB
influenzae	I-LIVB
strain	I-LIVB
found	O
in	O
CSF	B-ANAT
revealed	O
a	O
serotype	O
b	O
.	O

After	O
one	O
year	O
of	O
follow	B-PROC
-	I-PROC
up	I-PROC
no	B-DISO
Hib	I-DISO
meningitis	I-DISO
sequelae	O
were	O
noted	O
.	O

Despite	O
vaccination	B-PROC
compliance	B-DISO
and	O
absence	O
of	O
risk	B-DISO
factors	I-DISO
,	O
invasive	B-DISO
Hib	I-DISO
disease	I-DISO
can	O
occur	O
due	O
to	O
vaccine	B-CHEM
failure	O
.	O

Efforts	O
to	O
keep	O
the	O
low	O
incidence	O
of	O
invasive	B-DISO
Hib	I-DISO
disease	I-DISO
should	O
be	O
directed	O
to	O
the	O
maintenance	O
of	O
high	O
vaccination	B-PROC
coverage	O
rates	O
,	O
combined	O
with	O
the	O
notification	B-PROC
and	O
surveillance	B-PROC
strategies	I-PROC
already	O
implemented	O
in	O
each	O
country	B-GEOG
.	O

BRG1	B-CHEM
in	O
the	O
Nucleus	B-ANAT
Accumbens	I-ANAT
Regulates	O
Cocaine	B-DISO
-	I-DISO
Seeking	I-DISO
Behavior	I-DISO
Drug	B-DISO
addiction	I-DISO
is	O
defined	O
as	O
a	O
chronic	B-DISO
disease	I-DISO
characterized	O
by	O
compulsive	O
drug	B-DISO
seeking	I-DISO
and	O
episodes	O
of	O
relapse	O
despite	O
prolonged	O
periods	O
of	O
drug	O
abstinence	O
.	O

Neurobiological	B-PHEN
adaptations	I-PHEN
,	O
including	O
transcriptional	B-PHYS
and	O
epigenetic	B-PHYS
alterations	I-PHYS
in	O
the	O
nucleus	B-ANAT
accumbens	I-ANAT
,	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
life	B-DISO
-	I-DISO
long	I-DISO
disease	I-DISO
state	I-DISO
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
transcription	B-CHEM
factor	I-CHEM
SMAD3	B-CHEM
is	O
increased	O
after	O
7	O
days	O
of	O
withdrawal	B-DISO
from	I-DISO
cocaine	I-DISO
self	B-PROC
-	I-PROC
administration	I-PROC
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
which	O
additional	O
factors	O
participate	O
in	O
the	O
process	O
of	O
chromatin	B-PHYS
remodeling	I-PHYS
and	O
facilitate	O
the	O
binding	O
of	O
SMAD3	B-CHEM
to	O
promoter	B-CHEM
regions	I-CHEM
of	O
target	O
genes	O
.	O

Here	O
,	O
we	O
examined	O
the	O
possible	O
interaction	B-PHYS
of	O
BRG1	B-CHEM
-also	O
known	O
as	O
SMARCA4	B-CHEM
,	O
an	O
adenosine	B-CHEM
triphosphatase	I-CHEM
-containing	O
chromatin	B-CHEM
remodeler	I-CHEM
-and	O
SMAD3	B-CHEM
in	O
response	O
to	O
cocaine	B-DISO
exposure	I-DISO
.	O

The	O
expression	B-PHYS
of	O
BRG1	B-CHEM
,	O
as	O
well	O
as	O
its	O
binding	O
to	O
SMAD3	B-CHEM
and	O
target	B-CHEM
gene	I-CHEM
promoter	I-CHEM
regions	I-CHEM
,	I-CHEM
was	O
evaluated	O
in	O
the	O
nucleus	B-ANAT
accumbens	I-ANAT
and	O
dorsal	B-ANAT
striatum	I-ANAT
of	O
rats	B-LIVB
using	O
western	B-PROC
blotting	I-PROC
,	O
co	B-PROC
-	I-PROC
immunoprecipitation	I-PROC
,	O
and	O
chromatin	B-PROC
immunoprecipitation	I-PROC
following	O
abstinence	B-PROC
from	O
cocaine	B-PROC
self	I-PROC
-	I-PROC
administration	I-PROC
.	O

Rats	B-LIVB
were	O
assessed	O
for	O
cocaine	B-DISO
-	I-DISO
seeking	I-DISO
behaviors	I-DISO
after	O
either	O
intra	B-PROC
-	I-PROC
accumbal	I-PROC
injections	I-PROC
of	O
the	O
BRG1	B-CHEM
inhibitor	B-CHEM
PFI3	I-CHEM
or	O
viral	B-PHYS
-	I-PHYS
mediated	I-PHYS
overexpression	I-PHYS
of	O
BRG1	B-CHEM
.	O

After	O
withdrawal	B-DISO
from	I-DISO
cocaine	I-DISO
self	B-PROC
-	I-PROC
administration	I-PROC
,	O
BRG1	B-CHEM
expression	B-PHYS
and	O
complex	B-PHYS
formation	I-PHYS
with	I-PHYS
SMAD3	B-CHEM
are	O
increased	O
in	O
the	O
nucleus	B-ANAT
accumbens	I-ANAT
,	O
resulting	O
in	O
increased	O
binding	O
of	O
BRG1	B-CHEM
to	O
the	O
promoter	B-CHEM
regions	I-CHEM
of	O
Ctnnb1	O
,	O
Mef2d	O
,	O
and	O
Dbn1	O
.	O

Intra	B-PROC
-	I-PROC
accumbal	I-PROC
infusion	I-PROC
of	O
PFI3	B-CHEM
attenuated	O
,	O
whereas	O
viral	B-PHYS
overexpression	I-PHYS
of	O
Brg1	O
enhanced	O
,	O
cocaine	O
-	O
reinstatement	O
behavior	O
.	O

BRG1	B-CHEM
is	O
a	O
key	O
mediator	O
of	O
the	O
SMAD3	B-CHEM
-dependent	O
regulation	B-PHYS
of	I-PHYS
cellular	I-PHYS
and	I-PHYS
behavioral	I-PHYS
plasticity	I-PHYS
that	O
mediates	O
cocaine	B-DISO
seeking	I-DISO
after	O
a	O
period	O
of	O
withdrawal	B-DISO
.	O

The	O
blood	B-PHYS
lipid	I-PHYS
regulation	I-PHYS
of	O
Monascus	B-LIVB
-produced	O
monascin	B-CHEM
and	O
ankaflavin	B-CHEM
via	O
the	O
suppression	B-PHYS
of	O
low	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
assembly	O
and	O
stimulation	B-PROC
of	O
apolipoprotein	B-CHEM
A1	I-CHEM
expression	B-PHYS
in	O
the	O
liver	B-ANAT
Monascin	B-CHEM
(	O
MS	B-CHEM
)	O
and	O
ankaflavin	B-CHEM
(	O
AK	B-CHEM
)	O
produced	O
by	O
Monascus	B-LIVB
purpureus	I-LIVB
NTU	I-LIVB
568	I-LIVB
were	O
proven	O
to	O
show	O
excellent	O
hypolipidemic	B-DISO
effects	I-DISO
in	O
our	O
previous	O
studies	B-PROC
;	O
however	O
,	O
the	O
mechanism	B-PHYS
is	O
still	O
unclear	O
.	O

This	O
study	B-PROC
used	O
MS	B-CHEM
,	O
AK	B-CHEM
,	O
and	O
monacolin	B-CHEM
K	I-CHEM
as	O
test	B-OBJC
substances	I-OBJC
and	O
performed	O
tests	O
on	O
rats	B-LIVB
fed	O
high	B-PROC
-	I-PROC
fat	I-PROC
and	O
high	B-PROC
-	I-PROC
cholesterol	I-PROC
diet	I-PROC
for	O
8	O
weeks	O
.	O

The	O
lipid	O
levels	O
and	O
the	O
related	O
protein	O
levels	O
of	O
the	O
rats	B-LIVB
were	O
assessed	O
to	O
understand	O
the	O
effects	O
of	O
MS	B-CHEM
,	O
AK	B-CHEM
,	O
and	O
monacolin	B-CHEM
K	I-CHEM
on	O
lipid	O
metabolism	O
.	O

MS	B-CHEM
and	O
AK	B-CHEM
lowered	O
low	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
(	O
LDL	B-CHEM
-	I-CHEM
C	I-CHEM
)	O
and	O
preserved	O
high	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
contents	O
.	O

MS	B-CHEM
and	O
AK	B-CHEM
inhibited	O
acetyl	B-CHEM
-	I-CHEM
coenzyme	I-CHEM
A	I-CHEM
acetyltransferase	I-CHEM
,	O
microsomal	B-CHEM
triglyceride	I-CHEM
transfer	I-CHEM
protein	I-CHEM
,	O
and	O
apolipoprotein	B-CHEM
(	I-CHEM
apo	I-CHEM
)	I-CHEM
B	I-CHEM
-	I-CHEM
100	I-CHEM
expression	B-PHYS
,	O
thereby	O
preventing	O
LDL	B-CHEM
assembly	B-PHYS
.	O

In	O
addition	O
,	O
enhanced	O
LDL	B-CHEM
-	O
receptor	B-PHYS
expression	I-PHYS
increased	O
the	O
transport	B-PHYS
of	O
LDL	B-CHEM
-	I-CHEM
C	I-CHEM
to	O
the	O
liver	B-ANAT
for	O
metabolism	B-PHYS
.	O

MS	B-CHEM
and	O
AK	B-CHEM
also	O
significantly	O
increase	O
apo	B-CHEM
A1	I-CHEM
expression	B-PHYS
,	O
which	O
facilitates	O
high	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
formation	O
.	O

Monascus	B-LIVB
-	O
fermented	B-PHYS
MS	B-CHEM
and	O
AK	B-CHEM
can	O
perform	O
blood	B-PHYS
lipid	I-PHYS
regulation	I-PHYS
via	O
the	O
suppression	B-PHYS
of	O
LDL	B-CHEM
-	I-CHEM
C	I-CHEM
assembly	B-PHYS
and	O
stimulation	B-PROC
of	O
apo	B-CHEM
A1	I-CHEM
expression	B-PHYS
in	O
liver	B-ANAT
.	O

Acoustic	B-PHEN
Analysis	B-PROC
Before	O
and	O
After	O
Voice	B-PROC
Therapy	I-PROC
for	O
Laryngeal	B-DISO
Pathology	I-DISO
Background	O
Voice	B-DISO
problems	I-DISO
caused	O
by	O
pathologies	O
in	O
vocal	B-DISO
folds	I-DISO
are	O
well	O
known	O
.	O

Some	O
types	O
of	O
laryngeal	B-DISO
pathologies	I-DISO
have	O
certain	O
acoustic	B-PHEN
characteristics	O
.	O

Objective	B-PROC
evaluation	I-PROC
helps	O
characterize	O
the	O
voice	B-PHYS
and	O
voice	B-DISO
problems	I-DISO
providing	O
supporting	O
evidences	O
,	O
severity	O
of	O
disorders	O
.	O

It	O
helps	O
assess	B-PROC
the	O
response	B-PHYS
to	I-PHYS
the	I-PHYS
treatment	I-PHYS
and	O
measures	O
the	O
outcomes	O
.	O

Objective	O
The	O
objective	O
of	O
the	O
study	O
is	O
to	O
determine	O
the	O
effectiveness	O
of	O
the	O
voice	B-PROC
therapy	I-PROC
and	O
quantify	O
the	O
results	O
objectively	O
by	O
voice	B-DISO
parameters	I-DISO
.	O

Method	O
Study	B-PROC
includes	O
61	O
patients	B-LIVB
who	O
presented	O
with	O
different	O
types	O
of	O
laryngeal	B-DISO
pathologies	I-DISO
.	O

Acoustic	B-PHEN
analyses	B-PROC
and	O
voice	B-PROC
assessment	I-PROC
was	O
done	O
with	O
Dr	O
.	O

Speech	O
ver	O
4	O
(	O
Tiger	O
DRS	O
Inc	O
.	O
)	O
.	O

Acoustic	B-PHEN
parameters	O
including	O
fundamental	O
frequency	O
,	O
jitters	B-DISO
,	O
shimmers	O
,	O
Harmonic	O
to	O
noise	O
ratio	O
(	O
HNR	O
)	O
,	O
Normalized	O
noise	O
energy	O
(	O
NNE	O
)	O
were	O
analyzed	O
before	O
and	O
after	O
voice	B-PROC
therapy	I-PROC
.	O

Result	O
Bilateral	O
vocal	B-DISO
nodules	I-DISO
were	O
the	O
most	O
common	O
pathologies	O
comprising	O
44	O
.	O
26	O
%	O
.	O

All	O
acoustic	B-PHEN
parameters	O
showed	O
a	O
significant	O
difference	O
after	O
the	O
therapy	B-PROC
(	O
p	O
<	O
0	O
.	O
05	O
)	O
except	O
for	O
NNE	O
.	O

Dysphonia	B-DISO
due	O
to	O
vocal	B-DISO
fold	I-DISO
polyp	I-DISO
showed	O
no	B-DISO
improvement	I-DISO
even	O
after	O
voice	B-PROC
therapy	I-PROC
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Conclusion	O
Acoustic	B-PHEN
analysis	B-PROC
provides	O
an	O
objective	O
,	O
recordable	O
data	O
regarding	O
the	O
voice	B-DISO
parameters	I-DISO
and	O
its	O
pathologies	O
.	O

Though	O
,	O
few	O
pathology	O
require	O
alternative	B-PROC
therapy	I-PROC
rather	O
than	O
voice	B-PROC
therapy	I-PROC
,	O
overall	O
it	O
has	O
a	O
good	B-DISO
effect	I-DISO
on	O
glottic	B-PHYS
closure	I-PHYS
.	O

As	O
the	O
voice	B-PROC
therapy	I-PROC
can	O
improve	O
the	O
different	O
indices	O
of	O
voice	B-PHYS
,	O
it	O
can	O
be	O
viewed	O
as	O
imperative	O
part	O
of	O
treatment	B-PROC
and	O
to	O
monitor	B-PROC
progression	O
.	O

MALDI	B-PROC
-	I-PROC
TOF	I-PROC
mass	I-PROC
spectrometry	I-PROC
for	O
the	O
identification	O
of	O
lactic	B-LIVB
acid	I-LIVB
bacteria	I-LIVB
isolated	O
from	O
a	O
French	B-OBJC
cheese	I-OBJC
:	O
The	O
Maroilles	B-OBJC
In	O
this	O
study	B-PROC
we	O
identified	O
the	O
culturable	B-PROC
population	B-LIVB
of	O
mesophilic	O
lactic	B-LIVB
acid	I-LIVB
bacteria	I-LIVB
(	O
LAB	B-LIVB
)	O
from	O
a	O
French	B-OBJC
cheese	I-OBJC
Maroilles	I-OBJC
made	O
either	O
with	O
raw	B-OBJC
or	O
pasteurized	B-OBJC
milk	I-OBJC
using	O
MALDI	B-PROC
-	I-PROC
TOF	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O
MS	B-PROC
)	O
.	O

Samples	B-OBJC
from	O
rind	O
and	O
heart	O
of	O
Maroilles	B-OBJC
cheese	I-OBJC
were	O
used	O
,	O
the	O
LAB	B-LIVB
were	O
selected	O
on	O
MRS	B-CHEM
agar	I-CHEM
at	O
30°C	O
and	O
197	O
Gram	B-PHEN
-	I-PHEN
positive	I-PHEN
and	O
catalase	B-PHYS
-	I-PHYS
negative	I-PHYS
strains	O
were	O
subjected	O
to	O
identification	O
by	O
MALDI	B-PROC
-	I-PROC
TOF	I-PROC
MS	I-PROC
profiling	O
.	O

All	O
strains	O
were	O
unambiguously	O
identified	O
:	O
105	O
strains	O
from	O
Maroilles	B-OBJC
made	O
with	O
raw	B-OBJC
milk	I-OBJC
(	O
38	O
on	O
the	O
rind	O
and	O
67	O
in	O
the	O
heart	O
)	O
and	O
92	O
strains	O
from	O
Maroilles	B-OBJC
made	O
with	O
pasteurized	B-OBJC
milk	I-OBJC
(	O
39	O
on	O
the	O
rind	O
and	O
53	O
in	O
the	O
heart	O
)	O
.	O

MALDI	B-PROC
-	I-PROC
TOF	I-PROC
MS	I-PROC
identification	O
allowed	O
identification	O
of	O
three	O
genera	O
belonging	O
to	O
LAB	B-LIVB
including	O
Lactobacillus	B-LIVB
,	O
Enterococcus	B-LIVB
and	O
Leuconostoc	B-LIVB
.	O

Lactobacillus	B-LIVB
was	O
the	O
most	O
represented	O
genus	O
with	O
seven	O
species	O
:	O
Lactobacillus	B-LIVB
plantarum	I-LIVB
(	O
L	B-LIVB
.	I-LIVB
plantarum	I-LIVB
)	O
,	O
L	B-LIVB
.	I-LIVB

paracasei	I-LIVB
,	O
L	B-LIVB
.	I-LIVB

curvatus	I-LIVB
,	O
L	B-LIVB
.	I-LIVB

rhamnosus	I-LIVB
,	O
L	B-LIVB
.	I-LIVB

fructivorans	I-LIVB
,	O
L	B-LIVB
.	I-LIVB

parabuchneri	I-LIVB
,	O
L	B-LIVB
.	I-LIVB

brevis	I-LIVB
found	O
in	O
Maroilles	B-OBJC
made	O
with	O
both	O
kind	O
of	O
milk	B-OBJC
.	O

The	O
correlation	O
between	O
the	O
16S	B-CHEM
rDNA	I-CHEM
-based	O
identification	O
performed	O
on	O
selected	O
strains	O
and	O
those	O
obtained	O
by	O
MALDI	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
demonstrates	O
that	O
this	O
fast	O
,	O
economically	O
affordable	O
,	O
robust	O
and	O
reliable	O
method	O
for	O
bacteria	B-LIVB
characterisation	O
stands	O
as	O
an	O
attractive	O
alternative	O
to	O
the	O
commonly	O
-	O
used	O
methods	O
and	O
its	O
application	O
in	O
food	O
industry	O
is	O
discussed	O
.	O

Is	O
there	O
a	O
role	O
for	O
surgical	B-PROC
resection	I-PROC
in	O
patients	B-LIVB
with	O
pancreatic	B-DISO
cancer	I-DISO
with	O
liver	B-DISO
metastases	I-DISO
responding	O
to	O
chemotherapy	B-PROC
?	O

New	O
chemotherapeutic	B-PROC
regimens	I-PROC
have	O
improved	O
survival	O
for	O
stage	O
IV	O
pancreatic	B-DISO
ductal	I-DISO
adenocarcinoma	I-DISO
and	O
occasionally	O
major	O
response	B-DISO
of	O
liver	B-DISO
metastases	I-DISO
can	O
be	O
observed	O
.	O

Aim	O
of	O
this	O
work	O
is	O
to	O
analyze	O
the	O
outcomes	O
of	O
patients	B-LIVB
undergoing	O
primary	O
chemotherapy	B-PROC
for	O
liver	B-DISO
metastases	I-DISO
from	O
pancreatic	B-DISO
cancer	I-DISO
and	O
to	O
evaluate	B-PROC
the	O
results	B-PHEN
of	O
surgical	B-PROC
resection	I-PROC
.	O

Retrospective	B-PROC
analysis	I-PROC
.	O

patients	B-LIVB
with	O
extra	B-ANAT
-	I-ANAT
hepatic	I-ANAT
metastases	B-DISO
,	O
patients	B-LIVB
with	O
Eastern	B-PHYS
Cooperative	I-PHYS
Oncology	I-PHYS
Group	I-PHYS
performance	I-PHYS
status	I-PHYS
≥3	O
,	O
patients	B-LIVB
undergoing	O
supportive	B-PROC
care	I-PROC
alone	O
.	O

127	O
patients	B-LIVB
were	O
identified	O
.	O

Liver	B-DISO
metastases	I-DISO
were	O
unilobar	O
in	O
28	O
.	O

5	O
%	O
of	O
patients	B-LIVB
.	O

Chemotherapy	B-PROC
regimens	I-PROC
included	O
gemcitabine	B-CHEM
alone	O
or	O
in	O
association	O
with	O
other	O
agents	B-CHEM
(	O
44	O
%	O
)	O
,	O
oxaliplatin	B-CHEM
,	O
irinotecan	B-CHEM
,	O
fluorouracil	B-CHEM
and	O
leucovorin	B-CHEM
(	O
FOLFIRINOX	B-PROC
8	O
%	O
)	O
,	O
and	O
cisplatin	B-CHEM
,	O
gemcitabine	B-CHEM
plus	O
capecitabine	B-CHEM
and	O
epirubicin	B-CHEM
(	O
PEXG	B-PROC
)	O
or	O
capecitabine	B-CHEM
and	O
docetaxel	B-CHEM
(	O
PDXG	B-PROC
)	O
or	O
epirubicin	B-CHEM
and	O
fluorouracil	B-CHEM
(	O
PEFG	B-PROC
)	O
(	O
48	O
%	O
)	O
.	O

56	O
patients	B-LIVB
(	O
44	O
%	O
)	O
had	O
a	O
complete	O
(	O
7	O
%	O
)	O
or	O
partial	O
response	B-DISO
(	O
37	O
%	O
)	O
.	O

surgical	B-PROC
resection	I-PROC
was	O
carried	O
out	O
in	O
11	O
patients	B-LIVB
(	O
8	O
.	O
5	O
%	O
)	O
.	O

Median	O
overall	O
survival	O
was	O
11	O
months	O
for	O
the	O
entire	O
cohort	B-LIVB
and	O
15	O
months	O
for	O
those	O
with	O
partial	O
/	O
complete	O
response	B-DISO
.	O

In	O
this	O
sub	O
-	O
group	O
median	O
survival	O
was	O
significantly	O
longer	O
(	O
46	O
versus	O
11	O
months	O
)	O
for	O
patients	B-LIVB
undergoing	O
resection	B-PROC
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Independent	O
predictors	O
of	O
overall	O
survival	O
were	O
chemotherapy	B-PROC
with	O
multiple	O
agents	B-CHEM
(	O
HR	O
:	O
0	O
.	O
512	O
)	O
,	O
surgical	B-PROC
resection	I-PROC
(	O
HR	O
:	O
0	O
.	O
360	O
)	O
,	O
>	O
5	O
liver	B-DISO
metastases	I-DISO
at	O
diagnosis	B-DISO
(	O
HR	O
:	O
3	O
.	O
515	O
)	O
,	O
and	O
CA	B-PROC
19	I-PROC
.	I-PROC

9	I-PROC
reduction	O
<	O
50	O
%	O
of	O
baseline	O
value	O
(	O
HR	O
:	O
2	O
.	O
708	O
)	O
.	O

Surgical	B-PROC
resection	I-PROC
of	O
primary	O
pancreatic	B-DISO
tumor	I-DISO
with	O
or	O
without	O
residual	O
liver	B-DISO
disease	I-DISO
can	O
be	O
considered	O
in	O
selected	O
cases	O
after	O
primary	O
chemotherapy	B-PROC
and	O
it	O
is	O
associated	O
with	O
improved	B-DISO
survival	O
.	O

Applying	O
a	O
participatory	O
approach	O
to	O
the	O
promotion	O
of	O
a	O
culture	O
of	O
respect	O
during	O
childbirth	B-PHYS
Disrespect	O
and	O
abuse	O
(	O
D	O
&	O
A	O
)	O
during	O
facility	B-OBJC
-	I-OBJC
based	I-OBJC
childbirth	B-PHYS
is	O
a	O
topic	O
of	O
growing	O
concern	O
and	O
attention	O
globally	O
.	O

Several	O
recent	O
studies	B-PROC
have	O
sought	O
to	O
quantify	O
the	O
prevalence	O
of	O
D	O
&	O
A	O
,	O
however	O
little	O
evidence	O
exists	O
about	O
effective	O
interventions	B-PROC
to	O
mitigate	O
disrespect	O
and	O
abuse	O
,	O
and	O
promote	O
respectful	O
maternity	B-PROC
care	I-PROC
.	O

In	O
an	O
accompanying	O
article	O
,	O
we	O
describe	O
the	O
process	O
of	O
selecting	O
,	O
implementing	O
,	O
and	O
evaluating	B-PROC
a	O
package	O
of	O
interventions	B-PROC
designed	O
to	O
prevent	O
and	O
reduce	O
disrespect	O
and	O
abuse	O
in	O
a	O
large	O
urban	O
hospital	O
in	O
Tanzania	B-GEOG
.	O

Though	O
that	O
study	B-PROC
was	O
not	O
powered	O
to	O
detect	B-DISO
a	O
definitive	O
impact	O
on	O
reducing	O
D	O
&	O
A	O
,	O
the	O
results	O
showed	O
important	O
changes	O
in	O
intermediate	O
outcomes	O
associated	O
with	O
this	O
goal	O
.	O

In	O
this	O
commentary	O
,	O
we	O
describe	O
the	O
factors	O
that	O
enabled	O
this	O
effect	O
,	O
especially	O
the	O
participatory	O
approach	O
we	O
adopted	O
to	O
engage	O
key	O
stakeholders	O
throughout	O
the	O
planning	B-PHYS
and	O
implementation	O
of	O
the	O
program	O
.	O

Based	O
on	O
our	O
experience	O
and	O
findings	O
,	O
we	O
conclude	O
that	O
a	O
visible	O
,	O
sustained	O
,	O
and	O
participatory	B-PROC
intervention	I-PROC
process	I-PROC
;	O
committed	O
facility	B-OBJC
leadership	O
;	O
management	O
support	O
;	O
and	O
staff	O
engagement	O
throughout	O
the	O
project	O
contributed	O
to	O
a	O
marked	O
change	O
in	O
the	O
culture	O
of	O
the	O
hospital	B-OBJC
to	O
one	O
that	O
values	O
and	O
promotes	O
respectful	O
maternity	B-PROC
care	I-PROC
.	O

For	O
these	O
changes	O
to	O
translate	O
into	O
dignified	O
care	O
during	O
childbirth	B-PHYS
for	O
all	O
women	B-LIVB
in	O
a	O
sustainable	O
fashion	O
,	O
institutional	O
commitment	O
to	O
providing	O
the	O
necessary	O
resources	O
and	O
staff	B-LIVB
will	O
be	O
needed	O
.	O

Triterpenoids	B-CHEM
from	O
the	O
stems	B-LIVB
of	O
Tripterygium	B-LIVB
regelii	I-LIVB
Three	O
new	O
triterpenoids	B-CHEM
,	O
triregelolides	B-CHEM
A	O
,	O
B	O
(	O
1	O
,	O
2	O
)	O
,	O
and	O
triregeloic	B-CHEM
acid	I-CHEM
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	B-LIVB
of	O
Tripterygium	B-LIVB
regelii	I-LIVB
along	O
with	O
twenty	O
known	O
triterpene	B-CHEM
analogues	B-CHEM
(	O
4	O
-	O
23	O
)	O
.	O

The	O
structures	O
of	O
three	O
new	O
compounds	B-CHEM
were	O
identified	O
by	O
analyzing	O
their	O
NMR	B-PROC
spectroscopic	I-PROC
and	O
HRESIMS	B-PROC
data	O
.	O

Compounds	B-CHEM
4	B-CHEM
,	O
7	B-CHEM
,	O
8	B-CHEM
,	O
10	B-CHEM
,	O
13	B-CHEM
,	O
14	B-CHEM
,	O
17	B-CHEM
,	O
21	B-CHEM
-	I-CHEM
23	I-CHEM
were	O
isolated	O
from	O
T	B-LIVB
.	I-LIVB

regelii	I-LIVB
for	O
the	O
first	O
time	O
.	O

Compounds	B-CHEM
3	B-CHEM
,	O
5	B-CHEM
,	O
6	B-CHEM
,	O
8	B-CHEM
,	O
9	B-CHEM
,	O
10	B-CHEM
,	O
14	B-CHEM
and	O
16	B-CHEM
showed	O
inhibitory	B-PHYS
effects	I-PHYS
on	I-PHYS
the	I-PHYS
proliferation	I-PHYS
of	O
human	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
MCF	B-ANAT
-	I-ANAT
7	I-ANAT
by	O
24	O
.	O

1	O
%	O
,	O
69	O
.	O
6	O
%	O
,	O
72	O
.	O
8	O
%	O
,	O
21	O
.	O
6	O
%	O
,	O
23	O
.	O
1	O
%	O
,	O
43	O
.	O
3	O
%	O
,	O
25	O
.	O
5	O
%	O
and	O
23	O
.	O

5	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
at	O
a	O
concentration	O
of	O
10μM	O
,	O
respectively	O
.	O

Prevalence	O
and	O
Self	B-PHYS
-	I-PHYS
recognition	I-PHYS
of	O
Chronic	B-DISO
Constipation	I-DISO
:	O
Results	O
of	O
an	O
Internet	O
Survey	O
Although	O
chronic	B-DISO
constipation	I-DISO
is	O
a	O
common	O
symptom	B-DISO
,	O
to	O
date	O
no	O
international	O
consensus	O
has	O
been	O
reached	O
regarding	O
its	O
definition	O
.	O

The	O
aims	O
of	O
this	O
study	B-PROC
were	O
(	O
1	O
)	O
to	O
investigate	O
defecation	B-PHYS
habits	O
and	O
(	O
2	O
)	O
to	O
examine	O
the	O
prevalence	O
of	O
constipation	B-DISO
using	O
the	O
Japanese	O
Society	O
of	O
Internal	O
Medicine	O
(	O
JSIM	O
)	O
and	O
the	O
Rome	O
III	O
criteria	O
using	O
an	O
online	O
survey	O
.	O

An	O
online	O
questionnaire	O
composed	O
of	O
items	O
on	O
the	O
frequency	O
,	O
interval	O
,	O
form	O
of	O
defecation	B-PHYS
,	O
the	O
management	O
,	O
and	O
self	B-PHYS
-	I-PHYS
recognition	I-PHYS
of	O
constipation	B-DISO
(	O
reference	O
standard	O
of	O
constipation	B-DISO
)	O
was	O
created	O
.	O

A	O
total	O
of	O
5155	O
valid	O
responses	O
were	O
received	O
.	O

In	O
addition	O
,	O
constipation	B-DISO
symptoms	B-DISO
were	O
evaluated	B-PROC
through	O
a	O
survey	O
using	O
the	O
JSIM	O
and	O
the	O
Rome	O
III	O
criteria	O
.	O

In	O
the	O
internet	O
survey	O
,	O
28	O
.	O

4	O
%	O
of	O
the	O
respondents	B-LIVB
considered	O
themselves	O
to	O
be	O
constipated	B-DISO
.	O

Stratified	O
by	O
sex	B-PHYS
,	O
significantly	O
more	O
females	B-PHYS
(	O
37	O
.	O
5	O
%	O
)	O
than	O
males	B-PHYS
(	O
19	O
.	O
1	O
%	O
)	O
considered	O
themselves	O
to	O
be	O
constipated	B-DISO
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
prevalence	O
of	O
constipation	B-DISO
among	O
the	O
respondents	B-LIVB
was	O
28	O
.	O

0	O
%	O
using	O
the	O
Rome	O
III	O
,	O
but	O
only	O
10	O
.	O
1	O
%	O
using	O
the	O
JSIM	O
.	O

The	O
diagnostic	O
accuracy	O
was	O
73	O
.	O

2	O
%	O
for	O
the	O
Rome	O
III	O
and	O
78	O
.	O

1	O
%	O
for	O
the	O
JSIM	O
,	O
while	O
the	O
diagnostic	O
specificity	O
was	O
81	O
.	O
1	O
%	O
for	O
the	O
Rome	O
III	O
and	O
97	O
.	O

5	O
%	O
for	O
the	O
JSIM	O
.	O

However	O
,	O
the	O
diagnostic	O
sensitivities	O
for	O
both	O
measures	O
were	O
low	O
,	O
at	O
52	O
.	O

2	O
%	O
and	O
29	O
.	O
2	O
%	O
for	O
the	O
Rome	O
III	O
and	O
the	O
JSIM	O
,	O
respectively	O
.	O

The	O
online	O
survey	O
developed	O
for	O
this	O
study	B-PROC
was	O
able	O
to	O
provide	O
clarification	O
regarding	O
defecation	B-PHYS
patterns	O
.	O

The	O
results	O
also	O
suggest	O
a	O
discrepancy	B-DISO
between	O
the	O
self	B-PHYS
-	I-PHYS
recognized	I-PHYS
prevalence	O
of	O
constipation	B-DISO
in	O
Japan	B-GEOG
and	O
prevalence	O
of	O
constipation	B-DISO
based	O
on	O
the	O
JSIM	O
criteria	O
.	O

Development	O
of	O
Community	B-LIVB
Based	O
Learning	B-PHYS
and	O
Education	B-PROC
system	O
within	O
Undergraduate	B-PROC
Medical	I-PROC
Curriculum	O
of	O
Patan	O
Academy	O
of	O
Health	O
Sciences	O
In	O
response	O
to	O
continuing	O
health	B-DISO
disparities	I-DISO
between	O
rural	B-LIVB
and	O
urban	B-LIVB
population	I-LIVB
,	O
Patan	O
Academy	O
of	O
Health	O
Sciences	O
(	O
PAHS	O
)	O
was	O
established	O
in	O
2008	O
.	O

It	O
aimed	O
to	O
produce	O
physicians	B-LIVB
who	O
would	O
be	O
able	O
and	O
willing	O
to	O
serve	O
in	O
the	O
rural	O
areas	O
.	O

In	O
order	O
to	O
empower	B-PHYS
them	O
with	O
understanding	O
and	O
tools	O
to	O
address	O
health	B-DISO
issues	I-DISO
of	O
rural	B-LIVB
population	I-LIVB
,	O
an	O
innovative	O
curriculum	O
was	O
developed	O
.	O

This	O
paper	O
aims	O
to	O
describe	O
the	O
community	O
based	O
learning	O
and	O
education	O
(	O
CBLE	O
)	O
system	O
within	O
the	O
overall	O
framework	O
of	O
PAHS	O
undergraduate	B-PROC
medical	I-PROC
curriculum	O
.	O

A	O
Medical	B-LIVB
School	I-LIVB
Steering	I-LIVB
Committee	I-LIVB
(	O
MSSC	B-LIVB
)	O
comprising	O
of	O
a	O
group	O
of	O
committed	O
medical	O
educators	B-LIVB
led	O
the	O
curriculum	O
development	B-PHEN
process	I-PHEN
.	O

The	O
committee	B-LIVB
reviewed	O
different	O
medical	O
curricula	O
,	O
relevant	O
literatures	O
,	O
and	O
held	O
a	O
series	O
of	O
consultative	O
meetings	O
with	O
the	O
stakeholders	O
and	O
experts	O
within	O
and	O
outside	O
Nepal	B-GEOG
.	O

This	O
process	O
resulted	O
in	O
defining	O
the	O
desirable	O
attributes	O
,	O
terminal	O
competencies	O
of	O
the	O
graduates	B-LIVB
,	O
and	O
then	O
the	O
actual	O
development	O
of	O
the	O
entire	O
curriculum	O
including	O
CBLE	O
.	O

Given	O
the	O
critical	O
importance	O
of	O
population	B-PROC
health	I-PROC
,	O
25	O
%	O
of	O
the	O
curricular	O
weightage	O
was	O
allocated	O
to	O
the	O
Community	B-PROC
Health	I-PROC
Sciences	I-PROC
(	O
CHS	B-PROC
)	O
.	O

CBLE	O
system	O
was	O
developed	O
as	O
the	O
primary	O
means	O
of	O
delivering	O
CHS	B-PROC
curriculum	O
.	O

The	O
details	O
of	O
CBLE	O
system	O
was	O
finalized	O
for	O
implementation	O
with	O
the	O
first	O
cohort	B-LIVB
of	O
medical	B-LIVB
students	I-LIVB
commencing	O
their	O
studies	B-PROC
from	O
June	O
2010	O
.	O

The	O
CBLE	O
,	O
a	O
key	B-PHYS
educational	I-PHYS
strategy	I-PHYS
of	O
PAHS	O
curriculum	O
,	O
is	O
envisaged	O
to	O
improve	B-DISO
retention	O
and	O
performance	O
of	O
PAHS	O
graduates	B-LIVB
and	O
,	O
thereby	O
,	O
health	O
status	O
of	O
rural	B-LIVB
population	I-LIVB
.	O

However	O
,	O
whether	O
or	O
not	O
that	O
goal	O
will	O
be	O
achieved	O
needs	O
to	O
be	O
verified	O
after	O
the	O
graduates	B-LIVB
join	O
the	O
health	O
system	O
.	O

Antihypertensive	B-CHEM
medicines	I-CHEM
utilization	O
:	O
A	O
decade	O
-	O
long	O
nationwide	O
study	O
of	O
octogenarians	B-LIVB
,	O
nonagenarians	B-LIVB
and	O
centenarians	B-LIVB
Gaining	O
an	O
insight	O
into	O
the	O
utilization	O
of	O
antihypertensive	B-CHEM
medicines	I-CHEM
against	O
a	O
background	O
of	O
evolving	O
hypertension	B-PROC
treatment	I-PROC
guidelines	O
that	O
might	O
not	O
be	O
relevant	O
to	O
the	O
oldest	B-LIVB
old	I-LIVB
is	O
important	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
the	O
overall	O
trends	O
in	O
the	O
utilization	O
of	O
antihypertensive	B-CHEM
medicines	I-CHEM
in	O
the	O
oldest	B-LIVB
old	I-LIVB
by	O
therapeutic	O
class	O
and	O
chemical	O
type	O
,	O
stratified	O
by	O
age	B-PHYS
and	O
sex	B-PHYS
over	O
a	O
decade	O
.	O

Antihypertensive	B-CHEM
medicines	I-CHEM
utilization	O
was	O
examined	O
using	O
the	O
therapeutic	B-PROC
and	O
chemical	B-CHEM
groups	I-CHEM
based	O
on	O
the	O
World	O
Health	O
Organization	O
Collaborating	O
Center	O
for	O
Drug	O
Statistics	O
Mythology	O
's	O
Anatomical	O
Therapeutic	O
Chemical	O
classification	O
system	O
for	O
all	O
individuals	B-LIVB
aged	O
≥80	B-LIVB
years	I-LIVB
.	O

Regression	O
and	O
repeated	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
analyses	I-PROC
was	O
carried	O
out	O
,	O
and	O
defined	O
daily	O
dose	O
was	O
used	O
to	O
describe	O
the	O
utilization	O
per	O
thousand	O
older	B-LIVB
people	I-LIVB
per	O
day	O
.	O

Utilization	O
of	O
antihypertensive	B-CHEM
medicines	I-CHEM
increased	O
over	O
the	O
decade	O
from	O
187	O
.	O

28	O
in	O
2005	O
to	O
205	O
.	O

01	O
defined	O
daily	O
dose	O
per	O
thousand	O
older	B-LIVB
people	I-LIVB
per	O
day	O
in	O
2014	O
,	O
and	O
shifted	O
from	O
mainly	O
diuretics	B-CHEM
to	O
angiotensin	B-CHEM
-	I-CHEM
converting	I-CHEM
enzyme	I-CHEM
inhibitors	I-CHEM
.	O

Interestingly	O
,	O
with	O
the	O
exception	O
of	O
diuretics	B-CHEM
,	O
utilization	O
of	O
all	O
medicines	B-CHEM
decreased	O
gradually	O
with	O
increasing	O
age	B-PHYS
.	O

Single	O
products	O
use	O
increased	O
by	O
1	O
.	O
48	O
-	O
fold	O
in	O
2014	O
compared	O
with	O
2005	O
,	O
and	O
for	O
fixed	O
-	O
dose	O
combinations	O
the	O
increase	O
was	O
1	O
.	O
41	O
-	O
fold	O
for	O
the	O
same	O
period	O
.	O

The	O
increased	O
utilization	O
of	O
angiotensin	B-CHEM
-	I-CHEM
converting	I-CHEM
enzyme	I-CHEM
inhibitors	I-CHEM
is	O
consistent	O
with	O
recommendations	O
from	O
cardiovascular	B-ANAT
guidelines	O
formulated	O
from	O
large	O
randomized	B-PROC
control	I-PROC
trials	I-PROC
that	O
often	O
exclude	O
the	O
oldest	B-LIVB
old	I-LIVB
.	O

Interestingly	O
,	O
the	O
utilization	O
of	O
beta	B-CHEM
-	I-CHEM
blockers	I-CHEM
decreased	O
and	O
diuretics	B-CHEM
increased	O
in	O
centenarians	B-LIVB
.	O

The	O
utilization	O
of	O
calcium	B-CHEM
channel	I-CHEM
blockers	I-CHEM
and	O
angiotensin	B-CHEM
-	I-CHEM
converting	I-CHEM
enzyme	I-CHEM
inhibitors	I-CHEM
across	O
the	O
study	O
period	O
increased	O
in	O
all	O
age	B-PHYS
categories	O
.	O

Geriatr	O
Gerontol	O
Int	O
2016	O
;	O
••	O
:	O
••	O
-	O
••	O
.	O

Incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	B-DISO
cataract	I-DISO
in	O
Children	B-LIVB
of	O
Lahore	O
To	O
check	O
the	O
incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	B-DISO
cataract	I-DISO
in	O
infants	B-LIVB
.	O

The	O
descriptive	B-PROC
study	I-PROC
was	O
conducted	O
at	O
Layton	O
Rahmatullah	O
Benevolent	O
Trust	O
,	O
Lahore	O
,	O
Pakistan	B-GEOG
,	O
from	O
October	O
2013	O
to	O
April	O
2014	O
,	O
and	O
comprised	O
children	B-LIVB
under	O
15	O
years	O
of	O
age	B-PHYS
who	O
had	O
rubella	B-DISO
syndrome	I-DISO
,	O
herpes	B-DISO
simplex	I-DISO
,	O
birth	B-DISO
trauma	I-DISO
,	O
trisomy	B-DISO
21	I-DISO
,	O
Nance	B-DISO
-	I-DISO
Horan	I-DISO
syndrome	I-DISO
or	O
Lowe	B-DISO
's	I-DISO
syndrome	I-DISO
.	O

Of	O
the	O
38	O
,	O
000	O
cases	O
examined	O
,	O
120	O
(	O
0	O
.	O
3	O
%	O
)	O
patients	B-LIVB
were	O
diagnosed	B-DISO
with	O
congenital	B-DISO
cataract	I-DISO
.	O

Of	O
them	O
,	O
52	O
(	O
43	O
.	O
33	O
%	O
)	O
were	O
aged	B-PHYS
between	O
2	O
and	O
5	O
years	O
,	O
22	O
(	O
18	O
.	O

33	O
%	O
)	O
<	O
11	O
years	O
and	O
10	O
(	O
8	O
.	O
33	O
%	O
)	O
?	O
15	O
years	O
.	O

Bilateral	B-DISO
congenital	I-DISO
cataract	I-DISO
was	O
observed	O
in	O
91	O
(	O
75	O
.	O
83	O
%	O
)	O
patients	B-LIVB
and	O
unilateral	B-DISO
congenital	I-DISO
cataract	I-DISO
in	O
29	O
(	O
24	O
.	O
17	O
%	O
)	O
.	O

Environmental	O
factors	O
caused	O
72	O
(	O
62	O
.	O

07	O
%	O
)	O
cases	O
and	O
genetic	O
factors	O
caused	O
44	O
(	O
37	O
.	O
93	O
%	O
)	O
..	O
Congenital	B-DISO
cataract	I-DISO
predominated	O
in	O
boys	B-LIVB
compared	O
to	O
girls	B-LIVB
.	O

Early	O
diagnosis	B-DISO
and	O
adequate	O
therapy	B-PROC
requires	O
specific	O
technology	O
,	O
as	O
well	O
as	O
long	O
-	O
term	O
and	O
permanent	O
care	O
..	O

Biochemical	O
evidence	O
for	O
a	O
mitochondrial	B-ANAT
genetic	O
modifier	O
in	O
the	O
phenotypic	B-PHYS
manifestation	O
of	O
Leber	B-DISO
's	I-DISO
hereditary	I-DISO
optic	I-DISO
neuropathy	I-DISO
-associated	O
mitochondrial	B-DISO
DNA	I-DISO
mutation	I-DISO
Leber	B-DISO
's	I-DISO
hereditary	I-DISO
optic	I-DISO
neuropathy	I-DISO
(	O
LHON	B-DISO
)	O
is	O
the	O
most	O
common	O
mitochondrial	B-DISO
disease	I-DISO
.	O

Mitochondrial	B-ANAT
modifiers	O
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	B-PHYS
expression	I-PHYS
of	O
primary	O
LHON	B-DISO
-associated	O
mitochondrial	B-CHEM
DNA	I-CHEM
(	O
mtDNA	B-CHEM
)	O
mutations	B-DISO
.	O

In	O
this	O
study	B-PROC
,	O
we	O
demonstrated	O
that	O
the	O
LHON	B-DISO
susceptibility	B-PHYS
allele	O
(	O
m	O
.	O
14502	O
T	O
>	O
C	O
,	O
p	O
.	O

58I	O
>	O
V	O
)	O
in	O
the	O
ND6	O
gene	O
modulated	O
the	O
phenotypic	B-PHYS
expression	I-PHYS
of	O
primary	O
LHON	B-DISO
-associated	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O

Twenty	O
-	O
two	O
Han	O
Chinese	O
pedigrees	O
carrying	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
and	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutations	I-PHYS
exhibited	O
significantly	O
higher	O
penetrance	O
of	O
optic	B-DISO
neuropathy	I-DISO
than	O
those	O
carrying	O
only	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O

We	O
performed	O
functional	O
assays	B-PROC
using	O
the	O
cybrid	B-ANAT
cell	I-ANAT
models	I-ANAT
,	O
generated	O
by	O
fusing	O
mtDNA	B-ANAT
-	I-ANAT
less	I-ANAT
ρ	I-ANAT
(	I-ANAT
o	I-ANAT
)	I-ANAT
cells	I-ANAT
with	O
enucleated	B-ANAT
cells	I-ANAT
from	O
LHON	B-DISO
patients	B-LIVB
carrying	O
both	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
and	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutations	I-PHYS
,	O
only	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
or	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	B-CHEM
haplogroup	B-PHYS
.	O

These	O
cybrids	B-ANAT
cell	I-ANAT
lines	I-ANAT
bearing	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutation	I-PHYS
exhibited	O
mild	O
effects	O
on	O
mitochondrial	B-ANAT
functions	O
compared	O
with	O
those	O
carrying	O
only	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O

However	O
,	O
more	O
severe	O
mitochondrial	B-ANAT
dysfunctions	O
were	O
observed	O
in	O
cell	B-ANAT
lines	I-ANAT
bearing	O
both	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
and	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutations	I-PHYS
than	O
those	O
carrying	O
only	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
or	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutation	I-PHYS
.	O

In	O
particular	O
,	O
the	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutation	I-PHYS
altered	O
assemble	O
of	O
complex	B-CHEM
I	I-CHEM
,	O
thereby	O
aggravating	O
the	O
respiratory	O
phenotypes	B-PHYS
associated	O
with	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
,	O
resulted	O
in	O
a	O
more	O
defective	O
complex	B-CHEM
I	I-CHEM
.	O

Furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	B-ANAT
ATP	B-CHEM
and	O
increasing	O
production	O
of	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
were	O
also	O
observed	O
in	O
mutant	B-DISO
cells	B-ANAT
bearing	O
both	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
and	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
than	O
those	O
carrying	O
only	O
11778	B-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O

Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
LHON	B-DISO
that	O
were	O
manifested	O
by	O
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	B-CHEM
mutations	B-DISO
.	O

Improving	O
Care	B-PROC
Transitions	I-PROC
Across	O
Healthcare	B-PROC
Settings	O
Through	O
a	O
Human	B-DISO
Factors	I-DISO
Approach	O
After	O
more	O
than	O
two	O
decades	O
of	O
research	B-PROC
focused	O
on	O
care	B-PROC
transition	I-PROC
improvement	O
and	O
intervention	B-PROC
development	O
,	O
unfavorable	B-DISO
outcome	I-DISO
measures	O
associated	O
with	O
care	B-PROC
transitions	I-PROC
across	O
healthcare	B-PROC
settings	O
persist	O
.	O

Readmissions	O
rates	O
remain	O
an	O
important	O
outcome	O
to	O
target	O
for	O
intervention	B-PROC
,	O
adverse	B-DISO
events	I-DISO
associated	O
with	O
care	B-PROC
transitions	I-PROC
continue	O
to	O
be	O
an	O
issue	B-DISO
,	O
and	O
patients	B-LIVB
are	O
often	O
dissatisfied	B-PHYS
with	O
the	O
quality	O
of	O
their	O
care	O
.	O

Currently	O
,	O
interventions	B-PROC
to	O
improve	O
care	B-PROC
transitions	I-PROC
are	O
disease	B-DISO
specific	O
,	O
require	O
substantial	O
financial	B-PROC
investments	I-PROC
in	O
training	B-PROC
allied	B-LIVB
healthcare	I-LIVB
professionals	I-LIVB
,	O
or	O
focus	O
primarily	O
on	O
hospital	B-PROC
-	I-PROC
based	I-PROC
discharge	I-PROC
planning	I-PROC
with	O
mixed	O
results	O
.	O

This	O
complex	O
situation	O
requires	O
a	O
method	B-PROC
of	I-PROC
evaluation	I-PROC
that	O
can	O
provide	O
a	O
comprehensive	O
,	O
in	O
-	O
depth	O
,	O
and	O
context	O
-	O
driven	O
investigation	B-PROC
of	O
potential	B-DISO
risks	I-DISO
to	O
safe	O
care	B-PROC
transitions	I-PROC
across	O
healthcare	B-PROC
settings	O
,	O
which	O
can	O
lead	O
to	O
the	O
creation	O
of	O
effective	O
,	O
usable	O
,	O
and	O
sustainable	O
interventions	B-PROC
.	O

A	O
systems	O
'	O
approach	O
known	O
as	O
Human	O
Factors	O
and	O
Ergonomics	O
(	O
HFE	O
)	O
evaluates	O
the	O
factors	O
in	O
a	O
system	O
that	O
affect	O
human	O
performance	O
.	O

This	O
article	O
describes	O
how	O
HFE	O
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	O
care	B-PROC
transitions	I-PROC
.	O

Transcriptome	O
and	O
Metabolome	B-PHEN
Analyses	B-PROC
of	O
Glucosinolates	B-CHEM
in	O
Two	O
Broccoli	B-LIVB
Cultivars	I-LIVB
Following	O
Jasmonate	B-CHEM
Treatment	O
for	O
the	O
Induction	O
of	O
Glucosinolate	B-CHEM
Defense	O
to	O
Trichoplusia	O
ni	O
(	O
Hübner	O
)	O
Lepidopteran	O
larvae	O
growth	B-PHYS
is	O
influenced	O
by	O
host	B-LIVB
plant	B-LIVB
glucosinolate	B-CHEM
(	O
GS	B-CHEM
)	O
concentrations	O
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	O
by	O
the	O
phytohormone	B-CHEM
jasmonate	B-CHEM
(	O
JA	B-CHEM
)	O
.	O

In	O
order	O
to	O
elucidate	O
insect	O
resistance	O
biomarkers	B-PHYS
to	O
lepidopteran	O
pests	B-LIVB
,	O
transcriptome	O
and	O
metabolome	B-PHEN
analyses	B-PROC
following	O
JA	B-CHEM
treatments	O
were	O
conducted	O
with	O
two	O
broccoli	B-LIVB
cultivars	I-LIVB
,	O
Green	B-LIVB
Magic	I-LIVB
and	O
VI	B-LIVB
-	I-LIVB
158	I-LIVB
,	O
which	O
have	O
differentially	O
induced	O
indole	B-CHEM
GSs	I-CHEM
,	O
neoglucobrassicin	B-CHEM
and	O
glucobrassicin	B-CHEM
,	O
respectively	O
.	O

To	O
test	O
these	O
two	O
inducible	O
GSs	B-CHEM
on	O
growth	B-PHYS
of	O
cabbage	O
looper	O
(	O
Trichoplusia	O
ni	O
)	O
,	O
eight	O
neonate	O
cabbage	O
looper	O
larvae	O
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	B-LIVB
per	O
JA	B-CHEM
treatments	O
(	O
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µM	O
)	O
three	O
days	O
after	O
treatment	O
.	O

After	O
five	O
days	O
of	O
feeding	O
,	O
weight	O
of	O
larvae	O
and	O
their	O
survival	O
rate	O
was	O
found	O
to	O
decrease	O
with	O
increasing	O
JA	B-CHEM
concentrations	O
in	O
both	O
broccoli	B-LIVB
cultivars	I-LIVB
.	O

JA	B-CHEM
-	O
inducible	O
GSs	B-CHEM
were	O
measured	O
by	O
high	B-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
.	O

Neoglucobrassicin	B-CHEM
in	O
Green	B-LIVB
Magic	I-LIVB
and	O
glucobrassicin	B-CHEM
in	O
VI	B-LIVB
-	I-LIVB
158	I-LIVB
leaves	B-LIVB
were	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

One	O
or	O
both	O
of	O
these	O
glucosinolates	B-CHEM
and	O
/	O
or	O
their	O
hydrolysis	B-PHEN
products	B-OBJC
showed	O
significant	O
inverse	O
correlations	O
with	O
larval	O
weight	O
and	O
survival	O
(	O
five	O
days	O
after	O
treatment	O
)	O
while	O
being	O
positively	B-DISO
correlated	O
with	O
the	O
number	O
of	O
days	O
to	O
pupation	B-PHYS
.	O

This	O
implies	O
that	O
these	O
two	O
JA	B-CHEM
-	O
inducible	O
glucosinolates	B-CHEM
can	O
influence	O
the	O
growth	B-PHYS
and	O
survival	O
of	O
cabbage	O
looper	O
larvae	O
.	O

Transcriptome	B-PROC
profiling	I-PROC
supported	O
the	O
observed	O
changes	O
in	O
glucosinolate	B-CHEM
and	O
their	O
hydrolysis	B-PHEN
product	B-OBJC
concentrations	O
following	O
JA	B-CHEM
treatments	O
.	O

Several	O
genes	O
related	O
to	O
GS	B-CHEM
metabolism	B-PHYS
differentiate	O
the	O
two	O
broccoli	B-LIVB
cultivars	I-LIVB
in	O
their	O
pattern	O
of	O
transcriptional	B-PHYS
response	B-PHYS
to	O
JA	B-CHEM
treatments	O
.	O

Indicative	O
of	O
the	O
corresponding	O
change	O
in	O
indole	B-CHEM
GS	I-CHEM
concentrations	O
,	O
transcripts	B-CHEM
of	O
the	O
transcription	B-CHEM
factor	I-CHEM
MYB122	B-CHEM
,	O
core	O
structure	O
biosynthesis	O
genes	O
(	O
CYP79B2	O
,	O
UGT74B1	O
,	O
SUR1	O
,	O
SOT16	O
,	O
SOT17	O
,	O
and	O
SOT18	O
)	O
,	O
an	O
indole	B-CHEM
glucosinolate	I-CHEM
side	O
chain	O
modification	B-DISO
gene	O
(	O
IGMT1	O
)	O
,	O
and	O
several	O
glucosinolate	B-CHEM
hydrolysis	B-PHEN
genes	O
(	O
TGG1	O
,	O
TGG2	O
,	O
and	O
ESM1	O
)	O
were	O
significantly	O
increased	O
in	O
Green	B-LIVB
Magic	I-LIVB
(	O
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM	O
)	O
while	O
UGT74B1	O
and	O
MYB122	O
were	O
significantly	O
increased	O
in	O
VI	B-LIVB
-	I-LIVB
158	I-LIVB
.	O

Therefore	O
,	O
these	O
metabolite	B-CHEM
and	O
transcript	B-CHEM
biomarker	B-PHYS
results	O
indicate	O
that	O
transcriptome	B-PROC
profiling	I-PROC
can	O
identify	O
genes	O
associated	O
with	O
the	O
formation	O
of	O
two	O
different	O
indole	B-CHEM
GS	I-CHEM
and	O
their	O
hydrolysis	B-PHEN
products	B-OBJC
.	O

Therefore	O
,	O
these	O
metabolite	B-CHEM
and	O
transcript	B-CHEM
biomarkers	B-PHYS
could	O
be	O
useful	O
in	O
an	O
effective	O
marker	B-PHYS
-	O
assisted	O
breeding	B-PHYS
strategy	O
for	O
resistance	O
to	O
generalist	O
lepidopteran	O
pests	B-LIVB
in	O
broccoli	B-LIVB
and	O
potentially	O
other	O
Brassica	B-OBJC
vegetables	I-OBJC
.	O

Autoimmune	B-DISO
Myelofibrosis	I-DISO
in	O
Systemic	B-DISO
Lupus	I-DISO
Erythematosus	I-DISO
Report	O
of	O
Two	O
Cases	O
and	O
Review	O
of	O
the	O
Literature	O
Autoimmune	B-DISO
myelofibrosis	I-DISO
(	O
AIMF	B-DISO
)	O
is	O
a	O
rare	B-OBJC
entity	I-OBJC
of	O
steroid	B-CHEM
-	O
responsive	O
bone	B-DISO
marrow	I-DISO
fibrosis	I-DISO
that	O
accompanies	O
a	O
variety	O
of	O
autoimmune	B-DISO
diseases	I-DISO
,	O
particularly	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O
SLE	B-DISO
)	O
.	O

Rarely	O
it	O
may	O
occur	O
in	O
patients	B-LIVB
with	O
autoimmune	B-PHYS
markers	I-PHYS
but	O
no	O
definable	O
autoimmune	B-DISO
disease	I-DISO
(	O
Primary	B-DISO
-	I-DISO
AIMF	I-DISO
)	O
.	O

We	O
report	O
the	O
cases	O
of	O
two	O
young	O
women	B-LIVB
with	O
SLE	B-DISO
-	O
associated	O
AIMF	B-DISO
(	O
SLE	B-DISO
-	O
AIMF	B-DISO
)	O
.	O

The	O
first	O
patient	B-LIVB
was	O
a	O
young	O
woman	B-LIVB
who	O
had	O
pancytopenia	B-DISO
,	O
massive	B-DISO
splenomegaly	I-DISO
and	O
reticulin	B-DISO
fibrosis	I-DISO
in	O
the	O
marrow	B-PROC
biopsy	I-PROC
.	O

The	O
pancytopenia	B-DISO
and	O
splenomegaly	B-DISO
resolved	B-DISO
completely	O
within	O
weeks	O
of	O
treatment	O
with	O
corticosteroids	B-CHEM
.	O

Repeat	O
marrow	B-PROC
biopsy	I-PROC
showed	O
marked	B-DISO
regression	I-DISO
of	O
marrow	B-DISO
fibrosis	I-DISO
.	O

The	O
second	O
patient	B-LIVB
was	O
a	O
young	O
woman	B-LIVB
with	O
fever	B-DISO
,	O
anasarca	B-DISO
,	O
bicytopenia	B-PHEN
and	O
reticulin	B-DISO
fibrosis	I-DISO
in	O
the	O
marrow	B-PROC
biopsy	I-PROC
.	O

Steroid	B-PROC
therapy	I-PROC
resulted	O
in	O
rapid	O
clinical	O
improvement	O
and	O
resolution	O
of	O
pancytopenia	B-DISO
.	O

A	O
review	O
of	O
the	O
literature	O
revealed	O
a	O
total	O
of	O
30	O
patients	B-LIVB
with	O
SLE	B-DISO
-	O
AIMF	B-DISO
reported	O
to	O
-	O
date	O
.	O

Patients	B-LIVB
with	O
SLE	B-DISO
-	O
AIMF	B-DISO
are	O
young	O
women	B-LIVB
with	O
SLE	B-DISO
and	O
blood	B-DISO
cytopenia	I-DISO
who	O
are	O
found	O
to	O
have	O
increased	O
bone	B-DISO
marrow	I-DISO
reticulin	I-DISO
on	O
marrow	B-PROC
biopsy	I-PROC
.	O

Steroid	B-PROC
therapy	I-PROC
results	O
in	O
rapid	O
hematological	O
recovery	O
and	O
regression	B-DISO
of	O
marrow	B-DISO
fibrosis	I-DISO
.	O

Whether	O
AIMF	B-DISO
is	O
one	O
of	O
several	O
hematological	O
complications	B-DISO
of	O
SLE	B-DISO
,	O
or	O
represents	O
a	O
unique	O
and	O
distinct	O
subset	O
of	O
patients	B-LIVB
with	O
SLE	B-DISO
in	O
not	O
clear	O
.	O

Prospective	B-PROC
studies	I-PROC
with	O
longer	O
follow	B-PROC
-	I-PROC
up	I-PROC
are	O
needed	O
to	O
better	O
define	O
the	O
prevalence	O
and	O
clinical	B-PHYS
spectrum	I-PHYS
of	O
SLE	B-DISO
-	O
AIMF	B-DISO
.	O

The	O
clinical	B-DISO
prognosis	I-DISO
of	O
implants	B-DEVI
that	O
are	O
placed	O
against	O
super	B-DISO
-	I-DISO
erupted	I-DISO
opposing	O
dentition	B-ANAT
If	O
teeth	B-ANAT
are	O
missing	B-DISO
,	O
super	B-DISO
-	I-DISO
eruption	I-DISO
of	I-DISO
teeth	I-DISO
in	O
the	O
opposing	O
arch	O
can	O
occur	O
in	O
the	O
area	O
and	O
can	O
change	O
the	O
occlusal	B-PHYS
plane	I-PHYS
.	O

When	O
missing	B-DISO
teeth	I-DISO
are	O
replaced	O
with	O
implants	B-DEVI
,	O
the	O
oral	B-LIVB
surgeon	I-LIVB
must	O
determine	O
whether	O
or	O
not	O
the	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
teeth	I-ANAT
need	O
to	O
be	O
treated	O
in	O
order	O
to	O
normalize	B-PROC
the	O
occlusal	B-PHYS
plane	I-PHYS
.	O

In	O
this	O
study	B-PROC
,	O
we	O
evaluated	B-PROC
the	O
clinical	B-DISO
prognosis	I-DISO
of	O
dentition	B-ANAT
after	O
implant	B-PROC
placement	I-PROC
and	O
prosthetic	B-PROC
treatment	I-PROC
were	O
completed	O
in	O
an	O
occlusal	B-PHYS
plane	I-PHYS
altered	O
by	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
teeth	I-ANAT
in	O
the	O
opposing	O
arch	O
without	O
additional	O
treatment	O
of	O
the	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
teeth	I-ANAT
.	O

Twenty	O
-	O
two	O
patients	B-LIVB
(	O
9	O
males	B-PHYS
,	O
13	O
females	B-PHYS
)	O
were	O
treated	O
with	O
implants	B-DEVI
and	O
prosthetics	B-DEVI
without	O
addressing	O
the	O
super	B-DISO
-	I-DISO
erupted	I-DISO
opposing	O
dentition	B-ANAT
from	O
April	O
2004	O
to	O
August	O
2012	O
at	O
Seoul	B-GEOG
National	B-OBJC
University	I-OBJC
Bundang	I-OBJC
Hospital	I-OBJC
.	O

A	O
total	O
of	O
33	O
implants	B-DEVI
were	O
placed	O
.	O

Values	O
of	O
crestal	B-DISO
bone	I-DISO
loss	I-DISO
,	O
survival	O
rates	O
,	O
and	O
surgical	B-DISO
and	O
prosthetic	B-DISO
complications	I-DISO
for	O
an	O
average	O
of	O
29	O
.	O
6	O
months	O
after	O
prosthetic	B-PROC
loading	I-PROC
were	O
recorded	O
.	O

In	O
one	O
case	O
,	O
the	O
cover	B-DEVI
screw	I-DEVI
was	O
exposed	O
after	O
implant	B-PROC
surgery	I-PROC
.	O

The	O
mean	O
crestal	B-DISO
bone	I-DISO
loss	I-DISO
was	O
0	O
.	O

09±0	O
.	O
30	O
mm	O
.	O

Of	O
the	O
33	O
implants	B-DEVI
,	O
31	O
survived	B-PHEN
,	O
a	O
survival	O
rate	O
of	O
93	O
.	O

94	O
%	O
.	O

A	O
prosthetic	B-DISO
complication	I-DISO
occurred	O
in	O
one	O
case	O
but	O
functioned	O
well	O
after	O
correction	O
.	O

Favorable	O
clinical	B-PHEN
results	I-PHEN
from	O
prosthetic	B-DISO
complications	I-DISO
,	O
crestal	B-DISO
bone	I-DISO
loss	I-DISO
,	O
and	O
implant	B-DEVI
survival	O
rates	O
were	O
exhibited	O
in	O
implants	B-DEVI
next	O
to	O
a	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
opposing	I-ANAT
tooth	I-ANAT
.	O

Adenosine	B-CHEM
and	O
the	O
adenosine	B-CHEM
A2A	I-CHEM
receptor	I-CHEM
agonist	I-CHEM
,	O
CGS21680	B-CHEM
,	O
upregulate	B-PHYS
CD39	B-CHEM
and	O
CD73	B-CHEM
expression	B-PHYS
through	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
CREB	B-CHEM
in	O
regulatory	B-ANAT
T	I-ANAT
cells	I-ANAT
isolated	O
from	O
septic	O
mice	B-LIVB
The	O
number	O
of	O
regulatory	B-ANAT
T	I-ANAT
cells	I-ANAT
(	O
Treg	B-ANAT
cells	I-ANAT
)	O
and	O
the	O
expression	B-PHYS
of	O
ectonucleoside	B-CHEM
triphosphate	I-CHEM
diphosphohydrolase	I-CHEM
1	I-CHEM
(	O
ENTPD1	B-CHEM
;	O
also	O
known	O
as	O
CD39	B-CHEM
)	O
and	O
5	B-CHEM
'	I-CHEM
-	I-CHEM
ectonucleotidase	I-CHEM
(	O
NT5E	B-CHEM
;	O
also	O
known	O
as	O
CD73	B-CHEM
)	O
on	O
the	O
Treg	B-ANAT
cell	I-ANAT
surface	O
are	O
increased	O
during	O
sepsis	B-DISO
.	O

In	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	B-CHEM
leading	O
to	O
the	O
high	O
expression	B-PHYS
of	O
CD39	B-CHEM
and	O
CD73	B-CHEM
,	O
and	O
the	O
regulation	B-PHEN
of	I-PHEN
the	O
CD39	B-CHEM
/	O
CD73	B-CHEM
/	O
adenosine	B-CHEM
pathway	O
in	O
Treg	B-ANAT
cells	I-ANAT
under	O
septic	O
conditions	O
,	O
we	O
constructed	O
a	O
mouse	B-DISO
model	I-DISO
of	O
sepsis	B-DISO
and	O
separated	O
the	O
Treg	B-ANAT
cells	I-ANAT
using	O
a	O
flow	B-DEVI
cytometer	I-DEVI
.	O

The	O
Treg	B-ANAT
cells	I-ANAT
isolated	O
from	O
the	O
peritoneal	B-PROC
lavage	I-PROC
and	O
splenocytes	B-ANAT
of	O
the	O
mice	B-LIVB
were	O
treated	B-PROC
with	I-PROC
adenosine	B-CHEM
or	O
the	O
specific	O
adenosine	B-CHEM
A2A	I-CHEM
receptor	I-CHEM
agonist	I-CHEM
,	O
CGS21680	B-CHEM
,	O
and	O
were	O
transfected	B-PROC
with	O
specific	O
siRNA	B-CHEM
targeting	O
E2F	B-CHEM
transcription	I-CHEM
factor	I-CHEM
1	I-CHEM
(	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
or	O
cyclic	B-CHEM
adenosine	I-CHEM
monophosphate	I-CHEM
(	I-CHEM
cAMP	I-CHEM
)	I-CHEM
response	I-CHEM
element	I-CHEM
-	I-CHEM
binding	I-CHEM
protein	I-CHEM
(	O
CREB	B-CHEM
)	O
,	O
which	O
are	O
predicted	O
transcription	B-CHEM
regulatory	I-CHEM
factors	I-CHEM
of	O
CD39	B-CHEM
or	O
CD73	B-CHEM
.	O

The	O
regulatory	B-PHEN
relationships	O
among	O
these	O
factors	B-CHEM
were	O
then	O
determined	O
by	O
western	B-PROC
blot	I-PROC
analysis	I-PROC
and	O
dual	B-PROC
-	I-PROC
luciferase	I-PROC
reporter	I-PROC
assay	I-PROC
.	O

In	O
addition	O
,	O
changes	O
in	O
adenosine	B-PHYS
metabolism	I-PHYS
were	O
measured	O
in	O
the	O
treated	O
cells	B-ANAT
.	O

The	O
results	O
revealed	O
that	O
adenosine	B-CHEM
and	O
CGS21680	B-CHEM
significantly	O
upregulated	B-PHYS
CD39	B-CHEM
and	O
CD73	B-CHEM
expression	B-PHYS
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

E2F	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
CREB	B-CHEM
induced	O
CD39	B-CHEM
and	O
CD73	B-CHEM
expression	B-PHYS
,	O
and	O
were	O
upregulated	B-PHYS
by	O
adenosine	B-CHEM
and	O
CGS21680	B-CHEM
.	O

Adenosine	B-PHYS
triphosphate	I-PHYS
(	I-PHYS
ATP	I-PHYS
)	I-PHYS
hydrolysis	I-PHYS
and	O
adenosine	B-CHEM
generation	O
were	O
inhibited	O
by	O
the	O
knockdown	O
of	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
or	O
CREB	B-CHEM
,	O
and	O
were	O
accelerated	O
in	O
the	O
presence	O
of	O
CGS21680	B-CHEM
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-CHEM
,	O
the	O
adenosine	B-CHEM
A2A	I-CHEM
receptor	I-CHEM
agonist	I-CHEM
,	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
CREB	B-CHEM
are	O
the	O
possible	O
factors	B-CHEM
contributing	O
to	O
the	O
high	O
expression	B-PHYS
of	O
CD39	B-CHEM
and	O
CD73	B-CHEM
on	O
the	O
Treg	B-ANAT
cell	I-ANAT
surface	O
during	O
sepsis	B-DISO
.	O

Adenosine	B-CHEM
and	O
its	O
A2A	B-CHEM
receptor	I-CHEM
agonist	I-CHEM
served	O
as	O
the	O
signal	B-PHYS
transducer	I-PHYS
factors	B-CHEM
of	O
the	O
CD39	B-CHEM
/	O
CD73	B-CHEM
/	O
adenosine	B-CHEM
pathway	O
,	O
accelerating	O
adenosine	B-CHEM
generation	O
.	O

Our	O
study	O
may	O
benefit	O
further	O
research	B-PROC
on	O
adenosine	B-PHYS
metabolism	I-PHYS
for	O
the	O
treatment	B-PROC
of	O
sepsis	B-DISO
.	O

Exploring	O
Consumer	B-LIVB
and	O
Patient	B-LIVB
Knowledge	O
,	O
Behavior	O
,	O
and	O
Attitude	B-PHYS
Toward	O
Medicinal	B-CHEM
and	O
Lifestyle	B-OBJC
Products	I-OBJC
Purchased	O
From	O
the	O
Internet	B-OBJC
:	O
A	O
Web	B-OBJC
-	O
Based	O
Survey	O
In	O
recent	O
years	O
,	O
lifestyle	B-OBJC
products	I-OBJC
have	O
emerged	O
to	O
help	O
improve	B-DISO
people	B-LIVB
's	I-LIVB
physical	B-PHYS
and	O
mental	B-PHYS
performance	O
.	O

The	O
Internet	B-OBJC
plays	O
a	O
major	O
role	O
in	O
the	O
spread	O
of	O
these	O
products	B-OBJC
.	O

However	O
,	O
the	O
literature	O
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	O
of	O
medicines	B-CHEM
purchased	O
from	O
the	O
Internet	B-OBJC
and	O
the	O
impact	O
of	O
counterfeit	B-CHEM
medicines	I-CHEM
on	O
public	O
health	O
.	O

Little	O
or	O
no	O
data	O
are	O
available	O
on	O
the	O
authenticity	O
of	O
lifestyle	B-OBJC
products	I-OBJC
and	O
actual	O
toxicity	O
associated	O
with	O
their	O
use	O
and	O
misuse	B-DISO
.	O

Our	O
aim	O
was	O
to	O
investigate	O
consumer	O
and	O
patient	B-PHYS
attitudes	I-PHYS
toward	O
the	O
purchase	O
of	O
lifestyle	B-OBJC
products	I-OBJC
from	O
the	O
Internet	B-OBJC
,	O
their	O
knowledge	O
of	O
product	B-OBJC
authenticity	O
and	O
toxicity	O
,	O
and	O
their	O
experiences	B-PHYS
with	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
.	O

A	O
Web	B-OBJC
-	O
based	O
study	B-PROC
was	O
performed	O
between	O
May	O
2014	O
and	O
May	O
2015	O
.	O

Uniform	O
collection	B-PROC
of	I-PROC
data	I-PROC
was	O
performed	O
through	O
an	O
anonymous	O
online	B-OBJC
questionnaire	O
.	O

Participants	B-LIVB
were	O
invited	O
worldwide	O
via	O
email	O
,	O
social	O
media	O
,	O
or	O
personal	O
communication	O
to	O
complete	O
the	O
online	B-OBJC
questionnaire	O
.	O

A	O
total	O
of	O
320	O
participants	B-LIVB
completed	O
the	O
questionnaire	O
.	O

The	O
results	O
of	O
the	O
questionnaire	O
showed	O
that	O
208	O
(	O
65	O
.	O
0	O
%	O
)	O
participants	B-LIVB
purchased	O
lifestyle	B-OBJC
products	I-OBJC
from	O
the	O
Internet	B-OBJC
mainly	O
due	O
to	O
convenience	O
and	O
reduced	O
cost	O
.	O

More	O
than	O
half	O
(	O
55	O
.	O
6	O
%	O
,	O
178	O
/	O
320	O
)	O
of	O
participants	B-LIVB
purchased	O
cosmetic	B-OBJC
products	I-OBJC
,	O
whereas	O
only	O
a	O
minority	O
purchased	O
medicinal	B-CHEM
products	I-CHEM
.	O

Yet	O
,	O
62	O
.	O
8	O
%	O
(	O
201	O
/	O
320	O
)	O
of	O
participants	B-LIVB
were	O
aware	B-PHYS
of	O
the	O
presence	B-DISO
of	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
from	O
the	O
Internet	B-OBJC
,	O
and	O
11	O
.	O

9	O
%	O
(	O
38	O
/	O
320	O
)	O
experienced	B-PHYS
counterfeit	O
products	B-OBJC
.	O

In	O
only	O
0	O
.	O
9	O
%	O
(	O
3	O
/	O
320	O
)	O
of	O
those	O
cases	O
were	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
reported	B-PROC
to	O
authorities	O
.	O

Moreover	O
,	O
7	O
.	O
2	O
%	O
(	O
23	O
/	O
320	O
)	O
of	O
the	O
participants	B-LIVB
experienced	B-PHYS
adverse	B-DISO
effects	I-DISO
due	O
to	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
.	O

In	O
summary	O
,	O
patients	B-LIVB
experienced	B-PHYS
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
that	O
resulted	O
in	O
adverse	B-DISO
effects	I-DISO
on	O
their	O
health	O
.	O

Although	O
certain	O
adverse	B-DISO
effects	I-DISO
were	O
reported	B-PROC
in	O
this	O
study	B-PROC
,	O
counterfeit	O
products	B-OBJC
were	O
underreported	B-PROC
to	O
authorities	O
.	O

Further	O
public	O
awareness	O
campaigns	O
and	O
patient	B-PROC
education	I-PROC
are	O
needed	O
.	O

Evaluation	O
of	O
Mathisen	O
's	O
technique	O
for	O
ureteral	B-PROC
reimplantation	I-PROC
in	O
children	B-LIVB
with	O
primary	O
vesicoureteral	B-DISO
reflux	I-DISO
Although	O
cross	B-PROC
-	I-PROC
trigonal	I-PROC
ureteral	I-PROC
reimplantation	I-PROC
(	I-PROC
Cohen	I-PROC
)	I-PROC
is	O
a	O
commonly	O
used	O
technique	O
in	O
children	B-LIVB
,	O
it	O
represents	O
a	O
non	B-PHYS
-	I-PHYS
physiological	I-PHYS
transfer	I-PHYS
of	O
the	O
ureteral	B-ANAT
orifices	I-ANAT
and	O
may	O
prove	O
challenging	O
with	O
regard	O
to	O
endoscopic	B-PROC
ureteral	I-PROC
operations	I-PROC
in	O
later	O
life	O
.	O

In	O
1964	O
,	O
Mathisen	O
described	O
an	O
alternative	O
method	O
of	O
ureteral	B-PROC
reimplantation	I-PROC
with	O
lateralization	O
of	O
the	O
neohiatus	O
,	O
creating	O
an	O
orthotopic	O
course	O
of	O
the	O
submucosal	B-ANAT
ureter	I-ANAT
.	O

We	O
have	O
evaluated	O
success	O
and	O
complication	O
rates	O
of	O
both	O
techniques	O
that	O
were	O
applied	O
sequentially	O
at	O
our	O
departments	O
.	O

Forty	O
-	O
eight	O
consecutive	O
patients	B-LIVB
(	O
83	O
ureters	B-LIVB
,	O
24	O
males	B-LIVB
/24	O
females	B-LIVB
)	O
following	O
Mathisen	B-PROC
reimplantation	I-PROC
were	O
compared	O
with	O
53	O
consecutive	O
patients	B-LIVB
(	O
98	O
ureters	B-LIVB
,	O
30	O
males	B-LIVB
/23	O
females	B-LIVB
)	O
following	O
Cohen	B-PROC
reimplantation	I-PROC
.	O

Inclusion	O
criteria	O
were	O
primary	O
vesicoureteral	B-DISO
reflux	I-DISO
(	O
VUR	B-DISO
)	O
and	O
no	O
previous	O
intervention	B-PROC
.	O

Reflux	B-DISO
grades	O
(	O
Mathisen	O
58	O
ureters	B-LIVB
/69	O
.	O

9	O
%	O
VUR	B-DISO
≥	I-DISO
III	I-DISO
;	O
Cohen	O
66	O
ureters	B-LIVB
/66	O
.	O

7	O
%	O
VUR	B-DISO
≥	I-DISO
III	I-DISO
)	O
and	O
the	O
occurence	O
of	O
other	O
complicating	O
factors	O
(	O
ureteroceles	B-DISO
,	O
megaureters	B-DISO
,	O
posterior	B-DISO
urethral	I-DISO
valves	I-DISO
)	O
in	O
both	O
groups	O
were	O
comparable	O
.	O

After	O
Cohen	B-PROC
's	I-PROC
reimplantation	I-PROC
there	O
were	O
no	O
immediate	O
complications	B-DISO
requiring	O
intervention	B-PROC
;	O
during	O
follow	B-PROC
-	I-PROC
up	I-PROC
(	O
mean	O
28	O
.	O
2	O
months	O
)	O
three	O
patients	B-LIVB
(	O
5	O
.	O
6	O
%	O
)	O
suffered	B-DISO
febrile	B-DISO
urinary	I-DISO
tract	I-DISO
infections	I-DISO
(	O
UTIs	B-DISO
)	O
,	O
of	O
which	O
one	O
(	O
1	O
.	O
8	O
%	O
)	O
was	O
diagnosed	B-DISO
with	O
a	O
persisting	O
VUR	B-DISO
.	O

Persistent	O
hydronephroses	B-DISO
(	O
≥II	O
SFU	B-DISO
)	O
were	O
recorded	O
in	O
six	O
patients	B-LIVB
(	O
13	O
.	O
2	O
%	O
)	O
.	O

After	O
reimplantation	B-PROC
using	O
Mathisen	O
's	O
technique	O
,	O
two	O
patients	B-LIVB
(	O
4	O
.	O
1	O
%	O
)	O
suffered	B-DISO
significant	O
intravesical	B-DISO
bleeding	I-DISO
;	O
during	O
follow	B-PROC
-	I-PROC
up	I-PROC
(	O
mean	O
23	O
.	O
06	O
months	O
)	O
four	O
patients	B-LIVB
(	O
8	O
.	O
3	O
%	O
)	O
suffered	B-DISO
febrile	B-DISO
UTIs	I-DISO
,	O
and	O
seven	O
patients	B-LIVB
(	O
14	O
.	O
5	O
%	O
)	O
were	O
diagnosed	B-DISO
with	O
persisting	O
VUR	B-DISO
after	O
a	O
mean	O
follow	B-PROC
-	I-PROC
up	I-PROC
of	O
10	O
.	O

8	O
months	O
.	O

The	O
patients	B-LIVB
with	O
persistent	O
VUR	B-DISO
had	O
more	O
commonly	O
high	O
-	O
grade	O
(	O
IV	O
and	O
V	O
)	O
VUR	B-DISO
initially	O
,	O
compared	O
to	O
the	O
whole	O
group	O
.	O

Two	O
patients	B-LIVB
(	O
4	O
.	O
1	O
%	O
)	O
had	O
persistent	O
hydronephroses	B-DISO
(	O
≥II	O
SFU	B-DISO
)	O
.	O

Mathisen	O
's	O
technique	O
for	O
ureteral	B-PROC
reimplantation	I-PROC
yielded	O
a	O
significantly	O
(	O
p	O
=	O
0	O
.	O

0256	O
patients	B-LIVB
,	O
p	O
=	O
0	O
.	O

006	O
ureterorenal	O
units	O
)	O
lower	O
success	O
rate	O
(	O
85	O
.	O
5	O
%	O
patients	B-LIVB
,	O
89	O
.	O

2	O
%	O
ureterorenal	O
units	O
)	O
in	O
comparison	O
with	O
Cohen	O
's	O
technique	O
(	O
98	O
.	O

2	O
%	O
patients	B-LIVB
,	O
99	O
%	O
ureterorenal	O
units	O
)	O
.	O

Although	O
there	O
was	O
no	O
intervention	B-PROC
for	O
obstruction	B-DISO
,	O
persistent	O
hydronephrosis	B-DISO
was	O
more	O
common	O
in	O
the	O
Cohen	O
group	O
(	O
13	O
.	O
2	O
%	O
vs	O
.	O

4	O
.	O
1	O
%	O
,	O
n	O
.	O

s	O
.	O
)	O
.	O

Despite	O
the	O
advantages	O
of	O
an	O
orthotopic	O
ureteral	B-ANAT
orifice	I-ANAT
close	O
to	O
the	O
bladder	B-ANAT
neck	I-ANAT
,	O
as	O
achieved	O
by	O
Mathisen	B-PROC
's	I-PROC
reimplantation	I-PROC
,	O
cross	B-PROC
-	I-PROC
trigonal	I-PROC
ureteral	I-PROC
reimplantation	I-PROC
proved	O
more	O
reliable	O
for	O
VUR	B-DISO
correction	O
.	O

As	O
regards	O
optimizing	O
the	O
results	O
,	O
patient	B-PROC
selection	I-PROC
for	O
either	O
technique	O
could	O
prove	O
essential	O
.	O

Nevertheless	O
,	O
as	O
regards	O
the	O
difficulties	O
with	O
ectopic	O
ureteral	B-ANAT
orifices	I-ANAT
in	O
the	O
Cohen	O
technique	O
in	O
the	O
long	O
-	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
the	O
concept	O
of	O
anatomic	O
,	O
orthotopic	O
ureteral	B-PROC
reimplantation	I-PROC
should	O
be	O
pursued	O
and	O
the	O
technique	O
should	O
be	O
further	O
refined	O
.	O

Experimental	B-PROC
study	I-PROC
of	O
GeneXpert	B-DEVI
(	I-DEVI
®	I-DEVI
)	I-DEVI
system	I-DEVI
in	O
the	O
diagnosis	B-PROC
of	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
To	O
explore	O
the	O
application	O
value	O
of	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
for	O
detection	B-PROC
of	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
and	O
resistance	B-PHEN
to	O
rifampin	B-CHEM
.	O

A	O
total	O
of	O
150	O
samples	B-ANAT
were	O
collected	O
,	O
including	O
33	O
needle	B-DEVI
aspirates	B-ANAT
from	O
lymphoid	B-DISO
tuberculosis	I-DISO
,	O
23	O
needle	B-DEVI
aspirates	B-ANAT
from	O
spinal	B-DISO
tuberculosis	I-DISO
,	O
49	O
from	O
tuberculous	B-DISO
pleural	I-DISO
effusions	I-DISO
,	O
24	O
from	O
cerebrospinal	B-ANAT
fluid	I-ANAT
of	O
tuberculous	B-DISO
cephalomeningitis	I-DISO
,	O
and	O
21	O
urinary	B-ANAT
sediment	I-ANAT
samples	I-ANAT
from	O
renal	B-DISO
tuberculosis	I-DISO
.	O

Smear	B-PROC
microscopy	I-PROC
,	O
mycobacterium	B-PROC
tuberculosis	I-PROC
culture	I-PROC
and	O
the	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
were	O
used	O
to	O
examine	O
these	O
samples	O
and	O
their	O
positive	O
rates	O
were	O
compared	O
.	O

Rifampin	B-PROC
susceptibility	I-PROC
tests	I-PROC
was	O
performed	O
for	O
culture	B-LIVB
-	I-LIVB
positive	I-LIVB
strains	I-LIVB
using	O
proportion	O
method	O
,	O
which	O
was	O
compared	O
with	O
the	O
result	O
from	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
.	O

Of	O
the	O
150	O
cases	O
of	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
,	O
17	O
samples	O
were	O
smear	B-DISO
-	I-DISO
positive	I-DISO
,	O
with	O
a	O
sensitivity	O
of	O
11	O
.	O

3	O
%	O
(	O
17	O
/	O
150	O
)	O
;	O
30	O
were	O
culture	B-DISO
-	I-DISO
positive	I-DISO
with	O
a	O
sensitivity	O
of	O
20	O
.	O

0	O
%	O
(	O
30	O
/	O
150	O
)	O
;	O
and	O
96	O
were	O
positive	B-DISO
by	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
with	O
a	O
sensitivity	O
of	O
64	O
.	O

0	O
%	O
(	O
96	O
/	O
150	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
and	O
the	O
culture	B-PROC
method	I-PROC
(	O
χ	O
(	O
2	O
)	O
=	O
59	O
.	O
61	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
differences	O
were	O
also	O
significant	O
when	O
the	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
was	O
compared	O
with	O
the	O
smear	B-PROC
method	I-PROC
(	O
χ	O
(	O
2	O
)	O
=	O
88	O
.	O
60	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
or	O
compared	O
with	O
culture	B-PROC
plus	I-PROC
smear	I-PROC
methods	I-PROC
(	O
χ	O
(	O
2	O
)	O
=	O
4	O
.	O
26	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Separately	O
,	O
the	O
differences	O
were	O
statistically	O
significant	O
between	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
and	O
other	O
2	O
methods	B-PROC
for	O
diagnosis	B-PROC
of	O
lymphoid	B-DISO
tuberculosis	I-DISO
(	O
n	O
=	O
33	O
,	O
χ	O
(	O
2	O
)	O
=	O
20	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O

culture	B-PROC
method	I-PROC
;	O
χ	O
(	O
2	O
)	O
=	O
27	O
.	O
13	O
,	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O

smear	B-PHEN
results	I-PHEN
)	O
while	O
no	O
difference	O
was	O
found	O
between	O
culture	B-PROC
and	O
smear	B-PROC
method	I-PROC
(	O
χ	O
(	O
2	O
)	O
=	O
0	O
.	O
67	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
spinal	B-DISO
tuberculosis	I-DISO
(	O
n	O
=	O
23	O
,	O
χ	O
(	O
2	O
)	O
=	O
12	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O

culture	B-PROC
method	I-PROC
;	O
χ	O
(	O
2	O
)	O
=	O
14	O
.	O
81	O
,	O
P	O
<	O
0	O
.	O

01	O
vs	O
.	O

smear	B-PROC
method	I-PROC
)	O
,	O
tuberculous	B-DISO
pleurisy	I-DISO
(	O
n	O
=	O
49	O
,	O
χ	O
(	O
2	O
)	O
=	O
32	O
.	O
34	O
,	O
P	O
<	O
0	O
.	O

01	O
vs	O
.	O

culture	B-PROC
method	I-PROC
;	O
χ	O
(	O
2	O
)	O
=	O
49	O
.	O
69	O
,	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O

smear	B-PROC
method	I-PROC
)	O
and	O
renal	B-DISO
tuberculosis	I-DISO
(	O
n	O
=	O
21	O
,	O
χ	O
(	O
2	O
)	O
=	O
4	O
.	O
20	O
,	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O

culture	B-PROC
method	I-PROC
;	O
χ	O
(	O
2	O
)	O
=	O
8	O
.	O
40	O
,	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O

smear	B-PHEN
results	I-PHEN
)	O
.	O

The	O
sensitivity	O
for	O
tuberculous	B-DISO
meningitis	I-DISO
had	O
no	O
difference	O
among	O
these	O
3	O
methods	B-PROC
(	O
n	O
=	O
24	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Rifampicin	B-PHEN
-	I-PHEN
resistance	I-PHEN
of	O
the	O
strains	B-LIVB
from	O
the	O
30	O
culture	B-DISO
-	I-DISO
positive	I-DISO
cases	I-DISO
of	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
(	O
20	O
.	O
0	O
%	O
,	O
6	O
/	O
30	O
)	O
exhibited	O
agreement	O
with	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
test	I-PROC
.	O

The	O
simplicity	O
and	O
high	O
sensitivity	O
of	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
technology	I-PROC
make	O
it	O
a	O
good	O
diagnostic	B-PROC
test	I-PROC
for	O
rapid	O
detection	B-PROC
of	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
and	O
resistance	B-PHEN
to	O
rifampin	B-CHEM
.	O

Influence	O
of	O
climatic	O
factors	O
on	O
the	O
flight	B-PHEN
activity	I-PHEN
of	O
the	O
stingless	O
bee	O
Partamona	O
orizabaensis	O
and	O
its	O
competition	O
behavior	O
at	O
food	B-OBJC
sources	B-DISO
Stingless	O
bee	O
s	O
have	O
evolved	O
several	O
ways	O
to	O
share	O
contested	O
resources	O
to	O
ensure	O
the	O
coexistence	O
between	O
different	O
species	O
.	O

Partamona	O
orizabaensis	O
quickly	O
exploits	O
food	B-OBJC
sources	B-DISO
by	O
fast	O
and	O
direct	O
recruitment	O
that	O
does	O
not	O
rely	O
on	O
scent	B-DISO
marks	I-DISO
deposited	O
on	O
substrates	B-OBJC
.	O

In	O
this	O
study	B-PROC
we	O
show	O
that	O
the	O
flight	B-PHEN
activity	I-PHEN
of	O
P	O
.	O

orizabaensis	O
is	O
influenced	O
by	O
weather	B-PHEN
conditions	O
,	O
with	O
higher	O
activity	O
during	O
periods	O
of	O
colder	O
temperatures	O
,	O
higher	O
relative	O
humidity	O
and	O
even	O
during	O
rainfall	B-PHEN
.	O

We	O
showed	O
that	O
the	O
outcome	O
of	O
aggression	O
experiments	B-PROC
between	O
the	O
non	B-DISO
-	I-DISO
aggressive	I-DISO
species	O
P	O
.	O

orizabaensis	O
and	O
its	O
aggressive	O
competitor	B-LIVB
Trigona	O
fuscipennis	O
is	O
influenced	O
by	O
the	O
number	O
of	O
bees	O
that	O
arrive	O
early	O
after	O
food	B-OBJC
source	B-DISO
discovery	O
.	O

Therefore	O
,	O
the	O
increased	O
activity	O
during	O
less	O
favorable	O
weather	B-PHEN
conditions	O
and	O
the	O
fast	O
recruitment	O
of	O
nestmates	B-LIVB
following	O
the	O
discovery	O
of	O
a	O
food	B-OBJC
source	B-DISO
,	O
as	O
observed	O
for	O
P	O
.	O

orizabaensis	O
,	O
may	O
be	O
adaptations	B-PHEN
that	O
evolved	O
to	O
coexist	O
even	O
with	O
more	O
aggressive	O
and	O
dominant	O
species	O
of	O
stingless	O
bees	O
,	O
with	O
which	O
P	O
.	O

orizabaensis	O
has	O
to	O
compete	O
for	O
resources	O
.	O

Withdrawal	O
of	O
Anticancer	B-PROC
Therapy	I-PROC
in	O
Advanced	O
Disease	O
Because	O
of	O
Side	B-DISO
Effects	I-DISO
Withdrawal	O
of	O
chemotherapy	B-PROC
because	O
of	O
side	B-DISO
effects	I-DISO
may	O
be	O
due	O
to	O
""""	O
problems	O
with	O
toxicity	O
""""	O
or	O
""""	O
patient	B-LIVB
refusal	O
""""	O
.	O
""""	O
Problems	O
with	O
toxicity	O
""""	O
is	O
intended	O
to	O
secure	B-PHYS
patient	B-PROC
safety	I-PROC
and	O
decisions	B-PHYS
about	O
it	O
are	O
primarily	O
made	O
by	O
the	O
oncologist	B-LIVB
.	O

On	O
the	O
other	O
hand	O
,	O
""""	O
patient	B-LIVB
refusal	O
""""	O
is	O
influenced	O
by	O
the	O
degree	B-DISO
of	I-DISO
distress	I-DISO
the	O
patient	B-LIVB
is	O
experiencing	B-PHYS
and	O
the	O
patient	B-LIVB
's	I-LIVB
preference	O
.	O

Providing	O
sufficient	O
medical	O
information	O
is	O
essential	O
in	O
decision	B-PHYS
making	I-PHYS
,	O
because	O
it	O
is	O
a	O
decision	B-PHYS
made	O
by	O
the	O
patient	B-LIVB
.	O

In	O
addition	O
,	O
the	O
perception	O
of	O
side	B-DISO
effects	I-DISO
has	O
changed	O
owing	O
to	O
progress	O
in	O
supportive	B-PROC
therapy	I-PROC
in	O
recent	O
years	O
.	O

In	O
particular	O
,	O
cancer	B-DISO
patients	B-LIVB
are	O
concerned	O
about	O
changes	O
in	O
appearance	B-PHYS
.	O

In	O
our	O
study	O
(	O
4	O
/	O
2015	O
to	O
3	O
/	O
2016	O
)	O
,	O
chemotherapy	B-PROC
was	O
withdrawn	B-DISO
because	O
of	O
side	B-DISO
effects	I-DISO
during	O
treatment	B-PROC
for	O
solid	B-DISO
carcinomas	I-DISO
in	O
8	O
%	O
(	O
4	O
/	O
51	O
)	O
of	O
the	O
patients	B-LIVB
.	O

Two	O
of	O
these	O
patients	B-LIVB
experienced	B-PHYS
liver	B-PHYS
function	I-PHYS
disorders	B-DISO
,	O
and	O
2	O
developed	O
interstitial	B-DISO
pneumonitis	I-DISO
.	O

Patient	B-LIVB
refusal	O
was	O
observed	O
in	O
2	O
%	O
(	O
1	O
/	O
51	O
)	O
of	O
the	O
patients	B-LIVB
.	O

Molecular	B-PHYS
Mechanisms	I-PHYS
of	O
Resistance	B-PHYS
to	O
First	B-CHEM
-	I-CHEM
and	O
Second	B-CHEM
-	I-CHEM
Generation	I-CHEM
ALK	I-CHEM
Inhibitors	I-CHEM
in	O
ALK	B-CHEM
-Rearranged	O
Lung	B-DISO
Cancer	I-DISO
Advanced	O
,	O
anaplastic	B-CHEM
lymphoma	I-CHEM
kinase	I-CHEM
(	O
ALK	B-CHEM
)	O
-	O
positive	O
lung	B-DISO
cancer	I-DISO
is	O
currently	O
treated	B-PROC
with	I-PROC
the	O
first	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitor	I-CHEM
crizotinib	B-CHEM
followed	O
by	O
more	O
potent	O
,	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
(	O
e	O
.	O

g	O
.	O
,	O
ceritinib	B-CHEM
and	O
alectinib	B-CHEM
)	O
upon	O
progression	B-DISO
.	O

Second	B-CHEM
-	I-CHEM
generation	I-CHEM
inhibitors	I-CHEM
are	O
generally	O
effective	O
even	O
in	O
the	O
absence	O
of	O
crizotinib	B-CHEM
-	O
resistant	B-PHYS
ALK	O
mutations	B-PHYS
,	O
likely	O
reflecting	O
incomplete	O
inhibition	B-PHYS
of	O
ALK	B-CHEM
by	O
crizotinib	B-CHEM
in	O
many	O
cases	O
.	O

Herein	O
,	O
we	O
analyzed	O
103	O
repeat	O
biopsies	B-PROC
from	O
ALK	B-CHEM
-positive	O
patients	B-LIVB
progressing	O
on	O
various	O
ALK	B-CHEM
inhibitors	I-CHEM
.	O

We	O
find	O
that	O
each	O
ALK	B-CHEM
inhibitor	I-CHEM
is	O
associated	O
with	O
a	O
distinct	O
spectrum	O
of	O
ALK	O
resistance	B-PHYS
mutations	I-PHYS
and	O
that	O
the	O
frequency	O
of	O
one	O
mutation	B-PHYS
,	O
ALK	O
(	O
G1202R	O
)	O
,	O
increases	O
significantly	O
after	O
treatment	B-PROC
with	I-PROC
second	B-CHEM
-	I-CHEM
generation	I-CHEM
agents	I-CHEM
.	O

To	O
investigate	O
strategies	O
to	O
overcome	O
resistance	B-PHYS
to	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
,	O
we	O
examine	O
the	O
activity	B-PHYS
of	O
the	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitor	I-CHEM
lorlatinib	B-CHEM
in	O
a	O
series	O
of	O
ceritinib	B-CHEM
-	O
resistant	B-PHYS
,	O
patient	B-LIVB
-derived	O
cell	B-ANAT
lines	I-ANAT
,	O
and	O
observe	O
that	O
the	O
presence	O
of	O
ALK	O
resistance	B-PHYS
mutations	I-PHYS
is	O
highly	O
predictive	O
for	O
sensitivity	O
to	O
lorlatinib	B-CHEM
,	O
whereas	O
those	O
cell	B-ANAT
lines	I-ANAT
without	O
ALK	O
mutations	B-PHYS
are	O
resistant	B-PHYS
.	O

Secondary	O
ALK	O
mutations	B-PHYS
are	O
a	O
common	O
resistance	B-PHYS
mechanism	B-PHYS
to	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
and	O
predict	O
for	O
sensitivity	O
to	O
the	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitor	I-CHEM
lorlatinib	B-CHEM
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
repeat	O
biopsies	B-PROC
and	O
genotyping	B-PROC
following	O
disease	B-DISO
progression	I-DISO
on	O
targeted	O
therapies	B-PROC
,	O
particularly	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
.	I-CHEM

Cancer	O
Discov	O
;	O
6	O
(	O
10	O
)	O
;	O
1118	O
-	O
33	O
.	O

©	O
2016	O
AACRSee	O
related	O
commentary	O
by	O
Qiao	O
and	O
Lovly	O
,	O
p	O
.	O

1084This	O
article	O
is	O
highlighted	O
in	O
the	O
In	O
This	O
Issue	O
feature	O
,	O
p	O
.	O

1069	O
.	O

The	O
use	O
of	O
neonatal	O
extracorporeal	B-PROC
life	I-PROC
support	I-PROC
in	O
pediatric	O
cardiac	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-PROC
extracorporeal	B-PROC
life	I-PROC
support	I-PROC
system	I-PROC
(	O
ECLS	B-PROC
)	O
employed	O
in	O
neonates	B-LIVB
in	O
pediatric	O
cardiac	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
.	O

Twenty	O
-	O
five	O
neonates	B-LIVB
that	O
required	O
ECLS	B-PROC
in	O
between	O
November	O
2010	O
and	O
November	O
2015	O
were	O
evaluated	B-PROC
.	O

The	O
median	O
age	B-PHYS
was	O
12	O
days	O
(	O
range	O
3	O
-	O
28	O
days	O
)	O
and	O
the	O
median	O
body	B-PHYS
weight	I-PHYS
was	O
3	O
kg	O
(	O
range	O
2	O
.	O
5	O
-	O
5	O
kg	O
)	O
.	O

Venoarterial	O
ECLS	B-PROC
was	O
performed	O
in	O
all	O
of	O
the	O
cases	O
.	O

Ascendan	B-ANAT
aorta	I-ANAT
-	O
right	B-ANAT
atrial	I-ANAT
cannulation	B-PROC
in	O
22	O
patients	B-LIVB
and	O
neck	B-ANAT
cannulation	B-PROC
in	O
three	O
patients	B-LIVB
were	O
performed	O
.	O

The	O
reason	O
for	O
ECLS	B-PROC
was	O
E	B-PROC
-	I-PROC
CPR	I-PROC
in	O
two	O
patients	B-LIVB
,	O
inability	B-DISO
to	I-DISO
wean	I-DISO
from	O
cardiopulmonary	B-PROC
bypass	I-PROC
(	O
CPB	B-PROC
)	O
in	O
seven	O
patients	B-LIVB
,	O
respiratory	B-DISO
insufficiency	I-DISO
and	O
hypoxia	B-DISO
in	O
nine	O
patients	B-LIVB
,	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
(	O
LCOS	B-DISO
)	O
in	O
seven	O
patients	B-LIVB
.	O

Median	O
duration	O
of	O
ECLS	B-PROC
was	O
four	O
days	O
(	O
range	O
1	O
-	O
15	O
)	O
.	O

Hemorrhagic	O
complications	B-DISO
developed	O
in	O
15	O
,	O
renal	B-DISO
complications	I-DISO
in	O
13	O
,	O
pulmonary	B-DISO
complications	I-DISO
in	O
12	O
,	O
infectious	B-DISO
complications	B-DISO
in	O
11	O
,	O
neurologic	B-DISO
complications	I-DISO
in	O
three	O
and	O
mechanical	B-DISO
complications	I-DISO
in	O
two	O
of	O
the	O
patients	B-LIVB
.	O

Weaning	B-DISO
was	O
successful	O
in	O
15	O
of	O
the	O
patients	B-LIVB
.	O

Eleven	O
patients	B-LIVB
were	O
successfully	O
discharged	B-PROC
.	O

ECLS	B-PROC
is	O
an	O
important	O
treatment	B-PROC
option	I-PROC
that	O
is	O
performed	O
successfully	O
in	O
many	O
centers	B-OBJC
around	O
the	O
world	B-LIVB
to	O
maintain	O
life	B-PROC
support	I-PROC
in	O
patients	B-LIVB
unresponsive	O
to	O
medical	O
treatment	O
.	O

The	O
utilization	O
of	O
this	O
modality	O
especially	O
in	O
newborns	B-LIVB
with	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
should	O
be	O
taken	O
into	O
consideration	O
.	O

It	O
's	O
not	O
All	O
Doom	O
and	O
Gloom	O
:	O
Prune	B-DISO
Belly	I-DISO
Syndrome	I-DISO
Associated	B-DISO
with	I-DISO
VACTERL	I-DISO
Prune	B-DISO
belly	I-DISO
syndrome	I-DISO
is	O
a	O
rare	O
abnormality	B-DISO
;	O
its	O
association	B-DISO
with	I-DISO
VACTERL	I-DISO
is	O
even	O
rarer	O
.	O

This	O
association	B-DISO
has	O
been	O
reported	B-PROC
in	O
literature	O
a	O
few	O
times	O
since	O
first	O
reported	B-PROC
in	O
1993	O
and	O
so	O
far	O
the	O
majority	O
have	O
either	O
been	O
stillbirths	B-DISO
or	I-DISO
died	I-DISO
shortly	I-DISO
after	I-DISO
birth	I-DISO
.	O

We	O
present	O
a	O
case	O
of	O
Prune	B-DISO
belly	I-DISO
syndrome	I-DISO
associated	B-DISO
with	I-DISO
VACTERL	I-DISO
who	O
is	O
now	O
one	O
year	O
old	O
.	O

Targeted	O
DNA	O
Sequencing	O
Reveals	O
Patterns	O
of	O
Local	O
Progression	B-DISO
in	O
the	O
Pancreatic	B-ANAT
Remnant	B-ANAT
Following	O
Resection	B-PROC
of	O
Intraductal	B-DISO
Papillary	I-DISO
Mucinous	I-DISO
Neoplasm	I-DISO
(	O
IPMN	B-DISO
)	O
of	O
the	O
Pancreas	B-ANAT
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
characterize	O
patterns	O
of	O
local	O
progression	B-DISO
following	O
resection	B-PROC
for	O
pancreatic	B-DISO
intraductal	I-DISO
papillary	I-DISO
mucinous	I-DISO
neoplasms	I-DISO
(	O
IPMN	B-DISO
)	O
using	O
targeted	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
.	O

Progression	B-DISO
of	O
neoplastic	B-DISO
disease	I-DISO
in	O
the	O
remnant	B-ANAT
pancreas	B-ANAT
following	O
resection	B-PROC
of	O
IPMN	B-DISO
may	O
include	O
development	O
of	O
a	O
new	O
IPMN	B-DISO
or	O
ductal	B-DISO
adenocarcinoma	I-DISO
(	O
PDAC	B-DISO
)	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
this	O
progression	B-DISO
represents	O
recurrence	B-DISO
of	O
the	O
same	O
neoplasm	B-DISO
or	O
an	O
independent	O
second	B-DISO
neoplasm	I-DISO
.	O

Targeted	B-PROC
-	I-PROC
NGS	I-PROC
on	O
genes	O
commonly	O
mutated	B-PHYS
in	O
IPMN	B-DISO
and	O
PDAC	B-DISO
was	O
performed	O
on	O
tumors	B-DISO
from	O
(	O
1	O
)	O
13	O
patients	B-LIVB
who	O
developed	O
disease	B-DISO
progression	I-DISO
in	O
the	O
remnant	B-ANAT
pancreas	B-ANAT
following	O
resection	B-PROC
of	O
IPMN	B-DISO
;	O
and	O
(	O
2	O
)	O
10	O
patients	B-LIVB
who	O
underwent	O
a	O
resection	B-PROC
for	O
PDAC	B-DISO
and	O
had	O
a	O
concomitant	O
IPMN	B-DISO
.	O

Mutations	B-PHYS
in	O
the	O
tumors	B-DISO
were	O
compared	O
in	O
order	O
to	O
determine	O
the	O
relationship	O
between	O
neoplasms	B-DISO
.	O

In	O
parallel	O
,	O
clinical	B-PHYS
and	O
pathological	O
characteristics	O
of	O
260	O
patients	B-LIVB
who	O
underwent	O
resection	B-PROC
of	O
noninvasive	B-DISO
IPMN	I-DISO
were	O
reviewed	O
to	O
identify	O
risk	B-DISO
factors	I-DISO
associated	O
with	O
local	O
progression	B-DISO
.	O

We	O
identified	O
3	O
mechanisms	O
underlying	O
local	O
progression	B-DISO
in	O
the	O
remnant	B-ANAT
pancreas	B-ANAT
:	O
(	O
1	O
)	O
residual	B-DISO
microscopic	I-DISO
disease	I-DISO
at	O
the	O
resection	B-ANAT
margin	I-ANAT
,	O
(	O
2	O
)	O
intraparenchymal	B-ANAT
spread	B-DISO
of	O
neoplastic	B-ANAT
cells	I-ANAT
,	O
leading	O
to	O
an	O
anatomically	O
separate	O
but	O
genetically	O
related	O
recurrence	B-DISO
,	O
and	O
(	O
3	O
)	O
multifocal	B-DISO
disease	I-DISO
with	O
genetically	O
distinct	O
lesions	B-DISO
.	O

Analysis	B-PROC
of	O
the	O
260	O
patients	B-LIVB
with	O
noninvasive	B-DISO
IPMNs	I-DISO
showed	O
that	O
family	B-DISO
history	I-DISO
of	O
pancreatic	B-DISO
cancer	I-DISO
(	O
P	O
=	O
0	O
.	O
027	O
)	O
and	O
high	B-DISO
-	I-DISO
grade	I-DISO
dysplasia	I-DISO
(	O
HGD	B-DISO
)	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
were	O
independent	O
risk	B-DISO
factors	I-DISO
for	O
the	O
development	O
of	O
an	O
IPMN	B-DISO
with	O
HGD	B-DISO
or	O
an	O
invasive	B-DISO
carcinoma	I-DISO
in	O
the	O
remnant	B-ANAT
pancreas	B-ANAT
.	O

Using	O
NGS	O
,	O
we	O
identify	O
distinct	O
mechanisms	O
for	O
development	O
of	O
metachronous	B-DISO
or	O
synchronous	B-DISO
neoplasms	I-DISO
in	O
patients	B-LIVB
with	O
IPMN	B-DISO
.	O

Patients	B-LIVB
with	O
a	O
primary	O
IPMN	B-DISO
with	O
HGD	B-DISO
or	O
with	O
positive	B-DISO
family	B-DISO
history	I-DISO
are	O
at	O
an	O
increased	O
risk	O
to	O
develop	O
subsequent	O
high	B-DISO
-	I-DISO
risk	I-DISO
neoplasms	B-DISO
in	O
the	O
remnant	B-ANAT
pancreas	B-ANAT
.	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
as	O
a	O
useful	O
diagnostic	B-PHYS
marker	I-PHYS
for	O
the	O
distinction	O
of	O
systemic	B-DISO
juvenile	I-DISO
idiopathic	I-DISO
arthritis	I-DISO
and	O
Kawasaki	B-DISO
disease	I-DISO
The	O
clinical	O
features	O
and	O
laboratory	B-PROC
parameters	I-PROC
of	O
patients	B-LIVB
with	O
Kawasaki	B-DISO
disease	I-DISO
(	O
KD	B-DISO
)	O
and	O
systemic	B-DISO
juvenile	I-DISO
idiopathic	I-DISO
arthritis	I-DISO
(	O
s	B-DISO
-	I-DISO
JIA	I-DISO
)	O
tend	O
to	O
overlap	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
no	O
definitive	O
biomarkers	B-PHYS
for	O
these	O
disease	B-DISO
s	I-DISO
,	O
making	O
clinical	B-PROC
diagnosis	I-PROC
difficult	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	B-PROC
the	O
diagnostic	B-DISO
value	I-DISO
of	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
for	O
differentiating	O
KD	B-DISO
from	O
s	B-DISO
-	I-DISO
JIA	I-DISO
and	O
predicting	O
the	O
disease	O
severity	O
of	O
KD	B-DISO
.	O

We	O
analyzed	O
228	O
patients	B-LIVB
with	O
KD	B-DISO
and	O
81	O
patients	B-LIVB
with	O
s	B-DISO
-	I-DISO
JIA	I-DISO
.	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
were	O
compared	O
between	O
patients	B-LIVB
with	O
s	B-DISO
-	I-DISO
JIA	I-DISO
and	O
KD	B-DISO
.	O

Furthermore	O
,	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
in	O
patients	B-LIVB
with	O
KD	B-DISO
were	O
compared	O
with	O
respect	O
to	O
clinical	O
features	O
such	O
as	O
responsiveness	B-PHYS
to	O
intravenous	O
immunoglobulin	B-PROC
(	I-PROC
IVIG	I-PROC
)	I-PROC
therapy	I-PROC
.	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
in	O
KD	B-DISO
patients	B-LIVB
with	O
no	B-DISO
response	I-DISO
to	O
IVIG	B-PROC
therapy	I-PROC
were	O
significantly	O
higher	O
than	O
those	O
in	O
KD	B-DISO
patients	B-LIVB
with	O
a	O
good	O
response	B-PHYS
to	O
IVIG	B-PROC
therapy	I-PROC
.	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
in	O
patients	B-LIVB
with	O
KD	B-DISO
needing	O
plasma	B-PROC
exchange	I-PROC
(	O
PE	B-PROC
)	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
patients	B-LIVB
not	O
needing	O
PE	B-PROC
.	O

However	O
,	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
overlapped	O
between	O
severe	O
KD	B-DISO
patients	B-LIVB
with	O
nonresponsiveness	B-DISO
to	O
IVIG	B-PROC
therapy	I-PROC
or	O
needing	O
PE	B-PROC
and	O
other	O
patients	B-LIVB
with	O
mild	O
KD	B-DISO
.	O

Furthermore	O
,	O
patients	B-LIVB
with	O
s	B-DISO
-	I-DISO
JIA	I-DISO
showed	O
a	O
distinct	O
elevation	O
of	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
compared	O
with	O
KD	B-DISO
patients	B-LIVB
.	O

The	O
cutoff	O
value	O
of	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
for	O
differentiating	O
KD	B-DISO
from	O
s	B-DISO
-	I-DISO
JIA	I-DISO
was	O
369	O
.	O

6	O
ng	O
/	O
ml	O
.	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
were	O
significantly	O
elevated	O
in	O
s	B-DISO
-	I-DISO
JIA	I-DISO
patients	B-LIVB
compared	O
with	O
KD	B-DISO
patients	B-LIVB
.	O

Measurement	B-PROC
of	I-PROC
serum	I-PROC
ferritin	I-PROC
levels	I-PROC
can	O
be	O
useful	O
for	O
differentiating	O
s	B-DISO
-	I-DISO
JIA	I-DISO
from	O
KD	B-DISO
.	O

Changes	O
in	O
Cardiovascular	B-ANAT
Health	O
Status	O
and	O
the	O
Risk	O
of	O
New	O
-	O
Onset	O
Hypertension	O
in	O
Kailuan	B-LIVB
Cohort	O
Study	O
American	O
Heart	O
Association	O
cardiovascular	B-ANAT
health	O
metrics	O
are	O
intimately	O
related	O
to	O
cardiovascular	B-DISO
diseases	I-DISO
.	O

Acting	O
as	O
a	O
key	O
independent	O
risk	B-DISO
factor	I-DISO
for	O
high	O
morbidity	O
and	O
mortality	O
of	O
cardiovascular	B-DISO
diseases	I-DISO
,	O
hypertension	B-DISO
and	O
its	O
relationship	O
between	O
health	O
status	O
get	O
urgent	O
attention	B-PHYS
.	O

While	O
the	O
influence	O
of	O
individual	B-LIVB
health	O
status	O
changes	O
and	O
the	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
is	O
rarely	O
understood	O
,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	B-PROC
the	O
changes	O
of	O
cardiovascular	B-ANAT
health	O
status	O
and	O
the	O
morbidity	O
of	O
hypertension	B-DISO
in	O
Kailuan	B-LIVB
cohort	O
study	O
in	O
north	O
China	B-GEOG
.	O

The	O
Cardiovascular	B-ANAT
Health	O
Score	O
(	O
CHS	O
)	O
was	O
evaluated	B-PROC
by	O
the	O
follow	B-PROC
-	I-PROC
ups	I-PROC
of	O
2006	O
-	O
2007	O
,	O
2008	O
-	O
2009	O
,	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
.	O

The	O
study	B-LIVB
population	I-LIVB
(	O
n	O
=	O
19381	O
)	O
was	O
divided	O
into	O
5	O
groups	O
based	O
on	O
the	O
changes	O
in	O
their	O
CHS	O
score	O
between	O
the	O
first	O
two	O
follow	B-PROC
-	I-PROC
ups	I-PROC
(	O
△	O
CHS	O
)	O
of	O
2006	O
-	O
2007	O
and	O
2008	O
-	O
2009	O
(	O
≤	O
-	O
2	O
,	O
-1	O
,	O
0	O
,	O
1	O
,	O
≥2	O
)	O
.	O

The	O
morbidity	O
of	O
hypertension	B-DISO
was	O
collected	O
during	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
follow	B-PROC
-	I-PROC
ups	I-PROC
.	O

Data	O
analysis	O
showed	O
that	O
during	O
a	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
of	O
3	O
.	O

79±0	O
.	O

96	O
years	O
,	O
morbidity	O
of	O
hypertension	B-DISO
had	O
a	O
graded	O
relationship	O
with	O
△	O
CHS	O
.	O

As	O
△	O
CHS	O
scored	O
from	O
low	O
to	O
high	O
,	O
the	O
standardized	B-PROC
morbidity	O
of	O
hypertension	B-DISO
for	O
all	O
participants	B-LIVB
were	O
81	O
.	O
40	O
,	O
75	O
.	O
47	O
,	O
68	O
.	O
37	O
,	O
71	O
.	O
43	O
and	O
83	O
.	O
13	O
per	O
1000	O
person	O
-	O
year	O
,	O
respectively	O
.	O

An	O
increased	O
△	O
CHS	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10	O
%	O
decrease	O
in	O
the	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
(	O
HR	O
:	O
0	O
.	O
90	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
88	O
-	O
0	O
.	O
92	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	O
between	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
hypertension	O
and	O
elevation	O
of	O
cardiovascular	B-ANAT
health	O
metrics	O
.	O

Population	B-LIVB
-wide	O
prevention	O
,	O
especially	O
the	O
promotion	B-PROC
of	O
lifestyle	O
improvements	O
,	O
is	O
critical	O
to	O
reducing	O
the	O
morbidity	O
of	O
new	O
-	O
onset	O
hypertension	O
.	O

Phenozan	B-CHEM
,	O
a	O
Synthetic	B-CHEM
Phenolic	I-CHEM
Antioxidant	B-CHEM
,	O
Inhibits	O
the	O
Development	O
of	O
Spontaneous	O
Tumors	B-DISO
in	O
Rats	B-LIVB
and	O
Mice	B-LIVB
Synthetic	B-CHEM
phenolic	I-CHEM
antioxidant	B-CHEM
β	B-CHEM
-	I-CHEM
(	I-CHEM
4	I-CHEM
-	I-CHEM
hydroxy	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
5	I-CHEM
-	I-CHEM
di	I-CHEM
-	I-CHEM
tert	I-CHEM
-	I-CHEM
butylphenyl	I-CHEM
)	I-CHEM
propionic	I-CHEM
acid	I-CHEM
,	O
named	O
phenozan	B-CHEM
,	O
is	O
a	O
potential	O
antiepileptic	B-CHEM
drug	I-CHEM
.	O

In	O
pre	O
-	O
clinical	O
trials	B-PROC
this	O
substance	B-OBJC
did	O
not	O
manifest	O
any	O
toxicity	B-DISO
,	O
and	O
also	O
inhibited	O
the	O
development	O
of	O
some	O
spontaneous	O
tumors	B-DISO
in	O
animals	B-LIVB
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
inhibiting	O
effect	O
of	O
phenozan	B-CHEM
on	O
spontaneous	O
carcinogenesis	B-DISO
in	O
rats	B-LIVB
and	O
mice	B-LIVB
.	O

In	O
experiments	B-PROC
with	O
rats	B-LIVB
LIO	I-LIVB
and	O
mice	B-LIVB
SHR	I-LIVB
of	O
local	O
breeding	B-PHYS
,	O
with	O
high	O
spontaneous	O
tumor	B-DISO
incidence	O
,	O
phenozan	B-CHEM
was	O
dissolved	O
in	O
sunflower	B-CHEM
oil	I-CHEM
and	O
administered	O
by	O
gavage	O
in	O
therapeutic	O
dose	O
5	O
mg	O
/	O
kg	O
3	O
times	O
per	O
week	O
for	O
18	O
months	O
.	O

There	O
were	O
no	O
any	O
signs	O
of	O
toxicity	B-DISO
and	O
differences	O
in	O
weight	B-PHYS
of	O
animals	B-LIVB
during	O
the	O
phenozan	B-CHEM
treatment	O
compared	O
with	O
the	O
control	B-LIVB
(	O
sunflower	B-CHEM
oil	I-CHEM
)	O
.	O

Phenozan	B-CHEM
significantly	O
reduced	O
the	O
overall	O
incidence	O
and	O
multiplicity	O
of	O
all	O
tumors	B-DISO
but	O
only	O
multiplicity	O
of	O
malignant	B-DISO
tumors	I-DISO
,	O
compared	O
with	O
the	O
control	B-LIVB
.	O

Moreover	O
a	O
significant	O
decrease	O
of	O
overall	O
incidence	O
and	O
multiplicity	O
was	O
observed	O
in	O
pituitary	B-DISO
and	O
breast	B-DISO
tumors	I-DISO
in	O
females	B-PHYS
and	O
only	O
overall	O
multiplicity	O
of	O
tumors	B-DISO
of	O
pituitary	B-ANAT
and	O
lymphoid	O
tissue	O
in	O
males	B-PHYS
.	O

In	O
mice	B-LIVB
phenozan	B-CHEM
reduced	O
overall	O
incidence	O
and	O
multiplicity	O
of	O
lung	B-DISO
tumors	I-DISO
(	O
in	O
females	B-PHYS
)	O
and	O
also	O
overall	O
multiplicity	O
of	O
all	O
tumors	B-DISO
(	O
in	O
females	B-PHYS
)	O
and	O
only	O
malignant	B-DISO
tumors	I-DISO
(	O
in	O
males	B-PHYS
)	O
.	O

These	O
findings	O
allow	O
us	O
to	O
classify	O
phenozan	B-CHEM
as	O
anticarcinogenic	B-CHEM
agent	I-CHEM
.	O

Anticarcinogenic	B-CHEM
activity	O
of	O
phenozan	B-CHEM
is	O
important	O
because	O
clinical	B-PROC
study	I-PROC
of	O
this	O
drug	B-CHEM
as	O
the	O
possible	O
antiepileptic	B-CHEM
drug	I-CHEM
goes	O
along	O
and	O
it	O
is	O
known	O
that	O
such	O
drugs	B-CHEM
are	O
designed	O
for	O
long	O
-	O
term	O
use	O
.	O

Medicare	O
claims	O
indicators	O
of	O
healthcare	B-PROC
utilization	O
differences	O
after	O
hospitalization	B-PROC
for	O
ischemic	B-DISO
stroke	I-DISO
:	O
Race	B-LIVB
,	O
gender	B-PHYS
,	O
and	O
caregiving	O
effects	O
Background	O
Differences	O
in	O
healthcare	B-PROC
utilization	O
after	O
stroke	B-DISO
may	O
partly	O
explain	O
race	B-LIVB
or	O
gender	B-PHYS
differences	O
in	O
stroke	B-DISO
outcomes	O
and	O
identify	O
factors	O
that	O
might	O
reduce	O
post	O
-	O
acute	B-DISO
stroke	I-DISO
care	O
costs	O
.	O

Aim	O
To	O
examine	O
systematic	O
differences	O
in	O
Medicare	O
claims	O
for	O
healthcare	B-PROC
utilization	O
after	O
hospitalization	B-PROC
for	O
ischemic	B-DISO
stroke	I-DISO
in	O
a	O
US	B-GEOG
population	B-LIVB
-based	O
sample	B-LIVB
.	O

Methods	O
Claims	O
were	O
examined	B-DISO
over	O
a	O
six	O
-	O
month	O
period	O
after	O
hospitalization	B-PROC
for	O
279	O
ischemic	B-DISO
stroke	I-DISO
survivors	B-LIVB
65	O
years	O
or	O
older	B-LIVB
from	O
the	O
REasons	O
for	O
Geographic	O
And	O
Racial	B-DISO
Differences	I-DISO
in	O
Stroke	B-DISO
(	O
REGARDS	B-DISO
)	O
study	O
.	O

Statistical	B-PROC
analyses	I-PROC
examined	B-DISO
differences	O
in	O
post	O
-	O
acute	B-PROC
healthcare	I-PROC
utilization	O
,	O
adjusted	O
for	O
pre	O
-	O
stroke	B-DISO
utilization	O
,	O
as	O
a	O
function	O
of	O
race	B-LIVB
(	O
African	B-LIVB
-	I-LIVB
American	I-LIVB
vs	O
.	O

White	B-LIVB
)	O
,	O
gender	B-PHYS
,	O
age	B-PHYS
,	O
stroke	O
belt	O
residence	O
,	O
income	O
,	O
Medicaid	O
dual	O
-	O
eligibility	O
,	O
Charlson	O
comorbidity	O
index	O
,	O
and	O
whether	O
the	O
person	B-LIVB
lived	O
with	O
an	O
available	O
caregiver	B-LIVB
.	O

Results	O
After	O
adjusting	O
for	O
covariates	O
,	O
women	B-LIVB
were	O
more	O
likely	O
than	O
men	B-LIVB
to	O
receive	O
home	B-PROC
health	I-PROC
care	I-PROC
and	O
to	O
use	O
emergency	B-PROC
department	I-PROC
services	I-PROC
during	O
the	O
post	O
-	O
acute	B-PROC
care	I-PROC
period	O
.	O

These	O
effects	O
were	O
maintained	O
even	O
after	O
further	O
adjustment	O
for	O
acute	B-DISO
stroke	I-DISO
severity	O
.	O

African	B-LIVB
-	I-LIVB
Americans	I-LIVB
had	O
more	O
home	B-PROC
health	I-PROC
care	I-PROC
visits	B-PROC
than	O
Whites	B-LIVB
among	O
patients	B-LIVB
who	O
received	O
some	O
home	B-PROC
health	I-PROC
care	I-PROC
.	O

Having	O
a	O
co	O
-	O
residing	O
caregiver	B-LIVB
was	O
associated	O
with	O
reduced	O
acute	B-PROC
hospitalization	I-PROC
length	O
of	O
stay	O
and	O
fewer	O
post	O
-	O
acute	B-PROC
emergency	I-PROC
department	I-PROC
and	O
primary	B-PROC
care	I-PROC
physician	I-PROC
visits	I-PROC
.	O

Conclusions	O
Underutilization	O
of	O
healthcare	O
after	O
stroke	B-DISO
does	O
not	O
appear	O
to	O
explain	O
poorer	O
long	O
-	O
term	O
stroke	B-DISO
outcomes	O
for	O
women	B-LIVB
and	O
African	B-LIVB
-	I-LIVB
Americans	I-LIVB
in	O
this	O
epidemiologically	O
-derived	O
sample	B-LIVB
.	O

Caregiver	B-LIVB
availability	O
may	O
contribute	O
to	O
reduced	O
formal	O
care	O
and	O
cost	O
during	O
the	O
post	O
-	O
acute	B-PROC
period	O
.	O

Towards	O
next	B-PROC
-	I-PROC
generation	I-PROC
sequencing	I-PROC
analytics	I-PROC
for	O
foodborne	O
RNA	B-LIVB
viruses	I-LIVB
:	O
Examining	O
the	O
effect	O
of	O
RNA	B-CHEM
input	O
quantity	O
and	O
viral	B-CHEM
RNA	I-CHEM
purity	O
Detection	B-PROC
and	O
identification	B-PROC
of	O
viruses	B-LIVB
in	O
food	B-OBJC
samples	I-OBJC
are	O
technically	O
challenging	O
due	O
largely	O
to	O
the	O
low	O
viral	B-LIVB
copy	O
number	O
in	O
contaminated	B-OBJC
food	I-OBJC
items	I-OBJC
,	O
and	O
the	O
lack	O
of	O
effective	O
culture	B-PROC
enrichment	I-PROC
methods	I-PROC
that	O
are	O
amenable	O
to	O
regulatory	O
applications	O
for	O
many	O
of	O
the	O
common	O
foodborne	O
viruses	B-LIVB
.	O

Using	O
an	O
Illumina	O
MiSeq	O
platform	O
and	O
two	O
hepatitis	B-LIVB
A	I-LIVB
virus	I-LIVB
(	O
HAV	B-LIVB
)	O
cell	B-PROC
-	I-PROC
culture	I-PROC
adapted	O
strains	O
as	O
a	O
representative	O
enteric	O
virus	B-LIVB
species	O
,	O
this	O
study	B-PROC
examined	O
the	O
limits	O
of	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
(	O
ssRNA	B-CHEM
)	O
viral	B-PROC
detection	I-PROC
following	O
next	B-PROC
-	I-PROC
generation	I-PROC
sequencing	I-PROC
without	O
pre	B-PHYS
-	I-PHYS
amplification	I-PHYS
of	O
the	O
viral	O
genome	O
.	O

Complete	O
viral	O
genome	O
sequences	O
were	O
obtained	O
from	O
HAV	B-LIVB
samples	O
of	O
varying	O
purities	O
and	O
with	O
an	O
input	O
as	O
low	O
as	O
2ng	O
total	O
RNA	B-CHEM
containing	O
1	O
.	O

4×10	O
(	O
5	O
)	O
copies	O
of	O
viral	B-CHEM
RNA	I-CHEM
.	O

In	O
addition	O
,	O
single	O
nucleotide	O
variations	O
were	O
reproducibly	O
detected	O
over	O
the	O
range	O
of	O
concentrations	O
examined	O
,	O
and	O
their	O
identity	O
confirmed	O
by	O
alternate	B-PROC
sequencing	I-PROC
technology	I-PROC
.	O

In	O
summary	O
,	O
next	B-PROC
-	I-PROC
generation	I-PROC
sequencing	I-PROC
technology	I-PROC
has	O
the	O
potential	O
for	O
sensitive	O
detection	B-PROC
/	O
identification	B-PROC
of	O
a	O
viral	O
genome	O
at	O
a	O
low	O
copy	O
number	O
.	O

This	O
study	B-PROC
provides	O
a	O
benchmark	O
for	O
metagenomic	B-PROC
sequencing	I-PROC
application	I-PROC
as	O
is	O
required	O
for	O
virus	B-PROC
detection	I-PROC
in	O
complex	O
food	B-OBJC
matrices	O
using	O
a	O
culture	B-PROC
-independent	O
diagnostic	B-PROC
approach	I-PROC
.	O

Long	B-PROC
-	I-PROC
Term	I-PROC
Safety	I-PROC
Follow	I-PROC
-	I-PROC
Up	I-PROC
of	O
Subjects	B-LIVB
Previously	O
Treated	B-PROC
with	I-PROC
Non	O
-	O
Replicating	O
Retroviral	B-CHEM
Vector	I-CHEM
-Based	O
Gene	B-PROC
Therapies	I-PROC
Our	O
objective	O
was	O
to	O
evaluate	B-PROC
the	O
life	B-PROC
-	I-PROC
long	I-PROC
safety	I-PROC
profile	I-PROC
of	O
gene	B-PROC
therapy	I-PROC
using	O
retroviral	B-CHEM
(	I-CHEM
non	I-CHEM
-	I-CHEM
replicating	I-CHEM
)	I-CHEM
vectors	I-CHEM
(	O
nRCR	B-CHEM
)	O
,	O
or	O
cell	B-ANAT
products	B-OBJC
in	O
127	O
subjects	B-LIVB
with	O
hemophilia	B-DISO
,	O
human	B-LIVB
immunodeficiency	I-LIVB
virus	I-LIVB
(	O
HIV	B-LIVB
)	O
,	O
or	O
cancer	B-DISO
,	O
previously	O
treated	B-PROC
with	I-PROC
such	O
gene	B-PROC
therapy	I-PROC
.	O

We	O
assessed	O
the	O
occurrence	O
of	O
serious	B-DISO
adverse	I-DISO
events	I-DISO
(	O
SAEs	B-DISO
)	O
,	O
deaths	B-PHYS
and	O
presence	O
of	O
replication	B-CHEM
competent	I-CHEM
retrovirus	I-CHEM
(	O
RCR	B-CHEM
)	O
.	O

A	O
total	O
of	O
23	O
subjects	B-LIVB
remained	O
until	O
the	O
data	O
cut	O
-	O
off	O
date	O
of	O
31	O
July	O
2013	O
and	O
provided	O
safety	O
information	O
of	O
up	O
to	O
18	O
years	O
.	O

Of	O
the	O
104	O
subjects	B-LIVB
who	O
discontinued	B-DISO
,	O
the	O
primary	O
reason	O
was	O
loss	B-DISO
to	I-DISO
follow	I-DISO
-	I-DISO
up	I-DISO
(	O
47	O
.	O
2	O
%	O
;	O
n	O
=	O
60	O
)	O
.	O

The	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
for	O
the	O
60	O
subjects	B-LIVB
lost	B-DISO
to	I-DISO
follow	I-DISO
-	I-DISO
up	I-DISO
was	O
7	O
-	O
10	O
years	O
.	O

A	O
total	O
of	O
41	O
subjects	B-LIVB
experienced	B-PHYS
at	O
least	O
one	O
SAE	B-DISO
,	O
and	O
15	O
subjects	B-LIVB
died	B-PHYS
.	O

We	O
reviewed	O
SAEs	B-DISO
and	O
cause	B-DISO
of	I-DISO
death	I-DISO
(	O
none	O
related	O
to	O
the	O
active	O
therapy	B-PROC
)	O
,	O
but	O
no	O
evidence	O
was	O
found	O
for	O
safety	B-PHEN
signals	B-PHEN
related	O
to	O
new	O
malignancy	B-DISO
or	O
neurologic	O
,	O
rheumatological	B-DISO
,	O
autoimmune	B-DISO
,	O
or	O
hematologic	B-DISO
disorder	I-DISO
.	O

RCR	B-CHEM
results	B-PHEN
were	O
negative	B-DISO
,	O
indicating	O
no	O
evidence	O
for	O
in	O
vivo	O
vector	B-LIVB
persistence	O
.	O

Despite	O
the	O
loss	B-DISO
of	I-DISO
follow	I-DISO
-	I-DISO
up	I-DISO
,	O
which	O
is	O
the	O
limiting	O
factor	O
in	O
this	O
long	O
-	O
term	O
safety	B-PROC
trial	I-PROC
,	O
the	O
findings	B-DISO
from	O
this	O
long	B-PROC
-	I-PROC
term	I-PROC
follow	I-PROC
-	I-PROC
up	I-PROC
study	B-PROC
are	O
encouraging	O
.	O

An	O
HIV	B-LIVB
-	O
tailored	B-PROC
quit	O
-	O
smoking	O
counselling	B-PROC
pilot	B-PROC
intervention	B-PROC
targeting	O
depressive	B-DISO
symptoms	I-DISO
plus	O
Nicotine	B-PROC
Replacement	I-PROC
Therapy	I-PROC
Cardiovascular	B-DISO
disease	I-DISO
(	O
CVD	B-DISO
)	O
rates	O
among	O
people	B-LIVB
living	B-LIVB
with	I-LIVB
HIV	I-LIVB
/	I-LIVB
AIDS	I-LIVB
(	O
PHAs	B-LIVB
)	O
are	O
high	O
.	O

Rates	O
of	O
cigarette	O
smoking	O
,	O
a	O
leading	O
contributor	O
to	O
CVD	B-DISO
among	O
PHAs	B-LIVB
,	O
are	O
40	O
-	O
70	O
%	O
(	O
2	O
-	O
3	O
times	O
higher	O
than	O
the	O
general	B-LIVB
population	I-LIVB
)	O
.	O

Furthermore	O
,	O
PHAs	B-LIVB
have	O
high	O
rates	O
of	O
depression	B-DISO
(	O
40	O
-	O
60	O
%	O
)	O
,	O
a	O
risk	B-DISO
factor	I-DISO
for	O
smoking	O
cessation	O
relapse	B-PHEN
.	O

The	O
current	O
pilot	B-PROC
study	I-PROC
examined	B-DISO
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	B-PROC
5	O
-	O
session	O
smoking	O
cessation	O
counselling	B-PROC
programme	I-PROC
for	O
PHAs	B-LIVB
,	O
which	O
addressed	O
depression	B-DISO
,	O
in	O
combination	O
with	O
Nicotine	B-PROC
Replacement	I-PROC
Therapy	I-PROC
(	O
NRT	B-PROC
)	O
in	O
a	O
cohort	B-LIVB
of	O
PHA	B-LIVB
smokers	B-DISO
(	O
n	O
=	O
50	O
)	O
.	O

At	O
6	O
-	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O
28	O
%	O
of	O
participants	B-LIVB
demonstrated	O
biochemically	O
verified	O
abstinence	B-PROC
from	O
smoking	O
.	O

This	O
result	B-DISO
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	B-PROC
studies	B-PROC
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	B-PHEN
+	I-PHEN
smokers	B-DISO
with	O
depression	B-DISO
.	O

At	O
study	B-PROC
baseline	O
,	O
52	O
%	O
of	O
HIV	B-PHEN
+	I-PHEN
smokers	B-DISO
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	B-DISO
on	O
the	O
Centre	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	O
(	O
CES	O
-	O
D	O
)	O
scale	O
.	O

HIV	B-PHEN
+	I-PHEN
smokers	B-DISO
with	O
depression	B-DISO
at	O
study	B-PROC
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	B-DISO
at	O
6	O
-	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.058	O
)	O
.	O

Furthermore	O
,	O
those	O
with	O
depression	B-DISO
were	O
no	O
more	O
likely	O
to	O
relapse	B-PHEN
than	O
those	O
without	O
depression	B-DISO
(	O
p	O
=	O
.33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	B-PROC
programme	I-PROC
adequately	O
addressed	O
this	O
significant	O
barrier	O
to	O
smoking	O
cessation	O
among	O
PHAs	B-LIVB
.	O

Our	O
pilot	B-PROC
study	I-PROC
indicates	O
the	O
importance	O
of	O
tailored	B-PROC
programmes	I-PROC
to	O
help	O
PHAs	B-LIVB
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	B-DISO
symptoms	I-DISO
,	O
and	O
the	O
need	O
for	O
tailored	B-PROC
counselling	I-PROC
programmes	I-PROC
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	B-LIVB
.	O

Growth	B-DISO
arrest	I-DISO
of	O
lung	B-DISO
carcinoma	I-DISO
cells	B-ANAT
(	B-ANAT
A549	I-ANAT
)	I-ANAT
by	O
polyacrylate	B-CHEM
-	O
anchored	B-PROC
peroxovanadate	B-CHEM
by	O
activating	O
Rac1	B-CHEM
-	O
NADPH	B-CHEM
oxidase	I-CHEM
signalling	B-PHYS
axis	O
Hydrogen	B-CHEM
peroxide	I-CHEM
is	O
often	O
required	O
in	O
sublethal	B-DISO
,	O
millimolar	O
concentrations	O
to	O
show	O
its	O
oxidant	B-CHEM
effects	I-CHEM
on	O
cells	B-PROC
in	I-PROC
culture	I-PROC
as	O
it	O
is	O
easily	O
destroyed	O
by	O
cellular	B-ANAT
catalase	B-CHEM
.	O

Previously	O
,	O
we	O
had	O
shown	O
that	O
diperoxovanadate	B-CHEM
,	O
a	O
physiologically	O
stable	O
peroxovanadium	B-CHEM
compound	I-CHEM
,	O
can	O
substitute	O
H2O2	B-CHEM
effectively	O
in	O
peroxidation	B-PHEN
reactions	I-PHEN
.	O

We	O
report	O
here	O
that	O
peroxovanadate	B-CHEM
when	O
anchored	B-PROC
to	O
polyacrylic	B-CHEM
acid	I-CHEM
(	B-CHEM
PAPV	I-CHEM
)	I-CHEM
becomes	O
a	O
highly	O
potent	O
inhibitor	O
of	O
growth	B-PHYS
of	O
lung	B-DISO
carcinoma	I-DISO
cells	B-ANAT
(	O
A549	B-ANAT
)	O
.	O

The	O
early	O
events	O
associated	O
with	O
PAPV	B-CHEM
treatment	O
included	O
cytoskeletal	B-ANAT
modifications	B-DISO
,	O
increase	O
in	O
GTPase	B-PHYS
activity	I-PHYS
of	O
Rac1	B-CHEM
,	O
accumulation	B-DISO
of	O
the	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
,	O
and	O
also	O
increase	O
in	O
phosphorylation	B-PHYS
of	O
H2AX	B-CHEM
(	B-CHEM
γH2AX	I-CHEM
)	I-CHEM
,	O
a	O
marker	O
of	O
DNA	B-DISO
damage	I-DISO
.	O

These	O
effects	O
persisted	O
even	O
at	O
24	O
h	O
after	O
removal	O
of	O
the	O
compound	O
and	O
culminated	O
in	O
increased	O
levels	O
of	O
p53	B-CHEM
and	O
p21	B-CHEM
together	O
with	O
growth	B-DISO
arrest	I-DISO
.	O

The	O
PAPV	B-CHEM
-mediated	O
growth	B-DISO
arrest	I-DISO
was	O
significantly	O
abrogated	O
in	O
cells	B-ANAT
pre	O
-	O
treated	O
with	O
the	O
N	B-CHEM
-	I-CHEM
acetylcysteine	I-CHEM
,	O
Rac1	B-CHEM
knocked	B-PROC
down	I-PROC
by	O
siRNA	B-CHEM
and	O
DPI	B-CHEM
an	O
inhibitor	O
of	O
NADPH	B-CHEM
oxidase	I-CHEM
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
polyacrylate	B-CHEM
derivative	O
of	O
peroxovanadate	B-CHEM
efficiently	O
arrests	B-DISO
growth	I-DISO
of	O
A549	B-ANAT
cancerous	B-ANAT
cells	I-ANAT
by	O
activating	O
the	O
axis	O
of	O
Rac1	B-CHEM
-	O
NADPH	B-CHEM
oxidase	I-CHEM
leading	O
to	O
oxidative	B-DISO
stress	I-DISO
and	O
DNA	B-DISO
damage	I-DISO
.	O

Fractal	O
analysis	B-PROC
of	O
the	O
ischemic	O
transition	O
region	O
in	O
chronic	B-DISO
ischemic	I-DISO
heart	I-DISO
disease	I-DISO
using	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
To	O
introduce	O
a	O
novel	O
hypothesis	O
and	O
method	O
to	O
characterise	O
pathomechanisms	B-DISO
underlying	O
myocardial	B-DISO
ischemia	I-DISO
in	O
chronic	B-DISO
ischemic	I-DISO
heart	I-DISO
disease	I-DISO
by	O
local	O
fractal	O
analysis	B-PROC
(	O
FA	B-PROC
)	O
of	O
the	O
ischemic	O
myocardial	O
transition	O
region	O
in	O
perfusion	B-PROC
imaging	I-PROC
.	O

Vascular	B-ANAT
mechanisms	O
to	O
compensate	O
ischemia	B-DISO
are	O
regulated	B-PHEN
at	O
various	O
vascular	B-ANAT
scales	O
with	O
their	O
superimposed	B-PROC
perfusion	I-PROC
pattern	O
being	O
hypothetically	O
self	O
-	O
similar	O
.	O

Dedicated	O
FA	B-PROC
software	B-OBJC
(	O
""""	O
FraktalWandler	O
""""	O
)	O
has	O
been	O
developed	O
.	O

Fractal	O
dimensions	O
during	O
first	O
-	O
pass	O
(	O
FDfirst	O
-	O
pass	O
)	O
and	O
recirculation	B-PHYS
(	O
FDrecirculation	B-PHYS
)	O
are	O
hypothesised	O
to	O
indicate	O
the	O
predominating	O
pathomechanism	B-DISO
and	O
ischemic	O
severity	O
,	O
respectively	O
.	O
Twenty	O
-	O
six	O
patients	B-LIVB
with	O
evidence	O
of	O
myocardial	B-DISO
ischemia	I-DISO
in	O
108	O
ischemic	O
myocardial	O
segments	O
on	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
(	O
MRI	B-PROC
)	O
were	O
analysed	O
.	O

The	O
40th	O
and	O
60th	O
percentiles	O
of	O
FDfirst	O
-	O
pass	O
were	O
used	O
for	O
pathomechanical	O
classification	O
,	O
assigning	O
lesions	B-DISO
with	O
FDfirst	O
-	O
pass	O
≤	O
2	O
.	O

335	O
to	O
predominating	O
coronary	B-DISO
microvascular	I-DISO
dysfunction	I-DISO
(	O
CMD	B-DISO
)	O
and	O
≥2	O
.	O
387	O
to	O
predominating	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O
CAD	B-DISO
)	O
.	O

Optimal	O
classification	O
point	O
in	O
ROC	O
analysis	B-PROC
was	O
FDfirst	O
-	O
pass	O
=	O
2	O
.	O
358	O
.	O

FDrecirculation	B-PHYS
correlated	O
moderately	O
with	O
per	O
cent	O
diameter	O
stenosis	O
in	O
invasive	O
coronary	B-PROC
angiography	I-PROC
in	O
lesions	B-DISO
classified	O
CAD	B-DISO
(	O
r	O
=	O
0	O
.	O
472	O
,	O
p	O
=	O
0	O
.	O

001	O

)	O

but	O
not	O
CMD	B-DISO
(	O
r	O
=	O
0	O
.	O
082	O
,	O
p	O
=	O
0	O
.	O
600	O
)	O
.	O

The	O
ischemic	B-DISO
transition	O
region	B-ANAT
may	O
provide	O
information	O
on	O
pathomechanical	O
composition	O
and	O
severity	O
of	O
myocardial	B-DISO
ischemia	I-DISO
.	O

FA	B-PROC
of	O
this	O
region	B-ANAT
is	O
feasible	O
and	O
may	O
improve	B-DISO
diagnosis	B-DISO
compared	O
to	O
traditional	O
noninvasive	O
myocardial	B-PHYS
perfusion	I-PHYS
analysis	B-PROC
.	O

•	O
A	O
novel	O
hypothesis	O
and	O
method	O
is	O
introduced	O
to	O
pathophysiologically	O
characterise	O
myocardial	B-DISO
ischemia	I-DISO
.	O

•	O
The	O
ischemic	B-DISO
transition	O
region	B-ANAT
appears	O
a	O
meaningful	O
diagnostic	O
target	O
in	O
perfusion	B-PROC
imaging	I-PROC
.	O

•	O
Fractal	O
analysis	B-PROC
may	O
characterise	O
pathomechanical	O
composition	O
and	O
severity	O
of	O
myocardial	B-DISO
ischemia	I-DISO
.	O

Do	O
dynamic	O
global	O
vegetation	O
models	O
capture	O
the	O
seasonality	O
of	O
carbon	B-PHEN
fluxes	I-PHEN
in	O
the	O
Amazon	B-GEOG
basin	I-GEOG
?	O

A	O
data	O
-	O
model	O
intercomparison	O
To	O
predict	O
forest	B-PHEN
response	B-PHYS
to	O
long	O
-	O
term	O
climate	B-PHEN
change	I-PHEN
with	O
high	O
confidence	O
requires	O
that	O
dynamic	O
global	O
vegetation	O
models	O
(	O
DGVMs	O
)	O
be	O
successfully	O
tested	O
against	O
ecosystem	B-PHEN
response	B-PHYS
to	O
short	O
-	O
term	O
variations	O
in	O
environmental	O
drivers	O
,	O
including	O
regular	O
seasonal	O
patterns	O
.	O

Here	O
,	O
we	O
used	O
an	O
integrated	O
dataset	O
from	O
four	O
forests	B-PHEN
in	O
the	O
Brasil	O
flux	O
network	O
,	O
spanning	O
a	O
range	O
of	O
dry	O
-	O
season	O
intensities	O
and	O
lengths	O
,	O
to	O
determine	O
how	O
well	O
four	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
models	O
(	O
IBIS	O
,	O
ED2	O
,	O
JULES	O
,	O
and	O
CLM3	O
.	O

5	O
)	O
simulated	O
the	O
seasonality	O
of	O
carbon	B-PHEN
exchanges	I-PHEN
in	O
Amazonian	B-GEOG
tropical	B-PHEN
forests	I-PHEN
.	O

We	O
found	O
that	O
most	O
DGVMs	O
poorly	O
represented	O
the	O
annual	O
cycle	O
of	O
gross	O
primary	O
productivity	O
(	O
GPP	O
)	O
,	O
of	O
photosynthetic	O
capacity	O
(	O
Pc	O
)	O
,	O
and	O
of	O
other	O
fluxes	B-PHEN
and	O
pools	O
.	O

Models	O
simulated	O
consistent	O
dry	O
-	O
season	O
declines	O
in	O
GPP	O
in	O
the	O
equatorial	B-GEOG
Amazon	I-GEOG
(	O
Manaus	B-GEOG
K34	I-GEOG
,	O
Santarem	B-GEOG
K67	I-GEOG
,	O
and	O
Caxiuanã	B-GEOG
CAX	I-GEOG
)	O
;	O
a	O
contrast	O
to	O
observed	O
GPP	O
increases	O
.	O

Model	O
simulated	O
dry	O
-	O
season	O
GPP	O
reductions	O
were	O
driven	O
by	O
an	O
external	O
environmental	O
factor	O
,	O
'	O
soil	B-DISO
water	I-DISO
stress	I-DISO
'	O
and	O
consequently	O
by	O
a	O
constant	O
or	O
decreasing	O
photosynthetic	B-PHEN
infrastructure	I-PHEN
(	O
Pc	O
)	O
,	O
while	O
observed	O
dry	O
-	O
season	O
GPP	O
resulted	O
from	O
a	O
combination	O
of	O
internal	O
biological	O
(	O
leaf	B-LIVB
-flush	O
and	O
abscission	B-PHYS
and	O
increased	O
Pc	O
)	O
and	O
environmental	O
(	O
incoming	O
radiation	B-PHEN
)	O
causes	O
.	O

Moreover	O
,	O
we	O
found	O
models	O
generally	O
overestimated	O
observed	O
seasonal	O
net	O
ecosystem	O
exchange	O
(	O
NEE	O
)	O
and	O
respiration	B-PHYS
(	O
Re	B-PHYS
)	O
at	O
equatorial	O
locations	O
.	O

In	O
contrast	O
,	O
a	O
southern	B-GEOG
Amazon	I-GEOG
forest	B-PHEN
(	O
Jarú	O
RJA	O
)	O
exhibited	O
dry	O
-	O
season	O
declines	O
in	O
GPP	O
and	O
Re	B-PHYS
consistent	O
with	O
most	O
DGVMs	O
simulations	B-PROC
.	O

While	O
water	O
limitation	O
was	O
represented	O
in	O
models	O
and	O
the	O
primary	O
driver	O
of	O
seasonal	O
photosynthesis	B-PHEN
in	O
southern	B-GEOG
Amazonia	I-GEOG
,	O
changes	O
in	O
internal	O
biophysical	B-PHEN
processes	I-PHEN
,	O
light	B-PHYS
-	I-PHYS
harvesting	I-PHYS
adaptations	B-PHEN
(	O
e	O
.	O
g	O
.	O

,	O
variations	O
in	O
leaf	O
area	O
index	O
(	O
LAI	O
)	O
and	O
increasing	O
leaf	B-LIVB
-level	O
assimilation	B-PHEN
rate	O
related	O
to	O
leaf	O
demography	O
)	O
,	O
and	O
allocation	O
lags	O
between	O
leaf	B-LIVB
and	O
wood	B-LIVB
,	O
dominated	O
equatorial	B-GEOG
Amazon	I-GEOG
carbon	B-PHEN
flux	I-PHEN
dynamics	O
and	O
were	O
deficient	O
or	O
absent	O
from	O
current	O
model	O
formulations	O
.	O

Correctly	O
simulating	O
flux	B-PHEN
seasonality	O
at	O
tropical	B-PHEN
forests	I-PHEN
requires	O
a	O
greater	O
understanding	O
and	O
the	O
incorporation	O
of	O
internal	O
biophysical	B-PHYS
mechanisms	I-PHYS
in	O
future	O
model	O
developments	O
.	O

Detailed	O
Morphology	O
of	O
All	O
Life	O
Stages	O
of	O
the	O
Agave	O
Red	O
Worm	O
,	O
Comadia	O
redtenbacheri	O
(	O
Hammerschmidt	O
)	O
(	O
Lepidoptera	O
:	O
Cossidae	O
)	O
The	O
agave	O
red	O
worm	O
,	O
Comadia	O
redtenbacheri	O
(	O
Hammerschmidt	O
)	O
,	O
is	O
an	O
important	O
source	O
of	O
food	B-OBJC
and	O
income	O
in	O
Mexico	B-GEOG
.	O

Despite	O
its	O
importance	O
,	O
several	O
aspects	O
of	O
its	O
biology	O
,	O
morphology	O
,	O
and	O
behavior	O
remain	O
poorly	O
studied	O
.	O

In	O
this	O
work	O
,	O
we	O
describe	O
and	O
illustrate	O
the	O
morphology	O
of	O
all	O
the	O
life	O
stages	O
that	O
may	O
aid	O
in	O
understanding	O
certain	O
aspects	O
of	O
its	O
biology	O
.	O

To	O
obtain	O
all	O
life	O
stages	O
,	O
last	O
instar	O
larvae	O
were	O
collected	O
from	O
agave	B-LIVB
plants	I-LIVB
and	O
allowed	O
to	O
pupate	O
;	O
after	O
the	O
adults	O
emerged	O
,	O
they	O
were	O
allowed	O
to	O
mate	B-PHYS
and	O
oviposit	B-PHYS
.	O

The	O
frenulum	O
is	O
longer	O
in	O
males	B-PHYS
;	O
epiphysis	B-ANAT
I	I-ANAT
is	O
longer	O
in	O
females	B-PHYS
than	O
in	O
males	B-PHYS
;	O
the	O
abdomen	B-ANAT
bears	O
two	O
types	O
of	O
tubercles	B-ANAT
of	O
unknown	O
function	O
.	O

Eggs	B-ANAT
present	O
a	O
reticulate	B-ANAT
chorion	I-ANAT
;	O
primary	O
rosette	B-ANAT
cells	I-ANAT
are	O
highly	O
variable	O
in	O
shape	O
;	O
the	O
micropylar	O
formula	O
is	O
(	O
10	O
-	O
14	O
)	O
:	O
(	O
12	O
-	O
13	O
)	O
.	O

First	O
instar	O
larvae	O
are	O
white	O
,	O
becoming	O
red	O
as	O
they	O
develop	B-PHYS
;	O
L3	B-ANAT
in	O
the	O
prothorax	B-ANAT
is	O
subprimary	B-DISO
;	O
the	O
SV	B-ANAT
setal	I-ANAT
group	O
in	O
A1	O
is	O
comprised	O
of	O
only	O
SV1	O
on	O
first	O
instar	O
larvae	O
;	O
last	O
instars	O
have	O
several	O
secondary	O
setae	B-ANAT
.	O

Pupae	O
are	O
adecticous	B-DISO
and	O
obtect	B-DISO
;	O
there	O
are	O
rows	O
of	O
spines	B-ANAT
on	O
the	O
dorsum	B-ANAT
of	I-ANAT
the	I-ANAT
abdomen	I-ANAT
.	O

The	O
biological	O
significance	O
of	O
some	O
of	O
the	O
findings	B-DISO
is	O
discussed	O
.	O

Scald	B-DISO
burn	I-DISO
,	O
a	O
preventable	B-PROC
injury	I-PROC
:	O
Analysis	B-PROC
of	O
4306	O
patients	B-LIVB
from	O
a	O
major	O
tertiary	B-OBJC
care	I-OBJC
center	I-OBJC
Scalds	B-DISO
have	O
distinct	O
epidemiological	O
and	O
predisposing	O
risk	B-DISO
factors	I-DISO
amongst	O
all	O
types	O
of	O
burns	B-DISO
.	O

Though	O
scald	B-DISO
affects	O
all	O
age	B-LIVB
groups	I-LIVB
,	O
the	O
brunt	O
falls	O
on	O
the	O
minor	B-LIVB
age	B-LIVB
groups	I-LIVB
.	O

It	O
may	O
result	O
in	O
major	O
physical	B-DISO
disabilities	I-DISO
and	O
significant	O
loss	O
of	O
school	B-OBJC
years	O
.	O

Apart	O
from	O
the	O
economic	O
burden	O
on	O
family	B-LIVB
,	O
major	O
scald	B-DISO
burn	I-DISO
may	O
compromise	B-DISO
overall	O
development	B-PHYS
of	O
the	O
affected	O
children	B-LIVB
.	O

Most	O
of	O
the	O
scald	B-DISO
injuries	I-DISO
occur	O
in	O
domestic	O
settings	O
and	O
are	O
preventable	O
.	O

Despite	O
improvement	O
in	O
living	O
conditions	O
,	O
the	O
incidence	O
of	O
scald	B-DISO
burn	I-DISO
has	O
failed	O
to	O
decline	O
.	O

Our	O
aim	O
was	O
to	O
study	B-PROC
the	O
detailed	O
epidemiology	O
and	O
severity	O
of	O
scald	B-DISO
burn	I-DISO
amongst	O
all	O
age	B-LIVB
groups	I-LIVB
.	O

A	O
retrospective	B-PROC
study	I-PROC
was	O
carried	O
out	O
from	O
the	O
records	O
of	O
all	O
burn	B-DISO
patients	B-LIVB
who	O
attended	O
a	O
tertiary	O
burn	O
care	O
center	O
from	O
January	O
2013	O
and	O
December	O
2014	O
.	O

Data	O
of	O
the	O
patients	B-LIVB
with	O
scald	B-DISO
injury	I-DISO
was	O
segregated	O
and	O
analyzed	B-PROC
using	O
Microsoft	B-OBJC
excel	I-OBJC
spreadsheet	I-OBJC
.	O

10	O
,	O
175	O
burn	B-DISO
patients	B-LIVB
attended	O
the	O
burn	O
casualty	O
during	O
the	O
study	B-PROC
period	O
,	O
of	O
which	O
42	O
.	O

3	O
%	O
had	O
sustained	O
scald	B-DISO
.	O

56	O
.	O

85	O
%	O
of	O
patients	B-LIVB
were	O
under	O
15	O
years	O
of	O
age	B-PHYS
with	O
preschool	B-LIVB
children	I-LIVB
(	O
36	O
.	O

4	O
%	O
)	O
being	O
the	O
prime	B-LIVB
victims	I-LIVB
of	O
scald	B-DISO
.	O

The	O
%	O
TBSA	B-PHYS
involved	O
is	O
also	O
relatively	O
larger	O
in	O
children	B-LIVB
.	O

Scald	B-DISO
follows	O
definite	O
seasonal	O
variation	O
peaking	O
in	O
winters	O
.	O

36	O
.	O

8	O
%	O
patients	B-DISO
arrived	I-DISO
to	O
the	O
hospital	B-OBJC
without	O
any	O
first	B-PROC
aid	I-PROC
.	O

74	O
.	O
2	O
%	O
of	O
patients	B-LIVB
reported	O
to	O
casualty	O
with	O
in	O
24hours	O
after	O
sustaining	O
scald	B-DISO
injury	I-DISO
.	O

The	O
median	O
time	O
interval	O
between	O
injury	B-DISO
and	O
reporting	O
to	O
casualty	O
was	O
3hours	O
30	O
minutes	O
.	O

This	O
study	B-PROC
concludes	O
that	O
the	O
scald	B-DISO
is	O
injury	B-DISO
of	O
all	O
age	B-LIVB
groups	I-LIVB
,	O
though	O
majority	O
of	O
them	O
are	O
children	B-LIVB
.	O

The	O
first	B-PROC
aid	I-PROC
is	O
not	O
given	O
to	O
large	O
number	O
of	O
patients	B-LIVB
and	O
late	O
reporting	O
is	O
quite	O
common	O
.	O

These	O
are	O
the	O
factors	O
which	O
may	O
affect	O
the	O
course	O
of	O
scald	B-DISO
burn	I-DISO
.	O

Spreading	O
public	O
awareness	B-PHYS
regarding	O
safe	B-PHEN
household	B-LIVB
practises	O
and	O
educating	O
them	O
for	O
proper	O
first	B-PROC
aid	I-PROC
management	O
after	O
scald	B-DISO
may	O
have	O
significant	O
impact	O
on	O
the	O
burden	O
of	O
care	O
and	O
outcome	O
.	O

Effects	O
of	O
complex	O
life	O
cycles	O
on	O
genetic	B-PHEN
diversity	I-PHEN
:	O
cyclical	B-PHYS
parthenogenesis	I-PHYS
Neutral	O
patterns	O
of	O
population	B-LIVB
genetic	B-PHEN
diversity	I-PHEN
in	O
species	O
with	O
complex	O
life	O
cycles	O
are	O
difficult	O
to	O
anticipate	O
.	O

Cyclical	B-PHYS
parthenogenesis	I-PHYS
(	O
CP	B-PHYS
)	O
,	O
in	O
which	O
organisms	B-LIVB
undergo	O
several	O
rounds	O
of	O
clonal	O
reproduction	B-PHYS
followed	O
by	O
a	O
sexual	O
event	O
,	O
is	O
one	O
such	O
life	O
cycle	O
.	O

Many	O
species	O
,	O
including	O
crop	B-LIVB
pests	B-LIVB
(	O
aphids	O
)	O
,	O
human	O
parasites	O
(	O
trematodes	O
)	O
or	O
models	O
used	O
in	O
evolutionary	O
science	O
(	O
Daphnia	O
)	O
,	O
are	O
cyclical	B-LIVB
parthenogens	I-LIVB
.	O

It	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life	O
cycle	O
on	O
neutral	O
genetic	B-PHEN
diversity	I-PHEN
.	O

In	O
this	O
paper	O
,	O
we	O
describe	O
distributions	O
of	O
genetic	B-PHEN
diversity	I-PHEN
under	O
conditions	O
of	O
CP	B-PHYS
with	O
various	O
clonal	O
phase	O
lengths	O
.	O

Using	O
a	O
Markov	O
chain	O
model	O
of	O
CP	B-PHYS
for	O
a	O
single	O
locus	O
and	O
individual	O
-	O
based	O
simulations	B-PROC
for	O
two	O
loci	O
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	O
from	O
full	O
sexuality	O
are	O
observed	O
after	O
only	O
a	O
few	O
generations	O
of	O
clonality	O
.	O

The	O
convergence	O
towards	O
predictions	O
made	O
under	O
conditions	O
of	O
full	O
clonality	O
during	O
the	O
clonal	O
phase	O
depends	O
on	O
the	O
balance	O
between	O
mutations	B-PHYS
and	O
genetic	B-PHYS
drift	I-PHYS
.	O

Second	O
,	O
the	O
sexual	O
event	O
of	O
CP	B-PHYS
usually	O
resets	O
the	O
genetic	B-PHEN
diversity	I-PHEN
at	O
a	O
single	O
locus	O
towards	O
predictions	O
made	O
under	O
full	O
sexuality	O
.	O

However	O
,	O
this	O
single	O
recombination	B-PHYS
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic	B-PHYS
phases	I-PHYS
towards	O
full	O
-	O
sexuality	O
predictions	O
.	O

Finally	O
,	O
for	O
similar	O
levels	O
of	O
clonality	O
,	O
CP	B-PHYS
and	O
acyclic	O
partial	O
clonality	O
(	O
wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	B-LIVB
are	O
clonally	O
produced	O
within	O
each	O
generation	O
)	O
differentially	O
affect	O
the	O
distribution	O
of	O
genetic	B-PHEN
diversity	I-PHEN
.	O

Overall	O
,	O
this	O
work	O
provides	O
solid	O
predictions	O
of	O
neutral	O
genetic	B-PHEN
diversity	I-PHEN
that	O
may	O
serve	O
as	O
a	O
null	O
model	O
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	B-PHYS
or	O
demographic	O
processes	B-PHEN
in	O
cyclical	B-LIVB
parthenogens	I-LIVB
(	O
for	O
example	O
,	O
selection	O
or	O
bottlenecks	O
)	O
.	O

Blood	B-PHYS
Pressure	I-PHYS
and	O
All	B-DISO
-	I-DISO
Cause	I-DISO
Mortality	I-DISO
by	O
Level	O
of	O
Cognitive	B-PHYS
Function	I-PHYS
in	O
the	O
Elderly	B-LIVB
:	O
Results	B-DISO
From	O
a	O
Population	B-PROC
-	I-PROC
Based	I-PROC
Study	I-PROC
in	O
Rural	B-GEOG
Greece	I-GEOG
This	O
study	B-PROC
aimed	O
to	O
investigate	O
whether	O
the	O
effect	O
of	O
blood	B-PHYS
pressure	I-PHYS
(	O
BP	B-PHYS
)	O
on	O
mortality	B-DISO
differs	O
by	O
levels	O
of	O
cognitive	B-PHYS
function	I-PHYS
.	O

The	O
associations	O
of	O
brachial	O
systolic	B-PHYS
BP	I-PHYS
,	O
diastolic	B-PHYS
BP	I-PHYS
,	O
mean	B-DISO
arterial	I-DISO
pressure	I-DISO
(	O
MAP	B-DISO
)	O
,	O
and	O
pulse	B-PHYS
pressure	I-PHYS
with	O
all	B-DISO
-	I-DISO
cause	I-DISO
mortality	I-DISO
were	O
prospectively	B-DISO
explored	I-DISO
(	O
follow	B-PROC
-	I-PROC
up	I-PROC
7	O
.	O

0±2	O
.	O

2	O
years	O
)	O
in	O
660	O
community	O
-	O
dwelling	O
individuals	B-LIVB
(	O
≥60	B-DISO
years	I-DISO
)	O
using	O
adjusted	O
Cox	O
models	O
,	O
stratified	O
by	O
cognitive	B-DISO
impairment	I-DISO
(	O
Mini	B-PROC
-	I-PROC
Mental	I-PROC
State	I-PROC
Examination	I-PROC
[	O
MMSE	B-PROC
]	O
<	O
24	O
)	O
.	O

No	O
association	O
between	O
brachial	O
BP	B-PHYS
variables	O
and	O
mortality	B-DISO
was	O
shown	O
for	O
the	O
total	O
sample	B-OBJC
in	O
quartiles	B-PROC
analysis	I-PROC
;	O
however	O
,	O
MAP	B-DISO
in	O
the	O
highest	O
quartile	O
,	O
compared	O
with	O
the	O
second	O
,	O
was	O
associated	O
with	O
mortality	B-DISO
(	O
hazard	O
ratio	O
,	O
1	O
.	O
85	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
1	O
.	O
09	O
-	O
3	O
.	O
12	O
)	O
among	O
cognitively	B-DISO
impaired	I-DISO
individuals	B-LIVB
.	O

The	O
fractional	B-PROC
-	I-PROC
polynomials	I-PROC
approach	I-PROC
for	O
BP	B-PHYS
confirmed	B-DISO
this	O
finding	B-DISO
and	O
further	O
showed	O
,	O
solely	O
in	O
the	O
MMSE	B-PROC
<	O
24	O
subcohort	O
,	O
U	O
-	O
shaped	O
trends	O
of	O
MAP	B-DISO
and	O
systolic	B-PHYS
BP	I-PHYS
,	O
with	O
increased	O
mortality	O
risk	O
in	O
extremely	O
low	O
or	O
high	O
values	O
;	O
no	O
such	O
pattern	O
was	O
evident	O
for	O
patients	B-LIVB
with	O
MMSE	B-PROC
≥24	O
.	O

Elderly	B-LIVB
individuals	B-LIVB
with	O
cognitive	B-DISO
impairment	I-DISO
might	O
be	O
more	O
susceptible	O
to	O
the	O
detrimental	B-DISO
effects	I-DISO
of	O
low	O
and	O
elevated	O
MAP	B-DISO
and	O
systolic	B-PHYS
BP	I-PHYS
.	O

Epigenotype	B-PHYS
,	O
genotype	B-PHYS
,	O
and	O
phenotype	B-PHYS
analysis	B-PROC
of	O
patients	B-LIVB
in	O
Taiwan	B-GEOG
with	O
Beckwith	B-DISO
-	I-DISO
Wiedemann	I-DISO
syndrome	I-DISO
Beckwith	B-DISO
-	I-DISO
Wiedemann	I-DISO
syndrome	I-DISO
(	O
BWS	B-DISO
)	O
is	O
a	O
congenital	B-DISO
overgrowth	I-DISO
disorder	I-DISO
predisposing	O
to	O
tumorigenesis	B-DISO
that	O
results	O
from	O
abnormal	B-DISO
expression	B-PHYS
or	O
function	O
of	O
imprinted	O
genes	O
of	O
chromosome	O
11p15	O
.	O

5	O
.	O
Forty	O
-	O
seven	O
patients	B-LIVB
in	O
Taiwan	B-GEOG
with	O
clinical	O
suspicion	B-PHYS
of	O
BWS	B-DISO
were	O
referred	O
for	O
diagnostic	O
testing	O
based	O
on	O
methylation	B-PROC
profiling	I-PROC
of	O
H19	O
-associated	O
imprinting	O
center	O
(	O
IC	O
)	O
1	O
and	O
KCNQ1OT1	O
-associated	O
IC2	O
using	O
high	B-PROC
-	I-PROC
resolution	I-PROC
melting	I-PROC
analysis	I-PROC
,	O
multiplex	B-PROC
ligation	I-PROC
-	I-PROC
dependent	I-PROC
probe	I-PROC
amplification	I-PROC
,	O
or	O
high	B-PROC
-	I-PROC
resolution	I-PROC
quantitative	I-PROC
methylation	I-PROC
profiling	I-PROC
.	O

Twenty	O
-	O
eight	O
patients	B-LIVB
received	O
a	O
clinical	B-PROC
diagnosis	I-PROC
of	O
BWS	B-DISO
(	O
the	O
presence	O
of	O
3	O
major	O
features	O
or	O
2	O
major	O
features	O
and	O
at	O
least	O
1	O
minor	O
feature	O
)	O
,	O
18	O
had	O
suspected	O
BWS	B-DISO
(	O
the	O
presence	O
of	O
at	O
least	O
1	O
major	O
feature	O
)	O
,	O
and	O
1	O
had	O
isolated	O
Wilms	B-DISO
'	I-DISO
tumor	I-DISO
.	O

Nineteen	O
patients	B-LIVB
were	O
identified	O
with	O
IC2	O
hypomethylation	B-PHYS
(	O
including	O
1	O
with	O
isolated	O
Wilms	B-DISO
'	I-DISO
tumor	I-DISO
)	O
,	O
1	O
with	O
IC1	O
hypermethylation	B-PHYS
,	O
2	O
with	O
paternal	B-DISO
uniparental	I-DISO
disomy	I-DISO
,	O
and	O
1	O
with	O
CDKN1C	O
mutation	B-PHYS
.	O

Several	O
clinical	B-DISO
features	I-DISO
were	O
found	O
to	O
be	O
statistically	O
different	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
between	O
the	O
2	O
groups	O
-	O
clinical	B-PROC
diagnosis	I-PROC
of	O
BWS	B-DISO
(	O
n	O
=	O
28	O
)	O
or	O
suspected	O
BWS	B-DISO
(	O
n	O
=	O
18	O
)	O
-	O
including	O
macroglossia	B-DISO
,	O
pre	B-PHYS
-	I-PHYS
or	O
postnatal	B-PHYS
gigantism	B-DISO
,	O
abdominal	B-DISO
wall	I-DISO
defect	I-DISO
,	O
ear	B-DISO
creases	I-DISO
,	O
facial	B-ANAT
nevus	B-DISO
flammeus	I-DISO
,	O
BWS	B-DISO
score	O
,	O
and	O
the	O
molecular	B-PROC
diagnosis	I-PROC
rate	O
.	O

Molecular	B-DISO
lesion	I-DISO
was	O
detected	O
in	O
81	O
%	O
of	O
patients	B-LIVB
with	O
the	O
presence	O
of	O
three	O
major	O
features	O
,	O
compared	O
with	O
33	O
%	O
and	O
28	O
%	O
of	O
those	O
with	O
two	O
or	O
one	O
major	O
feature	O
,	O
respectively	O
.	O

The	O
mean	O
BWS	B-DISO
score	O
was	O
5	O
.	O
6	O
for	O
19	O
subjects	B-LIVB
with	O
""""	O
IC2	O
hypomethylation	B-PHYS
""""	O
,	O
compared	O
with	O
3	O
.	O
8	O
for	O
2	O
subjects	B-LIVB
with	O
pUPD	B-DISO
.	O

The	O
BWS	B-DISO
score	O
of	O
one	O
subject	B-LIVB
with	O
CDKN1C	O
mutation	B-PHYS
and	O
one	O
with	O
IC1	O
hypermethylation	B-PHYS
was	O
6	O
and	O
7	O
,	O
respectively	O
.	O

The	O
BWS	B-DISO
score	O
was	O
positively	O
correlated	O
with	O
the	O
molecular	B-PROC
diagnosis	I-PROC
rate	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
BWS	B-DISO
database	O
of	O
epigenotype	B-PHYS
,	O
genotype	B-PHYS
,	O
and	O
phenotype	B-PHYS
is	O
expected	O
to	O
promote	O
better	O
genetic	B-PROC
counseling	I-PROC
and	O
medical	B-DISO
care	I-DISO
of	O
these	O
patients	B-LIVB
.	O

Assessing	B-PROC
Commercially	O
Available	O
Personal	O
Health	O
Records	O
for	O
Home	B-PROC
Health	I-PROC
:	O
Recommendations	O
for	O
Design	O
Home	B-LIVB
health	I-LIVB
nurses	I-LIVB
and	O
clients	B-LIVB
experience	B-PHYS
unmet	O
information	O
needs	O
when	O
transitioning	B-PHEN
from	O
hospital	B-OBJC
to	O
home	B-PROC
health	I-PROC
.	O

Personal	O
health	O
records	O
(	O
PHRs	O
)	O
support	O
consumer	B-LIVB
-centered	O
information	O
management	O
activities	O
.	O

Previous	O
work	O
has	O
assessed	O
PHRs	O
associated	O
with	O
healthcare	B-LIVB
providers	I-LIVB
,	O
but	O
these	O
systems	O
leave	O
home	B-LIVB
health	I-LIVB
nurses	I-LIVB
unable	O
to	O
access	O
necessary	O
information	O
.	O

To	O
evaluate	B-PROC
the	O
ability	O
of	O
publically	O
available	O
PHRs	O
to	O
accept	O
,	O
manage	B-PROC
,	O
and	O
share	O
information	O
from	O
a	O
home	B-PROC
health	I-PROC
case	O
study	O
.	O

Two	O
researchers	B-LIVB
accessed	O
the	O
publically	O
available	O
PHRs	O
on	O
myPHR	O
.	O

com	O
,	O
and	O
attempted	O
to	O
enter	O
,	O
manage	B-PROC
,	O
and	O
share	O
the	O
case	O
study	O
data	O
.	O

We	O
qualitatively	O
described	O
the	O
PHR	O
features	O
,	O
and	O
identified	O
gaps	O
between	O
the	O
case	O
study	O
information	O
and	O
PHR	O
functionality	O
.	O

Eighteen	O
PHRs	O
were	O
identified	O
in	O
our	O
initial	O
search	O
.	O

Seven	O
systems	O
met	O
our	O
inclusion	O
criteria	O
,	O
and	O
are	O
included	O
in	O
this	O
review	O
.	O

The	O
PHRs	O
were	O
able	O
to	O
accept	O
basic	O
medical	O
information	O
.	O

Gaps	O
occurred	O
when	O
entering	O
,	O
managing	B-PROC
,	O
and	O
/	O
or	O
sharing	O
data	O
from	O
the	O
acute	O
care	O
and	O
home	B-PROC
health	I-PROC
episodes	B-PROC
.	O

The	O
PHRs	O
that	O
were	O
reviewed	O
were	O
unable	O
to	O
effectively	O
manage	B-PROC
the	O
case	O
study	O
information	O
.	O

Therefore	O
,	O
increasing	O
consumer	B-LIVB
health	B-PROC
literacy	I-PROC
through	O
these	O
systems	O
may	O
be	O
difficult	O
.	O

The	O
PHRs	O
that	O
we	O
reviewed	O
were	O
also	O
unable	O
to	O
electronically	O
share	O
their	O
data	O
.	O

The	O
gap	O
between	O
the	O
existing	O
functionality	O
and	O
the	O
information	O
needs	O
from	O
the	O
case	O
study	O
may	O
make	O
these	O
PHRs	O
difficult	O
to	O
use	O
for	O
home	O
health	B-PHEN
environments	I-PHEN
.	O

Additional	O
work	O
is	O
needed	O
to	O
increase	O
the	O
functionality	O
of	O
the	O
PHR	O
systems	O
to	O
better	O
fit	O
the	O
data	O
needs	O
of	O
home	B-PROC
health	I-PROC
clients	B-LIVB
.	O

A	O
Web	O
-	O
based	O
Alternative	O
Non	O
-	O
animal	O
Method	O
Database	O
for	O
Safety	B-PHEN
Cosmetic	B-OBJC
Evaluations	B-PROC
Animal	B-PROC
testing	I-PROC
was	O
used	O
traditionally	O
in	O
the	O
cosmetics	B-OBJC
industry	O
to	O
confirm	O
product	O
safety	O
,	O
but	O
has	O
begun	O
to	O
be	O
banned	O
;	O
alternative	B-PROC
methods	I-PROC
to	O
replace	O
animal	B-PROC
experiments	I-PROC
are	O
either	O
in	O
development	O
,	O
or	O
are	O
being	O
validated	O
,	O
worldwide	O
.	O

Research	B-PROC
data	I-PROC
related	O
to	O
test	O
substances	B-OBJC
are	O
critical	O
for	O
developing	O
novel	O
alternative	O
tests	O
.	O

Moreover	O
,	O
safety	O
information	O
on	O
cosmetic	B-OBJC
materials	I-OBJC
has	O
neither	O
been	O
collected	O
in	O
a	O
database	O
nor	O
shared	O
among	O
researchers	B-LIVB
.	O

Therefore	O
,	O
it	O
is	O
imperative	O
to	O
build	O
and	O
share	O
a	O
database	O
of	O
safety	O
information	O
on	O
toxicological	O
mechanisms	O
and	O
pathways	O
collected	O
through	O
in	O
vivo	O
,	O
in	O
vitro	O
,	O
and	O
in	O
silico	O
methods	B-PROC
.	O

We	O
developed	O
the	O
CAMSEC	O
database	O
(	O
named	O
after	O
the	O
research	B-LIVB
team	I-LIVB
;	O
the	O
Consortium	O
of	O
Alternative	O
Methods	O
for	O
Safety	O
Evaluation	O
of	O
Cosmetics	O
)	O
to	O
fulfill	O
this	O
purpose	O
.	O

On	O
the	O
same	O
website	O
,	O
our	O
aim	O
is	O
to	O
provide	O
updates	O
on	O
current	O
alternative	B-PROC
research	I-PROC
methods	I-PROC
in	O
Korea	B-GEOG
.	O

The	O
database	O
will	O
not	O
be	O
used	O
directly	O
to	O
conduct	O
safety	B-PHEN
evaluations	B-PROC
,	O
but	O
researchers	B-LIVB
or	O
regulatory	O
individuals	B-LIVB
can	O
use	O
it	O
to	O
facilitate	O
their	O
work	O
in	O
formulating	O
safety	B-PHEN
evaluations	B-PROC
for	O
cosmetic	B-OBJC
materials	I-OBJC
.	O

We	O
hope	O
this	O
database	O
will	O
help	O
establish	O
new	O
alternative	B-PROC
research	I-PROC
methods	I-PROC
to	O
conduct	O
efficient	O
safety	B-PHEN
evaluations	B-PROC
of	O
cosmetic	B-OBJC
materials	I-OBJC
.	O

Hypovitaminosis	B-DISO
D	I-DISO
and	O
Associated	O
Cardiometabolic	O
Risk	O
in	O
Women	B-LIVB
with	O
PCOS	B-DISO
Women	B-LIVB
with	O
Polycystic	B-DISO
Ovary	I-DISO
Syndrome	I-DISO
(	O
PCOS	B-DISO
)	O
frequently	O
suffer	O
from	O
metabolic	B-DISO
disturbances	I-DISO
like	O
insulin	B-DISO
resistance	I-DISO
,	O
hypertension	B-DISO
and	O
atherogenic	B-DISO
dyslipidemia	I-DISO
.	O

Accumulating	B-DISO
evidences	O
suggest	O
that	O
Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
is	O
common	O
in	O
PCOS	B-DISO
and	O
may	O
be	O
associated	O
with	O
metabolic	B-DISO
and	O
endocrinal	B-DISO
dysfunctions	I-DISO
in	O
PCOS	B-DISO
.	O

Thus	O
women	B-LIVB
with	O
PCOS	B-DISO
may	O
be	O
at	O
elevated	O
risk	O
of	O
cardiovascular	B-DISO
disease	I-DISO
.	O

Present	O
study	B-PROC
aims	O
to	O
evaluate	O
Vitamin	B-CHEM
D	I-CHEM
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	B-DISO
and	O
endocrinal	B-DISO
dysregulations	I-DISO
in	O
women	B-LIVB
with	O
PCOS	B-DISO
,	O
which	O
might	O
help	O
in	O
early	B-PROC
identification	I-PROC
and	O
prevention	B-PROC
of	O
future	O
symptomatic	O
cardiac	B-DISO
disease	I-DISO
.	O

A	O
total	O
of	O
44	O
women	B-LIVB
with	O
PCOS	B-DISO
,	O
diagnosed	O
by	O
Rotterdam	O
criteria	O
and	O
45	O
healthy	O
control	O
without	O
PCOS	B-DISO
,	O
were	O
evaluated	O
for	O
Vitamin	B-CHEM
D	I-CHEM
and	O
cardiometabolic	B-DISO
risk	I-DISO
factors	I-DISO
,	O
including	O
fasting	B-PHEN
plasma	I-PHEN
glucose	I-PHEN
,	O
insulin	B-DISO
resistance	I-DISO
,	O
dyslipidemia	B-DISO
,	O
hs	B-DISO
-	I-DISO
CRP	I-DISO
.	O

That	O
apart	O
,	O
several	O
endocrinal	O
parameters	O
of	O
hyperandrogenism	B-DISO
were	O
also	O
examined	O
.	O

Several	O
correlation	B-PROC
studies	I-PROC
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
Vitamin	B-CHEM
D	I-CHEM
as	O
a	O
cardiometabolic	B-DISO
risk	I-DISO
factor	I-DISO
in	O
PCOS	B-DISO
.	O

Results	O
were	O
expressed	O
as	O
mean±SD	O
and	O
were	O
statistically	B-PROC
analysed	I-PROC
using	O
SPSS	B-OBJC
software	I-OBJC
version	I-OBJC
16	I-OBJC
,	O
unpaired	O
student	O
's	O
t	O
-	O
test	O
and	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O

We	O
found	O
lower	O
levels	O
of	O
Vitamin	B-CHEM
D	I-CHEM
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

Hyperinsulinemia	B-DISO
,	O
rise	O
in	O
insulin	B-DISO
resistance	I-DISO
and	O
marked	O
dyslipidemia	B-DISO
was	O
observed	O
in	O
the	O
present	O
study	B-PROC
.	O

Another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
Vitamin	B-CHEM
D	I-CHEM
with	O
insulin	B-CHEM
and	O
Homeostatic	B-PROC
Model	I-PROC
of	I-PROC
Assessment	I-PROC
-	I-PROC
Insulin	I-PROC
Resistance	I-PROC
Index	I-PROC
(	O
HOMA	B-PROC
-	I-PROC
IR	I-PROC
)	O
.	O

Hypovitaminosis	B-DISO
D	I-DISO
was	O
prevalent	O
in	O
PCOS	B-DISO
.	O

This	O
was	O
related	O
to	O
metabolic	B-DISO
and	O
hormonal	B-DISO
disorders	I-DISO
in	O
PCOS	B-DISO
.	O

Possibly	O
this	O
combined	O
with	O
impaired	B-DISO
fasting	I-DISO
glucose	I-DISO
,	O
IR	B-DISO
and	O
dyslipidemia	B-DISO
,	O
could	O
account	O
for	O
Cardio	O
vascular	O
risks	O
in	O
PCOS	B-DISO
.	O

Further	O
prospective	O
observational	O
studies	O
and	O
randomized	B-PROC
control	I-PROC
trials	I-PROC
are	O
required	O
to	O
explore	O
the	O
above	O
hypothesis	O
.	O

Update	O
on	O
the	O
Role	O
of	O
Cardiac	B-PROC
Magnetic	I-PROC
Resonance	I-PROC
in	O
Acquired	O
Nonischemic	B-DISO
Cardiomyopathies	I-DISO
Cardiomyopathies	B-DISO
refer	O
to	O
a	O
variety	O
of	O
myocardial	B-DISO
disorders	I-DISO
without	O
underlying	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
valvular	B-DISO
heart	I-DISO
disease	I-DISO
,	O
hypertension	B-DISO
,	O
or	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
.	O

Several	O
imaging	O
modalities	O
are	O
available	O
,	O
but	O
cardiac	B-PROC
magnetic	I-PROC
resonance	I-PROC
(	O
CMR	B-PROC
)	O
has	O
now	O
established	O
itself	O
as	O
a	O
crucial	O
imaging	B-PROC
technique	I-PROC
in	O
the	O
evaluation	B-PROC
of	O
several	O
cardiomyopathies	B-DISO
.	O

It	O
not	O
only	O
provides	O
comprehensive	O
information	O
on	O
structure	O
and	O
function	O
,	O
but	O
also	O
can	O
perform	O
tissue	O
characterization	O
,	O
which	O
helps	O
in	O
establishing	O
the	O
etiology	O
of	O
cardiomyopathy	B-DISO
.	O

CMR	B-PROC
is	O
also	O
useful	O
in	O
establishing	O
the	O
diagnosis	B-DISO
,	O
providing	O
guidance	B-PROC
for	O
endomyocardial	B-PROC
biopsy	I-PROC
,	O
accurate	O
quantification	O
of	O
function	O
,	O
volumes	O
,	O
and	O
fibrosis	B-DISO
,	O
prognostic	O
determination	O
,	O
risk	O
stratification	B-PROC
,	O
and	O
monitoring	B-PROC
response	I-PROC
to	I-PROC
therapy	I-PROC
.	O

In	O
this	O
article	O
,	O
we	O
review	O
the	O
current	O
role	O
of	O
CMR	B-PROC
in	O
the	O
evaluation	B-PROC
of	O
several	O
acquired	O
nonischemic	B-DISO
cardiomyopathies	I-DISO
,	O
particularly	O
focusing	O
on	O
recent	O
advances	O
in	O
knowledge	O
.	O

We	O
also	O
discuss	O
in	O
detail	O
a	O
select	B-LIVB
group	I-LIVB
of	O
common	O
acquired	O
nonischemic	B-DISO
cardiomyopathies	I-DISO
.	O

Modern	O
Image	B-PROC
-	I-PROC
Guided	I-PROC
Intensity	I-PROC
-	I-PROC
Modulated	I-PROC
Radiotherapy	I-PROC
for	O
Oropharynx	B-DISO
Cancer	I-DISO
and	O
Severe	O
Late	B-DISO
Toxic	I-DISO
Effects	I-DISO
:	O
Implications	O
for	O
Clinical	B-PHYS
Trial	I-PHYS
Design	I-PHYS
Late	B-DISO
toxic	I-DISO
effects	I-DISO
are	O
common	O
after	O
definitive	O
radiotherapy	B-PROC
and	O
chemoradiotherapy	B-PROC
for	O
oropharynx	B-DISO
cancer	I-DISO
and	O
are	O
considered	O
a	O
significant	O
contributor	O
to	O
decreased	O
quality	O
of	O
life	O
for	O
survivors	B-LIVB
.	O

The	O
incidence	O
of	O
severe	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
may	O
be	O
reduced	O
by	O
modern	O
narrow	B-PHYS
-	I-PHYS
margin	I-PHYS
image	B-PROC
-	I-PROC
guided	I-PROC
intensity	I-PROC
-	I-PROC
modulated	I-PROC
radiotherapy	I-PROC
(	O
IG	B-PROC
-	I-PROC
IMRT	I-PROC
)	O
,	O
current	O
supportive	O
care	O
improvements	O
,	O
and	O
the	O
changing	O
epidemiology	O
of	O
oropharynx	B-DISO
cancer	I-DISO
.	O

Assess	O
the	O
incidence	O
of	O
severe	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
after	O
modern	O
definitive	O
non	B-PROC
-	I-PROC
operative	I-PROC
treatment	I-PROC
for	O
oropharynx	B-DISO
cancer	I-DISO
.	O

For	O
this	O
single	O
-	O
institution	O
retrospective	O
review	O
,	O
156	O
patients	B-LIVB
with	O
stage	O
I	O
-	O
IVB	O
squamous	B-DISO
cell	I-DISO
carcinoma	I-DISO
of	I-DISO
the	I-DISO
oropharynx	I-DISO
treated	B-PROC
between	O
April	O
2009	O
and	O
February	O
2015	O
at	O
a	O
tertiary	B-OBJC
-	I-OBJC
referral	I-OBJC
academic	I-OBJC
multidisciplinary	I-OBJC
head	I-OBJC
and	I-OBJC
neck	I-OBJC
practice	I-OBJC
were	O
recruited	O
.	O

Definitive	O
narrow	B-PHYS
-	I-PHYS
margin	I-PHYS
IG	B-PROC
-	I-PROC
IMRT	I-PROC
to	O
a	O
dose	O
of	O
66	O
Gy	O
(	O
to	O
convert	O
milligray	O
to	O
rad	O
,	O
multiply	O
by	O
0	O
.	O

1	O
)	O
or	O
higher	O
with	O
or	O
without	O
concurrent	O
cisplatin	B-CHEM
.	O

The	O
primary	O
outcome	O
was	O
the	O
prospectively	O
collected	O
2	O
-	O
year	O
cumulative	O
incidence	O
of	O
severe	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
(	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
grade	B-DISO
3	I-DISO
or	O
higher	O
)	O
occurring	O
3	O
months	O
or	O
more	O
after	O
radiotherapy	B-PROC
.	O

Toxic	B-DISO
effect	I-DISO
end	O
points	O
investigated	O
included	O
esophageal	B-DISO
stricture	I-DISO
requiring	O
dilation	B-PROC
,	O
aspiration	B-DISO
pneumonia	I-DISO
hospitalization	B-PROC
,	O
vocal	B-DISO
dysfunction	I-DISO
,	O
delayed	O
feeding	B-PROC
tube	I-PROC
insertions	I-PROC
,	O
and	O
osteoradionecrosis	B-DISO
.	O

Feeding	B-DEVI
tube	I-DEVI
dependence	O
at	O
1	O
year	O
was	O
also	O
considered	O
a	O
severe	O
late	B-DISO
toxic	I-DISO
effect	I-DISO
.	O

Secondary	O
outcomes	O
collected	O
include	O
physician	B-LIVB
-reported	O
grade	O
2	O
or	O
higher	O
neck	B-ANAT
fibrosis	B-DISO
and	O
xerostomia	B-DISO
.	O

The	O
competing	O
risks	B-PROC
of	O
recurrence	O
and	O
death	B-PHYS
were	O
accounted	O
for	O
using	O
the	O
Gray	O
method	O
.	O

One	O
-	O
hundred	O
fifty	O
-	O
six	O
patients	B-LIVB
(	O
median	O
[	O
range	O
]	O
age	B-PHYS
,	O
58	O
[	O
37	O
-	O
96	O
]	O
years	O
)	O
were	O
identified	O
;	O
130	O
patients	B-LIVB
(	O
83	O
%	O
)	O
were	O
HPV	B-PHEN
positive	I-PHEN
.	O

Concurrent	O
cisplatin	B-CHEM
was	O
delivered	O
in	O
131	O
patients	B-LIVB
(	O
84	O
%	O
)	O
and	O
5	O
patients	B-LIVB
(	O
3	O
%	O
)	O
underwent	O
an	O
adjuvant	O
neck	B-PROC
dissection	I-PROC
.	O

The	O
median	O
(	O
range	O
)	O
follow	O
-	O
up	O
for	O
survivors	B-LIVB
was	O
22	O
(	O
4	O
-	O
73	O
)	O
months	O
from	O
diagnosis	B-DISO
.	O

The	O
projected	O
2	O
-	O
year	O
locoregional	O
control	O
was	O
93	O
%	O
(	O
95	O
%	O
CI	O
,	O
88	O
.	O
4	O
%	O
-	O
97	O
.	O
6	O
%	O
)	O
and	O
overall	O
survival	O
was	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
82	O
.	O
2	O
%	O
-	O
94	O
.	O
0	O
%	O
)	O
.	O

Thirty	O
-	O
eight	O
patients	B-LIVB
(	O
23	O
%	O
)	O
required	O
a	O
feeding	B-DEVI
tube	I-DEVI
during	O
treatment	B-PROC
.	O

The	O
cumulative	O
incidence	O
of	O
severe	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
adjusted	O
for	O
competing	O
risks	B-PROC
at	O
2	O
-	O
year	O
posttreatment	O
was	O
2	O
.	O

3	O
%	O
(	O
95	O
%	O
CI	O
,	O
0	O
%	O
-	O
5	O
.	O
6	O
%	O
)	O
.	O

One	O
patient	B-LIVB
required	O
free	B-PROC
-	I-PROC
flap	I-PROC
reconstruction	I-PROC
for	O
grade	O
3	O
osteoradionecrosis	B-DISO
at	O
47	O
months	O
.	O

At	O
1	O
year	O
,	O
2	O
patients	B-LIVB
(	O
1	O
%	O
)	O
experienced	O
grade	O
2	O
neck	B-ANAT
fibrosis	B-DISO
and	O
38	O
patients	B-LIVB
(	O
23	O
%	O
)	O
experienced	O
grade	B-DISO
2	I-DISO
xerostomia	I-DISO
.	O

These	O
results	O
suggest	O
that	O
severe	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
after	O
modern	O
definitive	O
IG	B-PROC
-	I-PROC
IMRT	I-PROC
,	O
with	O
or	O
without	O
cisplatin	B-CHEM
,	O
for	O
oropharynx	B-DISO
cancer	I-DISO
is	O
likely	O
uncommon	O
.	O

The	O
importance	O
of	O
late	B-DISO
toxic	I-DISO
effect	I-DISO
reduction	O
in	O
current	O
and	O
future	O
investigational	O
strategies	O
,	O
including	O
clinical	B-PROC
trials	I-PROC
,	O
should	O
be	O
considered	O
.	O

Family	B-LIVB
close	B-DISO
but	O
friends	B-LIVB
closer	B-DISO
:	O
exploring	O
social	O
support	O
and	O
resilience	O
in	O
older	B-LIVB
spousal	B-LIVB
dementia	B-DISO
carers	B-LIVB
Spousal	B-LIVB
dementia	B-DISO
carers	B-LIVB
have	O
unique	O
support	O
needs	O
;	O
they	O
are	O
likely	O
to	O
disengage	O
from	O
their	O
existing	O
social	B-LIVB
networks	I-LIVB
as	O
they	O
need	O
to	O
devote	O
more	O
time	O
to	O
caring	O
as	O
the	O
disease	B-DISO
progresses	I-DISO
.	O

Previously	O
we	O
showed	O
that	O
support	O
resources	O
can	O
facilitate	O
resilience	O
in	O
carers	B-LIVB
,	O
but	O
the	O
relationship	O
is	O
complex	O
and	O
varies	O
by	O
relationship	O
type	O
.	O

The	O
current	O
paper	O
aims	O
to	O
explore	O
social	O
support	O
as	O
a	O
key	O
component	O
of	O
resilience	O
to	O
identify	O
the	O
availability	O
,	O
function	O
and	O
perceived	O
functional	O
aspects	O
of	O
support	O
provided	O
to	O
older	B-LIVB
spousal	B-LIVB
dementia	B-DISO
carers	B-LIVB
.	O

We	O
conducted	O
23	O
in	O
-	O
depth	O
qualitative	O
interviews	O
with	O
spousal	B-LIVB
carers	B-LIVB
from	O
two	O
carer	B-LIVB
support	O
groups	O
and	O
a	O
care	O
home	O
in	O
North	B-GEOG
West	I-GEOG
England	I-GEOG
.	O

Family	B-LIVB
and	O
friends	B-LIVB
served	O
a	O
wide	O
range	O
of	O
functions	O
but	O
were	O
equally	O
available	O
to	O
resilient	B-LIVB
and	O
non	B-LIVB
-	I-LIVB
resilient	I-LIVB
participants	I-LIVB
.	O

Family	B-PROC
support	I-PROC
was	O
perceived	B-PHYS
as	O
unhelpful	O
if	O
it	O
created	O
feelings	B-PHYS
of	O
over	O
-	O
dependence	O
.	O

Participants	B-LIVB
were	O
less	O
likely	O
to	O
resist	O
involvement	O
of	O
grandchildren	B-LIVB
due	O
to	O
their	O
relatively	O
narrow	O
and	O
low	O
-	O
level	O
support	O
functions	O
.	O

Friend	B-LIVB
support	O
was	O
perceived	B-PHYS
as	O
most	O
helpful	O
when	O
it	O
derived	O
from	O
those	O
in	O
similar	O
circumstances	O
.	O

Neighbours	B-LIVB
played	O
a	O
functionally	O
unique	O
role	O
of	O
crisis	B-PROC
management	I-PROC
.	O

These	O
perceptions	B-PHYS
may	O
moderate	O
the	O
effect	O
of	O
support	O
on	O
resilience	O
.	O

Family	B-PROC
and	O
friend	B-LIVB
support	O
is	O
not	O
always	O
sufficient	O
to	O
facilitate	O
resilience	O
.	O

Support	O
functions	O
facilitate	O
resilience	O
only	O
if	O
they	O
are	O
perceived	B-PHYS
to	O
match	O
need	O
.	O

Implications	B-DISO
of	O
these	O
findings	O
are	O
discussed	O
.	O

Axially	O
Chiral	B-PHEN
Dimeric	B-CHEM
Naphthalene	B-CHEM
and	O
Naphthoquinone	B-CHEM
Metabolites	B-CHEM
,	O
from	O
Root	B-LIVB
Cultures	B-PROC
of	O
the	O
West	B-GEOG
African	I-GEOG
Liana	B-LIVB
Triphyophyllum	B-LIVB
peltatum	I-LIVB
Root	B-LIVB
cultures	B-PROC
of	O
the	O
West	B-GEOG
African	I-GEOG
liana	B-LIVB
Triphyophyllum	B-LIVB
peltatum	I-LIVB
were	O
initiated	O
from	O
stem	B-LIVB
explants	B-PROC
of	O
in	O
vitro	O
cultivated	O
shoots	O
.	O

From	O
these	O
organ	B-PROC
cultures	I-PROC
,	O
three	O
new	O
binaphthalenes	B-CHEM
,	O
one	O
binaphthoquinone	B-CHEM
,	O
and	O
two	O
(	B-CHEM
bi	I-CHEM
)	I-CHEM
naphthalene	I-CHEM
glucosides	I-CHEM
were	O
isolated	O
,	O
with	O
substitution	O
patterns	O
related	O
to	O
those	O
of	O
the	O
naphthylisoquinoline	B-CHEM
alkaloids	I-CHEM
,	O
which	O
are	O
the	O
""""	O
normal	O
""""	O
main	O
metabolites	B-CHEM
of	O
T	B-LIVB
.	I-LIVB

peltatum	I-LIVB
.	O

The	O
structures	O
of	O
the	O
diglucoside	B-CHEM
dioncoquinoside	I-CHEM
A	I-CHEM
(	O
1	O
)	O
and	O
of	O
the	O
axially	O
chiral	B-PHEN
biaryls	B-CHEM
triphyoquinols	I-CHEM
A1	I-CHEM
(	O
3	O
)	O
,	O
A2	B-CHEM
(	O
4	O
)	O
,	O
and	O
B	B-CHEM
(	O
5	O
)	O
,	O
triphyoquinoside	B-CHEM
A	I-CHEM
(	O
6	O
)	O
,	O
and	O
triphyoquinone	B-CHEM
A	I-CHEM
(	O
7	O
)	O
were	O
elucidated	O
by	O
spectroscopic	B-PROC
analysis	I-PROC
(	O
HRESIMS	B-PROC
,	O
1D	B-PROC
and	O
2D	B-PROC
NMR	I-PROC
)	O
and	O
by	O
application	O
of	O
electronic	B-PHEN
circular	I-PHEN
dichroism	I-PHEN
(	I-PHEN
ECD	I-PHEN
)	I-PHEN
spectroscopy	I-PHEN
in	O
combination	O
with	O
the	O
exciton	O
chirality	O
method	O
and	O
quantum	B-PROC
-	I-PROC
chemical	I-PROC
ECD	I-PROC
calculations	I-PROC
.	O

The	O
root	B-LIVB
cultures	B-PROC
likewise	O
produced	O
the	O
known	O
alkaloids	B-CHEM
dioncophylline	B-CHEM
A	I-CHEM
(	O
8	O
)	O
,	O
5	B-CHEM
'	I-CHEM
-	I-CHEM
O	I-CHEM
-	I-CHEM
demethyldioncophylline	I-CHEM
A	I-CHEM
(	O
9	O
)	O
,	O
dioncopeltine	B-CHEM
A	I-CHEM
(	O
10	O
)	O
,	O
habropetaline	B-CHEM
A	I-CHEM
(	O
11	O
)	O
,	O
and	O
5	B-CHEM
'	I-CHEM
-	I-CHEM
O	I-CHEM
-	I-CHEM
methyldioncophylline	I-CHEM
D	I-CHEM
(	O
12a	O
/	O
b	O
)	O
,	O
the	O
naphthalene	B-CHEM
glucoside	I-CHEM
plumbaside	I-CHEM
A	I-CHEM
(	O
2	O
)	O
,	O
and	O
the	O
naphthoquinones	B-CHEM
plumbagin	I-CHEM
(	O
13	O
)	O
,	O
droserone	B-CHEM
(	O
14	O
)	O
,	O
and	O
8	B-CHEM
-	I-CHEM
hydroxydroserone	I-CHEM
(	O
15	O
)	O
.	O

Tubular	B-DISO
,	O
lactating	B-DISO
,	O
and	O
ductal	B-DISO
adenomas	I-DISO
are	O
devoid	O
of	O
MED12	O
Exon2	B-CHEM
mutations	B-PHYS
,	O
and	O
ductal	B-DISO
adenomas	I-DISO
show	O
recurrent	O
mutations	B-PHYS
in	O
GNAS	O
and	O
the	O
PI3K	O
-	O
AKT	O
pathway	O
Adenomas	B-DISO
of	O
the	O
breast	B-ANAT
are	O
rare	O
benign	B-DISO
tumors	I-DISO
although	O
single	O
cases	O
with	O
malignant	O
behavior	O
have	O
been	O
reported	O
.	O

However	O
,	O
the	O
genetic	O
basis	O
of	O
these	O
tumors	B-DISO
is	O
unknown	O
.	O

Employing	O
targeted	O
next	B-PROC
generation	I-PROC
sequencing	I-PROC
of	O
50	O
cancer	O
-	O
related	O
genes	O
as	O
well	O
as	O
Sanger	B-PROC
sequencing	I-PROC
,	O
we	O
profiled	O
a	O
cohort	O
of	O
18	O
mammary	B-DISO
adenomas	I-DISO
comprising	O
9	O
ductal	B-DISO
,	O
6	O
tubular	B-DISO
,	O
and	O
3	O
lactating	B-DISO
adenoma	I-DISO
.	O

Missense	B-PHYS
mutations	I-PHYS
were	O
detected	O
in	O
8	O
of	O
the	O
18	O
cases	O
(	O
44	O
%	O
)	O
.	O

Specifically	O
,	O
five	O
(	O
56	O
%	O
)	O
ductal	B-DISO
adenomas	I-DISO
and	O
three	O
(	O
50	O
%	O
)	O
tubular	B-DISO
adenomas	I-DISO
harbored	O
mutated	O
genes	O
.	O

No	B-DISO
mutations	B-PHYS
were	O
detected	O
in	O
lactating	B-DISO
adenomas	I-DISO
.	O

Three	O
of	O
the	O
nine	O
ductal	B-DISO
adenomas	I-DISO
showed	O
mutant	B-DISO
AKT1	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO

E17	I-DISO
K	I-DISO
)	I-DISO
with	O
two	O
of	O
them	O
harboring	O
an	O
additional	O
GNAS	B-DISO
mutation	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO
R201C	I-DISO
)	I-DISO
.	O

One	O
case	O
had	O
mutant	B-DISO
PIK3CA	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO

H1047R	I-DISO
)	I-DISO
and	O
another	O
case	O
a	O
mutation	B-DISO
in	I-DISO
GNAS	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO

R201C	I-DISO
)	I-DISO
.	O

The	O
three	O
cases	O
of	O
mutated	B-DISO
tubular	I-DISO
adenomas	I-DISO
showed	O
mutations	B-PHYS
in	O
either	O
MET	O
or	O
FGFR3	O
.	O

Of	O
note	O
,	O
we	O
did	O
not	O
detect	O
copy	O
number	O
changes	O
and	O
none	O
of	O
the	O
cases	O
including	O
tubular	B-DISO
adenomas	I-DISO
had	O
mutations	B-PHYS
in	O
exon	B-CHEM
2	I-CHEM
of	O
MED12	O
.	O

Our	O
results	O
suggest	O
that	O
ductal	B-DISO
adenomas	I-DISO
are	O
related	O
to	O
papillomas	B-DISO
of	O
the	O
breast	B-ANAT
and	O
screening	B-PROC
for	O
mutations	B-PHYS
in	O
exon	B-CHEM
2	I-CHEM
of	O
MED12	O
might	O
help	O
to	O
facilitate	O
differential	O
diagnosis	B-PROC
between	O
tubular	B-DISO
adenoma	I-DISO
and	O
fibroadenoma	B-DISO
in	O
difficult	O
cases	O
.	O

Lastly	O
,	O
our	O
data	O
exemplarily	O
demonstrate	O
that	O
mutations	B-PHYS
in	O
cancer	O
-	O
related	O
genes	O
per	O
se	O
do	O
not	O
indicate	O
malignancy	B-DISO
but	O
occur	O
in	O
benign	B-DISO
tumors	I-DISO
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Recent	O
advances	O
in	O
chitosan	B-CHEM
-based	O
nanoparticulate	B-OBJC
pulmonary	B-ANAT
drug	B-DEVI
delivery	I-DEVI
The	O
advent	O
of	O
biodegradable	B-CHEM
polymer	I-CHEM
-	O
encapsulated	O
drug	B-CHEM
nanoparticles	B-OBJC
has	O
made	O
the	O
pulmonary	B-ANAT
route	O
of	O
administration	O
an	O
exciting	O
area	O
of	O
drug	B-DEVI
delivery	I-DEVI
research	B-PROC
.	O

Chitosan	B-CHEM
,	O
a	O
natural	O
biodegradable	B-CHEM
and	O
biocompatible	B-CHEM
polysaccharide	B-CHEM
has	O
received	O
enormous	O
attention	O
as	O
a	O
carrier	B-CHEM
for	O
drug	B-DEVI
delivery	I-DEVI
.	O

Recently	O
,	O
nanoparticles	B-OBJC
of	O
chitosan	B-CHEM
(	O
CS	B-CHEM
)	O
and	O
its	O
synthetic	B-CHEM
derivatives	I-CHEM
have	O
been	O
investigated	O
for	O
the	O
encapsulation	B-PHEN
and	O
delivery	O
of	O
many	O
drugs	B-CHEM
with	O
improved	B-DISO
targeting	O
and	O
controlled	O
release	O
.	O

Herein	O
,	O
recent	O
advances	O
in	O
the	O
preparation	O
and	O
use	O
of	O
micro	B-ANAT
-	I-ANAT
/	O
nanoparticles	B-OBJC
of	O
chitosan	B-CHEM
and	O
its	O
derivatives	B-CHEM
for	O
pulmonary	B-ANAT
delivery	O
of	O
various	O
therapeutic	B-OBJC
agents	I-OBJC
(	O
drugs	B-CHEM
,	O
genes	O
,	O
vaccines	B-CHEM
)	O
are	O
reviewed	O
.	O

Although	O
chitosan	B-CHEM
has	O
wide	O
applications	O
in	O
terms	O
of	O
formulations	B-PROC
and	O
routes	O
of	O
drug	O
delivery	O
,	O
this	O
review	O
is	O
focused	O
on	O
pulmonary	B-ANAT
delivery	B-PROC
of	I-PROC
drug	I-PROC
-	I-PROC
encapsulated	I-PROC
nanoparticles	I-PROC
of	O
chitosan	B-CHEM
and	O
its	O
derivatives	B-CHEM
.	O

In	O
addition	O
,	O
the	O
controversial	O
toxicological	B-DISO
effects	I-DISO
of	O
chitosan	B-CHEM
nanoparticles	B-OBJC
for	O
lung	B-ANAT
delivery	O
will	O
also	O
be	O
discussed	O
.	O

EctD	B-CHEM
-mediated	O
biotransformation	O
of	O
the	O
chemical	B-CHEM
chaperone	B-CHEM
ectoine	B-CHEM
into	O
hydroxyectoine	B-CHEM
and	O
its	O
mechanosensitive	O
channel	O
-independent	O
excretion	B-PHYS
Ectoine	B-CHEM
and	O
its	O
derivative	B-CHEM
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
are	O
cytoprotectants	B-CHEM
widely	O
synthesized	O
by	O
microorganisms	B-LIVB
as	O
a	O
defense	O
against	O
the	O
detrimental	O
effects	O
of	O
high	O
osmolarity	B-PHYS
on	O
cellular	B-PHYS
physiology	I-PHYS
and	O
growth	B-PHYS
.	O

Both	O
ectoines	B-CHEM
possess	O
the	O
ability	O
to	O
preserve	O
the	O
functionality	B-PHYS
of	O
proteins	B-CHEM
,	O
macromolecular	B-CHEM
complexes	I-CHEM
,	O
and	O
even	O
entire	O
cells	B-ANAT
,	O
attributes	O
that	O
led	O
to	O
their	O
description	O
as	O
chemical	B-CHEM
chaperones	B-CHEM
.	O

As	O
a	O
consequence	O
,	O
there	O
is	O
growing	O
interest	O
in	O
using	O
ectoines	B-CHEM
for	O
biotechnological	O
purposes	O
,	O
in	O
skin	B-PROC
care	I-PROC
,	O
and	O
in	O
medical	O
applications	O
.	O

5	B-CHEM
-	I-CHEM
Hydroxyectoine	I-CHEM
is	O
synthesized	O
from	O
ectoine	B-CHEM
through	O
a	O
region	O
-	O
and	O
stereo	O
-	O
specific	O
hydroxylation	B-PHEN
reaction	O
mediated	O
by	O
the	O
EctD	B-CHEM
enzyme	I-CHEM
,	O
a	O
member	O
of	O
the	O
non	B-CHEM
-	I-CHEM
heme	I-CHEM
-	I-CHEM
containing	I-CHEM
iron	I-CHEM
(	I-CHEM
II	I-CHEM
)	I-CHEM
and	O
2	B-CHEM
-	I-CHEM
oxoglutarate	I-CHEM
-dependent	O
dioxygenases	B-CHEM
.	O

This	O
chemical	B-CHEM
modification	B-DISO
endows	O
the	O
newly	O
formed	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
with	O
either	O
superior	O
or	O
different	O
stress	O
-	O
protecting	O
and	O
stabilizing	O
properties	O
.	O

Microorganisms	B-LIVB
producing	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
typically	O
contain	O
a	O
mixture	O
of	O
both	O
ectoines	B-CHEM
.	O

We	O
aimed	O
to	O
establish	O
a	O
recombinant	B-LIVB
microbial	B-LIVB
cell	B-ANAT
factory	I-ANAT
where	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
is	O
(	O
i	O
)	O
produced	O
in	O
highly	O
purified	O
form	O
,	O
and	O
(	O
ii	O
)	O
secreted	B-PHYS
into	O
the	O
growth	B-CHEM
medium	I-CHEM
.	O

We	O
used	O
an	O
Escherichia	B-LIVB
coli	I-LIVB
strain	B-LIVB
(	O
FF4169	B-LIVB
)	O
defective	O
in	O
the	O
synthesis	O
of	O
the	O
osmostress	B-DISO
protectant	O
trehalose	B-CHEM
as	O
the	O
chassis	O
for	O
our	O
recombinant	B-LIVB
cell	B-ANAT
factory	I-ANAT
.	O

We	O
expressed	B-PHYS
in	O
this	O
strain	B-LIVB
a	O
plasmid	B-CHEM
-encoded	O
ectD	O
gene	O
from	O
Pseudomonas	B-LIVB
stutzeri	I-LIVB
A1501	I-LIVB
under	O
the	O
control	O
of	O
the	O
anhydrotetracycline	B-CHEM
-inducible	O
tet	B-CHEM
promoter	I-CHEM
.	O

We	O
chose	O
the	O
ectoine	B-CHEM
hydroxylase	I-CHEM
from	O
P	B-LIVB
.	I-LIVB

stutzeri	I-LIVB
A1501	I-LIVB
for	O
our	O
cell	B-ANAT
factory	I-ANAT
after	O
a	O
careful	O
comparison	O
of	O
the	O
in	O
vivo	O
performance	O
of	O
seven	O
different	O
EctD	B-CHEM
proteins	I-CHEM
.	O

In	O
the	O
final	O
set	O
-	O
up	O
of	O
the	O
cell	B-ANAT
factory	I-ANAT
,	O
ectoine	B-CHEM
was	O
provided	O
to	O
salt	B-PROC
-	I-PROC
stressed	I-PROC
cultures	I-PROC
of	O
strain	B-LIVB
FF4169	B-LIVB
(	O
pMP41	O
;	O
ectD	O
(	O
+	O
)	O
)	O
.	O

Ectoine	B-CHEM
was	O
imported	O
into	O
the	O
cells	B-ANAT
via	O
the	O
osmotically	B-PHEN
inducible	O
ProP	B-CHEM
and	O
ProU	B-CHEM
transport	B-PHYS
systems	I-PHYS
,	O
intracellularly	O
converted	O
to	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
,	O
which	O
was	O
then	O
almost	O
quantitatively	O
secreted	B-PHYS
into	O
the	O
growth	B-CHEM
medium	I-CHEM
.	O

Experiments	O
with	O
an	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
mutant	B-DISO
lacking	O
all	O
currently	O
known	O
mechanosensitive	O
channels	O
(	O
MscL	B-CHEM
,	O
MscS	B-CHEM
,	O
MscK	B-CHEM
,	O
MscM	B-CHEM
)	O
revealed	O
that	O
the	O
release	O
of	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
under	O
osmotic	B-PHEN
steady	B-PHEN
-	I-PHEN
state	I-PHEN
conditions	O
occurred	O
independently	O
of	O
these	O
microbial	B-LIVB
safety	O
valves	O
.	O

In	O
shake	B-PROC
-	I-PROC
flask	I-PROC
experiments	I-PROC
,	O
2	O
.	O
13	O
g	O
l	O
(	O
-	O
1	O
)	O
ectoine	B-CHEM
(	O
15	O
mM	O
)	O
was	O
completely	O
converted	O
into	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
within	O
24	O
h	O
.	O

We	O
describe	O
here	O
a	O
recombinant	B-LIVB
E	B-LIVB
.	I-LIVB

coli	I-LIVB
cell	B-ANAT
factory	I-ANAT
for	O
the	O
production	O
and	O
secretion	B-PHYS
of	O
the	O
chemical	B-CHEM
chaperone	B-CHEM
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
free	O
from	O
contaminating	O
ectoine	B-CHEM
.	O

Remote	O
monitoring	B-PROC
of	O
patients	B-LIVB
with	O
cardiac	B-DEVI
implantable	I-DEVI
electronic	I-DEVI
devices	I-DEVI
:	O
a	O
Southeast	B-LIVB
Asian	I-LIVB
,	O
single	O
-	O
centre	O
pilot	B-PROC
study	I-PROC
Remote	O
monitoring	B-PROC
of	O
cardiac	B-DEVI
implantable	I-DEVI
electronic	I-DEVI
devices	I-DEVI
(	O
CIED	B-DEVI
)	O
has	O
been	O
shown	O
to	O
improve	B-DISO
patient	B-PROC
safety	I-PROC
and	O
reduce	O
in	B-PROC
-	I-PROC
office	I-PROC
visits	I-PROC
.	O

We	O
report	O
our	O
experience	B-PHYS
with	O
remote	O
monitoring	B-PROC
via	O
the	O
Medtronic	O
CareLink	O
(	O
®	O
)	O
network	O
.	O

Patients	B-LIVB
were	O
followed	B-PROC
up	I-PROC
for	O
six	O
months	O
with	O
scheduled	O
monthly	O
remote	O
monitoring	B-PROC
transmissions	O
in	O
addition	O
to	O
routine	O
in	B-PROC
-	I-PROC
office	I-PROC
checks	I-PROC
.	O

The	O
efficacy	O
of	O
remote	O
monitoring	B-PROC
was	O
evaluated	B-PROC
by	O
recording	O
compliance	B-DISO
to	O
transmissions	O
,	O
number	O
of	O
device	B-DEVI
alerts	O
requiring	O
intervention	B-PROC
and	O
time	O
from	O
transmission	O
to	O
review	O
.	O

Questionnaires	O
were	O
administered	O
to	O
evaluate	B-PROC
the	O
experiences	B-PHYS
of	O
patients	B-LIVB
,	O
physicians	B-LIVB
and	O
medical	B-LIVB
technicians	I-LIVB
.	O

A	O
total	O
of	O
57	O
patients	B-LIVB
were	O
enrolled	O
;	O
16	O
(	O
28	O
.	O

1	O
%	O
)	O
had	O
permanent	B-DEVI
pacemakers	I-DEVI
,	O
34	O
(	O
59	O
.	O
6	O
%	O
)	O
had	O
implantable	B-DEVI
cardioverter	I-DEVI
defibrillators	I-DEVI
and	O
7	O
(	O
12	O
.	O

3	O
%	O
)	O
had	O
cardiac	B-DEVI
resynchronisation	I-DEVI
therapy	I-DEVI
defibrillators	I-DEVI
.	O

Overall	O
,	O
of	O
334	O
remote	O
transmissions	O
scheduled	O
,	O
73	O
.	O

7	O
%	O
were	O
on	O
time	O
,	O
14	O
.	O
5	O
%	O
were	O
overdue	O
and	O
11	O
.	O

8	O
%	O
were	O
missed	O
.	O

84	O
.	O

6	O
%	O
of	O
wireless	O
transmissions	O
were	O
on	O
time	O
,	O
compared	O
to	O
53	O
.	O

8	O
%	O
of	O
non	O
-	O
wireless	O
transmissions	O
.	O

Among	O
all	O
transmissions	O
,	O
4	O
.	O
4	O
%	O
contained	O
alerts	O
for	O
which	O
physicians	B-LIVB
were	O
informed	O
and	O
only	O
1	O
.	O
8	O
%	O
required	O
intervention	B-PROC
.	O

98	O
.	O

6	O
%	O
of	O
remote	O
transmissions	O
were	O
reviewed	O
by	O
the	O
second	O
working	O
day	O
.	O

73	O
.	O
2	O
%	O
of	O
patients	B-LIVB
preferred	O
remote	O
monitoring	B-PROC
.	O

Physicians	B-LIVB
agreed	O
that	O
remote	O
transmissions	O
provided	O
information	O
equivalent	O
to	O
in	B-PROC
-	I-PROC
office	I-PROC
checks	I-PROC
97	O
.	O

1	O
%	O
of	O
the	O
time	O
.	O

77	O
.	O
8	O
%	O
of	O
medical	B-LIVB
technicians	I-LIVB
felt	O
that	O
remote	O
monitoring	B-PROC
would	O
help	O
the	O
hospital	B-OBJC
improve	B-DISO
patient	B-PROC
management	I-PROC
.	O

No	B-DISO
adverse	B-DISO
events	I-DISO
were	O
reported	B-PROC
.	O

Remote	O
monitoring	B-PROC
of	O
CIED	B-DEVI
is	O
safe	O
and	O
feasible	O
.	O

It	O
has	O
possible	B-DISO
benefits	O
to	O
patient	B-PROC
safety	I-PROC
through	O
earlier	O
detection	B-PROC
of	O
arrhythmias	B-DISO
or	O
device	B-DISO
malfunction	I-DISO
,	O
permitting	O
earlier	O
intervention	B-PROC
.	O

Wireless	O
remote	O
monitoring	B-PROC
,	O
in	O
particular	O
,	O
may	O
improve	B-DISO
compliance	B-DISO
to	O
device	B-DEVI
monitoring	I-DEVI
.	O

Patients	B-LIVB
may	O
prefer	O
remote	O
monitoring	B-PROC
due	O
to	O
possible	B-DISO
improvements	O
in	O
quality	O
of	O
life	O
.	O

c	O
-	O
Src	O
Suppresses	O
Dendritic	B-ANAT
Cell	I-ANAT
Antitumor	O
Activity	O
via	O
T	B-CHEM
Cell	I-CHEM
Ig	I-CHEM
and	I-CHEM
Mucin	I-CHEM
Protein	I-CHEM
-	I-CHEM
3	I-CHEM
Receptor	B-CHEM
The	O
enhanced	O
expression	B-PHYS
of	O
T	B-CHEM
cell	I-CHEM
Ig	I-CHEM
and	I-CHEM
mucin	I-CHEM
protein	I-CHEM
-	I-CHEM
3	I-CHEM
(	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
)	O
on	O
tumor	B-DISO
-	O
associated	O
dendritic	B-ANAT
cells	I-ANAT
(	O
DCs	B-ANAT
)	O
attenuates	O
antitumor	O
effects	O
of	O
DNA	B-CHEM
vaccines	I-CHEM
.	O

To	O
identify	O
a	O
potential	O
target	O
(	O
or	O
targets	O
)	O
for	O
reducing	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
on	O
tumor	B-DISO
-	O
associated	O
DCs	B-ANAT
,	O
we	O
explored	O
the	O
molecular	O
mechanisms	O
regulating	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
novel	O
signaling	B-PHYS
pathway	I-PHYS
(	O
c	O
-	O
Src	O
→	O
Bruton	B-CHEM
's	I-CHEM
tyrosine	I-CHEM
kinase	I-CHEM
→	O
transcription	B-CHEM
factors	I-CHEM
Ets1	B-CHEM
,	O
Ets2	B-CHEM
,	O
USF1	B-CHEM
,	O
and	O
USF2	B-CHEM
)	O
necessary	O
for	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
upregulation	B-PHYS
on	O
DCs	B-ANAT
.	O

Both	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
,	O
which	O
are	O
produced	O
in	O
the	O
tumor	B-PHEN
microenvironment	I-PHEN
,	O
upregulated	B-PHYS
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
on	O
DCs	B-ANAT
via	O
this	O
pathway	B-PHYS
.	O

Suppressed	O
expression	B-PHYS
of	O
c	O
-	O
Src	O
or	O
downstream	O
Bruton	B-CHEM
's	I-CHEM
tyrosine	I-CHEM
kinase	I-CHEM
,	O
Ets1	B-CHEM
,	O
Ets2	B-CHEM
,	O
USF1	B-CHEM
,	O
or	O
USF2	B-CHEM
blocked	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
-	I-CHEM
and	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
-	O
induced	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
upregulation	B-PHYS
on	O
DCs	B-ANAT
.	O

Notably	O
,	O
in	O
vivo	O
knockdown	B-PROC
of	O
c	O
-	O
Src	O
in	O
mice	B-LIVB
reduced	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
on	O
tumor	B-DISO
-	O
associated	O
DCs	B-ANAT
.	O

Furthermore	O
,	O
adoptive	B-PROC
transfer	I-PROC
of	O
c	O
-	O
Src	O
-	O
silenced	B-PROC
DCs	B-ANAT
in	O
mouse	B-LIVB
tumors	B-DISO
enhanced	O
the	O
in	O
vivo	O
antitumor	O
effects	O
of	O
immunostimulatory	B-CHEM
CpG	I-CHEM
DNA	I-CHEM
;	O
however	O
,	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
overexpression	B-PHYS
in	O
c	O
-	O
Src	O
-	O
silenced	B-PROC
DCs	B-ANAT
blocked	O
this	O
effect	O
.	O

Collectively	O
,	O
our	O
data	O
reveal	O
the	O
molecular	O
mechanism	O
regulating	B-PHEN
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
in	O
DCs	B-ANAT
and	O
identify	O
c	O
-	O
Src	O
as	O
a	O
target	O
for	O
improving	O
the	O
efficacy	O
of	O
nucleic	B-CHEM
acid	I-CHEM
-mediated	O
anticancer	B-PROC
therapy	I-PROC
.	O

Distal	O
,	O
not	O
proximal	O
,	O
colonic	B-ANAT
acetate	B-PROC
infusions	I-PROC
promote	O
fat	B-PHEN
oxidation	I-PHEN
and	O
improve	B-DISO
metabolic	B-CHEM
markers	I-CHEM
in	O
overweight	B-DISO
/	O
obese	B-DISO
men	B-LIVB
Gut	B-LIVB
microbial	I-LIVB
-derived	O
short	B-CHEM
-	I-CHEM
chain	I-CHEM
fatty	I-CHEM
acids	I-CHEM
(	O
SCFA	B-CHEM
)	O
are	O
believed	O
to	O
affect	O
host	B-LIVB
metabolism	B-PHYS
and	O
cardiometabolic	B-DISO
risk	I-DISO
factors	I-DISO
.	O

The	O
present	O
study	O
aim	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
proximal	O
and	O
distal	O
colonic	B-ANAT
infusions	B-PROC
with	O
the	O
SCFA	B-CHEM
acetate	I-CHEM
on	O
fat	B-PHEN
oxidation	I-PHEN
and	O
other	O
metabolic	O
parameters	O
in	O
men	B-LIVB
.	O

In	O
this	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
crossover	B-PROC
trial	I-PROC
,	O
six	O
overweight	B-DISO
/	O
obese	B-DISO
men	B-LIVB
[	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O
BMI	B-PHYS
)	O
25	O
-	O
35	O
kg	O
/	O
m	O
(	O
2	O
)	O
]	O
underwent	O
two	O
experimental	O
periods	O
:	O
one	O
with	O
distal	O
and	O
one	O
with	O
proximal	O
colonic	B-ANAT
sodium	B-PROC
acetate	I-PROC
infusions	I-PROC
.	O

A	O
feeding	B-DEVI
catheter	I-DEVI
was	O
endoscopically	O
positioned	O
at	O
the	O
beginning	O
of	O
each	O
period	O
and	O
remained	O
in	O
the	O
colon	B-ANAT
for	O
three	O
consecutive	O
test	O
days	O
,	O
enabling	O
colonic	B-ANAT
acetate	B-PROC
(	O
100	O
or	O
180	O
mmol	O
/	O
l	O
)	O
or	O
placebo	B-CHEM
infusion	B-PROC
during	O
fasting	B-DISO
conditions	O
and	O
after	O
an	O
oral	B-CHEM
glucose	I-CHEM
load	I-CHEM
(	O
postprandial	O
)	O
.	O

Fat	O
oxidation	O
and	O
energy	B-PHYS
expenditure	I-PHYS
were	O
measured	O
using	O
an	O
open	B-DEVI
-	I-DEVI
circuit	I-DEVI
ventilated	I-DEVI
hood	I-DEVI
system	I-DEVI
and	O
blood	B-ANAT
samples	I-ANAT
were	O
repeatedly	O
collected	O
for	O
2	O
h	O
during	O
fasting	B-DISO
and	O
postprandial	O
conditions	O
.	O

Distal	O
colonic	B-ANAT
180	O
mmol	O
/	O
l	O
acetate	B-PROC
infusions	I-PROC
increased	O
fasting	B-DISO
fat	B-PHEN
oxidation	I-PHEN
(	O
1	O
.	O
78±0	O
.	O

28	O
compared	O
with	O
-0	O
.	O

78±0	O
.	O

89	O
g	O
fat	O
2	O
h	O
(	O
-	O
1	O
)	O
,	O
P	O
=	O
0	O
.	O
015	O
)	O
,	O
fasting	B-DISO
peptide	B-CHEM
YY	I-CHEM
(	O
PYY	B-CHEM
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
postprandial	O
glucose	B-CHEM
and	O
insulin	B-CHEM
concentrations	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
tended	O
to	O
increase	O
fasting	B-DISO
plasma	B-ANAT
acetate	B-CHEM
(	O
P	O
=	O
0	O
.	O
069	O
)	O
compared	O
with	O
placebo	B-CHEM
.	O

Distal	O
100	O
mmol	O
/	O
l	O
acetate	B-PROC
administration	I-PROC
tended	O
to	O
decrease	O
fasting	B-DISO
tumour	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
-	I-CHEM
α	I-CHEM
(	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
;	O
P	O
=	O
0	O
.	O
067	O
)	O
compared	O
with	O
placebo	B-CHEM
.	O

In	O
contrast	O
,	O
proximal	O
colonic	B-ANAT
acetate	B-PROC
infusions	I-PROC
showed	O
no	O
effects	O
on	O
substrate	B-OBJC
metabolism	B-PHYS
,	O
circulating	O
hormones	B-CHEM
or	O
inflammatory	O
markers	B-PHYS
.	O

In	O
conclusion	O
distal	O
colonic	B-ANAT
acetate	B-PROC
infusions	I-PROC
affected	O
whole	B-ANAT
-	I-ANAT
body	I-ANAT
substrate	B-OBJC
metabolism	B-PHYS
,	O
with	O
a	O
pronounced	O
increase	O
in	O
fasting	B-DISO
fat	B-PHEN
oxidation	I-PHEN
and	O
plasma	B-ANAT
PYY	B-CHEM
.	O

Modulating	O
colonic	B-ANAT
acetate	B-CHEM
may	O
be	O
a	O
nutritional	O
target	O
to	O
treat	B-PROC
or	O
prevent	O
metabolic	B-DISO
disorders	I-DISO
.	O

Form	O
and	O
function	O
in	O
gene	B-PHYS
regulatory	I-PHYS
networks	I-PHYS
:	O
the	O
structure	O
of	O
network	O
motifs	O
determines	O
fundamental	O
properties	O
of	O
their	O
dynamical	O
state	O
space	O
Network	O
motifs	O
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade	O
,	O
and	O
certain	O
motifs	O
,	O
such	O
as	O
the	O
feed	O
-	O
forward	O
loop	O
,	O
play	O
an	O
important	O
role	O
in	O
regulatory	B-PHYS
networks	I-PHYS
.	O

Recent	O
studies	B-PROC
have	O
used	O
Boolean	O
network	O
motifs	O
to	O
explore	O
the	O
link	O
between	O
form	O
and	O
function	O
in	O
gene	B-PHYS
regulatory	I-PHYS
networks	I-PHYS
and	O
have	O
found	O
that	O
the	O
structure	O
of	O
a	O
motif	O
does	O
not	O
strongly	O
determine	O
its	O
function	O
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene	B-PHYS
expression	I-PHYS
patterns	O
the	O
motif	O
can	O
produce	O
.	O

Here	O
,	O
we	O
offer	O
a	O
different	O
,	O
higher	O
-	O
level	O
definition	O
of	O
the	O
'	O
function	O
'	O
of	O
a	O
motif	O
,	O
in	O
terms	O
of	O
two	O
fundamental	O
properties	O
of	O
its	O
dynamical	O
state	O
space	O
as	O
a	O
Boolean	O
network	O
.	O

One	O
is	O
the	O
basin	O
entropy	O
,	O
which	O
is	O
a	O
complexity	O
measure	O
of	O
the	O
dynamics	B-PHEN
of	O
Boolean	O
networks	O
.	O

The	O
other	O
is	O
the	O
diversity	O
of	O
cyclic	O
attractor	O
lengths	O
that	O
a	O
given	O
motif	O
can	O
produce	O
.	O

Using	O
these	O
two	O
measures	O
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three	O
-	O
node	O
motifs	O
and	O
show	O
that	O
the	O
structural	O
properties	O
of	O
a	O
motif	O
,	O
such	O
as	O
the	O
presence	O
of	O
feedback	O
loops	O
and	O
feed	O
-	O
forward	O
loops	O
,	O
predict	O
fundamental	O
characteristics	O
of	O
its	O
dynamical	O
state	O
space	O
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional	O
versatility	O
.	O

We	O
also	O
show	O
that	O
these	O
higher	O
-	O
level	O
properties	O
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory	B-PHYS
networks	I-PHYS
,	O
as	O
both	O
basin	O
entropy	O
and	O
cycle	O
length	O
diversity	O
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	O
,	O
in	O
neural	B-PHYS
and	O
genetic	B-PHYS
regulatory	I-PHYS
networks	I-PHYS
,	O
of	O
the	O
13	O
connected	O
motifs	O
without	O
self	O
-	O
interactions	O
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
literature	O
.	O

Multiplexing	B-PHEN
Fluorescence	I-PHEN
Anisotropy	I-PHEN
Using	O
Frequency	B-PROC
Encoding	I-PROC
In	O
this	O
report	O
,	O
a	O
method	O
to	O
multiplex	B-PHEN
fluorescence	I-PHEN
anisotropy	I-PHEN
measurements	O
is	O
described	O
using	O
frequency	B-PROC
encoding	I-PROC
.	O

As	O
a	O
demonstration	O
of	O
the	O
method	O
,	O
simultaneous	O
competitive	O
immunoassays	B-PROC
for	O
insulin	B-CHEM
and	O
glucagon	B-CHEM
were	O
performed	O
by	O
measuring	O
the	O
ratio	O
of	O
bound	B-CHEM
and	O
free	B-CHEM
Cy5	I-CHEM
-	I-CHEM
insulin	I-CHEM
and	O
FITC	B-CHEM
-	I-CHEM
glucagon	I-CHEM
in	O
the	O
presence	O
of	O
their	O
respective	O
antibodies	B-CHEM
.	O

A	O
vertically	B-PHEN
polarized	I-PHEN
635	I-PHEN
nm	I-PHEN
laser	I-PHEN
was	O
pulsed	B-PHEN
at	O
73	O
Hz	O
and	O
used	O
to	O
excite	O
Cy5	B-CHEM
-	I-CHEM
insulin	I-CHEM
,	O
while	O
a	O
vertically	B-PHEN
polarized	I-PHEN
488	I-PHEN
nm	I-PHEN
laser	I-PHEN
pulsed	B-PHEN
at	O
137	O
Hz	O
excited	O
FITC	B-CHEM
-	I-CHEM
glucagon	I-CHEM
.	O

The	O
total	O
emission	B-PHEN
was	O
split	O
into	O
parallel	O
and	O
perpendicular	O
polarizations	B-PROC
and	O
collected	O
onto	O
separate	O
photomultiplier	B-OBJC
tubes	I-OBJC
.	O

The	O
signals	B-PHEN
from	O
each	O
channel	O
were	O
demodulated	O
using	O
a	O
fast	O
Fourier	O
transform	O
,	O
resolving	O
the	O
contributions	O
from	O
each	O
fluorophore	B-CHEM
.	O

Anisotropy	B-PHEN
calculations	B-PROC
were	O
carried	O
out	O
using	O
the	O
magnitude	O
of	O
the	O
peaks	O
in	O
the	O
frequency	O
domain	O
.	O

The	O
method	O
produced	O
the	O
expected	O
shape	O
of	O
the	O
calibration	O
curves	O
with	O
limits	O
of	O
detection	B-DISO
of	O
0	O
.	O

6	O
and	O
5	O
nM	O
for	O
insulin	B-CHEM
and	O
glucagon	B-CHEM
,	O
respectively	O
.	O

This	O
methodology	O
could	O
readily	O
be	O
expanded	O
to	O
other	O
biological	B-ANAT
systems	I-ANAT
and	O
further	O
multiplexed	O
to	O
monitor	O
increased	O
numbers	O
of	O
analytes	B-OBJC
.	O

Jak1	B-CHEM
-	O
STAT3	B-CHEM
Signals	B-PHYS
Are	O
Essential	O
Effectors	B-CHEM
of	O
the	O
USP6	B-CHEM
/	O
TRE17	B-CHEM
Oncogene	I-CHEM
in	O
Tumorigenesis	B-DISO
Bone	B-DISO
and	O
soft	B-DISO
tissue	I-DISO
tumors	I-DISO
(	O
BSTT	B-DISO
)	O
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	O
of	O
effective	O
therapies	B-PROC
.	O

Here	O
we	O
report	O
a	O
role	O
for	O
the	O
ubiquitin	B-CHEM
-	I-CHEM
specific	I-CHEM
protease	I-CHEM
6	I-CHEM
(	O
USP6	B-CHEM
)	O
/	O
TRE17	B-CHEM
oncogene	I-CHEM
,	O
which	O
is	O
overexpressed	B-PHYS
upon	O
chromosome	B-DISO
translocation	I-DISO
in	O
various	O
human	B-LIVB
tumors	B-DISO
,	O
including	O
aneurysmal	B-DISO
bone	I-DISO
cyst	I-DISO
(	O
ABC	B-DISO
)	O
,	O
and	O
the	O
related	O
benign	O
lesion	B-DISO
nodular	B-DISO
fasciitis	I-DISO
.	O

Ectopic	B-PHYS
expression	I-PHYS
of	O
USP6	B-CHEM
is	O
known	O
to	O
drive	O
formation	O
of	O
tumors	B-DISO
,	O
which	O
recapitulate	O
key	O
features	O
of	O
ABC	B-DISO
and	O
nodular	B-DISO
fasciitis	I-DISO
;	O
however	O
,	O
the	O
identity	O
of	O
USP6	B-CHEM
's	I-CHEM
relevant	O
substrates	B-CHEM
has	O
been	O
obscure	O
.	O

Here	O
we	O
report	O
that	O
the	O
Jak1	B-CHEM
-	O
STAT3	B-CHEM
signaling	B-PHYS
pathway	I-PHYS
serves	O
as	O
an	O
essential	O
effector	B-CHEM
of	O
USP6	B-CHEM
in	O
BSTT	B-DISO
formation	O
.	O

We	O
found	O
that	O
USP6	B-CHEM
directly	O
deubiquitinated	B-PHYS
Jak1	B-CHEM
,	O
leading	O
to	O
its	O
stabilization	B-DISO
and	O
activation	B-PHYS
of	O
STAT3	B-CHEM
.	O

The	O
tumorigenic	B-DISO
potential	O
of	O
USP6	B-CHEM
was	O
attenuated	O
significantly	O
by	O
CRISPR	B-CHEM
-mediated	O
deletion	B-PHYS
of	O
Jak1	O
or	O
STAT3	O
,	O
or	O
by	O
administration	O
of	O
a	O
Jak	B-CHEM
family	I-CHEM
inhibitor	O
.	O

Analysis	B-PROC
of	O
primary	O
clinical	O
samples	O
of	O
nodular	B-DISO
fasciitis	I-DISO
confirmed	B-DISO
the	O
activation	B-PHYS
of	O
a	O
Jak1	B-CHEM
-	O
STAT3	B-CHEM
gene	O
signature	O
in	B-PROC
vivo	I-PROC
Together	O
,	O
our	O
studies	B-PROC
highlight	O
Jak1	B-CHEM
as	O
the	O
first	O
identified	O
substrate	B-CHEM
for	O
USP6	B-CHEM
,	O
and	O
they	O
offer	O
a	O
mechanistic	O
rationale	O
for	O
the	O
clinical	B-PROC
investigation	I-PROC
of	O
Jak	B-CHEM
and	O
STAT3	B-CHEM
inhibitors	O
as	O
therapeutics	O
for	O
the	O
treatment	B-PROC
of	O
bone	B-DISO
and	O
soft	B-DISO
tissue	I-DISO
tumors	I-DISO
along	O
with	O
other	O
neoplasms	B-DISO
driven	O
by	O
USP6	B-CHEM
overexpression	B-PHYS
.	O

Cancer	O
Res	O
;	O
76	O
(	O
18	O
)	O
;	O
5337	O
-	O
47	O
.	O

©	O
2016	O
AACR	O
.	O

Measure	B-PROC
Up	I-PROC
Pressure	I-PROC
Down	I-PROC
:	I-PROC
Provider	I-PROC
Toolkit	I-PROC
to	O
Improve	O
Hypertension	B-DISO
Control	B-PHYS
Hypertension	B-DISO
is	O
one	O
of	O
the	O
most	O
important	O
risk	B-DISO
factors	I-DISO
for	O
heart	B-DISO
disease	I-DISO
,	O
stroke	B-DISO
,	O
kidney	B-DISO
failure	I-DISO
,	O
and	O
diabetes	B-DISO
complications	I-DISO
.	O

Nearly	O
one	O
in	O
three	O
Americans	B-LIVB
adults	B-LIVB
has	O
high	B-DISO
blood	I-DISO
pressure	I-DISO
,	O
and	O
the	O
cost	O
associated	O
with	O
treating	B-PROC
this	O
condition	B-DISO
is	O
staggering	O
.	O

The	O
Measure	B-PROC
Up	I-PROC
Pressure	I-PROC
Down	I-PROC
:	I-PROC
Provider	I-PROC
Toolkit	I-PROC
to	O
Improve	O
Hypertension	B-DISO
Control	B-PHYS
is	O
a	O
resource	O
developed	O
by	O
the	O
American	O
Medical	O
Group	O
Foundation	O
in	O
partnership	O
with	O
the	O
American	O
Medical	O
Group	O
Association	O
.	O

The	O
goal	O
of	O
this	O
toolkit	O
is	O
to	O
mobilize	O
health	B-LIVB
care	I-LIVB
practitioners	I-LIVB
to	O
work	O
together	O
through	O
team	B-LIVB
-based	O
approaches	O
to	O
achieve	O
an	O
80	O
%	O
control	B-PHYS
rate	O
of	O
high	B-DISO
blood	I-DISO
pressure	I-DISO
among	O
their	O
patient	B-LIVB
population	I-LIVB
.	O

The	O
toolkit	O
can	O
be	O
used	O
by	O
health	B-LIVB
educators	I-LIVB
,	O
clinic	B-LIVB
administrators	I-LIVB
,	O
physicians	B-LIVB
,	O
students	B-LIVB
,	O
and	O
other	O
clinic	B-LIVB
staff	I-LIVB
as	O
a	O
step	O
-	O
by	O
-	O
step	O
resource	O
for	O
developing	O
the	O
infrastructure	B-PROC
needed	O
to	O
better	O
identify	O
and	O
treat	B-PROC
individuals	B-LIVB
with	O
high	B-DISO
blood	I-DISO
pressure	I-DISO
or	O
other	O
chronic	B-DISO
conditions	I-DISO
.	I-DISO

Foreign	B-DISO
-	I-DISO
body	I-DISO
ingestion	B-PHEN
in	O
Egyptian	B-LIVB
children	B-LIVB
:	O
a	O
10	O
-	O
year	O
experience	B-PHYS
of	O
endoscopic	B-PROC
intervention	B-PROC
in	O
a	O
tertiary	B-OBJC
hospital	I-OBJC
There	O
was	O
a	O
lack	O
of	O
data	O
about	O
foreign	B-DISO
body	I-DISO
(	O
FB	B-DISO
)	O
ingestion	B-PHEN
among	O
Middle	B-GEOG
-	I-GEOG
East	I-GEOG
children	B-LIVB
.	O

We	O
conducted	O
a	O
retrospective	O
analysis	B-PROC
of	O
FB	B-DISO
ingestion	B-PHEN
among	O
Egyptian	B-LIVB
children	B-LIVB
and	O
determined	O
the	O
predictors	O
that	O
affect	O
the	O
occurrence	O
of	O
complications	B-DISO
.	O

This	O
retrospective	O
study	B-PROC
was	O
carried	O
out	O
on	O
1546	O
patients	B-LIVB
'	O
≤	O
13	O
years	O
old	O
,	O
presented	O
with	O
FB	B-DISO
ingestion	B-PHEN
and	O
were	O
in	O
need	O
of	O
endoscopic	B-PROC
removal	B-PROC
of	O
FB	B-DISO
.	O

There	O
were	O
711	O
males	B-PHYS
(	O
46	O
%	O
)	O
and	O
835	O
females	B-PHYS
(	O
54	O
%	O
)	O
(	O
mean	O
age	B-PHYS
4	O
.	O
56	O
±2	O
.	O
26	O
years	O
)	O
.	O

Symptoms	B-DISO
were	O
present	B-DISO
in	O
1414	O
patients	B-LIVB
(	O
91	O
.	O
5	O
%	O
)	O
while	O
complications	B-DISO
were	O
present	B-DISO
in	O
137	O
patients	B-LIVB
(	O
8	O
.	O
9	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
complicated	O
and	O
non	O
-	O
complicated	O
cases	O
as	O
regard	O
higher	O
age	B-LIVB
group	I-LIVB
,	O
duration	O
of	O
impaction	B-DISO
,	O
site	O
of	O
impaction	B-DISO
and	O
type	O
of	O
FB	B-DISO
(	O
p	O
=	O
0	O
.	O

001	O
,	O
0	O
.	O
001	O
,	O
0	O
.	O
001	O
and	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
.	O

The	O
highest	O
rate	O
of	O
complications	B-DISO
was	O
observed	O
in	O
FB	B-DISO
impacted	O
in	O
duodenum	B-ANAT
and	O
those	O
without	O
symptoms	B-DISO
while	O
symptomatic	O
cases	O
and	O
impaction	B-DISO
in	O
upper	B-ANAT
esophagus	I-ANAT
were	O
associated	O
with	O
higher	O
success	O
rate	O
of	O
removal	O
.	O

The	O
Evidence	O
Behind	O
Integrating	O
Palliative	O
Care	O
Into	O
Oncology	B-DISO
Practice	O
Palliative	O
care	O
services	O
provided	O
alongside	O
traditional	O
oncology	B-PROC
care	I-PROC
have	O
been	O
shown	O
to	O
be	O
beneficial	O
to	O
patients	B-LIVB
and	O
families	B-LIVB
.	O

This	O
article	O
provides	O
a	O
brief	O
history	O
of	O
palliative	O
care	O
,	O
a	O
pathway	O
to	O
implementing	O
these	O
services	O
into	O
currently	O
established	O
oncology	B-PROC
programs	I-PROC
,	O
and	O
a	O
brief	O
discussion	O
of	O
common	O
barriers	O
.	O

Potentiation	B-PROC
of	O
LPS	B-CHEM
-	O
Induced	B-DISO
Apoptotic	B-PHYS
Cell	I-PHYS
Death	I-PHYS
in	O
Human	B-ANAT
Hepatoma	I-ANAT
HepG2	I-ANAT
Cells	I-ANAT
by	O
Aspirin	B-CHEM
via	O
ROS	B-CHEM
and	O
Mitochondrial	B-DISO
Dysfunction	I-DISO
:	O
Protection	B-DISO
by	O
N	B-CHEM
-	I-CHEM
Acetyl	I-CHEM
Cysteine	I-CHEM
Cytotoxicity	B-DISO
and	O
inflammation	B-DISO
-	O
associated	B-DISO
toxic	O
responses	B-PHYS
have	O
been	O
observed	O
to	O
be	O
induced	O
by	O
bacterial	O
lipopolysaccharides	B-CHEM
(	O
LPS	B-CHEM
)	O
in	O
vitro	O
and	O
in	O
vivo	O
respectively	O
.	O

Use	O
of	O
nonsteroidal	B-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
(	O
NSAIDs	B-CHEM
)	O
,	O
such	O
as	O
aspirin	B-CHEM
,	O
has	O
been	O
reported	B-PROC
to	O
be	O
beneficial	O
in	O
inflammation	B-DISO
-	O
associated	B-DISO
diseases	I-DISO
like	O
cancer	B-DISO
,	O
diabetes	B-DISO
and	O
cardiovascular	B-DISO
disorders	I-DISO
.	O

Their	O
precise	O
molecular	O
mechanisms	O
,	O
however	O
,	O
are	O
not	O
clearly	O
understood	O
.	O

Our	O
previous	O
studies	B-PROC
on	O
aspirin	B-CHEM
treated	B-PROC
HepG2	B-ANAT
cells	I-ANAT
strongly	O
suggest	O
cell	B-PHYS
cycle	I-PHYS
arrest	I-PHYS
and	O
induction	O
of	O
apoptosis	B-PHYS
associated	O
with	O
mitochondrial	B-DISO
dysfunction	I-DISO
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
have	O
further	O
demonstrated	O
that	O
HepG2	B-ANAT
cells	I-ANAT
treated	B-PROC
with	I-PROC
LPS	B-CHEM
alone	O
or	O
in	O
combination	O
with	O
aspirin	B-CHEM
induces	O
subcellular	B-ANAT
toxic	B-PHYS
responses	I-PHYS
which	O
are	O
accompanied	O
by	O
increase	O
in	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O
ROS	B-CHEM
)	O
production	O
,	O
oxidative	B-DISO
stress	I-DISO
,	O
mitochondrial	B-DISO
respiratory	I-DISO
dysfunction	I-DISO
and	O
apoptosis	B-PHYS
.	O

The	O
LPS	B-CHEM
/	O
Aspirin	B-CHEM
induced	O
toxicity	B-DISO
was	O
attenuated	O
by	O
pre	O
-	O
treatment	O
of	O
cells	B-ANAT
with	O
N	B-CHEM
-	I-CHEM
acetyl	I-CHEM
cysteine	I-CHEM
(	O
NAC	B-CHEM
)	O
.	O

Alterations	O
in	O
oxidative	B-DISO
stress	I-DISO
and	O
glutathione	B-CHEM
-	O
dependent	O
redox	B-PHYS
-	I-PHYS
homeostasis	I-PHYS
were	O
more	O
pronounced	O
in	O
mitochondria	B-ANAT
compared	O
to	O
extra	O
-	O
mitochondrial	B-ANAT
cellular	B-ANAT
compartments	I-ANAT
.	O

Pre	O
-	O
treatment	O
of	O
HepG2	B-ANAT
cells	I-ANAT
with	O
NAC	B-CHEM
exhibited	O
a	O
selective	O
protection	B-DISO
in	O
redox	B-PHYS
homeostasis	I-PHYS
and	O
mitochondrial	B-DISO
dysfunction	I-DISO
.	O

Our	O
results	B-DISO
suggest	O
that	O
the	O
altered	O
redox	B-PHYS
metabolism	I-PHYS
,	O
oxidative	B-DISO
stress	I-DISO
and	O
mitochondrial	B-ANAT
function	O
in	O
HepG2	B-ANAT
cells	I-ANAT
play	O
a	O
critical	O
role	O
in	O
LPS	B-CHEM
/	O
aspirin	B-CHEM
-	O
induced	O
cytotoxicity	B-DISO
.	O

These	O
results	B-DISO
may	O
help	O
in	O
better	O
understanding	O
the	O
pharmacological	O
,	O
toxicological	O
and	O
therapeutic	O
properties	O
of	O
NSAIDs	B-CHEM
in	O
cancer	B-ANAT
cells	I-ANAT
exposed	O
to	O
bacterial	B-CHEM
endotoxins	I-CHEM
.	O

Learning	B-PHYS
in	O
Complex	O
Environments	O
:	O
The	O
Effects	O
of	O
Background	O
Speech	B-PHYS
on	O
Early	O
Word	B-PHYS
Learning	I-PHYS
Although	O
most	O
studies	B-PROC
of	O
language	O
learning	B-PHYS
take	O
place	O
in	O
quiet	O
laboratory	B-OBJC
settings	O
,	O
everyday	O
language	O
learning	B-PHYS
occurs	O
under	O
noisy	B-PHEN
conditions	O
.	O

The	O
current	O
research	B-PROC
investigated	O
the	O
effects	O
of	O
background	O
speech	B-PHYS
on	O
word	B-PHYS
learning	I-PHYS
.	O

Both	O
younger	O
(	O
22	O
-	O
to	O
24	O
-	O
month	O
-	O
olds	O
;	O
n	O
=	O
40	O
)	O
and	O
older	O
(	O
28	O
-	O
to	O
30	O
-	O
month	O
-	O
olds	O
;	O
n	O
=	O
40	O
)	O
toddlers	B-LIVB
successfully	O
learned	B-PHYS
novel	O
label	O
-	O
object	B-OBJC
pairings	O
when	O
target	O
speech	B-PHYS
was	O
10	O
dB	O
louder	O
than	O
background	O
speech	B-PHYS
but	O
not	O
when	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
SNR	O
)	O
was	O
5	O
dB	O
.	O

Toddlers	B-LIVB
(	O
28	O
-	O
to	O
30	O
-	O
month	O
-	O
olds	O
;	O
n	O
=	O
26	O
)	O
successfully	O
learned	B-PHYS
novel	O
words	O
with	O
a	O
5	O
-	O
dB	O
SNR	O
when	O
they	O
initially	O
heard	B-PHYS
the	O
labels	O
embedded	B-PROC
in	O
fluent	B-PHYS
speech	I-PHYS
without	O
background	O
noise	B-PHEN
,	O
before	O
they	O
were	O
mapped	O
to	O
objects	B-OBJC
.	O

The	O
results	O
point	O
to	O
both	O
challenges	O
and	O
protective	O
factors	O
that	O
may	O
impact	O
language	O
learning	B-PHYS
in	O
complex	O
auditory	O
environments	O
.	O

Secondary	B-ANAT
Ossification	I-ANAT
Center	I-ANAT
Appearance	O
and	O
Closure	B-PROC
in	I-PROC
the	I-PROC
Pelvis	I-PROC
and	O
Proximal	B-ANAT
Femur	I-ANAT
Variable	O
ossification	B-PHYS
patterns	O
of	O
the	O
pelvis	B-ANAT
in	O
skeletally	B-ANAT
immature	O
patients	B-LIVB
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-ANAT
radiographs	B-PROC
challenging	O
.	O

Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	B-PHYS
comparisons	O
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
.	O

This	O
study	O
evaluates	B-PROC
the	O
chronology	O
and	O
sex	B-PHYS
differences	I-PHYS
for	O
appearance	O
and	O
closure	B-PROC
of	I-PROC
pelvic	I-PROC
and	O
proximal	B-ANAT
femoral	I-ANAT
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
using	O
computed	B-PROC
tomography	I-PROC
(	O
CT	B-PROC
)	O
.	O

Patients	B-LIVB
who	O
underwent	O
abdominal	B-PROC
and	O
pelvic	B-PROC
CT	I-PROC
scans	I-PROC
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	B-OBJC
centers	I-OBJC
were	O
retrospectively	O
reviewed	O
.	O

Patients	B-LIVB
between	O
the	O
ages	B-PHYS
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-PROC
of	O
the	O
pelvis	B-ANAT
and	O
proximal	B-ANAT
femurs	I-ANAT
were	O
included	O
.	O

Patients	B-LIVB
with	O
a	O
history	O
of	O
orthopaedic	O
trauma	O
or	O
pathology	O
affecting	O
ossification	B-PHYS
were	O
excluded	O
.	O

CT	B-PROC
scans	I-PROC
were	O
assessed	O
for	O
the	O
appearance	O
and	O
closure	B-PROC
of	O
the	O
following	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
:	O
anterior	B-ANAT
inferior	I-ANAT
iliac	I-ANAT
spine	I-ANAT
(	O
AIIS	B-ANAT
)	O
,	O
anterior	B-ANAT
superior	I-ANAT
iliac	I-ANAT
spine	I-ANAT
(	O
ASIS	B-ANAT
)	O
,	O
femoral	B-ANAT
head	I-ANAT
(	O
FH	B-ANAT
)	O
,	O
greater	B-ANAT
trochanter	I-ANAT
(	O
GT	B-ANAT
)	O
,	O
iliac	B-ANAT
crest	I-ANAT
(	O
IC	B-ANAT
)	O
,	O
ischial	B-ANAT
tuberosity	I-ANAT
(	O
IT	B-ANAT
)	O
,	O
lesser	B-ANAT
trochanter	I-ANAT
(	O
LT	B-ANAT
)	O
,	O
posterior	B-ANAT
superior	I-ANAT
iliac	I-ANAT
spine	I-ANAT
(	O
PSIS	B-ANAT
)	O
,	O
symphysis	B-ANAT
pubis	I-ANAT
(	O
SP	B-ANAT
)	O
,	O
and	O
triradiate	O
cartilage	O
(	O
TRC	O
)	O
.	O

Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O

A	O
total	O
of	O
496	O
CT	B-PROC
scans	I-PROC
met	O
inclusion	O
criteria	O
(	O
240	O
males	B-PHYS
and	O
256	O
females	B-PHYS
)	O
.	O

The	O
order	O
of	O
appearance	O
of	O
the	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
was	O
:	O
(	O
male	B-PHYS
)	O
GT	B-ANAT
,	O
LT	B-ANAT
,	O
AIIS	B-ANAT
,	O
IT	B-ANAT
,	O
ASIS	B-ANAT
,	O
PSIS	B-ANAT
,	O
IC	B-ANAT
,	O
and	O
SP	B-ANAT
;	O
(	O
female	B-PHYS
)	O
GT	B-ANAT
,	O
LT	B-ANAT
,	O
IT	B-ANAT
,	O
AIIS	B-ANAT
,	O
PSIS	B-ANAT
,	O
IC	B-ANAT
,	O
ASIS	B-ANAT
,	O
and	O
SP	B-ANAT
.	O

The	O
order	O
of	O
closure	B-PROC
was	O
similar	O
:	O
(	O
male	B-PHYS
)	O
TRC	O
,	O
LT	B-ANAT
,	O
FH	B-ANAT
,	O
AIIS	B-ANAT
,	O
GT	B-ANAT
,	O
ASIS	B-ANAT
,	O
PSIS	B-ANAT
,	O
IT	B-ANAT
,	O
IC	B-ANAT
,	O
and	O
SP	B-ANAT
;	O
(	O
female	B-PHYS
)	O
LT	B-ANAT
,	O
TRC	O
,	O
AIIS	B-ANAT
,	O
FH	B-ANAT
,	O
GT	B-ANAT
,	O
ASIS	B-ANAT
,	O
PSIS	B-ANAT
,	O
IT	B-ANAT
,	O
IC	B-ANAT
,	O
and	O
SP	B-ANAT
.	O

Female	B-PHYS
ossification	B-ANAT
centers	I-ANAT
appeared	O
~1	O
to	O
2	O
years	O
before	O
males	B-PHYS
in	O
all	O
locations	B-ANAT
.	O

Female	B-PHYS
ossification	B-ANAT
centers	I-ANAT
closed	O
~1	O
to	O
2	O
years	O
before	O
males	B-PHYS
in	O
all	O
locations	B-ANAT
except	O
TRC	O
,	O
IC	B-ANAT
,	O
and	O
SP	B-ANAT
.	O

The	O
appearance	O
and	O
closure	B-PROC
of	I-PROC
the	I-PROC
pelvis	I-PROC
and	O
proximal	B-ANAT
femur	I-ANAT
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	B-PHYS
than	O
males	B-PHYS
.	O

Knowledge	O
of	O
more	O
precise	O
ages	B-DISO
of	I-DISO
developmen	I-DISO
t	O
and	O
sex	B-PHYS
differences	I-PHYS
better	O
characterize	O
this	O
complex	O
skeletal	B-PHYS
development	I-PHYS
.	O

Future	O
studies	O
may	O
use	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
to	O
further	O
evaluate	B-PROC
skeletal	B-PROC
maturity	I-PROC
,	O
assess	O
pediatric	O
pathology	O
,	O
and	O
aid	O
surgical	B-PROC
management	I-PROC
.	O

Level	O
III	O
.	O

Pediatric	B-LIVB
Orthopaedic	B-ANAT
Trauma	B-DISO
and	O
Associated	B-DISO
Injuries	I-DISO
of	O
Snowmobile	B-DISO
,	O
ATV	B-PHEN
,	O
and	O
Dirtbike	B-PHEN
Accidents	I-PHEN
:	O
A	O
19	O
-	O
Year	O
Experience	O
at	O
a	O
Level	O
1	O
Pediatric	B-LIVB
Trauma	B-OBJC
Center	I-OBJC
The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	O
the	O
type	O
and	O
severity	O
of	O
orthopaedic	B-DISO
and	O
associated	O
injuries	O
for	O
snowmobile	B-DISO
,	O
All	B-PHEN
-	I-PHEN
terrain	I-PHEN
vehicles	I-PHEN
(	O
ATV	B-PHEN
)	O
and	O
motorized	B-PHEN
dirtbike	I-PHEN
accidents	I-PHEN
in	O
a	O
pediatric	B-LIVB
patient	B-LIVB
population	I-LIVB
.	O

A	O
total	O
of	O
758	O
patients	B-LIVB
who	O
presented	O
following	O
either	O
snowmobile	B-DISO
(	O
n	O
=	O
87	O
)	O
,	O
ATV	B-DISO
-	I-DISO
related	I-DISO
(	O
n	O
=	O
308	O
)	O
or	O
dirtbike	B-DISO
(	I-DISO
n	I-DISO
=	I-DISO
363	I-DISO
)	I-DISO
-	I-DISO
related	I-DISO
trauma	I-DISO
at	O
our	O
institution	O
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

A	O
total	O
of	O
441	O
axial	B-DISO
and	O
appendicular	B-DISO
fractures	I-DISO
occurred	O
requiring	O
533	O
procedures	O
.	O

Snowmobile	B-DISO
and	O
dirtbike	B-PHEN
accidents	I-PHEN
were	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
fractures	B-DISO
(	O
63	O
%	O
,	O
64	O
%	O
)	O
than	O
the	O
ATV	B-LIVB
group	I-LIVB
(	O
50	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
0008	O
)	O
.	O

Snowmobile	O
injuries	O
had	O
the	O
highest	O
rate	O
of	O
spinal	B-DISO
(	O
23	O
%	O
)	O
and	O
lower	B-DISO
extremity	I-DISO
fractures	I-DISO
(	O
53	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
.	O

Snowmobile	B-LIVB
and	O
dirtbike	B-LIVB
cohorts	I-LIVB
had	O
higher	O
rate	O
of	O
femur	B-DISO
fractures	I-DISO
(	O
22	O
%	O
,	O
17	O
%	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
whereas	O
the	O
ATV	B-LIVB
cohort	I-LIVB
had	O
higher	O
rates	O
of	O
upper	B-ANAT
extremity	I-ANAT
(	O
18	O
%	O
)	O
,	O
hand	B-ANAT
(	O
11	O
%	O
)	O
,	O
scapula	B-ANAT
(	O
4	O
.	O
6	O
%	O
)	O
,	O
and	O
open	B-DISO
fractures	I-DISO
(	O
28	O
.	O
6	O
%	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Head	B-DISO
trauma	I-DISO
was	O
the	O
most	O
commonly	O
associated	O
injury	O
in	O
275	O
patients	B-LIVB
with	O
the	O
highest	O
rate	O
in	O
the	O
ATV	B-LIVB
group	I-LIVB
(	O
44	O
%	O
)	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
(	O
76	O
%	O
)	O
.	O

Snowmobile	B-LIVB
and	O
ATV	B-LIVB
patients	I-LIVB
had	O
higher	O
Injury	O
Severity	O
Score	O
(	O
11	O
.	O
3	O
,	O
9	O
.	O
6	O
)	O
than	O
dirtbike	B-LIVB
patients	I-LIVB
(	O
7	O
.	O
8	O
)	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

ATV	B-LIVB
patients	I-LIVB
were	O
found	O
to	O
be	O
younger	O
(	O
11	O
.	O

8	O
y	O
)	O
compared	O
with	O
snowmobile	B-LIVB
(	O
13	O
.	O
2	O
y	O
)	O
and	O
dirtbike	B-LIVB
(	O
13	O
.	O
5	O
y	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Pediatric	B-LIVB
snowmobile	B-DISO
,	O
ATV	B-PHEN
and	O
dirtbike	B-PHEN
accidents	I-PHEN
result	O
in	O
severe	O
orthopaedic	B-DISO
and	O
associated	O
injuries	O
with	O
each	O
vehicle	B-OBJC
demonstrating	O
significantly	O
different	O
injury	B-DISO
patterns	O
.	O

Injury	B-PROC
prevention	I-PROC
should	O
focus	O
on	O
improved	O
safety	B-PROC
mechanisms	I-PROC
,	O
protective	B-OBJC
gear	I-OBJC
,	O
safe	O
areas	O
for	O
off	B-OBJC
-	I-OBJC
road	I-OBJC
vehicle	I-OBJC
use	O
and	O
strict	O
laws	O
with	O
minimum	O
age	B-PHYS
requirements	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
:	O
Level	O
IV	O
.	O

Content	O
of	O
cardiolipin	B-CHEM
of	O
the	O
membrane	O
and	O
sensitivity	B-DISO
to	O
cationic	B-CHEM
surfactants	I-CHEM
in	O
Pseudomonas	B-LIVB
putida	I-LIVB
To	O
establish	O
the	O
role	O
of	O
cardiolipin	B-CHEM
(	O
CL	B-CHEM
)	O
of	O
the	O
membrane	O
in	O
response	O
to	O
the	O
presence	O
of	O
tetradecyltrimethylammonium	B-CHEM
in	O
Pseudomonas	B-LIVB
putida	I-LIVB
A	I-LIVB
(	I-LIVB
ATCC	I-LIVB
12633	I-LIVB
)	I-LIVB
.	O

Two	O
ORFs	O
of	O
Ps	B-LIVB
.	I-LIVB

putida	I-LIVB
A	I-LIVB
(	I-LIVB
ATCC	I-LIVB
12633	I-LIVB
)	I-LIVB
,	O
which	O
in	O
Ps	B-LIVB
.	I-LIVB

putida	I-LIVB
KT2440	I-LIVB
encode	O
the	O
putative	O
CL	B-CHEM
synthase	I-CHEM
genes	O
cls	O
and	O
cls2	O
,	O
were	O
cloned	B-PROC
,	O
sequenced	B-PROC
and	O
mutated	O
.	O

Only	O
the	O
double	O
mutant	O
lacking	O
cls	O
and	O
cls2	O
showed	O
a	O
reduction	O
of	O
the	O
CL	B-CHEM
content	O
,	O
83	O
%	O
lower	O
than	O
the	O
amount	O
produced	O
by	O
the	O
wild	O
-	O
type	O
.	O

Accompanying	O
this	O
change	O
was	O
a	O
40	O
%	O
decrease	O
in	O
the	O
content	O
of	O
unsaturated	B-CHEM
fatty	I-CHEM
acid	I-CHEM
.	O

Consequently	O
,	O
the	O
membrane	O
of	O
the	O
mutant	O
was	O
more	O
rigid	O
than	O
the	O
one	O
of	O
the	O
parental	B-LIVB
strain	I-LIVB
,	O
as	O
observed	O
using	O
fluorescence	B-PROC
polarization	I-PROC
techniques	I-PROC
.	O

The	O
mutant	B-LIVB
strain	I-LIVB
showed	O
reduced	O
viability	O
in	O
the	O
presence	O
of	O
tetradecyltrimethylammonium	B-CHEM
.	O

The	O
incorporation	O
of	O
exogenous	O
CL	B-CHEM
into	O
its	O
membrane	O
relieved	O
sensitivity	B-DISO
to	O
the	O
cationic	B-CHEM
detergent	I-CHEM
.	O

Pseudomonas	B-ANAT
Putida	I-ANAT
cells	I-ANAT
with	O
low	O
levels	O
of	O
CL	B-CHEM
die	B-PHYS
in	O
the	O
presence	O
of	O
tetradecyltrimethylammonium	B-CHEM
,	O
because	O
they	O
cannot	O
counter	O
the	O
fluidizing	O
effect	O
of	O
the	O
cationic	B-CHEM
surfactant	I-CHEM
.	O

The	O
modification	O
in	O
the	O
membrane	B-CHEM
phospholipids	I-CHEM
composition	O
allows	O
knowing	O
the	O
adaptation	B-PHEN
strategy	O
of	O
Ps	B-LIVB
.	I-LIVB

putida	I-LIVB
when	O
these	O
bacteria	B-LIVB
are	O
exposed	O
to	O
cationic	B-CHEM
surfactant	I-CHEM
.	O

NADPH	B-CHEM
oxidase	I-CHEM
-	I-CHEM
produced	I-CHEM
superoxide	I-CHEM
mediated	O
a	O
50	O
-	O
Hz	O
magnetic	B-PHEN
field	I-PHEN
-induced	O
epidermal	B-CHEM
growth	I-CHEM
factor	I-CHEM
receptor	I-CHEM
clustering	B-PHYS
A	O
50	O
-	O
Hz	O
magnetic	B-PHEN
field	I-PHEN
(	O
MF	B-PHEN
)	O
was	O
found	O
to	O
induce	O
epidermal	B-CHEM
growth	I-CHEM
factor	I-CHEM
receptor	I-CHEM
(	O
EGFR	B-CHEM
)	O
clustering	B-PHYS
in	O
our	O
previous	O
study	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
molecular	B-PHYS
mechanisms	I-PHYS
that	O
mediated	O
MF	B-PHEN
-induced	O
EGFR	B-CHEM
clustering	B-PHYS
.	O

Human	B-ANAT
amniotic	I-ANAT
epithelial	I-ANAT
(	I-ANAT
FL	I-ANAT
)	I-ANAT
cells	I-ANAT
were	O
exposed	O
to	O
a	O
50	O
-	O
Hz	O
MF	B-PHEN
.	O

Total	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O
ROS	B-CHEM
)	O
,	O
cytoplasmic	B-ANAT
and	O
mitochondrial	B-ANAT
superoxide	B-CHEM
production	O
were	O
detected	O
by	O
DCFH	B-CHEM
-	I-CHEM
DA	I-CHEM
,	O
DHE	B-CHEM
and	O
MitoSOX	B-CHEM
,	O
respectively	O
.	O

EGFR	B-CHEM
clustering	B-PHYS
was	O
analyzed	O
using	O
confocal	B-PROC
microscopy	I-PROC
after	O
indirect	B-PROC
immunofluorescence	I-PROC
staining	B-PROC
.	O

Results	O
showed	O
that	O
exposing	O
FL	B-ANAT
cells	I-ANAT
to	O
MF	B-PHEN
at	O
intensity	O
higher	O
than	O
0	O
.	O

2	O
mT	O
for	O
15	O
min	O
enhanced	O
total	O
ROS	B-CHEM
production	O
.	O

Additionally	O
,	O
enhanced	O
total	O
ROS	B-CHEM
and	O
cytoplasmic	B-ANAT
superoxide	B-CHEM
production	O
were	O
observed	O
after	O
exposing	O
cells	B-ANAT
to	O
MF	B-PHEN
at	O
0	O
.	O

4	O
mT	O
for	O
5	O
,	O
15	O
,	O
or	O
30	O
min	O
,	O
while	O
mitochondrial	B-ANAT
superoxide	B-CHEM
production	O
for	O
15	O
or	O
30	O
min	O
.	O

Pretreatment	O
with	O
Nox	B-CHEM
inhibitor	B-CHEM
,	O
DPI	B-CHEM
,	O
effectively	O
inhibited	O
MF	B-PHEN
-induced	O
cytoplasmic	B-ANAT
superoxide	B-CHEM
production	O
and	O
subsequent	O
EGFR	B-CHEM
clustering	B-PHYS
while	O
mitochondrial	B-ANAT
superoxide	B-CHEM
production	O
was	O
not	O
affected	O
.	O

Nox	B-CHEM
-	I-CHEM
produced	I-CHEM
superoxide	I-CHEM
mediated	O
a	O
50	O
-	O
Hz	O
magnetic	B-PHEN
field	I-PHEN
-induced	O
EGFR	B-CHEM
clustering	B-PHYS
.	O

Placental	B-ANAT
Pathologic	O
Associations	O
with	O
Morbidly	B-DISO
Adherent	I-DISO
Placenta	I-DISO
:	O
Potential	O
insights	O
into	O
Pathogenesis	B-DISO
The	O
pathology	O
that	O
underlies	O
morbidly	B-DISO
adherent	I-DISO
placenta	I-DISO
(	O
MAP	B-DISO
)	O
is	O
poorly	O
understood	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
placental	B-ANAT
pathology	O
,	O
especially	O
implantation	O
site	O
pathology	O
,	O
associated	O
with	O
MAP	B-DISO
.	O

This	O
was	O
a	O
single	O
institution	O
,	O
retrospective	B-PROC
case	I-PROC
-	I-PROC
control	I-PROC
study	I-PROC
design	O
examining	O
placentas	B-ANAT
of	O
patients	B-LIVB
who	O
delivered	B-DISO
between	O
January	O
2008	O
and	O
September	O
2013	O
.	O

MAP	B-DISO
cases	O
were	O
defined	O
by	O
the	O
need	O
for	O
clinical	O
intervention	B-PROC
at	O
delivery	B-PROC
beyond	O
spontaneous	O
placental	B-PROC
delivery	I-PROC
or	O
simple	O
manual	B-PROC
extraction	I-PROC
of	O
the	O
placenta	B-ANAT
.	O

Controls	B-LIVB
consisted	O
of	O
patients	B-LIVB
with	O
placentas	B-ANAT
sent	O
for	O
examination	B-PROC
due	O
to	O
a	O
history	B-DISO
of	O
maternal	B-LIVB
malignancy	B-DISO
with	O
no	B-DISO
clinical	O
suspicion	O
of	O
accreta	B-DISO
.	O

Placental	B-ANAT
pathologic	B-DISO
findings	I-DISO
of	O
maternal	B-DISO
vascular	I-DISO
underperfusion	I-DISO
(	O
MVU	B-DISO
)	O
,	O
acute	B-DISO
inflammation	I-DISO
,	O
chronic	B-DISO
inflammation	I-DISO
,	O
fetal	B-ANAT
vascular	B-DISO
obstruction	I-DISO
and	O
hemorrhage	B-DISO
were	O
recorded	O
and	O
compared	O
using	O
bivariable	O
and	O
multivariable	O
analyses	O
.	O

Three	O
categories	O
of	O
pathologic	O
changes	O
were	O
seen	O
more	O
commonly	O
in	O
MAP	B-DISO
placentas	B-ANAT
(	O
N	O
=	O
101	O
)	O
than	O
control	B-LIVB
placentas	B-ANAT
(	O
N	O
=	O
110	O
)	O
:	O
chronic	B-DISO
basal	I-DISO
inflammation	I-DISO
,	O
villous	O
changes	O
of	O
MVU	B-DISO
and	O
retromembranous	O
and	O
retromembranous	B-DISO
/	O
intervillous	B-DISO
hemorrhage	I-DISO
.	O

In	O
multivariable	O
analyses	O
adjusted	O
for	O
confounders	O
,	O
chronic	B-DISO
basal	I-DISO
villitis	I-DISO
(	O
aOR	O
5	O
.	O
6	O
,	O
1	O
.	O
73	O
-	O
18	O
.	O
18	O
)	O
,	O
plasma	B-DISO
cell	I-DISO
deciduitis	I-DISO
(	O
aOR	O
2	O
.	O
63	O
,	O
1	O
.	O
08	O
-	O
6	O
.	O
39	O
)	O
,	O
increased	B-DISO
syncytial	I-DISO
knots	I-DISO
(	O
aOR	O
3	O
.	O
92	O
,	O
1	O
.	O
57	O
-	O
9	O
.	O
75	O
)	O
,	O
villous	O
agglutination	O
(	O
aOR	O
24	O
.	O
85	O
,	O
2	O
.	O
78	O
-	O
221	O
.	O
75	O
)	O
,	O
increased	B-DISO
perivillous	I-DISO
fibrin	I-DISO
(	O
aOR	O
5	O
.	O
08	O
,	O
1	O
.	O
49	O
-	O
17	O
.	O
34	O
)	O
,	O
and	O
the	O
presence	O
of	O
subchorionic	B-DISO
/	O
intervillous	B-DISO
thrombi	I-DISO
(	O
aOR	O
4	O
.	O
01	O
,	O
1	O
.	O
63	O
-	O
9	O
.	O
86	O
)	O
remained	O
associated	O
with	O
MAP	B-DISO
.	O

MAP	B-DISO
is	O
highly	O
associated	O
with	O
evidence	O
of	O
intraparenchymal	B-DISO
placental	I-DISO
hemorrhage	I-DISO
villous	O
changes	O
of	O
MVU	B-DISO
,	O
and	O
a	O
lymphoplasmacytic	B-DISO
infiltrate	I-DISO
at	O
the	O
implantation	O
site	O
.	O

The	O
contribution	O
of	O
this	O
basal	B-DISO
chronic	I-DISO
inflammatory	I-DISO
infiltrate	I-DISO
to	O
MAP	B-DISO
requires	O
further	O
investigation	O
.	O

Hospitalist	B-LIVB
Co	O
-	O
management	O
of	O
Pediatric	O
Orthopaedic	B-PROC
Surgical	B-LIVB
Patients	I-LIVB
at	O
a	O
Community	B-OBJC
Hospital	I-OBJC
The	O
benefits	O
of	O
hospitalist	B-LIVB
co	O
-	O
management	O
of	O
pediatric	O
surgical	B-LIVB
patients	I-LIVB
include	O
bettering	O
patient	B-PROC
safety	I-PROC
,	O
decreasing	B-DISO
negative	O
patient	O
outcomes	O
,	O
providing	O
comprehensive	B-PROC
medical	I-PROC
care	I-PROC
,	O
and	O
establishing	O
a	O
dedicated	O
resource	O
to	O
patients	B-LIVB
for	O
postoperative	B-PROC
care	I-PROC
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
characterize	O
the	O
nature	O
of	O
patients	B-LIVB
co	O
-	O
managed	O
by	O
a	O
pediatric	O
hospitalist	B-LIVB
.	O

The	O
authors	B-LIVB
hypothesize	O
that	O
hospitalist	B-LIVB
co	O
-	O
management	O
is	O
safe	B-DISO
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
who	O
are	O
admitted	B-PROC
to	O
a	O
community	B-OBJC
hospital	I-OBJC
.	O

A	O
retrospective	B-PROC
review	I-PROC
was	O
performed	O
of	O
all	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
admitted	B-PROC
to	O
a	O
community	B-OBJC
hospital	I-OBJC
who	O
were	O
co	O
-	O
managed	O
by	O
a	O
pediatric	O
hospitalist	B-LIVB
.	O

Indications	O
for	O
hospitalization	B-PROC
included	O
pain	B-PROC
control	I-PROC
,	O
antibiotic	B-PROC
infusion	I-PROC
,	O
and	O
need	O
for	O
neurovascular	B-PROC
monitoring	I-PROC
.	O

Parameters	O
of	O
postoperative	B-PROC
care	I-PROC
and	O
co	O
-	O
management	O
were	O
assessed	O
,	O
including	O
presence	B-DISO
of	O
complications	O
,	O
medication	B-PROC
introduction	I-PROC
or	O
adjustment	O
by	O
the	O
hospitalist	B-LIVB
,	O
follow	B-PROC
-	I-PROC
up	I-PROC
adherence	O
,	O
and	O
readmission	B-PROC
/	O
complication	O
rates	O
after	O
discharge	B-PROC
.	O

Thirty	O
-	O
two	O
patients	B-LIVB
were	O
assessed	O
with	O
an	O
average	B-PHYS
age	I-PHYS
of	O
8	O
.	O

8	O
years	O
.	O

Twenty	O
-	O
five	O
percent	O
of	O
patients	B-LIVB
had	O
an	O
associated	O
comorbidity	O
,	O
including	O
asthma	B-DISO
,	O
attention	B-DISO
deficit	I-DISO
disorder	I-DISO
,	O
and	O
/	O
or	O
autism	B-DISO
.	O

The	O
pediatric	O
hospitalist	B-LIVB
added	O
pain	B-PROC
medication	I-PROC
to	O
the	O
original	O
postoperative	B-PROC
orders	I-PROC
placed	O
by	O
the	O
orthopaedics	B-LIVB
team	I-LIVB
in	O
44	O
percent	O
of	O
patients	B-LIVB
(	O
14	O
of	O
the	O
32	O
)	O
either	O
for	O
breakthrough	B-DISO
pain	I-DISO
or	O
better	O
long	O
-	O
term	O
coverage	O
.	O

Additionally	O
,	O
25	O
percent	O
of	O
patients	B-LIVB
had	O
pain	B-PROC
medication	I-PROC
adjusted	O
from	O
the	O
original	O
dosing	O
and	O
schedule	B-PROC
.	O

The	O
hospitalist	B-LIVB
team	B-LIVB
contacted	O
the	O
surgeon	B-LIVB
about	O
the	O
four	O
patients	B-LIVB
(	O
12	O
.	O
5	O
percent	O
)	O
.	O

In	O
three	O
of	O
the	O
cases	O
,	O
the	O
surgeon	B-LIVB
was	O
contacted	O
to	O
discuss	O
pain	B-PROC
medication	I-PROC
,	O
and	O
one	O
patient	B-LIVB
woke	O
up	O
agitated	O
from	O
anesthesia	B-PROC
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	B-LIVB
on	O
the	O
pediatrics	O
floor	O
.	O

The	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	B-LIVB
.	O

The	O
hospitalists	B-LIVB
rounded	O
on	O
and	O
discharged	B-PROC
patients	I-PROC
the	O
subsequent	O
morning	O
.	O

All	O
patients	B-LIVB
were	O
given	O
a	O
follow	O
-	O
up	O
appointment	O
and	O
schedule	O
by	O
the	O
hospitalist	B-LIVB
team	O
,	O
and	O
every	B-LIVB
patient	I-LIVB
followed	B-PROC
up	I-PROC
accordingly	O
within	O
ten	O
days	O
of	O
discharge	B-PROC
.	O

No	O
complications	O
or	O
hospital	B-PROC
readmissions	I-PROC
occurred	O
within	O
thirty	O
days	O
of	O
discharge	B-PROC
.	O

Hospitalist	B-LIVB
co	O
-	O
management	O
of	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
in	O
a	O
community	B-OBJC
hospital	I-OBJC
allows	O
for	O
better	O
medical	O
comorbidity	O
and	O
medication	B-PROC
management	I-PROC
.	O

Hospitalist	B-LIVB
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient	O
stay	O
and	O
help	O
streamline	O
communication	O
between	O
providers	B-LIVB
and	O
patients	B-LIVB
while	O
allowing	O
the	O
surgeon	B-LIVB
the	O
ability	O
to	O
be	O
more	O
mobile	O
.	O

Co	O
-	O
management	O
is	O
safe	B-DISO
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
who	O
are	O
admitted	B-PROC
to	O
a	O
community	B-OBJC
hospital	I-OBJC
.	O

Biosynthetic	B-DISO
Gene	O
Cluster	O
for	O
Surugamide	B-CHEM
A	I-CHEM
Encompasses	O
an	O
Unrelated	O
Decapeptide	B-CHEM
,	O
Surugamide	B-CHEM
F	I-CHEM
Genome	O
mining	B-PROC
is	O
a	O
powerful	O
method	O
for	O
finding	O
novel	O
secondary	B-CHEM
metabolites	I-CHEM
.	O

In	O
our	O
study	B-PROC
on	O
the	O
biosynthetic	B-DISO
gene	O
cluster	O
for	O
the	O
cyclic	B-CHEM
octapeptides	I-CHEM
surugamides	B-CHEM
A	I-CHEM
-	I-CHEM
E	I-CHEM
(	O
inhibitors	B-CHEM
of	O
cathepsin	B-CHEM
B	I-CHEM
)	O
,	O
we	O
found	O
a	O
putative	O
gene	O
cluster	O
consisting	O
of	O
four	O
successive	O
non	O
-	O
ribosomal	O
peptide	O
synthetase	O
(	O
NRPS	O
)	O
genes	O
,	O
surA	O
,	O
surB	O
,	O
surC	O
,	O
and	O
surD	O
.	O

Prediction	O
of	O
amino	O
acid	O
sequence	O
based	O
on	O
the	O
NRPSs	O
and	O
gene	B-PHYS
inactivation	I-PHYS
revealed	O
that	O
surugamides	B-CHEM
A	I-CHEM
-	I-CHEM
E	I-CHEM
are	O
produced	O
by	O
two	O
NRPS	O
genes	O
,	O
surA	O
and	O
surD	O
,	O
which	O
were	O
separated	O
by	O
two	O
NRPS	O
genes	O
,	O
surB	O
and	O
surC	O
.	O

The	O
latter	O
genes	O
are	O
responsible	O
for	O
the	O
biosynthesis	B-PHEN
of	O
an	O
unrelated	O
peptide	B-CHEM
,	O
surugamide	B-CHEM
F	I-CHEM
.	O

The	O
pattern	O
of	O
intercalation	B-PHYS
observed	O
in	O
the	O
sur	O
genes	O
is	O
unprecedented	O
.	O

The	O
structure	O
of	O
surugamide	B-CHEM
F	I-CHEM
,	O
a	O
linear	O
decapeptide	B-CHEM
containing	O
one	O
3	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
methylpropionic	I-CHEM
acid	I-CHEM
(	O
AMPA	B-CHEM
)	O
residue	O
,	O
was	O
determined	O
by	O
spectroscopic	B-PROC
methods	I-PROC
and	O
was	O
confirmed	O
by	O
solid	O
-	O
phase	O
peptide	O
synthesis	O
.	O

An	O
ion	O
-	O
gating	O
multinanochannel	O
system	O
based	O
on	O
a	O
copper	B-CHEM
-	O
responsive	O
self	O
-	O
cleaving	O
DNAzyme	B-CHEM
We	O
developed	O
an	O
ion	O
-	O
gating	O
nanochannel	O
composite	O
system	O
by	O
immobilizing	O
a	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	O
responsive	O
self	O
-	O
cleaving	O
DNAzyme	B-CHEM
into	O
PET	B-CHEM
conical	B-CHEM
multinanochannels	I-CHEM
,	O
which	O
could	O
control	O
the	O
ion	B-PHYS
transport	I-PHYS
by	O
regulating	B-PHEN
the	O
surface	O
charge	B-PHYS
density	O
of	O
the	O
channels	B-CHEM
.	O

Pain	B-DISO
and	O
alcohol	O
consumption	O
among	O
older	B-LIVB
adults	I-LIVB
:	O
findings	B-DISO
from	O
the	O
World	O
Health	O
Organization	O
Study	B-PROC
on	O
global	O
AGEing	B-PHYS
and	O
adult	B-LIVB
health	O
,	O
Wave	O
1	O
To	O
investigate	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
associations	O
between	O
self	B-PROC
-	I-PROC
reported	I-PROC
recent	O
pain	B-DISO
and	O
alcohol	O
use	O
/	O
abstinence	O
,	O
and	O
previous	O
-	O
day	O
pain	B-DISO
and	O
previous	O
-	O
week	O
alcohol	O
consumption	O
in	O
adults	B-LIVB
aged	O
50	O
+	O
in	O
six	O
low	B-DISO
-	O
and	O
middle	O
-	O
income	O
countries	B-GEOG
(	O
LMICs	B-GEOG
)	O
.	O

The	O
WHO	O
Study	B-PROC
on	O
global	O
AGEing	B-PHYS
and	O
adult	B-LIVB
health	O
(	O
SAGE	B-PROC
)	O
Wave	O
1	O
(	O
2007	O
-	O
2010	O
)	O
in	O
China	B-GEOG
,	O
Ghana	B-GEOG
,	O
India	B-GEOG
,	O
Mexico	B-GEOG
,	O
Russia	B-GEOG
and	O
South	B-GEOG
Africa	I-GEOG
is	O
the	O
data	O
source	O
.	O

Prevalence	O
of	O
alcohol	O
use	O
/	O
abstinence	O
is	O
reported	O
by	O
previous	O
-	O
day	O
and	O
previous	O
-	O
month	O
pain	B-DISO
.	O

Multinomial	O
logistic	B-PROC
regressions	I-PROC
(	O
crude	B-CHEM
and	O
adjusted	O
for	O
sex	B-PHYS
and	O
country	B-GEOG
)	O
tested	O
associations	O
between	O
recent	O
pain	B-DISO
and	O
alcohol	O
use	O
in	O
the	O
pooled	B-OBJC
multicountry	B-GEOG
sample	B-OBJC
.	O

Across	O
the	O
six	O
SAGE	B-PROC
countries	B-GEOG
,	O
about	O
one	O
-	O
third	O
of	O
respondents	B-LIVB
reported	O
alcohol	O
use	O
,	O
being	O
highest	O
in	O
Russia	B-GEOG
(	O
74	O
%	O
)	O
and	O
lowest	O
in	O
India	B-GEOG
(	O
16	O
%	O
)	O
.	O

Holding	O
the	O
effects	O
of	O
sex	B-PHYS
and	O
country	B-GEOG
constant	O
,	O
compared	O
with	O
abstainers	B-DISO
,	O
people	B-LIVB
with	O
previous	O
-	O
day	O
pain	B-DISO
were	O
more	O
likely	O
to	O
be	O
previous	O
-	O
day	O
or	O
other	B-LIVB
users	I-LIVB
.	O

With	O
regard	O
to	O
the	O
quantity	O
and	O
frequency	O
of	O
alcohol	O
use	O
,	O
people	B-LIVB
with	O
previous	O
-	O
day	O
pain	B-DISO
were	O
more	O
likely	O
to	O
be	O
non	B-DISO
-	I-DISO
heavy	I-DISO
drinkers	I-DISO
.	O

Overall	O
,	O
we	O
found	O
that	O
,	O
in	O
this	O
population	B-LIVB
of	O
older	B-LIVB
adults	I-LIVB
in	O
six	O
LMICs	B-GEOG
,	O
recent	O
pain	B-DISO
was	O
associated	O
with	O
moderate	O
use	O
of	O
alcohol	O
,	O
although	O
there	O
were	O
differences	O
between	O
countries	B-GEOG
.	O

The	O
findings	B-DISO
provide	O
a	O
platform	B-DEVI
for	O
country	B-GEOG
-	O
specific	O
research	B-PROC
to	O
better	O
understand	B-PHYS
bi	O
-	O
directional	O
associations	O
between	O
pain	B-DISO
and	O
alcohol	B-CHEM
in	O
older	B-LIVB
adults	I-LIVB
.	O

Extra	O
carbohydrate	B-CHEM
binding	I-CHEM
module	I-CHEM
contributes	O
to	O
the	O
processivity	O
and	O
catalytic	B-PHYS
activity	I-PHYS
of	O
a	O
non	B-CHEM
-	I-CHEM
modular	I-CHEM
hydrolase	I-CHEM
family	O
5	B-CHEM
endoglucanase	I-CHEM
from	O
Fomitiporia	B-LIVB
mediterranea	I-LIVB
MF3	I-LIVB
/	I-LIVB
22	I-LIVB
FmEG	B-CHEM
from	O
Fomitiporia	B-LIVB
mediterranea	I-LIVB
is	O
a	O
non	B-CHEM
-	I-CHEM
modular	I-CHEM
endoglucanase	I-CHEM
composed	O
of	O
a	O
24	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
extension	O
and	O
13	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
linker	B-CHEM
-	I-CHEM
like	I-CHEM
peptide	I-CHEM
at	O
the	O
N	O
-	O
terminus	O
and	O
a	O
312	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
GH5	O
catalytic	O
domain	O
(	O
CD	O
)	O
at	O
the	O
C	O
-	O
terminus	O
.	O

In	O
this	O
study	O
,	O
six	O
FmEG	B-CHEM
derivatives	O
with	O
deletion	O
of	O
N	B-CHEM
-	I-CHEM
terminal	I-CHEM
fragments	I-CHEM
or	O
fusion	B-CHEM
with	O
an	O
extra	O
family	B-CHEM
1	I-CHEM
carbohydrate	I-CHEM
-	I-CHEM
binding	I-CHEM
module	I-CHEM
(	O
CBM1	B-CHEM
)	O
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	O
of	O
CBM1	B-CHEM
to	O
FmEG	B-CHEM
processivity	O
and	O
catalytic	B-PHYS
activity	I-PHYS
.	O

FmEG	B-CHEM
showed	O
a	O
weak	O
processivity	O
and	O
released	O
cellobiose	B-CHEM
(	O
G2	B-CHEM
)	O
and	O
cellotriose	B-CHEM
(	O
G3	B-CHEM
)	O
as	O
main	B-OBJC
end	I-OBJC
products	I-OBJC
,	O
and	O
cellotriose	B-CHEM
(	O
G4	B-CHEM
)	O
as	O
minor	B-OBJC
end	I-OBJC
product	I-OBJC
from	O
filter	B-DEVI
paper	I-DEVI
(	O
FP	B-DEVI
)	O
,	O
but	O
more	O
amount	O
of	O
G4	B-CHEM
was	O
released	O
from	O
regenerated	B-CHEM
amorphous	I-CHEM
cellulose	I-CHEM
(	O
RAC	B-CHEM
)	O
.	O

All	O
derivatives	B-CHEM
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-CHEM
(	O
CMC	B-CHEM
)	O
with	O
the	O
same	O
optimal	O
pH	O
(	O
7	O
.	O
0	O
)	O
and	O
temperature	O
(	O
50°C	O
)	O
.	O

However	O
,	O
fusing	O
an	O
extra	O
CBM1	B-CHEM
to	O
FmEG△24	B-CHEM
or	O
FmEG△37	B-CHEM
with	O
flexible	B-CHEM
peptide	I-CHEM
significantly	O
improved	O
its	O
processivity	O
and	O
catalytic	O
activity	O
to	O
FP	B-DEVI
and	O
RAC	B-CHEM
.	O

Overall	O
,	O
1	O
.	O
79	O
-	O
and	O
1	O
.	O
84	O
-	O
fold	O
increases	O
in	O
the	O
soluble	O
/insoluble	O
product	O
ratio	O
on	O
FP	B-DEVI
,	O
and	O
1	O
.	O
38	O
-	O
and	O
1	O
.	O
39	O
-	O
fold	O
increases	O
on	O
RAC	B-CHEM
,	O
compared	O
to	O
FmEG△24	B-CHEM
,	O
were	O
recorded	O
for	O
CBM1	B-CHEM
-	O
FmEG△24	B-CHEM
and	O
CBM1	B-CHEM
-linker	O
-	O
FmEG△24	B-CHEM
,	O
respectively	O
.	O

Meanwhile	O
,	O
they	O
displayed	O
2	O
.	O
64	O
-	O
and	O
2	B-DISO
.	I-DISO
67	I-DISO
-	I-DISO
fold	I-DISO
more	I-DISO
activity	I-DISO
on	O
RAC	B-CHEM
,	O
and	O
1	O
.	O
68	O
-	O
and	O
1	O
.	O
77	O
-	O
fold	O
on	O
FP	B-DEVI
,	O
respectively	O
.	O

Similar	O
improvement	O
was	O
also	O
obtained	O
for	O
CBM1	B-CHEM
-linker	O
-	O
FmEG△37	B-CHEM
as	O
compared	O
with	O
FmEG△37	B-CHEM
.	O

Interestingly	O
,	O
fusion	O
of	O
an	O
extra	O
CBM1	B-CHEM
with	O
FmEG	B-CHEM
also	O
caused	O
an	O
alteration	O
of	O
cleavage	B-PHEN
pattern	I-PHEN
on	O
insoluble	B-CHEM
celluloses	I-CHEM
.	O

Our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	O
and	O
catalytic	O
activity	O
may	O
arise	O
from	O
CBM1	B-CHEM
binding	B-PHYS
affinity	I-PHYS
.	O

The	O
N	B-CHEM
-	I-CHEM
terminal	I-CHEM
24	I-CHEM
-	I-CHEM
or	I-CHEM
37	I-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial	O
separation	O
of	O
the	O
two	O
domains	O
required	O
for	O
processivity	O
and	O
catalytic	O
activity	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
N	B-CHEM
-	I-CHEM
terminal	I-CHEM
24	I-CHEM
-	I-CHEM
or	I-CHEM
37	I-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
led	O
to	O
significant	O
reduction	O
in	O
thermostability	B-PHEN
but	O
not	O
the	O
enzymatic	B-PHYS
activity	I-PHYS
.	O

Overnight	O
switching	B-PROC
from	O
oxcarbazepine	B-CHEM
to	O
eslicarbazepine	B-CHEM
acetate	I-CHEM
:	O
an	O
observational	B-PROC
study	I-PROC
There	O
are	O
clinical	B-PHEN
situations	I-PHEN
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	B-PROC
patients	B-LIVB
from	O
immediate	B-CHEM
-	I-CHEM
release	I-CHEM
oxcarbazepine	B-CHEM
(	O
OXC	B-CHEM
)	O
to	O
eslicarbazepine	B-CHEM
acetate	I-CHEM
(	O
ESL	B-CHEM
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
transitioning	O
patients	B-LIVB
overnight	O
from	O
OXC	B-CHEM
to	O
ESL	B-CHEM
.	O

A	O
retrospective	B-PROC
,	O
single	B-PROC
-	I-PROC
center	I-PROC
study	I-PROC
was	O
conducted	O
in	O
which	O
patients	B-LIVB
with	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
focal	B-DISO
epilepsy	I-DISO
on	O
a	O
stable	O
dose	O
of	O
immediate	B-CHEM
-	I-CHEM
release	I-CHEM
OXC	B-CHEM
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	B-PROC
overnight	O
to	O
ESL	B-CHEM
.	O

Patients	B-LIVB
were	O
switched	B-PROC
because	O
they	O
experienced	O
persistent	O
seizures	B-DISO
with	O
OXC	B-CHEM
but	O
were	O
unable	B-DISO
to	O
tolerate	O
increased	O
OXC	B-CHEM
dosing	O
due	O
to	O
adverse	B-DISO
events	I-DISO
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	O
Events	O
Profile	O
(	O
AEP	O
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	O
of	O
Life	O
in	O
Epilepsy	O
Inventory	O
10	O
(	O
QOLIE	O
-	O
10	O
)	O
,	O
and	O
alertness	B-PHYS
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	B-OBJC
Battery	I-OBJC
for	I-OBJC
Attention	I-OBJC
Performance	I-OBJC
version	I-OBJC
2	I-OBJC
.	I-OBJC

3	I-OBJC
.	O

Assessments	B-PROC
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	B-PROC
from	O
OXC	B-CHEM
to	O
ESL	B-CHEM
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O

The	O
analysis	B-PROC
included	O
21	O
patients	B-LIVB
(	O
12	O
women	B-LIVB
,	O
9	O
men	B-LIVB
;	O
mean	B-DISO
age	I-DISO
36	I-DISO
years	I-DISO
)	O
.	O

After	O
switching	B-PROC
from	O
OXC	B-CHEM
to	O
ESL	B-CHEM
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
AEP	O
(	O
P	O
<	O
.	O
001	O
)	O
,	O
QOLIE	O
-	O
10	O
(	O
P	O
=	O
.	O

001	O
)	O
,	O
and	O
alertness	B-PHYS
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Adverse	O
Events	O
Profile	O
total	O
scores	O
improved	B-DISO
for	O
21	O
/	O
21	O
(	O
100	O
.	O
0	O
%	O
)	O
patients	B-LIVB
,	O
QOLIE	O
-	O
10	O
total	O
scores	O
improved	B-DISO
for	O
17	O
/	O
21	O
(	O
81	O
.	O
0	O
%	O
)	O
patients	B-LIVB
,	O
and	O
alertness	B-PHYS
scores	O
improved	B-DISO
for	O
16	O
/	O
21	O
(	O
76	O
.	O
2	O
%	O
)	O
patients	B-LIVB
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	B-PROC
-	I-PROC
center	I-PROC
study	I-PROC
,	O
an	O
overnight	O
switch	B-PROC
from	O
twice	O
-	O
daily	O
OXC	B-CHEM
to	O
once	O
-	O
daily	O
ESL	B-CHEM
in	O
patients	B-LIVB
with	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
focal	B-DISO
epilepsies	I-DISO
resulted	B-DISO
in	O
improvements	O
in	O
side	B-DISO
effects	I-DISO
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	B-PHYS
.	O

Pregnancy	B-PHYS
at	O
high	B-PHEN
altitude	I-PHEN
in	O
the	O
Andes	B-GEOG
leads	O
to	O
increased	O
total	O
vessel	O
density	O
in	O
healthy	O
newborns	B-LIVB
The	O
developing	O
human	B-LIVB
fetus	B-ANAT
is	O
able	O
to	O
cope	O
with	O
the	O
physiological	O
reduction	O
in	O
oxygen	B-PHEN
supply	I-PHEN
occurring	O
in	B-LIVB
utero	I-LIVB
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
microvascularization	O
of	O
the	O
fetus	B-ANAT
is	O
augmented	O
when	O
pregnancy	B-PHYS
occurs	O
at	O
high	B-PHEN
altitude	I-PHEN
.	O

Fifty	O
-	O
three	O
healthy	B-LIVB
term	I-LIVB
newborns	I-LIVB
in	O
Puno	O
,	O
Peru	B-GEOG
(	O
3	O
,	O
840	O
m	O
)	O
were	O
compared	O
with	O
sea	B-GEOG
-	O
level	O
controls	B-LIVB
.	O

Pre	B-PHEN
-	I-PHEN
and	I-PHEN
postductal	I-PHEN
arterial	I-PHEN
oxygen	I-PHEN
saturation	I-PHEN
(	O
SpO2	B-PHEN
)	O
was	O
determined	O
.	O

Cerebral	B-ANAT
and	O
calf	B-ANAT
muscle	I-ANAT
regional	O
tissue	B-PHYS
oxygenation	I-PHYS
was	O
measured	O
using	O
near	B-PROC
infrared	I-PROC
spectroscopy	I-PROC
(	O
NIRS	B-PROC
)	O
.	O

Skin	B-ANAT
microcirculation	B-PHYS
was	O
noninvasively	B-PROC
measured	O
using	O
incident	B-PROC
dark	I-PROC
field	I-PROC
imaging	I-PROC
.	O

Pre	B-PHEN
-	I-PHEN
and	I-PHEN
postductal	I-PHEN
SpO2	I-PHEN
in	O
Peruvian	B-LIVB
babies	B-LIVB
was	O
88	O
.	O
1	O
and	O
88	O
.	O

4	O
%	O
,	O
respectively	O
,	O
which	O
was	O
10	O
.	O
4	O
and	O
9	O
.	O

7	O
%	O
lower	O
than	O
in	O
newborns	B-LIVB
at	O
sea	B-GEOG
level	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Cerebral	B-ANAT
and	O
regional	O
oxygen	B-PHYS
saturation	I-PHYS
was	O
significantly	O
lower	O
in	O
the	O
Peruvian	B-LIVB
newborns	B-LIVB
(	O
cerebral	B-ANAT
:	O
71	O
.	O
0	O
vs	O
.	O

74	O
.	O
9	O
%	O
;	O
regional	O
:	O
68	O
.	O
5	O
vs	O
.	O

76	O
.	O
0	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Transcutaneously	O
measured	O
total	O
vessel	O
density	O
in	O
the	O
Peruvian	B-LIVB
newborns	B-LIVB
was	O
14	O
%	O
higher	O
than	O
that	O
in	O
the	O
newborns	B-LIVB
born	B-PHYS
at	O
sea	B-GEOG
level	O
(	O
29	O
.	O
7	O
vs	O
.	O

26	O
.	O
0	O
mm	O
/	O
mm	O
(	O
2	O
)	O
;	O
P	O
≤	O
0	O
.	O
001	O
)	O
.	O

This	O
study	B-PROC
demonstrates	O
that	O
microvascular	O
vessel	O
density	O
in	O
neonates	B-LIVB
born	B-PHYS
to	O
mothers	B-LIVB
living	O
at	O
high	B-PHEN
altitude	I-PHEN
is	O
higher	O
than	O
that	O
in	O
neonates	B-LIVB
born	B-PHYS
at	O
sea	B-GEOG
level	O
.	O

Morphological	O
and	O
enzymatic	B-PHYS
response	I-PHYS
of	O
the	O
thermotolerant	B-PHYS
fungus	B-LIVB
Fomes	B-LIVB
sp	I-LIVB
.	I-LIVB

EUM1	I-LIVB
in	O
solid	B-PHYS
state	I-PHYS
fermentation	I-PHYS
under	O
thermal	O
stress	B-DISO
Thermotolerance	B-PHYS
of	O
the	O
fungus	B-LIVB
Fomes	B-LIVB
sp	I-LIVB
.	I-LIVB

EUM1	I-LIVB
was	O
evaluated	O
in	O
solid	B-PHYS
state	I-PHYS
fermentation	I-PHYS
(	O
SSF	B-PHYS
)	O
.	O

This	O
thermotolerant	B-PHYS
strain	B-LIVB
improved	O
both	O
hyphal	B-LIVB
invasiveness	O
(	O
38	O
%	O
)	O
and	O
length	O
(	O
17	O
%	O
)	O
in	O
adverse	O
thermal	O
conditions	O
exceeding	O
30°C	O
and	O
to	O
a	O
maximum	O
of	O
40°C	O
.	O

In	O
contrast	O
,	O
hyphal	B-PHYS
branching	I-PHYS
decreased	O
by	O
46	O
%	O
at	O
45°C	O
.	O

The	O
production	O
of	O
cellulases	B-CHEM
over	O
corn	B-LIVB
stover	I-LIVB
increased	O
1	O
.	O

6	O
-	O
fold	O
in	O
30°C	O
culture	B-CHEM
conditions	O
,	O
xylanases	B-CHEM
increased	O
2	O
.	O
8	O
-	O
fold	O
at	O
40°C	O
,	O
while	O
laccase	B-CHEM
production	O
improved	O
2	O
.	O

7	O
-	O
fold	O
at	O
35°C	O
.	O

Maximum	O
production	O
of	O
lignocellulolytic	B-CHEM
enzymes	I-CHEM
was	O
obtained	O
at	O
elevated	O
temperatures	O
in	O
shorter	O
fermentation	B-PHYS
times	O
(	O
8	O
to	O
6	O
days	O
)	O
,	O
although	O
the	O
proteases	B-CHEM
appeared	O
as	O
a	O
thermal	O
stress	B-DISO
response	B-PHYS
associated	O
with	O
a	O
drop	O
in	O
lignocellulolytic	B-PHYS
activities	I-PHYS
.	O

Novel	O
and	O
multiple	O
isoenzymes	B-CHEM
of	O
xylanase	B-CHEM
(	O
four	O
bands	O
)	O
and	O
cellulase	B-CHEM
(	O
six	O
bands	O
)	O
were	O
secreted	O
in	O
the	O
range	O
of	O
20	O
-	O
150	O
kDa	O
during	O
growth	B-PHYS
in	O
adverse	O
temperature	O
conditions	O
.	O

However	O
,	O
only	O
a	O
single	O
laccase	B-CHEM
isoenzyme	B-CHEM
(	O
46	O
kDa	O
)	O
was	O
detected	B-DISO
.	O

This	O
is	O
the	O
first	O
report	O
describing	O
the	O
advantages	O
of	O
a	O
thermotolerant	B-PHYS
white	B-LIVB
-	I-LIVB
rot	I-LIVB
fungus	I-LIVB
in	O
SSF	B-PHYS
.	O

These	O
results	O
have	O
important	O
implications	O
for	O
large	B-PHYS
-	I-PHYS
scale	I-PHYS
SSF	I-PHYS
,	O
where	O
effects	O
of	O
metabolic	B-PHYS
heat	B-PHEN
are	O
detrimental	O
to	O
growth	B-PHYS
and	O
enzyme	B-CHEM
production	O
,	O
which	O
are	O
severely	O
affected	O
by	O
the	O
formation	O
of	O
high	O
temperature	O
gradients	O
.	O

Complete	O
Genome	O
Sequences	O
of	O
Three	O
Outbreak	B-PHEN
-Associated	O
Legionella	B-LIVB
pneumophila	I-LIVB
Isolates	B-CHEM
We	O
report	O
here	O
the	O
complete	O
genome	O
sequences	O
of	O
three	O
Legionella	B-LIVB
pneumophila	I-LIVB
isolates	B-CHEM
that	O
are	O
associated	O
with	O
a	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
outbreak	B-PHEN
in	O
New	B-GEOG
York	I-GEOG
in	O
2012	O
.	O

Two	O
clinical	O
isolates	B-CHEM
(	O
D7630	B-LIVB
and	O
D7632	B-LIVB
)	O
and	O
one	O
environmental	O
isolate	B-CHEM
(	O
D7631	B-LIVB
)	O
were	O
recovered	O
from	O
this	O
outbreak	B-PHEN
.	O

A	O
single	O
isolate	B-CHEM
-	I-CHEM
specific	I-CHEM
virulence	B-PHEN
gene	O
was	O
found	O
in	O
D7632	B-LIVB
.	O

These	O
isolates	B-CHEM
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-PROC
the	O
genomic	O
resolution	O
of	O
various	O
bioinformatics	O
approaches	O
for	O
L	B-LIVB
.	I-LIVB

pneumophila	I-LIVB
serogroup	O
1	O
isolates	B-CHEM
.	O

Complete	O
Genome	B-PROC
Sequence	I-PROC
Analysis	I-PROC
of	O
a	O
Naturally	O
Reassorted	O
Infectious	B-LIVB
Bursal	I-LIVB
Disease	I-LIVB
Virus	I-LIVB
from	O
India	B-GEOG
The	O
novel	O
infectious	B-LIVB
bursal	I-LIVB
disease	I-LIVB
virus	I-LIVB
(	O
IBDV	B-LIVB
)	O
isolate	B-CHEM
BGE14	B-LIVB
/	I-LIVB
ABT1	I-LIVB
/	I-LIVB
MVC	I-LIVB
/	I-LIVB
India	I-LIVB
is	O
a	O
very	O
virulent	O
IBDV	B-LIVB
that	O
was	O
isolated	B-CHEM
from	O
broiler	B-LIVB
flocks	I-LIVB
in	O
southern	O
parts	O
of	O
India	B-GEOG
during	O
2014	O
.	O

Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
India	B-GEOG
,	O
the	O
complete	O
genome	O
sequence	O
of	O
BGE14	B-LIVB
/	I-LIVB
ABT1	I-LIVB
/	I-LIVB
MVC	I-LIVB
/	I-LIVB
India	I-LIVB
,	O
a	O
reassortment	O
strain	B-LIVB
with	O
segments	O
A	O
and	O
B	O
derived	O
from	O
a	O
very	O
virulent	O
IBDV	B-LIVB
strain	B-LIVB
and	O
an	O
attenuated	O
IBDV	B-LIVB
,	O
respectively	O
.	O

The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	B-PHYS
exchange	I-PHYS
between	O
attenuated	O
and	O
very	O
virulent	O
strains	B-LIVB
of	O
IBDV	B-LIVB
circulating	O
in	O
the	O
field	O
.	O

Brood	O
size	O
constrains	O
the	O
development	O
of	O
endothermy	B-PHYS
in	O
blue	B-LIVB
tits	I-LIVB
Altricial	B-LIVB
birds	I-LIVB
are	O
unable	B-DISO
to	O
maintain	O
body	B-PHYS
temperature	I-PHYS
when	O
exposed	O
to	O
low	O
ambient	B-PHEN
temperatures	I-PHEN
during	O
the	O
first	O
days	O
after	O
hatching	B-PHYS
.	O

Thermoregulatory	B-PHYS
capacity	O
begins	O
to	O
form	O
as	O
postnatal	O
development	O
progresses	O
,	O
and	O
eventually	O
nestlings	B-LIVB
become	O
homeothermic	B-PHYS
.	O

Several	O
factors	O
may	O
influence	O
this	O
development	O
at	O
both	O
the	O
level	O
of	O
the	O
individual	O
and	O
the	O
level	O
of	O
the	O
whole	O
brood	B-LIVB
,	O
but	O
to	O
our	O
knowledge	O
no	O
studies	O
have	O
focused	O
on	O
the	O
effect	O
of	O
brood	O
size	O
per	O
se	O
on	O
the	O
development	O
of	O
endothermy	B-PHYS
in	O
individual	O
nestlings	B-LIVB
.	O

We	O
performed	O
cooling	B-PHEN
experiments	B-PROC
on	O
blue	B-LIVB
tit	I-LIVB
(	O
Cyanistes	B-LIVB
caeruleus	I-LIVB
)	O
nestlings	B-LIVB
in	O
the	O
field	O
,	O
to	O
study	O
how	O
different	O
experimental	O
brood	O
sizes	O
affected	O
the	O
development	O
of	O
endothermy	B-PHYS
in	O
individual	O
nestlings	B-LIVB
and	O
the	O
thermal	B-PHEN
environment	I-PHEN
experienced	O
by	O
the	O
whole	O
brood	B-LIVB
in	O
the	O
nest	O
.	O

Nestlings	B-LIVB
from	O
all	O
experimental	O
brood	O
sizes	O
showed	O
a	O
decrease	O
in	O
cooling	B-PHEN
rate	O
as	O
they	O
grew	O
older	O
,	O
but	O
birds	B-LIVB
from	O
reduced	O
broods	B-LIVB
showed	O
an	O
earlier	O
onset	O
of	O
endothermy	B-PHYS
compared	O
with	O
nestlings	B-LIVB
from	O
enlarged	O
and	O
control	B-LIVB
broods	B-LIVB
.	O

This	O
difference	O
manifested	O
during	O
early	O
development	O
and	O
gradually	O
disappeared	O
as	O
nestlings	B-LIVB
grew	O
older	O
.	O

The	O
thermal	B-PHEN
environment	I-PHEN
in	O
the	O
nests	O
differed	O
between	O
treatments	O
during	O
nestling	B-LIVB
development	O
,	O
such	O
that	O
nest	O
temperature	O
in	O
reduced	O
broods	B-LIVB
was	O
lower	O
than	O
that	O
in	O
enlarged	O
broods	B-LIVB
during	O
all	O
days	O
and	O
during	O
nights	O
at	O
the	O
end	O
of	O
the	O
experimental	O
period	O
.	O

We	O
suggest	O
that	O
the	O
development	O
of	O
endothermy	B-PHYS
in	O
blue	B-LIVB
tit	I-LIVB
nestlings	B-LIVB
is	O
not	O
ontogenetically	O
fixed	O
,	O
but	O
instead	O
may	O
vary	O
according	O
to	O
differences	O
in	O
developmental	B-PHYS
,	O
nutritional	B-DISO
and	O
thermal	B-PHEN
conditions	I-PHEN
as	O
determined	O
by	O
brood	O
size	O
.	O

Elevated	O
Plasma	B-ANAT
Level	O
of	O
Interferon	B-CHEM
-	I-CHEM
λ1	I-CHEM
in	O
Chronic	B-DISO
Spontaneous	I-DISO
Urticaria	I-DISO
:	O
Upregulated	B-PHYS
Expression	B-PHYS
in	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
and	O
Epithelial	B-ANAT
Cells	I-ANAT
and	O
Induction	O
of	O
Inflammatory	B-ANAT
Cell	I-ANAT
Accumulation	B-DISO
Interferon	B-CHEM
-	I-CHEM
(	I-CHEM
IFN	I-CHEM
-	I-CHEM
)	I-CHEM
λ1	I-CHEM
is	O
regarded	O
as	O
a	O
potent	O
bio	B-OBJC
-	I-OBJC
active	I-OBJC
molecule	I-OBJC
in	O
innate	B-PHYS
immunity	I-PHYS
.	O

However	O
,	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
chronic	B-DISO
spontaneous	I-DISO
urticaria	I-DISO
(	O
CSU	B-DISO
)	O
.	O

We	O
therefore	O
investigated	O
expression	B-PHYS
of	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
in	O
CSU	B-DISO
,	O
its	O
cellular	B-ANAT
location	I-ANAT
,	O
and	O
its	O
influence	O
on	O
inflammatory	B-ANAT
cell	I-ANAT
accumulation	B-DISO
by	O
using	O
flow	B-PROC
cytometry	I-PROC
analysis	I-PROC
,	O
skin	O
tissue	O
dispersion	O
,	O
immunohistochemical	B-PROC
stain	I-PROC
,	O
and	O
a	O
mouse	B-LIVB
peritoneal	B-DISO
inflammation	I-DISO
model	B-DISO
.	O

The	O
results	O
showed	O
that	O
level	O
of	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
was	O
2	O
.	O
0	O
-	O
fold	O
higher	O
in	O
plasma	B-ANAT
of	O
the	O
patients	B-LIVB
with	O
CSU	B-DISO
than	O
the	O
level	O
in	O
healthy	O
control	O
(	O
HC	O
)	O
subjects	B-LIVB
.	O

Among	O
leukocytes	B-ANAT
examined	O
,	O
only	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
expressed	B-PHYS
more	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
in	O
CSU	B-DISO
blood	B-ANAT
.	O

Double	B-PROC
labeling	I-PROC
immunohistochemical	I-PROC
staining	I-PROC
revealed	O
that	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
(	O
+	O
)	O
inflammatory	B-ANAT
cells	I-ANAT
such	O
as	O
mast	B-ANAT
cells	I-ANAT
,	O
eosinophils	B-ANAT
,	O
B	B-ANAT
cells	I-ANAT
,	O
neutrophils	B-ANAT
,	O
and	O
macrophages	B-ANAT
were	O
mainly	O
located	B-ANAT
in	O
dermis	O
,	O
whereas	O
epidermis	O
tissue	O
highly	O
expressed	B-PHYS
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
.	O

IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
number	O
of	O
eosinophils	B-ANAT
,	O
lymphocytes	B-ANAT
,	O
mast	B-ANAT
cells	I-ANAT
,	O
macrophages	B-ANAT
,	O
and	O
neutrophils	B-ANAT
in	O
the	O
peritoneum	O
of	O
mice	B-LIVB
at	O
6	O
h	O
following	O
injection	B-CHEM
,	O
which	O
was	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
animals	B-LIVB
with	O
anti	B-CHEM
-	I-CHEM
intercellular	I-CHEM
adhesion	I-CHEM
molecule	I-CHEM
-	I-CHEM
(	I-CHEM
ICAM	I-CHEM
-	I-CHEM
)	I-CHEM
1	I-CHEM
and	O
/	O
or	O
anti	B-CHEM
-	I-CHEM
L	I-CHEM
-	I-CHEM
selectin	I-CHEM
antibodies	I-CHEM
.	O

In	O
conclusion	O
,	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
is	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
CSU	B-DISO
.	O

Blocking	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
production	O
may	O
help	O
to	O
reduce	O
the	O
accumulation	B-DISO
of	O
inflammatory	B-ANAT
cells	I-ANAT
in	O
the	O
involved	O
CSU	B-DISO
skin	B-ANAT
.	O

Patient	O
Satisfaction	O
With	O
Postpartum	O
Teaching	B-PROC
Methods	O
Postpartum	O
discharge	O
instructions	O
are	O
a	O
crucial	O
part	O
of	O
a	O
mother	B-LIVB
's	I-LIVB
birth	B-PHYS
experience	B-PHYS
.	O

Finding	B-DISO
the	O
method	O
to	O
provide	O
those	O
discharge	O
instructions	O
in	O
a	O
manner	O
that	O
increases	O
the	O
mother	B-LIVB
's	I-LIVB
satisfaction	B-PHYS
with	O
her	O
hospital	B-OBJC
experience	B-PHYS
is	O
important	O
.	O

This	O
quasi	B-PROC
-	I-PROC
experimental	I-PROC
study	I-PROC
examined	B-DISO
the	O
relationship	O
between	O
new	O
mothers	B-LIVB
'	I-LIVB
interaction	B-DISO
with	O
nurses	B-LIVB
providing	O
postpartum	O
instructions	O
by	O
the	O
traditional	O
and	O
class	O
methods	O
and	O
their	O
satisfaction	B-PHYS
with	O
discharge	B-PROC
teaching	I-PROC
.	O

The	O
results	O
indicated	O
new	O
mothers	B-LIVB
were	O
satisfied	B-PHYS
with	O
both	O
methods	O
of	O
discharge	B-PROC
teaching	I-PROC
;	O
however	O
,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	O
with	O
overall	O
satisfaction	B-PHYS
with	O
the	O
traditional	O
method	O
of	O
discharge	B-PROC
teaching	I-PROC
than	O
with	O
attending	O
the	O
discharge	B-PROC
class	I-PROC
.	O

High	O
-	O
Intensity	O
Intermittent	O
Training	O
Positively	B-DISO
Affects	O
Aerobic	B-PROC
and	O
Anaerobic	O
Performance	O
in	O
Judo	O
Athletes	B-LIVB
Independently	O
of	O
Exercise	O
Mode	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
high	O
-	O
intensity	O
intermittent	O
training	O
(	O
HIIT	O
)	O
on	O
lower	B-ANAT
-	O
and	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
graded	O
exercise	O
and	O
high	O
-	O
intensity	O
intermittent	O
exercise	O
(	O
HIIE	O
,	O
four	O
Wingate	O
bouts	O
)	O
performance	O
,	O
and	O
on	O
physiological	O
and	O
muscle	B-DISO
damage	I-DISO
markers	B-DISO
responses	I-DISO
in	O
judo	O
athletes	B-LIVB
.	O

Thirty	O
-	O
five	O
subjects	B-LIVB
were	O
randomly	B-PROC
allocated	I-PROC
to	O
a	O
control	B-LIVB
group	I-LIVB
(	O
n	O
=	O
8	O
)	O
or	O
to	O
one	O
of	O
the	O
following	O
HIIT	O
groups	O
(	O
n	O
=	O
9	O
for	O
each	O
)	O
and	O
tested	O
pre	O
-	O
and	O
post	O
-four	O
weeks	O
(	O
2	O
training	O
d·wk	O
(	O
-	O
1	O
)	O
)	O
:	O
(	O
1	O
)	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
cycle	B-PROC
-	I-PROC
ergometer	I-PROC
;	O
(	O
2	O
)	O
upper	O
-	O
body	O
cycle	B-PROC
-	I-PROC
ergometer	I-PROC
;	O
(	O
3	O
)	O
uchi	O
-	O
komi	O
(	O
judo	O
technique	O
entrance	O
)	O
.	O

All	O
HIIT	O
were	O
constituted	O
by	O
two	O
blocks	O
of	O
10	O
sets	O
of	O
20	O
s	O
of	O
all	O
out	O
effort	O
interspersed	O
by	O
10	O
s	O
set	O
intervals	O
and	O
5	O
-	O
min	O
between	O
blocks	O
.	O

For	O
the	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
group	O
there	O
was	O
an	O
increase	O
in	O
maximal	B-PHYS
aerobic	I-PHYS
power	I-PHYS
in	O
graded	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
exercise	B-DISO
test	I-DISO
(	O
12	O
.	O

3	O
%	O
)	O
.	O

The	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
group	O
increased	O
power	B-PHYS
at	O
onset	B-CHEM
blood	I-CHEM
lactate	I-CHEM
in	O
graded	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
exercise	B-DISO
test	I-DISO
(	O
22	O
.	O
1	O
%	O
)	O
.	O

The	O
uchi	O
-	O
komi	O
group	O
increased	O
peak	O
power	O
in	O
upper	B-ANAT
-	O
(	O
16	O
.	O
7	O
%	O
)	O
and	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
(	O
8	O
.	O
5	O
%	O
)	O
,	O
while	O
the	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
group	O
increased	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
mean	O
power	O
(	O
14	O
.	O
2	O
%	O
)	O
during	O
the	O
HIIE	O
.	O

There	O
was	O
a	O
decrease	O
in	O
the	O
delta	B-CHEM
blood	I-CHEM
lactate	I-CHEM
for	O
the	O
uchi	B-PROC
-	I-PROC
komi	I-PROC
training	I-PROC
group	O
and	O
in	O
the	O
third	O
and	O
fourth	O
bouts	O
for	O
the	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
training	B-PROC
group	O
.	O

Training	B-PROC
induced	O
testosterone	O
-	O
cortisol	O
ratio	O
increased	O
in	O
the	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
HIIE	O
for	O
the	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
(	O
14	O
.	O
9	O
%	O
)	O
and	O
uchi	B-PROC
-	I-PROC
komi	I-PROC
(	I-PROC
61	I-PROC
.	I-PROC

4	I-PROC
%	I-PROC
)	I-PROC
training	I-PROC
groups	O
.	O

Thus	O
,	O
short	O
-	O
duration	O
low	O
-	O
volume	O
HIIT	O
added	O
to	O
regular	B-PROC
judo	I-PROC
training	I-PROC
was	O
able	O
to	O
increase	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
aerobic	B-PHYS
power	I-PHYS
,	O
lower	B-ANAT
-	O
and	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
HIIE	O
performance	O
.	O

Translating	O
Neurocognitive	O
Models	O
of	O
Auditory	B-DISO
-	I-DISO
Verbal	I-DISO
Hallucinations	I-DISO
into	O
Therapy	O
:	O
Using	O
Real	O
-	O
time	O
fMRI	B-PROC
-	O
Neurofeedback	B-PROC
to	O
Treat	O
Voices	B-PHYS
Auditory	B-DISO
-	I-DISO
verbal	I-DISO
hallucinations	I-DISO
(	O
AVHs	B-DISO
)	O
are	O
frequent	O
and	O
disabling	O
symptoms	B-DISO
,	O
which	O
can	O
be	O
refractory	O
to	O
conventional	O
psychopharmacological	O
treatment	O
in	O
more	O
than	O
25	O
%	O
of	O
the	O
cases	O
.	O

Recent	O
advances	O
in	O
brain	B-PROC
imaging	I-PROC
allow	O
for	O
a	O
better	O
understanding	O
of	O
the	O
neural	O
underpinnings	O
of	O
AVHs	B-DISO
.	O

These	O
findings	O
strengthened	O
transdiagnostic	O
neurocognitive	O
models	O
that	O
characterize	O
these	O
frequent	O
and	O
disabling	O
experiences	O
.	O

At	O
the	O
same	O
time	O
,	O
technical	O
improvements	O
in	O
real	O
-	O
time	O
functional	B-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O
fMRI	B-PROC
)	O
enabled	O
the	O
development	O
of	O
innovative	O
and	O
non	O
-	O
invasive	O
methods	O
with	O
the	O
potential	O
to	O
relieve	O
psychiatric	B-DISO
symptoms	I-DISO
,	O
such	O
as	O
fMRI	B-PROC
-based	O
neurofeedback	B-PROC
(	O
fMRI	B-PROC
-	O
NF	B-PROC
)	O
.	O

During	O
fMRI	B-PROC
-	O
NF	B-PROC
,	O
brain	B-PHYS
activity	I-PHYS
is	O
measured	O
and	O
fed	O
back	O
in	O
real	O
time	O
to	O
the	O
participant	B-LIVB
in	O
order	O
to	O
help	O
subjects	B-LIVB
to	O
progressively	O
achieve	O
voluntary	B-PHYS
control	I-PHYS
over	O
their	O
own	O
neural	B-PHYS
activity	I-PHYS
.	O

Precisely	O
defining	O
the	O
target	O
brain	B-ANAT
area	I-ANAT
/	O
network	O
(	O
s	O
)	O
appears	O
critical	O
in	O
fMRI	B-PROC
-	O
NF	B-PROC
protocols	O
.	O

After	O
reviewing	O
the	O
available	O
neurocognitive	O
models	O
for	O
AVHs	B-DISO
,	O
we	O
elaborate	O
on	O
how	O
recent	O
findings	B-DISO
in	O
the	O
field	O
may	O
help	O
to	O
develop	O
strong	O
a	O
priori	O
strategies	B-PHYS
for	O
fMRI	B-PROC
-	O
NF	B-PROC
target	O
localization	O
.	O

The	O
first	O
approach	O
relies	O
on	O
imaging	B-PROC
-based	O
""""	O
trait	B-PHYS
markers	B-PHYS
""""	O
(	O
i	O
.	O
e	O
.	O
,	O
persistent	O
traits	B-PHYS
or	O
vulnerability	O
markers	B-PHYS
that	O
can	O
also	O
be	O
detected	O
in	O
the	O
presymptomatic	B-DISO
and	O
remitted	O
phases	O
of	O
AVHs	B-DISO
)	O
.	O

The	O
goal	O
of	O
such	O
strategies	O
is	O
to	O
target	O
areas	O
that	O
show	O
aberrant	O
activations	O
during	O
AVHs	B-DISO
or	O
are	O
known	O
to	O
be	O
involved	O
in	O
compensatory	O
activation	O
(	O
or	O
resilience	B-PHEN
processes	I-PHEN
)	O
.	O

Brain	B-ANAT
regions	I-ANAT
,	O
from	O
which	O
the	O
NF	B-PROC
signal	B-PHEN
is	O
derived	O
,	O
can	O
be	O
based	O
on	O
structural	B-PROC
MRI	I-PROC
and	O
neurocognitive	O
knowledge	O
,	O
or	O
functional	B-PROC
MRI	I-PROC
information	O
collected	O
during	O
specific	O
cognitive	O
tasks	O
.	O

Because	O
hallucinations	B-DISO
are	O
acute	O
and	O
intrusive	O
symptoms	B-DISO
,	O
a	O
second	O
strategy	O
focuses	O
more	O
on	O
""""	O
state	B-PHYS
markers	I-PHYS
.	O
""""	O
In	O
this	O
case	O
,	O
the	O
signal	B-PHEN
of	O
interest	O
relies	O
on	O
fMRI	B-PROC
capture	O
of	O
the	O
neural	B-ANAT
networks	I-ANAT
exhibiting	O
increased	O
activity	O
during	O
AVHs	B-DISO
occurrences	O
,	O
by	O
means	O
of	O
multivariate	O
pattern	O
recognition	O
methods	O
.	O

The	O
fine	O
-	O
grained	O
activity	O
patterns	O
concomitant	O
to	O
hallucinations	B-DISO
can	O
then	O
be	O
fed	O
back	O
to	O
the	O
patients	B-LIVB
for	O
therapeutic	O
purpose	O
.	O

Considering	O
the	O
potential	O
cost	O
necessary	O
to	O
implement	O
fMRI	B-PROC
-	O
NF	B-PROC
,	O
proof	O
-	O
of	O
-	O
concept	O
studies	B-PROC
are	O
urgently	O
required	O
to	O
define	O
the	O
optimal	O
strategy	O
for	O
application	O
in	O
patients	B-LIVB
with	O
AVHs	B-DISO
.	O

This	O
technique	O
has	O
the	O
potential	O
to	O
establish	O
a	O
new	O
brain	B-PROC
imaging	I-PROC
-guided	O
psychotherapy	B-PROC
for	O
patients	B-LIVB
that	O
do	O
not	O
respond	O
to	O
conventional	O
treatments	O
and	O
take	O
functional	B-PROC
neuroimaging	I-PROC
to	O
therapeutic	O
applications	B-PROC
.	O

Microbiomes	B-LIVB
of	O
Muricea	O
californica	O
and	O
M	O
.	O
fruticosa	O
:	O
Comparative	B-PROC
Analyses	I-PROC
of	O
Two	O
Co	O
-	O
occurring	O
Eastern	B-GEOG
Pacific	I-GEOG
Octocorals	O
Octocorals	O
are	O
sources	O
of	O
novel	O
but	O
understudied	B-PROC
microbial	B-LIVB
diversity	O
.	O

Conversely	O
,	O
scleractinian	O
or	O
reef	B-LIVB
-	I-LIVB
building	I-LIVB
coral	I-LIVB
microbiomes	I-LIVB
have	O
been	O
heavily	O
examined	B-DISO
in	O
light	O
of	O
the	O
threats	O
of	O
climate	B-PHEN
change	I-PHEN
.	O

Muricea	O
californica	O
and	O
Muricea	O
fruticosa	O
are	O
two	O
co	O
-	O
occurring	O
species	O
of	O
gorgonian	O
octocoral	O
abundantly	B-DISO
found	I-DISO
in	O
the	O
kelp	O
forests	B-PHEN
of	O
southern	B-GEOG
California	I-GEOG
,	O
and	O
thus	O
provide	O
an	O
excellent	O
basis	O
to	O
determine	O
if	O
octocoral	O
microbiomes	B-LIVB
are	O
host	B-LIVB
specific	O
.	O

Using	O
Illumina	O
MiSeq	O
amplicon	O
sequencing	O
and	O
replicate	O
samples	O
,	O
we	O
evaluated	O
the	O
microbiomes	B-LIVB
collected	O
from	O
multiple	O
colonies	O
of	O
both	O
species	O
of	O
Muricea	O
to	O
measure	O
both	O
inter	B-ANAT
-	I-ANAT
and	O
intra	B-ANAT
-	I-ANAT
colony	I-ANAT
microbiome	B-LIVB
variabilities	O
.	O

In	O
addition	O
,	O
microbiomes	B-LIVB
from	O
overlying	O
sea	B-OBJC
water	I-OBJC
and	O
nearby	O
zoanthids	O
(	O
another	O
benthic	O
invertebrate	O
)	O
were	O
also	O
included	O
in	O
the	O
analysis	B-PROC
to	O
evaluate	O
whether	O
bacterial	O
taxa	O
specifically	O
associate	O
with	O
octocorals	O
.	O

This	O
is	O
also	O
the	O
first	O
report	O
of	O
microbiomes	B-LIVB
from	O
these	O
species	O
of	O
Muricea	O
.	O

We	O
show	O
that	O
microbiomes	B-LIVB
isolated	O
from	O
each	O
sample	O
type	O
are	O
distinct	O
,	O
and	O
specifically	O
,	O
that	O
octocoral	O
species	O
type	O
had	O
the	O
greatest	O
effect	O
on	O
predicting	O
the	O
composition	B-PHYS
of	O
the	O
Muricea	O
microbiome	B-LIVB
.	O

Bacterial	O
taxa	O
contributing	O
to	O
compositional	O
differences	O
include	O
distinct	O
strains	B-LIVB
of	O
Mycoplasma	B-LIVB
associated	O
with	O
either	O
M	O
.	O

californica	O
or	O
M	O
.	O

fruticosa	O
,	O
an	O
abundance	O
of	O
Spirochaetes	B-LIVB
observed	O
on	O
M	O
.	O

californica	O
,	O
and	O
a	O
greater	O
diversity	O
of	O
γ	B-LIVB
-	I-LIVB
Proteobacteria	I-LIVB
associated	O
with	O
M	O
.	O

fruticosa	O
.	O

Many	O
of	O
the	O
bacterial	O
taxa	O
contributing	O
to	O
these	O
differences	O
are	O
known	O
for	O
their	O
presence	B-DISO
in	O
photosymbiont	O
-	O
containing	O
invertebrate	O
microbiomes	B-LIVB
.	O

The	O
Crystal	B-CHEM
Structure	I-CHEM
of	O
the	O
C	O
-	O
Terminal	O
Domain	O
of	O
the	O
Salmonella	B-LIVB
enterica	I-LIVB
PduO	B-CHEM
Protein	I-CHEM
:	O
An	O
Old	O
Fold	O
with	O
a	O
New	O
Heme	B-PHYS
-	I-PHYS
Binding	I-PHYS
Mode	O
The	O
two	B-CHEM
-	I-CHEM
domain	I-CHEM
protein	I-CHEM
PduO	I-CHEM
,	O
involved	O
in	O
1	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
propanediol	I-CHEM
utilization	O
in	O
the	O
pathogenic	B-LIVB
Gram	B-LIVB
-	I-LIVB
negative	I-LIVB
bacterium	I-LIVB
Salmonella	B-LIVB
enterica	I-LIVB
is	O
an	O
ATP	B-CHEM
:	O
Cob	B-CHEM
(	I-CHEM
I	I-CHEM
)	I-CHEM
alamin	I-CHEM
adenosyltransferase	I-CHEM
,	O
but	O
this	O
is	O
a	O
function	B-PHYS
of	O
the	O
N	O
-	O
terminal	O
domain	O
alone	O
.	O

The	O
role	O
of	O
its	O
C	O
-	O
terminal	O
domain	O
(	O
PduOC	B-CHEM
)	O
is	O
,	O
however	O
,	O
unknown	O
.	O

In	O
this	O
study	B-PROC
,	O
comparative	O
growth	B-PROC
assays	I-PROC
with	O
a	O
set	O
of	O
Salmonella	B-LIVB
mutant	I-LIVB
strains	I-LIVB
showed	O
that	O
this	O
domain	O
is	O
necessary	O
for	O
effective	O
in	O
vivo	O
catabolism	B-PHYS
of	O
1	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
propanediol	I-CHEM
.	O

It	O
was	O
also	O
shown	O
that	O
isolated	O
,	O
recombinantly	B-CHEM
-	I-CHEM
expressed	I-CHEM
PduOC	I-CHEM
binds	B-PHYS
heme	B-CHEM
in	O
vivo	O
.	O

The	O
structure	O
of	O
PduOC	B-CHEM
co	B-CHEM
-	I-CHEM
crystallized	I-CHEM
with	O
heme	B-CHEM
was	O
solved	O
(	O
1	O
.	O
9	O
Å	O
resolution	O
)	O
showing	O
an	O
octameric	B-PHYS
assembly	I-PHYS
with	O
four	O
heme	B-CHEM
moieities	O
.	O

The	O
four	O
heme	B-CHEM
groups	O
are	O
highly	O
solvent	O
-	O
exposed	O
and	O
the	O
heme	B-CHEM
iron	I-CHEM
is	O
hexa	O
-	O
coordinated	O
with	O
bis	B-PHYS
-	I-PHYS
His	I-PHYS
ligation	I-PHYS
by	O
histidines	B-CHEM
from	O
different	O
monomers	B-CHEM
.	O

Static	B-PROC
light	I-PROC
scattering	I-PROC
confirmed	O
the	O
octameric	B-PHYS
assembly	I-PHYS
in	O
solution	B-OBJC
,	O
but	O
a	O
mutation	B-PHYS
of	O
the	O
heme	B-CHEM
-	O
coordinating	O
histidine	B-CHEM
caused	O
dissociation	B-PHYS
into	O
dimers	B-CHEM
.	O

Isothermal	B-PROC
titration	I-PROC
calorimetry	I-PROC
using	O
the	O
PduOC	B-CHEM
apoprotein	I-CHEM
showed	O
strong	O
heme	B-PHYS
binding	I-PHYS
(	O
K	O
d	O
=	O
1	O
.	O
6	O
×	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
.	O

Biochemical	O
experiments	B-PROC
showed	O
that	O
the	O
absence	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
in	O
PduO	B-CHEM
did	O
not	O
affect	O
adenosyltransferase	B-CHEM
activity	B-PHYS
in	O
vitro	O
.	O

The	O
evidence	O
suggests	O
that	O
PduOC	B-CHEM
:	O
heme	B-CHEM
plays	O
an	O
important	O
role	O
in	O
the	O
set	O
of	O
cobalamin	B-CHEM
transformations	B-PHYS
required	O
for	O
effective	O
catabolism	B-PHYS
of	O
1	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
propanediol	I-CHEM
.	O

Salmonella	B-LIVB
PduO	B-CHEM
is	O
one	O
of	O
the	O
rare	O
proteins	B-CHEM
which	O
binds	O
the	O
redox	B-PHYS
-	I-PHYS
active	I-PHYS
metabolites	B-CHEM
heme	B-CHEM
and	O
cobalamin	B-CHEM
,	O
and	O
the	O
heme	B-PHYS
-	I-PHYS
binding	I-PHYS
mode	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
differs	O
from	O
that	O
in	O
other	O
members	O
of	O
this	O
protein	B-CHEM
family	I-CHEM
.	O

The	O
Therapeutic	B-PHYS
Effect	I-PHYS
of	O
Berberine	B-CHEM
in	O
the	O
Treatment	B-PROC
of	O
Nonalcoholic	B-DISO
Fatty	I-DISO
Liver	I-DISO
Disease	I-DISO
:	O
A	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
Aim	O
.	O

To	O
assess	B-PROC
the	O
efficacy	O
of	O
berberine	B-CHEM
in	O
the	O
treatment	B-PROC
of	O
nonalcoholic	B-DISO
fatty	I-DISO
liver	I-DISO
disease	I-DISO
through	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O

Method	O
.	O

We	O
searched	O
Embase	O
,	O
Pubmed	O
,	O
Cochrane	O
Library	O
,	O
and	O
so	O
forth	O
,	O
until	O
March	O
2016	O
for	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
using	O
berberine	B-CHEM
to	O
treat	O
NAFLD	B-DISO
.	O

Result	O
.	O

Six	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
involving	O
501	O
patients	B-LIVB
were	O
included	O
in	O
this	O
study	B-PROC
.	O

The	O
results	O
showed	O
that	O
the	O
efficacy	O
of	O
reducing	O
TC	B-CHEM
,	O
LDL	B-CHEM
,	O
ALT	B-CHEM
,	O
2hPG	B-PHYS
,	O
and	O
HbA1c	B-CHEM
in	O
NAFLD	B-DISO
patients	B-LIVB
of	O
the	O
berberine	B-CHEM
group	B-LIVB
were	O
significantly	O
higher	O
than	O
that	O
of	O
control	B-LIVB
group	I-LIVB
.	O

The	O
subgroup	B-LIVB
analyses	O
on	O
TG	B-CHEM
,	O
AST	B-CHEM
,	O
and	O
FBG	B-PROC
indicated	O
that	O
treatment	B-PROC
combined	O
with	O
berberine	B-CHEM
decreased	O
TG	B-PHEN
level	I-PHEN
in	O
NAFLD	B-DISO
patients	B-LIVB
significantly	O
.	O

Compared	O
with	O
other	O
drugs	B-CHEM
,	O
berberine	B-CHEM
alone	O
decreased	B-PHEN
TG	I-PHEN
level	I-PHEN
in	O
NAFLD	B-DISO
patients	B-LIVB
significantly	O
.	O

We	O
also	O
conducted	O
a	O
descriptive	B-PROC
analysis	I-PROC
on	O
insulin	B-DISO
resistance	I-DISO
and	O
radiography	B-PROC
results	O
that	O
berberine	B-CHEM
can	O
improve	O
NAFLD	B-DISO
patients	B-LIVB
'	O
insulin	B-DISO
resistance	I-DISO
and	O
fatty	B-DISO
liver	I-DISO
.	O

Conclusion	O
.	O

According	O
to	O
analysis	O
result	O
,	O
berberine	B-CHEM
has	O
positive	O
efficacy	O
on	O
blood	B-CHEM
lipids	I-CHEM
,	O
blood	B-CHEM
glucose	I-CHEM
,	O
liver	B-PHYS
function	I-PHYS
,	O
insulin	B-DISO
resistance	I-DISO
,	O
and	O
fatty	B-DISO
liver	I-DISO
condition	I-DISO
of	O
NAFLD	B-DISO
patients	B-LIVB
.	O

However	O
,	O
due	O
to	O
the	O
limitation	O
of	O
number	O
and	O
quality	O
of	O
trials	O
included	O
,	O
more	O
clinical	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
with	O
high	O
quality	O
are	O
needed	O
for	O
further	O
verification	O
of	O
the	O
efficacy	O
of	O
berberine	B-CHEM
on	O
NAFLD	B-DISO
patients	B-LIVB
.	O

Perfusion	B-PROC
Angiography	B-PROC
in	O
Acute	O
Ischemic	B-DISO
Stroke	I-DISO
Visualization	O
and	O
quantification	O
of	O
blood	B-PHYS
flow	I-PHYS
are	O
essential	O
for	O
the	O
diagnosis	B-DISO
and	O
treatment	B-PROC
evaluation	I-PROC
of	O
cerebrovascular	B-DISO
diseases	I-DISO
.	O

For	O
rapid	O
imaging	B-PROC
of	O
the	O
cerebrovasculature	B-ANAT
,	O
digital	B-PROC
subtraction	I-PROC
angiography	I-PROC
(	O
DSA	B-PROC
)	O
remains	O
the	O
gold	O
standard	O
as	O
it	O
offers	O
high	B-PROC
spatial	I-PROC
resolution	I-PROC
.	O

This	O
paper	O
lays	O
out	O
a	O
methodological	O
framework	O
,	O
named	O
perfusion	B-PROC
angiography	B-PROC
,	O
for	O
the	O
quantitative	B-PROC
analysis	I-PROC
and	O
visualization	O
of	O
blood	B-PHYS
flow	I-PHYS
parameters	B-DISO
from	O
DSA	B-PROC
images	O
.	O

The	O
parameters	B-DISO
,	O
including	O
cerebral	B-DISO
blood	I-DISO
flow	I-DISO
(	O
CBF	B-DISO
)	O
and	O
cerebral	B-PHYS
blood	I-PHYS
volume	I-PHYS
(	O
CBV	B-PHYS
)	O
,	O
mean	O
transit	O
time	O
(	O
MTT	O
)	O
,	O
time	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
peak	I-PHYS
(	O
TTP	B-PHYS
)	O
,	O
and	O
T	O
max	O
,	O
are	O
computed	O
using	O
a	O
bolus	B-PROC
tracking	I-PROC
method	I-PROC
based	O
on	O
the	O
deconvolution	O
of	O
the	O
time	O
-	O
density	O
curve	O
on	O
a	O
pixel	O
-	O
by	O
-	O
pixel	O
basis	O
.	O

The	O
method	O
is	O
tested	O
on	O
66	O
acute	O
ischemic	B-DISO
stroke	I-DISO
patients	B-LIVB
treated	B-PROC
with	I-PROC
thrombectomy	B-PROC
and	O
/	O
or	O
tissue	B-CHEM
plasminogen	I-CHEM
activator	I-CHEM
(	O
tPA	B-CHEM
)	O
and	O
also	O
evaluated	B-PROC
on	O
an	O
estimation	B-PHYS
task	O
with	O
known	O
ground	O
truth	O
.	O

This	O
novel	O
imaging	B-DEVI
tool	I-DEVI
provides	O
unique	O
insights	B-PHYS
into	O
flow	O
mechanisms	O
that	O
cannot	O
be	O
observed	O
directly	O
in	O
DSA	B-PROC
sequences	O
and	O
might	O
be	O
used	O
to	O
evaluate	B-PROC
the	O
impact	O
of	O
endovascular	B-PROC
interventions	I-PROC
more	O
precisely	O
.	O

Splicing	B-PHYS
variants	O
of	O
ADAR2	B-CHEM
and	O
ADAR2	B-CHEM
-mediated	O
RNA	B-PHYS
editing	I-PHYS
in	O
glioma	B-DISO
The	O
roles	O
of	O
alternative	B-PHYS
splicing	I-PHYS
and	O
RNA	B-PHYS
editing	I-PHYS
in	O
gene	B-PHYS
regulation	I-PHYS
and	O
transcriptome	O
diversity	O
are	O
well	O
documented	O
.	O

Adenosine	B-CHEM
deaminases	I-CHEM
acting	O
on	O
RNA	B-CHEM
(	O
ADARs	B-CHEM
)	O
are	O
responsible	O
for	O
adenosine	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
inosine	I-PHYS
(	I-PHYS
A	I-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
I	I-PHYS
)	I-PHYS
editing	I-PHYS
and	O
exemplify	O
the	O
complex	O
association	O
between	O
RNA	B-PHYS
editing	I-PHYS
and	O
alternative	B-PHYS
splicing	I-PHYS
.	O

The	O
self	B-PHYS
-	I-PHYS
editing	I-PHYS
activity	O
of	O
ADAR2	B-CHEM
,	O
which	O
acts	O
on	O
its	O
own	O
pre	B-CHEM
-	I-CHEM
mRNA	I-CHEM
,	O
leads	O
to	O
its	O
alternative	B-PHYS
splicing	I-PHYS
.	O

Alternative	B-PHYS
splicing	I-PHYS
occurs	O
independently	O
at	O
nine	O
splicing	B-PHYS
sites	O
on	O
ADAR2	B-CHEM
pre	B-CHEM
-	I-CHEM
mRNA	I-CHEM
,	O
generating	O
numerous	O
alternative	B-PHYS
splicing	I-PHYS
variants	O
with	O
various	O
catalytic	B-PHYS
activities	I-PHYS
.	O

A	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
I	I-PHYS
RNA	I-PHYS
editing	I-PHYS
is	O
important	O
in	O
a	O
range	O
of	O
physiological	B-PHYS
processes	I-PHYS
in	O
humans	B-LIVB
and	O
is	O
associated	O
with	O
several	O
diseases	B-DISO
,	O
including	O
amyotrophic	B-DISO
lateral	I-DISO
sclerosis	I-DISO
,	O
mood	B-DISO
disorders	I-DISO
,	O
epilepsy	B-DISO
and	O
glioma	B-DISO
.	O

Reduced	O
editing	B-PHYS
at	O
the	O
glutamine	B-CHEM
/	O
arginine	B-CHEM
site	O
of	O
the	O
AMPA	B-CHEM
receptor	I-CHEM
subunit	I-CHEM
GluA2	I-CHEM
in	O
glioma	B-DISO
,	O
without	O
any	O
alteration	O
in	O
ADAR2	B-CHEM
expression	B-PHYS
,	O
is	O
a	O
notable	O
phenomenon	O
.	O

Several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	O
in	O
the	O
catalytic	B-PHYS
activity	I-PHYS
of	O
ADAR2	B-CHEM
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

The	O
present	O
review	O
summarizes	O
the	O
relevant	O
literature	O
and	O
shares	O
experimental	B-DISO
results	I-DISO
concerning	O
ADAR2	B-CHEM
alternative	B-PHYS
splicing	I-PHYS
.	O

In	O
particular	O
,	O
the	O
present	O
review	O
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	B-PHYS
variants	O
of	O
ADAR2	B-CHEM
may	O
reduce	O
the	O
ADAR2	B-CHEM
editing	B-PHYS
activity	O
in	O
glioma	B-DISO
.	O

Dominant	O
expression	B-PHYS
of	O
ADAR2	B-CHEM
splicing	B-PHYS
variant	O
with	O
low	O
enzyme	B-PHYS
activity	I-PHYS
causes	O
reduced	O
RNA	B-PHYS
editing	I-PHYS
of	O
GluA2	B-CHEM
subunit	I-CHEM
at	O
the	O
glutamine	B-CHEM
/	O
arginine	B-CHEM
site	O
in	O
glioma	B-DISO
.	O

Heat	B-CHEM
-	I-CHEM
shock	I-CHEM
protein	I-CHEM
60	I-CHEM
of	O
Porphyromonas	B-LIVB
gingivalis	I-LIVB
may	O
induce	O
dysfunction	O
of	O
human	B-ANAT
umbilical	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
via	O
regulation	B-PHEN
of	O
endothelial	B-CHEM
-	I-CHEM
nitric	I-CHEM
oxide	I-CHEM
synthase	I-CHEM
and	O
vascular	B-CHEM
endothelial	I-CHEM
-	I-CHEM
cadherin	I-CHEM
Accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-DISO
was	O
an	O
independent	O
risk	B-DISO
factor	I-DISO
for	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
(	O
CAD	B-DISO
)	O
.	O

Porphyromonus	B-LIVB
gingivalis	I-LIVB
(	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
)	O
,	O
a	O
major	O
periodontal	O
pathogen	B-LIVB
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	B-DISO
response	I-DISO
of	O
CAD	B-DISO
in	O
vivo	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	B-PROC
was	O
to	O
identify	O
whether	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
heat	B-CHEM
-	I-CHEM
shock	I-CHEM
protein	I-CHEM
60	I-CHEM
(	O
HSP60	B-CHEM
)	O
induced	O
the	O
dysfunction	O
of	O
human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
(	O
HUVECs	B-ANAT
)	O
in	O
vitro	O
.	O

HUVECs	B-ANAT
were	O
stimulated	B-PHEN
with	O
a	O
range	O
of	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
ng	O
/	O
l	O
)	O
at	O
different	O
time	O
-	O
points	O
.	O

The	O
levels	O
of	O
vascular	B-CHEM
endothelial	I-CHEM
(	I-CHEM
VE	I-CHEM
)	I-CHEM
-	I-CHEM
cadherin	I-CHEM
,	O
endothelial	B-CHEM
nitric	I-CHEM
oxide	I-CHEM
synthase	I-CHEM
(	O
eNOS	B-CHEM
)	O
and	O
cysteinyl	B-CHEM
aspartate	I-CHEM
-	I-CHEM
specific	I-CHEM
protease	I-CHEM
-	I-CHEM
3	I-CHEM
(	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
)	O
were	O
measured	O
using	O
western	B-PROC
blot	I-PROC
analysis	B-PROC
.	O

The	O
apoptotic	B-PHYS
rate	O
of	O
HUVECs	B-ANAT
was	O
detected	O
using	O
flow	B-PROC
cytometry	I-PROC
.	O

P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
at	O
a	O
concentration	O
of	O
10	O
ng	O
/	O
l	O
significantly	O
decreased	O
the	O
expression	B-PHYS
levels	O
of	O
VE	B-CHEM
-	I-CHEM
cadherin	I-CHEM
and	O
eNOS	B-CHEM
protein	I-CHEM
at	O
24	O
h	O
stimulation	B-PHEN
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	B-CHEM
was	O
identified	O
following	O
a	O
low	O
dose	O
of	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
(	O
1	O
ng	O
/	O
l	O
)	O
.	O

P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
at	O
100	O
ng	O
/	O
l	O
significantly	O
downregulated	B-PHYS
the	O
expression	B-PHYS
levels	O
of	O
VE	B-CHEM
-	I-CHEM
cadherin	I-CHEM
and	O
eNOS	B-CHEM
protein	I-CHEM
at	O
12	O
h	O
in	O
HUVECs	B-ANAT
.	O

However	O
,	O
the	O
cleavage	B-PHEN
of	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	O
.	O

Consistently	O
,	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
induced	O
apoptosis	B-PHYS
of	O
HUVECs	B-ANAT
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicated	O
that	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
may	O
induce	O
dysfunction	O
and	O
apoptosis	B-PHYS
in	O
HUVECs	B-ANAT
via	O
downregulating	B-PHYS
the	O
expression	B-PHYS
levels	O
of	O
VE	B-CHEM
-	I-CHEM
cadherin	I-CHEM
and	O
eNOS	B-CHEM
,	O
and	O
promoting	O
the	O
cleavage	B-PHEN
of	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
.	O

A	O
new	O
marker	B-PHYS
for	O
breast	B-PROC
cancer	I-PROC
diagnosis	I-PROC
,	O
human	B-CHEM
epididymis	I-CHEM
protein	I-CHEM
4	I-CHEM
:	O
A	O
preliminary	O
study	B-PROC
Breast	B-DISO
cancer	I-DISO
is	O
the	O
most	O
frequently	O
diagnosed	B-DISO
cancer	B-DISO
type	O
in	O
women	B-LIVB
.	O

Tumor	B-CHEM
markers	I-CHEM
have	O
been	O
widely	O
used	O
for	O
assessing	B-PROC
the	O
treatment	B-PHYS
response	I-PHYS
and	O
early	B-PROC
diagnosis	I-PROC
of	O
recurrence	B-DISO
.	O

Human	B-CHEM
epididymis	I-CHEM
protein	I-CHEM
4	I-CHEM
(	O
HE4	B-CHEM
)	O
is	O
expressed	B-PHYS
in	O
ductal	B-DISO
carcinoma	I-DISO
of	I-DISO
the	I-DISO
breast	I-DISO
tissue	I-DISO
;	O
however	O
,	O
its	O
serum	B-ANAT
levels	O
and	O
their	O
diagnostic	B-DISO
and	O
prognostic	B-PHYS
potential	O
in	O
breast	B-DISO
cancer	I-DISO
have	O
not	O
been	O
investigated	O
,	O
which	O
was	O
therefore	O
the	O
aim	O
of	O
the	O
present	O
study	B-PROC
.	O

The	O
serum	B-ANAT
levels	O
of	O
HE4	B-CHEM
were	O
determined	B-PROC
in	O
36	O
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
,	O
11	O
ovarian	B-DISO
cancer	I-DISO
patients	B-LIVB
and	O
16	O
healthy	B-LIVB
volunteers	I-LIVB
.	O

The	O
association	O
between	O
clinicopathological	O
characteristics	O
of	O
breast	B-DISO
cancer	I-DISO
and	O
serum	B-ANAT
HE4	B-CHEM
levels	O
was	O
investigated	O
.	O

A	O
significant	O
difference	O
in	O
the	O
median	O
serum	B-ANAT
levels	O
of	O
HE4	B-CHEM
was	O
identified	O
between	O
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
,	O
ovarian	B-DISO
cancer	I-DISO
patients	B-LIVB
and	O
healthy	B-LIVB
volunteers	I-LIVB
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

The	O
cutoff	O
value	O
for	O
the	O
prediction	O
of	O
breast	B-DISO
cancer	I-DISO
was	O
determined	B-PROC
at	O
>	O
13	O
.	O

24	O
pmol	O
/	O
l	O
for	O
HE4	B-CHEM
,	O
with	O
a	O
sensitivity	O
of	O
61	O
.	O

11	O
%	O
,	O
specificity	O
of	O
68	O
.	O
75	O
%	O
,	O
positive	O
predictive	O
value	O
of	O
81	O
.	O
48	O
%	O
,	O
negative	O
predictive	O
value	O
of	O
44	O
.	O
0	O
%	O
and	O
accuracy	O
of	O
63	O
.	O

46	O
%	O
.	O

Furthermore	O
,	O
a	O
positive	B-DISO
correlation	O
between	O
the	O
serum	B-ANAT
levels	O
of	O
HE4	B-CHEM
and	O
cancer	B-CHEM
antigen	I-CHEM
15	O
-	O
3	O
was	O
determined	B-PROC
(	O
r	O
=	O
0	O
.	O
399	O
,	O
P	O
=	O
0	O
.	O
026	O
)	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
present	O
study	B-PROC
was	O
the	O
first	O
to	O
determine	B-PROC
the	O
diagnostic	O
value	O
of	O
serum	B-ANAT
HE4	B-CHEM
for	O
breast	B-DISO
cancer	I-DISO
.	O

A	O
significant	O
elevation	O
of	O
serum	B-ANAT
HE4	B-CHEM
levels	O
in	O
patients	B-LIVB
with	O
breast	B-DISO
cancer	I-DISO
compared	O
with	O
that	O
in	O
healthy	O
controls	B-LIVB
was	O
identified	O
.	O

HE4	B-CHEM
may	O
serve	O
as	O
a	O
novel	O
biomarker	B-PHYS
for	O
the	O
diagnosis	B-DISO
of	O
breast	B-DISO
cancer	I-DISO
.	O

Duodenal	B-DISO
Villous	I-DISO
Atrophy	I-DISO
in	O
a	O
TTG	B-PROC
-	O
Negative	B-DISO
Patient	B-LIVB
Taking	O
Olmesartan	B-CHEM
:	O
A	O
Case	O
Report	O
and	O
Review	O
of	O
the	O
Literature	O
Olmesartan	B-CHEM
,	O
an	O
angiotensin	B-CHEM
II	I-CHEM
receptor	I-CHEM
antagonist	I-CHEM
used	O
to	O
treat	B-PROC
hypertension	B-DISO
,	O
is	O
associated	O
with	O
few	O
adverse	B-DISO
effects	I-DISO
.	O

Here	O
,	O
a	O
case	O
of	O
severe	O
sprue	B-DISO
-	I-DISO
like	I-DISO
enteropathy	I-DISO
and	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
is	O
described	O
in	O
a	O
68	O
-	O
year	O
-	O
old	O
male	B-PHYS
taking	O
olmesartan	B-CHEM
for	O
3	O
-	O
4	O
years	O
.	O

He	O
presented	O
to	O
hospital	B-OBJC
with	O
a	O
five	O
-	O
week	O
history	B-DISO
of	O
diarrhea	B-DISO
,	O
vomiting	B-DISO
,	O
and	O
a	O
20	O
lb	O
weight	B-DISO
loss	I-DISO
.	O

Anti	B-DISO
-	I-DISO
TTG	I-DISO
was	O
negative	B-DISO
with	O
a	O
normal	O
IgA	B-CHEM
.	O

Biopsies	B-PROC
of	O
the	O
distal	B-ANAT
duodenum	I-ANAT
and	O
duodenal	B-ANAT
cap	I-ANAT
revealed	O
marked	O
blunting	O
of	O
the	O
villi	B-ANAT
with	O
near	O
complete	O
villous	B-DISO
atrophy	I-DISO
of	O
the	O
biopsies	B-PROC
from	O
the	O
bulb	B-ANAT
.	O

There	O
was	O
an	O
increase	O
in	O
intraepithelial	O
lymphocytes	B-ANAT
as	O
well	O
as	O
neutrophils	B-ANAT
in	O
the	O
surface	B-ANAT
epithelium	I-ANAT
.	O

The	O
patient	B-LIVB
's	I-LIVB
diarrhea	B-DISO
improved	B-DISO
upon	O
discontinuation	B-PROC
of	O
olmesartan	B-CHEM
and	O
he	O
returned	O
to	O
his	O
previous	O
weight	B-PHYS
.	O

Repeat	O
endoscopy	B-PROC
four	O
months	O
later	O
demonstrated	O
complete	O
resolution	B-DISO
of	O
inflammatory	O
change	O
with	O
normal	O
villous	B-ANAT
architecture	O
.	O

Long	O
-	O
term	O
olmesartan	B-CHEM
use	O
is	O
associated	O
with	O
severe	O
sprue	B-DISO
-	I-DISO
like	I-DISO
enteropathy	I-DISO
.	O

The	O
mechanism	O
of	O
intestinal	B-DISO
injury	I-DISO
is	O
unknown	O
.	O

Duodenal	B-PROC
biopsy	I-PROC
results	O
may	O
mimic	O
other	O
enteropathies	B-DISO
such	O
as	O
celiac	B-DISO
disease	I-DISO
.	O

Physicians	B-LIVB
should	O
consider	O
medications	B-PROC
as	O
potential	O
etiologies	O
of	O
enteropathy	B-DISO
.	O

Personalized	B-PROC
Medicine	I-PROC
Approaches	I-PROC
in	O
Prostate	B-DISO
Cancer	I-DISO
Employing	O
Patient	B-LIVB
Derived	O
3D	O
Organoids	O
and	O
Humanized	B-LIVB
Mice	I-LIVB
Prostate	B-DISO
cancer	I-DISO
(	O
PCa	B-DISO
)	O
is	O
the	O
most	O
common	O
malignancy	B-DISO
and	O
the	O
second	O
most	O
common	O
cause	O
of	O
cancer	O
death	O
in	O
Western	O
men	B-LIVB
.	O

Despite	O
its	O
prevalence	O
,	O
PCa	B-DISO
has	O
proven	O
very	O
difficult	O
to	O
propagate	O
in	O
vitro	O
.	O

PCa	B-DISO
represents	O
a	O
complex	O
organ	B-ANAT
-	I-ANAT
like	I-ANAT
multicellular	O
structure	O
maintained	O
by	O
the	O
dynamic	O
interaction	O
of	O
tumoral	B-ANAT
cells	I-ANAT
with	O
parenchymal	B-ANAT
stroma	I-ANAT
,	O
endothelial	B-ANAT
and	O
immune	B-ANAT
cells	I-ANAT
,	O
and	O
components	B-ANAT
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
.	O

The	O
lack	O
of	O
PCa	B-DISO
models	B-DISO
that	O
recapitulate	O
this	O
intricate	O
system	O
has	O
hampered	O
progress	O
toward	O
understanding	B-PHYS
disease	B-DISO
progression	I-DISO
and	O
lackluster	O
therapeutic	B-PHYS
responses	I-PHYS
.	O

Tissue	B-PROC
slices	I-PROC
,	O
monolayer	B-PROC
cultures	I-PROC
and	O
genetically	B-DISO
engineered	I-DISO
mouse	I-DISO
models	I-DISO
(	O
GEMM	B-DISO
)	O
fail	O
to	O
mimic	O
the	O
complexities	O
of	O
the	O
PCa	B-DISO
microenvironment	O
or	O
reproduce	O
the	O
diverse	O
mechanisms	O
of	O
therapy	B-PROC
resistance	O
.	O

Moreover	O
,	O
patient	B-DISO
derived	I-DISO
xenografts	I-DISO
(	O
PDXs	B-DISO
)	O
are	O
expensive	O
,	O
time	O
consuming	O
,	O
difficult	O
to	O
establish	O
for	O
prostate	B-DISO
cancer	I-DISO
,	O
lack	O
immune	B-PHYS
cell	I-PHYS
-	I-PHYS
tumor	I-PHYS
regulation	I-PHYS
,	O
and	O
often	O
tumors	B-DISO
undergo	O
selective	O
engraftments	B-PHYS
.	O

Here	O
,	O
we	O
describe	O
an	O
interdisciplinary	B-PROC
approach	I-PROC
using	O
primary	O
PCa	B-DISO
and	O
tumor	B-ANAT
initiating	I-ANAT
cells	I-ANAT
(	O
TICs	B-ANAT
)	O
,	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
tissue	B-PROC
engineering	I-PROC
,	O
genetic	B-PROC
and	O
morphometric	B-PROC
profiling	I-PROC
,	O
and	O
humanized	B-LIVB
mice	I-LIVB
to	O
generate	O
patient	B-LIVB
-	O
derived	O
organoids	O
for	O
examining	O
personalized	O
therapeutic	B-PHYS
responses	I-PHYS
in	O
vitro	O
and	O
in	O
mice	B-LIVB
co	O
-	O
engrafted	O
with	O
a	O
human	B-ANAT
immune	I-ANAT
system	I-ANAT
(	O
HIS	B-ANAT
)	O
,	O
employing	O
adaptive	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
-	I-ANAT
and	O
chimeric	B-CHEM
antigen	I-CHEM
receptor	I-CHEM
-	I-CHEM
(	O
CAR	B-CHEM
)	O
immunotherapy	B-PROC
.	O

The	O
development	O
of	O
patient	B-LIVB
specific	O
therapies	B-PROC
targeting	O
the	O
vulnerabilities	B-DISO
of	O
cancer	B-DISO
,	O
when	O
combined	O
with	O
antiproliferative	B-PROC
and	O
immunotherapy	B-PROC
approaches	B-PROC
could	O
help	O
to	O
achieve	O
the	O
full	O
transformative	O
power	O
of	O
cancer	B-DISO
precision	B-PROC
medicine	I-PROC
.	O

Effect	O
of	O
endodontic	B-PROC
access	I-PROC
cavity	I-PROC
preparation	I-PROC
on	O
monolithic	O
and	O
ceramic	B-CHEM
veneered	B-CHEM
zirconia	B-CHEM
restorations	B-PROC
Due	O
to	O
the	O
high	O
chipping	B-DISO
rates	O
observed	O
in	O
veneered	B-CHEM
zirconia	B-CHEM
ceramic	B-CHEM
restorations	B-PROC
,	O
the	O
use	O
of	O
monolithic	O
zirconia	B-CHEM
restorations	B-PROC
has	O
been	O
recommended	O
.	O

This	O
study	O
tried	O
to	O
compare	O
veneered	B-CHEM
and	O
monolithic	O
zirconia	B-CHEM
fixed	B-DEVI
dental	I-DEVI
prostheses	I-DEVI
(	O
FDPs	B-DEVI
)	O
with	O
respect	O
to	O
the	O
amount	O
of	O
damage	O
induced	O
by	O
endodontic	B-PROC
access	I-PROC
preparation	I-PROC
.	O

Monolithic	O
and	O
ceramic	B-CHEM
veneered	B-CHEM
(	O
n	O
=	O
10	O
)	O
three	O
-	O
unit	O
restorations	B-PROC
(	O
retainers	B-DEVI
:	O
first	B-ANAT
premolar	I-ANAT
and	O
first	B-ANAT
molar	I-ANAT
;	O
pontic	B-DEVI
:	O
second	B-ANAT
premolar	I-ANAT
)	O
were	O
subject	O
to	O
endodontic	B-PROC
access	I-PROC
cavity	I-PROC
preparation	I-PROC
in	O
both	O
retainers	B-DEVI
using	O
a	O
diamond	B-DEVI
rotary	I-DEVI
instrument	I-DEVI
under	O
continuous	O
water	B-CHEM
cooling	B-PHEN
.	O

The	O
number	O
of	O
chipping	B-DISO
fractures	I-DISO
and	O
microfractures	B-DISO
detected	O
using	O
the	O
fluorescent	B-PROC
penetrant	I-PROC
method	I-PROC
were	O
recorded	O
.	O

Statistical	B-PROC
analysis	I-PROC
was	O
based	O
on	O
Wilcoxon	O
rank	O
sum	O
tests	O
with	O
Bonferroni	O
correction	O
(	O
level	B-PROC
of	I-PROC
significance	I-PROC
α	O
=	O
.05	O
)	O
.	O

Only	O
one	O
microfracture	B-DISO
could	O
be	O
identified	O
in	O
the	O
group	O
of	O
monolithic	O
FDPs	B-DEVI
while	O
a	O
maximum	O
of	O
seven	O
microfractures	B-DISO
and	O
three	O
chipping	B-DISO
fractures	I-DISO
per	O
retainer	B-DEVI
crown	I-DEVI
were	O
recorded	O
in	O
the	O
group	O
of	O
veneered	B-CHEM
restorations	B-PROC
.	O

At	O
the	O
premolar	O
site	O
,	O
the	O
veneered	B-CHEM
restorations	B-PROC
showed	O
significantly	O
more	O
microfractures	B-DISO
(	O
P	O
=	O
.0055	O
)	O
and	O
chipping	B-DISO
fractures	I-DISO
(	O
P	O
=	O
.0008	O
)	O
.	O

At	O
the	O
molar	B-ANAT
site	I-ANAT
,	O
no	B-DISO
significant	I-DISO
difference	I-DISO
with	O
respect	O
to	O
microfractures	B-DISO
could	O
be	O
detected	O
(	O
P	O
=	O
.0767	O
)	O
,	O
while	O
significantly	O
more	O
chipping	B-DISO
fractures	I-DISO
occurred	O
in	O
the	O
veneered	B-CHEM
samples	O
(	O
P	O
=	O
.0293	O
)	O
.	O

Monolithic	O
zirconia	B-CHEM
restorations	B-PROC
seem	O
to	O
be	O
less	O
susceptible	O
to	O
damage	O
when	O
endodontic	B-PROC
access	I-PROC
cavities	I-PROC
have	O
to	O
be	O
prepared	O
as	O
compared	O
to	O
veneered	B-CHEM
zirconia	B-CHEM
reconstructions	B-PROC
.	O

However	O
,	O
no	O
conclusions	O
can	O
be	O
drawn	O
on	O
the	O
longterm	B-PHEN
performance	I-PHEN
of	O
a	O
specific	O
restoration	B-PROC
based	O
on	O
this	O
study	O
.	O

The	O
relationship	O
between	O
hemorheological	B-PHYS
parameters	B-DISO
and	O
mortality	O
in	O
critically	B-DISO
ill	I-DISO
patients	B-LIVB
with	O
and	O
without	O
sepsis	B-DISO
The	O
prognostic	B-PROC
scoring	O
systems	O
for	O
mortality	O
of	O
intensive	B-PROC
care	I-PROC
patients	B-LIVB
estimate	O
clinical	B-DISO
outcome	I-DISO
using	O
several	O
physiological	O
and	O
biochemical	O
parameters	B-DISO
.	O

In	O
altered	O
hemodynamic	B-PHYS
conditions	O
of	O
critically	B-DISO
ill	I-DISO
patients	B-LIVB
,	O
hemorheological	B-PHYS
variables	B-PROC
may	O
play	O
a	O
significant	O
role	O
in	O
appropriate	O
tissue	O
perfusion	B-PROC
.	O

We	O
investigated	O
if	O
hemorheological	B-PHYS
parameters	B-DISO
are	O
altered	O
in	O
critical	B-DISO
status	I-DISO
and	O
if	O
they	O
could	O
be	O
markers	B-PHYS
of	O
mortality	O
.	O

112	O
patients	B-LIVB
(	O
67	O
.	O
8	O
±	O
12	O
years	O
,	O
58	O
males	B-PHYS
,	O
54	O
females	B-PHYS
)	O
treated	O
in	O
intensive	B-OBJC
care	I-OBJC
unit	I-OBJC
with	O
different	O
non	O
-	O
surgical	O
diseases	B-DISO
were	O
investigated	O
.	O

Routine	O
laboratory	B-PROC
parameters	I-PROC
and	O
prognostic	O
scores	O
were	O
determined	O
and	O
hemorheological	B-PHYS
variables	B-PROC
(	O
hematocrit	B-DISO
,	O
plasma	B-ANAT
and	O
whole	B-ANAT
blood	I-ANAT
viscosity	B-PHEN
,	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
aggregation	B-PHYS
and	O
deformability	B-PHYS
)	O
were	O
measured	O
on	O
the	O
1st	O
and	O
the	O
2nd	O
day	O
after	O
admission	B-PROC
.	O

ICU	O
scores	O
predicted	O
35	O
.	O

2	O
-	O
41	O
.	O
3	O
%	O
mortality	O
rate	O
,	O
real	O
mortality	O
in	O
intensive	B-OBJC
care	I-OBJC
unit	I-OBJC
was	O
37	O
.	O
5	O
%	O
,	O
while	O
30	O
-	O
day	O
mortality	O
was	O
46	O
.	O

6	O
%	O
.	O

Whole	B-PHEN
blood	I-PHEN
viscosity	I-PHEN
(	O
WBV	B-PHEN
)	O
and	O
red	B-PHYS
blood	I-PHYS
cell	I-PHYS
(	I-PHYS
RBC	I-PHYS
)	I-PHYS
deformability	I-PHYS
were	O
lower	O
,	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
aggregation	B-PHYS
was	O
higher	O
in	O
septic	O
than	O
in	O
nonseptic	O
patients	B-LIVB
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
septic	B-DISO
patients	B-LIVB
calcium	B-CHEM
was	O
increased	O
,	O
osmolality	B-PHYS
was	O
decreased	O
,	O
while	O
in	O
nonseptic	O
patients	B-LIVB
WBV	B-PHEN
and	O
RBC	B-ANAT
aggregation	B-PHYS
were	O
higher	O
in	O
nonsurvivors	B-LIVB
compared	O
to	O
survivors	B-LIVB
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Worsening	O
of	O
RBC	B-ANAT
deformability	B-PHYS
from	O
day	O
1	O
to	O
day	O
2	O
predicted	O
higher	O
mortality	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Calcium	B-PROC
and	O
osmolality	B-PHEN
level	I-PHEN
were	O
associated	O
with	O
outcome	O
in	O
sepsis	B-DISO
.	O

Whole	B-ANAT
blood	I-ANAT
viscosity	B-PHEN
,	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
aggregation	B-PHYS
and	O
change	O
in	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
deformability	B-PHYS
could	O
predict	O
mortality	O
in	O
nonseptic	O
patients	B-LIVB
and	O
they	O
may	O
add	O
prognostic	B-PROC
information	O
over	O
the	O
ICU	O
scores	O
.	O

Further	O
investigations	B-PROC
are	O
needed	O
to	O
evaluate	B-PROC
the	O
benefit	O
of	O
our	O
findings	B-DISO
in	O
clinical	O
practice	O
.	O

2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
Dihydroxyadenine	I-CHEM
Nephropathy	B-DISO
Identified	O
as	O
Cause	O
of	O
End	B-DISO
-	I-DISO
Stage	I-DISO
Renal	I-DISO
Disease	I-DISO
After	O
Renal	B-PROC
Transplant	I-PROC
Adenine	B-DISO
phosphoribosyltransferase	I-DISO
deficiency	I-DISO
is	O
a	O
rare	O
autosomal	B-DISO
recessive	I-DISO
disorder	I-DISO
of	O
uric	B-CHEM
acid	I-CHEM
metabolism	B-PHYS
that	O
leads	O
to	O
formation	O
and	O
excretion	B-PHYS
of	O
2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxyadenine	I-CHEM
into	O
urine	B-ANAT
.	O

The	O
low	O
solubility	O
of	O
2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxyadenine	I-CHEM
results	O
in	O
precipitation	B-PHEN
and	O
formation	O
of	O
urinary	B-PHEN
crystals	I-PHEN
and	O
renal	B-DISO
stones	I-DISO
.	O

Patients	B-LIVB
with	O
this	O
disorder	B-DISO
usually	O
have	O
recurrent	B-DISO
nephrolithiasis	I-DISO
and	O
can	O
develop	O
nephropathy	B-DISO
secondary	I-DISO
to	O
crystal	B-ANAT
precipitation	B-PHEN
in	O
the	O
renal	B-ANAT
parenchyma	I-ANAT
.	O

The	O
disease	B-DISO
is	O
most	O
often	O
underdiagnosed	B-DISO
and	O
can	O
recur	B-PHEN
in	O
renal	B-PROC
transplant	I-PROC
,	O
causing	O
graft	B-DISO
failure	I-DISO
.	O

Lack	O
of	O
specific	O
clinical	O
manifestations	O
,	O
chemical	B-PHEN
and	O
radiologic	B-DISO
features	I-DISO
identical	O
to	O
those	O
shown	O
with	O
uric	B-ANAT
acid	I-ANAT
stones	I-ANAT
,	O
and	O
lack	B-DISO
of	I-DISO
awareness	I-DISO
among	O
clinicians	B-LIVB
are	O
among	O
the	O
causes	O
for	O
the	O
underdiagnoses	B-DISO
of	O
this	O
treatable	O
disease	B-DISO
.	O

Allopurinol	B-CHEM
,	O
a	O
xanthine	B-CHEM
dehydrogenase	I-CHEM
inhibitor	B-CHEM
,	O
is	O
the	O
mainstay	O
of	O
treatment	O
,	O
supported	O
by	O
high	O
fluid	B-PHYS
intake	I-PHYS
and	O
dietary	B-PROC
modifications	I-PROC
.	O

The	O
possibility	O
of	O
adenine	B-DISO
phosphoribosyl	I-DISO
transferase	I-DISO
deficiency	I-DISO
should	O
be	O
considered	O
in	O
all	O
cases	O
of	O
urolithiasis	B-DISO
in	O
children	B-LIVB
,	O
patients	B-LIVB
with	O
recurrent	O
urolithiasis	O
,	O
and	O
patients	B-LIVB
with	O
urolithiasis	B-DISO
associated	O
with	O
renal	B-DISO
failure	I-DISO
of	O
unknown	O
cause	O
,	O
including	O
patients	B-LIVB
with	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
and	O
renal	B-LIVB
transplant	I-LIVB
recipients	I-LIVB
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
a	O
41	O
-	O
year	O
-	O
old	O
female	B-PHYS
patient	I-PHYS
who	O
had	O
a	O
late	O
diagnosis	O
of	O
2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxyadenine	I-CHEM
nephropathy	B-DISO
-induced	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
,	O
made	O
on	O
the	O
native	O
nephrectomy	B-PROC
that	O
accompanied	O
the	O
renal	B-PROC
transplant	I-PROC
,	O
and	O
who	O
had	O
a	O
timely	O
intervention	O
that	O
prevented	O
recurrence	B-DISO
in	O
the	O
graft	B-PROC
.	O

Effect	O
of	O
Low	O
-	O
Dose	O
MDCT	B-PROC
and	O
Iterative	B-PROC
Reconstruction	I-PROC
on	O
Trabecular	O
Bone	O
Microstructure	O
Assessment	O
We	O
investigated	O
the	O
effects	O
of	O
low	O
-	O
dose	O
multi	B-PROC
detector	I-PROC
computed	I-PROC
tomography	I-PROC
(	O
MDCT	B-PROC
)	O
in	O
combination	O
with	O
statistical	B-PROC
iterative	I-PROC
reconstruction	I-PROC
algorithms	O
on	O
trabecular	O
bone	O
microstructure	O
parameters	O
.	O

Twelve	O
donated	B-PROC
vertebrae	B-ANAT
were	O
scanned	B-PROC
with	O
the	O
routine	O
radiation	B-PROC
exposure	I-PROC
used	O
in	O
our	O
department	O
(	O
standard	O
-	O
dose	O
)	O
and	O
a	O
low	O
-	O
dose	O
protocol	B-PROC
.	O

Reconstructions	B-PROC
were	O
performed	O
with	O
filtered	B-PROC
backprojection	I-PROC
(	O
FBP	B-PROC
)	O
and	O
maximum	B-PROC
-	I-PROC
likelihood	I-PROC
based	O
statistical	B-PROC
iterative	I-PROC
reconstruction	I-PROC
(	O
SIR	B-PROC
)	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
were	O
assessed	O
and	O
statistically	O
compared	O
for	O
each	O
reconstruction	B-PROC
.	O

Moreover	O
,	O
fracture	B-DISO
loads	I-DISO
of	O
the	O
vertebrae	B-ANAT
were	O
biomechanically	B-PROC
determined	O
and	O
correlated	O
to	O
the	O
assessed	O
microstructure	O
parameters	O
.	O

Trabecular	O
bone	O
microstructure	O
parameters	O
based	O
on	O
low	O
-	O
dose	O
MDCT	B-PROC
and	O
SIR	B-PROC
significantly	O
correlated	O
with	O
vertebral	B-ANAT
bone	I-ANAT
strength	O
.	O

There	O
was	O
no	B-DISO
significant	I-DISO
difference	O
between	O
microstructure	O
parameters	O
calculated	O
on	O
low	O
-	O
dose	O
SIR	B-PROC
and	O
standard	O
-	O
dose	O
FBP	B-PROC
images	O
.	O

However	O
,	O
the	O
results	O
revealed	O
a	O
strong	O
dependency	O
on	O
the	O
regularization	B-PHEN
strength	O
applied	O
during	O
SIR	B-PROC
.	O

It	O
was	O
observed	O
that	O
stronger	O
regularization	B-PHEN
might	O
corrupt	O
the	O
microstructure	O
analysis	O
,	O
because	O
the	O
trabecular	O
structure	O
is	O
a	O
very	O
small	O
detail	O
that	O
might	O
get	O
lost	O
during	O
the	O
regularization	B-PHEN
process	I-PHEN
.	O

As	O
a	O
consequence	O
,	O
the	O
introduction	O
of	O
SIR	B-PROC
for	O
trabecular	O
bone	O
microstructure	O
analysis	O
requires	O
a	O
specific	O
optimization	O
of	O
the	O
regularization	B-PHEN
parameters	O
.	O

Moreover	O
,	O
in	O
comparison	O
to	O
other	O
approaches	O
,	O
superior	O
noise	B-PHEN
-	O
resolution	O
trade	O
-	O
offs	O
can	O
be	O
found	O
with	O
the	O
proposed	O
methods	O
.	O

Social	O
capital	O
and	O
healthy	O
ageing	B-PHYS
in	O
Indonesia	B-GEOG
A	O
large	O
international	O
literature	O
has	O
found	O
a	O
positive	B-DISO
association	O
between	O
social	O
capital	O
and	O
measures	O
of	O
physical	B-DISO
and	O
mental	B-PHYS
health	I-PHYS
.	O

However	O
,	O
there	O
is	O
a	O
paucity	O
of	O
research	B-PROC
on	O
the	O
links	O
between	O
social	O
capital	O
and	O
healthy	O
ageing	B-PHYS
in	O
a	O
developing	O
country	O
environment	O
,	O
where	O
universal	O
social	O
security	O
coverage	O
is	O
absent	O
and	O
health	O
infrastructure	O
is	O
poor	O
.	O

In	O
this	O
paper	O
,	O
we	O
develop	O
and	O
empirically	O
test	O
a	O
model	O
of	O
the	O
linkages	O
between	O
social	O
capital	O
and	O
the	O
health	O
outcomes	O
for	O
older	B-LIVB
adults	I-LIVB
in	O
Indonesia	B-GEOG
,	O
using	O
data	O
from	O
the	O
Indonesian	O
Family	O
Life	O
Survey	O
-	O
East	O
(	O
IFLS	O
-	O
East	O
)	O
,	O
conducted	O
in	O
2012	O
.	O

Using	O
multivariate	O
regression	O
analysis	O
,	O
we	O
examine	O
whether	O
social	O
capital	O
plays	O
a	O
role	O
in	O
mitigating	O
poor	B-DISO
health	I-DISO
among	O
older	B-LIVB
individuals	B-LIVB
aged	B-PHYS
50	O
years	O
and	O
above	O
in	O
Indonesia	B-GEOG
'	O
s	O
most	O
vulnerable	B-GEOG
provinces	I-GEOG
.	O

We	O
test	O
the	O
robustness	O
of	O
these	O
social	O
capital	O
variables	O
across	O
different	O
health	O
measures	O
(	O
self	O
-	O
assessed	O
health	O
,	O
Activities	O
of	O
Daily	O
Living	O
(	O
ADL	O
)	O
,	O
measures	O
of	O
chronic	B-DISO
illness	I-DISO
and	O
mental	B-PHYS
health	I-PHYS
measures	O
)	O
,	O
as	O
well	O
as	O
across	O
different	O
demographic	O
groups	O
,	O
after	O
controlling	O
for	O
an	O
array	O
of	O
socio	O
-	O
economic	O
,	O
demographic	O
and	O
geographic	O
characteristics	O
.	O

Our	O
findings	B-DISO
show	O
that	O
access	O
to	O
better	O
social	O
capital	O
(	O
using	O
measures	O
of	O
neighbourhood	B-LIVB
trust	O
and	O
community	O
participation	O
)	O
is	O
associated	O
with	O
a	O
higher	O
degree	O
of	O
physical	B-PHYS
mobility	I-PHYS
,	O
independence	O
,	O
and	O
mental	B-PHYS
well	I-PHYS
-	I-PHYS
being	I-PHYS
among	O
older	B-LIVB
individuals	B-LIVB
but	O
has	O
no	O
influence	O
on	O
chronic	B-DISO
illnesses	I-DISO
.	O

These	O
results	O
are	O
consistent	O
when	O
we	O
estimate	O
samples	B-LIVB
disaggregated	O
by	O
gender	B-PHYS
,	O
rural	B-DISO
/	O
urban	O
residence	O
,	O
and	O
by	O
age	B-PHYS
categories	O
.	O

From	O
a	O
policy	O
perspective	O
these	O
results	O
point	O
to	O
the	O
importance	O
of	O
social	O
capital	O
measures	O
in	O
moderating	O
the	O
influence	O
of	O
poor	B-DISO
health	I-DISO
,	O
particularly	O
in	O
the	O
Activities	O
of	O
Daily	O
Living	O
.	O

Modulation	O
of	O
Interleukins	B-CHEM
in	O
Sepsis	B-DISO
-	O
Associated	O
Clotting	B-DISO
Disorders	I-DISO
:	O
Interplay	O
With	O
Hemostatic	B-DISO
Derangement	I-DISO
Interleukins	B-CHEM
play	O
a	O
central	O
role	O
in	O
the	O
immune	B-ANAT
system	I-ANAT
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
immunological	B-DISO
,	O
inflammatory	B-DISO
,	O
and	O
infectious	B-DISO
disease	I-DISO
states	O
including	O
sepsis	B-DISO
syndrome	I-DISO
.	O

Levels	O
of	O
interleukins	B-CHEM
may	O
correlate	O
with	O
overall	O
survival	O
and	O
may	O
directly	O
or	O
indirectly	O
affect	B-PHYS
some	O
of	O
the	O
regulators	B-CHEM
of	O
coagulation	B-PHYS
and	O
fibrinolysis	B-PHYS
,	O
thereby	O
disrupting	O
hemostasis	B-PHYS
and	O
thrombosis	B-DISO
.	O

Our	O
hypothesis	O
is	O
that	O
in	O
sepsis	B-DISO
-	I-DISO
associated	I-DISO
coagulopathies	I-DISO
(	O
SACs	B-DISO
)	O
,	O
interleukins	B-CHEM
may	O
be	O
upregulated	B-PHYS
,	O
leading	O
to	O
hemostatic	B-DISO
imbalance	I-DISO
by	O
generating	O
thrombogenic	B-CHEM
mediators	I-CHEM
.	O

We	O
profiled	O
the	O
levels	O
of	O
interleukins	B-CHEM
IL	B-CHEM
-	I-CHEM
1α	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
8	I-CHEM
,	O
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
in	O
addition	O
to	O
d	B-CHEM
-	I-CHEM
dimer	I-CHEM
(	O
DD	B-CHEM
)	O
in	O
patients	B-LIVB
with	O
SAC	B-DISO
and	O
in	O
normal	O
donors	B-LIVB
.	O

We	O
observed	O
the	O
highest	O
increase	O
in	O
interleukins	B-CHEM
IL	B-CHEM
-	I-CHEM
6	I-CHEM
(	O
322	O
-	O
fold	O
)	O
,	O
IL	B-CHEM
-	I-CHEM
8	I-CHEM
(	O
48	O
-	O
fold	O
)	O
,	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
(	O
72	O
-	O
fold	O
)	O
,	O
and	O
DD	B-CHEM
(	O
18	O
-	O
fold	O
)	O
.	O

This	O
suggests	O
that	O
interleukins	B-CHEM
such	O
as	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
have	O
a	O
close	O
association	O
with	O
coagulopathy	B-DISO
and	O
fibrinolytic	O
dysregulation	O
in	O
sepsis	B-DISO
and	O
can	O
be	O
considered	O
as	O
candidates	B-CHEM
for	O
potential	O
therapeutic	O
targets	O
in	O
SAC	B-DISO
.	O

Fine	O
-	O
scale	O
spatial	O
genetic	O
structure	O
of	O
a	O
fungal	B-LIVB
parasite	O
of	O
coffee	O
scale	O
insects	O
The	O
entomopathogenic	B-LIVB
fungus	I-LIVB
Lecanicillium	B-LIVB
lecanii	I-LIVB
persists	O
in	O
a	O
highly	O
dynamic	O
network	O
of	O
habitat	O
patches	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
metapopulation	B-LIVB
)	O
formed	O
by	O
its	O
primary	O
host	B-LIVB
,	O
the	O
green	O
coffee	O
scale	O
Coccus	O
viridis	O
.	O

Lecanicillium	B-LIVB
lecanii	I-LIVB
is	O
an	O
important	O
biological	B-PHEN
control	I-PHEN
of	O
both	O
C	O
.	O

viridis	O
and	O
the	O
coffee	B-LIVB
rust	I-LIVB
,	O
Hemileia	B-LIVB
vastatrix	I-LIVB
.	O

Successfully	O
managing	O
this	O
biocontrol	B-PHEN
agent	B-CHEM
will	O
depend	O
on	O
an	O
increased	O
understanding	B-PHYS
of	O
the	O
characteristics	O
of	O
its	O
dispersal	O
,	O
as	O
migration	O
between	O
occupied	O
and	O
unoccupied	O
patches	O
is	O
essential	O
for	O
the	O
persistence	B-PHYS
of	O
this	O
metapopulation	B-LIVB
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
employ	O
a	O
population	O
genetics	O
approach	O
,	O
and	O
show	O
that	O
in	O
our	O
study	B-PROC
system	O
,	O
a	O
coffee	B-OBJC
farm	O
in	O
the	O
Soconusco	B-GEOG
region	B-GEOG
of	O
southern	O
Mexico	B-GEOG
,	O
L	B-LIVB
.	I-LIVB

lecanii	I-LIVB
is	O
characterized	O
by	O
clear	O
spatial	O
genetic	O
structure	O
among	O
plots	O
within	O
the	O
farm	O
but	O
a	O
lack	O
of	O
apparent	O
structure	O
at	O
smaller	O
scales	O
.	O

This	O
is	O
consistent	O
with	O
dispersal	O
dominated	O
by	O
highly	O
localized	O
transport	O
,	O
such	O
as	O
by	O
insects	O
or	O
rain	B-PHEN
splash	O
,	O
and	O
less	O
dependence	B-DISO
on	O
longer	O
distance	O
dispersal	O
such	O
as	O
wind	B-PHEN
transport	O
.	O

The	O
study	O
site	O
was	O
dominated	O
by	O
a	O
few	O
multi	B-PHYS
-	I-PHYS
locus	I-PHYS
microsatellite	I-PHYS
genotypes	I-PHYS
,	O
and	O
their	O
identities	O
and	O
large	O
-	O
scale	O
locations	O
persist	O
across	O
both	O
study	B-PROC
years	O
,	O
suggesting	O
that	O
local	O
epizootics	B-PHEN
(	O
outbreaks	B-PHEN
)	O
are	O
initiated	O
each	O
wet	O
season	O
by	O
residual	O
propagules	O
from	O
the	O
previous	O
wet	O
season	O
,	O
and	O
not	O
by	O
long	O
-	O
distance	O
transport	O
of	O
propagules	O
from	O
other	O
sites	O
.	O

The	O
index	O
of	O
association	O
,	O
a	O
measure	O
of	O
linkage	O
disequilibrium	O
,	O
indicates	O
that	O
epizootics	B-PHEN
are	O
primarily	O
driven	O
by	O
asexual	B-PHYS
,	O
clonal	B-PHYS
reproduction	I-PHYS
,	O
which	O
is	O
consistent	O
with	O
the	O
apparent	O
lack	O
of	O
a	O
teleomorph	B-LIVB
in	O
the	O
study	O
site	O
and	O
the	O
presence	B-DISO
of	O
only	O
a	O
single	O
mating	B-PHYS
type	I-PHYS
across	O
the	O
site	O
(	O
MAT	B-PHYS
-	I-PHYS
1	I-PHYS
-	I-PHYS
2	I-PHYS
-	I-PHYS
1	I-PHYS
)	O
.	O

Although	O
the	O
same	O
predominant	O
clonal	O
genotypes	B-PHYS
were	O
found	B-DISO
across	O
years	O
,	O
a	O
drastic	O
difference	O
in	O
genotypic	B-PHYS
diversity	O
was	O
witnessed	O
across	O
two	O
sites	O
between	O
the	O
two	O
years	O
,	O
suggesting	O
that	O
interclonal	O
selection	O
was	O
occurring	O
.	O

In	O
light	O
of	O
the	O
dispersal	O
limitation	O
of	O
L	B-LIVB
.	I-LIVB

lecanii	I-LIVB
,	O
spatial	O
structure	O
may	O
be	O
an	O
essential	O
axis	O
of	O
management	O
to	O
ensure	O
the	O
persistence	O
of	O
L	B-LIVB
.	I-LIVB

lecanii	I-LIVB
and	O
preserve	O
the	O
ecosystem	B-PHEN
services	O
provided	O
by	O
this	O
versatile	O
biocontrol	B-PHEN
agent	B-CHEM
in	O
this	O
and	O
similar	O
coffee	O
farms	O
.	O

Estradiol	B-CHEM
prodrugs	B-CHEM
(	O
EP	B-CHEM
)	O
for	O
efficient	O
oral	B-PROC
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	B-CHEM
modulated	O
liver	B-PHYS
functions	I-PHYS
Oral	B-PROC
compared	O
to	O
parenteral	B-PROC
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	B-ANAT
estrogenic	B-DISO
effects	I-DISO
on	O
lipids	B-CHEM
,	O
hemostatic	B-PHYS
factors	I-PHYS
,	O
GH	B-CHEM
-	O
/	O
IGF	B-CHEM
I	I-CHEM
axis	O
,	O
angiotensinogen	B-CHEM
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	B-PHYS
effects	I-PHYS
of	O
oral	B-PROC
treatment	I-PROC
,	O
estradiol	B-CHEM
(	O
E2	B-CHEM
)	O
prodrugs	B-CHEM
(	O
EP	B-CHEM
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	B-ANAT
tissue	I-ANAT
as	O
inactive	O
molecules	O
.	O

Carbone17	B-CHEM
-	I-CHEM
OH	I-CHEM
sulfonamide	I-CHEM
[	I-CHEM
-O2	I-CHEM
-	I-CHEM
NH2	I-CHEM
]	I-CHEM
substituted	I-CHEM
esters	I-CHEM
of	O
E2	B-CHEM
(	O
EC508	B-CHEM
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	B-CHEM
anhydrase	I-CHEM
II	I-CHEM
(	O
CA	B-CHEM
-	I-CHEM
II	I-CHEM
)	O
binding	B-PHYS
.	O

CA	B-CHEM
II	I-CHEM
in	O
erythrocytes	B-ANAT
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
EP	B-CHEM
from	O
portal	O
vein	O
blood	O
during	O
liver	B-ANAT
passage	O
.	O

Ovariectomized	B-DISO
(	O
OVX	B-DISO
,	O
day	O
minus	O
14	O
)	O
rats	B-LIVB
were	O
orally	B-PROC
treated	I-PROC
once	O
daily	O
from	O
day	O
1	O
-	O
3	O
.	O

Sacrifice	O
day	O
4	O
.	O

Uteri	B-ANAT
were	O
dissected	O
and	O
weighed	B-PROC
.	O

Cholesterol	B-PROC
fractions	I-PROC
and	O
angiotensinogen	B-PROC
were	O
determined	O
in	O
plasma	B-ANAT
.	O

Oral	B-CHEM
E2	I-CHEM
and	O
ethinyl	B-CHEM
estradiol	I-CHEM
(	O
EE	B-CHEM
)	O
generated	O
dose	O
related	O
uterine	B-ANAT
growth	B-PHYS
and	O
important	O
hepatic	B-ANAT
estrogenic	B-DISO
effects	I-DISO
.	O

EP	B-CHEM
induced	O
uterine	B-PHYS
growth	I-PHYS
at	O
about	O
hundred	O
-	O
fold	O
lower	O
doses	O
.	O

This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B-ANAT
cholesterol	B-CHEM
or	O
angiotensinogen	B-CHEM
.	O

Preliminary	O
pharmacokinetic	B-PROC
studies	I-PROC
with	O
EC508	B-CHEM
used	O
intravenous	O
and	O
oral	B-PROC
administration	I-PROC
in	O
male	B-PHYS
rats	B-LIVB
.	O

Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-PROC
bioavailability	O
.	O

Further	O
high	O
blood	B-ANAT
-	O
but	O
low	O
plasma	B-ANAT
concentrations	O
indicated	O
erythrocyte	B-ANAT
binding	O
of	O
EC508	B-CHEM
in	O
vivo	O
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-ANAT
passage	O
.	O

Very	O
high	O
systemic	O
estrogenicity	B-CHEM
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B-ANAT
estrogenic	B-DISO
effects	I-DISO
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	B-CHEM
from	O
sulfonamide	B-CHEM
EP	I-CHEM
.	O

In	O
conclusion	O
,	O
tested	O
oral	B-PROC
EP	B-CHEM
bypass	O
the	O
liver	B-ANAT
in	O
erythrocytes	B-ANAT
furnishing	O
systemic	O
estradiol	B-CHEM
at	O
hydrolysis	B-PHEN
.	O

This	O
mechanism	O
avoids	O
the	O
hepatic	B-ANAT
estrogenic	O
impact	O
of	O
conventional	O
oral	B-PROC
estrogen	B-PROC
therapy	I-PROC
.	O

Externally	O
Connected	O
Zirconia	B-CHEM
Abutments	B-DEVI
with	O
Standard	O
Platform	O
are	O
Successful	O
Long	O
Term	O
in	O
Anterior	B-ANAT
Regions	I-ANAT
Performance	O
of	O
zirconia	B-CHEM
abutments	B-DEVI
for	O
implant	B-PROC
-	I-PROC
supported	I-PROC
single	I-PROC
-	I-PROC
tooth	I-PROC
crowns	I-PROC
in	O
esthetic	B-ANAT
areas	I-ANAT
:	O
a	O
retrospective	B-PROC
study	I-PROC
up	O
to	O
12	O
-	O
year	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Passos	O
SP	O
,	O
Linke	O
B	O
,	O
Larjava	O
H	O
,	O
French	O
D	O
.	O

Clin	O
Oral	O
Implants	O
Res	O
2016	O
;	O
27	O
(	O
1	O
)	O
:	O
47	O
-	O
54	O
.	O

Information	O
not	O
available	O
Retrospective	B-PROC
cohort	I-PROC
study	I-PROC
.	O

Peripheral	O
interactions	O
between	O
cannabinoid	B-CHEM
and	O
opioid	B-CHEM
receptor	I-CHEM
agonists	B-CHEM
in	O
a	O
model	B-DISO
of	O
inflammatory	B-DISO
mechanical	B-DISO
hyperalgesia	I-DISO
Activation	B-PHYS
of	O
opioid	B-CHEM
and	O
cannabinoid	B-CHEM
receptors	I-CHEM
expressed	B-PHYS
in	O
nociceptors	B-ANAT
induces	O
effective	O
antihyperalgesia	B-DISO
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
combinations	O
of	O
opioid	B-CHEM
and	O
cannabinoid	B-CHEM
receptor	I-CHEM
agonists	B-CHEM
directed	O
at	O
the	O
injured	O
site	O
would	O
enhance	O
therapeutic	O
effectiveness	O
.	O

Behavioral	O
pharmacology	O
experiments	B-PROC
were	O
performed	O
to	O
compare	O
the	O
effects	O
of	O
DAMGO	B-CHEM
,	O
a	O
selective	O
agonist	B-CHEM
for	O
μ	B-CHEM
-	I-CHEM
opioid	I-CHEM
receptor	I-CHEM
(	O
MOR	B-CHEM
)	O
,	O
ACPA	B-CHEM
,	O
a	O
specific	O
agonist	B-CHEM
for	O
CB1	B-CHEM
,	O
and	O
combinations	O
of	O
DAMGO	B-CHEM
and	O
ACPA	B-CHEM
in	O
attenuating	O
complete	B-CHEM
Freund	I-CHEM
's	I-CHEM
adjuvant	I-CHEM
(	O
CFA	B-CHEM
)	O
-	O
induced	O
mechanical	B-DISO
hyperalgesia	I-DISO
in	O
the	O
rat	B-LIVB
hindpaw	B-ANAT
.	O

DAMGO	B-CHEM
(	O
1μg	O
-	O
1	O
mg	O
)	O
or	O
ACPA	B-CHEM
(	O
1μg	O
-	O
2	O
mg	O
)	O
was	O
administered	O
into	O
the	O
inflamed	B-DISO
paw	B-ANAT
when	O
mechanical	B-DISO
hyperalgesia	I-DISO
was	O
fully	O
developed	O
.	O

When	O
administered	O
individually	O
,	O
DAMGO	B-CHEM
and	O
ACPA	B-CHEM
dose	O
-dependently	O
reversed	O
the	O
mechanical	B-DISO
hyperalgesia	I-DISO
.	O

DAMGO	B-CHEM
displayed	O
a	O
lower	O
ED50	O
value	O
(	O
57	O
.	O

4±2	O
.	O

49μg	O
)	O
than	O
ACPA	B-CHEM
(	O
111	O
.	O

6±2	O
.	O

18μg	O
)	O
,	O
but	O
ACPA	B-CHEM
produced	O
longer	O
lasting	O
antihyperalgesic	B-DISO
effects	I-DISO
.	O

Combinations	O
of	O
DAMGO	B-CHEM
and	O
ACPA	B-CHEM
also	O
dose	O
-dependently	O
attenuated	O
mechanical	B-DISO
hyperalgesia	I-DISO
,	O
but	O
the	O
antihyperalgesic	B-DISO
effects	I-DISO
were	O
partial	O
and	O
transient	O
even	O
at	O
high	O
doses	O
.	O

Using	O
isobolographic	B-PROC
analysis	I-PROC
,	O
we	O
determined	O
that	O
combined	O
treatment	B-PROC
with	O
DAMGO	B-CHEM
and	O
ACPA	B-CHEM
produced	O
antagonistic	O
effects	O
with	O
the	O
observed	O
ED50	O
of	O
128	O
.	O

4±2	O
.	O

28μg	O
.	O

Our	O
findings	O
showed	O
that	O
MOR	B-CHEM
and	O
CB1	B-CHEM
agonists	B-CHEM
directed	O
at	O
the	O
inflamed	B-DISO
site	O
effectively	O
attenuate	O
mechanical	B-DISO
hyperalgesia	I-DISO
when	O
administered	O
individually	O
,	O
but	O
exert	B-PHYS
opposing	O
effects	O
when	O
administered	O
together	O
.	O

The	O
antagonistic	O
interactions	O
between	O
the	O
two	O
classes	O
of	O
drugs	B-CHEM
at	O
the	O
inflamed	B-DISO
site	O
suggest	O
distinct	O
mechanisms	O
unique	O
to	O
peripheral	O
nociceptors	B-ANAT
or	O
inflamed	B-DISO
tissue	O
,	O
and	O
therefore	O
require	O
further	O
studies	O
to	O
investigate	O
whether	O
the	O
therapeutic	O
utility	O
of	O
the	O
combined	O
drug	B-PROC
treatments	I-PROC
in	O
chronic	B-DISO
pain	I-DISO
conditions	O
can	O
be	O
optimized	O
.	O

Thymosin	B-CHEM
β4	I-CHEM
:	O
Roles	O
in	O
Development	O
,	O
Repair	B-PHYS
,	O
and	O
Engineering	O
of	O
the	O
Cardiovascular	B-ANAT
System	I-ANAT
The	O
burden	O
of	O
cardiovascular	B-DISO
disease	I-DISO
is	O
a	O
growing	O
worldwide	O
issue	O
that	O
demands	O
attention	O
.	O

While	O
many	O
clinical	B-PROC
trials	I-PROC
are	O
ongoing	O
to	O
test	O
therapies	B-PROC
for	O
treating	O
the	O
heart	B-ANAT
after	O
myocardial	B-DISO
infarction	I-DISO
(	O
MI	B-DISO
)	O
and	O
heart	B-DISO
failure	I-DISO
,	O
there	O
are	O
few	O
options	O
doctors	B-LIVB
able	O
to	O
currently	O
give	O
patients	B-LIVB
to	O
repair	B-PROC
the	I-PROC
heart	I-PROC
.	O

This	O
eventually	O
leads	O
to	O
decreased	O
ventricular	B-PHYS
contractility	I-PHYS
and	O
increased	O
systemic	B-DISO
disease	I-DISO
,	O
including	O
vascular	B-DISO
disorders	I-DISO
that	O
could	O
result	O
in	O
stroke	B-DISO
.	O

Small	O
peptides	B-CHEM
such	O
as	O
thymosin	B-CHEM
β4	I-CHEM
(	O
Tβ4	B-CHEM
)	O
are	O
upregulated	O
in	O
the	O
cardiovascular	B-ANAT
niche	B-ANAT
during	O
fetal	B-PHYS
development	I-PHYS
and	O
after	O
injuries	B-DISO
such	O
as	O
MI	B-DISO
,	O
providing	O
increased	O
neovasculogenesis	B-DISO
and	O
paracrine	B-PHYS
signals	I-PHYS
for	O
endogenous	B-ANAT
stem	I-ANAT
cell	I-ANAT
recruitment	O
to	O
aid	O
in	O
wound	B-PHYS
repair	I-PHYS
.	O

New	O
research	B-PROC
is	O
looking	O
into	O
the	O
effects	O
of	O
in	O
vivo	O
administration	B-PROC
of	O
Tβ4	B-CHEM
through	O
injections	B-PROC
and	O
coatings	B-CHEM
on	O
implants	B-DEVI
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
cell	B-PHYS
differentiation	I-PHYS
.	O

Results	O
so	O
far	O
demonstrate	O
Tβ4	B-CHEM
administration	B-PROC
leads	O
to	O
robust	O
increases	O
in	O
angiogenesis	B-PHYS
and	O
wound	B-PHYS
healing	I-PHYS
in	O
the	O
heart	B-ANAT
after	O
MI	B-DISO
and	O
the	O
brain	B-ANAT
after	O
stroke	B-DISO
,	O
and	O
can	O
differentiate	O
adult	B-ANAT
stem	I-ANAT
cells	I-ANAT
toward	O
the	O
cardiac	B-ANAT
lineage	O
for	O
implantation	B-PROC
to	O
the	O
heart	B-ANAT
to	O
increase	O
contractility	B-PHYS
and	O
survival	O
.	O

Future	O
work	O
,	O
some	O
of	O
which	O
is	O
currently	O
in	O
clinical	B-PROC
trials	I-PROC
,	O
will	O
demonstrate	O
the	O
in	O
vivo	O
effect	O
of	O
these	O
therapies	B-PROC
on	O
human	B-LIVB
patients	B-LIVB
,	O
with	O
the	O
goal	O
of	O
helping	O
the	O
millions	O
of	O
people	B-LIVB
worldwide	O
affected	O
by	O
cardiovascular	B-DISO
disease	I-DISO
.	O

Differences	O
in	O
pain	B-DISO
experience	B-PHYS
and	O
cooperation	O
between	O
consecutive	B-PROC
surgeries	I-PROC
in	O
patients	B-LIVB
undergoing	O
phacoemulsification	B-PROC
The	O
purpose	O
of	O
this	O
study	B-PROC
is	O
to	O
compare	O
pain	B-DISO
experience	B-PHYS
and	O
cooperation	O
between	O
consecutive	B-PROC
surgeries	I-PROC
in	O
patients	B-LIVB
undergoing	O
phacoemulsification	B-PROC
in	O
both	O
eyes	B-ANAT
,	O
using	O
sub	B-PROC
-	I-PROC
Tenon	I-PROC
's	I-PROC
local	I-PROC
anesthesia	I-PROC
without	O
sedation	B-PROC
.	O

In	O
this	O
study	B-PROC
,	O
268	O
patients	B-LIVB
with	O
bilateral	B-DISO
senile	I-DISO
cataracts	I-DISO
were	O
recruited	O
.	O

All	O
operations	B-PROC
were	O
performed	O
without	O
sedation	B-PROC
,	O
using	O
a	O
clear	O
corneal	B-ANAT
phacoemulsification	B-PROC
technique	I-PROC
and	O
sub	B-PROC
-	I-PROC
Tenon	I-PROC
's	I-PROC
local	I-PROC
anesthesia	I-PROC
,	O
by	O
one	O
of	O
four	O
surgeons	B-LIVB
.	O

The	O
first	O
surgery	B-PROC
was	O
performed	O
on	O
the	O
eye	B-ANAT
with	O
the	O
higher	O
grade	O
cataract	B-DISO
.	O

The	O
other	O
eye	B-ANAT
was	O
operated	O
on	O
within	O
3	O
months	O
by	O
the	O
same	O
surgeon	B-LIVB
(	O
mean	O
interval	O
1	O
.	O
9	O
±	O
1	O
.	O
1	O
months	O
)	O
.	O

All	O
patients	B-LIVB
were	O
asked	O
to	O
grade	O
their	O
pain	B-DISO
experience	B-PHYS
during	O
induction	B-PROC
and	O
maintenance	O
of	O
anesthesia	B-PROC
and	O
also	O
during	O
the	O
phacoemulsification	B-PROC
surgery	I-PROC
,	O
using	O
a	O
visual	B-PROC
analogue	I-PROC
scale	I-PROC
(	O
VAS	B-PROC
)	O
from	O
0	O
(	O
no	B-DISO
pain	I-DISO
)	O
to	O
10	O
(	O
unbearable	B-DISO
pain	I-DISO
)	O
administered	O
after	O
the	O
surgery	B-PROC
.	O

The	O
cooperation	O
of	O
the	O
patient	B-LIVB
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	B-PHYS
and	O
head	B-PHYS
movement	I-PHYS
and	O
lid	B-DISO
squeezing	I-DISO
)	O
by	O
the	O
attending	O
surgeon	B-LIVB
.	O

The	O
VAS	O
scores	O
and	O
cooperation	O
scores	O
of	O
the	O
patients	B-LIVB
were	O
the	O
outcome	O
measurements	O
.	O

The	O
mean	B-DISO
pain	I-DISO
score	I-DISO
was	O
2	O
.	O
11	O
±	O
0	O
.	O
79	O
in	O
the	O
first	O
eye	B-ANAT
and	O
3	O
.	O

33	O
±	O
0	O
.	O
80	O
in	O
the	O
second	O
eye	B-ANAT
during	O
the	O
administration	B-PROC
of	O
sub	B-PROC
-	I-PROC
Tenon	I-PROC
's	I-PROC
anesthesia	I-PROC
,	O
and	O
1	O
.	O
50	O
±	O
0	O
.	O
60	O
in	O
the	O
first	O
eye	B-ANAT
and	O
2	O
.	O
10	O
±	O
0	O
.	O
57	O
in	O
the	O
second	O
eye	B-ANAT
during	O
the	O
phacoemulsification	B-PROC
surgery	I-PROC
.	O

The	O
patient	O
cooperation	O
score	O
was	O
1	O
.	O
60	O
±	O
0	O
.	O
75	O
in	O
the	O
first	O
surgery	B-PROC
and	O
2	O
.	O
08	O
±	O
0	O
.	O
72	O
in	O
the	O
second	O
surgery	B-PROC
.	O

The	O
differences	O
between	O
the	O
first	O
and	O
second	O
surgeries	B-PROC
were	O
statistically	O
significant	O
for	O
all	O
outcome	O
measures	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Patients	B-LIVB
who	O
previously	O
underwent	O
phaco	B-PROC
surgery	I-PROC
in	O
one	O
eye	B-ANAT
experienced	O
more	O
pain	B-DISO
and	O
showed	O
worse	B-DISO
cooperation	O
during	O
the	O
phaco	B-PROC
surgery	I-PROC
in	O
the	O
second	O
eye	B-ANAT
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-PROC
,	O
viz	O
.	O
,	O
less	O
than	O
3	O
months	O
.	O

Therefore	O
,	O
if	O
the	O
surgeon	B-LIVB
has	O
difficulty	O
in	O
the	O
first	O
operation	B-PROC
gaining	O
the	O
patient	O
's	O
cooperation	O
,	O
the	O
surgeon	B-LIVB
must	O
be	O
careful	O
:	O
if	O
contralateral	B-PROC
eye	I-PROC
surgery	I-PROC
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	B-PROC
/	O
analgesia	B-PROC
should	O
be	O
considered	O
or	O
the	O
surgery	B-PROC
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	O
of	O
recent	B-PHYS
memory	I-PHYS
on	O
the	O
patient	B-LIVB
's	I-LIVB
subsequent	O
pain	B-DISO
experience	B-PHYS
.	O

Yersinia	B-LIVB
ruckeri	I-LIVB
Isolates	B-CHEM
Recovered	O
from	O
Diseased	B-DISO
Atlantic	B-LIVB
Salmon	I-LIVB
(	O
Salmo	B-LIVB
salar	I-LIVB
)	O
in	O
Scotland	B-GEOG
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow	B-LIVB
Trout	I-LIVB
(	O
Oncorhynchus	B-LIVB
mykiss	I-LIVB
)	O
and	O
Represent	O
Distinct	O
Subpopulations	B-LIVB
Yersinia	B-LIVB
ruckeri	I-LIVB
is	O
the	O
etiological	O
agent	O
of	O
enteric	B-DISO
redmouth	I-DISO
(	O
ERM	B-DISO
)	O
disease	B-DISO
of	O
farmed	O
salmonids	B-LIVB
.	O

Enteric	B-DISO
redmouth	I-DISO
disease	I-DISO
is	O
traditionally	O
associated	O
with	O
rainbow	B-LIVB
trout	I-LIVB
(	O
Oncorhynchus	B-LIVB
mykiss	I-LIVB
,	O
Walbaum	B-LIVB
)	O
,	O
but	O
its	O
incidence	O
in	O
Atlantic	B-LIVB
salmon	I-LIVB
(	O
Salmo	B-LIVB
salar	I-LIVB
)	O
is	O
increasing	O
.	O

Yersinia	B-LIVB
ruckeri	I-LIVB
isolates	B-CHEM
recovered	O
from	O
diseased	B-DISO
Atlantic	B-LIVB
salmon	I-LIVB
have	O
been	O
poorly	O
characterized	O
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	O
of	O
the	O
isolates	B-CHEM
associated	O
with	O
these	O
two	O
species	O
.	O

Phenotypic	B-PHYS
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
isolates	B-CHEM
recovered	O
over	O
a	O
14	O
-	O
year	O
period	O
from	O
infected	B-DISO
Atlantic	B-LIVB
salmon	I-LIVB
in	O
Scotland	B-GEOG
;	O
26	O
isolates	B-CHEM
from	O
infected	B-DISO
rainbow	B-LIVB
trout	I-LIVB
were	O
also	O
characterized	O
.	O

Biotyping	B-PROC
,	O
serotyping	B-PROC
,	O
and	O
comparison	O
of	O
outer	B-ANAT
membrane	I-ANAT
protein	B-PHEN
profiles	I-PHEN
identified	O
19	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
clones	O
associated	O
with	O
Atlantic	B-LIVB
salmon	I-LIVB
but	O
only	O
five	O
associated	O
with	O
rainbow	B-LIVB
trout	I-LIVB
;	O
none	O
of	O
the	O
Atlantic	B-LIVB
salmon	I-LIVB
clones	O
occurred	O
in	O
rainbow	B-LIVB
trout	I-LIVB
and	O
vice	O
versa	O
These	O
findings	B-DISO
suggest	O
that	O
distinct	O
subpopulations	B-LIVB
of	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
are	O
associated	O
with	O
each	O
species	O
.	O

A	O
new	O
O	O
serotype	O
(	O
designated	O
O8	O
)	O
was	O
identified	O
in	O
56	O
biotype	O
1	O
Atlantic	B-LIVB
salmon	I-LIVB
isolates	B-CHEM
and	O
was	O
the	O
most	O
common	O
serotype	O
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	O
prevalence	O
during	O
the	O
time	O
period	O
sampled	O
.	O

Rainbow	B-LIVB
trout	I-LIVB
isolates	B-CHEM
were	O
represented	O
almost	O
exclusively	O
by	O
the	O
same	O
biotype	O
2	O
,	O
serotype	O
O1	O
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	B-DISO
outbreaks	O
in	O
this	O
species	O
within	O
the	O
United	B-GEOG
Kingdom	I-GEOG
since	O
the	O
1980s	O
.	O

However	O
,	O
the	O
identification	O
of	O
two	O
biotype	O
2	O
,	O
serotype	O
O8	O
isolates	B-CHEM
in	O
rainbow	B-LIVB
trout	I-LIVB
suggests	O
that	O
vaccines	B-CHEM
containing	O
serotypes	O
O1	O
and	O
O8	O
should	O
be	O
evaluated	O
in	O
both	O
rainbow	B-LIVB
trout	I-LIVB
and	O
Atlantic	B-LIVB
salmon	I-LIVB
for	O
application	O
in	O
Scotland	B-GEOG
.	O

Vaccination	B-PROC
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic	B-LIVB
salmon	I-LIVB
against	O
the	O
bacterial	B-LIVB
pathogen	O
Yersinia	B-LIVB
ruckeri	I-LIVB
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	O
incidence	O
of	O
vaccine	B-CHEM
breakdown	O
in	O
salmon	B-LIVB
.	O

This	O
is	O
largely	O
because	O
current	O
vaccines	B-CHEM
are	O
aimed	O
at	O
rainbow	B-LIVB
trout	I-LIVB
and	O
are	O
based	O
on	O
serotypes	O
specific	O
for	O
this	O
species	O
.	O

A	O
wider	O
range	O
of	O
serotypes	O
is	O
responsible	O
for	O
infection	B-DISO
in	O
Atlantic	B-LIVB
salmon	I-LIVB
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	B-LIVB
and	O
their	O
relationships	O
to	O
those	O
recovered	O
from	O
rainbow	B-LIVB
trout	I-LIVB
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
isolates	B-CHEM
recovered	O
from	O
diseased	B-DISO
Atlantic	B-LIVB
salmon	I-LIVB
in	O
Scotland	B-GEOG
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	B-LIVB
trout	I-LIVB
;	O
furthermore	O
,	O
isolates	B-CHEM
from	O
the	O
two	O
species	O
represent	O
distinct	O
subpopulations	B-LIVB
.	O

In	O
addition	O
,	O
a	O
new	O
O	O
serotype	O
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
the	O
disease	B-DISO
in	O
Atlantic	B-LIVB
salmon	I-LIVB
.	O

Our	O
findings	B-DISO
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	B-PROC
of	I-PROC
improved	I-PROC
vaccines	I-PROC
against	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
.	O

Making	O
use	O
of	O
longitudinal	O
information	O
in	O
pattern	B-PHYS
recognition	I-PHYS
Longitudinal	O
designs	O
are	O
widely	O
used	O
in	O
medical	B-PROC
studies	I-PROC
as	O
a	O
means	O
of	O
observing	O
within	O
-	O
subject	B-LIVB
changes	O
over	O
time	O
in	O
groups	O
of	O
subjects	B-LIVB
,	O
thereby	O
aiming	O
to	O
improve	O
sensitivity	O
for	O
detecting	O
disease	B-DISO
effects	O
.	O

Paralleling	B-PROC
an	O
increased	O
use	O
of	O
such	O
studies	O
in	O
neuroimaging	B-PROC
has	O
been	O
the	O
adoption	O
of	O
pattern	O
recognition	O
algorithms	O
for	O
making	O
individualized	O
predictions	O
of	O
disease	B-DISO
.	O

However	O
,	O
at	O
present	O
few	O
pattern	O
recognition	O
methods	O
exist	O
to	O
make	O
full	O
use	O
of	O
neuroimaging	B-PROC
data	O
that	O
have	O
been	O
collected	O
longitudinally	O
,	O
with	O
most	O
methods	O
relying	O
instead	O
on	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
style	I-PROC
analysis	I-PROC
.	O

This	O
article	O
presents	O
a	O
principal	O
component	O
analysis	O
-based	O
feature	O
construction	O
method	O
that	O
uses	O
longitudinal	O
high	O
-	O
dimensional	O
data	O
to	O
improve	O
predictive	O
performance	O
of	O
pattern	O
recognition	O
algorithms	O
.	O

The	O
method	O
can	O
be	O
applied	O
to	O
data	O
from	O
a	O
wide	O
range	O
of	O
longitudinal	O
study	O
designs	O
and	O
permits	O
an	O
arbitrary	O
number	O
of	O
time	O
-	O
points	O
per	O
subject	B-LIVB
.	O

We	O
apply	O
the	O
method	O
to	O
two	O
longitudinal	O
datasets	O
,	O
one	O
containing	O
subjects	B-LIVB
with	O
mild	B-DISO
cognitive	I-DISO
impairment	I-DISO
along	O
with	O
healthy	O
controls	O
,	O
the	O
other	O
with	O
early	O
dementia	B-DISO
subjects	B-LIVB
and	O
healthy	O
controls	O
.	O

Across	O
both	O
datasets	O
,	O
we	O
show	O
improvements	O
in	O
predictive	O
accuracy	O
relative	O
to	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
classifiers	O
for	O
discriminating	O
disease	B-LIVB
subjects	I-LIVB
from	O
healthy	O
controls	O
on	O
the	O
basis	O
of	O
whole	O
-	O
brain	B-ANAT
structural	O
magnetic	B-PROC
resonance	I-PROC
image	I-PROC
-based	O
voxels	O
.	O

In	O
addition	O
,	O
we	O
can	O
transfer	O
longitudinal	O
information	O
from	O
one	O
set	O
of	O
subjects	B-LIVB
to	O
make	O
disease	B-DISO
predictions	O
in	O
another	O
set	O
of	O
subjects	B-LIVB
.	O

The	O
proposed	O
method	O
is	O
simple	O
and	O
,	O
as	O
a	O
feature	O
construction	O
method	O
,	O
flexible	O
with	O
respect	O
to	O
the	O
choice	O
of	O
classifier	O
and	O
image	O
registration	O
algorithm	O
.	O

Hum	O
Brain	O
Mapp	O
,	O
2016	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Protective	O
effect	O
of	O
epigallocatechin	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
gallate	I-CHEM
(	O
EGCG	B-CHEM
)	O
via	O
Nrf2	B-CHEM
pathway	B-PHYS
against	O
oxalate	B-CHEM
-induced	O
epithelial	B-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O
EMT	B-PHYS
)	O
of	O
renal	B-ANAT
tubular	B-ANAT
cells	I-ANAT
This	O
study	B-PROC
evaluated	O
effect	O
of	O
oxalate	B-CHEM
on	O
epithelial	B-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O
EMT	B-PHYS
)	O
and	O
potential	O
anti	B-DISO
-	I-DISO
fibrotic	I-DISO
property	I-DISO
of	O
epigallocatechin	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
gallate	I-CHEM
(	O
EGCG	B-CHEM
)	O
.	O

MDCK	B-ANAT
renal	I-ANAT
tubular	I-ANAT
cells	I-ANAT
were	O
incubated	B-PROC
with	O
0	O
.	O

5	O
mM	O
sodium	B-CHEM
oxalate	I-CHEM
for	O
24	O
-	O
h	O
with	O
/	O
without	O
1	O
-	O
h	O
pretreatment	O
with	O
25	O
μM	O
EGCG	B-CHEM
.	O

Microscopic	B-PROC
examination	I-PROC
,	O
immunoblotting	B-PROC
and	O
immunofluorescence	B-PROC
staining	I-PROC
revealed	O
that	O
oxalate	B-CHEM
-treated	O
cells	B-ANAT
gained	O
mesenchymal	B-ANAT
phenotypes	B-PHYS
by	O
fibroblast	B-ANAT
-like	O
morphological	B-DISO
change	I-DISO
and	O
increasing	O
expression	B-PHYS
of	O
vimentin	B-CHEM
and	O
fibronectin	B-CHEM
,	O
while	O
levels	O
of	O
epithelial	B-CHEM
markers	I-CHEM
(	O
E	B-CHEM
-	I-CHEM
cadherin	I-CHEM
,	O
occludin	B-CHEM
,	O
cytokeratin	B-CHEM
and	O
ZO	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
were	O
decreased	O
.	O

EGCG	B-CHEM
pretreatment	O
could	O
prevent	O
all	O
these	O
changes	O
and	O
molecular	B-PHYS
mechanisms	I-PHYS
underlying	O
the	O
prevention	O
by	O
EGCG	B-CHEM
were	O
most	O
likely	O
due	O
to	O
reduced	O
production	B-PHEN
of	O
intracellular	B-CHEM
ROS	I-CHEM
through	O
activation	O
of	O
Nrf2	B-CHEM
signaling	B-PHEN
and	O
increased	O
catalase	B-CHEM
anti	I-CHEM
-	I-CHEM
oxidant	I-CHEM
enzyme	I-CHEM
.	O

Knockdown	B-PROC
of	O
Nrf2	O
by	O
small	B-CHEM
interfering	I-CHEM
RNA	I-CHEM
(	O
siRNA	B-CHEM
)	O
abrogated	O
all	O
the	O
effects	O
of	O
EGCG	B-CHEM
,	O
confirming	O
that	O
the	O
EGCG	B-CHEM
protection	B-DISO
against	O
oxalate	B-CHEM
-induced	O
EMT	B-PHYS
was	O
mediated	O
via	O
Nrf2	B-CHEM
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
oxalate	B-CHEM
turned	O
on	O
EMT	B-PHYS
of	O
renal	B-ANAT
tubular	B-ANAT
cells	I-ANAT
that	O
could	O
be	O
prevented	O
by	O
EGCG	B-CHEM
via	O
Nrf2	B-CHEM
pathway	B-PHYS
.	O

These	O
findings	O
also	O
shed	O
light	O
onto	O
development	O
of	O
novel	O
therapeutics	O
or	O
preventive	O
strategies	O
of	O
renal	B-DISO
fibrosis	I-DISO
in	O
the	O
future	O
.	O

CD84	B-CHEM
mediates	O
CLL	B-DISO
-	O
microenvironment	B-PHEN
interactions	B-PHYS
Chronic	B-DISO
lymphocytic	I-DISO
leukemia	I-DISO
(	O
CLL	B-DISO
)	O
is	O
a	O
malignant	B-DISO
disease	I-DISO
of	O
small	O
mature	B-ANAT
lymphocytes	I-ANAT
.	O

Signals	B-PHEN
from	O
the	O
CLL	B-DISO
microenvironment	B-PHEN
promote	O
progression	B-DISO
of	I-DISO
the	I-DISO
disease	I-DISO
and	O
induce	O
drug	B-PHEN
resistance	I-PHEN
.	O

This	O
phenomenon	B-PHEN
is	O
largely	O
dependent	O
on	O
direct	O
contact	O
between	O
the	O
malignant	B-DISO
B	I-DISO
cells	I-DISO
and	O
stromal	B-ANAT
cells	I-ANAT
.	O

CD84	B-CHEM
belongs	O
to	O
the	O
signaling	B-CHEM
lymphocyte	I-CHEM
activation	I-CHEM
molecule	I-CHEM
family	I-CHEM
of	O
immunoreceptors	B-CHEM
,	O
which	O
self	B-PHYS
-	I-PHYS
associates	I-PHYS
,	O
forming	O
an	O
orthogonal	B-CHEM
homophilic	I-CHEM
dimer	I-CHEM
.	O

We	O
therefore	O
hypothesized	O
that	O
CD84	B-CHEM
may	O
bridge	O
between	O
CLL	B-DISO
cells	B-ANAT
and	O
their	O
microenvironment	B-PHEN
,	O
promoting	O
cell	B-PHYS
survival	I-PHYS
.	O

Our	O
in	O
vitro	O
results	O
show	O
that	O
CD84	B-PHYS
expressed	I-PHYS
on	O
CLL	B-DISO
cells	B-ANAT
interact	O
with	O
CD84	B-PHYS
expressed	I-PHYS
on	O
cells	B-ANAT
in	O
their	O
microenvironment	B-PHEN
,	O
inducing	O
cell	B-PHYS
survival	I-PHYS
in	O
both	O
sides	O
.	O

Blocking	O
CD84	B-CHEM
in	O
vitro	O
and	O
in	O
vivo	O
disrupt	O
the	O
interaction	O
of	O
CLL	B-DISO
cells	B-ANAT
with	O
their	O
microenvironment	B-PHEN
,	O
resulting	O
in	O
induced	O
cell	B-PHYS
death	I-PHYS
.	O

Thus	O
,	O
our	O
findings	B-DISO
suggest	O
novel	O
therapeutic	O
strategies	O
based	O
on	O
the	O
blockade	B-CHEM
of	O
this	O
CD84	B-CHEM
-	O
dependent	O
survival	B-PHYS
pathway	B-PHYS
.	O

A	O
review	O
of	O
risk	B-DISO
factors	I-DISO
for	O
bovine	B-DISO
tuberculosis	I-DISO
infection	B-DISO
in	O
cattle	B-LIVB
in	O
the	O
UK	B-GEOG
and	O
Ireland	B-GEOG
Bovine	B-DISO
tuberculosis	I-DISO
(	O
bTB	B-DISO
)	O
is	O
an	O
important	O
disease	B-DISO
of	O
cattle	B-LIVB
caused	O
by	O
infection	B-DISO
with	O
Mycobacterium	B-LIVB
bovis	I-LIVB
,	O
a	O
pathogen	B-LIVB
that	O
may	O
be	O
extremely	O
difficult	O
to	O
eradicate	O
in	O
the	O
presence	B-DISO
of	O
a	O
true	O
wildlife	B-LIVB
reservoir	B-GEOG
.	O

Our	O
objective	O
was	O
to	O
identify	B-DISO
and	O
review	O
relevant	O
literature	O
and	O
provide	O
a	O
succinct	O
summary	O
of	O
current	O
knowledge	O
of	O
risk	B-DISO
factors	I-DISO
for	O
transmission	B-DISO
of	O
infection	B-DISO
of	O
cattle	B-LIVB
.	O

Search	O
strings	O
were	O
developed	O
to	O
identify	B-DISO
publications	B-OBJC
from	O
electronic	O
databases	O
to	O
February	O
2015	O
.	O

Abstracts	O
of	O
4255	O
papers	O
identified	O
were	O
reviewed	O
by	O
three	O
reviewers	B-LIVB
to	O
determine	O
whether	O
the	O
entire	O
article	O
was	O
likely	O
to	O
contain	O
relevant	O
information	O
.	O

Risk	B-DISO
factors	I-DISO
could	O
be	O
broadly	O
grouped	O
as	O
follows	O
:	O
animal	B-LIVB
(	O
including	O
nutrition	B-DISO
and	O
genetics	O
)	O
,	O
herd	O
(	O
including	O
bTB	B-DISO
and	O
testing	O
history	O
)	O
,	O
environment	O
,	O
wildlife	B-LIVB
and	O
social	O
factors	O
.	O

Many	O
risk	B-DISO
factors	I-DISO
are	O
inter	O
-	O
related	O
and	O
study	B-PROC
designs	I-PROC
often	O
do	O
not	O
enable	O
differentiation	O
between	O
cause	O
and	O
consequence	O
of	O
infection	B-DISO
.	O

Despite	O
differences	O
in	O
study	B-PROC
design	I-PROC
and	O
location	O
,	O
some	O
risk	B-DISO
factors	I-DISO
are	O
consistently	O
identified	O
,	O
e	O
.	O

g	O
.	O

herd	O
size	O
,	O
bTB	B-DISO
history	O
,	O
presence	O
of	O
infected	B-DISO
wildlife	B-LIVB
,	O
whereas	O
the	O
evidence	O
for	O
others	O
is	O
less	O
consistent	O
and	O
coherent	B-DISO
,	O
e	O
.	O

g	O
.	O

nutrition	B-DISO
,	O
local	O
cattle	B-LIVB
movements	B-PHYS
.	O

We	O
have	O
identified	O
knowledge	O
gaps	O
where	O
further	O
research	B-PROC
may	O
result	O
in	O
an	O
improved	O
understanding	O
of	O
bTB	B-DISO
transmission	B-DISO
dynamics	B-PHEN
.	O

The	O
application	O
of	O
targeted	O
,	O
multifactorial	B-DISO
disease	B-DISO
control	O
regimens	O
that	O
address	O
a	O
range	O
of	O
risk	B-DISO
factors	I-DISO
simultaneously	O
is	O
likely	O
to	O
be	O
a	O
key	O
to	O
effective	O
,	O
evidence	O
-informed	O
control	O
strategies	O
.	O

Aurantimonas	B-LIVB
endophytica	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O
a	O
novel	O
endophytic	B-LIVB
bacterium	I-LIVB
isolated	O
from	O
roots	B-LIVB
of	O
Anabasis	B-LIVB
elatior	I-LIVB
(	I-LIVB
C	I-LIVB
.	I-LIVB

A	I-LIVB
.	I-LIVB

Mey	I-LIVB
.	I-LIVB
)	I-LIVB
Schischk	I-LIVB
An	O
orange	O
-	O
coloured	O
,	O
aerobic	O
,	O
motile	B-DISO
and	O
short	B-LIVB
-	I-LIVB
rods	I-LIVB
bacterial	I-LIVB
strain	I-LIVB
,	O
designated	O
EGI	B-LIVB
6500337	I-LIVB
T	I-LIVB
,	O
was	O
isolated	O
from	O
the	O
surface	O
-	O
sterilized	O
root	B-LIVB
of	O
a	O
halophyte	B-LIVB
Anabasis	B-LIVB
elatior	I-LIVB
(	I-LIVB
C	I-LIVB
.	I-LIVB

A	I-LIVB
.	I-LIVB

Mey	I-LIVB
.	I-LIVB
)	I-LIVB
Schischk	I-LIVB
collected	O
from	O
Urumqi	B-GEOG
,	O
Xinjiang	B-GEOG
province	I-GEOG
,	O
north	B-GEOG
-	I-GEOG
west	I-GEOG
China	I-GEOG
.	O

Growth	B-PHYS
occurred	O
at	O
5	O
-	O
35	O
°	O
C	O
(	O
optimum	O
30	O
°	O
C	O
)	O
,	O
at	O
pH	O
6	O
.	O
0	O
-	O
9	O
.	O
0	O
(	O
optimum	O
pH	O
7	O
.	O
0	O
)	O
,	O
and	O
in	O
the	O
presence	O
of	O
0	O
-	O
6	O
%	O
NaCl	B-CHEM
(	O
w	O
/	O
v	O
)	O
(	O
optimum	O
0	O
-	O
1	O
%	O
)	O
.	O

Phylogenetic	O
tree	O
based	O
on	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequences	O
indicated	O
that	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
formed	O
a	O
distinct	O
lineage	O
in	O
the	O
cluster	O
that	O
comprised	O
the	O
genera	B-LIVB
Aurantimonas	I-LIVB
and	O
Aureimonas	B-LIVB
in	O
the	O
family	B-LIVB
Aurantimonadaceae	I-LIVB
.	O

The	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequence	O
of	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
shared	O
the	O
highest	O
similarities	O
to	O
those	O
of	O
Aurantimonas	B-LIVB
coralicida	I-LIVB
DSM	I-LIVB
14790	I-LIVB
T	I-LIVB
(	O
97	O
.	O
15	O
%	O
)	O
and	O
Aurantimonas	B-LIVB
manganoxydans	I-LIVB
DSM	I-LIVB
21871	I-LIVB
T	I-LIVB
(	O
97	O
.	O
15	O
%	O
)	O
.	O

Strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
contained	O
Q	B-CHEM
-	I-CHEM
10	I-CHEM
as	O
the	O
dominant	O
isoprenoid	B-CHEM
quinone	I-CHEM
.	O

The	O
major	O
cellular	O
fatty	B-CHEM
acids	I-CHEM
were	O
C18	B-CHEM
:	I-CHEM
1	I-CHEM
7c	I-CHEM
(	O
66	O
.	O

4	O
%	O
)	O
and	O
C19	B-CHEM
:	I-CHEM
0	I-CHEM
8c	I-CHEM
cyclo	I-CHEM
(	O
23	O
.	O
3	O
%	O
)	O
.	O

The	O
polar	O
lipid	B-CHEM
profile	I-CHEM
of	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
contained	O
diphosphatidylglycerol	B-CHEM
,	O
phosphatidylglycerol	B-CHEM
,	O
phosphatidylcholine	B-CHEM
,	O
phosphatidylethanolamine	B-CHEM
as	O
major	O
components	O
,	O
similarly	O
to	O
the	O
members	O
of	O
the	O
genus	B-LIVB
Aurantimonas	I-LIVB
.	O

The	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
was	O
66	O
.	O

8	O
mol	O
%	O
.	O

The	O
DNA	B-CHEM
-	O
DNA	B-CHEM
relatedness	O
between	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
and	O
Aurantimonas	B-LIVB
coralicida	I-LIVB
DSM	I-LIVB
14790	I-LIVB
T	I-LIVB
was	O
24	O
.	O

7	O
±	O
2	O
.	O
9	O
%	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	B-PROC
analysis	I-PROC
,	O
chemotaxonomic	O
data	O
and	O
phenotypic	B-PHYS
characteristics	I-PHYS
,	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	B-LIVB
Aurantimonas	I-LIVB
,	O
for	O
which	O
the	O
name	O
Aurantimonas	B-LIVB
endophytica	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O
proposed	O
.	O

The	O
type	O
strain	B-LIVB
is	O
EGI	B-LIVB
6500337	I-LIVB
T	I-LIVB
(	O
=	O
KCTC	B-LIVB
52296	I-LIVB
T	I-LIVB
=	O
CPCC	B-LIVB
100904	I-LIVB
T	I-LIVB
)	O
.	O

Infectivity	O
,	O
effects	O
on	O
helper	B-LIVB
viruses	I-LIVB
and	O
whitefly	O
transmission	B-PHYS
of	O
the	O
deltasatellites	B-LIVB
associated	O
with	O
sweepoviruses	B-LIVB
(	O
genus	O
Begomovirus	B-LIVB
,	O
family	B-LIVB
Geminiviridae	I-LIVB
)	O
Begomoviruses	B-LIVB
(	O
family	O
Geminiviridae	B-LIVB
)	O
are	O
whitefly	O
-	O
transmitted	B-PHYS
viruses	B-LIVB
with	O
single	B-ANAT
-	I-ANAT
stranded	I-ANAT
DNA	I-ANAT
genomes	I-ANAT
that	O
are	O
frequently	O
associated	O
with	O
DNA	B-CHEM
satellites	I-CHEM
.	O

These	O
satellites	B-LIVB
include	O
non	O
-	O
coding	O
satellites	O
,	O
for	O
which	O
the	O
name	O
deltasatellites	B-LIVB
has	O
been	O
proposed	O
.	O

Although	O
the	O
first	O
deltasatellite	B-LIVB
was	O
identified	O
in	O
the	O
late	O
1990s	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
they	O
have	O
on	O
infections	B-DISO
of	O
their	O
helper	B-LIVB
begomoviruses	B-LIVB
.	O

Recently	O
a	O
group	O
of	O
deltasatellites	B-LIVB
were	O
identified	O
associated	O
with	O
sweepoviruses	B-LIVB
,	O
a	O
group	O
of	O
phylogenetically	O
distinct	O
begomoviruses	B-LIVB
that	O
infect	B-DISO
plants	B-LIVB
of	O
the	O
family	B-LIVB
Convolvulaceae	I-LIVB
including	O
sweet	B-LIVB
potato	I-LIVB
.	O

In	O
this	O
work	O
,	O
the	O
deltasatellites	B-LIVB
associated	O
with	O
sweepoviruses	B-LIVB
are	O
shown	O
to	O
be	O
transreplicated	B-PHYS
and	O
maintained	O
in	O
plants	B-LIVB
by	O
the	O
virus	B-LIVB
with	O
which	O
they	O
were	O
identified	O
,	O
sweet	B-LIVB
potato	I-LIVB
leaf	I-LIVB
curl	I-LIVB
virus	I-LIVB
(	O
SPLCV	B-LIVB
)	O
.	O

These	O
deltasatellites	B-LIVB
were	O
shown	O
generally	O
to	O
reduce	O
symptom	B-DISO
severity	I-DISO
of	O
the	O
virus	B-DISO
infection	I-DISO
by	O
reducing	O
virus	B-CHEM
DNA	I-CHEM
levels	O
.	O

Additionally	O
they	O
were	O
shown	O
to	O
be	O
maintained	O
in	O
plants	B-LIVB
,	O
and	O
reduce	O
the	O
symptoms	B-DISO
induced	O
by	O
two	O
Old	B-LIVB
World	I-LIVB
monopartite	I-LIVB
begomoviruses	I-LIVB
,	O
tomato	B-LIVB
yellow	I-LIVB
leaf	I-LIVB
curl	I-LIVB
virus	I-LIVB
and	O
tomato	B-LIVB
yellow	I-LIVB
leaf	I-LIVB
curl	I-LIVB
Sardinia	I-LIVB
virus	I-LIVB
.	O

Finally	O
one	O
of	O
the	O
satellites	B-LIVB
was	O
shown	O
to	O
be	O
transmitted	B-PHYS
plant	B-LIVB
-to	O
-	O
plant	B-LIVB
in	O
the	O
presence	O
of	O
SPLCV	B-LIVB
by	O
the	O
whitefly	O
vector	B-CHEM
of	I-CHEM
the	I-CHEM
virus	I-CHEM
,	O
Bemisia	O
tabaci	O
,	O
being	O
the	O
first	O
time	O
a	O
deltasatellite	B-LIVB
has	O
been	O
shown	O
to	O
be	O
insect	O
transmitted	B-PHYS
.	O

Reintervention	B-PROC
after	O
endovascular	B-PROC
repair	I-PROC
for	O
aortic	B-DISO
dissection	I-DISO
:	O
A	O
systematic	O
review	O
and	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
Thoracic	B-PROC
endovascular	I-PROC
aortic	I-PROC
repair	I-PROC
has	O
been	O
chosen	O
as	O
a	O
less	O
-	O
invasive	O
alternative	O
to	O
open	B-PROC
surgery	I-PROC
for	O
the	O
treatment	O
of	O
aortic	B-DISO
dissections	I-DISO
;	O
however	O
,	O
the	O
advantages	O
have	O
been	O
challenged	O
by	O
the	O
postoperative	O
reintervention	B-PROC
during	O
the	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
.	O

This	O
study	O
aimed	O
at	O
evaluating	O
the	O
incidence	O
,	O
reasons	O
,	O
and	O
potential	O
risk	B-DISO
factors	I-DISO
for	O
reintervention	B-PROC
.	O

Studies	O
reporting	O
reintervention	B-PROC
after	O
endovascular	B-PROC
repair	I-PROC
were	O
identified	O
by	O
searching	O
PubMed	O
and	O
Embase	O
in	O
accordance	O
with	O
preferred	O
reporting	O
items	O
for	O
systematic	O
reviews	O
and	O
meta	B-PROC
-	I-PROC
analyses	I-PROC
guidelines	O
,	O
and	O
by	O
reviewing	O
the	O
reference	O
lists	O
of	O
retrieved	O
articles	O
.	O

Sensitivity	O
analysis	B-PROC
and	O
subgroup	O
analyses	B-PROC
were	O
performed	O
to	O
determine	O
the	O
sources	B-DISO
of	O
heterogeneity	O
.	O

Funnel	O
plot	O
and	O
Egger	O
's	O
test	O
were	O
used	O
to	O
determine	O
the	O
publication	O
bias	O
.	O

A	O
total	O
of	O
27	O
studies	O
encompassing	O
2403	O
patients	B-LIVB
with	O
aortic	B-DISO
dissection	I-DISO
were	O
identified	O
.	O

The	O
pooled	O
incidence	O
of	O
reintervention	B-PROC
after	O
endovascular	B-PROC
repair	I-PROC
was	O
15	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
12	O
-	O
19	O
)	O
during	O
33	O
.	O

7	O
months	O
of	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

The	O
3	O
most	O
common	O
reasons	O
for	O
reintervention	B-PROC
were	O
endoleak	B-DISO
(	O
33	O
.	O
2	O
%	O
)	O
,	O
false	B-DISO
lumen	I-DISO
perfusion	I-DISO
and	O
aortic	B-DISO
dilation	I-DISO
(	O
19	O
.	O
8	O
%	O
)	O
,	O
and	O
new	O
dissection	B-DISO
(	O
6	O
.	O
9	O
%	O
)	O
.	O

The	O
potential	O
factors	O
for	O
reintervention	B-PROC
were	O
the	O
mean	O
age	O
of	O
onset	O
and	O
diabetes	B-DISO
mellitus	I-DISO
determined	O
by	O
performing	O
a	O
single	O
meta	O
-	O
regression	O
analysis	O
(	O
P	O
<	O
.001	O
and	O
.044	O
,	O
respectively	O
)	O
.	O

Current	O
data	O
suggest	O
that	O
the	O
incidence	O
of	O
reintervention	B-PROC
after	O
endovascular	B-PROC
therapy	I-PROC
is	O
relatively	O
high	O
during	O
midterm	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Advanced	O
age	O
of	O
onset	O
is	O
a	O
risk	B-DISO
factor	I-DISO
and	O
diabetes	B-DISO
mellitus	I-DISO
is	O
a	O
protective	O
factor	O
of	O
reintervention	B-PROC
after	O
endovascular	B-PROC
therapy	I-PROC
.	O

The	O
possible	O
mechanism	O
that	O
diabetes	B-DISO
mellitus	I-DISO
protects	O
patients	B-LIVB
from	O
reintervention	B-PROC
should	O
be	O
explored	O
further	O
.	O

Assessment	B-PROC
and	O
classification	O
of	O
protocol	B-DISO
deviations	I-DISO
Deviations	B-DISO
from	O
the	O
approved	O
trial	O
protocol	O
are	O
common	O
during	O
clinical	B-PROC
trials	I-PROC
.	O

They	O
have	O
been	O
conventionally	O
classified	O
as	O
deviations	B-DISO
or	O
violations	B-PROC
,	O
depending	O
on	O
their	O
impact	O
on	O
the	O
trial	B-PROC
.	O

A	O
new	O
method	O
has	O
been	O
proposed	O
by	O
which	O
deviations	B-DISO
are	O
classified	O
in	O
five	O
grades	O
from	O
1	O
to	O
5	O
.	O

A	O
deviation	B-DISO
of	O
Grade	B-DISO
1	I-DISO
has	O
no	B-DISO
impact	O
on	O
the	O
subjects	B-LIVB
'	I-LIVB
well	B-DISO
-	I-DISO
being	I-DISO
or	O
on	O
the	O
quality	O
of	O
data	O
.	O

At	O
the	O
maximum	O
,	O
a	O
deviation	B-DISO
Grade	O
5	O
leads	O
to	O
the	O
death	B-DISO
of	O
the	O
subject	B-LIVB
.	O

This	O
method	O
of	O
classification	O
was	O
applied	O
to	O
deviations	B-DISO
noted	O
in	O
the	O
center	O
over	O
the	O
last	O
3	O
years	O
.	O

It	O
was	O
observed	O
that	O
most	O
deviations	B-DISO
were	O
of	O
Grades	O
1	O
and	O
2	O
,	O
with	O
fewer	O
falling	O
in	O
Grades	O
3	O
and	O
4	O
.	O

There	O
were	O
no	O
deviations	B-DISO
that	O
led	O
to	O
the	O
death	B-DISO
of	I-DISO
the	I-DISO
subject	I-DISO
(	O
Grade	O
5	O
)	O
.	O

This	O
method	O
of	O
classification	O
would	O
help	O
trial	B-PROC
managers	B-LIVB
decide	O
on	O
the	O
action	O
to	O
be	O
taken	O
on	O
the	O
occurrence	O
of	O
deviations	B-DISO
,	O
which	O
would	O
be	O
based	O
on	O
their	O
impact	O
.	O

Optimizing	O
Prone	O
Cardiopulmonary	B-PROC
Resuscitation	I-PROC
:	O
Identifying	O
the	O
Vertebral	B-ANAT
Level	I-ANAT
Correlating	O
With	O
the	O
Largest	O
Left	B-ANAT
Ventricle	I-ANAT
Cross	O
-	O
Sectional	O
Area	O
via	O
Computed	B-PROC
Tomography	I-PROC
Scan	I-PROC
Placing	O
the	O
patient	B-LIVB
in	O
the	O
prone	O
position	O
frequently	O
is	O
required	O
for	O
some	O
surgical	B-PROC
procedures	I-PROC
.	O

If	O
cardiac	B-DISO
arrest	I-DISO
occurs	O
and	O
the	O
patient	B-LIVB
cannot	O
be	O
safely	O
turned	O
supine	O
,	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
(	O
CPR	B-PROC
)	O
may	O
need	O
to	O
be	O
performed	O
with	O
the	O
patient	B-LIVB
in	O
the	O
prone	O
position	O
.	O

Although	O
clear	O
landmarks	O
have	O
been	O
defined	O
for	O
supine	O
CPR	B-PROC
,	O
the	O
optimal	O
hand	O
position	O
for	O
CPR	B-PROC
in	O
the	O
prone	O
position	O
has	O
not	O
been	O
clearly	O
determined	O
.	O

The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
determine	O
anatomically	O
the	O
optimal	O
hand	O
position	O
for	O
CPR	B-PROC
in	O
the	O
prone	O
position	O
.	O

We	O
reviewed	O
retrospectively	O
the	O
chest	B-PROC
computed	I-PROC
tomography	I-PROC
images	B-OBJC
of	O
100	O
patients	B-LIVB
taken	O
in	O
the	O
prone	O
position	O
.	O

The	O
vertebral	B-ANAT
body	I-ANAT
levels	I-ANAT
crossing	O
the	O
medial	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
,	O
the	O
inferior	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
,	O
and	O
the	O
spinous	B-ANAT
process	I-ANAT
of	O
the	O
vertebral	B-ANAT
body	I-ANAT
connected	O
to	O
the	O
most	B-ANAT
inferior	I-ANAT
rib	I-ANAT
were	O
identified	O
,	O
and	O
we	O
selected	O
the	O
image	O
level	O
at	O
which	O
the	O
left	B-ANAT
ventricular	I-ANAT
(	O
LV	B-ANAT
)	O
cross	O
-	O
sectional	O
area	O
was	O
the	O
largest	O
.	O

This	O
level	O
was	O
defined	O
as	O
the	O
optimal	O
compression	B-PHEN
level	O
and	O
correlated	O
to	O
surface	O
anatomical	B-ANAT
landmarks	I-ANAT
.	O

We	O
calculated	B-PROC
the	O
ratio	O
of	O
the	O
distance	O
from	O
the	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O
the	O
level	O
of	O
the	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
divided	O
by	O
the	O
distance	O
from	O
the	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O
the	O
spinous	B-ANAT
process	I-ANAT
of	O
the	O
vertebral	B-ANAT
body	I-ANAT
connected	O
with	O
the	O
most	B-ANAT
inferior	I-ANAT
rib	I-ANAT
.	O

The	O
level	O
of	O
the	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
in	O
the	O
prone	O
position	O
was	O
1	B-ANAT
vertebral	I-ANAT
segment	I-ANAT
below	O
the	O
inferior	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
in	O
45	O
%	O
(	O
99	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
33	O
-	O
58	O
)	O
of	O
patients	B-LIVB
and	O
0	B-ANAT
to	I-ANAT
2	I-ANAT
vertebral	I-ANAT
segments	I-ANAT
below	O
that	O
in	O
95	O
%	O
(	O
99	O
%	O
CI	O
,	O
86	O
-	O
98	O
)	O
of	O
patients	B-LIVB
.	O

The	O
mean	O
(	O
SD	O
)	O
ratio	O
of	O
the	O
distance	O
from	O
the	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O
the	O
level	O
of	O
the	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
divided	O
by	O
the	O
distance	O
from	O
the	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O
T12	B-ANAT
spinous	I-ANAT
process	I-ANAT
was	O
67	O
%	O
±	O
7	O
%	O
(	O
99	O
%	O
CI	O
,	O
65	O
-	O
69	O
)	O
.	O

When	O
the	O
patient	B-LIVB
is	O
positioned	O
prone	O
,	O
the	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
is	O
0	B-ANAT
to	I-ANAT
2	I-ANAT
vertebral	I-ANAT
segments	I-ANAT
below	O
the	O
inferior	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
in	O
at	O
least	O
86	O
%	O
of	O
patients	B-LIVB
.	O

Further	O
studies	B-PROC
are	O
needed	O
to	O
determine	O
whether	O
this	O
position	O
is	O
optimal	O
for	O
chest	B-PROC
compressions	I-PROC
in	O
the	O
prone	O
position	O
.	O

12	B-PROC
-	I-PROC
Lead	I-PROC
electrocardiogram	I-PROC
as	O
a	O
predictor	O
of	O
sudden	B-DISO
cardiac	I-DISO
death	I-DISO
:	O
from	O
epidemiology	O
to	O
clinical	B-PROC
practice	I-PROC
Sudden	B-DISO
cardiac	I-DISO
death	I-DISO
(	O
SCD	B-DISO
)	O
causes	O
a	O
high	O
burden	O
of	O
premature	B-DISO
deaths	I-DISO
in	O
the	O
population	B-LIVB
affecting	O
subjects	O
of	O
all	O
ages	B-LIVB
.	O

The	O
identification	O
of	O
subjects	O
at	O
high	O
risk	B-PROC
for	O
SCD	B-DISO
is	O
of	O
great	O
importance	O
as	O
the	O
prevention	O
of	O
many	O
of	O
these	O
events	O
would	O
be	O
possible	O
with	O
the	O
treatment	B-PROC
of	O
underlying	O
cardiac	B-DISO
diseases	I-DISO
and	O
the	O
use	O
of	O
implantable	B-DEVI
cardioverter	I-DEVI
-	I-DEVI
defibrillators	I-DEVI
(	O
ICD	B-DEVI
)	O
.	O

However	O
,	O
the	O
current	O
selection	O
of	O
patients	B-LIVB
for	O
ICD	B-DEVI
therapy	B-PROC
is	O
based	O
solely	O
on	O
left	B-PHYS
ventricular	I-PHYS
ejection	I-PHYS
fraction	I-PHYS
,	O
and	O
thus	O
a	O
substantial	O
portion	O
of	O
patients	B-LIVB
at	O
high	O
risk	B-PROC
does	O
not	O
qualify	O
for	O
the	O
therapy	B-PROC
.	O

Role	O
of	O
the	O
standard	B-PROC
electrocardiogram	I-PROC
(	O
ECG	B-PROC
)	O
in	O
SCD	B-DISO
risk	B-PROC
stratification	B-PROC
has	O
been	O
under	O
active	O
research	B-PROC
during	O
the	O
last	O
decade	O
and	O
multiple	O
abnormalities	B-DISO
of	O
depolarization	B-DISO
and	O
repolarization	B-DISO
on	O
the	O
ECG	B-PROC
associated	O
with	O
an	O
increased	O
risk	B-PROC
of	O
SCD	B-DISO
have	O
been	O
identified	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
basic	O
pathophysiological	B-DISO
principles	O
behind	O
these	O
changes	O
.	O

We	O
also	O
review	O
the	O
current	O
knowledge	B-DISO
of	O
the	O
prognostic	O
significance	O
of	O
ECG	B-PROC
predictors	O
of	O
SCD	B-DISO
in	O
the	O
general	B-LIVB
population	I-LIVB
,	O
and	O
in	O
patients	B-LIVB
with	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
(	O
CHD	B-DISO
)	O
,	O
heart	B-DISO
failure	I-DISO
,	O
cardiomyopathies	B-DISO
,	O
and	O
in	O
inheritable	O
arrhythmia	B-DISO
syndromes	I-DISO
.	O

Also	O
,	O
insights	O
into	O
the	O
novel	O
digital	O
ECG	B-PROC
signal	B-PHEN
processing	O
techniques	O
are	O
provided	O
.	O

How	O
Can	O
We	O
Estimate	O
Sepsis	B-DISO
Incidence	O
and	O
Mortality	O
?	O
Sepsis	B-DISO
is	O
one	O
of	O
the	O
oldest	B-DISO
and	I-DISO
complex	I-DISO
syndromes	I-DISO
in	O
medicine	O
that	O
has	O
been	O
in	O
debate	O
for	O
over	O
two	O
millennia	O
.	O

Valid	O
and	O
comparable	O
data	O
on	O
the	O
population	B-LIVB
burden	O
of	O
sepsis	B-DISO
constitute	O
an	O
essential	O
resource	O
for	O
guiding	O
health	O
policy	O
and	O
resource	O
allocation	O
.	O

Despite	O
current	O
epidemiological	O
data	O
suggesting	O
that	O
the	O
global	O
burden	O
of	O
sepsis	O
is	O
huge	O
,	O
the	O
knowledge	O
of	O
its	O
incidence	O
,	O
prevalence	O
,	O
mortality	O
,	O
and	O
case	O
-	O
fatality	O
rates	O
is	O
subject	O
to	O
several	O
flaws	O
.	O

The	O
objective	O
of	O
this	O
narrative	O
review	O
is	O
to	O
assess	O
how	O
sepsis	B-DISO
incidence	O
and	O
mortality	O
can	O
be	O
estimated	O
,	O
providing	O
examples	O
on	O
how	O
it	O
has	O
been	O
done	O
so	O
far	O
in	O
medical	O
literature	O
and	O
discussing	O
its	O
possible	O
biases	O
.	O

Results	O
of	O
recent	O
studies	O
suggest	O
that	O
sepsis	B-DISO
incidence	O
rates	O
are	O
increasing	O
consistently	O
during	O
the	O
last	O
decades	O
.	O

Although	O
estimates	O
might	O
be	O
biased	O
,	O
this	O
probably	O
reflects	O
a	O
real	O
increase	O
in	O
incidence	O
over	O
time	O
.	O

Nevertheless	O
,	O
case	O
fatality	O
rates	O
have	O
decreased	O
,	O
which	O
is	O
a	O
probable	O
reflex	O
of	O
advances	O
in	O
critical	O
care	O
provision	O
to	O
this	O
very	O
sick	B-DISO
population	B-LIVB
at	O
high	B-DISO
risk	I-DISO
of	I-DISO
death	I-DISO
.	O

This	O
conclusion	O
can	O
only	O
be	O
drawn	O
with	O
a	O
reasonable	O
degree	O
of	O
certainty	O
for	O
high	B-DISO
-	I-DISO
income	I-DISO
countries	B-GEOG
.	O

Conversely	O
,	O
adequately	O
designed	O
studies	O
from	O
middle	B-DISO
-	O
and	O
low	B-DISO
-	I-DISO
income	I-DISO
countries	B-GEOG
are	O
urgently	O
needed	O
.	O

In	O
these	O
countries	B-GEOG
,	O
sepsis	B-DISO
incidence	O
and	O
case	O
-	O
fatality	O
rates	O
could	O
be	O
disproportionally	O
higher	O
due	O
to	O
health	B-DISO
care	I-DISO
provision	I-DISO
constraints	O
and	O
ineffective	O
preventive	O
measures	O
.	O

Fabrication	B-PHEN
and	O
modelling	B-PROC
of	O
fractal	O
,	O
biomimetic	O
,	O
micro	O
and	O
nano	O
-	O
topographical	O
surfaces	O
Natural	O
surface	O
topographies	O
are	O
often	O
self	O
-	O
similar	O
with	O
hierarchical	O
features	O
at	O
the	O
micro	O
and	O
nanoscale	O
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	O
tissue	B-PROC
engineering	I-PROC
and	O
biomaterial	B-CHEM
design	O
limitations	O
.	O

Specifically	O
,	O
a	O
cell	B-PHEN
's	I-PHEN
microenvironment	I-PHEN
within	O
the	O
human	B-LIVB
body	I-LIVB
contains	O
highly	O
optimised	O
,	O
fractal	B-ANAT
topographical	I-ANAT
cues	I-ANAT
,	O
which	O
directs	O
precise	O
cell	B-ANAT
behaviour	O
.	O

However	O
,	O
recreating	O
biomimetic	O
,	O
fractal	O
topographies	O
in	O
vitro	O
is	O
not	O
a	O
trivial	B-PHEN
process	I-PHEN
and	O
a	O
number	O
of	O
fabrication	B-PHEN
methods	I-PHEN
have	O
been	O
proposed	O
but	O
often	O
fail	O
to	O
precisely	O
control	O
the	O
spatial	O
resolution	O
of	O
features	O
at	O
different	O
lengths	O
scales	B-DEVI
and	O
hence	O
,	O
to	O
provide	O
true	O
biomimetic	O
properties	O
.	O

Here	O
,	O
we	O
propose	O
a	O
method	O
of	O
accurately	O
reproducing	O
the	O
self	O
-	O
similar	O
,	O
micro	O
and	O
nanoscale	O
topography	O
of	O
a	O
human	B-LIVB
biological	O
tissue	O
into	O
a	O
synthetic	B-CHEM
polymer	I-CHEM
through	O
an	O
innovative	O
fabrication	B-PHEN
process	I-PHEN
.	O

The	O
biological	O
tissue	O
surface	O
was	O
characterised	O
using	O
atomic	B-PROC
force	I-PROC
microscopy	I-PROC
(	O
AFM	B-PROC
)	O
to	O
obtain	O
spatial	O
data	O
in	O
X	O
,	O
Y	O
and	O
Z	O
,	O
which	O
was	O
converted	O
into	O
a	O
grayscale	B-OBJC
'	I-OBJC
digital	I-OBJC
photomask	I-OBJC
'	I-OBJC
.	O

As	O
a	O
result	O
of	O
maskless	O
grayscale	O
optical	O
lithography	O
followed	O
by	O
modified	B-PHEN
deep	I-PHEN
reactive	I-PHEN
ion	I-PHEN
etching	I-PHEN
and	O
replica	B-PHEN
molding	I-PHEN
,	O
we	O
were	O
able	O
to	O
accurately	O
reproduce	O
the	O
fractal	O
topography	O
of	O
acellular	O
dermal	O
matrix	O
(	O
ADM	O
)	O
into	O
polydimethylsiloxane	B-CHEM
(	O
PDMS	B-CHEM
)	O
.	O

Characterisation	O
using	O
AFM	B-PROC
at	O
three	O
different	O
length	O
scales	B-DEVI
revealed	O
that	O
the	O
nano	O
and	O
micro	O
-	O
topographical	O
features	O
,	O
in	O
addition	O
to	O
the	O
fractal	O
dimension	O
,	O
of	O
native	O
ADM	O
were	O
reproduced	O
in	O
PDMS	B-CHEM
.	O

In	O
conclusion	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal	O
topography	O
of	O
biological	O
surfaces	O
can	O
be	O
mimicked	O
in	O
synthetic	B-OBJC
materials	I-OBJC
using	O
the	O
novel	O
fabrication	B-PHEN
process	I-PHEN
outlined	O
,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical	B-DEVI
device	I-DEVI
biocompatibility	B-PHYS
and	O
performance	O
.	O

An	O
Anechoic	B-ANAT
Space	I-ANAT
at	O
the	O
Carpal	B-ANAT
Tunnel	I-ANAT
Inlet	O
is	O
a	O
Consistent	O
Ultrasonographic	B-PROC
Entity	B-OBJC
which	O
Accommodates	O
Tendon	B-DISO
Displacement	I-DISO
during	O
Finger	B-ANAT
Flexion	B-PHYS
We	O
consistently	O
observed	O
the	O
presence	O
of	O
anechoic	B-ANAT
spaces	I-ANAT
on	O
standard	O
ultrasonographic	B-PROC
imaging	I-PROC
of	O
the	O
carpal	B-ANAT
tunnel	I-ANAT
inlet	O
in	O
normal	O
subjects	B-LIVB
.	O

These	O
spaces	B-ANAT
change	O
in	O
size	O
during	O
finger	B-ANAT
flexion	B-PHYS
and	O
have	O
not	O
been	O
characterized	O
in	O
a	O
large	O
sample	O
of	O
normal	O
individuals	B-LIVB
.	O

Ultrasonographic	B-PROC
quantification	O
of	O
these	O
spaces	B-ANAT
may	O
indicate	O
the	O
available	O
space	O
in	O
the	O
region	O
of	O
the	O
carpal	B-ANAT
tunnel	I-ANAT
,	O
which	O
allows	O
the	O
normal	O
motion	B-PHYS
of	O
tendons	B-ANAT
and	O
the	O
median	B-ANAT
nerve	I-ANAT
.	O

Transverse	O
ultrasonographic	B-PROC
images	O
of	O
the	O
carpal	B-ANAT
tunnel	I-ANAT
inlet	O
from	O
33	O
asymptomatic	B-DISO
volunteers	B-LIVB
were	O
obtained	O
at	O
Position	O
A	O
(	O
fingers	B-ANAT
in	O
extension	B-PHYS
)	O
and	O
B	O
(	O
fingers	B-ANAT
in	O
flexion	B-PHYS
)	O
.	O

Cross	O
-	O
sectional	O
area	O
(	O
CSA	O
)	O
,	O
perimeter	O
and	O
position	O
of	O
anechoic	B-ANAT
space	I-ANAT
relative	O
to	O
median	B-ANAT
nerve	I-ANAT
were	O
recorded	O
.	O

Analysis	B-PROC
showed	O
a	O
75	O
.	O
4	O
%	O
prevalence	O
rate	O
of	O
a	O
single	O
anechoic	B-ANAT
space	I-ANAT
.	O

Two	O
discrete	O
patterns	O
were	O
observed	O
.	O

89	O
.	O

1	O
%	O
had	O
a	O
decrease	O
in	O
CSA	O
and	O
perimeter	O
of	O
anechoic	B-ANAT
space	I-ANAT
from	O
Position	O
A	O
to	O
B	O
while	O
10	O
.	O

9	O
%	O
exhibited	O
an	O
increase	O
.	O

Mean	O
position	O
of	O
the	O
anechoic	B-ANAT
space	I-ANAT
is	O
ulnar	B-ANAT
(	O
7	O
.	O
49	O
±	O
3	O
.	O
57	O
mm	O
)	O
and	O
dorsal	O
(	O
2	O
.	O
18	O
±	O
1	O
.	O
28	O
mm	O
)	O
to	O
the	O
median	B-ANAT
nerve	I-ANAT
.	O

A	O
consistent	O
anechoic	B-ANAT
space	I-ANAT
at	O
the	O
carpal	B-ANAT
tunnel	I-ANAT
inlet	O
is	O
seen	O
in	O
75	O
.	O

4	O
%	O
of	O
normal	O
hands	B-ANAT
and	O
can	O
be	O
quantified	O
(	O
cross	O
sectional	O
area	O
11	O
.	O

75	O
±	O
7	O
.	O
36	O
mm	O
(	O
2	O
)	O
)	O
.	O

It	O
allows	O
for	O
the	O
accommodation	O
of	O
flexor	B-ANAT
tendons	I-ANAT
during	O
finger	B-ANAT
flexion	B-PHYS
.	O

Co	B-PROC
-	I-PROC
ChIP	I-PROC
enables	O
genome	B-PROC
-	I-PROC
wide	I-PROC
mapping	I-PROC
of	O
histone	O
mark	O
co	O
-	O
occurrence	O
at	O
single	O
-	O
molecule	O
resolution	O
Histone	B-PHYS
modifications	I-PHYS
play	O
an	O
important	O
role	O
in	O
chromatin	B-PHYS
organization	I-PHYS
and	O
transcriptional	B-PHYS
regulation	I-PHYS
,	O
but	O
despite	O
the	O
large	O
amount	O
of	O
genome	O
-	O
wide	O
histone	B-PHYS
modification	I-PHYS
data	O
collected	O
in	O
different	O
cells	B-ANAT
and	O
tissues	O
,	O
little	O
is	O
known	O
about	O
co	O
-	O
occurrence	O
of	O
modifications	B-PHYS
on	O
the	O
same	O
nucleosome	B-CHEM
.	O

Here	O
we	O
present	O
a	O
genome	B-PROC
-	I-PROC
wide	I-PROC
quantitative	I-PROC
method	I-PROC
for	O
combinatorial	O
indexed	O
chromatin	B-PROC
immunoprecipitation	I-PROC
(	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
)	O
to	O
characterize	O
co	O
-	O
occurrence	O
of	O
histone	B-PHYS
modifications	I-PHYS
on	O
nucleosomes	B-CHEM
.	O

Using	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
,	O
we	O
study	B-PROC
the	O
genome	O
-	O
wide	O
co	O
-	O
occurrence	O
of	O
14	O
chromatin	O
marks	O
(	O
70	O
pairwise	O
combinations	O
)	O
,	O
and	O
find	O
previously	O
undescribed	O
co	O
-	O
occurrence	O
patterns	O
,	O
including	O
the	O
co	O
-	O
occurrence	O
of	O
H3K9me1	O
and	O
H3K27ac	O
in	O
super	O
-	O
enhancers	O
.	O

Finally	O
,	O
we	O
apply	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
to	O
measure	O
the	O
distribution	O
of	O
the	O
bivalent	O
H3K4me3	O
-	O
H3K27me3	O
domains	O
in	O
two	O
distinct	O
mouse	B-ANAT
embryonic	I-ANAT
stem	I-ANAT
cell	I-ANAT
(	O
mESC	B-ANAT
)	O
states	O
and	O
in	O
four	O
adult	O
tissues	O
.	O

We	O
observe	O
dynamic	O
changes	O
in	O
5	O
,	O
786	O
regions	O
and	O
discover	O
both	O
loss	O
and	O
de	O
novo	O
gain	O
of	O
bivalency	O
in	O
key	O
tissue	O
-	O
specific	O
regulatory	O
genes	O
,	O
suggesting	O
a	O
functional	O
role	O
for	O
bivalent	O
domains	O
during	O
different	O
stages	O
of	O
development	O
.	O

These	O
results	B-DISO
show	O
that	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
can	O
reveal	O
the	O
complex	O
interactions	O
between	O
histone	B-PHYS
modifications	I-PHYS
.	O

Prognosis	B-PROC
of	O
Fibrolamellar	B-DISO
Carcinoma	I-DISO
Compared	O
to	O
Non	O
-	O
cirrhotic	O
Conventional	O
Hepatocellular	B-DISO
Carcinoma	I-DISO
Fibrolamellar	B-DISO
carcinoma	I-DISO
(	O
FLC	B-DISO
)	O
and	O
conventional	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O
HCC	B-DISO
)	O
share	O
the	O
same	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O
AJCC	O
)	O
staging	O
.	O

The	O
worse	O
survival	O
with	O
HCC	B-DISO
is	O
attributed	O
to	O
the	O
underlying	O
cirrhosis	B-DISO
.The	O

aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
stage	B-PHYS
-	I-PHYS
matched	I-PHYS
prognosis	B-PROC
after	O
resection	B-PROC
of	O
FLC	B-DISO
and	O
non	O
-	O
cirrhotic	O
HCC	B-DISO
.	O

Outcomes	O
after	O
resection	B-PROC
of	O
65	O
consecutive	O
patients	B-LIVB
with	O
FLC	B-DISO
and	O
158	O
non	O
-	O
cirrhotic	O
patients	B-LIVB
with	O
HCC	B-DISO
were	O
compared	O
.	O

Patients	B-LIVB
were	O
staged	B-PHYS
according	O
to	O
the	O
7th	O
edition	O
AJCC	O
staging	O
.	O

The	O
AJCC	O
stage	O
distributions	O
for	O
FLC	B-DISO
and	O
HCC	B-DISO
demonstrated	O
a	O
predominance	O
of	O
stage	B-PHYS
IV	I-PHYS
disease	I-PHYS
in	O
FLC	B-DISO
and	O
stage	B-PHYS
I	I-PHYS
in	O
HCC	B-DISO
(	O
FLC	B-DISO
stage	B-PHYS
I	O
-	O
23	O
%	O
,	O
II	O
-	O
15	O
%	O
,	O
III	O
-	O
15	O
%	O
,	O
IV	O
-	O
46	O
%	O
vs	O
.	O

HCC	B-DISO
stage	B-PHYS
I	O
-	O
42	O
%	O
,	O
II	O
-	O
32	O
%	O
,	O
III	O
-	O
20	O
%	O
,	O
IV	O
-	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Among	O
stage	B-PHYS
IV	I-PHYS
FLC	B-DISO
patients	B-LIVB
,	O
81	O
%	O
had	O
isolated	O
nodal	O
metastases	B-DISO
,	O
which	O
did	O
not	O
affect	O
overall	O
survival	O
(	O
OS	O
)	O
or	O
recurrence	B-DISO
-	I-DISO
free	I-DISO
survival	I-DISO
(	O
RFS	B-DISO
)	O
.	O

In	O
FLC	B-DISO
,	O
OS	O
was	O
significantly	O
affected	O
by	O
the	O
number	O
of	O
tumors	O
and	O
vascular	B-DISO
invasion	I-DISO
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Recurrent	B-DISO
disease	I-DISO
developed	O
in	O
56	O
(	O
86	O
%	O
)	O
FLC	O
patients	B-LIVB
and	O
was	O
treated	B-PROC
with	I-PROC
repeat	O
surgical	B-PROC
resection	I-PROC
in	O
25	O
(	O
45	O
%	O
)	O
patients	B-LIVB
.	O

Vascular	B-DISO
invasion	I-DISO
was	O
associated	O
with	O
recurrent	O
FLC	B-DISO
,	O
with	O
3	O
-	O
year	O
RFS	B-DISO
rates	O
of	O
9	O
%	O
and	O
35	O
%	O
,	O
with	O
and	O
without	O
vascular	B-DISO
invasion	I-DISO
(	O
p	O
=	O
0	O
.	O
034	O
)	O
.	O

With	O
respect	O
to	O
RFS	B-DISO
,	O
the	O
AJCC	O
staging	O
did	O
not	O
stratify	O
FLC	B-DISO
patients	O
,	O
compared	O
to	O
non	O
-	O
cirrhotic	O
HCC	B-DISO
.	O

When	O
compared	O
to	O
non	O
-	O
cirrhotic	O
HCC	B-DISO
,	O
patients	B-LIVB
with	O
FLC	B-DISO
are	O
not	O
adequately	O
stratified	O
by	O
AJCC	O
staging	O
with	O
respect	O
to	O
RFS	B-DISO
.	O

Our	O
results	B-DISO
support	O
classifying	O
lymph	B-ANAT
node	I-ANAT
metastases	B-DISO
in	O
FLC	B-DISO
as	O
regional	B-DISO
disease	I-DISO
,	O
rather	O
than	O
systemic	B-DISO
disease	I-DISO
.	O

Important	O
prognostic	B-PHYS
factors	I-PHYS
in	O
FLC	B-DISO
are	O
the	O
number	O
of	O
tumors	O
and	O
vascular	B-DISO
invasion	I-DISO
.	O

Hand	B-PROC
-	I-PROC
Assisted	I-PROC
Laparoscopic	I-PROC
Versus	O
Standard	B-PROC
Laparoscopic	I-PROC
Colectomy	I-PROC
:	O
Are	O
Outcomes	O
and	O
Operative	O
Time	O
Different	O
?	O
HAL	B-PROC
colectomy	B-PROC
is	O
a	O
technique	O
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic	B-PROC
surgery	I-PROC
while	O
improving	O
tactile	O
feedback	O
and	O
operative	O
time	O
.	O

Published	O
data	O
are	O
largely	O
limited	O
to	O
small	O
,	O
single	B-PROC
-	I-PROC
institution	I-PROC
studies	I-PROC
.	O

The	O
2012	O
-	O
2013	O
National	O
Surgical	O
Quality	O
Improvement	O
Program	O
Participant	O
Data	O
Use	O
File	O
was	O
queried	O
for	O
patients	B-LIVB
undergoing	O
elective	O
SL	B-PROC
or	O
HAL	B-PROC
colectomy	B-PROC
.	O

Patients	B-LIVB
underwent	O
1	O
:	O
1	O
propensity	O
matching	O
and	O
had	O
outcomes	O
compared	O
.	O

An	O
additional	O
subgroup	B-PROC
analysis	I-PROC
was	O
performed	O
for	O
patients	B-LIVB
undergoing	O
segmental	O
resections	B-PROC
only	O
.	O

13	O
,	O
949	O
patients	B-LIVB
were	O
identified	O
,	O
of	O
whom	O
6084	O
(	O
43	O
.	O
6	O
%	O
)	O
underwent	O
HAL	B-PROC
colectomy	B-PROC
.	O

Patients	B-LIVB
undergoing	O
HAL	B-PROC
versus	O
SL	B-PROC
colectomy	I-PROC
had	O
higher	O
rates	O
of	O
postoperative	B-DISO
ileus	I-DISO
(	O
8	O
.	O
7	O
vs	O
.	O

6	O
.	O
3	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
wound	B-DISO
complication	I-DISO
(	O
8	O
.	O
8	O
vs	O
.	O

6	O
.	O
8	O
%	O
,	O
p	O
=	O
0	O
.	O

006	O
)	O
,	O
and	O
30	O
-	O
day	O
readmission	B-PROC
(	O
7	O
.	O
5	O
vs	O
.	O

6	O
.	O
0	O
%	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
without	O
any	O
differences	O
in	O
operative	O
time	O
(	O
156	O
vs	O
.	O

157	O
min	O
,	O
p	O
=	O
0	O
.	O

713	O
)	O
.	O

Amongst	O
segmental	O
colectomies	B-PROC
,	O
HAL	B-PROC
remained	O
associated	O
with	O
higher	O
rates	O
of	O
wound	B-DISO
complications	I-DISO
(	O
8	O
.	O
6	O
vs	O
.	O

6	O
.	O
5	O
%	O
,	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
postoperative	B-DISO
ileus	I-DISO
(	O
8	O
.	O
9	O
vs	O
.	O

6	O
.	O
3	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
30	O
-	O
day	O
readmission	B-PROC
(	O
7	O
.	O
1	O
vs	O
.	O

5	O
.	O
9	O
%	O
,	O
p	O
=	O
0	O
.	O
041	O
)	O
with	O
no	O
difference	O
in	O
operative	O
time	O
between	O
HAL	B-PROC
and	O
SL	O
(	O
145	O
vs	O
.	O

145	O
min	O
,	O
p	O
=	O
0	O
.	O
334	O
)	O
.	O

Use	O
of	O
HAL	B-PROC
colectomy	B-PROC
is	O
associated	O
with	O
increased	O
risk	B-PROC
of	O
wound	B-DISO
complications	I-DISO
,	O
postoperative	B-DISO
ileus	I-DISO
,	O
and	O
readmissions	B-PROC
.	O

Importantly	O
,	O
this	O
technique	O
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative	O
time	O
.	O

Somatic	B-PROC
Therapy	I-PROC
of	O
a	O
Mouse	B-LIVB
SMA	B-DISO
Model	B-DISO
with	O
a	O
U7	O
snRNA	O
Gene	O
Correcting	O
SMN2	O
Splicing	B-PHYS
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
is	O
due	O
to	O
the	O
loss	O
of	O
SMN1	O
gene	B-PHYS
function	I-PHYS
.	O

The	O
duplicate	O
gene	O
SMN2	O
produces	O
some	O
,	O
but	O
not	O
enough	O
,	O
SMN	B-CHEM
protein	I-CHEM
because	O
most	O
transcripts	B-CHEM
lack	O
exon	B-CHEM
7	I-CHEM
.	O

Thus	O
,	O
promoting	O
the	O
inclusion	O
of	O
this	O
exon	B-CHEM
is	O
a	O
therapeutic	O
option	O
.	O

We	O
show	O
that	O
a	O
somatic	B-PROC
gene	I-PROC
therapy	I-PROC
using	O
the	O
gene	O
for	O
a	O
modified	O
U7	O
RNA	O
which	O
stimulates	O
this	O
splicing	B-PHYS
has	O
a	O
profound	O
and	O
persistent	O
therapeutic	B-PHYS
effect	I-PHYS
on	O
the	O
phenotype	B-PHYS
of	O
a	O
severe	O
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
mouse	B-DISO
model	I-DISO
.	O

To	O
this	O
end	O
,	O
the	O
U7	O
gene	O
and	O
vector	B-CHEM
and	O
the	O
production	O
of	O
pure	O
,	O
highly	O
concentrated	O
self	B-LIVB
-	I-LIVB
complementary	I-LIVB
(	I-LIVB
sc	I-LIVB
)	I-LIVB
adenovirus	I-LIVB
-	O
associated	O
virus	B-LIVB
9	I-LIVB
vector	B-CHEM
particles	I-CHEM
were	O
optimized	O
.	O

Introduction	O
of	O
the	O
functional	O
vector	B-CHEM
into	O
motoneurons	B-ANAT
of	O
newborn	O
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
mice	B-LIVB
by	O
intracerebroventricular	O
injection	B-PROC
led	O
to	O
a	O
highly	O
significant	O
,	O
dose	O
-	O
dependent	O
increase	O
in	O
life	O
span	O
and	O
improvement	O
of	O
muscle	B-PHYS
functions	I-PHYS
.	O

Besides	O
the	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
,	O
the	O
therapeutic	O
U7	O
RNA	O
was	O
expressed	B-PHYS
in	O
the	O
heart	B-ANAT
and	O
liver	B-ANAT
which	O
may	O
additionally	O
have	O
contributed	O
to	O
the	O
observed	O
therapeutic	O
efficacy	O
.	O

This	O
approach	O
provides	O
an	O
additional	O
therapeutic	O
option	O
for	O
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
and	O
could	O
also	O
be	O
adapted	O
to	O
treat	B-PROC
other	O
diseases	B-DISO
of	O
the	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
with	O
regulatory	O
small	O
RNA	O
genes	O
.	O

Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O
Proliferation	B-PHYS
,	O
Invasion	B-DISO
and	O
Drug	B-CHEM
-	O
Induced	O
Apoptosis	B-PHYS
in	O
Lymphoblastic	B-DISO
Leukemia	I-DISO
Some	O
studies	O
have	O
shown	O
that	O
extracellular	B-ANAT
pH	O
in	O
tumors	B-DISO
,	O
which	O
results	O
in	O
tumor	B-DISO
progression	I-DISO
,	O
is	O
less	O
than	O
that	O
in	O
normal	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
investigate	O
the	O
effects	O
of	O
extracellular	B-ANAT
acidic	O
pH	O
on	O
proliferation	B-PHYS
,	O
invasion	B-DISO
,	O
and	O
drug	B-CHEM
-	O
induced	O
apoptosis	B-PHYS
in	O
acute	B-ANAT
lymphoblastic	I-ANAT
cells	I-ANAT
.	O

The	O
cells	B-ANAT
were	O
cultured	O
in	O
different	O
pH	O
(	O
pH	O
6	O
.	O
6	O
and	O
pH	O
7	O
.	O
4	O
)	O
for	O
12	O
days	O
.	O

Cell	B-PHYS
proliferation	I-PHYS
was	O
assessed	O
by	O
MTT	B-PROC
assay	I-PROC
and	O
cell	B-DISO
invasion	I-DISO
was	O
assayed	O
by	O
invasion	B-PROC
assay	I-PROC
and	O
gene	B-PROC
expression	I-PROC
analysis	I-PROC
of	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
.	O

Drug	B-CHEM
-	O
induced	O
apoptosis	B-PHYS
was	O
evaluated	O
after	O
exposure	O
to	O
doxorubicin	B-CHEM
for	O
24	O
hours	O
by	O
annexin	B-CHEM
V	I-CHEM
/	O
PI	B-CHEM
staining	B-PROC
and	O
gene	B-PROC
expression	I-PROC
analysis	I-PROC
of	O
BAX	B-CHEM
pro	I-CHEM
-	I-CHEM
apoptotic	I-CHEM
protein	I-CHEM
.	O

The	O
results	O
indicated	O
the	O
enhanced	O
growth	B-PHYS
and	O
invasion	B-DISO
of	O
leukemic	B-DISO
cells	B-ANAT
at	O
pH	O
6	O
.	O

6	O
(	O
P	O
≤	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
the	O
cells	B-ANAT
at	O
pH	O
6	O
.	O

6	O
were	O
resistant	O
to	O
apoptosis	B-PHYS
by	O
doxorubicin	B-CHEM
(	O
P	O
≤	O
0	O
.	O
05	O
)	O
.	O

It	O
can	O
be	O
concluded	O
that	O
acidic	O
pH	O
increases	O
the	O
proliferation	B-PHYS
,	O
invasion	B-DISO
and	O
reduces	O
the	O
drug	B-CHEM
-	O
induced	O
apoptosis	B-PHYS
in	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
.	O

Extracellular	B-ANAT
acidity	O
can	O
influence	O
the	O
behavior	O
of	O
leukemic	B-DISO
cells	B-ANAT
and	O
therefore	O
,	O
the	O
manipulation	O
of	O
extracellular	B-ANAT
liquid	I-ANAT
can	O
be	O
selected	O
as	O
a	O
therapeutic	B-PROC
strategy	I-PROC
for	O
leukemia	B-DISO
,	O
especially	O
for	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
.	O

Safety	B-PHEN
and	O
immunogenecity	B-PROC
of	O
a	O
live	O
attenuated	B-CHEM
Rift	B-CHEM
Valley	I-CHEM
fever	I-CHEM
vaccine	I-CHEM
(	O
CL13	B-CHEM
T	I-CHEM
)	O
in	O
camels	B-LIVB
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
is	O
an	O
emerging	O
zoonotic	B-LIVB
viral	B-DISO
disease	I-DISO
,	O
enzootic	B-DISO
and	O
endemic	B-DISO
in	O
Africa	B-GEOG
and	O
the	O
Arabian	B-GEOG
Peninsula	I-GEOG
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	B-LIVB
and	O
animal	B-LIVB
health	B-DISO
.	O

The	O
disease	B-DISO
is	O
most	O
severe	O
in	O
ruminants	B-LIVB
causing	O
abortions	B-DISO
in	O
pregnant	B-PHYS
animals	B-LIVB
,	O
especially	O
sheep	B-LIVB
animals	I-LIVB
and	O
high	O
mortality	O
in	O
young	O
populations	B-LIVB
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	O
among	O
camel	B-LIVB
populations	B-LIVB
in	O
Africa	B-GEOG
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	B-CHEM
vaccines	I-CHEM
against	O
RVF	B-DISO
have	O
been	O
tested	O
for	O
safety	B-PHEN
and	O
efficacy	O
in	O
this	O
species	O
.	O

In	O
this	O
study	B-PROC
,	O
the	O
safety	B-PHEN
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	B-CHEM
antibody	I-CHEM
response	B-PHYS
)	O
of	O
the	O
thermostable	B-CHEM
live	I-CHEM
attenuated	I-CHEM
RVF	B-CHEM
CL13	I-CHEM
T	I-CHEM
vaccine	I-CHEM
were	O
evaluated	B-PROC
in	O
camels	B-LIVB
in	O
two	O
different	O
preliminary	O
experiments	B-PROC
involving	O
16	O
camels	B-LIVB
,	O
(	O
that	O
12	O
camels	B-LIVB
and	O
4	O
pregnant	B-PHYS
camels	B-LIVB
)	O
.	O

The	O
study	B-PROC
revealed	O
that	O
the	O
CL13	B-CHEM
T	I-CHEM
vaccine	I-CHEM
was	O
safe	B-PHEN
to	O
use	O
in	O
camels	B-LIVB
and	O
no	O
abortions	B-DISO
or	O
teratogenic	B-DISO
effects	I-DISO
were	O
observed	O
.	O

The	O
single	O
dose	O
of	O
the	O
vaccine	B-CHEM
stimulated	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
neutralizing	B-CHEM
antibody	I-CHEM
response	B-PHYS
for	O
up	O
to	O
12	O
months	O
.	O

The	O
presence	B-DISO
of	O
neutralization	B-CHEM
antibodies	I-CHEM
is	O
likely	O
to	O
correlate	O
with	O
protection	B-DISO
;	O
however	O
protection	B-DISO
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	B-PROC
using	O
the	O
virulent	O
RVF	B-LIVB
virus	I-LIVB
.	O

Highly	B-PROC
sensitive	I-PROC
detection	I-PROC
of	I-PROC
influenza	I-PROC
virus	I-PROC
by	O
boron	B-DEVI
-	I-DEVI
doped	I-DEVI
diamond	I-DEVI
electrode	I-DEVI
terminated	O
with	O
sialic	B-CHEM
acid	I-CHEM
-	I-CHEM
mimic	I-CHEM
peptide	I-CHEM
The	O
progression	B-DISO
of	I-DISO
influenza	I-DISO
varies	O
according	O
to	O
age	O
and	O
the	O
presence	O
of	O
an	O
underlying	B-DISO
disease	I-DISO
;	O
appropriate	B-PHYS
treatment	I-PHYS
is	O
therefore	O
required	O
to	O
prevent	B-PROC
severe	I-PROC
disease	I-PROC
.	O

Anti	B-PROC
-	I-PROC
influenza	I-PROC
therapy	I-PROC
,	O
such	O
as	O
with	O
neuraminidase	B-CHEM
inhibitors	I-CHEM
,	O
is	O
effective	O
,	O
but	O
diagnosis	B-DISO
at	O
an	O
early	O
phase	O
of	O
infection	O
before	O
viral	B-DISO
propagation	I-DISO
is	O
critical	O
.	O

Here	O
,	O
we	O
show	O
that	O
several	O
dozen	O
plaque	O
-	O
forming	O
units	O
(	O
pfu	O
)	O
of	O
influenza	B-LIVB
virus	I-LIVB
(	O
IFV	B-LIVB
)	O
can	O
be	O
detected	O
using	O
a	O
boron	B-DEVI
-	I-DEVI
doped	I-DEVI
diamond	I-DEVI
(	I-DEVI
BDD	I-DEVI
)	I-DEVI
electrode	I-DEVI
terminated	O
with	O
a	O
sialic	B-CHEM
acid	I-CHEM
-	I-CHEM
mimic	I-CHEM
peptide	I-CHEM
.	O

The	O
peptide	B-CHEM
was	O
used	O
instead	O
of	O
the	O
sialyloligosaccharide	B-CHEM
receptor	I-CHEM
,	O
which	O
is	O
the	O
common	O
receptor	B-CHEM
of	O
influenza	B-LIVB
A	I-LIVB
and	O
B	B-LIVB
viruses	I-LIVB
required	O
during	O
the	O
early	O
phase	O
of	O
infection	O
,	O
to	O
capture	O
IFV	B-ANAT
particles	I-ANAT
.	O

The	O
peptide	B-CHEM
,	O
which	O
was	O
previously	O
identified	O
by	O
phage	B-PROC
-	I-PROC
display	I-PROC
technology	I-PROC
,	O
was	O
immobilized	B-CHEM
by	O
click	B-PROC
chemistry	I-PROC
on	O
the	O
BDD	B-DEVI
electrode	I-DEVI
,	O
which	O
has	O
excellent	O
electrochemical	O
characteristics	O
such	O
as	O
low	O
background	O
current	O
and	O
weak	O
adsorption	B-PROC
of	I-PROC
biomolecules	I-PROC
.	O

Electrochemical	B-PROC
impedance	I-PROC
spectroscopy	I-PROC
revealed	O
that	O
H1N1	B-LIVB
and	O
H3N2	B-LIVB
IFVs	I-LIVB
were	O
detectable	B-PHYS
in	O
the	O
range	O
of	O
20	O
-	O
500	O
pfu	O
by	O
using	O
the	O
peptide	B-DEVI
-	I-DEVI
terminated	I-DEVI
BDD	I-DEVI
electrode	I-DEVI
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
BDD	B-DEVI
device	I-DEVI
integrated	O
with	O
the	O
receptor	B-CHEM
-	I-CHEM
mimic	I-CHEM
peptide	I-CHEM
has	O
high	O
sensitivity	O
for	O
detection	B-PROC
of	O
a	O
low	O
number	O
of	O
virus	B-ANAT
particles	I-ANAT
in	O
the	O
early	O
phase	O
of	O
infection	O
.	O

Identification	O
of	O
a	O
peroxisomal	B-ANAT
-targeted	O
aldolase	B-CHEM
involved	O
in	O
chlorophyll	B-CHEM
biosynthesis	O
and	O
sugar	B-CHEM
metabolism	B-PHYS
in	O
rice	B-OBJC
Chlorophyll	B-CHEM
plays	O
remarkable	O
and	O
critical	O
roles	O
in	O
photosynthetic	B-PHYS
light	I-PHYS
-	I-PHYS
harvesting	I-PHYS
,	I-PHYS
energy	B-PHYS
transduction	I-PHYS
and	O
plant	B-PHYS
development	I-PHYS
.	O

In	O
this	O
study	B-PROC
,	O
we	O
identified	O
a	O
rice	B-OBJC
Chl	B-CHEM
-deficient	O
mutant	B-DISO
,	O
ygdl	B-DISO
-	I-DISO
1	I-DISO
(	O
yellow	B-DISO
green	I-DISO
and	I-DISO
droopy	I-DISO
leaf	I-DISO
-	I-DISO
1	I-DISO
)	O
,	O
which	O
showed	O
yellow	B-LIVB
-	I-LIVB
green	I-LIVB
leaves	I-LIVB
throughout	O
plant	B-PHYS
development	I-PHYS
with	O
decreased	O
content	O
of	O
Chls	B-CHEM
and	O
carotene	B-CHEM
and	O
an	O
increased	O
Chl	B-CHEM
a	O
/	O
b	O
ratio	O
.	O

The	O
ygdl	B-DISO
-	I-DISO
1	I-DISO
mutant	I-DISO
also	O
exhibited	O
severe	O
defects	O
in	O
chloroplast	B-ANAT
development	B-PHYS
,	O
including	O
disorganized	O
grana	B-ANAT
stacks	I-ANAT
.	O

Sequence	B-PROC
analysis	I-PROC
revealed	O
that	O
the	O
mutant	B-DISO
contained	O
a	O
T	B-CHEM
-	I-CHEM
DNA	I-CHEM
insertion	O
within	O
the	O
promoter	B-CHEM
of	O
a	O
fructose	B-CHEM
-	I-CHEM
1	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
bisphosphate	I-CHEM
aldolase	I-CHEM
(	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
)	O
,	O
which	O
dramatically	O
reduced	O
the	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
mRNA	B-CHEM
level	O
,	O
and	O
its	O
identity	O
was	O
verified	O
by	O
transgenic	B-PHYS
complementation	I-PHYS
.	O

Real	B-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
analysis	I-PROC
showed	O
that	O
the	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
chlorophyll	B-CHEM
biosynthesis	O
and	O
chloroplast	B-ANAT
development	B-PHYS
were	O
concurrently	O
altered	O
in	O
the	O
ygdl	B-DISO
-	I-DISO
1	I-DISO
mutant	I-DISO
.	O

The	O
expression	B-PHYS
of	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
-	O
GFP	B-CHEM
fusion	B-CHEM
protein	I-CHEM
in	O
tobacco	B-LIVB
epidermal	B-ANAT
cells	I-ANAT
showed	O
that	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
was	O
localized	O
to	O
the	O
peroxisome	B-ANAT
.	O

In	O
addition	O
,	O
the	O
analysis	B-PROC
of	O
primary	B-CHEM
carbon	I-CHEM
metabolites	I-CHEM
revealed	O
the	O
significantly	O
reduced	O
levels	O
of	O
sucrose	B-CHEM
and	O
fructose	B-CHEM
in	O
the	O
mutant	B-DISO
leaves	B-LIVB
,	O
while	O
the	O
glucose	B-CHEM
content	O
was	O
similar	O
to	O
wild	B-LIVB
-	I-LIVB
type	I-LIVB
plants	I-LIVB
.	O

Our	O
results	O
suggest	O
that	O
the	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
participates	O
in	O
Chl	B-CHEM
accumulation	B-DISO
,	O
chloroplast	B-ANAT
development	B-PHYS
and	O
plant	B-PHYS
growth	I-PHYS
by	O
influencing	O
the	O
photosynthetic	B-PHEN
rate	O
of	O
leaves	B-LIVB
and	O
the	O
sugar	B-CHEM
metabolism	B-PHYS
of	O
rice	B-OBJC
.	O

Autoantibodies	B-CHEM
to	O
MOG	B-CHEM
in	O
a	O
distinct	O
subgroup	O
of	O
adult	B-LIVB
multiple	B-DISO
sclerosis	I-DISO
To	O
evaluate	B-PROC
the	O
presence	O
of	O
antibodies	B-CHEM
to	O
conformation	O
-intact	O
myelin	B-CHEM
oligodendrocyte	I-CHEM
glycoprotein	I-CHEM
(	O
MOG	B-CHEM
)	O
in	O
a	O
subgroup	O
of	O
adult	B-LIVB
patients	B-LIVB
with	O
clinically	O
definite	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	B-DISO
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	B-PHYS
including	O
severe	O
spinal	B-ANAT
cord	I-ANAT
,	O
optic	B-ANAT
nerve	I-ANAT
,	O
and	O
brainstem	B-ANAT
involvement	O
.	O

Antibodies	B-CHEM
to	O
MOG	B-CHEM
were	O
investigated	O
using	O
a	O
cell	B-PROC
-	I-PROC
based	I-PROC
assay	I-PROC
in	O
3	O
groups	B-LIVB
of	O
patients	B-LIVB
:	O
104	O
preselected	O
patients	B-LIVB
with	O
MS	B-DISO
(	O
group	B-LIVB
1	I-LIVB
)	O
,	O
55	O
age	B-PHYS
-	O
and	O
sex	B-PHYS
-matched	O
,	O
otherwise	O
unselected	O
patients	B-LIVB
with	O
MS	B-DISO
(	O
group	B-LIVB
2	I-LIVB
)	O
,	O
and	O
in	O
22	O
brain	B-PROC
-	I-PROC
biopsied	I-PROC
patients	B-LIVB
with	O
demyelinating	B-DISO
diseases	I-DISO
of	O
the	O
CNS	B-ANAT
(	O
n	O
=	O
19	O
with	O
MS	B-DISO
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	B-DISO
type	I-DISO
II	I-DISO
(	O
group	B-LIVB
3	I-LIVB
)	O
.	O

Recognized	O
epitopes	B-CHEM
were	O
identified	O
with	O
mutated	B-PHYS
variants	O
of	O
MOG	O
.	O

Antibodies	B-CHEM
to	O
MOG	B-CHEM
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5	O
/	O
104	O
)	O
of	O
preselected	O
adult	B-LIVB
patients	B-LIVB
with	O
MS	B-DISO
.	O

In	O
contrast	O
,	O
in	O
groups	B-LIVB
2	I-LIVB
and	O
3	B-LIVB
,	O
none	O
of	O
the	O
patients	B-LIVB
tested	O
positive	O
for	O
MOG	B-CHEM
antibodies	B-CHEM
.	O

Patients	B-LIVB
with	O
MS	B-DISO
with	O
antibodies	B-CHEM
to	O
MOG	B-CHEM
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	B-ANAT
and	O
spinal	B-ANAT
cord	I-ANAT
involvement	O
and	O
had	O
a	O
severe	O
disease	B-DISO
course	I-DISO
with	O
high	O
relapse	B-PHEN
rates	O
and	O
failure	B-DISO
to	O
several	O
disease	B-PROC
-	I-PROC
modifying	I-PROC
therapies	I-PROC
.	O

Three	O
of	O
them	O
had	O
been	O
treated	B-PROC
with	I-PROC
plasma	B-PROC
exchange	I-PROC
with	O
a	O
favorable	O
response	O
.	O

All	O
anti	B-CHEM
-	I-CHEM
MOG	I-CHEM
-positive	O
patients	B-LIVB
with	O
MS	B-DISO
showed	O
typical	O
MS	B-DISO
lesions	B-DISO
on	O
brain	B-PROC
MRI	I-PROC
.	O

Longitudinal	O
analysis	O
up	O
to	O
9	O
years	O
revealed	O
fluctuations	B-DISO
and	O
reappearance	O
of	O
anti	B-PHYS
-	I-PHYS
MOG	I-PHYS
reactivity	I-PHYS
.	O

Epitope	B-PROC
mapping	I-PROC
indicated	O
interindividual	O
heterogeneity	O
,	O
yet	O
intraindividual	O
stability	O
of	O
the	O
antibody	B-PHEN
response	I-PHEN
.	O

Antibodies	B-CHEM
to	O
MOG	B-CHEM
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	B-LIVB
MS	B-DISO
with	O
a	O
specific	O
clinical	O
phenotype	B-PHYS
and	O
may	O
indicate	O
disease	B-DISO
heterogeneity	O
.	O

Brassinosteroid	B-CHEM
/	O
Abscisic	B-CHEM
Acid	I-CHEM
Antagonism	O
in	O
Balancing	O
Growth	B-PHYS
and	O
Stress	B-DISO
In	O
this	O
issue	O
of	O
Developmental	B-PHYS
Cell	I-PHYS
,	O
Gui	O
et	O
al	O
.	O
(	O
2016	O
)	O
show	O
that	O
an	O
abscisic	B-CHEM
acid	I-CHEM
-	O
inducible	O
remorin	B-CHEM
protein	I-CHEM
in	O
rice	B-LIVB
directly	O
interacts	O
with	O
critical	O
brassinosteroid	B-CHEM
signaling	B-CHEM
components	I-CHEM
to	O
attenuate	O
the	O
brassinosteroid	B-CHEM
response	B-PHYS
,	O
thus	O
illuminating	O
one	O
aspect	O
of	O
the	O
brassinosteroid	B-CHEM
/	O
abscisic	B-CHEM
acid	I-CHEM
antagonism	O
.	O

Salvage	B-PROC
surgery	B-PROC
after	O
head	B-DISO
and	I-DISO
neck	I-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
treated	B-PROC
with	I-PROC
bioradiotherapy	B-PROC
The	O
purpose	O
of	O
this	O
study	B-PROC
was	O
to	O
describe	O
the	O
results	B-DISO
and	O
complications	B-DISO
of	O
primary	B-PHYS
site	I-PHYS
salvage	B-PROC
surgery	B-PROC
after	O
head	B-DISO
and	I-DISO
neck	I-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
HNSCC	B-DISO
)	O
treated	B-PROC
with	I-PROC
bioradiotherapy	B-PROC
.	O

We	O
conducted	O
a	O
retrospective	B-PROC
chart	O
review	O
of	O
268	O
patients	B-LIVB
treated	B-PROC
with	I-PROC
bioradiotherapy	B-PROC
between	O
March	O
2006	O
and	O
December	O
2013	O
at	O
the	O
Hospital	B-OBJC
Universitari	I-OBJC
de	I-OBJC
Bellvitge	I-OBJC
-	I-OBJC
ICO	I-OBJC
.	O
Fifty	O
-	O
nine	O
patients	B-LIVB
developed	O
local	B-DISO
recurrence	I-DISO
or	O
had	O
residual	B-DISO
disease	I-DISO
with	O
a	O
1	O
-	O
year	O
and	O
3	O
-	O
year	O
overall	O
survival	O
of	O
47	O
%	O
and	O
15	O
.	O
4	O
%	O
,	O
respectively	O
.	O

Salvage	B-PROC
surgery	B-PROC
was	O
feasible	O
in	O
22	O
patients	B-LIVB
(	O
37	O
.	O
3	O
%	O
)	O
.	O

There	O
were	O
16	O
complications	B-DISO
in	O
these	O
22	O
patients	B-LIVB
(	O
72	O
.	O
7	O
%	O
)	O
,	O
11	O
(	O
50	O
%	O
)	O
of	O
which	O
were	O
major	O
.	O

Bilateral	O
neck	B-PROC
dissection	I-PROC
was	O
identified	O
as	O
a	O
risk	B-DISO
factor	I-DISO
for	O
complications	B-DISO
.	O

Salvage	B-PROC
surgery	B-PROC
after	O
bioradiotherapy	B-PROC
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
complications	B-DISO
.	O

Neck	B-PROC
dissection	I-PROC
seems	O
to	O
be	O
related	O
to	O
an	O
increased	O
rate	O
of	O
complications	B-DISO
with	O
no	B-DISO
survival	O
improvement	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Head	O
Neck	O
39	O
:	O
116	O
-	O
121	O
,	O
2017	O
.	O

Acute	B-DISO
Ph	I-DISO
-	I-DISO
negative	I-DISO
lymphoblastic	I-DISO
leukemias	I-DISO
in	O
adults	B-LIVB
:	O
Risk	B-DISO
factors	I-DISO
in	O
the	O
use	O
of	O
the	O
ALL	O
-	O
2009	O
protocol	O
to	O
analyze	O
well	O
-	O
known	O
risk	B-DISO
factors	I-DISO
(	O
RFs	B-DISO
)	O
,	O
such	O
as	O
age	B-PHYS
,	O
immunophenotype	B-PROC
,	O
baseline	O
leukocytosis	B-DISO
,	O
enhanced	O
lactate	B-CHEM
dehydrogenase	I-CHEM
(	O
LDH	B-CHEM
)	O
activity	B-PHYS
,	O
time	O
to	O
achieve	O
complete	O
remission	B-DISO
,	O
a	O
risk	B-LIVB
group	I-LIVB
,	O
and	O
cytogenetic	B-DISO
abnormalities	I-DISO
)	O
in	O
patients	B-LIVB
with	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
(	O
ALL	B-DISO
)	O
in	O
the	O
use	O
of	O
the	O
ALL	O
-	O
2009	O
protocol	O
.	O

The	O
protocol	O
covered	O
298	O
patients	B-LIVB
(	O
137	O
women	B-LIVB
(	O
including	O
13	O
pregnant	B-LIVB
women	I-LIVB
)	O
and	O
161	O
men	B-LIVB
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph	B-DISO
-	I-DISO
negative	I-DISO
ALL	I-DISO
.	O

The	O
phenotype	B-PHYS
was	O
unknown	O
in	O
6	O
patients	B-LIVB
.	O

Three	O
(	O
1	O
%	O
)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O

182	O
(	O
62	O
.	O
4	O
%	O
)	O
patients	B-LIVB
were	O
found	O
to	O
have	O
B	B-DISO
-	I-DISO
cell	I-DISO
ALL	I-DISO
(	O
early	O
pre	B-DISO
-	I-DISO
B	I-DISO
ALL	I-DISO
(	O
n	O
=	O
51	O
)	O
;	O
common	O
ALL	B-DISO
(	O
n	O
=	O
92	O
)	O
,	O
and	O
pre	B-DISO
-	I-DISO
B	I-DISO
ALL	I-DISO
(	O
n	O
=	O
39	O
)	O
;	O
107	O
(	O
36	O
.	O
6	O
%	O
)	O
patients	B-LIVB
had	O
T	B-DISO
-	I-DISO
cell	I-DISO
ALL	I-DISO
(	O
early	O
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O
n	O
=	O
56	O
)	O
;	O
thymic	B-ANAT
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O
n	O
=	O
41	O
)	O
,	O
and	O
mature	O
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O
n	O
=	O
10	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	B-OBJC
parameters	B-DISO
(	O
leukocytosis	B-DISO
of	O
30·109	O
/	O
l	O
and	O
more	O
for	O
B	B-DISO
-	I-DISO
ALL	I-DISO
;	O
and	O
that	O
of	O
100·109	O
/	O
l	O
and	O
more	O
for	O
T	B-DISO
-	I-DISO
ALL	I-DISO
;	O
phenotype	B-PHYS
В	O
-	O
I	O
for	O
B	B-DISO
-	I-DISO
ALL	I-DISO
,	O
phenotype	B-PHYS
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	B-DISO
-	I-DISO
ALL	I-DISO
;	O
LDH	B-CHEM
activity	B-PHYS
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	B-DISO
of	O
translocation	B-DISO
t	I-DISO
(	I-DISO
4	I-DISO
;	I-DISO
11	I-DISO
)	I-DISO
)	O
,	O
the	O
high	B-LIVB
-	I-LIVB
risk	I-LIVB
group	I-LIVB
included	O
most	O
patients	B-LIVB
with	O
B	B-DISO
-	I-DISO
ALL	I-DISO
(	O
n	O
=	O
110	O
(	O
72	O
.	O
8	O
%	O
)	O
)	O
and	O
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O
n	O
=	O
76	O
(	O
76	O
%	O
)	O
)	O
.	O

Thirty	O
-	O
five	O
patients	B-LIVB
with	O
T	B-DISO
-	I-DISO
ALL	I-DISO
underwent	O
autologous	B-PROC
bone	I-PROC
marrow	I-PROC
transplantation	I-PROC
(	O
BMT	B-PROC
)	O
.	O

Allogeneic	B-PROC
BMT	I-PROC
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	B-LIVB
who	O
had	O
undergone	O
an	O
induction	B-PROC
phase	I-PROC
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	B-LIVB
included	O
in	O
the	O
investigation	B-PROC
was	O
59	O
%	O
;	O
relapse	B-PROC
-	I-PROC
free	I-PROC
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	B-LIVB
with	O
B	B-DISO
-	I-DISO
ALL	I-DISO
and	O
in	O
those	O
with	O
T	B-DISO
-	I-DISO
ALL	I-DISO
:	O
the	O
overall	O
survival	O
rates	O
were	O
53	O
.	O
3	O
and	O
67	O
.	O

5	O
%	O
(	O
p	O
=	O
0	O
.	O
1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
respectively	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well	O
-	O
known	O
RFs	B-DISO
demonstrated	O
that	O
the	O
latter	O
for	O
T	B-DISO
-	I-DISO
ALL	I-DISO
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	B-LIVB
's	I-LIVB
age	B-PHYS
was	O
identified	O
for	O
B	B-DISO
-	I-DISO
ALL	I-DISO
(	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O

A	O
lower	O
chemotherapeutic	B-CHEM
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-PROC
BMTs	I-PROC
did	O
not	O
affect	O
total	O
positive	O
treatment	B-PROC
results	B-PHEN
in	O
adult	B-LIVB
patients	B-LIVB
with	O
ALL	B-DISO
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-CHEM
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	B-CHEM
loading	O
dose	O
.	O

The	O
results	B-PHEN
of	O
the	O
Russian	B-GEOG
investigation	B-PROC
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-PROC
BMTs	I-PROC
in	O
adult	B-LIVB
patients	B-LIVB
with	O
ALL	B-DISO
.	O

Gold	B-CHEM
-	O
Nanosponge	B-DEVI
-Based	O
Multistimuli	B-CHEM
-	I-CHEM
Responsive	I-CHEM
Drug	I-CHEM
Vehicles	I-CHEM
for	O
Targeted	O
Chemo	B-PROC
-	I-PROC
Photothermal	I-PROC
Therapy	I-PROC
Gold	B-CHEM
-	O
nanosponge	B-DEVI
-based	O
multistimuli	B-CHEM
-	I-CHEM
responsive	I-CHEM
drug	I-CHEM
vehicles	I-CHEM
are	O
constructed	O
for	O
combined	O
chemo	B-PROC
-	I-PROC
photothermal	I-PROC
therapy	I-PROC
with	O
pinpointed	O
drug	B-CHEM
delivery	O
and	O
release	O
capabilities	O
and	O
minimized	O
nonspecific	O
systemic	O
spread	O
of	O
drugs	B-CHEM
,	O
remarkably	O
enhancing	O
the	O
therapeutic	O
efficiency	O
while	O
minimizing	O
acute	O
side	B-DISO
effects	I-DISO
.	O

Multidetector	B-PROC
CT	I-PROC
of	O
expected	O
findings	B-DISO
and	O
complications	B-DISO
after	O
contemporary	O
inguinal	B-PROC
hernia	I-PROC
repair	I-PROC
surgery	B-PROC
Inguinal	B-PROC
hernia	I-PROC
repair	I-PROC
(	O
IHR	B-PROC
)	O
with	O
prosthetic	B-DEVI
mesh	B-DEVI
implantation	B-PROC
is	O
the	O
most	O
common	O
procedure	B-PROC
in	O
general	B-PROC
surgery	I-PROC
,	O
and	O
may	O
be	O
performed	O
using	O
either	O
an	O
open	O
or	O
laparoscopic	O
approach	O
.	O

This	O
paper	B-OBJC
provides	O
an	O
overview	O
of	O
contemporary	O
tension	O
-	O
free	O
IHR	B-PROC
techniques	O
and	O
materials	B-OBJC
,	O
and	O
illustrates	O
the	O
expected	O
postoperative	B-DISO
imaging	B-PHEN
findings	I-PHEN
and	O
iatrogenic	B-DISO
injuries	I-DISO
.	O

Emphasis	O
is	O
placed	O
on	O
multidetector	B-PROC
CT	I-PROC
,	O
which	O
represents	O
the	O
ideal	O
modality	O
to	O
comprehensively	O
visualize	O
the	O
operated	O
groin	B-ANAT
region	I-ANAT
and	O
deeper	O
intra	B-ANAT
-	I-ANAT
abdominal	I-ANAT
structures	I-ANAT
.	O

CT	B-PROC
consistently	O
depicts	O
seroma	B-DISO
,	O
mesh	B-DISO
infections	I-DISO
,	O
hemorrhages	B-DISO
,	O
bowel	B-ANAT
complications	B-DISO
and	O
urinary	B-ANAT
bladder	I-ANAT
injuries	B-DISO
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	O
basis	O
for	O
therapeutic	O
choice	O
.	O

Since	O
radiologists	B-LIVB
are	O
increasingly	O
requested	O
to	O
investigate	O
suspected	O
iatrogenic	O
complications	B-DISO
,	O
this	O
paper	B-OBJC
aims	O
to	O
provide	O
an	O
increased	O
familiarity	B-PHYS
with	O
early	O
CT	B-PROC
studies	B-PROC
after	O
IHR	B-PROC
,	O
including	O
complications	B-DISO
and	O
normal	O
postoperative	B-DISO
appearances	O
such	O
as	O
focal	O
pseudolesions	B-DISO
,	O
in	O
order	O
to	O
avoid	B-PROC
misinterpretation	I-PROC
and	O
inappropriate	O
management	B-PROC
.	O

The	O
transcription	B-CHEM
factors	I-CHEM
MS188	B-CHEM
and	O
AMS	B-CHEM
form	O
a	O
complex	O
to	O
activate	O
the	O
expression	B-PHYS
of	O
CYP703A2	B-CHEM
for	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
in	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
The	O
sexine	B-ANAT
layer	I-ANAT
of	O
pollen	B-LIVB
grain	I-LIVB
is	O
mainly	O
composed	O
of	O
sporopollenins	B-CHEM
.	O

The	O
sporophytic	B-ANAT
secretory	I-ANAT
tapetum	I-ANAT
is	O
required	O
for	O
the	O
biosynthesis	B-PHYS
of	I-PHYS
sporopollenin	I-PHYS
.	O

Although	O
several	O
enzymes	B-CHEM
involved	O
in	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
have	O
been	O
reported	O
,	O
the	O
regulatory	B-PHYS
mechanism	I-PHYS
of	O
these	O
enzymes	B-CHEM
in	O
tapetal	B-ANAT
layer	I-ANAT
remains	O
elusive	O
.	O

ABORTED	B-CHEM
MICROSPORES	I-CHEM
(	O
AMS	B-CHEM
)	O
and	O
MALE	B-CHEM
STERILE	I-CHEM
188	I-CHEM
/	O
MYB103	B-CHEM
/	O
MYB80	B-CHEM
(	O
MS188	B-CHEM
/	O
MYB103	B-CHEM
/	O
MYB80	B-CHEM
)	O
are	O
two	O
tapetal	B-ANAT
cell	I-ANAT
-specific	O
transcription	B-CHEM
factors	I-CHEM
required	O
for	O
pollen	B-PHYS
wall	I-PHYS
formation	I-PHYS
.	O

AMS	B-CHEM
functions	O
upstream	O
of	O
MS188	B-CHEM
.	O

Here	O
we	O
report	O
that	O
AMS	B-CHEM
and	O
MS188	B-CHEM
target	O
the	O
CYP703A2	O
gene	O
,	O
which	O
is	O
involved	O
in	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
.	O

We	O
found	O
that	O
AMS	B-CHEM
and	O
MS188	B-CHEM
were	O
localized	O
in	O
tapetum	B-ANAT
while	O
CYP703A2	B-CHEM
was	O
localized	O
in	O
both	O
tapetum	B-ANAT
and	O
locule	B-LIVB
.	O

Chromatin	B-PROC
immunoprecipitation	I-PROC
(	O
ChIP	B-PROC
)	O
showed	O
that	O
MS188	B-CHEM
directly	O
bound	O
to	O
the	O
promoter	B-CHEM
of	O
CYP703A2	O
and	O
luciferase	B-CHEM
-	I-CHEM
inducible	I-CHEM
assay	B-PROC
showed	O
that	O
MS188	B-CHEM
activated	O
the	O
expression	B-PHYS
of	O
CYP703A2	B-CHEM
.	O

Yeast	B-PROC
two	I-PROC
-	I-PROC
hybrid	I-PROC
and	O
electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
(	O
EMSAs	B-PROC
)	O
further	O
demonstrated	O
that	O
MS188	B-CHEM
complexed	O
with	O
AMS	B-CHEM
.	O

The	O
expression	B-PHYS
of	O
CYP703A2	O
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	O
levels	O
of	O
MS188	B-CHEM
in	O
the	O
ams	B-CHEM
mutant	B-DISO
.	O

Therefore	O
,	O
our	O
data	O
reveal	O
that	O
MS188	B-CHEM
coordinates	O
with	O
AMS	B-CHEM
to	O
activate	O
CYP703A2	B-CHEM
in	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
of	O
plant	B-LIVB
tapetum	B-ANAT
.	O

Bioinformatic	O
analysis	B-PROC
of	O
RNA	O
-	O
seq	O
data	O
unveiled	O
critical	O
genes	O
in	O
rectal	B-DISO
adenocarcinoma	I-DISO
RNA	O
-	O
seq	O
data	O
of	O
rectal	B-DISO
adenocarcinoma	I-DISO
(	O
READ	B-DISO
)	O
were	O
analyzed	B-PROC
with	O
bioinformatics	O
tools	O
to	O
unveil	B-PHYS
potential	I-PHYS
biomarkers	I-PHYS
in	O
the	O
disease	B-DISO
.	O

RNA	O
-	O
seq	O
data	O
of	O
READ	B-DISO
were	O
downloaded	O
from	O
The	B-PROC
Cancer	I-PROC
Genome	I-PROC
Atlas	I-PROC
(	O
TCGA	B-PROC
)	O
database	O
.	O

Differential	O
analysis	B-PROC
was	O
performed	O
with	O
package	O
edgeR	O
.	O

False	O
discovery	O
rate	O
(	O
FDR	O
)	O
<	O
0	O
.	O
05	O
and	O
|log2	O
(	O
fold	O
change	O
)	O
|	O
>	O
1	O
were	O
set	O
as	O
cut	O
-	O
off	O
values	O
to	O
screen	O
out	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
.	O

Gene	B-PHYS
coexpression	I-PHYS
network	B-PHYS
was	O
constructed	O
with	O
package	O
Ebcoexpress	O
.	O

Gene	O
Ontology	O
enrichment	O
analysis	B-PROC
was	O
performed	O
for	O
the	O
DEGs	O
in	O
the	O
gene	B-PHYS
coexpression	I-PHYS
network	O
with	O
DAVID	B-OBJC
online	I-OBJC
tool	I-OBJC
.	O

Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
pathway	O
enrichment	O
analysis	B-PROC
was	O
also	O
performed	O
for	O
the	O
genes	O
with	O
KOBASS	B-OBJC
2	O
.	O

0	O
.	O

A	O
total	O
of	O
620	O
DEGs	O
,	O
3ated	O
genes	O
,	O
and	O
231	O
down	B-PHYS
-	I-PHYS
regulated	I-PHYS
genes	O
,	O
were	O
identified	O
from	O
163	O
READ	B-DISO
samples	O
and	O
9	O
normal	O
controls	O
.	O

A	O
gene	B-PHYS
coexpression	I-PHYS
network	O
consisting	O
of	O
71	O
DEGs	O
and	O
253	O
edges	O
were	O
constructed	O
.	O

Genes	O
were	O
associated	O
with	O
ribosome	B-ANAT
and	O
focal	B-ANAT
adhesion	I-ANAT
functions	O
.	O

Three	O
modules	B-PHYS
were	O
identified	O
,	O
in	O
which	O
genes	O
were	O
involved	O
in	O
muscle	B-PHYS
contraction	I-PHYS
,	O
negative	B-PHYS
regulation	I-PHYS
of	I-PHYS
glial	I-PHYS
cell	I-PHYS
proliferation	I-PHYS
and	O
extracellular	B-PHYS
matrix	I-PHYS
organization	I-PHYS
functions	O
,	O
respectively	O
.	O

Several	O
critical	O
hub	O
genes	O
were	O
disclosed	O
,	O
such	O
as	O
RPS2	O
,	O
MMP1	O
,	O
MMP11	O
and	O
FAM83H	O
.	O

Thirteen	O
relevant	O
small	B-CHEM
molecule	I-CHEM
drugs	I-CHEM
were	O
identified	O
,	O
such	O
as	O
scriptaid	B-CHEM
and	O
spaglumic	B-CHEM
acid	I-CHEM
.	O

A	O
total	O
of	O
8	O
TFs	B-CHEM
and	O
5	B-CHEM
miRNAs	I-CHEM
were	O
acquired	O
,	O
such	O
as	O
MYC	O
,	O
NFY	B-CHEM
,	O
STAT5A	O
,	O
miR	B-CHEM
-	I-CHEM
29	I-CHEM
,	O
miR	B-CHEM
-	I-CHEM
200	I-CHEM
and	O
miR	B-CHEM
-	I-CHEM
19	I-CHEM
.	O

Several	O
critical	O
genes	O
and	O
relevant	O
drugs	B-PROC
,	O
TFs	B-CHEM
and	O
miRNAs	B-CHEM
were	O
revealed	O
in	O
READ	B-DISO
.	O

These	O
findings	O
could	O
advance	O
the	O
understanding	O
about	O
the	O
disease	B-DISO
and	O
benefit	O
therapy	O
development	O
.	O

Activation	O
of	O
ephrinB	O
-	O
EphB	O
receptor	O
signalling	O
in	O
rat	B-ANAT
spinal	I-ANAT
cord	I-ANAT
contributes	O
to	O
maintenance	O
of	O
diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
Diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
(	O
DNP	B-DISO
)	O
is	O
severe	O
and	O
intractable	O
in	O
clinic	B-OBJC
.	O

The	O
specific	O
cellular	B-PHYS
and	O
molecular	B-PHYS
mechanisms	O
underlying	O
DNP	B-DISO
remain	O
elusive	O
and	O
its	O
treatment	O
are	O
limited	O
.	O

We	O
investigated	O
roles	O
of	O
EphB1	B-CHEM
receptor	I-CHEM
in	O
the	O
development	O
of	O
DNP	B-DISO
.	O

Diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
was	O
produced	O
in	O
male	B-PHYS
,	O
adult	B-LIVB
,	O
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
by	O
a	O
single	O
i	O
.	O

p	O
.	O

streptozotocin	B-CHEM
(	O
STZ	B-CHEM
)	O
or	O
alloxan	B-CHEM
.	O

Western	B-PROC
blot	I-PROC
analysis	I-PROC
and	O
immunohistochemistry	B-PROC
were	O
used	O
to	O
analyse	O
expression	B-PHYS
of	O
EphB1	B-CHEM
receptor	I-CHEM
as	O
well	O
as	O
the	O
activation	O
of	O
the	O
glial	B-ANAT
cells	I-ANAT
and	O
the	O
pro	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
cytokines	I-CHEM
in	O
the	O
spinal	B-ANAT
cord	I-ANAT
.	O

DNP	B-DISO
manifested	O
as	O
mechanical	B-DISO
allodynia	I-DISO
,	O
which	O
was	O
determined	O
by	O
measuring	O
incidence	O
of	O
foot	B-ANAT
withdrawal	O
in	O
response	B-PHYS
to	O
mechanical	O
indentation	O
of	O
the	O
hind	O
paw	B-ANAT
by	O
an	O
electro	B-OBJC
von	I-OBJC
Frey	I-OBJC
filament	I-OBJC
.	O

Diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
and	O
high	B-DISO
blood	I-DISO
glucose	I-DISO
were	O
exhibited	O
simultaneously	O
in	O
around	O
70	O
%	O
of	O
animals	B-LIVB
that	O
received	O
i	O
.	O

p	O
.	O

STZ	B-CHEM
or	O
alloxan	B-CHEM
.	O

Phosphorylation	B-PHYS
of	O
EphB1	B-CHEM
,	O
activation	O
of	O
the	O
astrocytes	B-ANAT
and	O
microglial	B-ANAT
cells	I-ANAT
,	O
and	O
level	O
of	O
tumour	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	B-CHEM
TNF	I-CHEM
)	I-CHEM
-	I-CHEM
α	I-CHEM
and	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
1β	I-CHEM
in	O
the	O
spinal	B-ANAT
cord	I-ANAT
were	O
significantly	O
increased	O
in	O
rats	B-LIVB
with	O
DNP	B-DISO
.	O

Spinal	O
blocking	O
EphB1	B-CHEM
receptor	I-CHEM
activation	O
in	O
the	O
late	O
phase	O
after	O
STZ	B-CHEM
injection	B-PROC
significantly	O
suppressed	O
the	O
established	O
mechanical	B-DISO
allodynia	I-DISO
as	O
well	O
as	O
activation	O
of	O
the	O
astrocytes	B-ANAT
and	O
microglial	B-ANAT
cells	I-ANAT
and	O
activity	O
of	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
.	O

However	O
,	O
spinal	O
treatment	O
of	O
EphB1	B-CHEM
-	O
Fc	B-CHEM
in	O
the	O
early	O
phase	O
after	O
STZ	B-CHEM
injection	B-PROC
did	O
not	O
prevent	O
the	O
induction	O
of	O
DNP	B-DISO
.	O

EphB1	B-CHEM
receptor	I-CHEM
activation	O
in	O
the	O
spinal	B-ANAT
cord	I-ANAT
is	O
critical	O
to	O
the	O
maintenance	O
,	O
but	O
not	O
induction	O
of	O
diabetic	B-DISO
pain	B-DISO
.	O

EphB1	B-CHEM
receptor	I-CHEM
may	O
be	O
a	O
potential	O
target	O
for	O
relieving	B-PROC
the	O
established	O
diabetic	B-DISO
pain	B-DISO
.	O

Activation	O
of	O
EphB1	B-CHEM
receptor	I-CHEM
in	O
the	O
spinal	B-ANAT
cord	I-ANAT
is	O
critical	O
to	O
maintaining	O
the	O
established	O
diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
,	O
but	O
not	O
to	O
diabetic	B-DISO
pain	B-DISO
induction	O
.	O

Spinal	O
blocking	O
EphB1	B-CHEM
receptor	I-CHEM
activation	O
suppresses	O
ongoing	O
diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
.	O

Regulation	B-PHEN
of	O
bone	B-ANAT
homeostasis	B-PHEN
by	O
glucose	B-CHEM
Synthesis	B-PHEN
of	O
type	B-CHEM
Ⅰ	I-CHEM
collagen	I-CHEM
,	I-CHEM
a	O
m	O
ajor	O
c	O
omponent	O
of	O
the	O
b	O
one	O
matrix	O
,	O
p	O
recedes	O
t	O
he	O
expression	B-PHYS
of	O
R	O
unt	B-CHEM
-	I-CHEM
related	I-CHEM
transcription	I-CHEM
factor	I-CHEM
2	I-CHEM
(	I-CHEM
R	I-CHEM
unx2	O
)	O
,	O
a	O
master	O
regulator	O
in	O
osteoblast	B-PHYS
differentiation	I-PHYS
.	O

Thus	O
,	O
a	O
direct	O
link	O
between	O
osteoblast	B-PHYS
differentiation	I-PHYS
and	O
bone	B-PHYS
formation	I-PHYS
is	O
seemingly	B-DISO
absent	O
,	O
and	O
how	O
these	O
are	O
maintained	O
in	O
a	O
coordinated	O
matter	O
remains	O
unclear	B-DISO
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
osteoblasts	B-ANAT
depend	O
on	O
glucose	B-CHEM
,	O
which	O
glucose	B-CHEM
transporter	I-CHEM
type	I-CHEM
1	I-CHEM
(	O
GLUT1	B-CHEM
)	O
takes	O
up	O
as	O
an	O
energy	B-DISO
source	I-DISO
,	O
and	O
it	O
was	O
found	B-DISO
that	O
glucose	B-PHYS
uptake	I-PHYS
promotes	O
osteoblast	B-PHYS
differentiation	I-PHYS
and	O
bone	B-PHYS
formation	I-PHYS
via	O
AMP	B-CHEM
-	I-CHEM
activated	I-CHEM
protein	I-CHEM
kinase	I-CHEM
.	O

It	O
was	O
also	O
shown	O
that	O
Runx2	B-CHEM
upregulates	B-PHYS
GLUT1	B-CHEM
expression	B-PHYS
,	O
and	O
this	O
Runx2	B-CHEM
-	O
GLUT1	B-CHEM
feedforward	O
regulation	B-PHEN
integrates	O
and	O
coordinates	O
osteoblast	B-PHYS
differentiation	I-PHYS
and	O
bone	B-PHYS
formation	I-PHYS
throughout	O
life	O
.	O

These	O
previous	O
findings	B-DISO
revealed	O
that	O
the	O
energy	B-PHYS
metabolism	I-PHYS
balance	B-PHYS
in	O
osteoblasts	B-ANAT
integrates	O
the	O
differentiation	B-PHYS
and	O
function	O
of	O
osteoblasts	B-ANAT
,	O
and	O
re	O
-	O
emphasized	O
the	O
importance	O
of	O
crosstalk	B-PHYS
between	O
bone	B-PHYS
and	O
sugar	B-PROC
metabolism	I-PROC
.	O

Chelation	B-CHEM
competition	I-CHEM
induced	O
polymerization	B-PHEN
(	O
CCIP	B-PHEN
)	O
:	O
construction	O
of	O
integrated	O
hollow	B-CHEM
polydopamine	I-CHEM
nanocontainers	B-OBJC
with	O
tailorable	O
functionalities	O
A	O
novel	O
'	O
chelation	B-CHEM
competition	I-CHEM
induced	O
polymerization	B-PHEN
'	O
route	O
was	O
developed	O
to	O
construct	O
hollow	B-CHEM
polydopamine	I-CHEM
nanocontainers	B-OBJC
with	O
tailorable	O
functionalities	O
.	O

The	O
mechanism	O
is	O
systematically	O
investigated	O
and	O
the	O
nanocontainers	B-OBJC
constructed	O
through	O
this	O
method	O
show	O
excellent	O
chemo	B-DISO
-	I-DISO
thermo	I-DISO
performance	I-DISO
in	O
vitro	O
.	O

This	O
strategy	O
is	O
facile	O
and	O
is	O
expected	O
to	O
be	O
used	B-DISO
for	O
the	O
construction	O
of	O
a	O
series	O
of	O
hollow	B-CHEM
polymer	I-CHEM
nanostructures	B-OBJC
.	O

Hemodynamic	B-PHYS
correlates	O
of	O
transient	B-DISO
cognitive	I-DISO
impairment	I-DISO
after	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
and	O
minor	B-DISO
stroke	I-DISO
:	O
A	O
transcranial	B-PROC
Doppler	I-PROC
study	I-PROC
Transient	B-DISO
cognitive	I-DISO
impairment	I-DISO
(	O
TCI	B-DISO
)	O
on	O
the	O
Mini	B-PROC
Mental	I-PROC
State	I-PROC
Evaluation	I-PROC
score	O
is	O
common	O
after	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
/	O
minor	B-DISO
stroke	I-DISO
and	O
might	O
identify	O
patients	B-LIVB
at	O
increased	O
risk	O
of	O
dementia	B-DISO
.	O

We	O
aimed	O
to	O
replicate	O
TCI	B-DISO
using	O
the	O
Montreal	O
Cognitive	O
Assessment	O
(	O
MoCA	O
)	O
,	O
compare	O
it	O
with	O
persistent	B-DISO
Mild	I-DISO
Cognitive	I-DISO
Impairment	I-DISO
(	O
PMCI	B-DISO
)	O
,	O
and	O
to	O
determine	O
whether	O
global	O
cerebral	B-ANAT
hemodynamic	B-PHYS
changes	O
could	O
explain	O
transient	O
impairment	O
.	O

Consecutive	O
patients	B-LIVB
with	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
/	O
minor	B-DISO
stroke	I-DISO
(	O
NIHSS	O
≤	O
3	O
)	O
were	O
assessed	O
with	O
the	O
MoCA	O
and	O
transcranial	B-PROC
Doppler	I-PROC
ultrasound	I-PROC
acutely	O
and	O
at	O
1	O
month	O
.	O

We	O
compared	O
patients	B-LIVB
with	O
TCI	B-DISO
(	O
baseline	O
MoCA	O
<	O
26	O
with	O
≥	O
2	O
points	O
increase	O
at	O
1	O
month	O
)	O
,	O
PMCI	B-DISO
(	O
MoCA	O
<	O
26	O
with	O
<	O
2	O
points	O
increase	O
)	O
,	O
and	O
no	B-DISO
cognitive	I-DISO
impairment	I-DISO
(	O
NCI	B-DISO
;	O
MoCA	O
≥	O
26	O
)	O
.	O

Of	O
326	O
patients	B-LIVB
,	O
46	O
(	O
14	O
.	O
1	O
%	O
)	O
had	O
PMCI	B-DISO
,	O
98	O
(	O
30	O
.	O
1	O
%	O
)	O
TCI	B-DISO
,	O
and	O
182	O
(	O
55	O
.	O

8	O
%	O
)	O
NCI	B-DISO
.	O

At	O
baseline	O
,	O
TCI	B-DISO
patients	B-LIVB
had	O
higher	B-DISO
systolic	I-DISO
blood	I-DISO
pressure	I-DISO
(	O
150	O
.	O
95	O
±	O
21	O
.	O

52	O
vs	O
144	O
.	O

86	O
±	O
22	O
.	O
44	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
lower	O
cerebral	O
blood	O
flow	O
velocities	O
,	O
particularly	O
end	O
-	O
diastolic	O
velocity	O
(	O
30	O
.	O
16	O
±	O
9	O
.	O
63	O
vs	O
35	O
.	O

02	O
±	O
9	O
.	O
01	O
cm	O
/	O
s	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
mean	B-DISO
flow	I-DISO
velocity	I-DISO
(	O
48	O
.	O
95	O
±	O
12	O
.	O

72	O
vs	O
54	O
±	O
12	O
.	O
46	O
cm	O
/	O
s	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
than	O
those	O
with	O
NCI	B-DISO
,	O
but	O
similar	O
clinical	O
and	O
hemodynamic	B-PHYS
profiles	B-PROC
to	O
those	O
with	O
PMCI	B-DISO
.	O

Systolic	B-DISO
BP	I-DISO
fell	I-DISO
between	O
baseline	O
and	O
1	O
month	O
(	O
mean	O
reduction	B-PROC
=	O
14	O
.	O
01	O
±	O
21	O
.	O

26	O
mmHg	O
)	O
and	O
end	O
-	O
diastolic	O
velocity	O
and	O
mean	B-DISO
flow	I-DISO
velocity	I-DISO
increased	O
(	O
mean	O
increase	O
=	O
+	O
2	O
.	O
42	O
±	O
6	O
.	O

41	O
and	O
1	O
.	O
89	O
±	O
8	O
.	O
77	O
cm	O
/	O
s	O
,	O
respectively	O
)	O
,	O
but	O
these	O
changes	O
did	O
not	B-DISO
differ	I-DISO
between	O
patients	B-LIVB
with	O
TCI	B-DISO
,	O
PMCI	B-DISO
,	O
and	O
NCI	B-DISO
.	O

TCI	B-DISO
is	O
detectable	B-PHYS
with	O
the	O
MoCA	O
after	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
and	O
minor	B-DISO
stroke	I-DISO
and	O
has	O
similar	O
clinical	O
and	O
hemodynamic	B-PHYS
profile	B-PROC
to	O
PMCI	B-DISO
.	O

However	O
,	O
TCI	B-DISO
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
exaggerated	O
acute	O
reversible	O
global	O
hemodynamic	B-PHYS
changes	O
.	O

Impaired	O
autophagy	B-PHYS
in	O
macrophages	B-ANAT
promotes	O
inflammatory	B-DISO
eye	I-DISO
disease	I-DISO
Autophagy	B-PHYS
is	O
critical	O
for	O
maintaining	O
cellular	B-PHYS
homeostasis	I-PHYS
.	O

Organs	B-ANAT
such	O
as	O
the	O
eye	B-ANAT
and	O
brain	B-ANAT
are	O
immunologically	O
privileged	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
autophagy	B-PHYS
is	O
essential	O
for	O
maintaining	O
ocular	B-ANAT
immune	O
privilege	O
.	O

Deletion	B-PHYS
of	O
multiple	O
autophagy	B-PHYS
genes	O
in	O
macrophages	B-ANAT
leads	O
to	O
an	O
inflammation	B-DISO
-	I-DISO
mediated	I-DISO
eye	I-DISO
disease	I-DISO
called	O
uveitis	B-DISO
that	O
can	O
cause	O
blindness	B-DISO
.	O

Loss	O
of	O
autophagy	B-PHYS
activates	O
inflammasome	B-CHEM
-mediated	O
IL1B	B-CHEM
secretion	B-PHYS
that	O
increases	O
disease	O
severity	O
.	O

Inhibition	O
of	O
caspase	B-PHYS
activity	I-PHYS
by	O
gene	B-PHYS
deletion	I-PHYS
or	O
pharmacological	O
means	O
completely	O
reverses	B-DISO
the	I-DISO
disease	I-DISO
phenotype	I-DISO
.	O

Of	O
interest	O
,	O
experimental	O
uveitis	B-DISO
was	O
also	O
increased	O
in	O
a	O
model	O
of	O
Crohn	B-DISO
disease	I-DISO
,	O
a	O
systemic	B-DISO
autoimmune	B-DISO
disease	I-DISO
in	O
which	O
patients	B-LIVB
often	O
develop	O
uveitis	B-DISO
,	O
offering	O
a	O
potential	O
mechanistic	O
link	O
between	O
macrophage	B-ANAT
autophagy	B-PHYS
and	O
systemic	B-DISO
disease	I-DISO
.	O

These	O
findings	O
directly	O
implicate	O
the	O
homeostatic	B-PHEN
process	I-PHEN
of	O
autophagy	B-PHYS
in	O
blinding	B-PROC
eye	B-DISO
disease	I-DISO
and	O
identify	O
novel	O
pathways	O
for	O
therapeutic	B-PROC
intervention	I-PROC
in	O
uveitis	B-DISO
.	O

Conservation	O
of	O
the	O
Red	B-LIVB
Kite	I-LIVB
Milvus	B-LIVB
milvus	I-LIVB
(	O
Aves	B-LIVB
:	O
Accipitriformes	B-LIVB
)	O
Is	O
Not	O
Affected	O
by	O
the	O
Establishment	O
of	O
a	O
Broad	O
Hybrid	B-LIVB
Zone	O
with	O
the	O
Black	B-LIVB
Kite	I-LIVB
Milvus	B-LIVB
migrans	I-LIVB
migrans	I-LIVB
in	O
Central	B-GEOG
Europe	I-GEOG
Among	O
Accipitriformes	B-LIVB
sensu	O
stricto	O
,	O
only	O
a	O
few	O
species	O
have	O
been	O
reported	O
to	O
form	O
hybrid	B-LIVB
zones	O
;	O
these	O
include	O
the	O
red	B-LIVB
kite	I-LIVB
Milvus	B-LIVB
milvus	I-LIVB
and	O
black	B-LIVB
kite	I-LIVB
Milvus	B-LIVB
migrans	I-LIVB
migrans	I-LIVB
.	O

M	B-LIVB
.	I-LIVB

milvus	I-LIVB
is	O
endemic	O
to	O
the	O
western	O
Palearctic	O
and	O
has	O
an	O
estimated	O
total	O
population	O
of	O
20	O
-	O
24	O
,	O
000	O
breeding	B-PHYS
pairs	O
.	O

The	O
species	O
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	O
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	B-PHEN
of	O
rodenticide	B-CHEM
-	I-CHEM
treated	I-CHEM
baits	I-CHEM
,	O
illegal	O
poisoning	B-DISO
and	O
changes	O
in	O
agricultural	O
practices	O
,	O
particularly	O
in	O
its	O
core	O
range	O
.	O

Whereas	O
F1	B-LIVB
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
×	O
M	B-LIVB
.	I-LIVB

migr	I-LIVB
.	I-LIVB

migrans	I-LIVB
hybrid	B-LIVB
offspring	B-LIVB
have	O
been	O
found	O
,	O
F2	B-LIVB
and	O
F3	B-LIVB
hybrids	B-LIVB
have	O
only	O
rarely	O
been	O
reported	O
,	O
with	O
low	O
nesting	O
success	O
rates	O
of	O
F1	B-LIVB
hybrids	B-LIVB
and	O
partial	O
hybrid	B-LIVB
sterility	O
likely	O
playing	O
a	O
role	O
.	O

Here	O
,	O
we	O
analyzed	B-PROC
the	O
mitochondrial	B-ANAT
(	O
CO1	O
and	O
CytB	O
)	O
and	O
nuclear	B-ANAT
(	O
Myc	O
)	O
DNA	B-CHEM
loci	O
of	O
184	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
,	O
124	O
M	B-LIVB
.	I-LIVB

migr	I-LIVB
.	I-LIVB

migrans	I-LIVB
and	O
3	O
F1	B-LIVB
hybrid	B-LIVB
individuals	O
collected	O
across	O
central	B-GEOG
Europe	I-GEOG
.	O

In	O
agreement	O
with	O
previous	O
studies	B-PROC
,	O
we	O
found	O
low	O
heterozygosity	B-PHYS
in	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
regardless	O
of	O
locus	O
.	O

We	O
found	O
that	O
populations	O
of	O
both	O
examined	B-DISO
species	O
were	O
characterized	O
by	O
a	O
high	O
gene	B-PHYS
flow	I-PHYS
within	O
populations	O
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	B-PHYS
distributed	O
across	O
the	O
entire	O
examined	B-DISO
area	B-GEOG
.	O

Few	O
haplotypes	B-PHYS
displayed	O
statistically	O
significant	O
aggregation	O
in	O
one	O
region	B-GEOG
over	O
another	O
.	O

We	O
did	O
not	O
find	O
mitochondrial	B-CHEM
DNA	I-CHEM
of	O
one	O
species	O
in	O
individuals	O
with	O
the	O
plumage	B-ANAT
of	O
the	O
other	O
species	O
,	O
except	O
in	O
F1	B-LIVB
hybrids	B-LIVB
,	O
which	O
agrees	O
with	O
Haldane´s	O
Rule	O
.	O

It	O
remains	O
to	O
be	O
investigated	O
by	O
genomic	O
methods	O
whether	O
occasional	O
gene	B-PHYS
flow	I-PHYS
occurs	O
through	O
the	O
paternal	O
line	O
,	O
as	O
the	O
examined	B-DISO
Myc	O
gene	O
displayed	O
only	O
marginal	O
divergence	O
between	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
and	O
M	B-LIVB
.	I-LIVB

migr	I-LIVB
.	I-LIVB

migrans	I-LIVB
.	O

The	O
central	B-GEOG
Europe	I-GEOG
an	O
population	O
of	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene	B-PHYS
flow	I-PHYS
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	O
of	O
individuals	O
in	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
re	O
-	O
introduction	O
programs	O
.	O

Apixaban	B-CHEM
5	O
mg	O
Twice	O
Daily	O
and	O
Clinical	O
Outcomes	O
in	O
Patients	B-LIVB
With	O
Atrial	B-DISO
Fibrillation	I-DISO
and	O
Advanced	O
Age	B-PHYS
,	O
Low	O
Body	B-PHYS
Weight	I-PHYS
,	O
or	O
High	O
Creatinine	B-CHEM
:	O
A	O
Secondary	O
Analysis	O
of	O
a	O
Randomized	B-PROC
Clinical	I-PROC
Trial	I-PROC
In	O
the	O
Apixaban	B-CHEM
for	O
Reduction	O
of	O
Stroke	B-DISO
and	O
Other	O
Thromboembolic	B-DISO
Complications	I-DISO
in	O
Atrial	B-DISO
Fibrillation	I-DISO
(	O
ARISTOTLE	B-PROC
)	O
trial	B-PROC
,	O
the	O
standard	O
dose	O
of	O
apixaban	B-CHEM
was	O
5	O
mg	O
twice	O
daily	O
;	O
patients	B-LIVB
with	O
at	O
least	O
2	O
dose	O
-	O
reduction	O
criteria	O
-	O
80	O
years	O
or	O
older	O
,	O
weight	B-PHYS
60	O
kg	O
or	O
less	O
,	O
and	O
creatinine	B-DISO
level	I-DISO
1	O
.	O

5	O
mg	O
/	O
dL	O
or	O
higher	O
-	O
received	O
a	O
reduced	O
dose	O
of	O
apixaban	B-CHEM
of	O
2	O
.	O
5	O
mg	O
twice	O
daily	O
.	O

Little	O
is	O
known	O
about	O
patients	B-LIVB
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
who	O
received	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
.	O

To	O
determine	O
the	O
frequency	O
of	O
1	O
dose	O
-	O
reduction	O
criterion	O
and	O
whether	O
the	O
effects	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
on	O
stroke	B-DISO
or	O
systemic	O
embolism	O
and	O
bleeding	B-DISO
varied	O
among	O
patients	B-LIVB
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
.	O

Among	O
18	O
201	O
patients	B-LIVB
in	O
the	O
ARISTOTLE	B-PROC
trial	I-PROC
,	O
17	O
322	O
were	O
included	O
in	O
this	O
analysis	B-PROC
.	O

Annualized	O
event	O
rates	O
of	O
stroke	B-DISO
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	B-DISO
and	O
hazard	O
ratios	O
(	O
HRs	O
)	O
and	O
95	O
%	O
CIs	O
were	O
evaluated	B-PROC
.	O

Interactions	O
between	O
the	O
effects	O
of	O
apixaban	B-CHEM
vs	O
warfarin	B-CHEM
and	O
the	O
presence	O
of	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
were	O
assessed	O
.	O

The	O
first	O
patient	B-LIVB
was	O
enrolled	O
in	O
the	O
ARISTOTLE	B-PROC
trial	I-PROC
on	O
December	O
19	O
,	O
2006	O
,	O
and	O
follow	B-PROC
-	I-PROC
up	I-PROC
was	O
completed	O
on	O
January	O
30	O
,	O
2011	O
.	O

Data	O
were	O
analyzed	O
from	O
January	O
2015	O
to	O
May	O
30	O
,	O
2016	O
.	O

Analysis	B-PROC
of	O
major	O
bleeding	B-DISO
included	O
events	O
during	O
study	B-PROC
drug	B-PROC
treatment	I-PROC
.	O

Analysis	B-PROC
of	O
stroke	B-DISO
or	O
systemic	O
embolism	O
was	O
based	O
on	O
intention	O
to	O
treat	O
.	O

Of	O
the	O
patients	B-LIVB
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
assigned	O
to	O
receive	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
or	O
warfarin	B-CHEM
,	O
3966	O
had	O
1	O
dose	O
-	O
reduction	O
criterion	O
;	O
these	O
patients	B-LIVB
had	O
higher	O
rates	O
of	O
stroke	B-DISO
or	O
systemic	O
embolism	O
(	O
HR	O
,	O
1	O
.	O
47	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
20	O
-	O
1	O
.	O
81	O
)	O
and	O
major	O
bleeding	B-DISO
(	O
HR	O
,	O
1	O
.	O
89	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
62	O
-	O
2	O
.	O
20	O
)	O
compared	O
with	O
those	O
with	O
no	O
dose	O
-	O
reduction	O
criteria	O
(	O
n	O
=	O
13	O
356	O
)	O
.	O

The	O
benefit	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
(	O
n	O
=	O
8665	O
)	O
compared	O
with	O
warfarin	B-CHEM
(	O
n	O
=	O
8657	O
)	O
on	O
stroke	B-DISO
or	O
systemic	O
embolism	O
in	O
patients	B-LIVB
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
94	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
66	O
-	O
1	O
.	O
32	O
)	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
77	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
62	O
-	O
0	O
.	O
97	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.36	O
)	O
.	O

Similarly	O
,	O
the	O
benefit	O
of	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
compared	O
with	O
warfarin	B-CHEM
on	O
major	O
bleeding	B-DISO
in	O
patients	B-LIVB
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
68	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
53	O
-	O
0	O
.	O
87	O
)	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
72	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
60	O
-	O
0	O
.	O
86	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.71	O
)	O
.	O

Similar	O
patterns	O
were	O
seen	O
for	O
each	O
dose	O
-	O
reduction	O
criterion	O
and	O
across	O
the	O
spectrum	O
of	O
age	B-PHYS
,	O
body	B-PHYS
weight	I-PHYS
,	O
creatinine	B-DISO
level	I-DISO
,	O
and	O
creatinine	B-CHEM
clearance	B-PHYS
.	O

Patients	B-LIVB
with	O
atrial	B-DISO
fibrillation	I-DISO
and	O
isolated	O
advanced	O
age	B-PHYS
,	O
low	O
body	B-PHYS
weight	I-PHYS
,	O
or	O
renal	B-DISO
dysfunction	I-DISO
have	O
a	O
higher	O
risk	O
of	O
stroke	B-DISO
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	B-DISO
but	O
show	O
consistent	O
benefits	O
with	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
vs	O
warfarin	B-CHEM
compared	O
with	O
patients	B-LIVB
without	O
these	O
characteristics	O
.	O

The	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-CHEM
is	O
safe	O
,	O
efficacious	O
,	O
and	O
appropriate	O
for	O
patients	B-LIVB
with	O
only	O
1	O
dose	O
-	O
reduction	O
criterion	O
.	O

clinicaltrials	O
.	O

gov	O
Identifier	O
:	O
NCT00412984	O
.	O

Objective	O
Assessment	B-PROC
of	O
Vergence	B-PHYS
after	O
Treatment	B-PROC
of	O
Concussion	B-DISO
-	O
Related	O
CI	B-DISO
:	O
A	O
Pilot	B-PROC
Study	I-PROC
To	O
evaluate	B-PROC
changes	O
in	O
objective	O
measures	O
of	O
disparity	O
vergence	O
after	O
office	B-PROC
-	I-PROC
based	I-PROC
vision	I-PROC
therapy	I-PROC
(	O
OBVT	B-PROC
)	O
for	O
concussion	B-DISO
-	O
related	O
convergence	B-DISO
insufficiency	I-DISO
(	O
CI	B-DISO
)	O
and	O
determine	O
the	O
feasibility	B-PROC
of	O
using	O
this	O
objective	O
assessment	B-PROC
as	O
an	O
outcome	O
measure	O
in	O
a	O
clinical	B-PROC
trial	I-PROC
.	O

This	O
was	O
a	O
prospective	O
,	O
observational	B-PROC
trial	I-PROC
.	O

All	O
participants	B-LIVB
were	O
treated	B-PROC
with	I-PROC
weekly	O
OBVT	B-PROC
with	O
home	O
reinforcement	B-PROC
.	O

Participants	B-LIVB
included	O
two	O
adolescents	B-LIVB
and	O
three	O
young	B-LIVB
adults	I-LIVB
with	O
concussion	B-DISO
-	O
related	O
,	O
symptomatic	O
CI	B-DISO
.	O

The	O
primary	O
outcome	O
measure	O
was	O
average	O
peak	B-DISO
velocity	I-DISO
for	O
4	O
°	O
symmetrical	B-DISO
convergence	B-PHYS
steps	O
.	O

Other	O
objective	O
outcome	O
measures	O
of	O
disparity	O
vergence	O
included	O
time	O
to	O
peak	B-DISO
velocity	I-DISO
,	O
latency	O
,	O
accuracy	O
,	O
settling	O
time	O
,	O
and	O
main	O
sequence	O
.	O

We	O
also	O
evaluated	B-PROC
saccadic	B-PHYS
eye	I-PHYS
movements	I-PHYS
using	O
the	O
same	O
outcome	O
measures	O
.	O

Changes	O
in	O
clinical	B-DISO
measures	I-DISO
(	O
near	B-DISO
point	I-DISO
of	I-DISO
convergence	I-DISO
,	O
positive	B-DISO
fusional	B-PHYS
vergence	I-PHYS
at	I-PHYS
near	I-PHYS
,	O
Convergence	O
Insufficiency	O
Symptom	O
Survey	O
[	O
CISS	O
]	O
score	O
)	O
were	O
evaluated	B-PROC
.	O

There	O
were	O
statistically	O
significant	O
and	O
clinically	O
meaningful	O
changes	O
in	O
all	O
clinical	B-DISO
measures	I-DISO
for	O
convergence	B-PHYS
.	O

Four	O
of	O
the	O
five	O
subjects	B-LIVB
met	O
clinical	O
success	O
criteria	O
.	O

For	O
the	O
objective	O
measures	O
,	O
we	O
found	O
a	O
statistically	O
significant	O
increase	O
in	O
peak	B-DISO
velocity	I-DISO
,	O
response	B-PHYS
accuracy	O
to	O
4	O
°	O
symmetrical	B-DISO
convergence	B-PHYS
and	O
divergence	O
step	O
stimuli	B-PHEN
,	O
and	O
the	O
main	O
sequence	O
ratio	O
for	O
convergence	B-PHYS
step	O
stimuli	B-PHEN
.	O

Objective	O
saccadic	B-PHYS
eye	I-PHYS
movements	I-PHYS
(	O
5	O
and	O
10	O
°	O
)	O
appeared	O
normal	O
pre	O
-	O
OBVT	B-PROC
and	O
did	O
not	O
show	O
any	O
significant	O
change	O
after	O
treatment	B-PROC
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
use	O
of	O
objective	O
measures	O
of	O
disparity	O
vergence	O
as	O
outcome	O
measures	O
for	O
concussion	B-DISO
-	O
related	O
convergence	B-DISO
insufficiency	I-DISO
.	O

These	O
measures	O
provide	O
additional	O
information	O
that	O
is	O
not	O
accessible	O
with	O
clinical	B-PROC
tests	I-PROC
about	O
underlying	O
physiological	O
mechanisms	O
leading	O
to	O
changes	O
in	O
clinical	B-DISO
findings	I-DISO
and	O
symptoms	B-DISO
.	O

The	O
study	B-PROC
results	B-PHEN
also	O
demonstrate	O
that	O
patients	B-LIVB
with	O
concussion	B-DISO
can	O
tolerate	O
the	O
visual	O
demands	B-PROC
(	O
over	O
200	O
vergence	B-PHYS
and	O
versional	O
eye	B-PHYS
movements	I-PHYS
)	O
during	O
the	O
25	O
-	O
minute	O
testing	O
time	O
and	O
suggest	O
that	O
these	O
measures	O
could	O
be	O
used	O
in	O
a	O
large	O
-	O
scale	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
of	O
concussion	B-DISO
-	O
related	O
CI	B-DISO
as	O
outcome	O
measures	O
.	O

Extracellular	B-ANAT
Potassium	B-CHEM
and	O
Seizures	B-DISO
:	O
Excitation	O
,	O
Inhibition	O
and	O
the	O
Role	O
of	O
Ih	B-CHEM
Seizure	B-DISO
activity	I-DISO
leads	O
to	O
increases	O
in	O
extracellular	B-ANAT
potassium	B-CHEM
concentration	O
(	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
)	O
,	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	B-ANAT
passive	O
and	O
active	O
membrane	B-ANAT
properties	O
as	O
well	O
as	O
in	O
population	B-LIVB
activities	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
examined	O
how	O
extracellular	B-ANAT
potassium	B-CHEM
modulates	O
seizure	B-DISO
activities	I-DISO
using	O
an	O
acute	O
4	B-CHEM
-	I-CHEM
AP	I-CHEM
induced	O
seizure	B-DISO
model	O
in	O
the	O
neocortex	B-ANAT
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Moderately	O
elevated	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
up	O
to	O
9	O
[	O
Formula	O
:	O
see	O
text	O
]	O
mM	O
prolonged	O
seizure	B-DISO
durations	O
and	O
shortened	O
interictal	O
intervals	O
as	O
well	O
as	O
depolarized	B-DISO
the	O
neuronal	B-ANAT
resting	B-PHYS
membrane	I-PHYS
potential	I-PHYS
(	O
RMP	B-PHYS
)	O
.	O

However	O
,	O
when	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
reached	O
higher	O
than	O
9	O
[	O
Formula	O
:	O
see	O
text	O
]	O
mM	O
,	O
seizure	B-DISO
like	I-DISO
events	I-DISO
(	O
SLEs	B-DISO
)	O
were	O
blocked	O
and	O
neurons	B-ANAT
went	O
into	O
a	O
depolarization	B-DISO
-	O
blocked	O
state	O
.	O

Spreading	O
depression	B-DISO
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal	B-DISO
events	I-DISO
could	O
be	O
reversed	O
within	O
1	O
-	O
2	O
[	O
Formula	O
:	O
see	O
text	O
]	O
min	O
after	O
the	O
raised	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
was	O
changed	O
back	O
to	O
control	O
levels	O
.	O

This	O
concentration	O
-dependent	O
dual	O
effect	O
of	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
was	O
observed	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
mouse	O
brain	O
preparations	O
as	O
well	O
as	O
in	O
human	B-LIVB
neocortical	B-ANAT
tissue	O
resected	O
during	O
epilepsy	B-DISO
surgery	B-PROC
.	O

Blocking	O
the	O
Ih	O
current	O
,	O
mediated	O
by	O
hyperpolarization	B-CHEM
-	I-CHEM
activated	I-CHEM
cyclic	I-CHEM
nucleotide	I-CHEM
-	I-CHEM
gated	I-CHEM
(	I-CHEM
HCN	I-CHEM
)	I-CHEM
channels	I-CHEM
,	O
modulated	O
the	O
elevated	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
influence	O
on	O
SLEs	B-DISO
by	O
promoting	O
the	O
high	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
inhibitory	O
actions	O
.	O

These	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
[	O
K	B-CHEM
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
on	O
neuronal	B-ANAT
excitability	B-DISO
and	O
seizure	B-DISO
activity	I-DISO
.	O

Trends	O
in	O
traffic	B-DISO
fatalities	O
in	O
Mexico	B-GEOG
:	O
examining	B-DISO
progress	O
on	O
the	O
decade	O
of	O
action	O
for	O
road	B-OBJC
safety	B-PHEN
2011	O
-	O
2020	O
We	O
explore	O
demographic	O
,	O
temporal	O
and	O
geographic	B-DISO
patterns	I-DISO
of	O
256	O
,	O
588	O
road	B-OBJC
traffic	B-DISO
fatalities	O
from	O
1998	O
to	O
2013	O
in	O
Mexico	B-GEOG
,	O
in	O
context	O
of	O
UN´s	O
decade	O
of	O
action	O
for	O
road	B-OBJC
safety	B-PHEN
2010	O
-	O
2020	O
(	O
DARS	O
)	O
.	O

Combined	O
traffic	B-DISO
mortality	O
data	O
and	O
population	O
counts	O
were	O
analyzed	B-PROC
using	O
mixed	O
-	O
effects	O
logistic	B-PROC
regression	I-PROC
,	O
distinguishing	O
sex	O
-	O
age	O
groups	O
,	O
vulnerable	O
and	O
protected	B-DISO
road	B-OBJC
users	B-LIVB
,	O
and	O
municipal	B-GEOG
size	O
.	O

Rapid	B-DISO
growth	I-DISO
from	O
1998	O
to	O
2008	O
in	O
traffic	B-DISO
mortality	O
rates	O
has	O
been	O
reversed	O
since	O
2009	O
.	O

Most	O
deaths	B-DISO
averted	B-DISO
are	O
among	O
young	O
male	B-PHYS
protected	B-DISO
road	B-OBJC
users	B-LIVB
(	O
reduction	O
of	O
0	O
.	O
95	O
fatalities	O
per	O
100	O
,	O
000	O
per	O
year	O
in	O
males	B-PHYS
12	O
-	O
49	O
)	O
.	O

In	O
spite	O
of	O
a	O
steady	B-DISO
decrease	I-DISO
over	O
the	O
full	O
study	O
period	O
,	O
mortality	O
rates	O
remain	O
high	O
in	O
vulnerable	O
road	B-OBJC
users	B-LIVB
over	O
50	O
,	O
with	O
a	O
high	O
mortality	O
rate	O
of	O
26	O
per	O
100	O
,	O
000	O
males	B-PHYS
over	O
75	O
years	O
in	O
2013	O
.	O

Progress	O
on	O
the	O
reduction	O
of	O
deaths	B-DISO
advances	O
in	O
Mexico	B-GEOG
,	O
in	O
line	O
with	O
DARS	B-PHEN
targets	O
.	O

National	O
road	B-OBJC
safety	B-PHEN
efforts	O
require	O
strengthening	O
.	O

Initiatives	B-PHYS
should	O
target	O
vulnerable	O
road	B-OBJC
users	B-LIVB
,	O
specifically	O
adults	B-LIVB
>	O
50	O
years	O
in	O
urban	O
areas	O
.	O

Strengthening	O
of	O
drink	B-DISO
driving	I-DISO
programs	O
aimed	O
at	O
young	O
drivers	B-LIVB
/	O
occupants	B-LIVB
is	O
promising	O
.	O

Diagnostic	B-PHEN
Yield	I-PHEN
of	O
Routine	O
Stress	B-PROC
Testing	I-PROC
in	O
Low	O
and	O
Intermediate	B-DISO
Risk	I-DISO
Chest	B-DISO
Pain	I-DISO
Patients	B-LIVB
Under	O
40	O
Years	O
:	O
A	O
Systematic	O
Review	O
Chest	B-DISO
pain	I-DISO
is	O
one	O
of	O
the	O
most	O
frequent	O
causes	O
for	O
presentation	O
to	O
emergency	B-OBJC
departments	I-OBJC
(	O
EDs	B-OBJC
)	O
.	O

The	O
majority	O
of	O
patients	B-LIVB
will	O
undergo	O
diagnostic	B-PROC
workup	I-PROC
including	O
stress	B-PROC
testing	I-PROC
to	O
rule	O
out	O
an	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
,	O
but	O
very	O
few	O
patients	B-LIVB
will	O
be	O
diagnosed	B-DISO
with	O
a	O
cardiac	B-DISO
cause	I-DISO
for	O
their	O
pain	B-DISO
.	O

Patients	B-LIVB
under	O
40	O
years	O
represent	O
a	O
lower	B-LIVB
risk	I-LIVB
group	I-LIVB
in	O
which	O
routine	O
stress	B-PROC
testing	I-PROC
may	O
be	O
of	O
little	O
benefit	O
.	O

This	O
systematic	O
review	O
sought	O
to	O
determine	O
the	O
diagnostic	B-PHEN
yield	I-PHEN
of	O
routine	O
stress	B-PROC
testing	I-PROC
in	O
low	O
-	O
and	O
intermediate	B-DISO
-	I-DISO
risk	I-DISO
chest	B-DISO
pain	I-DISO
patients	B-LIVB
under	O
40	O
years	O
.	O

Electronic	O
databases	O
were	O
searched	O
for	O
relevant	O
studies	B-PROC
.	O

The	O
quality	O
of	O
the	O
included	O
primary	B-PROC
studies	I-PROC
was	O
assessed	O
using	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
evidence	O
hierarchy	O
and	O
the	O
McMaster	O
Critical	O
Appraisal	O
Tool	O
for	O
Quantitative	O
Studies	O
.	O

Descriptive	O
statistics	O
summarized	O
the	O
findings	O
.	O

Five	O
primary	B-PROC
studies	I-PROC
were	O
included	O
in	O
the	O
review	O
(	O
all	O
level	O
III	O
-	O
3	O
evidence	O
)	O
;	O
7	O
additional	O
sources	O
of	O
relevant	O
data	O
were	O
also	O
included	O
.	O

Diagnostic	B-PHEN
yield	I-PHEN
of	O
routine	O
stress	B-PROC
testing	I-PROC
in	O
low	O
-	O
and	O
intermediate	B-DISO
-	I-DISO
risk	I-DISO
patients	B-LIVB
under	O
40	O
years	O
is	O
reported	O
between	O
0	O
%	O
and	O
1	O
.	O

1	O
%	O
.	O

Combined	O
data	O
from	O
included	O
primary	B-PROC
studies	I-PROC
demonstrated	O
just	O
4	O
out	O
of	O
1683	O
true	O
positive	O
stress	B-PROC
tests	I-PROC
(	O
0	O
.	O

24	O
%	O
)	O
,	O
only	O
one	O
of	O
which	O
was	O
definitively	O
confirmed	O
by	O
coronary	B-PROC
angiogram	I-PROC
;	O
additional	O
data	O
sources	O
identified	O
just	O
1	O
out	O
of	O
310	O
true	O
positive	O
stress	B-PROC
tests	I-PROC
(	O
0	O
.	O
32	O
%	O
)	O
.	O

Diagnostic	B-PHEN
yield	I-PHEN
of	O
routine	O
stress	B-PROC
testing	I-PROC
in	O
low	O
-	O
and	O
intermediate	B-DISO
-	I-DISO
risk	I-DISO
chest	B-DISO
pain	I-DISO
patients	B-LIVB
under	O
40	O
years	O
is	O
low	O
.	O

However	O
,	O
better	O
quality	O
studies	O
are	O
required	O
to	O
be	O
able	O
to	O
draw	O
definitive	O
conclusions	O
.	O

Transition	O
From	O
Hospital	B-OBJC
to	O
Home	O
in	O
Preterm	B-LIVB
Infants	I-LIVB
and	O
Their	O
Families	B-LIVB
When	O
the	O
day	O
of	O
discharge	B-PROC
from	O
a	O
neonatal	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
(	O
NICU	B-OBJC
)	O
comes	O
for	O
the	O
parents	B-LIVB
of	O
newborn	B-LIVB
infants	I-LIVB
,	O
they	O
are	O
filled	O
with	O
long	O
-	O
awaited	O
joy	B-PHYS
and	O
happiness	B-PHYS
.	O

They	O
go	O
home	O
feeling	B-PHYS
as	O
parents	B-LIVB
,	O
away	O
from	O
scheduled	O
routines	O
of	O
the	O
hospital	B-OBJC
,	O
monitor	B-DISO
alarms	I-DISO
,	O
clinical	B-DISO
rounds	I-DISO
,	O
numerous	O
tests	B-PROC
,	O
and	O
so	O
on	O
.	O
What	O
do	O
we	O
know	O
about	O
what	O
happens	O
after	O
these	O
little	B-LIVB
patients	I-LIVB
and	O
their	O
families	B-LIVB
leave	O
the	O
NICU	B-OBJC
?	O
What	O
happens	O
from	O
the	O
point	O
of	O
leaving	O
the	O
hospital	B-OBJC
until	O
when	O
things	O
get	O
settled	O
and	O
life	O
becomes	O
perceived	B-PHYS
as	O
normal	O
?	O

This	O
article	O
presents	O
a	O
short	O
summary	O
of	O
research	B-PROC
conducted	O
with	O
the	O
vulnerable	B-LIVB
population	I-LIVB
of	O
high	B-DISO
-	I-DISO
risk	I-DISO
and	O
preterm	B-LIVB
infants	I-LIVB
and	O
their	O
families	B-LIVB
postdischarge	B-PROC
.	O

Available	O
evidence	O
suggests	O
that	O
transition	O
to	O
home	O
after	O
hospital	B-PROC
discharge	I-PROC
,	O
a	O
phenomenon	B-PHEN
that	O
many	O
families	B-LIVB
experience	B-PHYS
,	O
is	O
challenging	O
and	O
requires	O
attention	B-PROC
from	O
clinicians	B-LIVB
and	O
researchers	B-LIVB
if	O
we	O
are	O
to	O
provide	O
effective	O
,	O
efficient	O
,	O
and	O
high	B-PROC
-	I-PROC
quality	I-PROC
care	I-PROC
.	O

Pivotal	O
debates	O
and	O
controversies	O
on	O
the	O
structure	B-ANAT
and	O
function	B-PHYS
of	O
the	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
:	O
setting	O
the	O
record	O
straight	O
Among	O
the	O
extant	O
air	B-LIVB
-	I-LIVB
breathing	I-LIVB
vertebrates	I-LIVB
,	O
the	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
is	O
structurally	B-ANAT
the	O
most	O
complex	O
and	O
functionally	O
the	O
most	O
efficient	O
gas	B-PHYS
exchanger	I-PHYS
.	O

Having	O
been	O
investigated	O
for	O
over	O
four	O
centuries	O
,	O
some	O
aspects	O
of	O
its	O
biology	O
have	O
been	O
extremely	O
challenging	O
and	O
highly	O
contentious	O
and	O
others	O
still	O
remain	O
unresolved	O
.	O

Here	O
,	O
while	O
assessing	O
the	O
most	O
recent	O
findings	B-DISO
,	O
four	O
notable	O
aspects	O
of	O
the	O
structure	B-ANAT
and	O
function	B-PHYS
of	O
the	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
are	O
examined	O
critically	O
to	O
highlight	O
the	O
questions	O
,	O
speculations	O
,	O
controversies	O
and	O
debates	O
that	O
have	O
arisen	O
from	O
past	O
research	B-PROC
.	O

The	O
innovative	O
techniques	O
and	O
experiments	B-PROC
that	O
were	O
performed	O
to	O
answer	O
particular	O
research	O
questions	O
are	O
emphasised	O
.	O

The	O
features	O
that	O
are	O
outlined	O
here	O
concern	O
the	O
arrangement	O
of	O
the	O
airways	B-ANAT
,	O
the	O
path	O
followed	O
by	O
the	O
inspired	B-OBJC
air	I-OBJC
,	O
structural	B-ANAT
features	O
of	O
the	O
lung	B-ANAT
and	O
the	O
air	B-ANAT
and	O
blood	B-ANAT
capillaries	I-ANAT
,	O
and	O
the	O
level	O
of	O
cellular	B-PHYS
defence	I-PHYS
in	O
the	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
.	O

Hitherto	O
,	O
based	O
on	O
association	O
with	O
the	O
proven	O
efficiency	O
of	O
naturally	O
evolved	O
and	O
human	O
-	O
made	O
counter	B-PHEN
-	I-PHEN
current	I-PHEN
exchange	I-PHEN
systems	I-PHEN
rather	O
than	O
on	O
definite	O
experimental	O
evidence	O
,	O
a	O
counter	B-PHEN
-	I-PHEN
current	I-PHEN
gas	I-PHEN
exchange	I-PHEN
system	I-PHEN
was	O
suggested	O
to	O
exist	O
in	O
the	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
and	O
was	O
used	O
to	O
explain	O
its	O
exceptional	O
efficiency	O
.	O

However	O
,	O
by	O
means	O
of	O
an	O
elegant	O
experiment	B-PROC
in	O
which	O
the	O
direction	O
of	O
the	O
air	B-OBJC
-	O
flow	B-PHEN
in	O
the	O
lung	B-ANAT
was	O
reversed	O
,	O
a	O
cross	B-PHEN
-	I-PHEN
current	I-PHEN
system	I-PHEN
was	O
shown	O
to	O
be	O
in	O
operation	O
instead	O
.	O

Studies	B-PROC
of	O
the	O
arrangement	O
of	O
the	O
airways	B-ANAT
and	O
the	O
blood	B-ANAT
vessels	I-ANAT
corroborated	O
the	O
existence	O
of	O
a	O
cross	B-PHEN
-	I-PHEN
current	I-PHEN
system	I-PHEN
in	O
the	O
avian	B-LIVB
lung	B-ANAT
.	O

While	O
the	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
is	O
ventilated	O
tidally	O
,	O
like	O
most	O
other	O
invaginated	B-DISO
gas	B-PHYS
exchangers	I-PHYS
,	O
the	O
lung	B-ANAT
,	O
specifically	O
the	O
paleopulmonic	B-ANAT
parabronchi	I-ANAT
,	O
is	O
ventilated	O
unidirectionally	O
and	O
continuously	O
in	O
a	O
caudocranial	B-ANAT
(	O
back	O
-	O
to	O
-	O
front	O
)	O
direction	O
by	O
synchronized	O
actions	O
of	O
the	O
air	B-ANAT
sacs	I-ANAT
.	O

The	O
path	O
followed	O
by	O
the	O
inspired	B-OBJC
air	I-OBJC
in	O
the	O
lung	B-ANAT
-	O
air	B-ANAT
sac	I-ANAT
system	B-ANAT
is	O
now	O
known	O
to	O
be	O
controlled	O
by	O
a	O
mechanism	O
of	O
aerodynamic	B-PHEN
valving	I-PHEN
and	O
not	O
by	O
anatomical	B-ANAT
valves	I-ANAT
or	O
sphincters	B-ANAT
,	O
as	O
was	O
previously	O
supposed	O
.	O

The	O
structural	B-ANAT
strength	O
of	O
the	O
air	B-ANAT
and	O
blood	B-ANAT
capillaries	I-ANAT
is	O
derived	O
from	O
:	O
the	O
interdependence	O
between	O
the	O
air	B-ANAT
and	O
blood	B-ANAT
capillaries	I-ANAT
;	O
a	O
tethering	O
effect	O
between	O
the	O
closely	O
entwined	O
respiratory	B-ANAT
units	I-ANAT
;	O
the	O
presence	O
of	O
epithelial	B-ANAT
-	O
epithelial	B-ANAT
cell	I-ANAT
connections	O
(	O
retinacula	O
or	O
cross	O
-	O
bridges	O
)	O
that	O
join	O
the	O
blood	B-ANAT
capillaries	I-ANAT
while	O
separating	O
the	O
air	B-ANAT
capillaries	I-ANAT
;	O
the	O
abundance	O
and	O
intricate	O
arrangement	O
of	O
the	O
connective	O
tissue	O
elements	O
,	O
i	O
.	O

e	O
.	O

collagen	B-CHEM
,	O
elastin	B-CHEM
,	O
and	O
smooth	B-ANAT
muscle	I-ANAT
fibres	I-ANAT
;	O
the	O
presence	O
of	O
type	B-CHEM
-	I-CHEM
IV	I-CHEM
collagen	I-CHEM
,	O
especially	O
in	O
the	O
basement	O
membranes	O
of	O
the	O
blood	B-ANAT
-	I-ANAT
gas	I-ANAT
barrier	I-ANAT
and	O
the	O
epithelial	B-ANAT
-	O
epithelial	B-ANAT
cell	I-ANAT
connections	O
;	O
and	O
a	O
putative	O
tensegrity	O
state	O
in	O
the	O
lung	B-ANAT
.	O

Notwithstanding	O
the	O
paucity	O
of	O
free	O
surface	O
pulmonary	B-ANAT
macrophages	I-ANAT
,	O
the	O
respiratory	O
surface	O
of	O
the	O
avian	B-LIVB
lung	B-ANAT
is	O
well	O
protected	O
from	O
pathogens	B-LIVB
and	O
particulates	B-OBJC
by	O
an	O
assortment	O
of	O
highly	O
efficient	O
phagocytic	B-ANAT
cells	I-ANAT
.	O

In	O
commercial	O
poultry	B-LIVB
production	O
,	O
instead	O
of	O
weak	O
pulmonary	B-ANAT
cellular	B-PHYS
defence	I-PHYS
,	O
stressful	O
husbandry	O
practices	O
such	O
as	O
overcrowding	B-DISO
,	O
force	B-DISO
-	I-DISO
feeding	I-DISO
,	O
and	O
intense	O
genetic	B-PROC
manipulation	I-PROC
for	O
rapid	O
weight	B-DISO
gain	I-DISO
and	O
egg	B-PHYS
production	I-PHYS
may	O
account	O
for	O
the	O
reported	O
susceptibility	B-PHYS
of	O
birds	B-LIVB
to	O
aerosol	B-OBJC
-	O
transmitted	O
diseases	B-DISO
.	O

Activation	B-PHYS
of	O
general	B-CHEM
control	I-CHEM
nonderepressible	I-CHEM
2	I-CHEM
kinase	I-CHEM
protects	B-DISO
human	B-LIVB
glomerular	B-ANAT
endothelial	I-ANAT
cells	I-ANAT
from	O
harmful	O
high	B-DISO
-	I-DISO
glucose	I-DISO
-	O
induced	O
molecular	B-PHYS
pathways	I-PHYS
Considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	B-CHEM
restriction	O
on	O
diabetic	B-DISO
nephropathy	I-DISO
(	O
DN	B-DISO
)	O
and	O
the	O
role	O
of	O
renal	B-ANAT
endothelium	O
in	O
its	O
pathogenesis	B-DISO
,	O
we	O
evaluated	B-PROC
the	O
effect	O
of	O
general	B-CHEM
control	I-CHEM
nonderepressible	I-CHEM
2	I-CHEM
(	I-CHEM
GCN2	I-CHEM
)	I-CHEM
kinase	I-CHEM
activation	B-PHYS
,	O
a	O
sensor	B-DEVI
of	O
amino	B-CHEM
acid	I-CHEM
deprivation	O
,	O
on	O
known	O
detrimental	O
molecular	B-PHYS
pathways	I-PHYS
in	O
primary	O
human	B-LIVB
glomerular	B-ANAT
endothelial	I-ANAT
cells	I-ANAT
(	O
GEnC	B-ANAT
)	O
.	O

GEnC	B-ANAT
were	O
cultured	B-PROC
under	O
normal	O
or	O
high	B-DISO
-glucose	I-DISO
conditions	I-DISO
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
GCN2	B-CHEM
kinase	I-CHEM
activator	B-PHYS
,	O
tryptophanol	B-CHEM
.	O

Glucose	B-CHEM
transporter	I-CHEM
1	I-CHEM
(	O
GLUT1	B-CHEM
)	O
expression	B-PHYS
was	O
assessed	O
by	O
western	B-PROC
blotting	I-PROC
and	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O
ROS	B-CHEM
)	O
using	O
a	O
fluorogenic	B-CHEM
probe	I-CHEM
.	O

Activities	B-PHYS
of	O
glyceraldehyde	B-CHEM
3	I-CHEM
-	I-CHEM
phosphate	I-CHEM
dehydrogenase	I-CHEM
(	O
GAPDH	B-CHEM
)	O
and	O
protein	B-CHEM
kinase	I-CHEM
C	I-CHEM
(	O
PKC	B-CHEM
)	O
were	O
assessed	O
by	O
commercial	B-PROC
activity	I-PROC
assays	I-PROC
,	O
sorbitol	B-CHEM
colorimetrically	B-PROC
,	O
methylglyoxal	B-CHEM
by	O
ELISA	B-PROC
and	O
O	B-CHEM
-	I-CHEM
linked	I-CHEM
β	I-CHEM
-	I-CHEM
N	I-CHEM
-	I-CHEM
acetyl	I-CHEM
glucosamine	I-CHEM
(	I-CHEM
O	I-CHEM
-	I-CHEM
GlcNAc	I-CHEM
)	I-CHEM
-	I-CHEM
modified	I-CHEM
proteins	I-CHEM
by	O
western	B-PROC
blotting	I-PROC
.	O

High	B-DISO
glucose	I-DISO
induced	O
GLUT1	B-CHEM
expression	B-PHYS
,	O
increased	O
ROS	B-CHEM
and	O
inhibited	O
GAPDH	B-CHEM
.	O

Also	O
it	O
increased	O
the	O
polyol	B-CHEM
pathway	B-PHYS
product	O
sorbitol	B-CHEM
,	O
PKC	B-CHEM
activity	B-PHYS
,	O
the	O
level	O
of	O
the	O
O	B-CHEM
-	I-CHEM
GlcNAc	I-CHEM
-	I-CHEM
modified	I-CHEM
proteins	I-CHEM
that	O
produced	O
by	O
the	O
hexosamine	B-CHEM
pathway	B-PHYS
and	O
the	O
advanced	B-CHEM
glycation	I-CHEM
endproducts	I-CHEM
'	I-CHEM
precursor	O
methylglyoxal	B-CHEM
.	O

Co	B-PROC
-	I-PROC
treatment	I-PROC
of	O
GEnC	B-ANAT
with	O
tryptophanol	B-CHEM
restored	O
the	O
above	O
high	B-DISO
-	I-DISO
glucose	I-DISO
-	O
induced	O
alterations	O
.	O

Activation	B-PHYS
of	O
GCN2	B-CHEM
kinase	I-CHEM
protects	O
GEnC	B-ANAT
from	O
high	B-DISO
-	I-DISO
glucose	I-DISO
-	O
induced	O
harmful	O
molecular	B-PHYS
pathways	I-PHYS
.	O

By	O
inhibiting	O
concurrently	O
many	O
pathways	B-PHYS
involved	O
in	O
DN	B-DISO
pathogenesis	B-DISO
,	O
GCN2	B-CHEM
kinase	I-CHEM
may	O
serve	O
as	O
a	O
pharmaceutical	O
target	O
for	O
the	O
treatment	B-PROC
of	O
DN	B-DISO
.	O

microRNA	B-CHEM
-	I-CHEM
145	I-CHEM
Mediates	O
the	O
Inhibitory	O
Effect	O
of	O
Adipose	O
Tissue	O
-Derived	O
Stromal	B-ANAT
Cells	I-ANAT
on	O
Prostate	B-DISO
Cancer	I-DISO
Adipose	B-ANAT
-	I-ANAT
derived	I-ANAT
stromal	I-ANAT
cell	I-ANAT
(	I-ANAT
ASC	I-ANAT
)	I-ANAT
,	O
known	O
as	O
one	O
of	O
the	O
mesenchymal	B-ANAT
stem	I-ANAT
cells	I-ANAT
(	I-ANAT
MSCs	I-ANAT
)	I-ANAT
,	O
is	O
a	O
promising	O
tool	O
for	O
regenerative	O
medicine	O
;	O
however	O
,	O
the	O
effect	O
of	O
ASCs	B-ANAT
on	O
tumor	B-DISO
growth	I-DISO
has	O
not	O
been	O
studied	O
sufficiently	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
ASCs	B-ANAT
have	O
an	O
inhibitory	O
effect	O
on	O
metastatic	B-DISO
tumor	I-DISO
progression	I-DISO
.	O

To	O
evaluate	O
the	O
in	O
vitro	O
inhibitory	O
effect	O
of	O
ASCs	B-ANAT
on	O
metastatic	B-DISO
prostate	I-DISO
cancer	I-DISO
(	I-DISO
PCa	I-DISO
)	I-DISO
,	O
direct	O
coculture	B-PROC
and	O
indirect	O
separate	O
culture	B-PROC
experiments	I-PROC
with	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cells	I-ANAT
and	O
human	B-LIVB
ASCs	B-ANAT
were	O
performed	O
,	O
and	O
ASCs	B-ANAT
were	O
administered	O
to	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cell	I-ANAT
-derived	O
tumor	B-DISO
-bearing	O
nude	B-LIVB
mice	I-LIVB
for	O
in	O
vivo	O
experiment	B-PROC
.	O

We	O
also	O
performed	O
exosome	B-ANAT
microRNA	B-CHEM
(	I-CHEM
miRNA	I-CHEM
)	I-CHEM
array	B-PROC
analysis	I-PROC
to	O
explore	O
a	O
mechanistic	O
insight	O
into	O
the	O
effect	O
of	O
ASCs	B-ANAT
on	O
PCa	B-ANAT
cell	I-ANAT
proliferation	B-PHYS
/	O
apoptosis	B-PHYS
.	O

Both	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	B-PROC
exhibited	O
the	O
inhibitory	O
effect	O
of	O
ASCs	B-ANAT
on	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cell	B-PHYS
proliferation	I-PHYS
,	O
inducing	O
apoptosis	B-PHYS
and	O
PCa	B-DISO
growth	B-DISO
,	O
respectively	O
.	O

Among	O
upregulated	B-PHYS
miRNAs	B-CHEM
in	O
ASCs	B-ANAT
compared	O
with	O
fibroblasts	B-ANAT
,	O
we	O
focused	O
on	O
miR	O
-	O
145	O
,	O
which	O
was	O
known	O
as	O
a	O
tumor	O
suppressor	O
.	O

ASC	B-ANAT
-derived	O
conditioned	B-CHEM
medium	I-CHEM
(	I-CHEM
CM	I-CHEM
)	I-CHEM
significantly	O
inhibited	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cell	B-PHYS
proliferation	I-PHYS
,	O
inducing	O
apoptosis	B-PHYS
,	O
but	O
the	O
effect	O
was	O
canceled	O
by	O
miR	O
-	O
145	O
knockdown	B-PROC
in	O
ASCs	B-ANAT
.	O

ASC	B-ANAT
miR	O
-	O
145	O
knockdown	B-PROC
CM	B-CHEM
also	O
reduced	O
the	O
expression	B-PHYS
of	O
Caspase	B-CHEM
3	I-CHEM
/	O
7	B-CHEM
with	O
increased	O
antiapoptotic	B-CHEM
protein	B-CHEM
,	O
BclxL	B-CHEM
,	O
expression	B-PHYS
in	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cells	I-ANAT
.	O

This	O
study	B-PROC
provides	O
preclinical	O
data	O
that	O
ASCs	B-ANAT
inhibit	O
PCa	B-DISO
growth	B-DISO
,	O
inducing	O
PCa	B-DISO
cell	B-ANAT
apoptosis	B-PHYS
with	O
reduced	O
activity	O
of	O
BclxL	B-CHEM
,	O
at	O
least	O
in	O
part	O
,	O
by	O
miR	O
-	O
145	O
,	O
including	O
exosomes	B-ANAT
released	O
from	O
ASCs	B-ANAT
,	O
suggesting	O
that	O
ASC	B-ANAT
administration	O
could	O
be	O
a	O
novel	O
and	O
promising	O
therapeutic	O
strategy	O
in	O
patients	B-LIVB
with	O
PCa	B-DISO
.	O

Visual	B-PROC
Analytics	I-PROC
for	O
Pattern	B-PHYS
Discovery	I-PHYS
in	O
Home	B-PROC
Care	I-PROC
.	O

Clinical	O
Relevance	O
for	O
Quality	O
Improvement	O
Visualization	B-PHYS
can	O
reduce	O
the	O
cognitive	O
load	O
of	O
information	O
,	O
allowing	O
users	O
to	O
easily	O
interpret	O
and	O
assess	B-PROC
large	I-PROC
amounts	I-PROC
of	I-PROC
data	I-PROC
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home	O
health	O
data	O
using	O
visual	B-PROC
analysis	I-PROC
techniques	I-PROC
to	O
discover	O
clinically	O
salient	O
associations	O
between	O
patient	B-PHYS
characteristics	I-PHYS
with	O
problem	O
-	O
oriented	O
health	O
outcomes	O
of	O
older	B-PROC
adult	I-PROC
home	I-PROC
health	I-PROC
patients	I-PROC
during	O
the	O
home	B-PROC
health	I-PROC
service	I-PROC
period	O
.	O

Knowledge	O
,	O
Behavior	O
and	O
Status	O
ratings	O
at	O
discharge	B-PROC
as	O
well	O
as	O
change	O
from	O
admission	B-PROC
to	O
discharge	B-PROC
that	O
was	O
coded	O
using	O
the	O
Omaha	O
System	O
was	O
collected	O
from	O
a	O
dataset	O
on	O
988	O
de	O
-	O
identified	O
patient	O
data	O
from	O
15	O
home	O
health	O
agencies	O
.	O

SPSS	O
Visualization	O
Designer	O
v1	O
.	O

0	O
was	O
used	O
to	O
visually	B-PROC
analyze	I-PROC
patterns	I-PROC
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat	O
maps	O
and	O
histograms	B-OBJC
.	O

Visualizations	B-PHYS
suggesting	O
clinical	B-DISO
salience	I-DISO
were	O
tested	O
for	O
significance	O
using	O
correlation	B-PROC
analysis	I-PROC
.	O

The	O
mean	O
age	O
of	O
the	O
patients	B-LIVB
was	O
80	O
years	O
,	O
with	O
the	O
majority	O
female	B-PHYS
(	O
66	O
%	O
)	O
.	O

Of	O
the	O
150	O
visualizations	B-PHYS
,	O
69	O
potentially	O
meaningful	O
patterns	O
were	O
statistically	O
evaluated	O
through	O
bivariate	O
associations	O
,	O
revealing	O
21	O
significant	O
associations	O
.	O

Further	O
,	O
14	O
associations	O
between	O
episode	O
length	O
and	O
Charlson	O
co	O
-	O
morbidity	O
index	O
mainly	O
with	O
urinary	O
related	O
diagnoses	B-DISO
and	I-DISO
problems	I-DISO
remained	O
significant	O
after	O
adjustment	O
analyses	O
.	O

Through	O
visual	B-PROC
analysis	I-PROC
,	O
the	O
adverse	O
association	O
of	O
the	O
longer	O
home	B-PROC
health	I-PROC
episode	I-PROC
length	O
and	O
higher	O
Charlson	O
co	O
-	O
morbidity	O
index	O
with	O
behavior	B-DISO
or	I-DISO
status	I-DISO
outcomes	I-DISO
for	O
patients	B-LIVB
with	O
impaired	B-DISO
urinary	I-DISO
function	I-DISO
was	O
revealed	O
.	O

We	O
have	O
demonstrated	O
the	O
use	O
of	O
visual	B-PROC
analysis	I-PROC
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high	O
-	O
needs	O
subgroups	O
among	O
the	O
older	O
home	O
health	O
patient	O
population	O
.	O

The	O
effective	O
presentation	O
of	O
these	O
data	O
patterns	O
can	O
allow	O
clinicians	B-LIVB
to	O
identify	O
areas	O
of	O
patient	O
improvement	O
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home	B-PROC
health	I-PROC
interventions	I-PROC
to	O
improve	O
patient	B-PROC
outcomes	I-PROC
.	O

Initial	O
experience	B-PHYS
using	O
a	O
femtosecond	B-PROC
laser	I-PROC
cataract	I-PROC
surgery	I-PROC
system	B-DEVI
at	O
a	O
UK	O
National	O
Health	O
Service	O
cataract	O
surgery	O
day	O
care	O
centre	O
To	O
describe	O
the	O
initial	O
outcomes	O
following	O
installation	O
of	O
a	O
cataract	B-PROC
surgery	I-PROC
laser	B-DEVI
system	I-DEVI
.	O

National	O
Health	O
Service	O
cataract	O
surgery	O
day	O
care	O
unit	O
in	O
North	B-GEOG
London	I-GEOG
,	O
UK	B-GEOG
.	O
158	O
eyes	B-ANAT
of	O
150	O
patients	B-LIVB
undergoing	O
laser	B-PROC
-	I-PROC
assisted	I-PROC
cataract	I-PROC
surgery	I-PROC
.	O

Laser	B-PROC
cataract	I-PROC
surgery	I-PROC
using	O
the	O
AMO	B-DEVI
Catalys	I-DEVI
femtosecond	I-DEVI
laser	I-DEVI
platform	I-DEVI
.	O

intraoperative	B-DISO
complications	I-DISO
including	O
anterior	B-DISO
and	O
posterior	B-DISO
capsule	I-DISO
tears	I-DISO
.	O

docking	B-PROC
to	O
the	O
laser	B-DEVI
platform	I-DEVI
,	O
successful	O
treatment	B-PROC
delivery	I-PROC
,	O
postoperative	B-PHYS
visual	I-PHYS
acuities	I-PHYS
.	O

Mean	O
case	O
age	B-PHYS
was	O
67	O
.	O

7±10	O
.	O

8	O
years	O
(	O
range	O
29	O
-	O
88	O
years	O
)	O
.	O

Docking	B-PROC
was	O
successful	O
in	O
94	O
%	O
(	O
148	O
/	O
158	O
cases	O
)	O
,	O
and	O
in	O
4	O
%	O
(	O
6	O
/	O
148	O
cases	O
)	O
of	O
these	O
,	O
the	O
laser	O
delivery	O
was	O
aborted	O
part	O
way	O
during	O
delivery	O
due	O
to	O
patient	B-LIVB
movement	B-PHYS
.	O

A	O
total	O
of	O
32	O
surgeons	B-LIVB
,	O
of	O
grades	O
from	O
junior	B-LIVB
trainee	I-LIVB
to	O
consultant	B-LIVB
,	O
performed	O
the	O
surgeries	B-PROC
.	O

Median	O
case	O
number	O
per	O
surgeon	B-LIVB
was	O
3	O
(	O
range	O
from	O
1	O
-	O
20	O
)	O
.	O

The	O
anterior	O
capsulotomy	B-PROC
was	O
complete	O
in	O
99	O
.	O

3	O
%	O
of	O
cases	O
,	O
there	O
were	O
no	O
anterior	O
capsule	B-DISO
tears	I-DISO
(	O
0	O
%	O
)	O
.	O

There	O
were	O
3	O
cases	O
with	O
posterior	B-DISO
capsule	I-DISO
rupture	I-DISO
requiring	O
anterior	O
vitrectomy	B-PROC
,	O
and	O
1	O
with	O
zonular	B-DISO
dialysis	I-DISO
requiring	O
anterior	O
vitrectomy	B-PROC
(	O
4	O
/	O
148	O
eyes	B-ANAT
,	O
2	O
.	O
7	O
%	O
)	O
.	O

These	O
4	O
cases	O
were	O
performed	O
by	O
trainee	B-LIVB
surgeons	I-LIVB
,	O
and	O
were	O
either	O
their	O
first	O
laser	B-PROC
cataract	I-PROC
surgery	I-PROC
(	O
2	O
surgeons	B-LIVB
)	O
or	O
their	O
first	O
and	O
second	O
laser	B-PROC
cataract	I-PROC
surgeries	I-PROC
(	O
1	O
surgeon	B-LIVB
)	O
.	O

Despite	O
the	O
learning	O
curve	O
,	O
docking	B-PROC
and	O
laser	O
delivery	O
were	O
successfully	O
performed	O
in	O
almost	O
all	O
cases	O
,	O
and	O
surgical	O
complication	O
rates	O
and	O
visual	O
outcomes	O
were	O
similar	O
to	O
those	O
expected	O
based	O
on	O
national	O
data	O
.	O

Complications	B-DISO
were	O
predominately	O
confined	O
to	O
trainee	B-LIVB
surgeons	I-LIVB
,	O
and	O
with	O
the	O
exception	O
of	O
intraoperative	O
pupil	B-PROC
constriction	I-PROC
appeared	O
unrelated	O
to	O
the	O
laser	O
-	O
performed	O
steps	O
.	O

Transforming	B-CHEM
Growth	I-CHEM
Factor	I-CHEM
Beta	I-CHEM
1	I-CHEM
(	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
)	O
in	O
Thyroid	B-DISO
Cancer	I-DISO
Patients	B-LIVB
:	O
a	O
View	O
from	O
the	O
Peripheral	B-ANAT
Blood	I-ANAT
Transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
beta	I-CHEM
(	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	O
conditions	O
,	O
including	O
cancer	B-DISO
.	O

The	O
level	O
of	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
in	O
patients	B-LIVB
with	O
differentiated	B-DISO
thyroid	I-DISO
cancer	I-DISO
(	O
DTC	B-DISO
)	O
has	O
not	O
been	O
examined	B-DISO
so	O
far	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
measure	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
concentration	O
in	O
serum	B-ANAT
samples	I-ANAT
and	O
in	O
PHA	B-CHEM
-	O
stimulated	B-PHYS
whole	B-ANAT
blood	I-ANAT
culture	B-PROC
in	O
vitro	O
and	O
to	O
analyze	B-PROC
possible	O
associations	O
of	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
levels	O
with	O
leukocyte	B-ANAT
,	O
lymphocyte	B-ANAT
and	O
platelets	B-ANAT
counts	B-PROC
,	O
the	O
histological	O
type	O
of	O
thyroid	B-DISO
cancer	I-DISO
,	O
and	O
stage	B-PROC
of	I-PROC
disease	I-PROC
.	O

TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
was	O
measured	O
in	O
22	O
DTC	B-DISO
patients	B-LIVB
and	O
20	O
healthy	O
controls	B-LIVB
using	O
the	O
duoSet	B-DEVI
ELISA	I-DEVI
Development	I-DEVI
kit	I-DEVI
for	O
human	B-CHEM
TGF	I-CHEM
-	I-CHEM
β1	I-CHEM
.	O

The	O
concentration	O
of	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
in	O
serum	B-ANAT
samples	I-ANAT
from	O
both	O
groups	B-LIVB
correlated	O
positively	O
with	O
the	O
platelet	B-ANAT
counts	B-PROC
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
serum	O
concentrations	O
of	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
between	O
DTC	B-DISO
patients	B-LIVB
and	O
control	B-LIVB
subjects	I-LIVB
,	O
but	O
PHA	B-CHEM
stimulated	B-PHYS
whole	B-ANAT
blood	I-ANAT
cultures	B-PROC
of	O
DTC	B-DISO
patients	B-LIVB
produced	O
less	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
than	O
those	O
from	O
controls	B-LIVB
.	O

Additional	O
studies	B-PROC
are	O
needed	O
to	O
determine	O
the	O
significance	O
of	O
these	O
in	O
vitro	O
findings	B-DISO
.	O

P	B-CHEM
-	I-CHEM
glycoprotein	I-CHEM
traffics	O
from	O
the	O
nucleus	B-ANAT
to	O
the	O
plasma	B-ANAT
membrane	I-ANAT
in	O
rat	B-ANAT
brain	I-ANAT
endothelium	O
during	O
inflammatory	B-DISO
pain	I-DISO
P	B-CHEM
-	I-CHEM
glycoprotein	I-CHEM
(	O
PgP	B-CHEM
)	O
,	O
a	O
drug	B-CHEM
efflux	O
pump	O
in	O
blood	B-ANAT
-	I-ANAT
brain	I-ANAT
barrier	I-ANAT
endothelial	B-ANAT
cells	I-ANAT
,	O
is	O
a	O
major	O
clinical	O
obstacle	O
for	O
effective	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-PROC
delivery	I-PROC
.	O

Identifying	B-PROC
PgP	B-CHEM
regulatory	O
pathways	O
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-PROC
delivery	I-PROC
.	O

We	O
previously	O
found	O
that	O
PgP	B-PHYS
activity	I-PHYS
increases	O
in	O
rat	B-ANAT
brain	I-ANAT
microvessels	B-ANAT
concomitant	O
with	O
decreased	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-PROC
delivery	I-PROC
in	O
response	O
to	O
acute	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
.	O

In	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	B-CHEM
traffics	O
to	O
the	O
luminal	O
plasma	B-ANAT
membrane	I-ANAT
of	O
the	O
microvessel	B-ANAT
endothelial	B-ANAT
cells	I-ANAT
from	O
intracellular	O
stores	O
during	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
.	O

Using	O
immunofluorescence	B-PROC
microscopy	I-PROC
,	O
we	O
detected	B-DISO
PgP	B-CHEM
in	O
endothelial	B-ANAT
cell	I-ANAT
nuclei	B-ANAT
and	O
in	O
the	O
luminal	O
plasma	B-ANAT
membrane	I-ANAT
in	O
control	B-LIVB
animals	I-LIVB
.	O

Following	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
,	O
luminal	O
PgP	B-CHEM
staining	B-PROC
increased	O
while	O
staining	B-PROC
in	O
the	O
nucleus	B-ANAT
decreased	O
.	O

Biochemical	B-PROC
analysis	I-PROC
of	O
nuclear	B-ANAT
PgP	B-CHEM
content	O
confirmed	O
our	O
visual	O
observations	O
.	O

Peripheral	O
inflammatory	B-DISO
pain	I-DISO
also	O
increased	O
endothelial	B-ANAT
cell	I-ANAT
luminal	O
staining	B-PROC
of	O
polymerase	O
1	O
and	O
transcript	O
release	O
factor	O
/	O
cavin1	O
and	O
serum	O
deprivation	O
response	O
protein	O
/	O
cavin2	O
,	O
two	O
caveolar	B-CHEM
scaffold	I-CHEM
proteins	I-CHEM
,	O
without	O
changing	O
caveolin1	B-CHEM
or	O
protein	O
kinase	O
C	O
delta	O
binding	O
protein	O
/	O
cavin3	O
location	O
.	O

Our	O
data	O
(	O
a	O
)	O
indicate	O
that	O
PgP	B-CHEM
traffics	O
from	O
stores	O
in	O
the	O
nucleus	B-ANAT
to	O
the	O
endothelial	B-ANAT
cell	I-ANAT
luminal	B-ANAT
membrane	I-ANAT
in	O
response	O
to	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
;	O
(	O
b	O
)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	B-PROC
that	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
inhibits	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-CHEM
uptake	B-PHYS
;	O
and	O
(	O
c	O
)	O
suggest	O
a	O
novel	O
regulatory	B-DISO
mechanism	I-DISO
for	O
PgP	B-PHYS
activity	I-PHYS
in	O
rat	B-ANAT
brain	I-ANAT
.	O

Gene	O
Expression	O
Profile	O
in	O
the	O
Liver	B-ANAT
of	O
Sheep	B-LIVB
Infected	B-DISO
with	O
Cystic	B-DISO
Echinococcosis	I-DISO
Cystic	B-DISO
Echinococcosis	I-DISO
(	O
CE	B-DISO
)	O
,	O
caused	O
by	O
infection	B-DISO
with	O
the	O
Echinococcus	O
granulosus	O
(	O
E	O
.	O
granulosus	O
)	O
,	O
represents	O
considerable	O
health	O
problems	B-DISO
in	O
both	O
humans	B-LIVB
and	O
livestock	B-LIVB
.	O

Nevertheless	O
,	O
the	O
genetic	O
program	O
that	O
regulates	O
the	O
host	B-PHYS
response	I-PHYS
to	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
is	O
largely	O
unknown	O
.	O

Previously	O
,	O
using	O
microarray	B-PROC
analysis	I-PROC
,	O
we	O
found	O
that	O
the	O
innate	B-PHYS
immunity	I-PHYS
played	O
a	O
vital	O
role	O
in	O
the	O
E	O
.	O

granulosus	O
defense	O
of	O
the	O
intestine	O
tissue	O
where	O
E	O
.	O

granulosus	O
first	O
invaded	O
.	O

Subsequently	O
,	O
we	O
turned	O
our	O
attention	O
to	O
investigating	O
the	O
molecular	O
immune	B-PHYS
mechanism	O
in	O
its	O
organ	B-ANAT
target	O
,	O
the	O
liver	B-ANAT
,	O
which	O
is	O
where	O
the	O
E	O
.	O

granulosus	O
metacestodes	B-PHYS
are	O
established	O
and	O
live	O
for	O
very	O
long	O
periods	O
.	O

In	O
this	O
work	O
,	O
the	O
microarray	B-PROC
-	I-PROC
based	I-PROC
methodology	I-PROC
was	O
used	O
to	O
study	O
gene	O
expression	O
profiles	O
in	O
the	O
liver	B-ANAT
of	O
sheep	B-LIVB
infected	B-DISO
with	O
E	O
.	O

granulosus	O
at	O
8	O
weeks	O
post	O
infection	B-DISO
,	O
corresponding	O
to	O
the	O
early	O
cystic	O
established	O
phase	O
.	O

A	O
total	O
of	O
6	O
female	B-PHYS
-1	O
-	O
year	O
-old	O
healthy	O
Kazakh	B-LIVB
sheep	I-LIVB
were	O
used	O
for	O
the	O
experiments	B-PROC
.	O

Three	O
Kazakh	B-LIVB
sheep	I-LIVB
were	O
orally	B-ANAT
infected	B-DISO
with	O
E	O
.	O

granulosus	O
eggs	O
,	O
and	O
the	O
others	O
remained	O
untreated	O
and	O
served	O
as	O
controls	B-LIVB
.	O

Sheep	B-LIVB
were	O
humanely	B-PROC
euthanized	I-PROC
and	O
necropsized	B-PROC
at	O
8	O
weeks	O
post	O
-	O
infection	B-DISO
(	O
the	O
early	O
stage	O
of	O
cyst	O
established	O
)	O
.	O

The	O
microarray	B-PROC
was	O
used	O
to	O
detect	B-DISO
differential	B-PHYS
hepatic	I-PHYS
gene	I-PHYS
expression	I-PHYS
between	O
CE	B-DISO
infection	B-DISO
sheep	B-LIVB
and	O
healthy	O
controls	O
at	O
this	O
time	O
point	O
.	O

Real	B-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
was	O
used	O
to	O
validate	O
the	O
microarray	B-PROC
data	O
.	O

We	O
found	O
that	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
induces	O
153	O
differentially	B-PHYS
expressed	I-PHYS
genes	O
in	O
the	O
livers	B-ANAT
of	O
infected	B-DISO
sheep	B-LIVB
compared	O
with	O
healthy	O
controls	O
.	O

Among	O
them	O
,	O
87	O
genes	O
were	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
,	O
and	O
66	O
genes	O
were	O
notably	O
down	B-PHYS
-	I-PHYS
regulated	I-PHYS
.	O

Functional	B-PHYS
analysis	B-PROC
showed	O
that	O
these	O
genes	O
were	O
associated	O
with	O
three	O
major	O
functional	O
categories	O
:	O
(	O
a	O
)	O
metabolism	B-PHYS
,	O
(	O
b	O
)	O
the	O
immune	B-ANAT
system	I-ANAT
and	O
(	O
c	O
)	O
signaling	B-PHYS
and	O
transport	B-PHYS
.	O

Deeper	O
analysis	B-PROC
indicated	O
that	O
complement	O
together	O
with	O
other	O
genes	O
associated	O
with	O
metabolism	B-PHYS
,	O
played	O
important	O
roles	O
in	O
the	O
defense	O
of	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
.	O

The	O
present	O
study	B-PROC
identified	O
genes	B-PROC
profiling	I-PROC
in	O
the	O
liver	B-ANAT
tissue	I-ANAT
of	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
in	O
sheep	B-LIVB
.	O

The	O
expression	B-PHYS
pattern	O
obtained	O
here	O
could	O
be	O
helpful	O
for	O
understanding	O
the	O
molecular	O
immunity	B-PHYS
mechanisms	O
of	O
host	B-PHYS
responses	I-PHYS
to	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
.	O

However	O
,	O
it	O
is	O
necessary	O
to	O
carry	O
out	O
further	O
studies	O
to	O
evalute	O
the	O
role	O
of	O
these	O
genes	O
.	O

Juicer	O
Provides	O
a	O
One	O
-	O
Click	O
System	O
for	O
Analyzing	B-PROC
Loop	B-PROC
-	I-PROC
Resolution	I-PROC
Hi	I-PROC
-	I-PROC
C	I-PROC
Experiments	I-PROC
Hi	B-PROC
-	I-PROC
C	I-PROC
experiments	I-PROC
explore	O
the	O
3D	O
structure	O
of	O
the	O
genome	O
,	O
generating	O
terabases	O
of	O
data	O
to	O
create	O
high	B-PROC
-	I-PROC
resolution	I-PROC
contact	O
maps	O
.	O

Here	O
,	O
we	O
introduce	O
Juicer	O
,	O
an	O
open	O
-	O
source	O
tool	O
for	O
analyzing	O
terabase	O
-	O
scale	O
Hi	O
-	O
C	O
datasets	O
.	O

Juicer	O
allows	O
users	B-LIVB
without	O
a	O
computational	O
background	O
to	O
transform	B-PROC
raw	O
sequence	O
data	O
into	O
normalized	O
contact	O
maps	O
with	O
one	O
click	O
.	O

Juicer	O
produces	O
a	O
hic	O
file	O
containing	O
compressed	O
contact	O
matrices	O
at	O
many	O
resolutions	O
,	O
facilitating	O
visualization	B-PHYS
and	O
analysis	B-PROC
at	O
multiple	O
scales	O
.	O

Structural	O
features	O
,	O
such	O
as	O
loops	B-ANAT
and	O
domains	B-PHYS
,	O
are	O
automatically	O
annotated	O
.	O

Juicer	O
is	O
available	O
as	O
open	O
source	O
software	B-OBJC
at	O
http	O
:	O
/	O
/	O
aidenlab	O
.	O

org	O
/	O
juicer	O
/	O
.	O

An	O
Encapsulation	B-PHEN
of	O
Gene	O
Signatures	O
for	O
Hepatocellular	B-DISO
Carcinoma	I-DISO
,	O
MicroRNA	B-CHEM
-	I-CHEM
132	I-CHEM
Predicted	O
Target	O
Genes	O
and	O
the	O
Corresponding	O
Overlaps	O
Previous	O
studies	B-PROC
have	O
demonstrated	O
that	O
microRNA	B-CHEM
-	I-CHEM
132	I-CHEM
plays	O
a	O
vital	O
part	O
in	O
and	O
is	O
actively	O
associated	O
with	O
several	O
cancers	B-DISO
,	O
with	O
its	O
tumor	B-PHYS
-	I-PHYS
suppressive	I-PHYS
role	I-PHYS
in	O
hepatocellular	B-DISO
carcinoma	I-DISO
confirmed	O
.	O

The	O
current	O
study	B-PROC
employed	O
multiple	O
bioinformatics	O
techniques	O
to	O
establish	O
gene	O
signatures	O
for	O
hepatocellular	B-DISO
carcinoma	I-DISO
,	O
microRNA	B-CHEM
-	I-CHEM
132	I-CHEM
predicted	O
target	O
genes	O
and	O
the	O
corresponding	O
overlaps	O
.	O

Various	O
assays	B-PROC
were	O
performed	O
to	O
explore	O
the	O
role	O
and	O
cellular	B-PHYS
functions	I-PHYS
of	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
in	O
HCC	B-DISO
and	O
a	O
successive	B-PROC
panel	I-PROC
of	O
tasks	O
was	O
completed	O
,	O
including	O
NLP	O
analysis	B-PROC
,	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
target	O
genes	O
prediction	O
,	O
comprehensive	O
analyses	B-PROC
(	O
gene	O
ontology	O
analysis	O
,	O
pathway	O
analysis	O
,	O
network	O
analysis	O
and	O
connectivity	O
analysis	B-PROC
)	O
,	O
and	O
analytical	O
integration	O
.	O

Later	O
,	O
HCC	B-DISO
-	O
related	O
and	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
-	O
related	O
potential	O
targets	O
,	O
pathways	B-PHYS
,	O
networks	B-PHYS
and	O
highlighted	O
hub	O
genes	O
were	O
revealed	O
as	O
well	O
as	O
those	O
of	O
the	O
overlapped	O
section	O
.	O

MiR	B-CHEM
-	I-CHEM
132	I-CHEM
was	O
effective	O
in	O
both	O
impeding	O
cell	B-PHYS
growth	I-PHYS
and	O
boosting	O
apoptosis	B-PHYS
in	O
HCC	B-DISO
cell	B-ANAT
lines	I-ANAT
.	O

A	O
total	O
of	O
fifty	O
-	O
nine	O
genes	O
were	O
obtained	O
from	O
the	O
analytical	O
integration	O
,	O
which	O
were	O
considered	O
to	O
be	O
both	O
HCC	B-DISO
-	O
and	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
-	O
related	O
.	O

Moreover	O
,	O
four	O
specific	O
pathways	B-PHYS
were	O
unveiled	O
in	O
the	O
network	O
analysis	O
of	O
the	O
overlaps	O
,	O
i	O
.	O

e	O
.	O

adherens	B-ANAT
junction	I-ANAT
,	O
VEGF	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
,	O
neurotrophin	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
,	O
and	O
MAPK	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
.	O

The	O
tumor	B-PHYS
-	I-PHYS
suppressive	I-PHYS
role	I-PHYS
of	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
in	O
HCC	B-DISO
has	O
been	O
further	O
confirmed	O
by	O
in	O
vitro	O
experiments	B-PROC
.	O

Gene	O
signatures	O
in	O
the	O
study	B-PROC
identified	O
the	O
potential	O
molecular	O
mechanisms	O
of	O
HCC	B-DISO
,	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
and	O
their	O
established	O
associations	O
,	O
which	O
might	O
be	O
effective	O
for	O
diagnosis	B-PROC
,	O
individualized	O
treatments	B-PROC
and	O
prognosis	B-PROC
of	O
HCC	B-DISO
patients	B-LIVB
.	O

However	O
,	O
combined	O
detections	B-PROC
of	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
with	O
other	O
bio	B-PHYS
-	I-PHYS
indicators	I-PHYS
in	O
clinical	B-PROC
practice	I-PROC
and	O
further	O
in	O
vitro	O
experiments	B-PROC
are	O
needed	O
.	O

Prevalence	O
and	O
Hospital	B-PROC
Management	I-PROC
of	O
Amphotericin	B-CHEM
B	I-CHEM
Deoxycholate	I-CHEM
-Related	O
Toxicities	B-DISO
during	O
Treatment	B-PROC
of	O
HIV	B-DISO
-	O
Associated	B-DISO
Cryptococcal	B-DISO
Meningitis	I-DISO
in	O
South	B-GEOG
Africa	I-GEOG
We	O
aimed	O
to	O
establish	O
the	O
prevalence	O
of	O
amphotericin	B-CHEM
B	I-CHEM
deoxycholate	I-CHEM
(	O
AmBd	B-CHEM
)	O
-	O
related	O
toxicities	B-DISO
among	O
South	B-LIVB
African	I-LIVB
patients	B-LIVB
with	O
cryptococcosis	B-DISO
and	O
determine	O
adherence	O
to	O
international	O
recommendations	O
to	O
prevent	B-PROC
,	O
monitor	B-PROC
and	O
manage	O
AmBd	B-CHEM
-related	O
toxicities	B-DISO
.	O

Clinical	O
data	O
were	O
collected	O
from	O
cases	O
of	O
laboratory	B-DISO
-	I-DISO
confirmed	I-DISO
cryptococcosis	I-DISO
at	O
25	O
hospitals	B-OBJC
,	O
October	O
2012	O
-February	O
2013	O
.	O

Anemia	B-DISO
was	O
defined	O
as	O
hemoglobin	B-CHEM
(	O
Hb	B-CHEM
)	O
concentration	O
<	O
10	O
g	O
/	O
dl	O
,	O
hypokalemia	B-DISO
as	O
serum	B-PROC
potassium	I-PROC
(	O
K	B-PROC
)	O
<	O
3	O
.	O
4	O
mEq	O
/	O
L	O
and	O
nephrotoxicity	B-DISO
as	O
an	O
increase	O
in	O
serum	B-PROC
creatinine	I-PROC
(	O
Cr	B-PROC
)	O
to	O
>	O
1	O
.	O

1	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

To	O
determine	O
adherence	B-DISO
to	O
toxicity	B-DISO
prevention	O
recommendations	O
,	O
we	O
documented	O
whether	O
baseline	O
Hb	B-PROC
,	O
K	B-PROC
and	O
Cr	B-PROC
tests	I-PROC
were	O
performed	O
,	O
whether	O
pre	B-DISO
-	I-DISO
emptive	I-DISO
hydration	I-DISO
and	O
IV	O
potassium	B-CHEM
chloride	I-CHEM
(	O
KCl	B-CHEM
)	O
was	O
administered	O
prior	O
to	O
80	O
%	O
and	O
60	O
%	O
of	O
AmBd	B-CHEM
doses	O
and	O
whether	O
daily	O
oral	B-CHEM
KCl	I-CHEM
supplementation	B-CHEM
was	O
given	O
≥60	O
%	O
of	O
the	O
time	O
.	O

To	O
determine	O
adherence	O
to	O
monitoring	B-PROC
recommendations	I-PROC
,	O
we	O
ascertained	O
whether	O
a	O
daily	O
fluid	B-PROC
chart	I-PROC
was	O
completed	O
,	O
Hb	B-CHEM
was	O
monitored	B-PROC
weekly	O
and	O
K	B-PROC
or	O
Cr	B-PROC
were	O
monitored	B-PROC
bi	O
-	O
weekly	O
.	O

Of	O
846	O
patients	B-LIVB
,	O
clinical	O
data	O
were	O
available	O
for	O
76	O
%	O
(	O
642	O
/	O
846	O
)	O
,	O
82	O
%	O
(	O
524	O
/	O
642	O
)	O
of	O
whom	O
received	O
AmBd	B-CHEM
.	O

Sixty	O
-	O
four	O
per	O
cent	O
(	O
n	O
=	O
333	O
)	O
had	O
documented	O
baseline	O
laboratory	B-PROC
tests	I-PROC
,	O
40	O
%	O
(	O
n	O
=	O
211	O
)	O
were	O
given	O
pre	B-DISO
-	I-DISO
emptive	I-DISO
hydration	I-DISO
and	O
14	O
%	O
(	O
n	O
=	O
72	O
)	O
and	O
19	O
%	O
(	O
n	O
=	O
101	O
)	O
received	O
intravenous	O
and	O
oral	B-CHEM
KCl	I-CHEM
.	O

While	O
on	O
AmBd	B-CHEM
,	O
88	O
%	O
(	O
n	O
=	O
452	O
)	O
had	O
fluid	B-PROC
monitoring	I-PROC
;	O
27	O
%	O
(	O
n	O
=	O
142	O
)	O
,	O
45	O
%	O
(	O
n	O
=	O
235	O
)	O
and	O
44	O
%	O
(	O
n	O
=	O
232	O
)	O
had	O
Hb	B-PHEN
,	O
K	B-PHEN
and	O
Cr	B-DISO
levels	I-DISO
monitored	B-PROC
.	O

Toxicities	B-DISO
developed	O
frequently	O
during	O
treatment	B-PROC
:	O
anemia	B-DISO
,	O
16	O
%	O
(	O
86	O
/	O
524	O
)	O
;	O
hypokalemia	B-DISO
,	O
43	O
%	O
(	O
226	O
/	O
524	O
)	O
and	O
nephrotoxicity	B-DISO
,	O
32	O
%	O
(	O
169	O
/	O
524	O
)	O
.	O

AmBd	B-CHEM
-related	O
toxicities	B-DISO
occurred	O
frequently	O
but	O
were	O
potentially	O
preventable	O
with	O
adequate	O
monitoring	B-PROC
,	O
supplemental	B-OBJC
fluid	I-OBJC
and	O
electrolyte	B-PROC
therapies	I-PROC
.	O

BJN	B-OBJC
Awards	I-OBJC
2016	O
:	O
IV	B-PROC
therapy	I-PROC
Claire	O
Rickard	O
Professor	B-LIVB
of	O
Nursing	B-LIVB
,	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
)	O
Centre	B-LIVB
of	I-LIVB
Research	I-LIVB
Excellence	I-LIVB
in	O
Nursing	B-LIVB
,	O
Griffith	O
University	O
,	O
was	O
awarded	B-OBJC
second	O
place	O
in	O
the	O
BJN	B-OBJC
Awards	I-OBJC
2016	O
for	O
IV	B-PROC
Therapy	I-PROC
Nurse	B-LIVB
of	O
the	O
Year	O
.	O

Here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
field	B-PROC
.	O

Recent	O
blood	B-DISO
pressure	I-DISO
trends	O
in	O
adolescents	B-LIVB
from	O
China	B-GEOG
,	O
Korea	B-GEOG
,	O
Seychelles	B-GEOG
and	O
the	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
,	O
1997	O
-	O
2012	O
Although	O
the	O
prevalence	O
of	O
obesity	B-DISO
is	O
increasing	O
worldwide	B-GEOG
,	O
secular	O
trends	O
in	O
elevated	B-DISO
blood	I-DISO
pressure	I-DISO
(	O
BP	B-DISO
)	O
differ	O
across	O
populations	B-LIVB
.	O

We	O
aimed	O
to	O
compare	O
recent	O
BP	B-DISO
and	O
obesity	B-DISO
trends	O
in	O
adolescents	B-LIVB
aged	B-PHYS
10	O
-	O
19	O
years	O
in	O
China	B-GEOG
,	O
Korea	B-GEOG
,	O
Seychelles	B-GEOG
and	O
the	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
.	O

Data	O
in	O
adolescents	B-LIVB
aged	B-PHYS
10	O
-	O
19	O
years	O
came	O
from	O
China	B-GEOG
(	O
1997	O
-	O
2011	O
,	O
n	O
=	O
8025	O
)	O
,	O
Korea	B-GEOG
(	O
1998	O
-	O
2012	O
,	O
n	O
=	O
10	O
119	O
)	O
,	O
Seychelles	B-GEOG
(	O
1998	O
-	O
2012	O
,	O
n	O
=	O
27	O
569	O
)	O
and	O
the	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
(	O
1999	O
-	O
2012	O
,	O
n	O
=	O
14	O
580	O
)	O
.	O

Elevated	B-DISO
BP	I-DISO
was	O
defined	O
as	O
SBP	B-PHYS
or	O
DBP	B-PHYS
equal	O
to	O
or	O
above	O
the	O
referent	O
sex	B-PHYS
,	O
age	B-PHYS
and	O
height	O
-	O
specific	O
95th	O
percentile	O
of	O
the	O
US	O
Fourth	O
Report	O
.	O

Overweight	B-DISO
and	O
obesity	B-DISO
were	O
defined	O
using	O
criteria	O
of	O
the	O
International	O
Obesity	O
Task	O
Force	O
.	O

Between	O
1997	O
-	O
2000	O
and	O
2011	O
-	O
2012	O
,	O
the	O
prevalence	O
of	O
elevated	B-DISO
BP	I-DISO
decreased	O
in	O
Korea	B-GEOG
and	O
did	O
not	O
change	O
substantially	O
in	O
China	B-GEOG
and	O
in	O
the	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
.	O

The	O
prevalence	O
of	O
elevated	B-DISO
BP	I-DISO
increased	O
in	O
Seychelles	B-GEOG
.	O

In	O
2011	O
-	O
2012	O
,	O
the	O
prevalence	O
of	O
elevated	B-DISO
BP	I-DISO
was	O
1	O
.	O

7	O
%	O
in	O
the	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
,	O
3	O
.	O
8	O
%	O
in	O
China	B-GEOG
,	O
3	O
.	O
7	O
%	O
in	O
Korea	B-GEOG
and	O
14	O
.	O

3	O
%	O
in	O
Seychelles	B-GEOG
.	O

The	O
prevalence	O
of	O
overweight	B-DISO
and	O
obesity	B-DISO
increased	O
over	O
time	O
and	O
reached	O
in	O
2011	O
-	O
2012	O
41	O
.	O

2	O
%	O
in	O
the	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
,	O
18	O
.	O
6	O
%	O
in	O
China	B-GEOG
,	O
25	O
.	O
2	O
%	O
in	O
Korea	B-GEOG
and	O
27	O
.	O

4	O
%	O
in	O
Seychelles	B-GEOG
.	O

Elevated	B-DISO
BP	I-DISO
was	O
strongly	O
associated	O
with	O
obesity	B-DISO
in	O
all	O
countries	B-GEOG
.	O

Although	O
the	O
prevalence	O
of	O
obesity	B-DISO
increased	O
markedly	O
in	O
the	O
four	O
countries	B-GEOG
,	O
secular	O
BP	O
trends	O
in	O
adolescents	B-LIVB
differed	O
in	O
countries	B-GEOG
of	O
different	O
regions	B-GEOG
.	O

CT	B-PROC
-guided	O
fine	B-PROC
-	I-PROC
needle	I-PROC
aspiration	I-PROC
of	O
abdominal	B-ANAT
and	O
retroperitoneal	B-ANAT
small	O
lesions	B-DISO
with	O
the	O
coaxial	B-PROC
technique	I-PROC
using	O
MPR	B-PROC
images	O
To	O
demonstrate	O
the	O
advantages	O
of	O
CT	B-PROC
-guided	O
fine	B-PROC
-	I-PROC
needle	I-PROC
aspiration	I-PROC
(	O
FNA	B-PROC
)	O
of	O
abdominal	B-ANAT
and	O
retroperitoneal	B-ANAT
small	O
lesions	B-DISO
with	O
the	O
coaxial	B-PROC
technique	I-PROC
using	O
MPR	B-PROC
images	O
.	O

The	O
study	O
included	O
retrospectively	B-DISO
50	O
patients	B-LIVB
who	O
underwent	O
CT	B-PROC
-guided	O
FNA	B-PROC
of	O
abdominal	B-ANAT
and	O
/	O
or	O
retroperitoneal	B-ANAT
small	O
lesion	O
(	O
<	O
30	O
mm	O
)	O
.	O

Patients	B-LIVB
with	O
suspected	O
lymphomas	B-DISO
or	O
sarcomas	B-DISO
were	O
excluded	O
.	O

Cytology	O
reports	O
were	O
the	O
reference	O
standard	O
.	O

The	O
cytology	O
was	O
diagnostic	O
in	O
48	O
/	O
50	O
biopsies	B-PROC
(	O
96	O
%	O
)	O
:	O
out	O
of	O
41	O
neoplastic	O
lesions	B-DISO
(	O
85	O
%	O
)	O
,	O
37	O
were	O
malignant	B-DISO
(	O
90	O
.	O
2	O
%	O
)	O
and	O
4	O
were	O
benign	O
(	O
9	O
.	O
8	O
%	O
)	O
;	O
7	O
out	O
of	O
48	O
were	O
non	B-DISO
-	I-DISO
neoplastic	I-DISO
(	O
14	O
.	O
6	O
%	O
)	O
.	O

No	B-DISO
procedural	B-DISO
complications	I-DISO
were	O
observed	O
(	O
0	O
%	O
)	O
.	O

By	O
using	O
MPR	B-PROC
images	O
there	O
is	O
an	O
effective	O
improvement	O
in	O
coaxial	O
CT	B-PROC
-guided	O
FNA	B-PROC
of	O
abdominal	B-ANAT
and	O
retroperitoneal	B-ANAT
small	O
lesions	B-DISO
.	O

A	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
on	O
the	O
efficacy	O
and	O
safety	B-PHEN
of	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
in	O
depression	B-DISO
therapy	B-PROC
in	O
comparison	O
with	O
selective	B-CHEM
serotonin	I-CHEM
reuptake	I-CHEM
inhibitors	I-CHEM
in	O
adults	B-LIVB
The	O
aim	O
of	O
the	O
study	B-PROC
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	B-PHEN
of	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
and	O
selective	B-CHEM
serotonin	I-CHEM
reuptake	I-CHEM
inhibitors	I-CHEM
(	O
SSRIs	B-CHEM
)	O
in	O
the	O
treatment	O
of	O
depression	B-DISO
.	O

Databases	O
were	O
searched	O
for	O
studies	B-PROC
comparing	O
efficacy	O
and	O
/	O
or	O
safety	B-PHEN
of	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
with	O
SSRIs	B-CHEM
in	O
depression	B-DISO
from	O
1966	O
to	O
April	O
2015	O
.	O

Stata	B-OBJC
software	I-OBJC
was	O
used	O
for	O
statistical	B-PROC
analysis	I-PROC
.	O

Twenty	O
-	O
seven	O
studies	B-PROC
met	O
the	O
study	B-PROC
entry	O
criteria	O
.	O

A	O
total	O
of	O
3	O
,	O
126	O
patients	B-LIVB
with	O
depression	B-DISO
were	O
included	O
.	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
did	O
not	O
differ	O
from	O
SSRIs	B-CHEM
in	O
clinical	B-DISO
response	I-DISO
,	O
remission	B-DISO
,	O
and	O
mean	O
reduction	O
in	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
score	O
.	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
had	O
a	O
significantly	O
lower	O
rate	O
of	O
adverse	B-DISO
events	I-DISO
compared	O
to	O
SSRIs	B-CHEM
(	O
summary	O
relative	O
risk	O
:	O
0	O
.	O
77	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
0	O
.	O
70	O
,	O
0	O
.	O
84	O
,	O
P	O
=	O
0	O
.	O
00	O
)	O
and	O
had	O
fewer	O
withdrawals	O
due	O
to	O
adverse	B-DISO
events	I-DISO
.	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
had	O
superior	O
safety	B-PHEN
in	O
the	O
management	O
of	O
patients	B-LIVB
with	O
depression	B-DISO
.	O

Both	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
and	O
SSRIs	B-CHEM
are	O
effective	O
in	O
treating	O
mild	O
-	O
to	O
-	O
moderate	O
depression	B-DISO
.	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
is	O
safer	B-DISO
than	O
SSRIs	B-CHEM
.	O

Redistribution	O
of	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
channels	I-CHEM
and	O
calcium	B-CHEM
ions	I-CHEM
in	O
nerve	B-ANAT
terminals	I-ANAT
following	O
end	B-PROC
-	I-PROC
to	I-PROC
-	I-PROC
side	I-PROC
neurorrhaphy	I-PROC
:	O
ionic	B-PROC
imaging	I-PROC
analysis	I-PROC
by	O
TOF	B-PROC
-	I-PROC
SIMS	I-PROC
The	O
P	B-CHEM
/	I-CHEM
Q	I-CHEM
-	I-CHEM
type	I-CHEM
voltage	I-CHEM
-	I-CHEM
dependent	I-CHEM
calcium	I-CHEM
channel	I-CHEM
(	O
Cav2	B-CHEM
.	I-CHEM
1	I-CHEM
)	O
in	O
the	O
presynaptic	B-ANAT
membranes	I-ANAT
of	O
motor	B-ANAT
nerve	I-ANAT
terminals	B-ANAT
plays	O
an	O
important	O
role	O
in	O
regulating	B-PHYS
Ca	I-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
transport	I-PHYS
,	O
resulting	O
in	O
transmitter	B-CHEM
release	O
within	O
the	O
nervous	B-ANAT
system	I-ANAT
.	O

The	O
recovery	B-PHYS
of	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-dependent	O
signal	B-PHYS
transduction	I-PHYS
on	O
motor	B-ANAT
end	I-ANAT
plates	I-ANAT
(	O
MEPs	B-ANAT
)	O
and	O
innervated	B-PHYS
muscle	O
may	O
directly	O
reflect	O
nerve	B-PHYS
regeneration	I-PHYS
following	O
peripheral	B-DISO
nerve	I-DISO
injury	I-DISO
.	O

Although	O
the	O
functional	O
significance	O
of	O
calcium	B-CHEM
channels	I-CHEM
and	O
the	O
levels	O
of	O
Ca	B-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
signalling	I-PHYS
in	O
nerve	B-PHYS
regeneration	I-PHYS
are	O
well	O
documented	O
,	O
little	O
is	O
known	O
about	O
calcium	B-PHYS
channel	I-PHYS
expression	I-PHYS
and	O
its	O
relation	O
with	O
the	O
dynamic	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ion	I-CHEM
distribution	B-PHYS
at	O
regenerating	O
MEPs	B-ANAT
.	O

In	O
the	O
present	O
study	O
,	O
end	B-PROC
-	I-PROC
to	I-PROC
-	I-PROC
side	I-PROC
neurorrhaphy	I-PROC
(	O
ESN	B-PROC
)	O
was	O
performed	O
as	O
an	O
in	B-PROC
vivo	I-PROC
model	I-PROC
of	O
peripheral	B-DISO
nerve	I-DISO
injury	I-DISO
.	O

The	O
distribution	B-PHYS
of	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
at	O
regenerating	O
MEPs	B-ANAT
following	O
ESN	B-PROC
was	O
first	O
detected	O
by	O
time	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
secondary	I-PROC
ion	I-PROC
mass	I-PROC
spectrometry	I-PROC
,	O
and	O
the	O
specific	O
localization	O
and	O
expression	B-PHYS
of	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
channels	I-CHEM
were	O
examined	O
by	O
confocal	B-PROC
microscopy	I-PROC
and	O
western	B-PROC
blotting	I-PROC
.	O

Compared	O
with	O
other	O
fundamental	O
ions	O
,	O
such	O
as	O
Na	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
and	O
K	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
,	O
dramatic	O
changes	O
in	O
the	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
distribution	B-PHYS
were	O
detected	O
along	O
with	O
the	O
progression	O
of	O
MEP	B-ANAT
regeneration	B-PHYS
.	O

The	O
re	O
-	O
establishment	O
of	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
distribution	B-PHYS
and	O
intensity	O
were	O
correlated	O
with	O
the	O
functional	B-DISO
recovery	I-DISO
of	O
muscle	O
in	O
ESN	B-PROC
rats	B-LIVB
.	O

Furthermore	O
,	O
the	O
re	O
-	O
clustering	O
of	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
channels	I-CHEM
after	O
ESN	B-PROC
at	O
the	O
nerve	B-ANAT
terminals	I-ANAT
corresponded	O
with	O
changes	O
in	O
the	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
distribution	B-PHYS
.	O

These	O
results	B-PHEN
indicated	O
that	O
renewal	O
of	O
the	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
distribution	B-PHYS
within	O
the	O
presynaptic	B-ANAT
nerve	I-ANAT
terminals	I-ANAT
may	O
be	O
necessary	O
for	O
initiating	O
a	O
proper	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
influx	B-PHYS
and	O
shortening	O
the	O
latency	B-DISO
of	O
muscle	B-PHYS
contraction	I-PHYS
during	O
nerve	B-PHYS
regeneration	I-PHYS
.	O

Chitinibacter	B-LIVB
fontanus	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O
isolated	O
from	O
a	O
spring	B-PHEN
A	O
bacterial	B-LIVB
strain	I-LIVB
,	O
designated	O
STM	B-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
,	O
was	O
isolated	O
from	O
a	O
spring	B-PHEN
in	O
Taiwan	B-GEOG
and	O
characterized	O
using	O
a	O
polyphasic	O
taxonomy	O
approach	O
.	O

Cells	B-ANAT
of	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
were	O
Gram	B-LIVB
-	I-LIVB
staining	I-LIVB
-	I-LIVB
negative	I-LIVB
,	I-LIVB
aerobic	I-LIVB
,	O
poly	B-CHEM
-	I-CHEM
	I-CHEM
-	I-CHEM
hydroxybutyrate	I-CHEM
-accumulating	O
,	O
motile	B-DISO
by	O
a	O
single	B-ANAT
polar	I-ANAT
flagellum	I-ANAT
,	O
rod	O
-	O
shaped	O
that	O
were	O
surrounded	O
by	O
a	O
thick	O
capsule	B-ANAT
and	O
forming	O
milky	O
white	O
colored	O
colonies	B-ANAT
.	O

Growth	B-PHYS
occurred	O
at	O
15	O
-	O
37	O
oC	O
(	O
optimum	O
,	O
25	O
-	O
30	O
°	O
C	O
)	O
,	O
at	O
pH	O
6	O
-	O
8	O
(	O
optimum	O
,	O
pH	O
6	O
-	O
7	O
)	O
and	O
with	O
0	O
-	O
2	O
%	O
NaCl	B-CHEM
(	O
optimum	O
,	O
0	O
-	O
1	O
%	O
)	O
.	O

Phylogenetic	B-PROC
analyses	I-PROC
based	O
on	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequences	O
showed	O
that	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
belonged	O
to	O
the	O
genus	O
Chitinibacter	B-LIVB
and	O
was	O
most	O
closely	O
related	O
to	O
Chitinibacter	B-LIVB
tainanensis	I-LIVB
S1	I-LIVB
T	I-LIVB
with	O
sequence	O
similarity	O
of	O
97	O
.	O

3	O
%	O
.	O

Strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
contained	O
summed	O
feature	O
3	O
(	O
comprising	O
C16	B-CHEM
:	I-CHEM
17c	I-CHEM
and	O
/	O
or	O
C16	B-CHEM
:	I-CHEM
16c	I-CHEM
)	I-CHEM
and	O
C	O
16	B-CHEM
:	I-CHEM
0	I-CHEM
as	O
the	O
predominant	O
f	O
atty	B-CHEM
acids	I-CHEM
.	I-CHEM

The	O
major	O
h	O
ydroxyl	B-CHEM
fatty	I-CHEM
acids	I-CHEM
were	O
C12	B-CHEM
:	I-CHEM
0	I-CHEM
3	I-CHEM
-	I-CHEM
OH	I-CHEM
and	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
3	I-CHEM
-	I-CHEM
OH	I-CHEM
.	O

The	O
polar	B-PROC
lipid	I-PROC
profile	I-PROC
consisted	O
of	O
phosphatidylethanolamine	B-CHEM
,	O
phosphatidylglycerol	B-CHEM
,	O
diphosphatidylglycerol	B-CHEM
,	O
an	O
uncharacterized	O
aminophospholipid	B-CHEM
,	O
an	O
uncharacterized	O
glycolipid	B-CHEM
and	O
an	O
uncharacterized	O
phospholipid	B-CHEM
.	O

The	O
major	O
isoprenoid	B-CHEM
quinone	I-CHEM
was	O
Q	B-CHEM
-	I-CHEM
8	I-CHEM
.	O

The	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O
the	O
genomic	B-CHEM
DNA	I-CHEM
was	O
52	O
.	O

4	O
mol	O
%	O
.	O

The	O
DNA	B-PROC
-	I-PROC
DNA	I-PROC
hybridization	I-PROC
value	O
for	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
with	O
Chitinibacter	B-LIVB
tainanensis	I-LIVB
S1	I-LIVB
T	I-LIVB
was	O
less	O
than	O
47	O
%	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	B-PROC
inference	I-PROC
and	O
phenotypic	O
data	O
,	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
should	O
be	O
classified	O
as	O
a	O
novel	O
species	O
,	O
for	O
which	O
the	O
name	O
Chitinibacter	B-LIVB
fontanus	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O
proposed	O
.	O

The	O
type	O
strain	B-LIVB
is	O
STM	B-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
(	O
=	B-LIVB
BCRC	I-LIVB
80923	I-LIVB
T	I-LIVB
=	I-LIVB
LMG	I-LIVB
29289	I-LIVB
T	I-LIVB
=	I-LIVB
KCTC	I-LIVB
42982	I-LIVB
T	I-LIVB
)	O
.	O

Functional	O
Impairment	O
in	O
Children	B-LIVB
With	O
Externalizing	B-DISO
Behavior	I-DISO
Disorders	I-DISO
:	O
Psychometric	B-PROC
Properties	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale	O
-	O
Parent	O
Report	O
in	O
a	O
German	B-GEOG
Clinical	B-OBJC
Sample	I-OBJC
To	O
examine	O
the	O
psychometric	B-PROC
properties	O
of	O
a	O
German	B-GEOG
adaptation	O
of	O
the	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale	O
-	O
Parent	O
Report	O
(	O
WFIRS	O
-	O
P	O
)	O
in	O
a	O
clinical	B-OBJC
sample	I-OBJC
of	O
children	B-LIVB
(	O
4	O
-	O
12	O
years	O
)	O
with	O
externalizing	B-DISO
behavior	I-DISO
disorders	I-DISO
.	O

Data	O
were	O
collected	O
within	O
two	O
clinical	B-PROC
trials	I-PROC
(	O
N	O
=	O
264	O
)	O
.	O

Factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
from	O
symptoms	B-DISO
of	O
ADHD	B-DISO
and	O
oppositional	B-DISO
defiant	I-DISO
disorder	I-DISO
(	O
ODD	B-DISO
)	O
were	O
assessed	O
.	O

Confirmatory	O
factor	O
analyses	O
revealed	O
that	O
a	O
bifactor	O
model	O
consistent	O
with	O
the	O
theoretical	O
assumption	O
of	O
a	O
general	O
construct	O
of	O
impairment	O
(	O
total	O
scale	O
)	O
and	O
additional	O
specific	O
factors	O
(	O
subscales	O
)	O
provided	O
satisfactory	O
data	O
fit	O
.	O

Model	O
-based	O
reliability	O
estimates	O
showed	O
that	O
both	O
the	O
general	O
construct	O
and	O
specific	O
factors	O
accounted	O
for	O
item	O
variance	O
.	O

Internal	O
consistencies	O
were	O
>	O
.70	O
,	O
part	O
-	O
whole	O
corrected	O
item	O
-	O
scale	O
correlations	O
mostly	O
>	O
.30	O
.	O

Correlations	O
between	O
the	O
WFIRS	O
-	O
P	O
Scales	O
and	O
ADHD	B-DISO
and	O
ODD	B-DISO
symptoms	B-DISO
were	O
low	O
to	O
moderate	O
.	O

The	O
results	O
support	O
the	O
factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
of	O
the	O
WFIRS	O
-	O
P	O
.	O

The	O
role	O
of	O
sub	B-ANAT
-	I-ANAT
hippocampal	I-ANAT
versus	O
hippocampal	B-ANAT
regions	I-ANAT
in	O
bitemporal	B-DISO
lobe	I-DISO
epilepsies	I-DISO
We	O
aimed	O
at	O
better	O
delineating	O
the	O
functional	O
anatomical	B-PHYS
organization	I-PHYS
of	O
bitemporal	B-DISO
lobe	I-DISO
epilepsy	I-DISO
.	O

We	O
studied	O
the	O
epileptogenic	B-ANAT
zone	I-ANAT
(	O
EZ	B-ANAT
)	O
by	O
quantifying	O
the	O
epileptogenicity	O
of	O
brain	B-ANAT
structures	I-ANAT
explored	O
by	O
depth	B-DEVI
electrodes	I-DEVI
in	O
patients	B-LIVB
investigated	O
by	O
stereoelectroencephalography	B-PROC
(	O
SEEG	B-PROC
)	O
.	O

We	O
compared	O
15	O
patients	B-LIVB
with	O
bilateral	B-DISO
mesial	I-DISO
temporal	I-DISO
lobe	I-DISO
epilepsy	I-DISO
(	O
BTLE	B-DISO
)	O
and	O
15	O
patients	B-LIVB
with	O
unilateral	B-DISO
mesial	I-DISO
temporal	I-DISO
lobe	I-DISO
epilepsy	I-DISO
(	O
UTLE	B-DISO
)	O
.	O

This	O
quantification	O
was	O
performed	O
using	O
the	O
'	O
Epileptogenicity	O
Index	O
'	O
(	O
EI	O
)	O
.	O

Age	B-PHYS
at	O
epilepsy	B-DISO
onset	I-DISO
,	O
and	O
epilepsy	B-DISO
duration	O
,	O
were	O
not	B-DISO
statistically	I-DISO
different	I-DISO
in	O
both	O
groups	O
.	O

UTLE	B-DISO
patients	B-LIVB
more	O
frequently	O
displayed	O
maximal	O
epileptogenicity	O
in	O
hippocampal	B-ANAT
structures	I-ANAT
,	O
whereas	O
BTLE	B-DISO
patients	B-LIVB
had	O
maximal	O
values	O
in	O
subhippocampal	B-ANAT
areas	I-ANAT
(	O
entorhinal	B-ANAT
cortex	I-ANAT
,	O
temporal	B-ANAT
pole	I-ANAT
,	O
parahippocampal	O
cortex	O
)	O
.	O

Our	O
results	O
suggest	O
different	O
organization	B-PHYS
of	O
the	O
EZ	B-ANAT
in	O
the	O
two	O
groups	O
.	O

BTLE	B-DISO
was	O
associated	O
with	O
more	O
involvement	O
of	O
subhippocampal	B-ANAT
regions	I-ANAT
,	O
a	O
result	O
in	O
agreement	O
with	O
known	O
anatomical	O
connections	O
between	O
the	O
two	O
temporal	B-ANAT
lobes	I-ANAT
.	O

What	O
can	O
the	O
Canadians	B-LIVB
and	O
Americans	B-LIVB
learn	B-PHYS
from	O
each	O
other	O
's	O
health	O
care	O
systems	O
?	O

Numerous	O
papers	O
have	O
been	O
written	O
comparing	O
the	O
Canadian	B-LIVB
and	O
US	B-GEOG
healthcare	O
systems	O
,	O
and	O
a	O
number	O
of	O
health	O
policy	O
experts	B-LIVB
have	O
recommended	O
that	O
the	O
Americans	B-LIVB
implement	O
their	O
single	B-PROC
-	I-PROC
payer	I-PROC
system	I-PROC
to	O
save	O
12	O
-	O
20	O
%	O
of	O
its	O
healthcare	O
expenditures	O
.	O

This	O
paper	O
is	O
different	O
in	O
that	O
it	O
assumes	O
that	O
neither	O
country	B-GEOG
will	O
undertake	O
a	O
significant	O
philosophic	O
or	O
structural	O
change	O
in	O
their	O
healthcare	O
system	O
,	O
but	O
there	O
are	O
lessons	O
to	O
be	O
learned	B-PHYS
that	O
are	O
inherent	O
in	O
one	O
that	O
could	O
be	O
a	O
major	O
breakthrough	O
for	O
the	O
other	O
.	O

Following	O
the	O
model	B-GEOG
in	O
Canada	B-GEOG
and	O
in	O
Western	B-GEOG
Europe	I-GEOG
,	O
the	O
USA	B-GEOG
could	O
implement	O
universal	O
health	B-PROC
insurance	I-PROC
so	O
that	O
the	O
32	O
.	O
0	O
million	O
(	O
2015	O
)	O
Americans	B-LIVB
still	O
uninsured	B-LIVB
would	O
have	O
at	O
least	O
minimal	O
coverage	O
when	O
incurring	O
medical	O
expenditures	O
.	O

Also	O
,	O
the	O
USA	B-GEOG
could	O
use	O
smart	B-OBJC
cards	I-OBJC
to	O
evaluate	B-PROC
eligibility	I-PROC
and	O
to	O
process	B-PHEN
health	B-PROC
insurance	I-PROC
claims	I-PROC
;	O
these	O
changes	O
resulting	O
in	O
an	O
estimated	O
15	O
%	O
reduction	O
in	O
US	B-GEOG
health	O
expenditures	O
without	O
adversely	O
effecting	O
access	O
or	O
quality	B-PROC
of	I-PROC
care	I-PROC
.	O

Such	O
a	O
strategy	O
would	O
result	O
in	O
the	O
eventual	O
loss	O
of	O
2	O
.	O
5	O
million	O
white	O
-	O
collar	O
jobs	O
at	O
hospitals	B-OBJC
,	O
physician	B-OBJC
offices	I-OBJC
and	O
insurance	O
companies	O
,	O
a	O
long	O
-	O
term	O
economic	O
gain	O
.	O

Only	O
a	O
few	O
would	O
agree	O
with	O
the	O
statement	O
that	O
Canada	B-GEOG
already	O
functions	O
with	O
a	O
multi	O
-	O
payer	O
reimbursement	O
system	O
as	O
evidenced	O
by	O
(	O
1	O
)	O
a	O
federal	O
-	O
provincial	B-GEOG
,	O
tax	O
-	O
supported	O
plan	B-PROC
,	O
administered	O
by	O
each	O
of	O
the	O
provinces	B-GEOG
,	O
providing	O
universal	O
coverage	O
for	O
hospital	B-OBJC
and	O
physician	B-PROC
services	I-PROC
and	O
(	O
2	O
)	O
roughly	O
60	O
%	O
of	O
its	O
residents	B-LIVB
receiving	O
employer	O
-	O
paid	O
health	B-PROC
insurance	I-PROC
benefits	O
,	O
underwritten	O
primarily	O
by	O
investor	O
-	O
owned	O
plans	O
,	O
that	O
are	O
less	O
than	O
effective	O
to	O
reimburse	O
for	O
pharmaceuticals	B-PROC
,	O
dental	B-PROC
and	O
other	O
healthcare	B-PROC
services	I-PROC
.	O

What	O
could	O
be	O
learned	O
from	O
the	O
USA	B-GEOG
and	O
particularly	O
from	O
Western	B-GEOG
European	I-GEOG
countries	I-GEOG
is	O
possibly	O
implementing	O
an	O
approach	O
,	O
whereby	O
at	O
least	O
upper	O
-	O
income	O
Canadians	B-LIVB
could	O
opt	O
out	O
of	O
their	O
federal	O
-	O
provincial	B-GEOG
plan	B-PROC
and	O
purchase	O
private	O
insurance	O
coverage	O
-	O
being	O
eligible	O
for	O
far	O
more	O
comprehensive	O
""""	O
private	O
""""	O
benefits	O
for	O
hospital	B-OBJC
,	O
physician	B-PROC
,	O
pharmaceutical	B-PROC
,	O
dental	B-PROC
and	O
other	O
healthcare	B-PROC
services	I-PROC
.	O

Aside	O
from	O
generating	O
billions	O
of	O
additional	O
needed	O
revenues	O
from	O
the	O
private	B-LIVB
sector	I-LIVB
,	O
it	O
could	O
(	O
1	O
)	O
help	O
eliminate	O
long	O
waits	O
for	O
non	O
-	O
emergent	O
physicians	O
'	O
care	O
by	O
appointing	O
newly	O
minted	O
specialists	B-LIVB
to	O
their	O
medical	B-LIVB
staffs	I-LIVB
;	O
(	O
2	O
)	O
offer	O
prompt	O
admissions	B-PROC
for	O
elective	B-DISO
cases	I-DISO
to	O
""""	O
private	B-OBJC
""""	O
wings	B-OBJC
of	I-OBJC
hospitals	I-OBJC
;	O
(	O
3	O
)	O
increase	O
available	O
funding	O
for	O
what	O
is	O
currently	O
an	O
undercapitalized	B-DISO
system	O
;	O
(	O
4	O
)	O
enhance	O
the	O
system	O
's	O
sluggish	B-DISO
operations	O
;	O
and	O
(	O
5	O
)	O
encourage	O
more	O
competition	O
among	O
various	O
providers	O
.	O

Although	O
such	O
a	O
two	O
-	O
tier	O
approach	O
,	O
such	O
as	O
available	O
in	O
the	O
USA	B-GEOG
and	O
elsewhere	O
,	O
is	O
politically	O
dead	O
on	O
arrival	O
in	O
Canada	B-GEOG
today	O
,	O
private	O
insurance	O
being	O
already	O
legal	O
and	O
commonly	O
available	O
there	O
.	O

Interestingly	O
,	O
this	O
recommended	O
solution	O
is	O
utilized	O
in	O
most	O
western	B-GEOG
European	I-GEOG
countries	I-GEOG
where	O
there	O
is	O
a	O
higher	O
percentagea	O
than	O
in	O
Canada	B-GEOG
of	O
public	O
(	O
versus	O
private	O
)	O
funding	O
of	O
their	O
total	O
health	O
expenditures	O
.	O

Because	O
of	O
various	O
vested	O
interests	O
,	O
attempts	O
to	O
implement	O
any	O
of	O
the	O
aforementioned	O
proposals	O
will	O
undoubtedly	O
result	O
in	O
considerable	O
political	O
rancor	B-PHYS
.	O

There	O
is	O
greater	O
likelihood	O
,	O
however	O
,	O
that	O
the	O
Canadians	B-LIVB
because	O
their	O
need	O
to	O
be	O
more	O
effective	O
and	O
efficient	O
in	O
their	O
delivery	B-PROC
of	I-PROC
care	I-PROC
,	O
and	O
their	O
overall	O
long	O
-	O
term	O
fiscal	O
outlook	O
will	O
agree	B-DISO
to	O
the	O
further	O
privatization	O
of	O
their	O
healthcare	O
system	O
before	O
the	O
Americans	B-LIVB
will	O
mandate	O
universal	O
access	O
,	O
use	O
the	O
smart	B-OBJC
card	I-OBJC
to	O
process	O
insurance	O
eligibility	O
and	O
claims	O
or	O
will	O
impose	O
price	O
controls	O
on	O
high	O
-	O
tech	O
services	O
and	O
on	O
pharmaceuticals	B-CHEM
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Stressful	O
life	B-PHYS
events	I-PHYS
and	O
leucocyte	B-DISO
telomere	I-DISO
length	I-DISO
:	O
Do	O
lifestyle	B-PHYS
factors	I-PHYS
,	O
somatic	O
and	O
mental	B-PHYS
health	I-PHYS
,	O
or	O
low	B-DISO
grade	I-DISO
inflammation	I-DISO
mediate	O
this	O
relationship	O
?	O

Results	O
from	O
a	O
cohort	B-LIVB
of	O
Danish	B-LIVB
men	I-LIVB
born	B-PHYS
in	O
1953	O
Exposure	O
to	O
psychosocial	O
stress	B-DISO
is	O
associated	O
with	O
increased	O
risk	O
of	O
a	O
number	O
of	O
somatic	O
and	O
mental	B-DISO
disorders	I-DISO
with	O
relation	O
to	O
immune	B-ANAT
system	I-ANAT
functioning	O
.	O

We	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	B-DISO
telomere	I-DISO
length	I-DISO
(	O
TL	B-DISO
)	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	B-DISO
burden	O
of	O
inflammation	B-DISO
and	O
oxidative	B-DISO
stress	I-DISO
occurring	O
during	O
the	O
life	O
course	O
.	O

We	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	B-DISO
is	O
mediated	O
through	O
somatic	O
and	O
mental	B-PHYS
health	I-PHYS
,	O
lifestyle	O
,	O
and	O
markers	B-PHYS
of	O
low	B-DISO
-	I-DISO
grade	I-DISO
inflammation	I-DISO
.	O

A	O
cohort	B-LIVB
of	O
Danish	B-LIVB
men	I-LIVB
born	B-PHYS
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	B-PHYS
in	O
the	O
Metropolit	B-LIVB
Cohort	I-LIVB
.	O

These	O
men	B-LIVB
underwent	O
a	O
health	B-PROC
examination	I-PROC
including	O
blood	B-PROC
sampling	I-PROC
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	B-PROC
PCR	I-PROC
-	I-PROC
based	I-PROC
measurement	I-PROC
of	O
TL	B-DISO
.	O

The	O
relation	O
between	O
stressful	O
life	B-PHYS
events	I-PHYS
and	O
TL	B-DISO
was	O
analysed	O
using	O
structural	B-PROC
equation	I-PROC
modelling	I-PROC
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	B-PHYS
health	I-PHYS
(	O
cardiovascular	B-DISO
disease	I-DISO
,	O
body	B-DISO
mass	I-DISO
and	O
depressive	B-DISO
mood	I-DISO
)	O
,	O
lifestyle	B-PHYS
factors	I-PHYS
,	O
and	O
low	B-DISO
grade	I-DISO
inflammation	I-DISO
(	O
C	B-CHEM
-	I-CHEM
reactive	I-CHEM
protein	I-CHEM
(	O
CRP	B-CHEM
)	O
,	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
6	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	O
.	O

Total	O
number	O
of	O
stressful	O
events	O
experienced	B-PHEN
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
TL	B-DISO
.	O

In	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	B-DISO
TL	I-DISO
(	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=	O
-0	O
.	O

02	O
(	O
SE	O
=	O
-	O
0	O
.	O
02	O
)	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

This	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	O
(	O
β	O
=	O
-	O
0	O
.	O
16	O
;	O
P	O
<	O
0	O
.	O
000	O
)	O
.	O

Thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
TL	B-DISO
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	B-DISO
mood	I-DISO
(	O
16	O
%	O
)	O
and	O
CRP	B-CHEM
(	O
9	O
%	O
)	O
.	O

This	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	B-DISO
TL	I-DISO
in	O
middle	B-LIVB
-	I-LIVB
aged	I-LIVB
men	I-LIVB
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	B-DISO
mood	I-DISO
and	O
low	B-DISO
grade	I-DISO
inflammation	I-DISO
.	O

Description	O
of	O
Ancylomarina	B-LIVB
subtilis	I-LIVB
gen	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O
isolated	O
from	O
coastal	O
sediment	O
,	O
proposal	O
of	O
Marinilabiliales	B-LIVB
ord	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB

and	O
transfer	O
of	O
Marinilabiliaceae	B-LIVB
,	O
Prolixibacteraceae	B-LIVB
and	O
Marinifilaceae	B-LIVB
to	O
the	O
order	O
Marinilabiliales	B-LIVB
A	O
Gram	B-LIVB
-	I-LIVB
stain	I-LIVB
-	I-LIVB
negative	I-LIVB
,	O
facultatively	B-LIVB
anaerobic	I-LIVB
,	O
moderately	B-LIVB
halophilic	I-LIVB
,	O
filamentous	O
,	O
non	B-LIVB
-	I-LIVB
motile	I-LIVB
bacterium	I-LIVB
,	O
designated	O
FA102	B-LIVB
T	I-LIVB
,	O
was	O
isolated	O
from	O
marine	B-PHEN
sediment	I-PHEN
of	O
the	O
coast	O
of	O
Weihai	B-GEOG
,	I-GEOG
China	I-GEOG
.	O

Phylogenetic	B-PROC
analysis	I-PROC
based	O
on	O
16S	B-CHEM
rRNA	I-CHEM
gene	I-CHEM
sequences	I-CHEM
showed	O
that	O
strain	O
FA102	B-LIVB
T	I-LIVB
formed	O
a	O
distinct	O
evolutionary	B-PHYS
lineage	O
within	O
the	O
family	O
Marinifilaceae	B-LIVB
and	O
its	O
closest	B-DISO
relative	I-DISO
was	O
Marinifilum	B-LIVB
fragile	I-LIVB
JCM	I-LIVB
15579	I-LIVB
T	I-LIVB
(	O
93	O
.	O
2	O
%	O
sequence	O
similarity	O
)	O
.	O

The	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O
the	O
novel	O
strain	O
was	O
36	O
.	O

5	O
mol	O
%	O
.	O

The	O
predominant	O
cellular	B-ANAT
fatty	B-CHEM
acids	I-CHEM
and	O
respiratory	O
quinone	B-CHEM
were	O
iso	B-CHEM
-	I-CHEM
C15	I-CHEM
:	I-CHEM
0	I-CHEM
and	O
iso	B-CHEM
-	I-CHEM
C15	I-CHEM
:	I-CHEM
0	I-CHEM
3	I-CHEM
-	I-CHEM
OH	I-CHEM
,	O
and	O
MK	B-CHEM
-	I-CHEM
7	I-CHEM
,	O
respectively	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
,	O
phenotypic	B-PHYS
and	O
physiological	O
data	O
,	O
strain	O
FA102	B-LIVB
T	I-LIVB
represents	O
a	O
novel	O
genus	O
and	O
species	O
,	O
for	O
which	O
the	O
name	O
Ancylomarina	B-LIVB
subtilis	I-LIVB
gen	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O
proposed	O
.	O

The	O
type	O
strain	O
of	O
Ancylomarina	B-LIVB
subtilis	I-LIVB
is	O
FA102	B-LIVB
T	I-LIVB
(	O
=	O
KCTC	B-LIVB
42257	I-LIVB
T	I-LIVB
=	O
DSM	B-LIVB
28825	I-LIVB
T	I-LIVB
=	O
CICC	B-LIVB
10902	I-LIVB
T	I-LIVB
)	O
.	O

Furthermore	O
,	O
a	O
new	O
order	O
named	O
Marinilabiliales	B-LIVB
is	O
proposed	O
to	O
accommodate	B-DISO
three	O
families	O
previously	O
classified	O
in	O
the	O
order	O
Bacteroidales	B-LIVB
.	O

Marinilabiliales	B-LIVB
ord	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
encompasses	O
the	O
families	O
Marinilabiliaceae	B-LIVB
,	O
Prolixibacteraceae	B-LIVB
and	O
Marinifilaceae	B-LIVB
.	O

Treatment	B-PROC
for	O
Rheumatoid	B-DISO
Arthritis	I-DISO
and	O
Risk	B-DISO
of	O
Alzheimer	B-DISO
's	I-DISO
Disease	I-DISO
:	O
A	O
Nested	B-PROC
Case	I-PROC
-	I-PROC
Control	I-PROC
Analysis	I-PROC
It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	B-DISO
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-DISO
of	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O
AD	B-DISO
)	O
,	O
as	O
several	O
immune	B-ANAT
-related	O
genes	O
have	O
been	O
associated	O
with	O
AD	B-DISO
.	O

Among	O
these	O
is	O
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	I-CHEM
TNF	I-CHEM
)	I-CHEM
-	I-CHEM
α	I-CHEM
,	O
a	O
proinflammatory	B-CHEM
cytokine	I-CHEM
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B-DISO
disorders	I-DISO
,	O
including	O
rheumatoid	B-DISO
arthritis	I-DISO
(	O
RA	B-DISO
)	O
.	O

Although	O
AD	B-DISO
and	O
RA	B-DISO
appear	O
to	O
involve	O
similar	O
pathological	B-DISO
mechanisms	I-DISO
through	O
the	O
production	B-PHEN
of	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
,	I-CHEM
the	O
relationship	O
between	O
AD	B-DISO
and	O
RA	B-DISO
remains	O
unknown	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
AD	B-DISO
among	O
RA	B-DISO
patients	B-LIVB
and	O
non	O
-	O
RA	B-DISO
patients	B-LIVB
,	O
and	O
whether	O
anti	B-PROC
-	I-PROC
TNF	I-PROC
therapy	I-PROC
for	O
RA	B-DISO
was	O
associated	O
with	O
a	O
lower	O
risk	B-DISO
of	O
AD	B-DISO
in	O
RA	B-DISO
patients	B-LIVB
.	O

We	O
performed	O
a	O
nested	B-PROC
case	I-PROC
-	I-PROC
control	I-PROC
study	I-PROC
of	O
more	O
than	O
8	O
.	O
5	O
million	O
commercially	O
insured	O
adults	B-LIVB
(	O
aged	O
≥18	O
years	O
)	O
in	O
all	O
50	O
US	B-GEOG
states	I-GEOG
,	O
Puerto	B-GEOG
Rico	I-GEOG
,	O
and	O
US	B-GEOG
Virgin	I-GEOG
Islands	I-GEOG
in	O
the	O
Verisk	O
Health	O
claims	O
database	O
.	O

We	O
derived	O
a	O
sub	B-LIVB
-	I-LIVB
cohort	I-LIVB
of	O
subjects	O
with	O
a	O
diagnosis	B-DISO
of	O
RA	B-DISO
(	O
controls	B-LIVB
)	O
,	O
or	O
RA	B-DISO
and	O
AD	B-DISO
(	O
cases	O
)	O
,	O
matching	B-PROC
cases	O
and	O
controls	O
based	O
on	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
exposure	B-PROC
assessment	I-PROC
period	I-PROC
,	O
and	O
methotrexate	B-PROC
treatment	I-PROC
.	O

We	O
also	O
assessed	B-PROC
relative	I-PROC
risk	I-PROC
of	O
AD	B-DISO
following	O
exposure	O
to	O
standard	O
RA	B-DISO
therapies	B-PROC
,	O
including	O
anti	B-CHEM
-	I-CHEM
TNF	I-CHEM
agents	I-CHEM
(	O
infliximab	B-CHEM
,	O
adalimumab	B-CHEM
,	O
etanercept	B-CHEM
)	O
,	O
methotrexate	B-CHEM
,	O
prednisone	B-CHEM
,	O
sulfasalazine	B-CHEM
,	O
and	O
rituximab	B-CHEM
.	O

Odds	O
ratios	O
were	O
adjusted	O
for	O
comorbidities	O
,	O
including	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O
diabetes	B-DISO
mellitus	I-DISO
,	O
and	O
peripheral	B-DISO
vascular	I-DISO
disease	I-DISO
.	O

AD	B-DISO
was	O
more	O
prevalent	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
among	O
RA	B-DISO
patients	B-LIVB
(	O
0	O
.	O
79	O
%	O
)	O
than	O
among	O
those	O
without	O
RA	B-DISO
(	O
0	O
.	O
11	O
%	O
)	O
.	O

Chronic	B-DISO
conditions	I-DISO
such	O
as	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1	O
.	O
48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
04	O
-	O
2	O
.	O
05	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
diabetes	B-DISO
(	O
OR	O
1	O
.	O

86	O
;	O
95	O
%	O
CI	O
1	O
.	O
32	O
-	O
2	O
.	O
62	O
;	O
p	O
=	O
0	O
.	O
0004	O
)	O
,	O
and	O
peripheral	B-DISO
vascular	I-DISO
disease	I-DISO
(	O
OR	O
1	O
.	O
61	O
;	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
2	O
.	O
43	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
AD	B-DISO
among	O
RA	B-DISO
patients	B-LIVB
.	O

Exposure	O
to	O
anti	B-CHEM
-	I-CHEM
TNF	I-CHEM
agents	I-CHEM
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	B-CHEM
drugs	I-CHEM
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	B-DISO
of	O
AD	B-DISO
among	O
RA	B-DISO
patients	B-LIVB
(	O
unadjusted	O
OR	O
0	O
.	O
44	O
;	O
95	O
%	O
CI	O
0	O
.	O
22	O
-	O
0	O
.	O
87	O
;	O
p	O
=	O
0	O
.	O

02	O
;	O
adjusted	O
OR	O
0	O
.	O
45	O
;	O
95	O
%	O
CI	O
0	O
.	O
23	O
-	O
0	O
.	O
90	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti	B-CHEM
-	I-CHEM
TNF	I-CHEM
agents	I-CHEM
studied	O
,	O
only	O
etanercept	B-CHEM
(	O
unadjusted	O
OR	O
,	O
0	O
.	O

33	O
;	O
95	O
%	O
CI	O
0	O
.	O
08	O
-	O
0	O
.	O
94	O
;	O
p	O
=	O
0	O
.	O
03	O
;	O
adjusted	O
OR	O
0	O
.	O
30	O
;	O
95	O
%	O
CI	O
0	O
.	O
08	O
-	O
0	O
.	O
89	O
;	O
p	O
=	O
0	O
.	O

02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	B-DISO
of	O
AD	B-DISO
in	O
RA	B-DISO
patients	B-LIVB
.	O

There	O
is	O
an	O
increased	O
risk	B-DISO
of	O
AD	B-DISO
in	O
the	O
studied	O
RA	B-DISO
population	O
.	O

The	O
relative	O
risk	O
of	O
AD	B-DISO
among	O
RA	B-DISO
subjects	O
was	O
lowered	O
in	O
those	O
exposed	O
to	O
etanercept	B-CHEM
.	O

Anti	B-PROC
-	I-PROC
TNF	I-PROC
therapy	I-PROC
with	O
etanercept	B-CHEM
shows	O
promise	O
as	O
a	O
potential	O
treatment	B-PROC
for	O
AD	B-DISO
.	O

Health	O
-	O
Related	O
Quality	O
of	O
Life	O
in	O
Patients	B-LIVB
With	O
α1	B-DISO
Antitrypsin	I-DISO
Deficency	I-DISO
:	O
A	O
Cross	B-PROC
Sectional	I-PROC
Study	I-PROC
Measures	O
of	O
health	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
in	O
patients	B-LIVB
with	O
α1	B-DISO
-	I-DISO
antitrypsin	I-DISO
deficiency	I-DISO
(	O
AATD	B-DISO
)	O
can	O
help	O
to	O
determine	O
the	O
impact	O
of	O
the	O
disease	B-DISO
and	O
provide	O
an	O
important	O
insight	O
into	O
the	O
intervention	B-PROC
outcomes	O
.	O

There	O
is	O
few	O
data	O
regarding	O
this	O
issue	O
in	O
the	O
literature	O
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
is	O
to	O
assess	O
the	O
relationship	O
between	O
HRQoL	O
and	O
gender	B-PHYS
,	O
functional	O
parameters	B-DISO
and	O
history	B-DISO
of	O
hospitalizations	B-PROC
in	O
patients	B-LIVB
with	O
AATD	B-DISO
.	O

This	O
is	O
a	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
of	O
26	O
patients	B-LIVB
with	O
severe	O
AATD	B-DISO
recruited	O
in	O
the	O
pulmonology	O
outpatient	B-OBJC
clinic	I-OBJC
at	O
a	O
tertiary	B-OBJC
care	I-OBJC
medical	I-OBJC
center	I-OBJC
.	O

Social	O
-	O
demographic	O
,	O
clinical	O
and	O
functional	O
parameters	B-DISO
were	O
recorded	O
and	O
HRQoL	O
was	O
assessed	O
with	O
the	O
Portuguese	B-LIVB
version	O
of	O
the	O
medical	B-PROC
outcome	I-PROC
study	I-PROC
short	O
form	O
-	O
36	O
(	O
SF	O
-	O
36	O
)	O
self	O
-	O
administered	O
questionnaire	O
.	O

Older	B-LIVB
patients	B-LIVB
,	O
females	B-LIVB
and	O
patients	B-LIVB
with	O
at	O
least	O
one	O
hospitalization	B-PROC
in	O
the	O
previous	O
year	O
due	O
to	O
respiratory	B-DISO
disease	I-DISO
had	O
statistical	O
lower	O
scores	O
in	O
some	O
dimensions	O
of	O
the	O
SF	O
-	O
36	O
questionnaire	O
.	O

Superior	O
FEV1	B-DISO
and	O
higher	O
distance	O
mark	B-OBJC
in	O
the	O
6	O
-	O
min	O
walking	B-PROC
test	I-PROC
distance	I-PROC
influenced	O
positively	B-DISO
several	O
dimensions	O
of	O
the	O
questionnaire	O
.	O

Higher	O
scores	O
in	O
the	O
mMRC	O
scale	O
influenced	O
negatively	B-DISO
the	O
HRQoL	O
.	O

These	O
data	O
suggests	O
that	O
older	B-LIVB
and	O
female	B-LIVB
patients	B-LIVB
with	O
AATD	B-DISO
have	O
worse	B-DISO
HRQoL	O
.	O

Hospitalizations	B-PROC
and	O
functional	O
markers	O
of	O
respiratory	B-DISO
disease	I-DISO
progression	B-DISO
influenced	O
negatively	B-DISO
the	O
HRQoL	O
,	O
suggesting	O
that	O
the	O
SF	O
-	O
36	O
questionnaire	O
could	O
be	O
useful	O
as	O
an	O
outcome	O
for	O
AATD	B-DISO
patients	B-LIVB
with	O
lung	B-ANAT
involvement	O
.	O

Disparities	O
in	O
treatment	O
and	O
survival	O
for	O
women	B-LIVB
with	O
endometrial	B-DISO
cancer	I-DISO
:	O
A	O
contemporary	O
national	B-PROC
cancer	I-PROC
database	I-PROC
registry	I-PROC
analysis	I-PROC
The	O
study	O
aim	O
was	O
to	O
identify	O
contemporary	O
socioeconomic	O
,	O
racial	O
,	O
ethnic	O
,	O
and	O
facility	O
-	O
related	O
factors	O
associated	O
with	O
stage	O
at	O
diagnosis	O
,	O
receipt	O
of	O
cancer	B-DISO
treatment	O
,	O
and	O
survival	O
in	O
women	B-LIVB
with	O
endometrial	B-DISO
cancer	I-DISO
(	O
EC	B-DISO
)	O
.	O

Women	B-LIVB
diagnosed	O
with	O
EC	B-DISO
between	O
1998	O
and	O
2010	O
were	O
identified	O
from	O
the	O
National	O
Cancer	O
Database	O
.	O

Variables	O
associated	O
with	O
the	O
outcomes	O
of	O
interest	O
were	O
assessed	O
using	O
multivariable	O
Cox	O
proportional	O
hazards	O
and	O
logistic	B-PROC
regression	I-PROC
.	O

Among	O
228	O
,	O
511	O
women	B-LIVB
identified	O
,	O
the	O
percentage	O
of	O
blacks	B-LIVB
with	O
stage	O
IIIC	O
/	O
IV	O
disease	O
at	O
diagnosis	O
was	O
nearly	O
twice	O
that	O
of	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
whites	I-LIVB
(	O
17	O
.	O
8	O
%	O
vs	O
9	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Patients	B-LIVB
with	O
advanced	O
disease	O
who	O
were	O
insured	O
with	O
Medicare	O
were	O
less	O
likely	O
to	O
receive	O
standard	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
care	I-PROC
postoperative	B-PROC
radiotherapy	I-PROC
and	O
/	O
or	O
chemotherapy	B-PROC
than	O
those	O
with	O
private	O
insurance	O
(	O
odds	O
ratio	O
:	O
OR	O
0	O
.	O
80	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
as	O
were	O
those	O
residing	O
in	O
the	O
South	O
(	O
reference	O
)	O
in	O
comparison	O
to	O
the	O
Northeast	O
,	O
Atlantic	B-GEOG
,	O
Great	B-GEOG
Lakes	I-GEOG
,	O
and	O
Midwest	B-GEOG
regions	I-GEOG
(	O
OR	O
1	O
.	O

3	O
-	O
1	O
.	O
7	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Those	O
residing	O
in	O
the	O
Mountain	B-GEOG
region	I-GEOG
were	O
even	O
less	O
likely	O
to	O
receive	O
appropriate	O
treatment	O
(	O
OR	O
0	O
.	O

7	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Five	O
-	O
year	O
stage	B-PHYS
IIIC	I-PHYS
/	I-PHYS
IV	I-PHYS
survival	O
was	O
42	O
.	O

8	O
%	O
for	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
whites	I-LIVB
vs	O
24	O
.	O

6	O
%	O
for	O
blacks	B-LIVB
(	O
hazard	O
ratio	O
1	O
.	O
3	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Other	O
factors	O
associated	O
with	O
inferior	O
5	O
-	O
year	O
survival	O
included	O
payer	B-LIVB
status	O
(	O
not	O
insured	O
,	O
Medicaid	O
,	O
Medicare	O
,	O
vs	O
private	O
,	O
ORs	O
1	O
.	O

2	O
-	O
1	O
.	O
3	O
,	O
all	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
treatment	O
at	O
low	B-OBJC
-	I-OBJC
volume	I-OBJC
centers	I-OBJC
(	O
<	O
5	O
vs	O
≥30cases	O
/	O
year	O
,	O
HR	O
1	O
.	O
3	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Socioeconomic	O
,	O
geographic	O
and	O
facility	O
-	O
related	O
factors	O
predict	O
advanced	B-DISO
endometrial	I-DISO
cancer	I-DISO
stage	B-PHYS
,	O
failure	O
to	O
receive	O
cancer	B-PROC
care	I-PROC
,	O
and	O
shorter	O
survival	O
.	O

Black	B-LIVB
women	B-LIVB
had	O
especially	O
poor	O
survival	O
.	O

Nationwide	B-PROC
standardization	I-PROC
and	O
concentration	B-PROC
of	O
treatment	O
at	O
high	B-OBJC
-	I-OBJC
volume	I-OBJC
centers	I-OBJC
may	O
improve	O
outcomes	O
.	O

Readily	O
Accessible	O
and	O
Predictable	O
Naphthalene	B-CHEM
-Based	O
Two	B-CHEM
-	I-CHEM
Photon	I-CHEM
Fluorophore	I-CHEM
with	O
Full	O
Visible	B-PHEN
-	O
Color	O
Coverage	O
Herein	O
we	O
report	O
22	B-CHEM
acedan	I-CHEM
-derived	O
,	O
two	B-CHEM
-	I-CHEM
photon	I-CHEM
fluorophores	I-CHEM
with	O
synthetic	O
feasibility	O
and	O
full	O
coverage	O
of	O
visible	B-PHEN
wavelength	O
emission	O
.	O

The	O
emission	B-PHEN
wavelengths	O
were	O
predicted	O
by	O
computational	B-PROC
analysis	I-PROC
,	O
which	O
enabled	O
us	O
to	O
visualize	O
multicolor	O
images	O
by	O
two	B-OBJC
-	I-OBJC
photon	I-OBJC
excitation	O
with	O
single	O
wavelength	O
,	O
and	O
to	O
design	O
a	O
turn	O
-	O
on	O
,	O
two	B-PHEN
-	I-PHEN
photon	I-PHEN
fluorescence	I-PHEN
sensor	B-OBJC
for	O
endogenous	O
H2	B-CHEM
O2	I-CHEM
in	O
Raw	B-ANAT
264	I-ANAT
.	I-ANAT

7	I-ANAT
macrophage	I-ANAT
and	O
rat	B-ANAT
brain	I-ANAT
hippocampus	B-ANAT
ex	O
vivo	O
.	O

Optimal	O
Duration	O
of	O
Coronary	B-PROC
Ligation	I-PROC
and	O
Reperfusion	B-PROC
for	O
Reperfusion	B-DISO
Injury	I-DISO
Study	B-PROC
in	O
a	O
Rat	B-LIVB
Model	B-DEVI
Reperfusion	B-DISO
injury	I-DISO
(	O
RI	B-DISO
)	O
has	O
an	O
important	O
impact	O
on	O
the	O
clinical	O
prognosis	B-PHYS
for	O
patients	B-LIVB
with	O
acute	B-DISO
myocardial	I-DISO
injury	I-DISO
who	O
had	O
their	O
coronary	O
blood	B-PHYS
flow	I-PHYS
reestablished	O
.	O

However	O
,	O
no	O
studies	B-PROC
to	O
date	O
have	O
investigated	O
the	O
timeframe	O
of	O
coronary	B-DISO
occlusion	I-DISO
and	O
reperfusion	B-PROC
effects	O
on	O
RI	B-DISO
.	O

A	O
total	O
of	O
100	O
rats	B-LIVB
were	O
divided	O
into	O
4	O
groups	O
based	O
on	O
the	O
coronary	B-PROC
ligation	I-PROC
period	O
:	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
,	O
and	O
each	O
group	O
was	O
further	O
divided	O
into	O
5	O
subgroups	O
with	O
different	O
reperfusion	B-PROC
periods	O
:	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
.	O

R0	O
was	O
the	O
baseline	O
of	O
each	O
subgroup	O
.	O

All	O
animals	B-LIVB
received	O
the	O
same	O
protocols	O
for	O
designed	O
ligation	B-PROC
and	O
reperfusion	B-PROC
periods	O
.	O

Evans	B-CHEM
blue	I-CHEM
and	O
2	B-CHEM
,	I-CHEM
3	I-CHEM
,	I-CHEM
5	I-CHEM
-	I-CHEM
triphenyltetrazolium	I-CHEM
chloride	I-CHEM
were	O
used	O
to	O
distinguish	O
different	O
myocardial	B-DISO
injury	I-DISO
areas	O
:	O
area	O
at	O
risk	O
(	O
AAR	O
)	O
and	O
myocardial	B-DISO
necrosis	I-DISO
.	O

The	O
differences	O
of	O
the	O
ratios	O
of	O
the	O
necrotic	B-PHYS
area	O
to	O
AAR	O
between	O
each	O
subgroup	O
and	O
baseline	O
were	O
further	O
averaged	O
to	O
calculate	O
an	O
overall	O
value	O
of	O
each	O
heart	B-ANAT
.	O

The	O
relative	O
RI	B-DISO
percentages	O
showed	O
significant	O
differences	O
(	O
0	O
.	O
8	O
±	O
2	O
.	O

3	O
%	O
,	O
4	O
.	O
9	O
±	O
3	O
.	O

3	O
%	O
,	O
10	O
.	O
8	O
±	O
3	O
.	O
1	O
%	O
,	O
and	O
20	O
.	O
3	O
±	O
3	O
.	O

6	O
%	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
at	O
different	O
time	O
points	O
of	O
reperfusion	B-PROC
but	O
not	O
at	O
different	O
time	O
points	O
of	O
ligation	B-PROC
(	O
p	O
=	O
0	O
.	O
593	O
)	O
.	O

The	O
effects	O
of	O
different	O
time	O
courses	O
in	O
RI	B-DISO
showed	O
that	O
the	O
L120R180	O
group	O
(	O
43	O
.	O

4	O
±	O
2	O
.	O

3	O
%	O
)	O
had	O
the	O
highest	O
RI	B-DISO
difference	O
with	O
the	O
baseline	O
group	O
.	O

Maximal	O
RI	B-DISO
occurred	O
at	O
the	O
timeframe	O
of	O
L120R180	O
in	O
our	O
animal	B-DEVI
model	I-DEVI
.	O

This	O
result	O
may	O
be	O
utilized	O
to	O
assess	O
the	O
substantial	O
benefits	O
of	O
RI	B-PROC
therapies	I-PROC
in	O
an	O
experimental	B-DISO
rat	I-DISO
model	I-DISO
setting	O
.	O

Dimerization	B-PHEN
of	O
EGFR	B-CHEM
and	O
HER2	B-CHEM
induces	O
breast	B-DISO
cancer	I-DISO
cell	B-PHYS
motility	I-PHYS
through	O
STAT1	B-CHEM
-dependent	O
ACTA2	B-CHEM
induction	O
The	O
dimerization	B-PHEN
of	O
EGFR	B-CHEM
and	O
HER2	B-CHEM
is	O
associated	O
with	O
poor	O
prognosis	B-PROC
such	O
as	O
induction	O
of	O
tumor	B-DISO
growth	I-DISO
and	O
cell	B-DISO
invasion	I-DISO
compared	O
to	O
when	O
EGFR	B-CHEM
remains	O
as	O
a	O
homodimer	B-CHEM
.	O

However	O
,	O
the	O
mechanism	O
for	O
events	O
after	O
dimerization	B-PHEN
in	O
breast	B-DISO
cancer	I-DISO
models	B-DEVI
is	O
not	O
clear	O
.	O

We	O
found	O
that	O
expressions	B-PHYS
of	O
alpha	B-CHEM
-	I-CHEM
smooth	I-CHEM
muscle	I-CHEM
actin	I-CHEM
(	O
ACTA2	B-CHEM
)	O
and	O
signal	B-CHEM
transducer	I-CHEM
and	I-CHEM
activator	I-CHEM
of	I-CHEM
transcription	I-CHEM
1	I-CHEM
(	O
STAT1	B-CHEM
)	O
significantly	O
increased	O
with	O
transient	O
or	O
stable	O
overexpression	B-PHYS
of	O
HER2	B-CHEM
in	O
EGFR	B-CHEM
-	O
positive	B-DISO
breast	B-DISO
cancer	I-DISO
cells	B-ANAT
.	O

ACTA2	B-CHEM
and	O
STAT1	B-CHEM
expression	B-PHYS
was	O
also	O
increased	O
in	O
HER2	B-CHEM
-	O
positive	B-DISO
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O

In	O
contrast	O
,	O
ACTA2	B-CHEM
expression	B-PHYS
was	O
decreased	O
by	O
HER2	B-CHEM
siRNA	I-CHEM
.	O

Next	O
,	O
we	O
investigated	O
the	O
co	O
-	O
relation	O
between	O
STAT1	B-CHEM
and	O
ACTA2	B-CHEM
expression	B-PHYS
.	O

Basal	O
ACTA2	B-CHEM
expression	B-PHYS
was	O
significantly	O
decreased	O
by	O
treatment	B-PROC
with	O
the	O
STAT1	B-CHEM
inhibitor	I-CHEM
fludarabine	B-CHEM
or	O
the	O
JAK2	B-CHEM
inhibitor	I-CHEM
AG490	B-CHEM
.	O

In	O
contrast	O
,	O
ACTA2	B-CHEM
expression	B-PHYS
was	O
increased	O
by	O
STAT1	B-CHEM
overexpression	B-PHYS
.	O

Levels	O
of	O
ACTA2	B-CHEM
,	O
STAT1	B-CHEM
,	O
and	O
HER2	B-CHEM
were	O
increased	O
and	O
relapse	O
free	O
survival	O
was	O
decreased	O
in	O
high	B-DISO
-	I-DISO
risk	I-DISO
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O

We	O
also	O
investigated	O
the	O
effect	O
of	O
ACTA2	B-CHEM
on	O
cell	B-PHYS
motility	I-PHYS
,	O
which	O
was	O
suppressed	O
by	O
ACTA2	B-CHEM
shRNA	I-CHEM
overexpression	B-PHYS
in	O
MDA	B-ANAT
-	I-ANAT
MB231	I-ANAT
HER2	B-CHEM
and	O
4T1	B-ANAT
mammary	I-ANAT
carcinoma	I-ANAT
cells	I-ANAT
.	O

The	O
number	O
of	O
lung	B-DISO
metastatic	I-DISO
nodules	I-DISO
was	O
significantly	O
decreased	O
in	O
ACTA2	B-CHEM
knockdown	B-LIVB
mice	I-LIVB
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
induction	O
of	O
ACTA2	B-CHEM
by	O
EGFR	B-CHEM
and	O
HER2	B-CHEM
dimerization	B-PHEN
was	O
regulated	O
through	O
a	O
JAK2	B-CHEM
/	O
STAT1	B-CHEM
signaling	B-PHYS
pathway	I-PHYS
,	O
and	O
aberrant	O
ACTA2	B-CHEM
expression	B-PHYS
accelerated	O
the	O
invasiveness	B-DISO
and	O
metastasis	B-DISO
of	O
breast	B-DISO
cancer	I-DISO
cells	B-ANAT
.	O

Association	O
of	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
with	O
long	O
-	O
term	O
clinical	B-DISO
outcomes	I-DISO
in	O
patients	B-LIVB
with	O
coronary	B-DISO
chronic	I-DISO
total	I-DISO
occlusion	I-DISO
There	O
are	O
limited	O
data	O
regarding	O
the	O
efficacy	O
of	O
β	B-CHEM
-	I-CHEM
blockers	I-CHEM
for	O
secondary	B-PROC
prevention	I-PROC
in	O
patients	B-LIVB
with	O
coronary	B-DISO
chronic	I-DISO
total	I-DISO
occlusion	I-DISO
(	O
CTO	B-DISO
)	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
association	O
of	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
with	O
long	O
-	O
term	O
clinical	B-DISO
outcomes	I-DISO
in	O
CTO	B-DISO
patients	B-LIVB
.	O

From	O
March	O
2003	O
to	O
February	O
2012	O
,	O
a	O
total	O
of	O
2024	O
CTO	B-DISO
patients	B-LIVB
treated	O
with	O
either	O
medical	B-PROC
therapy	I-PROC
alone	O
or	O
revascularization	B-PROC
were	O
enrolled	O
in	O
the	O
study	B-PROC
.	O

We	O
assessed	O
1596	O
patients	B-LIVB
with	O
stable	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
and	O
divided	O
them	O
into	O
the	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O
n	O
=	O
932	O
)	O
and	O
the	O
no	O
-	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O
n	O
=	O
664	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
all	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
.	O

The	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
duration	O
was	O
3	O
.	O

9	O
(	O
interquartile	O
range	O
:	O
2	O
.	O
0	O
-	O
6	O
.	O
2	O
)	O
years	O
.	O

All	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
occurred	O
in	O
11	O
.	O

6	O
%	O
patients	B-LIVB
in	O
the	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
and	O
13	O
.	O

6	O
%	O
patients	B-LIVB
in	O
the	O
no	O
-	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
:	O
0	O
.	O
81	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0	O
.	O
61	O
-	O
1	O
.	O
08	O
;	O
P	O
=	O
0	O
.	O
15	O
)	O
.	O

In	O
the	O
propensity	O
score	O
-	O
matched	B-LIVB
population	I-LIVB
(	O
570	O
pairs	O
)	O
,	O
all	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
occurred	O
in	O
12	O
.	O

3	O
%	O
patients	B-LIVB
in	O
the	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
and	O
12	O
.	O

8	O
%	O
patients	B-LIVB
in	O
the	O
no	O
-	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O
HR	O
:	O
0	O
.	O
93	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
67	O
-	O
1	O
.	O
29	O
;	O
P	O
=	O
0	O
.	O
66	O
)	O
.	O

In	O
subgroup	O
analysis	B-PROC
,	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
was	O
associated	O
with	O
better	O
outcome	O
,	O
in	O
terms	O
of	O
all	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
,	O
in	O
patients	B-LIVB
with	O
CTO	B-DISO
of	O
the	O
left	B-ANAT
anterior	I-ANAT
descending	I-ANAT
coronary	I-ANAT
artery	I-ANAT
and	O
Synergy	O
Between	O
PCI	B-PROC
with	O
Taxus	O
and	O
Cardiac	B-PROC
Surgery	I-PROC
(	O
SYNTAX	O
)	O
score	O
≥23	O
(	O
P	O
for	O
interaction	O
=	O
0	O
.	O
01	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
was	O
not	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
clinical	B-DISO
outcomes	I-DISO
in	O
stable	O
CTO	B-DISO
patients	B-LIVB
,	O
regardless	O
of	O
treatment	B-PROC
strategy	O
.	O

However	O
,	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
might	O
be	O
beneficial	O
in	O
a	O
highly	O
selective	O
group	O
of	O
CTO	B-DISO
patients	B-LIVB
with	O
a	O
high	O
ischemic	B-DISO
burden	I-DISO
.	I-DISO

Derivation	O
of	O
a	O
Predictive	O
Score	O
for	O
Hemorrhagic	B-DISO
Progression	O
of	O
Cerebral	B-DISO
Contusions	I-DISO
in	O
Moderate	B-DISO
and	O
Severe	B-DISO
Traumatic	I-DISO
Brain	I-DISO
Injury	I-DISO
After	O
traumatic	B-DISO
brain	I-DISO
injury	I-DISO
(	O
TBI	B-DISO
)	O
,	O
hemorrhagic	B-DISO
progression	O
of	O
contusions	B-DISO
(	O
HPCs	B-DISO
)	O
occurs	O
frequently	O
.	O

However	O
,	O
there	O
is	O
no	O
established	O
predictive	O
score	O
to	O
identify	O
high	B-DISO
-	I-DISO
risk	I-DISO
patients	B-LIVB
for	O
HPC	B-DISO
.	O

Consecutive	O
patients	B-LIVB
who	O
were	O
hospitalized	B-DISO
(	O
2008	O
-	O
2013	O
)	O
with	O
non	O
-	O
penetrating	O
moderate	B-DISO
or	O
severe	B-DISO
TBI	I-DISO
were	O
studied	O
.	O

The	O
primary	O
outcome	O
was	O
HPC	B-DISO
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	O
in	O
contusion	B-DISO
volume	O
by	O
≥30	O
%	O
and	O
an	O
absolute	O
increase	O
by	O
≥10	O
mL	O
on	O
serial	O
imaging	O
.	O

Logistic	O
regression	O
models	O
were	O
created	O
to	O
identify	O
independent	O
risk	B-DISO
factors	I-DISO
for	O
HPC	B-DISO
.	O

The	O
HPC	B-DISO
Score	O
was	O
then	O
derived	O
based	O
on	O
the	O
final	O
model	O
.	O

Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	B-LIVB
,	O
61	O
(	O
21	O
%	O
)	O
patients	B-LIVB
developed	O
HPC	B-DISO
.	O

On	O
univariate	B-PROC
analyses	I-PROC
,	O
HPC	B-DISO
was	O
associated	O
with	O
older	B-PHYS
age	I-PHYS
,	O
higher	B-DISO
initial	I-DISO
blood	I-DISO
pressure	I-DISO
,	O
antiplatelet	B-CHEM
medications	I-CHEM
,	O
anticoagulants	B-CHEM
,	O
subarachnoid	B-DISO
hemorrhage	I-DISO
(	O
SAH	B-DISO
)	O
subdural	B-DISO
hematoma	I-DISO
(	O
SDH	B-DISO
)	O
,	O
skull	B-DISO
fracture	I-DISO
,	O
frontal	B-ANAT
contusion	B-DISO
,	O
larger	O
contusion	B-DISO
volume	O
,	O
and	O
shorter	O
interval	O
from	O
injury	B-DISO
to	O
initial	B-PROC
CT	I-PROC
.	O

In	O
the	O
final	O
model	O
,	O
SAH	B-DISO
(	O
OR	O
6	O
.	O

33	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
80	O
-	O
22	O
.	O
23	O
)	O
,	O
SDH	B-DISO
(	O
OR	O
3	O
.	O
46	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
39	O
-	O
8	O
.	O
63	O
)	O
,	O
and	O
skull	B-DISO
fracture	I-DISO
(	O
OR	O
2	O
.	O
67	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
28	O
-	O
5	O
.	O
58	O
)	O
were	O
associated	O
with	O
HPC	B-DISO
.	O

Based	O
on	O
these	O
factors	O
,	O
the	O
HPC	B-DISO
Score	O
was	O
derived	O
(	O
SAH	B-DISO
=	O
2	O
points	O
,	O
SDH	B-DISO
=	O
1	O
point	O
,	O
and	O
skull	B-DISO
fracture	I-DISO
=	O
1	O
point	O
)	O
.	O

This	O
score	O
had	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0	O
.	O

77	O
.	O

Patients	B-LIVB
with	O
a	O
score	O
of	O
0	O
-	O
2	O
had	O
a	O
4	O
.	O
0	O
%	O
incidence	O
of	O
HPC	B-DISO
,	O
while	O
patients	B-LIVB
with	O
a	O
score	O
of	O
3	O
-	O
4	O
had	O
a	O
34	O
.	O

6	O
%	O
incidence	O
of	O
HPC	B-DISO
.	O

A	O
simple	O
HPC	B-DISO
Score	O
was	O
developed	O
for	O
early	O
risk	O
stratification	O
of	O
HPC	B-DISO
in	O
patients	B-LIVB
with	O
moderate	B-DISO
or	O
severe	B-DISO
TBI	I-DISO
.	O

Intensive	O
social	O
cognitive	B-PROC
treatment	I-PROC
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	B-LIVB
in	O
persons	B-LIVB
with	O
relapsing	B-DISO
remitting	I-DISO
multiple	I-DISO
sclerosis	I-DISO
:	O
observation	B-PROC
of	O
improved	B-DISO
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O
quality	O
of	O
life	O
,	O
anxiety	B-DISO
and	O
depression	B-DISO
1	O
year	O
later	O
In	O
persons	B-LIVB
with	O
multiple	B-DISO
sclerosis	I-DISO
(	O
MS	B-DISO
)	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
positively	B-DISO
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	B-PROC
treatment	I-PROC
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	B-LIVB
,	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
and	O
HRQoL	O
had	O
improved	B-DISO
in	O
persons	B-LIVB
with	O
relapsing	B-DISO
remitting	I-DISO
MS	I-DISO
(	O
RRMS	B-DISO
)	O
.	O

Given	O
the	O
chronic	O
nature	O
of	O
the	O
disease	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	O
changes	O
may	O
last	O
.	O

Can	O
Do	O
treatment	O
was	O
given	O
to	O
60	O
persons	B-LIVB
with	O
MS	B-DISO
and	O
their	O
support	O
partners	B-LIVB
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	B-PROC
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
control	O
,	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
function	O
,	O
physical	O
and	O
mental	B-PHYS
HRQoL	O
,	O
anxiety	B-DISO
,	O
depression	B-DISO
and	O
fatigue	B-DISO
were	O
assessed	O
via	O
self	B-PROC
-	I-PROC
report	I-PROC
questionnaires	O
.	O

Differences	O
were	O
tested	O
via	O
a	O
paired	O
t	O
test	O
.	O

Of	O
the	O
57	O
persons	B-LIVB
with	O
MS	B-DISO
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	O
(	O
response	B-DISO
rate	O
66	O
.	O

7	O
%	O
)	O
,	O
22	O
with	O
RRMS	B-DISO
and	O
14	O
with	O
progressive	O
MS	B-DISO
.	O

In	O
the	O
RR	B-DISO
group	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
control	O
had	O
increased	O
by	O
20	O
.	O

2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15	O
.	O
0	O
%	O
,	O
and	O
depression	B-DISO
and	O
anxiety	B-DISO
had	O
decreased	O
by	O
29	O
.	O

8	O
and	O
25	O
.	O
9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
the	O
changes	O
in	O
mental	B-PHYS
HRQoL	O
(	O
+17	O
%	O
)	O
and	O
fatigue	B-DISO
(	O
-20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O

087	O
,	O
P	O
=	O
0	O
.	O
080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
progressive	O
group	O
no	O
changes	O
suggestive	O
of	O
improvement	O
were	O
seen	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	B-PROC
treatment	I-PROC
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	B-LIVB
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
and	O
HRQoL	O
in	O
persons	B-LIVB
with	O
RRMS	B-DISO
;	O
and	O
that	O
improvements	O
in	O
anxiety	B-DISO
and	O
depression	B-DISO
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

Perineal	B-DISO
injuries	I-DISO
and	O
birth	B-DISO
positions	I-DISO
among	O
2992	O
women	B-LIVB
with	O
a	O
low	B-DISO
risk	I-DISO
pregnancy	I-DISO
who	O
opted	O
for	O
a	O
homebirth	B-DISO
Whether	O
certain	O
birth	B-DISO
positions	I-DISO
are	O
associated	O
with	O
perineal	B-DISO
injuries	I-DISO
and	O
severe	O
perineal	O
trauma	O
(	O
SPT	O
)	O
is	O
still	O
unclear	B-DISO
.	O

The	O
objective	O
of	O
this	O
study	B-PROC
was	O
to	O
describe	O
the	O
prevalence	O
of	O
perineal	B-DISO
injuries	I-DISO
of	O
different	O
severity	O
in	O
a	O
low	O
-	O
risk	O
population	B-LIVB
of	O
women	B-LIVB
who	O
planned	O
to	O
give	O
birth	B-DISO
at	I-DISO
home	I-DISO
and	O
to	O
compare	O
the	O
prevalence	O
of	O
perineal	B-DISO
injuries	I-DISO
,	O
SPT	O
and	O
episiotomy	B-PROC
in	O
different	O
birth	B-DISO
positions	I-DISO
in	O
four	O
Nordic	B-GEOG
countries	I-GEOG
.	O

A	O
population	B-LIVB
-based	O
prospective	B-PROC
cohort	I-PROC
study	I-PROC
of	O
planned	O
home	B-DISO
births	I-DISO
in	O
four	O
Nordic	B-GEOG
countries	I-GEOG
.	O

To	O
assess	O
medical	O
outcomes	O
a	O
questionnaire	O
completed	O
after	O
birth	B-PHYS
by	O
the	O
attending	O
midwife	B-LIVB
was	O
used	O
.	O

Descriptive	B-PROC
statistics	I-PROC
,	O
bivariate	O
analysis	O
and	O
logistic	B-PROC
regression	I-PROC
were	O
used	O
to	O
analyze	O
the	O
data	O
.	O

Two	O
thousand	O
nine	O
hundred	O
ninety	O
-	O
two	O
women	B-LIVB
with	O
planned	O
home	B-DISO
births	I-DISO
,	O
who	O
birthed	O
spontaneously	O
at	O
home	O
or	O
after	O
transfer	B-PROC
to	I-PROC
hospital	I-PROC
,	O
between	O
2008	O
and	O
2013	O
were	O
included	O
.	O

The	O
prevalence	O
of	O
SPT	O
was	O
0	O
.	O

7	O
%	O
and	O
the	O
prevalence	O
of	O
episiotomy	B-PROC
was	O
1	O
.	O
0	O
%	O
.	O

There	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-DISO
characteristics	O
.	O

No	O
association	O
between	O
flexible	O
sacrum	B-ANAT
positions	O
and	O
sutured	O
perineal	B-DISO
injuries	I-DISO
was	O
found	O
(	O
OR	O
1	O
.	O
02	O
;	O
95	O
%	O
CI	O
0	O
.	O
86	O
-	O
1	O
.	O
21	O
)	O
or	O
SPT	O
(	O
OR	O
0	O
.	O

68	O
;	O
CI	O
95	O
%	O
0	O
.	O
26	O
-	O
1	O
.	O
79	O
)	O
.	O

Flexible	O
sacrum	B-ANAT
positions	O
were	O
associated	O
with	O
fewer	O
episiotomies	B-PROC
(	O
OR	O
0	O
.	O

20	O
;	O
CI	O
95	O
%	O
0	O
.	O
10	O
-	O
0	O
.	O
54	O
)	O
.	O

A	O
low	O
prevalence	O
of	O
SPT	O
and	O
episiotomy	B-PROC
was	O
found	O
among	O
women	B-LIVB
opting	O
for	O
a	O
home	B-DISO
birth	I-DISO
in	O
four	O
Nordic	B-GEOG
countries	I-GEOG
.	O

Women	B-LIVB
used	O
a	O
variety	O
of	O
birth	B-DISO
positions	I-DISO
and	O
a	O
majority	O
gave	O
birth	B-PHYS
in	O
flexible	O
sacrum	B-ANAT
positions	O
.	O

No	O
associations	O
were	O
found	O
between	O
flexible	O
sacrum	B-ANAT
positions	O
and	O
SPT	O
.	O

Flexible	O
sacrum	B-ANAT
positions	O
were	O
associated	O
with	O
fewer	O
episiotomies	B-PROC
.	O

Parallel	O
-	O
processing	O
continuous	B-DEVI
-	I-DEVI
flow	I-DEVI
device	I-DEVI
for	O
optimization	O
-	O
free	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
A	O
parallel	O
-	O
processing	O
four	B-PROC
-	I-PROC
station	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
(	O
PCR	B-PROC
)	O
device	B-OBJC
has	O
been	O
developed	O
,	O
which	O
performs	O
continuous	B-PHEN
-	I-PHEN
flow	I-PHEN
PCR	B-PROC
without	O
optimization	O
of	O
the	O
annealing	B-PHYS
temperature	O
.	O

Since	O
the	O
annealing	B-PHYS
temperature	O
of	O
each	O
station	B-OBJC
can	O
be	O
controlled	O
independently	O
,	O
the	O
device	B-OBJC
covers	O
an	O
annealing	B-PHYS
temperature	O
range	O
of	O
50	O
-	O
68	O
°	O
C	O
,	O
which	O
is	O
wide	O
enough	O
to	O
perform	O
PCR	B-PROC
for	O
any	O
DNA	O
fragment	O
regardless	O
of	O
its	O
optimum	O
annealing	B-PHYS
condition	O
.	O

This	O
arrangement	O
lets	O
us	O
continuously	O
obtain	O
an	O
amplified	B-PHEN
amount	O
of	O
a	O
DNA	O
fragment	O
at	O
least	O
from	O
one	O
of	O
the	O
stations	B-OBJC
.	O

The	O
device	B-OBJC
consists	O
of	O
four	O
identical	O
cylindrical	O
stations	B-OBJC
(	O
diameter	O
20	O
mm	O
,	O
height	B-PHYS
55	O
mm	O
)	O
.	O

A	O
polytetrafluoroethylene	B-CHEM
capillary	B-DEVI
reactor	I-DEVI
(	O
length	O
2	O
m	O
,	O
I	O
.	O

D	O
.	O

100	O
μm	O
,	O
O	O
.	O
D	O
.	O

400	O
μm	O
)	O
is	O
wound	O
helically	O
up	O
around	O
each	O
station	B-OBJC
.	O

The	O
whole	O
assembly	O
is	O
designed	O
to	O
minimize	O
the	O
number	O
of	O
heating	B-DEVI
blocks	I-DEVI
(	O
for	O
providing	O
temperatures	O
of	O
denaturation	B-PHYS
,	O
annealing	B-PHYS
,	O
and	O
extension	O
)	O
to	O
be	O
seven	O
and	O
to	O
shape	O
a	O
compact	B-DISO
cube	O
(	O
height	B-PHYS
55	O
mm	O
,	O
base	O
60	O
mm	O
×	O
60	O
mm	O
)	O
.	O

The	O
reproducibility	O
for	O
continuous	B-PHEN
-	I-PHEN
flow	I-PHEN
PCR	B-PROC
is	O
reasonably	O
high	O
(	O
run	O
-to	O
-	O
run	O
and	O
station	B-OBJC
-to	O
-	O
station	B-OBJC
relative	O
standard	O
deviation	O
of	O
their	O
amplification	B-PHYS
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
)	O
.	O

Performance	O
on	O
the	O
optimization	O
-	O
free	O
DNA	B-PHYS
amplification	I-PHYS
has	O
been	O
evaluated	B-PROC
with	O
four	O
DNA	B-ANAT
samples	I-ANAT
with	O
different	O
annealing	B-PHYS
conditions	O
and	O
product	B-OBJC
sizes	O
(	O
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
)	O
,	O
which	O
has	O
demonstrated	O
that	O
in	O
all	O
cases	O
,	O
PCR	B-PROC
is	O
successful	O
at	O
least	O
on	O
one	O
station	B-OBJC
.	O

In	O
addition	O
,	O
three	O
DNA	O
fragment	O
s	O
with	O
different	O
lengths	O
(	O
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
)	O
have	O
been	O
successfully	O
amplified	B-PHEN
in	O
a	O
segmented	O
-	O
flow	B-PHEN
mode	O
without	O
the	O
carry	O
-	O
over	O
contamination	O
between	O
segments	O
.	O

This	O
result	O
suggests	O
that	O
this	O
device	B-OBJC
could	O
serve	O
as	O
the	O
PCR	B-PROC
module	O
of	O
a	O
continuous	B-PHEN
-	I-PHEN
flow	I-PHEN
high	B-PROC
-	I-PROC
throughput	I-PROC
on	I-PROC
-	I-PROC
line	I-PROC
total	I-PROC
DNA	I-PROC
analysis	I-PROC
system	O
integrating	O
all	O
necessary	O
modules	O
from	O
cell	B-ANAT
lysis	B-DISO
/	O
DNA	B-PROC
extraction	I-PROC
to	O
PCR	B-PROC
product	B-OBJC
analysis	B-PROC
.	O

S	B-PHYS
-	I-PHYS
Nitrosylation	I-PHYS
Induces	O
Structural	O
and	O
Dynamical	O
Changes	O
in	O
a	O
Rhodanese	B-CHEM
Family	I-CHEM
Protein	B-CHEM
S	B-PHYS
-	I-PHYS
Nitrosylation	I-PHYS
is	O
well	O
established	O
as	O
an	O
important	O
post	B-PHYS
-	I-PHYS
translational	I-PHYS
regulator	I-PHYS
in	O
protein	B-PHYS
function	I-PHYS
and	O
signaling	B-PHEN
.	O

However	O
,	O
relatively	O
little	O
is	O
known	O
about	O
its	O
structural	O
and	O
dynamical	O
consequences	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
S	B-PHYS
-	I-PHYS
nitrosylation	I-PHYS
on	O
the	O
rhodanese	O
domain	O
of	O
the	O
Escherichia	B-LIVB
coli	I-LIVB
integral	B-CHEM
membrane	I-CHEM
protein	I-CHEM
YgaP	B-CHEM
by	O
NMR	B-PHEN
,	O
X	B-PROC
-	I-PROC
ray	I-PROC
crystallography	I-PROC
,	O
and	O
mass	B-PROC
spectrometry	I-PROC
.	O

The	O
results	O
show	O
that	O
the	O
active	B-CHEM
cysteine	I-CHEM
in	O
the	O
rhodanese	O
domain	O
of	O
YgaP	B-CHEM
is	O
subjected	O
to	O
two	O
competing	O
modifications	B-PHYS
:	O
S	B-PHYS
-	I-PHYS
nitrosylation	I-PHYS
and	O
S	B-PHYS
-	I-PHYS
sulfhydration	I-PHYS
,	O
which	O
are	O
naturally	O
occurring	O
in	O
vivo	O
.	O

It	O
has	O
been	O
observed	O
that	O
in	O
addition	O
to	O
inhibition	O
of	O
the	O
sulfur	B-PHYS
transfer	I-PHYS
activity	I-PHYS
,	O
S	B-PHYS
-	I-PHYS
nitrosylation	I-PHYS
of	O
the	O
active	O
site	O
residue	O
Cys63	B-CHEM
causes	O
an	O
increase	O
in	O
slow	B-PHEN
motion	I-PHEN
and	O
a	O
displacement	O
of	O
helix	O
5	O
due	O
to	O
a	O
weakening	O
of	O
the	O
interaction	O
between	O
the	O
active	O
site	O
and	O
the	O
helix	O
dipole	O
.	O

These	O
findings	B-DISO
provide	O
an	O
example	O
of	O
how	O
nitrosative	B-PHYS
stress	I-PHYS
can	I-PHYS
exert	I-PHYS
action	I-PHYS
at	O
the	O
atomic	O
level	O
.	O

Expressing	O
sexuality	O
in	O
nursing	B-OBJC
homes	I-OBJC
.	O

The	O
experience	O
of	O
older	B-LIVB
women	I-LIVB
:	O
A	O
qualitative	B-PROC
study	I-PROC
In	O
nursing	B-OBJC
homes	I-OBJC
,	O
a	O
number	O
of	O
barriers	O
to	O
the	O
expression	O
of	O
sexuality	O
exist	O
,	O
such	O
as	O
the	O
lack	B-DISO
of	I-DISO
privacy	I-DISO
,	O
certain	O
attitudes	B-PHYS
on	O
behalf	O
of	O
the	O
staff	B-LIVB
and	O
the	O
family	B-LIVB
,	O
the	O
lack	O
of	O
a	O
sexual	B-LIVB
partner	I-LIVB
,	O
and	O
physical	B-DISO
limitations	I-DISO
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
describe	O
the	O
lived	O
experience	O
of	O
sexuality	O
in	O
elderly	B-LIVB
Spanish	I-LIVB
women	I-LIVB
residing	O
in	O
nursing	B-OBJC
homes	I-OBJC
.	O

A	O
qualitative	B-PROC
phenomenological	I-PROC
approach	I-PROC
was	O
followed	O
.	O

Data	O
were	O
collected	B-PROC
over	O
an	O
18	O
-	O
month	O
period	O
between	O
2013	O
and	O
2015	O
.	O

Purposeful	O
sampling	O
was	O
conducted	O
with	O
Spanish	B-LIVB
residents	I-LIVB
in	O
nursing	B-OBJC
homes	I-OBJC
in	O
Madrid	B-GEOG
.	O

Data	O
were	O
collected	O
using	O
unstructured	O
and	O
semi	O
-	O
structured	O
interviews	O
.	O

The	O
data	O
were	O
analyzed	B-PROC
using	O
thematic	B-PROC
analysis	I-PROC
.	O

Twenty	O
female	B-PHYS
residents	B-LIVB
participated	O
.	O

Three	O
main	O
themes	O
emerged	O
from	O
the	O
data	O
:	O
a	O
)	O
expressing	O
sexuality	O
,	O
b	O
)	O
sexuality	O
as	O
a	O
duty	B-PROC
and	O
c	O
)	O
respecting	O
vows	O
.	O

Female	B-PHYS
residents	B-LIVB
reported	O
key	O
elements	O
influencing	O
how	O
they	O
manage	B-PROC
their	O
sexuality	O
in	O
Nursing	B-OBJC
Homes	I-OBJC
.	O

These	O
results	O
serve	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
expression	O
of	O
sexuality	O
in	O
older	B-PHYS
female	I-PHYS
nursing	B-OBJC
home	I-OBJC
residents	B-LIVB
.	O

Assessing	O
sex	B-PHYS
-	I-PHYS
differences	I-PHYS
and	O
the	O
effect	O
of	O
timing	O
of	O
vaccination	B-PROC
on	O
immunogenicity	B-PHEN
,	O
reactogenicity	B-DISO
and	O
efficacy	B-DISO
of	I-DISO
vaccines	I-DISO
in	O
young	O
children	B-LIVB
:	O
study	O
protocol	O
for	O
an	O
individual	B-LIVB
participant	B-LIVB
data	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
Disease	B-DISO
incidence	O
differs	O
between	O
males	B-PHYS
and	O
females	B-PHYS
for	O
some	O
infectious	B-DISO
or	O
inflammatory	B-DISO
diseases	I-DISO
.	O

Sex	B-PHYS
-	I-PHYS
differences	I-PHYS
in	O
immune	B-PHYS
responses	I-PHYS
to	O
some	O
vaccines	B-CHEM
have	O
also	O
been	O
observed	O
,	O
mostly	O
to	O
viral	B-CHEM
vaccines	I-CHEM
in	O
adults	B-LIVB
.	O

Little	O
evidence	O
is	O
available	O
on	O
whether	O
sex	B-PHYS
-	I-PHYS
differences	I-PHYS
occur	O
in	O
response	B-DISO
to	O
immunisation	B-PROC
in	O
infancy	O
even	O
though	O
this	O
is	O
the	O
age	B-LIVB
group	I-LIVB
in	O
which	O
most	O
vaccines	B-CHEM
are	O
administered	O
.	O

Factors	O
other	O
than	O
sex	B-PHYS
,	O
such	O
as	O
timing	O
or	O
coadministration	B-PROC
of	O
other	O
vaccines	B-CHEM
,	O
can	O
also	O
influence	O
the	O
immune	B-PHYS
response	I-PHYS
to	O
vaccination	B-PROC
.	O

Individual	B-LIVB
participant	B-LIVB
data	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
of	O
vaccines	B-CHEM
in	O
healthy	O
infants	B-LIVB
and	O
young	O
children	B-LIVB
will	O
be	O
conducted	O
.	O

Fully	O
anonymised	O
data	O
from	O
∼170	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
of	O
v	O
accines	B-CHEM
for	O
diphtheria	B-DISO
,	O
tetanus	B-DISO
,	O
Bordetella	B-LIVB
pertussis	I-LIVB
,	O
polio	B-DISO
,	O
Haemophilus	B-LIVB
influenzae	I-LIVB
type	I-LIVB
B	I-LIVB
,	O
hepatitis	B-DISO
B	I-DISO
,	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
,	O
Neisseria	B-LIVB
meningitidis	I-LIVB
,	O
measles	B-DISO
,	O
mumps	B-DISO
,	O
rubella	B-DISO
,	O
varicella	B-DISO
and	O
rotavirus	B-LIVB
will	O
be	O
combined	O
for	O
analysis	B-PROC
.	O

Outcomes	O
include	O
measures	O
of	O
immunogenicity	B-PHEN
(	O
immunoglobulins	B-CHEM
)	O
,	O
reactogenicity	B-DISO
,	O
safety	B-PHEN
and	O
disease	B-DISO
-specific	O
clinical	O
efficacy	O
.	O

Data	O
from	O
trials	B-PROC
of	O
vaccines	B-CHEM
containing	O
similar	O
components	B-OBJC
will	O
be	O
combined	O
in	O
hierarchical	O
models	O
and	O
the	O
effect	O
of	O
sex	B-PHYS
and	O
timing	O
of	O
vaccinations	B-PROC
estimated	O
for	O
each	O
outcome	O
separately	O
.	O

Systematic	O
reviews	O
of	O
published	O
estimates	O
of	O
sex	B-PHYS
-	I-PHYS
differences	I-PHYS
cannot	O
adequately	O
answer	B-PROC
questions	I-PROC
in	O
this	O
field	O
since	O
such	O
comparisons	O
are	O
never	O
the	O
main	O
purpose	O
of	O
a	O
clinical	B-PROC
trial	I-PROC
,	O
thus	O
a	O
large	O
degree	O
of	O
reporting	B-PROC
bias	O
exists	O
in	O
the	O
published	O
literature	O
.	O

Recent	O
improvements	O
in	O
the	O
widespread	O
availability	O
of	O
individual	B-LIVB
participant	B-LIVB
data	O
from	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	O
individual	B-LIVB
participant	B-LIVB
data	O
meta	B-PROC
-	I-PROC
analyses	I-PROC
which	O
were	O
previously	O
impossible	B-DISO
,	O
thereby	O
reducing	O
the	O
effect	O
of	O
publication	B-OBJC
or	O
reporting	B-PROC
bias	O
on	O
the	O
understanding	B-PHYS
of	O
the	O
infant	B-LIVB
immune	B-PHYS
response	I-PHYS
.	O

Preliminary	O
results	O
will	O
be	O
available	O
in	O
2016	O
with	O
final	O
results	O
available	O
in	O
2019	O
.	O

No	O
ethics	O
review	O
is	O
required	O
for	O
secondary	O
analyses	O
of	O
anonymised	O
data	O
.	O

Xylan	B-CHEM
-	I-CHEM
based	I-CHEM
temperature	O
/	O
pH	O
sensitive	O
hydrogels	B-CHEM
for	O
drug	B-CHEM
controlled	I-CHEM
release	I-CHEM
Xylan	B-CHEM
-	I-CHEM
based	I-CHEM
temperature	O
/	O
pH	O
sensitive	O
hydrogels	B-CHEM
were	O
prepared	O
by	O
the	O
crosslinking	B-PHYS
copolymerization	I-PHYS
of	O
xylan	B-CHEM
with	O
N	B-CHEM
-	I-CHEM
isopropylacrylamide	I-CHEM
(	O
NIPAm	B-CHEM
)	O
and	O
acrylic	B-CHEM
acid	I-CHEM
(	O
AA	B-CHEM
)	O
using	O
N	B-CHEM
,	I-CHEM
Ń	I-CHEM
-	I-CHEM
methylenebis	I-CHEM
-	I-CHEM
acrylamide	I-CHEM
(	O
MBA	B-CHEM
)	O
as	O
a	O
cross	B-CHEM
-	I-CHEM
linker	I-CHEM
and	O
2	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
dimethoxy	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
phenylacetophenone	I-CHEM
as	O
a	O
photoinitiator	B-CHEM
via	O
ultraviolet	B-PHEN
irradiation	I-PHEN
.	O

The	O
influence	O
of	O
the	O
NIPAm	B-CHEM
,	O
AA	B-CHEM
and	O
MBA	B-CHEM
amount	O
on	O
properties	O
of	O
xylan	B-CHEM
-	I-CHEM
based	I-CHEM
hydrogels	B-CHEM
was	O
discussed	O
.	O

The	O
morphology	O
and	O
interactions	O
of	O
hydrogels	B-CHEM
were	O
characterized	O
by	O
SEM	B-PROC
and	O
FTIR	B-PROC
.	O

The	O
lower	O
critical	O
solution	O
temperature	O
(	O
LCST	O
)	O
of	O
hydrogels	B-CHEM
was	O
investigated	O
by	O
DSC	B-PROC
.	O

The	O
results	B-DISO
indicated	O
that	O
the	O
LCST	O
of	O
hydrogels	B-CHEM
emerged	O
at	O
around	O
34°C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	B-CHEM
content	O
.	O

The	O
drug	B-CHEM
encapsulation	B-PHEN
efficiency	O
of	O
as	O
-	O
prepared	O
hydrogels	B-CHEM
reached	O
to	O
97	O
.	O
60	O
%	O
and	O
the	O
cumulative	O
release	B-PHEN
rate	O
of	O
acetylsalicylic	B-CHEM
acid	I-CHEM
was	O
90	O
.	O
12	O
%	O
and	O
26	O
.	O
35	O
%	O
in	O
the	O
intestinal	B-ANAT
and	O
gastric	B-ANAT
fluid	I-ANAT
,	O
respectively	O
.	O

Xylan	B-CHEM
-	I-CHEM
based	I-CHEM
hydrogels	B-CHEM
were	O
proved	O
to	O
be	O
biocompatible	O
with	O
NIH3T3	B-ANAT
cell	I-ANAT
by	O
MTT	B-PROC
assay	I-PROC
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	B-CHEM
carriers	I-CHEM
for	O
the	O
intestinal	B-ANAT
-	O
targeted	O
oral	B-PROC
drug	I-PROC
delivery	I-PROC
.	O

Isolation	B-PROC
and	O
prebiotic	B-CHEM
activity	O
of	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
polysaccharides	B-CHEM
fractions	O
from	O
the	O
bamboo	B-OBJC
shoots	I-OBJC
(	O
Phyllostachys	B-LIVB
praecox	I-LIVB
)	O
The	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
polysaccharides	B-CHEM
from	O
bamboo	B-OBJC
shoots	I-OBJC
(	O
Phyllostachys	B-LIVB
praecox	I-LIVB
)	O
(	O
WBP	B-CHEM
)	O
were	O
isolated	O
,	O
and	O
the	O
characterizations	O
as	O
well	O
as	O
prebiotic	B-CHEM
activities	O
were	O
investigated	O
.	O

The	O
yield	O
of	O
WBP	B-CHEM
was	O
7	O
.	O

58±0	O
.	O

31	O
%	O
under	O
optimal	O
hot	B-CHEM
-	I-CHEM
water	I-CHEM
extraction	B-PROC
conditions	O
.	O

Two	O
fractions	O
,	O
i	O
.	O

e	O
.	O
,	O

WBP	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
WBP	B-CHEM
-	I-CHEM
2	I-CHEM
with	O
molecular	O
weight	O
of	O
83	O
.	O

50kDa	O
and	O
80	O
.	O

08kDa	O
,	O
respectively	O
,	O
were	O
purified	O
by	O
chromatography	B-PROC
.	O

Both	O
the	O
polysaccharides	B-CHEM
fractions	O
were	O
identified	O
as	O
heteropolysaccharides	B-CHEM
-	I-CHEM
protein	I-CHEM
complexes	I-CHEM
composed	O
of	O
15	O
kinds	O
of	O
common	O
amino	B-CHEM
acids	I-CHEM
in	O
protein	B-CHEM
part	O
and	O
rhamnose	B-CHEM
,	O
arabinose	B-CHEM
,	O
xylose	B-CHEM
,	O
mannose	B-CHEM
,	O
glucose	B-CHEM
and	O
galactose	B-CHEM
in	O
different	O
molar	O
ratios	O
in	O
polysaccharide	B-CHEM
part	O
.	O

The	O
existence	O
of	O
α	O
-	O
and	O
β	O
-	O
glycosidic	O
linkages	O
between	O
the	O
sugar	B-CHEM
units	O
was	O
confirmed	O
by	O
FTIR	B-PROC
and	O
NMR	B-PROC
spectra	I-PROC
.	O

Compared	O
with	O
the	O
blank	O
control	O
and	O
the	O
reference	O
of	O
FOS	O
,	O
WBP	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
WBP	B-CHEM
-	I-CHEM
2	I-CHEM
significantly	O
increased	O
the	O
numbers	O
of	O
Bifidobacterium	B-LIVB
adolescentis	I-LIVB
and	O
Bifidobacterium	B-LIVB
bifidum	I-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
contributed	O
to	O
the	O
production	O
of	O
organic	B-CHEM
acids	I-CHEM
,	O
suggesting	O
that	O
the	O
polysaccharides	B-CHEM
have	O
potential	O
prebiotic	B-CHEM
properties	O
.	O

Combination	O
of	O
diagnostic	B-PROC
laparoscopy	I-PROC
and	O
intraoperative	O
indocyanine	B-PROC
green	I-PROC
fluorescence	I-PROC
angiography	I-PROC
for	O
the	O
early	B-PROC
detection	I-PROC
of	O
intestinal	B-DISO
ischemia	I-DISO
not	O
detectable	B-PHYS
at	O
CT	B-PROC
scan	I-PROC
Acute	B-DISO
mesenteric	I-DISO
ischemia	I-DISO
is	O
the	O
most	O
severe	O
gastrointestinal	B-DISO
complication	I-DISO
of	O
acute	B-DISO
aortic	I-DISO
dissection	I-DISO
.	O

The	O
timing	O
of	O
diagnosis	B-DISO
is	O
of	O
major	O
importance	O
,	O
in	O
fact	O
the	O
recognition	O
of	O
acute	B-DISO
mesenteric	I-DISO
ischemia	I-DISO
often	O
occurs	O
too	O
late	O
due	O
to	O
the	O
presence	O
of	O
unspecific	O
symptoms	B-DISO
and	O
lack	O
of	O
reliable	O
exams	O
.	O

Recently	O
,	O
indocyanine	B-PROC
green	I-PROC
fluorescence	I-PROC
angiography	I-PROC
has	O
been	O
adopted	O
in	O
order	O
to	O
measure	O
blood	B-PHYS
perfusion	I-PHYS
and	O
microcirculation	B-PHYS
.	O

We	O
decided	O
to	O
perform	O
a	O
diagnostic	B-PROC
laparoscopy	I-PROC
with	O
the	O
support	O
of	O
intra	O
-	O
operative	O
near	O
-	O
infrared	O
indocyanine	B-PROC
green	I-PROC
fluorescence	I-PROC
angiography	I-PROC
,	O
in	O
order	O
to	O
detect	O
an	O
initial	O
intestinal	B-DISO
ischemia	I-DISO
in	O
a	O
68	O
-	O
year	O
-	O
old	O
patient	B-LIVB
previously	O
treated	B-PROC
with	I-PROC
a	O
TEVAR	B-PROC
procedure	I-PROC
for	O
a	O
type	B-DISO
-	I-DISO
B	I-DISO
aortic	I-DISO
dissection	I-DISO
.	O

The	O
fluorescence	B-PROC
system	I-PROC
demonstrated	O
an	O
hypoperfused	O
area	O
in	O
the	O
ascending	B-ANAT
colon	I-ANAT
,	O
therefore	O
an	O
ileocholic	B-PROC
resection	I-PROC
was	O
thus	O
performed	O
.	O

Opening	O
the	O
operatory	O
specimen	B-OBJC
,	O
the	O
mucosa	O
of	O
the	O
colon	O
appeared	O
totally	O
ischemic	B-DISO
,	I-DISO
whilst	O
the	O
serosa	O
was	O
normal	O
.	O

When	O
ischemia	B-DISO
occurs	O
,	O
the	O
oxygen	B-PHYS
supply	I-PHYS
is	O
interrupted	O
,	O
hence	O
the	O
necrosis	B-PHYS
of	O
the	O
enteral	O
mucosa	O
occurs	O
within	O
3h	O
,	O
whilst	O
the	O
necrosis	B-PHYS
of	O
the	O
full	B-DISO
thickness	I-DISO
of	I-DISO
the	I-DISO
bowel	I-DISO
wall	I-DISO
occurs	O
within	O
6h	O
.	O

A	O
diagnosis	B-DISO
during	O
these	O
""""	O
golden	O
hours	O
""""	O
is	O
of	O
major	O
importance	O
for	O
a	O
successful	O
treatment	B-PROC
.	O

The	O
combination	O
of	O
laparoscopy	B-PROC
and	O
UV	B-PROC
light	I-PROC
and	O
fluorescein	B-CHEM
dye	I-CHEM
should	O
be	O
considered	O
as	O
an	O
invaluable	O
diagnostic	B-PROC
procedure	I-PROC
for	O
the	O
diagnosis	B-DISO
of	O
early	O
stage	O
acute	B-DISO
bowel	I-DISO
ischemia	I-DISO
which	O
is	O
not	O
visible	O
at	O
instrumental	B-PROC
examinations	I-PROC
nor	O
with	O
diagnostic	B-PROC
laparoscopy	I-PROC
.	O

An	O
ultrasensitive	O
electrochemiluminescence	B-PROC
sensor	B-OBJC
based	O
on	O
reduced	B-CHEM
graphene	I-CHEM
oxide	I-CHEM
-	O
copper	B-CHEM
sulfide	I-CHEM
composite	O
coupled	O
with	O
capillary	B-PROC
electrophoresis	I-PROC
for	O
determination	B-PROC
of	O
amlodipine	B-CHEM
besylate	I-CHEM
in	O
mice	B-LIVB
plasma	B-ANAT
A	O
new	O
electrochemiluminescence	B-PROC
(	O
ECL	B-PROC
)	O
sensor	B-OBJC
based	O
on	O
reduced	B-CHEM
graphene	I-CHEM
oxide	I-CHEM
-	O
copper	B-CHEM
sulfide	I-CHEM
(	O
rGO	B-CHEM
-	O
CuS	B-CHEM
)	O
composite	O
coupled	O
with	O
capillary	B-PROC
electrophoresis	I-PROC
(	O
CE	B-PROC
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	O
detection	B-PROC
of	O
amlodipine	B-CHEM
besylate	I-CHEM
(	O
AML	B-CHEM
)	O
for	O
the	O
first	O
time	O
.	O

In	O
this	O
work	O
,	O
rGO	B-CHEM
-	O
CuS	B-CHEM
composite	O
was	O
synthesized	O
by	O
one	O
-	O
pot	O
hydrothermal	O
method	O
and	O
used	O
for	O
electrode	B-DEVI
modification	B-DISO
.	O

The	O
electrochemical	B-PROC
and	O
ECL	B-PROC
behaviors	O
of	O
the	O
sensor	B-OBJC
were	O
investigated	O
.	O

More	O
than	O
5	O
-	O
fold	O
enhance	O
in	O
ECL	B-PROC
intensity	O
was	O
observed	O
after	O
modified	O
with	O
rGO	B-CHEM
-	O
CuS	B-CHEM
composite	O
.	O

The	O
results	B-PHEN
can	O
be	O
ascribed	O
to	O
the	O
presence	O
of	O
rGO	B-CHEM
-	O
CuS	B-CHEM
composite	O
on	O
the	O
electrode	B-DEVI
surface	O
that	O
facilitates	O
the	O
electron	O
transfer	O
rate	O
between	O
the	O
electroactive	O
center	O
of	O
Ru	B-CHEM
(	I-CHEM
bpy	I-CHEM
)	I-CHEM
3	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
and	O
the	O
electrode	B-DEVI
.	O

The	O
ECL	B-PROC
sensor	B-OBJC
was	O
coupled	O
with	O
CE	B-PROC
to	O
improve	O
the	O
selectivity	B-PHEN
and	O
the	O
CE	B-PROC
-	O
ECL	B-PROC
parameters	B-DISO
that	O
affect	O
separation	O
and	O
detection	B-PROC
were	O
optimized	O
.	O

Under	O
the	O
optimum	O
conditions	O
,	O
the	O
linear	O
ranges	O
for	O
AML	B-CHEM
was	O
0	O
.	O
008	O
-	O
5	O
.	O

0μg	O
/	O
mL	O
with	O
a	O
detection	O
limit	O
of	O
2	O
.	O

8ng	O
/	O
mL	O
(	O
S	O
/	O
N	O
=	O
3	O
)	O
.	O

The	O
method	B-PROC
displayed	O
the	O
advantages	O
of	O
high	B-PHEN
sensitivity	I-PHEN
,	O
good	B-PHEN
selectivity	I-PHEN
,	O
wide	O
linear	O
range	O
,	O
low	O
detection	O
limit	O
and	O
fine	O
reproducibility	O
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	B-CHEM
in	O
mice	B-LIVB
plasma	B-ANAT
with	O
a	O
satisfactory	O
result	B-PHEN
,	O
which	O
holds	O
a	O
great	O
potential	O
in	O
the	O
field	O
of	O
pharmaceutical	B-PROC
analysis	I-PROC
.	O

Metabolic	B-PHYS
shift	B-DISO
of	O
the	O
kynurenine	B-CHEM
pathway	O
impairs	O
alcohol	O
and	O
cocaine	B-DISO
seeking	I-DISO
and	O
relapse	B-PHEN
The	O
glutamatergic	B-PHYS
system	I-PHYS
plays	O
a	O
key	O
role	O
in	O
the	O
maintenance	O
of	O
drug	O
use	O
and	O
development	O
of	O
drug	O
-	O
related	O
conditioned	O
behaviours	O
.	O

In	O
particular	O
,	O
hyper	B-PHYS
-	I-PHYS
glutamatergic	I-PHYS
activity	I-PHYS
and	O
N	B-CHEM
-	I-CHEM
methyl	I-CHEM
-	I-CHEM
D	I-CHEM
-	I-CHEM
aspartate	I-CHEM
receptor	I-CHEM
(	O
NMDAR	B-CHEM
)	O
activation	B-PHYS
may	O
drive	O
drug	B-DISO
craving	I-DISO
and	O
relapse	B-PHEN
.	O

Inhibition	B-PHYS
of	O
kynurenine	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
monooxygenase	I-CHEM
(	O
KMO	B-CHEM
)	O
shifts	B-DISO
the	O
metabolic	B-PHYS
kynurenine	B-CHEM
pathway	O
towards	O
production	O
of	O
kynurenic	B-CHEM
acid	I-CHEM
,	O
which	O
leads	O
to	O
a	O
reduction	B-PROC
of	O
glutamatergic	B-PHYS
/	O
NMDAR	B-CHEM
activity	B-PHYS
via	O
different	O
mechanisms	O
.	O

In	O
this	O
study	B-PROC
,	O
we	O
investigated	O
whether	O
drug	B-DISO
-	I-DISO
seeking	I-DISO
and	O
relapse	B-PHEN
behaviour	O
could	O
be	O
modified	O
by	O
the	O
metabolic	B-PHYS
shift	B-DISO
of	O
endogenous	O
kynurenine	B-CHEM
pathway	O
.	O

An	O
inhibitor	B-CHEM
of	O
kynurenine	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
monooxygenase	I-CHEM
(	O
KMO	B-CHEM
)	O
Ro61	B-CHEM
-	I-CHEM
8048	I-CHEM
(	O
4	O
and	O
40	O
mg	O
/	O
kg	O
)	O
and	O
its	O
prodrug	B-CHEM
JM6	B-CHEM
(	O
100	O
and	O
200	O
mg	O
/	O
kg	O
)	O
were	O
tested	O
in	O
two	O
behavioural	B-LIVB
rat	I-LIVB
models	I-LIVB
for	O
drug	B-DISO
seeking	I-DISO
and	O
relapse	B-PHEN
-the	O
alcohol	B-DISO
deprivation	I-DISO
effect	I-DISO
(	O
ADE	B-DISO
)	O
model	B-LIVB
in	O
long	O
-	O
term	O
alcohol	O
-	O
drinking	O
rats	B-LIVB
and	O
the	O
model	B-LIVB
of	O
cue	O
-	O
induced	O
reinstatement	O
of	O
alcohol	O
-	O
and	O
cocaine	B-DISO
-	I-DISO
seeking	I-DISO
behaviour	I-DISO
.	O

Our	O
results	O
show	O
that	O
relapse	B-PHEN
-like	O
alcohol	O
drinking	O
during	O
the	O
ADE	B-DISO
was	O
abolished	O
by	O
repeated	O
intraperitoneal	B-PROC
administration	I-PROC
of	O
Ro61	B-CHEM
-	I-CHEM
8048	I-CHEM
and	O
significantly	O
reduced	O
by	O
its	O
oral	O
prodrug	B-CHEM
JM6	B-CHEM
.	O

Cue	O
-	O
induced	O
reinstatement	O
of	O
both	O
alcohol	O
-	O
and	O
cocaine	B-DISO
-	I-DISO
seeking	I-DISO
behaviour	I-DISO
was	O
also	O
abolished	O
by	O
administration	B-PROC
of	O
Ro61	B-CHEM
-	I-CHEM
8048	I-CHEM
.	O

Pharmacological	B-CHEM
enhancement	O
of	O
endogenous	O
kynurenic	B-CHEM
acid	I-CHEM
levels	O
provides	O
a	O
novel	O
treatment	O
strategy	O
to	O
interfere	O
with	O
glutamatergic	B-PHYS
/	O
NMDAR	B-CHEM
activity	B-PHYS
as	O
well	O
as	O
with	O
craving	B-DISO
and	O
relapse	B-PHEN
in	O
alcohol	O
-	O
dependent	O
patients	O
and	O
drug	O
addicts	O
.	O

Comparison	O
of	O
the	O
analgesic	B-CHEM
efficacy	O
of	O
oral	O
ketorolac	B-CHEM
versus	O
intramuscular	O
tramadol	B-CHEM
after	O
third	B-ANAT
molar	I-ANAT
surgery	B-PROC
:	O
A	O
parallel	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
randomized	B-PROC
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
clinical	B-PROC
trial	I-PROC
Preemptive	B-PROC
analgesia	I-PROC
is	O
considered	O
an	O
alternative	O
for	O
treating	O
the	O
postsurgical	B-DISO
pain	I-DISO
of	O
third	B-ANAT
molar	I-ANAT
removal	B-PROC
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-PROC
the	O
preemptive	B-PROC
analgesic	I-PROC
efficacy	O
of	O
oral	O
ketorolac	B-CHEM
versus	O
intramuscular	O
tramadol	B-CHEM
after	O
a	O
mandibular	B-ANAT
third	B-ANAT
molar	I-ANAT
surgery	B-PROC
.	O

A	O
parallel	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O
randomized	B-PROC
,	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
clinical	B-PROC
trial	I-PROC
was	O
carried	O
out	O
.	O

Thirty	O
patients	B-LIVB
were	O
randomized	B-PROC
into	O
two	O
treatment	B-PROC
groups	O
using	O
a	O
series	O
of	O
random	O
numbers	O
:	O
Group	O
A	O
,	O
oral	O
ketorolac	B-CHEM
10	O
mg	O
plus	O
intramuscular	O
placebo	B-CHEM
(	O
1	O
mL	O
saline	B-OBJC
solution	I-OBJC
)	O
;	O
or	O
Group	O
B	O
,	O
oral	O
placebo	B-CHEM
(	O
similar	O
tablet	B-CHEM
to	O
oral	O
ketorolac	B-CHEM
)	O
plus	O
intramuscular	O
tramadol	B-CHEM
50	O
mg	O
diluted	O
in	O
1	O
mL	O
saline	B-OBJC
solution	I-OBJC
.	O

These	O
treatments	B-PROC
were	O
given	O
30	O
min	O
before	O
the	O
surgery	B-PROC
.	O

We	O
evaluated	B-PROC
the	O
time	O
of	O
first	O
analgesic	B-CHEM
rescue	I-CHEM
medication	I-CHEM
,	O
pain	B-PHYS
intensity	I-PHYS
,	O
total	O
analgesic	O
consumption	O
and	O
adverse	B-DISO
effects	I-DISO
.	O

Patients	B-LIVB
taking	O
oral	O
ketorolac	B-CHEM
had	O
longer	O
time	O
of	O
analgesic	B-DISO
covering	I-DISO
and	O
less	O
postoperative	B-DISO
pain	I-DISO
when	O
compared	O
with	O
patients	B-LIVB
receiving	O
intramuscular	O
tramadol	B-CHEM
.	O

According	O
to	O
the	O
VAS	B-PROC
and	O
UAC	B-DEVI
results	O
,	O
this	O
study	O
suggests	O
that	O
10	O
mg	O
of	O
oral	O
ketorolac	B-CHEM
had	O
superior	O
analgesic	B-DISO
effect	I-DISO
than	O
50	O
mg	O
of	O
tramadol	B-CHEM
when	O
administered	O
before	O
a	O
mandibular	B-ANAT
third	B-ANAT
molar	I-ANAT
surgery	B-PROC
.	O

Estrogen	B-CHEM
and	O
Progesterone	B-CHEM
hormone	B-CHEM
receptor	B-PHYS
expression	I-PHYS
in	O
oral	B-DISO
cavity	I-DISO
cancer	I-DISO
Recent	O
studies	O
have	O
shown	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O
OSCC	B-DISO
)	O
in	O
younger	O
patients	B-LIVB
.	O

The	O
hypothesis	O
that	O
tumors	B-DISO
could	O
be	O
hormonally	B-CHEM
induced	O
during	O
pregnancy	B-PHYS
or	O
in	O
young	O
female	B-PHYS
patients	B-LIVB
without	O
the	O
well	O
-	O
known	O
risk	B-DISO
factors	I-DISO
alcohol	B-DISO
or	O
tobacco	B-DISO
abuse	I-DISO
seems	O
to	O
be	O
plausible	O
.	O

Estrogen	B-CHEM
Receptor	I-CHEM
alpha	I-CHEM
(	O
ERα	B-CHEM
)	O
and	O
Progesterone	B-CHEM
Receptor	I-CHEM
(	O
PR	B-CHEM
)	O
expression	B-PHYS
were	O
analyzed	B-PROC
in	O
normal	O
oral	B-ANAT
mucosa	I-ANAT
(	O
n	O
=	O
5	O
)	O
,	O
oral	B-DISO
precursor	I-DISO
lesions	I-DISO
(	O
simple	B-DISO
hyperplasia	I-DISO
,	O
n	O
=	O
11	O
;	O
squamous	B-DISO
intraepithelial	I-DISO
neoplasia	I-DISO
,	O
SIN	B-DISO
I	I-DISO
-	I-DISO
III	I-DISO
,	O
n	O
=	O
35	O
)	O
,	O
and	O
OSCC	B-DISO
specimen	B-OBJC
.	O

OSCCs	B-DISO
were	O
stratified	O
in	O
a	O
young	O
female	B-PHYS
(	O
n	O
=	O
7	O
)	O
study	O
cohort	B-LIVB
and	O
older	B-LIVB
patients	B-LIVB
(	O
n	O
=	O
46	O
)	O
.	O

In	O
the	O
young	O
female	B-PHYS
study	O
cohort	B-LIVB
three	O
patients	B-LIVB
(	O
n	O
=	O
3	O
/	O
7	O
)	O
developed	O
OSCC	B-DISO
during	O
or	O
shortly	O
after	O
pregnancy	B-PHYS
.	O

Breast	B-DISO
cancer	I-DISO
tissues	O
were	O
used	O
as	O
positive	O
control	O
for	O
ERα	B-CHEM
and	O
PR	B-CHEM
expression	B-PHYS
.	O

ERα	B-CHEM
expression	B-PHYS
was	O
found	O
in	O
four	O
oral	B-DISO
precursor	I-DISO
lesions	I-DISO
(	O
squamous	B-DISO
intraepithelial	I-DISO
neoplasia	I-DISO
,	O
SIN	B-DISO
I	I-DISO
-	I-DISO
III	I-DISO
,	O
n	O
=	O
4	O
/	O
35	O
,	O
11	O
%	O
)	O
and	O
in	O
five	O
OSCC	B-DISO
specimen	B-OBJC
(	O
n	O
=	O
5	O
/	O
46	O
,	O
11	O
%	O
)	O
.	O

The	O
five	O
ERα	B-CHEM
positive	B-DISO
OSCC	B-DISO
samples	B-OBJC
were	O
older	B-LIVB
male	B-PHYS
patients	B-LIVB
.	O

All	O
patients	B-LIVB
within	O
the	O
young	O
female	B-PHYS
study	O
cohort	B-LIVB
were	O
negatively	B-DISO
stained	O
for	O
both	O
ERα	B-CHEM
and	O
PR	B-CHEM
.	O

ER	B-CHEM
expression	B-PHYS
could	O
be	O
regarded	O
as	O
a	O
seldom	O
risk	B-DISO
factor	I-DISO
for	O
OSCC	B-DISO
.	O

PR	B-CHEM
expression	B-PHYS
seems	O
to	O
be	O
not	O
relevant	O
for	O
the	O
development	O
of	O
OSCC	B-DISO
.	O

Homeostasis	B-PHEN
of	O
chosen	O
bioelements	B-CHEM
in	O
organs	B-ANAT
of	O
rats	B-LIVB
receiving	O
lithium	B-CHEM
and	O
/	O
or	O
selenium	B-CHEM
Lithium	B-CHEM
is	O
an	O
essential	O
trace	B-CHEM
element	I-CHEM
,	O
widely	O
used	O
in	O
medicine	B-CHEM
and	O
its	O
application	O
is	O
often	O
long	O
-	O
term	O
.	O

Despite	O
beneficial	O
effects	O
,	O
its	O
administration	B-PROC
can	O
lead	O
to	O
severe	O
side	O
effects	O
including	O
hyperparathyroidism	B-DISO
,	O
renal	B-DISO
and	O
thyroid	B-DISO
disorders	I-DISO
.	O

The	O
aim	O
of	O
the	O
current	O
study	B-PROC
was	O
to	O
evaluate	O
the	O
influence	O
of	O
lithium	B-CHEM
and	O
/	O
or	O
selenium	B-CHEM
treatment	O
on	O
magnesium	B-CHEM
,	O
calcium	B-CHEM
and	O
silicon	B-CHEM
levels	O
in	O
rats	B-LIVB
'	O
organs	B-ANAT
as	O
well	O
as	O
the	O
possibility	O
of	O
using	O
selenium	B-CHEM
as	O
an	O
adjuvant	O
in	O
lithium	B-CHEM
therapy	B-PROC
.	O

The	O
study	B-PROC
was	O
performed	O
on	O
rats	B-LIVB
divided	O
into	O
four	O
groups	O
(	O
six	O
animals	B-LIVB
each	O
)	O
:	O
control	B-LIVB
-	O
treated	O
with	O
saline	B-OBJC
;	O
Li	B-CHEM
-	O
treated	O
with	O
Li2CO3	B-CHEM
(	O
2	O
.	O
7	O
mg	O
Li	B-CHEM
/kg	O
b	O
.	O

w	O
.	O
)	O
;	O
Se	B-CHEM
-	O
treated	O
with	O
Na2SeO3·H2O	B-CHEM
(	O
0	O
.	O
5	O
mg	O
Se	B-CHEM
/kg	O
b	O
.	O

w	O
.	O
)	O
;	O
Se	B-CHEM
+	O
Li	B-CHEM
-	O
treated	O
simultaneously	O
with	O
Li2CO3	B-CHEM
and	O
Na2SeO3·H2O	B-CHEM
(	O
2	O
.	O
7	O
mg	O
Li	B-CHEM
/kg	O
b	O
.	O
w	O
.	O
and	O
of	O
0	O
.	O

5	O
mg	O
Se	B-CHEM
/kg	O
b	O
.	O
w	O
.	O
,	O
respectively	O
)	O
.	O

The	O
administration	B-PROC
was	O
performed	O
in	O
form	O
of	O
water	B-CHEM
solutions	I-CHEM
by	O
stomach	B-DEVI
tube	I-DEVI
once	O
a	O
day	O
for	O
3	O
weeks	O
.	O

In	O
the	O
organs	B-ANAT
(	O
liver	B-ANAT
,	O
kidney	B-ANAT
,	O
brain	B-ANAT
,	O
spleen	B-ANAT
,	O
heart	B-ANAT
,	O
lung	B-ANAT
and	O
femoral	O
muscle	O
)	O
the	O
concentrations	O
of	O
magnesium	B-CHEM
,	O
calcium	B-CHEM
and	O
silicon	B-CHEM
were	O
determined	O
.	O

Magnesium	B-CHEM
was	O
increased	O
in	O
liver	B-ANAT
of	O
Se	B-CHEM
and	O
Se	B-CHEM
+	O
Li	B-CHEM
given	O
rats	B-LIVB
.	O

Lithium	B-CHEM
decreased	O
tissue	O
Ca	B-CHEM
and	O
co	B-PROC
-	I-PROC
administration	I-PROC
of	O
selenium	B-CHEM
reversed	O
this	O
effect	O
.	O

Silicon	B-CHEM
was	O
not	O
affected	O
by	O
any	O
treatment	O
.	O

The	O
beneficial	O
effect	O
of	O
selenium	B-CHEM
on	O
disturbances	O
of	O
calcium	B-CHEM
homeostasis	B-PHEN
let	O
suggest	O
that	O
further	O
research	B-PROC
on	O
selenium	B-CHEM
application	O
as	O
an	O
adjuvant	O
in	O
lithium	B-CHEM
therapy	B-PROC
is	O
worth	O
being	O
performed	O
.	O

Studying	B-PROC
neuroprotective	O
effect	O
of	O
Atorvastatin	B-CHEM
as	O
a	O
small	B-CHEM
molecule	I-CHEM
drug	B-CHEM
on	O
high	B-DISO
glucose	I-DISO
-	O
induced	O
neurotoxicity	B-DISO
in	O
undifferentiated	O
PC12	B-ANAT
cells	I-ANAT
:	O
role	O
of	O
NADPH	B-CHEM
oxidase	I-CHEM
Overproduction	O
of	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O
ROS	B-CHEM
)	O
by	O
NADPH	B-CHEM
oxidase	I-CHEM
(	O
NOX	B-CHEM
)	O
activation	B-PHYS
has	O
been	O
considered	O
the	O
essential	O
mechanism	O
induced	O
by	O
hyperglycemia	B-DISO
in	O
various	O
tissues	O
.	O

However	O
,	O
there	O
is	O
no	O
comprehensive	O
study	B-PROC
on	O
the	O
role	O
of	O
NOXs	B-CHEM
in	O
high	B-DISO
glucose	I-DISO
(	O
HG	B-DISO
)	O
-	O
induced	O
toxic	B-DISO
effect	I-DISO
in	O
neural	O
tissues	O
.	O

Recently	O
,	O
a	O
therapeutic	O
strategy	B-PHYS
in	O
oxidative	O
related	O
pathologies	O
has	O
been	O
introduced	O
by	O
blocking	O
the	O
undesirable	O
actions	O
of	O
NOX	B-CHEM
enzymes	I-CHEM
by	O
small	B-CHEM
molecules	I-CHEM
.	O

The	O
protective	B-DISO
roles	O
of	O
Statins	B-CHEM
in	O
ameliorating	O
oxidative	B-DISO
stress	I-DISO
by	O
NOX	B-CHEM
inhibition	B-PHYS
have	O
been	O
shown	O
in	O
some	O
tissues	O
except	O
neural	O
.	O

We	O
hypothesized	O
then	O
,	O
that	O
different	O
NOXs	B-CHEM
may	O
have	O
role	O
in	O
HG	B-DISO
-	O
induced	O
neural	B-DISO
cell	I-DISO
injury	I-DISO
.	O

Furthermore	O
,	O
we	O
postulate	O
that	O
Atorvastatin	B-CHEM
as	O
a	O
small	B-CHEM
molecule	I-CHEM
may	O
modulate	O
this	O
NOXs	B-PHYS
activity	I-PHYS
to	O
protect	B-DISO
neural	B-ANAT
cells	I-ANAT
.	O

Undifferentiated	O
PC12	B-ANAT
cells	I-ANAT
were	O
treated	B-PROC
with	I-PROC
HG	B-DISO
(	O
140	O
mM	O
/	O
24	O
h	O
)	O
in	O
the	O
presence	B-DISO
and	O
absence	O
of	O
Atorvastatin	B-CHEM
(	O
1	O
μM	O
/	O
96	O
h	O
)	O
.	O

The	O
cell	B-PHYS
viability	I-PHYS
was	O
measured	O
by	O
MTT	B-PROC
assay	I-PROC
and	O
the	O
gene	O
and	O
protein	B-PHEN
expressions	I-PHEN
profile	I-PHEN
of	O
NOX	B-CHEM
(	O
1	O
-	O
4	O
)	O
were	O
determined	O
by	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
and	O
western	B-PROC
blotting	I-PROC
,	O
respectively	O
.	O

Levels	O
of	O
ROS	B-CHEM
and	O
malondialdehyde	B-CHEM
(	O
MDA	B-CHEM
)	O
were	O
also	O
evaluated	O
.	O

Gene	B-PHYS
and	O
protein	B-PHYS
expression	I-PHYS
levels	O
of	O
NOX	B-CHEM
(	O
1	O
-	O
4	O
)	O
and	O
consequently	B-DISO
ROS	B-CHEM
and	O
MDA	B-CHEM
levels	O
were	O
elevated	O
in	O
HG	B-DISO
-	O
treated	O
PC12	B-ANAT
cells	I-ANAT
.	O

Atorvastatin	B-CHEM
could	O
significantly	O
decrease	O
HG	B-DISO
-	O
induced	O
NOXs	B-CHEM
,	O
ROS	B-CHEM
and	O
MDA	B-CHEM
elevation	O
and	O
improve	B-DISO
impaired	O
cell	B-PHYS
viability	I-PHYS
.	O

It	O
can	O
be	O
concluded	O
that	O
HG	B-DISO
could	O
elevate	O
NOXs	B-PHYS
activity	I-PHYS
,	O
ROS	B-CHEM
and	O
MDA	B-CHEM
levels	O
in	O
neural	O
tissues	O
and	O
Atorvastatin	B-CHEM
as	O
a	O
small	B-CHEM
molecule	I-CHEM
NOX	B-CHEM
inhibitor	I-CHEM
drug	I-CHEM
may	O
prevent	O
and	O
delay	O
diabetic	B-DISO
complications	I-DISO
,	O
particularly	O
neuropathy	B-DISO
.	O

Substance	B-DISO
use	I-DISO
and	O
sexual	B-PHYS
function	I-PHYS
in	O
juvenile	B-DISO
idiopathic	I-DISO
arthritis	I-DISO
To	O
evaluate	O
alcohol	O
/	O
tobacco	O
/	O
illicit	O
drug	O
use	O
and	O
sexual	B-PHYS
function	I-PHYS
in	O
adolescent	B-LIVB
juvenile	B-DISO
idiopathic	I-DISO
arthritis	I-DISO
(	O
JIA	B-DISO
)	O
and	O
healthy	O
controls	O
.	O

174	O
adolescents	B-LIVB
with	O
pediatric	O
rheumatic	B-DISO
diseases	I-DISO
were	O
selected	O
.	O

A	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
with	O
54	O
JIA	B-DISO
patients	B-LIVB
and	O
35	O
controls	B-LIVB
included	O
demographic	O
/	O
anthropometric	B-PROC
data	O
and	O
puberty	B-DISO
markers	O
assessments	O
,	O
physician	B-LIVB
-conducted	O
CRAFFT	B-PROC
(	O
car	B-OBJC
/	O
relax	O
/	O
alone	O
/	O
forget	B-DISO
/	O
friends	B-LIVB
/	O
trouble	O
)	O
screen	O
tool	O
for	O
substance	B-DISO
abuse	I-DISO
/	O
dependence	B-DISO
high	B-DISO
risk	I-DISO
and	O
a	O
questionnaire	O
that	O
evaluated	B-PROC
sexual	B-PHYS
function	I-PHYS
,	O
bullying	B-DISO
and	O
alcohol	O
/	O
tobacco	O
/	O
illicit	O
drug	O
use	O
.	O

Clinical	O
/	O
laboratorial	O
data	O
and	O
treatment	B-PROC
were	O
also	O
assessed	O
in	O
JIA	B-DISO
.	O

The	O
median	O
current	O
age	O
was	O
similar	O
between	O
JIA	B-DISO
patients	B-LIVB
and	O
controls	B-LIVB
[	O
15	O
(	O
10	O
-	O
19	O
)	O
vs	O
.	O

15	O
(	O
12	O
-	O
18	O
)	O
years	O
,	O
p	O
=	O
0	O
.	O
506	O
]	O
.	O

Frequencies	O
of	O
alcohol	O
/	O
tobacco	O
/	O
illicit	O
drug	O
use	O
were	O
high	O
and	O
similar	O
in	O
both	O
JIA	B-DISO
and	O
controls	B-LIVB
(	O
43	O
%	O
vs	O
.	O

46	O
%	O
,	O
p	O
=	O
0	O
.	O
829	O
)	O
.	O

However	O
,	O
age	B-PHYS
at	O
alcohol	O
onset	O
was	O
significantly	O
higher	O
in	O
those	O
with	O
JIA	B-DISO
[	O
15	O
(	O
11	O
-	O
18	O
)	O
vs	O
.	O

14	O
(	O
7	O
-	O
18	O
)	O
years	O
,	O
p	O
=	O
0	O
.	O
032	O
]	O
,	O
particularly	O
in	O
polyarticular	B-DISO
onset	O
(	O
p	O
=	O
0	O
.	O
040	O
)	O
.	O

High	B-DISO
risk	I-DISO
for	O
substance	B-DISO
abuse	I-DISO
/	O
dependence	B-DISO
(	O
CRAFFT	B-PROC
score	O
≥2	O
)	O
was	O
found	O
in	O
both	O
groups	B-LIVB
(	O
13	O
%	O
vs	O
.	O

15	O
%	O
,	O
p	O
=	O
1	O
.	O
000	O
)	O
,	O
likewise	O
bullying	B-DISO
(	O
p	O
=	O
0	O
.	O
088	O
)	O
.	O

Further	O
analysis	B-PROC
of	O
JIA	B-DISO
patients	B-LIVB
regarding	O
alcohol	O
/	O
tobacco	O
/	O
illicit	O
drug	O
use	O
showed	O
that	O
the	O
median	O
current	O
age	O
[	O
17	O
(	O
14	O
-	O
19	O
)	O
vs	O
.	O

13	O
(	O
10	O
-	O
19	O
)	O
years	O
,	O
p	O
<	O
0	O
.	O
001	O
]	O
and	O
education	O
years	O
[	O
11	O
(	O
6	O
-	O
13	O
)	O
vs	O
.	O

7	O
(	O
3	O
-	O
12	O
)	O
years	O
,	O
p	O
<	O
0	O
.	O
001	O
]	O
were	O
significant	O
higher	O
in	O
those	O
that	O
used	O
substances	O
.	O

Sexual	O
activity	O
was	O
significantly	O
higher	O
in	O
the	O
former	O
group	O
(	O
48	O
%	O
vs	O
.	O

7	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
positive	B-DISO
correlation	O
was	O
evidenced	O
between	O
CRAFFT	B-PROC
score	O
and	O
current	O
age	O
in	O
JIA	B-DISO
patients	B-LIVB
(	O
p	O
=	O
0	O
.	O

032	O
,	O
r	O
=	O
+	O
0	O
.	O
296	O
)	O
.	O

A	O
high	B-DISO
risk	I-DISO
for	O
substance	B-DISO
abuse	I-DISO
/	O
dependence	B-DISO
was	O
observed	O
in	O
both	O
JIA	B-DISO
and	O
controls	B-LIVB
.	O

JIA	B-DISO
substance	B-LIVB
users	I-LIVB
were	O
more	O
likely	O
to	O
have	O
sexual	B-DISO
intercourse	I-DISO
.	O

Therefore	O
,	O
routine	B-DISO
screening	I-DISO
is	O
suggested	O
in	O
all	O
visits	O
of	O
JIA	B-DISO
adolescents	B-LIVB
.	O

NLRP3	B-CHEM
protects	B-DISO
alveolar	B-ANAT
barrier	I-ANAT
integrity	O
by	O
an	O
inflammasome	B-CHEM
-	O
independent	O
increase	O
of	O
epithelial	B-ANAT
cell	I-ANAT
adherence	O
Bacterial	B-DISO
pneumonia	I-DISO
is	O
a	O
major	O
cause	O
of	O
acute	B-DISO
lung	I-DISO
injury	I-DISO
and	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O
characterized	O
by	O
alveolar	B-ANAT
barrier	I-ANAT
disruption	O
.	O

NLRP3	B-CHEM
is	O
best	O
known	O
for	O
its	O
ability	B-PHYS
to	O
form	O
inflammasomes	B-CHEM
and	O
to	O
regulate	B-PHEN
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
18	I-CHEM
production	B-PHEN
in	O
myeloid	B-ANAT
cells	I-ANAT
.	O

Here	O
we	O
show	O
that	O
NLRP3	B-CHEM
protects	B-DISO
the	O
integrity	O
of	O
the	O
alveolar	B-ANAT
barrier	I-ANAT
in	O
a	O
mouse	B-LIVB
model	I-LIVB
of	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
-	O
induced	O
pneumonia	B-DISO
,	O
and	O
ex	O
vivo	O
upon	O
treatment	O
of	O
isolated	O
perfused	O
and	O
ventilated	O
lungs	B-ANAT
with	O
the	O
purified	O
bacterial	B-CHEM
toxin	I-CHEM
,	O
pneumolysin	B-CHEM
.	O

We	O
reveal	O
that	O
the	O
preserving	O
effect	O
of	O
NLRP3	B-CHEM
on	O
the	O
lung	B-ANAT
barrier	I-ANAT
is	O
independent	O
of	O
inflammasomes	B-CHEM
,	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
and	O
IL	B-CHEM
-	I-CHEM
18	I-CHEM
.	O

NLRP3	B-CHEM
improves	B-DISO
the	O
integrity	O
of	O
alveolar	B-ANAT
epithelial	I-ANAT
cell	I-ANAT
monolayers	I-ANAT
by	O
enhancing	O
cellular	B-PROC
adherence	O
.	O

Collectively	O
,	O
our	O
study	B-PROC
uncovers	O
a	O
novel	O
function	O
of	O
NLRP3	B-CHEM
by	O
demonstrating	O
that	O
it	O
protects	B-DISO
epithelial	B-ANAT
barrier	I-ANAT
function	O
independently	O
of	O
inflammasomes	B-CHEM
.	O

Regulation	B-PHEN
of	O
the	O
host	B-LIVB
immune	B-ANAT
system	I-ANAT
by	O
helminth	O
parasites	O
Helminth	B-DISO
parasite	I-DISO
infections	I-DISO
are	O
associated	O
with	O
a	O
battery	O
of	O
immunomodulatory	B-PHYS
mechanisms	I-PHYS
,	O
which	O
impact	O
all	O
facets	O
of	O
the	O
host	B-LIVB
immune	B-PHYS
response	I-PHYS
to	O
ensure	O
their	O
persistence	O
within	O
the	O
host	B-LIVB
.	O

This	O
broad	B-PHYS
-	I-PHYS
spectrum	I-PHYS
modulation	I-PHYS
of	O
host	B-LIVB
immunity	B-PHYS
has	O
intended	O
and	O
unintended	O
consequences	O
,	O
both	O
advantageous	O
and	O
disadvantageous	O
.	O

Thus	O
the	O
host	B-LIVB
may	O
benefit	O
from	O
suppression	O
of	O
collateral	B-DISO
damage	I-DISO
during	O
parasite	O
infection	B-DISO
,	O
and	O
from	O
reduced	O
allergic	B-DISO
,	O
autoimmune	B-DISO
and	O
inflammatory	B-DISO
reactions	I-DISO
.	O

However	O
,	O
helminth	B-DISO
infection	I-DISO
can	O
also	O
be	O
detrimental	O
in	O
reducing	O
vaccine	O
responses	O
,	O
increasing	O
susceptibility	B-PHYS
to	O
co	B-DISO
-	I-DISO
infection	I-DISO
,	O
and	O
potentially	O
reducing	O
tumor	B-DISO
immunosurveillance	B-PHYS
.	O

In	O
this	O
review	O
we	O
will	O
summarize	O
the	O
panoply	O
of	O
immunomodulatory	B-PHYS
mechanisms	I-PHYS
used	O
by	O
helminths	O
,	O
their	O
potential	O
utility	O
in	O
human	B-LIVB
disease	B-DISO
,	O
and	O
prospective	O
areas	O
of	O
future	O
research	B-PROC
.	O

Intravascular	O
Inflammation	B-DISO
Triggers	O
Intracerebral	O
Activated	O
Microglia	B-ANAT
and	O
Contributes	O
to	O
Secondary	B-DISO
Brain	I-DISO
Injury	I-DISO
After	O
Experimental	O
Subarachnoid	B-DISO
Hemorrhage	I-DISO
(	O
eSAH	B-DISO
)	O
Activation	O
of	O
innate	B-PHYS
immunity	I-PHYS
contributes	O
to	O
secondary	B-DISO
brain	I-DISO
injury	I-DISO
after	O
experimental	O
subarachnoid	B-DISO
hemorrhage	I-DISO
(	O
eSAH	B-DISO
)	O
.	O

Microglia	B-ANAT
accumulation	B-DISO
and	O
activation	O
within	O
the	O
brain	B-ANAT
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal	B-PHYS
cell	I-PHYS
death	I-PHYS
after	O
eSAH	B-DISO
.	O

In	O
isolated	O
mouse	B-LIVB
brain	B-ANAT
capillaries	B-ANAT
after	O
eSAH	B-DISO
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene	B-PHYS
expression	I-PHYS
for	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
and	O
P	O
-	O
selectin	O
.	O

Hence	O
,	O
we	O
hypothesized	O
that	O
extracerebral	O
intravascular	O
inflammatory	B-DISO
processes	I-DISO
might	O
initiate	O
the	O
previously	O
reported	B-PROC
microglia	B-ANAT
accumulation	B-DISO
within	O
the	O
brain	B-ANAT
tissue	I-ANAT
.	O

We	O
therefore	O
induced	O
eSAH	B-DISO
in	O
knockout	B-LIVB
mice	I-LIVB
for	O
ICAM	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
(	O
-	O
/	O
-	O
)	O
)	O
and	O
P	O
-	O
selectin	O
glycoprotein	O
ligand	O
-	O
1	O
(	O
PSGL	O
-	O
1	O
(	O
-	O
/	O
-	O
)	O
)	O
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	B-ANAT
-	O
endothelial	B-ANAT
interaction	B-PHYS
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	B-DISO
in	O
a	O
chronic	O
cranial	O
window	B-DEVI
model	I-DEVI
.	O

This	O
inhibition	O
of	O
neutrophil	B-PHYS
recruitment	I-PHYS
to	O
the	O
endothelium	B-ANAT
results	O
in	O
significantly	O
ameliorated	B-DISO
microglia	B-ANAT
accumulation	B-DISO
and	O
neuronal	B-PHYS
cell	I-PHYS
death	I-PHYS
in	O
knockout	B-LIVB
animals	I-LIVB
in	O
comparison	O
to	O
controls	O
.	O

Our	O
results	O
suggest	O
an	O
outside	O
-	O
in	O
activation	O
of	O
the	O
CNS	B-ANAT
innate	I-ANAT
immune	B-ANAT
system	I-ANAT
at	O
the	O
vessel	B-ANAT
/	O
brain	B-ANAT
interface	O
following	O
eSAH	B-DISO
.	O

Microglia	B-ANAT
cells	B-ANAT
,	O
as	O
part	O
of	O
the	O
brain	B-ANAT
's	I-ANAT
innate	B-PHYS
immune	I-PHYS
system	I-PHYS
,	O
are	O
triggered	O
by	O
an	O
inflammatory	B-DISO
reaction	I-DISO
in	O
the	O
microvasculature	B-PHYS
after	O
eSAH	B-DISO
,	O
thus	O
contributing	O
to	O
neuronal	B-PHYS
cell	I-PHYS
death	I-PHYS
.	O

This	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	B-PROC
targets	O
,	O
as	O
well	O
as	O
possible	O
therapy	O
options	O
for	O
patients	B-LIVB
suffering	O
from	O
eSAH	B-DISO
.	O

Evaluation	O
of	O
nutraceutical	B-DISO
and	O
antinutritional	B-DISO
properties	I-DISO
in	O
barnyard	B-LIVB
and	O
finger	B-OBJC
millet	I-OBJC
varieties	O
grown	O
in	O
Himalayan	O
region	O
Five	O
elite	O
varieties	O
of	O
barnyard	B-LIVB
(	O
Echinochloa	B-LIVB
frumentacea	I-LIVB
)	O
and	O
finger	B-LIVB
(	O
Eleusine	B-LIVB
coracana	I-LIVB
)	O
growing	O
at	O
northwestern	O
Himalaya	O
were	O
investigated	O
for	O
nutraceutical	B-DISO
and	O
antinutritional	B-DISO
properties	I-DISO
.	O

Barnyard	B-OBJC
millet	I-OBJC
contained	O
higher	O
amount	O
of	O
crude	B-CHEM
fiber	I-CHEM
,	O
total	B-OBJC
dietary	I-OBJC
fiber	I-OBJC
,	O
tryptophan	B-CHEM
content	O
,	O
total	B-CHEM
carotenoids	I-CHEM
,	O
α	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
compared	O
to	O
the	O
finger	B-OBJC
millet	I-OBJC
whereas	O
the	O
finger	B-OBJC
millet	I-OBJC
contains	O
higher	O
amount	O
of	O
methionine	B-CHEM
and	O
ascorbic	B-CHEM
acid	I-CHEM
as	O
compared	O
to	O
the	O
barnyard	B-OBJC
millet	I-OBJC
.	O

The	O
secondary	B-CHEM
metabolites	I-CHEM
of	O
biological	B-PHEN
functions	I-PHEN
were	O
analyzed	O
and	O
found	O
that	O
barnyard	B-OBJC
millet	I-OBJC
contained	O
the	O
higher	O
amount	O
of	O
polyphenols	B-CHEM
,	O
tannins	B-CHEM
and	O
ortho	B-CHEM
-	I-CHEM
dihydroxy	I-CHEM
phenol	I-CHEM
content	O
compared	O
to	O
finger	B-OBJC
millet	I-OBJC
.	O

Among	O
antinutitional	B-CHEM
compounds	I-CHEM
barnyard	B-OBJC
millet	I-OBJC
contained	O
lower	O
phytic	B-CHEM
acid	I-CHEM
content	O
compare	O
to	O
finger	B-OBJC
millet	I-OBJC
whereas	O
no	B-DISO
significant	I-DISO
difference	I-DISO
in	O
trypsin	B-PHYS
inhibition	I-PHYS
activity	I-PHYS
of	O
barnyard	B-OBJC
millet	I-OBJC
and	O
finger	B-OBJC
millet	I-OBJC
varieties	O
were	O
found	O
.	O

Barnyard	B-OBJC
millet	I-OBJC
contained	O
higher	O
acid	B-CHEM
phosphatase	I-CHEM
,	O
α	B-CHEM
-	I-CHEM
galactosidase	I-CHEM
and	O
α	B-PHYS
-	I-PHYS
amylase	I-PHYS
inhibitor	I-PHYS
activity	I-PHYS
compared	O
to	O
finger	B-OBJC
millet	I-OBJC
.	O

Finger	B-OBJC
millet	I-OBJC
seeds	I-OBJC
contained	O
about	O
10	O
-	O
13	O
folds	O
higher	O
calcium	B-CHEM
content	O
and	O
double	O
amount	O
of	O
manganese	B-CHEM
content	O
in	O
comparison	O
to	O
barnyard	B-OBJC
millet	I-OBJC
seeds	I-OBJC
.	O

Present	O
study	O
suggests	O
that	O
barnyard	B-OBJC
millet	I-OBJC
varieties	O
studied	O
under	O
present	O
investigation	O
were	O
found	O
nutritionally	O
superior	O
compared	O
to	O
finger	B-OBJC
millet	I-OBJC
varieties	O
.	O

Amphetamine	B-DISO
Withdrawal	I-DISO
Differentially	O
Increases	O
the	O
Expression	B-PHYS
of	O
Organic	B-CHEM
Cation	I-CHEM
Transporter	I-CHEM
3	I-CHEM
and	O
Serotonin	B-CHEM
Transporter	I-CHEM
in	O
Limbic	B-ANAT
Brain	B-ANAT
Regions	I-ANAT
Amphetamine	B-DISO
withdrawal	I-DISO
increases	O
anxiety	B-DISO
and	O
stress	B-DISO
sensitivity	O
related	O
to	O
blunted	O
ventral	O
hippocampus	B-ANAT
(	O
vHipp	B-ANAT
)	O
and	O
enhances	O
the	O
central	B-ANAT
nucleus	I-ANAT
of	I-ANAT
the	I-ANAT
amygdala	I-ANAT
(	O
CeA	B-ANAT
)	O
serotonin	B-CHEM
responses	B-PHYS
.	O

Extracellular	B-ANAT
serotonin	B-CHEM
levels	O
are	O
regulated	O
by	O
the	O
serotonin	B-CHEM
transporter	I-CHEM
(	O
SERT	B-CHEM
)	O
and	O
organic	B-CHEM
cation	I-CHEM
transporter	I-CHEM
3	I-CHEM
(	O
OCT3	B-CHEM
)	O
,	O
and	O
vHipp	B-ANAT
OCT3	B-CHEM
expression	B-PHYS
is	O
enhanced	O
during	O
24	O
hours	O
of	O
amphetamine	B-DISO
withdrawal	I-DISO
,	O
while	O
SERT	B-CHEM
expression	B-PHYS
is	O
unaltered	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
OCT3	B-CHEM
and	O
SERT	B-CHEM
expression	B-PHYS
in	O
the	O
CeA	B-ANAT
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-DISO
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	B-ANAT
serotonergic	B-PHYS
neurotransmission	I-PHYS
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	O
weeks	O
of	O
withdrawal	B-DISO
.	O

We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	B-CHEM
expression	B-PHYS
were	O
confined	O
to	O
these	O
regions	O
.	O

Male	B-PHYS
rats	B-LIVB
received	O
amphetamine	B-CHEM
or	O
saline	B-OBJC
for	O
two	O
weeks	O
followed	O
by	O
24	O
hours	O
or	O
two	O
weeks	O
of	O
withdrawal	B-DISO
,	O
with	O
transporter	B-CHEM
expression	B-PHYS
measured	O
using	O
Western	B-PROC
immunoblot	I-PROC
.	O

OCT3	B-CHEM
and	O
SERT	B-CHEM
expression	B-PHYS
increased	O
in	O
the	O
CeA	B-ANAT
at	O
both	O
withdrawal	B-DISO
timepoints	O
.	O

In	O
the	O
vHipp	B-ANAT
,	O
OCT3	B-CHEM
expression	B-PHYS
increased	O
only	O
at	O
24	O
hours	O
of	O
withdrawal	B-DISO
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	B-ANAT
hypothalamus	I-ANAT
.	O

No	B-DISO
changes	I-DISO
were	O
evident	O
in	O
any	O
other	O
regions	B-ANAT
sampled	O
.	O

These	O
regionally	O
specific	O
changes	O
in	O
limbic	B-ANAT
OCT3	B-CHEM
and	O
SERT	B-CHEM
expression	B-PHYS
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	B-CHEM
imbalance	B-DISO
and	O
negative	B-DISO
affect	I-DISO
during	O
amphetamine	B-DISO
withdrawal	I-DISO
.	O

Nutritional	O
aspects	O
of	O
night	O
eating	B-PHYS
and	O
its	O
association	O
with	O
weight	B-PHYS
status	O
among	O
Korean	B-LIVB
adolescents	B-LIVB
A	O
growing	O
body	O
of	O
research	B-PROC
has	O
indicated	O
that	O
night	O
eating	B-PHYS
could	O
be	O
associated	O
with	O
poor	B-DISO
diet	I-DISO
quality	O
and	O
negative	B-DISO
health	O
outcomes	O
.	O

This	O
study	O
examined	O
the	O
nutritional	O
aspects	O
of	O
night	O
eating	B-PHYS
,	O
its	O
related	O
factors	O
,	O
and	O
the	O
association	O
between	O
night	O
eating	B-PHYS
and	O
body	B-PHYS
weight	I-PHYS
among	O
Korean	B-LIVB
adolescents	B-LIVB
.	O

This	O
study	O
analysed	O
the	O
data	O
from	O
a	O
one	O
day	O
24	O
-	O
hour	O
dietary	B-PROC
recall	I-PROC
as	O
well	O
as	O
a	O
demographic	B-PROC
survey	I-PROC
of	O
1	O
,	O
738	O
Korean	B-LIVB
adolescents	B-LIVB
aged	O
12	O
to	O
18	O
-	O
years	O
-old	O
obtained	O
from	O
the	O
2010	O
-	O
2012	O
Korea	B-GEOG
National	B-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
.	O
'	O
Night	O
eating	B-PHYS
'	O
was	O
defined	O
as	O
consuming	O
25	O
%	O
or	O
more	O
of	O
one	O
's	O
daily	O
energy	O
intake	O
between	O
21	O
:	O
00	O
and	O
06	O
:	O
00	O
.	O

Subjects	B-LIVB
complying	O
with	O
the	O
preceding	O
condition	O
were	O
classified	O
as	O
'	O
night	O
eaters	B-LIVB
'	O
,	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non	B-LIVB
-	I-LIVB
night	I-LIVB
eaters	I-LIVB
'	O
.	O

Logistic	O
regression	O
analysis	O
examined	O
factors	O
related	O
to	O
night	O
eating	B-PHYS
.	O

Multiple	O
linear	O
regression	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
night	O
eating	B-PHYS
and	O
BMI	B-PHYS
z	O
-	O
scores	O
,	O
whereas	O
multinomial	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
night	O
eating	B-PHYS
and	O
weight	B-PHYS
status	O
.	O

About	O
21	O
%	O
of	O
Korean	B-LIVB
adolescents	B-LIVB
appeared	O
to	O
be	O
night	O
eaters	B-LIVB
.	O

Night	O
eaters	B-LIVB
showed	O
increased	O
breakfast	O
skipping	B-DISO
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
higher	O
energy	O
intake	O
from	O
snacks	B-OBJC
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
greater	O
proportion	O
of	O
energy	O
intake	O
from	O
fat	O
(	O
P	O
=	O
0	O
.	O

029	O
)	O
,	O
and	O
lower	O
Dietary	O
Diversity	O
Scores	O
(	O
P	O
=	O
0	O
.	O
008	O
)	O
than	O
non	B-LIVB
-	I-LIVB
night	I-LIVB
eaters	I-LIVB
.	O

Male	B-PHYS
adolescents	B-LIVB
presented	O
1	O
.	O
9	O
times	O
higher	O
odds	O
of	O
being	O
night	O
eaters	B-LIVB
than	O
females	B-PHYS
.	O

Adolescents	B-LIVB
whose	O
both	O
parents	B-LIVB
were	O
night	O
eaters	B-LIVB
were	O
4	O
.	O
4	O
times	O
as	O
likely	O
to	O
be	O
night	O
eaters	B-LIVB
as	O
those	O
whose	O
neither	O
parents	B-LIVB
were	O
.	O

Female	B-PHYS
adolescents	B-LIVB
showed	O
a	O
significant	O
relationship	O
between	O
night	O
eating	B-PHYS
and	O
BMI	B-PHYS
z	O
-	O
scores	O
(	O
β	O
=	O
0	O
.	O
28	O
,	O
P	O
=	O
0	O
.	O

004	O
)	O
.	O

However	O
,	O
night	O
eating	B-PHYS
did	O
not	O
increase	O
odds	O
of	O
being	O
overweight	B-DISO
or	O
obese	B-DISO
in	O
adolescents	B-LIVB
.	O

Night	O
eating	B-PHYS
in	O
Korean	B-LIVB
adolescents	B-LIVB
was	O
related	O
to	O
undesirable	B-DISO
dietary	I-DISO
behaviours	I-DISO
and	O
low	B-DISO
diet	I-DISO
quality	I-DISO
in	O
general	O
as	O
well	O
as	O
higher	O
BMI	B-PHYS
z	O
-	O
scores	O
in	O
females	B-PHYS
.	O

Male	B-PHYS
gender	B-PHYS
and	O
parental	B-LIVB
night	O
eating	B-PHYS
appeared	O
to	O
be	O
the	O
factors	O
that	O
significantly	O
increased	O
odds	O
of	O
night	O
eating	B-PHYS
.	O

These	O
results	O
suggest	O
that	O
night	O
eating	B-PHYS
should	O
be	O
considered	O
when	O
designing	O
nutrition	B-PROC
education	I-PROC
or	O
intervention	B-PROC
programs	I-PROC
targeting	O
adolescents	B-LIVB
.	O

Observation	B-PROC
of	O
Network	O
Dynamics	B-PHEN
of	O
Ryanodine	B-CHEM
Receptors	I-CHEM
on	O
Skeletal	O
Muscle	O
Sarcoplasmic	B-ANAT
Reticulum	I-ANAT
Membranes	I-ANAT
Rabbit	B-LIVB
muscle	O
vesicles	B-ANAT
derived	O
from	O
sarcoplasmic	B-ANAT
reticulum	I-ANAT
were	O
used	O
as	O
a	O
material	B-DEVI
in	I-DEVI
studying	I-DEVI
networks	O
of	O
ryanodine	B-CHEM
receptors	I-CHEM
by	O
cryo	B-PHEN
electron	B-PROC
tomography	I-PROC
.	O

Three	B-PROC
-	I-PROC
dimensional	I-PROC
analysis	I-PROC
reveals	O
the	O
dynamical	B-PHEN
features	O
of	O
these	O
networks	O
.	O

It	O
was	O
found	O
that	O
the	O
connection	O
angles	O
were	O
rotated	O
along	O
the	O
transmembrane	B-ANAT
axis	O
of	O
ryanodine	B-CHEM
receptors	I-CHEM
.	O

Majority	O
of	O
the	O
connections	O
was	O
observed	O
at	O
domains	O
6	O
/	O
6	O
of	O
ryanodine	B-CHEM
receptors	I-CHEM
while	O
a	O
small	O
group	O
of	O
connections	O
were	O
showed	O
at	O
domains	O
9	O
/	O
10	O
.	O

The	O
flexible	O
rotation	O
and	O
connection	O
shift	O
seem	O
to	O
facilitate	O
the	O
extension	O
of	O
an	O
annular	O
network	O
on	O
the	O
wall	B-ANAT
of	I-ANAT
the	I-ANAT
sarcoplasmic	I-ANAT
reticulum	I-ANAT
in	O
a	O
triad	B-ANAT
.	O

Effects	O
of	O
Montelukast	B-CHEM
in	O
an	O
Experimental	O
Model	O
of	O
Acute	B-DISO
Pancreatitis	I-DISO
BACKGROUND	O
We	O
evaluated	B-PROC
the	O
hematological	O
,	O
biochemical	O
,	O
and	O
histopathological	O
effects	O
of	O
Montelukast	B-CHEM
on	O
pancreatic	B-ANAT
damage	O
in	O
an	O
experimental	O
acute	B-DISO
pancreatitis	I-DISO
model	B-DISO
created	O
by	O
cerulein	B-CHEM
in	O
rats	B-LIVB
before	O
and	O
after	O
the	O
induction	O
of	O
pancreatitis	B-DISO
.	O

MATERIAL	O
AND	O
METHODS	O
Forty	O
rats	B-LIVB
were	O
divided	O
into	O
4	O
groups	B-LIVB
with	O
10	O
rats	B-LIVB
each	O
.	O

The	O
study	B-LIVB
groups	I-LIVB
were	O
:	O
the	O
Cerulein	B-CHEM
(	O
C	B-CHEM
)	O
group	B-LIVB
,	O
the	O
Cerulein	B-CHEM
+	O
early	O
Montelukast	B-CHEM
(	O
CMe	O
)	O
group	B-LIVB
,	O
the	O
Cerulein	B-CHEM
+	O
late	O
Montelukast	B-CHEM
(	O
CMl	O
)	O
group	B-LIVB
,	O
and	O
the	O
Control	B-LIVB
group	I-LIVB
.	O

The	O
pH	O
,	O
pO2	B-PHYS
,	O
pCO2	B-PHEN
,	O
HCO3	B-CHEM
,	O
leukocyte	B-ANAT
,	O
hematocrit	B-DISO
,	O
pancreatic	B-CHEM
amylase	I-CHEM
,	O
and	O
lipase	B-CHEM
values	O
were	O
measured	O
in	O
the	O
arterial	B-ANAT
blood	I-ANAT
samples	I-ANAT
taken	O
immediately	O
before	O
rats	B-LIVB
were	O
killed	O
.	O

RESULTS	O
There	O
were	O
statistically	O
significant	O
differences	O
between	O
the	O
C	B-CHEM
group	B-LIVB
and	O
the	O
Control	B-LIVB
group	I-LIVB
in	O
the	O
values	O
of	O
pancreatic	B-CHEM
amylase	I-CHEM
,	O
lipase	B-CHEM
,	O
blood	B-ANAT
leukocyte	I-ANAT
,	O
hematocrit	B-DISO
,	O
pH	O
,	O
pO2	B-PHYS
,	O
pCO2	B-PHEN
,	O
HCO3	B-CHEM
,	O
and	O
pancreatic	B-ANAT
water	O
content	O
,	O
and	O
also	O
in	O
each	O
of	O
the	O
values	O
of	O
edema	B-DISO
,	O
inflammation	B-DISO
,	O
vacuolization	B-DISO
,	O
necrosis	B-PHYS
,	O
and	O
total	O
histopathological	O
score	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

When	O
the	O
CMl	O
group	B-LIVB
and	O
C	B-CHEM
group	B-LIVB
were	O
compared	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
found	O
in	O
any	O
parameter	B-DISO
analyzed	O
.	O

When	O
the	O
CMe	O
group	B-LIVB
was	O
compared	O
with	O
the	O
C	B-CHEM
group	B-LIVB
,	O
pancreatic	B-CHEM
amylase	I-CHEM
,	O
lipase	B-CHEM
,	O
pH	O
,	O
PO2	B-PHYS
,	O
pCO2	B-PHEN
,	O
HCO3	B-CHEM
,	O
pancreatic	B-ANAT
water	O
content	O
,	O
histopathological	O
edema	B-DISO
,	O
inflammation	B-DISO
,	O
and	O
total	O
histopathological	O
score	O
values	O
were	O
significantly	O
different	O
between	O
the	O
groups	B-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Finally	O
,	O
when	O
the	O
CMe	O
group	B-LIVB
and	O
the	O
Control	B-LIVB
group	I-LIVB
were	O
compared	O
,	O
significant	O
differences	O
were	O
found	O
in	O
all	O
except	O
2	O
(	O
leukocyte	B-ANAT
and	O
pO2	B-PHYS
)	O
parameters	B-DISO
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
Leukotriene	B-CHEM
receptor	I-CHEM
antagonists	I-CHEM
used	O
in	O
the	O
late	B-PROC
phases	I-PROC
of	O
pancreatitis	B-DISO
might	O
not	O
result	O
in	O
any	O
benefit	O
;	O
however	O
,	O
when	O
they	O
are	O
given	O
in	O
the	O
early	O
phases	O
or	O
prophylactically	O
,	O
they	O
may	O
decrease	O
pancreatic	B-ANAT
damage	O
.	O

Functional	O
characterization	O
of	O
the	O
Aspergillus	B-LIVB
nidulans	I-LIVB
glucosylceramide	B-CHEM
pathway	B-PHYS
reveals	O
that	O
LCB	B-CHEM
Δ8	B-PHYS
-	I-PHYS
desaturation	I-PHYS
and	O
C9	B-PHYS
-	I-PHYS
methylation	I-PHYS
are	O
relevant	O
to	O
filamentous	B-PHYS
growth	I-PHYS
,	O
lipid	B-PHYS
raft	I-PHYS
localization	I-PHYS
and	O
Psd1	B-CHEM
defensin	I-CHEM
activity	O
C8	B-CHEM
-	I-CHEM
desaturated	I-CHEM
and	I-CHEM
C9	I-CHEM
-	I-CHEM
methylated	I-CHEM
glucosylceramide	I-CHEM
(	O
GlcCer	B-CHEM
)	O
is	O
a	O
fungal	B-LIVB
-specific	O
sphingolipid	B-CHEM
that	O
plays	O
an	O
important	O
role	O
in	O
the	O
growth	B-PHYS
and	O
virulence	B-PHEN
of	O
many	O
species	O
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
contribution	O
of	O
Aspergillus	B-LIVB
nidulans	I-LIVB
sphingolipid	B-CHEM
Δ8	I-CHEM
-	I-CHEM
desaturase	I-CHEM
(	O
SdeA	B-CHEM
)	O
,	O
sphingolipid	B-CHEM
C9	I-CHEM
-	I-CHEM
methyltransferases	I-CHEM
(	O
SmtA	B-CHEM
/	O
SmtB	B-CHEM
)	O
and	O
glucosylceramide	B-CHEM
synthase	I-CHEM
(	O
GcsA	B-CHEM
)	O
to	O
fungal	B-LIVB
phenotypes	B-PHYS
,	O
sensitivity	O
to	O
Psd1	B-CHEM
defensin	I-CHEM
and	O
Galleria	O
mellonella	O
virulence	B-PHEN
.	O

We	O
showed	O
that	O
ΔsdeA	B-PHYS
accumulated	O
C8	B-CHEM
-	I-CHEM
saturated	I-CHEM
and	I-CHEM
unmethylated	I-CHEM
GlcCer	I-CHEM
,	O
while	O
gcsA	O
deletion	B-PHYS
impaired	O
GlcCer	B-CHEM
synthesis	O
.	O

Although	O
increased	O
levels	O
of	O
unmethylated	B-CHEM
GlcCer	I-CHEM
were	O
observed	O
in	O
smtA	O
and	O
smtB	O
mutants	B-DISO
,	O
ΔsmtA	B-PHYS
and	O
wild	O
-	O
type	O
cells	B-ANAT
showed	O
a	O
similar	O
9	B-CHEM
,	I-CHEM
Me	I-CHEM
-	I-CHEM
GlcCer	I-CHEM
content	O
,	O
reduced	O
by	O
50	O
%	O
in	O
the	O
smtB	O
disruptant	B-DISO
.	O

The	O
compromised	O
9	B-CHEM
,	I-CHEM
Me	I-CHEM
-	I-CHEM
GlcCer	I-CHEM
production	O
in	O
the	O
ΔsmtB	B-PHYS
strain	B-LIVB
was	O
not	O
accompanied	O
by	O
reduced	O
filamentation	B-PHYS
or	O
defects	O
in	O
cell	O
polarity	O
.	O

When	O
combined	O
with	O
the	O
smtA	O
deletion	B-PHYS
,	O
smtB	O
repression	B-PHYS
significantly	O
increased	O
unmethylated	B-CHEM
GlcCer	I-CHEM
levels	O
and	O
compromised	O
filamentous	B-PHYS
growth	I-PHYS
.	O

Furthermore	O
,	O
sdeA	O
and	O
gcsA	O
mutants	B-DISO
displayed	O
growth	B-PHYS
defects	O
and	O
raft	B-ANAT
mislocalization	O
,	O
which	O
were	O
accompanied	O
by	O
reduced	B-DISO
neutral	I-DISO
lipids	I-DISO
levels	I-DISO
and	O
attenuated	O
G	O
.	O

mellonella	O
virulence	B-PHEN
in	O
the	O
ΔgcsA	B-PHYS
strain	B-LIVB
.	O

Finally	O
,	O
ΔsdeA	B-PHYS
and	O
ΔgcsA	B-PHYS
showed	O
increased	O
resistance	O
to	O
Psd1	B-CHEM
,	O
suggesting	O
that	O
GlcCer	B-CHEM
synthesis	O
and	O
fungal	B-LIVB
sphingoid	O
base	O
structure	O
specificities	O
are	O
relevant	O
not	O
only	O
to	O
differentiation	O
but	O
also	O
to	O
proper	O
recognition	O
by	O
this	O
antifungal	B-CHEM
defensin	B-CHEM
.	O

Subepidermal	B-ANAT
Calcified	O
Nodules	O
of	O
the	O
Eyelid	B-ANAT
Differ	O
in	O
Children	B-LIVB
and	O
Adults	B-LIVB
Subepidermal	B-ANAT
calcified	O
nodule	O
of	O
the	O
eyelid	B-ANAT
is	O
considered	O
as	O
one	O
of	O
the	O
types	O
of	O
calcinosis	B-DISO
cutis	I-DISO
.	O

It	O
generally	O
occurs	O
in	O
children	B-LIVB
,	O
and	O
is	O
not	O
known	O
to	O
be	O
associated	O
with	O
systemic	B-DISO
disease	I-DISO
.	O

The	O
authors	B-LIVB
report	B-PROC
histopathological	O
and	O
clinical	B-PHYS
findings	I-PHYS
in	O
14	O
cases	O
of	O
subepidermal	B-ANAT
calcified	O
nodule	O
of	O
the	O
eyelid	B-ANAT
,	O
including	O
3	O
older	B-LIVB
patients	B-LIVB
with	O
unique	O
microscopic	O
features	O
.	O

Clinical	O
records	O
and	O
pathological	O
materials	B-OBJC
were	O
critically	O
reviewed	O
in	O
each	O
case	O
,	O
including	O
von	B-PROC
kossa	I-PROC
,	O
CD3	B-CHEM
,	O
CD20	B-CHEM
,	O
and	O
CD68	B-CHEM
stains	I-CHEM
.	O

The	O
14	O
cases	O
presented	O
clinically	O
as	O
nodular	O
eyelid	B-DISO
lesions	I-DISO
.	O

All	O
were	O
treated	O
with	O
surgical	B-PROC
excision	I-PROC
.	O

The	O
authors	B-LIVB
found	O
2	O
distinct	O
histopathological	O
patterns	O
which	O
correlated	O
with	O
the	O
patients	B-LIVB
'	O
age	B-PHYS
.	O

In	O
young	O
patients	B-LIVB
,	O
the	O
authors	B-LIVB
observed	O
multiple	O
,	O
small	O
calcified	B-DISO
bodies	I-DISO
within	O
the	O
dermis	O
surrounded	O
by	O
chronic	B-DISO
inflammation	I-DISO
and	O
granulomatous	B-DISO
foreign	I-DISO
body	I-DISO
reaction	I-DISO
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
elderly	B-LIVB
patients	B-LIVB
,	O
lesions	B-DISO
were	O
characterized	O
by	O
a	O
single	O
,	O
large	O
,	O
well	B-PHYS
-	I-PHYS
demarcated	I-PHYS
amorphous	I-PHYS
calcified	I-PHYS
deposit	I-PHYS
surrounded	O
by	O
fibrous	O
tissue	O
,	O
without	O
chronic	B-DISO
inflammation	I-DISO
or	O
foreign	B-DISO
body	I-DISO
reaction	I-DISO
.	O

One	O
of	O
these	O
patients	B-LIVB
,	O
a	O
70	O
-	O
year	O
-	O
old	O
man	B-LIVB
,	O
also	O
suffered	O
from	O
gout	O
.	O

The	O
presence	B-DISO
of	O
subepidermal	B-ANAT
calcified	O
nodule	O
was	O
not	O
documented	B-PROC
as	O
a	O
preoperative	O
diagnostic	O
possibility	O
in	O
any	O
of	O
the	O
cases	O
.	O

Subepidermal	B-ANAT
calcified	O
nodule	O
of	O
the	O
eyelid	B-ANAT
is	O
a	O
rare	O
condition	O
,	O
but	O
should	O
be	O
considered	O
in	O
any	O
patient	B-LIVB
presenting	O
with	O
a	O
painless	O
white	B-DISO
to	I-DISO
yellowish	I-DISO
colored	I-DISO
nodule	I-DISO
of	O
the	O
ocular	B-ANAT
adnexa	I-ANAT
,	O
particularly	O
during	O
the	O
teenage	O
years	O
.	O

Clinicians	B-LIVB
and	O
pathologists	B-LIVB
should	O
be	O
aware	O
that	O
this	O
entity	B-OBJC
has	O
a	O
distinct	O
appearance	O
and	O
could	O
be	O
associated	O
with	O
systemic	B-DISO
conditions	I-DISO
in	O
elderly	B-LIVB
patients	B-LIVB
.	O

Cover	B-OBJC
Image	O
,	O
Volume	O
117	O
,	O
Number	O
10	O
,	O
October	O
2016	O
Cover	B-OBJC
:	O
The	O
cover	B-OBJC
image	O
,	O
by	O
Jacqueline	O
May	O
Bentel	O
et	O
al	O
.	O
,	O
is	O
based	O
on	O
the	O
Article	O
Activity	B-PHYS
of	O
ABCG2	B-CHEM
Is	O
Regulated	O
by	O
Its	O
Expression	B-PHYS
and	O
Localization	O
in	O
DHT	B-CHEM
and	O
Cyclopamine	B-CHEM
-	O
Treated	O
Breast	B-ANAT
Cancer	I-ANAT
Cells	I-ANAT
,	O
DOI	O
:	O
10	O
.	O
1002	O
/	O
jcb	O
.	O
25523	O
.	O

What	O
kind	O
of	O
processing	O
is	O
survival	B-PHYS
processing	I-PHYS
?	O
:	O
Effects	O
of	O
different	O
types	O
of	O
dual	O
-	O
task	O
load	O
on	O
the	O
survival	B-PHYS
processing	I-PHYS
effect	O
Words	B-PHYS
judged	I-PHYS
for	O
their	O
relevance	O
in	O
a	O
survival	O
context	O
are	O
remembered	O
better	O
than	O
words	B-PHYS
processed	I-PHYS
in	O
non	O
-	O
survival	O
contexts	O
.	O

This	O
phenomenon	B-PHEN
is	O
known	O
as	O
the	O
survival	B-PHYS
processing	I-PHYS
effect	I-PHYS
.	O

Recently	O
,	O
inconsistent	B-DISO
results	I-DISO
were	O
reported	O
on	O
whether	O
the	O
size	O
of	O
the	O
survival	B-PHYS
processing	I-PHYS
effect	I-PHYS
is	O
affected	O
by	O
cognitive	O
load	O
.	O

Whereas	O
Kroneisen	B-LIVB
,	O
Rummel	B-LIVB
,	O
and	O
Erdfelder	B-LIVB
(	O
Memory	B-PHYS
22	O
:	O
92	O
-	O
102	O
,	O
2014	O
)	O
observed	O
that	O
the	O
survival	B-PHYS
processing	I-PHYS
effect	I-PHYS
vanishes	O
under	O
dual	O
-	O
task	O
conditions	O
,	O
Stillman	B-LIVB
,	O
Coane	B-LIVB
,	O
Profaci	B-LIVB
,	O
Howard	B-LIVB
,	O
and	O
Howard	B-LIVB
(	O
Memory	O
&	O
Cognition	O
42	O
:	O
175	O
-	O
185	O
,	O
2014	O
,	O
Experiment	O
1	O
)	O
found	O
that	O
the	O
size	O
of	O
survival	B-PHYS
processing	I-PHYS
effect	O
is	O
essentially	O
unaffected	O
by	O
a	O
cognitively	B-PHYS
demanding	I-PHYS
secondary	I-PHYS
task	I-PHYS
.	O

In	O
three	O
experiments	O
,	O
we	O
investigated	O
the	O
differences	O
between	O
these	O
studies	O
to	O
achieve	O
a	O
better	O
understanding	B-PHYS
of	O
dual	O
-	O
task	O
effects	O
on	O
the	O
survival	O
-	O
processing	O
advantage	O
.	O

In	O
the	O
first	O
experiment	O
,	O
we	O
replicated	O
Stillman	B-LIVB
et	O
al	O
.	O

's	O
results	O
using	O
their	O
dual	O
-	O
task	O
conditions	O
combined	O
with	O
a	O
sample	O
more	O
than	O
twice	O
as	O
large	O
as	O
theirs	O
.	O

In	O
the	O
second	O
experiment	O
,	O
we	O
compared	O
dual	O
-	O
task	O
conditions	O
that	O
differed	O
regarding	O
how	O
strongly	O
the	O
secondary	B-PHYS
task	I-PHYS
taxed	I-PHYS
(	O
a	O
)	O
working	B-PHYS
memory	I-PHYS
load	O
(	O
maintenance	O
of	O
one	O
vs	O
.	O

several	O
items	O
)	O
and	O
(	O
b	O
)	O
processing	B-DISO
demands	I-DISO
(	O
switching	B-PHYS
vs	I-PHYS
.	I-PHYS
time	I-PHYS
-	I-PHYS
sharing	I-PHYS
between	I-PHYS
tasks	I-PHYS
)	O
.	O

A	O
third	O
experiment	B-PROC
focussed	O
on	O
low	O
(	O
i	O
.	O

e	O
.	O
,	O
single	O
-	O
item	O
)	O
load	O
under	O
time	O
-	O
sharing	O
processing	O
conditions	O
.	O

Results	O
consistently	O
showed	O
that	O
the	O
survival	B-PHYS
processing	I-PHYS
effect	O
persisted	O
under	O
low	O
load	O
but	O
vanished	O
when	O
the	O
number	O
of	O
items	O
held	O
in	O
working	B-PHYS
memory	I-PHYS
increased	O
beyond	O
one	O
,	O
irrespective	O
of	O
processing	B-DISO
demands	I-DISO
.	O

Implications	O
of	O
these	O
findings	O
for	O
explanations	O
of	O
the	O
survival	O
-	O
processing	O
advantage	O
are	O
discussed	O
.	O

A	O
randomized	B-PROC
trial	I-PROC
of	O
Plasma	B-CHEM
-	I-CHEM
Lyte	I-CHEM
A	I-CHEM
and	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
sodium	I-CHEM
chloride	I-CHEM
in	O
acute	B-DISO
pediatric	I-DISO
gastroenteritis	I-DISO
Compare	O
the	O
efficacy	O
and	O
safety	O
of	O
Plasma	B-CHEM
-	I-CHEM
Lyte	I-CHEM
A	I-CHEM
(	O
PLA	B-CHEM
)	O
versus	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
sodium	I-CHEM
chloride	I-CHEM
(	O
NaCl	B-CHEM
)	O
intravenous	B-PROC
(	I-PROC
IV	I-PROC
)	I-PROC
fluid	I-PROC
replacement	I-PROC
in	O
children	B-LIVB
with	O
moderate	O
to	O
severe	B-DISO
dehydration	I-DISO
secondary	O
to	O
acute	B-DISO
gastroenteritis	I-DISO
(	O
AGE	B-DISO
)	O
.	O

Prospective	B-PROC
,	O
randomized	B-PROC
,	O
double	B-PROC
-	I-PROC
blind	I-PROC
study	I-PROC
conducted	O
at	O
eight	O
pediatric	O
emergency	B-OBJC
departments	I-OBJC
(	O
EDs	B-OBJC
)	O
in	O
the	O
US	B-GEOG
and	O
Canada	B-GEOG
(	O
NCT	O
#	O
01234883	O
)	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
serum	B-PHEN
bicarbonate	I-PHEN
level	I-PHEN
at	O
4	O
h	O
.	O

Secondary	O
outcomes	O
included	O
safety	O
and	O
tolerability	B-PROC
.	O

The	O
hypothesis	O
was	O
that	O
PLA	B-CHEM
would	O
be	O
superior	O
to	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
in	O
improvement	B-PROC
of	I-PROC
4	I-PROC
-	I-PROC
h	I-PROC
bicarbonate	I-PROC
.	O

Patients	B-LIVB
(	O
n	O
=	O
100	O
)	O
aged	O
≥6	O
months	O
to	O
<	O
11	O
years	O
with	O
AGE	B-DISO
-induced	O
moderate	O
-	O
to	O
-	O
severe	B-DISO
dehydration	I-DISO
were	O
enrolled	O
.	O

Patients	B-LIVB
with	O
a	O
baseline	O
bicarbonate	B-PHEN
level	I-PHEN
≤22	O
mEq	O
/	O
L	O
formed	O
the	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
group	B-LIVB
.	O

At	O
baseline	O
,	O
the	O
treatment	B-PROC
groups	B-LIVB
were	O
comparable	O
except	O
that	O
the	O
PLA	B-CHEM
group	B-LIVB
was	O
older	O
.	O

At	O
hour	O
4	O
,	O
the	O
PLA	B-CHEM
group	B-LIVB
had	O
greater	O
increases	B-DISO
in	I-DISO
serum	I-DISO
bicarbonate	I-DISO
from	O
baseline	O
than	O
did	O
the	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
group	B-LIVB
(	O
mean	O
±	O
SD	O
at	O
4	O
h	O
:	O
18	O
±	O
3	O
.	O
74	O
vs	O
18	O
.	O
0	O
±	O
3	O
.	O
67	O
;	O
change	O
from	O
baseline	O
of	O
1	O
.	O

6	O
and	O
0	O
.	O
0	O
,	O
respectively	O
;	O
P	O
=	O
.004	O
)	O
.	O

Both	O
treatment	B-PROC
groups	B-LIVB
received	O
similar	O
fluid	O
volumes	O
.	O

The	O
PLA	B-CHEM
group	B-LIVB
had	O
less	O
abdominal	B-DISO
pain	I-DISO
and	O
better	O
dehydration	B-DISO
scores	O
at	O
hour	O
2	O
(	O
both	O
P	O
=	O
.03	O
)	O
but	O
not	O
at	O
hour	O
4	O
(	O
P	O
=	O
0	O
.	O
15	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O

No	O
patient	B-LIVB
experienced	O
clinically	O
relevant	O
worsening	O
of	O
laboratory	B-PHEN
findings	I-PHEN
or	O
physical	B-PROC
examination	I-PROC
,	O
and	O
hospital	O
admission	O
rates	O
were	O
similar	O
.	O

One	O
patient	B-LIVB
in	O
each	O
treatment	B-PROC
group	B-LIVB
developed	O
hyponatremia	B-DISO
.	O

Four	O
patients	B-LIVB
developed	O
hyperkalemia	B-DISO
(	O
PLA	B-CHEM
:	O
1	O
,	O
0	B-CHEM
.	I-CHEM
9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
:	O
3	O
)	O
.	O

In	O
comparison	O
with	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
,	O
PLA	B-CHEM
for	O
rehydration	B-PROC
in	O
children	B-LIVB
with	O
AGE	B-DISO
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-PROC
in	I-PROC
serum	I-PROC
bicarbonate	I-PROC
and	O
dehydration	B-DISO
score	O
.	O

NCT	O
#	O
01234883	O
(	O
Registration	O
Date	O
:	O
November	O
3	O
,	O
2010	O
)	O
.	O

Impact	O
of	O
systemic	O
alitretinoin	B-CHEM
treatment	B-PROC
on	O
skin	B-PHYS
barrier	I-PHYS
gene	B-PHYS
and	O
protein	B-PHYS
expression	I-PHYS
in	O
patients	B-LIVB
with	O
chronic	B-DISO
hand	I-DISO
eczema	I-DISO
Chronic	B-DISO
hand	I-DISO
eczema	I-DISO
(	O
CHE	B-DISO
)	O
is	O
a	O
common	O
inflammatory	B-DISO
skin	I-DISO
disease	I-DISO
that	O
affects	O
approximately	O
10	O
%	O
of	O
the	O
population	B-LIVB
.	O

Systemic	O
alitretinoin	B-CHEM
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
patients	B-LIVB
with	O
CHE	B-DISO
who	O
are	O
refractory	O
to	O
topical	B-CHEM
corticosteroids	I-CHEM
.	O

To	O
analyse	O
the	O
impact	O
of	O
alitretinoin	B-CHEM
on	O
the	O
skin	B-PHYS
barrier	I-PHYS
genes	O
and	O
protein	B-PHYS
expression	I-PHYS
in	O
the	O
skin	B-DISO
lesions	I-DISO
of	O
patients	B-LIVB
with	O
CHE	B-DISO
.	O

Fifteen	O
patients	B-LIVB
with	O
CHE	B-DISO
were	O
treated	B-PROC
with	I-PROC
30	O
mg	O
daily	O
of	O
alitretinoin	B-CHEM
for	O
up	O
to	O
27	O
weeks	O
.	O

Disease	O
severity	O
was	O
assessed	O
using	O
a	O
clinical	O
score	O
.	O

Skin	B-PROC
biopsies	I-PROC
from	O
all	O
the	O
patients	B-LIVB
were	O
evaluated	B-PROC
before	O
and	O
after	O
therapy	B-PROC
for	O
the	O
expression	B-PHYS
of	O
Ki	B-CHEM
-	I-CHEM
67	I-CHEM
,	O
various	O
skin	B-PHYS
barrier	I-PHYS
genes	O
and	O
thymic	B-CHEM
stromal	I-CHEM
lymphopoietin	I-CHEM
(	O
TSLP	B-CHEM
)	O
by	O
real	B-PROC
-	I-PROC
time	I-PROC
quantitative	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
and	O
immunohistochemistry	B-PROC
.	O

After	O
alitretinoin	B-CHEM
application	O
,	O
an	O
improvement	O
in	O
the	O
clinical	O
severity	O
of	O
CHE	B-DISO
was	O
observed	O
in	O
the	O
majority	O
of	O
patients	B-LIVB
.	O

Analysis	B-PROC
of	O
skin	B-PROC
biopsies	I-PROC
before	O
treatment	B-PROC
showed	O
a	O
significant	O
increase	O
in	O
Ki	O
-	O
67	O
-	O
positive	B-DISO
cells	B-ANAT
in	O
the	O
suprabasal	B-ANAT
layer	I-ANAT
and	O
a	O
dysregulated	B-PHYS
expression	I-PHYS
of	O
various	O
skin	B-PHYS
barrier	I-PHYS
genes	O
,	O
such	O
as	O
claudin	O
1	O
,	O
loricrin	O
,	O
filaggrin	O
and	O
cytokeratin	O
10	O
,	O
which	O
were	O
normalized	B-PROC
after	O
treatment	B-PROC
.	O

TSLP	B-CHEM
was	O
significantly	O
upregulated	B-PHYS
in	O
patients	B-LIVB
with	O
CHE	B-DISO
and	O
also	O
normalized	B-PROC
after	O
alitretinoin	B-CHEM
treatment	B-PROC
and	O
negatively	B-DISO
correlated	O
with	O
filaggrin	B-CHEM
.	O

Our	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
barrier	O
genes	O
and	O
proteins	B-CHEM
was	O
normalized	B-PROC
following	O
treatment	B-PROC
with	O
alitretinoin	B-CHEM
in	O
patients	B-LIVB
with	O
CHE	B-DISO
.	O

The	O
change	O
in	O
expression	B-PHYS
levels	O
of	O
these	O
genes	O
correlated	O
with	O
the	O
clinical	O
efficacy	O
,	O
suggesting	O
that	O
alitretinoin	B-CHEM
exhibits	O
a	O
disease	B-DISO
-	O
modifying	O
activity	O
.	O

TSLP	B-CHEM
is	O
upregulated	B-PHYS
in	O
CHE	B-DISO
and	O
seems	O
to	O
counteract	O
filaggrin	B-CHEM
expression	B-PHYS
in	O
the	O
skin	B-ANAT
.	O

Patient	B-LIVB
adoption	O
of	O
an	O
internet	B-OBJC
based	O
diabetes	B-DISO
medication	B-PROC
tool	B-OBJC
to	O
improve	B-DISO
adherence	O
:	O
A	O
pilot	B-PROC
study	I-PROC
To	O
investigate	O
the	O
effect	O
of	O
a	O
video	O
intervention	O
,	O
Managing	B-PROC
Your	O
Diabetes	B-DISO
Medicines	B-CHEM
,	O
on	O
patient	B-LIVB
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O
problems	O
with	O
using	O
medication	B-PROC
,	O
and	O
medication	B-PROC
adherence	O
in	O
a	O
rural	B-DISO
,	O
mostly	O
African	B-LIVB
American	I-LIVB
population	I-LIVB
.	O

Patients	B-LIVB
selected	O
their	O
problem	B-DISO
areas	O
in	O
medication	B-PROC
use	O
and	O
watched	O
one	O
of	O
nine	O
2	O
-	O
min	O
videos	O
with	O
a	O
research	B-PROC
assistant	B-LIVB
at	O
a	O
clinic	B-OBJC
or	O
pharmacy	O
and	O
were	O
given	O
an	O
access	O
code	O
to	O
watch	O
all	O
the	O
videos	O
at	O
their	O
convenience	O
.	O

Outcomes	O
were	O
measured	O
at	O
baseline	O
and	O
3	O
-	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Fifty	O
-	O
one	O
patients	B-LIVB
were	O
enrolled	O
;	O
84	O
%	O
were	O
African	B-LIVB
American	I-LIVB
and	O
80	O
%	O
were	O
female	B-PHYS
(	O
mean	O
age	O
:	O
54	O
years	O
)	O
.	O

Seventy	O
-	O
three	O
percent	O
watched	O
at	O
least	O
one	O
module	O
after	O
the	O
initial	O
visit	B-PROC
.	O

Improve	B-DISO
d	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
was	O
associated	O
with	O
a	O
decrease	O
in	O
concerns	O
about	O
medications	B-PROC
(	O
r	O
=	O
-	O
0	O
.	O
64	O
)	O
.	O

Low	O
literate	B-DISO
patients	B-LIVB
experienced	B-PHYS
greater	O
improvement	B-DISO
in	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
than	O
more	O
literate	B-DISO
patients	B-LIVB
(	O
t	O
=	O
2	O
.	O
54	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Patients	B-LIVB
'	O
mean	O
number	O
of	O
problems	O
declined	O
from	O
6	O
.	O

14	O
to	O
5	O
.	O
03	O
.	O

The	O
number	O
of	O
patients	B-LIVB
with	O
high	O
or	O
medium	O
adherence	O
rose	O
from	O
33	O
%	O
at	O
baseline	O
to	O
43	O
%	O
at	O
3	O
-	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

A	O
practical	O
,	O
customized	O
video	O
intervention	O
may	O
help	O
improve	B-DISO
patient	B-LIVB
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O
reduce	O
problems	O
with	O
medication	B-PROC
use	O
,	O
and	O
improve	B-DISO
medication	B-PROC
adherence	O
in	O
diabetes	B-DISO
patients	B-LIVB
.	O

Providers	O
should	O
consider	O
implementing	O
technology	O
-	O
based	O
interventions	O
in	O
the	O
clinic	B-OBJC
to	O
address	O
common	O
problems	O
that	O
patients	B-LIVB
have	O
with	O
self	B-PROC
-	I-PROC
management	I-PROC
.	O

Reduced	O
susceptibilities	O
to	O
biocides	B-CHEM
and	O
resistance	O
to	O
antibiotics	B-CHEM
in	O
food	B-OBJC
-	O
associated	O
bacteria	B-LIVB
following	O
exposure	O
to	O
quaternary	B-CHEM
ammonium	I-CHEM
compounds	I-CHEM
Our	O
aim	O
was	O
to	O
assess	O
the	O
effects	O
of	O
step	O
-	O
wise	O
exposure	O
to	O
didecyl	B-CHEM
dimethyl	I-CHEM
ammonium	I-CHEM
chloride	I-CHEM
(	O
DDAC	B-CHEM
)	O
on	O
the	O
antimicrobial	B-DISO
(	I-DISO
antibiotics	I-DISO
and	I-DISO
biocides	I-DISO
)	I-DISO
susceptibilities	I-DISO
of	O
food	B-OBJC
-	O
associated	O
bacterial	B-LIVB
strains	I-LIVB
.	O

Adaptive	O
responses	B-PHYS
of	O
bacterial	B-LIVB
strains	I-LIVB
were	O
investigated	O
by	O
exposing	O
the	O
strains	B-LIVB
daily	O
to	O
increasing	O
subinhibitory	B-PHEN
concentrations	I-PHEN
of	O
DDAC	B-CHEM
for	O
7	O
days	O
.	O

Following	O
adaptation	B-PHEN
to	O
DDAC	B-CHEM
,	O
a	O
threefold	O
increase	O
in	O
the	O
minimum	B-PROC
inhibitory	I-PROC
concentration	I-PROC
(	O
MIC	B-PROC
)	O
values	O
for	O
this	O
biocide	B-CHEM
was	O
observed	O
in	O
48	O
%	O
of	O
the	O
Escherichia	B-LIVB
coli	I-LIVB
and	O
Listeria	B-LIVB
monocytogenes	I-LIVB
strains	I-LIVB
,	O
and	O
3	O
%	O
of	O
the	O
Salmonella	B-LIVB
strains	I-LIVB
.	O

Reduced	O
susceptibility	O
to	O
other	O
biocides	B-CHEM
was	O
found	O
with	O
the	O
most	O
important	O
increase	O
in	O
MIC	B-PROC
for	O
benzalkonium	B-CHEM
chloride	I-CHEM
(	O
BC	B-CHEM
)	O
and	O
a	O
commercial	B-OBJC
biocide	B-CHEM
formulation	I-CHEM
(	O
Galox	B-CHEM
Horizon	I-CHEM
)	O
containing	O
DDAC	B-CHEM
and	O
glutaraldehyde	B-CHEM
,	O
for	O
all	O
species	O
except	O
Salmonella	B-LIVB
.	O

Increase	O
in	O
antibiotic	B-CHEM
MIC	B-PROC
values	O
was	O
more	O
pronounced	O
in	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
in	O
terms	O
of	O
antibiotic	B-CHEM
numbers	O
and	O
of	O
magnitude	O
(	O
from	O
4	O
-	O
to	O
32	O
-	O
fold	O
increase	O
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
Salmonella	B-LIVB
strains	I-LIVB
.	O

Most	O
of	O
these	O
strains	B-LIVB
had	O
acquired	O
resistance	O
to	O
ampicillin	B-CHEM
,	O
cefotaxime	B-CHEM
,	O
ceftazidime	B-CHEM
,	O
chloramphenicol	B-CHEM
and	O
ciprofloxacin	B-CHEM
.	O

The	O
effects	O
of	O
exposure	O
to	O
DDAC	B-CHEM
on	O
biocides	B-CHEM
and	O
antibiotics	B-CHEM
susceptibilities	O
depend	O
upon	O
the	O
bacteria	B-LIVB
species	O
.	O

Extensive	O
use	O
of	O
DDAC	B-CHEM
at	O
subinhibitory	B-PHEN
concentrations	I-PHEN
may	O
lead	O
to	O
the	O
development	O
of	O
antibiotic	B-CHEM
-	O
resistant	O
bacteria	B-LIVB
and	O
may	O
represent	O
a	O
public	O
health	O
issue	O
.	O

Analgesic	B-DISO
and	O
anti	O
-	O
inflammatory	O
actions	O
on	O
bradykinin	B-CHEM
route	O
of	O
a	O
polysulfated	B-CHEM
fraction	I-CHEM
from	O
alga	O
Ulva	B-LIVB
lactuca	I-LIVB
We	O
investigated	O
structural	O
features	O
of	O
polysaccharides	B-CHEM
from	O
Ulva	B-LIVB
lactuca	I-LIVB
and	O
their	O
effects	O
on	O
the	O
classical	B-DEVI
models	I-DEVI
of	O
nociception	B-PHYS
and	O
inflammation	B-DISO
.	O

Crude	B-OBJC
extract	I-OBJC
was	O
obtained	O
by	O
enzymatic	B-PROC
digestion	I-PROC
and	O
isolated	O
by	O
ion	B-PROC
exchange	I-PROC
chromatography	I-PROC
on	O
DEAE	B-CHEM
-	I-CHEM
cellulose	I-CHEM
.	O

The	O
fraction	B-CHEM
with	O
higher	O
yield	O
was	O
used	O
in	O
the	O
tests	B-PROC
(	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
)	O
.	O

Swiss	B-LIVB
mice	I-LIVB
received	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
(	O
1	O
,	O
3	O
or	O
9mg	O
/	O
kg	O
;	O
i	O
.	O

v	O
.	O
)	O
,	O
30min	O
prior	O
to	O
injection	O
of	O
0	O
.	O
8	O
%	O
-	O
acetic	B-CHEM
acid	I-CHEM
or	O
1	O
%	O
-	O
formalin	B-CHEM
or	O
prior	O
to	O
a	O
thermal	B-PHEN
stimulus	I-PHEN
.	O

At	O
same	O
doses	O
,	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
was	O
tested	O
on	O
Wistar	B-LIVB
rats	I-LIVB
on	O
paw	B-ANAT
edema	B-DISO
elicited	O
by	O
different	O
irritants	B-CHEM
(	O
carrageenan	B-CHEM
,	O
dextran	B-CHEM
,	O
bradykinin	B-CHEM
,	O
histamine	B-CHEM
or	O
serotonin	B-CHEM
)	O
.	O

The	O
results	B-DISO
of	O
infrared	O
characterization	O
indicated	O
the	O
presence	O
of	O
hydroxyl	B-CHEM
groups	I-CHEM
,	O
sulfate	B-CHEM
,	O
uronic	B-CHEM
acid	I-CHEM
and	O
glycosidic	B-PHEN
linkages	I-PHEN
in	O
all	O
SP	B-CHEM
fractions	I-CHEM
spectrums	O
.	O

SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
decreased	O
significantly	O
the	O
antinociception	B-PHYS
in	O
response	B-PHYS
to	O
acetic	B-CHEM
acid	I-CHEM
or	O
formalin	B-CHEM
(	O
second	O
phase	O
)	O
,	O
but	O
not	O
in	O
the	O
hot	B-PROC
-	I-PROC
plate	I-PROC
test	I-PROC
,	O
suggesting	O
that	O
its	O
analgesia	B-PROC
occurs	O
through	O
a	O
peripheral	O
mechanism	O
.	O

SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
did	O
not	O
reduce	O
carrageenan	B-CHEM
-	O
induced	O
paw	B-ANAT
edema	B-DISO
as	O
supported	O
by	O
both	O
histological	B-PHYS
and	O
myeloperoxidase	B-PHYS
activity	I-PHYS
assessments	B-PROC
.	O

However	O
,	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
(	O
1mg	O
/	O
kg	O
;	O
s	O
.	O

c	O
.	O
)	O
reduced	O
dextran	B-CHEM
-elicited	O
edema	B-DISO
,	O
showing	O
vascular	B-ANAT
anti	O
-	O
inflammatory	O
effect	O
,	O
with	O
bradykinin	B-CHEM
as	O
major	O
target	O
because	O
it	O
did	O
not	O
reduce	O
histamine	B-CHEM
-	O
and	O
serotonin	B-CHEM
-	O
induced	O
paw	B-ANAT
edemas	B-DISO
.	O

Therefore	O
,	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
acts	O
on	O
bradykinin	B-CHEM
pathway	B-PHYS
in	O
its	O
antinociceptive	B-PHYS
and	O
anti	O
-	O
inflammatory	O
responses	O
.	O

The	O
relationships	O
between	O
symptoms	B-DISO
and	O
quality	O
of	O
life	O
over	O
the	O
course	O
of	O
cognitive	B-PROC
-	I-PROC
behavioral	I-PROC
therapy	I-PROC
for	O
panic	B-DISO
disorder	I-DISO
in	O
Japan	B-GEOG
This	O
study	B-PROC
examined	B-DISO
the	O
relationships	O
between	O
changes	O
in	O
symptoms	B-DISO
and	O
changes	O
in	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
during	O
cognitive	B-PROC
-	I-PROC
behavioral	I-PROC
therapy	I-PROC
(	O
CBT	B-PROC
)	O
for	O
panic	B-DISO
disorder	I-DISO
(	O
PD	B-DISO
)	O
.	O

We	O
treated	O
198	O
PD	B-DISO
patients	B-LIVB
with	O
group	O
CBT	B-PROC
in	O
Japan	B-GEOG
.	O

Using	O
multiple	O
regression	O
analysis	O
,	O
we	O
examined	B-DISO
the	O
associations	O
between	O
changes	O
in	O
QOL	O
and	O
changes	O
in	O
PD	B-DISO
symptoms	B-DISO
or	O
comorbid	B-DISO
psychological	I-DISO
symptoms	I-DISO
during	O
CBT	B-PROC
.	O

Changes	O
in	O
anticipatory	B-DISO
anxiety	I-DISO
,	O
agoraphobic	B-DISO
fear	I-DISO
/	O
avoidance	B-PHYS
,	O
and	O
somatization	B-DISO
were	O
significant	O
predictors	O
of	O
changes	O
in	O
some	O
aspects	O
of	O
QOL	O
.	O

It	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-DISO
,	O
anticipatory	B-DISO
anxiety	I-DISO
,	O
and	O
agoraphobic	B-DISO
fear	I-DISO
to	O
improve	O
QOL	O
in	O
CBT	B-PROC
for	O
PD	B-DISO
.	O

Coupling	O
of	O
TRPV6	B-CHEM
and	O
TMEM16A	B-CHEM
in	O
epithelial	B-ANAT
principal	I-ANAT
cells	I-ANAT
of	O
the	O
rat	B-ANAT
epididymis	I-ANAT
The	O
epididymis	B-ANAT
establishes	O
a	O
congenial	O
environment	O
for	O
sperm	B-PHYS
maturation	I-PHYS
and	O
protection	B-DISO
.	O

Its	O
fluid	B-ANAT
is	O
acidic	O
,	O
and	O
the	O
calcium	B-CHEM
concentration	O
is	O
low	O
and	O
declines	O
along	O
the	O
length	O
of	O
the	O
epididymal	B-ANAT
tubule	I-ANAT
.	O

However	O
,	O
our	O
knowledge	O
of	O
ionic	B-PHYS
currents	I-PHYS
and	O
mechanisms	O
of	O
calcium	B-PHYS
homeostasis	I-PHYS
in	O
rat	B-ANAT
epididymal	I-ANAT
epithelial	B-ANAT
cells	I-ANAT
remains	O
enigmatic	O
.	O

In	O
this	O
study	B-PROC
,	O
to	O
better	O
understand	O
calcium	B-PHYS
regulation	I-PHYS
in	O
the	O
epididymis	B-ANAT
,	O
we	O
use	O
the	O
patch	B-PROC
-	I-PROC
clamp	I-PROC
method	I-PROC
to	O
record	O
from	O
single	O
rat	B-LIVB
cauda	B-ANAT
epididymal	I-ANAT
principal	B-ANAT
cells	I-ANAT
.	O

We	O
detect	B-DISO
a	O
constitutively	O
active	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
current	B-PHYS
with	O
characteristics	O
that	O
match	O
the	O
epithelial	O
calcium	B-CHEM
channel	I-CHEM
TRPV6	B-CHEM
.	O

Electrophysiological	B-PROC
and	O
pharmacological	B-PROC
data	I-PROC
also	O
reveal	O
a	O
constitutively	O
active	B-CHEM
calcium	I-CHEM
-	I-CHEM
activated	I-CHEM
chloride	I-CHEM
conductance	I-CHEM
(	O
CaCC	B-CHEM
)	O
.	O

Removal	O
of	O
extracellular	B-ANAT
calcium	B-CHEM
attenuates	O
not	O
only	O
the	O
TRPV6	B-CHEM
-like	O
conductance	O
,	O
but	O
also	O
the	O
CaCC	B-CHEM
.	O

Lanthanide	B-CHEM
block	O
is	O
time	O
dependent	O
such	O
that	O
the	O
TRPV6	B-CHEM
-like	O
component	O
is	O
inhibited	B-PHYS
first	O
,	O
followed	O
by	O
the	O
CaCC	B-CHEM
.	O

The	O
putative	O
CaCC	B-CHEM
blocker	B-CHEM
niflumic	B-CHEM
acid	I-CHEM
partially	O
inhibits	B-PHYS
whole	B-ANAT
-	I-ANAT
cell	I-ANAT
currents	B-PHYS
,	O
whereas	O
La	B-CHEM
(	I-CHEM
3	I-CHEM
+	I-CHEM
)	I-CHEM
almost	O
abolishes	O
whole	B-ANAT
-	I-ANAT
cell	I-ANAT
currents	B-PHYS
in	O
principal	B-ANAT
cells	I-ANAT
.	O

Membrane	B-PHYS
potential	I-PHYS
measurements	O
reveal	O
an	O
interplay	O
between	O
La	B-CHEM
(	I-CHEM
3	I-CHEM
+	I-CHEM
)	I-CHEM
-	O
sensitive	B-CHEM
ion	I-CHEM
channels	I-CHEM
and	O
those	O
that	O
are	O
sensitive	O
to	O
the	O
specific	O
TMEM16A	B-CHEM
inhibitor	B-CHEM
tannic	B-CHEM
acid	I-CHEM
.	O

In	O
vivo	O
perfusion	B-PROC
of	O
the	O
cauda	B-ANAT
epididymal	I-ANAT
tubule	I-ANAT
shows	O
a	O
substantial	O
rate	O
of	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
reabsorption	B-PHYS
from	O
the	O
luminal	O
side	O
,	O
which	O
is	O
dose	O
-	O
dependently	O
suppressed	O
by	O
ruthenium	B-CHEM
red	I-CHEM
,	O
a	O
putative	O
blocker	B-CHEM
of	O
epithelial	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
channels	I-CHEM
and	O
CaCC	B-CHEM
.	O

Finally	O
,	O
we	O
discover	O
messenger	B-CHEM
RNA	I-CHEM
for	O
both	O
TRPV6	B-CHEM
and	O
TMEM16A	B-CHEM
in	O
the	O
rat	B-ANAT
epididymis	I-ANAT
and	O
show	O
that	O
their	O
proteins	B-CHEM
colocalize	O
in	O
the	O
apical	B-ANAT
membrane	I-ANAT
of	O
principal	B-ANAT
cells	I-ANAT
.	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
a	O
coupling	O
mechanism	O
between	O
TRPV6	B-CHEM
and	O
TMEM16A	B-CHEM
in	O
principal	B-ANAT
cells	I-ANAT
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	B-PHYS
of	I-PHYS
calcium	I-PHYS
homeostasis	I-PHYS
in	O
the	O
epididymis	B-ANAT
.	O

Challenges	O
Caring	B-PROC
for	O
Adults	B-LIVB
With	O
Congenital	B-DISO
Heart	I-DISO
Disease	I-DISO
in	O
Pediatric	O
Settings	O
:	O
How	O
Nurses	B-LIVB
Can	O
Aid	O
in	O
the	O
Transition	B-PHEN
As	O
surgery	B-PROC
for	O
complex	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
is	O
becoming	O
more	O
advanced	O
,	O
an	O
increasing	O
number	O
of	O
patients	B-LIVB
are	O
surviving	O
into	O
adulthood	O
,	O
yet	O
many	O
of	O
these	O
adult	B-LIVB
patients	B-LIVB
remain	O
in	O
the	O
pediatric	O
hospital	O
system	O
.	O

Caring	B-PROC
for	O
adult	B-LIVB
patients	B-LIVB
is	O
often	O
a	O
challenge	O
for	O
pediatric	B-LIVB
nurses	I-LIVB
,	O
because	O
the	O
nurses	B-LIVB
have	O
less	O
experience	O
and	O
comfort	O
with	O
adult	B-PROC
care	I-PROC
,	O
medications	B-PROC
,	O
comorbid	B-DISO
conditions	I-DISO
,	O
and	O
rehabilitation	O
techniques	O
.	O

As	O
these	O
patients	B-LIVB
age	O
,	O
the	O
increased	O
risk	O
of	O
complications	B-DISO
and	O
comorbid	B-DISO
conditions	I-DISO
from	O
their	O
heart	B-DISO
disease	I-DISO
may	O
complicate	O
their	O
care	B-PROC
further	O
.	O

Although	O
these	O
patients	B-LIVB
are	O
admitted	B-PROC
on	O
a	O
pediatric	B-OBJC
unit	I-OBJC
,	O
nurses	B-LIVB
can	O
aid	O
in	O
promoting	O
their	O
independence	O
and	O
help	O
prepare	O
them	O
to	O
transition	B-PHEN
into	O
the	O
adult	B-OBJC
medical	I-OBJC
system	I-OBJC
.	O

Nurses	B-LIVB
,	O
the	O
comprehensive	B-PROC
medical	I-PROC
teams	I-PROC
,	O
and	O
patients	B-LIVB
'	O
families	B-LIVB
can	O
all	O
effectively	O
influence	O
the	O
process	O
of	O
preparing	O
these	O
patients	B-LIVB
for	O
transition	B-PHEN
to	O
adult	B-PROC
care	I-PROC
.	O

Coffee	B-OBJC
-	O
Antihypertensive	B-CHEM
Drug	I-CHEM
Interaction	O
:	O
A	O
Hemodynamic	B-PHYS
and	O
Pharmacokinetic	B-PROC
Study	I-PROC
With	O
Felodipine	B-CHEM
A	O
period	O
of	O
abstinence	O
from	O
coffee	B-OBJC
to	O
permit	O
caffeine	B-CHEM
elimination	B-PHYS
appears	O
to	O
enable	O
increased	O
blood	B-PHYS
pressure	I-PHYS
on	O
subsequent	O
exposure	O
.	O

We	O
hypothesized	O
that	O
this	O
would	O
offset	O
the	O
antihypertensive	B-CHEM
effect	O
of	O
the	O
dihydropyridine	B-CHEM
calcium	I-CHEM
channel	I-CHEM
blocker	I-CHEM
felodipine	B-CHEM
.	O

A	O
randomized	B-PROC
,	O
single	O
-	O
dose	O
,	O
crossover	B-PROC
study	I-PROC
assessed	O
hemodynamic	B-PHYS
and	O
pharmacokinetic	B-PHYS
effects	I-PHYS
following	O
2	O
days	O
without	O
coffee	B-OBJC
and	O
caffeine	B-CHEM
-	O
containing	O
foods	B-OBJC
.	O

Consistently	O
brewed	O
black	B-OBJC
coffee	I-OBJC
(	O
2×300ml	O
)	O
,	O
felodipine	B-CHEM
maximum	O
recommended	O
dose	O
(	O
10	O
mg	O
)	O
,	O
and	O
coffee	B-OBJC
plus	O
felodipine	B-CHEM
were	O
tested	O
in	O
middle	B-LIVB
-	I-LIVB
aged	I-LIVB
normotensive	B-DISO
subjects	B-LIVB
.	O

Pretreatment	O
plasma	B-ANAT
caffeine	B-PROC
concentrations	I-PROC
were	O
unquantifiable	O
.	O

After	O
coffee	B-OBJC
,	O
blood	B-PHYS
pressure	I-PHYS
changes	O
(	O
mm	O
Hg	O
)	O
averaged	O
over	O
study	B-PROC
hours	O
1	O
-	O
4	O
were	O
increased	O
for	O
brachial	O
systolic	O
(	O
7	O
.	O
6	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
diastolic	B-PHYS
(	O
4	O
.	O
9	O
,	O
P	O
<	O
0	O
.	O

001	O
)	O
and	O
aortic	B-ANAT
systolic	O
(	O
7	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
pulse	B-PROC
(	O
3	O
.	O
0	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
augmentation	O
(	O
1	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
relative	O
to	O
baseline	O
.	O

After	O
coffee	B-OBJC
plus	O
felodipine	B-CHEM
,	O
they	O
were	O
higher	O
for	O
brachial	O
systolic	O
(	O
4	O
.	O
0	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
diastolic	B-PHYS
(	O
3	O
.	O
9	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
aortic	B-ANAT
systolic	O
(	O
4	O
.	O
6	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
felodipine	B-CHEM
alone	O
.	O

The	O
pressor	B-CHEM
effects	O
of	O
coffee	B-OBJC
and	O
its	O
modulation	O
by	O
felodipine	B-CHEM
were	O
variable	O
among	O
individuals	B-LIVB
.	O

Coffee	B-OBJC
containing	O
caffeine	B-CHEM
(	O
127	O
mg	O
)	O
caused	O
maximum	O
pressor	B-CHEM
effect	O
.	O

Caffeine	B-CHEM
and	O
felodipine	B-CHEM
pharmacokinetics	B-PHYS
were	O
similar	O
for	O
coffee	B-OBJC
and	O
felodipine	B-CHEM
given	O
alone	O
or	O
in	O
combination	O
indicating	O
an	O
interaction	O
having	O
a	O
pharmacodynamic	B-PHEN
basis	O
.	O

Plasma	B-ANAT
felodipine	B-CHEM
concentration	O
-	O
diastolic	B-PHYS
blood	B-PHYS
pressure	I-PHYS
reduction	O
relationship	O
shifted	O
with	O
coffee	B-OBJC
such	O
that	O
doubling	O
the	O
felodipine	B-CHEM
concentration	O
would	O
eliminate	O
the	O
pressor	B-CHEM
effect	O
.	O

However	O
,	O
this	O
may	O
increase	O
the	O
risk	O
of	O
adverse	B-DISO
drug	I-DISO
events	I-DISO
particularly	O
during	O
the	O
timeframe	O
without	O
coffee	B-OBJC
.	O

Intermittent	O
coffee	B-OBJC
ingestion	B-PHEN
might	O
complicate	O
hypertension	B-DISO
diagnosis	B-DISO
and	O
management	B-PROC
for	O
many	O
individuals	B-LIVB
.	O

Elevated	O
Serum	B-ANAT
Krebs	B-CHEM
von	I-CHEM
den	I-CHEM
Lungen	I-CHEM
-	I-CHEM
6	I-CHEM
in	O
Early	O
Disease	B-DISO
Predicts	O
Subsequent	O
Deterioration	B-PHEN
of	O
Pulmonary	B-PHYS
Function	I-PHYS
in	O
Patients	B-LIVB
with	O
Systemic	B-DISO
Sclerosis	I-DISO
and	O
Interstitial	B-DISO
Lung	I-DISO
Disease	I-DISO
To	O
identify	O
predictors	O
of	O
poor	O
prognosis	B-PROC
in	O
patients	B-LIVB
with	O
systemic	B-DISO
sclerosis	I-DISO
(	O
SSc	B-DISO
)	O
associated	O
with	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O
ILD	B-DISO
)	O
.	O

Fifty	O
patients	B-LIVB
with	O
early	O
-	O
stage	O
SSc	B-DISO
-	O
ILD	B-DISO
who	O
had	O
never	O
received	O
disease	B-DISO
-	O
modifying	O
drugs	B-CHEM
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	B-PHYS
from	O
ILD	B-DISO
-related	O
causes	B-DISO
were	O
enrolled	O
.	O

The	O
baseline	O
variables	O
of	O
patients	B-LIVB
who	O
developed	O
endstage	B-DISO
lung	I-DISO
disease	I-DISO
(	O
ESLD	B-DISO
)	O
were	O
compared	O
with	O
those	O
of	O
patients	B-LIVB
who	O
remained	O
ESLD	B-DISO
-	O
free	O
,	O
and	O
the	O
Cox	O
proportional	O
hazard	O
model	O
was	O
used	O
to	O
identify	O
initial	O
factors	O
that	O
correlated	O
with	O
ESLD	B-DISO
development	O
.	O

Sixteen	O
patients	B-LIVB
(	O
32	O
%	O
)	O
developed	O
ESLD	B-DISO
during	O
173	O
.	O

5	O
±	O
64	O
.	O

7	O
months	O
of	O
followup	B-PROC
.	O

Elevated	O
serum	B-ANAT
Krebs	B-CHEM
von	I-CHEM
den	I-CHEM
Lungen	I-CHEM
-	I-CHEM
6	I-CHEM
(	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
)	O
at	O
initial	O
assessment	B-PROC
was	O
highly	O
correlated	O
with	O
ESLD	B-DISO
development	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

Receiver	B-PROC
-	I-PROC
operating	I-PROC
characteristic	I-PROC
curve	I-PROC
analysis	I-PROC
revealed	O
that	O
a	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
value	O
of	O
1273	O
U	O
/	O
ml	O
effectively	O
discriminated	O
patients	B-LIVB
who	O
developed	O
ESLD	B-DISO
from	O
those	O
who	O
did	O
not	O
.	O

Patients	B-LIVB
with	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
>	O
1273	O
U	O
/	O
ml	O
were	O
less	O
likely	O
to	O
remain	O
ESLD	B-DISO
-	O
free	O
compared	O
with	O
those	O
with	O
lower	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
levels	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
>	O
1273	O
U	O
/	O
ml	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
ESLD	B-DISO
development	O
(	O
OR	O
51	O
.	O

2	O
,	O
95	O
%	O
CI	O
7	O
.	O
6	O
-	O
343	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Finally	O
,	O
the	O
initial	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
level	O
correlated	O
with	O
the	O
forced	B-DISO
vital	I-DISO
capacity	I-DISO
(	O
FVC	B-DISO
)	O
decline	O
rate	O
(	O
r	O
=	O
0	O
.	O
58	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
natural	O
course	O
of	O
SSc	B-DISO
-	O
ILD	B-DISO
is	O
highly	O
variable	O
.	O

Baseline	O
serum	B-ANAT
KL	B-CHEM
-	I-CHEM
6	I-CHEM
is	O
a	O
biomarker	B-PHYS
potentially	O
useful	O
for	O
predicting	O
FVC	B-DISO
decline	O
.	O

Polymorphisms	O
in	O
Inflammatory	O
Mediator	O
Genes	O
and	O
Risk	O
of	O
Preeclampsia	B-DISO
in	O
Taiyuan	O
,	O
China	B-GEOG
Excessive	O
maternal	B-DISO
inflammatory	B-DISO
response	I-DISO
is	O
involved	O
in	O
the	O
pathogenesis	B-DISO
of	O
preeclampsia	B-DISO
.	O

Few	O
epidemiologic	B-PROC
studies	I-PROC
have	O
investigated	O
the	O
associations	O
between	O
genetic	B-PHEN
variations	I-PHEN
in	O
the	O
inflammatory	O
mediator	O
genes	O
and	O
preeclampsia	B-DISO
risk	O
,	O
and	O
these	O
studies	B-PROC
have	O
reached	O
inconsistent	O
results	O
.	O

We	O
examined	O
31	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
IL	O
-	O
1A	O
,	O
IL	O
-	O
1B	O
,	O
IL	B-CHEM
-	I-CHEM
1R1	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
2RA	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
5RA	I-CHEM
,	O
IL	O
-	O
6	O
,	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
,	O
TNFSF11	O
,	O
TNFRSF11A	O
,	O
IL	O
-	O
28RA	O
,	O
IRAK4	O
,	O
and	O
KIT	O
genes	O
and	O
the	O
risk	O
of	O
preeclampsia	B-DISO
and	O
its	O
clinical	O
subtypes	O
in	O
a	O
nested	B-PROC
case	I-PROC
-	I-PROC
control	I-PROC
study	I-PROC
including	O
203	O
preeclampsia	B-DISO
cases	O
and	O
233	O
controls	B-LIVB
.	O

We	O
found	O
that	O
IL	B-CHEM
-	I-CHEM
1R1	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
5RA	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
,	O
and	O
TNFSF11	O
were	O
associated	O
with	O
the	O
risk	O
of	O
preeclampsia	B-DISO
.	O

Although	O
the	O
significant	O
associations	O
observed	O
for	O
preeclampsia	B-DISO
overall	O
were	O
mainly	O
seen	O
for	O
late	O
-	O
onset	O
preeclampsia	B-DISO
and	O
severe	O
preeclampsia	B-DISO
,	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
(	O
rs2229238	O
)	O
and	O
TNFSF11	O
(	O
rs9525643	O
)	O
polymorphisms	O
were	O
associated	O
with	O
the	O
risk	O
of	O
early	O
-	O
onset	O
preeclampsia	B-DISO
.	O

TNFSF11	O
(	O
rs2200287	O
and	O
rs2148072	O
)	O
polymorphisms	O
were	O
associated	O
with	O
risk	O
of	O
mild	O
preeclampsia	B-DISO
.	O

Our	O
study	B-PROC
provided	O
the	O
first	O
evidence	O
that	O
genetic	B-PHEN
variations	I-PHEN
in	O
inflammatory	O
mediator	O
genes	O
IL	B-CHEM
-	I-CHEM
1R1	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
,	O
TNFSF11	O
,	O
and	O
IL	B-CHEM
-	I-CHEM
5RA	I-CHEM
were	O
associated	O
with	O
preeclampsia	B-DISO
risk	O
,	O
and	O
the	O
risk	O
varied	O
by	O
preeclampsia	B-DISO
subtypes	O
.	O

Preoperative	O
ultrasonographic	B-PROC
findings	B-DISO
of	O
internal	B-ANAT
jugular	I-ANAT
veins	I-ANAT
and	O
carotid	B-ANAT
arteries	I-ANAT
in	O
kidney	B-DISO
transplant	I-DISO
recipients	I-DISO
Hemodialysis	B-PROC
via	O
the	O
internal	B-ANAT
jugular	I-ANAT
vein	I-ANAT
(	O
IJV	B-ANAT
)	O
has	O
been	O
widely	O
used	O
for	O
patients	B-LIVB
with	O
end	B-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
(	O
ESRD	B-DISO
)	O
patients	B-LIVB
,	O
as	O
they	O
have	O
a	O
higher	B-DISO
risk	I-DISO
of	O
arterial	B-DISO
diseases	I-DISO
.	O

We	O
investigated	O
the	O
ultrasonographic	B-PROC
findings	B-DISO
of	O
the	O
IJV	B-ANAT
and	O
carotid	B-ANAT
artery	I-ANAT
(	O
CA	B-ANAT
)	O
in	O
recipients	B-LIVB
of	O
kidney	B-PROC
transplantation	I-PROC
(	O
KT	B-PROC
)	O
and	O
identified	O
factors	O
influencing	O
IJV	B-DISO
/	O
CA	B-DISO
abnormalities	I-DISO
.	O

We	O
enrolled	O
120	O
adult	B-LIVB
KT	B-PROC
recipients	B-LIVB
.	O

Patients	B-LIVB
in	O
group	O
A	O
(	O
n	O
=	O
57	O
)	O
had	O
a	O
history	B-DISO
of	I-DISO
IJV	B-ANAT
hemodialysis	B-PROC
,	O
while	O
those	O
in	O
group	O
B	O
(	O
n	O
=	O
63	O
)	O
were	O
not	O
yet	O
on	O
dialysis	B-PROC
or	O
undergoing	O
dialysis	B-PROC
methods	I-PROC
not	O
involving	O
the	O
IJV	B-ANAT
.	O

The	O
day	O
before	O
surgery	B-PROC
,	O
we	O
evaluated	O
the	O
state	O
of	O
the	O
IJV	B-ANAT
and	O
CA	B-ANAT
using	O
ultrasonography	B-PROC
.	O

We	O
followed	O
patients	B-LIVB
with	O
IJV	B-DISO
stenosis	I-DISO
for	O
six	O
months	O
after	O
KT	B-PROC
.	O

Ultrasonography	B-PROC
revealed	O
that	O
four	O
patients	B-LIVB
(	O
7	O
%	O
)	O
in	O
group	O
A	O
had	O
IJV	B-DISO
abnormalities	I-DISO
,	O
while	O
no	O
patients	B-LIVB
in	O
group	O
B	O
had	O
abnormalities	B-DISO
(	O
P	O
=	O
0	O
.	O
118	O
)	O
.	O

Of	O
the	O
four	O
patients	B-LIVB
with	O
abnormalities	B-DISO
,	O
one	O
with	O
57	O
.	O

4	O
%	O
stenosis	B-DISO
normalized	O
during	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

However	O
,	O
another	O
patient	B-LIVB
with	O
90	O
.	O

1	O
%	O
stenosis	B-DISO
progressed	O
to	O
occlusion	B-DISO
,	O
while	O
the	O
two	O
patients	B-LIVB
with	O
total	O
occlusion	B-DISO
remained	O
the	O
same	O
.	O

Twenty	O
patients	B-LIVB
in	O
group	O
A	O
(	O
n	O
=	O
11	O
)	O
and	O
B	O
(	O
n	O
=	O
9	O
)	O
had	O
several	O
CA	B-DISO
abnormalities	I-DISO
(	O
P	O
=	O
0	O
.	O
462	O
)	O
.	O

Upon	O
multivariate	O
analysis	O
with	O
stepwise	O
selection	O
,	O
height	B-PHYS
and	O
age	B-PHYS
were	O
significantly	O
correlated	O
with	O
IJV	B-DISO
stenosis	I-DISO
(	O
P	O
=	O
0	O
.	O

043	O
,	O
odds	O
ratio	O
=	O
0	O
.	O
9	O
)	O
and	O
CA	B-DISO
abnormality	I-DISO
(	O
P	O
=	O
0	O
.	O
012	O
,	O
odds	O
ratio	O
=	O
1	O
.	O
1	O
)	O
,	O
respectively	O
.	O

IJV	B-DISO
abnormalities	I-DISO
(	O
especially	O
with	O
a	O
history	B-DISO
of	I-DISO
IJV	B-ANAT
hemodialysis	B-PROC
)	O
and	O
CA	B-DISO
abnormalities	I-DISO
may	O
be	O
present	O
in	O
ESRD	B-DISO
patients	B-LIVB
.	O

Therefore	O
,	O
we	O
recommend	O
ultrasonographic	B-PROC
evaluation	B-PROC
before	O
catheterization	B-PROC
.	O

Lipid	B-CHEM
digestibility	B-DISO
and	O
energy	O
content	O
of	O
distillers	O
'	O
corn	B-CHEM
oil	I-CHEM
in	O
swine	B-LIVB
and	O
poultry	B-LIVB
Two	O
experiments	B-PROC
were	O
conducted	O
to	O
determine	O
the	O
DE	O
and	O
ME	O
and	O
apparent	B-DISO
total	I-DISO
tract	I-DISO
digestibility	I-DISO
of	O
ether	B-CHEM
extract	B-OBJC
of	O
3	O
distillers	O
'	O
corn	B-CHEM
oil	I-CHEM
(	O
DCO	B-CHEM
;	O
4	O
.	O
9	O
,	O
12	O
.	O

8	O
,	O
or	O
13	O
.	O

9	O
%	O
free	B-CHEM
fatty	I-CHEM
acids	I-CHEM
[	O
FFA	B-CHEM
]	O
)	O
samplescompared	O
with	O
a	O
sample	B-OBJC
of	O
refined	B-CHEM
corn	I-CHEM
oil	I-CHEM
(	O
CO	B-CHEM
;	O
0	O
.	O
04	O
%	O
FFA	B-CHEM
)	O
and	O
an	O
industrially	O
hydrolyzed	B-CHEM
high	I-CHEM
-	I-CHEM
FFA	I-CHEM
DCO	B-CHEM
(	O
93	O
.	O

8	O
%	O
FFA	B-CHEM
)	O
in	O
young	O
pigs	B-LIVB
and	O
growing	B-LIVB
broilers	I-LIVB
.	O

In	O
Exp	O
.	O
1	O
,	O
54	O
barrows	B-LIVB
(	O
initial	O
age	B-PHYS
=	O
28	O
d	O
)	O
were	O
fed	O
a	O
common	O
diet	B-OBJC
for	O
7	O
d	O
and	O
then	O
fed	O
their	O
allotted	O
dietary	B-OBJC
treatment	O
(	O
either	O
100	O
%	O
basal	B-OBJC
diet	I-OBJC
or	O
1	O
of	O
5	O
test	B-PROC
diets	I-PROC
consisting	O
of	O
90	O
%	O
basal	B-OBJC
diet	I-OBJC
plus	O
10	O
%	O
test	O
lipid	B-CHEM
)	O
for	O
the	O
next	O
7	O
d	O
in	O
group	B-OBJC
pens	I-OBJC
(	O
9	O
pigs	B-LIVB
/	O
pen	B-OBJC
)	O
.	O

For	O
the	O
next	O
10	O
d	O
,	O
pigs	B-LIVB
were	O
moved	O
to	O
individual	O
metabolism	B-OBJC
crates	I-OBJC
for	O
continued	O
diet	B-OBJC
and	O
crate	B-OBJC
adaptation	B-PHYS
and	O
to	O
a	O
twice	O
-	O
daily	O
feeding	B-PROC
regimen	I-PROC
.	O

Pigs	B-LIVB
remained	O
on	O
their	O
respective	O
diets	B-OBJC
for	O
a	O
4	O
-	O
d	O
total	O
fecal	B-PROC
and	O
urine	B-PROC
collection	I-PROC
period	O
.	O

For	O
Exp	O
.	O

2	O
,	O
567	O
male	B-PHYS
broilers	B-LIVB
were	O
obtained	O
from	O
a	O
commercial	O
hatchery	O
(	O
1	O
d	O
of	O
age	B-PHYS
)	O
and	O
reared	O
in	O
grower	B-OBJC
battery	I-OBJC
cages	I-OBJC
that	O
contained	O
9	O
chicks	B-LIVB
per	O
cage	B-OBJC
.	O

Broilers	B-LIVB
were	O
fed	O
a	O
common	O
corn	B-LIVB
-	O
soybean	B-OBJC
meal	O
starter	B-OBJC
diet	I-OBJC
from	O
placement	B-PROC
until	O
the	O
beginning	O
of	O
the	O
trial	B-PROC
(	O
19	O
d	O
of	O
age	B-PHYS
)	O
.	O

Birds	B-LIVB
were	O
then	O
randomly	O
assigned	O
to	O
1	O
of	O
6	O
dietary	B-OBJC
treatments	O
(	O
94	O
%	O
basal	B-OBJC
diet	I-OBJC
plus	O
6	O
%	O
dextrose	B-CHEM
or	O
94	O
%	O
basal	B-OBJC
diet	I-OBJC
plus	O
6	O
%	O
test	O
lipid	B-CHEM
substituted	O
for	O
dextrose	B-CHEM
)	O
on	O
d	O
19	O
and	O
were	O
allowed	O
an	O
8	O
-	O
d	O
dietary	B-OBJC
acclimation	B-PHYS
period	O
followed	O
by	O
a	O
48	O
-	O
h	O
energy	B-PROC
balance	I-PROC
assay	I-PROC
.	O

In	O
Exp	O
.	O

1	O
,	O
the	O
DCO	B-CHEM
sample	B-OBJC
with	O
12	O
.	O
8	O
%	O
FFA	B-CHEM
contained	O
the	O
lowest	O
(	O
<	O
0	O
.	O
05	O
)	O
DE	O
(	O
8	O
,	O
036	O
kcal	O
/	O
kg	O
)	O
content	O
compared	O
with	O
the	O
0	O
.	O
04	O
%	O
refined	B-CHEM
CO	I-CHEM
sample	B-OBJC
and	O
the	O
4	O
.	O
9	O
or	O
93	O
.	O

8	O
%	O
FFA	B-CHEM
DCO	B-CHEM
samples	B-OBJC
(	O
8	O
,	O
814	O
,	O
8	O
,	O
828	O
,	O
and	O
8	O
,	O
921	O
kcal	O
/	O
kg	O
,	O
respectively	O
)	O
,	O
with	O
the	O
DCO	B-CHEM
source	B-DISO
containing	O
13	O
.	O

9	O
%	O
FFA	B-CHEM
having	O
intermediate	O
DE	O
(	O
8	O
,	O
465	O
kcal	O
/	O
kg	O
)	O
content	O
.	O

The	O
ME	O
content	O
of	O
these	O
lipid	B-CHEM
sources	B-DISO
also	O
differed	O
among	O
treatments	O
(	O
<	O
0	O
.	O
01	O
)	O
,	O
following	O
trends	O
similar	O
to	O
their	O
DE	O
values	O
,	O
with	O
no	B-DISO
differences	I-DISO
noted	O
for	O
ME	O
as	O
a	O
percentage	O
of	O
DE	O
(	O
>	O
0	O
.	O
35	O
)	O
content	O
among	O
the	O
lipids	B-CHEM
evaluated	O
.	O

In	O
Exp	O
.	O

2	O
,	O
lipids	B-CHEM
containing	O
0	O
.	O
04	O
,	O
4	O
.	O
9	O
,	O
12	O
.	O
8	O
,	O
and	O
13	O
.	O

9	O
%	O
FFA	B-CHEM
had	O
similar	O
nitrogen	O
corrected	O
apparent	O
ME	O
(	O
AME	O
)	O
values	O
(	O
8	O
,	O
072	O
,	O
7	O
,	O
936	O
,	O
8	O
,	O
036	O
,	O
and	O
7	O
,	O
694	O
respectively	O
)	O
,	O
except	O
for	O
the	O
industrially	B-CHEM
hydrolyzed	I-CHEM
DCO	I-CHEM
sample	B-OBJC
containing	O
93	O
.	O

8	O
%	O
FFA	B-CHEM
,	O
which	O
contained	O
6	O
,	O
276	O
kcal	O
/	O
kg	O
(	O
<	O
0	O
.	O
01	O
)	O
.	O

Using	O
published	O
prediction	O
equations	O
,	O
the	O
predicted	O
DE	O
of	O
these	O
lipids	B-CHEM
for	O
swine	B-LIVB
was	O
3	O
.	O

5	O
%	O
greater	O
than	O
the	O
values	O
determined	O
in	O
Exp	O
.	O

1	O
for	O
all	O
lipid	B-CHEM
sources	B-DISO
,	O
except	O
for	O
the	O
DCO	B-CHEM
sample	B-OBJC
containing	O
93	O
.	O

8	O
%	O
FFA	B-CHEM
,	O
which	O
the	O
predicted	O
DE	O
was	O
underestimated	O
.	O

Likewise	O
,	O
the	O
predicted	O
AME	O
of	O
these	O
lipids	B-CHEM
for	O
broilers	B-LIVB
was	O
7	O
.	O
4	O
%	O
greater	O
than	O
the	O
determined	O
AMEn	O
(	O
Exp	O
.	O
2	O
)	O
for	O
all	O
lipid	B-CHEM
sources	B-DISO
.	O

Voices	O
:	O
A	O
Conversation	O
with	O
Allen	B-LIVB
J	I-LIVB
.	I-LIVB

Wilcox	I-LIVB
Allen	B-LIVB
James	I-LIVB
Wilcox	I-LIVB
was	O
born	O
on	O
30	O
September	O
1946	O
in	O
Columbus	B-GEOG
,	I-GEOG
OH	I-GEOG
.	O

He	O
studied	O
medicine	O
at	O
the	O
University	B-OBJC
of	I-OBJC
Michigan	I-OBJC
,	O
graduated	O
in	O
1973	O
,	O
and	O
after	O
a	O
rotating	O
internship	B-PROC
,	O
he	O
completed	B-DISO
a	I-DISO
master	I-DISO
's	I-DISO
degree	I-DISO
in	O
maternal	O
and	O
child	O
health	O
(	O
1976	O
)	O
and	O
a	O
PhD	O
in	O
epidemiology	O
(	O
1979	O
)	O
at	O
the	O
University	B-OBJC
of	I-OBJC
North	I-OBJC
Carolina	I-OBJC
in	O
Chapel	B-GEOG
Hill	I-GEOG
.	O

After	O
graduation	B-PROC
,	O
he	O
went	O
to	O
work	O
at	O
the	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
(	O
NIEHS	O
,	O
one	O
of	O
the	O
US	O
National	O
Institutes	O
of	O
Health	O
)	O
in	O
Durham	B-GEOG
,	I-GEOG
NC	I-GEOG
,	O
where	O
he	O
has	O
spent	O
his	O
career	O
.	O

He	O
developed	O
a	O
research	B-PROC
program	I-PROC
in	O
reproductive	O
and	O
perinatal	O
epidemiology	O
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time	O
.	O

His	O
studies	O
include	O
the	O
early	B-DISO
pregnancy	I-DISO
study	O
,	O
which	O
documented	B-PROC
the	O
extent	O
of	O
subclinical	O
pregnancy	B-DISO
loss	I-DISO
in	O
humans	B-LIVB
and	O
established	O
the	O
fertile	O
days	O
of	O
a	O
woman	B-LIVB
's	I-LIVB
menstrual	B-PHYS
cycle	I-PHYS
.	O

He	O
served	O
as	O
the	O
Chief	B-LIVB
of	I-LIVB
the	O
Epidemiology	O
Branch	B-LIVB
from	O
1991	O
to	O
2001	O
,	O
and	O
as	O
Editor	B-LIVB
-	I-LIVB
in	I-LIVB
-	I-LIVB
Chief	I-LIVB
of	O
the	O
journal	B-OBJC
EPIDEMIOLOGY	O
from	O
2001	O
to	O
2014	O
.	O

His	O
textbook	B-OBJC
,	O
Fertility	B-OBJC
and	I-OBJC
Pregnancy	I-OBJC
-	I-OBJC
An	I-OBJC
Epidemiologic	I-OBJC
Perspective	I-OBJC
,	O
was	O
published	O
by	O
Oxford	O
University	O
Press	O
in	O
2010	O
.	O

He	O
was	O
elected	O
to	O
the	O
American	O
Epidemiological	O
Society	O
in	O
1989	O
,	O
and	O
served	O
as	O
its	O
president	O
in	O
2003	O
.	O

He	O
also	O
served	O
as	O
president	O
of	O
the	O
Society	O
of	O
Pediatric	O
and	O
Perinatal	O
Epidemiological	O
Research	O
(	O
1996	O
)	O
and	O
the	O
president	O
of	O
the	O
Society	O
of	O
Epidemiological	O
Research	O
(	O
1998	O
)	O
.	O

He	O
holds	O
adjunct	O
teaching	B-PROC
appointments	O
at	O
the	O
University	B-OBJC
of	I-OBJC
North	I-OBJC
Carolina	I-OBJC
,	O
Harvard	B-OBJC
University	I-OBJC
,	O
and	O
the	O
University	B-OBJC
of	I-OBJC
Bergen	I-OBJC
(	O
Norway	B-GEOG
)	O
,	O
which	O
awarded	B-OBJC
him	O
an	O
honorary	O
doctoral	O
degree	O
in	O
2008	O
.	O

Hierarchical	O
Address	O
Event	O
Routing	O
for	O
Reconfigurable	O
Large	O
-	O
Scale	O
Neuromorphic	O
Systems	O
We	O
present	O
a	O
hierarchical	O
address	O
-	O
event	O
routing	O
(	O
HiAER	O
)	O
architecture	O
for	O
scalable	O
communication	O
of	O
neural	B-ANAT
and	O
synaptic	B-ANAT
spike	O
events	O
between	O
neuromorphic	B-OBJC
processors	I-OBJC
,	O
implemented	O
with	O
five	O
Xilinx	B-OBJC
Spartan	I-OBJC
-	I-OBJC
6	I-OBJC
field	I-OBJC
-	I-OBJC
programmable	I-OBJC
gate	I-OBJC
arrays	I-OBJC
and	O
four	O
custom	O
analog	O
neuromophic	B-OBJC
integrated	I-OBJC
circuits	I-OBJC
serving	O
262k	O
neurons	B-ANAT
and	O
262	O
M	O
synapses	B-ANAT
.	O

The	O
architecture	O
extends	O
the	O
single	O
-	O
bus	O
address	O
-	O
event	O
representation	O
protocol	O
to	O
a	O
hierarchy	O
of	O
multiple	O
nested	O
buses	O
,	O
routing	O
events	O
across	O
increasing	O
scales	O
of	O
spatial	O
distance	O
.	O

The	O
HiAER	O
protocol	O
provides	O
individually	O
programmable	O
axonal	B-ANAT
delay	O
in	O
addition	O
to	O
strength	O
for	O
each	O
synapse	B-ANAT
,	O
lending	O
itself	O
toward	O
biologically	O
plausible	O
neural	B-PHYS
network	I-PHYS
architectures	I-PHYS
,	O
and	O
scales	O
across	O
a	O
range	O
of	O
hierarchies	O
suitable	O
for	O
multichip	B-OBJC
and	O
multiboard	B-OBJC
systems	I-OBJC
in	O
reconfigurable	O
large	O
-	O
scale	O
neuromorphic	O
systems	O
.	O

We	O
show	O
approximately	O
linear	O
scaling	O
of	O
net	O
global	O
synaptic	O
event	O
throughput	O
with	O
number	O
of	O
routing	O
nodes	O
in	O
the	O
network	O
,	O
at	O
$	O
3	O
.	O

6x10	O
^	O
7	O
$	O
synaptic	B-ANAT
events	O
per	O
second	O
per	O
16k	O
-	O
neuron	B-ANAT
node	O
in	O
the	O
hierarchy	O
.	O

A	O
closer	O
look	O
at	O
school	B-OBJC
bonding	B-PHYS
among	O
African	B-LIVB
American	I-LIVB
adolescents	B-LIVB
in	O
low	B-LIVB
-	I-LIVB
income	I-LIVB
communities	I-LIVB
:	O
A	O
latent	B-PROC
class	I-PROC
analysis	I-PROC
Positive	B-DISO
school	B-OBJC
bonding	B-PHYS
is	O
a	O
significant	O
precursor	O
to	O
students	B-LIVB
'	O
school	B-OBJC
success	O
.	O

However	O
,	O
African	B-LIVB
American	I-LIVB
youth	B-LIVB
report	O
lower	O
school	B-OBJC
success	O
compared	O
with	O
their	O
White	B-LIVB
counterparts	I-LIVB
.	O

This	O
study	B-PROC
examined	O
correlates	O
of	O
school	B-OBJC
bonding	B-PHYS
among	O
633	O
African	B-LIVB
American	I-LIVB
youth	B-LIVB
who	O
were	O
recruited	O
from	O
community	B-LIVB
settings	I-LIVB
in	O
Chicago	B-GEOG
.	O

Major	O
findings	B-DISO
indicated	O
that	O
negative	B-DISO
peer	I-DISO
norms	I-DISO
,	O
exposure	O
to	O
community	B-DISO
violence	I-DISO
,	O
and	O
poor	O
mental	B-PHYS
health	I-PHYS
were	O
negatively	B-DISO
correlated	O
with	O
school	B-OBJC
bonding	B-PHYS
,	O
while	O
parental	O
monitoring	O
,	O
positive	B-DISO
self	I-DISO
-	I-DISO
regard	I-DISO
,	O
and	O
future	O
orientation	B-PHYS
were	O
correlated	O
with	O
higher	O
school	B-OBJC
motivation	B-PHYS
.	O

Students	B-LIVB
classified	O
as	O
having	O
high	O
or	O
moderate	O
school	B-OBJC
bonding	B-PHYS
were	O
more	O
likely	O
to	O
live	O
with	O
both	O
parents	B-LIVB
,	O
experience	B-PHYS
higher	O
levels	O
of	O
parental	O
monitoring	O
,	O
and	O
exhibit	B-DISO
positive	I-DISO
self	I-DISO
-	I-DISO
regard	I-DISO
.	O

Implications	O
are	O
discussed	O
in	O
view	O
of	O
these	O
findings	B-DISO
.	O

Prevalence	O
of	O
depression	B-DISO
in	O
patients	B-LIVB
of	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
:	O
A	O
cross	B-PROC
sectional	I-PROC
study	I-PROC
in	O
a	O
tertiary	B-OBJC
care	I-OBJC
centre	I-OBJC
The	O
present	O
study	B-PROC
aims	O
to	O
study	B-PROC
the	O
prevalence	O
of	O
depression	B-DISO
in	O
patients	B-LIVB
with	O
uncomplicated	B-DISO
type	I-DISO
II	I-DISO
diabetes	I-DISO
mellitus	I-DISO
and	O
to	O
find	O
its	O
association	O
with	O
various	O
socio	O
-	O
demographic	O
factors	O
in	O
the	O
same	O
.	O

A	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
,	O
single	O
interview	O
study	B-PROC
was	O
performed	O
in	O
an	O
outpatient	B-OBJC
department	I-OBJC
of	O
an	O
endocrinology	O
institute	O
.	O

Total	O
80	O
type	B-DISO
II	I-DISO
DM	I-DISO
patients	I-DISO
without	I-DISO
any	I-DISO
associated	I-DISO
complications	I-DISO
of	O
diabetes	B-DISO
were	O
included	O
in	O
this	O
study	B-PROC
.	O

To	O
diagnose	B-DISO
Depressive	B-DISO
Episode	I-DISO
,	O
structured	B-PROC
clinical	I-PROC
interview	I-PROC
for	O
DSM	O
V	O
was	O
applied	O
.	O

Severity	O
of	O
depression	B-DISO
was	O
assessed	O
by	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
(	O
HAM	O
-	O
D	O
)	O
.	O

To	O
assess	B-PROC
socio	O
-	O
demographic	O
characteristics	O
of	O
the	O
patients	B-LIVB
,	O
all	O
of	O
them	O
were	O
evaluated	B-PROC
with	O
a	O
semi	O
-	O
structured	O
socio	O
-	O
demographic	O
performa	O
.	O

38	O
.	O

75	O
%	O
patients	B-LIVB
(	O
N	O
=	O
31	O
)	O
were	O
found	O
to	O
be	O
suffering	B-DISO
from	O
depression	B-DISO
.	O

Among	O
them	O
48	O
.	O

38	O
%	O
were	O
moderately	O
depressed	O
and	O
none	O
were	O
suffering	B-DISO
from	O
very	O
severe	O
depression	B-DISO
.	O

Significant	O
association	O
was	O
not	O
found	O
between	O
depression	B-DISO
and	O
socio	O
-	O
demographic	O
factors	O
of	O
age	B-PHYS
(	O
p	O
=	O
0	O
.	O
920	O
)	O
,	O
gender	B-PHYS
(	O
p	O
=	O
0	O
.	O
251	O
)	O
,	O
economic	O
profile	O
(	O
p	O
=	O
0	O
.	O
583	O
)	O
,	O
local	B-PHYS
background	I-PHYS
of	I-PHYS
the	I-PHYS
patient	I-PHYS
(	O
p	O
=	O
0	O
.	O
646	O
)	O
,	O
educational	B-DISO
qualification	I-DISO
(	O
p	O
=	O
0	O
.	O
935	O
)	O
and	O
marital	O
status	O
(	O
p	O
=	O
0	O
.	O
644	O
)	O
.	O

Similarly	O
no	O
association	O
was	O
found	O
with	O
duration	O
of	O
diabetes	B-DISO
,	O
HbA1c	B-CHEM
and	O
BMI	B-PHYS
.	O

Exclusion	O
of	O
complicated	O
cases	O
didn	O
'	O
t	O
seem	O
to	O
influence	O
overall	O
prevalence	O
of	O
depression	B-DISO
,	O
although	O
reduction	O
in	O
severity	O
was	O
apparent	O
.	O

Thus	O
even	O
in	O
those	O
diabetic	B-DISO
patients	B-LIVB
who	O
are	O
leading	O
a	O
complication	B-DISO
free	I-DISO
life	O
,	O
a	O
detailed	O
psychiatric	O
analysis	B-PROC
to	O
rule	O
out	O
depression	B-DISO
is	O
mandatory	O
.	O

Evaluation	B-PROC
of	O
Spontaneous	O
Bone	B-PHYS
Regeneration	I-PHYS
after	O
Enucleation	B-PROC
of	O
Large	O
Cysts	B-DISO
of	O
the	O
Jaws	B-ANAT
using	O
Radiographic	B-PHEN
Computed	B-PROC
Software	B-OBJC
Spontaneous	O
regeneration	B-PHYS
of	I-PHYS
bone	I-PHYS
is	O
commonly	O
seen	O
in	O
the	O
small	O
surgical	B-PROC
defects	O
caused	O
by	O
enucleation	B-PROC
of	O
cysts	B-DISO
.	O

However	O
,	O
in	O
case	O
of	O
large	O
surgical	B-PROC
defects	O
caused	O
by	O
the	O
enucleation	B-PROC
,	O
spontaneous	O
regeneration	B-PHYS
of	I-PHYS
bone	I-PHYS
is	O
a	O
rare	O
phenomenon	B-PHEN
and	O
it	O
depends	O
on	O
factors	O
,	O
such	O
as	O
age	B-PHYS
of	O
the	O
patient	B-LIVB
,	O
intact	O
periosteum	O
,	O
and	O
proper	O
stabilization	B-PROC
.	O

The	O
study	B-PROC
included	O
16	O
patients	B-LIVB
,	O
who	O
reported	B-PROC
to	O
the	O
department	B-OBJC
of	I-OBJC
oral	I-OBJC
and	I-OBJC
maxillofacial	I-OBJC
surgery	I-OBJC
with	O
the	O
complaint	B-DISO
of	O
pain	B-DISO
and	O
swelling	B-DISO
in	O
the	O
jaws	B-ANAT
diagnosed	B-DISO
as	O
cyst	B-DISO
.	O

The	O
sample	O
included	O
equal	O
numbers	O
of	O
male	B-PHYS
and	O
female	B-PHYS
subjects	B-LIVB
aged	B-PHYS
between	O
15	O
and	O
40	O
years	O
.	O

Panoramic	B-PROC
radiographs	I-PROC
were	O
taken	O
pre	O
-	O
and	O
postoperatively	O
on	O
day	O
2	O
of	O
the	O
enucleation	B-PROC
.	O

The	O
dimensions	O
of	O
the	O
cyst	B-DISO
were	O
evaluated	B-PROC
on	O
the	O
radiograph	B-PROC
according	O
to	O
the	O
proforma	O
.	O

Subsequent	O
radiographs	B-PROC
were	O
taken	O
at	O
regular	O
intervals	O
of	O
1	O
.	O

5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	O
parameters	O
and	O
were	O
analyzed	B-PROC
using	O
MCID	O
™	O
analysis	O
software	B-OBJC
of	O
imaging	B-PROC
research	I-PROC
.	O

Mean	O
reduction	B-PROC
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	O
cavity	B-DISO
size	O
and	O
increase	O
in	O
the	O
mean	O
density	O
up	O
to	O
59	O
and	O
90	O
.	O

2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	O
respectively	O
.	O

Spontaneous	O
bone	B-PHYS
regeneration	I-PHYS
was	O
seen	O
even	O
after	O
primary	O
closure	B-PROC
of	O
the	O
large	O
cystic	O
defect	O
without	O
the	O
need	O
for	O
placement	B-PROC
of	O
foreign	B-OBJC
substances	I-OBJC
or	O
grafts	B-CHEM
and	O
it	O
also	O
eliminated	O
the	O
complications	B-DISO
resulting	O
from	O
placement	B-PROC
of	O
foreign	B-OBJC
substance	I-OBJC
.	O

Further	O
studies	B-PROC
are	O
required	O
in	O
a	O
larger	O
sample	O
with	O
longer	O
follow	B-PROC
-	I-PROC
up	I-PROC
durations	O
to	O
confirm	O
the	O
outcome	O
of	O
the	O
present	O
work	O
for	O
the	O
benefit	O
of	O
patients	B-LIVB
.	O

The	O
present	O
study	B-PROC
depicted	O
that	O
spontaneous	O
bone	B-PHYS
regeneration	I-PHYS
can	O
occur	O
with	O
accepted	O
results	B-DISO
after	O
simple	O
enucleation	B-PROC
of	O
jaw	B-ANAT
cyst	B-DISO
without	O
the	O
aid	O
of	O
any	O
graft	B-CHEM
material	I-CHEM
.	O

Hence	O
,	O
simple	O
enucleation	B-PROC
may	O
be	O
considered	O
as	O
a	O
first	B-PROC
line	I-PROC
of	I-PROC
treatment	I-PROC
modality	O
for	O
cystic	O
lesion	B-DISO
of	O
the	O
jaws	B-ANAT
.	O

This	O
simplifies	O
the	O
surgical	B-PROC
procedure	I-PROC
,	O
decreases	O
the	O
economic	O
and	O
biologic	O
costs	O
,	O
and	O
reduces	B-PROC
the	O
risk	O
of	O
postoperative	B-DISO
complications	I-DISO
.	O

Follow	B-PROC
-	I-PROC
up	I-PROC
is	O
necessary	O
along	O
with	O
patient	B-LIVB
's	I-LIVB
compliance	O
for	O
the	O
success	O
of	O
treatment	O
.	O

Scar	O
Assessment	B-PROC
After	O
Breast	O
Augmentation	O
Surgery	O
with	O
Axillary	B-PROC
Incision	I-PROC
versus	O
Inframammary	B-ANAT
Fold	I-ANAT
Incision	B-PROC
:	O
Long	O
-	O
Term	O
Follow	B-PROC
-	I-PROC
Up	I-PROC
in	O
Chinese	B-LIVB
Patients	B-LIVB
The	O
inframammary	B-ANAT
fold	I-ANAT
(	O
IMF	B-ANAT
)	O
incision	B-PROC
is	O
widely	O
used	O
in	O
Western	O
countries	O
for	O
breast	O
augmentation	O
surgery	O
,	O
whereas	O
the	O
axillary	B-PROC
incision	I-PROC
is	O
the	O
dominant	O
approach	O
used	O
in	O
China	B-GEOG
,	O
because	O
many	O
Chinese	B-LIVB
surgeons	B-LIVB
believe	O
that	O
the	O
Asian	B-LIVB
population	I-LIVB
has	O
a	O
higher	B-DISO
risk	I-DISO
of	O
developing	O
hypertrophic	B-DISO
scars	I-DISO
.	O

However	O
,	O
comparative	B-PROC
data	O
of	O
scar	O
assessment	B-PROC
through	O
different	O
incisions	B-PROC
in	O
Chinese	B-LIVB
patients	B-LIVB
are	O
scarce	B-DISO
.	O

The	O
aims	O
of	O
the	O
study	B-PROC
were	O
as	O
follows	O
:	O
(	O
1	O
)	O
to	O
evaluate	O
the	O
outcomes	O
of	O
scar	O
assessment	B-PROC
using	O
the	O
Vancouver	O
scar	O
scale	O
(	O
VSS	O
)	O
,	O
combined	O
with	O
patient	O
satisfaction	O
scoring	O
,	O
in	O
the	O
scar	O
assessment	B-PROC
after	O
breast	O
augmentation	O
surgery	O
;	O
(	O
2	O
)	O
to	O
compare	O
the	O
long	O
-	O
term	O
cosmetic	B-OBJC
effects	O
of	O
surgical	O
scars	O
between	O
axillary	B-PROC
and	O
IMF	B-ANAT
incisions	B-PROC
.	O

Consecutive	O
patients	B-LIVB
coming	O
to	O
our	O
department	B-OBJC
for	O
follow	B-PROC
-	I-PROC
up	I-PROC
care	I-PROC
at	O
least	O
1	O
year	O
after	O
primary	O
breast	O
augmentation	O
surgeries	O
with	O
axillary	B-PROC
and	O
IMF	B-ANAT
incisions	B-PROC
between	O
January	O
1	O
,	O
2014	O
and	O
December	O
31	O
,	O
2014	O
were	O
included	O
in	O
the	O
research	B-PROC
.	O

Internal	O
consistency	O
,	O
inter	O
-	O
rater	O
reliability	O
,	O
and	O
convergent	O
validity	O
were	O
examined	B-DISO
for	O
the	O
VSS	O
and	O
patient	O
satisfaction	O
scoring	O
.	O

The	O
baseline	O
characteristics	O
and	O
scar	O
scores	O
were	O
tested	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
and	O
Student	O
's	O
t	O
test	O
between	O
the	O
two	O
groups	B-LIVB
.	O

Sixty	O
-	O
one	O
patients	B-LIVB
underwent	O
implantation	B-PROC
surgeries	B-PROC
through	O
the	O
axillary	B-PROC
incisions	I-PROC
,	O
and	O
17	O
patients	B-LIVB
through	O
the	O
IMF	B-ANAT
incisions	B-PROC
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
age	B-PHYS
,	O
follow	B-PROC
-	I-PROC
up	I-PROC
time	O
,	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
,	O
implant	B-DEVI
volume	O
,	O
or	O
implant	O
projection	O
between	O
groups	B-LIVB
.	O

Reliability	O
and	O
validity	O
of	O
the	O
VSS	O
and	O
patient	O
satisfaction	O
scoring	O
were	O
satisfactory	O
.	O

The	O
scores	O
of	O
pigmentation	B-PHYS
were	O
higher	O
in	O
the	O
IMF	B-ANAT
group	B-LIVB
than	O
those	O
in	O
the	O
axilla	B-PROC
group	B-LIVB
with	O
statistical	O
significance	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
scores	O
of	O
other	O
subscales	O
,	O
overall	O
VSS	O
scores	O
,	O
and	O
patient	O
satisfaction	O
were	O
not	O
statistically	O
significant	O
.	O

The	O
scars	O
were	O
significantly	O
longer	O
in	O
the	O
axilla	B-PROC
group	B-LIVB
compared	O
with	O
the	O
IMF	B-ANAT
group	B-LIVB
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
VSS	O
combined	O
with	O
patient	O
satisfaction	O
scoring	O
constitutes	O
an	O
effective	O
tool	B-OBJC
to	O
evaluate	B-PROC
incision	B-PROC
scars	O
after	O
augmentation	B-PROC
mammaplasty	I-PROC
.	O

Scars	O
in	O
the	O
axilla	B-PROC
and	O
IMF	B-ANAT
can	O
achieve	O
comparable	O
cosmetic	B-OBJC
effects	O
and	O
patient	O
satisfaction	O
in	O
Chinese	B-LIVB
women	B-LIVB
.	O

Chinese	B-LIVB
patients	B-LIVB
with	O
proper	O
indications	O
can	O
receive	O
breast	O
augmentation	O
surgery	O
through	O
the	O
IMF	B-ANAT
incision	B-PROC
,	O
with	O
fewer	O
risks	O
and	O
less	O
trauma	B-DISO
,	O
and	O
get	O
satisfactory	O
scar	O
appearance	O
as	O
through	O
the	O
axillary	B-PROC
incision	I-PROC
.	O

This	O
journal	O
requires	O
that	O
authors	B-LIVB
assign	O
a	O
level	B-DISO
of	I-DISO
evidence	I-DISO
to	O
each	O
article	O
.	O

For	O
a	O
full	O
description	O
of	O
these	O
Evidence	O
-	O
Based	O
Medicine	O
ratings	O
,	O
please	O
refer	O
to	O
the	O
Table	O
of	O
Contents	O
or	O
the	O
online	O
Instructions	O
to	O
Authors	O
www	O
.	O

springer	O
.	O

com	O
/	O
00266	O
.	O

MicroRNA	B-CHEM
-	I-CHEM
26a	I-CHEM
protects	B-DISO
against	O
cardiac	B-DISO
hypertrophy	I-DISO
via	O
inhibiting	O
GATA4	O
in	O
rat	B-LIVB
model	B-LIVB
and	O
cultured	B-ANAT
cardiomyocytes	I-ANAT
.	O

Pathological	O
cardiac	B-DISO
hypertrophy	I-DISO
is	O
characterized	O
by	O
deleterious	O
changes	O
developed	O
in	O
cardiovascular	B-DISO
diseases	I-DISO
,	O
whereas	O
microRNAs	B-CHEM
(	O
miRNAs	B-CHEM
)	O
are	O
involved	O
in	O
the	O
mediation	O
of	O
cardiac	B-DISO
hypertrophy	I-DISO
.	O

To	O
investigate	O
the	O
role	O
of	O
microRNA	B-CHEM
-	I-CHEM
26a	I-CHEM
(	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
)	O
in	O
regulating	B-DISO
cardiac	I-DISO
hypertrophy	I-DISO
and	O
its	O
functioning	B-PHYS
mechanisms	O
,	O
overexpression	B-PHYS
and	O
suppression	B-PHYS
of	O
miR	O
-	O
26a	O
via	O
its	O
mimic	B-PHYS
and	O
inhibitor	B-CHEM
in	O
a	O
transverse	O
abdominal	B-ANAT
aortic	B-DISO
constriction	I-DISO
(	O
TAAC	B-DISO
)	O
-	O
induced	O
rat	B-LIVB
model	B-LIVB
and	O
in	O
angiotensin	B-CHEM
II	I-CHEM
(	O
Ang	B-CHEM
II	I-CHEM
)	O
-	O
induced	O
cardiomyocytes	B-ANAT
(	O
CMs	B-ANAT
)	O
was	O
performed	O
.	O

In	O
the	O
rat	B-LIVB
model	B-LIVB
,	O
the	O
heart	O
weight	O
(	O
HW	O
)	O
compared	O
with	O
the	O
body	B-PHYS
weight	I-PHYS
(	O
BW	B-PHYS
)	O
,	O
the	O
CM	B-ANAT
area	O
,	O
and	O
expression	O
of	O
the	O
hypertrophy	B-DISO
-	O
associated	O
factors	O
,	O
atrial	B-CHEM
natriuretic	I-CHEM
factor	I-CHEM
(	O
ANF	B-CHEM
)	O
and	O
ß	B-CHEM
-	I-CHEM
myosin	I-CHEM
heavy	I-CHEM
chain	I-CHEM
(	O
ß	B-CHEM
-	I-CHEM
MHC	I-CHEM
)	O
,	O
were	O
assessed	O
.	O

In	O
CMs	B-ANAT
,	O
the	O
protein	B-PHYS
synthesis	I-PHYS
rate	O
was	O
determined	O
using	O
a	O
leucine	B-PROC
incorporation	I-PROC
assay	I-PROC
.	O

Mutation	B-PHYS
of	O
the	O
GATA	O
-	O
binding	O
protein	O
4	O
(	O
GATA4	O
)	O
3	O
'	O
-	O
untranslated	O
region	O
(	O
UTR	O
)	O
and	O
overexpression	B-PHYS
of	O
GATA4	O
were	O
performed	O
to	O
confirm	O
whether	O
GATA4	O
is	O
the	O
target	O
of	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
.	O

The	O
results	O
indicated	O
that	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
was	O
significantly	O
downregulated	B-PHYS
in	O
the	O
heart	O
tissue	O
of	O
the	O
rat	B-LIVB
model	B-LIVB
,	O
as	O
well	O
as	O
in	O
Ang	B-CHEM
II	I-CHEM
-	O
induced	O
CMs	B-ANAT
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
TAAC	B-DISO
-	O
induced	O
rat	B-LIVB
model	B-LIVB
exhibited	O
a	O
higher	O
HW	O
/	O
BW	B-PHYS
ratio	O
,	O
a	O
larger	O
CM	B-ANAT
area	O
,	O
and	O
higher	O
expression	B-PHYS
levels	O
of	O
ANF	B-CHEM
and	O
ß	B-CHEM
-	I-CHEM
MHC	I-CHEM
.	O

CMs	B-ANAT
,	O
upon	O
Ang	B-CHEM
II	I-CHEM
treatment	B-PROC
,	O
also	O
demonstrated	O
a	O
larger	O
CM	B-ANAT
area	O
,	O
higher	O
levels	O
of	O
ANF	B-CHEM
and	O
ß	B-CHEM
-	I-CHEM
MHC	I-CHEM
,	O
as	O
well	O
as	O
accelerated	O
protein	B-PHYS
synthesis	I-PHYS
.	O

miR	B-CHEM
-	I-CHEM
26a	I-CHEM
was	O
not	O
able	O
to	O
regulate	B-PHEN
GATA4	O
with	O
mutations	B-PHYS
in	O
the	O
3	O
'	O
-	O
UTR	O
,	O
indicating	O
that	O
GATA4	O
was	O
the	O
direct	O
target	O
of	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
.	O

Overexpression	B-PHYS
of	O
GATA4	O
abrogated	O
the	O
inhibitory	B-PHYS
functions	I-PHYS
of	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
in	O
cardiac	B-DISO
hypertrophy	I-DISO
.	O

Taken	O
together	O
,	O
the	O
present	O
study	O
suggested	O
an	O
anti	B-DISO
-	I-DISO
hypertrophic	I-DISO
role	O
of	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
in	O
cardiac	B-DISO
hypertrophy	I-DISO
,	O
possibly	O
via	O
inhibition	O
of	O
GATA4	O
.	O

These	O
findings	B-DISO
may	O
be	O
useful	O
in	O
terms	O
of	O
facilitating	O
cardiac	B-ANAT
treatment	B-PROC
,	O
with	O
potential	O
therapeutic	O
targets	O
and	O
strategies	O
.	O

Membrane	B-PHYS
Protein	I-PHYS
Solubilization	I-PHYS
and	O
Composition	B-PHEN
of	O
Protein	B-CHEM
Detergent	B-CHEM
Complexes	B-CHEM
Membrane	B-CHEM
proteins	I-CHEM
are	O
typically	B-PHYS
expressed	I-PHYS
in	O
heterologous	O
systems	O
with	O
a	O
view	O
to	O
in	B-PROC
vitro	I-PROC
characterization	O
.	O

A	O
critical	O
step	O
in	O
the	O
preparation	O
of	O
membrane	B-CHEM
proteins	I-CHEM
after	O
expression	B-PHYS
in	O
any	O
system	O
is	O
the	O
solubilization	B-PHYS
of	I-PHYS
the	I-PHYS
protein	I-PHYS
in	O
aqueous	B-CHEM
solution	I-CHEM
,	O
typically	O
using	O
detergents	B-CHEM
and	O
lipids	B-CHEM
,	O
to	O
obtain	O
the	O
protein	B-CHEM
in	O
a	O
form	O
suitable	O
for	O
purification	O
,	O
structural	B-PROC
or	O
functional	O
analysis	B-PROC
.	O

This	O
process	B-PHEN
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	B-CHEM
in	O
an	O
unnatural	O
environment	O
,	O
a	O
protein	B-CHEM
detergent	B-CHEM
complex	B-CHEM
,	O
separating	O
it	O
from	O
its	O
natural	O
lipid	B-CHEM
partners	O
while	O
causing	O
the	O
minimum	O
destabilization	B-PHYS
or	O
modification	B-DISO
of	O
the	O
structure	O
.	O

Although	O
the	O
process	B-PHEN
is	O
difficult	O
,	O
and	O
relatively	O
hard	O
to	O
master	O
,	O
an	O
increasing	O
number	O
of	O
membrane	B-CHEM
proteins	I-CHEM
have	O
been	O
successfully	O
isolated	O
after	O
expression	B-PHYS
in	O
a	O
wide	O
variety	O
of	O
systems	O
.	O

In	O
this	O
chapter	O
we	O
give	O
a	O
general	O
protocol	O
for	O
preparing	O
protein	B-CHEM
detergent	B-CHEM
complexes	B-CHEM
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical	O
steps	O
.	O

In	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	B-PROC
the	O
composition	B-PHEN
of	O
protein	B-CHEM
detergent	B-CHEM
complexes	B-CHEM
;	O
this	O
analysis	B-PROC
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	B-PHEN
variation	O
often	O
causes	O
irreproducible	O
results	O
.	O

Systematic	O
Quantification	O
of	O
GPCR	B-CHEM
/	O
cAMP	B-CHEM
-	O
Controlled	O
Protein	B-CHEM
Kinase	I-CHEM
A	I-CHEM
Interactions	B-PHYS
The	O
diffusible	O
second	B-CHEM
messenger	I-CHEM
cyclic	B-CHEM
AMP	I-CHEM
(	O
cAMP	B-CHEM
)	O
originates	O
from	O
multiple	O
G	B-CHEM
protein	I-CHEM
-	I-CHEM
coupled	I-CHEM
receptor	I-CHEM
(	O
GPCR	B-CHEM
)	O
cascades	O
activating	O
the	O
intracellular	O
key	O
effector	O
protein	B-CHEM
kinase	I-CHEM
A	I-CHEM
(	O
PKA	B-CHEM
)	O
.	O

Spatially	O
and	O
temporally	O
restricted	O
cAMP	B-CHEM
-	O
fluxes	B-PHEN
are	O
directly	O
sensed	O
by	O
macromolecular	B-CHEM
PKA	B-ANAT
complexes	I-ANAT
.	O

The	O
consequences	O
are	O
alterations	O
of	O
molecular	B-PHYS
interactions	I-PHYS
,	O
which	O
lead	O
to	O
activation	O
of	O
compartmentalized	O
PKA	B-PHYS
phosphotransferase	I-PHYS
activities	I-PHYS
,	O
regulating	O
a	O
vast	O
array	O
of	O
cellular	B-PHYS
functions	I-PHYS
.	O

To	O
decode	O
cell	O
-	O
type	O
and	O
cell	B-ANAT
-	I-ANAT
compartment	I-ANAT
specific	O
PKA	B-CHEM
functions	O
,	O
the	O
spatio	B-PROC
-	I-PROC
temporal	I-PROC
dynamics	I-PROC
of	O
small	B-PHYS
molecule	I-PHYS
:	I-PHYS
protein	I-PHYS
interactions	I-PHYS
,	O
protein	B-PHYS
:	I-PHYS
protein	I-PHYS
interactions	I-PHYS
(	O
PPIs	B-PHYS
)	O
,	O
cAMP	B-CHEM
-	O
mobilization	B-PHYS
,	O
and	O
phosphotransferase	B-PHYS
activities	I-PHYS
need	O
to	O
be	O
determined	O
directly	O
in	O
the	O
appropriate	O
cellular	O
context	O
.	O

A	O
collection	O
of	O
cell	B-CHEM
-	I-CHEM
based	I-CHEM
reporters	I-CHEM
has	O
been	O
developed	O
to	O
either	O
visualize	O
or	O
quantitatively	O
measure	O
kinase	B-PHYS
activities	I-PHYS
or	O
PKA	B-ANAT
complex	I-ANAT
formation	B-PHYS
/	O
dissociation	B-PHYS
.	O

In	O
this	O
review	O
,	O
we	O
list	O
a	O
collection	O
of	O
unimolecular	O
and	O
bimolecular	O
PKA	B-CHEM
biosensors	B-DEVI
,	O
followed	O
by	O
the	O
specification	O
of	O
the	O
modular	O
design	O
of	O
a	O
Renilla	B-CHEM
luciferase	I-CHEM
based	O
protein	B-PROC
-	I-PROC
fragment	I-PROC
complementation	I-PROC
assay	I-PROC
(	O
PCA	B-PROC
)	O
platform	O
for	O
measuring	O
PKA	B-CHEM
network	B-PHYS
interactions	I-PHYS
.	O

We	O
discuss	O
the	O
application	O
spectrum	B-PROC
of	O
the	O
PCA	B-PROC
reporter	B-CHEM
to	O
identify	B-DISO
,	O
quantify	O
,	O
and	O
dissect	O
dynamic	O
and	O
transient	O
PKA	B-ANAT
complexes	I-ANAT
downstream	O
of	O
specific	O
GPCR	B-CHEM
activities	O
.	O

We	O
specify	O
the	O
implementation	O
of	O
a	O
PCA	B-PROC
PKA	B-CHEM
platform	O
to	O
systematically	O
quantify	O
the	O
concurrent	O
involvement	O
of	O
receptor	B-CHEM
-	O
cAMP	B-PHYS
signaling	I-PHYS
,	O
post	B-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
,	O
and	O
kinase	B-CHEM
subunit	I-CHEM
mutations	B-PHYS
/	O
perturbations	O
in	O
PKA	B-PHYS
activation	I-PHYS
.	O

The	O
systematic	O
quantification	O
of	O
transient	O
PKA	B-CHEM
network	B-PHYS
interactions	O
will	O
contribute	O
to	O
a	O
better	O
understanding	O
how	O
GPCR	B-CHEM
-recognized	O
input	O
signals	B-PHEN
are	O
streamlined	O
through	O
the	O
compartmentalized	O
and	O
cAMP	B-CHEM
-	O
interacting	O
PKA	B-CHEM
signalosome	B-ANAT
.	O

The	O
role	O
of	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
the	O
distribution	O
of	O
body	B-PHYS
fat	I-PHYS
in	O
decreasing	B-DISO
the	O
number	O
of	O
prostate	B-PROC
rebiopsies	I-PROC
To	O
assess	O
the	O
usefulness	O
of	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
internal	B-PHYS
organ	I-PHYS
fat	I-PHYS
measured	O
by	O
bioelectrical	B-PHYS
impedance	I-PHYS
audiometry	B-PROC
to	O
avoid	O
rebiopsies	B-PROC
in	O
patients	B-LIVB
with	O
persistently	O
high	B-DISO
prostate	I-DISO
-	I-DISO
specific	I-DISO
antigen	I-DISO
(	I-DISO
PSA	I-DISO
)	I-DISO
levels	I-DISO
.	O

A	O
prospective	B-PROC
study	I-PROC
was	O
conducted	O
with	O
92	O
patients	B-LIVB
who	O
underwent	O
prostate	B-PROC
rebiopsy	I-PROC
due	O
to	O
high	O
PSA	O
levels	O
with	O
negative	B-DISO
results	I-DISO
in	O
the	O
rectal	B-PROC
examination	I-PROC
and	O
a	O
lack	O
of	O
preneoplastic	B-DISO
lesions	B-DISO
.	O

The	O
patients	B-LIVB
previously	O
had	O
their	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
levels	O
measured	O
and	O
had	O
undergone	O
an	O
impedance	B-PROC
audiometry	I-PROC
test	I-PROC
using	O
the	O
abdominal	B-ANAT
Fat	B-DEVI
Analyser	I-DEVI
AB	I-DEVI
-	I-DEVI
140	I-DEVI
TANITA	I-DEVI
system	I-DEVI
.	O

We	O
calculated	O
the	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O
the	O
PSA	B-PHEN
levels	I-PHEN
,	O
%	O
PSA	B-CHEM
,	O
internal	B-PHYS
organ	I-PHYS
fat	I-PHYS
and	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
PSA	B-CHEM
density	O
.	O

Twenty	O
-	O
five	O
patients	B-LIVB
were	O
diagnosed	B-DISO
with	O
prostate	B-DISO
cancer	I-DISO
.	O

These	O
patients	B-LIVB
had	O
significantly	O
higher	O
PSA	B-CHEM
,	O
PSAd	B-CHEM
and	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
values	O
and	O
a	O
tendency	O
towards	O
higher	O
internal	B-PHYS
organ	I-PHYS
fat	I-PHYS
levels	O
and	O
lower	O
%	O
PSA	B-CHEM
readings	O
(	O
p	O
=	O
.	O

001	O
,	O
p	O
=	O
.	O

003	O
,	O
p	O
=	O
.	O

001	O
,	O
p	O
=	O
.	O

24	O
and	O
P	O
=	O
0	O
.	O
28	O
,	O
respectively	O
)	O
.	O

The	O
ROC	O
curve	O
showed	O
an	O
area	O
under	O
the	O
curve	O
for	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O
PSA	B-CHEM
of	O
.82	O
and	O
.81	O
,	O
respectively	O
.	O

Using	O
the	O
cutoff	O
points	O
for	O
95	O
%	O
sensitivity	O
and	O
using	O
the	O
3	O
criteria	O
as	O
an	O
indication	O
of	O
rebiopsy	B-PROC
,	O
74	O
%	O
of	O
the	O
biopsies	B-PROC
would	O
have	O
been	O
spared	O
,	O
leaving	O
undiagnosed	B-DISO
only	O
1	O
patient	B-LIVB
with	O
clinically	O
significant	O
cancer	B-DISO
-	O
Gleason	B-DISO
score	I-DISO
>	O
7	O
(	O
4	O
+	O
3	O
)	O
-	O
.	O

The	O
positive	O
and	O
negative	O
predictive	O
values	O
for	O
the	O
set	O
of	O
variables	O
were	O
higher	O
than	O
for	O
each	O
one	O
separately	O
(	O
PPV	O
:	O
66	O
/	O
NPV	O
:	O
63	O
)	O
.	O

The	O
cost	O
of	O
both	O
determinations	B-PROC
was	O
82	O
euros	O
.	O

Our	O
results	O
suggest	O
that	O
measuring	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
could	O
significantly	O
decrease	O
the	O
number	O
of	O
unnecessary	B-PROC
rebiopsies	B-PROC
in	O
an	O
inexpensive	O
and	O
safe	O
manner	O
.	O

Adenosine	B-CHEM
A2A	I-CHEM
receptors	I-CHEM
in	O
the	O
olfactory	B-ANAT
bulb	I-ANAT
suppress	O
rapid	B-PHYS
eye	I-PHYS
movement	I-PHYS
sleep	I-PHYS
in	O
rodents	B-LIVB
Rapid	B-DISO
eye	I-DISO
movement	I-DISO
(	I-DISO
REM	I-DISO
)	I-DISO
sleep	I-DISO
behavior	I-DISO
disorder	I-DISO
in	O
humans	B-LIVB
is	O
often	O
accompanied	O
by	O
a	O
reduced	O
ability	B-DISO
to	I-DISO
smell	I-DISO
and	O
detect	B-PHYS
odors	I-PHYS
,	O
and	O
olfactory	B-DISO
bulbectomized	I-DISO
rats	B-LIVB
exhibit	O
increased	O
REM	B-PHYS
sleep	I-PHYS
,	O
suggesting	O
that	O
the	O
olfactory	B-ANAT
bulb	I-ANAT
(	O
OB	B-ANAT
)	O
is	O
involved	O
in	O
REM	B-PHYS
-	I-PHYS
sleep	I-PHYS
regulation	B-PHEN
.	O

However	O
,	O
the	O
molecular	B-PHYS
mechanism	I-PHYS
of	O
REM	B-PHYS
-	I-PHYS
sleep	I-PHYS
regulation	B-PHEN
by	O
the	O
OB	B-ANAT
is	O
unknown	O
.	O

Adenosine	B-CHEM
promotes	O
sleep	B-PHYS
and	O
its	O
A2A	B-CHEM
receptors	I-CHEM
(	O
A2AR	B-CHEM
)	O
are	O
expressed	B-PHYS
in	O
the	O
OB	B-ANAT
.	O

We	O
hypothesized	O
that	O
A2AR	B-CHEM
in	O
the	O
OB	B-ANAT
regulate	B-PHEN
REM	B-PHYS
sleep	I-PHYS
.	O

Bilateral	B-PROC
microinjections	I-PROC
of	O
the	O
A2AR	B-CHEM
antagonist	I-CHEM
SCH58261	I-CHEM
into	O
the	O
rat	B-LIVB
OB	B-ANAT
increased	O
REM	B-PHYS
sleep	I-PHYS
,	O
whereas	O
microinjections	B-PROC
of	O
the	O
A2AR	B-CHEM
agonist	I-CHEM
CGS21680	I-CHEM
decreased	O
REM	B-PHYS
sleep	I-PHYS
.	O

Similar	O
to	O
the	O
A2AR	B-CHEM
antagonist	I-CHEM
,	O
selective	O
A2AR	O
knockdown	B-PROC
by	O
adeno	B-LIVB
-	I-LIVB
associated	I-LIVB
virus	I-LIVB
carrying	O
short	B-CHEM
-	I-CHEM
hairpin	I-CHEM
RNA	I-CHEM
for	O
A2AR	O
in	O
the	O
rat	B-LIVB
OB	B-ANAT
increased	O
REM	B-PHYS
sleep	I-PHYS
.	O

Using	O
chemogenetics	O
on	O
the	O
basis	O
of	O
designer	B-CHEM
receptors	I-CHEM
exclusively	O
activated	O
by	O
designer	B-CHEM
drugs	I-CHEM
,	O
we	O
demonstrated	O
that	O
the	O
inhibition	B-PHYS
of	O
A2AR	B-CHEM
neurons	B-ANAT
increased	O
REM	B-PHYS
sleep	I-PHYS
,	O
whereas	O
the	O
activation	O
of	O
these	O
neurons	B-ANAT
decreased	O
REM	B-PHYS
sleep	I-PHYS
.	O

Moreover	O
,	O
using	O
a	O
conditional	O
anterograde	B-PROC
axonal	I-PROC
tract	I-PROC
-	I-PROC
tracing	I-PROC
approach	I-PROC
,	O
we	O
found	O
that	O
OB	B-ANAT
A2AR	B-CHEM
neurons	B-ANAT
innervate	O
the	O
piriform	B-ANAT
cortex	I-ANAT
and	O
olfactory	B-ANAT
tubercle	I-ANAT
.	O

These	O
novel	O
findings	O
indicate	O
that	O
adenosine	B-CHEM
suppresses	O
REM	B-PHYS
sleep	I-PHYS
via	O
A2AR	B-CHEM
in	O
the	O
OB	B-ANAT
of	O
rodents	B-LIVB
.	O

Geometric	O
morphometrics	B-PROC
reveals	O
restrictions	O
on	O
the	O
shape	O
of	O
the	O
female	B-PHYS
os	B-ANAT
coxae	I-ANAT
The	O
methodology	O
for	O
sex	B-PHEN
determination	I-PHEN
in	O
human	B-ANAT
skeletal	I-ANAT
remains	O
depends	O
on	O
the	O
different	O
bone	B-ANAT
morphologies	O
presented	O
by	O
men	B-LIVB
and	O
women	B-LIVB
.	O

Due	O
to	O
their	O
direct	O
implications	O
in	O
reproduction	B-PHYS
,	O
the	O
whole	O
pelvis	B-ANAT
,	O
particularly	O
the	O
os	B-ANAT
coxae	I-ANAT
,	O
shows	O
different	O
characteristics	O
in	O
either	O
sex	B-PHYS
.	O

The	O
sacrum	B-ANAT
and	O
the	O
os	B-ANAT
coxae	I-ANAT
constitute	O
the	O
birth	B-ANAT
cana	I-ANAT
l	O
.	O

In	O
this	O
research	O
study	O
,	O
the	O
os	B-ANAT
coxae	I-ANAT
shape	O
is	O
analyzed	O
using	O
geometric	O
morphometrics	B-PROC
,	O
providing	O
information	O
on	O
morphology	O
,	O
regardless	O
of	O
size	B-PHYS
or	O
any	O
other	O
factor	O
beyond	O
the	O
geometry	O
itself	O
.	O

A	O
total	O
of	O
46	O
adult	B-LIVB
ossa	B-ANAT
coxae	I-ANAT
from	O
a	O
Spanish	B-LIVB
archaeological	O
collection	B-PROC
were	O
studied	O
using	O
geometric	O
morphometrics	B-PROC
.	O

The	O
results	O
show	O
that	O
there	O
is	O
a	O
restriction	O
on	O
the	O
shape	O
of	O
female	B-PHYS
os	B-ANAT
coxae	I-ANAT
.	O

In	O
contrast	O
,	O
male	B-PHYS
os	B-ANAT
coxae	I-ANAT
presents	O
a	O
greater	O
range	O
of	O
variation	O
.	O

The	O
biological	B-DISO
reason	I-DISO
for	O
this	O
difference	O
is	O
the	O
obstetrical	O
dilemma	O
;	O
a	O
concept	O
defined	O
as	O
the	O
anatomical	O
conflict	O
between	O
bipedalism	B-PHYS
and	O
the	O
full	O
-	O
term	O
birth	B-PHYS
of	O
a	O
neonate	B-LIVB
whose	O
large	B-DISO
head	I-DISO
requires	O
greater	O
dimensions	O
in	O
the	O
pelvic	B-ANAT
cavity	I-ANAT
.	O

Our	O
experimental	O
data	O
reinforce	O
the	O
validity	O
of	O
the	O
obstetrical	O
dilemma	O
as	O
source	O
of	O
the	O
restriction	O
on	O
the	O
shape	O
of	O
female	B-PHYS
ossa	B-ANAT
coxae	I-ANAT
.	O

Additionally	O
,	O
according	O
to	O
the	O
results	B-DISO
obtained	O
,	O
size	B-PHYS
itself	O
does	O
not	O
represent	O
a	O
condition	O
for	O
belonging	O
to	O
one	O
sex	B-PHYS
or	O
another	O
.	O

Single	B-PROC
-	I-PROC
cell	I-PROC
analyses	I-PROC
of	O
X	B-DISO
Chromosome	I-DISO
inactivation	I-DISO
dynamics	B-PHEN
and	O
pluripotency	O
during	O
differentiation	B-PHYS
Pluripotency	O
,	O
differentiation	B-PHYS
,	O
and	O
X	B-DISO
Chromosome	I-DISO
inactivation	I-DISO
(	O
XCI	B-DISO
)	O
are	O
key	O
aspects	O
of	O
embryonic	B-PHYS
development	I-PHYS
.	O

However	O
,	O
the	O
underlying	O
relationship	O
and	O
mechanisms	O
among	O
these	O
processes	B-PHEN
remain	O
unclear	O
.	O

Here	O
,	O
we	O
systematically	O
dissected	O
these	O
features	O
along	O
developmental	O
progression	O
using	O
mouse	B-ANAT
embryonic	I-ANAT
stem	I-ANAT
cells	I-ANAT
(	O
mESCs	B-ANAT
)	O
and	O
single	B-ANAT
-	I-ANAT
cell	I-ANAT
RNA	B-PROC
sequencing	I-PROC
with	O
allelic	O
resolution	O
.	O

We	O
found	O
that	O
mESCs	B-ANAT
grown	O
in	O
a	O
ground	B-CHEM
state	I-CHEM
2i	I-CHEM
condition	I-CHEM
displayed	O
transcriptomic	O
profiles	O
diffused	O
from	O
preimplantation	B-PROC
mouse	B-ANAT
embryonic	I-ANAT
cells	I-ANAT
,	O
whereas	O
EpiStem	B-ANAT
cells	I-ANAT
closely	O
resembled	O
the	O
post	B-PROC
-	I-PROC
implantation	I-PROC
epiblast	B-ANAT
.	O

Sex	B-PHYS
-related	O
gene	B-PHYS
expression	I-PHYS
varied	O
greatly	O
across	O
distinct	O
developmental	O
states	O
.	O

We	O
also	O
identified	O
novel	B-PHYS
markers	I-PHYS
that	O
were	O
highly	O
enriched	O
in	O
each	O
developmental	O
state	O
.	O

Moreover	O
,	O
we	O
revealed	O
that	O
several	O
novel	O
pathways	O
,	O
including	O
PluriNetWork	O
and	O
Focal	B-ANAT
Adhesion	I-ANAT
,	O
were	O
responsible	B-DISO
for	I-DISO
the	O
delayed	O
progression	O
of	O
female	B-PHYS
EpiStem	B-ANAT
cells	I-ANAT
.	O

Importantly	O
,	O
we	O
""""	O
digitalized	O
""""	O
XCI	B-DISO
progression	O
using	O
allelic	O
expression	B-PHYS
of	O
active	O
and	O
inactive	O
X	B-ANAT
Chromosomes	I-ANAT
and	O
surprisingly	O
found	O
that	O
XCI	B-DISO
states	O
exhibited	O
profound	O
variability	O
in	O
each	O
developmental	O
state	O
,	O
including	O
the	O
2i	O
condition	O
.	O

XCI	B-DISO
progression	O
was	O
not	O
tightly	O
synchronized	O
with	O
loss	O
of	O
pluripotency	O
and	O
increase	O
of	O
differentiation	B-PHYS
at	O
the	O
single	B-ANAT
-	I-ANAT
cell	I-ANAT
level	O
,	O
although	O
these	O
processes	B-PHEN
were	O
globally	O
correlated	O
.	O

In	O
addition	O
,	O
highly	O
expressed	O
genes	O
,	O
including	O
core	O
pluripotency	O
factors	O
,	O
were	O
in	O
general	O
biallelically	O
expressed	B-PHYS
.	O

Taken	O
together	O
,	O
our	O
study	O
sheds	O
light	O
on	O
the	O
dynamics	B-PHEN
of	O
XCI	B-DISO
progression	O
and	O
the	O
asynchronicity	O
between	O
pluripotency	O
,	O
differentiation	O
,	O
and	O
XCI	B-DISO
.	O

Can	O
We	O
Predict	O
Burnout	B-DISO
among	O
Student	B-LIVB
Nurses	I-LIVB
?	O
An	O
Exploration	O
of	O
the	O
ICWR	O
-	O
1	O
Model	O
of	O
Individual	B-LIVB
Psychological	O
Resilience	O
The	O
nature	O
of	O
nursing	O
work	O
is	O
demanding	B-PROC
and	O
can	O
be	O
stressful	O
.	O

Previous	O
studies	O
have	O
shown	O
a	O
high	O
rate	O
of	O
burnout	B-DISO
among	O
employed	B-DISO
nurses	B-LIVB
.	O

Recently	O
,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	O
in	O
determining	O
the	O
psychological	O
adjustment	O
of	O
employed	B-DISO
nurses	B-LIVB
.	O

A	O
theoretical	O
model	O
of	O
resilience	O
was	O
proposed	O
recently	O
that	O
includes	O
several	O
constructs	O
identified	O
in	O
the	O
literature	O
related	O
to	O
resilience	O
and	O
to	O
psychological	B-PHYS
functioning	I-PHYS
.	O

As	O
nursing	B-LIVB
students	I-LIVB
are	O
the	O
future	O
of	O
the	O
nursing	O
workforce	B-LIVB
it	O
is	O
important	O
to	O
advance	O
our	O
understanding	O
of	O
the	O
determinants	O
of	O
resilience	O
in	O
this	O
population	B-LIVB
.	O

Student	B-LIVB
nurses	I-LIVB
who	O
had	O
completed	O
their	O
final	O
practicum	B-PROC
were	O
invited	O
to	O
participate	O
in	O
an	O
online	O
survey	O
measuring	O
the	O
key	O
constructs	O
of	O
the	O
ICWR	O
-	O
1	O
model	O
.	O

422	O
students	B-LIVB
from	O
across	O
Australia	B-GEOG
and	O
Canada	B-GEOG
completed	O
the	O
survey	O
between	O
July	O
2014	O
and	O
July	O
2015	O
.	O

As	O
well	O
as	O
several	O
key	O
demographics	O
,	O
trait	B-DISO
negative	I-DISO
affect	I-DISO
,	O
mindfulness	B-PHYS
,	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O
coping	O
,	O
resilience	O
,	O
and	O
burnout	B-DISO
were	O
measured	O
.	O

We	O
used	O
structural	B-PROC
equation	I-PROC
modeling	I-PROC
and	O
found	O
support	O
for	O
the	O
major	O
pathways	O
of	O
the	O
model	O
;	O
namely	O
that	O
resilience	O
had	O
a	O
significant	O
influence	O
on	O
the	O
relationship	O
between	O
mindfulness	B-PHYS
,	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
and	O
coping	O
,	O
and	O
psychological	O
adjustment	O
(	O
burnout	B-DISO
scores	O
)	O
.	O

Furthermore	O
,	O
as	O
predicted	O
,	O
Neuroticism	B-DISO
moderated	O
the	O
relationship	O
between	O
coping	O
and	O
burnout	B-DISO
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	O
approaches	O
to	O
supporting	O
nursing	B-LIVB
students	I-LIVB
who	O
may	O
be	O
at	O
risk	O
of	O
burnout	B-DISO
.	O

Prevalence	O
of	O
Psychoactive	B-CHEM
Substance	I-CHEM
Consumption	O
in	O
People	B-LIVB
With	O
Obesity	B-DISO
The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
evaluate	B-PROC
the	O
prevalence	O
and	O
the	O
kind	O
of	O
psychoactive	B-CHEM
substances	I-CHEM
consumed	O
by	O
people	B-LIVB
with	O
obesity	B-DISO
.	O

Patients	B-LIVB
were	O
included	O
at	O
their	O
first	O
visit	O
for	O
bariatric	B-PROC
surgery	I-PROC
.	O

Socio	B-PROC
-	I-PROC
demographic	I-PROC
characteristics	O
,	O
anxiety	B-DISO
,	O
depressive	B-DISO
disorders	I-DISO
and	O
psychoactive	B-CHEM
substance	I-CHEM
consumption	O
were	O
assessed	B-PROC
.	O

The	O
prevalence	O
of	O
psychoactive	B-CHEM
substance	I-CHEM
consumption	O
was	O
compared	O
to	O
that	O
of	O
the	O
general	B-LIVB
population	I-LIVB
reported	B-PROC
by	O
the	O
French	O
National	O
Institute	O
of	O
Prevention	O
and	O
Health	O
Education	O
.	O

One	O
hundred	O
(	O
100	O
)	O
patients	B-LIVB
were	O
consecutively	O
recruited	O
:	O
60	O
women	B-LIVB
(	O
mean	O
age	B-PHYS
41	O
±	O
14	O
years	O
)	O
and	O
40	O
men	B-LIVB
(	O
mean	O
age	B-PHYS
46	O
±	O
13	O
years	O
)	O
.	O

Sixty	O
-	O
seven	O
percent	O
of	O
subjects	B-LIVB
consumed	O
alcohol	O
.	O

Consumption	O
rates	O
of	O
cannabis	B-CHEM
(	O
21	O
%	O
vs	O
.	O
10	O
%	O
)	O
,	O
cocaine	B-CHEM
(	O
7	O
.	O
0	O
%	O
vs	O
.	O

0	O
.	O
8	O
%	O
)	O
and	O
amphetamine	B-CHEM
(	O
6	O
.	O
0	O
%	O
vs	O
.	O

0	O
.	O
3	O
%	O
)	O
were	O
significantly	O
(	O
p	O
<	O
.0001	O
)	O
higher	O
in	O
people	B-LIVB
with	O
obesity	B-DISO
than	O
in	O
the	O
general	B-LIVB
population	I-LIVB
.	O

People	B-LIVB
with	O
obesity	B-DISO
have	O
an	O
excess	O
risk	O
of	O
amphetamine	B-CHEM
,	O
cocaine	B-CHEM
and	O
cannabis	B-CHEM
consumption	O
.	O

This	O
consumption	O
may	O
increase	O
the	O
risk	O
of	O
cardiovascular	B-DISO
and	O
psychiatric	O
morbidity	O
and	O
should	O
therefore	O
be	O
detected	B-PROC
before	O
surgery	O
.	O

Comparison	O
of	O
semiologies	O
between	O
tilt	O
-	O
induced	O
psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
and	O
psychogenic	B-DISO
nonepileptic	B-DISO
seizures	I-DISO
We	O
sought	O
to	O
characterize	O
the	O
clinical	O
features	O
of	O
tilt	O
-	O
induced	O
psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
(	O
PNSC	B-DISO
)	O
from	O
a	O
cohort	B-LIVB
of	O
young	O
patients	B-LIVB
and	O
to	O
compare	O
the	O
semiologies	O
between	O
PNSC	B-DISO
and	O
EEG	B-PROC
-confirmed	O
psychogenic	B-DISO
nonepileptic	B-DISO
seizures	I-DISO
(	O
PNES	B-DISO
)	O
.	O

A	O
PNSC	B-DISO
diagnosis	B-DISO
was	O
made	O
if	O
a	O
clinical	O
event	O
occurred	O
during	O
tilt	B-PROC
-	I-PROC
table	I-PROC
testing	I-PROC
that	O
the	O
patient	B-LIVB
regarded	O
as	O
fainting	B-DISO
,	O
but	O
neither	B-DISO
hypotension	B-DISO
nor	O
EEG	B-PROC
changes	O
were	O
present	O
.	O

A	O
diagnosis	B-DISO
of	O
PNSC	B-DISO
was	O
made	O
in	O
17	O
.	O

6	O
%	O
of	O
all	O
patients	B-LIVB
referred	O
during	O
the	O
15	O
-	O
month	O
study	O
period	O
.	O

Cohorts	B-LIVB
with	O
psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
(	O
n	O
=	O
40	O
)	O
and	O
PNES	B-DISO
(	O
n	O
=	O
40	O
)	O
did	O
not	O
differ	O
in	O
age	B-PHYS
(	O
15	O
.	O

5±2	O
.	O

2	O
versus	O
14	O
.	O

6±2	O
.	O

7	O
,	O
p	O
=	O
.	O

11	O
)	O
or	O
female	B-PHYS
gender	I-PHYS
(	O
80	O
%	O
versus	O
72	O
.	O
5	O
%	O
,	O
p	O
=	O
.	O

43	O
)	O
.	O

Psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
events	O
were	O
briefer	O
than	O
PNES	B-DISO
events	O
(	O
median	O
:	O
45	O
versus	O
201	O
.	O

5s	O
,	O
p	O
<	O
.	O
001	O
)	O
.	O

Negative	B-DISO
motor	I-DISO
signs	I-DISO
(	O
head	B-DISO
drop	I-DISO
,	O
body	B-DISO
limpness	I-DISO
)	O
predominated	O
in	O
PNSC	B-DISO
(	O
85	O
%	O
versus	O
20	O
%	O
,	O
p	O
<	O
.	O
001	O
)	O
,	O
while	O
the	O
positive	B-DISO
motor	I-DISO
signs	I-DISO
of	O
convulsion	B-DISO
occurred	O
more	O
often	O
with	O
PNES	B-DISO
(	O
90	O
%	O
versus	O
30	O
%	O
,	O
p	O
<	O
.	O

001	O
)	O
.	O

Behavioral	B-DISO
arrest	I-DISO
(	O
25	O
%	O
versus	O
32	O
.	O
5	O
%	O
,	O
p	O
=	O
.	O

46	O
)	O
and	O
eye	B-DISO
closure	I-DISO
(	O
85	O
%	O
versus	O
72	O
.	O
5	O
%	O
,	O
p	O
=	O
.	O

21	O
)	O
did	O
not	O
differ	O
between	O
PNSC	B-DISO
and	O
PNES	B-DISO
.	O

Patients	B-LIVB
with	O
PNSC	B-DISO
were	O
more	O
likely	O
to	O
be	O
tearful	B-DISO
before	O
(	O
30	O
%	O
versus	O
7	O
.	O

5	O
%	O
,	O
p	O
=	O
.	O

02	O
)	O
and	O
after	O
(	O
62	O
.	O
5	O
%	O
versus	O
7	O
.	O
5	O
%	O
,	O
p	O
<	O
.	O

001	O
)	O
an	O
event	O
.	O

In	O
conclusion	O
,	O
although	O
overlap	O
exists	O
,	O
the	O
features	O
of	O
PNSC	B-DISO
generally	O
appear	O
similar	O
to	O
neurally	B-DISO
mediated	I-DISO
syncope	I-DISO
,	O
while	O
the	O
features	O
of	O
PNES	B-DISO
generally	O
appear	O
similar	O
to	O
epileptic	B-DISO
seizures	I-DISO
.	O

Psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
and	O
PNES	B-DISO
likely	O
represent	O
similar	O
disorders	B-DISO
that	O
differ	O
primarily	O
by	O
clinical	O
semiologies	O
and	O
referral	O
patterns	O
.	O

Medication	B-PROC
Intervention	I-PROC
for	O
Chronic	B-DISO
Kidney	I-DISO
Disease	I-DISO
Patients	B-LIVB
Transitioning	O
from	O
Hospital	B-OBJC
to	O
Home	O
:	O
Study	B-PROC
Design	I-PROC
and	O
Baseline	O
Characteristics	O
The	O
hospital	B-PROC
readmission	I-PROC
rate	O
in	O
the	O
population	B-LIVB
with	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
(	O
CKD	B-DISO
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
CKD	B-DISO
-	O
Medication	B-PROC
Intervention	I-PROC
Trial	I-PROC
(	O
CKD	B-DISO
-	O
MIT	B-PROC
;	O
www	O
.	O
clinicaltrials	O
.	O

gov	O
;	O
NCTO1459770	O
)	O
is	O
a	O
single	B-PROC
-	I-PROC
blind	I-PROC
(	O
investigators	B-LIVB
)	O
,	O
randomized	B-PROC
,	O
clinical	B-PROC
trial	I-PROC
conducted	O
at	O
Providence	B-PROC
Health	I-PROC
Care	I-PROC
in	O
Spokane	B-GEOG
,	I-GEOG
Washington	I-GEOG
.	O

Study	B-LIVB
participants	I-LIVB
are	O
hospitalized	B-LIVB
patients	I-LIVB
with	O
CKD	B-DISO
stages	O
3	O
-	O
5	O
(	O
not	O
treated	B-PROC
with	I-PROC
kidney	B-PROC
replacement	I-PROC
therapy	I-PROC
)	O
and	O
acute	B-DISO
illness	I-DISO
.	O

The	O
study	O
intervention	O
is	O
a	O
pharmacist	B-LIVB
-	I-LIVB
led	I-LIVB
,	O
home	B-PROC
-	I-PROC
based	I-PROC
,	O
medication	B-PROC
management	I-PROC
intervention	B-PROC
delivered	O
within	O
7	O
days	O
after	O
hospital	B-PROC
discharge	I-PROC
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	B-PROC
readmissions	I-PROC
and	O
visits	O
to	O
emergency	B-OBJC
departments	I-OBJC
and	O
urgent	B-OBJC
care	I-OBJC
centers	I-OBJC
for	O
90	O
days	O
following	O
hospital	B-PROC
discharge	I-PROC
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	O
-	O
based	O
targets	O
for	O
CKD	B-DISO
risk	B-DISO
factors	I-DISO
and	O
complications	B-DISO
.	O

Enrollment	B-PROC
began	O
in	O
February	O
2012	O
and	O
ended	O
in	O
May	O
2015	O
.	O

At	O
baseline	O
,	O
the	O
age	B-PHYS
of	O
participants	B-LIVB
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	B-LIVB
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	B-DISO
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	B-DISO
.	O

At	O
baseline	O
,	O
the	O
estimated	B-PROC
glomerular	I-PROC
filtration	I-PROC
rate	O
was	O
41	O
±	O
14	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
and	O
urine	B-PROC
albumin	I-PROC
-	I-PROC
to	I-PROC
-	I-PROC
creatinine	I-PROC
ratio	I-PROC
was	O
43	O
mg	O
/	O
g	O
(	O
interquartile	O
range	O
8	O
-	O
528	O
mg	O
/	O
g	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	B-PROC
admission	I-PROC
was	O
cardiovascular	B-DISO
diseases	I-DISO
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	B-DISO
diagnosis	I-DISO
for	O
admission	B-PROC
was	O
community	O
-	O
acquired	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

Participants	B-LIVB
in	O
CKD	B-DISO
-	O
MIT	B-PROC
are	O
typical	O
of	O
acutely	B-DISO
ill	I-DISO
hospitalized	B-LIVB
patients	I-LIVB
with	O
CKD	B-DISO
.	O

A	O
medication	B-PROC
management	I-PROC
intervention	B-PROC
after	O
hospital	B-PROC
discharge	I-PROC
is	O
under	O
study	B-PROC
to	O
reduce	O
post	O
-	O
hospitalization	B-PROC
acute	B-PROC
care	I-PROC
utilization	O
and	O
to	O
improve	O
CKD	B-DISO
management	B-PROC
.	O

DEPRESSION	B-DISO
,	O
ANXIETY	B-DISO
,	O
STRESS	B-DISO
,	O
AND	O
THEIR	O
ASSOCIATED	O
FACTORS	O
AMONG	O
CORPS	B-LIVB
MEMBERS	I-LIVB
SERVING	O
IN	O
KEBBI	O
STATE	O
Depression	B-DISO
,	O
anxiety	B-DISO
and	O
stress	B-DISO
,	O
are	O
not	O
only	O
health	B-DISO
problems	I-DISO
by	O
themselves	O
,	O
but	O
also	O
associated	O
with	O
other	O
negative	B-DISO
health	O
consequences	O
.	O

The	O
national	O
youth	O
service	O
is	O
usually	O
characterized	O
by	O
a	O
number	O
of	O
new	O
challenges	O
and	O
experiences	B-PHYS
which	O
may	O
require	O
life	O
style	O
adjustments	O
by	O
the	O
corps	B-LIVB
member	I-LIVB
.	O

However	O
,	O
no	O
previous	O
study	O
on	O
psychological	B-PHYS
factors	I-PHYS
has	O
been	O
conducted	O
among	O
corps	B-LIVB
members	I-LIVB
.	O

This	O
study	B-PROC
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
depression	B-DISO
,	O
anxiety	B-DISO
and	O
,	O
stress	B-DISO
and	O
their	O
associated	O
factors	O
among	O
corps	B-LIVB
members	I-LIVB
serving	O
in	O
Kebbi	O
state	O
.	O

A	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
was	O
conducted	O
among	O
264	O
corps	B-LIVB
members	I-LIVB
from	O
four	O
local	O
government	O
areas	O
of	O
the	O
state	B-GEOG
.	O

Selection	O
of	O
the	O
local	O
government	O
areas	O
and	O
the	O
individual	O
participants	B-LIVB
was	O
by	O
simple	B-PROC
random	I-PROC
sampling	I-PROC
.	O

Data	O
was	O
collected	O
from	O
May	O
to	O
June	O
2014	O
using	O
a	O
self	O
-	O
administered	O
questionnaire	O
.	O

Data	O
analysis	O
used	O
chi	O
-	O
square	O
test	O
to	O
identify	O
the	O
relationship	O
between	O
categorical	O
variables	O
and	O
multivariate	B-PROC
logistic	I-PROC
regression	I-PROC
to	O
identify	O
the	O
independent	O
factors	O
for	O
depression	B-DISO
,	O
anxiety	B-DISO
and	O
stress	B-DISO
each	O
.	O

The	O
response	O
rate	O
was	O
97	O
%	O
.	O

Most	O
of	O
the	O
respondents	B-LIVB
were	O
males	B-PHYS
(	O
63	O
.	O
6	O
%	O
)	O
,	O
single	B-LIVB
(	O
85	O
.	O
5	O
%	O
)	O
,	O
and	O
above	O
20	O
years	O
of	O
age	B-PHYS
(	O
71	O
.	O
6	O
%	O
)	O
.	O

The	O
overall	O
prevalences	O
of	O
depression	B-DISO
,	O
anxiety	B-DISO
and	O
stress	B-DISO
among	O
the	O
respondents	B-LIVB
were	O
36	O
.	O

4	O
%	O
,	O
54	O
.	O

5	O
%	O
and	O
18	O
.	O
2	O
%	O
respectively	O
.	O

The	O
independent	O
factors	O
for	O
depression	B-DISO
were	O
;	O
being	O
from	O
the	O
North	B-GEOG
central	I-GEOG
(	O
OR	O
=	O
5	O
.	O

99	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
194	O
-	O
16	O
.	O
354	O
)	O
or	O
South	B-GEOG
-	I-GEOG
south	I-GEOG
;	O
and	O
the	O
perception	B-PHYS
of	O
earning	O
enough	O
income	O
(	O
OR	O
=	O
2	O
.	O
987	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
062	O
-	O
8	O
.	O
400	O
)	O
.	O

For	O
anxiety	B-DISO
,	O
male	B-PHYS
gender	I-PHYS
(	O
OR	O
=	O
0	O
.	O
411	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
169	O
-	O
0	O
.	O
999	O
)	O
;	O
and	O
being	O
from	O
the	O
North	B-GEOG
central	I-GEOG
were	O
significant	O
risk	B-DISO
factors	I-DISO
(	O
OR	O
=	O
3	O
.	O

731	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
450	O
-	O
9	O
.	O
599	O
)	O
.	O

Being	O
above	O
26	O
years	O
of	O
age	B-PHYS
was	O
an	O
independent	O
risk	B-DISO
factor	I-DISO
for	O
stress	B-DISO
(	O
OR	O
=	O
0	O
.	O
083	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
018	O
-	O
0	O
.	O
381	O
)	O
.	O

Also	O
,	O
those	O
who	O
had	O
ever	O
schooled	B-DISO
outside	O
their	O
towns	B-GEOG
of	O
residence	O
were	O
less	O
likely	O
to	O
be	O
stressed	B-PHYS
compared	O
to	O
those	O
who	O
had	O
never	O
(	O
OR	O
=	O
0	O
.	O
30	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
110	O
-	O
0	O
.	O
855	O
)	O
.	O

All	O
other	O
factors	O
did	O
not	O
show	O
any	O
significant	O
association	O
with	O
any	O
of	O
the	O
outcome	O
variables	O
in	O
multivariate	O
analysis	O
.	O

In	O
conclusion	O
,	O
the	O
prevalences	O
of	O
depression	B-DISO
,	O
anxiety	B-DISO
and	O
stress	B-DISO
are	O
high	O
among	O
corps	B-LIVB
members	I-LIVB
serving	O
in	O
Kebbi	O
state	O
.	O

There	O
is	O
need	O
to	O
expand	O
the	O
scope	O
of	O
this	O
study	B-PROC
to	O
a	O
national	O
level	O
so	O
as	O
to	O
get	O
a	O
bigger	O
picture	O
of	O
the	O
problem	B-DISO
.	O

Direct	O
Repair	B-PROC
of	O
Lumbar	B-ANAT
Pars	I-ANAT
Interarticularis	I-ANAT
Defects	O
by	O
Utilizing	O
Intraoperative	B-DEVI
O	I-DEVI
-	I-DEVI
Arm	I-DEVI
-	I-DEVI
Based	I-DEVI
Navigation	I-DEVI
and	O
Microendoscopic	B-PROC
Techniques	I-PROC
A	O
retrospective	B-PROC
analysis	I-PROC
of	O
the	O
clinical	B-DISO
outcomes	I-DISO
of	O
eight	O
patients	B-LIVB
with	O
the	O
lumbar	B-ANAT
pars	I-ANAT
interarticulars	I-ANAT
defects	O
treated	B-DISO
by	O
direct	O
repair	B-PROC
with	O
the	O
aid	O
of	O
intraoperative	B-DEVI
O	I-DEVI
-	I-DEVI
arm	I-DEVI
based	I-DEVI
navigation	I-DEVI
and	O
microendoscopic	B-PROC
techniques	I-PROC
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	B-PHEN
of	O
direct	O
screw	B-DEVI
repair	B-PROC
by	O
using	O
minimally	B-PROC
invasive	I-PROC
surgery	I-PROC
for	O
the	O
lumbar	B-ANAT
pars	I-ANAT
interarticulars	I-ANAT
defects	O
in	O
a	O
pilot	B-PROC
study	I-PROC
.	O

Direct	O
repair	B-PROC
of	O
pars	B-ANAT
interarticulars	I-ANAT
defects	O
has	O
been	O
used	O
to	O
treat	B-PROC
young	B-LIVB
adult	I-LIVB
patients	B-LIVB
.	O

Reports	O
concerning	O
direct	O
repair	B-PROC
by	O
minimally	B-PROC
invasive	I-PROC
techniques	I-PROC
for	O
pars	B-ANAT
interarticulars	I-ANAT
defects	O
are	O
quite	O
rare	O
.	O

Review	O
of	O
medical	O
records	O
identified	O
eight	O
consecutive	O
patients	B-LIVB
treated	B-DISO
with	O
intraoperative	B-DEVI
O	I-DEVI
-	I-DEVI
arm	I-DEVI
based	I-DEVI
navigation	I-DEVI
and	O
microendoscopic	B-PROC
techniques	I-PROC
.	O

Debridement	B-PROC
and	O
autograft	B-PROC
of	O
pars	B-ANAT
interarticularis	I-ANAT
defects	O
was	O
performed	O
under	O
microendoscopic	B-PROC
procedure	I-PROC
.	O

Then	O
,	O
percutaneous	O
bilateral	O
intralaminar	O
screws	B-DEVI
were	O
inserted	B-PROC
by	O
utilizing	O
intraoperative	B-DEVI
navigation	I-DEVI
.	O

The	O
clinical	O
and	O
radiological	O
data	O
were	O
collected	O
and	O
analyzed	B-PROC
retrospectively	O
.	O

Eight	O
patients	B-LIVB
had	O
a	O
mean	O
age	B-PHYS
of	O
28	O
.	O

4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	O
at	O
the	O
time	O
of	O
treatment	B-PROC
.	O

Symptoms	B-DISO
included	O
axial	O
back	B-DISO
pain	I-DISO
in	O
100	O
%	O
of	O
patients	B-LIVB
without	O
concomitant	O
radiculopathy	B-DISO
.	O

Autograft	B-PROC
was	O
used	O
in	O
all	O
cases	O
.	O

The	O
average	O
follow	B-PROC
-	I-PROC
up	I-PROC
duration	O
was	O
27	O
.	O

4	O
months	O
with	O
a	O
range	O
of	O
20	O
to	O
33	O
months	O
.	O

Symptoms	B-DISO
resolved	B-DISO
completely	O
or	O
partially	O
in	O
all	O
patients	B-LIVB
.	O

Low	B-DISO
back	I-DISO
pain	I-DISO
visual	B-PHYS
analog	I-PHYS
scores	I-PHYS
decrease	O
from	O
preoperative	O
6	O
.	O

8	O
to	O
postoperative	O
1	O
.	O
4	O
of	O
eight	O
cases	O
.	O

Of	O
16	O
pars	B-ANAT
defects	O
,	O
healing	B-PHYS
was	O
observed	O
in	O
13	O
(	O
81	O
.	O

3	O
%	O
)	O
at	O
last	O
radiological	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

One	O
patient	B-LIVB
with	O
bilateral	B-DISO
fusion	I-DISO
failure	I-DISO
refused	O
revision	B-PROC
surgery	I-PROC
because	O
of	O
mild	B-DISO
complaint	I-DISO
.	O

No	B-DISO
complications	I-DISO
such	O
as	O
dural	B-DISO
tear	I-DISO
,	O
nerve	B-DISO
root	I-DISO
injury	I-DISO
,	O
and	O
infection	B-DISO
occurred	O
.	O

Minimally	B-PROC
invasive	I-PROC
direct	O
repair	B-PROC
of	O
the	O
pars	B-ANAT
interarticularis	I-ANAT
defects	O
with	O
intralaminar	O
screws	B-DEVI
by	O
using	O
microendoscopic	B-PROC
system	I-PROC
and	O
navigation	B-DEVI
procedure	I-DEVI
can	O
provide	O
safe	O
and	O
effective	O
treatment	B-PROC
of	O
spondylolysis	B-DISO
with	O
satisfactory	O
clinical	O
and	O
radiological	O
outcomes	O
,	O
which	O
need	O
some	O
special	B-DEVI
tools	I-DEVI
with	O
steep	O
learning	B-PHYS
curve	I-PHYS
.	O

4	O
.	O

Evidence	O
-Based	O
Review	O
and	O
Survey	O
of	O
Expert	O
Opinion	O
of	O
Reconstruction	B-PROC
of	O
Metastatic	B-DISO
Spine	I-DISO
Tumors	I-DISO
Systematic	O
review	O
and	O
consensus	O
expert	O
opinion	O
.	O

To	O
provide	O
surgeons	B-LIVB
and	O
other	O
health	B-LIVB
care	I-LIVB
professionals	I-LIVB
with	O
guidelines	O
for	O
surgical	B-PROC
reconstruction	I-PROC
of	O
metastatic	B-DISO
spine	B-DISO
disease	I-DISO
based	O
on	O
evidence	O
and	O
expert	O
opinion	O
.	O

The	O
surgical	B-PROC
treatment	I-PROC
of	O
spinal	B-DISO
metastases	I-DISO
is	O
controversial	O
.	O

Specifically	O
two	O
aspects	O
of	O
surgical	B-PROC
reconstruction	I-PROC
are	O
addressed	O
in	O
this	O
study	O
:	O
(	O
i	O
)	O
choice	O
of	O
bone	B-PROC
graft	I-PROC
used	O
during	O
surgery	B-PROC
for	O
metastatic	B-DISO
spine	I-DISO
tumors	I-DISO
and	O
(	O
ii	O
)	O
the	O
design	O
of	O
reconstruction	B-PROC
or	O
construct	B-CHEM
to	O
stabilize	B-DISO
.	O

A	O
systematic	O
review	O
of	O
the	O
available	O
medical	O
literature	O
from	O
1980	O
to	O
2015	O
was	O
conducted	O
,	O
and	O
combined	O
with	O
consensus	O
expert	O
opinion	O
from	O
a	O
recent	O
survey	O
of	O
spine	B-ANAT
surgeons	B-LIVB
who	O
treat	B-PROC
metastatic	B-DISO
spine	I-DISO
tumors	I-DISO
.	O

There	O
is	O
very	O
little	O
evidence	O
in	O
the	O
literature	O
to	O
provide	O
guidance	B-PROC
on	O
the	O
use	O
of	O
bone	B-PROC
graft	I-PROC
in	O
metastatic	B-DISO
tumor	I-DISO
reconstruction	B-PROC
.	O

There	O
is	O
little	O
evidence	O
in	O
the	O
literature	O
to	O
support	O
the	O
preferential	O
use	O
of	O
one	O
graft	O
type	O
over	O
the	O
other	O
.	O

Approximately	O
,	O
41	O
%	O
of	O
respondents	B-LIVB
said	O
they	O
used	O
bone	B-PROC
graft	I-PROC
or	O
bone	B-PROC
graft	I-PROC
substitutes	B-CHEM
to	O
accomplish	O
fusion	B-PROC
.	O

There	O
were	O
17	O
studies	B-PROC
that	O
described	O
the	O
use	O
of	O
a	O
prefabricated	B-DEVI
prosthetic	I-DEVI
,	O
10	O
studies	B-PROC
describing	O
the	O
use	O
of	O
polymethyl	B-CHEM
methacrylate	I-CHEM
(	O
PMMA	B-CHEM
)	O
bone	B-CHEM
cement	I-CHEM
,	O
and	O
only	O
three	O
studies	B-PROC
describing	O
the	O
use	O
of	O
bone	B-PROC
graft	I-PROC
for	O
anterior	O
column	B-ANAT
reconstruction	B-PROC
.	O

The	O
use	O
of	O
structural	B-PROC
allograft	I-PROC
was	O
most	O
popular	O
among	O
the	O
experts	B-LIVB
for	O
anterior	O
reconstruction	B-PROC
,	O
followed	O
by	O
cage	B-DEVI
reconstruction	B-PROC
,	O
and	O
PMMA	B-CHEM
bone	B-CHEM
cement	I-CHEM
.	O

Achieving	O
bony	B-ANAT
union	I-ANAT
may	O
be	O
of	O
importance	O
for	O
the	O
maintenance	O
of	O
spinal	B-ANAT
stability	O
in	O
the	O
long	O
term	O
after	O
reconstruction	B-PROC
.	O

Whether	O
bony	B-ANAT
union	I-ANAT
is	O
required	O
for	O
patients	B-LIVB
with	O
shorter	O
life	O
expectancies	O
is	O
debatable	O
.	O

The	O
literature	O
supports	O
the	O
use	O
of	O
anterior	O
reconstruction	B-PROC
with	O
either	O
a	O
prefabricated	B-DEVI
prosthetic	I-DEVI
or	O
PMMA	B-CHEM
bone	B-CHEM
cement	I-CHEM
.	O

It	O
also	O
supports	O
the	O
use	O
of	O
an	O
anterior	O
construct	B-CHEM
reinforced	O
with	O
bilateral	O
posterior	O
instrumentation	O
when	O
performing	B-PROC
a	O
three	B-PROC
-	I-PROC
column	I-PROC
reconstruction	I-PROC
.	O

N	O
/	O
A	O
.	O

The	O
value	O
of	O
transesophageal	B-PROC
echocardiography	I-PROC
for	O
embolic	B-DISO
strokes	I-DISO
of	I-DISO
undetermined	I-DISO
source	I-DISO
Our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-PROC
yield	I-PROC
of	O
transesophageal	B-PROC
echocardiography	I-PROC
(	O
TEE	B-PROC
)	O
in	O
consecutive	O
patients	B-LIVB
with	O
ischemic	B-DISO
stroke	I-DISO
(	O
IS	B-DISO
)	O
fulfilling	O
the	O
diagnostic	O
criteria	O
of	O
embolic	B-DISO
strokes	I-DISO
of	I-DISO
undetermined	I-DISO
source	I-DISO
(	O
ESUS	B-DISO
)	O
.	O

We	O
prospectively	O
evaluated	O
consecutive	O
patients	B-LIVB
with	O
acute	O
IS	B-DISO
satisfying	O
ESUS	B-DISO
criteria	O
who	O
underwent	O
in	O
-	O
hospital	B-OBJC
TEE	B-PROC
examination	I-PROC
in	O
3	O
tertiary	B-OBJC
care	I-OBJC
stroke	I-OBJC
centers	I-OBJC
during	O
a	O
12	O
-	O
month	O
period	O
.	O

We	O
also	O
performed	O
a	O
systematic	O
review	O
and	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
estimating	I-PROC
the	O
cumulative	O
effect	O
of	O
TEE	B-PROC
findings	B-DISO
on	O
therapeutic	O
management	O
for	O
secondary	B-PROC
stroke	I-PROC
prevention	I-PROC
among	O
different	O
IS	B-DISO
subgroups	O
.	O

We	O
identified	O
61	O
patients	B-LIVB
with	O
ESUS	B-DISO
who	O
underwent	B-PROC
investigation	I-PROC
with	O
TEE	B-PROC
(	O
mean	O
age	O
44	O
±	O
12	O
years	O
,	O
49	O
%	O
men	B-LIVB
,	O
median	O
NIH	O
Stroke	O
Scale	O
score	O
=	O
5	O
points	O
[	O
interquartile	O
range	O
:	O
3	O
-	O
8	O
]	O
)	O
.	O

TEE	B-PROC
revealed	O
additional	O
findings	B-DISO
in	O
52	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
40	O
%	O
-	O
65	O
%	O
)	O
of	O
the	O
study	B-LIVB
population	I-LIVB
.	O

TEE	B-PROC
findings	B-DISO
changed	O
management	O
(	O
initiation	O
of	O
anticoagulation	B-PROC
therapy	I-PROC
,	O
administration	B-PROC
of	O
IV	B-PROC
antibiotic	I-PROC
therapy	I-PROC
,	O
and	O
patent	B-PROC
foramen	I-PROC
ovale	I-PROC
closure	I-PROC
)	O
in	O
10	O
(	O
16	O
%	O
[	O
95	O
%	O
CI	O
:	O
9	O
%	O
-	O
28	O
%	O
]	O
)	O
patients	B-LIVB
.	O

The	O
pooled	O
rate	O
of	O
reported	O
anticoagulation	B-PROC
therapy	I-PROC
attributed	O
to	O
abnormal	B-DISO
TEE	B-PROC
findings	B-DISO
among	O
3	O
,	O
562	O
acute	O
IS	B-DISO
patients	B-LIVB
included	O
in	O
the	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
(	O
12	O
studies	O
)	O
was	O
8	O
.	O

7	O
%	O
(	O
95	O
%	O
CI	O
:	O
7	O
.	O
3	O
%	O
-	O
10	O
.	O
4	O
%	O
)	O
.	O

In	O
subgroup	B-PROC
analysis	I-PROC
,	O
the	O
rates	O
of	O
initiation	O
of	O
anticoagulation	B-PROC
therapy	I-PROC
on	O
the	O
basis	O
of	O
TEE	B-PROC
investigation	O
did	O
not	O
differ	O
(	O
p	O
=	O
0	O
.	O
315	O
)	O
among	O
patients	B-LIVB
with	O
cryptogenic	O
stroke	O
(	O
6	O
.	O
9	O
%	O
[	O
95	O
%	O
CI	O
:	O
4	O
.	O
9	O
%	O
-	O
9	O
.	O
6	O
%	O
]	O
)	O
,	O
ESUS	B-DISO
(	O
8	O
.	O
1	O
%	O
[	O
95	O
%	O
CI	O
:	O
3	O
.	O
4	O
%	O
-	O
18	O
.	O
1	O
%	O
]	O
)	O
,	O
and	O
IS	B-DISO
(	O
9	O
.	O
4	O
%	O
[	O
95	O
%	O
CI	O
:	O
7	O
.	O
5	O
%	O
-	O
11	O
.	O
8	O
%	O
]	O
)	O
.	O

Abnormal	O
TEE	B-PROC
findings	B-DISO
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	O
therapeutic	B-PROC
strategy	I-PROC
in	O
approximately	O
1	O
of	O
7	O
patients	B-LIVB
with	O
ESUS	B-DISO
.	O

Trans	O
-	O
oral	O
fine	B-PROC
needle	I-PROC
aspiration	I-PROC
cytology	I-PROC
in	O
cervical	B-ANAT
(	I-ANAT
C1	I-ANAT
and	I-ANAT
C2	I-ANAT
)	I-ANAT
vertebral	I-ANAT
lesions	B-DISO
:	O
a	O
novel	O
diagnostic	B-PROC
approach	I-PROC
Fine	B-PROC
needle	I-PROC
aspiration	I-PROC
(	I-PROC
FNA	I-PROC
)	I-PROC
cytology	I-PROC
is	O
a	O
relatively	O
non	O
-	O
invasive	O
method	O
for	O
diagnosing	B-DISO
both	O
superficial	B-DISO
and	O
deep	B-DISO
-	I-DISO
seated	I-DISO
neoplastic	I-DISO
and	O
non	B-DISO
-	I-DISO
neoplastic	I-DISO
lesions	I-DISO
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
trans	O
-	O
oral	O
FNA	B-PROC
in	O
cervical	B-ANAT
(	I-ANAT
C1	I-ANAT
and	I-ANAT
C2	I-ANAT
)	I-ANAT
vertebral	I-ANAT
and	O
paravertebral	B-ANAT
lesions	B-DISO
.	O

Eighteen	O
FNA	B-PROC
cases	O
of	O
cervical	B-ANAT
vertebral	I-ANAT
and	O
paravertebral	B-ANAT
lesions	B-DISO
performed	O
by	O
a	O
trans	O
-	O
oral	O
route	O
without	O
any	O
image	B-PROC
-	I-PROC
guidance	I-PROC
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	O
department	O
at	O
PGIMER	O
,	O
Chandigarh	O
and	O
reviewed	O
.	O

Out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	B-DISO
was	O
given	O
in	O
15	O
cases	O
(	O
83	O
.	O
3	O
%	O
)	O
.	O

The	O
commonest	O
diagnosis	B-DISO
seen	O
was	O
granulomatous	B-DISO
inflammation	I-DISO
consistent	O
with	O
tuberculosis	B-DISO
(	O
33	O
.	O
3	O
%	O
)	O
.	O

Trans	O
-	O
oral	O
FNA	B-PROC
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	B-PROC
procedure	I-PROC
for	O
sampling	O
C1	B-ANAT
and	I-ANAT
C2	I-ANAT
vertebral	I-ANAT
and	O
paravertebral	B-ANAT
lesions	B-DISO
,	O
which	O
are	O
clinically	B-PHYS
and	O
radiologically	O
difficult	O
to	O
approach	O
.	O

It	O
helps	O
in	O
the	O
early	B-PROC
diagnosis	I-PROC
and	O
management	B-PROC
of	I-PROC
these	I-PROC
patients	I-PROC
.	O

Mediation	O
Analysis	O
for	O
Health	B-DISO
Disparities	I-DISO
Research	B-PROC
Social	O
epidemiologists	B-LIVB
often	O
seek	O
to	O
determine	O
the	O
mechanisms	O
that	O
underlie	O
health	B-DISO
disparities	I-DISO
.	O

This	O
work	O
is	O
typically	O
based	O
on	O
mediation	O
procedures	O
that	O
may	O
not	O
be	O
justified	O
with	O
exposures	B-DISO
of	O
common	O
interest	B-PHYS
in	O
social	O
epidemiology	O
.	O

In	O
this	O
analysis	O
,	O
we	O
explored	O
the	O
consequences	O
of	O
using	O
standard	O
approaches	O
,	O
referred	O
to	O
as	O
the	O
difference	O
and	O
generalized	O
product	O
methods	O
,	O
when	O
mediator	O
-	O
outcome	O
confounders	O
are	O
associated	O
with	O
the	O
exposure	B-DISO
.	O

We	O
compared	O
these	O
with	O
inverse	O
probability	O
-weighted	O
marginal	O
structural	B-OBJC
models	I-OBJC
,	O
the	O
structural	O
transformation	O
method	O
,	O
doubly	B-DISO
robust	O
g	O
-	O
estimation	O
of	O
a	O
structural	B-DEVI
nested	I-DEVI
model	I-DEVI
,	O
and	O
doubly	B-DISO
robust	O
targeted	O
minimum	O
loss	O
-based	O
estimation	O
.	O

We	O
used	O
data	O
on	O
900	O
,	O
726	O
births	B-PHYS
from	O
2003	O
to	O
2007	O
in	O
the	O
Penn	B-PROC
Moms	I-PROC
study	I-PROC
,	O
conducted	O
in	O
Pennsylvania	B-GEOG
,	O
to	O
assess	O
the	O
extent	O
to	O
which	O
breastfeeding	B-PHYS
prior	O
to	O
hospital	B-PROC
discharge	I-PROC
explained	O
the	O
racial	B-DISO
disparity	I-DISO
in	O
infant	O
mortality	O
.	O

Overall	O
,	O
for	O
every	O
1	O
,	O
000	O
births	B-PHYS
,	O
3	O
.	O
36	O
more	O
infant	B-DISO
deaths	I-DISO
occurred	O
among	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
black	I-LIVB
women	I-LIVB
relative	O
to	O
all	O
other	O
women	B-LIVB
(	O
95	O
%	O
confidence	O
interva	O
l	O
:	O
2	O
.	O
78	O
,	O
3	O
.	O
93	O
)	O
.	O

Using	O
the	O
difference	O
and	O
generalized	O
product	O
methods	O
to	O
assess	O
the	O
disparity	B-DISO
that	O
would	O
remain	O
if	O
everyone	O
breastfed	B-PHYS
prior	O
to	O
discharge	B-PROC
suggested	O
a	O
complete	O
elimination	O
of	O
the	O
disparity	B-DISO
(	O
risk	O
difference	O
=	O
-0	O
.	O

87	O
per	O
1	O
,	O
000	O
births	B-PHYS
;	O
95	O
%	O
confidence	O
interval	O
:	O
-1	O
.	O
39	O
,	O
-0	O
.	O
35	O
)	O
.	O

In	O
contrast	O
,	O
doubly	B-DISO
robust	O
methods	O
suggested	O
a	O
reduction	B-PROC
in	O
the	O
disparity	B-DISO
to	O
2	O
.	O

45	O
(	O
95	O
%	O
confidence	O
interva	O
l	O
:	O
2	O
.	O
20	O
,	O
2	O
.	O
71	O
)	O
more	O
infant	B-DISO
deaths	I-DISO
per	O
1	O
,	O
000	O
births	B-PHYS
among	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
black	I-LIVB
women	I-LIVB
.	O

Standard	O
approaches	O
for	O
mediation	O
analysis	O
in	O
health	B-DISO
disparities	I-DISO
research	O
can	O
yield	O
misleading	O
results	O
.	O

Integrating	O
Evidence	O
From	O
Systematic	O
Reviews	O
,	O
Qualitative	B-PROC
Research	I-PROC
,	O
and	O
Expert	B-LIVB
Knowledge	O
Using	O
Co	O
-	O
Design	O
Techniques	O
to	O
Develop	O
a	O
Web	B-OBJC
-Based	O
Intervention	B-PROC
for	O
People	B-LIVB
in	O
the	O
Retirement	B-DISO
Transition	O
Integrating	O
stakeholder	B-LIVB
involvement	O
in	O
complex	O
health	O
intervention	B-PROC
design	O
maximizes	O
acceptability	O
and	O
potential	O
effectiveness	O
.	O

However	O
,	O
there	O
is	O
little	O
methodological	O
guidance	O
about	O
how	O
to	O
integrate	O
evidence	O
systematically	O
from	O
various	O
sources	O
in	O
this	O
process	B-PHEN
.	O

Scientific	O
evidence	O
derived	O
from	O
different	O
approaches	O
can	O
be	O
difficult	O
to	O
integrate	O
and	O
the	O
problem	B-DISO
is	O
compounded	O
when	O
attempting	O
to	O
include	O
diverse	O
,	O
subjective	O
input	O
from	O
stakeholders	B-LIVB
.	O

The	O
intent	O
of	O
the	O
study	B-PROC
was	O
to	O
describe	O
and	O
appraise	O
a	O
systematic	O
,	O
sequential	O
approach	O
to	O
integrate	O
scientific	O
evidence	O
,	O
expert	B-LIVB
knowledge	O
and	O
experience	B-PHYS
,	O
and	O
stakeholder	B-LIVB
involvement	O
in	O
the	O
co	O
-	O
design	O
and	O
development	O
of	O
a	O
complex	O
health	O
intervention	B-PROC
.	O

The	O
development	O
of	O
a	O
Web	B-OBJC
-based	O
lifestyle	O
intervention	B-PROC
for	O
people	B-LIVB
in	O
retirement	B-DISO
is	O
used	O
as	O
an	O
example	O
.	O

Evidence	O
from	O
three	O
systematic	O
reviews	O
,	O
qualitative	B-PROC
research	I-PROC
findings	O
,	O
and	O
expert	B-LIVB
knowledge	O
was	O
compiled	O
to	O
produce	O
evidence	O
statements	O
(	O
stage	O
1	O
)	O
.	O

Face	O
validity	O
of	O
these	O
statements	O
was	O
assessed	O
by	O
key	O
stakeholders	B-LIVB
in	O
a	O
co	O
-	O
design	O
workshop	O
resulting	O
in	O
a	O
set	O
of	O
intervention	B-PROC
principles	O
(	O
stage	O
2	O
)	O
.	O

These	O
principles	O
were	O
assessed	O
for	O
face	O
validity	O
in	O
a	O
second	O
workshop	O
,	O
resulting	O
in	O
core	O
intervention	B-PROC
concepts	O
and	O
hand	O
-	O
drawn	O
prototypes	O
(	O
stage	O
3	O
)	O
.	O

The	O
outputs	O
from	O
stages	O
1	O
-	O
3	O
were	O
translated	O
into	O
a	O
design	O
brief	O
and	O
specification	O
(	O
stage	O
4	O
)	O
,	O
which	O
guided	O
the	O
building	O
of	O
a	O
functioning	O
prototype	O
,	O
Web	B-OBJC
-based	O
intervention	B-PROC
(	O
stage	O
5	O
)	O
.	O

This	O
prototype	O
was	O
de	O
-	O
risked	O
resulting	O
in	O
an	O
optimized	O
functioning	O
prototype	O
(	O
stage	O
6	O
)	O
,	O
which	O
was	O
subject	O
to	O
iterative	O
testing	O
and	O
optimization	O
(	O
stage	O
7	O
)	O
,	O
prior	O
to	O
formal	O
pilot	B-LIVB
evaluation	O
.	O

The	O
evidence	O
statements	O
(	O
stage	O
1	O
)	O
highlighted	O
the	O
effectiveness	O
of	O
physical	O
activity	O
,	O
dietary	B-OBJC
and	O
social	O
role	O
interventions	B-PROC
in	O
retirement	B-DISO
;	O
the	O
idiosyncratic	B-DISO
nature	I-DISO
of	O
retirement	B-DISO
and	O
well	O
-	O
being	O
;	O
the	O
value	O
of	O
using	O
specific	O
behavior	O
change	O
techniques	O
including	O
those	O
derived	O
from	O
the	O
Health	B-PROC
Action	I-PROC
Process	I-PROC
Approach	I-PROC
;	O
and	O

the	O
need	O
for	O
signposting	O
to	O
local	O
resources	O
.	O

The	O
intervention	B-PROC
principles	O
(	O
stage	O
2	O
)	O
included	O
the	O
need	O
to	O
facilitate	O
self	O
-	O
reflection	O
on	O
available	O
resources	O
,	O
personalization	B-DISO
,	O
and	O
promotion	B-PROC
of	O
links	O
between	O
key	O
lifestyle	O
behaviors	O
.	O

The	O
core	O
concepts	O
and	O
hand	O
-	O
drawn	O
prototypes	O
(	O
stage	O
3	O
)	O
had	O
embedded	O
in	O
them	O
the	O
importance	O
of	O
time	O
use	O
and	O
work	O
exit	O
planning	O
,	O
personalized	B-DISO
goal	I-DISO
setting	I-DISO
,	O
and	O
acceptance	O
of	O
a	O
Web	B-OBJC
-based	O
intervention	B-PROC
.	O

The	O
design	O
brief	O
detailed	O
the	O
features	O
and	O
modules	O
required	O
(	O
stage	O
4	O
)	O
,	O
guiding	O
the	O
development	O
of	O
wireframes	O
,	O
module	O
content	O
and	O
functionality	O
,	O
virtual	B-LIVB
mentors	I-LIVB
,	O
and	O
intervention	B-PROC
branding	O
(	O
stage	O
5	O
)	O
.	O

Following	O
an	O
iterative	O
process	B-PHEN
of	O
intervention	B-PROC
testing	O
and	O
optimization	O
(	O
stage	O
6	O
)	O
,	O
the	O
final	O
Web	B-OBJC
-based	O
intervention	B-PROC
prototype	O
of	O
LEAP	O
(	O
Living	O
,	O
Eating	B-PHYS
,	O
Activity	O
,	O
and	O
Planning	O
in	O
retirement	B-DISO
)	O
was	O
produced	O
(	O
stage	O
7	O
)	O
.	O

The	O
approach	O
was	O
resource	O
intensive	O
and	O
required	O
a	O
multidisciplinary	B-LIVB
team	I-LIVB
.	O

The	O
design	O
expert	B-LIVB
made	O
an	O
invaluable	O
contribution	O
throughout	O
the	O
process	B-PHEN
.	O

Our	O
sequential	O
approach	O
fills	O
an	O
important	O
methodological	O
gap	O
in	O
the	O
literature	O
,	O
describing	O
the	O
stages	O
and	O
techniques	O
useful	O
in	O
developing	O
an	O
evidence	O
-based	O
complex	O
health	O
intervention	B-PROC
.	O

The	O
systematic	O
and	O
rigorous	O
integration	O
of	O
scientific	O
evidence	O
,	O
expert	B-LIVB
knowledge	O
and	O
experience	B-PHYS
,	O
and	O
stakeholder	B-LIVB
input	O
has	O
resulted	O
in	O
an	O
intervention	B-PROC
likely	O
to	O
be	O
acceptable	O
and	O
feasible	O
.	O

Transcriptome	B-PROC
profiling	I-PROC
of	O
the	O
green	B-LIVB
alga	I-LIVB
Spirogyra	B-LIVB
pratensis	I-LIVB
(	O
Charophyta	B-LIVB
)	O
suggests	O
an	O
ancestral	O
It	O
is	O
well	O
known	O
that	O
ethylene	B-CHEM
regulates	O
a	O
diverse	O
set	O
of	O
developmental	B-PHYS
and	O
stress	B-DISO
-	I-DISO
related	I-DISO
processes	I-DISO
in	O
angiosperms	B-LIVB
,	O
yet	O
its	O
roles	O
in	O
early	O
diverging	O
embryophytes	B-LIVB
and	O
algae	O
are	O
poorly	O
understood	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
ethylene	B-CHEM
functions	O
as	O
a	O
hormone	B-CHEM
in	O
the	O
charophyte	B-LIVB
green	B-LIVB
alga	I-LIVB
Spirogyra	B-LIVB
pratensis	I-LIVB
.	O

Since	O
land	B-LIVB
plants	I-LIVB
evolved	O
from	O
Charophytes	B-LIVB
,	O
this	O
implies	O
conservation	O
of	O
ethylene	B-CHEM
as	O
a	O
hormone	B-CHEM
in	O
green	B-LIVB
plants	I-LIVB
for	O
at	O
least	O
450	O
million	O
of	O
years	O
.	O

However	O
,	O
the	O
physiological	O
role	O
of	O
ethylene	B-CHEM
in	O
charophyte	B-LIVB
algae	O
remained	O
unknown	O
.	O

In	O
order	O
to	O
gain	O
insight	O
into	O
ethylene	B-PHYS
responses	I-PHYS
in	O
Spirogyra	B-LIVB
,	O
we	O
used	O
mRNA	B-CHEM
sequencing	B-PROC
to	O
measure	O
changes	O
in	O
gene	B-PHYS
expression	I-PHYS
over	O
time	O
in	O
Spirogyra	B-LIVB
filaments	B-ANAT
in	O
response	B-PHYS
to	I-PHYS
an	I-PHYS
ethylene	I-PHYS
treatment	O
.	O

Our	O
analyses	O
show	O
that	O
at	O
the	O
transcriptional	B-PHYS
level	O
,	O
ethylene	B-CHEM
predominantly	O
regulates	B-DISO
three	O
processes	O
in	O
Spirogyra	B-LIVB
:	O
(	O
1	O
)	O
modification	B-DISO
of	O
the	O
cell	B-ANAT
wall	I-ANAT
matrix	I-ANAT
by	O
expansins	B-CHEM
and	O
xyloglucan	B-CHEM
endotransglucosylases	I-CHEM
/	O
hydrolases	B-CHEM
,	O
(	O
2	O
)	O
down	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O
chlorophyll	B-PHYS
biosynthesis	I-PHYS
and	O
photosynthesis	B-PHEN
and	O
(	O
3	O
)	O
activation	O
of	O
abiotic	B-PHYS
stress	I-PHYS
responses	I-PHYS
.	O

We	O
confirmed	O
that	O
the	O
photosynthetic	B-PHEN
capacity	O
and	O
chlorophyll	B-CHEM
content	O
was	O
reduced	O
by	O
an	O
ethylene	B-CHEM
treatment	O
and	O
that	O
several	O
abiotic	B-PHYS
stress	I-PHYS
conditions	I-PHYS
could	O
stimulate	B-PROC
cell	B-PHYS
elongation	I-PHYS
in	O
an	O
ethylene	B-CHEM
-dependent	O
manner	O
.	O

We	O
also	O
found	O
that	O
the	O
Spirogyra	B-LIVB
transcriptome	O
only	O
harbors	O
10	O
ethylene	O
responsive	O
transcription	O
factor	O
(	O
ERF	O
)	O
homologs	O
,	O
several	O
of	O
which	O
are	O
regulated	O
by	O
ethylene	B-CHEM
.	O

These	O
results	O
provide	O
an	O
initial	O
understanding	O
of	O
the	O
hormonal	O
responses	B-PHYS
induced	O
by	O
ethylene	B-CHEM
in	O
Spirogyra	B-LIVB
,	O
and	O
help	O
to	O
reconstruct	O
the	O
role	O
of	O
ethylene	B-CHEM
in	O
ancestral	O
charophytes	B-LIVB
prior	O
to	O
the	O
origin	O
of	O
land	B-LIVB
plants	I-LIVB
.	O

Simultaneous	O
thrombosis	B-DISO
of	O
multiple	B-ANAT
coronary	I-ANAT
arteries	I-ANAT
in	O
a	O
patient	B-LIVB
with	O
rheumatoid	B-DISO
arthritis	I-DISO
We	O
present	O
a	O
case	O
of	O
simultaneous	O
coronary	B-DISO
thrombosis	I-DISO
of	I-DISO
the	I-DISO
left	I-DISO
main	I-DISO
,	O
the	O
left	B-ANAT
anterior	I-ANAT
descending	I-ANAT
artery	I-ANAT
and	O
the	O
right	B-ANAT
coronary	I-ANAT
artery	I-ANAT
in	O
a	O
patient	B-LIVB
,	O
recently	O
diagnosed	B-PROC
with	O
rheumatoid	B-DISO
arthritis	I-DISO
.	O

Mediastinal	B-DISO
mass	I-DISO
diagnosed	B-DISO
by	O
endobronchial	B-PROC
ultrasound	I-PROC
as	O
recurrent	B-DISO
hepatocellular	I-DISO
carcinoma	I-DISO
in	O
a	O
post	O
-	O
liver	B-PROC
transplantation	I-PROC
patient	B-LIVB
We	O
presented	O
a	O
rare	O
case	O
of	O
recurrent	B-DISO
hepatocellular	I-DISO
carcinoma	I-DISO
after	O
liver	B-PROC
transplant	I-PROC
manifested	O
as	O
an	O
isolated	O
mediastinal	B-DISO
mass	I-DISO
.	O

A	O
62	O
-	O
year	O
-	O
old	B-LIVB
man	I-LIVB
was	O
referred	O
for	O
evaluation	O
of	O
atypical	B-DISO
chest	I-DISO
pain	I-DISO
and	O
abnormal	B-DISO
finding	I-DISO
of	O
a	O
computed	B-PROC
tomography	I-PROC
of	I-PROC
the	I-PROC
chest	I-PROC
.	O

He	O
had	O
history	B-DISO
of	O
chronic	B-DISO
hepatitis	I-DISO
C	I-DISO
liver	I-DISO
cirrhosis	I-DISO
and	O
hepatocellular	B-DISO
carcinoma	I-DISO
underwent	O
orthotopic	B-PROC
liver	I-PROC
transplant	I-PROC
as	O
a	O
curative	B-DISO
treatment	I-DISO
three	O
years	O
earlier	O
.	O

The	O
computed	B-PROC
tomography	I-PROC
of	I-PROC
the	I-PROC
chest	I-PROC
demonstrated	O
paratracheal	B-DISO
mediastinal	I-DISO
lymphadenopathy	I-DISO
.	O

He	O
subsequently	O
underwent	O
endobronchial	B-PROC
ultrasound	I-PROC
with	I-PROC
transbronchial	I-PROC
needle	I-PROC
aspiration	I-PROC
(	O
EBUS	B-PROC
-	I-PROC
TBNA	I-PROC
)	O
.	O

The	O
right	B-ANAT
paratracheal	I-ANAT
lymph	I-ANAT
node	I-ANAT
station	I-ANAT
4R	I-ANAT
was	O
sampled	O
.	O

Rapid	O
on	O
-	O
site	O
cytology	O
evaluation	O
demonstrated	O
recurrent	O
metastatic	B-DISO
hepatocellular	I-DISO
carcinoma	I-DISO
.	O

Pulmonologist	B-LIVB
should	O
be	O
cognizant	O
of	O
diagnostic	O
utility	O
of	O
EBUS	B-PROC
-	I-PROC
TBNA	I-PROC
in	O
this	O
clinical	O
setting	O
as	O
more	O
transplant	B-DISO
patients	B-LIVB
on	O
immunosuppressive	B-CHEM
medications	I-CHEM
with	O
enlarged	O
mediastinal	B-DISO
lymphadenopathy	I-DISO
of	O
unknown	O
origin	O
will	O
be	O
referred	O
for	O
further	O
evaluation	O
.	O

Phosphodiesterase	B-CHEM
type	I-CHEM
5	I-CHEM
inhibitors	I-CHEM
:	O
Irrational	B-DISO
use	O
in	O
Saudi	B-GEOG
Arabia	I-GEOG
To	O
identify	B-PHYS
the	O
criteria	O
of	O
phosphodiesterase	B-CHEM
type	I-CHEM
5	I-CHEM
inhibitor	I-CHEM
(	O
PDE5i	B-CHEM
)	O
users	B-LIVB
and	O
to	O
analyse	B-PROC
the	O
knowledge	O
,	O
attitude	B-PHYS
,	O
and	O
practices	B-PHYS
of	O
PDE5i	B-CHEM
use	O
amongst	O
Saudi	O
men	O
.	O

A	O
web	B-OBJC
-	O
based	O
,	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
survey	I-PROC
was	O
conducted	O
in	O
Saudi	B-GEOG
Arabia	I-GEOG
between	O
January	O
and	O
April	O
2015	O
.	O

Sexually	B-DISO
active	I-DISO
adult	B-LIVB
men	B-LIVB
were	O
interviewed	O
using	O
a	O
website	O
questionnaire	O
designed	O
by	O
the	O
authors	B-LIVB
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
analyse	B-PROC
the	O
data	O
.	O

In	O
all	O
,	O
1008	O
men	B-LIVB
participated	O
in	O
the	O
survey	O
with	O
378	O
(	O
37	O
.	O
5	O
%	O
)	O
reporting	B-PROC
use	O
of	O
PDE5i	B-CHEM
.	O

Of	O
those	O
using	O
PDE5i	B-CHEM
,	O
144	O
(	O
38	O
.	O

1	O
%	O
)	O
reported	B-PROC
erectile	B-DISO
dysfunction	I-DISO
and	O
234	O
(	O
61	O
.	O

9	O
%	O
)	O
reported	B-PROC
normal	O
erection	B-PHYS
(	O
recreational	B-CHEM
users	B-LIVB
)	O
.	O

We	O
found	O
several	O
demographic	O
features	O
,	O
including	O
high	B-DISO
education	I-DISO
level	I-DISO
,	O
health	O
field	O
occupation	O
,	O
high	B-DISO
income	I-DISO
,	O
smoking	O
,	O
and	O
increased	O
frequency	O
of	O
sexual	B-PHYS
intercourse	I-PHYS
amongst	O
the	O
PDE5i	B-CHEM
users	B-LIVB
.	O

Most	O
of	O
the	O
PDE5i	B-CHEM
users	B-LIVB
(	O
92	O
.	O
3	O
%	O
)	O
had	O
knowledge	O
about	O
PDE5i	B-CHEM
and	O
84	O
.	O

1	O
%	O
of	O
them	O
bought	O
it	O
without	O
medical	O
prescription	O
.	O

The	O
most	O
commonly	O
used	O
PDE5i	B-CHEM
was	O
tadalafil	B-CHEM
(	O
46	O
.	O
1	O
%	O
)	O
and	O
most	O
of	O
the	O
users	B-LIVB
(	O
79	O
.	O
9	O
%	O
)	O
reported	B-PROC
improvement	O
in	O
their	O
sexual	O
activity	O
after	O
PDE5i	B-CHEM
usage	O
.	O

Amongst	O
the	O
recreational	B-PHYS
users	B-LIVB
,	O
the	O
main	O
reasons	B-DISO
for	O
PDE5i	B-CHEM
usage	O
were	O
curiosity	O
(	O
38	O
.	O
5	O
%	O
)	O
and	O
improving	O
self	B-PHYS
-	I-PHYS
confidence	I-PHYS
(	O
25	O
.	O
6	O
%	O
)	O
.	O

Of	O
them	O
,	O
69	O
.	O
2	O
%	O
reported	B-PROC
benefits	O
from	O
PDE5i	B-CHEM
usage	O
,	O
mainly	O
in	O
the	O
form	O
of	O
enhancement	O
of	O
erection	B-PHYS
(	O
36	O
.	O
7	O
%	O
)	O
and	O
increasing	O
erection	B-DISO
duration	I-DISO
(	O
31	O
.	O
2	O
%	O
)	O
.	O

PDE5i	B-CHEM
use	O
appears	O
to	O
be	O
frequent	O
in	O
Saudi	B-GEOG
Arabia	I-GEOG
.	O

Most	O
of	O
the	O
users	B-LIVB
had	O
knowledge	O
about	O
PDE5i	B-CHEM
and	O
claimed	O
to	O
get	O
benefits	O
from	O
it	O
,	O
even	O
if	O
used	O
as	O
a	O
recreational	B-CHEM
drug	I-CHEM
.	O

Microarray	B-PROC
-	I-PROC
Based	I-PROC
Analysis	I-PROC
of	O
Methylation	B-PHYS
of	O
1st	O
Trimester	O
Trisomic	B-ANAT
Placentas	I-ANAT
from	O
Down	B-DISO
Syndrome	I-DISO
,	O
Edwards	B-DISO
Syndrome	I-DISO
and	I-DISO
Patau	I-DISO
Syndrome	I-DISO
Methylation	B-PHYS
-based	O
non	O
-	O
invasive	O
prenatal	O
testing	O
of	O
fetal	O
aneuploidies	O
is	O
an	O
alternative	O
method	B-PROC
that	O
could	O
possibly	O
improve	B-DISO
fetal	B-PROC
aneuploidy	I-PROC
diagnosis	I-PROC
,	I-PROC
especially	I-PROC
for	I-PROC
trisomy	I-PROC
13	I-PROC
(	I-PROC
T13	I-PROC
)	I-PROC
and	I-PROC
trisomy	I-PROC
18	I-PROC
(	I-PROC
T18	I-PROC
)	I-PROC
.	O

Our	O
aim	O
was	O
to	O
study	B-PROC
the	O
methylation	B-PHYS
landscape	O
in	O
placenta	B-ANAT
DNA	B-CHEM
from	O
trisomy	B-DISO
13	I-DISO
,	I-DISO
18	I-DISO
and	I-DISO
21	I-DISO
pregnancies	B-PHYS
in	O
an	O
attempt	O
to	O
find	O
trisomy	B-DISO
-specific	O
methylation	B-PHYS
differences	O
better	O
suited	O
for	O
non	O
-	O
invasive	O
prenatal	B-PROC
diagnosis	I-PROC
.	O

We	O
have	O
conducted	O
high	B-PROC
-	I-PROC
resolution	I-PROC
methylation	B-PHYS
specific	O
bead	B-PROC
chip	I-PROC
microarray	I-PROC
analyses	I-PROC
assessing	O
more	O
than	O
450	O
,	O
000	O
CpGs	B-CHEM
analyzing	O
placentas	B-ANAT
from	O
12	O
T21	B-DISO
pregnancies	B-PHYS
,	O
12	O
T18	B-DISO
pregnancies	B-PHYS
and	O
6	O
T13	B-DISO
pregnancies	B-PHYS
.	O

We	O
have	O
compared	O
the	O
methylation	B-PHYS
landscape	O
of	O
the	O
trisomic	B-ANAT
placentas	I-ANAT
to	O
the	O
methylation	B-PHYS
landscape	O
from	O
normal	O
placental	B-ANAT
DNA	B-CHEM
and	O
to	O
maternal	B-DISO
blood	B-ANAT
cell	I-ANAT
DNA	B-CHEM
.	O

Comparing	O
trisomic	B-ANAT
placentas	I-ANAT
to	O
normal	O
placentas	B-ANAT
we	O
identified	O
217	O
and	O
219	O
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
for	O
CVS	B-PROC
T18	B-DISO
and	O
CVS	B-PROC
T13	B-DISO
,	O
respectively	O
(	O
delta	O
β	O
>	O
0	O
.	O
2	O
,	O
FDR	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
only	O
three	O
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
for	O
T21	B-DISO
.	O

However	O
,	O
the	O
methylation	B-PHYS
differences	O
was	O
only	O
modest	O
(	O
delta	O
β	O
<	O
0	O
.	O
4	O
)	O
,	O
making	O
them	O
less	O
suitable	O
as	O
diagnostic	B-PHYS
markers	I-PHYS
.	O

Gene	O
ontology	O
enrichment	O
analysis	B-PROC
revealed	O
that	O
the	O
gene	O
set	O
connected	O
to	O
the	O
T18	B-DISO
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
was	O
highly	O
enriched	O
for	O
GO	O
terms	O
related	O
to	O
""""	O
DNA	B-PHYS
binding	I-PHYS
""""	O
and	O
""""	O
transcription	B-PHYS
factor	I-PHYS
binding	I-PHYS
""""	O
coupled	O
to	O
the	O
RNA	B-CHEM
polymerase	I-CHEM
II	I-CHEM
transcription	B-PHYS
.	O

In	O
the	O
gene	O
set	O
connected	O
to	O
the	O
T13	B-DISO
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
we	O
found	O
no	B-DISO
significant	I-DISO
enrichments	O
.	O

Assessment	B-PROC
of	O
Early	O
Treatment	B-PHYS
Response	I-PHYS
With	O
DWI	B-PROC
After	O
CT	B-PROC
-Guided	O
Radiofrequency	B-PROC
Ablation	I-PROC
of	O
Functioning	O
Adrenal	B-DISO
Adenomas	I-DISO
The	O
objective	O
of	O
this	O
study	B-PROC
was	O
to	O
establish	O
the	O
suitability	O
of	O
the	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
as	O
a	O
parameter	O
for	O
evaluating	O
early	O
treatment	B-PHYS
response	I-PHYS
after	O
percutaneous	O
ablation	B-PROC
of	O
functional	O
adrenal	B-DISO
adenomas	I-DISO
.	O

Seventeen	O
adult	B-LIVB
patients	B-LIVB
with	O
functioning	O
adrenal	B-DISO
adenomas	I-DISO
underwent	O
radiofrequency	B-PROC
ablation	I-PROC
.	O

Serum	B-ANAT
hormone	B-CHEM
levels	O
were	O
analyzed	B-PROC
before	O
and	O
up	O
to	O
6	O
months	O
after	O
ablation	B-PROC
.	O

MRI	B-PROC
findings	B-DISO
(	O
nodule	O
size	O
in	O
cm	O
,	O
signal	O
intensity	O
index	O
,	O
ADC	O
maps	O
,	O
and	O
nodule	O
-	O
to	O
-	O
muscle	O
ADC	O
ratio	O
)	O
were	O
analyzed	B-PROC
before	O
and	O
up	O
to	O
30	O
days	O
after	O
ablation	B-PROC
.	O

A	O
consensus	O
review	O
of	O
all	O
scans	B-PROC
was	O
performed	O
by	O
two	O
attending	O
abdominal	B-LIVB
imaging	I-LIVB
radiologists	I-LIVB
.	O

The	O
procedure	O
was	O
considered	O
successful	O
if	O
serum	B-ANAT
hormone	B-CHEM
levels	O
normalized	B-PROC
and	O
no	B-DISO
contrast	O
enhancement	O
of	O
the	O
adrenal	B-ANAT
lesion	B-DISO
was	O
seen	O
on	O
follow	B-PROC
-	I-PROC
up	I-PROC
MRI	B-PROC
.	O

Of	O
17	O
patients	B-LIVB
who	O
underwent	O
radiofrequency	B-PROC
ablation	I-PROC
,	O
complete	B-DISO
response	I-DISO
was	O
achieved	O
in	O
16	O
patients	B-LIVB
with	O
partial	B-DISO
response	I-DISO
in	O
one	O
patient	B-LIVB
.	O

Of	O
the	O
four	O
parameters	O
of	O
interest	O
,	O
only	O
ADC	O
maps	O
and	O
nodule	O
-	O
to	O
-	O
muscle	O
ADC	O
ratio	O
showed	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
prospective	B-PROC
study	I-PROC
suggests	O
that	O
apparent	O
diffusion	O
coefficient	O
values	O
may	O
help	O
radiologists	B-LIVB
monitor	B-PROC
early	O
treatment	B-PHYS
response	I-PHYS
after	O
CT	B-PROC
-guided	O
radiofrequency	B-PROC
ablation	I-PROC
of	O
functioning	O
adrenal	B-DISO
adenomas	I-DISO
.	O

TLR	B-CHEM
and	O
NLRP3	B-CHEM
inflammasome	B-CHEM
-	O
dependent	O
innate	B-PHYS
immune	I-PHYS
responses	I-PHYS
to	O
tumor	O
-	O
derived	O
autophagosomes	B-ANAT
(	O
DRibbles	B-ANAT
)	O
Autophagosomes	B-ANAT
derived	O
from	O
tumor	B-ANAT
cells	I-ANAT
,	O
also	O
referred	O
to	O
as	O
defective	B-ANAT
ribosomal	I-ANAT
products	I-ANAT
in	O
blebs	B-DISO
(	O
DRibbles	B-ANAT
)	O
,	O
have	O
been	O
previously	O
shown	O
to	O
stimulate	O
potent	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
responses	B-PHYS
and	O
mediate	O
tumor	B-PHYS
regression	I-PHYS
when	O
used	O
as	O
therapeutic	O
cancer	B-CHEM
vaccines	I-CHEM
in	O
multiple	O
preclinical	O
cancer	B-DISO
models	I-DISO
.	O

In	O
this	O
report	O
,	O
we	O
investigated	O
the	O
underlining	O
mechanisms	O
by	O
which	O
DRibbles	B-ANAT
induced	O
T	B-PHYS
-	I-PHYS
cell	I-PHYS
activation	I-PHYS
,	O
particularly	O
how	O
DRibbles	B-ANAT
activated	B-PHYS
antigen	B-ANAT
-	I-ANAT
presenting	I-ANAT
cells	I-ANAT
(	O
APCs	B-ANAT
)	O
.	O

We	O
found	O
that	O
DRibbles	B-ANAT
could	O
induce	O
a	O
rapid	O
differentiation	B-PHYS
of	O
monocytes	B-ANAT
and	O
DC	B-ANAT
precursor	I-ANAT
(	I-ANAT
pre	I-ANAT
-	I-ANAT
DC	I-ANAT
)	I-ANAT
cells	I-ANAT
into	O
functional	O
APCs	B-ANAT
.	O

DRibbles	B-ANAT
triggered	O
innate	B-PHYS
receptor	I-PHYS
signaling	I-PHYS
via	O
Toll	B-CHEM
-	I-CHEM
like	I-CHEM
Receptors	I-CHEM
(	I-CHEM
TLR	I-CHEM
)	I-CHEM
-	I-CHEM
2	I-CHEM
,	O
TLR4	B-CHEM
,	O
TLR7	B-CHEM
,	O
TLR8	B-CHEM
,	O
and	O
nucleotide	B-CHEM
-	I-CHEM
binding	I-CHEM
oligomerization	I-CHEM
domain	I-CHEM
-	I-CHEM
containing	I-CHEM
protein	I-CHEM
2	I-CHEM
(	O
NOD2	B-CHEM
)	O
,	O
but	O
not	O
TLR3	B-CHEM
,	O
TLR5	B-CHEM
,	O
or	O
TLR9	B-CHEM
.	O

DRibbles	B-ANAT
induced	O
PBMCs	B-ANAT
to	O
produce	O
pro	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
cytokines	I-CHEM
,	O
such	O
as	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
,	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
,	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
,	O
and	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
.	O

DRibbles	B-ANAT
induced	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
release	O
from	O
PBMC	B-ANAT
or	O
THP	B-ANAT
-	I-ANAT
1	I-ANAT
cells	I-ANAT
without	O
LPS	B-CHEM
priming	O
,	O
but	O
required	O
the	O
core	O
machinery	O
of	O
NLRP3	B-ANAT
inflammasomes	I-ANAT
.	O

Active	O
endocytosis	B-PHYS
was	O
required	O
for	O
inflammasome	B-PHYS
activation	I-PHYS
and	O
cross	B-PHYS
presentation	I-PHYS
,	O
and	O
blocking	O
endosome	B-ANAT
acidification	B-PHYS
or	O
the	O
ER	B-PHYS
-	I-PHYS
associated	I-PHYS
degradation	I-PHYS
(	I-PHYS
ERAD	I-PHYS
)	I-PHYS
pathway	I-PHYS
resulted	O
in	O
opposite	O
effects	O
on	O
these	O
two	O
processes	B-PHEN
.	O

Our	O
data	O
show	O
that	O
DRibbles	B-ANAT
could	O
induce	O
strong	O
innate	B-PHYS
immune	I-PHYS
responses	I-PHYS
via	O
multiple	O
pattern	B-CHEM
recognition	I-CHEM
receptors	I-CHEM
,	O
and	O
explain	O
why	O
DRibbles	B-ANAT
could	O
function	O
as	O
excellent	O
antigen	B-CHEM
carriers	O
to	O
induce	O
adaptive	B-PHYS
immune	I-PHYS
responses	I-PHYS
to	O
both	O
tumor	B-ANAT
cells	I-ANAT
and	O
viruses	B-LIVB
.	O

In	O
contrast	O
to	O
the	O
well	O
-	O
established	O
inhibitory	B-PHYS
effect	I-PHYS
of	O
autophagy	B-PHYS
on	O
the	O
inflammasome	B-PHYS
activation	I-PHYS
of	O
APCs	B-ANAT
,	O
our	O
study	B-PROC
demonstrates	O
that	O
isolated	O
autophagosomes	B-ANAT
(	O
DRibbles	B-ANAT
)	O
from	O
antigen	B-CHEM
donor	B-ANAT
cells	I-ANAT
activate	B-PHYS
inflammasomes	I-PHYS
by	O
providing	O
first	O
and	O
second	O
signals	B-PHEN
required	O
for	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
production	O
by	O
PMBC	B-ANAT
.	O

Self	B-PHYS
-	I-PHYS
assembled	I-PHYS
half	B-CHEM
-	I-CHEM
sandwich	I-CHEM
polyhedral	O
cages	B-CHEM
via	O
flexible	O
Schiff	B-CHEM
-	I-CHEM
base	I-CHEM
ligands	I-CHEM
:	O
an	O
unusual	O
macrocycle	B-CHEM
-to	O
-	O
cage	B-CHEM
conversion	O
An	O
edge	O
-directed	O
strategy	O
was	O
adopted	O
to	O
construct	O
highly	O
ordered	O
polyhedral	O
structures	O
using	O
flexible	O
functions	O
.	O

Half	B-CHEM
-	I-CHEM
sandwich	I-CHEM
M6	B-CHEM
(	I-CHEM
L1	I-CHEM
)	I-CHEM
4	I-CHEM
octahedral	O
and	O
M8	B-CHEM
(	I-CHEM
L2	I-CHEM
)	I-CHEM
4	I-CHEM
cubic	O
cages	B-CHEM
have	O
been	O
assembled	B-PHYS
by	O
flexible	O
Schiff	B-CHEM
-	I-CHEM
base	I-CHEM
ligands	I-CHEM
upon	O
coordination	O
to	O
Cp	B-CHEM
*	I-CHEM
Rh	I-CHEM
(	I-CHEM
iii	I-CHEM
)	I-CHEM
organometallic	I-CHEM
acceptors	I-CHEM
.	O

In	O
particular	O
,	O
the	O
rearrangement	B-PHEN
from	O
a	O
Rh	B-CHEM
(	I-CHEM
iii	I-CHEM
)	I-CHEM
-based	O
half	B-CHEM
-	I-CHEM
sandwich	I-CHEM
M2	B-CHEM
(	I-CHEM
HL1	I-CHEM
)	I-CHEM
2	I-CHEM
macrocycle	B-CHEM
to	O
M6	B-CHEM
(	I-CHEM
L1	I-CHEM
)	I-CHEM
4	I-CHEM
cage	B-CHEM
was	O
found	O
to	O
occur	O
in	O
a	O
solution	B-OBJC
.	O

Neonatal	B-DISO
infections	I-DISO
:	O
Case	O
definition	O
and	O
guidelines	O
for	O
data	B-PROC
collection	I-PROC
,	O
analysis	B-PROC
,	O
and	O
presentation	O
of	O
immunisation	B-PROC
safety	O
data	O
Maternal	B-DISO
vaccination	B-PROC
is	O
an	O
important	O
area	O
of	O
research	B-PROC
and	O
requires	O
appropriate	O
and	O
internationally	O
comparable	O
definitions	O
and	O
safety	O
standards	O
.	O

The	O
GAIA	B-LIVB
group	I-LIVB
,	O
part	O
of	O
the	O
Brighton	B-LIVB
Collaboration	I-LIVB
was	O
created	O
with	O
the	O
mandate	O
of	O
proposing	O
standardised	O
definitions	O
applicable	O
to	O
maternal	B-DISO
vaccine	B-CHEM
research	B-PROC
.	O

This	O
study	B-PROC
proposes	O
international	O
definitions	O
for	O
neonatal	B-DISO
infections	I-DISO
.	O

The	O
neonatal	B-DISO
infections	I-DISO
GAIA	B-LIVB
working	B-LIVB
group	I-LIVB
performed	O
a	O
literature	O
review	O
using	O
Medline	O
,	O
EMBASE	O
and	O
the	O
Cochrane	O
collaboration	O
and	O
collected	O
definitions	O
in	O
use	O
in	O
neonatal	O
and	O
public	O
health	O
networks	O
.	O

The	O
common	O
criteria	O
derived	O
from	O
the	O
extensive	O
search	O
formed	O
the	O
basis	O
for	O
a	O
consensus	O
process	O
that	O
resulted	O
in	O
three	O
separate	O
definitions	O
for	O
neonatal	B-LIVB
blood	B-DISO
stream	I-DISO
infections	I-DISO
(	O
BSI	B-DISO
)	O
,	O
meningitis	B-DISO
and	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O
LRTI	B-DISO
)	O
.	O

For	O
each	O
definition	O
three	O
levels	O
of	O
evidence	O
are	O
proposed	O
to	O
ensure	O
the	O
applicability	O
of	O
the	O
definitions	O
to	O
different	O
settings	O
.	O

Recommendations	O
about	O
data	B-PROC
collection	I-PROC
,	O
analysis	B-PROC
and	O
presentation	O
are	O
presented	O
and	O
harmonized	B-PROC
with	O
the	O
Brighton	B-LIVB
Collaboration	I-LIVB
and	O
GAIA	B-LIVB
format	O
and	O
other	O
existing	O
international	O
standards	O
for	O
study	B-PROC
reporting	B-PROC
.	O

Beneficial	O
effects	O
of	O
dark	B-OBJC
chocolate	I-OBJC
on	O
exercise	O
capacity	O
in	O
sedentary	O
subjects	B-LIVB
:	O
underlying	O
mechanisms	O
.	O

A	O
double	B-PROC
blind	I-PROC
,	O
randomized	B-PROC
,	O
placebo	B-PROC
controlled	I-PROC
trial	B-PROC
In	O
heart	B-DISO
failure	I-DISO
patients	B-LIVB
the	O
consumption	B-PHYS
of	O
(	B-CHEM
-	I-CHEM
)	I-CHEM
-	I-CHEM
epicatechin	I-CHEM
(	O
(	B-CHEM
-	I-CHEM
)	I-CHEM
-	I-CHEM
Epi	I-CHEM
)	O
-	O
rich	O
cocoa	B-OBJC
can	O
restore	O
skeletal	O
muscle	O
(	O
SkM	O
)	O
mitochondrial	B-ANAT
structure	O
and	O
decrease	O
biomarkers	B-PHYS
of	O
oxidative	B-DISO
stress	I-DISO
.	O

However	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	O
on	O
exercise	O
capacity	O
and	O
underlying	O
mechanisms	O
in	O
normal	O
,	O
sedentary	O
subjects	B-LIVB
.	O

Twenty	O
normal	O
,	O
sedentary	O
subjects	B-LIVB
(	O
∼50	O
years	B-LIVB
old	I-LIVB
)	O
were	O
randomized	B-PROC
to	O
placebo	B-PROC
or	O
dark	B-OBJC
chocolate	I-OBJC
(	O
DC	B-OBJC
)	O
groups	O
and	O
consumed	O
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	O
.	O

Subjects	B-LIVB
underwent	O
before	O
and	O
after	O
treatment	B-PROC
,	O
bicycle	B-PROC
ergometry	I-PROC
to	O
assess	B-PROC
VO2	B-DISO
max	I-DISO
and	O
work	O
,	O
SkM	B-PROC
biopsy	I-PROC
to	O
assess	B-PROC
changes	O
in	O
mitochondrial	B-ANAT
density	O
,	O
function	O
and	O
oxidative	B-DISO
stress	I-DISO
and	O
blood	B-PROC
sampling	I-PROC
to	O
assess	B-PROC
metabolic	O
endpoints	O
.	O

Seventeen	O
subjects	B-LIVB
completed	O
the	O
trial	B-PROC
.	O

In	O
the	O
DC	B-OBJC
group	O
(	O
n	O
=	O
9	O
)	O
,	O
VO2	B-DISO
max	I-DISO
increased	O
(	O
17	O
%	O
increase	O
,	O
p	O
=	O
0	O
.	O
056	O
)	O
as	O
well	O
as	O
maximum	O
work	O
(	O
watts	O
)	O
achieved	O
(	O
p	O
=	O
0	O
.	O
026	O
)	O
with	O
no	O
changes	O
with	O
placebo	B-PROC
(	O
n	O
=	O
8	O
)	O
.	O

The	O
DC	B-OBJC
group	O
evidenced	O
increases	O
in	O
HDL	B-CHEM
levels	O
(	O
p	O
=	O
0	O
.	O

005	O

)	O

and	O

decreased	O
triglycerides	B-CHEM
(	O
p	O
=	O
0	O
.	O
07	O
)	O
.	O

With	O
DC	B-OBJC
,	O
SkM	O
evidenced	O
significant	O
increases	O
in	O
protein	B-CHEM
levels	O
for	O
LKB1	B-CHEM
,	O
AMPK	B-CHEM
and	O
PGC1α	B-CHEM
and	O
in	O
their	O
active	O
forms	O
(	O
phosphorylated	B-PHYS
AMPK	B-CHEM
and	O
LKB1	B-CHEM
)	O
as	O
well	O
as	O
in	O
citrate	B-PHYS
synthase	I-PHYS
activity	I-PHYS
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	B-ANAT
density	O
.	O

With	O
DC	B-OBJC
,	O
significant	O
increases	O
in	O
SkM	O
reduced	O
glutathione	B-CHEM
levels	O
and	O
decreases	O
in	O
protein	B-PHYS
carbonylation	I-PHYS
were	O
observed	O
.	O

Improvements	O
in	O
maximum	O
work	O
achieved	O
and	O
VO2	B-DISO
max	I-DISO
may	O
be	O
due	O
to	O
DC	B-OBJC
activation	O
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	O
mitochondria	B-ANAT
efficiency	O
.	O

Larger	O
clinical	B-PROC
studies	I-PROC
are	O
warranted	O
to	O
confirm	O
these	O
observations	B-PROC
.	O

Dysplasia	B-DISO
discrimination	O
in	O
intestinal	B-ANAT
-	O
type	O
neoplasia	B-DISO
of	O
the	O
esophagus	B-ANAT
and	O
colon	B-ANAT
via	O
digital	B-PROC
image	I-PROC
analysis	I-PROC
Determining	O
gastrointestinal	B-ANAT
tract	I-ANAT
dysplasia	B-DISO
level	O
is	O
clinically	O
important	O
but	O
can	O
be	O
difficult	O
,	O
and	O
given	O
this	O
challenge	O
,	O
we	O
investigated	O
colonic	B-ANAT
and	O
esophageal	O
dysplastic	B-DISO
progression	O
using	O
digital	B-PROC
image	I-PROC
analysis	I-PROC
(	O
IA	B-PROC
)	O
.	O

Whole	O
slide	O
images	O
were	O
obtained	O
for	O
colonic	O
normal	O
mucosa	O
(	O
NCM	O
)	O
,	O
hyperplastic	B-DISO
polyps	I-DISO
(	O
HP	B-DISO
)	O
,	O
conventional	O
tubular	B-DISO
adenomas	I-DISO
(	O
TA	B-DISO
)	O
,	O
and	O
adenomas	B-DISO
with	O
high	B-DISO
-	I-DISO
grade	I-DISO
dysplasia	I-DISO
(	O
HGD	B-DISO
)	O
,	O
and	O
esophageal	B-DISO
intestinal	I-DISO
metaplasia	I-DISO
negative	B-DISO
for	O
dysplasia	B-DISO
(	O
IM	B-DISO
)	O
,	O
indefinite	B-DISO
for	I-DISO
dysplasia	I-DISO
(	O
IFD	B-DISO
)	O
,	O
low	B-DISO
-	I-DISO
grade	I-DISO
dysplasia	I-DISO
(	O
LGD	B-DISO
)	O
,	O
and	O
HGD	B-DISO
.	O

Characteristic	O
nuclei	O
were	O
circumscribed	O
,	O
and	O
parameters	O
discriminating	O
groups	O
included	O
nuclear	O
circumference	O
(	O
μm	O
)	O
,	O
area	O
(	O
μm	O
(	O
2	O
)	O
)	O
,	O
and	O
15	O
positive	B-PROC
pixel	I-PROC
count	I-PROC
(	I-PROC
PPC	I-PROC
)	I-PROC
algorithm	I-PROC
IA	I-PROC
measurements	O
.	O

In	O
colon	B-DISO
polyps	I-DISO
and	O
esophageal	O
lesions	B-DISO
,	O
average	B-DISO
nuclear	I-DISO
area	I-DISO
and	O
circumference	O
ranged	O
30	O
-	O
108	O
.	O

6	O
μm	O
(	O
2	O
)	O
and	O
27	O
.	O
5	O
-	O
48	O
.	O
9	O
μm	O
,	O
respectively	O
.	O

Differences	O
for	O
average	B-DISO
nuclear	I-DISO
area	I-DISO
and	O
circumference	O
met	O
statistical	O
significance	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
diagnostic	O
groups	O
in	O
the	O
esophagus	B-ANAT
and	O
colon	B-ANAT
,	O
except	O
for	O
IM	B-DISO
versus	O
IFD	B-DISO
nuclear	O
area	O
.	O

Pixel	O
intensity	O
(	O
brightness	O
)	O
separated	O
lesions	B-DISO
within	O
both	O
groups	O
with	O
statistical	O
significance	O
except	O
for	O
colonic	B-DISO
TAs	I-DISO
versus	O
HPs	B-DISO
and	O
esophageal	B-DISO
LGD	I-DISO
versus	O
IM	O
.	O

HGD	B-DISO
nuclei	O
in	O
both	O
groups	O
demonstrated	O
more	O
pixel	O
staining	O
heterogeneity	O
than	O
other	O
lesions	B-DISO
.	O

Hierarchical	B-PROC
clustering	I-PROC
and	O
principal	O
component	O
analysis	O
demonstrated	O
that	O
lesions	B-DISO
with	O
similar	O
diagnoses	B-DISO
tended	O
to	O
cluster	O
together	O
on	O
a	O
low	O
-	O
to	O
high	O
-	O
grade	O
spectrum	O
.	O

Our	O
results	O
confirm	O
that	O
quantitative	B-PROC
IA	I-PROC
is	O
an	O
effective	O
adjunct	O
reflecting	O
dysplasia	B-DISO
in	O
colon	B-DISO
polyps	I-DISO
and	O
Barrett	B-DISO
esophagus	I-DISO
lesions	B-DISO
.	O

Nuclear	B-DISO
area	I-DISO
,	O
circumference	O
,	O
and	O
PPC	O
algorithm	O
findings	O
distinguished	O
lesions	B-DISO
in	O
a	O
statistically	O
significant	O
manner	O
.	O

This	O
suggests	O
utility	O
for	O
future	O
studies	O
on	O
similar	O
methods	O
,	O
which	O
may	O
provide	O
an	O
adjunctive	O
ancillary	O
technique	O
for	O
pathologists	B-LIVB
and	O
enhance	O
patient	B-PROC
care	I-PROC
.	O

Unintentional	B-DISO
Injuries	I-DISO
in	O
Children	B-LIVB
Up	O
to	O
Six	O
Years	O
of	O
Age	B-PHYS
and	O
Related	O
Parental	B-LIVB
Knowledge	O
,	O
Attitudes	B-PHYS
,	O
and	O
Behaviors	O
in	O
Italy	B-GEOG
To	O
describe	O
risk	B-DISO
factors	I-DISO
associated	O
with	O
unintentional	B-DISO
injuries	I-DISO
among	O
children	B-LIVB
aged	O
<	O
6	O
years	O
and	O
to	O
examine	O
parents	B-LIVB
'	O
level	O
of	O
knowledge	O
,	O
attitudes	B-PHYS
,	O
and	O
behaviors	O
about	O
pediatric	O
injuries	B-DISO
and	O
related	O
preventive	O
measures	O
.	O

A	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
survey	I-PROC
was	O
conducted	O
between	O
May	O
and	O
July	O
2015	O
on	O
a	O
random	B-PROC
sample	I-PROC
of	O
794	O
parents	B-LIVB
of	O
3	O
-	O
to	O
6	O
-	O
year	O
-	O
old	O
children	B-LIVB
through	O
a	O
self	O
-	O
administered	O
anonymous	O
questionnaire	O
.	O

A	O
total	O
of	O
409	O
parents	B-LIVB
participated	O
.	O

Two	O
-	O
thirds	O
of	O
the	O
children	B-LIVB
had	O
experienced	O
at	O
least	O
1	O
unintentional	B-DISO
injury	I-DISO
in	O
the	O
previous	O
12	O
months	O
.	O

More	O
than	O
one	O
-	O
half	O
of	O
these	O
children	B-LIVB
were	O
boys	B-LIVB
.	O

The	O
leading	B-DISO
cause	I-DISO
was	O
falls	B-DISO
;	O
the	O
injuries	B-DISO
occurred	O
mainly	O
at	O
home	O
,	O
and	O
only	O
9	O
.	O
2	O
%	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency	B-OBJC
department	I-OBJC
.	O

Parents	B-LIVB
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional	B-DISO
injuries	I-DISO
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	B-LIVB
injured	O
.	O

Approximately	O
70	O
%	O
of	O
respondents	B-LIVB
were	O
aware	B-PHYS
of	O
security	O
measures	O
to	O
prevent	O
pediatric	O
injuries	B-DISO
,	O
and	O
this	O
knowledge	O
was	O
more	O
prevalent	O
in	O
older	O
parents	B-LIVB
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college	B-PROC
level	I-PROC
of	I-PROC
education	I-PROC
compared	O
with	O
those	O
with	O
a	O
middle	B-PROC
school	I-PROC
education	I-PROC
.	O

The	O
perceived	B-PHYS
utility	O
of	O
education	B-PROC
about	O
preventive	O
measures	O
of	O
pediatric	O
injuries	B-DISO
had	O
a	O
mean	O
value	O
of	O
8	O
.	O

9	O
on	O
a	O
Likert	O
scale	O
of	O
1	O
-	O
10	O
(	O
1	O
,	O
not	O
useful	O
,	O
to	O
10	O
,	O
very	O
useful	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	B-LIVB
.	O

This	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public	B-PROC
health	I-PROC
educational	B-PROC
programs	I-PROC
for	O
parents	B-LIVB
regarding	O
prevention	O
of	O
unintentional	B-DISO
injuries	I-DISO
in	O
children	B-LIVB
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	B-PHEN
and	O
injury	B-PROC
prevention	I-PROC
and	O
to	O
reduce	O
risks	O
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	B-DISO
occur	O
at	O
home	O
.	O

Aeromonas	B-LIVB
salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
strains	B-LIVB
isolated	O
from	O
Chinese	B-LIVB
freshwater	I-LIVB
fish	I-LIVB
contain	O
a	O
novel	O
genomic	B-CHEM
island	I-CHEM
and	O
possible	O
regional	O
-	O
specific	O
mobile	B-CHEM
genetic	I-CHEM
elements	I-CHEM
profiles	O
Two	O
strains	B-LIVB
of	O
Aeromonas	B-LIVB
salmonicida	I-LIVB
,	O
YK	B-LIVB
and	O
BG	B-LIVB
,	O
were	O
isolated	O
from	O
largemouth	B-LIVB
bronze	I-LIVB
gudgeon	I-LIVB
and	O
northern	B-LIVB
whitefish	I-LIVB
in	O
China	B-GEOG
,	O
and	O
identified	O
as	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
based	O
on	O
phylogenetic	B-PROC
analysis	I-PROC
of	O
vapA	O
and	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequences	O
.	O

YK	B-LIVB
and	O
BG	B-LIVB
originated	O
from	O
freshwater	B-LIVB
fish	I-LIVB
,	O
one	O
of	O
which	O
belonged	O
to	O
the	O
cyprinid	B-LIVB
family	I-LIVB
,	O
and	O
the	O
strains	B-LIVB
showed	O
a	O
difference	O
in	O
virulence	B-PHEN
.	O

Subsequently	O
,	O
we	O
performed	O
whole	O
genome	B-PROC
sequencing	I-PROC
of	O
the	O
strains	B-LIVB
,	O
and	O
comparison	O
of	O
their	O
genomic	O
sequences	O
to	O
the	O
genome	O
of	O
the	O
A449	B-LIVB
reference	I-LIVB
strain	I-LIVB
revealed	O
various	O
genomic	B-PHYS
rearrangements	I-PHYS
,	O
including	O
a	O
new	O
variant	O
of	O
the	O
genomic	B-CHEM
island	I-CHEM
AsaGEI	B-CHEM
in	O
BG	B-LIVB
,	O
designated	O
as	O
AsaGEI2c	B-CHEM
This	O
is	O
the	O
first	O
report	O
on	O
a	O
GEI	B-PHYS
of	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
strain	I-LIVB
from	O
China	B-GEOG
.	O

Furthermore	O
,	O
both	O
YK	B-LIVB
and	O
BG	B-LIVB
strains	O
contained	O
a	O
Tn7	B-CHEM
transposon	I-CHEM
inserted	O
at	O
the	O
same	O
position	O
in	O
the	O
chromosome	B-ANAT
.	O

Finally	O
,	O
IS	B-PHYS
-	I-PHYS
dependent	I-PHYS
rearrangements	I-PHYS
on	O
pAsa5	B-CHEM
are	O
deemed	O
likely	O
to	O
have	O
occurred	O
,	O
with	O
omission	B-DISO
of	O
the	O
resD	O
gene	O
in	O
both	O
strains	B-LIVB
as	O
well	O
as	O
omission	B-DISO
of	O
genes	O
related	O
to	O
the	O
IncF	B-CHEM
conjugal	O
transfer	O
system	O
in	O
the	O
YK	B-LIVB
isolate	O
.	O

This	O
study	O
demonstrates	O
that	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
can	O
infect	B-DISO
non	B-LIVB
-	I-LIVB
salmonids	I-LIVB
(	O
cyprinids	B-LIVB
)	O
in	O
addition	O
to	O
salmonids	B-LIVB
,	O
and	O
that	O
AsaGEI2c	B-CHEM
might	O
be	O
useful	O
as	O
a	O
geographical	B-CHEM
indicator	I-CHEM
of	O
Chinese	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
isolates	O
.	O

Evaluation	B-PROC
of	O
Pharmacokinetics	B-PHYS
,	O
and	O
Bioavailability	O
of	O
Higher	O
Doses	O
of	O
Tocotrienols	B-CHEM
in	O
Healthy	O
Fed	O
Humans	B-LIVB
Tocotrienols	B-CHEM
has	O
been	O
known	O
to	O
lower	B-DISO
serum	I-DISO
lipid	I-DISO
parameters	I-DISO
below	O
500	O
mg	O
/	O
d	O
,	O
while	O
increase	B-DISO
lipid	I-DISO
parameters	I-DISO
at	O
higher	O
dose	O
of	O
750	O
mg	O
/	O
d	O
.	O

δ	B-CHEM
-	I-CHEM
Tocotrienol	I-CHEM
has	O
a	O
novel	O
inflammatory	O
property	O
of	O
concentration	O
-	O
dependent	O
inhibition	O
and	O
activation	O
.	O

Therefore	O
,	O
inhibition	O
(	O
anti	O
-	O
inflammatory	O
)	O
property	O
of	O
tocotrienols	B-CHEM
at	O
low	O
doses	O
is	O
useful	O
for	O
cardiovascular	B-DISO
disease	I-DISO
,	O
whereas	O
,	O
activation	O
(	O
pro	O
-	O
inflammatory	O
)	O
property	O
using	O
high	O
dose	O
is	O
found	O
effective	O
for	O
treatments	B-PROC
of	O
various	O
types	O
of	O
cancer	B-DISO
.	O

We	O
have	O
recently	O
described	O
plasma	B-ANAT
bioavailability	O
of	O
125	O
mg	O
/	O
d	O
,	O
250	O
mg	O
/	O
d	O
and	O
500	O
mg	O
/	O
d	O
doses	O
of	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
in	O
healthy	O
fed	O
subjects	B-LIVB
,	O
which	O
showed	O
dose	O
-	O
dependent	O
increases	B-DISO
in	I-DISO
area	I-DISO
under	I-DISO
the	I-DISO
curve	I-DISO
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
.	O

Hence	O
,	O
in	O
the	O
current	O
study	O
,	O
higher	O
doses	O
of	O
tocotrienols	B-CHEM
have	O
used	O
to	O
analyze	O
its	O
effect	O
on	O
plasma	B-ANAT
pharmacokinetic	O
parameters	O
.	O

To	O
evaluate	B-PROC
the	O
safety	B-PHEN
and	O
bioavailability	O
of	O
higher	O
doses	O
(	O
750	O
mg	O
and	O
1000	O
mg	O
)	O
of	O
annatto	B-CHEM
-based	O
tocotrienols	B-CHEM
in	O
healthy	O
fed	O
subjects	B-LIVB
.	O

All	O
four	O
isomers	O
(	O
α	O
-	O
,	O
β	O
-	O
,	O
γ	O
-	O
,	O
δ	O
-	O
)	O
of	O
tocols	B-CHEM
(	O
tocotrienols	B-CHEM
and	O
tocopherols	B-CHEM
)	O
present	O
in	O
the	O
plasmas	B-ANAT
of	O
subjects	B-LIVB
were	O
quantified	O
and	O
analyzed	B-PROC
for	O
various	O
pharmacokinetic	O
parameters	O
.	O

An	O
open	B-PROC
-	I-PROC
label	I-PROC
,	O
randomized	B-PROC
study	I-PROC
was	O
performed	O
to	O
analyze	O
pharmacokinetics	B-PHYS
and	O
bioavailability	O
of	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
in	O
6	O
healthy	O
fed	O
subjects	B-LIVB
.	O

All	O
subjects	B-LIVB
(	O
3	O
/	O
dose	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
each	O
dose	O
of	O
750	O
mg	O
or	O
1000	O
mg	O
.	O

Blood	B-ANAT
samples	I-ANAT
were	O
collected	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
h	O
intervals	O
and	O
all	O
isomers	O
of	O
α	B-CHEM
-	I-CHEM
,	O
β	B-CHEM
-	I-CHEM
,	O
γ	B-CHEM
-	I-CHEM
,	O
δ	B-CHEM
-	I-CHEM
tocotrienols	I-CHEM
,	O
and	O
tocopherols	B-CHEM
in	O
plasmas	B-ANAT
were	O
quantified	O
by	O
HPLC	B-PROC
.	O

Oral	B-PROC
administration	I-PROC
of	O
750	O
and	O
1000	O
mg	O
/	O
d	O
of	O
tocotrienols	B-CHEM
resulted	O
in	O
dose	O
-	O
dependent	O
increases	O
in	O
plasmas	B-ANAT
(	O
ng	O
/	O
ml	O
)	O
AUC	O
t0	O
-	O
t8	O
6621	O
,	O
7450	O
;	O
AUC	O
t0	O
-	O
∞	O
8688	O
,	O
9633	O
;	O
AUMC	O
t0	O
-	O
∞	O
52497	O
,	O
57199	O
;	O
MRT	O
6	O
.	O

04	O
,	O
5	O
.	O
93	O
;	O
Cmax	O
1444	O
,	O
1592	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
,	O
of	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
isomer	I-CHEM
.	O

Moreover	O
,	O
both	O
doses	O
also	O
resulted	O
in	O
plasmas	B-ANAT
Tmax	O
3	O
.	O
33	O
-	O
4	O
h	O
;	O
elimination	O
half	O
-	O
life	O
(	O
t1	O
/	O
2	O
h	O
)	O
2	O
.	O
74	O
,	O
2	O
.	O
68	O
;	O
time	O
of	O
clearance	O
(	O
Cl	O
-	O
T	O
,	O
l	O
/	O
h	O
)	O
0	O
.	O
086	O
,	O
0	O
.	O

078	O
;	O
volume	O
of	O
distribution	O
(	O
Vd	O
/	O
f	O
,	O
mg	O
/	O
h	O
)	O
0	O
.	O
34	O
,	O
0	O
.	O
30	O
;	O
and	O
elimination	O
rate	O
constant	O
(	O
ke	O
;	O
h	O
(	O
-	O
1	O
)	O
)	O
0	O
.	O
25	O
,	O
0	O
.	O
17	O
,	O
respectively	O
of	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
isomer	I-CHEM
.	O

Similar	O
results	B-DISO
of	O
these	O
parameters	B-DISO
were	O
reported	B-PROC
for	O
γ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
,	O
β	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
,	O
α	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
,	O
δ	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
,	O
γ	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
,	O
and	O
β	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
,	O
except	O
for	O
α	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
.	O

This	O
study	O
has	O
described	O
pharmacokinetics	B-PHYS
using	O
higher	O
doses	O
of	O
750	O
mg	O
/	O
d	O
and	O
1000	O
mg	O
/	O
d	O
of	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
.	O

These	O
results	B-DISO
confirmed	O
earlier	O
findings	O
that	O
Tmax	O
was	O
3	O
-	O
4	O
h	O
for	O
all	O
isomers	O
of	O
tocotrienols	B-CHEM
and	O
tocopherols	B-CHEM
except	O
for	O
α	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
(	O
6	O
h	O
)	O
.	O

These	O
higher	O
doses	O
of	O
tocotrienols	B-CHEM
were	O
found	O
safe	O
in	O
humans	B-LIVB
and	O
may	O
be	O
useful	O
for	O
treatments	B-PROC
of	O
various	O
types	O
of	O
cancer	B-DISO
,	O
diabetes	B-DISO
,	O
and	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
.	O

The	O
effect	O
of	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
supplementation	B-PROC
on	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
and	O
weight	B-DISO
changes	I-DISO
in	O
pulmonary	B-DISO
TB	I-DISO
patients	B-LIVB
:	O
A	O
randomized	B-PROC
controlled	I-PROC
trial	I-PROC
Acceleration	B-PHEN
in	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
helps	O
faster	O
improvement	O
and	O
decreased	O
probability	O
of	O
the	O
transfer	O
of	O
TB	B-DISO
.	O

In	O
this	O
study	B-PROC
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
supplementation	B-PROC
on	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
and	O
weight	B-DISO
changes	I-DISO
in	O
smear	B-DISO
positive	I-DISO
pulmonary	B-DISO
TB	I-DISO
patients	B-LIVB
in	O
Iran	B-GEOG
.	O

In	O
this	O
double	O
blind	O
clinical	B-PROC
study	I-PROC
,	O
TB	B-DISO
patients	B-LIVB
were	O
divided	O
into	O
intervention	B-PROC
,	O
(	O
n	O
=	O
43	O
)	O
receiving	O
500	O
mg	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
(	O
GTE	B-CHEM
)	O
,	O
and	O
control	B-LIVB
groups	I-LIVB
(	O
n	O
=	O
40	O
)	O
receiving	O
placebo	B-CHEM
for	O
two	O
months	O
,	O
using	O
balanced	B-PROC
randomization	I-PROC
.	O

Random	B-PROC
allocation	I-PROC
and	O
allocation	O
concealment	O
were	O
observed	O
.	O

Height	B-PHYS
and	I-PHYS
weight	I-PHYS
were	O
measured	O
at	O
the	O
beginning	O
,	O
and	O
two	O
and	O
six	O
months	O
post	O
-	O
treatment	O
.	O

Evaluations	B-PROC
were	O
performed	O
on	O
three	O
slides	B-DEVI
,	O
using	O
the	O
ZiehlNeelsen	B-PROC
method	I-PROC
.	O

Independent	O
and	O
paired	O
t	O
test	O
,	O
McNemar	O
's	O
,	O
Wilcoxon	O
,	O
Kaplan	O
-	O
Meier	O
,	O
Cox	O
regression	O
model	O
and	O
Log	O
-	O
Rank	O
test	O
were	O
utilized	O
.	O

Statistical	O
significance	O
was	O
set	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

This	O
trial	B-PROC
was	O
registered	B-PROC
under	O
IRCT201212232602N11	O
.	O

The	O
interventional	B-PROC
changes	O
and	O
the	O
interactive	O
effect	O
of	O
intervention	B-PROC
on	O
weight	B-PHYS
were	O
not	B-DISO
significant	I-DISO
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

In	O
terms	O
of	O
shortening	O
the	O
duration	O
of	O
conversion	B-PROC
,	O
the	O
case	O
to	O
control	O
proportion	O
showed	O
a	O
significant	O
difference	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
.	O

Based	O
on	O
the	O
Cox	O
regression	O
model	O
,	O
the	O
hazard	O
ratio	O
of	O
the	O
relative	O
risk	O
of	O
delay	O
in	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
was	O
3	O
.	O

7	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
in	O
the	O
higher	O
microbial	O
load	O
group	B-LIVB
compared	O
to	O
the	O
placebo	B-CHEM
group	B-LIVB
and	O
0	O
.	O
54	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
31	O
-	O
0	O
.	O
94	O
)	O
in	O
the	O
intervention	B-PROC
compared	O
to	O
the	O
placebo	B-CHEM
group	B-LIVB
.	O

GTE	B-CHEM
decreases	B-DISO
the	O
risk	O
of	O
delay	O
in	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
,	O
but	O
has	O
no	O
effect	O
on	O
weight	B-DISO
gain	I-DISO
.	O

Moreover	O
,	O
it	O
may	O
be	O
used	O
as	O
an	O
adjuvant	B-PROC
therapy	I-PROC
for	O
faster	O
rehabilitation	O
for	O
pulmonary	B-DISO
TB	I-DISO
patients	B-LIVB
.	O

Reduction	O
in	O
Hospital	B-OBJC
-	I-OBJC
Wide	I-OBJC
Clinical	B-PROC
Laboratory	I-PROC
Specimen	I-PROC
Identification	I-PROC
Errors	O
following	O
Process	O
Interventions	O
:	O
A	O
10	O
-	O
Year	O
Retrospective	B-PROC
Observational	I-PROC
Study	I-PROC
Accurate	O
patient	B-PROC
identification	I-PROC
and	O
specimen	B-PROC
labeling	I-PROC
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	O
steps	O
in	O
the	O
prevention	B-PROC
of	O
medical	O
errors	O
,	O
thereby	O
improving	O
patient	B-PROC
safety	I-PROC
.	O

All	O
patient	B-ANAT
specimen	I-ANAT
identification	O
errors	O
that	O
occurred	O
in	O
the	O
outpatient	O
department	O
(	O
OPD	O
)	O
,	O
emergency	B-OBJC
department	I-OBJC
(	O
ED	B-OBJC
)	O
,	O
and	O
inpatient	O
department	O
(	O
IPD	O
)	O
of	O
a	O
3	O
,	O
800	O
-	O
bed	B-OBJC
academic	B-OBJC
medical	I-OBJC
center	I-OBJC
in	O
Taiwan	B-GEOG
were	O
documented	B-PROC
and	O
analyzed	B-PROC
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O

To	O
reduce	O
such	O
errors	O
,	O
the	O
following	O
series	O
of	O
strategies	O
were	O
implemented	O
:	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
for	O
the	O
ED	B-OBJC
and	O
IPD	O
in	O
2006	O
;	O
a	O
computer	B-PROC
-	I-PROC
assisted	I-PROC
barcode	O
positive	B-OBJC
patient	I-OBJC
identification	I-OBJC
system	I-OBJC
for	O
the	O
ED	B-OBJC
and	O
IPD	O
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	O
sample	B-PROC
labeling	I-PROC
combined	O
with	O
electronic	B-PROC
identification	I-PROC
systems	I-PROC
introduced	O
to	O
the	O
OPD	O
in	O
2009	O
.	O

Of	O
the	O
2000345	O
specimens	B-ANAT
collected	O
in	O
2005	O
,	O
1023	O
(	O
0	O
.	O
0511	O
%	O
)	O
were	O
identified	B-DISO
as	O
having	O
patient	B-PROC
identification	I-PROC
errors	O
,	O
compared	O
with	O
58	O
errors	O
(	O
0	O
.	O
0015	O
%	O
)	O
among	O
3761238	O
specimens	B-ANAT
collected	O
in	O
2014	O
,	O
after	O
serial	O
interventions	B-PROC
;	O
this	O
represents	O
a	O
97	O
%	O
relative	O
reduction	O
.	O

The	O
total	O
number	O
(	O
rate	O
)	O
of	O
institutional	B-PROC
identification	I-PROC
errors	O
contributed	O
from	O
the	O
ED	B-OBJC
,	O
IPD	O
,	O
and	O
OPD	O
over	O
a	O
10	O
-	O
year	O
period	O
were	O
423	O
(	O
0	O
.	O
1058	O
%	O
)	O
,	O
556	O
(	O
0	O
.	O
0587	O
%	O
)	O
,	O
and	O
44	O
(	O
0	O
.	O
0067	O
%	O
)	O
errors	O
before	O
the	O
interventions	B-PROC
,	O
and	O
3	O
(	O
0	O
.	O
0007	O
%	O
)	O
,	O
52	O
(	O
0	O
.	O
0045	O
%	O
)	O
and	O
3	O
(	O
0	O
.	O
0001	O
%	O
)	O
after	O
interventions	B-PROC
,	O
representing	O
relative	O
99	O
%	O
,	O
92	O
%	O
and	O
98	O
%	O
reductions	O
,	O
respectively	O
.	O

Accurate	O
patient	B-PROC
identification	I-PROC
is	O
a	O
challenge	O
of	O
patient	B-PROC
safety	I-PROC
in	O
different	O
health	O
settings	O
.	O

The	O
data	B-DISO
collected	I-DISO
in	O
our	O
study	B-PROC
indicate	O
that	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
,	O
computer	B-PROC
-	I-PROC
generated	I-PROC
positive	B-OBJC
identification	I-OBJC
systems	I-OBJC
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	O
patient	B-PROC
identification	I-PROC
errors	O
.	O

Truncated	B-LIVB
Bovine	I-LIVB
Integrin	B-CHEM
Alpha	I-CHEM
-	I-CHEM
v	I-CHEM
/	I-CHEM
Beta	I-CHEM
-	I-CHEM
6	I-CHEM
as	O
a	O
Universal	B-PHYS
Capture	I-PHYS
Ligand	I-PHYS
for	O
FMD	B-DISO
Diagnosis	B-DISO
Foot	B-DISO
-	I-DISO
and	I-DISO
-	I-DISO
mouth	I-DISO
disease	I-DISO
(	O
FMD	B-DISO
)	O
is	O
endemic	B-DISO
in	O
many	O
regions	O
of	O
the	O
world	B-LIVB
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	B-PHEN
animal	B-DISO
diseases	I-DISO
.	O

FMD	B-DISO
affects	O
livestock	B-LIVB
,	O
such	O
as	O
cattle	B-LIVB
,	O
sheep	B-LIVB
,	O
goats	B-LIVB
and	O
pigs	B-LIVB
,	O
and	O
causes	O
enormous	O
economic	O
losses	O
due	O
to	O
reduced	O
productivity	O
and	O
trade	O
restrictions	O
.	O

Preparedness	B-DISO
and	O
early	B-PROC
diagnosis	I-PROC
are	O
essential	O
for	O
effective	B-PROC
control	I-PROC
of	O
FMD	B-DISO
.	O

Many	O
diagnostic	B-PROC
assays	I-PROC
are	O
dependent	O
on	O
raising	O
high	O
-	O
affinity	O
,	O
anti	B-LIVB
-	I-LIVB
FMD	I-LIVB
virus	I-LIVB
(	O
FMDV	B-LIVB
)	O
serotype	B-CHEM
-	I-CHEM
specific	I-CHEM
antibodies	I-CHEM
in	O
small	O
animals	B-LIVB
(	O
rabbits	B-LIVB
and	O
guinea	B-LIVB
pigs	I-LIVB
)	O
that	O
give	O
broad	O
virus	B-LIVB
coverage	O
.	O

Here	O
we	O
show	O
that	O
soluble	O
,	O
truncated	O
forms	O
of	O
bovine	B-LIVB
αvβ6	B-CHEM
bind	B-PHYS
FMDV	B-LIVB
in	O
an	O
authentic	O
RGD	B-CHEM
and	O
divalent	B-PHYS
cation	I-PHYS
dependent	I-PHYS
interaction	I-PHYS
and	O
can	O
be	O
used	O
as	O
the	O
trapping	B-CHEM
reagent	I-CHEM
in	O
a	O
FMDV	B-LIVB
sandwich	B-PROC
ELISA	I-PROC
.	O

In	O
addition	O
,	O
inclusion	O
of	O
FLAG	B-CHEM
or	O
His	B-CHEM
tags	I-CHEM
facilitates	O
simple	O
purification	B-PROC
without	O
the	O
loss	O
of	O
virus	B-PHEN
binding	I-PHEN
.	O

We	O
also	O
provide	O
evidence	O
that	O
when	O
combined	O
with	O
a	O
guinea	B-LIVB
pig	I-LIVB
polyclonal	B-ANAT
serum	I-ANAT
,	O
or	O
serotype	B-CHEM
-	I-CHEM
specific	I-CHEM
monoclonal	I-CHEM
antibodies	I-CHEM
,	O
the	O
integrin	B-CHEM
can	O
be	O
used	O
to	O
detect	B-DISO
viruses	B-LIVB
representative	O
of	O
all	O
FMDV	B-LIVB
serotypes	I-LIVB
.	O

We	O
also	O
show	O
that	O
recombinant	B-LIVB
FMDV	I-LIVB
empty	B-ANAT
capsids	I-ANAT
,	O
with	O
stabilising	B-PHEN
disulphide	I-PHEN
bonds	I-PHEN
,	O
can	O
serve	O
as	O
an	O
antigen	B-CHEM
in	O
the	O
ELISA	B-PROC
and	O
can	O
therefore	O
replace	O
inactivated	B-CHEM
virus	I-CHEM
antigen	I-CHEM
as	O
a	O
positive	O
control	O
for	O
the	O
assay	B-PROC
.	O

Our	O
results	B-PHEN
demonstrate	O
the	O
potential	O
use	O
of	O
bovine	B-LIVB
αvβ6	B-CHEM
and	O
FMDV	B-LIVB
empty	B-ANAT
capsids	I-ANAT
in	O
FMD	B-DISO
diagnostic	B-PROC
assays	I-PROC
.	O

Novel	O
antibody	B-CHEM
probes	O
for	O
the	O
characterization	O
of	O
endosialin	B-CHEM
/	O
TEM	B-CHEM
-	I-CHEM
1	I-CHEM
Endosialin	B-CHEM
(	I-CHEM
Tumor	I-CHEM
Endothelial	I-CHEM
Marker	I-CHEM
-	I-CHEM
1	I-CHEM
(	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
)	I-CHEM
,	I-CHEM
CD248	I-CHEM
)	I-CHEM
is	O
primarily	O
expressed	O
on	O
pericytes	B-ANAT
of	O
tumor	B-DISO
-	O
associated	O
microvasculature	B-PHYS
,	O
tumor	B-DISO
-	O
associated	O
stromal	B-ANAT
cells	I-ANAT
and	O
directly	O
on	O
tumors	B-DISO
of	O
mesenchymal	B-ANAT
origin	I-ANAT
,	O
including	O
sarcoma	B-DISO
and	O
melanoma	B-DISO
.	O

While	O
the	O
function	O
of	O
endosialin	B-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
is	O
incompletely	O
understood	O
,	O
studies	B-PROC
have	O
suggested	O
a	O
role	O
in	O
supporting	O
tumor	B-DISO
growth	I-DISO
and	O
invasion	B-DISO
thus	O
making	O
it	O
an	O
attractive	O
therapeutic	O
target	O
.	O

In	O
an	O
effort	O
to	O
further	O
understand	O
its	O
role	O
in	O
cancer	B-DISO
,	O
we	O
previously	O
developed	O
a	O
humanized	B-CHEM
anti	B-CHEM
-	I-CHEM
endosialin	I-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
monoclonal	B-CHEM
antibody	I-CHEM
(	O
mAb	B-CHEM
)	O
,	O
called	O
ontuxizumab	B-CHEM
(	O
MORAb	B-CHEM
-	I-CHEM
004	I-CHEM
)	O
for	O
testing	O
in	O
preclinical	B-PROC
and	O
clinical	B-PROC
studies	I-PROC
.	O

We	O
herein	O
report	O
on	O
the	O
generation	O
of	O
an	O
extensive	O
panel	O
of	O
recombinant	B-CHEM
endosialin	B-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
protein	I-CHEM
extracellular	O
domain	O
(	O
ECD	O
)	O
fragments	B-CHEM
and	O
novel	O
mAbs	B-CHEM
against	O
ECD	O
motifs	O
.	O

The	O
domain	B-PHYS
-	I-PHYS
specific	I-PHYS
epitopes	B-CHEM
were	O
mapped	O
against	O
ECD	O
sub	O
-	O
domains	O
to	O
identify	O
those	O
that	O
can	O
detect	B-DISO
distinct	O
structural	O
motifs	O
and	O
can	O
be	O
potentially	O
formatted	O
as	O
probes	O
suitable	O
for	O
diagnostic	B-PROC
and	O
functional	O
studies	O
.	O

A	O
number	O
of	O
mAbS	B-CHEM
were	O
shown	O
to	O
cross	B-PROC
-	I-PROC
react	I-PROC
with	O
the	O
murine	B-CHEM
and	O
human	B-LIVB
protein	B-CHEM
,	O
potentially	O
allowing	O
their	O
use	O
in	O
human	B-LIVB
animal	B-LIVB
models	I-LIVB
and	O
corresponding	O
clinical	B-PROC
trials	I-PROC
.	O

In	O
addition	O
,	O
pairing	O
of	O
several	O
mAbs	B-CHEM
supported	O
their	O
use	O
in	O
immunoassays	B-PROC
that	O
can	O
detect	O
soluble	B-ANAT
endosialin	B-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
(	O
sEND	B-CHEM
)	O
in	O
the	O
serum	B-ANAT
of	O
healthy	B-LIVB
subjects	I-LIVB
and	O
cancer	B-LIVB
patients	I-LIVB
.	O

Identification	O
of	O
novel	O
macrolides	B-CHEM
with	O
antibacterial	B-PHYS
,	O
anti	O
-	O
inflammatory	O
and	O
type	B-CHEM
I	I-CHEM
and	O
III	B-CHEM
IFN	I-CHEM
-	O
augmenting	B-DISO
activity	I-DISO
in	O
airway	B-ANAT
epithelium	O
Exacerbations	B-DISO
of	I-DISO
asthma	I-DISO
and	O
COPD	B-DISO
are	O
triggered	O
by	O
rhinoviruses	B-LIVB
.	O

Uncontrolled	O
inflammatory	B-PHYS
pathways	I-PHYS
,	O
pathogenic	B-LIVB
bacterial	O
burden	O
and	O
impaired	O
antiviral	B-PHYS
immunity	I-PHYS
are	O
thought	O
to	O
be	O
important	O
factors	O
in	O
disease	O
severity	O
and	O
duration	O
.	O

Macrolides	B-CHEM
including	O
azithromycin	B-CHEM
are	O
often	O
used	O
to	O
treat	O
the	O
above	O
diseases	B-DISO
,	O
but	O
exhibit	O
variable	O
levels	O
of	O
efficacy	O
.	O

Inhaled	B-CHEM
corticosteroids	I-CHEM
are	O
also	O
readily	O
used	O
in	O
treatment	O
,	O
but	O
may	O
lack	O
specificity	O
.	O

Ideally	O
,	O
new	O
treatment	O
alternatives	O
should	O
suppress	O
unwanted	O
inflammation	B-DISO
,	O
but	O
spare	O
beneficial	O
antiviral	B-PHYS
immunity	I-PHYS
.	O

In	O
the	O
present	O
study	B-PROC
,	O
we	O
screened	O
225	O
novel	O
macrolides	B-CHEM
and	O
tested	O
them	O
for	O
enhanced	O
antiviral	B-PHYS
activity	I-PHYS
against	O
rhinovirus	B-LIVB
,	O
as	O
well	O
as	O
anti	B-DISO
-	I-DISO
inflammatory	I-DISO
activity	I-DISO
and	O
activity	O
against	O
Gram	B-LIVB
-	I-LIVB
positive	I-LIVB
and	O
Gram	B-LIVB
-	I-LIVB
negative	I-LIVB
bacteria	I-LIVB
.	O

Primary	O
bronchial	B-ANAT
epithelial	I-ANAT
cells	I-ANAT
were	O
grown	O
from	O
10	O
asthmatic	B-LIVB
individuals	I-LIVB
and	O
the	O
effects	O
of	O
macrolides	B-CHEM
on	O
rhinovirus	B-LIVB
replication	B-PHYS
were	O
also	O
examined	B-DISO
.	O

Another	O
30	O
structurally	O
similar	O
macrolides	B-CHEM
were	O
also	O
examined	B-DISO
.	O

The	O
oleandomycin	B-CHEM
derivative	O
Mac5	B-CHEM
,	O
compared	O
with	O
azithromycin	B-CHEM
,	O
showed	O
superior	O
induction	O
(	O
up	O
to	O
5	O
-	O
fold	O
,	O
EC	O
50	O
=	O
5	O
-	O
11	O
μM	O
)	O
of	O
rhinovirus	B-LIVB
-	O
induced	O
type	O
I	O
IFNβ	O
,	O
type	O
III	O
IFNλ1	O
and	O
type	O
III	O
IFNλ2	O
/	O
3	O
mRNA	B-CHEM
and	O
the	O
IFN	B-CHEM
-	O
stimulated	B-PHEN
genes	O
viperin	O
and	O
MxA	O
,	O
yet	O
had	O
no	O
effect	O
on	O
IL	O
-	O
6	O
and	O
IL	O
-	O
8	O
mRNA	B-CHEM
.	O

Mac5	B-CHEM
also	O
suppressed	O
rhinovirus	B-LIVB
replication	B-PHYS
at	O
48	O
h	O
,	O
proving	O
antiviral	B-PHYS
activity	I-PHYS
.	O

Mac5	B-CHEM
showed	O
antibacterial	B-PHYS
activity	I-PHYS
against	O
Gram	B-LIVB
-	I-LIVB
positive	I-LIVB
Streptococcus	B-LIVB
pneumoniae	I-LIVB
;	O
however	O
,	O
it	O
did	O
not	O
have	O
any	O
antibacterial	B-PHYS
properties	I-PHYS
compared	O
with	O
azithromycin	B-CHEM
when	O
used	O
against	O
Gram	B-LIVB
-	I-LIVB
negative	I-LIVB
Escherichia	B-LIVB
coli	I-LIVB
(	O
as	O
a	O
model	O
organism	O
)	O
and	O
also	O
the	O
respiratory	B-LIVB
pathogens	I-LIVB
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
and	O
non	O
-	O
typeable	O
Haemophilus	B-LIVB
influenzae	I-LIVB
.	O

Further	O
non	O
-	O
toxic	O
Mac5	B-CHEM
derivatives	O
were	O
identified	O
with	O
various	O
anti	O
-	O
inflammatory	O
,	O
antiviral	B-PHYS
and	O
antibacterial	B-PHYS
activities	I-PHYS
.	O

The	O
data	O
support	O
the	O
idea	O
that	O
macrolides	B-CHEM
have	O
antiviral	B-PHYS
properties	I-PHYS
through	O
a	O
mechanism	O
that	O
is	O
yet	O
to	O
be	O
ascertained	O
.	O

We	O
also	O
provide	O
evidence	O
that	O
macrolides	B-CHEM
can	O
be	O
developed	O
with	O
anti	O
-	O
inflammatory	O
,	O
antibacterial	B-PHYS
and	O
antiviral	B-PHYS
activity	I-PHYS
and	O
show	O
surprising	O
versatility	O
depending	O
on	O
the	O
clinical	O
need	O
.	O

Impact	O
of	O
AAC	B-CHEM
(	I-CHEM
6	I-CHEM
'	I-CHEM
)	I-CHEM
-	I-CHEM
Ib	I-CHEM
-	I-CHEM
cr	I-CHEM
in	O
combination	O
with	O
chromosomal	B-ANAT
-mediated	O
mechanisms	O
on	O
clinical	O
quinolone	B-CHEM
resistance	B-PHEN
in	O
Escherichia	B-LIVB
coli	I-LIVB
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
is	O
the	O
most	O
prevalent	O
plasmid	B-CHEM
-mediated	O
fluoroquinolone	B-CHEM
(	O
FQ	B-CHEM
)	O
resistance	B-PHYS
mechanism	I-PHYS
in	O
Enterobacteriaceae	B-LIVB
.	O

We	O
aimed	O
to	O
analyse	O
the	O
interplay	O
between	O
this	O
plasmid	B-CHEM
-mediated	O
gene	O
and	O
chromosomal	B-ANAT
-mediated	O
quinolone	B-CHEM
resistance	B-PHYS
mechanisms	I-PHYS
on	O
both	O
FQ	B-CHEM
resistance	B-PHEN
and	O
bacterial	B-LIVB
fitness	B-PHYS
in	O
Escherichia	B-LIVB
coli	I-LIVB
.	O

E	B-LIVB
.	I-LIVB

coli	I-LIVB
ATCC	I-LIVB
25922	I-LIVB
and	O
derived	O
isogenic	B-LIVB
strains	I-LIVB
carrying	O
chromosomal	B-ANAT
-mediated	O
quinolone	B-CHEM
resistance	B-PHEN
modifications	B-PROC
(	O
Ser83Leu	B-PHYS
-	I-PHYS
Asp87Asn	I-PHYS
in	O
GyrA	B-CHEM
,	O
Ser80Arg	B-PHYS
in	O
ParC	B-CHEM
and	O
/	O
or	O
a	O
marR	B-PHYS
gene	I-PHYS
deletion	I-PHYS
)	O
were	O
electroporated	B-PROC
with	O
a	O
pBK	B-CHEM
-	I-CHEM
CMV	I-CHEM
vector	B-CHEM
encoding	O
AAC	B-CHEM
(	I-CHEM
6	I-CHEM
'	I-CHEM
)	I-CHEM
-	I-CHEM
Ib	I-CHEM
-	I-CHEM
cr	I-CHEM
.	O

The	O
MICs	B-PHEN
of	O
FQs	B-CHEM
were	O
determined	O
by	O
microdilution	B-PROC
and	O
bactericidal	B-PHYS
activity	I-PHYS
was	O
determined	O
using	O
time	O
-	O
kill	O
curves	O
.	O

A	O
peritoneal	B-LIVB
sepsis	I-LIVB
murine	I-LIVB
model	I-LIVB
was	O
used	O
to	O
evaluate	O
the	O
in	O
vivo	O
impact	O
.	O

Bacterial	B-LIVB
fitness	B-PHYS
was	O
analysed	O
using	O
growth	O
curves	O
and	O
competition	B-PROC
assays	I-PROC
.	O

The	O
presence	O
of	O
the	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
increased	O
the	O
MICs	B-PHEN
of	O
ciprofloxacin	B-CHEM
and	O
norfloxacin	B-CHEM
4	O
-	O
8	O
-	O
fold	O
for	O
all	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
genotypes	B-PHYS
,	O
independently	O
of	O
the	O
initial	O
resistance	B-PHEN
level	O
.	O

Combination	O
of	O
the	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
with	O
three	O
or	O
four	O
chromosomal	B-ANAT
mechanisms	O
was	O
necessary	O
to	O
reach	O
MIC	B-PHEN
values	I-PHEN
above	O
the	O
susceptible	O
category	O
.	O

Killing	O
curve	O
assays	O
showed	O
a	O
clear	O
selective	O
advantage	O
for	O
survival	O
in	O
strains	O
harbouring	O
the	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
(	O
up	O
to	O
7	O
log10	O
cfu	O
/	O
mL	O
after	O
24	O
h	O
)	O
.	O

AAC	B-CHEM
(	I-CHEM
6	I-CHEM
'	I-CHEM
)	I-CHEM
-	I-CHEM
Ib	I-CHEM
-	I-CHEM
cr	I-CHEM
significantly	O
reduced	O
the	O
ciprofloxacin	B-CHEM
efficacy	O
in	O
vivo	O
.	O

In	O
terms	O
of	O
bacterial	B-LIVB
fitness	B-PHYS
cost	I-PHYS
,	O
maximal	O
OD	O
was	O
significantly	O
lower	O
for	O
all	O
strains	O
harbouring	O
the	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
,	O
independently	O
of	O
chromosomal	B-DISO
mutations	I-DISO
associated	O
.	O

The	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
,	O
in	O
spite	O
of	O
producing	O
low	O
-	O
level	O
resistance	B-PHEN
by	O
itself	O
,	O
plays	O
a	O
relevant	O
role	O
in	O
acquisition	O
of	O
a	O
clinical	O
level	O
of	O
ciprofloxacin	B-CHEM
and	O
norfloxacin	B-CHEM
resistance	B-PHEN
,	O
when	O
combined	O
with	O
three	O
or	O
four	O
chromosomal	B-DISO
mutations	I-DISO
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Cluster	O
-	O
dependent	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
in	O
Enterobacter	B-LIVB
cloacae	I-LIVB
complex	I-LIVB
Aims	O
of	O
this	O
study	O
were	O
to	O
:	O
(	O
i	O
)	O
evaluate	B-PROC
whether	O
the	O
cluster	O
membership	O
could	O
have	O
an	O
impact	O
on	O
hetero	O
-	O
resistance	O
phenotype	B-PHYS
to	O
colistin	B-CHEM
in	O
the	O
Enterobacter	B-LIVB
cloacae	I-LIVB
complex	I-LIVB
(	O
ECC	B-LIVB
)	O
;	O
and	O
(	O
ii	O
)	O
determine	O
the	O
genetic	O
mechanism	O
of	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
in	O
ECC	B-LIVB
.	O

A	O
collection	O
of	O
124	O
clinical	O
isolates	B-CHEM
belonging	O
to	O
13	O
clusters	O
were	O
used	O
to	O
analyse	B-PROC
the	O
hetero	O
-	O
resistance	O
phenotype	B-PHYS
(	O
MICs	B-PROC
were	O
determined	O
using	O
the	O
broth	B-PROC
microdilution	I-PROC
method	I-PROC
,	O
Etest	B-PROC
and	O
population	B-PROC
analysis	I-PROC
profiling	I-PROC
)	O
.	O

Different	O
mutants	B-DISO
(	O
ΔphoP	O
,	O
ΔphoQ	O
,	O
ΔphoPQ	O
,	O
ΔpmrA	O
,	O
ΔpmrB	O
,	O
ΔpmrAB	O
,	O
ΔarnE	O
,	O
ΔarnF	O
and	O
ΔarnBCADTEF	O
)	O
were	O
constructed	O
and	O
tested	O
for	O
their	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
phenotype	B-PHYS
.	O

Based	O
on	O
broth	B-PROC
microdilution	I-PROC
and	O
Etest	B-PROC
results	B-PHEN
,	O
it	O
was	O
shown	O
that	O
the	O
hetero	O
-	O
resistance	O
to	O
colistin	B-CHEM
depended	O
on	O
the	O
cluster	O
:	O
strains	B-LIVB
from	O
clusters	O
I	O
,	O
II	O
,	O
IV	O
,	O
VII	O
,	O
IX	O
,	O
X	O
,	O
XI	O
and	O
XII	O
were	O
usually	O
hetero	O
-	O
resistant	O
,	O
whereas	O
those	O
from	O
clusters	O
III	O
,	O
V	O
,	O
VI	O
,	O
VIII	O
and	O
XIII	O
were	O
categorized	O
as	O
susceptible	O
.	O

However	O
,	O
for	O
some	O
cluster	O
V	O
and	O
VIII	O
strains	B-LIVB
,	O
a	O
small	O
proportion	O
(	O
<	O
10	O
(	O
-	O
7	O
)	O
)	O
of	O
cells	B-ANAT
appeared	O
resistant	O
when	O
tested	O
by	O
population	O
analysis	O
profiling	O
.	O

From	O
a	O
mechanistic	O
point	O
of	O
view	O
,	O
analysis	B-PROC
of	O
mutants	B-DISO
revealed	O
that	O
the	O
mechanism	O
of	O
hetero	O
-	O
resistance	O
was	O
mainly	O
due	O
to	O
the	O
expression	B-PHYS
of	O
the	O
arn	O
operon	O
and	O
the	O
phoP	B-CHEM
/	O
phoQ	B-CHEM
two	B-CHEM
-	I-CHEM
component	I-CHEM
regulatory	I-CHEM
system	I-CHEM
.	O

Because	O
the	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
appeared	O
cluster	O
-	O
dependent	O
in	O
the	O
ECC	B-LIVB
,	O
it	O
should	O
be	O
advocated	O
to	O
determine	O
the	O
cluster	O
of	O
the	O
strain	B-LIVB
associated	O
with	O
the	O
infection	B-DISO
in	O
parallel	O
with	O
the	O
MIC	B-PROC
of	O
colistin	B-CHEM
.	O

The	O
resistance	O
mechanism	O
may	O
not	O
be	O
similar	O
to	O
other	O
Enterobacteriaceae	B-LIVB
since	O
only	O
the	O
two	B-CHEM
-	I-CHEM
component	I-CHEM
regulatory	I-CHEM
system	I-CHEM
PhoP	B-CHEM
/	O
PhoQ	B-CHEM
(	O
and	O
not	O
PmrA	B-CHEM
/	O
PmrB	B-CHEM
)	O
seemed	O
to	O
play	O
a	O
role	O
in	O
resistance	O
regulation	B-PHEN
.	O

Management	B-PROC
of	O
skin	B-DISO
and	I-DISO
soft	I-DISO
-	I-DISO
tissue	I-DISO
infections	I-DISO
at	O
a	O
community	O
teaching	B-OBJC
hospital	I-OBJC
using	O
a	O
severity	O
-	O
of	O
-	O
illness	O
tool	O
Skin	B-DISO
and	I-DISO
soft	I-DISO
-	I-DISO
tissue	I-DISO
infections	I-DISO
(	O
SSTIs	B-DISO
)	O
encompass	O
a	O
diverse	O
range	O
of	O
infections	B-DISO
of	O
varying	O
severity	O
.	O

The	O
Clinical	O
Resource	O
Efficiency	O
Support	O
Team	O
(	O
CREST	O
)	O
scoring	O
system	O
stratifies	O
patients	B-LIVB
into	O
four	O
classes	O
(	O
I	O
=	O
least	O
severe	O
to	O
IV	O
=	O
most	O
severe	O
)	O
based	O
on	O
the	O
Standardized	O
Early	O
Warning	O
Score	O
(	O
SEWS	O
)	O
.	O

The	O
objective	O
of	O
this	O
study	B-PROC
was	O
to	O
apply	O
CREST	O
to	O
hospitalized	B-LIVB
patients	I-LIVB
with	O
SSTIs	B-DISO
in	O
order	O
to	O
quantify	O
disease	O
severity	O
and	O
evaluate	B-PROC
appropriateness	O
of	O
antibiotic	B-CHEM
management	O
.	O

This	O
was	O
a	O
retrospective	B-PROC
,	O
hypothesis	O
-generating	O
,	O
single	O
-	O
centre	O
evaluation	B-PROC
of	O
hospitalized	B-LIVB
patients	I-LIVB
with	O
SSTIs	B-DISO
admitted	B-PROC
in	O
2011	O
.	O

Based	O
on	O
CREST	O
classification	O
,	O
the	O
empirical	O
antimicrobial	B-CHEM
choices	O
were	O
categorized	O
as	O
appropriate	O
,	O
over	B-PROC
-	I-PROC
treatment	I-PROC
or	O
under	B-PROC
-	I-PROC
treatment	I-PROC
.	O

A	O
total	O
of	O
369	O
patients	B-LIVB
were	O
screened	O
and	O
200	O
met	O
the	O
inclusion	O
criteria	O
.	O

The	O
majority	O
of	O
patients	B-LIVB
were	O
classified	O
as	O
either	O
CREST	O
class	O
I	O
(	O
n	O
=	O
68	O
)	O
or	O
class	O
I	O
I	O
(	O
n	O
=	O
102	O
)	O
.	O

Over	B-PROC
-	I-PROC
treatment	I-PROC
was	O
more	O
common	O
in	O
the	O
less	O
severe	O
classes	O
(	O
88	O
%	O
and	O
32	O
%	O
in	O
class	O
I	O
and	O
class	O
II	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Sixty	O
-	O
three	O
percent	O
of	O
class	O
I	O
(	O
n	O
=	O
43	O
)	O
were	O
over	B-PROC
-	I-PROC
treated	I-PROC
due	O
to	O
both	O
the	O
use	O
of	O
intravenous	O
antibiotic	B-CHEM
s	O
when	O
oral	B-PROC
therapy	I-PROC
was	O
sufficient	O
and	O
use	O
of	O
unnecessarily	O
broad	B-CHEM
-	I-CHEM
spectrum	I-CHEM
antibiotics	I-CHEM
.	O

In	O
contrast	O
,	O
25	O
%	O
(	O
n	O
=	O
26	O
)	O
of	O
class	O
II	O
were	O
over	B-PROC
-	I-PROC
treated	I-PROC
due	O
to	O
use	O
of	O
unnecessarily	O
broad	B-CHEM
-	I-CHEM
spectrum	I-CHEM
antibiotics	I-CHEM
.	O

Overall	O
clinical	B-DISO
failure	I-DISO
rates	O
remained	O
low	O
with	O
only	O
1	O
%	O
,	O
4	O
%	O
and	O
17	O
%	O
of	O
patients	B-LIVB
unable	O
to	O
achieve	O
initial	O
response	B-PHYS
in	O
class	O
II	O
,	O
class	O
III	O
and	O
class	O
IV	O
.	O

Retrospective	O
application	B-PROC
of	O
CREST	O
identified	O
opportunities	O
to	O
improve	O
the	O
management	B-PROC
of	O
SSTIs	B-DISO
.	O

CREST	O
can	O
be	O
of	O
great	O
value	O
in	O
discriminating	O
less	O
-	O
severe	O
SSTIs	B-DISO
,	O
which	O
can	O
be	O
treated	B-PROC
on	O
an	O
outpatient	B-LIVB
basis	O
.	O

Levels	O
of	O
bone	O
markers	B-PHYS
in	O
a	O
population	B-LIVB
of	O
infants	B-LIVB
exposed	I-LIVB
in	B-LIVB
utero	I-LIVB
and	O
during	O
breastfeeding	B-PHYS
to	O
tenofovir	B-CHEM
within	O
an	O
Option	B-PROC
B	I-PROC
+	I-PROC
programme	I-PROC
in	O
Malawi	B-GEOG
No	O
data	O
are	O
available	O
on	O
bone	B-PHYS
metabolism	I-PHYS
in	O
infants	B-LIVB
exposed	I-LIVB
to	O
tenofovir	B-CHEM
during	O
breastfeeding	B-PHYS
.	O

We	O
investigated	O
bone	B-PHYS
metabolism	I-PHYS
markers	B-PHYS
in	O
the	O
first	O
year	O
of	O
life	O
in	O
infants	B-LIVB
from	O
mothers	B-LIVB
who	O
received	O
tenofovir	B-CHEM
,	O
lamivudine	B-CHEM
and	O
efavirenz	B-CHEM
during	O
pregnancy	B-PHYS
and	O
12	O
months	O
of	O
breastfeeding	B-PHYS
in	O
a	O
national	B-PROC
Option	I-PROC
B	I-PROC
+	I-PROC
programme	I-PROC
in	O
Malawi	B-GEOG
.	O

Serum	B-ANAT
samples	B-OBJC
collected	O
at	O
6	O
and	O
12	O
months	O
in	O
tenofovir	B-CHEM
-	O
exposed	B-LIVB
infants	I-LIVB
and	O
in	O
a	O
small	O
sample	O
of	O
tenofovir	B-CHEM
-	O
unexposed	B-LIVB
infants	I-LIVB
from	O
the	O
same	O
clinical	B-OBJC
centre	I-OBJC
were	O
analysed	B-PROC
in	O
batches	O
for	O
levels	O
of	O
bone	B-CHEM
-	I-CHEM
specific	I-CHEM
alkaline	I-CHEM
phosphatase	I-CHEM
(	O
BAP	B-CHEM
;	O
marker	B-PHYS
of	O
bone	B-PHYS
formation	I-PHYS
)	O
and	O
of	O
C	B-CHEM
-	I-CHEM
terminal	I-CHEM
telopeptide	I-CHEM
of	I-CHEM
type	I-CHEM
I	I-CHEM
collagen	I-CHEM
(	O
CTX	B-CHEM
;	O
marker	B-PHYS
of	O
bone	B-PHYS
resorption	I-PHYS
)	O
.	O

Overall	O
,	O
136	O
tenofovir	B-CHEM
-	O
exposed	B-LIVB
infants	I-LIVB
were	O
evaluated	B-PROC
.	O

No	O
infant	B-LIVB
had	O
at	O
either	O
timepoint	O
CTX	B-CHEM
values	O
above	O
the	O
upper	O
normal	O
limit	O
,	O
while	O
most	O
of	O
them	O
had	O
at	O
6	O
and	O
12	O
months	O
levels	O
of	O
BAP	B-CHEM
above	O
the	O
upper	O
normal	O
limit	O
for	O
the	O
age	B-PHYS
range	O
.	O

Levels	O
of	O
bone	O
markers	B-PHYS
showed	O
no	O
differences	O
by	O
gender	B-PHYS
and	O
no	O
association	O
with	O
growth	B-DISO
parameters	I-DISO
.	O

Tenofovir	B-CHEM
-	O
unexposed	B-LIVB
and	O
-	O
exposed	B-LIVB
children	I-LIVB
had	O
similar	O
mean	O
levels	O
of	O
bone	O
markers	B-PHYS
at	O
6	O
months	O
(	O
CTX	B-CHEM
:	O
0	O
.	O

62	O
versus	O
0	O
.	O
55	O
ng	O
/	O
mL	O
,	O
P	O
=	O
0	O
.	O
122	O
;	O
BAP	B-CHEM
:	O
384	O
versus	O
362	O
U	O
/	O
L	O
,	O
P	O
=	O
0	O
.	O
631	O
)	O
.	O

No	B-DISO
significant	I-DISO
association	O
between	O
treatment	B-PROC
with	O
tenofovir	B-CHEM
and	O
CTX	B-CHEM
or	O
BAP	B-CHEM
levels	O
was	O
found	O
.	O

The	O
high	O
levels	O
of	O
BAP	B-CHEM
,	O
coupled	O
to	O
the	O
normal	O
levels	O
observed	O
for	O
CTX	B-CHEM
,	O
might	O
reflect	O
primarily	O
skeletal	B-ANAT
growth	B-PHYS
.	O

Potential	O
negative	B-DISO
effects	O
of	O
prolonged	O
exposure	O
to	O
tenofovir	B-CHEM
through	O
breastfeeding	B-PHYS
cannot	O
however	O
be	O
excluded	O
and	O
longitudinal	B-PROC
studies	I-PROC
that	O
evaluate	B-PROC
bone	B-PHYS
mineralization	I-PHYS
status	O
in	O
children	B-LIVB
enrolled	O
in	O
Option	B-PROC
B	I-PROC
+	I-PROC
programmes	I-PROC
are	O
warranted	O
.	O

Breakthrough	O
viridans	B-DISO
streptococcal	I-DISO
bacteremia	I-DISO
in	O
allogeneic	B-PROC
hematopoietic	I-PROC
stem	I-PROC
cell	I-PROC
transplant	I-PROC
recipients	B-LIVB
receiving	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
in	O
a	O
Japanese	B-GEOG
hospital	B-OBJC
Breakthrough	O
viridans	B-DISO
streptococcal	I-DISO
bacteremia	I-DISO
(	O
VSB	B-DISO
)	O
in	O
patients	B-LIVB
with	O
hematological	B-DISO
malignancy	I-DISO
receiving	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
is	O
a	O
major	O
blood	B-DISO
stream	I-DISO
infection	I-DISO
(	O
BSI	B-DISO
)	O
occurring	O
during	O
febrile	B-DISO
neutropenia	I-DISO
.	O

However	O
,	O
clinical	O
data	O
focused	O
on	O
VSB	B-DISO
in	O
allogeneic	B-PROC
hematopoietic	I-PROC
stem	I-PROC
cell	I-PROC
transplant	I-PROC
(	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
)	O
recipients	B-LIVB
are	O
lacking	O
.	O

The	O
medical	O
records	O
of	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
recipients	B-LIVB
who	O
received	O
oral	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
between	O
January	O
2011	O
and	O
August	O
2013	O
at	O
Toranomon	B-OBJC
Hospital	I-OBJC
were	O
reviewed	O
to	O
evaluate	B-PROC
breakthrough	O
VSB	B-DISO
.	O

Stored	O
viridans	B-LIVB
streptococcal	I-LIVB
(	O
VGS	B-LIVB
)	O
species	O
were	O
identified	O
by	O
using	O
sodA	O
gene	O
sequencing	B-PROC
,	O
and	O
were	O
assessed	O
for	O
drug	B-PHEN
susceptibility	I-PHEN
.	O

Among	O
the	O
184	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
recipients	B-LIVB
on	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
,	O
28	O
(	O
15	O
.	O
2	O
%	O
)	O
experienced	O
breakthrough	O
VSB	B-DISO
.	O

All	O
of	O
the	O
28	O
recipients	B-LIVB
with	O
VSB	B-DISO
were	O
treated	O
with	O
a	O
cefepime	B-CHEM
-	O
based	O
or	O
piperacillin	B-CHEM
/	I-CHEM
tazobactam	I-CHEM
-	O
based	O
regimen	B-PROC
.	O

The	O
susceptibility	B-PHEN
rates	O
of	O
the	O
VGS	B-LIVB
strains	B-LIVB
for	O
levofloxacin	B-CHEM
,	O
cefepime	B-CHEM
,	O
piperacillin	B-CHEM
/	I-CHEM
tazobactam	I-CHEM
,	O
meropenem	B-CHEM
,	O
and	O
vancomycin	B-CHEM
were	O
0	O
%	O
,	O
95	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O
.	O

Both	O
the	O
MIC50	B-PROC
(	O
minimum	B-PROC
inhibitory	I-PROC
concentration	I-PROC
)	O
and	O
the	O
MIC90	B-PROC
of	O
ceftazidim	B-CHEM
(	O
0	O
.	O
5	O
μg	O
/	O
mL	O
and	O
2	O
μg	O
/	O
mL	O
,	O
respectively	O
)	O
were	O
higher	O
than	O
the	O
MIC90	B-PROC
of	O
all	O
the	O
other	O
anti	B-CHEM
-	I-CHEM
pseudomonal	I-CHEM
beta	I-CHEM
-	I-CHEM
lactams	I-CHEM
(	O
APBLs	B-CHEM
)	O
.	O

Only	O
1	O
VGS	B-LIVB
strain	B-LIVB
had	O
a	O
penicillin	B-CHEM
MIC	B-PROC
≥	O
2	O
μg	O
/	O
mL	O
by	O
the	O
Etest	B-PROC
(	O
3	O
.	O
6	O
%	O
)	O
.	O

There	O
were	O
no	O
cases	O
with	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O
ARDS	B-DISO
)	O
that	O
was	O
associated	O
with	O
VSB	B-DISO
,	O
although	O
the	O
rate	O
of	O
viridans	B-DISO
group	I-DISO
streptococcal	I-DISO
shock	I-DISO
syndrome	I-DISO
was	O
high	O
(	O
26	O
%	O
)	O
.	O

The	O
crude	O
30	O
-	O
day	O
mortality	O
rate	O
in	O
the	O
VSB	B-DISO
group	O
(	O
10	O
.	O
7	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
in	O
the	O
BSI	B-DISO
without	O
VSB	B-DISO
group	O
(	O
9	O
.	O
3	O
%	O
)	O
or	O
non	O
-	O
BSI	B-DISO
group	O
(	O
7	O
.	O

0	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
77	O
)	O
.	O

Also	O
,	O
VSB	B-DISO
was	O
not	O
a	O
risk	B-DISO
factor	I-DISO
for	O
all	O
-	O
cause	O
mortality	O
up	O
to	O
60	O
days	O
following	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
(	O
P	O
=	O
0	O
.	O
43	O
)	O
.	O

APBL	B-CHEM
with	O
increased	O
anti	B-DISO
-	I-DISO
VGS	I-DISO
activity	I-DISO
(	O
APBL	B-DISO
-	I-DISO
VA	I-DISO
)	O
monotherapy	B-PROC
would	O
typically	O
be	O
optimal	O
for	O
treating	O
the	O
VGS	B-LIVB
strains	B-LIVB
in	O
this	O
setting	O
.	O

Indication	O
of	O
adding	O
an	O
empiric	O
anti	B-CHEM
-	I-CHEM
gram	I-CHEM
-	I-CHEM
positive	I-CHEM
agent	I-CHEM
to	O
APBL	B-DISO
-	I-DISO
VA	I-DISO
for	O
treating	O
VSB	B-DISO
should	O
depend	O
on	O
local	O
factors	O
,	O
such	O
as	O
the	O
susceptibility	B-PHEN
results	O
.	O

In	O
addition	O
,	O
breakthrough	O
VSB	B-DISO
is	O
probably	O
not	O
a	O
major	O
cause	B-DISO
of	I-DISO
death	I-DISO
in	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
settings	O
,	O
where	O
beta	B-CHEM
-	I-CHEM
lactam	I-CHEM
non	B-LIVB
-	I-LIVB
susceptible	I-LIVB
VGS	I-LIVB
and	O
the	O
ARDS	B-DISO
are	O
rare	O
.	O

Enforcement	O
of	O
the	O
Emergency	O
Medical	O
Treatment	O
and	O
Labor	O
Act	O
,	O
2005	O
to	O
2014	O
We	O
determine	O
the	O
incidence	O
of	O
and	O
trends	O
in	O
enforcement	O
of	O
the	O
Emergency	O
Medical	O
Treatment	O
and	O
Labor	O
Act	O
(	O
EMTALA	O
)	O
during	O
the	O
past	O
decade	O
.	O

We	O
obtained	O
a	O
comprehensive	O
list	O
of	O
all	O
EMTALA	O
investigations	B-PROC
conducted	O
between	O
2005	O
and	O
2014	O
directly	O
from	O
the	O
Centers	O
for	O
Medicare	O
&	O
Medicaid	O
Services	O
(	O
CMS	O
)	O
through	O
a	O
Freedom	O
of	O
Information	O
Act	O
request	O
.	O

Characteristics	O
of	O
EMTALA	O
investigations	B-PROC
and	O
resulting	O
citation	O
for	O
violations	B-DISO
during	O
the	O
study	O
period	O
are	O
described	O
.	O

Between	O
2005	O
and	O
2014	O
,	O
there	O
were	O
4	O
,	O
772	O
investigations	B-PROC
,	O
of	O
which	O
2	O
,	O
118	O
(	O
44	O
%	O
)	O
resulted	O
in	O
citations	O
for	O
EMTALA	O
deficiencies	O
at	O
1	O
,	O
498	O
(	O
62	O
%	O
)	O
of	O
2	O
,	O
417	O
hospitals	B-OBJC
investigated	O
.	O

Investigations	O
were	O
conducted	O
at	O
43	O
%	O
of	O
hospitals	B-OBJC
with	O
CMS	O
provider	O
agreements	O
,	O
and	O
citations	O
issued	O
at	O
27	O
%	O
.	O

On	O
average	O
,	O
9	O
%	O
of	O
hospitals	B-OBJC
were	O
investigated	O
and	O
4	O
.	O

3	O
%	O
were	O
cited	O
for	O
EMTALA	O
violation	B-DISO
annually	O
.	O

The	O
proportion	O
of	O
hospitals	B-OBJC
subject	O
to	O
EMTALA	O
investigation	B-PROC
decreased	O
from	O
10	O
.	O

8	O
%	O
to	O
7	O
.	O
2	O
%	O
,	O
and	O
citations	O
from	O
5	O
.	O

3	O
%	O
to	O
3	O
.	O

2	O
%	O
,	O
between	O
2005	O
and	O
2014	O
.	O

There	O
were	O
3	O
.	O

9	O
EMTALA	O
investigations	B-PROC
and	O
1	O
.	O
7	O
citations	O
per	O
million	O
emergency	B-OBJC
department	I-OBJC
(	B-OBJC
ED	I-OBJC
)	O
visits	O
during	O
the	O
study	O
period	O
.	O

We	O
report	O
the	O
first	O
national	O
estimates	O
of	O
EMTALA	O
enforcement	B-DISO
activities	I-DISO
in	O
more	O
than	O
a	O
decade	O
.	O

Although	O
EMTALA	O
investigations	B-PROC
and	O
citations	O
were	O
common	O
at	O
the	O
hospital	B-PROC
level	I-PROC
,	O
they	O
were	O
rare	O
at	O
the	O
ED	B-OBJC
-	O
visit	O
level	O
.	O

CMS	O
actively	O
pursued	O
EMTALA	O
investigations	B-PROC
and	O
issued	O
citations	O
throughout	O
the	O
study	O
period	O
,	O
with	O
half	O
of	O
hospitals	B-OBJC
subject	O
to	O
EMTALA	O
investigations	B-PROC
and	O
a	O
quarter	O
receiving	O
a	O
citation	O
for	O
EMTALA	O
violation	B-DISO
,	O
although	O
there	O
was	O
a	O
declining	O
trend	O
in	O
enforcement	O
.	O

Further	O
investigation	B-PROC
is	O
needed	O
to	O
determine	O
the	O
effect	O
of	O
EMTALA	O
on	O
access	O
to	O
or	O
quality	O
of	O
emergency	B-PROC
care	I-PROC
.	O

A	O
new	O
and	O
consistent	O
parameter	O
for	O
measuring	O
the	O
quality	O
of	O
multivariate	O
analytical	O
methods	O
:	O
Generalized	O
analytical	O
sensitivity	O
Generalized	O
analytical	O
sensitivity	O
(	O
γ	O
)	O
is	O
proposed	O
as	O
a	O
new	O
figure	O
of	O
merit	O
,	O
which	O
can	O
be	O
estimated	O
from	O
a	O
multivariate	O
calibration	O
data	O
set	O
.	O

It	O
can	O
be	O
confidently	O
applied	O
to	O
compare	O
different	O
calibration	O
methodologies	O
,	O
and	O
helps	O
to	O
solve	O
literature	O
inconsistencies	O
on	O
the	O
relationship	O
between	O
classical	O
sensitivity	O
and	O
prediction	B-DISO
error	I-DISO
.	O

In	O
contrast	O
to	O
the	O
classical	O
plain	O
sensitivity	O
,	O
γ	O
incorporates	O
the	O
noise	B-PHEN
properties	I-PHEN
in	O
its	O
definition	O
,	O
and	O
its	O
inverse	O
is	O
well	O
correlated	O
with	O
root	O
mean	O
square	O
errors	B-DISO
of	I-DISO
prediction	I-DISO
in	O
the	O
presence	B-DISO
of	O
general	O
noise	B-PHEN
structures	I-PHEN
.	O

The	O
proposal	O
is	O
supported	O
by	O
studying	B-PROC
simulated	B-PROC
and	O
experimental	O
first	O
-	O
order	O
multivariate	O
calibration	O
systems	O
with	O
various	O
models	O
,	O
namely	O
multiple	O
linear	O
regression	O
,	O
principal	O
component	O
regression	O
(	O
PCR	O
)	O
and	O
maximum	O
likelihood	O
PCR	O
(	O
MLPCR	O
)	O
.	O

The	O
simulations	B-PROC
included	O
instrumental	B-OBJC
noise	B-PHEN
of	O
different	O
types	O
:	O
independently	B-DISO
and	O
identically	O
distributed	O
(	O
iid	O
)	O
,	O
correlated	O
(	O
pink	O
)	O
and	O
proportional	O
noise	B-PHEN
,	O
while	O
the	O
experimental	O
data	O
carried	B-DISO
noise	B-PHEN
which	O
is	O
clearly	B-DISO
non	O
-	O
iid	O
.	O

The	O
lost	O
art	O
of	O
the	O
splenorrhaphy	B-PROC
In	O
the	O
case	O
of	O
the	O
hemodynamically	B-DISO
unstable	I-DISO
child	B-LIVB
,	O
splenorrhaphy	B-PROC
is	O
preferred	O
to	O
splenectomy	B-PROC
to	O
avert	O
postsplenectomy	B-DISO
sepsis	B-DISO
.	O

However	O
,	O
successful	O
splenorrhaphy	B-PROC
requires	O
familiarity	B-PHYS
with	O
the	O
procedure	B-PROC
.	O

We	O
sought	O
to	O
determine	O
how	O
many	O
splenectomies	B-PROC
or	O
splenorrhaphies	B-PROC
for	O
trauma	B-DISO
the	O
average	O
pediatric	B-LIVB
surgeon	I-LIVB
can	O
be	O
expected	O
to	O
perform	O
during	O
their	O
career	O
.	O

The	O
Pediatric	O
Health	O
Information	O
System	O
(	O
PHIS	O
)	O
Database	O
was	O
queried	O
for	O
patients	B-LIVB
≤18	O
years	O
coded	O
with	O
an	O
International	O
Classification	O
of	O
Diseases	O
9th	O
Edition	O
diagnosis	O
code	O
of	O
a	O
splenic	B-DISO
injury	I-DISO
from	O
2004	O
to	O
2013	O
.	O

Age	B-PHYS
,	O
gender	B-PHYS
,	O
grade	O
of	O
splenic	B-DISO
injury	I-DISO
,	O
and	O
operations	B-PROC
performed	O
were	O
extracted	O
.	O

Numbers	O
of	O
pediatric	B-LIVB
surgeons	I-LIVB
per	O
hospital	B-OBJC
were	O
obtained	O
.	O

9567	O
children	B-LIVB
were	O
identified	O
.	O

2	O
.	O
1	O
%	O
underwent	O
a	O
splenectomy	B-PROC
and	O
0	O
.	O

8	O
%	O
underwent	O
a	O
splenorrhaphy	B-PROC
.	O

The	O
average	O
surgeon	B-LIVB
performed	O
0	O
.	O

6	O
(	O
SD	O
=	O
0	O
.	O

6	O
)	O
splenectomies	B-PROC
and	O
0	O
.	O

2	O
(	O
SD	O
=	O
0	O
.	O

4	O
)	O
splenorrhaphies	B-PROC
for	O
trauma	B-DISO
.	O

If	O
these	O
rates	O
remain	O
constant	O
over	O
time	O
,	O
the	O
average	O
surgeon	B-LIVB
would	O
perform	O
1	O
.	O

8	O
(	O
SD	O
=	O
1	O
.	O

7	O
)	O
splenectomies	B-PROC
and	O
0	O
.	O

6	O
(	O
SD	O
=	O
1	O
.	O

1	O
)	O
splenorrhaphies	B-PROC
for	O
trauma	B-DISO
over	O
a	O
30	O
-	O
year	O
surgical	O
career	O
.	O

Nonoperative	B-PROC
management	I-PROC
is	O
associated	O
with	O
a	O
host	O
of	O
benefits	O
,	O
but	O
has	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
experience	O
level	O
of	O
the	O
pediatric	B-LIVB
surgeons	I-LIVB
expected	O
to	O
perform	O
an	O
emergency	O
splenectomy	B-PROC
or	O
splenorrhaphy	B-PROC
when	O
the	O
unusual	O
occasion	O
arises	O
.	O

Isolation	B-PROC
,	O
structural	B-PROC
analysis	I-PROC
,	O
and	O
expression	B-PHYS
characteristics	O
of	O
the	O
maize	B-LIVB
nuclear	O
factor	O
Y	O
gene	O
families	O
NUCLEAR	B-CHEM
FACTOR	I-CHEM
-	I-CHEM
Y	I-CHEM
(	O
NF	B-CHEM
-	I-CHEM
Y	I-CHEM
)	O
has	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
growth	B-PHYS
,	O
development	B-PHYS
,	O
and	O
response	B-PHYS
to	O
environmental	B-PHEN
stress	I-PHEN
.	O

A	O
NF	B-CHEM
-	I-CHEM
Y	I-CHEM
complex	I-CHEM
,	O
which	O
consists	O
of	O
three	O
subunits	B-CHEM
,	O
NF	B-CHEM
-	I-CHEM
YA	I-CHEM
,	O
NF	B-CHEM
-	I-CHEM
YB	I-CHEM
,	O
and	O
,	O
NF	B-CHEM
-	I-CHEM
YC	I-CHEM
,	O
binds	O
to	O
CCAAT	O
sequences	O
in	O
a	O
promoter	B-CHEM
to	O
control	O
the	O
expression	B-PHYS
of	I-PHYS
target	I-PHYS
genes	I-PHYS
.	O

Although	O
NF	B-CHEM
-	I-CHEM
Y	I-CHEM
proteins	I-CHEM
have	O
been	O
reported	O
in	O
Arabidopsis	B-LIVB
and	O
rice	B-LIVB
,	O
a	O
comprehensive	O
and	O
systematic	B-PROC
analysis	I-PROC
of	O
ZmNF	O
-	O
Y	O
genes	O
has	O
not	O
yet	O
been	O
performed	O
.	O

To	O
examine	O
the	O
functions	O
of	O
ZmNF	O
-	O
Y	O
genes	O
in	O
this	O
family	O
,	O
we	O
isolated	O
and	O
characterized	O
50	O
ZmNF	O
-	O
Y	O
(	O
14	O
ZmNF	O
-	O
YA	O
,	O
18	O
ZmNF	O
-	O
YB	O
,	O
and	O
18	O
ZmNF	O
-	O
YC	O
)	O
genes	O
in	O
an	O
analysis	B-PROC
of	O
the	O
maize	B-LIVB
genome	O
.	O

The	O
50	O
ZmNF	O
-	O
Y	O
genes	O
were	O
distributed	O
on	O
all	O
10	O
maize	B-LIVB
chromosomes	B-ANAT
,	O
and	O
12	O
paralogs	O
were	O
identified	O
.	O

Multiple	B-PROC
alignments	I-PROC
showed	O
that	O
maize	B-LIVB
ZmNF	B-CHEM
-	I-CHEM
Y	I-CHEM
family	I-CHEM
proteins	I-CHEM
had	O
conserved	O
regions	O
and	O
relatively	O
variable	O
N	O
-	O
terminal	O
or	O
C	O
-	O
terminal	O
domains	O
.	O

The	O
comparative	O
syntenic	O
map	B-PROC
illustrated	O
40	O
paralogous	O
NF	O
-	O
Y	O
gene	O
pairs	O
among	O
the	O
10	B-LIVB
maize	I-LIVB
chromosomes	B-ANAT
.	O

Microarray	B-PROC
data	O
showed	O
that	O
the	O
ZmNF	O
-	O
Y	O
genes	O
had	O
tissue	B-PHYS
-	I-PHYS
specific	I-PHYS
expression	I-PHYS
patterns	O
in	O
various	O
maize	B-LIVB
developmental	O
stages	O
and	O
in	O
response	B-PHYS
to	I-PHYS
biotic	I-PHYS
and	O
abiotic	B-PHYS
stresses	I-PHYS
.	O

The	O
results	O
suggested	O
that	O
ZmNF	O
-	O
YB2	O
,	O
4	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
and	O
16	O
and	O
ZmNF	O
-	O
YC6	O
,	O
8	O
,	O
and	O
15	O
were	O
induced	O
,	O
while	O
ZmNF	O
-	O
YA1	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
10	O
,	O
12	O
,	O
and	O
13	O
,	O
ZmNF	O
-	O
YB15	O
,	O
and	O
ZmNF	O
-	O
YC3	O
and	O
9	O
were	O
suppressed	O
by	O
drought	B-PHEN
stress	B-DISO
.	O

ZmNF	O
-	O
YA3	O
,	O
ZmNF	O
-	O
YA8	O
and	O
ZmNF	O
-	O
YA12	O
were	O
upregulated	B-PHYS
after	O
infection	B-DISO
by	O
the	O
three	O
pathogens	B-LIVB
,	O
while	O
ZmNF	O
-	O
YA1	O
and	O
ZmNF	O
-	O
YB2	O
were	O
suppressed	O
.	O

These	O
results	O
indicate	O
that	O
the	O
ZmNF	B-CHEM
-	I-CHEM
Ys	I-CHEM
may	O
have	O
significant	O
roles	O
in	O
the	O
response	B-PHYS
to	I-PHYS
abiotic	I-PHYS
and	O
biotic	B-PHYS
stresses	I-PHYS
.	O

How	O
do	O
different	O
delivery	O
schedules	O
of	O
tailored	B-PROC
web	B-PROC
-	I-PROC
based	I-PROC
physical	O
activity	O
advice	O
for	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
influence	O
intervention	B-PROC
use	O
and	O
efficacy	O
?	O

The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
investigate	O
the	O
impact	O
of	O
differing	O
delivery	O
schedules	O
of	O
computer	B-PROC
-	I-PROC
tailored	I-PROC
physical	O
activity	O
modules	O
on	O
engagement	O
and	O
physical	O
activity	O
behaviour	O
change	O
in	O
a	O
web	B-PROC
-	I-PROC
based	I-PROC
intervention	I-PROC
targeting	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
.	O

Insufficiently	O
active	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
(	O
n	O
=	O
492	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
one	O
of	O
the	O
following	O
intervention	B-PROC
schedules	O
over	O
12	O
weeks	O
:	O
a	O
three	O
-	O
module	O
intervention	O
delivered	O
monthly	O
,	O
a	O
three	B-PROC
-	I-PROC
module	I-PROC
intervention	I-PROC
delivered	O
weekly	O
or	O
a	O
single	B-PROC
module	I-PROC
intervention	I-PROC
.	O

Engagement	O
with	O
the	O
website	O
(	O
number	O
of	O
logins	O
,	O
time	O
on	O
site	O
,	O
modules	O
viewed	O
,	O
action	O
plans	O
completed	O
)	O
was	O
measured	O
using	O
tracking	O
software	O
.	O

Other	O
outcomes	O
(	O
website	O
acceptability	O
,	O
physical	O
activity	O
behaviour	O
)	O
were	O
assessed	O
using	O
online	O
surveys	O
.	O

Physical	O
activity	O
outcomes	O
were	O
analysed	O
using	O
regression	O
models	O
for	O
both	O
study	O
completers	O
and	O
when	O
applying	O
intention	B-PROC
-	I-PROC
to	I-PROC
-	I-PROC
treat	I-PROC
(	O
using	O
multiple	O
imputation	O
)	O
.	O

Completers	O
allocated	O
to	O
the	O
monthly	O
module	O
group	O
rated	O
the	O
intervention	B-PROC
higher	O
(	O
b	O
=	O
2	O
.	O
2	O
95	O
%	O
CI	O
=	O
0	O
.	O

02	O
-	O
4	O
.	O
53	O
)	O
on	O
acceptability	O
and	O
had	O
higher	O
levels	O
of	O
resistance	B-PROC
-	I-PROC
training	I-PROC
(	O
IRR	O
=	O
1	O
.	O
88	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
16	O
-	O
3	O
.	O
04	O
)	O
than	O
those	O
in	O
the	O
single	O
module	O
group	O
.	O

When	O
accounting	O
for	O
missing	O
data	O
,	O
these	O
differences	O
were	O
no	O
longer	O
significant	O
.	O

The	O
completion	B-DISO
of	O
at	O
least	O
two	O
action	O
plans	O
was	O
higher	O
among	O
those	O
allocated	O
to	O
the	O
monthly	O
module	O
group	O
compared	O
to	O
those	O
in	O
the	O
weekly	O
module	O
group	O
(	O
53	O
vs	O
40	O
%	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
;	O
though	O
the	O
completion	O
of	O
at	O
least	O
two	O
modules	O
was	O
higher	O
in	O
the	O
weekly	O
module	O
group	O
compared	O
to	O
the	O
monthly	O
module	O
group	O
(	O
60	O
vs	O
46	O
%	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
were	O
no	O
other	O
significant	O
between	O
group	O
differences	O
observed	O
.	O

This	O
study	O
provides	O
preliminary	O
evidence	O
that	O
web	B-PROC
-	I-PROC
based	I-PROC
computer	I-PROC
-	I-PROC
tailored	I-PROC
interventions	B-PROC
can	O
be	O
used	O
to	O
increase	O
physical	O
activity	O
among	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
.	O

Further	O
,	O
there	O
were	O
some	O
outcome	O
differences	O
based	O
on	O
how	O
the	O
tailored	B-PROC
modules	O
were	O
delivered	O
,	O
with	O
the	O
most	O
favourable	O
outcomes	O
observed	O
in	O
the	O
monthly	O
delivery	O
group	O
.	O

This	O
study	O
will	O
be	O
useful	O
for	O
informing	O
the	O
design	O
of	O
future	O
web	O
-	O
based	O
interventions	O
targeting	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
.	O

Stress	B-DISO
and	O
binge	O
drinking	O
:	O
A	O
toxic	B-DISO
combination	O
for	O
the	O
teenage	O
brain	B-ANAT
Young	B-LIVB
adult	I-LIVB
university	O
students	O
frequently	O
binge	O
on	O
alcohol	O
and	O
have	O
high	O
stress	B-DISO
levels	I-DISO
.	O

Based	O
on	O
findings	O
in	O
rodents	B-LIVB
,	O
we	O
predicted	O
that	O
heavy	B-DISO
current	I-DISO
alcohol	I-DISO
use	I-DISO
and	O
elevated	O
stress	B-DISO
and	O
depression	B-DISO
scores	I-DISO
would	O
be	O
associated	O
with	O
deficits	O
on	O
high	O
interference	O
memory	B-PHYS
tasks	O
,	O
while	O
early	B-DISO
onset	I-DISO
,	O
prolonged	O
binge	O
patterns	O
would	O
lead	O
to	O
broader	O
cognitive	B-DISO
deficits	I-DISO
on	O
tests	O
of	O
associative	B-PHYS
encoding	I-PHYS
and	O
executive	B-PHYS
functions	I-PHYS
.	O

We	O
developed	O
the	O
Concentration	B-PHYS
Memory	B-PHYS
Task	O
,	O
a	O
novel	O
computerized	O
version	O
of	O
the	O
Concentration	B-PHYS
card	B-OBJC
game	I-OBJC
with	O
a	O
high	O
degree	O
of	O
interference	O
.	O

We	O
found	O
that	O
young	B-LIVB
adults	I-LIVB
with	O
elevated	O
stress	B-DISO
,	O
depression	B-DISO
,	O
and	O
alcohol	O
consumption	O
scores	O
were	O
impaired	O
in	O
the	O
Concentration	B-PHYS
Memory	B-PHYS
Task	O
.	O

We	O
also	O
analyzed	O
data	O
from	O
a	O
previous	O
study	O
,	O
and	O
found	O
that	O
higher	O
alcohol	O
consumption	O
scores	O
were	O
associated	O
with	O
impaired	O
performance	O
on	O
another	O
high	O
interference	O
memory	B-PHYS
task	O
,	O
based	O
on	O
Kirwan	O
and	O
Stark	O
's	O
Mnemonic	O
Similarity	O
Test	O
.	O

On	O
the	O
other	O
hand	O
,	O
adolescent	B-LIVB
onset	O
of	O
binge	O
drinking	O
predicted	O
poorer	O
performance	O
on	O
broader	O
range	O
of	O
memory	B-PHYS
tests	O
,	O
including	O
a	O
more	O
systematic	O
test	O
of	O
spatial	O
recognition	O
memory	O
,	O
and	O
an	O
associative	B-PHYS
learning	I-PHYS
task	O
.	O

Our	O
results	B-DISO
are	O
broadly	O
consistent	O
with	O
findings	O
in	O
rodents	B-LIVB
that	O
acute	O
alcohol	O
and	O
stress	B-DISO
exposure	O
suppress	O
neurogenesis	B-PHYS
in	O
the	O
adult	B-LIVB
hippocampus	B-ANAT
,	O
which	O
in	O
turn	O
impairs	O
performance	O
in	O
high	O
interference	O
memory	B-PHYS
tasks	O
,	O
while	O
adolescent	B-LIVB
onset	O
binge	O
drinking	O
causes	O
more	O
extensive	O
brain	B-DISO
damage	I-DISO
and	O
cognitive	B-DISO
deficits	I-DISO
.	O

Vestibular	B-ANAT
-dependent	O
inter	O
-	O
stimulus	O
interval	O
effects	O
on	O
sound	B-PHYS
evoked	I-PHYS
potentials	I-PHYS
of	O
central	O
origin	O
Todd	O
et	O
al	O
.	O

(	O
2014ab	O
)	O
have	O
recently	O
demonstrated	O
the	O
presence	B-DISO
of	O
vestibular	B-ANAT
-dependent	O
contributions	O
to	O
auditory	B-PHYS
evoked	I-PHYS
potentials	I-PHYS
(	O
AEPs	B-PHYS
)	O
when	O
passing	O
through	O
the	O
vestibular	B-ANAT
threshold	O
as	O
determined	O
by	O
vestibular	B-PHEN
evoked	I-PHEN
myogenic	I-PHEN
potentials	I-PHEN
(	O
VEMPs	B-PHEN
)	O
,	O
including	O
a	O
particular	O
deflection	O
labeled	O
as	O
an	O
N42	O
/	O
P52	O
prior	O
to	O
the	O
long	O
-	O
latency	O
AEPs	B-PHYS
N1	O
and	O
P2	O
.	O

In	O
this	O
paper	O
we	O
report	B-PROC
the	O
results	B-DISO
of	O
an	O
experiment	B-PROC
to	O
determine	O
the	O
effect	O
of	O
inter	O
-	O
stimulus	O
interval	O
(	O
ISI	O
)	O
and	O
regularity	O
on	O
potentials	B-PHYS
recorded	O
above	O
and	O
below	O
VEMP	B-PHEN
threshold	O
.	O

Five	O
healthy	O
,	O
right	B-PHYS
-	I-PHYS
handed	I-PHYS
subjects	B-LIVB
were	O
recruited	O
and	O
evoked	B-PHYS
potentials	I-PHYS
were	O
recorded	O
to	O
binaurally	O
presented	O
sound	B-PROC
stimulation	I-PROC
,	O
above	O
and	O
below	O
vestibular	B-ANAT
threshold	O
,	O
at	O
seven	O
stimulus	B-PHEN
rates	O
with	O
ISIs	O
of	O
212	O
,	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
and	O
1696	O
ms	O
.	O

The	O
inner	O
five	O
intervals	O
,	O
i	O
.	O

e	O
.	O

300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
ms	O
,	O
were	O
presented	O
twice	O
in	O
both	O
regular	O
and	O
irregular	O
conditions	O
.	O

ANOVA	O
on	O
the	O
global	O
field	O
power	O
(	O
GFP	O
)	O
were	O
conducted	O
for	O
each	O
of	O
four	O
waves	O
,	O
N42	O
,	O
P52	O
,	O
N1	O
and	O
P2	O
with	O
factors	O
of	O
intensity	O
,	O
ISI	O
and	O
regularity	O
.	O

Both	O
N42	O
and	O
P52	O
waves	O
showed	O
significant	O
ANOVA	O
effects	O
of	O
intensity	O
but	O
no	O
other	O
main	O
effects	O
or	O
interactions	O
.	O

In	O
contrast	O
both	O
N1	O
and	O
P2	O
showed	O
additional	O
effects	O
of	O
ISI	O
,	O
as	O
well	O
as	O
intensity	O
,	O
and	O
evidence	O
of	O
non	O
-	O
linear	O
interactions	O
between	O
ISI	O
and	O
intensity	O
.	O

A	O
source	B-PROC
analysis	I-PROC
was	O
carried	O
out	O
consistent	O
with	O
prior	O
work	O
suggesting	O
that	O
when	O
above	O
vestibular	B-ANAT
threshold	O
,	O
in	O
addition	O
to	O
bilateral	O
superior	O
temporal	B-ANAT
cortex	I-ANAT
,	O
ocular	B-ANAT
,	O
cerebellar	B-ANAT
and	O
cingulate	B-ANAT
sources	B-DISO
are	O
recruited	O
.	O

Further	O
statistical	B-PROC
analysis	I-PROC
of	O
the	O
source	B-DISO
currents	B-PHEN
indicated	O
that	O
the	O
origin	O
of	O
the	O
interactions	O
with	O
intensity	O
may	O
be	O
the	O
ISI	O
sensitivity	O
of	O
the	O
vestibular	B-ANAT
-dependent	O
sources	B-DISO
.	O

This	O
in	O
turn	O
may	O
reflect	O
a	O
specific	O
vestibular	B-ANAT
preference	O
for	O
stimulus	B-PHEN
rates	O
associated	O
with	O
locomotion	B-PHYS
,	O
i	O
.	O

e	O
.	O

rates	O
close	O
to	O
2	O
Hz	O
,	O
or	O
ISIs	O
close	O
to	O
500	O
ms	O
,	O
where	O
saccular	O
afferents	O
show	O
increased	O
gain	O
and	O
the	O
corresponding	O
reflexes	B-PHYS
are	O
most	O
sensitive	O
.	O

Differential	O
Immunohistochemical	B-PROC
Profiles	B-PROC
for	O
Distinguishing	O
Prostate	B-DISO
Carcinoma	I-DISO
and	O
Urothelial	B-DISO
Carcinoma	I-DISO
The	O
pathologic	O
distinction	O
between	O
high	O
-	O
grade	O
prostate	B-DISO
adenocarcinoma	I-DISO
(	O
PAC	B-DISO
)	O
involving	O
the	O
urinary	B-ANAT
bladder	I-ANAT
and	O
high	O
-	O
grade	O
urothelial	B-DISO
carcinoma	I-DISO
(	O
UC	B-DISO
)	O
infiltrating	B-DISO
the	O
prostate	B-ANAT
can	O
be	O
difficult	O
.	O

However	O
,	O
making	O
this	O
distinction	O
is	O
clinically	O
important	O
because	O
of	O
the	O
different	O
treatment	B-PROC
modalities	O
for	O
these	O
two	O
entities	B-OBJC
.	O

A	O
total	O
of	O
249	O
patient	B-LIVB
cases	O
(	O
PAC	B-DISO
,	O
111	O
cases	O
;	O
UC	B-DISO
,	O
138	O
cases	O
)	O
collected	O
between	O
June	O
1995	O
and	O
July	O
2009	O
at	O
Seoul	B-OBJC
St	I-OBJC
.	I-OBJC

Mary	I-OBJC
's	I-OBJC
Hospital	I-OBJC
were	O
studied	B-PROC
.	O

An	O
immunohistochemical	B-PROC
evaluation	B-PROC
of	O
prostatic	B-ANAT
markers	B-CHEM
(	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
antigen	I-CHEM
[	O
PSA	B-CHEM
]	O
,	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
membrane	I-CHEM
antigen	I-CHEM
[	O
PSMA	B-CHEM
]	O
,	O
prostate	B-CHEM
acid	I-CHEM
phosphatase	I-CHEM
[	O
PAP	B-CHEM
]	O
,	O
P501s	B-CHEM
,	O
NKX3	B-CHEM
.	I-CHEM
1	I-CHEM
,	O
and	O
α	B-CHEM
-	I-CHEM
methylacyl	I-CHEM
coenzyme	I-CHEM
A	I-CHEM
racemase	I-CHEM
[	O
AMACR	B-CHEM
]	O
)	O
and	O
urothelial	O
markers	B-CHEM
(	O
CK34βE12	B-CHEM
,	O
p63	B-CHEM
,	O
thrombomodulin	B-CHEM
,	O
S100P	B-CHEM
,	O
and	O
GATA	B-CHEM
binding	I-CHEM
protein	I-CHEM
3	I-CHEM
[	O
GATA3	B-CHEM
]	O
)	O
was	O
performed	O
using	O
tissue	B-DEVI
microarrays	I-DEVI
from	O
each	O
tumor	B-DISO
.	O

The	O
sensitivities	O
of	O
prostatic	B-ANAT
markers	B-CHEM
in	O
PAC	B-DISO
were	O
100	O
%	O
for	O
PSA	B-CHEM
,	O
83	O
.	O
8	O
%	O
for	O
PSMA	B-CHEM
,	O
91	O
.	O

9	O
%	O
for	O
PAP	B-CHEM
,	O
93	O
.	O

7	O
%	O
for	O
P501s	B-CHEM
,	O
88	O
.	O

3	O
%	O
for	O
NKX	B-CHEM
3	I-CHEM
.	I-CHEM
1	I-CHEM
,	O
and	O
66	O
.	O

7	O
%	O
for	O
AMACR	B-CHEM
.	O

However	O
,	O
the	O
urothelial	O
markers	B-CHEM
CK34βE12	B-CHEM
,	O
p63	B-CHEM
,	O
thrombomodulin	B-CHEM
,	O
S100P	B-CHEM
,	O
and	O
GATA3	B-CHEM
were	O
also	O
positive	B-DISO
in	O
1	O
.	O

8	O
%	O
,	O
0	O
%	O
,	O
0	O
%	O
,	O
3	O
.	O
6	O
%	O
,	O
and	O
0	O
%	O
of	O
PAC	B-DISO
,	O
respectively	O
.	O

The	O
sensitivities	O
of	O
urothelial	O
markers	B-CHEM
in	O
UC	B-DISO
were	O
75	O
.	O
4	O
%	O
for	O
CK34βE12	B-CHEM
,	O
73	O
.	O
9	O
%	O
for	O
p63	B-CHEM
,	O
45	O
.	O

7	O
%	O
for	O
thrombomodulin	B-CHEM
,	O
22	O
.	O
5	O
%	O
for	O
S100P	B-CHEM
,	O
and	O
84	O
.	O
8	O
%	O
for	O
GATA3	B-CHEM
.	O

Conversely	O
,	O
the	O
prostatic	B-ANAT
markers	B-CHEM
PSA	B-CHEM
,	O
PSMA	B-CHEM
,	O
PAP	B-CHEM
,	O
P501s	B-CHEM
,	O
NKX3	B-CHEM
.	I-CHEM
1	I-CHEM
,	O
and	O
AMACR	B-CHEM
were	O
also	O
positive	B-DISO
in	O
9	O
.	O

4	O
%	O
,	O
0	O
.	O

7	O
%	O
,	O
18	O
.	O
8	O
%	O
,	O
0	O
.	O
7	O
%	O
,	O
0	O
%	O
,	O
and	O
8	O
.	O

7	O
%	O
of	O
UC	B-DISO
s	O
,	O
respectively	O
.	O

Prostatic	B-ANAT
and	O
urothelial	O
markers	B-CHEM
,	O
including	O
PSA	B-CHEM
,	O
NKX3	B-CHEM
.	I-CHEM
1	I-CHEM
,	O
p63	B-CHEM
,	O
thrombomodulin	B-CHEM
,	O
and	O
GATA3	B-CHEM
are	O
very	O
useful	O
for	O
differentiating	O
PAC	B-DISO
from	O
UC	B-DISO
.	O

The	O
optimal	O
combination	O
of	O
prostatic	B-ANAT
and	O
urothelial	O
markers	B-CHEM
could	O
improve	B-DISO
the	O
ability	B-DISO
to	O
differentiate	O
PAC	B-DISO
from	O
UC	B-DISO
pathologically	O
.	O

Vision	B-PHYS
Guides	O
Selection	O
of	O
Freeze	B-PHEN
or	O
Flight	B-PHEN
Defense	O
Strategies	B-PHYS
in	O
Mice	B-LIVB
In	O
prey	O
species	O
such	O
as	O
mice	B-LIVB
,	O
avoidance	B-PHYS
of	O
predators	O
is	O
key	O
to	O
survival	O
and	O
drives	O
instinctual	O
behaviors	O
like	O
freeze	B-PHEN
or	O
flight	B-PHEN
[	O
1	O
,	O
2	O
]	O
.	O

Sensory	B-PHYS
signals	I-PHYS
guide	I-PHYS
the	O
selection	O
of	O
appropriate	O
behavior	O
[	O
3	O
]	O
,	O
and	O
for	O
aerial	O
predators	O
only	O
vision	B-PHYS
provides	O
useful	O
information	O
.	O

Surprisingly	O
,	O
there	O
is	O
no	O
evidence	O
that	O
vision	B-PHYS
can	O
guide	O
the	O
selection	O
of	O
escape	O
strategies	B-PHYS
.	O

Fleeing	O
behavior	O
can	O
be	O
readily	O
triggered	O
by	O
a	O
rapidly	O
looming	O
overhead	O
stimulus	B-PHEN
[	O
4	O
]	O
.	O

Freezing	B-PHEN
behavior	O
,	O
however	O
,	O
has	O
previously	O
been	O
induced	O
by	O
real	O
predators	O
or	O
their	O
odors	B-PHEN
[	O
5	O
]	O
.	O

Here	O
,	O
we	O
discover	O
that	O
a	O
small	O
moving	O
disk	O
,	O
simulating	O
the	O
sweep	B-PROC
of	O
a	O
predator	O
cruising	B-DISO
overhead	O
,	O
is	O
sufficient	O
to	O
induce	O
freezing	B-PHYS
response	I-PHYS
in	O
mice	B-LIVB
.	O

Looming	O
and	O
sweeping	B-PROC
therefore	O
provide	O
visual	B-DISO
triggers	I-DISO
for	O
opposing	O
flight	B-PHEN
and	O
freeze	B-PHEN
behaviors	O
and	O
provide	O
evidence	O
that	O
mice	B-LIVB
innately	O
make	O
behavioral	O
choices	O
based	O
on	O
vision	B-PHYS
alone	O
.	O

Short	O
-	O
term	O
effects	B-DISO
of	O
a	O
vibrotactile	O
neck	B-ANAT
-based	O
treatment	B-DEVI
device	I-DEVI
for	O
positional	B-DISO
obstructive	I-DISO
sleep	I-DISO
apnea	I-DISO
:	O
preliminary	O
data	O
on	O
tolerability	B-PROC
and	O
efficacy	B-PROC
Positional	O
supine	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
syndrome	I-DISO
(	O
OSAS	B-DISO
)	O
characterizes	O
a	O
subgroup	O
of	O
patients	B-LIVB
suffering	B-DISO
from	O
OSAS	B-DISO
.	O

Several	O
devices	B-DEVI
designed	O
to	O
limit	O
supine	O
position	O
have	O
been	O
developed	O
,	O
but	O
evidences	O
of	O
their	O
efficacy	O
and	O
safety	O
are	O
lacking	O
.	O

It	O
is	O
unclear	B-DISO
whether	O
a	O
neck	B-ANAT
-	I-ANAT
worn	I-ANAT
vibrating	B-DEVI
device	I-DEVI
could	O
induce	O
positional	B-DISO
change	I-DISO
in	O
patients	B-LIVB
with	O
positional	B-DISO
OSAS	I-DISO
.	O

We	O
evaluated	B-PROC
the	O
efficacy	O
of	O
a	O
neck	B-ANAT
-worn	O
device	B-DEVI
to	O
induce	O
supine	O
avoidance	B-DISO
positional	O
feedback	O
over	O
a	O
short	O
-	O
term	O
trial	O
in	O
OSAS	B-DISO
patients	B-LIVB
and	O
its	O
impact	O
on	O
sleep	B-PHYS
quality	O
and	O
polysomnographyc	B-PROC
indexes	I-PROC
.	O

Twenty	O
patients	B-LIVB
with	O
positional	B-DISO
apneas	I-DISO
/	O
hypopneas	B-DISO
were	O
prospectively	B-PROC
studied	I-PROC
.	O

Baseline	O
characteristics	O
of	O
daytime	B-DISO
somnolence	I-DISO
and	O
risk	B-DISO
of	O
sleep	B-DISO
apnea	I-DISO
were	O
screened	B-PROC
and	O
the	O
efficacy	O
of	O
a	O
3	O
-	O
day	O
trial	O
of	O
supine	O
-	O
avoidance	B-DISO
therapy	B-PROC
by	O
vibrotactile	O
neck	B-ANAT
worn	I-ANAT
device	B-DEVI
assessed	O
by	O
reporting	O
the	O
self	O
-	O
perceived	O
change	O
in	O
quality	B-DISO
of	I-DISO
sleep	I-DISO
and	O
performing	O
cardio	B-PROC
-	I-PROC
respiratory	I-PROC
polysomnography	I-PROC
.	O

Comparison	O
between	O
baseline	B-DISO
and	O
treatment	B-DISO
results	I-DISO
was	O
performed	O
.	O

The	O
neck	B-ANAT
device	B-DEVI
produced	O
a	O
reduction	O
in	O
overall	O
apnea	O
-	O
hypopnea	O
index	O
(	O
AHI	O
)	O
(	O
mean	O
AHI	O
pre	O
=	O
16	O
.	O

8	O
/	O
h	O
and	O
post	O
=	O
4	O
.	O
4	O
/	O
h	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
oxygen	B-DISO
desaturation	I-DISO
(	O
pre	O
=	O
13	O
.	O

7	O

/	O
h	O
and	O
post	O
=	O
3	O
.	O
8	O
/	O
h	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
Respiratory	B-DISO
Disturbance	I-DISO
Indexes	I-DISO
(	O
RDI	B-DISO
)	O
(	O
20	O
.	O
0	O
/	O
h	O
vs	O
.	O

5	O
.	O
2	O
/	O
h	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
time	O
spent	O
in	O
supine	O
position	O
decreased	O
from	O
62	O
.	O

1	O
%	O
to	O
33	O
.	O

7	O
%	O
of	O
the	O
total	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
the	O
impact	O
on	O
the	O
perceived	O
quality	B-DISO
of	I-DISO
sleep	I-DISO
was	O
unpredictable	B-DISO
.	O

The	O
neck	B-ANAT
position	O
therapy	B-DEVI
device	I-DEVI
is	O
effective	O
in	O
restricting	O
supine	O
sleep	B-PHYS
,	O
improving	O
AHI	O
and	O
related	O
polysomnographic	B-PROC
indexes	I-PROC
.	O

However	O
,	O
at	O
least	O
in	O
a	O
short	O
-	O
term	O
trial	O
,	O
it	O
seems	O
unable	B-DISO
to	O
improve	O
the	O
patient	B-LIVB
's	I-LIVB
sleep	B-PHYS
quality	O
.	O

Operative	B-DISO
surgical	I-DISO
nuances	I-DISO
of	O
modified	O
extradural	B-PROC
temporopolar	I-PROC
approach	I-PROC
with	O
mini	O
-	O
peeling	O
of	O
dura	B-ANAT
propria	I-ANAT
based	O
on	O
cadaveric	B-PROC
anatomical	I-PROC
study	I-PROC
of	O
lateral	O
cavernous	B-ANAT
structures	I-ANAT
Extradural	B-PROC
temporopolar	I-PROC
approach	I-PROC
(	O
ETA	B-PROC
)	O
has	O
been	O
modified	O
as	O
less	O
invasive	O
manner	O
and	O
named	O
as	O
trans	O
-	O
superior	O
orbital	B-ANAT
fissure	I-ANAT
(	O
SOF	B-ANAT
)	O
approach	B-PROC
with	O
mini	O
-	O
peeling	O
technique	O
.	O

The	O
present	O
study	O
discusses	O
the	O
operative	B-DISO
nuances	I-DISO
of	O
this	O
modified	O
technique	O
on	O
the	O
basis	O
of	O
cadaveric	B-PROC
study	I-PROC
of	O
lateral	O
cavernous	B-ANAT
structures	I-ANAT
.	O

In	O
five	O
consecutive	O
cadaveric	B-OBJC
specimens	I-OBJC
,	O
we	O
performed	O
an	O
extradural	B-ANAT
anterior	O
clinoidectomy	B-PROC
with	O
mini	O
-	O
peeling	O
of	O
the	O
dura	B-ANAT
propria	I-ANAT
to	O
expose	O
the	O
anterior	B-ANAT
clinoid	I-ANAT
process	I-ANAT
entirely	O
.	O

We	O
also	O
investigated	O
the	O
histological	O
characteristics	O
of	O
the	O
lateral	O
cavernous	B-ANAT
sinus	I-ANAT
(	O
CS	B-ANAT
)	O
between	O
the	O
dura	B-ANAT
propria	I-ANAT
and	O
periosteal	B-ANAT
dura	I-ANAT
at	O
the	O
SOF	B-ANAT
,	O
foramen	B-ANAT
rotundum	I-ANAT
(	O
FR	B-ANAT
)	O
,	O
and	O
foramen	O
ovale	O
(	O
FO	O
)	O
levels	O
,	O
and	O
of	O
each	O
trigeminal	B-ANAT
nerve	I-ANAT
division	I-ANAT
.	O

Coronal	B-PROC
histological	I-PROC
examination	I-PROC
of	O
the	O
lateral	O
wall	O
of	O
the	O
CS	B-ANAT
showed	O
invagination	B-DISO
of	O
the	O
dura	B-ANAT
propria	I-ANAT
and	O
periosteal	B-ANAT
dura	I-ANAT
into	O
the	O
SOF	B-ANAT
.	O

In	O
contrast	O
,	O
no	B-DISO
such	O
invagination	B-DISO
was	O
observed	O
at	O
the	O
levels	O
of	O
the	O
FR	B-ANAT
and	O
FO	O
.	O

This	O
finding	O
supports	O
the	O
technical	O
rationale	O
of	O
the	O
only	O
skeletonization	B-DISO
of	O
the	O
SOF	B-ANAT
for	O
peeling	O
of	O
the	O
dura	B-ANAT
propria	I-ANAT
but	O
not	O
FR	B-ANAT
.	O

In	O
addition	O
,	O
our	O
modified	O
ETA	B-PROC
method	O
needs	O
only	O
minimal	O
dural	B-PROC
incision	I-PROC
between	O
the	O
SOF	B-ANAT
and	O
FR	B-ANAT
where	O
no	O
cranial	B-ANAT
nerves	I-ANAT
are	O
present	O
.	O

Our	O
technical	B-PROC
modification	I-PROC
of	O
ETA	B-PROC
may	O
be	O
recommended	O
for	O
surgical	B-PROC
treatment	I-PROC
of	O
paraclinoid	B-DISO
lesions	I-DISO
to	O
reduce	O
the	O
risk	O
of	O
intraoperative	O
neurovascular	B-DISO
injury	I-DISO
.	O

A	O
Systematic	O
Review	O
of	O
the	O
Diagnostic	O
and	O
Prognostic	O
Value	O
of	O
Urinary	O
Protein	B-CHEM
Biomarkers	B-PHYS
in	O
Urothelial	B-DISO
Bladder	I-DISO
Cancer	I-DISO
For	O
over	O
80	O
years	O
,	O
cystoscopy	B-PROC
has	O
remained	O
the	O
gold	O
-	O
standard	O
for	O
detecting	B-DISO
tumours	B-DISO
of	O
the	O
urinary	B-ANAT
bladder	I-ANAT
.	O

Since	O
bladder	B-DISO
tumours	I-DISO
have	O
a	O
tendency	O
to	O
recur	B-PHEN
and	O
progress	B-DISO
,	O
many	O
patients	B-LIVB
are	O
subjected	O
to	O
repeated	O
cystoscopies	B-PROC
during	O
long	O
-	O
term	O
surveillance	B-PROC
,	O
with	O
the	O
procedure	B-PROC
being	O
both	O
unpleasant	O
for	O
the	O
patient	B-LIVB
and	O
expensive	O
for	O
healthcare	B-LIVB
providers	I-LIVB
.	O

The	O
identification	O
and	O
validation	B-PROC
of	O
bladder	B-DISO
tumour	I-DISO
specific	O
molecular	B-PHYS
markers	I-PHYS
in	O
urine	B-ANAT
could	O
enable	O
tumour	B-DISO
detection	B-DISO
and	O
reduce	O
reliance	O
on	O
cystoscopy	B-PROC
,	O
and	O
numerous	O
classes	O
of	O
biomarkers	B-PHYS
have	O
been	O
studied	O
.	O

Proteins	B-CHEM
represent	O
the	O
most	O
intensively	O
studied	O
class	O
of	O
biomolecule	O
in	O
this	O
setting	O
.	O

As	O
an	O
aid	O
to	O
researchers	B-LIVB
searching	O
for	O
better	O
urinary	O
biomarkers	B-PHYS
,	O
we	O
report	O
a	O
comprehensive	O
systematic	O
review	O
of	O
the	O
literature	O
and	O
a	O
searchable	O
database	O
of	O
proteins	B-CHEM
that	O
have	O
been	O
investigated	B-PROC
to	O
date	O
.	O

Our	O
objective	O
was	O
to	O
classify	O
these	O
proteins	B-CHEM
as	O
:	O
1	O
)	O
those	O
with	O
robustly	O
characterised	O
sensitivity	O
and	O
specificity	O
for	O
bladder	B-DISO
cancer	I-DISO
detection	B-DISO
;	O
2	O
)	O
those	O
that	O
show	O
potential	O
but	O
further	O
investigation	B-PROC
is	O
required	O
;	O
3	O
)	O
those	O
unlikely	O
to	O
warrant	O
further	O
investigation	B-PROC
;	O
and	O
4	O
)	O
those	O
investigated	B-PROC
as	O
prognostic	O
markers	O
.	O

This	O
work	O
should	O
help	O
to	O
prioritise	O
certain	O
biomarkers	B-PHYS
for	O
rigorous	B-PROC
validation	I-PROC
,	O
whilst	O
preventing	O
wasted	O
effort	O
on	O
proteins	B-CHEM
that	O
have	O
shown	O
no	O
association	O
whatsoever	O
with	O
the	O
disease	B-DISO
,	O
or	O
only	O
modest	O
biomarker	B-PHYS
performance	O
despite	O
large	O
-	O
scale	O
efforts	O
at	O
validation	B-PROC
.	O

Of	O
Kindlins	B-CHEM
and	O
Cancer	B-DISO
Kindlins	B-CHEM
are	O
4	O
.	O
1	O
-	O
ezrin	O
-	O
ridixin	O
-	O
moesin	O
(	O
FERM	O
)	O
domain	O
containing	O
proteins	B-CHEM
.	O

There	O
are	O
three	O
kindlins	B-CHEM
in	O
mammals	B-LIVB
,	O
which	O
share	O
high	O
sequence	O
identity	O
.	O

Kindlin	B-CHEM
-	I-CHEM
1	I-CHEM
is	O
expressed	B-PHYS
primarily	O
in	O
epithelial	B-ANAT
cells	I-ANAT
,	O
kindlin	B-CHEM
-	I-CHEM
2	I-CHEM
is	O
widely	O
distributed	O
and	O
is	O
particularly	O
abundant	O
in	O
adherent	B-ANAT
cells	I-ANAT
,	O
and	O
kindlin	B-CHEM
-	I-CHEM
3	I-CHEM
is	O
expressed	B-PHYS
primarily	O
in	O
hematopoietic	B-ANAT
cells	I-ANAT
.	O

These	O
distributions	O
are	O
not	O
exclusive	O
;	O
some	O
cells	B-ANAT
express	B-PHYS
multiple	O
kindlins	B-CHEM
,	O
and	O
transformed	B-ANAT
cells	I-ANAT
often	O
exhibit	O
aberrant	O
expression	B-PHYS
,	O
both	O
in	O
the	O
isoforms	B-CHEM
and	O
the	O
levels	O
of	O
kindlins	B-CHEM
.	O

Great	O
interest	O
in	O
the	O
kindlins	B-CHEM
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	O
roles	O
in	O
controlling	B-PHEN
integrin	B-CHEM
function	B-PHYS
.	O

In	B-PROC
vitro	I-PROC
studies	I-PROC
,	O
in	B-PROC
vivo	I-PROC
studies	I-PROC
of	O
mice	B-LIVB
deficient	O
in	O
kindlins	B-CHEM
,	O
and	O
studies	B-PROC
of	O
patients	B-LIVB
with	O
genetic	O
deficiencies	O
of	O
kindlins	B-CHEM
have	O
clearly	O
established	O
that	O
they	O
regulate	O
the	O
capacity	O
of	O
integrins	B-CHEM
to	O
mediate	O
their	O
functions	O
.	O

Kindlins	B-CHEM
are	O
adaptor	B-CHEM
proteins	I-CHEM
;	O
their	O
function	O
emanate	O
from	O
their	O
interaction	O
with	O
binding	B-PHYS
partners	O
,	O
including	O
the	O
cytoplasmic	B-ANAT
tails	I-ANAT
of	O
integrins	B-CHEM
and	O
components	O
of	O
the	O
actin	B-ANAT
cytoskeleton	I-ANAT
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
provide	O
a	O
brief	O
overview	O
of	O
kindlin	B-CHEM
structure	B-CHEM
and	O
function	B-PHYS
,	O
a	O
consideration	B-DISO
of	O
their	O
binding	B-PHYS
partners	O
,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	O
of	O
each	O
kindlin	B-CHEM
family	B-CHEM
member	B-LIVB
with	O
cancer	B-DISO
.	O

In	O
view	O
of	O
many	O
correlations	O
of	O
kindlin	B-CHEM
expression	B-PHYS
levels	O
and	O
neoplasia	B-DISO
and	O
the	O
known	O
association	O
of	O
integrins	B-CHEM
with	O
tumor	B-DISO
progression	I-DISO
and	O
metastasis	B-DISO
,	O
we	O
consider	O
whether	O
regulation	O
of	O
kindlins	B-CHEM
or	O
their	O
function	O
would	O
be	O
attractive	O
targets	O
for	O
treatment	B-PROC
of	I-PROC
cancer	I-PROC
.	O

Well	O
,	O
I	O
Wouldn	O
'	O
t	O
be	O
Any	O
Worse	O
Off	O
,	O
Would	O
I	O
,	O
Than	O
I	O
am	O
Now	O
?	O
A	O
Qualitative	B-PROC
Study	I-PROC
of	O
Decision	B-PHYS
-	I-PHYS
Making	I-PHYS
,	O
Hopes	B-PHYS
,	O
and	O
Realities	O
of	O
Adults	B-LIVB
With	O
Type	B-DISO
1	I-DISO
Diabetes	I-DISO
Undergoing	O
Islet	B-PROC
Cell	I-PROC
Transplantation	I-PROC
For	O
selected	O
individuals	B-LIVB
with	O
type	B-DISO
1	I-DISO
diabetes	I-DISO
,	O
pancreatic	B-PROC
islet	I-PROC
transplantation	I-PROC
(	O
IT	B-PROC
)	O
prevents	O
recurrent	O
severe	O
hypoglycemia	B-DISO
and	O
optimizes	B-PROC
glycemia	I-PROC
,	O
although	O
ongoing	O
systemic	B-PROC
immunosuppression	I-PROC
is	O
needed	O
.	O

Our	O
aim	O
was	O
to	O
explore	O
candidates	B-LIVB
and	O
recipients	B-LIVB
'	O
expectations	O
of	O
transplantation	B-PROC
,	O
their	O
experience	O
of	O
being	O
on	O
the	O
waiting	B-DISO
list	I-DISO
,	O
and	O
(	O
for	O
recipients	B-LIVB
)	O
the	O
procedure	O
and	O
life	O
posttransplant	O
.	O

Cross	O
-	O
sectional	O
qualitative	O
research	B-PROC
design	I-PROC
using	O
semistructured	O
interviews	B-PROC
with	O
16	O
adults	B-LIVB
(	O
8	O
pretransplant	O
,	O
8	O
posttransplant	O
;	O
from	O
4	O
UK	B-GEOG
centers	B-OBJC
(	O
n	O
=	O
13	O
)	O
and	O
1	O
Canadian	B-GEOG
center	B-OBJC
(	O
n	O
=	O
3	O
)	O
)	O
.	O

Interviews	B-PROC
were	O
audio	B-PROC
-	I-PROC
recorded	I-PROC
,	O
transcribed	O
,	O
and	O
underwent	O
inductive	B-PROC
thematic	I-PROC
analysis	I-PROC
.	O

Interviewees	B-LIVB
were	O
aged	O
(	O
mean	O
±	O
SD	O
)	O
52	O
±	O
10	O
years	O
(	O
range	O
,	O
30	O
-	O
64	O
)	O
;	O
duration	O
of	O
diabetes	B-DISO
,	O
36	O
±	O
9	O
years	O
(	O
range	O
,	O
21	O
-	O
56	O
)	O
;	O
12	O
(	O
75	O
%	O
)	O
were	O
women	B-LIVB
.	O

Narrative	O
accounts	O
centered	O
on	O
expectations	O
,	O
hopes	B-PHYS
,	O
and	O
realities	O
;	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
;	O
waiting	O
and	O
uncertainty	O
;	O
the	O
procedure	O
,	O
hospital	O
stay	O
,	O
and	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O

Expected	O
benefits	O
included	O
fewer	O
severe	O
hypoglycemic	B-DISO
episodes	I-DISO
,	O
reduced	O
need	O
for	O
insulin	B-CHEM
,	O
preventing	O
onset	O
/	O
progression	O
of	O
complications	B-DISO
and	O
improved	O
psychological	B-DISO
well	I-DISO
-	I-DISO
being	I-DISO
.	O

These	O
were	O
realized	O
for	O
most	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O

Most	O
interviewees	B-LIVB
described	O
well	O
-	O
informed	O
,	O
shared	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
with	O
clinicians	B-LIVB
and	O
family	B-LIVB
,	O
and	O
managing	O
their	O
expectations	O
.	O

Although	O
life	O
""""	O
on	O
the	O
list	O
""""	O
could	O
be	O
stressful	O
,	O
and	O
immunosuppressant	B-CHEM
side	B-DISO
effects	I-DISO
were	O
severe	O
,	O
interviewees	B-LIVB
reported	O
""""	O
no	B-DISO
regrets	B-PHYS
.	O
""""	O
Posttransplant	O
,	O
interviewees	B-LIVB
experienced	O
increased	O
confidence	B-PHYS
,	O
through	O
freedom	B-DISO
from	I-DISO
hypoglycemia	I-DISO
and	O
regained	O
glycemic	B-PROC
control	I-PROC
,	O
which	O
tempered	O
any	O
disappointment	O
about	O
continued	O
reliance	O
on	O
insulin	B-CHEM
.	O

Most	O
viewed	O
their	O
transplant	B-PROC
as	O
a	O
success	O
,	O
though	O
several	O
reflected	O
upon	O
setbacks	O
and	O
hidden	O
hopes	B-PHYS
for	O
becoming	O
""""	O
insulin	B-DISO
-	I-DISO
free	I-DISO
.	O
""""	O
Independently	O
undertaken	O
interviews	B-PROC
demonstrated	O
realistic	O
and	O
balanced	O
expectations	O
of	O
IT	B-PROC
and	O
indicate	O
how	O
to	O
optimize	O
the	O
process	O
and	O
support	O
for	O
future	O
IT	B-PROC
candidates	B-LIVB
.	O

Nonsteroidal	B-CHEM
Anti	I-CHEM
-	I-CHEM
Inflammatory	I-CHEM
Drugs	I-CHEM
and	O
Bone	B-DISO
-	I-DISO
Healing	I-DISO
:	O
A	O
Systematic	O
Review	O
of	O
Research	B-PROC
Quality	I-PROC
Nonsteroidal	B-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
(	O
NSAIDs	B-CHEM
)	O
are	O
often	O
avoided	O
by	O
orthopaedic	B-LIVB
surgeons	I-LIVB
because	O
of	O
their	O
possible	O
influence	O
on	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O

This	O
belief	O
stems	O
from	O
multiple	O
studies	B-PROC
,	O
in	O
particular	O
animal	B-LIVB
studies	I-LIVB
,	O
that	O
show	O
delayed	O
bone	B-DISO
-	I-DISO
healing	I-DISO
or	O
nonunions	O
associated	O
with	O
NSAID	B-CHEM
exposure	O
.	O

The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
critically	O
analyze	B-PROC
the	O
quality	O
of	O
published	B-OBJC
literature	I-OBJC
that	O
evaluates	O
the	O
impact	O
of	O
NSAIDs	B-CHEM
on	O
clinical	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O

A	O
MEDLINE	O
and	O
Embase	O
search	O
was	O
conducted	O
to	O
identify	O
all	O
articles	O
relating	O
to	O
bone	B-DISO
and	O
fracture	B-PHYS
-	I-PHYS
healing	I-PHYS
and	O
the	O
utilization	O
of	O
NSAIDs	B-CHEM
.	O

All	O
human	B-PROC
studies	I-PROC
,	O
including	O
review	O
articles	O
,	O
were	O
identified	O
for	O
further	O
analysis	B-PROC
.	O

Non	B-OBJC
-	I-OBJC
English	I-OBJC
-	I-OBJC
language	I-OBJC
manuscripts	I-OBJC
and	O
in	O
vitro	O
and	O
animal	B-LIVB
studies	I-LIVB
were	O
excluded	O
.	O

A	O
total	O
of	O
twelve	O
clinical	O
articles	O
and	O
twenty	O
-	O
four	O
literature	O
reviews	O
were	O
selected	O
for	O
analysis	B-PROC
.	O

The	O
quality	O
of	O
the	O
clinical	B-PROC
studies	I-PROC
was	O
assessed	O
with	O
a	O
modified	O
Coleman	O
Methodology	O
Score	O
with	O
emphasis	O
on	O
the	O
NSAID	B-CHEM
utilization	O
.	O

Review	O
articles	O
were	O
analyzed	B-PROC
with	O
regard	O
to	O
variability	O
in	O
the	O
cited	O
literature	O
and	O
final	O
conclusions	O
.	O

The	O
mean	O
modified	O
Coleman	O
Methodology	O
Score	O
(	O
and	O
standard	O
deviation	O
)	O
was	O
significantly	O
lower	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
in	O
clinical	B-PROC
studies	I-PROC
that	O
demonstrated	O
a	O
negative	O
effect	O
of	O
NSAIDs	B-CHEM
on	O
bone	B-DISO
-	I-DISO
healing	I-DISO
(	O
40	O
.	O
0	O
±	O
14	O
.	O

3	O
points	O
)	O
compared	O
with	O
those	O
that	O
concluded	O
that	O
NSAIDs	B-CHEM
were	O
safe	O
(	O
58	O
.	O
8	O
±	O
10	O
.	O

3	O
points	O
)	O
.	O

Review	O
articles	O
also	O
demonstrated	O
substantial	O
variability	O
in	O
the	O
number	O
of	O
cited	O
clinical	B-PROC
studies	I-PROC
and	O
overall	O
conclusions	O
.	O

There	O
were	O
only	O
two	O
meta	O
-	O
analyses	O
and	O
twenty	O
-	O
two	O
narrative	O
reviews	O
.	O

The	O
mean	O
number	O
(	O
and	O
standard	O
deviation	O
)	O
of	O
clinical	B-PROC
studies	I-PROC
cited	O
was	O
significantly	O
greater	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
for	O
reviews	O
that	O
concluded	O
that	O
NSAIDs	B-CHEM
were	O
safe	O
(	O
8	O
.	O
0	O
±	O
4	O
.	O

8	O
)	O
compared	O
with	O
those	O
that	O
recommended	O
avoiding	O
them	O
(	O
2	O
.	O
1	O
±	O
2	O
.	O
1	O
)	O
.	O

Unanimously	O
,	O
all	O
reviews	O
admitted	O
to	O
the	O
need	O
for	O
prospective	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
to	O
help	O
clarify	O
the	O
effects	O
of	O
NSAIDs	B-CHEM
on	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O

This	O
systematic	O
literature	O
review	O
highlights	O
the	O
great	O
variability	O
in	O
the	O
interpretation	O
of	O
the	O
literature	O
addressing	O
the	O
impact	O
of	O
NSAIDs	B-CHEM
on	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O

Unfortunately	O
,	O
there	O
is	O
no	O
consensus	O
regarding	O
the	O
safety	O
of	O
NSAIDs	B-CHEM
following	O
orthopaedic	B-PROC
procedures	I-PROC
,	O
and	O
future	O
studies	B-PROC
should	O
aim	O
for	O
appropriate	O
methodological	B-PROC
designs	I-PROC
to	O
help	O
to	O
clarify	O
existing	O
discrepancies	B-DISO
to	O
improve	O
the	O
quality	B-PROC
of	I-PROC
care	I-PROC
for	O
orthopaedic	B-LIVB
patients	I-LIVB
.	O

This	O
systematic	O
review	O
highlights	O
the	O
limitations	O
in	O
the	O
current	O
understanding	O
of	O
the	O
effects	O
of	O
NSAIDs	B-CHEM
on	O
bone	B-DISO
healing	I-DISO
.	O

Thus	O
,	O
withholding	O
these	O
medications	B-CHEM
does	O
not	O
have	O
any	O
proven	O
scientific	O
benefit	O
to	O
patients	B-LIVB
and	O
may	O
even	O
cause	O
harm	B-DISO
by	O
increasing	O
narcotic	B-CHEM
requirements	O
in	O
cases	O
in	O
which	O
they	O
could	O
be	O
beneficial	O
for	O
pain	B-PROC
management	I-PROC
.	O

This	O
review	O
should	O
encourage	O
further	O
basic	O
-	O
science	O
and	O
clinical	B-PROC
studies	I-PROC
to	O
clarify	O
the	O
risks	O
and	O
benefits	O
of	O
anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
medications	I-CHEM
in	O
the	O
postoperative	O
period	O
,	O
with	O
the	O
aim	O
of	O
improving	O
patient	B-LIVB
outcomes	O
.	O

The	O
nanocomposite	O
nature	O
of	O
bone	B-ANAT
drives	O
its	O
strength	O
and	O
damage	O
resistance	O
In	O
human	B-ANAT
bone	I-ANAT
,	O
an	O
amorphous	O
mineral	B-CHEM
serves	O
as	O
a	O
precursor	O
to	O
the	O
formation	O
of	O
a	O
highly	O
substituted	O
nanocrystalline	B-OBJC
apatite	B-CHEM
.	O

However	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	O
mineral	B-CHEM
remains	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
that	O
100	O
-	O
300	O
nm	O
amorphous	O
calcium	B-CHEM
phosphate	I-CHEM
regions	B-ANAT
are	O
present	O
in	O
the	O
disordered	O
phase	O
of	O
trabecular	O
bone	O
.	O

Nanomechanical	B-PROC
experiments	I-PROC
on	O
cylindrical	O
samples	B-OBJC
,	O
with	O
diameters	O
between	O
250	O
nm	O
and	O
3	O
,	O
000	O
nm	O
,	O
of	O
the	O
bone	B-ANAT
's	I-ANAT
ordered	O
and	O
disordered	O
phases	O
revealed	O
a	O
transition	O
from	O
plastic	B-PHEN
deformation	B-DISO
to	O
brittle	B-DISO
failure	B-DISO
and	O
at	O
least	O
a	O
factor	O
-	O
of	O
-	O
2	O
higher	O
strength	O
in	O
the	O
smaller	O
samples	B-OBJC
.	O

We	O
postulate	O
that	O
this	O
transition	O
in	O
failure	O
mechanism	O
is	O
caused	O
by	O
the	O
suppression	O
of	O
extrafibrillar	B-ANAT
shearing	B-PROC
in	O
the	O
smaller	O
samples	B-OBJC
,	O
and	O
that	O
the	O
emergent	O
smaller	O
-is	O
-	O
stronger	O
size	O
effect	O
is	O
related	O
to	O
the	O
sample	O
-	O
size	O
scaling	O
of	O
the	O
distribution	O
of	O
flaws	O
.	O

Our	O
findings	B-DISO
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi	O
-	O
scale	O
nature	O
of	O
bone	B-ANAT
and	O
provide	O
insights	O
into	O
the	O
biomineralization	B-PHYS
process	B-PHEN
.	O

Long	B-CHEM
noncoding	I-CHEM
RNA	I-CHEM
XIST	B-CHEM
acts	O
as	O
an	O
oncogene	O
in	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
by	O
epigenetically	B-PHYS
repressing	I-PHYS
KLF2	B-CHEM
expression	B-PHYS
Recently	O
,	O
long	B-CHEM
noncoding	I-CHEM
RNAs	I-CHEM
(	O
lncRNAs	B-CHEM
)	O
have	O
been	O
identified	O
as	O
critical	O
regulators	O
in	O
numerous	O
types	O
of	O
cancers	B-DISO
,	O
including	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
(	O
NSCLC	B-DISO
)	O
.	O

X	B-CHEM
inactivate	I-CHEM
-	I-CHEM
specific	I-CHEM
transcript	I-CHEM
(	O
XIST	B-CHEM
)	O
has	O
been	O
found	O
to	O
be	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
and	O
acts	O
as	O
an	O
oncogene	O
in	O
gastric	B-DISO
cancer	I-DISO
and	O
hepatocellular	B-DISO
carcinoma	I-DISO
,	O
but	O
little	O
is	O
known	O
about	O
its	O
expression	B-PHYS
pattern	O
,	O
biological	B-PHEN
function	I-PHEN
and	O
underlying	O
mechanism	O
in	O
NSCLC	B-DISO
.	O

Here	O
,	O
we	O
identified	O
XIST	B-CHEM
as	O
an	O
oncogenic	O
lncRNA	B-CHEM
by	O
driving	O
tumorigenesis	B-DISO
in	O
NSCLC	B-DISO
.	O

We	O
found	O
that	O
XIST	B-CHEM
is	O
over	O
-	O
expressed	B-PHYS
in	O
NSCLC	B-DISO
,	O
and	O
its	O
increased	O
level	O
is	O
associated	O
with	O
shorter	B-DISO
survival	I-DISO
and	O
poorer	B-DISO
prognosis	I-DISO
.	O

Knockdown	B-PROC
of	O
XIST	B-CHEM
impaired	O
NSCLC	B-DISO
cells	B-PHYS
proliferation	I-PHYS
,	O
migration	B-PHYS
and	O
invasion	B-DISO
in	B-PROC
vitro	I-PROC
,	O
and	O
repressed	O
the	O
tumorigenicity	B-DISO
of	O
NSCLC	B-DISO
cells	O
in	B-PROC
vivo	I-PROC
.	O

Mechanistically	O
,	O
RNA	B-CHEM
immune	B-PROC
-	I-PROC
precipitation	I-PROC
(	O
RIP	B-PROC
)	O
and	O
RNA	B-CHEM
pull	B-PROC
-	I-PROC
down	I-PROC
experiment	I-PROC
demonstrated	O
that	O
XIST	B-CHEM
could	O
simultaneously	O
interact	O
with	O
EZH2	B-CHEM
to	O
suppress	O
transcription	B-PHYS
of	O
its	O
potential	O
target	O
KLF2	B-CHEM
.	O

Additionally	O
,	O
rescue	O
experiments	B-PROC
revealed	O
that	O
XIST	B-CHEM
'	O
s	O
oncogenic	O
functions	O
were	O
partly	O
depending	O
on	O
silencing	B-PHYS
KLF2	B-CHEM
expression	B-PHYS
.	O

Collectively	O
,	O
our	O
findings	B-DISO
expound	O
how	O
XIST	B-CHEM
over	O
-	O
expression	B-PHYS
endows	O
an	O
oncogenic	O
function	O
in	O
NSCLC	B-DISO
.	O

Assessing	O
the	O
physiological	O
relevance	O
of	O
alternate	O
architectures	O
of	O
the	O
p7	B-CHEM
protein	I-CHEM
of	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
in	O
different	O
environments	O
The	O
viroporin	B-PHEN
p7	B-CHEM
of	O
the	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
forms	O
multimeric	B-CHEM
channels	I-CHEM
eligible	O
for	O
ion	B-PHYS
transport	I-PHYS
across	O
the	O
endoplasmic	B-ANAT
reticulum	I-ANAT
membrane	I-ANAT
.	O

Currently	O
the	O
subject	O
of	O
many	O
studies	B-PROC
and	O
discussion	O
,	O
the	O
molecular	B-PHYS
assembly	I-PHYS
of	O
the	O
ion	B-CHEM
channel	I-CHEM
and	O
the	O
structural	O
characteristics	O
of	O
the	O
p7	B-CHEM
monomer	B-CHEM
are	O
not	O
yet	O
fully	O
understood	O
.	O

Structural	O
investigation	O
of	O
p7	B-CHEM
has	O
been	O
carried	O
out	O
only	O
in	O
detergent	B-CHEM
environments	O
,	O
making	O
the	O
interpretation	O
of	O
the	O
experimental	O
results	O
somewhat	O
questionable	O
.	O

Here	O
,	O
we	O
analyze	B-PROC
by	O
means	O
of	O
molecular	O
dynamics	O
simulations	O
the	O
structure	O
of	O
the	O
p7	B-CHEM
monomer	B-CHEM
as	O
a	O
function	O
of	O
its	O
sequence	O
,	O
initial	O
conformation	O
and	O
environment	O
.	O

We	O
investigate	O
the	O
conductance	O
properties	O
of	O
three	O
models	B-DEVI
of	O
a	O
hexameric	B-CHEM
p7	B-CHEM
ion	B-CHEM
channel	I-CHEM
by	O
examining	O
ion	B-PHYS
translocation	I-PHYS
in	O
a	O
pure	O
lipid	B-ANAT
bilayer	I-ANAT
.	O

It	O
is	O
noteworthy	O
that	O
although	O
none	O
of	O
the	O
models	B-DEVI
reflects	O
the	O
experimentally	O
observed	O
trend	O
to	O
conduct	O
preferentially	O
cations	B-CHEM
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
position	O
and	O
orientation	O
of	O
titratable	O
acidic	O
or	O
basic	O
residues	O
playing	O
a	O
crucial	O
role	O
in	O
ion	B-CHEM
selectivity	O
and	O
in	O
the	O
overall	O
conductance	O
of	O
the	O
channel	B-CHEM
.	O

In	O
addition	O
,	O
too	O
compact	O
a	O
packing	B-PHYS
of	O
the	O
monomers	B-CHEM
leads	O
to	O
channel	B-CHEM
collapse	B-PHEN
rather	O
than	O
formation	O
of	O
a	O
reasonable	O
pore	B-ANAT
,	O
amenable	O
to	O
ion	B-PHYS
translocation	I-PHYS
.	O

The	O
present	O
findings	O
are	O
envisioned	O
to	O
help	O
assess	O
the	O
physiological	O
relevance	O
of	O
p7	B-CHEM
ion	B-CHEM
channel	I-CHEM
models	B-DEVI
consisting	O
of	O
multimeric	O
structures	O
obtained	O
in	O
non	O
-	O
native	O
environments	O
.	O

Cartilage	B-DISO
inflammation	I-DISO
and	O
degeneration	B-DISO
is	O
enhanced	O
by	O
pro	O
-	O
inflammatory	O
(	B-ANAT
M1	I-ANAT
)	I-ANAT
macrophages	I-ANAT
in	O
vitro	O
,	O
but	O
not	O
inhibited	O
directly	O
by	O
anti	O
-	O
inflammatory	O
(	B-ANAT
M2	I-ANAT
)	I-ANAT
macrophages	I-ANAT
Macrophages	B-ANAT
play	O
a	O
crucial	O
role	O
in	O
the	O
progression	O
of	O
osteoarthritis	B-DISO
(	O
OA	B-DISO
)	O
.	O

Their	O
phenotype	B-PHYS
may	O
range	O
from	O
pro	O
-	O
inflammatory	O
to	O
anti	O
-	O
inflammatory	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
direct	O
effects	O
of	O
macrophage	B-ANAT
subtypes	O
on	O
cartilage	O
by	O
culturing	B-PROC
macrophage	B-ANAT
conditioned	B-CHEM
medium	I-CHEM
(	O
MCM	B-CHEM
)	O
on	O
human	B-LIVB
articular	O
cartilage	O
.	O

Human	B-LIVB
OA	B-DISO
cartilage	O
explants	B-PROC
were	O
cultured	B-PROC
with	O
MCM	B-CHEM
of	O
pro	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
M	I-ANAT
(	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
)	O
,	O
or	O
anti	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
M	I-ANAT
(	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
)	I-CHEM
or	O
M	B-ANAT
(	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	O
human	B-LIVB
monocyte	B-ANAT
-	I-ANAT
derived	I-ANAT
macrophages	I-ANAT
.	O

To	O
assess	O
effects	O
of	O
anti	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
macrophages	I-ANAT
,	O
the	O
cartilage	O
was	O
cultured	B-PROC
with	O
a	O
combination	O
of	O
MCM	B-CHEM
phenotypes	B-PHYS
as	O
well	O
as	O
pre	B-PHEN
-	I-PHEN
stimulated	I-PHEN
with	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
cartilage	O
before	O
culture	B-PROC
with	O
MCM	B-CHEM
.	O

The	O
reactions	O
of	O
the	O
explants	O
were	O
assessed	O
by	O
gene	B-PHYS
expression	I-PHYS
,	O
nitric	B-PHEN
oxide	I-PHEN
(	I-PHEN
NO	I-PHEN
)	I-PHEN
production	I-PHEN
and	O
release	O
of	O
glycosaminoglycans	B-CHEM
(	O
GAGs	B-CHEM
)	O
.	O

M	B-ANAT
(	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
)	O
MCM	B-CHEM
affected	O
OA	B-DISO
cartilage	O
by	O
upregulation	B-PHYS
of	O
IL1B	B-CHEM
(	O
Interleukin	B-CHEM
1β	I-CHEM
)	O
,	O
IL6	B-CHEM
,	O
MMP13	B-CHEM
(	O
Matrix	B-CHEM
Metalloproteinase	I-CHEM
-	I-CHEM
13	I-CHEM
)	O
and	O
ADAMTS5	B-CHEM
(	O
A	B-CHEM
Disintegrin	I-CHEM
And	I-CHEM
Metalloproteinase	I-CHEM
with	I-CHEM
Thrombospondin	I-CHEM
Motifs	I-CHEM
-	I-CHEM
5	I-CHEM
)	O
,	O
while	O
inhibiting	O
ACAN	B-CHEM
(	O
aggrecan	B-CHEM
)	O
and	O
COL2A1	B-CHEM
(	O
collagen	B-CHEM
type	I-CHEM
II	I-CHEM
)	O
.	O

M	B-ANAT
(	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	O
upregulated	B-PHYS
IL1B	B-CHEM
and	O
Suppressor	B-CHEM
of	I-CHEM
cytokine	I-CHEM
signaling	I-CHEM
1	I-CHEM
(	O
SOCS1	B-CHEM
)	O
.	O

NO	B-PHEN
production	I-PHEN
and	O
GAG	B-CHEM
release	O
by	O
the	O
cartilage	O
was	O
increased	O
when	O
cultured	B-PROC
with	O
M	B-ANAT
(	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
)	O
MCM	B-CHEM
.	O

M	B-ANAT
(	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
)	I-CHEM
and	O
M	B-ANAT
(	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	I-CHEM
did	O
not	O
inhibit	O
the	O
effects	O
of	O
M	B-ANAT
(	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
)	O
MCM	B-CHEM
of	O
neither	O
phenotype	B-PHYS
affected	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
pre	B-PHEN
-	I-PHEN
stimulated	I-PHEN
cartilage	O
,	O
in	O
which	O
an	O
inflammatory	O
gene	O
response	B-PHYS
was	O
deliberately	O
induced	O
.	O

M	B-ANAT
(	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
)	O
macrophages	B-ANAT
have	O
a	O
prominent	O
direct	O
effect	O
on	O
OA	B-DISO
cartilage	O
,	O
while	O
M	B-ANAT
(	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
)	I-CHEM
and	O
M	B-ANAT
(	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	I-CHEM
do	O
not	O
inhibit	O
the	O
effects	O
of	O
M	B-ANAT
(	O
IFNγ	B-CHEM
+	O
TNFα	B-CHEM
)	O
,	O
or	O
IFN	B-CHEM
γ	O
+	O
TNFα	B-CHEM
induced	O
inflammation	B-DISO
of	O
the	O
cartilage	O
.	O

Therapies	B-PROC
aiming	O
at	O
inhibiting	O
cartilage	B-DISO
degeneration	I-DISO
may	O
take	O
this	O
into	O
account	O
by	O
directing	O
suppression	B-PHYS
of	O
pro	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
macrophages	I-ANAT
or	O
stimulation	B-PHEN
of	O
anti	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
macrophages	I-ANAT
.	O

The	O
genome	O
-scale	O
DNA	B-PHYS
-	I-PHYS
binding	I-PHYS
profile	B-PROC
of	O
BarR	B-CHEM
,	O
a	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
responsive	O
transcription	B-CHEM
factor	I-CHEM
in	O
the	O
archaeon	B-LIVB
Sulfolobus	B-LIVB
acidocaldarius	I-LIVB
The	O
Leucine	B-CHEM
-	I-CHEM
responsive	I-CHEM
Regulatory	I-CHEM
Protein	I-CHEM
(	O
Lrp	B-CHEM
)	O
family	B-CHEM
is	O
a	O
widespread	O
family	B-CHEM
of	O
regulatory	B-CHEM
transcription	I-CHEM
factors	I-CHEM
in	O
prokaryotes	B-LIVB
.	O

BarR	B-CHEM
is	O
an	O
Lrp	B-CHEM
-like	O
transcription	B-CHEM
factor	I-CHEM
in	O
the	O
model	O
archaeon	B-LIVB
Sulfolobus	B-LIVB
acidocaldarius	I-LIVB
that	O
activates	O
the	O
expression	B-PHYS
of	O
a	O
β	O
-	O
alanine	O
aminotransferase	O
gene	O
,	O
which	O
is	O
involved	O
in	O
β	B-PHYS
-	I-PHYS
alanine	I-PHYS
degradation	I-PHYS
.	O

In	O
contrast	O
to	O
classical	O
Lrp	B-CHEM
-like	O
transcription	B-CHEM
factors	I-CHEM
,	O
BarR	B-CHEM
is	O
not	B-DISO
responsive	I-DISO
to	O
any	O
of	O
the	O
α	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
but	O
interacts	O
specifically	O
with	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
.	O

Besides	O
the	O
juxtaposed	O
β	O
-	O
alanine	O
aminotransferase	O
gene	O
,	O
other	O
regulatory	O
targets	O
of	O
BarR	B-CHEM
have	O
not	O
yet	O
been	O
identified	O
although	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
is	O
the	O
precursor	B-CHEM
of	O
coenzyme	B-CHEM
A	I-CHEM
and	O
thus	O
an	O
important	O
central	O
metabolite	B-CHEM
.	O

The	O
aim	O
of	O
this	O
study	B-PROC
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
DNA	B-PHYS
-	I-PHYS
binding	I-PHYS
characteristics	O
of	O
BarR	B-CHEM
and	O
of	O
its	O
corresponding	O
regulon	O
from	O
a	O
local	O
to	O
a	O
genome	O
-wide	O
perspective	O
.	O

We	O
characterized	O
the	O
genome	B-PROC
-	I-PROC
wide	I-PROC
binding	I-PROC
profile	I-PROC
of	O
BarR	B-CHEM
using	O
chromatin	B-PROC
immunoprecipation	I-PROC
combined	O
with	O
high	B-PROC
-	I-PROC
throughput	I-PROC
sequencing	I-PROC
(	O
ChIP	B-PROC
-	I-PROC
seq	I-PROC
)	O
.	O

This	O
revealed	O
21	O
genomic	O
binding	B-PHYS
loci	O
.	O

High	O
-	O
enrichment	O
binding	B-PHYS
regions	I-PHYS
were	O
validated	O
to	O
interact	O
with	O
purified	O
BarR	B-CHEM
protein	I-CHEM
in	O
vitro	O
using	O
electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	O
semi	B-CHEM
-	I-CHEM
palindromic	I-CHEM
binding	O
motif	O
.	O

Only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic	O
sites	O
are	O
located	O
in	O
intergenic	B-CHEM
regions	I-CHEM
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	B-CHEM
,	O
and	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
analysis	I-PROC
demonstrated	O
that	O
only	O
one	O
additional	O
operon	O
is	O
under	O
activation	B-PHYS
of	O
BarR	B-CHEM
,	O
namely	O
the	O
glutamine	O
synthase	O
operon	O
.	O

The	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
Lrp	B-CHEM
-like	O
transcription	B-CHEM
factors	I-CHEM
.	O

Detailed	O
inspection	O
of	O
the	O
BarR	B-CHEM
ChIP	B-PHEN
-	I-PHEN
seq	I-PHEN
profile	I-PHEN
at	O
the	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
aminotransferase	I-CHEM
promoter	I-CHEM
region	I-CHEM
in	O
combination	O
with	O
binding	O
motif	O
predictions	O
indicate	O
that	O
the	O
operator	B-CHEM
structure	I-CHEM
is	O
more	O
complicated	O
than	O
previously	O
anticipated	O
,	O
consisting	O
of	O
multiple	B-CHEM
(	I-CHEM
major	I-CHEM
and	I-CHEM
auxiliary	I-CHEM
)	I-CHEM
operators	I-CHEM
.	O

BarR	B-CHEM
has	O
a	O
limited	O
regulon	O
,	O
and	O
includes	O
also	O
glutamine	O
synthase	O
genes	O
besides	O
the	O
previously	O
characterized	O
β	O
-	O
alanine	O
aminotransferase	O
.	O

Regulation	B-PHEN
of	O
glutamine	B-CHEM
synthase	I-CHEM
is	O
suggestive	O
of	O
a	O
link	O
between	O
β	B-PHYS
-	I-PHYS
alanine	I-PHYS
and	O
α	B-PHYS
-	I-PHYS
amino	I-PHYS
acid	I-PHYS
metabolism	I-PHYS
in	O
S	B-LIVB
.	I-LIVB

acidocaldarius	I-LIVB
.	O

Furthermore	O
,	O
this	O
work	O
reveals	O
that	O
the	O
BarR	B-CHEM
regulon	O
overlaps	O
with	O
that	O
of	O
other	O
Lrp	B-CHEM
-like	O
regulators	O
.	O

Preclinical	O
fibrinolysis	B-PHYS
in	O
patients	B-LIVB
with	O
ST	B-DISO
-	I-DISO
segment	I-DISO
elevation	I-DISO
myocardial	I-DISO
infarction	I-DISO
in	O
a	O
rural	O
region	O
In	O
the	O
current	O
guidelines	O
for	O
the	O
treatment	B-PROC
of	O
patients	B-LIVB
with	O
ST	B-DISO
-	I-DISO
segment	I-DISO
elevation	I-DISO
myocardial	I-DISO
infarction	I-DISO
(	O
STEMI	B-DISO
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	B-PHYS
as	O
a	O
reperfusion	B-PROC
therapy	I-PROC
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	B-PROC
catheterisation	I-PROC
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

However	O
,	O
there	O
is	O
little	O
remaining	O
in	O
-	O
depth	O
expertise	O
in	O
this	O
method	O
because	O
fibrinolysis	B-PHYS
is	O
presently	O
only	O
rarely	O
indicated	B-DISO
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	B-GEOG
,	O
where	O
an	O
emergency	B-PROC
primary	I-PROC
percutaneous	I-PROC
coronary	I-PROC
intervention	I-PROC
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
STEMI	B-DISO
patients	B-LIVB
underwent	O
fibrinolysis	B-PHYS
with	O
the	O
plasminogen	B-CHEM
activator	I-CHEM
reteplase	I-CHEM
,	O
performed	O
by	O
trained	O
emergency	B-PHEN
physicians	B-LIVB
.	O

The	O
practicality	O
of	O
the	O
treatment	B-PROC
,	O
as	O
well	O
as	O
complications	B-DISO
and	O
the	O
mortality	O
of	O
the	O
patients	B-LIVB
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	B-OBJC
,	O
were	O
retrospectively	B-PROC
studied	I-PROC
.	O

The	O
mean	O
time	O
from	O
onset	O
of	O
the	O
symptoms	B-DISO
to	O
first	O
medical	B-PROC
contact	I-PROC
was	O
114	O
±	O
116	O
min	O
.	O

The	O
mean	O
interval	O
to	O
the	O
start	O
of	O
fibrinolysis	B-PHYS
of	O
13	O
.	O
5	O
±	O
6	O
.	O
4	O
min	O
was	O
within	O
the	O
30	O
min	O
mandated	O
by	O
the	O
ESC	O
.	O

Patients	B-LIVB
with	O
inferior	B-DISO
STEMI	I-DISO
represented	O
the	O
largest	O
subgroup	O
.	O

Occurring	O
in	O
39	O
cases	B-LIVB
(	O
25	O
%	O
)	O
,	O
complications	B-DISO
due	O
to	O
infarction	B-DISO
were	O
relatively	O
common	O
during	O
the	O
prehospital	B-PROC
phase	O
,	O
including	O
15	O
cases	B-LIVB
(	O
9	O
.	O

6	O
%	O
)	O
of	O
cardiogenic	B-DISO
shock	I-DISO
,	O
but	O
in	O
all	O
cases	B-LIVB
the	O
complications	B-DISO
were	O
manageable	B-DISO
.	O

No	O
patient	B-LIVB
died	B-DISO
before	O
arrival	O
at	O
the	O
hospital	B-OBJC
.	O

As	O
lysis	B-DISO
-	O
associated	O
adverse	B-DISO
effects	I-DISO
,	O
merely	O
two	O
uncomplicated	O
mucosal	B-DISO
haemorrhages	I-DISO
and	O
one	O
case	O
of	O
mild	B-DISO
allergic	I-DISO
skin	I-DISO
reactions	I-DISO
were	O
seen	O
.	O

In	O
emergency	B-PHEN
situations	I-PHEN
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	B-PROC
catheterisation	I-PROC
laboratory	B-OBJC
,	O
preclinical	O
fibrinolysis	B-PHYS
in	O
STEMI	B-DISO
still	O
represents	O
a	O
workable	O
method	O
.	O

Success	O
of	O
this	O
strategy	B-PHYS
requires	O
particularly	O
strong	B-PROC
training	I-PROC
of	O
the	O
emergency	B-PHEN
physicians	B-LIVB
in	O
ECG	B-PROC
and	O
lysis	B-DISO
therapy	B-PROC
,	O
and	O
co	O
-	O
operation	O
with	O
nearby	O
cardiac	B-OBJC
centres	I-OBJC
.	O

GH32	B-CHEM
family	I-CHEM
activity	B-PHYS
:	O
a	O
topological	O
approach	O
through	O
protein	O
contact	O
networks	O
The	O
application	O
of	O
Protein	O
Contact	O
Networks	O
methodology	O
allowed	O
to	O
highlight	O
a	O
novel	O
response	O
of	O
border	O
region	O
between	O
the	O
two	O
domains	O
to	O
substrate	O
binding	O
.	O

Glycoside	B-CHEM
hydrolases	I-CHEM
(	O
GH	B-CHEM
)	O
are	O
enzymes	B-CHEM
that	O
mainly	O
hydrolyze	B-PHEN
the	O
glycosidic	B-PHYS
bond	I-PHYS
between	O
two	O
carbohydrates	B-CHEM
or	O
a	O
carbohydrate	B-CHEM
and	O
a	O
non	B-CHEM
-	I-CHEM
carbohydrate	I-CHEM
moiety	I-CHEM
.	O

These	O
enzymes	B-CHEM
are	O
involved	O
in	O
many	O
fundamental	O
and	O
diverse	O
biological	B-PHEN
processes	I-PHEN
in	O
plants	B-LIVB
.	O

We	O
have	O
focused	O
on	O
the	O
GH32	B-CHEM
family	I-CHEM
,	O
including	O
enzymes	B-CHEM
very	O
similar	O
in	O
both	O
sequence	O
and	O
structure	B-CHEM
,	O
each	O
having	O
however	O
clear	O
specificities	O
of	O
substrate	B-CHEM
preferences	O
and	O
kinetic	O
properties	O
.	O

Structural	B-CHEM
and	O
topological	O
differences	O
among	O
proteins	B-CHEM
of	O
the	O
GH32	B-CHEM
family	I-CHEM
have	O
been	O
here	O
identified	O
by	O
means	O
of	O
an	O
emerging	O
approach	O
(	O
Protein	O
Contact	O
network	O
,	O
PCN	O
)	O
based	O
on	O
the	O
formalization	O
of	O
3D	O
structures	O
as	O
contact	O
networks	O
among	O
amino	O
-	O
acid	O
residues	O
.	O

The	O
PCN	O
approach	O
proved	O
successful	O
in	O
both	O
reconstructing	O
the	O
already	O
known	O
functional	O
domains	O
and	O
in	O
identifying	O
the	O
structural	B-CHEM
counterpart	O
of	O
the	O
properties	O
of	O
GH32	B-CHEM
enzymes	I-CHEM
,	O
which	O
remain	O
uncertain	O
,	O
like	O
their	O
allosteric	O
character	O
.	O

The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	O
discovery	O
of	O
the	O
activation	B-PHYS
upon	O
binding	B-PHYS
of	I-PHYS
the	I-PHYS
border	I-PHYS
(	I-PHYS
cleft	I-PHYS
)	I-PHYS
region	I-PHYS
between	O
the	O
two	O
domains	O
.	O

This	O
reveals	O
the	O
allosteric	O
nature	O
of	O
the	O
enzymatic	B-PHYS
activity	I-PHYS
for	O
all	O
the	O
analyzed	O
forms	O
in	O
the	O
GH32	B-CHEM
family	I-CHEM
,	O
a	O
character	O
yet	O
to	O
be	O
highlighted	O
in	O
biochemical	B-PROC
studies	I-PROC
.	O

Furthermore	O
,	O
we	O
have	O
been	O
able	O
to	O
recognize	O
a	O
topological	O
signature	O
(	O
graph	O
energy	O
)	O
of	O
the	O
different	O
affinity	B-PHEN
of	O
the	O
enzymes	B-CHEM
towards	O
small	O
and	O
large	O
substrates	B-CHEM
.	O

In	O
vivo	O
assessment	B-PROC
of	O
periodontal	O
structures	O
and	O
measurement	O
of	O
gingival	B-ANAT
sulcus	I-ANAT
with	O
Optical	B-PROC
Coherence	I-PROC
Tomography	I-PROC
:	O
a	O
pilot	B-PROC
study	I-PROC
There	O
has	O
been	O
increasing	O
interest	O
on	O
the	O
development	O
of	O
clinically	O
acceptable	O
,	O
more	O
sensitive	O
and	O
specific	O
methods	O
for	O
non	O
-	O
invasive	O
diagnosis	B-DISO
in	O
Periodontics	O
.	O

In	O
this	O
pilot	B-PROC
study	I-PROC
,	O
the	O
performance	O
of	O
an	O
Optical	B-PROC
Coherence	I-PROC
Tomography	I-PROC
(	O
OCT	B-PROC
)	O
system	O
in	O
imaging	B-PROC
periodontal	O
structures	O
in	O
humans	B-LIVB
was	O
evaluated	B-PROC
.	O

Gingival	B-ANAT
sulcus	I-ANAT
depth	O
measurements	O
were	O
obtained	O
and	O
compared	O
with	O
traditional	O
probes	B-DEVI
.	O

In	O
total	O
,	O
445	O
sites	O
of	O
23	O
periodontally	O
healthy	O
individuals	B-LIVB
were	O
measured	O
by	O
3	O
instruments	B-DEVI
:	O
North	B-DEVI
Carolina	I-DEVI
manual	I-DEVI
probe	I-DEVI
,	O
Florida	B-DEVI
automated	I-DEVI
probe	I-DEVI
and	O
OCT	B-PROC
at	O
1325	O
nm	O
.	O

To	O
obtain	O
quantitative	O
measurements	O
from	O
OCT	B-PROC
images	O
,	O
the	O
gingival	B-ANAT
refractive	O
index	O
was	O
also	O
determined	O
.	O

Discomfort	B-DISO
/	O
pain	B-DISO
perception	B-PHYS
and	O
the	O
duration	O
of	O
examinations	B-PROC
were	O
compared	O
among	O
the	O
instruments	B-DEVI
.	O

The	O
analysis	O
of	O
OCT	B-PROC
images	O
allowed	O
the	O
identification	O
of	O
relevant	O
anatomic	O
dental	O
and	O
periodontal	O
regions	B-ANAT
.	O

The	O
average	O
sulcus	B-ANAT
depth	O
measured	O
by	O
OCT	B-PROC
,	O
0	O
.	O
85	O
±	O
0	O
.	O
27	O
mm	O
and	O
0	O
.	O
87	O
±	O
0	O
.	O
28	O
mm	O
,	O
was	O
lower	O
than	O
the	O
values	O
obtained	O
by	O
manual	O
and	O
automated	O
probing	B-PROC
.	O

Discomfort	B-DISO
/	O
pain	B-DISO
were	O
prevalent	O
for	O
traditional	O
probes	B-DEVI
,	O
which	O
are	O
invasive	O
methods	O
,	O
than	O
for	O
the	O
non	O
-	O
invasive	O
OCT	B-PROC
technique	O
.	O

OCT	B-PROC
has	O
the	O
potential	O
to	O
be	O
a	O
reliable	O
tool	B-OBJC
for	O
in	O
vivo	O
periodontal	O
tissues	O
evaluation	B-PROC
and	O
for	O
reproducible	O
sulcus	B-ANAT
depth	O
measurements	O
in	O
healthy	O
sites	O
.	O

Further	O
technological	O
advances	O
are	O
required	O
to	O
reduce	O
the	O
procedure	B-PROC
time	O
and	O
promote	O
evaluation	B-PROC
of	O
posterior	O
oral	B-ANAT
regions	I-ANAT
.	O

Photonic	O
assessment	B-PROC
of	O
periodontal	O
tissue	O
with	O
OCT	B-PROC
(	O
top	O
)	O
in	O
a	O
clinical	O
environment	O
,	O
showing	O
tooth	B-ANAT
/	O
gingiva	O
features	O
(	O
bottom	O
)	O
.	O

A	O
method	O
of	O
providing	O
engaging	O
formative	O
feedback	O
to	O
large	O
cohort	B-LIVB
first	O
-	O
year	O
physiology	O
and	O
anatomy	O
students	B-LIVB
A	O
growing	O
body	O
of	O
evidence	O
demonstrates	O
a	O
critical	O
role	O
for	O
effective	O
,	O
meaningful	O
feedback	B-PHYS
to	O
enhance	O
student	B-LIVB
learning	B-PHYS
.	O

Effective	O
feedback	B-PHYS
can	O
become	O
part	O
of	O
the	O
learning	B-PHYS
cycle	O
that	O
is	O
not	O
only	O
a	O
learning	B-PHYS
opportunity	B-PROC
for	O
the	O
student	B-LIVB
but	O
can	O
also	O
be	O
used	O
to	O
inform	O
the	O
teacher	B-LIVB
and	O
ongoing	O
curriculum	B-PROC
development	I-PROC
.	O

Feedback	B-PHYS
is	O
considered	O
particularly	O
important	O
during	O
the	O
first	O
year	O
of	O
university	B-OBJC
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	O
strategy	O
that	O
can	O
help	O
attenuate	O
student	B-LIVB
performance	B-DISO
anxieties	I-DISO
and	O
solidify	O
perceptions	B-PHYS
of	O
academic	B-PROC
support	I-PROC
.	O

Unfortunately	O
,	O
the	O
provision	O
of	O
individualized	O
,	O
timely	O
feedback	B-PHYS
can	O
be	O
particularly	O
challenging	O
in	O
first	O
-	O
year	O
courses	O
as	O
they	O
tend	O
to	O
be	O
large	O
and	O
diverse	O
cohort	B-LIVB
classes	O
that	O
pose	O
challenges	O
of	O
time	O
and	O
logistics	O
.	O

Various	O
forms	O
of	O
generic	O
feedback	B-PHYS
can	O
provide	O
rapid	O
and	O
cost	O
-	O
effect	O
feedback	B-PHYS
to	O
large	O
cohorts	B-LIVB
but	O
may	O
be	O
of	O
limited	O
benefit	O
to	O
students	B-LIVB
other	O
than	O
signaling	O
weaknesses	B-DISO
in	O
knowledge	O
.	O

The	O
present	B-DISO
study	B-PROC
describes	O
a	O
method	O
that	O
was	O
used	O
to	O
provide	O
formative	O
task	O
-	O
related	O
feedback	O
to	O
a	O
large	O
cohort	B-LIVB
of	O
first	O
-	O
year	O
physiology	O
and	O
anatomy	O
students	B-LIVB
.	O

Based	O
on	O
student	B-LIVB
evaluations	B-PROC
presented	O
in	O
this	O
study	B-PROC
,	O
this	O
method	O
provided	O
feedback	B-PHYS
in	O
a	O
manner	O
that	O
engaged	O
students	B-LIVB
,	O
uncovered	O
underlying	B-DISO
misconceptions	I-DISO
,	O
facilitated	O
peer	B-LIVB
discussion	O
,	O
and	O
provided	O
opportunity	O
for	O
new	O
instruction	B-PROC
while	O
allowing	O
the	O
lecturer	B-LIVB
to	O
recognize	B-PHYS
common	O
gaps	O
in	O
knowledge	O
and	O
inform	O
ongoing	O
curriculum	B-PROC
development	I-PROC
.	O

SIRT2	B-CHEM
Deacetylates	B-PHYS
and	O
Inhibits	B-PHYS
the	I-PHYS
Peroxidase	I-PHYS
Activity	I-PHYS
of	O
Peroxiredoxin	B-CHEM
-	I-CHEM
1	I-CHEM
to	O
Sensitize	B-ANAT
Breast	I-ANAT
Cancer	I-ANAT
Cells	I-ANAT
to	O
Oxidant	B-DISO
Stress	I-DISO
-	O
Inducing	O
Agents	O
SIRT2	B-CHEM
is	O
a	O
protein	B-PHYS
deacetylase	I-PHYS
with	O
tumor	B-PHYS
suppressor	I-PHYS
activity	I-PHYS
in	O
breast	B-DISO
and	O
liver	B-DISO
tumors	I-DISO
where	O
it	O
is	O
mutated	B-DISO
;	O
however	O
,	O
the	O
critical	O
substrates	B-OBJC
mediating	O
its	O
antitumor	B-DISO
activity	I-DISO
are	O
not	O
fully	O
defined	O
.	O

Here	O
we	O
demonstrate	O
that	O
SIRT2	B-CHEM
binds	B-PHYS
,	O
deacetylates	B-PHYS
,	O
and	O
inhibits	B-PHYS
the	I-PHYS
peroxidase	I-PHYS
activity	I-PHYS
of	O
the	O
antioxidant	B-CHEM
protein	I-CHEM
peroxiredoxin	I-CHEM
(	O
Prdx	B-CHEM
-	I-CHEM
1	I-CHEM
)	O
in	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
.	O

Ectopic	O
overexpression	B-PHYS
of	O
SIRT2	B-CHEM
,	O
but	O
not	O
its	O
catalytically	B-DISO
dead	I-DISO
mutant	I-DISO
,	O
increased	O
intracellular	O
levels	O
of	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O
ROS	B-CHEM
)	O
induced	B-CHEM
by	I-CHEM
hydrogen	I-CHEM
peroxide	I-CHEM
,	I-CHEM
which	O
led	O
to	O
increased	O
levels	O
of	O
an	O
overoxidized	B-CHEM
and	I-CHEM
multimeric	I-CHEM
form	I-CHEM
of	I-CHEM
Prdx	I-CHEM
-	I-CHEM
1	I-CHEM
with	O
activity	B-CHEM
as	I-CHEM
a	I-CHEM
molecular	I-CHEM
chaperone	I-CHEM
.	O

Elevated	O
levels	O
of	O
SIRT2	O
sensitized	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O
intracellular	B-DISO
DNA	I-DISO
damage	I-DISO
and	O
cell	B-PHYS
death	I-PHYS
induced	I-PHYS
by	I-PHYS
oxidative	I-PHYS
stress	I-PHYS
,	O
as	O
associated	O
with	O
increased	O
levels	O
of	O
nuclear	B-CHEM
FOXO3A	I-CHEM
and	O
the	O
proapoptotic	B-CHEM
BIM	I-CHEM
protein	I-CHEM
.	O

In	O
addition	O
,	O
elevated	O
levels	O
of	O
SIRT2	B-CHEM
sensitized	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O
arsenic	B-CHEM
trioxide	I-CHEM
,	O
an	O
approved	O
therapeutic	B-OBJC
agent	I-OBJC
,	O
along	O
with	O
other	O
intracellular	B-CHEM
ROS	I-CHEM
-	O
inducing	B-CHEM
agents	I-CHEM
.	O

Conversely	O
,	O
antisense	B-CHEM
RNA	I-CHEM
-	O
mediated	O
attenuation	O
of	O
SIRT2	B-CHEM
reversed	O
ROS	B-CHEM
-	O
induced	B-DISO
toxicity	I-DISO
as	O
demonstrated	O
in	O
a	O
zebrafish	B-LIVB
embryo	B-ANAT
model	I-ANAT
system	I-ANAT
.	O

Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor	B-PHYS
suppressor	I-PHYS
activity	I-PHYS
of	O
SIRT2	B-CHEM
requires	O
its	O
ability	O
to	O
restrict	O
the	O
antioxidant	B-PHYS
activity	I-PHYS
of	O
Prdx	B-CHEM
-	I-CHEM
1	I-CHEM
,	O
thereby	O
sensitizing	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O
ROS	B-CHEM
-	O
induced	B-DISO
DNA	I-DISO
damage	I-DISO
and	O
cell	B-DISO
cytotoxicity	I-DISO
.	O

Cancer	O
Res	O
;	O
76	O
(	O
18	O
)	O
;	O
5467	O
-	O
78	O
.	O

©	O
2016	O
AACR	O
.	O

Grasping	B-PHYS
At	O
The	O
Moon	B-GEOG
:	O
Enhancing	O
Access	O
To	O
Careers	O
In	O
The	O
Health	O
Professions	O
A	O
former	O
HHS	O
secretary	B-LIVB
reflects	B-PHYS
on	O
what	O
's	O
needed	O
to	O
enable	O
more	O
minorities	B-LIVB
to	O
become	O
doctors	B-LIVB
and	O
other	O
health	B-LIVB
professionals	I-LIVB
.	O

Multivariate	O
Imaging	B-PROC
Genetics	B-PROC
Study	I-PROC
of	O
MRI	B-PROC
Gray	O
Matter	O
Volume	O
and	O
SNPs	O
Reveals	O
Biological	O
Pathways	O
Correlated	O
with	O
Brain	B-ANAT
Structural	O
Differences	O
in	O
Attention	B-DISO
Deficit	I-DISO
Hyperactivity	I-DISO
Disorder	I-DISO
Attention	B-DISO
deficit	I-DISO
hyperactivity	I-DISO
disorder	I-DISO
(	O
ADHD	B-DISO
)	O
is	O
a	O
prevalent	O
neurodevelopmental	B-DISO
disorder	I-DISO
affecting	O
children	B-LIVB
,	O
adolescents	B-LIVB
,	O
and	O
adults	B-LIVB
.	O

Its	O
etiology	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	O
from	O
diverse	O
pathophysiologies	B-DISO
that	O
affect	O
the	O
structure	O
and	O
function	O
of	O
specific	O
brain	O
circuits	O
.	O

Although	O
one	O
of	O
the	O
best	O
-	O
studied	O
neurobiological	B-DISO
abnormalities	I-DISO
in	O
ADHD	B-DISO
is	O
reduced	O
fronto	B-ANAT
-	I-ANAT
striatal	I-ANAT
-	I-ANAT
cerebellar	I-ANAT
gray	I-ANAT
matter	I-ANAT
(	O
GM	O
)	O
volume	O
,	O
its	O
specific	O
genetic	O
correlates	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	B-PROC
,	O
T1	B-PROC
-	I-PROC
weighted	I-PROC
MR	I-PROC
images	I-PROC
of	I-PROC
brain	I-PROC
structure	I-PROC
were	O
collected	O
from	O
198	O
adolescents	B-LIVB
(	O
63	O
ADHD	B-DISO
-	O
diagnosed	B-DISO
)	O
.	O

A	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O
Para	O
-	O
ICA	O
)	O
technique	O
-identified	O
imaging	B-PROC
genetic	O
relationships	O
between	O
regional	O
GM	O
volume	O
and	O
single	O
nucleotide	O
polymorphism	O
data	O
.	O

Para	O
-	O
ICA	O
analyses	O
extracted	O
14	O
components	O
from	O
genetic	O
data	O
and	O
9	O
from	O
MR	B-PROC
data	O
.	O

An	O
iterative	B-PROC
cross	I-PROC
-	I-PROC
validation	I-PROC
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	O
of	O
these	O
ICA	O
solutions	O
.	O

A	O
series	O
of	O
partial	O
correlation	O
analyses	O
controlling	B-PHEN
for	O
age	B-PHYS
,	O
sex	B-PHYS
,	O
and	O
ethnicity	O
revealed	O
two	O
genotype	B-PHYS
-	I-PHYS
phenotype	I-PHYS
component	O
pairs	O
significantly	O
differed	O
between	O
ADHD	B-DISO
and	O
non	B-DISO
-	I-DISO
ADHD	I-DISO
groups	O
,	O
after	O
a	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

The	O
brain	B-ANAT
phenotype	B-PHYS
component	O
not	O
only	O
included	O
structures	O
frequently	O
found	O
to	O
have	O
abnormally	O
low	O
volume	O
in	O
previous	O
ADHD	B-DISO
studies	B-PROC
but	O
was	O
also	O
significantly	O
associated	O
with	O
ADHD	B-DISO
differences	O
in	O
symptom	B-DISO
severity	I-DISO
and	O
performance	O
on	O
cognitive	O
tests	O
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	B-LIVB
diagnosed	B-DISO
with	O
the	O
disorder	B-DISO
.	O

Pathway	O
analysis	O
of	O
the	O
genotype	B-PHYS
component	O
identified	O
several	O
different	O
biological	O
pathways	O
linked	O
to	O
these	O
structural	O
abnormalities	B-DISO
in	O
ADHD	B-DISO
.	O

Some	O
of	O
these	O
pathways	O
implicate	O
well	O
-	O
known	O
dopaminergic	B-PHYS
neurotransmission	I-PHYS
and	O
neurodevelopment	B-PHYS
hypothesized	O
to	O
be	O
abnormal	B-DISO
in	O
ADHD	B-DISO
.	O

Other	O
more	O
recently	O
implicated	O
pathways	O
included	O
glutamatergic	B-PHYS
and	O
GABA	B-PHYS
-	I-PHYS
eric	I-PHYS
physiological	I-PHYS
systems	I-PHYS
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	B-DISO
,	O
such	O
as	O
sleep	B-DISO
abnormalities	I-DISO
.	O



Traitement	B-PROC
des	O
métastases	B-DISO
hépatiques	I-DISO
des	O
cancers	B-DISO
colorectaux	I-DISO
:	O
jusqu	O
'	O
où	O
aller	O
?	O

La	O
contraception	B-PROC
par	I-PROC
les	I-PROC
dispositifs	I-PROC
intra	I-PROC
utérins	I-PROC

"	O
CAPCIL	O
"	O
.	O
Adaptation	O
posologique	O
des	O
traitements	B-PROC
par	O
aminoglycosides	B-CHEM
.	O

Micro	O
-	O
adénome	O
hypophysaire	B-ANAT
à	O
LH	B-CHEM
.	O
Une	O
nouvelle	O
entité	O
nosologique	O

Cholestases	B-DISO
intrahépatiques	I-DISO
fibrogènes	O
familiales	O
et	O
anomalies	O
héréditaires	O
du	O
métabolisme	O
hépatocytaire	O
des	O
acides	B-CHEM
biliaires	I-CHEM
.	O

Le	O
calibrage	O
de	O
la	O
voie	B-ANAT
biliaire	I-ANAT
principale	O
pédiculaire	O
.	O
Intérêt	O
du	O
drainage	B-PROC
à	O
"	O
sortie	O
axiale	O
"	O

Pronostic	B-PROC
de	O
l	O
'	O
angine	B-DISO
de	I-DISO
poitrine	I-DISO
chez	O
l	O
'	O
homme	B-LIVB
à	O
l	O
'	O
aide	O
de	O
la	O
pression	B-PHYS
artérielle	I-PHYS
et	O
de	O
l	O
'	O
électrocardiogramme	B-DISO
.	O

Le	O
problème	O
de	O
la	O
toxoplasmose	B-DISO
congénitale	I-DISO
.	O
L	O
'	O
évolution	O
sur	O
quatre	O
décennies	O
.	O

Une	O
forme	B-ANAT
anatomique	I-ANAT
rare	O
d	O
'	O
épendymome	B-DISO
médullaire	I-DISO
:	O
d	O
'	O
épendymoblastome	B-DISO
métastatique	B-DISO
étendu	O
à	O
l	O
'	O
ensemble	O
de	O
l	O
'	O
axe	O
spinal	O

Migration	B-PHYS
et	O
douleur	B-DISO
.	O
Nécessité	O
d	O
'	O
une	O
recherche	B-PROC
épidémiologique	I-PROC
.	O

Glycochimie	O
:	O
implications	O
biologiques	O
et	O
applications	B-PHEN
thérapeutiques	I-PHEN
(	O
organisée	O
le	O
21	O
octobre	O
1998	O
par	O
l	O
'	O
académie	O
nationale	O
de	O
pharmacie	O
)	O
.	O

Modes	O
de	O
préparation	O
des	O
produits	B-CHEM
sanguins	I-CHEM
labiles	O
-	O
-	O
produits	O
disponibles	O
.	O

A	O
propos	O
du	O
traitement	B-PROC
des	O
décollements	B-DISO
de	I-DISO
rétine	I-DISO
par	O
déchirures	B-DISO
postérieures	I-DISO
.	O

Erysipèles	B-DISO
dans	O
la	O
population	O
jeune	O
d	O
'	O
un	O
hôpital	B-OBJC
militaire	I-OBJC
.	O

Stimulateurs	B-DEVI
cardiaques	I-DEVI
:	O
un	O
aspect	O
radiologique	O
inhabituel	O
.	O

Au	O
39e	O
ICAAC	O
(	O
San	O
Francisco	O
,	O
septembre	O
1999	O
)	O
.	O
L	O
'	O
infection	B-DISO
à	I-DISO
VIH	I-DISO
en	O
pratique	O
clinique	O
.	O

Manifestation	O
rare	O
de	O
l	O
'	O
hypothyroïdie	B-DISO
:	O
l	O
'	O
occlusion	B-DISO
intestinale	I-DISO
.	O
Rapport	O
de	O
deux	O
cas	O
et	O
revue	O
de	O
la	O
littérature	O
.	O

Vers	O
un	O
contrôle	O
de	O
la	O
qualité	O
des	O
soins	B-PROC
.	O

Les	O
entérostomathérapeutes	B-LIVB
.	O

Apport	O
de	O
l	O
'	O
immunologie	B-PROC
de	O
routine	O
au	O
bilan	O
de	O
l	O
'	O
uvéite	B-DISO

Les	O
synoviorthèses	B-PROC
à	O
l	O
'	O
acide	B-CHEM
osmique	I-CHEM
dans	O
le	O
traitement	B-PROC
de	O
la	O
maladie	B-DISO
rheumatoïde	B-DISO
.	O
Remarques	O
et	O
bilan	O
de	O
5	O
années	O
d	O
'	O
utilisation	O

Ce	O
n	O
'	O
est	O
pas	O
encore	O
du	O
cancer	B-DISO
,	O
mais	O
c	O
'	O
est	O
déjà	O
de	O
la	O
thérapie	B-PROC
génique	I-PROC
news	O

L	O
'	O
évaluation	B-PROC
de	O
la	O
mémoire	B-PHYS
du	I-PHYS
passé	I-PHYS
lointain	I-PHYS
et	O
des	O
connaissances	O
sémantiques	O
.	O

Traitement	B-PROC
esthétique	O
des	O
varicosités	B-DISO
.	O

La	O
stratification	O
dans	O
tous	O
les	O
sens	O
du	O
terme	O
.	O

Substitution	O
d	O
'	O
un	O
inhibiteur	B-CHEM
de	I-CHEM
protéase	I-CHEM
par	O
un	O
inhibiteur	B-CHEM
non	I-CHEM
nucléosidique	I-CHEM
de	I-CHEM
la	I-CHEM
transcriptase	I-CHEM
inverse	I-CHEM
.	O
18	O
mois	O
de	O
suivi	O
.	O

Toxicologie	O
du	O
méthyl	B-CHEM
-	I-CHEM
mercure	I-CHEM
chez	O
un	O
Insecte	B-LIVB
:	O
mise	O
en	O
évidence	O
du	O
métal	B-CHEM
dans	O
les	O
lysosomes	B-ANAT
par	O
microsonde	B-DEVI
électronique	I-DEVI
.	O

Indication	O
et	O
stratégie	O
de	O
nouvelles	O
biopsies	B-PROC
après	O
diagnostic	B-DISO
de	O
néoplasie	B-DISO
intra	I-DISO
-	I-DISO
épithéliale	I-DISO
prostatique	I-DISO
.	O

La	O
politique	O
gouvernementale	O
en	O
matière	O
de	O
médicament	B-CHEM
.	O

Oncogène	O
her	O
-	O
2	O
/	O
neu	O
et	O
carcinome	B-DISO
ovarien	I-DISO
:	O
immunothérapie	B-PROC
cellulaire	B-ANAT
intrapéritonéale	O
.	O

Etude	B-PROC
prospective	O
randomisée	O
en	O
simple	O
aveugle	O
comparant	O
phosphate	B-CHEM
de	I-CHEM
sodium	I-CHEM
oral	I-CHEM
et	O
polyéthylène	B-CHEM
glycol	I-CHEM
pour	O
la	O
préparation	O
à	O
la	O
coloscopie	B-PROC
.	O

Prothèses	B-DEVI
discales	O
et	O
arthrodèses	B-DISO
dans	O
la	O
pathologie	B-DISO
dégénérative	I-DISO
du	O
rachis	B-ANAT
lombaire	I-ANAT
(	O
mai	O
2000	O
)	O
.	O

Les	O
instabilités	B-DISO
antérieures	I-DISO
aiguës	I-DISO
de	I-DISO
l	I-DISO
'	I-DISO
épaule	I-DISO
:	O
résultats	O
à	O
court	O
et	O
moyen	O
terme	O
du	O
traitement	B-PROC
orthopédique	I-PROC
.	O

Place	O
du	O
baclofene	B-CHEM
intrathecal	I-CHEM
dans	O
le	O
traitement	B-PROC
du	O
tetanos	B-DISO
grave	O
en	O
milieu	O
tropical	O
.	O

Vaccination	B-PROC
de	O
l	O
'	O
enfant	B-LIVB
traité	B-PROC
pour	O
tumeur	B-DISO
solide	I-DISO
:	O
quelle	O
conduite	O
à	O
tenir	O
?	O

Pathologie	B-DISO
vasculaire	I-DISO
malformative	I-DISO
de	O
la	O
moelle	B-ANAT
épinière	I-ANAT
.	O

La	O
chirurgie	B-PROC
laparoscopique	I-PROC
colo	I-PROC
-	I-PROC
rectale	I-PROC
,	O
à	O
propos	O
de	O
449	O
interventions	B-PROC
.	O

Comment	O
je	O
traite	B-PROC
et	O
prends	O
en	O
charge	O
un	O
diabète	B-DISO
du	O
sujet	B-LIVB
noir	O
.	O

Campagne	O
de	O
dépistage	B-PROC
du	O
cancer	B-DISO
du	I-DISO
sein	I-DISO
.	O

Les	O
effets	B-DISO
secondaires	I-DISO
des	O
traitements	B-PROC
au	O
lithium	B-CHEM
(	O
premiers	O
résultats	O
d	O
'	O
une	O
enquête	O
)	O

Stéréologie	O
:	O
aspects	O
pratiques	O
des	O
principes	O
et	O
méthodes	O
appliqués	O
à	O
l	O
'	O
étude	B-PROC
du	O
éveloppement	B-PHYS
embryonnaire	B-ANAT

La	O
santé	O
du	O
duc	O
d	O
'	O
Enghien	O
durant	O
ses	O
primes	O
années	O
d	O
'	O
après	O
le	O
journal	O
de	O
son	O
médecin	B-LIVB
.	O

Vie	O
pré	O
-	O
imaginale	O
de	O
G	B-LIVB
.	I-LIVB
tachinoides	I-LIVB
W	I-LIVB
.	O
,	O
larve	B-LIVB
libre	O
,	O
pupaison	B-PHYS
,	O
lieux	O
de	O
ponte	B-PHYS
.	O
(	O
II	O
)	O

Signes	B-DISO
révélateurs	O
trompeurs	O
de	O
l	O
'	O
insuffisance	B-DISO
rénale	I-DISO

Enquête	O
sur	O
l	O
'	O
addiction	B-DISO
en	O
milieu	O
anesthésique	B-PROC
.	O

Alcool	B-CHEM
et	O
cancer	B-DISO
.	O

Pollution	O
chimique	O
de	O
l	O
'	O
environement	O
et	O
risque	O
toxique	O
pour	O
l	O
'	O
homme	B-LIVB
.	O
Le	O
rôle	O
particulier	O
des	O
dérivés	O
pesticides	B-CHEM
organochlorés	I-CHEM
.	O

Congrès	O
annuel	O
de	O
l	O
'	O
American	O
Thoracic	B-ANAT
Society	O
.	O
San	O
Francisco	O
,	O
California	O
,	O
USA	O
.	O
18	O
-	O
23	O
mai	O
2001	O
.	O

Considérations	O
cliniques	O
et	O
éthiques	O
.	O
L	O
'	O
accompagnement	O
de	O
la	O
personne	O
en	O
perte	O
d	O
'	O
autonomie	O
et	O
de	O
sa	O
famille	B-LIVB
.	O

Description	O
de	O
l	O
'	O
environnement	O
domestique	O
et	O
études	B-PROC
épidémiologiques	I-PROC
sur	O
les	O
pathologies	B-DISO
respiratoires	I-DISO
.	O

Stratégie	O
soignante	B-PROC
.	O
Quelle	O
écoute	O
pour	O
l	O
'	O
enfant	B-LIVB
sourd	I-LIVB
?	O

Intérêt	O
de	O
la	O
pharmacoépidémiologie	O
pour	O
le	O
praticien	O
.	O

Approche	O
étiopathogénique	O
et	O
clinique	O
des	O
asymétries	O
.	O

Modalités	O
des	O
traitements	B-PROC
locaux	O
et	O
généraux	O
,	O
médicamenteux	B-CHEM
ou	O
non	O
,	O
dans	O
la	O
prise	O
en	O
charge	O
du	O
nouveau	B-LIVB
-	I-LIVB
né	I-LIVB
suspect	O
d	O
'	O
être	O
infecté	O
/	O
contaminé	O
par	O
HSV1	B-DISO
ou	O
HSV2	O
.	O

Les	O
syncopes	B-DISO
:	O
évaluation	B-PROC
et	O
prise	B-PROC
en	I-PROC
charge	I-PROC
.	O

"	O
Arrachez	O
-	O
moi	O
ce	O
coeur	B-ANAT
!	O
"	O
:	O
de	O
la	O
crainte	O
du	O
rejet	B-PHEN
au	O
délire	B-DISO
après	O
transplantation	B-PROC
cardiaque	I-PROC
.	O

Méthodes	O
ablatives	B-PROC
dans	O
la	O
fibrillation	B-DISO
atriale	I-DISO
.	O

Standards	O
,	O
Options	O
et	O
Recommendations	O
2000	O
:	O
cancer	B-DISO
de	I-DISO
l	I-DISO
'	I-DISO
endomètre	I-DISO
,	O
stades	O
non	O
métastatiques	B-DISO
(	O
rapport	O
abrégé	O
)	O
.	O

Microgreffes	B-PROC
de	I-PROC
cheveux	I-PROC
et	I-PROC
de	I-PROC
poils	I-PROC
:	O
leurs	O
multiples	O
indications	O
.	O

L	O
'	O
apport	O
des	O
inventaires	O
a	O
la	O
connaissance	O
de	O
la	O
demographie	O
parisienne	O
ancienne	O
:	O
le	O
regne	O
de	O
Francois	O
Ier	O

Initiatives	O
et	O
resistances	O
dans	O
les	O
etats	O
arabes	O
.	O

L	O
'	O
artèriographie	B-PROC
bronchique	I-PROC
sèlective	O
dans	O
le	O
diagnositc	B-PROC
des	O
cancers	B-DISO
pulmonaires	I-DISO

L	O
'	O
evolution	O
recente	O
de	O
la	O
population	B-LIVB
active	I-LIVB
rurale	I-LIVB
en	O
France	B-GEOG
(	O
1968	O
-	O
1975	O
)	O

Note	O
sur	O
le	O
modele	O
de	O
mortalite	O
de	O
Brass	B-PROC
a	O
4	O
parametres	O

Evolution	O
et	O
structure	O
de	O
la	O
population	O
de	O
Madagascar	B-GEOG
(	O
extrait	O
)	O
.	O

Adaptation	O
de	O
la	O
microtechnique	B-PROC
de	O
fixation	B-PROC
du	I-PROC
complément	I-PROC
au	O
diagnostic	B-PROC
de	O
la	O
peste	B-DISO
équine	I-DISO

Association	O
cancers	B-DISO
de	I-DISO
l	I-DISO
'	I-DISO
oesophage	I-DISO
et	I-DISO
des	I-DISO
voies	I-DISO
aérodigestives	I-DISO
supérieures	I-DISO
:	O
implications	O
thérapeutiques	B-PROC
.	O

Traitement	B-PROC
des	O
grossesses	B-DISO
extra	I-DISO
-	I-DISO
utérines	I-DISO
.	O

Scintigraphies	B-PROC
thyroïdiennes	I-PROC
discordantes	O
avec	O
l	O
'	O
iode	B-CHEM
131	I-CHEM
et	O
le	O
technetium	B-CHEM
99m	I-CHEM

Etude	B-PROC
critique	O
des	O
tests	B-PROC
de	O
l	O
'	O
absorption	B-PHEN
des	O
graisses	B-CHEM
utilisant	O
la	O
trioléine	B-CHEM
131I	O

Les	O
hématuries	B-DISO
macroscopiques	I-DISO

Cinquante	O
ans	O
.	O
.	O
.	O

La	O
consommation	O
médicamenteuse	B-CHEM
chez	O
la	O
personne	B-LIVB
âgée	I-LIVB
.	O

Carcinome	B-DISO
sarcomatoïde	I-DISO
du	I-DISO
rein	I-DISO
:	O
à	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Facteurs	O
de	O
risque	O
et	O
stratégie	O
de	O
dépistage	B-PROC
de	O
la	O
colonisation	O
par	O
le	O
streptocoque	B-LIVB
du	I-LIVB
groupe	I-LIVB
B	I-LIVB
chez	O
la	O
femme	B-LIVB
enceinte	I-LIVB
:	O
résultats	O
d	O
'	O
une	O
étude	B-PROC
prospective	O
.	O

La	O
transmission	B-DISO
de	O
la	O
violence	B-DISO
sexuelle	I-DISO
:	O
description	O
du	O
phénomène	O
et	O
pistes	O
de	O
compréhension	O
.	O

Comparaison	B-PROC
de	O
deux	O
méthodes	O
de	O
cryoconservation	B-PROC
de	O
spermatozoïdes	B-ANAT
en	O
très	O
petit	O
nombre	O
.	O

Physiopathologie	O
de	O
la	O
spasticité	B-DISO
.	O

L	O
'	O
hyperstimulation	B-DISO
ovarienne	I-DISO
:	O
prévention	B-PROC
et	O
traitement	B-PROC
.	O

Indications	O
,	O
efficacité	O
et	O
tolérance	B-DISO
des	O
traitements	B-PROC
médicamenteux	I-PROC
susceptibles	O
d	O
'	O
améliorer	O
la	O
reprise	O
de	O
conscience	O
après	O
un	O
coma	B-DISO
traumatique	I-DISO
.	O

Choriocarcinome	B-DISO
ovarien	B-ANAT
:	O
à	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Aide	B-PROC
au	O
sevrage	O
tabagique	O
en	O
entreprise	B-OBJC
.	O

Clopidogrel	B-CHEM
et	O
thrombopénie	B-PROC
.	O
A	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Envahissement	B-DISO
orbitaire	B-ANAT
d	O
'	O
une	O
tumeur	B-DISO
à	I-DISO
cellules	I-DISO
de	I-DISO
Merkel	I-DISO
palpébrale	B-ANAT
.	O

Cas	O
pour	O
diagnostic	B-DISO
:	O
lichen	B-DISO
plan	I-DISO
entrant	O
dans	O
le	O
cadre	O
d	O
'	O
un	O
syndrome	B-DISO
génito	O
-	O
gingival	O
.	O

Les	O
déformations	B-DISO
des	O
bronches	B-ANAT
segmentaires	I-ANAT
dans	O
la	O
tuberculose	B-DISO
pulmonaire	I-DISO
récente	O
:	O
etudes	B-PROC
bronchographiques	O
suivies	O
d	O
'	O
une	O
hypothèse	O
sur	O
la	O
pathogènie	B-DISO
des	O
dilatations	B-DISO
.	O

Recherches	B-PROC
sur	O
la	O
pathogénie	B-DISO
de	O
l	O
'	O
ulcère	B-DISO
de	O
Shay	O
.	O

Coupes	O
axiales	O
,	O
frontales	O
et	O
sagittales	O
d	O
'	O
un	O
mal	B-DISO
de	I-DISO
Pott	I-DISO
dorsal	B-ANAT
.	O

Rétablissement	O
tardif	O
de	O
la	O
sécrétion	B-PHYS
excrétoire	I-PHYS
du	O
rein	B-ANAT
après	O
section	B-PROC
et	O
suture	B-PROC
primitive	O
de	O
l	O
'	O
uretère	B-ANAT
.	O

La	O
respiration	B-PROC
contrôlée	I-PROC
dans	O
l	O
'	O
anesthésie	B-PROC
en	O
neurochirurgie	O
.	O

Traitement	B-PROC
des	O
cervicites	B-DISO
chroniques	I-DISO
.	O

L	O
'	O
avenir	O
de	O
la	O
psychiatrie	O
:	O
espérances	O
et	O
utopies	O
.	O

Tuberculose	B-DISO
bilatérale	I-DISO
traitée	B-PROC
par	O
mycothérapie	O
et	O
par	O
collapso	O
-	O
thérapie	O
unilatérale	O
;	O
guérison	O
clinique	O
,	O
excellence	O
du	O
résultat	B-DISO
radiologique	O
du	O
seul	O
cóte	O
collabé	O
.	O

Action	O
de	O
la	O
cortisone	B-CHEM
sur	O
l	O
'	O
oestrus	B-DISO
succédant	O
à	O
l	O
'	O
accouchement	O
et	O
à	O
l	O
'	O
ablation	O
de	O
l	O
'	O
utérus	B-ANAT
gravide	I-ANAT
chez	O
la	O
ratte	B-LIVB
.	O

Surveillance	O
épidémiologique	O
de	O
la	O
tuberculose	B-DISO
en	O
Polynésie	B-GEOG
française	I-GEOG
de	O
1960	O
à	O
1990	O
.	O

Inhibition	B-PHYS
de	O
la	O
moelle	B-ANAT
osseuse	I-ANAT
d	O
'	O
origine	O
splénique	B-ANAT
dans	O
un	O
cas	O
de	O
rate	B-DISO
mobile	I-DISO
.	O

Avenir	O
de	O
la	O
cholédocolithiase	B-DISO
opérée	B-PROC
.	O

Influence	O
des	O
mouillants	B-CHEM
sur	O
l	O
'	O
anesthésie	B-PROC
locale	O
de	O
surface	O
.	O

Cytologie	O
de	O
la	O
gestation	B-PHYS
.	O
II	O
.	O
Cytologie	O
de	O
la	O
gestation	B-PHYS
pathologique	O
.	O

L	O
'	O
essai	B-PROC
quantitatif	O
des	O
drogues	B-CHEM
à	O
saponines	B-CHEM
.	O

Anévrysmotripsie	O
par	O
voie	O
haute	O
pour	O
un	O
anévrysme	B-DISO
de	O
l	O
'	O
espace	B-ANAT
recto	I-ANAT
-	I-ANAT
vésical	I-ANAT
;	O
résultat	B-DISO
au	O
bout	O
de	O
19	O
ans	O
.	O

Déshydratation	B-DISO
par	O
la	O
chaleur	O
de	O
gels	O
de	O
gélatine	B-CHEM
et	O
de	O
solutions	O
d	O
'	O
hémoglobine	B-CHEM
.	O

Le	O
médecin	B-LIVB
qui	O
n	O
'	O
est	O
pas	O
tout	O
a	O
fait	O
un	O
homme	O
comme	B-LIVB
les	O
autres	O
.	O

Evolution	B-PHYS
radiologique	O
d	O
'	O
un	O
cas	O
de	O
maladie	B-DISO
de	O
Hirsprung	O
vraie	O
.	O

L	O
'	O
opération	B-PROC
de	I-PROC
girdlestone	I-PROC
-	O
(	O
opération	B-PROC
de	O
sauvetage	O
des	O
complications	B-DISO
septiques	O
de	O
l	O
'	O
endoprothèse	B-DEVI
acrylique	O
de	O
la	O
hanche	B-ANAT
)	O
.	O

Sur	O
la	O
radiographie	B-PROC
de	O
l	O
'	O
ethmoïde	B-ANAT
en	O
position	O
de	O
rhese	O
et	O
la	O
pratique	O
des	O
incidences	O
angulaires	O
grâce	O
aux	O
appareillages	B-OBJC
tournant	O
autour	O
d	O
'	O
un	O
point	O
de	O
centrage	O
fixe	O
.	O

Le	O
stroma	O
dans	O
les	O
épithéliomas	B-DISO
momifiés	O
de	O
Malherbe	O
.	O

Action	O
de	O
la	O
delta1	O
-	O
déhydrocortisone	O
sur	O
le	O
leucogramme	B-LIVB
,	O
chez	O
le	O
magot	B-LIVB
d	O
'	O
Algérie	B-GEOG
.	O

Equipement	O
hospitalier	O
et	O
confort	O
du	O
malade	B-DISO
;	O
le	O
point	O
de	O
vue	O
du	O
personnel	B-LIVB
médical	I-LIVB
.	O

Trois	O
cas	O
de	O
grossesse	B-PHYS
chez	O
des	O
femmes	B-LIVB
ayant	O
subi	O
une	O
pneumectomie	B-PROC
.	O

Classification	O
des	O
voix	O
et	O
pente	O
d	O
'	O
excitabilité	O
du	O
muscle	B-ANAT
sterno	I-ANAT
-	I-ANAT
cléido	I-ANAT
-	I-ANAT
mastoïdien	I-ANAT
.	O

Les	O
hépatites	B-DISO
à	O
virus	B-LIVB
herpétique	B-DISO
du	O
nouveau	B-LIVB
-	I-LIVB
né	I-LIVB
(	O
maladie	B-DISO
herpétique	B-DISO
du	O
nouveau	B-LIVB
-	I-LIVB
né	I-LIVB
)	O
.	O

Foie	B-ANAT
et	O
diabète	B-DISO
sucré	I-DISO
.	O

Hépatite	B-DISO
filarienne	B-LIVB
des	O
anthropoides	B-LIVB
.	O

Rélfexions	O
sur	O
l	O
'	O
exercice	O
de	O
la	O
psychiatrie	O
en	O
milieu	O
asilaire	O
.	O

Contribution	O
à	O
l	O
'	O
étude	O
de	O
l	O
'	O
impression	B-DISO
basilaire	I-DISO
.	O

Sur	O
le	O
sens	O
à	O
attribuer	O
aux	O
méthodes	O
d	O
'	O
hibernothérapie	O
;	O
Essai	O
de	O
synthèse	O
.	O

L	O
'	O
urgence	B-PROC
chirurgicale	I-PROC
et	O
l	O
'	O
acidose	B-DISO
diabetique	I-DISO
grave	O
.	O

Pathologie	B-DISO
otorhinolaryngologique	I-DISO
chez	O
les	O
malades	B-LIVB
atteints	O
d	O
'	O
asthme	B-DISO
bronchial	I-DISO
.	O

Déplétion	O
en	O
histamine	B-CHEM
et	O
phénomène	B-DISO
d	I-DISO
'	I-DISO
Arthus	I-DISO
cutané	B-ANAT
chez	O
le	O
lapin	B-LIVB
.	O

Intoxication	B-DISO
par	O
le	O
perchlorure	B-CHEM
de	I-CHEM
fer	I-CHEM
compliquée	B-DISO
d	O
'	O
une	O
sténose	B-DISO
gastrique	I-DISO
.	O

Valeur	O
diagnostique	O
de	O
l	O
'	O
inoculation	B-PROC
au	O
cobaye	B-LIVB
des	O
produits	O
pathologiques	B-DISO
contenant	O
des	O
bacilles	B-LIVB
tuberculeux	B-DISO
résistants	O
à	O
l	O
'	O
isoniazide	B-CHEM
.	O

Le	O
róle	O
des	O
corticosurrénales	B-ANAT
dans	O
l	O
'	O
hypertension	B-DISO
et	O
l	O
'	O
artériosclérose	B-DISO
humaine	B-LIVB
.	O

Production	O
de	O
tumeurs	B-DISO
malignes	I-DISO
(	O
hépatomes	B-DISO
et	O
autres	O
)	O
par	O
injections	B-PROC
intrapéritonéales	O
d	O
'	O
or	B-CHEM
radioactif	I-CHEM
chez	O
le	O
rat	B-LIVB
blanc	O
.	O

Sur	O
un	O
cas	O
de	O
psychose	B-DISO
ovarienne	I-DISO
et	O
son	O
contrôle	O
par	O
les	O
frottis	B-PROC
vaginaux	I-PROC
;	O
emploi	O
d	O
'	O
androgènes	B-CHEM
non	O
-	O
virillisants	O
.	O

Conception	O
actuelle	O
de	O
l	O
'	O
épreuve	O
du	O
travail	B-PHYS
.	O

Les	O
stades	O
larvaires	B-LIVB
de	O
Centrorhynchus	B-LIVB
falconis	O
E	O
.	O
N	O
.	O
Das	O
1950	O
.	O

Problèmes	O
techniques	O
posés	O
par	O
la	O
télécobalthérapie	B-PROC
dans	O
la	O
région	B-ANAT
cervicale	I-ANAT
.	O

Classification	O
des	O
types	O
de	O
fixation	B-PHYS
monoculaire	B-PHYS
.	O

Complications	B-DISO
laryngées	I-DISO
dues	O
à	O
la	O
rougeole	B-DISO
.	O

Troubles	B-DISO
de	I-DISO
l	I-DISO
'	I-DISO
absorption	I-DISO
intestinale	I-DISO
au	O
cours	O
de	O
l	O
'	O
insuffisance	B-DISO
surrénale	I-DISO
chronique	I-DISO
.	O

L	O
'	O
allergie	B-DISO
tuberculinique	I-DISO
;	O
sa	O
place	O
en	O
pratique	O
médicale	O
.	O

Intérêt	O
de	O
l	O
'	O
artériographie	B-PROC
cérébrale	I-PROC
dans	O
l	O
'	O
hémiplégie	B-DISO
;	O
à	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Etude	B-PROC
histologique	O
des	O
lésions	B-DISO
musculaires	I-DISO
dans	O
les	O
dermatomyosites	B-DISO
.	O

Quel	O
traitement	B-PROC
proposer	O
à	O
une	O
femme	B-LIVB
atteinte	O
de	O
prolapsus	B-DISO
génital	I-DISO
.	O

Image	O
lacunaire	O
gastrique	B-ANAT
à	O
éclipse	O
due	O
à	O
une	O
tumeur	B-DISO
kystique	I-DISO
rétrogastrique	O
.	O

Utilisation	O
du	O
duodenum	B-ANAT
de	O
rat	B-LIVB
dans	O
l	O
'	O
analyse	O
pharmacologique	O
des	O
effecteurs	O
du	O
systeme	B-ANAT
nerveux	I-ANAT
autonome	O
et	O
de	O
leurs	O
differents	O
points	O
d	O
'	O
attaque	O
.	O

Amblyomma	B-LIVB
,	O
Hyalomma	B-LIVB
,	O
Boophilus	B-LIVB
,	O
Rhipicephalus	B-LIVB
d	O
'	O
Afrique	O
sont	O
porteurs	O
d	O
'	O
eléments	O
rickettsiens	O
et	O
néorickettsiens	O
et	O
quelquefois	O
des	O
deux	O
types	O
d	O
'	O
agents	O
.	O

Etude	B-PROC
de	O
l	O
'	O
intoxication	B-DISO
par	O
l	O
'	O
antimoine	B-CHEM
dans	O
les	O
mines	O
marocaines	O
.	O

Interet	O
de	O
l	O
'	O
anesthesie	B-PROC
generale	I-PROC
dans	O
les	O
examens	B-PROC
endo	I-PROC
-	I-PROC
bronchiques	I-PROC
chez	O
l	O
'	O
enfant	B-LIVB

Un	O
cas	O
de	O
fracture	B-DISO
du	I-DISO
plateau	I-DISO
tibial	I-DISO
externe	I-DISO
.	O

Les	O
indication	O
actuelles	O
de	O
la	O
sulfamidothérapie	O
en	O
pathologie	B-DISO
infectieuse	I-DISO
.	O

Principes	O
directeurs	O
et	O
conduite	O
du	O
traitement	B-PROC
dans	O
la	O
réhydratation	B-PROC
du	O
nourrisson	B-LIVB
.	O

La	O
place	O
des	O
frottis	B-PROC
cervico	I-PROC
-	I-PROC
vaginaux	I-PROC
dans	O
le	O
dépistage	O
du	O
cancer	B-DISO
du	I-DISO
col	I-DISO
utérin	I-DISO
;	O
objetifs	O
;	O
technique	O
;	O
résultats	B-DISO
.	O

Oedème	B-DISO
papillaire	I-DISO
bilatéral	O
d	O
'	O
étiologie	O
inconnue	O
.	O

Le	O
role	O
du	O
systèm	B-ANAT
nerveux	I-ANAT
dans	O
la	O
polyarthrite	B-DISO
chronique	I-DISO
évolutive	I-DISO
.	O

Ileite	B-DISO
terminale	I-DISO
chronique	B-DISO
à	O
forme	O
hémorragique	B-DISO
récidivante	O
.	O

A	O
propos	O
de	O
trois	O
cas	O
de	O
kystes	B-DISO
calcifiés	I-DISO
du	I-DISO
rein	I-DISO
.	O

Les	O
manifestations	B-DISO
oculaires	I-DISO
dans	O
la	O
maladie	B-DISO
de	I-DISO
Recklinghausen	I-DISO
et	O
dans	O
la	O
maladie	B-DISO
de	I-DISO
Bourneville	I-DISO
.	O

Le	O
syndrome	B-DISO
neurologique	I-DISO
du	O
delirium	B-DISO
tremens	I-DISO
.	O

Tétanos	B-DISO
grave	O
,	O
hiberné	B-PHYS
et	O
guéri	B-PHYS
.	O

Aspects	O
chimiques	O
de	O
l	O
'	O
endolymphe	B-ANAT
et	O
de	O
la	O
périlymphe	B-ANAT
.	O

Tuberculome	B-DISO
du	O
dispque	B-ANAT
L4	I-ANAT
-	I-ANAT
L5	I-ANAT
à	O
forme	O
pseudotumorale	B-DISO
(	O
recul	O
de	O
plus	O
de	O
trois	O
ans	O
)	O
.	O

NOTICE	O
sur	O
la	O
vie	O
et	O
l	O
'	O
oeuvre	O
du	O
Professeur	O
Alberto	O
Ascoli	O
,	O
membre	O
honoraire	O
étranger	O
.	O

Etude	B-PROC
oscillographique	I-PROC
du	I-PROC
couple	I-PROC
cardiorespiratoire	I-PROC
chez	O
les	O
prématurés	B-LIVB
.	O

L	O
'	O
épididymectomie	B-PROC
pour	O
tuberculose	B-DISO
génitale	I-DISO
;	O
la	O
directrice	O
du	O
récessus	O
épididymaire	B-ANAT
:	O
la	O
région	O
du	O
hile	B-ANAT
testiculaire	I-ANAT
.	O

D	O
'	O
une	O
adénopathle	B-DISO
hilaire	B-ANAT
droite	I-ANAT
à	O
une	O
miliaire	B-DISO
.	O

Rickettsioses	B-DISO
et	O
affections	B-DISO
cardio	I-DISO
-	I-DISO
vasculaires	I-DISO
;	O
à	O
propos	O
de	O
27	O
observations	B-PROC
.	O

Les	O
perspectives	O
nouvelles	O
de	O
la	O
chirurgie	B-PROC
cardiaque	I-PROC
.	O

Une	O
observation	B-PROC
d	O
'	O
un	O
cas	O
d	O
'	O
association	O
ulcus	B-DISO
gastrique	I-DISO
et	O
psoriasis	B-DISO
.	O

La	O
vitamine	B-CHEM
E	I-CHEM
stimule	O
la	O
croissance	B-PHYS
larvaire	B-LIVB
et	O
rend	O
plus	O
précoce	O
la	O
métamorphose	B-PHYS
du	O
crapaud	B-LIVB
accoucheur	I-LIVB
(	O
Alytes	B-LIVB
obstetricans	I-LIVB
Laur	O
)	O
.	O

Aout	O
1958	O
,	O
en	O
Chine	B-GEOG
.	O

Analyses	B-PROC
immunoélectrophorétiques	I-PROC
des	O
fractions	B-CHEM
proteiques	I-CHEM
du	O
sérum	B-CHEM
humain	B-LIVB
séparées	O
par	O
électrophorèse	B-PROC
en	O
gel	O
d	O
'	O
amidon	B-CHEM
.	O

Essais	B-PROC
cliniques	I-PROC
d	O
'	O
un	O
nouveau	O
neuroleptique	B-CHEM
,	O
la	O
thioridazine	B-CHEM
.	O

Fausses	B-DISO
-	I-DISO
routes	I-DISO
paramétriales	B-ANAT
du	O
lipiodol	B-CHEM
.	O

Les	O
mélanodermies	B-DISO
dans	O
les	O
parasitoses	B-DISO
.	O

Le	O
traitement	O
du	O
cancer	B-DISO
préinvasif	I-DISO
du	I-DISO
col	I-DISO
utérin	I-DISO
,	O
qui	O
n	O
'	O
entraîne	O
pas	O
la	O
sterilité	B-DISO
.	O

Observation	B-PROC
au	O
microscope	B-DEVI
des	O
productions	O
cristallines	O
de	O
la	O
souche	B-LIVB
Pasteurella	B-LIVB
pestis	I-LIVB
EV	O
(	O
Girard	O
et	O
Robic	O
)	O
.	O

Excitations	B-DISO
d	O
'	O
origine	O
périphérique	O
et	O
fréquence	B-PHYS
cardiaque	I-PHYS
chez	O
le	O
barbeau	B-LIVB
fluviatile	O
.	O

La	O
première	O
construction	O
,	O
par	O
Théodore	O
Schwann	O
,	O
d	O
'	O
un	O
appareil	B-OBJC
à	O
circuit	O
fermé	O
permettant	O
de	O
vivre	O
dans	O
un	O
milieu	O
irrespirable	O
.	O

LES	O
MALADES	B-LIVB
SONT	O
-	O
ILS	O
TENUS	O
DE	O
REMETTRE	O
'	O
A	O
LEUR	O
DESTINATAIRE	O
LA	O
LETTRE	O
DU	O
MÉDECIN	B-LIVB
TRAITANT	O
AU	O
MÉDECIN	B-LIVB
CONSULTANT	O
?	O

GUÉRISON	O
CHIRURGICALE	B-PROC
D	O
'	O
UNE	O
ENDOCARDITE	B-DISO
BACTÉRIENNE	I-DISO
DU	O
COEUR	B-ANAT
DROIT	I-ANAT

DOSAGE	O
FLUORIM	B-PROC
'	I-PROC
ÉTRIQUÉ	I-PROC
DE	O
LA	O
TRYPSINE	B-CHEM
.	O

L	O
'	O
'	B-PHYS
ÉVOLUTION	I-PHYS
D	O
'	O
UNE	O
TUMEUR	B-DISO
DE	O
SPITZ	O
.	O

HISTORIQUE	O
ET	O
FONCTIONNEMENT	O
DES	O
LABORATOIRES	O
DU	O
SERVICE	O
DE	O
CONTROLE	O
DES	O
MÉDICAMENTS	B-CHEM
DE	O
L	O
'	O
ASSOCIATION	O
PHARMACEUTIQUE	O
BELGE	B-GEOG
.	O

RÉFLEXIONS	O
SUR	O
NOS	O
100	O
DERNIERS	O
CAS	O
DE	O
GOUTTE	B-DISO
.	O

LES	O
DONNÉES	O
BIOLOGIQUES	O
DANS	O
L	O
'	O
ACROMÉGALIE	B-DISO
.	O

A	O
PROPOS	O
DES	O
MOLES	B-DISO
HYDATIFORMES	I-DISO
GÉANTES	O
.	O

RÉFLEXIONS	O
SUR	O
DEUX	O
CAS	O
DE	O
SUICIDE	B-DISO
'	O
A	O
LA	O
TOUR	O
EIFFEL	O
.	O

HYPERLIPÉMIE	B-DISO
PAROXYSTIQUE	O
AU	O
COURS	O
D	O
'	O
UNE	O
PANCRÉATITE	B-DISO
AIGUUE	I-DISO
AVEC	O
RETENTISSEMENT	O
ÉLECTROCARDIOGRAPHIQUE	B-PROC
.	O
CONSIDÉRATIONS	O
D	O
'	O
ORDRE	O
GÉNÉRAL	O
.	O

LÉON	O
GRIMBERT	O
1860	O
-	O
1931	O
.	O

LES	O
INDICATIONS	O
ET	O
LES	O
CONTRE	O
-	O
INDICATIONS	O
DE	O
LA	O
CORTICOTHÉRAPIE	O
DANS	O
LE	O
SYNDROME	B-DISO
NÉPHROTIQUE	I-DISO
DE	O
L	O
'	O
ENFANT	B-LIVB
.	O

ESTIMATION	O
RAPIDE	O
D	O
'	O
UNE	O
B	B-DISO
ETA	I-DISO
-	I-DISO
2	I-DISO
-	I-DISO
MACROGLOBULINÉMIE	I-DISO
SUR	O
DIAGRAMME	O
IMMUNOÉLECTROPHORÉTIQUE	B-PROC
.	O

LÉXPERTISE	B-PROC
MÉDICO	O
-	O
LÉGALE	O
RELATIVE	O
'	O
A	O
L	O
'	O
ALCOOLISME	B-DISO
AIGU	I-DISO
.	O
CONSIDÉRATIONS	O
'	O
A	O
PROPOS	O
DE	O
240	O
EXPERTISES	B-PROC
FAITES	O
DANS	O
LES	O
BOUCHES	O
-	O
DU	O
-	O
RH	O
ONE	O
.	O

ANTIBIOTHÉRAPIE	B-PROC
LOCALE	O
DES	O
LÉSIONS	B-DISO
TUBERCULEUSES	B-DISO
.	O
TRAITEMENT	B-PROC
DE	O
LA	O
TUBERCULOSE	B-DISO
PULMONAIRE	I-DISO
COMMUNE	O
PAR	O
DES	O
AÉROSOLS	B-OBJC
D	O
'	O
ANTIBIOTIQUES	B-CHEM
ET	O
DE	O
FACTEURS	O
DE	O
DIFFUSION	O
.	O

QUELQUES	O
CONSIDÉRATIONS	O
SUR	O
LE	O
TRAITEMENT	B-PROC
MÉDICAL	I-PROC
DES	O
CHOLÉCYSTOPATHIES	B-DISO
.	O

CESARE	O
LOMBROSO	O
.	O

EFFETS	O
DE	O
LA	O
CARENCE	B-DISO
EN	I-DISO
LYSINE	I-DISO
SUR	O
LE	O
PANCRÉAS	B-ANAT
DU	O
RAT	B-LIVB
(	O
CONTENU	O
EN	O
HYDROLASES	B-CHEM
,	O
TURNOVER	O
DES	O
ACIDES	B-CHEM
D	I-CHEM
'	I-CHEM
ESOXYRIBONUCLÉIQUES	I-CHEM
ET	O
RESPIRATION	B-PHYS
)	O

RÉSULTATS	B-DISO
APRÈS	O
DEUX	O
ANS	O
DE	O
33	O
ANASTOMOSES	B-PROC
PORTO	I-PROC
-	I-PROC
CAVES	I-PROC
TERMINO	O
-	O
LATÉRALES	O
.	O

CONSIDÉRATIONS	O
THÉORIQUES	O
ET	O
PRATIQUES	O
D	O
'	O
ACTUALITÉ	O
EN	O
MATIÈRE	O
D	O
'	O
EXAMENS	B-PROC
RADIOLOGIQUES	I-PROC
SYSTÉMATIQUES	O
.	O

EFFETS	O
DE	O
LÀBAISSEMENT	B-DISO
DE	I-DISO
LA	I-DISO
TEMPÉRATURE	I-DISO
SUR	O
LA	O
POTENTIATION	B-DISO
POST	I-DISO
-	I-DISO
TÉTANIQUE	I-DISO
DE	O
DIVERS	O
RÉFLEXES	B-PHYS
CHEZ	O
LE	O
CHAT	B-LIVB
SOUS	O
FLAXEDIL	B-CHEM
ET	O
CHEZ	O
LE	O
CHAT	B-LIVB
SPINALISÉ	O
.	O

ÉTUDE	B-PROC
CLINIQUE	I-PROC
DU	O
POUVOIR	O
ALLERGÉNIQUE	B-CHEM
DE	O
DIFFÉRENTES	O
FRACTIONS	O
OBTENUES	O
À	O
PARTIR	O
DE	O
LA	O
POUSSIÈRE	B-CHEM
DE	I-CHEM
MAISON	I-CHEM
.	O

PRÉSENCE	O
ET	O
R	O
OLE	O
POSSIBLE	O
DE	O
LA	O
VITAMINE	B-CHEM
D	I-CHEM
DANS	O
LES	O
GLANDES	B-ANAT
PARATHYROUIDES	I-ANAT
.	O

LA	O
COMPOSANTE	O
PRÉSYSTOLIQUE	B-DISO
ET	O
SYSTOLIQUE	B-DISO
DU	O
PREMIER	B-DISO
BRUIT	I-DISO
DANS	O
LA	O
STÉNOSE	B-DISO
MITRALE	I-DISO
.	O

ÉTUDE	B-PROC
DE	O
241	O
CANCERS	B-DISO
DU	I-DISO
COL	I-DISO
UTÉRIN	I-DISO
TRAITÉS	B-PROC
PAR	O
L	O
'	O
ASSOCIATION	O
RADIO	O
-	O
CHIRURGICALE	O
.	O

LUTTE	O
ANTITUBERCULEUSE	B-CHEM
:	O
PROBLÈME	O
D	O
'	O
APPLICATION	O
.	O

ÉTUDE	B-PROC
SUR	O
L	O
'	O
ÉTIOLOGIE	O
DE	O
L	O
'	O
ECZÉMA	B-DISO
DIATHÉSIQUE	B-PHYS
AVEC	O
CONSIDÉRATION	O
PARTICULIÉRE	O
DU	O
ROLE	O
DE	O
L	O
'	O
ALLERGIE	B-DISO
.	O

POSSIBILITÉS	O
DU	O
CATHÉTÉRISME	B-PROC
BRONCHIQUE	I-PROC
SEGMENTAIRE	O
ET	O
SOUS	O
-	O
SEGMENTAIRE	O
CONTROLÉ	O
DANS	O
LE	O
DIAGNOSTIC	B-PROC
DES	O
LÉSIONS	B-DISO
PULMONAIRES	I-DISO
INACCESSIBLES	O
AUX	O
PRÉLÈVEMENTS	B-PROC
DIRECTS	O
.	O

RETENTISSEMENT	O
MÉCANIQUE	O
DES	O
CONTRACTIONS	B-PHYS
MUSCULAIRES	I-PHYS
SUR	O
LA	O
CIRCULATION	B-PHYS
GÉNÉRALE	O
.	O

LES	O
FACTEURS	O
DE	O
GRAVITÉ	O
DANS	O
LA	O
STÉNOSE	B-DISO
MITRALE	I-DISO
.	O

ÉTUDE	B-PROC
DE	O
LA	O
TENEUR	O
EN	O
ACIDE	B-CHEM
DÉSOXYRIBONUCLÉIQUE	I-CHEM
DES	O
NOYAUD	B-ANAT
HÉPATIQUES	I-ANAT
CHEZ	O
LA	O
SOURIS	B-LIVB
AU	O
COURS	O
DE	O
L	O
'	O
ALLAITEMENT	B-PHYS
.	O

A	O
PROPOS	O
DU	O
PROBLÈME	O
"	O
TOXOPLASMOSE	B-DISO
ET	O
GROSSESSE	B-DISO
"	O
.	O

LE	O
DOCTEUR	B-LIVB
MARCEL	O
GASTON	O
(	O
1894	O
-	O
1964	O
)	O

INDUCTION	O
DE	O
LA	O
MUTATION	O
"	O
PETITE	B-PHEN
COLONIE	I-PHEN
"	O
CHEZ	O
SACCHAROMYCES	B-LIVB
CEREVISIAE	I-LIVB
PAR	O
UN	O
CANCÉRIGÈNE	B-CHEM
HYDROSOLUBLE	O
:	O
LE	O
STYRYL	B-CHEM
430	O
.	O

COMMENTAIRES	O
SUR	O
UN	O
SYNDROME	B-DISO
DE	I-DISO
LIAN	I-DISO
,	I-DISO
SIGUIER	I-DISO
ET	I-DISO
J	I-DISO
.	I-DISO
J	I-DISO
.	I-DISO
WELTI	I-DISO
.	O

A	O
PROPOS	O
DE	O
L	O
'	O
ALLERGIE	B-DISO
TUBERCULINIQUE	I-DISO
ET	O
DE	O
SON	O
R	O
OLE	O
EN	O
PATHOLOGIE	O
.	O

A	O
PROPOS	O
DU	O
TRAITEMENT	B-PROC
MÉDICAL	I-PROC
OU	O
CHIRURGICAL	B-PROC
DES	O
ULCÈRES	B-DISO
DU	I-DISO
DUODÉNUM	I-DISO
.	O

UN	O
NOUVEL	O
OPACIFIANT	B-CHEM
DES	O
VOIES	B-ANAT
BILIAIRES	I-ANAT
:	O
LE	O
BILIVISTAN	B-CHEM
.	O

L	O
'	O
OXYDATION	B-PHYS
BISMUTHIQUE	B-CHEM
DES	O
CORTICOSTÉROUIDES	B-CHEM
URINAIRES	O
:	O
APPLICATION	O
À	O
LA	O
MESURE	O
DE	O
LA	O
SÉCRÉTION	B-PHYS
DE	O
CORTISOL	B-CHEM
PAR	O
DILUTION	B-PROC
ISOTOPIQUE	B-CHEM
.	O

L	O
'	O
IMPORTANCE	O
DU	O
CARREFOUR	O
PARIÉTO	O
-	O
TEMPORO	O
-	O
OCCIPITAL	O
DANS	O
LA	O
PATHOLOGIE	B-PROC
'	O
ÉPILEPTIQUE	B-DISO
D	O
'	O
ORIGINE	O
VASCULAIRE	B-ANAT
.	O

EFFETS	O
DES	O
RAYONS	B-PHEN
GAMMA	I-PHEN
SUR	O
LA	O
TENEUR	O
EN	O
ACIDE	B-CHEM
RIBONUCLÉIQUE	I-CHEM
ET	O
EN	O
PROTÉINES	B-CHEM
DES	O
AMIBES	B-LIVB
.	O

Premiers	O
résultats	B-DISO
d	O
'	O
une	O
consultation	O
de	O
rhumatologie	O
dans	O
un	O
grand	O
centre	O
administratif	O
.	O

Les	O
applications	O
du	O
gaz	B-CHEM
carbonique	I-CHEM
en	O
odonto	O
-	O
stomatologie	O
.	O

Etude	B-PROC
histochimique	O
des	O
adénopathies	B-DISO
de	O
la	O
polyarthrite	B-DISO
chronique	I-DISO
évolutive	I-DISO
.	O

Sur	O
un	O
nouveau	O
type	O
de	O
réaction	B-DISO
cutanée	I-DISO
allergique	B-DISO
dans	O
les	O
suites	O
immédiates	O
d	O
'	O
une	O
vaccination	B-PROC
par	I-PROC
le	I-PROC
B	I-PROC
.	I-PROC
C	I-PROC
.	I-PROC
G	I-PROC
.	O

Le	O
blé	B-LIVB
et	O
le	O
maïs	B-LIVB
dans	O
l	O
'	O
alimentation	O
.	O

Syndrome	B-DISO
de	I-DISO
Budd	I-DISO
-	I-DISO
Chiari	I-DISO
par	O
agénésie	B-DISO
congénitale	I-DISO
des	O
veines	B-ANAT
sus	B-ANAT
-	I-ANAT
hépatiques	I-ANAT
.	O

Crise	B-DISO
comitiale	I-DISO
et	O
altérations	O
électroencéphalographiques	B-PROC
au	O
cours	O
d	O
'	O
un	O
traitement	B-PROC
par	O
chlorpromazine	B-CHEM
.	O

Un	O
cas	O
de	O
carcinomatose	B-DISO
miliaire	B-DISO
.	O

Considérations	O
générales	O
sur	O
les	O
vertiges	B-DISO
.	O

L	O
'	O
OMS	O
planifie	O
pour	O
l	O
'	O
Europe	B-GEOG
l	O
'	O
application	O
du	O
processus	B-PHEN
des	O
soins	B-PROC
infirmiers	I-PROC
.	O
Compte	O
rendu	O
de	O
la	O
session	O
du	O
groupe	O
technique	O
d	O
'	O
experts	O
en	O
soins	B-PROC
infirmiers	I-PROC
et	O
obstétricaux	O
du	O
Bureau	O
régional	O
de	O
l	O
'	O
Europe	B-GEOG
de	O
l	O
'	O
OMS	O
,	O
Nottingham	O
,	O
14	O
-	O
17	O
décembre	O
1976	O

Place	O
du	O
mycophénolate	B-CHEM
mofétil	I-CHEM
dans	O
les	O
glomérulopathies	B-DISO
.	O

Tumeur	B-DISO
cutanéo	I-DISO
-	I-DISO
muqueuses	I-DISO
:	O
aspects	O
épidémiologiques	O
dans	O
le	O
service	O
de	O
dermatologie	O
du	O
centre	O
hospitalier	O
national	O
Yalgado	O
Ouedraogo	O
de	O
Ouagadougou	O
,	O
Burkina	B-GEOG
Faso	O
.	O

De	O
l	O
'	O
information	O
à	O
la	O
parole	B-PHYS
.	O
La	O
position	O
du	O
psychologue	B-LIVB
.	O

Variations	O
,	O
en	O
fonction	O
de	O
l	O
'	O
anesthésique	B-PROC
,	O
des	O
effets	B-DISO
de	O
la	O
clonidine	B-CHEM
sur	O
la	O
pression	B-PHYS
artérielle	I-PHYS
du	O
rat	B-LIVB
.	O

Caenorhabditis	B-LIVB
elegans	I-LIVB
.	O

Le	O
coût	O
du	O
dépistage	B-PROC
du	O
cancer	B-DISO
du	I-DISO
sein	I-DISO
et	O
des	O
cancers	B-DISO
gynécologiques	I-DISO
en	O
France	B-GEOG
.	O

Diagnostic	B-PROC
des	O
adénomes	B-DISO
parathyroïdiens	I-DISO
ectopiques	I-DISO
médiastinaux	O
:	O
apport	O
de	O
l	O
'	O
IRM	B-PROC
cardiaque	I-PROC
.	O

Syndrome	B-DISO
du	I-DISO
pacemaker	I-DISO
en	O
mode	O
double	B-DEVI
chambre	I-DEVI
:	O
conséquence	O
d	O
'	O
un	O
temps	O
d	O
'	O
activation	O
atriale	O
très	O
allongé	O
.	O

Evolution	O
d	O
'	O
un	O
empyème	B-DISO
pleural	I-DISO
à	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
traité	B-PROC
par	O
voie	O
médicale	O
.	O

Infections	B-DISO
sur	O
dispositifs	O
intravasculaires	O
de	O
perfusion	B-PROC
.	O

Diagnostic	B-PROC
d	O
'	O
une	O
primo	B-DISO
-	I-DISO
infection	I-DISO
à	I-DISO
VIH	I-DISO
:	O
intérêt	O
et	O
limites	O
des	O
tests	B-PROC
sérologiques	I-PROC
.	O

Conference	O
de	O
consensus	O
-	O
Complications	B-DISO
de	O
l	O
'	O
hypertension	B-DISO
portale	I-DISO
chez	O
l	O
'	O
adulte	B-LIVB
:	O
texte	O
long	O
et	O
texte	O
court	O
)	O
.	O

Bloc	B-DISO
auriculoventriculaire	I-DISO
congénital	I-DISO
associé	O
à	O
des	O
autoanticorps	B-PROC
anti	I-PROC
-	I-PROC
SSA	I-PROC
/	I-PROC
SSB	I-PROC
maternels	B-PHYS
:	O
à	O
propos	O
de	O
quatre	O
observations	B-PROC
.	O

Aspects	O
échographiques	B-PROC
de	O
fentes	B-DISO
labio	I-DISO
-	I-DISO
palatines	I-DISO
au	O
premier	O
trimestre	O
de	O
la	O
grossesse	B-PHYS
.	O
A	O
propos	O
de	O
deux	O
cas	O
.	O

L	O
'	O
image	O
du	O
mois	O
.	O
Tumeur	B-DISO
de	I-DISO
Merkel	I-DISO
:	O
réponse	O
majeure	O
a	O
la	O
chimiothérapie	B-PROC
.	O
"	O
Il	O
n	O
'	O
y	O
a	O
pas	O
que	O
la	O
neige	O
qui	O
fond	O
au	O
soleil	O
"	O
.	O
.	O
.	O
.	O

Malaises	B-DISO
du	O
nourrisson	B-LIVB
.	O

Exploration	B-PROC
de	O
l	O
'	O
intestin	B-ANAT
grêle	I-ANAT
par	O
les	O
techniques	B-PROC
d	I-PROC
'	I-PROC
imagerie	I-PROC
en	I-PROC
coupes	I-PROC
.	O

Un	O
bilan	B-PROC
lipidique	I-PROC
très	O
perturbé	O

Traitement	B-PROC
de	O
première	O
intention	O
des	O
corps	B-DISO
étrangers	I-DISO
intraoculaires	O
metalliques	O
par	O
vitrectomie	B-PROC
radicale	O
.	O

Adipocytokines	B-DISO
et	O
résistance	B-DISO
à	I-DISO
l	I-DISO
'	I-DISO
insuline	I-DISO
.	O

La	O
syncope	B-DISO
.	O

Sténose	B-DISO
du	I-DISO
pylore	I-DISO
et	O
nNOS	B-CHEM
.	O

Bilan	B-PROC
pré	I-PROC
-	I-PROC
opératoire	I-PROC
des	O
maladies	B-DISO
valvulaires	I-DISO
.	O

Sensibilite	B-PHYS
aux	O
antibiotiques	B-CHEM
des	O
germes	B-LIVB
responsables	O
d	O
'	O
infections	B-DISO
urinaires	I-DISO
de	O
l	O
'	O
enfant	B-LIVB
.	O

Ostéosynthèses	O
par	O
plaques	O
à	O
flexibilité	O
variable	O
.	O
Etude	O
théorique	O
et	O
expérimentation	O
physique	O
.	O

1	O
/	O
6	O
Administration	B-PROC
d	O
'	O
une	O
solution	B-CHEM
sucrée	I-CHEM
associée	O
à	O
la	O
succion	O
-	O
-	O
allaitement	O
maternel	B-PHYS
.	O

Consequences	O
cliniques	O
de	O
l	O
'	O
administration	B-PROC
d	O
'	O
un	O
antagoniste	B-CHEM
de	I-CHEM
la	I-CHEM
GnRH	I-CHEM
au	O
cours	O
du	O
cycle	B-PHYS
menstruel	I-PHYS
.	O

Infections	B-DISO
puerpéales	I-DISO
invasives	O
à	O
Streptococcus	B-LIVB
pyogenes	I-LIVB
.	O

Anoïkis	B-PHYS
.	O

La	O
crème	B-CHEM
Emla	I-CHEM
.	O

Monitorage	B-PROC
des	O
efforts	B-DISO
expulsifs	I-DISO
pendant	O
l	O
'	O
accouchement	B-PHYS
par	O
l	O
'	O
électromyogramme	B-PROC
des	O
muscles	B-ANAT
intercostaux	I-ANAT
:	O
étude	B-PROC
pilote	I-PROC
.	O

Tumeurs	B-DISO
cardiaques	I-DISO
malignes	I-DISO
.	O

Sensibilité	B-DISO
à	I-DISO
la	I-DISO
pénicilline	I-DISO
G	O
des	O
pneumocoques	B-LIVB
isolés	O
des	O
méningites	B-DISO
et	O
implication	O
thérapeutique	B-PROC
au	O
CHU	O
de	O
Treichville	O
-	O
Abidjan	O
.	O

Les	O
médicaments	B-CHEM
du	O
système	B-ANAT
cardiovasculaire	I-ANAT
.	O
12	O
/	O
12	O
.	O
Les	O
antiagrégants	B-CHEM
plaquettaires	I-CHEM
oraux	O
.	O

Maniabilité	O
et	O
intérêts	O
potentiels	O
du	O
thromboélastomètre	O
modifié	O
(	O
Rotem	O
)	O
dans	O
le	O
monitorage	B-PROC
extemporané	O
de	O
l	O
'	O
hémostase	B-PROC
en	O
réanimation	B-PROC
.	O

Le	O
système	B-ANAT
rénine	I-ANAT
-	I-ANAT
angiotensine	I-ANAT
:	O
données	O
actuelles	O
.	O

Bacillus	B-LIVB
licheniformis	I-LIVB
:	O
agent	O
causal	O
d	O
'	O
érysipèle	B-DISO
.	O

Ectopie	B-DISO
muqueuse	B-ANAT
post	O
traumatique	O
de	O
la	O
paupière	B-ANAT
.	O

Pneumonie	B-DISO
à	I-DISO
Pneumocystis	I-DISO
carinii	I-DISO
sans	O
déficit	O
immunitaire	O
chez	O
l	O
'	O
enfant	B-LIVB
.	O

Logique	O
de	O
services	O
cliniques	O
,	O
logique	O
de	O
santé	O
publique	O
:	O
la	O
cohabitation	O
est	O
-	O
elle	O
possible	O
au	O
sein	O
du	O
projet	O
clinique	O
?	O

Quel	O
avenir	O
pour	O
la	O
pharmacologie	O
dans	O
la	O
recherche	O
thérapeutique	O
?	O

Traitement	B-PROC
par	O
kétoprofène	B-CHEM
intraveineux	O
d	O
'	O
une	O
polyurie	B-DISO
sévère	O
survenue	O
au	O
cours	O
d	O
'	O
une	O
intoxication	B-DISO
au	I-DISO
lithium	I-DISO
.	O

Lésion	B-DISO
inflammatoire	B-DISO
du	O
cuir	B-ANAT
chevelu	I-ANAT
.	O

Fibrome	B-DISO
ossifiant	I-DISO
géant	O
des	O
maxillaires	B-ANAT
et	O
hyperparathyroïdisme	B-DISO
chez	O
un	O
hémodialysé	B-PROC
chronique	O
.	O

Biologie	O
moléculaire	O
des	O
tumeurs	B-DISO
oligodendrogliales	I-DISO
.	O

L	O
'	O
acouphène	B-DISO
neurosensoriel	I-DISO
chronique	I-DISO
.	O

Techniques	O
et	O
indications	O
de	O
la	O
lithotritie	B-PROC
extracorporelle	I-PROC
(	O
LEC	O
)	O
en	O
urologie	O
.	O

Peptides	B-CHEM
antimicrobiens	B-CHEM
naturels	O
cutanés	B-ANAT
.	O

Pédiatrie	O
.	O

Immunoglobulines	B-CHEM
monoclonales	I-CHEM
pathogènes	O
.	O

Mise	O
en	O
place	O
d	O
'	O
un	O
systemè	O
national	O
de	O
recueil	O
des	O
effets	B-DISO
indésirables	I-DISO
des	O
médicaments	B-CHEM
au	O
Liban	B-GEOG
:	O
résultats	O
de	O
la	O
première	O
année	O
d	O
'	O
activité	O
.	O

Insuffisance	B-DISO
rénale	I-DISO
chronique	I-DISO
:	O
quel	O
régime	O
?	O

Aspects	O
cliniques	O
et	O
génétiques	O
du	O
syndrome	B-DISO
d	I-DISO
'	I-DISO
Alport	I-DISO
.	O

Rhabdomyolyse	B-DISO
et	O
intoxication	B-DISO
à	O
la	O
paraphénylène	B-CHEM
-	I-CHEM
diamine	I-CHEM
.	O

Apport	O
des	O
fongicides	B-DISO
topiques	I-DISO
en	O
dermatologie	O
.	O
Paris	B-GEOG
,	O
7	O
mars	B-GEOG
1990	O
.	O

3	O
/	O
4	O
Les	O
antalgiques	B-CHEM
de	O
niveau	O
II	O
et	O
III	O
(	O
1re	O
partie	O
)	O
.	O

Les	O
injections	B-PROC
intra	I-PROC
-	I-PROC
caverneuses	I-PROC
en	O
1991	O
.	O

La	O
prescription	B-PROC
d	O
'	O
activité	O
physique	O
en	O
cardiologie	O
:	O
indications	O
classiques	O
et	O
nouvelles	O
(	O
revue	O
a	O
partir	O
des	O
données	O
de	O
la	O
médecine	O
factuelle	O
)	O
.	O

Enjeux	O
d	O
'	O
une	O
prise	B-PROC
en	I-PROC
charge	I-PROC
pédiatrique	I-PROC
précoce	O
de	O
l	O
'	O
hémophilie	B-DISO
sévère	I-DISO
.	O

L	O
'	O
encéphalite	B-DISO
herptique	O
nécrosante	B-PHYS
.	O
Etude	O
électro	O
-	O
clinique	O
et	O
anatomique	B-ANAT
,	O
à	O
propos	O
de	O
deux	O
cas	O
infantiles	B-LIVB

Tumeurs	B-DISO
gastriques	I-DISO
sécrétant	O
des	O
taux	O
élevés	O
d	O
'	O
alpha	B-CHEM
-	I-CHEM
foeto	I-CHEM
protéine	B-CHEM
.	O

La	B-DISO
maladie	I-DISO
d	I-DISO
'	I-DISO
Alzheimer	I-DISO
et	O
la	O
mémoire	B-PHYS
humaine	B-LIVB
.	O

Fécondation	B-PROC
in	I-PROC
vitro	I-PROC
et	O
tabac	B-CHEM
:	O
intérêt	O
de	O
la	O
cotininurie	B-PROC
et	O
de	O
l	O
'	O
analyseur	B-DEVI
de	O
monoxyde	B-CHEM
de	I-CHEM
carbone	I-CHEM
expiré	O
.	O

Dosage	O
du	O
BNP	B-CHEM
pour	O
le	O
diagnostic	O
d	O
'	O
insuffisance	B-DISO
cardiaque	I-DISO
congestive	I-DISO
.	O
Utilisation	O
dans	O
le	O
service	O
d	O
'	O
accueil	O
des	O
urgences	B-DISO
.	O

Maladie	B-DISO
de	I-DISO
Refsum	I-DISO
avec	O
25	O
ans	O
de	O
recul	O
.	O
Un	O
pronostic	B-PROC
à	O
long	O
terme	O
tranformé	O
par	O
la	O
thérapeutique	B-PROC
diététique	I-PROC
.	O

La	O
signalisation	O
FSH	B-CHEM
a	O
-	O
t	O
-	O
elle	O
un	O
sexe	B-PHYS
?	O

Le	O
processus	O
d	O
'	O
adaptation	B-PHYS
des	O
adultes	B-LIVB
présentant	O
des	O
séquelles	B-DISO
de	O
traumatisme	B-DISO
cranio	I-DISO
-	I-DISO
cérébral	I-DISO
.	O

La	O
femme	B-LIVB
,	O
un	O
acteur	O
à	O
part	O
entière	O
de	O
l	O
'	O
industrialisation	O
:	O
Seraing	O
,	O
1846	O
-	O
1880	O
.	O

Les	O
fractures	B-DISO
de	O
l	O
'	O
epicondyle	B-ANAT
médial	I-ANAT
chez	O
l	O
'	O
enfant	B-LIVB
.	O

Thomas	O
Zeltner	O
,	O
directeur	O
de	O
l	O
'	O
OFSP	O
:	O
"	O
Comment	O
combattre	O
la	O
morosité	O
des	O
professions	O
médicales	O
"	O
?	O

Luxation	B-DISO
bipolaire	O
du	O
cinquième	B-ANAT
métacarpien	I-ANAT
.	O

Nouveaux	O
mécanismes	B-PHYS
régulateurs	I-PHYS
de	O
Bcl10	B-CHEM
:	O
une	O
avancée	O
dans	O
la	O
compréhension	O
de	O
la	O
survenue	O
des	O
lymphomes	B-DISO
du	I-DISO
MALT	I-DISO
?	O

Etude	B-PROC
randomisée	O
multicentrique	O
comparant	O
la	O
castration	B-PROC
médicale	I-PROC
par	O
triptoréline	B-CHEM
à	O
la	O
castration	B-PROC
chirurgicale	B-PROC
dans	O
le	O
traitement	B-PROC
du	O
cancer	B-DISO
de	I-DISO
la	I-DISO
prostate	I-DISO
localement	O
avancé	O
ou	O
métastatique	B-DISO
.	O

Carcinome	B-DISO
ou	O
adénocarcinome	B-DISO
de	O
l	O
'	O
hypophyse	B-ANAT
.	O
Profil	O
anatomoclinique	O
à	O
travers	O
quelques	O
observations	B-PROC
de	O
la	O
littérature	O
.	O

Dysgénésie	B-DISO
tubulaire	I-DISO
rénale	I-DISO
autosomique	I-DISO
récessive	I-DISO
:	O
étude	B-PROC
morphologique	O
et	O
génétique	O
de	O
2	O
nouveaux	O
cas	O
.	O

Actinopolis	O
et	O
les	O
machines	B-OBJC
tournantes	O
du	O
Dr	O
Jean	O
Saidman	O
.	O

L	O
'	O
electro	B-PROC
-	I-PROC
stimulation	I-PROC
intravésicale	O
.	O

Metastase	B-DISO
cerebrale	I-DISO
revelatrice	O
d	O
'	O
un	O
carinome	B-DISO
epidermoide	I-DISO
pulmonaire	I-DISO
:	O
apport	O
de	O
l	O
'	O
imagerie	B-PROC
multinodalite	I-PROC
.	O

Essai	B-PROC
de	O
l	O
'	O
halofantrine	B-CHEM
dans	O
le	O
traitement	B-PROC
de	O
l	O
'	O
accès	O
palustre	B-DISO
a	O
Plasmodium	B-LIVB
falciparum	I-LIVB
a	O
Dakar	O
(	O
Sénégal	O
)	O
.	O

L	O
'	O
observance	B-PROC
médicamenteuse	B-DISO
.	O

Stratégie	B-PHYS
diagnostique	O
d	O
'	O
une	O
artériopathie	B-DISO
des	I-DISO
membres	I-DISO
inférieurs	I-DISO
.	O

Syndrome	B-DISO
Proteus	I-DISO
et	O
hypertension	B-DISO
intracrânienne	I-DISO
.	O

Le	O
retinoblastome	B-DISO
:	O
a	O
evoquer	O
systematiquement	O
en	O
cas	O
de	O
reflet	O
blanc	O
pupillaire	B-ANAT
ou	O
de	O
strabisme	B-DISO
.	O

Échographie	B-PROC
veineuse	B-ANAT
des	O
membres	B-ANAT
inferieurs	I-ANAT
dans	O
le	O
diagnostic	B-DISO
des	O
thromboses	B-DISO
.	O
Méthodologie	O
d	O
'	O
examen	O
et	O
présentation	O
des	O
résultats	B-PHEN
.	O

Prise	B-PROC
en	I-PROC
charge	I-PROC
de	O
l	O
'	O
hémorragie	B-DISO
d	O
'	O
origine	O
diverticulaire	B-ANAT
.	O

Paludisme	B-DISO
:	O
un	O
vaccin	B-CHEM
ne	O
semble	O
plus	O
hors	O
de	O
portée	O
.	O

Goitre	B-DISO
amyloïde	B-CHEM
:	O
première	O
manifestation	O
d	O
'	O
une	O
amylose	B-DISO
systémique	I-DISO
.	O

Complications	B-DISO
cardiovasculaires	I-DISO
de	O
l	O
'	O
interféron	B-CHEM
-	I-CHEM
alpha	I-CHEM
.	O

Traitement	B-PROC
de	O
l	O
'	O
hypertrophie	B-DISO
gingivale	I-DISO
localisée	O
associée	O
au	O
port	O
de	O
dispositifs	B-DEVI
orthodontiques	I-DEVI
par	O
lambeau	B-PROC
de	I-PROC
Widman	I-PROC
modifié	I-PROC
.	O
Rapport	O
de	O
cas	O
.	O

Données	O
actuelles	O
des	O
associations	O
chimioradiothérapeutiques	O
et	O
place	O
potentielle	O
des	O
thérapies	B-PROC
ciblées	O
dans	O
les	O
cancers	B-DISO
du	O
col	B-ANAT
utérin	I-ANAT
.	O

Pneumopathies	B-DISO
interstitielles	I-DISO
des	O
connectivites	B-ANAT
.	O

Etude	B-PROC
pilote	I-PROC
de	O
la	O
thérapie	B-PROC
antirétrovirale	I-PROC
à	O
Djibouti	B-GEOG
.	O

Découverte	B-DISO
fortuite	I-DISO
d	O
'	O
une	O
tumeur	O
surrénalienne	B-DISO
.	O
Stratégie	B-PROC
diagnostique	I-PROC
et	O
thérapeutique	B-PROC
.	O

Sauver	O
notre	O
peau	B-ANAT
.	O

Le	O
soutien	O
à	O
la	O
parentalité	O
est	O
-	O
il	O
une	O
pierre	O
dans	O
le	O
jardin	O
des	O
parents	B-LIVB
?	O

Evaluation	B-PROC
de	O
l	O
'	O
influence	O
des	O
conditions	O
de	O
culture	O
sur	O
les	O
performances	O
du	O
milieu	O
gélosé	O
sélectif	O
MRSA	B-LIVB
-	I-LIVB
ID	I-LIVB
pour	O
l	O
'	O
identification	B-PROC
de	O
Staphylococcus	B-LIVB
aureus	I-LIVB
résistant	I-LIVB
à	I-LIVB
la	I-LIVB
méticilline	I-LIVB
dans	O
les	O
prélèvements	O
de	O
dépistage	B-PROC
.	O

Allaitement	B-PHYS
et	O
surdité	B-DISO
.	O

Quand	O
la	O
barbarie	O
surgit	O
au	O
sein	O
même	O
de	O
la	O
civilisation	O
.	O
Quels	O
enjeux	O
de	O
prévention	O
primaire	O
en	O
santé	O
communautaire	O
?	O

Ischémie	B-DISO
intestinale	I-DISO
après	O
chirurgie	O
de	O
l	O
'	O
aorte	B-ANAT
sous	I-ANAT
-	I-ANAT
rénale	I-ANAT
.	O
A	O
propos	O
de	O
treize	O
cas	O
.	O

Etude	B-PROC
comparative	O
du	O
traitement	B-PROC
des	I-PROC
fractures	I-PROC
de	O
la	O
tête	B-ANAT
radiale	I-ANAT
par	O
résection	B-PROC
ou	O
par	O
implant	B-DEVI
en	I-DEVI
silastic	I-DEVI
de	O
Swanson	O
.	O

Prévalence	O
du	O
VIH	B-DISO
/	I-DISO
sida	I-DISO
chez	O
les	O
clients	B-LIVB
du	O
Centre	O
de	O
Dépistage	O
Volontaire	O
Anonyme	O
et	O
d	O
'	O
Accompagnement	O
de	O
Pikine	O
/	O
Guédiawaye	O
,	O
au	O
Sénégal	B-GEOG
.	O

Interférence	O
de	O
l	O
'	O
hémoglobine	B-CHEM
glyquée	I-CHEM
labile	B-CHEM
sur	O
le	O
dosage	O
de	O
l	O
'	O
HbA	B-CHEM
(	I-CHEM
1c	I-CHEM
)	O
par	O
une	O
méthode	O
de	O
chromatographie	B-PROC
liquide	I-PROC
haute	I-PROC
performance	I-PROC
.	O

Encéphalopathie	B-DISO
toxique	I-DISO
par	O
ingestion	O
de	O
carambole	B-LIVB
(	O
Averrhoa	B-LIVB
carambola	I-LIVB
)	O
.	O

Fibromatose	B-DISO
solitaire	O
infantile	B-LIVB
de	O
l	O
'	O
oesophage	B-ANAT
.	O

Les	O
structures	O
hospitalières	O
de	O
soins	B-PROC
palliatifs	I-PROC
.	O

Comparaison	O
de	O
l	O
'	O
effet	O
antimiotique	O
du	O
flurbiprophène	B-CHEM
0	O
.	O
03	O
%	O
par	O
rapport	O
à	O
l	O
'	O
indomethacine	B-CHEM
1	O
%	O
pendant	O
l	O
'	O
extraction	B-PROC
extracapsulaire	I-PROC
de	O
la	O
cataracte	B-DISO
.	O

La	O
contrefaçon	O
des	O
médicaments	B-CHEM
et	O
les	O
moyens	O
d	O
'	O
y	O
remédier	O
au	O
Benin	B-GEOG
.	O

Rhabdomyosarcomes	B-DISO
localisés	O
des	O
membres	O
de	O
l	O
'	O
enfant	B-LIVB
et	O
de	O
l	O
'	O
adolescent	B-LIVB
:	O
expérience	O
de	O
la	O
Société	O
francaise	O
des	O
cancers	B-DISO
de	O
l	O
'	O
enfant	B-LIVB
.	O

Projection	O
olfactive	O
primaire	O
extrabulbaire	O
chez	O
certains	O
poissons	B-LIVB
téléostéens	I-LIVB
.	O

Pemphigus	B-DISO
vulgaire	I-DISO
de	O
l	O
'	O
enfant	B-LIVB
.	O

Influence	O
de	O
l	O
'	O
origine	O
ethnique	O
dans	O
l	O
'	O
évaluation	O
des	O
calcifications	B-DISO
coronaires	I-DISO
en	O
tant	O
que	O
facteur	O
de	O
risque	O
d	O
'	O
événement	O
coronaire	B-ANAT
.	O

Le	O
pistolet	O
sur	O
la	O
tempe	B-ANAT
.	O

Intérêt	O
de	O
l	O
'	O
analyse	B-PROC
factorielle	O
discriminante	O
pour	O
classer	O
les	O
syndromes	B-DISO
parkinsoniens	I-DISO
à	O
partir	O
de	O
la	O
tomoscintigraphie	B-PROC
d	I-PROC
'	I-PROC
émission	I-PROC
monophotonique	I-PROC
.	O

De	O
la	O
médecine	O
factuelle	O
(	O
evidence	O
-	O
based	O
medicine	O
)	O
au	O
"	O
libre	O
arbitre	O
"	O
.	O

Le	O
cancer	B-DISO
de	I-DISO
la	I-DISO
prostate	I-DISO
,	O
le	O
point	O
sur	O
le	O
dépistage	B-PROC
.	O

Syndrome	B-DISO
d	I-DISO
'	I-DISO
Evans	I-DISO
sous	O
D	B-CHEM
-	I-CHEM
pénicillamine	I-CHEM
au	O
cours	O
d	O
'	O
une	O
polyarthrite	B-DISO
rhumatoïde	I-DISO
.	O
Intérêt	O
de	O
l	O
'	O
association	O
corticoïdes	O
-	O
danazol	O
.	O

Le	O
chlorhydrate	O
d	O
'	O
heptaminol	B-CHEM
:	O
nouvelles	O
données	O
.	O

Agrégation	B-PHEN
erythrocytaire	I-PHEN
en	O
pathologie	B-DISO
vasculaire	I-DISO
.	O
Influence	O
de	O
l	O
'	O
hypertension	B-DISO
.	O

Occlusion	B-DISO
veineuse	I-DISO
rétinienne	I-DISO
et	O
syndrome	B-DISO
d	O
'	O
apnée	B-DISO
du	I-DISO
sommeil	I-DISO
.	O

Profil	O
psychopharmacologique	O
d	O
'	O
un	O
extrait	B-CHEM
aqueux	O
de	O
Piper	B-LIVB
umbellatum	I-LIVB
.	O

Quarante	O
ans	O
de	O
bioéthique	O
-	O
-	O
des	O
éclairages	O
du	O
Hastings	O
Center	O
.	O

Délirium	B-DISO
ou	O
.	O
.	O
.	O
confusion	B-DISO
aiguë	I-DISO
?	O
L	O
'	O
article	O
"	O
confusion	B-DISO
aiguë	I-DISO
-	O
-	O
application	O
d	O
'	O
un	O
programme	O
de	O
soins	O
basé	O
sur	O
le	O
caring	O
"	O
.	O

Les	O
insuffisances	B-DISO
aortiques	I-DISO
dystrophiques	O
.	O

Pharmacovigilance	B-PROC
update	O
.	O

Lymphomes	B-DISO
.	O
Comment	O
aborder	O
les	O
12	O
000	O
nouveaux	O
cas	O
annuels	O
de	O
ces	O
maladies	B-DISO
,	O
diverses	O
dans	O
leur	O
présentation	O
et	O
leur	O
evolution	B-PHYS
?	O

Cryptococcose	B-DISO
méningéé	I-DISO
au	O
cours	O
d	O
'	O
une	O
leucémie	B-DISO
lymphoïde	I-DISO
chronique	I-DISO
.	O

Corps	B-DISO
etranger	I-DISO
de	O
la	O
voie	B-ANAT
biliaire	I-ANAT
principale	I-ANAT
.	O

Cancer	B-DISO
du	I-DISO
rein	I-DISO
:	O
traitements	B-PROC
anti	I-PROC
-	I-PROC
angiogéniques	I-PROC
et	O
gestion	O
des	O
complications	B-DISO
.	O
A	O
propos	O
d	O
'	O
un	O
cas	O
.	O

L	O
'	O
ethnomusicologie	O
silesienne	O
:	O
une	O
"	O
science	O
militante	O
"	O
,	O
aujourd	O
'	O
hui	O
un	O
enjeu	O
nouveau	O
.	O

Extension	O
a	O
la	O
fosse	B-ANAT
infra	I-ANAT
-	I-ANAT
temporale	I-ANAT
des	O
tumeurs	B-DISO
malignes	I-DISO
du	O
massif	B-ANAT
facial	I-ANAT
.	O

Comparaison	O
du	O
midazolam	B-CHEM
et	O
du	O
diazépam	B-CHEM
en	O
prémédication	B-PROC
par	O
voie	O
intramusculaire	O
.	O

Dose	O
de	O
tolérance	B-DISO
à	O
l	O
'	O
irradiation	B-PROC
des	O
tissus	O
sains	O
:	O
la	O
moelle	B-ANAT
osseuse	I-ANAT
.	O

L	O
'	O
internat	O
en	O
gynécologie	O
-	O
obstétrique	O
à	O
Montpellier	O
.	O

Démarche	O
qualité	O
en	O
biologie	O
délocalisée	O
:	O
exemple	O
du	O
test	B-PROC
tétanos	B-DISO
.	O

Le	O
contrôle	B-PROC
glycémique	I-PROC
en	O
réanimation	O
pédiatrique	B-LIVB
.	O

La	O
transition	B-PHYS
épithélio	I-PHYS
-	I-PHYS
mésenchymateuse	I-PHYS
dans	O
le	O
greffon	B-ANAT
rénal	I-ANAT
.	O

Fibrose	B-DISO
rétropéritonéale	I-DISO
et	O
timolol	B-CHEM
en	O
collyre	B-CHEM
.	O

Approche	O
socio	O
-	O
historique	O
de	O
la	O
lutte	O
contre	O
les	O
infections	B-DISO
nosocomiales	I-DISO
en	O
France	B-GEOG
.	O

Quand	O
référer	O
aux	O
urgences	O
un	O
patient	B-LIVB
présentant	O
une	O
crise	B-DISO
suicidaire	B-DISO
?	O

x	O

A	O
la	O
recherche	O
des	O
vertus	O
du	O
resvératrol	B-CHEM
.	O

L	O
'	O
association	O
maladie	B-DISO
cœliaque	I-DISO
et	O
syndrome	B-DISO
de	I-DISO
Budd	I-DISO
-	I-DISO
Chiari	I-DISO
:	O
à	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Prise	O
en	O
charge	O
des	O
hypercholestérolémies	B-DISO
de	O
l	O
'	O
enfant	B-LIVB
:	O
recommandations	O
du	O
Comité	O
de	O
nutrition	O
de	O
la	O
Société	O
française	O
de	O
pédiatrie	O
et	O
de	O
la	O
Nouvelle	O
société	O
française	O
d	O
'	O
athérosclérose	O
.	O

Les	O
émulsions	B-CHEM
lipidiques	I-CHEM
permettent	O
-	O
elles	O
de	O
couvrir	O
les	O
besoins	O
en	O
vitamine	B-CHEM
K1	I-CHEM
chez	O
les	O
enfants	B-LIVB
en	O
nutrition	B-PROC
parentérale	I-PROC
exclusive	I-PROC
?	O

Traitements	B-PROC
de	O
l	O
'	O
infertilité	B-DISO
après	O
traitement	B-PROC
d	O
'	O
un	O
cancer	B-DISO
gynécologique	I-DISO
et	O
indication	O
de	O
la	O
congélation	B-PROC
du	O
tissu	B-ANAT
ovarien	I-ANAT
.	O

Embolisation	B-DISO
d	O
'	O
un	O
anévrisme	B-DISO
rompu	I-DISO
de	O
l	O
'	O
artère	B-ANAT
ovarienne	I-ANAT
du	O
post	O
-	O
partum	O
.	O

Traitement	B-PROC
chirurgical	B-PROC
des	O
diverticules	B-DISO
de	O
l	O
'	O
oesophage	B-ANAT
thoracique	I-ANAT
.	O

L	O
'	O
ostéosynthèse	O
par	O
plaque	B-DEVI
vissée	O
dans	O
les	O
fractures	B-DISO
du	O
condyle	B-ANAT
mandibulaire	I-ANAT
.	O

Le	O
mélanome	B-DISO
du	O
sujet	B-LIVB
âgé	I-LIVB
.	O

Effect	O
du	O
butyrate	B-CHEM
de	I-CHEM
sodium	I-CHEM
sur	O
la	O
sensibilité	O
à	O
l	O
'	O
interféron	B-CHEM
de	O
cellules	B-ANAT
normales	I-ANAT
ou	O
transformées	B-PHYS
par	O
le	O
virus	B-LIVB
du	I-LIVB
sarcome	I-LIVB
murin	I-LIVB
.	O

Coma	B-DISO
post	O
-	O
anoxique	O
réversible	O
sous	O
flumazénil	B-CHEM
.	O

Évolutions	O
technologiques	O
en	O
qualification	O
biologique	O
du	O
don	O
et	O
leur	O
impact	O
sur	O
le	O
risque	O
résiduel	O
transfusionnel	B-PROC
.	O

Intoxication	B-DISO
accidentelle	I-DISO
à	I-DISO
la	I-DISO
méfloquine	I-DISO
.	O

Régulation	O
du	O
récepteur	B-CHEM
:	O
implication	O
dans	O
l	O
'	O
activité	O
des	O
médicaments	B-CHEM
.	O

L	O
'	O
enzyme	B-PHEN
de	I-PHEN
conversion	I-PHEN
de	I-PHEN
l	I-PHEN
'	I-PHEN
angiotensine	I-PHEN
sérique	I-PHEN
dans	O
la	O
maladie	B-DISO
de	I-DISO
Crohn	I-DISO
.	O

Examen	O
programmé	O
de	O
l	O
'	O
épaule	B-ANAT
.	O

L	O
'	O
approche	O
du	O
corps	B-ANAT
en	O
exercice	O
libéral	O
.	O

Modifications	O
d	O
'	O
activité	B-PHYS
de	I-PHYS
l	I-PHYS
'	I-PHYS
adénylate	I-PHYS
-	I-PHYS
cyclase	I-PHYS
des	O
cellules	B-ANAT
KB	I-ANAT
au	O
cours	O
de	O
l	O
'	O
infection	B-DISO
par	O
le	O
virus	B-LIVB
Sendaï	O
.	O

Le	O
marché	O
privé	O
se	O
développe	O
.	O

Les	O
surdités	B-DISO
de	I-DISO
transmission	I-DISO
de	O
l	O
'	O
adulte	B-LIVB
.	O
Eléments	O
diagnostiques	O
et	O
principes	O
thérapeutiques	O
.	O

Clonidine	B-CHEM
:	O
du	O
traitement	B-PROC
de	O
l	O
'	O
hypertension	B-DISO
artérielle	B-ANAT
à	O
l	O
'	O
utilisation	O
en	O
anesthésie	B-PROC
.	O
II	O
:	O
Utilisation	O
périopératoire	O
.	O

Modalités	O
et	O
indications	B-DISO
de	O
l	O
'	O
analgésie	B-PROC
péridurale	I-PROC
basse	O
chez	O
le	O
vieillard	B-LIVB
(	O
a	O
propos	O
de	O
330	O
observations	B-PROC
)	O
.	O

Diagnostique	B-PROC
biologique	O
des	O
échinococcoses	B-DISO
.	O

Le	O
test	O
d	O
'	O
Ohkuma	O
:	O
une	O
évaluation	B-PROC
.	O

Résultats	B-PHEN
préliminaires	O
de	O
la	O
technique	O
d	O
'	O
excision	B-PROC
du	I-PROC
ptérygion	I-PROC
avec	O
autogreffe	B-CHEM
conjonctivale	B-ANAT
.	O

L	O
'	O
état	B-DISO
de	I-DISO
santé	I-DISO
du	O
monde	O
en	O
1989	O
.	O

Effets	O
tissulaires	O
du	O
laser	B-DEVI
CO2	I-DEVI
en	I-DEVI
chirurgie	I-DEVI
stomatologique	B-ANAT
.	O

Activité	O
anti	B-PROC
-	I-PROC
VIH	I-PROC
in	O
vitro	O
d	O
'	O
oligodésoxynucléotides	B-CHEM
phosphorothioates	B-CHEM
d	O
'	O
anomérie	O
alpha	O
.	O

Causes	O
des	O
gastro	B-DISO
-	I-DISO
entérites	I-DISO
infectieuses	I-DISO
de	O
l	O
'	O
enfant	B-LIVB
à	O
Dakar	O
.	O

A	O
propos	O
de	O
moyens	B-PROC
diagnostiques	I-PROC
actuels	O
du	O
rétinoblastome	B-DISO
(	O
cytologie	B-PROC
de	O
vitré	B-ANAT
et	O
marqueur	B-DEVI
)	O
.	O

Antidiarrhéiques	B-CHEM
.	O

Hypertension	B-DISO
intracrânienne	I-DISO
intermittente	O
révélatrice	O
d	O
'	O
une	O
tumeur	B-DISO
de	O
la	O
moelle	B-ANAT
cervicale	I-ANAT
.	O

Concertation	B-PROC
.	O
Discordances	O
pour	O
un	O
cancer	B-DISO
de	O
cavum	B-ANAT
.	O

Conséquences	O
gynécologiques	O
des	O
phlébites	B-DISO
pelviennes	B-ANAT
méconnues	O
.	O

La	O
photopléthysmographie	B-PROC
(	O
PPG	O
)	O
ou	O
photoréflexométrie	B-PROC
(	O
PRM	O
)	O
:	O
principe	O
et	O
reproductibilité	O
(	O
étude	B-PROC
de	O
la	O
validité	O
de	O
la	O
méthode	O
chez	O
le	O
sujet	O
sain	O
)	O
.	O

FIVETE	O
et	O
endométriose	B-DISO
.	O
Incertitudes	O
et	O
enjeux	O
.	O

Pharmacologie	O
des	O
corticoides	O
.	O
Notions	O
classiques	O
et	O
nouvelles	O
.	O

Le	O
syndrome	B-DISO
de	I-DISO
Noonan	I-DISO
et	O
sa	O
dysplasie	B-DISO
cardio	B-ANAT
-	I-ANAT
vasculaire	I-ANAT
.	O
A	O
propos	O
de	O
64	O
observations	B-PROC
.	O

Mobilisations	B-PROC
totales	O
des	O
maxillaires	B-ANAT
supérieur	I-ANAT
et	O
inférieur	B-ANAT
:	O
indications	B-DISO
et	O
resultats	O
.	O

Hypercalcémies	B-DISO
des	O
hémopathies	B-DISO
et	O
des	O
cancers	B-DISO
.	O

Le	O
SIDA	B-DISO
:	O
aspects	O
éthiques	O
et	O
politiques	O
.	O

La	O
relation	B-DISO
soignant	I-DISO
-	I-DISO
soigné	I-DISO
en	O
institution	O
gériatrique	O
.	O

Toxicomanie	B-DISO
et	I-DISO
grossesse	I-DISO
.	O

Cavernomes	O
cérébraux	B-ANAT
de	O
l	O
'	O
enfant	B-LIVB
et	O
du	O
nourrisson	B-LIVB
.	O

Hernie	B-DISO
de	I-DISO
Bochdalek	I-DISO
.	O

Fractures	B-DISO
du	O
rocher	B-ANAT
.	O
Bilan	O
de	O
123	O
cas	O
.	O

Hygiène	B-DISO
dentaire	I-DISO
et	O
éducation	B-PROC
sanitaire	I-PROC
chez	O
les	O
écoliers	B-LIVB
de	O
l	O
'	O
ile	B-GEOG
de	O
Tahiti	B-GEOG
.	O

Le	O
point	O
de	O
contact	O
dentaire	B-ANAT
.	O

Acromégalie	B-DISO
évolutive	O
à	O
hormone	B-DISO
de	I-DISO
croissance	I-DISO
basse	I-DISO
.	O
Influence	O
d	O
'	O
un	O
analogue	B-CHEM
de	I-CHEM
la	I-CHEM
somatostatine	I-CHEM
administré	O
en	O
infusion	B-PROC
continue	I-PROC
sous	O
-	O
cutanée	O
.	O

Etude	O
critique	O
de	O
la	O
lacorhinostomie	O
.	O

Thermalisme	O
et	O
répercussions	O
sur	O
l	O
'	O
axe	B-ANAT
hypothalamo	I-ANAT
-	I-ANAT
hypophysaire	I-ANAT
.	O

Le	O
ciment	B-CHEM
au	I-CHEM
verre	I-CHEM
ionomère	I-CHEM
(	O
C	B-CHEM
.	I-CHEM
V	I-CHEM
.	I-CHEM
I	I-CHEM
.	O
)	O
.	O

Données	O
de	O
l	O
'	O
ultrasonographie	B-PROC
en	I-PROC
mode	I-PROC
Doppler	I-PROC
pré	B-PROC
-	O
et	O
post	B-PROC
-	I-PROC
opératoire	I-PROC
dans	O
les	O
coarctations	B-DISO
de	I-DISO
l	I-DISO
'	I-DISO
aorte	I-DISO
.	O

Marqueurs	B-DEVI
de	O
membrane	B-ANAT
des	O
cellules	B-ANAT
de	O
leucemie	B-DISO
aigue	I-DISO
lymphoblastique	I-DISO
.	O

A	O
propos	O
du	O
syndrome	B-DISO
de	I-DISO
Cyriax	I-DISO
.	O
Pseudo	O
-	O
syndrome	O
de	O
menace	O
chez	O
une	O
angineuse	O
connue	O
.	O

Désobstruction	O
tumorale	B-DISO
trachéo	B-ANAT
-	I-ANAT
bronchique	I-ANAT
par	O
cryothérapie	B-DEVI
souple	O
.	O

La	O
pneumonie	B-DISO
à	I-DISO
Serratia	I-DISO
marcescens	I-DISO
:	O
une	O
complication	B-DISO
postopératoire	I-DISO
rare	O
chez	O
les	O
patients	B-LIVB
cancéreux	B-DISO
.	O
A	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Mécanismes	O
du	O
rejet	O
des	O
allogreffes	B-ANAT
rénales	I-ANAT
.	O

Imagerie	B-PROC
par	I-PROC
résonance	I-PROC
magnétique	I-PROC
du	O
cancer	B-DISO
du	I-DISO
rectum	I-DISO
.	O

Le	O
paludisme	B-DISO
chimiorésistant	O
en	O
France	B-GEOG
.	O

Traitement	B-PROC
des	O
troubles	B-DISO
psychopathologiques	I-DISO
associés	O
aux	O
dyskinésies	B-DISO
tardives	I-DISO
.	O

Orthodontie	B-PROC
et	O
parodontie	B-PROC
chez	O
l	O
'	O
adulte	B-LIVB
:	O
les	O
limites	O
.	O

Agranulocytose	B-DISO
aiguë	I-DISO
réversible	O
au	O
cours	O
d	O
'	O
un	O
traitement	B-PROC
par	O
la	O
ceftriaxone	B-CHEM
.	O

Fiabilité	O
du	O
monitorage	B-PROC
oscillométrique	O
automatique	O
de	O
la	O
pression	B-PHYS
artérielle	I-PHYS
.	O
Influence	O
de	O
l	O
'	O
hypotension	B-DISO
et	O
des	O
troubles	B-DISO
du	I-DISO
rythme	I-DISO
.	O

Evaluation	O
in	O
vitro	O
de	O
l	O
'	O
activité	O
antibactérienne	B-CHEM
de	O
cinq	O
ciments	O
.	O

Tests	B-PROC
de	I-PROC
la	I-PROC
vision	I-PROC
des	O
couleurs	B-PHEN
et	O
potentiels	B-PHYS
évoqués	I-PHYS
visuels	I-PHYS
dans	O
la	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
.	O

Hémorragies	B-DISO
articulaires	B-ANAT
et	O
musculaires	B-ANAT
des	O
hémophiles	B-DISO
A	I-DISO
avec	O
anticorps	B-PROC
anti	I-PROC
-	I-PROC
facteur	I-PROC
VIII	I-PROC
.	O
Traitement	B-PROC
par	O
des	O
lots	O
sélectionnés	O
de	O
PPSB	B-CHEM
(	O
concentré	B-CHEM
de	I-CHEM
facteur	I-CHEM
IX	I-CHEM
)	O
.	O

Ulcère	B-DISO
simple	O
solitaire	O
asymptomatique	B-DISO
de	O
l	O
'	O
angle	B-DISO
gauche	I-DISO
du	I-DISO
côlon	I-DISO
.	O

Possibilités	O
techniques	O
de	O
traitement	B-PROC
des	O
douleurs	B-DISO
du	I-DISO
membre	I-DISO
inférieur	I-DISO
.	O

Spondylolisthésis	B-DISO
à	O
grand	O
déplacement	O
chez	O
l	O
'	O
enfant	B-LIVB
et	O
l	O
'	O
adolescent	B-LIVB
.	O
Résultats	B-DISO
de	O
12	O
cas	O
de	O
réduction	O
-	O
fixation	O
postérieure	O
.	O

Hyposécrétion	O
lacrymale	B-ANAT
chez	O
les	O
patients	B-LIVB
jeunes	B-LIVB
.	O

Paludisme	B-DISO
et	O
grossesse	B-DISO
.	O
Situation	O
épidémiologique	O
à	O
Kinshasa	O
(	O
Zaïre	O
)	O
.	O

La	O
tonométrie	B-PROC
.	O

Infarctus	B-DISO
du	I-DISO
myocarde	I-DISO
aigu	I-DISO
.	O
Autre	O
traitement	B-PROC
,	O
autre	O
pronostic	B-PROC
?	O

Apport	O
de	O
l	O
'	O
échographie	B-PROC
dans	O
la	O
maladie	B-DISO
de	I-DISO
Crohn	I-DISO
.	O

Un	O
case	O
de	O
hernie	B-DISO
intra	O
péricardique	O
post	O
-	O
traumatique	O
chez	O
l	O
'	O
enfant	B-LIVB
.	O

Evaluation	B-PROC
des	O
effets	O
de	O
l	O
'	O
enveloppe	O
sonore	B-PHEN
.	O
Présentation	O
d	O
'	O
un	O
protocole	O
de	O
travail	O
électrophysiologique	O
.	O

Rubrique	O
iconographique	O
.	O
Maladie	B-DISO
de	I-DISO
Wolman	I-DISO
.	O

Prémédication	B-PROC
sublinguale	O
au	O
prazépam	B-CHEM
.	O

Vue	O
générale	O
de	O
l	O
'	O
hémostase	B-DISO
.	O

Fibrose	B-DISO
pulmonaire	I-DISO
apicale	O
et	O
polyarthrite	B-DISO
rhumatoïde	I-DISO
.	O

Place	O
de	O
la	O
rhinomanométrie	B-PROC
dans	O
l	O
'	O
allergie	B-DISO
aux	I-DISO
acariens	I-DISO
de	O
l	O
'	O
enfant	B-LIVB
à	O
propos	O
de	O
76	O
explorations	B-PROC
.	O

Approche	O
à	O
l	O
'	O
étude	B-PROC
du	O
rapport	O
existant	O
entre	O
le	O
type	O
morphologique	O
et	O
certains	O
caractères	O
du	O
système	O
dento	O
-	O
parodontal	O
.	O

La	O
couleur	B-PHEN
en	O
odontologie	O
:	O
caractéristiques	O
objectives	O
.	O

L	O
'	O
immunothérapie	B-PROC
adoptive	I-PROC
:	O
une	O
nouvelle	O
approche	O
thérapeutique	B-PROC
du	O
cancer	B-DISO
à	O
base	O
d	O
'	O
interleukine	B-CHEM
2	I-CHEM
.	O

Diagnostic	B-PROC
moléculaire	I-PROC
des	O
myopathies	B-DISO
de	O
Duchenne	B-DISO
et	O
de	O
Becker	B-DISO
.	O
Données	O
actuelles	O
.	O

Toxicologie	O
génétique	O
et	O
médecine	O
du	O
travail	O
:	O
perspectives	O
d	O
'	O
applications	O
.	O

Pathologie	B-DISO
ischémique	O
cérébrale	B-ANAT
d	O
'	O
origine	O
carotidienne	B-ANAT
.	O
Evaluations	O
préopératoires	O
du	O
risque	O
ischémique	O
:	O
l	O
'	O
angiographie	B-PROC
numérisée	I-PROC
(	O
valeur	O
diagnostique	B-DISO
;	O
limites	O
d	O
'	O
interprétation	O
et	O
d	O
'	O
exploitation	O
)	O
.	O

Grandeur	O
et	O
misères	O
de	O
l	O
'	O
optimalisation	O
en	O
radioprotection	B-PROC
.	O

In	O
memoriam	O
Ch	O
.	O
H	O
.	O
Best	O
,	O
membre	O
honoraire	O
étranger	O
.	O

Techniques	O
de	O
mesures	O
de	O
pression	B-PHEN
,	O
débit	B-PHEN
et	O
volume	B-PROC
en	O
exploration	B-PROC
fonctionnelle	I-PROC
respiratoire	I-PROC
.	O

Phénotypes	O
érythrocytaires	O
et	O
fréquences	O
des	O
gènes	O
du	O
système	B-ANAT
ABO	I-ANAT
dans	O
la	O
population	O
sénégalaise	O
.	O

Enquête	O
séro	O
-	O
immunologique	O
par	O
immunofluorescence	B-PROC
de	O
la	O
bilharziose	B-DISO
murine	B-LIVB
en	O
Guadeloupe	B-GEOG
.	O
Intérêt	O
épidémiologique	O
,	O
étrude	B-PROC
comparative	I-PROC
dans	O
différents	O
biotopes	O
.	O

Typologie	O
des	O
accidents	B-DISO
liés	O
à	O
l	O
'	O
éducation	B-DISO
physique	I-DISO
scolaire	I-DISO
.	O
Analyse	O
factorielle	O
de	O
correspondance	O
de	O
336	O
cas	O
observés	O
à	O
Genève	O
dans	O
trois	O
degrés	O
du	O
secondaire	O
inférieur	O
.	O

Apport	O
de	O
la	O
capillaroscopie	B-PROC
dans	O
les	O
acrosyndromes	O
des	O
mains	B-ANAT
.	O

Infection	B-DISO
urinaire	I-DISO
.	O

La	O
personne	B-LIVB
âgée	I-LIVB
face	O
à	O
l	O
'	O
infection	B-DISO
.	O

La	O
ménopause	B-DISO
.	O

Pancréatites	B-DISO
et	O
hyperparathyroïdie	B-DISO
primaire	I-DISO
.	O
14	O
pancréatites	B-DISO
-	O
-	O
500	O
cervicotomies	O
.	O

Recommandations	O
pour	O
améliorer	O
la	O
valeur	O
prédictive	O
des	O
données	O
des	O
phases	O
I	O
à	O
III	O
concernant	O
la	O
tolérance	B-DISO
clinique	O
et	O
biologique	O
d	O
'	O
un	O
nouveau	O
médicament	B-CHEM
.	O

Infarctus	B-DISO
cilio	O
-	O
rétinien	O
et	O
occlusion	B-DISO
veineuse	I-DISO
rétinienne	I-DISO
.	O

Les	O
césariennes	B-PROC
avant	O
32	O
semaines	O
révolues	O
d	O
'	O
aménorrhée	B-DISO
.	O

Amidon	B-CHEM
de	O
manioc	B-LIVB
:	O
excipient	B-CHEM
utilisé	O
en	O
compression	O
.	O

Demandes	O
d	O
'	O
examens	B-PROC
de	I-PROC
laboratoire	I-PROC
.	O
Ampleur	O
et	O
causes	O
des	O
variations	O
entre	O
médecins	B-LIVB
.	O

Hémorragie	B-DISO
intraventriculaire	I-DISO
aprés	O
endartériectomie	B-PROC
carotidienne	I-PROC
.	O
Rôle	O
des	O
suppléances	B-PHYS
de	O
type	O
moya	O
moya	O
.	O

Lasers	B-DEVI
YAG	I-DEVI
pulsés	O
à	O
angle	O
de	O
convergence	O
divergence	O
variable	O
.	O

Comment	O
évaluer	O
une	O
maladie	B-DISO
de	I-DISO
l	I-DISO
'	I-DISO
orifice	I-DISO
mitral	I-DISO
?	O

La	O
chirurgie	B-PROC
mucogingivale	O
.	O

Arend	O
Bouhuys	O
.	O
18	O
octobre	O
1925	O
-	O
15	O
juin	O
1979	O
.	O

Conséquences	O
pratiques	O
du	O
débusquement	B-DISO
enzymatique	B-CHEM
des	O
microorganismes	B-LIVB
.	O

La	O
pompe	B-DEVI
à	I-DEVI
insuline	I-DEVI
et	O
l	O
'	O
insulino	O
-	O
thérapie	O
intensive	O
.	O

Sécrétion	B-PHYS
gastrique	I-PHYS
nycthémérale	O
chez	O
l	O
'	O
enfant	B-LIVB
en	O
nutrition	B-PROC
parentérale	I-PROC
.	O

Microscopie	B-PROC
en	O
chirurgie	B-PROC
oculaire	B-ANAT
.	O
Les	O
sutures	B-DEVI
.	O

Contribution	O
à	O
l	O
'	O
étude	B-PROC
des	O
cancers	B-DISO
oesophagiens	I-DISO
multifocaux	B-DISO
par	O
imprégnation	B-PROC
au	I-PROC
bleu	I-PROC
de	I-PROC
toluidine	I-PROC
.	O
Implications	O
thérapeutiques	O
.	O
A	O
propos	O
de	O
cinquante	O
cas	O
.	O

Reflux	B-DISO
gastro	I-DISO
-	I-DISO
oesophagien	I-DISO
et	O
manifestations	O
respiratoires	B-PHYS
.	O

Pathologie	B-PROC
de	O
l	O
'	O
interface	O
vitréo	O
-	O
rétinienne	O
.	O

Les	O
ostéonécroses	B-DISO
de	I-DISO
la	I-DISO
tête	I-DISO
fémorale	I-DISO
d	O
'	O
origine	O
drépanocytaire	B-DISO
au	O
Bénin	B-GEOG
.	O
Aspects	O
épidémiologiques	O
et	O
radiologiques	B-PROC
.	O

Hydatidose	B-DISO
pulmonaire	I-DISO
métastatique	O
,	O
à	O
point	O
de	O
départ	O
cave	B-ANAT
inférieur	I-ANAT
.	O
A	O
propos	O
d	O
'	O
un	O
cas	O
.	O

Problèmes	O
de	O
la	O
détermination	B-PROC
des	O
points	O
isoélectriques	O
des	O
beta	B-CHEM
lactamases	I-CHEM
.	O

Amélioration	O
des	O
réponses	O
vestibulaires	B-ANAT
provoquées	O
par	O
la	O
vision	B-DISO
tubulaire	I-DISO
.	O

Effets	O
préventifs	O
du	O
gliclazide	B-CHEM
sur	O
le	O
développement	O
de	O
l	O
'	O
athérosclérose	B-DISO
induite	O
par	O
le	O
cholestérol	B-CHEM
chez	O
la	O
lapin	B-LIVB
.	O

Etude	B-PROC
des	O
rRNA	B-CHEM
de	O
Saccharomyces	B-LIVB
cerevisiae	I-LIVB
dans	O
des	O
mélanges	B-OBJC
eau	O
-	O
formamide	O
.	O

Etude	B-PROC
electrophoretique	B-PROC
des	O
proteines	B-CHEM
du	O
liquide	B-ANAT
cephalo	I-ANAT
-	I-ANAT
rachidien	I-ANAT
au	O
cours	O
de	O
la	O
sclerose	B-DISO
en	I-DISO
plaques	I-DISO
:	O
I	O
)	O
recherche	B-PROC
de	O
correlations	O
biochemiques	O
,	O
cytologiques	O
et	O
cliniques	O
.	O

La	O
cytomégalie	B-ANAT
généralisée	O
.	O
Etude	B-PROC
ultrastructurale	B-ANAT
de	O
prélèvements	B-OBJC
nécropsiques	B-PROC
.	O

Etude	B-PROC
expérimentale	I-PROC
du	O
L	B-CHEM
5818	I-CHEM
Labaz	O
,	O
utilisé	O
comme	O
vasoconstricteur	B-CHEM
en	O
instillation	B-PROC
nasale	B-ANAT

L	O
'	O
étude	B-PROC
de	O
la	O
vascularisation	O
hypothalamique	B-ANAT
chez	O
les	O
rats	B-LIVB
âgés	B-LIVB
.	O

Bases	O
pharmacologiques	O
du	O
traitement	B-PROC
symptomatique	B-DISO
de	O
l	O
'	O
hypertension	B-DISO
artérielle	B-ANAT
.	O
II	O
.	O
Les	O
associations	B-OBJC
d	O
'	O
antihypertenseurs	B-CHEM
entre	O
eux	O

Action	O
et	O
réaction	O
Méchanismes	O
bio	O
et	O
neuro	O
-	O
physiologiques	O

Altérations	O
de	O
l	O
'	O
appareil	O
sous	O
-	O
valvulaire	O
et	O
fonction	B-PHYS
ventriculaire	I-PHYS
gauche	I-PHYS
dans	O
le	O
rétrécissement	B-DISO
mitral	I-DISO
pur	O
.	O

Modifications	O
des	O
protéines	B-CHEM
sériques	I-CHEM
et	O
du	O
liquide	B-ANAT
synovial	I-ANAT
au	O
cours	O
de	O
la	O
polyarthrite	B-DISO
rhumatoide	I-DISO
.	O

Les	O
aménorrhées	B-DISO
psychogènes	O
.	O

Essais	B-PROC
cliniques	I-PROC
d	O
'	O
une	O
médication	O
à	O
visée	O
hépato	O
-	O
biliaire	O
.	O

Le	O
potentiel	O
photorécepteur	B-ANAT
précoce	O
chez	O
l	O
'	O
homme	B-LIVB
normal	O
.	O

Modifications	O
du	O
spectre	B-DEVI
d	I-DEVI
'	I-DEVI
amplitudes	I-DEVI
de	I-DEVI
l	I-DEVI
'	I-DEVI
électroencéphalogramme	I-DEVI
provoquées	O
par	O
l	O
'	O
activité	O
mentale	B-PHYS
et	O
détectées	O
par	O
le	O
miniordinateur	B-OBJC
.	O

Symposium	O
sur	O
les	O
sciatiques	B-DISO
chirurgicales	B-PROC
d	O
'	O
origine	O
discale	B-ANAT
.	O

Indications	B-PHYS
et	O
résultats	O
du	O
fixateur	B-DEVI
externe	I-DEVI
d	O
'	O
Hoffmann	O
dans	O
les	O
fractures	B-DISO
ouvertes	I-DISO
de	O
jambe	B-ANAT
(	O
statistique	O
de	O
82	O
cas	O
)	O

A	O
propos	O
du	O
traitement	B-PROC
des	O
paralysies	B-DISO
obstétricales	I-DISO
du	O
plexus	B-ANAT
brachial	I-ANAT
:	O
désinsertion	B-PROC
du	O
sous	O
-	O
scapulaire	O
sans	O
capsulotomie	O
.	O

Les	O
cellules	B-ANAT
pigmentaires	I-ANAT
de	O
l	O
'	O
endomètre	B-ANAT
chez	O
le	O
hamster	B-LIVB
doré	O
.	O

Tuberculose	B-DISO
ganglionnaire	I-DISO
cervicale	I-DISO
chez	O
un	O
nourrisson	B-LIVB
;	O
problemes	B-DISO
posés	O
par	O
un	O
B	B-LIVB
.	I-LIVB
C	I-LIVB
.	I-LIVB
G	I-LIVB
.	O
buccal	B-ANAT
.	O

Réaction	O
du	O
côlon	B-ANAT
aux	O
étirements	B-PROC
répétés	O
.	O
Etude	B-PROC
in	I-PROC
vitro	I-PROC
chez	O
le	O
rat	B-LIVB
.	O
Déductions	O
sur	O
les	O
territoires	O
fonctionnels	O
du	O
côlon	B-ANAT
.	O

Activité	O
vagale	B-ANAT
sur	O
le	O
coeur	B-ANAT
extirpé	O
de	O
grenouille	B-LIVB
entièrement	O
ouvert	B-PROC
sous	O
tensions	B-PHEN
mécaniques	O
définies	O
.	O

Altérations	O
des	O
foetus	B-ANAT
et	O
des	O
placentas	B-ANAT
au	O
cours	O
de	O
la	O
grossesse	B-PHYS
chez	O
la	O
ratte	B-LIVB
blanche	I-LIVB
pancréatectomisée	B-PROC
.	O

Hémoglobine	B-CHEM
instable	I-CHEM
au	O
cours	O
d	O
'	O
une	O
anémie	B-DISO
hémolytique	I-DISO
à	O
inclusions	B-ANAT
érythrocytaires	I-ANAT
et	O
urines	B-DISO
noires	I-DISO
.	O
Hémoglobine	B-CHEM
trauvée	O
à	O
Lille	B-CHEM
,	O
analogue	O
à	O
l	O
'	O
hémoglobine	B-CHEM
Santa	I-CHEM
Ana	I-CHEM
beta	B-LIVB
88	O
(	O
F4	O
)	O
leucine	O
-	O
proline	O
.	O

Distribution	O
de	O
la	O
radioactivité	B-PHEN
chez	O
le	O
foetus	B-ANAT
de	O
rat	B-LIVB
après	O
injection	B-PROC
d	O
'	O
une	O
préparation	O
d	O
'	O
hormone	B-CHEM
thyréotrope	I-CHEM
triliée	O
.	O

Inversion	B-PROC
et	O
désinversion	O
de	O
l	O
'	O
étiléfrine	B-CHEM
et	O
de	O
l	O
'	O
adrénaline	B-CHEM
chez	O
le	O
chien	B-LIVB
et	O
chez	O
le	O
lapin	B-LIVB
.	O

Recherches	B-PROC
sur	O
l	O
'	O
absorption	B-PHYS
intestinale	I-PHYS
des	O
acides	B-CHEM
aminés	I-CHEM
chez	O
les	O
Céphalopodes	B-LIVB
:	O
absorption	B-PHEN
comparée	O
du	O
glycocolle	B-CHEM
,	O
de	O
la	O
L	B-CHEM
-	I-CHEM
méthionine	I-CHEM
et	O
de	O
la	O
L	B-CHEM
-	I-CHEM
histidine	I-CHEM
par	O
l	O
'	O
intestine	B-ANAT
d	O
'	O
Eledone	B-LIVB
moschata	I-LIVB
Lamarck	O
.	O

Traitement	B-PROC
du	O
décollement	B-DISO
de	I-DISO
rétine	I-DISO
par	O
volet	B-ANAT
rapporté	O
:	O
essai	O
du	O
silastic	B-CHEM
armé	O
dacron	B-CHEM
.	O

Neocarzinostatin	B-CHEM
.	O
Une	O
approche	O
nouvelle	O
dans	O
la	O
chimiothérapie	B-PROC
des	O
leucémies	B-DISO
aiguës	I-DISO
.	O

Le	O
cycle	O
des	O
pentoses	B-CHEM
pendant	O
le	O
développement	O
du	O
coléoptère	B-LIVB
Tenebrio	B-LIVB
molitor	I-LIVB

Suppression	B-PROC
de	O
l	O
'	O
activité	B-PHYS
ribonucléasique	I-PHYS
par	O
la	O
pronase	B-CHEM
.	O

Les	O
"	B-DISO
patraqueries	I-DISO
"	I-DISO
digestives	I-DISO
.	O

Etude	B-PROC
de	O
l	O
'	O
orbite	B-ANAT
par	O
moyens	B-CHEM
de	I-CHEM
contraste	I-CHEM
.	O

Essais	B-PROC
de	O
vaccination	B-PROC
contre	O
l	O
'	O
hypodermose	B-DISO
bovine	B-LIVB
avec	O
un	O
vaccin	B-CHEM
contenant	O
une	O
collagénase	B-CHEM
brute	O
extraite	O
des	O
larves	B-LIVB
de	O
1er	O
stade	O
d	O
'	O
Hypoderma	B-LIVB
lineatum	I-LIVB
.	O

Diagnostic	B-PROC
différentiel	I-PROC
de	O
la	O
vascularite	B-DISO
nodulaire	I-DISO
.	O

Psychotoniques	O
et	O
doping	O
.	O

Action	O
du	O
pindolol	B-CHEM
sur	O
les	O
activités	B-PHYS
métaboliques	I-PHYS
de	O
l	O
'	O
adrénaline	B-CHEM
.	O

Détection	B-PROC
des	O
perturbations	B-DISO
du	I-DISO
métabolisme	I-DISO
des	O
sels	B-CHEM
biliares	I-CHEM
dans	O
les	O
syndromes	B-DISO
de	I-DISO
malabsorption	I-DISO

Intérêt	O
de	O
l	O
'	O
enregistrement	B-PROC
du	I-PROC
potentiel	I-PROC
hisien	I-PROC
avec	O
épreuves	O
pharmacodynamiques	O
dans	O
les	O
troubles	B-DISO
de	I-DISO
la	I-DISO
conduction	I-DISO
cardiaque	I-DISO

Dilatation	B-DISO
anévrysmale	B-DISO
des	O
veines	B-ANAT
pulmonaires	I-ANAT
par	O
insuffisance	B-DISO
mitrale	I-DISO
.	O
Un	O
type	O
rare	B-DISO
de	O
tumeur	B-DISO
médiastinale	I-DISO

Apport	O
de	O
la	O
neurochirurgie	O
au	O
traitement	B-PROC
de	O
l	O
'	O
hémorragie	B-DISO
intracérébrale	I-DISO

Les	O
schwannomes	B-DISO
dans	O
le	O
domaine	O
d	O
'	O
ORL	O
(	O
a	O
propos	O
nos	O
trois	O
cas	O
)	O

Le	O
vieillard	B-LIVB
et	O
l	O
'	O
institution	B-OBJC
hospitalière	I-OBJC
.	O

Les	O
glomérulonéphrites	B-DISO
aiguës	I-DISO
infectueuses	B-DISO
.	O

Conseil	O
de	O
L	O
'	O
Europe	B-GEOG
:	O
nouvelles	O
dispositions	B-PHYS
juridiques	O
pour	O
drogues	B-LIVB
et	O
trafiquants	O
.	O

Le	O
profil	O
social	O
,	O
économique	O
et	O
politique	O
du	O
Canada	B-GEOG
et	O
du	O
Québec	B-GEOG

Cancérologie	B-DISO
buccale	I-DISO
:	O
technique	O
d	O
'	O
examen	O
.	O
2	O
.	O

Traitement	B-PROC
des	O
varices	B-DISO
essentielles	O
des	O
membres	B-ANAT
inférieurs	I-ANAT
.	O

Les	O
stores	O
interieurs	O
a	O
bandes	O
verticales	O
orientables	O
ou	O
stores	O
"	O
californiens	B-GEOG
"	O
.	O

Absence	B-PHYS
d	I-PHYS
'	I-PHYS
activité	I-PHYS
électrique	I-PHYS
lors	O
de	O
l	O
'	O
épreuve	O
de	O
facilitation	O
garrot	O
-	O
hyperpnée	O
dans	O
la	O
tétanie	B-DISO
et	O
la	O
spasmophilie	B-DISO
:	O
incidence	O
sur	O
le	O
diagnostic	B-DISO
pratique	O
.	O

Etudes	B-PROC
sur	O
le	O
mécanisme	O
de	O
la	O
baisse	O
du	O
taux	B-DISO
de	I-DISO
complément	I-DISO
dans	O
le	O
liquide	B-ANAT
synovial	I-ANAT
au	O
cours	O
de	O
la	O
polyarthrite	B-DISO
rhumatoïde	I-DISO
.	O
3	O
.	O
Consommations	B-DISO
quantitatives	O
comparées	O
du	O
complément	B-PROC
total	I-PROC
et	O
de	O
ses	O
deux	O
premiers	O
composants	B-CHEM
(	O
C1	B-CHEM
et	O
C2	B-CHEM
)	O
au	O
cours	O
de	O
réactions	B-PHYS
antigène	I-PHYS
-	I-PHYS
anticorps	I-PHYS
.	O

Alexis	O
le	O
fistuleux	B-DISO
.	O

Hyperphosphatémie	B-DISO
et	O
hypocalcémie	B-DISO
secondaires	O
au	O
traitement	B-PROC
d	O
'	O
un	O
réticulosarcome	B-DISO

René	O
Moreau	O
(	O
1886	O
-	O
1973	O
)	O

Le	O
problème	O
épineux	O
du	O
langage	O
médical	O

Spondylodiscite	B-DISO
survenue	O
au	O
décours	O
d	O
'	O
une	O
septicémie	B-DISO
à	O
Candida	B-LIVB
albicans	I-LIVB

Relations	O
entre	O
certaines	O
variables	O
physiques	O
de	O
l	O
'	O
environnement	O
et	O
le	O
comportement	O
aléatoire	O
d	O
'	O
évitement	B-PHYS
chez	O
la	O
Souris	B-LIVB
.	O

De	O
l	O
'	O
évolution	B-PHYS
de	O
quelques	O
caractères	O
de	O
la	O
main	B-ANAT
chez	O
l	O
'	O
homme	B-LIVB
pendant	O
sa	O
croissance	B-PHYS
.	O

Fond	O
abiotique	O
de	O
l	O
'	O
apparition	B-PHYS
des	O
principaux	O
repères	O
temporels	O
de	O
l	O
'	O
être	B-LIVB
organisé	O
.	O

La	O
cystectomie	B-PROC
totale	I-PROC
.	O
Etude	B-PROC
de	O
73	O
opérations	B-PROC
pratiquées	O
entre	O
1964	O
et	O
1969	O
.	O

L	O
'	O
adiaspiromycose	B-DISO
pulmonaire	B-ANAT
chez	O
un	O
enfant	B-LIVB
de	I-LIVB
11	I-LIVB
ans	I-LIVB
.	O

Devenir	O
des	O
monoarthrites	B-DISO
rheumatismales	B-DISO
en	O
fonction	O
de	O
leur	O
type	O
histologique	O
.	O

L	O
'	O
hospitalisation	B-PROC
à	O
domicile	O
des	O
enfants	B-LIVB
.	O
L	O
'	O
expérience	B-PHYS
de	O
l	O
'	O
Assistance	O
Publique	O
de	O
Paris	B-GEOG
.	O

La	O
valeur	O
comparée	O
de	O
la	O
L	B-CHEM
-	I-CHEM
Dopa	I-CHEM
,	O
de	O
l	O
'	O
amantadie	B-CHEM
,	O
des	O
anticholinegiques	B-CHEM
et	O
de	O
leurs	O
associations	B-OBJC
dans	O
les	O
syndromes	B-DISO
parkinsoniens	I-DISO
.	O

Recherche	B-PROC
des	O
lysines	B-CHEM
et	O
ornithine	O
-	O
décarboxylases	O
et	O
de	O
l	O
'	O
arginine	B-CHEM
-	I-CHEM
dihydrolase	I-CHEM
chez	O
les	O
leptospires	B-LIVB
.	O

Les	O
possibilités	O
de	O
la	O
détermination	O
de	O
l	O
'	O
age	B-PHYS
foetal	I-PHYS
d	O
'	O
après	O
les	O
étapes	O
évolutives	O
(	O
transformations	O
)	O
des	O
os	B-ANAT
de	I-ANAT
la	I-ANAT
voute	I-ANAT
du	I-ANAT
crane	I-ANAT
.	O

Les	O
syndromes	B-DISO
de	O
l	O
'	O
artère	B-ANAT
cérébrale	I-ANAT
antérieure	I-ANAT
.	O

Albinisme	B-DISO
héréditaire	B-DISO
en	O
race	O
tachetée	O
rouge	O
de	O
Suisse	B-GEOG
.	O

Enquête	B-PROC
sur	O
les	O
causes	B-DISO
de	I-DISO
décès	I-DISO
dans	O
un	O
service	B-OBJC
d	O
'	O
insuffisants	B-DISO
respiratoires	I-DISO
chroniques	I-DISO
.	O

Les	O
angiodermites	O
nécrotiques	B-PHYS
.	O
Lésions	B-DISO
cutanées	I-DISO
nécrotiques	I-DISO
des	O
membres	B-ANAT
inférieurs	I-ANAT
d	O
'	O
origine	O
athéromateuse	B-DISO
(	O
à	O
propos	O
de	O
34	O
observations	B-PROC
.	O

Lésions	B-DISO
cutanées	I-DISO
et	O
agglutinines	B-CHEM
froides	I-CHEM
.	O

Normalisation	B-PROC
d	O
'	O
une	O
prothèse	B-DEVI
de	O
toute	O
l	O
'	O
extrémité	O
supérieure	O
du	O
fémur	B-ANAT
.	O

Hemolyse	B-DISO
et	O
prothesses	B-DEVI
valvulaires	B-ANAT
.	O

Le	O
praticien	B-LIVB
et	O
la	O
prévention	B-PROC
de	O
la	O
prématurité	B-LIVB
.	O

Sédimentation	B-PHEN
du	O
sperme	B-ANAT
et	O
sex	O
-	O
ratio	O
chez	O
les	O
bovins	B-LIVB
.	O

Influence	O
de	O
la	O
position	O
du	O
membre	B-ANAT
supérieur	I-ANAT
sur	O
l	O
'	O
excitabilité	B-DISO
de	O
l	O
'	O
arc	B-ANAT
soléaire	I-ANAT
.	O

Colite	B-DISO
ulcéreuse	I-DISO
et	O
syndrome	B-DISO
de	I-DISO
Behcet	I-DISO
.	O
Intérêt	O
de	O
la	O
coloscopie	B-PROC
.	O

Le	O
niveau	B-DISO
scolaire	I-DISO
des	O
jeunes	B-LIVB
du	I-LIVB
contingent	I-LIVB

L	O
'	O
activité	B-PHYS
électrique	I-PHYS
des	O
différents	O
lambeaux	O
ventriculaires	B-ANAT
du	I-ANAT
coeur	I-ANAT
de	O
l	O
'	O
escargot	B-LIVB
(	O
Helix	B-LIVB
pomatia	I-LIVB
)	O

Le	O
phlegmon	B-DISO
des	O
gaines	B-ANAT

La	O
maladie	B-DISO
de	I-DISO
Behcet	I-DISO
(	O
11	O
cas	O
)	O
et	O
ses	O
manifestations	B-DISO
neurologiques	I-DISO
(	O
3	O
cas	O
)	O

Différences	O
de	O
la	O
composition	B-PHYS
corporelle	I-PHYS
en	O
cas	O
de	O
myasthénie	B-DISO
et	O
d	O
'	O
astrophie	B-DISO
neurogène	I-DISO
.	O

Les	O
micromoteurs	O
et	O
le	O
choix	O
des	O
instruments	B-DEVI
rotatifs	O
.	O

Hérédité	B-PHYS
liée	O
au	O
chromosome	B-ANAT
x	I-ANAT
avec	O
pseudo	O
-	O
dominance	O
.	O

Quelques	O
complications	B-DISO
de	O
la	O
chirurgie	B-PROC
de	O
la	O
trachée	B-ANAT
.	O

Mise	O
en	O
évidence	O
d	O
'	O
un	O
"	O
recrutement	O
glomérulaire	B-ANAT
"	I-ANAT
dans	I-ANAT
le	I-ANAT
rein	I-ANAT
des	O
Téléostéens	O
d	O
'	O
après	O
la	O
mesure	B-PROC
du	O
Tm	O
glucose	B-CHEM
.	O

Etude	B-PROC
immunologique	O
des	O
hétérogreffes	B-PROC
chez	O
les	O
annélides	B-LIVB
oligochètes	B-LIVB
.	O

Un	O
cas	O
de	O
tumeur	B-DISO
intraventriculaire	I-DISO
cliniquement	O
asymptomatique	B-DISO
au	O
cours	O
d	O
'	O
une	O
sclérose	B-DISO
tubéreuse	I-DISO
de	I-DISO
Bourneville	I-DISO
.	O

Localisation	O
de	O
la	O
levane	B-CHEM
-	I-CHEM
sucrase	I-CHEM
d	O
'	O
Aerobacter	B-LIVB
levanicum	O
.	O

Incidence	O
de	O
l	O
'	O
intoxication	B-DISO
alcoolique	I-DISO
sur	O
la	O
teneur	B-CHEM
en	O
acide	B-CHEM
gamma	I-CHEM
-	I-CHEM
aminobutyrique	I-CHEM
du	O
cerveau	B-ANAT
de	O
la	O
souris	B-LIVB
.	O

Intéraction	B-PHYS
stimulante	O
entre	O
le	O
virus	B-LIVB
du	I-LIVB
sarcome	I-LIVB
murin	I-LIVB
(	O
V	B-LIVB
.	I-LIVB
M	I-LIVB
.	I-LIVB
S	I-LIVB
.	O
)	O
et	O
le	O
virus	B-LIVB
de	I-LIVB
l	I-LIVB
'	I-LIVB
hépatite	I-LIVB
murine	I-LIVB
(	O
V	B-LIVB
.	I-LIVB
H	I-LIVB
.	I-LIVB
M	I-LIVB
.	O
)	O

Le	O
roulement	B-DISO
présystolique	I-DISO
du	O
rétrécissement	B-DISO
mitral	I-DISO
étudié	B-PROC
par	O
le	O
micromanomètre	O
.	O

Présence	O
de	O
structures	B-ANAT
grillagées	O
dans	O
la	O
bronchiole	B-ANAT
de	O
la	O
souris	B-LIVB
après	O
stimulation	B-PROC
par	O
la	O
pilocarpine	B-CHEM
.	O

Effets	O
des	O
lésions	B-DISO
épileptogènes	B-DISO
chroniques	B-DISO
occipitales	B-ANAT
(	O
cobalt	O
-	O
alumine	O
)	O
,	O
chez	O
le	O
Papio	B-LIVB
papio	I-LIVB
.	O

Sur	O
la	O
séparation	B-PROC
des	O
acides	B-CHEM
chlorogéniques	I-CHEM
du	O
Café	B-OBJC
vert	O
:	O
Coffea	B-OBJC
robusta	I-OBJC
Lind	O
.	O

Etude	B-PROC
histochimique	O
et	O
histologique	O
de	O
la	O
névroglie	B-ANAT
du	O
cerveau	B-ANAT
.	O
Description	O
des	O
prolongements	O
épineux	O
de	O
la	O
névroglie	B-ANAT
et	O
des	O
boutons	B-ANAT
terminaux	I-ANAT
et	O
leur	O
participation	O
dans	O
l	O
'	O
influx	B-PHYS
nerveux	I-PHYS
.	O

Rhabdomyosarcome	B-DISO
primitif	O
de	O
la	O
valve	B-ANAT
mitrale	I-ANAT
traité	B-PROC
chirurgicalement	B-PROC
par	O
ablation	B-PROC
et	O
remplacement	B-PROC
par	I-PROC
une	I-PROC
valve	I-PROC
de	I-PROC
Starr	I-PROC
.	O

Sur	O
l	O
'	O
existence	O
d	O
'	O
une	O
substance	B-OBJC
diffusible	B-PHEN
exerçant	O
un	O
effet	O
antiérythrocytaire	B-CHEM
,	O
chez	O
les	O
embryons	B-ANAT
de	O
l	O
'	O
amphibien	B-LIVB
Pleurodeles	B-LIVB
waltlii	I-LIVB
homozygotes	B-PHYS
pour	O
le	O
facteur	O
ac	O
.	O
Résultats	B-PHEN
d	O
'	O
expériences	B-PROC
de	O
parabiose	B-PROC
et	O
de	O
télobiose	O
.	O

Association	O
chez	O
un	O
même	O
malade	B-LIVB
d	O
'	O
une	O
neurophacomatose	B-DISO
de	I-DISO
Recklinghausen	I-DISO
et	O
d	O
'	O
une	O
myotonie	B-DISO
de	I-DISO
Steinert	I-DISO
.	O

Transplantation	B-PROC
cardiaque	I-PROC
pour	O
fibrose	B-DISO
myocardique	I-DISO
et	O
polyvalvulopathie	O
.	O

Etude	B-PROC
ultrastructurale	B-ANAT
des	O
altérations	O
nucléaires	B-ANAT
et	O
nucléolaires	B-ANAT
provoquées	B-PHEN
par	O
la	O
ribonucléase	B-CHEM
dans	O
des	O
fibroblastes	B-ANAT
de	O
Poulet	B-LIVB
cultivés	O
in	B-PROC
vitro	I-PROC
.	O

Action	O
de	O
la	O
réserpine	B-CHEM
chez	O
le	O
papio	B-LIVB
papio	I-LIVB
photosensible	O
:	O
modifications	B-DISO
comportementales	I-DISO
et	O
électroencéphalographiques	B-PROC
.	O

Etude	B-PROC
des	O
débits	B-PHEN
périphériques	O
et	O
des	O
pressions	B-PHEN
des	O
membres	B-ANAT
inférieurs	I-ANAT
au	O
décours	O
de	O
la	O
chirurgie	O
artéille	B-ANAT
restauratrice	O
.	O

Les	O
nuisances	O
dues	O
aux	O
radiations	B-PHEN
ionisantes	I-PHEN
.	O

L	O
'	O
encoprésie	B-DISO
chez	O
l	O
'	O
enfant	B-LIVB
.	O
Conduite	O
à	O
tenir	O
.	O

Hyperthyroïdie	B-DISO
paranéoplasique	B-CHEM
au	O
cours	O
d	O
'	O
un	O
lymphosarcome	B-DISO
.	O

Angiome	B-DISO
du	O
nourrisson	B-LIVB
:	O
effet	O
favorable	O
de	O
l	O
'	O
hydrocortisone	B-CHEM
intraveineuse	O
.	O

Place	O
de	O
la	O
duodénographie	B-PROC
hypotonique	I-PROC
dans	O
le	O
diagnostic	B-DISO
des	O
affections	B-DISO
du	O
pancréas	B-ANAT
exocrine	I-ANAT
.	O

Résultats	B-PHEN
de	O
l	O
'	O
utilisation	O
d	O
'	O
un	O
nouveau	O
vaso	B-CHEM
-	I-CHEM
dilatateur	I-CHEM
(	O
E	O
.	O
U4200	O
)	O
en	O
pathologie	O
neuro	O
-	O
chirurgicale	O
(	O
à	O
propos	O
de	O
30	O
observations	B-PROC
)	O

L	O
'	O
origine	B-PHEN
de	I-PHEN
la	I-PHEN
vie	I-PHEN
.	O
II	O
.	O
Eternité	O
,	O
hasard	O
ou	O
création	O
.	O

Les	O
anomalies	B-DISO
héréditaires	I-DISO
des	O
enzymes	B-CHEM
digestives	I-CHEM
.	O

Enquête	O
anatomopathologique	O
sur	O
les	O
têtes	B-ANAT
fémorales	I-ANAT
prélevées	O
lors	O
des	O
arthroplasties	B-PROC
de	I-PROC
hanches	I-PROC
.	O

La	O
nutrition	B-PHYS
pendant	O
la	O
grossesse	B-PHYS
et	O
l	O
'	O
allaitement	B-PHYS
.	O

Les	O
urgences	B-PROC
en	O
neurochirurgie	O
.	O

Les	O
jeunes	B-LIVB
et	O
la	O
politique	O
.	O

Analyse	B-PROC
de	O
52	O
cas	O
de	O
tumeurs	B-DISO
de	I-DISO
la	I-DISO
moëlle	I-DISO
épinière	I-DISO
.	O

Réponse	O
hypertensive	B-DISO
à	O
la	O
thétrahydroaminacrine	O
.	O

Evolution	O
actuelle	O
de	O
la	O
parodontologie	O
.	O

Pharmacodynamie	B-PHEN
des	O
anesthésiques	B-CHEM
locaux	I-CHEM
du	O
chirurgien	B-LIVB
-	I-LIVB
dentiste	I-LIVB
.	O

Etude	B-PROC
des	O
fonctions	O
stomato	O
-	O
sensorielles	O
chez	O
les	O
porteurs	B-DISO
de	I-DISO
prothèses	I-DISO
.	O

Succion	B-DISO
du	I-DISO
pouce	I-DISO
et	O
orthodontie	B-PROC
.	O

Psoriasis	B-DISO
buccal	I-DISO
.	O

Les	O
perforations	B-DISO
coliques	I-DISO
diverticulaires	B-DISO
.	O
A	O
propos	O
de	O
35	O
cas	O
.	O

Les	O
implants	O
-	O
aiguilles	O
de	O
Scialom	O
.	O

Les	O
stéroïdes	B-CHEM
dans	O
le	O
traitement	B-PROC
des	O
aphtes	B-DISO
.	O

La	O
stimulation	B-PROC
vestibulaire	B-ANAT
adéquate	O
.	O
Son	O
utilisation	O
pour	O
la	O
mesure	O
du	O
seuil	O
du	O
nystagmus	B-DISO
d	O
'	O
accélération	B-PHEN
giratoire	O
.	O

Abolition	B-DISO
unilatérale	O
du	O
réflexe	B-ANAT
photomoteur	O
,	O
séquelle	B-DISO
d	O
'	O
un	O
zona	B-DISO
ophtalmique	I-DISO
.	O

Transplantation	B-PROC
orthotopique	I-PROC
du	I-PROC
foie	I-PROC
chez	O
le	O
chien	B-LIVB
.	O

Retentissement	O
métabolique	B-PHYS
et	O
hémodynamique	B-PHYS
du	O
diabete	B-DISO
sur	O
le	O
myocarde	B-ANAT
.	O

La	O
greffe	B-PROC
cutanée	I-PROC
dans	O
le	O
traitement	B-PROC
de	O
certaines	O
épistaxis	B-DISO
récidivantes	B-PHEN
.	O

Etude	B-PROC
sialographique	B-PROC
d	O
'	O
un	O
pseudo	B-DISO
-	I-DISO
kyste	I-DISO
traumatique	B-DISO
de	O
la	O
parotide	B-ANAT
.	O

Etude	B-PROC
immunochimique	O
et	O
électrophorétique	B-PROC
de	O
la	O
conidiation	O
de	O
Neurospora	B-LIVB
crassa	I-LIVB
.	O

Intérêt	O
du	O
blocage	B-DISO
des	O
récepteurs	B-CHEM
alpha	O
et	O
béta	O
sympathiques	O
au	O
cours	O
du	O
traitement	B-PROC
chirurgical	I-PROC
du	O
phéochromocytome	B-DISO
.	O

Fixation	B-PROC
tissulaire	I-PROC
de	O
la	O
quinidine	B-CHEM
.	O

Traumatismes	B-DISO
de	O
l	O
'	O
iris	B-ANAT
,	O
du	O
corps	B-ANAT
ciliaire	I-ANAT
et	O
de	O
la	O
choroïde	B-ANAT
.	O

A	O
propos	O
de	O
la	O
personnalite	B-PHYS
du	O
nevrotique	B-DISO
.	O

Individualisation	O
de	O
phénomènes	B-PHEN
divers	O
et	O
indépendants	O
parmi	O
les	O
variations	O
lentes	B-PHYS
de	I-PHYS
potentiels	I-PHYS
.	O
(	O
Variations	B-PHYS
contingentes	I-PHYS
négatives	I-PHYS
)	O

Maladie	B-DISO
de	I-DISO
Kaposi	I-DISO
,	O
en	O
nodule	B-DISO
solitaire	I-DISO
d	O
'	O
un	O
bras	B-ANAT
avec	O
adénopathie	B-DISO
satellite	O
,	O
chez	O
un	O
garçonnet	B-LIVB
de	I-LIVB
5	I-LIVB
ans	I-LIVB
.	O

Retour	B-DISO
veineux	I-DISO
pulmonaire	I-DISO
anormal	I-DISO
total	I-DISO
dans	O
le	O
sinus	B-ANAT
coronaire	I-ANAT
:	O
à	O
propos	O
d	O
'	O
une	O
observation	B-PROC
anatomo	O
-	O
clinique	O
chez	O
un	O
nourrisson	B-LIVB
de	O
8	O
mois	O
.	O

Etude	B-PROC
d	O
'	O
un	O
cas	O
de	O
xanthomatose	B-DISO
hypercholesterolemique	B-DISO
familiale	I-DISO
,	O
forme	B-DISO
pseudo	I-DISO
-	I-DISO
tumorale	I-DISO
avec	O
hyperalphalipoprotéinemie	B-DISO
.	O

Considérations	B-DISO
anatomo	O
-	O
cliniques	O
dans	O
l	O
'	O
anophtalmie	B-DISO
.	O

Deux	O
cas	O
de	O
mégalérythème	B-DISO
infectieux	B-DISO
épidémique	B-PHEN
d	O
'	O
origine	B-DISO
virale	I-DISO
vraisemblable	I-DISO
(	O
arbovirose	B-LIVB
à	I-LIVB
Tahyna	I-LIVB
)	O

Données	O
de	O
l	O
'	O
étude	B-PROC
du	O
métabolisme	B-PHYS
calcique	I-PHYS
dans	O
divers	O
cas	O
d	O
'	O
hyperparathyroïde	B-DISO
de	O
lithiase	B-DISO
et	O
de	O
néphrocalcinose	B-DISO
.	O

Intérêt	O
de	O
la	O
ponction	O
-	O
lavage	O
de	O
l	O
'	O
abdomen	B-ANAT
en	O
traumatologie	O
.	O

Bléomycine	B-CHEM
et	O
ses	O
phénomènes	B-PHEN
cutanés	B-ANAT
.	O

Prévention	B-PROC
des	O
adhérences	B-DISO
péritonéales	I-DISO
par	O
emploi	B-PROC
du	O
mélange	B-CHEM
hydrocortiancyl	B-CHEM
(	O
125	O
mg	O
)	O
tifomycine	O
(	O
suspension	B-CHEM
chirurgicale	B-PROC
,	O
1	O
g	O
)	O
en	O
intra	O
-	O
abdominal	O
.	O

Les	O
tumeurs	B-DISO
des	O
hémisphères	B-ANAT
cérébraux	I-ANAT
chez	O
l	O
'	O
enfant	B-LIVB
.	O

Les	O
ruptures	B-DISO
du	I-DISO
tendon	I-DISO
d	I-DISO
'	I-DISO
Achille	I-DISO
.	O

Activité	O
du	O
centre	O
anti	O
-	O
poisons	O
de	O
Lyon	O
1969	O
.	O
Répartition	O
des	O
intoxications	B-DISO
professionnelles	O
.	O

Enseignement	B-PROC
et	O
formation	O
psychiatriques	O
.	O

Sur	O
un	O
cas	O
d	O
'	O
intoxication	B-DISO
volontaire	I-DISO
nivaquinique	B-CHEM
.	O

L	O
'	O
apport	O
de	O
l	O
'	O
ophtalmologie	O
au	O
diagnostic	B-PROC
des	O
affections	B-DISO
carotidiennes	I-DISO
.	O

Fréquence	O
de	O
E	B-LIVB
,	I-LIVB
multilocularis	I-LIVB
chez	O
le	O
renard	B-LIVB
commun	O
(	O
Vulpes	B-LIVB
vulpes	I-LIVB
)	O
dans	O
le	O
secteur	O
nord	O
-	O
est	O
de	O
la	O
France	B-GEOG
.	O

Nouveau	O
système	B-DEVI
polymorphe	O
non	O
-	O
robertsonien	O
chez	O
des	O
"	O
Leggadas	O
"	O
(	O
Mus	B-LIVB
sp	I-LIVB
.	O
)	O
de	O
république	O
Centrafricaine	O
.	O

Le	O
traitement	B-PROC
chirurgical	I-PROC
du	O
strabisme	B-DISO
divergent	I-DISO
.	O

Corrélations	O
végétatives	B-ANAT
et	O
métaboliques	B-PHYS
des	O
activités	O
locomotrices	O
spontanées	O
chez	O
le	O
lapin	B-LIVB
curarise	O
.	O

Aplasie	B-DISO
thymo	O
-	O
lymphocytaire	O
du	O
jeune	B-LIVB
enfant	I-LIVB
.	O

Effets	O
de	O
l	O
'	O
alfatésine	B-CHEM
sur	O
l	O
'	O
état	B-DISO
de	I-DISO
mal	I-DISO
épileptique	I-DISO
.	O
Rapport	O
préliminaire	O
.	O

Evolution	B-DISO
sur	O
trois	O
ans	O
d	O
'	O
une	O
tumeur	B-DISO
de	I-DISO
Grawitz	I-DISO
,	O
sans	O
modification	B-PROC
urographique	B-PROC
.	O

Bilan	O
d	O
'	O
une	O
experience	O
en	O
externat	O
medico	O
-	O
pedagogique	O
.	O

Médecine	O
du	O
Travail	O
et	O
médecins	B-LIVB
du	O
Travail	O
.	O

Etude	B-PROC
de	O
l	O
'	O
activité	O
électrique	B-PHEN
de	O
la	O
musculature	B-ANAT
lisse	I-ANAT
de	O
l	O
'	O
estomac	B-ANAT
(	O
réseau	B-ANAT
)	O
chez	O
les	O
petits	O
ruminants	B-LIVB
.	O
Action	O
de	O
la	O
stimulation	B-PROC
vagale	I-PROC
.	O

La	O
résection	B-PROC
dans	O
le	O
traitement	B-PROC
des	O
tumeurs	B-DISO
des	I-DISO
os	I-DISO
.	O

Traitement	B-PROC
chirurgical	I-PROC
de	O
l	O
'	O
avant	B-ANAT
-	I-ANAT
pied	I-ANAT
rhumatoïde	B-DISO
.	O

Le	O
rôle	O
du	O
médecin	B-LIVB
du	O
travail	O
d	O
'	O
un	O
service	O
autonome	O
dans	O
le	O
comité	O
d	O
'	O
hygiène	O
et	O
de	O
sécurité	O
.	O

Les	O
indications	B-PHYS
opératoires	B-PROC
dans	O
les	O
volumineuses	O
mucocèles	B-DISO
du	O
sinus	B-ANAT
frontal	I-ANAT
.	O

Documents	O
sur	O
un	O
kyste	B-DISO
hydatique	I-DISO
de	I-DISO
la	I-DISO
rate	I-DISO
.	O

Essai	B-PROC
clinique	I-PROC
d	O
'	O
un	O
médicament	B-PROC
radioprotecteur	I-PROC
:	O
la	O
géranyl	B-CHEM
-	I-CHEM
hydroquinone	I-CHEM
au	O
cours	O
de	O
traitements	B-PROC
radiothérapiques	I-PROC
.	O

Paludisme	B-DISO
et	O
grossesse	B-PHYS
.	O

Etude	B-PROC
autoradiographique	B-PROC
de	O
la	O
synthèse	B-PHYS
des	I-PHYS
ADN	I-PHYS
,	I-PHYS
ARN	I-PHYS
et	I-PHYS
protéines	I-PHYS
dans	O
l	O
'	O
oesophage	B-ANAT
embryonnaire	B-ANAT
de	O
souris	B-LIVB
à	O
l	O
'	O
aide	O
de	O
l	O
'	O
actinomycine	B-CHEM
D	I-CHEM
.	O

Syndrome	B-DISO
de	I-DISO
MacLeod	I-DISO
:	O
à	O
propos	O
d	O
'	O
une	O
observation	B-PROC
.	O

Aspect	O
pharmaceutique	O
du	O
coût	O
des	O
médicaments	B-CHEM
.	O

Effets	O
exercés	O
par	O
différentes	O
fractions	O
d	O
'	O
histones	B-CHEM
sur	O
la	O
résistance	B-PHYS
naturelle	I-PHYS
des	O
souris	B-LIVB
à	O
l	O
'	O
infection	B-DISO
.	O

A	O
propos	O
du	O
refus	O
de	O
fréquentation	O
scolaire	B-OBJC
dans	O
le	O
cas	O
d	O
'	O
une	O
adolescente	B-LIVB
à	O
manifestations	B-DISO
hystéro	I-DISO
-	I-DISO
phobiques	I-DISO
.	O

Efficience	O
des	O
méthodes	B-PROC
bactériologiques	I-PROC
ulilisées	O
dans	O
le	O
diagnostic	B-DISO
de	O
la	O
leptospirose	B-DISO
humaine	B-LIVB
,	O
au	O
cours	O
d	O
'	O
un	O
épidémique	B-PHEN
.	O

Les	O
germes	O
du	O
groupe	O
Arizona	B-LIVB
dans	O
l	O
'	O
étiologie	O
des	O
troubles	B-DISO
entériques	I-DISO
.	O

Présentation	O
d	O
'	O
un	O
dossier	O
médical	O
pour	O
en	O
service	B-OBJC
de	I-OBJC
soins	I-OBJC
intensifs	I-OBJC
.	O

Essai	B-PROC
clinique	I-PROC
de	O
la	O
mesoridazine	B-CHEM
(	O
TPS	O
-	O
23	O
)	O
chez	O
des	O
patients	B-LIVB
psychotiques	B-DISO
.	O

Association	O
radio	O
-	O
chirurgicale	O
dans	O
le	O
cancer	B-DISO
du	I-DISO
rectum	I-DISO
.	O

Etude	B-PROC
des	O
effets	O
subjectifs	O
de	O
l	O
'	O
amphetamine	B-CHEM
chez	O
l	O
'	O
homme	B-LIVB
en	O
fonction	O
de	O
la	O
personalité	B-PHYS
.	O

Effets	B-PHYS
métaboliques	I-PHYS
de	O
l	O
'	O
insuline	B-CHEM
injectée	B-PROC
au	O
foetus	B-ANAT
de	O
rat	B-LIVB
à	O
divers	O
stades	O
de	O
la	O
gestation	B-PHYS
.	O

Interprétation	B-PROC
des	O
variations	O
du	O
volume	B-PROC
expiratoire	I-PROC
maximal	I-PROC
seconde	I-PROC
(	O
VEMS	B-PROC
)	O
après	O
aérosol	B-OBJC
d	O
'	O
acétylcholine	B-CHEM
et	O
d	O
'	O
allergènes	B-CHEM
chez	O
l	O
'	O
asthmatique	B-DISO
jeune	B-LIVB
.	O

Transfert	O
transplacentaire	O
d	O
'	O
une	O
"	O
paraprotéine	B-CHEM
"	O
G	O
.	O

Les	O
syndromes	B-DISO
paranéoplasiques	I-DISO
du	O
carcinome	B-DISO
bronchique	I-DISO
.	O

Le	O
syndrome	B-DISO
de	I-DISO
Dubin	I-DISO
-	I-DISO
Johnson	I-DISO
.	O

L	O
'	O
importance	O
de	O
la	O
périarthrite	B-DISO
scapulo	O
-	O
humérale	O
,	O
comme	O
manifestation	O
précoce	O
de	O
la	O
polyarthrite	B-DISO
chronique	I-DISO
évolutive	I-DISO
.	O

Sur	O
l	O
'	O
interprétation	B-PROC
des	O
niches	O
bénignes	O
ou	O
malignes	B-DISO
de	O
la	O
petite	B-ANAT
courbure	I-ANAT
gastrique	I-ANAT
.	O

Parenté	B-LIVB
responsable	O

Kystes	B-DISO
hématoques	O
de	O
la	O
rate	B-ANAT
en	O
relation	O
avec	O
une	O
pancréatite	B-DISO
.	O

Evolution	O
des	O
structures	O
microsomiales	O
au	O
cours	O
de	O
l	O
'	O
hypertrophie	B-DISO
compensatrice	I-DISO
du	O
foie	B-ANAT
chez	O
le	O
rat	B-LIVB
.	O

Réflexions	O
à	O
propos	O
de	O
175	O
radiomanométries	O
per	O
-	O
opératoires	O
pratiquées	O
parmi	O
418	O
interventions	B-PROC
biliaires	I-PROC
.	O

Le	O
cancer	B-DISO
secondaire	I-DISO
du	I-DISO
poumon	I-DISO
.	O

Thérapie	B-PROC
des	O
bronchopathies	B-DISO
au	O
cours	O
de	O
tuberculose	B-DISO
pulmonaire	I-DISO
,	O
sous	O
le	O
point	O
de	O
vue	O
de	O
l	O
'	O
examen	B-PROC
de	O
la	O
fonction	B-PHYS
respiratoire	I-PHYS
.	O

Essai	O
d	O
'	O
interprétation	O
des	O
relevés	O
individuels	O
d	O
'	O
accidents	B-DISO
dans	O
une	O
usine	B-OBJC
sidérurgique	O
.	O

Etude	B-PROC
sur	O
les	O
facteurs	O
de	O
non	O
retour	O
au	O
travail	O
des	O
cardiaques	B-DISO
opérés	B-PROC

Embryologie	O
de	O
la	O
peau	B-ANAT
.	O

Interprétation	B-PROC
des	I-PROC
résultats	I-PROC
de	O
la	O
méniscographie	O
gazeuse	B-CHEM
.	O

Le	O
diabete	B-DISO
de	O
l	O
'	O
enfant	B-LIVB
et	O
de	O
l	O
'	O
adolescent	B-LIVB
.	O
Etat	O
actuel	O
de	O
l	O
'	O
organisation	O
medicale	O
,	O
des	O
problemes	B-DISO
medico	O
-	O
sociaux	O
,	O
du	O
depistage	B-PROC
et	O
de	O
la	O
prophylaxie	B-PROC
.	O

Les	O
fractures	B-DISO
méconnues	I-DISO
des	I-DISO
sinus	I-DISO
de	I-DISO
la	I-DISO
face	I-DISO
.	O

Etude	B-PROC
des	O
effets	O
de	O
la	O
thioridazine	B-CHEM
sur	O
le	O
conditionnement	B-PHYS
electroencephalographique	B-PROC
son	O
-	O
lumiere	O
d	O
'	O
un	O
groupe	O
d	O
'	O
enfants	B-DISO
caracteriels	I-DISO
.	O

L	O
'	O
apport	O
bénéfique	O
de	O
la	O
radiologie	B-PROC
.	O

Un	O
cas	O
de	O
syndrome	B-DISO
de	I-DISO
Sheehan	I-DISO
avec	O
myotonie	B-DISO
.	O

Les	O
anévrismes	B-DISO
de	I-DISO
l	I-DISO
'	I-DISO
artère	I-DISO
splénique	I-DISO
.	O
A	O
propos	O
de	O
2	O
cas	O
reconnus	O
et	O
traités	B-PROC
avant	O
rupture	B-DISO
.	O

Rôle	O
des	O
conseillers	B-LIVB
médicaux	O
dans	O
l	O
'	O
Association	O
française	B-GEOG
des	O
Hémophiles	B-LIVB
.	O

Cinétique	B-PHEN
des	O
cellules	B-ANAT
granuleuses	I-ANAT
.	O

Angiographie	B-PROC
en	O
couleur	B-CHEM
par	O
la	O
méthode	O
de	O
soustraction	O
.	O

Les	O
radiocancers	B-DISO
en	O
O	O
.	O
R	O
.	O
L	O
.	O
et	O
en	O
pathologie	O
cervicale	B-ANAT
.	O

Apport	O
de	O
l	O
'	O
électronystagmographie	B-PROC
(	O
E	B-PROC
.	I-PROC
N	I-PROC
.	I-PROC
G	I-PROC
.	O
)	O
dans	O
l	O
'	O
expertise	O
médico	O
-	O
légale	O
des	O
traumatismes	B-DISO
crâniens	I-DISO
.	O

L	O
'	O
impédance	O
acoustique	B-PHEN
des	O
prothèses	B-DEVI
de	I-DEVI
l	I-DEVI
'	I-DEVI
oreille	I-DEVI
moyenne	I-DEVI
.	O

Dosage	O
automatique	O
continu	O
de	O
l	O
'	O
acide	B-CHEM
pyruvique	I-CHEM
:	O
Description	O
de	O
la	O
méthode	O
et	O
application	B-PROC
aux	O
dosages	O
simultanés	O
de	O
la	O
pyruvicémie	B-PROC
,	O
de	O
la	O
lactacidémie	B-PROC
et	O
de	O
la	O
glycémie	B-CHEM
.	O

Effets	O
du	O
bruit	B-PHEN
sur	O
le	O
potentiel	B-PHYS
visuel	I-PHYS
évoqué	I-PHYS
durant	O
l	O
'	O
attention	B-PHYS
.	O

Etude	B-PROC
des	O
effets	O
de	O
la	O
benziodarone	B-CHEM
chez	O
cent	O
goutteux	B-DISO
en	O
cure	O
de	O
diurèse	B-PHYS
:	O
effets	O
sur	O
l	O
'	O
acide	B-CHEM
urique	I-CHEM
et	O
l	O
'	O
acide	B-CHEM
oxalique	I-CHEM
.	O

Exploration	B-PROC
hémodynamique	B-PHYS
dans	O
la	O
pré	B-DISO
-	I-DISO
éclampsie	I-DISO
et	O
l	O
'	O
éclampsie	B-DISO
.	O
Implication	O
thérapeutique	O
.	O

Les	O
bêta	B-CHEM
-	I-CHEM
bloquants	I-CHEM
dans	O
les	O
troubles	B-DISO
du	I-DISO
rythme	I-DISO
cardiaque	I-DISO
,	O
l	O
'	O
anxiété	B-PHYS
et	O
le	O
stress	B-DISO
.	O

Le	O
pied	B-ANAT
en	O
médecine	O
légale	O
.	O

Spécificité	O
des	O
substances	B-OBJC
antitumorales	B-CHEM
.	O

Fractionnement	O
d	O
'	O
un	O
homogénat	O
de	O
nerf	B-ANAT
sciatique	I-ANAT
de	O
souris	B-LIVB
normale	I-LIVB
,	I-LIVB
Trembler	I-LIVB
et	I-LIVB
quaking	I-LIVB
sur	O
gradient	O
continu	O
de	O
saccharose	B-CHEM
.	O

Intérêt	O
de	O
la	O
tomodensitométrie	B-PROC
dans	O
les	O
hépatocarcinomes	B-DISO
.	O

Un	O
nouveau	O
cas	O
d	O
'	O
association	O
aniridie	O
-	O
néphroblastome	O
chez	O
un	O
enfant	B-LIVB
hémophile	B-DISO
.	O

Possibilités	O
nouvelles	O
d	O
'	O
étude	B-PROC
de	O
l	O
'	O
axe	B-ANAT
hypothalamo	I-ANAT
-	I-ANAT
hypophyso	I-ANAT
-	I-ANAT
surrénalien	I-ANAT
et	O
applications	B-PROC
cliniques	O
.	O

Les	O
récepteurs	B-CHEM
alpha	O
-	O
adrénergiques	O
cardiaques	B-ANAT
.	O

Carcinome	B-DISO
hépatocellulaire	I-DISO
et	O
cirrhose	B-DISO
biliaire	I-DISO
primitive	I-DISO
:	O
une	O
nouvelle	O
observation	B-PROC
.	O

Diagnostic	B-PROC
microbiologique	B-PROC
des	O
épiglottites	B-DISO
.	O

Hyperparathyroïdies	B-DISO
primitives	I-DISO
.	O
Technique	O
d	O
'	O
examen	O
et	O
étapes	O
du	O
diagnostic	B-PROC
des	O
lésions	B-DISO
parathyroïdiennes	B-ANAT
.	O

L	O
'	O
insulinothérapie	O
en	O
1984	O
.	O

Etude	B-PROC
des	O
marqueurs	B-CHEM
de	O
l	O
'	O
HBV	B-DISO
et	O
des	O
populations	O
lymphocytaires	B-ANAT
chez	O
le	O
polytoxicomane	B-LIVB
asymptomatique	B-DISO
.	O

Diverticules	B-DISO
et	O
kystes	B-DISO
arachnoïdiens	I-DISO
rachidiens	I-DISO
intraduraux	I-DISO
.	O
6	O
observations	B-PROC
.	O

La	O
cholangiographie	B-PROC
rétrograde	I-PROC
endoscopique	I-PROC
après	O
chirurgie	B-PROC
biliaire	I-PROC
.	O

Bromocriptine	B-CHEM
et	O
réponse	O
d	O
'	O
hormone	B-CHEM
de	I-CHEM
croissance	I-CHEM
à	O
la	O
thyrolibérine	B-CHEM
chez	O
le	O
diabétique	B-DISO
insulino	I-DISO
-	I-DISO
dépendant	I-DISO
.	O

La	O
réfection	B-PROC
du	I-PROC
ligament	I-PROC
croisé	I-PROC
antérieur	I-PROC
par	O
plastie	O
activo	O
-	O
passive	O
du	O
pivot	O
central	O
et	O
des	O
points	O
d	O
'	O
angle	O
.	O

Etude	B-PROC
de	O
la	O
validité	O
du	O
dosage	B-PROC
radioimmunologique	I-PROC
de	O
la	O
prolactine	B-CHEM
sérique	B-ANAT
et	O
hypophysaire	B-ANAT
chez	O
le	O
rat	B-LIVB
mâle	B-PHYS
.	O
Action	O
de	O
la	O
bromocriptine	B-CHEM
et	O
de	O
la	O
thyréolibérine	B-CHEM
(	O
TRH	B-CHEM
)	O
.	O

Mezlocilline	B-CHEM
:	O
action	O
des	O
bêta	B-CHEM
-	I-CHEM
lactamases	I-CHEM
.	O

L	O
'	O
embolisation	B-DISO
de	O
l	O
'	O
artère	B-ANAT
maxillaire	I-ANAT
interne	I-ANAT
dans	O
les	O
épistaxis	B-DISO
essentielles	O
graves	O
.	O

Cedème	B-DISO
aigu	I-DISO
du	I-DISO
poumon	I-DISO
au	O
cours	O
de	O
l	O
'	O
éclampsie	B-DISO
.	O

Chondrodysplasie	B-DISO
ponctuée	I-DISO
et	O
intoxication	B-DISO
alcoolique	I-DISO
maternelle	B-LIVB
.	O
A	O
propos	O
de	O
7	O
observations	B-PROC
.	O

Coût	O
de	O
la	O
prise	B-PROC
en	I-PROC
charge	I-PROC
initiale	O
des	O
enfants	B-LIVB
de	I-LIVB
poids	I-LIVB
de	I-LIVB
naissance	I-LIVB
inférieur	I-LIVB
ou	I-LIVB
égal	I-LIVB
à	I-LIVB
1	I-LIVB
500	I-LIVB
g	I-LIVB
en	O
1981	O
.	O

Effets	O
comparés	O
sur	O
l	O
'	O
excrétion	B-PHYS
des	O
ions	B-CHEM
et	O
de	O
l	O
'	O
acide	B-CHEM
oxalique	I-CHEM
de	O
charges	O
orales	O
en	O
eaux	B-CHEM
de	O
compositions	B-PHEN
minérales	B-CHEM
différentes	O
.	O

A	O
propos	O
d	O
'	O
un	O
nouveau	O
cas	O
de	O
lipome	B-DISO
retroperitoneal	I-DISO
volumineux	O
(	O
10	O
,	O
800	O
kg	O
)	O
.	O

Un	O
pharmacien	B-LIVB
à	O
l	O
'	O
hôpital	B-OBJC
:	O
pour	O
quoi	O
faire	O
?	O

Retrouver	O
sa	O
forme	O
après	O
l	O
'	O
accouchement	B-PHYS
:	O
quelles	O
kinésithérapies	B-PROC
?	O

Appréciation	O
de	O
l	O
'	O
état	B-PHYS
nutritionnel	I-PHYS
.	O

La	O
médecine	O
scolaire	B-OBJC
.	O

Angéla	O
,	O
Paule	O
,	O
Colette	O
et	O
leur	O
co	B-DISO
xarthrose	I-DISO
.	O

La	O
tomographie	B-PROC
d	I-PROC
'	I-PROC
émission	I-PROC
dans	O
l	O
'	O
exploration	B-PROC
hépatique	I-PROC
.	O

L	O
'	O
altérité	O
dans	O
les	O
langages	O
psychopathologiques	O
.	O
Troisième	O
partie	O
:	O
le	O
sexe	B-PHYS
des	O
mots	O
.	O

Evolution	O
de	O
l	O
'	O
embolie	B-DISO
pulmonaire	I-DISO
.	O

Traitement	B-PROC
de	O
la	O
lésion	B-DISO
primaire	O
dans	O
les	O
cancers	B-DISO
de	I-DISO
la	I-DISO
langue	I-DISO
mobile	O
.	O
Expérience	O
de	O
l	O
'	O
institut	O
Curie	O
(	O
1959	O
-	O
1972	O
)	O
.	O

Traitement	B-PROC
par	O
un	O
immunosuppresseur	B-CHEM
(	O
azathioprine	B-CHEM
)	O
et	O
la	O
prednisolone	B-CHEM
du	O
syndrome	B-DISO
d	I-DISO
'	I-DISO
Adamantiadès	I-DISO
-	I-DISO
Behçet	I-DISO
.	O

Accidents	B-DISO
vasculaires	I-DISO
cérébraux	I-DISO
ischémiques	I-DISO
et	O
drépanocytose	B-DISO
hétérozygote	B-PHYS
.	O

Leucémies	B-DISO
aiguës	B-DISO
et	O
tumeurs	B-DISO
solides	I-DISO
dans	O
l	O
'	O
évolution	O
de	O
la	O
maladie	B-DISO
de	I-DISO
Hodgkin	I-DISO
.	O

Les	O
obturations	B-PROC
canalaires	I-PROC
avec	O
pätes	O
et	O
cönes	O
.	O
Liaison	O
entre	O
les	O
deux	O
matériaux	O
.	O

Les	O
récepteurs	B-CHEM
de	I-CHEM
l	I-CHEM
'	I-CHEM
insuline	I-CHEM
.	O

Robert	O
Debré	O
:	O
l	O
'	O
humanisme	O
et	O
les	O
académies	O
.	O

Insuffisance	B-DISO
gonadotrope	I-DISO
associée	O
à	O
l	O
'	O
hypoplasie	B-DISO
surrénale	I-DISO
congénitale	I-DISO
à	O
forme	O
cytomégalique	B-ANAT
.	O

Comparaison	O
du	O
transport	B-ANAT
hémato	I-ANAT
-	I-ANAT
encéphalique	I-ANAT
de	O
divers	O
acides	B-CHEM
aminés	I-CHEM
chez	O
le	O
rat	B-LIVB
5	O
,	O
12	O
et	O
12	O
jours	O
après	O
la	O
naissance	B-PHYS
.	O

Résultats	O
du	O
traitement	B-PROC
chirurgical	I-PROC
de	O
la	O
maladie	B-DISO
de	I-DISO
Basedow	I-DISO
.	O
A	O
propos	O
de	O
30	O
cas	O
.	O

Dissolution	O
de	O
lithiase	B-DISO
vésiculaire	I-DISO
après	O
6	O
mois	O
de	O
traitement	B-PROC
par	O
dose	O
journalière	O
unique	O
d	O
'	O
acide	B-CHEM
ursodésoxycholique	I-CHEM
.	O

Corrélations	O
anatomo	O
-	O
cliniques	O
après	O
traitement	B-PROC
des	O
phlébites	B-DISO
ilio	O
-	O
caves	O
avec	O
un	O
an	O
de	O
recul	O
.	O

Tumeur	B-DISO
du	I-DISO
nez	I-DISO
.	O
Cas	O
pour	O
diagnostic	B-PROC
.	O

La	O
biopsie	B-PROC
hépatique	I-PROC
trans	I-PROC
-	I-PROC
veineuse	I-PROC
par	I-PROC
voie	I-PROC
transjugulaire	I-PROC
.	O

L	O
'	O
infirmière	B-LIVB
au	O
coeur	O
de	O
la	O
relation	O
d	O
'	O
aide	O
:	O
rôle	O
et	O
fonctions	O
.	O

Christian	O
.	O

Les	O
enfants	B-LIVB
réfugiés	B-LIVB
du	O
sud	B-GEOG
-	I-GEOG
est	I-GEOG
asiatique	I-GEOG
:	O
problèmes	O
spécifiques	O
,	O
tuberculose	B-DISO
.	O

Extraction	B-PROC
non	O
opératoire	O
en	O
cas	O
de	O
lithiase	B-DISO
résiduelle	O
ouverte	O
de	O
la	O
voie	B-ANAT
biliaire	I-ANAT
principale	I-ANAT
.	O
Place	O
actuelle	O
de	O
la	O
technique	O
de	O
Burhenne	O
-	O
Mazariello	O
.	O

Apport	O
des	O
doubles	O
colorations	B-PROC
dans	O
la	O
cytochimie	O
des	O
leucoses	O
aiguës	B-DISO
.	O

Hémicolectomie	B-PROC
droite	I-PROC
avec	O
anastomose	B-PROC
colo	I-PROC
-	I-PROC
iléale	I-PROC
"	O
première	O
"	O
.	O
Modifications	O
apportées	O
par	O
les	O
procédés	O
de	O
suture	B-DEVI
mécanique	O
.	O

Le	O
système	B-ANAT
porte	I-ANAT
(	O
vena	B-ANAT
portae	I-ANAT
)	O
.	O
Embryologie	O
et	O
morphologie	O
.	O

Conséquences	O
métaboliques	B-PHYS
de	O
l	O
'	O
alcoolisme	B-DISO
chronique	I-DISO
.	O

Rôle	O
de	O
lépaisseur	O
des	O
greffons	B-CHEM
dans	O
l	O
'	O
autotransplantation	B-PROC
ostéocartilagineuse	O
du	O
genou	B-ANAT
chez	O
le	O
lapin	B-LIVB
.	O

Effets	O
hémodynamiques	O
et	O
coronariens	B-ANAT
du	O
dinitrate	B-CHEM
d	I-CHEM
'	I-CHEM
isosorbide	I-CHEM
injectable	B-PROC
chez	O
l	O
'	O
insuffisant	B-DISO
coronarien	I-DISO
.	O

Les	O
solutions	O
de	O
controle	O
de	O
qualité	O
pour	O
les	O
analyseurs	O
de	O
pH	B-PHEN
et	O
de	O
gaz	B-PROC
du	I-PROC
sang	I-PROC
.	O

Anévrysme	B-DISO
de	O
l	O
'	O
aorte	B-ANAT
abdominale	I-ANAT
sous	O
-	O
rénale	O
.	O
Cure	B-PROC
par	O
exclusion	O
et	O
pontage	B-PROC
axillo	O
-	O
bifémoral	O
.	O

Cirrhose	B-DISO
et	O
cryoglobulinémie	B-DISO
.	O
A	O
propos	O
d	O
'	O
un	O
cas	O
et	O
revue	O
de	O
la	O
littérature	O
.	O

L	O
'	O
association	O
de	O
tests	B-PHEN
cutanés	I-PHEN
positifs	I-PHEN
pour	I-PHEN
la	I-PHEN
poussière	I-PHEN
de	I-PHEN
maison	I-PHEN
et	I-PHEN
négatifs	I-PHEN
pour	O
Pteronyssinus	B-LIVB
correspond	O
-	O
elle	O
à	O
une	O
entité	O
clinique	O
particulière	O
?	O

Impact	O
de	O
la	O
pathologie	B-DISO
cervicale	I-DISO
sur	O
le	O
syndrome	B-DISO
vestibulaire	I-DISO
.	O

Embryome	B-DISO
malin	O
du	O
médiastin	B-ANAT
.	O
Une	O
observation	B-PROC
avec	O
métastase	B-DISO
pulmonaire	B-ANAT
.	O
Rémission	B-DISO
complète	O
après	O
chimiothérapie	B-PROC
.	O

Double	O
marquage	O
des	O
plaquettes	B-ANAT
par	O
51Cr	O
et	O
111In	O
.	O
Application	O
à	O
l	O
'	O
étude	B-PROC
simultanée	O
de	O
la	O
durée	O
de	O
vie	O
des	O
plaquettes	B-ANAT
autologues	O
et	O
homologues	O
.	O

Syndrome	B-DISO
d	I-DISO
'	I-DISO
effusion	I-DISO
uvéale	I-DISO
avec	O
multiples	O
points	O
de	O
fuite	O
en	O
angiofluorographie	O
-	O
maladie	B-DISO
de	I-DISO
Harada	I-DISO
?	O

Greffes	B-CHEM
et	O
plasties	B-PROC
sclérales	B-ANAT
.	O
Indications	O
et	O
traitement	B-PROC
.	O

Le	O
phénomène	B-DISO
de	I-DISO
Raynaud	I-DISO
.	O

Dermatologie	O
:	O
le	O
rounge	O
et	O
le	O
noir	O
.	O

L	O
'	O
artérite	B-DISO
des	O
membres	B-ANAT
inférieurs	I-ANAT
sous	O
l	O
'	O
angle	O
chirurgical	B-PROC
.	O
Quand	O
faut	O
-	O
il	O
opérer	B-PROC
?	O
Quelle	O
opération	B-PROC
faut	O
-	O
il	O
recommander	O
?	O

Syndrome	B-DISO
de	I-DISO
Peutz	I-DISO
-	I-DISO
Jeghers	I-DISO
.	O
A	O
propos	O
de	O
cinq	O
observations	B-PROC
.	O

Principales	O
causes	O
d	O
'	O
échec	O
des	O
rhinoplasties	B-PROC
.	O

Cinétique	B-PHEN
de	O
prolifération	B-PHYS
cellulaire	I-PHYS
des	O
tumeurs	B-DISO
.	O
Signification	O
de	O
la	O
période	O
pré	O
-	O
clinique	O
.	O

Une	O
complication	B-DISO
grave	O
de	O
l	O
'	O
opération	B-PROC
de	I-PROC
Nissen	I-PROC
:	O
le	O
dumping	B-DISO
-	I-DISO
syndrome	I-DISO
.	O
A	O
propos	O
de	O
4	O
observations	B-PROC
.	O

L	O
'	O
acidurie	B-DISO
méthylmalonique	I-DISO
sensible	O
à	O
la	O
vitamine	B-CHEM
B	I-CHEM
12	I-CHEM
.	O
A	O
propos	O
d	O
'	O
une	O
nouvelle	O
observation	B-PROC
.	O

Valeur	O
de	O
la	O
courbe	B-ANAT
d	I-ANAT
'	I-ANAT
occlusion	I-ANAT
selon	O
Wadsworth	O
en	O
prothèse	B-DEVI
complète	O
.	O

Bases	O
de	O
la	O
lutte	O
contre	O
les	O
arthropodes	B-LIVB
vecteurs	B-LIVB
:	O
II	O
-	O
Moyens	O
actuels	O
de	O
lutte	O
.	O

Sur	O
les	O
activités	O
orthosympathiques	O
chez	O
l	O
'	O
homme	B-LIVB
normal	O
.	O

Chronicité	B-DISO
:	O
chronicisation	O
ou	O
chronification	O
?	O
Ou	O
de	O
l	O
'	O
évolution	O
morbide	O
à	O
la	O
relation	B-PROC
thérapeutique	I-PROC
.	O

Ergotisme	B-DISO
.	O
Forme	O
mineure	O
par	O
association	B-CHEM
dihydroergotamine	B-CHEM
-	O
chlorhydrate	B-CHEM
de	I-CHEM
doxycycline	I-CHEM
,	O
étude	B-PROC
capillaroscopique	O
.	O

Etude	B-PROC
comparative	I-PROC
de	O
deux	O
conduites	O
cliniques	O
en	O
cas	O
de	O
rupture	B-DISO
prématurée	I-DISO
des	O
membranes	B-ANAT
à	O
terme	O
.	O
Expectative	O
versus	O
induction	B-PROC
du	I-PROC
travail	I-PROC
.	O

Déficit	B-DISO
partiel	I-DISO
en	I-DISO
properdine	I-DISO
révélé	O
par	O
une	O
septicémie	B-DISO
à	O
Neisseria	B-LIVB
meningitidis	I-LIVB
.	O

L	O
'	O
oxygénothérapie	B-PROC
de	O
longue	O
durée	O
.	O

Experience	O
acquise	O
dans	O
l	O
'	O
emploi	O
de	O
prothèses	B-DEVI
dentaires	I-DEVI
squelettées	O
en	O
alliage	B-CHEM
chrome	I-CHEM
-	I-CHEM
cobalt	I-CHEM

Indications	O
chirurgicales	B-PROC
de	O
l	O
'	O
incontinence	B-DISO
urinaire	I-DISO
féminine	B-LIVB
.	O

Le	O
contrôle	O
de	O
l	O
'	O
entourage	O
(	O
"	O
contact	O
tracing	O
"	O
)	O
a	O
été	O
négligé	O
dans	O
le	O
cas	O
des	O
infections	B-DISO
par	I-DISO
le	I-DISO
VIH	I-DISO
.	O
Les	O
résultats	O
de	O
l	O
'	O
étude	B-PROC
"	O
look	O
-	O
back	O
"	O
réalisée	O
en	O
Suisse	B-GEOG
.	O

La	O
protéine	B-CHEM
C	I-CHEM
réactive	I-CHEM
(	O
pCr	B-CHEM
)	O
dans	O
différentes	O
formes	O
cliniques	O
de	O
l	O
'	O
infection	B-DISO
ourlienne	I-DISO
.	O

Les	O
dysthymies	B-DISO
:	O
un	O
modèle	O
d	O
'	O
étude	O
des	O
liens	O
entre	O
trait	O
et	O
état	O
psychopathologique	O
?	O

Hyperparathyroïdie	B-DISO
et	O
parathyroïde	B-DISO
intrathyroïdienne	I-DISO
.	O
43	O
observations	B-PROC
.	O

Un	O
cas	O
de	O
rotule	B-DISO
double	I-DISO
luxée	I-DISO
.	O

Maladie	B-DISO
de	I-DISO
Marchiafava	I-DISO
-	I-DISO
Bignami	I-DISO
:	O
disconnexion	O
interhémisphérique	O
,	O
syndrome	B-DISO
de	I-DISO
Balint	I-DISO
,	O
évolution	O
spontanément	O
favorable	O
.	O

Diabète	B-DISO
sucré	I-DISO
et	O
athérosclérose	B-DISO
.	O
Physiopathologie	O
de	O
la	O
macroangiopathie	B-DISO
diabétique	I-DISO
.	O

Technique	B-PROC
immuno	I-PROC
-	I-PROC
enzymatique	I-PROC
(	O
E	B-PROC
.	I-PROC
L	I-PROC
.	I-PROC
I	I-PROC
.	I-PROC
S	I-PROC
.	I-PROC
A	I-PROC
.	O
)	O
appliquée	O
au	O
diagnostic	B-PROC
sérologique	B-PROC
des	O
candidoses	B-DISO
et	O
aspergilloses	B-DISO
humaines	B-LIVB
.	O
Résultats	O
préliminaires	O

Conception	B-PROC
des	I-PROC
prothèses	I-PROC
conjointes	I-PROC
et	O
protection	B-DISO
du	O
parodonte	B-ANAT
marginal	O
.	O

Quantification	O
de	O
l	O
'	O
ammoniac	B-CHEM
dans	O
des	O
échantillons	B-CHEM
de	O
contenu	O
de	O
rumen	B-ANAT
et	O
de	O
fermenteur	O
à	O
l	O
'	O
aide	O
d	O
'	O
une	O
électrode	B-DEVI
à	O
diffusion	O
gazeuse	O
.	O

Syndrome	B-DISO
de	O
retard	O
de	O
maturation	B-PHYS
de	O
la	O
succion	B-PHYS
-	O
déglutition	B-PHYS
.	O

Programme	O
pour	O
l	O
'	O
élaboration	O
et	O
l	O
'	O
archivage	O
des	O
images	O
.	O

Sémantique	O
,	O
rationalité	O
et	O
subjectivité	O
.	O
La	O
problématique	O
du	O
plaisir	B-PHYS
.	O

Stratégie	O
diagnostique	B-PROC
dans	O
les	O
contusions	B-DISO
abdominales	I-DISO
de	O
l	O
'	O
adulte	B-LIVB
.	O

La	O
qualité	O
des	O
soins	B-PROC
donnés	O
à	O
la	O
patiente	O
A	O
.	O

Les	O
infarctus	B-DISO
du	I-DISO
myocarde	I-DISO
post	O
-	O
opératoires	O
après	O
pontage	B-PROC
aorto	I-PROC
-	I-PROC
coronaire	I-PROC

Synthèse	B-PHEN
des	O
diastéréoisomères	O
24	O
R	O
et	O
24	O
S	O
du	O
dihydroxy	O
-	O
24	O
,	O
25	O
cholécalciférol	B-CHEM
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O

Le	O
cancer	B-DISO
du	I-DISO
col	I-DISO
utérin	I-DISO
de	O
la	O
femme	B-LIVB
jeune	I-LIVB
.	O

Colectomie	B-PROC
subtotale	I-PROC
sous	O
coelioscopie	B-PROC
.	O

Glomérulonéphrite	B-DISO
extracapillaire	I-DISO
et	O
nécrosante	B-DISO
sans	O
dépôt	B-PHYS
d	I-PHYS
'	I-PHYS
immunoglobulines	I-PHYS
:	O
présentations	O
cliniques	O
,	O
facteurs	O
pronostiques	O
et	O
réponse	O
au	O
traitement	B-PROC
.	O
A	O
propos	O
de	O
42	O
cas	O
.	O

Cytokines	B-CHEM
et	O
anti	B-CHEM
-	I-CHEM
cytokines	I-CHEM
.	O
Espoirs	O
thérapeutiques	O
en	O
rhumatologie	O
.	O

Imagerie	B-PROC
de	O
la	O
pyélonéphrite	B-DISO
aiguë	I-DISO
.	O

Mucocèle	B-DISO
appendiculaire	I-DISO
:	O
intérêt	O
de	O
l	O
'	O
exérèse	B-PROC
par	O
coelioscopie	B-PROC
.	O

Fonction	O
des	O
muscles	B-ANAT
expiratoires	I-ANAT
dans	O
l	O
'	O
insuffisance	B-DISO
respiratoire	I-DISO
chronique	I-DISO
obstructive	O
.	O

Nécroses	B-DISO
cutanées	I-DISO
à	O
l	O
'	O
acide	B-CHEM
hydrofluorique	I-CHEM
.	O

Modulation	O
de	O
l	O
'	O
expression	O
de	O
l	O
'	O
intégrine	B-CHEM
alpha	I-CHEM
-	I-CHEM
v	I-CHEM
-	I-CHEM
beta	I-CHEM
-	I-CHEM
1	I-CHEM
à	O
la	O
surface	O
des	O
cellules	B-ANAT
cancéreuses	I-ANAT
humaines	B-LIVB
par	O
le	O
leukemia	B-CHEM
inhibitory	I-CHEM
factor	I-CHEM
(	O
LIF	B-CHEM
)	O
et	O
l	O
'	O
oncostatine	B-CHEM
M	I-CHEM
(	O
OSM	B-CHEM
)	O
.	O

Méningites	B-DISO
bactériennes	I-DISO
de	O
l	O
'	O
adulte	B-LIVB
en	O
réanimation	B-PROC
médicale	I-PROC
.	O
Analyse	O
clinique	O
et	O
étude	O
des	O
facteurs	O
pronostiques	O
.	O

La	O
place	O
de	O
la	O
radiothérapie	B-PROC
dans	O
le	O
traitement	B-PROC
du	O
cancer	B-DISO
du	I-DISO
rectum	I-DISO
.	O

Des	O
souvenirs	O
oubliés	O
.	O

Anesthésie	B-PROC
par	I-PROC
inhalation	I-PROC
en	O
situation	O
d	O
'	O
exception	O
:	O
le	O
respirateur	B-DEVI
Eole	O
2	O
NA	O
.	O

Lipome	B-DISO
rétro	B-ANAT
-	I-ANAT
péritonéal	I-ANAT
géant	O
.	O

Tendinopathies	B-DISO
et	O
fluoroquinolones	B-CHEM
.	O

La	O
presse	O
pharmaceutique	O
francophone	O
en	O
1995	O
.	O
II	O
.	O
Liste	O
et	O
caractéristiques	O
des	O
périodiques	O
pharmaceutiques	O
francophones	O
.	O

Comment	O
j	O
'	O
explore	O
.	O
.	O
.	O
Une	O
épilepsie	B-DISO
.	O

L	O
'	O
agrafage	B-PROC
dans	O
le	O
traitement	B-PROC
des	O
volets	B-DISO
.	I-DISO
Thoraciques	I-DISO
.	O

Allergie	B-DISO
et	O
conservateurs	O
.	O
A	O
propos	O
de	O
trois	O
cas	O
d	O
'	O
allergie	B-DISO
au	O
chlorure	B-CHEM
de	I-CHEM
benzalkonium	I-CHEM
.	O

Phagocytose	B-PHYS
èlective	O
de	O
polynucléaires	B-ANAT
neutrophiles	I-ANAT
par	O
les	O
macrophages	B-ANAT
médullaires	B-ANAT
et	O
neutropénie	B-DISO
auto	I-DISO
-	I-DISO
immune	I-DISO
de	O
l	O
'	O
enfant	B-LIVB
.	O

Troubles	B-DISO
et	O
comportements	O
.	O
Le	O
problème	O
des	O
fugues	B-DISO
en	O
gériatrie	O
.	O

Les	O
traumatismes	B-DISO
de	O
l	O
'	O
uretère	B-ANAT
.	O
A	O
propos	O
de	O
42	O
cas	O
.	O

Une	O
cause	O
rare	O
d	O
'	O
hémorragie	B-DISO
digestive	I-DISO
basse	I-DISO
:	O
l	O
'	O
angiodysplasie	B-DISO
du	I-DISO
grêle	I-DISO
.	O

Une	O
éthique	O
des	O
soins	B-PROC
.	O

La	O
désobstruction	O
des	O
tumeurs	B-DISO
malignes	I-DISO
de	O
l	O
'	O
arbre	B-LIVB
trachéo	I-LIVB
-	I-LIVB
bronchique	I-LIVB
sous	O
endoscopie	B-PROC
souple	O
.	O

Électroencéphalogramme	B-PROC
en	O
urgence	O
au	O
cours	O
de	O
la	O
souffrance	B-DISO
cérébrale	I-DISO
périnatale	I-DISO
:	O
indications	O
et	O
résultats	O
.	O

Carcinomes	B-DISO
cutanés	I-DISO
.	O

Episode	B-DISO
psychotique	I-DISO
aigu	I-DISO
induit	O
par	O
le	O
Qât	B-CHEM
.	O

Choc	B-DISO
anaphylactique	I-DISO
peranesthésique	O
:	O
conduite	O
à	O
tenir	O
.	O

Anesthésie	B-PROC
et	O
agents	B-DISO
transmissibles	I-DISO
non	O
conventionnels	O
(	O
ou	O
maladies	B-DISO
à	I-DISO
prions	I-DISO
)	O
.	O

L	O
'	O
infection	B-DISO
urinaire	I-DISO
du	O
nouveau	B-LIVB
-	I-LIVB
né	I-LIVB
.	O

Thérapie	B-PROC
de	I-PROC
sauvetage	I-PROC
avec	O
des	O
anticorps	B-CHEM
anti	I-CHEM
-	I-CHEM
récepteurs	I-CHEM
IL	B-CHEM
-	I-CHEM
2	I-CHEM
chez	O
des	O
patients	B-LIVB
transplantés	B-PROC
rénaux	I-PROC
à	O
haut	O
risque	O
.	O

La	O
sclérose	B-DISO
en	I-DISO
plaques	I-DISO
chez	O
l	O
'	O
enfant	B-LIVB
.	O

Gel	O
injection	B-PROC
adjustable	O
keratoplasty	B-PROC
(	O
GIAK	O
)	O
.	O
Evaluation	B-PROC
kératométrique	I-PROC
sur	O
yeux	B-ANAT
de	O
cadavres	B-ANAT
.	O

Une	O
patiente	B-LIVB
célèbre	O
:	O
Marie	O
Duplessis	O
,	O
la	O
Dame	O
aux	O
camélias	O
.	O

Survie	O
après	O
duodénopancréatectomie	B-PROC
avec	O
résection	B-PROC
mésentéricoportale	B-ANAT
pour	O
cancer	B-DISO
de	I-DISO
la	I-DISO
tête	I-DISO
du	I-DISO
pancréas	I-DISO
.	O

Recommandations	O
pour	O
le	O
diagnostic	B-DISO
,	O
le	O
traitement	B-PROC
et	O
le	O
suivi	B-PROC
du	O
cancer	B-DISO
de	I-DISO
vessie	I-DISO
.	O

Traitement	B-PROC
pharmacologique	I-PROC
de	O
l	O
'	O
ictère	B-DISO
du	I-DISO
nouveau	I-DISO
-	I-DISO
né	I-DISO
.	O
Un	O
nouvel	O
essor	O
.	O

Le	O
Prix	O
du	O
Président	O
de	O
la	O
République	O
Tunisienne	B-GEOG
des	O
Sociétés	O
Intermaghrébines	O
de	O
Médecine	O
.	O

Enquête	O
méthodologique	O
testant	B-PROC
la	O
validité	O
d	O
'	O
un	O
interrogatoire	O
portant	O
sur	O
l	O
'	O
alimentation	B-PHYS
passée	O
d	O
'	O
un	O
groupe	B-LIVB
de	O
sujets	B-LIVB
du	O
sexe	B-PHYS
masculin	I-PHYS

